<SEC-DOCUMENT>0001193125-14-108048.txt : 20140320
<SEC-HEADER>0001193125-14-108048.hdr.sgml : 20140320
<ACCEPTANCE-DATETIME>20140320160317
ACCESSION NUMBER:		0001193125-14-108048
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		28
CONFORMED PERIOD OF REPORT:	20131231
FILED AS OF DATE:		20140320
DATE AS OF CHANGE:		20140320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		14706850

	BUSINESS ADDRESS:	
		STREET 1:		9640 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9640 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d644794d10k.htm
<DESCRIPTION>10-K
<TEXT>
<HTML><HEAD>
<TITLE>10-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-K
</B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT&nbsp;OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>For the fiscal year ended December&nbsp;31, 2013 </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period
from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U></U> </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-36112 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:23pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS,
INC. </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>06-1591613</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State of organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>9640 Medical Center Drive, Rockville, Maryland 20850 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices and zip code) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>(301) 251-5172 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number) </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(b) of the Act: </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:64.15pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:156.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Each Exchange on Which Registered</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"><B>Common stock, par value $0.01 per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The NASDAQ Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(g) of the Act: None </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> <U></U> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by
check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or 15(d) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><U></U> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by
Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2)&nbsp;has been subject to such filing requirements for the past
90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to
be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark
if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein and will not be contained, to the best of the registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting
company&#148; in Rule 12b-2 of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">Non-accelerated filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> <U></U> </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The aggregate market value of the common stock held by non-affiliates of the registrant, as of February&nbsp;28, 2014, was approximately $698,022,185. Such
aggregate market value was computed by reference to the closing price of the common stock as reported on the NASDAQ Global Select Market on February&nbsp;28, 2014. For purposes of making this calculation only, the registrant has defined affiliates
as including only directors and executive officers and shareholders holding greater than 10% of the common stock of the registrant as of February&nbsp;28, 2014. The registrant used February&nbsp;28, 2014 as the measurement date because its common
stock was not publicly traded as of the last business day of its most recently completed second fiscal quarter. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The number of shares of the
registrant&#146;s common stock outstanding on February&nbsp;28, 2014 was 27,471,329. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>DOCUMENTS INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Portions of MacroGenics, Inc.&#146;s definitive proxy statement for the 2014 annual meeting of stockholders are incorporated by reference into Part III of this
Annual Report. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNUAL REPORT ON FORM 10-K </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#rom644794_1">PART&nbsp;I </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_2">Business</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_3">Risk Factors</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1B</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_4">Unresolved Staff Comments</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_5">Properties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_6">Legal Proceedings</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_7">Mine Safety Disclosures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#rom644794_8">PART&nbsp;II </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_9">Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_10">Selected Financial Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_11">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 7A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_12">Quantitative and Qualitative Disclosures about Market Risk</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_13">Financial Statements and Supplementary Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_14">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 9A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_15">Controls and Procedures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 9B</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_16">Other Information</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#rom644794_17">PART&nbsp;III</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_18">Directors, Executive Officers and Corporate Governance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_19">Executive Compensation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_20">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_21">Certain Relationships and Related Transactions, and Director Independence</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_22">Principal Accountant Fees and Services</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#rom644794_23">PART&nbsp;IV</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#rom644794_24">Exhibits and Financial Statement Schedules </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#rom644794_25">SIGNATURES </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This report includes forward-looking statements within the meaning of federal securities laws. Forward-looking statements include statements
that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in
particular, under the headings &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;. Forward-looking statements can often be identified by the use of terminology such as
&#147;subject to&#148;, &#147;believe&#148;, &#147;anticipate&#148;, &#147;plan&#148;, &#147;expect&#148;, &#147;intend&#148;, &#147;estimate&#148;, &#147;project&#148;, &#147;may&#148;, &#147;will&#148;, &#147;should&#148;, &#147;would&#148;,
&#147;could&#148;, &#147;can&#148;, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but
they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and
factors, among others (including those set forth under &#147;Risk Factors&#148;), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to develop and commercialize our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ongoing and planned clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate and degree of market acceptance and clinical utility of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our commercialization, marketing and manufacturing capabilities and strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant competition in our industry; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs of litigation and the failure to successfully defend lawsuits and other claims against us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic, political and other risks associated with our international operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to receive research funding and achieve anticipated milestones under our collaborations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intellectual property position; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss or retirement of key members of management; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to successfully execute our growth strategy, including any delays in our planned future growth; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our failure to maintain effective internal controls. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, forward-looking statements
should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. We do not
undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom644794_1"></A>PART I </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_2"></A>ITEM&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>BUSINESS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Except as otherwise indicated herein or as the context otherwise requires, references in
this annual report on Form 10-K to &#147;MacroGenics,&#148; &#147;the company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to MacroGenics, Inc. and its consolidated subsidiaries.
DART<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, the phrase &#147;Breakthrough Biologics, Life-Changing Medicines&#148; and the MacroGenics logo are our registered trademarks. The other trademarks, trade names and service marks
appearing in this report are the property of their respective owners. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for
the treatment of cancer and autoimmune diseases. We generate our pipeline of product candidates from our proprietary suite of next-generation antibody technology platforms, which we believe improve the performance of monoclonal antibodies and
antibody-derived molecules. These product candidates, which we have identified through our understanding of disease biology and immune-mediated mechanisms, may address disease-specific challenges which are not currently being met by existing
therapies. Some of these product candidates include therapeutics in the emerging field of immune oncology and are designed to promote tumor destruction by either enhancing or restoring the body&#146;s immune system to destroy cancers. We create both
differentiated molecules that are directed to novel cancer targets, as well as &#147;bio-betters,&#148; which are drugs designed to improve upon marketed medicines. The combination of our technology platforms and antibody engineering expertise has
allowed us to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. These collaborations provide us with funding and allow us to leverage the additional
expertise of these collaborators to advance the development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have three versatile, proprietary technology
platforms consisting of: (1)&nbsp;our Dual Affinity Re-Targeting (&#147;DART&#148;) platform, which enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure, and also includes the ability to
recruit any T cell in a patient&#146;s body to destroy targeted cancer cells; (2)&nbsp;our Fc Optimization platform, which enhances the body&#146;s immune system to mediate the killing of cancer cells through a mechanism called antibody-dependent
cellular cytotoxicity (&#147;ADCC&#148;) in which antibodies and immune cells cooperate to destroy targets such as tumor cells; and (3)&nbsp;our Cancer Stem-like Cell (&#147;CSLC&#148;) platform, which provides a unique discovery tool to identify
cancer targets shared both by tumor-initiating cells and the differentiated cancer cells derived from them. These versatile technology platforms can be applied in combination with one another to custom-design an antibody or antibody-derived molecule
that is optimized to treat a specific disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Antibodies, which are proteins produced by specialized cells of the body&#146;s immune
system usually in response to foreign substances, such as bacteria and viruses, or to cancer cells, serve as the primary resource for our product candidates. Many of our cancer product candidates are derived from our library of over 2,000 purified
antibodies. Our antibodies are targeted to more than 70 different antigens, or components of the foreign substance that induce the production of antibodies, expressed on the surface of cancer cells. In addition, we continue to generate new
antibodies for our library using our proprietary CSLC lines and soluble protein antigens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initially select a specific antibody based
on its functional properties related to a disease target as well as its distribution on tissues in the body. We then utilize one or more of our technology platforms for engineering and optimizing our product candidate. We believe our approach allows
us to take advantage of the enhanced properties of an engineered antibody or antibody-derived molecule to kill cancer cells and to interfere with autoimmune diseases more effectively than a wild type, or non-engineered, monoclonal antibody. Our
methods for improving the effectiveness of antibodies include the following: enhancing the body&#146;s immune system, targeting multiple antigens on the surface of the same target cell, increasing the strength of the binding of an antibody to its
antigen targets, and reducing the likelihood of an unwanted immune response to the antibody or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
antibody-derived molecule. We believe our differentiated product candidates have the potential to provide new approaches to treat cancer, autoimmune disorders and other complex diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have two oncology product candidates in clinical development. Additionally, we have several proprietary product candidates in
pre-clinical development and we expect to commence Phase 1 clinical trials on two of these product candidates in 2014. We believe the profile of our compounds provides us with the flexibility to pursue either monotherapy or combination therapy,
depending on disease characteristics, current standards of care, and overall safety, tolerability, and efficacy of specific regimens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
table below depicts the current status of our product candidates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g644794g97i90.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Margetuximab</I>, also known as MGAH22, is a monoclonal antibody that targets HER2-expressing tumors, including breast, gastroesophageal, bladder and other cancers. Human epidermal growth factor receptor 2
(&#147;HER2&#148;), is critical for the growth of many types of tumors. Using our Fc Optimization platform, we have engineered the constant region, or Fc region, of margetuximab to enhance the antibody&#146;s ability to kill tumor cells expressing
lower levels of HER2 than that of currently approved anti-HER2 agents (such as Herceptin) and also to increase margetuximab&#146;s ability to kill tumor cells through ADCC. We designed margetuximab to benefit a large sub-group of patients, which
represents 80% or more of the overall population whose Fc receptors (&#147;Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs&#148;) expressed on immune cells bind less effectively to currently available antibodies that have not been optimized by
our technology. Margetuximab represents a new class of bio-betters that may potentially help larger HER2+ patient populations than those treated with current HER2 therapies, as well as improve the outcomes for patients who would be eligible for
other HER2 targeted drugs and drug candidates. Phase 1 data from our open-label, dose escalation trial of margetuximab presented at the June 2013 Annual Meeting of the American Society of Clinical Oncology (&#147;ASCO&#148;) and November 2013
Chemotherapy Foundation Symposium demonstrated anti-tumor activity had been observed at a range of doses tested, including the lowest dose level of margetuximab, even in patients who were heavily pre-treated (frequently including with other
anti-HER2 agents). We currently are enrolling a Phase 2a clinical trial in metastatic breast cancer and we plan to commence a Phase 3 potential registration clinical trial in advanced gastroesophageal cancer in the second half of 2014.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><I>MGA271 </I>is an Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules which are involved in immune
regulation, and is over-expressed on a wide variety of solid tumor types. Inhibition of B7 family members has been shown to have powerful anti-tumor effects in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
several solid tumor types. For example, in presentations by others at ASCO and in publications in the <I>New England Journal of Medicine</I>, complete or partial tumor regression was observed in
patients with certain cancers who participated in clinical trials of antibodies targeting CTLA4, PD-1 and PD-L1, which are also members of the B7 family or their associated checkpoint receptors on T&nbsp;cells. We have engineered MGA271 to utilize
the same Fc optimization enhancements that we incorporated in margetuximab, and to target the over-expression of B7-H3 on differentiated tumors and CSLCs, as well as on the supporting tumor vasculature and underlying tissues. MGA271 is designed to
destroy all of these components of the cancer in addition to reducing its inhibitory properties on T cells. We expect to complete the first three dose expansion cohorts of a Phase 1 clinical trial by the end of 2014. We plan to initiate additional
dose expansion cohorts using MGA271 as monotherapy in other tumor types in 2014, as well as combining MGA271 with other therapies for certain tumor types. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGD006 </I>is a humanized DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor alpha chain is expressed on leukemia and leukemic stem cells, but not on normal hematopoietic stem cells.
T cells, which express CD3, can destroy tumor cells. In pre-clinical studies, we have demonstrated the ability of MGD006 at extremely low doses to recruit, activate, and expand T cell populations to eliminate leukemia cells. MGD006 pre-clinical data
was presented at 2013 Annual Meeting of the American Society of Hematology. In February 2014, we announced that an investigational new drug (&#147;IND&#148;) application for MGD006 cleared the U.S. Food and Drug Administration&#146;s
(&#147;FDA&#146;s&#148;) 30-day review period. We expect to commence a Phase 1 clinical trial of MGD006 in the second quarter of 2014. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGD007 </I>is a humanized DART molecule that recognizes both the glycoprotein gpA33 and CD3. gpA33 is expressed on gastrointestinal tumors, including more than 95% of human colon cancers. We have demonstrated that
this molecule is able to mediate T&nbsp;cell killing of gpA33-expressing cancer cells and CSLCs in pre-clinical experiments. We expect to commence a Phase 1 clinical trial of MGD007 in the second half of 2014. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our
current strategic collaborations, we have received approximately $129.9&nbsp;million in non-equity funding through December&nbsp;31, 2013. Subsequent to December&nbsp;31, 2013, we earned an additional $20.0 million under the Servier DART agreement
as described below. Our collaborators include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Servier. </I>In November 2011, we entered into a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier (collectively, &#147;Servier&#148;) under which we granted Servier an option
to obtain an exclusive license to develop and commercialize MGA271 in all countries other than the United&nbsp;States, Canada, Mexico, Japan, South Korea and India. We received a $20.0 million option grant fee and a $10.0 million milestone payment
upon dosing the first patient in the expansion cohort of our Phase 1 clinical trial of MGA271, and may be eligible to receive up to approximately $415.0&nbsp;million in license grant fees, and clinical, development, regulatory and sales milestone
payments if Servier exercises the option, obtains regulatory approval for, and successfully commercializes an MGA271 licensed product. In the event Servier exercises its option, Servier must pay a license grant fee, which we estimate to be
$30.0&nbsp;million, based on the number of different indications represented within the planned Phase 1 patient population. We and Servier will share Phase 2 and Phase 3 development costs. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In September 2012, we entered into a second agreement with Servier and granted it options to obtain three separate exclusive licenses to
develop and commercialize DART-based molecules, consisting of those designated by us as MGD006 and MGD007, as well as a third DART-based molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India, at which
time we received a $20.0 million option grant fee. In February 2014, Servier exercised its option to develop and commercialize MGD006 in its territories for which we received a $15.0 million license grant payment. In addition, we received a $5.0
million milestone payment from Servier in connection with an IND application for MGD006 clearing the FDA&#146;s 30-day review period. We may be eligible to receive up to approximately $1 billion in additional license grant fees, and clinical,
development, regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
and sales milestone payments if Servier exercises its two remaining options and successfully develops, obtains regulatory approval for, and commercializes a product under all three licenses,
including $5.0&nbsp;million upon IND acceptance for each of MGD007 and a third DART molecule. In addition to these milestones, we and Servier will share Phase 2 and Phase 3 development costs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Additionally, under both agreements, Servier would be obligated to pay us low double digit to mid-teen royalties on product sales in its
territories. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Gilead. </I>In January 2013, we entered into an agreement with Gilead Sciences, Inc. (&#147;Gilead&#148;) for the research, development and commercialization of up to four DART-based molecules. The time period for
Gilead&#146;s exercise of one option has expired. At present, Gilead retains a license to one and options to two of the original four programs. Gilead has exclusive worldwide rights for each of these remaining programs. We received an initial $7.5
million license grant fee for the first DART-based molecule, and are eligible to receive an additional $7.5 million in grant fees on each of the remaining two DART-based molecules if any are selected by Gilead. We are further eligible to receive up
to an additional $20 to $25 million in pre-clinical milestones across each of the three remaining DART programs and up to approximately $240 to $250 million per remaining program in additional clinical, regulatory and sales milestone payments if
Gilead exercises both remaining options and achieves all of the requisite milestones under each option and license. Gilead also provides funding for our internal and external research costs under the agreement. We are also eligible to receive tiered
royalties on the net sales at percentages ranging from the high-single digits to the low double digits, but less than teens, subject to reductions in specified circumstances. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Boehringer. </I>In October 2010, we entered into an agreement with Boehringer Ingelheim GmbH (&#147;Boehringer&#148;) to discover, develop and commercialize up to ten DART-based molecules which may span multiple
therapeutic areas. We granted Boehringer an exclusive worldwide, royalty-bearing, license and received an upfront payment of $15.0 million. We subsequently received three annual maintenance payments, including a $4.0 million payment received in the
fourth quarter of 2013. Also, in the fourth quarter of 2013, Boehringer&#146;s selection of a development candidate triggered a $5.0&nbsp;million milestone payment to us under the agreement. We have the potential to earn development, regulatory and
sales milestone payments that can reach up to approximately $210.0 million for each of the DART programs under this agreement. Boehringer provides funding for our internal and external research costs and is required to pay us mid-single digit
royalties on product sales. Boehringer purchased $10.0 million of our Series D-2 Preferred Stock in January 2011. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Pfizer. </I>In October 2010, we entered into a three year agreement with Pfizer, Inc. (&#147;Pfizer&#148;) to discover, develop and commercialize up to two DART-based molecules. We granted Pfizer a non-exclusive
worldwide, royalty-bearing license and received upfront and milestone payments and funding for our internal and external research costs under the agreement. We are eligible to receive technical, development and sales milestone payments that can
reach up to approximately $210.0 million for each DART program under this agreement. Pfizer is responsible for all pre-clinical and clinical development costs for the program. In addition, Pfizer is required to pay us mid-single digit to low-teen
royalties on product sales. Under this collaboration, one DART program is currently being pursued and we completed our research obligations under this program in January 2014. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently manufacture material for research and development efforts for all of our product candidates in-house. Drug
substance for all of our clinical trials is manufactured using current good manufacturing practices (&#147;cGMP&#148;) at our manufacturing facility, located in Rockville, Maryland. We contract with vendors to provide fill finish manufacture of drug
product. We currently have capacity to produce Phase 2 material for our antibody product candidates and all clinical and commercial material for our DART therapeutics. We intend to expand our manufacturing facility, which should enable us to
increase our production capacity. In addition, we have entered into agreements with contract manufacturing organizations to supplement our clinical supply and internal capacity as we advance additional pre-clinical candidates into clinical
development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to be a leader in the discovery, development and commercialization of antibody-based therapeutics for the treatment of patients
with cancer, autoimmune disorders and other complex diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Key elements of our strategy to achieve this goal are to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Rapidly and concurrently advance our clinical oncology product candidates in multiple tumor types.</I> We&nbsp;intend to pursue the fastest feasible pathways to approval and to address large, underserved markets. We
are developing product candidates that we believe could address disease specific challenges which are not currently being met by existing therapies. We are currently enrolling a Phase 2a clinical trial of margetuximab in metastatic breast cancer for
which we expect to have results in late 2014. We plan to commence a Phase&nbsp;3 potential registration clinical trial of margetuximab in advanced gastroesophageal cancer in the second half of 2014. We are currently enrolling the dose-expansion
portion of a Phase&nbsp;1 clinical trial of MGA271 as a single-agent in the treatment of 45 patients with solid tumors, including: 15&nbsp;patients with melanoma; 15 patients with prostate cancer and an additional group of 15 patients with other
solid tumor types. Servier has indicated that it intends to evaluate MGA271 in up to 75 additional cancer patients representing additional types of cancers beginning in the first quarter of 2014. We plan to initiate additional dose expansion cohorts
using MGA271 as monotherapy in other tumor types in 2014, as well as combining MGA271 with other therapies for certain tumor types. In addition, we are currently optimizing multiple DART therapeutics as candidates for clinical development. We
anticipate that we will begin Phase 1 clinical trials of MGD006, our first DART candidate, in the second quarter of 2014, and MGD007, our second DART candidate, in the second half of 2014. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Leverage collaborative relationships.</I> We have multiple programs in development under our collaborations and are working closely with our collaborators to advance these programs. We believe that these
collaborations help to validate and rapidly advance our discovery efforts, technology platforms, and product candidates while providing significant funding to advance our pipeline and access the development and commercial expertise of our
collaborators. To facilitate the capital-efficient development and commercialization of our proprietary programs, we intend to enter into additional collaboration agreements with biopharmaceutical companies. We anticipate that we would structure
these collaborations in ways that would allow us to retain development and commercialization rights in key markets. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Create new product candidates that combine the potency and target selectivity of our DART technology with small molecule and toxin conjugation technologies.</I> We are working with several companies to combine their
proprietary linkers and drug conjugates with our monoclonal antibodies. We believe that such linkers and drug conjugates can be combined with the selective targeting properties of our DART technology. Our goal is to identify and further develop new
clinical candidates, either antibody-drug conjugates (&#147;ADCs&#148;) or DART-drug conjugates, through these research efforts. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Establish commercialization and marketing capabilities in the United States</I>. We have retained commercialization rights in the United States for our clinical stage programs as well as the three DART programs that
we are developing in collaboration with Servier. We intend to build a targeted specialty sales force and marketing capabilities in the United States to commercialize our product candidates that receive regulatory approval. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Strengthen our leadership position in fully integrated antibody engineering and development capabilities.</I> We have built a powerful and fully integrated set of capabilities that are critical to our ability to
discover, optimize and develop antibody-based therapeutic product candidates in a rapid and efficient manner. We intend to build on our technology platforms, methods and know-how that comprise our capabilities in order to expand our product
pipeline. We intend to advance two additional oncology DART-based product candidates to IND submission and initiation of clinical testing in 2015. Our goal is to file one or more new INDs annually for the next several years. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Immune System and Antibodies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
immune system, composed of both innate and adaptive elements, defends against invading pathogens such as viruses, parasites, and bacteria, and provides surveillance against cancers. The adaptive immune system includes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">B cells, which mature into plasma cells and produce antibodies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Helper T cells, including those that enable, or help, the B cells to produce antibodies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Cytotoxic T cells, which can destroy tumor cells or cells infected with viruses. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">T cells and
B cells (and the antibodies derived from the mature B cell) of this adaptive immune system respond to small structural differences found, for example, on a cancer cell. This normally imparts exquisite specificity on these individual immune
components. As a result, billions of different structural variants can be recognized by the adaptive immune system, but each individual T cell or B cell or antibody can only bind and respond to a single structure or molecule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in the following illustration, the antibody is a Y-shaped molecule that has two identical variable regions at the tip of the arms of
the antibody (Fab region), which bind to antigens, and a constant region (Fc), as its opposite end that binds to Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Monoclonal Antibody Structure </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g644794g79f34_g.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An antibody&#146;s structure is amenable to engineering either the variable regions to improve its strength
of target recognition or affinity, or the constant regions to modify its engagement and collaboration with other components of the immune system, or both. The two variable region arms naturally target the same antigen; however, they can be
artificially engineered to target two different antigens, allowing the creation of a bi-specific antibody. The Fc region can bind, recruit and activate immune cells to amplify the immune response to targets bound by the variable region of the
antibody molecule. The Fc region can be modified to enhance the engagement with other immune cells and increase the potency of the immune response. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therapeutic monoclonal antibodies are typically derived from natural antibodies and are obtained from immune cells of mammals that have been
immunized with a desired antigen and are all clones of the unique parent cell. The antibody&#146;s ability to bind specifically to a target or antigen is also referred to as its specificity. Using this mechanism, antibodies can tag foreign
substances for attack by other immune system cells or neutralize the targets directly. In treating diseases such as cancer, researchers find antigens specific to cancer cells and create antibodies that bind those antigens to use the body&#146;s
immune system to destroy these cancer cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Monoclonal antibodies are often generated in mice and although they are relatively easy to
generate, they can have drawbacks as targeted therapeutics. The major drawback is that a mouse monoclonal antibody is recognized by the human immune system as a foreign target and therefore, the immune system attacks the antibody, rendering it
useless against its intended target. Many advances have been made to genetically engineer and humanize monoclonal antibodies. In addition, fully human antibodies can be created, which can reduce newly generated immune responses in patients treated
with monoclonal antibodies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cancer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer is a broad group of diseases in which cells divide and grow in an uncontrolled fashion, forming malignancies that can invade other parts
of the body. In normal tissues, the rates of new cell growth and cell death are tightly regulated and kept in balance. In cancerous tissues, this balance is disrupted as a result of mutations, causing unregulated cell growth that leads to tumor
formation and growth. While tumors can grow slowly or rapidly, the dividing cells will nevertheless accumulate and the normal organization of the tissue will become disrupted. Cancers subsequently can spread throughout the body by processes known as
invasion and metastasis. Once cancer spreads to sites beyond the primary tumor, it may be incurable. Cancer cells that arise in the lymphatic system and bone marrow are referred to as hematological malignancies. Cancer cells that arise in other
tissues or organs are referred to as solid tumors. Cancer can arise in virtually any part of the body, with the most common types arising in the prostate gland, breast, lung, colon and skin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer is the second leading cause of death in the United States, exceeded only by heart disease, and accounts for almost one of every four
deaths. The American Cancer Society estimates that in 2013 there will be approximately 1.6&nbsp;million new cases of cancer and approximately 580,000 deaths from cancer. The National Institutes of Health estimates that the direct medical cost of
cancer of all types, including solid tumors, in the United States in 2010 was approximately $125 billion and according to IMS Health the amount spent in the United States on drugs to treat cancer exceeded $23 billion in 2011. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Currently Available Cancer Treatments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. A cancer patient often receives treatment
with a combination of these methods. For patients with localized disease, surgery and radiation therapy are particularly effective. Systemic drug therapies are generally used by physicians in patients who have cancer that has spread beyond the
primary site or cannot otherwise be treated through surgery. The goal of these therapies is to damage and kill cancer cells or to interfere with the molecular and cellular processes that control the development, growth and survival of cancer cells.
In many cases, drug therapy entails the administration of several different drugs in combination. Over the past several decades, drug therapy has evolved from non-specific drugs that kill both healthy and cancerous cells, to drugs that target
specific molecular pathways involved in cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cytotoxic Chemotherapies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The earliest approach to pharmacological cancer treatment was to develop drugs, referred to as cytotoxic drugs, which kill rapidly
proliferating cancer cells through non-specific mechanisms, such as disrupting cell metabolism or causing damage to cellular components required for tumor survival and rapid growth. While these drugs have been effective in the treatment of some
cancers, cytotoxic drug therapies act in an indiscriminate manner, killing healthy cells along with cancerous cells. Due to their mechanism of action, many cytotoxic drugs have a narrow dose range above which the toxicity causes unacceptable or even
fatal levels of damage and below which the drugs are not effective in eradicating cancer cells. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Targeted Therapeutics </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The next approach to pharmacological cancer treatment was to develop drugs, referred to as targeted therapeutics, including monoclonal
antibodies, that target specific biological molecules in the human body that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
play a role in rapid cell growth and the spread of cancer. Included in this category are small molecule drugs as well as large molecule drugs, also known as biologics. With heightened vigilance
and new diagnostic tests, targeted therapies (including monoclonal antibodies such as Herceptin, Rituxan and Avastin as well as small molecules such as Nexavar and Tarceva), have resulted in improvements in overall survival for many cancer patients.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Next Generation Antibody-based Therapeutics for Cancer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While targeted antibody therapeutics have been highly successful in treating various cancers, the therapeutic effects of many such therapies
are often relatively transient. Acquired resistance to cancer therapies remains a significant clinical problem with patients frequently relapsing and the tumors metastasizing to distant organs. The significant need for improvement in the treatment
of cancer through antibody-based therapies is driving the growing focus on next-generation antibody-based therapies. Opportunities to create next-generation antibody based therapeutics lie in several technology advances including: antibodies that
target multiple antigens, Fc-optimization, and ADCs. Multi-specific antibodies and ADCs have the potential to increase efficacy for cancer treatments and reduce systemic toxicity. Fc optimization may enable modification of the antibody to enhance
the immune system&#146;s response and augment the therapeutic potential of the antibody, and may increase its half-life, which can potentially lead to less frequent dosing (a competitive advantage for injectables) and a lower cost of goods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Growth of the Biologics Market </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the last 20 years, recombinant biologic therapeutic drugs, including monoclonal antibodies, the largest subclass of recombinant biologics,
have had a dramatic impact on cancer therapy. The improvement of engineering technologies, efficacy and safety of biologic drugs have driven significant market growth, with worldwide sales in 2011 of $157 billion according to data from the IMS
Institute for Healthcare Informatics. Data from La Merie, a business intelligence firm, indicates that therapeutic antibody products represent approximately 52% of total biologic drug sales, with 2012 global sales of approximately $65 billion, an
increase from approximately $22 billion in 2006. Approximately 40 antibody product candidates have been approved by the FDA and international regulatory authorities since the first approval in 1986, and the three largest selling cancer drugs are
monoclonal antibodies, Rituxan, Herceptin and Avastin, which had 2012 worldwide sales of approximately $7.1 billion, $6.3 billion and $6.1 billion, respectively. Today, more than 300 monoclonal antibodies are in various stages of clinical
development. According to a 2010 statistical analysis by Tufts University, antibody product candidates have shown a 2.5 times higher probability of successful clinical development as compared to small-molecule drugs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Platforms for Creating Next-Generation Antibody-based Therapies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We apply our understanding of disease biology, immune-mediated mechanisms and next generation antibody technologies to design highly targeted
antibody-based product candidates. Our antibody-based platforms consist of: DART, Fc Optimization, and CSLCs. Through these platforms, we have designed antibody-based product candidates that have the potential to improve on standard treatments by
having: (1)&nbsp;multi-specificities; (2)&nbsp;increased abilities to interact with the body&#146;s immune system to fight tumors; (3)&nbsp;capacity to bind more avidly to antigen targets: (4)&nbsp;increased potency; (5)&nbsp;reduced immunogenicity;
or (6)&nbsp;the ability to target cancer cells which are resistant to standard treatments. Moreover, these technology platforms are complementary and can be combined. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>DART Platform: Our Proprietary Approach to Engineer Multi-Specific Antibodies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use our DART platform to create derivatives of antibodies with the ability to bind to multiple targets instead of a single target found in
traditional monoclonal antibodies. Our current DART product candidates are bi-specific. An example of a bi-specific molecule is illustrated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g644794g77g14_g.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because cancer cells have derived ways to escape the immune system, we have created DART molecules which
improve upon the human immune system, by creating alternative antibody-like structures with more potent immune properties than the parent antibody molecules from which they are derived. The two variable regions of an antibody are mono-specific and
are able to target only a single type structural component of an antigen. For many years, researchers have sought to create recombinant molecules that are multi-specific and capable of targeting multiple antigens or epitopes (i.e., specific part of
antigen bound to the antibody) within the same molecule. The challenges in creating such molecules have been the instability of the resulting bi-specifics and their inherent short half-lives, as well as the inefficiencies in manufacturing these
compounds. We believe our DART platform has overcome these engineering challenges by incorporating proprietary covalent di-sulfide linkages and particular amino acid sequences that efficiently pair the chains of the DART molecule. This results in a
structure with enhanced manufacturability, long-term structural stability, and the ability to tailor the half-lives of the DARTs to their clinical needs. This engineered antibody-like protein has a very compact and stable structure and enables the
targeting of multiple different antigens within a single recombinant molecule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DART platform has been specifically engineered to
accommodate virtually any variable region sequence with predictable expression, folding, and antigen recognition. To date, we have produced over 100 different DART molecules and have completed numerous <I>in vitro</I> and <I>in vivo</I>
proof-of-concept studies on most of these molecules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our DART platform may provide a significant advantage over current biological
interventions in cancer and autoimmune disorders by enabling a range of modalities, including those described below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;<I>Redirected T cell activation and killing.</I> In this version of the DART molecule, we are enabling the
cancer-fighting properties of the adaptive immune system to: (1)&nbsp;recognize and bind to structures expressed on a cancer cell (e.g., CD123, the first specificity in the example on the right), (2)&nbsp;enable the recruitment of all types of
cytotoxic, or cell killing, T cells, irrespective of their ability to recognize cancer cells (e.g., CD3, a common component of the T cell antigen receptor, is the second specificity in the example on the right), and (3)&nbsp;trigger T cell
activation, expansion, and cell killing mechanisms to destroy a cancer cell. The outcome is that any of the body&#146;s T cells, in theory, could be recruited to destroy a cancer cell and thus, are not limited to the small numbers of specific T
cells that are normally generated to kill a cancer cell. Furthermore, since any T cell could be recruited for this killing process, only small amounts of a DART molecule are required to trigger this potent immune response. Additionally, the compact
structure of the DART protein makes it well suited for maintaining cell-to-cell contact, apparently contributing to the high level of target cell killing.</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt" ALIGN="center">


<IMG SRC="g644794g18q24_g.jpg" ALT="LOGO">
&nbsp;</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;<I>Modulation of receptor signaling</I>. In another configuration of the DART molecule, we have taken advantage
of the two (or more) different specificities engineered in a DART structure to bind not only to particular cells involved in autoimmune processes, such as autoimmune B cells, but also to usurp the immune checkpoint signaling pathways programmed
within the cells to impede the pathogenic autoimmune responses. Our MGD010 product candidate targets both CD32B, a co-inhibitory molecule, and CD79B, part of the B cell antigen receptor complex, two proteins expressed on the immune system&#146;s B
cells. Using a single DART molecule, we not only target two receptors with a single molecule, but also promote the interaction of these two receptors to interrupt the autoimmune response. This is critical because interruption of the autoimmune B
cell response cannot be achieved merely by using two separate antibodies. In this particular example, the activity of CD32B on B cells is captured to curb a destructive immune response.</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt" ALIGN="center">


<IMG SRC="g644794g73g29_g.jpg" ALT="LOGO">
&nbsp;</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;<I>Simultaneous targeting of multiple pathologic factors, such as cytokines and growth factors and their
receptors.</I> Targeting multiple soluble proteins or receptors that are important to the perpetuation of an autoimmune disease or generation of a cancer may create therapeutic synergies within a single DART molecule. Examples of this DART include
the targeting of different inflammatory cytokines, such as TNF-a, IL-1, and IL-6, involved in the pathogenesis of autoimmune diseases or those receptors contributing to the growth of cancers such as members of the EGFR family including EGFR1, HER2
and HER3.</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt" ALIGN="center">


<IMG SRC="g644794g85w60_g.jpg" ALT="LOGO">
&nbsp;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;<I>Targeting multiple epitopes on a pathogen for enhanced neutralization and/or clearance</I>. Infectious
agents with slightly different genetic sequences or structures may perpetuate disease. Sometimes multiple variants may infect one individual and may evade the patient&#146;s normal immune responses. Creating DARTs that eliminate multiple infectious
variants of a virus or multiple toxins produced by a bacterium could be an advantage for prevention or treatment. Examples of this include targeting the major genetic and serological forms of dengue virus, the cause of a major viral disease
transmitted by mosquitoes, quasi-species of HIV, or different bacterial toxins derived from pathogenic clostridium species.</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g644794g37d02_g.jpg" ALT="LOGO">
&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have the ability to tailor a DART molecule&#146;s valency (number of binding sites), the
strength by which the binding sites attach to its targets, and its half-life in the blood circulation after delivery to a patient. Furthermore, when an Fc domain is incorporated in a DART, changes can be included that can modulate the DART&#146;s
engagement with different immune cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed proof-of-concept pre-clinical data and are developing specific product
candidates using this technology, including MGD006, MGD007 and MGD010, among others. We have been able to produce DART molecules in both bacterial and mammalian expression systems. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fc Optimization Platform: Our Proprietary Approach to Enhance Immune-Mediated Cancer Cell Killing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To enhance the body&#146;s immune ability, we developed our Fc Optimization platform which introduces certain mutations into the Fc region of
an antibody and is able to modulate antibody interaction with immune effector cells. Such interaction enhances the body&#146;s immune ability to mediate the killing of cancer cells through ADCC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADCC </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g644794g04y47_g.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Fc region mediates the function of certain antibodies by binding to different activating Fc<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs and inhibitory Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs on immune effector cells found within the innate immune system. By engineering Fc regions to bind with an increased affinity to the
activating Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs and with a reduced affinity to the inhibitory Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs, we have been able to impart a more effective immune response, and improve effector
functions, such as ADCC. This is another example in which small changes in antibody structure can confer improvements on normal immune processes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established a proprietary platform to engineer, screen, identify and test
antibodies&#146; Fc regions with customizable activity. In particular, we have licenses to use transgenic mice that express human Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs. These mice can be used for <I>in vivo</I> testing of antibodies
that incorporate Fc domain variants, including those antibodies intended for cancer therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have successfully incorporated
our Fc variants in our lead product candidates, margetuximab and MGA271. We have pre-clinical data demonstrating that these Fc variants have substantially improved the antibody&#146;s therapeutic effects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cancer Stem-like Cell Platform: Our Proprietary Approach to Discover Cancer Targets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CSLC platform provides new approaches to discover and identify cancer targets that are unresponsive to current cancer therapies. Cancer
stem cells represent important potential targets in oncology drug development because they are theorized to be the basis for tumor re-growth and metastasis and are refractory to much standard chemotherapy. Therefore, the ability to specifically
target and destroy CSLCs could potentially address an unmet medical need in many hard-to-treat cancers today. Using our CSLC platform, we can create antibodies that target and kill CSLCs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Building on our expertise in growing stem cells from normal tissues using proprietary media and culture conditions, we have produced CSLCs
from primary human tumor tissues. These CSLCs have been generated <I>in vitro</I> from a range of solid tumors and many have demonstrated tumor growth and differentiation <I>in vivo</I>. We believe that this technology holds great promise in
creating the next generation of oncology therapeutics that target both differentiated tumor cells and their precursor cells which traditionally have been resistant to conventional chemotherapy and radiation therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy has been to generate CSLCs from a range of primary tumors, including those derived from the colon, lung and ovary. We analyze and
characterize the CSLCs for the following: (a)&nbsp;ability for self-renewal, (b)&nbsp;ability to form tumors <I>in vivo</I> that differentiate with the expected histological characteristics, and (c)&nbsp;genetic and protein stem cell marker
expression profiles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have created novel antibodies that target antigens on both CSLCs and bulk differentiated tumor cells,
which are derived from the CSLCs. In addition to their value for identifying potential immune-based therapeutics, other opportunities include their use in small molecule compound screening and diagnostic applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have generated over 2,000 monoclonal antibodies that we have screened by immunohistochemistry (&#147;IHC&#148;) for lower-binding to
normal, non-malignant tissues. Many of these antibodies have been characterized for binding to primary tumors and cancer cell lines and we are developing the most promising of these antibodies into product candidates. This collection of antibodies
is selective for both validated and novel cancer targets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have utilized our CSLC technology to generate or characterize the antibodies
we use in our MGA271 and MGD007 product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Product Candidate Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have two oncology product candidates in clinical development. Additionally, we have several proprietary product candidates in
pre-clinical development and we expect to commence Phase 1 clinical trials on two of these product candidates in 2014. Further, we expect to advance two additional oncology DART-based product candidates into clinical testing in 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Margetuximab: Fc-Optimized Antibody for HER2-expressing Solid Tumors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Margetuximab
(&#147;MGAH22&#148;) is an Fc-optimized, monoclonal antibody that targets and binds to the HER2 protein on cancer cells and is intravenously administered in order to kill tumor cells or inhibit tumor cell growth. We are developing margetuximab as an
improved, more potent, anti-HER2 treatment for a variety of HER2-expressing tumors such as breast, gastroesophageal and bladder cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An important mechanism of anti-HER2 monoclonal antibody action is the mediation of ADCC. In ADCC, the anti-HER2 antibody binds to tumor cells
and then recruits immune cells, such as macrophages, through their Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs. Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R-mediated mechanisms play a critical part in the effectiveness of targeted tumor
antibodies including anti-HER2 antibodies. Therefore, we have optimized the important Fc region of margetuximab and thereby improved the cell-killing properties of margetuximab, compared to current anti-HER2 therapies (including trastuzumab).
Specifically, we increased binding to activating receptors and decreased binding to the inhibitory receptor on immune effector cells. As a result, we believe margetuximab has the potential to be effective in a much broader population than the
approximately 25% of breast cancer patients treated with trastuzumab today and may overcome resistance in populations who no longer respond to trastuzumab. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The HER2 gene and receptor have an important role in normal cell growth and differentiation. When the HER2 gene has multiple copies, which is
referred to as gene amplification, it results in increased HER2 protein production. This causes cells to multiply in number and grow more rapidly than normal cells, contributing to the formation of cancer. HER2 gene amplification and protein
over-expression occurs in approximately 25% of women with breast cancer. The level of HER2 protein on tumors can be detected by IHC and is scored as 0, 1+, 2+ or 3+, where 3+ indicates the highest expression of HER2 positivity. Fluorescence in situ
hybridization (&#147;FISH&#148;) testing is a method used to determine the number of HER2 gene copies that are in a tumor cell. Breast cancer patients with HER2 gene amplification and protein over-expression have a more aggressive disease, greater
likelihood of recurrence, poorer prognosis, and decreased survival compared to patients with HER2-negative breast cancer. Currently, anti-HER2 therapies are only approved for treating approximately 25% of all breast cancer patients whose tumors
overexpress HER2 at the 3+ level, or if 2+, when accompanied by HER2 gene amplification. As illustrated in the figure below, this population of 25% of breast cancer patients represents 60.5% of the 42% of all patients who are HER2+. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g644794g74d12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to study several patient populations in which we believe margetuximab, because of its optimized
structure, has the potential for particular benefit. The first populations being tested include breast and gastroesophageal cancer, but there is also potential to explore other HER2-expressing cancers such as bladder, ovarian and colon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initially presented data from our Phase 1 clinical trial of margetuximab at ASCO in June 2013.
We continue to explore additional intermittent dosing cohorts and expect to complete this clinical trial in 2014. We are currently enrolling an exploratory Phase 2a clinical trial in patients with metastatic breast cancer whose tumors exhibit
expression of the HER2 protein at the 2+ level by IHC and lack evidence of HER2 gene amplification by FISH. We plan to initiate a Phase 3 clinical trial in patients with HER2+ gastroesophageal cancers with HER2 protein expression at the 3+ level by
IHC or 2+ level by IHC with documented gene amplification by FISH that have progressed after standard first and second-line therapy. We expect to begin enrollment in this clinical trial in the second half of 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current Treatments for HER2-expressing Solid Tumors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The management of breast cancer is largely based on the stage, grade, hormone receptor status and type, and includes surgery, radiation and
drug therapy. Cytotoxic chemotherapies are a mainstay of metastatic breast cancer treatment, irrespective of hormone and HER2 status. Patients who have no detectable cancer after surgery are often given additional drug treatment to prevent
recurrence. This is known as adjuvant therapy. Some patients receive treatment before surgery to shrink the tumor. This is known as neoadjuvant therapy. While anti-HER2 therapies have initially been tested in patients with metastatic cancer, often
as single agents, benefit has been shown in the much larger population of patients treated earlier in adjuvant and neoadjuvant settings. We expect that this paradigm will also be true for margetuximab, but in a larger population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The management of gastroesophageal cancer is based on radical surgical resection of the tumor, which when carried out at an early stage of
disease may be curative. When surgical resection of the tumor is not possible, or the tumor recurs or metastasizes, chemotherapeutic agents are utilized. The incidence of gastroesophageal cancer has been declining steadily since the 1930s, yet it
remains a major cause of cancer death in the United States and a greater problem in the rest of the world. Gastroesophageal cancer is the fourth most common cancer in the world (989,000 new cases diagnosed in 2008) and the second most common cause
of cancer-related death in the world. Advanced and metastatic cancers are treated with chemotherapy and radiation therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several drugs
directed at HER2 have been approved for the treatment of early and advanced stage breast cancer and advanced gastroesophageal cancer. Most patients treated with existing HER2 therapies, such as trastuzumab (Herceptin), pertuzumab (Perjeta),
lapatinib (Tykerb), and ado-trastuzumab emtansine (Kadcyla, also referred to as T-DM1), will either fail to respond or become resistant to continued treatment. In addition, existing HER2 therapies are not effective in the treatment of patients who
do not highly over-express HER2. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential Advantages of Margetuximab </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Margetuximab is an Fc-optimized, monoclonal antibody believed to mediate its therapeutic activity against HER2+ tumors by a combination of
mechanisms including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Modulation of the receptor signaling resulting in growth retardation or the induction of apoptosis, or cell death; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ADCC and improved binding to immune cells to enhance destruction of HER2+ tumor cells; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Presentation of antigens by cells such as macrophages that engulf the tumor cells, digest them, and display the tumor antigens to other cells of the immune system including T cells. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R mediated mechanisms play a critical part in the activity of several antibodies including
anti-HER2 antibodies. Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R sequences will differ among people and a single amino acid difference in an Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R can significantly alter an antibody&#146;s Fc
binding properties. Clinical data shows improved outcomes in metastatic breast cancer patients who have a higher binding form of an activating Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R, CD16A, in response to treatment with chemotherapy plus
trastuzumab. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows the difference in progression-free survival between patients treated with
trastuzumab who have the higher-binding form of CD16A and those who have the lower-binding form of CD16A. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g644794g63f08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Knowing that approximately 80% of subjects express the lower-binding
Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R, we specifically optimized the Fc domain of margetuximab to enhance binding to the lower-binding form of CD16A. We believe margetuximab will have greater activity than trastuzumab and may overcome
resistance in populations of patients whose tumors do not respond, or no longer respond, to trastuzumab. In addition, the optimized Fc domain of margetuximab imparts reduced binding to the inhibitory
Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R, CD32B, a feature expected to further enhance the activating properties of margetuximab. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have conducted <I>in vitro</I> and <I>in vivo</I> pre-clinical studies that support the superiority of margetuximab compared to
trastuzumab. In these pre-clinical models, margetuximab exhibits enhanced anti-tumor activity against HER2-expressing tumor cell lines in <I>in vitro</I> ADCC assays and in human tumor xenograft models in human CD16A+ transgenic mice. We have also
demonstrated superior effects of margetuximab over trastuzumab in <I>ex vivo</I> studies using patient samples from the Phase 1 clinical trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development of Margetuximab </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the pre-clinical laboratory studies conducted with margetuximab, we assumed that margetuximab would have clinical benefit in patients
with tumors not currently thought to be targets for trastuzumab therapy, including those whose tumors express the HER2 protein at less than 3+ levels by IHC and lack evidence of HER2 gene amplification by FISH. We also assumed that margetuximab
benefits would extend to patients bearing the lower-binding form of CD16A. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2a Metastatic Breast Cancer Study </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We submitted an IND in January 2010 for margetuximab for the treatment of HER2-positive carcinomas, including breast cancer. We are currently
enrolling a Phase 2a clinical trial to determine if margetuximab has sufficient activity in patients with metastatic breast cancer who are not currently considered candidates for trastuzumab therapy to further evaluate margetuximab in this patient
population. We are enrolling patients with metastatic breast cancer whose tumors exhibit expression of the HER2 protein at the 2+ level by IHC and lack evidence of HER2 gene amplification by FISH. This group of patients represents an unmet medical
need which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be addressed by margetuximab. Margetuximab will be administered as a 6 mg/kg intravenous (&#147;IV&#148;) solution weekly on Days 1, 8, and 15 of each 28-day cycle. If fewer than two partial
or complete responses are observed in the first 21 patients evaluable for response at the first tumor re-evaluation on day 22 of cycle 2 of treatment, no additional patients will be enrolled and the trial will end. If two or more responses are
observed at the first tumor re-evaluation on day 22 of cycle 2 of treatment, we will expand the clinical trial to include a total of 41 patients evaluable for response. If five or more partial or complete responses are observed in these 41 patients,
then we will consider margetuximab to have adequate activity in this patient population to justify additional clinical development. We are conducting this clinical trial at six sites in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anticipated Margetuximab Clinical Trials </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to file a separate IND for margetuximab for the treatment of patients with HER2+ gastroesophageal cancers with HER2 protein expression
at the 3+ level by IHC or 2+ level by IHC with documented gene amplification by FISH in the first quarter of 2014. We plan to commence a 425&nbsp;patient, randomized Phase 3 clinical trial to evaluate the addition of margetuximab to standard
cytotoxic chemotherapy (irinotecan or paclitaxel) in the third line treatment of patients with advanced gastroesophageal cancers which have progressed after standard frontline and second-line treatment of advanced disease. We have selected the
clinical research organization (&#147;CRO&#148;) and intend to commence patient recruitment in the second half of 2014. The primary analysis will compare the overall survival of patients randomized to chemotherapy plus placebo to the overall
survival of patients randomized to chemotherapy plus margetuximab. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Anticipated Phase 2 Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate conducting exploratory clinical trials in patients with other HER2 expressing malignancies, potentially including bladder,
ovarian, endometrial, and colon cancers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 1 Clinical Study Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 1 clinical trial is an open-label, multi-dose, single-arm, dose-escalation study conducted to define the safety profile and
pharmacokinetics of margetuximab and to begin to explore the antitumor activity of margetuximab in patients with refractory HER2+ tumors. We enrolled a total of 34 patients in the dose escalation (0.1 to 6.0 mg/kg) and expansion (6.0 mg/kg) phases
of the trial. This patient population was heavily pre-treated with prior therapies, including 19 patients with other prior anti-HER2 therapies. In the absence of dose limiting toxicity, an additional cohort of patients was treated at the top dose.
We expect to complete this clinical trial in 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the dose escalation and expansion segments of the Phase 1 clinical trial of
margetuximab, a dose of 6.0 mg/kg has been well-tolerated in patients with refractory HER2+ tumors who were treated weekly for four weeks. Approximately one-third of patients received additional cycles of margetuximab treatment. Using margetuximab
as a single agent, tumor response was observed even in patients who had failed prior therapies including other anti-HER2 treatment. Responses to date include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unconfirmed partial response in one patient with mucoepidermoid carcinoma of the salivary gland treated at 1.0 mg/kg; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">confirmed partial response in one patient with breast cancer treated at 3.0 mg/kg; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">confirmed partial response in one patient with breast cancer treated at 6.0 mg/kg; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">confirmed partial response in one patient with a gastroesophageal junction tumor treated at 6.0 mg/kg; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unconfirmed partial response in one patient with colorectal cancer at 6.0 mg/kg; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">four patients with times to progression exceeding five months. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are exploring
intermittent administration of margetuximab as a more convenient dosing regimen. In this portion of the Phase 1 clinical trial, a patient with breast cancer experienced a confirmed partial response at 10.0&nbsp;mg/kg (administered every three weeks)
with a time to progression currently exceeding five months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Evidence of activity was seen at doses as low as 0.1 mg/kg weekly, to which a patient with
metastatic breast cancer whose tumor had progressed after two prior anti-HER2 therapies (trastuzumab and ado-trastuzumab emtansine) experienced stability of disease and time to progression that exceeded nine months. The maximum percent reduction
(below baseline) or increase (above baseline) in the size of target tumors at any time from patients treated with different doses of margetuximab is shown below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g644794g19e20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most frequent adverse events observed in patients participating in the dose escalation portion of this
trial were infusion reactions, which we observed in approximately 27% of patients on the day of infusion. Most of these events were mild or moderate in severity. Institution of pre-medications has reduced the incidence and severity of
infusion-associated adverse events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We assessed the <I>ex vivo</I> ADCC response of peripheral blood mononuclear cells
(&#147;PBMCs&#148;) obtained from subjects in the dose escalation portion of this Phase 1 trial. Each patient sample was divided and exposed separately to margetuximab and trastuzumab. Margetuximab outperformed trastuzumab in <I>in vitro</I> ADCC
assays, reducing the dose required to achieve equivalent cell killing and increasing total cell killing. The concentration of drug required to achieve a half maximal effect (EC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB>) on ADCC was
much lower for margetuximab (mean 3.5 &plusmn; 1.0 ng/ml) than trastuzumab (mean 40.7 &plusmn; 17.1 ng/ml). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MGA271: Fc-Optimized Antibody for
B7-H3-Expressing Solid Tumors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MGA271 is a humanized, Fc enhanced, monoclonal antibody that targets B7-H3 expressing tumors and is intravenously administered in order to kill
tumor cells or inhibit their growth. We are developing MGA271 to treat multiple solid tumors such as melanoma, glioblastoma, prostate cancer, and breast cancer. We believe that targeting B7-H3 using MGA271 has significant potential to treat a
variety of solid tumors because it incorporates multiple complementary mechanisms of action in one molecule. These potentially include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Enhanced ADCC through Fc Optimization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Targeting of both CSLCs and tumor cells; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Opportunity to differentially target tumor vasculature and underlying supporting tissues; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Potential for enhanced anti-tumor immunity by blockade of T cell inhibition (inhibiting the inhibitor). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MGA271 has been engineered to have enhanced binding to CD16A. MGA271 also exhibits reduced binding to CD32B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initiated a Phase 1 clinical trial of MGA271 in patients with B7-H3 tumors in August 2011. We have completed the dose escalation portion of
this trial without exceeding a maximally tolerated dose. We commenced an expansion phase in the third quarter of 2013, in which we are enrolling patients and treating them at the highest dose tested during the dose escalation portion of the trial.
We expect to complete the first three dose expansion cohorts of this clinical trial by the end of 2014. We plan to initiate additional dose expansion cohorts using MGA271 as monotherapy in other tumor types in 2014, as well as combining MGA271 with
other therapies for certain tumor types. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Role of B7 Family of Immune Regulators, Including B7-H3, in Cancer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The B7 family of cell surface molecules consists of structurally related protein ligands that bind to receptors on lymphocytes and regulate
immune responses. B7 homolog 3 (&#147;B7-H3&#148;) is a novel member of the B7 family of immune regulatory molecules. This family of molecules is an area of interest across the pharmaceutical industry, and is being explored by companies including
AstraZeneca PLC (&#147;AstraZeneca&#148;), Bristol-Myers Squibb Co. (&#147;Bristol-Myers&#148;), GlaxoSmithKline plc (&#147;GSK&#148;), Merck&nbsp;&amp; Co. (&#147;Merck&#148; or &#147;Merck KGaA&#148;) and Roche. The chart below describes our
understanding of various B7 immune regulator targets and current marketed products and clinical stage product candidates addressing such targets. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>B7 Immune Regulator Family </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:81.90pt; font-size:8pt; font-family:Times New Roman"><B>Antigen-Presenting&nbsp;Cell</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>T Cell</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Function</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Product or Product Candidates</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CD80 (B7-1) or CD86 (B7-2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CTLA4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Inhibitory</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ipilimumab (marketed by Bristol-Myers)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Anti-CTLA4 (AstraZeneca, Phase 2)</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">CD80&nbsp;(B7-1)&nbsp;or&nbsp;CD86&nbsp;(B7-2)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CD28</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Activating</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PD-L1 (B7-H1) or PD-L2 (B7-DC)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">PD1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Inhibitory</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anti-PD1 (Merck, Phase 3)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anti-PD1
(Bristol-Myers, Phase 3)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anti-PD-L1 (Bristol-Myers, Phase 2)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anti-PD-L1 (Roche, Phase 2)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PD-L2/Fc fusion (GSK/AstraZeneca,
Phase 1)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anti-PD1 (AstraZeneca, Phase 1)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Anti-PD-L1 (Merck
KGaA, Phase 1)</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">B7RP1 (B7-H2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">ICOS</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Activating</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AMG 557 (Amgen/AstraZeneca, Phase&nbsp;1)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">B7-H3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Unknown</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Inhibitory</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">MGA271 (MacroGenics, Phase 1)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">B7-H4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Unknown</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Inhibitory</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">B7-H5 (VISTA)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Unknown</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Inhibitory</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">B7-H6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">NKp30</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Activating</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our own analysis of fixed tumor microarrays representing more than 700 samples across various tumor types
including glioblastoma, thyroid, gastroesophageal, breast, pancreas, prostate, melanoma and ovarian cancers, we saw B7-H3 expression in approximately 70&#151;99% of tumor samples, with high expression (2+ or greater by IHC) in most of these tumor
types. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B7-H3 inhibits T cell activation and cytokine production. Other examples of inhibitors of T cell activation include the immune
check-point regulators PD1 and CTLA4. Anti-PD1 and anti-CTLA4 (e.g., ipilimumab) antibodies have shown therapeutic effects in patients with melanoma, renal cell carcinoma, and non-small-cell lung cancer and are being tested in individuals with
several other types of cancers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pre-Clinical Development of MGA271 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated the ability of MGA271 to mediate ADCC activity across multiple cancer types expressing varying levels of B7-H3 as determined
by flow cytometry. The cancer types tested included melanoma, lung cancer, prostate cancer, breast cancer, bladder cancer, and renal cancer cell lines. MGA271 mediated ADCC activity against all tumor lines that express B7-H3 at detectable levels.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MGA271 exhibited anti-tumor activity in mouse models when administered approximately one week after tumor cell implantation (as shown
below), or after tumors were allowed to become fully established (approximately three weeks after implantation when tumors were approximately 300 mm<SUP STYLE="font-size:85%; vertical-align:top">3</SUP> in volume). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Anti-Tumor Efficacy of MGA271 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>in a Pre-clinical Model of Renal Cell Carcinoma </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g644794g30v39.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cells from a renal cell carcinoma tumor line were implanted subcutaneously in immunodeficient mice that expressed the
lower-binding form of human CD16A. MGA271 was administered intravenously weekly at the indicated dose levels as shown by arrows above. All dosages of MGA271, including 0.1 mg/kg, inhibited tumor growth when compared to both control groups, vehicle
or lgG. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A repeat dose Good Laboratory Practice (&#147;GLP&#148;) toxicology study was conducted in cynomolgus monkeys to determine
the potential toxicity of MGA271. MGA271 was well tolerated when administered by IV infusion at four weekly doses of up to150 mg/kg. The no observed adverse effect level was considered to be 150&nbsp;mg/kg. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development of MGA271 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
expect to complete the first three dose expansion cohorts of a Phase 1 clinical trial by the end of 2014. We plan to initiate additional expansion cohorts using MGA271 as monotherapy in other tumor types in 2014, as well as combining MGA271 with
other therapies for certain tumor types. We submitted an IND in March 2011 for MGA271 for the treatment of patients with refractory B7-H3-expressing tumors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 1 Clinical Trial </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 1 trial is an open-label, multi-dose, single-arm, multi-center, dose-escalation clinical trial. This trial includes patients with
B7-H3-expressing tumors, such as prostate cancer, pancreatic cancer, melanoma and ovarian cancer, and tumors whose vasculature exhibits B7-H3 expression, such as glioblastoma, renal cell carcinoma and ovarian cancer. The clinical trial began with a
dose escalation segment in which patients were treated with increasing weekly doses of MGA271 from 0.01 mg/kg up to 15 mg/kg. We have not seen any dose limiting toxicity, and we initiated an expansion phase in the third quarter of 2013 at a dose of
15 mg/kg. During the expansion phase, we are recruiting an additional 15 patients to each of three cohorts that represent a distinct patient population determined by histology: 1) patients with melanoma, 2) patients with prostate cancer and 3)
patients with any B7-H3 positive tumor other than melanoma or prostate cancer with the limitation of a maximum of five patients with any single histologic type such as colorectal adenocarcinoma or histologic subgroup such as sarcoma. In addition,
Servier has indicated that it intends to evaluate MGA271 in up to 75&nbsp;additional cancer patients representing additional types of cancers beginning in the first quarter of 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enrolled a total of 26 patients in the trial through the dose escalation portion, with 15 different types of tumors. Ten patients received
additional cycles of MGA271 treatment and all have had stable disease at the first tumor re-assessment. The most frequent adverse events in the trial were mild or moderate infusion reactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because anti-cancer monoclonal antibodies are target-specific, the presence of the target on tumor cells is usually required for the desired
biological effect of the antibody. An IHC-based companion diagnostic for MGA271 would detect the presence of B7-H3 on the cellular membrane of tumor cells. A positive result detecting B7-H3 on the cellular surface is currently required for trial
eligibility, and we expect it will be required for identification of appropriate candidates for MGA271 treatment should the product candidate be approved. We are working with two third-party vendors for the development of the companion diagnostic,
and we plan to contract with a vendor for future commercialization based on the results. We plan to have a validated companion diagnostic ready for incorporation into potential Phase 3 trials and are working with a collaborator to develop it. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MGD006: DART-Based Molecule for Acute Myeloid Leukemia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MGD006 is a humanized
DART molecule that recognizes both CD123 and CD3. We are developing MGD006 for the treatment of hematologic cancers. The primary mechanism of action of MGD006 is its ability to redirect T cells which express CD3 to kill CD123 expressing cells, such
as leukemic cells. In February 2014, we announced that an IND application for MGD006 cleared the FDA&#146;s 30-day review period. We plan to initiate a Phase 1 clinical trial of MGD006 in patients with relapsed or refractory acute myeloid leukemia
(&#147;AML&#148;) or in patients with untreated AML who are not candidates for standard induction chemotherapy in the second quarter of 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Role
of CD123 in Acute Myeloid Leukemia </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CD123 has been reported to be overexpressed on malignant cells in a wide range of hematologic
malignancies including AML and myelodysplastic syndrome (&#147;MDS&#148;). Overexpression of CD123 is associated with a poorer prognosis in AML. AML and MDS are thought to arise in and be perpetuated by a small population of leukemic stem cells
(&#147;LSCs&#148;), which generally resist conventional chemotherapeutic agents. LSCs are characterized by high levels of CD123 expression, which is not present in the corresponding normal hematopoietic stem cell population in normal human bone
marrow. CD123 is also expressed by plasmacytoid dendritic cells (&#147;pDCs&#148;) basophils, endothelial cells and, to a lesser extent, monocytes and eosinophils. The anti-CD123 component of MGD006 is based on a humanized version of 7G3, a mouse
monoclonal antibody directed against CD123. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential Advantages of MGD006 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a targeted therapy for CD123-expressing cells, we believe that MGD006 will have fewer side effects than conventional chemotherapeutic agents
which broadly target rapidly dividing cells including cancer cells, normal hematopoietic stem cells and certain immune cells such as activated lymphocytes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because CD123 is expressed on the LSCs that perpetuate this disease, MGD006 will be targeting the source of the disease, and
potentially deliver more durable remissions. This would represent an advance in AML therapy, because the LSCs that sustain this disease are generally resistant to the chemotherapy which is the standard approach to disease treatment. The resistance
of LSCs to chemotherapy may be due to the fact that they are a rare, relatively dormant, cell type within the leukemic cell population and, therefore, are less susceptible to the primary mechanism of action of chemotherapeutic agents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pre-clinical Development of MGD006 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2013, one of our academic investigators presented data from a pre-clinical study at the 55th&nbsp;Annual Meeting of the American
Society of Hematology. The pre-clinical study investigated the ability of MGD006 to redirect T cells against CD123-positive AML blasts. Investigators demonstrated that MGD006 binds to both human CD3 and CD123 to mediate target-effector cell
aggregation, T-cell activation and proliferation. MGD006 induced a dose-dependent reduction of primary AML blast survival <I>in vitro </I>and <I>in vivo</I>. Notably, a short course of treatment with MGD006 in mice engrafted with an AML patient
sample induced a greater than 97% elimination of AML blasts from the peripheral blood and significant clearing from the spleen and bone marrow 6 weeks after AML cell infusion. The results of this study provide a strong rationale for the clinical
development of MGD006 as a novel molecule for the treatment of patients with AML. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our own <I>in vitro</I> experiments, we have
demonstrated that MGD006 is able to mediate T&nbsp;cell killing of CD123-expressing cells. In an <I>in vitro</I> model of T cell-mediated killing of AML cells, addition of MGD006 led to destruction of AML cells derived from leukemia patients. Three
leukemia cell lines expressing CD123 were exposed to MGD006 or a control DART protein in the presence of T cells. Dose-dependent increases in cell killing were observed following treatment with MGD006. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the chart below, primary AML PBMC samples were incubated with a phosphate buffered saline
(&#147;PBS&#148;) control, a DART protein control or MGD006. Treatment with MGD006 resulted in a dose-dependent decrease in leukemic blast cell number counts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AML Blasts </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g644794g37v45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We performed pilot toxicology studies in cynomolgus monkeys. Complete depletion of CD123-positive cells, an
indication of activity in healthy animals, occurred at doses as low as 10 ng/kg/day. Importantly, this effect was reversible as pDCs were observed in peripheral blood a few weeks following cessation of dosing. No significant infusion reactions were
observed at the lowest starting doses studied, including the pharmacologically active dose levels (10&#151;30 ng/kg/day). Administration of MGD006 at higher doses was associated with acute infusion reactions, which typically decreased or disappeared
with subsequent dosing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MGD007: DART-Based Molecule for Gastrointestinal Cancers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MGD007 is a DART protein
in which the first specificity is for the glycoprotein gpA33 and the second specificity is for CD3. MGD007 also contains an Fc domain which provides for an extended serum half-life compared to basic DARTs. gpA33 was identified through immunizations
using our proprietary CSLC lines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing MGD007 as a potential therapeutic agent for the treatment of colorectal cancer. Other
tumors of the gastrointestinal tract, such as pancreatic and gastroesophageal cancers, may also be potential indications for development. In a survey of normal tissues examined, the gpA33 antigen was expressed almost exclusively in the intestinal
epithelium. It was present in more than&nbsp;95% of human colon cancers, and in approximately 50% of gastroesophageal and pancreatic cancers. Studies by others with a radiolabeled monoclonal antibody against gpA33 demonstrated preferential binding
to tumors over normal colonic mucosa. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have conducted pre-clinical <I>in vitro</I> and <I>in&nbsp;vivo</I> proof-of-concept studies
with MGD007 or a basic DART form of MGD007 without the Fc domain. In addition, we have completed the <I>in vivo</I> portion of a GLP toxicology study in cynomolgus monkeys. We are planning to submit an IND in 2014 and commence a Phase 1 clinical
trial for MGD007 in the second half of 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pre-clinical Development of MGD007 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of <I>in vivo</I> experiments shown below demonstrate that a gpA33 x CD3 DART is able to mediate T&nbsp;cell killing of
gpA33-expressing cancer cells: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g644794g54r32.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cells from a colorectal cancer line and activated human T cells were implanted subcutaneously in immunodeficient mice. A
gpA33 x CD3 DART was administered intravenously daily for four days at the time of tumor implantation. Inhibition of tumor growth was observed at all dose levels tested when compared to animals treated with a control. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Oncology DART-Based Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have an active discovery effort and we have generated multiple product candidates, which are in various stages of research and pre-clinical
development. Several of these undisclosed product candidates are based on our DART technology, and are directed toward various oncology targets, both novel and validated. We intend to advance at least two of these programs to IND submission and
commence Phase 1 clinical studies in 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MGD010: DART-Based Molecule for Autoimmune Diseases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Autoimmune diseases including rheumatoid arthritis (&#147;RA&#148;), Crohn&#146;s disease, systemic lupus erythematosis (&#147;SLE&#148;), and
multiple sclerosis (&#147;MS&#148;), collectively affect more than 20&nbsp;million people in the United States. Autoimmune disease involves self-tissue destruction by T cells and antibodies due to lack of self-tolerance. Anti-inflammatory therapies,
such as TNF (tumor necrosis factor) inhibitors, have been able to improve diseases like RA; however, it has become increasingly known that, in addition to T cells, B cells play an important role in many common autoimmune and allergic disorders by
initiating and amplifying the pathological disease processes. Current B cell targeted therapies either cause depletion of B cells, thus limiting their applicability due to the potential for infections (e.g., rituximab, or <I>Rituxan</I>), or exhibit
a delayed onset of action and limited efficacy across patient populations (e.g., belimumab, or <I>Benlysta</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To address limitations
of existing B cell targeted therapies, MacroGenics has developed a novel CD32B x CD79B DART, called MGD010. In pre-clinical studies, this DART modulates the function of human B cells without B cell depletion. In normal conditions, B cells utilize
CD32B as one of the key negative regulators to ensure that tolerance to self is maintained and autoimmune disease does not occur. MGD010 exploits this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
mechanism and triggers this inhibitory &#147;immune checkpoint&#148; loop. We believe this molecule preferentially blocks those B cells that are activated to produce the pathogenic antibodies
that promote the autoimmune process. Studies in SLE patient B cells and humanized mouse models have demonstrated that MGD010 can block B cell activation in the absence of B cell depletion. To advance this program to the clinic, we recently performed
studies in a non-human primate model with MGD010 demonstrating a favorable safety profile and pharmacological effects on targeted B cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the chart below, treatment with MGD010 prolongs survival compared to a PBS control or a single dose of rituximab in a mouse model of
graft-versus-host disease. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MGD010 in a Chronic Graft-versus-Host Disease </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Transplantation) Mouse Model </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g644794g35e13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Immunodeficient mice administered human PBMCs by injection were treated intravenously either with MGD010 at 5.0 or 10.0
mg/kg or PBS control every four days (9 total doses) or with rituximab at 5.0 mg/kg for one dose. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Teplizumab: Fc-Modified Antibody for Type 1
Diabetes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teplizumab is a humanized, anti-CD3 monoclonal antibody being developed for the treatment of Type 1 Diabetes (&#147;T1D&#148;). Teplizumab has
been engineered to alter the function of the T cells that mediate the destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab potentially represents an advance in the treatment of T1D by addressing the underlying
disorder, rather than merely using insulin replacement therapy. In 2007, we entered into a collaboration with Eli Lilly. During the clinical development of teplizumab, Eli Lilly provided financial, manufacturing, and commercial support to us while
we conducted our Phase 3 clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2011, we published the results of Prot&eacute;g&eacute;, a Phase 3 clinical study of
teplizumab in T1D, in <I>The Lancet</I> and follow-up data in <I>Diabetes</I> in 2013. The primary clinical endpoint of this trial, a composite of glycated hemoglobin (&#147;HbA1c&#148;), and insulin usage, was not met. HbA1c is a form of hemoglobin
that reflects average plasma glucose concentration over prolonged periods of time. When T1D is poorly controlled, the glucose and consequently, HbA1c levels rise. Insulin use was measured as units used per day. Subjects were required to have a low
HbA1c level (&lt;6.5%) and low daily insulin usage (&lt;0.5 units per day). Similar numbers of patients in the 14 day teplizumab regimen and placebo (insulin only) achieved this endpoint. Although this trial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
did not meet its primary clinical endpoint, an exploratory, post-hoc analysis suggests that teplizumab, when used in a full dose regimen, may preserve insulin production by beta cells in the
pancreas, as measured by C-peptide, and increase the percentage of patients requiring very low doses of insulin compared to those on placebo. Preservation of insulin production as measured by C-peptide, relative to standard of care, is now
recognized as an acceptable primary endpoint by the FDA. The findings suggest that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in beta cell function (measured by C-peptide)
and preservation of glycemic control at reduced doses of insulin, particularly in children, if intervention occurs soon after diagnosis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teplizumab is currently being evaluated in a Phase 2 clinical trial, called At-Risk, for the prevention or delay of onset of T1D in patients
determined to be at very high risk for developing the disease. This clinical trial is being sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (&#147;NIDDK&#148;). In 2011, Eli Lilly terminated its collaboration with
us to develop teplizumab and pursuant to the terms of the agreement, we reacquired the commercial rights to teplizumab. We are actively seeking a collaborator for further development of teplizumab. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The At-Risk study is being conducted under an IND filed and sponsored by MacroGenics, pursuant to IND 102,629 filed in December 2009. The
clinical study is being conducted by NIDDK at TrialNet clinical sites. NIDDK, in conjunction with TrialNet, prepared the clinical protocol and is responsible for training and monitoring the clinical sites. MacroGenics officially transferred these
sponsor responsibilities to NIDDK in its initial IND submission. Under FDA regulations, MacroGenics remains responsible for submitting the appropriate documents to the IND, including but not limited to, IND Annual Reports, expedited reports, revised
clinical protocols provided by NIDDK, and new clinical investigator information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaborations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into several strategic collaborations for our therapeutic programs. Our current therapeutic collaborations have provided us
with approximately $129.9 million in non-equity funding through December&nbsp;31, 2013. Subsequent to December&nbsp;31, 2013, we earned an additional $20.0 million under the Servier DART agreement as described below. Key terms of our collaborations
are summarized below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Servier MGA271 Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Overview</I>. In November 2011, we entered into a collaboration agreement with Servier under which we granted Servier an option to obtain an
exclusive license to develop and commercialize the Fc engineered antibody we designated as MGA271 and certain other Fc engineered antibodies that also bind the B7-H3 receptor, collectively referred to as the MGA271 licensed products, in all
countries other than the United States, Canada, Mexico, Japan, South Korea and India. We received a $20.0 million option grant fee and a $10.0 million milestone payment upon dosing the first patient in the expansion cohort of our Phase 1 clinical
trial of MGA271, and may be eligible to receive up to approximately $415.0 million in license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises the option, obtains regulatory approval for and
successfully commercializes an MGA271 licensed product. In addition to these milestones, we and Servier will share Phase 2 and Phase 3 development costs. Under the agreement we are also eligible to receive royalties on the net sales of MGA271
licensed products at percentages ranging from the low double digits to the mid-teens, subject to reductions in specified circumstances. Under specific circumstances, Servier may defer payment of certain milestone payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Research Plan. </I>Under the agreement, we are responsible for conducting research according to an agreed upon research plan during a
specified research term. The activities under the research plan include the generation of data by us that the parties have agreed will be included in a data package, or MGA271 data package. We will continue conducting the current Phase 1 trial of
MGA271 under the research plan. Under the agreement, Servier may conduct separate development and clinical activities under the research plan, subject to our approval. The<I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
</I>term of the research plan begins on the effective date of the agreement and ends on the earlier of November&nbsp;24, 2015 or the expiration of Servier&#146;s option under the agreement. In
general, during the research term, each party is responsible for the internal and external costs it incurs to conduct its activities under the research plan.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Manufacturing. </I>Under the agreement we are obligated to supply cGMP produced MGA271 licensed products to supply Servier&#146;s clinical
development needs for its Phase 1 and first two Phase 2 clinical trials according to a clinical supply agreement negotiated between the parties. Servier is obligated to pay for such supply of MGA271 licensed product under the clinical supply
agreement at our fully burdened manufacturing cost. Prior to exercising its option, we can supply clinical material for Servier&#146;s additional needs at our discretion. If Servier exercises its option, upon its request, we are obligated to enter
into negotiations to execute a commercial supply agreement for MGA271 licensed product.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Option</I>. Generally, Servier may
exercise its option at any time after the effective date of the agreement until ninety days after Servier&#146;s receipt of the MGA271 data package which shall include results from completed expansion cohorts from the Phase 1 clinical trial. In the
event Servier exercises the option, Servier must pay a license grant fee, which we estimate to be $30.0 million, based on the number of different indications represented within the patient population in a planned expansion cohort in our Phase 1
clinical trial of MGA271. If Servier elects not to exercise the option, it will lose all rights to develop and commercialize MGA271 licensed products and we will be entitled to develop and commercialize MGA271 licensed products throughout the world
exclusively or with a third party or parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>License/Exclusivity</I>. If Servier exercises the option it will receive an exclusive
license to develop and commercialize MGA271 licensed products in all countries of the world other than the United States, Canada, Mexico, Japan, South Korea and India. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to Servier&#146;s exclusive right to develop and commercialize MGA271 licensed products under the agreement, there are additional
obligations regarding exclusivity and noncompetition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to these provisions, in the event that we seek to grant rights to a
third party to develop and/or commercialize certain DARTs that bind the B7-H3 receptor outside the United States, Servier has a right of first negotiation to obtain such rights. If Servier declines to enter negotiations or the parties fail to
execute an agreement granting Servier such rights within a specified time period, subject to specified exceptions, we will have the right to enter negotiations with a third party for the same rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Term and Termination</I>.&nbsp;If Servier does not exercise its&#146; option, the agreement terminates upon the expiration of the option.
If Servier exercises the option, the agreement will terminate in its entirety upon the later of the expiration of the last-expiring patent related to an MGA271 licensed product, the regulatory based exclusivity period or 12 years after the first
commercial sale of any MGA271 licensed product. The agreement contains customary termination rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Servier DART Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Overview</I>. In September 2012, we entered into a second agreement with Servier and granted it options to obtain three separate exclusive
licenses to develop and commercialize DART-based molecules, consisting of those designated by us as MGD006 and MGD007, as well as a third DART molecule, collectively referred to as the DART-licensed products, in all countries other than the United
States, Canada, Mexico, Japan, South Korea and India. Under the terms of the agreement, we received a $20.0 million option grant fee. In February 2014, Servier exercised its option to develop and commercialize MGD006 in its territories for which we
received a $15.0 million license grant payment. In addition, we received a $5.0 million milestone payment from Servier in connection with an IND application for MGD006 clearing the FDA&#146;s 30-day review period. We may be eligible to receive up to
approximately $1 billion in additional license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises its remaining two options and successfully develops, obtains
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory approval for and commercializes a product under each license, including $5.0 million upon IND acceptance for each of MGD007 and a third DART molecule. In addition to these milestones,
we and Servier will share Phase 2 and Phase 3 development costs. Under the agreement we are also eligible to receive royalties on the net sales of DART licensed products at percentages ranging from the low double digits to the mid-teens, subject to
reductions in specified circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Research Programs</I>. Under the agreement, we are responsible for conducting research
according to an agreed upon research plan for each option target during the specified research term. Each research plan and its activities are considered a research program. The activities under each research plan include the generation of data by
us that the parties have agreed that will be included in a data package, or the Servier DART data package. With our consent, Servier may conduct separate development and clinical activities under a research plan. The research term for each research
program begins on the effective date of the agreement and ends on the earlier of September&nbsp;19, 2016 or the expiration of the applicable option. In general, during each research term, each party is responsible for the internal and external costs
it incurs to conduct its activities under that research plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Manufacturing</I>. Under the agreement we are obligated to negotiate a
clinical supply agreement with Servier regarding the supply of cGMP produced material to supply Servier&#146;s clinical development needs for its Phase 1 and first two Phase 2 clinical trials for each DART licensed product. Servier pays for such
supply of each DART licensed product under each clinical supply agreement at our fully burdened manufacturing cost. Prior to exercising one of its options, we can supply clinical material for Servier&#146;s additional needs at our discretion. If
Servier exercises an option, then upon Servier&#146;s request, we are obligated to enter negotiations to execute a commercial supply agreement for DART licensed products subject to that option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Option</I>. Under the terms of the agreement, each option may be exercised by Servier within ninety days after Servier&#146;s receipt of
the applicable Servier DART data package. In the event Servier exercises an option, Servier must pay a specified license grant fee for exercising that option. The respective license grant fees are $15.0 million for the MGD006 option, which we
received in February 2014, and additional amounts related to MGD007, and a remaining DART molecule, which become exercisable after a significant portion of the Phase 1 trials for each of these programs is completed. If Servier elects not to exercise
an option, it will lose all rights to develop and commercialize DARTs that bind such option target and we will be entitled to develop and commercialize DARTs that bind the former option target throughout the world exclusively or with a third party
or parties, subject to Servier&#146;s right of first negotiation, as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Licenses/Exclusivity.</I> If Servier exercises
an option it will receive an exclusive license to develop and commercialize DARTs that bind to the option target for that option, and pharmaceutical products that comprise or contain such DARTs, in all countries of the world other than the United
States, Canada, Mexico, Japan, South Korea and India. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to Servier&#146;s exclusive right to develop and commercialize DARTs
under each license, under the agreement there are additional obligations regarding exclusivity and noncompetition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to these
provisions, in the event that we seek to enter into a transaction under which we would grant rights to a third party to develop and/or commercialize certain product candidates in Servier&#146;s territory that bind an option target in exchange for
certain consideration, Servier has a right of first negotiation to obtain such rights. If Servier declines to enter negotiations or the parties fail to execute an agreement granting Servier such rights within a specified time period, we will have
the right, subject to specified exceptions, to enter negotiations with a third party for the same rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Term and Termination.</I> If
Servier does not exercise any option, the agreement terminates upon the expiration of the last to expire option. If Servier exercises an option, the agreement will terminate in its entirety with respect to such DART licensed product upon the later
of the expiration of the last-expiring patent related to a DART licensed product, the regulatory based exclusivity period or 12 years after the first commercial sale of a DART licensed product. The agreement contains customary termination rights.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gilead </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Overview</I><B>.</B> In January 2013, we entered into an agreement with Gilead for (i)&nbsp;the research, development, manufacture and
commercialization of DARTs that bind to a first pair of specified targets; (ii)&nbsp;an exclusive option for an exclusive license to research, develop, manufacture and commercialize DARTs that bind to a second pair of specified targets in North
America, the European Union, Norway, Iceland, Turkey, Australia and New Zealand; and (iii)&nbsp;separate exclusive options for worldwide exclusive licenses to research, develop, manufacture and commercialize DARTs that bind to third and fourth pairs
of targets to be subsequently identified by Gilead and accepted by us within a specified time period after the effective date of the agreement, which we collectively refer to as the Gilead licensed products. The time period for Gilead&#146;s
exercise of the option to the second target pair has expired. At present, Gilead retains a license to one and options to two of the original four programs. Gilead has exclusive worldwide rights to each of these remaining programs. We received an
initial $7.5 million license grant fee for granting Gilead a license to the first target pair, and are eligible to receive an additional $7.5 million in grant fees for each of the remaining two DART-based molecules if they are selected by Gilead, up
to an additional $20 to $25 million in pre-clinical milestones across each of the three remaining DART programs and up to $240 to $250 million per remaining program in additional clinical, regulatory and sales milestones payments if Gilead exercises
both remaining options and achieves all of the requisite milestones under each option and license. Under the agreement, we are also eligible to receive tiered royalties on the net sales of Gilead licensed products at percentages ranging from the
high-single digits to the low double digit, but less than teen royalties subject to reductions in specified circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Research
Programs.</I> During specified research terms, we are responsible for conducting research according to an agreed upon research plan for each pair of targets for which Gilead exercises its option. Each research plan and its activities are considered
a research program. Upon approval by the joint research committee, Gilead may conduct separate development and clinical activities under a research plan. The term of the research plan for the first target pair has already begun. The research terms
of the research plans for the third and fourth target pairs can begin only after Gilead&#146;s exercise of the options for such target pairs. The term for Gilead&#146;s exercise of the option to for the second target pair has expired. Gilead has
fixed time periods to exercise its options for the third and fourth target pairs and we may decline to accept Gilead&#146;s selection of the third and fourth target pairs under specified circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During each research term, Gilead will reimburse us for all internal and external costs we incur to conduct our assigned activities under that
research plan, subject to specified limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Licenses.</I> Under the agreement, we granted Gilead an exclusive worldwide license
to research, develop, manufacture and commercialize DARTs that bind to the first pair of specified targets. Upon initiation of each of the research terms for the third and fourth target pairs we will grant Gilead a worldwide exclusive license to
research, develop, manufacture and commercialize DARTs that bind to the corresponding target pair. Gilead did not exercise its option with respect to the second target pair. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pre-clinical Milestone</I>. Notice by Gilead to pay the pre-clinical milestone for each target pair category must be provided to us within
specified time periods. Upon providing notice to pay a pre-clinical milestone for a target pair category, Gilead will become responsible for all research, development and commercialization activities with respect to licensed products within such
target pair category in Gilead&#146;s territory for such target pair license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Licenses.</I> Under the agreement, we granted Gilead an
exclusive worldwide license to research, develop, manufacture and commercialize DARTs that bind to the first pair of specified targets. Upon initiation of each of the research terms for the third and fourth target pairs we will grant Gilead a
worldwide exclusive license to research, develop, manufacture and commercialize DARTs that bind to the corresponding target pair. Gilead did not exercise its option with respect to the second target pair. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pre-clinical Milestone</I>. Notice by Gilead to pay the pre-clinical milestone for each target pair category must be provided to us within
specified time periods. Upon providing notice to pay a pre-clinical milestone for a target </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pair category, Gilead will become responsible for all research, development and commercialization activities with respect to licensed products within such target pair category in Gilead&#146;s
territory for such target pair license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exclusivity</I>. Subject to specified exceptions, during the term of the agreement, other than
with respect to the research and development activities pursuant to the agreement, we may not, directly or indirectly, research, develop, manufacture or commercialize a product that binds to both targets from any target pair category covered by the
agreement in a country where Gilead has been granted a license for such target pair. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Term and Termination.</I> The agreement will
terminate in its entirety upon the later of the expiration of the last-expiring patent related to a Gilead licensed product, the regulatory based exclusivity period or 12 years after the first commercial sale of a Gilead licensed product. Gilead has
the right to terminate the agreement at any time with respect to one or more selected target pairs or in its entirety, upon prior written notice to us. The agreement contains customary termination rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Boehringer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Overview.</I> In
October 2010 we entered into a collaboration and license agreement with Boehringer to discover, develop and commercialize up to ten DART-based molecules which span multiple therapeutic areas. Under the terms of the agreement, we granted Boehringer
an exclusive, worldwide, royalty-bearing, license under our intellectual property to research, develop, and market DARTs generated under the agreement (the Boehringer licensed products) throughout the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, we received an upfront payment of $15.0 million. We subsequently received three annual maintenance payments including one
in the fourth quarter of 2013. Also, in the fourth quarter of 2013, Boehringer&#146;s selection of a development candidate triggered a $5.0 million milestone payment to us under the agreement. We have the potential to earn development, regulatory
and sales milestone payments that can reach up to approximately $210.0 million for each of the DART programs under this agreement in the case of full commercial success of multiple DART products. Boehringer also provides funding for our internal and
external research costs and is required to pay us mid-single digit royalties, on a licensed product-by-licensed product basis, on worldwide net sales, subject to reductions in specified circumstances. We have the option to co-promote certain DART
products in the United States and may elect to co-fund Phase 3 clinical development in exchange for an increased royalty rate on net sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Research.</I> Under the agreement, Boehringer is entitled to select up to ten pairs of targets for which we would generate DARTs that bind
to such targets. Several of the targets were identified in the agreement. Subsequent target pairs are selected according to a process which permits us to decline to accept such target pairs under specified circumstances. During the research term of
the agreement, we are responsible for generating pre-clinical DART candidates that bind the accepted target pairs and generating data according to specified criteria which will be presented to Boehringer as a data package. If Boehringer accepts a
pre-clinical DART candidate it will be responsible for subsequent development and commercialization of such pre-clinical DART candidate. We have the right to co-fund a portion of the Phase 3 clinical development in exchange for an increased royalty
rate. We also have the right to co-promote up to two DART products that are developed under the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Equity Purchase.</I>
Boehringer purchased $10.0 million of our Series D-2 preferred stock in January 2011. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exclusivity</I>. Subject to specified
exceptions, during the term of the agreement, other than with respect to Boehringer licensed products, we agreed not to research, develop or commercialize any product using our DART platform that is directed to a target covered under the agreement.
Subject to specified exceptions, we further agreed not to grant any third party rights to research, develop or commercialize any product using our DART platform that is directed to a specified number of specific targets identified in the agreement,
until a specified time period or the date on which neither of the identified targets has been selected as a target subject to development and commercialization under the agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Term and Termination.</I> The agreement will terminate in its entirety upon the later of the
expiration of the last-expiring patent related to a Boehringer licensed product, or 12 years after the first commercial sale of a Boehringer licensed product. Boehringer has the right to terminate the agreement at any time with respect to one or
more selected target pairs or in its entirety, upon prior written notice to us. However, it must maintain research efforts during a specified time period of the agreement. The agreement may also be terminated by either Boehringer or us in the event
of an uncured material breach by the other party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pfizer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Overview.</I> In October 2010, we entered into a research collaboration and license agreement with Pfizer. Under the agreement, we granted
Pfizer a non-exclusive worldwide, royalty-bearing license and received upfront and milestone payments and funding for our internal and external research costs under the agreement. Under the terms of the agreement, we received a non-refundable,
non-creditable $5.0 million upfront fee. In addition, we are eligible to receive up to approximately $210.0 million per Pfizer DART molecule, as defined in the agreement, in technical, development and sales milestone payments if specified net sales
thresholds are reached. We are also entitled to receive royalties from Pfizer at percentages ranging from the mid-single digits to the low-teens on net sales of any Pfizer DART. Under this collaboration, one DART program is currently being pursued
and we completed our research obligations under this program in January 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Research.</I> Under the agreement, we are obligated to
construct Pfizer DARTs that bind to a first and second target identified in the agreement that are each expressed on cancer cells. During the research term of the agreement, which expired in January 2014, we conducted pre-clinical development of the
Pfizer DARTs in collaboration with Pfizer according to an agreed upon research plan. Under certain circumstances, Pfizer had the right to substitute the second target during specified periods. Pfizer exercised those rights at various times during
the specified periods which have now expired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Product Development.</I> Upon expiration of the research term in January 2014, Pfizer
will use commercially reasonable efforts to develop and obtain regulatory approval for each Pfizer DART in both the United States and other specified countries. In addition, Pfizer will use commercially reasonable efforts to commercialize a Pfizer
DART in each country where Pfizer has received regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Commercialization.</I> Under the Agreement, Pfizer has sole
responsibility and authority for commercialization of Pfizer DARTs at its sole expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Manufacturing.</I> Pfizer has the exclusive
right to manufacture Pfizer DARTs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>License.</I> Under the Agreement we granted Pfizer an exclusive, worldwide license to use, develop,
manufacture, and commercialize Pfizer DARTs. The license includes the right to sublicense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exclusivity</I>. Subject to specified
exceptions, until October&nbsp;3, 2015, we agreed not to research, develop, commercialize, manufacture, or grant any third party rights to research, develop, commercialize, or manufacture, (i)&nbsp;a Pfizer DART that binds to a cancer target for
which a Pfizer DART is under development in the agreement; or (ii)&nbsp;product candidates based on an antibody that we have supplied to serve as the basis for generating a Pfizer DART that is in development under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Term and Termination.</I> The agreement will terminate in its entirety upon the later of the expiration of the last-expiring patent related
to a Pfizer DART licensed product, or 12 years after the first commercial sale of a Pfizer DART licensed product. We or Pfizer may terminate the agreement in the event of an uncured material breach by the other party. After a specified period,
Pfizer may terminate the agreement for convenience upon prior written notice to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Green Cross </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Overview.</I> In June 2010, we entered into a Collaboration Agreement with Green Cross Corp (&#147;Green Cross&#148;), to grant Green Cross
an exclusive license to conduct specified Phase 1 and Phase 2 trials and commercialize margetuximab in South Korea. Under the terms of the agreement, we received a non-refundable $1.0 million upfront fee and are eligible to receive clinical,
development and commercial milestone payments up to $4.5 million if Green Cross commercializes margetuximab. We are also entitled to receive royalties ranging from the low-single digits to the low-twenties on net sales of margetuximab by Green Cross
in South Korea. In addition, Green Cross purchased $2.0 million of our Series D-2 Preferred Stock in January 2011. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical
Development.</I> Initial development of margetuximab under the agreement is being conducted according to a Phase 1 development plan that has been agreed upon by the parties. Based upon an amendment to the agreement, Green Cross is responsible for
all of its costs to conduct the Phase 1 development plan up to a specified amount and, we are responsible for all of our own costs to conduct the Phase 1 development plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Development of margetuximab under the agreement after completion of the Phase 1 clinical trial will be conducted according to a Phase 2
development plan. In that regard, Green Cross is obligated to use best efforts to initiate a Phase 2 clinical trial with margetuximab in South Korea within a specified period of time after the completion of the Phase 1 trial. The costs of conducting
the Phase 2 trial will be the responsibility of Green Cross. After completion of the Phase 1 trial, Green Cross has the responsibility for submitting clinical trial applications to the Korea Food and Drug Administration (&#147;KFDA&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Green Cross shall have the option to participate in any additional studies to the extent such studies are required by the KFDA to obtain
approval of margetuximab in South Korea. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Commercialization.</I> Under the Agreement, Green Cross has sole responsibility and authority
for commercialization of margetuximab in South Korea at its sole expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Manufacturing.</I> We are responsible for supply of
margetuximab that is used for clinical development by Green Cross in South Korea. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>License.</I> Under the Agreement, we granted Green
Cross an exclusive license to conduct specified Phase&nbsp;1 and Phase 2 trials and commercialize margetuximab in South Korea. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Consideration.</I> Under the Agreement, we received a non-refundable $1.0 million upfront fee and are eligible to receive clinical,
development and commercial milestone payments up to $4.5 million if Green Cross commercializes margetuximab. In addition, we are entitled to receive royalties which are determined by a formula that allocates the cost of commercial supply and third
party royalties against net sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Term and Termination</I>. The agreement will terminate in its entirety upon the later of the
expiration of the last-expiring patent related to margetuximab, or 12 years after the first commercial sale of margetuximab in South Korea. The agreement may also be terminated by either Green Cross or us in the event of an uncured material breach
by the other party. The agreement may be terminated by us immediately in the event Green Cross participates or actively assists in a legal challenge to one of the patents exclusively licensed to Green Cross under the agreement. Either party may
terminate the agreement in the event of a change in control of the other party upon 30 days prior written notice to the other party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual
Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and
maintaining patent protection intended to protect, for example, the composition of matter of our product candidates, their methods of use, the technology platforms used to generate them, related technologies and/or other aspects of the inventions
that are important to our business. We also rely on trade secrets and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to continue to expand our intellectual property estate by filing patent applications
directed to dosage forms, methods of treatment and additional compositions created or identified from our technology platforms and ongoing development of our product candidates. Specifically, we seek patent protection in the United States and
internationally for novel compositions of matter directed to aspects of the molecules, basic structures and processes for manufacturing these molecules and the use of these molecules in a variety of therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important
technology, inventions and know-how related to our business, defend and enforce our patents, maintain our licenses to use intellectual property owned by third parties, preserve the confidentiality of our trade secrets and operate without infringing
the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary positions. We
currently use multiple industry-standard patent monitoring systems to monitor new United States Patent and Trademark Office (&#147;USPTO&#148;) filings for any applications by third parties that may infringe on our patents. To date, we have not
identified any potential infringement of our patents by third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A third party may hold intellectual property, including patent
rights that are important or necessary to the development of our product candidates or use of our technology platforms. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product
candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. For example, certain patents held by third parties cover Fc
engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are invalid, if they cover margetuximab or MGA271 and we are unable to invalidate them, or
if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent
positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued,
and its scope can be reinterpreted by the courts after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we
are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, narrowed,
circumvented or invalidated by third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because patent applications in the United States and certain other jurisdictions are
maintained in secrecy for 18 months or potentially even longer, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending
patent applications. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention. We are participating in post-grant challenge proceedings, such as oppositions, that challenge the
patentability of third party patents and may have to participate in such proceedings again in the future. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent portfolios for our most advanced programs are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Margetuximab</I>. We own our margetuximab patent portfolio, which includes one issued patent and one pending U.S. patent application. Our
issued patent relates to the composition of or methods of making or using margetuximab and covers Fc engineered HER2 binding antibodies. This patent will expire in 2025. Related Patent Cooperation Treaty (&#147;PCT&#148;) and national patent
applications filed in a number of other countries are pending. Any patents resulting from these patent applications, if issued, will expire in 2025. Our current pending U.S. application relates to the composition of margetuximab. If issued, this
patent will expire in 2029. We filed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
related PCT and national patent applications in a number of other countries. Any patents resulting from these patent applications, if issued, also will expire 2029. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain issued patents and pending U.S. patent applications for our Fc Optimization platform portfolio provide additional intellectual
property protection for margetuximab. We own three issued patents in this portfolio, two that relate to compositions of matter and one that covers methods of use. In addition, we have four current pending U.S. patent applications relating to
compositions of matter, methods of using, and methods of making. The issued patents and any patents resulting from the pending patent applications, if issued, will expire between 2024 and 2030. PCT and national patent applications filed in a number
of other countries are pending. Any patents resulting from these applications, if issued, will expire on the same dates as our corresponding U.S. patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>MGA271.</I> We own our MGA271 patent portfolio. This portfolio includes two pending U.S. patent applications. One of these pending patent
applications claims MGA271 variable domains that bind to the B7-H3 receptor. Both pending patent applications cover the composition of or methods of making or using MGA271. In addition, related PCT and related national patent applications are
pending in several other countries. The U.S. pending patent applications and national patent applications, if issued, will expire in 2031. MGA271 is also covered by the same patents and patent applications from our Fc Optimization platform portfolio
that cover margetuximab. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>MGD006.</I> We own our MGD006 patent portfolio. This portfolio includes two U.S. pending provisional patent
applications that claims general composition of or methods of making or using MGD006. Any patents resulting from this application, if issued, will expire in 2034. We expect to file PCT and national patent applications in other countries in the
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Three pending U.S. patent applications for our DART platform portfolio claiming compositions of matter, methods of using, methods
of making also cover MGD006. These patents, if issued, will expire between 2026 and 2031. In addition, related PCT and national patent applications filed in a number of other countries are pending. Any patents resulting from these patent
applications, if issued, will expire on the same dates as our corresponding U.S. patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>MGD010</I>. We own our MGD010 patent
portfolio. This portfolio includes four pending U.S. patent applications. Each patent application claims compositions of matter, methods of using, and methods of making. If issued, any patents resulting from these applications will expire between
2022 and 2034. In addition, related PCT and national patent applications in a number of other countries are pending. Any patents resulting from these patent applications, if issued, will expire on the same dates as our corresponding U.S. patents.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Three pending U.S. patent applications for our DART platform portfolio claiming compositions of matter, methods of using, methods of
making also cover MGD010. Any patents resulting from these U.S. patent applications will expire between 2026 and 2031. In addition, related PCT and national patent applications in a number of other countries are pending. Any patents resulting from
these patent applications, if issued, will expire on the same dates as our corresponding U.S. patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>DART Platform.</I> We own our
DART platform patent portfolio. This portfolio includes seven pending U.S. patent applications, each of which claims compositions of matter, methods of using, and methods of making. Patents resulting from six of these U.S. patent applications, if
issued, will expire between 2026 and 2031. The remaining application, which relates to certain mutations incorporated into our DARTs, if issued, will expire in 2032. In addition, related PCT and national patent applications in a number of other
countries are pending. Any patents resulting from these patent applications, if issued, will expire on the same dates as our corresponding U.S. patents. A PCT application in our DART Platform patent portfolio also relates to a particular binding
component of our DARTs. Related national applications will be filed in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Fc Optimization Platform.</I> We own our Fc Optimization platform patent portfolio. This
portfolio includes three issued U.S. patents that cover the compositions of antibody Fc regions with certain mutations that affect their binding to Fc receptors. These patents expire in 2024. Related national patents have issued in a number of other
countries or are pending. The issued patents and any patents resulting from the pending patent applications, if issued, will expire in 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Cancer Stem-like Cell Platform.</I> We own our cancer stem-like cell platform patent portfolio. This portfolio consists of one issued U.S.
patent that will expire in 2028. Related national patents have issued in a number of other countries and will expire on the same date. In addition to patent protection, we will also rely on the use of trade secrets to protect our cancer stem-like
cell platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In
most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, the term of the U.S. patents may be extended due to delays encountered during prosecution which are caused by the USPTO or by delays
incurred due to compliance with FDA regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA Regulatory Review Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Hatch-Waxman Act permits a patent term extension for FDA-approved drugs of up to five years beyond the expiration of the patent. The length
of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent
applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our pharmaceutical product candidates receive
FDA approval, we expect to apply for patent term extensions on patents covering those products. We intend to seek patent term extensions to any of our issued patents in any jurisdiction where these are available, however there is no guarantee that
the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade Secrets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely on
trade secret protection for our confidential and proprietary information. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may
independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to
require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide
that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#146;s relationship with us is to be kept confidential and not disclosed to third parties
except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working
hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our confidentiality and other agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors
require them to assign or grant us licenses to inventions they invent as a result the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also included in our trade secrets are hybridomas which express antibodies that bind to proteins which are or may be expressed on cancerous
cells, including cancer stem cells. The antibodies produced by each hybridoma </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are unique and may have properties that are absent in antibodies expressed by other hybridomas. These properties could confer advantages and capabilities to product candidates developed with
antibodies that exhibit such properties. We closely control and monitor access to the hybridomas and the antibodies they produce. Before receiving such materials, our collaborators, prospective collaborators and all other parties are required to
execute material transfer agreement or other agreement which contractually limit their permitted uses and dissemination of such materials. In many cases our agreements with other parties granting access to and use of our biological materials require
them to assign or grant us licenses to inventions they invent as a result or their use of the materials or grant us an option to negotiate a license to use such inventions </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In-Licensed Intellectual Property </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into patent and know-how license agreements which grant us the right to use a certain technology related to biological
manufacturing to manufacture margetuximab and MGA271. We anticipate using this technology for future product candidates. This licensor has a business dedicated to licensing this technology and we anticipate that licenses to use the technology for
our future products will be available. The licenses typically include an obligation to pay an upfront payment, yearly maintenance payment and sales royalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into a research evaluation agreement for a technology related to biological manufacturing that we anticipate using to
manufacture certain DART products. This licensor has a business dedicated to licensing this technology and we anticipate that licenses will be available to use it to manufacture quantities of the DART products for clinical and commercial uses. The
licenses may include an obligation to pay an upfront payment, yearly maintenance payments, milestones and sales royalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
establishing our Fc Optimization platform, we entered into patent license agreements which grant us the right to use technologies to generate mutant Fc regions. The licenses include obligations to pay a yearly maintenance payment, development
milestones and sales royalties on products we develop and commercialize that include mutant Fc regions generated using the patented technologies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have a
manufacturing facility located in Rockville, Maryland. This facility has been used to manufacture all of the current clinical supply for margetuximab and MGA271 to date. We currently have capacity to produce Phase 2 material for our antibody product
candidates and clinical and commercial material for our DART therapeutics. We intend to expand our capacity at this location, or possibly elsewhere. For our Phase 3 clinical trials for our antibody product candidates and for commercial sale
quantities of such candidates, we anticipate that we will need to obtain additional manufacturing capacity through contract manufacturers to be able to supply the quantities required. We intend to screen multiple manufacturers to provide the drug
substance for commercial purposes for some of our product candidates prior to the filing of a BLA. We currently rely on and will continue to rely on contract fill-finish service providers to fulfill our fill-finish needs for our current and future
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our product candidates are biologics and are manufactured in disposable bioreactors in CHO cells in accordance
with cGMP. We expect to continue to develop product candidates that can be produced at our manufacturing facility and at contract manufacturing facilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generate cell lines internally that serve as the source for our biologic drug substance. These cell lines are then sent to a vendor where
they are expanded and banked, and are available upon our request to use in developing drug substance. All other manufacturing materials used in the production of drug substance are readily available in the ordinary course of business from a number
of standard biotechnology vendors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally expect to rely on third parties for the development and manufacturing of our companion
diagnostics. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not yet established a sales, marketing or product distribution infrastructure because our lead product candidates are still in clinical
development. We generally seek to retain commercial rights in the United States for our clinical product candidates for which we hope to receive marketing approvals and have done so to date in our collaborations other than our Boehringer, Gilead and
Pfizer collaborations. We believe that it will be possible for us to access the United States oncology market through a targeted specialty sales force. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to receiving marketing approvals, we expect to commence commercialization activities by building a focused sales and marketing
organization in the United States to sell our products. We believe that such an organization will be able to address the community of oncologists who are the key specialists in treating the patient populations for which our oncology product
candidates are being developed. Outside the United States, we expect to enter into distribution and other marketing arrangements with third parties for any of our product candidates that obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also plan to build a marketing and sales management organization to create and implement marketing strategies for any products that we
market through our own sales organization and to oversee and support our sales force. The responsibilities of the marketing organization would include developing educational initiatives with respect to approved products and establishing
relationships with thought leaders in relevant fields of medicine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our collaborators for any companion diagnostics we may
develop in the future for use with our product candidates will hold the commercial rights to these diagnostic products. We expect to coordinate closely with our diagnostic collaborators in connection with the marketing and sale of our related
product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, knowledge, experience and scientific resources provide us with
competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research
institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a large number of companies developing or marketing treatments for cancer and autoimmune disorders, including many major
pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In
addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. Amgen is now in late-stage clinical development of cancer product candidates which work by targeting antigens
both on immune effector cell populations and those expressed on certain cancer cells. In addition, other companies are developing new treatments for cancer and autoimmune diseases that enhance the Fc regions of antibodies to create more potent
antibodies, including Roche and Xencor, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors have significantly greater financial, manufacturing, marketing, drug
development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or
early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining top qualified scientific and
management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of all of our therapeutic product candidates,
if approved, are likely to be their efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic competition and the availability of reimbursement from
government and other third party payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if our competitors develop and
commercialize products that are more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products
more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or
other third party payors seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, certain HER2 biosimilar products may be approved in the U.S. prior to
margetuximab. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug
therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates may compete with many existing drug and other therapies, to the extent they are ultimately used in
combination with or as an adjunct to these therapies, our product candidates will not be competitive with them. Some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis.
Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third party payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to currently marketed therapies, there are also a number of products in late stage clinical development to treat cancer. These product candidates in development may provide efficacy, safety, dosing convenience and other benefits that are
not provided by currently marketed therapies. As a result, they may provide significant competition for any of our product candidates for which we obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our lead product candidates are approved for the indications for which we are currently undertaking clinical trials, they will compete with
the therapies and currently marketed drugs discussed below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Margetuximab</I>. Irrespective of HER2 status, metastatic breast cancers
are often treated with cytotoxic chemotherapies such as anthracyclines and taxanes, as well as capecitabine. Advanced and metastatic cancers are treated with chemotherapy and radiation therapy. In addition, there are several approved therapies
specifically indicated for the treatment of early and advanced stage breast cancer and advanced gastroesophageal cancer that are HER2+, including Herceptin, Kadcyla, Tykerb and Perjeta, and each of those drugs targets HER2+ tumors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>MGA271</I>. The most common treatments for solid tumors are various chemotherapeutic agents, radiation therapy and certain targeted
therapies including monoclonal antibodies such as Herceptin, Avastin, Erbitux and Vectibix, as well as small molecule agents, including, Tarceva, Sutent and Nexavar. No therapies are approved specifically for the treatment of tumors associated with
the expression of B7-H3. Yervoy, which targets CTLA4, an inhibitory molecule on T cells, is currently indicated for the treatment of melanoma and marketed by Bristol-Myers. In addition, there are several antibodies in development that target other
members of the B7&nbsp;family or their associated checkpoint receptors. These include anti-PD1 molecules by Merck, Bristol-Myers and AstraZeneca, and anti-PD-L1 molecules by Bristol-Myers, Roche and Merck KGaA and a PD-L2 Fc fusion protein by GSK
and AstraZeneca. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>MGD006</I>. The most common treatments for AML are various chemotherapeutic agents, radiation and stem cell
transplants. No therapies are approved specifically for the treatment of AML associated with the expression of CD123. We are aware of a monoclonal antibody currently being developed by CSL Limited which targets CD123. In addition, StemLine
Therapeutics, Inc. has treated patients in a clinical trial with a recombinant protein composed of IL-3 linked to a truncated diphtheria toxin payload. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>MGD007</I>. The most common treatments for gastroesophageal tumors are various
chemotherapeutic agents, radiation therapy, monoclonal antibodies including Herceptin, Avastin, Erbitux, Vectibix, as well as small molecule agents. No therapies are approved specifically for the treatment of tumors associated with the expression of
gpA33. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>MGD010</I>. Current B cell targeted therapies for autoimmune diseases include Rituxan and Arzerra for the treatment of
rheumatoid arthritis and Benlysta for the treatment of SLE. In addition, several other therapies are available to reduce inflammation, including nonsteroidal anti-inflammatory drugs such as Advil and Aleve; corticosteroids such as prednisone;
disease-modifying antirheumatic drugs such as methotrexate and hydroxychloroquine; immunosuppressants such as cyclosporine; and other drugs which target a variety of processes involved with inflammation such as Actemra, Kineret, Enbrel, Remicade,
Humira, Simponi, Cimzia, Orencia and Xeljanz. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation and Product Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other
things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. The processes for
obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA Approval Process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our
current product candidates are subject to regulation in the United States by the FDA as biological products (&#147;biologics&#148;). The FDA subjects biologics to extensive pre- and post-market regulation. The Public Health Service Act
(&#147;PHSA&#148;), the Federal Food, Drug, and Cosmetic Act (&#147;FDC Act&#148;) and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval,
labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biologics. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or
judicial sanctions, such as FDA refusal to approve pending BLAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil
penalties, or criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be
precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and
to authorize the creation and enforcement of regulations to prevent the introduction, or spread, of communicable diseases in the United States and between states. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process required by the FDA before a new biologic may be marketed in the United States is long, expensive, and inherently uncertain.
Biologics development in the United States typically involves pre-clinical laboratory and animal tests, the submission to the FDA of an IND, which must become effective before clinical testing may commence, and adequate and well-controlled clinical
trials to establish the safety and effectiveness of the biologic for each indication for which FDA approval is sought. Developing the data to satisfy FDA pre-market approval requirements typically takes many years and the actual time required may
vary substantially based upon the type, complexity, and novelty of the product or disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pre-clinical tests include laboratory
evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the pre-clinical tests must comply with federal regulations and
requirements, including good laboratory practices. The results of pre-clinical testing are submitted to the FDA as part of an IND along with other information, including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long term pre-clinical tests, such as animal tests of reproductive toxicity and
carcinogenicity, may continue after the IND is submitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An IND must become effective before United States clinical trials may begin. A
30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has not imposed a clinical hold, the clinical trial proposed in the IND may begin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational new drug or biologic to healthy volunteers or patients with the condition
under investigation, all under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&nbsp;in compliance with federal regulations; (ii)&nbsp;in compliance with good clinical practice (&#147;GCP&#148;), an international
standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii)&nbsp;under protocols detailing the objectives of the trial, the parameters to be used in
monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that
the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also be
submitted to an institutional review board (&#147;IRB&#148;) for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#146;s requirements, or may impose
other conditions. The study sponsor may also suspend a clinical trial at any time on various grounds, including a determination that the subjects or patients are being exposed to an unacceptable health risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials to support Biologics License Applications (&#147;BLAs&#148;) for marketing approval are typically conducted in three
sequential phases, but the phases may overlap or be combined. In Phase 1, the biologics initially introduced into healthy human subjects or patients, and the biologic is tested to assess pharmacokinetics, pharmacological actions, side effects
associated with increasing doses, and, if possible, early evidence on effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer treatments, initial human testing may be conducted in the intended patient
population. Phase 2 usually involves trials in a limited patient population to determine the activity of the biologic for a particular indication, dosage tolerance, and optimum dosage, and to identify common adverse effects and safety risks. If a
compound demonstrates evidence of activity and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at
geographically dispersed clinical trial sites. These Phase 3 clinical trials are intended to establish data sufficient to demonstrate substantial evidence of the efficacy and safety of the product to permit FDA to evaluate the overall benefit-risk
relationship of the biologic and to provide adequate information for the labeling of the biologic. Trials conducted outside of the US under similar, GCP-compliant conditions in accordance with local applicable laws may also be acceptable to FDA in
support of product licensing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sponsors of clinical trials for investigational drugs must publicly disclose certain clinical trial
information, including detailed trial design and trial results in FDA public databases. These requirements are subject to specific timelines and apply to most controlled clinical trials of FDA-regulated products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After completion of the required clinical testing, a BLA is prepared and submitted to the FDA. FDA review and approval of the BLA is required
before marketing of the product may begin in the United States. The BLA must include the results of all pre-clinical, clinical, and other testing and a compilation of data relating to the product&#146;s pharmacology, chemistry, manufacture, and
controls and must demonstrate the safety and efficacy of the product based on these results. The BLA must also contain extensive manufacturing information. The cost of preparing and submitting a BLA is substantial. Under federal law, the submission
of most BLAs is additionally </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to a substantial application user fee, as well as annual product and establishment user fees, which may total several million dollars and are typically increased annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#146;s
threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of BLAs. Most such
applications for standard review biologics are reviewed within ten months from the date the application is accepted for filing. Although FDA often meets its user fee performance goals, the FDA can extend these timelines if necessary, and FDA review
may not occur on a timely basis at all. The FDA usually refers applications for novel biologics, or biologics which present difficult questions of safety or efficacy, to an advisory committee&#151;typically a panel that includes clinicians and other
experts&#151;for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving a BLA,
the FDA will typically inspect one, or more, clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the biologic is manufactured and tested. The FDA will not approve the product
unless it verifies that compliance with cGMP is satisfactory and the BLA contains data that provide substantial evidence that the biologic is safe and effective in the indication studied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates the BLA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A
complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to
the FDA&#146;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. The FDA approval is never
guaranteed, and the FDA may refuse to approve a BLA if applicable regulatory criteria are not satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the PHSA, the FDA may
approve a BLA if it determines that the product is safe, pure and potent and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure, and potent. An approval letter authorizes
commercial marketing of the biologic with specific prescribing information for specific indications. The approval for a biologic may be significantly more limited than requested in the application, including limitations on the specific diseases and
dosages or the indications for use, which could restrict the commercial value of the product. The FDA may also require that certain contraindications, warnings, or precautions be included in the product labeling. In addition, as a condition of BLA
approval, the FDA may require a risk evaluation and mitigation strategy (&#147;REMS&#148;) to help ensure that the benefits of the biologic outweigh the potential risks. REMS can include medication guides, communication plans for healthcare
professionals, and elements to assure safe use (&#147;ETASU&#148;). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the
use of patient registries. The requirement for a REMS or use of a companion diagnostic with a biologic can materially affect the potential market and profitability of the biologic. Moreover, product approval may require, as a condition of approval,
substantial post-approval testing and surveillance to monitor the biologic&#146;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following
initial marketing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a BLA is approved, the product may also be subject to official lot release. As part of the manufacturing
process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release by the FDA, the manufacturer submits samples of each lot of product
to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some
products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological
products. After approval of biologics, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fast Track </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Fast Track
program, a provision of the FDA Modernization Act of 1997, is designed to facilitate interactions between a sponsoring company and the FDA before and during submission of a BLA for an investigational agent that, alone or in combination with one or
more other drugs, is intended to treat a serious or life-threatening disease or condition, and which demonstrates the potential to address an unmet medical need for that disease or condition. Under the Fast Track program, the FDA may consider
reviewing portions of a marketing application before the sponsor submits the complete application if FDA determines, after a preliminary evaluation of the clinical data, that a fast track product may be effective. A Fast Track designation provides
the opportunity for more frequent interactions with the FDA, and a fast track product could be eligible for priority review if supported by clinical data at the time of submission of the BLA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biosimilars </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Patient
Protection and Affordable Care Act (Affordable Care Act) signed into law on March&nbsp;23, 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#147;BPCIA&#148;). That Act created an approval pathway
authorizing the FDA to approve biosimilars and interchangeable biosimilars. Biosimilars are biological products which are &#147;highly similar&#148; to a previously approved biologic product or &#147;reference product&#148; and for which there are
no clinically meaningful differences between the biosimilar product and the reference product in terms of the safety, purity, and potency. For FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that
the biosimilar product can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biosimilar and the reference biologic may be switched after one has been previously administered
without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structures of biological products, as well as the process
by which such products are manufactured, pose significant hurdles to implementation, which are still being worked out by the FDA. To date, no biosimilar or interchangeable biologic has been licensed under the BPCIA framework, although such approvals
have occurred in Europe, and it is anticipated that FDA will approve a biosimilar in the relatively near future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reference biologic is
granted 12 years of exclusivity from the time of first licensure of the reference product. A biosimilar application may be filed four (4)&nbsp;years after the approval of the reference biologic. Although the patents for the reference biologic may be
challenged by the biosimilar applicant during that time period pursuant to the BPCIA statutory patent challenge framework, no biosimilar or interchangeable product will be licensed by FDA until the end of the exclusivity period. The first biologic
product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitting under the abbreviated approval pathway for the lesser of (i)&nbsp;one
year after first commercial marketing, (ii)&nbsp;18 months after the initial application if there is no legal challenge, (iii)&nbsp;18 months after the resolution in the applicant&#146;s favor of a lawsuit challenging the biologics&#146; patents if
an application has been submitted, or (iv)&nbsp;42 months after the application has been approved if a lawsuit is ongoing within the 42-month period. At this juncture, it is unclear whether products deemed &#147;interchangeable&#148; by FDA, in
fact, will be readily substituted by pharmacies, which are governed by state pharmacy law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advertising and Promotion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once a BLA is approved, a product will be subject to continuing post-approval regulatory requirements. For instance, FDA closely regulates the
post-approval marketing and promotion of biologics, including standards and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet and other social
media. Failure to comply with these regulations can result in significant penalties, including the issuance of warning letters directing a company to correct deviations from FDA standards, a requirement that future advertising and promotional
materials be precleared by the FDA, and federal and state civil and criminal investigations and prosecutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biologics may be marketed
only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or
facilities, require submission and FDA approval of a new BLA or BLA supplement before the change can be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses
the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adverse Event Reporting and GMP Compliance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverse event reporting and submission of periodic reports are required following FDA approval of a BLA. The FDA also may require
post-marketing testing, known as Phase 4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition,
manufacture, packaging, labeling, storage and distribution procedures must continue to conform to current cGMPs after approval. Biologics manufacturers and certain of their subcontractors are required to register their establishments with the FDA
and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must
continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals, request product recalls, or impose marketing restrictions through
labeling changes or product removals if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Companion Diagnostics </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA
regulates the sale or distribution, in interstate commerce, of medical devices, including in vitro diagnostics (&#147;IVDs&#148;). IVDs are a type of medical device that are intended to detect diseases, conditions, or infections, or the presence of
certain genetic or other biomarkers. If safe and/or effective use of a therapeutic depends on an IVD, the FDA generally will require approval of the companion diagnostic, at the same time that the FDA approves the therapeutic. The FDA previously has
required <I>in vitro</I> companion diagnostics intended to identify the patients most likely to respond to a treatment to obtain approval of a premarket approval application (&#147;PMA&#148;) simultaneously with approval of the biologic. A required
companion diagnostic has the potential to delay approval of the biologic and create barriers to patient access. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan drug designation to biologics intended to treat a rare disease or condition&#151;generally
a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the biologic and its
potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not necessarily convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first BLA applicant to receive FDA approval for
a particular product to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year exclusivity period, the FDA
may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exclusivity does not prevent the FDA from approving a different biologic for the same disease or condition, or the same biologic for a different disease or condition. Among the other benefits of
orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate seeking orphan
drug designation for specific indications under development with margetuximab, MGA271, MGD006 and MGD007. Such designation would be sought in those populations that are being, or will be, studied to treat a disease or condition that affects fewer
than 200,000 individuals in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws and Compliance Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, our activities are potentially subject to regulation by federal, state, and local authorities in addition to the FDA,
including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney offices within the
Department of Justice, and state and local governments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>International Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, a variety of foreign regulations govern clinical trials, commercial sales, and distribution of
product candidates. The approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pharmaceutical Coverage, Pricing, and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in
part on the availability of reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations. Third-party payors are increasingly examining the
medical necessity and cost effectiveness of medical products and services in addition to safety and efficacy and, accordingly, significant uncertainty exists as to the reimbursement status of newly approved therapeutics. Third-party reimbursement
adequate to enable us to realize an appropriate return on our investment in research and product development may not be available for our products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our headquarters are located
in Rockville, Maryland, where we occupy office and laboratory space under a lease that expires on March&nbsp;31, 2018. Our manufacturing facility is also located in Rockville under a lease with the same landlord that expires on December&nbsp;31,
2014. We have an option under each lease to continue the respective lease for five years under the same terms. We also sublease office and laboratory space in South San Francisco under a lease that expires on December&nbsp;31, 2018. We are seeking
to sublease a substantial portion of this space. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;28, 2014, we had 166 full-time employees, 130 of whom were primarily engaged in research and development activities and 35
of whom had an M.D. or Ph.D. degree. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not currently a party to any material legal proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_3"></A>ITEM&nbsp;1A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RISK FACTORS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Our business and results of operations are subject to numerous risks,
uncertainties and other factors that you should be aware of, some of which are described below. The risks, uncertainties and other factors described below are not the only ones facing our company. Additional risks, uncertainties and other factors
not presently known to us or that we currently deem immaterial may also impair our business operations. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Any of the risks,
uncertainties and other factors could have a materially adverse effect on our business, financial condition or results of operations and could cause the trading price of our common stock to decline substantially. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business and the Development and Commercialization of Our Product Candidates. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>All of our product candidates are in pre-clinical or clinical development. Clinical drug development is expensive, time consuming and uncertain and we
may ultimately not be able to obtain regulatory approvals for the commercialization of some or all of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the U.S. Food and Drug Administration (&#147;FDA&#148;) and non-U.S. regulatory authorities, which
regulations differ from country to country. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a Biologics License Application (&#147;BLA&#148;) from the FDA or marketing
approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. We have not submitted an application for or
received marketing approval for any of our product candidates. We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. Obtaining approval of a BLA can be a
lengthy, expensive and uncertain process. In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after product approval, if any, subject our company to administrative or judicially imposed sanctions,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the products, manufacturers or manufacturing process; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warning letters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">civil and criminal penalties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or withdrawal of regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizures, detentions or import bans; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voluntary or mandatory product recalls and publicity requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">total or partial suspension of production; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposition of restrictions on operations, including costly new manufacturing requirements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to approve pending BLAs or supplements to approved BLAs. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and foreign
regulatory authorities also have substantial discretion in the drug approval process. The number of pre-clinical studies and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or
condition that the product candidate is designed to address, and the regulations applicable to any particular drug candidate. Regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be deemed safe or effective; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results may not confirm the positive results from earlier pre-clinical studies or clinical trials; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory agencies may not find the data from pre-clinical studies and clinical trials sufficient; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory agencies may change their approval policies or adopt new regulations. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any delay in
obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact
our stock price. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. These limitations may limit the size of the market for the product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If clinical trials for our product candidates are prolonged, delayed or stopped, we may be unable to obtain regulatory approval and commercialize our
product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently enrolling a Phase 2a clinical trial of margetuximab in patients with metastatic breast cancer and anticipate commencing a
Phase 3 potential registration clinical trial of margetuximab in advanced gastroesophageal cancer in the second half of 2014. We have initiated a Phase 1 clinical trial of MGA271 that we expect to complete by the end of 2014. We expect to commence a
Phase 1 clinical trial of MGD006 in the first half of 2014 and expect to commence a Phase 1 clinical trial of MGD007 in the second half of 2014. The commencement of these planned clinical trials could be substantially delayed or prevented by several
factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">further discussions with the FDA or other regulatory agencies regarding the scope or design of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the limited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as our
product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to obtain sufficient funds required for a clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or failure to manufacture sufficient supplies of the product candidate for our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites or clinical research organizations (&#147;CROs&#148;) the terms of which can be subject
to extensive negotiation and may vary significantly among different sites or CROs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or failure to obtain institutional review board (&#147;IRB&#148;) approval to conduct a clinical trial at a prospective site. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The completion of our clinical trials could also be substantially delayed or prevented by several factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">slower than expected rates of patient recruitment and enrollment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of patients to complete the clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including possible deaths; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of efficacy during clinical trials; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">termination of our clinical trials by one or more clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to monitor patients adequately during or after treatment by us and/or our CROs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in regulatory requirements and guidance may also occur and we may need to significantly amend clinical trial protocols to reflect
these changes with appropriate regulatory authorities. Amendments may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a
clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or us, due to a
number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for the clinical development of any of our product candidates.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any failure or significant delay in completing clinical trials for our product candidates would adversely affect our
ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The results of
previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no products approved for sale, and we cannot guarantee that we will ever have marketable products. Clinical failure can occur
at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or pre-clinical
testing. We will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for use in a diverse population before we can seek regulatory approvals for their
commercial sale. Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to
the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials. Product candidates that have shown promising results in early clinical trials may still suffer significant setbacks in
subsequent registration clinical trials. Similarly, the outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final
results. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical
trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the design of a clinical trial can determine whether its results will support approval of a product and flaws in the
design of a clinical trial may not become apparent until the clinical trial is well advanced. We may be unable to design and execute a clinical trial to support regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product
candidate due to numerous factors, including changes in trial protocols, differences in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
size and type of the patient populations, adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. We do not know whether any
Phase&nbsp;2, Phase&nbsp;3 or other clinical trials we or any of our collaborators may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our product candidates may not be approved even if they achieve their primary endpoints in Phase 3 clinical trials or registration
trials. The FDA or other non-U.S. regulatory authorities may disagree with our trial design and our interpretation of data from pre-clinical studies and clinical trials. In addition, any of these regulatory authorities may change requirements for
the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal Phase 3 clinical trial that has the potential to result in FDA or other agencies&#146; approval. In addition, any of these
regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. The FDA or other non-U.S. regulatory
authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We use new technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved products that
utilize these technologies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our products in development are based on new technologies, such as Fc Optimization, bi-specific DARTs
and CSLCs. Given the complexity of our technologies, we intend to work closely with FDA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product
candidates. It is possible that the validation process may take time and resources, require independent third-party analyses or not be accepted by the FDA and other regulatory authorities. For some of our product candidates that are based on these
technology platforms, the regulatory approval path and requirements may not be clear, which could add significant delay and expense. Delays or failure to obtain regulatory approval of any of the products that we develop would adversely affect our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key element of our strategy is to use and expand our technology platforms to build a pipeline of product candidates and progress
these product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in a pipeline of product candidates directed at&nbsp;various
cancers and autoimmune disorders, we may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for
clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not
continue to successfully develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our stock
price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or
indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial
and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later
prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs
and product candidates for specific indications may not yield any commercially viable products. If we do not accurately </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other
royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if
we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize our products outside of the United States, which would limit our ability to realize their full market potential. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of
other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained
in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays,
difficulties and costs for us and may require additional pre-clinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of
our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have
negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval
in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products
will be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek fast-track designation of margetuximab and may seek fast track designation for some of our other product candidates.
There is no assurance that the FDA will grant such designation and, even if it does grant fast track designation to margetuximab or one of our other product candidates, that designation may not actually lead to a faster development or regulatory
review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval in the United States. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek fast-track designation of margetuximab and may seek fast track designation and review for some of our other product candidates. If
a drug is intended for the treatment of a serious or life-threatening condition or disease, the drug sponsor may apply for FDA fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a
particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Moreover, even if we do receive fast track designation, we may not experience a faster development process, review or approval
compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek breakthrough therapy designation by the FDA for any of our product candidates but that is not assured and may not, in any event, lead to a
faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval in the United&nbsp;States. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may apply for breakthrough therapy designation for some of our product candidates. The FDA is authorized to designate a product candidate as
a breakthrough therapy if it finds that the product is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products designated as breakthrough therapies, interaction
and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if
we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a
product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and, in any event, does not assure ultimate approval by the FDA. In
addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval
will not be shortened. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to obtain orphan product designation or exclusivity for some or all of our product candidates. If our
competitors are able to obtain orphan product exclusivity for their products that are the same as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small
patient populations as orphan drugs. Under the Orphan Drug Act, FDA may designate a product candidate as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than
200,000 individuals annually in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, if a product candidate with an orphan drug designation subsequently
receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the European Medicines Agency (&#147;EMA&#148;) or the FDA from approving
another marketing application for the same drug for that time period. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a product no longer meets the
criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially
defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because
different drugs can be approved for the same condition. In the United States, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically
superior in that it is shown to be safer, more effective or makes a major contribution to patient care. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may have undesirable
side effects which may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although all of our product candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or
anticipated. Unforeseen side effects from any of our product candidates could arise either during clinical development or, if approved by regulatory authorities, after the approved product has been marketed. All of our product candidates are still
in clinical or pre-clinical development. While our clinical trials for our initial product candidates to date have demonstrated a favorable safety profile, the results from future trials may not support this conclusion. The results of future
clinical trials may show that our product candidates cause undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other
regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities with restrictive label warnings or potential product liability claims. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates receives marketing approval and we or others later identify
undesirable or unacceptable side effects caused by such products: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require us to take our approved product off the market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be subject to limitations on how we may promote the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of the product may decrease significantly; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be subject to litigation or product liability claims; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us, our collaborators or our
potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from
the sale of our products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if approved, if any of our product candidates do not achieve broad market acceptance among physicians, patients, the
medical community, and third-party payors our revenue generated from their sales will be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commercial success of our
product candidates will depend upon their acceptance among physicians, patients and the medical community. The degree of market acceptance of our product candidates will depend on a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations or warnings contained in the approved labeling for a product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the standard of care for the targeted indications for any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations in the approved clinical indications for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">demonstrated clinical safety and efficacy compared to other products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of significant adverse side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales, marketing and distribution support; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability and extent of reimbursement from managed care plans and other third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">timing of market introduction and perceived effectiveness of competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the degree of cost-effectiveness of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of alternative therapies at similar or lower cost, including generic and over-the-counter products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which the product candidate is approved for inclusion on formularies of hospitals and managed care organizations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular diseases; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse publicity about our product candidates or favorable publicity about competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">convenience and ease of administration of our products; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential product liability claims. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates are approved, but do not achieve an adequate level of acceptance
by physicians, patients and the medical community, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, efforts to educate the medical community and third-party payors on the benefits
of our product candidates may require significant resources and may never be successful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to a multitude of manufacturing risks, any
of which could substantially increase our costs and limit supply of our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of manufacturing our products is
complex, highly regulated and subject to several risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The process of manufacturing biologics, such as margetuximab, MGA271, and our other product candidates, is extremely susceptible to product loss due to contamination, equipment failure or improper installation or
operation of equipment, vendor or operator error, contamination and inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could
result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such
manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, natural disasters, power failures and numerous other factors. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We must comply with the FDA&#146;s current Good Manufacturing Practice (&#147;cGMP&#148;) regulations and guidelines. We may encounter difficulties in achieving quality control and quality assurance and may experience
shortages in qualified personnel. We are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or
delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory
requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of drug product for our clinical trials
or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including fines,
injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and
criminal prosecutions, any of which could damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates and/or may be subject to product recalls, seizures, injunctions, or
criminal prosecution. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Any adverse developments affecting manufacturing operations for our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other
interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing
alternatives. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently have no marketing, sales or distribution infrastructure. If we are unable to develop sales, marketing and
distribution capabilities on our own or through collaborations, we will not be successful in commercializing our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no marketing, sales and distribution capabilities and we have no sales or marketing experience within our organization. If
any of our product candidates are approved, we intend either to establish a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates, or to outsource this function to a third party. Either
of these options would be expensive and time consuming. These costs may be incurred in advance of any approval of our product candidates. In addition, we may not be able to hire a sales force in the United States that is sufficient in size or has
adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to certain of our existing and future product candidates, we have entered into collaboration or other licensing arrangements with
third party collaborators that have direct sales forces and established distribution systems. To the extent that we enter into additional collaboration agreements, our product revenue may be lower than if we directly marketed or sold any approved
products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third party collaborators, which may not be successful and are generally not within our control. If we are unable to enter into these
arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third
parties, our future product revenue will suffer and we may incur significant additional losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition and if our
competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The life sciences industry is highly competitive and subject to rapid and significant technological change. We are currently developing
therapeutics that will compete with other drugs and therapies that currently exist or are being developed. Products we may develop in the future are also likely to face competition from other drugs and therapies, some of which we may not currently
be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research
institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical
testing, obtaining regulatory approvals, recruiting patients and in manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been
approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and
development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA approval or
discovering, developing and commercializing products in our field before we do. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, there are a large number of companies
developing or marketing treatments for cancer and autoimmune disorders, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by
using next-generation antibody technology platforms to address specific cancer targets. In addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. Amgen, Inc. is in
late-stage clinical development of cancer product candidates which work by targeting antigens both on immune effector cell populations and those expressed on certain cancer cells. In addition, other companies are developing new treatments for cancer
and autoimmune diseases that enhance the Fc regions of antibodies to create more potent antibodies, including F. Hoffmann-La Roche Ltd. and Xencor, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more
effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain
approval for ours, which could result in our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors
seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, certain HER2 biosimilar products may be approved prior to margetuximab. Even if our product candidates
achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act (collectively the
&#147;ACA&#148;) created a new regulatory scheme authorizing the FDA to approve biosimilars. Under the ACA, a manufacturer may submit an application for licensure of a biologic product that is &#147;biosimilar to&#148; or &#147;interchangeable
with&#148; a previously approved biological product or &#147;reference product.&#148; Under this new statutory scheme, an application for a biosimilar product may not be submitted to the FDA until four years following approval of the reference
product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a
competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#146;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their
product. Furthermore, recent legislation has proposed that the 12 year exclusivity period for each a reference product may be reduced to seven&nbsp;years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with
large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete
effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for
our products, it is less likely that our products will be widely used. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if our product candidates are approved for sale by the
appropriate regulatory authorities, market acceptance and sales of these products will depend on reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third-party payors, such as private health
insurers and health maintenance organizations, decide which drugs they will reimburse and establish payment levels. We cannot be certain that reimbursement will be available for any products that we develop. Also, we cannot be certain that
reimbursement policies will not reduce the demand for, or the price paid for, our products. If reimbursement is not available or is available on a limited basis, we may not be able to successfully commercialize any of our approved products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act
(&#147;MMA&#148;), changed the way Medicare covers and pays for pharmaceutical products. The legislation established Medicare Part D, which expanded Medicare coverage for outpatient prescription drug purchases by the elderly but provided authority
for limiting the number of drugs that will be covered in any therapeutic class. The MMA also introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States and several foreign jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals
to change the healthcare system in ways that could affect our ability to sell any of our future approved products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in
healthcare systems with the stated goals of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
containing healthcare costs, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been
significantly affected by major legislative initiatives. We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of health
maintenance organizations and additional legislative proposals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2010, the ACA became law in the United States. The goal of ACA
is to reduce the cost of health care and substantially change the way health care is financed by both governmental and private insurers. While we cannot predict what impact on federal reimbursement policies this legislation will have in general or
on our business specifically, the ACA may result in downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of, and the price we may charge for, any products we develop that receive regulatory approval. We
also cannot predict the impact of ACA on our business or financial condition as many of the ACA reforms require the promulgation of detailed regulations implementing the statutory provisions, which has not yet occurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be
required to limit commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability lawsuits related to
the testing of our product candidates in seriously ill patients, and will face an even greater risk if product candidates are approved by regulatory authorities and introduced commercially. Product liability claims may be brought against us or our
collaborators by participants enrolled in our clinical trials, patients, health care providers or others using, administering or selling any of our future approved products. If we cannot successfully defend ourselves against any such claims, we may
incur substantial liabilities. Regardless of their merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our future approved products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injury to our reputation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial participants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">termination of clinical trial sites or entire trial programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increased regulatory scrutiny; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant litigation costs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to or costly settlement with patients or other claimants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product recalls or a change in the indications for which they may be used; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diversion of management and scientific resources from our business operations; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize our product candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates are
approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity. We could also be adversely affected if any
of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perceptions, any adverse publicity associated with illness or other adverse
effects resulting from patients&#146; use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our financial condition or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently hold $15 million in product liability insurance coverage in the aggregate, with a per incident limit of $15 million, which may
not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage when we begin the commercialization of our product candidates. Insurance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
coverage is becoming increasingly expensive. As a result, we may be unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material
adverse effect on our business. A successful product liability claim or series of claims brought against us, particularly if judgments exceed any insurance coverage we may have, could decrease our cash resources and adversely affect our business,
financial condition and results of operation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business may become subject to economic, political, regulatory and other risks associated with
international operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to risks associated with conducting business internationally. Some of our
suppliers and collaborative and clinical trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic weakness, including inflation, or political instability in particular foreign economies and markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differing regulatory requirements for drug approvals in foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potentially reduced protection for intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in compliance with non-U.S. laws and regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in non-U.S. regulations and customs, tariffs and trade barriers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in non-U.S. currency exchange rates and currency controls; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in a specific country&#146;s or region&#146;s political or economic environment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative consequences from changes in tax laws; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties associated with staffing and managing foreign operations, including differing labor relations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We have no products
approved for commercial sale, and to date we have not generated any revenue or profit from product sales. We may never achieve or sustain profitability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company. We have incurred significant losses since our inception. As of December&nbsp;31, 2013, our
accumulated deficit was approximately $175.7&nbsp;million. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for,
our product candidates, prepare for and begin to commercialize any approved products, and add infrastructure and personnel to support our product development efforts and operations as a public company. The net losses and negative cash flows incurred
to date, together with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expected future losses, have had, and likely will continue to have, an adverse effect on our stockholders&#146; deficit and working capital. The amount of future net losses will depend, in part,
on the rate of future growth of our expenses and our ability to generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties
associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. For example, our expenses could increase if we are required
by the FDA to perform trials in addition to those that we currently expect to perform, or if there are any delays in completing our currently planned clinical trials or in the development of any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. This will
require us to be successful in a range of challenging activities for which we are only in the preliminary stages, including developing product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling those
products for which we may obtain regulatory approval. We may never succeed in these activities and may never generate revenue from product sales that is significant enough to achieve profitability. Even if we achieve profitability in the future, we
may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, develop other product candidates, or
continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require
substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are advancing our product candidates through clinical development. Developing pharmaceutical products, including conducting pre-clinical
studies and clinical trials, is expensive. In order to obtain such regulatory approval, we will be required to conduct clinical trials for each indication for each of our product candidates. We will continue to require additional funding beyond what
was raised in the initial public offering (&#147;IPO&#148;) of our common stock completed in October 2013 and the follow-on offering completed in February 2014 to complete the development and commercialization of our product candidates and to
continue to advance the development of our other product candidates, and such funding may not be available on acceptable terms or at all. Although it is difficult to predict our funding requirements, based upon our current operating plan, we
anticipate that our cash and cash equivalents as of December&nbsp;31, 2013, combined with the net proceeds from our subsequent follow-on offering and collaboration payments we anticipate receiving, will enable us to fund the clinical development of
margetuximab, MGA271, MGD006, MGD007, MGD010 and two additional pre-clinical DART-based oncology product candidates into 2017, assuming all of our collaboration programs advance as currently contemplated. Because successful development of our
product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and to commercialize our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future funding requirements will depend on many factors, including but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of other product candidates that we pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, progress, timing, cost and results of research, pre-clinical development, and clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs, timing and outcome of seeking and obtaining FDA and non-U.S. regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs associated with manufacturing our product candidates and establishing sales, marketing, and distribution capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense
and enforcement of any patents or other intellectual property rights; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our need and ability to hire additional management, scientific, and medical personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effect of competing products that may limit market penetration of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the economic and other terms, timing of and success of our existing collaborations, and any collaboration, licensing, or other arrangements into which we may enter in the future, including the timing of receipt of any
milestone or royalty payments under these agreements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we can generate a sufficient amount of product revenue to
finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through a combination of public or private equity offerings, debt financings, strategic collaborations, and grant funding. If sufficient funds on
acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, scale back or eliminate one or more of our development programs or our business operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be
diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available at all, may involve agreements that include covenants limiting or
restricting our ability to take specific actions such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third
parties, we may have to relinquish valuable rights to our technologies, product candidates, or future revenue streams, or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if
and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, scale back or eliminate one or more of our development programs or grant rights to develop and market product candidates that we
would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from our IPO and follow-on offering
and may not use them effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management has broad discretion to use our cash and cash equivalents to fund our operations
and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material
adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use to fund operations, we may invest our cash and cash equivalents in a manner that does not produce
income or that loses value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating loss carryforwards and other tax attributes may be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to utilize our federal net operating losses (&#147;NOLs&#148;) and federal tax credits is currently limited, and may be limited
further, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. The limitations apply if an ownership change, as defined by Section&nbsp;382, occurs. Generally, an ownership change occurs when certain shareholders increase
their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period, which is typically three years or since the last ownership change. We are already subject to Section&nbsp;382 limitations due to
an acquisition we made in 2008. As of December&nbsp;31, 2013, we had federal NOL carryforwards of $103.2 million, state NOL carryforwards of $58.4&nbsp;million and research and development tax credit carryforwards of $23.7 million available. Future
changes in stock ownership may also trigger an ownership change and, consequently, another Section&nbsp;382 limitation. Any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding
valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could
potentially result in increased future cash tax liability to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to
maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have limited capabilities for drug development and do not yet have any capability for sales, marketing or distribution. We have entered into collaborations with other companies that we believe can provide such capabilities, including our
collaboration and license agreements with Les Laboratoires Servier and Institut de Recherches Servier (collectively, &#147;Servier&#148;), Gilead Sciences, Inc. (&#147;Gilead&#148;), Boehringer Ingelheim GmbH (&#147;Boehringer&#148;), Pfizer, Inc.
(&#147;Pfizer&#148;) and Green Cross Corp. (&#147;Green Cross&#148;). These collaborations also have provided us with important funding for our development programs and technology platforms and we expect to receive additional funding under these
collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not perform their obligations as expected; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical
trial results, changes in the collaborators&#146; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new
formulation of a product candidate for clinical testing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are
more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the
commercialization of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or
products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or
commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual
property or proprietary information or expose us to potential litigation; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product
candidates. For example, each of our collaboration and license agreements with Servier, Gilead, and Boehringer may be terminated for convenience upon the completion of a specified notice period. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our therapeutic collaborations do not result in the successful development and commercialization of products or if one of our collaborators
terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our technology platforms
and product candidates could be delayed and we may need additional resources to develop product candidates and our technology platforms. All of the risks relating to product development, regulatory approval and commercialization described in this
report also apply to the activities of our program collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, subject to its contractual obligations to us, if one of
our collaborators is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with
us, we may find it more difficult to attract new collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For some of our product candidates, we may in the future determine to
collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive
agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number
of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and
complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership
without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether
such a collaboration could be more attractive than the one with us for our product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaborations are complex and
time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are
unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay one or more of our other development programs, delay its
potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or
commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or
expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our technology platforms and our business may be
materially and adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also be restricted under existing collaboration agreements from entering into future agreements
on certain terms with potential collaborators. Aside from our agreement with Green Cross, subject to certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specified exceptions, each of our existing therapeutic collaborations contains a restriction on our engaging in activities that are the subject of the collaboration with third parties for
specified periods of time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Independent clinical investigators and CROs that we engage to conduct our clinical trials may not devote sufficient time
or attention to our clinical trials or be able to repeat their past success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to depend on independent
clinical investigators and CROs to conduct our clinical trials. CROs may also assist us in the collection and analysis of data. There is a limited number of third-party service providers that specialize or have the expertise required to achieve our
business objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. These investigators and CROs will not be our employees and we will
not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of
our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers requires us
to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. Further, the FDA requires that we comply with standards, commonly referred to as current Good Clinical Practice
(&#147;cGCP&#148;) for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects are protected. Failure of clinical
investigators or CROs to meet their obligations to us or comply with cGCP procedures could adversely affect the clinical development of our product candidates and harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure of our third party contractors to successfully develop and commercialize companion diagnostics for use with our product candidates could harm
our ability to commercialize our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to develop companion diagnostics for our product candidates where
appropriate. Companion diagnostics are used to identify patients who could potentially benefit from our therapeutic product candidates. We expect that, at least in some cases, the FDA and similar regulatory authorities outside the United States may
require the development and regulatory approval of a companion diagnostic as a condition to approving our product candidates. We do not have experience or capabilities in developing or commercializing diagnostics and plan to rely in large part on
third parties to perform these functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to outsource the development, production and commercialization of companion diagnostics
to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third party contractors to successfully develop and commercialize these companion diagnostics. Our contractors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may not perform their obligations as expected; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may encounter production difficulties that could constrain the supply of the companion diagnostic; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may not commit sufficient resources to the marketing and distribution of such product; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may terminate their relationship with us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any companion diagnostic for use with one of our
product candidates fails to gain market acceptance, our ability to derive revenues from sales of such product candidate could be harmed. If our third party contractors fail to commercialize such companion diagnostic, we may not be able to enter into
arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with such product candidate or do so on commercially reasonable terms, which could adversely affect and delay the development or
commercialization of such product candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to contract with third parties for the manufacture of our product candidates for clinical testing
in the future and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which
could delay, prevent or impair our development or commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have a manufacturing facility located in
Rockville, Maryland. We manufacture drug substance at this facility that we use for research and development purposes and for clinical trials of our product candidates. We currently have capacity to produce Phase 2 material for our antibody product
candidates and clinical and commercial material for our DART therapeutics, but our current facility will be insufficient to support our needs for our Phase 3 clinical trials for our antibody product candidates and for commercial quantities of such
candidates. We do not have experience in manufacturing products at commercial scale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into agreements with contract
manufacturing organizations to supplement our clinical supply and internal capacity as we advance pre-clinical product candidates into clinical development. We expect to use third parties for the manufacture of certain of our product candidates for
clinical testing, as well as for commercial manufacture of some of our product candidates that receive marketing approval and that are not manufactured by one of our third party collaborators. We plan eventually to enter into long term supply
agreements with several manufacturers for commercial supplies. We may be unable to reach agreement with any of these contract manufacturers, or to identify and reach arrangements on satisfactory terms with other contract manufacturers, to
manufacture any of our product candidates. Additionally, the facilities used by any contract manufacturer to manufacture any of our product candidates must be the subject of a satisfactory inspection before the FDA and other regulatory authorities
approve a BLA or marketing authorization for the product candidate manufactured at that facility. We will depend on these third-party manufacturing partners for compliance with the FDA&#146;s requirements for the manufacture of our finished
products. If our manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA and other regulatory authorities&#146; cGMP requirements, our product candidates will not be approved or, if already approved,
may be subject to recalls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the
product candidates ourselves, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility of a breach of the manufacturing agreements by the third parties because of factors beyond our control; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility that we may not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to meet our manufacturing needs. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these factors could cause the delay of approval or commercialization of our product candidates, cause us to incur higher costs or
prevent us from commercializing our product candidates successfully. Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis and
at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely be
unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for our product candidates and to have any such new source approved by the FDA or any other relevant
regulatory authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and enforce patent protection for our product candidates and related technology, our business could be materially harmed.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Issued patents may be challenged, narrowed, invalidated or circumvented. In addition, court decisions may introduce uncertainty in
the enforceability or scope of patents owned by biotechnology companies. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not allow us to protect our inventions with
patents to the same extent as the laws of the United States. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because
publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file
for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our patents in the United States
and in foreign countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection from our pending
patent applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business
objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy depends on our ability to identify and seek patent protection for our discoveries. This process is expensive and
time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. Despite our efforts to
protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. The issuance of a patent does not ensure that it is valid or enforceable, so even if we obtain patents, they may not be
valid or enforceable against third parties. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product
and practicing our own patented technology. Third parties may also seek to market biosimilar versions of any approved products. Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our
products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid
and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and
factual considerations. The standards which the United States Patent and Trademark Office (&#147;USPTO&#148;) and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform,
worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United
States, and many companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries. Outside the United States, patent protection must be sought in individual jurisdictions, further
adding to the cost and uncertainty of obtaining adequate patent protection outside of the United States. Accordingly, we cannot predict whether additional patents protecting our technology will issue in the United States or in foreign jurisdictions,
or whether any patents that do issue will have claims of adequate scope to provide competitive advantage. Moreover, we cannot predict whether third parties will be able to successfully obtain claims or the breadth of such claims. The allowance of
broader claims may increase the incidence and cost of patent interference proceedings, opposition proceedings, and/or reexamination proceedings, the risk of infringement litigation, and the vulnerability of the claims to challenge. On the other
hand, the allowance of narrower claims does not eliminate the potential for adversarial proceedings, and may fail to provide a competitive advantage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Our issued patents may not contain claims sufficiently broad to protect us against third parties with similar technologies or products, or provide us with any competitive advantage. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even after they have issued, our patents and any patents which we license may be challenged, narrowed, invalidated or circumvented. If our
patents are invalidated or otherwise limited or will expire prior to the commercialization of our product candidates, other companies may be better able to develop products that compete with ours, which could adversely affect our competitive
business position, business prospects and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following are examples of litigation and other adversarial proceedings
or disputes that we could become a party to involving our patents or patents licensed to us: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our collaborators may initiate litigation or other proceedings against third parties to enforce our patent rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product or technology does not infringe our patents or
patents licensed to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third parties may initiate opposition or reexamination proceedings challenging the validity or scope of our patent rights, requiring us or our collaborators and/or licensors to participate in such proceedings to defend
the validity and scope of our patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">there may be a challenge or dispute regarding inventorship or ownership of patents currently identified as being owned by or licensed to us; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the U.S. Patent&nbsp;and Trademark Office may initiate an interference between patents or patent applications owned by or licensed to us and those of our competitors, requiring us or our collaborators and/or licensors
to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent rights; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third parties may seek approval to market biosimilar versions of our future approved products prior to expiration of relevant patents owned by or licensed to us, requiring us to defend our patents, including by filing
lawsuits alleging patent infringement. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These lawsuits and proceedings would be costly and could affect our results of
operations and divert the attention of our managerial and scientific personnel. There is a risk that a court or administrative body would decide that our patents are invalid or not infringed by a third party&#146;s activities, or that the scope of
certain issued claims must be further limited. An adverse outcome in a litigation or proceeding involving our own patents could limit our ability to assert our patents against these or other competitors, affect our ability to receive royalties or
other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive
business position, business prospects and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is uncertain
because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may be able to develop a platform that is similar to, or better than, ours in a way that is not covered by the claims of our patents; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we might not have been the first to make the inventions covered by patents or pending patent applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we might not have been the first to file patent applications for these inventions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not develop additional proprietary technologies that are patentable. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our commercial success
depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or
import our future approved products or impair our competitive position. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells.
Although we believe that these patents are invalid, if they cover margetuximab or MGA271 and we are unable to invalidate their patents, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps
materially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents that we may ultimately be found to infringe could be issued to third parties. Third parties may have or obtain valid
and enforceable patents or proprietary rights that could block us from developing product candidates using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial condition and
results of operations. Moreover, our failure to maintain a license to any technology that we require may also materially harm our business, financial condition, and results of operations. Furthermore, we would be exposed to a threat of litigation.
Invitrogen, Inc., for example, has asserted that we are required to obtain a license for use of a cell line. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the pharmaceutical
industry, significant litigation and other proceedings regarding patents, patent applications, trademarks and other intellectual property rights have become commonplace. The types of situations in which we may become a party to such litigation or
proceedings include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not
infringe those third parties&#146; patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference or opposition proceedings to determine the
priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate their patent or other intellectual property rights and/or that
we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These lawsuits would be costly and could affect our results of operations and divert the attention of our management and scientific personnel.
There is a risk that a court would decide that we or our collaborators are infringing the third party&#146;s patents and would order us or our collaborators to stop the activities covered by the patents. In that event, we or our collaborators may
not have a viable alternative to the technology protected by the patent and may need to halt work on the affected product candidate or cease commercialization of an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approved product. In addition, there is a risk that a court will order us or our collaborators to pay the other party damages. An adverse outcome in any litigation or other proceeding could
subject us to significant liabilities to third parties and require us to cease using the technology that is at issue or to license the technology from third parties. We may not be able to obtain any required licenses on commercially acceptable terms
or at all. Any of these outcomes could have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries
have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the
courts, and the interpretation is not always uniform or predictable. If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent
claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by
issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#146;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid
infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to
bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur
substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be
able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could
have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant management time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license rights that are important
to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently party to various intellectual property license agreements. These license agreements impose, and
we expect that future license agreements may impose, various diligence, milestone payment, royalty, insurance and other obligations on us. For example, we have entered into patent and know-how license agreements which grant us the right to use a
certain technology related to biological manufacturing to manufacture margetuximab and MGA271. These licenses typically include an obligation to pay an upfront payment, yearly maintenance payments and royalties on sales. If we fail to comply with
our obligations under the licenses, the licensors may have the right to terminate their respective license agreements, in which event we might not be able to market any product that is covered by the agreements. Termination of the license agreements
or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, which could adversely affect our competitive business position and harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other
proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships
with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individual&#146;s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived
by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. Thus,
despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection,
particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third
parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a
license to that intellectual property from that individual, or a third party or from that individual&#146;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade
secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time consuming litigation could be necessary to enforce and determine the scope of our proprietary rights,
and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade
secrets affords no protection against such independent discovery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology and pharmaceutical industries, we
employ individuals who were previously or concurrently employed at research institutions and/or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or
we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or
more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in
substantial costs and be a distraction to management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various
procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the
USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel to pay these fees when due. Additionally,
the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help
us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in
abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. In addition, we
are responsible for the payment of patent fees for patent rights that we have licensed from other parties. If any licensor of these patents does not itself elect to make these payments, and we fail to do so, we may be liable to the licensor for any
costs and consequences of any resulting loss of patent rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for
extending the term of patents covering each of our product candidates, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the
timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred
to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA
regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of
the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and
our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Legal Compliance Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do
not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development involves, and may in the future involve, the use of potentially hazardous materials and chemicals. Our operations
may produce hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations, the risk of accidental
contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and
regulations and fire and building codes, including those governing laboratory procedures, exposure to blood-borne pathogens, use and storage of flammable agents and the handling of biohazardous materials. Although we maintain workers&#146;
compensation insurance as prescribed by the States of Maryland and California to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate
coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. Additional federal, state and local laws and regulations affecting our operations may be adopted
in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we market products in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to
civil or criminal penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state
and federal healthcare laws commonly referred to as &#147;fraud and abuse&#148; laws have been applied in recent years to restrict certain marketing practices in the pharmaceutical industry. These laws include false claims and anti-kickback
statutes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment
to the federal government or knowingly making, or causing to be made, a false statement to get a false claim paid. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying,
soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed
healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exemptions and
regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor.
Most states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws, which may apply to items such as pharmaceutical products and services reimbursed by private insurers. Administrative, civil and
criminal sanctions may be imposed under these federal and state laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the past few years, a number of pharmaceutical and other
healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting to
pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability
for Medicaid rebates. At such time, if ever, as we market any of our future approved products and these products are paid for by governmental programs, it is possible that some of our business activities could also be subject to challenge under one
or more of these &#147;fraud and abuse&#148; laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees may engage in misconduct or other improper activities, including noncompliance
with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of employee fraud or other misconduct.
Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information
or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks,
self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee
misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible
to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions
or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on
our business, including the imposition of significant fines or other sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on the research and development, clinical and business development expertise of Scott Koenig, M.D., Ph.D., our
President and Chief Executive Officer, as well as the other members of our senior management, scientific and clinical team. Although we have entered into employment agreements with certain of our executive officers, each of them may terminate their
employment with us at any time. We currently maintain $1 million in &#147;key person&#148; insurance coverage for Dr.&nbsp;Koenig. The loss of the services of our executive officers or other key employees could impede the achievement of our
research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success.
In addition, we will need to expand and effectively manage our managerial, operational, financial, development and other resources in order to successfully pursue our research, development and commercialization efforts for our existing and future
product candidates. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from
this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience
competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and
development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we
are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to
grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
February&nbsp;28, 2014, we had 166 full-time employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, sales, marketing, financial and other resources. Future
growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of
their attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations which may result in weaknesses in our
infrastructure, give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial
resources from other projects, such as the development of existing and additional product candidates. If our management is unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate and/or
grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively with others in our industry will depend, in
part, on our ability to effectively manage any future growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price may be volatile and fluctuate substantially. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stock price is likely to be volatile. The stock market has experienced significant volatility, particularly with respect to pharmaceutical,
biotechnology, and other life sciences company stocks. The volatility of pharmaceutical, biotechnology, and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. Some of the
factors that may cause the market price of our common stock to fluctuate include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results and timing of our clinical trials and clinical trials of our competitors&#146; products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure or discontinuation of any of our development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issues in manufacturing our product candidates or future approved products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments or enforcement in the United States and foreign countries with respect to our product candidates or our competitors&#146; products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competition from existing products or new products that may emerge; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments or disputes concerning patents or other proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">introduction of technological innovations or new commercial products by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in estimates or recommendations by securities analysts, if any cover our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fluctuations in the valuation of companies perceived by investors to be comparable to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">public concern over our product candidates or any future approved products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">future sales of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the structure of health care payment systems in the United States or overseas; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of any of our product candidates, if approved, to achieve commercial success; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic and other external factors or other disasters or crises; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">period-to-period fluctuations in our financial condition and results of operations, including the timing of receipt of any milestone or other payments under commercialization or licensing agreements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general market conditions and market conditions for biopharmaceutical stocks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overall fluctuations in U.S. equity markets. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the past, when the market price
of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the
lawsuit and divert the time and attention of our management, which could seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock
may not be sustained. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013, we completed our IPO. Prior to the IPO, there was no public market for our common stock.
Although we have completed our IPO as well as a follow-on offering and shares of our common stock are listed and trading on The NASDAQ Global Select Market, an active trading market for our shares may not be sustained. If an active market for our
common stock does not continue, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares or sell their shares at or above the prices at which they acquired their shares or sell their shares at
the time they would like to sell. Any inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or
technologies by using our shares as consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Insiders have substantial control over us which could delay or prevent a change in corporate
control or result in the entrenchment of management and/or the board of directors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, our directors,
executive officers and principal stockholders, together with their affiliates and related persons, beneficially own, in the aggregate, approximately 78% of our outstanding common stock. As a result, these stockholders, if acting together, may have
the ability to determine the outcome of matters submitted to our stockholders for approval, including the election and removal of directors and any merger, consolidation, or sale of all or substantially all of our assets. In addition, these persons,
acting together, may have the ability to control the management and affairs of our company. Accordingly, this concentration of ownership may harm the market price of our common stock by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delaying, deferring, or preventing a change in control; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entrenching our management and/or the board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impeding a merger, consolidation, takeover, or other business combination involving us; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company&#148; and as a result of the reduced disclosure requirements
applicable to emerging growth companies, our common stock may be less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth
company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not
&#147;emerging growth companies&#148; including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive
compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. In
addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of
some accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same
new or revised accounting standards as other public companies that are not emerging growth companies. We cannot predict whether investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our
common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an &#147;emerging growth
company.&#148; We could remain an &#147;emerging growth company&#148; until the earliest to occur of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the last day of the fiscal year in which we have total annual gross revenue of $1 billion or more; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the last day of our fiscal year following the fifth anniversary of the date of the first sale of common equity securities pursuant to the prospectus filed with the Securities and Exchange Commission on October&nbsp;11,
2013; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on which we have issued more than $1 billion in non-convertible debt during the previous three years; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on which we are deemed to be a &#147;large accelerated filer&#148; under SEC rules and regulations. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We incur significantly increased costs as a result of operating as a public company, and our management is required to devote substantial time to
corporate governance standards. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we incur significant legal, accounting and other expenses that we did not
incur as a private company. In addition, our administrative staff will be required to perform additional tasks. For example, we are in the process of adopting additional internal controls and disclosure controls and procedures. As a public company,
we bear all of the internal and external costs of preparing and distributing periodic public reports in compliance with our obligations under the securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act and related
regulations implemented by the Securities and Exchange Commission and the NASDAQ Global Select Market, have increased legal and financial compliance costs that make some compliance activities more time consuming. We cannot predict or estimate the
amount of additional costs we will continue to incur or the timing of such costs. We must invest resources to comply with evolving laws, regulations and standards, and this investment will result in increased general and administrative expenses and
may divert management&#146;s time and attention from our other business activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to
practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed. In connection with our IPO, we increased our directors&#146; and officers&#146; insurance coverage which will increase our insurance cost. In
the future, it may be more expensive or more difficult for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make
it more difficult for us to attract and retain qualified members </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the corporate governance standards of the NASDAQ Global Select Market, a majority of our board of directors and each member of our audit
committee must be an independent director no later than the first anniversary of the completion of our IPO. We may encounter difficulty in attracting qualified persons to serve on our board of directors and the audit committee, and our board of
directors and management may be required to divert significant time and attention and resources away from our business to identify qualified directors. If we fail to attract and retain the required number of independent directors, we may be subject
to the delisting of our common stock from the NASDAQ Global Select Market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions of our charter, bylaws, and Delaware law may make an
acquisition of us or a change in our management more difficult. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of our restated certificate of incorporation
and amended and restated bylaws that became effective upon the completion of our IPO could discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you
might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. Stockholders
who wish to participate in these transactions may not have the opportunity to do so. Furthermore, since our board of directors is responsible for appointing the members of our management team, these provisions could prevent or frustrate attempts by
our stockholders to replace or remove our management by making it more difficult for stockholders to replace members of our board of directors. These provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">allow the authorized number of directors to be changed only by resolution of our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a classified board of directors, providing that not all members of the board of directors be elected at one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize our board of directors to issue without stockholder approval blank check preferred stock that, if issued, could operate as a &#147;poison pill&#148; to dilute the stock ownership of a potential hostile
acquirer to prevent an acquisition that is not approved by our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at stockholder meetings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit who may call stockholder meetings; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require the approval of the holders of 75% of the outstanding shares of our capital stock entitled to vote in order to amend certain provisions of our restated certificate of incorporation and restated bylaws.
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware
General Corporation Law, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a prescribed period of time. This
provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not anticipate paying cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to retain our future earnings, if any, to fund the development and growth of our businesses. As a result,
capital appreciation, if any, of our common stock will be your sole source of gain on your investment for the foreseeable future. Investors seeking cash dividends should not invest in our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our total outstanding shares of common stock is restricted from resale but may be
sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market could occur in the future. These sales, or the perception in
the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. After the IPO in October 2013, we had 25,020,288 outstanding shares of common stock. This included the
shares sold in the IPO, which were eligible to be resold in the public market immediately and the remaining shares that are currently restricted under securities laws or as a result of lock-up agreements but will be able to be resold upon the
expiration of the lock-up agreements 180 days from the signing of the underwriting agreement in our IPO. Moreover, holders of an aggregate of 17,458,764 shares of common stock have rights, subject to certain conditions, to require us to file
registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also filed a registration statement on Form S-8 to register all 1,920,168 shares of common
stock that we may issue under our equity compensation plans, and they therefore can be freely sold in the public market upon issuance and once vested, subject to the lock-up agreements described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future issuances of our common stock or rights to purchase common stock pursuant to our equity incentive plans or outstanding warrants could result in
additional dilution of the percentage ownership of our stockholders and could cause our share price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2013, we had options to purchase 3,200,958 shares outstanding under our equity compensation plans. We are also authorized to grant equity awards, including stock options, to our employees, directors and consultants, covering up to
1,402,459 shares of our common stock, pursuant to our equity compensation plans. We plan to register the number of shares available for issuance or subject to outstanding awards under our equity compensation plans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading
volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will depend on the research and reports that securities or industry
analysts publish about us or our business. We do not have any control over these analysts. We cannot assure you that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our stock or change
their opinion of our stock, our share price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our
share price or trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_4"></A>ITEM&nbsp;1B.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>UNRESOLVED STAFF COMMENTS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_5"></A>ITEM&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PROPERTIES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our headquarters are located in Rockville, Maryland, where we occupy office
and laboratory space under a lease that expires on March&nbsp;31, 2018. Our manufacturing facility is also located in Rockville under a lease with the same landlord that expires on December&nbsp;31, 2014. We have an option under each lease to
continue the respective lease for five years under the same terms. We also sublease office and laboratory space in South San Francisco under a lease that expires on December&nbsp;31, 2018. We are seeking to sublease a substantial portion of this
space. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our properties are generally in good condition, well maintained, suitable and adequate to carry on our business.
We believe our capital resources are sufficient to lease any additional facilities required to meet our expected growth needs. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_6"></A>ITEM&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LEGAL PROCEEDINGS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, we are involved in various legal
proceedings, including, among others, patent oppositions, patent revocations, patent infringement litigation and other matters incidental to our business.&nbsp;We are not currently a party to any material legal proceedings. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_7"></A>ITEM&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MINE SAFETY DISCLOSURES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom644794_8"></A>PART II </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_9"></A>ITEM&nbsp;5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock has
been listed on the NASDAQ Global Select Market under the symbol &#147;MGNX&#148; since October&nbsp;10. 2013. Prior to that date, there was no public trading market for our common stock. Shares sold in our initial public offering (&#147;IPO&#148;)
on October&nbsp;9, 2013 were priced at $16.00 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;28, 2014, the closing price for our common stock as reported on
the NASDAQ Global Select Market was $35.00. The following table sets forth the high and low intra-day sale prices per share of our common stock as reported on the NASDAQ Global Select Market for the periods indicated. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter 2013 (from October 10, 2013)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;28, 2014, we had 27,471,329 shares of common stock outstanding held by approximately 192 holders of record, which include
shares held by a broker, bank or other nominee. We have never declared or paid any cash dividends. We do not anticipate declaring or paying cash dividends for the foreseeable future. Instead, we will retain our earnings, if any, for the future
operation and expansion of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Performance Graph </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following graph compares the performance of our common stock since October&nbsp;9, 2013, the date of our IPO, with the performance of the
NASDAQ Composite Index (U.S.) and the NASDAQ Biotechnology Index. The comparison assumes a $100 investment on October&nbsp;9, 2013 in our common stock, the stocks comprising the NASDAQ Composite Index, and the stocks comprising the NASDAQ
Biotechnology Index, and assumes reinvestment of the full amount of all dividends, if any. Historical stockholder return is not necessarily indicative of the performance to be expected for any future periods. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Comparison of Cumulative Total Return </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Among MacroGenics, Inc., the NASDAQ Composite Index and the NASDAQ Biotechnology Index </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g644794g49z75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The performance graph shall not be deemed to be incorporated by reference by means of any general statement
incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended or the Exchange Act, except to the extent that we specifically incorporate such information by reference, and shall not otherwise be deemed filed
under such acts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds from Registered Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2013, we completed our IPO of 5,750,000 shares of our common stock, including 750,000 shares of common stock sold pursuant
to the underwriters&#146; full exercise of their option to purchase additional shares at a public offering price of $16.00 per share, for aggregate gross proceeds of $92.0 million. All of the shares issued and sold in the IPO were registered under
the Securities Act pursuant to a Registration Statement on Form S-1 (File No.&nbsp;333-190994), which was declared effective by the Securities and Exchange Commission (&#147;SEC&#148;) on October&nbsp;9, 2013. Merrill Lynch, Pierce,
Fenner&nbsp;&amp; Smith Incorporated and Leerink Swann LLC acted as representatives of the several underwriters. The offering commenced on October&nbsp;10, 2013 and did not terminate until the sale of all of the shares offered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We received net proceeds from the offering of $83.8 million, after deducting approximately $6.4
million of underwriting discounts and commissions, and approximately $1.9 million of offering expenses payable by us. None of the underwriting discounts and commissions or other offering expenses were incurred or paid to our directors or officers or
their associates or to persons owning 10 percent or more of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been no material change in our planned use of the
net proceeds from the offering as described in our final prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act on October&nbsp;11, 2013. We have broad discretion in the use of the net proceeds from our initial public
offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_10"></A>ITEM&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SELECTED FINANCIAL DATA </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated statements of operations and comprehensive
income (loss) data for the years ended December&nbsp;31, 2013, 2012 and 2011 and the consolidated balance sheet data as of December&nbsp;31, 2013 and 2012 presented below have been derived from our audited consolidated financial statements and
footnotes included elsewhere herein. The consolidated balance sheet data as of December&nbsp;31, 2011 has been derived from our audited consolidated financial statements which are not included herein. Historical results are not necessarily
indicative of future results. The following data should be read in conjunction with Item&nbsp;7, &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and the consolidated financial statements and
related notes included elsewhere in this Annual Report on Form 10-K. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Comprehensive Income (Loss):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost and expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total costs and expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income (loss) per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average number of common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,847,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted weighted average number of common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,847,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,237</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_11"></A>ITEM&nbsp;7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The
following discussion of our financial condition and results of operations should be read together with our selected consolidated financial data and the consolidated financial statements and related notes included elsewhere herein. This discussion
contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth under the section entitled &#147;Risk Factors&#148;, &#147;Forward-Looking Statements&#148; and elsewhere herein, our
actual results may differ materially from those anticipated in these forward-looking statements. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for
the treatment of cancer and autoimmune diseases. We generate our pipeline of product candidates from our proprietary suite of next-generation antibody technology platforms which we believe improve the performance of monoclonal antibodies and
antibody-derived molecules. These product candidates, which we have identified through our understanding of disease biology and immune-mediated mechanisms, may address disease-specific challenges, which are not currently being met by existing
therapies. The combination of our technology platforms and antibody engineering expertise has allowed us to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.
These collaborations provide us with funding and allow us to leverage the additional expertise of our collaborators to advance the development of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have two oncology product candidates in clinical development. Additionally, we have several proprietary product candidates in
pre-clinical development and we expect to commence Phase 1 clinical trials on two of these product candidates in 2014. In addition, we intend to advance two pre-clinical Dual-Affinity Re-Targeting (&#147;DART&#148;)-based oncology product candidates
to Investigational New Drug (&#147;IND&#148;) submission and commence Phase 1 clinical trials in 2015. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Margetuximab</I>, also known as MGAH22, is an Fc-optimized monoclonal antibody that targets HER2-expressing tumors, including breast, gastroesophageal and other cancers. HER2, or human epidermal growth factor
receptor 2, is critical for the growth of many types of tumors. We are currently enrolling a Phase 2a clinical trial in metastatic breast cancer and plan to commence a Phase&nbsp;3 potential registration clinical trial in advanced gastroesophageal
cancer in the second half of 2014. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGA271</I> is an Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules and is over-expressed on a wide variety of solid tumor types. We expect to complete the first three dose
expansion cohorts of a Phase 1 clinical trial by the end of 2014. We plan to initiate additional expansion cohorts using MGA271 as monotherapy in other tumor types in 2014, as well as combining MGA271 with other therapies for certain tumor types.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGD006 </I>is a humanized DART molecule that recognizes CD123, the Interleukin-3 receptor (&#147;IL3R&#148;) alpha chain which is expressed on leukemia and leukemic stem cells, but not on normal hematopoietic stem
cells, and CD3, which is expressed on T cells. We expect to commence a Phase 1 clinical trial in the second quarter of 2014. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGD007</I> is a humanized DART molecule that recognizes both the glycoprotein gpA33, expressed on gastrointestinal tumors, including more than 95% of human colon cancers, and CD3, which is expressed on T cells. We
expect to commence a Phase 1 clinical trial in the second half of 2014. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We commenced active operations in 2000, and have
since devoted substantially all of our resources to staffing our company, business planning, raising capital, developing our technology platforms, identifying potential product candidates, undertaking pre-clinical studies and conducting clinical
trials. We have not generated any revenues from the sale of any products to date. We have financed our operations primarily through the private placements of convertible preferred stock, the public offerings of our common stock, collaborations,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and government grants and contracts. From inception through December&nbsp;31, 2013, we received $151.3 million from the sale of convertible preferred stock and warrants. We raised $85.6 million
($83.8 million net of expenses and deferred financing costs) in October 2013 through the sale of common stock in connection with our Initial Public Offering (&#147;IPO&#148;) and exercise by the underwriters of their over-allotment option. We raised
an additional $77.2 million ($76.7 million net of expenses and deferred financing costs) through a follow-on public offering of our common stock and full exercise by the underwriters of their over-allotment option in February 2014. In addition, we
have received $199.0 million of upfront, milestone and annual maintenance payments from our collaborators and have been reimbursed $220.4 million through our collaborations and government grants and contracts. Although it is difficult to predict our
funding requirements, based upon our current operating plan, we anticipate that our cash and cash equivalents as of December&nbsp;31, 2013, combined with the net proceeds from our subsequent follow-on offering and collaboration payments we
anticipate receiving, will enable us to fund the clinical development of margetuximab, MGA271, MGD006, MGD007, MGD010 and two additional pre-clinical DART-based oncology product candidates into 2017, assuming all of our collaboration programs
advance as currently contemplated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through December&nbsp;31, 2013, we had an accumulated deficit of $175.7 million. Due primarily to
upfront fees and milestones paid by our collaborators, we realized a profit of $8.4 million and $6.7 million for the years ended December&nbsp;31, 2012 and 2011, respectively. We incurred a net loss of approximately $0.3 million for the year ended
December&nbsp;31, 2013, primarily due to the conclusion in late 2012 of the teplizumab Prot&eacute;g&eacute; clinical trial-related reimbursement from Eli Lilly. We expect that over the next several years we will increase our expenditures in
research and development in connection with our ongoing activities with several clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategic Collaborations and Licenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into several strategic collaborations which provide us with significant additional funding in order to continue development of
our pipeline and to extend our technology platforms and on-going programs. Our collaborations have allowed us to speed up the progress of our on-going pre-clinical and clinical stage programs. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Servier</I>. In November 2011, we entered into a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier (collectively, &#147;Servier&#148;) under which we granted Servier an option
to obtain an exclusive license to develop and commercialize MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We received a $20.0 million option grant fee and a $10.0 million milestone payment, and
may be eligible to receive up to approximately $415.0&nbsp;million in license grant fees, and clinical, development, regulatory and sales milestone payments. In the event Servier exercises its option, Servier must pay a license grant fee, which we
estimate to be $30.0 million, based on the number of different indications represented within the planned Phase 1 patient population. We and Servier will share Phase 2 and Phase 3 development costs. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In September 2012, we entered into a second agreement with Servier and granted it options to obtain three separate exclusive licenses to
develop and commercialize DART-based molecules, consisting of those designated by us as MGD006 and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We received a
$20.0 million option grant fee. In addition, we will be eligible to receive up to approximately $1 billion in additional license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises all three of its
options and successfully develops, obtains regulatory approval for, and commercializes a product under each license, including $5.0&nbsp;million upon IND acceptance for each of MGD006, MGD007 and a third DART molecule. In addition to these milestone
payments, we and Servier will share Phase 2 and Phase 3 development costs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In February 2014, Servier exercised its option to develop and
commercialize MGD006, for which we received a $15.0 million license grant fee. We also received a $5.0 million milestone payment from Servier in connection with the IND application for MGD006 clearing the 30-day review period by the U.S. Food and
Drug Administration (&#147;FDA&#148;) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Additionally, under both agreements, Servier would be obligated to pay us low double digit to
mid-teen royalties on product sales in its territories. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Gilead.</I> In January 2013, we entered into an agreement with Gilead Sciences, Inc. (&#147;Gilead&#148;) for the research, development and commercialization of up to four DART-based molecules. The time period for
Gilead&#146;s exercise of one option has expired. At present, Gilead retains a license to one and options to two of the original four programs. Gilead has exclusive worldwide rights for each of these remaining programs. We received an initial $7.5
million license grant fee for the first DART-based molecule, and are eligible to receive $7.5 million in grant fees on each of the remaining two DART-based molecules if they are selected by Gilead. We are further eligible to receive up to an
additional $20 to $25 million in pre-clinical milestones across each of the three remaining DART programs and up to approximately $240 to $250 million per remaining program in additional clinical, regulatory and sales milestone payments if Gilead
exercises both remaining options and achieves all of the requisite milestones under each option and license. Gilead also provides funding for our internal and external research costs under the agreement. We are also eligible to receive tiered
royalties on the net sales at percentages ranging from the high-single digits to the low double digits, but less than teens, subject to reductions in specified circumstances. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Boehringer</I>. In October 2010, we entered into an agreement with Boehringer Ingelheim GmbH (&#147;Boehringer&#148;) to discover, develop and commercialize up to ten DART-based molecules which may span multiple
therapeutic areas. We granted Boehringer an exclusive worldwide, royalty-bearing license and received an upfront payment of $15.0 million. In the fourth quarter of 2013, Boehringer nominated a bi-specific antibody therapeutic candidate generated by
our DART technology for pre-clinical development. This formal selection of a development candidate triggered a $5.0 million milestone payment to us under the agreement. We have received three annual maintenance payments, including a $4.0 million
payment in the fourth quarter of 2013. We have the potential to earn development, regulatory and sales milestone payments that can reach up to approximately $210.0 million for each of the DART programs under this agreement. Boehringer provides
funding for our internal and external research costs and is required to pay us mid-single digit royalties on product sales. From the commencement of the collaboration through December&nbsp;31, 2013, we have received $48.8&nbsp;million under this
agreement, including upfront, annual maintenance and milestone payments as well as research funding. In addition, Boehringer purchased $10.0 million of our Series D-2 Preferred Stock in January 2011. This preferred stock was converted to common
stock upon our IPO in October 2013. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Pfizer.</I> In October 2010, we entered into a three year agreement with Pfizer, Inc. (&#147;Pfizer&#148;) to discover, develop and commercialize up to two DART-based molecules. We granted Pfizer a non-exclusive
worldwide, royalty-bearing license and received an upfront payment of $5.0 million and have received milestone payments and funding for our internal and external research costs under the agreement. We are eligible to receive technical, development
and sales milestone payments that can reach up to approximately $210.0 million for each DART program under this agreement. Pfizer is responsible for all pre-clinical and clinical development costs for the program. In addition, Pfizer is required to
pay us mid-single digit to low-teen royalties on product sales. Under this collaboration, one DART program is currently being pursued and we completed our research obligations under this program in January 2014. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Green Cross.</I> In June 2010, we entered into a collaboration agreement with Green Cross Corp. (&#147;Green Cross&#148;) for the development of margetuximab. We granted Green Cross an exclusive license for all
indications for all pharmaceutical forms of margetuximab in South Korea. Under the terms of this agreement, we received an upfront, nonrefundable payment of $1.0 million and are eligible to receive clinical, development and commercial milestone
payments up to $4.5 million as well as royalties ranging from the low-single digits to the low-twenties on net sales of margetuximab in South Korea. In addition, Green Cross purchased $2.0 million of our Series D-2 Preferred Stock in January 2011.
This preferred stock was converted to common stock upon our IPO in October 2013. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Operations Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue consists of
collaboration revenue, including amounts recognized relating to upfront nonrefundable payments for licenses or options to obtain future licenses, research and development funding and milestone payments earned under our collaboration and license
agreement with our strategic collaborators, including Servier, Gilead, Boehringer, Pfizer and Green Cross. In addition, we have earned revenues through several grants and/or contracts with the U.S. government and other educational institutions on
behalf of the U.S. government, primarily with respect to research and development activities related to infectious disease product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of expenses incurred in performing research and development activities. These expenses include
conducting pre-clinical experiments and studies, clinical trials, manufacturing efforts and regulatory filings for all product candidates, and other indirect expenses in support of our research and development activities. We capture research and
development expense on a program-by-program basis for our product candidates that are in clinical development and recognize these expenses as they are incurred. The following are items we include in research and development expenses: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Employee-related expenses such as salaries and benefits; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Employee-related overhead expenses such as facilities and other allocated items; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stock-based compensation expense to employees and consultants engaged in research and development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Depreciation of laboratory equipment, computers and leasehold improvements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Fees paid to consultants, subcontractors, clinical research organizations (&#147;CROs&#148;) and other third party vendors for work performed under our pre-clinical and clinical trials including but not limited to
investigator grants, laboratory work and analysis, database management, statistical analysis, and other items; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amounts paid to vendors and suppliers for laboratory supplies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Costs related to manufacturing clinical trial materials, including vialing, packaging and testing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">License fees and other third party vendor payments related to in-licensed product candidates and technology; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Costs related to compliance with regulatory requirements. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is difficult to determine with
certainty the duration and completion costs of our current or future pre-clinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our
product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a
variety of factors, including the uncertainties of future clinical trials and pre-clinical studies, uncertainties in clinical trial enrollment rate and significant and changing government regulation. In addition, the probability of success for each
product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical
success of each product candidate, as well as an assessment of each product candidate&#146;s commercial potential. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist of salaries and related benefit costs for employees in our executive, finance, legal and
intellectual property, business development, human resources and other support functions, travel expenses and other legal and professional fees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other
income (expense) consists of interest income earned on our cash equivalents, offset by interest expense and other expense, including changes in the fair market value of the preferred stock warrant liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of financial conditions and results of operations is based on our consolidated financial
statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the balance sheets and the reported amount of the revenue and expenses recorded during the reporting period. We base our
estimates on historical experience and on various other assumptions that we believe to be reasonable. We review and evaluate these estimates on an on-going basis. These assumptions and estimates form the basis for making judgments about the carrying
values of assets and liabilities and amounts that have been recorded as revenues and expenses. Actual results and experiences may differ from these estimates. The results of any material revisions would be reflected in the consolidated financial
statements prospectively from the date of the change in estimate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While a summary of significant accounting policies is described fully
in Note 2 in our consolidated financial statements, we believe that the following accounting policies are the most critical to assist you in fully understanding and evaluating our financial results and any affect the estimates and judgments we used
in preparing our consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat
cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i)&nbsp;licenses, or options to obtain licenses, to our technological platforms, such as our Fc engineering and DART technologies,
(ii)&nbsp;rights to future technological improvements, (iii)&nbsp;research and development activities to be performed on behalf of the collaborative partner or as part of the collaboration, and (iv)&nbsp;the manufacture of pre-clinical or clinical
materials for the collaborative partner. Payments to us under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of pre-clinical or
clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to us from these agreements include the right to sell products resulting from the
collaborative efforts of the parties in specific geographic territories. We follow the provisions of the Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) Topic 605-25, <I>Revenue
Recognition&#150;Multiple-Element Arrangements,</I> and ASC Topic 605-28, <I>Revenue Recognition&#150;Milestone Method</I>, in accounting for these agreements. In order to account for these agreements, we must identify the deliverables included
within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received
is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, we had the following two types of agreements: 1) exclusive development and commercialization licenses to use our
technology and/or certain other intellectual property to develop compounds </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
against specified targets, which we refer to as exclusive licenses; and 2) option/research agreements to secure on established terms development and commercialization licenses to anticancer and
other therapeutic product candidates to collaborator selected targets developed by us during an option period, which we refer to as right-to-develop agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Licenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
deliverables under an exclusive license agreement generally include the exclusive license to our technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements,
research and pre-clinical development activities to be performed on behalf of the collaborator. In some cases we may have an option to participate in the co-development of product candidates that result from such agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that we
will (i)&nbsp;at the collaborator&#146;s request, provide research and pre-clinical development services at negotiated prices which are generally consistent with what other third parties would charge, (ii)&nbsp;earn payments upon the achievement of
certain milestones, (iii)&nbsp;earn royalty payments, and (iv)&nbsp;in some cases grant us an option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term
depending on our intellectual property rights and whether we exercise any co-development and co-commercialization rights. We may provide technical assistance and share any technology improvements with our collaborators during the term of the
collaboration agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not directly control when any collaborator will achieve milestones or become liable for royalty payments.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the units of accounting, management evaluates whether the exclusive license has stand-alone value from the undelivered
elements to the collaborator based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the collaborator and the availability of technology
platform and product research expertise in the general marketplace. If we conclude that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, we then determine the estimated selling prices of the
license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of our previous collaboration agreements, recent pre-clinical and clinical
testing results of therapeutic product candidates that use our technology platforms, our pricing practices and pricing objectives, the likelihood that technological improvements will be made, the likelihood that technological improvements made will
be used by our collaborators and the nature of the research services to be performed on behalf of our collaborators and market rates for similar services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upfront payments on exclusive licenses are deferred if facts and circumstances dictate that the license does not have stand-alone value. Prior
to the adoption of Accounting Standards Update (&#147;ASU&#148;) No.&nbsp;2009-13, <I>Revenue Arrangements with Multiple Deliverables</I>, on January&nbsp;1, 2011, we determined that our licenses lacked stand-alone value and were combined with other
elements of the arrangement and any amounts associated with the license were deferred and amortized over a certain period, which we refer to as our period of substantial involvement. The determination of the length of the period over which to defer
revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period. Historically, our involvement with the development of a collaborator&#146;s product candidate has been significant at the
early stages of development, and lessens as it progresses into clinical trials. Accordingly, we generally estimate this period of substantial involvement to begin at the inception of the collaboration agreement and conclude at the end of our
substantial involvement. We reassess our periods of substantial involvement over which we amortize our upfront license fees and make adjustments as appropriate. In the event a collaborator elects to discontinue development of a specific product
candidate under a single target license, but retains its right to use our technology to develop an alternative product candidate to the same target or a target substitute, we would cease amortization of any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
remaining portion of the upfront fee until there is substantial pre-clinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the
event that a single target license were to be terminated, we would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or
through the remaining substantial involvement in the wind down of the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upfront payments on exclusive licenses may be recognized
upon delivery of the license if facts and circumstances dictate that the license has stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of
pre-clinical and clinical materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue related to research and pre-clinical development services that represent
separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable is probable. We recognize revenue related to the rights to
future technological improvements over the estimated term of the applicable license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We typically perform research activities and
pre-clinical development services, including generating and engineering product candidates, on behalf of our licensees during the early evaluation and pre-clinical testing stages of drug development under our exclusive licenses. We record amounts
received for research materials produced or services performed as revenue from collaborative research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our license agreements have
milestone payments which for reporting purposes are aggregated into three categories: (i)&nbsp;development milestones, (ii)&nbsp;regulatory milestones, and (iii)&nbsp;sales milestones. Development milestones are typically payable when a product
candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the FDA or other countries&#146; regulatory authorities or on receipt of actual marketing
approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the inception of each agreement that includes milestone payments, we evaluate whether each milestone is substantive and at risk to both
parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a)&nbsp;the consideration is commensurate with either (1)&nbsp;our performance to achieve the milestone, or (2)&nbsp;the enhancement
of the value of the delivered item(s) as a result of a specific outcome resulting from our performance to achieve the milestone, (b)&nbsp;the consideration relates solely to past performance and (c)&nbsp;the consideration is reasonable relative to
all of the deliverables and payment terms within the arrangement. We evaluate factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment
required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-refundable development and regulatory milestones that are expected to be achieved as a result of our efforts during the period of
substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because we did not
contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no
continuing performance obligations, assuming all other revenue recognition criteria are met. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Right-to-Develop Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize in specified
geographic territories product candidates developed by us under agreed upon research and pre-clinical development programs. The product candidates resulting from each program are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all directed to a specific target selected by the collaborator. Under these agreements, fees may be due to us (i)&nbsp;at the inception of the arrangement (referred to as &#147;upfront&#148; fees
or payments), (ii)&nbsp;the selection of a target for a program, (iii) upon the exercise of an option to acquire a development and commercialization license, referred to as exercise fee, for a program, or (iv)&nbsp;some combination of all of these
fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborative partner.
Options are considered substantive if, at the inception of a right-to-develop agreement, we are at risk as to whether the collaborative partner will choose to exercise the options to secure development and commercialization licenses. Factors that
are considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to
the total upfront consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered
substantive, we do not consider the development and commercialization licenses to be a deliverable at the inception of the agreement. For those right-to-develop agreements entered into prior to the adoption of ASU No.&nbsp;2009-13 where the options
to secure development and commercialization licenses are considered substantive, we have deferred the upfront payments received and recognize this revenue over the period during which the collaborator could elect to exercise options for development
and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option, generally 12
months. If a collaborator exercises an option and acquires a development and commercialization license to a product program, we attribute the exercise fee to the development and commercialization license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon exercise of an option to acquire a development and commercialization license, we would also attribute any remaining deferred option fee,
in addition to the consideration received for the license upon exercise of the option, to the development and commercialization license. We then apply the multiple-element revenue recognition criteria to the development and commercialization license
and other deliverables, if any, to determine the appropriate revenue recognition method. This method is consistent with our accounting policy for upfront payments on exclusive licenses (discussed above). In the event a right-to-develop agreement
were to be terminated, we would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered
substantive, we consider the development and commercialization licenses to be a deliverable at the inception of the agreement and apply the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. All of our
right-to-develop agreements have been determined to contain substantive options. We do not directly control when any collaborator will exercise its options for development and commercialization licenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense and related Accrued Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our consolidated financial statements, we may be required to estimate accrued expenses. In order to obtain
reasonable estimates, we review open contracts and purchase orders. In addition, we communicate with applicable personnel in order to identify services that have been performed, but for which we have not yet been invoiced. In most cases, our vendors
provide us with monthly invoices in arrears for services performed. We confirm our estimates with these vendors and make adjustments as needed. The following are examples of our accrued expenses: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Fees paid to CROs for services performed on clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Fees paid to investigate sites for performance on clinical trials; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Fees paid for professional services. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenses related to clinical trials performed by our CROs are dependent on the successful
enrollment of patients. These expenses can vary from site to site and contract to contract. We base our estimated accruals on the time period over which the services are to be performed and the level of effort to be expended in each period based on
the estimated enrollment of patients in each trial. We will adjust accordingly should the estimates vary from the actual expenses. However, we do not anticipate that our payment of actual expenses will differ materially from our estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred tax assets
and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to
reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation
allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a
more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Our
policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded net
deferred tax assets of $79.4 million as of December&nbsp;31, 2013, which have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax benefits. The deferred tax assets are primarily comprised of
federal and state tax net operating loss (&#147;NOL&#148;) carryforwards and research and development tax credit carryforwards. As of December&nbsp;31, 2013, we had federal NOL carryforwards of $104.8 million, state NOL carryforwards of $60.3
million and research and development tax credit carryforwards of $23.7 million available. The federal NOL carryforwards will begin to expire at various dates starting in 2023. We are already subject to Section&nbsp;382 limitations due to an
acquisition we made in 2008. Future changes in stock ownership may also trigger an ownership change and, consequently, another Section&nbsp;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit
carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax
credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
recognize stock-based compensation expense in accordance with the provisions of ASC Topic 718, <I>Compensation&#151;Stock Compensation</I>. The fair value of stock-based payments is estimated, on the date of grant, using a Black-Scholes model. The
resulting fair value is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the option. The use of a Black-Scholes model requires us to apply judgment and make assumptions and estimates
that include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Fair Value of Common Stock</I><B>&#151;</B>Before our entry into the public market on October&nbsp;10, 2013, our Board of Directors determined the fair value of the common stock. The Board of Directors made
determinations of fair value based, in part, upon contemporaneous valuations to determine fair value. The contemporaneous valuations were performed in accordance with applicable methodologies, approaches and assumptions of the technical practice-aid
issued by the American Institute of Certified Public Accountants Practice Aid entitled <I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><I>Expected Volatility</I>&#151;Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical
volatility) or is expected to fluctuate (expected volatility) during a period. As we do not yet have sufficient history of our own volatility, we have identified several public </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
entities of similar size, complexity and stage of development and calculate the historical volatility using the volatility of these companies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected Dividend Yield</I>&#151;We have never declared or paid dividends and have no plans to do so in the foreseeable future. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Risk-Free Interest Rate</I>&#151;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected Term</I>&#151;This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years and we have estimated the expected life of the option
term to be seven years. We use a simplified method to calculate the average expected term. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected Forfeiture Rate</I>&#151;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. We estimate the
forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations for the Years Ended December&nbsp;31, 2013 and 2012 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents a comparison of our research and development revenue for the years ended December&nbsp;31, 2013 and 2012: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaborative research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total revenue</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>58.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>63.8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5.8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decrease in collaboration revenue of $2.9 million for the year ended December&nbsp;31, 2013 compared to
2012 is primarily due to the conclusion of teplizumab clinical trial-related reimbursement revenue from our former collaborator, Eli Lilly. Aside from reimbursing us for the continued monitoring expense of one on-going trial, Eli Lilly&#146;s
participation in the development of teplizumab concluded in the first quarter of 2013. This decrease is partially offset by the receipt of a $10.0 million milestone payment under our agreement with Servier, a $5.0 million milestone payment from
Boehringer, and the addition of our collaboration with Gilead. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grant revenue decreased in the year ended December&nbsp;31, 2013 compared
to 2012 due primarily to the completion of grants to study H5N1 influenza virus, small pox and West Nile virus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents a comparison of our research and development expense for the years ended December&nbsp;31, 2013 and 2012: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Margetuximab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MGA271</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DART-based product candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teplizumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other discovery and pre-clinical programs, collectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total research and development expense</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46.6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>45.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2013 our research and development expense increased by $1.2 million
compared to 2012 due to an increase in spending on DART-based product candidates, offset by the reduction in spending on teplizumab-related clinical development as we ended trial enrollment and began closing down the trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents a comparison of our general and administrative expense for the years ended December&nbsp;31, 2013 and 2012: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expense increased for the year ended December&nbsp;31, 2013 by $0.9 million
compared to 2012 primarily due to an increase in professional fees and other costs associated with preparations for public company operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change
to other expense of $626,813 for the year ended December&nbsp;31, 2013 from other income of $156,445 for the year ended December&nbsp;31, 2012 is primarily due to the change in the fair market value of the preferred stock warrant liability (which
was settled in connection with the Company&#146;s IPO). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations for the Years Ended December&nbsp;31, 2012 and 2011 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents a comparison of our research and development revenue for the years ended December&nbsp;31, 2012 and
2011: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaborative research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total revenue</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>63.8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6.7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in collaboration revenue of $12.6 million for the year ended December&nbsp;31, 2012
compared to 2011 is primarily due to two Servier collaborations, one of which was signed in late 2011 and one which was signed in late 2012. Grant revenue decreased as our contract with the U.S. government to develop a monoclonal antibody for the
treatment of West Nile Virus ended in September 2011. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents a comparison of our research and development expense for the years ended December&nbsp;31, 2012 and 2011: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Margetuximab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MGA271</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DART-based product candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teplizumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other discovery and pre-clinical programs, collectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total research and development expense</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>45.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>41.1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4.3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenditures in research and development increased by $4.3 million overall during the year ended
December&nbsp;31, 2012 compared to 2011. This was due to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Increased spending in support of the MGA271 Phase 1 clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Increased spending on toxicology related studies and increased efforts on our DART-based product candidates as a result of additional collaborations; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Despite ceasing enrollment on teplizumab-related clinical trials, we continued to follow the patients for an additional 18 months and closed down the trials in late 2012. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These increases were partially offset by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Completion of our contract with the U.S. government to study West Nile Virus that resulted in a reduction in spending; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reduced spending on our Cancer Stem-like Cell (&#147;CSLC&#148;) efforts. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative
Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents a comparison of our general and administrative expense for the years ended December&nbsp;31, 2012
and 2011: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decrease in general and administrative expense of $0.7 million is due primarily to reduced patent filing
and related legal expense, which was partially offset by an increase in the amount of bonuses paid in the year ended December&nbsp;31, 2012. Additionally, we realized a savings from the consolidation of personnel from three to two facilities in
Rockville, Maryland. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decrease in other income of $1.3 million for the year ended December&nbsp;31, 2012 compared to the year ended December&nbsp;31, 2011 is
primarily due to the change in the fair market value of the preferred stock warrant liability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table represents a summary of our cash flows for the years ended December&nbsp;31, 2013, 2012 and 2011: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by (used in):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>68.7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7.5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities reflects, among other things, the amounts used to run our clinical trials and pre-clinical activities,
including toxicology studies. The difference between net cash used in operating activities during the year ended December&nbsp;31, 2013 and 2012 was primarily due to less teplizumab clinical trial-related reimbursement revenue from our former
collaborator, Eli Lilly, and higher general and administrative expenses, offset by receipt of a $10.0 million milestone from Servier and a $5.0 million milestone from Boehringer. The difference between 2012 and 2011 was primarily due to upfront fees
received from our collaborators. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities in each of the years ended December&nbsp;31, 2013, 2012, and 2011 is primarily due to the acquisition of
additional lab equipment needed to further our research and development activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the year ended December&nbsp;31, 2013 includes net proceeds from our IPO and cash from stock
option exercises. Net cash provided by financing activities for the year ended December&nbsp;31, 2011 includes net proceeds from the issuance of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
our inception through December&nbsp;31, 2013, we have raised an aggregate of $654.5 million to fund our operations. Of this total amount, we have received $151.3 million from the sale of convertible preferred stock and warrants, $364.7 million from
our collaborators, including payments in the form of upfront, milestone and annual maintenance payments and reimbursement for research and development services performed, $83.8 million from our IPO and $54.7 million from government grants and
contracts. As of December&nbsp;31, 2013, we had $116.5 million in cash and cash equivalents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2013, we completed the IPO of our common stock, which resulted in the sale of
5,750,000 shares, including all additional shares available to cover over-allotments, at a price of $16.00 per share. We raised $85.6 million ($83.8 million net of expenses and deferred financing costs). In connection with the closing of the IPO,
all of our outstanding convertible preferred stock automatically converted to common stock at various ratios as disclosed in Note 4 to the financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;18, 2014, we completed a follow-on public offering of our common stock, in which we sold 1,800,000 shares of common stock, at
a price of $36.50 per share. Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 450,000 shares of our common stock at a price of $36.50 per share. We
received net proceeds of $76.7 million from the offering, net of underwriting discounts and commissions and other estimated offering expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our existing cash and cash equivalents, we expect to continue to receive additional reimbursement from our collaborators for
research and development services rendered, additional milestone, opt-in and annual license maintenance payments and grant revenue. However, our ability to receive these milestone payments is dependent upon our ability to achieve certain levels of
research and development activities and is therefore uncertain at this time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not generated any revenue from product sales to date and do not expect to do so until such time as we obtain regulatory approval of and
commercialize one or more of our product candidates. As we are currently in the clinical trial stage of development, it will be some time before we expect to achieve this and it is uncertain that we ever will. We expect that we will continue to
increase our operating expenses in connection with ongoing as well as additional clinical trials and pre-clinical development of product candidates in our pipeline. We expect to continue our collaboration arrangements and will look for additional
collaboration opportunities. We also expect to continue our efforts to pursue additional grants and contracts from the U.S. government in order to further our research and development. Although it is difficult to predict our funding requirements,
based upon our current operating plan, we anticipate that our existing cash and cash equivalents as of December&nbsp;31, 2013, combined with the net proceeds from our subsequent follow-on offering and collaboration payments we anticipate receiving,
will enable us to fund the clinical development of margetuximab, MGA271, MGD006, MGD007, MGD010 and two additional pre-clinical DART-based oncology product candidates into 2017, assuming all of our collaboration programs advance as currently
contemplated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Contingent Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table represents future minimum operating lease payments under non-cancelable operating leases as of December&nbsp;31, 2013: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;to&nbsp;3&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3&nbsp;to&nbsp;5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5 years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current obligations and contingent liabilities are limited to the operating leases at our three
facilities, including two in Rockville, Maryland and one in South San Francisco, California. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with an Asset Purchase
Agreement with Tolerance Therapeutics, Inc. (&#147;Tolerance&#148;) entered into in June 2005, we may be required to give Tolerance additional consideration as follows: (i)&nbsp;a maximum of $10.9 million if certain milestones are met, including the
initiation of Phase 3 trials and the filing of various regulatory product license applications; (ii)&nbsp;36,135 shares of our common stock; and (iii)&nbsp;royalty payments between 1.75% and 4.0% of net sales of products acquired from or patented by
Tolerance or other product fees earned by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2008, we acquired Raven Biotechnologies (&#147;Raven&#148;). The Raven purchase agreement
provides for certain contingent payments that are based on the achievement of development and commercialization activities for product candidates derived from the acquired Raven technology. We are required to make a onetime payment of $5.0 million
to the former Raven stockholders upon the initiation of patient dosing in the first Phase 2 clinical trial of any product derived from the Raven cancer stem cell program. No payment shall be made if the Phase 2 trial start date has not occurred on
or before July&nbsp;15, 2018. Other consideration includes a percentage of revenue (excluding consideration for research and development, equity and certain cost reimbursements) we may receive for each license of a product candidate derived from the
Raven cancer stem cell program. The revenue percentage in each case is based upon the execution date of the subject license. No consideration is owed for licenses executed after July&nbsp;16, 2018. There is additional contingent consideration of one
time payments of $8.0 million and $12.0 million, which depend upon the achievement of a specified level of sales of a product derived from the Raven cancer stem cell program. At our sole discretion, each payment can be made in cash, common stock or
a combination thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The contractual obligations table does not include any potential future payments we may be required to make under
our Asset Purchase Agreement with Tolerance or the purchase agreement with Raven. Due to the uncertainty of the achievement and timing of the events requiring payment under that agreement, the amounts to be paid by us are not fixed or determinable
at this time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_12"></A>ITEM&nbsp;7A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary objective when
considering our investment activities is to preserve capital in order to fund our operations. As of December&nbsp;31, 2013, we had cash and cash equivalents of $116.5 million, of which $26.0 million was invested in money market funds and the
remainder was in our corporate operating account. Our primary exposure to market risk is related to changes in interest rates and our current investment policy is to invest principally in deposits and securities issued by the U.S. government and its
agencies and money market instruments. We do not believe that our cash and cash equivalents have significant risk. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_13"></A>ITEM&nbsp;8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item is
set forth on pages F-1&#151;F-32. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_14"></A>ITEM&nbsp;9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_15"></A>ITEM&nbsp;9A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONTROLS AND PROCEDURES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclosure Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management, including our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls
and procedures as of December&nbsp;31, 2013. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in this annual report on Form 10-K has been appropriately recorded,
processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#146;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and
principal financial officers, to allow timely </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
decisions regarding required disclosure. Based on that evaluation, our principal executive and principal financial officers have concluded that our disclosure controls and procedures are
effective at the reasonable assurance level. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in Internal Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management, including our principal executive and principal financial officers, has evaluated any changes in our internal control over
financial reporting that occurred during the quarterly period ended December&nbsp;31, 2013, and has concluded that there was no change that occurred during the quarterly period ended December&nbsp;31, 2013 that has materially affected, or is
reasonably likely to materially affect, our internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management Report on Internal Control over Financial Reporting
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting.
Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, the Company&#146;s principal executive and
principal financial officers and effected by the Company&#146;s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pertain to the management of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of
the Company are being made only in accordance with authorizations of management and directors of the Company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#146;s assets that could have a material effect on the financial statements.
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All
internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s management assessed the effectiveness of the Company&#146;s internal control over financial reporting as of
December&nbsp;31, 2013. In making this assessment, the Company&#146;s management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (1992 framework) (COSO) in Internal Control-Integrated Framework.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our assessment, management believes that, as of December&nbsp;31, 2013, the Company&#146;s internal control over financial
reporting is effective based on those criteria. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_16"></A>ITEM&nbsp;9B.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>OTHER INFORMATION </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom644794_17"></A>PART III </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_18"></A>ITEM&nbsp;10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate herein by
reference the relevant information concerning directors, executive officers and corporate governance to be included in our definitive proxy statement for the 2014 annual meeting of stockholders (the &#147;2014 Proxy Statement&#148;). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_19"></A>ITEM&nbsp;11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EXECUTIVE COMPENSATION </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate herein by reference the relevant information
concerning executive compensation to be included in the 2014 Proxy Statement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_20"></A>ITEM&nbsp;12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate herein by reference the relevant information concerning security ownership of certain beneficial owners and management to be
included in the 2014 Proxy Statement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_21"></A>ITEM&nbsp;13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
incorporate herein by reference the relevant information concerning certain other relationships and related transactions to be included in the 2014 Proxy Statement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_22"></A>ITEM&nbsp;14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PRINCIPAL ACCOUNTING FEES AND SERVICES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate herein by reference the relevant
information concerning principal accounting fees and services to be included in the 2014 Proxy Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom644794_23"></A>PART IV </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="rom644794_24"></A>ITEM&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">The following documents are filed as part of this Annual Report on Form 10-K: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consolidated Financial Statements: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated Balance Sheets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated Statements of Operations and Comprehensive Income (Loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated Statements of Stockholders&#146; Equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated Statements of Cash Flows</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes to Consolidated Financial Statements</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Financial Statement Schedules: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">All financial statement schedules have been omitted because
they are not applicable, not required or the information required is shown in the financial statements or the notes thereto. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The exhibits filed as part of this Annual Report on Form 10-K are set forth on the
Exhibit Index immediately following our consolidated financial statements. The Exhibit Index is incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom644794_25"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">M<SMALL>ACRO</SMALL>G<SMALL>ENICS</SMALL>, I<SMALL>NC</SMALL>.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Scott Koenig</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scott Koenig, M.D., Ph.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>President and
CEO and Director</I></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1934, as amended, this Report has been signed by
the following persons on behalf of the registrant and in the capacities and on the dates indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Date</B></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Koenig</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Scott Koenig, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and CEO and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">March 20, 2014</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James Karrels</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">James Karrels</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President, Chief Financial</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Officer and Secretary (Principal</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">March 20, 2014</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lynn Cilinski</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Lynn Cilinski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President, Controller and</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasurer (Principal&nbsp;Accounting</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">March 20, 2014</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Paulo Costa</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Paulo Costa</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">March 20, 2014</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Fust</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Matthew Fust</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">March 20, 2014</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kenneth Galbraith</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kenneth Galbraith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">March 20, 2014</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Edward Hurwitz</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Edward Hurwitz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">March 20, 2014</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eran Nadav, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Eran Nadav, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">March 20, 2014</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Arnold Oronsky, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Arnold Oronsky, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">March 20, 2014</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Stump, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">David Stump, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">March 20, 2014</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Page<BR>Number</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin644794_1">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin644794_2">Consolidated Balance Sheets at December&nbsp;31, 2013 and 2012</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin644794_3">Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended December&nbsp;
31, 2013, 2012 and 2011</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin644794_4">Consolidated Statements of Stockholders&#146; Equity (Deficit) for the years ended December&nbsp;
31, 2013, 2012 and 2011</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin644794_5">Consolidated Statements of Cash Flows for the years ended December&nbsp;31, 2013, 2012 and 2011</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin644794_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin644794_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors and Stockholders </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MacroGenics,&nbsp;Inc.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of MacroGenics, Inc. as of December&nbsp;31, 2013 and 2012, and the related
consolidated statements of operations and comprehensive income (loss), stockholders&#146; equity (deficit) and cash flows for each of the three years in the period ended December&nbsp;31, 2013. These financial statements are the responsibility of
the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. We were not engaged to perform an audit of the Company&#146;s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit
procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also
includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our opinion, the financial statements referred to
above present fairly, in all material respects, the consolidated financial position of MacroGenics, Inc. at December&nbsp;31, 2013 and 2012, and the consolidated results of its operations and its cash flows for each of the three years in the period
ended December&nbsp;31, 2013, in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-right:21%; font-size:10pt; font-family:Times New Roman" ALIGN="right">/s/ Ernst&nbsp;&amp;
Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">McLean, Virginia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;20, 2014 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin644794_2"></A>CONSOLIDATED BALANCE SHEETS </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,481,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,743,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,004,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,046,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">971,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,457,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,927,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,035,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,267,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">885,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,782,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,746,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,169,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,739,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,583,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,237,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Lease exit liability&#151;current</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,438,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">628,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Deferred revenue&#151;current</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,267,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,123,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Other liabilities&#151;current</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">362,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,821,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,728,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Lease exit liability, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,006,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,445,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Deferred rent liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,904,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,801,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,135,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,956,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,867,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,984,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Series A-1 convertible preferred stock, $0.01 par value&#151;26,874,792 shares authorized, issued and outstanding at December&nbsp;31,
2012 with an aggregate liquidation preference of $27,000,000; no shares outstanding at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Series A-2 convertible preferred stock, $0.01 par value&#151;7,364,582 shares authorized, issued and outstanding at December&nbsp;31,
2012 with an aggregate liquidation preference of $7,000,000; no shares outstanding at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Series B convertible preferred stock, $0.01 par value&#151;71,401,237 shares authorized, issued and outstanding at December&nbsp;31,
2012 with an aggregate liquidation preference of $31,000,000; no shares outstanding at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Series C convertible preferred stock, $0.01 par value&#151;110,952,217 shares authorized, issued and outstanding at December&nbsp;31,
2012 with an aggregate liquidation preference of $45,000,000; no shares outstanding at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Series D-1 convertible preferred stock, $0.01 par value&#151;30,000,000 shares authorized, 14,446,227 shares issued and outstanding at
December&nbsp;31, 2012 with an aggregate liquidation preference of $9,400,000; no shares outstanding at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Series D-2 convertible preferred stock, $0.01 par value&#151;75,000,000 shares authorized, 63,681,176 shares issued and outstanding at
December&nbsp;31, 2012 with an aggregate liquidation preference of $41,500,000; no shares outstanding at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Common stock, $0.01 par value&#151;125,000,000 shares authorized and 25,177,597 shares outstanding at December&nbsp;31, 2013;
425,000,000 shares authorized and 1,098,914 shares outstanding at December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Treasury stock, at cost; 14,381 shares at December&nbsp;31, 2013 and December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,453,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,334,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(175,733,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(175,472,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,914,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,237,308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,782,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,746,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman"><I>See accompanying notes. </I></P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin644794_3"></A>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaborative research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,753,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,645,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,054,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,281,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,180,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,152,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,034,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,826,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,207,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs and expenses:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,581,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,432,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,088,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,086,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,187,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,868,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total costs and expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,668,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,620,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,957,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,205,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,249,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(626,814</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,467,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net comprehensive income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(260,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income (loss) per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average number of common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,847,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted weighted average number of common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,847,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:380pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>See accompanying notes. </I></P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin644794_4"></A>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY (DEFICIT) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:5.5pt" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT><BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT><BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B><br><B>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C</B><br><B>Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D</B><br><B>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D-2<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Treasury Stock</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid-In</B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;</B><br><B>Equity&nbsp;(Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Balance, December&nbsp;31, 2010</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,874,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,364,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,401,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,952,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,446,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,253,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">452,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">149,202,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(190,551,278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,634,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,347,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,347,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Issuance of convertible Series D-2 stock, net of offering costs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,427,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,830,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,014,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Stock option exercises</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Balance, December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,874,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,364,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,401,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,952,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,446,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,681,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,049,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163,449,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(183,834,158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,484,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Stock option exercises</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Balance, December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,874,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,364,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,401,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,952,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,446,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,681,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,334,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(175,472,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,237,308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Issuance of common stock, net of offering costs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,564,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,622,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Conversion of preferred stock to common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,874,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(268,748</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,364,582</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,401,237</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(714,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110,952,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,109,522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,446,227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(144,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,681,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(636,812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,060,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,637,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,860,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Stock option exercises</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,054,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,067,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(260,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(260,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:5.5pt; font-family:Times New Roman">Balance, December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,177,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">251,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">254,453,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(175,733,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,914,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin644794_5"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(260,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,193,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">959,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,147,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,347,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustment of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(150,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,459,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,351,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,551,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(834,071</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(133,782</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(570,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,312,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,271,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,346,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease exit liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(628,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(533,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(447,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,676,509</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,810,089</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,275,976</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by operating activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,172,123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,581,989</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,757,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,960,776</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(940,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(500,213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,960,776</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(940,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(500,213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of preferred stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,014,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock, net of offering costs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,871,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,871,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,085,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,738,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,475,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,342,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,743,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,218,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,876,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,481,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,743,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,218,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Noncash financing activities:</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of preferred stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,947,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:140pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>See accompanying notes. </I></P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin644794_6"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Nature of Operations </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MacroGenics, Inc. (the &#147;Company&#148;) was incorporated in Delaware on August&nbsp;14, 2000. The Company is a
clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The Company generates its pipeline of product candidates from its
proprietary suite of next-generation antibody technology platforms which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which the Company has identified through its
understanding of disease biology and immune-mediated mechanisms, may address disease-specific challenges which are not currently being met by existing therapies. The Company creates both differentiated molecules that are directed to novel cancer
targets, as well as &#147;bio-betters&#148; which are drugs designed to improve upon marketed medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2013, the
Company completed an initial public offering (&#147;IPO&#148;) of its common stock, which resulted in the sale of 5,750,000 shares, including all additional shares available to cover over-allotments, at a price of $16.00 per share. The Company
received net proceeds before expenses from the IPO of $85.6 million after deducting underwriting discounts and commissions paid by the Company. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Principles of Consolidation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics West, Inc. All
intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is
available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing monoclonal
antibody-based therapeutics for cancer, autoimmune and infectious diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the financial statements in accordance with generally accepted accounting principles (&#147;GAAP&#148;) requires the Company
to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial
statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to
revenue recognition, fair values of assets, convertible preferred stock and common stock, preferred stock warrant liability, income taxes, pre-clinical study and clinical trial accruals and other contingencies. Management bases its estimates on
historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, prior to the Company&#146;s IPO in October 2013, the Company utilized estimates and assumptions in determining the fair value of
its common stock. The Company granted stock options at exercise prices not less than the fair value of its common stock as determined by the Board of Directors, with input from management. Management used contemporaneous valuations in estimating the
fair value of its common stock. The board of directors determined the estimated fair value of the common stock based on a number of objective and subjective factors, including external market considerations affecting the biotechnology industry and
the historic prices at which the Company sold shares of its preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of
purchase to be cash equivalents. Cash and cash equivalents consist of certificates of deposit and investments in money market funds with commercial banks and financial institutions. Cash equivalents are stated at amortized cost, plus accrued
interest, which approximates fair value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts Receivable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding
amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors
including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of
December&nbsp;31, 2013 or 2012, as the Company has a history of collecting on all outstanding accounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to maintain certificates of deposit that serve as collateral for various operating leases and corporate credit card
accounts. Amounts classified as restricted cash on the consolidated balance sheets are $404,850 at December&nbsp;31, 2013 and 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of
Financial Instruments </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair market values of the financial instruments included in the financial statements, which include
cash equivalents and money market accounts, approximate their carrying values at December&nbsp;31, 2013 and 2012, due to their short-term maturities. The Company accounts for recurring and non-recurring fair value measurements in accordance with the
Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) 820, <I>Fair Value Measurements and Disclosures</I> (&#147;ASC 820&#148;). ASC 820 defines fair value, establishes a fair value hierarchy for
assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires
assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 1&#151;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 2&#151;Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or
quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 3&#151;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity&nbsp;&#150;
e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates financial assets and liabilities subject to fair value measurements on
a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such
inputs lie within the ASC 820 hierarchy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities subject to fair value measurements were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at December&nbsp;31, 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active Markets<BR>for<BR>Identical Assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Observable<BR>Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Unobservable<BR>Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,434,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,434,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,046,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,046,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,886,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,886,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at December&nbsp;31, 2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active Markets<BR>for<BR>Identical Assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Observable<BR>Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Unobservable<BR>Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,695,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,695,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,047,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,047,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,148,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,148,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2012, the Company transferred its money market funds from Level 2 to Level 1 because
the inputs are now based upon a quoted market price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Level 1 securities primarily consist of restricted cash, cash
equivalents and money market funds. The Company determines the estimated fair value for its Level 1 securities using quoted (unadjusted) prices for identical assets or liabilities in active markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines the estimated fair value for its Level 2 securities using the following methods: quoted prices for similar
assets/liabilities in active markets, inputs other than quoted prices that are observable for the asset/liability (e.g., interest rates, yield curves volatilities, default rates, etc.) and inputs that are derived principally from or corroborated by
other observable market data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a rollforward of the Company&#146;s preferred stock warrant
liability, which was the only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as defined in ASC 820: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total unrealized gains (losses) included in earnings</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(626,349</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of preferred stock warrants</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">679,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to estimate the fair value of the preferred stock purchase warrants, the business enterprise value
was established based on a discounted cash flow model (income approach). The Company utilized an option pricing method to value the shares using a contingent claims analysis, which applies a series of call options whose inputs reflect the
liquidation preferences and conversion behavior of the different classes of equity. After the equity value of the business enterprise was determined, the total equity value is allocated to the various equity instruments such as preferred stock,
stock options and preferred stock purchase warrants. Key management estimates relate to the time period to liquidation and conversion behavior of a particular class of stockholders. The business enterprise value includes assumptions related to
product approval, market penetration and costs to develop the product. Significant changes to these assumptions would result in increases/decreases to the fair value of the outstanding warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total unrealized gains (losses) on the preferred stock warrants included in earnings is included as a component of other income (expense)
in the consolidated statement of operations and comprehensive income. Immediately prior to the Company&#146;s IPO in October 2013, all the preferred stock warrants were exercised and converted into shares of Series D-2 preferred stock, which were
subsequently converted to common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Substantially all of the Company&#146;s cash and cash equivalents are maintained with major financial institutions in the United States.
Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents,
and accounts receivable. The counterparties are various corporations, financial institutions and government agencies of high credit standing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2013, 2012 and 2011, all of the Company&#146;s grant revenue was related to contracts and research
grants received from U.S. government agencies. Collaborations with Les Laboratoires Servier and Institut de Recherches Servier (collectively, &#147;Servier&#148;), Boehringer Ingelheim GmbH (&#147;Boehringer&#148;), Gilead Sciences, Inc.
(&#147;Gilead&#148;), Pfizer, Inc. (&#147;Pfizer&#148;) and Eli Lilly&nbsp;&amp; Co. (&#147;Eli Lilly&#148;) account for all other revenue. All outstanding receivables are due from the Company&#146;s collaborators and U.S. government agencies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table represents the percentage of all significant revenue earned in the
periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Servier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boehringer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilead</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pfizer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government Agencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eli Lilly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table represents the percentage of all significant accounts receivable: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilead</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pfizer.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boehringer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eli Lilly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Servier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government Agencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are
removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation is computed using the straight-line method over the following estimated useful lives:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory&nbsp;and&nbsp;office&nbsp;equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Shorter&nbsp;of&nbsp;lease&nbsp;term&nbsp;or&nbsp;useful&nbsp;life</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC&nbsp;360, <I>Property, Plant and
Equipment</I>. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by
a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of
the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the
carrying amount or fair value, less costs to sell. As of December&nbsp;31, 2013 and 2012, the Company determined that there were no impaired assets and had no assets held-for-sale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities
and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period
that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial
statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is
measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company&#146;s policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into collaboration and license agreements with collaborators for the development of monoclonal antibody-based
therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i)&nbsp;licenses, or options to obtain licenses, to the Company&#146;s technological platforms, such as its Fc
Optimization and Dual-Affinity Re-Targeting (&#147;DART&#148;) technologies, (ii)&nbsp;rights to future technological improvements, (iii)&nbsp;research and development activities to be performed on behalf of the collaborator or as part of the
collaboration, and (iv)&nbsp;the manufacture of pre-clinical or clinical materials for the collaborator. Payments to the Company under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and
development activities, payments for the manufacture of pre-clinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to the Company of
these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. The Company follows the provisions of the FASB ASC Topic 605-25, <I>Revenue
Recognition&nbsp;&#150;&nbsp;Multiple-Element Arrangements</I>, and ASC Topic 605-28, <I>Revenue Recognition&#150;Milestone Method</I>, in accounting for these agreements. In order to account for these agreements, the Company must identify the
deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The
consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the periods presented, the Company had the following two types of agreements with the parties identified below: 1) exclusive development
and commercialization licenses to use the Company&#146;s technology and/or certain other intellectual property to develop compounds against specified targets (referred to herein as exclusive licenses); and 2) Option/research agreements to secure on
established terms, development and commercialization licenses to anticancer and other therapeutic product candidates to collaborator selected targets developed by the Company during an option period (referred to herein as right-to-develop
agreements). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material
financial consequences to the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Exclusive Licenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deliverables under an exclusive license agreement generally include the exclusive license to the Company&#146;s DART technology with
respect to a specified antigen target, and may also include deliverables </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
related to rights to future technological improvements, research and pre-clinical development activities to be performed on behalf of the collaborator. In some cases the Company may have an
option to participate in the co-development of product candidates that result from such agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, exclusive license
agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i)&nbsp;at the collaborator&#146;s request, provide research and pre-clinical development services at negotiated prices
which are generally consistent with what other third parties would charge, (ii)&nbsp;earn payments upon the achievement of certain milestones, (iii)&nbsp;earn royalty payments, and (iv)&nbsp;in some cases grant the Company an option to participate
in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on the Company&#146;s intellectual property rights and whether the Company exercises any co-development and
co-commercialization rights. The Company may provide technical assistance and share any technology improvements with its collaborators during the term of the collaboration agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not directly control when any collaborator will achieve milestones or become liable for royalty payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the units of accounting, management evaluates whether the exclusive license has stand-alone value from the undelivered elements
to the collaborator based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research and development capabilities of the partner and the availability of technology
platform and product research expertise in the general marketplace. If the Company concludes that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated
selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of the Company&#146;s previous collaboration agreements,
recent pre-clinical and clinical testing results of therapeutic product candidates that use the Company&#146;s technology platforms, the Company&#146;s pricing practices and pricing objectives, the likelihood that technological improvements will be
made, the likelihood that technological improvements made will be used by the Company&#146;s collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upfront payments on exclusive licenses are deferred if facts and circumstances dictate that the license does not have stand-alone value. Prior
to the adoption of Accounting Standards Update (&#147;ASU&#148;) No.&nbsp;2009-13, <I>Revenue Arrangements with Multiple Deliverables</I>, on January&nbsp;1, 2011, the Company determined that its licenses lacked stand-alone value because it did not
have vendor-specific objective evidence of selling price (&#147;VSOE&#148;), and were combined with other elements of the arrangement and any amounts associated with the license were deferred and amortized over a certain period, which the Company
refers to as the Company&#146;s period of substantial involvement. In making the determination of the length of the period over which to defer revenue for contracts entered into prior to the adoption of ASU No.&nbsp;2009-13, significant judgment and
estimation is used by the Company and can have an impact on the amount of revenue recognized in a given period. Historically, the Company&#146;s involvement with the development of a collaborator&#146;s product candidate has been significant at the
early stages of development, and lessens as it progresses into clinical trials. Accordingly, the Company generally estimates this period of substantial involvement to begin at the inception of the collaboration agreement and conclude at the end of
the Company&#146;s substantial involvement. ASU No.&nbsp;2009-13 amends the criteria for separating and allocating consideration in a multiple element arrangement by modifying the fair value requirements for revenue recognition and eliminating the
use of the residual value method. The selling prices of deliverables under an arrangement may be derived using third-party evidence (&#147;TPE&#148;), or a best estimate of selling price (&#147;BESP&#148;), if VSOE is not available. The objective of
BESP is to determine the price at which the Company would transact a sale if the element within the license agreement was sold on a standalone basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Establishing BESP involves management&#146;s judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating
the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate
pursuant to the license. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables.
Deliverables under the arrangement are separate units of accounting if (i)&nbsp;the delivered item has value to the customer on a standalone basis and (ii)&nbsp;if the arrangement includes a general right of return relative to the delivered item,
delivery or performance of the undelivered item is considered probable and substantially within the Company&#146;s control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate
units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in
determining whether a deliverable is a separate unit of accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the separate units of accounting, the Company
evaluated whether the exclusive license had standalone value to the collaborator based on consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination included the research and development
capabilities of the collaborator and the availability of relevant research expertise in the marketplace. In addition, the Company considered whether or not (i)&nbsp;the collaborator could use the license for its intended purpose without the receipt
of the remaining deliverables, (ii)&nbsp;the value of the license was dependent on the undelivered items and (iii)&nbsp;the collaborator or other vendors could provide the undelivered items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reassesses its periods of substantial involvement over which the Company amortizes its upfront license fees and makes adjustments
as appropriate. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to use the Company&#146;s technology to develop an alternative product candidate to
the same target or a target substitute, the Company would cease amortization of any remaining portion of the upfront fee until there is substantial pre-clinical activity on another product candidate and its remaining period of substantial
involvement can be estimated. In the event that a single target license were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred
revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upfront
payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has stand-alone value from the undelivered elements, which generally include rights to future technological
improvements, research services and the manufacture of pre-clinical and clinical materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue related to
research and pre-clinical development services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable
is probable. The Company recognizes revenue related to the rights to future technological improvements over the estimated term of the applicable license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company typically performs research activities and pre-clinical development services, including generating and engineering product
candidates, on behalf of its licensees during the early evaluation and pre-clinical testing stages of drug development under its exclusive licenses. The Company records amounts received for research materials produced or services performed as
revenue from collaborative research. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s license agreements have milestone payments which for reporting purposes
are aggregated into three categories: (i)&nbsp;development milestones, (ii)&nbsp;regulatory milestones, and (iii)&nbsp;sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different
clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration (&#147;FDA&#148;) or other countries&#146; regulatory authorities or on receipt of actual marketing
approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk
to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a)&nbsp;the consideration is commensurate with either (1)&nbsp;the entity&#146;s performance to achieve the milestone, or
(2)&nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&#146;s performance to achieve the milestone, (b)&nbsp;the consideration relates solely to past performance and (c)&nbsp;the
consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective
milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company&#146;s efforts during the
period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the
Company does not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements
remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Right-to-Develop
Agreements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop
and commercialize in specified geographic territories product candidates developed by the Company under agreed upon research and pre-clinical development product programs. The product candidates resulting from each program are all directed to a
specific target selected by the collaborator. Under these agreements, fees may be due to the Company (i)&nbsp;at the inception of the arrangement (referred to as &#147;upfront&#148; fees or payments), (ii)&nbsp;the selection of a target for a
program, (iii)&nbsp;upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned) for a program, or (iv)&nbsp;some combination of all of these fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered
substantive if, at the inception of a right-to-develop agreement, the Company is at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in
evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront
consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, the Company does not consider the development and commercialization licenses to be a deliverable at
the inception of the agreement. For those right-to-develop </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreements entered into prior to the adoption of ASU No.&nbsp;2009-13 where the options to secure development and commercialization licenses are considered substantive, the Company has deferred
the upfront payments received and recognizes this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a
collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option, generally 12 months. Subsequent to the adoption of ASU No.&nbsp;2009-13, the Company&#146;s evaluation of whether
the option is substantive is consistent with pre-adoption of ASU No.&nbsp;2009-13. How the Company determines the selling price of the option is the only difference between pre and post adoption of ASU No.&nbsp;2009-13. Post adoption of ASU
No.&nbsp;2009-13, the selling prices of deliverables under an arrangement may be derived using TPE or a BESP, if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within
the right-to-develop agreement was sold on a standalone basis. Establishing BESP involves management&#146;s judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in
negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product
candidate pursuant to the right-to-develop agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration
between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i)&nbsp;the delivered item has value to the customer on a standalone basis and (ii)&nbsp;if the arrangement includes a general right of return
relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company&#146;s control. The arrangement consideration that is fixed or determinable at the inception of the
arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management
exercises significant judgment in determining whether a deliverable is a separate unit of accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a collaborator exercises an
option and acquires a development and commercialization license to a product program, the Company attributes the exercise fee to the development and commercialization license. The Company determines the selling price of the option license, upon
exercise, through management&#146;s best estimate. Management&#146;s determination of selling price includes such factors as stage of development, market potential and cash flow models used during the negotiation with the collaborator. Through
December&nbsp;31, 2013, none of our collaboration partners had exercised an option. However, one of our collaboration partners did elect to exercise an option in February 2014. See Note 13 for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon exercise of an option to acquire a development and commercialization license, the Company would also attribute any remaining deferred
option fee, in addition to the consideration received for the license upon exercise of the option, to the development and commercialization license. The Company then applies the multiple-element revenue recognition criteria to the development and
commercialization license and other deliverables, if any, to determine the appropriate revenue recognition method. This model is consistent with the Company&#146;s accounting policy for upfront payments on exclusive licenses (discussed above). In
the event a right-to-develop agreement were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such
termination. The Company&#146;s right-to-develop agreements have been determined to contain substantive options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For right-to-develop
agreements where the options to secure development and commercialization licenses to product programs are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the
agreement and applies the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. The Company does not directly control when any collaborator will exercise its options for development and commercialization
licenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses,
including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company&#146;s clinical trials, the cost of acquiring and manufacturing clinical trial
materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Income (Loss) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective January&nbsp;1, 2012, the Company adopted ASU 2011-05, <I>Presentation of Comprehensive Income, </I>which amended ASC Topic 220,
<I>Comprehensive Income </I>(&#147;ASU 2011-05&#148;)<I>. </I>The amendments in ASU 2011-05 require the presentation of the comprehensive income (loss) and its components as part of the consolidated financial statements. Comprehensive income (loss)
is comprised of the net income (loss) and other changes in equity that are excluded from net income (loss). Comprehensive income (loss) equals net income (loss) for the years ended December&nbsp;31, 2013, 2012 and 2011. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based payments are accounted for in accordance with the provisions of ASC&nbsp;718, <I>Compensation&nbsp;&#150; Stock Compensation</I>.
The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance
condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the
Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend
yield, expected volatility and the expected life of the award. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Income (Loss) Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic income (loss) per common share is determined by dividing income (loss) attributable to common stockholders by the weighted-average number
of common shares outstanding during the period, without consideration of common stock equivalents. Diluted income (loss) per share is computed by dividing the earnings (loss) attributable to common stockholders by the weighted-average number of
common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#146;s stock option grants, potential Employee Stock Purchase Plan awards and warrants and the if-converted method
is used to determine the dilutive effect of the Company&#146;s preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Company&#146;s initial public offering, net
income (loss) per share was calculated under the <FONT STYLE="white-space:nowrap">two-class</FONT> method under which all earnings (distributed and undistributed) are allocated to each class of common stock and participating securities based on
their respective rights to receive dividends. In the event that the Board </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Directors declared a dividend payable in cash or other property on the then-outstanding shares of common stock, the holders of the Series&nbsp;A-1, A-2, B, C, D, and D-2 convertible preferred
stock would be entitled to receive the amount of dividends per share of preferred stock that would be payable on the largest number of whole shares of common stock into which each share of preferred stock could then be converted. Therefore, the
Series A-1, A-2, B, C, D and D-2 are participating securities. All of the outstanding shares of Series&nbsp;A-1, A-2, B, C, D, and D-2 convertible preferred stock converted to common stock upon the consummation of the Company&#146;s IPO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted income (loss) per common share is computed as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(260,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: undistributed earnings allocated to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,361,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,717,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) allocable to common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(260,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,847,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic income (loss) per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(260,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: undistributed earnings allocated to participating securities and other add-backs to net income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,361,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,717,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) allocable to common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(260,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,847,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of dilutive securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,847,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted income (loss) per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following common stock equivalents were excluded from the calculation of diluted net income (loss) per
share because their effect would be anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-2 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,336,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,336,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D-2 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,391,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,391,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of Converted Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,189,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase Series D-2 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,313,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,249,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,885,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Standards Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2013, the FASB issued ASU No.&nbsp;2013-11, which amended ASC Topic 740 regarding presentation of an unrecognized tax benefit when a
net operating loss (&#147;NOL&#148;) carryforward, a similar tax loss, or a tax credit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
carryforward exists. The amendments in ASU No.&nbsp;2013-11 require an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for an NOL carryforward, or similar tax
loss or tax credit carryforward, rather than as a liability when (1)&nbsp;the uncertain tax position would reduce the NOL or other carryforward under the tax law of the applicable jurisdiction and (2)&nbsp;the entity intends to use the deferred tax
asset for that purpose. The ASU does not require new recurring disclosures. This amendment is effective prospectively for fiscal years beginning after December&nbsp;15, 2013. The Company does not believe this amendment will have a material impact on
its financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated all ASUs through the date the consolidated financials were issued and believes that
the adoption of these will not have a material impact on the Company&#146;s consolidated financial statements. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Property and Equipment </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consists of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,379,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,003,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,477,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,323,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,166,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,747,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,893,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,881,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,568,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,607,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,532,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,339,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,035,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,267,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense for the years ended December&nbsp;31, 2013, 2012 and 2011 was $1.2 million, $1.0 million
and $1.1 million, respectively. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Stockholders&#146; Equity (Deficit) </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2002 and 2003, the Company issued a total of 34,239,374 shares of Series A-1 and Series A-2 convertible preferred
stock (&#147;Series A preferred stock&#148;) for $1.00 per share resulting in net proceeds of approximately $34.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
October&nbsp;12, 2004, the Company entered into a series of transactions raising $30.3 million, net of related offering costs of approximately $238,000, from the sale of 71,401,237 shares of its Series B convertible preferred stock (&#147;Series B
preferred stock&#148;). In connection with the Series B preferred stock offering, 13,604,016 shares of common stock were allocated to holders of Series&nbsp;A-1 preferred stock as an anti-dilution measure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2006, the Company raised $44.9 million, net of related offering costs of $101,246, from the sale of 110,952,217 shares of its
Series C convertible preferred stock (&#147;Series C preferred stock&#148;). In connection with the Series C preferred stock offering, 10,003,300 shares of common stock were allocated to holders of Series B preferred stock as an anti-dilution
measure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2008, the Company issued 12,466,039 shares of its Series D convertible preferred stock (&#147;Series&nbsp;D
preferred stock&#148;) in exchange for all of the outstanding capital stock and convertible notes payable of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Raven Biotechnologies, Inc. (&#147;Raven&#148;). Subsequently, in March 2011 a settlement was reached with the former Raven stockholders bringing the total Series D preferred stock issued in
connection with the Raven acquisition to 14,446,227 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;19, 2008, the Company raised $24.8 million, net of related
offering costs of $156,788, from the sale of 38,337,678 shares of its Series D-2 convertible preferred stock (&#147;Series D-2 preferred stock&#148;). The Company also issued preferred stock warrants for the purchase of 2,875,327 shares of Series
D-2 preferred stock. The preferred stock warrants were exercisable at any time prior to September&nbsp;2018, but expired upon an IPO, and had a stated exercise price of $0.65 per warrant. On May&nbsp;16, 2010, the Company exercised a put notice to
Eli Lilly in accordance with the Series D-2 preferred stock purchase agreement, resulting in the issuance of 6,916,110 shares of Series D-2 preferred stock and a warrant to purchase 518,708 additional shares of Series D-2 preferred stock. On
January&nbsp;11, 2011, the Company raised gross proceeds of $12.0 million from the sale of 18,427,388&nbsp;shares of its Series D-2 preferred stock. Issuance costs associated with the sale were not material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to certain provisions in the Series D-2 convertible preferred stock warrant agreement, these warrants were required to be classified as a
liability. Management believed that the circumstances requiring cash settlement of the award were remote. The Series D-2 preferred stock warrant liability was recorded at fair value and has been adjusted to fair value at the end of each reporting
period using the Option-Pricing Method, with changes in value recorded as &#147;Other income (expense)&#148; in the accompanying consolidated statements of operations and comprehensive income (loss). Prior to the Company&#146;s IPO in October 2013,
all the preferred stock warrants were exercised and subsequently were converted into shares of common stock in connection with the IPO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends were noncumulative and accrued on the Series A-1, Series A-2, Series B, Series C, Series D and Series&nbsp;D-2 preferred stock at a
rate of $0.08, $0.0341, $0.0324 and $0.0522 per annum, respectively, and were payable when and as declared by the Board of Directors. Dividends had to be declared so that the Series A, Series&nbsp;B, Series C and Series D preferred stock were paid
in like-kind and participated equally to those of the Series&nbsp;D-2 preferred and common stock. No dividends had been declared prior to the conversion of the preferred stock to common stock in connection with the IPO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Series A-1, Series A-2, Series B, Series C, Series D and Series D-2 preferred stock were initially convertible into 1.506,
1.00, 1.14, 1.00, 1.00 and 1.00 shares, respectively, of common stock at the option of the holder. The conversion ratio of certain series of preferred stock was subject to change in the event specified dilutive transactions occurred, which included
the Company&#146;s IPO. There were no anti-dilution protections for the Series A-2 preferred stock and no adjustment to the Series A-1 preferred stock conversion price was to be made if a common stock issuance was at a price per share greater than
the conversion price of the Series C preferred stock. Upon consummation of the Company&#146;s IPO in October 2013, all outstanding shares of preferred stock automatically converted to shares of the Company&#146;s common stock at the applicable
conversion ratios then in effect. The conversion price was $12.39, $18.77, $6.95, $7.70, $12.20 and $12.20 for each share of Series A-1, A-2, Series B, Series C, Series D and Series D-2 convertible preferred stock, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2013, the Company completed its IPO, in which 5,000,000 shares of the Company&#146;s common stock were sold at a price of
$16.00 per share. Additionally, the underwriters of the Company&#146;s IPO exercised the full amount of their over-allotment option resulting in the sale of an additional 750,000 shares of the Company&#146;s common stock at a price of $16.00 per
share. The Company received net proceeds of $83.8 million from the IPO, net of underwriting discounts and commissions and other offering expenses. Upon consummation of the IPO, all outstanding shares of preferred stock automatically converted to
common stock at the applicable conversion ratios then in effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with preparing for its IPO in October 2013, the Company&#146;s Board of
Directors and stockholders approved a 1-for-18.7739 reverse stock split of the Company&#146;s common stock. The reverse stock split became effective on September&nbsp;26, 2013. All share and per share amounts in the consolidated financial statements
and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. In
addition, in September 2013, the Company&#146;s Board of Directors and stockholders approved an amendment of the Company&#146;s certificate of incorporation to, among other things, change the definition of a designated public offering to remove the
per share price requirement. The amended and restated certificate of incorporation also changed the authorized number of shares of common stock from 425,000,000 to 125,000,000, and authorized 5,000,000 shares of undesignated preferred stock with a
par value of $0.01 per share. There were no shares of undesignated preferred stock issued or outstanding as of December&nbsp;31, 2013. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Shared-Based Payments </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s 2000 Stock Option and Incentive Plan (&#147;2000 Plan&#148;) allowed for the grant of awards in respect of an aggregate of
130,725 shares, which was increased to 150,297 shares, of the Company&#146;s common stock in the form of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock and restricted stock units and other
performance awards. As of December&nbsp;31, 2013, under the 2000 Plan, there were options to purchase an aggregate of 23,657 shares of common stock outstanding at a weighted average exercise price of $0.83 per share. The 2000 Plan has expired, and
no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2000 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or
resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (&#147;2013 Plan&#148;) up to a specified number of shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;2003, the Company implemented the 2003 Equity Incentive Plan (&#147;2003 Plan&#148;), and it was amended and approved
by the Company&#146;s stockholders in 2005. The 2003 Plan originally allowed for the grant of awards in respect of an aggregate of 2,051,644 shares of the Company&#146;s common stock. Between 2006 and 2010 the maximum number of shares of common
stock authorized to be issued by the Company under the 2003 Plan was increased by 1,739,116 shares to 3,790,760. During the year ended December&nbsp;31, 2012, the maximum number of shares of common stock authorized to be issued by the Company under
the 2003 Plan was increased by 545,970 shares to 4,336,730. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (&#147;IRC&#148;), or non-qualified stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, under the 2003 Plan, there were options to purchase an aggregate of 2,559,011&nbsp;shares of common stock
outstanding at a weighted average exercise price of $1.52 per share. Upon the completion of the IPO, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan
that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Plan, up to a specified
number of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013, the Company implemented the 2013 Plan. The 2013 Plan provides for the grant of stock options and other
stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan is 1,960,168&nbsp;shares. The number of shares of common stock
reserved for issuance will automatically increase on January&nbsp;1 of each year from January&nbsp;1, 2014 through and including January&nbsp;1, 2023, by the lesser of (a)&nbsp;1,960,168 shares, (b)&nbsp;4.0% of the total number of shares of common
stock outstanding on December&nbsp;31 of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preceding calendar year, or (c)&nbsp;the number of shares of common stock determined by the Board of Directors. All of the shares available for issuance under the 2013 Plan are eligible for
issuance pursuant to the exercise of incentive stock options. If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled
without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the
exercise price of an option are not available for the grant of additional awards. As of December&nbsp;31, 2013, under the 2013 Plan, there were options to purchase an aggregate of 618,290 shares of common stock outstanding at a weighted average
exercise price of $19.06 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Exchange </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;16, 2011 (&#147;Exchange Date&#148;), the Company modified certain outstanding options with exercise prices of $1.88 and $4.69
(&#147;Original Options&#148;). These Original Options were canceled and replaced with options having an exercise price of $0.94 (&#147;Replacement Options&#148;), reflecting the current fair market value of the Company&#146;s common stock on the
Exchange Date. Original Options submitted for exchange were replaced on a one-for-one basis with Replacement Options. Additionally, the Replacement Options retain all terms and conditions of the Original Options except for the reduction to the
exercise price as described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total compensation associated with the Replacement Options consisted of the grant-date fair value of
the Original Options for which the requisite service period is expected to be rendered (or has already been rendered) at the Exchange Date, plus the incremental cost associated with the modification of terms. The incremental compensation expense was
measured as the excess of the fair value of the Replacement Options over the fair value of the Original Options re-measured as of the Exchange Date. A total of 1,921,894 Original Options were exchanged for Replacement Options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following stock-based compensation amounts were recognized for the periods indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">507,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">471,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,018,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,328,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">862,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">838,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,347,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employee Stock Options </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in
the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">53%&nbsp;-&nbsp;67%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">51%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">62%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.24%&nbsp;-&nbsp;2.19%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.18%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.35%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7&nbsp;years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected forfeiture rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">5.06%&nbsp;-&nbsp;5.57%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.57%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.58%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Expected Dividend Yield</B>&#151;The Company has never declared or paid dividends and has no plans to do so
in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Expected Volatility</B>&#151;Volatility is a measure of the amount by which a financial
variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. As the Company does not yet have sufficient history of its own volatility, the Company has identified several
public entities of similar size, complexity and stage of development and calculates historical volatility using the volatility of these companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Risk-Free Interest Rate</B>&#151;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most
closely resembles the expected life of the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Expected Term</B>&#151;This is the period of time that the options granted are
expected to remain unexercised. Options granted have a maximum term of ten years. The Company estimates the expected life of the option term to be seven years. The Company uses a simplified method to calculate the average expected term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Expected Forfeiture Rate</B>&#151;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or
canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equity instruments issued to non-employees are accounted for under the provisions of ASC&nbsp;505-50,<I> Equity Based Payments to
Non-Employees</I>. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the services required are completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity for 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Remaining<BR>Contractual&nbsp;Term<BR>(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,249,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,307,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,268,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,200,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2013:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,688,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,022,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2013, 2012 and 2011 the Company issued 1,268,049, 863,176 and 49,883 shares of common stock,
respectively, in conjunction with stock option exercises. The Company received cash proceeds from the exercise of these stock options of approximately $1.1 million, $46,826 and $53,225 during 2013, 2012 and 2011, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average grant-date fair value of options granted during 2013, 2012 and 2011 was $6.91, $0.94 and $0.94 per share, respectively.
The total intrinsic value of options exercised during 2013, 2012 and 2011 was approximately $5.4 million, $271,929 and $102,418, respectively. The total fair value of stock options which vested during 2013, 2012 and 2011 was $487,603, $879,024 and
$1,108,107, respectively. As of December&nbsp;31, 2013, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was $7.6 million, which the Company expects to recognize over a
weighted-average period of approximately four years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Income Taxes </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2013, 2012 and 2011 there was no current provision for federal or state income taxes
due to the taxable losses which resulted or use of legacy NOL carryforwards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The significant components of the Company&#146;s deferred
tax assets (liabilities) were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal U.S. net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,561,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,330,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,315,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,521,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credit, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,785,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,777,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Orphan drug credit, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,883,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,039,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,132,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,218,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,216,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,379,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,438,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,247,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,438,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,575,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred income tax assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,771,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,090,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(79,376,945</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78,090,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred income tax assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(394,952</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred income tax liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(394,952</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred income tax asset/(liability)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely
than not to be realized. In assessing the likelihood of realization, management considers (i)&nbsp;future reversals of existing taxable temporary differences; (ii)&nbsp;future taxable income exclusive of reversing temporary difference and
carryforwards; (iii)&nbsp;taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv)&nbsp;tax planning strategies. The Company&#146;s net deferred income tax asset is not more likely than not to be utilized
due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. The net increase in the valuation allowance in 2013 is due to the fact the Company generated research and development and
orphan drug credits and NOL carryforwards which increased the net deferred tax asset. The increase in the credits and NOL carryforwards were offset by the decrease in deferred revenue and resulted in a net current year increase to the valuation
allowance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has reported book losses from inception through December&nbsp;31, 2010. The NOL carryforwards of approximately
$104.8 million for U.S.&nbsp;federal and approximately $60.3 million for state will expire in various years beginning in 2023 through 2033. In addition, the Company has U.S. federal tax credits of $23.7 million which will expire in various years
beginning in 2020 through 2033. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The use of the Company&#146;s U.S. federal NOL and tax credit carryforwards in future years are
restricted due to changes in the Company&#146;s ownership and tax attributes acquired by the Company in a purchase. As of December&nbsp;31, 2013, $8.5 million of the Company&#146;s NOLs are limited for use over the years 2014&nbsp;&#150; 2027 in
which a range of such amounts could be utilized on an annual basis of $0.2 million to $1.4&nbsp;million. The remaining $96.3 million of NOLs is not limited and can be offset against future taxable income. Additionally,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approximately $1.8 million of NOLs will be recognized as a benefit through additional-paid-in-capital when realized. Further, despite the NOL and credit carryforwards, the Company may have a
future tax liability due to an alternative minimum tax or state tax requirements in which net operating losses do not exist. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States federal tax at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(91,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,926,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,350,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes (net of federal benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,460,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,480,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(855,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(512,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred state blended rate adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(344,178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research credit, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(225,605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Orphan drug credit, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(843,463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,895,671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,056,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other permanent items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">725,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustment of preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(496,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,286,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">787,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,991,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense/(benefit)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,592,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,533,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,246,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases/(decreases) for current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases/(decreases) for prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decreases as a result of expiration of statute of limitations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,707,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,592,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,533,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013 and 2012, of the total gross unrecognized tax benefits, approximately $1.2
million and $1.1 million would favorably impact the Company&#146;s effective income tax rate, respectively. Although, due to the Company&#146;s determination that the deferred income tax asset would not more likely than not be realized, a valuation
allowance would be recorded, therefore, zero net impact would result within the Company&#146;s effective income tax rate. The Company&#146;s uncertain income tax position liability has been recorded to deferred income taxes to offset the tax
attribute carryforward amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2013, 2012 and 2011, the Company has not recognized any interest or
penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly
decrease within the next twelve months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s U.S. Federal and state income tax returns from 2001 to 2012 remain subject
to examination by the tax authorities. The Company&#146;s 2001 through 2009 years remain open for examination, even though the statute of limitations has expired, due to the net operating losses and credits carried forward for use in prospective
years. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Lease Exit Liability </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2008, the Company acquired Raven Biotechnologies, Inc. (&#147;Raven&#148;), a private South San
Francisco-based company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven was considered a development-stage enterprise as defined in ASC&nbsp;915, <I>Development Stage Entities</I>. In connection with the
acquisition, the Company issued 12,466,039 shares of its Series D convertible preferred stock in exchange for all of the outstanding capital stock and convertible notes payable of Raven. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company undertook restructuring activities related to the acquisition of Raven. These restructuring activities included reductions in
staffing levels and the intended exit of leased facilities. All severance-related payments were completed in the year ended December&nbsp;31, 2009. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with these restructuring activities, as part of the cost of acquisition, the Company established a restructuring liability
attributed to an existing operating lease. The terms of the operating lease extend through 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in the lease exit liability are
as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$10,607,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(533,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,073,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(628,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$9,445,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future principal payments to be made under the lease agreement for the next five years and thereafter as of
December&nbsp;31, 2013 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,438,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,641,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,866,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,113,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,385,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,445,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase agreement provides for a specified total of certain contingent milestones that are based on the
achievement of certain product sales derived from the acquired Raven technology. Also, a onetime payment of $5.0&nbsp;million will be made to the Raven stockholders upon the initiation of patient dosing in the first Phase 2 clinical trial of any
product derived from the Raven &#147;Cancer Stem Cell Program.&#148; No payment shall be made if the Phase 2 trial start date has not occurred on or before July&nbsp;15, 2018. Other consideration includes a percentage of revenue (excluding
consideration for research and development and equity) received by the Company for license of a product derived from the Raven &#147;Cancer Stem Cell Program&#148; and a onetime payment ranging from $8.0&nbsp;million to $12.0&nbsp;million dependent
upon a specified level of sales of products derived from the Raven &#147;Cancer Stem Cell Program.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The contingent consideration will be accounted for as additional purchase price and recorded
as incremental in-process research and development expense when it is deemed probable that the contingencies will be attained. No additional amounts have been recorded during the years ended December&nbsp;31, 2013, 2012 and 2011. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Collaboration and License Agreements </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Servier </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
November 2011, the Company entered into a right-to-develop collaboration agreement with Servier for the development and commercialization of MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement, Servier made a nonrefundable payment of $20.0 million to the Company. The Company is eligible to receive up
to $30.0 million in license grant fees, $47.0 million in clinical milestone payments, $140.0 million in regulatory milestone payments and $208.0 million in sales milestone payments if Servier exercises the option, obtains regulatory approval for and
successfully commercializes MGA271. The Company concluded that the license grant fees are not deliverables at the inception of the arrangement. The Company has determined that each potential future clinical, development and regulatory milestone is
substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would
preclude revenue recognition at that time. In the event Servier exercises its option to continue development of MGA271, Servier must pay a license grant fee. Under this agreement, Servier would be obligated to pay the Company from low double digit
to mid-teen royalties on product sales in its territories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the research collaboration agreement with Servier
and has determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company concluded that the option is substantive and that the license fees for this option is not a deliverable at the inception of the
arrangement as there is considerable uncertainty that the option would be exercised and the additional fee to be paid upon exercise of the option represents its estimated selling price (i.e. no substantial discount was given). The Company&#146;s
substantive performance obligations under this research collaboration include an exclusivity clause to its technology, technical, scientific and intellectual property support to the research plan during the first year of the agreement and
participation on an executive committee and a research and development committee. The Company determined that these performance obligations represent a single unit of accounting, since the license does not have stand-alone value to Servier without
the Company&#146;s technical expertise and committee participation. As such, the initial upfront payment was deferred and is being recognized ratably over the initial 27-month period, which represents the expected period of development and the
Company&#146;s participation on the research and development committee. The Company further concluded that each potential future clinical, development and regulatory milestone is substantive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2013, 2012 and 2011 the Company recognized revenue of $21.3&nbsp;million, $9.1 million and
0.9&nbsp;million, respectively, under this agreement. Revenue recognized in the year ended December&nbsp;31, 2013 included a $10.0 million substantive milestone payment received upon dosing the first patient in a Phase 1 dose expansion cohort trial
of MGA271. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2013, $0.9 million of revenue remained deferred under this agreement, all of which was included in
current liabilities. At December&nbsp;31, 2012, $10.0 million of revenue was deferred under this agreement, $9.1 million of which was included in current liabilities and $0.9 million of which was included in long-term liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2012, the Company entered into a second right-to-develop collaboration agreement
with Servier and granted it options to obtain three separate exclusive licenses to develop and commercialize <FONT STYLE="white-space:nowrap">DART-based</FONT> molecules, consisting of those designated by the Company as MGD006 and MGD007, as well as
a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the
agreement, Servier made a nonrefundable payment of $20.0 million to the Company. In addition, the Company will be eligible to receive up to $65.0 million in license grant fees, $98.0 million in clinical milestone payments, including $5.0 million
upon IND acceptance for each of MGD006, MGD007 and a third DART molecule, $300.0 million in regulatory milestone payments and $630.0 million in sales milestone payments if Servier exercises all of the options and successfully develops, obtains
regulatory approval for, and commercializes a product under each license. In addition to these milestones, the Company and Servier will share Phase 2 and Phase 3 development costs. The Company has determined that each potential future clinical,
development and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there
are no undelivered elements that would preclude revenue recognition at that time. Under this agreement, Servier would be obligated to pay the Company between high-single digit and mid-teen royalties on net product sales in its territories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the research collaboration agreement with Servier and has determined that it is a revenue arrangement with multiple
deliverables, or performance obligations. The Company concluded that each option is substantive and that the license fees for each option are not deliverables at the inception of the arrangement and were not issued with a substantial discount. The
Company&#146;s substantive performance obligations under this research collaboration include an exclusivity clause to its technology, technical, scientific and intellectual property support to the research plan during the first year of the agreement
and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the pre-clinical development represent a single unit of accounting, since the license does
not have stand-alone value to Servier without the Company&#146;s technical expertise and committee participation. As such, the initial up front license payment was deferred and is being recognized ratably over the initial 29-month period, which
represents the expected development period. The Company further concluded that each potential future clinical, development and regulatory milestone is substantive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2013 and 2012 the Company recognized revenue of $8.6 million, and $2.0 million, respectively. No
milestones have been recognized under this agreement during the years ended December&nbsp;31, 2013 and 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2013,
$9.4 million of revenue was deferred under this agreement, $8.6 million of which was included in current liabilities and $0.8 million of which was included in long-term liabilities. At December&nbsp;31, 2012, $18.0 million of revenue was deferred
under this agreement, $8.6 million of which was included in current liabilities and $9.4 million of which was included in long-term liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2014, Servier exercised its exclusive option to develop and commercialize MGD006. As a result of the exercise, the Company
received a $15.0 million payment from Servier for its license to develop and commercialize MGD006 in its territories. In addition, the Company received a $5.0 million payment from Servier upon the achievement of a clinical milestone related to the
IND application for MGD006 clearing the <FONT STYLE="white-space:nowrap">30-day</FONT> review period by the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gilead </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2013, the Company entered into an agreement with Gilead for the research, development and commercialization of up to four DART-based
molecules. The time period for Gilead&#146;s exercise of one option has expired. At present, Gilead retains a license to one and options to two of the original four programs. Gilead has exclusive worldwide rights for each of these remaining
programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received an initial $7.5 million license grant fee for the first DART-based molecule, and is eligible to receive
additional license grant fees of $7.5 million on each of the remaining two DART-based molecules if they are selected by Gilead. The Company is further eligible to receive up to an additional $20 to $25 million in pre-clinical milestones across each
of the three remaining DART programs and up to approximately $240 to $250 million per remaining program in additional clinical, regulatory and sales milestones if Gilead exercises both remaining options and achieves all of the requisite milestones
under each option and license. The Company has determined that the other licenses are conditional deliverables, which are substantive options that were not granted with a substantial discount. The Company has determined that each potential future
clinical, development and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met)
because there are no undelivered elements that would preclude revenue recognition at that time. Gilead also provides funding for the Company&#146;s internal and external research costs under the agreement. Additionally, Gilead would be obligated to
pay the Company high single digit to low double digit, but less than teen royalties on product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the
research collaboration agreement with Gilead and has determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company&#146;s substantive performance obligations under this research collaboration include
a license to its technology and research and development services. The Company concluded that the deliverables do not have stand alone value and therefore, represent a combined single unit of accounting. Due to the lack of standalone value for the
license and research and development services, the combined unit of accounting (the upfront payment and the expected research and development reimbursements) is being recognized ratably over a period of 21 months, which represents the expected
development period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and Gilead have also agreed to establish a joint research committee to facilitate the governance and
oversight of the parties&#146; activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. Had management considered participation on the
joint committee as a deliverable, it would not have had a material impact on the accounting for the arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized
revenues of approximately $8.0 million under this agreement for the year ended December&nbsp;31, 2013. No milestones have been achieved under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2013, $3.6 million of revenue was deferred under this agreement, all of which was included in current liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Boehringer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2010 the
Company entered into a collaboration and license agreement with Boehringer to discover, develop and commercialize up to ten DART-based molecules which span multiple therapeutic areas. Under the terms of the agreement, the Company granted Boehringer
an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DARTs generated under the agreement throughout the world. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement, the Company received an upfront payment of $15.0 million.
The Company subsequently received three annual maintenance payments including one in the fourth quarter of 2013. These maintenance payments are being recognized over the estimated period of development. The Company has the potential to earn
milestone payments of approximately $41.0 million related to pre-clinical and clinical development, $89.0 million related to regulatory milestones and $83.0 million related to sales milestones for each of the DART programs under this agreement in
the case of full commercial success of multiple DART products. The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are
still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Boehringer also provides funding for
the Company&#146;s internal and external research costs and is required to pay the Company mid-single digit royalties on product sales. In November 2013, Boehringer nominated a bi-specific antibody therapeutic candidate generated by the
Company&#146;s DART technology for pre-clinical development. This formal selection of a development candidate triggered a $5.0 million milestone payment to the Company. From the commencement of the collaboration through December&nbsp;31, 2013, the
Company has received $48.8 million under this agreement, including upfront, annual maintenance and milestone payments as well as research funding. In addition, Boehringer purchased $10.0 million of the Company&#146;s Series D-2 Preferred Stock in
January 2011. This preferred stock was converted to common stock upon the Company&#146;s IPO in October 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that
the deliverables under the Boehringer agreement include the license, the research and development services to be performed by the Company, and the co-promotion/manufacturing services. The Company concluded that the co-promotional activities were
optional and were subject to further negotiation upon reaching regulatory approval. As such, the co-promotional period is not included in the expected obligation period to perform services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the undelivered element of research and development services had fair value. The Company concluded that the license
does not have value on a standalone basis (e.g. absent the provision of the research and development services) and therefore does not represent a separate unit of accounting. The Company concluded that because the drug candidate has not yet been
developed, the license is of no value to Boehringer without the ensuing research and development activities using the DART technology, which is proprietary to the Company. Likewise, Boehringer could not sell the license to another party (without the
Company agreeing to provide the research and development activities for the other party). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therefore, the upfront license fee and research
and development services were treated as a combined unit of account and recognized over the expected obligation period associated with the research and development services through September 2015, which represents the estimated period of
development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and Boehringer have also agreed to establish a joint research committee to facilitate the governance and
oversight of the parties&#146; activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. However, had management considered participation on
the joint committee as a deliverable, it would not have had a material impact on the accounting for the arrangement as the period of participation in this committee matched the obligation period for the research and development services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no material modifications to this agreement since the adoption of ASU 2009-13 on January&nbsp;1, 2011. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenues of approximately $14.4 million, $11.7 million and $8.9 million during the years ended December&nbsp;31, 2013,
2012 and 2011, respectively. Revenue recognized in the years ended </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&nbsp;31, 2013 and 2012 included milestone payments of $5.0 million and $2.0 million, respectively, for the achievement of clinical milestones. No milestones were achieved in the year
ended December&nbsp;31, 2011. At December&nbsp;31, 2013, $12.8 million of revenue was deferred under this agreement, $7.0 million of which was included in current liabilities and $5.8 million of which was included in long-term liabilities. At
December&nbsp;31, 2012, $14.0 million of revenue was deferred under this agreement, $5.0 million of which was included in current liabilities and $9.0 million of which was included in long-term liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pfizer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2010, the
Company entered into a three year agreement with Pfizer to discover, develop and commercialize up to two DART-based molecules. The Company granted Pfizer a non-exclusive worldwide, royalty-bearing license and received an upfront payment of $5.0
million and has received milestone payments and funding for the Company&#146;s internal and external research costs under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is eligible to receive milestone payments of approximately $17.0 million related to pre-clinical and clinical development and
$195.0 million related to commercialization and sales milestones for each DART program under this agreement. The Company has determined that each potential future technical and development milestone is substantive. Although sales milestones are not
considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.
Pfizer is responsible for all pre-clinical and clinical development costs for the program. In addition, Pfizer is required to pay the Company mid-single digit to low-teen royalties on product sales. Under this collaboration, one DART program is
currently being pursued and the Company completed its research obligations under this program in January 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated
the research collaboration agreement with Pfizer and has determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company&#146;s substantive performance obligations under this research collaboration
include an exclusive license to its technology, research and development services and manufacturing services. The Company concluded that the manufacturing services were optional and were subject to further negotiation upon reaching regulatory
approval. As such, the manufacturing services are not included in the expected obligation period to perform services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
determined that it had fair value of the undelivered element of the research and development services. However, the Company concluded that the license does not have value on a standalone basis (e.g. absent the provision of the research and
development services) and therefore does not represent a separate unit of accounting. Facts that were considered included the development of the candidate noting that because the drug candidate has not yet been developed, the license is of no value
to Pfizer without the ensuing research and development activities using the DART technology, which is proprietary to the Company. Likewise, Pfizer could not sell the license to another party (without the Company agreeing to provide the research and
development activities for the other party). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therefore, the upfront license fee and research and development services were treated as a
combined unit of accounting and recognized over the expected obligation period associated with the research and development services through January 2014, which represents the estimated period of development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $5.0 million upfront payment received by the Company is non-refundable; therefore, there is no right of return for the license. The
Company recognizes revenue associated with this non-refundable up-front license fee through the expected obligation period associated with the research and development services, which ended in January 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and Pfizer have also agreed to establish a joint research committee to facilitate
the governance and oversight of the parties&#146; activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable because it is a participating
right and not an obligation of the Company. However, had management considered participation on the joint committee as a deliverable, it would not have had a material impact on the accounting for the arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no material modifications to this agreement since the adoption of ASU 2009-13 on January&nbsp;1, 2011. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenues of approximately $3.5 million, $5.5 million and $5.2 million during the years ended December&nbsp;31, 2013,
2012 and 2011, respectively. Included in the 2012 revenues are milestone payments totaling $500,000. No additional milestones have been achieved under this agreement through December&nbsp;31, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2013 and 2012, $7,291 and $1.3 million of revenue was deferred under this agreement, respectively, all of which was
included in current liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Green Cross </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June&nbsp;2010, the Company entered into a collaboration agreement with Green Cross for the development of the Company&#146;s anti-HER2
antibody known as MGAH22, or margetuximab. This arrangement grants Green Cross an exclusive license to conduct specified Phase 1 and Phase 2 clinical trials and commercialize margetuximab in South Korea. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement, Green Cross made a nonrefundable payment of $1.0&nbsp;million to the Company. The Company is eligible to
receive clinical development and commercial milestone payments of up to $4.5 million. The Company has determined that each potential clinical development and commercial milestone is substantive. The Company is also entitled to receive royalties on
net sales of margetuximab in South Korea. The Company and Green Cross have formed a joint steering committee to coordinate and oversee activities on which the companies collaborate under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the collaboration agreement with Green Cross and has determined that it is a revenue arrangement with multiple
deliverables or performance obligations. The Company&#146;s substantive performance obligations under this agreement include an exclusive license to its technologies and participation in a joint steering committee. The Company concluded that the
license does not have value on a standalone basis and therefore does not represent a separate unit of accounting. Likewise, Green Cross could not sell the license to another party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $1.0 million upfront payment received by the Company is non-refundable; as such, there is no right of return for the license. Therefore,
the upfront license fee and participation on the joint steering committee were treated as a combined unit of accounting and will be recognized over the term of the agreement through June 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no material modifications to this agreement since the adoption of ASU 2009-13 on January&nbsp;1, 2011. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenues of approximately $100,000 under this agreement during each of the three years ended December&nbsp;31, 2013. No
milestones were achieved under this agreement during the three years ended December&nbsp;31, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2013, $650,000 of revenue was deferred under this agreement, $100,000 of
which was included in current liabilities and $550,000 of which was included in long-term liabilities. At December&nbsp;31, 2012, $750,000 of revenue was deferred under this agreement, $100,000 of which was included in current liabilities and
$650,000 of which was included in long-term liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Eli Lilly </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October&nbsp;2007, the Company entered into an exclusive license and collaboration agreement (together, the Agreements) with Eli Lilly to
jointly develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody. As part of the Agreements, Eli Lilly acquired the exclusive rights to the molecule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the Agreements, Eli Lilly made a nonrefundable payment of $41.0&nbsp;million to the Company. In May&nbsp;2008, Eli Lilly
paid the Company a milestone payment of $50.0&nbsp;million and in May&nbsp;2010, Eli&nbsp;Lilly paid an additional milestone of $5.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;28, 2010, Lilly notified the Company of its decision to terminate the agreement after review of one year of clinical data from
the Prot&eacute;g&eacute; trial in Type 1 diabetes patients treated with teplizumab. Such data failed to support the primary efficacy end point in the study. In February 2011, the Company reacquired the commercial rights to the molecule from Eli
Lilly. During the year ended December&nbsp;31, 2012, Eli&nbsp;Lilly satisfied its obligation related to the cost of monitoring patients under the Prot&eacute;g&eacute; and Encore trials. The Company&#146;s obligations continued through September
2012, which represented the follow up period for enrolled patients and the Company&#146;s final reporting of the trial&#146;s results. There is no additional clinical trial activity under the Eli Lilly Agreements as it relates to such trials.
However, Eli Lily continues to reimburse the Company for monitoring patients in one currently active trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended
December 2013, 2012 and 2011, the Company recognized revenue of $0.8 million, $31.2 million and $30.9 million, respectively, under this agreement. No milestones were achieved under this agreement during the three years ended December&nbsp;31, 2013.
</P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Commitments and Contingencies </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases office and laboratory space in Rockville, Maryland under a lease that expires on March&nbsp;31, 2018, and leases a
manufacturing facility in Rockville under a lease that expires on December&nbsp;31, 2014. The Company has an option under each lease to continue the respective lease for five years under the same terms. The Company also subleases office and
laboratory space in South San Francisco under a lease that expires on December&nbsp;31, 2018. All of the leases contain rent escalation clauses. For financial reporting purposes, rent expense is charged to operations on a straight-line basis over
the term of the lease. As of December&nbsp;31, 2013 and 2012, the Company had recorded a deferred rent liability of $2.9 million and $2.8 million, respectively. Rent expense for the years ended December&nbsp;31, 2013, 2012 and 2011 was $2.7 million,
$2.7 million and $2.9 million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future minimum lease payments under noncancelable operating leases at December&nbsp;31, 2013
are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,651,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,310,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,410,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,512,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,780,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,665,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Product Milestone Payments and Royalty Agreements </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with an Asset Purchase Agreement with Tolerance Therapeutics, Inc. (&#147;Tolerance&#148;) entered into during
June 2005, the Company may be required to issue Tolerance additional consideration as follows: (i)&nbsp;$10,950,000 if certain milestones are met, including the initiation of Phase 3 trials and filing of various regulatory product license
applications; (ii)&nbsp;36,135 shares of common stock; and (iii)&nbsp;royalty payments between 1.75% and 4.0% of net sales of products acquired from or patented by Tolerance or other product fees earned by the Company. Any additional consideration
required to be paid under the Asset Purchase Agreement will be recorded as research and development expense when incurred. No payments related to the additional consideration have occurred during the three years ended December&nbsp;31, 2013.
Additionally, certain agreements require the Company to pay royalties. Currently, the Company is not obligated to pay royalties, as no revenue from product sales is being generated by the Company. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Employee Benefit Plan </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2002, the Company established the MacroGenics 401(k) Plan (the &#147;Plan&#148;) for its employees
under Section&nbsp;401(k) of the IRC. Under this Plan, all employees at least 21 years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to 100% of their salary, subject to
government maximums. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employees are 100% vested in their contributions to the Plan. The Company&#146;s contribution to the Plan, as
determined by the Board of Directors, is discretionary. The Company&#146;s contributions to the Plan totaled $252,930, $225,195 and $217,097 for the years ended December&nbsp;31, 2013, 2012 and 2011, respectively. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Quarterly Financial Information (unaudited) </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>&nbsp;Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>&nbsp;Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP>&nbsp;Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>&nbsp;Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,366</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual net income (loss) per share includes the effects of income allocated to participating securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Subsequent Events </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2014, Servier exercised its exclusive option to develop and commercialize MGD006. Servier will gain exclusive
development and commercial rights in all countries outside of the U.S., Canada, Mexico, Japan, South Korea and India. In those countries, the Company will retain development and commercialization rights. As a result of the exercise, the Company
received a $15.0 million payment from Servier. In addition, the IND application for MGD006 has cleared the 30-day review period by the FDA, triggering an additional $5.0&nbsp;million payment to the Company by Servier. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2014, the Company completed a follow-on equity offering, in which the Company sold 1.8&nbsp;million shares of its common stock at
a price of $36.50 per share. Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 450,000 shares of the Company&#146;s common stock at a price of $36.50 per
share. The Company received net proceeds of $76.7 million from this offering, net of underwriting discounts and commissions and other estimated offering expenses. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Restated Certificate of Incorporation of Company (incorporated by reference to Exhibit 3.1 to the Company&#146;s Current Report on Form 8-K (001-36112) filed on October 18, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Correction to the Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.3 to the Company&#146;s Current Report on Form 8-K (001-36112) filed on October&nbsp;18, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fifth Amended and Restated Registration Rights Agreement by and among the Company, the Founders, and the Investors, dated February 3, 2014</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen Stock Certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 9, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Company 2000 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September&nbsp;4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Incentive Stock Option Agreement under 2000 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1
<FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-190994)</FONT> filed by the Company on September 4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Company 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Incentive Stock Option Agreement under 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4,
2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Company 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Incentive Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Nonstatutory Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1,
2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease Agreement by and between Red Gate III LLC and the Company, dated May 31, 2011 (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form S-1
<FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-190994)</FONT> filed by the Company on September 4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to Lease Agreement by and between Red Gate III LLC and the Company, dated March&nbsp;26, 2013 (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company
on September 4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease Agreement by and between W. M. Rickman Construction Co. LLC and the Company, dated December&nbsp;2, 2004 (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form&nbsp;S-1 (File No. 333-190994) filed by
the Company on September 4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to Lease Agreement by and between W. M. Rickman Construction Co. LLC and the Company, dated January&nbsp;31, 2006 (incorporated by reference to Exhibit 10.11 to the Registration Statement on Form S-1 (File No. 333-190994)
filed by the Company on September 4, 2013)</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Second Amendment to Lease Agreement by and between W. M. Rickman Construction Co. LLC and the Company, dated June&nbsp;1, 2011 (incorporated by reference to Exhibit 10.12 to the Registration Statement on Form S-1 (File No.
333-190994) filed by the Company on September&nbsp;4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Sublease Agreement by and between Amgen SF, LLC and Raven biotechnologies, Inc., dated November 21, 2006 (incorporated by reference to Exhibit 10.13 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the
Company on September 4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15&#134;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Collaboration and License Agreement by and between Boehringer Ingelheim International GmbH and the Company, dated October&nbsp;18, 2010 (incorporated by reference to Exhibit 10.15 to the Registration Statement on Form S-1 (File No.
333-190994) filed by the Company on October&nbsp;4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16&#134;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">License Agreement by and between the Company and Gilead Sciences, Inc., dated January 3, 2013 (incorporated by reference to Exhibit 10.16 to the Registration Statement on Form S-1 (File&nbsp;No.&nbsp;333-190994) filed by the Company
on October 4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16.1&#134;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">First Amendment to License Agreement by and between the Company and Gilead Sciences, Inc., dated October 1, 2013 (incorporated by reference to Exhibit 10.16.1 to the Registration Statement on Form S-1 (File No. 333-190994) filed by
the Company on October 4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17&#134;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Collaboration Agreement by and between the Company and Green Cross Corp., dated June 30, 2010 (incorporated by reference to Exhibit 10.17 to the Registration Statement on Form S-1 (File&nbsp;No. 333-190994) filed by the Company on
October 4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18&#134;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">First Amendment to Collaboration Agreement by and between the Company and Green Cross Corp., dated January 19, 2011 (incorporated by reference to Exhibit 10.18 to the Registration Statement on Form S-1 (File No. 333-190994) filed by
the Company on September 4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19&#134;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Second Amendment to Collaboration Agreement by and between the Company and Green Cross Corp., dated December 13, 2012 (incorporated by reference to Exhibit 10.19 to the Registration Statement on Form S-1 (File No. 333-190994) filed
by the Company on September 4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20&#134;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Option for a License Agreement by and between the Company and Les Laboratoires Servier and Institut de Recherches Servier, dated September 19, 2012 (incorporated by reference to Exhibit&nbsp;10.20 to the Registration Statement on
Form S-1 (File No. 333-190994) filed by the Company on October&nbsp;4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Option for a License Agreement by and between the Company and Les Laboratoires Servier and Institut de Recherches Servier, dated November 24, 2011 (incorporated by reference to Exhibit&nbsp;10.21 to the Registration Statement on
Form S-1 (File No. 333-190994) filed by the Company on October&nbsp;4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.22</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Research Collaboration and License Agreement by and between Pfizer Inc. and the Company, dated October 13, 2010 (incorporated by reference to Exhibit 10.22 to the Registration Statement on Form&nbsp;S-1 (File No. 333-190994) filed
by the Company on October 4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.23&#134;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Amendment No. 1 to Research Collaboration and License Agreement by and between Pfizer Inc. and the Company, dated August 9, 2012 (incorporated by reference to Exhibit 10.23 to the Registration Statement on Form S-1 (File No.
333-190994) filed by the Company on September 4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.24&#134;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Amendment No. 2 to Research Collaboration and License Agreement by and between Pfizer Inc. and the Company, effective October 13, 2013 (incorporated by reference to Exhibit 10.24 to the Registration Statement on Form S-1 (File No.
333-190994) filed by the Company on September 20, 2013)</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.25+</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Form of Employment Agreement between the Company and Scott Koenig, M.D., Ph.D. (incorporated by reference to Exhibit 10.25 to the Registration Statement on Form S-1 (File&nbsp;No.&nbsp;333-190994) filed by the Company on October 1,
2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.26+</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">2013 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.27 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.27+*</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Form of Employment Agreement between the Company and James Karrels</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;21.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Subsidiaries of Company (incorporated by reference to Exhibit 21.1 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Rule 13a-14(a) Certification of Principal Executive Officer</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Rule 13a-14(a) Certification of Principal Financial Officer</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Section 1350 Certification of Principal Executive Officer</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.2</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Section 1350 Certification of Principal Financial Officer</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS**</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH**</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Schema Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL**</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Calculation Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF**</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Definition Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB**</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Labels Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE**</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Presentation Linkbase Document</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment granted by the SEC. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">In accordance with Regulation S-T, the XBRL-related information in Exhibit 101 to this Annual Report on Form 10-K shall be deemed to be &#147;furnished&#148; and not &#147;filed&#148;. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d644794dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 23.1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in the Registration Statement (Form S-8 No.&nbsp;333- 192277) pertaining to the 2000 Stock Option Incentive Plan,
the 2003 Equity Incentive Plan, and 2013 Equity Incentive Plan of MacroGenics, Inc. of our report dated March&nbsp;20, 2014, with respect to the consolidated financial statements of MacroGenics, Inc.,&nbsp;included in this Annual Report (Form 10-K)
for the year ended December&nbsp;31, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-right:15%; font-size:10pt; font-family:Times New Roman" ALIGN="right">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">McLean, VA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;20, 2014 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>d644794dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 31.1 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Scott Koenig, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Annual Report on Form 10-K for the period ended December&nbsp;31, 2013 of MacroGenics, Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Scott Koenig</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Scott Koenig, M.D., Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: March&nbsp;20, 2014 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>d644794dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 31.2 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, James Karrels, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Annual Report on Form 10-K for the period ended December&nbsp;31, 2013 of MacroGenics, Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ James Karrels</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">James Karrels</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President and Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Financial Officer)</P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: March&nbsp;20, 2014 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>d644794dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 32.1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of Principal Executive Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the &#147;Registrant&#148;), certify, to the best
of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended December&nbsp;31, 2013 of the Registrant (the &#147;Report&#148;), that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The Report fully complies with the requirements of Section&nbsp;13(a) of the Securities Exchange Act of 1934, as amended; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Koenig</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name: Scott Koenig, M.D., Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: March&nbsp;20, 2014</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>d644794dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 32.2 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of Principal Financial Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, James Karrels, Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the &#147;Registrant&#148;), certify, to the
best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended December&nbsp;31, 2013 of the Registrant (the &#147;Report&#148;), that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The Report fully complies with the requirements of Section&nbsp;13(a) of the Securities Exchange Act of 1934, as amended; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James Karrels</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name: James Karrels</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: March&nbsp;20, 2014</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>mgnx-20131231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2014-03-18T16:29:55Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:mgnx="http://www.macrogenics.com/20131231" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="mgnx-20131231.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE179294--1310-K0007_STD_0_20030228_0" unitRef="shares" decimals="INF" id="id_4392741_AC85ED78-12A8-4CD3-B02C-03D641A84259_1_0">2051644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20060516_0" unitRef="shares" decimals="INF" id="id_4392741_161DBD8C-BF6D-41A6-9A35-61E9AFC09DCD_2001_3">10003300</us-gaap:SharesIssued>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE179294--1310-K0007_STD_0_20100516_0_932980x1165094" unitRef="shares" decimals="INF" id="id_4392741_00F45069-1DE0-458F-95BF-466244E25684_2003_6">518708</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE179294--1310-K0007_STD_0_20131031_0_930809x1035519" unitRef="shares" decimals="INF" id="id_4392741_CE5808A8-4461-468F-838B-41B5F0BBADC3_1001_0">1960168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <dei:EntityPublicFloat contextRef="eol_PE179294--1310-K0007_STD_0_20140228_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_06716E7B-1186-47A6-821B-2046879AB165_2_9">698022185</dei:EntityPublicFloat>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE179294--1310-K0007_STD_0_20140228_0" unitRef="shares" decimals="INF" id="id_4392741_06716E7B-1186-47A6-821B-2046879AB165_2_8">27471329</dei:EntityCommonStockSharesOutstanding>
  <mgnx:AdditionalClinicalMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20140228_0_921954x1218717_932504x931597" unitRef="iso4217_USD" decimals="-5" id="id_4392741_1E453099-695C-4017-9EE7-FE08D7334D48_2001_0">5000000</mgnx:AdditionalClinicalMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalLicenseGrantFeesUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20140228_0_921954x1218717_932504x931597" unitRef="iso4217_USD" decimals="-5" id="id_4392741_1E453099-695C-4017-9EE7-FE08D7334D48_2001_1">15000000</mgnx:AdditionalLicenseGrantFeesUnderAgreement>
  <us-gaap:SharesIssuedPricePerShare contextRef="eol_PE179294--1310-K0007_STD_0_20140228_0_932504x931597" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_8AC10A47-BE93-4970-B61B-2AE278873E87_2001_1">36.50</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharePrice contextRef="eol_PE179294--1310-K0007_STD_0_20140228_0_932504x931597" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_8AC10A47-BE93-4970-B61B-2AE278873E87_2001_3">36.50</us-gaap:SharePrice>
  <mgnx:AdditionalClinicalMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20140228_0_932504x931597" unitRef="iso4217_USD" decimals="-5" id="id_4392741_548FBFE7-8460-4C8C-8C05-EF2FBF492841_2001_1">5000000</mgnx:AdditionalClinicalMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalLicenseGrantFeesUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20140228_0_932504x931597" unitRef="iso4217_USD" decimals="-5" id="id_4392741_548FBFE7-8460-4C8C-8C05-EF2FBF492841_2001_0">15000000</mgnx:AdditionalLicenseGrantFeesUnderAgreement>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1310-K0007_STD_0_20110316_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_597327EB-0218-4353-B912-0E33FCAE09AB_1001_2">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1310-K0007_STD_0_20110316_0_929038x1089823_930917x978903" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_597327EB-0218-4353-B912-0E33FCAE09AB_2001_1">4.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1310-K0007_STD_0_20110316_0_929038x972906_930917x978903" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_597327EB-0218-4353-B912-0E33FCAE09AB_3001_0">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <mgnx:AdditionalPaymentUponAchievementOfMilestone contextRef="eol_PE179294--1310-K0007_STD_0_20050630_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_BCEFF5A9-94BF-433F-934B-46FEB7150FE2_3001_0">10950000</mgnx:AdditionalPaymentUponAchievementOfMilestone>
  <mgnx:NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20050630_0" unitRef="shares" decimals="INF" id="id_4392741_BCEFF5A9-94BF-433F-934B-46FEB7150FE2_3001_1">36135</mgnx:NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement>
  <mgnx:OnetimeMilestonePaymentToBePaidUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20080716_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_B248EC3B-1C9A-4714-A359-200666B1521A_1_0">5000000</mgnx:OnetimeMilestonePaymentToBePaidUnderAgreement>
  <mgnx:OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts contextRef="eol_PE179294--1310-K0007_STD_0_20080716_0_926437x923140" unitRef="iso4217_USD" decimals="-5" id="id_4392741_B248EC3B-1C9A-4714-A359-200666B1521A_1001_2">12000000</mgnx:OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts>
  <mgnx:OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts contextRef="eol_PE179294--1310-K0007_STD_0_20080716_0_926437x932953" unitRef="iso4217_USD" decimals="-5" id="id_4392741_B248EC3B-1C9A-4714-A359-200666B1521A_2001_1">8000000</mgnx:OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20041012_0" unitRef="shares" decimals="INF" id="id_4392741_260B9376-9ABE-4F76-A098-3A4D3894A72D_2001_3">13604016</us-gaap:SharesIssued>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE179294--1310-K0007_STD_0_20080919_0_932980x1165094" unitRef="shares" decimals="INF" id="id_4392741_00F45069-1DE0-458F-95BF-466244E25684_2001_3">2875327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:SharePrice contextRef="eol_PE179294--1310-K0007_STD_0_20131016_0_931707x926487" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_6D6277CA-83C0-4A60-9E9F-813163B49175_1002_1">16.00</us-gaap:SharePrice>
  <mgnx:AdditionalCommonStockIssuePricePerShare contextRef="eol_PE179294--1310-K0007_STD_0_20131016_0_931707x926487" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_828A0AEF-D94B-49F3-BEFA-23BDE7C1CFC2_1002_1">16.00</mgnx:AdditionalCommonStockIssuePricePerShare>
  <us-gaap:SharePrice contextRef="eol_PE179294--1310-K0007_STD_0_20031231_0_932980x930435" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_78BA309E-1A89-41B6-81DD-C761DFD62F26_2001_2">1.00</us-gaap:SharePrice>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F9A30717-4680-4175-802C-E2667C5D9848_2001_0">1246025</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1019_2200001">-38634058</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2001_25">36876018</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1031975" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1007_1000002">110952217</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1031975" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1007_1100001">1109522</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1124615" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1005_800002">71401237</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1124615" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1005_900001">714012</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1166280" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1001_400002">26874792</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1166280" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1001_500001">268748</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1166416" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1003_600002">7364582</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1166416" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1003_700001">73646</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1218718" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1011_1400002">45253788</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1218718" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1011_1500001">452538</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1225370" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1009_1200002">14446227</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1225370" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1009_1300001">144462</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x924490" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1015_1800002">14381</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x924490" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1015_1900001">-57742</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x929313" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1018_2100001">-190551278</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x930643" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1013_1600002">1000681</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x930643" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1013_1700001">10007</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x932586" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_1017_2000001">149202027</us-gaap:StockholdersEquity>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F9A30717-4680-4175-802C-E2667C5D9848_1003_0">1533986</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3019_2200009">-17484284</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1003_25">55218361</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestructuringReserve contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_4392741_3E51796F-7DCB-4DF3-8828-3D26324309E0_1001_1">10607499</us-gaap:RestructuringReserve>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1031975" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3007_1000010">110952217</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1031975" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3007_1100009">1109522</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1124615" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3005_800010">71401237</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1124615" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3005_900009">714012</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1166280" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3001_400010">26874792</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1166280" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3001_500009">268748</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1166416" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3003_600010">7364582</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1166416" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3003_700009">73646</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1218718" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3011_1400010">63681176</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1218718" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3011_1500009">636812</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1225370" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3009_1200010">14446227</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1225370" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3009_1300009">144462</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x924490" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3015_1800010">14381</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x924490" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3015_1900009">-57742</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x929313" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3018_2100009">-183834158</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x930643" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3013_1600010">1049030</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x930643" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3013_1700009">10490</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x932586" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_3017_2000009">163449924</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_63">1098914</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_CEDFB2F9-CB0F-4AB4-96B2-42BBD8B5586B_1001_1">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_4392741_ECE56403-768F-4BE4-873E-F0AB29008A6D_1001_1">3249541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:TreasuryStockNumberOfSharesHeld contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_65">14381</us-gaap:TreasuryStockNumberOfSharesHeld>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_62">425000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_61">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:RestructuringReserveCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_14">628768</us-gaap:RestructuringReserveCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_13">1237025</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_A175ADAF-41E6-4B88-8B1B-36A4BC1829B5_2_7">14339497</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_66">164334646</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_12">3739125</us-gaap:AccountsPayableCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1002_10">78090021</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_17">29728094</us-gaap:LiabilitiesCurrent>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F9A30717-4680-4175-802C-E2667C5D9848_1002_0">1592357</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_68">-8237308</us-gaap:StockholdersEquity>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_20">52947</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:ImpairedFinancingReceivableRelatedAllowance contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_A58CF258-E034-4565-8960-25F0E4CE467F_2_0">0</us-gaap:ImpairedFinancingReceivableRelatedAllowance>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_67">-175472403</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_15">24123176</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_19">2801653</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_60">10989</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_69">53746900</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:RestructuringReserveNoncurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_18">9445171</us-gaap:RestructuringReserveNoncurrent>
  <us-gaap:Liabilities contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_22">61984208</us-gaap:Liabilities>
  <us-gaap:DeferredRentCredit contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_7F4975E7-3665-4A2A-A2A5-A01BCA38E8CC_5_3">2800000</us-gaap:DeferredRentCredit>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1001_12">52947</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_21">19956343</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_4290C1C2-A712-4A7B-9941-AEEDFCB344AF_2_0">1100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
  <us-gaap:AssetsCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_5">49927008</us-gaap:AssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_8">147246</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_4">137634</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1002_2">3521722</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1002_9">78090021</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_6">404850</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1001_7">18695197</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:Assets contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_9">53746900</us-gaap:Assets>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1001_10">48148005</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_2">47743155</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1002_15" />
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_3">2046219</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1002_7">1247772</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_A175ADAF-41E6-4B88-8B1B-36A4BC1829B5_2_6">17607293</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1002_5">5218002</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1002_3">2777899</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1002_6">9379064</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1002_1">35330167</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1002_4">19039613</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
  <us-gaap:DeferredTaxAssetsOther contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1002_8">1575782</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:TreasuryStockValue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_64">57742</us-gaap:TreasuryStockValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2_7">3267796</us-gaap:PropertyPlantAndEquipmentNet>
  <mgnx:RestrictedCashFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1001_9">404850</mgnx:RestrictedCashFairValueDisclosure>
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1001_8">29047958</mgnx:MoneyMarketFundsFairValueDisclosure>
  <us-gaap:RestructuringReserve contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_4392741_3E51796F-7DCB-4DF3-8828-3D26324309E0_3001_3">10073939</us-gaap:RestructuringReserve>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1031975" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5007_1000016">110952217</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1031975" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5007_1100015">1109522</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1124615" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5005_800016">71401237</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1124615" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5005_900015">714012</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1166280" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5001_400016">26874792</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1166280" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5001_500015">268748</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1166416" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5003_600016">7364582</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1166416" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5003_700015">73646</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1218718" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5011_1400016">63681176</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1218718" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5011_1500015">636812</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1225370" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5009_1200016">14446227</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1225370" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5009_1300015">144462</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x924490" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5015_1800016">14381</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x924490" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5015_1900015">-57742</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x929313" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5018_2100015">-175472403</us-gaap:StockholdersEquity>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x929614" unitRef="iso4217_USD" decimals="0" id="id_4392741_13482182-00B0-4C8D-8B69-29C0966563E1_1001_1">52947</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x930643" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5013_1600016">1098914</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x930643" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5013_1700015">10989</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x932586" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_5017_2000015">164334646</us-gaap:StockholdersEquity>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_B0C5A374-4042-4D35-A840-49306675B84C_1002_0">18000000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_B0C5A374-4042-4D35-A840-49306675B84C_1002_1">8600000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_B0C5A374-4042-4D35-A840-49306675B84C_1002_2">9400000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x925736" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1002_12" />
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x925736" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1002_7">18695197</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x925736" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1002_10">48148005</us-gaap:AssetsFairValueDisclosure>
  <mgnx:RestrictedCashFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x925736" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1002_9">404850</mgnx:RestrictedCashFairValueDisclosure>
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x925736" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1002_8">29047958</mgnx:MoneyMarketFundsFairValueDisclosure>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1003_12" />
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1003_7" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1003_10" />
  <mgnx:RestrictedCashFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1003_9" />
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1003_8" />
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x929831" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1004_12">52947</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1004_7" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1004_10" />
  <mgnx:RestrictedCashFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1004_9" />
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_1004_8" />
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929865x923192" unitRef="iso4217_USD" decimals="0" id="id_4392741_A175ADAF-41E6-4B88-8B1B-36A4BC1829B5_1002_4">51360</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929865x923325" unitRef="iso4217_USD" decimals="0" id="id_4392741_A175ADAF-41E6-4B88-8B1B-36A4BC1829B5_2002_5">4881706</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929865x928802" unitRef="iso4217_USD" decimals="0" id="id_4392741_A175ADAF-41E6-4B88-8B1B-36A4BC1829B5_3002_3">8747790</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929865x929134" unitRef="iso4217_USD" decimals="0" id="id_4392741_A175ADAF-41E6-4B88-8B1B-36A4BC1829B5_4002_1">1323081</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929865x931760" unitRef="iso4217_USD" decimals="0" id="id_4392741_A175ADAF-41E6-4B88-8B1B-36A4BC1829B5_5002_0">2003706</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_929865x932226" unitRef="iso4217_USD" decimals="0" id="id_4392741_A175ADAF-41E6-4B88-8B1B-36A4BC1829B5_6002_2">599650</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1031975" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1002_46">110952217</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1031975" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1002_44">110952217</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1031975" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1002_43">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1031975" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1002_45">110952217</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1031975" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1002_42">1109522</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1031975" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1002_47">45000000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1124615" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2002_40">71401237</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1124615" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2002_38">71401237</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1124615" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2002_37">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1124615" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2002_39">71401237</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1124615" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2002_36">714012</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1124615" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_2002_41">31000000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1166280" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_3002_28">26874792</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1166280" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_3002_26">26874792</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1166280" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_3002_25">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1166280" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_3002_27">26874792</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1166280" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_3002_24">268748</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1166280" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_3002_29">27000000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1166416" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_4002_34">7364582</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1166416" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_4002_32">7364582</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1166416" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_4002_31">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1166416" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_4002_33">7364582</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1166416" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_4002_30">73646</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1166416" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_4002_35">7000000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1218718" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_5002_58">63681176</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1218718" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_5002_56">75000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1218718" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_5002_55">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1218718" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_5002_57">63681176</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1218718" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_5002_54">636812</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1218718" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_5002_59">41500000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1225370" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_6002_52">14446227</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1225370" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_6002_50">30000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1225370" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_6002_49">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1225370" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_6002_51">14446227</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1225370" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_6002_48">144462</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1225370" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_6002_53">9400000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_AE3405A7-B4C4-497F-A480-D4EB013D6919_1002_0">14000000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_AE3405A7-B4C4-497F-A480-D4EB013D6919_1002_1">5000000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_AE3405A7-B4C4-497F-A480-D4EB013D6919_1002_2">9000000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_4392741_7DFF7934-3E1F-4890-9756-6D72A10FBF16_1001_0">750000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_4392741_7DFF7934-3E1F-4890-9756-6D72A10FBF16_1001_1">100000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_4392741_7DFF7934-3E1F-4890-9756-6D72A10FBF16_1001_2">650000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_933025x1115783" unitRef="iso4217_USD" decimals="-5" id="id_4392741_3711A25F-96A0-467F-A53A-ECDB8E74A3F7_1002_1">1300000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_28E2613A-4DE4-4AD6-9A63-20E9BB1628E1_1_0">10000000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_28E2613A-4DE4-4AD6-9A63-20E9BB1628E1_1_1">9100000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-K0007_STD_0_20121231_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_28E2613A-4DE4-4AD6-9A63-20E9BB1628E1_1_2">900000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_63">25177597</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4392741_ECE56403-768F-4BE4-873E-F0AB29008A6D_3001_6">1688251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_CEDFB2F9-CB0F-4AB4-96B2-42BBD8B5586B_3001_5">4.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4392741_ECE56403-768F-4BE4-873E-F0AB29008A6D_3001_5">3200958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_CEDFB2F9-CB0F-4AB4-96B2-42BBD8B5586B_3001_7">4.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4392741_ECE56403-768F-4BE4-873E-F0AB29008A6D_3001_7">3022948</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:TreasuryStockNumberOfSharesHeld contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_65">14381</us-gaap:TreasuryStockNumberOfSharesHeld>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_CEDFB2F9-CB0F-4AB4-96B2-42BBD8B5586B_3001_6">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_62">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_61">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:RestructuringReserveCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_14">1438742</us-gaap:RestructuringReserveCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_13">3583552</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_0875464D-B24E-49ED-ABE1-C6FED51276A0_1001_1">3310884</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:DeferredTaxLiabilitiesOther contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1001_13">394952</us-gaap:DeferredTaxLiabilitiesOther>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_A175ADAF-41E6-4B88-8B1B-36A4BC1829B5_1_7">15532837</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1001_14">394952</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_66">254453673</us-gaap:AdditionalPaidInCapital>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_0875464D-B24E-49ED-ABE1-C6FED51276A0_1001_6">16665430</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_12">3169034</us-gaap:AccountsPayableCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_0875464D-B24E-49ED-ABE1-C6FED51276A0_1001_3">3512517</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1001_10">79376945</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_17">28821571</us-gaap:LiabilitiesCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_0875464D-B24E-49ED-ABE1-C6FED51276A0_1001_5" />
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F9A30717-4680-4175-802C-E2667C5D9848_1001_4">1707859</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_68">78914468</us-gaap:StockholdersEquity>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_0875464D-B24E-49ED-ABE1-C6FED51276A0_1001_4">2780398</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:ImpairedFinancingReceivableRelatedAllowance contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_A58CF258-E034-4565-8960-25F0E4CE467F_1_0">0</us-gaap:ImpairedFinancingReceivableRelatedAllowance>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_67">-175733238</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_15">20267323</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_19">2904227</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_60">251775</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_69">125782381</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:RestructuringReserveNoncurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_18">8006428</us-gaap:RestructuringReserveNoncurrent>
  <us-gaap:Liabilities contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_22">46867913</us-gaap:Liabilities>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_0875464D-B24E-49ED-ABE1-C6FED51276A0_1001_2">3410210</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:DeferredRentCredit contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_7F4975E7-3665-4A2A-A2A5-A01BCA38E8CC_4_3">2900000</us-gaap:DeferredRentCredit>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_16">362920</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_21">7135687</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_4290C1C2-A712-4A7B-9941-AEEDFCB344AF_1_0">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_0875464D-B24E-49ED-ABE1-C6FED51276A0_1001_0">3651421</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_A8BBB5D6-0E77-4986-8C5B-D1545DFED30E_1001_6">1800000</us-gaap:UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward>
  <us-gaap:AssetsCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_5">119457133</us-gaap:AssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_8">885166</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_4">971705</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1001_2">3315514</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1001_9">79771897</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_6">404850</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_2001_2">90434435</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:Assets contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_9">125782381</us-gaap:Assets>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_2001_5">116886259</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_E520CA8D-C4E5-4643-934D-00026792C56C_1001_3">64574000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_2">116481409</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1001_15" />
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_3">2004019</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1001_7">1438477</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1001_11">394952</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_A175ADAF-41E6-4B88-8B1B-36A4BC1829B5_1_6">20568069</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1001_5">5132458</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1001_3">3785612</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_E520CA8D-C4E5-4643-934D-00026792C56C_1001_2">42311000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1001_6">8216695</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_E520CA8D-C4E5-4643-934D-00026792C56C_1001_1">67532000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_B4806FB3-A6F3-4580-B871-953BDED216A5_1001_4">7600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1001_1">36561195</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1001_4">19883076</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
  <us-gaap:DeferredTaxAssetsOther contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3AC77723-3F9C-4D58-A43F-D2CB42C80A2F_1001_8">1438870</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:TreasuryStockValue contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_64">57742</us-gaap:TreasuryStockValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_49062366-AFDE-4E8A-81F5-98B13EF40527_1_7">5035232</us-gaap:PropertyPlantAndEquipmentNet>
  <mgnx:RestrictedCashFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_2001_4">404850</mgnx:RestrictedCashFairValueDisclosure>
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_2001_3">26046974</mgnx:MoneyMarketFundsFairValueDisclosure>
  <mgnx:OperatingLossCarryforwardsNotSubjectToLimitation contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_A8BBB5D6-0E77-4986-8C5B-D1545DFED30E_1001_5">96300000</mgnx:OperatingLossCarryforwardsNotSubjectToLimitation>
  <mgnx:OperatingLossCarryforwardsAnnualLimitationAmount contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_926437x923140" unitRef="iso4217_USD" decimals="-5" id="id_4392741_A8BBB5D6-0E77-4986-8C5B-D1545DFED30E_2001_4">1400000</mgnx:OperatingLossCarryforwardsAnnualLimitationAmount>
  <mgnx:AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_926437x923140_933025x1060690" unitRef="iso4217_USD" decimals="-6" id="id_4392741_27D9D216-2C99-4BAB-A64D-CFD17D02BBF1_2001_3">25000000</mgnx:AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_926437x923140_933025x1060690" unitRef="iso4217_USD" decimals="-6" id="id_4392741_27D9D216-2C99-4BAB-A64D-CFD17D02BBF1_2001_5">250000000</mgnx:AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement>
  <mgnx:OperatingLossCarryforwardsAnnualLimitationAmount contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_926437x932953" unitRef="iso4217_USD" decimals="-5" id="id_4392741_A8BBB5D6-0E77-4986-8C5B-D1545DFED30E_3001_3">200000</mgnx:OperatingLossCarryforwardsAnnualLimitationAmount>
  <mgnx:AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_926437x932953_933025x1060690" unitRef="iso4217_USD" decimals="-6" id="id_4392741_27D9D216-2C99-4BAB-A64D-CFD17D02BBF1_3001_2">20000000</mgnx:AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_926437x932953_933025x1060690" unitRef="iso4217_USD" decimals="-6" id="id_4392741_27D9D216-2C99-4BAB-A64D-CFD17D02BBF1_3001_4">240000000</mgnx:AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_4392741_CC7BC303-EC91-432C-A493-560C22E714EC_1001_1">1641905</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_4392741_CC7BC303-EC91-432C-A493-560C22E714EC_1001_6">9445170</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:RestructuringReserve contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_4392741_3E51796F-7DCB-4DF3-8828-3D26324309E0_6001_5">9445170</us-gaap:RestructuringReserve>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_4392741_CC7BC303-EC91-432C-A493-560C22E714EC_1001_3">2113118</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_926911x929956" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_CC7BC303-EC91-432C-A493-560C22E714EC_1001_5" />
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_4392741_CC7BC303-EC91-432C-A493-560C22E714EC_1001_4">2385374</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_4392741_CC7BC303-EC91-432C-A493-560C22E714EC_1001_2">1866031</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_4392741_CC7BC303-EC91-432C-A493-560C22E714EC_1001_0">1438742</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_927592x924490" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_7015_1800026">14381</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_927592x924490" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_7015_1900025">-57742</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_927592x929313" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_7018_2100025">-175733238</us-gaap:StockholdersEquity>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_927592x929614" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_13482182-00B0-4C8D-8B69-29C0966563E1_4001_4" />
  <us-gaap:SharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_927592x930643" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_7013_1600026">25177597</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_927592x930643" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_7013_1700025">251775</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_927592x932586" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_7017_2000025">254453673</us-gaap:StockholdersEquity>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_B0C5A374-4042-4D35-A840-49306675B84C_1001_0">9400000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_B0C5A374-4042-4D35-A840-49306675B84C_1001_1">8600000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_B0C5A374-4042-4D35-A840-49306675B84C_1001_2">800000</us-gaap:DeferredRevenueNoncurrent>
  <mgnx:AdditionalRegulatoryMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_6E4EFFB8-63AA-4023-AE34-4E4556B3092B_2001_4">300000000</mgnx:AdditionalRegulatoryMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalClinicalMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_6E4EFFB8-63AA-4023-AE34-4E4556B3092B_2001_2">98000000</mgnx:AdditionalClinicalMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalSalesMilestonesUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_6E4EFFB8-63AA-4023-AE34-4E4556B3092B_2001_5">630000000</mgnx:AdditionalSalesMilestonesUnderAgreement>
  <mgnx:AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_6E4EFFB8-63AA-4023-AE34-4E4556B3092B_2001_3">5000000</mgnx:AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance>
  <mgnx:AdditionalLicenseGrantFeesUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_6E4EFFB8-63AA-4023-AE34-4E4556B3092B_2001_1">65000000</mgnx:AdditionalLicenseGrantFeesUnderAgreement>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929790x925736" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_2002_2">90434435</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929790x925736" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_2002_5">116886259</us-gaap:AssetsFairValueDisclosure>
  <mgnx:RestrictedCashFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929790x925736" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_2002_4">404850</mgnx:RestrictedCashFairValueDisclosure>
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929790x925736" unitRef="iso4217_USD" decimals="0" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_2002_3">26046974</mgnx:MoneyMarketFundsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_2003_2" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_2003_5" />
  <mgnx:RestrictedCashFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_2003_4" />
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_2003_3" />
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_2004_2" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_2004_5" />
  <mgnx:RestrictedCashFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_2004_4" />
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_3BDA763C-6A4C-4FF3-9149-161594C90A7E_2004_3" />
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929865x923192" unitRef="iso4217_USD" decimals="0" id="id_4392741_A175ADAF-41E6-4B88-8B1B-36A4BC1829B5_1001_4">51360</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929865x923325" unitRef="iso4217_USD" decimals="0" id="id_4392741_A175ADAF-41E6-4B88-8B1B-36A4BC1829B5_2001_5">4893770</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929865x928802" unitRef="iso4217_USD" decimals="0" id="id_4392741_A175ADAF-41E6-4B88-8B1B-36A4BC1829B5_3001_3">11166619</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929865x929134" unitRef="iso4217_USD" decimals="0" id="id_4392741_A175ADAF-41E6-4B88-8B1B-36A4BC1829B5_4001_1">1477416</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929865x931760" unitRef="iso4217_USD" decimals="0" id="id_4392741_A175ADAF-41E6-4B88-8B1B-36A4BC1829B5_5001_0">2379254</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_929865x932226" unitRef="iso4217_USD" decimals="0" id="id_4392741_A175ADAF-41E6-4B88-8B1B-36A4BC1829B5_6001_2">599650</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_930809x1035519" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_CEFE3E7B-4B44-4AF5-B488-487F605811E4_1001_1">19.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_930809x1035519" unitRef="shares" decimals="INF" id="id_4392741_CEFE3E7B-4B44-4AF5-B488-487F605811E4_1001_0">618290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_930809x1047151" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_DF05FDD6-942B-4058-91EC-64FCE9E78EAA_1001_1">1.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_930809x1047151" unitRef="shares" decimals="INF" id="id_4392741_DF05FDD6-942B-4058-91EC-64FCE9E78EAA_1001_0">2559011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_930809x1108152" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_64A116EC-9085-4EE4-B831-C48EC76C741F_1001_1">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_930809x1108152" unitRef="shares" decimals="INF" id="id_4392741_64A116EC-9085-4EE4-B831-C48EC76C741F_1001_0">23657</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_930809x1108152" unitRef="shares" decimals="INF" id="id_4392741_C90827D6-1A8C-4D88-8F73-39EC41C6CE77_2001_0">130725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:OperatingLossCarryforwards contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_932628x924673" unitRef="iso4217_USD" decimals="-5" id="id_4392741_64DB01D3-145A-4FD4-B8E5-AC3518C59F55_1001_0">104800000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:TaxCreditCarryforwardAmount contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_932628x924673" unitRef="iso4217_USD" decimals="-5" id="id_4392741_64DB01D3-145A-4FD4-B8E5-AC3518C59F55_1001_4">23700000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:OperatingLossCarryforwards contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_932628x926821" unitRef="iso4217_USD" decimals="-5" id="id_4392741_64DB01D3-145A-4FD4-B8E5-AC3518C59F55_2001_1">60300000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x1135605" unitRef="shares" decimals="INF" id="id_4392741_764306B6-F14F-484D-B4D1-ABE3A9C3CEB9_1001_4">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x1135605" unitRef="shares" decimals="INF" id="id_4392741_764306B6-F14F-484D-B4D1-ABE3A9C3CEB9_1001_1">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x1135605" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_764306B6-F14F-484D-B4D1-ABE3A9C3CEB9_1001_2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x1135605" unitRef="shares" decimals="INF" id="id_4392741_764306B6-F14F-484D-B4D1-ABE3A9C3CEB9_1001_3">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x1165094" unitRef="shares" decimals="INF" id="id_4392741_A14DBE96-B642-4583-956D-2063B4B3E9A8_1001_5">1.00</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x1165094" unitRef="iso4217_USD_per_Warrant" decimals="INF" id="id_4392741_00F45069-1DE0-458F-95BF-466244E25684_2002_4">0.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x1184171" unitRef="shares" decimals="INF" id="id_4392741_A14DBE96-B642-4583-956D-2063B4B3E9A8_2001_0">1.506</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x1218712" unitRef="shares" decimals="INF" id="id_4392741_A14DBE96-B642-4583-956D-2063B4B3E9A8_3001_1">1.00</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x929177" unitRef="shares" decimals="INF" id="id_4392741_A14DBE96-B642-4583-956D-2063B4B3E9A8_4001_4">1.00</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x930400" unitRef="shares" decimals="INF" id="id_4392741_A14DBE96-B642-4583-956D-2063B4B3E9A8_5001_3">1.00</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x932774" unitRef="shares" decimals="INF" id="id_4392741_A14DBE96-B642-4583-956D-2063B4B3E9A8_6001_2">1.14</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_AE3405A7-B4C4-497F-A480-D4EB013D6919_1001_0">12800000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_AE3405A7-B4C4-497F-A480-D4EB013D6919_1001_1">7000000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_AE3405A7-B4C4-497F-A480-D4EB013D6919_1001_2">5800000</us-gaap:DeferredRevenueNoncurrent>
  <mgnx:AdditionalRegulatoryMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_94FD699B-92E5-447C-9EAC-689BBE2E7FC8_1001_3">89000000</mgnx:AdditionalRegulatoryMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalClinicalMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_94FD699B-92E5-447C-9EAC-689BBE2E7FC8_1001_2">41000000</mgnx:AdditionalClinicalMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalSalesMilestonesUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_94FD699B-92E5-447C-9EAC-689BBE2E7FC8_1001_4">83000000</mgnx:AdditionalSalesMilestonesUnderAgreement>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1060690" unitRef="iso4217_USD" decimals="-5" id="id_4392741_8B51BEDD-A85A-4478-BD89-92FBA68BB025_1_0">3600000</us-gaap:DeferredRevenueCurrent>
  <mgnx:AdditionalLicenseGrantFeesUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1060690" unitRef="iso4217_USD" decimals="-5" id="id_4392741_27D9D216-2C99-4BAB-A64D-CFD17D02BBF1_1001_1">7500000</mgnx:AdditionalLicenseGrantFeesUnderAgreement>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_4392741_7DFF7934-3E1F-4890-9756-6D72A10FBF16_1002_0">650000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_4392741_7DFF7934-3E1F-4890-9756-6D72A10FBF16_1002_1">100000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_4392741_7DFF7934-3E1F-4890-9756-6D72A10FBF16_1002_2">550000</us-gaap:DeferredRevenueNoncurrent>
  <mgnx:AdditionalClinicalMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1064508" unitRef="iso4217_USD" decimals="-5" id="id_4392741_C3ECECA6-3A94-410B-8A8D-77FC4FD67C23_1001_1">4500000</mgnx:AdditionalClinicalMilestonePaymentsUnderAgreement>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1115783" unitRef="iso4217_USD" decimals="0" id="id_4392741_3711A25F-96A0-467F-A53A-ECDB8E74A3F7_1001_0">7291</us-gaap:DeferredRevenueCurrent>
  <mgnx:AdditionalClinicalMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1115783" unitRef="iso4217_USD" decimals="-5" id="id_4392741_AAD40A75-0A64-4212-B7C6-A45F1A9287DB_1001_0">17000000</mgnx:AdditionalClinicalMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalSalesMilestonesUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1115783" unitRef="iso4217_USD" decimals="-5" id="id_4392741_AAD40A75-0A64-4212-B7C6-A45F1A9287DB_1001_1">195000000</mgnx:AdditionalSalesMilestonesUnderAgreement>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_28E2613A-4DE4-4AD6-9A63-20E9BB1628E1_2_0">900000</us-gaap:DeferredRevenue>
  <mgnx:AdditionalRegulatoryMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_8A02712C-A8E7-4986-9C8B-47D8D977B83C_1001_3">140000000</mgnx:AdditionalRegulatoryMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalClinicalMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_8A02712C-A8E7-4986-9C8B-47D8D977B83C_1001_2">47000000</mgnx:AdditionalClinicalMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalSalesMilestonesUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_8A02712C-A8E7-4986-9C8B-47D8D977B83C_1001_4">208000000</mgnx:AdditionalSalesMilestonesUnderAgreement>
  <mgnx:AdditionalLicenseGrantFeesUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_8A02712C-A8E7-4986-9C8B-47D8D977B83C_1001_1">30000000</mgnx:AdditionalLicenseGrantFeesUnderAgreement>
  <mgnx:AmountOfAdditionalConsiderationPaidUnderAgreement contextRef="eol_PE179294--1310-K0007_STD_1096_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_BCEFF5A9-94BF-433F-934B-46FEB7150FE2_2_4">0</mgnx:AmountOfAdditionalConsiderationPaidUnderAgreement>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE179294--1310-K0007_STD_1826_20101231_0" unitRef="shares" decimals="INF" id="id_4392741_AC85ED78-12A8-4CD3-B02C-03D641A84259_2_1">1739116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease contextRef="eol_PE179294--1310-K0007_STD_1826_20101231_0" unitRef="shares" decimals="INF" id="id_4392741_AC85ED78-12A8-4CD3-B02C-03D641A84259_2_2">3790760</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-K0007_STD_2_20060516_0_932980x930400" unitRef="shares" decimals="INF" id="id_4392741_161DBD8C-BF6D-41A6-9A35-61E9AFC09DCD_1001_2">110952217</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE179294--1310-K0007_STD_2_20060516_0_932980x930400" unitRef="iso4217_USD" decimals="-5" id="id_4392741_161DBD8C-BF6D-41A6-9A35-61E9AFC09DCD_1001_0">44900000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <mgnx:StockIssuanceCosts contextRef="eol_PE179294--1310-K0007_STD_2_20060516_0_932980x930400" unitRef="iso4217_USD" decimals="0" id="id_4392741_161DBD8C-BF6D-41A6-9A35-61E9AFC09DCD_1001_1">101246</mgnx:StockIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-K0007_STD_2_20100516_0_932980x1165094" unitRef="shares" decimals="INF" id="id_4392741_00F45069-1DE0-458F-95BF-466244E25684_1003_5">6916110</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <mgnx:StockOptionExchangeRatioDescription contextRef="eol_PE179294--1310-K0007_STD_2_20110316_0" id="id_4392741_597327EB-0218-4353-B912-0E33FCAE09AB_1_3">one-for-one basis</mgnx:StockOptionExchangeRatioDescription>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="eol_PE179294--1310-K0007_STD_2_20080716_0_928576x1218824_932980x929177" unitRef="shares" decimals="INF" id="id_4392741_D3E315EB-662F-452C-A760-C5F00B4D2EC9_1001_0">12466039</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="eol_PE179294--1310-K0007_STD_2_20020925_0" unitRef="pure" decimals="INF" id="id_4392741_9FB56779-F3A4-4483-8C1D-31CD2FD83EBF_1_1">1.00</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <mgnx:EmployeeEligibleAgeToParticipateInBenefitPlan contextRef="eol_PE179294--1310-K0007_STD_2_20020925_0" unitRef="Age" decimals="INF" id="id_4392741_9FB56779-F3A4-4483-8C1D-31CD2FD83EBF_1_0">21</mgnx:EmployeeEligibleAgeToParticipateInBenefitPlan>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-K0007_STD_2_20041012_0_932980x932774" unitRef="shares" decimals="INF" id="id_4392741_260B9376-9ABE-4F76-A098-3A4D3894A72D_1001_2">71401237</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE179294--1310-K0007_STD_2_20041012_0_932980x932774" unitRef="iso4217_USD" decimals="-5" id="id_4392741_260B9376-9ABE-4F76-A098-3A4D3894A72D_1001_0">30300000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <mgnx:StockIssuanceCosts contextRef="eol_PE179294--1310-K0007_STD_2_20041012_0_932980x932774" unitRef="iso4217_USD" decimals="0" id="id_4392741_260B9376-9ABE-4F76-A098-3A4D3894A72D_1001_1">238000</mgnx:StockIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-K0007_STD_2_20080919_0_932980x1165094" unitRef="shares" decimals="INF" id="id_4392741_00F45069-1DE0-458F-95BF-466244E25684_1001_2">38337678</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE179294--1310-K0007_STD_2_20080919_0_932980x1165094" unitRef="iso4217_USD" decimals="-5" id="id_4392741_00F45069-1DE0-458F-95BF-466244E25684_1001_0">24800000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <mgnx:StockIssuanceCosts contextRef="eol_PE179294--1310-K0007_STD_2_20080919_0_932980x1165094" unitRef="iso4217_USD" decimals="0" id="id_4392741_00F45069-1DE0-458F-95BF-466244E25684_1001_1">156788</mgnx:StockIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-K0007_STD_2_20131016_0_931707x926487" unitRef="shares" decimals="INF" id="id_4392741_6D6277CA-83C0-4A60-9E9F-813163B49175_1001_0">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE179294--1310-K0007_STD_2_20131016_0_931707x926487" unitRef="iso4217_USD" decimals="-5" id="id_4392741_6D6277CA-83C0-4A60-9E9F-813163B49175_1001_3">83800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <mgnx:StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption contextRef="eol_PE179294--1310-K0007_STD_2_20131016_0_931707x926487" unitRef="shares" decimals="INF" id="id_4392741_6D6277CA-83C0-4A60-9E9F-813163B49175_1001_2">750000</mgnx:StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption>
  <mgnx:StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment contextRef="eol_PE179294--1310-K0007_STD_2_20131016_0_931707x926487" unitRef="shares" decimals="INF" id="id_4392741_828A0AEF-D94B-49F3-BEFA-23BDE7C1CFC2_1001_0">5750000</mgnx:StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment>
  <mgnx:ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses contextRef="eol_PE179294--1310-K0007_STD_2_20131016_0_931707x926487" unitRef="iso4217_USD" decimals="-5" id="id_4392741_828A0AEF-D94B-49F3-BEFA-23BDE7C1CFC2_1001_2">85600000</mgnx:ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-K0007_STD_2_20110111_0_928305x1218718" unitRef="shares" decimals="INF" id="id_4392741_E5D769C1-45A4-482B-92DD-4742E71D844F_1001_0">18427388</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE179294--1310-K0007_STD_2_20110111_0_928305x1218718" unitRef="iso4217_USD" decimals="-5" id="id_4392741_E5D769C1-45A4-482B-92DD-4742E71D844F_1001_1">12000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <mgnx:ReviewPeriodByRegulatoryAuthority contextRef="eol_PE179294--1310-K0007_STD_21_20140228_0_921954x1218717_932504x931597" id="id_4392741_1E453099-695C-4017-9EE7-FE08D7334D48_1001_2">P30D</mgnx:ReviewPeriodByRegulatoryAuthority>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-K0007_STD_21_20140228_0_932504x931597" unitRef="shares" decimals="-5" id="id_4392741_8AC10A47-BE93-4970-B61B-2AE278873E87_1001_0">1800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE179294--1310-K0007_STD_21_20140228_0_932504x931597" unitRef="iso4217_USD" decimals="-5" id="id_4392741_8AC10A47-BE93-4970-B61B-2AE278873E87_1001_4">76700000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <mgnx:StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption contextRef="eol_PE179294--1310-K0007_STD_21_20140228_0_932504x931597" unitRef="shares" decimals="INF" id="id_4392741_8AC10A47-BE93-4970-B61B-2AE278873E87_1001_2">450000</mgnx:StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption>
  <mgnx:ReviewPeriodByRegulatoryAuthority contextRef="eol_PE179294--1310-K0007_STD_21_20140228_0_932504x931597" id="id_4392741_548FBFE7-8460-4C8C-8C05-EF2FBF492841_1001_2">P30D</mgnx:ReviewPeriodByRegulatoryAuthority>
  <mgnx:RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement contextRef="eol_PE179294--1310-K0007_STD_30_20050630_0_926437x923140" unitRef="pure" decimals="INF" id="id_4392741_BCEFF5A9-94BF-433F-934B-46FEB7150FE2_1001_3">0.040</mgnx:RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement>
  <mgnx:RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement contextRef="eol_PE179294--1310-K0007_STD_30_20050630_0_926437x932953" unitRef="pure" decimals="INF" id="id_4392741_BCEFF5A9-94BF-433F-934B-46FEB7150FE2_2001_2">0.0175</mgnx:RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement>
  <mgnx:LeaseExpirationYear contextRef="eol_PE179294--1310-K0007_STD_30_20080716_0" id="id_4392741_68398A8D-05E7-4A6A-B30C-8325801336B0_1_0">2018</mgnx:LeaseExpirationYear>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="eol_PE179294--1310-K0007_STD_30_20080716_0_932980x1010406" unitRef="shares" decimals="INF" id="id_4392741_39DBBCFF-222F-4780-97CD-52052C54D459_1001_0">12466039</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <mgnx:ClinicalDataReviewPeriodForAgreementTermination contextRef="eol_PE179294--1310-K0007_STD_30_20101028_0_933025x1218715" id="id_4392741_C2600ED8-DA1F-4699-AF1D-5F7678C39327_1001_0">P1Y</mgnx:ClinicalDataReviewPeriodForAgreementTermination>
  <mgnx:NonRefundableFees contextRef="eol_PE179294--1310-K0007_STD_31_20101031_0_933025x1115783" unitRef="iso4217_USD" decimals="-5" id="id_4392741_13FCA9A7-5517-42A6-A58A-E9E2759D07CE_1_3">5000000</mgnx:NonRefundableFees>
  <mgnx:CollaborativeAgreementPeriodOfContract contextRef="eol_PE179294--1310-K0007_STD_31_20101031_0_933025x1115783" id="id_4392741_13FCA9A7-5517-42A6-A58A-E9E2759D07CE_1_1">P3Y</mgnx:CollaborativeAgreementPeriodOfContract>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1310-K0007_STD_31_20101031_0_933025x1115783" id="id_4392741_13FCA9A7-5517-42A6-A58A-E9E2759D07CE_1_0">October 2010</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations contextRef="eol_PE179294--1310-K0007_STD_31_20101031_0_933025x1115783" unitRef="Molecule" decimals="INF" id="id_4392741_13FCA9A7-5517-42A6-A58A-E9E2759D07CE_1_2">2</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE179294--1310-K0007_STD_31_20110131_0_932980x1218718_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_0C3BE5E0-1948-4CEA-B45C-39051C69FFBA_1002_2">10000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="eol_PE179294--1310-K0007_STD_31_20110331_0_928576x1218824_932980x929177" unitRef="shares" decimals="INF" id="id_4392741_D3E315EB-662F-452C-A760-C5F00B4D2EC9_1002_1">14446227</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1310-K0007_STD_31_20080531_0_933025x1218715" unitRef="iso4217_USD" decimals="-5" id="id_4392741_1DD43E6A-D9A0-4B2A-B29B-5F7E8867F842_1002_2">50000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1310-K0007_STD_31_20100531_0_933025x1218715" unitRef="iso4217_USD" decimals="-5" id="id_4392741_1DD43E6A-D9A0-4B2A-B29B-5F7E8867F842_1003_2">5000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="pure" decimals="4" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_5_2">0.0135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_3_12">0.00</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="shares" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_3_14">1025602</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="pure" decimals="2" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_5_1">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="shares" xsi:nil="true" id="id_4392741_183E1637-EBCC-4160-B5CE-05609DD8F75A_3_9" />
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_3_11">0.00</us-gaap:EarningsPerShareBasic>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_5_3">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="pure" decimals="4" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_5_4">0.0558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_B4806FB3-A6F3-4580-B871-953BDED216A5_3_0">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="pure" decimals="2" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_5_0">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_16">6757340</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="shares" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_3_13">1025602</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="shares" decimals="INF" id="id_4392741_705AF870-30A3-4F00-8004-997561CC59CF_3_0">49883</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_F9A30717-4680-4175-802C-E2667C5D9848_3_2" />
  <us-gaap:Revenues contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_3_3">57207366</us-gaap:Revenues>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F9A30717-4680-4175-802C-E2667C5D9848_3_1">287961</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_B4806FB3-A6F3-4580-B871-953BDED216A5_3_3">1108107</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_3_9">1467444</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_4019_2200006">70400</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:IncomeTaxReconciliationTaxCreditsOther contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_3_5">7056607</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_10">133782</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:RevenueFromGrants contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_3_2">10152969</us-gaap:RevenueFromGrants>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_3_8">5249676</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_8">-76876</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_7">-12551066</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_3_10">6717120</us-gaap:NetIncomeLoss>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_4019_2200003">2347439</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_9">513</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_4019_2200004">12014815</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_18">500213</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_3_1">47054397</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_5">-1459435</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_3_6">4696</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
  <us-gaap:CostsAndExpenses contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_3_7">51957690</us-gaap:CostsAndExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_3_6">10868791</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_23">12085216</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_3_9">2991131</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_28" />
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_14">-4275976</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_4">2347439</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_24">18342343</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_3_7">725811</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_7F4975E7-3665-4A2A-A2A5-A01BCA38E8CC_3_5">2900000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_2534C117-6C12-4706-AE87-42F13BC8D088_3_1">217097</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_12">272988</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_3_1">1480185</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_11">-10271048</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_22">70400</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_3_0">2350992</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_19">-500213</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_3_5">41088899</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_705AF870-30A3-4F00-8004-997561CC59CF_3_1">53225</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:UndistributedEarningsAllocatedToParticipatingSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_183E1637-EBCC-4160-B5CE-05609DD8F75A_3_1">6717120</us-gaap:UndistributedEarningsAllocatedToParticipatingSecurities>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_2AB81895-1302-441A-A31D-C7EC1872EA7A_3_0">1100000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_13">-447019</us-gaap:IncreaseDecreaseInRestructuringReserve>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E175397-B9E7-4CA3-B8E7-3E8763BA259E_3_0">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarnings contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_183E1637-EBCC-4160-B5CE-05609DD8F75A_3_6">6717120</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarnings>
  <us-gaap:Depreciation contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_3">1147300</us-gaap:Depreciation>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_549F0920-A988-488D-844F-4D30ED54305E_3_2">2347439</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_11803776-7675-481C-8EB5-0C29096DAC88_3_0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_F9A30717-4680-4175-802C-E2667C5D9848_3_3" />
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_21">12014816</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_3_10" />
  <mgnx:IncreaseDecreaseInDeferredRent contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_3_15">232324</mgnx:IncreaseDecreaseInDeferredRent>
  <mgnx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_B4806FB3-A6F3-4580-B871-953BDED216A5_3_1">102418</mgnx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue>
  <mgnx:IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_3_8">-496208</mgnx:IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability>
  <mgnx:ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_882EB5C9-2193-4F8D-AA5F-002F3EC8066A_3_0">0</mgnx:ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_927015x925832" unitRef="iso4217_USD" decimals="0" id="id_4392741_549F0920-A988-488D-844F-4D30ED54305E_1003_1">1328504</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_927015x928963" unitRef="iso4217_USD" decimals="0" id="id_4392741_549F0920-A988-488D-844F-4D30ED54305E_2003_0">1018935</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_927195x1060404_931007x926597" unitRef="pure" decimals="3" id="id_4392741_07351A92-03EF-47D3-9A19-3B35431148A1_1003_1">0.156</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_927195x1074019_931007x926597" unitRef="pure" decimals="3" id="id_4392741_07351A92-03EF-47D3-9A19-3B35431148A1_3003_4">0.177</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_927195x1115783_931007x926597" unitRef="pure" decimals="3" id="id_4392741_07351A92-03EF-47D3-9A19-3B35431148A1_4003_3">0.108</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_927195x1218715_931007x926597" unitRef="pure" decimals="3" id="id_4392741_07351A92-03EF-47D3-9A19-3B35431148A1_5003_5">0.540</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_927592x1218718" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_4011_1400005">18427388</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_927592x1218718" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_4011_1500004">184274</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_927592x929313" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_4018_2100008">6717120</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_927592x930643" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_4013_1600007">48349</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_927592x930643" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_4013_1700006">483</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_927592x932586" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_4017_2000006">69917</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_927592x932586" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_4017_2000003">2347439</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_927592x932586" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_4017_2000004">11830541</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x1031975" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_1003_3">5909906</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x1124615" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_2003_2">4336037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x1166280" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_3003_0">2156114</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x1166416" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_4003_1">392274</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x1218718" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_5003_5">3391991</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x924898" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_6003_8">2885417</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x929614" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_7003_7">180784</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x932377" unitRef="shares" xsi:nil="true" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_8003_6" />
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x997107" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_9003_4">769468</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_26C768FB-CF90-4BAA-BF23-75BC52989B62_1003_0">8900000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_4392741_D01EC999-9BD1-4960-9126-CF893CF7C81F_1001_0">100000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_933025x1115783" unitRef="iso4217_USD" decimals="-5" id="id_4392741_27A11E37-EF9E-45BE-8039-7680448EDCBE_1003_0">5200000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_933025x1218715" unitRef="iso4217_USD" decimals="-5" id="id_4392741_799DDD92-BEEF-4A27-A6C7-D1FB6D2D3F0B_1003_0">30900000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_365_20111231_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_5AB24DD1-CBE5-4221-82E3-83BB44B842C9_1001_0">900000</us-gaap:LicensesRevenue>
  <dei:EntityRegistrantName contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_06716E7B-1186-47A6-821B-2046879AB165_1_1">MACROGENICS INC</dei:EntityRegistrantName>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_06716E7B-1186-47A6-821B-2046879AB165_1_5">Yes</dei:EntityCurrentReportingStatus>
  <dei:AmendmentFlag contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_D936B5CD-B367-4266-BFA7-C1868A68AAF7_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_06716E7B-1186-47A6-821B-2046879AB165_1_7">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_D936B5CD-B367-4266-BFA7-C1868A68AAF7_1_3">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_D936B5CD-B367-4266-BFA7-C1868A68AAF7_1_0">10-K</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_D936B5CD-B367-4266-BFA7-C1868A68AAF7_1_2">2013-12-31</dei:DocumentPeriodEndDate>
  <dei:EntityIncorporationDateOfIncorporation contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_5C45E0F4-422C-4528-9178-D29A4353C14B_1_0">2000-08-14</dei:EntityIncorporationDateOfIncorporation>
  <dei:EntityCentralIndexKey contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_06716E7B-1186-47A6-821B-2046879AB165_1_2">0001125345</dei:EntityCentralIndexKey>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_06716E7B-1186-47A6-821B-2046879AB165_1_4">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_06716E7B-1186-47A6-821B-2046879AB165_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_D936B5CD-B367-4266-BFA7-C1868A68AAF7_1_4">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntityVoluntaryFilers contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_06716E7B-1186-47A6-821B-2046879AB165_1_6">No</dei:EntityVoluntaryFilers>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_CDFFAE90-303C-4341-A301-08BBE18C622A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;5. Shared-Based Payments&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s 2000 Stock Option and Incentive Plan
 (&amp;#x201C;2000 Plan&amp;#x201D;) allowed for the grant of awards in
 respect of an aggregate of 130,725 shares, which was increased to
 150,297 shares, of the Company&amp;#x2019;s common stock in the form of
 incentive stock options, non-qualified stock options, stock
 appreciation rights, restricted stock and restricted stock units
 and other performance awards. As of December&amp;#xA0;31, 2013, under
 the 2000 Plan, there were options to purchase an aggregate of
 23,657 shares of common stock outstanding at a weighted average
 exercise price of $0.83 per share. The 2000 Plan has expired, and
 no further awards may be issued under the plan. Any shares of
 common stock subject to awards under the 2000 Plan that expire,
 terminate, or are otherwise surrendered, canceled, forfeited or
 repurchased without having been fully exercised, or resulting in
 any common stock being issued, will become available for issuance
 under the 2013 Stock Incentive Plan (&amp;#x201C;2013 Plan&amp;#x201D;) up to
 a specified number of shares.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Effective February&amp;#xA0;2003, the Company implemented the 2003
 Equity Incentive Plan (&amp;#x201C;2003 Plan&amp;#x201D;), and it was amended
 and approved by the Company&amp;#x2019;s stockholders in 2005. The 2003
 Plan originally allowed for the grant of awards in respect of an
 aggregate of 2,051,644 shares of the Company&amp;#x2019;s common stock.
 Between 2006 and 2010 the maximum number of shares of common stock
 authorized to be issued by the Company under the 2003 Plan was
 increased by 1,739,116 shares to 3,790,760. During the year ended
 December&amp;#xA0;31, 2012, the maximum number of shares of common
 stock authorized to be issued by the Company under the 2003 Plan
 was increased by 545,970 shares to 4,336,730. Stock options granted
 under the 2003 Plan may be either incentive stock options as
 defined by the Internal Revenue Code (&amp;#x201C;IRC&amp;#x201D;), or
 non-qualified stock options.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of December&amp;#xA0;31, 2013, under the 2003 Plan, there were
 options to purchase an aggregate of 2,559,011&amp;#xA0;shares of common
 stock outstanding at a weighted average exercise price of $1.52 per
 share. Upon the completion of the IPO, the 2003 Plan was
 terminated, and no further awards may be issued under the plan. Any
 shares of common stock subject to awards under the 2003 Plan that
 expire, terminate, or are otherwise surrendered, canceled,
 forfeited or repurchased without having been fully exercised, or
 resulting in any common stock being issued, will become available
 for issuance under the 2013 Plan, up to a specified number of
 shares.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In October 2013, the Company implemented the 2013 Plan. The 2013
 Plan provides for the grant of stock options and other stock-based
 awards, as well as cash-based performance awards. The aggregate
 number of shares of common stock initially available for issuance
 pursuant to awards under the 2013 Plan is 1,960,168&amp;#xA0;shares.
 The number of shares of common stock reserved for issuance will
 automatically increase on January&amp;#xA0;1 of each year from
 January&amp;#xA0;1, 2014 through and including January&amp;#xA0;1, 2023, by
 the lesser of (a)&amp;#xA0;1,960,168 shares, (b)&amp;#xA0;4.0% of the total
 number of shares of common stock outstanding on December&amp;#xA0;31 of
 the preceding calendar year, or (c)&amp;#xA0;the number of shares of
 common stock determined by the Board of Directors. All of the
 shares available for issuance under the 2013 Plan are eligible for
 issuance pursuant to the exercise of incentive stock options. If an
 option expires or terminates for any reason without having been
 fully exercised, if any shares of restricted stock are forfeited,
 or if any award terminates, expires or is settled without all or a
 portion of the shares of common stock covered by the award being
 issued, such shares are available for the grant of additional
 awards. However, any shares that are withheld (or delivered) to pay
 withholding taxes or to pay the exercise price of an option are not
 available for the grant of additional awards. As of
 December&amp;#xA0;31, 2013, under the 2013 Plan, there were options to
 purchase an aggregate of 618,290 shares of common stock outstanding
 at a weighted average exercise price of $19.06 per share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock Option Exchange&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On March&amp;#xA0;16, 2011 (&amp;#x201C;Exchange Date&amp;#x201D;), the Company
 modified certain outstanding options with exercise prices of $1.88
 and $4.69 (&amp;#x201C;Original Options&amp;#x201D;). These Original Options
 were canceled and replaced with options having an exercise price of
 $0.94 (&amp;#x201C;Replacement Options&amp;#x201D;), reflecting the current
 fair market value of the Company&amp;#x2019;s common stock on the
 Exchange Date. Original Options submitted for exchange were
 replaced on a one-for-one basis with Replacement Options.
 Additionally, the Replacement Options retain all terms and
 conditions of the Original Options except for the reduction to the
 exercise price as described above.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Total compensation associated with the Replacement Options
 consisted of the grant-date fair value of the Original Options for
 which the requisite service period is expected to be rendered (or
 has already been rendered) at the Exchange Date, plus the
 incremental cost associated with the modification of terms. The
 incremental compensation expense was measured as the excess of the
 fair value of the Replacement Options over the fair value of the
 Original Options re-measured as of the Exchange Date. A total of
 1,921,894 Original Options were exchanged for Replacement
 Options.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 The following stock-based compensation amounts were recognized for
 the periods indicated:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;507,142&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;471,809&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,018,935&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;355,020&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;366,586&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,328,504&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;862,162&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;838,395&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,347,439&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Employee Stock Options&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of each option award is estimated on the date of
 grant using the Black-Scholes option-pricing model using the
 assumptions in the following table:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="5" align="center"&gt;&lt;b&gt;Year Ended December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield..&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;53%&amp;#xA0;-&amp;#xA0;67%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;51%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;62%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.24%&amp;#xA0;-&amp;#xA0;2.19%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.18%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.35%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7&amp;#xA0;years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected forfeiture rate..&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;5.06%&amp;#xA0;-&amp;#xA0;5.57%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.57%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.58%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;b&gt;Expected Dividend Yield&lt;/b&gt;&amp;#x2014;The Company has never declared
 or paid dividends and has no plans to do so in the foreseeable
 future.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 &lt;b&gt;Expected Volatility&lt;/b&gt;&amp;#x2014;Volatility is a measure of the
 amount by which a financial variable such as a share price has
 fluctuated (historical volatility) or is expected to fluctuate
 (expected volatility) during a period. As the Company does not yet
 have sufficient history of its own volatility, the Company has
 identified several public entities of similar size, complexity and
 stage of development and calculates historical volatility using the
 volatility of these companies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;b&gt;Risk-Free Interest Rate&lt;/b&gt;&amp;#x2014;This is the U.S. Treasury rate
 for the week of each option grant during the year, having a term
 that most closely resembles the expected life of the option.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;b&gt;Expected Term&lt;/b&gt;&amp;#x2014;This is the period of time that the
 options granted are expected to remain unexercised. Options granted
 have a maximum term of ten years. The Company estimates the
 expected life of the option term to be seven years. The Company
 uses a simplified method to calculate the average expected
 term.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;b&gt;Expected Forfeiture Rate&lt;/b&gt;&amp;#x2014;The forfeiture rate is the
 estimated percentage of options granted that is expected to be
 forfeited or canceled on an annual basis before becoming fully
 vested. The Company estimates the forfeiture rate based on turnover
 data with further consideration given to the class of the employees
 to whom the options were granted.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Equity instruments issued to non-employees are accounted for under
 the provisions of ASC&amp;#xA0;505-50, &lt;i&gt;Equity Based Payments to
 Non-Employees&lt;/i&gt;. Accordingly, the estimated fair value of the
 equity instrument is recorded on the earlier of the performance
 commitment date or the date the services required are
 completed.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes stock option activity for 2013:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="42%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
 Average&lt;br /&gt;
 Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Weighted-Average&lt;/font&gt;&lt;br /&gt;
 Remaining&lt;br /&gt;
 Contractual&amp;#xA0;Term&lt;br /&gt;
 (Years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 Intrinsic&lt;br /&gt;
 Value&lt;br /&gt;
 (in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,249,541&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,307,101&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,268,049&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Forfeited or expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(87,635&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,200,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.90&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,532&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 December&amp;#xA0;31, 2013:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercisable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,688,251&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42,311&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Vested and expected to vest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,022,948&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;64,574&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During 2013, 2012 and 2011 the Company issued 1,268,049, 863,176
 and 49,883 shares of common stock, respectively, in conjunction
 with stock option exercises. The Company received cash proceeds
 from the exercise of these stock options of approximately $1.1
 million, $46,826 and $53,225 during 2013, 2012 and 2011,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The weighted-average grant-date fair value of options granted
 during 2013, 2012 and 2011 was $6.91, $0.94 and $0.94 per share,
 respectively. The total intrinsic value of options exercised during
 2013, 2012 and 2011 was approximately $5.4 million, $271,929 and
 $102,418, respectively. The total fair value of stock options which
 vested during 2013, 2012 and 2011 was $487,603, $879,024 and
 $1,108,107, respectively. As of December&amp;#xA0;31, 2013, the total
 unrecognized compensation expense related to non-vested stock
 options, net of related forfeiture estimates, was $7.6 million,
 which the Company expects to recognize over a weighted-average
 period of approximately four years.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_61BD0AB5-A6D2-4BED-9FDC-BEEF54329750_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Recently Issued Accounting Standards Adopted&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In July 2013, the FASB issued ASU No.&amp;#xA0;2013-11, which amended
 ASC Topic 740 regarding presentation of an unrecognized tax benefit
 when a net operating loss (&amp;#x201C;NOL&amp;#x201D;) carryforward, a
 similar tax loss, or a tax credit carryforward exists. The
 amendments in ASU No.&amp;#xA0;2013-11 require an entity to present an
 unrecognized tax benefit as a reduction of a deferred tax asset for
 an NOL carryforward, or similar tax loss or tax credit
 carryforward, rather than as a liability when (1)&amp;#xA0;the
 uncertain tax position would reduce the NOL or other carryforward
 under the tax law of the applicable jurisdiction and (2)&amp;#xA0;the
 entity intends to use the deferred tax asset for that purpose. The
 ASU does not require new recurring disclosures. This amendment is
 effective prospectively for fiscal years beginning after
 December&amp;#xA0;15, 2013. The Company does not believe this amendment
 will have a material impact on its financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has evaluated all ASUs through the date the
 consolidated financials were issued and believes that the adoption
 of these will not have a material impact on the Company&amp;#x2019;s
 consolidated financial statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NumberOfOperatingSegments contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="Segment" decimals="INF" id="id_4392741_4A2E9D0C-2DC3-42F5-ACF4-E28672139E4D_1_0">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_DBE76B81-1C3B-4D80-801B-268994A90001_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;9. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Operating Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company leases office and laboratory space in Rockville,
 Maryland under a lease that expires on March&amp;#xA0;31, 2018, and
 leases a manufacturing facility in Rockville under a lease that
 expires on December&amp;#xA0;31, 2014. The Company has an option under
 each lease to continue the respective lease for five years under
 the same terms. The Company also subleases office and laboratory
 space in South San Francisco under a lease that expires on
 December&amp;#xA0;31, 2018. All of the leases contain rent escalation
 clauses. For financial reporting purposes, rent expense is charged
 to operations on a straight-line basis over the term of the lease.
 As of December&amp;#xA0;31, 2013 and 2012, the Company had recorded a
 deferred rent liability of $2.9 million and $2.8 million,
 respectively. Rent expense for the years ended December&amp;#xA0;31,
 2013, 2012 and 2011 was $2.7 million, $2.7 million and $2.9
 million, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Future minimum lease payments under noncancelable operating leases
 at December&amp;#xA0;31, 2013 are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,651,421&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,310,884&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,410,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,512,517&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,780,398&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,665,430&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_4671AA9C-3721-4863-A298-72625DA7895C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenues&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company enters into collaboration and license agreements with
 collaborators for the development of monoclonal antibody-based
 therapeutics to treat cancer and other complex diseases. The terms
 of these agreements contain multiple deliverables which may include
 (i)&amp;#xA0;licenses, or options to obtain licenses, to the
 Company&amp;#x2019;s technological platforms, such as its Fc
 Optimization and Dual-Affinity Re-Targeting (&amp;#x201C;DART&amp;#x201D;)
 technologies, (ii)&amp;#xA0;rights to future technological
 improvements, (iii)&amp;#xA0;research and development activities to be
 performed on behalf of the collaborator or as part of the
 collaboration, and (iv)&amp;#xA0;the manufacture of pre-clinical or
 clinical materials for the collaborator. Payments to the Company
 under these agreements may include nonrefundable license fees,
 option fees, exercise fees, payments for research and development
 activities, payments for the manufacture of pre-clinical or
 clinical materials, license maintenance payments, payments based
 upon the achievement of certain milestones and royalties on product
 sales. Other benefits to the Company of these agreements include
 the right to sell products resulting from the collaborative efforts
 of the parties in specific geographic territories. The Company
 follows the provisions of the FASB ASC Topic 605-25, &lt;i&gt;Revenue
 Recognition&amp;#xA0;&amp;#x2013;&amp;#xA0;Multiple-Element Arrangements&lt;/i&gt;,
 and ASC Topic 605-28, &lt;i&gt;Revenue Recognition&amp;#x2013;Milestone
 Method&lt;/i&gt;, in accounting for these agreements. In order to account
 for these agreements, the Company must identify the deliverables
 included within the agreement and evaluate which deliverables
 represent separate units of accounting based on the achievement of
 certain criteria, including whether the delivered element has
 stand-alone value to the collaborator. The consideration received
 is allocated among the separate units of accounting, and the
 applicable revenue recognition criteria are applied to each of the
 separate units.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For the periods presented, the Company had the following two types
 of agreements with the parties identified below: 1) exclusive
 development and commercialization licenses to use the
 Company&amp;#x2019;s technology and/or certain other intellectual
 property to develop compounds against specified targets (referred
 to herein as exclusive licenses); and 2) Option/research agreements
 to secure on established terms, development and commercialization
 licenses to anticancer and other therapeutic product candidates to
 collaborator selected targets developed by the Company during an
 option period (referred to herein as right-to-develop
 agreements).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 There are no performance, cancellation, termination or refund
 provisions in any of the arrangements that contain material
 financial consequences to the Company.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Exclusive Licenses&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The deliverables under an exclusive license agreement generally
 include the exclusive license to the Company&amp;#x2019;s DART
 technology with respect to a specified antigen target, and may also
 include deliverables related to rights to future technological
 improvements, research and pre-clinical development activities to
 be performed on behalf of the collaborator. In some cases the
 Company may have an option to participate in the co-development of
 product candidates that result from such agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Generally, exclusive license agreements contain nonrefundable terms
 for payments and, depending on the terms of the agreement, provide
 that the Company will (i)&amp;#xA0;at the collaborator&amp;#x2019;s request,
 provide research and pre-clinical development services at
 negotiated prices which are generally consistent with what other
 third parties would charge, (ii)&amp;#xA0;earn payments upon the
 achievement of certain milestones, (iii)&amp;#xA0;earn royalty
 payments, and (iv)&amp;#xA0;in some cases grant the Company an option
 to participate in the development and commercialization of products
 that result from such agreements. Royalty rates may vary over the
 royalty term depending on the Company&amp;#x2019;s intellectual property
 rights and whether the Company exercises any co-development and
 co-commercialization rights. The Company may provide technical
 assistance and share any technology improvements with its
 collaborators during the term of the collaboration agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company does not directly control when any collaborator will
 achieve milestones or become liable for royalty payments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In determining the units of accounting, management evaluates
 whether the exclusive license has stand-alone value from the
 undelivered elements to the collaborator based on the consideration
 of the relevant facts and circumstances for each arrangement.
 Factors considered in this determination include the research and
 development capabilities of the partner and the availability of
 technology platform and product research expertise in the general
 marketplace. If the Company concludes that the license has
 stand-alone value and therefore will be accounted for as a separate
 unit of accounting, the Company then determines the estimated
 selling prices of the license and all other units of accounting
 based on market conditions, similar arrangements entered into by
 third parties, and entity-specific factors such as the terms of the
 Company&amp;#x2019;s previous collaboration agreements, recent
 pre-clinical and clinical testing results of therapeutic product
 candidates that use the Company&amp;#x2019;s technology platforms, the
 Company&amp;#x2019;s pricing practices and pricing objectives, the
 likelihood that technological improvements will be made, the
 likelihood that technological improvements made will be used by the
 Company&amp;#x2019;s collaborators and the nature of the research
 services to be performed on behalf of its collaborators and market
 rates for similar services.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Upfront payments on exclusive licenses are deferred if facts and
 circumstances dictate that the license does not have stand-alone
 value. Prior to the adoption of Accounting Standards Update
 (&amp;#x201C;ASU&amp;#x201D;) No.&amp;#xA0;2009-13, &lt;i&gt;Revenue Arrangements with
 Multiple Deliverables&lt;/i&gt;, on January&amp;#xA0;1, 2011, the Company
 determined that its licenses lacked stand-alone value because it
 did not have vendor-specific objective evidence of selling price
 (&amp;#x201C;VSOE&amp;#x201D;), and were combined with other elements of the
 arrangement and any amounts associated with the license were
 deferred and amortized over a certain period, which the Company
 refers to as the Company&amp;#x2019;s period of substantial involvement.
 In making the determination of the length of the period over which
 to defer revenue for contracts entered into prior to the adoption
 of ASU No.&amp;#xA0;2009-13, significant judgment and estimation is
 used by the Company and can have an impact on the amount of revenue
 recognized in a given period. Historically, the Company&amp;#x2019;s
 involvement with the development of a collaborator&amp;#x2019;s product
 candidate has been significant at the early stages of development,
 and lessens as it progresses into clinical trials. Accordingly, the
 Company generally estimates this period of substantial involvement
 to begin at the inception of the collaboration agreement and
 conclude at the end of the Company&amp;#x2019;s substantial involvement.
 ASU No.&amp;#xA0;2009-13 amends the criteria for separating and
 allocating consideration in a multiple element arrangement by
 modifying the fair value requirements for revenue recognition and
 eliminating the use of the residual value method. The selling
 prices of deliverables under an arrangement may be derived using
 third-party evidence (&amp;#x201C;TPE&amp;#x201D;), or a best estimate of
 selling price (&amp;#x201C;BESP&amp;#x201D;), if VSOE is not available. The
 objective of BESP is to determine the price at which the Company
 would transact a sale if the element within the license agreement
 was sold on a standalone basis. Establishing BESP involves
 management&amp;#x2019;s judgment and considers multiple factors,
 including market conditions and company-specific factors, including
 those factors contemplated in negotiating the agreements, as well
 as internally developed models that include assumptions related to
 market opportunity, discounted cash flows, estimated development
 costs, probability of success and the time needed to commercialize
 a product candidate pursuant to the license. In validating the
 BESP, management considers whether changes in key assumptions used
 to determine the BESP will have a significant effect on the
 allocation of the arrangement consideration between the multiple
 deliverables. Deliverables under the arrangement are separate units
 of accounting if (i)&amp;#xA0;the delivered item has value to the
 customer on a standalone basis and (ii)&amp;#xA0;if the arrangement
 includes a general right of return relative to the delivered item,
 delivery or performance of the undelivered item is considered
 probable and substantially within the Company&amp;#x2019;s control. The
 arrangement consideration that is fixed or determinable at the
 inception of the arrangement is allocated to the separate units of
 accounting based on their relative selling prices. The appropriate
 revenue recognition model is applied to each element and revenue is
 accordingly recognized as each element is delivered. Management
 exercises significant judgment in determining whether a deliverable
 is a separate unit of accounting.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In determining the separate units of accounting, the Company
 evaluated whether the exclusive license had standalone value to the
 collaborator based on consideration of the relevant facts and
 circumstances for each arrangement. Factors considered in this
 determination included the research and development capabilities of
 the collaborator and the availability of relevant research
 expertise in the marketplace. In addition, the Company considered
 whether or not (i)&amp;#xA0;the collaborator could use the license for
 its intended purpose without the receipt of the remaining
 deliverables, (ii)&amp;#xA0;the value of the license was dependent on
 the undelivered items and (iii)&amp;#xA0;the collaborator or other
 vendors could provide the undelivered items.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company reassesses its periods of substantial involvement over
 which the Company amortizes its upfront license fees and makes
 adjustments as appropriate. In the event a collaborator elects to
 discontinue development of a specific product candidate under a
 single target license, but retains its right to use the
 Company&amp;#x2019;s technology to develop an alternative product
 candidate to the same target or a target substitute, the Company
 would cease amortization of any remaining portion of the upfront
 fee until there is substantial pre-clinical activity on another
 product candidate and its remaining period of substantial
 involvement can be estimated. In the event that a single target
 license were to be terminated, the Company would recognize as
 revenue any portion of the upfront fee that had not previously been
 recorded as revenue, but was classified as deferred revenue, at the
 date of such termination or through the remaining substantial
 involvement in the wind down of the agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Upfront payments on exclusive licenses may be recognized upon
 delivery of the license if facts and circumstances dictate that the
 license has stand-alone value from the undelivered elements, which
 generally include rights to future technological improvements,
 research services and the manufacture of pre-clinical and clinical
 materials.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company recognizes revenue related to research and pre-clinical
 development services that represent separate units of accounting as
 they are performed, as long as there is persuasive evidence of an
 arrangement, the fee is fixed or determinable, and collection of
 the related receivable is probable. The Company recognizes revenue
 related to the rights to future technological improvements over the
 estimated term of the applicable license.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company typically performs research activities and pre-clinical
 development services, including generating and engineering product
 candidates, on behalf of its licensees during the early evaluation
 and pre-clinical testing stages of drug development under its
 exclusive licenses. The Company records amounts received for
 research materials produced or services performed as revenue from
 collaborative research.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s license agreements have milestone payments
 which for reporting purposes are aggregated into three categories:
 (i)&amp;#xA0;development milestones, (ii)&amp;#xA0;regulatory milestones,
 and (iii)&amp;#xA0;sales milestones. Development milestones are
 typically payable when a product candidate initiates or advances
 into different clinical trial phases. Regulatory milestones are
 typically payable upon submission for marketing approval with the
 U.S. Food and Drug Administration (&amp;#x201C;FDA&amp;#x201D;) or other
 countries&amp;#x2019; regulatory authorities or on receipt of actual
 marketing approvals for the compound or for additional indications.
 Sales milestones are typically payable when annual sales reach
 certain levels.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 At the inception of each agreement that includes milestone
 payments, the Company evaluates whether each milestone is
 substantive and at risk to both parties on the basis of the
 contingent nature of the milestone. This evaluation includes an
 assessment of whether (a)&amp;#xA0;the consideration is commensurate
 with either (1)&amp;#xA0;the entity&amp;#x2019;s performance to achieve the
 milestone, or (2)&amp;#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&amp;#x2019;s performance to achieve the milestone,
 (b)&amp;#xA0;the consideration relates solely to past performance and
 (c)&amp;#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. The Company
 evaluates factors such as the scientific, regulatory, commercial
 and other risks that must be overcome to achieve the respective
 milestone, the level of effort and investment required to achieve
 the respective milestone and whether the milestone consideration is
 reasonable relative to all deliverables and payment terms in the
 arrangement in making this assessment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Non-refundable development and regulatory milestones that are
 expected to be achieved as a result of the Company&amp;#x2019;s efforts
 during the period of substantial involvement are considered
 substantive and are recognized as revenue upon the achievement of
 the milestone, assuming all other revenue recognition criteria are
 met. Milestones that are not considered substantive because the
 Company does not contribute effort to the achievement of such
 milestones are generally achieved after the period of substantial
 involvement and are recognized as revenue upon achievement of the
 milestone, as there are no undelivered elements remaining and no
 continuing performance obligations, assuming all other revenue
 recognition criteria are met.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Right-to-Develop Agreements&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s right-to-develop agreements provide
 collaborators with an exclusive option to obtain licenses to
 develop and commercialize in specified geographic territories
 product candidates developed by the Company under agreed upon
 research and pre-clinical development product programs. The product
 candidates resulting from each program are all directed to a
 specific target selected by the collaborator. Under these
 agreements, fees may be due to the Company (i)&amp;#xA0;at the
 inception of the arrangement (referred to as &amp;#x201C;upfront&amp;#x201D;
 fees or payments), (ii)&amp;#xA0;the selection of a target for a
 program, (iii)&amp;#xA0;upon the exercise of an option to acquire a
 development and commercialization license (referred to as exercise
 fees or payments earned) for a program, or (iv)&amp;#xA0;some
 combination of all of these fees.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The accounting for right-to-develop agreements is dependent on the
 nature of the options granted to the collaborator. Options are
 considered substantive if, at the inception of a right-to-develop
 agreement, the Company is at risk as to whether the collaborator
 will choose to exercise the options to secure development and
 commercialization licenses. Factors that are considered in
 evaluating whether options are substantive include the overall
 objective of the arrangement, the benefit the collaborator might
 obtain from the agreement without exercising the options, the cost
 to exercise the options relative to the total upfront
 consideration, and the additional financial commitments imposed on
 the collaborator as a result of exercising the options.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to a product program are
 considered substantive, the Company does not consider the
 development and commercialization licenses to be a deliverable at
 the inception of the agreement. For those right-to-develop
 agreements entered into prior to the adoption of ASU
 No.&amp;#xA0;2009-13 where the options to secure development and
 commercialization licenses are considered substantive, the Company
 has deferred the upfront payments received and recognizes this
 revenue over the period during which the collaborator could elect
 to exercise options for development and commercialization licenses.
 These periods are specific to each collaboration agreement. If a
 collaborator selects a target for a product program, any
 substantive option fee is deferred and recognized over the life of
 the option, generally 12 months. Subsequent to the adoption of ASU
 No.&amp;#xA0;2009-13, the Company&amp;#x2019;s evaluation of whether the
 option is substantive is consistent with pre-adoption of ASU
 No.&amp;#xA0;2009-13. How the Company determines the selling price of
 the option is the only difference between pre and post adoption of
 ASU No.&amp;#xA0;2009-13. Post adoption of ASU No.&amp;#xA0;2009-13, the
 selling prices of deliverables under an arrangement may be derived
 using TPE or a BESP, if VSOE is not available. The objective of
 BESP is to determine the price at which the Company would transact
 a sale if the element within the right-to-develop agreement was
 sold on a standalone basis. Establishing BESP involves
 management&amp;#x2019;s judgment and considers multiple factors,
 including market conditions and company-specific factors, including
 those factors contemplated in negotiating the agreements, as well
 as internally developed models that include assumptions related to
 market opportunity, discounted cash flows, estimated development
 costs, probability of success and the time needed to commercialize
 a product candidate pursuant to the right-to-develop agreement. In
 validating the BESP, management considers whether changes in key
 assumptions used to determine the BESP will have a significant
 effect on the allocation of the arrangement consideration between
 the multiple deliverables. Deliverables under the arrangement are
 separate units of accounting if (i)&amp;#xA0;the delivered item has
 value to the customer on a standalone basis and (ii)&amp;#xA0;if the
 arrangement includes a general right of return relative to the
 delivered item, delivery or performance of the undelivered item is
 considered probable and substantially within the Company&amp;#x2019;s
 control. The arrangement consideration that is fixed or
 determinable at the inception of the arrangement is allocated to
 the separate units of accounting based on their relative selling
 prices. The appropriate revenue recognition model is applied to
 each element and revenue is accordingly recognized as each element
 is delivered. Management exercises significant judgment in
 determining whether a deliverable is a separate unit of
 accounting.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 If a collaborator exercises an option and acquires a development
 and commercialization license to a product program, the Company
 attributes the exercise fee to the development and
 commercialization license. The Company determines the selling price
 of the option license, upon exercise, through management&amp;#x2019;s
 best estimate. Management&amp;#x2019;s determination of selling price
 includes such factors as stage of development, market potential and
 cash flow models used during the negotiation with the collaborator.
 Through December&amp;#xA0;31, 2013, none of our collaboration partners
 had exercised an option. However, one of our collaboration partners
 did elect to exercise an option in February 2014. See Note 13 for
 additional information.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Upon exercise of an option to acquire a development and
 commercialization license, the Company would also attribute any
 remaining deferred option fee, in addition to the consideration
 received for the license upon exercise of the option, to the
 development and commercialization license. The Company then applies
 the multiple-element revenue recognition criteria to the
 development and commercialization license and other deliverables,
 if any, to determine the appropriate revenue recognition method.
 This model is consistent with the Company&amp;#x2019;s accounting policy
 for upfront payments on exclusive licenses (discussed above). In
 the event a right-to-develop agreement were to be terminated, the
 Company would recognize as revenue any portion of the upfront fee
 that had not previously been recorded as revenue, but was
 classified as deferred revenue, at the date of such termination.
 The Company&amp;#x2019;s right-to-develop agreements have been
 determined to contain substantive options.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to product programs are
 not considered substantive, the Company considers the development
 and commercialization licenses to be a deliverable at the inception
 of the agreement and applies the multiple-element revenue
 recognition criteria to determine the appropriate revenue
 recognition. The Company does not directly control when any
 collaborator will exercise its options for development and
 commercialization licenses.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_1_12">-0.04</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="shares" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_1_14">6847697</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_7A861361-B458-4BCA-B2A3-780291398B27_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes stock option activity for 2013:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="42%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
 Average&lt;br /&gt;
 Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Weighted-Average&lt;/font&gt;&lt;br /&gt;
 Remaining&lt;br /&gt;
 Contractual&amp;#xA0;Term&lt;br /&gt;
 (Years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 Intrinsic&lt;br /&gt;
 Value&lt;br /&gt;
 (in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,249,541&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,307,101&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,268,049&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Forfeited or expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(87,635&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,200,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.90&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,532&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 December&amp;#xA0;31, 2013:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercisable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,688,251&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42,311&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Vested and expected to vest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,022,948&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;64,574&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_ED3F576E-3908-476B-8A8C-B18746C56A37_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Effective January&amp;#xA0;1, 2012, the Company adopted ASU 2011-05,
 &lt;i&gt;Presentation of Comprehensive Income,&lt;/i&gt; which amended ASC
 Topic 220, &lt;i&gt;Comprehensive Income&lt;/i&gt; (&amp;#x201C;ASU
 2011-05&amp;#x201D;)&lt;i&gt;.&lt;/i&gt; The amendments in ASU 2011-05 require the
 presentation of the comprehensive income (loss) and its components
 as part of the consolidated financial statements. Comprehensive
 income (loss) is comprised of the net income (loss) and other
 changes in equity that are excluded from net income (loss).
 Comprehensive income (loss) equals net income (loss) for the years
 ended December&amp;#xA0;31, 2013, 2012 and 2011.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="shares" xsi:nil="true" id="id_4392741_183E1637-EBCC-4160-B5CE-05609DD8F75A_1_9" />
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_4D98375C-BD0E-42ED-9694-877963E7B0C2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company is required to maintain certificates of deposit that
 serve as collateral for various operating leases and corporate
 credit card accounts. Amounts classified as restricted cash on the
 consolidated balance sheets are $404,850 at December&amp;#xA0;31, 2013
 and 2012.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:StockholdersEquityReverseStockSplit contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_BE04CAF3-5AF2-47D5-A5A5-4F87A06DA3D1_1_0">1-for-18.7739</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_CEDFB2F9-CB0F-4AB4-96B2-42BBD8B5586B_5001_4">1.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_38E57D71-8D08-4612-8C1B-6013D381639F_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Property and equipment consists of the following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,379,254&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,003,706&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,477,416&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,323,081&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Furniture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;599,650&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;599,650&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Lab equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,166,619&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,747,790&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,360&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,360&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,893,770&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,881,706&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Property and equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,568,069&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,607,293&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Less accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(15,532,837&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14,339,497&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Property and equipment, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,035,232&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,267,796&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_1_11">-0.04</us-gaap:EarningsPerShareBasic>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_87185B9B-F07D-4FF9-960E-95E7D3915678_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following common stock equivalents were excluded from the
 calculation of diluted net income (loss) per share because their
 effect would be anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series A-1 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series A-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series B Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series C Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series D Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Effect of Converted Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,189,920&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants to purchase Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Stock Options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,313,970&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,249,702&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,885,417&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_3C828CA6-A2B3-4AB3-8772-51C5D15C4CB7_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;3. Property and Equipment&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Property and equipment consists of the following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,379,254&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,003,706&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,477,416&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,323,081&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Furniture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;599,650&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;599,650&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Lab equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,166,619&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,747,790&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,360&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,360&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,893,770&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,881,706&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Property and equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,568,069&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,607,293&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Less accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(15,532,837&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14,339,497&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Property and equipment, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,035,232&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,267,796&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Depreciation expense for the years ended December&amp;#xA0;31, 2013,
 2012 and 2011 was $1.2 million, $1.0 million and $1.1 million,
 respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_270395C1-5D83-4486-AC1A-BC061980F66C_2_1">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_CED2A8CA-DEB2-4AB0-A5C8-2BCCC2236743_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Future principal payments to be made under the lease agreement for
 the next five years and thereafter as of December&amp;#xA0;31, 2013 are
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,438,742&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,641,905&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,866,031&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,113,118&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,385,374&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,445,170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_4392741_ECE56403-768F-4BE4-873E-F0AB29008A6D_5001_2">1307101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_3_3">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_E3ABA86C-6B63-4AA5-94DD-4208D7B675E5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Financial assets and liabilities subject to fair value measurements
 were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="38%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 December&amp;#xA0;31, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&amp;#xA0;in&lt;br /&gt;
 Active Markets&lt;br /&gt;
 for&lt;br /&gt;
 Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&amp;#xA0;Other&lt;br /&gt;
 Observable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;br /&gt;
 Unobservable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,434,435&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,434,435&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,046,974&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,046,974&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total Assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116,886,259&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116,886,259&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 December&amp;#xA0;31, 2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&amp;#xA0;in&lt;br /&gt;
 Active Markets&lt;br /&gt;
 for&lt;br /&gt;
 Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&amp;#xA0;Other&lt;br /&gt;
 Observable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;br /&gt;
 Unobservable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,695,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,695,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,047,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,047,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total Assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,148,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,148,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Preferred stock warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_64851900-AD0F-4C52-8F1F-FEF8F6985E13_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Changes in the lease exit liability are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrual balance at December&amp;#xA0;31, 2011&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;$10,607,499&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Principal payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(533,560&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrual balance at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,073,939&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Principal payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(628,769&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrual balance at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;$9,445,170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_FD1FFE21-84BF-48E4-BFC7-BE6752DC51F7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;12. Quarterly Financial Information (unaudited)&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="54%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;1&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;st&lt;/sup&gt;&amp;#xA0;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;nd&lt;/sup&gt;&amp;#xA0;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;3&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;rd&lt;/sup&gt;&amp;#xA0;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;4&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;th&lt;/sup&gt;&amp;#xA0;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in thousands,
 except per share data)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,598&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,299&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,232&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,366&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(294&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,604&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share, basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share, diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.01&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,510&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,435&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,082&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,799&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,320&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,546&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,601&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,105&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share, basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share, diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Annual net income (loss) per share includes the effects of income
 allocated to participating securities.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_09E7C185-7A50-4501-96AF-241893149AA6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Basic and diluted income (loss) per common share is computed as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(260,835&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,361,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,717,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: undistributed earnings allocated to participating
 securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,361,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,717,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(260,835&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,025,602&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Basic income (loss) per common share&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.04&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(260,835&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,361,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,717,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,361,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,717,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(260,835&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,025,602&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Effect of dilutive securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Diluted weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,025,602&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Diluted income (loss) per common share&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.04&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_8652528C-2FB0-4C10-954D-D07CACA65F6E_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;4. Stockholders&amp;#x2019; Equity (Deficit)&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 During 2002 and 2003, the Company issued a total of 34,239,374
 shares of Series A-1 and Series A-2 convertible preferred stock
 (&amp;#x201C;Series A preferred stock&amp;#x201D;) for $1.00 per share
 resulting in net proceeds of approximately $34.0 million.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On October&amp;#xA0;12, 2004, the Company entered into a series of
 transactions raising $30.3 million, net of related offering costs
 of approximately $238,000, from the sale of 71,401,237 shares of
 its Series B convertible preferred stock (&amp;#x201C;Series B preferred
 stock&amp;#x201D;). In connection with the Series B preferred stock
 offering, 13,604,016 shares of common stock were allocated to
 holders of Series&amp;#xA0;A-1 preferred stock as an anti-dilution
 measure.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On May&amp;#xA0;16, 2006, the Company raised $44.9 million, net of
 related offering costs of $101,246, from the sale of 110,952,217
 shares of its Series C convertible preferred stock (&amp;#x201C;Series C
 preferred stock&amp;#x201D;). In connection with the Series C preferred
 stock offering, 10,003,300 shares of common stock were allocated to
 holders of Series B preferred stock as an anti-dilution
 measure.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On July&amp;#xA0;16, 2008, the Company issued 12,466,039 shares of its
 Series D convertible preferred stock (&amp;#x201C;Series&amp;#xA0;D
 preferred stock&amp;#x201D;) in exchange for all of the outstanding
 capital stock and convertible notes payable of Raven
 Biotechnologies, Inc. (&amp;#x201C;Raven&amp;#x201D;). Subsequently, in March
 2011 a settlement was reached with the former Raven stockholders
 bringing the total Series D preferred stock issued in connection
 with the Raven acquisition to 14,446,227 shares.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On September&amp;#xA0;19, 2008, the Company raised $24.8 million, net
 of related offering costs of $156,788, from the sale of 38,337,678
 shares of its Series D-2 convertible preferred stock (&amp;#x201C;Series
 D-2 preferred stock&amp;#x201D;). The Company also issued preferred
 stock warrants for the purchase of 2,875,327 shares of Series D-2
 preferred stock. The preferred stock warrants were exercisable at
 any time prior to September&amp;#xA0;2018, but expired upon an IPO, and
 had a stated exercise price of $0.65 per warrant. On May&amp;#xA0;16,
 2010, the Company exercised a put notice to Eli Lilly in accordance
 with the Series D-2 preferred stock purchase agreement, resulting
 in the issuance of 6,916,110 shares of Series D-2 preferred stock
 and a warrant to purchase 518,708 additional shares of Series D-2
 preferred stock. On January&amp;#xA0;11, 2011, the Company raised gross
 proceeds of $12.0 million from the sale of 18,427,388&amp;#xA0;shares
 of its Series D-2 preferred stock. Issuance costs associated with
 the sale were not material.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Due to certain provisions in the Series D-2 convertible preferred
 stock warrant agreement, these warrants were required to be
 classified as a liability. Management believed that the
 circumstances requiring cash settlement of the award were remote.
 The Series D-2 preferred stock warrant liability was recorded at
 fair value and has been adjusted to fair value at the end of each
 reporting period using the Option-Pricing Method, with changes in
 value recorded as &amp;#x201C;Other income (expense)&amp;#x201D; in the
 accompanying consolidated statements of operations and
 comprehensive income (loss). Prior to the Company&amp;#x2019;s IPO in
 October 2013, all the preferred stock warrants were exercised and
 subsequently were converted into shares of common stock in
 connection with the IPO.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Dividends were noncumulative and accrued on the Series A-1, Series
 A-2, Series B, Series C, Series D and Series&amp;#xA0;D-2 preferred
 stock at a rate of $0.08, $0.0341, $0.0324 and $0.0522 per annum,
 respectively, and were payable when and as declared by the Board of
 Directors. Dividends had to be declared so that the Series A,
 Series&amp;#xA0;B, Series C and Series D preferred stock were paid in
 like-kind and participated equally to those of the Series&amp;#xA0;D-2
 preferred and common stock. No dividends had been declared prior to
 the conversion of the preferred stock to common stock in connection
 with the IPO.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company&amp;#x2019;s Series A-1, Series A-2, Series B, Series C,
 Series D and Series D-2 preferred stock were initially convertible
 into 1.506, 1.00, 1.14, 1.00, 1.00 and 1.00 shares, respectively,
 of common stock at the option of the holder. The conversion ratio
 of certain series of preferred stock was subject to change in the
 event specified dilutive transactions occurred, which included the
 Company&amp;#x2019;s IPO. There were no anti-dilution protections for
 the Series A-2 preferred stock and no adjustment to the Series A-1
 preferred stock conversion price was to be made if a common stock
 issuance was at a price per share greater than the conversion price
 of the Series C preferred stock. Upon consummation of the
 Company&amp;#x2019;s IPO in October 2013, all outstanding shares of
 preferred stock automatically converted to shares of the
 Company&amp;#x2019;s common stock at the applicable conversion ratios
 then in effect. The conversion price was $12.39, $18.77, $6.95,
 $7.70, $12.20 and $12.20 for each share of Series A-1, A-2, Series
 B, Series C, Series D and Series D-2 convertible preferred stock,
 respectively.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On October&amp;#xA0;16, 2013, the Company completed its IPO, in which
 5,000,000 shares of the Company&amp;#x2019;s common stock were sold at a
 price of $16.00 per share. Additionally, the underwriters of the
 Company&amp;#x2019;s IPO exercised the full amount of their
 over-allotment option resulting in the sale of an additional
 750,000 shares of the Company&amp;#x2019;s common stock at a price of
 $16.00 per share. The Company received net proceeds of $83.8
 million from the IPO, net of underwriting discounts and commissions
 and other offering expenses. Upon consummation of the IPO, all
 outstanding shares of preferred stock automatically converted to
 common stock at the applicable conversion ratios then in
 effect.&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In connection with preparing for its IPO in October 2013, the
 Company&amp;#x2019;s Board of Directors and stockholders approved a
 1-for-18.7739 reverse stock split of the Company&amp;#x2019;s common
 stock. The reverse stock split became effective on
 September&amp;#xA0;26, 2013. All share and per share amounts in the
 consolidated financial statements and notes thereto have been
 retroactively adjusted for all periods presented to give effect to
 this reverse stock split, including reclassifying an amount equal
 to the reduction in par value of common stock to additional paid-in
 capital. In addition, in September 2013, the Company&amp;#x2019;s Board
 of Directors and stockholders approved an amendment of the
 Company&amp;#x2019;s certificate of incorporation to, among other
 things, change the definition of a designated public offering to
 remove the per share price requirement. The amended and restated
 certificate of incorporation also changed the authorized number of
 shares of common stock from 425,000,000 to 125,000,000, and
 authorized 5,000,000 shares of undesignated preferred stock with a
 par value of $0.01 per share. There were no shares of undesignated
 preferred stock issued or outstanding as of December&amp;#xA0;31,
 2013.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_CEDFB2F9-CB0F-4AB4-96B2-42BBD8B5586B_5001_2">10.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_34935A43-B737-493D-BF5D-08FD92D62423_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table provides a rollforward of the Company&amp;#x2019;s
 preferred stock warrant liability, which was the only financial
 instrument measured at fair value on a recurring basis using
 significant unobservable inputs (Level 3) as defined in ASC
 820:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="82%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total unrealized gains (losses) included in earnings&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(626,349&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Settlement of preferred stock warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;679,296&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_98C97BD7-F82B-4174-B110-019A2CB15E00_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="54%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;1&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;st&lt;/sup&gt;&amp;#xA0;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;nd&lt;/sup&gt;&amp;#xA0;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;3&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;rd&lt;/sup&gt;&amp;#xA0;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;4&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;th&lt;/sup&gt;&amp;#xA0;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in thousands,
 except per share data)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,598&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,299&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,232&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,366&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(294&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,604&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share, basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share, diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.01&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,510&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,435&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,082&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,799&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,320&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,546&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,601&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,105&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share, basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net income (loss) per share, diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_B4806FB3-A6F3-4580-B871-953BDED216A5_1_0">6.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_DB8959DD-08DC-42E3-9002-8261F1C12C45_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;7. Lease Exit Liability&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On July&amp;#xA0;16, 2008, the Company acquired Raven Biotechnologies,
 Inc. (&amp;#x201C;Raven&amp;#x201D;), a private South San Francisco-based
 company focused on the development of monoclonal antibody
 therapeutics for treating cancer. Raven was considered a
 development-stage enterprise as defined in ASC&amp;#xA0;915,
 &lt;i&gt;Development Stage Entities&lt;/i&gt;. In connection with the
 acquisition, the Company issued 12,466,039 shares of its Series D
 convertible preferred stock in exchange for all of the outstanding
 capital stock and convertible notes payable of Raven.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company undertook restructuring activities related to the
 acquisition of Raven. These restructuring activities included
 reductions in staffing levels and the intended exit of leased
 facilities. All severance-related payments were completed in the
 year ended December&amp;#xA0;31, 2009.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In connection with these restructuring activities, as part of the
 cost of acquisition, the Company established a restructuring
 liability attributed to an existing operating lease. The terms of
 the operating lease extend through 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Changes in the lease exit liability are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrual balance at December&amp;#xA0;31, 2011&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;$10,607,499&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Principal payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(533,560&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrual balance at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,073,939&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Principal payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(628,769&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrual balance at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;$9,445,170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Future principal payments to be made under the lease agreement for
 the next five years and thereafter as of December&amp;#xA0;31, 2013 are
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,438,742&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,641,905&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,866,031&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,113,118&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,385,374&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,445,170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The purchase agreement provides for a specified total of certain
 contingent milestones that are based on the achievement of certain
 product sales derived from the acquired Raven technology. Also, a
 onetime payment of $5.0&amp;#xA0;million will be made to the Raven
 stockholders upon the initiation of patient dosing in the first
 Phase 2 clinical trial of any product derived from the Raven
 &amp;#x201C;Cancer Stem Cell Program.&amp;#x201D; No payment shall be made if
 the Phase 2 trial start date has not occurred on or before
 July&amp;#xA0;15, 2018. Other consideration includes a percentage of
 revenue (excluding consideration for research and development and
 equity) received by the Company for license of a product derived
 from the Raven &amp;#x201C;Cancer Stem Cell Program&amp;#x201D; and a onetime
 payment ranging from $8.0&amp;#xA0;million to $12.0&amp;#xA0;million
 dependent upon a specified level of sales of products derived from
 the Raven &amp;#x201C;Cancer Stem Cell Program.&amp;#x201D;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The contingent consideration will be accounted for as additional
 purchase price and recorded as incremental in-process research and
 development expense when it is deemed probable that the
 contingencies will be attained. No additional amounts have been
 recorded during the years ended December&amp;#xA0;31, 2013, 2012 and
 2011.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_0A216D0A-527B-4D29-9786-2AC93498A4E8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment are stated at cost. Upon retirement or sale,
 the cost of assets disposed of and the related accumulated
 depreciation are removed from the accounts and any resulting gain
 or loss is credited or charged to operations. Repairs and
 maintenance costs are expensed as incurred. Depreciation is
 computed using the straight-line method over the following
 estimated useful lives:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="51%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td width="47%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Furniture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;10 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Laboratory and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;5 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Shorter of lease term or useful life&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_69705A38-3317-4E69-AA39-51FA7075ACA0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company considers all investments in highly liquid financial
 instruments with an original maturity of three months or less at
 the date of purchase to be cash equivalents. Cash and cash
 equivalents consist of certificates of deposit and investments in
 money market funds with commercial banks and financial
 institutions. Cash equivalents are stated at amortized cost, plus
 accrued interest, which approximates fair value.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_7F4975E7-3665-4A2A-A2A5-A01BCA38E8CC_1_4">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_3B1C6E92-D60E-4E8E-8665-F6867FF5EC64_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 A reconciliation of the beginning and ending amount of gross
 unrecognized tax benefits is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Beginning balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,592,357&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,533,986&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,246,025&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Increases/(decreases) for current year tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;115,502&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58,371&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;287,961&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Increases/(decreases) for prior year tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Decreases as a result of expiration of statute of limitations&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Ending balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,707,859&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,592,357&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,533,986&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_16">-14172123</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_CEDFB2F9-CB0F-4AB4-96B2-42BBD8B5586B_5001_3">0.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_5BE10077-4200-4C76-ABA3-DC1B19908A3C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;13. Subsequent Events&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In February 2014, Servier exercised its exclusive option to develop
 and commercialize MGD006. Servier will gain exclusive development
 and commercial rights in all countries outside of the U.S., Canada,
 Mexico, Japan, South Korea and India. In those countries, the
 Company will retain development and commercialization rights. As a
 result of the exercise, the Company received a $15.0 million
 payment from Servier. In addition, the IND application for MGD006
 has cleared the 30-day review period by the FDA, triggering an
 additional $5.0&amp;#xA0;million payment to the Company by Servier.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In February 2014, the Company completed a follow-on equity
 offering, in which the Company sold 1.8&amp;#xA0;million shares of its
 common stock at a price of $36.50 per share. Additionally, the
 underwriters of the offering exercised the full amount of their
 over-allotment option resulting in the sale of an additional
 450,000 shares of the Company&amp;#x2019;s common stock at a price of
 $36.50 per share. The Company received net proceeds of $76.7
 million from this offering, net of underwriting discounts and
 commissions and other estimated offering expenses.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_B4806FB3-A6F3-4580-B871-953BDED216A5_1_5">P4Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="shares" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_1_13">6847697</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_2FC347DA-C394-447E-98B8-809FE4D2A14C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;6. Income Taxes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 For the years ended December&amp;#xA0;31, 2013, 2012 and 2011 there was
 no current provision for federal or state income taxes due to the
 taxable losses which resulted or use of legacy NOL
 carryforwards.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The significant components of the Company&amp;#x2019;s deferred tax
 assets (liabilities) were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred income tax assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Federal U.S. net operating loss carryforward&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36,561,195&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,330,167&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 State net operating loss carryforward&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,315,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,521,722&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Research and development credit, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,785,612&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,777,899&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Orphan drug credit, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,883,076&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,039,613&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Deferred rent&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,132,458&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,218,002&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,216,695&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,379,064&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,438,477&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,247,772&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,438,870&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,575,782&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Gross deferred income tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79,771,897&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;78,090,021&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(79,376,945&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(78,090,021&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net deferred income tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;394,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred income tax liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(394,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Gross deferred income tax liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(394,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net deferred income tax asset/(liability)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company recognizes valuation allowances to reduce deferred tax
 assets to the amount that is more likely than not to be realized.
 In assessing the likelihood of realization, management considers
 (i)&amp;#xA0;future reversals of existing taxable temporary
 differences; (ii)&amp;#xA0;future taxable income exclusive of reversing
 temporary difference and carryforwards; (iii)&amp;#xA0;taxable income
 in prior carryback years if carryback is permitted under applicable
 tax law; and (iv)&amp;#xA0;tax planning strategies. The Company&amp;#x2019;s
 net deferred income tax asset is not more likely than not to be
 utilized due to the lack of sufficient sources of future taxable
 income and cumulative book losses which have resulted over the
 years. The net increase in the valuation allowance in 2013 is due
 to the fact the Company generated research and development and
 orphan drug credits and NOL carryforwards which increased the net
 deferred tax asset. The increase in the credits and NOL
 carryforwards were offset by the decrease in deferred revenue and
 resulted in a net current year increase to the valuation
 allowance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has reported book losses from inception through
 December&amp;#xA0;31, 2010. The NOL carryforwards of approximately
 $104.8 million for U.S.&amp;#xA0;federal and approximately $60.3
 million for state will expire in various years beginning in 2023
 through 2033. In addition, the Company has U.S. federal tax credits
 of $23.7 million which will expire in various years beginning in
 2020 through 2033.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The use of the Company&amp;#x2019;s U.S. federal NOL and tax credit
 carryforwards in future years are restricted due to changes in the
 Company&amp;#x2019;s ownership and tax attributes acquired by the
 Company in a purchase. As of December&amp;#xA0;31, 2013, $8.5 million
 of the Company&amp;#x2019;s NOLs are limited for use over the years
 2014&amp;#xA0;&amp;#x2013; 2027 in which a range of such amounts could be
 utilized on an annual basis of $0.2 million to $1.4&amp;#xA0;million.
 The remaining $96.3 million of NOLs is not limited and can be
 offset against future taxable income. Additionally, approximately
 $1.8 million of NOLs will be recognized as a benefit through
 additional-paid-in-capital when realized. Further, despite the NOL
 and credit carryforwards, the Company may have a future tax
 liability due to an alternative minimum tax or state tax
 requirements in which net operating losses do not exist.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The reconciliation of the reported estimated income tax benefit to
 the amount that would result by applying the U.S. federal statutory
 tax rate to the net income is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="53%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 United States federal tax at statutory rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(91,293&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,926,615&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,350,992&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 State taxes (net of federal benefit)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;609,476&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,460,289&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,480,185&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred income tax adjustments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(855,130&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(512,375&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred state blended rate adjustments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(344,178&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research credit, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(225,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Orphan drug credit, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(843,463&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,895,671&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,056,607&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other permanent items&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,931&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,627&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,696&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Equity-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;241,467&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;279,165&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;725,811&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Fair value adjustment of preferred stock warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;218,872&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,743&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(496,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,286,923&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;787,093&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,991,131&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Income tax expense/(benefit)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 A reconciliation of the beginning and ending amount of gross
 unrecognized tax benefits is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Beginning balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,592,357&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,533,986&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,246,025&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Increases/(decreases) for current year tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;115,502&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58,371&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;287,961&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Increases/(decreases) for prior year tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Decreases as a result of expiration of statute of limitations&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Ending balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,707,859&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,592,357&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,533,986&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of December&amp;#xA0;31, 2013 and 2012, of the total gross
 unrecognized tax benefits, approximately $1.2 million and $1.1
 million would favorably impact the Company&amp;#x2019;s effective income
 tax rate, respectively. Although, due to the Company&amp;#x2019;s
 determination that the deferred income tax asset would not more
 likely than not be realized, a valuation allowance would be
 recorded, therefore, zero net impact would result within the
 Company&amp;#x2019;s effective income tax rate. The Company&amp;#x2019;s
 uncertain income tax position liability has been recorded to
 deferred income taxes to offset the tax attribute carryforward
 amounts.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For the years ended December&amp;#xA0;31, 2013, 2012 and 2011, the
 Company has not recognized any interest or penalties related to the
 uncertain income tax positions due to the fact such position is
 related to tax attribute carryforwards which have not yet been
 utilized. The Company does not expect its unrecognized income tax
 position to significantly decrease within the next twelve
 months.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s U.S. Federal and state income tax returns from
 2001 to 2012 remain subject to examination by the tax authorities.
 The Company&amp;#x2019;s 2001 through 2009 years remain open for
 examination, even though the statute of limitations has expired,
 due to the net operating losses and credits carried forward for use
 in prospective years.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_DA70A941-06F8-4E5B-BE0A-A9A4593A979A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Research and development expenditures are expensed as incurred.
 Research and development costs primarily consist of employee
 related expenses, including salaries and benefits, expenses
 incurred under agreements with contract research organizations,
 investigative sites and consultants that conduct the
 Company&amp;#x2019;s clinical trials, the cost of acquiring and
 manufacturing clinical trial materials and other allocated
 expenses, license fees for and milestone payments related to
 in-licensed products and technologies, stock-based compensation
 expense, and costs associated with non-clinical activities and
 regulatory approvals.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_703094D9-73F6-47CB-9BCD-FAA551F9E244_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Future minimum lease payments under noncancelable operating leases
 at December&amp;#xA0;31, 2013 are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,651,421&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,310,884&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,410,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,512,517&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,780,398&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,665,430&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_CBA45BB3-EE6A-47FF-9D33-F3C12D427CFF_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation and Principles of
 Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The consolidated financial statements include the accounts of
 MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics
 West, Inc. All intercompany accounts and transactions have been
 eliminated in consolidation. The Company currently operates in one
 operating segment. Operating segments are defined as components of
 an enterprise about which separate discrete information is
 available for the chief operating decision maker, or decision
 making group, in deciding how to allocate resources and assessing
 performance. The Company views its operations and manages its
 business in one segment, which is developing monoclonal
 antibody-based therapeutics for cancer, autoimmune and infectious
 diseases.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_270395C1-5D83-4486-AC1A-BC061980F66C_2_2">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_270395C1-5D83-4486-AC1A-BC061980F66C_2_3">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_BC02AA88-3B5C-4AD3-B0C5-AD2F0A87DB12_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;11. Employee Benefit Plan&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On September&amp;#xA0;25, 2002, the Company established the MacroGenics
 401(k) Plan (the &amp;#x201C;Plan&amp;#x201D;) for its employees under
 Section&amp;#xA0;401(k) of the IRC. Under this Plan, all employees at
 least 21 years of age are eligible to participate in the Plan,
 starting on the first day of each month. Employees may contribute
 up to 100% of their salary, subject to government maximums.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Employees are 100% vested in their contributions to the Plan. The
 Company&amp;#x2019;s contribution to the Plan, as determined by the
 Board of Directors, is discretionary. The Company&amp;#x2019;s
 contributions to the Plan totaled $252,930, $225,195 and $217,097
 for the years ended December&amp;#xA0;31, 2013, 2012 and 2011,
 respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_4392741_705AF870-30A3-4F00-8004-997561CC59CF_1_0">1268049</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_C630E2A5-FDBA-4A9E-BD5C-BF1CB25EB388_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Substantially all of the Company&amp;#x2019;s cash and cash equivalents
 are maintained with major financial institutions in the United
 States. Deposits held with banks may exceed the amount of insurance
 provided on such deposits. Generally, these deposits may be
 redeemed upon demand and, therefore, bear minimal risk.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Financial instruments that potentially subject the Company to
 concentrations of credit risk consist principally of cash and cash
 equivalents, and accounts receivable. The counterparties are
 various corporations, financial institutions and government
 agencies of high credit standing.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For the years ended December&amp;#xA0;31, 2013, 2012 and 2011, all of
 the Company&amp;#x2019;s grant revenue was related to contracts and
 research grants received from U.S. government agencies.
 Collaborations with Les Laboratoires Servier and Institut de
 Recherches Servier (collectively, &amp;#x201C;Servier&amp;#x201D;),
 Boehringer Ingelheim GmbH (&amp;#x201C;Boehringer&amp;#x201D;), Gilead
 Sciences, Inc. (&amp;#x201C;Gilead&amp;#x201D;), Pfizer, Inc.
 (&amp;#x201C;Pfizer&amp;#x201D;) and Eli Lilly&amp;#xA0;&amp;amp; Co. (&amp;#x201C;Eli
 Lilly&amp;#x201D;) account for all other revenue. All outstanding
 receivables are due from the Company&amp;#x2019;s collaborators and U.S.
 government agencies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table represents the percentage of all significant
 revenue earned in the periods indicated:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;
 &lt;b&gt;Year&amp;#xA0;Ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2013&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2012&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2011&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Servier&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Pfizer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Government Agencies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Eli Lilly&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table represents the percentage of all significant
 accounts receivable:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2013&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2012&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;53.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Pfizer.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Eli Lilly&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Servier&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Government Agencies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_6453CC95-3581-4B37-8603-C6207D29BD24_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The reconciliation of the reported estimated income tax benefit to
 the amount that would result by applying the U.S. federal statutory
 tax rate to the net income is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="53%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 United States federal tax at statutory rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(91,293&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,926,615&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,350,992&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 State taxes (net of federal benefit)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;609,476&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,460,289&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,480,185&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred income tax adjustments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(855,130&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(512,375&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred state blended rate adjustments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(344,178&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research credit, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(225,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Orphan drug credit, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(843,463&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,895,671&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,056,607&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other permanent items&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,931&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,627&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,696&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Equity-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;241,467&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;279,165&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;725,811&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Fair value adjustment of preferred stock warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;218,872&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,743&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(496,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,286,923&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;787,093&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,991,131&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Income tax expense/(benefit)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_D48C115A-96CD-41B0-A3B7-DAC1AC41159A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Stock-based payments are accounted for in accordance with the
 provisions of ASC&amp;#xA0;718, &lt;i&gt;Compensation&amp;#xA0;&amp;#x2013; Stock
 Compensation&lt;/i&gt;. The fair value of stock-based payments is
 estimated, on the date of grant, using the Black-Scholes model. The
 resulting fair value is recognized ratably over the requisite
 service period, which is generally the vesting period of the
 option.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For all time-vesting awards granted, expense is amortized using the
 straight-line attribution method. For awards that contain a
 performance condition, expense is amortized using the accelerated
 attribution method. Recognition of stock-based compensation expense
 is based on the value of the portion of stock-based awards that is
 ultimately expected to vest during the period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company utilizes the Black-Scholes model for estimating fair
 value of its stock options granted. Option valuation models,
 including the Black-Scholes model, require the input of highly
 subjective assumptions, and changes in the assumptions used can
 materially affect the grant-date fair value of an award. These
 assumptions include the risk-free rate of interest, expected
 dividend yield, expected volatility and the expected life of the
 award.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_AA4B5B83-71E5-44C2-BD7A-454AC3BA1B4E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;2. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation and Principles of
 Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The consolidated financial statements include the accounts of
 MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics
 West, Inc. All intercompany accounts and transactions have been
 eliminated in consolidation. The Company currently operates in one
 operating segment. Operating segments are defined as components of
 an enterprise about which separate discrete information is
 available for the chief operating decision maker, or decision
 making group, in deciding how to allocate resources and assessing
 performance. The Company views its operations and manages its
 business in one segment, which is developing monoclonal
 antibody-based therapeutics for cancer, autoimmune and infectious
 diseases.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The preparation of the financial statements in accordance with
 generally accepted accounting principles (&amp;#x201C;GAAP&amp;#x201D;)
 requires the Company to make estimates and judgments in certain
 circumstances that affect the reported amounts of assets,
 liabilities, revenues and expenses, and related disclosure of
 contingent assets and liabilities. In preparing these consolidated
 financial statements, management has made its best estimates and
 judgments of certain amounts included in the financial statements,
 giving due consideration to materiality. On an ongoing basis, the
 Company evaluates its estimates, including those related to revenue
 recognition, fair values of assets, convertible preferred stock and
 common stock, preferred stock warrant liability, income taxes,
 pre-clinical study and clinical trial accruals and other
 contingencies. Management bases its estimates on historical
 experience or on various other assumptions that it believes to be
 reasonable under the circumstances. Actual results could differ
 from these estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In addition, prior to the Company&amp;#x2019;s IPO in October 2013, the
 Company utilized estimates and assumptions in determining the fair
 value of its common stock. The Company granted stock options at
 exercise prices not less than the fair value of its common stock as
 determined by the Board of Directors, with input from management.
 Management used contemporaneous valuations in estimating the fair
 value of its common stock. The board of directors determined the
 estimated fair value of the common stock based on a number of
 objective and subjective factors, including external market
 considerations affecting the biotechnology industry and the
 historic prices at which the Company sold shares of its preferred
 stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company considers all investments in highly liquid financial
 instruments with an original maturity of three months or less at
 the date of purchase to be cash equivalents. Cash and cash
 equivalents consist of certificates of deposit and investments in
 money market funds with commercial banks and financial
 institutions. Cash equivalents are stated at amortized cost, plus
 accrued interest, which approximates fair value.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Accounts receivable that management has the intent and ability to
 collect are reported in the consolidated balance sheets at
 outstanding amounts, less an allowance for doubtful accounts. The
 Company writes off uncollectible receivables when the likelihood of
 collection is remote.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company evaluates the collectability of accounts receivable on
 a regular basis. The allowance, if any, is based upon various
 factors including the financial condition and payment history of
 customers, an overall review of collections experience on other
 accounts and economic factors or events expected to affect future
 collections experience. No allowance was recorded as of
 December&amp;#xA0;31, 2013 or 2012, as the Company has a history of
 collecting on all outstanding accounts.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company is required to maintain certificates of deposit that
 serve as collateral for various operating leases and corporate
 credit card accounts. Amounts classified as restricted cash on the
 consolidated balance sheets are $404,850 at December&amp;#xA0;31, 2013
 and 2012.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair market values of the financial instruments included in the
 financial statements, which include cash equivalents and money
 market accounts, approximate their carrying values at
 December&amp;#xA0;31, 2013 and 2012, due to their short-term
 maturities. The Company accounts for recurring and non-recurring
 fair value measurements in accordance with the Financial Accounting
 Standards Board (&amp;#x201C;FASB&amp;#x201D;) Accounting Standards
 Codification (&amp;#x201C;ASC&amp;#x201D;) 820, &lt;i&gt;Fair Value Measurements
 and Disclosures&lt;/i&gt; (&amp;#x201C;ASC 820&amp;#x201D;). ASC 820 defines fair
 value, establishes a fair value hierarchy for assets and
 liabilities measured at fair value, and requires expanded
 disclosures about fair value measurements. The ASC 820 hierarchy
 ranks the quality of reliability of inputs, or assumptions, used in
 the determination of fair value and requires assets and liabilities
 carried at fair value to be classified and disclosed in one of the
 following three categories:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 1&amp;#x2014;Fair value is
 determined by using unadjusted quoted prices that are available in
 active markets for identical assets and liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 2&amp;#x2014;Fair value is
 determined by using inputs other than Level 1 quoted prices that
 are directly or indirectly observable. Inputs can include quoted
 prices for similar assets and liabilities in active markets or
 quoted prices for identical assets and liabilities in inactive
 markets. Related inputs can also include those used in valuation or
 other pricing models, such as interest rates and yield curves that
 can be corroborated by observable market data.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 3&amp;#x2014;Fair value is
 determined by inputs that are unobservable and not corroborated by
 market data. Use of these inputs involves significant and
 subjective judgments to be made by a reporting entity&amp;#xA0;&amp;#x2013;
 e.g., determining an appropriate adjustment to a discount factor
 for illiquidity associated with a given security.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The Company evaluates financial assets and liabilities subject to
 fair value measurements on a recurring basis to determine the
 appropriate level at which to classify them each reporting period.
 This determination requires the Company to make subjective
 judgments as to the significance of inputs used in determining fair
 value and where such inputs lie within the ASC 820 hierarchy.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Financial assets and liabilities subject to fair value measurements
 were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="38%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 December&amp;#xA0;31, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&amp;#xA0;in&lt;br /&gt;
 Active Markets&lt;br /&gt;
 for&lt;br /&gt;
 Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&amp;#xA0;Other&lt;br /&gt;
 Observable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;br /&gt;
 Unobservable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,434,435&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,434,435&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,046,974&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,046,974&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total Assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116,886,259&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116,886,259&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 December&amp;#xA0;31, 2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&amp;#xA0;in&lt;br /&gt;
 Active Markets&lt;br /&gt;
 for&lt;br /&gt;
 Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&amp;#xA0;Other&lt;br /&gt;
 Observable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;br /&gt;
 Unobservable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,695,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,695,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,047,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,047,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total Assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,148,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,148,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Preferred stock warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of December&amp;#xA0;31, 2012, the Company transferred its money
 market funds from Level 2 to Level 1 because the inputs are now
 based upon a quoted market price.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s Level 1 securities primarily consist of
 restricted cash, cash equivalents and money market funds. The
 Company determines the estimated fair value for its Level 1
 securities using quoted (unadjusted) prices for identical assets or
 liabilities in active markets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company determines the estimated fair value for its Level 2
 securities using the following methods: quoted prices for similar
 assets/liabilities in active markets, inputs other than quoted
 prices that are observable for the asset/liability (e.g., interest
 rates, yield curves volatilities, default rates, etc.) and inputs
 that are derived principally from or corroborated by other
 observable market data.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table provides a rollforward of the Company&amp;#x2019;s
 preferred stock warrant liability, which was the only financial
 instrument measured at fair value on a recurring basis using
 significant unobservable inputs (Level 3) as defined in ASC
 820:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="82%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total unrealized gains (losses) included in earnings&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(626,349&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Settlement of preferred stock warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;679,296&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In order to estimate the fair value of the preferred stock purchase
 warrants, the business enterprise value was established based on a
 discounted cash flow model (income approach). The Company utilized
 an option pricing method to value the shares using a contingent
 claims analysis, which applies a series of call options whose
 inputs reflect the liquidation preferences and conversion behavior
 of the different classes of equity. After the equity value of the
 business enterprise was determined, the total equity value is
 allocated to the various equity instruments such as preferred
 stock, stock options and preferred stock purchase warrants. Key
 management estimates relate to the time period to liquidation and
 conversion behavior of a particular class of stockholders. The
 business enterprise value includes assumptions related to product
 approval, market penetration and costs to develop the product.
 Significant changes to these assumptions would result in
 increases/decreases to the fair value of the outstanding
 warrants.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The total unrealized gains (losses) on the preferred stock warrants
 included in earnings is included as a component of other income
 (expense) in the consolidated statement of operations and
 comprehensive income. Immediately prior to the Company&amp;#x2019;s IPO
 in October 2013, all the preferred stock warrants were exercised
 and converted into shares of Series D-2 preferred stock, which were
 subsequently converted to common stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Substantially all of the Company&amp;#x2019;s cash and cash equivalents
 are maintained with major financial institutions in the United
 States. Deposits held with banks may exceed the amount of insurance
 provided on such deposits. Generally, these deposits may be
 redeemed upon demand and, therefore, bear minimal risk.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Financial instruments that potentially subject the Company to
 concentrations of credit risk consist principally of cash and cash
 equivalents, and accounts receivable. The counterparties are
 various corporations, financial institutions and government
 agencies of high credit standing.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For the years ended December&amp;#xA0;31, 2013, 2012 and 2011, all of
 the Company&amp;#x2019;s grant revenue was related to contracts and
 research grants received from U.S. government agencies.
 Collaborations with Les Laboratoires Servier and Institut de
 Recherches Servier (collectively, &amp;#x201C;Servier&amp;#x201D;),
 Boehringer Ingelheim GmbH (&amp;#x201C;Boehringer&amp;#x201D;), Gilead
 Sciences, Inc. (&amp;#x201C;Gilead&amp;#x201D;), Pfizer, Inc.
 (&amp;#x201C;Pfizer&amp;#x201D;) and Eli Lilly&amp;#xA0;&amp;amp; Co. (&amp;#x201C;Eli
 Lilly&amp;#x201D;) account for all other revenue. All outstanding
 receivables are due from the Company&amp;#x2019;s collaborators and U.S.
 government agencies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table represents the percentage of all significant
 revenue earned in the periods indicated:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;
 &lt;b&gt;Year&amp;#xA0;Ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2013&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2012&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2011&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Servier&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Pfizer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Government Agencies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Eli Lilly&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table represents the percentage of all significant
 accounts receivable:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2013&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2012&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;53.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Pfizer.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Eli Lilly&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Servier&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Government Agencies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment are stated at cost. Upon retirement or sale,
 the cost of assets disposed of and the related accumulated
 depreciation are removed from the accounts and any resulting gain
 or loss is credited or charged to operations. Repairs and
 maintenance costs are expensed as incurred. Depreciation is
 computed using the straight-line method over the following
 estimated useful lives:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="51%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td width="47%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Furniture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;10 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Laboratory and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;5 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Shorter of lease term or useful life&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company assesses the recoverability of its long-lived assets in
 accordance with the provisions of ASC&amp;#xA0;360, &lt;i&gt;Property, Plant
 and Equipment&lt;/i&gt;. ASC 360 requires that long-lived assets be
 reviewed for impairment whenever events or changes in circumstances
 indicate that the carrying amount of an asset may not be
 recoverable. Recoverability of the long-lived asset is measured by
 a comparison of the carrying amount of the asset to future
 undiscounted net cash flows expected to be generated by the asset
 or asset group. If carrying value exceeds the sum of undiscounted
 cash flows, the Company then determines the fair value of the
 underlying asset group. Any impairment to be recognized is measured
 by the amount by which the carrying amount of the asset group
 exceeds the estimated fair value of the asset group. Assets to be
 disposed of are reported at the lower of the carrying amount or
 fair value, less costs to sell. As of December&amp;#xA0;31, 2013 and
 2012, the Company determined that there were no impaired assets and
 had no assets held-for-sale.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Deferred tax assets and liabilities are determined based on
 differences between the financial reporting and tax basis of assets
 and liabilities and are measured using the enacted tax rates and
 laws that are expected to be in effect when the differences are
 expected to reverse. The effect on deferred tax assets and
 liabilities of a change in tax rates is recognized as income in the
 period that such tax rate changes are enacted. The measurement of a
 deferred tax asset is reduced, if necessary, by a valuation
 allowance if it is more likely than not that some portion or all of
 the deferred tax asset will not be realized. Financial statement
 recognition of a tax position taken or expected to be taken in a
 tax return is determined based on a more-likely-than-not threshold
 of that position being sustained. If the tax position meets this
 threshold, the benefit to be recognized is measured as the largest
 amount that is more than 50% likely to be realized upon ultimate
 settlement. The Company&amp;#x2019;s policy is to record interest and
 penalties related to uncertain tax positions as a component of
 income tax expense.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenues&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company enters into collaboration and license agreements with
 collaborators for the development of monoclonal antibody-based
 therapeutics to treat cancer and other complex diseases. The terms
 of these agreements contain multiple deliverables which may include
 (i)&amp;#xA0;licenses, or options to obtain licenses, to the
 Company&amp;#x2019;s technological platforms, such as its Fc
 Optimization and Dual-Affinity Re-Targeting (&amp;#x201C;DART&amp;#x201D;)
 technologies, (ii)&amp;#xA0;rights to future technological
 improvements, (iii)&amp;#xA0;research and development activities to be
 performed on behalf of the collaborator or as part of the
 collaboration, and (iv)&amp;#xA0;the manufacture of pre-clinical or
 clinical materials for the collaborator. Payments to the Company
 under these agreements may include nonrefundable license fees,
 option fees, exercise fees, payments for research and development
 activities, payments for the manufacture of pre-clinical or
 clinical materials, license maintenance payments, payments based
 upon the achievement of certain milestones and royalties on product
 sales. Other benefits to the Company of these agreements include
 the right to sell products resulting from the collaborative efforts
 of the parties in specific geographic territories. The Company
 follows the provisions of the FASB ASC Topic 605-25, &lt;i&gt;Revenue
 Recognition&amp;#xA0;&amp;#x2013;&amp;#xA0;Multiple-Element Arrangements&lt;/i&gt;,
 and ASC Topic 605-28, &lt;i&gt;Revenue Recognition&amp;#x2013;Milestone
 Method&lt;/i&gt;, in accounting for these agreements. In order to account
 for these agreements, the Company must identify the deliverables
 included within the agreement and evaluate which deliverables
 represent separate units of accounting based on the achievement of
 certain criteria, including whether the delivered element has
 stand-alone value to the collaborator. The consideration received
 is allocated among the separate units of accounting, and the
 applicable revenue recognition criteria are applied to each of the
 separate units.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For the periods presented, the Company had the following two types
 of agreements with the parties identified below: 1) exclusive
 development and commercialization licenses to use the
 Company&amp;#x2019;s technology and/or certain other intellectual
 property to develop compounds against specified targets (referred
 to herein as exclusive licenses); and 2) Option/research agreements
 to secure on established terms, development and commercialization
 licenses to anticancer and other therapeutic product candidates to
 collaborator selected targets developed by the Company during an
 option period (referred to herein as right-to-develop
 agreements).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 There are no performance, cancellation, termination or refund
 provisions in any of the arrangements that contain material
 financial consequences to the Company.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Exclusive Licenses&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The deliverables under an exclusive license agreement generally
 include the exclusive license to the Company&amp;#x2019;s DART
 technology with respect to a specified antigen target, and may also
 include deliverables related to rights to future technological
 improvements, research and pre-clinical development activities to
 be performed on behalf of the collaborator. In some cases the
 Company may have an option to participate in the co-development of
 product candidates that result from such agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Generally, exclusive license agreements contain nonrefundable terms
 for payments and, depending on the terms of the agreement, provide
 that the Company will (i)&amp;#xA0;at the collaborator&amp;#x2019;s request,
 provide research and pre-clinical development services at
 negotiated prices which are generally consistent with what other
 third parties would charge, (ii)&amp;#xA0;earn payments upon the
 achievement of certain milestones, (iii)&amp;#xA0;earn royalty
 payments, and (iv)&amp;#xA0;in some cases grant the Company an option
 to participate in the development and commercialization of products
 that result from such agreements. Royalty rates may vary over the
 royalty term depending on the Company&amp;#x2019;s intellectual property
 rights and whether the Company exercises any co-development and
 co-commercialization rights. The Company may provide technical
 assistance and share any technology improvements with its
 collaborators during the term of the collaboration agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company does not directly control when any collaborator will
 achieve milestones or become liable for royalty payments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In determining the units of accounting, management evaluates
 whether the exclusive license has stand-alone value from the
 undelivered elements to the collaborator based on the consideration
 of the relevant facts and circumstances for each arrangement.
 Factors considered in this determination include the research and
 development capabilities of the partner and the availability of
 technology platform and product research expertise in the general
 marketplace. If the Company concludes that the license has
 stand-alone value and therefore will be accounted for as a separate
 unit of accounting, the Company then determines the estimated
 selling prices of the license and all other units of accounting
 based on market conditions, similar arrangements entered into by
 third parties, and entity-specific factors such as the terms of the
 Company&amp;#x2019;s previous collaboration agreements, recent
 pre-clinical and clinical testing results of therapeutic product
 candidates that use the Company&amp;#x2019;s technology platforms, the
 Company&amp;#x2019;s pricing practices and pricing objectives, the
 likelihood that technological improvements will be made, the
 likelihood that technological improvements made will be used by the
 Company&amp;#x2019;s collaborators and the nature of the research
 services to be performed on behalf of its collaborators and market
 rates for similar services.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Upfront payments on exclusive licenses are deferred if facts and
 circumstances dictate that the license does not have stand-alone
 value. Prior to the adoption of Accounting Standards Update
 (&amp;#x201C;ASU&amp;#x201D;) No.&amp;#xA0;2009-13, &lt;i&gt;Revenue Arrangements with
 Multiple Deliverables&lt;/i&gt;, on January&amp;#xA0;1, 2011, the Company
 determined that its licenses lacked stand-alone value because it
 did not have vendor-specific objective evidence of selling price
 (&amp;#x201C;VSOE&amp;#x201D;), and were combined with other elements of the
 arrangement and any amounts associated with the license were
 deferred and amortized over a certain period, which the Company
 refers to as the Company&amp;#x2019;s period of substantial involvement.
 In making the determination of the length of the period over which
 to defer revenue for contracts entered into prior to the adoption
 of ASU No.&amp;#xA0;2009-13, significant judgment and estimation is
 used by the Company and can have an impact on the amount of revenue
 recognized in a given period. Historically, the Company&amp;#x2019;s
 involvement with the development of a collaborator&amp;#x2019;s product
 candidate has been significant at the early stages of development,
 and lessens as it progresses into clinical trials. Accordingly, the
 Company generally estimates this period of substantial involvement
 to begin at the inception of the collaboration agreement and
 conclude at the end of the Company&amp;#x2019;s substantial involvement.
 ASU No.&amp;#xA0;2009-13 amends the criteria for separating and
 allocating consideration in a multiple element arrangement by
 modifying the fair value requirements for revenue recognition and
 eliminating the use of the residual value method. The selling
 prices of deliverables under an arrangement may be derived using
 third-party evidence (&amp;#x201C;TPE&amp;#x201D;), or a best estimate of
 selling price (&amp;#x201C;BESP&amp;#x201D;), if VSOE is not available. The
 objective of BESP is to determine the price at which the Company
 would transact a sale if the element within the license agreement
 was sold on a standalone basis. Establishing BESP involves
 management&amp;#x2019;s judgment and considers multiple factors,
 including market conditions and company-specific factors, including
 those factors contemplated in negotiating the agreements, as well
 as internally developed models that include assumptions related to
 market opportunity, discounted cash flows, estimated development
 costs, probability of success and the time needed to commercialize
 a product candidate pursuant to the license. In validating the
 BESP, management considers whether changes in key assumptions used
 to determine the BESP will have a significant effect on the
 allocation of the arrangement consideration between the multiple
 deliverables. Deliverables under the arrangement are separate units
 of accounting if (i)&amp;#xA0;the delivered item has value to the
 customer on a standalone basis and (ii)&amp;#xA0;if the arrangement
 includes a general right of return relative to the delivered item,
 delivery or performance of the undelivered item is considered
 probable and substantially within the Company&amp;#x2019;s control. The
 arrangement consideration that is fixed or determinable at the
 inception of the arrangement is allocated to the separate units of
 accounting based on their relative selling prices. The appropriate
 revenue recognition model is applied to each element and revenue is
 accordingly recognized as each element is delivered. Management
 exercises significant judgment in determining whether a deliverable
 is a separate unit of accounting.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In determining the separate units of accounting, the Company
 evaluated whether the exclusive license had standalone value to the
 collaborator based on consideration of the relevant facts and
 circumstances for each arrangement. Factors considered in this
 determination included the research and development capabilities of
 the collaborator and the availability of relevant research
 expertise in the marketplace. In addition, the Company considered
 whether or not (i)&amp;#xA0;the collaborator could use the license for
 its intended purpose without the receipt of the remaining
 deliverables, (ii)&amp;#xA0;the value of the license was dependent on
 the undelivered items and (iii)&amp;#xA0;the collaborator or other
 vendors could provide the undelivered items.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company reassesses its periods of substantial involvement over
 which the Company amortizes its upfront license fees and makes
 adjustments as appropriate. In the event a collaborator elects to
 discontinue development of a specific product candidate under a
 single target license, but retains its right to use the
 Company&amp;#x2019;s technology to develop an alternative product
 candidate to the same target or a target substitute, the Company
 would cease amortization of any remaining portion of the upfront
 fee until there is substantial pre-clinical activity on another
 product candidate and its remaining period of substantial
 involvement can be estimated. In the event that a single target
 license were to be terminated, the Company would recognize as
 revenue any portion of the upfront fee that had not previously been
 recorded as revenue, but was classified as deferred revenue, at the
 date of such termination or through the remaining substantial
 involvement in the wind down of the agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Upfront payments on exclusive licenses may be recognized upon
 delivery of the license if facts and circumstances dictate that the
 license has stand-alone value from the undelivered elements, which
 generally include rights to future technological improvements,
 research services and the manufacture of pre-clinical and clinical
 materials.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company recognizes revenue related to research and pre-clinical
 development services that represent separate units of accounting as
 they are performed, as long as there is persuasive evidence of an
 arrangement, the fee is fixed or determinable, and collection of
 the related receivable is probable. The Company recognizes revenue
 related to the rights to future technological improvements over the
 estimated term of the applicable license.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company typically performs research activities and pre-clinical
 development services, including generating and engineering product
 candidates, on behalf of its licensees during the early evaluation
 and pre-clinical testing stages of drug development under its
 exclusive licenses. The Company records amounts received for
 research materials produced or services performed as revenue from
 collaborative research.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s license agreements have milestone payments
 which for reporting purposes are aggregated into three categories:
 (i)&amp;#xA0;development milestones, (ii)&amp;#xA0;regulatory milestones,
 and (iii)&amp;#xA0;sales milestones. Development milestones are
 typically payable when a product candidate initiates or advances
 into different clinical trial phases. Regulatory milestones are
 typically payable upon submission for marketing approval with the
 U.S. Food and Drug Administration (&amp;#x201C;FDA&amp;#x201D;) or other
 countries&amp;#x2019; regulatory authorities or on receipt of actual
 marketing approvals for the compound or for additional indications.
 Sales milestones are typically payable when annual sales reach
 certain levels.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 At the inception of each agreement that includes milestone
 payments, the Company evaluates whether each milestone is
 substantive and at risk to both parties on the basis of the
 contingent nature of the milestone. This evaluation includes an
 assessment of whether (a)&amp;#xA0;the consideration is commensurate
 with either (1)&amp;#xA0;the entity&amp;#x2019;s performance to achieve the
 milestone, or (2)&amp;#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&amp;#x2019;s performance to achieve the milestone,
 (b)&amp;#xA0;the consideration relates solely to past performance and
 (c)&amp;#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. The Company
 evaluates factors such as the scientific, regulatory, commercial
 and other risks that must be overcome to achieve the respective
 milestone, the level of effort and investment required to achieve
 the respective milestone and whether the milestone consideration is
 reasonable relative to all deliverables and payment terms in the
 arrangement in making this assessment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Non-refundable development and regulatory milestones that are
 expected to be achieved as a result of the Company&amp;#x2019;s efforts
 during the period of substantial involvement are considered
 substantive and are recognized as revenue upon the achievement of
 the milestone, assuming all other revenue recognition criteria are
 met. Milestones that are not considered substantive because the
 Company does not contribute effort to the achievement of such
 milestones are generally achieved after the period of substantial
 involvement and are recognized as revenue upon achievement of the
 milestone, as there are no undelivered elements remaining and no
 continuing performance obligations, assuming all other revenue
 recognition criteria are met.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Right-to-Develop Agreements&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s right-to-develop agreements provide
 collaborators with an exclusive option to obtain licenses to
 develop and commercialize in specified geographic territories
 product candidates developed by the Company under agreed upon
 research and pre-clinical development product programs. The product
 candidates resulting from each program are all directed to a
 specific target selected by the collaborator. Under these
 agreements, fees may be due to the Company (i)&amp;#xA0;at the
 inception of the arrangement (referred to as &amp;#x201C;upfront&amp;#x201D;
 fees or payments), (ii)&amp;#xA0;the selection of a target for a
 program, (iii)&amp;#xA0;upon the exercise of an option to acquire a
 development and commercialization license (referred to as exercise
 fees or payments earned) for a program, or (iv)&amp;#xA0;some
 combination of all of these fees.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The accounting for right-to-develop agreements is dependent on the
 nature of the options granted to the collaborator. Options are
 considered substantive if, at the inception of a right-to-develop
 agreement, the Company is at risk as to whether the collaborator
 will choose to exercise the options to secure development and
 commercialization licenses. Factors that are considered in
 evaluating whether options are substantive include the overall
 objective of the arrangement, the benefit the collaborator might
 obtain from the agreement without exercising the options, the cost
 to exercise the options relative to the total upfront
 consideration, and the additional financial commitments imposed on
 the collaborator as a result of exercising the options.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to a product program are
 considered substantive, the Company does not consider the
 development and commercialization licenses to be a deliverable at
 the inception of the agreement. For those right-to-develop
 agreements entered into prior to the adoption of ASU
 No.&amp;#xA0;2009-13 where the options to secure development and
 commercialization licenses are considered substantive, the Company
 has deferred the upfront payments received and recognizes this
 revenue over the period during which the collaborator could elect
 to exercise options for development and commercialization licenses.
 These periods are specific to each collaboration agreement. If a
 collaborator selects a target for a product program, any
 substantive option fee is deferred and recognized over the life of
 the option, generally 12 months. Subsequent to the adoption of ASU
 No.&amp;#xA0;2009-13, the Company&amp;#x2019;s evaluation of whether the
 option is substantive is consistent with pre-adoption of ASU
 No.&amp;#xA0;2009-13. How the Company determines the selling price of
 the option is the only difference between pre and post adoption of
 ASU No.&amp;#xA0;2009-13. Post adoption of ASU No.&amp;#xA0;2009-13, the
 selling prices of deliverables under an arrangement may be derived
 using TPE or a BESP, if VSOE is not available. The objective of
 BESP is to determine the price at which the Company would transact
 a sale if the element within the right-to-develop agreement was
 sold on a standalone basis. Establishing BESP involves
 management&amp;#x2019;s judgment and considers multiple factors,
 including market conditions and company-specific factors, including
 those factors contemplated in negotiating the agreements, as well
 as internally developed models that include assumptions related to
 market opportunity, discounted cash flows, estimated development
 costs, probability of success and the time needed to commercialize
 a product candidate pursuant to the right-to-develop agreement. In
 validating the BESP, management considers whether changes in key
 assumptions used to determine the BESP will have a significant
 effect on the allocation of the arrangement consideration between
 the multiple deliverables. Deliverables under the arrangement are
 separate units of accounting if (i)&amp;#xA0;the delivered item has
 value to the customer on a standalone basis and (ii)&amp;#xA0;if the
 arrangement includes a general right of return relative to the
 delivered item, delivery or performance of the undelivered item is
 considered probable and substantially within the Company&amp;#x2019;s
 control. The arrangement consideration that is fixed or
 determinable at the inception of the arrangement is allocated to
 the separate units of accounting based on their relative selling
 prices. The appropriate revenue recognition model is applied to
 each element and revenue is accordingly recognized as each element
 is delivered. Management exercises significant judgment in
 determining whether a deliverable is a separate unit of
 accounting.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 If a collaborator exercises an option and acquires a development
 and commercialization license to a product program, the Company
 attributes the exercise fee to the development and
 commercialization license. The Company determines the selling price
 of the option license, upon exercise, through management&amp;#x2019;s
 best estimate. Management&amp;#x2019;s determination of selling price
 includes such factors as stage of development, market potential and
 cash flow models used during the negotiation with the collaborator.
 Through December&amp;#xA0;31, 2013, none of our collaboration partners
 had exercised an option. However, one of our collaboration partners
 did elect to exercise an option in February 2014. See Note 13 for
 additional information.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Upon exercise of an option to acquire a development and
 commercialization license, the Company would also attribute any
 remaining deferred option fee, in addition to the consideration
 received for the license upon exercise of the option, to the
 development and commercialization license. The Company then applies
 the multiple-element revenue recognition criteria to the
 development and commercialization license and other deliverables,
 if any, to determine the appropriate revenue recognition method.
 This model is consistent with the Company&amp;#x2019;s accounting policy
 for upfront payments on exclusive licenses (discussed above). In
 the event a right-to-develop agreement were to be terminated, the
 Company would recognize as revenue any portion of the upfront fee
 that had not previously been recorded as revenue, but was
 classified as deferred revenue, at the date of such termination.
 The Company&amp;#x2019;s right-to-develop agreements have been
 determined to contain substantive options.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to product programs are
 not considered substantive, the Company considers the development
 and commercialization licenses to be a deliverable at the inception
 of the agreement and applies the multiple-element revenue
 recognition criteria to determine the appropriate revenue
 recognition. The Company does not directly control when any
 collaborator will exercise its options for development and
 commercialization licenses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Research and development expenditures are expensed as incurred.
 Research and development costs primarily consist of employee
 related expenses, including salaries and benefits, expenses
 incurred under agreements with contract research organizations,
 investigative sites and consultants that conduct the
 Company&amp;#x2019;s clinical trials, the cost of acquiring and
 manufacturing clinical trial materials and other allocated
 expenses, license fees for and milestone payments related to
 in-licensed products and technologies, stock-based compensation
 expense, and costs associated with non-clinical activities and
 regulatory approvals.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Effective January&amp;#xA0;1, 2012, the Company adopted ASU 2011-05,
 &lt;i&gt;Presentation of Comprehensive Income,&lt;/i&gt; which amended ASC
 Topic 220, &lt;i&gt;Comprehensive Income&lt;/i&gt; (&amp;#x201C;ASU
 2011-05&amp;#x201D;)&lt;i&gt;.&lt;/i&gt; The amendments in ASU 2011-05 require the
 presentation of the comprehensive income (loss) and its components
 as part of the consolidated financial statements. Comprehensive
 income (loss) is comprised of the net income (loss) and other
 changes in equity that are excluded from net income (loss).
 Comprehensive income (loss) equals net income (loss) for the years
 ended December&amp;#xA0;31, 2013, 2012 and 2011.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Stock-based payments are accounted for in accordance with the
 provisions of ASC&amp;#xA0;718, &lt;i&gt;Compensation&amp;#xA0;&amp;#x2013; Stock
 Compensation&lt;/i&gt;. The fair value of stock-based payments is
 estimated, on the date of grant, using the Black-Scholes model. The
 resulting fair value is recognized ratably over the requisite
 service period, which is generally the vesting period of the
 option.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For all time-vesting awards granted, expense is amortized using the
 straight-line attribution method. For awards that contain a
 performance condition, expense is amortized using the accelerated
 attribution method. Recognition of stock-based compensation expense
 is based on the value of the portion of stock-based awards that is
 ultimately expected to vest during the period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company utilizes the Black-Scholes model for estimating fair
 value of its stock options granted. Option valuation models,
 including the Black-Scholes model, require the input of highly
 subjective assumptions, and changes in the assumptions used can
 materially affect the grant-date fair value of an award. These
 assumptions include the risk-free rate of interest, expected
 dividend yield, expected volatility and the expected life of the
 award.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Net Income (Loss) Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic income (loss) per common share is determined by dividing
 income (loss) attributable to common stockholders by the
 weighted-average number of common shares outstanding during the
 period, without consideration of common stock equivalents. Diluted
 income (loss) per share is computed by dividing the earnings (loss)
 attributable to common stockholders by the weighted-average number
 of common share equivalents outstanding for the period. The
 treasury stock method is used to determine the dilutive effect of
 the Company&amp;#x2019;s stock option grants, potential Employee Stock
 Purchase Plan awards and warrants and the if-converted method is
 used to determine the dilutive effect of the Company&amp;#x2019;s
 preferred stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Prior to the Company&amp;#x2019;s initial public offering, net income
 (loss) per share was calculated under the &lt;font style="WHITE-SPACE: nowrap"&gt;two-class&lt;/font&gt; method under which all
 earnings (distributed and undistributed) are allocated to each
 class of common stock and participating securities based on their
 respective rights to receive dividends. In the event that the Board
 of Directors declared a dividend payable in cash or other property
 on the then-outstanding shares of common stock, the holders of the
 Series&amp;#xA0;A-1, A-2, B, C, D, and D-2 convertible preferred stock
 would be entitled to receive the amount of dividends per share of
 preferred stock that would be payable on the largest number of
 whole shares of common stock into which each share of preferred
 stock could then be converted. Therefore, the Series A-1, A-2, B,
 C, D and D-2 are participating securities. All of the outstanding
 shares of Series&amp;#xA0;A-1, A-2, B, C, D, and D-2 convertible
 preferred stock converted to common stock upon the consummation of
 the Company&amp;#x2019;s IPO.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Basic and diluted income (loss) per common share is computed as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(260,835&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,361,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,717,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: undistributed earnings allocated to participating
 securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,361,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,717,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(260,835&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,025,602&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Basic income (loss) per common share&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.04&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(260,835&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,361,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,717,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,361,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,717,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(260,835&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,025,602&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Effect of dilutive securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Diluted weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,025,602&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Diluted income (loss) per common share&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.04&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following common stock equivalents were excluded from the
 calculation of diluted net income (loss) per share because their
 effect would be anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series A-1 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series A-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series B Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series C Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series D Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Effect of Converted Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,189,920&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants to purchase Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Stock Options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,313,970&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,249,702&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,885,417&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Recently Issued Accounting Standards Adopted&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In July 2013, the FASB issued ASU No.&amp;#xA0;2013-11, which amended
 ASC Topic 740 regarding presentation of an unrecognized tax benefit
 when a net operating loss (&amp;#x201C;NOL&amp;#x201D;) carryforward, a
 similar tax loss, or a tax credit carryforward exists. The
 amendments in ASU No.&amp;#xA0;2013-11 require an entity to present an
 unrecognized tax benefit as a reduction of a deferred tax asset for
 an NOL carryforward, or similar tax loss or tax credit
 carryforward, rather than as a liability when (1)&amp;#xA0;the
 uncertain tax position would reduce the NOL or other carryforward
 under the tax law of the applicable jurisdiction and (2)&amp;#xA0;the
 entity intends to use the deferred tax asset for that purpose. The
 ASU does not require new recurring disclosures. This amendment is
 effective prospectively for fiscal years beginning after
 December&amp;#xA0;15, 2013. The Company does not believe this amendment
 will have a material impact on its financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has evaluated all ASUs through the date the
 consolidated financials were issued and believes that the adoption
 of these will not have a material impact on the Company&amp;#x2019;s
 consolidated financial statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_7F08A51B-E5A6-4DF0-9D16-B18A013BA405_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Accounts receivable that management has the intent and ability to
 collect are reported in the consolidated balance sheets at
 outstanding amounts, less an allowance for doubtful accounts. The
 Company writes off uncollectible receivables when the likelihood of
 collection is remote.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company evaluates the collectability of accounts receivable on
 a regular basis. The allowance, if any, is based upon various
 factors including the financial condition and payment history of
 customers, an overall review of collections experience on other
 accounts and economic factors or events expected to affect future
 collections experience. No allowance was recorded as of
 December&amp;#xA0;31, 2013 or 2012, as the Company has a history of
 collecting on all outstanding accounts.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_D3A7FFB4-F732-421B-A325-F876294BD6A2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The significant components of the Company&amp;#x2019;s deferred tax
 assets (liabilities) were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred income tax assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Federal U.S. net operating loss carryforward&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36,561,195&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,330,167&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 State net operating loss carryforward&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,315,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,521,722&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Research and development credit, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,785,612&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,777,899&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Orphan drug credit, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,883,076&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,039,613&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Deferred rent&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,132,458&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,218,002&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,216,695&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,379,064&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,438,477&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,247,772&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,438,870&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,575,782&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Gross deferred income tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79,771,897&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;78,090,021&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(79,376,945&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(78,090,021&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net deferred income tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;394,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred income tax liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(394,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Gross deferred income tax liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(394,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net deferred income tax asset/(liability)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_4392741_ECE56403-768F-4BE4-873E-F0AB29008A6D_5001_4">87635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_169BA3D6-187D-4806-829D-55E72F4462C9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company assesses the recoverability of its long-lived assets in
 accordance with the provisions of ASC&amp;#xA0;360, &lt;i&gt;Property, Plant
 and Equipment&lt;/i&gt;. ASC 360 requires that long-lived assets be
 reviewed for impairment whenever events or changes in circumstances
 indicate that the carrying amount of an asset may not be
 recoverable. Recoverability of the long-lived asset is measured by
 a comparison of the carrying amount of the asset to future
 undiscounted net cash flows expected to be generated by the asset
 or asset group. If carrying value exceeds the sum of undiscounted
 cash flows, the Company then determines the fair value of the
 underlying asset group. Any impairment to be recognized is measured
 by the amount by which the carrying amount of the asset group
 exceeds the estimated fair value of the asset group. Assets to be
 disposed of are reported at the lower of the carrying amount or
 fair value, less costs to sell. As of December&amp;#xA0;31, 2013 and
 2012, the Company determined that there were no impaired assets and
 had no assets held-for-sale.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_99F11B6B-56C4-4EFE-A5DD-A6B20B20A19D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 The following stock-based compensation amounts were recognized for
 the periods indicated:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;507,142&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;471,809&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,018,935&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;355,020&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;366,586&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,328,504&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;862,162&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;838,395&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,347,439&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:UseOfEstimates contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_664AB385-4DB0-4780-9518-B7402A032185_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The preparation of the financial statements in accordance with
 generally accepted accounting principles (&amp;#x201C;GAAP&amp;#x201D;)
 requires the Company to make estimates and judgments in certain
 circumstances that affect the reported amounts of assets,
 liabilities, revenues and expenses, and related disclosure of
 contingent assets and liabilities. In preparing these consolidated
 financial statements, management has made its best estimates and
 judgments of certain amounts included in the financial statements,
 giving due consideration to materiality. On an ongoing basis, the
 Company evaluates its estimates, including those related to revenue
 recognition, fair values of assets, convertible preferred stock and
 common stock, preferred stock warrant liability, income taxes,
 pre-clinical study and clinical trial accruals and other
 contingencies. Management bases its estimates on historical
 experience or on various other assumptions that it believes to be
 reasonable under the circumstances. Actual results could differ
 from these estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In addition, prior to the Company&amp;#x2019;s IPO in October 2013, the
 Company utilized estimates and assumptions in determining the fair
 value of its common stock. The Company granted stock options at
 exercise prices not less than the fair value of its common stock as
 determined by the Board of Directors, with input from management.
 Management used contemporaneous valuations in estimating the fair
 value of its common stock. The board of directors determined the
 estimated fair value of the common stock based on a number of
 objective and subjective factors, including external market
 considerations affecting the biotechnology industry and the
 historic prices at which the Company sold shares of its preferred
 stock.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_83C6A156-1978-40D8-869B-3551FB067713_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;1. Organization and Nature of Operations&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 MacroGenics, Inc. (the &amp;#x201C;Company&amp;#x201D;) was incorporated in
 Delaware on August&amp;#xA0;14, 2000. The Company is a clinical-stage
 biopharmaceutical company focused on discovering and developing
 innovative monoclonal antibody-based therapeutics for the treatment
 of cancer and autoimmune diseases. The Company generates its
 pipeline of product candidates from its proprietary suite of
 next-generation antibody technology platforms which it believes
 improve the performance of monoclonal antibodies and
 antibody-derived molecules. These product candidates, which the
 Company has identified through its understanding of disease biology
 and immune-mediated mechanisms, may address disease-specific
 challenges which are not currently being met by existing therapies.
 The Company creates both differentiated molecules that are directed
 to novel cancer targets, as well as &amp;#x201C;bio-betters&amp;#x201D; which
 are drugs designed to improve upon marketed medicines.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On October&amp;#xA0;16, 2013, the Company completed an initial public
 offering (&amp;#x201C;IPO&amp;#x201D;) of its common stock, which resulted in
 the sale of 5,750,000 shares, including all additional shares
 available to cover over-allotments, at a price of $16.00 per share.
 The Company received net proceeds before expenses from the IPO of
 $85.6 million after deducting underwriting discounts and
 commissions paid by the Company.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_37941699-65F4-4EBD-940D-EDDAC95AD000_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Net Income (Loss) Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic income (loss) per common share is determined by dividing
 income (loss) attributable to common stockholders by the
 weighted-average number of common shares outstanding during the
 period, without consideration of common stock equivalents. Diluted
 income (loss) per share is computed by dividing the earnings (loss)
 attributable to common stockholders by the weighted-average number
 of common share equivalents outstanding for the period. The
 treasury stock method is used to determine the dilutive effect of
 the Company&amp;#x2019;s stock option grants, potential Employee Stock
 Purchase Plan awards and warrants and the if-converted method is
 used to determine the dilutive effect of the Company&amp;#x2019;s
 preferred stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Prior to the Company&amp;#x2019;s initial public offering, net income
 (loss) per share was calculated under the &lt;font style="WHITE-SPACE: nowrap"&gt;two-class&lt;/font&gt; method under which all
 earnings (distributed and undistributed) are allocated to each
 class of common stock and participating securities based on their
 respective rights to receive dividends. In the event that the Board
 of Directors declared a dividend payable in cash or other property
 on the then-outstanding shares of common stock, the holders of the
 Series&amp;#xA0;A-1, A-2, B, C, D, and D-2 convertible preferred stock
 would be entitled to receive the amount of dividends per share of
 preferred stock that would be payable on the largest number of
 whole shares of common stock into which each share of preferred
 stock could then be converted. Therefore, the Series A-1, A-2, B,
 C, D and D-2 are participating securities. All of the outstanding
 shares of Series&amp;#xA0;A-1, A-2, B, C, D, and D-2 convertible
 preferred stock converted to common stock upon the consummation of
 the Company&amp;#x2019;s IPO.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Basic and diluted income (loss) per common share is computed as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(260,835&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,361,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,717,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: undistributed earnings allocated to participating
 securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,361,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,717,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(260,835&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,025,602&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Basic income (loss) per common share&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.04&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(260,835&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,361,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,717,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,361,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,717,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(260,835&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,025,602&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Effect of dilutive securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Diluted weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,847,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,025,602&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Diluted income (loss) per common share&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.04&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following common stock equivalents were excluded from the
 calculation of diluted net income (loss) per share because their
 effect would be anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series A-1 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series A-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series B Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series C Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series D Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Effect of Converted Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,189,920&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants to purchase Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Stock Options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,313,970&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,249,702&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,885,417&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_4946AB4F-68D1-467C-97C3-F02C25BF1DA0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of each option award is estimated on the date of
 grant using the Black-Scholes option-pricing model using the
 assumptions in the following table:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="5" align="center"&gt;&lt;b&gt;Year Ended December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield..&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;53%&amp;#xA0;-&amp;#xA0;67%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;51%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;62%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.24%&amp;#xA0;-&amp;#xA0;2.19%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.18%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.35%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7&amp;#xA0;years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected forfeiture rate..&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;5.06%&amp;#xA0;-&amp;#xA0;5.57%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.57%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.58%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_6A63C49B-2092-48BE-BD9C-57DDA4A2C929_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair market values of the financial instruments included in the
 financial statements, which include cash equivalents and money
 market accounts, approximate their carrying values at
 December&amp;#xA0;31, 2013 and 2012, due to their short-term
 maturities. The Company accounts for recurring and non-recurring
 fair value measurements in accordance with the Financial Accounting
 Standards Board (&amp;#x201C;FASB&amp;#x201D;) Accounting Standards
 Codification (&amp;#x201C;ASC&amp;#x201D;) 820, &lt;i&gt;Fair Value Measurements
 and Disclosures&lt;/i&gt; (&amp;#x201C;ASC 820&amp;#x201D;). ASC 820 defines fair
 value, establishes a fair value hierarchy for assets and
 liabilities measured at fair value, and requires expanded
 disclosures about fair value measurements. The ASC 820 hierarchy
 ranks the quality of reliability of inputs, or assumptions, used in
 the determination of fair value and requires assets and liabilities
 carried at fair value to be classified and disclosed in one of the
 following three categories:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 1&amp;#x2014;Fair value is
 determined by using unadjusted quoted prices that are available in
 active markets for identical assets and liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 2&amp;#x2014;Fair value is
 determined by using inputs other than Level 1 quoted prices that
 are directly or indirectly observable. Inputs can include quoted
 prices for similar assets and liabilities in active markets or
 quoted prices for identical assets and liabilities in inactive
 markets. Related inputs can also include those used in valuation or
 other pricing models, such as interest rates and yield curves that
 can be corroborated by observable market data.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 3&amp;#x2014;Fair value is
 determined by inputs that are unobservable and not corroborated by
 market data. Use of these inputs involves significant and
 subjective judgments to be made by a reporting entity&amp;#xA0;&amp;#x2013;
 e.g., determining an appropriate adjustment to a discount factor
 for illiquidity associated with a given security.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The Company evaluates financial assets and liabilities subject to
 fair value measurements on a recurring basis to determine the
 appropriate level at which to classify them each reporting period.
 This determination requires the Company to make subjective
 judgments as to the significance of inputs used in determining fair
 value and where such inputs lie within the ASC 820 hierarchy.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Financial assets and liabilities subject to fair value measurements
 were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="38%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 December&amp;#xA0;31, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&amp;#xA0;in&lt;br /&gt;
 Active Markets&lt;br /&gt;
 for&lt;br /&gt;
 Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&amp;#xA0;Other&lt;br /&gt;
 Observable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;br /&gt;
 Unobservable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,434,435&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,434,435&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,046,974&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,046,974&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total Assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116,886,259&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116,886,259&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 December&amp;#xA0;31, 2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&amp;#xA0;in&lt;br /&gt;
 Active Markets&lt;br /&gt;
 for&lt;br /&gt;
 Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&amp;#xA0;Other&lt;br /&gt;
 Observable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;br /&gt;
 Unobservable&lt;br /&gt;
 Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,695,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,695,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,047,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,047,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total Assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,148,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,148,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Preferred stock warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of December&amp;#xA0;31, 2012, the Company transferred its money
 market funds from Level 2 to Level 1 because the inputs are now
 based upon a quoted market price.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s Level 1 securities primarily consist of
 restricted cash, cash equivalents and money market funds. The
 Company determines the estimated fair value for its Level 1
 securities using quoted (unadjusted) prices for identical assets or
 liabilities in active markets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company determines the estimated fair value for its Level 2
 securities using the following methods: quoted prices for similar
 assets/liabilities in active markets, inputs other than quoted
 prices that are observable for the asset/liability (e.g., interest
 rates, yield curves volatilities, default rates, etc.) and inputs
 that are derived principally from or corroborated by other
 observable market data.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table provides a rollforward of the Company&amp;#x2019;s
 preferred stock warrant liability, which was the only financial
 instrument measured at fair value on a recurring basis using
 significant unobservable inputs (Level 3) as defined in ASC
 820:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="82%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total unrealized gains (losses) included in earnings&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(626,349&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Settlement of preferred stock warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;679,296&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In order to estimate the fair value of the preferred stock purchase
 warrants, the business enterprise value was established based on a
 discounted cash flow model (income approach). The Company utilized
 an option pricing method to value the shares using a contingent
 claims analysis, which applies a series of call options whose
 inputs reflect the liquidation preferences and conversion behavior
 of the different classes of equity. After the equity value of the
 business enterprise was determined, the total equity value is
 allocated to the various equity instruments such as preferred
 stock, stock options and preferred stock purchase warrants. Key
 management estimates relate to the time period to liquidation and
 conversion behavior of a particular class of stockholders. The
 business enterprise value includes assumptions related to product
 approval, market penetration and costs to develop the product.
 Significant changes to these assumptions would result in
 increases/decreases to the fair value of the outstanding
 warrants.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The total unrealized gains (losses) on the preferred stock warrants
 included in earnings is included as a component of other income
 (expense) in the consolidated statement of operations and
 comprehensive income. Immediately prior to the Company&amp;#x2019;s IPO
 in October 2013, all the preferred stock warrants were exercised
 and converted into shares of Series D-2 preferred stock, which were
 subsequently converted to common stock.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_CEC1BB82-61DF-4004-8E4C-322E1B0422EF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Deferred tax assets and liabilities are determined based on
 differences between the financial reporting and tax basis of assets
 and liabilities and are measured using the enacted tax rates and
 laws that are expected to be in effect when the differences are
 expected to reverse. The effect on deferred tax assets and
 liabilities of a change in tax rates is recognized as income in the
 period that such tax rate changes are enacted. The measurement of a
 deferred tax asset is reduced, if necessary, by a valuation
 allowance if it is more likely than not that some portion or all of
 the deferred tax asset will not be realized. Financial statement
 recognition of a tax position taken or expected to be taken in a
 tax return is determined based on a more-likely-than-not threshold
 of that position being sustained. If the tax position meets this
 threshold, the benefit to be recognized is measured as the largest
 amount that is more than 50% likely to be realized upon ultimate
 settlement. The Company&amp;#x2019;s policy is to record interest and
 penalties related to uncertain tax positions as a component of
 income tax expense.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_F9A30717-4680-4175-802C-E2667C5D9848_1_2" />
  <us-gaap:Revenues contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_1_3">58034668</us-gaap:Revenues>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F9A30717-4680-4175-802C-E2667C5D9848_1_1">115502</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_B4806FB3-A6F3-4580-B871-953BDED216A5_1_3">487603</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_183E1637-EBCC-4160-B5CE-05609DD8F75A_1_2">-260835</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_1_9">-626814</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9019_2200022">1067500</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:IncomeTaxReconciliationTaxCreditsOther contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_1_5">843463</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_10">375000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_183E1637-EBCC-4160-B5CE-05609DD8F75A_1_7">-260835</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:RevenueFromGrants contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_1_2">1281545</us-gaap:RevenueFromGrants>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_1_8">365979</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_8">834071</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_7">-42200</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_1_10">-260835</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9019_2200020">1860591</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9019_2200017">862162</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9019_2200018">83622358</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_18">2960776</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_1_1">56753123</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_5">626349</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_1_6">2931</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
  <us-gaap:CostsAndExpenses contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_1_7">57668689</us-gaap:CostsAndExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_1_6">11086759</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_23">85871153</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_1_9">1286923</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="INF" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_28">2947202</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_1_4">-225605</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_14">-16676509</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_4">862162</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_24">68738254</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_1_7">241467</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_7F4975E7-3665-4A2A-A2A5-A01BCA38E8CC_1_5">2700000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_2534C117-6C12-4706-AE87-42F13BC8D088_1_1">252930</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_12">2346527</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_1_1">609476</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_11">-570091</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_22">85871153</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_1_0">-91293</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_19">-2960776</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_1_5">46581930</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_705AF870-30A3-4F00-8004-997561CC59CF_1_2">1100000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_2AB81895-1302-441A-A31D-C7EC1872EA7A_1_0">1200000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_13">-628769</us-gaap:IncreaseDecreaseInRestructuringReserve>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E175397-B9E7-4CA3-B8E7-3E8763BA259E_1_0">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:Depreciation contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_3">1193340</us-gaap:Depreciation>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_549F0920-A988-488D-844F-4D30ED54305E_1_2">862162</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_11803776-7675-481C-8EB5-0C29096DAC88_1_0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_F9A30717-4680-4175-802C-E2667C5D9848_1_3" />
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_1_10" />
  <mgnx:IncreaseDecreaseInDeferredRent contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_1_15">102574</mgnx:IncreaseDecreaseInDeferredRent>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_4392741_67E35B1B-B4DB-4AFE-AC72-999E6A828674_1_0">1921894</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged>
  <mgnx:IncomeTaxReconciliationDeferredTaxAdjustments contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_1_2">-855130</mgnx:IncomeTaxReconciliationDeferredTaxAdjustments>
  <mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_B4EA3382-63D1-47F6-9B30-2F49AF425BD6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Repairs and maintenance costs are expensed as incurred.
 Depreciation is computed using the straight-line method over the
 following estimated useful lives:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="51%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td width="47%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Furniture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;10 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Laboratory and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;5 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Shorter of lease term or useful life&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
  <mgnx:TaxCreditCarryforwardExpirationYearRangeEnd contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_64DB01D3-145A-4FD4-B8E5-AC3518C59F55_1_6">2033</mgnx:TaxCreditCarryforwardExpirationYearRangeEnd>
  <mgnx:IncomeTaxExaminationYearUnderExaminationRangeStart contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_D23E5F33-A9FC-48D2-9DA3-0A318844F8E3_1_0">2001</mgnx:IncomeTaxExaminationYearUnderExaminationRangeStart>
  <mgnx:LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_F2224985-589C-4748-BA67-BAE0E547E393_1_0">P3M</mgnx:LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum>
  <mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_A8BBB5D6-0E77-4986-8C5B-D1545DFED30E_1_0">8500000</mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount>
  <mgnx:IncomeTaxExaminationYearUnderExaminationRangeEnd contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_D23E5F33-A9FC-48D2-9DA3-0A318844F8E3_1_1">2012</mgnx:IncomeTaxExaminationYearUnderExaminationRangeEnd>
  <mgnx:TaxCreditCarryforwardExpirationYearRangeStart contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_64DB01D3-145A-4FD4-B8E5-AC3518C59F55_1_5">2020</mgnx:TaxCreditCarryforwardExpirationYearRangeStart>
  <mgnx:PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_4392741_8F676B3F-F62E-442D-93CB-BEC8F684B120_1_0">0.50</mgnx:PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority>
  <mgnx:IncomeTaxReconciliationStateDeferredTaxesAdjustments contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_1_3">344178</mgnx:IncomeTaxReconciliationStateDeferredTaxesAdjustments>
  <mgnx:FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_64DB01D3-145A-4FD4-B8E5-AC3518C59F55_1_2">2023</mgnx:FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart>
  <mgnx:RoyaltyAgreementDisclosureTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_D95BDC40-736F-4251-927F-9DC8DA343B9F_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;10. Product Milestone Payments and Royalty Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In connection with an Asset Purchase Agreement with Tolerance
 Therapeutics, Inc. (&amp;#x201C;Tolerance&amp;#x201D;) entered into during
 June 2005, the Company may be required to issue Tolerance
 additional consideration as follows: (i)&amp;#xA0;$10,950,000 if
 certain milestones are met, including the initiation of Phase 3
 trials and filing of various regulatory product license
 applications; (ii)&amp;#xA0;36,135 shares of common stock; and
 (iii)&amp;#xA0;royalty payments between 1.75% and 4.0% of net sales of
 products acquired from or patented by Tolerance or other product
 fees earned by the Company. Any additional consideration required
 to be paid under the Asset Purchase Agreement will be recorded as
 research and development expense when incurred. No payments related
 to the additional consideration have occurred during the three
 years ended December&amp;#xA0;31, 2013. Additionally, certain
 agreements require the Company to pay royalties. Currently, the
 Company is not obligated to pay royalties, as no revenue from
 product sales is being generated by the Company.&lt;/p&gt;
 &lt;/div&gt;</mgnx:RoyaltyAgreementDisclosureTextBlock>
  <mgnx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_B4806FB3-A6F3-4580-B871-953BDED216A5_1_2">5400000</mgnx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue>
  <mgnx:IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_1_8">218872</mgnx:IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability>
  <mgnx:ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_882EB5C9-2193-4F8D-AA5F-002F3EC8066A_1_0">0</mgnx:ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense>
  <mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_5248DCD6-07E1-4CFA-8593-CC55529D5508_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;8. Collaboration and License Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Servier&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In November 2011, the Company entered into a right-to-develop
 collaboration agreement with Servier for the development and
 commercialization of MGA271 in all countries other than the United
 States, Canada, Mexico, Japan, South Korea and India.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Upon execution of the agreement, Servier made a nonrefundable
 payment of $20.0 million to the Company. The Company is eligible to
 receive up to $30.0 million in license grant fees, $47.0 million in
 clinical milestone payments, $140.0 million in regulatory milestone
 payments and $208.0 million in sales milestone payments if Servier
 exercises the option, obtains regulatory approval for and
 successfully commercializes MGA271. The Company concluded that the
 license grant fees are not deliverables at the inception of the
 arrangement. The Company has determined that each potential future
 clinical, development and regulatory milestone is substantive.
 Although sales milestones are not considered substantive, they are
 still recognized upon achievement of the milestone (assuming all
 other revenue recognition criteria have been met) because there are
 no undelivered elements that would preclude revenue recognition at
 that time. In the event Servier exercises its option to continue
 development of MGA271, Servier must pay a license grant fee. Under
 this agreement, Servier would be obligated to pay the Company from
 low double digit to mid-teen royalties on product sales in its
 territories.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has evaluated the research collaboration agreement with
 Servier and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The Company
 concluded that the option is substantive and that the license fees
 for this option is not a deliverable at the inception of the
 arrangement as there is considerable uncertainty that the option
 would be exercised and the additional fee to be paid upon exercise
 of the option represents its estimated selling price (i.e. no
 substantial discount was given). The Company&amp;#x2019;s substantive
 performance obligations under this research collaboration include
 an exclusivity clause to its technology, technical, scientific and
 intellectual property support to the research plan during the first
 year of the agreement and participation on an executive committee
 and a research and development committee. The Company determined
 that these performance obligations represent a single unit of
 accounting, since the license does not have stand-alone value to
 Servier without the Company&amp;#x2019;s technical expertise and
 committee participation. As such, the initial upfront payment was
 deferred and is being recognized ratably over the initial 27-month
 period, which represents the expected period of development and the
 Company&amp;#x2019;s participation on the research and development
 committee. The Company further concluded that each potential future
 clinical, development and regulatory milestone is substantive.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 During the years ended December&amp;#xA0;31, 2013, 2012 and 2011 the
 Company recognized revenue of $21.3&amp;#xA0;million, $9.1 million and
 0.9&amp;#xA0;million, respectively, under this agreement. Revenue
 recognized in the year ended December&amp;#xA0;31, 2013 included a
 $10.0 million substantive milestone payment received upon dosing
 the first patient in a Phase 1 dose expansion cohort trial of
 MGA271.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 At December&amp;#xA0;31, 2013, $0.9 million of revenue remained
 deferred under this agreement, all of which was included in current
 liabilities. At December&amp;#xA0;31, 2012, $10.0 million of revenue
 was deferred under this agreement, $9.1 million of which was
 included in current liabilities and $0.9 million of which was
 included in long-term liabilities.&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In September 2012, the Company entered into a second
 right-to-develop collaboration agreement with Servier and granted
 it options to obtain three separate exclusive licenses to develop
 and commercialize &lt;font style="white-space:nowrap"&gt;DART-based&lt;/font&gt; molecules, consisting of
 those designated by the Company as MGD006 and MGD007, as well as a
 third DART molecule, in all countries other than the United States,
 Canada, Mexico, Japan, South Korea and India.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Upon execution of the agreement, Servier made a nonrefundable
 payment of $20.0 million to the Company. In addition, the Company
 will be eligible to receive up to $65.0 million in license grant
 fees, $98.0 million in clinical milestone payments, including $5.0
 million upon IND acceptance for each of MGD006, MGD007 and a third
 DART molecule, $300.0 million in regulatory milestone payments and
 $630.0 million in sales milestone payments if Servier exercises all
 of the options and successfully develops, obtains regulatory
 approval for, and commercializes a product under each license. In
 addition to these milestones, the Company and Servier will share
 Phase 2 and Phase 3 development costs. The Company has determined
 that each potential future clinical, development and regulatory
 milestone is substantive. Although sales milestones are not
 considered substantive, they are still recognized upon achievement
 of the milestone (assuming all other revenue recognition criteria
 have been met) because there are no undelivered elements that would
 preclude revenue recognition at that time. Under this agreement,
 Servier would be obligated to pay the Company between high-single
 digit and mid-teen royalties on net product sales in its
 territories.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has evaluated the research collaboration agreement with
 Servier and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The Company
 concluded that each option is substantive and that the license fees
 for each option are not deliverables at the inception of the
 arrangement and were not issued with a substantial discount. The
 Company&amp;#x2019;s substantive performance obligations under this
 research collaboration include an exclusivity clause to its
 technology, technical, scientific and intellectual property support
 to the research plan during the first year of the agreement and
 participation on an executive committee and a research and
 development committee. The Company determined that the performance
 obligations with respect to the pre-clinical development represent
 a single unit of accounting, since the license does not have
 stand-alone value to Servier without the Company&amp;#x2019;s technical
 expertise and committee participation. As such, the initial up
 front license payment was deferred and is being recognized ratably
 over the initial 29-month period, which represents the expected
 development period. The Company further concluded that each
 potential future clinical, development and regulatory milestone is
 substantive.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 During the years ended December&amp;#xA0;31, 2013 and 2012 the Company
 recognized revenue of $8.6 million, and $2.0 million, respectively.
 No milestones have been recognized under this agreement during the
 years ended December&amp;#xA0;31, 2013 and 2012.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 At December&amp;#xA0;31, 2013, $9.4 million of revenue was deferred
 under this agreement, $8.6 million of which was included in current
 liabilities and $0.8 million of which was included in long-term
 liabilities. At December&amp;#xA0;31, 2012, $18.0 million of revenue
 was deferred under this agreement, $8.6 million of which was
 included in current liabilities and $9.4 million of which was
 included in long-term liabilities.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In February 2014, Servier exercised its exclusive option to develop
 and commercialize MGD006. As a result of the exercise, the Company
 received a $15.0 million payment from Servier for its license to
 develop and commercialize MGD006 in its territories. In addition,
 the Company received a $5.0 million payment from Servier upon the
 achievement of a clinical milestone related to the IND application
 for MGD006 clearing the &lt;font style="white-space:nowrap"&gt;30-day&lt;/font&gt; review period by the FDA.&lt;/p&gt;
 &lt;p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Gilead&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In January 2013, the Company entered into an agreement with Gilead
 for the research, development and commercialization of up to four
 DART-based molecules. The time period for Gilead&amp;#x2019;s exercise
 of one option has expired. At present, Gilead retains a license to
 one and options to two of the original four programs. Gilead has
 exclusive worldwide rights for each of these remaining
 programs.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company received an initial $7.5 million license grant fee for
 the first DART-based molecule, and is eligible to receive
 additional license grant fees of $7.5 million on each of the
 remaining two DART-based molecules if they are selected by Gilead.
 The Company is further eligible to receive up to an additional $20
 to $25 million in pre-clinical milestones across each of the three
 remaining DART programs and up to approximately $240 to $250
 million per remaining program in additional clinical, regulatory
 and sales milestones if Gilead exercises both remaining options and
 achieves all of the requisite milestones under each option and
 license. The Company has determined that the other licenses are
 conditional deliverables, which are substantive options that were
 not granted with a substantial discount. The Company has determined
 that each potential future clinical, development and regulatory
 milestone is substantive. Although sales milestones are not
 considered substantive, they are still recognized upon achievement
 of the milestone (assuming all other revenue recognition criteria
 have been met) because there are no undelivered elements that would
 preclude revenue recognition at that time. Gilead also provides
 funding for the Company&amp;#x2019;s internal and external research
 costs under the agreement. Additionally, Gilead would be obligated
 to pay the Company high single digit to low double digit, but less
 than teen royalties on product sales.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has evaluated the research collaboration agreement with
 Gilead and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The
 Company&amp;#x2019;s substantive performance obligations under this
 research collaboration include a license to its technology and
 research and development services. The Company concluded that the
 deliverables do not have stand alone value and therefore, represent
 a combined single unit of accounting. Due to the lack of standalone
 value for the license and research and development services, the
 combined unit of accounting (the upfront payment and the expected
 research and development reimbursements) is being recognized
 ratably over a period of 21 months, which represents the expected
 development period.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company and Gilead have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&amp;#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable. Had
 management considered participation on the joint committee as a
 deliverable, it would not have had a material impact on the
 accounting for the arrangement.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company recognized revenues of approximately $8.0 million under
 this agreement for the year ended December&amp;#xA0;31, 2013. No
 milestones have been achieved under this agreement.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 At December&amp;#xA0;31, 2013, $3.6 million of revenue was deferred
 under this agreement, all of which was included in current
 liabilities.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Boehringer&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In October 2010 the Company entered into a collaboration and
 license agreement with Boehringer to discover, develop and
 commercialize up to ten DART-based molecules which span multiple
 therapeutic areas. Under the terms of the agreement, the Company
 granted Boehringer an exclusive, worldwide, royalty-bearing,
 license under its intellectual property to research, develop, and
 market DARTs generated under the agreement throughout the
 world.&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Upon execution of the agreement, the Company received an upfront
 payment of $15.0 million. The Company subsequently received three
 annual maintenance payments including one in the fourth quarter of
 2013. These maintenance payments are being recognized over the
 estimated period of development. The Company has the potential to
 earn milestone payments of approximately $41.0 million related to
 pre-clinical and clinical development, $89.0 million related to
 regulatory milestones and $83.0 million related to sales milestones
 for each of the DART programs under this agreement in the case of
 full commercial success of multiple DART products. The Company has
 determined that each potential future clinical, development and
 regulatory milestone is substantive. Although sales milestones are
 not considered substantive, they are still recognized upon
 achievement of the milestone (assuming all other revenue
 recognition criteria have been met) because there are no
 undelivered elements that would preclude revenue recognition at
 that time. Boehringer also provides funding for the Company&amp;#x2019;s
 internal and external research costs and is required to pay the
 Company mid-single digit royalties on product sales. In November
 2013, Boehringer nominated a bi-specific antibody therapeutic
 candidate generated by the Company&amp;#x2019;s DART technology for
 pre-clinical development. This formal selection of a development
 candidate triggered a $5.0 million milestone payment to the
 Company. From the commencement of the collaboration through
 December&amp;#xA0;31, 2013, the Company has received $48.8 million
 under this agreement, including upfront, annual maintenance and
 milestone payments as well as research funding. In addition,
 Boehringer purchased $10.0 million of the Company&amp;#x2019;s Series
 D-2 Preferred Stock in January 2011. This preferred stock was
 converted to common stock upon the Company&amp;#x2019;s IPO in October
 2013.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company determined that the deliverables under the Boehringer
 agreement include the license, the research and development
 services to be performed by the Company, and the
 co-promotion/manufacturing services. The Company concluded that the
 co-promotional activities were optional and were subject to further
 negotiation upon reaching regulatory approval. As such, the
 co-promotional period is not included in the expected obligation
 period to perform services.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company concluded that the undelivered element of research and
 development services had fair value. The Company concluded that the
 license does not have value on a standalone basis (e.g. absent the
 provision of the research and development services) and therefore
 does not represent a separate unit of accounting. The Company
 concluded that because the drug candidate has not yet been
 developed, the license is of no value to Boehringer without the
 ensuing research and development activities using the DART
 technology, which is proprietary to the Company. Likewise,
 Boehringer could not sell the license to another party (without the
 Company agreeing to provide the research and development activities
 for the other party).&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Therefore, the upfront license fee and research and development
 services were treated as a combined unit of account and recognized
 over the expected obligation period associated with the research
 and development services through September 2015, which represents
 the estimated period of development.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company and Boehringer have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&amp;#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable. However,
 had management considered participation on the joint committee as a
 deliverable, it would not have had a material impact on the
 accounting for the arrangement as the period of participation in
 this committee matched the obligation period for the research and
 development services.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 There have been no material modifications to this agreement since
 the adoption of ASU 2009-13 on January&amp;#xA0;1, 2011.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company recognized revenues of approximately $14.4 million,
 $11.7 million and $8.9 million during the years ended
 December&amp;#xA0;31, 2013, 2012 and 2011, respectively. Revenue
 recognized in the years ended December&amp;#xA0;31, 2013 and 2012
 included milestone payments of $5.0 million and $2.0 million,
 respectively, for the achievement of clinical milestones. No
 milestones were achieved in the year ended December&amp;#xA0;31, 2011.
 At December&amp;#xA0;31, 2013, $12.8 million of revenue was deferred
 under this agreement, $7.0 million of which was included in current
 liabilities and $5.8 million of which was included in long-term
 liabilities. At December&amp;#xA0;31, 2012, $14.0 million of revenue
 was deferred under this agreement, $5.0 million of which was
 included in current liabilities and $9.0 million of which was
 included in long-term liabilities.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Pfizer&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In October 2010, the Company entered into a three year agreement
 with Pfizer to discover, develop and commercialize up to two
 DART-based molecules. The Company granted Pfizer a non-exclusive
 worldwide, royalty-bearing license and received an upfront payment
 of $5.0 million and has received milestone payments and funding for
 the Company&amp;#x2019;s internal and external research costs under the
 agreement.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company is eligible to receive milestone payments of
 approximately $17.0 million related to pre-clinical and clinical
 development and $195.0 million related to commercialization and
 sales milestones for each DART program under this agreement. The
 Company has determined that each potential future technical and
 development milestone is substantive. Although sales milestones are
 not considered substantive, they are still recognized upon
 achievement of the milestone (assuming all other revenue
 recognition criteria have been met) because there are no
 undelivered elements that would preclude revenue recognition at
 that time. Pfizer is responsible for all pre-clinical and clinical
 development costs for the program. In addition, Pfizer is required
 to pay the Company mid-single digit to low-teen royalties on
 product sales. Under this collaboration, one DART program is
 currently being pursued and the Company completed its research
 obligations under this program in January 2014.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has evaluated the research collaboration agreement with
 Pfizer and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The
 Company&amp;#x2019;s substantive performance obligations under this
 research collaboration include an exclusive license to its
 technology, research and development services and manufacturing
 services. The Company concluded that the manufacturing services
 were optional and were subject to further negotiation upon reaching
 regulatory approval. As such, the manufacturing services are not
 included in the expected obligation period to perform services.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company determined that it had fair value of the undelivered
 element of the research and development services. However, the
 Company concluded that the license does not have value on a
 standalone basis (e.g. absent the provision of the research and
 development services) and therefore does not represent a separate
 unit of accounting. Facts that were considered included the
 development of the candidate noting that because the drug candidate
 has not yet been developed, the license is of no value to Pfizer
 without the ensuing research and development activities using the
 DART technology, which is proprietary to the Company. Likewise,
 Pfizer could not sell the license to another party (without the
 Company agreeing to provide the research and development activities
 for the other party).&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Therefore, the upfront license fee and research and development
 services were treated as a combined unit of accounting and
 recognized over the expected obligation period associated with the
 research and development services through January 2014, which
 represents the estimated period of development.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The $5.0 million upfront payment received by the Company is
 non-refundable; therefore, there is no right of return for the
 license. The Company recognizes revenue associated with this
 non-refundable up-front license fee through the expected obligation
 period associated with the research and development services, which
 ended in January 2014.&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company and Pfizer have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&amp;#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable because it
 is a participating right and not an obligation of the Company.
 However, had management considered participation on the joint
 committee as a deliverable, it would not have had a material impact
 on the accounting for the arrangement.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 There have been no material modifications to this agreement since
 the adoption of ASU 2009-13 on January&amp;#xA0;1, 2011.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company recognized revenues of approximately $3.5 million, $5.5
 million and $5.2 million during the years ended December&amp;#xA0;31,
 2013, 2012 and 2011, respectively. Included in the 2012 revenues
 are milestone payments totaling $500,000. No additional milestones
 have been achieved under this agreement through December&amp;#xA0;31,
 2013.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 At December&amp;#xA0;31, 2013 and 2012, $7,291 and $1.3 million of
 revenue was deferred under this agreement, respectively, all of
 which was included in current liabilities.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Green Cross&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In June&amp;#xA0;2010, the Company entered into a collaboration
 agreement with Green Cross for the development of the
 Company&amp;#x2019;s anti-HER2 antibody known as MGAH22, or
 margetuximab. This arrangement grants Green Cross an exclusive
 license to conduct specified Phase 1 and Phase 2 clinical trials
 and commercialize margetuximab in South Korea.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Upon execution of the agreement, Green Cross made a nonrefundable
 payment of $1.0&amp;#xA0;million to the Company. The Company is
 eligible to receive clinical development and commercial milestone
 payments of up to $4.5 million. The Company has determined that
 each potential clinical development and commercial milestone is
 substantive. The Company is also entitled to receive royalties on
 net sales of margetuximab in South Korea. The Company and Green
 Cross have formed a joint steering committee to coordinate and
 oversee activities on which the companies collaborate under the
 agreement.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has evaluated the collaboration agreement with Green
 Cross and has determined that it is a revenue arrangement with
 multiple deliverables or performance obligations. The
 Company&amp;#x2019;s substantive performance obligations under this
 agreement include an exclusive license to its technologies and
 participation in a joint steering committee. The Company concluded
 that the license does not have value on a standalone basis and
 therefore does not represent a separate unit of accounting.
 Likewise, Green Cross could not sell the license to another
 party.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The $1.0 million upfront payment received by the Company is
 non-refundable; as such, there is no right of return for the
 license. Therefore, the upfront license fee and participation on
 the joint steering committee were treated as a combined unit of
 accounting and will be recognized over the term of the agreement
 through June 2020.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 There have been no material modifications to this agreement since
 the adoption of ASU 2009-13 on January&amp;#xA0;1, 2011.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company recognized revenues of approximately $100,000 under
 this agreement during each of the three years ended
 December&amp;#xA0;31, 2013. No milestones were achieved under this
 agreement during the three years ended December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 At December&amp;#xA0;31, 2013, $650,000 of revenue was deferred under
 this agreement, $100,000 of which was included in current
 liabilities and $550,000 of which was included in long-term
 liabilities. At December&amp;#xA0;31, 2012, $750,000 of revenue was
 deferred under this agreement, $100,000 of which was included in
 current liabilities and $650,000 of which was included in long-term
 liabilities.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Eli Lilly&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In October&amp;#xA0;2007, the Company entered into an exclusive license
 and collaboration agreement (together, the Agreements) with Eli
 Lilly to jointly develop and commercialize teplizumab, a humanized
 anti-CD3 monoclonal antibody. As part of the Agreements, Eli Lilly
 acquired the exclusive rights to the molecule.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Upon execution of the Agreements, Eli Lilly made a nonrefundable
 payment of $41.0&amp;#xA0;million to the Company. In May&amp;#xA0;2008, Eli
 Lilly paid the Company a milestone payment of $50.0&amp;#xA0;million
 and in May&amp;#xA0;2010, Eli&amp;#xA0;Lilly paid an additional milestone
 of $5.0&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On October&amp;#xA0;28, 2010, Lilly notified the Company of its
 decision to terminate the agreement after review of one year of
 clinical data from the Prot&amp;#xE9;g&amp;#xE9; trial in Type 1 diabetes
 patients treated with teplizumab. Such data failed to support the
 primary efficacy end point in the study. In February 2011, the
 Company reacquired the commercial rights to the molecule from Eli
 Lilly. During the year ended December&amp;#xA0;31, 2012, Eli&amp;#xA0;Lilly
 satisfied its obligation related to the cost of monitoring patients
 under the Prot&amp;#xE9;g&amp;#xE9; and Encore trials. The Company&amp;#x2019;s
 obligations continued through September 2012, which represented the
 follow up period for enrolled patients and the Company&amp;#x2019;s
 final reporting of the trial&amp;#x2019;s results. There is no
 additional clinical trial activity under the Eli Lilly Agreements
 as it relates to such trials. However, Eli Lily continues to
 reimburse the Company for monitoring patients in one currently
 active trial.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 During the years ended December 2013, 2012 and 2011, the Company
 recognized revenue of $0.8 million, $31.2 million and $30.9
 million, respectively, under this agreement. No milestones were
 achieved under this agreement during the three years ended
 December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;/div&gt;</mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock>
  <mgnx:DefinedContributionPlanEmployeesContributionAnnualVestingPercentage contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" unitRef="pure" decimals="INF" id="id_4392741_2534C117-6C12-4706-AE87-42F13BC8D088_1_0">1.00</mgnx:DefinedContributionPlanEmployeesContributionAnnualVestingPercentage>
  <mgnx:FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_64DB01D3-145A-4FD4-B8E5-AC3518C59F55_1_3">2033</mgnx:FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd>
  <mgnx:OperatingLossCarryforwardsLimitationsOnUseYearStart contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_A8BBB5D6-0E77-4986-8C5B-D1545DFED30E_1_1">2014</mgnx:OperatingLossCarryforwardsLimitationsOnUseYearStart>
  <mgnx:OperatingLossCarryforwardsLimitationsOnUseYearEnd contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0" id="id_4392741_A8BBB5D6-0E77-4986-8C5B-D1545DFED30E_1_2">2027</mgnx:OperatingLossCarryforwardsLimitationsOnUseYearEnd>
  <us-gaap:LeaseExpirationDate1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_925378x1075325_932294x1237431" id="id_4392741_7F4975E7-3665-4A2A-A2A5-A01BCA38E8CC_1001_0">2018-03-31</us-gaap:LeaseExpirationDate1>
  <us-gaap:LeaseExpirationDate1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_925378x1075325_932294x954146" id="id_4392741_7F4975E7-3665-4A2A-A2A5-A01BCA38E8CC_2001_1">2014-12-31</us-gaap:LeaseExpirationDate1>
  <us-gaap:LeaseExpirationDate1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_925378x989577_932294x1237431" id="id_4392741_7F4975E7-3665-4A2A-A2A5-A01BCA38E8CC_3001_2">2018-12-31</us-gaap:LeaseExpirationDate1>
  <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_926233x1150658_933025x1060690" unitRef="Program" decimals="INF" id="id_4392741_6EE19AAF-FCAC-44E0-ABF8-9107149E18E6_1001_4">2</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations>
  <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_926233x1241818_933025x1060690" unitRef="Molecule" decimals="INF" id="id_4392741_6EE19AAF-FCAC-44E0-ABF8-9107149E18E6_2001_2">1</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations>
  <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_926233x928673_933025x1060690" unitRef="Molecule" decimals="INF" id="id_4392741_6EE19AAF-FCAC-44E0-ABF8-9107149E18E6_3001_3">1</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_926437x923140" unitRef="pure" decimals="4" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_2_2">0.0219</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_926437x923140" unitRef="pure" decimals="2" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_2_1">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_926437x923140" unitRef="pure" decimals="4" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_2_4">0.0557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_926437x923140_930809x1218846" id="id_4392741_E10C6210-CDB6-4722-B93D-5B7FE8A31EE8_1001_0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_926437x932953" unitRef="pure" decimals="4" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_1_2">0.0124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_926437x932953" unitRef="pure" decimals="2" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_1_1">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_926437x932953" unitRef="pure" decimals="4" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_1_4">0.0506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_926437x932953" unitRef="pure" decimals="2" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_1_0">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:PaymentsForRestructuring contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_4392741_3E51796F-7DCB-4DF3-8828-3D26324309E0_7001_4">628769</us-gaap:PaymentsForRestructuring>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927015x925832" unitRef="iso4217_USD" decimals="0" id="id_4392741_549F0920-A988-488D-844F-4D30ED54305E_1001_1">355020</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927015x928963" unitRef="iso4217_USD" decimals="0" id="id_4392741_549F0920-A988-488D-844F-4D30ED54305E_2001_0">507142</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1060404_931007x926523" unitRef="pure" decimals="3" id="id_4392741_E7C36D1D-B4CB-4CC6-BAE1-C1DBAE88DEFD_1001_2">0.122</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1060404_931007x926597" unitRef="pure" decimals="3" id="id_4392741_07351A92-03EF-47D3-9A19-3B35431148A1_1001_1">0.248</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1060690_931007x926523" unitRef="pure" decimals="3" id="id_4392741_E7C36D1D-B4CB-4CC6-BAE1-C1DBAE88DEFD_2001_0">0.534</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1060690_931007x926597" unitRef="pure" decimals="3" id="id_4392741_07351A92-03EF-47D3-9A19-3B35431148A1_2001_2">0.138</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1074019_931007x926523" unitRef="pure" decimals="3" id="id_4392741_E7C36D1D-B4CB-4CC6-BAE1-C1DBAE88DEFD_3001_5">0.046</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1074019_931007x926597" unitRef="pure" decimals="3" id="id_4392741_07351A92-03EF-47D3-9A19-3B35431148A1_3001_4">0.022</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1115783_931007x926523" unitRef="pure" decimals="3" id="id_4392741_E7C36D1D-B4CB-4CC6-BAE1-C1DBAE88DEFD_4001_1">0.123</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1115783_931007x926597" unitRef="pure" decimals="3" id="id_4392741_07351A92-03EF-47D3-9A19-3B35431148A1_4001_3">0.060</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1218715_931007x926523" unitRef="pure" decimals="3" id="id_4392741_E7C36D1D-B4CB-4CC6-BAE1-C1DBAE88DEFD_5001_3">0.070</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1218715_931007x926597" unitRef="pure" decimals="3" id="id_4392741_07351A92-03EF-47D3-9A19-3B35431148A1_5001_5">0.014</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1218717_931007x926523" unitRef="pure" decimals="3" id="id_4392741_E7C36D1D-B4CB-4CC6-BAE1-C1DBAE88DEFD_6001_4">0.064</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1218717_931007x926597" unitRef="pure" decimals="3" id="id_4392741_07351A92-03EF-47D3-9A19-3B35431148A1_6001_0">0.516</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1031975" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9007_1000021">-110952217</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1031975" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9007_1100020">-1109522</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1124615" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9005_800021">-71401237</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1124615" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9005_900020">-714012</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1166280" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9001_400021">-26874792</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1166280" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9001_500020">-268748</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1166416" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9003_600021">-7364582</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1166416" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9003_700020">-73646</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1218718" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9011_1400021">-63681176</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1218718" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9011_1500020">-636812</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1225370" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9009_1200021">-14446227</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1225370" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9009_1300020">-144462</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x929313" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9018_2100024">-260835</us-gaap:NetIncomeLoss>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x929614" unitRef="iso4217_USD" decimals="0" id="id_4392741_13482182-00B0-4C8D-8B69-29C0966563E1_5001_2">-626349</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x929614" unitRef="iso4217_USD" decimals="0" id="id_4392741_13482182-00B0-4C8D-8B69-29C0966563E1_5001_3">679296</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x930643" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9013_1600021">17060634</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x930643" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9013_1600023">1268049</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x930643" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9013_1600019">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x930643" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9013_1700022">12680</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x930643" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9013_1700020">170606</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x930643" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9013_1700018">57500</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x932586" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9017_2000022">1054820</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x932586" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9017_2000020">4637187</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x932586" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9017_2000017">862162</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x932586" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_9017_2000018">83564858</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_8C56D4C8-8186-4803-95FF-A5E2A4D52196_1001_0">8600000</us-gaap:LicensesRevenue>
  <mgnx:NonRefundableFees contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_6E4EFFB8-63AA-4023-AE34-4E4556B3092B_1001_0">20000000</mgnx:NonRefundableFees>
  <mgnx:UpfrontPaymentRecognitionPeriod contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_928294x1218880_933025x1218879" id="id_4392741_A02777FF-0648-4528-89DA-11D6AB667AF3_1001_0">P29M</mgnx:UpfrontPaymentRecognitionPeriod>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_928294x1218880_933025x1218879" id="id_4392741_32D599EB-B747-4991-A350-5A6607ECDA0E_1001_0">September 2012</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x1031975" unitRef="shares" xsi:nil="true" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_1001_3" />
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x1124615" unitRef="shares" xsi:nil="true" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_2001_2" />
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x1166280" unitRef="shares" xsi:nil="true" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_3001_0" />
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x1166416" unitRef="shares" xsi:nil="true" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_4001_1" />
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x1218718" unitRef="shares" xsi:nil="true" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_5001_5" />
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x924898" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_6001_8">2313970</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x929614" unitRef="shares" xsi:nil="true" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_7001_7" />
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x932377" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_8001_6">13189920</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x997107" unitRef="shares" xsi:nil="true" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_9001_4" />
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_929865x1203065" id="id_4392741_7A379713-A59F-4D18-ABFE-BD7FACCB3457_1001_3">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_929865x923325" id="id_4392741_7A379713-A59F-4D18-ABFE-BD7FACCB3457_2001_4">Shorter of lease term or useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_929865x931666" id="id_4392741_7A379713-A59F-4D18-ABFE-BD7FACCB3457_3001_1">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_929865x931760" id="id_4392741_7A379713-A59F-4D18-ABFE-BD7FACCB3457_4001_0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_929865x932226" id="id_4392741_7A379713-A59F-4D18-ABFE-BD7FACCB3457_5001_2">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_930526x926068" id="id_4392741_D99B573C-62F1-4919-ACD3-004DEF67892E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table represents the percentage of all significant
 revenue earned in the periods indicated:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;
 &lt;b&gt;Year&amp;#xA0;Ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2013&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2012&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2011&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Servier&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Pfizer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Government Agencies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Eli Lilly&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
  <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_930526x932533" id="id_4392741_5C25CE43-9809-4695-9F05-5079B5C33DBF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table represents the percentage of all significant
 accounts receivable:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2013&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2012&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;53.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Pfizer.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Eli Lilly&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Servier&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Government Agencies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
  <mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_930809x1035519" unitRef="pure" decimals="3" id="id_4392741_CE5808A8-4461-468F-838B-41B5F0BBADC3_1002_1">0.040</mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_930809x1108152" unitRef="shares" decimals="INF" id="id_4392741_C90827D6-1A8C-4D88-8F73-39EC41C6CE77_1001_1">150297</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_930809x1218846" id="id_4392741_E10C6210-CDB6-4722-B93D-5B7FE8A31EE8_2001_1">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x1165094" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_BB48CF63-F973-425D-B658-1ED029F86EAF_1001_5">0.0522</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x1165094" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_6B0180B5-CB3B-4C4B-A1EC-F3DBD7E07A8F_1001_5">12.20</mgnx:ConvertiblePreferredStockConversionPrice>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x1184171" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_BB48CF63-F973-425D-B658-1ED029F86EAF_2001_0">0.08</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x1184171" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_6B0180B5-CB3B-4C4B-A1EC-F3DBD7E07A8F_2001_0">12.39</mgnx:ConvertiblePreferredStockConversionPrice>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x1218712" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_BB48CF63-F973-425D-B658-1ED029F86EAF_3001_1">0.08</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x1218712" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_6B0180B5-CB3B-4C4B-A1EC-F3DBD7E07A8F_3001_1">18.77</mgnx:ConvertiblePreferredStockConversionPrice>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x929177" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_BB48CF63-F973-425D-B658-1ED029F86EAF_4001_4">0.0522</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x929177" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_6B0180B5-CB3B-4C4B-A1EC-F3DBD7E07A8F_4001_4">12.20</mgnx:ConvertiblePreferredStockConversionPrice>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x930400" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_BB48CF63-F973-425D-B658-1ED029F86EAF_5001_3">0.0324</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x930400" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_6B0180B5-CB3B-4C4B-A1EC-F3DBD7E07A8F_5001_3">7.70</mgnx:ConvertiblePreferredStockConversionPrice>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x932774" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_BB48CF63-F973-425D-B658-1ED029F86EAF_6001_2">0.0341</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x932774" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4392741_6B0180B5-CB3B-4C4B-A1EC-F3DBD7E07A8F_6001_2">6.95</mgnx:ConvertiblePreferredStockConversionPrice>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_26C768FB-CF90-4BAA-BF23-75BC52989B62_1001_0">14400000</us-gaap:LicensesRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_0C3BE5E0-1948-4CEA-B45C-39051C69FFBA_1_0">5000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <mgnx:NonRefundableFees contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_94FD699B-92E5-447C-9EAC-689BBE2E7FC8_1_0">15000000</mgnx:NonRefundableFees>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1060404" id="id_4392741_B6F3765C-9874-42DD-8E27-78C82A383347_1_0">October 2010</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:PaymentReceivedOnCollaborationAgreement contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_0C3BE5E0-1948-4CEA-B45C-39051C69FFBA_1_1">48800000</mgnx:PaymentReceivedOnCollaborationAgreement>
  <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1060404" unitRef="Molecule" decimals="INF" id="id_4392741_B6F3765C-9874-42DD-8E27-78C82A383347_1_1">10</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations>
  <mgnx:NumberOfAnnualMaintenancePaymentReceived contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1060404" unitRef="Payments" decimals="INF" id="id_4392741_94FD699B-92E5-447C-9EAC-689BBE2E7FC8_1_1">3</mgnx:NumberOfAnnualMaintenancePaymentReceived>
  <mgnx:ResearchObligationCompletionDate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1060404" id="id_4392741_68EBE0A3-29CC-4105-8890-95B9262EA4F3_1_0">2015-09</mgnx:ResearchObligationCompletionDate>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1060690" unitRef="iso4217_USD" decimals="-5" id="id_4392741_6590BB29-0AB5-4D04-9524-904648945160_1_0">8000000</us-gaap:LicensesRevenue>
  <mgnx:NonRefundableFees contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1060690" unitRef="iso4217_USD" decimals="-5" id="id_4392741_27D9D216-2C99-4BAB-A64D-CFD17D02BBF1_1_0">7500000</mgnx:NonRefundableFees>
  <mgnx:UpfrontPaymentRecognitionPeriod contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1060690" id="id_4392741_12A67E73-6FD8-47C4-B825-120B59431F5C_1_0">P21M</mgnx:UpfrontPaymentRecognitionPeriod>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1060690" id="id_4392741_6EE19AAF-FCAC-44E0-ABF8-9107149E18E6_1_0">January 2013</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1060690" unitRef="Molecule" decimals="INF" id="id_4392741_6EE19AAF-FCAC-44E0-ABF8-9107149E18E6_1_1">4</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_4392741_D01EC999-9BD1-4960-9126-CF893CF7C81F_1003_0">100000</us-gaap:LicensesRevenue>
  <mgnx:NonRefundableFees contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1064508" unitRef="iso4217_USD" decimals="-5" id="id_4392741_C3ECECA6-3A94-410B-8A8D-77FC4FD67C23_1_0">1000000</mgnx:NonRefundableFees>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1064508" id="id_4392741_46C8EBB2-37B8-4DD5-9A99-9CB9A5474E5D_1001_0">June 2010</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:UpfrontFeeAndParticipationRecognitionDate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1064508" id="id_4392741_9E6D20FB-09D7-4E9C-A5E4-E2D80800EA83_1_0">2020-06</mgnx:UpfrontFeeAndParticipationRecognitionDate>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1115783" unitRef="iso4217_USD" decimals="-5" id="id_4392741_27A11E37-EF9E-45BE-8039-7680448EDCBE_1001_0">3500000</us-gaap:LicensesRevenue>
  <mgnx:NonRefundableFees contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1115783" unitRef="iso4217_USD" decimals="-5" id="id_4392741_E59158D1-3098-48A0-8CBB-5024D4703BF8_1001_0">5000000</mgnx:NonRefundableFees>
  <mgnx:NumberOfPrograms contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1115783" unitRef="Program" decimals="INF" id="id_4392741_AAD40A75-0A64-4212-B7C6-A45F1A9287DB_1_2">1</mgnx:NumberOfPrograms>
  <mgnx:ResearchObligationCompletionDate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1115783" id="id_4392741_AAD40A75-0A64-4212-B7C6-A45F1A9287DB_1_3">2014-01</mgnx:ResearchObligationCompletionDate>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1218715" unitRef="iso4217_USD" decimals="-5" id="id_4392741_799DDD92-BEEF-4A27-A6C7-D1FB6D2D3F0B_1001_0">800000</us-gaap:LicensesRevenue>
  <mgnx:NonRefundableFees contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1218715" unitRef="iso4217_USD" decimals="-5" id="id_4392741_1DD43E6A-D9A0-4B2A-B29B-5F7E8867F842_1001_1">41000000</mgnx:NonRefundableFees>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1218715" id="id_4392741_1DD43E6A-D9A0-4B2A-B29B-5F7E8867F842_1001_0">October 2007</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_5AB24DD1-CBE5-4221-82E3-83BB44B842C9_1003_0">21300000</us-gaap:LicensesRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_5AB24DD1-CBE5-4221-82E3-83BB44B842C9_1003_1">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <mgnx:NonRefundableFees contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_8A02712C-A8E7-4986-9C8B-47D8D977B83C_1_0">20000000</mgnx:NonRefundableFees>
  <mgnx:UpfrontPaymentRecognitionPeriod contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1218879" id="id_4392741_ABAD5EDF-8FB2-43D8-9906-C2DBD48CCE33_1001_0">P27M</mgnx:UpfrontPaymentRecognitionPeriod>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1218879" id="id_4392741_142E7A00-2666-4F87-BADA-AE388B30324F_1001_0">November 2011</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="shares" decimals="INF" id="id_4392741_AC85ED78-12A8-4CD3-B02C-03D641A84259_3_3">545970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="pure" decimals="4" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_4_2">0.0118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_2_12">0.00</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="shares" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_2_14">1083276</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_4_1">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="shares" xsi:nil="true" id="id_4392741_183E1637-EBCC-4160-B5CE-05609DD8F75A_2_9" />
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_2_11">0.00</us-gaap:EarningsPerShareBasic>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" id="id_4392741_270395C1-5D83-4486-AC1A-BC061980F66C_1_1">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_4_3">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="pure" decimals="4" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_4_4">0.0557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_B4806FB3-A6F3-4580-B871-953BDED216A5_2_0">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_4392741_D14188B6-EBE5-4506-926A-4FAA8884E1F4_4_0">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_16">-6581989</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="shares" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_2_13">1083276</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="shares" decimals="INF" id="id_4392741_705AF870-30A3-4F00-8004-997561CC59CF_2_0">863176</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_F9A30717-4680-4175-802C-E2667C5D9848_2_2" />
  <us-gaap:Revenues contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_2_3">63826098</us-gaap:Revenues>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F9A30717-4680-4175-802C-E2667C5D9848_2_1">58371</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_B4806FB3-A6F3-4580-B871-953BDED216A5_2_3">879024</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_2_9">156445</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_6019_2200012">46826</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:IncomeTaxReconciliationTaxCreditsOther contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_2_5">4895671</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_10">-780</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:RevenueFromGrants contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_2_2">4180279</us-gaap:RevenueFromGrants>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_2_8">8205310</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_8">91160</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_7">-1351650</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_2_10">8361755</us-gaap:NetIncomeLoss>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_6019_2200011">838395</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_9">-177321</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_18">940043</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_2_1">59645819</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_5">-150695</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_2_6">7627</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
  <us-gaap:CostsAndExpenses contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_2_7">55620788</us-gaap:CostsAndExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_2_6">10187894</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_23">46826</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_2_9">787093</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_28" />
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_14">-10810089</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_4">838395</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_24">-7475206</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_2_7">279165</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_7F4975E7-3665-4A2A-A2A5-A01BCA38E8CC_2_5">2700000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_2534C117-6C12-4706-AE87-42F13BC8D088_2_1">225195</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_12">185200</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_2_1">1460289</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_11">-7312331</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_22">46826</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_2_0">2926615</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_19">-940043</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_F65C283B-AD29-4811-AD09-3E376A277AEA_2_5">45432894</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_705AF870-30A3-4F00-8004-997561CC59CF_2_1">46826</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:UndistributedEarningsAllocatedToParticipatingSecurities contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_183E1637-EBCC-4160-B5CE-05609DD8F75A_2_1">8361755</us-gaap:UndistributedEarningsAllocatedToParticipatingSecurities>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_4392741_2AB81895-1302-441A-A31D-C7EC1872EA7A_2_0">1000000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_13">-533560</us-gaap:IncreaseDecreaseInRestructuringReserve>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E175397-B9E7-4CA3-B8E7-3E8763BA259E_2_0">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarnings contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_183E1637-EBCC-4160-B5CE-05609DD8F75A_2_6">8361755</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarnings>
  <us-gaap:Depreciation contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_3">959930</us-gaap:Depreciation>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_549F0920-A988-488D-844F-4D30ED54305E_2_2">838395</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_11803776-7675-481C-8EB5-0C29096DAC88_2_0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_F9A30717-4680-4175-802C-E2667C5D9848_2_3" />
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_2_10" />
  <mgnx:IncreaseDecreaseInDeferredRent contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_5E93DA0E-EFD2-4F0D-B647-9FCCF4BD3713_2_15">440815</mgnx:IncreaseDecreaseInDeferredRent>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="shares" decimals="INF" id="id_4392741_AC85ED78-12A8-4CD3-B02C-03D641A84259_3_4">4336730</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
  <mgnx:IncomeTaxReconciliationDeferredTaxAdjustments contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_2_2">-512375</mgnx:IncomeTaxReconciliationDeferredTaxAdjustments>
  <mgnx:LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" id="id_4392741_F2224985-589C-4748-BA67-BAE0E547E393_2_0">P3M</mgnx:LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum>
  <mgnx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_B4806FB3-A6F3-4580-B871-953BDED216A5_2_1">271929</mgnx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue>
  <mgnx:IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_26EE8B3E-B225-4B33-BC48-20F88ACCA153_2_8">-52743</mgnx:IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability>
  <mgnx:ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_4392741_882EB5C9-2193-4F8D-AA5F-002F3EC8066A_2_0">0</mgnx:ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense>
  <us-gaap:PaymentsForRestructuring contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_4392741_3E51796F-7DCB-4DF3-8828-3D26324309E0_4001_2">533560</us-gaap:PaymentsForRestructuring>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927015x925832" unitRef="iso4217_USD" decimals="0" id="id_4392741_549F0920-A988-488D-844F-4D30ED54305E_1002_1">366586</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927015x928963" unitRef="iso4217_USD" decimals="0" id="id_4392741_549F0920-A988-488D-844F-4D30ED54305E_2002_0">471809</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1060404_931007x926523" unitRef="pure" decimals="3" id="id_4392741_E7C36D1D-B4CB-4CC6-BAE1-C1DBAE88DEFD_1002_2">0.180</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1060404_931007x926597" unitRef="pure" decimals="3" id="id_4392741_07351A92-03EF-47D3-9A19-3B35431148A1_1002_1">0.184</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1060690_931007x926523" unitRef="pure" xsi:nil="true" id="id_4392741_E7C36D1D-B4CB-4CC6-BAE1-C1DBAE88DEFD_2002_0" />
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1074019_931007x926523" unitRef="pure" decimals="3" id="id_4392741_E7C36D1D-B4CB-4CC6-BAE1-C1DBAE88DEFD_3002_5">0.084</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1074019_931007x926597" unitRef="pure" decimals="3" id="id_4392741_07351A92-03EF-47D3-9A19-3B35431148A1_3002_4">0.065</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1115783_931007x926523" unitRef="pure" decimals="3" id="id_4392741_E7C36D1D-B4CB-4CC6-BAE1-C1DBAE88DEFD_4002_1">0.454</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1115783_931007x926597" unitRef="pure" decimals="3" id="id_4392741_07351A92-03EF-47D3-9A19-3B35431148A1_4002_3">0.087</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1218715_931007x926523" unitRef="pure" decimals="3" id="id_4392741_E7C36D1D-B4CB-4CC6-BAE1-C1DBAE88DEFD_5002_3">0.282</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1218715_931007x926597" unitRef="pure" decimals="3" id="id_4392741_07351A92-03EF-47D3-9A19-3B35431148A1_5002_5">0.489</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1218717_931007x926523" unitRef="pure" xsi:nil="true" id="id_4392741_E7C36D1D-B4CB-4CC6-BAE1-C1DBAE88DEFD_6002_4" />
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1218717_931007x926597" unitRef="pure" decimals="3" id="id_4392741_07351A92-03EF-47D3-9A19-3B35431148A1_6002_0">0.173</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927592x929313" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_6018_2100014">8361755</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927592x930643" unitRef="shares" decimals="INF" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_6013_1600013">49884</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927592x930643" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_6013_1700012">499</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927592x932586" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_6017_2000012">46327</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_927592x932586" unitRef="iso4217_USD" decimals="0" id="id_4392741_3A652EA5-8982-4F29-A10C-3F03823BB9FE_6017_2000011">838395</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_8C56D4C8-8186-4803-95FF-A5E2A4D52196_1002_0">2000000</us-gaap:LicensesRevenue>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x1031975" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_1002_3">5909906</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x1124615" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_2002_2">4336037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x1166280" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_3002_0">2156114</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x1166416" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_4002_1">392274</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x1218718" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_5002_5">3391991</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x924898" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_6002_8">3249702</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x929614" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_7002_7">180784</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x932377" unitRef="shares" xsi:nil="true" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_8002_6" />
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x997107" unitRef="shares" decimals="INF" id="id_4392741_3A82B124-9A8D-469E-9E71-BE30D94B96AA_9002_4">769468</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_26C768FB-CF90-4BAA-BF23-75BC52989B62_1002_0">11700000</us-gaap:LicensesRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_4392741_26C768FB-CF90-4BAA-BF23-75BC52989B62_1002_1">2000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_4392741_D01EC999-9BD1-4960-9126-CF893CF7C81F_1002_0">100000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_933025x1115783" unitRef="iso4217_USD" decimals="-5" id="id_4392741_27A11E37-EF9E-45BE-8039-7680448EDCBE_1002_0">5500000</us-gaap:LicensesRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_933025x1115783" unitRef="iso4217_USD" decimals="0" id="id_4392741_27A11E37-EF9E-45BE-8039-7680448EDCBE_1002_1">500000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_933025x1218715" unitRef="iso4217_USD" decimals="-5" id="id_4392741_799DDD92-BEEF-4A27-A6C7-D1FB6D2D3F0B_1002_0">31200000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-K0007_STD_366_20121231_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_4392741_5AB24DD1-CBE5-4221-82E3-83BB44B842C9_1002_0">9100000</us-gaap:LicensesRevenue>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-K0007_STD_730_20031231_0_932980x930435" unitRef="shares" decimals="INF" id="id_4392741_78BA309E-1A89-41B6-81DD-C761DFD62F26_1001_0">34239374</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE179294--1310-K0007_STD_730_20031231_0_932980x930435" unitRef="iso4217_USD" decimals="-5" id="id_4392741_78BA309E-1A89-41B6-81DD-C761DFD62F26_1001_1">34000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1310-K0007_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_FBF33EAD-9194-4BA9-9097-0147C607FFC9_1_3">-2.93</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1310-K0007_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_FBF33EAD-9194-4BA9-9097-0147C607FFC9_1_2">-2.93</us-gaap:EarningsPerShareBasic>
  <us-gaap:Revenues contextRef="eol_PE179294--1310-K0007_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_FBF33EAD-9194-4BA9-9097-0147C607FFC9_1_0">10598000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_FBF33EAD-9194-4BA9-9097-0147C607FFC9_1_1">-3366000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1310-K0007_STD_91_20120331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_3C9D4BFD-1E40-4C87-AC06-B28891269EB3_1_3">0.00</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1310-K0007_STD_91_20120331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_3C9D4BFD-1E40-4C87-AC06-B28891269EB3_1_2">0.00</us-gaap:EarningsPerShareBasic>
  <us-gaap:Revenues contextRef="eol_PE179294--1310-K0007_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_3C9D4BFD-1E40-4C87-AC06-B28891269EB3_1_0">20510000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_3C9D4BFD-1E40-4C87-AC06-B28891269EB3_1_1">4320000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1310-K0007_STD_91_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_3C9D4BFD-1E40-4C87-AC06-B28891269EB3_2_3">0.00</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1310-K0007_STD_91_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_3C9D4BFD-1E40-4C87-AC06-B28891269EB3_2_2">0.00</us-gaap:EarningsPerShareBasic>
  <us-gaap:Revenues contextRef="eol_PE179294--1310-K0007_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_3C9D4BFD-1E40-4C87-AC06-B28891269EB3_2_0">17435000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_3C9D4BFD-1E40-4C87-AC06-B28891269EB3_2_1">3546000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1310-K0007_STD_91_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_FBF33EAD-9194-4BA9-9097-0147C607FFC9_2_3">-0.24</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1310-K0007_STD_91_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_FBF33EAD-9194-4BA9-9097-0147C607FFC9_2_2">-0.24</us-gaap:EarningsPerShareBasic>
  <us-gaap:Revenues contextRef="eol_PE179294--1310-K0007_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_FBF33EAD-9194-4BA9-9097-0147C607FFC9_2_0">12299000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_FBF33EAD-9194-4BA9-9097-0147C607FFC9_2_1">-294000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1310-K0007_STD_92_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_3C9D4BFD-1E40-4C87-AC06-B28891269EB3_3_3">0.00</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1310-K0007_STD_92_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_3C9D4BFD-1E40-4C87-AC06-B28891269EB3_3_2">0.00</us-gaap:EarningsPerShareBasic>
  <us-gaap:Revenues contextRef="eol_PE179294--1310-K0007_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_3C9D4BFD-1E40-4C87-AC06-B28891269EB3_3_0">16082000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_3C9D4BFD-1E40-4C87-AC06-B28891269EB3_3_1">2601000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1310-K0007_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_FBF33EAD-9194-4BA9-9097-0147C607FFC9_3_3">0.01</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1310-K0007_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_FBF33EAD-9194-4BA9-9097-0147C607FFC9_3_2">0.14</us-gaap:EarningsPerShareBasic>
  <us-gaap:Revenues contextRef="eol_PE179294--1310-K0007_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_FBF33EAD-9194-4BA9-9097-0147C607FFC9_3_0">20232000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_FBF33EAD-9194-4BA9-9097-0147C607FFC9_3_1">6604000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1310-K0007_STD_92_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_3C9D4BFD-1E40-4C87-AC06-B28891269EB3_4_3">-1.92</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1310-K0007_STD_92_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_3C9D4BFD-1E40-4C87-AC06-B28891269EB3_4_2">-1.92</us-gaap:EarningsPerShareBasic>
  <us-gaap:Revenues contextRef="eol_PE179294--1310-K0007_STD_92_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_3C9D4BFD-1E40-4C87-AC06-B28891269EB3_4_0">9799000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_92_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_3C9D4BFD-1E40-4C87-AC06-B28891269EB3_4_1">-2105000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1310-K0007_STD_92_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_FBF33EAD-9194-4BA9-9097-0147C607FFC9_4_3">-0.14</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1310-K0007_STD_92_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4392741_FBF33EAD-9194-4BA9-9097-0147C607FFC9_4_2">-0.14</us-gaap:EarningsPerShareBasic>
  <us-gaap:Revenues contextRef="eol_PE179294--1310-K0007_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_FBF33EAD-9194-4BA9-9097-0147C607FFC9_4_0">14906000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-K0007_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4392741_FBF33EAD-9194-4BA9-9097-0147C607FFC9_4_1">-3205000</us-gaap:NetIncomeLoss>
  <context id="eol_PE179294--1310-K0007_STD_92_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_92_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_92_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_92_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_91_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_91_20120630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_91_20120331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_90_20130331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_730_20031231_0_932980x930435">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2002-01-01</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_933025x1218715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_933025x1115783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_933025x1064508">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_933025x1060404">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x997107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x932377">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x1218718">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x1166416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x1166280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x1124615">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_928305x1031975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_928294x1218880_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1218717_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1218717_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1218715_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1218715_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1115783_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1115783_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1074019_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:USGovernmentAgenciesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1074019_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:USGovernmentAgenciesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1060690_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1060404_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_927195x1060404_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0_926911x929956">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_366_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1218715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1115783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1064508">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1060690">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_933025x1060404">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x932774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x930400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x929177">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x1218712">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesATwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x1184171">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesAOnePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_932980x1165094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesDTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_930809x1218846">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlanTwoThousandThreeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_930809x1108152">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockOptionPlan2000Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_930809x1035519">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_930526x932533">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_930526x926068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_929865x932226">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_929865x931760">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_929865x931666">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_929865x923325">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_929865x1203065">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x997107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x932377">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x1218718">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x1166416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x1166280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x1124615">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_928305x1031975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_928294x1218880_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1225370">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesD1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1218718">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1166416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1166280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1124615">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927592x1031975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1218717_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1218717_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1218715_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1218715_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1115783_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1115783_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1074019_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:USGovernmentAgenciesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1074019_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:USGovernmentAgenciesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1060690_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1060690_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1060404_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927195x1060404_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_926911x929956">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_926437x932953">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_926437x923140_930809x1218846">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlanTwoThousandThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_926437x923140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_926233x928673_933025x1060690">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_926233x1241818_933025x1060690">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ExpiredOptionAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_926233x1150658_933025x1060690">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:OptionAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_925378x989577_932294x1237431">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">mgnx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SaleLeasebackTransactionDescriptionAxis">mgnx:SubleaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_925378x1075325_932294x954146">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">mgnx:ManufacturingFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SaleLeasebackTransactionDescriptionAxis">mgnx:LeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0_925378x1075325_932294x1237431">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">mgnx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SaleLeasebackTransactionDescriptionAxis">mgnx:LeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_933025x1218715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_933025x1115783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_933025x1064508">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_933025x1060404">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x997107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x932377">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x1218718">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x1166416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x1166280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x1124615">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_928305x1031975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_927592x1218718">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_927195x1218715_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_927195x1115783_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_927195x1074019_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:USGovernmentAgenciesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_927195x1060404_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_365_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_31_20100531_0_933025x1218715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-05-01</startDate>
      <endDate>2010-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_31_20080531_0_933025x1218715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-05-01</startDate>
      <endDate>2008-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_31_20110331_0_928576x1218824_932980x929177">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mgnx:RavenBiotechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-03-01</startDate>
      <endDate>2011-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_31_20110131_0_932980x1218718_933025x1060404">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_31_20101031_0_933025x1115783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-10-01</startDate>
      <endDate>2010-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_30_20101028_0_933025x1218715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-09-29</startDate>
      <endDate>2010-10-28</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_30_20080716_0_932980x1010406">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:ConvertiblePreferredStockSeriesDMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-06-17</startDate>
      <endDate>2008-07-16</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_30_20080716_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2008-06-17</startDate>
      <endDate>2008-07-16</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_30_20050630_0_926437x932953">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-06-01</startDate>
      <endDate>2005-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_30_20050630_0_926437x923140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-06-01</startDate>
      <endDate>2005-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_21_20140228_0_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-02-08</startDate>
      <endDate>2014-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_21_20140228_0_921954x1218717_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-02-08</startDate>
      <endDate>2014-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_2_20110111_0_928305x1218718">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-10</startDate>
      <endDate>2011-01-11</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_2_20131016_0_931707x926487">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-15</startDate>
      <endDate>2013-10-16</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_2_20080919_0_932980x1165094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesDTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-09-18</startDate>
      <endDate>2008-09-19</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_2_20041012_0_932980x932774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2004-10-11</startDate>
      <endDate>2004-10-12</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_2_20020925_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2002-09-24</startDate>
      <endDate>2002-09-25</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_2_20080716_0_928576x1218824_932980x929177">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mgnx:RavenBiotechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-07-15</startDate>
      <endDate>2008-07-16</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_2_20110316_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2011-03-15</startDate>
      <endDate>2011-03-16</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_2_20100516_0_932980x1165094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesDTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-05-15</startDate>
      <endDate>2010-05-16</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_2_20060516_0_932980x930400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2006-05-15</startDate>
      <endDate>2006-05-16</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_1826_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_1096_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1115783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1064508">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1060690">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_933025x1060404">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x932774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x930400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x929177">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x1218712">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesATwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x1184171">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesAOnePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x1165094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesDTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_932980x1135605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_932628x926821">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_932628x924673">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_930809x1108152">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockOptionPlan2000Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_930809x1047151">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandAndThreeStockOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_930809x1035519">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_929865x932226">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_929865x931760">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_929865x929134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_929865x928802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_929865x923325">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_929865x923192">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_929790x929831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_929790x925851">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_928294x1218880_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_927592x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_927592x924490">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_926911x929956">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_926437x932953_933025x1060690">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_926437x932953">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_926437x923140_933025x1060690">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0_926437x923140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_933025x1115783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_933025x1064508">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_933025x1060404">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1225370">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesD1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1218718">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1166416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1166280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1124615">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_932980x1031975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_929865x932226">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_929865x931760">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_929865x929134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_929865x928802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_929865x923325">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_929865x923192">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x929831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x925851">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_928294x1218880_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x924490">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1225370">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesD1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1218718">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1166416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1166280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1124615">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_927592x1031975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0_926911x929956">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x924490">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1225370">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesD1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1218718">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1166416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1166280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1124615">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20111231_0_927592x1031975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20111231_0_926911x929956">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x924490">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1225370">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesD1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1218718">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1166416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1166280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1124615">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20101231_0_927592x1031975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20031231_0_932980x930435">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131016_0_931707x926487">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20080919_0_932980x1165094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesDTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-09-19</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20041012_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2004-10-12</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20080716_0_926437x932953">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-07-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20080716_0_926437x923140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-07-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20080716_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2008-07-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20050630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2005-06-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20110316_0_929038x972906_930917x978903">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">mgnx:OriginalOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mgnx:StockOptionOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-03-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20110316_0_929038x1089823_930917x978903">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">mgnx:OriginalOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mgnx:StockOptionTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-03-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20110316_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2011-03-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20140228_0_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-02-28</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20140228_0_921954x1218717_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-02-28</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20140228_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2014-02-28</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20131031_0_930809x1035519">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20100516_0_932980x1165094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesDTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-05-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20060516_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2006-05-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-K0007_STD_0_20030228_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2003-02-28</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_USD_per_Warrant">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>mgnx:Warrant</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="Age">
    <measure>mgnx:Age</measure>
  </unit>
  <unit id="Molecule">
    <measure>mgnx:Molecule</measure>
  </unit>
  <unit id="Segment">
    <measure>mgnx:Segment</measure>
  </unit>
  <unit id="Program">
    <measure>mgnx:Program</measure>
  </unit>
  <unit id="Payments">
    <measure>mgnx:Payments</measure>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>mgnx-20131231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2014-03-18T16:29:55Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31"
  xmlns:us-types="http://fasb.org/us-types/2013-01-31"
  xmlns:mgnx="http://www.macrogenics.com/20131231"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://www.macrogenics.com/20131231"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative" id="Role_StatementOfIncomeAlternative">
        <link:definition>105 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>106 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>107 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <link:definition>108 - Disclosure - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>109 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
        <link:definition>110 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>111 - Disclosure - Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>112 - Disclosure - Shared-Based Payments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock" id="Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock">
        <link:definition>114 - Disclosure - Lease Exit Liability</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock">
        <link:definition>115 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>116 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock" id="Role_NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock">
        <link:definition>117 - Disclosure - Product Milestone Payments and Royalty Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <link:definition>118 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" id="Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
        <link:definition>119 - Disclosure - Quarterly Financial Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>120 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>121 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
        <link:definition>122 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
        <link:definition>123 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>124 - Disclosure - Shared-Based Payments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
        <link:definition>125 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables">
        <link:definition>126 - Disclosure - Lease Exit Liability (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
        <link:definition>127 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" id="Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
        <link:definition>128 - Disclosure - Quarterly Financial Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation" id="DisclosureOrganizationAndNatureOfOperationsAdditionalInformation">
        <link:definition>129 - Disclosure - Organization and Nature of Operations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>130 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities">
        <link:definition>131 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability">
        <link:definition>132 - Disclosure - Summary of Significant Accounting Policies - Summary of Preferred Stock Warrant Liability (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue">
        <link:definition>133 - Disclosure - Summary of Significant Accounting Policies - Summary of Percentage of Significant Revenue (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable">
        <link:definition>134 - Disclosure - Summary of Significant Accounting Policies - Summary of Significant Accounts Receivable (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives" id="DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives">
        <link:definition>135 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare" id="DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare">
        <link:definition>136 - Disclosure - Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Common Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesUsedInCalculationOfDilutedEarningsPerShare" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesUsedInCalculationOfDilutedEarningsPerShare">
        <link:definition>137 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities Used In Calculation of Diluted Earnings Per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment" id="DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment">
        <link:definition>138 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation" id="DisclosurePropertyAndEquipmentAdditionalInformation">
        <link:definition>139 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformation" id="DisclosureStockholdersEquityDeficitAdditionalInformation">
        <link:definition>140 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsAdditionalInformation" id="DisclosureSharedBasedPaymentsAdditionalInformation">
        <link:definition>141 - Disclosure - Shared-Based Payments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense" id="DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense">
        <link:definition>142 - Disclosure - Shared-Based Payments - Schedule of Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel" id="DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel">
        <link:definition>143 - Disclosure - Shared-Based Payments - Schedule of Fair Value Option Award Estimated on the Date of Grant Using the Black-Scholes Option-Pricing Model (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity" id="DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity">
        <link:definition>144 - Disclosure - Shared-Based Payments - Schedule of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation" id="DisclosureIncomeTaxesAdditionalInformation">
        <link:definition>145 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities" id="DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities">
        <link:definition>146 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit" id="DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit">
        <link:definition>147 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits" id="DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits">
        <link:definition>148 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation" id="DisclosureLeaseExitLiabilityAdditionalInformation">
        <link:definition>149 - Disclosure - Lease Exit Liability - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability" id="DisclosureLeaseExitLiabilityChangesInLeaseExitLiability">
        <link:definition>150 - Disclosure - Lease Exit Liability - Changes in Lease Exit Liability (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement" id="DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement">
        <link:definition>151 - Disclosure - Lease Exit Liability - Future Principal Payments under Lease Agreement (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation" id="DisclosureCollaborationAndLicenseAgreementsAdditionalInformation">
        <link:definition>152 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation">
        <link:definition>153 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable" id="DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable">
        <link:definition>154 - Disclosure - Commitments and Contingencies - Schedule of Minimum Future Lease Payments Receivable (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation" id="DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation">
        <link:definition>155 - Disclosure - Product Milestone Payments and Royalty Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation" id="DisclosureEmployeeBenefitPlanAdditionalInformation">
        <link:definition>156 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations" id="DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations">
        <link:definition>157 - Disclosure - Quarterly Financial Information - Company's Consolidated Quarterly Results of Operations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation" id="DisclosureSubsequentEventsAdditionalInformation">
        <link:definition>158 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="mgnx-20131231_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="mgnx-20131231_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="mgnx-20131231_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="mgnx-20131231_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2013-01-31" schemaLocation="http://xbrl.sec.gov/exch/2013/exch-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement" id="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalClinicalMilestonePaymentsUnderAgreement" id="mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement" id="mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalCommonStockIssuePricePerShare" id="mgnx_AdditionalCommonStockIssuePricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalLicenseGrantFeesUnderAgreement" id="mgnx_AdditionalLicenseGrantFeesUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPaymentUponAchievementOfMilestone" id="mgnx_AdditionalPaymentUponAchievementOfMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance" id="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalRegulatoryMilestonePaymentsUnderAgreement" id="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalSalesMilestonesUnderAgreement" id="mgnx_AdditionalSalesMilestonesUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmountOfAdditionalConsiderationPaidUnderAgreement" id="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BoehringerIngelheimMember" id="mgnx_BoehringerIngelheimMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClinicalDataReviewPeriodForAgreementTermination" id="mgnx_ClinicalDataReviewPeriodForAgreementTermination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAndLicenseAgreementEnteredDate" id="mgnx_CollaborationAndLicenseAgreementEnteredDate" type="us-types:dateStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAndLicenseAgreementsDisclosureTextBlock" id="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborativeAgreementPeriodOfContract" id="mgnx_CollaborativeAgreementPeriodOfContract" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" id="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertiblePreferredStockConversionPrice" id="mgnx_ConvertiblePreferredStockConversionPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertiblePreferredStockSeriesDMember" id="mgnx_ConvertiblePreferredStockSeriesDMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" id="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="mgnx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EliLillyMember" id="mgnx_EliLillyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeEligibleAgeToParticipateInBenefitPlan" id="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EquityIncentivePlanTwoThousandThreeMember" id="mgnx_EquityIncentivePlanTwoThousandThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExpiredOptionAgreementMember" id="mgnx_ExpiredOptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd" id="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart" id="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FutureMinimumLeasesPaymentsUnderLeasesLineItems" id="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FutureMinimumLeasesPaymentsUnderLeasesTable" id="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="GileadSciencesIncMember" id="mgnx_GileadSciencesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GreenCrossCorporationMember" id="mgnx_GreenCrossCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxesDisclosureLineItems" id="mgnx_IncomeTaxesDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxesDisclosureTable" id="mgnx_IncomeTaxesDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="IncomeTaxExaminationYearUnderExaminationRangeEnd" id="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxExaminationYearUnderExaminationRangeStart" id="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxReconciliationDeferredTaxAdjustments" id="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" id="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxReconciliationStateDeferredTaxesAdjustments" id="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInDeferredRent" id="mgnx_IncreaseDecreaseInDeferredRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LaboratoryAndOfficeEquipmentMember" id="mgnx_LaboratoryAndOfficeEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeaseExpirationYear" id="mgnx_LeaseExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeaseMember" id="mgnx_LeaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LesLaboratoiresServierMember" id="mgnx_LesLaboratoiresServierMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsLineItems" id="mgnx_LicenseAndCollaborationAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsTable" id="mgnx_LicenseAndCollaborationAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum" id="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ManufacturingFacilitiesMember" id="mgnx_ManufacturingFacilitiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MoneyMarketFundsFairValueDisclosure" id="mgnx_MoneyMarketFundsFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonRefundableFees" id="mgnx_NonRefundableFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfAnnualMaintenancePaymentReceived" id="mgnx_NumberOfAnnualMaintenancePaymentReceived" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" id="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" id="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfPrograms" id="mgnx_NumberOfPrograms" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OfficeAndLaboratorySpaceMember" id="mgnx_OfficeAndLaboratorySpaceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OnetimeMilestonePaymentToBePaidUnderAgreement" id="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" id="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLeasesLineItems" id="mgnx_OperatingLeasesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLeasesTable" id="mgnx_OperatingLeasesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="OperatingLossCarryforwardsAnnualLimitationAmount" id="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossCarryforwardsLimitationsOnUseAmount" id="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossCarryforwardsLimitationsOnUseYearEnd" id="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossCarryforwardsLimitationsOnUseYearStart" id="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossCarryforwardsNotSubjectToLimitation" id="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OptionAgreementMember" id="mgnx_OptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationAndNatureOfBusinessLineItems" id="mgnx_OrganizationAndNatureOfBusinessLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationAndNatureOfBusinessTable" id="mgnx_OrganizationAndNatureOfBusinessTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="OriginalOptionsMember" id="mgnx_OriginalOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentReceivedOnCollaborationAgreement" id="mgnx_PaymentReceivedOnCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority" id="mgnx_PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" id="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PfizerIncMember" id="mgnx_PfizerIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses" id="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" id="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" id="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RavenBiotechnologiesIncMember" id="mgnx_RavenBiotechnologiesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchObligationCompletionDate" id="mgnx_ResearchObligationCompletionDate" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RestrictedCashFairValueDisclosure" id="mgnx_RestrictedCashFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReviewPeriodByRegulatoryAuthority" id="mgnx_ReviewPeriodByRegulatoryAuthority" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyAgreementDisclosureTextBlock" id="mgnx_RoyaltyAgreementDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyAgreementLineItems" id="mgnx_RoyaltyAgreementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyAgreementTable" id="mgnx_RoyaltyAgreementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" id="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SecondRightToDevelopCollaborationMember" id="mgnx_SecondRightToDevelopCollaborationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesA1ConvertiblePreferredStockMember" id="mgnx_SeriesA1ConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesA2ConvertiblePreferredStockMember" id="mgnx_SeriesA2ConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesAOnePreferredStockMember" id="mgnx_SeriesAOnePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesATwoPreferredStockMember" id="mgnx_SeriesATwoPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesBConvertiblePreferredStockMember" id="mgnx_SeriesBConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesCConvertiblePreferredStockMember" id="mgnx_SeriesCConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesD1ConvertiblePreferredStockMember" id="mgnx_SeriesD1ConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesD2ConvertiblePreferredStockMember" id="mgnx_SeriesD2ConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesDConvertiblePreferredStockMember" id="mgnx_SeriesDConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesDTwoPreferredStockMember" id="mgnx_SeriesDTwoPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ServierMember" id="mgnx_ServierMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged" id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue" id="mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockholdersEquityLineItems" id="mgnx_StockholdersEquityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockholdersEquityTable" id="mgnx_StockholdersEquityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="StockIssuanceCosts" id="mgnx_StockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment" id="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" id="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockOptionExchangeRatioDescription" id="mgnx_StockOptionExchangeRatioDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockOptionOneMember" id="mgnx_StockOptionOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockOptionPlan2000Member" id="mgnx_StockOptionPlan2000Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockOptionTwoMember" id="mgnx_StockOptionTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SubleaseMember" id="mgnx_SubleaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TaxCreditCarryforwardExpirationYearRangeEnd" id="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TaxCreditCarryforwardExpirationYearRangeStart" id="mgnx_TaxCreditCarryforwardExpirationYearRangeStart" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandAndThirteenStockIncentivePlanMember" id="mgnx_TwoThousandAndThirteenStockIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandAndThreeStockOptionPlanMember" id="mgnx_TwoThousandAndThreeStockOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UndesignatedPreferredStockMember" id="mgnx_UndesignatedPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontFeeAndParticipationRecognitionDate" id="mgnx_UpfrontFeeAndParticipationRecognitionDate" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontPaymentRecognitionPeriod" id="mgnx_UpfrontPaymentRecognitionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="USGovernmentAgenciesMember" id="mgnx_USGovernmentAgenciesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>mgnx-20131231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2014-03-18T16:29:55Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DocumentandEntityInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureOrganizationAndNatureOfOperationsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesUsedInCalculationOfDilutedEarningsPerShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesUsedInCalculationOfDilutedEarningsPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureStockholdersEquityDeficitAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSharedBasedPaymentsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureLeaseExitLiabilityAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureLeaseExitLiabilityChangesInLeaseExitLiability" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureEmployeeBenefitPlanAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="us-gaap_RestructuringReserveNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_RestructuringReserveNoncurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_RestructuringReserveCurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromGrants" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncreaseDecreaseInDeferredRent" xlink:label="mgnx_IncreaseDecreaseInDeferredRent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInRestructuringReserve" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="mgnx_IncreaseDecreaseInDeferredRent" order="1.1300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_MoneyMarketFundsFairValueDisclosure" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RestrictedCashFairValueDisclosure" xlink:label="mgnx_RestrictedCashFairValueDisclosure"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="mgnx_MoneyMarketFundsFairValueDisclosure" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="mgnx_RestrictedCashFairValueDisclosure" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities" xlink:label="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLoss" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesUsedInCalculationOfDilutedEarningsPerShare">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0300" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1.1300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1000" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" xlink:label="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" xlink:label="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" xlink:label="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.1000" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>mgnx-20131231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2014-03-18T16:29:55Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DocumentandEntityInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureOrganizationAndNatureOfOperationsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesUsedInCalculationOfDilutedEarningsPerShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesUsedInCalculationOfDilutedEarningsPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureStockholdersEquityDeficitAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSharedBasedPaymentsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureLeaseExitLiabilityAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureLeaseExitLiabilityChangesInLeaseExitLiability" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureEmployeeBenefitPlanAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="us-gaap_RestructuringReserveNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD1ConvertiblePreferredStockMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_RestructuringReserveNoncurrent" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_RestructuringReserveCurrent" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockNumberOfSharesHeld" xlink:label="us-gaap_TreasuryStockNumberOfSharesHeld"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD1ConvertiblePreferredStockMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockNumberOfSharesHeld" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesD1ConvertiblePreferredStockMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalCommonStockIssuePricePerShare" xlink:label="mgnx_AdditionalCommonStockIssuePricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:label="mgnx_OrganizationAndNatureOfBusinessLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OrganizationAndNatureOfBusinessTable" xlink:label="mgnx_OrganizationAndNatureOfBusinessTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses" xlink:label="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment" xlink:label="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="mgnx_OrganizationAndNatureOfBusinessTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="mgnx_AdditionalCommonStockIssuePricePerShare" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_OrganizationAndNatureOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_MoneyMarketFundsFairValueDisclosure" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RestrictedCashFairValueDisclosure" xlink:label="mgnx_RestrictedCashFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="mgnx_MoneyMarketFundsFairValueDisclosure" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="mgnx_RestrictedCashFairValueDisclosure" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="1.1000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue">
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_USGovernmentAgenciesMember" xlink:label="mgnx_USGovernmentAgenciesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_MajorCustomersAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_ServierMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_GileadSciencesIncMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_PfizerIncMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_USGovernmentAgenciesMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_EliLillyMember" order="1.0600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_USGovernmentAgenciesMember" xlink:label="mgnx_USGovernmentAgenciesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_MajorCustomersAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_GileadSciencesIncMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_PfizerIncMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_EliLillyMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_ServierMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_USGovernmentAgenciesMember" order="1.0600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mgnx_LaboratoryAndOfficeEquipmentMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesUsedInCalculationOfDilutedEarningsPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesDConvertiblePreferredStockMember" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesDConvertiblePreferredStockMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ConvertiblePreferredStockConversionPrice" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="mgnx_RavenBiotechnologiesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesAOnePreferredStockMember" xlink:label="mgnx_SeriesAOnePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesATwoPreferredStockMember" xlink:label="mgnx_SeriesATwoPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesDTwoPreferredStockMember" xlink:label="mgnx_SeriesDTwoPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockholdersEquityLineItems" xlink:label="mgnx_StockholdersEquityLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockholdersEquityTable" xlink:label="mgnx_StockholdersEquityTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockIssuanceCosts" xlink:label="mgnx_StockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_UndesignatedPreferredStockMember" xlink:label="mgnx_UndesignatedPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="mgnx_RavenBiotechnologiesIncMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesAOnePreferredStockMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesATwoPreferredStockMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesDTwoPreferredStockMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_UndesignatedPreferredStockMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_StockholdersEquityTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_SharePrice" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_StockIssuanceCosts" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_SharesIssued" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_ConvertiblePreferredStockConversionPrice" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_StockholdersEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_StockholdersEquityTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_StockholdersEquityTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_StockholdersEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_EquityIncentivePlanTwoThousandThreeMember" xlink:label="mgnx_EquityIncentivePlanTwoThousandThreeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OriginalOptionsMember" xlink:label="mgnx_OriginalOptionsMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:label="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue" xlink:label="mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockOptionExchangeRatioDescription" xlink:label="mgnx_StockOptionExchangeRatioDescription"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockOptionOneMember" xlink:label="mgnx_StockOptionOneMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockOptionPlan2000Member" xlink:label="mgnx_StockOptionPlan2000Member"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockOptionTwoMember" xlink:label="mgnx_StockOptionTwoMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_TwoThousandAndThirteenStockIncentivePlanMember" xlink:label="mgnx_TwoThousandAndThirteenStockIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_TwoThousandAndThreeStockOptionPlanMember" xlink:label="mgnx_TwoThousandAndThreeStockOptionPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="mgnx_OriginalOptionsMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="mgnx_StockOptionExchangeRatioDescription" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_StockOptionPlan2000Member" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_TwoThousandAndThreeStockOptionPlanMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_TwoThousandAndThirteenStockIncentivePlanMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_EquityIncentivePlanTwoThousandThreeMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mgnx_StockOptionOneMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mgnx_StockOptionTwoMember" order="1.2300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="1.0700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd" xlink:label="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart" xlink:label="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxesDisclosureLineItems" xlink:label="mgnx_IncomeTaxesDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxesDisclosureTable" xlink:label="mgnx_IncomeTaxesDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:label="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:label="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_TaxCreditCarryforwardExpirationYearRangeEnd" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_TaxCreditCarryforwardExpirationYearRangeStart" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeStart"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward" xlink:label="us-gaap_UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_IncomeTaxesDisclosureTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_TaxCreditCarryforwardExpirationYearRangeStart" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_IncomeTaxesDisclosureTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ConvertiblePreferredStockSeriesDMember" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LeaseExpirationYear" xlink:label="mgnx_LeaseExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_ConvertiblePreferredStockSeriesDMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_LeaseExpirationYear" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="1.0100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalLicenseGrantFeesUnderAgreement" xlink:label="mgnx_AdditionalLicenseGrantFeesUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance" xlink:label="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalSalesMilestonesUnderAgreement" xlink:label="mgnx_AdditionalSalesMilestonesUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ClinicalDataReviewPeriodForAgreementTermination" xlink:label="mgnx_ClinicalDataReviewPeriodForAgreementTermination"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_CollaborativeAgreementPeriodOfContract" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ExpiredOptionAgreementMember" xlink:label="mgnx_ExpiredOptionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_GreenCrossCorporationMember" xlink:label="mgnx_GreenCrossCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LesLaboratoiresServierMember" xlink:label="mgnx_LesLaboratoiresServierMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_NonRefundableFees" xlink:label="mgnx_NonRefundableFees"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_NumberOfPrograms" xlink:label="mgnx_NumberOfPrograms"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OptionAgreementMember" xlink:label="mgnx_OptionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PaymentReceivedOnCollaborationAgreement" xlink:label="mgnx_PaymentReceivedOnCollaborationAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ResearchObligationCompletionDate" xlink:label="mgnx_ResearchObligationCompletionDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ReviewPeriodByRegulatoryAuthority" xlink:label="mgnx_ReviewPeriodByRegulatoryAuthority"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SecondRightToDevelopCollaborationMember" xlink:label="mgnx_SecondRightToDevelopCollaborationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_UpfrontFeeAndParticipationRecognitionDate" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionDate"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgnx_SecondRightToDevelopCollaborationMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableFees" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalLicenseGrantFeesUnderAgreement" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalSalesMilestonesUnderAgreement" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontPaymentRecognitionPeriod" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ReviewPeriodByRegulatoryAuthority" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfAnnualMaintenancePaymentReceived" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_PaymentReceivedOnCollaborationAgreement" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ResearchObligationCompletionDate" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborativeAgreementPeriodOfContract" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfPrograms" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontFeeAndParticipationRecognitionDate" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ClinicalDataReviewPeriodForAgreementTermination" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_RangeAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_LesLaboratoiresServierMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_GileadSciencesIncMember" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_PfizerIncMember" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_GreenCrossCorporationMember" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_EliLillyMember" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="mgnx_ExpiredOptionAgreementMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="mgnx_OptionAgreementMember" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LeaseMember" xlink:label="mgnx_LeaseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ManufacturingFacilitiesMember" xlink:label="mgnx_ManufacturingFacilitiesMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OfficeAndLaboratorySpaceMember" xlink:label="mgnx_OfficeAndLaboratorySpaceMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLeasesLineItems" xlink:label="mgnx_OperatingLeasesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLeasesTable" xlink:label="mgnx_OperatingLeasesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleLeasebackTransactionDescriptionAxis" xlink:label="us-gaap_SaleLeasebackTransactionDescriptionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleLeasebackTransactionNameDomain" xlink:label="us-gaap_SaleLeasebackTransactionNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleLeasebackTransactionNameDomain" xlink:label="us-gaap_SaleLeasebackTransactionNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SubleaseMember" xlink:label="mgnx_SubleaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_OperatingLeasesLineItems" xlink:to="mgnx_OperatingLeasesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_OperatingLeasesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_OperatingLeasesLineItems" xlink:to="us-gaap_DeferredRentCredit" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_OperatingLeasesLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_OperatingLeasesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_OperatingLeasesTable" xlink:to="us-gaap_SaleLeasebackTransactionDescriptionAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_OperatingLeasesTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="mgnx_OfficeAndLaboratorySpaceMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="mgnx_ManufacturingFacilitiesMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SaleLeasebackTransactionDescriptionAxis" xlink:to="us-gaap_SaleLeasebackTransactionNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SaleLeasebackTransactionDescriptionAxis" xlink:to="us-gaap_SaleLeasebackTransactionNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleLeasebackTransactionNameDomain" xlink:to="mgnx_LeaseMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleLeasebackTransactionNameDomain" xlink:to="mgnx_SubleaseMember" order="1.0800" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalPaymentUponAchievementOfMilestone" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" xlink:label="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RoyaltyAgreementLineItems" xlink:label="mgnx_RoyaltyAgreementLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RoyaltyAgreementTable" xlink:label="mgnx_RoyaltyAgreementTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_RoyaltyAgreementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_AdditionalPaymentUponAchievementOfMilestone" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_RoyaltyAgreementTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalLicenseGrantFeesUnderAgreement" xlink:label="mgnx_AdditionalLicenseGrantFeesUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ReviewPeriodByRegulatoryAuthority" xlink:label="mgnx_ReviewPeriodByRegulatoryAuthority"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mgnx_ServierMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgnx_AdditionalLicenseGrantFeesUnderAgreement" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgnx_ReviewPeriodByRegulatoryAuthority" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharePrice" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.1000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>mgnx-20131231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2014-03-18T16:29:55Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_4392741_928978_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_4392741_928978_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_4392741_933775_1_1">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_4392741_933775_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" id="id_4392741_926523_1_1">Accounts Receivable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" id="id_4392741_926523_2_1">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_4392741_938700_1_1">Accounts Receivable Net Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_4392741_938700_2_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_4392741_933113_1_1">Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_4392741_933113_2_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_4392741_933479_1_1">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_4392741_933479_14_1">Less accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1175455_3_1">Potential milestones upon IND acceptance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1175455_1_1">Additional Clinical Development Milestone Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1175455_2_1">Clinical milestone payments under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement" xlink:to="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1241607_3_1">Aggregate potential clinical milestone payments available to be earned under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1241607_1_1">Additional Clinical Milestone Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1241607_2_1">Clinical milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement" xlink:to="mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1241815_3_1">Additional clinical, regulatory and sales milestone payments under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1241815_1_1">Additional Clinical Regulatory And Sales Milestone Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1241815_2_1">Additional clinical, regulatory and sales milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement" xlink:to="mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalCommonStockIssuePricePerShare" xlink:label="mgnx_AdditionalCommonStockIssuePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalCommonStockIssuePricePerShare_lbl" xml:lang="en-US" id="id_4392741_1096799_3_1">Additional common stock issue price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalCommonStockIssuePricePerShare_lbl" xml:lang="en-US" id="id_4392741_1096799_1_1">Additional Common Stock Issue Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalCommonStockIssuePricePerShare_lbl" xml:lang="en-US" id="id_4392741_1096799_2_1">Initial public offering price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalCommonStockIssuePricePerShare" xlink:to="mgnx_AdditionalCommonStockIssuePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalLicenseGrantFeesUnderAgreement" xlink:label="mgnx_AdditionalLicenseGrantFeesUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalLicenseGrantFeesUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1241659_3_1">Additional license grant fees under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalLicenseGrantFeesUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1241659_1_1">Additional License Grant Fees Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalLicenseGrantFeesUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1241659_2_1">Additional license grant fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalLicenseGrantFeesUnderAgreement" xlink:to="mgnx_AdditionalLicenseGrantFeesUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_4392741_933723_1_1">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_4392741_933723_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_4392741_932586_1_1">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_4392741_932586_2_1">Additional Paid-In Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalPaymentUponAchievementOfMilestone" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone_lbl" xml:lang="en-US" id="id_4392741_959178_3_1">Additional payment upon achievement of milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone_lbl" xml:lang="en-US" id="id_4392741_959178_1_1">Additional Payment Upon Achievement Of Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone_lbl" xml:lang="en-US" id="id_4392741_959178_2_1">Additional consideration of asset purchase agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalPaymentUponAchievementOfMilestone" xlink:to="mgnx_AdditionalPaymentUponAchievementOfMilestone_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance" xlink:label="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance_lbl" xml:lang="en-US" id="id_4392741_1241628_3_1">Additional potential milestone payments receivable upon new drug application acceptance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance_lbl" xml:lang="en-US" id="id_4392741_1241628_1_1">Additional Potential Milestone Payments Receivable Upon New Drug Application Acceptance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance_lbl" xml:lang="en-US" id="id_4392741_1241628_2_1">Clinical milestone payments under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance" xlink:to="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1155390_3_1">Aggregate potential remaining regulatory milestone payments available to be earned under a collaboration arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1155390_1_1">Additional Regulatory Milestone Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1155390_2_1">Regulatory milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement" xlink:to="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalSalesMilestonesUnderAgreement" xlink:label="mgnx_AdditionalSalesMilestonesUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalSalesMilestonesUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1241610_3_1">Aggregate potential remaining sales milestone payments available to be earned under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalSalesMilestonesUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1241610_1_1">Additional Sales Milestones Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalSalesMilestonesUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1241610_2_1">Sales milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalSalesMilestonesUnderAgreement" xlink:to="mgnx_AdditionalSalesMilestonesUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_4392741_935944_1_1">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_4392741_935944_2_1">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_4392741_929248_1_1">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_4392741_929248_2_1">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_4392741_940280_1_1">Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_4392741_940280_2_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_4392741_921947_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_4392741_921947_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1218876_3_1">Amount of additional consideration paid under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1218876_1_1">Amount Of Additional Consideration Paid Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1218876_2_1">Payments related to the additional considerations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" xlink:to="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_4392741_931668_1_1">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_4392741_931668_2_1">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_4392741_928305_1_1">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_4392741_928305_2_1">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_4392741_923482_1_1">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_4392741_923482_2_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_4392741_927484_1_1">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_4392741_927484_2_1">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_4392741_930670_1_1">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_4392741_930670_2_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_4392741_938186_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_4392741_938186_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_4392741_928450_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_4392741_928450_2_1">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_4392741_937150_1_1">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_4392741_937150_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_4392741_926145_1_1">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_4392741_926145_2_1">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_4392741_938194_1_1">Assets Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_4392741_938194_6_1">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_4392741_926213_1_1">Assets Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_4392741_926213_2_1">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US" id="id_4392741_930917_1_1">Award Date [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US" id="id_4392741_930917_2_1">Award Date [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" id="id_4392741_927049_1_1">Award Date [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" id="id_4392741_927049_2_1">Award Date [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_4392741_929038_1_1">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_4392741_929038_2_1">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_930060_1_1">Basis Of Accounting Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_930060_2_1">Basis of Presentation and Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_BoehringerIngelheimMember_lbl" xml:lang="en-US" id="id_4392741_1060404_3_1">Boehringer Ingelheim International GmbH.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_BoehringerIngelheimMember_lbl" xml:lang="en-US" id="id_4392741_1060404_1_1">Boehringer Ingelheim [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_BoehringerIngelheimMember_lbl" xml:lang="en-US" id="id_4392741_1060404_2_1">Boehringer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_BoehringerIngelheimMember" xlink:to="mgnx_BoehringerIngelheimMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="id_4392741_926379_1_1">Business Acquisition Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="id_4392741_926379_2_1">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="id_4392741_928576_1_1">Business Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="id_4392741_928576_2_1">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" id="id_4392741_928408_1_1">Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" id="id_4392741_928408_2_1">Shares issued to acquire entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_4392741_938283_1_1">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_4392741_938283_4_1">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_4392741_938283_5_1">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_4392741_938283_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_4392741_938170_1_1">Cash And Cash Equivalents Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_4392741_938170_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_4392741_938600_1_1">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_4392741_938600_6_1">Net change in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_928679_1_1">Cash And Cash Equivalents Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_928679_2_1">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" id="id_4392741_925153_1_1">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" id="id_4392741_925153_2_1">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_4392741_932584_1_1">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_4392741_932584_2_1">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" id="id_4392741_932954_1_1">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" id="id_4392741_932954_2_1">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_4392741_925087_1_1">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_4392741_925087_2_1">Purchased shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ClinicalDataReviewPeriodForAgreementTermination" xlink:label="mgnx_ClinicalDataReviewPeriodForAgreementTermination"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ClinicalDataReviewPeriodForAgreementTermination_lbl" xml:lang="en-US" id="id_4392741_1218977_3_1">Clinical data review period for agreement termination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ClinicalDataReviewPeriodForAgreementTermination_lbl" xml:lang="en-US" id="id_4392741_1218977_1_1">Clinical Data Review Period For Agreement Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ClinicalDataReviewPeriodForAgreementTermination_lbl" xml:lang="en-US" id="id_4392741_1218977_2_1">Review of clinical data</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ClinicalDataReviewPeriodForAgreementTermination" xlink:to="mgnx_ClinicalDataReviewPeriodForAgreementTermination_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate_lbl" xml:lang="en-US" id="id_4392741_1095244_3_1">Collaboration and license agreement entered date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate_lbl" xml:lang="en-US" id="id_4392741_1095244_1_1">Collaboration And License Agreement Entered Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate_lbl" xml:lang="en-US" id="id_4392741_1095244_2_1">Collaboration agreement date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:label="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_1218875_3_1">Collaboration and license agreements disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_1218875_1_1">Collaboration And License Agreements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_1218875_2_1">Collaboration and License Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:to="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_CollaborativeAgreementPeriodOfContract" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract_lbl" xml:lang="en-US" id="id_4392741_1054969_3_1">Collaborative agreement period of contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract_lbl" xml:lang="en-US" id="id_4392741_1054969_1_1">Collaborative Agreement Period Of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract_lbl" xml:lang="en-US" id="id_4392741_1054969_2_1">Period of agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_CollaborativeAgreementPeriodOfContract" xlink:to="mgnx_CollaborativeAgreementPeriodOfContract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_4392741_930041_1_1">Commitments And Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_4392741_930041_2_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_923990_1_1">Commitments And Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_923990_2_1">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_4392741_930643_1_1">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_4392741_930643_2_1">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_4392741_931741_1_1">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_4392741_931741_2_1">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_4392741_930676_1_1">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_4392741_930676_2_1">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_4392741_923588_1_1">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_4392741_923588_2_1">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_4392741_935685_1_1">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_4392741_935685_2_1">Common stock, $0.01 par value-125,000,000 shares authorized and 25,177,597 shares outstanding at December 31, 2013; 425,000,000 shares authorized and 1,098,914 shares outstanding at December 31, 2012</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" id="id_4392741_929610_1_1">Compensation And Retirement Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" id="id_4392741_929610_2_1">Compensation and Retirement Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_930849_1_1">Compensation Related Costs Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_930849_2_1">Stock-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" id="id_4392741_923900_1_1">Components Of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" id="id_4392741_923900_2_1">Deferred income tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_4392741_932121_1_1">Components Of Deferred Tax Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_4392741_932121_2_1">Deferred income tax liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_925034_1_1">Comprehensive Income Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_925034_2_1">Comprehensive Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" id="id_4392741_931760_1_1">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" id="id_4392741_931760_2_1">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US" id="id_4392741_931666_1_1">Computer Software Intangible Asset [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US" id="id_4392741_931666_2_1">Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" id="id_4392741_932519_1_1">Concentration Risk Benchmark [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" id="id_4392741_932519_2_1">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" id="id_4392741_931007_1_1">Concentration Risk By Benchmark [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" id="id_4392741_931007_2_1">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" id="id_4392741_930526_1_1">Concentration Risk By Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" id="id_4392741_930526_2_1">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_4392741_930739_1_1">Concentration Risk Credit Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_4392741_930739_2_1">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" id="id_4392741_932490_1_1">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" id="id_4392741_932490_2_1">Concentration Risk [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" id="id_4392741_931347_1_1">Concentration Risk Percentage 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" id="id_4392741_931347_2_1">Percentage of all significant revenue earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" id="id_4392741_931347_12_1">Significant Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" id="id_4392741_929058_1_1">Concentration Risk [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" id="id_4392741_929058_2_1">Concentration Risk [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" id="id_4392741_927911_1_1">Concentration Risk Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" id="id_4392741_927911_2_1">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_4392741_1218865_3_1">Contingent consideration recorded as incremental in process research and development expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_4392741_1218865_1_1">Contingent Consideration Recorded As Incremental In Process Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_4392741_1218865_2_1">Additional amounts recorded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" xlink:to="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractTerminationMember_lbl" xml:lang="en-US" id="id_4392741_929956_1_1">Contract Termination [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractTerminationMember_lbl" xml:lang="en-US" id="id_4392741_929956_2_1">Contract Termination [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractTerminationMember" xlink:to="us-gaap_ContractTerminationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" id="id_4392741_937884_1_1">Conversion Of Stock Amount Converted 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" id="id_4392741_937884_2_1">Conversion of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ConvertiblePreferredStockConversionPrice" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice_lbl" xml:lang="en-US" id="id_4392741_1042584_3_1">Convertible preferred stock conversion price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice_lbl" xml:lang="en-US" id="id_4392741_1042584_1_1">Convertible Preferred Stock Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice_lbl" xml:lang="en-US" id="id_4392741_1042584_2_1">Conversion price of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ConvertiblePreferredStockConversionPrice" xlink:to="mgnx_ConvertiblePreferredStockConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_932377_1_1">Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_932377_2_1">Effect of Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ConvertiblePreferredStockSeriesDMember" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember_lbl" xml:lang="en-US" id="id_4392741_1010406_3_1">Convertible preferred stock series D.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember_lbl" xml:lang="en-US" id="id_4392741_1010406_1_1">Convertible Preferred Stock Series D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember_lbl" xml:lang="en-US" id="id_4392741_1010406_2_1">Convertible Preferred Stock Series D [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ConvertiblePreferredStockSeriesDMember" xlink:to="mgnx_ConvertiblePreferredStockSeriesDMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" id="id_4392741_931255_1_1">Convertible Preferred Stock Shares Issued Upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" id="id_4392741_931255_2_1">Convertible preferred stock series</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="id_4392741_937189_1_1">Costs And Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="id_4392741_937189_6_1">Total costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="id_4392741_927176_1_1">Costs And Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="id_4392741_927176_2_1">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" id="id_4392741_933025_1_1">Counterparty Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" id="id_4392741_933025_2_1">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" id="id_4392741_932533_1_1">Credit Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" id="id_4392741_932533_2_1">Summary of Significant Accounts Receivable[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_4392741_922004_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_4392741_922004_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_4392741_940132_1_1">Current Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_4392741_940132_2_1">Provision for federal or state income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" id="id_4392741_926068_1_1">Customer Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" id="id_4392741_926068_2_1">Summary of Significant Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xml:lang="en-US" id="id_4392741_930500_1_1">Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xml:lang="en-US" id="id_4392741_930500_2_1">Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" id="id_4392741_933631_1_1">Deferred Income Tax Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" id="id_4392741_933631_19_1">Gross deferred income tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCredit_lbl" xml:lang="en-US" id="id_4392741_936235_1_1">Deferred Rent Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCredit_lbl" xml:lang="en-US" id="id_4392741_936235_2_1">Deferred rent liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="id_4392741_935667_1_1">Deferred Rent Credit Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="id_4392741_935667_2_1">Deferred rent liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_4392741_935260_1_1">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_4392741_935260_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_4392741_935460_1_1">Deferred Revenue Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_4392741_935460_2_1">Deferred revenue included in current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_4392741_935460_12_1">Deferred revenue-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_4392741_936354_1_1">Deferred Revenue Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_4392741_936354_2_1">Deferred revenue included in long-term liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_4392741_936354_12_1">Deferred revenue, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" id="id_4392741_939213_1_1">Deferred Tax Assets Deferred Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" id="id_4392741_939213_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_4392741_937966_1_1">Deferred Tax Assets Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_4392741_937966_6_1">Gross deferred income tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" id="id_4392741_938419_1_1">Deferred Tax Assets Liabilities Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" id="id_4392741_938419_6_1">Net deferred income tax asset/(liability)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_4392741_938851_1_1">Deferred Tax Assets Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_4392741_938851_6_1">Net deferred income tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" id="id_4392741_940324_1_1">Deferred Tax Assets Operating Loss Carryforwards Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" id="id_4392741_940324_2_1">Federal U.S. net operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" id="id_4392741_937819_1_1">Deferred Tax Assets Operating Loss Carryforwards State And Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" id="id_4392741_937819_2_1">State net operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="id_4392741_940635_1_1">Deferred Tax Assets Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="id_4392741_940635_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_4392741_938837_1_1">Deferred Tax Assets Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_4392741_938837_2_1">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" xml:lang="en-US" id="id_4392741_940412_1_1">Deferred Tax Assets Tax Credit Carryforwards Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" xml:lang="en-US" id="id_4392741_940412_2_1">Orphan drug credit, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="id_4392741_939013_1_1">Deferred Tax Assets Tax Credit Carryforwards Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="id_4392741_939013_2_1">Research and development credit, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xml:lang="en-US" id="id_4392741_939012_1_1">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xml:lang="en-US" id="id_4392741_939012_2_1">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_4392741_934093_1_1">Deferred Tax Assets Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_4392741_934093_14_1">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US" id="id_4392741_933424_1_1">Deferred Tax Liabilities Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US" id="id_4392741_933424_14_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_lbl" xml:lang="en-US" id="id_4392741_927219_1_1">Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_lbl" xml:lang="en-US" id="id_4392741_927219_2_1">Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" xlink:label="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage_lbl" xml:lang="en-US" id="id_4392741_1218878_3_1">Defined contribution plan, employees contribution, annual vesting percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage_lbl" xml:lang="en-US" id="id_4392741_1218878_1_1">Defined Contribution Plan Employees Contribution Annual Vesting Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage_lbl" xml:lang="en-US" id="id_4392741_1218878_2_1">Percentage of employee vested contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" xlink:to="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" id="id_4392741_938911_1_1">Defined Contribution Plan Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" id="id_4392741_938911_2_1">Company's contribution to plan total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" id="id_4392741_926177_1_1">Defined Contribution Plan Maximum Annual Contributions Per Employee Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" id="id_4392741_926177_2_1">Percentage of employee contribution to salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_4392741_940263_1_1">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_4392741_940263_2_1">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_4392741_939791_1_1">Depreciation Depletion And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_4392741_939791_2_1">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_4392741_930617_1_1">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_4392741_930617_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_4392741_923166_1_1">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_4392741_923166_2_1">Shared-Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_DocumentAndEntityInformationAbstract" xlink:label="mgnx_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_4392741_951207_3_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_4392741_951207_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_4392741_951207_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="mgnx_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_4392741_922019_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_4392741_922019_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_4392741_921974_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_4392741_921974_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_4392741_921989_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_4392741_921989_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_4392741_921984_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_4392741_921984_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" id="id_4392741_924673_1_1">Domestic Country [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" id="id_4392741_924673_2_1">U.S. Federal Government [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_4392741_925621_1_1">Earnings Per Share Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_4392741_925621_32_1">Net income (loss) per share, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_4392741_925621_2_1">Basic income (loss) per common share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_4392741_925621_12_1">Basic net income (loss) per common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_4392741_924397_1_1">Earnings Per Share Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_4392741_924397_32_1">Net income (loss) per share, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_4392741_924397_2_1">Diluted income (loss) per common share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_4392741_924397_12_1">Diluted net income (loss) per common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_931897_1_1">Earnings Per Share Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_931897_2_1">Net Income (Loss) Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_EliLillyMember_lbl" xml:lang="en-US" id="id_4392741_1218715_3_1">Eli Lilly &amp; Co.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_EliLillyMember_lbl" xml:lang="en-US" id="id_4392741_1218715_1_1">Eli Lilly [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_EliLillyMember_lbl" xml:lang="en-US" id="id_4392741_1218715_2_1">Eli Lilly [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_EliLillyMember" xlink:to="mgnx_EliLillyMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan" xlink:label="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan_lbl" xml:lang="en-US" id="id_4392741_1055795_3_1">Employee eligible age to participate in benefit plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan_lbl" xml:lang="en-US" id="id_4392741_1055795_1_1">Employee Eligible Age To Participate In Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan_lbl" xml:lang="en-US" id="id_4392741_1055795_2_1">Eligibility of employee participation plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan" xlink:to="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_4392741_932976_1_1">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_4392741_932976_2_1">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" id="id_4392741_940160_1_1">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" id="id_4392741_940160_2_1">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_4392741_929567_1_1">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_4392741_929567_2_1">Unrecognized compensation expense recognition period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_4392741_924898_1_1">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_4392741_924898_2_1">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_4392741_921997_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_4392741_921997_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_4392741_922042_1_1">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_4392741_922042_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_4392741_921942_1_1">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_4392741_921942_2_1">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_4392741_921970_1_1">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_4392741_921970_2_1">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_4392741_921955_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_4392741_921955_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US" id="id_4392741_921996_1_1">Entity Incorporation Date Of Incorporation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US" id="id_4392741_921996_2_1">MacroGenics incorporated date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_4392741_921993_1_1">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_4392741_921993_2_1">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_4392741_921937_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_4392741_921937_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_4392741_922027_1_1">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_4392741_922027_2_1">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_4392741_922003_1_1">Entity Well Known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_4392741_922003_2_1">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" id="id_4392741_928802_1_1">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" id="id_4392741_928802_2_1">Lab Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_4392741_932367_1_1">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_4392741_932367_2_1">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_4392741_927325_1_1">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_4392741_927325_2_1">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_EquityIncentivePlanTwoThousandThreeMember" xlink:label="mgnx_EquityIncentivePlanTwoThousandThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_EquityIncentivePlanTwoThousandThreeMember_lbl" xml:lang="en-US" id="id_4392741_1218846_3_1">Equity incentive plan two thousand three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_EquityIncentivePlanTwoThousandThreeMember_lbl" xml:lang="en-US" id="id_4392741_1218846_1_1">Equity Incentive Plan Two Thousand Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_EquityIncentivePlanTwoThousandThreeMember_lbl" xml:lang="en-US" id="id_4392741_1218846_2_1">Equity Incentive Plan 2003 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_EquityIncentivePlanTwoThousandThreeMember" xlink:to="mgnx_EquityIncentivePlanTwoThousandThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ExpiredOptionAgreementMember" xlink:label="mgnx_ExpiredOptionAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ExpiredOptionAgreementMember_lbl" xml:lang="en-US" id="id_4392741_1241818_3_1">Expired Option Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ExpiredOptionAgreementMember_lbl" xml:lang="en-US" id="id_4392741_1241818_1_1">Expired Option Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ExpiredOptionAgreementMember_lbl" xml:lang="en-US" id="id_4392741_1241818_2_1">Expired Option Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ExpiredOptionAgreementMember" xlink:to="mgnx_ExpiredOptionAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_4392741_937097_1_1">Fair Value Adjustment Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_4392741_937097_2_1">Fair value adjustment of warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_4392741_928161_1_1">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_4392741_928161_2_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_4392741_932133_1_1">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_4392741_932133_2_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_926674_1_1">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_926674_2_1">Summary of Fair Value Measurement Financial Asset and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_4392741_929790_1_1">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_4392741_929790_2_1">Fair Value, Hierarchy [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_4392741_925736_1_1">Fair Value Inputs Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_4392741_925736_2_1">Quoted Prices in Active Markets for Identical Assets Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_4392741_925851_1_1">Fair Value Inputs Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_4392741_925851_2_1">Significant Other Observable Inputs Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_4392741_929831_1_1">Fair Value Inputs Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_4392741_929831_2_1">Significant Unobservable Inputs Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xml:lang="en-US" id="id_4392741_934853_1_1">Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xml:lang="en-US" id="id_4392741_934853_2_1">Total unrealized gains (losses) included in earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" id="id_4392741_925195_1_1">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" id="id_4392741_925195_2_1">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" id="id_4392741_927929_1_1">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" id="id_4392741_927929_2_1">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="id_4392741_927992_1_1">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="id_4392741_927992_2_1">Summary of Preferred Stock Warrant Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_4392741_930398_1_1">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_4392741_930398_2_1">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" id="id_4392741_934561_1_1">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" id="id_4392741_934561_16_1">Balance end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" id="id_4392741_934561_17_1">Balance beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_4392741_931938_1_1">Fair Value Of Financial Instruments Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_4392741_931938_2_1">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd" xlink:label="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd_lbl" xml:lang="en-US" id="id_4392741_1231890_3_1">Net operating loss carry forward expiration ending year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd_lbl" xml:lang="en-US" id="id_4392741_1231890_1_1">Federal And State Net Operating Loss Carry Forwards Expiration Year End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd_lbl" xml:lang="en-US" id="id_4392741_1231890_2_1">Net operating loss carryforwards expiration ending year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd" xlink:to="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart" xlink:label="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart_lbl" xml:lang="en-US" id="id_4392741_1191832_3_1">Net operating loss carry forward expiration start year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart_lbl" xml:lang="en-US" id="id_4392741_1191832_1_1">Federal And State Net Operating Loss Carry Forwards Expiration Year Start</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart_lbl" xml:lang="en-US" id="id_4392741_1191832_2_1">Net operating loss carryforwards expiration start year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart" xlink:to="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_4392741_932226_1_1">Furniture And Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_4392741_932226_2_1">Furniture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems_lbl" xml:lang="en-US" id="id_4392741_1074447_3_1">Line items used to disclose Future Minimum Leases Payments Under Leases (Line Items)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems_lbl" xml:lang="en-US" id="id_4392741_1074447_1_1">Future Minimum Leases Payments Under Leases [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems_lbl" xml:lang="en-US" id="id_4392741_1074447_2_1">Future Minimum Leases Payments Under Leases (Line Items)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable_lbl" xml:lang="en-US" id="id_4392741_1079572_3_1">Future minimum leases payments under leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable_lbl" xml:lang="en-US" id="id_4392741_1079572_1_1">Future Minimum Leases Payments Under Leases [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable_lbl" xml:lang="en-US" id="id_4392741_1079572_2_1">Future Minimum Leases Payments Under Leases [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:to="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_4392741_937408_1_1">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_4392741_937408_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_4392741_925832_1_1">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_4392741_925832_2_1">General and Administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_GileadSciencesIncMember_lbl" xml:lang="en-US" id="id_4392741_1060690_3_1">Gilead Sciences, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_GileadSciencesIncMember_lbl" xml:lang="en-US" id="id_4392741_1060690_1_1">Gilead Sciences Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_GileadSciencesIncMember_lbl" xml:lang="en-US" id="id_4392741_1060690_2_1">Gilead [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_GileadSciencesIncMember" xlink:to="mgnx_GileadSciencesIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_GreenCrossCorporationMember" xlink:label="mgnx_GreenCrossCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_GreenCrossCorporationMember_lbl" xml:lang="en-US" id="id_4392741_1064508_3_1">Green Cross Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_GreenCrossCorporationMember_lbl" xml:lang="en-US" id="id_4392741_1064508_1_1">Green Cross Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_GreenCrossCorporationMember_lbl" xml:lang="en-US" id="id_4392741_1064508_2_1">Green Cross [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_GreenCrossCorporationMember" xlink:to="mgnx_GreenCrossCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairedFinancingReceivableRelatedAllowance" xlink:label="us-gaap_ImpairedFinancingReceivableRelatedAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairedFinancingReceivableRelatedAllowance_lbl" xml:lang="en-US" id="id_4392741_935402_1_1">Impaired Financing Receivable Related Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairedFinancingReceivableRelatedAllowance_lbl" xml:lang="en-US" id="id_4392741_935402_2_1">Allowance recorded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairedFinancingReceivableRelatedAllowance" xlink:to="us-gaap_ImpairedFinancingReceivableRelatedAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_931752_1_1">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_931752_2_1">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_4392741_927850_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_4392741_927850_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_4392741_927015_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_4392741_927015_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_4392741_931901_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_4392741_931901_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="id_4392741_932628_1_1">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="id_4392741_932628_2_1">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="id_4392741_929033_1_1">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="id_4392741_929033_2_1">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_4392741_932322_1_1">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_4392741_932322_2_1">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_929775_1_1">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_929775_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxesDisclosureLineItems" xlink:label="mgnx_IncomeTaxesDisclosureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncomeTaxesDisclosureLineItems_lbl" xml:lang="en-US" id="id_4392741_998101_3_1">Income Taxes Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncomeTaxesDisclosureLineItems_lbl" xml:lang="en-US" id="id_4392741_998101_1_1">Income Taxes Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_IncomeTaxesDisclosureLineItems_lbl" xml:lang="en-US" id="id_4392741_998101_2_1">Income Taxes Disclosure [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_IncomeTaxesDisclosureLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxesDisclosureTable" xlink:label="mgnx_IncomeTaxesDisclosureTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncomeTaxesDisclosureTable_lbl" xml:lang="en-US" id="id_4392741_1129057_3_1">Income taxes disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncomeTaxesDisclosureTable_lbl" xml:lang="en-US" id="id_4392741_1129057_1_1">Income Taxes Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_IncomeTaxesDisclosureTable_lbl" xml:lang="en-US" id="id_4392741_1129057_2_1">Income Taxes Disclosure [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncomeTaxesDisclosureTable" xlink:to="mgnx_IncomeTaxesDisclosureTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd_lbl" xml:lang="en-US" id="id_4392741_1095822_3_1">Income tax examination year under examination range end.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd_lbl" xml:lang="en-US" id="id_4392741_1095822_1_1">Income Tax Examination Year Under Examination Range End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd_lbl" xml:lang="en-US" id="id_4392741_1095822_2_1">Income tax examination year subject to examination, Range End</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd" xlink:to="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart_lbl" xml:lang="en-US" id="id_4392741_1066509_3_1">Income tax examination year under examination range start.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart_lbl" xml:lang="en-US" id="id_4392741_1066509_1_1">Income Tax Examination Year Under Examination Range Start</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart_lbl" xml:lang="en-US" id="id_4392741_1066509_2_1">Income tax examination year subject to examination, Range start</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart" xlink:to="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_4392741_940829_1_1">Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_4392741_940829_6_1">Income tax expense/(benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_932576_1_1">Income Tax Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_932576_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_4392741_937524_1_1">Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_4392741_937524_2_1">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" xlink:label="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments_lbl" xml:lang="en-US" id="id_4392741_1008132_3_1">Income tax reconciliation deferred tax adjustments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments_lbl" xml:lang="en-US" id="id_4392741_1008132_1_1">Income Tax Reconciliation Deferred Tax Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments_lbl" xml:lang="en-US" id="id_4392741_1008132_2_1">Deferred income tax adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" xlink:to="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" xlink:label="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability_lbl" xml:lang="en-US" id="id_4392741_1218853_3_1">Income tax reconciliation fair value adjustment of preferred stock warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability_lbl" xml:lang="en-US" id="id_4392741_1218853_1_1">Income Tax Reconciliation Fair Value Adjustment Of Preferred Stock Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability_lbl" xml:lang="en-US" id="id_4392741_1218853_2_1">Fair value adjustment of preferred stock warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" xlink:to="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_4392741_939032_1_1">Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_4392741_939032_2_1">United States federal tax at statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" id="id_4392741_937994_1_1">Income Tax Reconciliation Nondeductible Expense Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" id="id_4392741_937994_2_1">Research credit, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_4392741_938677_1_1">Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_4392741_938677_2_1">Equity- based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US" id="id_4392741_937171_1_1">Income Tax Reconciliation Other Reconciling Items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US" id="id_4392741_937171_2_1">Other permanent items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="id_4392741_938982_1_1">Income Tax Reconciliation State And Local Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="id_4392741_938982_2_1">State taxes (net of federal benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" xlink:label="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments_lbl" xml:lang="en-US" id="id_4392741_1166640_3_1">Income tax reconciliation state deferred taxes adjustments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments_lbl" xml:lang="en-US" id="id_4392741_1166640_1_1">Income Tax Reconciliation State Deferred Taxes Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments_lbl" xml:lang="en-US" id="id_4392741_1166640_14_1">Deferred state blended rate adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" xlink:to="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl" xml:lang="en-US" id="id_4392741_934433_1_1">Income Tax Reconciliation Tax Credits Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl" xml:lang="en-US" id="id_4392741_934433_14_1">Orphan drug credit, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_4392741_938987_1_1">Increase Decrease In Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_4392741_938987_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_4392741_935454_1_1">Increase Decrease In Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_4392741_935454_14_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_4392741_938916_1_1">Increase Decrease In Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_4392741_938916_2_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncreaseDecreaseInDeferredRent" xlink:label="mgnx_IncreaseDecreaseInDeferredRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" id="id_4392741_947179_3_1">Increase decrease in deferred rent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" id="id_4392741_947179_1_1">Increase Decrease In Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" id="id_4392741_947179_2_1">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncreaseDecreaseInDeferredRent" xlink:to="mgnx_IncreaseDecreaseInDeferredRent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_4392741_938117_1_1">Increase Decrease In Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_4392741_938117_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_4392741_924543_1_1">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_4392741_924543_2_1">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" id="id_4392741_934505_1_1">Increase Decrease In Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" id="id_4392741_934505_14_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" id="id_4392741_934983_1_1">Increase Decrease In Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" id="id_4392741_934983_14_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_lbl" xml:lang="en-US" id="id_4392741_936295_1_1">Increase Decrease In Restricted Cash For Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_lbl" xml:lang="en-US" id="id_4392741_936295_14_1">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestructuringReserve_lbl" xml:lang="en-US" id="id_4392741_939820_1_1">Increase Decrease In Restructuring Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInRestructuringReserve_lbl" xml:lang="en-US" id="id_4392741_939820_2_1">Lease exit liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:to="us-gaap_IncreaseDecreaseInRestructuringReserve_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_4392741_926487_1_1">I P O [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_4392741_926487_2_1">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember_lbl" xml:lang="en-US" id="id_4392741_1203065_3_1">Laboratory and office equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember_lbl" xml:lang="en-US" id="id_4392741_1203065_1_1">Laboratory And Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember_lbl" xml:lang="en-US" id="id_4392741_1203065_2_1">Laboratory and Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LaboratoryAndOfficeEquipmentMember" xlink:to="mgnx_LaboratoryAndOfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US" id="id_4392741_929765_1_1">Lease Expiration Date 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US" id="id_4392741_929765_2_1">Lease expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LeaseExpirationYear" xlink:label="mgnx_LeaseExpirationYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LeaseExpirationYear_lbl" xml:lang="en-US" id="id_4392741_1088217_3_1">Lease expiration year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LeaseExpirationYear_lbl" xml:lang="en-US" id="id_4392741_1088217_1_1">Lease Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LeaseExpirationYear_lbl" xml:lang="en-US" id="id_4392741_1088217_2_1">Operating Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LeaseExpirationYear" xlink:to="mgnx_LeaseExpirationYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_4392741_923325_1_1">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_4392741_923325_2_1">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LeaseMember" xlink:label="mgnx_LeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LeaseMember_lbl" xml:lang="en-US" id="id_4392741_1075325_3_1">Lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LeaseMember_lbl" xml:lang="en-US" id="id_4392741_1075325_1_1">Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LeaseMember_lbl" xml:lang="en-US" id="id_4392741_1075325_2_1">Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LeaseMember" xlink:to="mgnx_LeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_4392741_921954_1_1">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_4392741_921954_2_1">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LesLaboratoiresServierMember" xlink:label="mgnx_LesLaboratoiresServierMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LesLaboratoiresServierMember_lbl" xml:lang="en-US" id="id_4392741_1218879_3_1">Les Laboratoires Servier.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LesLaboratoiresServierMember_lbl" xml:lang="en-US" id="id_4392741_1218879_1_1">Les Laboratoires Servier [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LesLaboratoiresServierMember_lbl" xml:lang="en-US" id="id_4392741_1218879_2_1">Servier [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LesLaboratoiresServierMember" xlink:to="mgnx_LesLaboratoiresServierMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl" xml:lang="en-US" id="id_4392741_928685_1_1">Lessee Leasing Arrangements Operating Leases Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl" xml:lang="en-US" id="id_4392741_928685_2_1">Lessee leasing arrangements, operating leases, renewal term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_4392741_936129_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_4392741_936129_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_4392741_935778_1_1">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_4392741_935778_6_1">Total liabilities and stockholders' equity (deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_4392741_924388_1_1">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_4392741_924388_2_1">Liabilities and stockholders' equity (deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_4392741_934201_1_1">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_4392741_934201_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_4392741_929787_1_1">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_4392741_929787_2_1">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_4392741_929095_1_1">Liabilities Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_4392741_929095_2_1">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xml:lang="en-US" id="id_4392741_928673_1_1">License Agreement Terms [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xml:lang="en-US" id="id_4392741_928673_2_1">License Agreement Terms [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems_lbl" xml:lang="en-US" id="id_4392741_1007346_3_1">License And Collaboration Agreements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems_lbl" xml:lang="en-US" id="id_4392741_1007346_1_1">License And Collaboration Agreements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems_lbl" xml:lang="en-US" id="id_4392741_1007346_2_1">License And Collaboration Agreements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_LicenseAndCollaborationAgreementsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable_lbl" xml:lang="en-US" id="id_4392741_1051041_3_1">License and collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable_lbl" xml:lang="en-US" id="id_4392741_1051041_1_1">License And Collaboration Agreements [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable_lbl" xml:lang="en-US" id="id_4392741_1051041_2_1">License And Collaboration Agreements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US" id="id_4392741_936716_1_1">License And Services Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US" id="id_4392741_936716_2_1">Revenue from collaborative research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="us-gaap_LicenseAndServicesRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="id_4392741_934341_1_1">Licenses Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="id_4392741_934341_2_1">Recognized revenue under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum" xlink:label="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum_lbl" xml:lang="en-US" id="id_4392741_1071792_3_1">Liquid investment maturity period to be classified as cash equivalent maximum.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum_lbl" xml:lang="en-US" id="id_4392741_1071792_1_1">Liquid Investment Maturity Period To Be Classified As Cash Equivalent Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum_lbl" xml:lang="en-US" id="id_4392741_1071792_2_1">Original maturity of financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum" xlink:to="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorCustomersAxis_lbl" xml:lang="en-US" id="id_4392741_927195_1_1">Major Customers [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorCustomersAxis_lbl" xml:lang="en-US" id="id_4392741_927195_2_1">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ManufacturingFacilitiesMember" xlink:label="mgnx_ManufacturingFacilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ManufacturingFacilitiesMember_lbl" xml:lang="en-US" id="id_4392741_954146_3_1">Manufacturing facilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ManufacturingFacilitiesMember_lbl" xml:lang="en-US" id="id_4392741_954146_1_1">Manufacturing Facilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ManufacturingFacilitiesMember_lbl" xml:lang="en-US" id="id_4392741_954146_2_1">Manufacturing Facilities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ManufacturingFacilitiesMember" xlink:to="mgnx_ManufacturingFacilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_4392741_923140_1_1">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_4392741_923140_2_1">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_4392741_932953_1_1">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_4392741_932953_2_1">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_MoneyMarketFundsFairValueDisclosure" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure_lbl" xml:lang="en-US" id="id_4392741_1138489_3_1">Money market funds fair value disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure_lbl" xml:lang="en-US" id="id_4392741_1138489_1_1">Money Market Funds Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure_lbl" xml:lang="en-US" id="id_4392741_1138489_2_1">Money market funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_MoneyMarketFundsFairValueDisclosure" xlink:to="mgnx_MoneyMarketFundsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" id="id_4392741_925477_1_1">Name Of Major Customer [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" id="id_4392741_925477_2_1">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="us-gaap_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_4392741_937453_1_1">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_4392741_937453_6_1">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_4392741_924600_1_1">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_4392741_924600_2_1">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_4392741_939292_1_1">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_4392741_939292_6_1">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_4392741_924425_1_1">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_4392741_924425_2_1">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_4392741_928832_1_1">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_4392741_928832_6_1">Net cash (used in) provided by operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_4392741_930909_1_1">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_4392741_930909_2_1">Operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_4392741_935636_1_1">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_4392741_935636_2_1">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_4392741_935636_6_1">Net comprehensive income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_4392741_935636_12_1">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_4392741_933727_1_1">Net Income Loss Available To Common Stockholders Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_4392741_933727_6_1">Net income (loss) allocable to common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" id="id_4392741_934779_1_1">Net Income Loss Available To Common Stockholders Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" id="id_4392741_934779_6_1">Net income (loss) allocable to common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_923522_1_1">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_923522_2_1">Recently Issued Accounting Standards Adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="id_4392741_932362_1_1">Noncash Investing And Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="id_4392741_932362_2_1">Noncash financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_NonRefundableFees" xlink:label="mgnx_NonRefundableFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NonRefundableFees_lbl" xml:lang="en-US" id="id_4392741_980010_3_1">Initial fee received from collaboration or license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NonRefundableFees_lbl" xml:lang="en-US" id="id_4392741_980010_1_1">Non Refundable Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NonRefundableFees_lbl" xml:lang="en-US" id="id_4392741_980010_2_1">Non-refundable upfront payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NonRefundableFees" xlink:to="mgnx_NonRefundableFees_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived_lbl" xml:lang="en-US" id="id_4392741_1218889_3_1">Number of annual maintenance payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived_lbl" xml:lang="en-US" id="id_4392741_1218889_1_1">Number Of Annual Maintenance Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived_lbl" xml:lang="en-US" id="id_4392741_1218889_2_1">Number of annual maintenance payments received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:to="mgnx_NumberOfAnnualMaintenancePaymentReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations_lbl" xml:lang="en-US" id="id_4392741_1218881_3_1">Number of molecules to be developed and commercialized as per collaborations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations_lbl" xml:lang="en-US" id="id_4392741_1218881_1_1">Number Of Molecules To Be Developed And Commercialized As Per Collaborations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations_lbl" xml:lang="en-US" id="id_4392741_1218881_2_1">Commercialization of molecules</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" xlink:to="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="id_4392741_923679_1_1">Number Of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="id_4392741_923679_2_1">Number of operating segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" xlink:label="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement_lbl" xml:lang="en-US" id="id_4392741_1248549_3_1">Number of potential shares to be issued as additional consideration under asset purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement_lbl" xml:lang="en-US" id="id_4392741_1248549_1_1">Number Of Potential Shares To Be Issued As Additional Consideration Under Asset Purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement_lbl" xml:lang="en-US" id="id_4392741_1248549_2_1">Common stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" xlink:to="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_NumberOfPrograms" xlink:label="mgnx_NumberOfPrograms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfPrograms_lbl" xml:lang="en-US" id="id_4392741_994023_3_1">Number of programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfPrograms_lbl" xml:lang="en-US" id="id_4392741_994023_1_1">Number Of Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfPrograms_lbl" xml:lang="en-US" id="id_4392741_994023_2_1">DART program</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfPrograms" xlink:to="mgnx_NumberOfPrograms_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OfficeAndLaboratorySpaceMember" xlink:label="mgnx_OfficeAndLaboratorySpaceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OfficeAndLaboratorySpaceMember_lbl" xml:lang="en-US" id="id_4392741_1237431_3_1">Office and laboratory space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OfficeAndLaboratorySpaceMember_lbl" xml:lang="en-US" id="id_4392741_1237431_1_1">Office And Laboratory Space [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OfficeAndLaboratorySpaceMember_lbl" xml:lang="en-US" id="id_4392741_1237431_2_1">Office and Laboratory Space [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OfficeAndLaboratorySpaceMember" xlink:to="mgnx_OfficeAndLaboratorySpaceMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" id="id_4392741_923192_1_1">Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" id="id_4392741_923192_2_1">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1088486_3_1">One-time milestone payment to be paid under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1088486_1_1">Onetime Milestone Payment To Be Paid Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement_lbl" xml:lang="en-US" id="id_4392741_1088486_2_1">Onetime purchase payment under purchase agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts_lbl" xml:lang="en-US" id="id_4392741_1218863_3_1">One-time milestone payment to be paid under agreement upon specified level of sales of products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts_lbl" xml:lang="en-US" id="id_4392741_1218863_1_1">Onetime Milestone Payment To Be Paid Under Agreement Upon Specified Level Of Sales Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts_lbl" xml:lang="en-US" id="id_4392741_1218863_2_1">Onetime payment paid under license of product</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_4392741_934856_1_1">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_4392741_934856_6_1">Income (loss) from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_4392741_933732_1_1">Operating Leases Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_4392741_933732_2_1">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_4392741_933732_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_4392741_936689_1_1">Operating Leases Future Minimum Payments Due Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_4392741_936689_2_1">2014</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="id_4392741_935061_1_1">Operating Leases Future Minimum Payments Due In Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="id_4392741_935061_2_1">2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_4392741_934077_1_1">Operating Leases Future Minimum Payments Due In Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_4392741_934077_2_1">2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_4392741_936161_1_1">Operating Leases Future Minimum Payments Due In Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_4392741_936161_2_1">2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_4392741_933250_1_1">Operating Leases Future Minimum Payments Due In Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_4392741_933250_2_1">2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" id="id_4392741_934235_1_1">Operating Leases Future Minimum Payments Due Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" id="id_4392741_934235_2_1">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLeasesLineItems" xlink:label="mgnx_OperatingLeasesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OperatingLeasesLineItems_lbl" xml:lang="en-US" id="id_4392741_1110547_3_1">Operating Leases [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OperatingLeasesLineItems_lbl" xml:lang="en-US" id="id_4392741_1110547_1_1">Operating Leases [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OperatingLeasesLineItems_lbl" xml:lang="en-US" id="id_4392741_1110547_2_1">Operating Leases [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OperatingLeasesLineItems" xlink:to="mgnx_OperatingLeasesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_930013_1_1">Operating Leases Of Lessee Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_930013_2_1">Schedule of Minimum Future Lease Payments Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_4392741_938759_1_1">Operating Leases Rent Expense Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_4392741_938759_2_1">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLeasesTable" xlink:label="mgnx_OperatingLeasesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OperatingLeasesTable_lbl" xml:lang="en-US" id="id_4392741_1152792_3_1">Operating leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OperatingLeasesTable_lbl" xml:lang="en-US" id="id_4392741_1152792_1_1">Operating Leases [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OperatingLeasesTable_lbl" xml:lang="en-US" id="id_4392741_1152792_2_1">Operating Leases [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OperatingLeasesTable" xlink:to="mgnx_OperatingLeasesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_4392741_939188_1_1">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_4392741_939188_2_1">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:label="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_lbl" xml:lang="en-US" id="id_4392741_1127191_3_1">Operating loss carryforwards annual limitation amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_lbl" xml:lang="en-US" id="id_4392741_1127191_1_1">Operating Loss Carryforwards Annual Limitation Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_lbl" xml:lang="en-US" id="id_4392741_1127191_2_1">Net operating losses limited for use utilized on an annual basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:to="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_lbl" xml:lang="en-US" id="id_4392741_1080740_3_1">Operating loss carryforwards limitations on use amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_lbl" xml:lang="en-US" id="id_4392741_1080740_1_1">Operating Loss Carryforwards Limitations On Use Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_lbl" xml:lang="en-US" id="id_4392741_1080740_2_1">Net operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd_lbl" xml:lang="en-US" id="id_4392741_1237406_3_1">Operating loss carryforwards limitations on use year end.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd_lbl" xml:lang="en-US" id="id_4392741_1237406_1_1">Operating Loss Carryforwards Limitations On Use Year End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd_lbl" xml:lang="en-US" id="id_4392741_1237406_2_1">Net operating losses limited for year maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart_lbl" xml:lang="en-US" id="id_4392741_1237405_3_1">Operating loss carryforwards limitations on use year start.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart_lbl" xml:lang="en-US" id="id_4392741_1237405_1_1">Operating Loss Carryforwards Limitations On Use Year Start</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart_lbl" xml:lang="en-US" id="id_4392741_1237405_2_1">Net operating losses limited for year minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:label="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_lbl" xml:lang="en-US" id="id_4392741_1198426_3_1">Operating loss carryforwards not subject to limitation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_lbl" xml:lang="en-US" id="id_4392741_1198426_1_1">Operating Loss Carryforwards Not Subject To Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_lbl" xml:lang="en-US" id="id_4392741_1198426_2_1">Remaining portion of net operating losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:to="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OptionAgreementMember" xlink:label="mgnx_OptionAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OptionAgreementMember_lbl" xml:lang="en-US" id="id_4392741_1150658_3_1">Option Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OptionAgreementMember_lbl" xml:lang="en-US" id="id_4392741_1150658_1_1">Option Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OptionAgreementMember_lbl" xml:lang="en-US" id="id_4392741_1150658_2_1">Option Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OptionAgreementMember" xlink:to="mgnx_OptionAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:label="mgnx_OrganizationAndNatureOfBusinessLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OrganizationAndNatureOfBusinessLineItems_lbl" xml:lang="en-US" id="id_4392741_971196_3_1">Organization And Nature Of Business [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OrganizationAndNatureOfBusinessLineItems_lbl" xml:lang="en-US" id="id_4392741_971196_1_1">Organization And Nature Of Business [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OrganizationAndNatureOfBusinessLineItems_lbl" xml:lang="en-US" id="id_4392741_971196_2_1">Organization And Nature Of Business [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="mgnx_OrganizationAndNatureOfBusinessLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OrganizationAndNatureOfBusinessTable" xlink:label="mgnx_OrganizationAndNatureOfBusinessTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OrganizationAndNatureOfBusinessTable_lbl" xml:lang="en-US" id="id_4392741_986628_3_1">Organization and nature of business.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OrganizationAndNatureOfBusinessTable_lbl" xml:lang="en-US" id="id_4392741_986628_1_1">Organization And Nature Of Business [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OrganizationAndNatureOfBusinessTable_lbl" xml:lang="en-US" id="id_4392741_986628_2_1">Organization And Nature Of Business [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OrganizationAndNatureOfBusinessTable" xlink:to="mgnx_OrganizationAndNatureOfBusinessTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_4392741_927825_1_1">Organization Consolidation And Presentation Of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_4392741_927825_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_931858_1_1">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_931858_2_1">Organization and Nature of Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OriginalOptionsMember" xlink:label="mgnx_OriginalOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OriginalOptionsMember_lbl" xml:lang="en-US" id="id_4392741_978903_3_1">Original Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OriginalOptionsMember_lbl" xml:lang="en-US" id="id_4392741_978903_1_1">Original Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OriginalOptionsMember_lbl" xml:lang="en-US" id="id_4392741_978903_2_1">Original Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OriginalOptionsMember" xlink:to="mgnx_OriginalOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_4392741_937594_1_1">Other Assets Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_4392741_937594_2_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_4392741_936298_1_1">Other Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_4392741_936298_2_1">Other liabilities-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_4392741_934087_1_1">Other Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_4392741_934087_2_1">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings_lbl" xml:lang="en-US" id="id_4392741_940189_1_1">Participating Securities Distributed And Undistributed Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings_lbl" xml:lang="en-US" id="id_4392741_940189_14_1">Less: undistributed earnings allocated to participating securities and other add-backs to net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PaymentReceivedOnCollaborationAgreement" xlink:label="mgnx_PaymentReceivedOnCollaborationAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PaymentReceivedOnCollaborationAgreement_lbl" xml:lang="en-US" id="id_4392741_1095988_3_1">Total cumulative payments received to date under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PaymentReceivedOnCollaborationAgreement_lbl" xml:lang="en-US" id="id_4392741_1095988_1_1">Payment Received On Collaboration Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PaymentReceivedOnCollaborationAgreement_lbl" xml:lang="en-US" id="id_4392741_1095988_2_1">Received including upfront, annual maintenance and milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PaymentReceivedOnCollaborationAgreement" xlink:to="mgnx_PaymentReceivedOnCollaborationAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" id="id_4392741_936416_1_1">Payments For Restructuring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" id="id_4392741_936416_14_1">Principal payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_4392741_936514_1_1">Payments To Acquire Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_4392741_936514_14_1">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_930605_1_1">Pension And Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_930605_2_1">Employee Benefit Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority" xlink:label="mgnx_PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority_lbl" xml:lang="en-US" id="id_4392741_1136112_3_1">Percentage likely of largest amount of tax benefit being realized upon ultimate settlement with taxing authority.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority_lbl" xml:lang="en-US" id="id_4392741_1136112_1_1">Percentage Likely Of Largest Amount Of Tax Benefit Being Realized Upon Ultimate Settlement With Taxing Authority</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority_lbl" xml:lang="en-US" id="id_4392741_1136112_2_1">Percentage of largest amount likely to be realized upon ultimate settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority" xlink:to="mgnx_PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:label="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_lbl" xml:lang="en-US" id="id_4392741_1193094_3_1">Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_lbl" xml:lang="en-US" id="id_4392741_1193094_1_1">Percentage Of Shares Of Companys Common Stock Outstanding For Increase In Shares Reserved For Issuance Under Stock Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_lbl" xml:lang="en-US" id="id_4392741_1193094_2_1">Percentage of Common stock share outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:to="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PfizerIncMember_lbl" xml:lang="en-US" id="id_4392741_1115783_3_1">Pfizer Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PfizerIncMember_lbl" xml:lang="en-US" id="id_4392741_1115783_1_1">Pfizer Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PfizerIncMember_lbl" xml:lang="en-US" id="id_4392741_1115783_2_1">Pfizer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PfizerIncMember" xlink:to="mgnx_PfizerIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_4392741_930809_1_1">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_4392741_930809_2_1">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_4392741_931386_1_1">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_4392741_931386_2_1">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xml:lang="en-US" id="id_4392741_924435_1_1">Preferred Stock Dividend Rate Per Dollar Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xml:lang="en-US" id="id_4392741_924435_2_1">Accrued noncumulative dividends on preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US" id="id_4392741_934823_1_1">Preferred Stock Liquidation Preference Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US" id="id_4392741_934823_2_1">Aggregate liquidation preference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_4392741_932596_1_1">Preferred Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_4392741_932596_2_1">Convertible preferred stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_4392741_932596_12_1">Undesignated preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_4392741_929540_1_1">Preferred Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_4392741_929540_2_1">Convertible preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_4392741_929540_12_1">Undesignated preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_4392741_932934_1_1">Preferred Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_4392741_932934_2_1">Convertible preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_4392741_932934_12_1">Undesignated preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_4392741_926142_1_1">Preferred Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_4392741_926142_2_1">Convertible preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_4392741_926142_12_1">Undesignated preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_4392741_933055_1_1">Preferred Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_4392741_933055_2_1">Convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_4392741_937707_1_1">Prepaid Expense Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_4392741_937707_2_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_4392741_939370_1_1">Proceeds From Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_4392741_939370_2_1">Proceeds from initial public offering net of expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses" xlink:label="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses_lbl" xml:lang="en-US" id="id_4392741_961833_3_1">Proceeds from issuance initial public offering before offering expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses_lbl" xml:lang="en-US" id="id_4392741_961833_1_1">Proceeds From Issuance Initial Public Offering Before Offering Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses_lbl" xml:lang="en-US" id="id_4392741_961833_2_1">Proceeds from initial public offering before offering expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses" xlink:to="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_4392741_938994_1_1">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_4392741_938994_2_1">Proceeds from issuance of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_4392741_940632_1_1">Proceeds From Issuance Of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_4392741_940632_2_1">Proceeds from issuance of convertible preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_4392741_940632_12_1">Proceeds from issuance of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="id_4392741_937117_1_1">Proceeds From Issuance Or Sale Of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="id_4392741_937117_2_1">Proceeds from sale of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="id_4392741_939698_1_1">Proceeds From Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="id_4392741_939698_2_1">Cash proceeds from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_4392741_928864_1_1">Property Plant And Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_4392741_928864_2_1">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_4392741_929865_1_1">Property Plant And Equipment By Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_4392741_929865_2_1">Property, Plant and Equipment, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_925725_1_1">Property Plant And Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_925725_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_1037793_3_1">Property plant and equipment estimated useful life.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_1037793_1_1">Property Plant And Equipment Estimated Useful Life Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_1037793_2_1">Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US" id="id_4392741_927780_1_1">Property Plant And Equipment Estimated Useful Lives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US" id="id_4392741_927780_2_1">Leasehold improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_4392741_938855_1_1">Property Plant And Equipment Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_4392741_938855_2_1">Property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_4392741_925379_1_1">Property Plant And Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_4392741_925379_2_1">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_4392741_940861_1_1">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_4392741_940861_2_1">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_4392741_940861_6_1">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_928618_1_1">Property Plant And Equipment Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_928618_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_4392741_925467_1_1">Property Plant And Equipment [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_4392741_925467_2_1">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_4392741_930445_1_1">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_4392741_930445_2_1">Property, Plant and Equipment, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_4392741_928464_1_1">Property Plant And Equipment Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_4392741_928464_2_1">Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:label="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xml:lang="en-US" id="id_4392741_1072861_3_1">Property Plant and Equipment Useful Life And Values [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xml:lang="en-US" id="id_4392741_1072861_1_1">Property Plant And Equipment Useful Life And Values [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xml:lang="en-US" id="id_4392741_1072861_2_1">Property Plant and Equipment Useful Life And Values [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xml:lang="en-US" id="id_4392741_932294_1_1">Property Subject To Or Available For Operating Lease [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xml:lang="en-US" id="id_4392741_932294_2_1">Property Subject to or Available for Operating Lease [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl" xml:lang="en-US" id="id_4392741_925928_1_1">Property Subject To Or Available For Operating Lease [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl" xml:lang="en-US" id="id_4392741_925928_2_1">Property Subject to or Available for Operating Lease [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" id="id_4392741_928965_1_1">Quarterly Financial Information Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" id="id_4392741_928965_2_1">Quarterly Financial Information Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" id="id_4392741_926885_1_1">Quarterly Financial Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" id="id_4392741_926885_2_1">Quarterly Financial Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_4392741_926437_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_4392741_926437_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_4392741_930818_1_1">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_4392741_930818_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="mgnx_RavenBiotechnologiesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RavenBiotechnologiesIncMember_lbl" xml:lang="en-US" id="id_4392741_1218824_3_1">Raven Biotechnologies, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RavenBiotechnologiesIncMember_lbl" xml:lang="en-US" id="id_4392741_1218824_1_1">Raven Biotechnologies Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RavenBiotechnologiesIncMember_lbl" xml:lang="en-US" id="id_4392741_1218824_2_1">Raven Biotechnologies Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RavenBiotechnologiesIncMember" xlink:to="mgnx_RavenBiotechnologiesIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="id_4392741_924049_1_1">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="id_4392741_924049_2_1">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_4392741_926233_1_1">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_4392741_926233_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_4392741_924269_1_1">Research And Development Arrangement Contract To Perform For Others Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_4392741_924269_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_4392741_939407_1_1">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_4392741_939407_2_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_4392741_928963_1_1">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_4392741_928963_2_1">Research and Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_4392741_929876_1_1">Research And Development Expense Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_4392741_929876_2_1">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ResearchObligationCompletionDate" xlink:label="mgnx_ResearchObligationCompletionDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ResearchObligationCompletionDate_lbl" xml:lang="en-US" id="id_4392741_1219855_3_1">Research obligation completion date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ResearchObligationCompletionDate_lbl" xml:lang="en-US" id="id_4392741_1219855_1_1">Research Obligation Completion Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ResearchObligationCompletionDate_lbl" xml:lang="en-US" id="id_4392741_1219855_2_1">Research obligation completion date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ResearchObligationCompletionDate" xlink:to="mgnx_ResearchObligationCompletionDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_4392741_938076_1_1">Restricted Cash And Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_4392741_938076_2_1">Amounts classified as restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_4392741_938076_12_1">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RestrictedCashFairValueDisclosure" xlink:label="mgnx_RestrictedCashFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RestrictedCashFairValueDisclosure_lbl" xml:lang="en-US" id="id_4392741_1089936_3_1">Restricted cash fair value disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RestrictedCashFairValueDisclosure_lbl" xml:lang="en-US" id="id_4392741_1089936_1_1">Restricted Cash Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RestrictedCashFairValueDisclosure_lbl" xml:lang="en-US" id="id_4392741_1089936_2_1">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RestrictedCashFairValueDisclosure" xlink:to="mgnx_RestrictedCashFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US" id="id_4392741_932808_1_1">Restructuring And Related Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US" id="id_4392741_932808_2_1">Restructuring and Related Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_928489_1_1">Restructuring And Related Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_928489_2_1">Lease Exit Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US" id="id_4392741_926911_1_1">Restructuring Cost And Reserve [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US" id="id_4392741_926911_2_1">Restructuring Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" id="id_4392741_926104_1_1">Restructuring Cost And Reserve [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" id="id_4392741_926104_2_1">Restructuring Cost and Reserve [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" id="id_4392741_934071_1_1">Restructuring Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" id="id_4392741_934071_4_1">Accrual Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" id="id_4392741_934071_5_1">Accrual Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" id="id_4392741_933081_1_1">Restructuring Reserve Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" id="id_4392741_933081_2_1">Lease exit liability-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="us-gaap_RestructuringReserveNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveNoncurrent_lbl" xml:lang="en-US" id="id_4392741_935871_1_1">Restructuring Reserve Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveNoncurrent_lbl" xml:lang="en-US" id="id_4392741_935871_2_1">Lease exit liability, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveNoncurrent" xlink:to="us-gaap_RestructuringReserveNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_4392741_935451_1_1">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_4392741_935451_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_4392741_929313_1_1">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_4392741_929313_2_1">Accumulated Deficit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US" id="id_4392741_934838_1_1">Revenue From Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US" id="id_4392741_934838_2_1">Grant revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US" id="id_4392741_934577_1_1">Revenue Recognition Milestone Method Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US" id="id_4392741_934577_2_1">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_924259_1_1">Revenue Recognition Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_4392741_924259_2_1">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_4392741_933119_1_1">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_4392741_933119_2_1">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_4392741_933119_6_1">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_4392741_929243_1_1">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_4392741_929243_2_1">Revenues:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ReviewPeriodByRegulatoryAuthority" xlink:label="mgnx_ReviewPeriodByRegulatoryAuthority"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ReviewPeriodByRegulatoryAuthority_lbl" xml:lang="en-US" id="id_4392741_1249203_3_1">Review period by regulatory authority.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ReviewPeriodByRegulatoryAuthority_lbl" xml:lang="en-US" id="id_4392741_1249203_1_1">Review Period By Regulatory Authority</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ReviewPeriodByRegulatoryAuthority_lbl" xml:lang="en-US" id="id_4392741_1249203_2_1">Review period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ReviewPeriodByRegulatoryAuthority" xlink:to="mgnx_ReviewPeriodByRegulatoryAuthority_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RoyaltyAgreementDisclosureTextBlock" xlink:label="mgnx_RoyaltyAgreementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RoyaltyAgreementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_1203629_3_1">Royalty agreement disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RoyaltyAgreementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_1203629_1_1">Royalty Agreement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RoyaltyAgreementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_1203629_2_1">Product Milestone Payments and Royalty Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RoyaltyAgreementDisclosureTextBlock" xlink:to="mgnx_RoyaltyAgreementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RoyaltyAgreementLineItems" xlink:label="mgnx_RoyaltyAgreementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RoyaltyAgreementLineItems_lbl" xml:lang="en-US" id="id_4392741_1086595_3_1">Royalty Agreement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RoyaltyAgreementLineItems_lbl" xml:lang="en-US" id="id_4392741_1086595_1_1">Royalty Agreement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RoyaltyAgreementLineItems_lbl" xml:lang="en-US" id="id_4392741_1086595_2_1">Royalty Agreement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_RoyaltyAgreementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RoyaltyAgreementTable" xlink:label="mgnx_RoyaltyAgreementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RoyaltyAgreementTable_lbl" xml:lang="en-US" id="id_4392741_1081226_3_1">Royalty agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RoyaltyAgreementTable_lbl" xml:lang="en-US" id="id_4392741_1081226_1_1">Royalty Agreement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RoyaltyAgreementTable_lbl" xml:lang="en-US" id="id_4392741_1081226_2_1">Royalty Agreement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RoyaltyAgreementTable" xlink:to="mgnx_RoyaltyAgreementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement_lbl" xml:lang="en-US" id="id_4392741_1164792_3_1">Royalty payment as percentage of net sales under licensing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement_lbl" xml:lang="en-US" id="id_4392741_1164792_1_1">Royalty Payment As Percentage Of Net Sales Under Licensing Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement_lbl" xml:lang="en-US" id="id_4392741_1164792_2_1">Maximum royalty payments percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" xlink:to="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleLeasebackTransactionDescriptionAxis" xlink:label="us-gaap_SaleLeasebackTransactionDescriptionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleLeasebackTransactionDescriptionAxis_lbl" xml:lang="en-US" id="id_4392741_925378_1_1">Sale Leaseback Transaction Description [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleLeasebackTransactionDescriptionAxis_lbl" xml:lang="en-US" id="id_4392741_925378_2_1">Sale Leaseback Transaction, Description [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionDescriptionAxis" xlink:to="us-gaap_SaleLeasebackTransactionDescriptionAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleLeasebackTransactionNameDomain" xlink:label="us-gaap_SaleLeasebackTransactionNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleLeasebackTransactionNameDomain_lbl" xml:lang="en-US" id="id_4392741_924314_1_1">Sale Leaseback Transaction Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleLeasebackTransactionNameDomain_lbl" xml:lang="en-US" id="id_4392741_924314_2_1">Sale Leaseback Transaction, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionNameDomain" xlink:to="us-gaap_SaleLeasebackTransactionNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_4392741_931590_1_1">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_4392741_931590_2_1">Sale of Stock, Name of Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesMember_lbl" xml:lang="en-US" id="id_4392741_926597_1_1">Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesMember_lbl" xml:lang="en-US" id="id_4392741_926597_2_1">Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesMember" xlink:to="us-gaap_SalesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_4392741_928220_1_1">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_4392741_928220_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_4392741_925701_1_1">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_4392741_925701_2_1">Schedule of Dilutive Securities Used In Calculation of Diluted Earnings Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_931404_1_1">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_931404_2_1">Components of the Company's Deferred Tax Assets (Liabilities)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_927124_1_1">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_927124_2_1">Computation of Basic and Diluted Income (Loss) Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_930769_1_1">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_930769_2_1">Reconciliation of Reported Estimated Income Tax Benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_4392741_925602_1_1">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_4392741_925602_2_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_4392741_931816_1_1">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_4392741_931816_2_1">Schedule of Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_926102_1_1">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_926102_2_1">Future Principal Payments Under Lease Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_4392741_931140_1_1">Schedule Of Property Plant And Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_4392741_931140_2_1">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_928012_1_1">Schedule Of Quarterly Financial Information Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_928012_2_1">Company's Consolidated Quarterly Results of Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" id="id_4392741_924950_1_1">Schedule Of Restructuring And Related Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" id="id_4392741_924950_2_1">Schedule of Restructuring and Related Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl" xml:lang="en-US" id="id_4392741_926756_1_1">Schedule Of Restructuring Reserve By Type Of Cost [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl" xml:lang="en-US" id="id_4392741_926756_2_1">Changes in Lease Exit Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_4392741_930578_1_1">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_4392741_930578_2_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_924843_1_1">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_924843_2_1">Schedule of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_931898_1_1">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_931898_2_1">Schedule of Fair Value Option Award Estimated on the Date of Grant Using the Black-Scholes Option-Pricing Model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_928772_1_1">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" id="id_4392741_928772_2_1">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US" id="id_4392741_924499_1_1">Schedules Of Concentration Of Risk By Risk Factor [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US" id="id_4392741_924499_2_1">Summary of Percentage of Customer Concentration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SecondRightToDevelopCollaborationMember" xlink:label="mgnx_SecondRightToDevelopCollaborationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SecondRightToDevelopCollaborationMember_lbl" xml:lang="en-US" id="id_4392741_1218880_3_1">Second right to develop collaboration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SecondRightToDevelopCollaborationMember_lbl" xml:lang="en-US" id="id_4392741_1218880_1_1">Second Right To Develop Collaboration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SecondRightToDevelopCollaborationMember_lbl" xml:lang="en-US" id="id_4392741_1218880_2_1">Second Right to Develop Collaboration [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SecondRightToDevelopCollaborationMember" xlink:to="mgnx_SecondRightToDevelopCollaborationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1166280_3_1">Series A1 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1166280_1_1">Series A 1 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1166280_2_1">Series A-1 Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1166416_3_1">Series A2 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1166416_1_1">Series A 2 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1166416_2_1">Series A-2 Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesAOnePreferredStockMember" xlink:label="mgnx_SeriesAOnePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesAOnePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1184171_3_1">Series A- 1 preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesAOnePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1184171_1_1">Series A One Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesAOnePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1184171_2_1">Series A- One Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesAOnePreferredStockMember" xlink:to="mgnx_SeriesAOnePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_930435_1_1">Series A Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_930435_2_1">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesATwoPreferredStockMember" xlink:label="mgnx_SeriesATwoPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesATwoPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1218712_3_1">Series A- two preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesATwoPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1218712_1_1">Series A Two Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesATwoPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1218712_2_1">Series A- Two Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesATwoPreferredStockMember" xlink:to="mgnx_SeriesATwoPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1124615_3_1">Series B convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1124615_1_1">Series B Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1124615_2_1">Series B Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesBConvertiblePreferredStockMember" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_932774_1_1">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_932774_2_1">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1031975_3_1">Series C convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1031975_1_1">Series C Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1031975_2_1">Series C Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesCConvertiblePreferredStockMember" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_930400_1_1">Series C Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_930400_2_1">Series C Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1225370_3_1">Series D1 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1225370_1_1">Series D 1 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1225370_2_1">Series D-1 Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:to="mgnx_SeriesD1ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1218718_3_1">Series D2 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1218718_1_1">Series D 2 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1218718_2_1">Series D-2 Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesDConvertiblePreferredStockMember" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_997107_3_1">Series D convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_997107_1_1">Series D Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_997107_2_1">Series D Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesDConvertiblePreferredStockMember" xlink:to="mgnx_SeriesDConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_929177_1_1">Series D Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_929177_2_1">Series D Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesDTwoPreferredStockMember" xlink:label="mgnx_SeriesDTwoPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesDTwoPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1165094_3_1">Series D-2 preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesDTwoPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1165094_1_1">Series D Two Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesDTwoPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1165094_2_1">Series D Two Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesDTwoPreferredStockMember" xlink:to="mgnx_SeriesDTwoPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ServierMember_lbl" xml:lang="en-US" id="id_4392741_1218717_3_1">Servier.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ServierMember_lbl" xml:lang="en-US" id="id_4392741_1218717_1_1">Servier [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ServierMember_lbl" xml:lang="en-US" id="id_4392741_1218717_2_1">Servier [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ServierMember" xlink:to="mgnx_ServierMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_4392741_938471_1_1">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_4392741_938471_2_1">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged_lbl" xml:lang="en-US" id="id_4392741_993514_3_1">Share based compensation arrangement by share based payment award equity instrument number of shares exchanged.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged_lbl" xml:lang="en-US" id="id_4392741_993514_1_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Number Of Shares Exchanged</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged_lbl" xml:lang="en-US" id="id_4392741_993514_2_1">Total original Options exchanged for replacement Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_4392741_926550_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_4392741_926550_2_1">Options granted, maximum term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US" id="id_4392741_927740_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US" id="id_4392741_927740_2_1">Expected forfeiture rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_4392741_928648_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_4392741_928648_2_1">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_4392741_926378_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_4392741_926378_2_1">Expected life of option term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_4392741_926378_12_1">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_4392741_925061_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_4392741_925061_2_1">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_4392741_924177_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_4392741_924177_2_1">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_4392741_926498_1_1">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_4392741_926498_2_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" id="id_4392741_923350_1_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" id="id_4392741_923350_2_1">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_4392741_929330_1_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_4392741_929330_2_1">Aggregate of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_lbl" xml:lang="en-US" id="id_4392741_993610_3_1">Share based compensation arrangement by share based payment award number of shares authorized after increase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_lbl" xml:lang="en-US" id="id_4392741_993610_1_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_lbl" xml:lang="en-US" id="id_4392741_993610_2_1">Increase in aggregate of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue" xlink:label="mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue_lbl" xml:lang="en-US" id="id_4392741_1203694_3_1">Sharebased compensation arrangement by sharebased payment award option exercised intrinsic value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue_lbl" xml:lang="en-US" id="id_4392741_1203694_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Option Exercised Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue_lbl" xml:lang="en-US" id="id_4392741_1203694_2_1">Aggregate intrinsic value of options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue" xlink:to="mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_4392741_939053_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_4392741_939053_2_1">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_4392741_924337_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_4392741_924337_2_1">Shares, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_4392741_930255_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_4392741_930255_2_1">Weighted- Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_4392741_930128_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_4392741_930128_2_1">Weighted- Average Remaining Contractual Term, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_4392741_931512_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_4392741_931512_14_1">Shares, Forfeited or expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_4392741_926164_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_4392741_926164_2_1">Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_4392741_928357_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_4392741_928357_2_1">Weighted-average grant-date fair value of options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_4392741_939707_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_4392741_939707_2_1">Aggregate Intrinsic Value, Outstanding, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_4392741_928127_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_4392741_928127_4_1">Shares, Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_4392741_928127_5_1">Shares, Outstanding, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_4392741_928127_2_1">Common stock share outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_4392741_927714_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_4392741_927714_4_1">Weighted- Average Exercise Price, Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_4392741_927714_5_1">Weighted- Average Exercise Price, Outstanding, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_4392741_927714_2_1">weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_4392741_925836_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term 2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_4392741_925836_2_1">Weighted- Average Remaining Contractual Term, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_4392741_938271_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_4392741_938271_2_1">Aggregate Intrinsic Value, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_4392741_929888_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_4392741_929888_2_1">Shares, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_4392741_928214_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_4392741_928214_2_1">Weighted- Average Exercise Price, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_4392741_930352_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_4392741_930352_2_1">Weighted- Average Remaining Contractual Term, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" id="id_4392741_933472_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" id="id_4392741_933472_2_1">Fair value of shares vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_4392741_928585_1_1">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_4392741_928585_2_1">Equity Award [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_4392741_929456_1_1">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_4392741_929456_2_1">Weighted- Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_4392741_925340_1_1">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_4392741_925340_2_1">Weighted- Average Exercise Price, Forfeited or expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_4392741_927283_1_1">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_4392741_927283_2_1">Weighted- Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_4392741_928548_1_1">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_4392741_928548_2_1">Additional shares sold under over-allotments option to underwriter, price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_4392741_928548_12_1">Price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_4392741_930312_1_1">Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_4392741_930312_4_1">Ending Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_4392741_930312_5_1">Beginning Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_4392741_930312_2_1">Shares of common stock allocated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" id="id_4392741_928283_1_1">Shares Issued Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" id="id_4392741_928283_2_1">Common stock, price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_4392741_931089_1_1">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_4392741_931089_2_1">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US" id="id_4392741_929134_1_1">Software And Software Development Costs [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US" id="id_4392741_929134_2_1">Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" id="id_4392741_926821_1_1">State And Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" id="id_4392741_926821_2_1">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_4392741_932980_1_1">Statement Class Of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_4392741_932980_2_1">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_4392741_927592_1_1">Statement Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_4392741_927592_2_1">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_4392741_926570_1_1">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_4392741_926570_2_1">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_4392741_932756_1_1">Statement Of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_4392741_932756_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_4392741_924693_1_1">Statement Of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_4392741_924693_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_4392741_926289_1_1">Statement Of Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_4392741_926289_2_1">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_4392741_926771_1_1">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_4392741_926771_2_1">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_4392741_934682_1_1">Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_4392741_934682_4_1">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_4392741_934682_5_1">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_4392741_934682_2_1">Total stockholders' equity (deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_4392741_925186_1_1">Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_4392741_925186_2_1">Stockholders' equity (deficit):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockholdersEquityLineItems" xlink:label="mgnx_StockholdersEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockholdersEquityLineItems_lbl" xml:lang="en-US" id="id_4392741_1086872_3_1">Stockholders Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockholdersEquityLineItems_lbl" xml:lang="en-US" id="id_4392741_1086872_1_1">Stockholders Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockholdersEquityLineItems_lbl" xml:lang="en-US" id="id_4392741_1086872_2_1">Stockholders Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_StockholdersEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_927127_1_1">Stockholders Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_4392741_927127_2_1">Stockholders' Equity (Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" id="id_4392741_925324_1_1">Stockholders Equity Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" id="id_4392741_925324_2_1">Reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockholdersEquityTable" xlink:label="mgnx_StockholdersEquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockholdersEquityTable_lbl" xml:lang="en-US" id="id_4392741_976939_3_1">Stockholders equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockholdersEquityTable_lbl" xml:lang="en-US" id="id_4392741_976939_1_1">Stockholders Equity [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockholdersEquityTable_lbl" xml:lang="en-US" id="id_4392741_976939_2_1">Stockholders Equity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockholdersEquityTable" xlink:to="mgnx_StockholdersEquityTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockIssuanceCosts" xlink:label="mgnx_StockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockIssuanceCosts_lbl" xml:lang="en-US" id="id_4392741_1065608_3_1">Costs related to the issuance or offering of stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockIssuanceCosts_lbl" xml:lang="en-US" id="id_4392741_1065608_1_1">Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockIssuanceCosts_lbl" xml:lang="en-US" id="id_4392741_1065608_2_1">Related offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockIssuanceCosts" xlink:to="mgnx_StockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" id="id_4392741_929323_1_1">Stock Issued During Period Shares Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" id="id_4392741_929323_2_1">Shares issued in connection with acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_4392741_926238_1_1">Stock Issued During Period Shares Conversion Of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_4392741_926238_2_1">Conversion of preferred stock to common stock, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_4392741_932873_1_1">Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_4392741_932873_32_1">Number of shares issued or sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_4392741_932873_2_1">Common stock number of shares sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_4392741_932873_12_1">Issuance of common stock/convertible Series D-2 stock, net of offering costs, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment" xlink:label="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment_lbl" xml:lang="en-US" id="id_4392741_953379_3_1">Stock issued during period shares new issues including underwriters over allotment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment_lbl" xml:lang="en-US" id="id_4392741_953379_1_1">Stock Issued During Period Shares New Issues Including Underwriters Over Allotment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment_lbl" xml:lang="en-US" id="id_4392741_953379_2_1">Initial public offering number of share sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment" xlink:to="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_4392741_930668_1_1">Stock Issued During Period Shares Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_4392741_930668_2_1">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_4392741_930668_12_1">Stock option exercises, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_4392741_930668_14_1">Shares, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_lbl" xml:lang="en-US" id="id_4392741_952345_3_1">Stock issued during period, shares to underwriters for exercise of over allotment option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_lbl" xml:lang="en-US" id="id_4392741_952345_1_1">Stock Issued During Period Shares To Underwriters For Exercise Of Over Allotment Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_lbl" xml:lang="en-US" id="id_4392741_952345_2_1">Additional shares sold under over-allotments Option to underwriter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:to="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_4392741_935837_1_1">Stock Issued During Period Value Conversion Of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_4392741_935837_2_1">Conversion of preferred stock to common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_4392741_935837_12_1">Settlement of preferred stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_4392741_936512_1_1">Stock Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_4392741_936512_2_1">Issuance of common stock/convertible Series D-2 stock, net of offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_4392741_936512_12_1">Preferred Stock purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="id_4392741_934355_1_1">Stock Issued During Period Value Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="id_4392741_934355_2_1">Stock option exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockOptionExchangeRatioDescription" xlink:label="mgnx_StockOptionExchangeRatioDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockOptionExchangeRatioDescription_lbl" xml:lang="en-US" id="id_4392741_1192933_3_1">Stock option exchange ratio description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockOptionExchangeRatioDescription_lbl" xml:lang="en-US" id="id_4392741_1192933_1_1">Stock Option Exchange Ratio Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockOptionExchangeRatioDescription_lbl" xml:lang="en-US" id="id_4392741_1192933_2_1">Description of exchange ratio of original options with replacement options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockOptionExchangeRatioDescription" xlink:to="mgnx_StockOptionExchangeRatioDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockOptionOneMember" xlink:label="mgnx_StockOptionOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockOptionOneMember_lbl" xml:lang="en-US" id="id_4392741_972906_3_1">Stock Option One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockOptionOneMember_lbl" xml:lang="en-US" id="id_4392741_972906_1_1">Stock Option One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockOptionOneMember_lbl" xml:lang="en-US" id="id_4392741_972906_2_1">Stock Option One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockOptionOneMember" xlink:to="mgnx_StockOptionOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockOptionPlan2000Member" xlink:label="mgnx_StockOptionPlan2000Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockOptionPlan2000Member_lbl" xml:lang="en-US" id="id_4392741_1108152_3_1">Stock option plan 2000.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockOptionPlan2000Member_lbl" xml:lang="en-US" id="id_4392741_1108152_1_1">Stock Option Plan 2000 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockOptionPlan2000Member_lbl" xml:lang="en-US" id="id_4392741_1108152_2_1">Stock Option Plan 2000 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockOptionPlan2000Member" xlink:to="mgnx_StockOptionPlan2000Member_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockOptionTwoMember" xlink:label="mgnx_StockOptionTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockOptionTwoMember_lbl" xml:lang="en-US" id="id_4392741_1089823_3_1">Stock Option Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockOptionTwoMember_lbl" xml:lang="en-US" id="id_4392741_1089823_1_1">Stock Option Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockOptionTwoMember_lbl" xml:lang="en-US" id="id_4392741_1089823_2_1">Stock Option Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockOptionTwoMember" xlink:to="mgnx_StockOptionTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SubleaseMember" xlink:label="mgnx_SubleaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SubleaseMember_lbl" xml:lang="en-US" id="id_4392741_989577_3_1">Sublease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SubleaseMember_lbl" xml:lang="en-US" id="id_4392741_989577_1_1">Sublease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SubleaseMember_lbl" xml:lang="en-US" id="id_4392741_989577_2_1">Sublease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SubleaseMember" xlink:to="mgnx_SubleaseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_4392741_924078_1_1">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_4392741_924078_2_1">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_4392741_931597_1_1">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_4392741_931597_2_1">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_4392741_925770_1_1">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_4392741_925770_2_1">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_4392741_929519_1_1">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_4392741_929519_2_1">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_4392741_930713_1_1">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_4392741_930713_2_1">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_4392741_932504_1_1">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_4392741_932504_2_1">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_4392741_929873_1_1">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_4392741_929873_2_1">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_4392741_931707_1_1">Subsidiary Sale Of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_4392741_931707_2_1">Subsidiary, Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" id="id_4392741_940843_1_1">Tax Credit Carryforward Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" id="id_4392741_940843_2_1">US Federal Tax credits carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_TaxCreditCarryforwardExpirationYearRangeEnd" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd_lbl" xml:lang="en-US" id="id_4392741_1060487_3_1">Tax credit carryforward expiration year range end.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd_lbl" xml:lang="en-US" id="id_4392741_1060487_1_1">Tax Credit Carryforward Expiration Year Range End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd_lbl" xml:lang="en-US" id="id_4392741_1060487_2_1">Federal Tax credit expiration ending year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd" xlink:to="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_TaxCreditCarryforwardExpirationYearRangeStart" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeStart"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeStart_lbl" xml:lang="en-US" id="id_4392741_1105119_3_1">Tax credit carryforward expiration year range start.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeStart_lbl" xml:lang="en-US" id="id_4392741_1105119_1_1">Tax Credit Carryforward Expiration Year Range Start</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeStart_lbl" xml:lang="en-US" id="id_4392741_1105119_2_1">Federal Tax credit expiration start year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_TaxCreditCarryforwardExpirationYearRangeStart" xlink:to="mgnx_TaxCreditCarryforwardExpirationYearRangeStart_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_4392741_931202_1_1">Text Block [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_4392741_931202_2_1">Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" id="id_4392741_931282_1_1">Trade And Other Accounts Receivable Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" id="id_4392741_931282_2_1">Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US" id="id_4392741_924490_1_1">Treasury Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US" id="id_4392741_924490_2_1">Treasury Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockNumberOfSharesHeld" xlink:label="us-gaap_TreasuryStockNumberOfSharesHeld"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockNumberOfSharesHeld_lbl" xml:lang="en-US" id="id_4392741_930050_1_1">Treasury Stock Number Of Shares Held</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockNumberOfSharesHeld_lbl" xml:lang="en-US" id="id_4392741_930050_2_1">Treasury stock, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockNumberOfSharesHeld" xlink:to="us-gaap_TreasuryStockNumberOfSharesHeld_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US" id="id_4392741_940705_1_1">Treasury Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US" id="id_4392741_940705_14_1">Treasury stock, at cost; 14,381 shares at December 31, 2013 and December 31, 2012</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_TwoThousandAndThirteenStockIncentivePlanMember" xlink:label="mgnx_TwoThousandAndThirteenStockIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_TwoThousandAndThirteenStockIncentivePlanMember_lbl" xml:lang="en-US" id="id_4392741_1035519_3_1">Two thousand and thirteen stock incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_TwoThousandAndThirteenStockIncentivePlanMember_lbl" xml:lang="en-US" id="id_4392741_1035519_1_1">Two Thousand And Thirteen Stock Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_TwoThousandAndThirteenStockIncentivePlanMember_lbl" xml:lang="en-US" id="id_4392741_1035519_2_1">Two Thousand and Thirteen Stock Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_TwoThousandAndThirteenStockIncentivePlanMember" xlink:to="mgnx_TwoThousandAndThirteenStockIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_TwoThousandAndThreeStockOptionPlanMember" xlink:label="mgnx_TwoThousandAndThreeStockOptionPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_TwoThousandAndThreeStockOptionPlanMember_lbl" xml:lang="en-US" id="id_4392741_1047151_3_1">Two thousand and three stock option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_TwoThousandAndThreeStockOptionPlanMember_lbl" xml:lang="en-US" id="id_4392741_1047151_1_1">Two Thousand And Three Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_TwoThousandAndThreeStockOptionPlanMember_lbl" xml:lang="en-US" id="id_4392741_1047151_2_1">Two Thousand and Three Stock Option Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_TwoThousandAndThreeStockOptionPlanMember" xlink:to="mgnx_TwoThousandAndThreeStockOptionPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_4392741_928294_1_1">Type Of Arrangement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_4392741_928294_2_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US" id="id_4392741_923475_1_1">Type Of Restructuring [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US" id="id_4392741_923475_2_1">Type of Restructuring [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_UndesignatedPreferredStockMember" xlink:label="mgnx_UndesignatedPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_UndesignatedPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1135605_3_1">Undesignated Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_UndesignatedPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1135605_1_1">Undesignated Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_UndesignatedPreferredStockMember_lbl" xml:lang="en-US" id="id_4392741_1135605_2_1">Undesignated Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_UndesignatedPreferredStockMember" xlink:to="mgnx_UndesignatedPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities" xlink:label="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities_lbl" xml:lang="en-US" id="id_4392741_939773_1_1">Undistributed Earnings Allocated To Participating Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities_lbl" xml:lang="en-US" id="id_4392741_939773_14_1">Less: undistributed earnings allocated to participating securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities" xlink:to="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_4392741_934467_1_1">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_4392741_934467_4_1">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_4392741_934467_5_1">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" id="id_4392741_940382_1_1">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" id="id_4392741_940382_2_1">Unrecognized interest or penalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="id_4392741_933309_1_1">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="id_4392741_933309_2_1">Increases/(decreases) for current year tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_4392741_933112_1_1">Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_4392741_933112_2_1">Increases/(decreases) for prior year tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xml:lang="en-US" id="id_4392741_940586_1_1">Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xml:lang="en-US" id="id_4392741_940586_14_1">Decreases as a result of expiration of statute of limitations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward" xlink:label="us-gaap_UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward_lbl" xml:lang="en-US" id="id_4392741_936884_1_1">Unrecognized Tax Benefits Resulting In Net Operating Loss Carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward_lbl" xml:lang="en-US" id="id_4392741_936884_2_1">Net operating losses, recognized as a benefit through additional-paid-in-capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward" xlink:to="us-gaap_UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" id="id_4392741_936554_1_1">Unrecognized Tax Benefits That Would Impact Effective Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" id="id_4392741_936554_2_1">Gross unrecognized tax benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_UpfrontFeeAndParticipationRecognitionDate" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionDate_lbl" xml:lang="en-US" id="id_4392741_1218973_3_1">Upfront fee and participation recognition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionDate_lbl" xml:lang="en-US" id="id_4392741_1218973_1_1">Upfront Fee And Participation Recognition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionDate_lbl" xml:lang="en-US" id="id_4392741_1218973_2_1">Term of the agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_UpfrontFeeAndParticipationRecognitionDate" xlink:to="mgnx_UpfrontFeeAndParticipationRecognitionDate_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod_lbl" xml:lang="en-US" id="id_4392741_1001330_3_1">Upfront payment recognition period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod_lbl" xml:lang="en-US" id="id_4392741_1001330_1_1">Upfront Payment Recognition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod_lbl" xml:lang="en-US" id="id_4392741_1001330_2_1">Expected period of development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_UpfrontPaymentRecognitionPeriod" xlink:to="mgnx_UpfrontPaymentRecognitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_4392741_931855_1_1">Use Of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_4392741_931855_2_1">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_USGovernmentAgenciesMember" xlink:label="mgnx_USGovernmentAgenciesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_USGovernmentAgenciesMember_lbl" xml:lang="en-US" id="id_4392741_1074019_3_1">U S government agencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_USGovernmentAgenciesMember_lbl" xml:lang="en-US" id="id_4392741_1074019_1_1">U S Government Agencies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_USGovernmentAgenciesMember_lbl" xml:lang="en-US" id="id_4392741_1074019_2_1">Government Agencies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_USGovernmentAgenciesMember" xlink:to="mgnx_USGovernmentAgenciesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_4392741_929614_1_1">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_4392741_929614_2_1">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" id="id_4392741_935273_1_1">Warrants And Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" id="id_4392741_935273_2_1">Preferred stock warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" id="id_4392741_936341_1_1">Warrants Not Settleable In Cash Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" id="id_4392741_936341_14_1">Preferred stock warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US" id="id_4392741_925122_1_1">Weighted Average Number Diluted Shares Outstanding Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US" id="id_4392741_925122_2_1">Effect of dilutive securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_4392741_924805_1_1">Weighted Average Number Of Diluted Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_4392741_924805_2_1">Diluted weighted average number of common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_4392741_924805_6_1">Diluted weighted average common shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_4392741_929768_1_1">Weighted Average Number Of Shares Outstanding Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_4392741_929768_32_1">Basic weighted average common shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_4392741_929768_2_1">Basic weighted average common shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_4392741_929768_12_1">Basic weighted average number of common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>mgnx-20131231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2014-03-18T16:29:55Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DocumentandEntityInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureOrganizationAndNatureOfOperationsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesUsedInCalculationOfDilutedEarningsPerShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesUsedInCalculationOfDilutedEarningsPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureStockholdersEquityDeficitAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSharedBasedPaymentsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureLeaseExitLiabilityAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureLeaseExitLiabilityChangesInLeaseExitLiability" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureEmployeeBenefitPlanAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20131231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_DocumentAndEntityInformationAbstract" xlink:label="mgnx_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="us-gaap_RestructuringReserveNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD1ConvertiblePreferredStockMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_RestructuringReserveNoncurrent" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_RestructuringReserveCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockNumberOfSharesHeld" xlink:label="us-gaap_TreasuryStockNumberOfSharesHeld"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD1ConvertiblePreferredStockMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockNumberOfSharesHeld" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromGrants" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesD1ConvertiblePreferredStockMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_2" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncreaseDecreaseInDeferredRent" xlink:label="mgnx_IncreaseDecreaseInDeferredRent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.1200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestructuringReserve" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mgnx_IncreaseDecreaseInDeferredRent" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalCommonStockIssuePricePerShare" xlink:label="mgnx_AdditionalCommonStockIssuePricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:label="mgnx_OrganizationAndNatureOfBusinessLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OrganizationAndNatureOfBusinessTable" xlink:label="mgnx_OrganizationAndNatureOfBusinessTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses" xlink:label="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment" xlink:label="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="mgnx_AdditionalCommonStockIssuePricePerShare" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OrganizationAndNatureOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OrganizationAndNatureOfBusinessTable" xlink:to="mgnx_OrganizationAndNatureOfBusinessLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mgnx_OrganizationAndNatureOfBusinessTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairedFinancingReceivableRelatedAllowance" xlink:label="us-gaap_ImpairedFinancingReceivableRelatedAllowance"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum" xlink:label="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority" xlink:label="mgnx_PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairedFinancingReceivableRelatedAllowance" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="mgnx_PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_MoneyMarketFundsFairValueDisclosure" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RestrictedCashFairValueDisclosure" xlink:label="mgnx_RestrictedCashFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="mgnx_MoneyMarketFundsFairValueDisclosure" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="mgnx_RestrictedCashFairValueDisclosure" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_USGovernmentAgenciesMember" xlink:label="mgnx_USGovernmentAgenciesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_MajorCustomersAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_ServierMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_GileadSciencesIncMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_PfizerIncMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_USGovernmentAgenciesMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_EliLillyMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_USGovernmentAgenciesMember" xlink:label="mgnx_USGovernmentAgenciesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_MajorCustomersAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_GileadSciencesIncMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_PfizerIncMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_EliLillyMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_ServierMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_USGovernmentAgenciesMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mgnx_LaboratoryAndOfficeEquipmentMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities" xlink:label="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesUsedInCalculationOfDilutedEarningsPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesDConvertiblePreferredStockMember" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesDConvertiblePreferredStockMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:label="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ConvertiblePreferredStockConversionPrice" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="mgnx_RavenBiotechnologiesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesAOnePreferredStockMember" xlink:label="mgnx_SeriesAOnePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesATwoPreferredStockMember" xlink:label="mgnx_SeriesATwoPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesDTwoPreferredStockMember" xlink:label="mgnx_SeriesDTwoPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockholdersEquityLineItems" xlink:label="mgnx_StockholdersEquityLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockholdersEquityTable" xlink:label="mgnx_StockholdersEquityTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockIssuanceCosts" xlink:label="mgnx_StockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_UndesignatedPreferredStockMember" xlink:label="mgnx_UndesignatedPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="mgnx_RavenBiotechnologiesIncMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesAOnePreferredStockMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesATwoPreferredStockMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesDTwoPreferredStockMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_UndesignatedPreferredStockMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="mgnx_StockholdersEquityTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_SharePrice" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_StockIssuanceCosts" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_SharesIssued" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_ConvertiblePreferredStockConversionPrice" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityTable" xlink:to="mgnx_StockholdersEquityLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_EquityIncentivePlanTwoThousandThreeMember" xlink:label="mgnx_EquityIncentivePlanTwoThousandThreeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OriginalOptionsMember" xlink:label="mgnx_OriginalOptionsMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:label="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue" xlink:label="mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockOptionExchangeRatioDescription" xlink:label="mgnx_StockOptionExchangeRatioDescription"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockOptionOneMember" xlink:label="mgnx_StockOptionOneMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockOptionPlan2000Member" xlink:label="mgnx_StockOptionPlan2000Member"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockOptionTwoMember" xlink:label="mgnx_StockOptionTwoMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_TwoThousandAndThirteenStockIncentivePlanMember" xlink:label="mgnx_TwoThousandAndThirteenStockIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_TwoThousandAndThreeStockOptionPlanMember" xlink:label="mgnx_TwoThousandAndThreeStockOptionPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="mgnx_OriginalOptionsMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="mgnx_StockOptionExchangeRatioDescription" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_StockOptionPlan2000Member" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_TwoThousandAndThreeStockOptionPlanMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_TwoThousandAndThirteenStockIncentivePlanMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_EquityIncentivePlanTwoThousandThreeMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mgnx_StockOptionOneMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mgnx_StockOptionTwoMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd" xlink:label="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart" xlink:label="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxesDisclosureLineItems" xlink:label="mgnx_IncomeTaxesDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxesDisclosureTable" xlink:label="mgnx_IncomeTaxesDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart" xlink:label="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:label="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart" xlink:label="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:label="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_TaxCreditCarryforwardExpirationYearRangeEnd" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_TaxCreditCarryforwardExpirationYearRangeStart" xlink:label="mgnx_TaxCreditCarryforwardExpirationYearRangeStart"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward" xlink:label="us-gaap_UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="mgnx_IncomeTaxesDisclosureTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_TaxCreditCarryforwardExpirationYearRangeStart" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_TaxCreditCarryforwardExpirationYearRangeEnd" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureLineItems" xlink:to="mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_IncomeTaxesDisclosureTable" xlink:to="mgnx_IncomeTaxesDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1.0100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" xlink:label="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" xlink:label="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" xlink:label="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="mgnx_IncomeTaxReconciliationDeferredTaxAdjustments" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ConvertiblePreferredStockSeriesDMember" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LeaseExpirationYear" xlink:label="mgnx_LeaseExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_ConvertiblePreferredStockSeriesDMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_LeaseExpirationYear" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve_2" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:to="mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalLicenseGrantFeesUnderAgreement" xlink:label="mgnx_AdditionalLicenseGrantFeesUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance" xlink:label="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalSalesMilestonesUnderAgreement" xlink:label="mgnx_AdditionalSalesMilestonesUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ClinicalDataReviewPeriodForAgreementTermination" xlink:label="mgnx_ClinicalDataReviewPeriodForAgreementTermination"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_CollaborativeAgreementPeriodOfContract" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ExpiredOptionAgreementMember" xlink:label="mgnx_ExpiredOptionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_GreenCrossCorporationMember" xlink:label="mgnx_GreenCrossCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LesLaboratoiresServierMember" xlink:label="mgnx_LesLaboratoiresServierMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_NonRefundableFees" xlink:label="mgnx_NonRefundableFees"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_NumberOfPrograms" xlink:label="mgnx_NumberOfPrograms"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OptionAgreementMember" xlink:label="mgnx_OptionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PaymentReceivedOnCollaborationAgreement" xlink:label="mgnx_PaymentReceivedOnCollaborationAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ResearchObligationCompletionDate" xlink:label="mgnx_ResearchObligationCompletionDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ReviewPeriodByRegulatoryAuthority" xlink:label="mgnx_ReviewPeriodByRegulatoryAuthority"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SecondRightToDevelopCollaborationMember" xlink:label="mgnx_SecondRightToDevelopCollaborationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_UpfrontFeeAndParticipationRecognitionDate" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionDate"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgnx_SecondRightToDevelopCollaborationMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableFees" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalLicenseGrantFeesUnderAgreement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalSalesMilestonesUnderAgreement" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontPaymentRecognitionPeriod" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ReviewPeriodByRegulatoryAuthority" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfAnnualMaintenancePaymentReceived" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_PaymentReceivedOnCollaborationAgreement" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ResearchObligationCompletionDate" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborativeAgreementPeriodOfContract" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfPrograms" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontFeeAndParticipationRecognitionDate" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ClinicalDataReviewPeriodForAgreementTermination" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_RangeAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="mgnx_LicenseAndCollaborationAgreementsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_LesLaboratoiresServierMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_GileadSciencesIncMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_PfizerIncMember" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_GreenCrossCorporationMember" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_EliLillyMember" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="mgnx_ExpiredOptionAgreementMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="mgnx_OptionAgreementMember" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_LeaseMember" xlink:label="mgnx_LeaseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ManufacturingFacilitiesMember" xlink:label="mgnx_ManufacturingFacilitiesMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OfficeAndLaboratorySpaceMember" xlink:label="mgnx_OfficeAndLaboratorySpaceMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLeasesLineItems" xlink:label="mgnx_OperatingLeasesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_OperatingLeasesTable" xlink:label="mgnx_OperatingLeasesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleLeasebackTransactionDescriptionAxis" xlink:label="us-gaap_SaleLeasebackTransactionDescriptionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleLeasebackTransactionNameDomain" xlink:label="us-gaap_SaleLeasebackTransactionNameDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_SubleaseMember" xlink:label="mgnx_SubleaseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="mgnx_OperatingLeasesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OperatingLeasesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OperatingLeasesLineItems" xlink:to="us-gaap_DeferredRentCredit" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OperatingLeasesLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OperatingLeasesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OperatingLeasesTable" xlink:to="us-gaap_SaleLeasebackTransactionDescriptionAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OperatingLeasesTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OperatingLeasesTable" xlink:to="mgnx_OperatingLeasesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="mgnx_OfficeAndLaboratorySpaceMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="mgnx_ManufacturingFacilitiesMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleLeasebackTransactionDescriptionAxis" xlink:to="us-gaap_SaleLeasebackTransactionNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleLeasebackTransactionNameDomain" xlink:to="mgnx_LeaseMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleLeasebackTransactionNameDomain" xlink:to="mgnx_SubleaseMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalPaymentUponAchievementOfMilestone" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" xlink:label="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RoyaltyAgreementLineItems" xlink:label="mgnx_RoyaltyAgreementLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RoyaltyAgreementTable" xlink:label="mgnx_RoyaltyAgreementTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mgnx_RoyaltyAgreementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_AdditionalPaymentUponAchievementOfMilestone" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementTable" xlink:to="mgnx_RoyaltyAgreementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" xlink:label="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan" xlink:label="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_Revenues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_AdditionalLicenseGrantFeesUnderAgreement" xlink:label="mgnx_AdditionalLicenseGrantFeesUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ReviewPeriodByRegulatoryAuthority" xlink:label="mgnx_ReviewPeriodByRegulatoryAuthority"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="mgnx_ServierMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgnx_AdditionalLicenseGrantFeesUnderAgreement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgnx_ReviewPeriodByRegulatoryAuthority" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharePrice" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:label="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="mgnx-20131231.xsd#mgnx_RoyaltyAgreementDisclosureTextBlock" xlink:label="mgnx_RoyaltyAgreementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="mgnx_RoyaltyAgreementDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g644794g04y47_g.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644794g04y47_g.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-36AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:3YK87)R96QS:CPO<F1F.FQI/@H@("`@/"]R9&8Z4V5Q/@H@("`\+V1C
M.F-R96%T;W(^"B`@(#QD8SIT:71L93X*("`@(#QR9&8Z06QT/@H@("`@(#QR
M9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S`T>30W7V<\+W)D9CIL:3X*
M("`@(#PO<F1F.D%L=#X*("`@/"]D8SIT:71L93X*("`@/'AM<%)I9VAT<SI5
M<V%G951E<FUS/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N
M9STB>"UD969A=6QT(B\^"B`@("`\+W)D9CI!;'0^"B`@(#PO>&UP4FEG:'1S
M.E5S86=E5&5R;7,^"B`@(#Q)<'1C-'AM<$-O<F4Z0W)E871O<D-O;G1A8W1)
M;F9O"B`@("!)<'1C-'AM<$-O<F4Z0VE!9')%>'1A9'(](B(*("`@($EP=&,T
M>&UP0V]R93I#:4%D<D-I='D](B(*("`@($EP=&,T>&UP0V]R93I#:4%D<E)E
M9VEO;CTB(@H@("`@27!T8S1X;7!#;W)E.D-I061R4&-O9&4](B(*("`@($EP
M=&,T>&UP0V]R93I#:4%D<D-T<GD](B(*("`@($EP=&,T>&UP0V]R93I#:51E
M;%=O<FL](B(*("`@($EP=&,T>&UP0V]R93I#:45M86EL5V]R:STB(@H@("`@
M27!T8S1X;7!#;W)E.D-I57)L5V]R:STB(B\^"B`@/"]R9&8Z1&5S8W)I<'1I
M;VX^"B`\+W)D9CI21$8^"CPO>#IX;7!M971A/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"CP_>'!A8VME="!E;F0](G<B/S[_[@`.061O8F4`9,`````!_]L`
MA``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0(!`0("`@$"`@,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1
M"`#U`2P#`1$``A$!`Q$!_\0`C0`!``$$`P$!`0````````````@&!PD*`P0%
M`0(+`0$`````````````````````$```!P`"`0,"!`(&!@4("P`!`@,$!08'
M``@1$A,)(10Q(A4602-187$R)!>!0C,E&`KPD7.W.*&Q8F,T>!EY@T6%M29&
M=K97*3D1`0````````````````````#_V@`,`P$``A$#$0`_`(972\6G1+?8
MKI?+))6J[6:37EK+.SCLSJ9E)-QX!5R^.IZ3@<"D*0I`*4B:92D(4I2@4`IS
M@.`X#@.!3J-NJ[BT/*2A8(I:W1\8C,/JZF[2-*MHQP?VTG2K8!]0%$?`B7^^
M0ABF,4"F*(A47`<!P'`<!P'`^"(%`1,(``!Y$1'P``'XB(C]`#@<8+H&$`*L
MD(B/@`!0@B(C^```#Y$>!R\!P'`^>0#QY$`\_0/Z_P"S^G@!$``1$0```1$1
M'P``'U$1$?H``'`_)5$SCX*<AA](&\%,`B)1_`P``_4H_P!/X<#]\#I2,E'P
M[![*RSYI&1D<V6>/Y!\NFV9LVJ!!46<.%U3%3333('U$1^OX!]?`<"FZ/H%,
MTF$+8:18&-@BQ5,W55:F.1PS<E\^6T@Q7(D\8.!*'J*54A!.00,7R4?/`K'@
M.!Q^ZEY]/N$]7J`GCUE\^L?P)^/]\?/X?CP.3@>\>JVI,5BJ56SD,VA4[*Y*
M>O3)#-ZTL!11LC@IF0"A75@,`D?G\-#`(>%!\\#P>`X#@?A0X)D.<0$0(4QA
M`/Q$"AY_C].!O/\`Q=?'Y5^E^6*6F1EF]OV;7(.OR-XL[,#A"Q,.5(\G#TVI
M$622<_I#`T@*CERJ!57[KPH)2)D123#*9P'`<"Q&F=7NN6R-';34<.RV[@^3
M.DN\G:3`.9<"G+Z3&;3I62<TR6`/P41<)G*(`("`@`\#2X^4_'.JV`=EG63=
M8&MC9A7(=)QJ,=(V=6S5JNVV7%)_&U6K+2!'$TW5B810BK\KEZZ!-5TFB4$S
M)*E$,:O`LYNZVM(9U*J8PBR6MQ3$,I[OH/+)Q92F.[/66[DAH]U.B(%!,CC\
MHD$WH`RGI#@5?G1[NI2*TKI`19;NK&(JV!.'1,W9HNE/)R(F2%15,'J2`E*Y
M]H01]\#^V`$\<"M.!8B)ZYYK"ZV]V5BTDB65Y]PZ(Q/(+'AVDV^!5.2GFZ)A
M^Y,[?-U1(**BAVR8B8Q"`(AZ0OOP'`XG"Z35NNZ7,8J#5!9RN8B2JQRHH)F5
M5,1%`BBZQRID$0(0ICF'Z%`1$`X%A\9[$4_;I*V1E9BK$P5JKG\SB58"1G(Q
MBK@[9F^(X2]1(]XY42./V+CTN"$*)OS>#^@+^\!P(?7B7[.(]CJE'5.-CE,O
M59F,/J]T:TZAO+4+$\MK\$1=,;.R5,4&*27GZ"0$@4*=<>!.2H6N;HEMK=WJ
M[ANTL50G8RR0#M['1\NU;2T.[3?1Z[J)EFSV*DD4W")1.@X1505#R4Y3%$0X
M&?O7>P.R:9UD^.B`D$7$\OW)B]PJN^,,@Q;'7&GZ%#Q5Y;5IHPH#5[5V<36[
M$C7EU44G#51BDEY,X6/Y3]7`L]>?CAQMN]Z@R\;$;#E<;M?;)AUJTS.KGJN1
M:K:8ED\1-(DLL)<\O8NJ[`S@,VRJ#B->IKKM5S`)TB@0/=#QZUT@ZG7O4>RE
M1R.-[4;'_P`)D(G"6G.HJ4SNJ7[;='=::\H[U_GLP^B)*(K=*I[5BL==%X@,
MA(&3*HD!2B8HA7+GXVNM+G3NT2M)E]/OF9=8HG(ZLYJ)MJQ"F62\[)IK8\O,
MQ)M>L\?'YU4J_GL:X19O$%$W#QU+(K)(J#^5,0JZB=6ND./C\@%<M;2V[76J
M=UJHFM0<[!6;(+3:<WJEG663E:?`6E@RF:VPVZLVJ.<)*R[8_P!@O&"W\)@8
MQC'"$'Q:Y=FNI]P7)[=5$;Q5<VS?5=>JN>65-M))6^9IB#4:;!SS--,&<RHV
M-)D=+(@D9NNY;%]28I>2"'C-NS6R]_M&R_'-QKCO2(1Y>G%AAJWU]RK-:]L\
M1'MZY8`/0J%,&9Q$<TJ'A9,7@S1W*3-)H#Q10QD/!PE]*_&CB3S3NCK%HEK6
M=5;LQH^JYKHE`GM0R?4+54GV>0,G-,92NZ1FS"0J"@RH,RE=-%45EFAOR&`A
MP,`!96W_`!Z]5>P^1T<,#L.KK)6/N;!](]-0W9G57D38G,['GD5-+KD/546R
MT"R9`U%=NP5=+./J!1.FJF50P4CB7QV=$9+L[%='^L$AV&I:E`T/6V^YW?3I
M7.Y\]ZK>6QC\9VR4IPRCX):"L#VS1(Q3)"5(LS;1JI')Q]21TSA(9'XZ.NMH
MV/J-6(>QW*CQ6ZZ%HV?Z+E#K<,0V/1*LUJ]+L-NJ5\@KIE:<E7TX2S$B"I.6
MSMH91JL()E./J`W`QJZQ5.O+K=ZQG>!26H%SH9ZL9W9K5JIJ^A/REH-<UZS:
M+A"LH(A&L+5WK$Z#EDT<^ITV,!P5$0\<#(U\B':70.N>U:QTER.F953.ME(I
M,%FT9F<IEM,E#6)&UYW$.W5^?V>2BQM2ER5D)LR[&31>)F2<-R+&!1453'#V
M]C^+S%<HS#3H">O4[`:SFO7HNL%U*R[/AS?/KSHB%?1LTCC\1AQ'*>OQ";Z-
M<"WC)5P<1=N$_7Z#$.F54)/W!0XV#L";U'#S\`]!`/(B`@4Z!1,3^H!]8^0_
MK'^G@:R@?@']@?\`FX'W@.!FW^)KX_>JW=2/NLQKFAW=[<<]EVY)C%8%PPJK
M-W6)$@#"VE6R)?>6*8B))PDNU<)L_P!/.S<(@4Z@@JD8X;D<9&LX>-CXB.2]
MB/BF+2-8H>M13V6;%NFU;)>XJ8ZJGMH)%#U&$3#X\B(CP.]P'`<!P-$SY4^F
M]VZJ=E;98'AIRPY9M5EG[U0+[+KKR3AU)S;U69L].L$LL9116S5Z1>J"F*QO
M<>1YD5P\F!8$PQE<!P'`<!P'`<``B`@("("`^0$/H("'X"`_T\#RHR"A(565
M7AXB-BEIR0-+3*L>S0:'E90Z*;<\@_%`A/N79T4BE$YO(CX\_B(B(>KP'`>?
MX?P_'Q_9Y\?]7G@.!+:M=V=VI[?JPC6G]8BE>GCJYN<?>I5\5G1RW^2-(6AI
M<!</E$)]F_(JHV`A"-1(W5,`#[@@H`5Y-_(?LL@?,$*_0<#SB!R#=VW8VDU3
M-LS/5Z^AIB:#HCY],(IV!T]FV<VY?+.'@+KBY.J<I2+$2322(%Z>H?<C/:JU
M[D*[';&M#T/L]9ZG<V5HE<+;;_C3*1CKE8KG9FTWCCJ;8'6D%WTZ<D4Y.=R1
MD0XCY!1,HG#QM8[TT2H;!HRG5?*<Q>8%J6>Y_5=AR[3\AC&.4[+>Z8,@\=:@
MEC\;."EGBZLF_`S!NT?D51]KW5/*I@$H6.H/>71\TTS1M#J.8==HR%U6@-<Q
MNN+H9&P;X=)TYA[!V+$U$9R;8QWB*Z`JJ.E7:JSHZJ@KBIZO`!87*]MTG$=8
MAMLRJ=)3-`K\S(S,4]C&#4(I`)?[I.3A%(14AX]Q6GS)ZHU48G**7VQ@('@2
ME,`2^=_)SOB5YI.@TV@=;,LG:=9Y"XO2YEB$#6&]_GYBN3U2FE]$7!X\EI]I
M*P-G?I*H)NFR?NN/>#PL1,Y`\(/D6VMA-X7)U.CX/GL1UPO5OO\`D])H&:*5
MJF0LK>856$L+-]%M[`HZEF+LCIPY]:KC[P7;@YS+F*"9"!9VO]M-FJ>>*YO6
M)6(@8T>QL7VH93T=%F3M41KD*T^UC'T7)*.U6B4(V\%4^S4;*^3E\"<2"8HA
M>NS_`"3]@9[1Z3K<%6<)S31*C9Y2YRMGS7(H:N2.FV:>KSFJV!_JCE9W(N+<
MVG:^^<(.6HG0;F,L98"@L!%"!2[;O/=H#6,MV+.,2ZO8]9\FGK'9H5IE6.)5
M*)L,U:85S`2KBY^U/N9B<:IQ[M3[1J5XW;,U3B=(A1$>!#&0>N).1D)1R8`=
MR<@]E')D`,B4KM^[5>KF0`IO4B4JZPB3P/DH>/K]//`GO;/DH[`WV@*TZ]U;
M!+I:U:,\S4=UL^-5V8WDE+?Q+B"=1J5^=+'(D]4BW:J8/BLP>%.J=4#@L8R@
MA1E_[Q:)JM#/5-)RSKC=KDI0&F8#O5AQZ,?[P%.CX[])CD"7921^R+.Q\<`)
M(2OV'Z@E_?*J!Q$W`2'?'=I-W:WKI.B^]<NJL7TZF?;K3HA/\H8<@$:+-"C,
MF]BX"`#ZWPB=$1'Z(!X+X"&'`<"3O4N8ZO,-9C8OMU2I^RY#8_8B7]DJUGL5
M=F\Z?*+@"%J,T@%TC6*!)ZO;D&PE,X20_GM_4=,45@W*>L'QM=-\#NE8WWKN
MG<&TF[K[@(>?8:M9;)5[15+0Q24]ITT7D7</8(1\G[#I#U`<A5DDEDQ`Q"FX
M&2+@.`X#@.!0^A9EG6M5M:GZC1JGH=5<+INU:_<X"+L<3]XB15)!Z1C*MG2"
M+UNFX4*FL0"JD`YO28/(\#08^0,F*LNWVT5SKY28.AY=2+'^Q(N)KJCI2*?S
ME52"-N$XV!R[>$12?6DCM-)-`2-RH()B0H")A$(:B(%`3&$"E*43&,(@!2E*
M`F,8PC]`*4`\B(_0`X'$W<-WC=!VT<(.VCI)-PV=-5DW#9R@J4#I+MUT3'26
M15(("4Q1$I@'R`\#FX#@.`X#P/T'Q]!_`?Z?']'`<#[X'P(^!\!^(^!\!_:/
MX<#YP'`<#H2LK&048_FII^TBHB+:JO9&2?KD;,V35$OJ47<+J"!"$*'^D1$`
M`!$0#@<C!^QE6#*4C'C:0C9%J@]8/V:Q'#1XT<I@J@Y;KIB8BJ2J9@$!`>!V
M^!&@EP[`F[#_`+3/28=#'S12CDDZ<RJY#1[?P!IHDXB4HDL;A\J5`(DZ8$*G
M^;R(`*XA)?@.`X#@6@W./U:3SN4;8W*MHJY_<,U"'4]A)Z[C2J_XUG#R#LWV
M<7)'\E,"RI3%%,AR`)#&`P!7=/;VII5H)M=Y*,E[<C'-R6"2AF9F,8ZD0+_-
M.U;',;T@4/!3&`"%4.`G*0A3`0`J3@<:JJ2"2JZZJ:"""2BRZZRA$D4$4B"H
MJLLJH)4TDDDRB8QC"!2@'D1\<#])G(JFFLD<BJ*R9%454CE42624*!TU4E""
M8BB2A!`2F*(@8!\AP/UP'`<!P'`W5O@[SO6J7TOAY_0[H]F*AH<X]M&/49R9
M)TA0*,*KAJ<S5^8HO$4[A,)KR`,/4+9FF)#)E*HNN7@9DN`X#@.`X'&LG[R*
MJ/K42]U,Z?N(G%-9/UE$OK24#ZD4)Y\E'^`_7@:)'R+?'7J72_1Y&:11G+YA
M=UGW2](TX4%'[UO(2RZSW]HZ`HU2$&5O35.<$7)BD0F"![J7A;WD$@@5=NIN
M\7O$M!L;G)]FKN7EKJJ5BU!O3;%!0L!'R"R+)%^$[),&;-=JHZ7335(F8Y54
MCF*;P03&`(Z8SF*609]#T5*>DK'^FF<+JR$@82(E7=G!59K#L1.J$5#(J>11
M;@<_I$QC"(F,/`NGP'`<#Z'CR'D/(>?J'GQY#^CS_#SP(YYYGFPU_8]'N5OT
M!A/TBS-VR<-!H-W*9R_;G-^DIHQZAQ;5[]NM#'0.9(ZXO_=$YO`^1`)%\",U
MUQ[2K%NE+T:)U25B*7"H&2D:TU/]HNP;HD3.YBXYNFDI&R[*U+IE!VJ\(99`
MH?E]7I3]`2:$?(B/@`\CY\!^`?U!Y\CX#@?.`X%MM:S"#U^C2E(GEG3-%X*3
MN/D62ARKQ<NT]1F#_P!@%"(ODD5#?S$%?)%""(?E-Z3E#OYIG\-EM'@:+`J.
M5V$(V,4SMXJ=1R_?.5#.9%^H4QC$;_=O%#'*BGX32*(%*'T\B%=<!Y_A_#\?
M'`<#Q;%8X*I0DC8[+*LX6#B4!<R$D^5!)NW3`0*4//U.JLLH8")ID`RBAS`4
MH"80#@>#GVCTS4J\E9J1,HR\894S=P7T';/XUX4`,9C*QZP%<L'8$,!@*</!
MR"!BB8H@/`KC@.`X#@6XUG.6^KT.;HSF<EZ\G+)IB61B%Q3."S<PJ((2+<!*
M63AUE0#[AJ8Q05*'X@(`/`_.19RAE&>UZC(RKZ;/$(',[DWRRZ@.'SH_O.P8
M-UU5OTV*25'TMFQ!]"28!^)A,(A<G@.`X%:9U;(VC7BLVR:I5:T>$A91!S-T
M*X-U%Z[;8<WE&3A'YD#I.F1GC-0X(.T3%69N/0L3R)/`AMFY5\8GQ<=U<@JN
MW8S5;M1H*W,C&7:TG2;`C(56P-@*E-U:<A[0YMT:PFX%]ZDEDO9]LX>E1,3(
MJ)G,&9+#LBKF!Y#G6,5%W*/ZUFM5BZE"OIM5JM+O&,4B"*;J369-6+15\X'R
M=0R:*1!,(^"@'TX%U>`X#@.`X#@<2R"#DGM.$4G"?K34]M9,BI/<14*JBIZ#
M@8OK25(!BC^)3``A]0X%O]>SF&U_*]&RNPHI+PNB4FS4V1(L0#D(WL,.[C!<
M``@/A5J=R"I#!]2G(`A]0#@:*O7/XRNX79.P/(FHYL[K%9A)R2KL]IVC%=U.
MD-7T))+1$J,8LX:*S%J5;NVY_*<4T=@`AX.<@?4`LSVYPB#ZR;W<,(A[R;1G
M>=M:[&VRU$B20C!>Z2$"QF[#%P\<#R062BX)633:%,LL=915)0QO3Y`H!&S@
M.`X#@.`X#@.`X#@.`X#@.!YLS#1-ABG\'.QK.7AY1LHTD(V00(X:.VZH>#)J
MI'`0^GXE,'@Q#`!BB`@`\#Q*11*EG-?:U>EPK6#AFICJ`@AZU5W+A4?*KR0>
MK&4=R#Q7Z>I54YC>```\%```*MX#@1NUTG9,U_S\<D6JY*1]UXL@2:91`BP`
MI]X:U@L87:T$+/\`]D".]+@'7CU?7T#P)(AY\!Y\>?`>KT^?3ZO`>KT^?(@7
MS^'GZ^.`X#@.!VF+%]*/F<9%L7DG)R+INQCHV.:KOI"0?.U2H-63%DU35=/'
MCI<Y2)I)D,=0X@4H"(@'`J^%S6]3E[JF:IU:?C;E=+3`TZ"A9R%DX9ZXG+%*
MMH>.;F:R35JX#R[=%]7Y?(%`1_AP-NC+_@0Z@5RBIPNHRVC:?>7/MK25U9V=
M]1FS1;T"!VE<K<&JHQ:1Q3#Y`7QI!P80\BH`?E`)F=0OCUS;I)8[:^Q;2==7
MIEX:H_N+-+Q.5^R58TXR$A(ZT1:K>M1$M&3C5F!FRB@+G*Z;&*58IQ21,F$^
M^`X#@.`X#@.`X#@?!\@4?2`"(`/I*(^D!$`^@"(`/@/]`\#!'2O@XS2V:;=]
MJ[9Z?8M=N6@WBRWR9I]+]^BT9N_LDZ\F%(YU*E6<W*=9LTG)4"&3<10"0@>4
MP#Z<#5NU+KMK^=VK4&CS)]-:U7/[A<HAU:%Z#;DZRTAJ_8Y");RCBPJQ!8I.
M-4;MTS%<F6]HY3`8#"`@(A87@.`X#@.!\,8I"B8YBD(7QZCG,4A"^1`H>HQA
M`H>3"`!Y_B/`^\!P'`<!P'`ZH/V(OQB@>LQE"LPD#1@.D!D0CS*F0*^%E[GW
M0,Q7*)/=]/H]0>//G@=K@.`X#@.`X#@.`X&P1\"G4Z$TG4KEVAN*+&1C<2=M
MZOGL.L*:YRZ/.Q8/7MJ<MC`<"%K-;=E38B8`\NWYE2"!VQ1X&VD[C(U^HU6?
M1[%ZJQ73=,E7;1NY49N4C`=)RU.LF<S==,Y0$IR"!@$/(#P.]P'`<!P'`<!P
M'`<!P'`<#5:^7;_F5XCH79[%A.%=9=/N.U,!D60:'OU#O6/8='KL0(5S(U1O
M/QD'<MF:LQ/Y%2+"/B5`$ATY%4A@\AERZ5UC>.RWQA9ZV[GVE.T;7VEPJ=M6
MFNB5Z*K\55DMRBY2;K=4A:S$-VC>+89_4;#',4TCF5=&79G47646.<XABAL'
M_+PR4!DUPE8?L.^O.P1E8>/ZA6FU(CZK39NPL$@<I0C]^]G9Z6*29*D9NBN!
MVY4%U2'4`Q"F`0U'M9["M,GTJG9J_HENF9*S.OM'J\>S$AF3A5T,<BQAD52>
MS8Y-J_*(/$4E4P;$#ZF$P^D`D4(>!\?]/[/]'`<!P+`]C,EM&QT9"M5:YK5-
MVVEFD@Y;*"J2(GT45$_2WE5F9/U%,T:</N6P)F]LRY`!0HCZ#IA>J$8.8J%B
M(M[*NYUY&QC%@[FWY4B/I=PT;)H+23LB!2HE</%""H<"AX\F_B/D1#U.`X#_
M`*>1^@!_#ZB/T_$>`X#@1R+UOKA=X+N8V*Q+O0;*K#7W+YPJW)-BD1HW<(R/
MOE<E@$&7J],88#-P5](@/MA[?`D;P'`<#A<_<_;./LOMOO/MUOL_O/=^S^[]
MHWVWW?V_\_[7WO3[GH_/Z//I^OC@1UP1'L0G(7[_`#Q=Q"K`DT<E82:(-A55
M44,"[ES"NV1DREJ!&YR)MDG*9G(*^KR)?08#!)#@.!\$0`/(CX#_`*!_Y1X%
M0R52ML+$,K!,U.U0\!)^O]-GI:MS<9"2'MB`'^QEWS%"/=^D1^OMJ&X&U-_R
M[E<MK#$NP=ID(Q9M2;5IM;1J$JH8`2F96O5MRRMQF:8_F.UCS.&"(K!^0ZX*
MI@/J2.`!L1<!P'`<!P'`<!P'`<!P'`B3W%[S]6^A.6O-<[2:S`9O7`(Z2KT.
ML<\I>+[,-T?=3K>>TF-*XL=PGW1S$("31`Z:/N%.N=%+U*%"$7;OXCL%^22`
MT&[]A+!H<W8]6C\3?9`E;VD."G5*C4V2J5VL>>YM6XQ1*/C9;69=B_2NDFNX
M=R,F@[19"N+2-9)E#,4R9-(YFTCV#9!DP8-D&3)FV2(BV:-&J1$&S9NBF!4T
MD$$2%*0I0`"E``#@6TW2[$S7%->T,ZI40HV97NVE4,(`!5:]6)251`!$0#U&
M5:E`/Z1$.!_-?4;(2!V+V2:MGD@S6/(-G3INDX<,I%T@HBZ>,UE2'5:N5TG"
MA#G()3&(<2B/@>!W.`X#@.`X#@.!'/LYFNA:AGZ$'G=D-#R#:99O9"(,Z_3&
MUD9D52!-)>72\.61H=P`.R$`?;6,3P8/65/@7KJ47,0=7@(>P3ZUIFXR*9LI
M6Q.$$VRTP]02`B[TZ*8`!14-]`$WYS@`&.(G$P\"H>`X#@.`X'&59$RJK<JR
M1ET"(J+H%5(9=%-Q[GVZBR(&%1)-?VC^@Q@`#^@WCSX'P')P'`N?B%0@="VG
M(,_M+B09UJ]Z?0Z7/O(E9!O*M(BU6B+@G[J-7=(.FR+ULW?F.D91)0@'*'J*
M8/H(;.G7[X.7^`=Q,MUH^H5_4</HDE+VD(:Q0JT+>T;&TAWJ-0;/F+5.2K,\
MQ8S;I)RHY(HR-ZFQ?#8/5^4-@"WK4]C5+`_OJE<:TB(AI&6M#NVC&I5:-K\2
MS6?2LC.K2_IBFD/'1[=19PJX$J*2)#&.(%`1X%+8U(XW-9E4IWK\\S>2QV?8
M*SM&E<B5K3G.9:,EWCE^O*U=U4!-7';.1D%UE3JM1,11<YS"(F$W`]&[ZEG&
M:Q%KG;[>*O4XRCT6?T^W+S4RR:*U_.ZJ@LYL=VDF9U1>H5F&2;G^X>>V**9@
M](F]7@.![]5M%>O%7K=UJ,PQL-3M\##VBL3\8L#B-G*]8(]O+0LQ'N"^"KL9
M.-=I+)'#Z&3.`_QX'O<!P'`<!P'`<!P'`Z$JU=OHR19,))Q"OG;!VU93#1!D
MZ=13MPW42;R39K)-W<<Y78K'!4B:Z2J)S%`#D,41`0_GK=H/A\[4=A?DCRG?
MYO3>Q/:[KA)?(#FW66[ZWV*AT8C1$F51L/[@U6Q5"D04'!5N!ZQP,G6WU2C)
M)E'Q3%[-MU3H-18JM'3@/Z''`<"WVLYQ`[#E^A939RG-7M&IECI<N*?D%DF-
MCB746LX0$!+X<-0<^XF/GZ'*'`UQ.IGP`KIOD;1W#O*3E@R?*@RRO,I!9,9A
MJT<K)-W-OO0I(KM$)!)(BIF,4F54I%?2+TI@$O`MQ\TO2SJ7U9RO)K1AN6HY
M[=KUI2\`[-&6:UOHA>LQ-4F)*3($'-S4I'H.CR(L?"R1$S%`#!]?6/`UVN!R
M$255*L=))50C9,JSDZ:1U"-T3K)MR*N#D*)4$CN%B)@8P@`G.4H?40#@<?`<
M#IR)Y!..?J1#=H[EDV3H\8T?N5&;!S(%1.+-N]=HI+JM6JS@"E44*0YBE$1`
M.!9?!9C;9FNS*VW5^+@I9*??)0GV8I(/'4<"ZP*E=1[8R[5)@S6`$V+@%14=
MMP`YRC]%%`OIP'`<!P'`<!P+$UOK#<Y+8=(U6CWV^*R4C5W-@DH2-B&%B;Q%
M;KK8BUA>SC)^DNB_J==;$360*1-!2.2]PXK>D#&X%7>C78WZD=9W<42_P<-K
M!1I)0/\`MFRUPBS'$/\`U21?/]'\`#>;%'_2PY;<FA0_ONZRX@KNQ`/XG!.+
MD&L\)/\`[/\`5_5P+N=>M6SUUO\`AC)>[PU+?'V3+A]_0A=9\WC/;O4$HH]D
M7-R0@FK5FS(05%53*`F0A1$3``>>!_2ZK]DKULBFT[5IZ%LL(]+ZV<Q7Y1C,
MQ3LG@!];:0CEW+1<O@0^I#B'UX&.'Y;*=V!U_J2XZX=<*(K<KCV=TW.<2N,F
M\?2,-3:%C$Y-A/[-:-%L,0RE):`I<MGE:?5U=PT9O78+SJ)46ZIQ`.!AZQ_J
M7WRJQ\GZ,6NC['B&!9_\EVJVJ8L?3O5M$I^1%Z2]B>N>Q[`QSBGZLT3HF@!0
MLL[!3QJRX*JS8/F2B[)-L*9O:<@$2'_2[NW9$,MTO8\X^1*>[`V+XDNU&&5_
M2L]UW4(.T5;LQD^N7^?Z]0&V2M3TFON&L->,U@X=4R3Q-W'6R=6;+/45WIC+
M$#W,]VK>YOO;1ZEH6Y[E39W.-!Q'!,X:*:?KCVI67L^W^-FD2L/U7T_.*7I3
M//HJIM^Q4L\N=EG)RK2CQS(LCQSYZ9BN((A7^*XS\I4IUNLL9-WSOO!:Y:+7
M\>]>V>I.8C:J78H*],^S\*/:K8<RV_0]XU".G_U3*G<FC/%HC"$H@PS-DZ;L
M4C@+?@7+L^4_(5EB]'KM<B>\^RPN*?(3V:@L8QBQWO>5:[KO6FP:/B`Y=<]%
M[6TO7:_=*H\RN&=6%]4WM^"QU.6B#23%\W.L5L`AMG<!P'`<!P'`L3V0[%Y)
MU8R><V#;-"J&74B,?0=?"Y7YY(QE,C[-;Y9K6ZBA9YB-CI5:"@WUBD6Z+I^H
MC]NR0.998Q$R&,`:VL)K'8._[Y-+9QL]VZ#?*W-1S72&'4S:-ELF^_&'\DU.
MBXAFW0M'62?M;Q[&QU;M<$R0*F[I2\'8ZR=3R]BW)"+.`#8`Z.=MX?N?@D;J
MA:=-Y9H==L]HRC>,5M*B:MKQ'>,YD`A=)S"P+)$31>J0LGZ'#%ZF4J4E$NVC
MP@%(X*4`F!P'`<!P,;W?#X^8_OE;,*;W?0Y&FY=DZUVEK#"UEBBI;K=*6<*N
MU9,X^7D`7BZ\Q:L(9P"KDS9XN)E@*FF3ZJ`&";Y&OCI9(=N>MO6'IAE#6*+9
M,."0D@37?K,VZL??;"SG=&TFUOCOWPHMV2S<KAVX,HHIZ4V[9,QS)(B%8?(]
MU'RSX_\`X_\`-L@IYR6#3-BVFKOM2TIXV(A,7+]D5:RS:T<S2]2AXFFPTRY:
MBQCRF,5,1!54RBYSJ&#`71J1;=,NE6SJ@P+ZU7B[2Z4%5:S%E34DIN4416=&
M;-$U%$R>EJR;*N7"AC%2;-45%E3$23.8`]'M[07G1K4S8SV$LU'BM!0K[&U2
M<-2;*EHQZS7I,/,=*7<E3:OWE!;OR@)T/UM%@+A$HK)>XB(*"%NV3UG(LVDC
M'.VS^/?MD7C%\S72<M'C1P0%4'+5RB8Z*Z"R9@,4Q1$!`>!V>!Y<W-Q%;B)&
M>GY%I$0T2U4>R4D^5!%JT;)!Y.HJ<?(B(CX`I2@)SF$"E`3"`"'X@I^$M$2Q
MGJY+,)N&DD2N&,E&N4W35PD8/]51,1]"A!^AR&`IR&`2F`!`0X'K\"D+??J=
M0F[%Q;9YI#_JK@[2):F3=O9.6=)D]Q5"+B(UL]E)%1%/\RGLHG!,OU-X#@=^
ML6NM72'1GZG-Q\]#K*+H%?1ZWN)IN6IO0Z:.DSE3<,GC4_T516(FJF/]XH<"
M_4_AVG5K'L_WN5K+I/*=+L%JJE9M2/E9I^XZ>\.RDXB5*4H#%NG9D5CLO<_*
M\3;+BF(BBH4H6G$A@#U"42E\@'J,'I+Y,(``>H?`>1$?`?U\"=/Q7=@,(R/O
M=GDEK6BTB$K1:QK=;L323?H3*IS25"G&'Z*[KD6G*2;Y=\]*5L+06QS*&-Z!
M*(_3@=WY$,#J6:Z+):CU(R?LG?NM=T>`\9.R=;]DH]<SFSR2JRJU,CK'K-6H
M;*<JZ_H.M%NFYUTVR0"U54$R:1U@[W0GX[^Q_=ZCZ5<H;(XNF5Z-DDJ93;KI
M.VMZ2VC;BS0;RDZZD*;4<GUZ1N<:RCY%JD9LF^A_"ZAR_<@8H^@,J'7[_E]]
MQI5UJ^B:5W$SB.EJ=.M)R&KF=]=6]RB%7#=L)0-)O=BNDW#2`(.%CBFFK7SI
M&$A#F+^*?`R)UGX5^KT9H45J]COF]2M^C52NC/LSN\'U)@7KH%"JG-)5GI;4
MNN[*<0.8@!Z)0\@80_$PC]>!7?RQW2WUOK_B>=TRTV"CG[%]W.F76^SW&KSD
MG7K+!9]I6Z55*]$B+%%NFLI$N['6(AQ#F<I+$5*E(G])@,(#P+!X)\H^Z[7W
M,ON8M^M"S'J91M[[*]=+1M?Z9>F"V73?6V%DG3S2]&T"<CF&2JUB]6"OO&*4
M"R7+,0J#ED\<JK)J+$1#\[1\F?8'_C^JG3KJYE>5:;`*2/69W9[1)J:;:W4I
MFFY,;=;KOKL-;,ZBG>84:JY/1*N@L5M/R(/["M+ME6"9D/3[P90H"N]6++IT
M;K=7@NO\_LU@B)T(?38",SJ5TZ;@:N\3J5F"-N<<@O:I*(KK\Y(Q_P"TY.BT
M6$&ROH,($X&M=M7R`][ZL/<*L5J!U)UG=0^:O%L)@NU#31L@9P.79?/ZKU:A
MY3KTWS9^J72Y.(FHZT/6AWB$>X1`MA,(N2@DIZ0ZZ783N%_E+\V/8E;:^T#%
M;KPM\H58PFUNMEPEY@U1=Y!=)Z#S>%JN#,Z\;9XFXYO%,2J-)J1,K#G%L<1%
M454@$/0P'M!HQ<-^0Y/M[W9[A]<,LP"7ZH.86&M%EP^?[[Q4[HV4&MTA7Z5;
MZCG-IIUBH?:.T3<2VH#6,_5YX[E@_:@X8F%5%,))=6;CW1S'2/A(;=K=,L]G
MV_L'E/=;'NQU<?6./D6[^.@JLCV`Q^1O4353HT5YL>5Q-+:P4Q,,6Q#F=2;]
M'W3D/Y.&QOP'`<!P,4?S`=Q#=/\`K5`/UH?'#1&U7USCU@NO9"G6S0.O5$A'
M.;Z!>GAM,H]*]N?NR]_"D!5:_"E79MY.P3;1)=P1+U$4#&Q\9W2/,-6GV\7*
MHUQ;%,!D<KN^O]'I>&0W/K7UE[[OZQ1=OCG'0;L#,VQ[>\I:9:G/IMKM4$5)
M&$;RKS[)`XH@J'`V;HR"@X1255AH:*B%9Z56G9Q6,CFC!29FW#9HR7F94[5%
M(TC*KLV""1W"PG6,DBF43"4A0`/5X#@.`X#@=$(N,+)J318YB6968HQ:TL#1
MN$FK&-G"[MO'*/P3^Z.Q0=.E52(B<4RJ*&,``)A$0Q;_`">?'C=>_$7E#:I:
MS`9V?+5KD])%6&KR,W'V"0M2-?;I.%9&,EV;B+_3F\(<@?X9UZ@<"(>GQX,&
MH;W!Z&=1<T[?=8XBI_+\;'--P'0*U"=J+A'9YJ+ZE]<M!2=DF&\]GFOT*FRF
M5YU?UG1VT.XB;Q/-Q;`H1T]620!>..$_DJE(X+W9[L83K7B:TC:]6LO;3/=4
MF"Q<BCV>ZXZ0C$Q59FVLFS9-(B97R0S$:U+Q3=$C./(5%5N@1FZ3$0PY;IBH
M]0MD1J4:W.WZ[;5+RDIB[PWJ%CFU_7%:5L^)NES>2-8A_P"59*L^L0`4!6:%
M\F1#@7=OO7C5LQRK)-BN]8?P-0VT;`O0E'K1VDX>14%]C]K+OO6@5NP;V<CA
M=:+2.<'#MFS4<@0$#)'.%_?C\^/"@?))L4UCNSQ<T\PZKTR5MVAO*_*+P,XS
MDET5X2@IP,XBDL$=.A97GWR0F3534;QJY#IG3,8HAS=XOBS:_%]+TBBYY(2]
MLP6WL7*U&NTZDT_<R]J8HMU+=#7MQ&,V$6O9UEE0>MUT$4$7+$X%33(+94I0
ML/UD+CJ&WTJP=B)2(A<!HH6/1]IDITZQ8Q/.:!5IJU3S)4C8?O'3N;_3$X]H
MW;^7+IX[211`55"`(2"Z.=;FU>D+3VFO<#*0]VU`9$F05:[D9C9<,Z[JR#B1
MI=>FE2A]I':3;(8R$E:G*(D]M4Q&OJ`B2@"&#CO7,/=9T'=-2PN3B:!C.K7:
MDU)A[K1_!N=YF*K&.:W8M'HJ4:R6>2\3:9Q,4P*R;*N)YO'@X`3_`%(H&Z#\
M9'4[!.YOQQ9I@4A\@NP[C3,VIM9I^R8IEXT'&FV6Z2\2"Z2-:M\;(Y,V[&1]
M@B;(^56:2$W-@I)"V%9+UHB8@!&2C_\`+FVO/>VF..+DQIF^]<F.BLK!;K=9
M[%,2\ZG5ZVHZL#:#N%%O,G(H+*V5:,0CEQC#/FQONA$Y4D_H4-C1#X^NL%=[
M`99V4S'-JUCNCYBC.QAO\KZ]!TZN7.NSU6F:NI#VNNPK!E&.58U"7%5H\2(D
MZ)Z/:.91'TD*$VN!QI(HH`8J*2:)3',H8J1"I@90_P!3G,!``!.8?Q'\1X')
MP'`CGVJZT4SMICDAC]UE[#6$!MV<:%6+E4%HYO;:1?\`)K_7-+H=MKCB6CY6
M.3D(BT5=L8Q5FZJ:S<RJ1B^E0>!YK_I3U#E--M^SR76C$7VKZ!!6"LWC07.;
MU56TVV$ME>5J-I8V&5-&BXE0LM47/&/U%A,J\CCBV5,=$1)P(.WWX7>LUV[*
M5CL(SLEQI$?59;K5,PF6TVN9'&PM3#J6R81^-5++;^KG#G7L=S%JWBD"R];K
M4]'1LN45B*E*1PL0X3/SWI+URRG9H3;L[H$73;!4,IM>.T*K5EC$U_/,^J^B
MZ>\V+57]/J,-&L&<;:-8OZK5[8'YSK*/!C6P$!+_`!`N`N0_ZX8#*15H@I+&
M,S?PUVU*+V^X1;NF0+AA9MB@Y"NRT/J$XU58F1D[W&2=1BW"$HJ!GB2T>W,4
MX"D00"UYN@O2(]RTG1#=3>OAKWL<3>X'5[<.4TW]PZ-"Z@!PT>+N<I^D_=V)
MC>@4-^JINC*%?>H?>`_D>![>D=*>H6PFDSZIUFP[0SS431(&8/<,SJ<\>4AL
MN5FELWC9`TC%KF=M:(I9)`8@JGJ"/!ZL"/H!0X"%"4OH#URS39<1U?,J;%YK
M"]=J!L],R3'*!`UJI9/59K?9ZI2^G:0VKT+#M'!KS.,:>C'`O[X-R,W3O^4*
MJYE`";/`<!P'`UUNX.2_(%6M_P"\;&B]0*WWEH/>FC9G0,(O]YT^B.<HZI)5
M:DM:VK2]TZY[`Z4JL_F,%HQG]Z/)UY@^DYE5\HS<%%8K44`SFX5B&7==<MJN
M28]G&>931ZPR]+2F994HVDTIG)O3B\FWL57HQ,B+7]4E555SF.95=0Q_4HH<
M_DPA=S@.`X#@.`X#@.!JU=`ZQ#YG1-\^-#>Z?$%VG#;EJ+W9ZS8FB,C!=G\A
M[`7ZX6RI]E6?WB?F[UK58F>/&32BX*N8N<8K,7(D.1(.!$C4<+MD#7(WX^)F
M>EQV;K['WKL;\&'8R7]V9F[?#TR$6DM+^-S1Y-PH5W99-M4T!AF+19;USE24
M8NTP^YA`(<+?"USWOGULL],OU9G*/)O7TG1],HLLC]EHW7K?<_D/MY:)<(N2
M`O%W3-+@U*X9JF`"/&OMG_,@X,`AEZZFZ/$_*ITWU[HOVP"!KG=#K:QKU4T"
M1BF#5@A.K,F;L^%=M,UBR$2`:1HK)N<9!HU`J3&1_4XHP))&2]82^^(_I?8^
MGG7F=:Z7$M8S8]*O$S,WA)LND\*QB*T\>5FEQ#=ZB<Z3E@,8U5E$C%'\98P"
M`&`0`)5=TNK57[B=>;QBMA.V82<FV+,42RKHBJ:H7^'(JM6K`3T$.K]L1P<S
M9Z0@"9:/<KI!]3^0#0IQ3JS+Z[V9N+#11@)K#>I6F2-5E3UV60L=)W#L/27X
M)KL(N7;E(SLF;Y)))%5=&]/M/)PI$#E_PZI2AD7OD.7M-J%@ZJIWS_*[!\[H
MIMM^2#L.,F,*QQ'K`U1=2:N;L;+_`+.)U'?&4:Y:HB41<QE;3>OP(8?:*8)O
M=4J&7M#IM+[R6S,TLOQ?-J$3'/BXZU.H).(+A/6@C=G%I;;.UU0@C$;!O47&
M-562)@%>O50C1J4PKK+J"$A?CM3#?_DQ[6=O,DBTVO7VA8-!=,+1I[3T(1'9
M/L32]/<7>R3->,W+[-K@^O4,NK5AG3B<%Y&3=M&ZATFBGI#8'X#@.`X#@.`X
M#@.`X#@.`X#@.`X#@8M?F#W/(\MZ2Z_G.F;/;,2DNQ5!T#*JO:\^Q>[]@[U%
MQ:U0DY73;3&9;GJC6R.X*FYJUD7DK+@Z8MH)L(.CN"*E1(H'WXR-$[9S5*G,
MF[$DZP7FL8=5LMI-&WCKE>;DF^NZRM%AYE*N:]@FA0#:Y8AIL70Y2!EW[-S(
MNDERS:0HIID`0`,I/`<!P'`<!P'`<!P,5/R;],KYM$-0^U/5A**B^\O5$LQ.
MY&=^L$;#;EG,H"2^F]5=(?$]`+4K5XUI_NU=?U%@[&DT?)&2+]R)P@/)M,=^
M4KJ!"3]6F;1G$LYFF]HH5K22-$[/U([49/+*)HJN6_\`*>UW3L;OK-1C*LC>
MV209>ZB8#-G91$,+?ZAV4JUY[2]\MULM8DMLS76JKEWRE]7<QSM.G06=8JRJ
ML/6NO??C+&B#V2E=-@[#'1JLM9YPQ@,K#O7+4J"!8$0$)07QWI68WS*N\O5,
M&E@WC"8]=XTK<?()D@NS77FS`UE="P68?HB=J];VR*2)*U5Z8%"QUB;M7"?T
M4/Y#;7ZP=E,H[?8+FG8W$YT9_.M1KK>=AU5TOM9>'>%4493U4LT88QE86VU"
M=:N8R59*?S&C]JJD/GT^1#%A\PO=NYT>/K/0SJ[:%8+M1V5KLA(W'08D2K.N
MKG68CDT->MJ='`1!E>;,<RL#2$#>E1:945>%$"QY@.&%*SN8[J]D^3X-UNSU
M.UZ?<9*'POJKB[=<QG5WT641552DK(^'RN2MU](7-CN$VN/I19I.%UC@=4HB
M'G]9NEEHMVP[=U$1[&2_8/HIGNM4'7N^-MD*?`0Z':7Y':W#M!T/`*C?H@C2
M=NO5?.)F*A9*;AI$BJ<=*,$81-91/[D.!D\[*6?3NQ&N5GXW>K-B>5+5-2JR
M-L[,;77B$]74;JB[<&B9:QQZB1/M66TZ^FFM!45@;TF0]3B4,4K=H53@9\\*
MQ#,.MF/9S@V,55A2<MRJJQE.I=9CBC[,?$1B7I!1PN?RO(2LBY.HZ?/%C'</
M7BZJZQSJJ',(78X#@.`X#@.`X#@.`X#@.`X#@.`X#@:ZGRPR_6WL?V+<].>P
M&[ATDE<FZH3G8#-.SBFR5C-+#H;77IFW9AK>#P%+T6&/G.M96_HM#*>\L7C\
MCLIGL45%$$ON%@#(?\5%.JL=TRSC88&V:QH5@[;I-^V6CZ+N,55(#4KK=]CK
M]??#(66MT-LTI%9;PM4C(J'C8Z(3"/:14:V(D)P`5#!D<X#@.`X#@.`X#@.`
MX&O/WTRM[\>?8">^13,XIVKU/W25@8CY&<Z@FBRZ.<V<`;5^E=Z:O"M"F`%(
M-,Z$3I":!`.]A?8ECE.LS<J\"@^W63W,LK2.\G5B#@M`WK'Z5*0EBS8%F#RF
M=V>H=Q0)*:5UGM2AR.H:>"PPRIIBDOG!%T64Z5,H`9!VH40Q@XVI5,5MF99Q
ME4G.VKI7VMSF?[%_'5=IIN\)/4^B1#IFML7470$G:B[Z,MW6^PS)48T5SG$T
M,J5H94SAF<.!,?X^M@G^G'>/7<GJ7NRN"=F.N.]=P9?+A6!JQH?8'`5:,VN5
MKI1A]3>+C=OK5H0"::$3`GZQ')O"``J+@<(<=:+*^M>6V?O5NEF+/;%VO@6O
M9';[VX07,VKM3"N*3%,S&JM/*[J.SC&*`1..BV*?D5#IK.#`99<P\#ARB-W&
MTV&BZ/3DGU([P_(/E4V7K&_D&97A/C9^+!S(,6MX[3R)%!,S;]D^SBKE!*`2
M3_GIN'#-N"A$F#Y%0,IVC6C.OCDZR95BG7/,U+E?9E]&X5U$Z_L'8K6?:=IL
M!5W:;NRRIQ^[69%>JNK/>[(Y'TMF173I90IU$P$,I?QW=)4^F6031;Q9TM2[
M/[G8QUKMAN*C8476F:Y*-"(JLH8BP`XBLRSJ-],'5(H/0C'Q#8IO;*NNX,<)
M_P#`P+]E_D![X(?)-H'0SJ77^C,-'9YU;SWL3(7SMW:->K02J]RN<U3W5=B%
M\Z6<MUEF:[1NL1,S4IO9]TQE!'T%X$Q+E\J73_)=^K'4C3M,=NNQBHYA!:)%
MYEE^M:!G697/5QBX^CQ6AZ)6Z?,U;-6]WFI1$D26>>M%3(.$5%_:*H4XA5?R
M6]YXCX[^IER[%.:2]TZV$GZ;F^49BPD20Z^A:UI4^UK%'K"LP=N[+$QRL@Z,
MY>.`24.FS;*BF0RGH*(8\G'?SY-.H.^]-JC\CF.=/G6*=VM:A>OT#<.J5CU<
MUHP3;KHP4>T:K:&AIBCJ'N\#+.6ZK-21BA:D3.DJL'DI$DW`23E?G0^,F$U)
M+'Y3L"]9VY#;I[KM9G2^5ZRG3L]UJ#N#ZB)5G2+\>E%IE'"QV:-72B7$@^1;
MR""1G29_M0%;@0<T7_F,,$B]&^0G!?TNU8_;^M(NJ+AFR6;$>PFM46UZ$2FS
M_P"NV36Z-GV7(6',Z/0-#C"(>IT\,%@ARG?LE?9\"(2KBOFDZD85A/6-WVWW
MZ$GMQV;J5GW9A`,-P_<Y6$U2L60IF$A:\NI)*E-7!K'F>L'CQ2-?E2D(Z-;*
MNG2:""9C%"[6*?-3\;78C:,LP;'NPR5PO&UPZ\AF3U&@:3%T:US+*"_<\G06
M&AS52CJ;_F7"P/\`/?P)GI9%B?\`D+IINA!`0L+CWS`X]F'6M]MG<K>:W>H^
M4[%]GLVK^@];NK_:%Q1JY7<+MI8I_!7R/5H]EF*Y+U!DL4KV9??:0\CX$S-5
M<J*RHA?_`$'YF>@&<5G++7*:;>;%':YBD?V4@F>>X5MNB6"L]>9,XIM=LTVM
MTV@S$YE^<G.4X!(3J#$I_:4$A3@F<2AS]H/E]Z*]9XO.FMHW%N_L>XXT[W#)
MAHE%O^K1RN4N8P[B"V*VK9Y6K"E4<J=.U$R_K$F9JT,!5!]8%26,F'L?#SV@
MUKN?\;75OLWNKN`?ZQJU8N$G<7E6A4J[`KO(/3[Q4V)X^&0<O$61/TB`;@<"
MJ&*=4#'#P!O`!DMX#@.`X#@:>W>#LDKM?=?L-B78[N/UOZ_U?)-QI^?]5L8[
M??%`;LKAU\825(H)WEWCMQT""@W1+E,:G)2,4L$;*MF!$V+<S4ZZ:@*E#;VA
M6`Q4-$Q9BL2FC8Q@P,6,8DBXTHLVJ3<2Q\8D=1..8@*?\I`IC%13\$`1`//`
M]/@.`X#@.`X#@.`X#@>3/0,):8*:K%EB(V?KECB9&!L$#,,F\C$3<)+LUH^5
MB)6/=IJM7\;),'"B*Z*I3)JI',4P"`B'`UY(SH?\EW4%.P=?.E"W5S6>L*LQ
M+K=;K;V0T74*SHW4BK3RYWB&:3]?KE,N"&YYWF+]VK^UO1)Q<D$<1)@[,*:1
M%1"(W;WJU&]*K;\*76*-M;^]GS#+_D#2G[Q)LT8UW<KO;(?++QH%K&+;G50B
M&]AN]DD':#,AU"M$%2(@<_H]0A;JG."L^_U/=G*8Y&OQH?(^X.0GCU&*@TQ9
M0Q2^H0#U&`O@//T\\"*&<%4:_%!6`*<2JI=`3*%4((@)3&PATJ4Q1^@@8H&#
M_3P,T,5T][0K9E\>_=SI8UR:\WUG\;?7;K7LW7[9;1-YU7M'S&.JU8T.AV&A
M:9`5RW'IE^HEHEY`#)/HUQ'2D<]%,YD544Q.$O\`H]T4V:(WBR]Y>\[C.)/L
MH[JJV88/D^7RLU:\JZF8\_,B\M$34K19HF!D+=K&IRB95;39`CF7K:MT(]H4
MK0JGNAE^X#@8$-;^(ZF]J?EVUOLUVVZ]Y)N/5&6Z79=F.<H7YQ'6%[&[;6-'
MF)29<I4\QB/H\B=1DE$P?&'VC@K[9?(B8"AY&2=;?D/Z6=^^Y<_@N`X=NO6O
MO=O6.["ZV.X;87.+!UZA8.O0E(T2ISV;%J\U/Z*6%K<>X/6$8IP@W!042N%4
MRG6*D'Y[G?!W$7_J7M.<]7]MW`VZ6+2\9WG-)/M)V(V'<L_B=+P:ZRETK$,T
M97>:M)Z-!V0D\^8NW$8W%7P9J90JJ;8""%-67KY\H/R-]A.CS[NIUUP[IMU\
MZ6[I6NTMO0H^_-]YN._[/GL<^:T"'J$?#5F%:T'/6DK(+.G@2KI=\9NIZ"B=
M0H#P,.>0]:^]7>S!/D2Z78AD.%..M>U?-AV'G]2[0V;3_P!'O^+CF6^TBYW>
M/-E!Z\Y<W>0DHZ`C@@'D<_`R/O.F[I)(HI.`#+C>^E/?6N]N?F8;4+&*)H'7
MKY-^MS2,I^T.MLA:O8\\TC/>HUNQRJ4&9S:2C5Y6;&Z7B6104DP<-F,<P/\`
M<G5./K;E#L]._C8[29'V+Z):5H=0IC.LX-\'T=TAO[M"XPDR_A.QB5S@)5S`
MQ31NFJK(P(P[=P49AL/VQP]2?X'`#!9;KE\4/<3-NMWP)YS9:=18ZX=".UFH
M:SV5;1U\@G3:`I]MDM2>1[VOR39--.XOG;>RL@60:^I4#G`IO)2&,4+26SXT
MOD_@.@]5Z9U/':#?,]TWY".S>]]OL^8]BX/+9K3>MLWKJ>AYGDD5H@0MB;0\
M)KQW9_W)[;-9\U9,2-3$`'*Q0"M^P/QK]R+7VF>=MFW4"2N%/[%]/,KPC5>I
M>"?(Y8.I[KK_`&G+BR5?2I2VCTV$JM3W#"YRENDD19?8I?:.3K"FQ$H![X7-
M7^/;O%U2['YGL'2OK'@MSH&C?&'G/0*Z9#HO8Z99Q74Z<IDTXG6DPUO\]392
MV;;E\<,L*+I-HQ0F)@[0R@IMO4D/`RG?#IU>UCI=\;'5WK#N3&%C=4R6N7:&
MMK2NS3:PPI%Y;5;Y9XQ5A+M"E;NDG4'.-E1``\I'.*8_F*/`R8\!P'`<!P-2
M;8Z#\F\+VISW0#;UW4LL9LG<N]41*CY7NF#?\*-"BJ9W(KJ%,I=[@'QW3^E9
M];>D2+]<$6X/+:I=F*[=VU(HH5(X;;/`<!P'`<!P'`<!P'`<!P'`UQ/FB_\`
M&]\7?_Z0[Y__`+%Q3@0`KO\`X\*Y_P#+%^2C_P"[L9X$8*'_`/Y25S_Y?Q?^
MX%;@;D_0C_P+=+O_`'3>N?\`W/T[@2RX#@.!AA^8CY3KO\;=2R)OB^#L^R>Q
MZ9_FS>GN<N+,]K1:]@O7S/W>@[5I:[F,BIAX;]MQZC%-!,R14E3+J#ZC&3]!
M@EK=ODHZ591C/7[>=EWRD9+G/9RF-[MC\[<G;I!C:(Y3/D=-<LFSUBS>M"2C
M6K+`8K=0Y%7+D2MD"JN5$T3!"KLS\_?03#.M64=H,[T:*["T37-R;XE!MZ2Z
MF8"2CGL,]A_\U)J;9V&KEDX5;*Z_/-)-[&/FK1\\;.4?MP,"I3\".FI_.(G<
MZ]\B&D])]=ZA[?EG5CHO([QF;)%CN)ML+LT9+#'O/\RZA8(.CU1SD?H4*1`T
M8_+(G="F!C^A0X)!/GX_ODNZ,=J(V&S?(MJP][V+5RJO;=N.:YW'.JPS0M4]
M"0+C4;+%.7T<TAKBA#6U\=K)O6,A*JM%2`1XM[A1'@7%P_Y7OCK[([,EU^Q#
MM?FF@ZT]/9$X*L18V%HVN2E0,L%G)GUHF(.-J&C&A"-E5'`03^1]"*1U/]F0
MQ@"!?<_YT<`H>D8/A'3?;<-VG>+#W\P+J[MV?R#6W3!Z]GM[MTC4=/DZ;,1R
MU<KD[::;+_9-5EV+^5;QCER0KIN(G*`!DI)\BW2E3&E>P1.P-2'(4=K#KDK;
MOT^T`">Y#;DZ(&9'@1@`LP6C]T*E;^U]EZ?;'W_5]O\`S>!-;@.`X#@.`X#@
M.!\$0`!$1``#ZB(_0`_M'@8)&WQ$[BE?8"A?\;38W0^L=Q_^-R(Z^)]>JFGL
MQ-,2W-]V-1ICKL@6TC(N*6CKC]1V9Y^BA.JQH_IQW0I>5!#.YP'`<!P'`<!P
M'`<!P'`<!P-<7YH0$>[WQ=@`"(_M#OG^'U__`"+BG`@!7@$.^%;\@(?_`-8O
MR4?B`A_]78SP(PT,IO\`X4=<'TF\?_#^*/GP/_\``*W`W)>A'_@6Z7?^Z;US
M_P"Y^G<"67`<!P-<OL/\<_>'NE\F'8G>S;>_Z;XKF_6RJ=2NOEE1S'%-_<[A
M0-49R-P[)O#U"[2<NE06#FQK,X91RX:M)1^U;`1,2MRF]80^ZU?&OWVJ<)\2
M&&;5C#2VT7XU/D2[(MPO\E:,SDHRR=3#4B9>X+L1(%6V2$D4?W#-%8-8OV%)
MB+.P;&,@0I"J@'G=B/C'[M2'7[Y*4<_Z^-;%9K?\UU%[UXAG#.[YW$/-<P^G
M/L]DY=]5W2TX:%K4S-J1KKPSECL'2@H*>4C',F10+A]G.D/>#LUJ?R8;?&=6
M)C-C]P/ABSK#J!0)'1<F?2T7V(-9IF:G,=D)6+M:$0,]7FK@@+2A_8AE3B`)
MNC?P#P*/\?7?CLSMG7F(U+JI3^C-2Z8_&1V0Z6I:C#ZM0;]%[5I>\XLAD5<E
M*`QSHJ5AB\]J2RJMA.64:MG#1Z==$H*+'*H<.3K7TI[_`.DN?APZY:YTOCNJ
ME,^)ZWEMNF=D2:YE5LA-=6I]`DZ1#0V&5ZD2<E<S-M=D%TY:?6F&L<F@?R*O
MN*E*50(ZY_\`'?\`)9`81T@Z,R/0^IMX3HU\HE"[,6?M^SVC(CIZ_F*V^66W
M/+50ZFJ^1O(R9JI;P=6,LDHR=%;PS9!)NY<&*@@%TR]2[>__`.85F>H$#+Q$
MITX9;%7?FZO=)8+D>.*CO):')9#$PD^U(?[2,0M&SN$;,DR53]2[?T+%^A//
M`W%>`X#@.`X#@.`X%@^T'7FJ]K,(T#`[G8[Q3H.^M(8`M^:SQ*S?:G-UBRPM
MRJMGJLVLRDFK.8@+376;M(%VSALM[(I+)*)'.0P:FB5.8]-]EWDDIKOS==NL
M-ZF=DIS4^UG8',]TI..]<,FG+3)5[>[?&W',HRP5JW]A96H0MS;3FAK031O'
M+-GRPI1Z9?4B8-SYD]:R+-I(,7"3MB_;(/6;I$P'1<M721%V[A(X?0Z2R)P,
M4?X@/`[/`<!P'`<!P'`<!P'`<!P-8WYYLSC-<[:_&'29>T:'3V3NN]Y)$T[E
MMVE<^N"*D72\5<)-FMGA1"0;L'1A]+E$OY5T_P`IOIP,<6#8+!XEWJ]BOW[:
MK]^M?&%\BDE(GV75;#J"T0DP9Y&Q:A7E;$830Z#U9\(.4T?/OF(F8X?D`>!"
M.F=.:>[^-:"T4VT=KT9%;I(%S&M->QEX;T(CP,46F/T1*G)F_3$ZE[Q?9_30
M_D?:>4?[O`WNNA0^KHQTO-X`/5U.ZZ#X*'@H><?IP^"@'T``_@'`ECP'`<!P
M'`<!P'`<!P*%BLOS6"OEKU.$SZDQ&FWR.@X>[Z)&5:$8WBWQ%91,VKD79K6V
M8I3L['0#<XD9H.5U4FQ1$$RE#@5UP'`<!P'`<!P'`<##!VV^/7XWM-[#OI_L
M%O=RRR=[#/Z;+Z7U>8=OY;&,<[73<`:&HM8E]%PI&SPQ-'DY!"*C8)<60(A+
M)M6[5R5P8``0F'U+[\=:>W]AU2AX9(VY*5Q.7<P<C&7+.K5G36R5R+M%ISY*
M^Y<>S1D:VOF8FNM"F85.6C14;I2$6L@H"9@3`X3<X#@.`X#@.`X#@.`X#@.!
MKF?-2Z;5[N3\6%IG5THBLO#=T,Y;V"14(TAAO=TS?,Y"H5-216$C5"<L[2JR
M)F"!S%.Z,S4*GZCAZ>!"'.(^3O\`\A]BJM!9'N%IIGQ2=WD;-!0I@>.H&0U&
MPY5$9K&3?L>Y^F2%XDX)XG'(*^%G!6RBA""0@FX$):WHE)C/AR9V?]V0J<1%
M]&'-'7?+NT"F;7MMDKBC*4MPR]PSE.V)W7_=8QHE^[^\_E^WZA\<#=;Z<5R4
MIW4/JM49R,>PLU5NM^'5R8AI),Z,C$RD'F-7C)",?HJ?G2>L';4Z2I1^I3D$
M!X$D.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X&![YTNK^%7C&8OM=KVF,LF3
MP^E7S&9>=+UIK?:&Y6BD=FY[/:>>GXY3IR0B7M3["/;W#PJ5(L[%<RT))/%A
M.DHDLH9,/`^&3JA/Y9:--VG3J)W$S>WS];FJID]?[D;/AUBO$UF5YU*<VG2[
MDPZ_X=`,(?KV,_KEB!9W$N9"4,"JA3D!H995(P;`'`<!P'`<!P'`<!P.E)24
M?#L'<I+/FD9&L$#N7K]^X2:,VC=,/*BSARN<B**1`_$QA`.!#.2[Z8K'S[R)
M2:V^6C&IP23LL5$LU8QZH`B"AVC=W),I([4H_P!U040]S\2@)?`B%9,.Y_7E
M\S7=GN;F/40046^PD:[/H/5A3()O8;E)'+-UW!Q#TE*50?48?Q_CP,97=7:*
M)W%SZ=PNY9+4;5BDTZ:.9*(T.%8S\K*O(MP+B*F&(&$Y:=)QZX`HV=L%0DFY
MA$4W*?DQ>!KQ[IV6U7XOI5ABG0VOU3K-2=$BF>@72[P5`JEGN6H6AG).&2;:
M1T"^Q]ML\JQJ3%%-#[9VX5%`KPP)`FDJ/N!?OKI=>N^M0>?]O;O\;&:2/9MY
M8IFSVKL11<O862J6;3H"R/VR>K1V#1=T3J,-H11:I*.95:L/G*DJ15TB<IC%
M]`3CE>Z</89]":N&VVBMV=)01:GT(;EF;U@<YO/ML"V>.K<>R)Y#QZ6P@0?Z
MP\<"8>6]Z-68%9K1UZ@-8KZ:B1UD7CN*L"R[;U%]U-"QPB_WR:YT@$"*+*+E
M*;ZB4P>0$,SF;:+6]3J,9<:NY%9A($$CAJKZ2OHF12`H/(F20`1%!\R4-X,'
MX&*)3E$2&*80KO@.`X#@.`X#@.`X#@.`X#@.`X#@.`X$0^^D=C\[U&VRJ[S7
M;U9LJN];9T"RL\RSE_JU_BUK[/Q%/K]NJ5+C*[;';J<HUFFF<RW>A'.BQ*C`
M'QB^EL(@&M;UXGZY\<_<FHV'0Z/3^O<Q>Y1_DCIMV'V+5/DG^9/NK45)!:)K
MJD'4LMG)ZM]>\>>6%G%3RZB2+E`6T<F*B"7D2`&X=P'`<!P'`<!P'`BEL';[
M+LM,\B&+D;Q;FPJ(G@J^ND9HQ<D^@I34X(*LF!DS>0.FF"[@HAX%,/QX&*W8
M>PFC;4Z`MED"1]>05!5C4H8RS>#;G*(^VN[*=0RTN^)Y^BS@3`4?]F1,!\<"
MQW`<!P+:ZECV9[57DZMJ-0B[=#MW1'S)-Z"[=]&/""3U.8J68K-92,57(0"*
M^PL0%D_R'`Q?IP*KJU5K-(K\95*=`Q58K4*@+:*@H5HFQC6")E#JG*@W2``]
M:JRACJ',)CJ*&$QA$PB(A[ZOA=(S=<`7;G#TG07*"R!RC_`Z*@&3,']H<"V$
MOAF0V!8[Z0RZG&>^H3&EHN!;0,J4X_7UA-5XD7)D4\_7U`L`\"X61,IG%ITK
MS/=?[`T.">K)&FX&K:8G86#LJ":B;9=M$;#`ZA`)NF8J>2@+8`4('MF,!1\@
M&3_,-6V^V_X?/.V^87"75$0;TCL=@:59M:H_3PBA:\CT"CUYXI_#UM85W_$1
M3#R``%[7>R=L*01+][]><INS4H_XB5R#L7%,7AR_Q.2L;13LR8-CA^/H&>6#
M\?S_`$#R%"S?R9=<L_!8^WMM!PE!K^5U)7B!AK3`-S@4PF!:RXQ9=4@$"?D'
MP91PF'@!$?``(@%D.[?RET#,.B6F]L>GFC8=M$E1;MA=0</9QY/66C59#7]?
MI>=NYNZ0U,DX6X%3A8*Q.Y!-JDJ@X7,S])0-]2"'S%OD^:V%QE&4.JU8.X.W
M6^BN-8OMLZ29',P&-YSELSJ5KS&B6NSQ>^:?%W:*_6I^K/&1FK9:7?*&BWS_
M`.W08ID,(7ZZH_))U^[DVFDU''H[11D[GUC@>TRREEKL5%M*95)_4+9CZ%#N
MYF=BDW$)J;*\4.;0<1I4UVP)Q:YR.C@4`$,1W5WYTM(O>U6R.VQIU\>XGG]0
M[UZ3O09#6-DB=/ZC9IU%T:Q4VEW357]MF+%3-.:;>A`E0CVM<3:O$)-P4GMG
M`ITR!-.G_./U<OU9=*4W--ZM.O+:EF&1U'KI58_(+AJU]LNR9]:=6H+NN2E0
MV.>R-K#JY[1YJ0F%).T1Z]>-$.FTBBW<E226"O''S']5XWLC2^L,]!:I6+Y9
M[?CN6V)S9&&>12.8[5N])97S/L@O-54T@^F+68T5)M6LK(P<%,UJ&E'K=J[D
MTSJ&%,(QWKY_,B#KUJ6PY/UG[*2<_#]5]&[4X;%:K4ZQGU1W>DY-;H2B:G(5
MZRQMUM3^/A<GGK(S<SZKADFX5AQ4>12,D0$P4"_UB^93&**FR-?\![/UU*HT
MC!KMV@F$:919:O=/FW8^9/!Y:RV]\QTE1XZ>2ZA"R#A.KMK&I&PBR3UZ5`I_
M0`=2[_-5U_I+_26R^(=F'T7GO:*3Z9L[LZKF44S-+]V(@IBXQT[2*AI.C;#3
MJ8T;Q<?3%'HR,X\AX]?[UJR154DU#,DPR\0DF,U"Q$R:/D(@9:+CY,8J6(U3
ME8P7[1)T,?)ILG3]D209"K[:P(KK)`H40(<Y?!A#U.`X#@.`X'CV*&)8Z_.U
MY21F(=.=AY.&4EJ[).(6P19)1DNQ-(P4PT$'43,,BK^ZU<I""B"Y2G+]2AP-
M./3.JMBZLVG8LXK3"SX17I:P-HE;(>B5DD.U/S3_`"$5JVV&7JU-U?L)VSNA
M1L/6;"-0G*PZ%P]:_:-H8WOM%Y!JK[21PSV?&QO%MDHBR=/=FSVIXWNW6:A9
M3-N<0HV@WW=$,;P;1&4]#X)1]7WRX)J-K[OR<#GKQU/BT<+-SM7#-RBHJ58Y
MBAE(X#@.`X#@.!CJ[<=JOVX61RO-)$!L2A#M+;9V2H#^WDE"B1:%BETS?2>4
M*/A=4H_X,H^D/YP^4@Q%V.4&"KECG2I"X/"0$Y-E0\',+A2*C'<B"0@3^8;W
MSM_`^/S#Y_IX&&+JU\CVU:KO%)SZ^P%,>UC1)?\`1T$:O7Y%A*U==6->.6KM
MJX_5'QY!@DN@478NBJ"1#UJ%,0"^.!FVX#@.`X$`];^17%,DV!#)GT=8;&$:
M^_2KY;(#[-6+ILJK[!4F";190B]A68G5$)'V#I@T$!(7WE"G3*$_"&3-Z#@8
M%$C@0X'3$!!1(P`8ITS>/`@<@^0'^O@:\?::$[V1?9=PL$EIDT]E9M9]DSW,
ME+46D?MY-V@9BPCHN*75:101J0(DE4'WE0YP,HJ91,Y3F#->QR^\O&+$UKWK
M5'$H=DS-+(UA/.:I%EDC-TC2*;`8N@C($8E=B<$O4X,H"8!Y,(\#L&PVK.@\
M35KV&Q_4!,69V70R(G\?4`,U@YV$:^`'^@@>/X<#C+UTPXQ_=>YK`SBP_P!Y
M:TK3%N5./GSY44M,I,&4'S]?)O(^>!.3HO6,<H6TQ\(3*\PCV5U8+0:"Z%"J
MC=9K.-0-(PJZ+E*)*NFJN=%5O]#?F,N7S^`>`RS]F^K.6]L,@<XAII)Z.I+J
MZY;?5/V3)-JY+EG,ATFK:G4B)OACWR1&!K/4&A727M>5FHJ)E,03`<H6[TSH
MUG&B]GZ;VXC=&W+*-7KM3JN?7`F0Z$E4:KM.=4B[/-"JE#UZ$<04PI/0$+9I
M5\8AH]>+>JM)%TT5<*-5C)<"TGQT?'U"]&G?;J>.G5I"V]ENU^O[&VG*XYG7
M(Q6/V&X3EBR+,E4)MNU0@DJ$WM$H<[".(,<60DG2Z9U#+G-P*?<_#UTZD*M0
M*9+,]*E8"A1_<^M';.KL5%>[9_WSEK18=^S*^/HZ'8O)FB.;-9PE(9LB=HXA
MY&.9N$EQ52.94.D'Q&8PIF-2SMWO7:AS-9AI5,U7%M@:W?-*YKF+VBC5"PT"
M+_8\[4,AKU>D64K2[7(Q\N%@BIQ>71=&,Z554`AR!7-2^,?':!O)>P]-U'?(
MNYRYLVD].B7]NIUF@-NN664>,SVOW[3Y"UY[.WP;;,5N$9)S:T#-03>85:)J
MN43G`PF"&?4/X+,KS+K@GF7:'1]*VR_3_576^I,^W9Z9,N<IR[--PM:UFT]A
MUVB9&LP<[25K@Y91BSAR^%ZJ@JP31;%1:@*)PD#/_#;UQMTHS?W#6NTMH83E
M3P^H;Y6I368E.N=M&'7*<6G<@>=CF$72(Y6QRE9%0C)56"5KQ9.-02:/2N$2
M>D0N=?/C%Q*[XCMF`-]#V^F4#L1O.T;]KR-8LE'>.;?.;\XE7.CTIZUNN=W"
MO!G[IQ*BK'MP8?J,4Y;MW#5ZFX1*KP)UYS0:SE.>T/+J6T<,*=FU,J]!J;%V
M_>2CME6:=",:]`M'4G(K.9"1<-XN.2(===1198P"<YC&$1$*SX#@.`X#@.!%
MCME4:W_DENMT9X%9=PT"2QF>HO[5R"7C\[W;1*VX,Y<M,[J&NI3E/GZD0TN_
M.[;KI3#;[!P)W2`"X`I3AJ>XKG4GTAVR2LSC1+QV3^4?8K:XO/7WXK\"[+:=
MM>?XC<9#.T\CAM7[[]B9ZQR5NTB+S*@^&\C+7!^SKT<V!PC`1RHK%<HAMW=7
M,^UG+.OF3T+>=8>;EM,!4F9-2U9XQ:1A+A>I!9Q+61W%1K)HR185IA)OU&<2
MB9,%DHQNW*J)U0.<P7[X#@.`X&/SMUVE<4<S[+,]<G1MZS9(MEL:7Y1K+1\W
M(NDQBS_ZT\[:+%.*H?1HF<!+Y5,'MAB3,8QC&.<QCG.8QSG.8QSG.<PF.<YS
M")CG.81$1$1$1'R/`X5T$72"[5RD1=LZ06:N4%`]2:[=PD9%=%0O^LFJD<2F
M#^(#P+'9UUAZ^Y+8#VK.<GJE5L@HK-TIMFB^=R#)NY1%NY0C%I1\_P#TM)R@
M82*`W!+UD$0'R`B'`ON!1,/@H"(C_``\C]`\C_U!P.)%9%PD"[9=%R@)SI@N
MV63<(BHF82JI@JB8Z?N)F#P8OGR4?H/`Y.!]*82F`Q1\&*(&`?Z!`?(#_H'@
M8K+Q\56<7/2+/=T]0M%?A;19Y&RN*@PK<2Z28FEGPR+^-93+J2][[-5RJKZ3
M'0,<A%``/[H"(93D44FR"#9`@)(-D$6R"1?[J2#=,J**9?/\$TB``?V<#F`Y
MR@)2G,4IO[P`80`W]H`/@>!^>`X#@=^)E'T'*QDW%KF:R</(LI6/<D\^I!]'
MN4G;57P`AY`BZ)1$//U#Z<#.7UZ[)UC<(H&:H(0-]CFQ3S59.MY*X(3TE4EH
M%14?<>Q:AQ_,4?*S8P^E3R'I4.$EN`X#@.`X#@.`X#@.`X#@.`X#@.!'W,>M
M6'=;J_=TNL>#8SDTU:E9VQR"%,ID#0F=QN4@=[)I/;K,5B%_59`KV9<B*SE4
MKI9),YA3*/@"\#649[UV6P7MWJ/:G:\X[8U3M+MFV9;F/5CH8IL4198[M,R0
MZWIU'>LAJU19W*T9=0>JV&[>W;WV,VAQ$1K\D<LZ1=D]3E9L8-ESK;VYZY=M
MJ_89WKYLV9ZV6DS!:S?D,ZN,7;B5"T%(I[T6_<,#$,JT65;K`R?E3!E))HG5
M;**$`1`)(\!P/#LU@CJG79RSRZH(QE?B7\P^4$0`0;1[91TJ!?5]!4.5/TE#
M^)A`.!KE6NRR-RL]@MLN8325DF)"9>>1^B:C]P=<K<G\`2:I&*D0/P`A`#@4
MTY<MF39R]>.$&C-FW7>/';I5-!LT:-4CKN73E=4Q4D&[=!,QSG,(%*4HB(^`
MX%B<H[083M]AGZKF&@,+-/5Q-5T\8$92<>9]&(J((+34&I),VJ<U#).')$S+
MH"8"F,`B`%,4PA?S@1D[@YUINJ]?[I2<DEB1EOD3Q3H&WWIHM>Q1$:^(\DJP
MSF`<-DXEU+E2(!55#`BH"8HG$I51.4('_&;B78')K[IR^E4ZU46EOZDS9(1U
ME**366M"5@350=0[<CQ=O[K-B1S[ZY"^%2+$\&,`AP,K%RO<%1VS5:7,X67>
MG.5HP9$34=K$2#^:N)55$DTFZ9A`HG,/U,(`'D?/@+3#V(CO?$"U5^+7^"@R
M;8KC^T40;F2`/'_I\"X]/U"L7)8S)H=>-DP^J<;)^RFLZ*`>3&9*I**(N1+_
M`!(`@H`?7T^/KP._=;["4=F561,9S(+E\L8AL<@/'(`/@53B;R5JU+]?*AP\
M"(>"@8?IP*=@=GI,THDW7<N(-VJ(%*G+)%3;>L?P+^H(G5:E`1_`5!3#@77*
M8IRD4(8ITU"@=-0ABG34(/U`Y#E$2G*(?@("(#P/O`<#&EWH[O73K1::A1<^
MJM?DYB?K2]GE)RW,Y9Q'-&IY-6-CF<.W8/HQ)^Y$S%<SDQU#%1`4B^GR8>!)
M_I+V1NFV9/7MG<-VM*NT=;+!$`M4U)!LT0=0#AN1O(1QWSAVY*#ILZ`%DS**
M)B;UD'R41#@;"?7'N+$:&9A2])49P%Y4]IK&RY0*V@K6N(@FFD3R/MQ,XN/C
M_#B/LKG'^2("()`$Z^`X#@.`X#@.`X#@.`X#@.`X#@.!`30^D\FXGMQVK*M9
M>-NTE_=,5,IU';*;3-;AL4I39S0).R==:;'#!5^TQ77/5I&AB:Q1",M]^"LP
M]=,G3=S[1BAK.:C3OD4Z)872>K_7ZC4'!=$E=3RWHC&=X58-)"ZZQ&]A=YL^
M@YWUQZ04MU*VJPML6ZNTK3II0+[>5AE6[>&<HL&9'!/?1#8JZ:=E,PJ>J6;X
MS):/["U?=NM='-8JNKV.M3O7+=O_`%Z;V9:L5SL;%[2TE;*VLD?99=0J#EE,
M.(V;C'8BT%D5)#R4,AETN=<SZM2ENMDBG%P40B55VZ.0ZIQ,JH1!NV;H)%.J
MX=NW"I4TDR`)CG,`<###V$[36K:'*\%%`ZK&=(K?R((BH`_G?:/ZDGME71,)
M%0$Q0.FS((H)"`"85#@!P"'5DLU<IT(_LUMGHBLUV+(FI)3DZ_;QD6R(JJ1%
M(7#QTHFB055E"D('GU&,(``"/`HG8Z"38<?T#.FDPG&A?Z=(0\=.H*JJM6RT
MBW(O&2`J,5`.[C#+E3,J5,P@NV,8H>H#?4,9_3/H+LF#[JVTV^SU(+!5R,LL
M.Q:5R6DY-]91G8I2.1=E1/&L$XZ/;F5]PZ;HWNB<@>"?0#\#,#P'`C+:MNL$
M+99N(81L(NSC)%=DBLY(^,NH#<0(<RADGJ2?J]T#!]"@'C@6'LMCD[7+N)J6
M4*=RN!2)I)`8K=HW3\@DU:IF,<4T4_(C]1$3&$3"(B(CP/!X'Z(<Z9R*)G,F
MHF8ITU$S&(=,Y1\E.0Y1`Q#E$/("`@(#P.R^?OI-TJ^D7;A\]7]/O.G:IUUU
M/04"$`RB@B80(4/`!^`!P.IP*XJ6AV>G'*2->BXCO5Y5B'PG78'#S^;V2^H%
M&:@A_K)"7^L!_#@7TC^PL*J)2RE>DV?GP!U&3EL_3+^'DP)J@S5$O]7U'@7=
MKMRK-K((P<LW=K$)[BK(WJ;OT">0`3*LU@(L!"F,`"8H&)Y'\>!1VI85D&UH
MQ2.JT""NOZ&#L(9>4!ZB\BROQ0,]39/HUXQ>(I.C-4Q.3UB01(`^//`J6@9W
M2,KK#2EYY6X^IU9BX>NVL+&"Y,U2=2*XN7SCUNUW+A19TN/J.8QS"(_U<"M"
MF.0Q%$SG343.51-5,PD4243,!TU4SE\&(HF<H&*8/J`AY#@9XNK^RDV/,V+Y
M^X(>W5P4H*VH^0!15\@B`M)D"`(B",VT*"WGZ%!<%2!_<X$C>`X#@.`X#@.`
MX#@.`X#@.`X#@.!;S0L\IUX1K<Q8\^J5_LF8V`-$RXEJ8L%3UK1HN&EXJ&L%
M?F'D?)+5::%E,NF7ZBW3,LBV=JAX,4QB&"`7QK=/=/P^,V3LMVR=0%C[U]Q+
MJ%_W^9K[XTW7,YJL']S$X_URSB86*517.<<IHIMDSD*0'\HX=NCB?UIB`7)^
M06R?I^7U:LIG]*MFMZ3A4H#X$[&OL'#I4!#S]2`_=M1'^OQP-=;NYV.F.IW7
M*V;E`U6)NLG7+%GT(C79N1?14<Z2NEVA*HZ<*OHY)9VFJP;2IEDP*40.H0`-
M^41X&*7Y>>P=$_=E(S@-;@BA0S$#0,R*+]*8K]LM<9&S=6LLNV^T*63AG57?
ME33=I^ZTC5#B58Z:KDI1"7_QW=GL:<8O_DM*;54;!I^+UZ[VZVUV/D',P-<S
M.&F7SH'L=8&;=U`7"*KC-3PNI#NWY6A3D1'P)/'`O`S^3;H,_5=I->T.=J"S
MJJ%R,<Z=D10=P[A)HJ1M$N%X%-&;LI`?HD4AF9EY9-4_MF;`H4Y2A=6![C=8
MK/3,MT*!V*MR--VF\K9EFDXBVG")6+06R+Q=U456JL2F^@IIHE'JBJG(I-`3
M`H>1#UD]06GL/R*]<*O^^EY>RHL&69WJ"SB\OI)99@SKEQLQ"KP$1)+FCUDD
MAD6YO<]\ICMD2`855">DW@(JUKM5@>M,-(OU0U*LR5>HKIY*WV3<*/X="JLW
M9G3]*0DPG&,8O^E.4$E!;NR$,@X]`@F8P^`X'3HO9?#-+C;9*TK08^6;T:*1
MG;4@XC)^#E(J"=(J+L9PT/8(F*E74/(D2,#=T@BH@N;P4AA,(`(1=#NC?]&V
MZUY+UZH^66)A5:3!6XUBUV]V#-U94THZ!B]9QS)M`3`*`Q=JI>GU>A0Z1A,(
M!X\<"W.E?(:]IFOZ?4TY?+(VM8YG@.)>$DXF_2MCT?7S0$J>2I5/L$>U:QD'
M%UBW-T&BCE^V(F\;`<Z:@&.44PO3C/<BGI8;0]%[`:YGBUDT%Q+N8EEGU*O+
M4[5O%,8YU.0)ZL5M8K"_7I#ERHC(2R281IP]`E/^)C!?NX]G\`H53IEXL^I5
MUK5]$;B\HDC'%D[`K;&2:)7#A["1E?CY26=LV21P%PK[`$;F'TJ"4_Y>!;&.
M[PXI+=@(;!HV6*_4LE0KD]7;PS.^<P<U8;8X9'K]+9LDH@SD7DE"R*#XCXRA
M60)J`F8Q5`$`"O8[MKUOEM#3RJ.URLN[PO.+U=K')IRX1CVT-C"FXK3"T'C2
MU5_/)*AZ!:HO3JBI^0`$WTX%^>N'9G#+#V'+CM?T>%E=)^WO\*\J+9O*_J+)
M]2DDE[$W>JJQZ;%I]D9N/MBHJ4KH4S^P*GH-X"O=O[:[`U['H=2NJ6/TS5M?
MA,[:ZMJ-AU.[R-%S3-JC+.R,ZZP>NX2,E)R7LUA453.DBB4I4DUDQ$#^5!2"
MX,SW#HF*T'.I'N`]KN!ZS<XZ?=/LN@I"<UIPW+5Y%VSF+!!KT:ORLL_HY62*
M+T9)PT;HM4G)4ES%5(<`"TNJ=RY^*W_)J9D\E0+CD.G=+.QG96*M:#9Q,*34
MYF,7^HT=Q"S3.4;-1K#T"_XQ`4165\B7W$C%$`#,=\%6W6K=\5S_`%2\DAFM
MOU_`JI?K$UKS1>.@BS*<VLV<A%,'+Q^X:M"DD0$B9UU3%\C^8>!G^X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@>+8[%"U*"E++8Y%O%0D,S5?2,@Z/Z$6[=(/J/T\
MF454,($3(4!.HH8"E`3"`"&";L/NLIN=R"4,DI'U6#!TRJ,.H!07;LW"B0N9
M*0,41`TG*BW3,H4!$B)"$3+Y])CG#$I\E.,:1V`Z@7O+<EKP6F]35NR>3C84
M9.+AP<,JUI-;GII;[^:>,(Y+[.)8JK>DZI3'`GI(!C"`"$8M<ZD[);+A\M$[
M&YY'R@]D^NV34'"))>3JWW=KL%;SMY&3T,V6>/BNJXFVL:#7R=Z+1!55-)0I
MC>@IBAUS]1MJ::=U:G(G/8YC`YW\76K]<KNX82U59)1FP62BH1<+45&R#]%6
M1*]GE51^]1(JQ(<3J'6+Y$PAY&/=-=@JI_AH-.9;"L"=58#3O^($HO:<X_9<
M[8:=Z(=PL5N\6_<S]W:/YGOQ_P!X8CK^<8P#^?@1YO/4?LIG6!LYYMF#26LN
M;?*?IO9N#S9"VUB/>W/([:@LPA'E>DROUH**=N0$50:.CHK)I^1,F`AZ#!'&
MQ=:NQ=[JG8Y[8LKC(B?V+MMU]V!A4&]QK<^R2HU;]@;6DZE57#1D\7@&1@1>
M)&(3[E8JH-RJI^DQ@N9V"ZIZEJ=Y[OGJ<5&0T-L&583&9W)KR4;'Q=GLN<3"
M<Q,UY^W;*'=Q**Z$>1M]PY0(CY.F/D2`80"J<2P)]:+!>)W5LMW>H34]D+#+
MWMJUW<J=IB[UDE,LY<D)4XRK)"NUBX"38E=M'3Q0A?3_`"01_.;P$6'/2_1L
M^[&V.WSW6R#[89HK2HZ+KJ*UMIU323G4E"+)R:S"TR!7#21CBI"F8"D.F(J>
M2*&+YX$I+;B&M6.X][+*C209M]TZT9W3<]9GG(%91_=(ZC2T?,UDRI'I2-3P
M\H[(V%TN"+98?!R'$@^0"VMPZY;=`V/K5HT16=+L*%0ZM0&'7VKXUJ=6SG1Z
MO8F"3-XNNRF)]08&=K,BL91N_117`3G1*?U&+Z?4'HQ&#ZEA=MZS:QE&#3=O
MA,^R?2LVG\6E-4J#^^T=_?+9(VIO.M;K)IQ]6F#+J/S)O!:@'VZ1A2*!RAZQ
M"["]%VR/[9YOLY<E;KUN\==(O'K\E5[E6TF^+V%Q9S3DG('^_!@O9X>":*^E
M`T<AZG*A/!`('CR$;JOUP[&K93C74R9R.-K\#E'8".TV8[%)76LNX*:K$#<9
M:UHR5=KS90;A^];`C(E:JD713*0"AZS`'GT!-?JWE%GSBP=GYVWUEG"/M*[*
MWJ]UB2(K$O'\Q29%%B$"].\CU7#EJW!4[GVVZYDU4A.<1(7UCY#B;Q78K!^[
M4QV6QC*S]AJSM&85_+]!S9G?H&BV^.FJJ=,*S,14I;SEA7L;Z&R7E,QA,014
M#P7^680JW<L([<W7L#F?:^8QS5D%;1UTF,9TG(>KO9.DTS2<PD4[[.3T&V4N
M]P;1M:O-3L]9?-RSC=F9,B<D4WI]:::?N!ZL#TMTBJ7+K&IG^13=+SG.^@?;
M;&9&O6C3JK>9ZDZ5L3N8E*C192TM5(E"S/)1]+F_QC%J$<V`13$X%2]1@RS?
M$]*7OICU]ZNUS1:M]I:Z-C</0-)J9)%@^=1YC./N))NQDHQVZB74A'JH)*)B
M151!02B3U!ZO64-HZGW"NWVN1EKJDFA+0<L@"[1V@/@0$!]*K9RD;PHU>-50
M$BJ1P`Z9RB`AY#@5-P'`<!P'`<!P'`<!P'`<!P'`<!P,=WR(.9)*F9VW0>ND
MHIW9Y0LDQ35,1J]<H1:;B-4=I%$"K&9BFL*?J\@4QQ'\0`0#7T[7]K*_U4K5
M3G)>J25S?7*:D8B,AXV69PYT214>1\]D73MVU>!]JD9=%+TD3,83J@/X!P/>
MZV=G\[[/51]8*6#^(F(%=NTM5.FS-AFH%=VF91HY!1J<[>2AI#VE`;NT_2!S
M)'(<B9RB7@2.X$3.\>UVG`.LE_O]`,S3T=Z^IF>9JO(,T9!@ROVGW*$HU<E'
ML<Y*9O(-H5Q-&>&04`4UOM_08!*(\#P]`[OXMC%XD,NO+S0)V0SMSFE5V34H
M"C??9IF=KTDC)G3T]'GVCMHG!.[6Z<I.3IL6;M&.1=IF<>P0Q?`47VT[)5.E
MMJQ$^S8;.G.6Z/J5;K]'A3V&RWJ^R3=^NQ@Z['@LT1<D8QK!RL=919)N!2G-
MZ_`%]06`QW7:SN%)1O\`4(^T1T$XF)N#13MT&:ORBKVNOU(J6,1B9R[]35O*
M(+-O<]?U604+X#T\#U-2TJKX[GUITZZJ/T:K3F",E-JQC(TB_3:+/VD<4[=D
M51(S@2.'I!,`&`0)Y'Z^/`A&!]W^P^+-8"2E;V^+/47,$M;22.0V)F-5J5H,
MS+7-$L1ECD)$4F=-()?;*K"5XIZO_9ORF\!=^U]C:92KY!TBQ5C3V#.Q6RNT
M2*T=2C/29>ZM]L016KL*WM2KE)1X,D=P1$'2#55FFX$4CJ@8I@*%)J]Q,H(V
MTN91A].?4O*VES6GM(94&06SR4?YZNBUM\%6K.=RDVDYB*=+>V4IRH(N3IJ`
MBH<2#P/-7[J9@$?!NHZE[?.RECBK%:XBHQ&5RRMP7SNLF:E>:@O"/'3([.A/
M_NR_8.E3E6?"!@21$Q1#@<=C[PX?!H1#F,;Z1?$9S*F&UQY\]S^5LP!FKMY(
MLGMCD/;5;?I"-?/%JC($=>T9#\I"^M0?0`6NG>\T!2]DO@3@6:U86UPO'=7J
MTMG^?O+$X@HR[+2JU@NMQEFYT%(RL),#L@]+@0.FH(E33.8%``)%W#LQ1*-9
M*_"SU=TU.OV.9IE>8Z>WHKY3+2S6@ILCU%B>U*N$%'(2AI)!,R[9LNW;+*`F
MJ<AP,!0\5/MQEZ^A1N?-X?2%_P!8N5UH47>B4Q0N<O;+FK99WHS=&S+2*2@L
M:,@V4-(NA;`B0$S"05"E$0#PXOM'5=AA[/5\E=W*H7N?RFYW_&+1<:21A!7>
M.KZ2K-"X4XD@N]1FHIC-';"H@]1:KJ-5BJE2$@^H`R"=$-HO.^XAFFG2RJ:D
M):*'!RLF#LAU7#.T*-2MI>+BW8G!4[5M*MEQ$JON`DEZ"AX$0X&/7Y&GO962
M[$M(^#8Z/^QZM&567S,U"96IS%)2:B`N74^LM"MU&W[R0G"K)"8WE1!!)(I/
M!3#Z@S&==Y_1;3A^96'6HXT5HLK5VCFS,U6BT>\%R"JZ+1Y*1JZ2*D;,24<D
MBY=M_24$7"IB@``'@`R_?'DK:E;/?6Z,F[+2F4,Q</HDWA1BI99!X"<>[0`_
MD6CHL<P<`J*?I]TOH`_GTE\!E8X#@.`X#@.`X#@.`X#@.`X#@.`X$(.^]:?S
M.-QTRR;F73J=NCI23,3ZF;1CYF_AE'(AX^J2;U^W`X_ZI1]7X`/`UVNT/66I
M]HJ&RJ%AEI"MRD!**SM4LL8W;/%8J559*L5DGK%SZ"R,._04*#A$JJ*@BF0Q
M5"F('D//ZJ]5:CU8J,Q!P<R_M-BM3QC(VNTR+1LP,]6CFRC=C'1;!N988Z%8
MBX6.FDHLNH914QSG$1`"A*3@0V[^9'<]HZKWZLYO&'G-(K,S0-6S^OIJHH*V
M.UY/>8&],:V@LY60;)N9]M#K-$14.0GO+$\B`?4`U[^ZD8Z>=\M9T2(IT#&O
M+):*',3^=ZIG\/>I1U86E.JS-PI&D67$8X)Q%HD**)?N0;."@LD/N"(`$A^T
M.5[CH-,I0O5+;>XF1[`,],>P-:IU;=6O&J!^QY-I%4XE:1M%87TIY"6.0$#O
M4Y5B[1,;W1]8%]`!</#ZKV'KF1T=T^80V?%SV*U]BVPJMTVKPSC1XUPDY#('
MDLY6L<S'YY:RO@%Y(MDG[I!9=R(N%?(GX%>6/&-"UWJ:KBNMWMF.FW"B1,7>
MKU&0C-9@C9`E&$X^49PS$\0S<MF9VH,RBF*!50)[H`'GP(>#I/5'_,+_`(D_
M_P`>'B?^(7,\ISH?]P?>?M3_`"Q^Z`)<?]ZH?K/ZR#G_`&/\CV/`_G/YX%!V
MWI$^M>P*:<ZTV,7:DU/,=3C4)JA'F[K!GSHD.E_E]7[DO:4F\'G<D$6=<&C:
M/(L5TL)E%%2E$#!Z*'3V[-L\V'#8_<D6^(Z2UT\*Y57&<L7-DJDIJ,PI..SR
MEO">16GX:N2;MPHT;I-V:BOO?S51`H!P('FF^P!-RAU*MH16>BMJH;K0[/)T
MJ'G4'E-1FB-TBLX4'$4FTE8MZB9Z@J98P`/T4,9/SY"2*O3_`%"LZ>RS_&KM
M(YYFT/TWCL3=:;/4Z*NC:SJO[W..+/#F9FEHE2*MJK264DVSA$11;F.!!*H3
MZ`%Z%>DT.UKFN5.`O3R-A-*ZP9]UHC$WD(1^[K;&@1\M'H6MTNG)-23+F3+)
M^L[4"-BIF*(`H("'@*2MO0UU;KTULSS58U6-;S&(3;/]=SX\_;JV?&VM>8FK
M%-LBUL;M:Q1K4$(=VZ:(,1<?=KCZECD`0,%DLBQ':HW?)B6GLB>D8Z!IF\(Z
M?-VZMP*D55<IT9>P"G,9GJT?>55IBW6!HX9H&00K;0_L"*3@_H2]0A??,.J<
MUUFJUKEZNWSS2).HY1=*SG3>KXO#539+2_>1XD@6EIT,UG=H2SY44$FR_L-F
M*;SS[JX^2``AF0Z09@7&.H?7C+SJH+R50S&!96-9L!?;/;GA5I6VD$Q!,"AF
MUB?N4?7Y'U%3`?/CQP)5$55(`@150@#^($.8H#Y_I`!`!X'X$1$1$1$1'ZB(
M_41_M'@9CN@U<9QF-O[`F)#OK3;955V<O]Y-"&*C$LVIO^S%%57_`.FX$X>`
MX#@.`X#@.`X#@.`X#@.`X#@.!1>C?MC]@W/]Z>@*G^V9K]PB<""(17V"_P!W
M[0*"!1<^UY]KZ@/N^GQ]?'`UQE00!54&IUU&H*J`U4=IIHNE&P',#<[I%)5=
M)%R='P*A2J'*4XB`&,`>1#\<!P'`H23_`,K_`-Y1?ZQ_EP.C?9K_`*&$N-6"
M[_9>V'O?IHO`&P@S]OQZO:_+Z/ZN!`]?_;K^?1Y]];S[?CV_/NG\^WX\`*?G
M\/'T\<#BX#@.`X#@4*E_EG^^G7L?LC_,K[%'[SV_T;]X?8>%/9]WQ_O/T^CU
M>?\`7]'][\OC@5UP'`<!P'`EK@`R_P"W)4')2?HOZF(Q9S'/[_W7M$_42IIB
M3T"S$?0/J]7GW?4'C\1X%^^`X&9_H9[W^0Y?<\>W^];/]M]1'RCY8^OSY```
:?N?<_#S_`-?G@31X#@.`X#@.`X#@.`X'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g644794g18q24_g.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644794g18q24_g.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-/6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:2\^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@/&1C
M.G1I=&QE/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CYG,3AQ,C1?9SPO<F1F.FQI/@H@("`@/"]R9&8Z06QT/@H@
M("`\+V1C.G1I=&QE/@H@("`\>&UP4FEG:'1S.E5S86=E5&5R;7,^"B`@("`\
M<F1F.D%L=#X*("`@("`\<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B+SX*
M("`@(#PO<F1F.D%L=#X*("`@/"]X;7!2:6=H=',Z57-A9V5497)M<SX*("`@
M/$EP=&,T>&UP0V]R93I#<F5A=&]R0V]N=&%C=$EN9F\*("`@($EP=&,T>&UP
M0V]R93I#:4%D<D5X=&%D<CTB(@H@("`@27!T8S1X;7!#;W)E.D-I061R0VET
M>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R4F5G:6]N/2(B"B`@("!)<'1C
M-'AM<$-O<F4Z0VE!9')08V]D93TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R
M0W1R>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I5&5L5V]R:STB(@H@("`@27!T
M8S1X;7!#;W)E.D-I16UA:6Q7;W)K/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE5
M<FQ7;W)K/2(B+SX*("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T
M(&5N9#TB=R(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#
M`P,#`P,!`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`-4`E@,!$0`"$0$#$0'_
MQ`"#```"`@("`P$`````````````"0<(!@H$!0$"`PL!`0``````````````
M```````0```'``$#`0,("00`!04!``$"`P0%!@<(`!$)$A,4.2$5%G9WM[D*
M,4%7E]=8F-@:(C(C%W%"0R0846&Q<B89$0$`````````````````````_]H`
M#`,!``(1`Q$`/P"^/A-\)OB[Y6^+OB=R!Y`\3JWHVP:-6[\^NMU?7[7X9W.N
MX;7]#K,:LM&UG0X2#:BU@X1JW`&[5(IBI`8P"<3&$&H?XX_A7_D7J'[T=]_B
MOT!_CC^%?^1>H?O1WW^*_0'^./X5_P"1>H?O1WW^*_0'^./X5_Y%ZA^]'??X
MK]`?XX_A7_D7J'[T=]_BOT!_CC^%?^1>H?O1WW^*_0'^./X5_P"1>H?O1WW^
M*_0'^./X5_Y%ZA^]'??XK]`?XX_A7_D7J'[T=]_BOT!_CC^%?^1>H?O1WW^*
M_0'^./X5_P"1>H?O1WW^*_0'^./X5_Y%ZA^]'??XK]`?XX_A7_D7J'[T=]_B
MOT!_CC^%?^1>H?O1WW^*_0'^./X5_P"1>H?O1WW^*_0'^./X5_Y%ZA^]'??X
MK]`?XX_A7_D7J'[T=]_BOT"Y.5_@X\5><\X/%?DU+XBUJ#SWD-L'**L;)6T=
M!V1TWN\%G_#K7=/I\>[>/]&=RD82%O=98R!#L%VJBAVX)JF.B8Z9@8W^7'^"
MOP7^J&H_?[J_0.WZ`Z`Z`Z`Z`Z"(-8Y!85@PTPNV['F.2&T6SLZ502Z/>*W3
M#W.VOU4$6E=K)+!(L#34NLJY2#V+<%#E%0O<`]0=P4A+^7^],^1$W20XNEKG
M'RH\MY?Q]W+4[OJD-&Z37>6DS4G-LQ-Z_P`JAHJ9CV7'G9U7L#%1%F<SB#Q9
M_8VPBQ(FF(J`M(GDIY5:CP>SNXU7E?8=!W&T;GB#CGO4,^QTF66#QUYG:":1
M!:-EBEAH^&[9;:2RBM4J\;".)F8KULMD;&"M)"F5J[2<M@N/Q@UOR'[7L7"#
M#?\`Y;HM*[!<6MBY%\A-B@\`^?X[>(",Y<P>;X?02R&RY-D$O7KA)9=7Y%M,
M3K:O1"DB07$FS8E([9.D@MGN')WFEL?.&^<*>"3[!<V3XTX]GNO\C]LY!T:Y
MZ;&.K5L;FR#CV'TJDTV\9\Y;?/D#4WLM-SRSY86;44DFS<RWJ]8,EQB\V&W4
MJOL]*_Z\AMSA:Q5QVS/\YNJ5VAJ#>Y2(1=2L.TD%6T=-&AE'I5C1ZKYFU77:
M@4PD[]QZ"7.@.@.@.@.@4;SE^)-X1_M^YJ?A^[UT$=?EQ_@K\%_JAJ/W^ZOT
M#M^@.@.@.@.@5UY@]!V7+^%4[=<F?:A!UR)U''!Y)6O"T%E]SI7$I:_PZ7(J
MWX_[HW>2#.[P>?&<*$>-$5'T<Q]Y=MO0X034("N.4<%QQ\J#[+^/OCRM>+\K
M5JU@$3!\D-6OFDZ-:ZP7BU*F?1.?X[;.2==+>]&JFO3&JR$??I&`0*QLURCZ
M0LTFI1BB9`50NEJ%`XM^+/C58M@Y!F?\KMET&M\<LYN$WH[.-6E>3^K\9X=X
MVP^ZS5(>!-T:MWFIQ,<BX?V=)FI(%2B&SA=9R[0;`<)W\<7DIR_G)2[.NZB*
MSD&O5VQNBV3,#VAG(.92(?>@T%<8%ZZ80+RQ,GK8H-7BA6WK:/$!(IV(H@8X
M,$U;1H+(,QT/5K.)@KV;TJS7>9*FHDDLM'5B'>3+ELW.L8J0.G2;,4T@,(`*
MARA^OH$$UGEKXLN7FXU3D]&;KK?"WE<%?KM(GWOTTL>0-=0K\`]=2]0I.R(Q
M+R3Q_7ZG5K#(K'9$>N4GX)+JMRK)MUCH]!1#+^,G('Q<WG,;)!0DK=.;MUKG
M(;+Z9!/Y&H6#&^1MUN)L^NNU>07DWRAC(VMZA2^+6:-(GZ1O:)?BO9B$L\BH
MQK3Y1DX(/0.>\3W(W3-IJ$Q5V\QI?)C"L_CI)+__`$8U-['5-ERMWF8N4K)Z
M.UXZY,S@&RX<9:&J\5CJ]/BZ(P,BU28,`?(MSOC`X;H#H#H#H%&\Y?B3>$?[
M?N:GX?N]=!'7Y<?X*_!?ZH:C]_NK]`[?H#H#H#H#H/`@!@$I@`Q3`(&*(`("
M`AV$!`?D$!#H$%Z+YG>$G$7;[I@><X<]D*77IMP:\7O"87/X2M.=)6742MC=
MM7$E*TC9WD4HBFB]E"N?4N\(HD4#@C[0P:Z?D3\B%M\@NLMI\T0ZIV1YPI+P
M^4T9TH15^V;22K;YUM=F7044:KVNPDCVX*II"*+!NF1NF900566!=CUF5ZF0
MOM5&ZB2I54ET1$JR1B_+W34*8AR#W[#W`0$!`!_5T%Z;!Y+^9LS@ERX\WG:9
MB^Y9=H)G6)9K;XJ*FK2UB6[QBZ*SC+I[LULB:+DD>5!8'3AT0[<YR=@$P"`4
MXJTLQBK#5Y]\Q4EHR)L-?G'T6FJ5JK*1\7+,I)W&IN%2*$;*OVK<R13F*8I#
M'[B`@';H-WC>_(?XK.17%6!A.15^A[7DG(!.NL[/BJI[4XN*)(BSP\E)0VEU
MFA.TY^&KM>G(Q/YU*Z5+&RC)%1,H/6R_LU0;7G[NB/J-4'67JU=;.%*Y#EHI
MJ2$86GEJB3%!&"1K*<*!8E&#;QR::;9-L!44TBE*0`````R_H#H#H#H%&\Y?
MB3>$?[?N:GX?N]=!'7Y<?X*_!?ZH:C]_NK]`[?H#H#H#H#H$]>8?G+6^-/&F
M[YO1M*CH;DAIT>PK51@(2224N=:K<T^;HVF[+-V_M5Z\@VK0.4F+M?V)S/5D
MS-Q,=,PD#14;N&ZY#F05*H1(PD.;U"(@8/E$3&/_`*C>K]/J'OW_`$]^@]W*
MJ;,JAG/J0]DH*2I5"'*HFMZA(9,Z0E!0JA3@("`AW`0^7H/<AR*$*HF8IR'`
M!*8H@)3`/ZP$/D'H.$DLY4=NFZ[8"MTP[HJB`B54.X``#W[D/W`1'Y/T=NP]
M!RE2J"BH5`Q4U1(()&$O<I#=O](B7]8!T'HU3631(#@Y57';_E5*4`]0@(^G
MN(`'J])1[=^P=`X#Q-\A.?U1UZ-R;B7&NM6ICUXE*7G*KLY>ADM;AW;@J3^V
M/[+Z5CY:X-V$2.67J,_7*!/<GRG9/H-ZEJ9R9LW,]301>&02,[1;+*.6R3D4
MRBNFW<*H-55T"*]P(<R29C%`!$I1'L`??H#H#H%&\Y?B3>$?[?N:GX?N]=!'
M7Y<?X*_!?ZH:C]_NK]`[?H#H#H#H,5NMZI.:UF1NFBW"K4&G0YF)):V72P1-
M7K46:3D6D1&A(SLX[8Q;$7\L_0;(^U5+[5PL1,O<YR@(*5Y&^%+B%R>N^E[6
MA8-"IM\UJ/0F$)JI65A*TII:G"`*?3E"O/V+DTT6;2]B9PU^<$V2B?J,W!!1
M3VH`I#&/#)'\5];K^P<^=@PRL<<Z7I</&P\>E,RHJ[%97LFW:9^PDV<A$-6L
M%7I27.FXDF:BSI8&C98BHD:`LZ(#L.6?`7QM.+!<^:')W/(%K$UBJ*2.AN5I
M69BJ#/@@*+=C9;%5*TLT"QVXX*),VQR>H[TYTB'265!,Q0B34/"1PNVS7LLV
MBGD/0LR:0T0M;LKSE-LVHVJQ,=%L"4UY'R39R1>JHNV**991=B"AYAMZ3`9!
MR95TH"L?(;XD>+_'6VV'5!Y9U+CIDEL9R4G1\DLM1GM#NY[:@FLN\JM!CX6;
M0GIJG$740]FJHBNM%D7!-90Y"D4$-<AJ=V*KHKM),J9#F*V42,(>U+W.!5!`
MWJ-V$`*/80*/R]N@G[C+B55Y'<@,IQ.YZC'X[`:!:FL(YO4DU4>IM%UB*&9Q
M#)L!DVPSEC=$*QCSNE$F9'JZ8JF]/R&#]"SC'Q7Q7B'F<?E>(U1&O0:`INIF
M7=&*^M-QF@1*DO8K?/&33<S,PY`/TB!$4"=DD$TD2E3*%B>@.@.@.@4;SE^)
M-X1_M^YJ?A^[UT$=?EQ_@K\%_JAJ/W^ZOT#M^@.@.@6]Y`>9;_CE7HRJ9Y;<
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MR%27D'BRSM1%,J8"1(`3`.PU[G[R/USBUD_$NXSAYW/LQGE'Z4JJX='L=HB(
M]L@VH]<M[U50P2<5GY#./<#&[F4`R'MO6=HB<0["Z>0'DY<\%P/CQ_V!-5BF
M\>U#.:S+5.9F82V3[Z.?KK4EW8IQF]2=J!G42J#")21,FF1(A5%`.J5,Q`KY
ML>ZZUR"N*5XVS1;!I-S1A(Z`:S%E>)+NFL'$I>R:,&35NDV9LV_K]2RPI)$%
MPY4475$ZISG$(A<K.TU&Y6[8%TSF[+G$WI%(O<`[A\OZ/2(CW^7]';H!5BFJ
M[1>>U737;@'L3HJF1,DH4PF273.3LHFLD<?44Q3!V,`#^D.@_0+\3O*:Z\N>
M'=6T314(DEUK%FL.83CN'(]20F#4U*+)'3;M)^\?KDE96'D&ZKL05%,[@QS$
M`A3`0H,IZ`Z`Z`Z!1O.7XDWA'^W[FI^'[O701U^7'^"OP7^J&H_?[J_0.WZ`
MZ"J>M;>6QRVY<7N/E]K+/F5`<<)O4:?'ST8ZEZS0I*UDG:KD5BT!1%H[CV;"
M8O$<=1%DL!W#QFP=*D1422/W!7''KQV77=-CEN3_`"<KFJ98-BJ->S33\)WA
M]@>X6_87D/D%?R?4K>O>J`E)4[/:%M\5%I0-CBXEFD[M<)`M5BC!-9%_&.0>
MW`5^%JT/'5^O1K2(AHEDSCHZ/9)`D@V9L&J+%FB7])S^Q:-R)@8PF,)2AW$>
M@UP?S#Y=1NC7B)C-`JUCN#>W6G2[2%=J4)*V*>F+168NL0D(DC%Q+5VZ429Q
MMP?&]0$[`97N80`.@UA-?P#=,">-XS8\?OV72<DF8\0G=JQ(P;*7."7MA)'2
MRJ(Q4FHFF(BH1!=0Z?8?6!>P]@B!J=P=`AG28)+_`"@H4H@)>X&$`,'8Q@#U
M`'?MW'H.1T'$.R04=HO#`;VR)1*00-V*(?ZNPF#M\HE]8]O_`!Z#E&$P%,)0
M`Q@*82E$>P&,!1]("/Z@$W0>L,C(22K-DJDW;OGSYNP0]Y=MF+3VKMPDW;G=
M/7:R;1@V!54/:++*%22(`G.8I0$0#=5\;G'S0_%O7)&D<AK\A:LTY!3%,LL'
M>:ZLX4RW&M5?QQH:3HEG5=K*#%-[T96/1CK0`(Q,F[9IM%RLW!V?OH/6Z`Z`
MZ`Z!1O.7XDWA'^W[FI^'[O701U^7'^"OP7^J&H_?[J_0.WZ"KW+CDM`\5LQ@
M]!LK0"0UDU'-<I=VN3E8ZMTG-2Z99VE8#2-)MTRDO#52D5477M%G3LH(+O3M
MF9CI"Z!4@*P\7'&K5+K8HSE/O]_K6TO:78=/C\5Y%U#:M2ODMK3.4DGF=7-Q
M`NISYB4@>,MG&H$L"5&DU+)!C=W;B7@A81;6)!P#\.@.@B/8=QQ/C_7F]XW#
M3:%ED"LY&&C9N\V&*@/G.0<@5Q\QP0/UTGDS*.2-04!FS(LNH5+U>@0)W`*_
M68_#7R:87?,TA[]G>X45T*;*8<TJQ1<K8\YM0).%*_/$204-,TNUQJA3+LS.
M44#+I`<HE4;J*$.&CUR_X&\EN%5U/7]3HDA)TMR5X\@-;JK5]-4&5B"3:T+&
M.)2::L_<JI-R*@(":,D#H.B&=)@0%"G(<P4M=)NSG;"V6*D0BG=P`_\`J)_Z
M?]/;TCW^0!^3N'Z>@8OXY_'Q?>>^NJQT7.PU8R;+Y.G2FSRDBX=DEGE;G9-Z
M(5RHM6")UU[).1T&]33744;-V0![8RAC@1(X/`Y\>!:H3=74OW!=HA4+G7H)
M)![BL]-/G5:OWS:V`A7E>M-@D'3NNW-X1/\`Y"O5S1K]8P"<[0_K5.&NAQ[X
MN7#7N5V><2=&^=L:N]KNCFF6Q&Q5Q=:>IJS",E):0]XK+MU''=.C-(LQ4`%8
MK=0RI%`4,E\HAN4<F,0TS$.&."\>\LGN1&I976]!I&><CIRC,X*]<CI3C&O`
M7%K8&5-CCPBJL@B2V*UZ.>(1;)Q+M:B+PC0#JI@H`4X@WW/IEI6XMX)_SNC*
M`VC>0+51U9J749!A$8\CQ[H2?&)_A,8ZJ,FK)<BU-E.X3?MHUH\:$;C*FE$$
MU$X\2AW<)=N8-FN.3O)]/G]2(V,\<[%+;D7F;6=W3]`Y)S5-K+-M%5&/J%0>
M6J@W_/+)7)B4L$PV5&7EU)ALQAVZY`,=$&F>/Y?=7'#;`C\F$KHEN2=-5:W\
M^B%CD[H]?,IV89Q<M/(1S=I[HYF:^@T=D0=I$E4$5R)R)0?E<]!<3H%&\Y?B
M3>$?[?N:GX?N]=!'7Y<?X*_!?ZH:C]_NK]`[?H-8L[^`\D7DL7,$)LM;@*QG
M:,#%M[PWL67SE#R^C/D[%)Z/A.AY18[U1IYKMRNMUQ*\YAL=69.IBN2$8H1<
MH-/<"!LRQ<7&0<;'PL+',(B'B636-BHF+:-X^-C(YB@1LRCX]@T31:LF3-LD
M5-)),A4TR%`I0```.@Y_0'0:Y>X.G%[YU\H[3=1&1L^,SV?X_E3&1`%PSG+Y
M?'L^TIY(U1!4HDB7FHW.WR:TG(H`5Q((Q35FHH9*/(F0(]L6?LY:TQ.DUFP6
M?+MDK2!FU6VG-9!"!T.':F."QH62=.&C^%O=,<K%`SFO6)G*PCG])FP*>E0H
M=KR;Y.S>U\3-0XT<X_<:,$G#Q\I1.8N8P<ZMC3ZVTM\VL=42WO/&1[#;<26F
MIB)0;O7:9IBJ*BN=5-^P5]@R`-<#*N.LW?.0C?`;#:JS7Y<L:M-KR-<?H7MK
M-11*\E:F?T*D:^HYA9US+P#A-VW.JX;H`U,)S#[0`0,&VQP0P;CCXF:GJUDV
M/F=D"<+M[7.;/#R&F/:OB<E&0U>B+`Y;H*Q5DO4FO).GY+4!P(D!3D$GI]!A
M$.P9#IGY@+QDY^J+6`UJY[4\(J*2J>*9/?+;&I^DWI,H2UR<17:2[2`/E`6\
MFMZ@_P!O<>P=!;#BUR7X->0YFWVW$AI&AW/*YABC(FMM"2@-IR&?>L'01J4O
M%6B):7&K_.D:=P5F[0,:/D$2K`W76*13TA??H#H#H#H#H%&\Y?B3>$?[?N:G
MX?N]=!'7Y<?X*_!?ZH:C]_NK]`QSEY+YD.#Z'G>G[<EQ[CMGHVD9G%:D6<:5
MV3J+I_F=RG9FU1$N^408QCBEU"`DII5TX50;-F\><ZBJ8`!N@@K@7@3RHMKM
MR.NFF<>MTOW("#R]I`Z[QWRF.S^D2>*9U1HJM9JQAYE>Y:5:+0TF&Z*LNNHM
M8'<<DN\!)DDD@B4R@,0Z`Z`Z#7G\H/('QOUK39"=D.8<=B_-.@UYO3I1GF-+
MLW(`UC@8]^YF(O,^0N1T*.D4)"/C'LFZ6CSKR-=L<*9\L=F_117717!:_&;R
M-8OODHWHEF%7(M5=/W4;!P%O%2-K.D@W<*(MI/-;%)@V]NM+H)@X3@94K&P-
MR']`MUO2*H@PDQ1+[1-0O;N51%5)0OR&(<HIJI*IG#L8AR")3%,'80$0$.@4
M[R?\6=%T:1=Z-QTL#G"M+]E(G>5*-F[-!8U=S2+0[-^WD(:IOF<A0)&2:*&0
M,\AR'8F(H8'$<N!C&Z!%UVR.PXO>5*5J>9K9QHI4E%6J,XS9OC66/:_\0RU+
MO*0.F-Y@RE*'_,S=**H%[%<)('[D`.$)A-\IA$1_^XB/_P">@;EX/:!N^A<Z
MYMK@>KV;%WD!QVO4GHMYA*W6[C6P9N+)54\MK.D52U1[N.L<!.7!-XLBR;.8
MB9.V9OSL)%F(+J"&[SQ>VF=VO-WSV]5Z/I^MYS=;5D6TU&'<NWL%!Z=1'B;2
M7<UAZ_32?O*7<(EVQL,"JX*#D\',,Q7`JWM"@%C.@.@.@.@4;SE^)-X1_M^Y
MJ?A^[UT$=?EQ_@K\%_JAJ/W^ZOT%-?)-M=ALO)N0HSZWTBS5*EZ-4G^8Y1?Y
MSQ[[S2D=6S^"A/:V>-X][CH?$7DK7K9%2-P*B[2A[Q8VSH'!3)(@"XM2!L98
MKF-?QC)<[RNK1K&*A*+4X>OM6<<2139@LT:$&0=)EF)2<EQ-(21UG!S.WKQR
M914QE5U5!,H8)/Z`Z"M_,:U:'1>)/)^ZY(DY6U*H\?MALN=E9(^\O2W2#S^P
M25;68M?9J^^/D)9LD=%'TF]LJ4I.P^KH/S!(06YHEDY:O5I-.31),K3#ITH^
M>S[R8#YS>V*4D%CJ.)26GG3H[MTZ5.=5PNL90YC&,(]!RGK!G)M%V4@S;OV*
MQ0]X;.D2+MS@00.0QR*%,4#)'`#%-\AB&`#`("`#T%Y.+ODAUS%9*+SB=7F>
M3E`2,BQ9TAB\<6S?JBU+Z4B-Z1*-`DY2\L&I"@"</.`+CT@!&\BD7TI"&P]F
MVKTK5H]V[JKN6:RL01A]*J-<:[.433*(ZDVJ;UE'7[.+:QB;?4'[ELJ!T@>-
M2).2?ZT%%4^QQ#QK.4Y=LU(DZ7L-1KUQI0IJR3IO8BE13@U6B)CC8HJ=(LTD
M*G*1B114))-'+5=N!1'VI2]^@2O1N(O$JFZ4[ONAP7._E+PG7<D3-H?':F78
MR&2$9'<%E92P7&K9J#_D;FC8Q`!>9J4PVE(U)(XBWEC"95,-U3@9B/"C(<!K
M,UP0KM";8IK+"-T".OE+E7UL<Z@1\S*FQL]DOD\_E[7:Y)%N`H!\Y.U%F`E.
MV`B'H,D4.!PIEV^@/>5>ZP($/GNW\G9J:S"3;G34C[;3LQRK)\!6OL4JD8R;
MN%N=MR64=QKL@BE(17NKM(QT5TSF"\?0'0'0'0*-YR_$F\(_V_<U/P_=ZZ".
MORX_P5^"_P!4-1^_W5^@\\D>)_D4W7DK5;!)ZQQC9<96MS@F5NR:*E[=!V^Y
MY=6M!4LU4<H+WS)-H8TO3&D<[6;SKJKNH$+6V(BQ6<,TD4%D0=MT!T!T'@0`
M0$!`!`0$!`0[@(#\@@(#\@@(=!I4<H>(WBXN>]7F9X[9SS;DJ@WND^WO@<8K
MQQXIG'1W;VTFNC<F&.'Y!I.)MTW8V,CM)X-7%&JI/"*HL%2B4X)A8W`\>\!>
M>$9K:OQOW.%L#,Z8FF^:5*VC6(!18OH`5'<E4G^D\>VB7K$3";_VZ(=A$.Q>
MP=!L'<8]"X(2<0E!\/[9Q9^:U$2?_P`U@4CES`Z*91#TIO:U1SMG;-0@]NY%
MVY#@/Z0Z"JGD;9\/K-)UZNVV$NUIYFHP:ZV*M>,#B*9<J:_$JN0$9&1L3LQ*
MC5,85>F-\X'T,WT'=&`Y3H.78))"%&<JX4W.Z1<!-<XKG7M;E(XC9PWPRC1B
MM?P-L^:+"LQEM)8"H#S<;:D!4SKI/BM*<W=E,9G#"`)K=`R!J46X-$&)`;%:
M)MVK!NS3!!-HBW*5)HU9(-RD(W10(4I$DTP*4A0`"@```=`NO(^+7(S8Z[R:
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MV]REG"*GM`^4GI[A^CH-1O"7$<ID]*@(Z-5@G^>5V&S6XTUTW]TF\[O%$C&M
M:ME%M$4/_N(>?KLW'+(K)+%*94`*N03I*D4.&?6*U5^D0<C:K788NJUV(2*K
M)STU((Q<:R(H8$TBJNUU$R"LX5,!$DB^I590P$3*8X@40Z.O</[;S,,UF;1G
M$1BN,N0(NCIVBYQ`.^2-]CE.QBK913K9#N'>/Q#Y$>Z-BLR9I<2&!1I#$[IN
M@!N^*8-D_'BH$I.1U-.N19RLC3,J^DI6SW6XOF#1-BVF;]?;*]E;?=YM-HD5
M,KF2>.#(I@":()I`5,`^^Q;AE6`U9*X:S;V56BWSP(J`8`@]F+5<YXY!.A6J
M'385N_L]VLKD/]C*-:N%@`?6<")@8X`LNQ<M-/UB\`TT[#M[H/$M5F@HK4\#
MT/+XWD[I`*.%2O8W69.7N].<9337<>4HGAZ/-N+$Y!4R3F6;=E&A@>YPFY,<
M5-@I)<KXW1BV8AC$#!Q+WC]8Z,\RZX9M6%RKM:ZX)2W[=%N^JDB9FJ1O+Q2T
MA%N7!%2`Z,N54I0,.,T_^:_.LM?%48,(?BF:T^S]?N`;&:@W<MF*;_T?GD,A
M)01<=O\`7[J+7U?)Z.@N_P!`=`=`=`HWG+\2;PC_`&_<U/P_=ZZ".ORX_P`%
M?@O]4-1^_P!U?H+&\Z>-VR;O;*&PRODMF6*#<J1>\C4C=#HCRW72#?3@L+0\
MV#C#)06AYW-UOD!3*S7GH(+J*2+!-GV<*MP(U4*N#&HE9LXC&*K.2),MA;)$
M3E2+MG02'L2@D=T9PS`K5514Y!$XI@!?5W[`'Z.@[#H#H#H$Q\_\_P"(MPUA
M.JQ_%6-W3F=8ZA'V%W.4ZZ6C`5:%1CNG5>K5[Y![[FTG"6B(JYW<6Z;0D<FG
M.S\L9@NE'QYF[=RNW"N?'7@)1,CD8F^:M:K!R(UV%DGLO5)[1'TI.TG(%'RQ
MUDXO&ZG9'\VZ8*0Z*GNR%DG74S;ET2`)I!(IA0*%^%5`*5=PNJ4B:2:SITY7
M4*FDBBB0RSATY75,5-%%%,ICJ*'$"E*`F,(``CT"<.0WEQSR)T!G@O%./>[+
MI$L,HVE-<C*-=-#Q?/0BV*\A(KQ<70VZMHVVP-&+999-M"F0@B>Q,+F5+Z11
M,%7*O?\`&WEV6NUYVLE[WB?8E9O;QN+TM(T4T6\]"Y:_2*5;XVG-LZI"@J%,
MC#UZ-9LE"B4ZPN51%8P63(`J(D<)_P#(W5*!DG"?91!4HAW`R:Q/4FH40_0(
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M`5%\:SZ>M,M5K,1A&1!D%_F-@Q=OFK=T[.4P-2Z`Z`Z!,TV[:9MS=Y.TV^*H
M0=FY`3.::[C$M+J),D=.H56QRE9?8*=5'JYDV\K8\FN-1D'3^'1,9XW86-L_
M]E[)THH`<;5N05&RJ20J)D)G0-8DXU>7@L9SQ%A,:`^B6Q@37LD^1Z_C:_FU
M!9*F`'=ELSZ(@VW^WWDZPD1.%*KN]LFJRK%QR`>5._TL"*.%N,M-D;2C@K,Z
M@=F;;2;BC]$KER*LT9\BJAG",524'(%]WB'QDR/SA7=/&4&NU,]DCF=#BIAC
M$-*R@[CJL=O(EJC./^:$88C8C@L8V>$@R)1Q9!$4W*<>D"!0]C_Q=!>22W:X
M6:6(I<86F:!4"1S:$)E-XJ<7;,T3K[%(B+&)1K,R@\(D+1%,H`\`_OJG8?:*
MG*8Q1#I,YQ;@1IMP=1VC<>ZGQY>S:J(0ESXT7#3^/T,V?F.!3L[)#9U=X2`]
MF^'MZ'2K4R!#=RJE*!O:`#H>./$KCWQ9BY]'#Z,E"/[LM'R%RNTS8+%?-`O*
ML>@HE$GM&AW67L-NG6,6BY5]Q:JO3,F0+J>[))`H?U!(NR['GV!9Q8-6U"97
MA*=6S0[9VNQB)>PR\A+V2<C:O5JY7JY7V,G/6.S6JT33.-C8]DW7=/7SI)%(
MACG`.@K)&^1CC6\O[',)(^OU*Z/DJTT^:[G@NP5E-A<[C4IV\U3+):0DJ<E'
M16K66K5EZZCH%=5-](^R*FU*LJL@FJ$_X!R!SCDOGPZ5E[BP*P+>U7&CRC*U
M5:>IEB@[?0;$_JENK\O`6-BPD&KV'G8Q9$Q@*=%3T^I,YBCWZ";.@.@4;SE^
M)-X1_M^YJ?A^[UT$=?EQ_@K\%_JAJ/W^ZOT#E;?58>]5.T4FQ)O5:_<*]-5:
M<2C923@Y!2'L$:YB9--C-0KMA,1#P[)V<$G31=%R@<0.DH0Y2F`-:Y1Y7?#U
MN>?4$J&5Y!Q3RJI;YJ,97,2)?%+[O643\A6X2LQ_)R2O#2&S%EH.-LP5"L34
MI9[%<-`?P9(F*]P4D5V#H-FUNNDZ;H.D#"=!RBDNB8Q#IB9)8A5$S"FJ4BB8
MB0P?(8`,'Z!`!Z#[=`=!&^IX[D^X5<U*V/-J1J-2,[1D2UZ^5B'M,4WDFQ%4
MVLHS:3#1VFQE6A%S@BZ1]"Z7K'T'#N/0(QY?FSVJYCI'&S@94\OX^EG'3,]L
MT&E4^*AT+59H9\10C5Z[A6/ODVVBB`JF20<^^'(Y`GL0]DEW4"H%<;Z34LE8
MH6%PTU#4X"IN1=J,U4H%K<K(T1<*,VQ';M-))H+SLDB=PHFGZS@*@D*)O2`=
M!CND6^V9\G9-9IZ&9V\LO-,7E0!=PLX09L')48]T"3LYW1COTQ$P?^0>W<![
M#T&+[S#)[!G#BG0-ZLN=RZTO%2S>?A6SGWE(8I90YF+PK*4BG"K)X17N().2
MB!R$$>X`)1";:6P4BZA68EQ89"VN(N"C8YU99@41EIQPU:IHK24H5#_C(]='
M*)E"_*(#_N,8>YA"XN%<K;OB+IJUE)<9G,6YTSSD-//!%O7H=,_KD)6$DG)^
M\,$>U]:QDC&]S.4H^HA1_P!90O?-TQ[SYI%K2L[VRY]QJGRTJ8P^3KB:5>U^
MP7*@WZJZC1.3$1*34=(!3HJ#M=/8.*E&/&#@LJT`[Z304;NFS1,.@-XV,_D]
M+'5[?N_(N[VAS*T*YS*$[-Y2S@I_6\MI%BH6=Z_+1%;R&"37M5.B;(HNRC0.
M%6]^:M5UHE8R!>@L+Q2XMT/B'ESK*L\F+/.0\C>+GHDD^L_T89"-EOLNI-SZ
M<!5Z)6:5GU&K0/U!,UAX&&C(UL)CG*B*RJRJ@65Z`Z!1O.7XDWA'^W[FI^'[
MO701U^7'^"OP7^J&H_?[J_0.WZ!+WF=QWD+H&3YM>>/.:YUH-JRRVA-M7!^.
MU<W[D-6IMR\B!KRV&-KP24H]4":D&8-I2:?QKT:TO[C/$26+%J(F#'^`_,"7
MSVSXIP[W1NUA=#UF/M4IG.7I:39]TW##FD50*QKZ%=Y5Z!:9N6M.DW+1JY:G
MU@>7^*8M<\93*@UMDY.H1B=T#P>@.@J'STTQSC?$7;]0;NYMFG2ZF$L_&N,5
M'TTZBADX]E)L&`)!W8G>LW9TSNS"1-FF8RQSD(0QRAKXY1H\+KN=U;1Z\TD(
M^(M+!5VU8RJ::;]F9J\<Q[ILM[`ZC=8$G30X$53,9-4G8Q1^7L`1[R0BMIE:
M;")XC=8VBS3:U1[BQ2K\J9E%ZX**Z2C9D"L?(E6.F\43540`J9G"1!(!P^4!
M##+9.NZI49NQDB9&UR$%"K/_`)HA6_:1G'C9$HG29M_4L*?O"W<XE#VADT^_
M8#B``(=+E=SEM!HT+;)JIR-*DI0'(+5^3]J9=(J#@Z"3M`5V[1T9F_(7VB7M
M4DU/2/RAV[&$,US[6*Y,34_7ZA88NP.ZW+-8^TQC,3JFCWS@RB!$Q<"F1,R@
MF04)ZD3J$!1(Q3#W*(=!\MUQ+0]9O69/(;3%JOFM><^TT"F$%X9.U)MY5O*I
M%5CTBC$SB3])J5DLA(=T$DC"<"G[F((;/G#/0@OF&5YNNH)I6DJK4R1*8WJ-
M[**(DI#*AW^4$SP;EN7_`/<AO_IT%K>@.@.@.@4;SE^)-X1_M^YJ?A^[UT$=
M?EQ_@K\%_JAJ/W^ZOT#M^@]3D(H0Z:A"J)J%,0Y#E`Q#D,`E,0Y3`)3%,4>P
M@/R"'0+!N_&_(?'1Q[YK<G.(^3UMOMK/%-'OT*M>7=MND6QC<VJUAN=.QNMM
MS3!IRD8)6YLKIRPIU<6CHEBL\7,U03.H'8.5X[^0N^:>&C9]R^L]=8<F*LUJ
MMGELDK>/O\XJL%19ULZ;Q6@Y3>W.@Z$RWG)KU((G%C.)*QSZ,704CY2.8OB'
M1Z"U&[\M^.W&=>`8[5ID=4)>TH/'E=KC:'L]NM<PPCE4$)"48U*DPECLJL2Q
M7<IIK._=/=DSG*4QP,(!T$*[5R)R/;>'N@WW%+O6=3I=A5)GLA*5UVG(-8M^
M_DXV/L4!:(U<B;^#EV<>_`CJ.?H(.D@<I^U2`J@=PU[LXTBVS6JZ9F#C(7M.
MS_.2LF-1NZ*"D?!3A"@@3W%HQ59LF9B+D5,JV^;_`&J*22)@5$IC%[AV6_7"
MOYK0)#1[0X?$AZT=H@LU8-?>W3U>7?-V#1%LD*B*17!W*I0]:AR)E)W[F#]8
M8%5[%'VZMP-KB/>2Q=BBF,U'>]H^[NRM'Z!'"`.$0,<$EBE-V,`&,'</D$0[
M#T'>^HWJ]7<?5W[^KN/?N'Z![_I[]!@4)$YIFD^8T.SJU3L&@SP/A:E<(,']
MNG&XG<B1JV7<`JZ4*98YO9(%`@'5,(%]1_E"6M,A]XEKED[[,;+6*[3(J9]_
MU2*F2&4D)V..LS*:-9'+&O?>&Y6!G(%(11H<KKV:@J"!0`H/[\>E45B\OM%L
M.[,HG;[4=)JP`P"DT;UM`T?[P8/_`"NWCEPJ!_U>R23Z"_\`T!T!T!T"C><O
MQ)O"/]OW-3\/W>N@CK\N/\%?@O\`5#4?O]U?H';]`=`"'?Y!^4!^00']?0>.
MP=P-V#N`"`#V^4`'L(@`_I`!$H=__#H%$^6V'T*N95&[S6=*F\_IV61KZ.NB
M%:T?DY4;#87=WLE2K=08Q5?P;D9QLJDTJ,T^]!WMIFTF<8FJ)R*I$,L)@['+
M+A7].\7BE@J]K)IC5I$3L`[T=(]D?M=`?9QIJ]4?7>-G+EI>RVFR1$DA6059
MR#^TS;M9H5/VJY5"F12!;PB(@`"(B`?H`1$0#O\`I[!^KH,$TN9H<!2)R1TN
M3@HBF`BBVE'MC316BBJ.ETTF*2K=9%R5RLH\$GLTP3.83!\@?)W`(H9)$<-&
MJT8FFYCE6;=RP<1B95H]>.62(HS<L56I3-CL%FYBF2,F/LQ((=ODZ"'9AQN!
MMAK;6!C:N;&@BS'LCYRND:=4>&2<&7]DGW]_1=-EB)>[$23,W42$XK'`?]@2
MZEB]&O%FJF@W*`0=26=NRRM8E'2B[5-%5)47GJ7.5P@W=,&+I`CD`6*=,BI0
M,';_`%=PF:LWBJ:)!R4QGUM@K(S0<R<*$U$.$Y2/8SK1'L9-QZ!*186:JZ2I
MB=_2JF("4PE,`]!:?CM">13C+XO][FF]H_[,Y)6[06!N,S$*>O=C5I'2;;1:
M.A9W5?7;1#VPUQB]FGMC-''(FDTC6Q^Q_9"(E#OL-Y&>6^@\L\MP[D\3C5I6
M-W[DUI/'YG?X#`]GQ34+/5L[XSOM\=;M6F3W1+IG(9\[L+<:JF<YS@ZDFZHH
M&$![)@_/H#H#H%&\Y?B3>$?[?N:GX?N]=!'7Y<?X*_!?ZH:C]_NK]`[?H#H#
MH#H*Y\IZ;L%YR)_#X@IGKZY-[#5I9]1=8;I#FNN4N-FVJUYR*YRAJK>'-:A[
M_5Q<L@DV\1(*LUS)F%!1+VA1"J'"NIV.'@N1N4<DF=&SRSZCN%F5K7'.EO;*
MEE=)I1L6R@[NL\>[+<F=8E-/JQFACS<U)0D1#Q<=99&2;)1[3W<QE0H;R'S/
M_H_1K94&YY&:C8IBG/0)_8D/*RD,\8J/FC0B9/9INI)-=%5F`E]!5EDN_8OJ
M[`"]Z'8Z?S0RF8"_Y-8Z_44K>1HWA;-(.6RLPZKPD63E&3V*^:G9`8/5%6KA
M,/\`258AR"8_R@`9O>-HRO!I3*<VETG4*%W=-JO3(V#BP-$0K!FJRB&BCTP*
MHIL8I!X\;MB@F"JH"?U"3TE,;H)7?N:O7GD::4=P,&^E7XPL.+]TQC5Y24<E
M.I\UQP+J(B^?+E3,())@8X@`]@^7Y0]+=-5FM5:P3=T=QT=48N(>+6-S*D!2
M,2AQ1%!XD[;^S5]X0735]E[$"&%43@0"B)@`0Q#B[4<UFZE!QO%F!3F:Y9IV
M2E(F,KJ,F\7=3PN$R21'K>7$S]@:.,V3242<^S2:-TR@/I3`!$&$>5;;\MOB
M63\&G)N">QZ[?Y2K6RX\.N4>[7?"KI<VZ:2CW/FF,:KG;.4C\YV!:V1JJT",
MH"2DB#8?<!`X`H`4J\$1>1"?)KD5'66P<I\CHZ->D[?=N&_,"PV77YVAU"S6
MQO2>'%LP_:[@$K<IBN?0S*;NQLA9:09G7<IQXMHPR)2OCAM3=`=`=`HWG+\2
M;PC_`&_<U/P_=ZZ".ORX_P`%?@O]4-1^_P!U?H';]`=`=`=!X,4IRF(8`,4Q
M1*8HAW`Q3!V$!#]8"`]`O?C]P`HG%_\`[3O>?K,M*WV9^GD?CNK[JYM]\G<N
MS>24>/LQP*-GINT3\_`8WG2RZ,?[E7E(<)",;)'<I*OBF=*!%$;KN*<GKC%\
M3^0:<A2>9L%57#QT[1SIS0(UY+H)RTPY;YZY&[ZA#S,::KL$YP8A2Q2:R<8X
M[K'1?(/F[(*/[/E%NQ:U2=.L)6H/0:KNZW,^S4)"SS18JH,9-N4PE4]B#S_2
MZ1]0J)*`8HB/<IC!2_'<^T$]/8J<F'%*T;0(FW2]@KLL2(BI)*K,7'NP,$(I
M^K$,?8+HK)**)F33*9)(R9!.84P$H=IK^`T3<97/9BVO9Y!WFT\:>A@@I-%H
MD[5.XCW:K.2(LV=>I$[F+1-[1(4ER@4Q0.`&^0+P8;Q[9<G+3-Y_8!1)3C5Y
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M7HWBB9_+S,HSN$742(5J<>Z5`UYK;Y&P'@;`RLKNU3C9@K+J281S%)`.=C/.
MZ>;Y1ONH<^ZW2*72>(.(8:._RD?51MZU:Y%V]O<;CIV=)(5U>U1TW:ZMFMCS
M<DI$0@/"-;1,NF399P0$BD"?IW>_%YGTO,W.Z:=QCS>3K.GR^,33R_6"M41I
M#ZU7J_6[;8J6K&VM>)B$K36H"WQCJ0%-$3,"/4P6.F8>P!D=OY'^-5WN=?XS
M7'7.*:O("X_-1*]ES^Q4'Z=3#JQ1:<[7HYLW35!R$S8X59-Y',C*%>/VRJ:K
M=-0BA#&##>8O)!UPL;9?E^(85!KW+DQ";OGN&VP%(B`SIARFIN-6/1^/^4Z$
MW239/W9=QF*Z_C8]R#I(".VGL#&];E,0!!V&Y1HWE#E](J'_`&Y>-HM;_BOD
MFELN7W)#C*AD>^>-3R`4[78Q]-8MF=PH5+QB7!E%D>3,ZRJ+)^_;P[J)(G(/
M'4=+`#D-F7A1QSG^..'UZO:?)T.^<B9]JSD^1>ZTVFL:A([_`*1'M2PA--NH
M(MD'\K:9*O,&::ZCDRGLCIF31]"($(`6ZZ`Z`Z`Z!1O.7XDWA'^W[FI^'[O7
M01U^7'^"OP7^J&H_?[J_0.WZ`Z`Z`Z`Z`Z`Z!5O-3A?*:-EO&?B[@&95R#P*
M<YMY5K_*U!G+1<*U#(Z#=IKD5=5Y!I)/`FKO.ZQLU:A64@*8NGBWSDNX7[IE
M.<H+,J/CMYZ;?Q/96*K:"]XYZ%OVY>2+3^26!Z78KEFC"Q(\K]8E664V*V/J
M%6[=,S#[*<[J465.L.D4XJ>C)11!9VS.FDL`9WS-XD75+AMC_BAX[\3M3T'2
MXB*X9_1[G0O5\PJ.+4NP838LY0L&]V^_#=1OC#3:E4<O421BT(MS)O47C5DU
M66;"H)`='R`X<8GRAN>%W';6-JMR7'BY_P#9F>4I.Z6."SX-18KQ3FIZ58:K
M!/H]M8+GGJT:J,"Z7.)8\)%X`$."X@`6GZ`Z`Z`Z`Z`Z!1O.7XDWA'^W[FI^
M'[O701U^7'^"OP7^J&H_?[J_0.WZ#XN'#=HW7=.ET6S5LBJX<N7"I$6[=NB0
MRBRZZRABII(I)E$QC&$"E*`B(]N@QZKW:F7BO(6VEVZL6^J.@<F;6:KS\5/U
MYP5DJHB\%":B7;N-6!HLB<BOI5'V9BB!NP@/0<>GZ#0M"9*25!N]0O$<B"(J
MOZ?98:RLD@<>U]W%1U"O7J!`7]W4]'<P>KT&[=^P]!#W);E=C?$^M52PZS)6
M95_H=R99WF5"SZD6W3M0TZ]OX^1F4JM0,[HD1.VFRR2$)#O'SDR+?W=FR:J+
M.%$DR^KH*NV#RX\+:?:"UFYV#7J:1A4\CN5YM-IXZ[I"4G'8G<W4K'YBGN=J
M>T%.,Q=[892$=-3$LAHTK-=`P.3(E#U=!-*'/?C*]TCD?DL1;+38+[Q1HT+H
M.SP5;S#2[`XC8.P.[(PC&M0+$U1V?3)U:1JCQJ+&N!*+E=I^[B7V_J3*$'G\
MN?#XN$VGD04-_7H.;WG1<]V9FUXP[PZNF"SV11L7-Z:ON=,0H:DYEL-2X&<9
M/G;R62;HF;.B"B*IBJ%(#`DM+SU6(KT\-VJ[:)ME7<7:MO)";CXPDU4644TG
M7]D8)R*[59:&C(9^BZ=+@7V;5!4IU1(`@/00'R-YKX1Q@/FL=?']XMEPV,\Z
M?+,VQ7,[YN&EWN+JD6TG+?9*_1\O@;-.N:I4X9^W<2$F9(C)`KE$GM!57134
M"&T/*GPU/KBF./[=H<!+I:#G.1KW6S8CL%?R)AK6MTVJ7W.<NG=8E:6VHU5O
MUKKMWBQ:QDL\8N!>.R,Q`'8@B(3!CW-G#MMV[0N.M8#3:WKF=U1MH+NK:CCV
MF92K:\U>6J5H[;2\^<W^L0#>ZT->VPKAB219&4245*4Q?4DHFH8(UR'R<\1=
MKUJ.Q:IVR\Q-PLMUUC.<^?WO(=0H5#U:\X;+SL)K%4RS2K35(VA7JQ4IY67Y
MG3!C(J/#-VBRR22B22ARAU,;Y6.$T[AVX<AZUI4Y:,UX];2RX_Z*XKF>7N7L
M8:=,6VK4BM155J+6`-8[G&6^PW2.3AY&,;N6$FFX]HW5.0IC`&#6#S&<-Z_"
MU&<%ER6G$;AH\]BK:.K'$KD3/ST#NU:E'L5+X/<8!AG:DO4]G26CU5D:X]12
MD7;,"N4$U6YBJ"#/8651G8:)FV[:29-YB,82J#.9C7D-+M$9!JD[2;2L1(HM
MY"*DD"+`1=LNF19!4#$.4#%$`#L^@4;SE^)-X1_M^YJ?A^[UT$=?EQ_@K\%_
MJAJ/W^ZOT#M^@I-Y%>--_P"8'#K8>.>:76-H=HTEO4&9I6:=S,;"3-=A;[5[
M+<*+.2U>:R$Y#0NB52&>03MVV:O%&[>0.86S@@&04!;NN<&=]ROQU<D^.F65
M[-Z)!Z_D6E6G2X_&G.Y;;K=RY)Z)J-82F?FAXHPH[N5RRW8E&*P\ZG%0L=*(
M*KF/&,4T&Y4'`8IP6Q[G3QHPWD=O6;<4>/U'O_([9-MTIMQECJB[R1\U1AL]
MRC"^%5>KE>CIF`KF:Y\@O47UAOJLZ<L\E#NCKHLDI-99JF#`.6_%OD9K\]PI
MY$9!;<8B>4?$"V6FU*UK0V5T+@VCMM<R*4RG7JS\XP))6]T\I4I;WVORA6TD
MNU,V!%P@J1=02A2;</&WSJWFW\M$9O4>*-1I'D(X^<;,.Y/ST'!ZS-V_/(_)
MV&DP^D)835Y86L!,#;X#1EF<5(3\HDK'K(E=G:G'LW`)S<\4.?%5Y><H>1.0
MV/B;7XC0N']1XQ8$:VR.OV2QT^7QJ3U*SY!>M&A4ZRTA)EN_L>J+%G6#-[V(
MVCT3(*+'66*`52M7BGY86_@%/</YN,XDS5ZT&_:CH&G[#-;1RK).W+6=-K:7
MSAR@M<A4ZU4#W_2R7F3D7BM.E67T04CD(UBFHBU:@AT%C_(QXQ]AYNX#Q<QJ
M.U_/&=KX]PDI.V/9+M4I$MHU._Q61AG[&C2\)5`:QL3@F_2D@\+I\4@MZGD&
M"3)HB?OZDPFKDIQ3Y,S7(7C%S$XOS>`Q.TXOBVIX#=LMV0M[2QZR4'776=69
M^XJ%HHT2XM59G*1=,T9&9":*41E(Q91NL#4P$4*%3+7XQ^7>EZ#R,J-WU/CE
M$\:^6'*_C3ROVB3JD'I3K:3/\"J/'D9#,*#$3*A*95(.W:)@:"J<TYDI1^QA
MWATP;JN>RI`L+Q0X.;WE7/3D'S$T>=QVJ5[8LS-0)3.<BL^Q:`;2K2VU"7O$
M#KMPD=I%4^5/*]`2KF,;52J'4@0/(N%C*&%-`H!4&-\6G.UO6(?/T=JXSU>I
MX+R/YE\P>-<U`16H25YG]^Y!N.0AL?6UA^_:1\93J3D)^03MY(-H)&4=S;F.
M;I@JW2%43ABLCX*=8JN?Z!B.=<FV5SQ[6<7X*Y_<VVJ0S.H6N)M7"/D!0KG7
MYJIR&(TVGE*WLF)L)N#4DG:JEE"5^;G"L@L"7M4`M30O&#IF>YYC^1Q-_H#J
MF83Y4''-JESTI]+930[1ASUQ>;#]#]2M4DV>S%]W.*G=`<1WTCDGCP\I#QS,
M[QT9R!PZ!UO0'0*-YR_$F\(_V_<U/P_=ZZ!3_@YFO+DT\5G$5OQKS3QQSV(I
MUC0`H<MN.X<FJEJCQF.QZ*:6/;Z[0N/=UJ,:Z3L)GA&Y64H[(=F5$YS%4,=,
M@-?^D7GE_8[XC/ZD^9/]J70'TB\\O['?$9_4GS)_M2Z`^D7GE_8[XC/ZD^9/
M]J70'TB\\O['?$9_4GS)_M2Z`^D7GE_8[XC/ZD^9/]J70'TB\\O['?$9_4GS
M)_M2Z`^D7GE_8[XC/ZD^9/\`:ET!](O/+^QWQ&?U)\R?[4N@/I%YY?V.^(S^
MI/F3_:ET!](O/+^QWQ&?U)\R?[4N@/I%YY?V.^(S^I/F3_:ET!](O/+^QWQ&
M?U)\R?[4N@/I%YY?V.^(S^I/F3_:ET!](O/+^QWQ&?U)\R?[4N@/I%YY?V.^
M(S^I/F3_`&I=`?2+SR_L=\1G]2?,G^U+H#Z1>>7]COB,_J3YD_VI=`MCEO.>
M813G3XH%;YF'C49Z<WV?E0;#&%2W;E')4>7L"G"_94KPAJ\O,<=(J=KD(TST
5S]>+5B&,HX<31&R"Z:#4ZSA,/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g644794g19e20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644794g19e20.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```K&P``M4X``.%F``$,9/_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@!00)+`P$1
M``(1`0,1`?_$`3X``0`"`P$!`0$````````````'"`4&"00#`@$!`0`"`@,!
M`0`````````````'"`4&`P0)`@$0``$#`P(""`4%`0$!``````8#!`4!`@<`
M-30V$%!@,105%A<2$S,W""`P0!$R<"%!$0`!!`$#`@(#!@\'#0L+!0`#`0($
M!08`$1(3%"$5,2('$$$R(Q:647%",W.S)'2T-775-G;7(%!AP;(EMS!`8+%R
M0\,TM2;6AY=28L+35(24A8:V=X&1TE-C1,341547@I-D)S<2``$#``4%#04%
M!P0#`0````$``@,1P7)S!!`AL1*R8#%!47&!D=$R@L(3=%!ADC.%(E*#LS1P
M\*%BTB,4($+BDU-C!203`0`"`0(%`P,%`0$!`0````$`$2$Q41#P06&A('&Q
M4&"1,('!T?%`<)#A_]H`#`,!``(1`Q$```'OX`#$&O'V-R*X$C$D@```````
M``````````````````````````YT$$D;G24Q]6I+E_=,-,,XZ:*@&?``````
M``````````!Y2U0```````````````!5LCOR?M#(LW:3:.^4*"JI:H``````
M``````%$33S<#7SH*4J(A.GA5$M<`<<2QI#)[S+'J,(9@QI;LLD`````````
M"K9'?D_:&19NTFT=\H4%52RQ_3UF),\8HRIIIESWG\/">X]!]0`````5D(F-
M'-U+N%>"$3H@51+7`$($O$5$JF(,\?H_)IINIXS7S7C>#('T/Z?<```&LGN*
MA$*$&%Q3R>3]H96F[2;1WRA055-@*OF0/B;<?0WDT8SIA3*D2FA$Z'Y-:+ZF
MU@````IH;F6!,N5A-'+D%7RUP!SL)W*YGE/Z:4;V1<;">4CDG$LH0*:P;66O
M)M```!SR+*&P$?F5-?([\G[0R+-VDVCOE"@JJ2@9DB0S1ZSTGM/";>1<9XU$
MV\V@CHU(V@VXRQXS"&MFW&1/(;@;$5N/&;`62*F'B+(D`%K@"B99`J.90V$D
M,_!I1GB6R6P`````"O9ZB"B:"PX!5LCOR?M#(LW:3:.^4*"JI/I&AJ1*1#Q^
MS,GF/X>TSQASV&7,0:H9`V0T0Q)OALQ'!FB(B:B=RM9G3YEC2#CRFVD/EK@"
M`"4B'S[GH-U(Z!FR23:@`````#E06.([+!%BSGB>,DHUWR?M#)\W:3:.^4*"
M!360````````````````;Z3&````````````"AILAYR22QI0TPY))J/D_:&3
M)NTFT=\H4```````````````````````````````'.`GDUHG$EH`JV1WY/VA
MD6;M)M'?*%```````````````````````````````!4HFXI22R7$(3-+/F1W
MY/VAD6;M)M'?*%```````````````````````````````!SS)M(F))+7G+DT
M8LB>3R?M#*TW:3:.^4*```````````````````````````````#GZ2&59+D%
MG0"K9'?D_:&19NTG.WRA3WD[@``````````````````````````````Y_DN&
M3)B-O/.>4K:1WY/VAD6;M)JWZI4QD;'9&[\82E^S/@``````````````````
M```````````Y[%C2$2Q1,!QE(V+ZGD\G[0RM-VD\A?9WSCF?`Y_J'7*R7W,P
M?8R)Y21P```````````````````````````4\-W(\)I)F/D>,K81WY/VAD6;
MM)Y"^SOG',^!S\8Y?#[IT,AT:JI+OA_/G,[UFM)Y^"\.J[8`````````````
M``````````````*<FLFL%FR>`"K9'?D_:&19NTGD+[.^<<SX'/QCE\/NG0R$
M@TCU7'_G'J]U]UCG-8/LY5:U\?DWF@%@0`5+/X>\^9^CRF:-#-Q/,3L;L```
M```````````````001R5X+C$_'/4ALL`>3R?M#M$W:3RH]G?..0<#G\%E\/D
MNAD)=I)JN'^>+3;K[KJ6:PEOXSD[3L[@KXTOM)KVGY7/6&T3#DE']--(;-1)
M`/T8`D8TL_!X"PYN)K!L1K)L1X3[@QQGC6S9S5S9#"GM/X8XV$P!GS4S9S&'
ML/Z>,R!A#:34C93$GI/P?$R!$!@S5B;2PQ6T^!Y"._)^T,BS=I/(7V=\XYGP
M.?C'+X?=.AD)!I'JN/\`SCU>Z^ZQSFL',.O;'`>TZIU_\;/1V,*_[M/WJE3:
M`^GKU[,Y)W-\Z*E7"V!6`M,083H1:2D:Z;$:L;2`````````````````"J9E
MB`">RS0!5LCOR?M#(LW:3R%]G?..9\#GXQR^'W3H9"0:1ZKC_P`X]7NONL<Y
MK!S#KVQP'M.J=?\`QL]'8PK_`+MI'I?YJ4_UF%[PVMM!262XRZO0-/M+]PTV
M]VB[W2S9=9O[J>W4+S&&Z(:WM-+G;O=U^.@GY^=!#GD=#3G"='BDI=$JR6O(
MZ)%-!-W-0-H-;,^8D]A\#Z`^1[#'F5,,;(::;H:4;V1^2`1\2$1Z2$5"-4,"
M6>)H!1,VLU'R?M#O\W:5R-]G?.*8,#GXVR^'W'H9"0J2:KX?GBU2Z^[1YFL'
M+FO;'!.TZIUX\:_1V.X`W>._2_S3J9K4+V)N'8?GK,$.](81G+F5.T"]-(&G
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M*JV9N9;>LOHFR(_`1`3B6F`*LEI#]`````````````````````IB;*1=D<;L
MG'RU0BVIFY]O/UGNL_3\S'!V-+[^/DR.;N5IS^0M[]TYJ=O.B7*CZ0J.23&O
M0"";W<LY'V;M34"FO.S3J[]9L'ZQ4MJM9F]UMZRZ7-D1PH:Z7P)@*^']-;+2
M'Z``````````````````````!50\9S,LY5[]/S,<'8TOOX^3(YNY6G/Y"WOW
M3FIV\Z)<J/I"HY),:]`()O=RSD?9NU-0*:\[-.KOUFP?K%2VJUF;W6WK+&DV
M1'L!EB53>#FH1Z65+CFT````````````````````````X*V<J]^GYF.#L:7W
M\?)D<W<K3G\A;W[IS4[>=$N5'TA4<DF->@$$WNY9R/LW:FH%->=FG5WZS8/U
MBI;5:S-[K;UEK'-D1V%(B,@7S`*FDO&--B-4-I,(9$\)]CT&,-B-1-D,";$8
ML_I]S&&>-?-A->,Z8X_1]#R&=-:-@-<,\>0^Y^3'F<-=-F-9-A,,>X_)CS/F
M"**[UH6F_J*9:B+1._CY!CF[D`Y_(62^Z<5YWG1;*Q_(54)(C6YL$7NYS21L
MW82H%-:(Z=7?IU@_6*K55K,W:MO67VS9$>:*WEC"P`/D5>+2'Z``````````
M````````!SY,0:<3`5P)K/D>$L*6@(Y/T5(R^'Q'U\:EL6]0GD^UFMRJE4[>
M=$N5'TA4<DF->@$$WNY9R/LW:FH%->=FG5WZS8/UBI;5:S-[K;UECR;(C]AH
MI.A.IQ2,(7P+CFT```````````````````\1CCYGL/$:T;>?`]IDP`"+#2B,
M.YTM?Y>*OTSPI1R28UZ`03>[EG(^S=J:@4UYV:=7?K-@_6*EM5K,WNMO66H,
MV1',!&A:`LP>,Q97DM(?H```````````````````````````'.N2(UK7M6IS
M=J-FN:,@;%UJJ=3SG9IU=^LV#]8J6U6LS>ZV]9;'S9$8I^3<2D`59+2'Z```
M````````````````````````!!!XCV$8&D:E`7.S3J[]9L'ZQ4MJM9F]UMZR
MV/FR(Q10M8;0<US62=BXYM``````````````````````````````*:X*+:>:
M]$UY]$]"Z455LM>ZV]9;'S9$8`%937S*%I#]````````````````````````
M``````B\ADS4$3)1ZJ=DKW6WK+8^;(C```JR6D/T````````````````````
M``````````"L<$3)1ZJ=DKW6WK+8^;(C``HR>4DDM*?H````````````````
M``````````````%<(\WBID/2E8:9XIMYONE@#$'-0]Q=`WXV8````````%?3
MPDA'J-1)'-9/D94C\UDWD]YF#$$<&U&X&>,$9\U8S17\FP\A+(````````(P
M(L,P6*`````````````**D3GM*G%JCUFM&;-2-O)J*P&WFSGU-5,D8(V\S9N
MY7\B(FPKR=$"UP``````````````````````````````````````````````
M````````````!7(@@V,\I;&,-BK?1B;/5Z*5]]^Q=.V)R5C6\TB=[5-\WRHD
MQ&8S'=XNRYN'6"#]$P/'\W0.;FEUNVSL9;^;9/=@#/9G"\7;%5PZ6UNLMCL;
MD[P%/:X3MCNIV]6LU7[S'04```````````````````````J/U>1@^[E=BQ_[
MY/P:IULYZ/WBV/L8@>'[_=-[?-O?1X/J#7.#&_7]^\]S=\>3[X]-R&.W?'9/
MZ?/UMY7S'=[??G]S.3Z'Y-N)T``````````````````````````!_#FF2(8,
MPY*Q<<````%'R*3HN9\```````````````````````````$*DU`'.@Z+@```
M`A$FX``````````__]H`"`$!``$%`OT/G[&+:R1,-PSE8B'V\KHY*Y:%D`^<
MM)1CL)^4*4"MBO.9-CPK;35&CESDZ;/1B-<R+>6C!F5CK[.AQ.9%ES3P6:->
M"S1KP6:->"S1KP6:->"S1KP6:->"S1KP6:->"S1KP6:->"S1KP6:->"S1KP6
M:->"S1KP6:->"S1KP6:->"S1KP6:->"S1KP6:->"S1KP6:->"S1KP6:->"S1
MKP6:->"S1KP6:->"S1KP6:->"S1H8GS:AOU#F3D.2W`,W'H%?N=_*S(7E@X^
M2SG(-HJ4S*]B8`IR^1L[4:JU2S6>2XE'N<ES<K(Z:_>KI(I0B1S;E&:EE\.!
M!$=4>1>6#I8>B\D'4U==.E#O`!/D5$*A9G(N2X>1E,I&::()*%,U(?Q,R<AR
M6X!FX]`K]SG;UFP3J]9VNU54T$F,I&R=-*/F22VDB&!7:-I*.>L4'"#I%PX;
MM$(^2CI9JX<-V:%E]BEG[F0<6P^1U)+$L)&L9O"X%%LJX#A5[8UBG&1Q:/P4
MN4J8D$!MQIK]ZNF:R,'P$HY=M634<R`*%:BCMJE9&S43,,JKHVV552I?\Y'^
MO4D5Y_\`,3K<F]9JVSL]&CL.0F@V+-6DDQ?-J.&];*JI4OL435I^Q*34/"(L
M)!A*M?R`D2:$QED6<)WI"VR";S4#G2?>,1=9>YTJ&;CT"OW.R:,*%\#08R2\
MD[A\]4A;H/(C8;C(C(7FTV%D<KE"8CC%<M;ADTTPVZ"IQG)147D*V4;#))?B
M"2$\B-M+R9)(E=XR;.E48K)J\^G`9$1BH.KVL/\`M9@$BHKB2UK-2B4?1[1A
MH[B)V8D"V$))A^V2N0;-?O5TE>,#U63G0-0A'W..<IRE\/A@A9+06#Y!NE["
MDW@'^%YY5>5Q(11D:K^/\NM`GF,3:B\!AV8(64WATREI@K$R5>:(<5FQ`7>Q
MDQ'M4,.S5I=CH1;@P7^QG:QJ@ZQD\0D`@O"!L\CI/$`#,6N,6`KJ>S)R');@
M&;CT"OW.,BQL'1<`0($24_E.`C(0J._2U\OD8:AFMA[!6I*'HG8[@,@CA&@L
M4C[=][GCWC0P\BC!JWRE%T>)F@[XEB7CDF]]RX7QK'*UC\;NR+;0=)C-F+/[
MS,:37O.1E)B^/XA`@G#^1A9ICD`:>0]#H746]P@^E&A'"/U7SA5HS2R2H\BF
MV56KQ,4R*U*W>F^4+%(^N78Y"L#*73,2U^]7249-)V+^I@RMAD\ME\:V8YG<
M)SM<_`_PE9K-1Z"F1T8*999T%W;*_,PLW)`LO;&\+^Z0SY\A)#4\<.W^4:3S
MIUBMBDQ">G,G(<EN`9N/0*_<Z<C+IF,'P"*'G:.+VUJ,H(Q4R0N\3LWTF^Q4
MTD=(XRC$5F6-O!U+L6QI;)68V9MWP^"-!]?VSA+89^`I.9@6!V`FO[>1OSV&
M+TFP\ICI:RDL"-GCJW$T>G)78<CE&C;'39I,S(6VF91]BB.>5LQLT;L$<0N&
MTJ-!U\,7/$57#5KB]!I%QV-HF)=H8VBT972@7>L]LQ[$V1(F+M1*,:_>KIG<
M8AY))MX5BW4B<4!$+>ABX00:>V8E1H3B4&7LT\4AJ4BMB@(<,6&.QJ-?0D-'
MCL5^[^08_CZ4F<&1KV,"L\(13BN+D85J,:RUF&;`)]]F8B0<YNGH-D'NUT73
MH,W'HFL9!)!*^S>/->S>/->S>/->S>/->S>/->S>/->S>/->S>/->S>/->S>
M/->S>/->S>/->S>/->S>/->S>/->S>/->S>/->S>/->S>/->S>/->S>/->S>
M/->S>/->S>/->S>/->S>/->S>/->S>/->S>/->S>/->S>/->S>/->S>/->S>
M/-#@`)B;S^5ED+9DTMA2YDA$9+=0<NMB=L]9@NLC8<>FTW;@MPC?FN+C'(6]
M331>!FX]@,P/DDY_%/F[.+R(;G`D0A+X@D8'IS)R');@&;CV`)\E.Q@X&"+U
M,P_(!..5IB*7C*M-$9Y$#<D^RZ(Q\]F3D.2W`,W'L!E)^:Q91B^V8;LLW1BK
MU7$XJ-0T-K+0*72!I7'.1J,,Z#2<@+K-Z,U0S<>P&1I8`C3[#TA"R4=F*7QP
M2E.'FL<TQ]TYDY#DMP#-Q/"&3B%\=$4@2CW7V5;<A6$&+GD](H$!`&8[E(&;
M:$45I15)&VYXTL<YDY#DMP#-Q-LS+LYC&F6'99.2LO%0;*,E8R;8]>9=Q%/9
M!F<<##\1'LGQ11.N@)"7;"FORDOFGS.<5C7C[.EI?476\7\T,W')'/>!.?#<
M=E)O0,./AV/+2A(58B)':4PQ*1,A>*&2"\B9]<9K6O:#.-YF0E(_,9`:#K,#
MDIZ7'M7V6*6U:-;G&9.0Y+<`S<<D<]X$Y\RM]P,'_<`Z)P1Q>!DP&PKD`GQU
M>ECPAQI$..N,WW-[A+!;J);1&;KV[QSC/P?HGIS)R');@&;CDCGO`G/F5ON!
M@_[@92YXQKSKG3[@8NY_R.ZG60?C5X_<OBLA0%!T6+I:3G/T9+RA3'SB[,XA
M9'K9C"45U,S`K=61RR/MT*9F"K(^;R"LC9$9JA)%=+,0,YL:YF!72`Z01Q1#
M]2Y`?@[**Q;[;32&6XMU%RF,_#V">LZNRN*;S1J;6*9T);(\76<4>*Q$O;!U
MR"K\\TQ#,VP9=E;[@8CD;8LWR??\9OCY?PQAFAY1X?XM^X&0LQ%$,1"F9C:7
M(UBZ!G6$&Z#!6V9R9'0(P.Y+6E9>PO2O14+TD]>)A'A*M`@SB$C,<P21=5@*
MV,+0<`\YJ.`*D*30PR32J@R!/&]XN$60ZX1CUXHS*&S&&L([+Y2XW2MB?4R?
MFEARC?%>J$_,/5Z7A+RM.S5A6G>O>:)6,[25.Z0H;I5BJD=E)?UNEY/ZE3\Q
M]9I>%4+$T[K"Q.]3UJEX2A)960]:)>44)+*S-3I&D.H3IIR%ABE>V4*DTE?5
M2?QU,$J-+2A.Z0N-DK8M,AL4E[3A&Z(4);$Y.A@E5E4K3HM0M3K=>8))MO5"
M>LOL2"5'<*/2.0@LY-DG[/%C95@%Z*<4B1?.J8C"EIK,G(<EN`9N.2.>\"<^
M96^X&#_N!E+GC&O.N=/N!B[G_/O.^/N=33>D/J&I,*1K<6)L;0<@K_=R.`8D
MNB[GSQ*/9"N09J7EU5+$4QW)GGDEH>/&9,^TB:#+F;UYO%>8Z\\A?,^I#H3$
M++@P.%HU[G=G'2U,/M%&>/>G,G(<EN`9N.2.>\"<^96^X&#_`+@92YXQKSKG
M3[@8NY_S[SOC[G4TWI#ZF<=XA]WS88$@NJQRQD)5Z9Y!C0=C!Y3Q<.O"(Z'Q
MN*@C/#0Z_DBB"B(F`NP^.D*,Q%KQ\(*JP9&DLDX30QP1VS>GF.BE?,&B$@)6
M9[HMR&114@BI\Y$PRO'!Q7J9+A<<<:G"H:&;4E4UDYPD'QENV<MWK>;(8(;:
MLWK.1:S$W#C[*-DXZ98RTQ%0+*+E8R;8RDK&0C&)F8F>92$C'Q+.'FX<@9O7
MK*-:0T]"D3-99%NE!DXX3IJ*)HIP)0.%+?NT/E8R5I:@2P9*.B(+!F>=ZS.C
M!N!K`MS)<;,\*2Q,8X_$U@D6Z)?,KF-E\U2D8W"WJB:SP3<MVK_(E]BIQ@MP
M@V.,I*IK'N%ET6YYDQ9)<TQTJDB99N71<'N,E4T3S.SA!R:`5]B1D6N6[J62
MK2E^:G39U+1%:6ROY!NVKI:.K2DAGYVT<Q5G^LTNVJX;K+#YDOB_1T[:*80U
M+OT+<#^.>ZMED;,%^=S6@8G7CL4>\1IH,.%)$9D2@0F)"*-XM^P)R7#9;,0!
M\*$J.60MZ<2MDM%IIG=R$C-P9%!*1YY'J2\N.235G!'<8O,R(NZMC!X[8>>K
MA*JT,,'3*R?T#J.(8;.6B1`W!+G<+`'C1L3PH8WLB7!XU9E0V'M_+I0Y:19>
M)!5TRP>2<A%O([#8NY`F-\O$7686$'>/F]9B(K3$`>\!7/G,1K&H<]$2GSF(
MUG%W>V$L4/6\E!YPL7=3./F=&`CT2N'YM[)YO@8-Z')M7D4<!D<W>OW#=VRR
M*"1+]W/3S1W'Y!$XM^Z+S*.48EPZPD'IR<Q[Y@40S!X]/3Z+?-)YJT>OSK(D
M9(L7/PH.3G*415B-O&TDX,LHQ#AC$S#>47G,EPUS*`E4IM>W(D)1H.2Z4PM$
M'4)X43E$I>^`DAV,H,2%L@J(R\%<F#KMWOH:R!M]$-T7WHT<'V5XI&I3GIGR
MAQ[6QM9>TAQW%R3UU'VDML`#039S#!_GE97&D<G,!L>.W6$6+AAO2(CT2A2V
M-8R#P]*T[$B;`C%D_*3M))`PP8S9OC(\01;%V*VC5Z7Y;;-VA[B)LW=G^9FK
M5F=8P00<G>?63-@:@J::QIGMBR8%(DFFJ4Y_8,(^<@K;;YO\C8V.C[Z=^:8R
M-CT='D5%L8/7E$3K+Z,TH+X=LF:0.?TXMSK#"M%,>=.9N0J=W52$H;LSK'*A
ME>ZDWMC?).,EGSF8/(2:<%V*H>69F&9/N%AK[B9OY_Q3]P/R(YZ`>>?R&YM#
MN;/R*W\?WW\F?]T[\Z_0IWY&Y?Z,T0_GD%^/MTFK9D_(T58;`4I=-"FB[*(4
M"O'F40A@09EY"IW=7$<,2K'P>/%C`LS)]PL-?<3-_/\`BG[@?D1ST`\\_D-S
M:'<V?D5OX_OOY,_[IWYU^A3OR-R_T9]6BT07$<_$$C3(YXB#JB1,@6Q3])VN
MRRL@:R3>3%"QU3.L`\>BT-'K1<;UAF3[A8:^XF;^?\4_<#\B.>@'GG\AN;0[
MFS\BM_']]_)G_=._.OT*=^1N7^C-DIDAI-XA2=HB^>;Y6C3#)+,S#GIS<X0:
M8ZL-A&YU=D0%LCTRT95E?<H`\IO+A=.5ID$(K&U-1*CSU^$_+]=!M*)&HDLY
MNR$#V,?58U24]R@"L34R%:2WN,!^7^KQ?QEAX%J)*'@8EI,W$%EZ9$!:L*&`
MM65KD4$I$>KQ>LK;D4$NC[S(53>6'H6HWN/`RRZTY#KG'N"$>!3+1E63NR,!
MV17K`6\SMR0`WQGK03H_]=AGA+C<0LK8<!ZJUV0P:QI88"RC^F1@.Z+J6C-L
MM[C@7E/K$6I(>X(1X50X$$KK#D.4O]Q`7PM"\7N?^X8-Y0<1F,YG)8<]PV.D
MV;;[+\@8Q<MVIYGV09/CP!YYSC.PTX6AW-F;R.!))F`WW/1'`E+2G?ER:B2&
M&T;SL-*#^O&M-9")C<>5`"`B)F6>6K>^N+KXZ\%Z/CL^/,W(5.[J8[-39J<P
M><)DB>LLTD?A@G)4P82HSFPM:MI3.+Z.?-<[.'*J6=Y3P@/D-R;3&I02'9I]
M&"8]#O\`(#F'0/AAW`+9$S&`/2<S&,52<*??D-S:'<V?D5OX_OOY,_[IWYU^
MA3OR-R_T9UHVJ(X>0%VC7-T>//G6*(]2,!GZSELR_(J7)YR"G5V#Y]G58OM%
MH:^84C>IJ-V]JB$7&-*^41/RTV#%*U2'B5;9`1')1W='1]ZWE,5\:#)FUO\`
MTD(ZO-OV>/DT"++-\LW=(_-5R)^16_C^^_DS_NG?G7Z%._(W+_1^0N1TH!7\
M?)*.>!\K"AY!DS$4C9*`NEV[=TE?$Q:C[,W(5.[KC-8A=.R*.*5H(J_(J)E9
M2^@F4_WG7Z%._(W+_P"@]=XJ>W!DQ$SHYTYFY"IW=<'&/H8]15QXS<S>1V4R
M_&)U@<2Y3G7Z%._(W+_Z##'Y&9FPQ&/8:%?OV44R,LR6.B)]E(O7LSL4,XX6
MAI1&:C>O,Q0MTE'.<<R#*[)5E4X+]9EBN"-)*N%0^DGF7D*G=UX8P#HH'I#&
M3J0UE':?V<S<A4[NOLH[3^O).:*`$T[S=:@^S+R#3NZ^R!X%XJTCX1]$>HQK
MP_Z'[%O)LCS!DO,O:X7+:4(,>@Q8[AX:*'X[^%.Y+&APQ9Y6#GA+0U#:QZ!>
M)NGKW)0&QLK.P=MCTMB6ZBIV#H54+!5&0#<D#AEH@R\,#1%(9)`HUHS-85ZO
M<8B-C!J>B#TC(<JQ`U(0.1QR;KZT#J1ML_!7RBI1'-95E.P<E'6G03=5,H&5
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M4(>[F1=%1<01`98>3C\MT<D<U%RX833DE.RQU.-IJ2R$5^&ZO(#?TZ=^Z&.-
M6Y?!K*>\(1KWA"-.LA8K?+,LD8QC;_>$(U[PA&G.5\?O$?6F'M69=!4K/>$(
MU[PA&G&2,8O%6N3,:,;_`'A"->\(1I?+(`Z1];8@TGEP$13KF$)_K&TO-3H9
M"Y0%[K4<IXK;W^\F/-5S)CW^L;3TF3!O6]<NGWPOBLJEA6%/,CV-FN0,DKJX
MTR++',K^T0'Y"U,&F2\E0,1%*/UHOKAESYTX-Y@_:(^:/XO_V@`(`0(``04"
M[)/LG(,G@P:I$KWL1/;WBS?.Q$]O>+-\[$3V]XLWSL1/;WBS?.Q$]O>+-\[$
M3V]XLWSL1/;WBS?.Q$]O>+-\[$3V]XLWSL1/;WBS?.Q$]O>+-\[$3V]XLWQB
M-(.VDM`I1S3L-/;WBS?(;:R?:^PT]O>+-\AMK)]K@]J)-J4>H)7IO4%;VT1(
M/$EH23;I=@)[>\6;Y#;63[7![42;4^XICQ8QM<UM?8">WO%F^0^UD^UP6U$F
MU/N*8\6,[7-;7!PS)^S?#\<W9D!?&C:[7)4$[==>3V]XLWR&VLGVN#VHDVI]
MQ3'BQC:YK:Q;;97;<K;E!;ZLY20K20;UKUU/;WBS?(;:R?:X/:B3:GW%,>+&
M-KFMK%MME=MRMN4%OLI_JS_8VP:/:70<52V-C%9-3TD]TRCW#]3TS*:29.5U
M_(I;5R*MBOR5M5I6E>KY[>\6;Y#;63[7![42;4^XICQ8SM<SM8MMLKMN5MR@
MM\E/]V?[$?\`-_\`@2XJWO%>.U!;YI'F+1-_=-?%=K^Z^2_-5TR4OMB_,7.J
M/+K(_P!P$=0$KY\AZ;EM/6+B/N]1#^FCYB_IY=(:5;.&^JR\3;5N]9.Z_P`_
MY"%=6I)V5^8I35;[ZZHI?35;[ZZ_JFOZIJE]]-?,4KJE]]-?,4KJY--37R$*
M:[]?U35+KK=?,4U2ZZW7S5-4NNIKYJFJ774K\U37Q7?W\=^J_P#NOAMU_P#/
MAMZ/ZIK^J?U\E+5M*6:^:IJZM;Z>E1O3&-81EOFLEI=VY<ZK!0]U6L>Q95C^
M`*^`BMM*=N=\3'<2/;00;2-[5.;5`\$_X(4X"0X$2X5WPH]JO=*]VCS;.M[7
M;NVBCAPK1TDI5PP34M<#VT$&TC>U3FU0/!/^"$^`D.!$N%=\*/:KW2G=H\VS
MKL>V@@VD;VJ<VJ!X)_P0GP$AP(EPKOA1[5>Z4[M'FV==CVT$&TC>U3FU0/!/
M^"$^`D.!$N%=\*/:KW2G=H\VSKMF0/&+=X0/'K<;VF<VJ!X)_P`$)\!(<")<
M*ZX4>U7NE.[1YMG7J3]ZA8I(OEK(R309MW,TU6;B?`2'`B7"N^%'M5[I3NT>
M;9V!3<+I4J\=W4$N%=\*/:KW2G=H\VSL'"S*$8BL4M%$8%1-/57+;^I3NT>;
M9V'E.[1YMG8=ZW4<4\M<:/=M[$GVW=B3[;NQ)'"J3;;T`[UY0I_WLQ?.HX?]
M<%6HA91Q%]$B]=(NHITX<*]$>G8J\I%1^KO_`"[H>N5TUV#A953HCD[%G_D4
M3IY9:F[Z"^9DXZ2%)N5?RO6*R*+A/R6'U;;;9;T7(I7UM23LZ;;KK:^)<_HJ
MFG=6EEEO3;==9=XUYJM:W5Z%6;1>Y)FS0N_Y3__:``@!`P`!!0+LDB.7K(R4
M/=')=B&/!DW"=B&/!DW"=B&/!DW"=B&/!DW"=B&/!DW"=B&/!DW"=B&/!DW"
M=B&/!DW"=B&/!DW"=B&/!DW"=B&/!DW"=B&/!DW"/B9=H[B)]:1=]AF/!DW"
M3.Z"^Z=AF/!DW"3.Z"^Z3N[#6[/"2,8.&9+&/G+J7CF2J,Y%N%>P#'@R;A)G
M=!?=)W=AK=BG?!C?BC=(7=>P#'@R;A)G=!?=)W=AK=BG?!C?BC=87=9V:>L'
MC`ADG#UC%.)"Q8>>(I=>,>#)N$F=T%]TG=V&MV*=\&-^*-TA=U*MRB=R&/H2
M/`24TQBKK"V'ONZZ8\&3<),[H+[I.[L-;L4[X,;\4;I"[J5;E$[D,?0D>`.>
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M2>K:4LUYE(:6<+.:^4QFD&C5KJDQ*VT</GCNDCN`GQ\MN0KN1!O(?O)%O`]N
MY+NT%NT?]!Q]`MX^/X\NXMIQ4=T'7T]`W$];W,VEU4VS=*LZR>J2XFT=HRY%
MO`]NY+NT%NT?]!Q]`MX^/X\NXMIQ4=T'7T]`W$]=D6\#V[DN[06[1_T''T"W
MCX_CR[BVG%1W0=?3T#<3UV1;P/;N2[M!;M'_`$''T"WCX_CR[BVG%1W0=?3T
M#<3UV]'F3YRS'F3%P2[M!;M'_0<?0+>/C^/+N+:<5'=!U]/0-Q/7JL>R7O3C
MF"-[5TFBFJ^2O3+>/C^/+N+:<5'=!U]/0-Q/8%1NW6K1FTMJ7<6TXJ.Z#KZ>
M@;B>P<W"KR:R(J\26C[K;=?-3T=?3T#<3V'.OIZ!N)[#DT.[E[?1DOH(I\+O
ML2%\=V)"^.[$P4LG$./6K77FEG_>XI%-=]Y-&:<6TL7Z`D6@),>R(.PT/'=#
M>VEZWA&^J]_01S4FRE126D'[WHD5+T8_SZ7TSON4:=`O%1[YD21$<RC>L;;K
MK*^+=ZK6M:]",G)-DW#]^[MZ*5K37S5?T*,VBUR35LA7HNMMOM\"RU2E+:="
M;ERC11TZ6M_Y3__:``@!`@(&/P+<E+@SA'.,4CFT^8,^J:/NI^#9AS$61:].
MMK<(%'9''N)Q?J9-LJ?TIVX]Q.+]3)ME3^E.W'N)Q?J9-LJ?TIVX]Q.+]3)M
ME3^E.W'N)Q?J9-LJ?TIVX]Q.+]3)ME3^E.W'N)Q?J9-LJ?TIVX]Q.+]3)ME3
M^E.W'N)Q?J9-LJ?TIVX]Q.+]3)ME3^E.W'N)Q?J9-LJ?TIVX]Q.+]3)ME3^E
M.W&F8ATC@7MIW@O\ACW..L!N'Q?J9-LJ?TIVXU#87?&X?%^IDVRI_2G;C4-A
M=\*'DK3[3=*U'TZR$;:=8KSL-'K1T\;1I*,TT=$;=_[3>O<#B_4R;94_I3MQ
MJ&PN^%#R5I]INE._?@3.?04+;E-8W`XOU,FV5/Z4[;%#87XC:U#R5I]INE._
M?@3.?04+;E-87G8C6U]<C,5)-&':[6$C.F8?',G<^1FL-0-(WZ/]SVJ/"1Q8
MOS)9&L%+8Z*7$-%/]WW^W<7ZF3;*G]*=N-0V%WPH>2M/M-TIW[\"9SZ"A;<I
MK"-X:E/=G0L+<.VE@O60_F-0$G"J,_MO%^IDVRI_2G;C4-A=\*'DK3[3=*=^
M_`F<^@H6W*:PC>&I3W9T+"W#MI8+UD/YC4SD0Y5+_E,UM6BC?]Z)\D;W&>M.
MCB<UI:*<Z^9%_'J3HL/1K-%*WF?$CAH6ZTS:?X+Y)Z6]:,+@?-::".1=EW0J
M#O\`M#%^IDVRI_2G;8H;"[XK4/)6GVFZ4[]^!,Y]!0MN4UA&\-2GNRL+<':6
M"]9#^8U,Y$.53=VM'D4UBO)-8\0R2]_:R2VY*\F(O?$M\JGAU:UVG=*\S_<`
M[2N#H3\9(*2QKCT+],[X_P#BO.CCU#YFK133Q<B[`^)O6@W%@-)%.^-Y?KL'
M_P!T?]2+L#-%,UIH.HYKZ.75)7R)O@=U+^_&]E/W@1I6J[%8<.'_`+&=:(PL
ML4A&_JN#J.@^P*2QM/(%2QH!]P68E9R50":%02<N8E4$E9B5OE4O:"?>J0QM
M/(%GR9B5VCTK,2NT>E9B5VCTJD'.NT>E4\*WRLZW@J.!;P5'!DHX%V6]"^QF
M7:/2J'YPOT6&^`(L_P#GPQPM<:3JBBDKY\G24/\`(>Y]'&5K.PT.L?Y0B["1
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MGWOA:IKIVA2VZE)8.A3=WQ9&<]62"^\)R?1/;GEPRO;'Q`HQRRO<P\!*,4H>
M7:].:CB'O]R?$ULFLYI'!UI][X6J:Z=H4MY4I+!T*;N^+(SGJR07WA.3Z)N`
MU8GO:WW$A:KI9"+14MY4I+!T*;N^+(SGJR07WA.3Z)N"?'*USBYU.:A.C$<E
M+FD<'6I?,<!V=\VE\QG2$SGJR07WA.3Z)N&9SU9(+[PG)]$W#-U*,R_VJ&^\
M)R?1-Q$-]X3D^B;B(;[PG)]$W$,@B>&%K];/R$+]1'T%=L?H/(Y_O<G[>YL7
M@GZF);JT'-PN`X5^L?\`"S^E8:>8TRO@82>,EHIRED;J&9DYLSJ1JY61R"EA
M*^6/X]:(]^4M8ZAJ(D-(HRPQ2"F-TK0>2E?)'2[K4D;,S!(X#IRLAP4I9$80
M:*!OZSN,>Y>1BYB^'RW&B@>[B'M+RIVM?$>!PI'05^DPW_4SJ08P`,&\!EI<
MUI/(J6-`/N&76::'+YC^D_Z*7`$K[(`RZS#0X+YLOQ'K5+M_+KSQ1O?QN:#I
M6O#%&Q_&&@'^'[*O_]H`"`$#`@8_`MR39?-`UF@[W'SH2%^M2ZC>HW$Q7;="
MCO*CN)BNVZ%'>5'<3%=MT*.\J.XF*[;H4=Y4=Q,5VW0H[RH[B8KMNA1WE1W$
MQ7;="CO*CN)BNVZ%'>5'<3%=MT*.\J.XF*[;H4=Y4=Q,5VW0H[RH[B8KMNA1
MWE14F&;&TACJ-\K_`!GQM:-4G</%=MT*.\J*GMK\-U6X>*[;H4=Y45/;7X;J
ME-:J"99=H3L+B"_S6_R\Z;A,.7^<^FC[/$":EY.)DU9*.)QT!"&&6F5V]]EW
M5N!BNVZ%'>5%3VU^&ZI36J@F67:%-W=D+#\K_P`MZ-AJ@M[@8KMNA1WE14]M
M?ANJ4UJH)EEVA3=W9"P_*_\`+>C8:H+:\G#ZNIJ`YPHH)"W4<\`YD7PE@`/#
M34"G3.=%JM%.^?Z?;L5VW0H[RHJ>VOPW5*:U4$RR[0IN[LA8?E?^6]&PU06T
M+L5J"\&E26JE-=G0FLQ9=2\9J!2@QIDI)H[/MN*[;H4=Y45/;7X;JE-:J"99
M=H4W=V0L/RO_`"WHV&J"VA=BM07@TJ2U4IKLZ%A[#M(4=L:5%_BOU-:FG>]R
M`\X[_$WJ39)FN<'&C,OER_PZTV7$4ZKC1FSK??\`"AB9G:L+J/XKYPZ'=2$D
M6=CA2.1;Q]HQ7;="9>5%3VU^&ZI36JDRR[0IN[LA8?E?^6]&PU06T+L5J"\"
MDMU*6[.A8>P[2%';;I4'(ZI#E4-NK)#>>$Y(>YLY,-<C9R1M<*1_=V'+L,Z`
MO*<UIC\_>HS?+XN5?(A^!O4L=+A`UAC@:X9LU/E#@Y5OQ_"HGX@CSI)"VD#^
M:C>7ZAOP_P#)>7(_7&IK4T4=:[9^%W4B_"FEH-&]0ODR_`[J5$S7,/O%&E?/
MA^-O6O\`\\C'T?=(.A4C#ST6'=2!Q,4D8/WFD:?8&^5G*I("I`"I(%*I`%*I
M(%*I#12J2!2J0!2LX"S`+,5OE?:`*[+>A?:`*[(Z%]H+LCH6<+LCH5!&9=D=
M"S9-9I(<NV_I*\RDZ_'PKMOZ2O[GVN5=EO0OLYEVG=*^UG79'0OLYE\Z3I5,
M[B\^]4^1'\(1_P`=C64\06J,1+0/YB@,3(]X&]2:5/?/VBGW584]X4;LU+$7
MB%VY2]W9"BY]DI]ENA0VJD;503K*9=#:<H;UNE17=:CMMTI_-7DPW*_PY'W`
MTC)]7]K:SHHRX_RA:T3&-=[@`IWQQ2EA?OAIZD'S12-9Y;LY:0I>[L-47/LE
M/LMT*&U44;503K*9<C:<H;UNE17=:CMMTI_-7DPW*_PY'W`TC)]7]M2]W8:H
MN?9*?9;H4-JHHVJ@G64RY&TY0WK=*BNZU';;I3^:O)AN5_AR/N!I&3ZO[:E[
MNPU1<^R4^RW0H;511M5!.LIER-IRAO6Z5%=UJ.VW2G\U>3#<K_#D?<#2,GU?
MVT[%2NE$CJ-XBC,*/NE-Q,3I2]O&11Q?="?9;H4-JI=ZH)UE,NO$Y0WK=*BN
MZU';;I3^:O)AN5_AR/N!I&3ZO[<\R:)CI.,A"2**-L@X0%J.III18`ZDC]^%
M,N1M.4-ZW2HKNM1VVZ4_FKR8;E?X<C[@:1D^K[@-:5C'.]X!6LV*,&R%%=UJ
M.VW2G\U>3#<K_#D?<#2,GU?<$R2)S&AK:,]/&FR&2.AK@>'J3]8@;U:[0Z5A
MN5_AR/N!I&3ZON&PW*_PY'W`TC)]7W#0C"ZGV"ZFDT;]'N/$M^'XC_2I`?\`
MPUC)]7W$2W7B&3ZON(ENO$,GU?<0^:1I>',HS<J^2_I"[)_6^=S<7+^WMD4H
MIC*^4.D]:>UO9#CEBQF/PS9,2YSZ32[@<1P."@F_^;`V*1TU!(+CFU3QDY0U
MV\NS_H=!AI2V(-;FH'%R)\>+D+V".G@XQQ#+-+&:)&Q.(Y0%\X]#>I12/SO,
M;2>C*^7%QA[Q+1P[U`XBO.PL0;+K@4Y^OVEK,)#E\V3XBJ3OY?)P^(G9$.!K
MW`=`*#,5-+(P<#GN=I.6D;Z[3NG_`$:\L4;G\9:"5K0QL8[W-`T92QXI:5\F
M+X1U+5;F&75AD>UON)"U)9'N9[W$_LJ__]H`"`$!`08_`OW!9UE-B5T("(IY
MDZ0&)%"CG(QJED'>,0T<]R)XKZ5U#A7&04=5,L%:V!$LK:!!DSG/<K6MA@E'
M$62KG)LG!%\=1Z$][3@O)8^K%IC6<(=K)$B*O4CUSS)+,/9/2UBI[F/45&R&
M.POQ7TSS"PK)]V"-&QZ-$D2(T6DK)U7-N+>=WB=`#)`E5@R/\>'%:.^;*C34
MM:Z-,[N'#F5\4_68CE("#8$--B#<O][(][F^C=?3_8+<#M!"/;N:SY,">,QR
M^9]S%Z[X@AM>/NF0.IL]R;M:KME\5U0XLOEPG9=`J9MG[0"T<N62CQ&JMRRF
M@JI0($B<2VGSP&$(*)TV->1Q-D<F^;4C0N-[0+[VS85>X25\*2^SD8F%N+DI
M[6).?'4GD]35QI*$(J\(_BC_`!7Q;>8S,Q%M>.1CE8>%?45S8S23[W)8%"LD
M4VOR6H`.+'99C?TU"YZJ-WK^LG%E1GU#CV32XLDKI#A5W2J5D"*5@9$&!:FN
M)$,K0+MOUW.WWV5$7;0:>KJ`5$&#&:.)$AM""'&`).(P1XL<(1`$QJ>"-1$3
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MO$?]:/9W_2)BNIOWT?[8[1/L"_Q^[[5?^QG_`'?9_7>(P,6-/&^V%E<B4*JK
M*:SG'\EI'6$5O2NWBC,A,,W<ZL>TW3^!NOAITZ1C<>XB5V*X9:6%U6V<F..9
M<YB$C(4"#2.IY5BR-WP7(\BJKF#\4&YVPUBVTW#S1+#KVB6-%/D9#"L.PJ#Q
MQ2+>D`7"UGSZPK9".&>='J@>"H\C/#?(XU1CU57SZF31.JAY#:V095[46DV!
M&)<1X@,>?7OK.4OIH6-.F.&1J]1C%V:HED,&,ZC8IAA*XXAE5J=1@C/#'>8;
M7^".4;%<GCQ3T:IZ[&9P(.0W$F3)%(D0TGB'6TL9]A/&2.H)&WF"#2,Q^WJO
M)[WI2KL*BS?&J;C_`/#DH40;(Q&`9D^0GAWT3J/"XBN>T:@)X[M5GALON6O_
M`(>0?\NN_<60XUA<\`99[.&1JZ#=W;)QZ:6&6.X!7X^CDQV;2O>K7SS25:@&
MM]7UE367V$"Z27/!82XHY]%&M:!0`BY"D5\1=Y1YR/AQV*(\@;D:797M1$7;
M42BJ;`GETW+LQ(EA,2TRVJ-35U+7V-?6XE<74B):R(?75XNO(W8TKG=-KFMV
MU=6UQV]>]"4XNC%I8YK+%[*QOEKS55G"DW((X8(8;D59DP@W"5KB](K%:S6%
MQSF'`?D]%?@*"KI4D6@;F!;7=8&VGQ)<ICX=0D6L:1Q(ZEZ,AWQC>FYFL<LV
M7=[.LG,Q@&86U;&F"RB#5=_"!EW;H`;YOFM9$ZS2&:G53@YZ>OJI_P#QI/MK
M>M(.YLP-N8USD$6P6O/3L/6AR#)+AMRH!BEN>@HPY"[=1_58T+F.O)$0%?=0
MF77M(I*>B\BE-F,=BN+&R&GFDG1YR$G]U(C=%1-$Q2-?ZJJ_CMCOR?MZFYB6
M%?9369-,QN34U-M=QI-.&-BA&RK`3XNZ3S.4H>4@G%&#8KA%WS&3>2XK:ZMR
M>RHJBJ#6*"0$$-D(J29-FLA>^Y==6MXA&FR;[KOZO]:'_6CV=_TB8KJ;]]'^
MV.T3[`O\?N^U7_L9_P!WV:0TZ7&A!<4,=I99Q1QN/((T,<*/,YC5*<KD:QOI
M<Y=DTRO=+C)/*!\H4)3B262,)[!ED,C<NL\`R$:CGHG%%5-$.9[1!"-Y2D>O
M%@QC:KWO<J^"-:U-UT1:Z?#G='M^OVL@1W`[N("?%0[1N<X*R(,H9F([;D(C
M7)X*B^XD8LR**2[H[1R2!,,O<.,R/L)ST>O7='(C/#UE8[;T+[DVP%<UCX%<
M4@)\[O8Z0X90[(5DB4I$`)1J[QW73;.'80I=:\3CLL(TH!X+@L15>9LL3W`<
M)J)XNY;:%)BF%)CG8T@3@(PP3#>F[2"*-7,(QR>A47;194LX8L8#'%/(D%8$
M`1L3=Q"E(K1C8U/2JKMIDZJGPK.$7D@YE?*!-BD5J\7(R1&>03N*^G9=&E2S
MABQ8XWFD29!6!``(TY$*8Q%:,8V-3=55=D332#<U['M1['L5',>QR;M<UR>#
MFN3T+_5:M]Q:V\-E2DCMHT"+BTJ.XDE$:4Q6Y#C5\_FX2<-F.8Q6^E%U/?<>
MTW*8%78QJVHL?,F>RZ+6RXL;[DJ*V4V5[/V1"!"I>G'$O@G+9J:J(61^T:UK
M8(9,AM("Y;[)H0$F';U)25Z3<`$CY)6,Y/X;N5&[KZ-6RKFN7E;D4<0+E_8^
MS1_FT9B#Z0YC_P#\>;R0ITVJF_ANU%][4&M$]Y15\.-"$0K0,(\<4+`,<]L4
M$:,URM9XH,;&?01$U3G?G]AB63>6R:VMA5$S#0V4^%).P\AH8^04%S8F:\@6
M[H%48O'Q35:.=[3<@JWR)T$M?"GF]F5>D^763WVD,<83L'C%.^/..XC4$O)K
MGJJ;+[EK_P"'D'_+KOW'DMC:&\S8,!Y,6OJ+NY\O!)<K(Y[8M/73P5`3*B\7
MRG":J(J^A-&G2Y`8T.,%\F1*.1@XX8XV\WF(5RHQ@VL3=5]&VC"HY\HZ@B]]
MSETMY41SP5>UB384JXK8$:PB<GI\8!Q&>*>/CI"$D!8QPW%8YQ6(CQ,9U7D9
MX^NUH_'=/>U$L:RPBS84X2'B2`E:K)`E(@D>/?9RHI5X_3\-/(XHD&/="$4C
M48Q6^E'NWV;MI@E(-"$1SAC5[>;VLVY.8W?DY&[^.VN75%Q5RL1>HW;FW=',
MWW^$BIZ-)C?67S%:EMTWU?N9T(DP<`:MD;\'%))*U$;[^^G#0C.;$1SV<DY,
M:[?BYS=]VH[BNVFO%+C$8XB":X9Q/:XJIN@FJURHI%3WO3JYN[$JI#H:V5;6
M*`3K2!PX@"2"/:!J\W.487<4^J5-0)5Y/?&2U*@:V-&@6-K93B]%TES(E541
M)]E)Z0&J\BL$J#:F[MDU%F1I(WQYL(5C&<NXG/A'&PHY*B,C##&K")\)J;;^
M.GE0X5$/Q(1",5@TX(3UW[\6_%N1WC[RZZ:D8A."EX*]O/IHJ(I..^_!%7T^
MC7(1&$;ZOK,<CT]9C2-\6JJ>L-Z*G\"_U%DBZMJVHCD)TAGM)T6`%Y=E=TV%
ME%$QQ.*;[>G0I]9.B6,$_/HS($D,N*;ID<(G2D1WD$3@5BM79?!R;:R"^QC(
M38]*I@BE%)%A@-+F-?,BQ61A2I"N2`-%/R>Y@W$=LB(YJ;[^T2+791=8V#V<
M^RP&8U(J@D8++*^(.ZG+)M.M'+W\%HJMH.W=N+UG.^%MJX]ISK^VKIN/^T'#
M,7BX?&43,?DU<Z/BS+8$R"^.X\F7:FO2O0SE4H>*(/9->7"Q7)+0)K?`ISKB
MN2C\JCE#GU`1M:99UY!L>_DNC-8/C'<+D<?(C4YJPDE\61">=[C/AS.CW45Q
M%Y+'D]L:3'ZX57B[@1[-T\'*GCHGV!?X_=]JO_8S_N^S4*C0!#QY5]6>8*%P
MVEBU_P`<.3.$I'-V-"0B$&J>LU[45/%-`R>1`9#ROY&9]CHSCEQB@@*-<,BX
M^,!6GBK_`#V>LGV`-U;T"2=B.9MI(DIV66M;+^4;"5H)QZ6XAS)-+4Q*3J3K
M'/;RRGT8K$<\AD-/=N20-$CJ!B:MJJ/#O.9CXU'JG1;R7'+4`B^S:EB2BP@U
MN38Z]T=<J"=A1I+$/KN4[F%3TQ+6<:_ZH\AP\1([KHGE?D/R`@BR9SZED]U<
M7?*NIR<HW%0J<AKLJJL+(6C,RGA6]"_K>;W@>42JI;52*V'&O@U_16=<N'Q6
M-XO1R[*CR<B$`ERZ&ZWH"5$R%<=G00,?9$&/)HEW5LMHI)T^0=#*%_;&>WJA
M4;V]-^WR:C1)J7A'PB]I+GEL2!*S(HDMSF.FSC"8$,<74Z3"-9X;)XKJ*D.Q
MO)$>3!S&[MSUUD:AC2,JG]B^I1T.JEP_B6+U>FQRD:OI*KW>.J)\_P"4#B!E
M8R]TSSUGDH*05&P61PKBL6W1;&U/:H]4(H#OYN8YA&L16I)K)_G,W+[:I:^Q
M':7![22EH\H^3`.G39$.((3&^`PJP/AZ-U55EQX$BV'W-Q;2[&\J6-9-LS2Z
MBK9CDYE;5Y7AZ(E*K"1S,>=0%,/F41&.Y)?P$O<B6T`S+::@%79`:,*UMX]3
M'CQAGQ^'DK!5`JLH7E;*)7]-Y3>,AWJ$?U3S<L'U[[)6'9'RFQBB;1NID6F0
M0XUF-H$6V;NUX^)VKX;H-535)*G3[:+&#74"M[5I)4=2`K'COX=R-F95-6AY
M5BY7(4E;.(C>/3(GP6D`65F*OE8K2RICAW4BQE.RD-W8][%:KLDJ9L&&>JZ+
M3)72XGAQ<W=>:+6+91%@3^R!W<-9Q+)T<_!.8G3S.>64YJ_5N<Y5^BOI_J9`
M40:VR$"%RCU,R2Z&5UUYC!*"P:5[>S)VD01."$</@]>2*J^&HDJ!2Y)&OJ>7
M8CIIU388FV.PTBN2/YA+9;V*M-22'F5BLZ*R_45>DWU5U"2R<!]BD2,D]\5'
M)&?-0+.Z='1_K(!Q]^._CQ]R@94Q+4C:^WJ[;GUL;'C!#P)K#,??)(*/+'K$
M8BJ)L+<;E7UT=JXD1L8D2QW^,GQ<'=3J`?D[QVB%2;-5U@5WE,\6Q_N?N#M<
MQ$<%%]$<#BN.X(!"<9_PS.&QK%*_Q7UB*FZZM?\`P\@_Y==^XS`V'7M?"C9G
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M^3&0OQB)9QI-O<'M<1L@MM[4T]AMWUDM!N`WDXSO72E\HG5M+VF#2<3F79YZ
MWEO&:0%SVL>F&;%Z]T!8$FR9TY\65!7H-4;XCVHSC#&''<4E>:9=[/6$PZI#
M82L+&#&XLV%.NKLB4@3,\\20WNW=FY@AC:CUD?"T.$<V-2K6#A%C3T4H[IO2
MQW(9N6OR&*^E,ZM-*@UM1#)VP#M^Z4:W;@C5V3VAY+''42A6=#FM?"B8Y%Z=
MW9`R(4)(#9L*KQNOGSI,`D7<JGL+13>D8V_65;(%4"JX0IN21)D*S1,66R/=
M$Q^;\LJ"+.]EPYN/2HHHCX3!#K*V0WH<@R6->Y7YO-;,Q4(<@QW.Z*"8+60)
M,QN3U\8%6Z];7XH":9\&3&13E/.LE?OS$T6W3UA>58L^B/<8G$N*PM;?R)\.
MMG0;R+"%)<*?7PK&1$EQSUXW,7MWHYG)J[;[Z^4!9&'Q1O$]2E@C2'.>LS!K
M#')T"08>+NN;",EO,ZK'FM%"L9K6]JTC$>HQ4T?#>U`OLPL#XY*?-CX]D5OB
M5=D4')5O&`I9'JVA;6-(&?H'(8T1JF8FR:=?G)2MC/CP'PTKI@X#\<=#PYF-
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M^^C_`&QVB?8%_C]WVJ_]C/\`N^S0K.3%+,0LE\9@A%`#Q%7S[0OQIW-9U'QJ
MTC`L])9#AC\.7))DR$/^;0RNWA3>LUZ6+&!$XLH0T;ZD7K/5HG[N:=C>HQ58
MYJK(M*CJY!(')I(T>%&BW+4DMOYW8UUBPD2FLI1J4[QDZ<N-'DB,\?3'R>J)
MJ&PM.:=RH[;(K)8\M@UA5E(M>D]8PY(1DL)?W?\`%BV$XG';X2HW5G(D+:E)
M4PVSCPXU):.E2(RR0Q"/K>K&#&LTBR#M:90$(@5\'[:F2)9B1@QY@(8A-A7!
M[1[S54:W<DBF;5-L8IH\0_,K>#T$-.3W-\41\%+9II;&"?THT6;)1SI-4MW#
MC,.&,^,Z;85:*:,#GU9#47IM<J+M2$@K:B/?06V,6!,I+4,V-#>0P1R;-K8A
M0UD4YH[V!.9[02'-7I/?I*P]F`4]UM&HFQG(5"+:S*U;>-#3XO;F:N;U$7X.
MWAOOX:A1AI+GAM;JMI*R33P;*R^-LZ(%]'D6HF0!+5@?&-ZJ[EW9ZZ\40G3$
MHON*S<`L@M8]9!.(12S0GDC32Q(D>P8,X%:10\ND3U';+J8.WAEIJP)<@9'N
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M?5)CL)6V4JVGO@F*%YVQH2L@K/\`5E)$+!F2>CQ5P&F0C&N1R^&KBI=C@CLJ
M<:E96Z:MXP+"U4<Q8WB):XCA272`KZNZM:SQY?4Z';NED%^+A'@L@V<BR',L
MXK)D2("M'`\SG+)"[D%P@.0PT5[-VZ6/'L233-@Q[)PJZMM;)[8<M%[4KD@0
M9&RR7-5@V?#>1%8B<TVU"5URQG?QG3`M)$L!O'$9/2K+)G#?$:2L#'L'($KI
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MROI@;=['P#DB1U#VS#$:QRJ1K?61E\X(KF6E&"7*1(0ZF6:VCP+D-!,?71`7
M#Y@'!LCHU&3APR&9\8)KV>MK$(-'2-CY%FUL^K@1LG>@8M.D:!,M)DJV2ID2
M^L\<*"[@`)N1'N1.3?':AQ3*XK19!;H(/=T\FN-3/G2.Y[8,>',M`Y5TY#8_
MB7L'1A/=Q>;ZK3YCJ7*X*EAU,VGAS:^M',R(=U;MH8+*9@K@XG$6V(T3NX?'
M1.7/?I^OJ#BDV+;0+F4>L@R8TI:1"55K<N.RLJI@`W9IDD\I0_780I<,:/8I
M#,1R+H5]!J;JKKY*_<2W8(<8TT2>"R0!BSYSDC]1%:BOX<MMV[MV<O\`525^
M*8%&M8XF#Y7U]E,.BK'D>)#.9#B1(=W;2D%OP<YX8[>I\%7(F^G5^68**B9V
M[RBNJC)H-_3F*-1IVY!EC5%Q$,7FJL^YB,V:N[T7;5?:45%G,&_QJ;:PZJ_Q
MPF"G:6JL:VHDVI35^462QI-3)*-C-GC85AX?+P;MRK.G'N8Y9TBVMISL@E5,
MVXF6-I;S9TZRF2:(TBI(MG),X[.@[BT3VIX*FW[@_P"M'L[_`*1,5U-^^C_;
M':)]@7^/W?:K_P!C/^[[-2:Q)9(3)G3%(.%J*?M>JQTH4=_)JQC2`(K&F;\8
M%7<V;/1JI?GCO4D:]&Z,Z"@`QQ1X;YMK8.C]2.C2R%:6X*-CU5%9':-GU')1
M#DWEC-)%'B\*$8H(0U!5XG<NNH$9[(XA--*DG(K3F\.3=N+&[>-)D-B"/,+0
MQ+&/"C2X<:4(9YYJ\W?B<=CW`EQNPV8YNR^NNKRTEWMD<UQ"O8#5(,+RQ(]U
M/@V0AH=_)Q15,B"C(X_58V/LS;=%>KI,NU639NM&VO<2:V.6$\KZ.NHI82UW
M58UP)(:UA/5(QXW^AW'=%<0<L@@K?8_>)$CQ8\>,+Y/XL#%0P0"%Q:"*:,#J
M>K\!5V3PUB/\^E<W$6H"*<5=$BVDF&)TGHP#6@'-/V1`F8DD.SA'<)'<6+J9
M9DM+"L/+I5K&K`0"+'G)+B'%>A<5K]K,,:&V.U?_`%*JGOZ2?!LC12#R#'[Z
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M6:Z1"B1)"3)EO`972#2A36&:O$+-TX\5Y(GCMNCJ>:*YL.A1,AI60I`H\H49
MT:MEUQ4&I$X,C3EE*<PFL1'FWW]5>*0@FLFR2PSVO`,FJC&HV5]PC6RZN)1.
M-T($1NVXVB(@VN<[=KFKPU&L8]M+%!AW<G(8],V-"2,RRFQ.SF?'H%)"1'-1
M'#$U6H)?#Q;LU+6S)-.%]KB!\0()@QN:*,>6:6LQBN\5,UQMMO1J47S(W<$D
M8S+C*>("3&#(QFH?3AZ\57,[H$R.]5>WF-S7?!<FK:%761JI+2MHJ_\`FN*&
M#'B,I.HO$$:,X:-BSW%=UA(YN[55.7BJZ#"BV\B-C?R5GU$XP0UR299K'*6W
M<B"R,^,]L..T&[1D9\%%\>2ZRR_=LR'9=H"DB-(U_:!<,9;@NS6-X^83PC=L
MJN5.G_#HX`R'1"E$\;)+!B*\#G)MU&C,UXGJWZ#D5-5T`62W8Y%=#LZKS,`:
M8<J536QE/*K9#'UAH_!"NY,(QK"M=X[ZC$@SK%E5!G>;0<??V3ZN-;I"'`9.
M:](C+%_`8D>@W'5G5W=[^J^X=/L"S8DE\Z81R0^=K8.E-EME2#+%=*CHQS&L
MZ8'C&\34:Y%V]RPM).0V<NRE5LBFB'E0<?(&NJY,T<\L1L)E0.--0A`L:Y9"
M$7@U-MEY.6!1K(E/K(TJ383H[FQF^<3SL?TSS>@`(4'%*Y'L"-C0^HUJM5J;
M:?6Q94F8A)/=%/*2,PCB=M%AMV9$!'"U$CPV;^KNYV[E\5U:_P#AY!_RZ[]P
M>UM(,UQYHX8;:-$NKFNK+X->Y[X(K^I@3X];=,BJ5W'N!/\`!=O@^&K1[4DE
M;<=))<:3-ERH31BC=HT$.%(,2+7QW`\'#"UC'+XJF^I#HM=,,TM7)HXX;.[N
MK>/4TLQ.,JJH@6<^4*E@F3P5D9!^'A\'PTZ%VL\XGP\=@/?,N+.;(?%Q6QF6
ME&(DJ7*-(>D.3.>GBY=Q\1_`:U$LZYL>S2KM2$,>I^4%Z^HC&-9^<G+6U9+%
M\"L>:R^,7H#9Z7-39KG(L>'=QSO2%,%95TN#/G55G66,='("?6V=;(BSH4H;
M7JG)CTW:JHNZ*J:AVJ1[<DV&6ND(63DN13$E3*HDHD*=8CEV9F6<X2SBIU3H
M1^S]M_!NPJXE;([:/31:*-T[.Q">+"@VPKR"^++%)9*!-AV@&%&=KT*U6^G0
M[*'YX*:@8P9AOE1DC_.>T60Z.6_8^T<.\D,=*)\9)0CG([B[=B(U(-)5"<"N
MK@]O$"XI#.&)'.<C5*9SRO\`%WI557^K4,NXG6),Y%5E!28]`QMN8"MJWO'/
M<MA2O;&9%CLE/=]T]_`\.2<UX^#A3\,H,&DFMI,EU7CTP<J+*:^)!8RSD#%/
MM&U\Z0T?!\?N3*-HV[N\=DQ84Y,E*\S;>-81,?-3QF2L/E3L9#E`K*3:N:4$
M8IE@C58?W6\9'C3U'DU)A4`BQJZ!EN=060W`!&!"-%S*\#)AUP(KGQ1U4<[5
M;&X+]9X\MG\D30Z>!6TJ#=CGGL$U\MOSRRQ2S2O=B>,I5QR#\Z:QXW_&.<OQ
MS?BN&[]6UP/'*P6&8QF-%@^1)+G2/E*RUM65+;&7#&`;Z_MJ.9<B%TUYND\7
M.:YFGU\VYJH=@:^P":*!*L(D>:2&'V@8X4TMD4IF'=&".,1SGHG%J#=OZ%U(
MDQC"D1SF(8!P$:4)A$<KAE$4:N80;VKNBHNRIHGV!?X_=DW=I4%+:2V`'*E1
M[B\KU.R*-`QT(.NLH@7=(2;(O'?7XGG_`#IRW\^:_$\_YTY;^?-?B>?\Z<M_
M/FOQ//\`G3EOY\U^)Y_SIRW\^:_$\_YTY;^?-?B>?\Z<M_/FOQ//^=.6_GS7
MXGG_`#IRW\^:_$\_YTY;^?-?B>?\Z<M_/FOQ//\`G3EOY\U^)Y_SIRW\^:_$
M\_YTY;^?-?B>?\Z<M_/FOQ//^=.6_GS7XGG_`#IRW\^:_$\_YTY;^?-?B>?\
MZ<M_/FOQ//\`G3EOY\U^)Y_SIRW\^:_$\_YTY;^?-?B>?\Z<M_/FOQ//^=.6
M_GS7XGG_`#IRW\^:_$\_YTY;^?-?B>?\Z<M_/FOQ//\`G3EOY\U^)Y_SIRW\
M^:_$\_YTY;^?-?B>?\Z<M_/FOQ//^=.6_GS7XGG_`#IRW\^:_$\_YTY;^?-2
MK"AK'Q)LV.R))DFLK:Q*2,-_58'E9SIG!C2>/J[?UW62I,[V51'`KECHW/<8
M%=6+V]R4F\.2^_JE'"17_`X.V?NN_CLF3TD*NQ",F/98>LD6."0^QQR^D.I*
M.<MD*-W$M16`A3&193>J1&EC[([;U6_)W(_9#G&=PH:BEQK*EK:<L%AC"]?L
MIY<GI[()6M7@79K$7;WTU5QIU"N,/%-R%(E$^%$@&KJE<CMG4@I,:$0T=);J
MA0.,Y'O4A'*]SG.55]RVMHMY2!%?XHS$)T;(\77(WU$1LF1)6RQ8[;BK\KL5
M)(Y>LTC>JQK_`$HFTBI!ESG85:9+09=>4\ZG[R[L+BB#6,>QN0>9A&*%<2*D
M)9*.B$+NW9KTY+HDN1703RAY#[/HS))H@"R&1R>T+&6$`TSQN(T+VF<BMWV5
M'+]'4H(1L$(4@K!B&U&#&QKU1K&,:B-:UJ>A$T3[`O\`'_8#Y>?V746<V4[&
M(<?!Y-KA:Y#U\HF74N-*@3;@@#PZBFI*_IS3,(HNHU[E:1-M7F-V\"ABOQ2]
M6FC3,7I?D_06@"5%5;/-!J]^`70I-D^*51_%N(!=O'DB8^RHQ[&9N,S12`2[
M"_S6!BW<7!G,9!K`DG0C]`R*F[.*'64I./%G#=S)N3>3,M36%QRCT4Y+.%!C
M#M9@H=:^Q8,(YLZNC,:&01HQHIF.]5/W!_UH]G?](F*ZF_?1_MCM$^P+_'_8
M"S&_DOD&10"XK'NV_)6F);V<>62WFP']VG>@"*`H8Z<?5Y=3?QT2?Y%D>/\`
M3EDB]ED]9Y5/)P$$O<CC]8_*(_K<6OW\7-<GO:QIIY\JLGBB9','.3%'9?5U
MU+"/C<B[M;2)'F19]0RO(V*Y+`*.Z`U*-VR&V==XR"1<3K:JNKVVMK>TJ1TT
M3(I=YE.0OL[G'XHILX;*;SZ)+`QG)'B02<T]9'OU$I'1+JZO9L(UF*DQVK-:
MV+*F.<<8]I(&Q1AC0F'*C$5[T<5_JC1[D5->0R/.-Q6=51V%PRIDNH:F]NQ"
M-5TUG9>"1Y\EL@>Z(US`N>B%<Q='_6CV=_TB8KJ;]]'^V.T3[`O\?]@+_DMY
M+$)DF(PL=K\AG6.-5S\5F>?3)%M<V+;,@;BPABJBL=$&#JB22-W)G)Z:R.!/
MR*7E=76Y$L3&[^SG5MA;3ZWR:GD2UFR*MK0/:*[D2F!5Z(;HHWDFW%5P^2?$
MHV7448M]&NH;LFK<0F,;/B1$B,CW4^_HNI&D/CN21#W**2UJ*]$Z;=_/*3')
M&-RKL?0EP)65.S!T4-;86?1!'M67-Y!Z)I,HTE[0&\32'=3XS?;5GD-#49+;
M^;>SM,;HY6-9<N,%Q[+(=E83*Z?;HEY2K+IA=]U?_>&H1JHH=W(Y,AP:=3OM
MAY?[1<9S>?G0;&H#5QHL9N.'R!IX!I@[?S$<ND5H!CC/&5"[\VHU=>:+=9)#
M<"WP.N2!774F%5$0^?4`>[-`'\42P%W>XRKZS'#8OU*:)$0TB0D9[@(>69TB
M4;I+PZLD[_7,=^V[G+XJNB?8%_C_`+`:YOM2I,7=C4C$]J2\R/$XER`E\VVD
MOG5;[F3`F+7=K7-&4(?4853D5?61J+EDG%:BHK,-^6$IF+&IZ`&.1[:`REHV
MR[#LHT6*.4Q+=)`!2MN1PA;NGJ[K*QK-<DI,9E8A6SXL!F0P66\2PDY76TEE
M"NH\)W3:,M)*K6B<BKN4)BM1S.6Z4[:FVI+FO/*OIH)>-0B5V/#6??V<P\"E
MA&*<X*ZLDG?'&CWN=L/WO0GNG_6CV=_TB8KJ;]]'^V.T3[`O\>L2JZV9"J%R
MB^+4R+ZQC)*CU8@U%C9-8$!)$6.^QGFAM$'JNX;<EXN5$31)MD^))D0[S(J1
MMG7B6/`N@4=U-JH]S$!W$OI"LA14)Q0CV(JKQ56[?O\`A'B;JN1$OZ*NJ8D&
MUS"/1<+FLR'SB::!3S(<T-I*FU2)'<YC4(QCM_%&HFLQFY`:M;)D9D;MJ>JR
MD66Q<:AAQW&XR4O>A#&'"(DD)9*QD$+AW/+CZ^ZFL[!MGYSFQF*L6JK+F_G6
M2T$$$5QPUU9'FO`"#$()".1K6[N3?Q746X@BL`Q9G5Z0[2MG5$YO1.6._K5]
MD"-,!N\2JWDQ.;=G)NU47W.9B#$W=&\B/:QO)W@UN[E1-W+H<-\J.V88;BAB
M..-))1,^&08%=U7C9[ZHFR:/^M'L[_I$Q74W[Z/]L=HGV!?X]7F,3,5H[BNA
MSCPG#LN<@4I@"*U%/&*,@';[?0T+'5HJRJAAKC&%V+R(@DC*!@PC#Q:)@^)/
M0GHT2QN;&%50!*QI)EA)#$CM>1W`8^J9S&J0KUXM;\)SO!/'0+.GL(=I72FJ
MZ/.@212XID:Y6.Z9P.>-W%[51?'P5-OW]%9U4S%0M3'A4HWY#6VDRPII0KCS
M;S?&Y=?.B+561.`QN,F[^FW;W]>3SX.&5[F32E`#!J>=357;N!&8TDH-A.L9
M4FS>4;NH92>NWA[Z*JUDJGQS/&3,=L[$-;98;EF!T,F7`L*JM61+,3)6RW=D
M20KP=OLQ_4C]1S53I.U5AOAY`*U9WO=,RFSH[F]3>PE.#WMEC@PTTG>.K>GT
MFIQ%Q:_UT=[DX4RCOW8OCD*@L*FP@A$^JE938Y-61I$FU*Z2-PV5E+U(L9B,
M=S//?RV1&KK-SRP@B^UB1[:\(?A\>>P3,N!CJCQEU0.&Q'%D"JAUBS.MTUZ'
M@_FOHUO5%QMM+YO@:266,>S):K:_+Z@[5P2QI0HB5Z'Z'416*16H_9=U;L3O
MUCNG<W=VL1I&15D[_'+&:9SRM`I-^*.57;>G1/L"_P`>LJ_+4[[<[7_4\_[;
M$UC,^F?7OL<5R,60QZZW+(CU5JJ55K4OB2I46-./!>P=JI0G0$CIE&GQ:^]:
M^:%B/LKW(KO))H:YQB5T(US-)*[*&:0&,:2R.QR(XSA"4Q-W\&;\4A'6&:QG
M6UI&I*>N"4,=9EG+'(.QA94A4!$C!BQ"E*1V_$8UV:YVS59:M\J]:1*CJM)?
MP<EK7.BF<%71[:`T8B[\?%KF#(Q?!S471+:<.3(:AX<.-"@L86?83[&4*%!@
M0A%*$;Y$F2=J>L]K&INYSFL:JH>22KD5)(TLD0D:184=ENX;6.YLD4-I:QMO
M7V5KW,(UR+NWWU_?BJL(M]9T%E69-!LZLM1CTC*9L^5!@6IS5Z4@;.J%+CNK
M6G,93EZ(PA<]?%J.;;`M\F#D]G6V41AY0<;;B_;1[3'J2^KXRP&VMPT^\.U:
M3K(1-U?PX[C55I9>+>;"AI(.2WD4F-)E$UQ`GK.RK3P^WEO@UEA%?+ZLM@GO
M&00V)QZG)$LLAB2X,F7;9"6!%L87EMH/'UO;'Y.):5_`?9S_`"/H=1BIS1?A
M[/Y)[BL(QKV+MNU[4<U=EW3=%W3P5-,F.C1UEC8HARE"-9#!.^$-AN/4:QWT
M-]M'_6CV=_TB8KJ;]]'^V.T3[`O\>LJ_+4[[<[7_`%//^VQ-9+]_?X(>H'WG
M.^UMT7&\E\RZT"7#GA-`25&DP)X$0\2;`GQ#!."2%">EJ^*.5J[M545F.8Z6
MX*>TL["R,>S[B3(F6=D<LZ?+E2CD7USF<J^"(U/>34G%,MN9$"0CX$YJPXMP
MDV!*C&!8UL^%.@P)`Q28YQ,>WQ5/J7(K55JRJ>ARNPN[;)K@UI)-95)(AYEB
M6,,9'(VMQNBIXK>C%3P:(:;_`,*_OS!@FK(TXMOD==40)<W(I>*0Z&=-CSV!
MN95[`:^;#"QB.C\1HJG[CI+NUZIJ^QL(:R-=4V0&C6QH&62<N9D)A5%)M>Q;
M2Q:&R/%'%,&&K7#1L=T?I>''BF+;NAW555SKJ-D&.K[2HOL^:28>NKSUI)%@
MVUKI9)L!A.;`;[=*2KG>EF]-V%<RIB?SATH`\J^6S`?SI-Y<<F[N?YDA7[O^
MNNZ7+I^'#9/=/^M'L[_I$Q74W[Z/]L=HGV!?X]95^6IWVYVO^IY_VV)K)?O[
M_!#U`^\YWVMNKC_FGX&#5']\/^TDU/\`O.M_`@ZQC[_=^"R-6DC'.\2R86J:
MXM=&[VQCU9;B`*\EP(G0DK(F1:5YR#:C'.Y-]5%79%RU@)U]:X>";6IC-ED;
M9ZS3O?6`)<#BRK0$>PG5P9ZJC7DY(A.;&NXMV2VR&2$DD=9&ZR1A*C223O>P
M$:.CW;M%UY)6MYKX,1=_>U:XUD-/`JK>OJJJ]$ZIMCW%?(J[@DP$='GDU=0<
M$Z/(@$8]G3<U41'H[UMD_<4T,-;76DNUBW$[H6&0)0KT*AL/:-`_FJU6QM[0
M\UHHL;8?5(GPTUY@\.0*QJV/4&&AGR'M'2#&^^EL48^!8%'U4209J\4=X-Y.
M\-2Q=Q9FCPX=C.?9AJ)KJHP:ET,=BD.>HVAF'BGGC&HQ\GJ1=D1=2PRYD^&6
M!5FMK`<FKF#+7ACLC$,">+IN+#DC'-$KD(C6-5_%7<D<B360VF):1*.NO'PY
M@R1PQH]S(CQ:?O3QV32(V>:4SBX##M^BJ+KOI<J3'X08\F0-T9[5')D2940=
M;\:H_N][X)7H-W%4"WF[CNFL0;BM1'OI>9AL)M<*WLY>,1Q5U97-L9,N2=:.
MXDB7@1C6M4"(KGIZR)XZJ62(I(?G<6E9`@[D/9K<VPC2GUQ$4`*Y&1X@NHC^
MXYD9XHQ/1J>Z'-FSUA38E>,4"LF3#64N<IT`&K&`;W2R?<I%5OJO:UBN5..R
MJ62V9,$"-41+J4^3!)&=$B6)G`K6'"56G;(GE;LQO%=E\'JU=1+RI<9\":A%
M"XX"1WKTBO"3U7IL]J%&J(YJN8[TM54_>:"WV@0*F?1S+3H,;>5L*RJXTR/5
MVEIWDD=@P@`]&#7'XOV5ZN5&-17/1%E9%AOL_@8;.CO2MDH;$*;&[SMIL&NN
M8KE6N8Y[JZS@3(YV?&>**G)$<U41DJ9D0CQ;ZP).BTD3V28;E)JT`/)ZF=<V
M-A<R8SG1(:RX8B2".ZNSQC:CO530H()89KJ>XR:DF&CT-;C(?,*C([2#.8RF
MJ'DKHK62`NV<-?CD^,79SU3W*J9AV:7-=E=C,JJC#\+K8E0>)?6WF*EMYMHD
MJNESCU\6E(JE52"BQNDUSUW)K-,T#DL\`L)]JM!@4?$X\6N\BL:ES\=B6Y);
M2PS6)9UD>[<01.NB@X(C?!=M>5NI<DF./;X'8]]74LF;5#2/GU`589IX_BAV
M!>TXC$OK/<1B?5)HDM`R(Z27N.@)871Y0>JO/I20/]<)V;[.:OBBZDV+Z^WM
M$&-K>SHZ\UI8/ZBJG(<,'QCVM^J7WM9(=&%%UK:43IG&HC#YD5W`PG>L,C=_
M%%]"Z;-?77%HBU\F/VU'7&M)J=4D?XY8P/72./CZS_0W=-9)]^_X(>JV0Z'8
MSD>TD7HUD,DZ0U9*L$AWA%ZS8H-]R/\`0QOCJZ]5S=GQV>NWCOQBA3DGT6.]
MY??35$51'-]VC%PC"<8OQ_Q'/@WQZ0NIR>OU+$5?>U;*D>9'[=(T14F1WQE*
ML:.,2R(Z/^NQ#<=QD3P>WQ36,??[OP61H]?21S5T2.QK%'=TK@',5JJCY$?K
MJCC0R;>H]/!R:IZV8:O=%F3&!.T5>QA'#5';HQR.W1WAJ=6V^/7XX<L)8LNN
MOJ;L%E1BN/'=]S3##(2.7I+Q>B;+[R[ZG&IZJ[ZTD;7RCRI<V]M)(H(%2-$9
M,N+>PGN!'$WB`#7])F^S6IKY53\<S5L%JS^M$3&I26<5L%SFJ:;$(\?9QI2M
M^)(1S6.147=$U?T-OB5S1VM-31\CC!8YEL.ZI9?-HBU90#`LB:TXG">)C7MZ
MB;-([5";Y/9<WS\KQ,&_'IC35/#^^7P_34B=[SB>G60?YO9<_P"3SFM?T\>F
M/\WY/X;X_M^-VIZ5Z?H;XZQ?("XME:W%M3OA0IDBDG)&H(A"$FD%=-<O0I)K
MR-V57IS]#=];OPOVA-C86>77@AAB9+%L[F-:2FS9XABC312,EJ)4H:.*A%>-
M=MO0JIJ8"UK\AFU^0UR'KH4&BR2LQNACONF9*2+/GRLDN(\:R/.`)"QX[(49
MW3V4&ZKK)LBCXS[3X2Y%;NCW%77#RF'82IA7*.1;1:2/.8UD22GUP[6\'-U'
MJODEERI14L0]4<C+]^/P8D<H+%*JJD$F.BMF%DQV*6,WX3V;+H$D>#>T")YW
MFK[A4B5^1P<BK[Q'NBI:2"1I@["KIVB(J,]=`-#Z$U(%;4>>N/B=-)&.;6OR
M.NC6U?8L&.;60+"NFQR79Y3!(A1\N;D]*ZIC/PC-1Q,DLH*EIDKKV/"AOI0"
MBUCLEI1R6Q*Z!#&)O2ZC./AJ]Q],7]I'EV+6+[:,@7Y8D@TDC3QR#PN<RR26
M>*04EZ.#&>T;VN]9%UCE=(P[.R-MJH$6JD/9DO1Q&+&)UAA-+[[_`#7D=5G)
M43BJ_27;5D\./9T\..%97="52VLVWM4:B(DFL[HAIER#Z)N2ZKZOR;(FNL:[
MS%)SZ:2VKAIPY]G83E^*AV/O=%WK;^&CVWR8S96@LO+/+VXQ.6V*[DK>]!7_
M`%TM;X;]9/5VT^J\ER7DRK2U[_R63Y6YJC4G8LG_`%IUHFVW0^%R\-0;7Y+Y
MPULZQ\N2`_%YS;6*NZ)WDZ!]=BUWC]>7U=M7-?Y'D^]-$66Z7Y'*\OLD1&KV
M]-+^MV4OUOK;/'5#+^3V7;7QU`R/\GIG=U6RJG5OH_PZH'A\)_AK(?Y@RMWR
M=15?PH);O.-F\O\`-[_[PJ_^S]_5"#R'*F^?A>9A7T,MH*GIJB=.^*OJU1G;
M^JTGI35U,^369N2EF,ANCLQJ:Z99J]RM[BEC_#LH;=MU(SP1-5E=Y+DC5LZY
M;%LQU+);7PD0?4[.SF?6X5C[W1=ZW+PU(MODQFW&/8LKE@+C$[S4RO?P[R/`
M^NFKF^E3)ZJ)KR?R;(U=Y:EGYBE-)6HXJTCNR\Q^L^9?%[='X6ZI]'4.Y^3&
M;<9LU(*5WR8G><1E7_WJ97?7HT)/_6KX:MZ[R7)=Z>'WCIGDLGRZQ39B]M43
M/K=C,]?ZVSQ\%U1R_DWF6UX9P6`^3<WNJOB_AU+P'PJL*^E'/]*:R!OD&5O^
M3S4<]1T$M[;?=$7;'U3\;N\?[WJ@'Y!E;?E`PKV/?02VCJ>D]C.-^]?"I>_G
MNU">E$75Y+^3.:;4<M(CX_R:F]W:*XY`=Q1Q_AVD1.GR4C/#@J+[^JFO\ER1
M%MH'?MEK2R4KZ].CUNTMI?UNOG_4])WK<_#4FX^369\8UCY<M=\FYOFYUYM9
MWD:N^O'KO6WZR>KLBKIE-Y-D?)\!MAYDM-)\F:CA/+VC[+ZRV>G#91?"Y*B:
MB7/R6SGC,G^7I7)BT[SB.O2<7NY==]>CP/5X]5?5Y>&K>N\DR9ZT]>ZP=,'2
M27U]BC6C=VE1,3XNQL%ZNR!9ZVZ+]#5)*^3N8-2\ENB,`_'9C9-6K2]+N+L'
MPJN(OI0C_#CXZOQ>0Y4_Y/B0KWCH93Q6V[6OZ=`]/"V+ZVW$?OZQ]GD.4_YP
MH]6.\BE<*C@X+=L@=_\`2%=UO#J>E&N^AJ\E_)W+]J*7V;XZ8[,[NT7N'1^X
MHX_P[2)NWGU&>'35':IZ[R/)VK<5X[!LQU'*;7UR$$\W:7$SZW76#.'%PG^L
MCU1-2K7Y,YJK8MEY:L!N,S5M#N\/NV+!^NGK?'Z\GJZ%3^49`QQ:YECYB2HD
M,J&(]%7LRV*_$LL6[>(?A)J-;_)C-T;*LDK$KW8Q.2W`Y0N-WLFO^O`K?5X]
M9?5YKMJTK/)<D>ZJK7V;IHZ62^LGM8P+^RJYJ?%3[)W6V0+?656N^AJDG?)W
M+T2\ENB,C+CLQ)M8K9#H_<7<;X=9$56\T(_P4?K:O@^096OD`7&>1*"6H;;C
M_>Z$GHMC.]YH_3K'V_)_+/\`.#X"KC\OC4?&,'_G`O\`](^'O\9]2BKJ_D_)
MW+W)03&0WA9CLQTFV5\M8?<T`4]:VAM5.HI!^""];T:_$>3_`*,?*C\1ROK?
M_P!C_6?_`/@_7=5E1CU=7SRV>0Q8TXEGCL3*(M;$'76LT$YU78-?"3E<18L=
M3E:K8[3J_P![=+V7DX)R6)\B1ZS;'$089,L...X^"3UZL00DDDK)X30>Y?SZ
MS(S>+N#6M925YL(MLN?+;;"JC4Q[N%(K\A>ZJ!4Q9EE2%`^NI[%#E+**=Z`:
M.'Z%?PV@5IZ.-CYJN=?5IH4$MF>"<T&^LHQ[:%)N_P">94:Z,-TM#2=RFZW/
MD]'(]VH^2VOGH;J+6I4@FU&2WE*\<#KED*!J5DZ,U&O,55=_NO#?T:'>%BV9
M)#9M7:GAOO+=:FPNJ4`X]7>6=6LOLY]O%&)OQQ&JKW(CG\G>.C_K1[._Z1,5
MU-^^C_;':)]@7^/65?EJ=]N=K_J>?]MB:R7[^_P0]0/O.=]K;JX_YI^!@U1_
M?#_M)-3_`+SK?P(.L8^_W?@LC2?DN'_PM8W^5`?\+3/R7#_"K/2?2=_(=HM#
ME`S2(ES`,*1%;'>89X<A"1RC>X;F.8KD1?0J*GI33BUTG(YUI8B@U"3KH]A:
M2AU\<K_+ZP)ID@G0@QB2'+LB;N<Y7/5SO'1..^ZB?QV].ZM7;_RZMFY!"NH\
M<M13;NM(UO6M;=C+/;8@[.XG3ELIG2Z;RV,;H1C\D:T35;J9//S4$&+(F&0;
M>1.E&$\Q.#=TY/X,\$UCL.YIJR%$S*AGY!0/K;*3.DPP5SHG5B7+3P8HE*4,
MX;FD$O'ER9Q\.2D,5W`0F/(1Z^AK&-5SW+M]!J:Q^-(QZ555V80[.=B=B6=%
MDDG"J>!)++*`)$?4G)&(A1(CSHYOPE:[U?<:&LIKSRL[)9(&2'94BI[-L,O0
M*^&%+=]^@7EW092P1!+Q7BY?<+CT:T9(M0&)%,($>86**8%G4-`)9CCNK&6`
M6+NZ.INLWWV^YY/YG7^;H'N/*^]C>8]O_P"O[+J=ST?]]QV]Q:3S>K\Y0:&6
MH\PB>9H)4Y(58'5[I!JWQWX[?O++R^YRW(,#?Q`*QNZC-+#&HDA&,;&B,FQB
M2G4QS(U.`U4'47P]*HFTB[K<BO,NMA#2M-;7F7S\E+#')CP['LVQW2UK:]QX
MQP'V:`;U&5KO@N34`$W-Z3'P4U%D5I*J;#+IN.&/-D/J18]:F!4G982J\,F-
M(AN]5W%9O)C7O:C5I&./".*02WL8/E]X?)HT>MM+JPL:Z$F026L-<$@PI3!.
M,K6[N9[^VZ^Z?]:/9W_2)BNIOWT?[8[1/L"_QZRK\M3OMSM?]3S_`+;$UDOW
M]_@AZ@?><[[6W5Q_S3\#!JC^^'_:2:G_`'G6_@0=8Q]_N_!9&D_)</\`X6L;
M_*@/^%IGY+A_A5GI/I._D.U4?DW_`.*DZJORE!_"1:H6T-H6N;*`=QT&*,3J
M*QR(U5ZX2[;)]#4,9,EE.825'8]O;5WBUQ6M<GA#W\4750:UA39Z6PS-1(B1
MUV4`HREZJ'*)NS^Y][3YE)A5K!E%'VS2-6.5(T9Q5,Z)`&>R*.MA.,[DH8Z#
M&KO';5;977<LB7`VJ!@XW<NV(`9589C5X_`+X^E-1["`3)GOK@2XM+&FOM)T
M&ABSW-?-C4T23*>&&.2YC=_2Y&M1B*C$XZCW5K-;"K9:`Z1C",_EW+.8F.&$
M97HKF_P:K;^)G<XS:.%;5U%5R88%BU<"Y,P\F"R:'&PWDN''(S[F&>41H-UV
MU'M63HR5TIK71Y9B)'$1'[\=ED=+97;>A?'5;(B^T.K9C%99WMBVM#938\FQ
M#>$+)\MN(H[Q*&P6#+,KQS'QNXX[,\$3?33`*,P2)NPHGM(-Z?1:]BJUR:C!
M)"IDBQ?:4?/W9BDY5N)<,O55*;L?+^NR61I$`1RGZ'0;X;_!33\N"*.E)YS1
M6B&/-ANC+'KZ"35S6>7-A.M?-U*5O0(DAD=K-^;'+[A0S0Y7(_SDHX./U5/-
MMJJI^3LD+.ZNF=C06M;DDADM7]\&:87;":BL5F_CK-%J!4(ZSV?0*&=:QK<$
M\EA?^=H\O0K)D>PB`IF@"/9I2`F]4WJ\6^G0B\"#ZHV$Z96\2CYM1W`C?J2-
MWV5/HZIL6EUI91;>+&DC,*PKXYW=U:"JA@KZZ64,BVDL(7J/&%5<P**[;P]R
M%$O[^III%DKD@BLIP(:R>+F,=TE.]C51'D:GTU3W([LAOJFE26YS(OF<^-#6
M0K$W)T6F(QQ$$WQ<J>#4].AF"1A0E8THBB<UXRC>U',(-[55KV/:NZ*G@J:'
M+R&ZK*6.8G1"6RF`B-,7;ETP]9[5*]&INJ-WV3Q]&@3(9PRHDH(Y$:3&*PT>
M1',Q"!.`PU<,HBC<BM<BJBIILW(+BNIHA"MCC/92PQ!E.]%5H!*9[>J9R-5>
M+=UV34>=7RH\V%+$T\67$,.1&D!>F["A,)SAD&Y/0J+I]C>6<&I@,<UCI=A*
M%%#U"+Q&)KS.:CS%=X-:F[G+Z-1[.IG1+.NEM5\:=!D"E13M:]PW*,X7/&[@
M1BM7Q\'(J+XIHME=64*JKP\4+,L)(HD=BO7BQJE,YC>9'+LU/2Y?!-`LZ>?#
MLZZ3SZ$V#(%*C%Z9'!*C#!<YBN$9CF.3TM<BHOBFCV=Q80ZNNBHCI$ZPDBB1
M0HYR,;U#G<P;>3W(B>/BJ[:'94MC"M8!7/8R7`D"E`5XG*PH^H)SFH03TV<W
MTM7TZ/8VDZ)6P(K.I)G3Y(8D2.-/JSR#O&(3?X5726-'9P;:"Y[Q=U7R12@H
M82[%"YX7.1AA+\)B[.;[^I$^QEQH$&()QY4R8<46+&"Q-WE/(,Y@A#8GI5RH
MB:\PH;6ON(2&?'=*K989862!(U2`>\+WH,S$>BJU=G;*GT=$D2"C``(W%,8S
MVC$(0T5SR$(]48QC&INJKX(FCFQV\JKL<5[!R'U<Z/-0+BM5XNIT'OXM,Q-V
M+Z'IXIOIYBO:,0F.(1[EV:QC$Y.<Y?>:U$T27CEW5W<<+F,,6LF`EH%Q!H43
M3=)[E$I1+R;OMR;XIK=?0FC'QJ^JKP491)(=6302^AUVJ\'6:)[G"0[6JK%7
M9';+MZ/<E?)V^JKI8+AMF-KIH)3XJFZB!4XQ/5XFF4+T8JILY6.V^"ON3J^E
MOJFSG5CR,L(4*<`\J(X,@D0O7CL>I6-'*$X:KMLCVJWT^Y6BN[Y<9YW;_+KL
MD"+:5\&8F.9"LE]K!F%``\):5):)Z[2)(Z:B7JHS5O,'+OIMM+MH#KDV144?
M&I2]#%<=BT+HE-%FV0H]87&`0R"<IRD>KG*]4=NUI\MK<OIJES[.@N01;+`X
MN12(T['ZTE;&1EB:^@$[(J&<1P>FC>:[^G4/'9%D*W/'FW<XT\%:VG`4MW>6
M-V1@*QDN<R&&.^QZ;6H5R<6^]Z/=N7AQD4O"\:R^IP:_R'SKHV0;NU\O1YH5
M)Y844BNJ3681G<^4)[E?NQJ\5121)%C!CRB9#[/I+(QY8!2'QQ^T+&7D.T+R
M-(H6-"Y5=MLB-7Z&I1@D8419!7C*-R/&1CGJK7L>U5:YKD]"IHCY,@,=BB5$
M><K!-5?'PY$5J;ZR@@WM(-]S-<Q['(]CFJ9VRM<W=%1==22<,<?E$Y.9B,$S
M=21=DY/5J;KK(R!(PHW3=VD&YKV.3I,\6N:JHNH))!A`&D2:BD,1HV?6T^J>
MJ)JW*`HS"=VO$@GM(QVT0"+L]BJU?'5(0Q&"&T[^1"/:QC?B2>ESE1$U-+',
M(XUAUVQ`D:1B[0Q(NSF*K5V76-%,1@ALG.5Q".:QC4[8_P`)SE1J:0D<X3C\
MLB)S"1A6;^MX<F*J:QTA'M&QMF%7/>Y&M:GCXJYVR)II(QPR!I71&<P%85G-
M)-BJMY#5R<D1R>'\.D551$1';JO@B>H[52Z-(!(:E=LK@%&9J+W,CP51N<B+
MXZK'.5&M;80G.<J[(B))&JJJKX(B)K&^VDQY'&/)Y=`PR\?7;Z>FYVVH*JNR
M),C*JKX(B=9GBNL.[:5'D=/S!"=`PR\%4%9LC^#G<57BO_FTW^Z3^WK"Q@DQ
MS$&P:$8(PR/&OE\3P>UCE5J^'O\`N4@0S(IC-)3;B%($0B<8CM]V->KDV]S&
MP#E1WG8:K5X6&&XK4Z4]-W#1W-J;K[E&$,T3934B[B%)8DAK5ES/2QK^HB*B
MZ_QR5_T@O_I:1K+,;+!*C9$;-:V8C^\]"(A.LCN.OQO:?]/E?\;J1/;9");@
MD2'`29(;(.J=S%&OQ1B*1[6C<[Z6OKU?_P!`9_Z6I-K=RH3IP99V,CL>&(\H
M6!BN;Q&KE5?7([QV][42VML$JK*T@<>SL)P8$J9&1C^JQ!2#0'%:T9?7:F_J
MO]9/'4J?+<&L;%1SG"/+$\KF,:YSG,9L-[O!OH1%T&XM+_(6JE>"JF5\2))#
M7VD"-:`N01YS7599>P[".Q^X3!=X;;[:/(K+473C$:,JS$=`7DYJN3BV6@5>
MFR>]JIE4UWCP(\>FM*B9WF3RZIXUGRX!QR'0X-5:1;^&)(J]2%)<$15V17:8
MTMQ6O>P;4(3NXHD>Y&[.)PZJHQ'*BKM[VC7N)>T'"(L^7C1<8*L_,(]3*I_Y
MSCV0[.IFQ(MUR^,C\)$-X1MDMV^.9MJ'&^5-!:3(D*(*=(AVM>5I)#`L&4_$
M1UZ;3%:JIX)JOO\`&<GQIEA#HKV@6/89'Y.L=MSVI&6]9:PX5V^'9PBQ$398
MKD*%SF<F[[ZIX-IDM/:6T.K@Q[.>&=$1DR<&.,<N6UO-JHTYT5WH3TZI[W'+
MZ@2QJH%]6)%L+YU0UH[V%VOF5;;PH5T6LMH#FHK']H5'C5S/5WWU40+W)*JT
MN(L(0K*P'-CHR9+1/C3IR43EYN]]6HJZQJVHKS'_`#'&;&=,'`L[CL84YEE4
M3:<KFV$0%D:ML83)O6C2$BR.!&_!\=]5=;DV3U5O>1TE][/'9A.TW6GRI$=G
M7(.&20L>(5@E(HAJ16<MDWUC<ZFN\?\`,,9O6W08-G:)%@6*.@3:X@"S(HYY
MH,@+)RFCG2.?I'&UW!=M0X&3Y/56MR,U@21+9;"F)T9%A*D0HRSC`KS3GPH1
M!A4S@"4BLWXIZ-49ZB[Q]+''<AK\@C0[2Q:.LL70NHU8DL\9)1HJ\2J\)D";
MHG:U_!VVFP\IRBJM+59LZ1UVW0['I1#G5T.$^R/$JC6)(<?9BF='$I-M^*>C
M4>+6WM&&?6WN/Y#$%83A^63CX_;Q+9E=9=!2&;#F+%X*]K'J-51W%VW%<IN+
MNVQT5IEET*V/7U%LDRMK61JFOJ@1Q3I4>M/82'MA<R'6.#ER1O!.&ZGJH%[2
M1YK)]-:Q>]F"=`DGI+>%<"@6'1(XO86#H71-Q1RH-Z^JOHUE>0WMKC<>RRJ9
M6F?64]QW]?`!55[8(/YPEQ:H\Z7(W<I"=L'U48W;U=UOL;%D-9!+;UYHHY+Y
M,<P6/=XL25';(&LB&1R<2CY)S&JIK(YN5Y%CSQVDF$6JJJ[(EMXM0P(SI,''
MES:ND,.+)*1'#C]-Z`:G'F_X2SX8K:J0DJ')CC4D^.C$>8+QM5ZM>Y>**[Q\
M%U.!?W^.E?(K,4K1!A9(:^XDQRH=5R)B6=K75$P$2<G!0UZ,>""C%0;UYKIS
M?-:WQ:J?X]&]]/LFI@[^_P`;*I:'%:48H&2GON1<=':#+-9.M:RFDUT&2VP:
M@:YC2@C<'.:_XQR:5/-:WT?\NC?\9JP/>Y!CA&&HZFE$*%DTB^4JUEG>SVRQ
MFM:RI+1P^%RK6P`]8"/Y$Y;NU^-:W_IT;_C=6MQ:Y!C;H!PY3'C!B9-(MGR/
M/<UEY3"..)85E>+&&PHTMPC@BFD#F&=U7JCF)K\:UO\`TZ-_QNJYCNR9!FY1
M40[:9-Q%,Y\NKG,F&=81L;>"2.9(!*`+Q5CE&-7N:BO1J+:3Q9&[*C2;XSIM
MN7!S8'(+)'5U(&BD5DB#`-.(&((2)*<UW)G$?+86R>SNM2HL\BB33Y0LJAC9
M>7!Z^6^-70BQY4N^#80"]]"7EV\9%=U1O,[^]ZJ8K:4F/(+O=J@N2%RXD3G8
M2R>.0'DRRS^ORZB;D=TT?T_J=O=R"NC752/!LLSNI]H%U&-#F$R$<^`M6:;5
MPSM,D)85G*J!.ZCD1X&\FHUWIT2QFTU5,L`WN`0A3Y5?$D31PS>T#'!&B#E%
M"\[(Q1R2-<Q%XN0CM_2NID=V.%^2L60<3*^!A,4]*.D=38WY9,KY<"C=)D6:
MY#+F-*)AW.:)'N>)!C8_6;1;>H)*#"RDB4IKK$!U0EJ"UM>Y@ZTI*2MC6$.-
M8=PQI&=5^R(KGNW1RV+)N&J?$XR#2%Y7C(Y,3R_R*%)-9%;&Q>8ME,??E-%[
M<<ULM$8QZ1^DCR/O!Y#CP>R9%1_"PQ.LKX4.U6_R`20Z*4VHB.LZ_P`@%"<K
M^I)3=47J=1Q$U%1,.[K$X\$1G#J,=!("825UY)LYLEP,9G]Y*CR(H`CA),CR
M2N>/HB?N[G:#M<=&E1RR-RAFXA7P*R''%?=/#W5$YU/%--/8X]\9,8ICJ(J(
MCD&[U=8:VCQ]YZI)4@N41:_%HTR"M,*LMBO>I'8N^.Z4Z:R.B-':-E>JC`Q2
M=1RZDCFX\B8^]F1$?'FX?"@5<2(.12?(\E?--2QI)YUA#-,=,$XY7B(U$<P6
MR)K'VU&'CF4'3C$ECIZ*(\DR4^V`"<R9);C=P.."MJ%60UA20FR$YL8\ANFC
M'(3&^GCIFVI.UFX7#KZF-5I!H'X_(#.DTD>9YQ)EFF=>.\[BL5%1XQHUFL7%
M0XE'DU)2M=.95TT+E+E+:5@.VG3?DY<AKH8*\I3*XSX82-:YO5Y<>(%CXR\&
M.2)<98\.9@\6#6_)U^."/+FSIDVC%,AWX,GY!;'<=CU#X])6[/U2,Q6E003#
MG*3R?%ZVR8>X;.HV5D2W<^HG)`JCPRR^H;XEC4;NI&N1FL:8*DGMHK'';E+&
M$;!C`J8MJ"3$[,TJQ-C["0Y)V(=K6&DH-S&HJ-]9%=RQ&B9Y\^5'2&*IQR+,
M4OQXNJAML7O8K$X+X)(?!`_=><@:)NE,*!CA@U"3:R%(COPB(&JE1Q,N1Y/,
ML["32N=%>"6&-VKAR!B.S9P.JUSG:@.Q;&(I5?.(EBZIHHTFPZ`X,DL:,%`8
M[D!@-FS&,&IDBJT2JBO<UF^],VHQ,T*(V/4`)#7"X)HDJ[;<ECY+'NK(]"X8
M:R-2HTL:6$L<!R?6WN^#J.3%\;KW2"6T,-D:!01YDZ)3N')=)D1(\6CO)3B]
M=@A_%0Y#T:]51J?#;CWE6(2ZXS8E<*3")AL"8V3>^<P16D6\L28X@&58J!Q2
MCE!6*%Y?#J*Y.&E)C..UG>.GP12CPZ"--F0ZPA=ILJ)$CTUS).5C=DV%$D$X
MN56MW3DW&%K<1L:JP9!+YN!N&P+60^](.M-40Y\PN,=J6L.$ANXD!&(87>J5
MXB-VT<]!C53YQR@,*Z'11)LB(`L@+;"1$BBJK4\D@`J[9K(YW[?!:JZQML#$
MK*LGCA3EN59A<2WGEM70Q&Q@)CFQ5L8M?8'Y)->R.%T1/5-T')J65:*MB6J4
MQ'\JW'X$^4"P[3?[BA^7SDDE9(^`WI%W^@NL7[#&[,%NM4>1>RQ^S?\`G1;)
M(!DIXIXL_%G@8.=;M:DOI@:H1+R51-];1I,'&*3Y4I21B=`5)6%4=BH0K-[>
M.L<@BE"JD4;-G(YR(FR^C60"90VBY".19&Q>>_`5C6<ZJ:9`4_F;(F`VL://
M.;=2`[,!.FB*]0L7J:;(^3-3\J?DPA>@>DIFF6]2KY*U\<##0D*Z?]0URCW\
M/1K(1R*&V==-"DG'IQO9^Z+9'<L:.(T.2VOP&U8!HK=2(S>#U7`3GRZ?QFJ<
MU[CU>"Z=2Q26G*AJ&S63^U:LEW:PH\J/U^KNJ,8UWCX<?J=9"V3CMAWYLD/Y
M'.=@PC6`L4$6'W4B.(V(53UGL"I.D*96B*1R[!89&H[4Z=)IW1LG976SX<B+
MA]?(R%5'+E)4/6C'12?NZ1$:+F/M-TY;JUJ[[5DJ?CUBZE\NBGGP/D$G:]BN
M.,<^3R;CJ6OGRY*O!\5"*9K/[R@_6U;ID]"PHV!&O\\8K65;8MKW]DTL.G>R
MH@]_5^7M`[J[R&\E\";JY-9=W>%E7)7J9M*5<2$>""8DR6G9PHRXG!$P4>J&
MPC9"DEQ#/7;JJ3U-&?<T48BI:6#*N5;8W7U-Q+IF$1($JR@,K*U8DQZ;[IVX
M7;(B\=6`<GK+;MSI-`Y78IQCU=OYS/'7CIY$6E:R55.Q]@C/.5TD*']52<EX
M:KI&44Y)-TP]O%E&R3&/)[,P@V\YL$Y*^955O1217=%VXPL&N_AZ-DR\5E@'
M40BV,;'W#QSJ4L.3UHPZ-J<,;`$PIB$<4LM)LD($16G5GJ\;$EUC@VNY0NWD
MW&*P*NV<1:F$6U%Y>E1!Y1HENXK0.Z"\T]#GL1JZH]J>]*HY5H-ZS,#2%YL8
M>8`8-EZP^-Q/+8'R3>]P7A2(-VWJO4J(F@HF/G3'#RI*NB6.(BB5,?'?('E@
M3VS)].&8.^-D:=(L=Y^HP/CT6HO+5\,3&#&RUFM8,;48QC4._9K6MV1J)JQ%
M.AQ9HVTQ'M'+CBD,:_NHZ<D:9KVH[9=9"$`AA$.R,U@A,:,;&^'@QC$1K4TX
M,V+&F!\LENZ4H`I`^2<=EX%:YNZ:O`1@BC@'*:@PA&T0F)VX5V8-B-:U-UU#
M!,C1Y8'1YJN#)",XE5L0RMW&5KF+LJ:N@10!C`8L7@&.)@1-WBB5>(QHUB;Z
MI`2XX90'][S#($PPG[09"IR&1',=LJ:G`AQ@1`I%AJ@8P1@$BJQ=U08FM:BK
MK'020BD!),V($XV%$].F_P`'C>CFN348,&)&AB6AA/444`HX^:RIR*[@)K&\
MEV].L2"8;"B+DE(,@B-1XR#?91FO8]CD5KV/:NRHOIU7"@PXL(;J8;W#B1Q1
MV*[N9"<E8%K&J[;6."*QA!DNZMA!D:CV/8Z8%',>QV[7-<GI35(R!"B0F/K3
M.>R)&#&:]W<?"<T+&(Y=5#'M:]C[."US7(CFN:LD:*US5\%14UB/80(4'JMO
M.KV<4$;J<%J>/4Z+&<^/)=M_HZ3Z>J!8%?!@J4L_J+#B`C=3BV-QY]$;.7'?
MW_<J30JV!#*20%I"Q8<>.0C5B$<K7O$-CG)R3?Q]_P!S\5UWZ!=]_B4;_'?^
M6?6_\:_]I\+^'44E4ZZ[")>09>51L<MX]#?3L7$&9WL6KM9,NO9&+WCHY"(A
MPN*`;QHY%?JU--;?!HI=X21AD3*;D%_D43'5KJX?1L+*/.LF.&MJ.2X`G'*0
M(7(USUV36'1,@=C]/CYI%VZ;F.0XJS*X]'*%&@K!K@QI'W%")>\B+UC>K]R\
M4\7)JGZ=;`K8HI5X"!Y73FQ^NLZ\-[9,A7\.DD.=(K!9!'1)G3?[YMT]54_<
M2/UG]GG](F*Z3Z7[UY$^QK;F;1L*<52D,4E8$6K2NKW5TAH!"[2TES;@D@96
MM>LH#6M>[B+X5VF3.MG!:*#MYM'`!K;OOKI+4=.H@!ZU.R$V'TW)S"J*G%RO
MZVIT>XQF+\G8\9"]6/C\.9UV+5SILF[M2OQJ9*D1628[([%CSA/&96M<$O43
MC<]Y2PX?0$=7D%C0*-]1-2]N80Z6/(9#C$G@)31(\A7*XKMW\^7`HVI>&CU%
MH<))3584,"44;T[<*;M>P2M<F^H9Y=78Q0I'FHI9$*2`2*Z(9$12$&UJ;KJ]
M^G$_!`ZH?^??@$G4_P"](7\AVL:^_O\`!$U%_5^#^%3]8?\`K/1?Y4BZK/R(
M+\*DZQG\O57X:'5#^2S_`(0FJ;\J0/PH6L-_N+[^W4:3Z::QW[+8?R(ON4WW
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MWMLEE5]>0K*RU-4Q;*W&TU363KT,(E-"L+,3N01%.US_`*:MWD?K/[//Z1,5
MTGTOWOQO(:B%()`I(MDMFWS,4,-N,U58QXM<!GF3E>9+"0-ZL-%%']5"*;D-
MK=6-I;...">->I+<6V6<*XEV-Q73<?+'A]8C8*8Y3!-"=Z@D<Y^[>:+RU>_3
MB?@@=4/_`#[\`DZG_>D+^0[6-??W^")J+^K\'\*GZP_]9Z+_`"I%U6?D07X5
M)UC/Y>JOPT.J'\EG_"$U3?E2!^%"UAO]Q??VZC2?336._9;#^1%]RF^^0_@1
M?<_U<:1+:IIK2,:W"-I,ALK2HI:PS:ZT.R9/GTSPSQME(%8(V(0;#&F,&]R,
M>[6365)7U\:"MS4!2?4R"R*VS*'!\3:5D/J%**.*D?\`S?TP;1T6+NGKJ35"
M1*`%U.FNFO86191*AM=61Y%3%M#@ER8THDB8OF85;$"WF=C'N548-SD/:Q@]
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MG`+/51-]U\?WQO?IQ/P0.J'_`)]^`2=3_O2%_(=K&OO[_!$U%_5^#^%3]8?^
ML]%_E2+JL_(@OPJ3K&?R]5?AH=4/Y+/^$)JF_*D#\*%K#?[B^_MU&D^FFL=^
MRV'\B+[E-]\A_`B^Y_JXU"'B4/*I=;&H.]!#H\7BY#275\2VZ,BKRWK[%2J2
MF$NS!.8_F7EONB:.V<7-"REMI#B_+6CK\:D#7M(*=.DHJQJ0ZW'TV^+&U7?'
MJ5=_'5$./C$'*JA`WTN766&$3<W!.NX;*QV/U#15OW=0'MVDEC;8^(0;;$:[
MDW61UQ:U];CE:@"T%<N%S,+%CH)-OD`(>/A%+#%':C\@A09O5$-.FLM6O]*-
M;[MA+E%8"-%R#`I,DY7(P0(X,_Q@IC$<O@T8AL557WD35#`;D=.LW)H0K#'H
MJ3@]>YA&&XHI5>/ERD@(-BJCF^&R:LK9V64+:RGGI5VDY;&/VT"Q7T0I1>?$
M4E?]ROCJ#1BO:M]Q95[;:OK6RQ+,F5CT<YDZ.#ES)&<C%]9/#PUY]\L,>\E\
MS2F\T\SC=EYJHU,E?U^?#NU$WEP].VIE&2^JV7%?6/NIU:Z6))D2I&P9'V!P
M<N8XC6&:O-?#9VJNX3*J/RN[FNK:B?Y@#M;*>T[HSHD,W+B<Z'8K>*>.Z:N:
MY<CJ$G8[%?.O8G>AZ]3#&WF23/'RY1PL:NZJ[5";Y4TG2R@BAQTGF`.-T5"L
M"HZY>7W4Y"D:WU??75^JY-2[8J3I9(O?@VHR=5P>%EZWW*[K,5OK;>*:HH0L
MBJ"2\GB=]CT9LT*FN8?2>;N:]G+E)#TAN=R;X;)JULWY71-KZ.:E;<3%L(_;
MUL]R[-B2R<N(9"K]2OCJ#2+>5GF]E`\TKZWNQ=Y,KN+G=['#RYDC\6*O)/#P
MT2]^6&/^3!L6U!;/S.-V0[1S%(V`X_/@DI1IOP].VI5"N057G4*N6WEUG>![
MV-6-".0LXP.7-D9`&:[DOAQ=JLMOE=0^67,TE=53O,8_;6$\1>@6)$+SXF.P
MOJJU/?U<U_G]5WV.Q>^O8O>"Z]3#X\^YGCY;QP\$WW=[VJ,[,GI7!R8I`8^5
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M;BGCJXKR9!5,G8_$[^\BNF!0]5"\/NJ<SEO'#ZR>+M4DMF44CHV22'Q*`Z3P
M*.WDC<C"`@.Y;2"L>NRHWW]7[79/2M=BWCD;5G@WI$Y]+^<4Y?<OQGAZWOZH
MHC<EIG2LG#W&/`2<%27(%WV+7-Y;R6+MZ6ZM[/Y54?E]!*[&ZF>8`[>KF*[B
MD::3EQ`97>'%?'?5?3#O:Q]K:UZ6M;7MEB67.K5'U4G1@\N18RB3ER3PVT>\
M=EU"VGBV/E,BR6QCI##9^/W"0_/@V3ZOP?3IU+Y_5>;,K/.G5_>"[MM3T^MY
MBH>7+M.EZW/T;:A73<OH'5-C8+4P+!+&/VDNR3;>"`W+B22F_P`%/'5Q5KD5
M1YCC\5TZ\A=Z'N*J&U&.=)G"Y<HX6H1/%WT=4D[Y3TO9Y*=8M!)[X'1MY".X
M*&`_EM((C_#9OOZOT=D=0U<53?(T6:'>D1/2MCZWW-_^K5%''DE.\^3B<?'1
M-G!5]T%B[.)7)R^ZFM7_`'.KB>_+*)L+'YC*^[E+8Q^C53B$40XLY_+8!WD:
MK4:OCNFJVJ9?U3K*XK_-JJ$DP2R;"MZ2G[Z*+ER-&Z+5=R3PV34B\3+J!:>)
M/952;+S&/V8+$B[,A%/SX,D.7ZGTZ2A6]K$N5KO-TK%EB[Q:O@XG?H#ES[7@
MQ5Y^C9-1+[Y74'DL^=Y9"L_,8_92;#_D83\^#Y'^]].K>I^4%5YE01/,+N#W
M@>YJX7%CNZFBY<HX>)6KR=X>.J6;\JJ/M,C,Z-0R?,`=&V.PG1>&`_EM((TO
MJJC??U?,+DE.Q^+-1^1M=-"BTK7;;.L4Y?<R+O\`5:H1CR6F>_*6D=CC6S@*
MMVT3VC(M;ZWW5P>Y$7COJ[G?*RB[3&Y3(-_)\QC]*HF$.2,.-/?RVC&?($YB
M([TN3555MOZI;&]@^9TT))@NYLZ]0K(29#%RY'CJ!.7)/#CJ3?\`RKHO)85A
MY5+M/,8_91[+DUO8E/SX,D\GIZOI\=0Z:PNK%E[D$:!-)TKRDKXC`R]H]<R"
M&762I,Z5+:-7HQ'(W9/A<G,8Z#=@R.RB5RFN8N/Y%<7>/+07DRL97QK*,)(\
M,$ICT\Z;T-U3J]-Z^"(SJ62-<CE''A#?LOP']'GQ=]!>#T7_`,NL9+),,`UL
MA!1Y7(QG5/N$+.3O#D4KT:GT573F0Y0)+J^KB5\YH2->L2:PDB0^*?C];.T,
MD;E:OCL]-8?^L]%_E2+IGD]G"LO*XCZJQ[,[#]E91)DELF#)X*O2D@=\)J^*
M:QK\NU7X:'58>@MZ^X#!CRX$PE?)')9&FAD-4L4SAJJ,,-')NWTZIORI`_"A
MZPVTQRW@7==U,BC=[6R1RXW<!\D<4/5$KF]1B$;NG\.DUBEQ1V,.VJYA;;M;
M"`=DF)(Z!!1C=(PU5C^G("YB[?5-7W,;\NLX4WOV>8P^V.,O<P(X>U/+#Q5>
MH`4@S6*Y/!'.1/<_Q@/_`/EW>_#3_%/^4?8?X=8TW#\0CY0RRMTBVJGMXE9V
M\?HD>R.#N"#XR)2HJH=>8Q=/9S%YIM:VE]`I*P*V[X]-"IKR)D3@P8T.&*2E
ME:UQ'P#35M4D>J-&=,?%KDY)NN&S[,6/6%)"EW3)]+D_M`3V>UD\\N'%;`.R
MQ5R=S.@N"]6-XO1!O)X;JCFTCJF!3U=?_.*`@T.4MS2J#M;3D)VN2M:U+'J&
M1SG^'Q1%4?U'NH/FWJ.:Y[6<DYJQJM1SD;Z5:U7)O]/4C]9_9Y_2)BND^E^\
M\FHQ1)KX&-X_6W-R,-56S*TBSK`I3><SYBLF0@CI*^0HAQ%ZY2;;(OHU$@56
M-8_(D64RK%`4>6F/$'&LJ&?DQ5M)H*!_9SJBHAM[H0QR&M,5&(]5U7VED&G<
MA0W4EL6NLPQJ56RLNBXAC`,ALIE5-D5B]<ZG*4)$1HF\G,7X.C6!!Q(%!68G
M<V,R-!.RR@S)0[\M=56D:U-`A2W1)$6DG.&G$;7,<BJB[:),OAELCVSZ0-13
MVD:IIW`E9&.XO:R3'G4W=#7'GXQ!3@LGE*)*:J.Z:>.BU9<=IH5EOB@HD>QR
MMK81R7YX,>QD/O(-5-J@0:"3)>(F[^X>X7)`]-475$-,>@,=+90/MHI+PHK)
M1Y#;6U?%G8W#)4IYQ5QX%0^P,<KXS6Q7L]_?9LN9B<*&(R8C-:=+Z1*9"ILN
M':'BS[&*&E\Q>:.&$%SQ0Q2^*2V*YS=G;7L:/1LBTE0>PA#M76@B2RSZRT-4
MGCGJN@PP&&-%,\9$<YO38G+9S^+=`LK*M')FQV#8,W6DA^L&[F(XK`&$,Y8$
ME.K'>]'/C%]<:M=XZ+:5U:.-/-'[5\CJR"KT5;#85!M,8@POEI71^N]B(^0X
M+%(KE:BZQVNL,:J),>T'$=+GR:>%8V5BIK>'6=I"[BT@GZ->&4II+@AE$$/8
MBHC6JCVPZ6@P]:Y)9O+#U5:WS5E.F+U-Y`S!ED*8\)*BSGV)((]@-:I&>!%7
M=NJ,D>[QZO-<0DJJN#9R+)DV;*KTFSY72'#JIHT"*,[?FYS4W\/2J;T,25D>
M*$GU=M661X`)-RX[V1"MLR10%)1B@NL70(SRI'4J%Z2<]D9ZVJS\B"_"I.L9
M_+U5^&AU0_DL_P"$)JF_*D#\*%K#?[B^_MU&D^FFL=^RV'\B+[E-]\A_`B^Y
M_JXU"Y)?>9>=_P`Q_)VRJZ>>D[R"_P"]WLK@,B%%"['N^;OP<7FK4$G5X:RJ
M%BE>6JA1KJCZL%%CN@@*;V?X;(&V&Z*(3'E[4K.[>7E)?,ZCGNV5B)C`[2-D
MEE;'K,PKZ6LQG&Q9+-XRAT1Y5RL:004<'DLR##7=R_&-*X>VSU5*J.9EF(Q)
M5W-.&VH(^*R@GL+RQG&&S'HLB6"IA(4Z]N)"DV!Q\=2I$*$ZREA`0D:`PX8K
MIAFM51QVR)*M`%2N\.3UXIIZ7^)9-CU7C\.EM8HXP_-:R1E$[+(,%K[&ZK5?
M6-#6X^PB!9RY/DV'';<:*N;79VLC>U(7MIPF'A@YOW-E,7&S,QKRF##BD=W<
M:LEULF8LAC=A$]?J;[:5E578Y(I5ML#=)E6-S9P[5EJF?4*Q0!@1J&?$+`(=
MH$(59+",:]ZH-RL:CXSK^/6Q+96N[N/4395A7#7F[I]O+FP*R25%%LJ\@,V=
MNGCZ?WG,5H`M+)1B2"()B$.@T5HT,]$Y%0;7*B;[[;Z8L6N@QE$KG#4$2.%1
MN>U6O<Q1C;Q5[7*B[>E%T0/E==TC-5IA=E&Z96N+UW-(SI\7M<=>:[_5>/IT
M1HH40;3#0)FCCA8TH6J56B(C6(CQM4[_``7P]=?HKKIEJZXC.,5G`D*,]O"%
MNL)G%PU3C$5R])/[W[VVH4V;4Q"G@V#[1GQ3&#D3GP9%=UYXF(C+!PXTER-Z
MR/XKLJ>*)ILA\&&Z0,#HK#NC!<9D9Z;/CM(K.;0/3TL^"N@D\LK^I'>$D=_9
MQ^8"1Q]&.\+NGN)X`^JQ4VXM\$T<D:)&CDE$ZLIX`"$^27T=4[AM:IB;>^[=
M?W6-316?8?)VV?;(+LF2N\(^#*K^DY[S#Z+$C32>A%]947WMEBY%+NY\\\>>
MMVZ.^/!C@-D#L>E8J^S<L<#2,&ZBEJ/H(O3ZB(_TZQ\M9CBW`',LG3R0JF%8
M6T@L4875U'&/-Q3+8T7S#JF<BF%&"KQ(UTD/+Q@#K,=0-$ED..P2X,*%`6!$
MK,G2SN7W$JB#,B3X>2UL8(D[AC'B>QS1O:<9=4/Y+/\`A":IORI`_"A:PW^X
MOO[=1I/IIK'?LMA_(B^Y3??(?P(ON?ZN--Q";!P6;63J`5M(BYN"PELLI$FY
M\JALJQ0E:,9:1S%G&<_UG#9Q8HW>OJVKZE,8+`QW*)M("UQ&M?4U%\U*NFM/
M->R(\I!RU\TZ!55[]W@WWVUE\?)<VRC&[#&W54RD$SVD6U&Y(]S3#)965+$?
M+!'@5JN)VKDC?5C?U/![$U!D!F6%E%':Y/"A6UE;S+V1<0:_)[>%#M6V=B]\
M^1&G1P->+J^+!JC4W:C573@2@!D@?Q5X3C883N#VD9R&1',7@]J*GT%30K0E
M;`?9@&H@V+X<=TX0E](Q2U'W`QK]!';:D?K/[//Z1,5TGTOWYHIOFL>'R&:N
MC0FUUY;V4V1Z\M_:UU#66DPH@QQ.<1_#BQ$W=MJFK9^44;;%959*;&9&O"-X
MGE&;"8>:RK=7PBV)8!F1VG*-3O&Y&;JFL2\MK+"PZ+;OK=C#D2^ES6JX=3H#
M)PY\%VW].VD_S:O_`$__`&:Q_P#E]8[]EL/Y$7W*;[Y#^!%]S_5Q[MHF8T%-
MDMMBC:MRUEA45Q[A0W4F'&KGU;[KLPGJY4^Q8)YD,D-AT<TKVN&[:!.HZ]U3
M6IW,$-6X5>'R]];*-7GAHRIDS*OB`\9S4[<I!;>A?W$C]9_9Y_2)BND^E^_,
M$5J60!8"S4$2.&N.[HV,1\.4QK;.#8!`9&N1XCC:TX2L:YKO2B@O9MU=2SC/
M5E/')Y6R--9CMM<V^,`D**L9*Z=":[*UCF$:0Z-:IW$=NJF!C\:WEVJ3JT\8
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M!I*L=69\HJLZKO@L5.+E3),ZILAC/Q/$_:)CN$CQU*F`0&05<Q,?#:71;1P_
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M354(N1C[2LK`X]P\C&V2?'@R,3L.CU06((L>X?8XRYW<C`T""D\$C(HVOU7_
M`)1_^&/[G^KC^H2/UG]GG](F*Z3Z7[_U_P"4?_AC^Y_JX_=&IA8^"T)!QA,L
MGEGY#'Q[JUZV3ZWLJ`1X$Y]]<]5F_0;TF^LU.?)=M2SBQ.:3$*C(Z/$;_)#6
M0(LRKOKL5>[H)0.C/(>+4FM0BF$=($YCW+P83;4C]9O9Y_2'BND^E^_^-4$B
M<L";=64UM:\D*::(4E=36%I*$::$*PX;VP(A"-0I&*1&+Q1=EVE7D?(V.@1"
MU07\Z.\#+(^^[+R'M:\T(<Z8EUYD#ME$-R%<3C\)'(G=^:G[;Y`]'K>1WG#A
MYIY)MOV'XS\V^([#_'>I_>_W,JOE=?MIH"1C]M+E0)'2*U6/Z,V":-,BDV7P
M>(C'M]Y4TYM"ZDM*=N,$HZ`>9Y!ETBSP>UD6,BQDY-13U\[E65D4Y1NW.41&
MH`8D)T6\-6>./OZ:PQ'),RQ[-\ALYJ3V942PJQTS[6''CA$M<]ES-I6/0ZF8
MH$>Y.F_PT&?DV*45[-CQFP@RK2NCS#BB,(4S(["%8YR":4[W;?1<NH]125\2
MJK(B/2-`@A9'B@0A'%>@@C1&LYE>KE_A7^L\=P>T6<*VR</5KI#(J/K&JI3!
M""7+ZJ.CFDDCO0?J*B[>G64XQWSXDC#HB2[RSL$!!HX[.OVQVI92)#6\HA_5
M*KFM8UWANNHULF6XRM5-(0,.R2^JEKY9A/:,HHTSNNW.03WHCD:Y515U+K8V
M3X[(L:]ABSX`+JM+-A"CL0D@DN*.2X\9@!N17J]$1J+XZHBERJE+'R2S6GIY
M<.?'G0I4]K'N>+O(CS1@M9PXJY[D:CU1N^ZHFD*ZYJFB4TF.A%L8B,61#:Y\
ML"/4W%316,52-]+$3QU5"AR(EL2UF5L=C(%K3\PQ+1#+%M',DSX[I$(G17AT
M>H0OU#7>.I#39EBH71!H:4A<AJ!K&"XC@H60CI:=$:F:K>3MDY)MJ!4&R;'Q
M6MJ,1JNL)<US+"R$=.0"P(3I*29@S-\6J-KD<GHU(C19D.'<1Y]O#6@DV,%U
MRX-1-?"+/2O&9979E>S='<=MEU+QZSB7Z>6I2+:W,:K[JDJOE$5X*KOI`I"R
MAI(,SCN@7-;[ZZNYA\NQ\K,<#U[L,&UAV$VM9SZ?W3`A&/,&]Q/51JLY*[PU
MN"1&\G^3P,D9D+K.H2K?`.9P?%OF'?A07'=Q2!8!/1SY(J:!;/RG'&U<E#K&
MLG7=8D"0D9.4E03%D]N5([?%_%R\??TW%(=]7R;PE2&\#%"=I&R*T[U8(T:0
MU5CR7/VY<&.<[AZVW'QUE4>=`G'@XA6T,NSEP>F>02?D<MT:LJHD)_1:4Q&-
MYJ]3-1/1MJ[`=TW&[#&QAD7M7E4=M),K(<A'.CV!G&*^$2N.C%V.,KQ^'BJ+
MJ-=+EF-)3S#]K#MO/:ORV5*WV[:-.[KM3GW^H:Y7:6C9=5+[M`))6G;8PW6B
M1E;S20M>AN[Z"M\>7'CMJRKK!X:P%;&JSNM)UE4`AF):DD"!%:)UAWX#<P;(
MI0C817;#<Y479UO77-5/J6]7E:0K")*KF]#P/RF@,^,G15/6];U??TB-S'%7
M*LL5>B-R&I55GG;S!!1$E^,LS/%H_AN3T)HN/AR*B+?`\#4@[:`^W"O#J[%K
M6R%F#^*];Q9\'QU(J/)SN@IG,'`85P&:)XY=N2H+;6A7QW!'T(M3\6)51Y%(
M]Z_!X^,!)66XS&6V8\M6DB^J@^9#&3I$)`ZDIO>,&5.*J/DB.\-7?W&^OEX_
MD=ICEA$>5#JV17J(@CM(@Q;CF0I(BIX>KR5OCMO_`%GC<V196<1,:M)%J")"
M\L[6P/*JI]&85EWU9-DNCNJK62+8!`.^.5V_-HW,\M%>9)T4)1D:1QZ9YVNQ
M5:A^*>LM)Q7Y.&I1$!NBJ5ZO61U^6O+_`#.\[7RSLN'7KO\`'_E!\J/E#R\L
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M;&);C68WQF8R>9=$E,7[F*68`8$\.DF^J:79,Q`%-1YAEN8BN*<\]V163LA=
M);&IYX3U<4*""P^Y7]9Z.V1$3PWU?YAD?&PJ)D/%DJ:<=I;AC^98^L@G>7=3
M'?%K;-(YWL=&ZRG1JHJ[-75]*O;#&C$FXQF=#&(V69P"R+R>DVIDAIX^,5T6
MFBQV-1I6]:497[DYN74MR$H**3(P#$\<%70[&:2*.TQK(6W!`/E#I`(RIGA$
MB=1HG/81WUMVVZXY;6E?41^TN\OO+VOFY#,RYTB=>T:5<&9'E2L;IXW<-,G(
MB($2,:FZ.>[6+6!P8W81X6!NQ*TE1Y4@4F!*!?3[:/*KAEJ-YPCQ930*CGQE
M'M]4B(B^US'JT3`FRIF`Y/2V=KW8:0A*(W0GUQIT6',<(K'QF[-:-[MG[[:R
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M1I%N\<,\]O/<]E5S`"<_BK",1Q7JGKM3;5]8'Q+)+@];*]I,FG`R#8PQT+I+
M6FC26C-BH8]R3*B16##QN9VS7<F!9LY$P+&B63:FSC7)<IR^P&4T:Q6SNHUA
M)ME@J`)VEEBGV/3V>YC%$S;EJEAV>,%M0PL;]G%:>EQ2-9Q<?R29CU[/*,D&
MU^1EE%KX50U0R3@?*J$&JJUSRCV=KVF7LJ-*B#R+V@6!J\4H)`.+`J*VLHAS
M6",QA$',/7$<U?0YNRIX+_9Q2NA3DI(=C>@K[K)5A,L$Q^N?%EG[OH&86*-3
MR0,%UCL<`7/UDW5NK.KJ(;7SX8.,6W\4G%6--I!,N)U(6I/$@T.0LL7MC':0
MRJC'.8Q5]5D&',Q8#)BF)#F"#9S'NGRPV\JJDIB[7T@_-VP1QTE'0G;*,#M_
MH*X)+.LQVHK9N&Q[^$&386OC++E"U/2)9-IW+S96O8\H61W](KV>NK'\FN-&
M(HB\T3DB-7Z@B_5(J>E-?X^3_P#;!_Q6L?6K,L?OP7A"SNQ9,ZUK`"$E%1<'
MC>-GG\E[@^&Q/5]14UAD!EW5MK[^AMBRZ5!!9,9;0DB;+USG=*5$*XHVC1C-
M^"^+MO#4ZMJ+P\*"*/#>R.P$-[6N(%'/7D:,1_K+_#JVC7ML:P!'KQF",@HH
MT813\5<G0`)?@ZL@W\]L)QJZ05$=`#'=C]Z"=-"6A8\HV!,\=4$4K>3R5O4W
M<O#PT.PO5YSDL;.*ANB$:2(L:6\<4[3PVCKK!"!V^Z(K4CE^HU?6=9(=$G1(
MB/CR&-8YPW]4;=T:1KV+X+[Z:1/E3*]*?^ZUO_R6L2N!74&ODSI6,,GOG!C.
M?8CGMCI,"!QS"#&>[J*]SD&]4;Z./IU%@5$@<FC-*IPPXPH:%';U4N/8^?7C
M)JLZS4H)T48O4>@O7]9%7;W#P:NV-$B-BQGM"P45Z(YZ.Y+N4#W>/T]3X]O9
MEFA%`0HV/''8C2=9K>7Q(1KZ%U[0X0Y+;=M;$COQ1O:1C=:TXRG6%<AJIC&#
M?#&-KTB2>4SBU7JO!435@>QD^8BC74J'4W/:CA^=U(XT(H;+HA8..G*2<HO4
M:UOQ7T=]7]A7G=&F1(+BQSM1CG#)S8G)$(US%\%]]-?I/*_Z+7?_`">L.LH;
MCJ6V?5MN;,#(7<`"2"LE_06=$EUHI=E(8@!]0+V\R;(F^VJB+5N*ZJE)CB!K
MY%:UDBQC3UMPY5-E/X=:'*Q0\$32L8]!L(]6O1WA[B1X$\D</18[@T87)NK6
MJJ[D&Y??U&BSK`DB.]LA7#<,#47A&,]OBP37>#FIK+:H61U_;UU[B\?O(<*"
MXF.U5B"<L_KC(Z<U[TEA`%YY&[!.D)ZK?!-8IV:,#9FQX,JU@-K7.\PS'EC!
M$Q)XI#'G@NEUER>3P8Y#B07B[U7_`+X'K<A!;/Q,^*P)5>M?B%]D8UO5M+`4
MYI#4--:%$J0&B]4O%OCX>.^O\2R/_95[1/\`0[2-;\KFM3T(WV9>TE$3Z2)B
M.O3E_P#LT]I7^B6O3E_^S3VE?Z):63-I[J9(<B(X\KV19](,Y&^#44I<,<]4
M;[WCIY*ZLOH!"-X/)"]DWM!BO>Q%W1KW`PUBN:B^]KTY?_LT]I7^B6O3E_\`
MLT]I7^B6B1I8,HE1RIQ+'D^R[VC'"1OT"")B#F/3Z::_1N?_`+&LY_T)TP8T
MRT8QM:P8V>S'VDM8QC4XM8QK<11&M:B>":].7_[-/:5_HEKTY?\`[-/:5_HE
MI3RZR^E&5$:II'LF]H)BJUOP44A,-<[9-].)"K\@AD<WBY\7V4>T*.]S?3Q<
MX6',56[Z].7_`.S3VE?Z):].7_[-/:5_HEHD>4+*I,<K>!0']E_M',$C?]R0
M9,0<Q[?IZ_1VQ_V.9U_H3I@A-RP0AM1@QC]F/M)8-C&ILUC&-Q%&M:U/>TNR
MY?OMX?\`]:>TKT_-+51;9`PX[682U>5LF`^K.D=ES8"KNI`(&.2,YU:,2[.8
MUWOKXZM09U\7=P<AO8#&+A]W)_FV)8%#7.0\:GE`+SBM;ZR/7EI"QY+P$3?8
M@<,R8;TW39=G,Q]'>*+K\<3_`)K9;^8]+M<3]]O#_-;+?S'JKO+AJLFSI%TN
MRQ"056&"^LXM:]8A6L*)25H!.]9$5=]_WW^C_!]'_P`^R:L^UQ!EA,@K&$2G
M929'!L8DFTF2H4`1>]<B3H<<@&O/,`WM^F_ZGWZ&YDQ[O%1S\P!$FI55,HUQ
M%Q]C2B(4\(\"U,-Y9PEV5`JCF</#UO&)%L,<DR9:1?`EI0W4&5.`5L\HK^PD
MUL'RJJ2(P(6G@(#N7O)X=)?41IXN.F<LR%7RC!MJ*VB1@K'H+"PGAKHD>3(/
M'+-G`8(?5D2-^3?0J\=7PIT&)50H0QDJXBQY+)\H7<FC'F!FDF%CVE<$X5$I
M6@C*AMV\?#^IDQ/LS5T*7YM'AS@4UR2Q>*%B5A?#M:RU\MN:244DZ)T$B,AS
M)348Y_1>FL=\SQ&VR!TP=K,GSVU$WNP5U;=3A$^*C1H*R"$JRQ.R<2-$-,1K
MR*'QU6EM1!CV98$,EB"/S[<,]\<;I@@=17$Z(Y"N1O)=]OWYO/R%4_;I'[CV
ML?K<_P#MR/ZG[//RU>?]TKO^MO_:``@!`0,!/R'T#>-B=VF"G8&K'XK*8,)\
M$H0B$H/>"1QG$#@?A82ZYHSN.D`:JJ'*(`&J:NWV)98P^4S@2*#Q9&?&I-,,
M#;;V(&9LC44/0.335J3.$A#VNRA*QYP8O:IV[S$#"XIA-,I#%H<3\%IW=&Y>
M]1?0S!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8S&@6$4>D"]?L*E^X
MP8W0A^J2#:&A6:J#3ZT[F<!A'(+PZID=]L""/#\$TW'/@2BG7]E5>DPZ!*T"
ME_A>R%F1"BH6XPJ3?;#:RZY]5U`R_G1CB9PXCOQ'VIT>`5M0U$.;6*U8`(.B
MCO14^,7J%POHJ,V"+/\`0/L0"8+T;8+!-)1#G#4JGCJ[,Q(=Y&YJA<ZXAQ26
MA?E%G`Q;L=@:'K!ST5>SI<'_`%J7[C`;TQ6PZ[1K`5J-8S.<6*8B.6TAZX.Y
M$//HZ!-`21Y`%.55Q.0>\(BV`"Z,*LU0R!X995`"N"QY4AU@3E0I!MA<:OE'
M"M:2)6IN-L7C6,#6/KI+!JGG5FF.5&%Q89P<"U@"76HFU8B#2?JJ=\R,[#((
M--=%B2;CT1^EJB\A``_M7GQ2%$:!,ERP3E[H.2M2#"5T`J%WN@GI@$">$!BC
M,HBQ+@)`M51\%L^4OU74][02C8SZ:#8CV^BJW^L2T@'(&Z`D'H?-@&(+MH#1
MTK>P,])>CM6F<#.C6:F-59BLID,];2H+$X#.)P?8(67$RB3HM@,"Z.H1@E!O
MX&&Y23R<(.P/3XF6J@@-.TU$&G1D4D.CI#3U5/*7008!,NR"LI4.!A,D0DG:
M\I(MNN@'$%TJ-(M*J908G1F@O)&6;AX:T68[,L.L<`W&)T3]$$D&JB,N6E:"
MSNTL9QD5O961B%0_9H3$0+2F:AH0IKUWJ`,PP4&L[7(NETJ+RR-Z&YFJ?!1V
MOR+T[JH-6*7HXPLWT9U([>`XKDZ(PRCI3.91%(EDV,F1R^YB'*#*,JN&.`VZ
M,'U^C,S;4XVQ,^ZLGZXOR$LWDJ_';`T;D3`'G'[-8RC,%L"""H&J74GE1B\)
M`AT-DUQ%^Q3]IDCW(8X6T;6D`A5#$/?\.<:3!1%6?QQR`HPY>!DBA^!E@V$T
M.5:5`HSL$#!M.Y?\B`?-D!*W$4MHR7C*%J^7Z2`XB].N.^76X.[#H@O>D8$R
M9`WO(2#Q>)P4O/!!Y/!4G#^A80`5"95UQ@A7*[8ZZ:WQDW9G+Z;H*3#/>D*I
MD%@;CS`79-Z9P(LK"Y)X.R5CS85&V64&Z5PL%?ELYNTM)(I<S([HLEB.R-\$
M+6@0>B]YB46F2>PGG)DLW>.);7Z3A&R06@+R`/)2\70HI44'#5A5XU2,S&S<
M/M+'YBVW@5LH*7M=4ENM!J9R:357.^E2W<8!<"4/7G.I9:`*`PMEDT^<XZ5)
M]!6`D"/T;-*U,J$W=R(P*@QV<E#$268X/0DSYK"32$(%R]W,6(1--J*BH82!
M@ZA]<U2;]8*7[C!4)Q5M"D$%BDTH%BJ(.6E9!(Q8.$%K92I!*N>ELE2P)ROC
MFI%C_#A#W[;6QT-,X>J-:YVM]AZ*9IHC$+!,.#"L-B3RN'*#7<P'&<4KNEDD
M&ER<GTTSV,V@WC!.$Q)QW26IF=BK!>R=INB"/W2)8`4.BA!2\V(>(+/!,)5C
M(R7>%Y[4TNLT(!L$P"3J:$C$(+MT[=+SEN&K_F8G)MV9%;U!-T.):%&<"C:%
MAFV">"-427*SP,8^)7"0%LB+UD)D/V)P]4S&B1!)X`UU9H%&D>#R6:]C-NA:
M589I4PL`63*Q*-8E22/5C6)8)_.\V060[X2(N??;(&*@B,;@_5;`00K,$RDY
M?(O-L+B@X.'9#QM-5800M"=6UDV1*]D1,#;2L<<5AD)R%Z+N$L0CQ-JL69"X
M$7<HU#EHDYU<M[ZI%1:]Y"Z3BA%#BV2%%J)EV=Y[%P)6:+BTQ=@)28+D*AQ?
M35F)5Y`4/!"PIJ['\Y]@8NN"'..DECUO'QRIHZ+OJ"S9,%_6#3O:D_)IFBUB
M@N]<P/'A*PU2%A4FJS5^XR92+1Q"KE"6I4#]&E^XPU^R3OE7G9:,*>P=7N`=
M;0\M12&_]4`L)KJ2@J23#Z@(*-,A,3`\6!(ZBT9"R\%`A/!6H&K$Z\Q^/7%3
M(!T6(9@7)"`,50,Y<2_@8@1,6CKZ`DZ(VKEO`3L$B:8$%#]$!DR@D@P"]/Y,
M[3I@]R:]_P`U+VQ(2DNE.O`B",(`(`KCOL[VDJ%\8>AW$VQIKAYB52HO24Y'
M#MID.IB7&06!!H&X)J4QKQW&T0+)E,CFIV1^[J@"@.XH?.@1\Q4,0V;N1-E?
M!>DBH`_MI40+41KY!:IZND@J)FA"Q"1+:1AKVAJ0S:S$L:C&^>JJ"*_'(Q?E
M80=2&<[E!7PI3BMJI=0P8-D4<4=.1+YM/HXX2YH:N",5B$ZF.J&LPU`&Q9!V
M,V>U^H#0>18LZC*Q7TW:H6B:,Y.<V=PI^$\Z)VFJZ64JCK\MA:P)J&@`,#%7
MO@+VL2*$]\.J.^N0E3'P.;L&846IBU%P"W)*XR6=(AQ%U;>`[2BM.)E5X]-Z
M^I6_4$.FNE9!4I^[/UJ>D'.I<.'2-+2#L<WC<JI65BD_Y.YT84IU"P-.0-\`
MS;I4.!M7>D+M9H)<QRII>XEZ`@P/`N7'>V*)VM$%00'R?4E,N18^CA06]>(>
M@LP=?H?GSY\^?/GSY\^?/GSY\^?/GSY\^?/GSY\^?/GSY\T9:SLUT?&K_P!>
M4ZZAEM`*E&S5E?4\:WA^I"!$5<?M*-Z,:8AB@4B(0?\`J^D\R6AS)I!C=Z"Y
M`_JFGH"Q`<QX(KKV0>772:96>#G>?J-H`!]A<5L[7+TL$>O@Q68=Q@HF>^44
MO&EV-TV^&^"LP.Z@YY#+[$^)]CTOW"P44%89T7&U:E!_#YDZGR.&=5NNZM(/
M12&8C4FAE'`RED3AETIB3HK#48$"$L6NYP$1C&-?8A;]P2Z*61'+PYJV7"<V
MFT^853.L78^OP9Z($1K:4GI5J*9"(P\%7]OCM)(:W>0E::$EW?;\B[->D.*>
M8_7BBLR,QF9U&"76S5^PN,N9UX19#*D$8R)6&E.FH@F%8V]%V.\A0-CAEMI$
MHK?!@.*O74OW!=O*,<FZ%"N[9OT$-,&NUS(^OALU4(W;I_6*%QF.BP37MV.T
MYYEKJOB!U]VN@?F>K]K?P1;)(:2SN24-,0-5C3-9:T,J:IU/12_<7R07:&@R
M4H&7P64JI`Z``H5`7R!`4FN&J@5!&$0:N2M\99RI$^NJ#N&EQM4FU*$(%>,=
MX'&>:21!ZCIVA#/T['&Z%R"K6PG>+F3A:P'\&14"JD$SG<&?H2-9I:*HVHPD
MI,,84D009P[ZW0?!96R\>/6A(%RAR!7^)S2*P^!.T27'-TW*6P4Q*5>SK#K@
M-BL,:*K5)D('H[.WLO,K89!?,-0#^E5`2OK)10%-1?H-&TA@"/%7\MU.TL0-
MY=)M9M?]B#)R4_:"1%Z6)H"!+4&%$)QI239(U%,=EJI[4A>FE^X]:'&(`&3/
M@ZILR*H+PP&]^,)6W^-&@(H='!<P.(=3&(YZ8$Z$%5M"M_61OWI*Z_HU(DF:
M5/5\HN-(=911S+`FO`@5200[#`Z`R5OT!"E2_<>M#C$`#S?0FZC)AZ331W1_
M'"'`#=+C(W:BNB""8?C]9ZU,%%B1@3FR#RXJ[J]*UX/\IU1TUX$11$&Y:IXV
MP2Y4,ES0`+YI4NPR%%/?*YH\!`)N@9]I%Z/A:ZP$-M2='CT8(%0!S4:DG"DA
M."!1(X*V3-_EE%#!JXR6?,/!C`5_GH$U]3$2"0HVS.*5:A)G@S]&+8N@:YN`
M"5L!24>!9PC3X(GF"95A+^PV,.472RRP&?+)E1@(Q(;DB^*E%K`*LXP;\7DA
MY4BO0UC34>O!%9D9C,SJ,$NEFC%PNZ)+NAA@Y@G,&;B.@.SL$NZWKCSR\8-9
MDNY=O<.C-4Z*=J(E_AJP2PZ+D6'KT%Z62"(&HB=>OO3W^(U-ZHV`+-64P,-C
M@L+=#<[2U`U<CEC;K(1X9:81Q1HKK&0H[?CEPZ`IH-7F'LP>N@KJEC0J5%*Q
MDK1ID%4/<QE'X$8#6OKNC!7K?2"9#Y%0_7)`O:*N<&Z-J[Q*(;SJ)F;S[I@N
M*S0]PGFAPNP$K[486*E9:K2&I1[)Z:%S$#%0*(E!%8E\26="`F50XM;VL2,+
M=F\B34!A%ALW`8%YR!*[=#12F+#-MUH]!#6HAXO+I).70MWA;PQY/IX,"R3+
M8"OOSZAGP2,Y4*\8HU,ZK>.]XWGHBQ"SG=NH`G`R4=H)5UJ3]0KT:9)[-%05
M*]10:L(?WANR_7EY!+TF&"1@-O=22Y<Q9*[>905RMZ4T!*/YMLH8-L.L!+Z'
M)IC@>MM,/FF6'$K=5[_L*RZT.D%S![9/UVS0\L;6Q7E?CQ30CM+?^P%URRZT
M<-)YRK-"`TST\3?R/8(=#\LSHX^97I\7\0B4QZH70@+M<-89:;:EGZULW--3
M&=[R-U?)`'U2YU"?"RS)K/:CR2+VZ(SR9*ITG\*=M!9TZ@ZY:)2@"_KYI@RI
MFU1>9@.\D6=BP4/'\)('#7V-_A[9$)D'**`O@EV*&MC;]@1@1QWIUS,X78TO
M?T8:&7_`[%_?T(IJULSI?15^,!'!W;V5A&M3A7S+E%A\]CC!OJL++W1LH1F)
MBQ9I/CW5@8L39PMONG8`Y6*#X(Q[`)9HYU6%S)2=(\'U\@CIU`?12_<>M#C$
M`#S?0FZC)R[;T"`[0S8\[W*@CB:#3#NV^QA8?Q,!,:BJQJ8+6<F=)EQ?E$F%
M\-LO["5'6=DR%L>9I(Y[8(GD9CPLV8<@M,<2N*POS=Q;?0?@7)*]7`H5U"/5
MP\H>=PI<".D\!67L2AW,?+Y_`4C&+L?S@SC-_1:X#B&49LB>@P6*ODFY4G.)
M:]*FI?E0S%<(2OU]E%]HCQA7Z!4OW'K0XQ``\WT)NHR<NV]0@.TLQ9`L2E(>
MQLB12(0_*`*6)G1J?B75:BVC<80MK&D^[G+-F5-8E0<0&9)F"?[NE]YIT2*`
M(;@\NL#ANAU9CZHGQ<AUX=KQU\:M'E+&@%6D7,*DC/B\C-5EFM8WU,\PU%C6
M9_-7`OU-?(G";@U.$?61*S0/!M<)A/G)^'\!`S^)8JXLAFV.,_OG7DWO4E@3
M,4,C2('M)T<%QFA7Z2#K8`M4X5(L@+7$)2.4PS`[;M;,RI919,H@_P!]7$XA
M"J@L>SKQ5!F$G$:E.S)N1JR+E&J&7-&2"IE5I#/93ZR\2P.`65ZP]`"@JEJH
M0BUM!:[S2BJT!8*5%FBI"2=.A"6PLT6*/(VQA:A+"9+3H*PRB4!B"KN'`2RK
M5,N"[[GX)V0+HT$I0PG+6_;%&K&U-D&!:'S%505'%I?+Y:6`6R\RPBP=ZC\=
M49AB@'/JW")7H0C;62R"0U[!89B@4H%5T`RK[2TY@VK"E<0YEJ6LNAE@5^#]
MA$;YC36F6\686`!#\J*)P,(T9":P*BZ11DPQJ.&UI:2WHCD7A\%-*2BXSFGY
M_($'`4HTX(6GKH_D&B5K!JJ.=!Y]=IKE3X.=Y^HVT(DZ$;J'5+V1[4!I!4.T
M1J!]8'Q>'H-%SH9/+0F?LPNA0.M(EU]XV#.EZ1$%88B7\)M<Y^[.AH/CB+"G
M.LHP<+=V,;>K-"TMP+9//>=65:+E!^[$+YR9?E7S:P&\9LR@!J*X")W\;&Z4
M`&.\'^$*OK@"U=(]&F1ZT,Q]X"9R``RC@`@LDB+U6:2`U=MH@=0!5<``M7:'
MI'[$\LY8!IPQVXHLY]NMF.&4IG7X502TZG!75;")8Q9TILX`S92Z.L'^8KA7
M;GY9#+V"!2^G`V/#K.8.*O5='2%=,;1[?5H5!G+H?N!F6FN3>(:-X>0(!S7$
MDDH-XBS:Z35"'6/G+\*9$IQX"TQOB0A`U/A31TC.%C%K]'62!9'CVFC*L1G4
MJ77-*\@^VQ&X`YFAN)/UMU`P[<@0"NL\$:E:K;Z0M>"NQ<I;+V#J77&J8`+5
MAZ<N<*+W*Q)J0J`Y)G-+`]"]^W7,IIG=SZ-,!TO9$^-TM8X)H]Z0U(;2Z!7B
M@E!*^R,,XK6-I9"ZXW(H:X("AH`ENNXN0U-4.P"[)"`5,`3#;06"NJ?ES#^4
M!GPV_*<T0<MTM$&5@E=&'K35`$/V*)1Q%>7==H%[<P:9M9NP186UD.F='NE2
M>"1DQ%A%LUV&,@'/`8X/%YJX,9$QFE-00<2S.)"4A$3XW44M";N^Q(^>M@#,
M-07*HTXS#T804$<!LYF#KNG9EA(/#!O8!![2@2XZ0-`R-?M+PX.XH%"N0\29
M-TW_`$FCR@#,4#>)<,M:MRZ0H&>7RZ`2M)/:,W=IFZMUE9D&5:!N*`^WH&HS
MY8^JWS^-GUSS+(PQG5U$N(L29NAU?$PJ>]?YE>I<`9H4X#-M&V\YM^JZ&7SV
M,ARC106["/<ORV4#HM<+#.N)%I%*,\A<@2@A.B>PB!GI/+VV".K$0FNO80DA
M'(Z!M*:4DL6!E&CH(KBE`_T"Z_YY<*EN#I-90U4D")HZR`,X=3*Z'1*L(VQ3
M?=$$7,>R@;KY<PRDT![NK0P[I'1(>/\``9?R6^*#%\)$3(:F:#,;6;(RR51I
M@D49=<OPY"_QI-9R0ILL=B2RX'0])(`0H6Q"<,MAEA#?3_\`UNHF@4&BZ_\`
M&YZ+P6.D#7O;8"P`;RI5'9%)@J'@`(2<TSBEO%!-B^]?3#1$KMK:H+:E64O8
M$EK=U!6#D=-@R0]%T!4`3XYF;CCPQC!R@)QV0#:\D2A2JLYMD%OHH#DH/2@K
MQ?!JDD650$`&%:`5!U4@X(Z"%A=,/PVH6)2=@":),`$]C^:N)@%E-*-D:`RQ
M"@)G"8ADLPDZW_$/89-M$V-EFZ_C)9A)NL+T`X&&LS.AK!?D:&B,:QP-HEZ`
MNEXB\.EZEH``@:8OJD'W5D`6EU`1M0MH$VD$2"=W$0`($ZN8>H!YJBKJ1PD_
MU[,6K(5:M9XSYA\P&(*#84ZRJX:GN1&1@@.$8424OC$$DPB=DU6NBN\7HCCY
M"=L_C63J7SKU/F6(20'ZEO)68U0N0OH:>(^/I;-^`!9FA8AFJ`-66CJ>V!D6
M24%;H+VXKI#[RDG9"8I-<@D9W3>I]HGXJQ8DNU\ACS@9R_J(-MT`.X"SPGB/
MG&_#YH>YZ-_K,J8B2]A2]A&MHZ1"I6Q2-Y2.@$#4F2\MLDTVSU'N!YUL@H!'
MXPUK<%R*;54#9C]\@S8S452X>GB/CZ>C&V6+&#F0NDSY?)@*&!<(:A^F@VW0
M`[@+/">(^<;\/FA[GIWTV3*X/OLJ.F2^/7AQ!SZ!P^;Q%+K&V)"WIP]YCRTK
MLFK8_P"+RU,/Q!4JDLM:44..SJZ"ML:^M.$=2=5IALHNP'2,B/50+^;[7#@^
M^D%];0;;H`=P%GA/$?.-^'S0]ST;XIHKL1&:#R9*S1I0$7Z;?-">@9`!`+.H
MBS5!&NGYK$':JXK]"5.?8`^[DV$,?*J#@KU/"DA,POGPR['6(#"O/&)9X$H4
M%K;\B/\`Y"V.XZ&`,"ZRV`0>L2#.^O83<JVB+ZN1FL`I40#/V(D&756%L9JQ
M)T90)&NNIM:.D'F1TD9]!P;,+`>=M:]8HF)*KT]@LFTT6T#-RKJ"#:&V"X%6
MJ^D2PQV`Z,_-5/:"W8J1U^/#4W@-8J-4$[]H976W`1!/=WG@JQ*F%XZQX@"?
M$EIT9#$72&@:0LLF(5$7BLY2,-`4;@Z;J)B&:J\W1`3<9ZTN4%Y,)ZQ?+D`W
M'*2=#"^S:C'9PNA&2#">F>'JC9(@AQQI"YMFBG2Z-8+T;^X"W9U88EHD'MDE
M9:4Z$2/Q?,8M("4+FB>I\6]J;-T3IZ.6EC`:=#KQR4A6Q"UMM41,/34V0"M0
M!WG>93GX_P#WL3"('H96%'(E;(0O46(_=6EO"Z2J,M<<PIC6:!I9HI:".VF'
M2"3]B<&;:5T_]]8H:/9#.IX8.Q7$,&RTBK"]%77AK4!0[S^5_C?CL$QUF3ZF
M?Y5JZFEPWIG6!C'HQ+*6&V.AH+()20_C6G)5E9-HO2=!<S#CRV'=T(.1/M/S
M<Y!+P]Y7@?0A=58D!-3I+3QMEMA&9=GV5PH=Z(A<W!)Y)T,@SKPN?LB(6ED2
MLFL5.Z#OL3?V'?!!V"87&".`1=@59W@%>@'766!WB!'`(KV&9B1018_W::!T
MAA'O#E8#M(]QS^`/#EK_`'_X8G]#QTL*%D;*P]GSGN)CA!;4F\MS,89/CMT8
MQMX[5'<.$N^>))8H$+4_49!0C?@T\1\?1\@:WU$ZGQ.!BUI2)Z\@HQ,*0F&+
MC9*=A\U$,H4S;^59,!!!$&,J*"]:%V1%;I;VF#R=EUM-S018^I\IS>G4PZ%U
MG>_(J336KY*:C<&1:#!:0]2[IX*8H-R0JZ;2)CWBQ;R>8/)!7!>%4*@I*+P6
ME-DEHZJDV7D,V#"F2C[C4RS*P(](+/">(^<;\/FA[GHWP-EECOO[O/>E!.2N
MNEJIR*J4)+]*'MD)KP(.4@9,W;U_!WN'8++757`DMMQ#B80ULAHS3005YP:.
M06E]:L9=OIK(=QD+@Z)L)(,BUYI`H"^C&L(]ON0$NA!K'&5[!=!T**!UG>1L
M'YG0`(OO1%C<00X8%P<.IU.?37,%Q15F5:Z1(0J.JC&D%\W/<:ZEH$#4BB$4
M+[K+A*T@Q*ARK)*6U%74=?53_D.1BWF-/0I*IAW)&!DL1:L(]5:CNXLO2DF2
M*>5Q`^W?HLXT)XCYQOP^:'N>C?#&"6==QU$=Q4*.YJ@1SR4@L`.@Z6'>.,[G
MB`8Q$T#MOM<&[3)`8Q8(FVC"3)`J\=]1V`6R+;@T\1\?6;:"ME"PDJ9L#,KV
MI</DRC$FPG^9SS?Z;)6C.U-^3A^:'N>K?KPG'"(&"K(&5F"AMG&6!09STM/$
M?'UE14MN`G%<U,GI8DQ#>`,&U4Y^75,>7^4.+(2H,L(1YX#?J?/FA[GJW[+2
MG)]:I`,3%SX\%+=G>S@%[#8EH]-*4!,CY[/Z+P)%7D.=P#X$"\\91<!F$C!<
MC0/RC2.I?'EBPV:T"_7+!SL0@*Y#%(Z#0>:LU2`:RBDIXH@SJO#)Q99^A/7D
M9MD^Y"1(L[=$\I[D.J1X=O$?'UT(+;_K)VB3$_F'.\76U]=>EQ_"?I]IXCX^
MO^$_0Y;E3!3L,&>A^EUL+EFX0&%;$*&1<>S+Q'Q]@,`HSW9QB3NTKXC?U4/,
MB&3YN!._J=O]/[QZVC%K8LNS#^3#^]J7+`%T>@3Y13_S\)8,"FP&!$@XO=8,
MLS(K@U&&4?\`C?C2L3NHY*=4*2KM7Q7M8_*#"`Z\B@BZ];&$%(0M(ZJ8$JV:
M#%2',$)FI-[6PR$GK;!8GWB0&6CEB5$82IVDHA*/IDSG6P2UE1W#A^Y*`U8"
M8GT)!-*Y(\%MQ?P>FJ7W`\I49B/%#.DC5O1B"XB]IV5PF!3SE7D@1\JW"KBV
MAS2`M>=[/D;K>"PS,[.6P[TQ97,MA99?I![Z82((783D4V)3+.DN[P3)(@NF
M=E=3172/YL%1,!,"$5$XE!*@OH:(&=_F]@J_?A",@1%X:1(&B]B%]:6/!I*8
MKBMA9F)(\2IQ7!;,IFE$Y+<W*VN)K_B/`C;QFY)S$D!&W&08CKQ'*<!Y_NY5
MVG:?]@6T%&#?2CIP/7,F6=[A^NI8+6<S&G3M`+/`=ZHU\"RQ1RF^UZ#4X\%&
MM8N4^F1M)>K;CU:09Z.4\2^NQKQ[<2>GV!(KMHKS`>_=D\Z4*E-Y@XW92D`-
M3,_D91H`R(C$L%"69>^Z^RPLI15/1>Q?Q0!`;*4/BF5X;BQI'"&0:,QCL>P+
M$#FE4:6DX]`ZTH<4EP.?J;8*YF_91J3@S0]FV4G8XYR^;RVF53-$LU!CX8ZD
MC]:$V1%*%B)"EMJ>Q>J3/5B,?OKW!JD=&+4L]F[I;&O':!?LQ]!.1;KP8)@2
M)F\!AE/"%^]\3)DU6^ER08WE+9[LO0)`(7R1%DU2`MO`$M,O29^6BT,>PD8T
M`<@M`TYZ<.`X5'MPB]>CKEBQ4!(G9B)JUM7@#"35C1"K>8(VD$>TRJK*DM)X
M#]U2`<T8/O9\SO%]7-:*&,K(AJQ/7F2-:E!VU[11JA^VC-C(:Z-#C`%#+>(@
MU67!\JL2O/-D8=SA](HMQE2+:`#UO-J#</`/._\``4T%64JJ0"%C$=9!=0X,
MR09TG$\^[`V]+.1M^A"_DBHX>YF6DL'=T;H,P5U*MM>DTR"U57Y]$1ODOV%Z
M0\`$F27U"^K&IR>^1J;9N`8%.Z)UX`,O%>O$V;RNC?,!P@U26DQ5PL2E\5Z_
M+R^"PYGIHAP\G7*D_$KX``#BO7WPSQH6GWJ+HN5HI?FTU.REJ^*]>R42J>K0
M*T"<*@QYZ*""90``G6U/9,:UUB-Y7%?<X+HTV9HJ6E$(XENB4,3$,A"5H<Z/
M#SU83N*Q^<LPFBB(R5:K`7ZNM"@H%!5]A:Q[H1^LOB2?'IBT<6+2*(G^WCJ]
M$*`VTQXT=-<QN!G7-UWQ=8,E0E!<YV-4RN:Z[^D5DO1MK7MW5(`+.X?=4)ZT
M-D6A2/*E9Q&5EM_;U-'Q_]H`"`$"`P$_(?M+`9BC)M5ZNKJXH;%AM6..YN^G
M_P!>7LY[.>SGLY[.>SGLY[.>SFLY[.>S@&\H4$T92$`S>WV2UG>#FISZ_9+V
M=X.:G/K/._*<XVQDU':,3T&-A?XFMHB]8:X%\2J;K5M'L-_!]AO9W@YJ<^L\
M[\ISC;/B?">1%RKM.6[GV&UG^+FI!Y7Y3E&R?$^$\B+G&Y.6[D2$ND&`)GN<
M&Y"+=0E<,"Y-[#CK#7G&DPP35BZ%K0=/K[V=X.:G/K/._*<XVSXGPGD1<J[3
MENY.1[>@,S7O0O11<"!NNWUU[.\'-3GUGG?E.<;9\3X3R(N5=IRW<G(]O0&9
MK^<^2>.^8E`UF15Y:)M#I:**VT-GO708(U+'MW%M8NOEG^8FOZ`$ZJ<J&O"1
M<M#4(ZM+TG^T_J(A0=/J3V?X.:DWF?E.4;9\3X3R(N==ISW<G(=HY'M-'UC0
M.Z1_,?)/'?,\F'GOB#\/XS1]X'][P/'^+@.#DB,/]$_W('2NY/\`M)F&V+<Z
M*IW)6-(0Q>;76KJI_E8-E8E&S5&ZIKXX..MD#"FJHT54'R5S"^0AB<@J"F@P
M<LJ@*$G1E?:A<<HA$21,(FE.L$.]AX;MU?O]`66*YM)[66#X@"AGNP6G'=8%
M1^Y@]L>[%,H7`,@7!:,=EB"S/=@-&.RQ!2Y[L<I;8/S!E".;2(;D[9-.GLS_
M`'4SQ'LS_516R/9G^JE@![I_JIU%[KG^TSW?O/\`,E$'^9``I';)T#V3_&?U
M,,`=L?$_U49*L(WG#J9Z,`**N?I`M&$ZF!:U0TV@1122'!VBYJ]KC5)%5N5R
MKC58+OJ0V#HUPP>`GR/:<IVX)TN,WIRC?/&?#@:Y'M/-PY3OGA/C.3[IIBU/
M:>5]:(PLP4`('8N961="?A8WJMR$+,ZB<7-.4;YXWX<*7(]IY.'+=\\)\9R?
M=-,6I[3SOL`C.:<HWSQOPX4N1[3R<.6[YX3XSD^Z:8M3VGG?8!&<TY1OGC?A
MPI<CVGDX<MWSPGQG)]TTQ:GM/.^O$;'3(MR%=!J[2GJ5H<$<6'3:<PWSQOPX
M&N1[3R<.4[YX7X3F^Z:8M2>=P/$?7L?-M$!G7$UHM)1_:+E"P(I'J,Y0@P!9
M6TZYSR<.6[YX3XSD^Z:8M3VGG?8A&L[3=&7O0D8H)2*B;.9X3XSD^Z:8M3VG
MG?8Q&KCT>U75(6C^X)4#9GC07^Z6G+?O/.^RB-YWV41C#K+OO4[_`.3_`%!0
M_P#KS'CV2Y\%O08]^&_]2O,VU_\`>T_-JB2VP$R*:<`>A4SL@6*,KTXH?`PH
MV[D<@=C!OV..JH`_9E@^:!!-!<4;4&,;>T9J%^FYQIO!-T1/QPD!I1#8$!Q6
MKG"Y"N1T'X@O.D#DP<#U^I*-?A&K.01SP0GV4`4`:`&`.@<>Y.4+\1NUM@^.
M(-0:(T_F<S?S-<NO'O`Q!C]N=@.(!BK$:1-$31.'9XRMM7*O?B2$"K'6UA:R
MXF$^UAS:P/\`Y5__V@`(`0,#`3\A^TC&2HOBEP`\XAL+N[?9/+-GV5%RS9]E
M1<HV?947+-GV5%RS9]E1<HV?947*-GV5%RS9]E1<LV?947*-GV5%RS9]E1<L
MV<(G(\"V,U6"!5Q6_O\`8_*-G"+SLT_L<<LV<(O.S3@\1#G&^$45723(#/LQ
M/!,B#*V^RFB(FM(Z94\RY9*%-OND_+]@\LV<(O.S3@\1#G&_B7RY5WG,=G[!
MY1LX1>=FG!XB'.-W`/"9<BVG,=F!W'6'*LP@.!&EE8L3<.EQ)C-56T;6/GZ[
MRS9PB\[-.#Q$.<;^)?+E7><QV9SO?@6\'\)R'=`,&/0C#\REBPRU6M_K?+-G
M"+SLTX/$0YQOXE\N5=YS'9G.]^!;P?PG(=W"!S/9!U`,0KK#4=X]*4?DBJP-
MCM>;2"+EL&:BFJE^"?[*:7^%'HLP"Z<++'UJ%Y18[Z3_`"F(C3K]0Y1LFMB\
M[-.#Q'PG.-_$OERKO.8[,YWO'*]YX;X0J9RKA`YELX(^/^9YOYS5]IXC@>=\
MW#G>S@8JG%+/]ZG-7\1FHTN'X7]N_#@`;&@"%NE'=NS_`!O]S1<Z@,AAL5/]
MC&'V7"PS95VTX&&3W;+*KT3AX4%@LNL?L(@TWDEJ)ZL+[V:@)YEB5HZ)L8Z0
M*&S>U"_H`115[L!ID[L56;[$1IGL$2L_816F[`BMOW!*4HV"*VW<$%4?L(A;
M'N$$6-]B8%@[,NPU>[/,H#*LEGLGG@+G^:F(!#<N?XJ`T2&Y/\5*$'V3_%3H
MXD[S.[T!I_,YJ_F?/4^6LYJ_F(JE.NJ_S/\`.?U,`0&V/B?Z":O?=F?XJ:-,
MKQB?[&%!PHM=#KK%&UK!Q/:JBZWJ&1"`-`-",G>PU'<OA@\Y/E>\YWO'+=B<
MYV.-\G.-L\Q\IY&'DOC@XYKMGF/G.7;.%.DY'M]:ZR-P6JJNZUF8/15J5[A%
M$II,<&B49H@$*Z=4#C9)SC;/,0\C#R7!AS7;/,?.<^V<*=)R/;[`X5DG.-L\
MQ#R,/)<&'-=L\Q\YS[9PITG(]OL#A62<XVSS$/(P\EP8<UVSS'SG/MG"G2<C
MV^O<+*C`%P!5IH;R\N5#<ARI.N\YQMGF/E-3WP\E/#PYKMGF/G.7;.%.DY'M
M]@=9N[:A7&F9IE0")[,5BTW%;!N;2RP!H<##FNV>8^<Y]LX4Z3D>WV)PJ2T5
M;E;6CB'05L04=S$\Q\YS[9PITG(]OL;A7]ROWG08XR@]J,:L#J:AI_A3D>WV
M5PN1[?97"4L++6QJMQP0/JH)_P"O;UZQ`84%8-Y]N%G]NG*WT_\`>[.4;,[=
MN'H*J"#L/$_`"FH)@&`K2)R/<"Q7?'$I+;_$+=/Y?[AIAOQ:?P!<MG5,HWE"
M&FJ\'1XWSJFR4<[/"RW-D-U"O%&)`J-76#JLTY%B\-V91]2/F74:?R3F'^8@
M2UQ,6FHOO+0#/7$5'E@@=+!@:Z\4;4C_`$'HLN_93NBQ*N%*PFU@QQ``*D2Q
M'41PCP#'0!*`P!L<7;,W1E[T)F90]=%7[*G_`)5__]H`#`,!``(1`Q$``!``
M"2"0`````````````````````````````````"0`D`222222222222222220
M````````````````2<"`````````````02````2"22"``````````2<"0"`"
M"22``````0`00```"0`""2"````"2"0\"`"0"`22`0````"0"0```2""`00`
M0````2`2<"20220``00`0"2"``2``"22````````"0``2<"```"00`2"00"`
M2`````2`0"0```````"`"`\`22222222222222222``````````````"`0"<
M`````````````````````````````````0`2<```````````````````````
M`````````2`22<```````````````````````````````````0\`````````
M```````````````````````"0`2<0``````````````````````````````"
M2`"2>(`````````````````````````````````20^N2````````````````
M`````````````"`0"2>NT-L`````````````````````````````0`2>NU::
M00``0``2```````````````````"2`00NLF'IVZ"2`0"0022`"`00"0"20``
M`"0``"`"2>NU:8$:\0"2`000``````````````````20`2>NU:8$:^`#O+Q`
M`0000`"02`0""""`2``2``"(NT,(=2%Y*$'YY-=.PWK!);+;;)))+;;8``"3
M&#HT0C"HACS"@%F-/Q8BT(;U*2XK$$-V*2``0`````````````````````24
M09&PR,4=N(0`20```````````````````````"9&PR,4=N(20`"`````````
M```````````````9&PR,4=N*"0`222"""00"`"""``000""2`22",TXE$,/^
M*2``0```````````````````0"20``;PR,4=N(`00"``````````````````
M`2```0```',4=N(0`"0````````````````````````````3#=N("0`0````
M`````````````````````````"=N("``"```````````````````````````
M```5J(``"0``````````````````````````````06(```0`````````````
M``````````````````6(``00```````````````````````````````7(``"
M0`````````220"2`0"0`0`0`````````"0``````````````"02"0220`2"0
M````````````````````````````````````````````````````````````
M2`+0?R;R#B0$@)R```````````````````````!*R!24N3Z0\2!R````````
M````````````````````0`0`````2````````````````````````````0``
M```````````````#_]H`"`$!`P$_$/00.[Z*&5D3-@(@6\`.45O4*)%Y4@>&
M?5$(W0\2;X_BG88PHM>_%]M"T0,M]B@%H='-#(84BE"+_A(/?PZ'SU*QU/SE
MT+9:<@QSZG0W;9+P5Z[D;CPQV?BZH-IV``4EC``X@4^5-PL\XBQ:_0M^_?OW
M[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OM7VWER/G3ZACZ.--M>!_UO)PT7
M/XP@1-*8%VN'UG$'I;=V>G\3T1QZ0P0U,,@'AS$[`OA#+3.":%`(8/'0QZ"6
M^]!(]$OC/A*C+6/J$MI#FF&M)4PULJ,H7(.$+C?TCTC;5Y=KL'@:F!S\<]7M
M9[%%!+:3IX[26E<<8X"%4O20^+5X'MA+-.Y5`;#+(%32CE/!(\><I<\W))5@
M2@'-D2_&_P#5)AIMKP(T>ULXCH^4/$A4JPSC:)`+B4L"FOEA4D"ET@_(UU%]
MKL=;@X_@/?2>WH11!\"]I>01`Y!*+;'R-[F8<N)4`,)[1X@70DE"*1>PR&CW
MM`*M!$:I(M$)LD&C25%E005S=(;@`6(I_#!?I*2A%']4V;DA#<V>K/:'TY94
M(`0-2H/E@6"6`K0B2171]6/0$,I^):KX_P`\\';%@:*I&(>,\P5:2`4<5@KK
M>P)+ZJ6V^</L&_$-K+"-M"A[IZ8+6H/1MO"-;#6HZ7[G"R!EVMB[J@5@F4AE
M(VKC*!`*L#`IW@+$YJ!;;Y\RP)1#<+(J\*DG,EM-201EL-^]V.J+4A;8.<Q[
M^Q9T08RVK4I+89)E*7D4E@)I];LI+,)8TJGQ&V0H\^EH;_B*<2XJ#+V&:C#I
MR:U(#215(.HC>X#@^$+:0V@A710P55T7M#^@%3P)_P`P<LK*%EAK1K,.EZ8R
M&(XK8/B</(Q@/Z[(3"]NUQ5P)0JE79U[0:U;(DRHD;9W!=#]H3U5R?H.`!KP
M(S%4MN/]VH$+``W9.T]]&JHL2=%\L6,GK%65NGLEW<%%$X;T2<=&:0E!-.FD
M87^O9XL0!\5&A[95/?(\FYQK;N8*8DUR[LU*UL(,M@P#'8HF"#].S4K'SDMI
MYWNE\,EE1+7*_43A]8*Q".+V8X$'!/*"E#8,V.,;LA015E`-44,74Z0&#4FH
M/P8#!-2A4KKW,?I]+ZI#`,MN7$H-<R1,N1@8X2!20=XXFI\006XF14"DS#R)
M(%S#":!=(J-(7JC*"($"%CWY=?2E7P&OZ,R++%@J\LG%.+H'LD:<N"WET&T/
M,*'?,]%E(2W"Z-_^D`R>0DF?'6*D[@W!Y&S,82FO%U\J`D46MQB>OE>6@IC"
M58^#>SMQX"E)ENBG[Z#,4-:*025ND(83RI%8@[R]_P!(0;M4K#C-5SIB:6;!
M,(.VM'U>9)P.PD9M19)57=)#*+_$N_2K\[29I6@98QMGG^$=M4$PBU=8PM+W
M43A2802\DNIY+86C9>W5]"LZ6;@IF!+_`-$"@ZB_50:;:\".EA<$++;XCD'!
M;VZ2,`0A-4#&-#*)UQ[4TY*8A/:A'+25VF><"Q`*TC$$L"$=RWUPK$:A%Z9C
M_3"O%70JI80X9%CV$;R\ET\4<<\?7!=4$=4BPJ4"DLEE"KJ*<77R(Y<(O=JQ
M%(;,"X(-&R@3W:T])X.9Y]-4)>(:_D1JBWD#-,]V4%C,3MO9,B(FQ&,!7*D<
MOS.8_G'3E2%)TO84F#DC;O0F+&`@U6NTF[40.^!+0&0NNEZ.^`3U'7R(0-A<
M\$!%G@&LI<O1]8LK-F5]!B!-9`<EU1AK>!B\#"`S2W&D==YY)I-#&IE`RVT@
M-\*6WW(K/#,KVB2V5.-8Z"H@IBH==$6\$M?T=<C)ZGB<@`,>E'9QE\4Z$`@W
M?XYO:?380$MI&S7+PH+`&C.XO=7O@PBR]/8@J5TH!H.+PI<DD'0'1CN?OL0/
M+D[MCP<%3:)X>CUQ(XJ)L+,7.N+Q5!!R)F/RGYMX`HN+2%E\DS(S;CS8_6%X
MP^6P/L((RNA-0(711)X036B3`@Y!&/((QGP^NP)@\I[<!M$WZ.<:;:\",6OX
MI>JO_P!,O+=\6?>B;!5H,;88*NK"X-;E(E:/,2/;WH+6N#&_W>HN.,3+G+B=
M*VC[4*!#0J)(<08.LDE\29[SHG)K_1B*4#$?8'TY2-C^:I":6B56:(5+T[+%
M',P#B,T5SLT0X,V`J`V5DJ,<38U0;&\Z%FMW*L$5$(H"%\[07/`*6,E0B^0?
MV3J`%7<.;0$LR_D#PS^\I<4[(68*]4K%05MH1Y!3@-6\.!V331&Y(?W9#N$A
MA..4`R@9*'-6UC8X8"7OEO6R06ES+,!L.7&E638\\Q[!A!<GT\WP-61@)&(2
MRG]F`&/Y%:A$F&(ON<SOPK17Z1AU5,,%07J/8J"1D<'7PXKY/86IE"?4A;;W
MG6F2P]$A)GL.2,^L`J,/0E*(-.]=JBFUM(Y.L+O"A1TLV1!P``A_T6OX<YDP
M3X$?51V9(SDU4`26>$B"^2;PF[[G30`N0XZ5->A@H)?YB!4\RC0X[JQ\,JW1
M_DAQ@4FS70A2N4&J_68F7W)FA5EP4)QRFF/P&@$)FGF[05)<0+I$)Y=4AO\`
M%R*E\`QM.0/CPM45!15H+`1H"SX`$GI#SCGQ@4.G)RX'8X`R)Q`CZ&L./4>O
M!.DN4V_0U*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E2IO-H9GE&`Y6J_
M^LJJ^L4GW1@7V`/SI6_4'KCN4:*4O'2VMT5>.JU#1=,!D-4RK#!`B&C;`LSE
M*E.\XFUQ/60L(KOBR;%P`X,T#OQ*?2#``'V$U9#%Y+?"3#@2-G&4:ZFY!!B`
MH\P0<EXX[%0HTK//\<';WV.6--M)'_K4'?.*`KB__)O.W/J!N<7=2^^3;:9X
M*"=C319N+#Z+X:\UV@*XK+C'"H<VGFF2),:PL6&Q83(C2C]AFVK5IIE(><.V
MAII'?.._7:GT$2D8UI\)L(*@2HO0303]<B!O#XI\6M#6TL5#ZR0*<:\9)(`(
M8N1`/,YFY"Z]TW??K3`%$OV$T[^C2851$"UE&%;<Z(7Q^HO!*#P'"Z=X7RHI
MP#!=E6"[%?\`0XTVTIBF9FE"3V1T>@"CV=S`"^OKPX9">UAG1"<&XH0\G."`
M@T25[QNT.A),;;H`>)UJ5)=<OP%""6&.Y-A;M4"S1>X`X;J6YA'H&FVF1N`T
M3AQ>ER$W+F_CGT&"`8B@#D&J?IJ*L&+.N^G)<D!1'UPR>QD<Y2G5&5/]'<%U
MR,,UH*[0@;T5RQ^9EH$'IS\N`MI@M!@'!8_T*6S';EGE`7RL3U1EA6FSR5-S
M$3"'B-U#O1@A0$5XM%3K(F)XP3\.62H-&753L*`(D)?X<C![8[#&8"AS4V&!
M(-`0D3Q#V)0<'#^&$:]H\\,`3=CZU.SXAJGW0*75EFL4GB7)H[%8=%]ZH0K#
MV78H4(\1GM]WP4VI*U4<=O2829""0_HR,ZMMG*/Z`TVT5.L`'A1&:O<1)C5%
M2\5E^IMN$0P;#1-TRU-8*RWJ`P)FUH&R%^LF-AS>'8EGF-<B@S\/LRVT<3]I
M9'+F4)M.`!$U"YL,C,[P_KX--M%3K``J:6PK0ZMPL'J6.K36)/=8P'\<)PZJ
M9T'_`!?>&0T44()@*83A^FS&/J^A\X"$&)&O3$4\M%GU`&`541C)$:E"T/OM
M0#OAHXQS`&BH+)U0ML2EP0IW$65W$)A#G>>R$J7^,1LJ72J*.[F^4"00[SZK
MX[4'CPRD)]`'A7RRN=4]F1X85;7*OT4==&L/`&OKU4@GO=0>(S)!Z1RB#?H5
M3*F,5=<'`!<3@\$$K%TL;)D-JI!!5G)L\FD-#,JKL,@E+@:D+KW3=]^M,`40
MQW-TWRX?[@6('EGEG6!:.RLD+PAZ,L`*V3H$=%84B*+:D!"\CHPD6#W2-3#D
M,A$VP1[^9149`,,23JQ%M:0M^Z()@",-"%[I2XF1,C%6!:Z#JQ6H"LEC"%]8
MDI/[FHIGPQ;0ZRNN9V.6_>:3A8OQ%9$`$=A';'O(-MK:S'19#BA=IKF6A7>@
MFZ[LF\]<3*:0ETPG&)'46GY&)K(<+R0W33=O`ZU';,.2S`A'0(DX7V41&^99
MI<`$KQ6*K`5<VB%A(2TM281]=&@?SH%S#D"GH$4OGR7"BBB%'1V-P)L7%EOP
MB!!;P(AI)%#2;UX8$E"@9NI&)S>!&Z`!].*F_CA';J(_^ZRB!)^Q(9U/ZPO_
M`'VK"8(0>\XAVW^SP&6T$XK!>TC'U3.T5HI#)WRR.L4+94"4'Q-JT$9F1+6D
M+@?24F%$$'\17.MI=GAAO91SKNGE0UI@O[(U+S3OWXC=J&1%`P-]R0)3I&$4
M;6O=32D\S$]5:8>X0Y00(H>/>Z90XC_8HZTK1UF-U0JB5UXI&G2'3@E8?-5;
M5/9AF`_Y.]UTM,H)8ZMV[^!>/I#A?/P_X?EC-(X9CU[=FOFD9FGD0SU#IXPA
M@'<R"S'*6-U(A!C3$C3DB_H#JZB5\0FN?U<C,E,0W#W@W)-1G:1P\9$3F@-,
ML-ABP;P,MU7]S;0RBDGKB\U/QE@G*5>3GC-K"(EG?G"PQ##JY@)'!2[;4HAV
M*+4&LKM+M&=:2R%6J)8.:%/=S""K;SVX?9SEP09OM?I=+,$!B<HG8Q(&/TB8
M2R1G5EHTKGN"PA25Q][UT3OX`6SLR"4$P8(5Z"+-LJ=VDXUG]7Q:;:*G6`!4
MTMA$^0;<49HVI_;3I+B*AP7+93/%%W$ZW`61(5$.H"JS<1LP5Q,-TR4P(&MH
M'D\!-BK++N!+.A=`J=%3(D'_`-I8Y2;I1:,#+DMSFP^+GI9"@*H`*JT`957`
M!*N_9:^2*T"Q<)5>QK)EX74L-<%U9&"!3H(,M7@0;,`E#4.I):4S]%2C'>6E
M/T/Q1#6.0#S#4<H20;-:$'7$4K_A$\*F5]>X.3X1IMHJ=8`%32V$3Y!MZ49H
MK""<EV8:P8`B];B]7DKJ"(E#3AEMJP'!H2X"@@*NF84LV$8,S=&9%HCO.8!K
M&A9K`>H/?%%64M1S5%0]S/D8-`EQIT.-BMB3),KO6TZ<ZO/$5A*Z^FP($HY(
MY#K34^$4GE)8G2-C\`P?,.E6<.Z("Y/^B>-9#*`8)6<7HPC35X"^V95JIT_W
M)3_))Y0@V%PMJ4:>$/88E0D%P?ZH.7X;AM:TF!/=*UAXZ_>3`I5"B6JL($1&
M%R38,EG2`>P"46V<$78\5D,1Y&^1611#'8!%<P!QLR";1B5<X<*1X+IQ\$0O
M,`]UEK1R!)<]55M4Q@`07IJG''`]2V6D>U1Z@T,@`5#(4%G%:#.J()!=<Z"&
MSO)8+M(EU/O)@[H4!34<-RX&MC`Q+`BY9(,*Y%]/F4=VKY25W0X(`LTY5[3K
M6_09J&<+W171R9H%8:$4+Z"ES,Z2#L,.H-0=`%L6B7)2X019C,0!0`4=`"U>
MP14#=;&ILF<V.%/+`-!NTX9`-A-8`PRR?)3UB4WE#I)B1).39TD#JT3\FE=;
M)'7VAL79@XYR%S+//>>P;);@&V*+-N3`'@S0._$I]8,(HQ^D4\#%(A=&XX?4
M8IY8%!&C-VP;_0;+(0:T@31T$SDFFJ$QS,1;OVVALU.O_$AD28K*1',_.VRT
MFY@$"QPMHQZ)H5!')&@AO0%I9E@6A-/<J\^:]J9$,7SUP4:*A8&8G@AS\Y0]
M::4+/F'<%BX#=8LM:H1(%E(@'J1:'@K@).(`!7$3WEA="B3:C%43?%4P<JJ`
M$5,[0*4P<Q8&JD;$@()"@`98UW02!(N90M'1X)^!/E6$'JK;#7!WCZQ";Q3,
MLM4X#E?(349':031."G"_<<BVS24![/#,YXX%Y-L@1N:%P;%L@7`#(S@V67#
MWJ_@#[,!2!0<C4K"*&Z%,EE+0*J+&PH7$L0/TDRB$S8SK8LESS,]Z.IF)JC8
MU60($;``["EHNM?PDY%H$)!=.QW,^X7*A4%4,8:PW%7.37&FS:NS'#]E85!(
MXK*F@Y%6Z)L&*#W?"B5J\ATE=`/F-_\`2)FR+,TG0%.WS9,B],0_PW9#>@]9
M.T<(=?HG(&`<)P_$TR73);=D71\YDG<+*,E<+Q,?15&7/C^,MV`8N_<IU9&V
MCAQH<!1,4,71KG@-:_`!J2O[1\OU(V9J(N+'86@T")N*Q`NRS(TM)A'@RXWB
M=;RF&3UWT`7D-`Y4,3"6CI)D#+=-`():UB@NFU;`PP/!\R4O5'RXG1XZ%R8U
M(\_9Z3W`EX%D\13"(B@C6?/`P13:T97E<\X8NN)UO"9FAH":-:#C#S7X66!'
M[XGRP"!V1YL,!!I\<<L:FL1;E.G)IE\QDA4NBW`11$PE*[SF:=#08VPL62O<
M/36/*/39<9#"3.+;3O"!R7E`"`$%2(T[.@EN@BW+T,UL&O=?XY[J81&B7M48
M+>`9DDG#UH*XWJ!Y-R^$H)/0S:?LQ"VAEI_+%WZ;7""GTY2Y$EC.O*--);[Z
M.A^!,AE`=.'AZ>5'$V4.,FK1`SA-E(;19:,L9ZMHY*%\/Z4V\BBN=:>K7$0)
MR1:#_P`0#:EXL%7S/_J.2AK"03L6K&Q5"/%3;V_:V.O0TRQ!"Y/3?+0A!4+2
M#D*HQVIIN%\6)O9:^84PC,1L8NCY%+0>RT4%]ME#^ACR&M+4=%0B9]18:P*I
M0MI.?BI#HN)+5L_["W,%@RRB-2U!$4)&LBZZL*JRDV\C0U2WQ0=W8XX($VW+
M=0(+;+Z8IO,]?JU)%K_:^<(1+XWH((J)XW5.>F1(2'EL]9%JWW#4(,0M4X8R
M98KRLQM.Y45>9`V49W#B(.-`DC(J!>29"I0P-"$9.*PQ380(72P05#>&HL6A
M%Z05N`<=51'0.C%NQ.\3RH&4=5C6Q@R54\U1)2$Z\O!Q)M5#:VQ=D;]K0Q+I
M)D(^6J7V\I"@M,SH[GE)I.--9!"L&EW8LE@!<$4@+OB>8S%`BD2":?[`DHR@
M+HCM'"_:N"R9$1CD",0^/.@T&+BM2?!V#P,H1*@*>@A.Q%M^R$6ODNR(4"P[
MI*$T-U5LS-R/R$0%CCJ'KQ@"+!XH]JMI.:IQ3]^L(I2`0/0R#5=QVB295<+<
M&3R2N9.F[T$4]FMZ4&.6[/I;3?3:SNEX<S*OLE+(T0I4.1#&7UF,Y2.$XVE:
M<N81:1E>!L2^[#E*AK$U(/!3X&K6M*@%KP3>7^D7S%(IA3XI37DVS@/Y-N>A
MHKR+.P4$ISQP4H23>NXX'+SRU?\`L0EY+#0):.R,90C?"Y>*-#"3N?[W4FZN
M&D@_>(P$!PE8Y;L^H>?K/8Z+4F,3'@:M:;B?`!6)O+_2+YBD4PI\4IKR;9P'
M\FW/0T.<U;)H:X0TA;SAE/6]&*ZKEWVOA6\$PRDK/)<>R_U9)<7LA4J.3CT0
M5H-\"4NJK7LD_$,N``CKN&HUX\37RJ=Z6]3#/KD]/#2T(#<9]2>F\O\`2+YB
MD4PI\4IKR;9P'\FW/0T!;WVJ=M]/`5=J5YQ''6ZY2%(>K5LG%W)I3M"GH6U"
MI"#B#T74Y&0/>3WQ(:(/-QDZ.T#5`X8LY3'SFG8.5JKCX5S'-IZ^0'#%X2H.
M._&]LM:+@B!R@]"Z[@5"+L:)P+[]E5%C&^._$QT4.>5IB"3=0KD<SUS2PCS$
M+0MB&6QU5$6[I.\/JR@I>)?=1"IOME1`N%4^`J#GN0A?=*-7@`R-Z*`;4K,#
MADQDD[G)F=#$6"BA-HJ'*&I(FLG/JKZ;%&+-13P"[>)>;*A:$W+!WZNK@=XI
MPJ/CNZ&YT+,QYB#C$^%AY$`"Q(3!Y-X!-4Q`H,>L6:&6*J!0FJS')^A:1.0\
MS"@HRN_N-6Y,`8@9/K(4=>E1C7DN_P#HFJXD.'H6A+,UY``ZP<IQNA46M"BA
MI!<+*!Q`%:VC(C8!A`@LJ+@MP#CG@)0:%A;M.+H`&6T*IJBXDDW.>9IKT,U*
M1B+CBSCKF1"!2H=%8ML-7KSBN%C#3J,ON`$LB+Q"=QNC2>;!=<34J,U'+19@
MBBC[,O$.892OT0B42(54/C>PP1C<T+*3:1SH*4HK4"LS)/O!Z2#J"E!HFE!:
MDJ?M:2(;,0H11&1?3($]:%IM!M#;QG(ZS<T3%\\B4W<()31F)JXL&#K:L#(D
M!9`R?*#8SBC#GOQR+60R$+19^%1<%FA';%D@]C@EAO"DF$!8=6<AG<DT1B";
MA,0@$HV#-[1(*TTH-6=MFPF4B3#TMZW5P*11X%"M0\R-A>UVP("0$AT$E>P$
M>XR3L9R"@E3)$3%VP(0]`"X-?.[D@E9R4PB)"(8`"KV`C:V3^1NC03'*C$&@
M"NP-K^Q'*MI=:7%V3$`X<TO*>>5!A3@V?+L3/J:B<52!`KRHXVZ\^`;>EPBT
M^`-*#G0A$S<<4Y-$M`%]T%J(N&.6[/H[Q8=A%<Q2)GO`MM&/M;@>6Y@EXD.E
M%?8-PBX.C@2[C!BI0%DZ;1WN!1.!ME%>L?3'^3"BK.&#_-<:VA?&K"D"CJ);
MGH9%0Q2F8U</`&H'[0K?Y*\5YX"(=Z]J`0Z]J.SPM;KE;U(</<B%E?Q/IS%&
M6I(<43>CKU]C!+S6OPKB:F%/BE->3;.`_DVYZ&BY9]1#S3D(832W3;.QHW;Q
M2(4]4$1-F%914\^:$L2\F@SM*CRY8&@7H!+(&:3_`.`S*HZ7TH"HTERA&:"W
M(C@]-+?<4J%Q$3%=$LJ9VK#CZ.V<?.P_%=5*P$+2\W+DJ^Y`$0VNW-_B[DM9
M"F!Q+E4,4JZR!D&B8"DX',H"8I;6BK@Q'$9H`0A':#;K^Y.QI26KE.0))AK9
M:(/7WKD$*@N*L/4D<;V<:;\K6,D$T>/%NM1X4G>%^]G<%\9L`7WQH2/&W*]-
MXXI37DVS@/Y-N>AH5VM7XBV;%#<1:),%H_A2D$Z_NE2G=*T!6069-+46C:(G
MAFY@(]P_-=6A@0&&$#BO'!11RX&.6[/K+C$8J#=7`7Q1&2$LS5@IUJ>:"Q(]
M,#(S[C;`)T0540`6KT\!_)MSU-#O"&(^\ZQ\W4\_Z5!##&]=.]!CENSZR4XC
ME87A#2!A;OWT@DN7OPRFQ-$3&UE4K2;/ERZ,C4Q].N"/Y-N>IHK[S3);GL:K
M[C@)U7X&_P!%B*$0UU!)G9B/*U&HM'OC6R")QZS'?Y2<_+_`*\13-"_(YMTB
M<BQ=MZEOKO"@F.]0\3Q56<HAE0,6RA+UPE!LXVU$3F%;TT6?H!7VYT`CA<4/
MH]7):X\I:_NA``H"`P`5`3ENSZ]#*G:;+0%,27,*T1OZAYO%C\^#'+=GV/\`
M!^-NZO<43T$QD<U],94[-?*!EZ.-%(3W&<MV?7P(Q>]RZ_8A<9R<R\TU8\QG
MHWG'SB_9.U^D0J!$N<3;P!D0&ZL`)_-X>)R"&<=WHF#T_*-Q%^J6\98&@MP,
M?*NO"IA6S*_\>"U<A^DKF>,)?H38(X?F,*#YX?`I,B5[P*?W\>,TYF!`5=<\
MZBF-C().G_&5PN!P)OH#L-I"[%X%"TI1$S<B/ZSHK3!X%:E(!?'X@%PS+^K3
M\7+K@E`7]Z0JOS6KIH.&?[T_KB,#0Z)U>9JI@8#`Y\7M_F.:!.4VXW2`]!.Y
M@34"%2/F,:VB2+?#*=K%P[>F-5J"(P(+VVFJB"9D-HJ^V%>32BFM*_5&X,%G
MB^!.R:F8^"R$1(L&#^.!Q:%(Q>,+CGSO\4R0Q8'=@J+=#/3#S5"&+36:'G_+
M+1`I*/1'A(BR2[O_`!ZS#J9!Z"/&32@LM^Q'/`P9`AYQ4"[WO_L68FQ@O/\`
MRVBK`F*"H4>IF+`F$#?A2:V\>IQ1@$:/XM7=Q>,P6A16@35UDB0V!3;*J9$3
M7-G!T:*5YJ[(,*%X#/-MH[3.H7^N@OA(G`Z$07R6RC0=C-(/,;6-B1JFKB%M
M*WB7%4B\N)3^LB9Q`K8O#W<2G[Y,?1]9AF';6F3YX*,1,8MTQ&<4"\BL/`(Y
M/[F>"X)RV@X.&#0KRLDM*E'@MYGL[G`\R5&<FO6GH\#E5>\-!/8V70*;&=F]
M+F=IX+:A5.X<P(2!4B_03DA3F@1!7POR\272!K9!9,7^/F1=^^*/+/GCE<(9
M;8LMV0AI]4/,14+3Y^=C?CGF,HT$';JQ'9AHV0`O9+`HHO+'!@@5UF":A5,*
M%Z1&=Y&9Q.4`>!DT"3EA"5H=*(A%-;#%N(J.EQQD@&$ZD\:L5PO?0LSU?K30
MMQPYY'84`\Z7&)1JJPB6*6/3,-YQ+=6[,!<:E8.UE@E6`6-"Y!E+0O!L4%8"
M/?$Z!KR:B@=+BCJ%IP)Z>O/!"@^ICZ=HJ!.'#HUU5*R%9+3@(OLS-L$[*X6^
M%84T<8L=+(U<5PTJV=!E/1F+]J#4JJ(T;:-EDQ;#-O0PC5.'T@75U7-:CR+4
M^GKB)@SS_P!\`3%?A0=2``\H9BD#M1P:O&[==0'*:J9;`'!42*GE$E70(5A?
M&[=Z!:F;&[3F`-10101$5$=1-0PHZTM5(J2<``'&[=Z[3A;E)I.Q07`+ZKC&
MFF!FI5\;MU3`Q3Q;7A6E:1<1<1$6$<(C1$ABD5CBJ&*8``GREWGXIKB48E+E
M]Y5"H7-/H%E1_5-[5IQ"@,#:J>A0+0<+P4G9X4:A2,@S#=`IN'5XB5>0^K,\
MH"6!1Q%*,AJAF&!T%69I;[X838ZH_P"F<@%>A1=K.9.36[<&\FM')MOTL\%1
MLWRX[#@E`3NE^F'*1'K1>:=(#!O:!,T`YO?!Q:+<C-F%L9/5E^W;5?)__]H`
M"`$"`P$_$/M)>]LA29;!5)4-6QW.L\:\R*G(U%9L_P#KP49%&1!D49%&11D0
M9%&11D89%&11DIV@PC>!<I[Q>?XGF9O*RL?9)AER7O\`94Y1ER7OZ)Y:0#BF
MZ:9!,^S%17<F&0MO90A8P].::+O7!Z+-UR]8%VW*81[?891ER7OZIY:2R#R#
M>/)_808Y!SXAKE=9S#;^GY3@+YQO?Q7NG&R`:[OQ'\?BIY>!GP!4V(4#FUOL
MD,?3A!R65DO4AB9,IC4BJZ!84+4!UW`G"++&=952^O%&7)>_JGEI+(/(-X\G
MP(?.]W$B\@!!>@%#?YE.9`SU6CK]=*,N2]_5/+260>0;QY/@0^=[O01>2<CV
M0Q..@'%G736](<LP/5!J1723"B2%R[;S6(;-BA^^%H/IS0XJ9:,;3FS^(@UM
M.T78H"AK;>#AQ,"+)<D.DV&T4Q=UP/*$9%"(FHCD3J/U$AHNL/DO><SV]+3D
ML@X\IF//?'\SF7-AG.^K/F,'=7798/M8E]G:,B`M7!(H#K$YGLG-]O[GY)BC
MI_.B%@XOYNS^&>'^2$)$0GLZ7OA_#M`5HUFOZ/S'QGVSP;0=;]EJ^V3\F_!D
M6UDL<M\>)_O/[@<\WHH_NUT\=IRC_,<%C2N2;7KTP]*G^8_N'.JY5DBT$`&G
M*-,&+FP9?.R)@P6N2BRNR33=(C4H2R$0@L6THRX@PDBQ(39\/'H@SB!3(5`3
MK!$<1R(ZQ-&7R(N-37H#K5UUBR`L`*`*!`@B(YAOT(L-`I"X&@N"4[,IV93L
MRG9E.S*=F4[,IV93LRG9E.S*=F4[,IV93LRG9E.S*=F4[,IV93LRG9E.S^BS
M7"JHJY56RKJL;,I2IILH&NT,E)@"#V!F;3W2C\+`XQH!![`SLD=8_"Q>TW(,
M7I!U`)VO.(_`QBDZBP^XL[>W$?@8X>=18?<N%190JA=T(4+5HZPZF!$!$;$2
MPCD31CU@7<OYE62[V):9W6POWI(L4T\G6(*EK87[TESE7^8V8]5!?=',Y5_F
M+G75$.=<C<Y5_F`(7];+;US=SE;^8V_7;=5^]ZS_`"']3IIVUC\:3_(?U*:!
ML#'XTG^>2Q,7UH4WK9H\%QN2KHF6^C/><J_S"2'30DB%K!1-$:82/!1MDDL2
M%E:>62)M"A5P.:0`5`8`ST,2["M0=!R-6:QOF6**@V4*KE58>*K#98@+!S3B
M\QJSJI^4?RSFO)B)6=?G*^<QI7S?U$UW=\$P8U_@(U1U_K_`$QHE:W<H?!P@
MM;Y^'/9QK=S_`-G#FEX`!DI.ES\A\1+RN.!+;LX=OU8#C@<&@!`.@`$IM^IX
M:-HLMS5Q!F:11P:(4RMN&Q+QU0/5A+TEM^>;_2MU@%WE3\A\3FNW!X+[!&$O
M26WYYO\`2MU@%WE3\A\3FNW!X+[!&$O26WYYO]*W6`7>5/R'Q.:[<'@OK@RT
M#!,F.4H4<5=MKCQ'*5MC,@;6+T<\0DDI?UG\\WSE/)AF1FL/D7-AAL#6-Y$\
MO8?B<UV^P!,X45#ZK0$,N7O!IW1%6-*:<@P>!MK`17Y6%529U!?!P8(!0P;T
M+V]*W6`7>5/R'Q.:[<'@OL(/K`"!0+"+0%I=`=(D"R$!2"Q$PB4FO$`N\J?D
M/B<UVX/!?8@-A-,`!HWKLZ"5U@[BBXBX6FT+FB9T/T#958NK+K2R]8@#0?QS
MS7;@\%]D#FNW!X+[(#JA;M312J'9X#4?U"?C_P!>6+%9QF/C$&8V6W%$Y1_G
M_P!\5`:?S#E"OU0M<4YX($9O(!74`*%`!>`.+O\`("@I7*.5WAV5`C34O!T>
M(9GA%!!M1'4-&()ILF,VB`["AQ%('`++9U3*#[`@IHO`='B`)YU!JD1!281V
M>#DS806@X*JT`95W>(@%`;=VV0T-;+NW;*@*_(PUNM9R?4J=9YFP,`@)8T@F
M2*%-,9H2H'@'``````*XK7>K7*TM4XZ1N&*5--:4"G;BJ#+2![!$_9@;823J
MI2UJ\5#3U)C3*+'#*4JB;6!CB8SZY9:`4`B(CDX<D*N04&U3:JY5RO$N&2$E
M4`0*`:M6K69W@R6:X4:++IK/_E7_V@`(`0,#`3\0^TAQ04R`I=;JZNB9OTII
MK;;NBJZZ_P#UY5R*Y#<BN17([D=R*Y%<CN17(KD#C00!64,#[04KYOF(K"G5
M]DNY.=]OLJ!7)SOMZ(.53'Q'TE@(."]G$+[(+G<AQIMVCK$-?3UYMJNM,CJ$
MVKQWBU3<#D#O]AJY.=]O5!RJ+P><;1X7[#'<'(^TTG-?]OP/#ER':_F_8>#C
ML9=KN/\`O:*]7'R'^?S<\;!+I0`Z%;4Q05W&.CER@P@WAK1E67\L:6`%4ZJ9
MO$#D(I0JX*Z,6#=/KZN3G?;U0<JB\'G&T>%X!/E^SCHF6HL:%I8B5D5O%N+H
M(I"W06Y?KJN3G?;U0<JB\'G&T>%X!/E^STZ)@7NMN/4#FQJMI6L<W(34$#+C
M)%E$;:6J*Q;<7O$+^V!#/M5:J@X+,[SGC^87H=NVU:*4*XHK+P&+^*9A0!`"
MAR"=0G*W\1$:%I'"/<^HNRXV`QYWVG,-^+F4Y7L?,062><;1X7Y_C,Y)SYG+
M]K"V=(!&*].".3S_`%/X9F9JE^[7^9SW?^C^)F)K_"B'/JYW_P!C\D\O\,8J
M.%#N:WMD_)O%`MTA0W4N_'\M>^.&573QD_AQ[\+`7$70E$35135*RG#]:5"5
M=-*%=%)PIY%7GX*DHEI6H.;X<#Y%P!#=A>4EBF;S<2:EDI(P&!J7D%\-M@%P
M<LKD#1BY5P`$MB4A2V:C+\E<#<Y`^&J"$.J8.L1',B(HF$32CJ1"H"N6Z=2=
M+J^D)MY"`%!5!$3"(F(X"PM(M&=!E"T,_0`@(*`J/,KPSHB>6-TEM5E]U)CZ
M]6)_(1.L:JR^ZESO<83^0N-WO54ONI<*:3D2=,(68Q.]UE/Y2X7"-$)/9"=\
M?H?RC#!2X0D]FH:HS:(9WPQ$HHI-8_,<%H*,`=K&H*`@V?XR@P&E%/:Q@39;
MR=(,:#**>UC4Y5_B'M-P"'L)B<J_Q!!KH(0K3"5B<B_Q``"HH#%&Q6A/]1E+
MKO.R:X(YZYX?N].^J:7GE6+OA^.,=)+!H+:SL\(1PI+`E'<PI[SFG^8C:M5F
MX;9O':<J_P`1"W083(T<5DZ/2!E%?/UB1I(^(H94-%AK68C795;%<JXU7,I1
MK='H8"ZZ0!70````T```8`K2+?T#&*032F+.F(`$T#_8(_!CA4%5\[/B<TY\
ML`4;O!_`'M-;U/B/A3V6<IW_`)5X>CE>I\O'G%Y+NG/N7!Z-9B7I]\=3VA"F
M`:DQX8T?5B>N+P:H:GJJK$*^LO&I2::++K$5ZD1VH@'<4@),.2TH98]"[>GJ
M8_*\IO)=GT\=9DWI]\=;VX4#4^PG9C\KRF\EV?3QUF3>GWQUO;A0-3["=F/R
MO*;R79]/'69-Z??'6]N%`U/KKMAC""8,,L5MYNJ*#/T.$O*.824<U=F.+2F(
MKR79CY_ELF#.DODG)DC!'27I]\=3VX4#4]_K_$><02X*"A<&#M'SC;%(E@6-
M*2Q&5**>J:[73;,!4.+3:472:]A]/'69-Z??'6]N%`U/L-V(40`BRT4+*T-6
MKU@83`0-B!1'(C8Y.)DWI]\=;VX4#4^Q79-XBR*JY6JFLHW"MU@W1P+):&+:
M@.4*T6K.K2ZLOWEEM\N>%`U/LIVH&I]DNU4`DBB=0=2ZK&L"9ZJ*^5I8+7X_
M]>``%!<Y`L\X53-[9R?_`!_[XB8/?=%`TTRAU.CP@Z\ZHPD#-N`Z\1:=FQ5$
MTA0TS;F-_839_`A0V`XUKB-YX3.<GI3%`ZD0:`$>>)RF@0-+SBWK%O[&@Y1-
MV&6LZ<77"N"D4!%`<B;G`8X58*%<``+5<`;'%S%M8`J!JQDO.ND3@UXE>)F*
M.EXQ]2T:).+V03]GAM1,I555755RKU7BEE$NBL#590%<N9>7WIY9A&%`:Q=<
M1(!HBB>R9@62[EZQ5;=>+DH`I!@"\`P"XZ3/VL;%V2;`TM67Q?!\\,H`@*(B
H)A."8`)@``H`H`,`%!IQOYL-U`L,T`M+H#I,9481M'+#HU9_Y5__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g644794g30v39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644794g30v39.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!7P'``P$1``(1`0,1`?_$`((``0`"`P$!`0$!````
M```````("08'"@4"!`L#`0$`````````````````````$```!@,!``$#`P(#
M!`@$!@,"`P0%!@<``0@)$Q$2%!46"B$7(B,8,==X&3(D)5>7F+@Y,U:V64$T
M)K<X6'G9.A$!`````````````````````/_:``P#`0`"$0,1`#\`[^,!@,".
MO6"I^:>?+.E+%T&=RT"!QEPL227F5"(=8@8+"($G-EDW<%46G:!SC:Q"*+M*
MH)YAI(S""MB,*^A@0X'+<M[_`/4Q#S<QRV;]/I:HL:$>6?3_`*W"42"@J23+
M;@C\<MQL:N<>;K&;G:+;:F1M4U,8@-E/[81L$F!(92D3$N)02B]'A+NF_0OL
M*P^L:RGSM9(6RG;,]/9YYS+>)E%<5BD50^%0[BIWO[^^0)SI.9;2F?-\[8P*
MW3[WY3'-QET3`3-FE!A*@P+5><NUK1M;I*9\OW?R3,.8[`C-)L-\M(W^VZJM
M1OD\)?YX]5ZFV2HK!U>$S2X$O3`IV,I0;]_V!UO6MZV$6PL+P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&!@MF5E7US0&559:T/8;`KF<M)S#,85*$!3K'9,R*1`$J:'IL4:$G<&U
M5\>M&DF:$6:#ZA%K8=[UL-67)Q_RKT.IKQ9>W.U-6ZHJ4X9U:#L.NXO*M0C1
MQ[,I4)8Z6[MJHIN;51\=;QG)`:TF.VB(^\L7Q`^@?H0\E<P-M^.'5"#G^HDG
M2+JA-;G&\2(%'"[.5ICV-#&#]FS`+?\`K.U1\8;2&P:C1NCQMQ6DHA[(_P`O
M`@#6TZ>)?[=7LTNE76)7I$$\\*WBS0^3?4&_1K0;M=+6*Z@G5=CA\XE[B.'F
MFN(D>OUM,R.H5B4X(T(2]%FF!<'@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#0G3$\OJM*>D4PYIY_:^GK>;E
MC"5'Z:>+C8J&121$O>T*%]6"LR21B7,S,9'V90>O"4<B'^9^/\`!`&,.\"N3
MRS])>M/1$IXG=A>?3'S)S^A46C%&RW$W8,3NUT=[5J>Q]UO(X%NM&VGZ]?V]
M'IS;'4P+P,\2006\.@!,TH+'H+EL!@,!@,!@,"GRMK`.FGMU>S0;`+$A@*_\
M\*WB1#Q-V-O:&:P"P=+6*Z[EE=J4;RZ*'N'[,<MI-*E)2(W:Q,<'1/V!"8,+
M@\!@:YLVX:DI1@3RNY;2KFI(NK<B&9+)+-F\9@3`I=U)"A2F:D[Q*G-J;CG)
M0F1FF`("9LT8"ABT'>@BWH,Z;G%O=V]"[-*Y&Z-;HC3.+:Y-RDE:WN+>M)`I
M1KD*Q,,U.K1JTYH3"C2Q"`8`6A!WO6];P,?>I[!HU)(9#9%-(FP2^QUCVWUY
M%7J1,[5))XX1IC5R:1H88QKEA#G*%C!&T![@M*0E'C2H23#S=!*`(>@_TB<W
MA<]0N+I!9?%YHV,\DDT-=G&)O[3(T+7+X6]KHS,8JXJV=6L3HI)$Y(V*6]S0
MFB"J0+DYI!X`&EB!H-<G=)T"EJ=YO=;<->MU,1V122)/UH.<F;&R$-$EA]DN
M5.R9F<)$O/3-R5<SVDT*6$T(QZ_[3*V3KZB^GU#.)O9$#K8J,'SV5LL3)FDV
MC-;Q0U[6`1@?YY,UNVZ*11M$9_10]/Z_7PI2=?XC3/Z:_K@9M@:;J?HKGV^U
M,S1T9>M-W0KKEX)CUA):GLZ$V*I@;^HVLT0QS,B'O;P;%W@_;<H^Q,NT0<+X
M#/H'?V"^@;DP/+:WQE>_U']%>&MW_2'16QNWZ6X)%_Z6](/C_/9W'\0XW\)T
M1?*#YDYOVFE_=K[@Z^NL#';$LB!U+$UT[LN5LL)AK8N8&UQDLA6`0-"%=*9"
MU1./)U2PW_+($ZR-\2(RMB^@=G*`:WO6M_7`S;`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8%('\>_\`]O!3_P`7_=?_`*M+:P+O\!@,
M!@,!@,"GRMK+9Y[[=7LR-<?L1F/K3SPK>%.ZV;UK.8$S2%Q!TM8KR-VKMYF#
M"S-UDP_13H$C3VR&+FH:PHX@!XC"3`A"X/`8''A[?_QT.L.\(S1JWGCMNSKC
M?JR?IP8^PCN*U25D:2HIN7%P!?ZV<:PIQ`C8W9$9'Q%KTJQ`:!4D$5^.<0(@
M1*H+2_/3R!L;CWGCF.M)GZ#]DO<HI1AC7[DA%>V=$T/.JMS;G<Q_<81'(C+*
ME<Y6?6)1B@3:$"E<G5*T0=F!`BV8$@@)4^F-#7+;%0U?:/+T6C\OZPY+O^LN
MC*!CDE?6^)LTQ6LZU7!;8K5ZEK@<E)8V.R*)G4F:S!C-`5I88E-%_B)+$$*K
MD/FWW)5E@<'QR*3^Z550U'2/.BBQ7.C[@8X:!EZ\3]0RR^^T;,G\(?[;JV+R
MZ`]%IYF!"LT%FGBM0TIW!`!"B&I+6*@P-H\R^_ZS@=S(Z@76-%Y!<]7>BRB3
M1]%U&]!AR>Y[&]28E>?)\@A$47V*=#:P=C^7765*5JV.I6H`5;BI*=!"<5._
MO#=`.)^Y).!:GF4(GR^Z67TUA71#IT'-.IQV#4]@T=%>HK5GM6.-8T2_SU[9
MJ<#2='/+`S*6=)&V0]9^&`@HMR"#[B0S[S[XC[>B/+?7U2]*V/>;5<U[<V0R
MJP2^S;E)MFO4]^:K6VX39-^5*X(+IM.P&DN=R"2,[J['+$T/,5:0(MI65&<2
MH^H8BT\V=GF<+\\T+'^)0<]/'/[]QE&+^A5&=-5[6<DZ^IRI&B:L-JPRL+4J
M^4Q.01..HY`8SR)(7*)#'EKTD6N;<?LK8SA.`:D_Y?7ILYP>NG)YGMTDV%5=
M,UDOJUO1=F3<88G935Z03NU$D-L9P)L9L9KO>JUX7E:.'N+O)2'EM?OPS2@#
M4'")%H,II[RUZ$A'2\R0'MMP1*B;`]8KSZWM*;0KKZQF!OLOGF9<W6TY4['A
ML4>N1OGR!1%^DE[$CE3<!,@,D*4PH*H;@UI?J0&I(9YY>F3[1MIU_9C;/U4K
M>J7YMBMHF63UXKNR+=.=1U[VO#;;GO2E7LLJFKRU4I#]5''%_P`;>-+%U*P+
MBD;]-!>FPC8@ZO<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@4@?Q[__`&\%/_%_W7_ZM+:P+O\``8#`8#`8#`IZK2V()9/MS>S##G5<
MY.E4>>5=0"=$*XW*&$IJE1/3%C/1B!"LD+,U(I&ETW.Q`]+6PQ8AV(>R]';,
M`,(0N%P&!S;^K_O@/C&H54[Y-I.P;UE\!L93%;GC-R<H]S4S#XM$B`N;8IFS
M1<4JH>*U0M0M4M1)D(]">!%+RW$HY&8:$&_O#<G#/M]7]T<XU7/NKJSOFG[Y
ML$E6Z.U757P9Z+V7#XTUN3TK(A!"2Q6CF1^C,J5/D9TC<#E;>M.;P"6_$4:8
M$K9PPLKZ]Z)D7.;7STOCC"ROYEQ]=<\\[/`'L:X`&F.W',=1QY?FW\$].(;T
MU)?J-*$W8B-F?_$"+7],"M)3[E0NU8W+VOEKG^Q'NQ]VAS+25;26[)+2\:HY
MWGG6UL2ZIZO<92[51<-L6A&T;(9`7IY>8^XQQJE*1(C(1J4B%8X)@X&R"O3.
M703@3KGJ>8G4O>ED<P6@IJ+<:J2.W=0,74S][1TZGA,1L9EZ/8@3.N7`I\N5
MM4.JP@;RW?MX\A>F-&::8C(#:\I[7O'DZ+UY$^O:C;[XZ3MIXMIXKZN.`4"=
M2C<*FIJOH].K#F;S_JFLRI&MH40@;H:D/3%/RM8[_.W[;TABE4:B2AB\8]D^
M<9Q9E90"$55T?+(];"RAV>+7&U1"N"JL#).GN:P=2T%&7(QVMAML).Z617P3
MTA)A4>.0MCPGV4YJ$*8Y*K4!'J@O>JNK`H2J;BN3E#I*J5T^J'J[H63I8ZDK
M*PX=77/_`"#*&V-VE<C[)2;(8GU1$4JV0M[>400SC>5#T(Y*0A-)"G5*@V^O
M]5%DRE%'PR"TK8U+3UZ[)YHHRY:SZ688(;+$%1=+4M:5K0>?PUQI*YK)A(CI
M"DA(-)1FO"A4WJ4:Q(XMI)P?LT$IO17I6Y>2^=QW93L$K><F,=CU+'IR"R)1
M)&).QPNPK.B-<K'>,L\:87`^7R@M?+4X2$2EP94A16S%(U)NR`HU(1%8O3.V
MWKMDRK":ZK4?,&^_99YI!=@+Y,3>J2](GQ?_`*OSK1,+.4_LAPJU=M*IC.VP
MM.4Y)QEA<?RS=#"AV&86W[&5+55SSNCT7+O9-KR6$6E-Z/)?*KA-*.44FER5
MUSY'^JI;6\/62Z_88[G/S;S^^CD>CG%"VMQI"!2G`J$M_'3*`]"O/8WG"W>@
MN>N>:MKB\IP]=(1&K9O$)HW$4@TQ:.1RV^=5/4\<=IK&Y5>4?N5$RH:=3?DK
M'1NBCFSZ=#`M)"M0Y_<D"$/I=['32G'RK;JLEN;WOEKI;L_K&D*(C43A7ZC;
M4UKJB8(BJNEDE8G*9;&FEXF?2'5,3=5;4I?!IV_<??T!9@T))0UV@L%K/TYJ
M>U^TW;AN+U'=W]QHXEM$^63=4HH(VOH>?3;-4CC/$4K;&B^76Y&$29UO&--3
M:I41$"!^6+3#FM0L;DJI<2%DN`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&!X,IE,9@\9D$SF<@98G$(FRN<CE$HD;FC98_'8^RHSG%X?'QX<3DZ
M!K:6M`G,/4*#S`%$E`$(0M!UO>!0;_&PNZH;5X(F4>KBR8;-)#!^L>LW28L$
M??D#@^1AJLWHJT)O73L^,Y1VW%M:9Q%5>EK4J-+"0N*+.T2,8B#@EAT(8#`8
M#`B=VYUY`N&><)GT98C>J>FB-NT&BC-'D;LQQXV1S6S9S'JYA#*?)).M;HW%
MVE5)Y0F$XNK@>6C:VX!ZLW>P$[#L*TIY[:D0RMXI-H_S>SW>YH>:[H[/OE-S
MMU/35P5_5/*U'6`1`9-8$-MEA))C=SRQS4&GGHF%$2V!W^EN11ZT@:36S0W#
M"?7*&3[IJ-U0PTK*E'/4VZ6>>+X9U@&:Q(V.OO4C#0JCH=9!]UN7O<E10U5$
M6]6UI'X2H1BB1)#4FT`"0[5Z#7O-'5G-G6?KY9\QYEO"L[UBL7\X*XBDC?ZP
MEC5+6IDDI?3UEN@V)S6-*A04D=`-S@0?LD>]#T6:$7T^F]8%W^`P,-L.O(+;
M<$E]86=$V&=UY/XZ[1*:0V4-R9WCTFC3ZC-;W9F>&U6`Q.K0KD9X@#"+7^S?
MUU]-ZUO`RXDDI.4400460006`DDDD`2RB2BPZ`6446#00%EE@#K00ZUK6M:^
MFL#6=HTS6MT)H*DLN-_N5/6MH0:YH47^L/[/^BV56KK^M0J2?>P.C4-Q_17/
M_-_#5[/0*?\`HGD&@_PX%2_)GBE75$55/J$NJXY5TG0TPAM=1MNJ!9NSJ^AD
M<EU=3)ZFZ*]V%$*\)V.MKY7.RMNT%XK@5?MC<%E1C0MB<XHLPL)TQ7SXY*B=
M&7MS@"MGR95)TW()'*[]9[>MRZ;SDUJ265Q")0)Y?979=SV)/;/5N@HE`V9&
ME.`\EC;]-I!B39)H-&8&`O?ECQ?)H)&Z]D43NI];8A)I9*8U*W?L/LAQM]G5
M3NOVBJIHP);Y5WZ;=^J]E5=1]"T+XL*0BC*I&D*"8@%L`=Z#9#/P!R%'GMCD
M#!3+:Q.$9G5'V1'2F:43MK:&.7<W52II"DEK5'D,I(CZ%M@=6*QM!#:6E"V*
M2OM-5)SU``'!#&83YI<35ZC>6J.4K\C"^UGT12ZV*R>Q[:G<-3U#U?+(A.;_
M`*O989.9Y(XK&Z_G\J@K<KVT-R-*@:Q!4`;BDA:U:!0&!K/*;D=MJ:45Q7<=
MG$/D;M)&JPXU;TDN>][CM2'VM#*G?Z8JB<E3NV[5ELSDB.H8/(CTL>CKDYJ(
MTWAW]"T(?KO>!N"TN#^>;NYUK3EFV4]N2RH*L9Z^9V5N:^B+\K"12$%8-36V
MP];8<PINR*YDEB+&]0S)7+87A2K3B>4Y+AHK2PDDXL/QP_STY*@U[H.EF&NI
M(;<K:H(=DLDDMS7E-V?]Y%5.ST4HM53`9K9,@KM==[Q3[$GCSG.SVDR9.K9L
MXI8YG_DJ-FADBCA[EU5/%=FGUA\DX77A-NCU3W^];##\MSV+S:5R),9E^F@E
MH6@'ZQSP0&/?IP4^FI/]/SR$Q3GO:S`KD0^+*:N;Z=[6YFZILCF.&B@]:UY$
M8'6Y=DFO,8A%-\CM7*=85Z]2)SO0<%M.!QP$;:94,R5P]XF!SRV)P%R(@@HD
M)03->/,;C&9\\T%S)9U2);)K#F^H5U,5L@?7^4,ZA)&GRKRJDDSJN,ASW&P+
M)<_1@`C_`-6$':]O=Q:<D)J5P+*4@#2G.7EVOYP[#GO3L:Z;L93$)[-K:G+_
M`$T2HLHE!-5UF-$:9V5OMM<_77+*\L(-6`CPE+(\D0UGEJE>L4*'5Y<3#U.U
M`6T8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'/C[:](UW<5$]+
M><$*<E"F2OM+E3'L2\DA4M<*JX%YYTYMDC46E>*BOD+K*'N829H9SS(]`VXH
M2][0%GK702%@+/6#"M[^*/R%Q]SM(.PI3S[WY%>VK!D3+5K!,$%751;=<P&L
MH>E<YBOCJI[<K(9VPJ12Z9N856DQ)82A-Z5L4?'\X5!HB0[+\!@,!@10[6Y,
MBW:U`/=%RB4/D&&=,*QLB(SB/(65X<HA85/6+&+1@CX*/29$Y1F3M9$FBB<M
M>V."<U,N0&G$[^,8@'%A5X\>#,"6,LM3Q_JFWX/*;V@G3M2];RV*06H$(KZJ
MGKBW4-O6O#66.&Q(^.T]^&XE+&UB5M!!YK<VN2D)P59QFSMA(F">2M<U]TFS
M6\R7%8)=)1+IF4=G0GE4++#2H''>G991&^>UT['-]-`[!=(Z@B+@YN")D,5A
M*)?7$Q2,XPK6TPP_'`K+KF>^VMT,<&G\)F;U6GG-6T*L=GB<J8I$Z5_,0]-6
M0]"B4V;V=>L5Q23:9G5*KV@7@(5?BJ2C?L^PP`MA;K@,#B"_DL3+W/CS5S@*
MBED_AD=46!=8$*GS,G78!D_=(V2FA6XWKH,B'QZ,(4WPH1_<W!`<J3Z6C7:*
MWH.ON$$M?!^3^YKWP9%UMD)JUECN*UK%*7/?HG8'7Y73VVTMU0Z`2L3OT+D:
MD453D;%^C_>L^,1?W?T!KZX%J?M$@OZ2<NU?7?--OV51-J6UUMSO5K39U5R)
M\B\CC1<QDZU"6L7N;`<0I-BI+L%(8ZI#M[1+D18TZD(R#!@$%([9VKZ<7_-G
MCL&J6^\X')[#\X/06'TIR2<GD;A"V_H;CZ#<:(WF?[IU>9N'R2T]]5VO9K%'
MCCTRQ6\,L<;R0A.+,&CP!G83HH;[7Y*X\FW<=[OW19G'T&BG1L&[>OGHN\AQ
MBQY#=$TZ/D33`.A(94T7XQZG@G/]!RI:L9(Y)2(TT+7UB$$:<XD"4(>I-NPI
MU9/-'G%6=H=5=$<E^@4/M0NF;SF,INB6TQ5L$:.0+R98KT5;O0D9:GI;7W0L
MXO6%11*BCL6<'!_1NJJ8;7D_$@2."\(6"H(.C6>@O?-D%=>]C4GR;SM3PX7;
M\ND'6ES2:MO]471\@06K,S*FAEP/EA4O6<9YOI\+6U(0,C&F+95TY&0A_&/:
M4^TH27\@.P8;;G$?`L`G=UN5D=13CDI)-YFFECG*)78;V[5*37,4NIZG$D=R
M5QP9%&9K9+.D<=.BP"XU6X!^T)GVF[`%:W"W7=E1'J57/>@;ROA3M&S^C9/H
M?7T\?+6FU.\Z3&->@\#J/SZ0P:O%A;S'J=<)=3[TN2-R.*)$R>2L10WE:4K$
MG/<20L0Y)O)J</67TBI4?4$XMUL#4_)\E@=;3.;)W>-UK-F29=9M%^0NJ8@S
M-+#%XPGA#>I@R1\T0E,=U&C&TUV6+5(P'["OVY_2+U,BRB^Y/`5_,P8A"&GV
M=G\%BTFYEME[D0(SY4]`-41@\->)0S]!L*)[>NC(-*R"=.)#6E"E&W;-2)C1
M'#,`&SJ\]@;6<>R.E$MM2VE*NY*YA@_4DRE\0?6B/L5JRM/1=8T_-F-JJMZ=
M+J5SZR9`G)E,J<92:.`L+6W)&AN*0F+@K1*M!%Q?9W7_``O:7G!(WD+H&3]%
M\YW];'=4RD**72VMN=I9V%WUQ#.[-LB10!`^MY,B_LD38YU?,1HE28J.LIVG
M([6VIN6I30L3\TO0CH;L7KSI.$V)*J4::EK9/=C3!*R:V!ABMNN[O6W5DZIQ
M+,6)".[YY84DJ^.5[%&8+Z\/D6B(A2V3?BD)"R4X`B"]K`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8&DSNEN<D[T;&S[_I,B1$.@V,Y@.M6"EO1+T6K
MV@,9S6H;\%<6Z%K@[)$GV7HW1NOLV'[OZ8&[,!@5.=+=96Y>5N3/@7ST=F]-
M>T?;VX'3/6+HS)Y/47#T9D:<PU.D,1B4`163U7)&K_-B\*UO\9`$>G5\-(1$
MA3+`TI;33#.,JQB_E_P?"&NW^R.LH_,G>5R&ZC%EF&HXG)@J6>[^[.[IHL2K
M'";HU:QP/(2HW099LS?S2&!K)+1E&%HPT;_%PYMKKGCS:?B8@A"HD\LZIZ:0
M3Z9*2"RW>8*:DMF24S%%"K01&[1(4<4@J812(!@B"%*A2:#_`!J#1"#I`P&`
MP&`P&`P*EH6YPAP]K[;(B3A%5SFV>;U<(9L3'%;0I7-\GUU!9IQB.4EMA@U"
M1^TWFD"V6KT%1\(@;WK[=AP+:<!@:WN"WJTH&KYU=-R3)GKZK:TC;C+9S,WX
MTTMJC[`U$[.6+5`4Q*A8I,W_`$`2G(*-4J3A@*)+,-&``@SQN<6]W;T+LTKD
M;HUNB-,XMKDW*25K>XMZTD"E&N0K$PS4ZM&K3FA,*-+$(!@!:$'>];UO`TCT
M?T_07(E;#N'I2SX[4-9$R*/10^9RG\_3,F?94O"VLB16:W(EYJ4E0IWO9J@P
M`4R4@`SCS"B2QF!#R'SL#F2,WHNYJD5TPECNQKIIVZ%=X2ZKSD(V6EV)=IO>
MK`?)`H3%Q5E96LT6C#]*EQ)Y2405(B])Q:-V&GXMZ;\,3*L;8N=COQIW5M)P
MU%8EA3=YAUD1AD1P-T,6$,\RC)TFAK.;8<9?5*$9+>MCH'5.X'B++3B-,.*"
M,,@L7T1XKJ5OHQXL/H*&QEEZ2:87(*:?5*:1*V&4QRQE+&B@DE7OC:R+6F&1
MF6+I(B(0N+Z<V(E!Y^B@F[,",(0QLWT\X616K85*OE]ML0L.JFFSGZ>-T]A-
MFU\PLC#3;ND8;*?"YU-H4P0-X98N[N"8@:M`YJDZ@:HC\<9NCBMC"0M0OM$W
MDUPWK*HM1>:);9JN-$0NXD#.<G=I+4BQ:MET=;T*YV0(GQ'&U;B]&KOQ1ED:
M,.&$9H-B++^P,0JOM#EZ[;?G]"59<4;F%MUB7(SY=#T*9\2GEI89*B8'-EL>
M=7-I0L,W;X-.E)3(^J&14XD,KP:!$M$0J&$K8?-6]G<W73=%D\^UC8*J4VM4
M1TI36$Q$P2QVQG8ED)DK=#Y6@*G3U$6V`O;DQ25U)2'IF]T5GA,V/>@;"4:(
M`2AP(9._GAQ)(IE+)](^:ZRDDEG#M+'^3&R-I/?V=>_SY8QKYX_D19X5K8JU
M/TY51I")Y6HT2=4Z_CZTJ&:$0]"#U:=[?YYO6PT]65])GA;,W(OI1?'DBV+/
MR-IE<<Y,NZ,<ZW5+HU)](CHRYQMCMZ7HVI&=I6$US^IIZ4LQ.2:8$/>I[C7F
M"@9L]V-3U,Q&"35_;9&R*GYI`XG'MS!,9J?8\MC<73N*]:AA<9D\^/V\.#:S
ME(4*QQ`6>:4,PHK8`DU@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"#W>UY=8<
M]TV?9?*?.=<]%ND8)DDDLEHL:[ATLCBT!BT9<I`O>V=07!IH9*G8\Q!\($8?
MQ-@UO[ON']?H$-1^6'875W<E"-/1'0W,=:\[5_:$)K2QN?U4$O11;SI/(G.6
MMZ='8R7,BF`PTV!+H\02U[*!L]<);M>:'82/Q?N/"SW`8'+!*O,_SYD/\@ML
MJY]XSYR=JWE7D_9]^R2"+ZIB:F)OETF]LUU'3+.<V$QM$VJYD-A>E:/:T9>S
M=IE)A?U^T6]8'4_@4_WUTM<79-GV%P_Y[3(Z$_V\>D\1[,[L1(D[I&>=-*-)
MC7^C>?3U!:IIL#L%<RJ=_DCV`UFKPDT)[@,3J-*A"&3VE-J;\I^?JMYPY,IX
M-A7_`'/)G2(<S4`E=UQTVO\`NAS*)=)]<%UV,K(='HQE9"3126QI\^F&C*2@
M$(T\:D](08&\.'N-M\P1V;3RT)>3=/8/0SLVSGJOHE2V@;UE@S!`AVA88=$$
M`P_)$:1J5G,_1H='BOL(;FPK9I@1+52LXT(4_P`>_P#]O!3_`,7_`'7_`.K2
MVL"[_`8#`8#`8#`J6A<%A$/]K[;=(E#HK%G.<^;U<2F;.,<CS0R+IA)S.H+-
M;C)'*5;8C2J)`_&-Z$@@2Q6(Y1LDD`-C^T`=:"VG`8')[[@^(_7W7E;QZM.$
M+QN0]FL*>2&8]&,_4GH?UY*JL7LR):A?(1!(E2<JD%G5J-C+EQXG36Q-Z7;,
M8R-Y:+Z!&9H`2`\N/'2]JKY-@=<]\]&==E796#POB4?,YT]0NYVVJ'.I&0MM
M,K9*EA+/8M?1:%?MAJ-''PL[8V%MX&]I3&AW]QY@`!:/Z)\<J>X:FJRG3OVF
M?#6KI2F+%MAHERYV0)I+4$1=UW]QXPSC:&1\&HDC[&G(Y.B)4!3)##!_0U22
M'_%@4O1#P=Z9DD!5,W0O1U<R^UK$Y&[PY2MV[V;<S=WXUCM>N.-:!Y"7L,=>
MX^SE/3;$ZGY2->9PC/<&OZRR1N&T)BT*TY:6&X);YV^IW0,]TEMRZ:"I>C9/
M-N2Y=8-;0:]KRZIA*9ZYA?+<M9QD-64K=//]40&!1VT+=35:G4P<"TUC0L$9
M7B&K7''!3GA^-O\`-+T(B//'*O$JO_25T+R%S1=4PF[O$Y9T!<G/LOO&`UY=
M0K0XQA%A'QWDJ_61%#:D!^$H?HP@`64ZN,;9B@.VT!2XA<%E+7S=?S1UAUOV
M@\-E-V58+S6=:\_\6U>]67-X=$(A3$/4EV'.C[+G2:G)LKA4XM^ZW,:]R,:(
MU)BDC7%V`H!QQH#MEAKGS8KSL?EBJN2N'[EJ>I=0KGSD8,:L*]:RLR8S>*OD
M[B#[#834C##OWC5E2.QCE+8JVR9YD2$;8>5']$-A05ZG\T(A!%[FKSB[9YJL
M:%RED<.7)4U<K-??$=YH5/\`9%KER&Z&[O[MV$]*RMXZ!"CHX!53.%4UU%U#
M6WHV%5-"GM^5Z4FJ&Y,$PHT)0\\<<=$5;WI:%\@6QVGN990AZ#5N=.0KKWIW
MH-FO6T;;M^-SF,W@_P!%W+!(A3W*,N9&%L=ANC=`U;RF<G.0G@$HV0G`,T*S
M+G_C_2*U5%]R<UKYJ46';K3[.NZ:6.KW81*\RTNP^@&JZ/.B9/ZU%7AY^CN7
MSU#TL<#BP'CC#TYFGLA3J,\Y1H-`1.FNP*=[Z[`Z:0\/3Z[^CFJ.]H1KFNX"
MHCN,$,<EEE>4%#JLE,FG<TYZ3(;<BL\D4&V@C2M%;3JKAT?72$1\;;$;F>0B
M"<-X^+UKK5_G0GHN:50XP3A3GAIK2:UQ;S[-FV-=5RQ+T;R3<,E9[=TP0J9'
MJ(//=4O(I.M6F;6G!G9;(-2UN3:-Q*"&`^.7.]G5WWEU=;UR\ERZ&3ZPV7H]
M-_J,D$+-@6T,8=>X;!GL4JF0:?>?H8[6?,K&BLD;GLN2M5EV@V$QF+-#8I5(
MS4B0)X=.F`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P(_]9?\`\6.E_P#A_N7_
M`/;J1X$0/%+_`-H_SE_X0*/_`/HEKP+/\!@4@N7_`/TCPW__``@V7_Z\:FP,
MDM2^K?\`1>PI=RSPC8;Q5W/5;30^$=D][Q0SX',EP9QE[D_-/%SP8E6-LCN<
M\6_PI3-M:&T0).8("7:Q[&42E"3-FSWEKR:Y&C[5!JW)C4(C2IKK&@N?JK:A
M+9_=]SS(Y5^SJP@K<+:EVF=JVG)OE4+W5P-/4'&C6.[LJ^,M6J"&,\0<E6'%
M);-.TNPCF.4]U7XQD,TATT*"7:(<OTEIP*?XGR)3#B4`I,HA\+7Z"ID3Z466
MJF<FT:XJ1#)*0%)@LGP*0/X]_P#[>"G_`(O^Z_\`U:6U@7?X#`8#`8#`8%/E
M;5'6%:>W5[2&OH#$X6^6YYX5O8-GNL:9$#0MGLX'TM8K`9+94>B)*&\R`UF9
MDJ8:H[[CAE$`UL6_I@7!X#`YX^O?=*NX#T?!^=^8[9Y&6':@-S2JW9_T<[WT
MQQB(2JM)W5\'9ZT:$M75G*'=7)GT<R=5NSQE#0_CLYNOE+'\>CPR#BOWCYLM
M-NN2.]67;SE7MF5M?JRJXH?3JBXI!7MF0HRLJFFC//6%;-8$SR%"%1)9ZYLI
MQ*U.GV$YF$9K7QF!$()\^EO<KEY[\W%7XRTB\="O"JS(%7;=5\?EZ>%/;P9,
M5BL*I2SNJF-RHI8\(6YN/&B;]IB].*SXD^U";1FS@!#F=>Z-$PR]Y[#T=>O4
MUYQKKB:QNOWCI2(2A,Y&.SE6M;41=SM3L6K(<?)"ZO2VF>FH,\DNA\@2$`/?
MBDQR<L`#%00][?J[8L<K7H!UG]!\Z&]`U6LI.&0CDRD^_8!>%UN]W="SU#6E
M741>S(AJ&)+>>)XY2Q[1`5'!2RMH(2!7JBE:@E`8(8?ZV5ZW2F.<I<<=EUIR
MR7:%/]..E"Q26LBF\VZ$W!`[*O.R(Q5(:AK2L55:OJ^\;0@4O=W(+NW#4Q8H
M"9D5&@/W]AH20V*;WIU<A[7LWC\[B*"RPV)4=/N@H?):OZ[0R"6/<#2V:GK*
MD`6-"I]0M50VJ'Z[5WYZXM)^\7L;6CCSOLK;B-*0%8$Q.*^D`=A<E<Z=3%PX
M5>@O^H83:P(..0:E0XH"9,J9X"Q"D@66.:>Q-VE/Q[4Z0)-&[U]WQ`_V8&%\
M_=826Z.ENP^=Y-2#M4QO+#E5`&22/4\C$K66Q&K73V"I8YD3'XF2N00AI7)(
M%^8@2J75:Z&H7`G:],V+`'(BPC'(_;WSVB+I*&V1SJX6Q/#CIR:_R3_2[TDO
MA"2-U3:JJE+AL`J=-56KHBLK6GK-(*:)._E+1M;2O5ITYIWY!NBM!(R*>B/,
M$UZ'E?,K!(9L;8<*:;@>Y`\.566(PUDG;.?WR,Q6Z5J.T'V.-L)=4-;2V8-K
M0Z*4JPY*2YJ@)M&B,_PX$&:+]A")!-^7XW?D):Z^1]HTW*+RYV;(RU3=VL63
ML<RZ:)KSFF%$P+\)T>GB02?GI[;YK*',):%"RDD."DXE*W)33BPGISYW]SAU
M#;4XIFGG2P'>5P&'EV`YN$@J6R(1$'B%*+'FU2H)1$)7,8TQL\M8W>?UK(4"
M%4A,.)7;959I`C"2_DV$T\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"I;VY
M[O@7GMYUW;<$ZBK]-SI\VJZ"A$58%)#<:ZSBVHY(VEO-<WE4G6$,K*RM"1<X
M*3]DG"&%)HDL`C3@8%3?A![;<O2'S2YZI]SK7J\VUN:(?%^=WR(5#R3TSTL1
M+U<#C#`!++HY+:%J&<0YN3O;,MTJ,:79<WO"+:<_7P'$;2*E87#?\T#]5']D
M&\[_`%'G7R?_`)07^DG^U`%?S'_`@_Q=$V!3'Z?^H?\`3_Z[^+^&7_59^-@?
M6^WNVI!K:B">/O5)3:8$\U&MM_H7A"L5!Y9`])Q$J&2.]+VD_MZXQ7H6RPG)
M0D#3`V;H[ZB++&'%!T?<?LST1_(.25M-J=O"CRK+40OD*5U]3:/6TS5YV2RU
M(//+:01[I)AAJ%2&/OR!I4/+G/FU2A<&Y5HY.0<C+)V@`'?[+91RSYR<IKI`
MX)87SYS!SM"TY"-FCC04V,,=9RU92!FCD8CS42)6]2B5R)S*2(42<L]R>GI>
M`L.CU:G_`!A#_D"@;7Z`N%!Z0=L0]9#[5/8WADXZYA?C4JT'%5*RDD25S<)!
MIO6*F9TZ?N]F`0JE[IH(SV%"87'$AH2$ZO:D+9\#0G3$#OJRZ>D4/YIZ`:^8
M;><5C";'[E>*<8KY11M$@>T*Y]1BK.22>(LSR9(&9.>@":<M!^'^1\X`C&`.
ML"N3RS\VNM/.XIX@EA>@K'TWS^N46C*VRHTW'T3I)T:+5MBQ]V1(Y[NRVVX+
M"?W!'MS<W4L+.,@*0(7`.P"+TG+!L+EL#1W1'3%`<E5DZ7+TK;L%I6L6A4F;
MU,OGSZE96Y0[+2U)R!B:"C1"7/\`(G$E&<),W(2E*Y0$D>RRA:`+Z!5)K^1K
MY2%A2NRZW;F9Z_6JAIDMN/7(76#75A@0Z4!`M%+%E-%ED-IAZ89>U!A0"BMA
M$,W990!F!"X"G;FJ?H2M(I<E&V+#[8JJ<HU2^(S^!OJ"219_3H'):RN7Z>[-
MIQZ8Q0U/3:I1+"=[T<D6IC2#@@.*&`(?AO*]JBYIJZ275>T[9:TJR('1Y/))
MI(-J]-34HEDH985&R#](4RQ6,YYE<B0H"`EE#$-0I`'Z?U^N!&"6>HW`,&A%
M261+NG8$PPB\PRA363^N3R8"9\981)BX;,Y<Y$`8!K8A`8G*3BD+E(7HIO8T
M1YY.CE8/F*V,-E(>YN27/I([D-!>D+5]%$?.0*MR#',:D;NDBA,]611/(M-W
M[/5SQ#`SP/A\?*<!OA#*+2X:0*7_`#<"%=;5/7E;^W5[2&$1A&P/-L^>%;SZ
MQ%Z90O/.E$O'TM8K#M[6Z6JU)9*C]'9DJ?0"`E$Z`2'Z`^OUWL+@\!@0@Z8X
M5A_2=IUM=I5W='T!:M85_8=6,\UYTL"/PAU=Z^LZ1UY+93%Y&&2PF;HE[>;(
MZM9E96R2DYH#$_\`B&,.]:"&7<D<@PSC^.VLSQ:Q+AMA[NRX7&\[)L"\Y6SS
M&>2*>.->UQ5XCSW5BB\1;RVU)#ZJ9TY)(4>A!$4,6QB^_P"F@S^]>?(!T0W5
MJU6%MZVBJNZJSOB.$LRU(C"JFE4O6WV-)7H*QO<2U\=4+!;"L3!"4,\K?VZ-
M!_MP(&5EXJ\(597T:JAGA<N>ZUCM<]?U.HALHE@G)LDT"[6<*J,M-CD2I*VM
MSR,,9CM*QMABAR)4B/8V9M**",TX!:@`>$/Q/Y6E,YBLZO>P^D.ISXBGJIJ1
M1SHJPXK-(NZQ>CV.]FNIXC+$3)7D4<)@QPMXZ(?WT@;DJ5+U#\6C5JE)_P"-
MH`P_>U^-7/,,=JI75!<72](LU$V!>]D4I`Z\EE6JZYJ>0=$RI;+K!U`838E.
MSUCCA:98\.2-G4$%!<6AI=EZ!.I"E6'E#"7[7Q_"X[+NK+*BE@VQ%;8Z[<(*
MIG=J-+W%%$QA;56$2(AU>1*K@OD+>(U'8G$$(W!4E2+6YS^KD]N*HT9AJH6P
MAJCE#A!PY#<J9AD!Z+N23<U\_P#/C]2M<4S/75G<S%;I(I9$W)'*)D[QICB+
M,^EU?#H$E98H`;9M:F*>W@:I4?LXC18;&I_C2.TYTS?G4C?<]ZS.7=&(6IMG
M$)G3Y7JZMFQ#%75:MKY/%&F/UI&I*VAKAH=ES0T[4.RP0FU<;I9M6IT4I+"/
M<@\AN4I+!)97;BXVT%@F5(]N4"[C32]E*<`P7OSH]JZDO,Y&I%$S"B7Y)9;.
M26PJ!%C+;VO8B#BE1F]':""1GC'TB5:'=C]$NG*SK&)=RN'3[?9CY'*H;W^U
M)%`>C;8CSTV1TZ8NC4V3J&NE2T\8_LK:>DE+BW*'=<E6EH$"=*6D"%EMW>9?
M,UY6M2%U.Y$VA%B\U16$1.@WRMGUJCO]J44!L*.3YF51=(MCSRET<M2QX<<<
M$RH*EM7Q=S7(#DHOF":6$9_+GS3N7@2>V^[2:VJQD<#L]I7J7V-P>NVEND$]
MM1;;,]GI5NS&=KXTWV`0<VQB:FM!#$N>I.3\IZA8)=LT?T$%T.`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P-<VY;E9T+6<UN2Y)JPUU6%=,*R2S.9R59I$SL;
M.BT'0SCAZ"8>I5*3S`$)4I`#52Q4:6G3EF'&%EB"ETSEQ[]KV]LL[O.N)U6O
MG^2<N=^<^'':02>OI_<X%B)R;8]TMUDYPURCDRB#D>S.7YD,@+>X)C(]LS2]
MU4J5HRTJ(+1^1.+>7N#*A(HCDFH6&F:N*?G64GQ]G<)$_+7>3/04I3E())*Y
MD\R.82EZ/1H$R4*IR7JCBD:4A,6()!!)8`E#@,#%YM-H?6L.E-A6#)F.%P6$
M1]WE<PETF<DK-'HS&F%">YO3Z]NJXTE&W-;6WIC#CSC1A`66#>][^FL"H6@8
M7+/3*Y8'W7>T=?(SQ_4CX"6^=G/$H2+&A78+O\&RVSO2ZXV>:2<8^2)M4#_M
M?'W,C0HXQG_K)I('-Q+VE"Z+`8#`8#`HCZ^A7K5;W0UG,M2R&DJ]YBA$]CJB
MK'N5<K0:][$BK=%N7B+2*OR!KYM:R5NE$VEO10GBJ38^5'`.3*SK2WA,?]#-
MC&%@];]E4TA@]/1+IB]^<JIZ?DU<UH.T:4?+AK>/29AM:3QQI#*H:BA[K,53
MUL2:9*%2!,GT)2,P1>@!&;O_`!;"6<5B$3@C&GC,(B\=AL;2*G5<DC\59&V/
M,:9:^NRY_>UB=I:$R-`2J>7US4K51@2]#4*U!IQFQ&&#%L(O=Y4Q_J"YDF%4
M"J=XNDA[E%52`4&C5XNO.<J$NK>U899T=DT4MUD(&YQB20J5PU`[I/B.1[4F
M(OA_(*^_Z[#GWEGF9ZHOM=2\4R5P'H*?]*\%=G\"/2:X^A7%_=^4X+T/T$">
MTO)9%:;C72AYZ'<JLK%V&CD#@G1$.S@Z,3?I/^0246;@25IOS.ZLKSINO(<Z
M(H.Y\Y55Z7SKT:1],*[(5*;5F#7(..5_/K)11E:ZCYCJC>-363&[<5ZAX$UB
MC32G"`1I_P!J<0;WYHYDJCEWU\L^)U)_=#;/)/."N).["M2_;ZZ$>ANYG3UE
MMHQH9/T#9=GR9G;Q)4!>_P`)&L(1?+]YOP_*88,07?X#`Y&OY#O9OM=1?%<^
M>*;YM@_/E4#G!L<L7I[GWIB377<$4JPY4H3,K[J.&4-2Z^CD\L/"G)7/R-<_
MF-(E&DH%"0TTE:()H^;O5WN19G&O/LQOO@3GZ3SF0Q%`H<YY9W84AYPL>7Q\
M2@94?FTRHQDY$N)##)-((Z$A:J3!>4^U!QFS?P&S1ND9(2I]F)?TO&^7JWCW
M(]M/%*7I;75G/U.PZ>,I$?4G(W">218B;4#B3)VQU:#H^Y/I",MR*,+#I0A^
M4D0P@,%O`I12^L'=MX3*0]@40DF#17<H\X.\EU'\F/,,5.2)RZ6XPKOC=]L"
M;N41TV`ELA?(KT;T!,X*6C3N!FG)+"0Z+"$2C>QAZ#IZ-JH^RVMS)SMVGU'U
M+;E])^.XG6G0\,F](=4K"V>]I3;KQ<MSTS3O/M7)IC4]L0>A:-G,@-@RK\U.
MU&$,6_Q$@##%!H>]*?1"SK8Y@\X41?<$NYB]"E=E)*<N2MYG(J<J.G&MRY8N
M]H@?9-U]=1^X80@EI#:^1")*2&&)D/+6N6ODM0%)&X\12TU*$[VLRPG/T0[E
M!&/0?H*M>8><J6TDNN96=/JA>ZQJCI_I:2)["8(I5".=UO\`L",,O-M&HR#P
M!D!CP6E6S%I*5E*@)#BE`2G\E.Q(QT+PKP@IGW0$-L[I2U^6F*P)<D',8RYS
MZ4OL*;H4UV^]N#*T*-'%KHG*INVIG@O1!0D*I>468`&Q?301D\^^@9NZ>CO5
M5`6%?<FZ$=')#U!=,0=*\ZBJ^].<ZLJMK[#5Q*KJGD=716M8S,^=KQBU;REE
M:0-CD_/Y3K^AOIFAEF)=E@"*]@^S_>$4CMGV6TTYR4XUU":A]`>C6IL6N5PI
MYLJJOSD[62\DVA%G$92\;#^_K4)D"!W8EA0@M[1^,H`J(6;.*`4$CH+[%S!S
MZF[MCLYWSVP<R\&P_KB26JE0.PMWZA4\W2-B8HFC))<+5*->_P"Z32)W=S!$
MPU.E9?Q$C>-4H-<42H\(GM'4O7?#?1?G96%MRMX>I!U5SVBD73S]:LIG#Y17
M/]T]5=I1N8R:22*,D/1#SK]LND['4T`#K:!L;%+FT)EJM$W`&$P+#/+WTCN+
MOJY^B6]Y3<^-U.U,WF-[2U0)R/56ZQ6/JY[;@RV%30A5:<A6.#7&X!7C.[G/
M0XO'4[BME($A!11K8L+&%UV`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!I?H7H6
MGN5J>FU\WS-FNOZOK]K_`%.02!S^8T8QFG%I&MD9&M(6>Z2*42)T/)0M;6A)
M/7.*X\I.G*,-,"'85LT_S_</>UNP/L[M^(/E:TI7RQ#,^+N`I8$D*V"O0#1G
MLG2O7[2C5KF.2='G(]$J(Y%MF*VJM2C=_P")0_;/5)PN.P&`P/!E,IC,'C,@
MF<SD#+$XA$V5SD<HE$C<T;+'X['V5&<XO#X^/#B<G0-;2UH$YAZA0>8`HDH`
MA"%H.M[P.%^N*9>?3/\`D$$NA=F]2[\S;-IE;W[&J(O"?6"EK#I&&5;-H-5:
M1XBM)/\`(UR5!05A]$N"*1M3=(FM)IV84IYA*,A`K0:P.[P``%@"66$(``"$
M```#H(``#K00A"$.M:"$.M?36M?TUK`^L!@,!@,!@<''%?-MA2>R9]*(GY4^
M9UJPU!Z"=,!37GU[;L=;>W&-&V]53,]6?94;-3KW(J?046QZ92_QFXQ4VIV\
MT)!FC@K%8=X^`P&`P*?*VKE-!O;J]GDB86))A6-YX5O,5#9-YFZRIFAQP^EK
M%:!1ZNVYR$,J&P_Z-GY.FU-O\<*P\XT.M;,WK07!X#`C_P!(=*\W<O5_N;=0
M6W6]25^^.!<23+K)>VYM12AX=DZCXXHRM2S9BR5O#DC*-WIN1D*E!Q(![^/8
M`BWH,ZJ6WZLOJNXQ;=*6)#;6K&:(1.,5GL!D+9*8L^I"E)R)2)O>6A2J1FG(
M5Z4U,I*^[1J94282:$!I8P!#_.U;+I^IHRFF-WS^M:SAQ$BCS8CE5JRJ+PR,
MDRQY<BFZ*MZ9\ER]M:RY$ZNZ@LAO)`;I2>I&$!.A#WK6P_"&PJ,:K20TT"<5
M.W763"WFR&VJ@R:'H[2*KMT?](Y!/4,&TM+E@(6XRA/\2QT+2Z0G+P?:8;L[
M7TT&F(%U-P+*66T)_5_1G($BCM(_E2&Z9K`K>I=W9:B^-(\IUKY:$CCTA4(8
M#\:$IP`:I=CDGT*"H"(7VZ-U@>Y.;CXIBCE5@++M3EN-N]ZK$JND@3F<5,SN
M5QN$BVV'HE-6!?W1.JL)8^B<D8RAM'Y@U6SR=AV+[P?4/-9NN>$I?/+)H^/]
M.\DRBSHF=.%UOU`S733KW/(RHKT>V^R5EDP!%)5,@9CH.8T[(?#'1(6)L$F^
MQ5LO9?TT&=UK!>=).]QSI>H6^N9,JE-6IHA";5KQT;7Z+NM4/3\";;(@[A'E
MZR'[896^!3+EBUL#H3QM$AVH./`A1Z(#_8=Q\T0HRZ'`VU*+B1U0EH)#T0M'
M.(`PF5>4])5[NV/ET*1.B04*+=D1"I40I?!)M'E`-,`(0=#%@9)`7NE[?@S%
M8%7.]7VA6LS9W0Z-3:`N$4FT&E;`^.8U3T:Q22.FN;`^L[P\I1&*A)SC25"H
MO8C/N&'>]!$)S\J.#'R8RJ<R&D%TG>9C*K'FSNW2JX+TE$)1RFX;1B]SVN[Q
M6MI!9CE7<%.LBQX8W+WP#&UMQ3H448C4!,1*%"8T)8W+/*>J>(*+"N=;'V2*
M[>(/!#'AZ9#GP:Q[L:?QF#P**)4"!L=75S62BQ9$UHD:0DDW9BX\K>@ZWK[M
M!&#C?DWA>K52Z[>1F3]0VK:YY1"68"N.X+<:(XP0.[)N;8M60--9U@31FKV/
ML=YH7K3DV,)#<DVZ(_L&`04Q&BPGW@,!@,!@,!@,!@,!@,!@,!@,!@,#&9K,
M8U7<.EM@31U)88=!8R_3&6/B@I2>G9HU&&I4]OKJ>0B(4K#B6YK0FG"`468:
M((-Z"$0OIK857T_[S>2%^6C`J6J+M&#S.S[/E#3"X'$TD+MQN5R*4/JD")I9
MTRUZKUL:DZA<J,"6`1Z@HO[MZUL6L">W373]+<A5*\73>\L_:\.;7!IC[8E0
MMKC(I=-YI)%86V)5Y7<,8DRZ23JP)>Z#"F;6EM3GJU`_N%]H2BS3`!`B@.8K
MIZLMUA[9]#8NG8!Q!X)D7&7"Z]8VR6'<LIRBS`M5T7'^)M7';!['=DB@6PK"
MQ*VN`D&B2-!@U@U"[`MWP&`P-=VU;=9T/6TSN&Y)Q&ZVJ^O&-5(YI.):Y$-+
M!'V=)]H3%2U8H%K6S#CS`$IR2]#/5*32R20&&F``(*CXG5MJ>L$MC=S=00Z5
M4_YZ0F5));SWQ]+D*MAG'6RUIV!3%[X[&C:OXEK'52=:$*^)5<L+`-8+1;C)
M2Q_:F;@!YZE.G1_R/X,D2$$I4J7P[L=.F3)R@$)TZ<CNZI2B2""2@A+)))+#
MH(0AUH(0ZUK6OI@7B8#`8#`8#`8'"77]'L/0'3+];M;^:7B74$=CW8-B0]^9
M^D^D;/;.S&R457?CY%Y3+)#"6MR9FN.6%(UC)MY:6Y2B'HW\M,=K9Z904,8=
MVF`P&`P*?*V@CM#_`&ZO9U<;/L2P$\[\\*WE32Q3<V%F,U8(!=+6*U_LBN]1
M6%Q5T+AX5#>-=H+VJ>W+2Q6=_P!<^'XB2@N#P&!SE]X^6/3[I?'._5_/?1'7
MO0+U4<BO)/(*D>^EZFJNP(9'KR;HTG&_<O6++*.=X/#5T8'&=-Z]I>B=&/#$
MLVG)=D0B30K0][@#R`O.HZYG<BN3M/LNF;`N._[$OUWIJDNA:_D4*A)<U4,H
M$+!+98MY^:&^Q+$7(V$"N3O+6ULK4O=%9WXZ7>@[5J0G#ZK\:NG=]`UES^7'
M$LGA;KT]2#[<2!2Z-C4)/2K8[N22S'-$8Z*$X5CDWQUT,,3IR-C5&FZU\0=C
MUK`I+9O(CT9MYH?)QT#)H>U=37)PIZ`<@V);R.:IE3-&"72LN,:'Y+*,&Q+%
M$G.C]M%49-9X_"0@7#9G":+RSR@F&`1[#:\QY#]1.@7,^F`436]`<H3IPXX;
MI'5=S;Y%GU851$J!D=LW#:]409-RRQUA<EB\R3Z1P*LXD@89*]'OHT;N\FJ#
MDR(9Q(`\U5PMW)_I>XVX4NCDMMO>F^<;27-UIW%55A4*V61;7/\`S3>B6?<:
M5=#M759K/*:U@LH9&MA.E9OZRL?DR:.&M1(0[=#'%.%EJ[E272;K_L7K.X>9
M8O:T2C]00_G'DRA0'T\X#M2)N;RT7!T+:<E23!S2P9LE%IVLD8&Q&%_6I5*=
MM@A)YN@"6Z#H/Q^6"OH2@:(XPX)N;F280254KQHC!;%E'2^(R6!QJ0UV\0NM
MX)&VMWA:F1L$B<+A`*1.R(DMS)7M2"-&"7)2]K$NQ!!CH#ASJJPK/]'C*GX^
M1UU![DNC@N^8#HBP.?(Y&NB7OC3JIOM:WFM]:(U,E;DPRCI)M=%\C;W&1H$X
M%#D0(+Z<D4G_`%V$C4'%W5P?/:[ZPC[2Y5!<O0OHJEZC+KZL[=U!Y%45'V#Z
M'UK=-BPDFV(')F9"AEVN?FI[4O/[=<@IU#DX*T2$Y5LP!IX5W]"\C^@G'U'7
MW:T`L+I]P:!P3TBK9S2N765UW(K;JQDW9U'&>="R.L!]FR"71]TB?.1LG`N>
M&$]F>VEM&J+<W9M,/-6`#<?!T8EU_+^,*)<V'H]WKRFNI^MNZ.@K$N)OG7]N
M93-JLG2N)\L5C2LQE=I70JDM*1^=6FG>8@4?*75:815(52L0S#=FFA%BQ></
M1KBRANDS9E^\%D3M_J>$.%,.,.M^7H(72=8V1ZKW7;=I5=8L4IVRJ]=DL;N:
MMK&;).^3%.^Q]5MJ<U,=<WE%IK0(%@=$'D[K8?//F8HU1>J]8FBLE1NKSTDG
M<TMN29\16%,$C],'8AXFEBN(8K,GDD]UB^S'QT^Z*K&X05`P;#O`L1P&`P&`
MP&`P&`P&`P&`P&`P&`P&!S(5UVQSSRKZZ>ZLXL2;H7AW<X[Y6P6MZI@2EOE]
MQW5:Z6G[U9"*>IZNVY=^N3BRE4@<DR(Q`G#H+:(_YG`Q(E+./+"PSE_D^W[M
ML^*=X^BC.SBO]D_5%O,/+[8Z_N"J^%(=(R#"!)DQQ`PLUF=1R-F-++EDY-)&
M!&(.VQA"D;RC#5H6QX#`8&E^@NA:>Y:J:67=>TV:X%7,-1A4.;PX_,>K7KE`
M]$-,;C3*B+4/$JF$D<!`1M30WD*7%R6FED)R3#1A#L*T:EYZN'T'L.%]:]Z0
METKJAXBL8YQR'YXRSX3APY^0'FK6'HOL-O3&'-,PO\TD9:B/Q$P2EEKX@WZ&
MA4OOS*4P7+8'(=,O8WS4BWO\FMY^ZGB[?74*\S+/Y*E$E%#K0/*:NBBNTX#)
MQU>8WI8,>[J'C3%'5JC\@E.8W[T1L.E'W["$0=>.`P&`P&`P/)=7]B8MM@7Q
MZ:6;;V[)&!FTZN*-NV[OJ\!QB%E;-*SB=KW98!,8(I,5]YQFBQ;"'?V[^@<<
MM+^1W0M:71(9#8/C1Q-T,N<^M;+N%OZGM?L]X67F.(S6[GBPHV^2EI)K\]DD
M$N@;(Z%E)PIRV\E46B)`:3\^SU!X=C3(_L4F;P.\<>FF0-)BIQ0@<V1Q1NK>
M-:SN2MG=T8%J`X],)4U.Z`]*I+T+[R%))A0]!&`0=!ZV`P&!3U6D/F,8]N;V
M<)1;$JLENE_GE74BA[#(X_7S*AJB.#Z8L9""`197"8C&79_825R,Y:%7(%#N
M[[.5C`)7LD!1187"X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8$&O0:8=L5WS^]6+PZIY:)G5>DR*<6`GZM8+9D,3<:TBD*DSZZM\.2U#*8D
M\$SI2\(404XUJG;?^-L_0]:'LL00C_Y$W_Z!=8<WPWIWM$/'2"%WW5M66E1#
M!R_&+KCLH86V7M;J[R1OMO5K3F<-1ZY.F4M84/Z,?LO1FE7RC%KX=X&^.O.[
MH7S.[1>GX/#9%T?V#:C:L6TMR?5RE`.?2A$G.VA-GT_=U@]LM-4<Q.0M`=YD
M_B(;4V@C*3!6K=`2##E,\:_XS_=O%'IO!>V.G[LI=QB57EV;)M:KF:S2P)S:
M<RL^!RF&'MTA/EM=PQ,C;T@YLJ<'-R.$:I4K$98$Y'_6-JTP=T&`P&!41[<=
M@6;Q9PE.+8Y_M^O*VZ4+?(VFH^'3N*!L!9>CZ!U3;DE40R!HR5LB?I0NB1RM
M>G-0)C0HC$(#5@TZ#\E04$3/(6H.AN^:@Y<]//3R;,]MVP>QK;!Y)I%@C35%
M*4H)B?E3BC8[K.AK4<K03'H";1S85"%\<#3Q1IF5$$("4BX2TX0=%6`P&`P&
M`P&`P&!H#ICE?GCL>JW&D^G:FB=R5BYN")X,B\L3*!`0/C:6J);9"P.S:I0/
ML9DC<0N/+3N+<J2K2"SS`@-"$P>MA32G\#_)0<S>HDY3>^9(W,!+"D?N>GWO
M>]5\28FU>-M3QYH>XH"T")FG:74>B2TJ=:OV6H^?0"];ULO00N_I"C:@YKJN
M'4?0E=16IZD@"%6WP^`PMK):(\QIW%T7/KH8F2$_79JYY?714O7*C1&*5JY4
M<H/,,.-,&(-K8#`8%/E;1ZPV3VZO99-[&1SEFD/GA6[O7;,FA"")G5S$!=+6
M*DU#5KJB=G$R;J`/"94LTYGE(SOL5!(V5O16C!A<'@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@08]+NA:>Y@X2Z@M>\ILWP.#)Z?F\2*=5I
M"]<>Y2N>L"^'0V-M#4U)5SHZO$@DCRG3%%$$C^,(Q'&[+3E'&EA1#Y,]\VGU
M#YR<8<@>9+,G<K4J;GBKJPZBZSMZ#R-%0?'S\PQDEK>&-LCST0P./1=[J"4?
MY3$P,PA1L)1Z=6[.I";>R#`O^Y!XBJ3CUEE2V-+)19EV6LX(Y%?_`$S;+IJ5
MWE>\N2)`(TSK-Y6:44%%'V1*#\9DCC64ACT?1:T0@1DZV8(P)CX#`8%=75_>
MH*JGR'EGF.OA=1=T2YE)>6"CF1XTSQ&IXLX!&!+<74=BEIES=352HQZT,D)X
M#7^1F:TE9D*LT8ADA'LW@L=9TWT_U=U/8(>H>[)1S#=;&[W0YL^V:"4U%'*N
MI(8JIOE.N#U*]%3M4HM&;)4'EC-D4F-^18\K5)QXBRPVUXI?^T?YR_\`"!1_
M_P!$M>!9_@,!@,!@,!@,!@,#^=W-*J5U-W#>_'XKV\P(FFZ0L.*0B[NJC>SH
M.9>3P\M?HBZ]<))M/:24FN5A%]9MJ8:"')V9>,3>A6MJ,_:P*;8=%A_1$P(+
M>CX^H%7)=@1;D.O9E8%N6$NC%=*_[<SBLJ_L:#5E,7U&T6Y8U</UO3*OX,&R
MHI71SB9&PJW9*$I^,2*!?(6086,.+R*L-U%\75Y"+UICLN`)8+Q9Z@L/GLP(
M#+:ETT%Z)&=[2M9S\YMRNGY#,5R6P(W%7]E88PODAB8PY`VOBIO&<UJ$BY4%
MH]&L]]'>EL"7SIKNO_7DC]+[!)NE\+;;@W4.O+Y'P<I+94ACT:,=,:JL^W%C
M"-G2DJABW/SE`P%B5_;@63<T-/4[1Z^6>1U=/^?["F!GG!7!D8=.>:AL6G(V
MDBO^IZRP%HWY@LB[KU='"0;=`J#-J4[DE3:3C++T1]X!&F!=_@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#\;BXM[0WKG9V7(VMK:T:EQ<G)Q
M4DHF]N;T1(U*Q<N6*1E)TB-(G*$8::8(("P!V(6]:UO>!SB]?5P\_P`AJ$2+
MFRJG%157FU$9@)SD/99S$%YEO2]S5XN7H&:/<I1I<Z-[4X41#7HXT;Y/7$L]
M%(UB?;>PEC)*4.>@F_Y`^1U/>05!2ZFZSG\PMB1V5./W]8]C3!$WL9CT[)6I
M,PLK8PQ5I.5HHY'V9J2[V`H:I<K-5*#S#%(BQ$DD!;/@,!@4[V#U]=_<$ODG
M/7F(^LK-!HP]+(GT'Z0/+.FEM1U6O1&C2OE:\LL2G>F3HWH%)O0@+%VCMPN'
M[V':Y0N7#`W:"<_*7'M(<;01RA=/LKL>[2UZ-F%KVM.GI3-+FO*Q5H/H\65<
MEC.@?UF:S)W-$(6QF?$B0E"TE0)D:,LE,6&"]T<K6UUS6**LZOZ]M#D=&K,D
M"&>NM8PFLYHJL6(R./K(^NB#T58S`]:;&_12T9@3D`TQ^Q"WH0M_0&P!KGS8
MX,L+SYJDZDW[L.UNH:RCT9KR&4S%;)@]9Q%'2<5@2%^;ALT8601C;GE^)D21
MR1`4#=U2T9.FHG9.P",/V8%D.`P&`P&`P&`P&`P.#3B5';#?8<Z:X!%_XX<!
MKIN]`.E4I4$[X<7^1>D,)0BZHF2E<P+9$R-#"AE$A3$J-FP-8K^<XYI-:PB4
M&%!+WH.\O`8#`8%/E;#MD?MU>P;(35V1'B_/"MPU,;"%TE5O*J`?ZEK%$`ZQ
M"'YO1(D$PT_;6`V4VF*46T821_)HP0P!"X/`8#`8#`UO<-FM-+U98%LOK-))
M$T5Y$WJ6KX_#D*-TEK\0RHC5FV:,-C@XM"%QD#H(O1",@U4G`<H,`#9@?K]<
M#6?(_2+=UGSG6G1;=`)O5;59+&>]IH;92-*U2UD*2+UC:I`[H"E!AR#[52`W
M[0*BTJK0`_4P@KZZU@85#/1#A2PH%.K2AG7'/S_6U9BBX)Y/$=H14$2C(YLW
MF.4/"X/ZEQ(;/NE!!!Q:#19@]JU2<],7]R@@XH`:IA/J%S[8_2$'YWA$4N1]
M26),'&KHQ>VHE'FJEE-T-'./^K)UIE8%]F37<3;/&JAO^V%@SX>!E1*?JV*'
M`IU")$$/T6!Z<T!6O1P^>I#&K4,0MM@`IR77ZW-,(441!+Q/YWF/5B6F90Z'
M6`ELO]Z&4/"E#Z<H;XNO86X"I(0N<4JE0$K0;8XF["9.X:927G%*:N2G(<\+
M$Q462W0?2HWR6-2ID:GHN0M:6E;FN=O;6\O]5TD.3.JIN=DRY.<4<C+^/Z["
M7^`P&`P&`P&`P&`P&`P&`P&`P&`P,/L"P8+5$*D]D6;,(W`*_A;.LD$MF<O>
M4$?C,<9$!?RJW-Y>7,],A0(R`_[1F##K>]ZUKZ[WK6PIM0QNU/8I<BDECM$X
MH_RH(4)G.'5"[$O4$NCT+*)&I`5*;N;MG-\DJ_D16846H9H@9I.\SQ(,"UYT
MF;3"&XT+KF-C98RRM$;C;0UQ^.Q]K;V-@8&-O2-+*R,K2D*0-;0T-:`I.A;6
MMM0IRR4Z<DL!1)0`@`'0=:UH/4P&!HFR.H.<:@@<KLZS;SJF%P&#LJR0RJ4/
M<ZCJ=M:&E"#[SCS=A7F''G&"V$L@@D!BA2>,!1(!FC``05?[8.B_6TPT<Y0V
M9R3YA.1>PI:],&\5OU9WE&U(0[_(L8\@Q!,.:>8).GU]-,!`T4WE[4<(+B8T
MH5(D9H7#5_7T%JB%1BMZRA\;@%?PMG1Q^)0R(,R"/QF.,B`OXDC8S,S80F0H
M$9`?]@"P!UO>][W]=[WO89A@,!@,!@,!@,!@,!@,!@<"71CMSA2-U$6/#NH?
M!6_Y@#L.M8^ZT%3/EWS7*.LAI9UT(P1!_%"7-!*'1^E]KP`+Z)P4GFFMZE2)
M`I4@4A5:*).#OMP&`P&!3Y6RRV57MU>Q=D1VNV*/(_/"MTU3*H1-)+*WF0P`
M/2UBC`\V(WOT"AB*'3`U^$L+VV-JE]1`1@),_/&8,9987!X#`8#`8'R,`#`"
M+,"$8!A$`8!AT(`P"UL(@B"+6]""+6_IO6_Z;U@:1Z/AEB3?F^]Z\I)PC<<M
M>84G9L+J9VDRYS9(E'Y_(8,],4'<WYPC[,_O#7'VB0+$QRDU$@5J2DY8ME$F
M#T$&PKNI[QDYX@%6M\*G]@W#;,^C8:,#6=Z"?V.I+4HXOFRIEM-TJGIAXHZ.
M5PWQ(F'1-\=_R-&I5@7\U[7`=P+4I_XH0R9I\JX]&[7L2WXOU'T(RR>022]+
M#JS_`+/I!S*H>W>EFR'LMT6Y#3'.HU)DJF;ZR1(3>U:DOZPW,#>Z+2$24`30
M;+#TEGEM#17S9E]-%_W*SN<OGUNW5`(4-EI61PNG>@+NI.*\^3FX8^DEE5/C
MG-'8=5QM0T(FN3JGAF0H7QR)*3:":1^,$B.+>,H!Q-7L]A4)D+],'2U[BF%[
MV5+G]D@,5-D-AS-MC;`M4-<.JR'P.O8@PM<9AS4W(D#6U)BP$(M&'".4FGGF
MA,'`8#`8#`8#`8#`8#`8#`8#`8#`TKT)T/3G+%3RF[;XG+3`*ZB*71J]V<A&
MG+')P4?<6TQF+LJ,M0\2R92-9H*5K9VXA2XN2PP!"<DPP6@["LVO^>;C]'IQ
M%^CN\X0[5CR]$GI!,.7//"2[*VH=ST9J%WB-^]T-:96K:I3:I)Y853)71FU+
M!"A:`-=^>\:,,3!<Y@,!@1:ZT[!ISC2NT<ZM56_.[U*7HB'5/45>LQLQN:\[
M&7EB&SUM3U?(C2W28RYR^W8Q!!LM(@3!&K6GIDA1IX`Y#/%SR+J55['>D%M=
M4<Y5_#)[SNHYYO&H.827]+:=<\^2OLP=F6\TDB>RD33')5-*79(.2W(=E(U+
M*W+G`\U`(P:%O6A#N8P&`P&`P&`P&`P&`P&`P&!'/J6'],3FIU;#R7<T#H:X
M#'QE5([!L>KA7!&4["F.,$^-1L,#)(KL]8YD;"$E1^7K\?8=[^T7UP.-BL^C
M95`.T&-J*ZDX^0%)^AD%32?K^%^%&X913];)]CDQB2P!%UVUS3\-NE3Q/"1M
M.WP6S&P+N8$[:LP`=F:#NSP&`P&!3U6DBL9\]N;V23JMT,$9X]YY5TSUT\))
MRAEYMCPT/3%C*BIFN;$C,U&P=4:ZJ%*3;6>8L-"%-H[YMZ-T$(7"X#`8#`KV
MLW@<ZSNM%75:SJ'HV+GIJ*G=(PZJX;-E+#7T&U9$941R53=G:TY@DBZ1&J2&
MQW3EK4YZ8I\9T2T8#34J3:8(Z1GR"`PP#D."+>WNP7LKFRWGZZ+`<C[.?4I_
M0<HE21"X/Z22Z*>1JXNR_O9K*7(2"5"W2)`L=$WU-6.JMT$&K9YV/V]//3"8
M<\<SIG1ZJ*D;GIVL9ZV*>=I<JIY:B=N7Y#?5TNUE]@;9G2#P1TBZN?UTVMD:
M;1BE1JYUV:%(L2_D@("('6<H]-IS$(4R=#5UV&<LD:/JTN2TWQ[!91&*Y)Z,
MA%,Q=KXRAD,NKEJ;S>X$]`67.+J7/KC.;&E3!'2WZO4VW9LC6B%#>>&_^UII
MT2LH3DFHEL'[GLR.5[_=ZM^I7ZD*UZ:CMEW[?]*\OG,=.M8);4J!KLAJHBZ>
MB)$%X%/]'((:L61TG2YU+;CS-J`CASO'^[V#I*HC^EW3N\RP^5'QN3W[9;'&
MNH)A1\KX^IKS18H.M*@C!%6J44WUA>G3?;]AK):H31Y%++`2KV#[!I2`MZ4D
MT+:O'@,]-XV$[VD/IL$]D_0?3\K=&WK6/WK';<C\9D5[3ATJ:.'INA&*/S98
MQL=+*(XG(4)R1-8CP'@(%]X#@`"TO`8#`8#`8#`8#`8#`8#`8&H;ZME11=13
M>V4M4V]=Y\*;4SB755"Q=MFMNS+:AS0MNV^$19XD$6;7AR3A7;4F%FN";04I
M!H]"WL.@B"N/A;V$@O?5J2:L:\XE]"ZH1P>6637,\M6^:/KR)5'!;4J8PE/-
M:IETJB5U3U<R6(VKCM)MMQJ'0@J/\LP1>]A^H37ZTZ_IWC6MR)_:JQ\=7:1/
M"2(U74L`:12ZY;QL5U,+(8ZUIZOTAY+I,Y@[*#@_4LO9:5"G^]4M/3)"CCRP
MA_SYR#<5ZVW%NW/1M*QJ[>BBPUWYCY#8'D,JH[BE(;M80AD@E@=Z:;?ZK<FA
M3K3Q.#B/QF<P9B*/%IDH-J%(6QX#`\MX?&6/(A.3^\-;&WA,+)$O>'!(V(@F
MF[WHHH2I:<01HPS>OH$/W?7?_P"&!`;JOT'A%*K8A4%#Q\GJ[L.X"5NJ6YLK
M24-&UK@B0F@3NUE6U-"MN+'3-(Q,9FQN4C=_L`<,L25O)6K=Z3X&#T!PI9,!
M=)_US>L\@/0GIA-Z]D;!%[0E#+)$_/G/:=R;%*J/45SW`0.6Y#!:&:9*:#]9
M<2C@3*7E[-4N:P1HR4Z8(3<F<:^T%0=ZWCUU;-C^8#M'.P'#F5FZ<CE=P_JP
MM[:H!S5'Y=$6(-$%264`0,,P>F":K!*SI`K>D1BP!(RRB"P#*-#H>P&`P&`P
M&`P&`P&`P&`P&!IGH2[F#G"G)Q=LJBEE3:-U^A0.CY':A@KQ95A*6Q6]-K0L
M7L4(8`&/3Z2Q$N.UZX*8`S26Y,>=H`_C^W8<IG-='5!W0>OY7YC]PX'-?.MU
MO1VNI^\^':@Z_BG73(4HZ#5=%R6E5,PL5;%KT:X6GMP9QNG99'#%R9+O;?\`
M0TL`3MAV,X#`8#`I\K:72^3>W5[-TGJF45RW1#SPK>/1"02!_@#T@M:.ZZ6L
M5P#/(LDADLD;PP,8G!:<@_$D"9I=M'HS!_B_CC).,"X/`8#`8#`8'BM$;CL>
M->SV!A96,^2O1TDD9S0UH6TV02)2B0-JA^>S$1!(W5Z/;FM*G&J/V8>(E,4#
M8MA+!K0>U@,!@,!@,!@,!@,!@,!@,!@,!@,#Y&,!8!&&""```B&,8Q:"```Z
MV(0A"%O6@A#K7UWO?]-:P.3SS9]&*9H^"^BL:J@:/JOI2\_:[T34<V\TT?+(
MQ(9O;*>56(QN,>L)P<TK@K::^Y\1MJDIR>I^Y["P-S3OYBAJU!B5(I"Y;D7B
M&9QJQ3^S.V)>QWEW5+F-0UIW1E(<@4KRE"WQ(D"Z4;R=%'Q2M/BL7WI.$I\D
MY_\`^I9B>`1Z\X!(@(R@LOP&!B,]G\%JN'2*Q+-F<5KR`Q%M.>)5-IO(&J*Q
M.-M)&PA.<GV0OBM"TM2$L0PZV:>:`&A"UKZ_7>L#G+](;6FGKWQ'T=1?*O/7
MZGR*Z5V[3*5]V=*MLKK>NW4NL?Q;%:G/C^J34+7:]Y2`+I'BQ-\I5@C<&WLD
MS1:]V)&(@P-P?QK>)*3Y2\MN;[&@D99S+8ZEK.,W=<EF#:$A$LE2J8A62&*1
M-6Z:T:MW%Z[87<MO;TFC=)M':4+-%@/6'[$'0%@,!@,!@,!@,!@,!@,!@,!@
M,#1O2;OT(Q4?8#IRI$:YG70:=M0`K*+VX^NL:K9Q>53VUI%ITO>6,(GA*TM;
M(>J6;`E^AYXR`E`WK8];T%"KGX>]&]P7+6_1OK)U34,IEU82Z*SR%T_Q'S?7
M571^,2.&NB%Y:$:KIVSXI+>DYM#35",LD]J/-;0B*3E""<$?]0ATN8$=^L'^
MS8MSS9TAIUY>(_8K0SH%C"[QRD73HZ3)"2WYIT_:B]*M$P@:R=RA3'!*RFTG
M;F60F7#*5'D+""#$:@.8J.>QG?%D\U))5$9[SO%[:YIX([1[KZ0/DE-2-0*T
MW3ECHM\JB*<UR"`*9ZQK>>K`?8)'S54T**5.JUKD2U$2AT4D-WO83/J/TVZJ
MLKJ"MYJ<.NVSEFT?1N7^;2/G(ZNW@%R1=7&>1'OH,F_EUJ#DA8UCAN=QE6A7
MLPX^2VIHV<F-T9^4,Q0`-W\T7=*;T]?+/D$KYKZ`YD5LWG!7#(EBO0R>G$TD
MD:0/3UEK=29A!3%QW.R;CYAJH2;6UBY&M_((,^J;1?V&#"[_``&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P(#>IT@KZ/><';HK0F#]!8A)>9K?KTZ0Q)(
M8Y3(+Y9L+=J]B+/"&8I4A,D$VDDLDR)N:&[1Q/Z@X*B4^S`!,V/0<_?\;7P&
MZ<\N[8LCJKJ&R:WW)[9H!OK&/4M6CC(I$;%TLLDL!L9]5V:^/T6BS>DG$2<(
M82T@1LXG9NWM0K,"O-#\.]AU^X'R,8"P",,$$``!$,8QBT$``!UL0A"$+>M!
M"'6OKO>_Z:U@533GTO,M282&DO->JO\`6Y;<>=#HW-[812+41XFH9[*$02M)
MMOI(I&[MLME#"):6<HA\#22>3;"`PM04@^W9H0^H#YH;LN8QR\/2*UQ=OW''
M')/)(36KG&P1#C&A7TO12A,93W-PU[TT2*3,"G[RTTQFJF128P(0&D&-_P#0
M@`;P]!V7L>3\[/\`7_$\"H&;S:PT,CKV9I+\G\QKMA8*]ED)DC$M?(JKAD.E
MIKE)F]U6)/C3*@ITWX^S-_<(6@AP([^/E/=]\U<S0/E_LR!\U1J*\\U+555T
MY*:+LV=3R23@F*-3DSR)UL!NE,&B;3'Q:3(FX:72$X_Y##C]""$(`"$%N.`P
M&`P&`P&`P&`P&`P&`P&`P&!R:\]>HO>]-]/R'@&?+>!>@K,-Z;L-NBQ\_P#1
MN&M?1C96LRLAQ=8M7$@A;57)S+(K3@$56"2)F5)MK7FIR$R4:$)P1J#PZRL#
M5]PTW7M\P9;7-GM+H\11>X,SL:0R2V8P1Y3N<?<TSPSN#7+("_QB6LRQ"XHR
MS`F(UQ`A:UL`M[`(0=A#IV\EO.M[AE:5\Y<MPDZ(U,EF3?$FDIYG"/:QIL:8
MM=A6"Q3YP12I.Z6U'9S.&9,ZO#=*SWI"Y+BM&J"C!;%O8;>:>$.2&/HU7UHT
MTE&T-_+'1RD`YN2X27\,B5O4);:V>INW0@;X*OFJP'FOFDAE62!*U$O2IL")
M.:J&488$00QK2QT\[]N;V9R8;8T5'7/GE74,/<9U#7**L\R-*Z8L9UW)*Z<5
M_P#DS&&F!<M$!<DW^2)42<5_TB]X%PN`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&!3Q.]F][^BL>J1*+\_E+S,DD4MJXE!8!&-%H][O;$3(:.JS:O18"'
M!KYBKU_+F[R44<:67)WV/E'%Z.0&:`%P^!7MTAZ/4W24_%SY6,<FW6O8*M*E
M4MW*?.:-NE=@,21Q$E+02:Z).N7MU=\[5[HQP3C.>YFZ-)0TYNAI"E@_M*$&
M@R^(NG>VA%R#TUM-"P5`M$6L0>>/+<LE+!2QB$>TZQ*V=07BG#&;*Z9<DXM:
M+7L:4$>@1AQ/T$W.1?T.&%K,%@<'J^'QVO:UAT7KZ!1!K3LD4A4*86N+Q2-,
MZ0.PI6MBC[*E1-32WI];W]A)!0"P_7?TU_7`RS`8#`8#`8#`8#`8#`8#`8#`
M8%770-@]64ATE(K>L.]^6J0\\FJL7%O,E5R6.R5LM9;1=XT%EAWZ]+YDQ[BS
M22LLY81LI((I1LU%]QWZF8/XX^:$&*3ZO[)Z3YY?:\YV[I\S[][8:>DEL\5,
M5)]#P.UFQJY!2V$H3*C5L.@[P[R8"4E4Z-J8@2A\2J/V^>2:H6ENNQ1XX.@J
M($R5/$XN1,U"%7,"(ZR$RM4V'_DMJF2EMJ8#ZH;U/Z1'_P`A"<Z!-$4/\!%]
MY>];_')^OQA#(L#^?I8ZRO(-9SGY7.5W^-9$-6=N'61OMM)-'5S[;BRIX["4
M7F*+.C/'(F]`0=2L#B(4-"88\`;TZ$)292<25\FPA_0+P&`P&!3Y6UI1&P_;
MJ]F"-:E@7*K//"MX++PR6N[#@R+]P!Z6L5]^Z*NTWBT=:;"CXVUW($!YCY[H
MSC-V,D*K9Q1I8`N#P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!"SOOJ=PY
M)YU>9O"XX7/+SL"21ND>8JN%L_0[0Z-M)4:QUE$S-IRS#26-&L">\OBC_#I%
M'FE>IV+6B=X$534%"^5'GNBJBW>DW:$6I9+;."7:[8S']S/H6_>S;N,<'R?V
MC4]4-;(_26UK1?[5E`W)J8R&MR*1H2TB10#3>FWL(4.^*D&]IO1]FZ(DO<7I
M-T%4M'59=4XY:F]2U]#ZEKKH"2V%5KC'%UBLI-G1Z%IY!1Z5F<#RFA<M9]B?
MC]B6)TBM#K6U)@=;W-W*O/7(D`U6?.54Q6K8H<N->'L+&E.42&9R12'05TPL
M.9NQ[C,+%FSG]-;5O+XN<'15O6OE/%]-?0)`X#`8#`8#`8#`8#`8#`8#`8#`
M8#`P>PZRK:WHNJA%L5[![/A:Y0C5KHA8<389K%UBIN4`5MZE4P25`YM*A0A5
M%A-)&,K8BC`Z$'>MZUO`HI_CI4C2\7XJ<;0C-15?';+5]+]O0A78C%`8HT3I
M3"VSJZQ$S;$%$M;VE._G1=O3,*$LAO$HVD*`B("$O6B2]!#H.P&!P:<2V%/H
MW8<YB44Z9\`^>X2D]`.E4R7G/KIQBTB[AAJ!QZHF2Q7&$\Q-,BRBPG)W_-&?
M"G7[W7Y6Y6WIPK1!("G3!WEX#`8#`I\K:UH+8WMU>S!#W98Y.M4^>%;P*=$*
M8])64EJE(.EK%?1MZ)<_,[8@D:<+8\)Q[5MAJQ%H8A%?+\I9@`A<'@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@4(_R#Z@E^N$;VZZK/JWL_G.SN8*8D[[#6
MCFKI6?4I7\P<US]'_A56A%(>J2`EZAJ!LP"0[1Z4\HLX8-C$'[=!"GKA\KJ/
MH+KIY7<..?0/7U0\MH5\1HCO#T8OF<7WSK!K]MJ)1R.=871`9`I-22V^7JO6
M6,)X5`85%CD[$E$OD3NY/R(MY3!.#H2C/*E6<"QFP^XK7:.CO0?L-JC1">7W
M6BKH5R=+OK0\.3<T+*[YFI2(E(X[4=<DJ7,:@49B*9"5^$$X]Q4+C"QJ-A`7
MPVZ*FZ"P^RZ6L;A_T-HQ=TMZ&]P=CU_8=\<@V5551-]7VW*T$MA;',+`DY"5
MMC]A+VU(,O;;]IQ(E6M%%*#!"#]0Z6\!@,!@,!@,!@,!@,"MI5S7W.=T+T_8
M;?VP)FJ2S::*AE`5U^Q6M]_LC8^WF4+D<Y,;G-&!F>A1;3D4>`P8S#GX"K]/
M<`:2-+>,P--).-_2HJF^+X7_`,PHQ'8--2!W<^C)A^UQ/AEM1U=$D+9'H>!V
M=&TMWF7[(5DJ4079Z`F5ONE>GI>7^J)RB\"XK`CIUM3DVZ"YQMFFJYM!TIB:
MS^-@9F&S64+@-TBR@#HW+U!Z,+<YM@MF."%&:CW^1I<W?:HW^<WNB/YVU4$2
MS.&N@1V%QW+A=D3@]GYT3DDV;'C4\J+(O@\J0O3VI<9:($[$)`X."%P(1_$P
MCCK1K90RE;>XQW\2*H0VUR5RW;G/MA=*R^R.C)->#-=,^9)7"([(2GTHJLFM
MLBC2QJ&5JVMD[FC.0FF(0D%#6$N+^-,C)&N>UXAA*2A.7`P.S+2K2EH0_P!F
M6_8$+JVNXJC$X26=6#)F:'Q)A1!WH/Y#M(']8@:T)8QBT$/R&A^\>]!#]1;U
MK`YR?4N^[P]8^"ND.6?,SCBY.C8M:K''F474,[=H9S-1#J3'Y_$Y6:&D%E[N
M\0EM\+%1L9.2_G(FYMB8`?<<6^'C"6F/""G\63R/]"?.*_>J)MV;S]_9N,61
M3\-BT+<_[K4C8?ZR_-4T-=EZ'\*JK)G+@W?`WBT9\JLH@D7_`$0CV+^F!VNX
M#`X2NC+CKFD;@(G,.[C\3;_D0.NZUBCKSK3/G/1,HZG&U3KH!@A3^GA*M!.'
M1XE]GP!.^B6J3#1MYRG\!2>!0%5HHDX.[7`8#`8%/5:6]5UF^W-[1^O9]%9F
M]U'YY5U7EGM4<>$;HN@4Z(Z8L9\.B<I3I3##&=^+9W=*I$F.T$S1*@`OI]!:
MP+A<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@0D[#]`>=^*T+,VV0\O$OM^:M
M[DX5;SK5S<7,+RL\AI`:8ZN<?AY:M&2RPMA)3FG.\H?%+5&&5.28:N<"`@_J
M'%5Z>J/:KW;J(]7RY6BQQY7A\L$8]TS2TJBC54LE<$YB="UI0]'V#+8$7VK-
M(JZ"7?K9T,9RZPCYR0D+8XORW[UA(=6OA+ROTQQ;Y?\`.'.O6AK>FN"$IYNJ
M5Q-O=FN1:KJ-R>=R*3QF`+I*R*U[(_ND>;'<.E!J(\]&089M*0<>4G`>:%O>
M`P&`P&`P&`P&`P&`P&!79Z=\Q1OI'EV>*GZT.A*O74S"[*M>*N'/]WSJE%[A
M*(_7DB,:B9:K@[BW'2=C2G!^\*-3L181[V(/TWO?U"+O@?1":!>?7/\`?[C<
M'1MLV'UC05%6=9I][7O85Q,K3*@19R<%9]<LLW=W1)`4KPIE1WYY:'[-K0ID
M@3A#TE)^P+M<!@<ATR\<O-24^_R:H7[EB+N%=37S,L_K641H4QM`@IUZ*-[3
M@,8':!C@EG)#NG>-L4B6I_QR5!;?K1^Q:3_?H(@AT_=`]-\]<I04^R^D+EKN
MEH0488F3OE@R=MCX7AQ`2(\#'&4"H[3I*Y(J`'Z)VQL(5N"D>]!))&+>M;"O
MD/7'=78`!H>%>9A<_5.YDZ`1V-WY&9/"].#>I4!*!(*2XV:U3+=$^">T'A7-
MJN;KJ];CM[!]2U1>Q`V&>5OY74KJ;L%U]=3:PO0+H:/JDSLQ6-U(;'WJ!UV]
ME)]@&II#G"+L[!050$E*AB.3*43$H?B1_:(UT/,!HS`L]P&`P*L?:ZV;4HOS
M%Z?M:DI-((A:<01U0IA[[%WTR,OA*]QO6L&52@1OQ01B;"WQM<CT)YFPB!^.
MI'H81!WO6PA/6CQW<P6RPS=+_&PY`JR0NDL1*))<D5[CY/%.F`EX?$RJ0S`*
MUBYB:I*^.B,0AKQE`6EJ%AY6M?)HP6AZ#HFP-6W/8<BJVNGR:1*H;&OB2MYS
M.B9*JJDV")9K*7!\>F]D3EH7&SIK7<"9VUL$X?F.*YT>429&WISSON&(`2AA
M3JG]]N=WBDJ_NN'\[=2S5$YU->]_W=$6*/58FDO,]&\R6L.E+LLFQ3I!:S+'
MY:A8)^0>!N01!;('5W0(EBDI.#\4XH(27BOJW2\RZ@:>?&.L+F/@<DNUYY<B
MW4XVZ"ET5).GX]2@NA'FF6U+N=_W;`J3UD4<(M[/C)+"H=TJEO+5"-($+8:W
MIR[*:O'V)L*04I;=8W`P-'FE6S,ZO=6SV*V`T-COKJ.T%NVIP<HFZNR)$Y:1
M*BCO@,&$WXC`#^W[1:WL+C<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@8W,)E$*\
MBS_.9_*HW!H5%6M6^2B83!\;(S%HVRH"MG+G=_D#TJ1-+.UHB0[&:H4'%E%A
MU]1"UK`YN^P/:R;V"9':PX)994R-UL"6M587TKJ==8EZ]$#3&JT;D?Y^<D/@
MF1=:$=;#B-_DVW81L<J-F"6:;\[SHO1(P]+C?Q$<Y:N?[@]#AJ'D^RG1))9E
MS$98RZW7NU5Z(;>L8W3OOIDU.SN_4[XS*VY.:F@+"DCM*QT]/]B!B7E[T?@=
M(S2TM3`U-C$Q-C>RLC*WHFEF9FE$F;FII:FY,6C;VQL;T99*1`WH$A("B22@
M`+*+!H(=:#K6L#T,!@,!@,!@,!@,#%9=.8=`6]$ZS63,L7;W-Z:HXVJGMP3H
M"W%_?%.DC2S(/G&$2QR7G?7XR2]"'L(1#^GV`$+0>'JWZJV^$1O5CPG;XI9=
MR),W:DS1L]0QA:=2`3F1O\OXS4H8_O3AL01;^B#?Y/\`\#_,P/:B$[AD_0N#
ME"90QRE"TOCU&750R.*9P"V2&..:IG?61Q"08,:%T:G-$:2<0;H!@!@_KKZ?
M3>PRS`8'*I_)V]7B>4..WFGN4.HX+&^L)'94;A-G5]&FV!VE+6.DIA#;`031
MNG3'((S-V>M@R`S:("0]>!K=C_IO:`S?VF[T$+?XR/H;Z06+P=(*]9>9'#LB
M&T#8C+253R45N\[<\1^IX%'*VA!K+6[L6ICZ2;RTML+6C6B>3D+VO-"JT4(T
MP1?VA#H\'TOZC#`("7RYK("D81`3C<_0R%I&T)XM;T2)P5-W/3RX)D(3-ZV:
M80C5G`+^NP$FBUH`@^3KU]=S"C2TWG+QPE4F%C`G5*_3:>*TJ8\8=A*/4I4_
MG>G4*4Y)F]"&6`PL8PZWH(@[WK>@_G^W?:GLX[^[$A?54VZ=J";+NI4W,6[!
MI;^ZMEU36-&RCH:/.KS`JYE<ZKV*M<SH9E?$Y3H2B=V9$UN`$@!*D80;$#`_
MHA<]^:?-E$SE+=TA)G'2_4($YI*OJGJ:6*;DNHG:@7W*"(0M>2$\.IEC%K_+
M`U0AGCC660$)?P;UK>]A8'@,!@,!@>6],;+)&U2RR%G:WYG6?#^8TO3>D=&U
M7^.H*5I_R4"XD]*?\"H@!@/N!O[3`!%KZ;UK>!ZF`P(K=L4=<?2G,=J491'1
M:[E&P[*928RFO5H@IEA/\-8%R]*&6`CC&1.:Y5H7Y^C6E3>F=$SLE6-(U7Y:
M86E!)0@A4I(O$>TGBL8O7D>ZYJ&K?GXJM'SFMK=6\8KV.*RWD"R)>QR@#)74
M6D'4\L<*TNED3EO:0R7N;M+4SJ-_.6+&@Q84$X8;SK?R%!6O1L8FK5?3:;RG
M`.P91WA`.8@TFA32IDZ-D_/)_/VCW&]-V*H0.M8QQ(\NK\ULI$,0N*9V7`T)
MU-3)22,#V*GC=/1#V?MF.U&P5K&`MOF]68)HQ5RUQ=ET@DZCIJR580RALC)"
M;25^/9E"4W6E8`J!)AE"_J#8-["XG`8#`8#`8#`8#`8#`8#`8#`8#`8#`KDZ
MW]*JAYKDRNEX(P/'2W5_[;,EA/.=7N["W+(7$``T(VR^AK3DRI%67,]/M^A@
M,4R"6KT>S2-[$WI7`P.RL"AV-PKLOV(FK?+7"5P.U:Q87PM8W6V]0R0JO+JB
MG!`MTE4`Y<Y]F@&&2^I/0$66I5&D]D6&4DJ9G6E;-:6Y2+8"A!T9<E\*47Q^
MFDCU"DTDG]SV)\!UP=*6^];G5^6ZL3?%^*7+ITK3IQ((NTA(++:XVSD-D:9B
M2PEH4!&M;^X)EX#`8&$V-9=<T]"G^RK;G\)JVN8FE*72F?V-*F*$0J-(CU:=
MO(6/\JDR]L8F9*<O6%$`,4GE@$<:`&M_<(.MA5!YI7_"GN?75`9)ZW\I=^SJ
MPY4.9U+7%0W334PF$`@K(D7#D!:>.0F3.#ZI0_8N2!4A)3;0(PH0GZV`:H[6
M@N5P&`P&!"!3Z)<K(;BOZC%TQE">><R5IJV;A3%UE8SDEC</)/=2W%0#]&C#
MBXK5B)(W%K""BTWT>D2PLYH$X@)6[2!K4KUGXK%6O,MK'369)HIUG)G.&5(;
MNLINN.6RUA;"%S_'%1[2SN+2XO2!<J+0)$[.J=37]5HT3)IS2I5:E.&ZNX^=
M.;>DJ!>V'JYJ>':G:Q=$5ZO0&9?*RC$1M4HG-_,<5;%$@+5DS1IF?\S_`+*,
M0.6S#1%GI"`N2="H("EZE>X/`._^WZ_?Z>N&TI5UG)82Q<Q1)N/JGT`81BC\
MMC!=?1UB?'Z956SH8VE71@D98%#JZHVO:O8WD[ZNH-.187@\G\>T3Q37SY6'
M/T<=(Q#Y#/)98KBW.4D>Y"'4@E[D8O6!0!=EBA.U-Z)/\*4HM,64)0$C\E8-
M4X'JUB@-+]#>E//='STZB88FG'4O5@TX3D?*W+["39]M-X3MZ`G<;*4$KV^!
MT9%_D&$1CM-GAA1:)WL98CMZ^S8:(_TZ^@_:W_7>PKG_`-$]#N/^/_2/Q=-U
MBJY)(U&_U_2;X[3_`$]I>V_YRMB*6M-9MS"7L`]@T_*P_P"+83QI+D'E_G&M
MR*BI&AZQKVO"UVG=7'F>*MI^GU^^TP!DHEKJZ%+WN9RY5HX?SN[LI6N2C8Q;
M,/'O>]X&\V2-QV,IS4D;8&6/I5!WY!Z9D:T+4G.4?8`KYS24!"<LP[XRPA^[
M>MB^W6M?7Z:P/:P&`P&`P&!H'IGHN(<K5$^W-.(G;4W8&%<RMQT;I*K9?<5A
M+U+ZYIVI)MKA,(;G)Y5)4YJC1BE1L`"$Y(1"&/7]-;"'G"OK;S+Z'2UZBE`P
MGIY`6R,,E?#IG:7.5C5U6JPR'RAMATFC;?8CNW&1(^9,S^YZ).:1*@+0[3J-
M?'O:<[0`M!P&`P&`P&`P*EH7!81#_:^VW2)0Z*Q9SG/F]7$IFSC'(\T,BZ82
M<SJ"S6XR1RE6V(TJB0/QC>A(($L5B.4;))`#8_M`'6@MIP&`P&`P&`P&`P&`
MP&`P&`P&`P*PO8#J3I#BSA>S^GN85_+2:;U`(J62-NZT72E#")1!&]H>S'6)
M07]J3:OE3C<,@>M-Q#`@/<RB7$S9J8`#%1J<&PYDN6O:?TZ]$*/:W*VYK17/
M<=N>3.T1IJJO..MY;.?2CHLZ(FKVV?,-6QVS+FM*!<XUZA/,+"[VG+R6I)&R
MR?E3"WLX"L@+C.3/&%.]1Q`?V7&H?#*<42@BRD7GG54LD,YK613\Y4)X%9G?
M'0<F-_N3W]>XW$PHU6)^.#"4*E-\29"X$!*48'0@V-C:R-K>S,S>A:&=H0I&
MQI:6Q(G0-K8VH$Y:1"WMZ%(64E1(424H!9118`EEEAT$.M:UK6!^[`8#`8%9
M7L9T'#.9O-CK6TI8NIK3HU5%*P5O&;V;(C)8'/K4+;3G"`0L^#S38F>>N3K(
M$!(D[3HHXU0,K[@@_P`&Q!#AE_C+>F+^Q=G]!MD^Y/:[+CTGA]^=+B5\@\7L
M,[O>NK`L2TZC0NX(]N`-V[!C?/#.ROR]K2QQE*4)$"AQ1DE)MEBWL(=PFO9S
MST:1A369:UB<^.`#!DKT'3O,W3W-WZ0<4>8F4`=':Z*>A4=3%I3B#=&G:6C3
ME?`=]QFO@.^P),5EWQPS=(2-U#V5RQ9QBGX]%IH'T!5,J7!--+`:%,>WLLK6
M+DJP(3`_<0:6`X&]_00=;_I@2Q`,!@`F%B",`PA&`8!:$`8!:T((@B#O>A!%
MK?UUO7]-ZP/K`KF[R767S[5TSZ!Y<XVHGHZS=M+B5;Z:RK!:J>^"F(NS3*>/
MR_3Z.OYP=+CM/VQ?]C_8ETJ4.`U(S!B+^T01O\K+"L3MSGBKK@O_`,_><>=J
M64US7]A\F&P>TFVX%SE%9]%E3>\(G>+K*SB2F"')(PA:RE`352S3F$T(#2_N
M2!&(+HU"A.C3GJU9Y*5*E)-4*5*@T!"=.G(`(TX\\XT02R222P[$(0MZ"$.M
M[WOZ8'\_WSR_D=UW8/K'V185?\6=%V/(/15KY)A55537[[7#K/6:0<N5);K,
MYD./Z^]Q6,JT<K528L_2H;@C3-2!.>H4C^PO>MAU%?Z=?0?M;_KO85S_`.B>
MAW'_`!_Z1^+INL57))&HW^OZ3?':?Z>TO;?\Y6Q%+6FLVYA+V`>P:?E8?\6P
ML'YYY@Y[Y.@1-9<X5#!Z?A8%`ERQKAS,2B5/[N9K?Y$@ES\=M1(9I*%NQ;VI
M='96M<5(M[$:</>_K@;WP&`P&`P&`P&`P&!2!_'O_P#;P4_\7_=?_JTMK`N_
MP&`P&`P&`P*>JTJ&KJR]N;VD%>P&*PQ[MSSRKJP[/=8XSHVM=/9T?TQ8S&=+
M)2H2EEF/#\8SM"5,)2=L1FR4X`_7Z!U@7"X#`8#`8#`8#`8#`8#`8#`8&+O<
MWA<:5%H9'+XO'UQJ<"LI&]O[2U*C4IAAI(%):=>K(.&G&<0,&AZUL.Q`%KZ_
M76\"OZ^_1>.L5@'<U\>00[M+KX]"A6+*SKR1H6^K*3:G@@9[5.>I[R"0[1*E
MXB<F!L]*W["XRQ\!K06IH5_?]X0Y6O9:@U?6K8+G>].VJ%G_`&*7.HJ?T%T7
M=MCJ^<O+[S-C>V*03%DY[J0"V3B:!]178ZM:)&GV^E3*Q7>((71<J3,C:,L)
M(3'_`(L?"K;P^Y]8M"7MKS6[#<+(9:Q=74/%-YI[UGM=#C3I,D2,B4/A;7'C
MVR"R5,[Z,++,0%[,<TV]!$+17W"#L'P&`P&!SP^\'MG9_C9_IR>(YS-"[YAU
M\_W$;3'1ZMQX@;U'9+`?VJJ-0:9$5?2=.L:U[7*2C"U7YFA_*686(D&@@&:&
MG?._VI[X]7Z(='OES@B*U5.U$ZD,8.O^Y9W*G3D2L(RU-+*,ES5K4D6A]B7A
M;0WE4K#J(18@MN2I?Q#G-^;A'[)"%I]+^851Q^9BO;J^4/7>753@TJ&A;=71
M+(Q.47A+4X$B+=(GSW0I!2JI^?H*J^8W0DS0D.>5I9P].;JXC$(S83AA-(4M
M6KJH?:YJ&KX`]JV\UI5/,)@$4BKJI:CU*18>V*'!B:4"LYO.5H"#1DB'LL1A
M)8MZ^X`=Z#:&!&JSN,./+L^7=S<G\TVWL\6AG[LZBJNGOS#T<4IT(W]U19U^
M06E!`#-;W]=_>`(O]NM;P(EF>+WFZA`9^P.?W*B5&PF?C+.9[LO_`)F.0&CT
MHV$]&30]I5\A"(HY6:;HL9(R!&'&[&`7RFZ&#?F9)8R9^73WI3Z:U<K3B+.;
MD[UT#"^D60DX@U0<06XM_7%27TX/"'9AA6CBS5H3#BR`@V;K0S_E"GGW*Y#]
MAS>`I1&J0[7N;KYQ<IU`VMPK"M.68Q75_/[$I4')7=R_N1SA)X(@#&4Z0)GZ
MRW[B1J-P)5;`+X`!!K013_CH<"^K!'/=TUST[TUWCPE7L?G4)9X75A\!@J:;
M/T1;XJ,OX:XG?1<`M1764*:1E@2B11=L;_\`-U]?GUK>P;#HN3^./$DA.(<>
MA&:Y>TGXI44K&Y]H]#7+T4QF#3J0K$I1-4S28F4:U)4BK6QEE((ND+U]^];U
ML/T#H(4<<?QB_.#AOI:JNK*7?.E55GT\[.SS$D\VL^*/L6,6/,9>XFLT[M*"
MM618L)TUOY^P!`J)V$W01;WO6MAV'1)@,!@04[_M?L^E*<.LKC>K.?[5<H8C
MELLM-KONQ9I7Z5N@<6BS@_FJX<.&Q.2F/<@.4(!%[(4C2%:#O7T$+8M[`&H?
M*+J?L[L_GMBZ2ZDISGVHH%<4!JZRN>D]+V--YO(GB,S1J?':0!LUKEL69$<5
M<FI.)HTC+0K'$)XU"K1FR]$E"."TG`8%"TB]O9BP]2.'(A/E-Z&OMOIHJ_V:
MVL;.ST"-1(:8CUB)*Q4V\S@6W8C3CAJB3N*4DHPX\D?W*0?=H.M[%H+Z<!@8
MK,IU"*Y8E$IL*8Q6"1E&((%<BF4A:(NQ)1B`88$*AW>UB%O($(LH8M:$9K>]
M!WO_`&:W@4A]_>]7&W/5`6J^\Q7[4'1M\QY1#XPQ-5;`EM[5S!76;3F/PE5-
M[3?Z1;Y(U)8_7:)Z/=U+/IT1.;V8A"V)!%JE90PAJ'Q7=[2YDL5/P+*9"]6/
M7]DT;=?><,>K'H%PYEZ&J&0R'JQ7#Y]![QJ4VRK.1MD>N"03H4GKU0,YM<!M
M"!S)4$&?`#9(=(F`P&`P&`P&!3U6E3P2MO;F]GZ'-2YM=+7\\JZG\Z/5R24/
MQ3K*CNF+&93%Z%'(7EU11Q+MN:2`:1-A:-#H0-F:)T8,8A!<+@,!@,!@,!@,
M!@<R/\C?VCZ7\@VKE15S;%^;)FZ7JX6RGD[%>L>M22O1*"`IH&8A=XFDKZ>5
MNV)&LA1*Q$N!BYP./&:<F"G3[!I08`(4>9?\J><]!4Q94CZXYUK\RS(U8`&N
M-*Z/M[EKFZJ"868PLR\PZ;+.XNY8?+$#PE6&+A[<$!"ME,)T22(PH\)WT";;
M[_)*K%":44@K#F!M$J+-4I]S;UB\^C0)DA`CRQ_K!U%69T&F1N"@:?>TZ9.8
ML$,LPL1FR=B$$(>+K^0!:DI,"FAU2<+,1GVGKMB>.O.Q+9<0-Y9I9)*5UCM!
M^7<V4,+D9^0`8SA*E3<$0!E!4&"V6(0?XC]@>YY*5HJ"QZBW9V,+/_!;J\\W
MO;N^-/0OM%O:YH<"N7J495[&V!)$9M4F5J0.!(M#*T2$/U&`SNSU8FGY&T:^
MX(X5HPAM;]5G_'V[":#7D9WQC.5)U747=41W''`HU1^.!2Z(0M(-E[-']Q6M
MC&'$;_(QNV_+8[<B+'T%.+FE4MK^D8NE,8KPYTKCF:3P13)'N1.XV-G@==63
M;2=9&75C+;'4M<M>A*#5BY2$*8@H(1&AT:>5/5_3UD>4M#<=>2?$W39143^^
M,]U]IM(.-*QD#7*9HC'+YN#E)UG5VUI#;2N!02]$LJ60R'87B#,:=O.<$+@Y
M[($`-#^^G6,3Y<\Z()YM1O@6:<A2*:6O$[96DW-:_&U\S>?-[08].$\L6PW&
MG.@;HN-/8]LOXBBW&8N@$*R0I/U-O_/&0:I3;")G\3V\.\8G8?5-?\8<\\UW
MBE7QNM)+8/\`>NT]4H[0Q,0=)V9&X1F5LD(G\S>V^3JRDH75$6@4H"#F]*;L
M)!RC9A@=?-R]!?R.&@G8J@\]//AZ-_'1F:"9UK,9CO9QAZHE41]LC8.?0?(2
M#11V_P#,^P)?UT$9I@OL+"-N^BO?Q0/9E^4_;U)EFDZ`:GY`X6X\O1N1@-V0
MATY)9)-/7FVI&,[1X3!E)Q1)08`9A:@\L*4!A.P:N.R'(6E'3_97\A"OV\H)
M`EI<'\NX=7<+:0G*MZ6$.4FYNX8O1]TE2J"B"-&`D1AQ@]B$F//3G;^@?(I_
MXU+A%;OWTP]&W5.28G`X-G3?6'I)RVRB5[,4(CE#W'4:7FMD:5#8ZG[-6"VF
M2A:C?L+-TG3_`&D[#ER_DCP[SFD*[FA7YR6U2]AQ1MK>Y9G9#C7_`$O%+V>B
MW=@>8`TMS?/'RR;]?[/B2@QN<0!9&P:4\3V::=IN3GG$JM:"^+^,7VQR'Q]Y
MMS>G.I>R^:*8D\)Z?N)1'HA;UY\_0*7J8F9&*\6K72/,2"V9&OF$;7R_]6_3
M7(CY0N>M?5)LY/LC>PLW[\][>,:KXWZ$LOCSL/G"SN@85!S'2K6M.DD5PPEX
MEA3DU?6/.VH"Y,J+\Q6U*3`Z^YW)$WC.*5'$GD@_'/"JS@3^1?9,X["@E9=0
M=@\<7)0[]3=B2::N_+7%G?+-+85:D751A,U0([=DP=B>32U`'X:K;FD87=%L
MA$>F5%MYYZ$\P.A;_G)>>'_?%/\`_P`K?6G^XS`?\Y+SP_[XI_\`^5OK3_<9
M@/\`G)>>'_?%/_\`RM]:?[C,!_SDO/#_`+XI_P#^5OK3_<9@5,^P_IWS%=G.
M]<5AS9U)UG65WS^]XE"H),*6,["Y.01I4]QF9J':76W+F&B%<UG=9PQ@:U3F
M;%(ZF4OCTY)T99(2R=*%!(:1\8._J?Y46=)TYV9W'UST9<L5#39PK*L)Z[>Z
M4J69Q>2,4J<FZ25E`K+HA/:M"R8MY3.+;(6YT+&A=0H4*MN4GE;-`G"YJT/:
MW@^-UK8,@BEW&H9:RPF4N<1/LWGOJZ*U\*6(F-<?&$LP?SJ52";F%<^@3D*!
M%#_)&`S["`C.$6`0444;_(][(>)/QC)KO:_/E93'2$XA359L>YRC?=%K]"TK
M%I6Q+Y(G+>H@PU[)XZ[SQW2-XD+6U1U3*5"ET,``90$X%*E.'07OUCI=VULZ
MO.9O26TV\03S4KS%?.'K^.L3@G3#T0H.;WFUZIK=N5")7_5.(D)GY/R@'O1>
MRRQF!#Z_YB-WOPOQ:[\FO1^3KC#/B(.EB'C:G&'9I17Y2LI2YVGV!&W%-\*3
M^I9OX`DJ@[>B2S=F_<$(?YE]4^FCX66*.>4+?'##BT^P%W+WI2,4TF-4[^OV
M.`Z@A'0.BRT!7]%0D^E6PF?X2`J`?YF!23[E]:]Z5C1W.Z3L2+<8<N\OVUTW
M&HI;<8K[L/J*R)U.X*FB<R<#8991U<<OTC-%E*$R!.V+9:5!URN1.*'1*0"7
M2,UP-*#`?#GJ#KBPUW9E4^;Z_@JZ^5:$L:IFJ%5S/+X[2KB&5R1,*_=]NKI0
M(K,I&]+JC%2R^31-2,IAD`1MR1X1N>V8[2/>A&A?QJ^?6QC^TA_\YN5)?^.8
M-,I=*Q]&Y%K]0,#\GQN+:PV1Q'!_Q6LS[=:V%0X_E`^[6_B%_BT$&NP/0QL^
MW;[Y$6>[:*,&2KU6O8_'4B&8+7R:+4M&K%L2H`K&\0@AV(2H2!0$`OKH@0M?
M;L..JP/=&9H>YI=Z)M8D<<Z,JU9,N-#>19O).+&JGBN.VCI9C%)X4Y6HAZX?
M+_>[\>7^,@?]2-C@ZYC2K?\`"D3KHV2:O4!V"A4>S]K[T(IN\].+V!Q^70=N
M:N]>XK-94PC-`*&<A;0\=UP2\``'8_M`N=DGTV'6Q;W]?M#_`$#YY]`6$>>K
MZ2]1^UYZ0?\`4&H;S\=4_&4#2IC0"T>F2+J/@1%YA_S!?<4>;.S517^SY1?0
M/VADT)\?O-F&/I4N7<HP&W9N2(PT$^Z9<)=U;.P*SAE&J'!/+^E)':C\A7*#
MRM#$8F/)WH6]_;]NM[U@;MZKG7,/,?+,X<[SK0MTYM3-;?!9=6$(HIZMUG=X
M_.'%)$OVZ?3\!B4E&[1M<-U"4L+$W"1`3B%\OT#]-;"NSR5ZF\AK%DU@5?YD
MT\\5PO?6M9-I^^(>5;DJR/R4BOG-N@VFMYM6;0=N:')9"UCP%"WL9SI]6\(E
M($B8O05&M!>?@,!@,#&9G-(?7,4D,\L"51V#PB)-*Q^E,OEKRW1V,QQD;B1*
M%[N^/CLH2-C4VHR`;&:<>:`L`=?7>]8&@)OW#QQ6D6I.;6-U'0T"B/2*5B7T
M'(IE:4.C+3;[=)FMI>F)TK]8\NR(J2M+@U/R`\*I-L:<(%R;[AAV>5H890GZ
MKYF57ZJY52W_`$ZHZ60L.I.LH8BQ(J;;*5CV@`[_`)Y\$`Z"D100LQ@%P@;3
MZ-"@,`IV'1`PF;"ONN:U9H'[=WJ^-3[83L?9?G=6DT=T$ULN>3YECSEOI.PV
M0ULKMGF<@?&^MHB:6U!4_HC&!"T@6GGGEIP#.'O87`X#`8#`8#`8&G;QZ$HS
MF:!K[/Z$MRO:9@#<+XCY58TJ:(JU'+!`$82UMQKJJ3C=WI9H&PIT*0)RQ2/Z
M`*+&+>M;#G8MK^1S"K71SLG@6',951P)X.B-D>B790)/37(=:R(Y/L:9G@<$
M"W:O+I:US-&%B105H0,KRM$:2(6P)1[4!#@C]@+8K_H"THO;"/IZ[^I[4>$<
MP-L"Y;\DT#8E$N(3.L23Q6.5)RI6*27:Y+K=G*='-2W,DHDP7M=HM88K:68T
M"4ER"5GA_P!FT;SU!YY`["O;HFKI^[6DBET6::OX3YB[,AA[0".-C:F=C3;4
M@LAMZ$S+]S)RRB0L:XIK.UHD1J<1^_E"'14[^[O.5*(QI(M[13(I8X!)7.,.
M=?&5$S3!.?\`.-*2>>)`11D6&A.1:"<5H6E9V@Z'_G[V()``_P`H%_(`Z\N!
M.5KE[JWG2Y7U,G`I;6'H3G'A_E4A^+*3(S0%2,4]]U8;8Q)@QKB`KS6J(E[`
M+9^TQ&A$#(`%E5!]+_R6KI-5N"&IO%DV,"^#2!S%:MR&'IBQJW!(:K=]TS=?
M2C=HLDYN&6(M.>9O0Q:T$8Q!-`4$SGPG^0NN8B"H\M\:X[(AI0_F*G%%VQ*6
MPI4,"CY0MY12F+':"4(902S3M&:WLL0Q$[T9HLL/YV_\DF0=YJ>X8;#/1&R>
M3K`OB"TE&TR=%R+'K&:H5#(=(WV0R)C9)"ZV;`(6^ODB7"6FKM;)4.J5,F4E
M@T:4;LXD(7:<6^X_?X^1.7/.#S!Y3H/H*]F+EB`11OM"F%-NR%%03T6B`Q'O
ME^PZ<<[4]3\6LA4K(4+UK@HDKS$?UI1^2Y.C@(P\I0'Y?0GP]]J+!Y*M>4/*
M/F*2M))T?Z'M&KX':L\N?LSHBTXY''QG>9K<UR3:B(:"R)M`XQ*G4+#%(F^,
M$*;TFC$+.R*31$`/#4?\??R,ZDZ3H!QZ<F?,OGM(*DD,=8ZYH!SZ[I>3+IF_
MMD,G]F2B1VI$U=)N,$E/ZL9*9@8S@E3XO4O2Y"RHD:4P#>U(=[#H.#X,WX[:
M^%):O$7/I9AQ3GMPYSJ;TPC#NA7EDED[0MXV/UMKMO2DJ"PZ"I7HR4"M7HK0
M1@^,TTK8?M0>!G:R!6B/9O=+M6MT"=<,T<8J9_Z?*B2)K-$?HUFCK'>W='08
M6PD[1NC1'JS7)5I5H1@#`%BV3@2TKSR>[(A24TA?[D>A\A,TG2HDIRMBYQ=?
MB1I2P@#^3NPJHL52K<#!!UL:OYBSS?Z_)L>][%@+#\K>Y98E*3QOW0[OC)B=
M.JV0:KKGF0__`+2-+$!*H4[@U8UFJ6-Y`OIL:4P[>Q_3?VF%[W]V@Y-/9[PU
MZG;+0K\5P=]]`]8'/=0W-/X-9TTXVZ4L]D0VNUV!2S9NDI$X\PH>AU4`%8T1
MDCU(&]V'&TJ,L^,?@J-&:6E*D0;\\BO'KN.&U!=)U&2A4\U]'.E7M%$G^;W5
MW/YHR:U$Z"IZA=C+`B->/O+4SD:=A2/Z\]E2.3NSHU*EQ:E@=#`0G),,"5?I
M/0GIE#N(;Y:)XQ=O(8Q*VF-UHZ*B?3BA^KJF(8K4LB(ULM99)#[:YMYTL^<I
M7]KF6T"31J\@TE>;\BE60G(TJ,"D?S"X5]'O++N>(O5K1GL?EV<7+`[OAS"H
MH7FRFNNIC.83#2H-+73\>-@>+:CSFC->P(A.I*$!*UO++).+<-EG?&:'4KOT
M4Z2KS9H7?T83QM:W%["?'N\?`SOFGS`E`3!'MS?+`K^=TW$D9>FY00M&$I&5
MH&OE4#T2DV$HH,TB7LI;CBM.1MG6O@C;#@E,T$R)O?;MP<=SU<=O1AH6AMBM
MHU;<BS]8.TC.("$[98`?(2H-V66/0!A,.!>D/7LU"4-@\^ZWNP!I9)I0N1O2
MCDVZ/S2#2Q*/RVO^Z6^<`*D9J$9:LD9NTXC$FC1B"`8"BSPV9KTTE+(45_<C
MS*]/X`?KZ`5?@4+65UI"C=)!*!F)CN<+SN)8K1B,).*+'M,6=L18?O*+^8C1
M@5S>IGL=Y9(>5'QHZQICLE^-')F]QKVKY?RMU_R78B"Z(<B<YC6K["[ML.`5
M$EK*7-SDS@.3/#&^G/+>F/$9^*<1L\D01V\4_97SRE]*3,RE.8NYUW5,I<(U
M,^KV2*5QU'WW9$MFZHAPB4=D\IZ36%6&_KX>0S1TLAGU+'%C(;231)DQ0Q%J
MSQ!<%+>_NH)'$Y$ZUMY/=+BB*)C<U+_+.M[;Y$Y=KE"SIT:P3TNDZ5TNZSK&
M0Q=O1%B-6GJ(OHO20!X_MV'17SAP/^0_2'9;EZ\Q.IV*4<AV+':GEEHIJ$YT
MO;NN0#X>IZ1.I3_'*_(XPDC7,[V+E$HCJ.6*&"%`C#+-5X&1W6A`0F"(YQ0A
M_0,_>OM#_P#UI\P/_/#U;_\`Z]L#QWVUO8&+MISS)J%\J(ZT)OI^0ZOO>?4#
M0VD?70A:^9<X>?J=*5]0AWO_`!"U_36\"#ED>Q-[5(L"U3VVO!%I?QJ"DA<3
M0^J=UR6:G*3U!J,@DB$Q;A-ZEB@P]80,D&@(Q?<<'9>OJ/\`PX'.'_(`[QZX
M[WY[I"H8C3<5>STEM2B;H9;R`H]#Y6WN[+#:4L*6S)F6K+NX<Y=K";-)<$:U
M\@--9GB1+6YNCZT\Q*0E^=0$,;_C4]1]W<-0[H>.1GS0ZN[!9+62\\V`G6Q"
M<ABNJYKQ6Q68*OW1KA$^)4M)S39"%6I6-JQ%IM_4$*,LP9JA.%%LL.NV(^M?
M02XHO]]^*_J;&5`B2]C#%H9SM-$I:D1FPFE[4.G04&/$E+*^@M&:(V,6_KKX
M]?[=AD-@^P1]=(5:MP\KO8R3'I0IA!;*^XN;9XN6;5&:``"0<9MMP;1"*#]1
M&_>H!HH(?\6];V'6P_G4VIZSNIWI5*.HP4XCB]K-R>YJJ!&9AQ;R<GET3?3^
MAY$Y5VQR:KE\!<Q.-F,57-;3''^1+E@YPC<U3BB3*S$)`25X?T.I_P"W%>5_
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M2Z)KZA.CY<CL@B6O%@0&20.R)"4VJF4A-MGDBIQ6.)AFCTA1JL.\C`8#`8$3
MNZH0HLGD._8&@H=5TN\RJ`KF>,TVB)J0U9(9@J5HPPU]3#O.:5[6*(ZO)5I'
M)`JUSPD4(MM'SH-'.):0@T.;&5\*=_OG+U(0,CAN7/TP=_"-^\@I/$YA<')2
M'5!WF%-4;('H9T>&Z]9.UR"B9+^AGN91L;5NDP!N+(@J(\2:H+T2$EZ5\_>P
M(/UA6\)D=2+E5<5CZF6%Z#.'<1L_I@:&?5;(N'5E`,M/D0=$_#NG5C.4R?26
MEW"LBZ)B+86`"A,Y[,,3IR@E3S1SZBYW]?+/C2*W>@+B`_\`G!7$A,>^AK;?
M[>DC68/IZRT&VEA>)`$)[1']:1Z.TC*UHH*@PP>M?4>\"[_`8#`8#`8'\@MB
M_D*>K2SJA"_ROT#LJN:V=;V_-D@&6,I)97]=P=WG0MO!\>K&3L<@=9!&82PJ
MC#6]D<=KU"@A*6F/^<>QZ&$V>E;)Z6["D@K:YTYJN@?.P4ZU$I]*/5&Z6BLY
M?<*(P2(P:QFNJT7NL*AYRJ@XA'K?[1I$V//[J5L)"EQ4%'#:\#\M2>*G0?;Z
MN(O,^FO0W9+!%F4]IK^'<>54BYSXZKYB4JPN+A&:ZZ?ZVC]+TQ%HZ6O,&8J+
MJVLI^C7+C3%6A*#-B-/#T/6'P0L3D/E6/SB+U9QE6*R,(9;9]@,4>Z/G$]OE
MK@$28"3CS)%95Y6-4S#;S\XJE0B"F6O:@;485",X>U.Q[3Z5!?5_';\JY)%^
M%U6I#U+TSSC9$EL)7-)A'N2NM:"EM>3-GE$<8'"`3ET:(]";*7P.5"BVP,RQ
MJ<EA:K1C-L_XPZ.^P`7K._E.Q2M*-#/>\/2V=H]B)&2B>.IP,B!.(D0QZ'^F
MP.`P]N6G;&/ZZ-5E*#2_MUH`@:V+6PC),/XXGGK80#2I^[='3@L\G2<XN86T
MADP#D^E&U>B#0/4.6A,)TJW\OV[^H?D_Q?3Z_P!<#5[#_%(\:F)8)UU3MM+7
MS]24NA+X'H"SXXN0G*1??LEL3P=ZBC2V)2!"%\0$Z8OXPBV'6_LT$(0EG"_#
MCCVLD)J"K+3[]JTL:4Y*2.N_1;LN);1A-3)TFC$Q#3<1"'[BB49&@A,),*WH
M@L(@""'0<#^>G_(JXF34QZ126-UMT6=>K,X-M,PMT?.E>YJOM2_8G8TK:!&Z
MC-EFVG9+?:D/A+*V'HE87A_3$QYI;5I)BAQ*+%O[`Z\/"'R5XV?/-&@;!0RJ
MT(S?LA+EPKNL7C7TAZ+8F`^QFN:29I$D-4\R=*BI$<@1003<A6?IZ86]$"_J
M+8A[,$$H?1_Q\N:<<DV-`N"^E.TC>@YT)HBB)?T+ZG=X+JO9X.Z+0AL%2\QE
MQLV<,\S.=HN4>U%-B]"-$9^H[..^\)&R#@JA_C+><O3TZX10SZY^INH:RY\L
MD1LWY.;N:>QK*A9,51FRV<,-G,LKJ!0QFP:-G'39ET\(S$>UI#B<O6#6E?=O
M7R!T@F^;MFI0'?MGU8]/8X,XG81!.G_*<V3F*`:,_'4#U8_(DO6IPE[,^@RT
MBA(`T.M?=]1:"+0?Z:XU[Y0#%MJ]@K]<@'!#HX,YY.X1>1D#+V/[1-@X50-:
MZ("=HS_.TI"LV+8`?'LKZ#T8'R'G+U8;_CVU>G=$.@ME[+4AG?F^B>2OJ'[-
MEGH@PCKNM#4RC>]"^3Y1J2Q:WK[0`WKZ[#Y*BGM(T`)!_?;S&G(`$Z3C&LY:
MZEKA:(96B]`<E"I%UU8Z)4<IT$6S$Y2-(6`8OJ`?VZ^S84$_R#?4CTX\_>34
M%63]]XZA5G]7A?(#`9OR_,K[17!$(]%1L+A8MDLK9.(ZC:XRE.;W!.RE"`[J
M%R%2^@.2G'#1C-T$_?,CT6]2O2SCRL.E*AK/SD1MBXMTA,V6SB]>C#)R"RH(
MH)8Y03)JVB7.:6-0%1(1@+?DB9))7PHIK=$@="^HA;`&TNYI/Z:L/(?0;_T9
M1OEM;%,1^M7Q^F]8*2>J+H,L),R!*=&F&-=7GU_'R)=(I)(4B1(UD&+D8"G$
MT@X1Q>B]BT'*C_&;M'I1WZ0Z::*4X8X>8KV62JT;/C]D7E7=IT.7!4#D^QID
MM/ERKK0K2H;+U`FV*C/1G)(VK1C5H$6E@0EFE!.`$.U?5Z^M\>^U-(O._DR=
M"(,&4H>:G]%94G+7;,^0Y.H01ZT>)(08G1IR]A)/V>Y?-LT.QEE"`+Z!##9?
MT9UO)T(4MS>(]FV0TEI3=*D\9Z$X%MA.F)(,3J'`LIJM*Y:O5KB5`R0F(RTZ
M<PY4,G6C2DX_CT((=3Z/>?4X-/6W5_'!OA&N&H3_`);VH\^>-;%D&DIRL1Y2
MO];H"X;-D*I&8XKSA')B#35(1;,..("5OY1!JT$0\<(OH1BOCCUEY(,$(U*6
M\0"@O:&FVY"[:)`%,C0N7-8%<5<EQQ+<!66`G:Q&:-($P[ZF%?305%^RRCS2
MG//E/%-O8'I/T#5,'Z`)G=W45:UY6MN9(:F_L3?C$HGE/'>C\'TA<K4BU@R1
MF0)RRECJ[D(WM40G0C/_``MI0T+X=V=R'4!%WS.FO3&TO,*K[,J[F!J8X#-9
M#YH=`]!VW9,)?^D#K9(D$<3\Y3.P!Q6MGV;)]1MU>(E&)"\,KL(Q26H;4+<%
M"%T5[]BPIYHNZ(L@_D$O5E%/54V0RI8=(N*^>1/4XT[1)Z2%1)P=HK0</0!.
M?]J?P='(T*+8`FZ%K6AZV+8<P_.G75+W!8?-U'0N5R*M9G2MC<)NJ>T.5O*^
MD6OH'317S"$71LU=)9"*RN^\GV2\].X`)T!RAJ<"I8>$U8I;Q:%HD8=77W4Y
M/P@'(D'\F[KU`L,+4FDNC7U-RE%I"28`+K]3&N()^#8FI:S-$:&5\1!:?[E0
M0)M_4L`$X>LR\I4DX.)<@A7\:6R;-7)@BTBE7=]S<82YY$H*;M$Z`M%;_5'4
MDWT(9BD`-'B2G@V6G`9]WS)B2@A.6O47H[$"/T[GWRZ\U.46T!:@DM5(>MI"
M$W\<P:,C6@Q#G[APIO"8'16S?Q_UO12DHL`1'IQ_X=!4C_("CWJHZ\(.;K95
M$\B=#K2)8H20J)\N<Q=B7=;%)K7R#SE!*+V06JGLR/L58(Z[@0EQ6WMVB2YO
M4+'`DL1!&_M'@1R_C'T;W=-.-9D^U_93OPTX*W:$EDR2P_/<^5H>E*M-CB]?
M4MI1&ZI_.(2UV>E9BG!V;1%-9"I.VIBTAQAHM.!7U#I5%QWZ!+-@)</7NY4"
M3[MC-/B/(?$[8];^T`OC+)6RNH)TSE$B,WK9FA-Q@Q!U]`B!O?W:!K@3IYY&
M(V:>P?H*O.)"$M!N#P?SQK=.45O8Q'_J"5JX9<BG0X8]A^PP7V"+#K>O\6M_
MT#@,LGQ*[;=?<IXJ<RFWF?,TAD4C[#.*DEK<H-UN3[DE!T(TUQ+K=<7Y@AL8
MI-HN:2O<ETX$(=QP!R5<K!LQ,>608:,._7_EI2+_`.Y9Z?\`_C[5O^X/`?\`
M+2D7_P!RST__`/'VK?\`<'@8#+?&JG+&`9NT.K_06S%:@)0%JV8]1."O2P*=
M0-2E`-H;8JUQQ(2C,%]2BDR(@H&]?=H/W[$+85'^FW\7^C[-Y6L3_1LBGDHZ
MTT^0]VK@^Y;,CZR**C#I['%-@BD+RY1YM6(OU&%@<1;.*.,-/5A*`(`@C$((
M0Z_B1\+]G5+/Y5T9;;DPF\N,5<]94'5+.ADS:]N3/<;MT10#-<&@H/E)=FAA
M5KN7`B3!`6:B4&:,4:V0:>+\D.[+`8#`8#`8#`IZK2!N\-]N;V=7.T;&L-/.
M_/*NI6TL<Z,A`V>KV\SIBQFT,%KK42A$2<RX:2>@&L#I[4O;I^4J.^JW97QE
M%A<+@,!@,!@,#^0S1_F"^R_VW2\X/%`>C;'SDBZ,_6!SDKGV8-/0$.IV0SQ]
MCU0=%3QIDU2NC7$JS>YXV)E:YZ=&8"$II+5[V+YTYFM!_35I;RKX<I:6I+1_
MLZ&ZKR3!2#'T)U%*)1TU>(EJ/>MEN#78-U.TR<H8=L0=;^&/!:$9>M:"60`.
MM!T%B.!$3HG@/B;KB2,4QZ=Y7HR^)9&&/<9C\CM&NHY+WIGCVUZIT_1$#B[H
ME"HAK"Y+CSPD:%\833ABUK6QBWL/>YOXKY(X]!,0<L\XT[S_`*L(4?%.MU1!
M&&&#ENXIIZU&=2`QF1IAN@6#4C</Q-&[%I/M:?L&M?*/ZA)W`8#`8&GY3SU0
M4Y?ETIFU'4_,).Z?B_J<CE-:0N0/SC^$C3MR+\YW=F56X*_Q&](405\A@OC)
M*``/T"'6M!G41A4-@#*3&H'$HS"8ZG.4*$[!$6%JC;*0H5F;.5'DM3,E1(2C
ME)PMC,$$O0ABW]=[WO`C1V#PARYWI$XG!^IX`_6%%X/(E$KC+:QVS<E3#0OR
MEM/:#5REPINP*_<W</Z>I,+"2L.4$%['L00:'_BP-+\:>1?GYY^3AQL7D:D7
MZJ)4ZPUQK]:<;?/1EALHXDZO3/(E[43$K3MN;Q%&(YZ8$BC2DE"6J`(O>@&A
M"89H862X#`8#`JD]&_+UR]%T[G%)'V_U?1%,RFLTU:3^AJ97U<164_3DR%Z?
ME,DDB67UW)I`;('(MS3HS]EKRTWXK8F^PH!FC1FA(SBSDZ;\DPN1PV8]=]%]
M:E.S@SGQ]UZ&65ZL<($U,S2%J+C\4'!(/#A`:U@0!,."K$J^@RP?%\7U,V8&
MS.GZ!4],5&[5.DO;H3G!0ZNC&Z%VKS!/&JN+<:/T1Q*7C;FF3O<6F;82UO0"
M]IEQ)K>=\R<8M!V`?VC"%<W&GBW">(K;%:M<]]>EL[1.UG6%<T_J.V[^K20T
MW;=H6DA7)IK-[2B49HF&N$JD3RX+0N)JK:\DXQQ3$'#$/X_MV%SF`P&`P**_
M?3ACK7T9Y5B7+/-A$5_:4CG7[PN4Z07D;3!B\F%IDZRMHZ>5JBKJ*FD5.EZS
M;PO2:$RG$K6-O$6>9H8_C"-O\=GS#[=\K(U=--]`D5^?4ED%QRP4)\3OY99Q
M+;=#42GC<A71>#'4'5HH>QSF+:3[<!JGM\.T-B0%%_3ZG&C#H6NUQL1IIZSW
M*HX>98%HHH'*3Z^A!,V9ZV/E,P`S*_V^R)[`D,>EK#"U"]RV6`MS6M;BE1CW
MHTU,<`.RQ!PP^=GBOW7QMZ+L'7K9YQVC'F=)-H0=#5;MZP4%)G>MVF0-K_%^
MA7NWG1#SBK<^BVF?-\E$M):DC=&%B+28PG2I4H/+5I@[[L!@,""7<G"Q7<D=
MBD4<.MNS>88^P(9PU2%MY'M6'UDGM)IG:%E;5K3:`)765C:D;:S(FDTM`23^
M(`H+DL^71WR`^(-?^?7F='?.MJ-B4`Z][=O6M$D%C]?0RI>FK5KV?UQ5['&#
MPB9QUHR1*H*\51540BUM&((%)B4Q+O01$[$64,`66X'^*@@"I.>F-$<$M02:
M08).H4(U`0'`$6,1"M(:0J2G:"+_``F%#`8`7T$$6MZUO`HN/_CF>91TI%-@
ML/3Y,MTSJ(X1(R^U^JA/Z6,J7$MW,C*=^46N>]:C^W(@L_:42@10CBPF"T(S
M6A8%X+`R-\98F6.-`%1;3'VEN9&P"YQ<GA:!O:D9*!$!8[O"M>[NJH*8@.C%
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MFD2V.H5RP\TE()5\1!IQ@R]`&+8L"^7`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%/E;1^Q67VZO99.+%;
MYPSR'SPK=VKME0P=)$3*YAW^I:Q48(>N=$[X\'3A9IV2J5@G0XM$8+2K1.B`
M@*#O87!X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%/5:([;2^W-[&67(:Y>V!7YY5THJ5)!
M8=)HL\1^OM],6,`AHL5Q?YU,$4PF07L"LT3DV)6)$)*825I#HPL9QH7"X#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`Y6H;TK<+EZGH&7?2MJ*[\5>LUR\RROBE7;;R*N&?S@B
M?$;U8\2M[?.Z?\B+L"/<S(8I$DGGZ62Y.SF[B:QNHR0FD%!N%,H]7P^K\O4I
M(IY]&V1KSZ@B8S\B;])$5\*O@])668V'`6EUTH?BYT8_?D?.EV6)"!#HL0#A
MF;%K03!E%D^W4>G-81%#1/GA*&FP'"5(7R=,=D=+"B]8EQV++9$WKIQM;725
MU+1RM:CTUH!(DZO?YYH-&Z+`+[\#ZLJQO;N!LS$ZL=%>=UEGNUA5I"E[1"[+
MZ3VY1YEGT\C\,>+$<RGNO&HLV(ULWO@WQ[_&$>M`TH5!A!!PP:!L/8G4T]KX
M?")C+6NI/-Z<N<6BLAD;="8M8_4!DGF"YD:%CFDBT<+<:R0MYC](%"4*1&$\
M\DG:@X&AC`'ZBT'H1N3>U;['6![7UGYI1I<\,K6ZK8X\V7U%MXCZMP0D*U#(
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MW2CM:+5&GIKL;I\;'&1557:ZQG=5*!J*S)6DI7-`A_$2B3E';VK-`$?V!W]V
M!G5E63[=0-ICKBR43YX66H?+$KB$+&F%V1TL)?'6:<S1EBKW8CQ^M5TU)PP^
MMVMU->WG90S5FFU$=^.2>=]A0P_=9<]]M8%7,_G+'2_G-9;U#(3*I8SUQ"K)
MZ:%,;`=(ZQ+WAOA,2"]5NU,VY-*U:,"!!I6J3)?RCP?*:6#[AZ#*FY[]IUK>
MA6*(!YD-JA6C3*3VY79G4PE3><>2`TU$I$FJT],)0E&/98]EC&#8@[^T6]?3
M>!@]3V3[=617D8F\AHGSPJ9Y?T:A2OKN?61TL"7Q<XA>K1:1/>F&NGEG_(.+
M3!/!M.J.!LDT&_N^OUUH/J!6-[=S%58*9YHKSN@&H583M"FA1*K+Z3$GL!E;
MVAA=4=B1$QEKQTT.(O(WHQ*1^5^,M`I0J`&D%[#KZA\H[)]NE5LR*MS*)\\$
M<>8J[A<W2VRILCI8,`D+S*Y+/6%PKMF&"NA/QLPAR*&)G)ST8C`C`B?4'QG#
M,&8`L/I_L;V[9K"KR%(J*\[I`RS9#-E;W8C39?2>HC71L31LRIJ0R_\`-KQ*
M\[53<YT,(;-(DJL/R(SOGV4'[!"#`^@.E/7_`)Z0U*OD=7><4@+MZ_JDY\9P
M1VQNGS!L\BM^0ZCC-('G\ZLT82XZTJM_(L$5LP_1?_0+'O\`I@9Y;-C>W=;U
MC/[`CE%>=UMOL+B+])VNL(#9?2?[WGJQD;E#@5%8D"15XR,ATB>MD?`C+4*R
M"S3QA!]VMBU@;"_4?:'_`.3O,#_Q*ZM_W48&O:IL;V[L6NXI-Y%17G=4[S)&
MW]075W/++Z3_`'A%AB4GE%('\,>KQZ:"EQB<H!VP%*3=EA-T$?VF:$`(?-?V
M3[=30Z?E.]$^>%?@AEB/D(9SY;9'2P"[`9FAO9EB:Q(GIJKIR,W#WM0Z&IDN
MU>DRS9J([8B0@^,0P^F>QO;MSLV=P%517G<S,40BM>2-GLYQLOI/<)GJZ;+9
MZC>8M%MI*\4/H7ZNP0U(<[A6)$I/Q/R':<9WU.T4'R]63[=-5G0&`)J)\\'I
MBF47L.0.UG-MD=+;A$!7PA7!4S-%I8)371#V%\L0J7JSF?\`%2*"-EL*[\@P
MD7P:.!8MD^W4')AIK+1/GA8HY38D/A#B1#[(Z6$9#F:3.`D;G8DCV\5TV%@A
M\.3A_)<=I]G+/B^FB231[T'`P7JGI3U_Y/YMO'IB75=YQ2N+T36,OM*01N)6
M-T^=)GIHAS.I>5[>QEN=9M[<)R4)DHM%?.>45]W_`$AAU]=X&_OU'VA_^3O,
M#_Q*ZM_W48&O:FL;V[L>LH'/I'17G=4C[,8JRR-VK&?67TG^]H&N=D12Q1%I
M5J.UX]L07YG&;\*D*56H)":'>@C%]/K@?-=63[=3@F9&O5$^>%=#BUB3"$-Q
M$PLCI8)DQ9HRX!1MEB1S;/73F6.'S%.+\ENVHV2L^+ZZ.)*'K8<#Z8;&]NWB
MQ+"A"VBO.Z/LT*;8.X,EB.ME])BA]BCER9^-=$$1$AKQ6[@70=0R@)=`+DR3
M>A+4XB?E+']^@.]C>W;;9T%K])17G<\L4NB-B2=YL]OLOI,,(@2R#N->M[/%
M90-97B9['(K$U.%)[.6B2*BQ$,#@,\1.BR_D!/K&]NX:H@)+-17G=8`)E83-
M"G@^*67TGHJOV5T;7I>KL26;>:\;!?M%E.:2DRG\/2E;LY:3\9`P_?L(+6L;
MV[KJO91-8[17G=;#U'T)2M!7<#LOI/4NE!HUB9*-"Q_N&O&1F_*))/$>+1ZH
MD.RRA?3>Q?0.PRJ0RKV<CK`^2`^#>9"LAB9W-Y.2I+(ZK&J4E-B(]:8G3!'5
M0`"4'`(V$&M[UK8MZ^N]8&L><K\]A.D^>J(Z+B]:^;4=C5^TS5]U1V/R2R.H
M2Y$QL5IPACG+2SOP&^L5J`#TV('TLA5H@XXG1X!?8,8?H+89)7=C>W<W2RU2
M]45YW5UN.6%,X4UIYA9?2>E$P98H[FM3=8C"6S5XZ;+B,R`3M4V?E_CK1IMA
M&807H0?J'S'K)]NGNP[&A"RB?/"/,T&1PA2S6([V1TL&(6,=+$#LM=44-VDK
MI2\#40@QN*(<]K$J4'S+"M$"-UHS8`^EEC>W:6UH]71=%>=RN.O=>S&:J[83
MV7TGN!Q]ZBTD@K$W5V[Z'7@)$&73!#,%3DV_$B,1"1L2[Y3RS=$EFA\SNR?;
MJ'NU8-S51/GA.T]@6(5"'UVBMD=+"05@S&0N:2K=B3?]4KIO4!AY;I%4K(+:
M$"M9IR>T?^3\/S&E!]6G8WMW7D&=I='J*\[K5=6Q4P$$06"V7TG^Z'4AWD32
MRKUC?J05XS-8R8ZWN)KFJ")0$T:1&;HD)AVRRAAFCF^^TS>VN"\B`>93F<A0
MJUA+:ALGJG:UP-3)S#BT*/1U5E%;5*Q@T67]P@A^\6OKO6OZX&,UO._;:<UW
M`IL^TQYR5H^3&%Q:4O-<S*S.EQ2^`.L@8T+LXPF5"8:Y=V,4DBJM6-`NVB5J
MDFU1`_A.,+^T8@UKSKTIZ_\`2$5GLLC-7><4<10"_NAN?%Z:2V-T^6J<I%SG
M<LTI232!M_3ZS6E#CK^_PA0K;A#$`\2,TOY2RS/N`$,\C%C>W;_.+,B:^BO.
MZ,-,"715(PSE[LOI/]L6:5(8RD?W%="M(*\6.WXL47*1-B[:],C%^:4/X=&%
M?0S8?)ED^W1=LHZWU1/G@9'E==N<W';(+(Z6W`$CRWR5I82Z[4C_`+=?KP)@
MXHG,;D1K2/:,2)*;]3M&!T#8?4XL;V[B;S5[4T45YW3HBPK"%"GQWC-E])A;
M:O900.=3,RQ)R:\5XV&%Q$+A#D['K\(*I:8[/:$L!`@#,&6'S:MD^W5=09SE
MT?HGSPM9V0.$90IH+`[(Z6%*'0N02EECJM<BT_5TSM04<;1.ICHN$:H+V%`C
M.V#0QZ"`095))-[5L4=?WM!6?FE)5S.RNCJBCC-9?46GB0*V]">K3LC5M?6"
M-#IR=3B=$$?,<45\I@?O&$/U%H/PPB9>V$MA<0E3K4OFY!W231=@D#E"I/97
M3W[DAZ]Y:4CBLBTA_2JS<&S]<CZA2)(K_&4'D?D$C^,P8/H+8>'5MD^W5AQ'
M<E?Z)\\*L<@RRQ(T*(3JR.E@R#\*#6'*80TRH/Z%73NVCC]A-,=(D#,,)^S1
ML[HE$<`H[9A0`D)Q#T5T1<$QZZJ7IN%T_%++Y9NB#5B>OHYZG#Y`9:U3WGNH
M;Y;7IO66`SL+_P#D(4UJ!;E`=I@%Z4(C/MV+6ONV$_\``8#`8#`\L#&RENYT
M@+9VLM^4(]-Q[V!O2!=SV\(RC=(3G().EAB/1A`!:*$/8/N`'?T^NM8%5S5Z
MJ,+IURGH#5$RY/2SEU=+.$6;J$<TB)C$OZZA-)+[W?:[.K<K8I*BB.XZSKFA
M*_"5",/D:(U)M``D.U>@MEP&`P&`P&`P*X.Q^_Y3QW8M1Q=WX\O"TJ^N>T*@
MI*(7)`)WSBECRBWKFE"N,QZ!EP*8W+&KD<G!K+2"<5ZI)'3VY,V!-4B4:*3*
M1$A8_@,!@,!@,!@0(J#OZ!VCT+W-1#[7E@4RDX08ZMDT^LFWPL$7BTRBED@N
M<[<\BB8MW7.*"NV=)2C@I+=772']11'`5DDZ2;*/.#\OG9Z!P_T5K2W+.A=6
M634;;5-]/U(FL%JI6YLE3V6@KFKK7CTR,8T2E0KC2630JVVL_P#3'#1+FWG_
M`"D*B@&@WK`L!P&`P&`P&!75<O?ZVBNQN?.79WS);J6#]+SY94M6]'HI'4SI
M#'VR4-8++66-Y%=-4[<+?31%K9VQ4A7/BYF0ITKDE-U\8T?QK#`SCA_MMB[>
M9>A7IDJ2TJ9-Y[Z6E?-CY%[A0LS/-G!YBU=598PI(LCK,Z//[82NC7:B4!;>
ML/\`U%-LD6E12<[8TY03=P&`P&`P&!75V]W^MX?D52*)7S);MATS8=C5!5TF
MO.$R.I@,4%F%W6$96T+8$E?/,[0VS/WI*];3JG(EI9!D)VY:282>I.T>G(#6
MM(>L-<WGW%,>*F"H+`:G.+3#HVO@3M?(:]6JBY3RZN@S?8+C,JK9Y*OL>MZW
ME1\Z3;ATD=TA2*2E[*&4`K2M-\@6OX#`8#`8#`@EZ$=M&\$42YWVJI=^N&,1
MI+)'N8DL]G4Y60F&-Q&+NLM=S&XRV)K%UDYF3BULZC3/'&!*YNKJ:0:```;"
M#Y`U77'IS'[8[(WR%"^?;.$M;8K6DNE]A2NP.>()^S6^TJ507<Q)E]+R^X6G
MH:1+FMF<R&YUTPQ5V);'(0@J#"R2S#@A:#@,!@,!@,"/O4/0L?Y>I:46X]L+
MU-'!`JCT6@5;Q;:7<QM>U)[(6R%UA5<-)6&%)S9-/IP^(6U.(>_B3Z/$H.V$
M@DT00JOD'M"^,_%/)W?+?Q98$CY^Z$1TX=/'%IN*LM2NKW6Z;9;:?CT1A<$5
MA3S2\9@ED#H2J,2H6]I),;S@&`/V(M6!*%Z6`P&`P&`P*JH_Y7PUBZMUT!_>
MZQ5M6H>K9OW0P\RF,<)(A#7UC8%)GT4_6.HFI++J>.3"3''=U<TC&)2600_.
M9BD1IA.OQA!:K@,!@,!@,!@1`MKDM#<_5W+G1TSG"Q3%N3FNV7FOJ9+8P;8W
M.Z;08D$(27#(WPYX,*7.%?5V:\MC&ATVA$D4/ZI9I5]^BRPA+_`8#`8#`8#`
MJ,=_+ESL:_>ZK#O*_4=B4GWY6\!I^VZ.CE6O58/K=6U/_P!R$M5LC%<L;N12
M^IW!N:+0<$KZK`V$_KH0E["6B#\A8PW1P'YYP[@$73P(?;EQVLGZ3Z`6WDJW
M<%A3NPG6*;.@T/A25C$_3N82]VE<@$3%MFN$D5F@=78G:-*IV(AL1Z`%A>`P
M&`P&`P*MY3Y_W'(O21H[]_U:)54?BT-8:P@'/\NH)EES75E:J"&I1;;56$Z,
ML1J_:<UNJ0(3%#Q*M,BA["WZ3-031MR71!H9OPUQ?;'),OZDDDYZ+CMV(>I;
MV?ND9(T-=&?VJ/CEJ2>(5Y`7L]K=`VM/]*HJ;%JQ;`$MXTX#25>SSMJ1A,"4
M6%B.`P&`P&`P*M^Q?/\`N/I[JOFGI"+=:):UC/+J%:[0&B9903+<->;N!Y6N
MB5WO)4!=8D,+66$C@ZPIE8#ER5P#%_\`K2YMV0M6F&A#`:)\ETE*]R.G9X[\
M62IP5V!TY8&VP56,K%:LO_U,J6@T^OKIOE+*5KU;524TE9$B:#1TUH;DC"0W
M(-`V/:,`AA<-@,!@,!@,"`'HCQ.]]Y4R=1X+'KB"Q!Z:YJUR<JQN<(;T.("J
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ME+`-NBI(S3&@I&>H.-$%_F`P&`P&`P&`P&`P&`P&`P**.X^:;[L3TJX<L.)]
MH6A4RDK^^']E8%$(VWCJ*&_LBJV!]E7]Y(,H?2U/0/\`=5Y/5(G;Y'&.?@QS
M\5(T_I[D0<]*PO7P&`P&`P&`P*=O57EZQ^A%O-J])U?<U$P*+]#<_HXO%*&*
M8(E)@W"_6>6V)+;ET[?DTK!,6V$L:LG3%%#&I,RA<?R53K^K!,1IF\+7X,VR
MYGAL6:9[*&V;S5M86M#*IBSQG]EMDH?DJ,HAS?T<2_6Y(&.$NJH`C](PKU0"
M-C^P)FPZU@95@,!@,!@,"HGV]JF?VMYZW\GC-ZSBEH?#ZXF4WGJ*KR"V>?67
M^W6PM?$8:79!BXQ1"(/J0%:5/R=$W&KWU.46BTL1I1+"U@6*4)7\^JJJHK7=
MD6Z[7K(8@E-8T]I29@2,$TE4=0'F$1E3/]MSBM:Y#/B&,!!3P\I26TAX7`,5
MA0I-F[)"&XL!@,!@,!@:'Z3J.87O44DJ6'W)+*&W-_QF256)7S8UJ[&1P569
MLN7,U?/+UL]MA$LD;2(:(A_$C<%#26<8>E)"LTG4IPB#Y"51/*BX"YD9I1=\
MPNJ+2.AZ3GE>[LAO1JI]7+3-ZOC$F>JZ73Y$J(W/H?'Y"YG@C8UK<0Z-+/LI
M`H5N`2"3@!9M@,!@,!@,#`;2CTXEM=S&,5M8`:IG3^PKFF-63^U6Z;GP=Q7%
M_CADJ"*O"U"S/+LU$C&:C+6B-1!5A+&H(4DA&G-"LWR0YOG/.]5VJV&]+V]>
M-9.W2/7C6SQF^5"*<SR(S"O>O+PK9TDK):R83*Y*6&Q&6(I'1W95[>L"7)CU
MJ]$J2$K#4.!;A@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#4\OIJ(S:T:?MUX
M,>`RND?[@?LTM$M((:3?[DQU-&)#^M(S$9QR[[&U(':;XS2?B-^HA??K_#@;
M8P&`P&`P&`P->V+6<<L]'%$,D&Y%DPZPH19C3ML4E)1BD<`?4TA8@+!&IE.C
MFT:]*'1Y0=`&87]=:&'?]<#86`P&`P&`P&!J>]:;B/0U.V/1\],>"89:43=8
M;)38^M(;GLMH>"-IU8FQ<I1N"=*LT7O_``#&0:$._P#:'>!MC`8#`8#`8#`8
M&O:DK2.TO5-94[#QN1L2J>O876D7,>5)2UW,CL$C;;%F0;JL(3(R%;D-L:BM
MGF@)*`8;]PM`#K?VZ#86`P&`P&`P&!KVLJTCM3QMRBT7&Y&-CK85MV6I$ZJ2
ME:K4BNBUII<4P`4:2F2@`VE2V=K@HRMAV,A'HHL0S!!V8(-A8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'-'6GHGTT_\`J]=G,M^]
M0PGE7<$OJ11CG#AR?\L#`1VMS6W1,@48LVI^L9!-(^E.MJ;OJDPY,U)33DR<
MU,%-^"IV-2%&'ZN:_?&:NO-=K=!]><:VI6C-$>Y_](</<H"&NCV1[72J\'^K
M6"..*-RNR2/`;`J)$@2@FBH.R6=>N-V8S_>2+XR@F=T+[/4#SM/>HJI>JJNV
M;VASG?O(/,$;@<!:8<Y/O0=X=L5HFL^GH34@':8,J72HEE$I"YF/!C:`G:(W
M:?\`)WLL`P@?R;[+S=/U+TZQ=45WT-"*]L3T9YUXKI:#6/&:W9G3E"96OSHW
MR-IBMGBC#\M`JCL^LEI6A;W=(O?4Q^UR8XL\*4\K`N3YY[;B?5E1]+VM5$4E
M3)'*'NGH2AX_(YB2R#9;4>N?]_HK[9$%_07QT&NK5SF9"UO1&JQ(UJ@38>,1
M!8!%B$'.]SSZB^GT!XN\_P#TYZ'MV@.@N;>M;SA-*W10;%SV=3METLSV-9TL
MJEAL2NK39[.D;78C@S/\<*5*VQPC[>6>F4?C%B`+>UR<+C9+ZVQZ!]6P[EFR
M>2NE:Y5V[/K>JF@[(E:^@"H[;]B5'''&2[:D40:KK=;3@[#9J)J'^SW60L;8
MF?0*D9I>@%'F#3AZ'-OK_0'5+QP7'ZK@EI+GKNR`]$V,B;EB.+IU?/L>YE5;
MC-A;O-)N2;7M"I39P@19N`VDN.E#IL0A;+(`(W`MEP&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!0WTSPF"
M:=9\L65W=Z@1UPHFO.Z6*_\`C'F"=UK0-)31PZ5_<#TZTK34:OS3^U3*W66(
M+W<E*T19&S_K3X0F++7J%YH2#"`C/+/-7GASY2[,JYX]8*U;.;;K[Q.N:A)<
MH:N>RFWDKLS70*VQ7VOEUCJYSI'<<N6V/\+$=%W$]E<R"R3498"U)PA!#'+)
M\NZ+<Y'>I=S^P<%4]\6%V[YU7-'K@EK)SG&)94?>=(UE*&WF*)D\[IYPRL;V
MNMNLW=2*)P)6%.Z.3(C`:4<[;`<K-#".P^(JYJG@GU]0O7;<;Z]ZTORV.=9P
MZ.*^5<\41-*G[>CS16B*AXX6$N<L$3K-8]R=`WN+&RKS&]W#%A@0E&NIXMK5
M874^:E+4_47EWSI1M;VG`;!@,8H5?%);;M=S>+SR"O\`8ZL<@WT%+&N:QYT=
M(TYA!<RV1FJQA5G:3JP'%'F;-+,W@5'\U^6W/U:<\<,H+\]@HOT?YT\[7/$)
MMR?`&M)S=3E`VE>R:>2M?7B&57,RRB8.5]?CV$ZN.FR-D/0`*G0G9(@'_#LC
M0873WFKP!$N]JNES3ZK<L3.UZD[_`+AO:%4LB1\Q:ZHF5HV$*1+)U1-VVPAL
MQ==5P2R%.3@3II(,;V]2SH"#DZEM5#&E4(0V3XV<ZT;!O4KU@O&)656*_<YL
M*8Q/E>IV*\ZBL&5L5'DVJIE_5<\C\#@$SDKS$JND'5[VG0%`4I6\;<N;M)%9
A05(@`"'41@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g644794g35e13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644794g35e13.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`Y@&D`P$1``(1`0,1`?_$`+4``0`"`P$!`0$!`0``
M```````("08'"@4$`@,!"P$!`0$!`0$```````````````(!`P8'$```!@,`
M`0$$!P,&!@X'"0$"`P0%!@<``0@)$1(3%!4AU187EQ@9.5D*,2(C5[AY))34
M5E@:03(EM>7&UC=W2'B(F&E1LS5U)I:V83-#T[3$-J>W.!$!``(!`P,!"`,`
M`P````````$"$5$2`R$Q08%A<5(30P0%!J$B,G(C!__:``P#`0`"$0,1`#\`
M[^,!@1?[2<+E9>5[UD5!6/'ZFM.*UO*);'I[(Z^(L](R%19J4O[OM!$5TBCC
M0ID"QH;SB&Y2O$N;T2TPM0I0+R2QI#@YUK<\A?>,DYDYND4!Z2^YV<P[^'I>
MO+O;$\1U+2\H<>E+SB$"J55JMG=AF4#=XG$*S<WMY<5<@U%D;$YIC7IO*0*$
MY/H6`/:B/DP[@G]W5U>0;&##ZD<?)KQOX]WGB8%95BI0K8=T%R+7UP3^XGZ<
MNK2=;[=+4$WL<Q>P;02HIF+9V79"EO6"]Z<>%O,8[VN=_G)U4/G#5EUI<26%
MD62JJ.<W%2;_`#0FN5LA6Q1KG>U-%R6ZX0&.NLC;%2(D)CR4X:/2F>\2EE[*
M,-NM:S&9G"9F8GI&6"WSWKW%5\FI=EK;Q961=338D[2QJPY&U7/N/I*=BARY
MH3*9XZID],2H4B1HDZ\\X2(H:50/27>@;%H6Q%IK6,8G)$S/>$D_S)=%_P"A
MG+/Q#2_\BLW93XOX9NMHCASCWCW%;S=82NUO%M8E!*XG8+M%8JWO%T"DPY_$
MD)"8UML1":II:'::FU\,.,`4B&$Y63LD6SO=^T7H616L]YPV9F.T/Y=&][=Q
MU`"LQU9XL+)OS[8SQ!&9D!BN?4='7$44:#M?/EH2*:E?SM$U^UZ"1`^&4G;W
MKW6Q^@_836L=IR1,SWA)3\R71?\`H9RS\0TO_(K-V4^+^&;K:(VT)WGW':4B
MNAILKQ96-2;37<_61>O7]VNC4@(N&*$+GA,DL!J2GTS%A1YO<4S<0<!$88K4
ME:5:T;L'H'9F16LYS.&S,QVA^NGN\^X:6A##(Z?\6=D=&R5UF;5'G&&L5SAB
MJACCJU$YJ7&9*7,FFYEHY&SGHR"AIM)P&G;4ZV6+8@^P):M8CI.2)F>\82.+
MZ4Z,&``]\92P.Q`"+8?O"(U[.Q:UO>O0<'+']'K_`+(0[_\`3K7\F;LI\7\,
MW6T1OI_O3N*P;2O&%3CQ:6-54*K9];VRM;)=+F$[I+J;%*AX)7/K4S&4LQ%1
MA.V!0)]B*,7K3#MJ];+]HL&S!9%:S,Q,]&S,XZ0]#IKNCMNF:M5S:G_%]8G1
MDU(>F=M35BQ7.3$W)>@<#C`.#H2]:J*6)DX&@D'O1A/3E%F!]0Z-T9LL!BU:
MQ&8G,D3,SUAD-H]V="5G6Y\N4\02)?+ES$J%"X$?:XF<Z:SOY&I<V6`('535
MAZM`O?7`C2,HXYN]LL0]"&1K>MEY7RXF,Q.9B&;YCO#4=X>0SR%UIR=S+>]=
M>'JU+DNJY#'TNY.8&SHF+,,FYN^7_$"8AOTM*JZ2[FA<G((]X7LEG;O@M""6
MJ]R>()(N2V#\4^3/R4]'=&PBHNA/"7<''M2R-'+5,GZ%E/24?GK#!C6*)/;Z
MQ$KHE]S$#6._VKD#<E9RM)EWOB#EX#Q%C)*-V$/EY&\QEOWOY.+3\:5^\!2[
MDZ6PRK;"N.#3R0W@S6(98U?1"QVZ"1R2?8]JK6-(F%IG2)4<O3'IWQW`4)/L
MG7O@#TIT%[F`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&!JF[:/J?H^L9-3-WPEIL6L)B%K!)H<]B6@;'@#*]-TA;`J1MRI$L"%*\-*
M<[6@&AT+9?LB]H&Q!V$2%OB<\<;E`JVK!QY"J%?`JB.D`J[C2UJ<5:*.(98N
M:G.41T!A[F8K<X;(E[$B,7,:TQ2SJA)"?>)A:*!K0;@5<,\AK.B&_K%1SY6H
M^B&L2!0BM$+&$I[`Z-46-@S/(CD9)I;(LES+"#QLR)Y.2F.J-I%M&2H+3_T>
M!&UN_;0S'^[`K7^U;:^!9_@,!@,!@,!@,!@,"H[RN4'(KT'P^*/7-/*<^[CL
MJLYXZC@:U<B'8+6V;/VHKN6Z1.S3\?"'_P!-;7I3-FEG[*+]0;]G+I7=GKCH
MFTXQ[UN.0HP*9`55Q?OSRG6]^8:2"[MUX[-1?\L(XXX@B8*+^^$HS[V29K]E
M0,9KYM\W\OVR?.!N'N=B6?#^XU[00N;P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&!6`W?MH9C_=@5K_:MM?`L_P`!@,!@,!@,
M!@,!@5*>5?IJ&<W#X@#,H]-7\-N]F5E5L>W"VA(\":Y$^`6#0.,D`J<FWY;%
MR0E#^*6@V>)/_-_HA:%O8;I:*YSHFT9Q[UM>0HP.:4,-EX_XKLR9`BLD%$"?
M$2!(=*PL;F*-E*C+S^&+3&/NDNVL"@:C7N]`V;H6Q_S=:]?HP.EK`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`HQZOH.6=-=/7]$)=YH.
M@^9JVJNMXQ99G)W'>ZYH.XJPK)7!B"'ZSI?<[@Q3JS;`8Y+*8\\K4RQ$WID+
M3KV4)>_BB1&#"$_C>AMF3NX8I^5_R9>89@9(RW5M=<GISRYT_&[G:>F>:)-+
M@:='ZHIT_-$)E47;Y$A+&D2NR=>!T:C5B80D0R/4O0=4V`P&!6`W?MH9C_=@
M5K_:MM?`L_P&`P&`P&`P&`P&!7'Y)X"5:59UW6XY#((<*PK%+@.IG$%@6R81
M(J91]W839#%'799FVV0,VU85:,[TWHM406/>M^SK.O%Y]SG?Q[U3O^K0?^<?
MY?O_`!/?\!YR=#_5H/\`SC_+]_XGO^`\"H3]+&SOUM?TQ?U6/*%]TOY'/S1_
M;_\`,W(/O%^U_P!X/V0^SWM^Q]FOLW\%_2^GP'Q7O?\`\7V?HP+>_P#5H/\`
MSC_+]_XGO^`\"JSS/^)BR?&=X_K1Z^J7RP>4J<SF`2BK69KCL_Z=?OLRI*G%
MAQZ(KU"O[-%,3QI0B1NXS2-EJ0:T<`/M:$'UUL.YNM%JQSKB`.3@I.6+W"$Q
M5:N6*#!&J%2Q6Q(#U*D\T6]B,./.,$(0M_3L6][P,VP&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&!RP>=*U+`.Z/J>KHY2T=9Y+"(+`Y]0'04?
MB/4)W6LZL:PYY-(C.:>Y&LJC*:M.H6!<Q1F*(1RF.6;M9&GU/($AKFSC;$VU
MN@GKXM^0#^(+$MFG97QO3<"FRV)M*]L[=YS8`,%7=(0*//AB%JB\FKUV=7%]
MYMLR/FO9:Q5"FD:J%JQ#4+68\!1(D:4+JL#6-FW935*(F=RN6VZQJ1ND3EMF
MCZ^S9[%8$B?'?16S]M3.JE3JU$.;EHC6Q^X($,WV->OL^F!_8^XZA2V,UT\I
MM2MT]N/C.9(62K3YQ&";&>&`E.K5&OC7"#'0,F<&<I*@/,$I)2C)"628+8O0
M`MZ"!#=^VAF/]V!6O]JVU\"S_`8#`8#`8#`8#`8$(NTO^KK_`-H2$?\`[K.O
M%Y]SG?Q[TW<Y.A@4NET#S.+SV*>C1=4M>^K"_':37P..OLT$IW#5H[>VL%=?
MVV,==DJT>W'_`'.^2EHM*BQ?X8(_9'\S`NBP.<'^+`_8E=&_]('._P#_`+?"
M,"_ZIO\`FKK3_H_AO_TXVX&P,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@5.=0>//J*QKFFE^<D>4_J?CJ93Y.R@?:\7Q:L^G.:V];'8BRP]N
M=(;1%O-A;;"5C@E8B5+KIN<B2G):,U1L!9YIAH@UY4?C,[;/L*NY[V;YE>J^
MEDE:3"-S=MK>FZMJ#B.LY@ZQ20I9`U,]I,M+)G5_GD+5#0EE.#2:Z$$N!?M`
M-%LD>R<"Z;`Y@OXA+GB^;PFE#N=/5U<BHF/<N=U00ZQ*GY\5=8%RN0W/%*SB
M[5R_*:P2D+#*=9[E+;!*!6D`!2B.;:M%DGIQ&"/*"+,!XZZ2#T]5T4?N-[*A
M%V*O*#PUV$DZ#31(B6U?5O%E-<.5I`9M1&NC5:AU2I554OT8>(*F9E#B8[R0
MU66JTC-3FF*-A;)S14]KU'Y?+/9;;ZCM#JIX<_'!7#JTR^U(-0L$>HVT;Z>L
MM(",(4'/U35#&5[>!4G,5?$+$!ZW9J@8??>Z"66`+O\``8#`8#`8#`8#`8&A
MK^HX%Y,,9:@2URA;A%)6CEC6]-B(I>H*6HDBQ.3H!0U2(11I1JD)I9H3=;`(
MO^3?KZZNEMJ;5W-.?E:N+_3!MC_%3_\`E1F[Z_##-LZR?E:N+_3!MC_%3_\`
ME1C?7X8-LZRA+^39/^?K[5?>6[??U^7WY3^8CY"3]YOV`^TOOONX^;_-_C_L
MO\R_PKW/Q7N_??3['K].7FNS=MCNG$[MN9?)V]S1T[U7855\M5+Y".A./W:M
MZ[W/G6W:=T,,@LE0J5&LKDVSEI226-#<TW]&G.1"^/\`\#&6;O83A'B$&)B)
MIO\`.51,Q;;['.EYSO%/VOR[XR>@+AMCR^]>]HP)C<JA0OE&VE&QBA+B%WN2
M!HT4E=E:ZP)N8V"B[@,I22>G3ISO?:"6(_1)AI1W-:N9O\BE$?+T/I_$C^7.
M.:^#3>D>;N;I&:WL.O<@]&9"8W7LSMYB-KU_0%"(2)2=@!K8"2@^@`A.>X?-
MWQE97(?-G.,8\V/DOK&T*1=)2OL3I^.<RC!9'0J9\7.ZA@;IZ!KG\>=4B>#H
M'(M$B]AW4_%DIPFN&EBS1:DH,1XH\R_'_+O1D+NBWO.=Y/>N*_C"&6)'N@K3
MYO?2(+-3)#%'A@:SWI2XVY,!IA1=W<B'9,).F+/$K0E`V:$H1H!ANWQB?Q0O
M.5+2_O`CN'I7IBXH=-.LYO+.1G1^KU7+'5GY^6.;V"-MZAO;34">$>^:](#-
MLI(=)41GMA)`#7M>H6Q_ZWEX;?\`/3H#\"7SZTP'^MY>&W_/3H#\"7SZTP'^
MMY>&W_/3H#\"7SZTP'^MY>&W_/3H#\"7SZTP'^MY>&W_`#TZ`_`E\^M,!_K>
M7AM_STZ`_`E\^M,!_K>7AM_STZ`_`E\^M,#V(]_%K^'B2O[''$,XO@I=('AL
M9$9JNC)`6E*5.JTA`G,4C)7GG`3@./UL>P`&+0=;]`[W]&!TS8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8'/OY>::0UF>1U$O[5\S$??+?LFIJ"JODOQ\WA5D98Y-
M9TH;3&=B;85$)[5[@C8SG=%'%KL\+5[[HC9I9PP:]L99.PTSX)+^:+8MJUFP
MBQO+]*#WF@X1:\6;?)O=E#V+$GFOWZQY="T<VI5CJYD9'P:S[40ER;G-<9HY
M*F"262;[HP]/[T.F[`8#`K`;OVT,Q_NP*U_M6VO@6?X#`8#`8#`8#`8#`8#`
M8$(O^O\`_P#=[_XS9U^CZN?U/1LT4'CFNJ@3[[=M6I0*GQ,OW<[)*^=;:]2+
MV]2@*CX[1GRW9W]![&TWK[S6]Z'O7KK4YGY>,=,JQ&[/G"2&0HP&`P*9O%9*
M.#Y#>_E?2\:P"UH;/&'OFPVKK]VL52$V/33HM,I=4DW?JL3:ETC.1PDZ5)'8
MS6CDS8:8J/,&`GX;:<)87,X#`8#`8#`8',%_%E_LXZ0_[?\`S1_O79N!T^X#
M`8#`8#`8#`8#`8#`8#`8#`8#`8%=WDP@-J3&CJ^E%+\YPWJ&QJ+Z%J3H2.UK
M+;[5\TJ2EU2+G20I9%$+:"VNC(SR9"MT4F&E>BML;@TK%R=;HPDS91@5!>"*
M?^/B==3]@IJ+J;HRGNO(=%V]LM*K;DO*&=$531U8RBQ7V=**GY:GM9SB8PEI
MJS=FR%0X*FKT2JB7`6MZ+"`(O4.H[`8#`K`;OVT,Q_NP*U_M6VO@6?X#`8#`
M8#`8#`8#`8#`8$(O^O\`_P#=[_XS9U^CZN?U/1_N];UW]KUUO7KSUZZ]=?RZ
M^TV]>NO_`$Z]=;UCZ/J?4]$W,Y.A@,!@<Q_C[HSO7@N4>?BWBN.7:T)1<G<M
ME]*<@PDNUJZC"7I*/S^=V0YH4;:^C<W@<("QL3HWK50G=*G-.VJVF(+$>4/T
M#\MWE(\_FW!#IQ_A\5!S?M8FTN*2=L54A5&H]G`^)+3+5;2I2HU`R?:T`TTL
MPLL6]"$$6M;UL)G]\]N>52@;P30#C3Q-J.Q*F^Q;&^'W09TK`*V(4R=R5.93
MK%DT/=41[LB^SY2(G8SSS/52)1Z@`$`0B,#T.4NU_*3:E/=4S'HWQ-+*"LZH
MJ_+E'.U9D=0UQ)@].30QFEJL=;$OI#7M/6:A.Z,C:1MW7!5)!A>-;T5H286C
M0@P3Y2?X@,)I6S_X?(PPC1@-G%D]IU@0:85H6MF`*.&U*`$F"!ZZ"+98]!W]
M.P[_`)-A-WNSMSRGT5.JUC?'_B77=8Q21U*P36P)PIZ;K>!$P:R7AU>T;Q4)
M;*J2*E#LJA[>U)51[R4>)"X?,P`3@#\,8,T/UQMVYY3+A9>B%O4OB6<.;W6M
M:C=YQ234CZ=K>7??S9#<D<CFVFB5!*$`(4X252F(+*>UGO&Y'[S>SPZ_F^T$
M'@>4G^(&T,.S/X?00@:$'8P@[1K$`Q`]=>T$(Q-IF@"WK^3>PBUK?^QO^3`A
M;_%=WIU0NXOXUBZOCM<PP&96M0-P6182FW(B[`J[HA.V2K37RX8Q-Z,I?)%P
M].*W9LH)]TU&Z2ZT47Z[%[(7H^._LCR;=%VC-8AV]XNCN):]9X";)(I:@>BX
M-:B>03(B0L;877YL184)3P4<Z,CHK<2W+1FDR4+4,DT(AJB=@"WW`I^\A_?W
M>G)EK0V#<J^)>TN^8/(:]32M^M:%7NPU<SQ65G221-"BO3F%15UBNBUR0-#2
MC<C%9@DB<93F665HP91VP!G_`"=VMUW>]87?,;@\=EE\\V#6M<-\O@]0O\V,
M7++/FBR+/ST.JF"=R>!U_'E+N6\M29N$[$$&MA)R\.S=@T7ZF>;_``WYG\G^
M1_)_??9?>_8\OVOVOVO+%>+EMG;SUS:-U<UB,8B+?UFT1%HB<3#[E_Z;_P"8
M_H?Z7^A?J7[5^K_MOX_\]^P?GOL+<_W_`-AP12.7\3RQ3AM\CGV\W)>+1;DO
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M#FSI8Y3K<VKRH>Z,0#B4&ER<PA6>9ZAA-/\`E"[OO*14]TX]6C)ZS`@ZV\//
M+[]Q,Q1.J]0"<1#O'GNF[,NVP9(.3P\^T29,^.-PJG"$G)Y@V(F=O92@KTIO
M^%&""3=P=I=P\ZUGYU2GGHU+8MA\OW;Q37M&6(LJZ#1&+THS=85]SHID[^R0
M4E-($:IAJ8R[%CFF+?E<@4*"V@`UIJP9AVC`WM7G7/2%&\I><@N36G..A7[Q
MK/%Y)Z!NJT&*NQS>4`9..(3T$TQZPA51$8)%'UP@4\E1I:I65'6TLMI/(`9[
MS9!NRPTS*['ZGY+F_&MG7=?G;,CX@05CXTJ823VCK%Y1LEFG'1-BR-\C]N2#
MK%#>D8FO3]CQ&UGB2PLLU?"5A#L6W+UYR783`I1D!NKRI]2WNEN<FF>>>H'S
MG*-5MX^/(%VB^SVLD=/2AWL&Y>4E-9,,0IA\467`;,:FZ+Q-?*7!QE;8F);'
M)6F#HGXU*,GZ0VO:WDDZ1@E%>,)=7E"UO8/0/D`J-=*G1BLRQGJI(374GA_(
M2WJ&;F.*J*PVV7%2G2I(\YI2D"<)GO#P%$Z5A"/:@`0Z8?/A>_W:P*>3OD*K
M8L=T-3W'5X<]I&*]K*L`A'"^J;A=J75)[<;(CSBX6";)H:XL![V6W0UADRA<
MW*B2/0HTI6<2$@'3I[I#L<CQ:4C*88]<MVKTC<LLZOZ#@D4D,_;I+$^1.,)1
MJ2MS>^ADL9J^QX^T]$6HX5XV&DN3<VFFLKRM2'IQ[^))*"N;QU^=2[EGCVJQ
MWE4$+MFQ8'*.3>9))/[ML*S#+3L"V+_B4VM-TMZ1UY7E0VO;3Q4#=!F=*A8'
M-I:WERECLF<S2R2&]L-6#"S'EWJKI>QN[.-7J[HI+J5WV=XTKGL"<<KN,FG"
MZ)U!/>?^B8(IKV9-L=G3##W1@G4TK"^CTDE`H86ES&)(W)U>A?+2@!"^#`YX
M_-R7.9?5,X@71D!X>4<=J+.YDU3KMU-UG<?+45L*SUJ&W%=CQ>WYG6(P:1,+
M#IL:3V="L-0M*_0E!RL\8TY)80D#XC:YNJMHJ_MSMR1XT.;N?'>-M#E7$A\>
MM@.,\26(_E+3$ZI9+W8<!BR!_3DMF]B+<Q+G%6<?L6AB^G8L"YO`8#`K`;OV
MT,Q_NP*U_M6VO@6?X#`8#`8#`8#`8#`8#`8$(O\`K_\`_=[_`.,V=?H^KG]3
MT;+W:#Q^:L-2Z:F'Y'JH12K;QM&=N2;7[?\`2?X,+C\3HD+1[K7M;(]SO>S?
MY_M?[&3M_P"O=[59_MM]B260HP&`P&`P&`P&`P&`P*@_-KXY[,\G?&K70%.V
M1#:MLF)WC6EU1:1S]$[+8D>N@9<B1&-;M\C;W9R3A.2R0P\H8$B@(CDX"Q@T
M`8AA"@'R57=_$N^+;F1=UE</?G&UF0ICG4*AJJ)0'GZ/;?ERR7KSTR,8MO=,
M1=*%M+$E%I1L"TH_0!?T>_:^G0=O6`P&`P(]?E+YC^>M,G%0M4F2)ANF0]',
MKT;"F,YQ:K[EC9\GDMOMZHU(,U+8+VV>A*AT!O2HP`0^H_4(=Z#")WP%Q':%
M4QNC+'Y1H.<T_#I9*)W$:ZE58Q5\BL6F<V?W^53&41UK<&T\EE?)1(I4Y+'!
M0F]V8K/7'"-V+W@O4,(?_%KXW96;6)LGX5Y4D/W,1-K@E6$/5'5\Y(H-#&:0
M/DM;8NPMZQB.0I6--*I,Y.?PVRQ%C<'!2H'H1IYHQAMUVXUY.?+SC/33OSE3
M3AT%#4+>W1>X%-?1H<]94S.V+&1DVCD'R_2T*I@9'%2B;E`A"/;T:@TE.,HH
MP81!K:'^-'Q\0!RM-WAO&'-D><KPB<E@EPJF^HH8`5F0J9.Z%_E<4FH#&HPJ
M0Q^1/;8F5K$BD)A)ZA.68,.Q`#O0;(B_'/,<"Y\G/+%=4M`ZXH:R8_/HW-:\
M@;$BC#1(4=H-"QBG:UTVVE%*'!\DC8N&4I7J!FJS`Z!H1F]`!K0:?K7QJ<A0
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M:Y.R9C<FXPE(\@3JR1`$6(!@9UQEXP:8XGD%<2*"S>RINKJ7FEUYAK\J>GQ$
MQ/'(9,;RD?05DN#:1&(K'$[8=,YPYM28MM1`2LC,QQIK0($9!2?>Q!93@51>
M8NW)15_+4*CL-C?)4FD?0G2-*<RM*?MZ$3NP^=&]SN=W<8^TNDSB\#C4D/5"
M)=RTY1!KI\"R)Q';,5J@!"$LT-&>(GPUKO&E.;ZN24WNPSV>]%H8^GDM64I3
M4=YXYBKL3&I$J*W7]6L#H]:.=@:WI-\U-,2&G)=;T-/H0MBT%Z&!7=V]Y#X9
MQK,*4JH$)#9=O7REL)\B$776K4]*Q)DAU7%1<N62N<V7;TICD;CB52^3AG:&
M=,`*I6[NK@$DHO0"E!I0:9>O+I`F3J!%0ZJB+0W6R;I>K.*YGT>7(:U40:'=
M9W!4:.X8K4QD60RM;,GYO0-+P@:W5^1$&-K>\J]%;V,@.U.P\FG+LIJ\?,38
M4@I2VZQN!@:/&E6S,ZO=6SV*V`T-COKJ.T%NVIP<HFZNR)$Y:1*BCO<&#";[
MHP`_9]D6M["XW`8#`8#`8#`8#`8#`8#`KUFD\A]==SA?YN_H(VS#H<AO"XN(
MQ@3B6J9$<:0FULLLP7O#2TX]Z^C^0.\[1$SQ8COESF8CDZZ/NW9M`?F,U>&K
MWA7R_P"[/[#;8=@7[6;7?.=N'QVEGNM$:2_#^FO9]G8_;_\`L^G,Q;9MQ/<S
M7=NRE;![IJJRG%6T02<L,F=$*+;DJ0-J@8E1*`)Y*8:O9)I10Q)RU"DL`A!]
M=!$8'6_3VM>L36T=X7$Q/9L_):8#`8#`8#`8#`8#`8',#_%Y?L;9I_V@*)_W
M\=,#I^P&`P&`P&`P&`P&`P&`P&`P&`P&!5MY@.?)'T]QZJJ2.<:L/=PG:RH4
MYN]!R?I^8<F,:UH9RWI6*4K[)A3['7-V#'G+2;8&4Y3I,J-.">((AI2]8%8G
MA(KMFYY[.Z<YVF?CRBOC_O9OYUJVU#&1!WK?/9+K9]4RVP)5'6U_:4MB268P
M2/L+%+8FK2+#TBPAW`L$46:GVF-+-$'4)@5%>3#Q;G]\RBN9]%K3KFLIG#*5
MZ/YV=QVQSZFZ+BSG673K1#V>5/D7CQ]F5>="+>@0HB!9&WXM6L(*-4'$JT2@
MDS^8&C*_\(P:UM2M$[!TJ)9R7`.G>>^TSJ)>Z>2K+,=.E.:^=X?0$-?B;O)L
M--'F^$R<4%:9(]M^H28Z&NR#19+F42<+18;WKJNJ^K?S*3]MKN"0V!-SEXSJ
MW<W%!"XPR19$X.0^I[33C<%J5C0H2%2X1!(`;-,"(S8`!UZ^FM8%N.`P&`P&
M`P&`P&`P&`P&!@\DK*MIDN+=)?7L'E3F2F`C*<9)$V%\7%(RS#32TI:MT0*E
M`$Q9IXQ!+T+0="&+>M>N]YL6F.TRR8B>Z#OW5UA^=_[)_=Q`OLK]Q?S?[-?8
M^/?9_P";?:'W'S/Y-\N^7?,?<_S/?>[]Y[/T>UZ9UW6^5G,YRC$;\>,,G[$@
M4%KSGF;O$`A<3@SLI5Q-`I=(?'&>,N*A"9*V<\:(]:RHT2DU(,X@`]EB%L&Q
M`#OT]=:S..9F_6<EXB*]$WV,8S&5G,,$(8QM;>,8QBV(8QB2$B$(0A;WL0A;
MWZ[WOZ=[SG/=<=GJ9C3`8#`8#`8#`8#`8',#_%Y?L;9I_P!H"B?]_'3`Z?L!
M@,!@1JA?8_+-B/G1$9A=\UL_O_)2Y4W]+-261I"EE)J$25^6*C+`+5[3_(D)
M">+.8A*C-_#>K<I#[SVB#=!#5[EY,.!V>AJVZ<<^JZB247<CL^L533XR0;VD
MLEZB[T[QV3-<'9P)A223+HX\,"TI>6C1FB1Z2F#.T`L.QX&+R'RS>-B)'UT5
M)^T:&8"+8@K99D#=G:9ID4==X"[RJ205#*E<G/+!'8\TBFT/=6@P;DJ1[3N;
M>H3&Z`<4,&@W$]]R\?QR]89S*]=&U0AOBPD;&NAM:CE:`U]>RI0VN+S%"23$
MXS6U,X2UI:CU+2E//*5.A(0C2EG:,+V(/[L7;G(<F8+^ED>Z/I]YB/+#@L:>
MB)>WS=E4Q&HG-M:1/3HWS*4%J=L#>L:D!8_BR]*!B2GEC3FZ`>`980]^G>L>
M;N@:F?KUINYH-/JDBBJ3H99.&=V"!IB2^%H@.<J02L"\M&NC*YC:3BEIY*XE
M.:%">2I]G9!Q1@PPN#]W\F6`[\SQ5ENF*HK`[!KD%M<[U9)1K(Q:]AUV.$+[
M&^U9%;/B5%,&1I##&I2MV:XI$@?93F%ZWLT`B]![$&[7Y,LR^)ES#`.@:QEU
M_5\&0;E]6LDD2K).T&Q%:VMLP1[)!_@JYRAKD\)DSPE3&G*6E0<$I6`D?J'0
M';M?DQBZ+:N2'CH&L6_I-Z"CTW4\IDB4$P.5N4=5R]K9S4NO5,DD3K$D)KHD
M;#C2W!4W!TI*)&2((]A*'`8$,NFN_>7N/Y9&8C?LY<HBMDE>S"U3%K=#Y7,4
M$9@$*G-55DX2:6EPUH?G9E;7*PKICS0@'M*/2I6K'Z>A:=086$S<"'GY\N8_
M??!?;AT^:_G#_(;\C^Q,S^>?F<^`^?\`V'^5?(OC/E?V,_\`B+YW[/R7[._[
MH_%?"_TF!59Y:NQN$UJ_J/D_O2L/M%3G+?*E<]P`&#I*;T?,[?L^2RVT:]K>
MGJR8*O>89-9"8K4QTTE4XB?!H4R]U2%J&P8`!5@"/'@19JPICH2YJ8D?C5C_
M``-TS;G+%*]>L[BW='VST^_SGF2;S&4PR,1R:22Z9-*Y;6<PADM9-DN+&4>F
M*6'>AIR4@24KV@ZG<!@,"L!N_;0S'^[`K7^U;:^!9_@,!@,!@,!@,!@,!@,!
M@,"$7_7_`/\`N]_\9LZ_1]7/ZGHVWU"^0*.TQ)7.RXFIF\2+61\I='$BTUM/
M6*#GYO`A,`O3JD:A+I(KV$W>P#UL>@>QO6PBWDTS-OZ])5;&.O9O9O-3G($)
MR0O9*4U&F-3$["$&RDYA(!$E[``0@!V`O>M>FM[UKT^C>1/=3[,!@,!@,!@,
M!@,!@,#4]TT12W1T%4UA?U4U_<U=+71F>U4(LN*,TRC![O'EY+HRN1C,^I%J
M$2QM7$!&69['M:U[0?I"(0=AMC`I\\AWB._4!MF'VK^?CO/E?[)5VCK[[`<P
M71]W]=O7P<EDDC^V#I'OE2OWLT7?:3X)4M][OWZ%`C*]D/N/400$_P!6@_\`
M./\`+]_XGO\`@/`M+\</C:_3O;[<0_G&[#ZT^]A9"5?M=76K]Y)4!^Q9,I)]
MFOR/EJ'Y"9*/M1_NN/VC/C--R+7H'W'J,*,YYXD^[WCH&^I)`H6AB5==W=L]
M8TIV6YJI_`!+5_C7MFUZ-N*+V='$+;-`K#9,O:XC/X>0TF%J7I,GGQXSFY.5
M[P\(9+37CP[QY?BO(=GQ_GB:3&2UG6?E`YU?JQHZW>5HK?G-A75W=,PO^I>F
M.?7V]WMVYE6/B^K4"1G<4:E9\<B;GHL@U&HV6J2)P^N!4#Y;8Q)C[%OGBQ^Z
MXM#H/Q+)>.[5>'NZN.XK&HS<2CJCKN=IFV]$R&RXB0^1U!5-K1K;VN@[*]EJ
MS!J`)O?J0F;P,%IGQ,=QT@_U9RVOKM;9$*3]:>(7IQX[92V166HG$X?X_.>:
M7@ELUPOB\DE**Y-OB>:5$8WUZD0Q)Q;S&I[+.7KB-)50-!LJS>,.WKH8_-3`
MXQP9)J-C?64RY!N+FQ'(K>Y/20B=D\?-7,<6?J2<FNJKKEKE#%5Y):C=S4`U
MZ!`R@:58BG)<WJ3-%X$GTW+74<EXI\\D^D53RJDK-\A#;T3*J.H&0R&N9?8<
M>9R^+(Q1L0#,%]2RB=PALG5FR2**31(FQ\=_ER0Y'L1NEGOR@!C;HV6[;UO^
M"KJOE7B.56_0]1U"R6C8-SP.R>8HR%/!KSX_L6C(A`R4=KW-!+4E*JGS+#)>
MUH!-YJ;3>K/*1&'N/Q"70:LY[XM[LIB^Z'=%?+;T_MWC\L;S%]",5DFW+1R%
ML[C>.T9#,G[GVNXDM,F;Q,HA.I"&4`3R)QE[+%VID-:4XQ'*BC-;&'J+N(NV
M9IUH!&\\X/49@-C^7#E[RHO?1KA:]+/K'7]=U1RY!H?,.:)(U()JLLQWL&-6
M)%S(VS_*8THCZEJ<358'@!16_8#)_)MX[^O^E>DNEK=J=FN$TM#5OC?;N6GF
MONIG*F4K58$)[`DKCUP^M,>9+E@:9KES#S'(E993P[HRSS$JX],RGF+QC*P*
M2_(+"9=QYT0_\X6M,[/KSF(APZ.M6CJY(NQ!8=EG49,KLYP/C1/(\=L7L^C3
M'R]']SC,M;FUEV;84@3(ERD!L3*`O2JU`6Z]#<W7+Y&:H\N=STO7CLYS>6NU
M`<`<<QF2F-,0=RJCXXNN&V!>,H1+K#=XY&R4,KOM]E83-JE@=K282C+",9GL
M`&%0O;VKNYQ?:6YV[2DT_B;]&*WZ9F-NRMFN*(S6PNMGF3]AU^[MO3'(\.DG
M8_/I`[XNJ$-A[4W0\2>9OL80A4-!4+3MHFM8J"P_Y87^JI^<'X!X_*-^L-]P
M7R7W"KWWWO?HS_E:^,^RWQ7N_G'YB_\`X.^*]KYG]IO\"]/COZ+`OA\@=+>+
MU(U,':'D7K7GH]NYQ"T"CUS73'$CHHB@125.Y1Z/)`A3*W"6!4RP_1B!CVF<
M='+%!FB$PAG&Z&&8<U6/P7>ETR+HOG*41&<WA?7.U039VFJ91,]264<U(938
M4>JET9V:8A2DQZ"[FS?(B1E-J-%[YU)-$N`)0$`M!/7`8#`K`;OVT,Q_NP*U
M_M6VO@6?X#`8#`8#`8#`8#`8#`8#`BA;/,KG85F)[2BMNRFL9"7%D\44&1Y"
M6>8>@(6JEN_85EN38H)+/$>'1A>_;T+98=^NOY,Z5OBNV8S"9KF<YZHD]441
M8\&I>12.1=%3^PFI(OCY1\6?B#2VQ:-6]HDQ!QPA/J[6AHC3-&@_H]_S@:_D
M_ER^.T3;$1$(O$Q'=,AJIF>'TNVP<N^9VGD1SBC?B[`+)+^=D-QB<L08T`OX
M\)_RHH&_HW\3H?M:_E]W_1YSFT;LXC"XB=N,O!B7.5IQZ3L#ZZ]2V=)6UH=D
M+BNCRY/L"%[3)%`#S6I:(]]7%Z1K@@]V;_1"%[L6_9]D7H+6S>LQC;!MG67I
M\P6',+!'=HI:[B==1FZ9;&V`O:5$F`UL2+:?:-L)VD3D#.)3:'O01'",-WK^
M4>\<D1&,:,K,SG.J5&<UF`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M!3QYMW&KXIRA75J6/?+?S0ZTEU'2MP5%<DJHV7=#5?&+@A9DD41=/<E=PAM7
MR`%9O[6I<6]6[E&(Q,:Q2E6@4!-)+`8$*/`9R^I8/?=(RCO3E3LYSB7.D;Y-
MJIGX]6;70"K:I(M*6W0\"GSBXN>Y2YV1+)C(0"$4YMC8:UIT8B0!,T;O10=+
MV`P&!6`W?MH9C_=@5K_:MM?`L_P&`P&`P&`P&`P&`P&`P&`P(<=Z?_\`-$Q_
M][1#_P"IVS.G%_M')_E+%@_]A,O_`+I;O_T9.1/=4=GK9C4<>>F2M60ZXPUQ
M*UTI^-N"4+98%8D.3%,,I-"EVY,*`XY`B"Y(D0_]HI+$<6;K?\TP7L[%N[S:
M<;M$UQUQJD=D*,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"A;S`>2
M1SY\K^Q*CJFS[&YFM6-S;G2..]ZJ^.W3J*-NC'T*@M8UMC%)PC;R@C]C6<3]
MVAVU:9P!M`C+%HH03#3P[)"*7\/]7_$#9=?3]GT?(NV[-Z?L:%Q-7?EL=/\`
M-+?S%`WMK*?30M:"M8#%(/#XBU*#7(CWIR?9SFM"47]!^BM>QH.I;`YS?X@[
MR-V-R'3Z:I*&N4SGBXI-3]R]`&7$.,$/ZA(QTTS$EP:H802_1>1113/[QMAY
M;$AABD.P-T5:7HP6BU!Z`S8:3</(1TQ.>LD-XU=T/)%M&&>7+E+Q[P?EE#&:
MO#6DUYHOGE*'6\[7Q(5KW`4-QZG#\YS@R3,ZTB3)RF]H:3$IC0IV'8!A-_FB
M?7_8/E\L]RZ%Y[9^=9(A\<%<(&&,L]SLEV%/T?UT]99X)`H?6*)Q),S*!+SC
MD^T0BCQ:T3HSWF]#UK07?X#`8#`8#`8#`8#`8#`8#`8$9^NX'*[(HF4Q2%-(
MWN0JUT<5)&PM2C2FJ2D#^WJU?NCEZA*E]LE*6,?LB,#L6@[T'U%Z:W?',5MF
M>R;Q,UZ-8(;HZS0H4:+7)VS-(TJ=+HS=C,@=F:3D@*T/8?=B]G8O8]?3UWZ9
M6WC^).Z^CZOORZT_T2__`.QV3_\`*QLX_B-U]$=^?YQT?!S+;*CO.2V3#?+7
MDKT^Z62=&P_(WQ5I/M8QD;6D:TZDI->SL*DKU*,T+6]?1EWBDXS/AE9M&<1Y
M36YWO!]N9//B)-"BH._5_+38FZM13SIYT%<F`8!:48<%&E+`<C6IS"Q>P(P`
MO36P[]/Y>5ZQ7&)S$KK:9[I'Y"C`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8'.[Y^JMZ->HMRS>L&[WYXXKHGF_HNJ[3FKG?L`9WM&WV8Q/3J1!+,CS
MVM&K6RYXC)#L<G(A($Q1#U[X9QJ@`2/YH?#X=+2.OWI2\[:F/F4KGR56*AHV
M$5T15=)5/]R5:5A"FR?2*2E6`[PQO=U3`[SI]?9":W:="D:99\O*`0><H+`G
M`E#HPP,-L.O(+;4%EE96;$V&=U[.V%QB\SADH;DSO'9/'7=,-(Z,KTUJP&)5
M[:O2F"+-*,#L`P;WK>L#4*[CWE9RZ#0]7K^>:@5=*MJ,M$CO$V!1X5E%@)8Q
M1=,I'*?@=.2AT1188FI.M,&-8G:Q;2%FA3;V5@10;OVT,Q_NP*U_M6VO@6?X
M#`8#`8#`8#`8#`8#`8#`8#`8#`C#S59DNLD=TBE:\E:")W+*XM'BR4*-$%NC
M[?I-I"W>TD()&KTG]H6_?'[,/'L6_:'O7IK5WK%<8T169G.=6`<C?_SKK7_M
M"2[_`'X>\WD[5_XE.\^]-W.:S`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8'/SY9>Q>,!V)3W/5S2>]XK8/+_3_.75Y@HSPW>?2U<2HB#A.D!D%5.,1C
M/V35?:V%RQ6CTO3.!RB/N8RE.TYQJ7:<819\!\7KDKIWHAZKF_)[8$,@]%1V
MF:C@+YQ/<'*8D%(HKRLBT8>[6],+)96ALN.W8BXV.L9$2E"$'P[4-0=LL&U8
MP`#JLP&`P*P&[]M#,?[L"M?[5MKX%G^`P&`P&`P&`P&`P&`P&`P&`P&`P(25
MI/>=*+>+893KK8U3C)+2E$E=V]R(/1'1]S4G@3K&()A91Q;AIN4)Q`VH#[(1
MBUO7IK>MYTM%[XG'A$36N>OEJ+FB^*?B,OZ3726?L+.DEMV260QL]8<>$MX9
M5;F[')G%)L!`]B3G%'@%K>_3?H+7T95ZVF(Q'AE;1$SG5+3\UW.G];D3_P`8
M5?Y+D;+Z2K=74_-=SI_6Y$_\85?Y+C9?23=74_-=SI_6Y$_\85?Y+C9?23=7
M4_-=SI_6Y$_\85?Y+C9?23=74_-=SI_6Y$_\85?Y+C9?23=74_-=SI_6Y$_\
M85?Y+C9?23=74_-=SI_6Y$_\85?Y+C9?23=75_5/U/SRJ/)3$6S$QGJ#BR"0
M?%*`^V:<,)98/:&F"`/M#%K7KO>M:_V<S9?23=75O_)48#`8#`8#`8#`8#`8
M#`8#`8#`8#`J\\NC]"([R>G7S[IOL/DYE':D.3$VAP_%I9+KH4N)C;)3"(H>
MU0R"V"\`A;LG*-.7'?!DD@.2)]"/#L02S0K`\(-B6-*NQNJF",]'>2/L'D]J
MH.HG2'W3WA'+!K]-$[K7S27)YQ6,8C$[C$5!*EBJ*)6IT*=T:%`8B*VI2*2C
M@C2*3`Z@L!@,"L!N_;0S'^[`K7^U;:^!9_@,!@,!@,!@,!@,!@,!@,!@,!@,
M#6KG3%//3@L=GBIZU=G5Q4&JW!S<X+%U[@N5GBV,Y4L6JFHU2J4'#WO8AC$(
M0M[]=[RMUH[3+,1I#X=T-1N_IW3%3[WZ:U]-=1#?T:UK6M?^Q_Y-:UZ:QNMK
M)MKI#0]GL=)P&S:-@A7/M1N1-K/4F;5+@.%1=(-G`QHVG99A24IC&2O$>:]:
MWL)N]!#HOZ/YV]"#59M-9G,]$SB)B,1U;X^X6C/ZEZG_``ZA_P!3Y.^VLJVU
MT@^X6C/ZEZG_``ZA_P!3XWVUDVUT@^X6C/ZEZG_#J'_4^-]M9-M=(/N%HS^I
M>I_PZA_U/C?;63;72#[A:,_J7J?\.H?]3XWVUDVUT@^X6C/ZEZG_``ZA_P!3
MXWVUDVUTA$'M6KZSA]6QIVB5=P6+.HK0AZ03G'(BP,C@)(<6[#.2B6MC>E4[
M3FC)!L0/:]D6PZWO7T:R^.UIMUF>R;1$1TCRL6SDLP&`P&`P&`P&`P&`P&`P
M&`P&`P&!27Y][RG'/W"C%,X7T-/N;$3ST[SM`;%F5+HRU_0K_5<UFGR:=0_G
M5$:W+RE5PJ&HWYFA+$-+HQ"UJP^_#Z^P,-->%VU*-L.S+K2U1UCYB>AG)M@L
M=4.K%Y,D*I+"(^A/?SBRG:L!FU!7!0I4>>#W*W7Q"@7PFP^A>M>HM!T,X&DK
MFZ8YPYR!%3.A>@:2H<$Z<E+-"!W-:T$J\$R>$6D@EC5%13=^8]2%R2:<"-FD
M)/?&EZ/+]H.O;#ZA_57TASP@N%GYX77U2Z*_Y"SBD+!1BNT8.FN%\8`(%;H)
M\9ZR.?035S9PMC>>IVI)1#)T0089[7L`%O00H;OVT,Q_NP*U_M6VO@6?X#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`C=;]5O\XMWG:9M2YE3-E:/\O7OJ=Q6'IW%
M82[HF(28+,G*2G@6G%[93/>!$,OV-""+UWKVMZNMHBLQJF8S,2DCD*,!@,!@
M,"$?>_\`S.QG_I8A?_J'O.G%_KT1?MZIN9S68#`8#`\='(6!Q<E[,WOC.N=V
MKT^:-2-S1*G)M]K>@A^/0D'C5(_:%OTU[P(?7>!^F)_8I2SMTAC+TTR*/O"4
MM<TOC$XHW=G=$1VO4E8W.;><H1+4INO]J84,0!?[&\#UL#R0/[$8^J(N6]-(
MY,D:4;^JCH'%&)]3,3@L7-R!Z4-&CMN!+2N<&Q202I$7HDTY.:`(MB+'K0>M
M@8ZZ2^)L;Y%XR]RB.L\DFZIT0PN/NCVVM[Y+UK&TJ7]Z1Q=I5J25[^J9V)$<
MM5%I"S1ITA0SC-!+"(6@_C-)O"ZWB[Q-[$E\7@4+CR<"M_E\T?VF+1=C2FJ"
M4A:EX?WQ6A:6Q.8J4%E!&<:`.S#`AUOU%K6P^I-*HPM>%,>1R-A5R!$$P:QC
M3/#>>\)`%;+T:)2V%*!K2`E;-![6Q@UH/M:]?Y=8'V'/+.G<TC*H=6TAY<"3
ME"!I.7)2G-:G3:$)0>D0#-"J4DD!#O8Q``((=:WZ[U@>E@,#4]DWO2E-+HTW
M6Y;-=UBLF">3JXP7/I>Q1(#TCA;80\RY8A4/JY"G,1QMK4E'K3=CT6G+-!L>
M]>V'U#;&!JS[]*2]]\-]\56?$?>G]Q?P_P!X42]]]]OR_P";?<[[KYO[S[T_
ME?\`A/V>]/F_P_\`2?#^Q].!5CYVV!,]<71-=IVZ2C$@A'3-'65!)MR;S,1U
M3=L#L"O'1XEL1EL;@1\CBH6%*W.S4`"MY^+]@!)VT)I1Q"\TH81L\)_8UX=)
M7/T7`[AZS[1OQRK&`P-V75_UGX\N?>'5->J)D\.?R)]0#JAS/E\A52IO9U0"
M$[FF*0C(2FFD#&,L>M!T:8%"_G6BUG796%6\L0CCRRKS@E_+G^-="]`U95T'
MM.P^>*'0.T+?YE'JC9I@]Q\E+;5T+F-`A;EYRHMN9RVX;B<4J4I4100@8DXT
MZ"<NMV"+Q[E"XHTFDGEHX[[_`(ATO)V>#ZCD%XOIOCFOX"JI*8R=1+']XC5E
M5V\1=9"]1W28Y8N$O$H+--2!^*T%CG-%(RFB_+Y9\?E?2G0'3:MY\<%</:65
M=#**<4R2.)!=/66BU&6$=,4Y3#)J/EFI1*=:6(5BWX@\SU4[+]@L`7?X#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`CQ>O/Z>[%T%=P3J50)Y@"A]4,SM%#0)UVC7
M\MI+4&A5:&0K2J$X6@&BQE&!WH)@];]?77I=;[<],Y3:NY\]?T/)H4US=M<;
MYMJ9&2Y@-94+A(GTY:MB2@TA83\\CIRY0X&(W<G:H(BQA$`.A%ZV+0MZ#L*;
M1/B"*X\RUC^4:=?Z6O0G_P`W/'UWF_,CX:LV3K+9EET-*)^ICBAMONV8(%BC
MJ-B5$11[.;"GY6F,-&;('8+>I;]'NZW1F@FBWK8/0&O8"'^=ZY%HCQ$MFN?,
MOW6M#R6`BE`G.^+9G6Y#'U#(C^U+Z>XACJ@_>]A?6<+@I<0D.Z;Z/=#UK0=?
M3[01?1Z)M$^(@BN/,M8?E&G7^EKT)_\`-SQ]=YOS(^&K-DZRV?85#R6;ML)0
M-U\6U##8E'R&1>OC;Z>A5RU200C)V^R$Q"I0"5.Z@280S![V(.Q&;V$(?I]K
M(M$>(ELUSYE"7IVBI+6<`8WYWO6U;)2J;"B3:%@FKXJ<V@DXX:]0!R+)6K%W
ML+"`IA``('L"]DT6M[WK>];Z4M%IQB(Z(M7$=Y6T9P=3`CU;T-Z%D3\W+*AN
M%DKUA):`)G%F<X:ROYRIW"L6&C<P.#FUNAH"C49Q)6B0Z+"#9.Q?SMCW[-UF
MD1_:,RF8MXEBU*5YU?&#;H^^OH6-661*=,^J7^3UI'HR;5VR&5U3/(W;Y8@;
M0R_2QY5)#RP*MC]G206M"`$_W1>3-<](Z-ZXZ]R!U]U<U2YE<9[?T<E$12J#
M#'J/HZ_CC<I=4^TYP"TQ2]&Q-ZE)O2@0!^V`T.]>S_(+7J'=3/'CI'5D1;/6
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MV))]A2)T4!L/[RO*=0R^:S5RNSR`]"12NNJ?)KS$UUJWTI1JZ:2_GRI^.;IN
MWG2[V-P3<R@3R"YG&\(\SM;!(5*1;%G<?PS22RJO?&)5@1%56/V3:]@<N6+T
M'-.YXA4M%]S="&Q'I.H*1M&][JK.A[+\;38WJ)#&'.5^/>CY;.(F\7+-W=D+
M?7*F4NVDA<I`B-5$-Z1U&%J=US?I"?>)WQ42OLU#)&BP9QV7XLS.Q$TACK=!
M'94PK.FZ]/2++/A:<LAEC/V@FR:+J9&V;`A*0'*#P`((-*+2:#6E)-3#S/Y7
M;2E=/46SW]&YO-/('=_7%RNGC*MZK^G.9!-85$DBD0K3K>1M!*+IB+VS+T!K
M#&X['2SQ/#6,#DB&<E,*V((WW!!97='D>.M5EH"YQ])6EY#_`!2W_P`G7E*^
M:K1:S8+X\8Y2-<R#H&-BLE;%&M/4$;BZ@<Q;+$A;E(65:[/;CI*H0B/4E"$$
MS_+58GDHCO1=XJ>2+8Z,K^`TGQ!RE<];12J*;A-@0JS.B91VW8E96)'Y.MD]
M43AYE2=!1AZ=:Z1MJ<4)FB2$*X_V2"QZ4!`3LSK+R2<TR*?<RM_6/3!B>,6Y
MY`5\)Z!E52(G&:I:FK3FOQ^3^K;LMDV@.%;[=Y+SG3MM=&3TMX4L\(869>F0
M:0*9&V'M:4HX,^[Z8GOOZCO*!=56K95TM$>3O'M7?$'-4EBK*IESA<EXW8WU
M3TEU59<1CT;1Z4J)$ZPPRLF<_P"$;0&:.3.*<`2@`,`(-/\`37D"\DT0:8]6
M<XOF\N=[S1H?(Q.NF'EMI.4+*FYZ=JIN+GMCIFRF)77/&/45A3W@:`TE,'%T
M1/*A!&D;^8J5&N4P)<TORU.&POFS=^NU\P^V[A^3_P"__P"\'[UOB&S[)_FJ
M_1*^<_>C\7\K^Q_WH?<A_N[\1\M^"^)_PGW'Q?\`-P+ZNG;,EG2704A\=//=
MZWGRO=$#IN"=46!TG6,'J28Q^/PR4S:5UY$*=4HK1T\F*))/UC"XNPC4;0,M
M(B90A$K`-1LG81,X+I)KH7RI=00J^NI^G.KNTC>+*'>V"QKL:*DB,!<>4'&V
M++((;JWBE4IFS1;A%KG;W`IU,=$:<0#%H!I/;TJ4F#"_;`8#`K`;OVT,Q_NP
M*U_M6VO@6?X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$(^]_^9V,_
M]+$+_P#4/>=.+_7HB_;U3<SFLP&`P&`P&`P&`P&!A=A5S`[9A[O7]FQ&/SN$
M/_R_YU%90V)7AC<Q-3HB>VL:MO6%F$&F-SPVIU1`MZ]HI00`P.]"#K>@S3`8
M#`CA?7'O*W4JF-+.CN>:?N]9#D;XVQA59L"CTO4LC3*-MVY,RH3WE"J-+8Y'
MMH2_'HM[VD6?#%>^+'[`?0-KP&L:VJEI<&"KJ]@];,3M('F6.K+`8FPPYI<Y
M5(E/QL@DK@W1U`W(UD@?5G]*L6F`$I5&_P`XP8A?3@:BO3C7D[IQYCDBZ(YR
MIFZWV)-J]DCKM9=?1J7KVUA=5J)R=(\!0\MZLP^.N3@VD'*&\W9B,XTK0AE[
MW@>[^5WG+W7N?N/J_P!U]\'Y@?8^QC'Z??=]G_LC]ZGK\'Z_;C[(_P"Y'S#_
M`._^5?X'[7PW]%@0'[K\7$EZ9O"*=;\O=D7%P3U[&:Q/I1RMRLF!AL2'6/4V
MGETE+/$+5J"4KFABF08M*W8]:VJ?C4QA/OQA,T:(M$8C#(_'[XTG/CZ?W#T+
M>?5-M=N=;WHRQ6&3:^[5;&B(I6>M80K<W*-5Q6];QY8Y,D#BI3R\J%RH@E4>
M!0L$$P`2?0>AA:;@,!@5@-W[:&8_W8%:_P!JVU\"S_`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`BMV!7$XLZJF]DKYF*?Y"V3B.2$+6:Y-K5\0C;2
MW(L_V%;LK0(="`-6#>PB-#O8-;]GUWK6MWQS$6S/;";1,QT[L22VCVKM2GTJ
MYBBWPNSRM*?=VA%"C/A]F!]][!GVC5>['[OU]!>Z,]-_3[(OY-[MX_B_AF;Z
M)K9S6CW;U_AJ9];6+[JK5G0G!I"[;=(1&=.S,E"8L5HPMYR[XD&].9>T>S#"
MO8U[!1I0O7?M^@;K3=YB$VMCPT.U=YIW9S?VLKFGI5,='E29(I/5P#1*54-4
MG^)+&A-TN'LX`2_38O70=ZT(._3T%K*^7[89O]DI*4[<@;>3OQVJ]L2`C83F
M\H0)XP?)0.@7$"L8!M!OOS?C!(]HMZ4!]D/NM&%;]=^W]$6KM\Q+:VW.8B3>
M6KR"H^@NSV&L'>(VQ&*"O7R#UU)ZJ_*S/D37SY2?-//TXL"H[^D/3Z![3ULO
M<GBTFAM9%<:="CUKQH_W24*<TX!H)4_-!>4ORBVG0W34;AS2WW%TE&>9.&NH
MJ::G?DF14S=CO6U_2EU:>F9A4]$RNR6>+].P>HF-D/##79$YL!;\_P#^"&%*
MPC*`(.@CQX]#MG4'*%?VLCN8-[NJAVG\9ETW4TJ[<Y2-%+8C/I(PNT&G-'/K
MY(G:NY]7H493,\)QJMDKUJ(;@F+)2+""@!-G`8#`8#`8#`8#`8#`8#`8#`8%
M8#=^VAF/]V!6O]JVU\"S_`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`CDP\E<^1F!]"UDR5\%'!^JYE;-@7XQ#E$T6`GTMO)F)C]INHEZ
MZ1J72-!E+0G`3M,SGMZ5%K7M)"B![V+819A/A_X%K:)R6)P*L+,BXY,QP",#
MG2+JCK%7<<9BU5N1[S742KN\'>[W*WZRA<1=U)BE*R1][;6?9I@]FIC-#'H0
M3)Y^YWIOEJL6JGJ)A9,&@+0Y/[X!N$\R.4O+M(I6]+9%*93+)E,WB136;2Z2
MOKB<K<'9X<5SDM/,V(X\>_3T#=6`P&`P&`P&`P&`P&`P&`P&!3[,/+A'HIUF
M=11="RAXHMEZ_K'@67=1II_$$K4R]86S5"&U8["&VL%909$_1-F)?FMG>7G2
MY.:@=E@@@1*""O?#"&Z/RS^,HCRQ2RU3>[^7`UJH\>D"KE/.M7##AQ91.V[I
M.RI&NB9#T!S$A.?$K`Y)U@R`CV/28X!G^U%K>!87^M;XC_WC7('XX0GZTP'Z
MUOB/_>-<@?CA"?K3`?K6^(_]XUR!^.$)^M,!^M;XC_WC7('XX0GZTP'ZUOB/
M_>-<@?CA"?K3`?K6^(_]XUR!^.$)^M,!^M;XC_WC7('XX0GZTP'ZUOB/_>-<
M@?CA"?K3`?K6^(_]XUR!^.$)^M,!^M;XC_WC7('XX0GZTP'ZUOB/_>-<@?CA
M"?K3`?K6^(_]XUR!^.$)^M,!^M;XC_WC7('XX0GZTP'ZUOB/_>-<@?CA"?K3
M`?K6^(_]XUR!^.$)^M,!^M;XC_WC7('XX0GZTP'ZUOB/_>-<@?CA"?K3`?K6
M^(_]XUR!^.$)^M,!^M;XC_WC7('XX0GZTP'ZUOB/_>-<@?CA"?K3`?K6^(_]
MXUR!^.$)^M,!^M;XC_WC7('XX0GZTP'ZUOB/_>-<@?CA"?K3`?K6^(_]XUR!
M^.$)^M,!^M;XC_WC7('XX0GZTP'ZUOB/_>-<@?CA"?K3`?K6^(_]XUR!^.$)
M^M,!^M;XC_WC7('XX0GZTP'ZUOB/_>-<@?CA"?K3`?K6^(_]XUR!^.$)^M,!
M^M;XC_WC7('XX0GZTP'ZUOB/_>-<@?CA"?K3`?K6^(_]XUR!^.$)^M,#<5%^
M2KQ_=.6`DJGGKL?G:Y++7MKF\((+7MIQ62RE<V,I&E3LL1,S>X&K59+:E]33
MME@%LLH(A[]`A%O03=P&`P&`P&`P&`P&`P&`P&`P&`P*>Y'XE6^0=9JKOWT"
M_(J$>>S:Z\A$BYC*KB.CTLZQJVHFBIHQ+6BV-/)2]DA*[4<;7MV:/DBA<XNZ
M(._F92<0B-A/HCG5B(ZT=.M0R)VW)77G5AYU.B8DZ/Y$6Q1^RY)9::1%*]!T
MO^;'+Y*:F&7O>R?<E@WK6A>OJ&>7%3=;7]7SM5=MQL,N@3ZY11W=6`;J^,H%
MCA"9<Q3N,'B<8XYM#L6%ME4:1*ME@4!+/T3[HX)A(S"QAL[`UG5E/5O2C/)V
M"L8T7%FB9699UPR1&4Y/+H%RLBY9R^659<EV:]N+F>E,D\WDBY>-,0(I$F&?
MLM.222$!80/E/5O)+8KN\7N-%KK3J>'V9`J_E0G)Y),CL3N)?73G9#46T)G$
MEA</M*MJ:/CV>K2J%*73?[*8PD)ZD)P?=:U806[JNLFE[08@RFL[=@,QK"Q(
MR-P=F@$B@L^CSC%):Q"=6%>UOC8%W8'90GVH1*DRLG1GMDFEF!"/09@V-J%F
M;6]G;$X4C:U(4C:WI0",&!,A0IRTJ1.$9HQFB"204$.MB%L6]:^G>]X&A:+Y
MU8*(E_4,N8I`\/9W471`NBI`B=B419<7?SJ-H^D5,?9SD990E;.)%2*=P`,\
M/O@&KS"M[&$L(Q!GDTIZM[#FE/6',8T6\S&@YA(I[4CT)R>41D0EDKK::U#(
M'4M&VN*-O>/F-=V(\-VR'`E6F!I9[\!85)1!Q09\YMJ%Y;7!G<TX5;:ZH5;:
MX)1B,`!2A7)S$JM.(90P&A"<0:(.]A%H6M;^C>MX&'U36$%I&KJVI>KV(,6K
M.HH##JPKN,@<'9W!'8+`8\W12),075^7NCXYA:&!I3I]*%JI2K.T7[9QIA@A
M#V'PQRGJWB5G69<D=C1;;9%Q-=?LUDR0#D\GBDS=5J20H8(2<U*W$]C;C&%'
M*EQ>C4:9.<I`<'2@1ONB?=A^;0INMKF2PA'94;#)4]<V=!;DA98G5\:=LEDU
MJ[A?85)`&,3FUFK1,KH#1GPBD1R%3KU`H)-+WL.PV=@1UY2YU8N4*+B]%1N1
M.TJ9HJ_64^)'Q\3HTKFI%9%H3.SU:902@"%)[+8MF1B4L0=:V840$0M:%O>L
M#/#*;K8VYDG01D;"*WT-8N%-I)AMU?-#)K9UE39-G"-A8].>HV(*F3LR95M7
MM'M=K96B]':*V(&P_5P4]6]]U\]57;4:+E\"D*R-KW=@-<GEG"K61&4,LTCB
MC3C'W%I=TQC7)X\C5@]TH+]H9&@C]H&Q!$&S,#6=94]6]-IILDK:-%QE/8UF
M3>X9F66Y/+G\[LBQW7;U-)*,;TXN0T1CTY[][M,FV2B(_P!J226#^;@))3U;
MR^S*QN*11HMRLBFV^?-=;243D\IC(R@M!"QMDZ(+;$;BG97/Y\AC:(O8EJ92
M-/HGU(V5L8]B#'^E:19>F><K_P";Y(\ND<CO0-)VK2+_`"%C+2&O3$RVM!7Z
M!NCRT%+RCD)CHUH7XP].$X`RMF@#H8=A]=8&T(PQE1B-1Z-D'F*B(\QM+&2I
M."$!J@II0)T!9YH`?S`F'`3Z$+6OHUO?T8&'PNGJWKR:7#8<.C1;-,;\F$=G
MMMO07)Y6F2^612MH54,?=3$;DXK&]G^75W7;.W:(;R4B8>D?OQEB4FGG&@L&
MGJWM1ZJ60SZ-%R!XHRS`W#5:PQR>4'V4L@$!GU7@DH$[4XH$KN8""V>^H=)G
M`"M%KX[WWN?B"4YI09\YMJ%Y;7!G<TX5;:ZH5;:X)1B,`!2A7)S$JM.(90P&
MA"<0:(.]A%H6M;^C>MX&&U/5L$HZK*TI2K6+[+UE3]?PVK:ZC7S-X>_L[!*_
MCC;$XBQ?.9$X.\@=_E$?:$Z?XI<K5+%'N_;.-,,$(>P^%BINMHU;=C7JR1L*
M&U+9AM85_8,J"ZOA^Y#$J:<+(=:V:ALJES.CK:*-KK<D(_B4:1.J6:7Z`J-/
M`G2A(#`^F.=6+IB(UY$G^1.T:(KKHKFOHIN6-"=&J-7OO-EX0:[62.K2EH=@
M"TR5QA!:!48#83B25`C"][$'0=A(K`UC4%-UM0L)#7-3QL,3A@9=9,[TS!=7
MQZU]J[>LB66[8KMM?(G-W=-BD=B3EU<=D[/^'3;5[)3EDIRRB0!^C:>K<^XV
M^_S8T6*W6NLW>GD4PTY/(#2JW?92R35TC0V<#B&/*"SY/'$:H*DQ(-:3LL0"
MS@%&F@&"XZ>K>_ZSEU.V[&BYA6\[;R6N5QHUR>6<MV0$+DCF20)SCSBTO2/V
M%R$HS0DZDH?J#T]?3>];#9F!K.N*>K>HU-D*Z\C1<<46Y9C[<-B&%N3RX_:.
MR)*U,+*^248'AQ<`-IB]LC"$K:9'I.B![CV@$A&,P0@P.PN=6"PNAN<^BET@
M>&^0\XL]VLK`P)"41C-(DMX,,28WLQX,.+VN(4,P8>G,2[)&$(MF&!,"+U#L
M(2(P&`P&`P&`P&`P&`P&`P&`P&`P&!Q]`@$K7^5]N>2H+9&N\TGFN>)0\6:K
M@EDEE%>(=%Q2Y-K:RMEG`;$D%+Y_4ORE`W_*1NA@3ISM1O289@@E[#L%P&`P
M&`P*@/.%.Z%@?";^??/-:SK,B43R.PBIZ8$PS)\BCG<TE8Y6EB,FLD<+2KUK
M#6\&;`.+NZN)R=0%,6C#\*48Y"0AV'+=>5$$,5"5G6#4^W?U+-8;XL*"K7Q4
M74@J7H!`(GNN,]E62U7:JJ<,FAZ"457;D=<&N-EM*M?II/3U\V(Q;&-&2(S0
M?]`A)I4%*FTN&G,7:3DZ6&)"C"$IBK18=*!IB3CE!Q*<1WKL`1F#$$/IK8M[
M^G8?1@,!@,#F;_B48#U9=',LCK2O^;+-N3EN.T%>UKVD]59-JD0KS;X8X\!D
MY_:YM`IA8,1L>55M6BMT<YL>EBS;('%RDK4Q`+2^B0XL\(</<:L:;^3A@G$M
MI:W8)Y"GGRT\FV!$U+Q%9,\*JW\7)'&\0,MVOFNWX*:\5".M8Z^JI2PS(AJD
MBZ/.<S,T(`%9YP1'!V5X#`8#`8')%V:XW-&_-DNG#U3=;WPXM,\\;L/Y%K:W
MN7[;M]_U5<JF+N'HJV^9+ICLR:JPYRDE&2TURDDK?G!E<UIY:!L(4J$J`&BE
M08OX6(!*VKLKGQ];(+8\9O5NY0[/2>6^6R^!V3%U$TZ9?.KXLNIXFRI-*6QG
M8YM.-E%2%=#Q^]<UJ*%",T6(*4W0]AV"X#`8#`8'`/9$"Z+#WUWU)J"KF=F7
MI)EGFA'``QFN;,8>Q*X='7FU<U5)++KN-NKU-%+9Y<L.2PA6EH..-SB6&//D
MCCJ@IR<CRCR"PN\\%<*@\9N+M)SYC@LIKWBUWJ7@1OAS.]P><0!F<>GV&I)^
M5T^[(&*6M<<),L8L*V+I9RO3H/:7/!)`#C=G)30X'1Y@,!@,"AO^)'CU?2GQ
M2WW'Y<AL9[F3TE`U4=%J^#<3@&57$<VNJQA:9-&:I]\UR9I3L;>Y+2"920>P
MIW!(G4:T!<4C'H*IO(">7T-UU==HPF+6I-.@K#,\0#WX=K(#4UTI"XI#D'2:
MIW[`<:\>3HPRAJQP2LJ9V56#\W4,PS8V:WZ.#HO6Q;#./%=`)6B[ZY=?VV"V
M1'^HFIC\L@_+O-Y/!+)C:J:/DEZ;BH^14T]FL@;&F)3I&>W)3EM?%)E+H-'$
MB?Z/00A&8`.P7`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`P^PW5>QP"</;4?\*YL\/DSJW*?=$G_#KV]E6JT9_N5!
M9R<[W*@D(O9,`(`O3T%K>O76!Q5T-U/Y&>;_`!4\9>8I_P"_[<Z)06%;$&9>
MD>4;WC%6OM?2ZO;!OAUH]8GJ>8,D+8K$@,T8O@T3FC-$YJ4?O='>\*&1[Q*I
M"ZJS/-`X4[WI5?'$^HZB],=O=1MO+T=>85WG3U@]-,*Z4('@^#6M8'&L9ARF
M60:K)0L:@E#5KI(!8VA5$Z5IBE)Z9*>'CU3YS$-G(>8(<7RW(&_IFY.M^L.6
M;GYS;K.`_O\`0.^*H]()E?DS3/FJX:U=DK&6)?9H]`S&-,=$N5R<E+M64(H`
MU(2&\4WD]<O)S"9C9::IJIK"',Q+,:R-T.ZGCEYV@R+7-TDJ-3#K]JU%6]>/
M]"V$W-S,E6?+SC'M&I*6B"2N&)./V@MLP&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!B\W)9E,+EZ>1JU""
M/'Q=_)?ER0(AJD3,:TJP.BM,`*9:(:A,A$,8-:).WL0=?S!?[78<B'.O,?B?
MK:@_'9*K'\CW<O17`Z.]8>7P[6EL5'/H/R.YWPHL>2$00^SG*%<I058:<CLL
MQP.;`SM];F?1I:GWVCT(CB\#-(7S7XK"^EH99D;\B=VJ(NH\VDAE-;<WZIMJ
M+:VSR<E.TC6V'6DQG2KG#5\.<97[&M2-RQ_?T\72(P&?#N"D\7Q&@\_CEAY*
M?_XE#RWO33-7:"6FFIU)":KAT92O3NH=IXYUI3*KL>YJP<6B)/E?LEE1A>WQ
M=&H:]K5LF5K%Z]0>@V4`PD@+*/'G1W+U.=\=<"3]IV)UUWJ_TW4PKNU-*PKR
MM#X'2R2224=;I9>12U+5;7KY;B]V4G@?5;NH4RTW2<G:E(C*WZ&A>7@,!@,!
?@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g644794g37d02_g.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644794g37d02_g.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-/6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:2\^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@/&1C
M.G1I=&QE/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CYG,S=D,#)?9SPO<F1F.FQI/@H@("`@/"]R9&8Z06QT/@H@
M("`\+V1C.G1I=&QE/@H@("`\>&UP4FEG:'1S.E5S86=E5&5R;7,^"B`@("`\
M<F1F.D%L=#X*("`@("`\<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B+SX*
M("`@(#PO<F1F.D%L=#X*("`@/"]X;7!2:6=H=',Z57-A9V5497)M<SX*("`@
M/$EP=&,T>&UP0V]R93I#<F5A=&]R0V]N=&%C=$EN9F\*("`@($EP=&,T>&UP
M0V]R93I#:4%D<D5X=&%D<CTB(@H@("`@27!T8S1X;7!#;W)E.D-I061R0VET
M>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R4F5G:6]N/2(B"B`@("!)<'1C
M-'AM<$-O<F4Z0VE!9')08V]D93TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R
M0W1R>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I5&5L5V]R:STB(@H@("`@27!T
M8S1X;7!#;W)E.D-I16UA:6Q7;W)K/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE5
M<FQ7;W)K/2(B+SX*("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T
M(&5N9#TB=R(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#
M`P,#`P,!`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`+$`E@,!$0`"$0$#$0'_
MQ`""``$``P`#`0$!`0``````````!P@)!`4&"@,+`@$!````````````````
M`````!````<``@`#`PH%`@0$!P```0(#!`4&!P`($1()$Q0Y(2(5=G>7MUBY
M"C$6UQ@:UA=!(S,U,B0F-G)C=+2U-QD1`0````````````````````#_V@`,
M`P$``A$#$0`_`+Y>B;Z)WI=]K/2[ZG=@.P/4ZM:-L&C5N_/KI=7]]UZ'=SKN
M&U_0ZS&K+1M:T*%@VHM8.%:MP!NU2*8J0&,`G$QA#5#_`!R?18_(O3_O0WO^
MJW`?XY/HL?D7I_WH;W_5;@/\<GT6/R+T_P"]#>_ZK<!_CD^BQ^1>G_>AO?\`
M5;@/\<GT6/R+T_[T-[_JMP'^.3Z+'Y%Z?]Z&]_U6X#_')]%C\B]/^]#>_P"J
MW`XQ_P!NMZ)B;M!@ITBHR;YTDNNU9'U?=B.W*#442NED&YM9!99)L9PF"AB@
M($$Y?'P\P>(<G_')]%C\B]/^]#>_ZK<!_CD^BQ^1>G_>AO?]5N`_QR?18_(O
M3_O0WO\`JMP'^.3Z+'Y%Z?\`>AO?]5N`_P`<GT6/R+T_[T-[_JMP'^.3Z+'Y
M%Z?]Z&]_U6X#_')]%C\B]/\`O0WO^JW`?XY/HL?D7I_WH;W_`%6X#_')]%C\
MB]/^]#>_ZK<#.3M?Z'/I69UW@]*[):7U%K$%GG8;8.T59V2MHW_8G2%W@L_Z
M=:[IU/CWCU_HKN4C4X2]UEC($,Q7:J*'0!-0QT3'3,&C7[<?X*_1?ZH:C^/N
MK\#;?@.`X#@.`X&:7??L7V`Z;V7'.SD>UB[MT@J[U[3^Z5-CJLL\TK+:K:WT
M>WKG:>K33%1P_F*;D4@7RVZ$(U.H$`Z6D4?,9H<"!BUU_P!=TY+*/2^W&LS;
M/39[0[YZRW7]'<G\*TU:_F0EY3LGJ6%N*UJ$LSGYV,K<G8,*CDBE;J@RDD@9
MHF(9)-%+@>ZIW?;L%T]R7TJ-,[>]F]*F:SV0P/L;VF[36G8\UI]8:O+Q!]8\
MZELPZJ5-G7<Z@W=%<(7B<=2L?&F`M@DW<<\*HX534%LD%SNJ_J5=D[I9.@&)
M:MA=.L>A=GNI&;]B-&TYAH3'+H@]BMJY7NB4;%Z!+Q%CBKY:.O%4E8F:ND&X
ML\7/-X651=Q[)^!5"`&Y7`<!P'`<!P'`R-[R_$F]$?[?NZGZ?N]<".OVX_P5
M^B_U0U'\?=7X&V_`<!P'`<!P.#*1D;-QDC#3,>REH>78NXR5BI)JB^CY*-?M
MU&CZ/?LG)%&[MD\:JF3524*8BA#"4P"`B'`B&NL,/ZV8BT99O5J7G&)9O5WD
MA7ZGF%>AX6J0U>;J*OW*=8KE;;M(Q,CEX\,H)4$R^U<+B8PB<XB(<&F;_CNI
M15%3:S4?[WJ+>P!6Z?/)M#SKU&$)(MYM&0B$5)!%H0C9HL!O:G!-4AO(43";
MR\"-ZGU+Z:?W)SW9RF930B=BJJXDZW.7:$5DDEX"<L%1@(2;>C66\B6G1]VF
MZ*SCHU[,I1Y9=S%HILEG)D4_9`%PN`X#@.`X#@.!D;WE^)-Z(_V_=U/T_=ZX
M$=?MQ_@K]%_JAJ/X^ZOP-M^`X#@.`X#@9<]ZNRUXSC0,\S^A,K-!2<65KH:U
MR(\*SJLM[(LRV&H23%PT*TGFIV;-119(71#`HHD0J1S&*8H9+:;VWM&1X]9)
M2P*2$Q2*T6^/35F.(JLNY1U--"'DZZW.NJ9-K#%E'";M`RH^1DX\RWC_`,!#
MP6&Z4<'-&[`YNO+0$P\8I3L$>8C4B.V*CE!9BN1]&/T5D7!3(F42\!]HW53-
M[1,1*8H\"SG2^N=I'W=6$U2&[1Q4%A<JM,?[J8=+IS,K*6\S2IR$E*6Q^T&,
M&N1Q'%@=-Q3L#J1;NT%_%JFDJ0XD,'TC,GS*3:-W\<\:R#%VD59J]9.$G31R
MB?Y2+-W*!U$5DCA_`Q1$!X'*X#@.`X#@.!D;WE^)-Z(_V_=U/T_=ZX$=?MQ_
M@K]%_JAJ/X^ZOP-M^`X#@.`X%4^VMGWNK4F$=X%%/Y2<<S2K>?\`HNM-[-),
MH4(]=4CMFU<G5(10'J9$Q\&SDQ@/\@%\OB(8!]GM2[&ZI"64DA8!5U*$@WD9
M5(ZTL/H6%A9PH`4QW%=009Q\=+JI>)16.W*)E")>W\R9/#@0-CL=I3#-*XPV
M22CIV_`V<_3SEHFU41,FLY548LWRC5%)@_D&C(Q$W"R29455"B(>;Y3F#]-5
MUZAXK76=HT"2=1<.]E6\&T.QC74FNH]6;N')4R-&9#'(@@S:**'-\@%(3P#Q
M$0`0_/5$]&LF6S">)61A"6^;90SV!E9#R!&O(U1RT?K(J`Z:/6I#OHTP@B==
M!0B9S`(@4?G%#Z#/3>TS;+;AU:JVVP$H[GZE7H=BCH[>)2C:I9"MF+5LYCV"
MAR1QGBT:Z*<B"K5I[N=H4GF,4Y?`P:*\!P'`<!P'`R-[R_$F]$?[?NZGZ?N]
M<".OVX_P5^B_U0U'\?=7X&V_`<!P'`<"B_>/8OY"SQQ7ZSJL/2;Q(MS+JUA6
M-&1G+75WY',6^9QKHC5V-:4$RACIOC`D'F1$A54S"!@#YJLRJ&P5RZZ?):)I
MA+[5;#)MWU"C54U4I"M-%'3]TNV=(F:))(E!LY10+Y%EP5!`%/$HF$.!+<@V
M?N#-/<GWN1$UO.Z\">8ZJ0>40*0?`0_X"`@/@`^/\?DX'!LE2JMQ:MF%MK<'
M9F+-ZE)-&4]&-)5JV?HD.1%XB@\253(X335,4#`'CY3"'\!X'?@4H%`H%*4I
M2@4I2@`%*4`\I2E*``4I2E#P``^0`X&B_0O4]MD-2/67^D,['2&5=+&0^8VB
MR*LY4[)H1(R$A2P<P,BBO_++-%3V[07K7VB!RB'S$@\H;=<!P'`<!P'`R-[R
M_$F]$?[?NZGZ?N]<".OVX_P5^B_U0U'\?=7X&V_`<!P'`AS=]]ROK9GKW3=>
MLO\`+M:0D8V"C4&D=)S]DM5IG%Q:U^FTJJ0320L5OM\^Z`2-(Z/;+N50*<_E
M!)-0Y`S\)ZD_4VXV.M&W_$=7Q*#1?`A5M7[&9K0QS>$D),R3=`E@MU2NVBI9
M.$B?RE!U:$X-D50"D47(L)2<"COJ?V#?-'73M/6N(IJ]?AWD'#US0'U2<1E.
MD8&1157>NFMOEXY!A=G"YTFXLSLQ78%:"8S7VOB98X5;:LI)W76+&?<ME9H\
M2P2F7D40Z#)67(V0&0<L$5!]HFR5?$.9,AOE]F(`/`\]>&MZ:9W/M<R7C#WY
MM#&+55;`0BD:K)IJI']F[*J;V`>V;@H1,5!]F502"?YH#P.[Q6,ODQ4:"EKS
MN%KUMD%F,5=IXJ/FJ\)*OGCHR2KL\&F[0(@C&D*HJ#<%/FIJ&*`@4W@%^.I'
MI_\`='K)M.C;%/7G-^P->5EE9;*:<IH]RIX-(63%^LX/%69*M2+2.D!C9`&!
M8IW'.X9\@0JHNVIP*/`O)H'J#-\PND7F=XP#3*KI-O@,U?9E3)R<H8O='L-V
MW:+PNS5RO25<L-EACESAS9(FPR#H'"@'KL@#@$B'152`(_AO5UZRR%;I%LD7
M4I#UV1;1!]'LB]=TL]3I4G.]:I;L[%5NI6-;,F;/5+0XI#5EXQS(K-XF$FW\
MZ8.546:H2]4/4LZHW71*)E,58M`:WN]SG\IIPTWC^GPQ*9=36;3Z8WI&F2C^
MK)1&=VY]:\=L+!LRE5VZCI9D`I>=-9$Z@1E:?5)S:&OG>G.*SFMJOUHZ291)
M:LX90%JS]H;7V%*C4'.PQ=2":L,>:NN<=E92/8RYY8&_O"[OP8D=')[,X:1T
M^QH7"I5:VM6RS-M::Y"6-NT<&(==JA-QC632;+&)\PRR";H"F$/D$0'PX'HN
M!D;WE^)-Z(_V_=U/T_=ZX$=?MQ_@K]%_JAJ/X^ZOP-M^`X#@.!C!ZI2;B*VS
MI-;[+YDLW;NMXI,;*NA$D%";S>H*AI9D:2<*&!FSF;+1H6XP\.LIY#&=/CLT
MS"L]33.%9%4B*)KMG")%45TEFKILX2(JBN@L0R3AJZ;JE,FL@LF82*)G*)3%
M$0,`@(AP*[*Y%:,[EZK.8C,@[I50ET9<W570K)/A@DF@:7:RTTTS)=L27D.O
M<[.@W.D8\2T?5I05A%>&$P^W(&;?:WNFZ@-TG63R@Z%B![';9.1BLOM#^(K2
MM8@7<HU,W?Q,Y%R$E5='AW;ETJ*+V*D%V*:)2H*"BH42<"96/<SK%7:%#2=W
M[$T64NBCJZ14E3:%%VG1;<S<U9(BL&M,1M#@9=FP)<14!NW<'51;@NF8YQ(0
M1\@2)9?68Z2UIK*(Y#TYWG1(^[5&$C;I1]+ME3RO.V]HB#-7K&PUF=+.Z!J,
M:[8/1=I^T^CD_:HN3>4J8"8I@OGT&_<`9KMNI9YUOV["!ZYNKH]A\^R2ZU_1
MU-/SI]9%B)1E2HEK>2E1I%EJ4Q83IILHUX=L^8/'YTVZJ[=55(%0WUN^&Y'I
M-\R?4+W0*[:=`PR2M4OD5KEFAEY:@R=XKQZI;'D`J"A2-UINOG]W6$Q3AX%(
M8OE.0ABA#@="^G?\D$S8>ON?J45-XM(IUA5B\6BR/U\9;]>3O2)*O3F*[)C#
M1*`34`WG2:)$,02K%!4`[BH=+.KE#<P+^K8W6HZ4KDG7)V-FEG$W*SZD_4[/
MHEU@K%+S\Q*OYFQ6-M;=9LDBK(2"[IZ[=R[A1PJJ82B4.HL'0[J%9VLZVEL'
MI@*6F.UN(M,G%?2]?L-GBMXLK2W[#&62S5^4C+%/Q^A6%BBXD47;I9-4"`F`
M%2\2"%D:53:[G=0K-#J#%6,JM/@XVMUR-6D9274CH2':),8QC])33V1E7A6C
M1$B93KKJJ>4H>)AX'I^!D;WE^)-Z(_V_=U/T_=ZX$=?MQ_@K]%_JAJ/X^ZOP
M-M^`X#@.!B?ZG7JN=(^M:EFZJ[#F4WVLNUDK#-?0,)K,%5)>LP,#-IHR5>3U
M*PWF5B:K7WLPDFF^CV:(OIA-,B3TK9-,S=<X?,%5?5*EZ/I4@2#Q.T$ZO.@;
M$@LULVRGU[<<R#VJH.@JFD3]9J:5UJ39N*8-H&?=OY1L!#$1G%$_9-RALWC&
M[9-V$J7\ZY!=(VWPR*I&LNU1!>/L56DCD`XPUQJ\BFVG:M,)@/\`T'B"?M`#
MS)"H00.(?OL>(Y+V"I3K/=GH4!H-3<*>\HL)QKYG</(E#_DS5;F&YD)>M3K4
MP`9)XQ707*(`'F$OB40PB['^FIKF*)OK/BAYG=,I:E4<*UM)LV':Z4P3`3F*
M,3'(M([58AFD'_6C46TV4A?G,G9O,J(9RL7S230,Y8+D<HIJK-UA(!RJ-G38
MXINF;UNJ5-PQ?-%2B19!8B:R)P$IRE,`AP)VZJ]?+=W+[$9AUYR^&/<9"P7N
MEO=!=1R)I.$SK,X6UQ$M=[K>WS4%FE>BH^"8+IM"NCIJR$DH@U;%465`H!_0
M1QB*ENM'99UUA9SD_.83JF76+8\`C[5.R=EELGG,VLM3K&OY%%V"==R,](YZ
MY;Z-7YNMM';A8\,)I1D@<L>FP;-0OWP'`<!P'`R-[R_$F]$?[?NZGZ?N]<".
MOVX_P5^B_P!4-1_'W5^!MOP'`<!P/YL'J7T2]YKZBG<BNZ6RD&5EMNX7+6:V
MYD@5_P#5F6Z`\))9U98%RKXEE(.,K::$$8R(G38O(A5F;R'1\O`HD_FX6*43
M1DY>+CUUA`J+=Z_:MG*YC#X%(@V55*NN<P_(!2%,(C_`.!:3K_UV[O7.UQ&C
M=4,%[3+V]N5-K%:7GV9V.LP#EF8Q5`BYNW:`PK>96JL+^/BHQDW+MB<H^8"%
M-X'`/HJJKKNIB68P]J]0CK8.,LC*&:O]DSRP5[0\WBTB>Q(UE=DA:-,VQYA?
MTB97Y[Y1S*5=%3Q!>18B9-$0G56:AF\*>SK34.A6D8KZ?4LRLJP2KJ4$"`._
MIP\\=R6*)#>Z_P#-][%;V'L_G>?R_+P,^+UU0ANY-TB-[Z_=7,XM4_6GR<G'
M[SOI$*EU]W!=LBHW3AK#DS^I6:;[)TM1$13+8%(N)31'RJ1,V<2>(!O[Z;>^
M5B;+=.LUMZGY[TF[(95`5NW73),F9U53&M(H\XL\A(?9L+MM5A:ZC;J$YG8U
MS'O&[]BTFJ_(`5H^2_YK=PY"4L]M4?V9[DK:S0UT)O$NK>:Z/B\/H#$_MX#1
M-TU:U4*0TN/I<FB8[*Q0.-UW*F,7(2#<QVAIZ;=L$SF<1;PB8:`\!P'`<!P,
MC>\OQ)O1'^W[NI^G[O7`CK]N/\%?HO\`5#4?Q]U?@;;\!P'`<#YZ_4^V7+-X
MTV1ZT,>KO7#>9#$5(H;]KW96IR=PKN<VVUPD=9D,VS"#J$I5+K-6P]6DH^1G
MG"5BA(V/1>-$#B]<G50:A7GKKN[CJJ*/\F^GET(>D:^`)S^!L'O7J^F*`^/M
M%`N=.UL95S\H^`NK4CXB/_4#Y1X&EE5]83$U!00UG$.S>-J^7_SLJOFK38:F
MV,`@!CDF<`G]0E?="A\OM',:U$`_B4.!(,QZI?5FW1;F"ZW2SOMKK#OVS`,7
MR]FNTG*XHJW(8'FWR5T9P</@]2]FY3,J[M'N;ETB8Q8]G(+@#<P9ZYWT'SY6
MYSNF[+6J2H$_96]U@NJN8GL37IMD5D1,=8)BO9K/+$87^\.')P</I9_'1L(K
M(%][8P$<N)E3AH4`**G*0I3*''R)ID*43&$"E`B:9"%`1\"E`"E*`?(```<"
MF!^O&8^HEV0>UYS-Z*ZQ+"\8U++M<T7%=6NN8,K/I6J73+)5I@H7W.)V#<7A
MG3(7-'4I;(8'+R+8NY"-;/DA<**(IA?W!9"[]9]:KG3;09MI<LSL-"E[#U-T
MD*Y5*C.EA,W^AF-UP?086CP];ISFTTB&F6,I`2T;&1I)N"]\(X;`\BG#M^%_
M^`X#@.`X&1O>7XDWHC_;]W4_3]WK@1U^W'^"OT7^J&H_C[J_`VWX#@.`X'RY
M]T,^L'5CLGNEJT2)F66'[MH9MDH6U)Q$I)T:)G;'5JQ"7;--(GXUF\;4*Q0]
MAK*CV)7E3-HZ4B'R239P9PS<($"N3G9<C:U=Q=1TVB.ZJV6;M#S4/9XFP-UI
M!X<$F$2P1@7,F]E)R27$$VK!JDL]=*B!$DCG$"\"9,SZX;QV#]WE[8-JZNXJ
MY\BR22K=JS[.Z-'G$#`+*->)/XWKW7I!'^#A^F]MYTS?,:1"OE5X&H&5Y'FN
M(U%"BY33XJEUE)PH_<M8_P!Y<R$W,+@'OEAM5@DW#ZP6ZSR)OG.9*3=.WRYA
M^>J(>``'FMN[#9-UY@XZ7TZR'92%A6694JCP$>[M&E:+*HE\3Q%`HD.1>>LC
MM/Q#VZQ$R,6)!]H[<-T@,H`96Z_K/:#L<=G[:4KG7_)F\HD[6P5PUE[K.ZM`
M%36*>`["Z-GM]SZ9AX65\Y#.:[29=NW\I10>RDFB=1#@7^ZX^I;)XV;.LGWC
M`<<RO$QD*_GM>TSK7(2,-FV6N9R1;0E62NV.V.#8.Z'09"<?HM#RT7+S+:,7
M<D.]20:BJ\2#0G<Y5M;NX_2S,J^";VT9Q+:WV0O:K8Q#+53,4L=T+"H4TH8!
M'W,+]H.K-T8](X`9\G!R)TO'W%82!>7@.`X#@.!D;WE^)-Z(_P!OW=3]/W>N
M!'7[<?X*_1?ZH:C^/NK\#;?@.`X#@5#[:]CK!B,;0:5F-5AKUNNV3DS7,RKU
MHD7T12(2/K4,I/7K3]&DXQJ\E4J%GT0*)G#9BF:0E9)\QCFXI'>>\H!G-GW5
M#/Z_JSKLAI+.KZSVAE&7N#C8G&>5*F-JA&G456-7,BI-?:GC\^@4E%S@+M5S
M*69\4?%_+NQ'Y`LU(R,?$1TC,S$BPB(>(9.9.7F)=\UC(F*C6:9EGDE*2;Y5
M!E'L&B)1.JNLH1),H")C`'R\#+/L;WMTV2K2[#II389\271>(PW97:(Z=B,A
M>F:J)INW&/U-..4M.NBDF8_N\ZJV;5+VI0,BK+$`Z7`KEG>&]FVHVS59GK)I
M^S6Z0D@KUWWFK:WENW7:WJMXXDX1DR8V"5R>[1E3:1ZP+-Z_`UUI&1X`)$V1
M#E,(A^,]K%1I+A)EJ#>[8H_5`HD9[KFN@XV0_G`IBBC+Z%6H&N/2B!@$#MGJ
MR8@("!A`0$0\Q:G3#L;&2'6["I>OZIK.X0KVB5^$I<FPN+6JQ-K1^A9G4KXZ
MKZ\BSJ6?Y_%OE)1T_?G;IN3MTVC457CA!$X?5UUYZX57K[#3ZC>P6G2M/T!W
M%S&N[;HKQG)Z1J4]#QQ8F(<3CJ.91D-"UZN1H"UA8&):,86&;&.5JV(=9PJL
M%A^`X#@.`X&1O>7XDWHC_;]W4_3]WK@1U^W'^"OT7^J&H_C[J_`VWX#@.`X&
M>'>7/-$3LV%]D<XID]IZF(AIE0T;-*BW0>WJ;R38F-2-8[/GL6X<M2V6XT&T
M9U!R`0I%".9>)!^@T%1\+5NL%)K!W(ST(]9OF%-UO8+V8P-6U#C,LT7./HM^
M<1(!=$NNMU&F5#,8]HJ`@Y-(N#2'S3%:LG:P`B8/&UN'9WPL5H?:E.`VNV1L
MRH]K_6V.7D6O5C+)!B=-W`3CV'7;A*]BKG&JD$%I.X$;M&;KR+14-'&+[8P=
MSJZRVN3REFM;AH1P'S")"Q8G8H-RN3BQ3\JH(E%=B@H1LDJ81,*228"'F`1,
M'IZ];)RL0\5`13KW2.AX^RL6Z:1"H'.XMS==E/S3HQ/*"TTXCE_=B+&_Z3=,
MA"@`%$3!S$NR[K7Y8ND4N]0]B@F+V0@H=&O2;.Q5&+"($\3(0)V1O>HE\J@(
M"1V5=(_MCF\PAY1)X!IKU3A4V>9(SIZEG]8>69^YD#KT2KUZK'FFA%#)MG]B
M:5IDQCCRXJ>U#Y"%$J?E\P%.)PX%">WOJ+ZOUUVK6<+BJ91G<]!Y1+=F,ZFG
M<?8)GWSK3FN&;!:]QM$S&-K'!,G]PI.TYC&5UN@#Z.:&)=(CVXE-[54P>5E/
M5X7A9*LRLIC;R,IUDF]LS.JJ3-FJ,0TNU_RS?NN_7D+E/W1>QJ1.*9>WNNPN
M_>U95G)+^YMP7\R9RHH/`F#K1ZIU:[+:[G6<0N%7VI5O1X%DI&:%/6:FN&C.
M[.</@=]4JB]=CGRTJZB/Y*E5A;3B!E&+TZ*1TBBBY*H0*43GK0W^3ROM+::L
MVPN@7.FW^FR?3J+V&OZ="0W:''-.L>AYUDT6P<6"P9PU4NU\T',W"SJSQ3][
M4*]6Y9M(.?;%:NO$/H;@GZLK!PTFO]'^WDHJ.?K?1+\LK%>U>-$7"GT9*$31
M))1_G4'V*X$("R?@<`#Q\.!VO`R-[R_$F]$?[?NZGZ?N]<".OVX_P5^B_P!4
M-1_'W5^!MOP'`<!P'`BS5;+0H.#]WT.$?34"]'P633J<I9(]#P`Q07=+,V#I
MM'J)@81*<QTU`_B7@82UFB05)?6C^7G<DZ83LZZD&Y)!0J@MVH.'0LD4_*DD
M<Y@;K@!CG#VAO`/'^'`BWLSU[B>RV8K9E.6FRTM`T[$6%O-5LR8NB.HD7!2-
MWC%P=)M(LE4G1Q`AQ`4ERIJE'S)@`A[65GX&E-*=0)$)Z9&:BFM4;.?E=/W+
M-JQ;0:K^4=E.@JJ\=%.!UCH@*GF,93P#P#@<+&\1S?`:BK1,MA'$%6UIE]/+
MM74M)3;A:6D$FK=RY4>RCARY$#(,4B%(`@0I2!X!XB(B%K\4W6ZN;0;),\<2
MTX^,1O7I%_%).WW^U4`^F2*62?A(0C52*E+*X%P;V:[@JB;=5/SK&$A114#7
M:`SZG5N&CX*-@8\[.-B7T(FM(()R<@YCY=Q[[.)2,D^*N]D33\@(N7YECG%X
MY,*BOF./CP.P>U"IR;!S%R-7KLA&/6TBR>1SV$C7;!VSF%T74NT<LUVRC==M
M*.FZ:CE,Y1(NHF4QP,)0$`Y:%?@6RB2K:$B&ZJ`$*@HA&LTE$2IL$XI,$CIH
ME,F!(M(K8/`0\&Y03_\```!P.IE:#19YHW83E+J4RQ:-$8]HRE:Y#R+1JP;^
M/N[%NV>,UD46B'C\Q(I0(7_@`<#U***+9%)NW220;H))HH((IE21112*!$DD
MDB`4B:29"@!2@```!X!P/TX&1O>7XDWHC_;]W4_3]WK@1U^W'^"OT7^J&H_C
M[J_`VWX#@.`X#@5#H.F;W9ZAN*VL4J#PB0K4U(QV<6&3D$7<.^B#MG`,Y)VY
M6=N47IV:R)/%TF1-%<5R^1#Q3,40RBDY:&7>J5M],HI2\ZRD`3:H/1;RKA!=
M)9)T\9*)>55%<I3'.FH'E,!B^8H?-'P"$NN.+U/KW59W,*Q>[)>!+9W]L>J7
M&2:2-@BS3S=DDBQ4.V(EXM"I1Y3@<Q?.=0YC&\!,`<#_`#<.Q^=4[L#FW7J;
MC9Y>\Z'!N9ZNR[.(1?PL9YE))HV:/G)%323)61+$N0,NFB+=`I2^V.4I_$H2
MDXO#%O>65$-'R)GKV.4D"R()@5@3R)*KE2`3?/5**:)@,H'S2*>!!^41\`EC
M*JRNVO*BM*ETJ#.V5RBM+VA)U,,6PG9',Y06EU8I-T)&I''B<14(5M[0WF5,
M4!$W`W&KZ3U"#B$9&8)8'Z<>U*\FTT&S9.5<`B3VK]-NT_\`+(IN3_.*4GB4
M`'_CP.XX#@.`X#@9&]Y?B3>B/]OW=3]/W>N!'7[<?X*_1?ZH:C^/NK\#;?@.
M`X#@.!G=VUS/NY=.P/6"P8#>LIC^N-7F7QNRN>:5'M7Z5LA'4G%E7?-F:M9E
M'4BZCZP#T(\J,A&BVD135.8Z?F``J9N[;*[?K*=[H5,;P_T8P5B8J59%6C6U
ME*W349`_;0Z148U!FD4%$FQBI>U,!SJ*B)C`5,*SY\P=J2EMN5FIZ%0FGJR:
M1W*CPQTEHY!#VKMT(N%CI-2^9$AEU0$J:GD`W@`%'Q"0(62K-F9L+577U?L3
M%\V4+%V:%6C99!VS!51)4C";9"N"K4%R'*<J:OD\X&`0\?'@>)VG6:YA69V?
M6;;%V.5KE119*RR55B`EY5!O(R+2,2<JE.LU:L(Q)X[3]X=.5D6R("`G/XB4
M!#3#'.O^8]BNJ56L[1S>:FCO.=U*WMID2C`W6$AK(QAYU6!?-!$T>]B7WLB^
MT:ND5R"FJ8`44#R'`+Q95G<3DN<T[-8)Y(R$13(-I!L7TLHDK(ND6H&_Y[LZ
M"2"'M%#G$?*0A2$#P*4```X$@<!P'`<!P,C>\OQ)O1'^W[NI^G[O7`CK]N/\
M%?HO]4-1_'W5^!MOP'`<!P'`_P`G(14ATE2$434(8BB9R@<AR'`2G(<A@$IB
M&*/@(#\@AP/#2U$@U1>/HB&A8^??,$88L^:-:.7D3$I(';@E&$<)*)H)H-SF
M!)`@$0]J?SG*8/,!@R8F.L-QNN57"<FFI8JHS=2N@2"0']SE%JXK&.&2QXQ!
MNB<S5U*(.E?<_%,$TTDO:F\"BF0X1IT8Z24:MT:>RC.9ZQ0M<JJJUD8N;$X+
M9G+J6LZRX+-7#HI(M)HS%6/(<I44@\H><?*8QA-P)FE<-U>@*1$J\I9[(U?N
M9*)DX=M$A9XQZU*]5B7L)88H[9TTD8"U1I_F@LF9NX;KB4X%,40X&OK$J963
M,J30&"16K<J3$$TT@9)@B0"-`22\$D@;E\">4OS2^'@'R<#E<!P'`<!P'`R-
M[R_$F]$?[?NZGZ?N]<".OVX_P5^B_P!4-1_'W5^!MOP'`<!P'`<"LG<C9K_@
M'6C7=4R.B0VJZ_6JE(K9/E4U96562TS05$A+7J7'O7CALI)3$LL!A:QC0WO\
MHJF#5J'MU4Q`,C6?KA'H654RV7[`7O84DIU/NW=JPZ)TZEXL,VA^KE,NT/3W
M.A3-5["3697BHV-/WN03=5,#S,HWD8==JDHY$PG1"?MQ]13KMTIE=.<0&5Z)
M9%5L!P/N/956*L'`UE/&]B[!0_7Y]+18R3E67CI/.%;`>QRT:HQ(C]'^)$5B
MJF]F0(GV7U4-GZU^H)OU0V2ATE;TY\1:=:*=HFPU5C/JZ9@-F['5.3GZ9N.M
M%._>P\IU^?VZ#?5J4>,FK96N*`T>KBJ@9<0#=UB^8RC%G)QCQK(QLBU;OH^0
M8N$7;%\Q=HD<-'C-VW.H@Z:ND%"G34(8Q#D,`@(@(#P.5P'`<!P'`<#(WO+\
M2;T1_M^[J?I^[UP(Z_;C_!7Z+_5#4?Q]U?@;;\!P'`<!P'`\%IN69IM-*F<W
MUZ@4[3J!82()SE,OE<B;5690&KA)XS.\AIIJ\8++,GB!%D%!)[1!9,JA!*<H
M&`*@:SZ9G476ZWIM6=T-]0XO5.J<5TJET,MFG%)8UWKI"V:<MS"BT6NL4EJC
M44RS-B="HNUC@561,5)03)ID*4(XT_TJ<)T*P]J='E)J_P!^T/LMUEO'5HL)
ML=YLMJQFAY58`AY>MY]4\]JSVEO:W1:Q=(%*3*G&2+27.=X]\'X'52.@$Q9;
MTBIM:N>LZ?I\BUTNW]B^MO7[KUOE,<0;,N*6AEB->O\`#/9&&I4^-BG4XZY_
M[ER2+EG*RTJ!8\B")CJ'!554+?U"H5;/ZI6J+1J[#5&ETV"BJQ4ZK78YK$0%
M<KD$Q0C(:#A8IBDBSCHN+CVR:*""1"II)$`I0``#@>BX#@.`X#@.!D;WE^)-
MZ(_V_=U/T_=ZX$=?MQ_@K]%_JAJ/X^ZOP-M^`X#@.!D1V)]1/:*AW?A.FO6_
MKQ&:_*5.(P:W;=8K1;?Y,8Q=<W709NM-F%7EG)20\=)U&C5"8L:[A^9P$FHW
M1BF+55TJHH@$/]^/6$D.O%I"O=9:]U_W%I"X7GNXR,];]I6@H[4C;AM4CU^Q
M/+^O9Z3`W`NAW>Q7J"DWD@X*8(]BPCP2$_M7`J-@V/K&N9C:GD5"0>F9O8;+
M)_SBV;PU9NM?F7C^1S2;;5736T4Q:2"S][_M_;'2<;,E*F)XMZH1!V"2Q@((
M?.*EZAG>(V\#G(Q5A''_`/\`O2OU-_N"^G\8^A/]FRH',7K)_MS[K_N-[0"A
M[;Z?]T]KX!Y??O'Y.!!].]3GNE1.O.*7&X:PXO\`=?4`Z77K.NH[B3KE+0!C
MZAE+[3S6,P"$<A"5N/;OQM6>;!`3JK%T5=J*-$>J$3*!W`'#4#O3HFLY[O\`
MZ=771?N_;NL].T#(^V4MLF[1Z6%0\I:;7@^9Y+(5.TV9SKM`M=&81IIR:?R$
MBQ;-6*+E-8Z0'2(4@D#)9YZTW:AY6.DVN35SDH:MX=EV7[;WN:T3!K+-TO=L
M^VOL+)8U`STY86-0M4-U\C6/6^H2.RLP>RD(@Z1DF:**JS<2I\">LU[9=QM:
M]2F\X$^[,[!G.)Z)W)[N=<*_:?<.N)LR;T[(.OU(OE"S[KN\4SBT:+$]IZW.
M6@;&5W;2NJO+5AH]!%&0<-SHIAJ)Z04SM&@=:Y_7=O[(ZKV!LMJV7>Z"R1T)
MAE,=#TZ&P?L-L./PIZNVS3-J&X]^M$!5F;B9/(+/RJ/D?,U(U3$R1@U=X#@.
M`X&1O>7XDWHC_;]W4_3]WK@5>_;V=@,&IGHY])JS<-MR.J62*J>F)R=?LNDT
MV"FXU1?=-1=H)OXJ4F6K]F=9HX35("B91,F<I@^0P"(;-?W4=8?S'8-][^??
MZAX#^ZCK#^8[!OO?S[_4/`?W4=8?S'8-][^??ZAX#^ZCK#^8[!OO?S[_`%#P
M(PG[UZ?-LO\`6]8M-QZ;V74Z<U%E4=*G[#B<S?ZJR$79A:5RXR+QS8H-L)GZ
MX^S:N4B>*ZGR?/-XA4O3^NOI=ZSJ^(:=9-IQ2.B^O9*4.99#4M5PNIY'#.<[
MN)[_`$U9.$A6#6RL6,1<2MGYXMC+LX5\NP:B[9.`2`!"PE36].RC:^\W.J:7
MUI@M#7H\EG4<_B]4SB/B:S5+%>9/3;NTJ=<8SS:"KC[2=!D_IBS/6R!'L^_;
M-57JJPM4/($@?[H=#@_AHG4</_7XZQ_[MQO_`/:0@(#I7_</_?X@/_>?^X__
M`#N!P27[T_4F%$BDKITY3B\MFS67,8TECQ0C#.;&?WWSS]$9E>`WJ$V;Z2<>
M+J/*W7'VZGSOGF\0_+3+MZ>VU$@D]DMW336DZNZ<OJR33)_$;X2NO7@-@>/(
M(MI=RI8AT[!DC[11O[,ZGLB>81\I?`.T7U+H@Z976-=:+U(<QVDQK2&T6/7M
MV.+,K]$1\$G5F$5=6JD@9"TQK*LHDCD4'Q5TDV!`;E*"0`3@<5KH?0)D:/.R
MO/3YH>)N@Z1%':V;%FYHS1#0PUPU]CS)/2"RN@UX18#*)^5][F/L/:^S^;P/
M55O?NG5-BBP50VOK15(0KZ6DRP];T?+8**+)3TH\G)R0+'Q<RU:`^F9J1</'
M:OD]HX=+J*J"90YC"'??W4=8?S'8-][^??ZAX#^ZCK#^8[!OO?S[_4/`?W4=
M8?S'8-][^??ZAX#^ZCK#^8[!OO?S[_4/`RF[K=A<!E/41]&.<C-QQ^1A:QN_
M<=U9)AAIE+=Q=>:R70W<8B.<SD@WFE&D2@_E7J+5$[@Z957"I$RB)S%*(?R+
MK+_WQ_\`_&E_]NCP.BX#@.`X#@.`X#@.`X#@.`X#@.`X#@=NP_[;._\`TS#_
'`/(H\#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g644794g37v45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644794g37v45.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```3S0``21D``%AR``!E.O_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@!/@&T`P$1
M``(1`0,1`?_$`.X``0`"`@,!`0$````````````("0<*!`4&`P(!`0$!`0``
M`````````````````0(0```%`@0%!`(#`0`````````$!08'`Q4@`C<($`$3
M-A@P0#47$A90L!1($0``!0$#!`L*"@<$"@,!```!`@,$!08`$1(A$Q0'("(S
ME+34%365U;80,#%!(S1T%C9V0#+2D[/3=876=U%AD4*2)!=QT5(W4(%B<J)3
MQ"6UIB:&"$42`0```````````````````+`3`0`"`@$#`P,$`P$!``````$`
M$2$Q4!`@,$%184#P<7"`@9&AP=&QH/_:``P#`0`"$0,1```!O\!6V?(Z,Q\2
M")D'1GK``````````````````````#['I@1D,:'HS^'L229#\F``````````
M`````````````````"'Y,```````````````````````````$/R8````````
M```````````````````(?DP``````>#(FP!P3G`$G*RD`````````````17.
MY/#'1GN259#\F``````"%D:PL```;%=614````````````!!<Q0?P\R9Z)3$
M3"9I7++C`'!!S@9/+&K`(;QK30``!L'58G0```````````^QR3JSV(``(?DP
M"G::PB``#-Q<3<@0LC6%@``#8KJR*@```````````*J"5A*L``$/R8!3M-81
M``!FXN)N0(61K"P``!L5U9%0```````````%4I*0EL``"'Y,`IVFL(@``S<7
M$W($+(UA8```V*ZLBH```````````"!)E<R(?L'X/L95(?DP"G::PB``#-Q<
M3<@0LC6%@``#8KJR*@```````````(CF2R#!B\X9X`E:3\(F$S2IB:PV``#,
MA;/<@0WC6F@``#8.JQ.@``````````!]B#!D@F*=8=F`"'Y,`IVFL(@``S<7
M$W($+(UA8```V*ZLBH")YC`'S/B<H'H";X``````*VC,),0``$/R8!3M-81`
M`!FXN)N0(61K"P``!L5U9%0&J"5@@``S^;OH``````*RB4A)$``$/R8!3M-8
M1``!FXN)N0(61K"P``!L5U9%0&J"5@@``S^;OH``````(0'JR6@``(?DP"G:
M:PB``#-Q<3<@0LC6%@``#8KJR*@-4$K!``!G\W?0``````4Y$WCQ!BLPV8P)
M4D_B)A,TJ8FL-@``S(6SW($-XUIH```V#JL3H#5@*S@``9Z-U8``````^Q6*
M2\/;GF#U1S3E&4R'Y,`IVFL(@``S<7$W($+(UA8```V*ZLBH#5!*P0``9_-W
MT``````$*3+QG@``$/R8!3M-81``!FXN)N0(61K"P``!L5U9%0&J"5@@``S^
M;OH``````(/'L26```(?DP"G::PB``#-Q<3<@0LC6%@``#8KJR*@-4$K!``!
MG\W?0``````5^$HS,```(?DP"G::PB``#-Q<3<@0LC6%@``#8KJR*@-4$K!`
M`!G\W?0``````>-.01L,;G4GBC-1+0B`3%*F)K#8``,R%L]R!#>-::```-@Z
MK$Z`U8"LX``&>C=6``````/L>F!$DQ8=Z<$R42<(EDR"G::PB``#-Q<3<@0L
MC6%@``#8KJR*@-4$K!``!G\W?0``````````0_)@%.TUA$``&;BXFY`A9&L+
M```&Q75D5`:H)6"``#/YN^@``````````A^3`*=IK"(``,W%Q-R!"R-86```
M-BNK(J`U02L$``&?S=]``````````!#\F`4[36$0``9N+B;D"%D:PL```;%=
M614!J@E8(``,_F[Z````````1\/+'5GJ22Y#\F`4[36$0``9N+B;D"%D:PL`
M``;%=614!J@E8(``,_F[Z```````#Y%7)UQY$D42Z(F$S2IB:PV``#,A;/<@
M0WC6F@``#8.JQ.@-6`K.``!GHW5@`````#['I@```0_)@%.TUA$``&;BXFY`
MA9&L+```&Q75D5`:H)6"``#/YN^@``````````A^3`*=IK"(``,W%Q-R!"R-
M86```-BNK(J`U02L$``&?S=]``````````!#\F`4[36$0``9N+B;D"%D:PL`
M``;%=614!J@E8(``,_F[Z`><(A@'`.>`9],Q````ZH[4A^3`*=IK"(``,W%Q
M-R!"R-86```-BNK(J`U02L$``&?S=]`(OFE&```;'I=^```8E*WRS0K#)1D:
MSRTH``]39)0Q(9;,8$$8```F@9MK&)DXKX,#@``]@6GF)#+9X,J\```)KDJ"
M-Y;>``#CG(/@?<``'Q/L#XG\/N``#CGT/H`?$^P``.*<@_0/@?<``'Y..<H`
MX9S````"$!X$C>>R/9GO2#YQC)!-,FR`4KDTSMB*IZ@Z$\V7!@`JO.<8/)_$
M4CTQYHZ$M^`!4H2N.F(KGL3SIYTN1`````!Y8QT>O.N/V>Q,4GK3KS^&5@"(
M)Y$[`Q8>;,]F;S-(`,#F&3HSOS%!TIG4_A[@`&-SD'U,=F+R3!_#W`,]'I@`
M````````#'!',^9U9Y<]&=`>\)I@`A:32`````````/P4OET8`````````!A
M\XYATY9^#DG*.N)@``A^3````*TCSIZ$XAY$Y!:^```5`%OX`````````!A\
M]`1_(YG`/T6BD4R8``(?DP```"%)VYY,[(Z(Y!.X```J`+?P`````````#'Q
MA4Q<1H/9G<%A!&(FZ`"$1)T`````````^15*?__:``@!`0`!!0+@X)(7V[*4
M<R`]U%PN.37H46<LTO5.3HW>3T,NYQN9$:2:B/AK.,A>TX7M.%[3A>TX7M.%
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M7-)R4QG,Q%0W%#Z4C]""W8=3XY83O2W&Z6F@O1)A!MHY%`LB<'FZ%A'<W[VY
M!^]N0&7HY#%$L]'(7H_O;D'[VY`S'0L+#FLB<+(G"R)PW`)9(O$>/;$G%#4;
MV1.%D3A9$X61.%D3A9$X61.%D3A9$X61.%D3A9$X61.%D3A9$X61.%D3A9$X
M61.%D3A9$X61.%D3A9$X6@A^!Q434[,A.%#<Z=BAOXX2/WKBCCO7CN'T>Q[6
M=,_<S*HJ3C4HCI\K#BAOXX2/WKBCCO7CN'T>Q[6=,_<[C$IKMY+AT\@'T+%#
M?QPD?O7%''>O'</H]CVLZ9^Y<#M5V._(HSN$P@T'XS#3E0WTSG,H''TSD]P$
MWXS#ZZW'PT'=4$-_'"1^]<4<=Z\=P^CV/:SIG[E^/=]-IR,-;<[A2%CD9><H
ML,Q50ZBN065=0IM-V*Z!$A4ZHO9TDW,>280+.*F@=%<$@\JW)XXH^Y5N;QZ*
MX.BN#HK@W`4U7+$>/;%34LT;]%<'17!T5P=%<'17!T5P=%<'17!T5P=%<'17
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M.?W2&+G^DEJRN3W"Q(:6&FON=?6:ZUE=[K342)JYX@^G2L*J&DP@JJ%=`N)L
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MH^K42[QOR&+\AB_(8W`*R49B/'MB4TTI&]^0Q?D,7Y#&[0R7-S!BBO/DI2??
MD,7Y#%^0Q?D,7Y#%^0Q?D,7Y#%^0Q?D,7Y#%^0Q?D,7I'_#@=C(\??Q*'EMJ
MIN>$N1A4*0(E9*C$B_,T50V2)*%&%J5*@DB1^]<4<=Z\=P^CV/:SIGQW>:R8
MHGU3]M#?QPD?O7%''>O'</H]CVLZ9\=WFLF*)]4_;0W\<)'[UQ1QWKQW#Z/8
M]K.F?'=YK)BB?5/VT-_'"1^]<4<=Z\=P^CV/:SIGQW>:R8HGU3]BQI$)/\LK
M3`V4=QE9M9QE59DI(;U41#?QPD?O7%''>O'</H]CVLZ9\=WFLF*)]4_89^>?
MED0FZXXZ.G8W?ZH=I0L]U)'C5FO$NZ72W,KI2800LA1`M-,2#2Z+QQ1]2ZSQ
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MUL;^N?Z+!_)O5GTZ>3MYI,49YT-)/3W(A:BF<5U4^DIH'TE-`^DIH'TE-`^D
MIH'TE-`18IG%"5.GN1#M=>X1GY.GN1#R9^X!\-OQ*DP>)4F#Q*DP>)4F#Q*D
MP>)4F#Q*DP,&/IZCI#Z>Y$(3DW#+ZGT]R(D;;1+$G.7PE?P\)7\/"5_#PE?P
M\)7\/"5_!O;0)(;2_P!/<B'RZ]PC#;'3W(AT-K<([6[X2OX>$K^'A*_AX2OX
M>$K^'A*_AX2OX19#TVQ$0Z>Y$?9\Y?96*G2I4N&2G3I<L62I3J<<E2G4Y9Z=
M.KCJU:5"EES9<^7CEIT\G/%6KT2U+ESY9N7"I3IULF+GSY9>5&O1,TN/^>AU
MO1ELW5K+ZTLJ+:<)J>)%-MY3?K_:=1SOV2T.O"BCG6'.G5U`VQ'.G24GYS*V
M;I9(GS<RKEXRLI*.9:FA2*'8Q<SN4&S"JA+CX0JZJK.EX1VKR9(99<1W0N.:
M2<$P5>:D]W:[S*A&"U5/DXKD1YJ#/B17EA[ML\J*+G>C).R=)&=:;CI6G7(N
M"8S%0\[#RMD<$9,9Q':$!Y)ED!-3#CQ>:O'#L?KR8F=P.9R*J_ZBRAHSB(&(
MUCPTFF&HUC>0XR6<HGEMEM!RFRR8FDC#9C]OM@HM-!I.2M78S+-+#5:1%J<N
M+H7H.)N<\]MN*G1HR#M\+HKS78$=Q=F&H!9BCFD3;_GSMVE'J]DP/HA&^8H>
MD#;XJ<LSLVU5$?+(.WS(AO5=@9X!D'8!8QW[$V__`)%Y$V_E#/W7$8^ZXC'W
M7$8^ZXC"V^MO#E,'G]MY5`FR#M\1DUU.';ZYV^VLL`M]?-2)M_/\\\B;?ZIG
M[KB,?=<1B](]J]J\3YE*:*=51HEAK]H=S(;F><2Q<T3G!26ETM.A0Z1(2NH.
M20#A(FVIIP$R91RS5[/-ERY\MG3/(;VLA=@IR,G.*/JD.43J"2AI"HJ12&41
M+JYX<0,C:08?;J$KNK63`U=9,:).IV@M(4Q2`LE34IN;(AF);?&1S)\RO]R<
MJ,_UUE1Q_P#9/M9"[!:?:TBN!TE'><EE[<T1PS2J56Z8?$J&FH2IFJ))U:R8
M&KK)C4X*:2QF.PZE5L_.#Z%4G6A),S<\T"II<JIP&W3G/'_V3[5V4B%=JQ^L
MNJFU9),("@OD3NWZD;:)B*,BPFF(WY-&\J(I&3JM+V"J9.I,O7E1%Y41>5$7
ME1%Y41>5$7E1%Y41>5$7E1%Y41>5$7E1%Y41>5$7E1%Y41>5$7E1&=;4LN3K
MJ/W5_]H`"`$"``$%`OZ)C__:``@!`P`!!0+^B8__V@`(`0("!C\""8__V@`(
M`0,"!C\""8__V@`(`0$!!C\"[D;!>L*4E'.2U4[EJ==TLM3[5E%P\&:4CN0:
MEDC$&HYI53-E5*V.Y3&\XYM$"Y*"3J63CI..UFT3+U8U8M(E./&FGC!RR<(L
M6[HBQU7S`8V0`@BOC5SI,6*[):JYV/D&"%,45K$I.A7%-*122Z\RVE1BTYB2
M4E15!PV>E6F"Z,"=R12);<IA&T%K!?.6#^F:K/K4*WI,L8DW7AD:%8U`YASI
M2Y%M(=N7IZ=$'6<O)<MM`+=:*IVJI9C.)5/JKC=9395M$HQ1H5TXDVC%Y"(Y
MA4^F1Y"R!!245O6'`.(;&F*@>\GQQ%DD#.-&=NKE5Q$$BYID@Y7VPAX<-UB2
M<'*A),3J*I`X;-'Y@*L@<4UD%2BU*HBND<+C$.`&#]%MT7WB_P"+6W1?>+_B
MUMT7WB_XM;=%]XO^+6W1?>+_`(M;=%]XO^+6W1?>+_BUMT7WB_XM;=%]XO\`
MBUMT7WB_XM;=%]XO^+6W1?>+_BUMT7WB_P"+6W1?>+_BUMT7WB_XM;=%]XO^
M+6W1?>+_`(M;=%]XO^+6W1?>+_BUMT7WB_XM;=%]XO\`BUMT7WB_XM;=%]XO
M^+6W1?>+_BUMT7WB_P"+6W1?>+_BUMT7WB_XM;=%]XO^+6W1?>+_`(M;=%]X
MO^+6W1?>+_BUMT7WB_XM;=%]XO\`BUMT7WB_XM;=%]XO^+6W1?>+_BUMT7WB
M_P"+6W1?>+_BUMT7WB_XM;=%]XO^+6W1?>+_`(M;=%]XO^+6W1?>+_BUMT7W
MB_XM;=%]XO\`BULYG%L.+!YF]OQ77_%T?%==X_!W6=2SDW4\_P`EO)-_#P,L
M_9*T_$.I8BB3@[1LWC&SY4J2*HD1*X<+$1+D*`7!:4)2=03Q9KU6D:0I)[.R
M@KH41%2R^==<@#&LV3TCAN804256467`R*9,Z4E]DI9>6JAR0S^GYF5AUI1$
M\//U!3+-%I&3LPD=D9^L_P#Y<BJH$<)HN%B`90AK'<*+SLC&$]:.3*9D)!)2
MGX,U9IKH5$>*009MWY1?-W2J?EG"P)%5-@`HC?8T@VDZ@FWQ(1E3,>ZJ%\V>
M*1%-1RIEVD''`S8QZ962:PXKU056,)0O.-W<K[\W]9_:EY_I>OOS?UG]J7G^
MEZ^_-_6?VI>?Z7K[\W]9_:EYWU[4,ZN=M%Q^C:4LF@JY.32W:#%&Y%`IU3XG
M#D@9`R7WVY]>]!R_%+<^O>@Y?BEN?7O0<OQ2P)<IR@D$/.>17V9+D$;A*)`<
MWWA=D3\-N?7O0<OQ2W/KWH.7XI;GU[T'+\4L::IQTH[CRNU60JJMG#0VD($2
M44+FG*::EP%6+ENN^&0U%2E)S\8A4KF98T[43D\69C*O()L+I]A8MWRTHU9"
MF'DEE4B9V\!`N#;`VF4J.G(*!D&`/XN7E'U.+)2!15!($4V<9,OI)NH(8C>6
M13+<7PWW6>10P,NZA(>H(*E)^JT#L"QD1/5"5$S-L=LJZ(^<MFVE(@Y6(2Y$
MRH!<-D3/8:7C:6D3U>E!5BX,Q/%RRM#H.W,]<V1<G?LT<W'.-'.H0-(%(0``
M')8(5S3DQ33YY3#*M81.45CU^5Z5?N0:(2!>3W3G0W2:QR9YLK<HEG"_I[E?
M?F_K/[4O.^U?]P=J(3O"_O/*<$C/ACVM)QO1<NQ0.]BZ2/R_.HN:6II>\#F:
MPOJN9FO/R^`@O5C//!Y-,P)EVU25[#T;3-.F94._A8VB*&>RTTUJZIC/$G$7
M*R#;D>!1:-2+`"07)F732.<QU0*6TS'NAII*G*SK.D*]J!ZF_D.58I[#-HM:
M:@X^.Y/,W>)/I*+(#=P9T3-(B.(AS76C**EW<$VI&EOZG##S#)V]=3,MZ_M9
MMHP3>QBK!JWC1APGE5%C%<+YXQ"E*`!>:T=4=8!`M5J=U;QFK2,;P3][)$DD
M6;Y!\\GG*CR.C-!THS)$$FX%5$NVO/X+S0E1LU7T8==%P9!&0DHTXK-Q$R1M
M*BG;)V`%$?!CN'QVJZ.:MUTF<7K0UAQC)+E"1.*3)A4+EJU2,JH[.LN9-%,`
M$ZAC*'\)A$<MMS7W\_XS:6C6#D4FC55(J)#"HH)0,V04&\YU#'-MSC;SS_A'
MY5O//^$?E6.CRDLAC``SK8126)<(#M#WCA')^RQ$>4EE\`"&=<B*JQ[Q$=N>
M\,0Y?V6\\_X1^5;SS_A'Y5HF-?N15:.E52K$**B8F`K9=0+CD4*<NW(%MS7W
M\_XS;<U]_/\`C-MS7W\_XS:K5DB*@H3D'")G3M0-M4T,4=HHN<@Y!_1WA=58
MB@G]99,NT<N4@N!K&_NHK$+X[;FOOY_QFVYK[^?\9MN:^_G_`!FVYK[^?\9M
MN:^_G_&;;FOOY_QFVYK[^?\`&;;FOOY_QFVYK[^?\9MN:^_G_&;;FOOY_P`9
MMN:^_G_&;;FOOY_QFVYK[^?\9MN:^_G_`!FVYK[^?\9MN:^_G_&;;FOOY_QF
MVYK[^?\`&;;FOOY_QFVYK[^?\9MN:^_G_&;;FOOY_P`9MN:^_G_&;9O-K8<6
M/SQ[?BNN^-I&*Z[Q>"R))"18L3N0<F;E>.T&QERLFRCQX*(+*$%4&C1(RJEU
M^!,HF'(%DY:G99A-1JIU$B/8YRDZ;BJB;"JGC2,8"J)CX2CE#9U]^;^L_M2\
M[D]Z0WX$VV<#Z0XX$YV%7_<':B$[PO[SRG!(SX4M32]$O73"(7623F(?6Y0E
M*.9:/E8PJ$M%OHR95.]1CWZ"XHK$.F140+B(<H#>,P]Y`]63RM2O7ZL22H:>
MJ1L@/)\4S2!D\ID`CF[0C9F0A4!O6+@Q'$1-?LZ^_-_6?VI>=R>](;\";;.!
M](<<"<["K_N#M1"=X7]YY3@D9\*]:24A0II:3-)GD:EJ6F!F0.YBX!RZBHKR
M`HE+(SSADFU167/FR_X3&$+3RE)Q$/%4LE5TLVI]:"CE8R/F8Y%M'!RL5%4P
MYY4SK.-S+%`I%1;WE``V=??F_K/[4O.Y/>D-^!-MG`^D..!.=A5_W!VHA.\+
M^\\IP2,^%5,ZJ2G:WJ6CYZ(@2TXK3<6YJ*)B5HY)Z68CY");JW,7\B[6(H5<
MR8YXF$N.XEP2TA/,9F)1E:JG9*G(:H3*#,Q%,N54N3F#Y%55=1B)%2JG3;8A
M!LB<J9=J4`LK1S>IH9:J$05%2#3?(G?E%!,5ETLT!LKA!$HG.F'E"$`1$+@&
MSZ*I^I(F7D8XISO&C%VFLLFDDX%HJN4"CY=LFZ#-BH3$0#Y+[[-J5?5)$M:B
M>&;$;Q*SM,CLZKW'H2&$1PD<O`(.93,('5_=`;/*99U-#N)YAI&EQB;Q(7*0
ML\(O"77X5%&6+RQ2B)DOWKK/4:9J**FU8X2@]3CW1%CHE4,<J2V$,IVRQDS`
M14MZ9[L@CW*^_-_6?VI>=R>](;\";;.!](<<"<["K_N#M1"=X7]YY3@D9\*I
M^-IK5Q+5A#O6SI>5D6"K1/-*E2>9E@DNX>-T8Y=)1%-0ZCDHI+$4S:?E+.92
MIX%O3JB\J["'CD7[216Y#*1N#1:0<L'CUF+\Z^=`X)F````VH#?:Y>EZKIYG
M1(5;$48N6BZB293U45"S69255OZB0C`AF$$F<O\`*F%<1<''/G$`$I1H2?D:
M?J"!C]4&J"J&E=K2$$\B+WY5&BA(A@H^29HSCE<8Y9T3,'51\H6\X'/=:KX-
M&FZDY8KC6EJ[K:G)16!D`9(4TW:P3Q9X\G`1%A&JTZV9*HJHG7*L10^!,IKQ
MM3-#,:?GFE7TB?7JO.RSJ(?1["^J(ZJ&L&LTJ!PB@SE/6%:7;$)F%5#"1,3'
M`"$OM3\VC`S<+&4SJ.@J"F.6(-_`750A+-'9XM!&0;M#ON26[-3$HD4Z),\`
M`;;6,A24RP@9@5T3$D)&+Y8;%0*(Y](6>DM;SJ!X#8MK:KDG4M%N'R6M#6&E
M(NN1G`$=R*=0N2O7:*2<PB5L@Y<`8Y$\N;`;KQMSC%=#.^OK38.#IJ+9]#&=
M%(R"9AT-M=A2.LX,3)_MCLX0&YTTUL^O@.LD9=,HZ&YOQ)$6;F/D_P!L+<XQ
M70SOKZW.,5T,[Z^MSC%=#.^OK5:+EY'JH_\`8<::$8X;JF_^30V'"L>6<E+<
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M4\QE8B,];I4$X"8BBPKN`.DSBVQXP6`2$BH`>0SQE#B0RZBQE,`%,6^RC1^T
M;/FBN#.M7B"3ENIFU"JIYQ%8ITSYM4@&"\,A@`=C7WYOZS^U+SN3WI#?@3;9
MP/I#C@3G85?]P=J(3O"_O/*<$C-@>GZKJ?DJ73;H.CM.1:A?7(.0$R)\_&Q+
MQL.,`\&.\/';VY_]9K#\/V]N?_6:P_#]C&"MC'$"B($+3578CB`?%+C@2$Q&
M_6(!;$>LE6XWCY-:FJJ$_P#;Y"%73N'^VWMS_P"LUA^'[>W/_K-8?A^T;"Q=
M9:5)S$@SBXYMZO54CI#Z0<)M&B&><0:3=+.N%2EQ',4A;\H@'?U&;^D*#?1$
M4SEW<:\G-99*:>N8:2@'41/K.XT6><+'Z(]734O,8@"0I[P$`N!PFU8HA*RS
MR2TMC6"M<EEL:+1H$@M4"Q"'6<%(S!N*=WDBH`7PW[.OOS?UG]J7G<GO2&_`
MFVS@?2''`G.PJ_[@[40G>%_>>4X)&;![]@07T"FSU:>_]&]HH[O[RH8UKJ[>
MMW#BC72"E5M)1Q*M/55THZ<1B"K1LH1.'GLZ*;M,#>53']-UIIO-A`)O)>IY
M2?!I3";I&%9)R*3(!;-$7B:2J09]`YQ"ZZ\]^SK[\W]9_:EYW)[TAOP)MLX'
MTAQP)SL*O^X.U$)WA?WGE."1FP>_8$%]`IL]6GO_`$;VBCN_K1+=QJF00*W;
M+I!5VLY"F)HP+)WF.K$JQ#@4D<X`@F;&8#@%_P"H*@E92=@)U66K*;DD#TS4
MWK9$QC1TDQ,C#(2@$3*70;A\D!2@0I@R9=G7WYOZS^U+SN3WI#?@3;9P/I#C
M@3G85?\`<':B$[PO[SRG!(S8/?L""^@4V>K3W_HWM%'=_$K9"5-K3Y,8>624
MIM*G2LQSPQI:D]?\=)BWN*;<DQ<W>.Z^R'*_J#I^G.,[_3K1.1=R;7:;H``P
MY:_Y^9\E=@NLM&K5'-OH>0U4R,Z6&=/`+#1[M*KH>/1,RCFZ;=J"B+7$&?4!
M1P.<,`J8;B@A1VL`U4C5IZ*7J!>;E=8<E5U.2#!E)HMGKLK!^].A`.4CG)<;
M-X13Q;?Q#6U6-JBFDIBE];=`4K3,4SFWJ,0K3TAR*"S(\"@X)'RB=1$DEEC*
M*)**'P!FS@4MJ6UAL9^=<U;5"FO/ER&<2SY[%B2E8NJ',(V1II952/C_`%?-
M$-C$S2!#>4N/B`]UH"+1GYR9C*FU&P==302\[(3I!JEU,-&XRK<7[IT$?RJW
M=+7IHYM$V9"XNUL9_#4T_JMZ5=%,(B.=,6;DZ:@B"BX+2"J+?`B'A"^\;5<Y
M7IR4;.'>M#6&Z<LM(ACGCW+BH7*J\>LH:31!1=DH84SF(`D$2[41"W,,K\]!
M]<VFSG14;F,NA>BL*(J$_DVP7&%NJNCE_48=G"'(BHX,5=>Y%$404/\`R;D+
MBBX501R?K,%N897YZ#ZYMS#*_/0?7-N897YZ#ZYM5J9XF0;%-R#>NNI%&2)=
M4T,(8@;2;A;;"%V0@Y1_1WA<B<8^=E]99,<ZW4C2IWZ+&[6YW(-5<0?[MUN8
M97YZ#ZYMS#*_/0?7-N897YZ#ZYL\.HV6:&Y!@PS+@6YE,B"F6]JX<I7#_O7[
M/5P8I#*F+7M'F!(F`#J"%0QX@0@JG33`Q_`&(P!^D;<PROST'US;F&5^>@^N
M;<PROST'US;F&5^>@^N;<PROST'US;F&5^>@^N;<PROST'US;F&5^>@^N;<P
MROST'US;F&5^>@^N;<PROST'US;F&5^>@^N;<PROST'US;%R+)XL6'-YV'QW
M77X[^5LWA\7QK_U6>0XT!0B3PD6DY;U[K-CE!@I$2M17"+B5D89?E!XCN0$5
M>MP*KDNNRVB7KI_"OU9XB=074_`1=.1D>$HS:*\E(LXJ])<T>("0RZ@BLH/Q
MKK@`!J1>CZ>5GS.@?&EU(MJ=^9V6["X,X,03BJ%WAM44+"PC*FR51&+0LJ^A
M6K=&0/$.@S;J.07727T9FJW$Q`3*`)IXKRE`0"T?/$I6&"8BD&+=A(:&07#=
M.,:Z#&B!AO`ZS!IY-%0UZB1<A1"S^H6%,0S69E`=`_D$F20+.-.,!GV+)@*+
MXQ;UQ*`"L/Q[[/!I>GHN#&0,0SP8]L1$RP)8LRD)@RE;H9PV!(+DR8AP@%_<
MK[\W]9_:EYW)[TAOP)MLX'TAQP)SL*O^X.U$)WA?WGE."1FP>_8$%]`IL]6G
MO_1O:*.[^^HNK4I%DL#Q2/5TZ%7>QKIGR*TEBR(YE)P#B-=BY%L3`553/)&Q
MD(2XPN%]73:/:P*TJ[462C(QQ$-.4S)M]*,1BX:L\T(IYOXA`)^C9U]^;^L_
MM2\[D]Z0WX$VV<#Z0XX$YV%7_<':B$[PO[SRG!(S8/?L""^@4V>K3W_HWM%'
M=_I-SRK)4Q!C,/4JAJ^$IX*@FX%HI$.]&*R*#"4<QB<J\`J*KE)`PE"XMX`;
M*\=S$@_FFR-0RK2FZADX@8*0J&FDM'-'2KJ-%HQS1S***I`;,IYPJ0'$`$1V
M=??F_K/[4O.Y/>D-^!-MG`^D..!.=A5_W!VHA.\+^\\IP2,V#W[`@OH%-GJT
M]_Z-[11W?PIU&,I>2(6/<O52K5Q&Q<T7-Q9GZ1%XN1;M4V0',7:>67,X)\4`
M-<46DXI$N(4Z]P&:+OHB1`1S**V>;NX:0D6QVYP6N`#BFL4P"!R%V=??F_K/
M[4O.Y/>D-^!-MG`^D..!.=A5_P!P=J(3O"_O/*<$C-@]^P(+Z!39ZM/?^C>T
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M*\+)A(/'NF/&PO4ATA+,D/E\G^@TK44LPA8TJJ:)GTBX3:M@56&Y),551`N-
M00R!:LG:4U%F;/\`6IK&?LUM/;`1RR>5&Z7:ND1,H&-!PB<#$-X!`;<\Q72+
M3ZZTVLW5371.N@)%43E43.`,VP#A.01*;*&SA%G"J:")%UQ.JL<J:9`%FY`,
M1SB!2Y1MSS%=(M/KK<\Q72+3ZZW/,5TBT^NM5J#:3CW"Q^0<"*#QNJJ;#4T,
M<V%,BAC&PE*(_P!G>%TG<@Q:J^LLF;-N':"*F$6L;<;`HH4V$;K<\Q72+3ZZ
MW/,5TBT^NMSS%=(M/KK/%FKA%RER#!AG6ZI%D[P04O#&F)BWAL]7"JIRIIIU
M[1YU%#F`A"$)4,>8QSF-<4I2E#*-N>8KI%I]=;GF*Z1:?76YYBND6GUUN>8K
MI%I]=;GF*Z1:?76YYBND6GUUN>8KI%I]=;GF*Z1:?76YYBND6GUUN>8KI%I]
M=;GF*Z1:?76YYBND6GUUN>8KI%I]=;.<K1F;Q8,YI[7!CNQ8,6=PXL/B[JE<
M+UB\$JL*O2ZL'R-$"T/2[M\C(/(87.;TGR[A'=]V`,@#95Q!U4[G9Z`HV4HW
M5MRFUCH]&ET9=8H\HNUTD5PE7K`$T=N9,I110P9L1-?95R]JZ1<PTK-TU5-3
MP(QL<5.=J6FVC1$C[32%*JQ9RCMBDNZ;D(.(Q;B&(%DV$E4,C)TC&^NHT]2Y
MF;%N2(/7B+UM,8Y$A3JR)&[>3<@U`Y"YHRN(<0@%DYF3J5Y4\BPI5A0\(LY8
M,XXL92T<X!TFS,1H)].?+KD3%9R<0%3-%VH6T=^T:OFXF`PH.T$G*(F+\4V:
M6*<F(OBM7*""::**.MO68DBBD0J:222=3NR)IIID`"D3(4+@`,@!W)[TAOP)
MMLX'TAQP)SL*O^X.U$)WA?WGE."1FP>_8$%]`IL]6GO_`$;VBCO@]??F_K/[
M4O.Y/>D-^!-MG`^D..!.=A5_W!VHA.\+^\\IP2,V#W[`@OH%-GJT]_Z-[11W
MP>OOS?UG]J7G<GO2&_`FVS@?2''`G.PJ_P"X.U$)WA?WGE."1FP>_8$%]`IL
M]6GO_1O:*.^#U]^;^L_M2\[D]Z0WX$VV<#Z0XX$YV%7_`'!VHA.\+^\\IP2,
MV#W[`@OH%-GJT]_Z-[11WP))_%4_5+"+=,M/92TU'-&D>_2%4$@(T50D79SJ
MB(B-PE#(4;+4\NRGEDF4S"T[*U$U8(*4Y#3M0E(>+C)!V=ZF]SRI%4\9TFZJ
M*.<*"ARCDL#!1&<8QJYZF2C:I>QZ)*:F%J.17<5$G'.DGB[\>3TFJPXE6R1%
M<T;-B?QFBFL94,*^/!-*ICD:@8-F?+--/UQ;-9R,%H^?@+-1:X,*V97#&%Z?
M<K[\W]9_:EYW)[TAOP)MLX'TAQP)SL*O^X.U$)WA?WGE."1FP>_8$%]`IL]6
MGO\`T;VBCO@)Q3*!S@4PD(8V`ICW;4HGPGP`(^.X;K5!6$71[BE:9AJ%?,F]
M!-ZO?52G5%6:8FO$'CVY"OB1B!Q#1BJ@4BXY[*B`8K5!#JPT<V@ZZKNC:_DY
MH)M%12GPC6\0ZGH30-'*X?/"/XG--5"!F5"GQ'$G@M#4!(M8Z-@*2_JN+*J"
MRB;D\Z%<LZ@:0I"1J:`N6!V9JA,=UG"W84;B7B:^T54M5Q3.!]6=5L7JT:M6
MTJA+&F'#>1;/W\X4S=,I63$^@)%12..>VQL7BL:)/-5'``9=%?E"EI=:$EBY
MD1'-%?(%,H5!2_;E_>M5S'E2<<\GZT-8;`';N5<K/G@,ZA<MP=OW%Y1=/W.#
M&LJ.5101&WGTKTDY^7:;3`ZBF%=#;K*&54'^3;#MCFVQO#LX1,3J)XEU]NBH
M9)0/Y-R.U.7;%\%O/I7I)S\NWGTKTDY^7;SZ5Z2<_+M5JH.I!02\@[1=ZNJD
M-]30Q=LF<PE-=?\`M[PNH+E\E_\`)9,N%N[603R-8W+@((!BRV\^E>DG/R[>
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M=R>](;\";;.!](<<"<["K_N#M1"=X7]YY3@D9L'OV!!?0*;/5I[_`-&]HH[X
M/7WYOZS^U+SN3WI#?@3;9P/I#C@3G85?]P=J(3O"_O/*<$C-@]^P(+Z!39ZM
M/?\`HWM%';!_-2[DK*,BVJSU^[.50Y&[5N03K*F(D114P$('[H"-O;V/Z/F^
MJ[>WL?T?-]5V]O8_H^;ZKL1(U=MQ,I=A%.%J55,,1L(8UDH8Z*67_$(7!EM[
M>Q_1\WU7;V]C^CYOJNWM[']'S?5=GCND)M";;QZY&SQ5!!X@"*RA,X0@@\;M
MS")B9<E_>5@9O&KO1E3(.-&<)+YA<OQD5LT<V:5+XRC</<K[\W]9_:EYW)[T
MAOP)MLX'TAQP)SL*O^X.U$)WA?WGE."1FP>_8$%]`IL]6GO_`$;VBCMAK&]T
M)S@2O>*X^WX[_P`<;O%:<BY_EGU3J/DG1K])Y3Y'>:!H^';9_2L.&[+BM!.:
M(*PY&1U#4VTJX\.4@-@K$9AN=JE-F1#"-2$:D>9S.CI.$=OXK&]2E*<3G,^C
M@-5*,FO$Z->.D8B1*[=YG\/Q-MA_3:J',`XU3)H+ZQ*Y6?EF&%8'5Y94G7!Y
M46FA21"%C!=".C@>]4$_CB(V\\U(=&UYUM9W+.YC50FX>'(=4C9K5Y$0$B1$
M@P%456.`84_&8;<]ZK][U7_?;GO5?O>J_P"^W/>J_>]5_P!]N>]5^]ZK_OMS
MWJOWO5?]]N>]5^]ZK_OLTEFDQJH4<,SG.D1RUJ\Z(B=(Z0XRIJHG$,*GB,%O
M/-2'1M>=;6IT[T^IIR%1U;`T@UT6,K;R#VH'!FS9ROG9I/\`E43%O/AO-=X`
M&WGFI#HVO.MK2-+RTGJ=;Q\IH>?6CF-:I/":$_:R*694<O7:)<2S0H&O3-M;
M_`.6WM-0O[)_B5O::A?V3_$K>TU"_LG^)6]IJ%_9/\2M[34+^R?XE;VFH7]D
M_P`2M[34+^R?XE8T!"2NJ)TS.^7D!4E&59+.<\X303.4#M'3)+-`#<+MI?\`
MKMYYJ0Z-KSK:U51;934RBK24TE"/5%HRM\VY76BH^7!5M@FCFS((R)2[8"CB
M`?%;SS4AT;7G6UE:JGJBU>-)!5FT9&1B$ZD09YIF42)F!-X@_6S@@;+Y2[]5
MO:ND/XIGJNWM72'\4SU7;VKI#^*9ZKM[5TA_%,]5V]JZ0_BF>J[>U=(?Q3/5
M=H.HF-3T0J]@)B-FF:3OEX[51U%/47S=-R1%@@J=N=5``.!3D,)?`(>&WGFI
M#HVO.MK/ZID3ZFGC2/6BT5&[*,K;23FE9=A#HB3/S225R:[\IC7F^*`^.WGF
MI#HVO.MK35,R,CJ:183L:ZBW:K)A6Z;M-!VD*2AVYUW[E$JP%-D$Q#A^JWM7
M2'\4SU7;VKI#^*9ZKM[5TA_%,]5V]JZ0_BF>J[>U=(?Q3/5=O:ND/XIGJNWM
M72'\4SU7:5CJ;FM5CU&7>(O7)IMM5KE4BJ".8*5`6!XTI4Q+X<0&&_QV\\U(
M=&UYUM;^D^CZJ/6+DSESE?0ZOY%T#1L[HNC\JZ=IF+]^_!=DP^/9GS2::><4
M,JIFR%)G%3_'4/A`,2AKLHCE[@@DF1,!,8X@0I2`)SC>8X@4`O,8?".S-@.0
M^`XIGP&`V!0OQB&N^*<OZ.[B3.10H&,6\A@,&(@X3EO"_;%,%P_HL7.)D4P'
M*H3&4IL"A,I%"X@'"<OB'PALU%UU$T444SJK+*G*FDDDF43J***'$"D3(4+Q
M$<@!8IR&*<AR@8ARB!BF*8+RF*8,@E$-@<Q"$*90V)02E`!4-<!<1Q#XQL(7
M9=FHX<+)-T$2"HJLLH5))),N4QU%#B!"$*'A$;`("`@(7@(90$!\`@/C`>Z*
M:J9%4QNO(H4IR#A$#%O*8!`<)@O_`+=F(B(``!>(CD``#PB(^(`LFX;K).$%
MB`HDLBH55)5,V4ITU"")#D,'@$-AI&81TC#AS^;)GL/^'.W8\/>M5M*/)%W$
MTK5M32;*I73-^M%*/=`@W+^'I\\BV40=-T)V13!,Y4E"'5`,%^6R&KF@9V.@
M6#.DJIK5S+U(L]JPI'$4]:MO5=FI)3!%&:+45C.'!3*J&00^(4@!:;JAB2`B
MV]-41J]K!U%.8EVZ5E%ZD>'92#)-V:11T*.<`45DCYM14I<`7CE-;_\`1%0A
M4+*6:T;+Q"<'!OXQR9)IRGR$HWS"_+(YEHVCG:B2J94OYAR.?Q)[E:K(HU14
MFVD-7>K\*ZDW+BGEB-ZN<O'DHLE%1S96;!1A%LFS0C'/%,HLLZ,!APXLV&MR
M74;&9J2DU1TB=H>\3M3O:'AW)FQQ$I!$R`J81R!X+:CE4VU0RKFN*WU@3-2P
MU/U$M34E/R#M2H')T590LO!E3.R41)NCA/(C=X=J-)TU.2SYW/HZM*\E\#C6
M3,T^$4X3G,Y!O'4_'X"U'+P#%9-/"OA1<"`XE,)<0T'K3G'$Q65%C36K^,<@
MG4[VG*FI*HUUVQ35`O3D=(),YL]1.5TE%D\9SJ)#XVX;;7/"(A_VYAK&4D&G
MAP)KU#"1<I*-TO"4I2OSF4$H>`RHY`OV&NR9+,2S2=U=?TK#5ZBUEWS)%J:;
M%DY?BG&-W"+63&;?N%&RV=(KC3(!`NNM7:T-5J\>^IIG)&<&IV:;-G9)=E&+
MKI0DDLWSCQJ:]9-<Z!#(+GP%`1S1CD.YK")6;/)2*H^.?(*O,3Q!5V#9F507
M.!8AUAQ''%MP&^U6PTM(0JKB-G=5R"$RQ@EBG8QM?1\C)2B;2%/(K\J.HA*+
M,#?&KB4*83&`P@"8TG2M1.6W+FM:JU(C"P8A'JMJ$C7KB1EG:Z24G(I:4ZIF
M)O6#.%S9WX(X<1!-:0:P[NF&<3'ZXH/52PCUX!RN;1JACVVCR3IPE+MLD0NL
M4Q4DB)YT+P$P9+:IDZB69NY.EM96O2C5)!DT%@E)IT_2BZ"+\S+/."M55B'R
MD*<P!=L:@B)26DXZ*IW47/UK`@PF7T*5*JT9=VVY7SC%PV%X[BF[5'-E4QID
MSH[4<5M64>[GP0F*ADM3S'6(5C)E93,?#U85H>65>"V6*]ATI,Z9R9T<&(HF
M`!\-M>32/JFHH^.HBO)QK2BC6><`YS*,?$JG@!E5CK2B\=&/GJABI$6*?%M3
MF.4!+:4K*$,S>2$5$13AN9UB=-5E%7L>S7SN:5(8XX5C_O9#6JJFIF4AEG</
M7U$0'K%'T^L"B$15E*O*I>Z#3YY%R#UW&@P%)/&L8QDC&.(',4"#JZH^J5&8
MS>L^H@6ED&+(K(B-"T\N,_+`H1.2DTBKNX]FV05\K\9]F\-X7"J$=(4RTB_Z
MY.]3;5DO`.G2Q$EXD\@UGG+HLRWSRD=M;FY"I`L-^(X`(7:EW%0':+RL/+Z_
M::<O&3862#\()"&9)/09BJOHIUTBAB(!S!?X/T;&OVLA,2D8C1VI%S5U(I,)
MI]#%)4O*,H4)D`9.&XO71'+%NV*!\9"@82@7$>^SQ!Q4YXRI&E%Q$G400LHS
M93<:^?0A9-)!X`9YU$EEE$C`6X$E3IWYHX>&T/4A'G*,M':N.5#.'JQWIU9-
ME`G>!IYQ5SRIS*D`3XC8A`;2;R36IR07?ZF*4UH0H(Q;B/0B'=12Y(4(I4II
M-P>5!,%@5O,='.+;3R91O"J2.9)!=W6-4--6^KQR$*6&D7"<Z1LS=S4@W1E'
M>C+H(N7BI2&*W,FFQS@Y%`PUQ#TDK3[2F]4#35*R91CZ(<.G,NRJHS6&T)9\
ME(MR,D6@%$^,B(G':@%V6^G*<J=W'2;RC?\`])4''MY2.CCQ*;MI(TE,RA"*
M,#/'^;.U.N8@&SHXBW7Y<H]\5BYZ*CYF-7N%5C)M$'K4YB_$/F7!%"9Q,<I3
M?&*.4+1\.YHBE5XN)445C8]6!C3M62BPE%P=NB+?`0SH2`*O_-$-O?9ZF[IJ
M`=)R;1E'R1'$/'+$D&$:.*/9/2J-S`[:,#944SXB)#\4`M)2<A2U/OY"98I1
MLL[>Q#!VM)QZ*C99)F_,X04TMLFJR1,!3WA>B3_`6YD_J&F(&;>QV1B[E8ID
M^<-B@?.`1)5RBH8J8*;;#\7%E\-GSMG'L6CN463<2;ILT00<2*Z214$EWRR1
M"J.UDT"`0IE!,(%"[P639HMTY%)C/SM001I-JS<K4XM4#IPZ>-H9?1P5:(%.
M[5*4P#G!(<2F,-F[BHJ7IV?79E,1HO-0D;*+-2&,!S$;J/FRYT2F.%X@6[+9
MG4+FE*>7G(\J!&,LI$,3OVI6A0*TS+D4,X31"A<E_P`O]VZT^+5PZ=N*EJ65
MJB2<NQ2%4SV4%(N83S2:92-&35NFBD7P@0F41&_8-GM72>KQ.KX3-Z.YEEH4
MTY&"0PJMRBHKB=MCH'-C2`UPIB.(MU]]G+:2F=5,@V>R?+;QN^+3KM%W,Y@S
M7E9RDNDH1>3T8PIY\P"K@'#?=8]-MZCU9(4ZJ54JL"BI!)0JA5E,\L4\60@,
M3E55'$:\FV-E&R92ZP:%AWI)B$F7#UJI3CDLPI3S=XUBF-0M':1TIR+9HOCY
MI%4;DC`42"6ZS*7;ZTX)^_8IU)F$UYJ!;135W5DBUD9EY&Q3!LV1C#*:$DW3
M32$$4FQ<.&\1,)U3U+JT.HI,-ZA44,M!F.>?:`4K2<.<2XC3#4I`!-R/EB7!
M<:R%14JWI&4*E)RLBA,PK:)<F0FI9/,SCTCUHF91"5DD1PNCW@LL7(I>&Q:3
M&L9I21F<6X#09"JD8P4FKA40',MEY$OQEQ2`12+NF$+P&ZTH$C4>K-]RV@U:
MS`NEH1<TJW8"(L$9`ZA1.\38F&]$#B.:'XMUF5/+2FJ=Q!1RIG#"'<EIYS&L
MW!\YG'#=FNFH@DX4SQL1P#$;$-XY;>K!*CU9%IK"8OJ\52""#PG<B].7DD":
M!A.\,*H^3RJ#B\.6R"_]0Z%BI%.;83SIVF>G'Z4X[C8YU$L4ZD9/DU$IQ!FR
M=B"&='$@)2X#``7"RDF6M*#?/6,7+QB`.YR"3CV_+\X:?EW3".9-FR,<JZ<X
M$@*D())MT2D`M^,Q\?K+JTQ<N>LV+/0>+UDS68]8+\-_+F9VFE[OAR8KK-GC
M2I=6C5VS<2;MFZ;K0:+EJZF\'++ELNF4JB#B6S9=).40,O<&.^W^8U(=.,OK
M;?YC4ATXR^MM_F-2'3C+ZVW^8U(=.,OK;,'E0U%JTFW46?''N91Q#/EV8XBJ
M>05<8SID%0H&$OQ1$`&TIRG4&J^1Y;%@::TXT`[Y7-%AAC!E,^FIIXQQ<B&=
MQ9K]VZSN&AZCU9140_,N9]%1JD$QC7AG2!&KDSMBU(DV<&<-DBIGQE'$0H%'
M(%GL$6N*%@]*AHVGTI*'=4^@^:0<3(-Y-C!)"9$Z8T^5PV`IF(AHYDC'+A#%
M9O4Y]:E-NY1"5<S0-&K^FH:G`D%8,E/-UT8"-:IH-U&$<"F;,4^(RRZBB@G-
M@P29GU2ZM'AIKD[ED72T&X&6Y'/G8GE,52GT_DM3;-\[BS(Y276,]4J75HH\
M-*-9LSLZT&9R::8MS-&4N9<Q15&49M3BFDO?G4TQP@(!;_,:D.G&7UMO\QJ0
MZ<9?6VY=Y6C.1-&TSEC3VO)6B77Z5RAG=$T:[]_'A^#53*,CYIY&TY-OVBEP
M&S;EG&.7"!\(Y#854P&ZQZC8QI7!XVDT9^0,(X7U0S2[(CE5W*R&!1==U(R+
MB]18^,2`?(%P`%BU97TM&U"G*MXA!E3=-T\,<_2J:;=-D6$+%OG4VN@^9',Z
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M1[A')L:I5F$"/2T!3%'$IINY`BS5@]JA:H7DM+(H*$$J<HH2(;HE5#;%3)<'
MA^""4P`8I@$IBF"\IBCD$!`<@@(6_I5H:?\`3^[^H_JK_P#Q?6/DC->8W9GD
MS2_YO1=PTG;8;MK\&KCW0J7_`,,]M&P4NW!U&2](Q\<_;B8Q,ZU=Q***I043
M$JB9\)LABB!BCE#+8].S%=5O,L&Z4:G`&=N8))U3BL.];/XR09.64"U4>RS9
M5H4ND.](,*5Y?WAO9STC-5#,U(A5C6L7LX\5B4G,M),(=6"8-'C=E$MF2,2Q
MCUA*DBW31,4?W_%:D7$1.5#'NZ/FZIEV+L%(ARLY2K-SI-0Q;LCB).U%FZN`
MA#E3*NB0-J?'M[1E/,):?CU8*JW5:0<\BM&*2\9./'K]ZJ8F>BS1SAB89%5(
M4%4#E.D-QKQ#%:!J`DC./IN$D:PF5W[UPP$T[,5PWCVLW(2Z2$<BGC(A&(E;
MD;:.FD4MUQK:H?L#6G]!1NQUO?8&JSZ"LN\:SFM9,XEG%4KZY/:5<1P.6Z\N
MQHJH7\%)QSPSMXZ(O-";0C$S)4P-I&0F3)"4\XC*8BJ[G:NJR#57.VE#P-/Q
M%'1$9*S;UPQ&3%[)2;;E,J*:0.$2*J9=J4!M3WJ]5%`5;)SFM&'H+EI&GIUI
M'L6TK#OY`QI""]8RN22;=9L6[`[S1D3>`#6'5:JVIIG7GK3#1`U$@TD7=,\@
MR]/R%1%F4(5:11D.42(1BB&B'>804VV=$OA&`B$Z6C:HIZ`KZ?J9\\CI)_#O
MQHJ?]7VS&*9IRS-RS3EUS`=10ZRHHEOPE'QPY"RL'1$6E35#S<Z\F::J&I$W
M,I6".DDB"/8ITQCZ=BFR08!?/5-LHJ6X,AN\?_0/^A^#5Q[H5+_X9[:FO=^&
M_P#'-[:LJ2IF6:0GKF[JQ)_(N8E*8.B2!I\9AN"+95PU)Y4Z0D-MO`:_Q6D*
M6;'@"ZRT-8[N@64D5L=.#>M8R.3J)Y4/)SITMHN&%\FJB9<X$7.`@:X;@U-3
M<?,I4XQKF/J)>IY).EW55KQSNGH/2'B+6'9"+I1)"9;JHJ"&YI[<^$I#6U0U
M*$]#0B^L.HX.EGD>E3S63;HIRW+SAK4C9R:4.-[Z-CFZNB7W)BJ(8\EUFB+U
MT5\]2:H)NWI6Y6A7CHB12KNBM2G5*V*X5`39L#&`E]UXVU0_8&M/Z"C=CK>^
MP-5GT%9=XCC2#F36&.U@SFL`NW;E!PM4,H67DH%R71[E(19X@C>7=!!$NWLI
M(1\W,P]1)5G.5Q#U"ST([N(D:B00:RD>5LX:JLWL,\;MRD516(85"_O64S]:
M5`,^KK!::RC5"@RI])8M0,8M:);`E&J13B,!D1NKB$ADSWG#]&2Q)9&IJA+7
M!:C:52>NG7)3N6<2#2-5ATVBS'D]"'"%+&KF2*U303*4MV7],?R)5=0PDN2(
MJ.#G9Y!.+<OZECZM?\JSNGE=,CH(.5)$15041`NC^*^X+CLF$O+PU.24)2E/
M5-3K0K!9"HHVBCE&!*L^=-57[%<B09I=1$Y3+)_H->;O'_T#_H?@U3(RKHS*
M,6I^92D7I$CKG:,%(YR5XZ(BD4ZBQD&XF,!2@(FNN"T.QFZ0D5G,=',62,Q$
MOZ;4B:A9H-4TVDTQ1>3<?*,2OVY"J&0<MD5$3&PY;K4$6=8ZQH*IDW51#1AZ
M6-!JR+A8T0'+Q0T1W,%`I(D!OQ@3:B:Z^T2I*Q$@Y*DM634K?6,I`@P<U/IL
M*>KY*>&M)1`I:S`2-"B#DZ:NC&+FTLWA$*)7I9C5BUU8ZRW-$,FYX`*?/)N8
M<Z581T48KQ)CZO1[(%%&HE5!N)Q-FE%/BAJR*R8UL>ET]9B+W5ZH)X7"XJ@7
M%1:'#I`9X58($%#O,R90I$LV4MRV'!?[)U!OBEOQ+:`>U+&J4L2/INJV-#1#
M]9@^EJA<+K4\K5,VJK!N96+C&$>T2:(HHJN0<*BJ<^$``0V,^]IJ-4JDDA3=
M*,:YB&"S!C+4\X06J%6EIM)6<<Q47)L)!HJ[1612<BX2%(A\(@(!;V3J#?%+
M?B6WLG4&^*6_$MO9.H-\4M^);>R=0;XI;\2V]DZ@WQ2WXEM[)U!OBEOQ+;V3
MJ#?%+?B6WLG4&^*6_$MO9.H-\4M^);>R=0;XI;\2V]DZ@WQ2WXEM[)U!OBEO
MQ+;V3J#?%+?B6WLG4&^*6_$MO9.H-\4M^);>R=0;XI;\2V]DZ@WQ2WXEM[)U
M!OBEOQ+;V3J#?%+?B6QS!2%1*"4IC`F1S20'4$`O`A!4JA-/$;P!B,`?KMZV
M:`C_`%1PX/Z5:5_W#^F_)N@Z5ZS7>IGK/I'\]F=.S.9\CG,>6W__V@`(`0$#
M`3\AZ4'W)77(P-+1UPM,5"80<:@;'KYGE16=DT*LM!7O2)'4>4<0Q)Y/AE#L
MU;#/J6TUHO+F%7JDMS>1($Q0/WD<,5*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E
M2I4J5*E2I4J5\!4J5*E2I4K_`#9OB/\`P1^74)J_\/@MRR"4,2K;FT)!HS`B
MG(^_OQ]=8#F0957;)=?A\Y*`;F5@;LJJS@?IH/'CQ_N]#)!?B;*68'L@0(")
M[D399N!;`6,U:=8$"`3+7)N6)=L7C7U@!V!BSQ,?F7#+-^&.3(M"T3($_69:
M10AQ72Q6`4==-'TE"2.]YJ3-2SV!KIR0]X:N,_)T@*5_[=(/?U>(EL1,LND$
MCY=3<T[E@`GXKJW!WP(,-RECI_K!E'?4@!PO$)I@V3Z9ER8OM9,KDA9E0J/0
M_C=VP5E9\>'X\/N_L4ESI@X<F>[^Q27&F!@P)\>'X\(]#^-W3!6$["I4K@9X
M%Y-E/VJV9\!XM?MUAF=K-7]25*E2I4J5*E2I4J5*E2I4J5*E2I4K_%F^8_\`
M)'X1)&;-"]+M58LR[)6]!?2"RXQ2<L/9LWAH`;$\ON_`<1ACG:!J.?[EQ9KE
M1[-F\-0)'@,ZR\TXE)EA&=>CW9Q1FO+#V;-X:7(=3:!"B=B%B[*!)DXB(JC'
M6UWE#!5H,@N@K*6U4+EB^O=P0UD'1$MQ4)BS)!3/5P;("AMK6K2N[RZ$0M@>
M>,\B/9LWAH&3/`HE2H#6K1ON0//)-Y1Z:)<\LAT+!)^&2Z^AD2@7)"SH8>B%
M4^OGZ<UQ&HD.N@TX`(M%ZE"7YV+:;%!H,E4#AL]*TS%BF%RV`A8L>^@X%.V;
M2&XJ4VN?@[D4[9M(;FY12Y^'J.'#A*O8('*^INL3%T[ZH"WT<_Y%5E*VO'U`
MX<.'#APX<.'#APX<.'#APX<.'#AWY8_B?^0M=8]TVHA?D-TJF6@C4*4FF`$+
MSG70C:6B[==6>43(?7#V;-X;[@,(5G4VB](=>^RINW,$8E"C/.4,P%5)00:;
M[8;^YU[[_D/!GVG:>"%\XBO)%/VP2S*:/?+NUP70%6P'+#V;-X:METOH9I7K
M-%(T$9JF\_::#Q/95Y8>S9O#5LO%&/(.S_3K8K(+'D3BHF(V(/+1[-F\-6RT
M%!NUC79(LG6A/4/)M>Z&OCFEJ!HA-9-C,[>%!J#.KA&(LT0VR";8?\J1%VN.
M2A7O`>IBO5M1IY?K@CX<!3[%!0CHF+XK;.P2^'5CM;9@.:!Z*5V\5CW$B"\>
MGWQWKMXO'J)$-X]'OCL4J5/J\V")L<#JEU9._%C7T1NI&WW,+FNJE2I23*AA
M1?LMKY@[VNR*WI#1L-P&?,I4J5*E2I4J5*E2I^S%>MO\GV9@[FI&$)MAPLN,
M[L>:@9+;UP0M3U,Q=5W-O$]7$HB`<A^;(:_>B402PTD""!HJC[>S+@,6I9N8
MRJ;`]95Y$OD![-F\-6RP`YE-G0K^985A(``O<`6'#T/+#V;-X:MEBVZ5]GL`
M@B4,8=C9Y]"=Z>+<L/9LWAJV6G+6^:@\'S%^*_.;C*@B"$.C/*CV;-X:MEC"
MU#4&$0EJX/4(-KA<K^J]P-)1$F8!F2&2`Z(P$P;!$2$?U\9-(#/852PS>4@7
MB9PE8C5:BI$#:!Z#8D[IK1#\!9G"KH%ULP+NV\O*^89.AI5LC>*,PQAV=ZK9
M&\49DC+M[#1HU[K`PZ2TBC`7P/E!W8_.@=-4UV&C1I97*B&FD79>.]['DKE)
M.*(`6^8T:-&C1HT:-&C1HU]N<<^Y976>KH/"SR>O+>\A,0!QZ-BIN(D\>J8W
M]?!#N&^>@]",:GYY2*A*19_U0T!I"'`VZ>#>.V6HY59#8OR$3'<8!1C]5V;-
MX:MECV;-X:MECV;-X:MECV;-X:MEE,;2$N!X3N7BD*6*L+S*ELXT.3S\H.B-
MI?<!#O14%X(F6@I;7)#V;-X:MEL`J24D)*<<)FG4!POR>-2"Z6SWX^&>/"SJ
MY\@L0J:)/5K=.HS:X-!;`IUJY5K-!JX;AP5%`S*X*G$".941AR])0%D0L'<>
MH89].\"R(T#N/$<,>G9*E2L!%7H5J`N7H#Z>!H28W"]FMG;V2I4H%T7:M%<C
MT/3O-<Z(B3J;^PRL^:5*E2I4J5*E2I4J5[.?.O\`[W]%Y_1L>S9O#5LL>S9O
M#5LL>S9O#5LMU-45"D-46]#LI4J2O:.AX)!MZ\49[*5*DT8D`\\TY$?/A?:A
M;>*?X*+[<L/9LWAJV6:4?9RX'_`Q4S(,+(*&S>F6@[[3<"N"I8H=&6"3$/!T
MRZHM7I\/>8$QFT!=B_QW].G3ITZ'O,"8Q:(FQ7XZ?"+*S6EG^GK+Y^?X"4`*
M0C!@'>N7+ERY<N!Z7;XSA%8%;6*GS.)I%J>$KTG8+/A<O!\=5J74G0[W3ITZ
M=.@C^PO,1%&"+H3XPP_'0DM+'&N@SXM_5Y;M*):[6O`Z=.G3ITZ4AX<2I<;'
MH@&.GS[3[Q]][\/PI9`/1"LI5GI7$^^(P,ML7??\!VA#+N06LG5FL";M0H%`
MVBF5W=;U;$/(?!WNI<D(&.ZP"W$/L3,XPKNQ,)V`144Z0`2&UF@.\K1+J:/T
M6@`AAG/@2P+`.'J\*6^JI9!&,`>]PSGP):%`#+"M$NIL_1:$3L_TH<U\&]+K
MQ%9=0%%?B0FHQ=LM=,,B*2^IM1ZZ)F?')`2U0VS\C@))C!`7#P0'"]?Z[N3!
MW6OHMB5LM>AJ9>HR$'5E>XZ@O;D6PF*OI.I):`O"`E#HE?,A"12:M]@:AE>T
M,@NV`*D."WR`+,CLMCA4!GE40W:;^;-N'(^]4O\`1,P$Y3@?;SWF1>@*CV]A
M8&Y^!._R:KA9@J.J5"YM>T%E!$B;,MBNRF(]X<?WS01Q#S6&@FD81#$FEZ"K
M`W>,H4;;I(U`_,IPXF`570%'8DN<>%Z[`MRIF"ECJ6M8)-OV:Q:U<!*H&G8J
MOOUF<T,`P@,_X!;374R5&(8%K9@3'5',)=P?YG1<$8J.`QHEW\)7Q5_0T88E
MF30UH]+J(Y#4+05Y2P+Z8?*(>AK15SK:09`.8JFQ%['4J&(VDUJ(CH?ZCY"#
M#7P^3-`)Z:@`HPA4-!6MJ:]H;]07=MZ0.*`(XP=%!:E$*PPU=4L;:98"!W#8
M#C@)IQ*-D-!!?)>&P50:0;!/7/>K2(*P6Z7JRQ^M!F.WSF+*J*I@K/5T8U$R
M.9E\4!"?$TS(JLJA*ID+*'QN6?C:*W!J,DB*B&52=1(0V_FQNVK7*>O04L!$
MU+5T,[ZBQ)%<U^9Z:$\W)]2^;+6H3EISZ`@G@IYQ0A.??#76NO"C#XWJ!G.2
M"M3?<=J?W)HCX;3;)#3LHVIVFC1HUDH4W&!2##9A8,]X)C+RTZV\XDZ'B^W@
M;==X`1<EL;7SQ0C4,?B,5EZ\@4@`UD=M[::F?*YCT[->-4EMI6IU-&OM`Q?W
M#TOK],$M2RJ6*5P8:@PHN.>2DV$(;CI*1_9=1$8&"P56CNZP-+T),7LW+27)
M#2I@R9'L=_6+0XIN<X4+F9VY.JT88N/7K/:R#(P/;G$)%=C%07(7^D`?\`BC
MRNI'"3_##^Q?U-^G279#C@>;DM,$0`R[5RJG9)M1K!8R%<;(#95!%B+HEC`]
M5%^\"J4">4%6%DERFBA5'P6DPN/L@\WW[138R)Y;"%O8(;U_O7+,447AG.=3
MY+5=2^JQ&(7//3U#+=,%&V7TN>\[7\(06,2'(L`:@>>;Z]KN.2CK*[/%2J![
M"\)S^Y[;KHW")QT`3B)RMC60!!=Z1<]M%9NTC5"Z)\[)`*Z+\WWZ)3`K<VM[
MK"V5L2#>A!*'P@4F.V*)FU>YF=7-GKF4:S5D?&'3`94=32.W[:0%^+9=:2+8
MI$:9D^M;!.5241:JJ"M1_4Y>SWN=C06@*!;J0E[,O<JP4:*'4AVC]<]75N@=
M+"JM'J09Y>7,#N,MO?1+G(M.C_I1W@M['D6G1_TH[PV_1ERY<N7+ERY<N7+E
MRY<N7+EVS]/!!,<V&Y!F?U82$W__`/_:``@!`@,!/R']F!RYRYRYRYRYRYRY
MRYRYRYRYRYRYRYRYRYRYRYRYRYRYRYRYRYRYRYR%2I4J5*E?N<__V@`(`0,#
M`3\A_:K4J5*E2O\`YD;ERY<N7^ZC_]H`#`,!``(1`Q$``!```0`222222222
M22222222222220`2000``````````````````````````"``````````````
M`````````````0``````````````````````````"``````3;;;0````````
M`````2000`````!6VVT```````````````0`1?\`_P"I)K;;;I))))))))))
M)````!`DDDD`%;;;0````````````!```($DDD@`K;;:`````````````(``
M!`DDDD`%;;;0````````````!))(($DDD@`K;;:````````````!()!`+DDD
MM;?;;;;;;;;;;;;;;;:0```($DDD@`K;;:`!```````````(``!`DDDD`%;;
M;0`(``!```````````($DDD@`K;;:`!```(``````!```!`DDDD`%;;;0`(`
M`!```````(`((!<DDEK;[;;;;:```!;;;;;;3!)!!`DDDD`%;;;0`(``!```
M````!```($DDD@`K;;:`!```(```````(``!`DDDD`%;;;0`(``!```````!
M```($DDD@`K;;:`!```(```````!`(`+DDDM;?;;;;;0```+;;;;;:0(``($
MDDD@`K;;:`!```(``````````!`DDDD`%;;;0`(``!```````````($DDD@`
MK;;:`!```(``````````!`DDDD`%;;;0`(``!````````!((($DDD@`K;;:`
M!```(````````((`)DDDM)-;;;=)````))))))(````($DDD@`K;;:`!```(
M``````````!`DDDD`%;;;0`(``!```````````($DDD@`K;;:`!```(`````
M(````!`DDDD`%;;;0`(``!`!```!```!((+MMM1`)))(@`)))((!)))((```
M`````````````````````````````!())(``)((`!)))(``())``````!!()
M)`!!`)``(``!))(`()(``````````!)`((`!``````````(``````````())
M!``(```!`(``````````````!`!((`!`````````````````````)((!``(`
M````````!/_:``@!`0,!/Q#IE4)&#4;`\R$Y(Q6ED168<E>@_(AS\U2HJJI[
MHHR&)DO&)J>I^5G]=$#"?;8`P%:VL5V2*<]M<!U%,JHLX50H4*%"A0H4*%"A
M0H4*%"A0H4*%"A0H4*%"A0H4*%"A1X%"A0H4*%"C[Q]U]Y]5C+'8!J6(7)A]
M)0-UKLN1:*MK:BAXX8-X?W'0AJ!J(Y0C6:B@^Z]X=R5]P_33`H4*%'Y%O.E(
M_CJAAU\^?+D*&Q#`0!;-=BO/GR00NX,0*0V6)57U9;:(-*)L-$U/AI@I5@T*
M5-"/`1^V=E`6H1Z6\60&AS*V=I!'IUKR(+:'FKDRB3MAOR!*9Z\/J">$Y=6?
M^A=Q_0LS^C(NYD(F")R1>E>><N/8&\>N];D>KC0/N0@R`NRS5#`EH0!2H0"4
M#TZ"AZ0=^[&`"X&C`=;]_P#M>HEO\[,#UG]KU$M_G8@>G6_?>D'?NQA`N0IP
MO8H4*/?2`.D\#&82@"=YLN5SMDYM._`J!7U"A0H4*%"A0H4*%"A0H4*%"A0H
M4*%'WC[K[3ZK.685``]`V1-2\F@$@1D_`A0B(0\LHQXY.WEH6%Y%ZQ2`J(OU
M[5%;]6]Y;48\<G:P9B!X09%T0+-=OB3*<?Y,ORRC'CD[3/62-BQ[B/([TSGN
M(*87S5RO"BM$RTJ-RNVREK@@JI!&*N.)[B0+&I$*\H1=I)SI*;%L5`T%F9#5
MU'(*,>.3LH]639K:PEL,L>>-[>:B']J+(<47T72R+[R>:ETYZ4&%',J.-9);
MU]4*5WS%`+[K,'M:'>1WL\NK0P`64('!#AN@V3D@4*=?"HR13,W%0_=UF(E"
M(N#8$[P?NXS$"A`70L@]@J5*OQ091B2^=#<>!N9Y#"P)C-M4M`^I*E2I4J5*
ME2I4J5*E2I4J5*E2I4J5?>#X/_:&R*P2;3@@._YR0;,D"_$GIQDV*9F(!L2'
M55`X^M48\<G;\+SEJ\!CBET=5EBT*+U/M1P0S@5DTLY#U'$#/H=5EOX'J&U&
M6A"A\P1=>GS<!2Z29H2N3SU$(8-(Y51CQR=K:B^)K=P#H>7AE5/7*0PY[,**
MORJC'CD[6U!N=>(49AYCO(*D)V;G_1#QFO+*,>.3M;4#Y:HR?&+52$`11`:*
M"V]+L]@L94C(-Y!T5]%,OMO>PL^4Q&4S;DF>B*B^>BS)(3'Q2CYREAR(Q?5S
M5><,D>PCZ0+ZD0`S<1ISV%-_RCE>@J5]&/P!ELXPM+#N5]&/T%EMYPI:+JJ5
M*O;A<B-!9A"*W@3\<I",:8%!L-JG85*E3_J0?AT#;*`,CO,[AL%\BD#)LQY5
M2I4J5*E2I4J5*E7VLN-\6]W$OJVJ:&8L3=<6'Z,:3S,0YPW&M]0L128B@-0"
MA*,!M6<\9,JO%'[@JBP\S`D;OJC1J8`0S%(.7!(C`-0JY+*,>.3M;4*94$3`
M?EM^NN((UB-%L@,A.548\<G:VH'*'[6>H.ON$Q4IS0&(AP<MY,HQXY.UM0BV
MUJ*"Q90D2-"$MQ&8`AM'\M48\<G:VH-,V%+GPN#C"("JL`"-#$,:A4-8M"S>
MY"J,B'YM5/N@^(#@7'D%)1,'(@H5(0VS&SRHT.0*NBW(132.N/"=!-[JCD%D
M:@"<-6>R\#7FC?14EC<;!?FJX(;'O"QN-@OS5,0-IV*E2KYL&)G))/NE`IWF
MSACE1$-RA`X>Q4J5-8ES^)]`*RWWNY@^(O1"3D`7S*E2I4J5*E2I4J5*OO9T
M/_535GK?&E>]GDLO%&.+71FH"^,^`X`^[RY"[:1[DN&ZKW*^:E02[*=;>&7P
M6TN=-FP3-16ZX2%O*;W&&V=0`'ZKX\<G:VH48\<G:VH48\<G:VH48\<G:VH/
M%R]%0(3>ZCJ,.%L%$JTG5GNNN9FX,11<LSUNNPL&VJ7DRHQXY.UM0#5@`N]"
M!5'"L!<K"+-9JPDI6DG<_#:C`2$C%#@S"?(M5%(BG*:`4=&EH`\//,82@>B=
M.%B6P<+SAD6%+Q>D@)E\CN76H4H`T=X3+Y'<NM8H5)I[)$B1N301-RJ%9J&1
MX+B-,X(WZTIH`='9(D2+K/*LQJ"]U#7>Y^R^*:&N8$&3S2)$B1(D2)$B1(D2
M/L;\+1]7\K]&U&/')VMJ%&/')VMJ%&/')VMJ``D&B+5!5%(X[&S9LFL4F66?
MH8LSV)LV;+,)!?7^0"F$./"UES]ZBK1+9,CEE&/')VMJ)%K[D9-?]N*H@)G;
M-'^IUFRJ+ES"@=#T6[-2I?K2+4TDV'L2Q.;)RI_O91:T((.ZG3ITZ=,V3E3_
M`'LHL*5!43UAANWBP@B-%S'1/_,,Q%9*'"D\!_?OW[]^_&.C<CP]<[:@1T)R
M4,S):ZDKAOHR=64&%M5F&@5</<+%BQ8L6]6',`HQF*MZ!.+HG\LS&EA7TDG.
M``!=G-B1$^7>+%BQ8L6+>.3NIRLTMET`G^Q/+O\`H2N__P`+A65@`*S1T=X(
MLHJ$5`NM+W_Z1!U*,7O+"^JJ`>J=].+9`(D$(2PJ8($\.F4=Z?R6]QAMG5`+
M#4J25#%5]0(H]AJ$/H=_',%Y0'>S(7WEQ0`[6H0+[H2C:(D%$;.JKE(AXC%5
M)2D'O2^Z$HVJ)1`"V$R%]Y,4!.UBG9]^5Q>T>F]/$N,Q%G1BX]AO@SG^A=/?
MVPH3+MFZ/B4LX]>+-29S#[3VS3:]66(CA$PR8K8/[7`T86ZMAJ3G(@JF8Z(7
M"BJT$*?(XIN4PZSOB[*$'(;*L*=75"C7,68#UO[GMF.T)N$YH0`F5#K`,9-P
MKB'8V3=/%V[F6-K=Y[5K./+,-D?@Y3B8(JTE%BZ<F'!TI2,@I9KP>S,1`T/8
M)E7H;`!6ZVM'Z)$CJ.+K<81(]X"?VP^U*0FC$)JIT5U6&FD7F3LJ+2U.D`:!
M-QVR7?:5;;`^N=H?*PD!0$0I#Y5[0]J@J2*;EJ?+`M?#_7I`$X6IS2,7U$TX
M%G+1Z!Q+?_.5?Y9`O"N!\'()1!I:+@4A_P")'PT012EIP4"!B/E[1%=+62"A
MS!X+5_,"1GW(IZ)8L$")4Y[$"YC/:)K_`)`C9E(U"V@V].>V50P*<#I?GQE1
MT"_6<PAN-X9E15,PA)!=X_H@88FF0QP"SGF:&&I^"I*+79V#5:C2W[8([3@\
MSA"OHO,]7GLW?>6I3.801*PS3D[,I7UH'$(%(O+[Q2PQ8@;HY>B8-!AD4#J5
MT!4"=(0/8EB@X!G+-3$?-U?**PM$6VN(^Z"0S8_5U,AX=IK[TKY5H061#]O2
M<2$788=)**'XCF+S5,_;=-_YTA"+9`2'GN=S8=V2)$B1?QXB1.8H:0G4P(AL
MR5(6%JG$4ISBQ*HC#TV\V@BXFJ%@AA8<MUI!HI[J*/FDZZ5^V]<I;B!]68R%
M&JAY>DB1]Y0H?^Z#'Z9>!=[F-GA3HB,+Z['Z`]ZJM0`08)F8%'0,$ZV1O=N$
MB@1U!B)<<.U$X>ID*;[5*`@J#AD&->9==8V!`KQ*BZF8^C8B(!/:A)KJH.3#
MJO'](@\%N-:``*$2I_1&_3JW^]MHA!)`LXBZ/0ITAU6:48F^YUA1E];E'"T8
MX]E!,SA:AL%(=NS1#1/'BP_5U?!4`E&\/+/GW'0==06L]I((LH^YO@BNA3&F
M'NG`T$:R#*F#="J,7%H/!Q+'D*PK2!Z`*@59M7V;`D&\?`);;AM;+`+&D`@+
M.O&L^?JV42Z]A3!AN-T4Y'N]WF_WQ4+#/5H->KY%=`>R!%^6?/N&O[<*KVPP
ML<OLYAKN8>69=WDLSF'N@'9U.PJJ2L9D@=`1ZLB^$U(B=R!HI@)SHW;C/KJX
M51I!Q!S(;"D0AGP"*B;#7"PAT/??KX%`D%CW"O5$U*/804V[>Z_R]^P\C]SO
M$7AO0VM/JF9TCQ-V.`[F6.D>)NQP'<RS-FS9LV;-FS9LV;-FS9LV:9@YN`*P
M#9`BS0AQD!`S_]H`"`$"`P$_$/URLEDLEDLEDLF^/=>#3A+ERY<N7+E]CKP:
M<>Z\&G'NO!IQ[KP:<>Z\&G'NO!IQ[KP:<>Z\&G'NO!IQ[KP:<>Z\&G'NO!IQ
M[KP:<>Z\&G'NO!IQ[KP:<>Z\&G'NO!IQ[KP:<>Z\&G'NO!IQ[KP:<>Z\&G'N
MO!IQ[KP:<>Z\&G"5*E2I4J5*[-RDI*2DI*2D"OW-_P#_V@`(`0,#`3\0_:I1
M*2DI*2DI*.0-=[KD#7>ZY`UWNN0-=[KC\0UWNIB8F/%B8F)B8F)B8F)B8F)B
M8F)B8F)B8F)B8F)CQFN]UR!KO=<@:[W7(&N]UR!KO=<@:[W7(&N]UR!KO=<@
M:[W7'TPUWNI3*93*\-,IE/AIE,IE,IE,IE,IE,IE,IE/C-=[KD#7>ZY`UWNN
I0-=[KD#7>ZY`UWNN0-=[KD#7>ZY`UWNN0-=[KD+9:6EI:6EI;^Z?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g644794g49z75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644794g49z75.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0UV4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!1````=P````&`&<`-``Y
M`'H`-P`U`````0`````````````````````````!``````````````'<```!
M1``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"MD````!````<````$P`
M``%0``!CP```"KT`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!,`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#TC#P\,X=!-%9)K9KL;^Z/)&^PX7_<>K_,;_<J^+5DMHJN^T12*!%.
MQL`[6P[U/I^U("Z/^4&_YM:2FQ]APO\`N/5_F-_N2^PX7_<>K_,;_<J\7?\`
ME@W_`#:THN_\L&_YM:2FQ]APO^X]7^8W^Y+[#A?]QZO\QO\`<J\7?^6#?\VM
M*+O_`"P;_FUI*;'V'"_[CU?YC?[DOL.%_P!QZO\`,;_<J\7?^6#?\VM*+O\`
MRP;_`)M:2FQ]APO^X]7^8W^Y+[#A?]QZO\QO]RKQ=_Y8-_S:THN_\L&_YM:2
MFQ]APO\`N/5_F-_N2^PX7_<>K_,;_<J\7?\`E@W_`#:THN_\L&_YM:2FQ]AP
MO^X]7^8W^Y0NPL,4O(HJG:?S&^'P0HN_\L&_YM:+6YYQK@^P7%NX"P`"1MW?
MF^WV[MJ2G__0],QO^3JN_P"A;I_94_4?_H'?>S_R:AC_`/)M7;]"W4?U4,/J
MC^?N_P`T_P#I-)38]1_^@=][/_)I>H__`$#OO9_Y-`WU?Z>[_-/_`*32WU?Z
M>[_-/_I-)2?U'_Z!WWL_\FEZC_\`0.^]G_DUGY><RDMHQK;+\VT350=`&SM^
MT7N]/]#C5_Z7_"?S5'K7_HD*NKJ;*V-/5WVO:T!SWXK?<0/<_;4VK;N24ZOJ
M/_T#OO9_Y-+U'_Z!WWL_\FLT?M(<Y];OCBV#_J<A,;>J#_"TO_LW,_\`2R2G
M3]1_^@=][/\`R:7J/_T#OO9_Y-9?VGJG[E1\_7M;_P!'[`__`*I,S)ZN1[V4
MUNUXOML$3[>,''_-_E)*=7U'_P"@=][/_)I>H_\`T#OO9_Y-9I/4W#^G5U>3
M<:QT?VK+O_1:;[/E.U?UC+'E730T?]/#M?\`]-)3I^H__0.^]G_DT,2:LDEI
M;).AC]QO[JHNPL:P1;G9K_,6/K/_`++,H1\+&Q\;%RF4.L<USWN+KK++7EQ8
MW=[\ES[.WT$E/__1]&QG9OV>H!E7V?T1#M[M_P!!NR6>GL_>W>]&#^I1_-4_
M]NN_]()8_P#R=5/^A;Q_54`W'CZ-_P!]O_DDE,]_4?\`14_]NN_](*OE9^=C
MN92VBJW*N#O0H;:Z7;8WOL=Z&VG'KW,]6Y_[]=7OONHJLCEY.+CAC&LOMR;B
M6X^.'6!SW`;C])VVNIG^%OL_15?U[*U'"PJJ`^W(-MV9?!R+P+6@[=WITTMW
M;JL6C>_T*/Z]MGJ9%U]UB4RP,+.PVO>YM5^5>0[)R76.!>X<;6>B[T:*_HT4
M;OT7_"6^K;9:W]1_T5/_`&Z[_P!(*.W'_=O^^W^]+;C_`+M_WV_WI*9;^H_Z
M*G_MUW_I!+?U'_14_P#;KO\`T@H[<?\`=O\`OM_O2VX_[M_WV_WI*9;^H_Z*
MG_MUW_I!+?U'_14_]NN_](*.W'_=O^^W^]+;C_NW_?;_`'I*9;^H_P"BI_[=
M=_Z02W]1_P!%3_VZ[_T@H[<?]V_[[?[TMN/^[?\`?;_>DIEOZC_HJ?\`MUW_
M`*03,-AHR#:&M?+I#27#Z#8]SFL_ZE1VX_[M_P!]O]Z>L-%&1M#@)=&^9^BW
M]_W)*?_2],QO^3JHT_0M_P"I0LS-.&RLO>+;+GBNFBMGOL>1NV5S9^X'66/=
M^CIJ_36_HU"K)L9ALK^SN>P42UV^MH>0QNUC?4LW?I'.V?I&_P!=5\'$>'NR
M\C%KMR[:]I#',V4L)WMPZ-/YO=[[\CZ>5?\`I/YBO%Q\=*3X'3\BE[\S*NKM
MZA>`+K`TEK&C5F-C2YNS'K_S[K/TUG\B[%_^E9_F_P#F:JNIL,[,&D:B"XMX
M_/EK6?YGN3?9KI$T4@;R2!4TRSLR3>W])_PG_@:2FU%_^E9_F_\`F:47_P"E
M9_F_^I%2.&&M;ZNYI#'`D,QVR3KZONW[75?F?F?Z1+&PZ:Z6T.%N0]C6M+['
MU^H37`<ZQU)K_2/_`.U'^D24WMN1_I&_YA_\FFFW_3,TT^CW,?\`"?RE5'3\
M,.#OL9+@_P!0$N!]Q$?Z3Z'_``7\TDWIO3VAH'3:SL:YC9962&O_`)QDN/T7
M[O>DILS?_I&_YA'Y7JO3U"FYC;*\NAS7O=4T@L<"]I<QU32RYS?4W-_F_IJ1
MQ<)H@X-8$!NK:@(;]%O/YNU1JHP&`,JPJV"20QK:AJ9<70UWY_TTE,QFU$-(
MRZ"'ASF1MU#/YQS?TOT:X]Z1S&P2+VN`8VSVUN=[7?0<WTW.W;I4Q76-!B`?
M*OM_:2].L\X@\>*__))*8G)>"1N)(<&&*7G4^<_0_P"$_FT+$ROM-.:37;6:
MK;*B;:S5NVM;^EI:^?4H=_@[?ST8UT`2<1H'F*__`"29AK;1<&AM8=N+&`MX
MVAO##^<Y)3__T^_OOQ:<'&LOPK,TMH!:*J?6<`17N8/W=_M_S$6C+PL?V58=
MV.'`'V8[@#'L:#Z#'?N_G(N']K^R4;?3CTF<[OW6HOZ[_P`%_P!))2(=3H):
M#5D`NDC]7N@`';[B*_;N_P`]/^T:MCW"F\ECMA9Z+P9DMW,W-VV,]N[?6B?K
MO_!?])+]=_X+_I)*:[[\3)<T7X=CRT$UFVDF)&U[6[A[=S'(.#G8EC795?3L
MC%>ZQ];]^/LL,.]-UI#-SWU6;&V;_P#1^]7OUW_@O^DE^N_\%_TDE(1U2H\T
M9#?=M&ZEX_=[[?Y:<]4QVO+#7D;VR(&/<9@[?:YM6Q_]=KMB+^N_\%_TDOUW
M_@O^DDIKV9V'<6UW8USP=KF[\:QS1N&CC^C<UCF[]CMWZ1B)71A5735BM98U
M@<'MJ`T][0QM@'TFQ]#^6B?KO_!?])+]=_X+_I)*0_M2K='H9$1,^A9'P^BE
M^U:?=-.2-O\`P%I!]HL]I8QW[VW^NC?KO_!?])+]=_X+_I)*0/ZCA6Q5;5<6
MO(`%F/:&EV[:!^DJV_2;N0:W=-N!->&ZJP,<6NLQG5QIO/Z1];6M]W\I7?UW
M_@O^DHW?;/1LGTXVN_>\$E/_V0`X0DE-!"$``````%4````!`0````\`00!D
M`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``
M:`!O`'0`;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````!P`(``$`
M`0$`_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!
M`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@!1`'<`P$1``(1`0,1`?_=``0`//_$
M`*L``0`!!0$!`0$````````````(!08'"0H$`@,!`0$!`0$`````````````
M`````0(#$```!00``08'"P@*`@`#"0`"`P0%!@`!!P@)$1)7&)C8$Q465I?7
M&124U%75IUAX66DJ(;;6%\<YB4HQ(M(CEC>W.+@*0211,AIB-(0E-29F2"D1
M`0`"`0,$`P$!`0$!`0`````!$2%A`A(Q05&!(C)B0E)QH8(3_]H`#`,!``(1
M`Q$`/P#HIX<?#CT,R5H9J+D#(&HN`IE-YE@+&TBE<KD6-HXZ/LA?72.(E3D[
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M?^9%_AI?M6J=V_X]O__1Z_.%9^[<T@^K1B?\U&^I'1K=]I3\JLE`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%!H'_F1?X:7[5JG=O^/;__TNOSA6?NW-(/JT8G_-1OJ1T:
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MHX@7RNIEEI)B@4J&#.(%FG)6<<88TD&.6-N9'W)`L3OZE(VKR7:0)1,.^KN1
MFY@$.1*TS1"5RG3QI(3HC@*/ZDA5B]U'#`B+N)BK;(<\9E;<`XQD^5GR&SR;
M1^'-+U()&@QVV,CJ^MK!'H^\21W>SDK](8TB\7HT3,,`KV4\_P`,:7;F\VXA
M!J1%H`^U/>_LON+!V9L>^O:IZ6OU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL
M'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4]
M[^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>B
MOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ
M[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^
MXL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![
M4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J
M>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9
MFQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^
MR^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU
M![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z
M]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL
M'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4]
M[^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>B
MOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ
M[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^
MXL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![
M4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J
M>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9FQ[Z]J>BOU![4][^R^XL'9
MFQ[Z]J>BOU"8FK.SK=M+$IM)DN',[8)<\?Y$48UDF/\`8B',4%R"F>"H1!L@
M)G,+"P2Z9I@L+G'<@H!IC35)1Q@[&<I5@6`,RI,5W2<HA0:!_P"9%_AI?M6J
M=V_X]O_5ZY^&.Q,DEX9.E;)(V=J?V5=K/B,*YH>V](ZM:P),;:U)(52!<2>D
M4!*4$@,#88+\T8+"M^6UKU(Z-;OM*;!>,,:DN2UY*QY!BG=R8[1AQ=2XDP`<
ME\:LA3-=H\M7!;[*E3'9L1DI_<@Q"3^`*`7S.8$-K5E74L8C2%6B7H8\QHU[
M:V`96Y:E:4"=6@9BQ#&6THE)*<!R5L+&8*X2"Q!*M<5[V#^6]!@3='_9UMC]
M6C.W^ELJHL=827HA0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!01HP3_FENC]9>*_\`#K4ZB^$EZ(4&
M@?\`F1?X:7[5JG=O^/;_UNOSA6?NW-(/JT8G_-1OJ1T:W?:4_*K)01HW1_V=
M;8_5HSM_I;*J+'6$EZ(4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$:,$_YI;H_67BO_#K4ZB^$EZ(
M4&@?^9%_AI?M6J=V_P"/;__7Z_.%9^[<T@^K1B?\U&^I'1K=]I3\JLE!$??5
M-*U6E^T@(@]1YC7EX`S&>XJ9)&'*5)%3`5C>3C>FQ$B:Y=#3D#PX(K"+2KAJ
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M1)#%93*@;-Q^ZYYA<-=X%'U!(]0M4A(BTL9?)WDAQ1FITEP`-&-V/L<8&XPA
M*L*Q81/9,&B%!H'_`)D7^&E^U:IW;_CV_]#K\X5G[MS2#ZM&)_S4;ZD=&MWV
ME/RJR4$:-T?]G6V/U:,[?Z6RJBQUA)>B%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!&C!/^:6Z/UE
MXK_PZU.HOA)>B%!H'_F1?X:7[5JG=O\`CV__T>OSA6?NW-(/JT8G_-1OJ1T:
MW?:4_*K)01HW1_V=;8_5HSM_I;*J+'6$EZ(4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$:,$_YI;H
M_67BO_#K4ZB^$EZ(4&@?^9%_AI?M6J=V_P"/;__2Z_.%9^[<T@^K1B?\U&^I
M'1K=]I3\JLE!$??6)QR8:7[2H),T)'E&W8`S&_HDZP(A%IGEEQO)UK4X%V`,
M%[*$*H%A@O\`T6%;\MKT6.L+AZG&L'0O#?>RSX90N3J<:P="\-][+/AE"Y.I
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MF.X\4A#$AC<=0[.1\Y(TMP!@2$&K=0M4E:L8`F#,'81ZDT0Q?E_IO0G-)@T0
MH-`_\R+_``TOVK5.[?\`'M__T^OSA6?NW-(/JT8G_-1OJ1T:W?:4_*K)01HW
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MID$SQNVZQ9K63:+,C[8`FAU?8T1#QNS:A7A-+$`PTH(>:>3>_)8XJXUG'NR/
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MT$H5JM:3<1+"<*(]U3+'^T$22\P)GNF3:N9L82/!C.`F`9X9UAZ0OF"4&A+M
M?EY+C%8/]-[6H5JC9+>.UPWH)8ZTNRU*&(\@0@C0+,:37QL(0%(49H26<EJ-
M=5`B%`N:;8LD7@N2]Q\E@BO:6O&6/O\`ZBSA3=-\S]"F6/T4I<+PW*`[_P#8
M^X9B8XI)&)/FC(KB>`(DS7"\+R>[@I-N;<)B=.1*1Q>QAQ"<(CQ\@N9X(-^0
M5Q_U*7"<)4:W'SC,O%X/!_#GXCV7#30$"1&(<#ITB1Q]T#&<2>D,C<AG*L2)
M4UEB4D#N18PVUN2Y8+<H[+7AYF%L2'C"<1%0E"9`^!WM0:!6G)4)%\SD$M9S
MR+&'!,L!9&DF"SU@#1H?R"`8L(-(.%R""+F7L)>AQCON1X?>*OQUG=4!-#N$
M\&$E'"Y+.$ZQ3L--TB2P3##+B4EQ5VBB\T(T]@E6\$2*]C;\^]N;RALSX*V?
MZ43K1_\`8)GG,-5H<;X13F>"N<4Q:.[>R5U36'SE5[)DKW@?(#6H&4(5DQEC
M%H;<RUQ`N(5N>)DK8OG@=84XBC'MYNGF'9?*$L=\:.S^?%I\V3Q!*H\[9-S<
MK:(),HO-&3'4WCL;D<`;(OBM_1D!N8@:B1('%$A2DGID@;I$6;IBHB'4=58*
M#0/_`#(O\-+]JU3NW_'M_]7K\X5G[MS2#ZM&)_S4;ZD=&MWVE/RJR4$:-T?]
MG6V/U:,[?Z6RJBQUA)>B%`H%`H%`H%`H%`H%`H%`H%!`[B#;]XIX?V$U.19I
MS93D23&G1["F&VM4.TMRS.S+$E(V9J3)4K@M2LB`]62-S<?<YA2,HP``A,5'
MI4YY8BW.CIE_U_=F,H3)]VUVVV.R7K?D3+R)[G9$9P7+GUOSI&9)/GY6Z.C?
MD&<2(#J)N)LQ&VL<WEJ7!>,U58I6H)-2FE'RFYWQ&(ALFMP0<H,XKDP?B[\2
MR*MAH0FJD-LWR%0)0NY1`&JN:T/T<3\T2<)8+!$0,=N9>_/O:]@A5JG+\P^/
M9&[\-MB3HSQP-LDBY*+FIC)3"5<U0>Y[E#(&!8UK\SHBG%1<H?Y#31BN$RWA
M.3GVM>RM4Y1_E]^S>XN[`*Z6,<;"3NZ$X(3SE$KUBB9JXM7>XBQDD6<)M+C`
MI`DE@%;FJ"[7&(7]W;DYPE3Y6]O^7\MJA_V`6:Q9S7Q2,`RH2?D)+:Y5K5CI
MH0*".9<JQZIR8\/*WBZDJW(.UK"%SQ__`#BO;EY6?*7M_P`O[;#G_8X:;B3(
M-L^'K+4X[^&\9RF%35B<2AB"$`D9:*,X+&WB2%>#YX3!"N:(1@K7_JV#:S)\
M/$OFSI_V1X]8M7>.<-2=W3\A`FNY^4D=UW.!<KW:899^AM@>#%_><@%)/Y?R
M>#O;E#3*_#5]6SE_V+6JXDSCI;HC+#A"\*6YQ;)3VPMQ9(@A#9&8CDN<3G`Q
M648`0A&6YI0@C#:UN4(KW93X^9?%]TN.\Q>!6R3A%8X=6_G>!.31C:7%9KD8
M<84.Y9A86_(4J/(3A,#RB$)*,/)_5N,-[VO3/A:V_P"GW;B9\6!BN)%)N"#D
M!V<!"\.4IBVS4<$W`2#"$!9)@T.+9:0)6$TL8A?^R&_-$&URP\G.&N?!QV_Z
M?RW&*W%;;%J9-P3MZ4B`7(689%FY^FCB!2(%Q%A"TH,5(E`TU[AO81UQ`"#\
MG+;EO:U+T3C'^H?P/'/EK6(Q'-.%%Q*XP\`'886T.#'-4*Z,998B5)@G5/'5
M10S3.?;F^`$#FAM>P[\MPA7HO#]06_[$>KZ.Q9LGU/XA<,0CY"Q.\DUYBJ=J
M"JN"XP)+'HLM+5(SCN8+F<A/Y;!O>_-I:<)\P^K?]DOAOI;B(D=MAH<Y`%RW
M9Y-AI2F<_`""$12KP3>_N1-DY_+>P+W,L*_-ORAM;DO=9PED-L_[$'">7JK)
MU6PLC92K@&.ZYSPAFTU*$0;6N$NX&:`NRWGF?^.0FX?_`(WM2X.&YD5KX[O"
M==TUU:3;Z/$E6-&3S'3&F;V-3SP6"*][(GK&3>LN5>P[<@[%\P5^6UKWO:_(
MN#CN\,J-?%ZX9;NIND2;K8)*-L4([G.DJ\2)N8"X0WM98])6]'<V]QVY`6,Y
MXK<M[6O:U^2W"<=WA0\N\9#AM8@QLNR8KVOQ+D)(C=&YG)AV(IE&LBY)<E;@
MH+*\,A@K([B?+-:$@0SU"X\!"(HLJX?"W.$449+A>,^%1=^,-PQ6-L1NZW=/
M"AR5<WE.1)30]KI"Y@3G$D'@+6,C`V.3RWN`0*`V&D4)RE18["`(NP@#L&W"
M<=WA':6?]AGA11FYY:'85^F:E,)268GB>&<Q#L(Y,;8KP1"Z10B.M2H)]^41
M1I2@9`P!Y?"<EP\Z7"\-WAC'_P"HGU7D8;EX@UGWJS8><:$IO/@."&=4TK!'
M*1$(1^ZU$_+<P%.H"31IN8B-,'X.X1``+EM9:\)\P_M^,IMI*K7%B3@M[S2<
MD\9?BY;D1O>,2-BY.K/N%N4V=5N,Y.WV).2@&8<,LPXI,+FA$.X1V,I>AQC_
M`%!?>#CDSSE'CCA&0:!ICAEC+5Y9V4@ZJR!,N/N-&-:WFR3&;PK&D2%#"I"0
MF\+8RX17*+Y0EB9\%;?]%GW_`+(>0QB+)A7#DP,G/\'8@QR<<AR%<A*4'&'!
MLM4-T@RHC5+6\DH))XRDH23+F<XHN_Y;ELGPU+:J_P#8!FPA`F?$PUQQ:A5>
M#NJ0XDP)')59-X8XQ0>4B<I=B>,OU@(+A+*(%984,\JXO"WM>U^>R7L\`.$M
MQ!I6&QF4^-QM(>)3S!K$6)X4?B>Q'A#!*%9")U8,K\[_`.\<VQ1P4B?F%6N#
MP?,%S;*U3E';:`_Z_N-)0&QF:=]^(KEU0/F"6$NV>FY,TN`AF"4K0K4CS$)6
MYC)5+.:;:P%H!A&'E$,=[\ME+SGQ"Z(Q_P!<GA<,IME$AQIDW(RD1H#E:F:9
MIGQ![@=_>74G+#8.YPP0S5QIGA#1`YE[CM_5YMKWM=4)SW))Q3@L\+:&>`LT
M::8O6>YPI@E^5:J8SSG62%7)*\/><RB175"$`7*;<WGW.%_6,YPK6O2H.6[R
MDS$=%=)H%X`4*U!UBBQZ<!``+&/`^+VYQ'=.0-,4:H<D\7`O5J;$&""(XTP9
MH^>*XA7N(5[U+GRD8P16,11+9#%HXPQI%8I.39&P,[>S);$HR[DI"K)VY.F)
M\$E)OS2P\G(`/Y`\EJ(KU`H%`H(T8)_S2W1^LO%?^'6IU%\)+T0H-`_\R+_#
M2_:M4[M_Q[?_UNOSA6?NW-(/JT8G_-1OJ1T:W?:4_*K)01HW1_V=;8_5HSM_
MI;*J+'6$EZ(4"@4"@4"@4"@4"@4"@4"@ACO;O-AGA_X)=\V9?5J%IIBB[!CV
M`LYA?E1DN<J4JA2V15B`,!H$A0@)Q'+5YH;D($@!&"L89<HDTL1,S4-8G#YT
M6RYL3FHCBG<2)H-49\D@DSEK9KNZDK+136*"ICAJ8BO%'W0]28CFY9)ONM"E
M."$YI4'C<%8;O1]_%\UEJ9J..WHZ":K!0*!0*!0*!0*!0*!0*#Y$$(PB`,(1
M@&&X1!%:P@B"*W(((@WY;""*U^2]K_TT&/73$.)GM-9&]8OQV[H[&A/LD=(5
M&G!-8X%A!`=8A6V&E6-`$8K6%R<MK7O_`/&BW/ECIUU!U,?5`U;WJ]KL\*C"
M@D&*77"F-7!082$-PA)&<KC)Q@B@AO>U@WOR6M>A<^6+'7AH\.YY3@2J]%]2
M22RS@GA$U:]XK8E%QA`878(U;'%FY683<)M^4L0[EW%:PKAO<(;V4<I\HK;%
M\"KAPY\@3M$FC`\;P1(ERMJ6MV1L(MZ.)2=C.;#@7,)2MXR5D56(7-#<Q.I(
M4H#BQ^$\-:P5!99H)2QNF.Z1&,>%AP[,3,<?98WIOKTZFQQK:6Q)(YSBN&3^
M7JQM!`227=RD\P9GAV5ORH8;FJ%?A`FG&WY;WY+!M:TG*9[I81'"F&H!8FT#
MQ)C*$V3B3"(M$8%%8W8@2,1HT@B;,S4B\&)*,\=R[AY.9<8KAY.6]$MDV@4"
M@4"@4"@4"@4"@4"@4"@C1@G_`#2W1^LO%?\`AUJ=1?"2]$*#0/\`S(O\-+]J
MU3NW_'M__]?K\X5G[MS2#ZM&)_S4;ZD=&MWVE/RJR4$1]]4TK5:7[2`B#U'F
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M-T+`P(<%9F/E<^E9Y!QK3#(8TF[(D7='YTN0*_Y1`3I$X#%*DPE,2::"+$1,
MU%M:VK>EW$!WIS%CCBB;>.^#H_)4S>-SUGUCRQCR>S"`8GBBT#<X12>)H>S9
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M3;T$YM[Q=#&K\=0T^2DLFW#)RV[09[G`=G6.[DXXZCS_`!:*&IQ:BZIB;0H6
M:32>8.Z<XI#<L)XC%YH3#K"$&P`WL"PGM29]$*#0/_,B_P`-+]JU3NW_`![?
M_]#K\X5G[MS2#ZM&)_S4;ZD=&MWVE/RJR4$:-T?]G6V/U:,[?Z6RJBQUA)>B
M%`H%`H%`H%`H%`H%`H(][2[/X@T[PC,\^YOD0&"$0Y%S[$$W3FOTH?5(3`LL
M/B+8H4)?',ID"DOP25/88`VM89QPRDY1QQ98BYJ&C/3W5W+O%,SHP\2OB%PH
M<>P]&O!G:/ZBO'.4QQHBIJJSDARAD!J6$$7?1NYA*960)606*0'EEJ3"2VA.
MVI39URU,\?C#I0JL%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H(T8)_S2W1^LO%?^'6IU%\)+T0H-`_\R+_#2_:M4[M_Q[?_T>M/
MAOS:*8\X7FE4JFCXBCS`CURPFA-<5US+@&X/C0QL;(VI2""SE2YS>7EQ3I$B
M8D!AZE2<`LL`AB#:\CHUN^TI>J-B<)I%+^B4Y&8"5\5QN?EV2MHQJ[.;#CI,
MM6MITE=FWW+[N0$A<6U0GLG,+"K$<2,`2KB#>U5FGFB^R>#YD]P^-1[(+8JD
M$^;"W>(,RQ"],SD](ST\T6HK$I'IL;SDZUT;,</ZU&E.L6I6M[*M5D%F)DQI
MH"U*V=T?]G6V/U:,[?Z6RJA'6$EZ(4"@4"@4"@4"@4"@4&%]@]@\1ZMXCF&<
M,X3!OA..X2WB6NKJM%<Q2L4F7\&W,3$W%\JM[D;VKN%.B1)PC/4GCL$-OZ;V
M+$7B'/WK1@++'&7SQ&>(%N8QNT1TKQX^&N&EFI#[<(T<S3MZLL*?*V4&WF>X
M'5I>E2$*@PLRQP7P00IPBNQIRPN<ZM3/'$=734$(0!"``0@``-@A"&U@A"$-
MN0(0AMR6"$-K<EK6_HJL/J@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@C1@G_-+='ZR\5_X=:G47PDO1"@T#_S(O\-+]JU3NW_'
MM__2ZC].,*L&Q/!TU:PU)V^,.;)-]6L,HEB:7L2N1,H?<+9'G<I59"W/<<<T
MCPC.;PFMS@E6D*6IP`2L*YQA`0"G9J9K=,LC%Z"O1JA0?*\PLF8BUVI4+U7>
MTF><8/.1R)@CBN27.?*I=/%*3+<5=Y:)U1NQC?[D/5!6<XHI4K<%QOA['U+,
M:\.2*XRR]CW)+7DN2.3)CR2Q>8M42=R'IU<2WJ$07:[%T-9$DV>)DZ/!>/XK
MCG:0QJ1-BLI<LL3&D/AEYP3%!8Q;,6_L*CLWTTV73R-,N4E1_!.992U60/CZ
MQ"*>FG%<R`A/4&,+DV&.*0L*L?/2*;G)#N6US"A7"'D$8F&$O9#:'>8&9>V1
MNCW@ZE+RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9
M&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9
M&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9
M&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RECC+O#CX8V!L;2_+V7F_)L$QS!&<]\E$
MH?-S]TB43>B)N$LLLLLO8`U4O<5ZHTM.C1IRS52U4:60068:8``F"]TXAI(T
MFX;$5XHN9779[(N*\GX;X:C&M5)L$X#FV<L\3*8Y[<FVSBTDY#D4AG&393(8
MXTV"L.$I4L:]"0(T);>A,/"4O7'JO_C4[N./Z;]DG!\T$0)4R%#C?+J)$B3D
MI$:-)N%N8F2I$J8L)*=,F3D[``)(3D$@L$``VL$(;6M:UK6I3/*7H]D-H=Y@
M9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@
M9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@
M9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@
M9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@
M9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@
M9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@
M9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@
M9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@
M9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@
M9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@
M9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@
M9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RD]D-H=Y@
M9E[9&Z/>#I1RD]D-H=Y@9E[9&Z/>#I1RED+2#"N.]?7';S%V+&U\:88R[0-*
MQO12.<3O(KL6H>=2]5G1P$?*\D266RU<`Q:J&(`#UQH"`7L658!80AM4F;I.
MRB%!H'_F1?X:7[5JG=O^/;__T^OSA6?NW-(/JT8G_-1OJ1T:W?:4_*K)01HW
M1_V=;8_5HSM_I;*J+'6$EZ(4"@4"@4"@4"@4%E9(R/!<00.6Y/R;*&F%P""L
M:^22R4OBCW,V,K,VDW.5*E`PA&::.]K6`424`P]0<()10!F#"&X<TL/B>1^/
M_G5%EO)K?,L7\*3`\L-#BS&*PQ>PO^V,Z9U2M(LEDA$E,*\`P)>:),J/)-,\
M6)QC;&\SW><Z+DTZ_P#&_I'Z=/C*RM$;9FF.QYK;V-@86Q`RL;*TI"&]K:&A
MK2E(6UK;4"4!29$WMZ(@!1))80EEE@L$-K6M:U5A4Z!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"-&"?\TMT?K+Q7_AUJ=1?
M"2]$*#0/_,B_PTOVK5.[?\>W_]3K\X5G[MS2#ZM&)_S4;ZD=&MWVE/RJR4$1
M]]9.VQ72_:1:Z)I"J)7X`S&QD`C<1E<R5EK7?&\G2)#UK?$&5\7MK.4:.UU3
M@H+*0(2N4Q2<47:X[%CK"G=?C6OXRS)V5MJ?4M0J3K\:U_&69.RMM3ZEJ%2=
M?C6OXRS)V5MJ?4M0J3K\:U_&69.RMM3ZEJ%2=?C6OXRS)V5MJ?4M0J3K\:U_
M&69.RMM3ZEJ%2=?C6OXRS)V5MJ?4M0J3K\:U_&69.RMM3ZEJ%2=?C6OXRS)V
M5MJ?4M0J5'D'$8U,B;(ZR:4R[)D:C;$A4.CW()!K1LZS,C,VI"[G*W%U=7'#
MJ9`WH4I0;B,..,`6`-N6][6H5/ASL97V8OQD]DT4;G#IES%O";PW*T[N45$<
M.9XD[UN5)XR[&$^#7.&-X&^W8XP%<A':Q"DY,H:4@@FV!XU.`)LG7_C=<8_3
MH>B6Y>HD"B\?A,)0Y,BD0BC.WQ^-1J/ZC;0-3(Q,C4F+1MK4U-J/"125$A1)
M2@@++`&P0AMR6JL5*X>OQK7\99D[*VU/J6H5)U^-:_C+,G96VI]2U"I.OQK7
M\99D[*VU/J6H5)U^-:_C+,G96VI]2U"I.OQK7\99D[*VU/J6H5)U^-:_C+,G
M96VI]2U"I.OQK7\99D[*VU/J6H5)U^-:_C+,G96VI]2U"I.OQK7\99D[*VU/
MJ6H5)U^-:_C+,G96VI]2U"I.OQK7\99D[*VU/J6H5)U^-:_C+,G96VI]2U"I
M.OQK7\99D[*VU/J6H5)U^-:_C+,G96VI]2U"I.OQK7\99D[*VU/J6H5)U^-:
M_C+,G96VI]2U"I.OQK7\99D[*VU/J6H5)U^-:_C+,G96VI]2U"I.OQK7\99D
M[*VU/J6H5)U^-:_C+,G96VI]2U"I.OQK7\99D[*VU/J6H5)U^-:_C+,G96VI
M]2U"I.OQK7\99D[*VU/J6H5)U^-:_C+,G96VI]2U"I.OQK7\99D[*VU/J6H5
M)U^-:_C+,G96VI]2U"I.OQK7\99D[*VU/J6H5)U^-:_C+,G96VI]2U"I.OQK
M7\99D[*VU/J6H5)U^-:_C+,G96VI]2U"I.OQK7\99D[*VU/J6H5)U^-:_C+,
MG96VI]2U"I.OQK7\99D[*VU/J6H5)U^-:_C+,G96VI]2U"I.OQK7\99D[*VU
M/J6H5)U^-:_C+,G96VI]2U"I.OQK7\99D[*VU/J6H5)U^-:_C+,G96VI]2U"
MI.OQK7\99D[*VU/J6H5)U^-:_C+,G96VI]2U"I?CJ'D:*Y5DVX<UAAKX='W'
M9UC3I3)%#YA!76YK?J+JFA56/C<Z8HW)$8+*"!<P9R0L!P.09=Q`$$5Q.*3/
MHA0:!_YD7^&E^U:IW;_CV__5Z_.%9^[<T@^K1B?\U&^I'1K=]I3\JLE!&C='
M_9UMC]6C.W^ELJHL=827HA0*!0*!0*!04]V=FIA:G)\?')O961E;UCL\/#LL
M3-S4TM3<F,6.#DY."PPE(@;T"0D9IQQHP%E%@N(5[!M>]!S`3&99)X_N<UF'
ML8J9EC+A1X-EY)V5<JHBE;#(-JITPGD*D,0C_NWP!B>.%W$%2E3F$'>+"+E.
M;B6%<:UHD\Z_\;^D?ITK8TQI`<-P&)XMQ;$V:#8^@S,EC\4BD?2A1M3,U(PW
M\&007RB,...,$(T\\T1BA2H,&<<,9HQC%6%\T"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$:,$_YI;H_67BO_``ZU.HOA
M)>B%!H'_`)D7^&E^U:IW;_CV_];K\X5G[MS2#ZM&)_S4;ZD=&MWVE/RJR4$:
M-T?]G6V/U:,[?Z6RJBQUA)>B%`H%`H%`H/,M6HVU&K<7%6F0-Z!,>M7KUIY2
M5&B1I2AGJE:M4>,LA,F3$%B&88,00``&][WM:U!S$YLRKE7CHYTD&IFK$S><
M?<-[#SXA2[3;%,8;)%V=Y"F5>["<;XV./L.SM'S"TP1IKC+]PF?_`*FM`>0%
MK3+9U;^L7/5T:X>Q!CC`>,H9A[$D4:X5CN`LB9AC,=:$X"$R1&GL(9J@\8;6
M-7.CFK,,4K59UQJ%BLXP\X8S3!BO6.N99*H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!&C!/^:6Z/UEXK_PZU.HOA)>
MB%!H'_F1?X:7[5JG=O\`CV__U^OSA6?NW-(/JT8G_-1OJ1T:W?:4_*K)01'W
MU'*P:7[2WB":/*E]\`9C"X@DBUR0I`,`L;R>ST<B,:T#B<:\%(N==*4,`"3#
M>2QA@`_EHL=84[QYQ!^C#3;T[9M[NE#&IX\X@_1AIMZ=LV]W2AC4\><0?HPT
MV].V;>[I0QJ>/.(/T8:;>G;-O=TH8U/'G$'Z,--O3MFWNZ4,:GCSB#]&&FWI
MVS;W=*&-7R)^X@H`B&/&6F@``#<0A"SOFP(0A#;E$(0KZZVL$(;6Y;WO_10Q
MJY\\X[&[W\9*<Y1T&UF;\.PG`./'D39L]LOCO(,S>L83YO2@3G$8PBV1'7&B
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M9V6VF#,DX%LZQV<F['4A?Y3%"DX=1=4PMHD+S)HQ#W=0<:AL6(\)B`H)9UQ!
M#<8;6'<3VI,^B%!H'_F1?X:7[5JG=O\`CV__T.OSA6?NW-(/JT8G_-1OJ1T:
MW?:4_*K)01HW1_V=;8_5HSM_I;*J+'6$EZ(4"@4"@4'-AN'M/E?BE9S?>&?P
M]IBIC^)8\,16[>WS+X55%66(W/-;G3%L$=$/@[/9SV:6<E,]RJR+OYY1J4LP
M+22Y*QSKAN(X_*6\C5?5S#VF^#X;@#!T>\0P>'IC+W/5#+5/\H?EPK'/DOEK
MJ`D@3Q)GY7;PAYUP`++!8M.G+)2DD$%UF9N;E(>B%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!&C!/^:6Z/UEXK_P
MZU.HOA)>B%!H'_F1?X:7[5JG=O\`CV__T>OSA6?NW-(/JT8G_-1OJ1T:W?:4
M_*K)01HW1_V=;8_5HSM_I;*J+'6$EZ(4"@4"@YVM[=QL\[K9V=^%_P`-5]*2
M/!*>Z3<7;%K/4FQC`\44*U#:^P9A?6X10;S0\HDQ.K&C/]V74B$W)!E*2UZE
MNFC<1$1REM]TWT[PKHW@V,X)PA'RFQC9R@+9'(E)10I/D&7GIB"7F;2]Q`&P
MW![=AD!M8/+8A&F`4E3`*3DE%AK,S,S<I440H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!&C!/\`FENC]9>*_P##
MK4ZB^$EZ(4&@?^9%_AI?M6J=V_X]O__2Z_.%9^[<T@^K1B?\U&^I'1K=]I3\
MJLE!$??6,-LJTOVD1.BF0I24&`,QOA`XW+I7#59BUHQO)U:0A:X1!Z8U[DSF
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M8M\ZME^VCN+Z]J%G5.Q;YU;+]M'<7U[4+.J=BWSJV7[:.XOKVH6^3-4<5%`&
M:;+=E"RRP",,,,W3W#``L`+7$,8QBSO8(0!#;EO>_P"2UJ%O.3JYB!0FNM3S
M;8P]&$)@A*R=V=OS4U@E<OA17/!GD15@E<V_.OR_U>3\M$M:^I\9C,*F&W<:
MB[\[OK=?8>./Z(^29,E65Y&)O<-7M<V2ZAQE4YE$OEAI-Y!&7),04K6"L39(
M(LH(2P!#94P7:9-`H-`_\R+_``TOVK5.[?\`'M__T^OSA6?NW-(/JT8G_-1O
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M$E`N(8Q7L$(;7O>]K6H+8,GT+##'/(A,G9G&#M#2]OB^4,RXE\9RVN-A6B?5
M1*IF$N"LLUW;3P&@)\(8$PD0.;S[7#5J;KNEQ5]E(9LH1F58W/RE"R7Z8QSQ
M/('=K1L\?=$<DD/DZ:Y)E+:R1^1IV)P.=%ZYJ,(1EG!(`J&(`@#\$,)EU9J2
M\7#Z8YA(Y-CD^8-V/G]ADZAKD*IEQY/%3='7LUR;3W-,QMK\M;#Y(WL8)`-&
M29X4`E?N8A2$0@B$$0*5FK.W1'C.KIMNY:_-Z;&,!;$>=9"]$$O!$4FL?NTP
M=A1O*MP"L1/TQ5Q8#PN<6I"D2'``1<(1JU%[<@2P"%J./+,X2>58C+-1A689
M7B2/>XW%IQ3EQP9XR?(3G9C;YJU1]Y"%&.5HB&MMD@F]Q(,&$\M*(#B*U@B`
M*X^6U[5G$3YA<UJN"4,&0'7'XF&,Y"1Q3(-V]G(MD$<+1/R`+BE.1">G"T*6
MNQ"6Y3N04>$HBZV]D@C@BYYMB^:-B^F#-=<OIZC\[7X^*CS3D(MAGUFMC3'9
M$)B#6X$F.B$UO&]NA4.<%AK826_%IU``I[GF!264\H!BN6&]V+Z8,UUR_-]C
M,Y<\=DQAJR6KCD[LV1](?DU#%(XO5&.+<H;37UU)B3P2NC9`I&2E4%7($`PM
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MYES"T(`\S\E@VO\`EI>;I*Q5OX=CP!^.#,<&33(?,,:!-`IP3*E"7(]N4SPE
MG,N6)2"%!3N&_P"2QX2[7YOY.3DI>;HK%6_1%C].CQT''(Y;/UJ>S&>Q"F*V
M7.0\BF%J`FANYBF9-R'0+X78W^[5@N$T%PAO;^BEYNBL4^4V.&PC'1N-3I!-
MW%K/:5[.?(7.7O*R='$.!J@TY29,AJ+/EW(OW3<)2FQMCBPA#8(K<VUZ7FRL
M4_J7&L<2XZ48NN?(ED95,CJP'GN4H?W*2C0/%E=E0[RM:O.D/N\OW:/P*CW1
MX8CD!S!!Y@>1>;*Q2DEP3',+Q6;C%V7')L?*F=YBBF\IF#I9<K;)*%R\8H#9
M8X.I+Y[I/(<#P%&@5A4D@M;P0PW`&]ES=]RL4LZ,..M4(B[9@E@GF/T#,XIU
M[`T0A7E,ATD#F7,W)PNH;T1[S*%\M<5#RYNYX"+!/&;SS+%DW#8(`A7<WW6J
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M43SF!R2V2)F3)(PZP@A$U*6!%B^)`5.25XD3F:D6IU").E;U04GN,P8!*C;.
M^=U1,'_YQLBXF77O40H-`_\`,B_PTOVK5.[?\>W_U.OSA6?NW-(/JT8G_-1O
MJ1T:W?:4_*K)01'WUED<A^E^TJ^3.Z1F1N.`,QL")0L$():EY>L;R=$U-Y=P
M`'>ZA<J'8`+?T7%?\M[46.L*=[0W1_Z4>&_\8(/[5"I/:&Z/_2CPW_C!!_:H
M5+4]Q+.-A"(2RLNNFA<]@^4-ELO@`T6R4E>FTW&FO;`ZJ[-!TTELA67\2$RD
MBYMS4:92*Z9N*M9>NM<KW*E7RVHV]YZ,A<-Y!PT^'YBQ6W(]L,/9$S[D@94B
MS_G=]F*=?*,B3%48:X."=,Y.0S71+$&YT5GB1IC!W-.,&-4J$8K.-,N@FY[8
M;'_:&Z/_`$H\-_XP0?VJK-2>T-T?^E'AO_&"#^U0J3VANC_TH\-_XP0?VJ%2
M>T-T?^E'AO\`Q@@_M4*D]H;H_P#2CPW_`(P0?VJ%2>T-T?\`I1X;_P`8(/[5
M"I/:&Z/_`$H\-_XP0?VJ%2>T-T?^E'AO_&"#^U0J3VANC_TH\-_XP0?VJ%2>
MT-T?^E'AO_&"#^U0J3VANC_TH\-_XP0?VJ%2>T-T?^E'AO\`Q@@_M4*D]H;H
M_P#2CPW_`(P0?VJ%2>T-T?\`I1X;_P`8(/[5"I/:&Z/_`$H\-_XP0?VJ%2>T
M-T?^E'AO_&"#^U0J3VANC_TH\-_XP0?VJ%2>T-T?^E'AO_&"#^U0J3VANC_T
MH\-_XP0?VJ%2_([B)Z,IRC#U&U&%R""@",-..FC:444`-N40S#!C"```V_IO
M>]K6H5+T)>(1I(N,))0[/8@6G*1!`F)1RQ&J.4#'?D`!.4G\(8<,=_R6L&U[
MWO\`T4[UW*J+[*9(.(SI3'6QW7JMAL>*E;.C6*C8^E>DQ4D5C1E#-]PH6ER$
MWFF+E=@<A`!W+L;S@WL+FBM>]K-3U3K%QT6DW<3W39_@!TQ8\UX_3/AC6\+&
MJ!3*7,T/D2MQ;3%J=&T.(SCW)$RC>#T@?`G&#&4$DX!@^0-[\D[U94S%T_-H
MXD&LK[C@;DMSYK]`<GKF)W$DC3MDM%-(VPR2P%I3$!W>6$MD.>F@1P$YRJR4
M*<WP0QE@%8=K#IB^N"MU=,OAJWSUA6XV.89=NA@5'D5P8GMN53.#NR-"VM+J
MX67DM3RPLK^L=^4YD)/(&$"HPTLX\F]Q!L`7,LN+QT*W5JMTGB!</./P15BZ
M?;_8CD2Y6S/3.^R&59:B4=FZY')+KQC-$HC]HYXI4)4+E8E$<E)(-)***%8=
MS`W,NO-KQFGO@.\7#'10$W&$-VHP%)H.D0NK:YL:S*:7(`%*&5JG5:[I)`K?
M75^7.*9\4+U?/+5FF%C+$(L(;%!L`*[F[R<9B*K#^^T\X7N+&A+&V_;36N)L
M[,>8V)8M%9*R%D,QIABE6>G!&HPG-&UE>Z+F",O[G++L:/\`K7YX[<J_,G&>
MT+HAG%&X?.0&Q4\13;#$R]N1NBQF.4*W=8R7$O06*NILG)?6]L4+$G(>&Y:D
MD`TQUK\I9@K6OR+.,^$5W[CW\.]H\)XOD6<I3S%HTH?$.M^8T_AB`^&YKB7Y
M3Q2.<B(SP0>0(^8H_O`\I5N0?-EKQEKQXGO'\>\10G5B;Z'/F.9&3EE/F-1D
M^,9>A#X=-H7:(+L>(822[1A/)H\NBJAZN[O!M@*?#75$%%#!S+6OSDRUMV];
M7WI)_P!@R^3\5XG)V!PF\CR.^28YDR)DN)27#D!Q(UM:_(KHV)I*UQR<Y<MD
M`UOBD($G,<"P)#C%*Y(?8GD`87>EI.V,U+8EL7Q7\38T+AGZ@08DV8/?E+X5
M*[%;,XMPXF@J9O3(#FA4J/G05!\@\H#U!Y0`(23!)A)^<=S0C#>EI&UA_"?%
M\?9UD&*M&9L9ZM8$QHM5OMI;-B-\8;EV3LB-'&WM4Q7;H-',2QU(Y&O4H)0)
M3!>-[>Y4QQIMP#N"UJ6<=5X;$<2%]32U$BU-S?PY7N&&1`L]S?=B<WY-BSRC
MG`G-V*&C;V?&L"F)3HP%-04)W.-/1&B-$<"PK6Y@K"(\OTUTXAK\.3.1NVVT
M?#830T46Y&A!KI,,M+9,5-;N2`7/<G?)8D#4?%BV?W2'FE(2U8U-RA<H06&"
MXF/"R,S;CSZ2S^9J,'\3W0?%^+5AS1:#-$MQ&]9%G[0G+8F>SX)ZD0<M1F.K
M#E,F+7"3A`UB"6@,*"*]S0B%0B([PS5KCNECB#,C\1LQQ)-9,^/KDH:U+"MA
M./6S"B6*E%)#@/#6>47D:>6E12I8,L9"D0&XPH)8K"+%X2UBQ,>(1@EV43Y8
M_P`Q6E\?5!$HP^R9T=8O$8;A+5-L##(^I<CUC3%RI.Y1!YE3X!E2#+366'JP
M'J@%\XZPA#%3V?\`RF!B7;74_'V+U>/IIQ&FK,S^K&_<[*LTE&-V:>)D[R6(
MI*2BM!HG&8PG&P6%SD9GB\0[#Y+F7,Y.2A,3?1"4J#:*FD-I#UQJ]Y7^S<H&
M>8:;OJ?&3W.PS1#\`Y&X_B4.$8G"6*Q=@E>"O8(;7Y>?RCN]F?\`,)KO&QO#
MNDF`S-=)3N&SR>%JH:C@[I)7K/4@/RH]-J("<%G-VRD0ZIIHKDRH28(SW+W6
M%6<.XKB'_6O0J;ND*[Z[<!A4%JN^Y2:)8>T""8F42S=G:!]"8?R`L:>>W+,W
M"9A"4^##X0`4P21\G)<')^2F%O<FMFC/7"JV)Q\VXJSAE?7?)N.VAT9WMNB<
MJE9*YK3NS`C5M[0OYME99QRA$B7G%AN8,7*$P7.Y;WHD1,=&'80@X$V-Y4Q3
MB#QS0R-S"+NC<^QF2((GCSQQ''YG7IG1G?V%:>U'',[\SN:,I0D6IKEJDIQ8
M1E&!%;EI@^21.0-J.&!EDQC.RID[5/)9L9&N,C9N0$T)F1D>,<Q(1.1C&.1M
MKD)I&X":TUS[D7+N;=,5SN7P8.2I4O5%]M>&9"%HW*%Y9U<B#B8#P9B^+VAS
M`M,+YI@/!C5-+>D/&#F&BMR7%R<@KV_\WH5*Z7_?#0F4,3U&G[9?##BQR)I<
M6)Y;S)FE++7-+LC.0.*,PQ.<2>6!4C4#!<0!A':PN6U[7Y+T*E$CAI:E</Z$
MY4V;SKJ'C^#$@CV6PXAA,\ADJELA0)(,X:]:U364Q5$8[R1U0*23,@.RY4:8
M868H+.,$`)@2PA!:+,SB);EJK)0:!_YD7^&E^U:IW;_CV__5Z_.%9^[<T@^K
M1B?\U&^I'1K=]I3\JLE!&C='_9UMC]6C.W^ELJHL=827HC37Q-^)&_8(=8SI
MOI^UE97X@V>Q)&#'4-;"T+HAQ&WO@+B_61D`*P5VI`:C:@G+6](ON%,`DH3B
MOYK<3<*J2UMB\ST95X9W#?C^BD'DLIF\G-S%MIFQ7>3[#9X>S%#F[R!^<%%W
M17%XVZNP/'0(<W.AHC1F'W"J=UO*L4A+_P#72I$0;MU_\;/ZK)0*!0*!0*!0
M*!0*#R+EZ%K2'+W-:D;D*8(1*%JY22D2$!$,)81'*5`RR2@B,'8-KBO;EO>U
MOZ;T&'A[+:XER9HA9FP&$RYC('1(QL,3'E6"!DSV]KUOBU"SM#")^LZ.3HM<
M?_7*3DE#.,/_`*@0W%^2BU/A8FR.[&KFHAL03;&9=9L9K9_XT\BFU<T2A\=9
M1=D-;27<+*U15B?7%<-O->$H30@*O<-U`/R?UK4(B9Z-`6GO_8+S)L1LWA_&
M$_U[QCCC!^5)EDJ.`S!>52=.)$VX[A[Y*USI=,^`3)DEK$H"`F75!*!_7."'
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MT^@;IFZ*.AARE"9DT9D,E<R9W5Y0R`@YP`WE*W:PT@3"07'R%\MES=]TBND]
M$9X+IIOO$TT=83>)3'FV",;^B5'0+&^AV"H1'U<0`N`K=X4GL_RC(2AM3O8#
M%)9JT`AJ0W/Y]N481",9ZWE?CVVIE[&8.E6>(S'8U%MA\TZY":).G?7:2X,6
MPULE4C:RD2U&=&E;C,XA,T*1N.$KL?8927GV4$EW%SP6$`0B:[,"XDT'4XMR
M'',BNF[_`!`,P*HV_.#^")9;V`:'3'CV8X-"]INU2.%0_'D)9GAA1^,AJDZ,
M8+%%*P%&6M_<E!`+TADG9#2?"&UKS$W?,)V6%`(>2-.WLL%SEE[%<>7%FJKJ
MC1O;1C6919.Z+16&,H*HS_VRB#!`+-!:]")F%#U\X>FHVK4V<,CX1QF\QJ<.
MC>[-;A)'[+>:,D."I"^*&]6ZD&"R=D.8D_\`N*FLDRXK`L,(PB$&]KF&7$)F
M95_)6ANE^9L@N&5<O:O81RAD1V&T"=);D''T>F#JX`86]"TM"568_HEY1[>B
M;FTDD*80+I[@#?G`OSQ\X7,8B65L3:^8$P&G>TF"L(8APLDDQR%3(TN)L:PS
M'*>0*&P"DIM/>R(>RLQ;J<WEK3@D"/L8(H)P[`O:PA<I+F>LKO38]@*-R5/*
M2#Q!*\+78;^L=4T:92')6^F#*,&]*EQ2(*H]V&80`5U(QW.O<`;\[EM:A:[Z
M!08TR)A;#N7_`!/^MG$V-,H>3WC#Q!^L2"1:;>(_&WN'QKXG\I6IS\6>,_%B
M;W1X'F>&]SE<_E\&'D"Y8?"X=CR.-T/@$3C,&B3/[K\4Q:'L+7&8XU^,%RIT
M7^+F1E2HFQ%[M<UIR@[P10?"'G#,%RC&*]PN:@4"@4"@4"@4"@4"@4"@4"@4
M$:,$_P":6Z/UEXK_`,.M3J+X27HA0:!_YD7^&E^U:IW;_CV__];K\X5G[MS2
M#ZM&)_S4;ZD=&MWVE/RJR4$:-T?]G6V/U:,[?Z6RJBQUA"KB<\2-7J0@AV`]
M>(H'-F]6?C;,.$<.M(`.IS%9PN>E!D><MI!Y1R:-MQQ)HDA)PTY:\U,<(9I2
M-*M4$25VQ>9Z/WX9'#=#J,SR;.N?7TK,6]N>C5<BSWFET/L\'-RAZ66<C<>P
M58<F3^+HPV#`2%8:0639R5)PBL$M&0A2I4&Z;Q'1MEJLE`H,/9,V'P!A52C1
M9DSEA[$JQQ3%+6])DS)D*@:E>C/7>+"%:,B4O;4:J3'.7_K@,!801'_W=K\[
M\E"E@8UW5U,S).)'C;%>P>+9_-XC#UL_DT?BTI0.ZEEA;<XH&IPDJX]*,:(I
MJ1+G5*`TSPM[`LJ)'?D`:`0FBUB^S`T_XHNM$-E3M#(RQ;"9P?&2S7=>=@'7
M3+64HN&[LVW=4UDT_9HT7C]:$A+;D4F$N@RDIP3"CA`,3J0$IN)J8R1%Q=Q3
M->N>V+5L?&9Y+VO"N?,8,$(/3$IEN6(E%6FT]":UJ'-6?CXN(3F;&/I31X"R
M958ZR4P"LP)00C%S^;:F)J4Q5Q*,Z[;7B#RE<[?JAX:I9\3)=GQO9YKFC9QF
MQ&N6(6U04!O=S\7JL4O$W*\:IQ"'8@7@PA%:P0'F\M[VDQ4K%3%VEM@J7;'S
M;#+F_9IQO#,29G.5RXAEA[4\+YG%T!!'A;0U4Z.(CV-8[!47N7=:$H2&X[6%
M8%R>6PK6J[IZ0CC6&>+Y/F?QC/-W\&X)<PC`$$9QYJ!'9JI5``4H%<9TBE^:
MI0VM8CAG%!%<"1=R"*%<(;!M;PLF,XG"Q,=]N?\`J7D<Q+GZ9:QG8ASKG1X8
M\P+V5(Q.6>]?SF>*S40V\;6HM*VX;G!$L69I(]J$9P%I:-B3H@)U`@)BR1<T
MP%FNW1(OO$(;0WA-I'%F4$[%;G;T9O=U*Q2(:<.U^:X9#`MXVD#4G)!%&*7$
MD%K;6$8:<:6:66>,5K"+YMS+&R:O'18F8\)G3+4;&F<L9(<7[9I&[:AF:YV7
MD-LODN,L"!*WR!(UKV9K.2,L62M#45XL;GA>4#^[OSBUIH!6N&]K634]DBX[
MY8]UMX:NEFJZ9,/&&!,:FR9!(0R9LR')\>X\=LD-+D40W%I0M,T31)M>6Y(@
M4-UE*8LDP%DZDXT9?-Y_):SGM!G_`%,I3XSQ1",1,BM@@S>Y(T"]T.>UQCS)
M9+*W!4Z*&]J:U"H;I*G=Y<"@FHF1,'P!1A:<-RN4)8;W%>Z9F>J1$1T0HQ?P
ML-3<1Y(C618E'WKFPM^E$BA\#<PPY7C^,+Y6WR-K7!9V<J&IG-.2F0RI865<
M2X9HPFWL>,ZPS.?>4U$45F=US<MBR9*F1$%I4:<A(F)#S24Z8HL@@H/+>_-+
M)*"`L`>6][\EK6_+>LJ_>@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@C1@G_-+='ZR\5_X=:G47PDO1"@T#_S(O\`#2_:M4[M_P`>W__7
MZ9M:Y%E:(\%/62383DD.BV26/6/`J]@<9Y8\N-K"BA1*SS'5#D2T2$,?72QD
M$H;$;F:WKD[:L5E*3B;EE"$&=FI^TVI4FVEVH5VD;C"2,@-@56C&,LLH87/8
MA!5$IA>0Y#G5;%<D/*A?#HF!K?Y)%,3)A.B8DL)K0I`44N"B*3*;@H5'_KT8
M"S_NW)L^8CBL\;7:\)736S(M)/C")(DE.!5#'OP>BS1(7<N,HAH98M?<18J+
M,LE,(1DV>2BK)R;O/A+B:R\/'S?MDV70A:CU?3Y*6S*6Y0CT*F+=BR/.\FD#
MIBV2P[("*9-B]K96EX6"CSA:Z8I6/P98`6$'E,#>]K"2;:O+4AP@M:^*`K=\
MB;Q&X[U[=<^Y.GB^$37)._+CLJSYV;(@V)HH>[%0"%,,#3,S8S/#>=9.0M,7
M7N<%&6C*"E1IQEGHU:W3'2'0MD%)Q-Y3C=''X<7J7C/)Q$B:'!;DEBRAD)^8
MG"/()#=6YQ\K'$SUCDGBT;]&+61"5>.E!J57?W47R@_]:M35XZ.<=,]44#M6
M.+$_RU#)IGMY<]"WN;"ZDQ#'^<H?C:,*1LQ``J6YR+0<.1Y=W!G>U(;C5$#5
MVN(!@@<_EL4,J=[K"Q55/5F+)FLNS^:(+CR$Y096=W%CU\?'\$CBO$&S?C1Y
MF"MY.6C+23P$`TO86R4L[0G5A)3(E!%TMBBK!,+&$9H1IFYNB,15L>0CATH8
M)/TF6&[3;7QTRBA2O:)'/7_?C9IP>4:610Y;CYW*;4)>K*6.,]U<+<3F\0T:
M%.9X(P0^=X:]S+N]T=JN:9K%K`[GE,X770#0B3*H^A6MC$]33.LRG$F9VUQ>
M5<B5M[;*Y?I"]R5$A,?EYRRQ1:L)8%)@C`VL._+29F9N>J1$1%1T9@BC!L'!
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M;<KI])<?`UTP*2X1B(0B9*GI1M)DPN-.".=O6061`UM+E;3@9ZM\9S\=*37$
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M+N74,+0GV7-N<>PV0S5PUTP*]HHXWC<5+5&MI,F.3\N+`867<AK0GZ<(BE*F
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MP]/+['FO*L;6O4<C;W+G5O)\8W.`PQF/0>6R)6AN)"$MX4,45R=&G-6E1B/5
MIV^1M:@982G!&,X5*D7W*UA"@E3F=F.+)44(EZN#RLU<%U0"9'Y!$ET_5F+"
M%C:0H\G"8$V*7WQT$`F:[*F-76572EC-L*E69EM3KU`&S(KU+<IQQJ:L12EH
MA>4%P;.+BG@,E>VEJD")OE8VM`N\2@*8'Q(O5J#^8F0(3PJ%)A)/*.PJ?"0-
M$*!0*!0*!0*!0*!0*!08#>]I->XXAE3D]99B*%O@T]=,83!8-8::GC<Y88$E
MRE(6)W-3IS@H[QO'"P#XYJ!<B1N:PF*%)I191H@%J58D&P.'(I-XYCJ1SIM9
MYA+9<;`H^V+4CL6G7S(J)%3D,<N\V;Q,:1U618[W2E+/4E75W`841X0XHTL`
MJ5.-V8P6#'Q64R,BM+I`E#G-69(_L"1XD8%SICJ1/40F:)N;F%M<G9P.9)9'
MU+6*Q"<RQSEX),3<P]0G`:*GH\C%M3KK)AQT+#E^%NA4L@*')T<6IG*XFMWA
M+FPJI4A=DKL(H+9=0IBR$]SLA$<%?9N),4W(L0`1EA4O?']E,&RI^Q5&H]D5
MF=7?.,`#E#$A28AT]QSR#C94,D+>&%V,;P-!YQD<<B7`*(1X%XD(KJ+$^!`,
M814LXT0H%`H%`H%`H%`H%`H+)F&1X+`%4.0S*4-,=79!EB""PE&XJ/!JI-+7
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M41'3E,@5J<6R$[W-'Y@D1,R9<L6(7Y1_=HBB@#4JS/ZI10[_`)*)4K^QYD*%
M98@\6R3CF1-\M@TU9D<@B\C:Q&W1.S2O+\(G4E!/+(4D#_I"84<66<28$19@
M`C"(-@O*@4"@4"@4"@4"@4"@4$=EVVFN+<AC+HJRU&+-,PR@Y87C[NGNX+&=
M7DUGEI,!=(JI=4:%0W-2A%.U)+(8H5FD([.Z@E'X7W0<46,M3X5\_8K"R6?-
M>,%4^:TLV?$DX6,[2I2NR=,Z%XT/.(GI"%\.;P1]4XQ8:4\2M(!5=466F/,\
M'<!!H@"IZK>D&VNND8QG'<R/&4V,&,9=$%L_C$P0)'MZ;'Z%-IC(!QD[6%E:
MW!6K9D!$A2*CCP%7`4@$-6+D2DGG%BI>USVGUV9O+03KE^%(",>PQRR%,5RE
MTL6V,T*96>(2!\D0G6Y?BU:WL3)D%@5+[IC3A(B7QO$>$NRU-X05*YT&<<4N
M>26W$".8H1Y'>8*?DIGC!J1T2J':%)%+&E7O+6M5("6MP$UFR=MNL2DGC6(R
MW!,8<466>4(1&E[^9%_AI?M6J=V_X]O_T>OSA6?NW-(/JT8G_-1OJ1T:W?:4
M]S['")."F,**4"*,L0:>2-026=<%[%&'$%GIAGE`'R7$`)A=Q6MR6$'EY;5E
MJ4B'"T,A<4U]:6[.QXY-@G".%<2VDZ.`*68<E<M<E>6W_$$M;D@,@.5HE[CE
MV6#E3PC,$[A<DR0*<!B:PQ#M*:Y=<,W6X>N*D.;6K+L<N3%D+2".%)H0R@D%
MF8Y2T6PVE>I,Z$.,H<6)9*9/&==(;'3CDC:VE"84RTI:!R5')E:2I<U3%>3^
M&_*,WEY-4Y2S9!3Y%DF29ENMDT$P0]1)TOCW-6N\YUH=XJ]^.LZS4IYDD3QW
M(F@EC=2+-S>F$Q>$/:5*EP7*38M],,BS31-UF16X3`=EQ"@A6X<QB\ADJ%)"
MI>CFD#;(?KWC_"+`1#9ZS9F9CQ2MM>L9M<B+=5B%0F$8$U(:@-".R@-2^F.C
M86F)]S)R$_A3C_`$E$^'4C\*H.\$`(/"GF\@?"'&<WE$+DMRBO>]$?M0*!0*
M!0*!0*!0*!0*#5AE+AEILJFYZ,=\Q!0?KRS'G+(1XD6/#KG1F&;`:9L^FTVA
M"<1F0/`NC\DC[`E?&]\&6220M"(@QM.*'SK2FN73"0[AJBJ?'7#RAUGH4;3B
M'*RC.[87'FV6MLP5Y0>7Z>+I,2IEXLC&M#KCMVBLY,CEFIS8EZTMH"<'W?<1
MX/<]2UD8ST[R5B3%4AA<+SG'$D_`3L;?&V2EF)G50WPE=M!L;*<^S]6YP5+E
MEO4R8YG\8-+:TC`^M]R36P:LP([*!)@B[FZ6'!N&ZVPV8Q:9I\@1EL.BT/9F
M]OBT'Q@ZQ&$-LRC^N\VUB9%T>9%N5)0O;<;M.,IB$!$=5K7%?[K0E'F/)HQ"
MO4I>3).&=+73&B339'(<K$R0.E>)X_B>!K(M$Y/`EDT9B,)VQ!,$V0T2C*TQ
MBSTQRA>VL\A3)"VPE4UN3*E"%8>7S^=4F>NJ>5$*!0*!0*!0*!0*!0*"/&?L
M%+,W+\"K4DO31.V$\_0_.1I2B,FR.\H\DV&6L5HN687)(]9B]WERL9EUMPK?
M!7)M;W.*PKWL6.[%4)U1F$!?<H2%GRC&5KE-<_9;V0B0G;&SR-NAL^R'CEBQ
M:Q(GI`V90;%\T8(U%@O7N@!"]C.7*7`@8!IO<O\`>BV`2^%XT,;VP2&&9FD;
M,N8!V<$@7)L>G]0@=8SEO87-^*TT9>W:<JW5DC,%G>P2HHQ&N$\G+V=L(2>'
M)$(9U2EY,CS71=\F\]/>UN2,>-T&B@M8OU'1UMPL_P!IOC%#J[F;&6;(M&'?
M("S-RMHF$.DDB@JTET3)(ZPKE)3FGN:M-NTH+`J6^\4:,R#"3W%GR`Y?9##H
MOJ=`-724\LQK(7<I8&,Y%=)Y*9R:I8\P15T2&R8J0N"1"W)U!7B4P9!UE2H"
M>Z<T6E?@##C3K[AR!X98'EY?F+'[2:R,JY^6K5ZXEI\8K5K<SD*'%:Y.`6:.
MHU8&]N*/4JCB&]*04,XT0+F").<LPT"@4"@4"@4"@4"@4"@UU(M*<E,D-20)
MES3C19&5^XV5]LYNVS37]_DZ>0CGV='?/\0A[00@S[&B6)VQ7/'4MP;WE6%V
M3*G-J;U!S7X(D](J+>G9D]HU7=29]A+(;OD),)VP8";N#`&/L4J9CI7(LOQ&
M1H,S#R0(S)*Z,RZ.33(KTEE2=*4RMJQN<&E*6%88#GW$+88BNAT]@NJ49UKC
M.:X0K<HUKSCG6KRVFN&)'(H\[X\CRU[_`%FIC8`P9QA+TRFYBCRU"UN`T,H+
M4)"6\LXD[P]B!)HMYNEL2?ACHY&W;`D!RXB9EV;L([/8E;QM.,S4;)"'/;7%
MVMV/<H2@,>39#((?6EM7ZXI7%B90'-Y+<6Z&I3%"GP!"BPOHE;'M<71)FN`9
MGDT^)<5V+,6O>(X<SQ1CE$23KXK*6K&ADB(GI3ADB71R3C'-8(>ZHAI&EI/3
M%'HDQQJH3?=2KJ6U7?S(O\-+]JU3NU_'M__2Z_.%9^[<T@^K1B?\U&^I'1K=
M]I3\JLE`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!H'_F1?X:7[5JG=O^/;__T^OSA6?N
MW-(/JT8G_-1OJ1T:W?:4_*K)06`\Y6QC'9_$,5/^08:S9,R`WOCK!H`Z21I0
MS"7ML:*+42!='(ZI5ENKPF9R#+#4#(*'8L%A"O\`D"*]@O\`H*"\RJ,1U2S(
MI!(V%B62-Q+9X\D>7AO;%+\[G7`$EK9B%J@@UT<31&!L$@BQAHKBMR!_+0$T
MJC"R0.,322-A52IH2)U[M&DSPWGR!K0J[%"2+7%F*4"<4214$X%RS#2P@'88
M>2]^6U!7J!06PGF\,5OZB*))=&%4I2&F$*XTG?VHY_2G$I"'`XE0S%JQ.)!I
M2!44>((B[7"28$=_ZHK7N%ST'A0NC8Z65W;'%"XV0+E+6NNA5IU=D3FB%8"Q
MN5W3F&>YER08K6-)'S3"[WY!6M0>Z@MYAET4E0G4$7D\>D@V)Q.9WL+"]-KP
M)F=T][V4-;J%O4J+M[B1>U[#(.YAH?\`R&U!<-!1'^2QR)MI[S*9`R1IH3!Y
MREU?W5`S-J<-Q`!81ZYQ/3)2@W&8&W*(5ORWM;_S0>11-(<D51E"JED93+IJ
M`TR&HU#\UDJI:6G3IE9YD93F*@G/P"4JPDT=TMC;!+-`*_)80;W#PF9(QV2L
M>&XZ>PLIPCI2PZ0(#)2Q@6,1+>0)4O->$HEUCVPI"F#<PX1X06*!:XA<EORT
M'G<<IXQ:&]([.V1H&UM2]F32-"YN,OCZ)O6QY8J1H4C\D6J7$I,I9E2UP3DE
MJ@"$0,T\L`17$,-KA5FZ:PUX<QLC3+8RZ/)2)"Y&-#<_-2YS+;G-(!P;5XT"
M94:J`B<$!@3R#;@YAI(K##>X;VO07-081S=LI@#6MJ8WS/\`F+'N'F>2N"AJ
MC[ED*3MD91O+DD365JD+<>YGD`5*2$M[&"`&][V!^6BQ$ST?OA/8K!.R+`[2
MG`>6X%E^.,3Q>/O+WC^2-TF;6Q[LB2N-VI:K;3CRB%UD"TD[P8KV%X,P-_Z+
MVH3$QU9A4J4Z-.>K5GDI4B4DU2J5*30$)TR<@`C3SSSS1!+)))+#<0A"O8(0
MVO>]^2B+=;)O"WNS%=FET7=K2A(N7QF[8_M2^TB0M@@`<EK%=*K-\;I&\9@;
M'F)_"`*N*UAWMRVH*JL>F9N0'NK@[-B!K3'73*7)8O2I4"=19;9MN0>L/-`G
M*.LXW]S\T0K"\/\`U.3G?DH+6_6GC'QDRLWZQX'XXDB8M;'6KROCWC)_1FC/
M+*5LJ'QC[J=$QAB4T(3"`F`O<L5K7_JWY`O<9Y)9A)1AQ0#5`AA(+&8`)AXB
MP7,,"2`5[",$`L-Q7L&U^0-N6_Y*"B&2R+$R`F)FR6/E2E22%2GC1CRW`D!Z
M<9*Q2`\EF$ILXFDB3MR@RPPEW#<!!@N7D`*]@_DCET4AR5,NETGCT51+%8$"
M19(WIM8TJI<86:<6B3*'-2E)/5C))&*Q8;W'<(!7M;DM>@K:92G6)R%:0\E4
MD5$E*4JI,:`].I3G@":0>0>4(19Q)Q8K""(-[A$&]KVOR4'[4"@\*QT;&XQO
M)<'%"@.=UUFMJ*6*TZ4QS<Q)5:X+<W@/,`):NNA0'G6)+L(RY1)@^3F@%>P>
MZ@MYKET4>W9Y8663QYW?8X:61(65K>FU>[,)QW+<HEY;DBDU8UFFV#?FA/`7
M<7)^2@]CH^LC'=ML]/#4T7>75*Q,]G1P2-]W5[7!.&B9VVRLXKW<ZK`)S+E)
MRN<<98`KA#?DOR!5:!0*#\4ZA.J*L<E/)4DW&:78U.:`XJXR31D'`L86(0+C
M*.+$`5N7E"(-[7_+:]!^U!:)60(&>6J-(FT1.*0R0N&K32I(S&%HY>:,HHJ*
M*A@6W"GDAAAX`A0CO95<0PVL#EO:@NCW2GYYY?AR?")@`,4@\*#GIRS+#$68
M>'G<XH`PEBO:XN2U[!OR?T7H+`49@Q(D2-R]5E+'29`[N![2TK5$VC)*1T=4
MP4HU+:W*3',)*UP3@7D7&24(1@+'`O>UN>'E"_;JTH2"E(E*>R8\28)"BYQ=
MB#A+32B482C;B\&8)6<<`!5K7OX00PV#RWO:@H[O+(M'UC<W/TEC[(X/`[%M
M"%W>6YM6.A@EB%N"6W)EBDDY<.[@YIB+6*"*_AE!0/\`YC`6N'@EN0H#`2T)
MTZG$0A13F,\MM-ELE98X6X&)0E"4EH1O"U&%6-.$\%S+%W%<%AAY>3EM05Q,
M],RQ9=N2.S8J<+-B)ZN@3+TIZRS,Y&JB&YVNE*-$?9L7GH3@$'\WP1HR1V"*
M]P"Y`J=!27M_8HRW'/$D>FF/M"<9!2AU>W%&TMQ!BH\M*E+.7+SDZ8H:E2<`
MLNPA6N,P5@VY;WM:@JU!2W=\9(^G)6/SPULB12N0M:=4[N"1M3J'-S4@1MK<
M2>L.)*-7."LT)1!(;W,-,%8(;7%>UJ"J4"@MYKET4>W9Y8663QYW?8X:61(6
M5K>FU>[,)QW+<HEY;DBDU8UFFV#?FA/`7<7)^2@]CD^LC,<UIW=X:FH]\<0,
M[(2Y."1"<\.YI"A46UM9:HXH;@XF)4II@2";#-N66,5@\@;WL%5H%!H'_F1?
MX:7[5JG=O^/;_]3K\X5G[MS2#ZM&)_S4;ZD=&MWVE*W-6.G'+F)<AXR:,B3G
M$KI.8F\1MOR7C1U\23V$+'-*,A/(8L[V"(QO=F\P5A@-+N6<&W+X,THSFF@K
M,8:5O8L;"?;/<2[TTS?]/:E:M\H_S#7[E;_KL;7R[<G%.22=]\I3V!M[>W.4
MBV+R3,96Z;/XX=H>I.5LK)"%BA\6GKQJ%1Q9C0O*=$0&D8E`S";B))LM4O.*
MZ-@7L6-A/MGN)=Z:9O\`I[2M4Y1_F&4<P<-S**_3>(ZQ$Y\SSLEDIAS!)\WP
MS8_-4T:7N;8LR5&<9SQ5A5X`[21]O(KQZ-Y4$R@"G2"<U-B%2WG>"3#YA9(G
M-K-;\";RPC,.U^4&7&TF43#8AFX?H7.8XXR+AV,-[A((*ZY;.V%3$BDLQ)F8
M8-C5)D-&D0)_"-3T[LC:6C1N5AVN(P7&%P!C7%">L4R5%*DN8D&72]`(>@QJ
MO@L_UP:HR9N"1KQDZ,Y,:LN7/EP#;R!RSXOCSZPN[#R,H"TQ`#E:9&%R1*63
MX^K7RZXPXC[3,<!H87/Y8Y1<V.:[KLER.<RK'[JIB<E=)[.W/<!'+VIK5LZ2
M6`_5^O8$,+*;$[DF0KTIO@1IBO"JCF3&5$UYPGN#AC#6GN#$6%L<+I9AXW8%
MQRIFV?K6"1%M^3G*%Y82P_-N.'=IR("2.[CFZ530],\6=&(US3('M6<N**&$
M`%`F8F9FT=\B0'C)JL1X@=,?K,MF98;\89E<L@1I=-=?HLA0Y@(ANLB3%D<5
MK!YPEZ"=1-?DF.Y!=P.'NY$`:9U&C4)$+=[@0TROQRE!CW'&[<:S5[C=8UD6
M-8%DFQVT4T5G8NE&OZ&4)#7K.F%9[A.:S^S])5=G_$\JQ@TS*/O2`@I?)B[.
MYIHT0%Q;4M2DQ6K->F4@VS@3-#L4[4PN7RR6RE\R,>5F$V50-PLEC4)B>,PQ
M9TGL+:)S*%\3?)\X+W<+@4QJ7F--[^E'[G/1HG9J1$U)KLUVKM:.(U!T6S`,
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M:P:X`UPAKH;BW`^P<4RW.'IVA3A(R\Q*,2R>$QB<8>E`,JM7NX>PC_+W0UP4
M/386>G2+QF.?N13_`%+#%S-KCB&C\QQ(XYHP\+'7Z\M&IIAK(K;A?7]W?(RA
MDN)G;.4I@:S)F"%S\]2EO;4N)X^NC!3S'5:!6J7,A9R\E,)0:F;['B[KRLB$
MXMVSQ#@'JYRF-N+QEC'6YVM2'7'94U_ASB_;"81B^7L;+Y%+I:@02N0RV,2?
M'^KC!)(W(@.B1,0M8$=@IQ*!JS`7&)F^U)A9QT#=<UY1E&34V^/$(PP3)O$O
M,QK@[.<-AV+HWXFCK3'Q>2\<=<329>W>.!M5UZWPBX_PSBJ/-#S`CL6"I>D-
M+G%)X'VS6<8#BQJP#M%LUL\\,4O>7"0,.XN?X@]1J+MJEE`F2N\-*;,;1(PA
M\6*K7)/$(PZUT]N3FV_IJ3#6W=$=85CA><$;9'"&(\@Q_/FUVU&LDC=LCC>&
M:)Z?;`P]EA#^R7C+"BM(I.0YXREAILJNO2G)KC"<6'W(03;F<MKBNB#=NB>D
M-R&#M$W?`F0V[)QN[W$#SW9B;GPD.+\XYP@\SQY(#')H5MY5W%@28QA@U#BA
M&HL<A&-R3E$JP%C,O<`;VJLW?:$6-5]1-BM+Y>0MQ9'#9!@9TU4FC['-?7-\
MBISS@[;V4O6"A3.%Q1U53-MC(,.9+6QU=(!HTKL8B:7!$X61B(`K3$J(LS$_
M]6W%=6-KF.,;!ZVS5NRT+'KGLM&-E=>-FL29&QR=,<?RF7'J\JY!_P#V=.IC
M=:^MT*SVVF.!K.YMET#TWR18`BXS2""KEN,3"QY1JCN9+'0U9E'"<;R4_2/A
MH;C:L2)^ABO#\'A;IE_+6PL<E.*WV0PMQR06.-*)##8X3()(:R%N*!J>3E!:
M"YW-(!<7':>[+N0<$;U1UHTHFL-;7/*61M&QX#A,E;CI[&VIRV?C[YC=OQSM
MI,F]SDV06J/GDOC<\EK6ORONA=TKS%C#TY9@'&US27&=6#\RX;R9'&7*NL<@
M&HC>;]N>)8W[.8+V-<7-,EC$7QY&\HXDR0AN?.%RA<!MRGC+&D8.@C+$_P`B
MMW!8L3:6>VV6FIBQYT;'YIB3*"'B#Q39(4/5Y.Q"1J4_X59&IH<XJ%[Q1E%5
ME`,SD$I)9YG)HRB&U98B`6]G4K6ZZE:0:QIRU`"T1QIQ=9[5W1-S=C7B1-C]
ME./ZTM`X=BINP[D>+X+BL<E^/H\VQ!A2:3(8[@Z`QU`NDZ!&T9,B^Y1`U0G8
M\%FP,8*"6:ONFN4D#%BN_5'_`"05Q,,+X<V)R;.)-F!ABT$P-N5)29*]Y0Q$
M\VCPV72["TMQ!)@)8_+G)\&]I=JF2<!2!2$&B(3B*3C)+:3B@"97XS3*#O'>
M*>^XRD;KB=_?UC6]2;+$CPIX]G>.5$]2IWW7C%)&#Y%,'X4C.8GC&!.>KS!R
M/:C5+@=[B7(/#(AH22TR5D^-KN=,0\0F1950CF#:NE<0CNY#M-(E,02Z#LYT
M>PK),0;A1Y0>ABRZ<O)\;O!IA/(8VLKNQ')I&OC%TPE+:C<B7X2UE/C_`.+A
MU#Q?OACZ2ZIPK)`,A1G$F/\`5+75IG13A+(#DTM3F^)0[+$6V"C$^?UN;7"2
M!12M^>8L\,2YH:Y*F*+94R9,-F*&Z$J1-9\L;S;73=EJVUW*R=B:(3:,Q#/F
MX?#<?4LPB.1\6,+K)M=,28W8H!LXHLG7SM.[-I*)M3*R2D:M,2XKKW+,1D&"
MM801<5'_`!:#)B+B93Q/IX#8Z"RR7N6.E^ALUE7BC(N'"&B,SC%V7\H#V;?\
M@I4$_0I9A+W.#7ASHA4H`.R4PM(K*0C(6'J4Q[*_'-+]20?B@':SQE\DIF77
MW9EFRG$I#,<?QF<X8@$6EL4:60V.9HBS#,[9G?4I4;R>A)&Z0]680S*(_)A)
M1C;6]L]UE"93%Z-MS_C51+)/!)G;(&688&)EHSSH,P2EL21B1W`>4L$BG:$3
M<^F/A@>;[G.$0O"$8.=:Q@N6P[ZO%4Q,9NU#V&QK.,FX]6M.-LARG'4Y07/7
MQESC\K.B+:N=1)#T:5)+UZ.-R=R51L@:GW08G2D%G'&$@#8TKEN,*)B)S&"8
MN,3E@#6S6_.$$P3*L'Y<R?XO+/?RW>&3S#,P>03AC1+G<F0OS79UE<*2$HBU
M3RF,'<=B58U!+FK`*Y?(6*^MVZ)F)B&8VS$3$RFM%F(48CC)'AOC])1LK:D;
MA2"4K27*1O-TI02KN+VO3I4)"QR5<WG&F`)*"(=[WL&W]%8;:F%6FV9HKGQM
MV#P^F411'E'8E69N!B=]=6%6W94@4.V#<<G83SY"!-LA7-C3DJ*,:%L9U0%9
MR8];&3C"#DQ:I$GL9&KBJE07?"VVM\X[`3638=DV1,'[MZF9#B67L8L&4X+&
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MS;)L?Z`L<W<XWD^)JFIPCT'?)`#:2,Q"'*<OX_B39DHM(N3N"I4E,8&]Q$I<
M@L[L4<L$`;)\?3]=A]?N('F?`&SN(9DDRQDR6.C%AUMQ`Y(I%K7"\6Y`C:='
MJ2\R=1*HJJFQ[M%,W0S)F.9ZZ&"(.+CYZ:0J$X%SF04RD)1BX42=0;C$!8(8
M9"2,CCD$*#LCX$L66,)6!*@%;C0"0:VDSFSID,".0"OK*![2J1WN`8TH0)W$
M=UP[6&ROQ7QFO"_$@R8]92CC\RBFN,%>8X!,65H)E^/4:5T0XWXD6$<MXE<8
M,B>)8UVC:2$Z?0QS+D1"H*`USD`2@E67JKB.NR1.V*6/EV:<1K"*?RFRM))<
MGA4AF,)CB]I@Y[#)Y+.INHS7MU)'Y+BTB*NSC-(9`2M="8&H&6C0W7B-9"4X
MD9-S)"O`(J4H-(GS*4]RJ4LZQ,ESMBAKP9@"63=WD*EVALUBFR=L?R&/3N"R
MO%"H99D.C>3V.2ML[`T'AL-J<22RR_"(S4@@DG_F6%IMKINRU;:[E9.Q-$)M
M&8AGS</AN/J681'(^+&%UDVNF),;L4`V<463KYVG=FTE$VIE9)2-6F)<5U[E
MF(R#!6L((N*C_BT(#B+B931TTU6[0P662IUQ9-=/)I(U3=D7#EF"+K87']@X
MKL(]S-N:)^E)E$\6*G^*N=U:,AU+4([^#;C2C_=Z48QFE\-,(XH/ZC<:RF7?
MKBDV?8_EN,.^4\91J>86Q_$)GC^[4F@^;&*,RX&;'@'N*6I3;RF%J3"V$UF>
M4=R;H6Q*?<HQD^-Z-XY%[W))O<LTJ]RB[W*/&$PXJ_,MREG&`-/`8:#^@0K#
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MV_X]O__7VK:-^WFZGFM75_Z@GZD?U-P7]57ZQ/UC>7?D)XC2^3GE=XK_`/RW
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B4V__`)O^HK]17EO_`(C\O_*/_P#"^Y?_`+53-M?'CH__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g644794g54r32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644794g54r32.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```890``7RT``'M```"6U/_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@!)@%4`P$1
M``(1`0,1`?_$`3(``0`#``,!`0$````````````&!P@$!0D#`@$!`0`"`@,!
M```````````````%!@0'`@,(`1```0,#`04%!P0"`P$`````!`,%!@$"!P`0
M(#!`%5`3%#8W$1(T1#46%R$Q10@R,V!P(R01``$$`0(#!0(&#`D)!@<```,!
M`@0%!A$2`"$3,2(4%0<@01`P43(C%D!A4C/3))0UM7:V=W%"<W2T)74V%U"!
MTK,TE=66-\'18D1419&A<D/4)@@2``$"`@0&"P\#`@4%``````$"`P`1(3$2
M!$%187$B$Q`@0(&1L<$R(S,%,%#PT>%"4G*2LG.#LQ1TH<(&@B1@<&*BTN)#
MHV05$P$!``(!`@0%!0$!`0$````!$0`A,4%1$"!`83!0\'&!D:&QP?'18.%P
M_]H`#`,!``(1`Q$```'W\```!CHV*````````````````````#+YJ```````
M``````````````&7S4!\?G/[?>``''.0``````````#*5=W1JNPZ8_7WX```
M`,ODAAMF><5']5[5M7G^N[)I&.<\:G2[0>D8``````````*7BK]=$K00``,T
MGDD=876;&-RE85R8L^QPX%3'1EZE?$7.\.(=^0$DQ\#FGQ+1!49:QT))```"
MEXJ_71*T$``",G5G,/Z4879$9]35B;L>?BO-R?BN*2PC)H`F1F@O$J8X)]BS
M2*'4EL%9F5B^RK3T(-1```%+Q5^NB5H('X,5$5-\'*`!E\O[$PZ_BHJ:2,CT
M>?(<<J<C!IH@95I8I#B3E;%@G4D_.Z.@((3H[@M<```%+Q5^NB5H(%/F/2WS
M88`!E\O_`!,3,E-I>C[=<,&Y^?\`DE9TI;)+BDBQR&'5'9$Q.C.].<90+H,R
MF]32(```*7BK]=$K00!A,YQMX``Q^:(SL;SOV-5M^:^LU91F9P"DB(&PCHRA
M2T"!G:E6EUD=)@2XKHZ@^Y=YH``BV/,5]A6>ZI6@`4O%7ZZ)6@@#'QGH]1@`
M#*YJ@KV1Q;"CLK%Y]B?G6$R.<5T3PC!\SNCD'7GQ)89V+$*9-.ET``I>*OUT
M2M!`\?\`6?N;V`V9X9`&(C/9ZP@`&7S4`````````````*7BK]=$K01C:K[X
M^?SGLVTZ$`&.R!F]3E@`R^:@````````````!2\5?KHE:#@2F^E]J6KS_7V%
M9[HE:"`,N&53U-.A.I.8?TH8U`````````````"E8J_Y]A=G[=MGGKG\\:EX
MJ_71*T$`91,PGJ89$/-P@)=9LPW*````````````0;$L6&JEZ)W7;O.4SRH$
M4O%7ZZ)6@@#&!31Z:``&7S4```````````,\0FT;LE=?=WW1^0ZUO'K.O+V?
M:=!@4O%7ZZ)6@@#.!Y^GLB``9?-0```````````I>*OUT2M!I:*O_"X]_.Y8
M]T2M!`I>*OUT2M!`'G*5$>NX`!E\U```````````"EXJ_</CD0O%G]46'35+
MQ5^NB5H(%+Q5^NB5H(`\^C\GH.``8W-D```````````QE5M]RG(AM26'3HI>
M*OUT2M!`HB'V/>LOKG]??@&/BG#TD``,OFH``````````#A\._RLU[[,]+;W
MY*F65`BEXJ_71*T$```9B.I-9@`&7S4``````````!E.N[GD/?%Z+F]6"+X\
MQ6&!;[WE]<`5!59RWK3!_P!^@,>&0SU_``,OFH``````````97KVY9SEUS[_
M`'KNB5H(``$!@Y*?3D:`,J&;#T^(.0<^1S2#FH````````#@<,FIHVZ\GEU=
M#TR5^S.M,UP6V;YE];=WW1X``@,')3Z<C0!B\IL]-#-9A\J0M\T6;E``````
M``!04-LJ%8M@UE8]*@`=/B=\=P,J=34<!7%?E;'L$4`,S&'3U[``,OFH````
M````#J^O,\8M6^^/9O:/@CMNW"``$!@Y*?3D:*SKLOGJBVC:.W*``/+POXV*
M``9?-0````````&(*GZ&Y7+HVK:M````0&#DN#T]L5C<VR[#$=9C=L^G(T``
M``#+YJ````````'GS2_3NYK=YUJJ.N=ZR^N0*QKDO/9N-['(ZJ0IUAJRM36E
M]AU&5R>$(#!R4^G(T````#&YL@``````&?H79V-:QOGT^OWC_C]?.BJS=-%6
MV@@5U`RG,[>$"A).QI^)X/1V3Z<C0(#!R4^G(T````#+YJ```````SE![4S#
M`;?OZ9UGJVQ:8^/#ED#5=ZM^U00%,5*?T->JM8]@BA`8.2GTY&@5569FU++#
M?WZ````&7S4`````!6>!;<BUK>&Y[=YT@D5,=+B97)QHOY<>7/[NJX;7!`0&
M#DI].1HZ;$[XC%9UCV"*```````R^:@````!XTZO]Y^F%\\DW))T*L*Y,5?7
M)GD=G#2>P*G^/B#PTC8,[&`5W`RDSE\#L>_J````````R,?DTV````#-5"LW
M<<8K]/EG6.'@'S"X_7QM7,Y<GN[*=R(JY\:6`JWNC9]\S^TZN<3RL?I.C'G'
MW-X_+YU7=PSU,Q.PHJV_8[H```'G`6L6218E)'3NCD$6)218E)2-(J6G)R1C
M?W[)2)X>#\>'"P).5@G3T5M7*W:5EL\D*[(O7:W*IJ:L+(RHA@1_0XV+9LQ-
M1HDIG>"K5LW?8$,-9@```'E0>JX```!U9Y6FMC6````.L/(4VD:[````/&,Y
M9[(@```H(OT````ZLS<703T```'2&?2U"R0```?(S:1LUV``````````<4Y0
M.G.X``````````````````!6IX_%D$K*)-RE%D!!NDUD````````````````
M548O*V.L+<(\?<[T@)J0UX``````?__:``@!`0`!!0+@"L[:V9P[*4]:.RE/
M6C7>6>_NU52M4Y92-IUF=/TX:GK1,6O()Y#3`<FH9)<H_F95QR(WH*2^R13A
M*9KG9:-A3N\9'1U"EY4[3?EKO4/?RFB&5'&%Z%?XK;(GYP9HZZEJS-ANEMV8
M=63*.*&;;9W#KVPG)N/PVO4BE<<B0MF1H$HX@S.*N3[;.X9>^4DS!5Z0R?CL
MD,::Q,U@$G,1.>GB916/.`$VB3H_;%)Q'$I$I?1)-G=VY_:M^[U#WW5E9WT8
MR+QIQ$78&$IR18&(=T4]:'9B$>:VXX:Z.C=&&]K*S\05]WMS)/2I=$\=Y$@6
MC<<Y"NQ'EF)3J2"RUDD5DP?X+D"0$AQJ6KYA-@4W<#K,>Y.LF&/,7R^,!R6-
MO0?]<FN%R8F6S6%SV6&,[1+SLN.6*7IVDB]LB99B7!9I,8*PK'#YBPP,4+C/
M?N]0]MUUMELE<LR.TCHC_91C40O441W%/6@YW:6NM)Y%:N@C^PGK/\QBL5J/
M-X@6^L&5VN4,Y>:FT6$.DD8&/4HG(\>+*S.S`&AS]$B<J9>9$7>W);'6;M.;
M6MZ"3R2)?CL'*@!,D?IN"P21]FL1BZ_Y)@'2YAD\6.)$9'@X(C!*D'UVX%WJ
M'MGD4LF\5NQS!,.FPK.^-,@OFZIZT'-+4Z:2Q"U)NX;"Q-ZV7H9-7V7#8EEC
MDX`8/MCZA>"BB(-D7%M9^))X6ZN[TX8<>W<T'&Q*&1EL0N)3G9@ZJ;I"\*"P
M<200`Q3##;BXK[C?(-,7LB<XTLFJ^2<2219P;L?R"0@3+"\N;K(@PO0TMX%W
MJ'N?V-[ZW&$#<\FE/VZ@[-;AF]Y?AV.B7]A'"^9M,I#>"IUE%G@9J&6F161P
M_+[W*V!QS-+D,5S/([+!4I=*I(A)'G*4Y82&^>OM^6BLI2P$M/+I"F3(1F*:
MS5INGTD$PJW9*E%93.9^^Q673?*+5!2SL[QQL`G60W]%(S/T7;F*+R5P<97M
M=:/54(8ZR-\;MMWJ'N9S.;6_'V)\>RF.2_=JDDGFK5(E%+3]9$Q8YS21"X5C
M2I=V*H186KB&%*L<FQY$Y>E(80Q2>MV'8*HY"P*/C23\4PRK]^),?THV8VB3
M/1Y@K8XX]`QO'!GXK&,8/0?X1'9-?.\,#28MEQHB,#+L$#.I\9BBK&[[F//)
MFTG+[W^3MS^PK>Y.F,<0-<#$F.ZIZT<UCSR9LR&5,GUTCL#C48F6Y*(5DI1[
MI!<Y/%Z"7<(;BGK1S6//)FI9(GZ>/S*UILK3=ZA[F8)4ZP^%XRRJ\/SWIQ=&
MQG&*DD>!"(>V40ZQ[9E7-3UHYK'M:4A1DVD,WE*(HP]VKO4/<S4^NT=QYAJ/
M'1^3:S2]M+%$NC1F)M=K`\!-4;;E59JPM;ZUYAYF1R)KBK3C::F2BYAC[/&6
M[9=ZA[F>XZY2?'6+`U$97NJ>M'+3&Q_%7;AB1!-2DB,Y))PM#!(XP;;O4/<R
MJ*SF0[%L1'0RSNJ>M'+33_5J;$R%1B@$($A#-CSR9MN]0]S,D7;FQ'#JBX4Z
MW5/6CEII_JR%,:0MAQE"SF`?6//)FV[U#W,URN#T2QS#3760;HKJBX9QY;*\
MZ9(Y=C%PE$D:MF//)FVZ")7'T_3<G[YE&KKC+!)T1F.ZIZT<J0NB*A*&YIRX
MK'V02-LNS'GDS@9=ECY"87#LR1B;N^ZIZT<K/FITGHCZU`L;1L=2W`-"!I/K
M>T;;K'OK&YG1X>&/'N,'MM"R?NJ>M'*91E;HR`P"%BPAAFG^K?KYHW,T2)^B
MN/\`$*1H4FU(I*PQ)J>\D0B.MY>3(&"ZBY#A9LE4]:.1*6J,.V31)T<)O,`(
M2Q8X^[5(]J<.U*+MQZ3D)O5\T;F?&$N18ZQ8HI=*]9=2(*QX2#*@T4<;3II8
MV&(2RZ1L,9$C.8>2:CA6UW94XYE>W=-4.239',]U0VW+(_=&YD^]F+CV,X>2
MEE;=4]:.1.+1;PD9,7E.8`@B-@>]%_H&QTE;6VJ@1DHZ9;DY8<D.>=85'\SM
MSYNJ>M'(Y#K-)6]X\Q_&XY)=^+_0'25M;:KT^42'36R-;,E7S1PU/6CD)*_O
MF2GQN"09VR-DCW23:]WNXZ@J9"2.I>^(H!Q5BD;LUM;(ULR6ROFCABEN!&<>
M-DA2+"QV%NKI('%$8<?1R-A`;.T,]KIMD*B=MKK(VEGL]V4R/32PM;(G%_H&
MVOFCAJ>M'%G.1@H:J^1'(L_9<0PQ*)1G2E;[4V;(`UKQ]\L]^ON=U6UX^;KZ
ME4:D3HJR15G8;=D7^@;;@9'U+AJ>M'#^[&0@VZ,9,R*HW-HS8%+6\`X2+#LK
M.$I+ZG7_`&TZN^H^TMH#EM?_`/#8:N4@G&['$4'CJ>M'"R%!LAN^0(A`XY"Q
MJUI2ALQ80U)!;(92V1>!M*8":::5BUE54@V&H96UW;W<]46A5$>1`S`S'R91
MR;OS+U9JUU9JUU9JUU9JUU9JUU9JUU9JUU9JUU9JUU9JT[Y/M;G;[T/=->!8
MCM`G1!M3E$P@B`44F$$7#I*XM6M\DC]EC)EF(OIOW"P:^X6#7W"P:?\`)T4C
MRX,LCAX7W"P:?)S&V)KCN1HS([%)9%4;OO&(ZK/H72OYQ:+I!U9JTFY-RM_`
M9L2RH:0W83@59A^)\6:<\)XM<KOQ/BS3OA?%KLTI8CQ8DE^)\6:9L*8M9V_\
M3XLT'A/%HCC^)\6:-PNCU;[)B.G3'$3<D?LF(ZD..H\]A1W&\?8A:Q&*UH%C
M:+`B,F'FQJ<$<<Q-%U^R8CIWQNT&.\EQ(WO1=^+XZ1'_`+)B.GS'$==&Z.8M
M9&6W[)B.@,<1,%;[)B.B<*-!;E^)\6:<\1Q*UPX+M.)G9(>";86H$V3><*P+
M$CX].P'`-376#3FN00&?%[P^+N?!=<DSB%./6LA_E[@+8PA!$IX)H:#@$-AC
M'0C-&XRRQ)LX#DW".[<)AW'H3+%XDQ0UOX%]EJEC?B#'K==^"L9>$Y5-=%6N
MRC@!<=V-,FIS?8G`T[(6-$)O/(WBN;9HEL=>G0W*D9R/`<GG9%G9T#B4^_L#
M`YP\Q_'`6<)\,PXSF3Q-W+L&;VQZZ)P8+#@4@HVX#IB<4+^M5L9QJ)AX.5_U
M-%BXV/,C@87(G3D-@@K&Q@^,AL78&&CH>)>+_]H`"`$"``$%`O\`GO<4\5Q"
M4S+ZIAGT.O1=*WV^WW>:^=XM'8"JO.?.\0D-(O5&`?Q*#<@,IS?SO$4701UU
M,+OK"AE;N;^=XBB"*VJ,*%%[!1DKN;^=XB*%R^JQY.@2HMZ-O+*=[[!5%U;-
MOSO%\67W?,!?"[:N2OC^Q@OA=AMQ2JB(:"!/8P7PNB%UC%DD^Z3^=[&"^%N*
M6+(I;;39\[V*NLF.F"5<OI%%-"S9\[V$3WUM;+:VVZ(J@=5K%M01V_.]A%?M
MHJJW=!B6B)!?"[?G>PBOV-)\*B`+>C307PNWYWL)Q+20T!>0NGL"^%V^$I[_
M`&#6M+:$6)N544K4$M@7PO8IB:AEJJ=B2>Q2Z^V@E%;$]M:&>+[`<"%$K0Q;
M1$2OVW_Y+G;J^REA5%+RR;!40?$51T6I^ME]+[=[^2YY.ZVQ1+N''>5N6MM#
M(6)LVUNMZESMUU++:+W.!-EMMEN\V_!;"7,8>Y%N46=N=-\40J$&@@OOMOP1
M+F,/=W#B=H8,82W^2YQ=94Y6RVB=B%U._P!IE2D[DZ7VV:=3+;$FT,\D88,8
M2W9_)<T=X>U$511:^E*4TI^M@]?>7VG5I["3Q1:>QR/T,$,'1M^"V_R7,EFV
MBU5&-,2;1:#(:K[?8(^)T*ZR+7742;M=\\7Z<F\\FX-M$"IL;?@MM43_`!'+
M^(2K=W!YNK++;+3O92P15*U*KIWU>GDE:!%'1(VG?ML5O4LHWT731YHT0U0P
M81`6FEG4)*IU#G(=N91J(4MI;2ZGO6I!=TIM*0*6N3[SW.=<78AN7ZF43KPH
MRVD;FX>BE[85:C>V#)^."U0H6NJK#4N\4+KQ0NO%"Z\0+[EY`R=_BA=(K#+*
M4)%JA0A"NN^1U[Z>K$A5%.6,:532>G`ZZ<!KIP&B6H5=(5I%'L\"%KIP6AV%
M)%7IP&NG`:Z<!HQB2(O2;!+4^G`:(:1%DA&4<>G3@-=.`UTX#2;/W)?_`&U_
M_]H`"`$#``$%`O\`D'NW>[SEKK?1@XC$9&!DC9+$5(F(YP*P5:J=RW-4\K\6
MH!5$^<IY7XB)%Z&NJK=RJ8HM9S=/*_$4701UU0'OK"A5;N;IY7XBB""VJ,"%
M%TQ1DKN;IY7XBBE$]=4N[^Q:V^O+!=/[Q_#:FXK;3ROQ>X1][F)1]?VI09O^
MT.QI1]?V1=%A;@W22.SNP]C2CZ_IE:FV-MIYES@;3ROV-)_UD"$?:X\SWK*J
MTU3ROV*U-9CR;+(^@ST<G,YW*V4\K]A,56Q9,I5)=;3,D[Q-*?OZSJY[:>5^
MPF#_`#U'TFNUQDTA7D)\H^O[:>5^PF#_`#C#%U]RES^.Y*:E'U_;3ROV%"XZ
MX.M)>*SM1FR4?7]M)'?0;L%--191G*-A%CFX+.I^R4?7^Q8T:'&EFTTAQ.V!
M("KJ22]N*.V^T?N.P(<RAN!$F?UI"Y,'^>_\GSJ*?>JEL%X8L>8B9`Y2KHEK
MGJ/!?^90UXBV]\GSQ@ZQ8)]SK"Z[J=$ZU(231NV^[7P?.CH7DD7M*,-8B"%B
MU]XSXG8B$LK10NQ,#G8OT!E;Y1)W5U:=\SXE$)96G>!BZ6(6(K\GSC2V-T3;
MBB%#BW9)6C3M'HA=2^MM;M`CUNO,(%166(6(KL^3YJ*6O"SH_AAM@MZJJND5
M+T5BG5T4'VBTKI$5=>O_`,8NEB5B*F?$[?D^9CL5(?K&Y[BT9<)P_7O;OJGL
M]J[9=W'3EZ:\&C;KNVZW098J-"#5R=IGQ.WO!>ZY?HC@D/1WB,5M**5+(:CB
MPE'0T]Q4H#W=/%HH:*6542VC?OL3MLNJ5W5ZG-1>11<&,ODD=7]728!-]!O"
MAK&.2U5*UK6M*^RMY/OV;4%4$Z7^Y[W.C!#D(=ZSHZZR(GI1Q25KUD42VCT*
M99XX+7BQ=(NP2RGBQ=>+%UXL72[H$/JTP2ZWQ8NE#Q$K!W,,BSQH=->-#UX\
M+5'@>XGEEV\I:O30-=-`UTT#130(0F(T"C6>`!U5L!K0:/HH*]-`UTT#730-
M&,*1-Z+4&FETT#1+0(LD&R##4Z:!KIH&NF@:HPVV%?\`;7__V@`(`0("!C\"
M_P`02P[MU=IRS8GSU8\_=1]JL)&4>0P%JG.U2K!X9()0\FQ.B@>*!:YVZ_E<
MH[MJ`OI;4I655\&[?E<H[J-85B6(RC6S5JY8Z;6.<:U!<M95$[L^5RCNO3+2
MF>,@1J=8CFSG,2S3QQ8;<0I610.[/E<H[KTR$JEC`,:^UYTY619S2Q1::;0E
M61(&[/E<H[J;)0)>DH)XS'W&LZ35SP69R]*J66+94V1_I6E1X`=S]%9GEC6.
M6;)Q3VGRN4=VU6M<U4I2M&4L4MTHS;28`L3L[T^/O.C-L_:7<$)(I5DA*$BI
MNO+.OO.C-L&Y76A(YZN3PKS0&Q,@"/E<H[SHS1J;E0VDZ2O#P.:*,.Q\KE'>
M;6N<V!=4)Z`)TC&K:$D[/RN4=XPI#A`*@)23ASB)*)4<=')L*N()MBF>`1K)
MS4O:?*Y1WC1\5.P4W6E_/5EBS6X:S",VT^5RCO&CXJ8M@36:!G@O/4WA=?BV
M$9MI\KE'>-"5<^T%2R""^_*RHZ(Q;*,VTMZQRUG\G>*T:H%X1-.F$9\L!I/-
M&RC-WF#+"DZNUI^*&FT<T.)V=!-H\$!IQ,I#&-IJ-<;-BUS4XY=X0RSU[E`B
MQY^$Y81\5/<!\`^\-W3KBP$+F#315^L:Q5>#*8MWDZ:C/,-A*0E9(6DT))Y(
MM">^)<>W'P#[PW>^M5"0H>XF$WE23H*,LN7;="D*5E-GD,:U:`ELBC2G^T;0
M4CJ3[PW<5FH"-3S&G%S.\/)`0BA(V[>;EV=4)N7CT4TGR0'KP@-I/269S\*:
M=W?9L@I:\Y4.%/.20![(/<&\W+&J$W+QZ*:3Y(_N5:B[^BGG;ZO#-%EA(''P
MP/@'WANTW2ZT-#G*Y/"O-`1@`A[UQ[B=HE33@"5+2F5F=>_$G%6EXY2V"PPL
M_>FH)I._`+SRD70X!7Y(LL)`X^'9'P#[PW7;?WL\);N0L-@"VK'%$$2"J*L<
M%(NS:2A4B9BB@'T<NT;^,CCCI%:6`"DG>BG^VNW_`)#_`,>.),)D<>$[\-YN
M7:#X!]X;J"`"IY50$%=Z(0D4A/AXXG.:ER.Q17#FO380M4R9SE)(3@335'1!
MUSU4'EE'175[^J28T66D>LJ?%"';R6K14$:,\)RXHZ(=)Z1K\F]LMYN7::^;
M,[-FI6.>/=!;;(4\!5']R=4QZ(K\,_!`0*@)1-2+8'^JSRTP7BG5-2%:P>6B
M+'9S:G58ZD#?B?:+NAZ"*$[YK,/AI(`"T^XD\9VC7QT<>S-M%LYP..`P\BS9
M%<P>+=9(!()H."7)'1C2QX=BP%6W,2-(^*"G4AMD4S6=*C$!5OPAY_360#+S
M1/)XXLIH3!2"0<8@NAUTDF9G9IHEZ.+:#5J;#:5!5*3.8_JY(Z4@KR"0XSNX
M-+9T%"TDSK$R,6,$;T=`&FD8W%"?LCEB=_O6MR6@E/`#%EDM)&0B#K7F9(23
MU@&\)&DG`,,)4TZT`X@&6LG+(03HD81'7->T/'$M8W[0AU&N9FTH`Z8IF)Z/
MI#`95&.L;]H1UC?M".L;]H0%EUJ1<2CG"M6'U1A-0@H+K<P9<X1UC?M"-7KF
M4Y2H`4"<-OAUNRX)RM"8P24,!BA:>$1SD\,<]'M)\<:AN\-JO/VZG;(IH3YL
MQYV3$)[G%X6]S>:+$P!.<N=C).^8ZIO@CJF^".J;X(U:$H;RA*9Q86$N4^<E
M,XZEKV1%#3<_5C6+5;3B*1'5-\$=4WP1U3?!`+)2T@"H)\H@)<;;4L"NS*<=
M4WP1JVTH;5C"8(=LNSQIJCJF^".J;X(ZIO@C[QAVPJ=031(T$5X10?\`-O\`
M_]H`"`$#`@8_`O\`$%N6CNTWS[>X_<"]);G]LQS=6H^AC%=?=5I[>NCMX=*M
M$I64R&*06CEA=VNZFPT;N4H8\\*EHB6,*IM_U3,-IO?9MX5>P@6B'%2*I4GK
M16<@A2F4V62HR%<A@$\,MUJ_/3])?=M:4]'*=8\>[5?GI^DONIL6:<8G%B2;
M<\5$LT6%!,LV[%?GI^DONO3+2F>,@1J=8CFSG,2S3QQ8:<0I>(*!W8K\]/TE
M]UZ9"52Q@&-?:\Z=FR+.:6*+;3:$JR)`W8K\]/TE]UI"CF!/%&JLZ-J6&?!C
MB0"]])&YS_\`1UQ:E1J[(,_Z@:(5<KC]P7VU2)642(E.BR`=HK\]/TE]VMV$
MV\<ANF\^O^T;35NK<3>2W]P5&@)<U9H(]$`R.'#1WGO/K_M&RK^2=L.(=>;5
M)J[@BT5X%*'%YHKI,A#UY?=4E+E]";*20D(U:C8RC'.LTGO/>?7_`&C81_)_
MY``X^X)W9CTIB86>/$@4TK(`=OJTI0IU95)(D!/%"OST_27WGO(%=L>Z(/:G
M\I3;OSZ9,W>9!]94J0<>!`KFLR"0ZI2@D2$S.0Q#$-A7YZ?I+[S)N%Q3-]6\
M`!62<4.]O7J\%/:RWTF[H3(C1LS*IC!7B%%<Y0;YV@X7'S^@Q`"@#-GKV5?G
MI^DOO&ZS>[FTZXU=W7+16\"2D3`(2XE,L%`$%QEI++9\U)40-]:E*_788_EJ
MT(-T=);L%4EK2H3G50*)@UT<VR8^Q*`ABZSEA)*@)DU9)#:*_/3])?>.]_@/
M^[L-7CM^TCLJD\U1"RGS:`:)U\!E.->="YHH:1Z*?^1P\%0B\^O^T;17YZ?I
M+[QWO\!_W8^V6L-W1M-MQ6)`KEEXJ\$-]F=EI".Q;IHM_P"HX59L6$\XTFB+
MSZ_[1M%?GI^DOO'>;PS)-U4PXS:/IK3BK,L,([*[("P^PW9>7,Z:C+!QRHIE
MYNS>?7_:-I]I]G<=1:M2L*YTI3Y]<N\266@5.J,@!62:A"^Q[UJGS]JN]2!D
M6U`4H)IF#*@Y\$.]HWB6N=5.BH8@,PHV;SZ_[1WF<[2[6N[WWVI!NP*9)-J>
ME3*BJ2A,2M891?[[>U6KPY<KP2?Z>(5#)LE-[?#")5E*E;TDPN_W&\!W6+YM
MA:2*,:A([36ZNFU*LXN\+O:7:JDI[(N0"W)^=793+$94X^:*X-[5HW9.BVGT
M4>,UG@J`B]_@/^[W#YG)NY+94E%HRFJH9371`O:[U=%(6DJ2$K42L!13HZ'I
M`C>A-Q8H;K6KT$X3GP`83'VW82)75E`053G;6*U<DZC*>P_>%O75"';J\VD+
M?:0JT1(:*E`C.1!866U*&%"TK3O*02/UV_S.3=_9-VNZ2I];"P`,)-Z>A[L)
MAYI1O+*"X4C237H3K%'^U0(E/;=(2!FGRB+"5%2ADERG:?,Y-W(NS76.+"1G
M)D(_^J/[GM&YW<MH)H`UCJE%4IXW)&F=D2$K1A=YO*BM]:IDG"3MU9]FV=%K
M&:!&K945$:,_#)NX_P`E[26A[M`*(98!%H*'G$<2B))%-*BF+FA]02Q>&UK6
ME(D"4ON)3ED`D8:Z33W!6>+9T6L9H$="-:[C-6\(FZ9Q\SDW:C^1=O`.=HN)
MG=V.)2O#0RK(`<O2@`ZZLJDD2$U&<@([-FE5%V<P?^R]M"%IFH))KQ1-`DG8
MUKJ1]MA)H$'5MA3XPFKRQ-TSV?F<FZTW?L><U$%RJ5A)IG/!3^L/WS^4J^YO
M;BW1=6`96$DT*T98+-=`JI48&L4I5D2$S.0Q#)"76U*0XDS"A6,HEABP]?[T
MXTXGFJ6X01.5(*I;1?PU1H"C&:HHZ9[_`&CQQ-PT?I"L^T^9R;J7>U.MW?LU
MDZ;BL&&@4?J4C+#5V[`0Y>7W%:MUY2B`4D^:*J%2/-%`E:,Y@MV+#-U*FQA)
MDJE1SRH&#8IJA&J5:4D8JYF>.BN-,H3G4(Z1]O>IBEQ:LR9<<*0R'+,BJF6"
M-,Z&+!LJS[352<KG@W0U?KXVMGLUQP)UA313AE7*5.7`8EV(U]_VL/\`O.<Q
M)R?]('Q(<O+O/=65*E0)DSJ@FZ.!M:I>8%\:3*$IO3FN=255-A)IKYJ1.<HM
M7M8;&*M7!$KFC2])5)\D-%:B9I/O':+^&K9TU61!<;5.9Q'=;3;KC3;B$=(@
M\]2Q3.7G3\W>&"+5^<Z`&:4"A"=['E,SEV+1%E&-5$!6L*W*M&JG+"FVM%(,
MLL3-<3KBQJT"0HYU'^[:&VE14016,.]'1SLY?`;N+Q=LV>=DPX\1$=+>$K5B
M21QQ*ZZE&68)X3$W'DD^L(UB'4;Q2HP'''4#.4I,=<U[2?''6-^T(+85(C'0
M(ZQOVA'6-^T(ZQOVA`M+!GBI@*UB*<HCK&_:$%9<20,1$6PH)]8@1UK?M".M
M:]H>..M;X1`NR*237@KW.ZD/R8>4DE-F8T*O.X<<=2WP1U+?!'4M\$:M"4MT
MUI2)P4+"7*?.2)QU+7LCQ1(--SS1K%JUB<13Y8ZEO@CJ6^".I;X("F2EI`%0
M3Y1"4.-MJ6!79KCJ6^"-6VE+:L833!#LG9XTU1U+?!'4M\$=2WP1]RVY*2Y@
M6:,U?^;?_]H`"`$!`08_`OB#2H,5D8]QZ=6$VS>Q7_C<MF35`6G(USE:C^FF
MG)$_R7#_`'867[5U7^2X?[L++]JZKX.EO9U-N_I[DW[-=-VWYVW7W^TP*D&A
MB,(08E>U"$&%1H5[&:[G,$IF[E3LW)\OV..K\\R](1,<E6C@MS#(V_CC;6-'
M:YJI8ZM&@BJFQ.[QI\GRKK_\UYK\7#_=A9?M75<0WX;DU=1QF!>V8";7QY+C
M&WZL,PIJ^>J)LY;4V_Y_=#GS037R!7@9L_(T(G@9$1IVNDE9([K7#D1$5B1]
MJ+M79L1.7$TE9GE+'K22SOA`+3PNJ"(\CG`"_=2R5<X(U1NJD<JZ=O&$N]0:
M^SR3!8^+W@9;:^DM[BL3..M4>%L;6EHHLX^TM:R5X1SQO8$JKMVNY\0*ZK7*
MX=>+*,4K*G%)6)D^KYO3:7CM<>WO;3(Y5-(L`WM=+4[=I+$;AGCH%PE<1W!7
MVV0YF:78X)A&627P<:K8-A57+LL''NJN"&MQU#Z#IF(8\=S"&W,5>0GJ+C.;
M:MOLF-2U=G@E13#9B%7(L!8];UF#3LJS*-"\@%+M[B`.5.5`=!P`$<5K@=QK
M!8G/N4N[*MK0^KU929!<4KZBPL*!TSTX6FEW45E74`BS910RAB7PT?Q(H_41
MO-?L>/\`J9,_3D'X@4:2.KEE=8#+#K;?.;'`H4\PHTI%::TK&ODS611D4WAE
M38YPT>JM5C53`Z[*LGO$HX?I'ZCVL.=97<JF)9YM2WK*YJLF0K!$M$I*]Y/`
MZF)J%$<K$75.+;(+J\LV>I=&+T"%A5>ZZFQC''?0L8/:%;3LE`C6A,@)8RUF
M]0;]'(K%V[=.,5MHMU,D9Y;^L7J)CV3U);J:=@<8K(]VP5;)HW2&QX]=40J^
M*43D"Q6KH[FO#/K:+'12/\-;#PB8[(LI`5#]:*K?XA;*-&>TN_LVHJ:?`E>R
M>]9KI'A$C^`L4?XCJ=+I+K$1K51_)=>2>Q<W3,CJG56/6):BZG-E-<"OM`E`
M!\`SD_\`-*>2-C6-U4CWM1NJJG%/=RLNHP5.0*9*>>2:Q(\WPQF1I;F/_B#A
M22-&=S]K0$<C7JU5T^`,S)+F!31Y!O#QG33H-TD^BO4487,TA[1HKG(QJ[6(
MKEY)KQ%J&9ACKK*=Y>D.&EK$ZLI;:$&QJVQ_I-"NLH,AA0(G,K'IMUU3B;C$
M"^K9=_7,*295!D-=*"R.5@)*[>Q_A3O1A=JJHGKM=HO"XTW**/S])3X7E"V,
M9L]9HQ(<D1L=ST>Z4T*[NFG>V\].)F.);P5O:^M9<3:OKM\7%K'O0;9IA_Q`
M[E3^#<W[I-94^/FF.'APDC.EG%:17LC,F*](I#;7JK!2%$Y&.^:Y6KQ8Y3"O
MJZ9CU2&5(L+:(;Q,2,*%$9/DN<\*/5W3B$:_1J*JHJ:=O`L;C7]>Z_-$'-93
M/(X%ET21&ST82&=HS!EM@O0S@/1#L%WG-1.*VJN[^LK+&W<UM=$F26"-)5YF
M1AJC5^]L+)*T;'.VM<1=J<^7$W%Z[(:J9D%<TSYM3'EC)+`D8WAY6K$7O.B2
M%V%1-5$_D[1?A)BY9KV6K)E36[/#G>!]G=5ES=0JY)`V/&R6M30GD.W[6M9L
MYZD8BO([>K1L<]R#&0I%1J;EV"$UY2OT3DUJ*Y?=Q7W=1*9-J[6&"?`E,:1B
M'BR1H43^F9@S!?M=WF/:U['<G(BHJ?$1_P!3)GZ<@_$>#NZFLN8:$0J1+6#%
ML(R%:CFM)T)8C"ZB-<J:Z:\^(4"PQVBG0:US'5T*94P),2O</1!NA1S1WABN
M&C4TV(FG$2ZDTE1(N(`^E!MCUL,UE"%JY>G$G$"Z5''J]>3'(G/B1>`I:D%W
M,&T,NX#70QVDH3/FBD6#`I+,-ON1SE3B'^["R_:NJX`LHLT?A^IL2)++&1>I
MMUWH-='+W.'R_$3/"K'38Q)1$EI-4CNH99.F[IJ+3EVZJO#9<<]D\C6O;MD3
MSG$J/31=PW+M=]K[?&-QC):GI6T/7DP:M)#K289<EK7&#BH_,*R*3(SQ(JA=
M_M3_``A7ITF[VOXR+)<;J)CYE%EOJPT-I/RAS85P`]980<;Q@=++/T8\4&1R
M12U<HTC,:)7HY7O5J74%!Q[RMO<6QZ,>9ALL.-V\;(*$PX#[!'Y-9V89-Q9U
M<EQ3R?HQ$=&:W8/5.(."MJ)3K$DC(#M;!OZ"/":R;>NGU\;._$C5F0-DC,I9
MCH*)U'HJ:<]W&+MQ;8*=51;0E^>+:NIXMQ7GAQ(L[$8XNKU0_6)RJHI+^4%`
M:[T<[C!,VHJ%E\+'ZG(J>9CZV,&OG0O/15;PV->>85*UY8WEJQS)U&JHR]U7
M)KQZCU*8G`KX/J1+P&<V\?D%>6/BCJ3'L<B6O0C!%YA-GUDRN*V(]@A,>]K7
M]UO`<M-7RXM##K,EJC/NK:HM(W2ER:_RLF'PZ]K)].L_P'7F>+U^=L3[I<LQ
M[R")'J+_`-8*KU"C9D6XA;ZNMK/JL1_EM:'K6*7A?(2!8KD&-&'75R>]N>$'
M0%-:93E0[.G$CA74?$KZO%CT`<N]?;+5V$:J@8_62FQA1AO0N_O*[<CI,>W"
MMD:=Z.5^,19<JP@O-CEO$6<V7B41L5P0%IY99C)(Y"L>]'#<UY51!\?5E\57
M75+Z;T,.PKP**4IBX_5UKKBN%MZ@I*R!02A;MW;]W=UU3B%);`CKC?\`BI9>
MJ\?*TGQ>K*K+;#254.C97*GF3)7B9J,(KVH+PX$T<JZ)Q<2VXU'C?7S",7QF
M<AKVM.["9E)E,^TE%>7:WS&.^'8]8*Q6O=XD6BM1-'<6.3Y-BGAZBMB6./X5
M/C6].6+!JC$21/MYT0<A;.1:9+)CLT3IM;$#HU=SE>_B1:3AV)03LXRPT[9E
M-A'"7#)6'F;1PO"1K,0F15R\(".`UJ+KJI$V:\>GM9FKKJ6^AQWTL!8QH99-
ME<DM(LR]2Q+6$;91Q3JOKK'?=$$&<X@([>^QS-.*B[IBOH\LRS/+GU!FS)"M
MC2:2OM,-RN@QF,_JHR4UT"IE5D5Z#3Q`5<][-'-UXK!W];:5@*F7318E!%EG
MM)--X;TT@#,Z;+):_C6#PK)T@ZR&1R]2PVD<955X^,826(@'RAV=H`!1($D>
MNN;NRMZJ.X*(WI*"LFB;MT14TY\_B(_ZF3/TY!]A7.5&M:BN<YRZ-:U.:JJK
MR1$3BPH\*_P]QZIALBE%;Y!/E75]913`CD?/AT5;H.!%')*\/XU]\5FJ+HY.
M$E>-]-,ZB-T<>J4%IC%F5$55<.NFHTU>(KTT[TC<U/DX"\PECE>(;R@5[2*$
MCFHKQ*0>K'J-W+5.2^S#_=A9?M75<#2RM*ZN4VY0I.FQHBE1FF]1]<@]^S<F
MNG9KP^L\ZK4V0V2_'+/B)7N5Q7#6*V6INBLIB:.VZ_-7[2\-C0;NHFR'(Y6Q
MXEE#DF<C$W.5H@F>]4:WMY<1TR._JZ5TIKWQVV$L4=Q1B<,9"M:Y=W184S&*
M_P";O>UNNKD3A<8BY)3GR%%F-6G%.`^>CZY[F3A+'1V]#Q%8N]GSVM3733GQ
MD]I0TEY.-C=B*$VL7RB%*N(TWH/J[JND6-I$K6TUB`RE:4YA*C!/U;JB(M5G
MK<6R:3337V*6+1+CXY5*VJL_)Y:F%*O`>:/+-1?#M@K)4S&J[N\#\YMX%4IH
M<^P$EA(9$4D.K$,UD=B'5BN;!"9KB^]B+SXI*F%3VV39!D3)LBJI*7RX4E\&
ML&$MA8RI5Q/JZ^%$CMD,:BD*CB%>UC45==+./88QF,&#02,:B9)>'AT:UN.R
M,IJJZV@LM@@R`UTQD8=F,<D@HA1!+KWE;HY2X+(H;JOEK7V%G7V<A].>OL8E
M7)B1)94'7VLRQKFJ6:SH^+`#JMYI[M9T"319/'K*W+Q8-.RI\>F?CT7(I`H)
M(L>1X>\->1XLEUG'&V2^$V.A"HCGISTM<&\-9)/J:F19/L.B'RN5(@Q:JPL*
M>(=9'4+:PJV\B'>S:B;#=O+@TJ#AV:*5F,0LTCP"-Q!DN=BTXLD+;B._ZWK`
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M='@7FJ*GQ,?]3)GZ<@^Q98P63X4-D2M4[E:1S#`@6T&R/!.@31S>%L@PUCEV
MO:[IE73B'ZA'M(&/U-':Y%,LYYHTTLXM1>0&U5%B,?IEG2I5;3O5C@C:US]0
M,1C$3=PF.XM<RIMJZ-(EM"6GM(;'`B[5,[K2HHA)HCO>J:^U#_=A9?M75<#\
MRK*^QZ.[I>.AQY?2WZ;^GUQDV;MJ:Z<-M73E(B3?%NKG5D#RYS%+U'1/";5"
MV,K5VHB)W4[./$0*6I@R$:K4/#KH<8R-=\YO5"%C]KO?SXH[C&:5MO'AT;(C
M@R9P`4LF>+(H-N*+DH&Y1C5BM.)8(S:B99ZD8B>'3GOR&;+R*/C@6Y9ZEW.,
M@#1QIT\,K,JF;CL6_/:Q[P?6BQZV>\HH:B`9#Z=0FUK6-F)CN2(:NLL6JL8L
M*/.:7Z[4\L%',&6J5\1]M2[84.`^1';&:Y&)U]R*FS:ZNP=,FIB1XAK:2ME8
MX9YA,IY%E8)-"3!%^LL=V&>5BU"!$=,1K?X.,<ANR(U<S%W$L*\Y:X5I--D`
M0!C5-E82328[I4*,/K>)B:-2:XJ;GMV)KC64T>0Q:/)<>AVE:Z1+HR7-/95U
MRV&Z=&/5-NJJ2)6RX`BA>R7JS14=O]V4I99T(E%G+\5+E]='Q44>QLB8Y34]
M3)9$MG79HU=%N5JMY&)#>HVE5C7<MW"^H$FWJ1O:"ZBI"H,8\@FVX+0D?P;<
MQMVW4],G?218K!QG+&CZ.3?V\N+]DK+QNP_(\ZAY]98V#'6BL)%A`\D)&K39
M`6XDL6I6301WO:R$,KM-$>WB)D0\TN?K$S++[)9YB!<6DE@R1DZ%9UD:@=/Z
M<!SZ60&*V1UB.;X9CMO\5)L&IN0#BW&!P\4O0`HQQ1V=]!9)`',=&6#^A+-$
MF$8<'>ZZ[7J7<B[G^G5;)9/LZS"ZNDK)16>"%86>.0H?EQ"C\21(@ITVM9N1
M2O0:/YJY$YQKZ5<H&C^N$KU);B+ZD!)T++K/'EII##Y&*S+'E5\)\DYF#9$:
M[K.^_*QJ)Q@<TF9T7CL+G/MS2#X5+*VYM2P;&K*3H1<R@,KX2P+%=`IU'(5J
M.ZBM[G%V=ULV`MQ@%O@S=:Q)JQ/-;"+/\T1RS8W4Z"QD3H]W=V]1-.)=EC3)
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M3N[]-VBZ=B\+CRXU_5_U@-5=1D>U==^%'.?&:[R=`>+\QZ;><?9O1_=TUX\(
M"MR:(_I/+U;;%[VHBZ,5J*WQ=C`CQ^JN[DW=JO$"NFU=S;S9\;Q@XU0M(PJ`
M=9U]*%!^=W5,V9(/968F(("E(UNKW(UJ:JE"6HR"#&6WR:@;D<T%:.@=<8E"
MEV=M$ZH[0L\;&U<$AV&?':%S6[=V]KVMS24]N/UMK4BIL@H7`K[O(`_4_)&H
M:K-:4=+*/=3[N&./(')#&47TVQ-HT77C'L\CMQ-+*3)MH]G!=59)-KY1(%QY
M?&#XR'.;'PA3PV*8[[<[FQ'*@WINW:4IK>):R@Y`\\2J/3@C38\JW;&257T@
MREEQ?ZQODW-A:H@2.8N]X^6N+8;B@*:/<9#775W)L<D%*F0*RMH_+QD`VOJY
M\$TV?+E6;&)I)8P36N=W^SC.9DNNQ653^FTK#H^20XJ6P[.<*^Q^ELK>3233
M25C.=`EVCO#A+'1QA,1JN1Z\2<#FNHB53JFUL8RLJ[VFM(Q()Z[PL84^W/Y;
MECI$.:I#+7"1D7:J/=R[V2VQ:_'SXCB_J;"]/[&,)M@+(O#628\`%S%.Z4:#
M+*&;D@MT;H,5PV.5'IQ;8D@Z5V/B#?5-3+9(<MR?+L9J*N\M(\H'BMB53XLZ
M0$:H)'^(@&15TTXN9<./BR&JL,JLLD2?*LA!$KYDUL\[\:E1)EB"1/.6%$0H
MIL<OA]ON=KP;U&LVTKKFPQ:!?4T6NC2XT&*;(*VO6GB34FSII)+X]G/1"O:Y
MC7L[&HO$.'*!2R,6)Z@S/2QQ1QI[,A??5F,2+DU\\K)'ES:^5.@E#X9L9%$S
M0G65.7%/7J&!6XA)B5A;+)[7'LJLH`IT^[?6>6+;TS5J*<[Q*/8^:Y@]Y6ZK
MIPL2=29':]"B/DUA(IHU::-644.:&#-GS'3;2`94C$.U>F)A2.;\U%T72=)G
MT&3PY];<SZ:;1RFX]%L`/KL>9E)Y+I$C(14RL=2$1[!)*\2\OT?3W:\-/BZN
MJW5'I7EGJA?1+.+!D21,90R!8C2SV#+,&$I;IQ3FZ!>]Y<K$*YCEW0KQ]7D%
MC%F+?)&/!%2`%:!Q7P`;VQJ/-+VO\9$983T``:+XJ4]CE$)XTW\9WCEBU&K0
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M=RDW;MW/7X*K(*O)UQR375?EH9(`VJ6$`GF+9RV4`U9>U$>4=PT471G"E1FZ
M[MFNJ+D<V])/M3WMMF,T0QVEO$A5T;,@D@V"18`YZQ`6;ZDKHKY0V,>X3E[-
M>/'U=4_&IGEC:A9&)S9F,$?"9.BV`VE6D-"ZQ62(C>^[5ZL5S%56N5.`XWTK
MP5*WS#QL*-D^0QV7:VTM)UD^_4-DQ]R69)U5SSJ]^URM14:NG$&/?5GBH]7"
MF0JP`Y$B**N\8R,-9<)D4HDCV,8<1K8YT^D`F[8J;EUJ#67F@I]"I_*KBJN;
M2FN8B2P-CS1MLZN5%EO#.$QJ&8YRL)M1535$X?9'B7$GK+1/EU\G)\CD4UB?
M&H,&NI9-M4%M'0;>3"C5H>_*857N;N?N<JKPW+%\UFW(?-D@$M+RWM(U2EX=
MI[5M/!GS#Q*QDMS$;H)C4:-$&W1B(WB1D)8MF>3)O1Y.2O/?W9,?^L81QQ!O
M/JZL_P`F=9@9%9L(X+E9M33YK=(;F8_&'-A7LC(QVXG$'=FM)DJ=+EDFW+')
M8S@27V)6O$4CQJ-4;IHUN@4KX)P('#QX)IXZ8Y"8V$CR@BG1QE0\B.XK^F=V
MI6H1R([1>)7IY#<6OJ_JTS&ZPR/(<U:*'"'$JI"$>1"G+`<`3^;M7JSFO`<K
M/',;($D.M#J.?9#I/K#(J0TT^^BX^Z:2LBV4N`+I*78K]B]JKSXJH=@3(K"!
M4BKQ#K9N59%)KIWE4\EG`+;P262QK:0&:3>KSM>XFQC7[FL8B6!+B(4[K3&Y
MN)S-DJ0#J4EA('*E1TZ)&;"/,)%ZB=]/EX2RI+%E+8'NIM[9E.MX3Q-E*I(5
M'&G1CTM_0SX1:X%>)S1-+X<SD^D8O&71<FN9.5GS.HK<=M[`X/+I9:*NQL=!
MX-Q(\@I%/*.:;+(5KF?33';6IMU6)/Q.Y=BQ!/OY#N_D!?!6]_Y$ILAJ'561
MT;P3@$HF%6,5209)WJ0@E=SXRF[F6;[2=D9Z5O5<'HJ"NH:6-6Q([T0CVDD%
ME^)DD>W8U7R-$:FGLT/\U)_2C^QXB-#A'@!FOQ<40;7&-)K'6HVO*,[2)K-D
M$$CQJB;$U1NBIV^Q9PJR%D%H\UE2>,I\:B2Y=E<5C+(!+"M1((S20`DQFKN(
MC'M;RW)MUX`7'_2KULQ&Q2OG-;;9S7W,?'QB4;>K'>6;>3@>),G(7T>O\'M0
M_P!V%E^U=5]ET/\`-2?TH_PQ\$Q>%+KHL^,A[O*2"(R(*`1586+%D-T;OVIH
M]J+U7Z[4T;N=Q4P(=='.^%B4F8DZ6$9I9+%MO$'Y@KW-7IR-A'(W;IL:NB>S
M-O,&]4I%.*<\)#8QD-'!OZ(;Q1@QE\M.Y!6%4`G01[AL5^I7O=JFO'0R'UA@
MU-6NB2&89BD.):26:]Y@K6Q4I*U^G_W!M<O+LX"#J%-T1#%U3OZAR]-B,ZAB
M+]\*_35R^]?9A_NPLOVKJOLNA_FI/Z4?X)?I[A3RPH4$SH^6Y'M(QL9!D<*1
M!`Y-C]$>QS%1%1\AZ*U-!(]RU]2(\F4.OB!B,D2R=625!-V[ROY=Y?M<D[$Y
M<1_U,F?IR#[);2GEQ*N3(N*&F+?V$59L#&HES:QJ^5D$R+R:85:,^[1W<WZ:
MZ_-7T\QI^85>:S9<;U4;FDF!&IQ$8''\E=$P^\*&H:@:L=E`&B#&B[3",TG>
MU0B\+-M[&!5PT>T:R[&7'A1D(_DQBGDD&)'O]R:\^(ME-OJ:'73E:D&?*M(,
M>%,5[%(Q(LHIV@D*\;55-BKJG$6KE6]7&LY[4=!KI$^*&=,:JN:CHL0A6R)#
M5<Q4[C5[."TH[:L)<@'UCU+)\5]F$6T;NJ6`TJRACVF:NJMTT<GR\0_W867[
M5U7V71*JHB)$*JJO)$1),C557W(G`L>].Y#8E/421ER#*5`.1'(UKE18L1#,
M>,@G[51FG>.Y-45HFJ]QG1XX`.DE4\EP1#$Z0=R(BF,K&HI2JB?.75?@C_J9
M,_3D'V;>PJ(E3*(\];`FEO8CK"GK:NQG`A6%K90&->LR'!`;<]NCD1O>5'(U
M6J7I9]Z.VU?-ARG2J7`<?QBIM)9$T?'.XM,(4DD6&KE7:NYJ(OP#/8XM%RV9
M(LQ0Z"#8U#K>KA7,J'-`.XM&MB37Q8%?#*92O8Q2N8JC9S?QA,6<V?E>'Q?2
M3U!QJGL7XQ=R1.]0;6ZC39365YXCY4`MBTA@P^H)G=1$1Z]K;;%+NGLW^IMR
M#T#7"ICZ2P.8$2AA8PVW2-:H"0&N3'C1)J3G.(--^YRZZ\L8IX]7.BY]3>L7
MJ%D.6VKZ.:'3&K$%_P"%L36Q@OC'J[>'(C!C-Z[D>J;4[->&,O<H/DY2^FM@
M\!S5-94K%&F452.$@ZP0F%1[N>KN?V5(N;@S@PX^QOT;.H8I2NV"``::;RD=
M_F1.:Z(BKQ68;7T@Y&-PZ:6+*9\Q2"*WQGC$"**H3;&L,KD9HJ*]_>5-J,UX
M'54D(<&$-SG[&*][R%?\\QS%<\QRNT[7*O)$3L1$^&/^IDS].0?9F5E15MNI
MS;:CG"JS6=?50IJ0;($DD>QD64N#'?!*QFCV=8;UU16KJFG`7N__`)]Q/TZ_
M$9B+DU/FF'W<P:JQOXHVOIHPYRCE]BNUVM]_M0_W867[5U7V/62:S*K&M#97
ME-4.@BK\?D``.:5`&,$DZHDRE*OSN\1S=?=IRX&"78R;4[-^^=+%"`8NY[G-
M1PJ^+#BM0;5VIHQ.2<]5^"W]-12YC+.O&.S)9QXK9$"!+B'&)P'.ZX^J=B2=
MKV=UO>5-^]-$=<-E$ES<A:)YE<-`BC@B$D#"`;$>3<Y7/<YSU7GRY)IS^&/^
MIDS].0?9EAO,*M\_KUEP7/QRC&\M@8C3ITY(VCEPB;(KN\[1_9]KBLR#$O1_
M(O3C'HF,W$&_-E:.'XB9)*!U:^F">9-D-E]US#*U_3<%>;6N:BN]F'^["R_:
MNJ^Q\:_7/&OZ;\%C"PM(\K(W>'`K/&Q0'K8TO=NG:2"C:PK1M7I[E3[I-=-.
M$B-<DFTF*V3<V*\WRY>B]UKG=_PT=7*@T7Y5<O-R\4/\U)_2C^Q'_4R9^G(/
MLVF>6/J)ZUU77)5U\'%<!RU8$29:2$CUE?`J*KR\Z#DV)T1Q._S>KG=O+@%;
MDT_U\J;R5564JEI/4O+A9#C=Y$CJ)DTD?H5L-BVE<,K";%^]H[M[-?9A_NPL
MOVKJOL?&OUSQK^F\+.%&?-LILAE;3Q&,<]"V,AA'"ZNSO=,;1J[:G>>NC4[=
M4G9!D4@LO+,E<V3:O(_<D06O4%"33N*1BKW].ZWDQO=;JO%#_-2?TH_L1_U,
MF?IR#[(\(S&UR###2?*,@Q_.`4\N145UY7V3SURAL([##\PAR(2.*,B#:@B)
MWT5=4@>H.0^K\7U8+2P;*MQHE15T574U3+?HMGR"-I)$D9K"5%CL:[7:K.Q=
M^B:>R:**+:`?5>G5C$,2?53Z^-)>N3U).K6298`@M(NBZ=4"O'NY:Z_8]#!D
MN-(L@7-3?+"C,U<D&#*>JN(1ZM&-3N&J,3FO)>7$S(\G+%?$N)R2\>K1A!_5
MD0#BCU0K&(]V]Z(C-^KTZ>[75_PT/\U)_2C^QYG]9\N29T'Q4*VSB:MBD,V0
MZ,W^K?O758B_+RX_[_8;C.!X%2V\256#D3<JRVT8+'(Q)!I0'5Y*F-_6-@X;
M`M>_8NNCT[FG-2^H%]>TSKJ1!D0G4.'8W"QO&8S)6G4[H$&:P<U_-I'C&_7M
MUY>U#_=A9?M75?8QI4DHP1XXGG.8KD8,01-5Y"$>O)K&,355XAY17^8TS6Y%
M7X:R3)CLD1[2'(D.45B`74CO":.LE=S-5U31.2Z\5U'!4CHM;':`;RJBE(NJ
MO(4FU&MWF*]7+HB)SY?#0_S4G]*/\3(R''HS)L^)8U37PW5T^S?*A&FC'-!'
M%7IN#*?'5>F0F@6N^<O-.!4E76Y;$F%C&E;KG&IU9%8P#4<1CY9M0(7GR35=
M?=[4/]V%E^U=5]C0J'&[NK;4>:DC9@6/,8:7'9%Z3V0M@.HG4:_=U`OVNZB#
MU[N[C#JFL`V/!@Y;C``"3[E)O-[U_CE(Y5<YW:YRZ_"PE;4$N3.*C'1QS(D)
M1CVN53*28]C'(CD1-$Y\^(=+<43ZWR^*Y&S/,:^8*01TA[^FT<4KRC5&D[53
M3E["5Z7Q$$ZO).W>75^Y%;*&!!_>M%3:_M]F9,J;*=1C?:T4.\OZP#I%C0XY
M.M(\6ZMX0QZEZ\2(1=',[[-=4VJFY*C',`]4<L]3\;MJ"^GY8+)[$MXF.R83
MH;ZBPB61($)`OLI,@@GA3_ZGZJK=/9A_NPLOVKJOL6OH<=`<V3964L"J>%J_
MBK&=)LJ4TGS6G&T[=JZZ#YD7DW@=:QWB)\AWB[>;S594][41^Q7=Y(X43:-/
MDYKWG+QC7ZYXU_3?B!_V`?\`2$?V;6XQY\&/*')JXLNQL8WCHE15S["/"L+4
MD'FDQ(03Z[-'<N>UVFBJ%/73TWS6#)BS#FQ3$:#!*F;*D?/98/=CCFSW)$5[
ME=JCD[W/X)%WDEK#IZJ-HA9DTFQF]WS!#:FI#R":=T;$<]WN3BHM+F_C0X=]
M$6?4OZ$V06;!;%9-)-9$BQC2V0P12M<0CF-8/<FY454XKZ63D]:VQM!UA80Q
MN+(`\=TJI3N+.CB+`B^::?B_5(SK:IMUU3@N(1<@A&R$)Y45U>U#Z.F0`LDS
MH(9BA2!(L(0'[B@85QAHB[FIM=I#_=A9?M75?81I"`/*4(WD2/%:Q\@VQ->F
M%I'B8XCO<BN3@M:''LG":-)%%FDE0(@@0"FC!F,\6]+!ZL18IV/Y([D[B1;S
M-"&^\UT+=H^=.<U>D%/>T;=-Q'?Q6(OOT1?'YC*ZMC:RB6,>(H6`=609#1J"
M&]K&M5J\E?L75PT=M7FB_!401561S"U^1T-I))7XY=3XB1(QT.9PYD6$6,9X
MQKS:URKKR[>!S`AFQV$WH@K&!+K9;=CW,7J0YP021ZJWEJWO)S3E[8_[`/\`
MI"/[,N#`AU\^8*WHYX(MM;0J>J*Z%8A-LLC6&V-)A$:FUX-XG%1>Z]%X"CO1
M_P!)\,_$9FMYA]]A\^X8NQOXN.-30PSO#R.QZ[MJ)V_!E5=!H;'(+*WH;REJ
MXM9$!+D1["VH[*OC37]<P/#QA.D;2$:JO:U_8NO&&WJ8'E5FS_!:[],9-..)
M6^95&1/6G2/.DQB2^Y5V?@'C\0A'(P6BN:WFCKSTZ+C=M.FY>/T5)$RR*M>6
MFIF89"QJ/D`+.<DD)(ODSZ4S8K6M>X['IMYKWL8QF5C5S!'BGJOF^;V.8/\`
M!#J;.DN6WQ:Q\&;'.,\BQL5M!B(%HT<!&:O1$T1&`B6.16+9/IK8%<_(LDN\
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MO0V=A'&1TB09*JCB10QGG08VNW#J-S4VHQI2:KNV-XC5\``XT.&%D>,`2:,&
M(:;6M3_M7M5?;K?Y%W^N)\/A&*2RLG+M'6US/$R5?]R39JT/V]>]I[N!S[2`
M&N$9I+Q:YITD*BC*,;&%5$V[BRGH1Z?PIR[/9\3Z?W<3&",])JT$RXM*3S6N
MD,3,+LBUHW$`4`YNKF%T^=L3Y.&2<XS_`!_(:)(TAKZVMQP%;)?*<C?#E\4P
M`G-8)=55->?M0_W867[5U7V$/`:")*JJ0T<4B^R4@BMC&B%^?$CG3:Q[$3NN
M$UV\S^ZNT:/5<H+$CD-+HYL"L@3)97%*(,S&JB;,(C4VA::0>:35R-Y,=M31
M/B*W^1=_KB<>$8I+*R<NT=;7,\3)5_W)-FK0_;U[VGNXUM97U>K7?^VUI$?8
ME8O\63.^:+5/N?X%;QTJZ(,&J?2%^><O\J=^I7\_=KHGNX'_`&`?](1_C(?[
ML++]JZK[!DX+AI"P*.`90Y5DFU[$^C(X9849>XY1J]BM1J*BR')[@HYSH5>,
MQ7QZV&"(P\LW4,X<831(209VFYZHW55Y)QGR-D!527U1TT0K%4G_`.H8\WN<
M^]S3W>Q%)#LA`#*GP8*`?7L,H_$NZ;R]53-5ZHO/31.&LE2$E&3=N.T*1T=J
MY5;]$U[T;M;R[>?P$KJ^>=M\1S/!QJUJR9?41R:L,,:.Z8R,U^=S]Z(NG`73
MKV7!IC(O2AQEVRRB81[7)U58GA1$=K]UN3M3CI5T08-4^D+\\Y?Y4[]2OY^[
M71/=\(_[`/\`I"/\884RI)7`B>G5B*OE/F1)*6L=<GJ7++8*.]Q8;4?W=A='
M?'GG9.@MH&2`5CG]=2^8RH[^B..R.N]Q'*+7Y$1NJ\DXJ*OT[C>15D"+2FS3
M(S@ZS[&5'`BEA-9*ZS>^5Y41&[7$<JN548WF3PX`@ZQ7'-T1,%U3/^>8FQ$W
ME?IS<O->)0"1`3QF`0;X4I&+'EM<U46.9"L*-1E3DNYJIP[PWI]C5;(JY06$
MGQ@5+#Q"DC"E,+'<"L&57($Z?-<G/V*I'/8B^>U+M%<B+M\1VZ?)PBRI+7F)
M]YB1M#S)"JNB((#%UYK[UT;]OCOJ[%JEW8UB[[N2-?NG<D@[D_@>U?E3A65\
M5HWO^^R'ZEDF7WJ4[]7KJO/3DW[7%;_(N_UQ/8'_`&`?](1_C(?[L++]JZKX
MZ'6CK9]W?68U)754(;OI4WJ-KBGV$5J.>U41!L(_EV(G/BQGYG,@8_#A`):4
MM!&BB.0,F.)Z[IIFN<=K30U>W13O5".W;&[=JC/XMTR5D(X5M(=LZ0@,+$:^
M/&$S<]5433+N?_&5>Q-/@>X;4>]&.5C'/Z;7O1.ZU7[7;$<OOT73BS\PAMKP
M3Y*2#F?+(?PBQ*^/"Z31!@J^2\CXONVZ;OM<_P`3CV]E]SX&KD/W=OS>L@>W
M_MX_$L0NW_)XY05O\&O54FWCZ*AJ8.O_`*VS65IV]O@T;KQ72[4],AB2XU6U
M*YDINT<LSMKGOD=XC0N7DGVUX18D?J2M-'3I&A93OEVNT1H6Z>YB-3Y?AK?Y
M%W^N)['F*'I=S8CX31J&=MZ3SL/N7Z;7J:L_@^,A_NPLOVKJOC+"GJK"':WT
M"$>8M3&DLZA%"FB`\1HZ.,BF<UKDU5P]VJIPKLML/J;C3W?W?JWHLZ2'WLD.
M:YZ+U&^\[G(CN:!3B!`CH]PJV&&#&(=ZFD(``F!;O._ON<K6)K\O`O,*HMJ$
M'B'JP=J^L0;5&G4W=.7%61O:WYO>XD2XU=Y#!,"$_J2KI9H7!:PK@-T/-.D/
MI,)V:-UU^UPZ/C-9)NBHJL=,5%B587?^.25$ZBM[=J:;D[%XWY/;O>%W_L]2
MKHD#3[@YO]HE-Y^_14^ZXR(<2&`30SH`A=W<K!^40#[6N?N=]^.YW\*^Q4_V
M_4_TCX6NB073WJ_11M."/M;HO?5QW-:O/W<`@3JYT7PP51#^*C'85RD<NU&A
M>Y[>3O?]@0_W867[5U7Q=@>-`LIH)DIK:NR$]_@8M>9B#&%TA';((X[%5I47
M;JNJ\]W/IU$)J3""0<NS,O6GRN;7.:XZHG3"KVHO38C&<D737GPJJJ(B)JJK
MR1$3M55]R)QT&2EL):KHV)5C6<=R_<ITOH4=]I7HO!@^1!JH`D\8V1:R%\=K
M'1S_`*&,!JK'(]FK>^BIHJ\09MBUU@>0$,SH%>O@@N,-KVHD=-$*Y&+H[?N1
M?DX:,3&#&Q-K!C:C&,:G8C6MT1J<$&TI`.>Q6H8/3ZHE5--X^J,H][?=JU4X
M)+;=7!7',P\D9G5JBDO&$<=O50=8-Z)T1-3NJWL]@/AIE:&-&E19HF'@23&Z
MT9=Z(0K+`3'B<[Y&-73W^_AJ321RR.]O?%"0`5[R[=HRGDO31O;WN:_80*)*
M>[!63LANL2J\L.VO2CL<DH`E-95H6-GNM1M:L8S!F)':$Q!*C'+V\0R>/A=/
M_#*R9U/%`V;_`*TU3MF[?INT3LX_.5?^61_PG'YRK_RR/^$X_.5?^61_PG'Y
MRK_RR/\`A./SE7_ED?\`"<?G*O\`RR/^$X_.5?\`ED?\)Q^<J_\`+(_X3C\Y
M5_Y9'_"<?G*O_+(_X3BQKH\.'.'7E")\D4Y=B]:'&FMUT"YNYHI3=>?;QI7.
MH*8"_P#F[NWB*?3Y60`&Z@GI_P"/5.$?D6;`N>:*L1MM"@5VO;_LL:0FNGR[
MF\=*!88_$9[^C.@,5W\H]"[R+]M57@)["QCVS/$-CLC4LY)LI'2&KJ\@*^8U
M_AD0?>>[N-_S\'/`G`I40Z1"Q;J>D,ZNCB&1'QQ3YCNI$3Q&UI&=QRHJ>[A$
M3):!57DB)<5VJK\B?C'#WK=U*HQKG*C;&&YR[4UT:U#:JO`H(#3(;CB,81K.
M,D&,K`(W?U#&)M"15=W6NT5WNX_/E/\`[SA?AN/SY3_[SA?AN/SY3_[SA?AN
M`QY$HTYYHY)*.J!LL1L&)Z,<A"!-M87GR9\YR=B<1)P[BN$.;%!+&*5-BQY(
MV2!-,UD@!#(\!V(_1S%YM=RX_/E/_O.%^&XDVIK`$\<7H:Q*J1$FSR^(DAC-
MZ$9LAJDV.-N=SY,15]W$QPI#JQ811A(RY?$@N*X@^INC:RGH<34Y*Y/?QL+D
MN/B?V[27-<QVB]G)TA%X_O5CG^_*S_\`)XT^L]-R^2:)4_\`BBZ+P*E'33"1
M39#%H1722HR07^+E,C,L6[D1RPDW[M?DX_.5?^61_P`)PT8I\(A'KHU@Y0'O
M<OR-:UZJJ_$TL*RD8\3!L6SS*,\J3@-8/OY[\A;;.B4TZ"6&V"!E9*M2.*9#
MDZ[$:B,35VT-TF#X&E$S&Y-62G^JM-TW6Q+2)+#9^&\N\&KV0Q/%O^^)NT[%
M7C_II@'_`";CO_#N*QWU%Q.O\MM`6:MK<8QV*EAT!2!>767]5O\`$UANON(+
MEN<QO/EQ_P!-,`_Y-QW_`(=Q:5:8%A]8ME73:]+*KQ7'8MG7K,C$CI.KI7EC
MO#3XG4WB?HNPC47@8O\`#C!"=,;!]0N(8Z\I-C4;O(_RU-Q'::JOR\?]-,`_
MY-QW_AW`J]<%Q*TZ19A/&V^+X],GD25,D2VC+)6L:I&14/TA\NZ)C4]W'_33
M`/\`DW'?^'<6]A]1<3E>;$AD2#+QC'35]9X.&R)LJ8WE:>$9*V=4W-=Y5UX_
MZ:8!_P`FX[_P[@CZ(U'0T$HBR"5-=1LAQ81([8K(H(U;#,"(<<S:1TA^Z.N]
M-=K]Z[.>.4^O\Q#_`-R\1A,K`5JQ[*LL5+6@C`+(;6SP37U\A7@)OK[%H>C(
M9R5X7N1%3MX_NY3_`)"#_1X'$C0H%(YDAAUE5E9"#)>U@R,Z"D8,:])RDU5.
M>JM3@\:3%@WG5D==I[2K@GD!U&,:A80@R.Z/T>J-[$<JK[^%3ZM4'--.5/7M
M7G\BI'147B=&2O!,)+FVTT<JPCQY!8?F<N1+%#C[!@VP*Q#H*./75HF-3=[^
M`S)4]MO'&TC20)M:-0E1XW-:NJR2;7C<J.1=%[.+"S\LCE9.AUL5M88$9U;!
M=7DL7NEP0=%'!E6"3T;(7<J/2./DFBZ_W<I_R$'^CQBLR!75$.OJ;2?*O(?A
M4;YO"D4%M7Q8BM8SID2/:2P2._R3HZISTX">MEP\?CBCH)8L2F:3JEWO<XY"
M-G1=55JHB)MY:<`II`0CEC%!&2\K88(5B584@!NIN-X[:Z8P&P^JNWM>[LUY
M?W<I_P`A!_H\$A08%=3&(\2^.C5P7R&,&1"*P6CP[.IMT5=?FZI[^)3+!L2_
M0ZB<)9U:)KXVQ'H]&.4IM6EW)RY=G']W*?\`(0?Z/%J5U8"<EG9>8L%.!&**
ML:L"#"\OK$:`?0K]T)3;%W+UC$77GHG]W*?\A!_H\$EFF1RP23_%OI#TP)%6
M\"24/Y<:,64HS0E:FQS')HYG+3C_`*:8!_R;CO\`P[C%+/%<5P[&YU#E,"YE
M3*W'ZVKF'KHT6>&1"#)KH(RJIB26.VN5&+LY^[XJVR*/D$L-;1^MF.>F`L-'
M#K'5MA2S8]2.PF2'OA/MUMI1[GJ`*R0C&]+3IN3L^)ECKY`8D\D4[(4J1'68
M"-+<)S8T@\1IXKI00F5'.&A![T33<WMXKXDC)Y!+R[]<C>FI<I\!6#FPJ?SR
M7'))A1/".JPS'18*C%O"1K7%[%Y<9E77E@>X/B'J'DV)0[>6&*&;95M;X&3#
M/-2"")"?+$R?T7O$(;7J+7:BZ_$RQ197@9)8QQQYW2'(\&=XG-%*Z!OH3>'(
MJ.VN[KM-%X]09%;F<W(\:+E>#X;A>;VM73M,R=;6<:HR^SK5@08E?8UM<:0H
MP%<-X>NWN[D1^[U%Q>YMIF0-PW*@UU9=V(8(K"5`L*:OM4C3EK8D&$>1!-)<
MW>T3-6JFJ)\5ZDQS7V2RW5'ILZ]IH.=T5#$G3,A\_=62+['VX]!CP'8Q!"1O
MT!R.*KU[%8FO'^#G^)ESY;Y!]9_K-X#&O/\`Q/D6OEOB/)O+?)O,?QC3PW7Z
M7<ZG\?XE,R+3;KWQD:S<_P`PLVUY;6%'\+"MS4K9B4YK6''[HY#@*5O;KNT7
MXJ7`D];PTZ*>'(\/)DPC]"2)P2]"9"+'F1#;'KM()[",7FUR+SXM*`%+-\LN
M)T2TEA/DN4S2LM84@TN/:U\J==29559)).Y[SQGB(5?OBNT3AM/0P_!PD/)E
MDWR),R3*F3"N/+FS9TTTB;-F23.W/(5[GK\NFGQ,^IL!*>!:0I5=."TI@.+$
MF@?&DB0\8@I`5($BIN8YKV]J*B\3\<%3SRT5E#C0)%5/RC++.$.-#..3$2`&
MRO)2518L@+7C)%Z)6.:FCN7!:V@B$CADRRV$TTF9,L9UA8'8(9I]A86)Y4V9
M**,#$W/>NC6HB:(B)\2\;TW,>US'M^5KDT<G^=%XMGLHB3275.7'IY+JYO;X
MJT1EWDJ(Q;JRGE@P7$[VP*C[VB^Y-/"^13.IXCK^:?6+)//M/!^6^$\_\V\X
M\M\L_%_#=;H=+^+KS^QB((PBJ)ZC*@R->HR)VL(C578]/D7X7U;9T-;,<9LP
ME<DD*SF1'OZ393XF_KMC.)W4>K=NO+_(^24U-/\`*[:UH[.OKK#4C/"3)<0H
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MGU?EU+'N8L;!,5-%:8DD!(QB&,-YHYXA@'"56>]'<91`;FL*'"QWU<N,"Q3*
MLBJ[;+9L^B%M=7PJBGJR)/O+A7O^@;N</HN5NF@TXL[NR6!+KL&]3:2ARZ>;
M&+''ITS"KIC!^8EI)\A\FFLX<J0SNJG/>WY%4GJ'8D=#7%*K+2XSB2QQ?2R&
M4D=@KBP?*W*V9&G3BHH51$1NUR<_\A7K<K?('CSH+VVA(GF*RQ@5[$:^*E0P
MEEXAIMJLZ+5?N]W%^R/;Y=<9:_$#OL2^HP\W'?"P92_2BKTRFLJR+3H__P!.
MUS_M\"BFR#,78%(RF`[&K&>'-O,8%^YAEJQX4R32-L'@8Q#(/PP#!W*7<JOW
M<>IPRV]P2L*7%0>H)[P>:)>1;H<RU'1S'):U8[MU\>S62\J#81=R?2,:+N\9
M$N*VF1VV;"Q5190/,VY4&SE53902-DW3LMJX#62":A'SVHD;;HS9SXLO(;*#
M86$G);"5D#8`[-@*V01HFUM8`EO"@S),:/5,$Y";7,4KR(CG*B\6QLFN\X@Y
M4E'7^?1,4%GCH[J)K2^%6S=B]1,C^$(/=NW$3[>B\81'KYY:W$WY-7I@,[#V
M7S[T.7(LQ8SH#*^%/NUN7.0R%\2%SMZ]_O[./7%N(S;"Q,6'-%F+\S^M`)4;
M(5K5CBE6"WU<"W=,&14.YHV/>XR;6Z*K4XPR-C%B&VK15Q$+8@#*`.5;K,DN
MO'M#.C0YK&)<*9&=4;7=-&^[3X[_V@`(`0$#`3\A^`@^R^0@^>E>N_\`S`T;
MMZ6FCA6^1-)?,I]1A!^,H$=Y%]-#B2-%)BU#?C1@@%@`HM:VBGN[^(-<N-[,
MQM>H1+RP=1D#IUCQ07I&&8<U(A4;%-.7FG!WC:&H#=@RBGC-4*6.F32D.KY<
MLH>WD=9T^0RXM@49Z/A3O^&G"#M7U^BX,B"PRA=S(:%&0@.=+*KH*[7YDS#=
M3S6#R#X:'R#;TJ"LR5_YJKC\XNH&^%#H1RTY,$1U&>2AE>U->IO)ET]/R%3]
M>?4!EX`CS:4(O$U#"P?F4I^8EZJJ3L)[ORY0[3^4G7C)$G"0BT8/:,#M$UMP
MZ]Z["("XJF&ZD\KI(`:.&AR>Z&5UD;%!@T&#%5'A-KFN,&>[AVQ4D*[D$E\!
MLW@0_I/5XC@<1*_<*U]YV,R!!.#P;!N@K,34B9A3$@,R7'Q]`8P,4(B!34$=
M<"0YG,KB!O`3.NR=J@H1W9=W`/1%:`HN$4Z'@-A!@HU;$%$79O$1ME(@<.$5
M3%DPPQE)?<X#:XVY,]M8E?$E\O;P:.\B,'X-%(\D],]#QH@-^-31BYAI_@/2
M>8[U(5Y.T!N!"X:&/6L%6VF@@8H"%1G'/.-95,6Y'M:FSG:HMYAT7_;X3UF6
MCL&XH530=UHH7D%=BZ-7MI).F7T:QH"M-Y2V8/#L3-XJQ)VXNS.`<'TW.B4K
M!(!Z]W$%=:WA#F&%EYV?7A188>$O<DNHR+(=$73V^]]$-E.R%:A;S*EIW[T0
MO$53'M'!1\30`_X!%7@=5=!D"9$BKHD:6'8%"`*`T],`E/;5"IAM.A:6[*FO
M,-,<#$"0N*YC1><X];9?;!+E/X16QF*HP:5&AMPPLI2,.$8`[13(=6E/-!\X
M/$Z=$QYF3ION&Y3_`#KUCX!8^`7"<R=VQ(AHT&+]2IF<;^.IV)Z"@?#5>ZY2
M8DED@5M$75>!3X58[=OLDASR5V!(FCA!TMDU=&S>F0N@EMPX/]9:AJM.>;$Y
MVOUB<=><XF9"L40324G@Q'X(D7/8&9LO58WFXO/>'3]7`FZY%CU*'I%4<2UY
MCTI12CWMYZC8JQA4OOQ,\VQQ\71?X&GPV(GAJN+XZ$(20FV0K(G-\56>2H,X
M&]><;](@L39HL+QBP6W36VBN*NB#@HP-4X0D#31PF;MC)50-=@'G;U+5TZ4D
M4OAEM8Z?2T)\(SPDD(*J>14TA[&N[_.V5FFN3EDHG\,\X=`U%3#L=JV1#_I^
MU+C,S@/@J@-1@K<]-M`&+AA+8+3VZ>)O`5@F?+`:$B:AO*4O,U.K;;=.N*%#
M@8J`9O\`/LI-Q(ZQI8'0Z]OVS)@\!@H9N=ETX+'C\BNCYB;P+#PQ":8Z1!#$
MX$MZ;`;D<;K\#:[-,)!F,(L?QM"L0\=!?U(AR@B#EH?SC+WQ/,7,HN:W"%`[
M)AR!"Z2IDSN/-:"1!-3Y+`S>;U*8K*=$6#[">Q@QP8`P",C3[A*6%\R_UGR3
M52&3X\#B>(+:*4))E>^QHIB0S$YK,1!/$8603U8K_93AP,ITD/,3!:"GK*G8
M-2HCYFJ/FB;$80^Z+@O;TU4'&JEJK-=B"E'0UGN[ZV4LQ<P@:,=D-*:!85E1
MIAPH,;MI!@MZY,)7SJ4;GQ]`E0WQ*JVN)H&1'2XUMK9E&HUJ>2H;(1H<%3!5
M/+8JY0XV8B5FZ4Y3V>1I3,>G(+?Y>0U9C#_XW4MP-1GP=#Q8OVV]?1:,+!@S
MI&:/\1J`43A\HC4H'(>X"TSP<MJ7U1@L]Q3LWX*5LWD:E5FT6L@!X8X$U?(P
M;*/FFG4EQ@O.'\;*5YMA`4)RS+E!/2L(DWC*KF$,[,^&)$"!4D;PGX]N1^0'
M9Z/<T?<;Y,4U8UM0SEOCE3/$*J!H(8YFN8&*%$B6@/%="8^U773,$[WX%Q"P
M'+,_9Q;6W,^Q(Z`NL&:N=LP83P)@(T3(`SV]2HY!UHOM<W'O%DC?ZGA%F4`#
MX#@F9N:;X>3O<-F%%H>_P&O($%<Z.;0383Y4KS`\Y(K5I6Y*5\=I$X`#9&/R
M0-:C&-%9A\`6I*PJX8'UEFCZ>SRC55UN@$2PX@0D;*.)0/6@2.MR=;6_4)AV
MI-J_(AK5T6+2]8"843E<%Y@[S&&'`!@`#S:"@?`+(*^+TIG!=Q)`4\B>\(JO
MQ56ZK:!-SHP)<M!550<:IK!,@1OUI&0JSHX0^::85!RO3NE]6-1<XP@D-`Y<
MX,(!J90U&4A`V_Q`/U\:H&_/H?.1B>*]=^F=`V88V]SI$1@')@B=JC.(]OT[
M@7`EZN9/]22<&-B97H55*8AG*47W1%(EK]1XKS3H>TQT\&O5+$-*%"$F-%`*
M".C6;M:1CAVR.J,'530\Q>"81Y]#<>S!P+T71"U!V[PZ4A:4IS]:-A4K6O=-
M0$-F@*O92;`+A3-%1<OUWG@3G$VDA<%=10'SOD1$%#\%H=-F4SYD,WZQK%_U
MESJLK%5]?CC=.*=#N=C*6%TNQ]G"5T2NN<,#X5:Z"*%4!B>TJ)=5A_\`\G7.
M,FY]7UP-T0O9&P`%<1+B<E(1``0SW:R,#!^&M=$\<A\"[773FYSV,@1]"JG5
MZ?,/0D25!PH';.#TX=P>W15]8MD$5Q;,8O%&..\Z`\S7C:_FM`D<*NC>"`JP
M"[+.J]5\G0/UT>DCPA.C(^EY`%JQ.\UD'JQJXW6F7(ZHT!C1N-"&M-H:.C%Q
MP4E?P*P+("'Q&K3)[VZREV``8##:"Y[(,C:;/K!IAG%G@M.M'$&>_P`(JBF2
M+8M@MOB^BA>-\?"S;X'-G*$""E9;2MC+XQ]57&IO(M;IAH"KKEE?=@%?(1_*
MVV@#8$$X,3<?QNS!9O6GJYC=8O.,:!NJ%$FT'8+="Z"F2,)4OQ=.=ZWS[SZ:
M;-I!BTSUD,1IUN7UWP@66G>AYZAMZ=R*$A"NS@_9E"?6:)A4+TO"29]&Q6=R
MF0#QH`U3<U#77IX17KG*Y7Y2:J3(05F/:V[SI#0UU_%S`*3L:[H,$3O(9I5J
M'F$8AOBA,11:)LE4H8"B*'XG-=J*X[:@OF(9>$^X<W&'TH1OX'\5).D9`V"!
M(RO$DP1G=S!!K@?C]-)2%(#]MC3%U^D[KN<#P$8FVWC,-[:!?1TY2VE5RS0*
MF@5R`O\`FQ?9@#1Q#S*40JCZA"0[ZW6(`R=*C@C8^SY`(C$TYRG1KQSY3R$Q
MUJ(K$H/!KJ#AF0$HM3->H@V(AVB;-M@BE<V(TY+A$9$68D9;+6)RL*E0JJK\
M*K8>B;\(%T.-AX>#U%T'Z<"6*CR=%0=4(\'$OU6$`NA#%]F,#/4#00XC!H#K
M</Y4ZQ_J2,:=!9O1^!5L/1-^$"Z'&P\_X)PLFGL*)IN:D^`&/==UH57`]=S&
MU%W/`!E8P,WE"'*Q3^VZO1P!`>AL5`A(V7.6Q\DNMD->#P$G2]<8WT3H`LP<
MFE\&3VNA<4(B1OPC`(2!FD4$77TF.:D^`&/==UH57`^/S?655Y/!,+RR?'DO
MV\4E`ZZ+\D<!5<PA)PA>Q,X]CM0OT+C8EMQ6^/*[2I.&[$S3=UFSF.:FDIY`
M&MAX-FD0]^,"Z!UR)2-0]M8]_P`C<<+CV2:!,N2`$3-[`:H/`]?5YC0-W*:&
M2SR[LPPSN`5X8.4R$./D-#%"2RD1X@/"HGW`+IW0=1N..C^D`0@73JG.#U]7
MW-'(P$LX>\[M;S;GNYJ]OQM[J4]LOMCC_!24A)!-&>2?F/>'/0(%0Z7`&SOS
MU5#KLAJ)J"4X=,+"RS<XO6>WIQI.B<J#:3$D!F<F<!-9#`;T>+6!914R-%'=
M"Z36(.\C-H]!QP1T7>CM8?)+R#M7>IP5D!65_P`D'6>5\GD4Y<3J!0-(R=E2
MGK#,4FUJ^>@$%GY>0P@(KO.2>P(JQEZ)KU8T_P`[KQ`%!D)@.`7N\]4WW#62
MPB9RP`J&@<N>\)BVTL+K:/SE#M<A>5%$8WAB4K7,FLOE%%J,!^_@-#A>P3-L
M?7@AS67:N1P?WJM;`G>_E;OR>[*@B\WF<"VVKX,3S"^XB7L=<>B&^,#^B&'*
M!TX9R=(B=7L[6'PRY<N7+ERY<N7ML6*"46$AFQ<"\.>+U>T"*WKS@U,8Z;A0
M2T%$Z=M.4`2OA^XE,$.X+T7*!NJ5,*O&TI)`'HSEN*F@0D,`+5<++%,$="PT
M&UQ@'!VL"P;35H\G'CQI*4#8/(U9YA@BR0#[Q$*$5L\.+:0#3Z%ONEEQMTH(
M3>HT$TR(8!$G(U1\-*142.Q#-(#W-.$%M9BN@`K[+?`O_0D1P16#X(-,KC%W
MJ/5G!$-%:*#LI=4/"2P]!YE,-W/,''@ED&\6ZR5'3P+,_:5X<`BD57PES8.D
M;K<HX\"I:;@X3YJ?0;[KQX2QG5>M(-Q<A!GP2*8*AB]4&1^7`21EB3E^80K8
MQC6*4VAJ3'/L#&`K3P+):R3D)XV2&6H"/LS(B8]"^;WB-L!ZDP[/&,I>M2"C
MKC@*L6S#23$O@1B%I'D8?X&L8:.!9`$X4=QG+FW'[L(G,'(,)JCX&-MAOBJ(
M3/.*&'\#$N0;5(AOKX,663K=E8)*EI9\!B0_9*XF*K&Q0SPE\ST?LW35514^
M$?>'$M'YC'%CX1]B/;\($A.-H`1ZA\&099[8(*C!?];SN\``?!0*;3BKWOV#
MD7(`AGWP[N\^+T!^V8F^V\^(^%=RZ!`Q#X8*VO@_'V93,S`R"U\:W!B0?!_$
MN$2^H1W-@OHQL>R-@O(0%]!ANYU=6V&@'P"]5EW1GN?&,$O<Z(N>/EBRB-`R
M[]91#&/&?`+&F%CS9&09[(28C4>992YOIPM/^,IZ:IF,)*BB0-@GC.@I.ZQ&
MX1ZF_)])^!C/Z1+0-:!BD@Q3GVVIR^P\<@_D37M`E>4B5*,)F/\`W$(Y:UZN
M+%^;L^$P0:#[/+-E&+C60R!PBP&"3)D$"0A)+%J``,*Q6$W1);J$VF9-N@(<
M^9$@`C?R(GO1L(07:%B+C&0UM6+VG+HN>Z?E7IK?K)R\"![T>1/!K"IM#YOY
M\,0@M(?*LUL2AX"60`C@B0D\H34",%C9G0TWD[U>:'2Q"S4A\+N+/$R!J;2`
MA.^N)L?B_P#_V@`(`0(#`3\A_P#04OK1ZAW'4D_Q\5JC]@->^\")B7J"[W[F
MOT3")6HXCH<^/O@(*P5XKU?5O#[OC1=M]4[2?GZUX?=\6<>XR_*<SGC!KL\O
MFWU9/WN&5@)H-^SZQX?=\6FB?#>3M4N#O@?<V<D[IV_.6BO1#]!OK'A]WQ:7
MV-J/M1RY6?DJ]CLG3/>$J'ZAZQX?=\6Z8=U:]I7C<XR8\3GUCJY>Z3=S>7I/
MU8F>_I_N+WR?C`4X:-G/6KY'A]WQI:O[`IR234X]3]![ODWF#3RON=W)TZ?)
M_H/=\05BNG[!_GJ\<5PF:JT5T_J_CY/]![OA8%4['<?QW6NIP$P(KRS'A]WR
M>T^IRX<?HC3[%_;^`JBI!58<O=\'A]WR:4+#^K[&/DJ;<[L"/7CN[XF#A']5
M>7Q>'W?(X[-;P'!2K^^!.](#^P/V\(]'H*@\<\[V?O<D*Y72!8?_`'R/#[OD
M=]%[^#YV@X"'W?M^N2#J.\_\.GZ]<^@]WR/#[OD=]%[YM`J/=?7YXQ#7;]OT
MY_0T>'T'N^1X?=\CEJDS.Y_?3&!V,#0^M7>KU\?H/=\BW1<L<6SY$<J!*O8R
M,'L)0+P-1+QEQXS?\_GQ^@]WY-P`4AJ3V?N/6=+A-P\_7QHVMQ3\MYWJ>I=^
MV_)I-CK?HQQ[_(1-5M'3N_??XYZ80.UOO?\`!T_ZY]%[_`?7!4Y8.#E^V,"8
M*$H'?V(XJW\!^Q_WVSE5()*<']SIQX;:3(4&NR'`1`>XOT`^=]>$KM0OM@`$
M@"\<.'7?[D;YB#;<<+O?VY@RO47YFS3^KY/W87KKF)B_8WE7T@<K,"_YKUA@
ML`H'G_=?Y>.P(X/?[S7Y;]G"S6^R(`]-NOR:X]=#0"]%.P_URNM%P0%4%Z+O
M:JOXU\#]U_EFP(X/?[S7Y;]G.70Z]9^U^/LX]Q->5]UM_CMCZT).E\_K?7[B
MGQ9BKO7=Q.PWY$K`>!%1;R^TPX;J<C\5\!RV)]O8'`G??4&9QX9YX+UFKOO>
MI)GN)KRONMO\=O%]6$DQ@)RY&I,HR*Q:#C=]_OSP97D*UG?O@1F5MQ[&CS]L
MA*H-4VD"Z'">0XJ7(+27_20_EA[YU-7H;'W?\/<R1"<K?WEO\<>V?NO\O(^J
M"&+G^C_@N%HJ(L3N\[+U;Z$F$=07VUH_?GP8:;.BROWW/O,B38#X<E&OMY]M
M_P`_!]']YU>^CS?#8_&)VZG,O*OY<JJ]>S]?\(]_']U_EY--D<=!'Y->HOZ)
ME[=+QS^F+;^J`]\.%U"[8:YQ%;<L$$]QMVWA<W>@(BG5IV9^V.O$7\X^?MJ]
M'.7%=[[7T/?"6R'6'6.^1^[YT"ZJ\$'O<)K[1G?94Y]7[#^@72]G7_[D7NFU
MM?GM[$,4"O&5:[=3]/Y.?N7]!W1*<M+AXMM/`'[F:=A[87$#@-!^,=`1T*>Y
M1+]QQ3$0Z6#:%X!I./)%5$)Y.T(E]C[]<)!UJM^`4X]_7%"=MSG/V.>^.`V_
MY1*/Y&?M1_6SFF?9+YOW;7\YU$DZ0-@+TS5:#-<Z&+G'/*X4_3*:*9D.J^GG
M*$(M'2*NC:<"/3/JG^\^J?[SZI_O('1SGZ"+KD?1SC#*J'&,TW9V>N?5/]X$
M%`L8ILU[:[L,OED<#:1&AQU-FL#K3ZNN?Y;_`+X;!FQ"Z<B1.IZJ+7IS+0`L
M&N784-1=&\_SN?Y7/\KEEA2Z8=!E-\S?3A<9\W"H>UE3[\8N3Z/[8SU.G1W]
MNOVP^/?93?SJ/8]N,_RN?Y7/\KD$H(6O=?M:FOSD=S&7W)N>^\_RN.%B:BA[
M<2]\EL(25[MUTZUT_.?Y7/\`*Y_E<?6%0``='@KUD6[?_P!;_]H`"`$#`P$_
M(?\`T'6&\LU>UXOK;@AB;=(];!K\L6M^(0M"=0VNH;OV:FYS!IML3=(E240V
MT"R,V@%(E&$K`Q]S!VG6G4$+UY^4_H0=1TY;^'RK]KQ:<'#[XL/Q!PZ/=<E-
M?8C^ORG]/$^&\G:I<&?&^YLY)',[/LY<&=1?H-^4_IO8VL^U&9=K/R%>QV3I
MGN8U#]0ORG]$V'_U(9@OZ7:;/=]G?)NF="_5`].A!U,V1R@TO!;,4:A48-(C
M4YIZ+][LKR+WLM]_4_M'D=1Q(`""33ANVZ6CY-^T>+91?`&T=R\TTKP+JH\#
MJ!Y0=DMC\G_:/!()6P6#E3A`HH$8,T2AN)8.W[O+M^4?B[`LE7*L5J=0`TUT
M`!E**?0'W7\!#Y1^&=>[8"]"!^70"H92PL([X%AH37;R&,05@!P("[`VJV5^
M2_C-K?S/6,%.MWD:W23`&(J[:]NH:\`8U',()=>M:%V$(XA#3*I!``:VJW7R
MC].[))NKTWBEQ'\@(Q1O2]Q#6D6=@:,_:/E#^G>X"Y"L-FJ4*Z-=T0Y\@'L=
MVN_J+I\'[1\G?P]7MZ@T"PHK1L+;*.P/35R80O"Y)-O#]H\CO<E3<$7[Q.V^
M,=M^0FS&94(!U5T&6F2GF^F,/01H&,GR6S["BL`%5UMOC^T?)EB"K:8-\PZH
M9N:1O>6Z3L$#@`'B#1V6[3@J:K76LV3V9J$J#8<#=_?R&R,G\\WGV^0@0"%R
M:3DLXYU!=0$E]F.K-=9[Z?!$YR^W^?K@)`:DMU00.J#]L=54@@Q%ZHFUTRFO
M0>A?R+[H."H^6N86LU6](142(N.Z'D`.2I>`$WQO(%QVE0=I\[FC1V><Y?;_
M`#]?S3E>`A]:.76<RTSS,<RGO:/YD5-\G\&"Q9;LOUW?IY"K3Q_GZZ6FY=$5
M'H5PX,41,A9)RA8@?H;GMA?^'`:->?Z+V/'0[K_MG?\`CWQU(VN<BZ^VA^.?
M7%IK4<!MH]>`^8%!DH!^[4>.PW0GG^B]C-#NO^V=_P"/?.)-Z>O\OY_#E#>P
MZ'V.,.7V_P`_6[$^D/(/*+$51"FL11G.D$0N#<#;W5WBB(MVUOWV\B/Z7K>4
MDQ-["M_?7@?A/8G<7E/;[,P\Y:X##IU'XG?*&]AT/L<>)R^W^?JWJF8XK3U!
MIW6"KFM"Q;=K302T($@.(PV(.*<#H&C#AI11QTB$'(B.4[YS3$,Q3J/D0H&?
MU9,1/.@?=^G+TP_K?7[/MFX,<'`^Q].?1>QY#E]O\_50%T:=%%>`BNYY.L&#
MP`BTP-V@2V%3#)]I09#D.P.57P"`I7W_`&Q]B0$&S5>(]W'OGUKGVN=$/S_C
M/"=$[AN>0]N+_6-279U_]?F^/T7L>0WT.:\Y.W'J&H\O1^&X(8$RF:3AQ?<%
M#AZ,32L70!H[<H=!5F0?LK5'4XIZDP*D%LB+79AMLGO@?J:C\./OTZF<(G^)
M./IK%X"7W9_P!Y/J7;Q@`AS%_C'V#Z$U[^K6O9$4*$UN*+.0T+./N3`)UPI?
M:FFL!6'.?<1B?WW^V.HG@/UER==9LIBCG&<]/:3$3JNKA&@`\-C]XC^^&3%!
M&U*ZJZKS?)1BI")V"V_EQ)0/>%_4/X>ND4.4`.&RC5%]\_;.?];$^V<U^MZ?
MUGW-]^UO6*B?M^D-XX$[6#%UJ_?O<OHID3+]3]\''U$)JZ5_&?3/]Y],_P!Y
M],_WBPHNL_5'6"`P#LG?<N?3/]YTJD*>9HN?;3$/YQT$WZ^OAV^NO[PF-2!'
MH7^_3\PO+G1=*=="@[&?XG/\3G^)PFCA@Z75AK_F7X]58U)8ZUQ]\6)AFHR-
M,ZP2,;31I]TG.?XG/\3G^)R=%&S6\K^+C`B*&1IU2NWKOG/\3B]\341&ZXY_
MC(BR)*]T:\Y_B<_Q.?XG"EF%$1I['3_];__:``P#`0`"$0,1```0````@```
M`````````````````$`````````````````````@(``````````````P````
M$,-$````````````X```@$`0`$`D`DD`$````'````@$]$@@D`@``$D@```X
M`$```AY$@$DD$D$D@```'`$$``$RP`$@D``D`D````X`$@``C#@$D$```D`@
M`O`'``@``$$`$DDDDDD$$``X`X`````@````````````'`:``@``$```````
M``````X6X`$@$`@````````````'0'``@$@@`````````````I`X`$```@``
M````````"8'`'``D``$```````````X%X`X``@``@``````````'`'`'````
M`$```````````3`X`^`$```@``````````T@'````D``$``````````$H`@`
MJ`$@``@``````````/```#``@`DD`````````:P#```8`$`D``````````'H
M``?`#``@``$`````````:```8"H`$@``@````````E```#0S`````$``````
M``<``^'V`8`````@``````"C2`%L+`#`````$``````%M"0PC`8`Z`````@`
M````NDQ'`#`K```````$`````I/%1X`\````````$@````#CN*SVQV(?````
M```DDDDD;@'_`-!`QR(-(`````````!`````)````!(```!`````)````!(`
M```(```````````````````````````````!))`)`````````````````()`
M````````!__:``@!`0,!/Q#X#4QZR,OG4@4*5_\`+^_8H$GK:!LINH`M\Q5S
M;T<80]8:].IP^*:^F"@`/2"L:4G`!>D-HIVJ_$][/R=%ZD,IK7."'U=&D([`
M8<N*$!5'0OR'-5,WUWKH)!9TA_#;F]HN3N0#5PAPRRM6\BDP0D\$V-2B<]G,
M/?)`^%N[#5]>\DH!*B]&3<YH">;.^;>$TN6K"LH`Q!!,+RE`\Z+;.:S\7B""
M$24EG0`U[AIX'\6<J;)#L"%`*>,*G*/3"F0$8`.OU-UX1#[JE96"3;:'*$<(
MDF^T1"RI-XYR2:$.Y.B-0&(O*-D!#E=K7<X7DSQIF(SS%9`]=B@.@9CL6(8&
MS&:'-FX[E-Z8A5T\(,G38QI5W!@+&'PC'!G3>3/_`./29B`\%L#<'YT8&J-%
M8Q"494COF-!S$+T`<<A).^(OLNE:DY!"407<,4H'5(`BFD("K>EN`.6@=R,=
M'?F'X`3P]\2)65+D^2"+'-)4:B3%BM+@!LYB_)?:T*$#0@^.L?UB[XMSP$5*
M=4(OF7^OYJ0[>TQD64C>USS"<IH-=R<-5=@.,?+``$37A`W[/DZ[&&)T,?)=
MP7*LIKK^O(2W2E)S!BUU],^TRXP/"55X7IF*@G*'@&AQK@B"9034#`\KS>$!
ML&EL=\A_Y51@0%%OPZ)!F`(8*!>!`Q@8T7<>MU.JFL8Q-P:JQ]#%_#\0P/R'
M&3M2(HF3GK`Q[1GW_1!AY"ODI"DM@!`^')0>"W&M`$`"K,6LPK7C.E";M'9\
MO;72-P-G`D4`-\]9A&U0^;V`(XNBG$62M"+KW'4X<+A[4V>79-2.$^E`-@%Q
M'\N*KF$"%8BES0>@+A*`3E\#H=^[*-=\Y&M:@Q,"\C$AS`]B/K2.42DX;C_-
M3!:`+0@A\";HQIIZFV_07`B@_1)DC,PJI:NC_!>L&18B\"I(&1:OH%AXG<SJ
M.F4BX:)^J2=$.X#C$:4TW-V)5J;*Y53BY#E`<:@)B)M6!M"@U.$-T:WE_@@1
M``1AS1XA-?CGG7,-31,1+I=B)\8!N9/L:T1R-K)-C3>5,T!(HB#A?%KRU4=T
M+P%BFN0V\[5!E>;W]1I^&![K(C#083<,$5"B&"=M@4+%0&$V.6C@A58D-7')
M*EPW["$!\KP7X=E)9)!>2E@C*"IL(S.3\?!!Y&R$%`8:D2>47*0MG^[?8>HQ
M44*U,;48<,AF)3&4`D`4^UM&[?;,K*NKY<^US@&YA\SB@HUJ?L&<,\#4&3F<
M,4NJP`-)+'7I$H(IJ/H!UVBM5"3;[!;MADBC0@>>X)X;#J1Y`4,WT6Q+PYED
M"1:PP]!%(\*V$4R<7:*TC,WQ9(4$K<VG49O>;V,4$NW)2RN!\Q9UP4VR`\@V
M'"Q#[@H*^!0362LXP"4?0*R8AO#0;*QE`[$22QTT+!DC'$.$D'M+THH!"GA(
M#+&&T'>%KV01AV'D'C;/MGM@:I$MR!USX_M69-D95*U,#(?IE3_$E>HID8#U
MH^4B7J86')7U^1>5AUQFL'B%=XHO;F.0N_VO,Q9^D<S):/C-J$1#=8ZP4K>S
MO,,@5RFQ^(0G",8$<9895Z-D"HA+AB<2C2U"IC4LS^I-*!A/62G%`@Z"ZQ15
M"AZ?F*3H[(G.S^0L)W*6;ZR(9W*)!-@M8YB*-*6?`D@]8\#8=&CSND/[@A^^
MVU&EY@L)\.@5``T$L\&;03YRAMH^IO@:N4[YGI@^8C1''9>W#,I.2XFQ)/<1
MDQX)E=Z:<WKCMU@C".F)]W=G"%7X8B93:[<88K*,PS>\=,JV=X#_`#43^?0E
MQZHLFK0QQG-186!-@`YWP*`K>?(JTG7SYH306(.O&,<LPW)^1.#(/?U0%8G5
MQ(.%N_$ANQ)"8@2+NM[,'B(7G!_*FA=^L&24\$F&P=P>`!>.QB3_`$[L&6)N
M55T&0R+PI?!>Q(8-Y";9#,#>5RSB$X-*#L2UC;IBY[P<ROI\D]^V6WS$@`D1
MR[R"`<N)YIE8U?WY!Q.+OKB8IC@KWT3>K7C*@H5(5`A<00S'%B%^1^_:2#&B
M@(:@!#10([H?9[ET">629(44SU['F:N+'"$7[9OB*OP1Q#LT81'26$#,;YZ-
MN^Q$5*"@#D>Z!J((*:06M38S90;?0%]8]KG+F=6A%40`KDEI/\H+<BDR@/O`
MN%J(OP)0'GDN[`<7Y`4ML/6$'3.]$3J>&GB-XWG940!Y12\1Q@+*3!+6+$"-
M$D"+P0"82BC2<N`,5RN%5B0^E_C2*4-/5`?3X_:9RV(>`Q).M`UPKS-N5U6V
M=!`A;>'X!,E=*LGP11Z2;*R#8D@HKJ[!8)ZWV>?[M0T0S5P9&AHW5M#'W2H\
M$B4;S)=,T$9,(P8-0,:RA8_^#,F@=%2WSW("JTMDCT,/LF/OUX=[O4+`QI&`
MR":BN9&>]!W].A),N^#[DMI,+!J:.2C)QHS7S<&Q+:'-]=]WN\_DY=>X#@F2
M2\;_``RY_&M+9]R9?):-JT0L7BP+1L_%`@X-\TO,P$BOCMAM)0^G)C`1;;$&
M,E'*USM8)474L]YT^VS&3+ZX<E`?N>J[VTP:1I5>KY&KNB-C2AA0%YR?.3)T
M:593I/6#[7P6;U)::BRL,J`A$$+9#UW.)<<OW6JA48*'P_=!KI=GX@UXK85/
MFE!'031P`KZOVN)YI!SZ.&-V9.H,.PVRYZ]4?&_89VP,V"0B@XA`*,1^'I4H
M/D3'EE_S5*@L-;<"@D`R($0ZR,`['EXX-W$KT7AUN7QU`H$LUSZL;]ESB@&"
M`P"HSYEA?E,/`!RF^-H2^L%`$8YN:;SLC(ZTBABAQ\#2+.2RO(U+OL?Z"F,Z
M<V"Q-26,903$95R[H@F^:CK-5`BN=57Z/WV/@H)FVU>#@FX%<S;4CW]!?!`Z
M\:%+8A@$`&QJ+8C,F,?!E,K&5DW&]==FC!(-3P72B>;JPGQ*R[5H]SE(0U6Y
M'%01W-`<`$\1TX*45,A+%(0N=B[IOA`$HJ446=T,]SD>$>!8GS,(VW!`N_)\
MJKKY[;W]'HP-!4B74%3#(?,+=D54,]L:0@364J;X^L/HDK7RG@.H=&!%IXF[
M'H%ZB2*WZ./*[03+.0HYYBX]I`_O6*0%`N]1]JO;9Q?7/3I%+C&01B*;S8.J
MP\BI-^A;<*1D?!#AS>06,"TXCLDF1$O*)!2*UV,>4I.',(H<<"HY*$9&[)69
M#10D;/3^]UX#=R&1O4.-";_:(T[FM0'X/#AS>06,"TXCLDF>Z;_$\3%3D%<7
MET1-#-5+9ACUZZM[%W#H]EE7KO*;@`3I&)'B%(?B*I\'$3E^B#<B>0V`Q+BC
MY62/2I+GK)F@K]++19X+I,7N>H*CPRL<12.1C4DF5!LO+HB:&:J6S#'KX]9O
M[6;/9V6J-1^.1[NT2@*8`"0G#/WBW9GL0$?_`"<KA;\6*0QLJ!.1?)0S%PS1
M<]I!F2:4V%\CC=,>--H:B)SG)+!Z3EQ/#H.LD5W"T3!A!#;)5,1FG./Y;4G7
MB>O#UO8961(N#5B15"XQO;PJ1<-DYB$QA<"<A)U@OAWA!A@^T"<Z4=05'7R?
MG8`2;D6G[`<G4FGH+S#<VGA);;J#9=GF'&QX\LZK2Y8=:CP-P!U--,,OJS5*
MX;T&).KZ4X3!*\P<7%L10=E<PL\Y/8*YN#J;VXOI_9N$O"P;>:`$XG<,!DL]
MZ.Q2&`[$F0@-OT!P`"^FH45!.:$2P"`L8R@97"A#$,`@C)3R&P:&:$AIJ"SJ
MT5`1"+4`8%ID4[^VZR*$\V2_:-:&K1M5N07-U)KNV5(*-E&#ZKV6@O`KXLT6
M#UFY.T*@H!E;C8_\F9QM"*H@!7`R<#9FWQ)$E)J&4H#5Q_W/T3,)$60@*EZ;
M&`!32HZP@OG0(=#!L`@R`;)H>"+61HONH1B3FD"UXC<TT7A+51I!A@7_`*+,
M*9E(X`4'H:VK>XP$B:CC!P&*%;UIC.RS(7X=*E2I4J5*E2I7SG-&L>$GG@("
M!^E;80H3KN1@05*B+<1,D`DJ%P/9^W[ZN[IZN`BN%"F'!GJ.$]0H-1].:+P+
M`P'FHE*N``JXK)2E^@CIJ`-N)ZH\@4;!EL$OD$B1(<9==`HH:`5NL!<B#A:*
MBB40\!(-:]X$/%<!QI"H6]R_]1(#?+<8E#.Q5/F:9'P5JH)2127_`$TB&Q3!
M9TY\@T<Y%`IK*0$T+2BC)@6AU\+EY;/7])']_P!]R,H@6*F;?DQ042#"[A)&
M,]<G%`EK3)8-$=`6B_RWQ4DT`)!9X*%OZ%<QA.7(+9Q0%22:HN,L8\K^)1$8
MYYN4-\KTB$,"6THIG@4#J\X9#T(STS[>`^!8C^UJ)B00BLH<*<=V'+1O1T*5
M/=.%0QS#MEL1+BDO'X5N%;#H"G2$V$93&;!$@U]`(ZSG'"U/#8"YK_:1%^P8
M+C?O-"Z_]JK;H'%E,VB91AS2/!810,-(Y/4NK0D;$O\`J?IQU'"T&6'->C2=
MHW\7/`EA@QE1K%^89)O"HX$$%#`BWGPN^"Y93A<4J;\_A492"?U)\G<@.;FD
M1.-*',G_`-4N_1(<E)-QGX!W$)A6"*N_PQN;RLHJ4%9^-<`$B@[X`2Y'\)@?
MS@>D;"VCEJ$H1$QIRB&P.0',>:R%VX)@MMY'`Q"JZV=7G!BA:RQ`(V%)Z/@E
M%L`"MZ:.[<254"&</7RG!OPLP#!=>$`YR;J4,D.<,5E$8ZS1Z4H_64:(>'^G
MP`6(^B:&:\,7<)0B:\44(H6J]$0.G7Y/S'"N)"Q"$%RDR%MF#Y:T<!R4`E(+
MNT92=AX4=<`-MH`$MQ0*H49D(,)`*T:S=6U;B)8)Q+JLR>'P2;&DQIRLCG';
M7PS)$P.FU23"DJ86GK]IJ`D7U)`^0ER46$@FE2EM1U)UK"/N$IQ+PTK>UG2C
MQ*!<"_-$V\A=OR(Q&;T)?/M@`.7G`,\+K`H`YL@U3X+VY!Q38D`UCZU*-(XD
MK$ZA1<A!+-*3IN/9Q@,LF,8G\9?_V@`(`0(#`3\0_P#0=>-++N=YS/6N$:,'
MJ).DBD:]L"$^(5WL8::#T&IKONZ73M71"S02H@8C!H44@E%52V1"JLMP$Q$!
M`!`Z"UG3CY2V1EDS=5T@FBJ!M4"_*FTP)@.\T*+2+LWB2N,!"5HV2!:I+`,D
M"0.01K1[EX8\A\I;,6<[1+T12RREYR$:%KU2&^"(-KV@Z/E'4"J+0&W6CY2V
MZ]%U*EX2PLEA>,)**[H&FN88!I)$,+%8FM7DC8]2[^4MEQRMULG3?<;%E,&=
M#J=BSN#6Y.AN:^IV`;OH=N(:KL].6:'-#T/`QMG+)<,RW"`B-B)!XCZ)M4#.
MVJ(Z'`)@U)ZG]\\EOWDD4R*!V@(:4A-OR;]\\:RU#$*TFU9P'<"8)>?*4CLF
MH4)(80^3_OGA,`JA0E3@/(H$`B!"\B5L$J_0<&CY0V0AT"R&",Q(#TR([(VM
MBC"RO``IV#;[N_E#974)HJ+`.JOX-J@+@*W;0=L@40CL$5B406%57E"H]U=`
M&@#Y*V>7^`!4*/7:+TFL+FK5"M*#PT0:-UWX&=F9084Q1IH-H0@]((T0D`5N
MU5.]`$W\H;4G^RAM+=@"!R3LLB$82=7VQ=[D#[K:S]\^43:D9!Y18%+-P!8;
M4'-'#F(MGD[*=FC1;'/WSY/-D"B@W3M6!0@VZ62532;[,G(5K.04FZ^'[YY+
M2)66MA#MH/XYPT3Y"FIR&`%5>@&UR"L*!,EBH6FD%&XGJ&'D]5=*E6`;T3Q_
M?/DT9M82*4BMC=)BY@9,P>W6]U:KRJKXG&F$3$>3!W"&]XVNR24I@-&GEUKR
M1@N)`A=-)5YI@0COY`C/2CB0-X`"/&S0V4&WWD;EWT!VV[/D],%3G,Q&'0*"
MO04PR?&*@-U.D#I.N04ZKVAKV!RN@>6"-Q!*1"H!.M*A$T0P!:A;;`<@<@K=
M<ZRS+M!XS9#C5-FS3\F@GW3C@#K];>#>*OT'BH7`0=H\!YFRV58(=#5L-'-N
MHT\X&=$A0X+3L3R"1``X<\///MSZZ^FDML%0ZL,:-$1:'8!I1H%G$.48.`-!
M_P#>5V[^$AH9*5#LV0ZBUV9,#!@,7B&Q#X2Q0/6LCE0(GG4$Z)>4BER;UE%&
M:V$AI1"GP4-#)2H=FR'46NS+\+[)=."QV%$TW>;#DD?U<W;BP\`UZZ#K0%2<
M*/"RB`(L=AP(^':D$*G+K;H[`:PJ'8-F].N_D(512<ZPH=D#I>N#B2P!I4U`
MA#G<O7PI6@IBBA-!)&QH&&*!NAPEBOW3U2S8<DC^KF[<6'@&O703-I%VN@;*
MR]@*P,WB`D;0DMJ0(I4EGGST`5<J<KU7;CD4%PU<P`X*H[F6:Y1%%0>\"E)?
M(>^5B@SKG;WR05]-ZP&7;H2NMLY_$24/L%FY!=)NQSUIYG*V*NX0/`]>A@W$
MH,[W!8>40-%P&\8VLVA.R4$44$/,4!:$@$HE>!7J7@`\#_&U(`:&(+II.8\8
MPFYA.%8".M:-[8?PNV7/$<M3CA[SO9XK[=N.E[;YFWJ5[L<\R7IQ_@'I``)3
M8A%#F0KR8UZ0MWD`$U`(&SOSH4"9!1W!Y;@O'.L+-\^GU7137\@-`E6JDS:R
MO+]@A>>Z0=APF56%H`5;5`N"]HD2I79`8.AXNS@@;F@MH>!-G,!]6J8L]B4<
MP0YK@SN\8_P+>QB/#,T94^M"*<C;5%77G#<GY9%%I0=PA7?8RMDPH*V"-%5)
MIWQ?5'ZT&L2"J`4+.K'9F:0>^*/10,-`R[Q$X$JN@#E7H&4M;!K.QQ/2"WII
MDDGE^Q=`MQ`.0*);$95``,"0F@T#"@S``#@``!V"8_%8;.DX+<D5Y'&H_$R3
M(QRUT;:^39R$E$#D\@BUL5MQ>AMLC4@5=:@&CUILNH`Z"5$&O(\(X&[HKGO%
M70H=+S!`=46A<\)9P!'E*ZU?S=:.Q3[I??"]LJI:*2$%M$N,SSQI*1:9"@HB
ML%""S`02@V1O6WB>^6T%4*4,$TR)A4^.'#A3GTF%$"2080JK!2M^5S).42AH
M1-/AA220G2&P*,`*@%<1EC"HH821"010ON"\0_4\'84I-]C+Y0P!ADJR7$$`
M7TTRS;$3`!JHTH1A'=OIZ9]$_P!9]$_UC9*0Y[-6+"D(+8&I.00$W5T;*=D-
M0%B@DT+^$L^YO+>F-(CH5``=M%-7(5,-<FDWN"/`/(Y]$_UGT3_6?1/]9L>X
M,15*CJ!1"C5A,`"N&K*$\@BU`&'T3_6,:/04:FU(C5"AMH%*`C0$!2]0TA3E
MGT3_`%GT3_6?1/\`6!U)Y>50W<E0J/\`^M__V@`(`0,#`3\0_P#0(A5\UQ7@
MX-RV;];42`M"A0J5M'J<1E*MT`?@(![!#I\0_E(YR=U=;4C`<6<DQNT``U8R
MI@,0;.$&PA",$#%D-M83@**L%E&_E.)<4.>G2):.P!7H7Y5B,%750VD1KEN"
M25UZ`CPY%9($W<2(@;;#2`I[SDU\IQ.EXSP)>B*664O.0L1M>J1WRB#?P!LF
M**(%46@-NM'/RG%UG[K%+U1"R6%XPZXKJH::YA@&DD0<&BXFM7DCAZEW\IQ#
MO=9J9/<%U9=SARY<RA(.M>#F::2YL41NI=-L[%KZ=&K$<<CUK!W`%PZRQC$0
M)$VA>&>BQ`1#WZVO=&]K=WUO3;44C$!J0!`R?*GHL)80TH6Q5P3$T^)CL8DT
MNI\I`="?7-8`'>YX/X:A.OS96J"\JI747Y/B.!``%50`#:KP85%LAPBWCLD&
M6\^NU<"A,`JDQ5"K\HQ"P0IK"2A6V**R`&[]L@T[K$)^)NOMUYTPH4VGR9F)
MU,=40;1:42*K1FZ-^D)`F4$"(,@0@<FP6$JU8&1*.M6KD@531F3Y3Q<]Z8`X
MR!`F`##$8$20.@(:NA"L_*7TQ<G%6_28D`5W2%CG>,>D#5)$@2"T_P`INF(X
MM!X@`0$/`$4,-_/QMBL9VQHQ'SNDUH=,TXH[!#9A4@*\''X^0N#Y(6$JK`"J
M@8*!U8B@_P`EP4BEZ8.@0*5,B`%$K\HZ)'>CGCRI`Z#(3B<.Z0>"`^B(/%$%
M@C,"G*T1$6H,KY:"91S'20Q*/&\G`:D4^Y>'&.WY`"&+7<`0"##$96?"T$F6
MQU$I0DQ\FY?K5H6&#8T5$%:R@.K$*YLT9*$%PP!3=%!>E!5I%'.SD@3*A`-7
MPR%ALB0ZX5OM!@MB)RS0<;18043&('R5^*9_*5CH;=J@5`*+<@%<LE%L5(`6
M^9+LH#:TTJ)*VO$F\GTJ1(EIW`)'W\C9\[P\<_''OZZB6Y>AD.CK&%9AX6Z5
M:C:$$]-UXLJ5BCH'0````#S?MWB2P<JX'>M^U#;2,>ZPME$$+8"W-H8KZW0.
MLB,XILU!8AL<`V$U;6T#P/@#]NPE@Y5P.];]J&VD9^F"S=^2'KL<J9KCWL?:
M8.U"O5?7/R"6M9-6HXZ*%K48IH%*+LH38*NPJB6*TZ$=S2/">22.)1A$'.UK
MWG3'!I(VS1=A-:\:L\$J3;2@9$HCR.I5Q^T:58@[,$]SBJ9KCWL?:8.U"O5?
M7/\`5LV+0^R$(@!@%:=3"(W.M=Z+C[ZT-/>NXZ5&!A#US;E<R`,01'&]]H!(
M3D]"(#'R+X(:#+T_?VQ4CV6^U4FCD+[,Z?U9U[0YC\EL5A]7$?P1@:U=HY7/
MV[UP_)UG=R4!*(<``')C<V"@,"(.%#@IN$(BL@0D3D0\&9*!0H+M**AN4O%,
M+$.>'?"`@WM''`_(V"?>N._T?:_J$C].*Z_7!T,_<?:V?G_61$EE'0-42+QI
M^$>R4J':EKZUH>(:\?V[R`%8E[4.3[R]_?&77'IP1[(BZBQBJE1@AUBDAHH%
MM*6P+AW.:/P$)%V@\K5KPB?)746EW6E6$U-&$K(*P5LDEJ;4"AA?9';BEK@Q
M/`.S;OSWVHG(<VGBB&PH0]DT$/.>K.J%>TU"IWKK6'=[R1!5`.S@WOU=N!B)
MEL?UJ:+Q5+N-Q`!9ZB1@\``5,`Y7(>"5()W>C[B/VRX"WQR#=`F!8T-/"_1&
M;2R5U"BBQU;CXFJBJ]U=K]\,/A>(=-`>L#[XSJQ(!6@6S0;DFO)2"RD:4$!U
M0NYT$C3X<+W0G=D$-;Y]<$U$RO`8$"H078XKI_IE]FL=67VXQ,A8@O\`LCLH
M]^_:;UX?9J/8`QY*P42"DM_DFT.IAH.NM0HI[0JD0\X.$TZ,B12"ZP]6,B!%
M1':QS1Z3R4:-%QP02RLJTCEO3B\8*8H#`""6)=CL=>%&0:*KT:%LM>P+TR&>
M0:.]AWG%QKV41\/)-F$;.,W@@A.3>G,'T](67(YYW$AL```ENGT],^L?ZSZQ
M_K"[UK8`:D$HN]QTN+'9[M"*3B3@*CG$BFDT;^$"?<V8TAA3I-,U8[E+W,"X
M0VN`;L*!!XG#GUC_`%GUC_6?6/\`64+A'V"DMJ`X!RUQB36>Q+(@#LM.K#ZQ
M_K'=>20"-I8!;U$W@3.B#`0;$HUJ)>KGUC_6?6/]9]8_UD[EDPQH'4+X4KR_
$_K?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g644794g63f08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644794g63f08.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```7LP``;NT``(=(``"<?/_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@!+0'L`P$1
M``(1`0,1`?_$`/X``0`"`P$!`0$!```````````'"`4&"00#`@H!`0$!````
M`````````````````1```0,#`@4%``(!!`,!````!@0%!P`"`P$($"`4%A<P
M0#4V&!4W4+`Q$A-@$2$C$0`!!`$"`P,##@D&!PL,`P`#`0($!081$@`A$R(4
M!S$5E1`@0$$R(Y/3U#75%C8W,%$S)+26MG<(84)VUK<X4%)S-"6UAG&18G*2
MTD-38\,78*&QP8*R@Z.S1'2$)J88$@$```````````````````"P$P$!``(!
M!`(!`@0'`0$````!$0`A,1`@0$$P4%%A<6!P\(&0D:&QP='Q@+#_V@`,`P$`
M`A$#$0```>_@``!J1MH`````````````!SH)W``````````(<.@8`!#1SR*R
MG1HH`=;BP8`````````````*OEH````"KIS--U(U+ME029R+"6R!"63K^5?+
M0``&ED5'W)^.+9:.7H+8`````````````*ODC'Q,D2<5A,*3@20"$BMQ()K1
MLYHAL!OI+(/.205?+0````'%LD>7JE9ZP````````````"KY%!YS;"Z9"!I)
M98]X-((&)#(Q,>;^:(6/-X`!5\M```"D1S".LQR,+I2T7LNV?L``%?#O$```
M``````5?)*-E/6;,5A(Q+P'L!K!5<W,RA[37B)"4RT@`*OEH`#P'O!&9B"83
MG$3U+`]EHR>@``<H#J^`````````5?(D)B-D)U(0,06&`-<(!/>:H;H>8UHV
M`LN`"KY:`%$CGZ=AB:0`<X"W,O@*16=4@``<H#J^`````````5?+)'^'Z/:0
MD1:6_`-;(?-P,4>\ULC(E\FP`%7RT`.:124_H'!SC*"G6(K@7-EW6RG9/Q8<
M``Y0'5\`````````J^2;+^3T62:56-H+`@&LE9S;B-#<3XF)/46\`!5\M`#D
MB8DZ,DUD;FH$ZG.(MK+]#4K*MEB2UP`*2%>P`"`#L:2B`````"KY:```````
M````J^6@!YB"2?P`#G`='R')9(LT26E=G2H````%`"SY,``````*OEH``:D>
MHV,Q)ECSFLGM/T9\P!C#XF9,^`5?+0`KV<:S^A@%(2EI?PK@=0S036I<&4RL
MZF`````H`6?)@`````!5\E4'[)(*O$)F--3,T6;*OFSF)-A/*:<>`MN67`*O
MEH`5R.$I_3.#5S4"53G$='P#33DY+V5L````%`"SY,``````*OEH````````
M``"KY:`$`E`CKV``<X#H^`8PH9+FK(&.LH```*`%GR8``````5N/````````
M```;&3Z#E^0.=N`<XBDIU"*XG4,`%4)9@*,6=-@```4`)E):`````````-O/
M@1R;(8TR9L1\S-@UL^!M8``,<59+;@T4U\EDYPG1\`$9RQJ1Q9=T```$;E*`
M`````````7&,:4X)K(D)+*LDR$8FRF.,V?@OZ;\`"M1S'.YH`!S@.CX`-4-!
MEKG9"9UA``````````````*(GV)((!,H;,;H0J;J:22N:Z;.:L7H`*TG&(_H
MS!2DYR'3PKB=0P`?`A^7*65C+QGL`````````````!%9A3<#!$3DKFRFBGL,
M@1@3$1Z2T;4`5@.:AW*!'AB26#G"='P`"#Y<\?JSGL=60`````````````:T
M4B.@0``````!7DY+G>X`\YZ#G`='P`"ODNSDA65*+G@`````````````YUG,
M`_I3```````(!.3)WD!SX.<IUK*Y'4,``AN63;(REJ79T8`````````````!
M4$C$Z&```````%<CAB?TM@^)'Y(QS@.CX`!JA'$LQ6<R3J,`````````````
M#CT=-R3@``````"MY2(ZMF2/.#T'.`Z/@``AN69+*1F1*[FY'2$`````````
M```X.'>,YT&J$H$5&GDL$7%[RP(``!5\X6G5XZ*%)3FL=32N1U#``!!,L[6:
M@8F7]V5`.@(```````````*V%)CK8:*?4QY%Y))@3;3-&Q@``%;#CX?T+`T@
M\YOYS@.CX``(<EF.P`4!,,;N:@1.=9P````````#R'\^!_04<8C>B"B:C7#8
M3TG@-U.J(``!7LY#'?T&-/F98YP'1\``$#2Y4`S]F7/R?0_12`Z$@````%8R
MS@``,&<#CLF3T`:R;,``````<[C92]@*&%#CI<5R.H8``````!R1.MA^@```
M`5?+0```XZG30E8````````%7B"SHJ#7S&&YG.`Z/@``````%'BZYZ@````5
M@+/@``````````````^1CS*G.`Z/@``````%"3!2ZE9IQ-!^"L1VI``*N%B2
M@Y74E,U$L,5_);(X-X(L,$2X=.0```````#GX58+Z%<CJ&``````````<FCK
M*``5?+0%<3<#82+R0S23S'Y,(2">4^Q&A;0```````&#,,;J<X#H^```````
M```0D4?,L;V8,T@M>6@*.GZ-H,,1@3R8$Q)\30R;323)ETP````````#G`='
MP````````````"-B20```````````````#F*9L``````````````````%O"8
MP`````````4L+BGN``!54^A:8`$`D%E\@`"HQE2T@`-`*8%K"8@#52I9*Y8<
M`%8R/"[X`````````.=I?PRP``*!&]%PP`4](3.C1E``<WS&'3,`$''/LON3
M\`1><S2[Q:0`%7R-B](````````````````!\S_3]@&&,R``8TR1AS+G^@``
M````````````````````JJ<P2?#4"=2>"HA7<\Y8(E0IV;H32;Z;Z70`````
M`````````````````!K13`UHQAKQ=HH^:P6E*E%IRNA-1]"$BVQ;<```````
M`````````````````````````````````````__:``@!`0`!!0+G:WYF>[_>
MQQ%\=$0UX4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.O"D
M1UX4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.B./`82)N60$*IP#VM2
ML)6H:<G8N:EYY(K5'$32>1"R6,I$;90%O>0]](]&9<^3!'6$_,\+IEF$I<11
M1+I$&LK5)[GE.C8K<L#1(A.K:%+%(9$P9?+)FIR,Q\2I$"R1\K^ZU(OS/*_#
MS*4-WB:._P"%<(JCQU3VVVV6Q%FZDR:Y%'P=Q]Y#WTC(?`N+)Y"`:2&H:X*:
M=Y*PM#@FDR_NH0(-2L:X2(])!T0:CN*W"P?>HT)R.\Z@S%8H(8A2+&XFB^\M
M3F4)J\(+A%S$2[3%J[3%JN#A#)?4B_,^CMYT_P#<RFDJKXS><&?"JP>[A[Z1
MEVPP9FR_ER"J8MO$.C3Q3V!LSR3ZQ4SKHZ2IL")-P(F!"3M'AP5P+V`!81=Q
M6PH%KL.D%A-CC=&+#F4-D'!S*D&Q]`*L?)(OS/-+XX_/BX6S+RT83%!DBBF+
MHS.)!(#6)L$J-PZ`2#I+5L#2U?;X$ERO`DN5X$ERO`DN5X$ERO`DN43,4H16
M=^SA[Z1J=@]N9U(6!BIK>F=[PT[R5A:'![F+(R+D^37-@X/*_.UM6.7\&548
M21C%'1S/T3*289."<V(VDC&'*U4Z)T:$2D7*4.O)(OS/'$J39K^!(&BYAC>8
M]!R&M--+=-OWRMMUC&^3QJSK8=BNW)9&'-N*^_>SA[Z1KM>@O6XSAV.)!4`\
M:A,;X*>P-F>2<?CQO:&OB[M_\LVV12S?PKC%[$ZJ36-EI.M1Q<))\;Q%[$^Y
M]88%*&XZ2C!!R2+\SP-8O;)%+7L%VML!`""[L(,W)M^^5276VEA#B5)EZ(7W
M/(EO-N*^_>SA[Z1U*:NJ35HI3ZZU:;I\IDSRY@=UG%W<K&=LPR0SY\+V6H6%
MY6&[6W$6,]!\N`MD5G#E2J;QE(C:S+1Q(.21?F>$X+1#^:'D;,0K.$]6KESH
M-9<90/)B$[Q13ME4.*NUW2X\!"1)T>1),P>BE&,XG:WQECCEW%??O9P]](U$
M6V[7M!MK$*-^'+1+'>JS.GC8;3O?%Y1*7%KQ1@XX&IY"'EZ4'D>OY`O0Q.T8
MK2&+NYE"*(L+=H'1IV:_<DB_,\)N<`U.5X9VVY)A`#+%YFS42"`R7X%L81XX
M)M--+=-OWRI)KEQN7<O_`'Y9+9798)0>]S/I4.2?Y:$N28X@5RI=X$ERO`DN
M5X$ERO`DN5X$ERI1CV7(U!`A4H7!?J0]](]K(OS/#-FQ)\3*?1JYX>7;]\K1
M'\DXI-5R)8S9,2.!=!0%6>ENC_HJ/?H/J0]](Y,C^Q8G/(\-.)QK5>AT75ER
MXL&+5_8;;U3LU(5/\HW_`,I2QU:V[+J1#]NFI,-Z9FQT;WI#QD7YGA*PPY&<
M=6L4F/UO"?/X)&"/(OT&5,0G>**=LJAQ5VT\LU[I?VXY4XLBY*BCH:U9IS]+
M='_14>_0?4A[Z0C3$-BSIB'^0RIB#5?3<'NEDG+Q0U;%XZ&2?JG7`<NXF+L6
M3,[<D;'N^,L8B6J6(Z`R,T?))_GF]];0R3LB:0@XO+ES1'A@VZ#T;G+#AB?#
MFQBO&1?F>$NYB5/&C:=BR%HX.3(T/%Q$"AY;GTTTMTV_?*\2#X=\:5N3<#Z6
MZ/\`HJ/?H/J0]](]K(OS/"4L;YDCT6E20$6+EV_?*\5B7&M3/PDE-V^/8+1Q
MZ01BSO;%N,]#='_14>_0?450]%BY3X4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.
MO"D1UX4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.O"D1UX4B.O"D1UX
M4B.FF+(X87'A+$A^.I;C'<BSMF#A.&CFZ%F)R89!0)GP\211ME4.*NWD3YDF
M%.PO&+/@*9:D(2FGT-T?]%`)0,X@7NP6KNP6KNP6KNP6KNP6KNP6KNP6KNP6
MKNP6KNP6KNP6KNP6KNP6KNP6KNP6KNP6KNP6KNP6KNP6I*K2+L%[@@QY,Y^$
MIVYW)QU@;\AF(XG!"3,#G2]>B:D+<X)79#P2.[<N7*'QH2Y>96K2H$MD\0_D
MS<'\8'2M&Y`00\8_]JV_?*\CNTMV)NPIM4+2;&H\Q$_H%PFR'`]^3X2K\GPE
M7Y/A*OR?"5?D^$J_)\)5^3X2K\GPE7Y/A*OR?"5?D^$J_)\)5^3X2K\GPE7Y
M/A*OR?"5?D^$J_)\)5^3X2K\GPE06$#<?,;F&#O68XU/M0\\'I!<V_Q,[9%(
M"`E0B5/D;FN?!(`83E)27`4FTMC*3K6\CB605M]L/$Z1X3Q0:YL(JVK&47Y)
MB9%!)&(]E>42?EV_?*\CY\2TY]5+&:0]DDQ=-:=T337[U3,-C&89)W94*D9E
M%O*2?#,SAJE(IMUM8\4Y-%SC@EIFS-C3,BW5JQ3HU9$PW,+IB:6.96@B6K)1
M<497FF!N0+X>D(P.\W&8GI\'8P=,@V##7"8!%S)[[78:D=$F=Y`QQ1MERN2B
MWDR8[,U@S;;8X,MRG&Y2[+N>,2A.HP*\'O%(0)+:P1N")L3:+C[.XZ`@AIH-
M0X*#RS$!A^%QM&V*QBLC4$QHW./0EYUM"!.S5HB4;9C/.*#BIO31B)IWE"R-
M+8IXE#K*&!Y:1R36$HX$(D+EN%R`PEYL_P!JV_?*\K"H3IW)4GNQ$9(%")A0
MG=D3[K_>/+N@8&G;[,%\LLGKRP..1;'#W&I:38N.3+BQ<-OWRO*1-J9%E?TF
M"Q6B<$SAC;9&P*IP]YN%$3$X%]JX2=)-?7E(6<#:/<\8DD@-O"?W!=D9V;(Q
M$`TE<Y!2Q/MERN2BWE+:S)D2S51;<V/3ZSPUAF;WD^.VC+#FUEJN:X4]>76=
M^((T2Y+G!'PR8\>7&L#Q)QQUM^^5Y71IPNN@[@M2O2E+@683$%>7F:_>;S"#
M5(!!3#H+"'KR\VY'>-&,AW.#S*D6)'!-63+BPVY,N+%PV_?*\S/]BJ0XZ8Y5
M7QO"([&*K3:.#:9QXI(LVYKW)1?Y=W64:D-SB3,$P%.%(BE`BQ1>DF,QRN2.
M?C%V2K"PD21X+2&2B51H]E).*\\T,CP1Q8X8%R=#MOPX<8Y4ZLV%Z$<*@<)V
M9*ND3'$^V6]TRV\R:Y0C*:7,R99:G8/^A&B8>CPBRP&3SA[B6I`2QH";2P-4
MT"E+Q<:=7&X;';W)Z&&YY&QZ+`-J'7!E#T61U$&(F;NU1C5R;%C4KP<\P$#R
M+1D[*+0`8X/0R.$ECB*"SOI6W[Y7F6?;.1WAH+<95D*"`4Z*<\2".".@>"`:
M-"6-&=8U[E?9Y\^%+@=5:W=5+V#`G0I5(/*RMF;D<F]W'N$I#4&0=DA8_H66
M069H6M<O.2AP#Y%<EJ%EE#,2PH/&*4DYY7>5X['(-)^UU$JX*EB1!A4+T*32
MMOWRO,]*K4)%WBFKO%-7>*:FTBPN2G,QMV=2J8FU9G5LC>NS*F9O6Z@Y\^KI
MM]-5D5C<A<SDYM[,@/9'+-QY#&\=L,8B_'.RLZIP]67B0XS&,,G#ZZIN$^+P
MQ,/.;0,--B53(B2)]LM[IEM]=^?&>,YLTUTNT](N_L/F.X.D^5Y`#0D9`67V
M1]#H%)BO!M5A5/FX+FEJ=*S#@\IQUM^^5]>7X^2FKMAM_P"&'TC+_P#(\]]?
M?9CL4+D2/AM^^5]><8D>91TL89+[%"A:6Q4Q,0>:\Q2>,,E*1T('Y,!UKF"S
M.T6\LF6:/%-R+1M024RES&RL>`_55(J@]>B[HG]VO"'HMQ,.5P-I`=B"0SK0
M\\H2#@P-Y[)^JT3)9*2ZLA!)R1*I-)@N;O8[F$K`IBDZ6B3T^)5,B)(GVRWN
MF6WVN\%-G6QOREW]ATQRF'/&-*?A*["W%(V\96&4@]X;+C(4MUQEL99EF<T$
M!PU2G(,XK%<M#5K[I(@'K:\2`/-8U;(`KBO*YE%!19[!<V-KG;E&QW/CK;]\
MK[4]9G9W'Q4-W$HG8I$MP#Z_6CTT*P"-!B<&LGN#=Q"TJ+?_`+(M:0@WXT[9
M!K.@<A2)&T1%$,*LZ-0BVUC25$RQ4S-*A1#K7D?&Z$6=!@9821,^5WA5<UI$
M,6(;Q`JB=<J8[H/&;<WL]OWRONT8LW)7[_`V1O-`4^='NOKH]U]='NOKH]U]
M='NOKH]U]='NOKH]U]='NOKH]U]='NOKH]U]='NOKH]U]='NOKH]U]='NOKH
M]U]='NOKH]U]='NOKH]U]='NOKH]U]='NOKH]U]='NOKH]U]='NOKH]U]='N
MOKH]U]='NOKH]U]='NOKH]U]='NOKH]U]`^,\Q,WM#67<PNYIE.%8FYF63,S
MX0@LB.!00\D@EC^(-)?/#0+@O+Y.7(3^/9"7GVO(4D:`2'[)YN4#P`7XCT/X
MOCRA'67'+RU.'!)NL)7/DDH[>(^:2N67\1;O:'49F3F]H$>)N0\R46EM$=1,
M(E@C@Y):%3<R32'"A&;L:+#G3(N2^*B)UD.*X>(!`AY#D+[U38X.-T8W&`P\
M!P/Q-AWNX/QP(5+FT"%G]`0\DCA;L=*#80D4@.?\'==;9;;=;?;QU<6^U?RY
M5B1/FI>X(&I)_O\`X^6`1I,&&/!!B_/#=+3ZR-^FX24\@\53NHP9HADBZ26`
M65YGV3=MI8YB3G%[V3O\XJ=P!\M9GZ:2?.9R!-Y\10E+CF>Z&+?/I"C%6ER(
M)8C3;T2*BF'_`/'/**]S9QZ)WAG@-CAE[:R?'"3[8./L%/\`_P`H_8WAB915
MJS,TR$FVYY>XHLBB]`>Z0/*#8/HHDSM4I*-NS\HBAPC@_*GYNC$Q'WI"&N<.
M#T%"BH+BC_QG_]H`"`$"``$%`O\`1-/_V@`(`0,``04"_P!$T__:``@!`@(&
M/P(33__:``@!`P(&/P(33__:``@!`0$&/P+U]D.HLX5D^FL9%1:LAG8=U?:1
M%TDP):,5>C*`ONF+S3V<>XO<*QRVM9F7^(O>K"?519,N1W?Q#RB*#JF(Q7OZ
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M0XHM@K8<8LCNXY9`'?%9(<-$>\6PR-UVO:O/C^&3%KJQM3TV6XU?V61HRVLH
M<F\FT6*0I5;'G64.3'L#MZ\PDE6=7WQP$<NNWC)8.29#D#HN">$^87>)3FY!
M:0#DG5F89;7P,L++BS(SK255Q:8$892J0348NO-SM?#B\Q_`I.>WE]CU'*R`
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M08T31;T-N=P3ZOO`:<V'C72ZL27:QYGFCPMP.22%,Z3Y98Y3V4N6+WH8$<X!
M-YAO$N](<V_QY<9/E65T+`]*.!\:NJ:*);55PZV[^K2),FD?'158@GHFB:O3
M7C*#8I>;+B?XJYS,L2U-M4C.6%38<4&.(]T@4EQ8A@0(@Q[7;=ZZ>ZT1OA?8
MU64$GGP[%KZ[O8D"]CE9?&ICX".?760H$L<"?9V5(2S2(QW)TA54:<EXMRV>
M4]P'DU_66]O;&#-S%,4;<XG*OTJ*BCCG-MC1K@H:Q[F-4(5'M7WQZ/2I<6WQ
MRE>ZO\(VV\!(D>;ML<YM+&IRL@93K/\`-V8J$+)3Q+U>DNU"N1FN[&\E9EK+
M"^J/#`C;D-Y7$61-M1972BEX^=#R8A7S6#ZBK):CR%:Q7-Y:KP^':6]7)+CO
MB]@1,=EPXI:ZL973,IL:BQ"&3:#A39<^-BQG]\5&DCMW[AF>PJ,;QX1_O/'^
MP.?>N?4W]>&SKB$85\4ZD0;GBUV*O2>-W+7\?`L?;BT$53'L5MHL:.69'?$L
M71APW2H<L$D<V(]\031NZ9&HYG)4XJ8DW$ZLD:C@^;*P`V%BB#6;VE=7$;%*
M%)E>0K-[@FZ@WO[2HJJO#6,:UC&-1K&-1&M:UJ:-:UJ<D:B<>/4"(YW?:SQ2
MRRXDHFK%'"D6DX`2L)R1SU)`)V6]KE_+QBF%CH+PJ9A8"!2MQVHAK4U:RY8&
M2)-FWO<)\"-U)W7*X8B:-:1ZIKY?9B?TO\2_[2LMX>(N:8F,HWN&09,CIV$&
M1B[7L>QTQ'->UR:*B^3C[<8A^LM-\MX#"@9;C,V9(?TX\2)?54F2<GEV!`&4
M\I'\O(B>ID-.^I*6XJ;;#*VJ@),:QV0"S:0"%7SXSW1_S<$68V8T_)^QL)[M
M>?!ZZ9!C!QB1E=GA=3D'7<+2\H<?;;V;)W4W`Z!YH9D0*HX:M-!<B[M[=*C)
M.XEK1747O\2*8G5+YO.1[JZ2]W3%HLZ!TS[=.QU-NJZ:KZEK=S:(62C@+!Z=
M*;NZ-FR9=C%KXS$?*#("-R&EHNY6KIQ+/(QBMB`&M$R`,&+NN;:S/<X\F0GC
M!H::EF6R2*>.TC92(-_1Z3E?M1.)V.T^,0I2Q*&@R(-NW$?]!SZ_(A2CPW1K
M7S9W)'=&.GNWMZCE>P>YX)#1-*]E$@G29<;J_4NP4;/-Y`@GRS$2@5@*N#(D
M-$:8_;$$75CB(]%1+FOEUU5%G472[]%DX1/CF+U[(5/'\T,+0L7(.\VAQ@%W
M#O/4(1J-UW)K9T)\4I*OO*XRM?8GPV3%=9S[R)-:.+=*>@`RCGB2L0`1SGB*
M56[&IJS3@IXD>EE(.5`B#%&PFP/,GDM>^K6EIH`J!TV\A36ULAPY$,9X[F@>
MN_1J\4F3+B&.P_/$5TGNS*N`9HD0Y1(B$="$YVJ#U]RGEX^S6/\`H:N^3\?9
MK'_0U=\GX`1^*XV]\8R2(SW4=8Y\<Z,>-#@<L741D&5S=S=%T<J>WZGA'^\\
M?[`Y]^"_B23\>6V"?[^4Y5Q@$,3J@-3E&6QZ[)IMHTNV!2B/!#+E@.TX!1N@
M&<\BO?N1.GY-->`R8Q1R(\@0SQSA>T@C!,Q""*(C55KQD8Y%14Y*GLQ/Z7^)
M?]I66\$,_!1HXI'D<@L@RL`D<]RN5!@!>C"$>J\FL:C6IR1-./L-_P#V;,/Z
MP<5U]2X<V):U,H<VOE.O<FEI'E"YB-W>;=2(I'#7FF]CDU]2DS,G6;?X[%E@
MK%ZG^CBO,"6*(2TAHU'3?-KYYG@[;-CBN7RZ:5_A_<RYLAD?NLV7=5[VU]D6
M_;.\[6%S%(K)"136%F4SG)V_>S.;JOEXCPX@F@BQ`"C1@L]P$`!M$$3/^",;
M41/5D4MDITAR2P3$6,1HC;J^?&L0;7N81$3O$1N[ES;KQ8VM9*OJ2SL+^1D;
M9U58C$6NG38$BOL!5K#Q9,<$&>&65Q!.8_0C]S-FC=`V%$LZ`,6,TV*+6-DH
M6N-78^Z6M.8S#C)*=.AMGF;U$*B/0B[T<[GQ2"*V=NHF6P(QW^:YA#Q+JU=<
MS8DD=E5SHNSOKU49!C&<;55$)S76YM1$NPS[F6^>Z4&<`<B!/7)HN7@FPI"0
MN\/E0KZ(T@G272-&>]KN&C6H^7-EW5C*-88O9RI$Z8$Q)<O$UF.KG'TB,:HS
M+.?UF-1K531&;$33@46J/<P%A6%98U,R(6LCV%0>IC6<&,D:8&J8::Q\&X.$
MBS>]O>QWNM4UXKL?J^\>;ZP+@1>]&61(Z;BD+[Z=41Q7;B+S7G^/UOA'^\\?
M[`Y]Z_"I$>DDY7B-7)OR9=BT6^BT#[!9-6P=%8DD3;"JBGC4TMA'N8IT5.HC
MT:Y6\20YK86CTQ;P%OLFQ=Q;B:-\>6'*LKC5V4CD"./O=A#K*N",4AVJ(Q/)
MVU3C#LBKL5D9OE<W',4/84R6L>D.:3/J8AK.6^9+!*&QP3N55;MU77CQ6R^J
MSZW\)K4_B'?P;R@KHBW#V2N^FLR0I5C&N:84OS;(L2!_);7[5<GNM.`8]*O(
M-5+C\HMD?'9%O.85KXYY)X+A7U5&A=X%"V$:]IMS7\M-.,Y\/`^.61TC,-QJ
MFFFR-`2V1Y%?YNI#1X7FQ<E!'K(M<"TVHJ'<W06NB;N2.;_$SESFN1'-<VFF
M*US5YHJ*F9Z*BIQ_>7R_T+-_KGQ_>7R_T+-_KGQ_>7R_T+-_KGQ_>7R_T+-_
MKGQ_>7R_T+-_KGQ_>7R_T+-_KGQX/1[#QHRG,(&79[3U<V#(',K`=T%<4K)(
M3M=>6K989@9RL<U4;R_'K[$3^E_B7_:5EO"QES+%4D(7HJ!<AJ$,AD=L42B[
MWO0J/Y;=-=>!)=WE/3]?=T/.MG"K^ML]UTN]F%U-NO/3A\BEMJRWCC)TB'JY
MT6>$9=$=TWDBE*QI-JZZ+ST]3(:=]24MQ4VV&5M5`28UCL@%FT@$*OGQGNC_
M`)N"+,;,:?D_8V$]VO/B<I(5#YE=FTC"*BTN<A'C,'OM-CA[?()EI;2P38@0
M#M8Y*X#48USI`E15[2<`*Y!M<4(R.01>N)%>Q'*@SHUB&&BKR=HFY.?JS["+
M7'MCQ([S#KXQHD8LE6_S>O./'C"8Q.T]5=JC$7:USM&KX=`6LKX`<_QJDR1D
MFYR(58."VX=`1*F'OK2LN+=C9VHQ(X'7V:)IKP>#YF/91ZFHK,@R28.:",ZJ
MIK>Y/2PCQ(I!O=:R>O"D$>)'"VC#R<KG-:M_7VJAAT.-8WCEQ:VZLEG,.?E-
MY9U%5";&BA,1PM*ISGN1JZ*1OD1'<"*EN4?5E2H/0DT]Y#F@FP3]WE1)L"76
MAG5\D)535AQC=M5'>Y5%X.!*8]J&IQXF69'('-!$6KQX4YL%9$4!1D=:3E<T
MST`BB38%>WN5K5/9'QF4R#)KBW6/2ELX_0GTL;*JW$YEI=.9&>['HL.1<1Y)
M.4K;$<YWNF.9Q0QG525\/(\'/EU>KY'7D(^OO`55@)7L:T)H)`V<,T8J(USV
M$55:GD3UGA'^\\?[`Y]ZQXPR`%(+\HP1AO>/1=O;:URJWG^/U8HLFI(%T.$\
MKXK9H]_2[PUK)#$5%:JAD-8B$8NK'[4U1=$XK$NL5H[!M,!L2L8>O!LAPF;-
MD`0V-:SS>WIM]X5%#R]SPB(B(B)HB)R1$3R(B>TB<>.W[[\T_2&\/<3=(2*X
MGN$1BO4P%3R*YVU&]7_S<>(=I#@P075C4P62RB#%2WE18%Q`5$DF$U)<B/&C
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ML>02LE@4UQK'5QJNJGS2,CL$HGMCN43G.8JIQE!X5H&`#*<>Q&HEM5I^N*9B
M64R[R-."82]CJP;(P>7-KVL=^/A>]1YUO+)8S;:39V=E+6=+L+`K"R)$A83X
M49?R3&-:T36,8Q$1.'R+&QR$SY3;&)9-\Z=BVH[&W6Z7&IZ.CN5:.')<HX[!
M],HXZJ/J;7.U[$O(!+%()]`K+(:_59@KP61I'HF%B$$V,ZVCB(K)22>06-]R
MQJ)73Z^0OFFGQ6UHH,8ZN+/)/R/)DR7(K&6?1@-)DJ*!6L8QK6.WHU&LVIZW
MPC_>>/\`8'/O5F0<F\1<B=7CK(4^-X<TEE%IHX(!-T)UE9C$AIMM'F6$4VTK
MFLZ;O>T7ES/CR'S.BM:B<"!.R>DE9"6#16ANFQ@9=T0$^NB26/D,1Z[%8)SM
M'*FBZ%IK3+K;,FCGF+66-X,7G6)5N!&8"LF3!N5UH0!Q$?WAZ->Y"[=-&IZW
MQV_??FGZ0WB=N5$U%M35=-7*R-HB?C5>"3XTR/"DFKYD>LD&$22P-BL$P(QC
M@:Q4>`,@S7.37FB<5TNY\9L*?4I/@I+8^@J!ME1R21-?&&]N+07.+):NQB-,
M-SG*B(Y/+Z_^'#]Y\'_7.+>Q$_I?XE_VE9;Q_G`/A6?\[C_.`?"C_P"=QHAP
MJJ\D1"LU5?\`?]25A<:DN9,JO#`/8VS"XZ&JA,LXTJ5$W#F7\:]EJYD-R.[M
M"-L7371.?%1!!BUS()?^=9U4:#/QWNJXU!R)V/P[^6^ZN*$S?.?8DMC1ARS(
M%Z:;UY>LFVA(TZ:R$!QEBUL99<X^G)!QP(K$5[E7RN<UC$[3W-:BJGA[(977
MW=_$D,$M+(6"#N\%;&BE9%%!<R.^=`$I\"&3L`=(5'-_Q>UQC-+*A6Q2Y59$
MJH,V+$:^MBS&5UA9M'/F%.%!N-&JS;6C0I.SS:C>?%K2V#X\"#1X]3WMM>S)
MHH\&$Z^MI]350#]1J,&22^L*_<XC=$V\NUKQ&E,S#&>A-><<0K[RM&V22,=T
M60P'4DM4CPR6JQR)Y'<N.[3H5O-Z%4^^N)%8*"0&/T`Y@X+KFU[W80CNB==Z
M]B*R3(5HGNZ>C57B9.)49(L9@12Z<B"HALR>`3*ZW#'V%*61?A`"''NK>/O6
MP=!=T2H5$5G/B#1%J)5:2RQ/ZU0W2IE;)*HPVC*V="?YHE65<]\3OD4G4!+.
M-R2$\FG/UGA'^\\?[`Y]ZM/#2GS^5XE0JU;>CO?#"@=;Y'C=6LH\<,JU3O$0
M$S'Y,X96.BE4C7^^:(Q7;N(__B3E&88_CWB'.9;BETEL^M\+?$:>YXF2@VD0
MT/O&)9#--#1L^$4J#(4;^@1C>DGJ^&5)5Q%R2?8W5[(^H)IYZ>KRF#6TJDF2
M;*W%*C,AICZF&4*.ZF\Q$["HB\6%?D-S=S1X3X$7EW4+.GSJ\]3E43),FCV-
MF!63S+(D8U)K@P8LAQ"IW<#=?=N3C#KVCQIN8YA-QS%),^IE6T2CZIYU3$-:
MRB39[V@801WJNU5U55X\895Q`;56TGQ=R:1:5;9(IC:VQ,@"38#9@%4,IL.2
MYP^HSLOVZIRXK#-5ZNERXI"(Y4T16'$--FC45$T3V]>&29O>5'%?R;&<-KG=
M9S&<^HUW+E_)Q(IZV1*A6%+)\\T$-)<.(MC<UM5/CP:TIYKW,6,5;'FN]B[T
M;VDXP^KR5AQ7L.G".S'*DMER&25>1ZM-(84[2D1KDU[:^N_AP_>?!_USBWL1
M/Z7^)?\`:5EO"NZTWFJK^4![?_ZW'Y>=\(#Y-P,K33%<(C"-U(#35CD<FND=
M%TU3U,VR"C6L3,,FI(E-4V=K%9__`!OI09U4>97S@QI$\120K(CMK=&O>QK7
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M'^P.?>JV5F^-^*M$&!6!@Q?$7`Y!Q5L^K-^>FJ;<\8K>@.).,30;F.>JZNUT
M7B)@<&)99!0CB,K08RW&+&>64SM%U5+)@&'END>^*3J=3K+O1=>?!KJ;B=[A
MXUL#1ZZ!D8V1[697C!%>.T-";JZ"TYRD8T;E<N@MVJM<GJ1HV34D&X%"/WF'
MWL6XD0ZMV.)&.Q6'`Y[.3MKDW)Y>*B',PW'CQ*(*QJF.M;':&'%<3K/BL8QK
M6OBE/VWC?N8]_:5%7GPB(B(B)HB)R1$3R(B>TB<>.W[[\T_2&\5<D8"&[OM*
MK6([GTSM?MW(UVW=IP&+)J-&R"C'[\;<WM/:W=L?$1';57BV9BYXE7;-KY[8
M$ERK&0,Z2%H8IT<&.;:X9=%W;>SQE-5XD09%I$QZLB)CUNR,@OK!*%WOKL#9
MR$`2T*=K6)U%8B(J=I=5YERE*3S!T[B;5=Q\Y>=->Z!B&[QWGN%=IU.]:;=G
M+3RKZW$9%?EQL/GXC92;2%.CU*V9^]E6"^,8#FVU4Z(:&:"CVN17<_Q:<?WE
M\O\`0LW^N?']Y?+_`$+-_KGQ_>7R_P!"S?ZY\?WE\O\`0LW^N?']Y?+_`$+-
M_KGQ>9K_`/Z#R^Z\R^;/]&]SFUW>?.-Q7U/^>?6>=T>CW[J?DG;MNG+75,0F
MS#$DRY>+T$J5(,Y7E/(D540IC%>O-Y"D<JJOMJOX5/Z7^)?]I66^QO"/]YX_
MV!S[U2R)!1@``;S&,9[1B"(;5>0I2/5&#&-B:JJ\D3BSLJ3)L6)%K946!9V0
M)D&/$#*L3=*"`D]ZB`1TZ0FT6CW=5_N=5]=X[?OOS3](;ZE)_E_^_C\'BH_I
MJ9&IO5-VFCVN\FJ:^YXBM':/A!A1U:9_OB->Y7;W$781NB;G<O+QDO@K4W%G
M?76.%^M%C:R*H%=6G#=@K%%'@=.QG%>^%'+'0N]&;GN56\M4;^"SG_9G]L,?
MXP?^B&-?ZFA?A4_I?XE_VE9;ZT=(6ZJ1W)D1P:@EC#99E:K'$11P'&24]%&Q
M7<F^1.`TY;2N';21J:/5DFQF6)Q-1ZN*&$XB22C1!NYHU4Y+ZC*M9L1+(D0D
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M.Y6!)7BZ^^:,STT:HT<CE\G`;*KEBFP9'50,D*JHWJ`Q(YF\T14<(XG,<B\T
M<U4]9X1_O/'^P.?>KEV,4YF@L[:H*"$KR=)A3C(.0V(0OD&*;T>BY5Y(U_/E
MQG&"U?@F7!HF?$P>%)F]4,;&L5%BG0[]8Q21X@@63I)0]4?3(I$7_K7>7U)M
MU8P9%A=16/J,1C1K*T@D-D61$C08(VBKI\))NV0QAE:_=H,3M/*NMSAF2VME
M*9X??P\NR*HD.MYX=F5OEW!+;+8Y$.QY)D:PBL8%[]R!'HS3FNN'7M'C3<QS
M";CF*29]3*MHE'U3SJF(:UE$FSWM`P@CO5=JKJJKQXPRKB`VJMI/B[DTBTJV
MR13&UMB9`$FP&S`*H938<ESA]1G9?MU3EZD9[)*1UCH_1=BN75RL5%14>W;M
MV\?/9_\`Y_RC@YR6QCL&U-PEZVCT5[6Z+N,Y/;XS')YUU0B9E^.5T*AIW6+!
MWTXE?%JDL7AK3-&0X8+:=SB.$I$:TC573GI^"SG_`&9_;#'^,'_HAC7^IH7X
M5/Z7^)?]I66\#?*EB?$1[MXT5NY6[7;4_(-\BZ>WQU.]B[CWS?TM6[NZ=;7I
M_D-=>CR\O"D%+$D'KL=TM6[NAJW<W\@JZJFOM^ID^7'FRHM5*A8X"#""RA-%
MMB0JZUBRUG.DU<N]A+`+*8X?=I,1".]WU&ZIQXGOJ<7K+ZPRZS)>X[E9KIE9
M(K$;C4.IC4\AX30K^(>O/">V*Z(8;=LE54P.:\8M'OK?(1!J[3-YLQ!9;+[R
M>,9U;,PR%9R4NK*=91P2@O:X994G1FHWD>)Z[\>#5WM\^R^I%.'*B3,KDR9T
MG(2W='-R2'6S%MH;XQG0P'8`P9$9J#38TX]^[@+9>0YMUH6%DB1>XY2.#.+D
M!\FN%;WX;;XT:=)A8M.&)"EFN5^QKN\=X8,PPU>28^"\O?-'0F42V/G8<F4A
M_P`WW6.464Y3ECIL,KI$R0YCV:(4BHU[O"#';3`W=SQ&NQ-V23HMGB[[8EGA
MG=@U$"/*+9C4-(Z6!TTKQ*0SQJ@4:Q7D7BMM`54VEF2EIJNUE.L\9FU<2EQ;
M.I-Y`E-ZT`]X*TEQ$[R-(3A:O,,9GMZ.J^(\NI2U98V.$^%R4,VK?*C':RMS
MV^!=U\>>!CG1R*RX$XB)JG2+JJ*F[AB^?I]1'9=W$B'5VN6W%K9PZ0\P9*Z#
M/M@K8K9G&QI'(I)!E&PC1[U1O%N4..Q=EWBUM@\(QK:O<3''MR59,+,.VU'H
M&QKD')Z4;=+"6.-BIKVVMZE(HRTF-6^.NG5$_%GV&53+7-ZS(PY!"'D%?8U3
M#P(]8XFEF%'H>4_9HJ=5?#;S?7^;+ZEB5]7>V(K&DFXR/&QY3;6LZNFP)X)5
MU*O2ULI%ZT)1![X7LN8-G$HSPEC`L<R\0;6MC&&\)`U5IG.03:_WEZ-433QC
M(5J?XI$]9X1_O/'^P.?>KF9\/62F1"I)!*]T+?WYFU6+,)!Z7OO?AP.JH=G;
MZB)MYZ<>(F)^&N19I:9#EL[PY7!>\.NG9%(O(Q!2+\DR:T,<<?9+WL,B.V%:
MNC=S.?JUS[6MA6+JBQ!;U:S(XY'<+2*CTC6$7J([HS(_4781.TW7EQ#DY+CE
M3=2(".9%-/B#,08GO0CXZN7F6*\C451/W#5?:X1$1$1$T1$Y(B)Y$1/:1./'
M;]]^:?I#?63?^(S_`.L/CP4G0X<T\45;?EG3&">^)%=W6U8K"G8-!`[&WDYV
MJJ]/QI^#SG_9G]L,?XP?^B&-?ZFA?A4_I?XE_P!I66^QO"/]YX_V!S[U<L;C
M1;H-_P":B/J7X\FZX[\-XR!;#;N8YRD<W:]$5'*-7:<^*EME_#EE+KWN\.%;
M9$`+@EF&VC!)L#&/3$F+U].H_J&>NOE<OE]=X[?OOS3](;ZPL4JO:,J(CE&J
M(_DY'<E<UR>5OXN%Q:1:75$DFQCG;;4$QL.Q'W5I_P`U5[@%0D60KTWMY=IK
M5]KA+^/G6=7CDAR(BUMU;#/6D[QM]]/'''9U7ATU9SY.Y\>+5<:?DUI1,I(=
MA"EW<B7*C=>\)2VK@QS.:R'MCF-(`':FJ#`K>:M=^!SG_9G]L,?XP?\`HAC7
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MGN$9@T>Q7"(K?]Q?5P>VM%R4^,.Q+(`S:^C%(F!-/-+"V*4\'O`(A2"V^Z=V
MFIY.+N#E8?$"TFVV<7LZF,:L-8MB4-G*#YH@]23/WQ11&Z^\L11B3DWU?"?$
MP1Z>?4WLO,IEC5Y'/FU^.V4NBI8DFL!</@1Y1I<<39$@S(RMV%*-N[DWBUDV
MU)'H*3'_```M[S$,?9)<M?07-?D625<[(:)_83O`Y=0'NIFHCF`5C43FNN'7
M%)C/UPS&3C>)EL*B9;1*1Q)$JIB$M9)9U@]H6E"=556JNKEX\895Q`;56TGQ
M=R:1:5;9(IC:VQ,@"38#9@%4,IL.2YP^HSLOVZIR];9*]VRPZ@U@O:A4(U4(
MO45A!IH-=OXU3B)",0I)KF&5SG[G[D:0JIJ5RJJKTV\4>%S\:JG8/F-O45.,
MW+W$'8&_-:A;^0BBFE0BPY]KTT:0(N2-TUYJOX#.?]F?VPQ_C"Q%R*B$46)X
MX,@R6T!A!D93PVO8]CI".:]KDT5%\G'VEQ_TS7?*./M+C_IFN^4<?:7'_3-=
M\HX^TN/^F:[Y1Q]I<?\`3-=\HX^TN/\`IFN^4<?:7'_3-=\HX^TN/^F:[Y1Q
M]I<?],UWRCC[2X_Z9KOE''VEQ_TS7?*./M+C_IFN^4<?:7'_`$S7?*./M+C_
M`*9KOE''VEQ_TS7?*./M+C_IFN^4<?:7'_3-=\HX^TN/^F:[Y1Q]I<?],UWR
MCADJ#*CS(Q-VR1%,.0!^QRL?L*)SV.VO:J+SY+P0))T-A@J)"B?)"T@E.US@
MH1BO1S%,UBJW7W2)RXCVY<JHVU<R;)KHE@EC'?#E3H?5[U&C2!O<(Y8_0?NV
MJNFU?Q<"M;R[JZBN.K$!,L9H(@#*03CM03SO9U'=!CB:)Y&-5R\D5>`U1,GH
M664B#YR!"=;04D%K^ZDG=\8Q3:K&6$!YD=Y%"QS_`'**O%;YMMX,]+=M@^M6
M$=LILL=2;N]F0;@[V].!)T$5RZ(PJHQ>TJ)Q,L[&2&%7U\8TR;,D/08(L6,-
MQ3G,1W)@Q#:JJO$6R@N(^),$T\=Y8TF(1PW>Y<Z-,$"2+7\3V-7U;6MB2F'F
MT9XL:U`UI-84B9"!8Q@D<YB#4A(,D9-&JNC7IKY>&@/8Q6G=91*?HM*A2LM)
MP&R8<(PQ;W@/(C/0C4?M][5'>1?7R)TZ2"'"B!)(E2Y16`C1HX6J\ISF*K1B
M$-B:JY5T1.&`'X@8^\I"-$QK3E7<1SMC41W1VKJY?+KIZK:_):.JOH0S-D#C
M6L&/-$([45K3A0[']$VQRMW-T7:JIY%7BJ#:XAC=@&C8T=.&72UQ@U@6;=H(
M0GQU''C)L3WMJ(SDG+EQHG'CM^^_-/TAOK9AAQ!,*T2N:]$75':IS\O$>[`9
MS9"]4#6Z-VLWF.+>BKKS1./!FLO<7CW]MEME)!271APG&QJ:T%0`\Z.IXY"M
M?*):C1W2</LLUYJUJ?@;#%\CCDETUGW7OD<4@\5Y.Y38UA'T/&>,S-LJ(Q>2
M\]-/)Q]G+#]8KOY;Q]G+#]8KOY;Q]G+#]8KOY;Q]G+#]8KOY;Q]G+#]8KOY;
MQ]G+#]8KOY;Q]G+#]8KOY;Q]G+#]8KOY;Q]G+#]8KOY;Q]G+#]8KOY;Q]G+#
M]8KOY;Q]G+#]8KOY;Q]G+#]8KOY;Q]G+#]8KOY;Q]G+#]8KOY;Q]G+#]8KOY
M;Q]G+#]8KOY;Q]G+#]8KOY;Q]G+#]8KOY;Q]G+#]8KOY;PS'<5@N@5;)!Y?1
M?*E3".DR513%>>64Q55VU$TUT1$XD9-$Q.EL\H:\TP!YFV*27,)#!7_G,]8\
MQ6HD*.UC5<(G21.RB:KQB=+''6T.45$V[G?6VMRZS:E+,O[PEG<S64P:$8+]
M)@)!&CCG(T>J[7JC=5X?0T\X-S47LFR3(CS9L''[>%0R1C$S'<>DPJ"6(3)C
M'D8:6=AI#!<F=MR$990;.GHYN)@O<DR6/6P[F6*7D7G+##8108S(WUT3S-74
ME#*(!3-D$71@]K--R<6$H]G`-CLVO,XD=CGRI+[.3(CS^D`T^*:X#$B6,JP>
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MOK<TI(<*;8S)]*8<*%7/&R6>8,@CQ&CZO8<U)`FJ]G+>Q%;JFO%+"E_P:43Y
M,4<"-(N$9CS'N*%!#)8Z2<6ERFOW)U.W)>_7RO7R^N\=OWWYI^D-];._R"_^
ME.$A0V!/,C[NH.2S43$-(.YA$WHHW/:BZIY>,:FY'>7M";#32ST<C'35D0W5
MG/KG%<AF1BE`X/FH735NU6ZKQX`SH%G>)'MKLU9/JH\N0E0@J>QK)W>5AAT9
MWF4"T+UW/U1P8S/(C%]G9=!OH<WZJ5<X];77D8$+ND:7C^"+FF1BD;IK;*47
MIHX3=@%&AD8/75_$Z+=XYD-$6O\`.(3LFNI9#UL:_&0Y7YI$VKM9Z%LI-7)&
MC!(N[KNZ:Z.XF8S!H<@&2M9-%96I8\5]3"M:Q\<-C4GE1Y9E;(CRS/`CE1&E
M-'*C-6LW+EPI$&9'/WS*289=>;8,RLEUM;FE7@59M@-NX,Z88MQ:">WK.BI(
M3>C7:,YWWU?I;3SBF-V-CB]S*%6%K;B0._@X=7205T>TD6+!V.16+>ZL.,?>
M!-W)RUX@4'U9RN1D);*16V-9%BU<N16)$O28Z6?(=!LY$<X'3HYG?F[BHT<8
MRJJ(/M75H:#8U<2`F4K42[!@7Q\B#B+[1EK/@)!/)*"O'YMW-?)2/U&N[&NB
M\8[#OHDVGR:.VHE95WFMK94>37?46US:VE1&P;YC:EA(M2YK>KN.!2"WQ_?.
MR=78KDX;0+1R?,9G4`YOFOZK@S"39G.2[9`AAA4TABD&4K#(4HV;-S^423?P
MI5Y:3/JS5)4TE=7P7`O9N!$\0KU[[&;>#AG@5M5*`PRJR/W9S%_*[N6-QZNA
MOB1,EDPJ^-:$\TCCQ[63BHLRDUYXWG1;)SJJD*G>3#"^.PZ*+?NXS5IAM^J&
M$GKJM[(F+6LZRO[VQKZE1U4#)G7L&@K[+SQD,,`XI8Q'EU7M,1=[9%/<X[>U
M%U%=2./5&=52SI"MVY#)/9L+6V,V*2OJ*S&)4J21']D>UOY1VSBS7(8%5$BQ
M:7'+#;&J;2BGPK.^#)GK6/BVMM:%MH`:SH/'8L9%"=[W-&QVURIZN:76-J1M
MU7TI30S"&A2144@AR9HV*CF[X,-Y#(JHJ)LUXIL^P'QYR/+?$0DNC>[&9>41
MK@>2&G3(XK&MGXZQGG6&/IE>[\[<3FS1/?%8Y/4Q*7`C8Y:@QR5>VMECV2WD
MZBBW44E(>&QK)<&#.5'091V'U)L&U6MW.1%UXM;";2K18]3?P_VF1X902IA2
MLQ^WBW^1U\Z^K3O0:EL8\RK$T,I&M?TMG93<NN'6F/TD7(\TDXWB9K"ON)[:
MQA#R:F(2V.:24C-#C.Y5TUYKQXPGNH@8%P;Q=R8MM`CF20"%9$0#YT0$A%<A
MPQI2N8U^J[D37UKAE8T@WIHYCDU:Y/Q*G%RQJ(UK2[6M3R(U#'1$3^1$XLQR
MWE;U";HHSD75S.J==0L>[7;L3VO:X\+Z\K*AF/Y?:6\;([*S[TA*N!7K2C;*
MAE`=@A*-;57DZ@RHK6:)IKKP"5%,*1&DA'(CR`/:4)P&8A!&$1BJP@BC<BM5
M.2I[-D),H*^4DLUS(DMD"ZK#FR&,V'<D*QZJU[Y\1B#?K_,Y)HG$(`,7JF!K
M[Y,HALZ&Y`Y"@1`\\=MSE?/Z06]MVJKM1?+Q8VU951(-A;E*:QD1VJQ9)I!>
M\22J/=TF%ER/?#.:UJE)VGZKSXB-\P0-L%L5D5%8]4"V%=-R*,B(KUUV7@VR
M>>NXJ(JZ\6L\C7W![0M2_;,AU$*+#91W,C(:UL:'2UU9'W#N9'7<YZ.U<,:(
MC6,1O$:W%C]>.SB'ER0S6,<DCKSK*7<R"&>C_P`Z5;6>:0WJ[^F4CG-T5>"X
MRVLC)0'BRH)JO:O=2Q)O569'(U7:O')Z[]^J]K<NO"UX\7JV1',M!O$T3DZC
M+J$.LM$*]']0O>ZT38Z[E54`U!IHWEP=UIC-5.=*EDG'=(C[W$DEJXU(1SG:
M[MCJJ$$.SW&T3>6K47AZLHH+%(^Q([8Q[=26U9&I;`G9>FCY-5#''54YH)B(
MFG"YG&<7O(`'!5UHX5/#KZQ)4&%6G(QT&MCSY1NX0&"8I3.T8J[M[M');54B
MGAFK[V<2SMHI![F3K`I`&6:;5=W>FEBC<QZ*CAJ-JMTVIQ=6_F\)O/.,P\06
M&\(4CP:&/YP67#AD&QDIJ6[[%72G*17$5C?Q<2ID"""))FQJZ))(%%;U8U2(
MH*T.S7IM9$"9S6Z(G)?66T+&<1H[6B9B!)=78V-F(+IF6]]024LJ*LT)6P70
M%5ZOV-9K_P!+_-XK[,7@-X*4]S(F=6,<-G`#,&J.1TB14Q%R!S0R`CU74`M6
M^K'CY/C]/?AB$<:*.VKXTY(Q'HB/>#O`WJ)2(U$=MTW(G/BK%:XCC=B*D:@Z
M@4NEKSBK1-VZ`A"?'5D>/V$][:B,Y)RY<:)QX[?OOS3](;ZZYZYPAWR%1G5*
MP>Y4.?DW>J;EY\0YQB@&!S'"&A"HTCW=`@MHV+S7WPR?[_$/ZTXY3Y!YN[QW
M'SK!#,[IWOH=YZ'6:[I]?NP]VGEV)QG-3'>0-3"\+:L42N$YS*^*R.3#6QA@
MB-5(X6A88B,1$3:CG:>5?9ME=VLAL6MJ84FPFR'^04:*)QBN_P"$[:WDGE<O
M+C(CSVBCVU/D,U.Z,V;QT-F8TRAW[=-RQQ=2+NT[?=MR\W+[`S#':B4*'8VE
M,<,8QR]`"JQS#OC'/Y`@F"$X+W+V6M?SY<7.3Y/64M#XGV1<0J/"/%X&8U(O
MJE4T$R*Z5:P'>=F1)P%"QY4&)3D]UHQ'.Y>JSJD&/J$:(?4>UG4*_P!P-FY4
MW$=IR1.?J>.W[[\T_2&^NBF`CT?*DE<7<[<FNYCN2>US?Q"L221@Z1!J1KU(
MYY$&1BMZ0F([R(G/AQ(KU>QC]CE5CF=K1'>1R)[2\9'X;NHZ^*2KQ"%;MR+K
M,2PGD>:I7S:YB@:J@1EPBL3J+HHG+_.[/LR;5UUO78[AM772[_))1$DS+>Z?
M5!+.!61H`6A`RO!W?J/<0Z.(;9V4:/5X_%#%Y$&96>=YV+9%BT@W=)EI2LCU
MDM\VMDDW073XLN2CA#.Z-S`J=7:1?8&5XM52AP[&YJB1X9C.>P*F:01VQSO8
MCGLCR^ETGKH[1CUY+Y.,TRVU;B)/$5\W#J##H&.91"+`\-H-).C:RDE!GE&`
MYVB>]H-2%5=4:B*]4;ZE?BZ5622,>N`VUAE5G0T-U<L%7T<1)4&DD$IXLA8+
M+VV<%#$(K&)#"9->UP@<MCL6#0_PP,DXJ.^B/CI&M@2+2-87=&R>-%\XI(AQ
MF@D@[;Q(SIJK7<\-GT%)&R+-28WB:V-==6#:U'R#5,1UL:1**1GYR,^NJ:ZJ
M[CQA/=1`P+@WB[DQ;:!',D@$*R(@'SH@)"*Y#AC2E<QK]5W(FOKJS_+E_P"Y
MX;UQ`D*Q%V[T:3:BZ:Z>7373B.X32PZG8UTA1-*R%U%:9NI=GO2O5=OEY^3C
M$LDM9$\GB#D17MH$&6<^J4]17,AB4XPCZ`7H%Z=/<[1Q/+[-\0I:NV]?'Y%2
MGDYK?$%1HWG^/SAQBSB-5A;4US:D:J:=D]O,#&=Y5U0L*,-R>3DOL#,Z;&7/
M2\GTD@,%@GH(LGFQ\B",BJUK26$1CP-U5$U)S5/+QX@>'&"^$F;8[)SB1X?Q
MZJ'8U<@$+%Y>-O`6XL[BRF&(=FR:-2,*_3?KJ_8O97U'B*QA1%8X9!D:CQD&
M]-KV/8[5KF.:NBHOEXK0V&+8[.%3(U*@4RDK9(ZI&[=J5K#1GM@HW:FG3V^3
MU/';]]^:?I#?7!:8A1]%7JG3V\]^W77<UW^+Q9QV*KFA&0;5=IN5&G&FJZ:)
MKPX$EG4$Y6JK=SV:[5W)S8YKO*G'A=:T=;'2EQ"7:2;J4LU&/CA("(42N#*D
MO/(<4C=C>BQ=%7M:)VO9M#BT=5=-RG(Q.[NU=2'@TXE,5K1IVGKYQEQ.,7QQ
M$:BT=#55A-NBHX\.$$,@FK>3G%.USE7VU7V!F5:%P6'E4Y6QR2+8-$$<EI!$
MCE):R',CQ&",Q':O5&.TVNY+Q4Q+3"?#]]74084:7>3,BA1?]'1!C$LZ0\5\
M.&-R1F[G.:U&:\]/:X#-@2HTZ'(9U(\N(<<F,<?DWA.%SQ$9JGE1?4WF(,3-
M43>1[6-U<NC4W.5$U5>&=4@Q]0C1#ZCVLZA7^X&S<J;B.TY(G/U/';]]^:?I
M#?7W/_QOTEGJ`HKF9>THZ@IIK)>,SXU?*F$(``]D_O-?/'(8-J]CDCF_CYKQ
M;2Z7(<SLG7$%L$XKVYC2@!8TG4;(BB@UE<C)C5Y(1=RM37335>$D_77Q2ZR&
MZ_4^LM5OZN_J;^JF.(7?N_G;MW\O&:8<:WFFQFN\.X$^%4%(CXH)S38M^>-U
M;O[R_P`YGW.UU?OYZ[6Z>R:#'@?G&/\`AFT9[!S%W`[S3$;:6+B)_P!K>%C5
MY4_[+U/$"#:9K9X70>'>*U5@(5)8QZJRN+>ZB6,];`IWC))EPX0XH8\>,/LF
MDN>CD=V4XK<=NH]4_,%G>$6+]"7U0SI%KEM+7WF66,^&(P-4JJF5OT`UK&'1
M475-&\7_`(IW,"E\WNB$EXE30$F#DD$ZTEUM8:[LI$LT=1VCBQ7^\B9T!;GJ
MK]R,&?%S2/#[SNN3R<<!E8VV@\-C>9,6%E&32)`3W39<J17=^!#8%LD2.*CR
M*]&]E*@T&NQ*!(<W`X$^OM$M5FWUUX@6I8E8N+QQS@D!6QZAK+%W7ZSB"?TT
M5%;O7QHS2OL'%F)EN1U^)MFFE'AQ(=(2MPT(:H#2Z`-+M*^246S0;Y94<Y%U
M=K38Z<U'8UU1F;\!OAS+#(+C,;6QA4A[W*\OC2[2[E+"IZXJ.=TBB(QS$56N
M`UPV<5>390"F@OR"!`MZVLJ13=T"!.BLD";/ES)9>]R3M(A.P(*"1VQ=ZIN_
M`9M2T$99EM.IWLB1&Z=23TS@.:.%%5$=(-'$]HT]MZIQ=8_0^'7C3%\/<CFX
M;(E4%[3VLR5(/C5F^=F16$0SUAI+C-8B;7)UC,_F;$:S,34];:4^&S,]MY6%
MUUN*0&0"F?"K&DZ`Y3S%9"6P878F]W;1_MZ^I+CMK,&L[)E5D#X:9O9N@BK0
M+7;)EQ3"[G+$:V@/<+81RQ^CO_+,W+N<N2*^954_\,+9>(.RD8$EAM8DJVKK
M*\KV/?(8&Z[W6@:(H7*9!=/15W:KALS'*ZLMLW)C>)OL(N2R3QH[CEJ8CK<D
MDPBC+WMIU7^=S=QXPDO`18UT3Q=R9]Q&A/<2%'M'H!U@"(1[G/)%%+5S1JJJ
MJM1/7F&K$:DXAO=<U4#E>1CFZ+RU</U#*U$CR#[-\IC=2:-<Q=/=-\NQ.)D3
MOI7][Z7OJLYBZ:Z\DZBZ[N)PN^$+WP"@W.9HHM6D;O;[XNJ]O^3C)L=B5LU<
M\@XC'/97Y(P!Q9=0IJAZ0FD264[BC6;&YJ-NY&::KL;[)N\H,X:S!![G21B?
M_>7DQKV5X-O\]C'(IBI_U(GK[7%EX@WF\M_X@25F,-(360E,(QB",YSDWH^X
MFE)(=[1!]%?4AW%GCM'8VU>B)`M)]3`EV,%&N5Z)#FR(Y),9$>Y5[#DY\&NG
MT%*ZXD(%LBV=5P5LCMCB<".AIR@[T1`!<K&:N[+5T3EQ+Q5/]%U<J&R`C*V+
M5[8L0:CT!'A6%?85*@V#V=,D<@MBZ;>&T/F>MR6M)9DO"%OZ^FM6R;4@11$G
MMCCKP5$5X8488!-BQPC$(:-:U."919T^.QST\#JDOYE;7,D5M;5-66URV10]
M:+#KVBZB=M&CVZ\N*.,.0>)C\.S@Y$VJI.X1*B[(":.ZA)8L;"(0T'SFULI6
MA>'JDYO5R*J<3+GZN4/G>QCOB6%KYHK_`#E/B$&@219D[N_>94=X6HU6/<K5
M;RX(.H/#-&K))Z@@X+AJ&%*K7=VD5RL%V`$A.;L4?+9II^`S+(,>Y7%;3D-#
M+TT,L57E$$TY!N:YCE@1RO-VD5O8YIIQ4>(V*?Q"W.;9<^52$)B<S(Q7$+*'
M3Y<<-C5^8N]2)D/H",]54J/<'I[4V$5NGJ1QY%C])?LB/<2*RZJH-HR,1^W>
M2.V<`Z!>[8FJMT5=.*]+;&J"T2IV^:DL:>NFI6;$:C/-_>8Y.Y[$8FG3VZ:>
MIX[?OOS3](;Z^!_D&_\`N2?6B\3)63Y#"R*--J925L&?"AUQ'U0XC`19*+7O
MEFB2F1FH8?63J(Y4\G$[([W,LUJ[&4*$$D"JR&NBU\9D6($`DC1)E/.)&0K&
M=1R(_:XCG.TU<O'_`(5R,LRT52DM)OG$E_%3(?\`/>_MC]Y=7=R[EU>72[MM
MTY^[[7$/)H&79I+FABRAAB7N00#5Q@S0NCN>:-$J*]\E&H[5B.>K$>B.TU:F
MGC`HG7$FBDTD*UBS)SSGAK)R%])<&%#.K&1^[BEEDB`UON!!V:KL7V(:3)*.
M/'CB(>0<SVC$$(6*0I2D<J-8,;&JJJO)$XBU%=WH?A3@Q>K,EMZ@6S@N*J%F
M:.1-D_('@Z,5KNV&*QQ-J.ZC>!1HH&`BPXXP1XT<:-&&/'&@Q``)B:-8,;4:
MUJ<39I[#Q#6[L/#V59DC#RRXC";FMYE<A])4#$&:Y(8,.JW]1X@N8UW91^YG
M8XFW)X?B"LVJG>)<V:I[26+%;B%75<FN\/**IIA6'<9PR]9DO>@6=64Y=SGJ
MU4'54TN^SR5=G\.J27#GAS2U9(+XI75I'HY$VV<EQWONM9"BC%"C,8\1W/+V
M2&4A./$";,G9\V535&?AQV!#??1:K(*[S02KPZ$"X9DJ5;I1=!S4[M#;8=_>
MY2G1!Z+&Q;$ZOQ(B0K+P^P>BK3RK*PC`QZSF9/*%F=R99E@KZ:;"KG"[N*/H
M0,?38UC$>K<X8B9O$J,BZY,$CK<RN\40LARNMHKWSV])##!+!I!OL:Z,XCQ0
M(Q2(WWU.S,MSR_$!HYS/&&Q+50\GMX`0U,*3'B>'6*Q8P)JLC&MNCWK<'IF<
MWLN=L['&.Q;AOB(LFGLO#2(2YAW4^+C:XK3XU"L,K=.[O/&VYMLER,!A2]XB
M$VM:W>Q'(T@[.UKLPH@K2Y/-RV/D$HC:JRRK*LK2\@BHZILX\%&U4'JN++$Q
M'N<?8_M;FL]?E]W5G@1IU93'E`)9PR3X*]-S.H"1$&PJF;*#N&FJ*U'.17=E
M%XH;M<+\UYF](+C]+'S2(D&[?TV%-71FRC5D5K9?:"X(F*---J-7EZJR)TJ-
M#`CFM4\HXXX4<]=K&J0KF,W.7R?CX`LJ;$C)**P$99$@(4D&)^3"!2/;U2O]
MIK=57U/';]]^:?I#?7QI3FJ]H8[%5K>2KKUV^W_QN/\`,S_\MG'^9G_Y;./\
MS/\`\MG"1F1R#56/?N<YJIV?]SA99!.4[GM>KNJ1$W,TV]E':?S>'R3A<XI-
MNY4*1NNQC6)R:Y$]RWCKR1.>16HW5"D;R;Y.37(G`ED"<Y0B0(]"D;HQOD3L
MN37R\>(GAM);&^K^*T\"94+TS)-8I65#W-,5QG#*-R6BZ=A.36_RZ_@\<BQ[
M*SDU.<-R,<VJL)DBR!`MJR&VXCV%26:4TBLC$CC.$D4;NZ\QJP;-JZ^NE6EM
M-BUU=!"X\R=-,R/%C!;Y2&,56L8W_P!?"^&/A.*3&PL9!NR'(9`RQ1SH[3?Y
MY8.Y$B4J*S<",J)(E.3M-_F-AXS0C[`_?[&>1J-E6]F]C&R;&5HKM'EV(C6:
MJ@AHUB<D]9&MI-362+2&SIQ+(\&*:PBC1SW(R-,()T@#$<1RZ-<G-5_#87X<
MX/DL#"SWU?<WEQDLZ)%FN#!K.D,$.(&6QX^H4RNW>X<O9T>B;D=E>-9S<U-G
MD>%9,6A=>0^[0PWT,@!28,U(XT`))';<UW38UNB-\KM57U(D'(:BDO,DO&6M
M-A$"^6*R$&SG11!EW!Y%@]D*NB4PWC,64Y6D$FC1N1S^+3'\KN*7)*VA_AH>
M#$K>9(BS:^59AFVX+>9C1GN,SSB.?'`(717O;!C$U.,-+CE=66N;_5O$TL(F
M2R#Q8ZG6IB>=WR2B((O>V'U]OW7'C"2\!%C71/%W)GW$:$]Q(4>T>@'6`(A'
MN<\D44M7-&JJJJU$]@0\G6!,L[;Q9O:_")Y2V08D"E@PS5%4*='C-KR$.1&C
MC*]'DT5!/T5%=R1R+JBHBHJ>147R+^#\)/\`\_,OV2E^OLAYAF?<O"Z!.:>C
MA0%$V2>,4+"H(-6)G=4F1'D>!TR8KR\M6,<QVG`:#%:L%97B7>39VY,R2K4:
M^9/E/U-,ED1J:O>JZ-1&IHU$1/85?.R^KD3Y-9'+%B/!9V$'8`Q$*]CF0Y`F
M/[:>54UX"<>.S^H`HS,UR&[5-XW(]NJ=^YIJGJB\YUM?8]#?T>_0X\OH]39U
M.EUQDZ?4Z;==/+HG$(4BAICBK7J2N&:KA%'`(KMZDA,>!6Q7J[GJS1=?4\=O
MWWYI^D-]@>&EA(R>NQ\F*94EI&C6'33SV1'PIG<(CGR0.23K6)[EI%V*JZ<N
M!-U1VT3&ZIY%T:B:I_(OX/PDDD5&`\]Y3`ZCET;WN9AUJ2*#7R;SMADV_C5-
M/+[/<0CVC8Q%<][W(UC6IY5<Y=$1$X"LN9%B]Y*P$;O$@0.\')[@(>H]O5*_
MVFIJJ^IX[?OOS3](;[`P\]%D(,=L,3LY=D"26(^2[KF[B^.8*L,+IDBF@H[G
MKKK_`"<,P5,^L!Y:RTV_7U*QF[NC+!7I#2'R7H]W39U.MO\`_9Y<`E91XH6>
M8TL=),:14$J>[@FOD!40"K(<20H$BF>A=6IJJLV^15XOI%/XR6T"JDV4F775
MXJ3WNNA2W]XC5S'#D[2M@"*@=_E?LW+S7C&,=H?$*QJ;NEC1O/F3`J1O=DI4
MA-`\I0,<CH2]9JOT:5R.W=K541>)QLN\0;#/P654)L&*2N2&RKE*57+*ZCEF
M*0C6)MV<FKKS\B<5TFS_`(B)<&'8$$CCS*P,-D;KF$)C7N-8##U%4NB)JFJ\
MO78IA*=$3\OO2L+8OCCD2J>%0U<V^D65/UFO""\:>$$48SD=T'&ZNUVS:L.`
MV3-F)#C"C)+L9))L^3TF(SK3)9??)$DFFKWKY5X61$S3,;5MM>0HQXXX<E:^
MKCR[4%M9GGEPZM7*H]&^MJ?-PFQ7=03YJ]M$)JR@JY;,_CY%%?X?RJ$,P^5Q
MJNNKC7)LGSJ7<6*N)`F!'`7S*&/:$+)%'8(2LZCWJN)5C(.04J)'JN^Q<>G9
M1)A]ZM<MCA-9U%Y3P:JD/.QW'ZTA)B7"CCB#+1!L([579RV-/R<8K&P%(I\G
M%`SRJFV<R^R2QL6X%&QN^N:<0PU<(44;["-W./'"Q4D*K.NBY]<6N-6TW***
M',C0DD2+`J9`:@%;L@4E3&E5L(C&/)&8_KCZZSG34*KT>JQP8EBMY8/2@M\D
M'8GD+BD_'VW$&AQA]U>URU-L<<V10P<C/$AL>9OOSGNW=3I)K?4^*1'6\+'+
M&HA$J!8Y82!V34QDV19#ORIFE97R8XYD,`@=L[I)1IMVN76N[\=P67EUCL45
MG_X>Y$R1":N/7MUG,:NQE^^YM*^A+&@QP2E9^6,3>KD8NE#36])-BV=G'\-W
M22CQF=W&"&;+N+'.9\V:C#UT62&FBQXC8_65PI;W;6N1NO&,4<:!:U+KR[I[
M:?W_`!&TL'&B9Q:W689-93[Z0X==5/I8+T@!`[<5#H[<U4V[,?N)[KVUD)CS
M)4N9<XCD'7Q&;FN<,@VKWU<1`RK[ZNU-9)TCJQR1V]%6J@.;XA(<+IEBUDRP
M(67B<ULJ]9:9^"@PP9J]3C\R3#X^`DNP'J]\<9-58Q=NSV#D+KF6,,J-"/(H
MHI;8L!DRT;TVMVP62@#MSQQ/<Y@WM*C%[2)KSXRH^1RZ*QIQ_P`.D@N'2)1X
M<R#YR;-MH]N>B-N*'S\&?%`)>A^=-5C&IQAI<<KJRUS?ZMXFEA$R60>+'4ZU
M,3SN^241!%[VP^OM^ZX\827@(L:Z)XNY,^XC0GN)"CVCT`ZP!$(]SGDBBEJY
MHU5556HGL:#&A094R8N1UI/S493/:#IRPJU0B1SG(208:>3W6GKO"3_\_,OV
M2E^ID3R7-76.QJSNX5B*=:06%#$I;DU&ML9G518T*;-#[UNYJCV?X[=32(65
M4,H$=D,AC1[*,43&6%D^F@N4C"*W;+MA.C#_`,8R;4Y\60*F^J;(U/IYT'!G
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M5M.K&VB^=X7YB\LM\`8Y'OVK"$FC42-\JD[/E5.(^513+D5;.LX%-5_5\]=)
M=:V5C<,H@QX4J9/@56C)SG=0A)`Q,8-RJ[EP&);V]=C]P^/!D'H+:VI?.T%+
M.2")`'+;6V5C"ZDN1*&@^F8C7[TVJJ<=S<"TOG@#+/9/Q_S/);4LA7$:@..4
M.?<5LJ5,2UD=)(T,<J2JC?[WR]@L995\&P8)RN&R=$!+:-RIHKF-.QZ-<J?B
MXA!/04I@UI'&KA%JX)!P"O?U'EA,<!6Q2/)VE5FBJO/U/';]]^:?I#?8TYF.
MS75F1(!1U%D@&RD@R"$'^<=V)[V56(WEKY/+Q#L[_P`4A657`E!-,I'4$+?;
MQ^?4B->R+'437^17H]'-\J<^+>SQSQ+#B],X8"0*-]%$+T'#B,&8`3/CRB&4
MT@2DW/=Y2:>1.!T'U['!S.,7O9,N?11%[^+O1B>;%C:.`)$CE:U"M%O7I<_=
M+P*7GGB#Y_Q]L.6TE8E-"C]:2]B)&>L@<8!`]%_:Y*NNFGD7@DIGBHVLQ\]P
M66R(['*]_<ZQ9#I#(",6.[J]('O**I.UY57CPE:FBN;*S4RMU3=T68N4+R[?
M+TVED#:J^TKT_'ZE.R/D%A'E4<2G9"E,A5[T=8UV6FS&792XQAE#*=:6KV.>
MQ>37!:_57<8W9&OKF<^ACSN],)W</GZUE7UMDL>ZLG@8S276W5R62%!HUB&1
MB_S$3B\QB!8D>^XIGT;;I:^$&S!";!DPX:F,%K7S3Q72WE[3FCZCE5K&;G:J
MQUQ8R:5DDUG$I2!A-8&X/B#,)[\:<,39DL<6BZC`!<NT2D]O:W27#-D%[+65
MC+Z)\A_=$,L\@ID)V0&=TW]YFLIIKJ\;'^]L@JX7MZI22"F;*\SU^4Q7"%`C
M5XYLS*G4XY=J98WOZ3H]93MBL)O<7I$=V_:X)9`MYT.J,_%WGQ\<>*:.5,-F
MEN*&.ZPEM/8]T'?'=+.-'Z'<C6KHB+NKP^>;$[J_ZAL22H@#E/#@AIEE%&A6
M<Q><+^<^:94_Z3;^)%XI3/R6SL7428:""V3"K1,97X.+(O,\'9$"!'-)-ON]
M'([<0L@.[5-W+&I6'6#Y%]C0,>AP7SY<.KBH^K7+I=C<RFOHL@CS)EO:Y2IR
M#4#4&0;"HKG#V/\`#W%KTX[(&'28-K:!=''(A9%<`J[*/*=+'*8NZ$>VM'R]
MKFJYSF-1?;XS6MQJYZ"99;4=K'K942L'"IYT*PQA"3P2VUYI94K*O'T2%'7W
MIGN%U38HQRHQS"FP1X8RDGFCQY5A4$Q/))F43)@9CD8=\_*["P/YQ+JU2H1?
M8GCM^^_-/TAOLR5DQ23;&ZD`-!#,L)/62LJSR&275=3%&P,.!$<00]ZL'UC]
M)BF>16HO^`LOE^&N2>'LNJS3*KG,9X<OK;R'-KK"WED)W",ZK6S#,BQXVQ.J
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M+.*&<:#&FY$DWSBV*.'$(9!P&S"5V@722LU1Z.>@TXR[$[[%G8O?X@VE/+`*
MZC7\(\2^C%E07LG1HD+I24&+MB5G+7DYWK26U)B"Y2&%`M+6W>^^@T$:MKZD
M#))E4TD$PTF7($KU$-@MJ])V][.SNQC,P44^V)D]1'OPT39((DR!2.CQBS+*
M<=S#C9'AR)T>/JB+U3'8C>2ZIZV)A.18NRF!:U-[=55N*_C6A/-]"YW7D758
M"$-*@,D+-XG)(D(ON5T=N1JV`<?@UN-R(+IU9,?DT>9D!1$D#;7.M<:!7M\S
MCLX:N.->]F7:U$5.UZVTR&RWNC5D92]`/.3-DO<T,*NB,7\I-L9A&`"W^<4B
M)QA]C'Q08+G,<@R+'HU;<Y-%J:>NE8R26R<MCDGFZ6(;Y'==([&QW*4B[47V
MUI,M#7R:L=S',7N,IS2$`Z/+D0B;#,:QLF*4D97A*B-0H7-?HFNGK+:_LWN'
M74M;-M9SV)N>D6!'))/TV:MWE48UVM_G.Y<6V:W>+1(,"."F6GKJW*HEW=3Y
M]]*%#KZBTA#K8@J.P<:6'>WJR>FUSE7W"\95CMW1,QW)</D53+2!'M4NX)(M
M[`6PJIL*R[A5O,PXAO:Y%`S8\:IS];-R$>+Q[B@JZ[OME/+DD:G*`O7Z`X8(
M9J^6^48[G#0>CDW/(C>**^LO#N8F.SF8RRZG.R*N'/J9^1=!KH$&G[L^3<OJ
MY$A!E<YT7<[7:FB*J>Q/$-V,OH'U/BMCF/T-[*MI\V+-QTE(V=!).A0H]7-'
M;LD5,YR,&IHRH?RKM\L*O!NZ$&)'AAW+J[I1@L"/<OMNV,]?FV818OAX-<FQ
M^+45["9!D<A8,FBBVWF27*CIB4=L@4J;,%WD;2MZ8T=L<]=$6U'E47&S65Q(
M6VN<EJ[ZTM[;(;TR[3'G`G8U11J^"`/8C!`YS`L3:B>5SO65%)C[L=)BY)!#
M9C5V]Q;4DJ_CA4+X%.*PJZ*[)'JC&:Y9FU&%*U$8US45VMM(AW\7'LCM\5I\
M7+CL=T.7A8(%39ML&0(MG)Q9<BAPE)[ZJQQ@4A&,1R;&II$C29AK&3'B@#(L
M)`XP3SCB$UA9APP@QH8C2GM5[FB&,:*O9:B<O6BR5U5BN$0>[93#R:?B]Q93
MK//PY!$)'C):5Y::IAQDAF5)#^J^4]#(FQRZ;DQNQM(6)4\?$<3LL865BQ9+
MIN;'GS@'';7PB55:V.D<$=%V.?)>Z2JNW::(GK*8"7UG0$H[V'D,616@JI6^
M?7C.D+O,6X@6,(XXQC=5B.&NA6-=Y6IQC5-92J'/:RJRW+K^ZPZULST5/<"N
MW&6F,EI78WUUEUASDE$":.\/6.Y&+L8-.*3'+VP'93ZT<EF\)I,J-#BDF2#0
M*J++FL'-E1*F$1D<9"HCG,&G)J:-3U<GQ=#I%=?T5G5#DJBN;'--B%`$[V)S
M>,17(KD\JHG%T]\;"\0L_JMA='4UN.'F&H[:ZPZ^#?.R6]VT]8X1;-X>[M1!
M'*(3UW.<J=K.LTR@57!M\U/CPTIZBPD6T2LK<9JWP(C7V4FNJG29<H\HY'Z`
M:UK5:FJ^MPRL;(KQ8G7Y-'O\OC2"R4FVP:=$D5%3%`.,2.>))L>U)ZA1*U!M
M5NY>7%3<`BX7=8EC/=Y^.T%UD%Y3JF2M9V[^V%`Q6Z'.D0=[F0V=5!B]WMWK
MR_P&Y[W-8QC5<][E1K6M:FKG.<O)&HG".:J.:Y$<US5U:YJ\T5%3DJ*GK&U3
MIT-+,D99K*Y9(4GOAM)TG2VQ-_>'1D+V=^W;NY>NCQSRHP#S'/;$`4XQFE.&
MB.(V.-[D>9S$7GMUT]0L^TG0ZV"#9UYL^2&'$#U2,"/JR)#QA'U#$:U-5YN5
M$XU3_!YIUE,O89\;JKV;7K2W4RI:XQ(8RKWQD5[4EM8^"S;N]SJ[3W2\6/B=
M>/R'([27B&;-LJRPRBX;4S@PKBVA"'T!'1P'="N'VVKKKJO'@IAF#835RSYM
M@0Y=5`F7DP$>I?!K][&$G2!R3G@08D9Y2;M3$:S:B[EUXS"S'X>XVDCPSMY%
M9G1BWDA(A'QYZPR1J&*U%D+(#TWJ0A"O&C416H]7;4\/:;%(F-QKK/<4AYHL
MW.+IU1CV/TLZ)WB(DZ0`?7E291&%&U&;51P_([=V;.9+APX%QC^06.-7(*V8
MEC5%FU_2<DVJG)RDUTL1D5CM5]OFJ:.7^)3*WD>.3C-+%PND>-[FEA185?:&
MG=%_)XNK95;#HJ+[MR_R<0ZW*[R;)H/$'"#YG32[6;(E"@66,S+2'>11O.YW
M34E=`)(+I_T8A<8EF=G:6S*_Q&9X@VM72%FRNY1<<JPR*ZD`Z&XJAW-6$KO)
MM71KTXR#Q%Q?"*2P\+L<N"UQ9$ZTE1\EMHD4T<$FU@"8Q888VZ2UW::16IKY
M=':8KB'A_BU7?/S/P[K\YJ9US9EJQ0V6)I[AOL6B$??$%!A:JP:]1Q2(B*B)
MP[)Z:*F)6U3FY\4RR756AQ'A3Z]L&0!*G3<\T2>D[:9'/79L\KD77C^'&PL\
M:J/KNE[G""Q^#<*M40RDQL,+?:E`JB#W=6E*NURHFJ)SX\7)F4XG#3*_">97
M19U=1S)!:RQ;=2R0J^0,QAG.&/'<%Y#N[7O";M&KR3-XF4CP:776V-/;466$
M7DFUB.D3*^:9\6P!-$.176M%)%'>J.U:Y[_^`NN%V4XCBS009%1)(]5<\BTD
MZ55`(][N9"%B1!N<[VW*OM_X/M:T;VC)85LZ$PC]=C'RHI0->_;SVM5_/@_A
M,:RK27):+)ZM+(7>O-B'O+.VGQWKN"V5TA-L&M?V-=471./!*]+:U1`>&.(3
M\=M@C[WU9\J723:QAJ[<!&=W:67JO45CMJ>3CQTIO.]3U_%3);>[J"_GG2K@
M6$TTL0K+\WW]5J%T=TD>G'AA?4)<+MLCP;!:C!;6IS6#+F8K=PJZ"H>\C4$6
M1,CG!*.8@EZ6JZMUTT5'%!?5V$U=E(GFE/B8%6GK:,85$`045)31R)<Q$$N\
MSFLW)HB-1$TX\=L)(J`3Q$Q^%F&/G,U4$1I03*RW>CMNI%%:6RHK45W9%JFG
M/CP^PR->U4+*<+):`)=(DWN4BHOG3TMX(7,"V7I(&</)S4:]&.:O)VO'AED-
M1*A@Q_P^Q&QQ?N!4+W^0T\%T*(8:C%W==$7<57*U57\>O%_X7X_E>'@\+<@N
M"S5ESH=L7,ZNME20'D5D,0Q^:)#=L=&JXA$<_5RHH]=$P[,:V;$9CF(^&<7`
M(]<93.M']Q+/[J?<T*1E"D:4Q%7<CMS5Y<9S@:WM0EKD/B',S>IEHDSS>,96
MU8PP;!>[=Y&]PX;]SAL(C55ONN?'@[E.66>),N<`M,CFWX:)ELVOFAM%K60&
M5/?1..I1AKO?E+TTWN[/+CQIR&CLL7+/\19^.2Z.-<Q9TNL""J+/2S@Y!'&-
MCGALH4]X4Z*OVZ[OY./&+Q*R%V)T\J[QYH8F,8)'G@Q:'.``L*K>-+`03+-L
M[2:-NC1,&-Q'Z:[M&X=13Q.#8MKR6-@$B;2@EW,R1;$C&3VBPTF(%?\`)_\`
MDU__V@`(`0$#`3\A[PFU9D/,[)7Y\[\X[,`(L9?P`\8T:-&C1HT:-&C1HT:-
M&C1HT:--6V[TMBFL6>CN8G.XG'TZ4)J-(+VR5Y$O$2Y/HD*3M!Q9R[#Y)`(V
M]M8-FV>_(']X"YF>K`7&>9;C_8<W(?3K]4`N^G866*NCBM7>6]ZPYMK,)2<W
M3A>PAASP&Z,(H_6,S;*7MK.U,`/78(PD^5,\'KDG`.07(?@7J(;8*8.?U%KE
MB#"#X3C"@/GI;M%89N3K8ZM$&73E-=L/Z5"#2'X.X^<`2SY7K;UHW>,7/0^,
MYP%E`MM*M*1G\6W1:)]B9G"$-P#09;'QUZ@KVB)9I6$L?V<D00H@/G%Z;]&`
M4P4`%$>BXZ>D9!#4A-3KH\]Z&:@0A3U\`5*':"OU1T#<40<02#1^F$NHIN-<
M$+/<D(."`9=P7.DZN9-HCVU&P%08<..<VJ7:(])''.+/J"MB,_=5NQ7>@IA%
M2(>+0CP)Y(0'48W7%W\6,>ZGV4TG7CQ<$X:/A&0@V(OD?,7*5=%%O],M+7,/
MPD[CB\A]]U'DD^<H$\U>>ES^)I;T9@`=.U",!A@U*0`#*#T%GC\>22,B6>;%
M)0Y3VA300C3`_)[0,!5-RN#J>W90MYZ$7H:6@:Q667F%`L58382#+YL_3/$)
MM-/$_43A<8Q7&,TB&:"M'-/@BD#AE4$#0L,=![XGX==OBR\:X0D$*!<TY+5^
M-\C0U[9[K5>*)I=;G=3B0/',)S3\D!<_I8N0QI)V9<)1-"(VNU3CB2>S(;I"
M&"9[PDPY<S&1'O`Q%ZNHFD[[5JU:M6BLS])X$K)"WT>(O<EZ_.T)&_P$N+,Y
M01,#,>7++O(;%90V>IJ*#T>>]#-0(0IZ^`1-=QUJ\\TP8C7)M+OF`9\`LZE$
MOZ6:6&)LD705-5'2B)I)&,%&[^&6\F#6&3T'E*HRM@DZ!3',.1?MD@,*CM0=
M$7@*!:?&OT7N3VW?V6ZG<M6),HU$*$/A'R[\1Q$0\PS0WU:>*$M0LG(/!`O]
M#30V#5J'TPPSCP)`(`-'2V]4JY<0(!^V_NP`75!SR-B&:#@K@\R,@*0;#SYC
M]>W`<C>0*S<$`U)E"61%]H6)0,2N#`V(2*#Y7VR[Z"SQ^/))&1+/-BR93C/*
M0V:\7V-)94X/3?FX"D!7X%6<!T9IN\%S4,:G+3$26`B=WKHA7`@5D_;L!%#P
M"@>AM;V"-W6F!VN!A@1&BE[D\G+F25O"7E5<\U@(?>^1H:`>8$66D<X(&!%#
MBP8"$KC0"R4?KW/0G7VV]AOQHK<GX1RX\!4XHW(R+C$$),`K(]9,J#RWZ^6D
M$Z9H$3`@HT`%JO308S&1B2,UK4HR-Z&B[?D==>Q?&!R8&65NS`LDL+!?F@6L
MW[C4>P&AU9EZIHSZCU%E]'S8+(:W&$ZS55JG6\"'2_U4/IPPGF$E%!?](^[5
MV'W++[JCF*'<#\%]Z:KBZU93B*>O,&N81$:%R'6/-R'(?/R1DI##5B#P56R5
M<"5ST;@%$]3#`,M.<6'*9/E#$)D0G8$C?6V0@!4A(G(CA6/,4>23:;243KA]
M[,>%]>1%U=>6_7L:[,G56;:WTSE.@F,R*BV1.G*UQ\+E91V94"1]<TFS6@2(
M]B:24`P6JJ_=&'):4!/Y^0M.LPX[/-^F8U<*>X!O4M24!8F14VY;3L%+#<"D
MW./1&&Q%+1A0SY7OP)?$>X]$*$7'U];!Y,?`?<+5/#49ZU(#.[*Y3:J?4<"-
M-$>YMC<ZLPH^B\,?H21@H@!4,'N/X7KO-2JI489QX$@$`&CI;)`ZHG=W6FQG
MXPXT[?I",:XF9<ES^\\#`EF(4Z*BC>#M=(,$RD55)R%/M?/NUV-1%Y70!62L
MGL[K5JU:M0L<3DLFHRE>NUK;:'Z9>^3A6WN227P2K,1ZF\+HQ])`H/@M_P"G
M9`$!4C>TK6G.!)$FH;;_`$-!JYO39MWIZ42NCSEVN7@XZ"2?'DJ+/`XFGM,Q
M-'$X;M/0$1)2J"-\2F!..I<D(&.ZP"NL<(CJ"*"311-)GII7P4'L-B<V"H($
M4":.*C.NC-H#H$C<OTVMK9A\`?\`51$H*J)@^:.'+UQG@E.,.\"&-#?`4"G>
M^W$#&8=%5MM>3#0JGG(\!3C1W]=CCFJ73>K<_`6@%&^/5RTT9$KGHW`*)ZF&
M`9:<XL.4R?*'3?V=/>M4L_\`O9-^97Z*1;>QXS@U=%+0M#04?*=KEZTV6Z0(
M$J^CC/\`S/,W^I-]^\DP46H:>@?^7IZ6N)_DL)Z@<7_DJAUX0U2>1$Y*8X<*
M<\H<%[;+S*;7.CF+%J[?OU8C-PS#5"`SJS=#4+'QK;R!T!KFQ'HC;"E0DI"B
M5K+8C<ED#$/"S+'=P3R=`>(2G6R0KJZ7TU`/&.KIM_7OC02>(12];6!\([PY
MEG5-U#C6YR.5.]\.S<T(QX9M]:99'*LRN$R!B8V/1&Q!@@)@:2J4.!%V4DB$
M9<]6X89QX$@$`&CNMG=K(3>-84=9!Q/V/:Y>^),-;1^0%&LR<3'P6O@)-;A^
M);8H1:0+D;^1:P]I]>**.[\L.&%&Q%8(@E=`,>F&7J0)N,,%N@O'[7(8'(\=
MVMMH?&-&C1HT:-&C1HT:-&C1HT:-&C3Z"QRDJQ([4ZJ?1`.*C0CLF+'.LZZ=
M@1P;375=PG/4RW!5;6:NN":63F%-%.U<)_E*F2(8!EISBPY3)\H=K72_SF&-
MD#UA">)L?ET<_MF])TJ,_H`]K\6=H^";`&"@`HCXG'CQX\>/'CQX\>/'CQX\
M>/%T&!N1BRD2@CLP>B'>',BH*6HXBJAW@?*`;=N6$M,X\>#,58H8O?1)$7>$
MMD4RDIM2!&#5*M#K@\]]'`UMP&7H_&7H/)2`W(]0U`*429535B,?!%FM+[6:
MX27N?5OG"RW30*N%E"R%AXB!_<3K*\0I=#C;#5@?]BA1U0X1C$``````0`T`
M'`=UNV^6S:G"[PXM4>C@)+8DP7[N*76DBZVC^#\@48LK?N<4V3Q08,&#!@P8
M,&#!@P8,&#!@P8.0C\A4GXT"0#+,O!K]^9\[>11=I4F\9LG<:7T=GDR>K94R
M8LH;?V]171.L".,T#;8+P"$.Y$`>^DH.EYG+R62YU*F0@PV)&;M91S*]<R6>
MZG),_P!Y3AN5:(O0CA!"`$?W'.X`AP9U>(V'6]."#<IR#"`1QU#<6KF/:MGH
M#P"'Y&-($%-Z@(%<.E<E\FVSHO[3(P9(-+R8!)ZOK.8W^FANV6HH.85VKDWS
M0UX9D+@Z,"SUM?.U@N.F(1PF*/QG8TZKJ)DI!^,6'6TB0@''L>K\2U+KU2`8
M,)T11(^"=%=;*=*7BC%BT?OTF35MF?TCBA4^#)F+O-F(9_<A,4:DAQP+-*ON
M^GUQ43,Q5)3_`.MW:XQ2LY-KQ>]9\"?%"+0Q)(BX*4%V3:<B(R9R@&P@XUX<
M;ZDIM>"AU0[3Y'3[B079@X6W2CQ9-IB%@WF`2X:N+:O.#=>@^LV,`>F]LZ@-
M?F%I,`6<""['`(90>'LTEB!UD95NBC.1XPBDT4J.I/=D!2H37FF(4-;?//AH
M^LR[60H@JD-M$:7-M\FL=PSR(K,?)&QIMBQ_!R,?5]<1E_-'/&7TJ74E@;0&
M6.4"1%?0QN%/>5R7@^V8*S:I")D;Q3(W;K4IZV"Q0M$0N!J41L).P#2=V!:H
M+EN4*IMMLAUQ;+'V2?EM%?12W+@8VC]$6R;"=4-<2XS$\#-$+DIWHUJ_)YCL
MTH]$+]#Z=K:"`4&:ZQ[KT6_Y(8P`````!`#0`<!WV_RG()GI9''YR@5K,1^Q
M+Q_2X=K7:N;P9PJ$[[DH*&)L\Q(D2$%`HUP]D&TRFJY!4`2.NZ#O@2B8S-M"
M;G&+J<?BKX:3"<S=>]G]5+(![0K:4U\%MKA&J<_&ML*A>T_QIP0!4N6V0E&D
MJ.G+_A--(WIJQB`\W*;<!:?/2OAC'=D\4D>+5"B/`VH<1%NGU^U:J&D<XMD6
M._\`4#V0RUBKK(VUHQ-$]'SY$BH0;DD*T"9N%M&IYP;KT'UFQ@#TWOARX^&;
MRM"%PCD=#,P:H_Z&%28"O62CI$1/-W]BN8\#!N7W.-XH6N:C>VQ@'I]OSJ*W
M*(_HY(=!0>0\:X`!`(INI(O`9!#$H`@8Y*APOD3XD,Q^/@MGQ.=Z(_#/PS2%
MLH,BHGHSF2\<&LU/4XI;:P"Q>'(G?'F4=DDCV>!-)?U3*UT\R=D2MI+[\!F"
M<3;?2O;8<N;H``(F:'$$<'S$BHH;DA4:Z.RM8F!@E<"[<_52R`>T*VE-?';E
MIQCMKSW[4V0#R,N-VH%#OCF"[&"&7`#RP*WMO`/KD$$=%)V0)>4]^#RK$%=Z
M<\M<KD1'K:(_D,B7./NL`0M+G9:F;4NK&J9WDJ2R9WM"B&$@O.7-GE,9J7&0
M489GM29*]"`Y"P7LT[#9,^"<('CN^5I,5;*`??8`<%;L0(*8;<HPARZ829-S
M.0\>W'1BK.@J=[B/GMI]/2)-TPP5J\@(#4H%),-H0RDY#-CR+<4XU-!&1)!%
M7O8$4P-&]_W=SUTW:B`US)(2S]AQ'_2\#LS]H=UJ&FWEX8IIO'(>>$.D7D[=
M+N"$GJGXV$8!0J]?;1@C)RG0(7N</(42%+SBT'@LA0;#CH*85#=_13;9O&<8
MGQ9(?/V(-<&B;X,K2J)'3NEQ`C2H_IR.?JPJ3/9]#R6-P(A,UCXL7`87BF@D
M^"F@=&+C>F.VUF&XTE2`;]9K1>L,%W=B`OF(-X,%(!!`L!D?@#.#YK?$'!I%
MG!\,;D4P.(7"R5*TX51?'&AVY(X@$L*I3+6[X-8&K</?T7KUVR=30OB/ONH\
MDGS@"N)WRY"#+#YHD,!PA``D`00`#)?*O\*LSX\FQ'77B)XH,E/',474IF(T
M!<0K)PC,%H@^</IERDNN/=G4Q,0!?-1$E*-(+<,J>Q(GV&^VNU)'`LM^KR1J
M>`9)`7+@76F35\`VS2(.9T!;6@8$Q\D7;L]^J#CH<%F60#BX+5Q@#F&KT*%_
MM`?#;<?G1'F.A'']5_\`&?U7_P`9_5?_`!F@KP_(I-ZW`_XQX"H-0>LT*O[Z
M#(P3&S:9&4/$,WA$04J;`>3O(;XH`L,,E3>:OD&#<O4]T8XLJ]^4UB.,A10*
M[0&TQL,Z^Q41^1Z*9TCQ:D\Z`MR25ZEB</$*B($J]OS0?`T!J-5^DRR(@U1*
MPCA>P!U,&KS,Y49&R#Z,&^70[><X6A2C@MCQK4X[U<4XU-!&1)!%7P"8Z\MO
M`CW9"X,D\R@4'V(^$M8S)O*[304N4='U5856R(`'P_CQS<44"[A`LLP"Y!*+
MOH'3K_4$?JP:^5P9S#MO3E5H6VY\*W?IZ-:/!H?@'WW/*[OS]PI\<0_"[NSI
M(%-54#YPHJB*52.Y5F'%3HK8?J_]JCPK;YQM8`E&Z"O3DFI*<]<!PY0/RR4'
M@A`IY+:PF>D/YVH3CB361`#5"%>CUMS:@?J(&02N=H5N0JN+)C/GQNESW(\[
M":;&Q98ID*(:,+4/M4.N+%?Z*D=)[&1C.OL2^=D?&,[O$ZAW.`,$N=(G:M7`
M+-$C;*B8W"24"R?03JE?3B$RY=K#SJ;SDGAEH4X,WL;%S@2IXMZ5%O4_"!UO
MI!69L*DH<;"Z'+!G\KH+4*BVN&@%W(1V639[GA-@L2P_#$24I#2@[/-:XJ@L
M<4HX+8\:U..]7%.-301D2015\85J34\8%[;@Y?@6Z&^C2N0#K]K##962?_+4
M`M]M<:QHD&_X46/5D-4/1U%+3_":`FFD1)RM6CTTXH@I*@'2%+HN1=7O/7*Y
MH!`8!%QAWG<ZB(FA[C#_`*QZ5P`&`5#C3!=FFXX)$^\[&S57N#AA7#?ARB7I
MW=2XX;G_`.\LM4D4?`X3K&*TOE84Q:$83[&U0]R;Y%M0)Z,"V/:J/@R8#;0`
M"`3ND%V@,Y8T[`L?+$T@,(:7LPXI&VQ05R-TO'W:+JS=*)Z.8G>I8*N02N0Z
M"O#LPXN,%=CIHOK5=*Z"Y0+G):7>[>52!R8=]T6-C6(X-!<ZE%YW'?PMMH'-
MR(MN^G0*3@0X.)U1NK1,:`,0"S.-]Z,\7,A%<"V5'_=RF064@,FB]PQ_>)4R
M491`,R>1+L8TB@^T!4?[)"=5G@TGMUGQV(_%"BL!1/Y]5OU]OT2[Q(N4MD%G
MT+@C15T_)S1XSZ:;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;DV
M1EP<YR/=.[+;XK[B9;&Q,(L%86#*KL*(QQ^_?:P!SZB[(>>0OKCU>@V.R"2I
MV)\-&!FTI>2@0EVD>3Y!TBG<&U)!)9/LK*2\5<"NNF?KX"-"=D!JX#`$#^_Y
M%GZ6_,PG.#<L,"'(7M`(D-):+J0E0-Y5**PH#;FM!5^Q5>.HFIJ`C^TAV+UW
M%[5&>>`20#J')=X61#DT;0,.]>+R#"^B:D_JPF+C_8A*7DC7V]^P9S.QP#(.
MAX(T9L25OX$];VX]1.V>`$2_U<%&I:QI):K7BPZM&IGQ!)/"P=E`[SQD-SC$
M`,M6"/HS$:/S^V'>JGK""\EYO8*_PJFK[8*.<=EI/LX=8*<Y0)H%G[DA/J+`
MBW!&)?(45NK.PR'5V4"XYJ*J,[)A7<-N?[GK6%@E*>*0V"-6OI(_8F9QA#=5
MT&`/^`1%Y7432=C">WP&9#44>2]QRR-9`VND()>GZ,`XPE`'RFT,$`@B"(T1
MV(G(_7IAI1?4I"\81LU%&>J7#X8D-N4"ZT=^?ETX@Z$N^&@A1,785B)$\@.=
MI!,B.,Q("?WMR1CIXB';`?Y^BI)CF.>@AI=.P#7.=)](?E.^+HM2OV%N/UQ!
M(MMED0RXJ,#T'Z%T_,.LW]R6T&8H)"^#WL,B7$`@&*\&<5I1RMD[37722W4B
M`,'(1RM3//,M):^O,5'J%,"SV"PP1^B<@HSASI-4V;X5Z2P[<4TP=2BH_9*Q
MD<HO&/(3-X*JJ#VXY_`]>7CNW"Q$QL+H)_0IE@Y:,MI_GA9Y!(BD!H$OY@"3
MH*H+`S`U'_)[RL!&2"6J8.T9%I"4RE[V.PZK-S@`,*.GO!,C:E5F`Q()6MA#
MI"MK@21X'8==A)"`R&LW"+:Z'GT^W/\`#7__V@`(`0(#`3\A_P#Q-/_:``@!
M`P,!/R'^83_+KU_#ER_S=?\`[Q/Y\^OOYDR?XJ?_V@`,`P$``A$#$0``$```
M````````````````))))))))))(```(`8`````````````!````!!`((!!``
M`)`<`````````````!)()(!)))(`!````!$`````````````!``(``)((``!
M````)-)))(`````````!)`(``))((`!```)`/8``!`````````!!()``)))(
M`!`!(``$@``!`````````!!0)``))((`!`(`(($;``!`````````!,B)``)!
M)(`!`)()`,C```))((`````!``````````!`!````J@`````(`````!`````
M```(`!`)`!(`5J`````(`````!+:(`!`!`)`!`)`!``!<`````(`````!```
M```````!`)````!'(````(`````!)))))))))))````(``&@````(```````
M```((``````!`!```%X```!``````````)!`(``!``)`````+C``````````
M`````!`!!!!``(`((``)B``````````````!()`)!)``(`)```!E(```````
M```````````````(`````!T```````````````(```````(``(``!A@`````
M````````!````````)`!````<*`````````````!(```````)``````,*(``
M````````````()!(```(``(```$+K0```````````)!))!````(`)````$`!
M9````````````)!))````(``````%MJ220````!````(```````````(````
M````0````!```)`````````(``````````!0````!```````````````````
M``````%3:0`!`)((()`````````!(```````````0`!!`))))(``````````
M``````````!3:3`!()(!)```````````````````````````````````````
M`````````````````````(`````````````!(`!```!```(``(`!````````
M```````(`!``````((`!(`!`````````````````````````````````````
M```````````!(((`(!(`````````````````````````!(((`!(`````````
M```````````````````````````````````/_]H`"`$!`P$_$.\^9(8*)$H!
M`>=^197T"M]T9`/&D2)$B1(D2)$B1(D2)$B1(D2)"$(P.O)M(QEEVF5`%2SN
M+N"QAV)18,M4@Z8VS0T?LO3A5KSJTO>M1).BSQ8$@\4D=]5J`(P6/7+/AJ'#
M8^GNF<V/8JQ%6T805*7+J/<@ZSD0V!GBOX"AO:GB^CVGR+)U<6$_1LOOFQPQ
M``U$26`"6HBRO5?P)]X+/A@`P6NJN#6R@80!.CB;"B'%B(6B21?CO*+`XP`3
MB>R\Q.OX*7.7W*W"*_$8)`3-1LM,-S!53LQ._AXH^@4=R@S4J25#%4\```9?
M(8W:;IEUH`N&*^*</(XCQ"\[=1#J'%AU3%`(G2V>GB2NKK#\3-=$.KV^R\9&
M!FIHSZ0N:K84CA@I)F"Y$LXCU$>8JFL6GUCA%H\D#9X"ANP]>'#!SRLU`?7S
MO`!A5F_"GW)<CE3U#*)@&9?@K+@0NZND5JDYU%FQ"I40?!@F85S/9.N*:5Z-
MVY@S)K.2)(.@OQN71"4H!5;@7;CN"(FCO)GQUF$JFC.'W(LX1'S;JV"(OR[.
M"4"ABS1"1(V%B"3,1B02,FWH,QC16?;7$.;5I;Y,L_K/"SEC"D.KU`HY2MG^
MX(@I.E8@[-+0"&M6.R+:Y8^A`%,1-'@"$FC0R*L"C<G)U!%L;P>-URK-%F9*
M30@CN1=KFQ"D6F02$M9,,*(?E-.?$!SAYX#5E&<_B0UYF"YB8JM1I!R(+?H%
M%<G?K/9<$+,9>$6GB[JK0![%2>:!%(1==!@".A;C6@""@1G?<N7+ERX1':S'
M7Q$Y(L\7=07K&"VP"`3?!BVW>U-702BQI3%QB"Y9=GM$2(]$.KV^R\9&!FHF
M3=2<WVFE@1J@K;L01"``X='XN/F%1RJ!Y;<Z`2BSZI33(Z=KXO#H;*F/UHIP
MAFN!B0L?0NAPLK@G"R8YKV8O^GLZDX-2F4KCD`=)2?%VJGIN=V\YPLY3BS1Z
M1=V("G/84P/R./-,CHZW'4H1C9<_CH%]T)0M$0``$.@/4HPJ[*<,CH:*@S]X
MF4<`MG&PV*\E4E5<%0"/F3KH:@>1!*)31(`F0T(^BH:>AD0&Y$!@)N@R;-O0
MD$C)MZ#,8T5G#&SZWW0@K)1V5O'8:B0VIZ7`@-$*F5.*MLF85W(*R_!%#<%=
M=0E;6,G.$`)7*;1;+XSI\,1=PHA6+DO;..Z.5/T3#0]_AP?3#>XAR>",3D8:
MB-#YVL31\1<`>X?!:R''?<^$_P"9E3`!]W`:H*VY<)PD"IP9^61QPQ/5N6_-
MTM[@3V-3"*$ZZH4@B(HC$1H1Z#$7E`1%ZN@&UZ"G`J554)#!G"4SBVV,AIM=
M%ZSYFV$H2+`V:A'`I5F-'.LF4D?<A8(L-99"JP/);A)@%"Q/B]\S@0U!&9)A
M%V8\.]%+-3C5*L$K(:I.ZM@0?EOEQ\HOX)<F'[V:_"KJP"9O#DIX%)I$`!T,
M*/(QA@7JX?-[G2LR:H"9VIP>YU1PAKE$<**X-,L%68NJPUP*NOT+0A:B&LO#
M,W>2JTUA=K)M%!LXR1="H4DD+IAI(MG72#RIUTB<Y`%D%@.E7H*#[:<Z820(
M3A'?2F,\>K\J*EABX,74Z.T"W9X[%Y@G*_L`#%#28U!E2QP(=V:,52H^]CT(
M5AQ8ZXNX2;PIR3^M#_U28B55V<%ZS'&X5T.G&6KZX\1F^T$_PSK"U1=HERNU
MRY*$2W[68(F/8`S.@8\^$UU$XO8$H;8]*F(>+=(Q\UR@$NA(`)9"J"PASA_<
M"^Z$H6B(``"'0&F1G2*S8FYO6I,5!('4(*K(TV&SG'25@MIXP-(I0'17NIGO
MS\(A8/@9H<@);$UZKVT`JVX:^(G(,O?N7+ERY#3NB4<8P^:R59_K0U^FNN3L
MN>?;?>W;!<E"]4N6(2B.)?@!FZ+\BOL*&B.;E8%SKQ-0(DRDJ!BR$QOSI<.<
M`K6[H=W0>[/&6/:!:2%6ZFD>202P:#M'B)TC.+0"?R6]QAMG5`+BD'4/M-$$
M/J%TJCRD@,UG@E3!V!ETM(1C@D-T%)(CT-6AMO/V&!B>&PJ>X,%$P!>C%JRH
M038$QX2+T,28FR)#O<WEFB4`"6J#D!!@;.FL8\5ZIU"H-7.C+,=P['%G]B[4
M6JER#C3@]SJCA#7*(X45P:98*LQ=5T"^`E""22)6HB3H;/>=[Q*B#`G"ZCG`
M/A6DL>4*UNZ@_'0Z#TC-2V\/]%&>?I3^XX:GR5-9(*!M7AR8E8=CA?3%TBQ)
M2YO2?Q;["$E^70&XIT.DY9!K;VS'>.GV&&&7Q,&-W-0'L&:@?&@Y+&!&;IM.
MUYF#V$5$*E;5=""/<@G_`&U=11A,88EBBES9,)41Q&V;5:2IM":RHT5D/S#)
MI?O,P(D8+?M!Z)X#6#E,L\%\N`!W.48.J[!"P4+;(3W6ZNW\;44O<O+H(KBV
M109<2^051_A&`=\P+[H2A:(@``(=P/MHZU+ER4B/,OV3+6[KEN#?AK.Z.H$,
MH^H'3YY;5'/7P@T'#(TYK`'D'WO&+V`31T!`/O4=#B:#!@DC-96H3&WB^E."
M07C+6WL>GL%6?ZT-?&D2)$B1(D2)$B1(D2)$B1(D2)`R:,T5H+4J-+U:"[4F
M:Q%$FDQTU8)[KMVUL"#8$9Y^(@(+P9J.%5B-,Z<-AQA030\7YMA'"BN#3+!5
MF+JNWG[(>V[(BH&J</C30&F1)L[(A`,:181QG9=4/X@LJ`.>O"JF*`1/$;MV
M[=NW;MV[=NW;MV[=NW;F@)^F0VQ9&D!Y2(@S^5+00P&*"^C#I7B4,(^C3;9W
M&3^Q49W'UD5;#B<>&"CPQGJF12E6)@B8I&<$6YSYV%?"P`%F@7H>$CI,D:=A
M3!Y/J('6IK:^=]EZB>EYJ>KH`7%P4497),%!'V==\,'F]/D-G+-"DU@4==5U
M"S>(Z#GAP```@&@[@9/"`;&ZP[]>\A2H\H+-$A+AIVNF;J-=(_#0_<^OYOX:
MCJJ>(S9LV;-FS9LV;-FS9LV;-FS9C-<CT]84-R&HKF@H\2B<*Z;MY3`T&42(
M^<ILS<B2H"()A5,TI@L$93:RRC]8T&%PDK*8B!0!96+LV)Q.]\^7(/(3T0PH
M<[7'0\(',G-'`9JEREP6Z<1["BV@;PPBXP;XNW*QI/%``LK:/S5>47U7SL`^
M#H%'PT`W:I8THX\H5LS-*%@FD9N=/9"KXP9><Z)%@I(`"(VS`0$[TN5@)3%0
M,)6H,\C?.2-0PULD5,Y;#NR_E3GM*W0!T[*H8DC3\%S)?TQ(TR3R7P3PB-*;
M!>_\QROW_!R10<F`O0.'!P8T7'!.X\LLLR1*;%.A0;'%A+=$'>4V*+UQX19,
M&G<WJM3R@0X1O`<0]`V!O7%)5)"YLWPR!D8%K"+S0[1(3;Q"KR`[!*X%:DO,
M$38=E^E#.3K79PFY]-3$TG*`=:1#`&ZT#=N1@F2VT9D9BS#S6PX<)S?1F1'(
M0I[$F`5A10U:&G!="ZG>8*`:`Q*Y$TEM@V-(>#0SS<QE"0M,C&[=GD&^(K[2
MA\U"G(4G_451[A08:/M60+VJ99/613B<!0DP#,+VQ/:(I$Z2Y@;3H>;]T(R@
M$!YC-?3FY'MCB*@-A@"A`8$Q[<MJM$:DZXM''A^`%218,*LBGB.NU;`E42B,
MHAM-*OCUS)!@=_Y+*20!TV\O'+S"I2Z(&A?A8[$4H!AV8M!;_P#S=M]$H<.H
M2@&BH>Q.H'@@*RH7<@D<#?[I>IZ:EPHM4.@YX<```(!H.\'_`)@/.M1$+2/R
M91H$&:6*%3WOWG]1PW:G^H34?(8H#H+%@@/-P<G,&I853A5,BD)&#G_>J$.>
M!Q7T)-=!0!Y+C<!$:E!)#78Q_P#9<*RL`!0Q^`&OV^=JR#@)=0]98-:QQ%AM
MV#\.0WJ@N*/V4$W,2:3_`#DDTQF=="$5J^F.07.,+HAF*XY)=BO`K``Z_)R5
MR!5@#]LQ<!JIUKCFO3U)AVBY"O$%S36>&!7RNF$^G$K4U=R=APX3F^C,B.0A
M3VN6Z!5?678<;Z"--(-*&$O`(V29DX:C`BLS#<6QF(0;\R,(+5PR@$*6H08+
MQ&W5@Z'2$I'P.%,&,`+P9RQPD+E"?1Y,R>.HZ`&:K#JF*!%,%-13<$@L(9R)
MW@U-(K(G0H3-.6YZLDYG,PI@7UGXX@&$K*,$9&FL*H6*.0W+82/FF/\`$H2&
M(XMR2T3JW$/<">8,^`%R=UQ.XZA5E.!*A9_TX4!X%((%KJ*`_473T+NH_J*1
M74@%7/\`LN%96``H8_&#\W>%J^/QEK"?-500^)@"&"2^=#'2RV-4G4.L9,A.
M\S3D@8`@>489Z,R(I26Z"#HB.\V1*G(/2O\`ZMD#%0EB@$GU1T^`T];,IHTT
M=I2[*4`<,&04B^91>>/#+7\:%Y8&`[_^GT&4<K]>C'!&^B(K==@:B^!DJB70
M570S:#&3[B%-!O1/<DT!OOL'8=#-Z!Z>?`DN0A]]$72$P;C8+;M\AX/<)TVI
M6N]CQE+;`J!/X17N71^2&+)/BP1%'HU1@EXTI&[('O/[O2&?U]>C/SG_`*1<
M`D8@=[T0LOAE_-?X-GDLS!$-P5.'F)@$X"20Y0>#1"8%+1OPRS%QL2I-.#\!
M?O%'(0(0%T)V"&TE$S'K[$^@5#<XEFQ]H10N&A4G`#01:`>4;'&\O&X$MLRG
MU(`$!M+D:18LZCO+4<>@B(A)(IKSH1%C,RM=4B*63K4'1!TJ=0`+*I6>AR08
M)?*#=U0Z[9OG(TTV1S4$MO:4TM1X!VJ;Q5D(B#)LL?\`VQ[13FLI:A&1QAJ1
M0LK/AI5-&</N19P`N(7)340D..:\WBJ4^AHL90Z`#$Q=Q=?DBYP@@>AK<)70
MFD7P-F:4GA9VY,`>WTDA,C%#0%LE]I9/;`,8I5K]$528F9/X04.):PD5;/']
M,7/GGM&9N4^A7G`VY+\DNWP"K>%OJE:%E+*M60;$-,LJ8.J41S4,6;/*0"ZQ
M>AJ3!@[K![3X09B0BP'68#OT=B9,F+]X`%J1+HX2,CP?3Y;"&;YS\]*&T-2J
M!4KM<:X2OJ@>AYE<=GK$'>(PY%^<,0<%=5A41(;PTU0%0]&$6$R`H.QCJ6BC
M2I(T\H`TKTP(X_'V>:;#28TK"'8##9;(00:N(5GY=2`U%33GNV,N(KB@=`D-
M*#L&MS5GKPS``;]H-HRJ$\_LF\C=/^C@^I2Y*X\92VP*@3^$5^=AL$J.$AUD
M$X!*L('$M#D?8^%]ED$_+VA_XLLXFB:>+*C1>'>.;0[WUTY*R7`!$H".Z8`N
M.377^D(21`_6YJ&`;22`,S=H/+P@8=D>X/43L%8G'_O-'OY0]C\88C(6DIS-
M(/S\YM!`L0_(H`.7"\L7J14`F,FSP@<3I&KR5&+5Y#)^<".#%B-"<M,H($/[
MK[+1K6P^)B5PLL%"YOU@;%,"XB];)G0"O+$D*L;A1SAZ,;$*UL9X'=I[6O#;
M+M!*^'I/,A)O@QGA8*?XM(%"LU0AT;Y9O>)9^4PN824)9=D!G4ZQD:.SQ9%%
MBE@><*0Z;9O,5\TDM`9?PSUD%SH(NB^_50.Y#,S'[L&4<!IF;L8<XX4XZIE\
M*A`S5;FH&KNH&CRMK$)N:70IBU8*/^S[PFU5AM"4R@]\]K<N/5"CZE4!'`W3
M_HX/J4N2N/&4ML"H$_A%?%2:PB%]0+ZT&B]_W>DU[,^Q3=0S`V7'Z[B/>DPY
M/(`]&J3,0*B9.'2!8M<([7(3(MAX`A$G0YK'C\Q?);9CKD8DY$01V3-J025;
MJBW!U7,,^F)""'*WWF@E/6QIR/DL[<_'OS()KNR$.63AZ'AL4G0#Q4A0`.OX
M:3-FE3X*&("`AC5*T"S'6*?R/9$S5#OD`[>DX7/QY@QMA(O,J!L>S8N1-P!.
MP_ZEG*X-T@@<7LJ<&9B2K0]$2PL*&"0+9J,%-3TO6F4G*@Y0@%9-X&X7RQTJ
M.%[QMY`6%(H]([/+E69F7^S'*R;U`1V2IL>D&T,Y%6N/']>ZLJB)@%'.D<`?
MY"BLZ(#B%-S%NX+;!S6?@N0-/(F2@#>$D?A0]*BZO-'+>56104D,G3$B"E=Y
M/?Y9U?PMPIMG8"J23?IQ,$$?V$&\QA20S,`'T2G8$4TB%K56/Y#^E8L6+%BQ
M8L6+%BQ8L6+%BQ8L6+%BQ8L6+%BQ8L6+%BQ8XQ6K@@AV1(UW-$\21L1%P;U3
MFQR+V00*K`4(#.\\PP?-]"!_[,>X3P#V9F`9O;"]*WE[7<T6*<(.9SQ@DXRN
M[B42DNIY'VTA51ZJ,PJKM%7R,=@0O<CY`XW(*$[F?Q`W)`V#A!=4+CK>79QG
ML)=@2MLPBC!(8X(2[B@)@M-9_I,@CT,P/RA.R,OU[0QKID)H7YB7U1BZRO%(
MAFB^DMW>`\TSM)'N*<BVC<CWO7M6M8@QZ@A`EJ=I5[!\G+NRD$AT!""TM\5>
M-!M\M>X?C$Q`.O6!R-:NP1;@C%_(FV`*DR-:,AAX][^T"=<Y80VB21E7\CM@
MBY'`)RZO9D]@\53P/971D/31016D@&J'?&,LP1BPY0"ZLWP4%VJ=*^]GE5S]
MV&<,DD^Y)%;`#$Q?I+J5)*ABJ^`50,`>"W&M`$%`C.Q9+#=P<V/`HZ]S;B92
MYYOO<`1Z?WE@"$?VLMN'0<\.$!`-$TGUZZ:2/E+G$J`,2U.XV]&*S3]:;Q7U
M^)C(=4D-V/8>UNYZ!`BH7G;7L%V<)F-/]S:(T"VAYP$NAGXQBV?$CX7D8&F0
M`A>@%"M$5ZI68XK@7%JTZU#CEG<J!/C=?J`6+$!:,5=KFS`"<T2-XNVU!4HJ
M7`VXU2$H3DI-73[B4"1.M8Q!$X=I!26+%-8_7GY<Q^$,:9M!<<<N8NG/27!&
M<#A#?N,($PZI9!*;C6"8"LL8K"4?NV%YM`%SJ.3J^GK]53`\#.P/;B+,4.1`
M`40$4;3N:'`)I^^IE20HNA,:_+2AO$..Y(DB)4U7R9-Y@3,>^JCX.`E%M6EF
MW5PJSQF_'UP`21?<"Y1'_">?ZD]$-AI9*:`3D.NDJ%?PS__:``@!`@,!/Q#^
M81_+KW_#DR?S=/\`[Q?Y\^_O[ER_XJ?_V@`(`0,#`3\0_D&(8_QX>/ON3$GW
MSDGFQR.1\XXP_3$?,K*ROG'&28/^?WIPX:R_I]X,RGXP=X\^5KUFO[YK^_T)
MS]\XQX^^_P!L3W]Z+<Y9C]X<X\[QGK[UX,>/O7@SU]Z.'$SC[YR?KG'W8S'C
MH_G[QXZ>OO/70<N+<6_?)K)DR?;&SL"3*Y7*Y7'[Y/OC[^:N3)<"F!<GWWK[
,X_&3>)B&)D_P#/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g644794g73g29_g.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644794g73g29_g.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-/6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:2\^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@/&1C
M.G1I=&QE/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CYG-S-G,CE?9SPO<F1F.FQI/@H@("`@/"]R9&8Z06QT/@H@
M("`\+V1C.G1I=&QE/@H@("`\>&UP4FEG:'1S.E5S86=E5&5R;7,^"B`@("`\
M<F1F.D%L=#X*("`@("`\<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B+SX*
M("`@(#PO<F1F.D%L=#X*("`@/"]X;7!2:6=H=',Z57-A9V5497)M<SX*("`@
M/$EP=&,T>&UP0V]R93I#<F5A=&]R0V]N=&%C=$EN9F\*("`@($EP=&,T>&UP
M0V]R93I#:4%D<D5X=&%D<CTB(@H@("`@27!T8S1X;7!#;W)E.D-I061R0VET
M>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R4F5G:6]N/2(B"B`@("!)<'1C
M-'AM<$-O<F4Z0VE!9')08V]D93TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R
M0W1R>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I5&5L5V]R:STB(@H@("`@27!T
M8S1X;7!#;W)E.D-I16UA:6Q7;W)K/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE5
M<FQ7;W)K/2(B+SX*("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T
M(&5N9#TB=R(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#
M`P,#`P,!`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`*@`E@,!$0`"$0$#$0'_
MQ`"````"`P$!`0$!````````````"08'"`4*!`,!`0$`````````````````
M````$```!P`!`@,#"0<#`P,%```!`@,$!08'"``)$1(3(10Y%79WE[?76+D*
M,975%AE9&B(R(T$D&%$T%V%",V0U$0$`````````````````````_]H`#`,!
M``(1`Q$`/P#>/9-[)O:[Y6]KOB=R!Y`\3JWHVP:-6[\^NMU?7[7X9W.NX;7]
M#K,:LM&UG0X2#:BU@X1JW`&[5(IBI`8P"<3&$&H?XX_97_`O4/K1WW[U^@/\
M<?LK_@7J'UH[[]Z_0'^./V5_P+U#ZT=]^]?H#_''[*_X%ZA]:.^_>OT!_CC]
ME?\``O4/K1WW[U^@/\<?LK_@7J'UH[[]Z_0'^./V5_P+U#ZT=]^]?H#_`!Q^
MRO\`@7J'UH[[]Z_0'^./V5_P+U#ZT=]^]?H#_''[*_X%ZA]:.^_>OT!_CC]E
M?\"]0^M'??O7Z`_QQ^RO^!>H?6COOWK]`?XX_97_``+U#ZT=]^]?H#_''[*_
MX%ZA]:.^_>OT!_CC]E?\"]0^M'??O7Z`_P`<?LK_`(%ZA]:.^_>OT!_CC]E?
M\"]0^M'??O7Z!<G*_L<=JO.><':OR6E\1:S!YYR&V#E%6=DK:.@[(Z0N\%GW
M#K7M/I\>[>O]&=RD82%O=:8R!#L%VJBIVX)JF.B8Z9@8W^G'^"OP7^:&H_;[
MJ_0.WZ`Z`Z`Z`Z#YGKQK',W<@^73:LF#9=X\<JCY4F[5JD==PNJ;_P"U-%(@
MF,/_`$`.@S/,<QN/J/%G1>8U+T.NZOAN;Y+;=EE+/F4Q&6I*0JM0HRVAO&\<
M+)T*9)IW6R)JHM7!D50]X3\X$`P#T&*:%W#]CSSBE(\V^=N1Y1BV(7:K8S<,
M-J6+Z?/ZUL+Y;<I>/B*-F5^8VBE9O14;]*.+1"$*[CY<T(@LZ<@Y7;MFAG9P
MHRU=Y"'O-LXTS6!(-H[/I:4[B<'R9JFC1<%)7&FV;A5QM/J85MC8J%=[/154
M1LDY"O#R<1*3,=(P[TGH+E,<1(#&.+_)UU;^&'#_`)`<DY.E9_H/(O,./DG)
M1,*E(QT`\U;=:Y79"&I=-B)!].3BRSZ6G@2;MC+NEDD4SJ*G]))50H;2Z`Z`
MZ`Z`Z`Z`Z!1O.7XDW9'^G[FI^7[O705U^G'^"OP7^:&H_;[J_0.WZ`Z`Z`Z!
M='-7N09#Q*A).$AWM(TS<T[70J&VRZ4UBE977ZA8M2KVAV>@RVY:C<'!JYB]
M$L$9ELR#>3D4EE';Q%%HU;KN'*)#`C/7>9O-C>=TXY6J70WO*<'VOCCQEV>D
M95EN/:%L--U]*X0#P.77$FZ9K6\P66L&KW()QLRC9>WWJ@1%/JRK6=;F5657
M.`-<[?/`NX<8\IY4<'[]DN((\'K3>MD?8:[J5AD1T>X9)R$E)Z8F<OV2JI4^
M*:MG^8UVP#6$)L9Z6>R<>T;E#TDFZ9C!&X;LWP2V"2'&+>.;7*3<>-E1J-7J
M6#9[;%,<K)L&CLYNE1O.8VDER@<T;SFFWO,'5%CF,1(6E218)1(.&J[%<CA0
M>@^N?[>O%O4(&OT"S\F]>MUUA<TY?8U7[F9/'ZN\39\T,XKF6:`^90>>8Q1L
MV+)UBNU=`*][I'HHI.5EC.0>&4#RA:?*/AAL-NJO%3.N-MS:T5EQRR7=J=1K
MS./R)N\]TR3XOS6%8'J9(MK'KDDY2G&GY$H*H-U#QZK_`-Z304]/TQ#'>C\J
MN2/;)PK-L6LT?-ZWNFF7Y22H]NVF_,=&H,'2WTDY0MU:/?'5OSVU.X;.IR1J
M<(C+6ES!)*2%Y051]5I'KM4P>5D]T<WO+J/=YAY0UI6=JL7)6-;-;DG?<\:V
M$&9"69G4[P#&)+98"*FTG#=%Z=LV.J1'S'23-YB%#O4J\4K2JM"WG.K?6+[2
MK&U%]7K?3)Z+L]8G60+*MS.X>>A'3V+DFQ7"!TQ.BJ<H'(8HCX@(`$IZ`Z`Z
M`Z!1O.7XDW9'^G[FI^7[O705U^G'^"OP7^:&H_;[J_0.WZ`Z"$:5I-"QS/[C
MJNI6V#H><Y]796V72XV1\E'0=<KL*T4>R<K)/%1\J:#9ND(^``8YS>!"%,<Q
M2B'G\TCNZZIO'!O:.4/&65SGC=6,FVV_46^VW3F2-^VW'Z1"##5C%!TCCK;U
M<XCLVT3D3J,ZP\Q;%*_(E0HCP9IZX56*=%L%0<)>'=_YPX]S/MMK@:%C^-=P
M&MVYGO4#6'<Q::R//?'K#'0-0YW<'=%A9%FK=.,^K/8AM:FK:2?,E4+!")G8
MF6:.UUU0V)Q(XRG[;!=/AH>V5B[;#M3G-+#LUBJM1FZ7F19.A50U;BEJ]1+!
M>-"LKR[VQNY<2=KL\U8)*9L#]X0RADDF[9%`)WQEY)<X(=ON#?E.YRJSOY:_
MIR>(RM!;E:15=I#M%\1_!2,81LRD5THLR#0S'WY1=\8ZR_O#E8I4PZ"3:#K<
M_+QDC-Z%<DV=<AVCB3DW$D]:0=9B6+1,57+Y\`&:1K=LV2*(F57$?*`>TW00
M*MV6OVZ$BK34)Z*LE=F&Y'T+8:_(MI.*D6WG,4CJ/DF*JJ"Q2*IB7S$-XD.4
M0'P,`@`76;N-Y[EEPSS&=5G(-?2=$]-E08<CYXVG[%Z9SM4%9)-&.DF+0S]R
MB9%!PX4:)NER&(3S'`W@&A&>RYIKE@KM:T'-:\[CFDTTFZX^N#:%L[2%MT8?
MU8.6:-Y*).E$2J"HF!L]2,59!4P>4Q?,)@"`<A.#L;>N/^_Y3A-H>99-\B)Z
M'FM(D'5BNB\9=ZHS4B(^QXTUE(J=2G,>SR]Y[&*58R]/*R<04>^6=LD#O!.=
M4,/\;+!K7;AB(;A5&<<IGE!R(OB5KY*2:^,Z?5H:IR%#:I5FM7>S2)-0;9_$
MYDWH[XL#3*W#M$5CW)RB$J?W1=:9.T!X%1L1+=5*Q;$X:PUPEGKT+825ZW1*
MT!:X(LU&MI(L-9X)R8[B%L,8#GT'K0XB=NY(=,1$2]!(>@.@.@4;SE^)-V1_
MI^YJ?E^[UT%=?IQ_@K\%_FAJ/V^ZOT#M^@.@YLO#Q%@C7D-/14;-P\@D*#^)
MEV+62C7R`F*847C%ZDLU<I"8H#Y3D,'B`=!C'1.`.$7SE'5>7;5.?HFJ-ZM,
M9ULS6G+0S>C<J,FD8"1BH[-.2E+F(:8@M(@ZC(ND7\.\421E6!VX-R.O=#"A
MT$KF^256IZJM5IM/3<Q%?;I0T,HQ7:0\`@A'(%9H-8N.:,SE2B6'H@BD5,$R
M>FGX$`"^'08OEI21L,M(3$FL9W)2;I=Z\7$O@!E%!$YQ*0OB":")`\"E#V$3
M*`?L#H,AXWR:<[!MFXY,VRRTP$%CSE%LRTQP\:2-8MROOI(]9)%1DE[JP7>*
M&%RQ(FY=BLS(8ZGHG#R"%\Z%1*YJ%%M^<7!LX>56\5^1K-@;-'2C%VK%RB`H
M.0:O4@%1HY*4?,FH`")3``^`_LZ#':/'/<<NO7&"F\<M$CZ5Q;R*-E&NA5.Q
M/EIFS6PTC.R,M)I2!#10$L!I5N^]-FH"[,L8Y,=8"C_I`0U9+Y[D=DT>NW>;
MJE%FM7I$8K_+$\_;1;RZUF'>JK@*S`#G-(M&1UW"OI+"GY4U%#^F8IC&\0EK
MFR5II.,*N\L,`ULLNU6>Q5;=S,:WGY5D@)RKNXV%7<DD7[9$R9@.=)(Y2B4?
M$?8/@%LTW3KK1%@-`S*P-!$/5B7XG?12P![/_:*G#W<_@'^]$R9__KX=!9^R
MX2PYOX=)3S!Z?)]_C:Q?J)F^R4Z;M5:LU-;6I-@VM=?3L=2F(.U(5"]QS%%M
M(H).3+-!]-^S%*19LW*(*UX[\D-GX57:7Q6UEM)>,G'6Y6>,T8+N:*D9*J16
M@3S):E*3.DM6TO%EEG3!\R0RK'J.TLFC7I691F+`-81?MHL@>E!!4%T$5RD5
M3*LDFJ":Z1T5R`H0#@19%0"J)*E`?`Q3``E'V#[>@_7H#H%&\Y?B3=D?Z?N:
MGY?N]=!77Z<?X*_!?YH:C]ONK]`[?H#H()IFFT3'*1.:1IEB:5&C5HC-:P66
M01>*QT,V?2#6+0>2)F+9VJU8E>O4BJKF*"*!#"HJ8B93&`,I:;RDHE^K3^O8
M??JW=6\M'*-IBYT2R1,^A"MG[<Q#-8]W$.GB:$UZ2GB<R@![MX^42BIX@0%>
M<7^.9>,])L--+J-]U4;#<I2Y*S%^<(JNX]U+)H%>,XY%%1<$4GCA$SER<3B*
M[I0RGE+X^'051R8;+:CLV?\`'VQ.I!OE!<LLFU:#6F3Y[%):P[:72&HM0I-B
M=L%FKQ_G\&Y<O)27C"*%0E')H])T"C4%$5@ALAQKRMNO'S>:0B&"7V"2%.M:
M-AD;!9]9(DG@'_82;&,BOY6O-97$H`YAY]A)1K@O[4BJ>50H3B!Y/V[*#H0?
M*^)BF%?!1)I'<G*!&/TLF?>H<$6XZ]4CKRLY@\NN<Q04?*+25144-X_*++Q*
MV`.S>.:F=5.SQ,`Q-!3+:=<K-*[)KW2*BB759N"0J'HI`:R"%C8J&5`C=TDL
M*+E11+T_$J@&Z#OT7C]E]JY`'YL5N3N+RY6O/4Z0,.J\9A6F#%FW;PCTZS!J
MT4>?*C=.)!%1,[M1L18AE2%$QBB`5/R3CN!<9L^;[WR'VG/J1I&2)-DJVQD]
M<@X51W\ER3J8B"RE,9NG%DE58J4>JJI$;II^KY_(J54G@7H-*XSR7X_<BV\L
MZPW8J)J`P/I&GF58EP/-PB;@XIMW$O7)!%A8(UFY4`2I+K-2(*F]A#B/LZ#<
MN!6ZPQ-Z@:\UFCM:_,/G`2<:Y.D9@J8&#A4JB15_8V>*JMTR`=,2F/["CYO8
M'0:-?\1\+GMQ8<BKA6YO0-1KSPLC0GFAWF[WBI93(_);>(7E<DS>RV"1SO,Y
MYXT0'UY.'BVDDJ*JOF<>"IP$-*]`=`=`HWG+\2;LC_3]S4_+]WKH*Z_3C_!7
MX+_-#4?M]U?H';]`M71.%FYT9R]M?!_E;>\<E#KN'RF,[`Y>;AQ^F%W"HN'#
M2/C[F>:N^:$>+',(GAGYVJ/CX),R@'09SMG,3D%6(&>POGOQ?KY(70X:4H4E
M9:!;VM2KMTC;!'+1#Y.E3%_?*Y=+33UL[%1NQ7N,/.E4$ODC"F`H`&/;)%NI
MO'<'M%JX\U1IK+S1APB_W;3V%VQ+1T'[1E+,,\T,MTRP[:S^72C1#`3+>N_9
M`^ERE*8X$-XA_%HGF;1C`I2F#"U,T1*8E7O>IP.G1JA"^T$&MEGJ5CNB-$Q+
M["G>2<L<`_:!O^H+MC\[U_*[?8];Y$V?3<<T&4MJZN8;+H]]S/1\5J4//*K&
MN><Z`Q>Z359&8RZU&&/5>%BVS!]#GAV;QJH55`2J!=V)<_,&U:\N\=E;YGT/
MK3!VG',AJ]O"UY%IKDY#'3<8WJ3B/AHZT+K%()CPSM)G.M1_T"W6*`+'#<QR
M>Q5%4@"4Y%$%T52`8JB:A3)K(+)'`2G34(82G(8!`P"("'AT"KN3/;1A[L=M
M>>+EQ3P'2(.5+8HZJ`T0>X[,RJ3M.15]Q@EH^5-ELF_>H`<74*V4CO6$5%HU
M4YCJ""9->E>3M9G#Y%R1O?(*.G4Q>O6U(O&G6<U/L+95<RCV:II*M*1>>WF"
M<*F$YEF22PI>;RN$D#^*8!2\?"0T0)S141%QIU!$5%6+!JU65,(^(F6602(J
ML81'VB8PB/07?QVL&CU+DKQ^L6.3"4!JK[6:/0Z])N8MS.,)"(O]@8UJUUVR
MP+.4@W-GJ3JNO7+MY'^^-@\69'!5454"*D#V)8YI]DMDO><STZ"AZOL>5NH(
M;0TK#I^]I=QJ5L2D%Z-JF>.)8"S)*K:AAGS59B]\[V&F(UVR557*FBZ<!J+M
MM<Z$N3;S3:$ZI.FTM?-[5(UA%/3(TS9TK(1HJ^NQC)`%%4G)0:-C+*LC""\>
M/E`WF(J00!M'0'0'0*-YR_$F[(_T_<U/R_=ZZ"NOTX_P5^"_S0U'[?=7Z!V_
M0'05UK$C5([/K,:Z1,18(!W'+1[FNSL>REHNP+/"BDVB'D7()+LW[=VMX>HF
MH0Y/3`QA#P*/0(`TGCE8'^=VBB8GJ$OE\3/(MG#.BSB"UWR^!GHF696&O3M*
MB))S_,&924%8(QNZ;?(KPD80Z8`>/5((E$/WX>8[M6/9_+U?=]=/KEJF[W*6
M%E,>^3$FE!Q,J1F52+1DI])"17!Q)$7>"EY"-VQEQ(D'E\>@\DG)[3+3R`Y$
M:WI.F++3$PPTK0:;4H:7\SMCF],I%SFZG`T^KQ[L#MX(C=K"@O('1(FN^DEE
MEUS',8H%"EGS)G)M%&$DU0?LE@*"K1VF5=`WIF`Z9O3.`@51(Y0,0P>!B&`#
M%$!`!Z#>W&[N([1Q]28UK032N[8ZR*DW(SG9=(NM4>.3`"@%3NTTN1M=8IDD
M'^B+GUBN0(`%0DDR@5(0?1A'(S%>3%0&[XE?X6[Q#90K6;9-%O=K+4I,?$JD
M-<:RY$DQ6Y1)0IB^1PD":HE$R)U2>!Q"2:KD.9;C3W="UJEPMYJKI0')(^80
M/[Q%R!"^"$S7I=HHVF*W/-/VHOF"[=TF(>P_AX@(>?;DQPDI?'70X=!SR68M
M,<D2JREAB'U?C=%Y/9O75/\`VTVQS]E:*@.JTIL8I@5D$TDII)(OB5G)G*<W
M0.7X!\%N']#0JO)[(-6?<J)>5BWZ>?[!*2E;=56N(R""D9/&I%2J<='15<LZ
MC=51D]6D?>IMDF=1L)T/.L0X7M=M9SFB<OWUHL=F:1$)4N,L/1;E*-FLE-%5
MN>D[0:5RFDF0@&4FY5LRK&G6%PW:"05@(]*```KE\P:\H_).1S1U):*?`-%^
M2(B/7*PM6R3=(XZT5BL]_P"-Y(R4AI4XE<4?^S*)$P2@%EC^H;P((@'02=ER
M.[C_`"2#T..F?9)G=7?B'N^K6>N7Y_263903%*]A;9HK.@S%](4"B)58:BOX
MU80]CTI1\>@U=AG$_8*Q9(72>1W,':-^O\4L+]M6X=>/QW#8I\LT6;'*CE^?
MHQQ;0DV*Y."0SKR02$?*IZ!#@42ANKH%&\Y?B3=D?Z?N:GY?N]=!77Z<?X*_
M!?YH:C]ONK]`[?H#H*9WQ2M$S.<+9!'P5!(D(5+R>]FL`>8T;[H!_9XE,4PJ
M_P#ZX*>/0+-Z#,:B/*9'E@BX1<U!WQ(=YUZ3AFH>(2ML3?T6RA@<HE!`D^Y,
M[DR$#_\`(HR!F<?854@>((][KO%?/JYL<7<\!>6M_N>TS2ELU+"J;2EM*8-H
M@Z1F\IMIX:%D(>8H#JSR#7T#%=.THJ;D4UEDP27!P<X<7*>$G`)=9DCN7-[4
M(J<6]+UZ?;:`7AZS!8P`*C,)'4:Q-R3GRF\2^9I.^WP$2G_8/0-!A>%';"PW
M/)79G&7Y9=*;4F"<I(Z1?K%)\@B`4RJ2#3W12Q3EPAW4E(/%DTFZ#-J4ZJQR
ME(7V]!:=KI_#W6,8K7(.$L-9Q6J5NOKNJ'R(SH\-C<[GL9[ZLS<PRCE6+9Q$
MA#'EVQV[JK3L?(QCUR44Q9'6$AN@@^+9_P`OM\C7+.>FXS'LC0DSH0_(8E#?
MU#==NIQD&ZC.<H_'^\(RD9A#R1$ZA%)JP&D!6(!74="($53,B#+,<P[+<#@G
M<%EM61@32[H9&U69Z\>V"^WR:4(!%[!H-]G%WUJNDXX`/:L_=*@D7P31*DD4
MJ903GR^N'_BAR1U5GQ?M/'#+Y#D1B[&[[)!:58[/7:Y7-=K]J_E5MI%)IN;U
MNPG/M>AYS8`!PDX2CVST(-G(NA7,4WJA4/#C8>)N`\>;/FM=@].O1;[,R]^V
MC_R*G<N:>I.3K5K`/E[?9$UTFDG6W:%?*+%RWB#IF2#_`$$2.444PW-B5CC=
M2JTI1;L[L>I8V@I`W/#F&3T7D?MVN8O9(=R5S6[!3-Q3QR%BI",@G)/4ASK#
M(.&0E%N+MVS,*``Y[AMONR:,-ESG:LQTZ-FZ*BW-!;79LMF<PKNL02@(`W<2
MU2FTVLA1]*9IKD^4X\$`C7?C[W'G*B<S5L&[N@.@4;SE^)-V1_I^YJ?E^[UT
M%=?IQ_@K\%_FAJ/V^ZOT#M^@.@X-EAJ_.0SUE9V+)_#@BHN[(](!DT4T$S*'
M<D4#P5;JH$`1!1,2G+^T!#H%*S:L/\J2JT*5=O`E=NU(WW]<%%THM,YS(*.U
MS`0`$&Y?,83?[0_:(^`CT$*J%TIN@0J-EHUJK]RKB[IVR3G*Q+LIN+4=QZYF
MS]J5ZP660]X:+%$IR"(&#V#^P0$04_1A.K?N3;J<]NC*\EM.:W\SC_\`IDCF
M#])''6BGG_YBUU'%!@E(<OL0%LJ<Z8>8ZHB%F*IE=H'9.$R.VJX>FHS<)E<M
ME@-[/(HV5*=)4#?L\!*/CT&3ICC]D.^6:PY?C7&NE:S?TER1]]F:T9;*\QS=
MP<Q%R*;+KM&)'`SE6Q_*N2`CR2]G7$I3%9)$_P"X(#3>*_;YH^!0%(/I%SLG
M(.[9^LN\SXU[>RDAEV)*NCBH,=AF=3TC-D@1CA.9-"?F7,Q:3E$P@^0(<4`!
M@JBG@59PNJ4I$DUG+EPNH!$TD4B&6<.7"ZI@(DBDF43G4.(%*4!$1``$>@5K
MN?<AC&;E*L<7JA8=>;J2KJ$M?(Z(HMAT3"\Q.T*<KYU"050>LKER"G&:Q!2*
MWK0A!(N0\KN6()3H"%+,>2/'_)LOV75LUG9SE5R+<JP%PU=K>8-]2]OLZPJ1
M]1C9V6H,U2Z]+T?)J"Q43;-V<#"FBXAOX%$3KK+.5`FELBJ[R'NG&9Q<*5.U
M!MRCXR[K2]?SYP[6BK$TH4.WS?0JV25=MDFJZ;JC7YV!8U=1$BB(SRH"F3UE
M$N@<+V^N/37#*1`5RB/))',*=$R]6B4;!+#.3LHH\EU9QQ[PY*1N1$C"0=F$
MHBDF4"&`B9/+XFZ"RN#"@7&J[COQURO!Y%<EM;NL(]\GE,OGF>2++C[EBJ1Q
M\?,PE,^QUA*(``B0?E$Q@_WB(AN#H#H%&\Y?B3=D?Z?N:GY?N]=!77Z<?X*_
M!?YH:C]ONK]`[?H#H/X(`("`@`@("`@(>("`^P0$!]@@(=`I_98Z`=WB_P`'
M'QI&$$Y<R4(XCT!40()'+$6$P9N'L,U3=KJK&3`G@4A3`)``/#H,N8)QYRKC
M325:!D<&[AH%U+.)V15DY5U-2TK+.$46OO<C(NQ`RIF[)LD@D4A2$(DF4/`3
M>8PAFKE]'<0HBYTF<UZXWG,]TO#$*EGTGA3FYEVG2V4:NJ>-IJ-2I<#:FVFH
M-)!T<(YI,13XC5557T#(D%<0".8UP6VS17DE)<AM7TVJ8:^4:J5G$W1L^@^1
M%AC"%4!=#;-?QV+@(BG0\N0Y/5K]9\\P4@"1U.$$RC4H-CI%&I>9U.%H>=5.
MO46DUQM[I!52J1+2$@HM`1\ZGNT>R322]=PH(G66/YEW"HBHJ<YS"80S-RTY
MV<;N%L(R=[/=D27">(D-.RJMG:2FC6PSE8K9L[3B%735I6*M[R<"KSTTO'PS
M4OB)G`F#R""Q9G:)7FT"B^CZMFTMF)C@X9<8L3T2.L=$!!(_J(&W*V1SEG8=
MGED!(`K1JS>,J2"A1`8YX8I7(A8%:F("=@X^0JJS1>NE(M'Q"D<U%G%@UB'"
ML7Z42@"#=`(MNJT,F@9$ONYDR@*0B02CT%3<B'[VM4B,U&MM7KG5,JN=&L..
MJQ`H%L[V]2-Q@JXSH,$NY<-"+HZJTEU:Z]8*K$9O6L@8%_`I`.0&2Y5GM[=W
MRT;WM3>*BM*L\$G2*=G<%*EL,'B.5(RP3QZ>6S$20;VZ_7"?21D;3,-TTV2R
M[-FR9`9HP(NY#:,G=-`PCC!R&VV*53;,8W+[4>AQRX'5=V'5'#16O9TE$H$,
M'I?*-V?LX\3&]JZBI2E*;R`(!O?!LMC\/Q'(<;BU"K,<LS6DT!%T4OE%\-3K
MD="+2*GL`3+R*[(RZAA_U'44,8?:(]!;'0'0*-YR_$F[(_T_<U/R_=ZZ"NOT
MX_P5^"_S0U'[?=7Z!V_0'0'09KY$9BYMD.RGJS"%?V:.=D(]]S(B20D(<R"Q
M3)CYC)B\.S7!,R9/]1P*)@+_`.G0)1V7E7`XSR$QCCK)TBS3]HUN32C'\C%+
MM$D<[5?/?<(G^:8I9-2236?J%.OZ9P;B5DF98HJ`'@`=IZTK3+G7Q_L%Q8QI
M5W^"[I2<9G7[9L!F^L2%FSJ=M5=C9%8GG1L]@R>)>J1Z!3@JX8LI0J0#_P`P
M&#:]NMU4S^L35UOEF@:53JVT,^L%JM4JR@J_#-"B!?6D9216;M&_G.($3*)O
M.JH($(4QS`40QC([!MG(4ONF&-)?`\<=@`+;_?JL0FNWB/.'M5PK'K8R].FQ
M3U(?%"U75IZHD$%&4"N04W0`O?8.VK"S5U1F(B%M5L3&==V-S<7%U2D]!NKY
M^5-RNGK%TM;O^;;'(MG3---L\.],@@W$Q4`:$,1!$/TU7&:IJEAH7%*$H6;S
M=\?6I:U[OMW\G0,O/Y=7(@8F6G:G0;@^CE9M"UE9*1S5TZ(NF5FXDD$@`%7"
M@)!J6>X%95'0\B7'+3M&.2C:+??R[%5#7[#*4I.43:+&BF[JFZ>AI%3:1BC_
M`,@+%:LFY2IB;R`7V>`51PHXLZX5.-U3FJYEK1LM*N4FKE]>>R5.1H5-:)Q2
M$:WOC&FY^P95YY?%U7;])I*2*SYRS:*>9J1H=0QC`P_@-I$1S(L^UU^TY/L>
M,J9!8&D0T"X,&T:C=FJ[J3:N7L>Y<,`,W<1YV*)EVZ0+D(F\2,"YO-T&T.4T
M/'OY7AGQEA!]&,OO(JH6R?CSE%P*F<<8XJ3WU^N]$0'U6SS2*558Y<3AY5#R
M@`;_`'>`AO;H#H#H%&\Y?B3=D?Z?N:GY?N]=!77Z<?X*_!?YH:C]ONK]`YRR
MV2`IM<G[?:Y>/K]7JL)*V2R3TJY39Q<)`0;%>3F)>2=K"5)K'QL<U4664,(%
M(F03#[`Z#"X]SSB&V3I3J;LNH5.-OD(ZML--7/CUO=1A8^@I3]/K#'3;9*6#
M.(]I2LPG)J_PR+*PRQF<2M[\4PKE*FN*0=:T=R#BM2FFF/K7/:7!-<:TJK9A
MJJS[!]L*7/Y.ZIMUJM:[5Z5"4&&S2:2=)F1LB_DAS><H>N`G(!@YL7R+8\O+
MU<\=XX;$-"C<Q<R;';[*:@7.+UCT&]YN6<(-\<5OU099\>"D[;FEEC5;6D><
M!JYBE$VS,#F2>)A]FC\6Z-G%.^6<JKP1RL<HO)71PY<O9VS7)PX`??;I:K1,
MKR%CM=M*!A]Z?/W+ARLV'P$X%2*7H,37[/J-J=7>TS0JW&6NLO'#%\K&R'KI
MF9R<8Y(\AYN)DF"[26K]@AWI"K,I%BX;/F:P`=%4AO;T&.MMQZKY_7V<A1R7
MG:.1RJ;MMQGKF[ZIHFY1U8N2!42+W&"K.DVB9JU<0IL6J=PO8GJ(*,?!-,78
M&6*FJ&KL;3U1+*Z&3<'D._UP*^W&_NX`K<L4M/F57,H+?W,B;(ZI&@I%7.@4
MJ!W`',F'D$O0<O1;597<O'Y+F"_IZ9:(EW.2$\2/4FFV39RR4,A.:=+Q2)3F
MDI0#D,SK45X>I-39BD`!00<F(&1,OEKQA&>:;K$MQ-V.`3!XX;LCWZQY[6WJ
M>?1<PLVH,,5S+6=[<;'H&C6*<6EY<`BA=R=JFU2^'IE;@0+@R/9^1EQW*_9Y
MIG&IWF.<UVO,9&OZ(-@^66LE+K%9&&*-(`DVBYX7_O*_D]P3*HQ%H8')?$X>
M4&+TK$+Y>F3:6C6C%A"NQ/[O*RKP$4ERIJG14.@V;D<O52%43,'F%,I1$/8(
M]!L#(L22SERO-2DN>9L"[52/3,V]=O&L6"ATE5$445#F4<*JJ(%$3G\`*``!
M2A[1$*9@S#HW<(O$J#@'$)QAXV5JA,D12\R;?1.2MR4O-U(13VE*^BZ!C-2.
M/[#E0F?#_:<?$-P]`=`=`HWG+\2;LC_3]S4_+]WKH*Z_3C_!7X+_`#0U'[?=
M7Z!PFCT"KZQGE\RR\,#RM*TJF6B@6^+(Y79GDJO<H-]7;`P([:G2<M3O(F16
M3!1,Q5"";S%$!`!Z!=L[VM:7=FE/C-+Y,\G=$B:[ELI@UCCYN4QF*'3,'D++
M0+.7)[Q)5/&*],_(QW><,47LC%.8R<DV[AX1R].#C_C#Y9KM49[,V*]6PG(#
M>(68TGD%1.15Y9P$=@<72[A;,O;RX9]'V_-DL0-GUL;0<Q*)2[F0D(U>;F9B
M*BW4B]=&C&0(A=7&#@'D/%+4MCUVAV&\S%IVIY-+V1"?/2X^(;H3FH7_`%UR
M"C2DTRH.+=--[9I4FDWF;&M-33>*!!@DZ(V2\APW$HFFJF=)4A%$E2&3434*
M!R*)G*)3D.0P"4Q#E$0$!]@AT%'ZI+M,OI:3>CY`IH-DL\JSJ53HM>A4&</(
MSDBBY70<W2P%C7433:5%-&2KJ2E7I3E101%-!)R\4;-5PS75."C>)<S%ZG;R
MC):_=D4U+O/-J_Z=:9I)+K.HZC9W$J2`.ZAFE:.L)&C$55UW*OF>.U%G2IC`
M%*ZYB^HP,%9Z\Q][A9B;@YN%JEXAF2TRQC9V2C73.%F$$DDA6]XCWZJ:Y4%2
M$4,*?@4!]@]`O_$>)G([CSFUGLG*3>]<B;E8GTA;+M;:)96L>REZI581-O"C
M-VZ>HZEO</H2$8.%`:"[109D5$$DBG,J<X3;CK0=DWV$HZ4D6_7ZF8]+.-4N
M;ZV3KBRR<EN-]*-ISC,UY&6<%=RS;CKEU@CG#U(A3%+99!+Q`%69R@#+,UX]
M6&XBN]LXR%2B&RXMRI.&)DYF063,(.`;-G@$!HW2$/+ZRA#`8WL*4P`(@&^X
M2'8U^(C8.-3%)A%,F[!H0P@)P1;)%2(90P%*!U3@7S'-X!YC"(]!U.@Q!P5/
M_-]-VG?%%O>S<C>2>NWZ&>&3\IU\^H\JTP3)U4SB'B9C)YIC\7)(@`B3P?F,
M7_<(B&W^@.@.@4;SE^)-V1_I^YJ?E^[UT%=?IQ_@K\%_FAJ/V^ZOT#M^@.@.
M@\_&K\2>5D_/[0M-XCJFL3T[S-@-0E-#KO+9&HP6R\1&FK-K)5<'J--?ZM3"
MYO*9OGYD(UXV79Q+-TO&KKH2#P\DN`AR1[>'+"Q5VKRE]L6H1.AT7AU>ZM(W
M#.>05AM=WTS5=!T59O0\DFV]PTK.:E<8C">/D*-<E+#).X!Y;']A.\3E$7+7
MWLH?!Q?X8=Q7->4G%K0-`E)-W1J558=CH@'UU\ZI\#2GZ?+)=]DIXQ34[-9;
M!(4)#2*$SCV:D9.13Y>`3<*SWC&MSN0]%G0'0+2[HE\M3?$J9Q[S&.0G=<Y;
M:A6<4I\*L8X(A7E#GLVESTN*8"9*J0])AG"4LK[/29O#"`^82]!>D;GNE<8<
M)H=(XXT"H['*U5RJYO49>=`=9A/WYS,A*3-UN4/8D:A<X9:_V:Z/S/S-9(K&
M-4*NHE[XV*1(0#NY3R>B-!FYJF7+*=LPC0:W`OK+-UC7J$X9P9H.)59MI66K
M>MTYY<,4N3)FX?I^)(VQ.'I4C`HJV2+YO*&36W>-X2$REQI4Y;KE"S#'$FF]
M264)9Y;;'HS2H2=,IFAPT.0E7BY>G/KS,4G1H"21AD)<[PK25264*1$BRB06
ME,=RCA"LK<*>XWL\99X)>LU2<A8JE:2O=8FTZ',#38"LPD.SH\D_F+^SMJHQ
MCN*8H/7\/+I':OT$%TE$RAQ<`YD<"J1E=!RG)]J:KT?+*W0LOJSF6KM\05DH
MYG=HWC]57J4S(TZ*9VKY;T=N,4>49`HS<R+=ZIZ@$:NS(A#;9WC>"5?K<-:8
M'1+=H$3.MKV\;O:9D>LR#*(CJ'CD5N;RQVLZM*0>UVBS%"LD0Y8SYVZD2NG*
MHK@M[JFY70"R$^YUPSCXR04N&N,:O8Z\VK2-GK"=;O=I70LU@L2-&=5.E2U7
MJ4G$Z]*UO1CGKLE_*BDP5A,IBU<^BL()]!M.@WNI:C1:9I=!FVUEHNA56OW:
MFV)FFY2:3M6M,4TG("8;)/4&SQ)"2BGR2Q2JIIJE*?P.4I@$`!77.7XDW9'^
MG[FI^7[O705U^G'^"OP7^:&H_;[J_0.WZ`Z`Z`Z`Z`Z`Z`Z"J)/&:7-;/5-V
MEDY&1N]&HMFH%.2=NTU8"M1URE(F3M4Q$Q8M_,VLTZG`LV:[WU1-[BAZ)2E*
M=7SA:_01RXU6'O=1M5(L)':D!<JY.56<38/WD4^4A[#&.HB3(RE(Y9M(1KLS
M)X<$W""B:R)_`Y#%,`"`>?G5)+M2)P,/EN/U2\[3=[_KE/XZU*FYA:-KK#EM
M+:^IFM42T*OWYPT+%IYW4JEP-:)MK7#GD8I)"D/F+9<15D"F"^GTAVT\!OL[
M8H6<?O'E1YHW*Z:(_F;O=X^A97R`;Y'R(TG7+:A.69)O6[C*5&L62VRLQ#Q[
MR6<1TJ_1#T4%TV:)`HV]UOL\:=$9%3JIM]BS&\(9"7C!@CURXY#1C"BNLYE-
M.R6BV/2L\MC2"K3BW93INJS[9J_OB;8?YC=J)*K"[*3TPKM_(=I^"I6=UK)6
M^O[RWE([8LQLE@7UO9:9/3T#=,-P.KDK.E3^F.ZW)VVI7^D-LHK53(F12*:Q
MLC$JL3D:+B=P%P,IOLBU8]YTQ'5'ZH5'0[9(G>C.\C9HN?O;7%\B[9;B9/`H
M1KM6+RA@\L>A69^^K[96NQ<HS4?N72)HMF+4'E9=7*93LSSJHYPT!AGE6HE1
MKE#8E,^,5E3(.OQ\95V@&DQ&2,#:#:H$\7'_`#CY?^3_`%>/0+(YR_$F[(_T
M_<U/R_=ZZ"NOTX_P5^"_S0U'[?=7Z!V_0'0'0'0'0'0'0'0'0'0`^WV#^P>@
M2;-8)P-X#\CN+\S.;/.YHE"-IX^8YI:D],U5X]%-!OQXSI-WHLDO<?\`XOP3
M#V7)*0A86)63B85I+70SMP^,H(@(9JW%UVF]94T!.N7W3K=KO(W5)NMN=,;4
MKD7H$?4;C;\;ODU!::[8D5H$6MF=9R++9E2O66.D/<D(OP=MWQV)?>$@Y'%1
M]VD;?QCR^0U_4[1/W+1(FBOM,4W.8U2$O5ET2\:3(6QO#6](C5FQF922U?N-
M-UTU6J[U*3&>C9`'CU&.3?H!:U80[*M0?UM@WU>VV:6@UVUY96^S6GDO?/?W
MU5D<`NR#B9T"1CY2'?OH>+XST!\2,6>`=O6&+!4C<D5()'<A\MCX3]O?F!98
M3!.,^WVBGS.55J.J6N#0&NP6&6E,*I<6YXVNLB<Z5(3D11ZY!7AEG<PR72?E
MFB6;ROI-)JY*<[LX>A`A")D*FF4I$R%*0A"%`I"$*`%*4I2@!2E*4/``#V`'
M0*/YR_$F[(_T_<U/R_=ZZ"NOTX_P5^"_S0U'[?=7Z!V_0'0'0'0'0'0'0'0'
M0'0'08=V3@5D?(+D7#;YL$G;+9&UG-*CGL%D2%@G:_G3M2LZ:_UAQ-7J)@YA
MDVT9"0MS&N.T8R5168,W=8:KE(<YS@`5]"=I_AE7ZG'TZ-JVE!&QQY1%-Z]W
M#79.><0<K@#GB\-0=STC<'4FK2XO#W`0D?%@H5G')IE6;D37$ZIPZ6F]JG@Y
ML**J&@9$\F2G6U)RB="_Z!$+,'>OTW.,_M3V,7A[,Q6CGL?4,FK[.$62,52O
MECR*1PME1,H(1G4NU#Q@NT'L32D,)_*Y[8<QM&0KR$-8K3-U&@U+0,\R_&]"
MD<URN3LB>>U&]6'(LBA(9&;;L@=LSQ[=P'J^15)<-'Y#PQP##-`C]*SBK241
M9(+&*WQ]JA'-GGY*%IV15D\(Z;U"LPCY^M'1[63EJ\UD'RQB*.7,B55R90%7
M+HRP:HZ!1O.7XDW9'^G[FI^7[O705U^G'^"OP7^:&H_;[J_0.WZ`Z`Z`Z`Z`
MZ`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z!1O.7XDW9'^G[FI^7[O705U^G'^"OP7^:&H_;
M[J_0.N>N!9LW;LK=P[%JV7<`U:)^JZ<B@D=4&[9+Q+ZCA82^4A?$/$P@'0($
M[:O<EWOD#-2.I<IKSB]-R_3[!0\KSW"JI7;-+[%E'(C2;?>EZ;E=O+6X>3<5
MUBCFE4\LT>UG;R"$^V<KG)&Q_HIG"I^%_=JV36>2ZZV\Z94:MB9<IN>B:ACC
M'CIH,9=>-]ZNW+"N<7>+6$2-W2=35AT*ZV<3OGUF43@D$8^5\0`Z+`"^0&,<
M\N1-TOO;@YH:1P(M=@N.JY[%:EFD3/Y="2DC<8.YY?=_Y$V\F<,WD80]BO>?
M,(V=+%JL$W:*TRP(5L98Y0`03+JM]X!,;5P'99;RJY6O^#4WIW)O_P`AKPMR
M-YQJ/4=)9<78&3SUD]OSBQM](:V%:TG:O3PT>Y]S3LBRA#,TW:BJ!@K>Z[#R
M#8Y5VL+%H.@[F[Y4(;3E[I.DR>F<BZGS)T[BX_YEV>`RY\VX]1,='<>M"M>@
MX$#)349"[IHRS*"04.Y(DY]'Q"([UL#*PH]XV_\`%+DER$KU6K.2UG.XW([C
MN_(NSZ1?]5IO*VI#NO*^MQ$O*R5@PS*(:*M"='A4JV9FK)PJ+Q\BR0:%9"L#
M(.#G(#7*1VX^XI?"Z;,,QQ'5-VGN.&T6%;9>2&,KU8<WIEOH=:Q)_LK:)WG9
M<WJUP?+5]=.0.J\=3YGS:,<F0*U(D'8FN7?.O=NS;R_W-&N6S)N:->M%_J%E
MQ7+*3,HZMQ?A:Q?*E!WRG5`[LC^1TC3*WB*LA:XB>8I&(^=R;;W%,WH)`8,@
MZ[?.`+"_<#8_,N5?*IQP0F;-S#-M%Y9\C.<R[A'6([!\A?9TR;W]6Q!IZTZ6
M9="^0AV;E=DG8G#I/W0CP[AN(=^F9QN?(F%[0-/U&R\N(#E]I,[):ALVA2>O
M[QFLA7N"G%K3[+<JO(;=EU8M->S(FT\@8&>I%6DE):%&6=J3,BHX+ZK,P)!A
M34+;RTJ=:YWI5SD+9=:BJIBSLW(?=LEY!\HK149_8++W(,C_`/C0)B%>U.M(
M<8+]4N/KRSU^:K>?N7XL:LP565$I/<!6!CV2:ANCOLI]UA]$VW6)6?SI]S"0
MX[:C6KWLUYB']'7SN*M5#2XQZCJ+2-WRW46@/IA>':R<J*[WY<8/B-'"C1-N
M5,,^OMWT2,@MYRC@A>>7^S<?.2&><-./-)F4[7JEYGZ?RSU"VZ`[Y7GXO:QO
ML[&S$<:I<2:H\GI)4;"C78.V^X@FY9N%U4P"C-DT;FWJ&)<9,*A87DP_WOB7
M1.ZQE&D5.T[=LV.:/87N`T_&+5QEU>PW?"I^7::?M3;&;E#RT(P=3+F"LME]
M];'D2E445Z!K7&W'*M?.XCQ@T!+5>3&H5"V=M&B\K'%KG-HY$U&E:%O;70\Q
MJ+'2+)D*&BIYS6Y6R5)XX7?TT600R2[A85&)U2"KT'HCZ!1O.7XDW9'^G[FI
M^7[O70*?[''=T[:O&KM6<1<0W?F+C^8:S0ZSH#.XT2S2DFWG:^ZEMCT:PQR$
M@BA%.$2*.X67;."^4Y@%-8H]`V#^O/V>?[@6`_OJ9_@?0']>?L\_W`L!_?4S
M_!.@SKB'<V_3Z<<G]TE\;Y=<<ZE.Z'\FDN5D6N>@6BT3C*$/)JP4*O9[A_,$
M^WK<`M-/#Q\8@Y2CF)W:QD$4S*G$P6[1.]7V1,PJ$!0,ZYL<8Z12:JP)%UVJ
MUA9]#P<.P(<ZON[&/95]%NB"BZIU5#`'G55.90XF.8QA"6_UY^SS_<"P']]3
M/\#Z`_KS]GG^X%@/[ZF?X'T!_7G[//\`<"P']]3/\#Z`_KS]GG^X%@/[ZF?X
M'T!_7G[//]P+`?WU,_P/H#^O/V>?[@6`_OJ9_@?0']>?L\_W`L!_?4S_``/H
M#^O/V>?[@6`_OJ9_@?0']>?L\_W`L!_?4S_`^@/Z\_9Y_N!8#^^IG^!]`?UY
M^SS_`'`L!_?4S_`^@/Z\_9Y_N!8#^^IG^!]`?UY^SS_<"P']]3/\#Z!:_+?O
M#=L:^<ZNT_IU/YH8S/T+#-FY4V#7+.PE)4\90X2\<,-CSRIR<ZH>((=%K.7:
1?91J`D*<QG+D@"`!XF`/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g644794g74d12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644794g74d12.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```3&P``7#L``'07``")VO_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`YP'!`P$1
M``(1`0,1`?_$`.X``0`!!`,!`0`````````````'!08("0,$"@(!`0$!`0``
M`````````````````0(0``$$`@`%`@8!`P4```````4#!`8'`0(`$"`P"!06
M$1(3%3870%"@(R(R)34F$0`!!`$"!`,#"`,,!0L$`P`#`0($!081$@`A$Q0Q
M(A5!,B,0(#!184(6!U(S)'&18G)#--0EM39VED"!4T144,&"DF-S@V2$-2:Q
MHV47E$4($@$```````````````````"@$P$!``(!!`,``0(&`@,````!$0`A
M,1`@,$%046%Q0)%P@/"!H<%@H+'1X?_:``P#`0`"$0,1```!W^```````&G<
MR$+K*F=HL4_"X#H%^F')E:8TDKE))&+>.\=HQ/+C+C)[(4)V+`*V9MG.````
M``````````8-%0*:5HE(ATM0E0M8G0_2!#MG0+Y+:+Q,?C,`A(O(AXR?(%*8
M<YU#-XJ8``````````!^$`F+Q%)22^#)$RS*@```````````````````````
M8U&E\U8$#@``OLV>'H%)1+E.T````````````````````1L>=TT\G4````*Z
M>SXAP[)D>7&#\/T'X<9^GZ<I\`^@<Y6"X#L@``````````PD/*60D`````;>
MS>:2P"%262;0`````#C**6\=,I)CZ6Z=H@\M"61+)Y,OBO@````&O<\F9:X`
M```!]'L?*P3.`1T7"9````````H!BT6T3"`:Z9<>E`IR9H6;+B]@```8KGC@
M+*`````!GZ>E<DL_0`1X7L32`````"$R`B80`#73+CTH`'(FV:S+D``%(/&>
M8E``````'JZ)T)R``!#!E"7$````#'TCDD```&NF7'I0`!3S:A<YQ@`&CT\X
MH`````!D4>MLN<J@``/TB$RY````(E(,)%```-=,N/2_ADHEP$8%AK:YT3<W
M<Y+`%%/#Z0^``````>CHS_)G```!&!.Y>@``!Q&#!,@```-=,N/2U4JY4$^U
MH12#J%=3?O9WP:OCRB``````%\'LQ/PO@```'Z1J92@``&+953G```!KIEQ[
M6;DLLE8L\^ULPLX_#8Q<[#`>9(TX``````&[HW$DN@````B`R[```,)24@``
M`#73+CTHOL[Q?J08M,`+V3?;8/%V8C@`V-'<.N0"8O@`[A[.02V````"%C+L
M[0`!9YC"2,````:Z9<>E%P'&<!T3@!Q%@)Z%K)1/!V6.`7V30?9>Y!Q:)8(!
ML\/0F2B#E->98)>Q/1DL?@!:A>Q*(`!C85`X@"&"S"LDV%5!KIEQZ4`4DX4D
M$D!9%29UF"YRR/`&`#/XH9(1$Y)A#IB2`>N,DDG0%M$2%BE,,D2_``<)12?`
M`#&<J``,;BSBMDKDH`UTRXIK<)?Z2&6&5<N<E=9#!?USF:>!XH@!S%\F7Q;Y
MB(40X`#V+%:)P!A"2J7\8\DMEBF6`!U2FD\``&,1508N%XD7E=(O)Z+!+L+4
M.":OPXSD(Y*0=-)46JGP7W<YIGB#,?P`5@F0IQ&Y;@`/643834##\EDM4K9#
MA?!E*<8+")<+]``,:BH'P=,LXIQTRBE8)-.^##4D::QN2\EC5+C(Q)P+%+C7
M,2YS#/)V:QP`````>GDS!)F/@C$O$PZ,@BKEGD_'R"%#,4^@`"'B.BO`AD_2
MT2XRTB="Z0=0POEM8N`'97JE@I?J]9,W+,FS2,>;P`````'HL-C)+8!89BD5
M$RM+K`!$1ER``#Y,'27"/2QB,213\,<B13,H^P6.872R,O>*46\7&=LC%-P%
ME3(9/#V4T`````WO&VLE<````'X6"9-@``&(9>@!$@(X)_*X<X`(1(\FK%2T
MRW2:B3%Y4V#6`>78U&`````&XPWCDF@````A$RZ*@```6:8MDG`C0ZQ^%?+V
M``!BH5J:[P!9IG+<RP`0">*LM4````&T(]"Q)````!UR/C*4````Q6.V58``
M```_#"N64E'6+IN<ZP`#3(>9X````&>!Z;"1````"!C(4U;&S8^P``"Y3%<E
M$[0````!1#$264%I-SLC/T``'FW-)8```!E">L<O@```$-&0YUC5J;*SZ*(8
M]%3)<+Q!<I?)A>7(7,`````0F62;)3E```.(\[9HM/P```E@]B)?1\```A8G
M8D\`%ID0$0GV<IG"``8Z$,DR'*```?!#I+!DJ`````:K#S7$3@``JI[4"]SD
M`!2B&C*,O,```````'`8S%HE#.(KA13[*R749.G:``````+`-'YIA(@``/:B
M7L5D%%(E+Z,E@``?);Q03K'V?!]'"<A]``^`?9\%5+J.X`````````4`U/F`
MIB\12<)ZS"%2K'P?IEL#\/P^S\/TMXHY=Y(AWP````````````#_V@`(`0$`
M`04"[\!NJ8&)@AY"@E@:EW"=XBRN8,8.U?9!*:0:OI'9$M$[7^";,\W<(18R
M:]0\2V$VL//RZS+@E\6GBMNH,9-'[PDLB4%^14/*Y)W[\(\.N)-T7GMA2**6
M=^_(A]NLRR7L-0-WO(%@\JL^21\"YG]D.Z=DDMGS"H,7&681QW;K8=)X7=;D
MR(6O4%KJEOE1/^:'HL0-<+TB"WB!FC1IQLC3(]-[!H&W@X=C2;4<P9^/`!NR
MD50AI$N7I?0L^!0@>`D;&$#6$W;T4#;2X=20EAP&HP6&&O*C!OV[ZG-3'$TK
M+27'9/1[)RO*86PECX]2@4[QI6OJ'+J@1Z@YS&BJ\8TI(<F$84,%82;:D&VH
MIQ1`Y6)LFB3!G_(.VK6T:R1\KZ5895\TJJ3W2\UZUSLQ\Q*@=\!+_IP_EJZ:
MO4/Z?/+=KZN$IOYIG7F91:%A33;J!2B21=Q"O,6P07%:V,'M"->X`/SIKHJY
M_I,KET<A`>U/+J2R/9===TMV18UX9)"F`^GJM;5:`>A/I.HSP)%08^RQ$@>N
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MS'Y&"E0WL6_:0JJ(C(I"8E9ON>-L`]^6;8ZF2RWPQCID<?3/-H9*MY"V[DLF
MS2-9;QQV4?\`3</YETC796/$ZYMD;-<]3]^S%L;GM!]:LT[OBC7_`+1KF*J[
M2`IU2=D^8.1)5B<&=J9S!<0J!CZ(37JN'\RZEV_UN*HM3:3YZ?,:S=A8GNU1
M"%K#GUANMQT99,FPUEU8S\.(RI[3EO9F4I2BHJ/!%12?7</YERU@[7Z#."AW
MQ/,=9.`AH4N$*<+)JYVJ^?ISP%S(D&@D?/Y>]GDQ[OAG7_H`;=7,DG?8EXIT
M4"1TTWD8+KWWU3T#K[RTWV+A_,N,L7N-4S!?.[B0G_5+DY"59ZLBQ)PL@LAG
M@%)'4(D35TW?-N7EK,?;55]V,@'TJD!#TM7US&PND>!]C&?AF"9^SGNNS7BS
MMLDDD@EV+A_,N%"3#&SDHU<.LF@3E8&>9C1ZY@818EU4=].5`27*POEYHR3)
M&?\`=\,X!]Q/&U,R.P.T6_XR9=;!;[[+NS</YER3:,/L[T,C[BWC`E1T\;[M
M7/.(&\Q><\KY,;'+AZ(M1?N-H\IV.M6DXJ>'PDE9%>;1*4=#=NL[<0./CJ<J
MB%#7;$+VK"TS[115T<(],@*:!`<08;C8OV;A_,N6"Q3#9T3)/N,/GNN5%%%M
M^6^^B>KQ^/+M(0<VDT/XDSO8A).;2+R,BJ+G,S&/E+9,JZQFU;!:.2Q:22)9
M_%9*)Z/%*`>\+'G:N3A_EIK\VX*[/O+IG=DF<0?:U)<XKY"T8SH7Z#S;#P#"
M'?KH=TVQOMM#M_A\_,A.P(QYBT@^S1K9`)XNT>M'^G*X?S+H=/V+#1L[7(<-
MHE.'W#:L%U.&E<PMILFDFBG3BN-8QTDEV#EE[C$N[#QM!WNU:2`.)0CLUB^H
MD$Q^SL>?B]#V44J>$Y4+Z\MS@EKPPKJ.,VJ=5QL,`5K.$3!-"/,4GG0IC&R5
M79SFONFQ]OBIT%ZS"F2Z=/B=FC"M561"+0X##6_*X?S)<R*;*MF\@(\-H',G
MG#:K17#HO"H.77M)9%HA8#Q70!*@$HQRJ?;Y"7!)KZ$CSV44WQ%F0HB?!URP
M*&4ZWC3U(LS48$\*JZI\_&]WZ^EJVS_X7D0:>KB2PZ3%'.#Z#Z/(`9"]B,M;
ME\L8F'D*Q'FOOA-O6&F4Z_Z;&Q\'G*2E4F;D,]DGK\R.3LS;T^8*QU`O-\AW
MQML&B^DPF&6T!(E"CBTH.E(=8XG'OM?'S:_-P\C`0DJE"026S2`Q]@^:LFK+
M''S8SFJ_^_XM<7D-9O0P=^@=_L4UOIK8$DP]+%')E_T>)+O5>F(%K](/R:3E
MR+($Y/A2&Z6,/;+FI,]:I:6HMAD_*2\)&M]?EWY2IWAC%XLS^WQGIM'/T`VV
M/ESQANAA<E(F`LKM+8FNIB51ML@WGX9R>(3F,#Q;5?5TUY2)C['+<2+3?<B+
M8&VKMZVE+4KND8-QUM&94D&5U5;1]BE/?H0QB4;NZBTSOR\MP&P>XNYX7.ME
MJUB7^)[QMKC;5G$`S19\+9DAIEC7+N-$'D0+N$8S'U6ZT!8?;<Y^;/*?:[.@
M6,8QCIL`7N9A8HCJ7%\CD)''GN84PRF-K_Y>/8@SZ257C&[(0S=L&W)=!%TB
MT16AI=G.DUG>\U&:<&I>Q9#5)D*^K[U%*:/I\Y;I;SN.X?`I4N5>4\WSI7_'
MFM%-GL8[GA"\^8"'^"4QYR8:_,`T`DS%PPU"%\Y!9*Y#=&^/N]B]6<8VQ$DL
MC->),\?L1L2>RH@\TVE#;>:K%D%HR<DS^0)H6!]L)Y3T&:Y4SKRD0!C)1(<2
MP5=MHN$:<.0X1;#`''$<MHK'6SG$9CZB2D;$*ZFHVW:-V;1N/9\6'$F\[A+Q
MHY'N^WX/.?@43Q]&RNU\==<5HED@WZYFA]AEW,O+QXDV%E>ICAK8HK+(213+
M,5$TU=>B:1E<T@$,('&,E8.7!B)!2P1XC%7;AK%6Q9F.XA0_:03WGY=5O[8F
MW;\+'GT[$(_X;0[4U7</$6C5!BUZY`$9R0+%B;QTUY%HJ.,NQL3;"MM8DSWP
M"`LX\VZIF(<A'[9RW>M^9PFH,90F,:1"-\[.@(^RH6<"DHX8[7B$\]+<,EU^
MG9'9552;I5^S6,NNS/@CUD[8/V91EW'[+V$8Y*JI-TJS`*G7_3Y5TGM*1O:\
M9W.6UV3G_%*NR13S.CLEF$3@XXIY<"B\CUL&!XU_84!X_84!X_84!X_84!X_
M84!X_84!X_84!X%RB,G%I&.4KIX@NBY1[9(<R+L!F[X`4VVUTUC,;4LASU^3
M/CWO'W'9I1[Z"V+%_P!"O8/FB"Y&-QX;%A$DB49F#$KXD`Q<AUKZ!_#]>P'@
MC"(.Q8^LKG#4C["#(BXQ6YA;]>P'C]>P'@7%XR#6SC&V"L8*0E808&'F/;G[
M`.\CL/A,BGC7331+3KWTT5TO[Q>5&[9QG&>N!./1SFTL?^9V_P!W46/D7I&*
MQ5A%&'09$)&V2@`O%&0<`0]LCZW=XAL<@9L%,>F15\W?OU92ZCJNF^BFG7G.
M-<8E*YM4!7B:#[MW/XPQZPMIA!Y5`BO4Q<>D?6-_EK?7;Y]>A\^9#&B"TDGN
M0,?$1@;_``%$TUDW55AT%%F-F!^%)FW8\)V+`5=_></^DK8L!1VTFC)WG1K9
M9?AM58YWE%!%LCW9)%H[+QEB^&&?FED!F<&<])578O2HY358=R($1XEHG*"\
MBX&5R@H[ZLYQKC8N)3VUED6WV1E\<<\(RH6YPC)=7/"!T@XPD5D:V$G<M5QI
M[OWX3;2W;A,;(L\)A"G&L;S\-8H-XQ$H_P`>S(C\R,:CC?*+=NVU_AE/M?H)
M37?B7)\G?'BJ?B2H]5GE>KSZ6R=92#?>',-T:9C,_:IQW,YES[=HG9AO@<-A
MP4R@ZEJO"'O#?A!M+\\(#))P@$*:X0CFR?",8'-M4@\+:;,$ZN2W%^R?I-O2
M_0_E_P#_V@`(`0(``04"_N=?_]H`"`$#``$%`O[G7__:``@!`@(&/P).O__:
M``@!`P(&/P).O__:``@!`0$&/P+Z?':VSNJ6QB9#>YC5SJ5V.2*4M#$QQ\SL
M)-?D9IS8%_-L.@W=%&QY6-773DJ\0;YV,9%#BW5FRGQWU*1C=8R\G,[GU!02
MI]X")#@U:15ZAY+PL<KFH/?KQ"S*LQVZM:TWK/?L'/Q6"^I?0$>.R`8MGD,.
M+82$43E$V$^3UVIJWQ36%0T%)<7$F9C=9D^K)./5I.PN:XMC7LC0[F[KIED5
M6L:,O;L(P!'IO5$U5).77^/FHNS=9.<@U`^-.C5ZF<0T!C9TJ0G202C?U=FI
M47;RXA?F/+LJ-N+V@["<#!H-`0MLRI"DE(/;9$6X`T]T=0MW,(!@-7*FYO&2
MGL\<R"#,Q?\`#Y)M6(^/7$D\;))O80"Q#T=W902F:9%W@ZJ&:O+35>+LL[&<
MIKKFFR&HQEN,205GK%E9WX62*=L)169*_I2H[][G/,Q!(U=W$6)=X[<Q+A:B
M1>VU,:QQ2/*IJZ+)6,YSC2LA!"M9)E:KPAA$D$*Q-43A^)TE!?62`A5%G-OA
M,KQTT&!=U_?P3R'GGCF;WZ]/IL$Y^[GIMY\97455_CT4>/4^+SJ+$[&E6=8Y
MK/N2]*55P)8+&)-!(&G-%&,WCS33GQ4XM:XM=P)ET98%;(=-QL@Y=LVM6Q[/
ML!WBW,,)MBC$>3'`)S_%6ISXP%UI0VN(Q[W,+2I/8BA45C26X:WU#J53G2+Y
M]M5$".+J:0T+O.-49JWB>HH%F,(:&]R*K+W>/R7W%=CRJD[2+!NI4RGDD:F\
M0YS([B#YI]7&16%5A>21[6MQ&!F=1%OH\&/'M:.?(9&]2_9[52BCPBO^(QRL
M,K=%:U=>,8QJ1BMR#([VC@WLN"2;C41($.8[IH2/WE^-]PJ:*10P^X,(7OM1
MWEXQ:H@0+:^I9^'9+:3L?IHU*LH\RN/&Z$Y\ZU-!6+'B`W[M)#4=JB;'NT3@
M]IVEND3\"@SRN<\48;[B"28^ND5D`;Y*.?;0I[4&1B^7S(J.5O/C\L[9K75]
M9DF45L+(@'KCV<^/52ZR1+,`,6N;*E/GA*UK?@-*[5%T1>/S.N,>L8X*['\S
MP>DQ^?,QJ>DF-67S!-M2RZ6<*'9RCB+N5C'#8]R>[XHO&`2$_,:O2+D]_>1[
M+-)WY:V=>V)7P*]3@!^#Y<QMGJR2-44F]JN1VO@G./\`F*ZYQS$30H=M,*LW
M'9,W\4L%+[?'5@0Y%J`M,R_'SV.20;<]NU-%XC976X[U<U+44TN;4#A'GK`=
M,[;U22.K"=DB2^OCD>5(^_=Y=J^"\878T\F+^:7XDS:/CDJRJZ@6-'ABD=/^
MJ9-1/NQK"R/<KMG55@--%=HG-:_&+#%KV%(MY3JVID$FXN5)=JE>^P9#?7Q;
M^1;PAF0:C8<P&!<_[VG/C&)>28I8T\O*LTF8?6."Z`^$4P26Z]UIZG)E,%"'
M5]$^Y$59"_#16<TKF1J2WDS;;*LGQ.!$)*H:QA9F*&0-@9UC<6\"L&DASD[8
M75ZYE71&<#(HWB5[&O41=O4&KFHO3)L<]F]G@NBJFO\`IU5W>3Y);TU#>VF2
M4N.R?18U9#NK8LHTB84T&ICVLY1$F/432R',8OLTY<8SB\>VLXTC#[&1:X_>
MO!53I4>7)63UVRX$Z`>IGQ3,E*UPWAYZ)HJ+Q2CEY-;),JJJ]I33AT^(,9-@
M9$136.RJ3'DIJR9O70<B,!AF#Y:JOFXP8A,BMI%9^7XZA:2K)!Q]'ME4T/LP
MF6Z'4LOF1Y>O4D1VR.B4GL1OEXG8^&XLKFGD3ITF%#MAURI61K`I3R*\18<*
M*62!Q3.74RO7GHFB<6&.Q<WS,.%3!6HPXD*56,B04MQF&<0+/TQ;DD('751`
M>9PVKXH[BTB'R&YDNM8>*02E%"QZL8$.'V*6%8@(M9418^I=NPSGH\A/'=KQ
MD4U]M;U]C>7.-Y!&GPG0T-26^+0NRKI$%#12C*-[/UPRH]K]=.7%=>$S.[_$
MP*XE3:7LJHQ&S=<P"R72]A*NQQ^145Y8Y':`?'"SILY:.\>,AR:-+EFEY'$H
MXDL)DBMC"2BA=D$D=D>.'8Z0WS/3W=WNHB<N+_.FFD%LL@K*BK-'*T"QHHJ=
M#((D14$AVD/UO/JY4Y<!RMM[<.6+ETG-(]<^-1JWU6;'='ECDVOI?KDR$K7?
M"$^3M%[.*8+\BOIU?CV86674]=*;5=**^U#.'-JW&!7AE'A%?8$=YG[TY(BH
MG%Q0BR2U+CUA36U'`K5J<4#)JH=OOZVEX"A'=SW1]_PNL=S43DY'\/BGL+7I
M$_+IGY;.Z;XS'^EC.*0V>UW;KI8]0*?]G_!XQ05[F=[;P\6+6R!`/68L$TB3
M4/:Z&05G$HP6M8QR#:T[0&;UVM\WBNM?DL;*+W&;BLI+.ACR*@=28;X5N0;I
MJ2`6E?.87>-FU--JM]Y%1R(O'Y.4M'`<Z@P::9EO82YP^X?0C$DKT\PO*2<^
MTM1L<NUO39S]FFF(SYDJ7')A^1@R6$R-T=DF5'CGCM!*ZHR+VZMD*OEVNU]O
M&9N6[NH)\TR'&\DDGB]@KZV?BXQ,@I`0\0K.F]1(K^JC^?&)S[[*KW([#$;:
MVM(DRQ%3B?,2VKUKGP9@Z^MA@[0`GN5FQK7:KS54XQNJ@YGE577XC>6U[0Q(
MZ4LF+#D64KNXXNUL*N7&,*F>]Z1-[%4:$7Q7GQ'HV9ID,:VC*`K,L$.F]7*>
M/)[AJRXJU?H\B.1/AD%VZ-(/DO/GQV3,GOTOWYE&SX^5]*F[XN31=J#D>F^F
M>C,AM8FB`0.WZU7B)DGXBO)+X65$S(421&H%4MU*B]K-?+LQ5`K8\4R<V`ZS
M0AU7:WPTCUD3,LEB^CYB3,\5EH&C*;&IT@L\TR+&1]7LL(<I]F75LKJZ>73[
MVY^&LRR_](F6]S;6ZS(.,VDNU->%$:41\B?1F=!GB(-S@R8O1(-Q'?9I$@@W
M]"%&!$#U'N(3I1Q-"/>1WF(_8SFJ\U_TE[+O.,9@G&BN?$6VB'GM1/\`R$4A
MIO[GDY\.:'(+"U5N[_VZAMM%5J+Y6OL(T`;M531%1=OVZ<*UE/G9VII\0531
MHQ=4UY(?)0D\OA[O#^MC><C:B_"44*@,YZ?6]KLA`@U_<5W"==,JJ]=->^I0
MDV^/CZ;8V'A]FO#60<^I`O?R1ENZ30+N_1_KR/7M557PT7G[.!RH4D$N,5-P
MI$4PS@(WZQE$YPWI^XO_`"@[\49#%!.V;Q4L1>^NS[DW,VUT=7%",GL(;I!_
MA<'BX#CL:FCKJP=M?:6%FK?885<![:Z&5/J>Z6W_`)G_`(FR^[M!/\83ICXU
M9S\=M5#[>M8J_8+G\_N\;OKBBD+IO+56,J"I-/NF2.4:&9_!=JB\#CY9"K\R
MA-T1QWM937*-\.4N$!8)=J?IQE>Y?%_`\GHXEK"B/D%B.#:Q6QRI(C[4,@GB
M*>/)$URZ;V/7[=%Y<3!>MU'4KC#C6`_4H>^!)-^ICS&];=%,7[K7Z*[A[1&$
M1PG;2M&1KU&[37:]&JJL=I]?_)1[W*+6-4UH.75.Y5(8NBJV/$CL1QY<HFG(
M8VN<O[G$BH_+UAL5I55XW6[^FN1SQ^9NX;TZ@:8;T7^25QT5/UJ<V\%DR3%D
M2#O<4QSD<4QB/7<\A2O5SR/<OBJ\U^B@5->)3SK*7'@Q`I_*2))6A$WVZ)O=
MS7V)Q&A1P]9F,THAH)C6M):7)]@F,7I(C5D6MO(1N[](G%<E_$URG>MO.R:O
M(Z#>MO9AW6$J0.Q&UI3#%+*NT)T+'Y<QKP5,KQ2GSN@-8Q[:5D57C5<N4`LH
M?.->9'CH(O0NYD-/]^KVI)9IRC)X\);TD>JGPK*W'D2SJTBHV5=`3II..^.]
MCEFATVO:_FG@Y.$>,,T2I;+>;0W-R$3K)R(CBO"*P:$@'Z<P.10*O/9KQ&(&
M?DC>VM#VVPF59',&>1(;M?'DMGV<KK5;?N0_YJ-?=8G$%69'DCVPY\R<49YL
M22VQ27NT@SG2(!#=A$5WP6!<%S=$U<O%?KE]]+;#+-?*;,B8NOJ@Y6[H!ENB
M8]">)M;K\%0=%SD3XJE\>(._*'RDC"FME]S35R/L2FW+"*98G:-`D'5-6B:S
MJHG/1>?$)'WE%)44&2R>K\;FA?-LG;NTDQGBR91UT(/+J!4<AY/85G$5"$QF
M0]M3([TC`VL-I;W_`'7M0J><L>I=_*;GD,GLUX9_5.,F?Z0XA&_B"UBM]>1?
M+#8_\,S%]((GC)TZS/\`8.X*[\-P#.'4MDL%&R+5Q[G70E4)951$8D1$YME/
M5F[VB;Q*5<3M9/;UD28-(-ACSWSIQW;9-1#2?;UK$D0O%Q3N`!Z>Z]5Y<3G/
MQ?)7]E%AR=`!J9#ICI6WJQ(+06Y%/*@*[0R>5GE7IN>FFL]2T^2Z0.QUZ%#.
MEK+[Y&Z=@R&P[Y7:J_0^B?"YZ\DUXG.D#NPMKI,&)(<[&,E5CSV"M2/V#VU+
MF6PD<[0I8JF$#^4<WB:A[4$?T^PBU,M9+#QVCL9VBQ(C7&$QIBGUY;-W/@PO
MQ)1(6-:CHI`G6T!I071M5#4%&XZ/'9F1-6`7XCT\$X7HW%67;/=5.Z=A$?I9
ML]^N7:5=)[?:']8GU<.4)1E1CW#>HWM?M(SDYCMJKH]J^*?Z.C9.VURB:%7U
M..A)M*YJ[VI/L2HCNRK6D;IK[Y7<F(NCE:2\RJR?,/YFQ(@]15U9'5=4B5T-
M%5D<*:)JO,A%3<]SG<_I).930*ZLQ`7[(YS7=,MY-8Y@='>XY8<17O5J^"O8
MO%%C*;25N-L9EU\BZ*PDU5+%QJ`]JIH[XR&DN;KRZ8G:>'RGR/#)@\?R$[NK
M8`<-7X[DRM1$Z>0UH]/VES6Z-G@V2Q^U2-^&LBJGPR4&5UK&K:XY,*PAF,5=
MK+"KE,T#<4LA4^')%R^Z]&/U8GTNCVM<G)='(CDU3FBZ+]2\,(^N@O(.2DT9
M'1([GCF(BM26QRCU;)1KE3>GFY^/$<OX:H.K#LBW40GH]=U(MP9=QK:._M]P
M+(KN;CMT*OU\1"1:>+%=!GS+2-VW5CM983]JS93AA(P9B258F[>CD73B+829
M4BIATQ9LH<F7E-U$A!=8?SKO'R+=D:3'Y>09]XA?<1O%:W$D_,3,O3!SQQEI
M[*_GT\KU#FXDW)LNMX=#>])>8'/FR>W3W-$T3B`VM;Z*"!!F1&ER'+17T^:2
M9NV3[2#%Q$@#3J]7_!5MCTM43>QZ<N(Z2?S-J7J&$^,_;@,'J23N>14L99DN
M!"?,8UR:($,:/Y4U$[FKJ2H#F$.8VRI+>R*<V+UHWM+63J6&UC6#+MV&2S<Y
M?JVIPBK-PZ8WEN9*QBS&KD3QV%B94!!.=]:L>GV<(EKAE/8-Y;C4V028)O#S
M=.OLJHX5W+X:S&Z?;PC+AMWB9%\5OJQ7045/'=;TQ;>I`/ZE,87+[>7`["GL
M8%K`-^JFULN/.B%Y(OPY$8A!/Y+[%^D2#!05AFEK'<^IKG^8$$"JX?JUGHJ+
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M+)\4NNJOJZ[I!I:3GX=G&`NGBJ_,Q+_"65_VWB7S%LJ.9.QZT=HKK"CE$KCF
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M.-.771*6N-KW$YC5T6?(1TEWW.DWR?.Q+_"65_VWB7SO7<8L7TMQY4.1C>K`
MM1L31L6\KE5H;*/M71%7:87B(C%Y\)3V01T.7A$YYJ=Y^I&LA"3XEAC\I[1K
M80T3F0>B'C>!&Z;7O^=,L[&0.)`KXQYDV49=HH\6,-QCF(OL8,;%5>)MX12A
MIHFZ!CE<]>4.K$]=A7CU5J39[OBG7GYEVZ[6-^F%>3`[+?,B-MBJY$Z@JM&[
M*J/KR=M<'4VB\T<5>,AS@O,5Q(](QW77RXO2E***<>YJ*@[><XTM/X)4^?%S
M6@"\UY0@>R;`$Y&+DF.;NK.IR:^1TN/S/#<O-IDV^#^(-O6F;(@6,84N*9JI
MYA%;N3715VO9X.3[KDT^CBX[CP`V&7VXB$A`/N["H@C78>^NWL\PZ^*Y=&#3
MXDDN@V>US9)B2I-M=63T/=7]AL=86DA/=1VQ$9%@1]=(\4>@@,Y)SU<OSL2_
MPEE?]MXE\\3VED19,4S)4*=#,^-.@2Q?JI4.2)4(`X]?%/%%5%U153C\+9.X
M(,OAQE,"2QK00\I@!T:^QA#3R`LH^J=Y%3DW7J#^&N@_FP/RUJI&V7>#9:9$
MX;E1XJ@1M($!5:O+U"6%SWIX],+?ND^FQ[&&,<Z+*F,D6KV[O@U$14//>YS>
M8]XF]-KO8]Z<0\7I%;&L<H/'Q2K1FC5APC`=ZI.&U$\J5U,$JM7P0JL^OB)7
MPQM%$@Q@Q(XV-1C6!`-!L1&IR3DWY^J<E3FG$K&5\M!E2R[W&^36AK[ABH3(
M*(>C&HT<C<DP#=>2.(B>'T22&`[^WL)#*W'ZAC]IK:WD(O;QF^U@!HU2&)X"
M"USE\.)4RRDMLLDNBMFY#;-8K&RI:-T'%AC57+'J:T:]*,/]!-R^=SOH,2_P
MEE?]MXE\O<NG:L=7XO*8(<F(Z4TMY8U\.3UHR(IA`&R4Y1N5$U=IX\7$(<B8
M@ZV7!A(\5I42GZR),\4B2[8$:'>$45'=H/\`:-=4Y\N(,R":4VPEV:P8X[!\
M*)&L@B"8DJ;#ZSQ.`"(YK&JI'*CG/V^]RXG5<AXB$A23@Z@2#(PB",\2$^&]
M_3W[-=CO.WP<B+\D>1%DF@6$&0.;6V,9=LF!.!S#)"O@NWP<U?*1BJUR*U53
MASY3!1,DIWC@9'7"5>F.6H]X;"&CO.M7:B3J@5==OF&JJ\;OF3[6P,V/`K(<
MJPFR'^Z")#"^1),[^"((U7C(,LG*_J7-B8X1/7<L2"WX-=!14Y;84$8Q)]>W
MZ:W_`#"G`TDW9%J:9S]-65<,G[8<?WV]W.3:NOB@45.+J[7S5F)C+B5)JB[7
MVCW#/E,X>J::L,P4)=/!T9WU_0E6L5&7E28-[0%]K;:KU,$/)%=TYX=\=R>U
M"\55Y%Y!LX092,]HB.;H8#OX<<R.8OVM^@<0CD8QC5>][ET:UK4U<YRKR1$1
M.).>2=5@=,]3A,=R(B`I.HK)]VK>>DK()`]&+XI$&W]-?H<2_P`)97_;>)?(
M9RQ9&R.()Y#D$]S8X9.SMRG<U%0+#=5NU7::[D^OC:.8=7D%!BZ-TU<*O,(\
M`7AX1SA8K?M3@I#SY#);9$<A7(@Q$257G,4#W=-C?C1Y!7KKXZKPP)GRYD('
M54>D9',$D5I9Q]I1AU8R.-7E<FNC&ZN7EP1[8EC/EG1\\KF@DRI!FF*N^814
M:\A$*=5U(OB[VZ\-:8;AJ\;2MW?>&_W7)]G+]]-/D@9=$1[P1&]GD4,>YRV.
M-F>CYC6B;IU9M8Y.ZC>W>Q6>!'<1YL0PY$26`,J+($[<(\>0-I0F&Y.3AE&Y
M%1?J^4]1'*HY^8SP4K-BZ$2N%^W6I/\`NGB`R._[)'TU/CE:W=-N;"-`!Y=R
M,4Y$:\SDU3X<<>KW?P6\1ZZC$WJ5%;`Q_'8Q%W=U;RNE75C2:^<N^:5"&7FO
M31[E\.*VG:_JOB1T[J0Y$ZDN<55-.F&5/>-)E/<YR^U5^AU3Q3FG&6XDOEBM
MECRFC9SVLK+Y7K-CCW.7R0K@14^S?]!5X5!.\$O+Y+X\\X=>K"QJ$U#WTEKD
M5%&\T?2.-=4^(9.!`CB8".`8P1P#3080!8@PB8GL8,;41/H<2_PEE?\`;>)?
M)D3"SBJRSJ:L,(81]P#JL!6%<AE20SHNC]HH?!53]SBJ,.$.&V"&,,W1Z[E>
MHCO([1#R3ZM1KN7@Y?;Q,,089+H[)ML`\B!#AND3F3VGJZU\49'H<"A>\143
M7D7716C1>'1Y`WF+_7_D</>`BV6-S:J.TNA1NV.E2$WZ>#-=.'03*6M1S*@F
M^)$0X4+6I;C)%Z3Y;"H$K;-'H[>OG'S3VMIQ"-UEBU/1*[EJA"VMK.:U^UQ&
M]7MYC%>FY=KE5OL^6SP>4_X^+.%)IMR\RXS9O,Z*%GUI33A&C:)[D?H?7\M%
MC0R;H^-T"2"LU_5V=Y(<8Z::Z<ZZ)$7_`%_36_Y@SA:Q:)BU%/N1%1UK,&U\
MP[>:.:Z)!<C47P7KK]7$.N35U3@<=EK-3S=,V4W$=PZL*\MJOJJ8CS:?^<;]
M7T>#7R(Y&R9,_$)SD]U0W`%FU;7<ON6<)=/X_P!!EF2*N^/",S#:7FCFMCU:
MME7AQ<O"9:F8S_T_T6)?X2RO^V\2^5LR0*4$W>B`(O<L<D]NJNF-CQEBMZ;8
M@-NK^HY$>Y$7WTT6IA*4<=R0B-4[DD&$*171IQMRB$+KN%U7:(UB*[3DFO$B
M&)UC&DZ5D@$:4GQTC3@4[V"<KHXHKY!RS3B34@T0[!M]U7*A0O'TE16O8Q"-
M,G1.QIXZM,WRF8^.5JH[[R+K\S%;[?TXKY[<<M^>B.JLD*""U2<].G$NDAR'
M*ONL$[Y?S!F.=NZ.12JAJ_P*%HZ-FGV;:_YN`VR29:4^28UE-Q?2F3:<1Z^;
M2KDO8QJ^#(>DZ0"1Z0#J.01=.HY=4TY?E:BNR7K_`)@$_+MDJV]2QI:R(_,4
M`2;&CU",]>0D0+W](KVJ'5J:JNO&--FDSCIWMA>UR8RP5',RJ5Z=+CP:JSKB
M1]L+T^\DE>T:/%UD</1&OY[<HK\>]6O\:QN5&B2K_L'OCP)9HT,DBMM)L-I*
M\,Z!,E]N_P`S=Q$\$U1/F@BQAN-(DF''CA8FKRF,]!B&Q/:Y[W(B<08<K1&T
M%*>UN2,7S2K(@W39R"ZBZN*>4_IA9JOW6I[.$EVJ-2]OY,C(;U6\T;8VCNNL
M5CN>H*\"M`/ZAL1/H[*:Q/CTIJR_C+KIM-46462YVOL_9D)^_P`".-=1F&PH
MU^MA&H]J_P"M%^=;VY%VLK:V9,U\>8`/(Q/^D]$3BBBF_G*P!S9J^UUA:.?:
M3U<OBYW=S'IK]GT6)?X2RO\`MO$OE%#2RGI$CJC@14F2.V"YI5.UP@=3IC5I
MUW\D][GX\/6;83IG4Z74[J6>1O[?J(#?U2.W=%"NV:^[N73QX1R2Y*.0D8K7
MH<B/:6$)0PR-=NW(^*%=HU^XWDG#BE(\I'KJ\A'*][U^MSG*KG+\JO(YK&-3
M5SWN1K6I]:N7DB<3JVN/(LI!@&CZ442;<'C'>-4&]?20RECD$]4<CG;=JIKJ
MG&,WY$VGMJ.MF2QJFBAG%BC[Z.YOW7QYF]CD]BM^3()[]=\V\MI;]=-=TF><
MSM=$:FNK_J^9`!6T=I92;2"2R@1:V$>PE28`9<B"24V+#8>0@62HKVZJU/#7
MP5%6@=&KXJ3/RXH<AIP`DP3M)%KK8EM'M76H7R!$60`N0E:GN;%VZHNBZXD0
ME%BCK/"DQ=E+>>F2_5^AB3P.JHTHZ62!-'=V[4*B#;O3ZN*VPK*&OO#UF0WT
MBE,:DL9ZUMQG*(2975SX<L3A%ENB%+&&BJ9KG%5B\UX>>)3EJH%].]/])QN+
M;1Z2SMXC(3SA'$?)F)-M?C@(5NYY-2,71-6\2O5J&VJGPA1I$H-G`DU\D,>8
M0@HTET66,,CMBE&K>IMV;N6NJI\P5U+#U*C#!LMC;D16%M"J\=0!4545=A6O
M/JG@H4U\>,;PIBZQ$>S+<D35?_;:F2GHL(FGLLKP?437DJ0G)\K&_I.:W]]=
M.,0JTC1$N+S,;ZAMHK8EL,$*LJP6A8TJ)-,Q(1Y9UA,W(A"::KY4XL\N?^$^
MI'F4T)D%*S)P-JUM+E]<2192I)4C600`3?\`L;]=47[.+S,Z^)B'3QVYMH#K
M&66Y;4Y5$@O""$7%XK&I/[BQEO<%&F?[Z)M1^O+'\<M["LJ,@N:ADZ57R+FL
M:ZHL'-C[*2:PDD<EEE*<?X(]FY_S;V(Y-R2J2W!I]I:^0UGCHFJ/5.,7E+KN
M-052OU\>HD(+">*N7WVK[?G'K6:JZ^M*.AT315<VTM8H"MT54UU#N\.>G#MJ
M(C=R[43DB-UY(B)R1$3YEK`DND)*IYF.09(VC%N(7*"'%7.C(X[7&&QT=>JO
M+9]O!YHZ;(C`9D/X7B]*/5.)96WJIZ?IPA^KH]HTF1W>8_1\O/C%V!BW?:9>
M1L:GM7UKAUJSW$F!]-D%>1#BF-+`*CM!N&W1-7(BHJE)#.R0P,DT,KA^#),9
M4:<*^'G&J\_EQ+_"65_VWB7S>I.F18;/TY4@4=O_`%BO8G">D5%Y<:^Z2#52
M6PW>U-+.:V'5\_\`ON$7TZHI&+]ZULUFRV?^AJ`GB/\`_P":G"+<978E]J@I
M(4*FC.^MCGR4N+#;_$.Q>&D=1Q[$[.;9%X63?&1WZ3'W!IO27ZMFW3V<-$$;
M!"8FU@QM1C&-^IK&HC6IQ9U2>%%F&4P6IX[0S[0F1QA_Q11;UC&_4U$^=,K1
MSX-:F2?E?^68Z*38&[2#(?0`J(V2UZS51P@*3(:V671[D$XD=4U0FQO&:V,:
MRIE#94T^#7V5]'<6IL[)$KA-F202XANIZA(CN,SNA;-ZHXZ(W?QDT_L\>.N$
MU]#DY#U]1&#47E[+Q6%CU[5#$"(*,>I__8'9R@1D8D18_>.&UC'Z<0/4YT:(
MX?YF83<$&57-1*VOBY`V;)5&)J@`.E,1VG/S<4,=S*?%I'K?YKQD6N+?E%5%
MR?"L8IZ3(I2S[&YGC&>8$H'.$_08VN>@]6^;/!RKBLMH_P#^OB`5:R86?%C2
M)F74!8=>DEX11EED,%96T+GIMW*J[T>U/EIY['!)-RI%R*QDL5=-)";(D=5?
M[G9PQM:Y/=W[E]O%OFTENA\QG=W`:YNTD;&H;>TQZ,OF=L<2&SN"-]AC/^6R
M,>QAQ1T1`):R)9F1HL!Y@AE!23).HP,1PC,7WN6NB\^,:!&)/>#&;^RRBK<Z
M4)_4G7(IC)'</:!$-$4<]^Q&[5\.:\$JI>29+^&H,FLM1QK2X@-KJ=U+9I;@
M*`JUP.U!W":$WN75G+5/'CU6HR.S?7%RJ=ET5^-759)J`Y!)8T,HT/\`8I\7
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MX6CF]G-E1=K_`'V]N=XM'Z<MR;>?S!M>][FA:K!-<Y503%>\JL&B\F-4I'.T
M3[SE7BNAW9G1ZLQ")*(R?#JGJC(Y2"$VRL`2H,!9!VM'U2C>QF[54XN*WTZ_
MKX2PL=GUU/\`CO&I0;6'8625Q;7\<1,>_#$YD4SU[>*R+US/<Y@W.(-S7=*L
MMK.3.A61/5QO[4<T%1&M<AA3!KCBQO58-J@H-<T'6?TSR+%&Z,:,CFSH98,N
MM='DE'V$Y=9<5J/78&0[I`WE8WQ78W7ZN'B:1Z"*K'$&CW(,CA[NFY[-=KE'
MO737PU7YF%.=N<@H,J%H1K?=ASI47;HFJ*S0?+ZT\>,:![85?Z<[GXN@%+%<
MJI]Q54?N_=\/E_-&K/5%N+A^89:L6(&"D^0,MJLF1C,I@]KEC[*B2U&F\NQK
M_'1>,*FU4]U7"BQ'-GPIU5^TA(L*('20(LV,4BE(-R(W8O3\?;Q.NH59.M11
MEF-CP&`'U[<L"1TAO@M5Y!$BR9#$>,G/R>9$U33BW6IDR:W(KO(FWUXV93&@
MM/+E6M;,,"M;-E17QX=?&"Y-ZJY3[5:O->,?&XMK/ABMQ+E+\;=,J;67`0!M
MI8B5DT-D"-W.WJCC&ZJIIIJF[BKDWQ\D#"KJ622OBR+J<F\I;Z;V`LB2/-<V
MVM(U0K-_6<1%U3?JJ<OED$7F@XT@BHGBJ,"]RHGV\N,3:[35:@#^7AH57%3Q
M1.:(_P"=@!/N-S.,-SOJ>>ML1"3Z_.1=/ES5;"5:-!$@8E'JPULV=`-WEHEJ
M]6LDPRA6.,\J.+K%W,:QC?,[1>*&&5(5G4.Q-DB;>LD2/VFV%*KX[WC7TM`N
M*YCR[1*1BE:BD7;IMXRB!7]K9[;V_.&%,A6:%JH$#&:R?%E/G]]T"55A.&Z.
M)@@L1IGJNYRZMXQJ\AMDPF7.302QPQA2!24QP\AS(_J+'*Y>I)`SJO\`=:C7
MM335%XHR622H0B87#-82ZN5.MK%8[[['PVMJ>*:H@+%O8U64JL8SN7\WZ+RY
MK.H)<JP`D\<6)*L.[NF?%*-KD+.M;6K.>'J[1)!);T:Y5TWZ;.`V/I<)X>TH
MT-5LJ[-M@2=:5\LD@@I/J#V"#$F"9J%0/?L56]3=H[C)I5C/2P&\]&2":/#L
M*^L1A:AI)3*R)83)SV";*54)M(OQ$5KM'M=Q59(.N2[G8RDGJ41B/[>[II?2
M=90!BZK`)/18[#1U?JQQ1(U_E7E%EXS#KHE9,"TH$KH0(#-ONJ,H`C%TC@>B
ML>QR;AO:K5YI\FS<F_:KMFJ;MJ*B*[;X[45?DM2R`N(2U]%98[9)6[EQ^0:=
M5MT8].BH2S'.733>CN?+@NB6#Q%O!Y'VI;2<6&&W';^N=S'BO.H8^^R\[FM1
M&N\%Y<5UA"2SBFJA$C0F!M[%D<40UF:V-#6/W'2)$++-YAJBM<-K&+Y6-1#I
M%$@DE2C33Z*Y>I*D:=8J[E717[4\.7R*B*BJW3<FO-NOAJGLUX_,)?8DO&V+
M_&2G<Y6_QD:]%_<7Y,^K=J-9'RZ_4"-1$3M3V4B1$Y(UC6_LI6\D31/9\T4K
MM8<WI;]8L\/<1#(0;Q.:46YBKHC]45%1S7:*BHJ<2(DB#12Z@P*<`Z*16HM3
M#90>H^DNB"&4<D9(RW$M5<I7*9TDBEWJ[7B58K)"Z=8WDZ_MY'1V/N)MC&DP
MSLL$$X;'QFQI\IHVL1G2[HJM5%=JA[&7TD,;8G3`SI@"((VA!'"S5RM"`+&L
M;JJKHG-5^;4`3;K!MKX#M%U5.I9'EIO3[JZ2/WN+&-S_`&++\S@IKIJC8N2V
M(FHJMY.7:GC\GV^S5=$U]FJ^Q.,X2[>&6"AIHMP,@\:N,;LILKHSD>!E=.?.
MFS:AK8+1"L4:H$?N9N79Q.R2FZZO%%CG"QT0@S=5TB(T@!@GBC=1[FE5C55$
M8J\]?;P>#:U-E3R(`IBS&'[$HPNC4<?(HHFDA2I`B&M:T^H6M7]8QS%T5.,4
M/$`V.V^99&.":Q''"P%(2RBL7IEV,)U$3?S7ERXJ)BPI+]<*R/(K0<BBO*H9
MY]6&,L,-=,L(@HYXA#F^(X/7T;SUX;DMG:T\QC28S-+"KZ0T+:&UL(L&77]Q
M)M;#KQ]MF-6O1@C(X>N[1=O#F_HN5O[RZ?+DLM?Y&AME;_WCX)A"_P#ND3C'
MH.FWM*2KCJG\(4(+'>Q/O)\ZDLM.51F.+3R+X;0>J#BR%5=4T;T9*Z^/"I]2
MJG[WR.E((:27B0#SHU$*\+7;VC<_WG,:[P^KBDIY#9+I-Z=0`>$;7@BZN:`!
M9SU(UP12YQ&1QJU'ZF(U%T3GPZO?>U+R&(2$Z,Z6'5[^JL,P5;N\&G^&_P!C
M7+HOCQ&BU<J'+9'L*V@;#KC1_P!A0D]E(WX>YK61:Z0G2?IR&J;?'CT)FB$[
M6L/UG3(&G4M$E$$)K.YVF:$$1SB.&XGBW:CN:H>U6WA2`B:;8,$D3BR2`BK-
M<(#5<FJK%3J(ON[/-KISXBRFHYK94:/*:UWO-;("PS6NTU3<U'\_E/D$=NF(
M7DI'Y$!J>3'KDZM&W(Q-\!UE@[1D]$Y#?MD?[;=QD@O069"632XP.!`DACR8
MNK9U\V7,>&41C7`@$+'(5&>=5Z>G/;IC[!RU]"@XRM>8,Z.J6!)8%I1123%%
M9."Z<0,8SNHT:M'JYO/<B\9&:K?-@AD6DVR63+],6E="!AD`$-XO,LULA^0P
MAL+NT^`U_@G/C')SPG=*F9%1Y`2*3HB+75)+<5@"*5J;&]2NJ58TR>95*UW%
M(&0UTOM,2)!/7A;&A'8/UK%94VB[ITQXCGM*RO.%KU48TTYJB+P1F.X_(I]9
MH&C@`'7USQ"<>/W,T4:&0XD$@]=P_AE)M73;JU_$:5(/*6>UL,!(9TK$@DUQ
M^0V5(.V.S>A/65&Y=A-J*WRIL5VM[,LQ6;%L&4*L+;.KUEF+&K.C.U2N<HF-
M'*U3P3^#Y-O&?3_NRLU[<'U*&MQ7&(3_`+J(KN_8=.2KX(GBBI\EA/V;0Y-3
MT]R)43R;A1_13HFB:;^M4J]R>/GU]OTMW'555(66RAL31J(B%K:V1R5.;O,5
M?'C.8?LC9S=%1$7RIZGT;1=&?<5SI>J_I+S]OR.:NNCFN:NUSF.T<FB[7L5K
MV.T7DJ*BI[.+"2_U"QD6=8M+)/;VMC:E]'59"NK0NFR"]",]THBNVZ.>KN:K
MP:GDC<L"0!D4@A&+'=T1J-6-&<+QG"K.DFCFN1R:>/$8[,C!Z789;!N)MY-G
M6%O*L"XFBQ#C;->=YV"K@,9'(5R]`,?5'\EXVRIT4A,=BR['X1R#%&B2H3HT
MDK2"T#(:V([16M5RCU3DBZ<5.D/KQ(-),IX(I#C$"^GN`#9+CR`'_7MD@:B?
M$373AM3$FVG8DET_=1[2VMKD25%1+[\59`%/G%'#_:Q"5":.<C6;>:::*Y?%
M55?W_ECTHU^)DM_0T*)KSZ4FP'+EJGMT;$@OU7V)PB)R1.2)]2)\[):\/Z\M
M3*)&^M),5O=1U;XZ/0P4T^WBLMF*BMLZZ%8<N7FEQAG(W3V*PCU14]BI\LFQ
MES+84QT6#&@$B64N,&L6#(66A@PPE9"F$-*1CW=R,S=PVZ(G`A+*EZ#A64'5
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MMK=Q][I"D:ZHJ0Y`J6H_@,W.?+QX@RBY]+<U=5W-XV.AV_=;&&[#L=9;8A()
MK$4MS$+TVA)%C$5$5W4WC4>WJ>7@DFG+!NY_6B`#7!L`C>\LH;I2,.Y.HZ*[
MT\1#(CVZJT:\N(XXP;&<V6&O-&-$B;PE2VB2)U:U'O*/S2HT5ZZ^X/EO5NJ:
MB='9+5DD$0D:26.H8BFL:I;>NC$>]R%::3%3PV^5VC7:*YNH"!@=5!Q)4VR(
MP!#CCLBX[3W3Q?SF.]B:W+54C4-M&W38YR\I]:R2X\V`I6+&C](YSG#80JI\
M4(!F4[#^I6`@M0K1(1SM6*YK7.3H28;88G_BG8CUT-'_``Q>1:HB2OB/%K('
M/8[R^5JL=S5%3BFGN8K29$:URI=R*CE#DMM-N8.J+X(.MF!8G\%J:\_DQ?,8
MXM7T5E(J)[VIYNQN1L+&*5?]E'FP=B?4Z1]O+Z3.*_5-16]=,V]3S?M$-P->
ME[$7M?>]O^KC\R@<]77E%-8B^T4C$J8:NU1--.O'>FGCR^9.JZV8"`><T<<D
MB0$IQ]DXK>^C[0F`1.]BHX*N1=6L>NG/14F8KZ`LAE]D&31YY*`M*Q]7BMB5
M^]8P;N_AA+)MHQ5"'XBNCM57/3>B<;\:I94`,2/5RRPS383R3ICID/N(D2-(
MFFI$+%B"4YW%50R936)X#3=6K>(B7"QF^HHWHZ=QN=_PSG1]VS3=TUV;O#E\
MW':U-KX^+U-ADLY/T9UG_5%0-_LW,"TY6_NZ_/5%1%14T5%YHJ+XHJ>U%XO<
M5(J[\6O9D:,BLV:TML]]Q3$1/T.G)*)/^Y^01:]LK<^TJXTPT*O+:S(57)E-
M'8SXM>$4@DD\..JN1$$;^([PXE%O.K$A1(L7M8Y*GLWV3Y$FX9W97F\X3#B1
M8[B`:B;7DY[=VSC/BX[&GG*:+$/3NL$R2&(<ULB6R0V/&RF%/25-=OUUCZ1%
M&U$T;\/C%)<5+",^/87CYGH=;.R1H]V.6HX("-#7/?VLJ:HQ]8D=$:KONKYN
M/2+F*"(L"HKKNTZ(TZ+'7<"(R'3H57O7JQ+(,YSG>*C"Q%\55;M`):L5<>R9
M-MA'NR3"G7/\@=!;5*PHE;8+3*)0\G+VRLVILTXS8EO^)0Y`S\2/6<H\B;2"
MKQD(2F?6249^&MHX'2Z:#U*V3N73?SX:IFHPRM:IF)X-*K4ZC4YKR:_7Y9%3
M/WM8786/)`[IRH$V.]#0["&7Q%+AR&->QWUIPE'DE='_`!5B?JKMZ..,-G7Y
M.Z:V7?01*=4-7WBR"]8+M[(LI%8B)M"O"***5ST8H^M)L+&9(4?9N@()TF9+
M.=PF17N:UJNVLW*J:.55XK`38D4[("+'K(\M>L-JI$<#08#N<PYVPV.1'*CG
MHW=S\>.G7B"KJ\P/ABFG,L0L<<MD83V=R_I($4TB-&OE1JZ::-;HIU)O&PD&
M#!B.L9B18;H=4VGCQNW[Y029J17>5Y&J=-WCKHO$D*0VO$<,F%):V7+744BM
M@4\D*JDC<QSJZM`/EHY-FOO*JK,&\,GI3BOD'`RSLQQVR22A3G2XL<<QH8$O
MOA(9"@09$+JY%W.<JMA4SS1YU^I\2JV*61*(*;FUM$==6Y#RC'/)-'8#NW;E
MT8V.]>>Y>(L"(-`Q848$2,)ONBCQA-"$:?8P;$3Y,EQ.1L3UFK.".1Z(K06`
M])-9*7DO*+8!&3_H\2H$T+X\R%(-$E1R)H0$F.1P3A(GL>,C%1?M^D_,&&J_
MK(-!(8W3E\(]H,B[O_%;QEXO9*Q_%;)=%^\I;:NU<W]/;!3G]6GT:N>YK&-1
M7/>Y=&L8U-SWN7V-8U-5XN\S*Q6DRZT?(@[_`'F8]6)Z=1#\$5$?'$XW_B_0
M464-3;7WS!XA?O\`*C`R"%4^-6!7.>B(UDYSXRK[$D?,A4920FR9($EF=-M(
M5<@XRE0+6Q12']Q8SBKJK`C;S1JZN1=$61K72(B)5^N5ZN-'D)8U+GO&,[>@
MYR`,]6M7IKKY2-YZZHD&X6%"1+B6"-(?66D&Q-&:R"^:T5F\#!N2UC!<YJ0_
M,5';D3V\"L`MVB.I%$WJ,>_IM>J#<5&:H$A1Z/Z:^=B.1':.U:BL*QA&+IJP
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MOZC]IB;M2-1VNO!+)S=:K`XSPA=]P^6WL/8_:O/STV-R%1WA_P"YI]7S!9G7
M@VT^:;RRMC?AQLBC-;W[5T]WU$*MD)KS>13>QOTE_!_XO%RF_6:?S.PAI^K_
M`)3^<^/W?]?#_JL<#B#35%YK57UD5>FJ<D5$M/-K]FGM^CKL.K7JRTS*2^N<
M1GOP,?`UI<BLET7<S;"7H,7P4AN(T**-!1H@`QHXF^`P@&T0F)]C6-1/H+*C
MG:]M9121GO;R(%SDU%($J*BM-'*B/8NJ:.;Q*JKE?_DF-R$J+U%Y=R4;-T*X
M'JJZQ[N'H=%U7XF]OW?E[J428UI0!BSX@"C9%M(T>0V2`,W<%\A&C(GB$@7;
M7*BKPCXUE;*]@PQH[BEAN[:M!());5A1(+6K#4CTU5^XRHQJ;^7$SOIUE:/L
M35S[(DU\)BV`*IA6PX$H4"#"CK!:X[W/8UC>JKU1ZN;Y>#Q83Y!&2)A)I'R7
MC<3J$8(2-^$(+%08@M;N5%([35[G+S^>_.:6.20SI##F-1&9O+:5D=%0-U#"
MGZR[I&*O)/-*C;A<W-#M!,B'%)BR@CD1I`7(\)P&:CQ%$].3F/8NJ?,1T4'>
MVDZ0"LI*YJZ.L;B<_HP(FOW!*1=Q7^`@->1>35X@4W6[N8WK3+:PTT=97,\K
MY=I.7[R--+*[IM7]6)&L\&I\RXQ2?M&Z8'K5DQ4U6NMXZ.?7S4T17;!E\I$3
MF\+GM]O%E17$5\.SJ9AX,V,3Q&<#U8[1?!XW::M<GE>U45.2_1QQJNG?8]<P
M_=5=><25IR]W^:^/&'$\.[Q?,X[O.NKNTE8T<:*SW51O<.T]O/Z(LB01@8\<
M1#G,1=!A`%BD,5Z^Q@QM55^SB?\`F!8@(%]T)D'&(LACF%KL4CO5\8BL?Y@R
M;TZK**FB<E8GL^BCYY01W2;&KC=GD%4!GQ<AQKJ=4PA(WF^VJ7:GB:ZZ^8?@
M_B)95\@<N#.`R3$DB75A@D3RN3ZE3P<B\VN147FGTJ-;Y,*R&:J17?R6+9%.
M*KEAO77X-'?R'_!^[&F.V>X9NSY"'.1@0A&\IC%<T8Q"&U7/(1[E1K&,:FJJ
MOAPS\Q+8!!14`6-@L"0-1O%6RDVR\H.$C4(.;?"T;&1='"@_4IWHGS7_`)BX
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MF\/C4N145O($/K$!5V\">88MR-ZKQ1)!7M'N7354TUXF9%`CE-A%E)65D5=%
M&0Q,7GG=K(R2`!F]SJB4]=T\#$^$OQVI[Z*&3&,*1&D"8>/(`]I0G"5J/&41
M&*K2#(U=45/'Z295V4<<N!/CEBRXQ4U88!FJQ[%]O-%\?%.'8;>')(.,)9.-
M6Y_>R"D`K6N&9_@2\I4(UDI/$HU8?[Q-JN<J-:U%<YSET1J)S555>2(B<`LI
MPW#_`"]AG0T<1$<UV<R0+\-ZLY?_`!&.9-R:_P#N+VI_NR?'^?,_,/"(+G4$
MEY).1T\4::41WKN?8P@C:FE0=RZD:B?LSN?ZI?A_0X#)54;_`/(X(-7-<Y/V
MMRQ--&\]5Z_^KC`9?_"YY`W:+HY62J/((.UOL7XDEJKK[$^A#AV+;7Y//C)*
ME37,ZD/%*9[^FZZL53R]X716P8_O&+YE^&U5XC4U6-S8\?>\ABN4DJ;+.Y2R
MY\TR^8\R8=RO(]?%5^KA:W)Z.LO(:H[:*PBC.X*N31213*G7B&T^^)S'I]?%
M9E'Y?V(XKZZQ!-)BV5A]9H)H&E;UX393A&F`$Z/N1.N.9J[VIPF[!L/1VB:H
MF-TSD1?:B+V*:Z<?W'Q#_+5-_0N),L'Y;XY:F`/<.NK\;QILR6[5$00%GM@P
MT=S_`)0K$T]O%HPGY258,@J+JJH9&,EQ[#^]+/O&H2J6-."0U22-,$NY'J=N
MW:N[3B-ZK^3]7'GOAS;6=6"HL)EGJZ:`8("V<@PI':&8\AVHP87D*OM1.+!L
M+!,4?&@&#'6=^&:-(\F0\#9!1QOV3J.[9A6;U5$35W+7GQ_<?$/\M4W]"X_N
M/B'^6J;^A</DTN.T51(*/HD/5U$"`8@MR.Z3RQ(XGN'N3715TUX5KD145-%1
M>:*B^**GM1>"V>(PBVV+%(21:8;&V=[4O*[>>QP]JHQKQ*[5YJUSD:]=7`5K
M]6/98U$P4V(]SQ]0>J."<2[319(7HTT29'?Y2"(UI&.Y*B?2'/;V0J-U61EC
M5WSE:A:BV"CFPY,='?SAY'$Z3@)KW(R.%HN_3B%9?F!7I18\@A/_``H-\ADK
M)9"-\TJ\ZB!E5U`Y_F%7.^.9%TE:-11/8,;&C&-K6#&QJ-8QC4VM8QK=$:UJ
M)R3Z!XR,:09&N80;VHYCV.3:YCVNU1S7(O-.)F9_EG!>:M7=(M\2BM>617KS
M<6;2#U<21!7Q?&3SA\1ZC\HU14T5.2HO)45/8OT&&RN?[/E6/F7:NU=H[:(Y
MR:^S5J<0I?\`P>58?(\-4T-D5="\VG-$1)GCP[]U?_K\\N*88P,O)$1GJ5F<
M?7I</`5-4F7&A!]W8N9SCP&+U"KS)L'S5\:,0\Z=,,LVZNIRM)9W=F1$0T^<
M5$1-RZ:#&W081HC&(C4^:M>>790XY"C=(6JG&K94@3%U=%6=%V38P3?><`@B
M_4].+:TQZ5DF96K*WLJ''[^^A]C&^,IFC]0DABRY"=5VKSS9$N3TV[&O1.7%
MF'*ORT)E=K;6P;3((UY(PR4.YGO8G[7`B&M9]7%A5&U!1PD*-S&)JFKE=PL*
MTKF2+CU"T)10&W<Y8V,U%M)8X-%(L1'A.MZFK$W>Z.]A@*]$:T;FM1>`G&'9
M6P[&TE>MI.&BV%#-JF`@XZ2$Q_75\*Y4LIS'"9%8I-PEW>5/FFR#&Y[\6RDK
M6]Q/C`235W73;M$+):57A!:,:G)IF.#,&G)AD3EPV'GU6N-O5Z"%D('DFX7/
M<Y4:QS+OIL=3$*O\C8LCJB\F/+[RM(-S7C>U'L>Q4<Q[')JUS')JCFN3P7Z!
M7.5&M:BJYRKHB(GBJJO)$3AT+!*QV5R4>H2VS#=IB%:]%VN6=D2L*&6\+O?C
MP&S)+5]YC/'@&09;/3*<D`[JPG/!VU#C[U3FF.TSB'9'.FNG>'<:8Y/Y1K5V
M?22L@Q9T;&LO)N,;X:MI;LW-56P"%JNAS"N\9(FN5R\WL>J[D?39732ZF8FY
M0J9FL6:)KMO<5\QFZ--CZ_>&Y=%Y+HO+Y\.5R_9I4>1YD56_!*PGF1NCE3R^
MSBQ.G\A'H[1--4T6NM*RR:YGUN:L;5$7DJ\EY<,?^FQC_P#KM1W_`#_-//L9
M<:!!BC4LF9,..-%CC3Q>8YG,&-O[J\(R@[W%L1?KU\JE1ECW]V']#%*Z4U"5
ML4J?_P!C*'N5.8!+R+P*II(;(4(2O?M17D-(.5=QY<R25SY$R;)?YB&*YQ'N
MYJO^@O$5C"B(U6$&1J/&]CDT<Q['(K7-<GL7A\K$;"SPB2][BOCT;PEQXY'+
MN<I\7L12J474=[[XHXIW:_K.%ZU1C^91FHFDBAGOQNW?]?\`4E\255*JI[?5
MF<_NI[-+S'\RQ]R(JO6?BUK-B#TUUZMOCP;NC9II_P`3HOLX07XRQD1UU7MI
M5S`A2]$UU7M)9P241-%U\OLX4_XKQKHH[8IO7:OI([]%2=UM1W/CINS3%W&5
M-S8X;VMD2G-Y^9D6/()(>GE7P;[.-E-2Y??$]GIN)W@HKO'DEM;1*RDU54]L
ME.-(=#28C'=_OF367K=F+7_\!C9%KB*B?_EV_P"OAILTM[+-RHJ.["RZ4#%V
M.31=$QBN0,":/5.7?K.>GZ7`H\<0HX`L:((`C:((AL3:P8AL1&#8QJ:(B<D^
MF+3Y-3P;JN-KK'FA0FQRIIU8Y4VGB2&IX$$YA&^Q>#6/Y9W+4:NY_P"',@*O
ME\5Z=?<C8NJ>QC)#/XQEX[7+,<M*5^[8,TJ.JPI#N?\`-+$*E@2_=7]61WSK
M&1H]Y)?Y<2I+4<W>1QOP\\S/*WWGJ1J>'MXKC,5'-+`AD1S5U14=&&O)?;\I
M9]K.AUL$',TR?)##BB^KJ2)#QB9KI[5XZ>"8](M1/:BMR6^2308FQ%73?',>
M.MS>\N;>SBNCD_XAOCQ&N,SL7YA<QB-D1!2`)$QFFD-]TM)CB$.`<AGLDRGR
MI?+D1OA\]5541$3557DB(GBJK[$3AK7VE<QSXQ9C&NFQFN=#!S/+:BDU6,%/
M>?[K?;Q&8/)*(KYM<>WA##;0#%FU47=W-E#$,[B2H`-B[RL1S&Z>/$+M;,<M
M+*KD7,!T,,J6.76Q=>O)`2.`C";=.3$7>[V(O$-T8-X9MA7'M(KVXQDC1+&C
M[MXY$@M4.-!GOV?#BR'BDD^ZQ=4X@]&CR56SZV39#<:G-!Z';ZZ0)S+!T4L&
MRDJGPQ%:W7VJG$)S<2R$+9E?(FO=*+C@$KI`M_2JK`?X@?*2=*5OD4`SQTW)
MO*WGQ$7\*/B]Q6R))FS;NN:^!8CW=O5RNQ]08]).B?'`XS&:\TX`KZ.ABH2L
M,61U,DFG-%N4W=O!8`.-(&57/Y;Y/7&1NO(#N(_43&XVZK-W2,=9SNC=>;H=
MNYS*_N:M.6_<@BK[-.(_7N,?&GIAA2V1\>L'$=<.W="=$DFR78*N%RW1G@(1
M^GZ]OLC]QDS?+6&BRTATD2.T]B3=TK6.DD\]T7H:IH!RE8[3GQ'4^77INE6F
M@R!LBXU'#,DEW[;@G3H%E@L(^[R-"8<;R^83N?$?KY!DLGHUAZPBNLVQEF=?
M?K/D>G1H2-LQ(_R%%TMFB:)PWJRL@DJE2^F=W&4Y(X9H9-^XIHS;1D,EGY_Y
MYT^[1--"<DX;O@=QMJ742]Y+G3>K5$W;XLCNY)NYW[UU>3<1?KX`]V+X^0L:
MM]'`8U1`/(%4ZN5:QD@P'F2`JO7X6NSGX<!4%!2`6.+H`4-5!&H`^;X0=@$Z
M8O.OE3ESXV1P!`Q5W*T(V":KOKVL1$U_T23ZUV'I?37O/5.W[#H^WN>Z_9^G
M_&Y<$(N38#CTM^[63C&=X_4[=?T:_OI%.U47_P`MP0F,_P#^A\":WGTH=[=8
MX]?LZEE7W@T7_5%X=V?YJ?DI;LY[.T_,BHCD5/-IN98I#8QZZ>"/<G/QX1&7
M7Y<R45-=X/S6_+5K6KJJ;5[G*H[M?W$TX:UUM^7@6KXE)^:_Y8JQO+[R!RXI
M/WFKQ15MB6!N'^7X(<P\6PBR:W3T3I%**SBG-#+$V\^LPCF;>:+IQC\7T#.Y
MT\=+#0[08+DT<'5#':CVLL9]9`IR[MOD<,ZL?]U5XBCI/ROR%&S`RRBEY595
M..Q&=JCO+)9"+D5G#)(<W03#1AN?K[$Y\05M2DQ>+.C2Y!PXW"Q@LVL<#J(*
M!-NLDR.QWRY^U.DL>F<QB.U>0:\DH?6*FNDY581Y!A2/S`SVJN<CA31;^RCU
ML27+LA"),T;SK!C$)%\%TT6`IJ.AB-+&EOLM<DG230I;=_8QX@F8T(,\!_*I
M2N*!1<T:PGCQ`62W&XVL>7ZHP#[2;TY?G[%(!2#K^K'3R]52,8Y>>U/;Q`67
M<X^W9'EMM!P\=L-TB6_?V)8$B1DA&PH\;5.H,@9#C*G)X^(2RLH81109D><D
M2BB11S)AM_:SPI(D3WPW0D5-![BL(J>;B%W.77LET:OD0Y2)%QJ,&RD'WHRT
MDH&A[@$Z+O\`AMCE#'\J;Q/Y\0%-D.23'0JZ37$<>P"'U#NM=9T]E?$A"=8@
M1?AE$T6SV)Q"4DW(#^G5\FO:29E.1%8:-)1_6+9!6T2)8S&M>NR3(80XON/;
MHG%6WJQ'%A4UA&KN^O)4T[Z4J*MDY[Y]@<MA'1NO4*52*Q/O)Q0C@+@RG;2V
M"8RHBT9I7X>^)ZKZ*7>^0^GTW]QT54/COXI_1?PMT>PD^@>E^D]+TO<O>>C]
MIY>PW?K.C\/7QX'V70[;3X7;=/H;?^SZ7P]/W/\`3/_:``@!`0,!/R'SD;I!
MI@`A58@8=F`JWN[=+F!B9^^Y.0Q&T],1@`80@`6$XQ,KO^6*B(Q%MDES;1!Q
M^B9JL@B5XLGE!0DT!>&;:94P&Y#3R<+Z=??"O]?G5#"I3#JL"*@>]!S9\&:.
MIJ)G$:PH.7F>.C5N%"`$.+3LUV42B8L^6"'/MI*ZL6;>50T7Q:ZR#-G7+9EB
M6K%<HC0BC\L.@*B)R2CF=*D;E=>&"L+BO]>&"@";QM5,+EA06X`<'!]N#XB^
M(H"N-<&FI;^D!?BX5W2-U[,,$Z[@!<GE5T,:GR"691S3JX\)')HS.E#YLUC(
M*I''BG]%Q0,<O/!8#+<"Z0&9X>:4W_7&YR2P-^FN7+#CW"!I3M=9P*ZW=H@=
MMBYBK*;(#P0:>&[<`'9<$"!`V`'H6:8WOMTB/]1)1M"W3/2Z`>5UN$6IT%OZ
M=I%HDV"KYUTM_,?3'\9#_JQMU5P8.>ZKXRN6Z1`P!12'/AW`0D#SG.S=K8-,
MK+LB@FHL/OYS#)8PAUVS:Z&=MQB_K!#%?]'T%,@57#PDU8)N)VJ@@78`[H=9
M0S02$,,#S45NU6+@,;G\?X-^2DO"&LJS`/Y;.V#ND!)X"1*N=PAC`;\U9^NQ
MH>5Y"VVIM'OI1E(<(Q`2R@Q/B@V6]WLU>M]A?K0&9ZC>,7QX3&#G]D(F6E9"
MJFW^HXVZ#ERSX9J&UE40%HA7-\+P9(Y)X%+?9A549-XBAIJ@IJF\#>8B!;%%
M-?R_M0\Q!K0EU@KZ'7O$]UK)0W:247[9M0?8J;I)RA\@J!Q#15$:<X=3E2U7
M>7@I7W_[Q)*T.'L]6"D@!X.]^DT%[$1/-B;23%G.`)P!VW_SD7-&DG5Q_P#P
ME$!HFX]_N4V<S7]8<#PAA<!2"LAGQ6V;YPBY<<A"R%/=`XM`H"0#"5P<GVS(
M@UU4ISXJA_EJ4(4CZ*+HRLNS*DL8>-@X;,_I'/)D-0-8PUW>WV+D"M&N1Z$8
M;<-69<;Q,YLH<1VRFRBHK.4SKJ]4[9-K/[N55FJO,,P=+O6@S$_F(O:(N(5<
MY!R7&`39)BB7;_V[(,>+9J-S"';?%8]N^K+H_P"6!*R$LXQD.^-[F-Z/'*UA
M0+*X8:/DM@`0/"O8*Q!L*3"K1I<FE/F+(6Q@EPV93'4HIZKBYDZ%H+R!8X*.
MLB=0%)"XX`2N9^W,$[T\=GZ9)`PGLK$U2;'G^G<`%GNS0+<2.<]V0/#\$IH-
M@M?C;CJ.".3MP@GC)[I;96D383W!8M:[7;T)&W4-)Z9^Z[P:EA*]_8E]S_,-
M\KV<)`)0I]..DFF']CP8(CEFK`$23[%-73M>;.S798@3L`93)TP_&;4L<4YT
MP96_*(1J]HJ2)8$P-[1"$H=5P:%S$++EFR9+LO+"^-[4H#2X'*;Y0:,.T$[/
M7(-HO2FST%'J+R%"J^TD^[*HY!@!M*:'T&R[>?)85V`5F08-0C`%[L6M#]0Q
MP@P!XWL@>7;,4,`PG#+W(1+JST+7$>B@%`NT3A"\O8#I2R47X0SAP`>I\;+V
ME(*-GG))2S2M5*8HJ`5#)L@"[^&.ZNCW=-:'-BD!_2!R/`S=Y"<%I=GWSWDZ
M?I.&]T(TR8'"X`^:6K,%$:\/T(C64ZL"Q"8F::?C$%&X(Y`\KTPK-=H-$54L
M'+;H0EN`;(C#`8HDQ("T*`>CMBK%Z5[4BNPB,CJ"*PHEKU:(@'RE$5D^@QS5
MSRJ>W&L`Y%8YW;GQL]%]!W0J^BU>#;(1GC-_82]WBN;#U?L_V9,,?A3B2LM'
M(H$N7RR@I:[30&+K=]90(U*FOWQTHA]=Z!Q7`CF&FVB6IC#U@`H"52VU"V>-
M*`]`IIV']'C)&NN9'L#1.F5^:LRNVWX+7,"D$U`77)N&6'Y"B[]U>518OE<C
MP@1\P>6AX2)G][`\3)!YXH.AN'5(R0;5A+O>R'M[T0B@0TB;$?L<4GQT'@;#
M5`5XD5D*7"=P`M2C#G\6-9;*5TEU/A9N<.4U]LS>6`+P9QJ.ZH/Y;L-((118
ME.OO\8E!`Q$AZ]D;(5@$Z51G[L\]$M]O"3'K(,17?@'V<=J"2:OFM'_#`?2/
MHS:!<'VM5?->H>FXN-HL)IQ:D<Z4^E?3B^B\*6]1[:[H%TY7&;X`#^VG^C;>
M`-%HFZ1)RKP9H<CH%.NL+$!/',W2@_EL-36#4X8$';1&[.8K^G$2H2DY[`/=
M5<U7YVY1Q(QE`%SDE#-&?=*#M6`<$HD+7L4H_$6Q.C+,$H&@@GLC\HK2PM2-
MDVTKJ@:2T//4$9;7C]GE4S.2*)T>3S9E5]IM20HP[[4,?D=,?K@$=L?"@)$$
M/2-'_9S70I]QO1+PT#/H[W[<D/JKE.X.,^C(,"B8B^CQ,S2/,13[!X_WRV>.
M:?"4D/5:;)51TNQ8[NHM))S]QC*R`"$/%'T,8&E7'<8:%=88X:,0'&J8QM,@
M)2F6&FL45PJ^B"(['2/LRI[@UL9XDT"+)O3>+^VZ>VE6#OZGFGRW.*D\LQE\
MX?;["A$SVKT_/C,1A<#;4OTD6.?!=>M];VJ)",==^5G1=$JMAB#6C".;E#_&
M]R;43%4P&_#)B^V\6`<C0"++_"3P!06=EI4WMX6!=T):J]6.<J)$+#49-/)V
MS;ZH.*I!X*3BGFD+&?06%20,CX]$Q-DE47%9/%Z!5#;76@G;3ZLOHOM'#VN-
M7+L7G5FL%?39[+LPIP5C?X)XR"%0`V5^@,?_`)SOWR?<%M!1Z>?:$_7-F?NV
M)3D8MOE,PFUMB4JX"2/]L?3-YJ5+5WL]!6$2=A"1T4C>!,UFC3Z&O`<KU@]P
M!G*I_(PT#&I$9?0F:%Q1US#F4$;WB.G/:RK:0S58#\[&&(ZX71'Q*D/2_$'(
M>(Y\473`1)MUC=5B]BDEJ82YN"K-!+E#BCQ+VB393JWL//2>EF4`/6*VA=01
M$2OK6))H81/,Y`@?8&.V]"=4'$Y`TG[O(G!]#-@A-?SB&5`W0%SQ>2V,E&:_
MB^J1R1!85]1ZN)Y]R9HN(BB(C$=(G(GWV>CZ+++E`@*A3>)[N&J4%07<J_;W
M!Q"N5^4#A/8F-KH2RLUS1@-!V.+C,T\LD:,A6"V'0`ENH@68'C%EB"SX#)5#
M9F.4M9:T)HYX3.![J8HUQ:$V4A]Z^^,"0OM7_3$?<X=7G%=JE8!("O3^OZQS
MJ?P`PY]`X@,*9L?S@T/T`98012H`GB9-QG8]S07.I!:.E3`8Z/R<B';?E6D@
MW+]!)RV!^X3EFR+7WR>P$S'K?;O;+2S-"<(>.="YTE>$+L?HOADCMX#GTO)4
M'D:N7-.'L^VO6KQ<5P5G'1%#7-ISO!Y.JF-M6W-`K0V)"40[&)+[Q\6-N$0:
M838#285?D`^AVGD)%1?O:(XSN@W<I"6('T'<Y5YE#X&J)'$+.>T\M,U7Y))>
M<F7$<7QGKC))&*<0DS@F_IC3#HF4HT1,#U2IV.[U2]2"8_T[@""J'?0O:XX:
M#MD[]-$I%QZAAH]N'X';BGV3PHUFS<6"JA3_`,.!4:F5"Q?[M"@,%"DN13,/
M5/1AN)1%OT/QL?8>KOP(0]Z`;[3?0YW/<W9'8<!:\>^QRK6^X)22`\@N<@^=
M8"5`V;!AF#Y;,%%9+'TNRAC.3>+](3'=D#97@&@00>P#DAO?@90VW"Z7+V;(
MH0;LAT96_L9-$F<K3H#O+K[&=0X2`6SUJ3^E7[,WF,IQ#`W<&(0QW[D%/3:#
MEH/!Y']Q?@,,'+R$W&M;,.$LJ?0:P:Q30G8%=C,V/$*-<6!;/6!:B$.N>Y%1
MUHHDX70UP>X=3C7&B!]F5B"86A2%0MU_EAZK`J(DXTZ*K1V:#P4@S_4O$V$*
MC0R,=X-V+5RV(%/HZ,H4(3F_:96D$YX&9P'E/EI@5;$#`1L@B]-0%R0*-,5\
M-B=H'1,*(ATU]T':D6M#%XJ=$ON_5=%##0&\8Z!%1`)Q(BRI.F%V+?6%T("&
MG($IP;X>UW8@31T-)M$,-B;#B\YL+:8;!JO`G',7V=$4,"+8>"M`FM)VZS$8
M8H5Y"Z&#C9(6Z'1-FHJ1>BO*:\&W(S2#YB^C96#B'T5>Q%&177W@=)[AQ%]"
M]]2+4J.>FW1*_P!``>7.-+6,S:,@:=8EB^JC,CBZP`TKFYM+-LWWW=/G-..0
M?K$TZ.\2D(U;**`F_B"O_.=U\\5HGP?V7LOYO^G4&K.<T?D:.$CS%0$T:#5G
M@[J+=HP6T0#TT>+L5?EW^4G_`%T@W#K"><C"HN,=&UL5JMO(P5*4?.K]VW(M
M$X@9@:0`^$YQYCD&6,PI:L4(Z82$X6F6[J@![&/)13O/OR4+(4IU70W7&U'1
MK!M!61$$1$$1$1V(FD3!%LI.VF>D)!MC2DI4!D[X)@B-2(^G(P*GAU#%ERDE
MS@$XQFT,19!X!`EE4EOH[6!ZNTIA(.4!><NV@'#&)$!GU08MIC<:*JW;*E84
MW;_@#R&(@&%E"H;]X`U!:*T?*ZL&,<FO++N+.)G,-J7VK<P^U>E!.YCFL.VQ
MGM"#@V4C03?V=ULQ!]K@KB<W*U`=XA2^%/;+H/=SC^<GM-T/LI1%.Q-0!ED?
M52O5P\`@@(H6G-#Q.7Y8G^57_EZD0)N#_+16Y-X"8``0!`#T!W!86)#;>38?
MZC*?5``20A[A@.H]?1Z(=)RN5+P<^GP$E_=,N3$Y0N-(86X2"*P_/E16#^MZ
M6Z[C@>Y@-SGTF20XXU;,<>;15ST"P$?\@70$B9]N*O$2\>91P#D/2-]2&%HO
ME,4MI%);(W"$C#,9S["93O&<P`[JX8GI]"B.^/5)F>=HT3'09G]OJM^H<66,
M*/=+;>9%\U8$6O(P.3EV_P"[?L@F117U4M^>4I<FHTJ$!%1]OT7;RA^QT@#'
MR=![!,!"QH[$4FN5KSTB];13&#;XT`CQ%G:=L<P/4O.D>W(B75#VVY1A$T6A
M;]W?G&SU=OO[!%7RD%"#-G!WN&<>!(A0#LR7!DF0]R5?\?73F",==\\3@N:7
M9Z4Y*LBXB2">?KO.<<!6T)2]6U[_`(X+&7P,JG=;,-WZ8P!KHTT`=F9OC#.D
M1CUQO/W!A6`D!B#P<$:#;HY>H*-31R\19N-XE,/6TLJ#$],8K5C/*.I`;F(>
MDY7)2O`/8/P*W::&G=!&?0<0,JZ,-?BDR(,)##9V`B"'HBM%3/;F'@94O47C
M<`+^Y+\25L_!0PQ%G0!$T%'X=)A$FC8NTZ;FB.\Y2&ZLP99>AY#:;&O)**,@
M.L@,A#QHMH8HTD<GC0!?\_)X.$=`9H)2)>^A:&A:GM[U%^')3N4'@L2:=)I'
MUU68X`46.8'B(+0F)$,KBCA%XKUQ38%FJ-70%@^'PIWZ#(D8YU6K)&B1!0I]
M/:-%"Y#=Q0SV0V3NWNOH/1-Q-<Z-TLT`(V@8.-DQB?JJ`M&;B_B3HO3$SK7*
M3*N$W$=]L8+]!^RE@^AICS9_3V,K&XXS&0L[T0\@EICYI4'CL?=@EG%$FQ"`
M":HZN7BW6S6@!86H0SDS0`VC\\-S^/`9-V+!%F?$`W(<1L4*$DPL!7KZR[:Y
ML&]4'*:.2KRQZMYHFM'8*:7$HA4SX`0]T5"""<@">\,KBLY#*E,E2E3-[3AT
M*D=0Y'L=7I<-H-Z%W:G9SQTY_>AL\(KL&S,DJ,($Z<%3?!S<)Q(]W[U)H/C$
MAC1IIB\MJM:GO(7*""DKMYJPKUXN>RGR/:E7TQ)`%2O_`&&R->)M#V`&*;M.
MSF[.9L%/8<,HA"'DYT@CI'8CR)[')<^W`J&RU3U0/6]_P)!F5(`"N*]/99+`
M(W9SN>B)X5QD]W]5YO'*\"B0YAJ;OF/88'V2*.A9L/8'M/$`!`7H@60;`D)A
M9&#5@',9Z:C.';2_GR07$*I@R00`,`=3LE9X%RY<N7+EWI,,9THZB4EQB7O1
M$>8`]N+!P5"4/-:R!\D>*`L2Z'"")L1QP;GEK.PC(,&C(#_@&]/`*KQB00Z#
M5_4Q"ZPV8XT:#@[X2$ORK8HC+CA\4"&-P(OV[`\)KH<),IM16`]X2"Z;`?`A
M:Z!"]X%+-(>^TQ#:47QG2@``V1#G)_3>H!@VJT4<*<!*%#8MUS.3#@6O<+]=
M%VZ'S$>.>RCAY:1RJ8'50VTX`PO.#$00NR'EC+B!E("4N$B^8XCHN7>DPQG2
MCJI"S'H./!T0H!V8>J]-T6"F04K$LSZO%'=DZJWDVZ4=3G22T8@DT@4+2B"\
MRV$3K52_B0^```\#UJI?Q)?""(Y?&Q,-G(Z-6AAHF>@*"(.Q'P;3)OJ@?4J&
M];WA2;"[O%:;2CAEU<T#Z_\`F=Y+O@"X:A>.EC<G>F%$A\`(.73ML[IHGXUL
ME9-VL2XWG)0\;DG\:LB8G0:UW$T$EU`Y>Z4Y)B2N'4[M%7.D&7"E@(V!,,YC
M(V\)$"0)VZX@W@`E5J)K5:"B>`_8$CUC`#:X:))O`OTH,(1F_P`$]?`6+=/!
M&^.HSZ)8G\%LAC0[H=R9;!ZR>`$=S![G;L;5[$(4XSV\N6HL%(!2`V'.??<0
M?8!J]KAGZ*S03[#>LMDP8QJW'4J8&@]F;6EK<JFJW^A<./?0PC(@B9R.=&CQ
MD&E2W$0`&Q#TG<P9'B#CBD`?Z,2UM^\<,)8)ZIMX,=5#L<'`QA(N3<2-6[PG
MSIF5B;$5@%]95-"V$("LP2+W#>(23PQ5)NF-(=0;-OK5P2^UA8,XX6,]4\#2
M`@"'F%?6W6[\!^:'$<H#5?K'2Z2X*@K6#'`C-A]/UW&LVMG*N_KCTWF]CVAK
M]#?4<O`^V^T(D;AG"T:B2@%"Q-IC<'M?W!\DF:,SW.&<^!*A`!MPXQ,Q4#B*
M>KD8:+FH3$Z[62B9]^\:#CN10].PO&4?G53!`SGEI]01C(Z-PB#>!:B<7`#Z
M56<%QK/U,"6V@#829HDM!Q@%WM=H;='.CXCW3?)QP.4D>/0+-==:I7%2EE!5
M@6T';49@-5.3XE!G<(]I(HE<DARX'55"X$V\=P3*%@XP'1R^EB^Q[R2DCO)4
MB'\5(Z;OKNS@AP",@&61P.S6W'*DIR`+7,#?/])_V8I'\]ERCT]>+7>VZ?['
M6L?Q,*YZ?H"/_61[BT-^&$B@$;E2B_+1@-&2[(>;0?NJ0[34,4GL/UFAKH#(
MV504[7;+]F=)TZBP.FU@$T*?S_C54,?,F\G^6(&#JK<4K"FG99^E@C`P0;R,
M](\&)[*E76-\,IF`4`H&("*'PJT65@&E0H';UJ;3HIDMT3C%J"-PHC;T9=A)
M%=&H1IO)55;&I%8"@X`_6IN@@M."1#$U2@<[SEHB?MG^D<0'OYG_`.[?3_O/
M\/ZS_]H`"`$"`P$_(?\`V=?_V@`(`0,#`3\A_P`I4R?+GS)\R?,GS)\R?,GB
M?CSYD^9/_!'_`!C?\Y?_V@`,`P$``A$#$0``$``````````(``!(`)!)````
M`````````````(((((`!`)``!!!```````````!(()(`````````````````
M``````````!``````````````````````!`````!)!))!(``!```````````
M`!(`````)(````````(```<:````````````(``(```````!(`$DF0``````
M`````(`````````!(``DDEP``````````!`````````(```$DDEB````````
M`)```!`````!````EO\`I(`"0``````2````````"````!+;K)<`0``````0
M````"````0````)?OK+$```````"0````````"````!);/))@0``"``"0```
M``"``"0````))9)+,``"""0`0020``"`````"2`!));M=4``""````"22```
M`````"``++O]Y(@`"`00```""2``0``0`220`99;?+$0``20`"`0222`2```
M`"`"0"[IMOZB``````0`00"0"0````2""`1?]+Y@```````0`2```0`````"
M"2`1K;9>``````````````````0``"0`1?MI`````````````"````0`"0``
M`7)+0```````0````````````````";+4``0````"`````0"22220``````-
M&`````````0````""0`200`````"4````"```""```"``200```0```2````
M``2```20``0````````2`2"0```````2```0`20```00"```22``````````
M"2"2`"202"0``````````````?_:``@!`0,!/Q#SF5&\`$:H;2"I6G]!$[P[
MT,'H:T2Z/WVE9T/7M\=.=I?-:J\Q#Z8G4UAPM+I,%M48\0F(FM!$VW7^21P7
MU1UN^+<&XR6T3@6<#$K0U4'/;%.=U#TPQ%4^?7E<7UU^1J:A=>08-'4LD)<(
MR1UHETFC`*92$S"_@#8[PZ^P$)P[,1&"].K!V\%6M8=#C.=M68O`9@%R:("*
M(N+945%+IWH92!X-DUL0OR.\I4_:&+-=:GS9R3^3KDQV#U67&-'&I!J^(D6-
M$]&0&^D2,X;BW%-[Q7,69@,@80>=Q'I1"A4N\/F=NS#$1A3AO'#4E`5-<OZW
M5PPJC@$WVVN3ZS'9YH6,2EPF:$4+W#1&L_%S,+@FB@F<63@RX[0AC(/$VS+I
M?^JF6#]5?3[):%LNJ$&``,6*7-F#W`E>=5_6BFI&N<\S"*P+17?<,Y?6+X-?
M@$;_`*V4;NZL6I0-(ZNR6#M_)HFX(YU@&B%EK\ZI<)[!]R:6.#>P%09():\*
ML(CH2H9HRR+\JX,#!DCT*3',Q-'H1!S%SAJ+KT2B(6/?)"Q:XSQ0YPNPJ^"4
M,1B=[A1ZO(DAZG+LI#E+P9:I9,I1!54\N6U'[#6KX7"NDMPDS3:BL7AI&-@Q
MT.30]]7#P3$#'\C>1*.2<K15_J%`H`5$``JJZ`,VO_'!DF:"@((';(7B@L&"
M`A13;D2!NAJM-4$8L)H@)PA!"J1!P3N"7(POBPB-+`AG:9-(728=;S7QJ'EM
M^@V`Y^0%\"-1(NY.--FW/8PEAHDG!(IPPTM2Q@RJ+<!`.Z<%,6PZ0-VA29*9
M7T[*8T%-*LA=+4'A,9I3CKDED43='BF$FP#SD*"\#!(AD^*$,-\.G\>?%XPK
M9#J]`W"U'X$U+;[B0]N52OB*P'+;D9B01;1E[<U:!4]A(`#1K!W&J1$X*-*6
MJQRX*CJ^`7,-]Y"0/K6GJ6SE<21<0#6T\88F:(8R;'.#_#VT/GF^%0P`N$F8
M57-^!>,1%UW#0Z'TZ&>AL?&W8^6O]A)@(%;`*([0+2DVVD;+%D4HT^TG3IGN
M`Q]MIR%`/CJF)P#3(KLY-<SKZ>H4-B`0(P6S/`B"DBTNBTO_`-L9BX;[(\8H
MAJ#)%Q2Q=RV\(UZW+'0R$9>-HU:D&&3/CB>O;-'K`?Z=O#BYHP;A^_ST2X$+
MBNN\F68P66!35CO+B,$TTERE?'E&H0@:(BA1VJM5?:N#-FDV)ZS;[S1>\"45
M:7`#Z#T=4QDKN>9Z?C\J#27B2@)O`OWH+EGLQ1"$(I$@46&Q!=;>&=$'P;%X
M2Q@<<7X75U!>!UK8J"A/%RH)B#FS%D64N#?O66XPQ:>`/OK^/$Q&--KAFQA,
M,B.]$'E$"A?B$HP>G75M_MBH*CDUXA+>K@`Z^MN=I5VB%@9+0`O)Y+!1VIJ1
MS58SUAL5S3K/)0+JGC31>UB0J`56&,6'7SHZ=N9LK3E);1QQ(-WJ+UFX:KK'
M$(OC;C?RH00W.VWYIYZ@I^N8;4D1,$'@N`O.N34K1F":(58&R4@$L(OZ_`#\
M`@'X'?E(*&]W&2._<+J(D6GUGL4[!IVY!N<#H#!9/#,6SC(I`:"#9!\ZJ=(D
M<DZ*TOR/`)NE2QR<4HYO_4"N@29!/"$1\^/K`);0`=K<Y'AX2#`#[*PXNI(K
MCA8A%'D+JKAU42J'9M%)=>5IF%JB(<5555555JKM5=JOCRC5:NQT6X:<R9*.
M-`O/`U.MS[]K<[Q=E3Z!1@L,="FN*.\DI/J\T3_D>+/O)4)0@@]C;(HQ(T#C
MWJ8I^,*1F6E@&*PBPW`IU*BGC>TU^#C&4XPHY#_&H3%1_AC?,9<MN8!MO4@,
M6([L&%OWITNFX[G]!]'R1"W_`&(6^4P42%;8'$MV<%V@.QU-`6I;N2U#\*#"
M`);O3Z$:G`FP%'[QX!'$L:F`MF%GANZ"6?&+B^J=CCY5A',2EM?B>RJ"_0O]
MC%7RX*!N'5S>X2]GH?Q;8]N8Q3&\U@)LFSYXN5@WG=W\MYB,M@A2F4Q.6<XP
M'D^+4O[)$*B=>!"$#:NDF+69SO2?_LW0(J0>4G9G--`:4Z9-6$_(0&>`A@.:
M4?`U0X-0ZTJ.'BF"'5H,$(U%%X#UX'F_YN^$X0`5R!7)%N540(V'?%ENM')1
MX/HJ=M180UVB-,)LN4HDD.*">LZP\4"5(TH3J4_2$8WM]G<6QT[<#@LE>U@A
M3G&F@9A-_2LBLF2PN?*&U">#SH'"IIZGJ"B=:D(D1`5\W2%D@-.\@0;=97*;
MKX_WBE$BEG&9,A$3&M@5\*;.9$,#]"XI8$J1V&4((*3P&Y:*-(E_H;RXY?Q\
MA%^?LA^+*A`C0#`6'3!,IXEK&+L7!74S#W2Y#%;Y-))F4IT<XXE_QS`C"YZ*
M`2Q;:H1-:K!6R)3G!3.V_LPJ<4=&*%0$`"`(A$1TB.%!Y+5Y-2#I&ZZ-$9T0
MUMG4P2$^42EZD425?CJAR-L;0?[R&T!>#Q/8-\(K8-F"(*%[['_$2#I:"CT%
M\N6'+.H$VPF8^2@N5P#)7UON!Z;F;PI(4N0QW!&ENZ6K#U0.J"#G0\*+Q)D`
M>@O%26?>U!-+8B+V"(:II0$QA.?,EI`AJ*5%74G3-(JO/<GQW[RWX!I"%'-G
M-[;MGWV%M/KZ,QO=EB^\ZTE=QGQ&G1#;SH98(\;EEM@N0`K:,@YPS9>R`?*1
M3_?NE?%B3`Q#`=(760@AH^]':!0'H`\F4%5<%Q2UNV")Q`STSZB/I`3A41\X
M@#*Z"HD,!>77M$))`J8'5Y;N-1%][4&*(2-0/?JR#H!\C=-GA-":`3H4H`0Y
M.:51IX!KLXZNUVK^#K@.(:49N5QZ-03!AAK$,>L3`RO.EL"\S'26<M3*LP"K
MKNHW_JR>Q!7)F;;U'FQ*M40Y42!'!F@V4?$>@O>7R<2BE5=`!?0&@.DGQ8;!
M`2#2XX"0".$XNVR@R05]ZC/N`*A&&O!&I9&/V.RZ.>O_`*L+-=8HBB8@"@B$
M0)L["6D+:9D8"`!07%N;"VG$D%+5V5[3%J;(C[5Y9"E$$^3^`\$@@```[%[P
MLSMWZ;*TP>@4J`UC@RSKTD!4-R0!DDSBJSP\7N!B4%TO@RWAI1G-FG&S[QT+
M&ZTU_!!(1(AP^+5EP1]T[&&(,%$PJS$8LNUP7!DP$GI7B;0%Z5E$`$^=L0T(
M^L-Y%F(T`#&T<]T9XIE)YXRB&4CLEZ)S3R!A>7B\RB>@,K3J!)K")'"939[[
M.V[GL7@6K"6@CLG66D&4X+.$0B$]57:$DN88Q#U&N8IK9%2Z$TS-`25B&ZD>
M-R1WIBH364L!?.\72E&44#(=X0J.MN$!(V>?=<Q4:-%.TG:)"2#&#IN#I&8<
M#ZXTGBKL$&@[M+$6A(`,8E:4".R:'6(\;UH0B=1)I?Y>"HRA.L*)N<K,W80V
MR5B0Y\0YTIFVAU7Q;93BL%DV&4)4P^^&V03M*(/+PUMMAK00LM4;AUB%@#J;
M#<\J7.)&W%ZDI7]6V=Y%N#Z@[0S$$F*V@!/$P4^W?N*[O=E,D1ECS%T]#J1F
MS1MWKQ`"G0[;$6\MNE(`2P.P'.5.OW<2H"Y&#Z9)343=<LZ+:VYC99_'9$R?
ML2(,'H^35J3&6Y:OY+.D!@M,B/D,XS#2;NHP;6J83;>XU`DQ*FZ]OBVAH.R5
MU*Y@U'S8]2@/#?!PI'55_<;`!EGU]#MS#V."`Z(J/>N%T_(>%4[FZL'M%Z##
M3+)M<"*0G1_9YELH#(48I"NTS7PIVNL7!$%BD7M#."BXJHAHNUT>S_:F:7_?
M*>YMFT%!5L;9JN!0##ER8PJ5T!N[2(T-7'OS7S;RBROS!N"F8N!?AB!..5#E
M`[,.CF-A@I='2'D#%1;D+I67R[>.,Y%NG!8-VTZ3P?\`"?9!'WQ`]#!V!+4Z
M0,?`P,[M):2.*K'O7:,:TC7"W'4$%E'Q00?$>G`8FM`]+#?274R?)<)]@1LQ
M'J,"?:J#.B1&<GD6(?CPD2-"GLJJ+1.@(B;-%H@8C"E:1G&=@$X64"NO+H&X
M)N$+9&NVW+PJDG$W&_7IX%]V1,JG'\3C"VW33H&A8(`=$#ZT?H*XX%Y5[/)H
M03KDR/AA<@;#Y\"<4E)YR!BJSF"RCB/A+Q-.&@98MA7L.$D>)FS_`"\$+Z-@
MS7#8'+GO::UOJ:E/(Z5I0Y(TU^XX`%06J)5H5>#CN(@?XNDI+%6TU84.VAII
M:>F]`W?5U0V,O@=*W#QRWD6S?]K/+)^&4/&W%":.)V,T1UHQW9(L?)D=N0@Z
M=,`L^B'P';^;Q'SU)>QNR044CT%$1B;$TB<(XS[<3NW)BM2%B`,YYX7E<(BB
M-,)[;_%CU+0XG`X.OTG@"_)S:@^3?0(%KETM\T,4(O+G0NN:5:U9`6-"'&,B
MN\C;\DUNZUDB7%MI:.*==_O>K4ULB)(*"-,.N(TXH+F+#IH8`$1:_P"%3$5/
MD+A3/9<'0HP-<:"*8*C7>H[71YGD:1+HD,92H-'MM;2#VA!L;UJZ/WP)9P&0
M-`@W)L!@?2>6HZTO'C\@\1L-ZSL)X4DMH-E.?,HRUB+*L<FHJS]O;J2B0PH7
M82$:G1PP)^A`=`(`.#N:I<8A7)9CI5.<MR5<$)A]`('75:L@%"YD7ZE.1?BQ
M5-R%2(&AEFIDYLUTYYV'P*=ZRWU*H[#:`SE,0UK]1O!DF&FVSDG6$O.=UAG.
MMU(*ZE9&#1:Y(D,0MMQ9*NZ'W:51P]K9.*V8CB:1=6466DF1!]?J)&5T&4[R
MTC@>69K47G;UIV2[B/F1#J:7U\1H&$<FZ$-DY4%@3U>RD#>]6O;.J&L9`3(H
MA#T!GI&^E#`HLJ]2\I>:A`Y<"8X&1&WT^HN]N9O(>PB:G_32N\OQIG'6M@[+
M\/&?GEQ"`/N(/F788'!TA@9@@>QM4#L':'KJ?#T7HDBG<E]T)0M40@B,<;UU
M\0:+>6`84'1+[E-@?KFZ!"@DZ?VK_P!$"/Y:R5["L;(/2]4P(4].XV)(Y+QB
M[4!408@G`I\I[T=")-J5-W(^DID;RLUP;62$,21!@3D>CX]0B[4\0@!E-O0C
M@4'87HB<H#82/,VF[>>[Q!:73<R9V9`%,3\1'F.(7A&T%[C]%/4,3QQ;VVA_
M"&>THW0.-*1>/9^M!OH\/H]`[@`D/#$`/`%0`!T%G8#GJ<%`-1`&_:W^J39W
M-)Y(<[1DB+5"J@4B-K<IDL(TVPM,H>-YZ%C,55>%E895:4KTM<81"]O`&B*(
MHHZXR6-A$2"A`10Q$=B/4-[-8]L_1>C83KM#0SP81$`SN<MBFEIBF#,`75(%
M(P&=A<P!#T1`8BZ)H$V8JJJJJJM5=JKM5["F;E%5$"PBB8H>)J;X%\V@J^*6
M[2A=8<>,9'[F(D6+M@61IHWC#5@81*QJJ5/#[@=I;`=%U6P.!J/O8"R['T"#
M"-M.AO"T>,W%:-HC<`Y#9(\$IPZ0/H!`>0!XQ-*FI>L89UL\(6"LBCO7Y@\#
M4/(*T?O3*@ES8P%GY&WJ&A#T$/2U?U8O"@X)@5DP&!N7/SZ`JOR1P9L$>`'7
MHLCE+KS2=]@\8Z26+3\(`H^)_MQJ64!V28Z-:HW&^%A2K!XW.-AKD_S'5OGG
MT<&VQ@L%*)P/CNC3["[\09%P$SD_02'@,'.1H)T`<11A/#&ZKHS<1[A18+K$
M#$'/+.R)+1)X5,L%M!MU=HL"0BS9[E?%P@Q"\:`0`@`"("`8CI,<9C@$!>K/
M#5X6B*(B,1TB<B>DZ.)HF8?*IBD`7%)0C7%]:C[[GZ*D^^@]/,BL<8B*(B,1
MTB<B??B_*0.&;).5YH9$``"8X`%-UV(1X1H0CF_-B*SY,+,%F1U2AH.%K;6I
MX)$C>@^H4OV8TD`D:AE9?!;MV[=NW;_`7EFR@WB;$,1E_HWWBD!)&4.P(8+,
MBS4BCY(`[*HM*5Z(1`D1B6<KT$0L/#<>`RJ@)Q``5QA:KRL5%<#5K$``````
M`(`&@#O("B6C'K.R8P\5P995XI8+C%G&=J8$^@BIU`.42*?2G]O`IDW'_P#D
M(LQ2,*X+`)[NX%<&#%/=0$EA`3778H6=4(E/<"2L%[(/`G750<Q8LZ6W3`8D
MV3&:+,#`)7=VG<OP@?F;=+5$F]W13?!SGDA^CO!4-?KMV_P%Y9LH-XFP'$$N
MM1%JB$$1C@X`>L;D4@-*F8D4;9RBI&:1Y'8A;V:P#I@QX#T',5:TTR&S8`R@
M$5*B2<``'@0,H!%2HDG"(IFD/P;4#E7%);BX"/X@S!R(@B>!^2XW?&T15HN%
MR!]A,]GT#3IY.#^`_P"P=YI4=]T[%M[MRX4OP9SNJZT6B468=GAA#)G)?;:!
M!2R0ZSH!`V+4#^L"\W;1B[K-/2(8([OCW2HN]"0P=P:U0ELKEA>`N/=J%_`>
M*QQ(&`+=]V3-JR811\#U.I6G)-*``KFR""9\PX%H*LA1"5B']-2ODS,I*G^D
MY,^-BX/@1^W(8ER^=^I^Z>LI!OSA!#''-&7:!T3CL(112JE+7:E\PT/';!G3
M>"SN0F*!5!U^X6`8>P7A"^P_3?9UTD&;%_0IKY9.*,:AD1,"GZ-1;5&OF,I`
M)/IN(!8.,48?;5J'.86U0HTID1CH/4T@"6"-"O9(>GJQE1K9FJW0&D2[A8%!
M)>@/)PFO2H+D'N?1(!(!#`(6.5D&``2N6Q9H0$'.EL]]!<@`#S2Y/^$;JMN%
MK=YI<DXAJ6L$C1*B]^Q'=@62*+.T[2S*[@&Y`!VA>CAP143&ZBJC[ZF96.&U
M[>@$(7-,9!?P^4:Q'ED7Q:X@6]^[JA+[H2C:HE$`*XX_:VD)NC(%$973<XFG
M81@W($O?8>J*Q(/7!C*<]TX,KD8Y`P0_,@>;;),/B2`9F>Y,M@`8L`CB'H=@
M-5E#2`/N"2OIE147,5S^\5E61G4+!0MVM,M=6$!PE?:RL01M':M-RY]A7%$4
M%-^.M;I_)%XCX!F1PL]G7HGV`%BM%J``L%&,*H`+W63HY`/7RK8,9C<3M2B&
M'[`+W"X%GF44`77])_H647_>G+C_`%:-KK=5"SV$"/\`JV-EH'`ON!AKI4C(
M3Y,!Z#%PAWXA!Z=QW(&D@$H9`(+84*1^PF06%L<:M3*P#=@9)\2[RL1JQL5:
MAU@E``EOMLMT=,9W@"_PSY(*E73B'+?]-Q#"H+_D,JCS\&"5=F"1!7B"!Z:?
M`F'N%,1NL[CB$'%7[:73S7:)6!ED#>S^$JI2`X1AWQV2%`C-5C9]=J\E<IA1
M85[/"[JE'AS*9_U&<@_YFN=S_4/V_5_M?ZS_V@`(`0(#`3\0_P`I5R_+OS+\
MR_,OS+\R_,OB/CWYE^9?_!#_`!C/\Y?_V@`(`0,#`3\0_P`I(7HK(_-$N(_-
M$')/FB3Y1<O8ESCY1#M2_*IOM2?*+_;MX?,GCY5<WTAT>?CU.F\F<9<O8\_'
M&:[9D[.7QXSI[Z^LWG\8='GY`?67+BY>ER_)D>Z8Z/DQO0R8?*AG:L^5'UV+
,?EA]=%OS"W_&K__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g644794g77g14_g.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644794g77g14_g.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-/6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:2\^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@/&1C
M.G1I=&QE/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CYG-S=G,31?9SPO<F1F.FQI/@H@("`@/"]R9&8Z06QT/@H@
M("`\+V1C.G1I=&QE/@H@("`\>&UP4FEG:'1S.E5S86=E5&5R;7,^"B`@("`\
M<F1F.D%L=#X*("`@("`\<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B+SX*
M("`@(#PO<F1F.D%L=#X*("`@/"]X;7!2:6=H=',Z57-A9V5497)M<SX*("`@
M/$EP=&,T>&UP0V]R93I#<F5A=&]R0V]N=&%C=$EN9F\*("`@($EP=&,T>&UP
M0V]R93I#:4%D<D5X=&%D<CTB(@H@("`@27!T8S1X;7!#;W)E.D-I061R0VET
M>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R4F5G:6]N/2(B"B`@("!)<'1C
M-'AM<$-O<F4Z0VE!9')08V]D93TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R
M0W1R>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I5&5L5V]R:STB(@H@("`@27!T
M8S1X;7!#;W)E.D-I16UA:6Q7;W)K/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE5
M<FQ7;W)K/2(B+SX*("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T
M(&5N9#TB=R(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#
M`P,#`P,!`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`+8!O0,!$0`"$0$#$0'_
MQ`"+``$``@,``@,!````````````"`D&!PH%"P$#!`(!`0``````````````
M```````0```&`@(!`P$#"`<#"P,%``(#!`4&!P$(``D1$A,4(146%S%!(B.W
M&'@Y,B2U=[AY"D(T.%%ALK-TM"4U=38W@3,9H5)VMB@1`0``````````````
M``````#_V@`,`P$``A$#$0`_`._C@.!6AVZ[:6)ICHI9]M4X6V!N5_?ZUIBH
MW-\1EN##&;"NZP8[6;!,GI"=_5UJ*&BD8W/!!N!$J3DI91@1%C%C(<NAF@$`
M5NWXCR:Y-E7S:K)WVNNV_!>5@M]U`G8?U@Y4SC2O9<8:V].X_IIV<*'X!:;&
M$^0Y#Y%P.A+J!W^G>P\>GVIFUCLWCW>U:*0$S9X3I$S.W["TT[GB35OLM#VM
M.`A.!-)2`A02)*F![37("AAS@HM4G*"%U'`<!P'`<!P(M[G;<U1HSKA8^RMQ
MK5`8Q!&TH+5'6O`#I184V>#P-<*K:%-V?4:[2^;R%00A1$@"+TB,R:9Z22C1
MA#D$?:9MO=97F_.P>RK>>[>F2E1)8[3-?V_.JWJ75QA<C<JHY6U=,4#=V(M;
M)8LV9)+='Y>)4M7N03!CSG&,9$%P72_LQ>2>YMCNON]+.E-[(:2KZLKTU[M^
M?J2G2SC:;L5UD<3<:ULZ1E%)QRUZKZ61KT-SNH!\U:WJ_!XA9)!X#H=X#@.`
MX#@.`X%0_>#NI9NB^@<TLVDSDS9<UASNO:'K"4KD2=R0P236F\&-ZB='MRLL
MU&O51:.(5ZI"2>$9`W$"?!H#"_46(/7SIBK`;K!_&QKO>^D&Q07(;_C8<%KS
M$VTC90(SWQ/BQT.=!I%A)JK](:$PD2,97ZG)?H^G`[UND/M#4=@E"N\#N=:T
M-^Y6N?V7%[U9D12=L3S]F6EF`A=\1-H*P44"-6$C2BPN*3A]EM>R5!'I*)&E
MP,+NN`X#@.`X#@0RW[W<JKKXU?L+9:UQFKTL:3DLT&@[<>47([3L]^P:E@U:
MQ8HS`Q&N\F=0XP,S`#`HD)2A68'V4YF<!ZX2[+VV>V\GZN\-I+SM1ZLMV<#W
MEECD*L:6PBO:62*%0UK7#:JC<8=&U"T(HP6,!7S3`G+EIY8CSS3#!B&(.N7_
M`$YF_5\;(Q/8C5S8^</%MS/5XZM7Z`6_)LEJ)K+:EM1))@-##8#F465A^E4(
M>X>J3X=#0_)<$2DG)^1FE#-,#ICX#@.!SG]TN_\`LOK/9;3`M;)\]0$JN]1K
M3V0LYV8&C7]^]E^>;*@E4T`9,V2[TZQ^DM=%OQ,G-<F."$'35[$240W@]>,"
M"'AK#[=KHI];LM((56S=>P8:X;CS16FL.VFRL:]@U3]?D4U\K"P)#`T,?IY]
MF(3KLV+G3RQM3(Z*GA46^E8]3@2E]9*4,7V@[AK6/M=J:8"S1JJZ?I&S=HY+
M:RA':C>OON=L&AFK\PLZ\XH]5JKKUQ9(74K_`'6],,.0O@G0UR6."')F$04R
MXK'`V#'.X.S*1-:(K;].&3*JZA2636UNW<[VXT.][2>Q];^OYFW'OU^2UG&*
MEAD)<&N#R8TR'.:X"EF*.>%J<:="4`"@HH)6ZO\`9C.K:@&[LZNBJZJKEMTQ
MK6'3^1O%574HN>,+'&4TH[W\_0-S?S()"$:&6U9"%#*D?`ILK$PG-8;[)OM`
M!Y"MJH.SW:VDG:DB[(O".;OO=VZA:_3BQZ^&RT]5C!K5N%M5<M1UK0E7/UOU
M;%TC7$J[EWW]D1JY-(43L_(6R(C7$"/]\))H;EF7>9<4=@[^Y1O5>LK"EU5,
MFP,CMM2P;!NJ:M7QEI;:^&:H0Q70TH/J=2Z6$9L)/7IU01C"Y$TIBG)H/+/4
M")+R:(/+69W@6;644M0I_P!=J5:+,I:3[HNTZ0R/9A<QU<JJ72U+4B26EPB?
M*JAP^3"YYE9%R((2TL!+&6F,?6]:<)3A*$GW`\1,>W2\*]D%YR*.5$AG;T@%
M<ACC7MB70V1.J*3C6C^F%/7ELW+6=ZC=)N<X5DBN:[D\*-3K1NIBQV1%FE#;
MB<G$%AT"U/,U]CU96EANL<4PYTGE?PV9N416J@+ED67RB.MKXLCBM:62G+6*
M6-0N$F,-"67@P9618"'SXP%??:SL?;=`5!1S#0KZYL-M;`;2533C2MC9E/$S
M%/"`)9-9]Q*H<HOX9=.-\C+JBN'<I*KD.?LY*>>`P7Z>`8R%5FNO;/L4]0C7
MJ3N>7'8:U)/55*1TN&'/D#IF$V%:FZN\5D5#32&=88ZK?,(Y?4U$4"_/"Z0Q
MM67%G=.!6K1-AZ54C4E!_5V=TFPUJ:XK(I1==535E[32"QN,.DV/O$1QK#-M
MBMN[-TIUZ>-5&%XK'+C>CV].]:NDXR%S1L:5O8TY.#LF&CS@(;`SW`7'`<V*
MJKZI![#1TF=3^>J'RR+F9XL9&*F!O2W]>M'Q*M$,-I01KZ\7G,()(']D1NII
MF2#LGX4NQI620`"8^LW:'+ME]PFFAHU4=;D5++$.U\BCDT;;G4/UOL,*U0M]
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MZ+$%E#3@<5`2`!C[+W*6M8.:SLR+U(F=7P^"Y;HY2L!O"/K*BNV<WYV$M>C.
MNC@*P)#2Q$K^S),BK":S%D<DXVY,2REB^4B6>L)J0)H?_DIMK]P7][+\"JY^
M_P#^];^ZS]W_`,7WK\%/=_?)_=#_`!>_%+\-?O1^&?VQ_P")>[]V_F>U]/:]
M/Z7`N'X%*-U=K-M.]ZVGKWU_Z@&;:O5`O^(9?-R3NY6*@-?H)9):0A>OJ1@F
M+E&YD]V+8[$D5%_:R9N;@I&@T>"CS\F^L``PY/>=9]P%3;-=96VE/3O3/:;%
M>-4L=*Q>9*PS106R)W]&XUMLMKE:,?`A8K/B\*LAF0G&F%DHE2%<4!(M(``[
M`AA4!14VM!$^V;K'LPA2L&VVK[TCA=Q(4H!IVJPF)81[]>W_``8!P2C%L#MV
M/A+7%C"'^J+\GIC,`&'`,!_-W1FUXE+ZOVZU>$G2;7ZP+US_``-`><-(TW-7
M;E@'XF:Y3<PK(1*HQ93,4,*(0O(FYY`0I)R`SR/`=7VF6W%4;R:X5MLM3BT\
M<6GS4/+E'G/T%2>OYFTGC:YI7$T;\>#6J7PB1)CT"X@80^1E8-+]1)A8Q!*+
M@.`X#@?0J5)4*52N7*4Z-$C3G*EBQ4<6G2I4J<L1RA2I4'"`40G(*!D0QBS@
M(0XSG.<8QP.-6]-B%/:;MBEO<@\Y1HMJ9*W^/:?,)N#`-5\W0VC4L$XVT=$1
MN,`<8Q'1A/9H)[H<A]O"AQ!@`SQ!X'FK?MF$496LQMNQW037#X2TFNKH:4#*
MAP<#Q#`G;&)D1!\FN4AD+F<4C0IB\9&>J.`'&/'G.`EWI"V,75YJS<_:'V(!
M>HML)MXNK9(FIB-M1DFGD'A`!KT&M&H%9Q-,(IPE=O.V7\]:\IP"+];RL/\`
M?R40WFJ,!N!Q[F=D:H:PVYM+U6WG2FKI'M.$MM*+W15ET674,3-&`(YK;U"0
M].DE#%'VDDT*AV^S%KNI:2`F9,*,R#..!>S#Y?%[!B48GD(?FR4PV:1]GE<3
MDK*J+7,\@C<@;T[LR/36L)R(I4WN;:K+.),#GP,L>,X_+P,CX#@.`X%"5Y=S
M=B+;FLRG-"=0OWK4-'2UPKVW+RGMU,5"TBCLQA%Z)16==/2N+S9^LJ2110,*
M9U5)D:9N0+`B)]T[./5P/!J;<I?O9UEV=Z_[MKR9ZB;80ICC4M>:MESJQ2J0
M5Z^I'0IZIW8JH9DQ^RR6O5Z>8MA1)ZQ*6E,\9.0*RDV5)(S`XEW^(6;4MB61
M0=[1[$/OBCI0?![1CH<YRB/7D%A4,TTC1X@@^TX3/F4TET:58,>V<E4!_)G'
MC@9I2-_6WIOL#6NW]!X$JLBISCT<CAF5(DC7=-/NQQ`Y]4$BR'R6,MZ1)_DM
M2@81B;WA.G4EX]8,<#V7>JVSE2;D:_5ALI1[^&0UQ:D:2O[.<8$)+HSK/(TC
M[%)(AP,8FJ51)[3J&YR2"SG*=:F,!Y%C&!9"07`<!P'`\<[N[5'VET?GYS0,
MK&R-RUW>7AU5IV]K:6IM3&K7%S<EZHPI*B0($9(S3CC!!+++!D0LXQC.>!ZW
MKLZ[!G7L_P!J/Q(8E:XG4>A%[Y%-48RH^0G3S9Q&8)LF.R3TW'!+SEPF@DV4
ML=`:#`T+$6`7I`>I4>L*_91)$,39%;VO*5J\$B3I4+8W)S%CL^/#@>6B9V!E
M0D!,4+WEZ<3BTZ8@L(AF&CQC&,\#L1Z^ZWKWH>T"E.U&ZV7Y3M)MY+H&LD-0
MP-KQ)[$<)<L0KFZC-3:GC19Z<<BEL::G)6<Z&Y-*2EN*EP..."D3`-X&W4W>
MY9]:*44VW!ZX+<UVUO5+414@NF,7+6]\.M0M;BH)2)I-=57PQ`V2.+QE$<H`
M)T5MASS]EEY%D8#/3G.0Z%V5Z:)(S-,BC[F@>F%^;$#TR/+6J)7-CLT.B4I<
MVN;<M3#,3K$"]$>`TDTL0@&%CP(.<XSC/`\GP-1RW7^AI].H[:$[I*HIK9<0
M+0DQ.Q);6T-D<ZBY38M4N3:5'9:\,RQ_9"V]Q6'*"`IE!6"CS1C#X$(6<AXI
M]J#6Q!@MODM7T>B#/%#W#"D+["H$GQ,U4QD:^TY'%"TS@V`Q(E$JES:ID:Y#
M@)PESBG-<#0#.+&=@/J7:RZRG/DXF;GK[19TDL-,ZEV3*E]4P$U[FZ)U1H$C
MV7-GQ0PB7R1(Y(&A,6K"N-.`<4F+"9@02P^`B_!;2ZVMRE5A5+K_`&]K185A
M+XK:KS(E-$.]4O\`9\116N0WQ"TI^D4M[<^FM3M*CG%"0ZKU*<X#D=E.!8%0
M'T@R&S]7]$-=-3:<FM'5[$PR*%V>_/<DM(NP$4:?,6,Y2".L\.<"9+'VN.L,
M$+8<0V/H6DMI0-"%I+0IL`PF\C-$8&SV_5C6-HKB0TZTZYT2U5)+E`%DJJYK
MJ.`-]=R5868G.+6/T+1Q\F..ZLLY&2,)JA,8,(R@"QG&0AS@/X;JOU>%&UWV
M17="CB$(:VV!..&R(UZ..1)EIJ4J)8SPI8%(WY;6%LJJ;$&N25M'[13&Z@$H
M++(48R/@:)F3EUHREJB;Y816F$A:5UH99((OFC13CH0X7-L,VQB9*FR(9?41
MXEUD7&TSQI=5A2+`W)Z(<R%)^#0FA'D)-K*(H]PP]A7TU5*X,E13END>%E>1
M%3B0-]GKVUULI`]X.9QX=4=ANC,C4OI1_N`=STA)BK!HR@9"&TRBBB"BR22R
MR222P%%%%`"64446'`"RRRP8P$!8`XQC&,8QC&,<#6EHTG3-X-3<Q754=8V^
MQL[CEW:&:T8%%9^U-3ME,<CRZ-S=+&IV2(7'*1085[Y0`F>V,0?5Z<YQD/&.
MU9T!#R!3I]K^GHLFAQ48?!S%WBD+9"(J16C*]LD+=Q2%8@2EL94`CLB<DC6H
M]XH+4B7*2B!%%'&A$'CL:PZU!>X5)0Z\T=B15LVH&:NG[%30+#S`6AJ?\2MK
M:X6YX8/FQ9N;91C[23DH1D%D+_ZP#`3?T^!&PF[>L!EN0&KZ6<Z:-MZ_>&&P
MLNCDAE3IK`Q)H;(5=F0"-AA)!`77#G$9:]J']I3^QZVYS5FK2,%J#!F9#(M<
MNOJ@]9KIMW8:&?>R16]<Y;D@DTOF"J,Y4-[`\2]=.W5@9T</BD.;S2724K0J
M5;@Y%.+VM^*F`H7&@3E!"&^X9K?KO7+Y*I-7M"TO`Y).RG`B;R"&5;!XN^3(
MAV5&+74F5.S(Q(5\A*<UIHCE`59AV#C19&/R+.<\#PT'H?5>#"#7E;4W0,0'
M"UJN<@@\)KZO&$<2<+'97^&K)>"-,;2E$PJYU'$SHTC7X)*&Y(2U23)AA(32
M\!H^R9)UIQN$3QOMH_39JKJ%,D9:K&;IRVU$3#X^P47+QP*#LLG0/*/[(3-U
M53UQ,9F1&>#T-#L:8D1@+49&7P-S59!M3;!A4$LNF(1K_+:_=6V%R&MIM7<4
MKYUC"IKAS@_/-?.L0?&!N-;\)X@\29T4M)B4S'V:K7JQD>T:<=D0;,_">K/N
M/^&7X:P#\-O?^3^'OW-COW'^3]O?>KY'W3^SOL'W_O1_XEZ_C^KY_P#6//N_
MI\#/^!S!]<!_X&2?;;0:S$XX_L31VS5[W:O*<0>R==-([(VI(+'K+8*,*S<Y
M'(VIT2/6&5U,"(PQL=&_XI_I%Z0X#<V[6M<^MAKKN^-:GM!!-WM57M=8>LLZ
M6Y]AJD!ZA/@J;4%8I@!%B<*FNYC*$UN1!@O0E4F$JP9!DL>1!'7:%K)[0=6Z
MQ[5=*(0XL.]NHI$IKZ\];G3&$<WEC#%E03=BM*K'18`0I43&,.19KU!EAA>,
MFJQ$&$%A`Z>2PT34-L0B\JUAMMUNZ"=8=-V@EW:3S09(7H3<"$0XLCRC%X-;
M9!'W(DU&N3#Q@9"HD8<X^F,Y#Q-`[%']6FVRBYUJDU)HEM]+V&/;9,X`C$SZ
M_P!\.HTL?@NU*!(7C(&N(3$S)#+.<E!"`.<IG$SU"(P#(=DY!Y"H@E4E.*4I
ME)19Z=008`X@\@X&#"3B3B\B+-*-+%@01!SG`L9\X^G`^W@.`X'-=W-[;R"[
M9R'JFUXE#BRJ)1'6V7;]VK&50B%M3Z^/F/6TT>RNJ?/E#:>PY`1$&`P()S?%
M\G'B#D*P`@!&>,QI@AT>8(?$F9!'8M%VANCT;86PD"5M9F1I2EHFYN1DA]("
MDZ1*4$.,Y^N?&1"SG.<YR'B=#Z1CV_.P+GN1<:IK;.N;0>4/SS6BJ3J"4,*V
M%V4KDI6?++O>U*W);<NI36H*0\MK/-%\-;(2S5/J$6C-+X$B*B?'_L^V::>Q
M:R6QU;=4Z95O\>ZT:CD*8]'B0A.&<S3#>*:,2L(!8DE@`3B1P8E06$QJ80_+
M"$)Y_NF!+W;6^JPUIUTM>W[?,"?#6:*.;)B-%I<N;K8DDER-1'(M5\<9`!,/
MD$CL)Y<"VQ*B+`,1OOB$+'M@&+`2GZDZ,LW6KK6TRH^Y$9S59L`H^,()='U!
MPE"B(N#D)6_$P<\W.18$?!D#J2T#P'.0!$BS@.<AQC/`L3X#@.!\9^N,X\^/
M./RX_-_S_P#TX'&5H8W+Z/:+BT8LM`;'-A=4+?LXNP&E>6,D^P85:ECRJQ*S
MO^/'G8"8_P`5L^/R$L65@?4(E>28G.])F,!R&RMDZOM,J15EMCJPJ1,FXVKJ
MU=(*M&L-&E8[A@KAC`K%UKL09(RA+(5:32`9240Q>6QYP0K)R6/U&8#&.S6C
M8%VWZ6UQV\Z-Q=>/8JE8H[QV]*7RG"58<L@<.5FF6]KY.&=.4`_-UT(_?+7L
M6#"PFK4_O$D8-+7(?`<P<??FF3LK5(V%:6O:'E$0X-RPK/C!J<\/J#Z@_P!(
MH\H6,@,!G](!@<AS]<<"VCI;[&<]=>S.:EM!\RATLVRF2!)(%*Y3@MDU]V)>
MLI6>/V4')PPI6>`V@(M.UR,7DLE*L"D7CR$LH_W`]A-C.,XQG&<9QG'G&<?7
M&<9_)G&?SXSP/G@.`X''7_J+^R=1,79?U<T!)324JE"U/>\4[8%8P',T/<BB
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M$*K",L10#5+X^3%Z<P)P$%@%D)/N&BQ@!8LX"_\`ZX:9L/7;073FB[95#567
M5&N-20><8&HPLR@DC##&E$YL@581F`5%Q]07E"`P(A`,"GP(.<XSC@33X#@5
M'=D6H-M;-7OH9,Z_A+1+&#7R7W_.7%X>+*=86CKFU'JH#&#7^QG*--SBA,GL
M>B=@&"5+T:8)J_(`%DX`-$I7E&!AW57J=M-1TDL&Q=BDDF@1LNI*AJ\E$!DN
MP[_L4Z6UL-"!3AYO?;20O#@YN<;AZNUG>6I&YM:FKXV<-+06)4F29PG2DA`J
M].NKL"=H-+LP*`-SS(+JNWLLOJ5Q"([/N-#HX9=EGN\7AF@=ERR90K#>^SF*
M4U3D/RH^P$1_@F2*48CPY`FR>0'B=I=4+KUPK.77):THM6;(W'9_6JC<0-MV
M-NM".?Z%U%KS7$3D4/9SX"7(RH1/-@KDJS[;E:T20MZ=6K!K<%=A0NPG4@U?
MT%WRFRC0QZO-UV'9:>::HK*UG1ECM]C8)U1MW2C8BQM@K.9[+-LZ0'V@\830
MESB,*3B2IG=T''4*]H.RU9..4&!).HNN386+=5%VZGL<&C5-;$[,WA86;PD#
MK9+_`&['G6%6_?BA3/[5CZX$_8ER!:@H]Z.^RFX"M,O4JFXG"\`U:E0=D-5P
MCK=V1J:`Z`UN3J[5U@.L+W::MX-G;*BDYBL.2P-6<[292T4U7[98DJL"8.J&
MMSD,&":H0+RD3BPPTA(#!JC`!B#INX#@.!7#VP:WSO;/26>T57T%*LMUED\H
MU:_P0=A"K`^55S&+K@4GM-@;Y88I2-:9T>ZX:'1&G*<!_!--/Q@S'G`>!"K6
MC1_;^'[X,MJ38A\AU9579^P:U+8(ME);/6:U]8Y#!2ZXU1U:C-*GNI[?%F&F
MFD29[D+H]I`+UDH9_F)U*T;DI/*#]>Z&F&W%I7SM1=%;PUK>FB:M6@=&Q5@C
M=MI*GL*Q=7ZXM:>6UN-$66P$@4:^L'ZR%<X3L@E>5B96K:&]0`DXL1I.>!$U
M-H)NY6E'2^PK"F3W7C_0NHVY=E4LSMVRMUV1#X-M[<5^3V9U*6ZX;UKQ+[.B
M&L='0J&((V:]H75(%6J-%\`PP@8<!&NE]2]T]@*>D<LI2*[!0O7"<;.MS*^T
MJ_;'RB0V'-:@JK5M%%8_8D<G.Q+Q%VB0QJ9[2S>3R-^"0)*A6NR-(M2IG8A&
M$"D+A-1]&;/UIV0WUN<J%/<AFLNI_7^L]:+JLB\G*TGNQXS56N<0B@F&T8\M
M>F+VYAFZ8VN<G=R4%H4RP+GZD!B8!RS&0KLI;K6[&=.*@N)[JBO:8M?9J^'>
MKZP7SIO?VZ.KJ>J=&U.]L77<T11V_8-@PZ;7+*+[L5Z3,)"XMO1)CFM&\K2S
M2SC&S@=$VFU%Q+6C5>A:)A$`6U=':UK6.,)$"=)2BG#S'7(23#C(4[_-&PI.
MVRV1*I$N5J'%S3%EIURTXTXH``#"'`27X#@5*]I6D]@7>QU_MCJ?EN8]\=1/
MMB2TPI5B"C9[N@#@7@VRM6+(4!$5A;";6:B1`0#/%Z6A^PG5%B)")0,0:QU6
MV8K_`&ZI"*7=7A+DT)7DQQ89C!I$2)%,ZJLR,*<M4_JJ=M9H2U#5+H._E&)5
M)9@`9-+P6>#'MF@SD(B7ROE?7%LBJ[-:?9G=ZHN<IF&)=FU,QA(<L4/]>M'I
M;HGN'#F!*$7S;.HT@_)4@`6'!KQ%QFY%GW2<G!"LS:.WM6=7^Q2<K]5IZCL;
M3_9=NKZU]CE-<M:]]IC3K92]59!-;2QPL)K).AD68-K$IQ:M8RB/+.0.?I7"
M`62I`7@)<RR*1R;QJ1PB9LB&1Q.5LSE&Y/'W,H*AO>&1V3&(G%O5%Y\X$6H3
MFYQ@6/T@"\"#G`L8S@)6=+VW4EJN7+.JG8R4N#[)J[C"V8:-VI)563EUV:RL
MPL%J*Q=7%0/.7"UM=2Q`0*2L"$<NC@4RH(/2F/,$'2#P'`K:[0M^D.A6OI#[
M%&1+8.RUSOV*EU2IW)WI46%;STE%E*X.I10L*$U?5ZB%EYD:W]`M.WI_:]P!
MRDCR'.UKS3"ZG(>\#F,K5V5==H2EUM386WW7]-YM.X94/Y<ED)Y@L8&0QMPQ
M80,Z/'I)0MB<HLL`/(L<",>[-P/KH)9KC7J"V%3*2P,-B[P6G1T3/G$TU;TP
M<9*WQ^?3](S(SBE`YC)&A6I`@()]U8F:B5B\!!@"<9P%F=F2:E]_#*KZP=#5
M[.W]56L,-J]TVRLRK7$6(E<J'#.VRFI]+J^D[>,(G4B0(OC/UE.`3#%64Y@4
M2@859ZH!H6XDDL<99"DY!;-%XO&&4!)))84C+'8S&H^W8`66`./80,[$Q-"+
M&,?T"4R8G\P0_0*_M)*S6=HFRT?WXL9L6AT7U@ECTBZ_(`\I3B$5]VZTGJ&&
M6;N2AI5@"%7'&%20H:JY)-!G(,`/=,>V9[0C0Z0^`X#@.`X%*W;CHM/;:;H7
MNWJ2RISMWM5VMR$QQH`\(TFSM$*CA.5B:R2XTOT_*/?"@#7Q12;ZLMDA`'T>
M@*LTP(02H:\8%L?4T/N2M5BD^,RY$:,;<Y%?$D$5D#<>-ODT)EC:+`3FB6Q!
M[(.0KTI@0C+/*SG&/0(.<AIM#;;SU<;0..Z\72."W3^^W./QSL(KAG3J%1<#
M=_<*9(;NI%&=&`T6'"*?(+;YR407D;BRB"K$$:A.`984B=JU<:WT#OM;JW3R
M2$S_`%@L!;"9?:J^OF96[TOJ_LI=@'5_:ZR2V2TE'P8M%<K2B^\*)H3*?4T*
M%8B/2`L9180A2^,C7(FATC[ZB*<&AX1*&US0GA\EJ$JD&2S2\^?Z(P^?(18^
MH!XQG'UQP.P__3P]FKI<4)4]?&QDJ,<]A-?HJ4X4O-GU7G+G?>N38,AL:51R
ME0/(G2Q:DP,EJ>PXSD]4@^(NS@P?S#0AT^<!P*C>XWLO:^N+6C+G#@-<DVDN
MQ4X5[K'7RWVU!*R7B2`&\6-)D>1>O%?54W*@N3F,6/0H.RE1>H(E81A#U[[*
MW.B3#NZR61.LTG,P?WF:V-/']08LD$\GTG6FNDGECVL-SDT]:ZN2@8L8SGP6
M5Z0!QC&/'`\I&8<1;4X!&Y2TVN5K#6CI`Y1OA<-111;+G6A=>)-)"FA:[+4[
M?ZER(Z1!`:!2H2E*U;4S%JW'"8XM,,/`ZD]H;9J_L`ED)T!U%''T/53I^DKX
MB\I%6ZHO\/\`9&=1EI:'NKM5X`[-AHTK[4-=H0H7:9*RCC2W!?A.A$+(BQC-
M"43BXLT;9E[N[+6N.QN.-"EQ<G%88G:V./L#*B&H5JU)N?:2-K2T-J7(A9_1
M+))+^F,8QC'`QGJVUQ=-Z[P8NSJZF%>BUXJU2],_7!5,E0FIOMX9V36F5;K2
MUC5A#C#Y,RRQHH*6>#)C>S8$O`$)IZ8_(=-_`<!P'`<!P(!7;<=D13L,T.I=
M@DIC?65O5)NO(K%BX6]J/*DCS5B+7HZ!+C'%2B.=D`H^9,G/(0I3R2SOE9P<
M$ST@](3]X#@.!7U<':CH)1MA/E3SO8IA667%3/9F,'K6)V+=<C@YV,>H:>=M
MM,PZ?'PA467^F(EUPC-"#]+(?'UX$B->MIM=-L8BJG6M]S0&XXRVK<-;VKA3
M\E<ET9=\A&/[$ES$+)+]$'W`"Q"RA<TJ17@./.2_'UX'Q>.UFL>LJ5L6;%;"
MTM1A#W@>67\6+-AT!.>L%C]LT3.FDSPVJ70)(_H/)`#,`S^7QP,@IO8&B-B8
MZ=+J"N>K+KBZ8\"57(*JGT6GS2B5&!$,"1<NB[HZ$(5@@`SG!1P@&>,9^G`V
M]P'`@!M=<EDUWM1UKU[#9*:RP^\K_N.(6HS`;VI6"61N,ZJ7//F-K/5+D2E:
MW%H)A&T*[`T9B<T8TP0#$(O(P""?_`<!P'`<!P'`YS-_*L=.MS8Y[[*JI9W%
M9J7>[HPL/935T>1G*BX"_8$G8X3O1$F)&`7]>CGO%MM@ED`P-<T"+<!A&<2>
M<`)X)E+%)V1.M1J&:41:3LI2I*J(&D>8[)HU(&X)I)Q0\>^@=V)]:%F,X_ID
MJ$YOYPBX%0&N]1T-H_9UK=55]UQ$UW6YV=/TQ4:WR=4T($!,(O&7-9?WVU+L
M:2E$%*SE+LG1%NU7/*H[*Y.:EPW$&B/)3^R$7H)&[,U&O&;==NP[VX2.<U.R
M!EVM]MO0,DF[*:K&+!MT4E8E`O!2NR:Q$6%AE:8O(AA4)P*L>HDWW1!Y38>G
M7NUHQ''JN9496VP%-RUMMG7*VD>/"VO;8C?ZUJ.59QCRLB,I(")K?4(_40M;
M5`PF`'Z`XX'2!UF[YLF_FN22?.+(57U\5L]JJHV@I@X_(G.J+MC!)1<B:P%'
M"RJ41"2EB`[1]=GUEK6E65^F(TLX(`F9;5KUY158SVY;9E35!ZTK&*/4UG$L
M>S\)VUBCD?0G.#DN/%]3#1A()R$HDL(SCS1!*+",P80Y#CBC4\L+>+8*2=BU
MY,;I&<RIB5P736G7\`BU-"ZQJE7RDC\ZMPA#+1VY>N0%O#^=CR:F1#3H0B]D
MO``AYK86ZATG!T*Z/QA=8ULV!)F>L*%J)EQDV0VU<<O.^!$(<UIP9]W"/*L?
MR7)3]"T3<2::,0?`?(21^Z5@=8VO,3T?H:0,5H=RG9BL=;(O:Z#D13JQU"T&
MIOLRQK_DR<99@D%*:Z1]6..P!J/P`EV>`8$62(1BXG(3]U2U?JO3:A(#KQ3K
M<-)$(,@,^4[K2R</\WEKF/"R66!+%!(0X6R:7/`AJ5(OZ)0<@(+])))80A$.
M[&R4=E>RCAUL5,[O#/KE6?V!)NS2YHRK4(32HRX9`ZQ+2J%2!((/QY_;Q*?Y
M$M-),P:S1L(RA>#S\DC#I2B$1B\`BD:@L)8&J*PV&L+3%XI&6)$0VLL>CK"@
M(;&9E:6],`M.B;FQO2EDDE`Q@("P8QC\G`R+@.`X#@.`X'+5V,T"?UN;&/>]
M];-9Y6DFSTN:46\<-:DQIC?0%W/BA.R1;;UC;TH1`;X9.%AQ#5/0%@"$"LPA
MS%ZQF&>V&S5J-GD3.K;G!,U2*.2)I/1+D:D"9U8Y`P/2(1*A.<#]:C<VAW;5
M60Y_I%'$F?3R'/`A[I/!Z'I;\5NC_:6%1]1I7N\HGLITTL/X#<RK@S9\]M^F
M^N4PE)*0L1]P0)Q1IGZO'U8(QQ5)$924)AAR1*0$.=G8#7"V-(MBK$T[O0XY
MRF5;A)>J]L`Q*)(@O"D750>3!K29\>1$"<!D)Q-[ZF+&/*!Y2GE"SG&,"R&M
MFR1V-7$WKR[*3DPH1>E*2M%/ZGEP,9R2D?V_`BUD>?2,""%SATT:AFM;NB,\
MDJD*D81X\<#V0/6QOQ7/8UJQ#-@H40".RD)AT-NBL5"CW7FI;BCI2<J90=T"
M+P<8D*4'`6-:H6,87M*I,HQ@.3!`"$F[[O2K]9:9LF_KHE".&U=4\4<YC,I"
MMSC(4;6V%8R%.C3X%@QP>'56,I(@2%>3UBT\H@H(C#`AR'K0MGMJ;1W[V6G&
MXEQ)5S$JE*7[J4=6"U3E011]"H5IZN+Q`H`<_'Q+9*(_+M(U1>,?)<E(@!\$
MEEE@#2@D<TDD@A=:U5%5<_N2VI6UUY4<!;_'RY3-GTS!*(LX>?T$3$T$^M:Y
MK#,A(1H2##3!!`'.<!U-2^#?_BNU0KSJ7U!D3)+>QC=5D=[$VMV$$U$.9-4P
M1^(`P6[L3*4ZLHS);<UHQF1.L6-4$(3SRL'9![A2GY`;7H:C:XULJ&"4=4K*
M%C@E?LQ+0TI\X`-P<U0LY/=I$^*0!#EPD4C<C#%:U0+ZF'&YQCP`(`A#3;'4
M#OVH[/NVGL>4KTFEFNK\P/._=AM2A0E(M27D#(?8EI7$GA&,L9OVCDHEQGQR
M<S&437@M#D19Z@.!AUS,S,T1QG:H]'VMO8V%B;4+,R,K2C3M[4T-#6E*0MK6
MV-Z0LI*A;V]&0`HDDH`2RBP8"'&,8QC@>2X#@.`X#@.!5ML=_-=ZQ?[BNQC^
MS=5.!:3P'`Y@NR#M3V`NI;L'IEUI00:AQ@;T94-X;FR.QB:RBT*EB-6DS9E5
MT(I3,$E?I!9S8R#.:5<E*3@21=Q4"-(`H4D%#P$L.FC;77V31N2:0QC59+HS
M>M!QEJF,@HA*_H)ZP6/!7U;]E8OF#7$E1-[C<:=[DOJ)?G1W+"_DNIX?GY-,
M.P:,(H=VFTNJ6AEA13;6@;BH*O>SN!/,-8GVH#)8C9UVRM%6`\(XO)(1LW&H
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MQ_\`&WT__P`4FP/^"78+@6F<!P'`<!P'`<#P\BCS%+F!\BDI9VV0QF3,[G'Y
M$P/*).XL[XQ/*(YN=F=U;U0#4JYM<D"DPD\DP(BS2AB"+&<9SC@<T%21]]ZP
M-GFOKKL-R<G#4Z[%<CD_6G:L@5J%F(N,DPQ[FNCDO>UHC!9?H'A4-?!#3S1&
M.;$+*0(AJ"/:+":&S&N5;;8TC.:&M=(K'%IHB($D>F@WX<H@TM:%`7*'6+"G
M0.0GLTS@[^02O;U)8@"":5D`LY+,,#D*UUL.M;LBHN3Z:73)&6%]U'5^J1V=
MKW=:@`&IDV-@RE-AKAMOHQ&^@;E4VQ\=2!C5@MP1#+9I)@"@T(<A3$<#1VOE
MVH[WK[$E41YQ@<]C+Z]5]<=5/X!)Y14EO0Y6)JG5?R%&;Z3R3VAV*%E,:+'I
M5(C"C@YS@6?`?9#9[(=,=^-9-I*T691L.R]O5-I=M?``^K#19D6LUV5,%0V7
MA,`02B[$IN6GEX(6>GW5+*I4(Q"]`L^0EIW/S^0;)[DTUUZ.*X:'7*M:D8=S
M-AHX0(PL5V20RR'2'4?5K^((@>]7T=?XJKD#JDSZBG%04C`9C]3C/`U$_O['
M%6)YE$F=6^/QJ-M*]\?GIR.*1-;*R-*4Q8X."LX7I*3HT*,@0\^/R!#X#CSX
MQP,'U.>8?2U=2OO9W)B4A5-);6=4_5;K*)'G\0)*BL8\;#'YLPQ=048H'>6V
M#M@"=IS[(S&6&8$H%C*<XP183ZTHUVLV%J+-VHVM6M\FWCVP7-THNYS0FB5L
M520]O#D5<ZP5F::8=E#7M0M)@"#\EB_\5>??6'"-%[9G`^S=?8ZR*^_#36;5
MEL;Y?O'M@XN4/H&/+P"4L=;,"`K&;"V7LPLDL\2"LZ:9S!K,Y,!X<W4)",H)
M@LF`X%KFBFF%<:':ZQ6AZ_6.,F<25;G,K4M"1Y"?-KIN.7'!<[%MF<K\B-.6
MR&7/@A&8",PS"-&`A(6+VB"^!,/@.`X#@.`X#@8M.8/$+,ADKKNP(XT3"#3F
M.O$3F$5?D93@RR*-R!`>UO3*ZHCL"*5('%O4F%&`S^4(L\#DFC5?2_KCV2!U
MW6H[/#Y2TO1OLPZZ+CDB@Q6HEE8M`OF275Z6OA^<A6VI1)*@/V:(P6#G>-"(
M-"'`P>T$-L;&4%$=EJH?*MEJUS8#E"MLDL(GD=/$BF%6V5%U076"6;"G,H1:
MELD\.?22U)(RQ@R:7@PD6?08+@:-LZO)=W2:?2NE[%2QF%=U'62/*UL7A"0R
ML]_Q5R0X"URID-&$HM;2^U<;:RPJ,!_41N8D@]>""0!`>',)&WW,@;C#U+6Y
M1YZ;'%RCTJBCXE-02"'2Y@6'-<EB<@;SP@4('EA=DQJ<\HP(18$#SX\9X%E?
M3UM!/-0NR.C$416G'U;NG/(SKC>L!$:9AL=)"ZHW?-26HWI\"]E-+H:_`^$H
M/].<J&=:>4/ZX+$`)V?ZE7:::VOMA7VA*9<<V492E>P?8JSV(@0@8M*U9D\R
M5#6K9(/`_2JB5=,\>,<BDHL>VH=%H3#<"RE(R`.?AU=6YD;7!Z>5I#>UM:10
MX.2]2/`"$J1*6(X\\P6?S!`'/C'Y19\8Q]<\"_KK;J^)]:.J[YW(;:P)TD.R
M%ZM2.J.NO6(:;()\I;+*"(B"-#(U*"AJ6^RM@SL`<75;@K(V"%$B$+/ZU41D
M)6:QTQ/X;^(=Y;$R))8&X>S#ZFG^QD]38];:WKRD_LQ.FX#@8C,M=54\R"`U
M-*0O/MFB*,4"]0C`YP'X-BK$MB0S2M-,M3\I%FW^S7STD2=U)`ES)K[4K:8!
M/8VS=@E%8%\5@@B(T13,09X&[/QA"<G!@@Y`(.DG2_4*IM&-=(!KA3J-5F.P
MY(H6/LH>1A52ZR)X^'Y<IO9LZ=<^HYXF4W?SC5BP\8A8!ZPDE>D@HHL`2GX#
M@.`X#@.`X%6VQW\UWK%_N*[&/[-U4X%I/`<#AQTW8E=?Q_8NE7K/N2RBMVMN
MJZEBH?U5.[B;<;_-&V1KA9R(9JJ0QV6(U'N"R+(PYQGSG'C@8KL3>=OZB;6Z
M<[*:[00%FWG+&W8#4*#0#Y)2<$GE%Z0A`OK%2\EBP(Y7$H/9L:1/+J$./`$)
M!OD1?K]>`NSU`TEKK6&I@QV2-\<MR\;!,63+9N^IC'VJ132^+=E1ICI.9)(W
MI[1K7!7'!.RLU.U-HA_$1MI10`E8%D>1!SB[D7[)NK+83M+I/4:&J\ZI;.:L
M0UBM."0E00AA6KNV>R\7ET3A4_8&H`L(HDAE+2@/&YH482`X^TT0L8#A.C+X
M%5\>94T<8&./(RP%)&)G;6=.67C`0!*;D9*3'I"']'&,Y*\_3\N<\#J+_P!*
MQ&7LR6=DMB%&GD0M=,M<:X3I0X%A$X3F%069/\I<\>,^V):E9YRTIC!8QD60
MX#C.?T<8X'8)P*L]X_\`C;Z?_P"*38'_``2[!<"TS@.`X#@.`X#@.!$;>+3:
ML][M<YEK[99S@QX=C&Z35[8L>R$B:T];,5/RZ5Y;,$</44<W2J%/P`*"L@,+
MPI(R<E,S[)YH<A41I;LW.Y8YSW47;4;%$-]-8UQ$5MN.%G%-B"[HB(K`H)L]
M42)7A*<^U_:K'@M6K"E`/+0[94)CP$^``P&.KWF/VIW3:`QBEEB"0V?K96FT
MDRVK?XP<2XDU[0=BU^CB<`KFQG)O&8G1NLVM\Y$Y-+0J'\DGX)JS!(0YR/@0
MRF29,E[2NW`M*F3I2S;GU@5&EIB"DX#%2K4^`'*E1@"0`"-2J.%D9IF<9&8/
M.1"SG.?/`U;LM_[FT?\`\R?1W]L"/@2NWV_G763_`)<5#_X@[@X$#^RL(1Z(
M;+EC#@19L';"C`"QY`849-8J`PL8<_099@!9"(.?H+&<XS].!<KVJ'1RL-L^
MG6WK9*;F/5F`S"](`H?G$E.@KFK]BK&J2.,FMTEE0Q`)98ZDSAI?&IG7J/;3
M-JY4#TB*R,.>!NW:#9JJM1:8DEX6V[9*86A(47%XTT#)6S"U)<Z""EB=>5FR
MEC&KE<NF;N<2D1$I0'8QDWWA^"0#%@,LZM-+[)KS[^[R[AMZ4S>K;!M:C94P
M!-PN:M8:.0F_:%;:JP(XSU82HHBG,`KDRDKTY=Y&,TPS)H4Y)@@N%X#@.`X$
M`]\>R;6SKF;Z2<MC#9Z!/?\`:*.HX$&!Q`R6FADRLDH\2I\`%>WX;65*6>#)
MAH<FG9]7Z!0_`O`3\X#@.`X$(NP32"`[]ZYR"E96YK(9,6QR;K`HZWV(/IEU
M)7;$A&+8%9<74A$6=@YI<19)7)L#`!Q:U"E*/.`G>H(<^&LU[3"7+)SKWL:V
M--=[JZZ.^(/?]9`4DIBGU204`<?NJM4I^23W^I;89Q%.K:L3`&4GR>-.9Z,@
M#@09EJPK26AW;T&HIA2G>W#735?8)%MU*(TH+5-#!#[/61-/2=3S1U0B&B,E
M2R?M:A^1-9Q@E25*D..]`0Y%G`<\G84001VA=E8$Y!"<`MH@'"`F(*3EB.45
M57JA0>(LD!8!'J5!HS#1YQZS31B&+.1"SG(8?IU_,)ZVOXZ:._[T[\";/?'_
M`#D+S_ACU@_Z=D<"GJP2"%;3'TBH@E2D5V94*16E4%@/3*DJFTHB2H2J2#0B
M*/3J"1Y`,`\9",.<XSC.,^.!VJ=R8DM?]@G6-:MKC3->O".'[-5+")&[^TF@
MU?[2SMO@!\`/>UJC!;5'G>8P)@>&ID5'C+QA0`TLL01"SY#5>R>P\)UAK)=8
M<Q)6OCLM4H8Y6E:1_P!*J>7'8\A4EMD,KBOF0OW%SV_2=Z4E$!R068!.4(1Q
MG@`,^0LYZGM")=K'"YKL7LT)JD6]6U@FF47H\HAA7-5411$5DRO]9ZZ5B$:%
M)!*I;3\%*AIQ>AV>LJ%8Q&APGR`+>.`X#@.!%K=?995IYJU<^RR*H+"OA144
M04RH-6U>E+4RZ2ED*$Z<X10S"E.&YE9R5`ESHMP0J$A;$YZ@)!V2\%"#&-#]
M[]?.Q37F*[&:[2@MYCCT66@E$87&)RIA6LR(3$'O$&F[42::)M?&L1X<@'C(
MDRY*,M4F,-3G%F""9G`<"K;8[^:[UB_W%=C']FZJ<"TG@13U]VOCVQ]D;)PJ
M$5]/VZ*ZU6LKH]YM>1!BB.&3VTXXB3*[#C4#;T<F7S0\BO3W%*E6KG%K;T:E
M4<("0Q1@DT00YH[\C:>E.VWL*@I_LLT;N>#ZZ[D,)BLT"9`'[3A[E3-H.N3C
M,@)*(!):S+4JC,^,`]WU"S^?@?3UF5>HVBN>1]DDZ;S_`,-H\ED]-:$1YS(&
M6`,%PL-:+7V6RB/#CVW>VG9$8U,A_I]93"E,R'/@\`LA9?NQM?&-+]=IE=SX
MW?>>1D'-D,J2NR#0@=+5NB:*?L:MZ\:B_5@P8WM]-"8K&'_=FXA0=GQ[?U"K
M^D]-VU)KA9M;;,B3VA:FUZB33S<&6&8"(Z6V58"<(G-$RJAX$-$RU@1A.VQL
M(,X`A"W%G%8#D6>!S22"NYEKY:%@:UVBI-6R^HE:?[(DQX,E%V+5+I@P^!6*
MB]7T,PXM!>$Z_`?/QW`@TL7Z6,\#M6_TZ<$>J@ZB$%SMT,=IO,K]L#8+9='"
MF%0PMLEFF%DE<8E`8VU.,I=6&.I7"01.O&PM&:X+DB(O*D(C3BR_4/`7.:H;
M*PG;[7^O-AZ^:)1'8W8"9]!F,S9`B;9?%9!$92^0>9122(VQQ=VP#O&9A&ER
M$X256I2FB3^X2:86((LA#O>/_C;Z?_XI-@?\$NP7`M,X#@.`X#@.`X#@.!#7
M:WKWTQW?S&5&T>OT)M5ZA8#R8?+UF7J,S^+I50Q&J4##84*=HW-VMK4G#R88
MD)<`I3#,Y$(O(OKP,RU?TVU=TMA;C`-6J2@U,1A[<\/4B)BC><)XE3R$`R@.
M\OE+LI<I5+G0DHP0"U#FM5'%@%D(18#G..!R_P`Y_FF=MO\`?!JS_A*K[@:F
MV6_]S:/_`.9/H[^V!'P)7;[?SKK)_P`N*A_\0=P<""/93_P)[*?_`,*:?_[O
M%.!VO3>J:TO"I'.J+A@<4LVM)Q%DK)+H--F-!(HS(&PY,G&)*Y-+F0H2G^T<
M6`TH?IP82<`!A8@F`"+`03H;IFZT];+0C]RU1J]'4=B0M2-77SY,IA95I$5F
MH&'TA/K1DL^9S!A@*I/C_P"P>U)DIZ?'T*&#'C'`L_X#@.`X&N[?>+"CU36@
M_P!1Q=NF]K,=>31XK*&/"T+:TRZP6V-N2V&1AT<1*D(4#>_2,E,E..R>3@HL
MW(LF`\>K`>NA[NMENXZY8]ID7V#Z.5+K4DBNQ"1^H\^!R4AY'8-I_9[>$N'O
M0"K@L'*-M$4``O<SA%C.19_7_3Z!UQ=;.S_=+=%Y2B+=B6AE.ZR4DAK1U>X[
M8$"F*=W>G"QB)'&D;3%C6TNWK&&>WKX^M<E(S/BIL%#2`_79]?H$%X'`<!P'
M`A)M=UPZ0[ON,<?=H==H1:$JB*4YOC4X,,?8E8+,UGF".-94=@01XC$SPQ#/
M&(SX(EPD>#!B'@OU"%G(;3UHU*UKTX@`JOU@IB#4M!SG`UW<&B&-7QE#Z\G!
MP`U[DSVK-6/\I>S"\8!E8XJE2G(,8#Z_3C&,!Z[?L/\`YHG93_$\F_9)7/`P
MK3K^83UM?QTT=_WIWX$V>^/^<A>?\,>L'_3LC@4_SG_<8O\`WJ4U^U:'\#VK
MES4G4>Q-;R:G[TKB(6O6$Q1X0R6#SED1/\?=20&!.3C.1+BC`E+$2D`3DR@K
M(%"8\`3"A@,"$6`@]KIT[=;VJEFMMRTOK''&FSH\%07#YA,)78MJND`)5`R4
M:37F;3E\R3P3/LB$7@QJ`E/P4(0/7Z,Y#P+,>`X#@.!"_?BY=JJ'UU>;"TUU
MI3[8W>DD\2;&RH%4L20TE9'G9U`EDC^)W5G)P"RP(,^[[(1X&/SYQYP'.,A1
M7GM$_P!1'G&<9Z)&'.,XSC.,W^T9QG&?IG&<9=/&<9QP.=J$[-=A>EW<=%G7
M7GK_`&[5B]=G%$=S<O7;7MHH)]7-UH'YT7KULI6L30I6H:)6B;S%+LE7F83I
M&/!9[A@L#8I5)SP]F$E,/-3)S5)&$JDP@DQ0EP:$_"8\981&D8/!@(#L$F9R
M'UXQC`O'G'`^_@5D[JT;MK(=F-0-G=3XY0TW?-?8ALW")7"[VL><5DVN2&^$
M5/$MCLQ/L)K6S%!ZIE-K4_!Q!Z4D(@J09"/.<9\!N6@I9V`NKM,,;.TEJM"6
M%%%#5<&,I+8"S+!>'Z:`4A]EDD2>:T/7R&/Q]0C]6<N!)RTXHWQCXHPYR((1
MAZ<#7)QHC9*331*7'[KF&_VXDDV'KI",*]AJ.Z%%FFM[[6<5DX#!%SR,1Z.M
MS48D?PEI</`%.5/Q4N3,IR@J/[K]>C=R.TG4W7JGK!5L+^_ZIV5'=[U4=*'E
MR@NG"ZTX9)XPF.>RA>RRRZUY.UOC"SI\YPJR2K/4>G!'D>0N3B<4C<)C,:@T
M*8VZ,0^'L3/%8G'&HDM(U,$<8$!#6RM"$K'I+)1MS<E++#G/^R'R+.<YSG@5
M.0#4>&=YMG7_`&K;JAX_<1HQBL[6+3)0R+52$Z=[%J@Y8KBW4CYR=0EPLQ5+
M\@*8(*H%D:8T]&M4?_N",->ZGV'9QB6R=9=D\E)MM-0I214MV^DL:=/8+5\/
M"NKK]C91P2S5$3NB%!(<RS<8\%K_`))0_2(.`\"&_<+J+(;OHM3?%-MXC=@]
M?HO*U3:E1)\FK;!J9U;U!DZ@1I1?@U>N:@X^VF@'G(@JTYI1?Z2G@=;'6<EJ
MI!UYZ4MU(R1HF%6MFLE--<3E#(+.4#XG;(,S('%PR6/`#TJ\]Y3J<JTYP0'I
ME?NE&A"8`0<!`#KDDFUC#I+9\<U=K.E;-9J_W,VDB^N\ZN:SI;5#-=%4*=FK
M<=Y_-)$S1&N;/>8.\1&P'!S8FHCTJ2I`C;@N0OL\)X$^0V@&G>R*^MK=+[2V
M/K'3VK*PU;LJS[+=%-07S;5FS62*YI0MD5"VLJ%CEE"UTS)TY2^<EJCCQK_4
M$LC.`ASG/C(7(<!P'`<!P'`<!P'`<!P..><_S3.VW^^#5G_"57W`U-LM_P"Y
MM'_\R?1W]L"/@2MWTS@?=;9V09P+!/7+099WISC/M&&[`7$84`S&,^0B,+#D
M6,9_+C'`@GV2?\#]_P"/S#9H<4/'YAEFV7"P&%BQ^00#`"S@6,_3.,^,\#NB
M;,8PVM^,8QC&$*3&,8^F,8P07XQC'YL8X'[N`X#@.`X#@5"]M/523VC-&K;6
M9=RBELZW7N@N01Y,#)G6)>D)3)DRN/8*-E,7RRJ1A2!$4J]2D(<YS@10OIP+
M>N`X#@.`X#@.!ZR_L/\`YHG93_$\F_9)7/`PK3K^83UM?QTT=_WIWX$V>^/^
M<A>?\,>L'_3LC@5!S,H1Y,.3`SC!BJW:32E9%GP'W5%MPPHOU9QC.<!]8\><
M^,^,<#VU'`<!P'`<!P'`BWNL':X>K-U%Z/8K[.U!L-6E4]FSCA$1,N1&FD%G
M'&'#`8W@?"&H2@;5\\.6O[4"G^;CXGO<"O3J'ZB6#K_CTIO"\949L!V![`9.
MD6Q6Q,E5*9`Z%N+X>6Z.<"@KN[!RXD1=*X!#E:MS@I2]J20&F@*3$HT:4+K^
M`X#@.!3#B2//475O9)L+?RZ`RB@I=L3/-I:/*A;Q(OQFF]AW\:S(0:_.<)<8
MT!CQ)%]C)$39'EC6YN&7`EQ]Q2F283&"&$?-"Z#LFN8=8%^;*FIG7<[<27$W
M9LJZ%YR<3$%2E#A)7%!1HXP1IB6#T/"A$,J1.$60"6!5&_I9'@7`CWVI;$2Y
M$QP?1>A7XYFV!VW0NZ:3RQL,SE=1>KS68%#;MLJ!%9P-`]2!(<..QSU9"(YP
M5'&%_I)\9X$@/].@I:JVH[;[31K&L+:]2=Q)JUP1O7JC%:I#4%S1:*VS``".
M.SDTT(ESV[@R9GZ&&%CSCZ^<8#EHVEW2F$)[A]QMZXXM<9+!HUL8_P"O$_B;
M<:,]-,=;Z=:HU4SZ<TI?Z!KS%)#$3W]N%C'D1Y(P_3!@_(=-<8DS!,(]'IE$
M'A#((M*69KDL9?FXP"AO>6)Y1DN+4YI!X]03$ZU$H`/&,_7'GTBQYQG'`U5U
M_73+=`-E[`T7:DT?4T?M^&Q[GZ^T\V?5\9KZ`[3%MZN26KJB^25O9I&MB<+L
M)PSB41W*9"K&FR8XD)TR@\P!60O4Z]-;YOJ9J+5M'69(HU*;%8EUERZ=O$,"
MZ!B`I=;5L3FW)`W1@;VG1O"IA8W.<F(4JA420H4DI@G&%%"'DL(32X#@.`X#
M@.`X#@.`X#@.!QSSG^:9VV_WP:L_X2J^X&K=B`!.G>A*4S'J(5]F>D))X?.<
M9$6&T<J,8"(.<"!GW2`_7'YOIP)/[S?SK;L_R]M;/VVW7P(-=DG_``07Y_Z3
M"_VFPG@=T;;_`.7(/^Q)?^H+X'[>`X#@.`X#@.`X#@.`X#@.`X'K+^P_^:)V
M4_Q/)OV25SP,,TX"(?87UM!`'(A?OSTD/TAQG.?04>\&&"\8^OI++#D6<_FQ
MCSP)H=[1N3NY'8/`L8#\/7'5M*#QY_3`-'/5F1#\_P"U@:C./I]/&,?GX%2,
MH_WBOO[[:&_;)".![:'@.`X#@.`X#@.`X#@.`X#@<XUXN[CO[V=O\1?O&=4N
MJ61Q(Y+$3Q9,1V_O?8$&13%IEKZA%C!*F-ZY5O)",M91H1>9$Z&'8]0`!](2
MUO.ZZ\USI^R+XMM["PUW5L5<Y?*7$0@B5&I4(,82M384,6,K7Z0.9Q*%`1CR
M(]8I+!C^EP.=K3AQ?+W1S;?FS%2-SMO<961)DR9(>)8WU12$:6KF>IJ-CQYH
M<"*1Q%M2B/=!`P'"MY/.-'ZA!P+(2]T?O=NU'[!]Y'Y_4%I(;:O6ZGVC.(-%
MDM,NE6EKS)F&3^GQD(!*A0.=I!F9S^E[1&/K],<#DOJP;FY5^R/DD\J7^<!=
M9]*1*<>Z)6_6&ZKY>]C58'Y]T1ZI['@?J\^<?3/`M[Z?]I4</ETBT"FSZ4,"
M!O<;-UE.6JL"4AAZY0K<)I4F<FB]8CHJNP>Z-!>/J)N,4@QCP2`/`N$VAH!-
MLE4#O7R9^5PF>-;JQV!3%FM8Q$/M4W7!5P'VM;#9%97@].H8Y`G+"HP#/ZY"
M<>5GS@?`NSZNMQ'W>#3B`7!/&%/%+ECKS,:9O^,(O'V:RWG3DB6P6Q_L;(0A
M#]@/;PU?:C>''G)2)>47G.1`SG(6%<!P'`<!P'`<!P'`<!P'`XXI:9E3V?=M
MZD8<!,#>VMR#P'SZ<DH=3JW`4+.,YS^L%@S/JS^3/_)C@:TV#_\`D/0#_,XT
MC_:4?P).[S?SK;L_R]M;/VVW7P(-=DG_``07Y_Z3"_VFPG@=T;;_`.7(/^Q)
M?^H+X'[>`X#@.`X#@.`X#@.`X#@.`X'K+^P_^:)V4_Q/)OV25SP,6TH_F-=:
M_P#&O5O]FR;@3![U/YR6QW\/>K/]D37@5+2C_>*^_OMH;]LD(X'MH>`X#@.`
MX#@.`X#@.`X#@.!SZ;):\;=:>;@7MMAJS0B[;W7;;T4'ENP5"P:7Q2&7I55X
M5]$T-?DVO594\<&B)V%%)Y"FI`0\LPUR5Q)7H\'D9$6+(0AAU?:T[6]CU[4Q
M+MLM:7S4C1?76:M]R(J$MN60R67-M3>,9]8JT4V;%(&YR**0NF*M=!B=PM*Y
M:I5O#J61[Q.4^,Y*"H^$N<6T,MV\]$-AY$TT\_UU=5NSC7YRL5R1Q.)V]K7:
M$Z>K!KN1UW*7HU$P/AD7)D)[0[(2E&53<M2"+&#Z9\!@$AJJP>S6?;`I=)#3
MYVR:[:$[CU_++;B8C5,'G5NWY$X^Q0_66&2U/X:)9)7MMCRM2XX2'')4&#"0
MFC",T/D*,XM.8FNC)"L;FACPF%*%JD;(_J"F-XAKLRE80N\?DK4YC2K65S9%
M:89!Y)X`#`,O./'`OUZFNJ"0[N:/[5[)(S,U#<L^NZK9GUY7M(&=80JCJW6)
MF=B&N;)R\$8=5-06S+Y8\L;L`H(RW-J*&>`H[)2;.0FB&5=H9>0U@/JAN,>Q
M(0X:,28JRZB_=`&^8#@G$UQ<F9?]M%P+)_\`6_L[+5]M8(_J_I][Z\"_/K,T
MS==%=2HC2\PER*P+9?)1/+AO6=M28]&R2FZ;>E+A-9\LCR14$M2GC+:XN06Y
MMP:`LX:!$4,P`#!"`$)_<!P'`<!P'`<!P'`<!P'`XWI+_,V[<?X@]>O\*%:<
M#7&P?_R'H!_F<:1_M*/X$G=YOYUMV?Y>VMG[;;KX$&NR3_@@OS_TF%_M-A/`
M[HVW_P`N0?\`8DO_`%!?`_;P'`<!P'`<!P'`<!P'`<!P'`]9#OZ(0^SCLKR,
M0A9_>P<@^19R+/I+KB`@+#YSYSZ0`QC&,?FQCQP/":4?S&>M?^->K?[-DW`F
M#WJ?SDMCOX>]6?[(FO`J6E'^\5]_?;0W[9(1P/;0\!P'`<!P'`<!P'`<!P'`
M<!P'`U-;E"4;?S,BCUZTU5ES,+8I&M;6:U*_BE@-C:L,"`!BMO12MI=4Z%48
M`L(1&%!`,0<8QG/C@97!J_@=81AMA5:0F(UY#68`RVB)0:-LT2C+468/)A@&
MYA8$3>U(0#'G(LX**#C.<^<_7@1)M7K,Z];RL\-T6_I?K=8MJ95EKUDXE531
M!T?'E<2/`RELD//;,ERA6#(<>#'$"H?C&,>?&,8X$UVQL;F5N;V=G;T32T-*
M)*VM;6V)"$#<VMR$@M*B0-Z%*64F1HD:8H)91180EEEAP$.,8QC'`_;P'`<!
MP'`<!P'`<!P'`<!P'`XWI+_,V[<?X@]>O\*%:<#7&P?_`,AZ`?YG&D?[2C^!
M)K>`83NZV^?1YQE#U^ZPD&X%CQZA*[FO%07D&<9SY"$!6?/GQ]<\"#O9!G__
M`!9<X/\`9-,K,DP.?&<#*.MZ`EFEBQGS@0#"Q9QG'Y\9X'=4G#@*<@(<8"$)
M)00XQCQC&,`#C&,8Q^3&,<#[N`X#@.`X#@.`X#@.`X#@.`X'K']^_P"9QV5_
MQ9.O[.X%P/#:4?S&>M?^->K?[-DW`F#WJ?SDMCOX>]6?[(FO`J:D10CU]:IP
M>/<57K0"4KU9\!R:?<T(`#U"\9](?.?KG\W`]L[P'`<!P'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#D)[$H--]$]]]CMDY[`9](=0]TB
MJGG'XUP"&R*P4%(7/6U?M]6R&%6XT1-N=7^.1:7L+"A<VAY^,8A]\9R88L#!
MG.`U'K,Q23LKVQU004)"IXLUBUIV#A.T-Z[)2N"2F#URX.M/86NU=4]62J8M
MC$OGTNE$P6)S'(:(@:5K;21C,,R(00B"8O;W4UF:Z[L,O8*@KB>6=K;9VNT;
MUYV"=*QBSO/);0\DK2<R:95Y9CW#8\E62)SK&0H)JL;7)6A(4":U*<LTX.`&
MEXR%92A<H[37&*:@:?,$XL./SZP*Z6[`WX97\SC-04/3L0FK',Y@N<Y=+V1@
M1/%D/B:/?9[*QHO>5&JCLB,]L!8Q!#O!"'`0A"'Z8#C`<8_YL8\8_P#TX'SP
M'`<!P'`<!P'`<!P'`<!P'`]>MW=Z<W-JCO?L'L4Y5[.)5K#M7*&&UH_<$0BS
MW+F2O["'$62+S:N;*!'D3BMB9ISA'<.#0M4%!1K$BKV@&9.).``/$]+&G%R[
M>[U:Z7LS5[-XUK#JO/5%SRZY9=%7R)1Z:SMA8'9K@5;5MF0H6U5+G`;Z\@7.
MRE*6)&@0IA!,,P<:268$N_\`46Z:W=`-P\[XQ>OIK96OUL4]`JZM)^@<;=)<
MZ4I.JM7/R=E=)8P,"5<\DU_,(Z_%!`Z`),(1N"8TM1DO!J?W`J2T*U,MGL3V
M5I.OZ?@\W/J*(7!6EDWO>SA$I`P5W`(+6\O:YHM94$C?VYN1/]A2Q0Q@;VUL
M1Y..`,T1YV`$%&C`'L\>`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.
M`X#@.`X#@.`X#@.!\8QC&,8QC&,8QC&,8QXQC&/IC&,8^F,8QP/G@?R``"\>
MD`0@#YSGT@#@./(LY$+/C&,8\B%GSG_ESP/ZX#@.`X#@.`X#@.`X#@.`X#@.
M!\9QC.,XSC&<9QXSC/UQG&?RXSC\^,\!C&,8QC&,8QC'C&,?3&,8_)C&/S8Q
MP/G@?R``"PX`6`(`8\^`@#@(<><YSGP$.,8QYSGSP/ZX#@.`X#@.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#
M@48]E_:U:6A6W&KM5M-5P28:_32$K+6V@GCTND:>;U=4Z:\JCHYRFT03-J@#
M(H21!RMU&Y.05Q1F!HB3/2(KT^O@?4\=MDT+[:6_2EI@E:I]36!OMF'V5L(^
MO3X3*$-VTUKRBV0L1C8PEJ2(H1$H!#Y;'TKN:I`:<4L5J,>L'M8QD-S5UW6:
M3V2GEB]#F]8FS-&OMH[45^_V/1$^@+)L)05-MPW:?V/KVXR1O0E60UM#7[2D
M)`/C+3TJDD\LD1`_<P'[:V[I]#[&:;HD1\MLRL8S2%"LVT;W(;GIBQJO;IIK
MP_JS&IKMZK2I,Q)7.?P]9(0!:R#42?)RQP-*+3%G8-+$(/Z8>YO2U5`;VG4\
M'>%&+->8C7<^G-:WG15@UW;CI"[A>@Q>H)%`J]7-:EZG:*SI<8!G:0-V#E`G
M,P"<\L@8L<#63GVCJUNV&I[$-@E]$:US_7G>ZV-@&O9FG994=O0%=JF34+DF
M>5[9)C$JICBB%BF2Y<<I*(7)7%-D`B3O)8@X#/8=W5Z6RN+6K+7%+?\`6Z&K
M];G7<%(@MN@Y_7#S;&L3,>6F6W12[=)$"4<^B(#U28/@L1"T.%A`QIPEF8%@
M,MJ;MSU4NQ)=^:_CFRSG(J.AE=V6KKQ3K-;Z&T+/K.VW4UCK.Q:5KDZ-8EUC
M0V9O!(B4JQ,D+"6''OGX)38R=P-!6/VPIIT9J<+6UMDL/=)1V@U5HQM)6NP%
M5/L+M&N4LMK&;6&[,*B,.B](-C?G1I1-"]N="C%Z0Q(<+TX$+(L`#>G:GO!=
M6F]75@V:L51%;VVIO*>O\:JBIY>J?$K*Z1NM*TF=R6]*%XHZH2.V4\8@<(-*
M)]!H`B<G!(`7JP/TB#PSIW&:KQFE=.+8>6VWI<[;NTBZW)2M=4C4LSN:9R/,
M1C$.DD]AR-FAC>M5E2&*ERW(3L*<$)P`;E@S32\$9\AHEY[W:167/KK"ZGH_
M8V[:CV-U3EFS$7MJJ*3LR>OB<IDE##&"(\CJYBC`WA^(CJQ6X$2Q2!:GS&G%
M,E2*`"$N*,"$8X#WARR,S#35_M=4?>M.7SH+>>Q,C4:JZJW*X362V/6]^-\.
M3O,8K=V>9)-H-`(I6Z)V.>OMD>2<*4GNX4A]U.0,+$[,[H](*[8H')FETN&Y
M6"::],6V;LZ4-25@6JFJK6B2&'DM-T7']@-63*^B9YJ%9C)2H(G,.&]4+*3T
MDC%@(W=EO=M4^NE&7NDU><I-9M^PW7BN[OCDX8:5GEGZ]UXANDQ"MI0^Z)PP
M$(F&'@M1@,-5,Y:U4G`:4,H9QA(3"\#":0>TC5UK;9>ED;O-$\XKG:JH])Y=
M!R($\YEBO8"Z&Z*.D`21A@QD2E[A<I9I4!T2.Y0LI1MB52=C.<$"QP+(>`X#
M@4:;Y=K-GZ9]@^MVNN*O@#]K+-8%6TVV)M5V<I$DG=5M-O;`"UOBDI9R$9V8
MZ.*,5@/3'EU$K)&/"9</(1E^C&<AX1I[@Y*N[1K.U7=(76L:TLJJ";&B?]CG
MITD14M,LK4R$57-=@,X(";B,I8%7)EJ$M*LS))BGY[<JS[F,`]O@;XA7=7I;
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M'T9;NT,:%D='`84Y*%8%V]Q.<C.-",O`PS]E[KM+5D"NR>RY)L!4)5$TU%]C
M9/$[EH*?5S.Y'KY,Y$FBL<NBOHN^H2U4Q@:U]5EIS#DXL*DHQA"H(*$(.,AG
M%8]LVLMP1V^W6`PS:%XE&O"NLPRRH!:QVVDNZ2L=TF'`J.:P"JU,?+EDC@]@
M%)CE"1S&0F3I4A!BA=E(2')G`T++>U9-94MT-#K8E>F%DN'L3ENE&SD%NVLG
MV'VI6[W!Z*LVR))"%\<=E:,V,2Y&Y,3,I"J!E<F-0J<>WD7KSD(9UVX=A-TZ
M-0*K&W5ZGXM?>P]G+;4F**MY:K>TC611NNU6/]LWK,\&1Y4D<<NS4TH&YM:R
M\B]I0Z.Y!><#$((!!EMH]P&I-31'7&3.::YI^OVLU_<=D:4A](4_,;EE,LKQ
MB:(<_P`D&0WPI"MPB71YCF92U7E6),G)2I%(QF@$7@`PCS*^]"G";RI2O*PI
M'8:YJGOG3=RVRA=T5+2EF62K,;CGR+-;$C1UE'(U]LOD>:$SXI^]#@%<F%'7
M,A.WJ2L'+`#+"+M>=Y;_`!*<:R/=T*U=X4M;_6O*]J7ESU1U5N1SE#U8L8V#
M70MYE[9!'-XDDP@%4Q*KV5<I=/ML?H+4D>X%3D1Q"<06*6SW1:/52DC+N2\V
MY;,:>*$A&TTLEM&4K/[4C-.ZYV,4-1"[@N=TCS4,,`B[XC3J%!91X3',"9(>
M<-*$LO(N!&KLT[L*UUQJ.]X]J^LDUB;!UW6](SQ+.VRE9U9.N->9O9_C"ZLV
MJW+%8BD49B[K9E=N*AP9"E2PDDT!J<1AH!&E%F!.479]JTD^W&]>ZSHF61G=
MJ*=?#O"L0)Z^]XMD)FG;'*.H$##CU*E<&=HTY?;9+Z'/P1,Q!RKU>DH6,!8A
MP'`<!P'`YC-KN[^^->MVMAJ#88YJ%((I15ZZF4[&*0E,XGD7VZV)3[(L5?KW
MQ[ID@I0X05697:J8GG*L+4)20"-)GW5`!YQD87':T[+.=JW?O+7TFL"NWAHU
MQOR*57'6E@A$N@[U#2'NGH189K!-Y)+)`Y,=A/ZHR4?**7,I")(4G'@D1>3`
M9%P,&%VDZU#=-K\(&.\GB#:8-MR&W?<S53DH54VW2J@6E"\VO6;%.\A+1O%C
M1I(O"$"#VR2UYI9H$AQ^2C/2&MX7W6Z'2YGN>0.4IM2LV2EJ3CNR*U?;U(69
M7`K'H:6O!,8C-J4VV2*/IWJR8N_S!6F9D64*;*E8Y*TY1!1F#RQ"#RYW<+J,
MU5U9,SF#;?=?3:K+,JNG9#KE-J+F[3LPY67>S<%XI&)Q.H2$BYWE2^UVD)RE
MG$C--)$4D5>^,C*8_!81=V>[>7^I6N\K&@4<D.6N!=:<\VMB^N%EZRW5%=@6
M.TF*[WNF&V1VRN6.K>SQ2HH[(FK),@0";P+T;>4:\A7Y;?0/(:]T\[@UZ6,V
M+*MV;>`SQRBM,*DV`M9+)=);PUSLM5*K6L=_8F>0P5M>I5,V"PJVDV5;9&(P
MG9DPW)Z>$XU.!!`HP2`+4R-SD<RT[OG:*#U7;T#=J>KVWY&76>RE53*EIE]Y
M*UK]5-T"-[BTB(2.HXX^D"2#+7(C#B#B#A8+-P<68``5I:P=H^YICOUT/VYE
M,:X)J2[/&%C2TI8VM\GLD#_5%IRFK3K;B5?6["+*2+"W1+*8^A5I271F<AEI
MER<6#"LE9"9D-D:8]L$^V5WSL[7>9U7$H9KM-D5^+]%+F:USX<\[`)]2[:24
MKL"-U`O/,91^Q*5(W!G^"63ZVA.889[F?`N!";2SNTW*VMGFOT!;(5H_,)+M
M8P;7)(U"JIF-LNMBZDRFA@3!+`ICN'%/DR$;345CO<?1)PJ4AS6O,PZ$92A.
M&+`,A.CKHW`[&=H=A=F8%?,5TGCE6ZB7C+-<;46U$=>H[`D]AM4`B<V97ZOP
MS)0ICH86;F8)R57VC@A=^J,]LO\`HY$%VW`<!P'`K'VXZV(QM]?I]JSJ<%)8
M,\Z*;,Z32BNLQ4#D>Y(-B9!`'W$\22`UZ3%(E<--@^!$),HC,G*!EFX/*R5X
M$$/Z5Z+F"N(!J!")ML$]62LH^-[[H=A)HKB9[?+]E9;OI7)=;S*9G/"R6O9\
M.<XFQ)R"4V3OM<:A.D(`(9?H\Y#P$8Z4KF>(6P0&_P#<UAM%@U_T4V)T0T\S
M&-?R:]6P2([!5>VT\X6=<QX;+D6+/G#!7[`WMY*9OPPMYF"C#\AP>;D6`V+<
M?2BQWHW+H]-+Y=$#`X]5=8=<`AQZ$D$O3?)*IM>.V[&[V0J5\C5(C22I+%DF
M1QTTG(32PB")=X%]`PJP^E^Y=D6V][#VIW)999M78$"ULKVG[5JFA$U>5_3+
M?JK<OX_5^]*JR=[%F*B?O<ML_'RI!A0[(TV4HLIT9:<.`CP&W[(ZLK>VC?('
M+-RMHHU9$C0ZR;R:Q6'BJ*1Q4[.Y0_<=AKV-(105*ML&;*X^;5[?"3C@'.)S
ML>ZJUWJ&(@HH)/`T:MZ5KQM*`V.P[*;FQ>R9B1UYV-UQ:[2*%Z]9KMEKRL[&
M(CI#]:%CL)EIR=38MG.R>'-1!X$:QD:B24YN22`F'Y&`-I;"]/LPN1]O"3Q+
M:IWJY]MC1_5O4)O6LD,=@G-X];K><K3='20.#)84<>G>!W&@7"CSXRHE3:J"
MU*5.`+Q9,]/`P.CND)PJ4^-.1UX5VC4-O9-2W88NB]7T4OKZNFP=644YT^MI
MF$QQQM68N;*R.:IS^<G=5;@O5`"#.#R3C31&X"7NU?6!!-TMM:UOV_+%G:ZK
MZ8HR6US6%.US,+)IU[8[+L26MKE/;65VM5]@163K"WJ$L"!APS@+*39)":8<
M8=ZPE@#0FIW3JOU7L+5)S:=A39/5>FDLWU!2D#<(.M"^M51;DG11QB]9N,R5
MS5Q.<#J<=6A>,+D-+D;N4M`$12<161##'M>NG:S-97+KV?*VVECIKKI]4M^:
M_6E]XZ4-<F^Y*@OZW4-O2`F)D$60B4UG-FMR:4Z(AP-.>B,DY&9E/Y_5B#5L
M.Z2=C*1ANLQ&N.],7KRR->--[?T\5R64:UD3R-6!&+IN4RT9$_JHVHM-I61Q
M>PE"(PV83K3LX<411AXCDIAR40>5'T;V%4<530'3S<-)3T4L+1"MM`-CQV11
MB.VGN:U_7"6:-Z.UJU4)[!A22O[06MMCO9&259;PS@^44/!&1D8R(/%W7T0S
MA\8;_J'6[<0JD-=-HM9-:]?;D@<KH]NM::*E&I5?$5I53Y$9Z.=1$F.MTFBR
M%,GDJ<;<I//P48-$<E,.",@,FE'79*)7WIU#L8EC,V2Z[5KK+"[:M5Z<24::
MJ[.W"K5OGU"T.XM20*XUP7V#`:?GKHK4FC)P0A(3(`A-&89Z0!T'<!P'`JHW
M#ZOHYN)<UT63,;$PU1NX.O*8Z-BB945RN71I^>[?07'%KH;W_P"WT>#E\*DK
M2D-3-OQB\C4)0&_*!_1X$78-T4Q9DKG7^LYI?KW,VJ`Z@;VZV7I(?NCA#,[T
MG._JZ//5LW:-_629V,C\@2/K<K/)(5`=AGA-(`8?X(S[@8^=TK7A9<!GT;V2
MW.C%F2=KZ[K4ZX-;G^&Z]8KMKKRM[3:X^T/UJ68RCM*3J+'LYP00]J3G%(U;
M(TEDIS<E$A,/]98;*V'Z6TFQ#S;+D\;"N,6_$#1_575>-*V:`)5KI![#U.NT
M=[0BY/4XR8:"0-B^6)$1:J/FDD8&F+.#\WU&!&6&'3CIGN:[L71=MY[AQYSW
M=GLZU%GU86]7-"`B5/5`NTFD\@F-2-`*>>;*E+M-6V3R&6.BB1C62`DP[*L`
M$F$X$X0F!L*X.I.Q]L5SE(-O=HFB>2J<:([*:7V(Z5=2Y-8H/%[6O#;+B\Q@
MS2KGDNPT(JH(A:5"2B<#7)0\B![ZE4#UB*X&IY[TNWOL)`MBOWHMSXK/KIM3
M2Z.Z(5A-8#KS^'D)KBGV2RF&TW>4R2%GVE)G.=6/.)-'$@UQQ;JUMZ0LGVTJ
M<(1YQ@-N;0]1LSOB?;A6/$-G#ZZ=]GX1I#$R67,*?5;`!%I[*9A(WJ%V6=&[
M&B$BFU67JEE/V<^-:!<RJ2D@!8^2>$8@9##=?.E-92!]+*\WE##?PK[)Y=V$
MJ(_`Z440*$C#,=<%=&*:8AD=/LN5*8K'V-P6B7(5YZUR.RD`$@XL9V1*,A(_
M97JEK3<?<,O9+8^?SJ10&(:]IZ0J*H*ZF=G4LLAKC()>Z2:V)H]V)5]BQE]E
M8;"0`:6PQJ,*)0@2-@<G84#R#)8:4U5Z=GS6F0:OG&;'_?:)ZFTQN[KW6K0I
MKP]N>1U1M)8T3FM<,KJ^#FSCA0LI-HC@FKWO8\.Q&218"D]KTC#Q=!]/=E:W
MN/7J[5SM''AJ]0M5+`TWMXJ0TJ8Y)+HJ*Q)E'9\[KH:$FQD:BKIF2_1=,64J
M.,>R,)A"\E9%]!!IJ+='^QM.06BFC7C>Z,5Y-:ET&E&@TD?I+K2FG;#/H1/[
M<?K+E4M`QJ+4:5L6?FL#LGPSX)6*`%+46!*<J$YPTX0R-XZ-Y_7T7D=8:D[@
MIJ<JJ\-(Z3T3V;;+`H]':\KE=?TE#I+7K78]6/Q<^AZ*`6-((5-'5&K`M1O#
M66:I"H+)P86#&`_%>W17/9<FV4K#7[<)+26M.UM7ZP0ZU:TDE&H;1FF)%J/"
M(C7=;JXQ8IT^BP&2-2J+P=L#(4XFP]8:<F%E&H38.%Z0RM;U\RB3]]J#:@J+
MSALUR@NND0N&6KG<AO*JZQ=W4#',]>8%(8TD"M,7.$P@^O+ZK^>K,3A`E,RD
MP$8S!Y](=`'`<!P'`<#GXVHZ3[!V8N#=MR_>IA4*U_WYD-'O-T08W6=HFUQ1
MY'2L(BT-3-U47$_602TPA?(`1O)N7+,<5J$(E'J)#[A>!B"4\?ZC=<7^;[8O
M6RT6@NS4)V&V/A.Q$*@MAPL2HFJ'N&:^P.A"2\.:Q\<C),]K6N'G'F.&2D8L
MEK<E"+$(.3!A"';[J;N!>\]A6TL-E<`?)9:^E^X=00ZB]=*3<:@EFQ3I;\&5
M(:X0;+/AULR*%7!-ZM*;R&R..J5A85RHX_WUAV<XP5P,;C/1W:FR=+28[=;:
M98^SZ;Z"4;I[42.+T?'X(X:^12!S.$WN6IL1L#,Y$TVU82&TXF@1N8R\LS<L
M;4!I0"21J<C)#;H>F"?**D0DMEH:F4GLE7FR5$[.TY:>M6F1M:P<N<4&URUF
M9D5V0A[NV8/EMM$H;)TZ$G%%O#.%I`IS\(./TL"#:]J=6%S7ZHNV87=M9&Y/
M:M\=8ML]?,MD\:HP,.C;:\V;:DKL9%93%%";%=#"8[#6N1$LQ#,>M.6K2D6%
M)[CDXX>,!B]]]+!-\EVP4X;#KHL=/=(]/]6XLYL]?)UB^#V+IU<:B[H-<0BU
M\HRB?VMUEI*("E@,`1_5BC0_,R(P(BPL`8*#V,FFIEST7M)L#"K2M.Y87:4&
M.LBN:8_"N'0QBL"#&PIL0,L!43J8.;QAA,/.<CCUKSD]8I5&%!R00`D``K5J
M?ITV,88YK*SW/O<TV05H;3LEA&D,9A>M[=64,KJV%5.KJ:@U]6R`RSIC([>E
M5>,*T1R!"6M9$05>1'?09@_(?W47093VM[EH)8>OUR6;%+NTUG$>>YE.9C,;
M/L6)W+#WZ&O,5V&B3554ELQ3":>'=2Q\-<AJ&(@`$2D(0F%*@_7`9%JOTL$Z
MCN.ADVJZ[V5JMC5%\V&8KJG#54R=B_>NHG8.6RV:JJLGR-OE^%05U>R)U:U;
M`Z+E+O\`!4MPQ`("$W`"PGOJ!IL;JO9&[T_,L`$VQN'M2\[*%-8(WEAS`2G:
MOX+",1`:O+T[?>,9`X<)1\W!:+`L*,`]G'HR(03DX#@.`X#@.`X%5&SG8PZ4
M#M5/Z@;H*EEU9ZX=>UP;Y['+FM(ZNECGH&&2?=BHZWK-"E7I&<M]E9T8D:Q<
M8X%G@^,C3X+R5ZACX'@=8^TQNFNKAVY.W[!0NK>NLB,J8ZLK7ANSS-L-"GD-
MO'@0-\4GSK'8#$C*WGL.>5[>A>2%!2AN3J%V?*L`4ZCT!O..=I_7_+:6E6P4
M=V6B+G5T*LAKIZ1.);)-R94EM1^RC^[E>(ZR4Q8FSWJ82@I>4<U($+,I4NB<
M63DH#B@B&$/YE7:EU_0NFJ^OR0[+1%-6=J2>40J`KD+'.7N62&7P4:X$]C)5
M9,45<K/0OD`$VG?;Z54SD',>`>5P4^,A\A7[NEW7!UE@&S4EB)>NTU=(E=.J
M=,:XB*FEK2%&ZF;)0&'V2LFU_M4=K-.?#F>+P22&R!"C8USJ>]-1("RS2EI@
M$X@W]07;O0LBIBY+XOZZ-=8Y5M9W'!J.89E4SI<<C62V>R6NXG(%$645A+JL
MCEEMT[=9,ZKLM,?;D3TM/9BBE`AYS@W.`Q>]NZ6D:*;+FN,YP@5EZY5]JE4&
MQ,&_#U_F(K^G[K;ED3*OF!D5UU)H&Q1F(1AS7Q$].F7KWDI2G<$YY2Y.E"'`
MN!+J(=G6C4T@=A6,W7Y'T,:J2CX]L;9QK^Q32.K8;3<G'(D[3-EC8^QIN<G-
ML/<(DXI/2@)5'85)O:R#!AI(3`Q;=+M&UET9:M7)!;2^1K(_M78S+#H>[1^.
MOBTN/Q1QCILC=+/D",+6-Q^[T>3J&\L]O(*,?#AN1?QT9H25.20RV2]GFAD/
MO9JUIDNR<*:+F=WZ'1(J,*4$KRUMLRL)O3.L%@\FG!4>,@,0G4M;UA)K>R.K
MHC=%.#B\`(SDP&!!/+@.`X#@.`X#@.`X%/NT?:$NUPV&VOAX*X+G%,Z/Z`AV
MZO92P)W!39CQ8,XF3XU5)5\.SEP3QUJ:U<2@;VYO"U:G49)`:E&#)991_K#(
MZ,[.V86M"':C=Y#0.J]03*3P1BJ:RX%LLU[&U?/,6(SGN;0WK)?&X'$QQ*4,
MZU*:WKTRM*)'A2#R4J%C.0A#;S3VFZ"/]&?O',FQT:=JHS:(J1)7M\:GZJ9*
M[C"5A5BK$-3E1(5LKY^-OS\P#22QF+1H,95!+RGQDW`?7-^U7KYKNJZBNJ5;
M.0I-7-\"DV*F=FEKF4H=9>&#GF)9Z>1#XO&7F:-:6O59(R)":N;TI3">')2\
M2<S'IX%>>Z'=2YZS0ZW,Q\G6QYG)&[=<:DTPK52VXY9$69BEL(KRPI79>P""
M(5@F>V59"HE.2G#+)'#W4YP2J",)#SC@FE<"2U*]O&NSI0E@;%;`W)0L3K-J
MV6=]=ZSD53.EO3QPGSTWQ&+R)*Q**X>*HCUGH+54"=%BA3'&]K=Q(6PHH\:D
M7DWVPP&^NZVDM=VS82V)$K@ED4-6M8ZAS^K`5-(I8[798'[UALG-83Y1#9%!
MF"(0>.GLD;4N+6J,>SC%*="H+4%IE(B$XPF8W]FFBKE7]P6B3L-&4T'H."5M
M9MO.SLPSAB50F"7`C-75E(U["]1=OD*Q',RR!EH@I$B@X:D.4X@!/_5\#$=S
MNT#6O1>?:MP.Z%<D).VDF#G'F%X9H\]N2&&L37&USR=-),F1-:IP.:QNH$39
MA&C*/<\*'`!N4_QRE!I09HN[+=%FW8PK4Y;L="B+X-FJ*LL1#*.3C:2K/<6L
M+R@JY581;`.MD=G+&T83"XZ:\`>AY%@&$WKS@.0G/P'`<!P'`<!P'`@3N[MG
M+M=)+IM5]8Q^,26T=N]LH)1+0FEP78UECM>)661V-=D[&F9E[8M5N46K.&K<
M-Q63PDY=%281V!DA&6,(Q:K]JDFVAN#8TMLHR!0[5G6:P+YK6SK6>=B6-5?4
M$<Z$,<R'.86%JVEA&)#&8%-E+.HPSG%O*Q>(@(#S$V`"%@L))4IVI=>FQ+Q-
MF.G=K*QEZVNZM47;+C\GO4>9VZHV\DHYZL-+(92SL;`]Q:,Y."4\*D"E4!F4
M^2%WQS@B+P']1'M,T!F]7V[<S+LM#TM<T0RQ>2VL^RMGFL#512,SH0BX#)LQ
MV<1B.R=ZC=A'@R5'G!N1*T;Z?^J0&*#<X!P(_3_MXHYF/BUC5[+ZQFVNRW7'
M:&[Y"[N:RV(A=PWC7%XAL><(W&ZD=ZGPK"@+?Y<G1.QSL>W+D1BD@TM*<1ZQ
M\".W7)W2?O9D1M?<\JU#@J!+JG.]J+K2Q&:W1'I323"SR&)Y:FEY:;5K-EBL
MFCD0BDA-!*).@D`F\#N4`*,DQ./!G`E8H[8=>9^/7J4:YVC4L^JNR;RD]3V1
M(9R=;M=RQF21JCY+>)YU8PIPJ@]SG+^JB#(6YI@*L-S:N:A"-2*CQB`#@1_H
M?O;UQVS?=4XY0;M#6:77O>\JK28UK>*VPH1.FF&1LVP4*.05FO8ZZDM>SR7R
M4<21N*1G.>D`RFQ=G"@9*DDTHL)V0OL[T)L*26+%HILS`5KA5D/L6PI<X+RI
M''XD.!U"O,:[4F<1G<B8FJ$6/%ZY<2A$O:Z..#JF;#,>E0,O.<<#:-2[F:XW
MC3LVORLYZO>ZIKM,\KIA)7*OK+B*IK;V&*HIPN<2HO,H='Y<[-IT1<D[@C4(
MD"@EP3'`$E$=ZL8X$):&[O=";FU3C.V4AL=?3\5D4_556&%32,RMWL+\1@FO
M"MLAT>C,+8)$Y6$\NL5:</.`1TIT"E0&_P!9$284<`L+':*OJG=FJMC%U4+8
M,?L^KID4M-CLPC1YQJ!8-L<%32ZHE"=60E<6MV:'5$<E6(E9)"M(I*&4<6`P
M.0X#;O`<!P'`<!P'`I%M2K+[@W;G9=E5%'&PW][3K+,K*O;#L"$RJ8TC$;_U
MOMUXDC7$;?-B:A"M9XW-H5;63R0?+2'+\-RH";W#2O3D*BMG.K+:*DZ"VNMI
MOK[7.!3S:G:CK=,CNJNE\+M2<:W0-_J?9F,.DCON6Q-W8HPY.3A(S7?!\C):
MFAI0I6%"/!IYI@Q'%A+:QNFG<:Z3K<V2LFS->VG;J=;UT!MNV5O5TLOVO]?C
MHIKO1KYKZSP(^VXF&-7M$YC,8M)UKH9)FM+\ML<0$E%A.*$:+`;(9^K?;>G9
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MU;5L5<ZD)']N&]GU<:AF3<@`L$>8[*#2E*@:(K&2R<A%[L(T9V+V$V$ZI8U.
M&MI;++O>/O6MW8LFH5IGTJH9]U'I.>039D#4[6+*XZU*6(HV4P1.T-V'<M,K
M=%DD5ITP1D@-]07#]DVJ]Z[)PO6-WUI>ZI:+8U9V[J?:*,L-SJ98U5K,BZ]C
M\[C"N)/3M!6E]D3'\A%.!'$'IT2C&!)_;R$.!^H(5PV7U'[>S>0;%T4BLC6Q
M-IUMGOO7^_EH3M>CL,S9^$2-BDM4SR95'`6@IG%`W9K<)95:=,R2%:ZI536S
M*32QHS1X+#@.D+@.`X#@.`X#@.`X%%\IJ;8V!]J&[[U3L4B*L[<_0FB'FK9W
M<D(FDJUW(M36B>R^!S6I;770_P",K;RI97]G(59"<*D)YZ<:@X@E3\4\D053
MW=U<;4:XU@[SB)PC7>(6#LSVJ]<%EP_6#5^$6S/-1->%%22-Y;GJT9`QKFE@
MD0F:<OCL4X30Y`ULK<B0(R0EY\AP((2CDO2_N#-R''8Z6610H-O7SL(>]V'V
MKH#8.PU3Z_'Q=UU^3:YAK*/W371$>OF)3$N,H@NF90C0`,.7&&ICDXTQIHQA
MMV,]7^WVODYU:V.U&9M,8)<E9UQM155KTG9%@;.V52)B79NX&BWUMH0VVI4D
M?[LD=BIY&QE'R##D2A)?,J#RB#40/1G@9F_=4M_/4SLN6BLFI"SYYW!:I]BX
M?8%,D82:XHVMJPB,SB(4N&)5E#-WA\A:LYK3X/4(`)C"<'+0C]6`AALGZI=M
MX?:)FS%(3_7=[NJ!=H^U&\57P.U3;"3U7**GV@HV,4JZPR=/D?C*^116SXJF
M8S%J%<W('-$6(7H]><#%D(?NV'ZH]K=CF#L4>)79VOC%:&[6K>BM=M(XRBL0
MF`QJY]695(YU-S%J!Q0+7]#5\G>W%.C:CBU"]U+29,.4$X,"$H8:/W@THOG8
MCL1ZT<S)J;6QQOVOT"?L[8*>CTY?M=GVNM,K,BFR=0-2JQI&PM9GI=[@4986
M].Y@3.;DA4#Q@K!!1F,!:WV(:K;`W_(]*[9UH?JC169J'LV"[BXQ=JN9-4$F
ML?>:NL"JI`UG/<$:7Y^;'AN;YV):D\(S"3QD9*,$#`O.0KP4=1>V"F9/=%&6
M7KV+21\[/B>S95/QIK`'M>![!8R"X3:5+9!-.:]P$4Z;P(PRW+SE8%@SDGX.
M3/`<!T>\!P'`<!P'`<!P*B.S2NIOB^.J[9N(1.335IUPW?2L]FM438'62N;#
M6NR-83.C'&PE+4SHUZW["@\HD;0H<E`2\A1(#3E`\A**,&$(,WEUH[8SK9F<
M;M6>P:<5^Z5'0>Y3$9(]/HU;+=>>Z359],S&$5Q"+\CK^C`PEDQ!.N3K1`*6
MR5:L>DQ04AB<C(`EA&?5SJ*V[VYU.H4S9^9TY2D18^G%_P!*Z&8ZXA-BLEO-
MJS8J&5NYKG_9.)35*SHVEZK@F)IFYP9&]0>%T7B6*A"1B.R0$-]G],.R4YH6
MQ6F4(M9*WV>0%Z>*JTMI#?NY6R[#9R[4*VR[;8HE<+;L$J4'P"G7UY39RC8X
MR2K,:S5QX\F'EE%$""84TT7W3V&N6L]A[]DFL,4G[!IIO9K5(XI4*^TE\4;'
MC94RM2*K6,[Q+HX2[R))'&^$GCD+@<2VF"/.`!&A&6'U<",\UZ1+FLNFJVIZ
M2W-73"EC72:MZSG^0L)4K<U1=S!F=13%IGK0VK6AK*=*J]^M!)U9*@](Y')S
ML`P1CSG(0E(ETXWSN>4=?<^V>>=0XP_Z6[.'64N8J#46PH9)%5Q&M<WIXO")
M;,XVA,/G+M-I7\\*'XK<V-C.'!(5"H\.1#".U+]3.W$0C&G-43^Q-?55<Z6=
MAUQ[,PZ20YSLU/-Y_2=PM.QB]P12%K=8QEGCMKLLIO(DA,0C5FM?PT9I^5>3
MLA`8&$:F=+=S4)$4U66=`M2[[9::H#96D:*L^Q[ZW4DPY>RW@UK8^&,3/6QV
M=3Z1IJ(32+JPH)KF*C7&J<D@4(20&^18"S7JZU-V)U"JBRH)>MC-S['GRSC'
MZBZ;8K1M&](SK55!$6C[*AJ>,W-=38S6=,V(#TVJER8A>E*(:"5($B;(RP9&
M(*U:@ZJNP.AZWT>-B,TT_EMK];-U;/*J&:I.XW`@KR[J+V?9Y2CD:NU'%)$'
M![K*Y8NLDWEL$SHWIMP24,!AN?>%X"V#K7U`F.E^O#[`K+E\6F=J6A>EX['V
MDN@#8Y,];M,\O>P'6=/46KAM>A9>289&0KBD:0Q7@M2JR4-0864(W)80L!X#
M@.`X#@.`X#@0QWDVRE&F5-N-VL^M-M;(Q>*(91)++35*]UBSN%;0&'15VEL@
MGKZ794UAH'-E0(6@8!$-F5J[(Q8])&0^<\"/E#]M&OL\KN`3_9@IHT&.N@B-
M/U"PW:FZ]?V"7737LP8F)ZCEDPUIBUG2,\B*.9S\6C")QPB/"K`(`BPY\>0F
M<^;9ZNQBQSZ?DFQ5),%K)2792KKAYL^&-DV1)&&"@L]Z7+8RM>27=&@::Y-"
M^J#S2@$DM0L*A"P3GU\#`8MV$:)3>'SVP8?N-K/)8/5C6WO=E2MFNNO%[#`F
MAW<#FEF<9<Y)W\::/I'IU3B3(AJA%X6'XP63ZQYQC(:HLGMCT`JUVUB1/VRU
M6.3+MN_2=BJ2>1N>0EXK[((DV.:IV?Y3+`20EO8(UA\;<,(%8O=#]X51#>/`
M#S/`0S7<;L'UQT;>:"9+XF;%&%%_V.O@S*:ZR:-1XF,L;)#)-,)+9,AS(71M
M%]RX\-B2-AYJ?!QV71[0$!!G)^/`12+[HJ/<(-U^SV.4S>TKC_8%,*BAL8DD
M?C[(NKRF7BWI,Z0YH8[9LT#W]S"YPVR)B<$ZB.M"ES=R_LY2,PDHLL`C`E]7
M>VYLHWCV,TGE4)*BS]4U1TQ?592HA\,<RK6JNSE$GBDC<SFHQK1?=QU@%E1!
M2V'DA4+`*$RM*?@98AB*"$TN`X#@.`X#@.`X#@.`X$#.P7=MZT*IM;?`M9+@
MV%KF)LTOE5LO%3/=7-8JEAD.:"7A9*I,DL6;Q!:[-ZLC)P2BF@IP4X$G'ZRP
MXR#U!@5+=I%!RV+5\OV8-C^B-AV^K;5-04KLW=5"-EFV7"9$B9SHA8D;9X;9
M4H*Q&)<XN9K>APJ,3JQKD9Q62L"P'`@E$\[A:GQR>/\`5L@V5HECLB*-\M=Y
M5!'BU80VRR,-,#C;),9JZR-A6/1+DQMD4B<D0.3@H5%E$I42LHXP02QX%P,+
M8>PC1.4U[-K8CFX>M3Y6E:B806#.6NZ*_61F$GRI2M1Q=+*74A^&E8ULE6-J
M@EO(4"+.6FDC`2$8@YQP-:S?M3T,@5DZMUHZ['5BXJ]PF^4.U+S!@G,+=J\7
MM4:"),E<7R7E2,"!I1S*2E&L+"/&#L.C^0:WE^%!8P8#]&Z797K-HA+:;AMZ
M2UJ9'>Y`66X-I:J319DS'HW6593&P5LF>B9`[MJ@;9(7B+IHPV?'":-5(7E&
MGQC&!B$$(=W-WA0BGJ4H_:86H.S<\U+LZN:.L6P-DH0.I7*O::!>KLECK5#W
M(H^Q$T@G<SA,E5@;Y"0QI%"1N5F%D_),-'@O`3RI#;S\4=M=NM2I'#4\1E6N
M""D)]#GE,^G.J>U:9O.'KG%CFI:!2T-9S`Y,$ZBSZR+T>!JRPY2$'!.S[^0`
M":W`<!P'`<!P'`<"K_L1[(GKKV)B<C>-/+ZO2L),MA4:4VE5DAIE!'(_8EBS
MHBOX37CFU3RQ8O*S7Q_>UZ/VU)"`UM+`L![B@&0F>@-NTYO_`$'8+]!ZCLZ7
M0/73;68$*AK=-+,N6F'782*+`'KSVQI>(W7T\EK>I=GV-)B7E*F2*5!PFU66
M9D.,^O`0RY=OOI"V%3TY?MUK>D*JQMP[62,ZYJ_#B!MXYFZ5T4?+?_'O+"(^
M?,BME+`I]LPUS(&F`')V/1P/Q+NPG1%LK%ONI?N-K.EJ-VE:B"-=DF777F(6
MXS5$WI79?%$,AP_Y;%4A;FE<2K4I`&"/3)3`FFA`7GU<#%A=DVF@-MVG2H5W
M0G%UO].M-UL)7WIBGW4>X\_&"4LL<:)!A_SARGCI$P_>1.U$DC-.C.<.8!93
M9]?`WY2VR^O&R#-(Y%K_`'A55U,,/>3(]*GBKIW&IPVQY[*3`6Y;7=9'7%P(
M0J3$1@3R\&"#@TD6#`9$#/G@5PU#W?Z87;=C?1\!D`Y%(7*0;<-2)1&I!$)@
MJ<&C4T4=$IDC+%8F]O$OD"6Z43JO60I(A1*%[PB9%IP2<!`'U!*70_>N*[Y1
M&ZI;%ZFMNF1TEL!,M?)%#[L9FJ-3[[PPZ/Q"1J')SB[:[/!\8RJ13).$3>N,
M`X)32Q@/++'CTX#;:#<#5)TO%5K,V;)4:X;#HOF!64DBM&&*K13'MZ/#DX(C
MH22\#?RW)`VY^2<ER1\@I-^M$#!>/5P/R5UNAJ';\_+JFJ=GZ"LFS#8R=,RX
M!!;;@LJEXXJF5&HE3]B/,CXM=/LY(I)$$XSVO!7CR/QC.,Y"-<8[0=?+0W:J
M;3NAY=6-\E3ZL=@)Q,;.JRX(I,4-626B'VMV11`))'(V2]9RZ23[_&&EG&KT
M>2<(!8"4?@0A%!KO;7N=U`T]NZ;4%8TC0*Y[`X;2,H>D*.:P!K,"YW?<;35S
M;#_A/\D;7`F00Z,NF)L]X,*`4CB8,*_5G)A81!^]V[4V^';LU1J%:&I6R-6Q
MO82?V'5FO6R,L(K<ZK[>FM:,ZI]>ALK$P3EYL!GAKRV(Q',[NXMJ8#B284<$
MD!`_="$D=$-MC-QJ6?YX]PDNL['K:ZKKU[N&NB'P<E2P^SZ0L)ZA#XC;W\UK
M9#G9J>FY"B=T9HTB<?Q'$L(@^H.<Y":'`<!P'`<!P'`C+NI5LNO'3O:NEX`0
MWJ9U;>N5UUK#$SJO"UM:B53BN)'&H^0XN8RC@-Z$UU<B@FGY`+!0,Y%G&?'C
M@<[F['6UV9VWK53VKM:LL"<ZY!U85OJ[+6^/655%<JV39B&1W#>_'VW-);34
M^L*T:/,2EEE,+/&G!D`6[^^I4C3X."K*#]&X>CLUI/7+O`V0MBI(5+7>Z]-M
M7*QIF3,S0?9%CD$UYJPSTE;"`O$?2D2^*,I,Y5C../(493'(2<KU99J8@960
MA52-"6IO16=_,M((#;,V1IS;S0?;>RKYC5_5HY4EM"RU%7TC@\7H&HKFA6KM
M75;75GTW#FQ(O&6JA3RD(?L)%3B>8,X."@L"2]:>R4.:=.[PKO4YC?+.J_L/
MO#:B]J/OK:N`V/+)JT7W2CA4TBFI-O--+1ZNV=8ED!B60J(T@:E"?Y2;*@E0
M:L.S@H)K=LFCFV6W,YH:4:XVBKA*&G*CW*6X;`YJXHA5<T]HEUK2GTA1DZ@<
MK6EHIUB9N[(\+@FA+9FP>5:8)*_V5)8:%VCTWWK8];>KC6;7ZF(=L*AT=LO4
MZ^YI8\XO6$4RM?7S6@AX:\4\VQ9JK%0VX3N[6N)+32$'T*+(QE0F4'B,.&$@
M:8*E=L]W5WVPHBY\90:^=:%`Z]V:02N,>&5!=ETV[)=@%$&:Y*%`W(I0;"(8
MWI1J%)!0`^AR3C$`K)N`<"ZO@.`X#@.`X#@.`X#@.!"'LIHBP-H-`=P==JI3
MM2NR;HU^LJNH0E?',ME9SY+)XXL;6HIQ=C2S2F](-2<'`S1!R$&/KGZ<"BOL
M6ZX>S/8FO3*"K1H@3O4CSH]KM4[42Q6/5-9)6>[:H5B73TB]W614U,K6MR+*
M?AI/N8F8GQE;&Q;D\Y3[`CAGC#Q_85I?)J2U?[WMB+`J^%O$BVHGNO!M-3EH
M:_O=.$M;MD'UXK!]$_NS0V*GV"1QAFK6\+U9R@*IK1I@C<%Z56C":G-"*U/4
M!<F[M;V)(=>FITL"]]<.R>EMO;IM^.;!UC^%^Y[JX:]/%<I6S6Z]XWK#6U0Q
M&;:]Q<38'X9\'.:T3Q@T9ZH:M9DPD)^0CK4V`J*3==%Y5EJA&W9[IG9S<:R=
MAZ8N?:*&6%,4J';QN3MBJSV^UD-.1^$."B)R4H^4FQAJ:@$IURK):$\9HQG@
M"1/;UU\[;;GV#$Y3K[9JB*,L"TVW,@#-'33*L3M[K==UQ^)5_&6-2JF,$D;Z
MWQVQ(([OB)^="519S0F;$HFS*18I.4&!I;;?37L&DT\TZI5IHN";@Z&Z>UQ5
MLB#7LDV&A>NCWL3LM72(A%#Y'>2-NJ>0LBRM*ORUDK6^--K>D0.;N,"E:,XH
MD"8(2DU;;)#9G<SO_>GV*<RQJJ]4=.]5)`,!IZYG77&>=/;\FS`S/>4:)*_8
MKZ/S]F2JE!0,8P:OQC(0"]0`A=7P'`<!P'`<!P'`K+[9M6;:W`U7C]2TNC85
MLQ;ME]6+14DR-[*C[?B*5->D*GLO."O-(4!$M(C[&>,@G`?4>9C``_I9QP*S
MMA]"^QV[-^8=/GEKACEK[5W9'K/M37KS'+"JF!PA)0]=DQ=)*D$@JUNIO\8I
MULH@4`=!*GYUF'V6K:/92)2\X"`@`0MVXU2GFBND54#?(S5E7W[8/=A--A#;
MR)/C:&/QN)/EE7Q9%4S&U[J=ZZL:&PUO;HN>U)`XE,=D+64:,*$*/"H9)Y`>
M`HG3^YMC*=TYV,U/IVS5T,U\<]_M?+/@?[QU:5Y,KK?[ZL]IELVVSHZ[9;KX
M35<[JNU)&E<40@!B4<];&,E,W8^.E]!H6$PGK+MVC[SUR>X!J165AT$/JF>M
M$;-KZ>[+)S9A4$G3R"03-O)4VA^%*1[L]I?&-R!"PO+0W-:U"D-&>$DM,062
M8$ONI/67;G6ZL;JK:\\N5=U`0O@D7T_K64V17E\W725;1>`%L#M'Y9=$0KR'
ML$]C#5(_1]STSFF<G!L:4_LK3S?7@L(0\Z[.LC=[5J_8??\`<5DF609!=;-K
M,IZ\-7TLW()!?.RFS\NM^0PL<EC55-[NTL,B1,T>?EC[@9@TKTJ-1)L`:2,M
MX@EMU2U!NG2L]W?,V>UU@M2QG9K:BSMO8N_1+8%GMA4S.UF((#'15,Y,C=!X
MT::-A0Q(U9E\P<62IR;@G"0&<>O@0MF.@O8]9?8E55OS]IAJNE*/[(''8^&2
M",V+5,/@`-<W>#2R-LZ!LIN.4XVVF\7ZC.?\AE;](9:I)=?7D*4H\H0<I0Q&
MC.FS8"!U_P!9K']SJFK2?TF'M.;]GK(AKNRXDR;][V"W/$J=D:9Y:FE"[6.L
M1GRYE,5`,."-`!*`.,YP0#P&5=:_75N72>RNAD]N?6;6NBH7IIH];6G<KF%1
M6<W2^8WE)%CA5QT9M5Y:T4&C)B&.R4,67*TR-6L7NB->M<#562_DEA$&6[7=
M6FYE^[X6#>K)>+G'Z>EVP_7TZ(FPM-1ZM0@IG605AVK(UH$3_5CL\FN,`NAU
M2A8V\]4;]L!=E)KE\M.E2%$!L&,45V'2?M87;7[)ZLU?9]3UY*'RH]/I$U;2
M-##']6M?Y*IRV3RZ2*;4UFZNU@;!6FSIBC'10<[(?A-N`M23VRPB-$&\^EAM
M<7FH-Q+_`!('!MB.V79#N+?]6$N*=0C/7U>NFZ"MXM)`HU19)Y"66_AN>YIA
M"`'WDBHDS'D(L"R%R/`<!P'`<!P'`<!P'`_.E^+[`/A?'^-^G[?Q?;]C^F+U
M^CVOU?\`]SSY\?[7G\_`_1P'`<#XQZ?(O3Z?/J_2\>//J\8_I>/]KT^/_IP/
MG@.`X#@.`X#@.`X#@.`X#@,^/&?/Y/S^?R>/S^>!]"7XOQR_A>Q\7QGV?B^W
M\?T^<^?;]K]7X]7G\GY^!]_`<!P/C'I^OI\?E_2\>/Z7Y_/C\_`^>`X#@.`X
M#@.`X#@.!]*CX_L&_+]GXWMB]_Y'H]CVO'Z?N^Y^K]OQ^7S].!]@/1Z`>WZ?
M;](?1Z/'H]'C'I]'I_1]/I_)X^GC@?UP'`<!P'`<!P'`<#X#Z?3CT^/3XQZ?
33X]/I\?3QX^GCQP/G@.`X'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g644794g79f34_g.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644794g79f34_g.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-/6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:2\^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@/&1C
M.G1I=&QE/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CYG-SEF,S1?9SPO<F1F.FQI/@H@("`@/"]R9&8Z06QT/@H@
M("`\+V1C.G1I=&QE/@H@("`\>&UP4FEG:'1S.E5S86=E5&5R;7,^"B`@("`\
M<F1F.D%L=#X*("`@("`\<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B+SX*
M("`@(#PO<F1F.D%L=#X*("`@/"]X;7!2:6=H=',Z57-A9V5497)M<SX*("`@
M/$EP=&,T>&UP0V]R93I#<F5A=&]R0V]N=&%C=$EN9F\*("`@($EP=&,T>&UP
M0V]R93I#:4%D<D5X=&%D<CTB(@H@("`@27!T8S1X;7!#;W)E.D-I061R0VET
M>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R4F5G:6]N/2(B"B`@("!)<'1C
M-'AM<$-O<F4Z0VE!9')08V]D93TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R
M0W1R>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I5&5L5V]R:STB(@H@("`@27!T
M8S1X;7!#;W)E.D-I16UA:6Q7;W)K/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE5
M<FQ7;W)K/2(B+SX*("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T
M(&5N9#TB=R(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#
M`P,#`P,!`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`.P!.P,!$0`"$0$#$0'_
MQ`")``$``@,!`0$!`0``````````!P@&"0H%!`,"`0$!````````````````
M`````!````8#``$#`P`%!P@'"`,``@,$!08'``$("1$2$R$4%3$B%A<Y02.U
M&'BX>5$R)#2VMS@989%STR4U=G%3E%4F5M>8=Z@*$0$`````````````````
M````_]H`#`,!``(1`Q$`/P#OXP-.DF[WNB&T-VTPN;/!E_8=#=3ZY:I>+EM3
MDACD]>.CI)"S.*)<YQT3VH<%#2[PRW6<Q_TF7`"<>P/`RA)P@]I86J0=MQQD
MMY@HJRZKO*!2&3-=J[KRQIA"8LRU]=#G1;3IXL;4'2-,_DDRCNU+$2<[M)<C
M:V8MS;2QF)33M`_6"&:W\BD7Z',XWFM<,MT5-6/2UO&Q:`JK:I%G*_K!1A7S
M7:URD*HJI+L\F0UG'&DV$"-$]N#2>8X*4`4J1&<A<"G0`>/?OD06-E/];,$8
MK*[>>K^KSB/HKJ.E%UW0B#$MDM8ZF8%3:.9LK:SS*=EIS8E,W=E,6,4G2-+F
M),O(&-$,H1OQA"%V>49_!QA?SI"HO;U'=20+BUJZ@KARNBKXRTMMC1-0I98T
MYVA"6#;M*$(VMGESF20O9I`B:'A!IS1#.;BRE!0MA=.>^1:DZ[LV3P%VC-GN
M<6KJTJQH^VKS9&.,J*;JJW;?U$PP>#RMQ6S!!-EJD\^?,!3DN9F)U:6(YZ2`
M<E:40C=%!?O`8#`8#`8#`8#`8&OA[Z^=J>ZMZ=JJ^#XZS5%".4F+L.FI0VMB
MQ&Z'5Q`1R*+=,LTE6J7-0C>76OI$A8G0D:<E+[&^3D%#"+97R"",:G\@$[B%
M0\XR#KJB[7C+_<1=*I9M;$-@K$WT36DWZ=?6XNI:X=`OMBCLUQ4QTZ:,D:?7
MAM8W%J2/@A"4GI0",`0'S6EY+88NB72(JX9+N@2'FVX&*E9YT"^T<RS.JD=G
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MVAVEIAR$P0R]MQ>A!`-7>)=?`KYB-R/-U0V4&P*5=62%!)/W$ID=_P!F$=1M
M,S;3$]\WPNL1Y<Y\952>6%HF(M$V,[?^-;R2AI=#"4,@)[8.%FF"U?XUZ[<+
MF$F#P.>Q-#;(1L*%G5VNYAY>LCF-"2A+4OYY40>%9MA_F$H2Q.@]'HPIM`'[
M_E"%2*W\,"J(QZ?,3_><#7+9;PQT/P\.9P[GA+#[#FZ.^#XBH4W_`'[-U]G2
MI^N2Z4QL6^1P.--;F]8<I-,()1[,-]X9_,?%C9=P0FUH[>?5B&9R%^XY6<1U
M#)XO2"2$$06LWJ51282V;3E@U8K\GG]GS%T@#`6K-0'1UF3D-6M)D!(E!N\#
M-W3QI1EFZ?L6^V,?*SI&[INJ$75,D5\<E16W;@BT\9FB%1EX;Z8NQ?/8RIB;
M7-"80B4)4[BU/1C$\G*%:'>]'!3EAMBP&`P&`P&`P&`P&!KE[LX;AO<CO2R$
MZW3JV>ZKE+RDL)`PH6Q]<[5YSL(AF(NWGY]2'.S<J8H]:A<:9?G<@A/&CV@#
ML!!FQ_0(7Z`\5Z^].AY?<BJX(.0QRVW.7[?1%S&B$5A6_6)O,SY7[REJJEK9
M<Y^W(ZQJ*PUL%VN=D2!B_(B<W1<;M684H$4$))F/CZ:UG,_45).ES`96N^^M
MGKKAQG"Z*I"DL%(57[`[Y41`]$HDJ=*XHD0()MN&YF*DOZBC:C9.OC^,01F3
MXLERKJEEZ.<+E@[ZA8.O7CKIF<G2BT;QT`NU(83)X<31CIT*X6"J4ET?"$<F
M%N.-;8R-X$B<@@E1]S\6S#0^VA/&=955KN;XI/>H&^S:)Y3MNV+^JB!(Z52P
MF9J;5LXBUT#8&:3]-83X@>X-6:.Y7LUG1)V5$XJ%9Q(EZ]26G"6,(C.\0<9K
M>+\_NJ6PN:)@^TMR7`>0IB\=><J1>[ZYD,5KR12"00JP8G''&RX6NK6=-SO-
MG8D\O3RX-SLD6$D*"?>E)-P-V<19$L9B<8C:$#06BC\=961&7'V=''F$M*U-
MJ9`G`R,#<(;>QM`24^M)D9`MDIB?:6#>PAU@9#@,!@,!@,!@,!@,!@,!@,!@
M,!@<8_""UZYY:^+>@3J3JZJEC3P#W9:U62BG')S=I?Y`YU!F];*G"F>D=HH5
M!S6"51%A:RY8S(S!3(UQ-)5&HW--M`K3*`OH@[6\BE?\JV5TW)Q'2&"/W#S/
M=D1GMK,_*:)E8^@I5*ZX;XZVT3%N>+@E;],*;?(I8:Y0WES<P"LAS96\E<\:
M`XJ-)P]9#>'2+U%XU-[(FIMWT](/*)P;57.+WT)1%%,4Y#"7.00XFS9L*(1"
M+-A47FJ2PWUQ1QU\.2MSHC3M9"Q&03[]*U89M`>S.H7M+SATVLNV..D:Z!\A
MTMX]=^+@U["4Z>!01%;MG5#[FV9I$P;=-NVK6>OP3&3&+UQK.8@"O*`V)"`I
MU(0_3C_JGLB7OO`MH6O>L=GT'[)M_K>EY)4**HH?$&>$MU,L]_2:N)G&)>T"
M,F"^:;+H[21["L4F,ZXATWM,A1&IM''A/OEBK:`NC=Q];,A"L43*`][\,-4,
M&MEC^GCS`5).I*X22)Y1PT+P1$E$D7M`AH]NIZ(Y>G0#-().**./"8&W4(@C
M"$8!!&`8=""(.]""((M>H1!%KUT((M;]=;U^G`_K`8#`8#`8#`8#`Y()!"#O
MZW=G66]U;5<'@9'G:@,;?>YH^XJ%/3=9.J>O>?S(?3REH##V4MJI&[I:M1P9
MQ=#9:XHDA4I.^Y83`C"H`%^N9>L^];QM..VR5%9-^XE;U)TS4%KPB2D\M1ZI
M:LJ2GG^W(''U\7?&RREW6+C?#%**Z:U3\C=V(:!<E=5WVS8C3ITBLP*8Q/LK
ML*_.1>HK\E4^+L>GFGQ?7C;=D5U:%!4.33C7TR_LCBY0ZMX0U'-+A+;;HQJ@
M12M0HV\FN)"O04P'!8:<L4-R(+4WCU_TVT1COVVJ\ON$4\R^.>'TL=$N?5%9
M01U9KY5OG/U=7@IW8SH]$'31D8K@=YJ;"8:3$5;()(M;A&^Y>?O:0L/NMWK#
MLQFEW9UP1VZ6*,5ER)V#QY43)S\LJ6'.`)Q"[VB?(JVSH]8M@K?EEJ)S:CK\
M7F,:AF$VGH5Z??W@G!,,M,0&Q'OUQY/8:ICS_P!35##>@1IY>4R4714IC;!.
M72W+OE30YL<6@D$@TK"HC;Y+WM*I4@"K6D[2,B#2IQ4G)4B90I+#W/'A2$JY
MOXMY^I2</[;(99!8:>E?!L;TJD4=CBMX?WF2!KR+/BTXY6Z1&KD[R"-M!QFP
MB&V-1&]@!_F!"Y^`P&`P&`P&`P&`P&`P&`P&`P&!KX>ND?%O5BV&UL^WEQ#!
M7"@)`L5P.$K+%I=C5TW*0-K[&G`R-,6W8@Z!OP6F0N2%1H@M*H^!:H)'KVFC
M#L*8VH/PCS:H;FJVM^CN#>>%]W(6='+9Y3LRYO87]>4QS9EL%.SOJ$TPYFE4
M'?)"QE@?(^N),;'I`H4ISR_0\0]!@5,NO"]-'VDYTS<W/'=O5]\R6HEE:TQ1
MD*J=IKI%:%,Z?04U+4]8TFFDC/5*>)O<H4.LHL1Y5F+$;<E`/2H!:%$DP+-U
MOT9XO(S8BR[+:0<H\I=K>Q2TW*3;+97]1W>P3@Q$6T3$DJ1S%#'9#+V)V^#9
M:21H#E**0-&TYQ:@T@P&M!*;-V+XEXXE@Z%@Z4X29459/,@D5<I&JTJ40)X(
M_2Q-($<H>HB2F>"RX\Z2%)*W0I:>DT4:I`X*0F;%HXSW!^,NLKQ&]GS*'1R=
MS_@CIB?$;.8X"QRN54;9\IT8[*4YQK1$6YV7NSF8H<%B8H?P(P;,,,+"+0=[
M#K>@V*L3&S1AD9XU'&IO8H]'FIO8V%D:4A"!J9F9I2$H&MJ;$"8!:9$WMZ%.
M`DDDL(0%E@T$.M:UK6!ZN`P*F]!]+$4Y8-0U^D_9TD<K067;-KRF5J%)$<JG
MFBBH\C>+8LET,1'E'!7:>Y(P,K:$ST(T>ZF*C/D*1&E&!C+_`.07FR*P:+6!
M)%]ILK/,FV7R9A:EE"79N9GU]`6UH>II;"B")X$?+T-21IED+>I5R0Y&!I+"
MN(*^;[@P).P\%[\F/'3!(FN+K+"E"IV=5-8-9.F:H;>?D261W=`$UF4U#7%R
M98.N0()W:D35EF,3&88%U<%(PI2R-J!!+V'VNGDAY%9H7#)\OL)]+CTR9ULD
M'LJM+*4NL$C+3/SJI>Y+;3&FBAKO5#$RV:F.85"A_)0`_*)E!)?R;3G[+"].
M`P&!4Z[WKB&F8K(F7HIYYGJZ'7++A323,]O.=;0]DM"=-AD;4"E+DW2P]O33
M&4MIT::#-K!`4*B!(4H_>'9)6PA4=RN_PN+K`DMPH[VX&CEURIN>T+A=L6LJ
MBV*W$ZJ0,"F,.$A;)\C<@OR&5;8U0DX7()OW>B=:+V/9>O9@4:YSKGQ-T9)(
MP^3/R$<9VW'J]H6;\YQZ&I/ZK%=)IO65@)(RVRTOH0V!*?R71,E=F>()2=B<
MP$MXU!ZM5^/$K5;."%IE5]<2S2YF._>G.:ZB@54!*9T'&79=S5$D;`R0B`'C
MT\EO\JF453'4T@(D9^G&NAO!R$E_:@'N+=L`M:T,+"N/8OB7=T\U1NO2O"3B
MELB31^:6"F6VE2BHB;R^)E1DB+RB5E'/(P/[_'286S@1*U6C3TP6M+HL0=$%
M>T/$N+J'P[]$-[$T7U?7C]N9LC#DH=HT@M&Q**G"./NJU$8VJW)F)DKHXE-:
MU4WG"(,-)T`8R1;`+>P[WK`NKSVT\],M31E'RRCJ-%1XOR:R'E47J):K(S:]
MT6*WA3'A0?8HT9M4\G'F*!I][]RD0]CW[_=@33@,!@,!@,!@,!@,!@,!@,!@
M,#";*AQUAU]-8&1)'R'#F<8>HN.4QD_221L)#Z@/;53FP+=_5O>DJ92,252'
M]=.?[3`_K!U@?!7M0U94T/8:_K.O(=!H5&6Y*TL4:C,?;&IJ;D",K1)!129*
MG!H8_;KU&8/W&FCWL8Q"&(0MAFGX=I_^5MW_`,$F_P"ZP/I(1I$ON^U2IDWO
M]/?\!!1/N]/T>[XPA]WIZ_RX$.WE?'/G/,4#/.B[:JBG(<$T:4B36U,8O#&@
M]5H&C!HD"V3KD)2U;L'H+X"-C-WKZ^W`C7G[L;B7JTU<EYKZ+YYO)P;"AJ')
MHK*P81+7UN2EB"`:M<PM+@H>$B/0QZU\QA`2][WZ:%@3%:-)U/=,&D5;V?`(
MM,8;*&U4UNK.\,R!2#XU)>P`6(#AD;4-;N@-]IZ1:G$4J1J2RSB3`&@`+097
M"8^LB<-B<6<9$[2]?&HTQL"V5OXP&OTG5,[8E;CY`]FE_P`V:\/)B?:A4,.M
M!&>8+>M:UOTP,GP&!2:SN>+"F?3;O:L=D+#'6)]Y#DU$IWYV8VR:&QJ5+K7C
MLQ]#X"^E`9Y/&9<P`/(<BC5!.A!;RB_4.Q@,`%57/Q*(/W?)*]AO3%BUNWN]
M(7GS[8)D/AT-*3+*SO6SSK6>(G4K4Y@<4='1>-.JLUF:VYL^Z)21GX416RST
MR=:6%F(OQ779$S99XWSE<]I6'K&3]/&,R=$P&LJF8(*(7\QPF#'G(@;.(8*=
MB2=.%`6$>E('!L+^78?:(&!$5=^+Z"5C8U06"SS%AE:FO*TK2N9/JTZ5KNQG
M^3&UK8-D6>5,X7+'DHMRJ.63"86L[J7DYM`I*/'M.:0!.H(^88;2,!@,""X_
MSU7;3;]BWJZM""5V=/M1YH32J1-J%Q=85`HNR(4#37,-6*2SCF.)_G].+VH)
M(V5]VZNR@T[W^TKV!Z5L6Q0-#1T,NO"QZCIV*C.$G*D=H2R'P)D.4@!H8DJ=
MSE"]K1J%7LWK?Q`&(>_77T^N!YU-7KS9T(UJ)#0%NTK<[2VF%:7.M3SB%3U,
MUG&;%L@#@HBCDZ:;CQ[!O80G;+'OT^FL"<1@`8`19@`F`&'81@&'0@"#O7IL
M(@BUO0@[U_)O`^#\.T__`"MN_P#@DW_=8'^;9F<6MA$U-H@BUL(@[0I=Z$'>
MO3>MZV5Z;UO6_K@1'7%!P.I+`M&;UTWIHBWV\.-/,O@[`A2M4243]B+=D#G9
M*9J1!)2))=,6)2WHG<\LL&UP&9(8;[C@C&,)NP&`P&`P&`P&`P&`P&`P&`P&
M`P&`P,6G4Q9*[A,QL"2G#31R#1:0S%_4%@T,PADC+2K>G4XL&Q!T,92%$8+6
MO77KO7Z<#APJ1E5]UO2;R(]@-3?:=LWB!5+J9A$S3E22ON9*)=5R@^M*VK&'
MNP53"UNYD9^W6O3OL@3@Y."@8QF:W[MB#/[?Y%K&PQ-TS@"))0?0L(."^4[T
M74#<C@MDUM,4'\\SN(':-$-QC]'A*@!+<&M;H]*L1B,+V'6Q:W@=#WB9\@CG
MVW2LAB-SH6R&]G<TO".L.J:\1!`E2&28"39L:MV&)=>W2BL[C9B/RK4<5KXB
M#MJ4GU^VT(8;6\!@>0_N"QI8GIU;FM0^.#:T.3@A9$@P%JGA8C1G*4K6F,,U
ML!:AP/+"2`0M>FA#UO>!SAU[T!W59<;>7:NKAZ!5RVP:#YF:I$MG'/B5CKNH
M.M.J^D8M#Y@WU*R/E6QY[61GDJL8Y(`/:9R6.S:GUHHU>HVM&H'@2`^"OV16
MY0L,M2[^M&:NHCV/W:]0FP&R-LB.:2F+TK5#=!Z_C$M7L%-;BCCN1SF03%VB
M@UC:E0.#&CV$K[DPE&>6$,M=V=5Q.,4)5KY9EYT9:4K3\#,D#:HC1$-9(I9E
MC]C6'J;=76?=#JHIL4,"?`V>0.3,8C1G,S@FD3:J7'$G+7$@982DU7OW[8<=
MZ5LA@LU\AMF%#L>H8SSJ77\BDRJJY;:O1K%27-\N6,;Y1L,:H\?3$3^>1/:@
MJ22XB6$+#5Y@D342FT`-IW%QMP`%TVRVC.;'L-BB'2\@A]32>UF"/LDL<X8R
M5I5O[3+B#(O$X4S.<356^JDVV<PE#L!2$("0'FE%E^T+LX#`J+W-V75O!/-,
M_P"D;6VK<6^+DI&B'0AF$`4KM2S)&;MM@570M)L)IBV3S-]&!.5H!9FDY&C5
M)@?A(-%H.1Z,4"_]!3!9U=Y!&YFO/J>PC#GK<;FI89=5O-48<#S%;%2=+PEY
MVMC+$VQ!O.`0X..DXUSFX!..-.'L6QC#^;%Y<0P=TUT3QB%MYAZ^K1&KD-<V
M+5;:EB+/-%342)>*L[@B#&6BC5AUU-0)]H%J1>F,$7H[1@!:V'TV'7)P5U0W
M]M\;\Z]5-[-J-CNFM&64/<:"(9A<:EY`CV2<1M.::,PT]*P3)J7HRC!BV,PH
MD(A?7>\"W.`P&!^19Y!PC@%'%&C3F:)4`+,`,1!VRRSM%'!#O>RC-E&A%[1>
MF_:+6_T;U@?K@,!@,!@,!@,!@,!@,!@,!@,!@/7^3^7>!AECP=ILZO)Y6S_L
MT+%84,E$'>A$;UH_33+&-<PN6R=[]-:-TC7C]O\`TX'$YR.FF%)M\KX*NM'M
MBZ#XE,05?(41H!DI;"J0K9P*7O"'"-"7MRAT\A@4NA&`UO:1>480=[#/0.!<
M;`K)93Q:G*]TP7R(<U,ZU_M*F&8V,7O5#4;]OKIOEH]66Y32NU!80[+4SN#Z
M)V^1128$8B5R;9/H(`]%[#L)Y]OJK>H:5K3H.E).EF-6VU%&V8PU_2^@=J6U
MQ+W\B1>F]PC&YZ9UI9J->D,]#D:U.:09K1A8M:"8L"CKKY!J!9F&S9@K36:=
M!JQMMIH<^9M-=/D@:)Q<+C;9-&*Z\K9`PZ<I-+9,PVB;^,6)RV\O?ZHE!'SI
MO0[88/)O*5RS#X&EF\A.L=N6%&6V.6UX=!50+*K=JH:6)H1;S_/8R-:$MK9X
M=)G!*D").H5GO)RLHMI*7FBV#09/8_>=<,C!=ZB$H9>N_=.D>8V"UWBM)NX4
M,9<:9ZCL-1UD=*6!/MU>Y"@G$P;V]>E;R=^BH*M&4?M<C5$$!0I'T_6CYVW-
MK&L.IH1`&VN+BLJJXU;]D538AA*Q!RS1[W*>C;;06.AGKO!&%ZC[<C>65E^:
M,I3BV5"8(QX-&O+;@!<JP?(?%(K#V2P"(!:,<:"HI>UK/$-LVIYK$[#F5047
M3A-D/<IKEN/"6@2%JW"5QTK1KP,C90%"I(:G*<2]$!#-(1WY53[&&55.8M8M
M5V*L3\P)7JI)1&%ATO:I5U@^.48K2.-OVH`DR0&GY@=/O%9`0%I$#8H5GA)*
M+'H`2QR[<C]=<+L%[DB-L3.4'Z)Z2ILI0S$*$S:ZM%/7;-Z^CSH44J5+3-+3
MV!A3`7;T9LL3@6?L`0`V$`0L(YN;:RMK@\O+@B:6AI0JW-U=7-40A;FQM0$&
M*ES@X+E1A29&B1I2A&&FF""666'8A;UK6]X'&-:/0#CY3>L$O52S2L/%_-3W
M(HIPM#UQ2@A%:<U)-/8IWV&^MBD)?SE.!A!K7"-'`UM,V@&L"$LXXS8PG?`@
M/I2["*)JY?(T+.XR^Q)4XH*YI2MF$@2V46C<TU&)G@$'CC<5H1ZM4O>3P&J!
M!U[4Z,HTP6]:#KU#I=\8O+4AXLX%Y<YEF*Y*XSBL:Q1$S]4A,+/;]V'*G)SG
M$^3MJ@H0BU38AF$F6D)C0[]#""P"U^G`O?@,!@:W>H8XV4ETSR=TU`2CHW)K
M6O:,\OWZD9AC1L]NUW94)F:*"+IRV$>U$\RVKK'8F,YC>#@;<$+8<N0`.^U5
MC*P-D6`P&`P&`P&`P&`P&`P&`P&`P-07E,ZWO.MG3GKC+CYU9(SU?V6\S1,T
M6E(FDF1,O.M&5BU(7:X[V51L_P!R:02%D2O")OCR%2':14[K0[-]P"=EC#7P
M5X<^1'TD;S<DBZ?Z"N!?H*I^Z"L_JB]"[8<7P7H,YZ:%,2F\>CD.UI3^NG1M
MR`M*E#H(`Z%H/KL)'YQZ,NOQL])UKRSU1=LXOKA_I=W)@_*O3%T.!3W:5!7H
M+0A,_--\6)\28<SBUB(@[U#9(XATM^^*V@4C$'>ADA.?F8X/G%Q1J']N\J,`
M5W:/)S4ZJ&R+I/:1KI2@E1@G.RN<W_V:"):XN"<!CG%31;$)&_%_&7K7W@QA
M#573-OP>^ZPA]N5TO,7Q.9MFER0"HO9#HSN!!@TCU&7]$+T-;9'&G8DU$N3#
MT$92@D7T]-AWL)0"(0!!$'>]"#O0@[U^G6];]=;_`.O`PW@KH\/C!ZR*IZ7+
M@MG`/<5CZ_9%:K/^".\I=@2LWT$TC,,WI)'ZAZ)4AU\?NV6E;)($._4HH\X8
M@[`,#4;/_&K*G6PH[,XC?$M1RB8=#5[=MUVR8P5"P2D`*#K2X&NDRH_7\>J5
M/5\ODQE@6$@,D+L]MQCBYM;<27M1K2)O*("48[XT:NAUB5=:<7L&;`G$&;79
M#,9'+8Q3UBN]KKY)<$@O652Y]73BM'LR&SF2V-+G8]2Y1C3-L")<%*2646C;
M_M`]95PT5&H-/XHQ6;9\]@RB\"^F(#1$@=*YC<1;K%0=!&=6'PXZ>HZQ7SA7
M#Y?<P0Z4&O"AX.0-1FR"=;]NA8&"1[QNL$]HMBAG1<F<U5@O$`[$:+#45LZ%
M)F%--.Y9^38EJR6-N;TP?DW!YA!X!-#"N5)RB#4`SMJ4(@G_``EA)MA<&-=R
M15^:+DOJX[!E4AYXN7G%5/3DU7QET11B\)%")#+7MJ8(E7C-$4;T1NNFE&0$
M2$Q*:A),+4EJ-G#%@8:X<=V$X]5/G5CTY,<TE-2<YP^JN>H])'O\1';*N*-M
M%D+-7U=31$HBUL\7>VA3:KQ'&8EI2K2VQI=G9645HU2D3I`MAS!2)7.E$U[4
M8GLV4O,>;W%SFLP/*V0?-;*F;XZ3>SYL:GWL>TFYA84C<W+1&Q"^`*G1>A;T
M#6\#0'YDNKWGIVT5'BEH.2K&Z&IVMEEWD6M.-*C"%$4K!VV!?%N78^\IQZVE
MG]V$EA.>]%B^1OC/J$7K]V:6$(39&1FC+*SQN.-2%CCT>:T#(PLC8G`E;FAG
M:TI2)M;4*8O6@$I420D!8`Z_0$/U]=_7`_1V=FI@:G1^?7)$S,;&VKGAZ>')
M0!(W-+2V)C5KBY+U1N]%IT:)(2,PP>]^@0AWO`EGPZ<JNG65MH_*I>D=5(JS
MCJ5^B/CEJ^2(C2#FV&.'O:Y?UM(&=4'02)A;118TD9^0/R(([K9P=>JD@W07
M%\@G:UY3&_F?QN\#2]LA=\*HPDL3J[IE2P(IDU<<TH[Z^*/$M#"X;$QO?05L
MF"V&-MJ[0BD2$(G`\K98BC2PJ1_RG:G,_P#J59U;Y&UEV[]%1G0V^W[C360)
M[UZ#_+%,Z9S!6R=-I1KWA;@LFT00>A?LV'7K@6X\=G5?1L*Z2G/C<[6G:2Y+
M%8JP#>_*W3P6)NBCQT-0B%^3Q&5,EF1YIT4R(;LJ20K4B=S.;P`3NZ%46L^,
M`PC,.#>!@4![]_U/CC^W]S!_3KY@??TM<UDT7T_Q,X"?R@<XWE-I[S1:#">U
MM1NFFWYS%@3/G2;D/7V7YU"4L?Z]=HH:1I1I$H529%L1>S0%BP*6)_)':M=U
M)<'5TJBD6LFCIG>701M$)'ZZ:5H-(Q<_\[:;:W;T\..G9B.0VO8]W2B$2:6,
MZ06OM1H%J8D:]$7M.`P+(M?D(56C<1-0TW0MC2>*_P!7*F.F9O>"B2P>),M:
MU7?\=L9SA"H$<D!CD]2.Q"%$#'_X,2E,(^,1AIIX=$A*4!`CEY3$M#<D\HWW
M,H4]V#6UD<TTS<,LL*S;QYZ@5Y/+?,FQC_.#CM0-8(R5;5E1]"X@=7I&PH&)
MJ.^?1+7LX_>D@`QM5Y`;<YZZ!\D#O8-663;?,M"=,T4T2>QD4RA2!LY^K:?\
MV\W'N94-@SBH+E4Z2QV6RU;)I"F("F^U0.`STQJQ1L2,`?JV>1L7/+YU&T6G
M($D\ETK\EUIT!S['K(M*%4_`XE#8;S32UIO)$@M&<B3L$*@$43JG%3K6B7)R
M6.CJ2F2I3S%'\V%UJ\[-:.B^&+,ZCJ(C]FWF-PCH!$%N5ND9F2*-6A28YI&'
MI.BDL<6N\*G4:3RZ)C/;G5`H/;W9M&2>'VA-$6`-4/'7DZG;,QS&W[COZP^@
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M:H_,50HM&JX8YOD<^=0Y?,G3?`MTA5F`3B#%ZH\K_P"VT7C<_GO)URUA"+1X
MQL;MFB#RWZ#V',K6@=01Z$2*P(87!H<Y*'",V`:AL1I/CZ,\X\#TE5:V,:)2
M$:0(7<Y&Z'6]14VTW";%8E&&J1JA&1H<%N*%WC&'UA,;VY:G<TDU@Y:=M+<4
MJM8<@7H#20&HUR,T.A'%;+.&%G<!@,#GO\HJ@OF_R+>/SMB=^J2@Y)7]U\,V
M1.%!8OP=13:Z'N$3:EY3)UN];)9(U,95#E#"I7F;`0F./(T:/6C`X%XAA$`0
M@#UL(@[V$6M_IUO6_3>L"&N@Z#K#J&F+`H2XV+4@KRR&,UF>4Y0_MW1K5`&!
M6R2F-N&M?,SRR*/!!+@V+"MZ,3JR`"]=A]P=AX'BKZ]L\$@FGC;[-D@7?KWF
M>/(7:O[.7ZVD)["Y;&H_$P.^V+9N_P#2YJQ`+*9YLDT(9R9Y+TH%L7W)GQAK
M)\D'-VO&KU*LZM@R#3=PEV;/T*'H5E0E""R<R]5R<XI`QW0G3EZ^)EK"]UNP
M(I`(.@IT,@V6I%L(511>![.]>F_TZW_DV'>A!WK?UUL(@[V$0=Z^NMZWO6]8
M$>VO5L(NVMYE4]D,X'R$SMD4L3Z@WOXU`"CO:8E<FU3K^<0/+.N++5HE(/09
M"HD`];^F!LD\+_<DVF"&5>//JV4;>.KN7H\W+(-/G7>R5'4G,`C@M,#N1"89
MO>G"9Q8(2F28%:V(XMR+*5#V+:HS8`WVX#`8#`8#`U:^5OR!G\,48SM=6M:&
M<]?=$/*FJ^3ZN4>TXEWGJE($QUL*5D:W[TM95(TG_F'Q2+6BA!`0EV(`E01A
M#0%SM1Y%$0`YC<9(X6#94SD3Q9-WVT^B$=);<N&7J-N,TG3XJ-]3QZ6.!FRD
M1`M^U(A***#K7H+U"=\"`:_H1V\H_5I_'K08O3\@\_.4=F'?$Z;#%"<B=/&C
M2WJ"<>1YV2C*WM=*S$P'&8B*,T-"SEZ3[V`\X`1AT*^1OM=#P91L&@-&0AHF
M_4UXN"2B^*N>F@A.@0/DV`VDI$[XZMJ+1!;!3E.,.@.C\J"$I,E0)RTVAE#4
M%""%2^+.4DW*%5N31(I:KM:^[7E"^VNH+W>="'(;HN^3:^>1R)0:;K1R2+,@
MC-MT?;M>TEO:R0!``(S#?4+>X&O>MC@7_P"<*FR*[T%U9O']RA=Q_0<J1!V>
MUL-@]3KH2TUG3RQP)]Q&I5N+Q!9(3T0A>],FT#8PA&+TT'1Q@4![]_U/CC^W
M]S!_3KY@3AUGS3%NN:&F=$RN2RN#$28^,O4?L.`JD#?/ZXF\'E3+-X-/X.Y.
M:!T1-THBDJCZ16E-,(-!O9>P#"(`Q!V%2;-\6%5S%#33;!+/L6G$=0<N23C8
MC479JPE)KS1,L0QU*]I$>K'@DN20NP5AD8($9)&8E(X'`--`=\O\SL@)UI;B
M2O:0>I:]QV53)T/EW,7.W+*PAY-9AD)(;S<QV,PQ60)/LVE*;^TKZELE4)P$
M8(:78TY7Q%%Z]^A!3>4>&"J'R#--;L]]7-%(D=Q_2G%]@%H&BH7M^G=9<_)G
MPNO5R23RNN7UXKEV6*)$J&_%QT;<C>M?%[RBC2]';"6;3\8<4M2Q+\D3CT)>
M#-5G5EDUG8O1]`-0*V,K^R15/$JVB4<C25[<H&NL*$LC\AK!"5(?Q+NF/>D(
MQI1C+!H(M![<P\:U?OCQ)IW%+2L*`VXOZIFW6<-LE`V0"3'0>8V13L8HV=P<
M,2F,3>XE*JTE,%C(`*4+DE.6`5C"H(5DG$$#`%K4%**U'/[[14XL:23TZ50B
M:0F1V&L88'%9`M339&\(%BM#'X+%HW"&C;0C>-DHBB6[00ED%[/V>;LTTP*E
MS/Q<4%/XO6D.DC[/#6.$<5/G"$HT@7,S>XVA3"U%`C(NNE3B4S"-0S:M99`2
MGV/+V_24*!Q7K?4L9"@96!!O67!_0DQY;=:J16Y+NIE;K=7.\OD3$]QSFRG9
M9NM*FGI$IE2>#G-=7L-3RZSI,!.1M0">)E\96`3B"%*C,%H0@R'E+B>RE+!6
M&N@B'2"0[F/IB4VMRA5)A%![E[16LGYVE=*O\+O(^@H+%Z<=?RDGM*4O2(#`
MG^Z)3&HRUS@L-^?6@D&I_&-%*U5U2SN_0%VV54O-K%.H_P`L5!,`UV2P4<CG
M<(?JRVJ#(X]"&>:60YP>M9.X1^-G2%>N_%M:LS0PJ%.PJ@A)$3X*B,#CO+31
M"K4LN-/7(_*M@<JU=,49<(6ONF2?1VGH^.P'9(]Q)VCJR:Q_]S#<I1@$AVUB
M.4'Z/2&E[```9[RER:R<ND7`Y@G#[8T]OJS/WL6E+W2.PB#M[M+"HA&(*F.9
M(%6L>BT*CA8H_$4@EAQ*0:YS7B.5+%!QIFO8%M<!@,"(K\HJK>G*9LF@+KBJ
M&:U9;$4<X=-(VO#_`#:YJ<B]:T>E/UK9K>[-:L!:M"K*V$]&M(*/*$$PL(M!
MS\<AS:TN9KDDWBYZPDKC*+4J2-&R[DF\Y!KXC>M>2V\W:%C=52P6_@5732Y)
M8&>6(P"$<:224O#H90AG##9I@4:[@Y@F=VQ^O[BYYD*&NNV.6I"IL[E>S%6O
MC0&/_P!OHJ44W/A`V#;I4ET,I8FAY1F[V06(TI3Z:^,?N"\W+U_T)Y=^(Y:T
MV-7A!!4K;)9S_P!=\U30'OD51VJUI]LMD5C)DQ@0*TREK7#TM97,O18ST9B1
M<0(LWZ%ASAPN'V1Q9?LN\<=_/CG)7FOV0V:\DW"^ZV$[H?EL"H21FTL6"_FE
M=J4UZ!99&G#O9AA1)2P.MDCT8(+-X%;N@:ZLE8LKCH/F]X31+KGF.0GV#0TE
M4"V4W239A'P3.E9ML`B]KZZMY@"8UKR!B]A1QA9VO;L(A8'4IP-VO6W?W,\)
MZ&KM.L8%;D-=%;.KAZ$`,KJ"WXJ,#=8=72U-K0#"'B+/?N"68(!>EB$Q.J`'
M19X,"YN`P&`P(COJ\ZOYFIJR;^NF4HH75E3Q-TF4TDB\6OC0M+65[OA3$^NC
M%SJYJAEI420OU.6+#RB"@B,,"'8<>%?2"T.N+RFGD5Z/95\=GUKLFHES?4+P
M9L\7,_+.E8W"+1/X!?S*6R+*^4+W*E180C&>H`FU[2@;*"%F\"MM^6!9VWBM
M.;.:&M-*.NNG7M5"*395`!GM<);4Q/RSJ]YT$H!HT%?5$P[,<%!HP^U0J`40
M#0Q;$'`Z+:=K7ECPH^/9PU*):-IJVCXR\65=MM/Y8%$UM^TI`82JF<[>"PF;
M52&P;.EZ@M*VH`F&&B&:C;R-[`65K0:V>/:WMJ]K9F'DVZ_CRJ/7[>$<U%N>
M:7>!_<AX]Y./4B<XK7*8H>M%)K6LHLT#U,UI80&B/4!1:T`L!A.@V5X%%NWN
MG9Q3;17M'\X,""Q.W^J'M977+U<J]Z-;FQP+(T*7WG8@`!,VUU'2K.:)U=51
MNM%'G%%)M>[WF>T-G7C\X@@W!7/;54D?=UT[L*1O#E9%_P!U2'U-F=Z7G+Q`
M6SVRY2L-$8H$-S</YEO2[&(#>V$)TP=[^,0QA=_`H#W_`/JM_'IPOU2B>_N6
M?F,W]`%_<RAT0)_>+?TU\ZU644'_`"C,#K^7`_/K>>2<727CTY_CLD?HHVVW
M>D_L6?KX\Z*VE8^P?F^H9-89$&5*49A)IS)*;(7QO;DFV+XUK:E4)C0C).,`
M((CCGDNDDB7UA/"^;SDG*MY]%O\`RY3]Z&VRW'2UZL9+*9=7<,E,NIPB$#.B
M%1V59<+4M#6Z%/SF\$A4HU:MH3D'[V4'X>(V3WO:-0V]=_01$J*F=E]"7LC3
M:=;[D%LQ-&SUW>ULP-OC,!@:UACL5IYA@21F+80%-"?6Y$6VE.:OVGF^P`5>
M\>ODALZ.<U<@)^NJZEQ46M'F6Z+,C_33U:;?8\SGJKFYB'-K#<;#@:=G+=8P
MGD4%TH<F%6%X=U2PM"(E<F;CQE%B">N=?+>Q]!N#RRL]:5Y^=<>8))U37+?#
M>G*^GJ0F*QE;&TJ^`]$2,EA88SSE9B=/-&I8<0H5OK.!+M?['$TUN/*$'[U?
MY:H_-)4GB#[6\'5";.H:+YNG,_HOH!@OVG8Z#IJOI%(:1G;18+7"8@*0D/-D
M,R6%N[8>@;5+2[.J4X!BM.9H6PS:+>4J!+I0M/G5=N-?4FYQ3MF95C=RN5(G
MAJL=EX4G*6*V@H31TEE0J&74CCY;E(V+Y%9_WK*T*3OIZ:P+)K.EI:BX]B'3
MSI5T;@\FDU=UU/7BM;<N6-5?&*XU/2V%2L;[&N!^8S&A@(AB5[_\0.*:U1YA
MY`B$R8XT0`B"F<9\KRV=0"LW"N^?FRR;2L7LNPN(R8M`[\B3]5!=A02JIA;O
M[P6"\=19.CE50N$5C9!QJ\ID(=DP%)P`MJA6FTD/#)F'R53B<-M/P>`\NGO'
M4=D6UU!4LEII]N1ICU?UXKXZ?M1R[I4KNQ+!Y`.0Q@3LZ,A$=$FC0%3J:^I]
M*26\!2H9`8CSQ=5PS+Q%W_<\OD,[9+?01_R.N25P?I(2Z3JO72"W+T>V0^/E
M29H6KD0EM8HF!$V(#T2@U.44W%?;CV6$&\"-ZZ\@#A3\&DLBE_[S;3E<:Y?\
M4!06Z=65$&&KW"R.Q%<QKQJDZR3K(8)[K9(LE:8"V;2-Y7OA!B<"<2-$6>6(
ME8&'R7R!=*6]9G'#I65/IVR0(>]^I>7Y'4T(Z13.M57>&JN6[37+Y6_6L97$
M>0&59%9J0%R!LIC=W,I0S;T%!^1*VB`$JM_D7Z<LVX^%&&K^>8FS1^Z)EV%6
M'0L%F=L(BWV(V1RQ)7"!SAIB\M;X(XH7E@BSK'U;LVN)1!(I(E.*3&IVTSW#
M"&[/`8#`UQ^2[A+^NW3+&=7LG!5?5_/\EU<'(MXIRM?>5U;C0F]"FEY&``CE
M];6.A*_#25OWHPE4WG:,V48:G)U@4HXHZM_K4U<[JIA$CZIZ)IR5+JAZGHIS
M%L+S4-UQL.R7QM++,WLU;"Y2`O\`*1QQ#[B%[6>'8!C&49O07#P-6W1VIOX]
MNBA>4>AF!VD-;/+8QP[R6T=%THU2JR:79!:3,'3T18R?0M;<7/J<X0UVP:">
M[QK9Y0AZV689L,0[)K_HWSHS)!(^/$K/0O/?$BE]LGF;L&PH<K#+NK^E7"(%
M"9HM3@'`;:N8>1'!N6DI9)(S"S@20\104R<XI&/>@J[SK=PKP@BQP?XPNKJV
M8!)7BL;ZJ-Y"(F05-<<0.VWS"'NB8S?S:1Z6%[4MJC?J!6WG%F!$+];T">L"
M`8%?3MXN^KQ]CM!2]1R-?R^-PGON#-A:@]/"G'1Q;+`.PF)J3!-]'"&FK`M\
MP"47L:YE-^?>AGE`&`.SUG>&F0M#4_L#F@>V)\;4+PRO+4L3N#6[-+FF*6MS
MFVKTAAJ5<@7HSP&DG%B$6:6/0@[WK>MX'HX#`8'(#WUTB'R?]6'TI#UX'/Q_
M<26,$4Y<49_W$>ZQZ\B9NA$QTLTO>TD@I[GA;OW*/;LQ(Z23>_J:400,(9>(
M6Q"V(6_40M[WO?\`EWO?KO\`1],"-;AMJ#T364QMNQW,37#X2TF.;D82#YW!
MQ4"&!,UL#&B#ZFN4AD+F<4C0IB];&<I."'6O3UWH/8YZX$\D7/<48O,;#OBD
MG;$E:'5QM+Q^3`3*DBCAP\Z_AWR/<WPB6K4(W2O^D8BA:`2`QQ^<*)>_J#&Y
M61OXQ_<A)\=NQ1YQ[KKCH)1%9A$?&9R^],\HIZL;$:M,SSU+UPV(2C7:?V!'
M`J%J)36'-+FJ.:VE((P],YR0M0H]QA1?L*#<((0AB$,8MB&,6Q"$+?J(0A;]
M1"WO?UWO>]X$']'="UCRI2D]ORX'8UK@T`:PK%)"(O2E^DSVN.`@C,(B3;K?
MRO,PF3X>2@;4A>MB-4':WOT`$8@A^'BNXWL]H=YOY$.T&`I!VIU`Q-[>S5\H
M,$L1<B<UD*/RM?\`-\6^7W:22(19A;G,U@-`,7OH]EC^B;8C`W2X#`IOW['Z
M^>N4+1<K'LTVE6JOM1*VXY;Z5D-E"^MK)J>:1ZP*ME+;$DNMN$U6I[!CS:2%
MA2>BQ_">)M3[T<J!O`@XR!='=%M/CWZCE=7L=07_`$9<3Q(;'K-YD0])5%,V
MG"IU3EC&(=@3.*IC?W*-/C-,T3`N-,6-BE!IH5J!*@#/P,@A/C4JB$S6&.">
MT;L>J9J^[93T;4W+[X^0LZE*WN26.DGD"F2LIJ&"(+2=6:/2>9N;JQL3K)%[
M(S.2OYDZ4/P)`IPME0-&1'G.MB*M@ZY^<(^GFEISD"J2JT:YVV[6[:4RMN2$
M"4(&]L3[0))'-U9*,'P^\M&`H`QF#"(P85LB?CBY]BT#Y>K,X^;2F%\IUS;5
M50YEE#NTK")G#;I@Q]>3=OL;:%@;A/&U,<4F`)VBVW:`,>]BT/7ZN!CI/C@B
M[ES].N5["Z.Z2M.@934)5(QF!3!WJA.;7,+;CVHV-J667Q6I8[-)=)XJ0QI$
MB-=*5[[HY$5LI:4KV:>,T/F7>,JL91`NJ(C9-R7S8\CZ\9:K;['L]V>:[C4T
MBKS2*<T-3RVI$E?UM$897C]!'(*1Q;_MFHQ,6Y("5&RA&".V:$;]=^-F,V]S
MMQ)R;7#`$FKJ!O>DU,HD+C*?PTD:Z"K^*29FM-I.5(D05$U<[SC!YD4?46P$
MD+R9(J6G_P"KZ`,+Q].<UP_J2N&JOI6_2B(&Q>Q:WMN$2Z&#8-OD1L:I98VS
M6#2!.URUAE4,D"9N?&HO9S<[M;@WJBMB",GW>P8`@FOO'75,$=H7)55BW).Y
M=#^M9KVB?*9H_1(]SE-RV!2KW1DD"_)H_"8^SD0X47?SE"1L;DJ`")6`H)(P
MI2PIL#S'[QNUH>Y,DN@5MW?45HQB_.B+]C5JP5W@*J4-#CU2X&+[KK_\5-Z\
ME\(=:ZD8@I=ITJYI4K4"AM1*2505"?1@@EFL^,:PJSDV3\=,<AL9WK:6L=X,
M3Q)99)B)#9*DJ_Y).I3.'%1*E34$"]Z"ZV"N$F5*4QQGT+V=\P]#$,**=9^,
M,3K4+BV<^_G)?(W?^H5#IO%99/6:)N+_`$[PV_2MPCR*NY0=#'2-,-HR)+,#
MOO#WY"O8EX"MD[(1B&$\`2)R'Q79[875\KZ.=7IC!S9>\ZL3DBK4TGKR2.]:
MUS-Z"4TL[P:V)77U:0*'R_9KQ*I&]MQ#2B+$U%K$B<UR<-$CU@3%OQX5HW.-
M4R&$V?<E?2^H.A>A>A(W+(XZ05<Y+EW4LND\MNFNWQOE<!D<=6U_(C)2:E3Z
M`B*>&XA,G&G7@4`$<,+_`.`P&`P-!WE(YQGW/-I(O+1RC$G653>OXLAAO=-$
M1@G8E73?*[&+:@V7,[<4'85MX\])=&.;$?L.SUS26>@$/8`$DC"PU7V=`;JK
MB#V[5<F;YG7%D1IKE\+E#69[T;RPNY&CTI^@^OO3*B=^XE2G,]#4RDLPDS01
M@%K09P:42H*.3J2"%2922<F5)51):E*J2J"Q$J4JI,<$9*E*I(&(!A8PB`8`
M6PBUO6]ZP-;/(=DJ?%%U,R<<S=P4$>._KZ<N9_%TL=%)IS3RQT9)%"EZDG)+
MTX*1#"T5G9RXP]S@8S!A)3.)A[=K6Q&[&`/(\S'*#US;9@O*[0497N<<*9V:
M&^1*KHRE&H4S6H&CT21CI9B9TX=[5V'111F@.HBP[,7QCW>_T"C&(804Q/K+
M*&-FDT:=4+[')&U('U@>VP\"IN>&9U2E+6US0J"][`<E6I#@&`W_`)!?7TWZ
MZP/U=FEJ?VEU8'YM1/+$^MJYF>F=R3@5-SLT.:8U$XMJ],9K9:A&M2'#+,!O
MZ""+>!,'AOZH=>5;8(\4]YR)6MKUX0OTR\<UFR-68><]5^V[&YS'E)]>%(]Z
M432G"S1JH]HS?R+HWOX@[U]J26(.H#`8&@WS/=RS>*IHOX[N4)0)GZKZ:CBY
MPL.PFD7S*.6.8/G$TS>W5QA8O1!.9>$1S)#R=["<->8:K!L&TQ6QAKAJFKH1
M2=<0ZIZW9P,4)@K*F8V)!K?R*!E$^XQ4Y.2G>M#7O3PM,,5K5(_4:A4<,>_T
MX$@ZUZ[]/IK_`*=[T$.M?R[$(6]!"'6OKO>]^FM8&/\`CHYMUY,^I$?3TY;]
M./!/&-@JDM%LJXH1C%U)U?%3QI':V3TY@?@?*HH-<$25DV+0DSC(O>>'W@3&
MEX%[?)WT+.>JKAUXF.69@[14]YCK;+O(C?43/V4LH3G&0@WI%3$7=RO4M)>7
M1:/WHTY7NT:U1XPY8,.PG!&4%H*[KR#U'`895M9QELAE>5Y&VJ(0N*,Q.B&Q
MACK*F`D;T"8&M>XP02P>\TT>]FGG#&:8(1@Q"V&6J%"9&G4K%JI,A1(DRA:N
M7+3RDB)"B1DC4K%JU6>(LA*C1IBA&&FC$$!98=B%O6M;W@:W..:U4>5WI]B[
M8GK8J-\>W)LT<T_#D*=DYQ#9TW?L>4J6:3=B2)K4A`%SK^`K2CVR`$G%[`8K
M+/<M>T0/0T.EC`8#`H'Y!A:5Q7ER-*0A.9I9WER*WOJ(P(1D.")@M%%/D"14
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MYM5J68C[9$`U04$Q46'KHO*E+GF.<AO(Z=KJIR^AC+399K+KYM]]A].12T:;
MN(NDY'1,.M:-U;+6=YLR;2)"ZKXI^>)CB5X;6WVE^Y6:-.G"R',$F?F3M+R(
M40L>75XBC"_<[=#PHAV<U[J*+E="UY(H[,(HU&KSCQ(&'4YHQP>2$96PD)SG
ML[180AW[=!)74G2<PI^5T!350P"/6->G2\PF$;K]LG$P70*NXXQUQ!G2P;`G
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MA$'>O3>MZW]-ZWK`YAIS`_\`D_=:D1T@HUN\8W<EF*#H"M%Z@C?$W8<U4FJU
MT`4F>W2:.4+T0X:,4M.][+1LDB^0CT*(,T(T-I@P"`(0!AV$8!;`,(M>FPB#
MO>A!WK^3>MZP(1Z,Y[K#JJE9[0=Q,YCO!+!:?L5AB,S29\CCPC-`NC<UBCCK
M7RL\PASV02O;59>]#*4DZUOU`(81!Y'B\ZSGTO'8_C7[E<&^2]>\X18DH$L>
MT)(V+LKEAVV8P0CH%F1KRQI7AS6(/:SS=OV$W:1ZT(1OKI5L!8::[1H!?XL^
MLD_*:O[K?&/2SU(Y?PK+EIAYR*K9H::<^3_CUZ<E(A[(+;C5!CK"?E'O:EL,
M&D"(PXDS0`G?`@GHFD$][U\"/H)&X0"QXA(&>QZ3MAB&,B35)<,/4Z<X1.V%
M65Z'E"0.102UA(=^U4A,-*%K?KKT#?\`>*+O]5W-0[NWVFUHH1UWSL^)ZFZQ
MK--H))#18"5((UIL"+$_3:BMK<9D_P"98U`-?%H(STNA"$E&+83CY`^W*]\?
M_,TPO^<(5DH>BE+?"JCK!EW[I1<5S2X1J"O:QC!`=#,&OD+L'W*#@A'I$W$*
M50@B"1O6PY=N?:TL5H46+>_13ZFFO6_3$C*L7H&7I]_(WM2_[?1$4J"%;$(?
MX^MJB8=EM+8F+WHH6RAG?K;&'>@LA@5EF4/LCM6_HKXY*`?'*,O$\8R)KUQ<
M;'ZB.YXY>-5!2.Y:%8'6RDMKW-K8V:.)Q;T842<:L%K1(-F`#?/VET9"O%QR
MO2/*W&M;,#KT19"!!SOPASJVEA"VB>6IK*(7V+-M%_SZ2L*G:3!/TI=E&_54
M;Z%FF_.LV:$(=XQY2:N2:C/BBR3K;.N.Q)*YVMTG>CZ'8I5>-YRS>E<PG#RH
M,U\X&LE2/:-F1;WHMO:R2BPAT+9FQ!;7`U8WZEF/DBZ17>,:E7MW8J,@Z=AD
M_DWO"+JS4:F-5\[^UPC/'\)?DHM:1VE=J8C8W\PL6S6:-A-T(.S#1DB#I3@L
M&A]8PN)US7T;:(?!8+'6>)0^*L*,IO98[&V!`0V,S,UHB=:+3(6]`F`46'7Z
M`A^OKOZX&5X#`8%`>_?]3XX_M_<P?TZ^8$N]&<G07I!RK&5NLPM*K+,IISDZ
M^M;:I>7$P^?QE'.68E@G4<"I<FB1QUXB\R:TB72Y$X-RLO9Z%*H)^)2F).`&
M"._`-%/\7Z/BCXOLUZ3=5456W/5P/#U8#F]2AX@]60^7PB..*:2.Q2UU#,UC
M3.%YCBZJ#%)ZY6()QGZP=^H8S)O&[1DGMMXM=1+KL:B)'>M1=-R2KF&Q=M=4
M2&_*3)@2*%V4\QXIF&\KU^VJLV5,M;AN7X13I&!1]D%9H*D(9S"N%**@-@U_
M9C`7,M2:M+7ZFN6-;6R<Q4WZF783RM?;@VX(]HP:6-(ER\S\4GV(/X\'H'0C
M/3UV$;RCQH4E*:K:J(/L*_FNC0J;$%-ZB9[)3IX3;+;:%O/MV2MCL),KCBUT
M&A42^2+""SV96SN.FHW[,:H9.M:P,5=^,KNDD[Z=GJ2VD]5/_2/2W-KLY22N
M'N2));&^2N86V+&LU=QMX)1M@FV>6C(6U^`\"%\K>C:96K*`)0,D`30M5T5R
M]!.D2JZ7O\BL&O)]3\O4SFI[:J22E1*R(`_N4>=8C(-,[FM;'UD<624Q1\5-
MSHUNC>X-JY,;KY2-F%$F%A'-9\"T'5+_`$G+H[J=N$PI"47I/&Z72>9+9!)+
M`L+I!O*;[=GMJNBTC9\PDTC"2$10_P#1DZ'0"R4Q)28HD@L)TLZBX+;<NHV:
MRX+SM[YZLU9;5>[;',2!(&6KJXG=6G[?4VB3=.S9^R]BN/M(WL&M*?B,]W\W
M[=A5_H7QMT3TC-;.F4ME=U1,N\(57\%N^)5K8HXE$K:::G<7UTK11,$NFAP=
MP+8@HDBL``MJUO2N"<S1+B2L)UH&!YDU\8O/T]M"QK(?99>NFFY[;@=UW53B
M&TUZ>DK;F]7ML";H`.900;<=_P"#Q_=:M)QJ-N5-Y3P-.$MT^^3@*(+#8M@,
M!@,!@,!@,"%NBN?*GZLI"RN>+QBR6959;$77Q27,2G?QFC1K-!,2N36LT$1K
M6_L;B22M;EI7H<B7)RCR]Z&6'>!H*X[L&V*!MF7^,3KJ0KI'>='QO4JYPNM[
M!\'];[DI,IVUQ:>EJ!_S2JV:N++`RS)$`0S=&D`6Z]Y8S#A!LNP*)=P\RSZW
M6JN[YYH?$,"[BY3>EMA<R3Q5O1#;(#SR-`FE!V(8'8-N5476REC:W!.;O9:9
M284I#[?:9L0621:Y^\]'C27M4J9)!6KK)U;C'I*SJB@DVER1U]3KF8B7;0G#
MTG.23*II\G^9*<'9&G5G/#[]`(6C!@:+.?YI:X5MI<\=)M);%U1RM+$58W<6
MB),!'YKI:V_EZ^N2'G[+`6?%K=B'Q.Q(->AB<\9I8P@]`AP+'8'[>/56=$?-
MFS)F(7V2:Z?'78^[#3%:T`E_6U'>=?!@;JM!K]4]R8D,M7I"3MZ]X$R@1>M^
MWZ8$J>:=:?*/(SXR:\>!:51*(5=V'>#6T&:]R7=D,S?5\)C\B4$B]2S5L=9I
M*N^R'O6Q)S%1@@>FQ;W@1+@01T3<J^EH"D<8K$'&R;8GTLCU3T35C.4,QSLR
MYYXI&V0>)%"!Z!2MYJW0E*]0,00$(4YHO=K?I@;HN1J'JCPL<#7%T'U!-29!
M:SDUK^C.W+M3(]+7.<V6>C+3HH/"D^M%J5,9BIRU/%H:U!$6`T9@1!"4:L-U
M@5/XUJRW;<LV;^2CL5D,9^F>@X^3'Z?J9>;I:FX]Y1&IV[0BEV;8P``GL"8%
M&EO4U6E@+,4.1_VV]`"687@;)<"AO;_2UB5BFKCG+EUF0SGN;JYS<(3SG#U8
M=J6B$($96MSSHRRBRP&[;:LIAG,&O4&FA]BY>`I*#1GJ:'0;4>".)JZX)YWC
MM(PA>XRV1JW!RG=S6W(]_/-KNNJ7#`X6%:DS7C$:H4NLC=_7X"1&&!0H"B$H
M!;`3K>PNC@,!@,"@/?O^I\<?V_N8/Z=?,"_V`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P-:ODVX26=GU%&Y!4\C3UCV)S?(C+<Y#N?0-`%$;,0)M`60V4#``1KC5
MEKM9/X61H!>\DU*:`_99@TQ8=A4#B[JM)UC4ZY_?(FKJR\JNE+E4G3E%/(MA
MD5*7E%-_;2F*K23-_,HCKF8#\@PK_J4X-1Y8PC$,!OM"WA8!F#`66'8S!B"`
M`0Z]1"&+>M!#K7^7>]X%1?"6<3+;"\L-Q0LP)]'V=Y#)$363DC%ZL<G?Z[J2
MM8%<$PCP@;VG6-;U8C.I)VK*]2U*A&;O0M[#O`UO7/\`Q?/*9_V/$FO_`.NI
M>!G&!_7"!6E/FXJ;UW[/QWCBZ$5`]/K\HE=_TTD$`?K_`)H0!^NO3Z[W@2;Y
MAOXIWCS_`+*7:/\`3])8$88%=;4_XGO%I_B8<^?T3.,#<O\`_P"@Q.:3P(P2
M]V3'K*LK+K_C>RK[3%EB.3"I.*WY#U$P5NQ`="T>QM"DY&M6:%K8`ITPA"_5
M#O`LJ)4F7[TO1JDZY$X!`O1+DAH#TBY$M#I4D6I#RMB*/2+$QH3"AAWL(P"T
M+6]ZWK`@3IKH^L^2Z0G%]VRM5$Q2%HB`I69I*^[D\XECN>%NA]=PIK#H1SQ,
MIL^G%(4"8L(A;,,V8+6BBS!!#U?%?Q=9D)4SWO7LMI3@[HZL:FP#M%-F;6-?
M*U!(SM.5<\N0@1ON^T,8"1@72I47[1.D@&+9GOTF`88&Y3`8#`8#`U[]U*B7
MJ<<$U@W*"#I?,.VZ\F3<S!'H:\<0I.%V!9\]D7V^A:,`T,:!E3)E"C>OB+5.
M24K>]&*"M;#81@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@:B^P_%XZ6K=RCL3C
MF^W'C[K]QC;;$;!DI4.;K(I3HF*,(?2.,'0-1N"UH(DCC'`:^%KD"%8C>6]-
MOXO><6`D!05=6>./RK]")C:YZC[PH6G:1=B=MT](X9I>91.Z[#CRC7P.T<26
MK:\MD6JK3/:(0RCU30@4JPEC$``]:WZX&[>@J&J?F"FZ]H&C(:VP&J*MCJ6,
M0R*M?RC(;VY,(PXX]2J4F'+7-V=%QYJM<M4&&JEJP\T\X8S3!BV'*M<_\7SR
MF?\`8\2?W=2\#.,#]^"/XV];_P"&Q?7]XJFL"2/,-_%.\>?]E+M'^GZ2P(PP
M*ZVI_P`3WBT_Q,.?/Z)G&!V6SZ!0RTX1+JUL6--$R@4]CCS$)E$WY(6N99'&
M9`@/:WIF<TAGZAZ)P0*3"AA^F_:+Z;UOTW@:#6OQG>1_D0D-=<']4T%;',S9
MLPBMJ:[QBMDN<UI!@]XOL8/#[UJ9<9))K!V$H7Q-J5];A*424`"-*#-!]X@F
M"@?%C=$PO2N>H?)7T!#>AYS2+P;)^?>=J8@SA7W*M+S@9!B4JSS&F2N;S,;<
MM%M3&[`V.SX,DMHWO9B=-HWXS"@V=W#$[+;G9!<%,*U3O-8RUZ:I#4KL_#00
MRX(82L.<#H^0->:)HAEE-9BD\Y@?=!*),/,VA<]B0G!/0AG]66G$+BB"29PQ
M6K&C&K7-#PSNZ$]GE$0E#.?M'((;,H^LT%PCDMCC@$2=:B4!T849KUU[BQ`&
M()%P&`P&!$S=1U8-MOOU^`C7WUNR",)(29-7MV>WY>QPM(:D5#B$*2O+BN:X
M%&W1R0DK7%&RD("75>4!2LT>>`!@0EG`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8''O<_\7SRF?]CQ)_=U+P,XP/WX(_C;UO\`X;%]?WBJ:P)!\OHQ&>5[
M@8@>_4I/QSV*J)#Z:U[%!LTI),89ZZU[A>XGZ>F]^G\OZ<"-\"NMJ?\`$]XM
M/\3#GS^B9Q@=K6`P&`P*(]`V,]TUTUQ1&:];8JRH^KN@9U#+S7ZC:$;Y,&:!
M\I7).8L:8[E_"I*=FQYK]J*"J'\IOV"?[;7H7O6@AAEE=M,E*7ITE%7U19MB
MJH*T\21J"4S'H;7C6F<++ZOGEKUW`VF&V"YRAG4N+A-Y'&"M/)DF-:V>/I4)
M9R<\W9YX-!5.Q/)5:$IF')+C6-&WK'%IO?-Z\D7%S\`VC7V8V9(:SYAN:1*F
M=LDR&PGB$,L-CUE-#<O.>53VS>Q(V#/,]2!;*,"37#R?3>2S#BEMI_E*SY4V
M=#V]TC2]Q1=]=JCC]@5%87.#+82*;08DQYN-CBR]\C<N@*M8J7$'N+.X1Y(8
M)O4'+CTJ883_`-A73=3;<'+?)O/,AC-=V/TTJMZ3O]QRJ+ESPFK:BH:.QMUF
MSC%H*I<V=KDE@2>1SQ@:6S\@>-N0%*E2P].J^W`G,"M-IWAV/S#TKQ53S^]R
MKLIRLV#=LN+K%ZAKJK:?=[$#`2.?G2L'.>'SF?-D!B2V!IY$]D*G5([LS<XF
M+DY8&[:@996PF:6^3*(-/,E==;0VAKCL"GYE6[_:<F<"WBEJ_=ZW9(>%5^UL
M5>VFT+6ARB2V>T'-3B46QL/Y02LQM/T4?OW)_G#$Y;Y(Z]K.7WA,%2FY;7@C
M)'O'R.$UM":QA>EI:[MF4S2'5ZM@SDHDC3+)@Z3!U)1"=4+R!"6SA()TDV;\
MRGXPMYS-TZCZ)_>XPN=8SZE;/HBQB:SM2K;&.ASD]1]X=(7%;'B[JWR*O91,
MX3)(]*8/-6Y:F4HG$W98QFD'`+-)$'86AP&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P./*W#-J?+GY53Q:T`2=PXN;@A#]="`GYK;E&C=[W]?>/:O>MZ_1K0<#/
M<#]^"/XV];_X;%]?WBJ:P,_\O7\6/@S^QCV#_MU2>!'.!7BRPZ-ZN\51`_J4
M9Y):8-&']&]F(XA8:M,+W:_6U\:@H._37^=Z>F_I@=J^`P&`P*:]:\LRSHAX
MYZFM=7:LHJR.<+0?[-ALH+KZ/V8V."F3U9.ZE>&=YC$B<6I*:E-C\^4FE&@/
M`84H+!OTWKUU@:\.W/'I<$R@DREZ61RGHZ?W#)."6:_T,0B=1P]\60'D6=VO
M-7N:UW7-E/1E0RZ2RA;8Q&C(S(5?XDHM%]RGV:L*3DB"1N.^.+25-5&/%N,Y
M].Q7D;J:S+3YG@HX'3$.L"7UC8'/,HJQS!>T?H]T=:M8I>JL"U9*[E*V<\:U
M<C3HAN8`KCU>]!,:OQVJVD=92"M+\?8/8=5=A](]81^4N$`CLP:59'4KC:&[
M*K!VBJUQ;2E#<1'[24I&QU+5E*TJA(2I&6=K9A`PG/J;E,WH%VINR(-:DBHF
M_>>9+(Y%4-M1]A8YBE0(IS']Q2PX--8')M:99K`)VPA)"M1[.1+"5B%&K2*T
MYZ8(MAC$+Y#FZ>WZ#OFXNC)+<UF4C'^BH]M:?7L(@4>?$'0(JDT)K:H_%2@"
MC;%`R:F*TA*/4NJ]6:XJ!JEIGM*"$*52_P`+L:D$`K.`MM^KRDD(H"ZN<71;
M-Z9KVT0;A]US]UL!XFM9,LO..8JGN)O4NPVW]H"4[GI6U%EDFI?>42:6$X*O
M%]$5*A8HW;LJ!]X+QL"V#4=9A?'_`,N">K9W%]:&-5L8_P!ZAZS:9RV+UVW@
M#[R-C%OTP+E570;;5MM]-6PCDC@\+>EI_`YZZLRM"E3)(FH@E-0"G4[:V*B!
MB/<4[BB@1:XP9V@B`<I&6'6P!#O83_@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@<=UJ?Q;?*[_`.H>-O[L;%@2#@?7X_P?/YM85O>]A_'^-2Z#`ZUKU^7[_H^I
M2A:%Z_YOQ?;:WKT_3[O^C`SOR]?Q8^#/[&/8/^W5)X$<X%>K'_XL_%/_`(D-
M0_[#V1@=E<TG,-KB.+YA/Y0Q0R)M6TWY6329S2,K"U`5JB41![H[+S2$+<E$
MJ4`!LTXP!0-BU[A:U]<#(42U&Y(TCBW*TJ]O7I2%J!>B/*5(UJ-44`]*K2*B
M!F$*4JD@P(RS`"$`8!:WK>];P/IP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&!QW6I_%M\KO_J'C;^[&Q8$@X'W>/?^-I&_\,^V?[RE78&<
M>7K^+'P9_8Q[!_VZI/`CG`KU8_\`Q9^*?_$AJ'_8>R,#M1.))4DFIU!11Z<\
MHPD\@XL)I)Q)H=@-*-*'H0#"C`"WH0=ZWK>M^F\"@'CC2DQZIKFK9I*+10VH
M.Q.L*UKED(#L"**U\TW)(W:,0YI)V(6DC!$DCYMO;4P?0I(WIR""]!+*`$(;
M`\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@<=UJ?Q;?*[_
M`.H>-O[L;%@2#@?=X]_XVD;_`,,^V?[RE78&9>6[>Q^7'B<`M[$`GACJDXD.
M]^H2C3;1IXHTP&M_0(S"@Z"+>OKO6O3`C_`KU8__`!9^*?\`Q(:A_P!A[(P.
MU7`H+X__`/R'K'^WUUS_`+R3L#*^BNLWRJK1K;GJF:8>>ANB+.BTML=%!$<Q
M8JXB<*JF"N+"QR*R++L-_2.Q4;93I+*&]J:TR1M<W%T<#Q!*(T2G4GDA]3SV
MS3M/P"O)'V#)(5Q[.9X2]^M86Q9L#6NS>=&W,QM>UZ-]C;PO97R()@;3K/S!
M8BDJ=&N3[6Z1GC$0`,GM+M;D2DG%J:;<Z4I6NW-\:XL_-"&5V'&FA2X1V:JG
M1%%I,F*4N`1&1AY5,JH)3E_J.O@%L1H=>F]AD$IZIYNA-DE4_++NK:/V>;&E
M4QW"'*4MB=_(C*-F=I$:[K$>S][0)AQ]A7+BM'[+&>C1GG%!&64,00KK5/E,
MX9MCGYCZ617Y"(A6KX_K8H'<WD#$UR!NE2+\DH'&W%F;75Y&%\,9&P;J%,2,
M\P+2(*H>@%;WL(3!8/<7'54QR+2ZQ>G*0B$9G,.2V'"7MXL:,D-\Q@:T]&G(
MF,6/"X&!D,9]S@4,:U)\R<HD7RC&$O0AZ#'#>^^62NI(GR!^]&.FV_.JI:;=
MAY29[CRJ/R1AD#F2BCK.RN*=Y,5N4GD+8=^60IR4PRE+0`2H!VPZUK86W?'Q
MDC#*[R22O#7'H['VQ>]OS\^."1J961F:TIJYS=G=T7FD(6UL;D1`SCSSA@*)
M*`(8Q:#K>\"M<-[BX]L&!S6SX;TM3#[7M;+V!ML&7I9\P%,<)4RQ8E;XH.4K
M52Q.!C12A6M*"VJ5/QIE^A^X@PP/KO03/5EKUK=T&9;-J*;QRQ:^D>W$+#,(
MFY$.[`[_`(AT6LKD)O<4PA$*0)'5N/($(.]A]Y>_3>]>F\"0<!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@<=UJ?Q;?*[_`.H>-O[L;%@2#@?=X]_XVD;_`,,^
MV?[RE78&8^6S^+IQ9_84ZE_WJU!@8!@5]GH=&]B>)Y./ZE&^16O3AZU]-[,0
MU?::U-O0M?76@J"0[WK^77TW],#M2P-<O($E:ZHMKJ'G.QU)<.LV6]3W1=U5
MM3][VLJX:LM(#58J:4U@M6@)0S3]D#EJ]K?TC>8H6LJIL$-8420H2FG!\?1=
M2=$07K^NNUN<Z[C5ZF`H&3\RW#2KU8""KY,IBJR?L]G0.PZVEK\W+XF>[QJ1
M)G)$ZM3F8@`M0.19Q*G1R31)P0E,*[[@;;^>.JT?*E26G(KXY`:N;Y93)]_-
M!!%$/L/M&UIC'_OYS*8&UMLYK.QH[920,O`T(-KDCHR@"E2.B?91P0B>$>,J
MX:[K>[*U.*@M@*7/PI4QX^H-,UB\A.*26S"&[I5++FH29U0F.4<KE<KL".[3
M&'B$`:8DL)I>QI,"3H5S+U)774M'S&IH.LJYE-C=%1[K^PE5S1>7T_T!"JTH
M@$-4I55).#`KFT<ON*RI*A:621,RIN1'L;>$QQ5*R]EMQ81-7_/?D:JOG+F^
MB8U"=Q]BH>U[FC=G;J.[JTC%@W=7<B6RF1U+8%?6#,X8^@K.&)Y&]$_M6RFI
MTDF-)!K20Q044,A8'O\`%'CVO"F7CE=9;<6K]9^YSQQ]`\S212FDB*6C;;2L
MV_X-.&YO8U2QC;5+C'W6#,BLM6XA3H]#^A)B<.C/8$/9YTYTZ%Y`D7#EC3.!
MQJ002G?&2P\H]'.C'.TGY"F7^M%<.GZ^7MC,)I/6V=%#TT:6H"2&?6W#2@LH
M6B!%&;&6%DKS@MT^03QCO\:55^W4)=5^U)%9834]@OJMX9X^\$O[#/VRL;(>
M6YC1KR6F7MC.4SR`(6X1R$AQ4E#3FC*$6,*1])<5]7]IE]'VC+J)@5'OUA4-
MRSSA&Z0=[3BU@CGC56'6K'?UDS&P9/'&4J()X\T1K[IIC+<+[Q6J*.7"4@1_
M=EIM!T"E%%$%EDDEEDDE``4444`)99998=`+++`#6@@``&M:UK6M:UK7I@?W
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#CILDS:CRQ^64\>M!$3..06X.@^O
MMV4GY8BJ@!@O7>]_((2K>M_HUZ:U@2-@>GX[R_G\V3<+U]OX[QE6.;^CU^;\
MATU7!7M_3KV?%]MZ_P`ON]W\GI@99Y;/XNG%G]A3J7_>K4&!@&!7^<_\9?B:
M_P`1"$_[I;7P.U#`UV\;,+59%G=8=!SE$1)[0;>J[BI6%R)Z!^245O5-0#;*
M^8(/7@58CB8<S/!B!:[N^F\"<QV='0\U6([VDZ*#+NANIK:KGH.G>;*0HB*W
M#/+7JBXK?,7SBZ%%.1N.QVGY%5487(OO4%5VHO=G9Z<;72;)#I,G**+3&;$/
M>]AU@2(J[!Y^C=J1#GN?VG`XMT/)D$5^[JM(^JW\YED4N;SEC)&ETB)9T36@
M<)$8B4Z9"G+38M?"2?E2IA:W[=!"?4'9]H4Q>#11E1\^QRY7[?-5I]12ATEM
MZ(J5;&>#55,(3#W1G:E*ZN9RA=)&YJYL4:3M<H:6\HLD6SE)8=[&$/:9?)1R
M$95//=JSRU&JHTO1]/0:\8=%K$`H;I1'J_GB%F/;9#829M)=$,%C:-R>R6\Y
M[<STS'M=ZEEK!_3>PS^S.Z^1Z=LIOI^R+TAT9LAR<X>Q)XN;IW<5)4AL+W"@
M<9<5C.UN+6T2B:)P[/:FQ6>2O<$H=GD%#)ULS`QH'<])PNO7.?WI8M4P)+J]
M[DHZ,I(5-'JTU,G?JHG,LBREF;FIIA35*E]@M[9%3U,B9&]L<`Q]02I*$K4$
M)]JAAZ4Q\@W%4"AE>V%)^DJQ2Q"VHB\SNKW9N>3)"*PXI'%C0@D;M#&Z.IG5
MUD88XJ?$X7$E(0:H0ZV8(\LL)!^RPM%#IA%+"B<9GD%D3-+X5,V%JE$3E4=<
M$SLPR..OJ$AR9GMF=$1AR1P;'-O4EG$G%B$`PL>MZWZ;P,DP&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&!QRV%_%>\MG_\`)'(_]U"%X$E8'L>.?^-@+_#%
MFO\`>?@6!D_EL_BZ<6?V%.I?]ZM08&`8%?YS_P`9?B:_Q$(3_NEM?`[4,"@O
MC_\`_(>L?[?77/\`O).P,:Z8X4B_4G8O/=JV]`8#9%'57S]T5!7J.RTY6>Y%
MV)9DTH5UA[FU,Y*<*=2C(C\">RE"@:DL1`C2@A+'\FQ`#QJCI3IKG?J'H0J#
M5G3L\YYZ9O.!W8?9KW9SM%)U432P4Q5=0R.NS*X(KJ0`G![0GJ9,HBAY#P@2
M%$N`B56T_P!J$2D,7[)\:D,[?Z=:I7=T6BDEI-+Q5==&(5RE6H_;V"W%8%HU
M7)8M/84F+3%EHE<?CT5<1@7:5@$!3\9(B3"C3/0*9R'Q[=@REX+G%UQ%#>CW
M>7'-+<P](PRL>TK3Y6C`)33O[U8S(GU>7`X0:TSVHKJB]CC7J&S:(M?&UHU2
M=,G5%*A#+"N4U?/W9=W78UN#<KE=?QOMSC-SAG&3-9[W"+GLJ6UI3/-M:5]=
MT)K-?0,UD=R0BL5B/\R8[_O%C3&_$148W5,G$W;^Z"^46XOZQH6PZPZ!@$.J
MBXI76W0/D\>5U2/5F+H"4\5;W/T(V6U!YO%9RJ@TE;F:QH>W0UN2NC>J1:).
M0.JXDE9\A)>E`9[RGP1<%.79S5:L_'6:K]CX+Y$WVSFV)N#BK:89:/;O3=7W
MVV0RKB76/-JEQA$/:6=V:CG(T#<>K-+^?[4L*P1)(7-X&H^9<U\;<[T/87X/
M]M*MKAKB<AU&EIKBP`7H3U8]EM*TY$W&J$191H0@WL@KTUKTT'6M8%O<!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@<=-JE#9_+GY5V1RU]JZ/;OQY/VE(9
M]#%\07<WLL7(>TW_`+U'I_CZM(,0?70#RM@WO0OI@2-@>WXU"QO'FKF![;K[
MHB">,]2@EAI?ZQ;*OG/2<=<HJA6##ZA*5O+;'EB@DL7H(1)`AZ]=:P,C\N1!
MK1Y;>(WER`),US#B;J&'1M:=KVIW&3QZQZOE3NSIC!:T`:\F/*`J=EAWL>R@
M[WZ>FL#`<"!)&0<^=V^)*)M18EK^H[G#-2VXG7O4?LQ7M)V<[2YX$6'U&%$S
MHEA0C3-Z]@=F!UO>M[U@=G[BXM[0@6NKLN1M;6VI%"]Q<G%40B0($*0H1ZI8
MM6*1E)TJ1,0`0S##!!``&M[WO6M8%#/'*9I]I^V;/;]#,A]V]:]2VY6KH(HX
MDN35I)[>D*2$S-"!0`HXQCFS,T`=FP[8=!5-BU.>#W%F@$(+_P"`P&`P'I_+
M_+^CU_\`;Z>O_7Z8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`TQ^
M3;QA3+J"<P3K+D^P(M4/9E5Q59`-G3QN<7"H>@JB5N(WH=07(G9`C?&TAJ>S
M3%K&_("SUC2J.-ULHTLP.R0U,D\T>:=^/!$4'`M$021*!Z1&VI,^P8G(:=:1
MBW\0W\$;B,>/M=X;BM[^4"/[(A2,.O8,0=_7`WF^,[QT-W!<$L%ZFM@&W?U)
MT'(FV;]'7BH:0L*21O#.WC;8M!8)'0G*-16JJX;5!J1E0;,&<+YCE!V]#.^,
MH,B\DOCYC7D!I^,QY+-W&G+XIJ8$VES;>[&W$.SI5]D)$1S<;IR9E!J<J30.
M7M)XVY^:!FE@7(QZ%H0322A!#0<KYJ\S\)5&0Y\X)IRZ7Q(8)"EMVI.LH)!Z
MJDFRM^PM_61.SVYNL>*$*M>AAJ,"1:(K>]@+$+6M8&S/QK>+>U*:N1R[;[@F
M,&G/5*R%KZZJBN*L`ZG4QR[6[\H(72=DASM($Z1[FUBS,U.46]R(].E]R<K:
M5,7\`A#&&Z^5Q")SMC51F;QB/S&-KAI35T?E+,W2!D6F(51*Y$-6TNJ96@4B
M2+4Y9Q?O+%[#0!%KT$'6]![Y111!19))99)))8"BBB@!+***+#H!9998-:"`
ML`=:UK6M:UK6L#^\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,#Q9*7(38X_E1)0U))48R.I<95/I"E2R)I"-">%E4/*9$84L4-1+ELL2@!0@
MFC)T+0=Z%O6\"B$;\CE+MK0W--[Q^Y:+MYN1%)9]6THY^O5X+89(EWM*[`CD
MVA]=R2!3Z**%Q0S6QW9G-:C7(AEF>X`]C*+#W_\`F3<>_P#W_.O_`->NC_\`
M\28'J1WR)\;2241Z'%7,1''Z6.:-CC)5B0>RZJ;GY^<3P)&Q@:7^S(9$F!<_
MNJLP)*1"6J$J5'""`HL8]ZUL/5L#OGDBLYV^UC)K@1K)]%1E$2R+0>)3^T'.
M(K#TY*LEMEP*SBDN*BSL:C4%G!1N`DRK9)@#-%^P01;#%O\`F3<>_P#W_.O_
M`->NC_\`\28'P./DKY<`F-+BIUX65)C23M,4%KWE_HY[E<G<@%[$F9V@I55S
M8RI%2XWT+"H<EJ!N(]?D4J2"0C-"%MJF76,ZUK"W6W&9HC=E.K"C=9C&6)0%
M8V1=X<@[7&Q@EP`K7$.AT<+/"B/5DFB(5GD#.*]"QA#H)#P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P(C8[QKF16?;M/-3LK/GE&QVNY38[
M8-H<R$S0S6FCEJ^&*$CF:F`WNYC@EA#B(PM*8:-/LH.C-!V8#6P^RF+C@-^U
M)6MX5F['NU=6U#X_.H.[+VY<R*W..RAN)=&90>TNQ"1R;U*A&>$6R#BP&@WZ
MZ$'6]8$G;&`(@`$,&AF>[V`V+6A#]FM;'[`[WZB]NM_7T_1@?UZ_R_R8&&6+
M7T0MB"2VM9^QHI)#)NPN,<D;*X$%*$RYL<TXTYP?8<`P):@G8M&$&ZU[R#@`
M,!O0PAWH*!Q?IKDCC<W^JA$_WX6"XT\%DW=DQ@=*VU>G[#RJQ_24FS7I6RZV
M@KNR-MCV0H=QR)W&IWI?LI=MQ4ITZ,TLS86_I&_X3?A=J&PM*_H]5!=UDT))
MP2%"D0&*YG5J]&W2-:R!2N#A]['3E"X&TJ@SX33`^OO*+WZ:V$RJEA21.L/V
M$Y1M$F,5&I490U:T8"RQFZ+(2$Z$>>>=HO>BP!UL1@OIKUW@8S`9HCL"#1&>
M)&2619%,8^SR%+';`C+I"9LR%/2,A80TRR(OQ*5XC4B1Z/T4J0JBP*$Y^A%C
M#H6MZP,OV,&A!!L8=#'H6P`V+6A#T#T]^PAWOU%H/NUZ^GZ/7`_K`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&E]]Y#LBV>_>\+`%:G5=!P]U
MI/D1DAKU2[VQPZ)VPZLC#?09,C/72:`R\B3.<,.<$9!@$1I(D>G+03=;V:#>
M@U5D\P7693W$4+O^"V+&JF:_%!4M01A(Z<77=UL]TUT^E7/A=K')*]J&=Q*5
M43?Q\941@;%+%K>+V#:#TJ=6B.).`K":.PZ[OAVG;"Q,-#SN67-3J+QU&5)U
M$+F&X[!Z`N\F*S&OW>[+)*OJ/S5LJ[E0F&)T[JDE$54IG)S??NE@S4ZE.J*]
M`GB)\BVO8O4LWX>M2!V(3PQ2-@]0=/PJPE!3FB@=C-_8D+<(_7U(1J1?+H2M
MWH27W-:RLQ)H8]-)"*-FA"'W$[T$C^)Q-=-KS^R[4Z`"[[E''$#:_%_'G):Z
M"5H;"F=#RE:Y]#WND*+5*$ZD-MNZ>($A4"]#BSF!22+6A?('`S&A+(E7$UJ=
MG57:/.G3$Y<[E[%L;HRFI_25)2^V(7;D+NM!#A-30Y3N.IS8G6\QJY2TFQ]Q
M3R]<P)26QL2*B%!J4SW%A55@XTDC%.93T2U4=839T"+SG"EC78:5KEQ,K(Y8
ME-J,<:FSFT"T=\:&AI773LXFO(4Y8&5RUL2U4$T\HLX`>#6$,N>1]ZUC9C;R
MV]T4[F6)Y`8YT"1#.=;FC*@R'.\.L4JG%MS]8RB7JH%TR3:<@C[)(F$IB:MM
MC`K5DI23TPRP$J0P>MN')A;58UDS=#4%:4D'`?`C1\*C;+,FV<IB8[U8T*;7
MVI;4S8)2G(+Z'AVCT1B$\8!2!D,4Z,2F$#/$(03M&X79;1T[Q!:[Q5%GWI=\
MCJ7BR`W3'+TYUM1:71B5KK][663?=(=:;*35W4\BC+G*UFY_#782A;+'(@H@
MO1"H17RAT38#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`@OG7]P7[M1_U:_V/_=I^WUL?=?L5_Y;^\K]Y\M_?'^4^3_2_P!J_P!ZWYC\
MO]S_`*1^2^;W_7`G3`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'_
!V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g644794g85w60_g.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644794g85w60_g.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-/6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:2\^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@/&1C
M.G1I=&QE/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CYG.#5W-C!?9SPO<F1F.FQI/@H@("`@/"]R9&8Z06QT/@H@
M("`\+V1C.G1I=&QE/@H@("`\>&UP4FEG:'1S.E5S86=E5&5R;7,^"B`@("`\
M<F1F.D%L=#X*("`@("`\<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B+SX*
M("`@(#PO<F1F.D%L=#X*("`@/"]X;7!2:6=H=',Z57-A9V5497)M<SX*("`@
M/$EP=&,T>&UP0V]R93I#<F5A=&]R0V]N=&%C=$EN9F\*("`@($EP=&,T>&UP
M0V]R93I#:4%D<D5X=&%D<CTB(@H@("`@27!T8S1X;7!#;W)E.D-I061R0VET
M>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R4F5G:6]N/2(B"B`@("!)<'1C
M-'AM<$-O<F4Z0VE!9')08V]D93TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R
M0W1R>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I5&5L5V]R:STB(@H@("`@27!T
M8S1X;7!#;W)E.D-I16UA:6Q7;W)K/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE5
M<FQ7;W)K/2(B+SX*("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T
M(&5N9#TB=R(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#
M`P,#`P,!`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`*X`E@,!$0`"$0$#$0'_
MQ`!]```"`@,!``,!````````````"0<(!08*!`$"`PL!`0``````````````
M```````0```'``$#`@$("@,``@,!``$"`P0%!@<(`!$)$A,4(3$5=G?7.0HB
M%I>W&%B86;D:02,743*!0R0E$0$`````````````````````_]H`#`,!``(1
M`Q$`/P"^/A-\)OB[Y6^+OB=R!Y`\3JWHVP:-6[\^NMU?7[7X9W.NX;7]#K,:
MLM&UG0X2#:BU@X1JW`&[5(IBI`8P"<3&$&H?ZX_A7_D7J'[4=]^]?H#_`%Q_
M"O\`R+U#]J.^_>OT!_KC^%?^1>H?M1WW[U^@/]<?PK_R+U#]J.^_>OT!_KC^
M%?\`D7J'[4=]^]?H#_7'\*_\B]0_:COOWK]`?ZX_A7_D7J'[4=]^]?H#_7(\
M*_\`(O4/VH[Y]Z_01VQ\$OY?^4@5K5&<9\,D:NWGS51Q9&/(;6'<"A:2."-#
MUM:8;[4I'I3Y72I4A9F4!P"A@+Z.X@'0;"X_+\>"II5C7IUQ!RUM220Y;">X
MN-MVI&K$@#MRO"3AK"IL)8DL.=H8%0<BM[(IB!O5Z?EZ#[U;\OGX+KS`1MKI
M7#W,+A5YE`7,/9*MM6UV"`E6P*'2%Q&S$3L#N.?(`JF8OK24,7U%$._<!Z#8
M/]<?PK_R+U#]J.^_>OT!_KC^%?\`D7J'[4=]^]?H#_7'\*_\B]0_:COOWK]`
M?ZX_A7_D7J'[4=]^]?H#_7'\*_\`(O4/VH[[]Z_0'^N/X5_Y%ZA^U'??O7Z!
M<G*_P<>*O.><'BOR:E\1:U!Y[R&V#E%6-DK:.@[(Z;W>"S_AUKNGT^/=O'^C
M.Y2,)"WNLL9`AV"[510[<$U3'1,=,P,;_+C_`(*_!?ZH:C^_W5^@=OT!T!T!
MT!T$=ZQK6:X5GEIUC7KG!Y_G5+C_`*3LMKL+KX:.CFYUT6C5$I2$5=/Y*2?N
M$FK)FV36=OG:R;=NDHLH0A@1GR6\F?(39-"Q'/O&G;L"4K.W8SMFOXCL.F5Z
MX6Q#D%N/&62.&C\"'=!?#GDMA>ERT,NF_<2LRHM)LFC5X1.,(L@<Y0K34:9R
M9YCV_E;H#3COR32D/(S@)(GBYRULNFN:9GO";#==XP1%-O\`B6C8W-WVO6&!
MO.2<@H"0440AZBZ?V4TJ$DA((E3*H4(OK?C/>5^BYWQMY#5G`,BM^[\HN`-W
MU'+KUR4SFR53D#E/#"0>HZF3-,HS3C5@M'K)I:)D8M@T9K)2$Y9VH@E*NRG8
MIBL#*?+OC""E`X$TPV)6BZ>/;).3E2F>7N(81G$A;RI8O0LZM1,?C'^+4&.<
M2UOPFHZDC"KV&"BHYZ4D>U1-\&J@B8I0K++^4/C#P2TN[4'AWPH7@>.OQV-:
MQR"L3"NZ9@S$^M<E(JEQM!RW%\4=Y$]KL+N4[F18VS+5N>/0$IPH*)-A7EU7
M`B#IJ9SBPF^[_N6`5V5D%77'9SG57U#57OT-&8Q%[#IKU1O`\?8^\/YEN6;V
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M8;G+_0];S1FN59IFU'C'#XU>JD(;W@<`I!)E]]\N9!'XM\Z4<=_4H`"&`IOD
M$YQ9^C`-*KRLVYI&UDT<$-"R5XE;#!HMHLZ9V<:YBIY61;/8D"I@F=LH!DU$
M?T!^3MV#K%XT,:'Y)L)/S6S=J[XO\UIK/;?Q_F]NIOTQ(LXFXP$0]BHRPV'-
MTK3"T?<H*E/K$6<JC:WMGZT"\4(+91)1(53A&'#3Q/R5?T.KRW(VNL(KC[Q(
MOT^ZX9<;E[<CHZMZU(DP^<VGR+\M;<DFFSU;E+L<XY<2\*U=$5;4EL[[IE"2
M,)FP/RZ`Z`Z`Z`Z!1O.7\2;PC_;]S4_Q^[UT$=?EQ_P5^"_U0U']_NK]`[?H
M#H#H#H#H$I^9O;:O0\]S+'EWD7&V/?I.QP4R\$[)G*/\RJT<C(SE1>2H@218
MUVWV.2C6SA(%$T7R1%6Y_6110A@XYE*_84(>2V^(F(RCR$5<!C8B-JKAQ7IJ
M*=(.4T0/!.XE9LO'G8G$HA[9P54*0ZHF_P#D(G?OW\J_?2LJ]>2<I)O'4C)2
M4@Y6>R$C(/EU'3U^^>.3J.';UXY5,HJJH8QU%#"8PB(B/0>/L'?OV#N/R"/;
MY1__`#\_02[(4"EM,;A-#;:?#2%WDK*M#O\`,$6IB2T3&IE<>F176.J"YA("
M)%3'%(&ITUR%34,H4P=`];Q.^5CC)PUXW/L4VIEIZ-A7U*W7-M,5.G-+'7@A
M["QKZ#9)=9&=;2Y7Z*\6L*A"LS%`IB^DQA[@`=1V/\A\6WK,&FQY1H==MN=N
M6:[MS/M'A4"PAF:/OR+"RLG@-W];EHQ,.[EJ]3071#Y3%](@(@M_F1RWY>9W
MM,#`\>,Y5M.4S>2\?;;.6&4KCQO)4I_?.8%1R^U2K:)=UU^]M[IYEDHY]<0"
MK!:)2_\`])0?27L`+V>\_/)`YS"I6VE2[^TW%':.4!];@4<@KDJPS#-<>EZ6
ME44;37FE!K]L0K!*Y-/I.2B(]Q)W249M3*1;]0_9N`-EX,<AM&W#;>;L-/Z@
MEH.69EK,-4\@9S>6*Y;?(+X,MG9Z$51F2/8I6'*BV%DA'566=BK*RHQ<@^.<
M[!S&JJ`RSH#H%&\Y?Q)O"/\`;]S4_P`?N]=!'7Y<?\%?@O\`5#4?W^ZOT#M^
M@.@.@.@Q<V$N,++A7SL4Y\8N0"#4DTE5HTDN+14(T\@B@LW658E>^@52D4(8
MR?<`,`_*`?S5.0VN[/N&O76\<@;/)VG4#34E!V$9'_I:0"\'(NV"U6@(=/LR
MK\!"/$E4D&;<A$R=A,;U*&.<P0M\O;MW'MW[]NX]N_;MW[?-W[?\]!-;C![B
MUP]EO:SN$)4G]@-!(1QGIB3AP!ZM&$D4T3)@V61/)ME$A1(H+@I">Z)?1W$`
MCREOZU%V:+?6^(7G:\@JH+^,;J`FHL!DCE1.)1.B#@B"PE.9(3D!0`[";_@0
M\MH=P+^PR[VLQBT-`.'AU(N,<K>^LS;"!0]LRGJ/V*90!,4GJ/[93`7U&[=^
M@P!A])3&`.X@41[?_/8._;Y`'Y^@ZQO"IG&'9B[N>?S._P!-MMRUU*@Z;#9D
MW691GZVMJC&2)&KEO[DFZ&S,ZS(S"JQH\"D<&533<+HBFW)Z0Z8^@.@.@.@.
M@4;SE_$F\(_V_<U/\?N]=!'7Y<?\%?@O]4-1_?[J_0.WZ`Z`Z`Z`Z#E'\RWC
MRBL\S6^\I:[*Y'74S[$[LLZP&+"K7"VI:,\.`QD6\0[,IZPM[`_5<G8^V)EV
MB"CHJB9B*I&#F/Z#V'D9%1BC%J2#]2+;N%';>,.]<GCF[I8H$5=(,3*BT1<J
MD#L90I`.8/G'H/'T&]YU8ZQ5K%]*VNJDMT<5BZ01CE%$0(B\5`H).S(.B':N
M0*0#$])P_0]?K+^D4.@U1T)9.5<&C(X6I)&15&.B&IE'0MRO'(_"1K<PA[K@
M4O<*F3Y/4;L'0966A+EG,\U^(1EJ?:XP[2;AG[1RI'R<>]3'WH^6BI2.7*H@
MZ:N2=RJHJ@=)0@AW`P"'0?T?.*FR16Z\9L0V5I+MI%*\9E4YF8?@N42(V0(I
MLRMC%RJ<0`CN+L[9VU7`W82K)&`?E#H)_P#C&GK!/XIMZQ;"\`GOI>L6@"!1
M=`7U=Q;`)@#U_P#U[C\_0"3IJN(%0<MUC&2!8H)+)J"9$QA*"H`0PB*0F#L!
MOF[]!Z.@.@4;SE_$F\(_V_<U/\?N]=!'7Y<?\%?@O]4-1_?[J_0.-N-XJ&?0
MYK!=;%%5F'*LFV!]*NB-TE7*H&%)LW*/=5RY.4AA!-,ICB4HCV[`(@&1K]A@
MK7#L;!6I:/G(231]]A*1;I)XR=)>HQ#&271,8@B10HE,7_[$,`E$`$!#H,ST
M!T&(L$_!U.!F[39I:.@*W6HB2G[#.R[M!A$PL'#,EI&6EI1^Y.FV91T:P;*+
M+K*&*1-,AC&$``1Z#D[\B^NZWSNNV/:9A6*76S\?LNC[,_AJCJ=SI&:O-6>S
M22(0NKT/-YE-W*M'+J*$Q(XEP=0KA9B=,Y&C,5U15#G'M,FD[N]RCU:S+T";
MCIET:7SFSQKB#M5,.Z4,HBPEX1VD@NW2-\HH+I%.R<$_2;JJ)]C"&WW![G;F
MN4E*HQSQE86L8<ES<.0<E1=R'MM@*HD99RLBKW<@L8#)E(4J9BE[?\`&D1D>
M\F)%C%1J(N7\D\;L&3<IBE%9TZ5*BBF!C"!"^I0X=Q$0``^4?DZ#.7.E6*B2
MOT'9&R#21.R2?)`V=HO$%&S@RJ:2J;AN)B#_`-B)@$/G`0^;YNX23LUKQVQK
M4-]CM+EJ$ZC*TW9W!NX5`J#JPM#-A;2,<JG(/55G!1*J*CH10.J/MB)`,`CT
M$E9EQJY"<H(A/259.MPN=1\\7/5-?V"YQ5-I3:?;,B3*U:8.52.IZP2C./=@
MY62CH]X<A3]U!`1Z#H@R7QI<KV?C<TWC(XN=+N#6X[;A^M9K49QM^J"3>NTS
M9LTT728]=_>Z7ID.PB[Y"T]T:.C)ZIR34SMR)Y)@"3E=H`>S3?&#RVMK_:X>
MLP7'6*CMARS98!/2IV5A)70ZO`7[C!7,BR_C]!NFN%,I>B57%+Y#*^RK5I*)
MJ$Q7'*QUJZF_6,0H6)R?QDZ5CG/.@\E(.T465RVBQ]9H;6N1]?I^9SRE59\=
MKI1)&TH1N8YY5X.-1:Z#+(D_4AH9M4'B3SZ;%NE,1K850=OT!T"C><OXDWA'
M^W[FI_C]WKH(Z_+C_@K\%_JAJ/[_`'5^@;;?,DHVF2E4D;O$EL"-.<2CR*AG
MQ@5@UWLH@U;F=RD:8HI2*C-)MV1*IW3**AA$IA[=@V.ITNJT2-7AZ=!1]=B7
M$BZE5(R+2%NP(_?>W\6LW:`84&A5S)`82)%(GZNYO3W$1$*;\LN8#C&RR&7Y
MU2+Y:=YLK%BVSEFA19A]4G3^9.1!O*?38HEC9="*.8WO-VYE#@N0"*@F03'*
M%XXY1ZK'L%9)%)M(J,FJC]NB?W$6[TZ!#.D4E.YO6DDN)BE'N/<`[]!3[R'9
MM=]>X3\CL]SF*<V*XSV=O%(JJ,S^AY=D820C[!+T%IW,1-1S?(2*<PZ::@@D
MJ=\!%!`AC=`FVFWNI:;6V%XH\PWFZU-"L9LY0*9%PP=HJ"F_@9J-6*F]@+)!
M.@,UD(UVFB\8.DSHK)D4()0"(N0'%W&^2T0U9:77%`L4.W51J>CUIP2"T:FF
M5[F$(&S)(+**QIU/TEHQ\F\BG/\`^YL?YP!-UZXCZ'QAGSS%_(IH^.F>MB)[
MA48%07%+B!4'WUM5HC4S]Y3UR%$I3SL>5_!E[>XJ,>'=(0JOL&LXBQE6ZV87
M9>_2D<X9N6LA0(N3LOH,45%?0E982."LO!9+E(9-8'9/;$/1_P`"/005.ZQ?
M;9).992I2+R0>"3WIB]6:-CE%`3*":7J802=E>%333*`%3_Z>P?\!T'[5S0+
MK6S2KV:I.;Z$W>1RS8E;!:SUV3:F$AS%6KUI5DGK)&9,?T@0[N/]D1#TB*0&
M,;H/Z!'CVQSAWL_CKXQUBGM*EL>;-:C7[D_=N2>Q,-=6F&QIB]GLC1BZ1EZY
M;&MEDWC1]'N#E413)\,H4Z10`0:RFFFDF1)(A4TDB%333(4"D33(4"D(0I0`
M"E*4.P`'R`'01!K6QPF1.,^"?0`L==[HVJCF87<%:1U>068/'1I5^N<AB^T5
M9!-/TB)"@0YE!,!4Q[A*"LU#HQ3B=6E8Y*$:,UY%U,'>MBQ;9@V1,X<O5WXJ
M@U2:-VY!.=0QP(4@"(CVZ#"T>\U32:O%76CS+>PU6<(X5AYMHDY39R2#5VX8
MJN68NT&ZB[0SEJ<$U0+[:I0`Y#&()3"&V=`HWG+^)-X1_M^YJ?X_=ZZ".ORX
M_P""OP7^J&H_O]U?H&&[+R\R?)I.J55K/0MXT"U:15<\2H58G8Z0L<8M-6!G
M$34C+LF1WBT6%?:KJ*&2<%2.LN4B(=A,)BA:KH/J8Q2%,<YBD(0HF.<P@4I2
ME#N8QC#V`I2@'<1'YN@AC.^0&::I89JMTB2E9AQ!BL#B3+7II&O.?84!-4&,
M^JR+%K&`Q@$I3*$,J0?6F!R_I=!6CR%^17&/'7E\%=])C9^[72_2K^O93DM.
M-')VJ^S,6R)(3#D7TLX:Q-<J5::+(J2LL[/[+0'"*9"+N7#=NL'&5R@\JVB[
M=KA=IQ#CKCO$Z]O)-HZNMC@;3;M*?;)%-`53^A-EK#>-S+.[6Z41.4B<X,:I
M9(\A"D:22:0"F<+O\8?))E&W.HFBZ:V:XAL,@=)DPA9J5*YSR]R!@`H$SJ]N
MTV:"D@Z-\I(65(SE0[^E$'8`*H@R$0.D8Q3`8AP]1#%,`E,'<!*<ABCV'L)1
M$!`?G#H%;\FO&+G.GK2MXP=Y%XEICQ5>0D()-@JIC=YD51%592>JD:!5J5-/
ME1$3RT$5/U',)W+-X/0(QTG.]%Q:WA0-CI<IGEN5!=2+;R2B3VO6UHV$05E:
M%;V@?0=PC"E_2.#<Y7C8H]G39N;]'H-8J;25T&W1>>YI!3NHZ-.+D:P6=YM%
MN;G=9EV=0B*:+6"@R.W#9(5E"E4=.OAV38!]:ZR28&.`=M&`\,ICQJ<(.,FW
M+,H:I<C<1>04GRM+2@;!%:QE^U;`YE-;S.^+Q@M6%_?XO'Z.>0J\VX!P[9R5
M;(DT7)'R#Q!<'TVVRQ],JMEN$L1VI%56!E[')D8(`Z?&CH2/<23T&C83I?$.
M?AFQO03U!ZS=@[_+T&GI$R[D+FT'+':0]^SNYQL;8H91VW.=LZ;.$@79/42J
M%1>1[Y`%#%-V]I=$WK(;TCZ@Z#$7+#:;8L2N.&5]JC1ZM::I.5E$8!L1/Z)-
M,MUB&D"(B<@O52N5?<5!0_J<!W*8WZ7?H,3QCSS0,DQFHYCHLI4YR3HC3]6X
M::J*<FW9R=7C@*E!+R3&3:MSLII)K_U."IF62.*8'`XF,8`"?N@4;SE_$F\(
M_P!OW-3_`!^[UT$=?EQ_P5^"_P!4-1_?[J_0-G-B60&T$-7-FE)'22@7M=QK
ML9^L?N%1^'*Y&2^']\7I6W_6"XC[P)_H`;T_)T'AUVLZO/1T4YR&^L*38XMR
MX%RC.13>6K\ZP>))IG0?I*,WKAJZ8J)`HW62(/81.4P"!NY0^,GSJ>J%$>5^
M_6QU?++8Y"9E[7.+BLD@X=SA"-UV,6D82G:1;-DB1%$A03``*)BD(`@4H9S*
M\WA,DHL'0J\91:-@R.RINW":*;QZH[>N'BCE\9`A"+.C"OZ3'[=S`4/F#L`!
MRP_F;,2T4UAXU<HVL?)RV-4RGW_(K[*M4%W,9F%AM-DJ=EK%ELADBG)#5NZ!
M$+1JTDKZ&K=\S9(K*$%RCW#E.5LE>1401/.Q`N'7;X1JG(M%WCSU=O2#)F@J
MJZ>&.(AZ02(<3=_D[]!:3-N$7,+D(S3;9?P\Y`Z)`S)2HEE9'+9.F4=ZD<0$
MIS6S60H]1<MP'L8#D=*`'8#!_P`#T#[^(/`+S,XC4W@:'3<LOF5P,452$Q:\
M[VTG.0C$J)DRDA<UO\?`R^?J((-O5[,5:+(HT`2%20D628_HA8ZEZ'7KP\GH
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M%_7T5Y!PW-$)2!#"559$14.D)DQ`2&,`AN^69O7,@SNGYE4B.BUVEPC2$C#/
M5@</5TVX&,L\>K%(D11X]<J'65$I2$]PX^DI2]@`,[:;=5:/#.;'<[+`U.`9
MB0KJ:LDLPA(IN=4?2D15_(KMFI%%3?(0HF]1A^0`$>@S#)ZTDF;21CW*#U@_
M;(/63QJJ1=L[:.DB+MG+=9,3)K(+HJ%.0Q1$#%$!#Y.@]/0*-YR_B3>$?[?N
M:G^/W>N@CK\N/^"OP7^J&H_O]U?H';]!HEAT6M5JWT>BR"ZYK)H"\PE`LFZ1
M5`!"!C59.2?/E3J)E;-$DTRIE$/4=150H%*(`<Q0W1TZ;L6SEZ\63;-&B"SI
MTX6,!$4&[=,RJZRIS=BD322()C"/R``=!$F'[;5.0%,7T&C,YQ*HGL,W`P<I
M.,DH\UD0@7(,7,]%-"N7#@D*Y?D520,X*BN?V3&,D0!#N%3?(=RWE>.E/I.=
M9]4*G>MCWYQ:H.J1.A-WCS-:U2JK&,7&D:'H<7'J-Y"R5VOMI^/8(PK==JM,
MR<NU;"X;(&<.402;D>F\@<`G7EJRHG#-O+22@N)-@;A%1<T8N'!Q,*GP$_BE
MOI%J8$$3B!3/EIE0H`'J%0?5Z@N2[\K7)!*E6>#M_%*`F;`_J]@CXFXX'NT<
M*[6<=Q#MM#R2=.U^KYPM&E;22B:@^U//E$P#N7UF*'J#)\1?,I4S9)GV8\N:
M)N%7YFI03R(99=`Y#9KI8.02]71;M_UQSB2I*,[00-,HJ)FDCR,Q&1T<\]Y1
M9=!IZ%`#6MEXY2W/'6L^W/F#5(JA0.8Q5BA\SXZ9W9UCS#J"MI6H3#;DQL]5
M5B7^DM7R34/52(19.G,U%%`<.9LP@L`7-A86%K4+$UNMP\37:Y`L&\5!5Z`C
M64-!0D6T(";6-B(B-0;1\8P;$#L1%%,B90^8.@JUR+;Q7(GXC@_2$_UUTC5I
M.B--/BX0R[IMB&,HW.`L]TTS3YF.431HJZM:@G#:KLW#AM+S4XY:_`IBBDX<
MMPL3:^.M8\;%1=;KQ$9SU-PFCRKNY\F>,Y)VPVVA6G.Y.0!UINSY^SM4I-2M
M(V;/XU56PN#Q[I-A:6$>Y8O6JCQ9F^9@R^Y76&I5(L%]D#G=PE?@7=A6-'B1
M<[QFV:F=)@S,!@14%V7T@F;U`3](!$>WR]!'^(:5>]0@!L]KS,<^AI-!O(U1
M5:RMYEW,Q3L#'0<.H\D>Q<QGK0]"A#'[@L0X&``#L)@B#F%Q\L^YAB$G720T
MZWRG7("[V//[&[.RA;Q74G#9&49BX%%RT"48-"',W(X)[*I%%4S'+Z@[A<TI
M0*`%*`%*4`*4I0``*`!V```/D``#H/GH%&\Y?Q)O"/\`;]S4_P`?N]=!'7Y<
M?\%?@O\`5#4?W^ZOT#M^@J-R2@,]L%]XZP4W.7:I:9<;Y9:UE-KHZ<>=>*DX
M//+7I\\-@-)"9!*$-7Z`X(0X)+'%ZHBD)?;64'H-[W#9:/A=$@27XM@O4Q?)
MN'RVE42MQL=*Z%K]UL:"K<M=K-?37A(UR[4BV[N2DUSJ,HV)B6CM\[6;,VRJ
MI`\G'/CS&\;:]8:15;C9)ZA/;`ZGJG6;&G'+GHQ)$RBTE$1<NU;MWDA&.7)@
M5*5P!C)G]1O4)E#B(4<\HW'+4]"_\8Y!8Y4I+2K!AR.BU:\Y=7S,PN%KRK4B
M4]]-S-`;R+QBQF;K1[+GD2]2B3+(*2T:H^0;G,\^%15!$+;E%Q[4G)FJRFLU
M2EW&MO7L;9:5IR[O*;E6Y2,.=*3BYVKZ2TJLQ&R,<JF8BZ1TO4F8H@/03)F=
M%VODX#=WD#,V68ZZ$!7Y&Z'7%EG5D8B/90^!Y5+@P?70%B=_8LL\#&ME^15J
ME,$[DZ!GN%<:\GX[Q\H2@0[Y[;+.5N-\U.Y2)K3JNAN6W<R2MNN;M)-TK'MC
MB(M8IDFRA8\H^EHS0+\G0;_I.G9WCE.DM!U2YP%!I<29))Y8+&^*S:G>.1]#
M**CD"E5?S<[)*_\`6TCV2+A\[5$"(HJ'$"]`KO5.46Y\@6DC`9&I;>+>1R#9
MRT_](?Q\<WY.75JX2.DF^IM;F6DO!8'#+%."B3R6;R-J4+V$&<2IV.(>CCAR
M#Y1\.J@VI&1_P^ZC1VCX\Q*56]9J\R[1KS*+BF:6F+%N-`GY!E-:!8P2#XF?
MG:K*.'3@0.Y.(=S%!L^N\O:%O?COLN@Y]&R0VSDM5;?QMS;)+`1DC=QY%WPM
MBR5?)IN,0=.4!DJ-;TGZT\N@HLT:P<2]E`4,P2%?H&#5ZBQD9FT#FLP5.PQ$
M928FE20/T_6G-,&$&WA'1G:9A'N#]!$1.'?O^D/R]!MT>P:1;!E&1Z!6S".:
M-F#)L03"1NT9HD;MD""<QCB5)%,I0[B(]@^4>@]?0'0'0*-YR_B3>$?[?N:G
M^/W>N@CK\N/^"OP7^J&H_O\`=7Z!V_0+5YI:W2\;Y&\/[[H<BX952@5SE#HB
MK..9K2U@L%@2J>>9+5*I3J^S`\E:;U;IW9DHN'BF9%'D@]>$12((F'L$H\><
M;OEDN[GEGR8BT&6YV>#=U_-<N(^;S-?XK9%++M7HYS!O6QU8V9U6WF9MGE]L
MC<3$D'Z*,:R.,3&M#+!=GH*F\P^:&)\'\R2T[:WUB392[]:O4V"J]7F[)-76
MZ'9+.X>EQ(QK):,835A52]EH:0<,VQU!'NH`%,(`G*!X#9[IV^V'F5RSH=(N
M&^7>5A;:WR./;&E,&Q&<C8F/CV)8B"E062U#38Q%@E](VN72!!>3(HXC(Z.(
M8O<&)@"JZ@``'55/V*4H`8YS=@`I2E`.XCV*'8`#Y@#H%D<A/)9G-(M<AB_'
M9K7]_P!V:232!FQ2L/T=BF3RL@[^!(.G:%&$>J2LNP6]1E:]7R/)(!()'BT:
M!BJ]`I+:='Y$9-I2FI\E&>?<JKBR9C,5:S1-CGLQ-F4%+RBL4>!RG([%$VVA
M40J`E!)1^C(!-2Z7Z3Q^J/=,H;.VYUYU&,*Y):CFNYX^SMC`TK7Y:S9ZK::W
M+QY%`25?1\[G#^W'7:$.8!]:C9$?08I_3Z3%$0WPO-'BJM&DD6&X4N:777;L
MF%9@W#R2ODO*/%2(,82'H)&B=N?3,@Y5*DBA\(7NH8`,)0[F`.@GQK\$O_%*
MFTW;<8*9_B+O=CTN_P`=3;+9"6:!XUQ&L3!'3RBYY$LU%:Q7KE-U>-C"W&79
M?$/).4*X;$>J1R:"70,@FM>R>M2$E$V+3L^@)2&?Q45,1LU<J[%OXJ3G824L
ML)'231](H+L7TQ781Z_:I*E*HX9-%ER`9-(YBA'D#R[XIVES26=:Y+X'/N]+
M"2'.FL-KU`DG%\"&=*,98:<BTGU5+*6.>HG16%F"P)JD,4>Q@$.@D7,M;RO:
MJT:YX]I-#U6HDE9&#/:,ZML#=*^2:B%2HRL2>8KK^1CRR4<J<H+("I[B?J+Z
M@`#!W"0N@.@4;SE_$F\(_P!OW-3_`!^[UT$=?EQ_P5^"_P!4-1_?[J_0,GY:
M<@2<8L+LNMD@65GE6L_G5&JT'+6!"H5Y]=M;T>IY32?UMN+MH_:T^F-K7<V:
MTQ*G07^`C4UEBI*G*5(X*01YU8;H6@95JFY8"AN.\\<IFW5C.='RQB[J&>Y=
M>=SW)_Q1@J8:(Y!W.CNXO1M`U;'I:*2FE&KZ*C86&=R19)F@LLD8)=AO.-QA
MGK)G]$CLZVY;1-1CZ8O2*26$IRDE-2VETJFVS,:^@_2NBD-\=I+NSOF,&J#@
M6K\E:EY`BOT8T^,.'UX[^62P[?MV$T67X[3-1H>]TZMO(*=AK?2+T^J]KT>4
MY,V;*!L[Z+MC(IH&Z8?QI?SZK>/C7KZ)5>$!X*3<$E5POAS>XG5OFGQSN6%S
MTTO4Y20=U^W9]>FC)&1>4#3Z+,M+/0K@A'N#$2D6\7/1Z97C43I"\CU5T`43
M%7W"@GC4_(UFO&217SSF53]*QWD'%0+69F,_JN>VC3ZQ?`<J/&:-JQF_U1DZ
MJT_2K/)QK@S'Z8<PDDP`!0DFS59)3H$D[WSUY6<^+3_XQE+*2PW)[,+UFAG-
M7LR+/2KY#H(*KO%M>U.,<-DX.".P2,=S`UU9)KZ.Z3E](%'T=!0-!A9,&M\M
M42QL;"2537<5F6KK4K96#!-`Z2IV29(\R38S<#`15)1$2F(?L<!`W?H,E=]6
MLUZ:`PD1(W9&425=))N7KMP^4;B8S<KMX]766.W;&-W32+Z2E$I._J%,@E#V
M7?8+_IE4HE.L)V3J#RZ)590(1D1\.Z19"W9L/BIAVB945S(LV2*0*""9.Q>X
M@)S"80R60I8.Y:WLNUN;FT?%KHJ49Y5?;4[RJ?O`NS70.0Y7+UR8Z/L$<F39
M"0J@*'*82CT#]/"MS-N4_J:O$1WM6C)5"5H\G+9BKJ3JJ6M^PGZPZ8+NJ?14
MW;([J%;/JVY>.TV:[^4;)$CS`@W3_3,(-/Y"^*XN\;G?-R7VV=A)JWSV62+6
M&%"SKU=!AG^!ZUB\E^L%(C;M#4"TV.:>::62;2CF)^*C$FAVJ`@183$"+ZWX
MB[NU5XMV.R;U!R=NXK4O)*A7(OZ!U2PYS?@RK;3:@T?:5!:!LUNL5H(:,7$(
MANO*'1K$\U9OHP$6[8K$0OSP:XTWOC#F-UK>H7&@Z1I>C:W<MAT+2:%1IG.T
M;Y;[JA#I2,W-5:3M]P8Q3MBTAVT6P:QJC:/8P<<Q:D1,=!1=8+H]`=`HWG+^
M)-X1_M^YJ?X_=ZZ".ORX_P""OP7^J&H_O]U?H&L<@[#3*AA&S7+1JC&WZA4O
M+KY<[A2IAE"R,9:J[4JQ)V*6@GC*R%-`.$9)G&'2[/0^&[F`5.Q0$>@1WEWD
M<XXM\XJ^#;?PJJK/0K=4ZO3K1DF=T3CU'XZ]TIC<,M;PF!%KUJU1V>,BLZN'
M(V)8IS]C0C*RO*-YQVT.@+99N4)C8^2CCS"WB95NO#UY4['5]VDLXKM@A1P"
MSS[>KX[;,TXP/]1<.XVUM7S-W2M9WQ:FQL%#*R\TK%F>K,"*-#.4RA.G$OEC
MQOV#2\ZSO->*LCB:]RR*4Y&Y3/V*G8Q3V%ES5M-OZ1'W*BM:;9I>5<KR3&XG
M<+HI(I2$9#V9DJ]202F"`<&6V"Q-(!D]6]AQ,2R$1+2\=5HA6//9;$6':_$K
ML8!A(/HY!X]5,8B1/6LDB554@**$*;U=!PL^0OE)N>J<C+U9>3W&J;R[XFGJ
MY_DM`N]<<P4K5J0QDW\FU66L;F/!*XOI*0EA>OGK!8Z"2YDTVIBH@7U`M>@U
MJ^3,@YEL_)(EF*DBE,C(14@$9)L#%%0J"L>N5=!P9ZJ*9P(1(1.8`$/^>PAI
MSY\]DWKN1DG;M_(OW"SM\^?+K.7KMVN<5%W#MPX,==9PJH81.8XB81^?H)<J
M]$S27R:\W2=U1"OWVO/&S>N9Z:).NM8"+@44CD<^X"S@'QO<+[B!139>UZG'
MZ)R]!J](T>PT%"Q-H-..53LT:,8]!^S!T*0>E5--PV[&((JD(X.'H/ZTC"8!
M,41*'0>F%SAXA>Z73M,>GQV,M,C#).K9?H.?:Q-?@I1T5L%GDVC&/<S"L&W^
M45EFZ"IDB`8PE[$,`!T499X7&U;TS.;E:=NG,",G8XN4QW0\A<1=[@K588]^
ME(U=^VO$R^%O3IF>0(FYAT5V;AM+HJ&1]0+A\,J'3@MJ>9UR>1SVR:M0F^@L
M:JI9Y"N2]MJT1;EZY%LU5I6XN:L9^V?M(%)-FLNNZ*@5F@0AQ]12E'L&"9<C
MN/,DWKCN.WC&9!K<&TZ\J3EEJ%(=-[2TJQ7![,ZKBR$XHG-MJZ1HJ+\[852L
MP2.*HD](]@D&H72G:#`,K70K96KO5Y+WPCK)4)V+LL`_%LNHU<@RF(9T]CG7
MP[E(Z9_;4-Z#E$H]A`0Z#9>@.@4;SE_$F\(_V_<U/\?N]=!'7Y<?\%?@O]4-
M1_?[J_0-OU[)J3NF<6K)=(92<I0KPP)#6Z%B[!/5A2P0!G3=Q)5R0E:U(Q4N
M:`L+9`S*3:$7*E(1ZZS58#HK*$,&$F..W'ZQ.;8\L&%XY.N[[]&_KTZF<QI4
MHYNGT,O$N8?];%WT(NK8_HIS`L5&WQ@K>P=D@8GI%%,2A[#8-AIYMA93XQE!
MK'%V:;NL98#9U4#3<=<K*U9,;';6$J,.+]G9I]E&MT7K]-0KITD@F14YBD*`
M!FZ_EF8U*<&SU7.:'6;*-8AZ2-AK]0K\-.#3:\DBC`5(9:.CFS_]6(-%NF1F
MP]SX5L4A033*!0[!6;;\5U"S:N-SIKE!]7;=F3[)[*B$Y]!S]/824@+U>Q5Q
M=9([=P(+`DHJ@4Q%'!4U$A$`4*H0.77R0\/^?UD=VG8M*I3B.XX<?(5:I9U(
MVW2\[^/9TC]82,T)HE:86R5?DG;Y8'Z*A&H"LY20.S9F,8&Y>P*[TG.-0XOS
MD7%/;3&L9BY50L@\1JTF9PLS9*KF15C)8CALD=)PBN`^TLF44U/TC(J#V-T$
M4U&BV6\JRR5<9%>&A8Q:6D#+."-R$03]7I3*HJ/91VZ,0P)D^<XE'Y0[=^@U
M(A#J@)DTU%`(F*I_0F<_MI!V]2BGI*/MIE[AW,/8`_YZ#]&Y7!W#<K0JQW9G
M"`-"-DSJN3NA5)\,5NDF4YU%S+>D"%*`B)NP``]!T#\`,5POR*:+H6+<WZ]=
M:]R+S*JQ,Q2'=9L<CGKR;SP3MT9UG)UQ4KV-<V"&FY%!\9P1#_\`I:R?R%*1
MN/<.G?`.)>?\?<34X\1EBOFDY.D#MK"U_7)F,MKBN0;T"G4J\3*-8.%=A7FC
MH!69HK"LHQ.;L@H0A4R$"@W)#QDZ'LVY\AKY7+Y0HRD[;@N&9DP87,+O:'<7
M/8):75OBXV]5$72<)I]`TA4B,-8?BI)I)F@G<@@0ZAG0CT&C1_BHVNWJ7NV:
M_MU/-=;)QTY<8K6(:DPZ@T^N'Y%6&6>4^(L#YU6(.8NM+S:#D"H`K\/&2SE5
M,GJ5,1,H"%^^!W$I[PRRNZY4YM;.\M9O7+5HL5;3LUFEJEV-KA:L11.^J%!"
M)D;)"R$6O'MW3!LR06A6C`54?BP<JJA=OH#H%&\Y?Q)O"/\`;]S4_P`?N]=!
M'7Y<?\%?@O\`5#4?W^ZOT#M^@.@.@.@.@4+Y<\&Y/<M\US/C3QTK<:M"6B[A
M<-?O5DL;.N5*N05.20-68*25[O)J4<RUAE2/_AF+%VJ4L44QP*!BB(4-J_@:
MR[)LITG6^4&M6C:[G3\QN-F;5ZL*OZO1XYY6:I)R#$KJ1=O5[E:48\S,@I%,
MZBVX@0"G0]'<.@Y\[?2XAPF#SB"EK%^K43F,:]VV:@H*TRY84\H[5016LQ6,
M*FG!,GA4S`<.P-DU0.4A^P'Z"<Z?D?)OAUQXC.4MLQV.<Y#R*;NJ%&EL8O&=
MAA$5&;AU5+).,",S.(2NW8B[OZ/37$/CRMB&,"7NM3+!IWB_S""U[GIQKHME
M;J.Z^K;I2P2C-(ZB7QJ%,I]BM:+111(Z:R;9P\ADBJB0P&]L3``_+T'=+7^,
M_&S+'=;T!'/:-$6C-VDJI&:Q.LXM&ZQ+"2:O&LN,G?W)&TJI&+L7RJ2B+AP+
M0J0@4"`!0[!8EH[:OVK9\Q<MWK)X@BZ9O&BR;EJZ:N$RJH.6SA$QTET%TC@8
MARB)3%$!`1#H/1T!T!T!T!T"C><OXDWA'^W[FI_C]WKH(Z_+C_@K\%_JAJ/[
M_=7Z!V_0'0'0'043Y_:KRBSC)(^*XG5"HET"^RDC!SW(36)F`B\+XBT"+@)&
MPW/D'K#&3E6,I:V-3@XU88J':)'1?RHHE>K(-`4$X<_7#SF+/\5(UQ<Z3H*T
MMB&YQNEW;C>PY5OK;5;7SXML!=LY-R2\DW)SD&TS/1R<6Z'HKN9C:QDS&5;0
MU0.P=M57YVB"[(R8.'9>0OC9S@XLR5'Q;2:;'\C^3G#RRW[,N,ERNE3@-G61
MT;/)UO"-%*ZK+G^/(DZ4,<SID9RW.P(#Y,QFIR*F"POCYX2TS@KQ^@LOA19S
M%ZERM+#K=Y1;^VO;[LJT32<?#G4*#A.MU]+NSBFYNWMMB"H8H+++&.%CMQQB
MA\ALEOF+Z7%EEJ7H-?=P,L@'I*Z:"J!58^8BUC%.#29@I)%%XR6`!%%T@0_8
M>W;H.8WAAP&-XZ>4#+D?RDWG*8"KYOJB6"4&O0#EW:;/=;QR`3>9IC#FX_1:
M?T5CC>_GLK=1D,TH1$JK@A7*K5(05$))S[D9!^8/D3!Y-R^SFO47A_1M2OE=
MK_&ZV25EA+;?>6.?HZ#!K<5^6%2EA3K>L7/.Z%6G6H*1E37>UBNIFC$Y9Q(*
MK,U!"YGB+S5WDFA\ZZ+B,%K55\=L1K5*)P_JFP0%YJZE4N@0$TER>KF+0FFL
MXZ^-N/,=H"3'Z"%T@E'_`$D>2+&^XT("J@.TZ`Z`Z`Z`Z!1O.7\2;PC_`&_<
MU/\`'[O701U^7'_!7X+_`%0U']_NK]`[?H#H#H#H,;-0L/8X>5KUAB8V>@)V
M.>P\W!S3!K*0\S$2391G(Q<K&/DEV4A'/V:QTET%B'253.)3%$HB'05?Y$\&
M^+/*JN5:J;;E32?A:7"3-4K25:LMSS-Y'4:SL8V*MN;C*YC8J?*/,QN,1#M6
MDO6UUE822;MD2.&JGLI"0%%;!4.0',K4>"?&.O\`CTOO$*M<..6>:;QI6Z6%
M;+CXY2<KXUJRC:B4/BQ=:9.*SUT<;7'DC8X6Z</#A"01W#>00#T^D`M-R\UK
ME!9^<O%+$L%RKE+&YUG"V]Z/N^GP<,YI.!Z89;BIHA<9R4-/5/(QDJ\?ZE-,
ME%#.F!V$5,1[<5/>6*FD8%.\8*[R@WN+Y"DY6X_Y';GQ%B,=PFZR_'`FS<E7
MN]CRM4M=ZK-]RVL:+K\=Q3NU\AJE5)QE,6F+K<FXSXTA%L',8Y<F];0P;_2/
M#OS4V/CO1HO3-LK^6V#E-QBI''_R$PNHQ#O5=F<1>%:O8;=Q2V2DW2NV8E4=
M\N<VR5_'U:7G91618E<LD'J9G:[)(3AT`Y?PYX^YCICKD"TRZ@2G)^RTJN4_
M2>1YZ37HO4-'-"045"/IN=E(UFB1G(60D.@=_P#"`D#@$44U!.F@B4@6CZ`Z
M`Z`Z`Z`Z!1O.7\2;PC_;]S4_Q^[UT$=?EQ_P5^"_U0U']_NK]`[?H#H#H#H(
M7W/D7A/&6JQMXY!:S1<>J,S86=2B+!?K`QKT;*6>08R,DR@(]=\HF#R6=1\0
MZ7(@F!E#)-U#=NQ1$`BBZ^0'A%G#O-&%]Y5874'VPUR!N6:LK!HE=C'=KIUH
M5;H5NW,F[EZFLVJT\Y=$2:2+@$6;A41(103E,4`\\IY#.#4)8=@JDORNPN-L
MG']I*/\`;89YH,"@^RUK"6.&J$NK=DCN@^@?HZTV%C'K%7$IB.W:20AZS@'0
M3GCFXXYR&I3?1\+T^C:W1',A(1!+7G]DB[/"DF(A4$)6'=/(IRY(REXQ8P%<
M-5O;<(B8/60.X=PSVCZ30,@I4[H^I7&O4"A5A!LYL5OM<HUA:]"MWC]K%M%I
M*4>J)-6B3B1?(HD$Y@`5%2E^<0Z"'M3YE\4<0/<4M=Y"9/G2V?3=#K=W;VNY
M0\2YJ]@U"*EYW.H69;.'!5V4G=H:`>NHQ$Q04=H-%3I@8I#"`:XCS[X3KW?.
M,U+RFPU*_:]!4ZS9A4G6B5UE.7F#T,7A:$_KC%X]05D2752/6)%$('N2"B9B
M(%.</3T&YY1RVXP[KH&CY5C6^Y-I^DY$Y,TTRCTB\0-BLM,63DG,,N,W%1SU
M=TW0:S+-5DLJ!3)(O$S(',54/1T&*S/FGQ'V;2[#C.5<D<8OVM55U8F<_F]8
MT&MR=UCW-0DU86V)C7$'XRKG]6)=`S:0%%)0K)</0L)#"`=!^[GF5Q0:9YK&
MM+\B<?+F6$WN1S#9+V2]P"M8S/18F7B("1I-SED7JC6"LS2;GV30S-<Q5OB'
M21`*)CE`0B*Q>47QT5*`J%JLG-7C?$5R_M)EY3)MWJE7".L:5=E3P<^2-<D?
MG36=PDRD9J[;B(+MURB10A3?)T%W8*<A[/"0UEKTDTF("PQ4?.0<O'K%<,)6
M'EFB+^,DF3@@B1=H^9."*IG#Y#$,`A\_097H%&\Y?Q)O"/\`;]S4_P`?N]=!
M'7Y<?\%?@O\`5#4?W^ZOT#M^@J%SYJ/(Z_<-^0M)XD3IJSR)M6>OX+-)U"=;
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M54K9?6S`SD[46[YL5<Z1`*8!*%-M@XI>36KWWD1=^-U`L"-SY?*</[XTV%3:
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MCG<VI7&:E:2K;ZM4PK%5EC:#,:=L=IF'=LL4K),D6;`R#:,;$3*@91T%"*AP
MF\A4&RR^#A^,N>5J=X<<O^?_`#4R_79;:J`]F]OF=I><G76*8?2XJ%0=2-&J
M]]?[7$*W-W8W;!LW:1`ID;NE#)^T$4H^'WGOE&';CQRJ[W)-$J_(O&^#$Q9[
MIFYTLFE*[R9XP<GLQLFAZ!-,-%N=^);=!T_)UY68?6-)%!B_E:RT15CDS+)D
M4"Y]%\>O):HY]1,[F*S%7.R4'S61G,:U[;.72KC9]^PQU+R%C<;?=(ED2-AX
M'4(^%EF5<DH",CHUJY5@"NF31-%P``'0:`````````=@`/D``#Y@`/\`@`Z#
MYZ!1O.7\2;PC_;]S4_Q^[UT"G_!SROYPYSXK.(M+R7Q7;!R&SR"K.@(UO9*S
MRCX=9]!7=!UL>BOWSN/I^G:Y6KW")QDH[78&)(,4#J*-3*I@9$Z9S`U_^.7R
M3_V1M]_K5\?WW\]`?QR^2?\`LC;[_6KX_OOYZ`_CE\D_]D;??ZU?']]_/0'\
M<ODG_LC;[_6KX_OOYZ`_CE\D_P#9&WW^M7Q_??ST!_'+Y)_[(V^_UJ^/[[^>
M@/XY?)/_`&1M]_K5\?WW\]`?QR^2?^R-OO\`6KX_OOYZ`_CE\D_]D;??ZU?'
M]]_/0'\<ODG_`+(V^_UJ^/[[^>@/XY?)/_9&WW^M7Q_??ST!_'+Y)_[(V^_U
MJ^/[[^>@/XY?)/\`V1M]_K5\?WW\]`?QR^2?^R-OO]:OC^^_GH#^.7R3_P!D
M;??ZU?']]_/0'\<ODG_LC;[_`%J^/[[^>@/XY?)/_9&WW^M7Q_??ST"U^6_+
MCG7.<ZO$_9+)XG=EI-PI.S<J9#.<Z?\`*SAA-2>T2<UPPV.OV.!@K!`;`_J]
9-=4ZKOW,^NXGG3!L\;,#M6IE7BJ*1@__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g644794g97i90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g644794g97i90.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0NZ4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!*@```ED````&`&<`.0`W
M`&D`.0`P`````0`````````````````````````!``````````````)9```!
M*@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"1T````!````<````#@`
M``%0``!)@```"0$`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``X`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#TNRS9!-=MI<7ZUG0;3IN][/I?FJ++VN+`:,AN\P-TZ:[??#_:AYEE
M-;:_5:")?!(<8]W_``:%7U"FH$L`;.I]EG];P2L=PFCO1^QOW-V5ES`][N&@
M.=SY^[Z*K8]F4Y[!=6[:Z02W>(,M$NWV?1^FHC-.32X#Z#P6F6N8?`Z/VN4:
M<P666/K!#JK'UOW,<P;_`&[]N_9ZK?H;+6>Q)#?-;`"270/Y3O\`R2IGJ&&Y
MP;4YUAWACM7MB3'+OI?U%7%N']NV"FO[6!ZV[8>_MW>I]'>CV]3-1#7@21.C
M2=/\Y)5MFFW&O+A4YSMO/TQ_U4(OI-\7?YSO_)+.RL@6^F;&U/`DLWM>>1M]
MFS?^:Y-CVV5ASJ&4-#R-Q:'B8&W66A)3I>DSQ=_G._\`))O39XN_SW?^27.=
M1S:CFVBVO$<YL";&W[H`W-W>E4^OO^:]#/5&NV$MPR:FEM9VY/M:="UOZ!,.
M6(-7LRC#,@$#?5Z!UNV?T&08,:'SC=_.?14F.#WM::KF;A,N<8'D[;8Y<X[J
M5;J64.9AFJL0QA;DPT?R?T"+5FORP,1C,-X@N%9^T`>WO[Z6I>['NHX)@613
MT?ILXEW^>[_R23FAHD$R"/SB>_Q6,VO+]'T7TXOI[@?3;O+2!_Q@KVN:YK-B
ML]/K?5N:YE5;8$-J!'YS=3N<]/!MC(HO_]#T/.R/0%6M8W.L'Z1[F<'\W8RQ
M5AGMW@>I1MELGU7`P=V_V^G^;M]G[Z-U*P5BF;/3EUG^%-4Z_P`EEF]5&7[K
M6-&2X!T>UN1NY_ZS[O\`MS8F\52()7\%Q!$?JV7Y>(W'LRGW,^ST@NMMDD-#
M=7[O;^:G8<@N]XJ-9<=KFN=/IP#2[:YFWU'?X3W*MU0FGH^:?6?+:+'"U]NQ
MPT_[D;'>CM_?]/V*T=Y=2X'VAON_2<RT;?8UNR[_`*"<5B)F4#DOI(J.R`"'
MP_6?IMM:S_P)UB=^0ZMQ:=O!/N#V:#S?^;_PBC..[(EN3[]VTU%S7^YI^@P7
M![J_^M)78["\.8=I=I_.1+CX;V7>Y$UI2!8NV5EOM82X,)G\^VF=/W6L<YZ>
MO)IV#=:)_KO?_P""/8UR3BR@,8UY8#/-KFD\>3]R)M(_PMG_`&X4$N/U#+JK
MS;F.RJZW-(ECNI6T$>UO_:9E+V4_YRK_`&ZC_N;3_P"Y>_\`](*SGY@KS+6?
M;#5M(_1_;651[6_X%V/8ZO\`SU/%KS,D,L9?<<=\Q<S,:\:2.&XW[XV*N=9$
M"M_W;;@],(DB0%#],QZ(6>O96+*K-['`N:]O5,@M(!VDM=]G_>6GBFFFK;Z[
MWE\.<++GW00-16^W\Q%<<AQGZ.GYMK@/NV?])("\N$DAO<BU\_\`4J:,`->O
MD`UIY#+38><I?])F""`09!X*+1],_#_OS4(<<D^9,E%H^F?A_P!^:G+'_]'T
MF^IMC6`V75PY_P#,SKK^>6M>DSTGN#6NN&XP-U;VC0;M2^MJK=3>&MIEP;+K
M.7VL[_\`=;_T8J7J->X,8\.#MI!]?)[_`-DM_.3>(<5:?:NX28@Z_8Z]_3VW
M464^M;5ZC2WU*R`]L_G5N+7;7HGV1L#WNT$3I_<LK,S+\7"RLNTTM%%3K&$O
MLVRV9];:S>VOZ/\`->]&J956'&LQZSO5=[W.&YX;NV;C[:_W6-]B<M;?[/\`
MUCU_M%T!NT4[AZ>HB?3V^YW]93.&#'Z1X@SH1KY'3Z*S&]3P77?9VW@W;S7L
M]\[FG8YO'[X4[P7EL.\OYVUFL_\``?2_M(F]+0`!==[;[\(.B+K61^X[;/\`
M6T4OLC?WW?A_<L^\M<&C=R?WK1_TJ%%M):6F1[3K^EO/?^4_:[^V@EGD=.<^
M][AF9=8)'LKL:&C0?1;Z;D6K'-5;:S99:1/OM(<\R9]S@UJPNH936YUS?7:V
M"/:<S*J(]K?\#13957_8>I4T9N14VZEX?6Z=KAU#+@P=IYI"B$AQ&@"=>I_[
MUG.,\(,B0-*TC_WSN^GYE+T_,JC^SJ/^Y&7_`.Q5O_DDAT^@$'U\HP9@Y5I&
MGC[D^Y=A]O\`Z"Q5#]X_XO\`Z&WO3'B5.IL.)D\#_JFH!<">42@C>=>W_?FI
MRU__TO1L@9!#V5N<SB(TU]3>[7_BD".H[F'<^`9<-PX_E'>OFM))3])M;U$;
MO>\SWD=O`>I^=*G0[/KNWV;K61&W<`)/NW&7._J+YI224_3YR\B/Z/)TTWM\
M?=_FJ=607;O5K-4&&_G2/WO9]%?+J22GZF]:OS_S3_<EZU7G_FG^Y?+*22GZ
MF]>OS_S3_<EZU?G_`)I_N7RRDDI^IO6J\_\`-/\`<EZU7G_FG^Y?+*22GZF]
M:KS_`,T_W)G6,>-K9))'8^/P7RTDDI__V0`X0DE-!"$``````%4````!`0``
M``\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`
M90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````
M!P`(``$``0$`_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#
M`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@!*@)9`P$1``(1`0,1`?_=
M``0`3/_$`.4``0`!!`,!`0`````````````(!`4&!P(#"0H!`0$``@(#`0$`
M`````````````0(%!@,$!P@)$``!!`$"`04("P@/!@,'`@<$`@,%!@$`!P@1
M$A,4%2'2D]-4E)464]15U5875Y<8"1DQD2)2-M;76$'1DK(C,W,T=+1UI;5V
MEE%A,J.S)&-EF'%"@H/#)36!PJ'!8D-$Q"81``$#`@,#!`X(!0,$`@(#``$`
M`@,1!!(%!B%1!S&1$U9!88$B,I+2D],45187&''10F(CE-05\*%35*3BHPBQ
M4J(DP3/A<O%#8__:``P#`0`"$0,1`#\`^^\HIH1I3KJL)2G'+G.=.V4V\@Y5
MJ*P;P0,*XIMTII&4YY/PEXY?WV,=S4[=RG#O*PM7$56DYS_W@^>3/["TY_\`
MW:4<F`+C](RM>6,_?3WVE#O3`$^D96O+&?OI[[2AWI@"?2,K7EC/WT]]I0[T
MP!/I&5KRQG[Z>^TH=Z8`GTC*UY8S]]/?:4.],`3Z1E:\L9^^GOM*'>F`)](R
MM>6,_?3WVE#O3`$^D96O+&?OI[[2AWI@"?2,K7EC/WT]]I0[TP!/I&5KRQG[
MZ>^TH=Z8`GTC*UY8S]]/?:4.],`3Z1E:\L9^^GOM*'>F`)](RM>6,_?3WVE#
MO3`$^D96O+&?OI[[2AWI@"?2,K7EC/WT]]I0[TP!/I&5KRQG[Z>^TH=Z8`GT
MC*UY8S]]/?:4.],`3Z1E:\L9^^GOM*'>F`)](RM>6,_?3WVE#O3`$^D96O+&
M?OI[[2AWI@"?2,K7EC/WT]]I0[TP!/I&5KRQG[Z>^TH=Z8`GTC*UY8S]]/?:
M4.],`3Z1E:\L9^^GOM*'>F`)](RM>6,_?3WVE#O3`$^D96O+&?OI[[2AWI@"
M?2,K7EC/WT]]I0[TP!/I&5KRQG[Z>^TH=Z8`GTC*UY8S]]/?:4.],`3Z1E:\
ML9^^GOM*'>F`)](RM>6,_?3WVE#O3`$^D96O+&?OI[[2AWI@"?2,K7EC/WT]
M]I0[TP!/I&5KRQG[Z>^TH=Z8`GTC*UY8S]]/?:4.],`3Z1E:\L9^^GOM*'>F
M`)](RM>6,_?3WVE#O3`$^D96O+&?OI[[2AWI@"?2,K7EC/WT]]I0[TP!/I&5
MKRQG[Z>^TH=Z8`GTC*UY8S]]/?:4.],`3Z1E:\L9^^GOM*'>F`)](RM>6,_?
M3WVE#O3`$^D96O+&?OI[[2AWI@"?2,K7EC/WT]]I0[TP!/I&5KRQG[Z>^TH=
MZ8`GTC*UY8S]]/?:4.],`3Z1E:\L9^^GOM*'>F`)](RM>6,_?3WVE#O3`$^D
M96O+&?OI[[2AWI@"?2,K7EC/WT]]I0[TP!/I&5KRQG[Z>^TH=Z8`GTC*UY8S
M]]/?:4.],`3Z1E:\L9^^GOM*'>F`)](RM>6,_?3WVE#O3`$^D96O+&?OI[[2
MAWI@"?2,K7EC/WT]]I0[TP!/I&5KRQG[Z>^TH=Z8`GTC*UY8S]]/?:4.],`3
MZ1E:\L9^^GOM*'>F`)](RM>6,_?3WVE#O3`$^D96O+&?OI[[2AWI@"?2,K7E
MC/WT]]I0[TP!/I&5KRQG[Z>^TH=Z8`GTC*UY8S]]/?:4.],`3Z1E:\L9^^GO
MM*'>F`)](RM>6,_?3WVE#O3`$^D96O+&?OI[[2AWI@"?2,K7EC/WT]]I0[TP
M!?N.(JM9_P#\QC'_`+5)Q_\`NTH4P!95!;TU^7=2VV6RK*LXQCD6G]G_`.+.
MFW<F#<5N,"08D&4O,+PI*L<O<S]S]GDSJ.V%7:#0JNT4K__0^Y+>"?<A8`IY
MM64Y0TM7<[G=Y,_^S]C&I[("EO9/95SHFWU4!KT2<_#1TI+24:&?(RTD&P<6
M00:,V0\EIPI#N11$J<YJ&F^:G"<8SGE5RJR0DU6:>J=6^#4!Z&CO:VH4+\]4
MZM\&J_Z&CO:VB5*>J=6^#5?]#1WM;1*E/5.K?!JO^AH[VMHE2GJG5O@U7_0T
M=[6T2I3U3JWP:K_H:.]K:)4IZIU;X-5_T-'>UM$J4]4ZM\&J_P"AH[VMHE2G
MJG5O@U7_`$-'>UM$J4]4ZM\&J_Z&CO:VB5*>J=6^#5?]#1WM;1*E/5.K?!JO
M^AH[VMHE2GJG5O@U7_0T=[6T2I3U3JWP:K_H:.]K:)4IZIU;X-5_T-'>UM$J
M4]4ZM\&J_P"AH[VMHE2GJG5O@U7_`$-'>UM$J4]4ZM\&J_Z&CO:VB5*>J=6^
M#5?]#1WM;1*E/5.K?!JO^AH[VMHE2GJG5O@U7_0T=[6T2I3U3JWP:K_H:.]K
M:)4IZIU;X-5_T-'>UM$J4]4ZM\&J_P"AH[VMHE2GJG5O@U7_`$-'>UM$J4]4
MZM\&J_Z&CO:VB5*>J=6^#5?]#1WM;1*E/5.K?!JO^AH[VMHE2GJG5O@U7_0T
M=[6T2I3U3JWP:K_H:.]K:)4IZIU;X-5_T-'>UM$J4]4ZM\&J_P"AH[VMHE2G
MJG5O@U7_`$-'>UM$J4]4ZM\&J_Z&CO:VB5*>J=6^#5?]#1WM;1*E/5.K?!JO
M^AH[VMHE2GJG5O@U7_0T=[6T2I3U3JWP:K_H:.]K:)4IZIU;X-5_T-'>UM$J
M4]4ZM\&J_P"AH[VMHE2GJG5O@U7_`$-'>UM$J4]4ZM\&J_Z&CO:VB5*>J=6^
M#5?]#1WM;1*E/5.K?!JO^AH[VMHE2GJG5O@U7_0T=[6T2I3U3JWP:K_H:.]K
M:)4IZIU;X-5_T-'>UM$J4]4ZM\&J_P"AH[VMHE2GJG5O@U7_`$-'>UM$J4]4
MZM\&J_Z&CO:VB5*>J=6^#5?]#1WM;1*E/5.K?!JO^AH[VMHE2GJG5O@U7_0T
M=[6T2I3U3JWP:K_H:.]K:)4IZIU;X-5_T-'>UM$J4]4ZM\&J_P"AH[VMHE2G
MJG5O@U7_`$-'>UM$J4]4ZM\&J_Z&CO:VB5*>J=6^#5?]#1WM;1*E/5.K?!JO
M^AH[VMHE2GJG5O@U7_0T=[6T2I3U3JWP:K_H:.]K:)4IZIU;X-5_T-'>UM$J
M4]4ZM\&J_P"AH[VMHE2GJG5O@U7_`$-'>UM$J4]4ZM\&J_Z&CO:VB5*>J=6^
M#5?]#1WM;1*E/5.K?!JO^AH[VMHE2GJG5O@U7_0T=[6T2I3U3JWP:K_H:.]K
M:)4K]]4ZM\&H#T-'>UM$5HFMNZ;.A.B$U^,%6I"DCGQP(@,D"YG'X#X9C#*7
M&EMKY%<W/.;5R<BTJ3RXTJIJ=ZUOLS,DE!NAD.],X$0^&MS'+C#BA75LY7C&
M<\N,*RWR\G^_4]E2_:`5O[4*J__1^V/B&SG%9-Y/)U_O<ZG[7\;E+/!6]JG^
M2U:_L"&_PX;4*#RJ_P"B)HB:(FB)HB:(FB)HB:(FB)HB:(FB*`_%I:]XXS<W
M95W;*`W2E:KM=(1NZ^ZCU#,[.A284[<:AT0N'MH"I>+>W&AD[+RNXLHW`"-2
M3K<_&0QJQTJ:'?;*1V5!7A[C>)NS5G;6J[P3O$^3*TBE_5VP9]H>OF]E0>N0
MM\MN\%RW,DILV"FJZ58+)"4&SU^N7.0D,OGJD8++ICO.RA>84E6=N;XN/6"\
M]BRV_P`=8$VG>%H&,Q+;V2,B+0V]C]]2(N3BJP6LZ@.1C-V'AFH<AL9,MFRK
MBV!W%-+4PZ38MP8.W8*W(E@X*P<1+U?]:-NT\.#)5HWVPS8*XKB8$1?2+LB4
MDTNV>!;JO:^'S+)A]UJF(8(&=2/@1_1.93HX0('<Z)H5M)W8MUJMD\C<V]4.
MO/6IZ;2:SM[LE/&[)TR<(%ER7$$S>Z`5`<NDG)-MXS(G61>4N.BM"<V5![2E
MEHH31$T1-$31$T1-$31$T1=3[[(S+Q)+S0XX[3C[[[[B&F6&6D9<=>>=<RE#
M;3:$YRI6<XQC&.7.B+0H7%)L,?"RU@8OX[<9!4N][B3"S8&TQAD;2MM(:AV2
MXV(N+D8,649!CZWNA7I)CE9Y\C'3`I0:2&'4N:*:%91MKO=MENZ_+BT"PD3!
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M55EX^"VOCY*)WFD2";#/,%Q@+@3&7$<W*TKD`$&J*&-"^L4WMN=8C7!ZQMT[
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MC`V;#,OK>35LA@1>_P`HP!:@TM91$#=+GG.9SG4%M**5VE<=DQM+<;=6]\`(
M>T"-;T$[4U(O:VL,U@T-@>1V?K8TS88:U[NVJ<FV)&V[YPHKY((@T=$,-+60
M0LDT`)Y394(JDGZS"@1XL2;+;3;E10LTFFQ8I))M%>9#N^X,7PZSM1ITK@&U
M%DM.G0O%14'7SA6S`QW,R+7/6H1CKC#VT65["\:4YO+NF]693;"1V_I<Q9C*
M?3G;)EP>^^LJ>'#8'B*%A;C74/O#0)PD#N5/CF*:<(&P]%BI9>=P\IQ0B@Y4
M7H!JJ)HB:(FB*$W%#OMNMLO-3C]0<V],KL)PI<3W$$J+LE1LA\T7.\/C>U^`
M8!,]&;@0@(\39W=S4J=7F-<>&2!E*<N9?PI@I"Q.Y<2F[E<!W*+BCML'VMH-
MIZ1NE/E[C;;;H[+HN2=R;ENS3(2KP,3;;2?/U2?AB=J'%C-F#R"+2;*!A,*C
M$KZ[F%(`4>-P_K+[O3Y"XE@[?0:J;7*)Q!RG;%I@KW39*(MVVW#3PA;N;;>L
M$3:.Q#\UF[;G<0QE6SS&&7BW2X;(KGX3[CQ**0<+Q=WPS<W;6JG5JL)KV\&X
M-IAZJL<.98F:W5*1>MS*'+-V8IZ:?"D+/,JJT3(C+&8'&%P4:&MM_JS)I,J*
M+JLO%UN#%S:AH^NU;LJ\77<#;_;E1D18BY&J26UO&)LIP:V&>NK<?.8Q=0K!
M9=VWK''`1S<*ZS'1B0W"7'25%#0IH%BD)QF;E63>:L[2`KH38YD;*9EK=7]I
M-[+\\],UR<L-:F(]VB#2-4MM#(3*0*D2+,JAYNN&H>"?)-Z-!CI*!22X6]Z[
MAO#795S<42OUZ]1L?4)N8H\97K379&HBV^(>(9!=)GSIJ"W'K*9B*D!XBZ5R
M0(K]D;$>R.V.Z,^UB5!%%*?10FB)HB:(FB)HB:(FB+&+M50KU3+=2))X@:.N
M-8GZK($"91@I@*PQ1<04\-EQ*V\$-,&*4CG8SCG8QRXSC1%YXSW!-N;96+K+
M2=SH3-KW0V9W/X=;>D`*Q-P,+0=R]N=AMO2;K7<$X(/DK;&.[(+E&HHGJX:L
M3?4E'*ZAUXXIJ%OGADX9C^'Z2F#'[2NQ,3FU6U%)+9(E+-*J%L.WUKWHGI21
MB%622D^QJS+!;G"-BQ075007@GW&V,**<5DA-5+S10FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O,;</C(W:I$P4UB+H1,+8=X['M+4U
M"4J\3]@JZZOQ,;%[)$34W!0EP</W(Q*UC=60/;$BVH@IJ4`$$;06DU:QH5J!
M4FY'&CNO1Y_U!&CZ4;:VMQ=N$.RAVU^YX!3^R-]F>&#;_-X&VB]:EWK%L%W0
MXA"P1H;)BBS&Z^ZWAI#SG*DE`MW#\1=Y33=WRW0J^=8J1Q";#;"5>3=I=PJ`
M+Z]]('A@4+;K/0+%8';4#ZK3O$"0^_%*/#(>#C4,9>8=6M],J*<BBC>^/'B-
MCXW=3.WVW=(L,_M,)9:Y.!2-&W)357;94)KB#V^E[S(;@A69-=J](.W#V;`R
M#!%=)-$1\SA"2ENHZ34*:!5=+^L.W!W7W@CZ=38"LUW;RUQFT4W2[<]MIN7N
MY8BPKKM=NY8;D+(5.A6.$-P]5MS-J38%9">C8$ZF0I_"LY2I!"`%417'IO':
MQ;1$Q=?VRJ=QI%AM8TRU-0=GM$;+5E'$/3=JJ'-0P(=YJ4@,/+4Z^CD%DN.O
M,9GHB1#93EM'/:)0*6^YV\VY-%W2I=$RY3(BN3<-MX"5?I>D72PP,IN%N#<Y
M2CC5XU52M!#VT*%&#"/0"["@B,M<@7F%9E`3&L/N2HH**+AOU@=FV\*V=:W,
M7MA*LW![>Z2W`16X^9J<U!052GK+M]L['U6`FKM;")V9W'W$J!C!!'2J9%:Y
M&^A1E.'W8JIPUJMCTSBCW8G-W-J]I)R0VX9E+36[M9[834]F=][,_&N5Q'#%
M@"NOA/2<2Q38XLG>R6YEK*)DX`H$($S_`+93KXC<J*!>BVBA-$31$T1-$31$
MT1-$31$T1-$47]B_XZ:_MF5_KI.I/*/I5G^!W%*#4*J__]/[8^(?\F3?Y!7[
MW.I^U_&Y2WP>ZMZU/\EJU_E^&_PX;4*#RK])JU>+M,/=28D5ZUU^`LM6A9Q:
M59.CJ]<)&J2UFB1U85A"19F2HT0\]C*<YRL!KDSCDSRD6GI+A7X>I>+A860V
MJK)$77:?2=O8</"#F6PZ%MW$W2`J=+YS!C3A%6"KNXT]&D`.J6+(QLP6(8A\
M=];69J=Z*X/<-FQA%]^,Y[;>"<O")-^:&FU*D,XCYDV9J%CE9:*C.N]CQ$G/
MS^W\&;)OBCLNRA<2*Z6IY;*%85**C3PM\/B84*NIVIJR86.W!C-U@(_`Y.&A
M-PX:I#4*)M0ZNM=*W(QU)#:B6>171HCVTL83T>,)TJ=Z+K!X7MD(&BV';VF4
M:*H,#8@8@5Q5088CS(HNM6"2MU2FX?K;,@"-,5.X2STL`XXPZVV>KGK;<3RI
MRJ453:>&/8:ZR^)VS[:04I+YLF+>\<MR2&=,L29>ESR)*12$>,W)J9FMNX0I
MMHA+K+;\<TM*,*YV5*G>BUV5P1;$'[D8W%/BI@A`M.C:A!T<<T"&IE87#L;=
MB15QK_J_%1%O%W"C`]J*ZT+-.2[Q@J(8#+*FU1\>H5B-$6RZAPY[1;?V^.N-
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MP-X>MD)`^6D<U(8"8GK2S9"9>!L5DK<X/:0B[/.9+@9>O3D9*5LEV4M\W(DL
MQKHK9)LL>4\A;Y9+CA*E5CW#QLR2[82#*+'GEV@:/'FCI(Z9DI%]R,,@),65
M$D3I(@Z)L2IJJ14B_*".,214I&"'//N%C,O()4JT`\+FQ<2:!*05)=K,S&NR
M#P\]4[7=:I87')B4E)R:R?8*Y8XN:E$SDU-%%G)*?>2:2^IU_#B\\[1*K/:!
MM3M]M:,6'0JT-713&8P)3#!4B6V)$0;+PU?KD3B2,,[$J=:&)=:C(@/H(R-;
M=6@5AI*U8R456PM$31$T1-$31%#C>FORLAOA2)&:I=WN]616ZN+M[ZF/3P;5
M-W*'W>JY]ILT_.0^6@JL.BH("?R6:O"#8:.EXMO*L'O!GE(7FC9*?Q9TV*V6
MW)VZVXW=G;'LQ';,W#<*DM-6L,O<;B*JFV^Z$-Q5E=4ER`V;?%[F5:QQ49'R
M;;V8.;GVNL#/+=;<)7"ML/*M'27#OQJTZG;M;7P0._ED`N6VN\NVYMY;D+61
M*.S&R>\G$#O=LI:XO+QC1.$[HQ<"JN9(%2MXU%OBV<IZ%2%MDV*3=CV5W?MF
MVC\'6*4$-N`U;>*29GBYKATW)K\B\495N('XIS9R\EVFOM[B6;$K)@9K=@BB
M4]A$$,+;:4XZSRE"SZ7"W@J@D!>ZWLSO;:-X:CNGOU>[F6]ZWI$N-2<FMT+#
MP\4JP(SD*)W(D2:&]"1XY8>7T5;+3L<^H-XS+.B<O+R+-^#.`WNV1W/F]JM\
M(N_R@-6J$51*;N#'@;F[ETN\F3MJDMT3ITJ^>I49'A/1IFX[T2^3(C1C+&(O
M+*5*:8PXHAV[0M06K:'B@CK9B=HT#."3=PW5XGY8.0A*_8:\\PJ,XW(R2VLD
M]Z9UZ>E(R[1[^W,MUJGE*!C4Q%5;DA\X+&=0MDG85I*IO$#)M&1FU.WFY&W]
M6AMA-V(TSUDK.[1DA<[/-M<$ZF&(\"PV"N/UC<PQ^K6#!$FVF4%E9,68DDMD
MNFE%ODV+8^X6S5DJ,[N%8J=M)/.O)W3WADJK48.@6GU2W!:13-GW=O(-$_M?
M+UJW[36I^?;G$5"^\C\%4G2)I16&W#FU+(#LY5[":E531$T1-$31$T1-$31$
MT18NY<8%IQ;2RG<+;6I"L8&(SR*0K*58Y<-\F>[C1%P]=:_Y4[YJ1XO1$]=:
M_P"5.^:D>+T1/76O^5.^:D>+T1/76O\`E3OFI'B]$7:Q;H,AS#31+BEY0XOD
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MU"I@3LP53)*%CLJ02I5Y"HFPT=`357"I\0/`6*OP=7GHU`!V69>"K>#>Q@9!
M:EJ>*ZHN2(7EU:LO.NOK6XM:U95DH6(#[%<,4>\`5!4G%2/BWBR(V5HLO=:'
M,`N'S^X]I/2+,TV;@I1ADZP[NV4MYM+V&W79@C*TYQE.$E-2KXC:OAP;D7Y9
M&W]>3)E08E:)/3%FX*?@`-P3=U0HEU["^>L,7<62(EVT9_X3'EJQW%9QHHJL
MFL->V>M5IA[I/PK9]EA.Q\"2&>V1DE)K<PY8JPU.`!D#QME9JED>7)1*)%DI
M$5)+44)ADA67,DJK:C;?8-J//;Q2(+,?,E57$BTY&ENH,(V_ODQNQ4.E0ZI>
M>;7-P[4=,BXQR)0<8ZODSE6<:*:K$H#9#AKJDQ"V&J58ZK3E?9?"C):M6?<*
M`/3$/L4X/-<.)B+$&Y+U-B-V\@0V(@O+\8,!#ABM,(''::22I4@?76O^5.^:
MD>+T4)ZZU_RIWS4CQ>B)ZZU_RIWS4CQ>B)ZZU_RIWS4CQ>B+M=MT&SAE3A+F
M,/M8?;Y!G\\K>5N-XSGD1W,\YO/<SW=$75ZZU_RIWS4CQ>B)ZZU_RIWS4CQ>
MB)ZZU_RIWS4CQ>B)ZZU_RIWS4CQ>B)ZZU_RIWS4CQ>B+*DJPI*5)[N%8PK&?
M]V<<N/\`^&B*,&Q?\=-?VS*_UTG4GE'TJS_`[BE!J%5?_]3[8^(?\F3?Z.O]
MZK3[7\;E9G@K>M3_`"6K7^7X;_#AM%4\JCWQ!<0,QLX>R+"UF*GVHC;'<#>2
MW*EI4V,<Q3=NIBCP\E%5[J<=(I?LDHNZ8<841T8S6!<X7SNDQE%V,Q=GLT7&
M]Y9R#L$\U%K(+C),3OA;=I)>I`BC5>S[@C-28YI"S9>ITG;R3MJI$$=WFL+E
M6YB'<%+;YW,9:(&5GDRZG*K='WH<#MV*G2]^6D<E?^BO\3Q%[ER54H;KM.V\
M&N>Z5QHT!4!V+L9)P$='WG:B7W;9?M;(D7ZS1<A$QD`6#S%BLI/<Z(EKF,N9
M0B"QM3M-`/\`YHI$CB!L&(G_`.*K,MH^(OXT3@7LUU$-"'\.>UN^G)@M9TD(
M7?97<`"3KV5]$*,6/$(IB>A?PAI3ZG594E&.3&#F8>SMQ$*S),78V80>>JU/
M!<7]KDZBV>;1ZV'9[)&<.UAIHXTW.R$&/!\2*I]5=39LL5_MEV5J(M7,<-:`
M8=2<O+3;.6N?E:9,8KR[-O\`)4$II6@J:?S651_$M<IV4X?PX&G0<B%OL"2P
MS*B%SA,=6;#2)K*]TA32#(Z'*4&'4A3'HCIQA'23A%LN\SG)QF,`[_;R?P%/
M2$F.@\+^"IG:XUS)HB:(FB)HB:(FB*")?$%=X/B:M6TI5CJ>8$_<2H@UR+DX
M:I)F8^!*HNS"YR/Q,3&_-%/0N6F[D2_$8'KTP<6^DY#(I*0N8LBG=HB\R-IZ
MHA7%"=>Z?&;4U-%JL4[+35>AJ49+;L5N)<@<-3$1O!%,6N&KVU$A8I<5PL:7
M%CRY(XU]H<EQYA3R'B+T;LZY=NM6%ROF1,?/(@Y9<(?/X=S!`RZ0"%1IDUAA
M27LQ(QF$+)YF<*Z%*N3/+HBTKM3N!9+#<YFN3\Q72FP:77)`6.CK%"VR67(C
M&'Q,[8").KU^`A08F96@9;([J5%+)ZPI+`@Z&FUD4AM$31%Y';L<7?$W46=T
M2Z5`UB5:3N/N?M/ML[9:D2U#YW"I>X-<<JU=CGXFUIG[<F9V7@;W*2[B04M@
MG0@:</,I>RV["L`.R587..#=ZY57>2_;>SD,'4HK8'BXWUVP,FMN\+%D`]@S
MMK7Z`&)()LZD3\?/0>X"_6+"D,O#$Y%ZHZE.7<9)14>YG''O_MSN#?-I%XJ$
MK-QN\3%4V^G6:TT/*6ZC-TRGCV)IF)DK+%P3]VJU[E.F*=ZPQ&-!6&):=Z-6
M7'%DH**0M7X@]Z6N)2K;3V-#J*X?N)&;?S+%@I4&$<TW)<,FX>^/.59:?<IV
M!'N[-AJ8[*1&,F`+A>L+RO!'1KQ*B@HO1;10FB)HB:(FB)HB:(FB)HB\R.*G
MC!W1V)X@HJG0850)VPBZ5MM<[^_+QYRIJ+@+B%Q7`V.R,2[4F/'@Q-*/VJK\
MR<HAG+;<*%*8RKGNM+9*0%J:B\<>^Y6W.SU^GO4NP/;N2EK6]7XFIF@%P`>W
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MT"S>D\3-X.O=^%MTA(L479+;**O6Z9S=`KE5DZF0Y;^(%J:BMQ`9W<(\QDN+
MI^V$9ALJKIEHZ2(40<RMH$H5*)446B*=QQ[Y2J*^Q/1<(FU568VM@-UZY!TB
M3>A<2VY._<-46XU,B9/-S$$4_M+<H=^*7T3N'Y]_&'&U#*YNH4T"SNS\6V]=
M/J2IQMZA[B24QP:[P<2;<;3H,6-(V]GJY5-EI^L>MC%@W"'3)T"/*O<BK_LG
M'IDX)3&$L+6RX\]*B@7J[$?SY/\`1C_\/*T4*/?$3>['MSMBJR5/DQ-D[A[*
MTYE6(K$X0V#N/O3M_MW-.QT0HH-L^89A;20H)M;F&\EX;Y^%)Y4Y*0O/:]<7
M?$]0!-RU6&&@(J:IP&[(T;&&TIM4>0U6>%[>K??;V7D)$*\&C@7R=<H$.3(0
MG6'P1PR3F,/I=;:>Q"F@V*:UJW0N]6H]<BW1[#';BV2Z;?5<B6N5$:[)K<;?
MMS8REYD2Y"FR\IMN?-CQIV5`!#SK[V27A5%,\W+C.94+3Q7$GN3%[3;V6C,Q
MMY:I[;'B0V+V<BI^M1$BU5IJ"O:>&%BU2&0")PTE$GUG=J8PUA)2VQ'4-(Y7
ML,Y6Z2FT+)^#'B+O._<7.L;@"5V/M5,I.TGK:!7Q2Q&6+O98NS%6$UD<TTLL
M2`LX$;'S4,.]_#M1,FQE:W,KPO1"**>(?\QE_P"C"_X@+HH6DM_+M,[:;%;T
M[C5U(2[!0-I=QKM!(DF'"8Y<S5:=,SL8D\9IX9T@)1H",.H2XVI:.7&%)SGE
MP10S3Q+<0E:W`O=,ME*2NOQ5LX-1:;;SH2NP,@BE;\\0,KM7<IK<2OXW")-C
M9,YN(-`@VXP8G+2@VSC61T$=$DIH%@-+XX=R;F\1+=9I<32(N4N&XTI,BU9Z
M9L,7P_R`&T5MVPN,[2";W!VPJF1U?NL]#6NP0@<D[$SL='D.!,A/$)S"FG.I
M4;-[H[NVS8&=W4FHL8FT$5J2L%7CK`Q!5NHEK!9E'FU@&5&9NEAS!N88;Y<R
M`PI^>;R=$CG94F5!&VBD'MA9C[KMKMY<I5D0>3MM&J5FD6(]MYH!D^>@(^5,
M9":)(*(;$;(*5AM+CKB\(QC"EJSRYR4+9BO_`,,Q_:9?]5#T11PXB[]:-O:7
M79*H*<1*SVYVV],=<&@D620:C+9:08>3<BX=TP)DN32&^KH>>OF)5^%E*N3D
MT4A0F/XSM^*0#:!]R]OH6&LE3D96`,2PU$X@9"[M<'6U^\$)MZ'B-O5FG6;+
M+;OW=07*ADR/2(^T,R<4XCK#L*:#>K$7QL;Q#[8W6\+-I/24O:S=2$9D8JG8
MF(&Q[_;0;=;PEVJ)EAV=R/6;:PN4N^V#<K"`S0*X@ZKO]"W*$R!;2A"4%5,#
M=/<?=O;S9Z%L,8[%,[B2,K,1<?6;_2\V>VW*P/1%H=IU#JE,VAO799<].RP`
MI#YJ9I8<7`L&&FI:;9(=$E1LKVE*L59#@PZRV6QBUL,K*'9?R4R.0IM.7F6B
M5,C*(;:<SE*7,MMY7C'+S4\O)@H5ZD?XJ*_LQ']<-T10WXE]S-X:9-4&L;+Q
M0L[;+;7-U96*A"8,>68G+-38FND5&#EC"[!6QJ]5I:7F>ADS^LMN#,*PM"T9
M3G.BD4[*BA)\;>]*MO;.3&56"C-QB]N.'R1VM"L$4R9#W.Z;AWCB)]=BQA*O
M;IJ5]76MMMD'B@F"<`G,D#/*=1T:T\V%-!57U?&!N=8V8*3J9,05';K7"-5M
M&-7:M7+$W:=KW=V:A2"+!5;NYNCZI.VV!C+:.#9X2Q(@SXBR+6VPT\&QA]\E
M%*C<_=6];=E[.MCOU1\*;L6V-3W&C[#&&EW%DK<V\U.@1$KS:?.D1%+!3)R1
MK22\L3@)LRH4%*A!5/R3$J%)_10I)L?Q#/\`)-_O,:(HR[&?QLS_`&S*_P!=
M*U)Y1]*L[P>X%)_4*J__U?MCXAOR9-_HZ_WJM/M?QN5F>"MZU/\`):M?Y?AO
M\.&T53RK'[QM9M_N0]"D7:M"3[U?49V4LA\X?H6)%V.?D0",`EBID8F1?AQ%
MD!DX=$?6*TIQM66T9Q(<16A57-:ZF(*W-;+;6L6T6]MTV-Q;0Y:VS@\VIPYP
ME$G>HJ-A+8^IMPM8SK<U%PXS3C2T*93AK&4(2K*LYG$ZE*[$P-KBIM^M683A
MUV8`JY-.!HP0<`5-`6%;`LE.L',R\3&,0<04#.-2B9R.3#P0R`0VAR6F1`4]
M7:2AGE1IC=6M=JCHV4IAV*[C[*[9AV2M6V.K:XF<J%7@:57W8:<L4,`'4ZNY
M).UZOOPD7+B0<G&0ZY<G+#10S^$=+G'W,8Y&)U"*["IP-J#3:%:0^'?9B/KD
MO4@J)'C0$V;`2!H;1TREUHJJ%MG5545(=I=I0+-7+:2N-:!>&:`SR]`EO&<X
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MN2#E*M38"*\$/)3ZS5P1Z140<<6M`A\NI_*<#,NJPVZ]S4JSC&<Z(HN\+M>(
MB[E>I)4F?+=K5.G/3!<="7J%HXUE5*VIPJO1`5W/>;BCZI%*$!ZL`.V40,VW
M(3#KYQJ,-$4U]$31%C+-+IPY`1;%3K+!4;8Y:X1Q+,#%MD`6V?"E8R=M(3R!
M4N"V.:C9TX<LYO*226#'VW%J2ZYA1%C06RVSD9!XK$;M-MI'UI,!:*FFO!42
MK"0::M=TQJ+I6L1+$4V!B`MZ(8/$H'T?5I#`C.'T.=$CFE-3O7&Q;*;-6]Y9
M%LVDVRM#[A<P>X]8J%59MYPZPL0PL^:MR2BB5J+G!:['MF.9SSR6P1TN95AE
MO"2BJN,-M9MC75`KK^W-#@E1<LU/QBH:H5^,5'3K$'(UAB:!4%'L9$EF:U+E
MQZ"6^:\D$IYC"NB<6A1*K/-$31$T1-$31$T1-$31$T181/;9[;VJ1-F+1M]2
M+)+24"JK2,I/52!F)$^L+#LL<NN&FR`!!)4"N/N<PQD-:E#Y9EC$<SFE/X61
M6.!V+V2JJ"VJOL[M96VY"1A9@]N!V^J4.@V7K=E1<Z[*%HCX@=),C`7!M,L$
M^OG.BR:<%-*2_C"]$JNX#939J*%E`8O:3;*-"G(NRP<T&!0JJ&++PET;B&;C
M#R@X\4VS(1=L9KP"9,=W"V3T@CX?2O#+?-*:G>JTW:;:N3#5'26V>W\A'K:M
M;"P3:97"PULWRTQ]XO#*A7XUQA35SNL0),2J<IY)&4%:+(Z1]M#B2BJ#[3;5
MBN0+HNV>WXSM5E(:<J[@],KC+E;FZY4S*%7IB!6W&I5#RD#19$B%"('RV\+$
MON!M*2.M3>2+8&B)HB:(FB*,%CAXF=P?&3D7'3,:[(((=CY4(:1!<?CY%J0`
M?<$,:>86\$>*T^RK*><V\VE:<X4G&<$6N#-D]F9&1/F)#:/;$Z6E8^7B9.4,
MH55*D9*+L$A9I:>C3SGXE9)D?-RMUF22V7%*;)(EC7',*64_E934[U1*V!V(
M6VEI>RFTBVD19<&EM6W%.4VF%D#IR3/B$HS#93B+-DK-)$/#_P`4X_($N*3E
M;[N5DJ=ZRA[;C;PB6F9\BATQ^=L1=>D+!-/5>#=EIT^HDQ9M3-F9)8*C),NL
M&083L<X^M:PG0V%,Y0IIO*2BJM8FSFT0`DC'@[5[<!`3$79H.7"$H]8&$E(6
MZM0S-RB)$9F+0R=%VUFNQZ),=U*FCT@#X?2YAAOFD6VHC^?)_HQ_^'E:(L;E
M(>)G!F@IJ+CI@-B1AYAD24"&D!F9:O2P4_`2C3!;3S3<C!SL8,:&_C&'1BQV
MWFU)<;2K!%C4_MIMQ:VI9BT[?TFRLSRR')QF?JL%,-3+A=6D:,6N6;D0"42*
MRJ3,%P[F7L+RN**>$SRL.K;42J[D[>4!-5>HJ:-3TTDGG=8IR:S"XJK_`#RT
MGKZ:O8"[)=YYR,/9YS.>5W&%_P#%W=$6.?$;LGUA9?Q/;6]:<[`Z0GXOJEUA
MSU51!M5?GO=D=(KU;;K,:D#ES_V:8\;#/,PPUS"5.]7R*VRVW@I9$_";?4B'
MG6\1R6YJ*J<#'RR$Q%?]4HE*)$0!DQ.(NJX[,'QA?\!'_P#;HYK/X&B56R@_
MYC+_`-&%_P`0%T18W,0\388F4@)^+CIR"G(XV'FH68"&DXF8B9,9T*2BY2--
M:?#D(Z0#?6T^PZA;3K2U)4G*<YQHBL\S1J38W)%VPTZK3SLPQ6199R9K\3*.
M2@U*G#+-31Y%9PCZC6*E9)$B0C$.Y4D`Y]Q]C#;JU+R16&3V<VBFY")EIG:O
M;B7E8".A8>"DY.CU@^0A8FMDEF5V+B32HMTF.CH`L]]T)AE2&A7'G%-)2I:L
MY)572M[<;>4T*4CJA0Z958^;YW;0%;J\'!A2_/P1A?:@L8"*Q(<[!;O+TJ5\
MO2K_`!L\I%E$?'@1(`45%!"1L9&B#1\='1XS(8$>`&R@8,((,9#8XH@H[:6V
MVVTI0A"<)3C&,8QHBORO_P`,Q_:9?]5#T18W)0\3,H$;EXN.E6P)$&8!;D@A
MCD!2T6^DJ-E!$E-.I&D8XI&'&'T<UUES&%(5C..71%CLCMQMY,'8DY:ATR4D
MDVB,NZ9"1J\&:=BZ0H<''P]OP62"Z_BT1(%8C6!I#G=;89CAD(<2EAK""*PR
M6Q^RLS(S$Q,;0;72LM80IJ-GY22V_J9TC.1UC`F(NP@3!I42Z3)A3T98I`8U
MIY2T%,'$-NX4AYS"BFIWJJ-V<VBDX:&KLEM7MQ(5^N2),Q7H(VCUDN&@I8T<
MT,R4AHQ^+<"BY$L21(:=?80AUQM]Q*E92M6,E%5L1MMMEM#32$---(2VVVVE
M*&VVT)PE"$(3C"4(0G&,8QC')C&B*[2/\5%?V8C^N&Z(L;(AXDN2CIDJ+CB9
M>(9/'B94@(9Z2BV)7`R9-B..<:44$S))#9P^EI24O8:1S\9YJ>0BQT';C;R+
M/BI2,H=,CI."'`#@Y$&KP8A\,)%#6H*+%BC!P6R(X>-#O4VT.AE2$LM3!R48
MPDLC#A%B:.'O8)H9\-K8_:!L0EN*9)%1MI2T#$,P3H+\(T^PF%PTZW#/Q@RQ
M4JQG`ZQVLM\W+:.0IJ=ZRDO;3;B0*J9Q^W])--H3+(]%,+JL$252V!U`+'8J
M9#P"WJXRPN+%RA(>64IR,UG&,=&CD*%FVB*2;'\0S_)-_O,:(HR[&?QLS_;,
MK_7BM2>4?2K.\'N!2?U"JO_6^V/B&_)DW^CK_>JT^U_&Y69X*WK4_P`EJU_E
M^&_PX;15/*M/[K24B'80V@Y`T5I4*.XIL8I]A"EY.D4Y7E#3B4Y7E*<8Y?N\
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MO3MZ<]V97TB9X[1*G>G;TY[LROI$SQVB5.].WISW9E?2)GCM$J=ZI)"UR<8`
M;)&3DNV)'B$G%.)..<4@81E;[Z\(0ZI:\I:;SGDQC.<_L:)4[U%='&S`Q89N
M+@[8X>:C(K$R?&P=A8L8C`CTI%@,,.2)!5??"+#'F&2)%9@H@$<TAQU92A5"
MDE%.W>LC'XNX%.5XF%WR#PU(2K!+Y3S!`@,/'7J]T9FR'NB33KH\40_M^:6[
MC#:GA!U-X>0EQ:4Y)4[U:QN-W;DU0R0[#="LG5B3MX&6$J<1(P<$29ZPEQKB
M9CF2+<#$1[\B2XQEQGJ[2V6UK.0H3!*E5<EQB5^-,!;6N]NQQ"KV(7()>2A4
M=)4H6DG,#D#N2B6D!V46\B=6*6\VVPI2<DX99Z9Y@E3O7ZUQH;>.,P!>;/;6
M`+2W67*W($*6R).9LL`]:$#12E2O2GR$5!B/ND"M(44\XPI@1LHA33+A-JK8
M/BJ9M\7-R51S8)#$;C;X(-F4G78OIY_<7<.P;<1<;*.A]M)BQ(^5AFB"WVL&
M/,C$93D?K+*Q\DJ=ZIR>+^MQ#KX%C/ML7,1+U$&LPH4@Q.`P2[S6;-:6CUR<
M?+929!0X-+E>F*0UA9"1<."M/MOL*<)MWJYM<6%9=D@H/M"]LV&0`K<B-7B6
MW!9GJ]PMD?4*PI\,B6;R*U,FRK#[;[N4#-C.<KKK;N,M8)4[U(#MZ<]V97TB
M9X[114[UYP7WZR.FT6\W2DFT*[2!E.MEBJI9[$W%(8.)KTP9$/F,H=Y74-$N
MB96G"OPL85W>[KPC-^.V4Y1FV:93)D-P^2UN)(2X/8`XQO<PD`BH!+:BJ^H]
M/_\`%[/]09#DF?0ZIM(X;ZSAN&L='(2T31MD#21L):'4)&RH6)_:F43Y-KYZ
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MXF7&174<)<`YP<QV$;\.PFFX&NZIV+KW7_$K5D5M/)::GL9;EK26L+968B.1
MN(@AM>0$BE>6@VJ2VY[NY^ZU>K]IV'W')`@C]K]QI""G(XE[HYBT&NT]5#&9
M#D9.*8%60V-+CK>/%):`PZXK+3170/->ZY?F%EFUE;9CEUP);*9@<QPK0@]F
MA`([8(!!V$57S!FV59CD.97N3YQ:N@S*WD+)&$@EKARBK20>P002"*$$@K!5
M6GCB3+`M8I=.>A<1521*O)LD.+(N2)%?2Y=C8EQ<B:PP1&RR%LQP1`[HY)3C
M;SIC0K:QW.ZL=LWE;$L$EOO&2(,P!VT>DJ'IT=/1P'8),0Q,S%PVMBYU^J13
MLHY(#(@Z^_9B\.2#RVF5KPL@HL=`S01*]M:8$F^/X$.3']7:066V[,GA&$3T
M8:*82=:\EC1C#3DV`:'$@P<J^@=3KBG,M`CMJ2TI+F2XVJ:MWE;"8/XN#K7+
M1LP+!!4<+<*K^KLW!R,<W89:E1>X,.])%3[;\OED9B8H8QV361V,$]:4.AA'
M1OD-BRHJ*<NU7_:EWB4"NAL3N,\"1MT)#R!<9/JD0#;3*6$HV-?;"DL`DH:&
MCV$G'=%AD9M*&QF4<J<=Q9*BG+M7K2-_-A_Y!K_IIU"LHS[&?QLS_;,K_7BM
M2>4?2K.\'N!2?U"JO__7^V/B&_)DW^CK_>JT^U_&Y69X*WK4_P`EJU_E^&_P
MX;15/*M);O\`Y2@_V&-_7Y/4A4=RK56BA-$31$T1-$31$T1-$31$T1-$31$T
M1-$31$T1-$31$T1-$5JF)V$KPF#Y^8BH,'+R!\&S$@)&"9?<2M3;&"37F&<O
M.);5G">=SLX3GDQW,ZJ^1D8Q2/#6[R:?]5P7%U;6<?2W=S'%%6E7N#17=4D"
MO:79%3$3.A-R4)*1TS'/*<0T?%&C2`3JV5J:=2V4(Z\PM33B<I5C"LY2K&<9
M[NC'LD:',<'-W@U"F"XM[J,36T[)(3R.:X.!IL.T$C8KCJRYDT1-$31%88VU
M5B9+4!$6.!E3D-+?6'&S$><6AAMB+*<>4.*0Z\EIL:<"<4K..3#9C"L]QUO*
MB*O[5B^L=4[2`ZWU_LKJO7!^L=J=E]M]F]#TG2=?[%_[SH>3I.J_PO)T?X6B
M(_*Q8SS@Y,D`.^UV9TK#Y@[3S?;9SL9#=(TXXE:.UY)E8XO+C'6'T*;1SEXS
MC1%7Z(FB+O%%?-(;%&2E;SN<X;2IQMK&<X3E>>5QY;;:?P4Y^[G&B+7&.$W:
MM+1#"-G=O6VRV1!B4MQ]:;R\.`YET%A:T/I7ED-[\-I/+S6UXPI.,9QC."FA
M639X?ZLIQEU6WE1RL:5%G!\Y:KV4CRX4G.30D@PCK',:)'EK-($I4G&.1XUY
M?_$XK.24*L^.&#;I/,Y-J*'CF1>81'_95O\`!B%2:9AR-Q_#_P`R?DD)<<;_
M`.%WFX2O"DXPG1*%!>&2DCPW8+VWU:D8_)$Z4[B47!G/D%60L$R:)(?=)RXZ
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MGYZ+#XW3X6Z-]F#^7DI\P?$SVI%XG^I<D?5`<++BN:AS>C*N12N3.]4^GN(3
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M]/ST6'QNGPMT;[,'\O)3Y@^)GM2+Q/\`4GV0?"M[+O3\]%A\;I\+=&^S!_+R
M4^8/B9[4B\3_`%)]D'PK>R[T_/18?&Z?"W1OLP?R\E/F#XF>U(O$_P!2?9!\
M*WLN]/ST6'QNGPMT;[,'\O)3Y@^)GM2+Q/\`4N7V0'"SAO#O2;T<S*U(QGXZ
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MOOEK!A1J+)A5$R,A+(W%30]@.B2(61=`$9JN8V(C19"$>!'E`49+4^SAY$>V
MZ$SCJYY:%;^QC(V,CC8&QM```%``-@``V`#L!>-ODDED?+,\OE<XEQ)J22:D
MDG:23M)/*=JU"]L1Q"&1]A>-W/C7+457MJA8"=9D36&`K#1X:Y]LR3\<B,ZN
MT/*6.R#N*1C#Z3FQE+>;:Y^&$V5=FY=%,V'XB8^>L5LN6Y,!+6$RI6Z#@G(R
M2FV8\,V;>H9$:0Z`0PD,9\?%=D6LF):?<$ZZE8[.&L=5039V%<U;`[O.;<PU
M9(NPSMY0YNK*SNX`MJLD69FPW"9-EJT5%1S#;P2`Q5NCM$HREI8D>.['!Y2(
M:3A1.SVE=X[8O=H*7J1WQDKQ&PUFIT_.1#DI/']L#0-;?KYD(T6[+"LLQ2&2
ME*PRL9;<@4VR:1ALA"^E)O4HNSRO8T^&8\9HJT4SQNX,/C_8PU_TTZA<BC/L
M9_&S/]LRO]>*U)Y1]*L[P>X%)_4*J__0^V/B&_)DW^CK_>JT^U_&Y69X*WK4
M_P`EJU_E^&_PX;15/*HE\7=QD=OZ[/7*)%".DH&IA%!B2/3X!?><G"1L()R,
MXT_AOD?SG\%6,\N/_P!-8+4V:SY)D.99K;1L?<0LJT.KA)+@-M*&FWL+9M&9
M':ZEU5DV17LTD=K<R%KG,IC`#7.[W$"*[.R%`K/$Y>P"IR)F8W;\4\<^P0$*
M?SK"Q'O3E:WHSM44X4PX^\G+,F.Y@H5ETL)E#S?,?-:;<Z1GSWX@YS#)>6UW
M!9-F:^6.-WXH:9(K_P!3)().QX.-C2^-H<*/E:UV)OK8X3:=N(<OO;&ZS)]N
MZ.&:5GX)>(I\K_<&AI`&V-P,<CFQRN+78HX'N;@?20?%)?Y^,$FTPVW\)#O,
M[11Y9\L9+K8C)K<J5+!+DBR&36@4UR,8B2%(STV',N/,IRM24J4OBL^(N=WM
MO'=BULH;4BR:YSW/HR2Z>YKGN(<&]$P,<1WU:N:*D`D\V8<(=-Y;=S6!OLRN
M+YKLR>UD;8P9(K&-KVQM!87]/(9&`][3"UYP@D!N-O<5VY5B@FF8>`K,*;+;
M5-6!<EDT3!H,U*;3V7<7$U`Q,C9&963BHMR#ZIAI`)2,.8<><)QT/5W>@[B3
MG]]9M9:V5O#+)EHEQ8FXFR/LY;GI(V.E#WL88\%!&\5Q.=)WO1NRL?!O2F5Y
MB]][F5W<00YP80S"[`^*/,8++HII&0&..202])B,L9PX6,B./I67</BIMP,(
M4.6NAR4U`0]H.))<7(,XF1ZKM3M9>Q'\##2CSS#]HEKD:"RXA*V^E0UA"%*2
MM*^U%Q'S2&TDCE-E)=PQ2N).(8Q#9V=PTT#R09GSR1M(!%0V@)!!Z,_![)+B
M_AEA&8Q6%S/;L:T!AZ(W&89A:.&)T8!%O':Q2N:2'82_$X`M+:KZ1M]*DJN7
M%!5K!MUJ.W)B(XY<X_#UXFTS^];98)8+)[#V;!!,T@8,]25(YY;3J.1*4HPF
M_OWG4D^72VT5OTUW:VKL+ND+(C-)?@M<T.!Z2,6[&2&HJ\.%``*<7PNTY#:Y
MO#>3W?06%[>M+V"(2S-MX<J+7M>6$=#,;M\L((-(W,-22ZM,1Q:W0>C/SST-
M1!)Y\&J6&)")*FTADPMBV<SNN_&IR^\&*[,@<WJJG7C@FE-*RXTT\\A`SU'\
M3,V9D[[UUI9MO2R&5C29,)CEL?7"S:6@O;X!+I(P0<36O>!&_EBX+Y#)J&/+
MF7^8ORYLEQ#(YK8L398<S_;@_8'.$3__`+`UL4K@X!KWQL<Z6/*=E=^K#8;;
M8(6=<!FHL]_=VSA"1KS\G;*F#39>G]2A9()GD0Y&R(-LRU'82TVZMP3..5SI
M>1K*Z,U?F&:9S<9==/CDAFDO)&@.)E@;#)`&LD')@<V>D9H#5AVNQ=[@N(W#
M_*LCT[:9O8Q30W-O%E\3RYH;#<NN(KHODB/*96.MJRC$X4E&QN'OXE2O'-O\
M^;%1$948MER?OVRE:$F(V(@"Q'VMTZIP'S4I7ZV/-[@QQ3MFBC>):>P(]+,A
M1BD)`PZ0K+1&5^L81O\`XVKPI9S*\4>^L)O#N%M_,RL14ZO7#@X"/G;-MW%6
M*>*FQMN.#>X$4^KP>W^Y$B?:=XK%*[^S4<!&(#7#O%Y`R*47U=X<Z*"E?X[*
M*:O#[?MQKM7[-';MP<)`;CT*;J=7N05;:*;@&[).;-;5[HS@<0LJ3F\%@0$O
MN*_%-D-&$MD)`Z3GX4I2$P1NY$6_-0B:(FB+27$?4]T;UL7N=4=E;N1MSNE.
MU8P.G6\1(N"XV1Z1EYT80PMDAN&+FP&G@&I)"%/Q:R<%LXZ5E&JR8RQW1D"2
MFRO)7M]I686A[2\$LKM7S_UKB/\`K+=]&=G>"Z`C;+M=OQM;:8V2WLWA1+B.
MSCU,K<T.+5YBV];5)CHAU*%5F;;*7)/6$9P9;B"'W2(L[3K3.;R[S%^GXGD7
M]H[\9Y`HYN")\8V4JXLF8Z0MH,;',:`Q^-FQ3Y?;6]J,U>T&UN!^&T5V'$]K
MNX'1N#`:G"X.)Q-PN^F&.8+&CP1CSLR9PX8S!LDH=D14@6TPAL@Y0@_(.+DM
MY.7,MH_`1SN1/<QC6YK6U6:(FB)HB:(O##BRM^Y>\FSL)7>)B0#V*JCW$IBN
MR#S7#]N>UB%J`<1<L4Z^XO\`+;@&5J>:DG!^A+C1@$/I0^@A#F$H4RK0\XN+
MR[M&Q9D!!#ZQ2O1/V`!V%V(N(->R`*]GM+Y4XA9KJ+4.00V6LF-RS+?WC`7"
MRN1AC:V;HINF?.Z-^*E'1M8';0\&@+3DO!]N!N]MYM#L;2MCP`]U]O9#B)L%
M*MTJYLON>TF#VK-W-EQ9#<D/<KUFBJ>8I^,Y2$,)CG,QW.Y"TYRC*%\N37-]
M;VMC!91B6V-P6N/1OV,+S5^/$&\FWDV=E=_AQG6I\JR+3&5Z;LVWN2/S9\4L
MGJESWELZY<'SBXZ1L1[VK@.C/1_;&RA]JM;NOIQ-$31%0R4G&PP!<K,2`,5%
M@,K).DI(M@$`(=O'*M\LPIQH<=E&/NJ6K"<?[=$7G^QP\4*.O-UM0G$%5@)"
MTR%PDVHEE$6TW#-LR%C*FG\,*O&4DR=`JX%>0"9AMCL60IXIZT*;3@1@BHC-
MA:=-2U=K58XD:X-=E$!S]8?B8H"<LL7<ZYLBS5F[?7TB77F@E3,AT%FFFC$%
M-S0X@HV<H2TLIXBL@>SU`OE"B1J_Q0,HA$4MF&B[!88LX2;Z*/W0)L0%]@3+
M!;H(Q%@B'YH.KXE4(?;9=:>$SE)"NKC$4V=I3X*,K\+1!+_3[F7"5R+=AG(&
M7;)DCZL`(%!O3A`#L]/FI`5:`S1V7$OO,M-(:'RZMYMQ2B+;NB*SV&1=AX"<
MEF$-NO1</)R++;O.Z)QT()\EM#G,4E?1K6UC&>3.,\GW,Z(H8U7C`(3`Q+ET
MJF'YMV3@(F5>KR<L"M&VI&X,W"CMQT;)7Z-"SFI[>D.9?<G78_)A83;Y(F'R
MNSB+G!<:`%MDZG$5ZI`I)L9=+R^3(VKE$8C;-N]#;;&.1V!(-QR0)%CY=LL?
M+W4V#2'4MB+*8;?);(LUE^)!-7MK$1.HK9(\[NI!;81M;!+-$NM3=E+A(TP2
M=M+3G:(QX-HR.Q,QR<,Q:6XAQ2LN/_P3CI%B2^-6`%K(MBDZ69'J=BJS($1R
MK"$24AVZ2,R/7F@6!0'9&5$9`@W')1]D;ECWWQVTMOLK=)8(I3T.W^O,$_/H
MC'(H;%BMD&(.^4V24ZU5+-*U9XTK#+:6!7#38=UQ#2''\)94C.7.=E24D6::
M(FB)HB:(O''=+ZS>UT/<W<:C@5S:@H&F7NW50(HZ4F>NDB5VP2$0,^9T-D99
MZT\R&E3G,0E//SGDQC'<U\RY[QIU7E>>9SEEMD%L^VM[N:)CBV8ES8Y',:XD
M/`J0`339N7VOI7_C/HO/=,:<SN\U-?QW=Y86\[V-=`&M?+$R1S0'1EP#7.(%
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MKN7$X/<08P`2\BA:VKMH!!T7B/\`\<=/:6TGF6HLCU:\SVC<;VW3H@Q[.3`Q
MT;&D2N)`C!!#W49L+@1ZI9QR9SCEQGDSG'+CNXSR?LXS_LU]#+Y$31$T1-$3
M1$T1-$31$T1-$4VQ?YL/_(-?]-.H7(HS[&?QLS_;,K_7BM2>4?2K.\'N!2?U
M"JO_T?MCXAOR9-_HZ_WJM/M?QN5F>"MZU/\`):M?Y?AO\.&T53RK16]`HQL\
M,*8.P6,]`BI>')9;?8=3B1DE82XRZE;:\85C&>3.,]W&JOCCE8Z.6,.C/*"`
M0?I!V*T<TL$K)H)7,E;R.:2"/H(VA:;<K\"[TN'82(<P_EU3_21H:^F4^<F4
M?4[SF<])EZ21@A><\O.?QAS/X>.77";*S=BQ6D1Q5KWC=M78S79MJ_OCO=WW
M+M7.W,LQ9@P9A.,-*4>X4HSHQ3;LI&2P4Y&=Z-FQ6.>H%5L,0]"E1O4`WRHP
MU:X$@BO%]:AS<2$:YDN&<"?<0*7RKPVO*FE<Y6%)SA6<9Z=[DN77UJ^TD@P1
M.<QWX9,;JL=B8<3"TFCMM#4';4$$K(9;J3.,LO8[^&ZZ2=K)&`3-;,W#*W`\
M890X`N;LQ`!PH"""`JR!IM6K,7#0\)!QP0$!!C5J)1U=#[XD$(TEEF,P83TQ
MCHW,3RJPMQ72*SE2N56<YURV659=E]M:VMI9L9#!"(F;*EL;10,Q&KB-]2:G
M::E<&8Y[G&;7E]?7^82R7-S<.GD.(@.E<:F3"VC0ZO(0!04`H``JC%4J^,IS
MBMP&,H;':1G$/'8RAH3#6!6T\@WX+8V&&^CQCN(YB>3DY,:Y/VW+MG_H0[`!
MX#>04H.3D%!3=04Y%Q_O.;FM<UN=I)/XK]I=7$?"Y75-3V:FO*5WIKT`ES#J
M8.'2[ASI<.)C`L.8=Z<PKI,+PQSL.=9D2'.7EY>>^XK[JU9S86-D'8A9Q8JU
MK@;6M7&O)RU<X_2YQY25QG,\R+2PYA.64I3I'4I1K:4KR86,;3<QHY&BG'-<
MKRFDCJ@8;+",BY0SF+!RTC((F0`LI;RQS$Y#!5EEKDQ_!LYYB>1/<T]1L<(9
MZG%@%-F!M.];A;LI]EO>C<W8-B#-,S#S(,QGZ0XJGI'U[]V-VVM>^?WSM[N^
M-3M7>#"PT8XX]&Q,9'O/(PV\Z"`*(XZVE:G$H<6PTVI:,.+RK&,YSCESG/W<
MZO#:6MNYSX+:-CB*$M:`2.7;0#LJEQ?WUVUK+J]EE8TU`>]S@#2E0"30T`'T
M+$AMJ=M!JV-4,42JE5D4`6+:AI.$`F`E1X($1%AB/HE635%LC1E?`&1AW*^:
MP".WC\!EO">PNHN9>U>V!\,W73MN*&;7VECN-01=0KQ$,TX($!&BN-QCT<L)
M"QHZ*%8;SA&,H9&:1CD2VC&%2BO%8I]8I@A8%5A`((,XQL\D:/:Z%EPAB-CH
M0/"4<N<-#1L%#A@",(YK(8`;`S"&V&6FTD62ZA$T1-$31%%C;_A1J>WO$MNQ
MQ-QULMLC9MVJZ'6I*K2.('U8A0Q"8D[+T2H.&%FUDNFQF5<I!;R$H>4GF_@I
M5C$6V26-IFN89S"UWKMS3&2:C8R-@H.QWL3.[4]E=^;,KF>QM<ND+?5X:X=F
MW:Y[MI[.U[OY;E*?677031$T1-$31%`S=K8_B#W[A<4;>"'X8+7M^BU1]@'C
M67=]H*2&;C7Y<9I:RJ];89\R3S$&HPE73LC(?<<YS+J4-YS@;NQS"_9T%XRU
M?;XP:?B@[*[G#;0[Z5KL*\JU!IC5VJ[;]KU#;9'<92)VR!H-\QPPEX&V.5A+
ML#AMQ!H<35K@`KELMM)Q&[)P]5V^IL9PQUO:J)L;9<C!Q3F]\O.,04I/8D;2
MF&E[799AUV<)&>(<%64I0S9#J4J;Z)O\.]E:9C9,BMX6VK;4.V@=*30FKJ%S
MCMY:5V5[07-IK3^L=,V]CE&709)#D,<U7,;ZZ]X8Y^*7`^61Y+R"XM+JM#B`
M1A&V<.LVO3TT1-$6(7NE0NX=7D*C8$97%R+T44YR"Q9V6RX28`GHLCJ4Y'2\
M,;@:4C&7,LEBD#NX3S7&UHSE.2+2`7";MI'-6$0(^U-1MH3/IFH=PJ`,B2TS
M4-'U\-I0!U<*8P%6(F'#:CQ.3J>,#)R2T3E;N7"*][<<.U5VVFV)R*E91UZ.
MZI'P@+0<%%Q495XV$D86+K20(Z*9;4*)F5?*Z1K+&</Y2AM+0R>KY(K)!\).
MT]=B("M1GK&S4JPNINP=3Q(@(A(]^G21TM%.#88B69%EIP^>EUO#H(2)GMDG
M"&D8;"ZH19/MQP\43:V:@YNK/2K3T!49NF``K'JX<4F,LEG;M\X2D"#K4.T(
M=)S@[+KW5N@'6IG"\M9=6ZXX1;WT1=PX[9;R!GB!A6GN<A;YF'<C(3S%9STV
M&&2'<I5R<WN(5W<_[-$5:Q2J\,PR,-+4L<8?+"F!V!)-IAA0S[A(V66FZ^EM
MO(Y+JG$<W&.8M658Y,YSG1.ZB:57D.8=1+4M#J<-)PXD232YA++K#[.,+Q7\
M*QAI\5I:?Q5MISCNIQR$[J[5U&%=<R\[.5!QY3B'5.K8EEN*=:9<';<RM4!E
M67&QWEH3GEY<(7E..YG.-$[JZ\TR`5C"53%-RG#66,)R+*9QAC*V7<LXQFO\
MG19<';5S?N<Y"<_=3CD)W56(KH#>,I;LU90G*UKRE';2<96ZM3KJ\X3!XQE;
MCB\J5G[N59SG/=SHG=7/L$/X4US]U.>\>B=U.P0_A37/W4Y[QZ)W4[!#^%-<
M_=3GO'HG=3L$/X4US]U.>\>B=U0LG_J^^#.R3LU8I[8G:^7G)^6DIJ9E7X^4
M4_)RLH8\=(R#RN<WSG33'UN*SS4\N5?<Q]S6"DTSD$LCY9,KB,CB230[234G
ME[)6[V_$;7-K!!;6^IKEEO&P-:T$4:UH`:!LY```K3]G#P._J\;4^CI7QNJ>
MZNG?9$7,?K7-\3M?]:KKQAY*?9P\#OZO&U/HZ5\;I[JZ=]D1<Q^M/B=K_K5=
M>,/)3[.'@=_5XVI]'2OC=/=73OLB+F/UI\3M?]:KKQAY*?9P\#OZO&U/HZ5\
M;I[JZ=]D1<Q^M/B=K_K5=>,/)7-OZM[@<6KFYX?-IF\<BL\]R.E^;^"E2L)_
M`6M7*O..3'<Y.7..7DQW=/=73OLB+F/UI\3M?]:KKG'DKA]G#P._J\;4^CI7
MQNGNKIWV1%S'ZT^)VO\`K5=>,/)3[.'@=_5XVI]'2OC=/=73OLB+F/UI\3M?
M]:KKQAY*?9P\#OZO&U/HZ5\;I[JZ=]D1<Q^M/B=K_K5=>,/)3[.'@=_5XVI]
M'2OC=/=73OLB+F/UI\3M?]:KKQAY*?9P\#OZO&U/HZ5\;I[JZ=]D1<Q^M/B=
MK_K5=>,/)7-/U;W`XI+BL\/FTR<HQC.$*CI?G.<JDIREOFK4GE3C/+GESC')
MC/[/<T]U=.^R(N8_6GQ.U_UJNN<>2N'V</`[^KQM3Z.E?&Z>ZNG?9$7,?K3X
MG:_ZU77C#R4^SAX'?U>-J?1TKXW3W5T[[(BYC]:?$[7_`%JNO&'DI]G#P._J
M\;4^CI7QNGNKIWV1%S'ZT^)VO^M5UXP\E/LX>!W]7C:GT=*^-T]U=.^R(N8_
M6GQ.U_UJNO&'DI]G#P._J\;4^CI7QNGNKIWV1%S'ZT^)VO\`K5=>,/)7/[-[
M@<Z/"_H^;3<N5J1T79TOTF,)2G.%Y_#YG,5E7)C\+EY<9[FGNKIWV1%S'ZT^
M)VO^M5USCR5M':7A0X=MB9N1LFT&V=&H$[+Q2H.2E(`0]@LN(66*>N/=<=P]
M_P!NLP)IS.,<G*IM/^S7<LLERK+973V-@R*4MH2!MI4&G.`L1G.K]3ZAMH[/
M.L[FN;9K\8:\B@<`0#L`VT)'=6_>JM^7!_?)]K:RBUJG;3JK?EP?WR?:VB4[
M:=5;\N#^^3[6T2G;3JK?EP?WR?:VB4[:YK":3A&<2("^>CGYPC)?*WGG*3S%
M\X1..?C">7N<N.3..[HE.VN'56_+@_OD^UM$IVTZJWY<']\GVMHE.VG56_+@
M_OD^UM$IVTZJWY<']\GVMHE.VG56_+@_OD^UM$IVU-`;^;#_`+/\`U_TTZA7
M49]C/XV9_MF5_KQ6I/*/I5G>#W`I/ZA57__2^V/B&_)DW^CK_>JT^U_&Y69X
M*WK4_P`EJU_E^&_PX;15/*M);O\`Y2@_V&-_7Y/4A4=RK56BA-$31$T1-$31
M$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T16
M:QN2+->G7HAQ;4LU#2CD6ZB.S+K;D4`OJ"<1$I*"5*+03A.<#X>9R_G',YZ.
M=SL$4$Y7>#B/:J5GCH"EWPZ8A@!2XFQF[>S)$W858OT*P8=&NF;;T:'=`Q!&
MD1O99%7!F4=7<D48(`2U($$6T\V#>FW!77"3+A1"HO=K;J%A4P%$!9);IY5V
MCX"Y,-D7RIV>/M`#%=,=-(F@6\AIRSAX=UMA+B5$6-PV]?$)-LP$HC:UR+`)
MS3&IF*E-M=Q1)?#LH+>)"TK'>D)2,<C&8G-0&`1EX)]*'Y@8A2G$=$R21?@N
M]?$*_BOE/;6N#`D6+;&+EF?BUW%<DR@[DJV9MSD>*Y)C=A-T`^'%C2SI'&`E
MM*5*HRH<D`,@BFOHB:(FB)HB:(OG$WK^M/O].WDW:J,)ODS'0M5W-OE;B(_X
MJJ^9U"+@[5*QD>'ULO;DHLKJH@J$=(ZZXXOF\Y2E9SG.?E#4&L>+,&?9W!EF
M94RUEY,V(='9FD0D<(Q5[,?@4\+OO^[;5?H%I#A%P6O=)Z7O<XT]BS>;+K9\
MYZ>^%9GPL=*:,F#!5Y<:,`:/L@"BUE]KGNE\OS/S15;]&6L1[[<9_:?^W8^C
M6Q?!G@+U;_R,Q].GVN>Z7R_,_-%5OT9:>^W&?VG_`+=CZ-/@SP%ZM_Y&8^G3
M[7/=+Y?F?FBJWZ,M/?;C/[3_`-NQ]&GP9X"]6_\`(S'TZ?:Y[I?+\S\T56_1
MEI[[<9_:?^W8^C3X,\!>K?\`D9CZ=/M<]TOE^9^:*K?HRT]]N,_M/_;L?1I\
M&>`O5O\`R,Q].GVN>Z7R_,_-%5OT9:>^W&?VG_MV/HT^#/`7JW_D9CZ=/M<]
MTOE^9^:*K?HRT]]N,_M/_;L?1I\&>`O5O_(S'TZ?:Y[I?+\S\T56_1EI[[<9
M_:?^W8^C3X,\!>K?^1F/IT^USW2^7YGYHJM^C+3WVXS^T_\`;L?1I\&>`O5O
M_(S'TZ?:Y[I?+\S\T56_1EI[[<9_:?\`MV/HT^#/`7JW_D9CZ=/M<]TOE^9^
M:*K?HRT]]N,_M/\`V['T:?!G@+U;_P`C,?3I]KGNE\OS/S15;]&6GOMQG]I_
M[=CZ-/@SP%ZM_P"1F/IT^USW2^7YGYHJM^C+3WVXS^T_]NQ]&GP9X"]6_P#(
MS'TZ?:Y[I?+\S\T56_1EI[[<9_:?^W8^C3X,\!>K?^1F/IT^USW2^7YGYHJM
M^C+3WVXS^T_]NQ]&GP9X"]6_\C,?3I]KGNE\OS/S15;]&6GOMQG]I_[=CZ-/
M@SP%ZM_Y&8^G7T`<*^X&X^Z&R=4NNZ$&W#S\NUAZ.-2PB/<MM<6,,_$W!^"0
M.,F`7,(>5R,80A#N&^L-MM,O-HQ]'</,UU'G.F;2]U/9"',"2`[8#*P4PRE@
M`#,6W8-CJ8V@,<T+XIXNY!I'36MLPRO1>9&?*F@%S:EPMY23CMQ(23*(Z`XC
M5S<71O<Y['$R(UO"\Q31$T1-$31$T1-$31$T1-$31%-L7^;#_P`@U_TTZA<B
MC/L9_&S/]LRO]>*U)Y1]*L[P>X%)_4*J_]/[8^(;\F3?Z.O]ZK3[7\;E9G@K
M>M3_`"6K7^7X;_#AM%4\JU!NPJ#:G!GI8LX7+4(PI2V!Q%C(82;(YZ1UXDT7
MH\X5SN7N<W&,8SR_[(<YK&ESW`-'*3L`0,=(]K&-+GG8`!4D]H+5V"J;G*DX
MEY+*DC8,4G`T5G*1,XY<%*QVORX&SC[B_P#A_P!^J]-%4CI6UPXN4>#O^CM\
MBMZO.`"8'T+\/@GPO^W_`/;M<JY]-4<=7Y925QUO^:_]I&?]S^!TG_;_`/W;
M^&_@_P`+\'E_![OW-3TD?>=^WON3:-O9V;]FW8HZ&7\7\)W>>%L/>[:=]NV[
M-O97?T=:\KG/1P'OIJZXMB='6O*YST<![Z:)L3HZUY7.>C@/?31-B='6O*YS
MT<![Z:)L3HZUY7.>C@/?31-B='6O*YST<![Z:)L3HZUY7.>C@/?31-B='6O*
MYST<![Z:)L3HZUY7.>C@/?31-B='6O*YST<![Z:)L3HZUY7.>C@/?31-BQVV
MVG;.A5F<N=TM)%8JE:C29>>L$TU%`1<5&B(RX0686_+(;:;0G')CN\JE9PE.
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M<IC;R/N!!=WKT>-*SE89%`5+14>9T61BS1NTL98:>02RM/.[O1D,KY.8\TI>
M2ER?-(,MM\YEL9&Y7,\L9*1WCG#E#3V2*'NM<.5K@.C'F>7RW\^5QW;#F$3`
MY\8\)K3R$CL`U'<+3R.%<*-W_P"'R/W,<VA+O<HW>F0AC"H]%?>(C0,E\JF0
M96Q#//5Z'EE,Y;=ZH64R_EI]I>$YPXC.<G%I#44V2#4,>6N.5%Q`=5H<ZG*Y
MD9(D>RM1C8US:M<*]Z5T)-39'%FQR1]^!F(:"6T<0*\@<\`L:ZE#A<X&A!IM
M"W(WZKNH0ZT=-.-.(2XVXV!'+0XA>,*0M"TRN4J0I.>7&<=S.-:V0YI+7"C@
M=H6=!:X!S34%<^CK7E<YZ.`]]-0FQ.CK7E<YZ.`]]-$V+4-MWKV>I%U'HEBE
M;4#+D5L>V9*S"1F8EB#>E#HETH@U4XE3>0GP%K>3S,YPSR*3SN16$DV*P37$
MMP]P,FU&&V>X*5@4TN3/9I$EV17TQGJPJ4$GY0A3`<;,Q#%P!=-CE*S(@M.9
M40PUA.=%*O$EOOL="6BX5.<LMDB)"D$5P2;),KJ,QV2[+6Y:X,-!D"GDND-1
M-6A7CY(C+:!0!?X1UU*4N902BXJW^X?5@2QT??#9=R&'&>.C8Z,%5)LNFUJ?
MMP@9`Q4@(F.*7`U:2>=ZVL=L/J)"2E,Y9=P@BRBN;F[.VV5%A*];961E#H$F
MT!"IA%#Y,KX<D/$D2HKI9`[!`J2S1E)RA6<K'+&(3C+!+#KA-BM$EO/LI"V"
M:J\U9[!%S4+*@PJQ"*ZI_,E)2<179F."AU`%F8D9"1'LK*!@T?\`>DK8)RTR
MML=Q:2C8@.]NP<G(AQ0&X!)1T@2","TU$\YLO$H7&1T8:P3UC`KD/)R\P,",
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M;7YEUK'<R2?C_P!J$X__`-C2B;.VOSI6?*COW*/;&IIVDV=M<<]14GG9>-R[
ME:N=RLLY3S>1/-SSNLY5E>5<O+W.3DY.[HFQ<.0+V0KP+7C]$V=M.0+V0KP+
M7C]$V=M.0+V0KP+7C]$V=M.0+V0KP+7C]$V=M.0+V0KP+7C]$V=M<E)`Y$<Q
MTS.>;^'SF&<8POG*[B.0C/*GF\G=SR9Y>71-BX\@7LA7@6O'Z)L[:<@7LA7@
M6O'Z)L[:<@7LA7@6O'Z)L[:<@7LA7@6O'Z)L[:<@7LA7@6O'Z)L[:FD-_-A^
M3[G0-<G@TZA749]C/XV9_MF5_KQ6I/*/I5G>#W`I/ZA57__4^V/B&_)DW^CK
M_>JT^U_&Y69X*WK4_P`EJU_E^&_PX;15/*H8<<4/*V';3<F#@X\N5F);:B9`
MC8T!E9)AQI*9EM@45AO"G'GWG%8PE.,9SG.=:OK:UN;[2&I+.S@=+=26<K6,
M:*N<XM(``&TD]@+=N&M]9Y9Q!T;F&87+(;&',8'R2/(:UC6O!+G$[``-I)7E
MA';-;F1L_8#)FE6"4@8@:F4E<<T"](>LFTVTFZ^UH#48*QEO&)1^S56N24E@
M3'(HH-W+6,.?_P!SQ:#2NH(+V]EN\IGDLHFP080TNZ6SLKRT:&`4[\RPQ2RX
M.5[#A`=]KZ.NM=:3NLMRV"QSZVAS&=]U=!Y>&=!F.8Y=F#S(XU_#$%Q/!!TG
M)'(W&2W[%\=KF\;CNW!T7M*3'QFR!TU9(J/C(VQUU@I$[O2PI[%?K4Q+760?
M.,VW@"O_`+4U)J9C!YK#;*L-MMLX[CK#53G9#-;Z9<RWRA\DK&L;+$#TE^*]
M'$]\[BYUK&_\$2EL39\+#A:UBQ[,TT,UFJ;>[UHR6[U!'%!(^1\$Y:8<K-.F
MGBCM6!C;Z:/_`-AT`=.^U+I!C<^17Y[;A%BJ>]3PVT$JW(34G6X*C4^U4B=D
M4HDO6&R0+>\UAD[$$D&QW58ER+/*?2IW`4.&,.\X[G&4X[K\A%]EFK'1Z7D$
M\LD4=O!-;R.[_I98Q?2OE;AEGPSOD>X5Z.!D;'.<=BQT>J799G.@F2ZWA-M!
M%/-=W-O=PL)CZ&"8Y7#'"_'!:AUK'#&PAO2W,LLC&,%"I*;<;9#[<[N6`6O1
MLV-2V=E]K*_%%R$C,2D;B2KT[?P28V-=E"RQP'!H=(+SXHN&6>D?R^IOI7W%
MKW[(=/LR+4]['8V\S<I&4V<;'.<][,<4ERTL87N<&D,Z-SF,PMJ[&1B>XGRK
M5.K)=4:*RV;,[NW?GSL^S":1K&11OP30V;VO>(VM<\.EZ9K)),3L+.C#L$;6
MM\]A)'B)D-ULW8X??RW5F/AKQ*VR@4R?WGC(0J3K]2XKW+13*W:86Q1NW_31
M6[0M;KH$:,&W9U/XC'AS.HB%-/;]LHO+5,&PTOB!I]3X=:)3[`3*%P-VIZKY
MN9+V;</<*2F2W:[=2;LY<ZR8;!2<CMZ1.%-+%ZQ:.:,M0C&!D-,-8U&S:BBU
ML:_Q!5BS\,B;`?Q#&RT_2MHH?=>+W;F+BU$.;D#;>!8N(CN;$1+5VS-$461F
M9EC$'V<4%,U1]5BR;)%C99DTVHO7O5$31$T1-$31$T1:UW@VFH^^NV=QVDW'
MBD3-,N\2J*F`\X9R\UELA@^-E`%DL$L,2T'+!L&ANK;<2R6.VO*5<WDS5[&O
M:YCAWI%%9KBQP<T[0OFNV0X#&]QN*@_@EW,WRM-VV/X2U&;HQM+7%XCXJP8L
M]J&7)UT0)JQ%'U0<SM$!;A2BI%_#P;A3&!S37RL^>Y4;F?5>;9-,2<LL36(4
M[,D-J]VWD\*68"FQK)'Q-`91HVV^,461V.8QM'KER*2&O89),UNSZ&,)KRN:
MUYJZI/T8[OTR\S5'A*MM.UD%H*;@VY>MUVS8VUE):C18A:'*M4KB$5$^I;ZC
M&PLJ='(#<S',/C,/,.O-N(S>M;35=]IC-+31&96UIJ=X9T,MPUSHFTE890X,
M#G`NA$C&N`)8]S7T.%8?(9\IMLVM)\\M7SY8TNQL80''O7!A&(@'"_"XM.QP
M!:=A4`:5LIO=`V^J0<M`;QB,@\4RMRIG;\L<VV;75ZK"RQ!3=MG^).?$GK)?
MK;U%QF184JRF*=4_V`XUG#;F&OG;1FC.)%EQFMLWU9IPW,<4`=-FS+US;>:1
MUAT0$-CTXIT;G>J87VP<YL7K;G])*:^OYUJ31]QH/-+/)<R]7DDC9%%9O@:Z
M6C;N*5^*80EK&R8'73BR?O7O%LQG1MJO6C7UDO"5U/X?RR[@932",MKZ!3Z%
MN,I=YN>9EU#:VEJ;PK[N,*QGD_9U9F#$WI`2RNVFPT[7+_T578L+L!&.FRO)
MW5!B<X<2Z3>;QOS282IQFZ5OBI@(^S`2=X/+A2)"/0$B4A:TY"6*$()2O#CW
M_<L+&0MS^%3EI*$L^L66L(LURG*])9G?S.R*WD8YL3VQ-#PUV+"^4/C>!R#O
M7!Q`[TXB2[SFZTS+EV99AJ3+[*(9O.QP,C72$M);3$R,M>TGE/?-+03M%*4\
M\ZY1-\HZ\#U6#N)LW)R3Q\G+)DM[BQ61.F:41+6>0K430FI8EIG.7%&O.`\C
M?)SFTN+RC&O9KW--,R92^_NK*&.VC#6LP60<7=AD37ON<()V!C0_;V2!4KRR
MUR_/F9DVRM[J5\[R7.Q75`WLND<UL&(@;<3BWZ`30*7])XQ.&BE1T8P'Q.R4
MNT^&$QD8C:'=.?&,--:/=;<:ZM5,$X.+4&^\C#?1.N,H0K*.BZ/&O-LTX=:[
MS26X=+H*&,AQ-1=6L9`&$=F:E!5H-:@$D5Q56^9?KC1^7QPMCUC*\81L-O</
M!)K_`/Y5J:$CD)%-E*+=[/'CPK@0;<K*;T1YK'*;_P#<`Z/?VD&I":&*)4!'
M,5P\HIH)DUIMQ;.74X?PIO.<.)6VC4W\)M?RW!B@TP]AV=Z9[<X:D@8B913$
M02`:;*$=Z03L3>)&C(X1)+G[7#;M$,VVE":`1FM*@&E=M1R@@2NK-CAKA6Z_
M;:Z7F0K]IA(JQP1ZA3`E&PTV`/)QA:@I`<0\3)(12%Y:?:;>;YW-6A*L9QCS
MZ]L[G+KV[R^\CP7<$KXWMJ'87L<6N%6DM-'`BK20>4$A;K:74%]:VU[:OQ6T
MT;7L-"*M>`YIH0"*@@T(!'9`*P^Z;/;<;AG-R5RK34V8TD!#;SLC,"X2B,C+
MM#!HZ("1$9RAN,W%F6E8RG.',&<J^<IIC+75785@*X=]GS6R&BJH\^DS%ER;
MERSV_+D@_<`JN!9SY%[M_I9"5FF*;'J?,>4X4I]MU[I,/$DK>(HBUO<CATW#
M@XS>"S[-3,1.;B],,63'2,B_8CRMTDS6UG8MT4](U*95+OPU;F41[!8[S4+!
M!IZNX$24R#DBV3M>CASW#F2*Y7-L[S`D7ZK6*_R+%G19H%A;44[8MG9X0V-?
MM#AT!.DQE\+7A.!AVI`622<TZ\\C#C1%A%=O&RM:F,%U3;?<..OM6$@J2$XQ
M?I4R/=J3,W`7`Z/'EIVWFK=K<(V]'-G-$1R"ECO-A!-OC-*RR19?MQ2=A=]1
M6IF%J]UK5@A#=O;PN5>N=M??*Z`^35$$PL^FTF8DXT%R%E8%EQQ`QL0V*H=E
MH)8PZ62+=PO#9L['.&D0U9-A#3(L6(:-BK3;!WHL2/M0-WC>Q&E3;H40['6V
M,'.94PTCD<:PC.,M94VHBW8<TX^$8PRI:7GA2&FE()<#6EQQI:$*08TT^Z*O
M"LXY'$H6IO/X6$YSCDT10,%VOXC$Q::]%8'KE58DJ47&Q)4M7<%.1\%9AI*U
MO6C$+UB.<NL\:(&0R1&=6B#HX8MPH020/=8419N!M%N)9`["'N8(!94O6'9Q
M<>-./0$E"]C4O=ZS3\VB)C1Q$LB"YVPF1X][!+6"32,%-+RMA2%+(K8%4.*\
MELLA^W/03L=#U<6&BQ#:6]'G3$+M':`)LDQ*J^;G$5-;P`PQK24J'<S&ONH<
M;:1ET=)%S]4N+!;!9"[F6T4U(41$<(P335MDK9`GVMQ"S5.1B&Q8*1N:1#XU
M:<OD!P3B$+CB'&GH9PBFMHB:(FB)HB:(OGOXC97C+;WYW<13-K>,.5J:+]9$
MUV2IT=9':J=$8D7L!%5]P6R##KB7F.3+.4-H3E&<<F,:^5-5:2XFW>I,[N<L
MS"\;E\ES(Z,-EN`T,+CA`#1A`IV!LW+[YT#J_@I9Z*TM:YW!DYS>.QB;,9(K
M4OZ0,`=C+^^+J\I=MWK2W;''C\CO'/Z*M?YU:P'N5Q;]IWWGKKR5M_OQP`_M
MLC\S9IVQQX_([QS^BK7^=6GN5Q;]IWWGKKR4]^.`']MD?F;-.V./'Y'>.?T5
M:_SJT]RN+?M.^\]=>2GOQP`_MLC\S9IVQQX_([QS^BK7^=6GN5Q;]IWWGKKR
M4]^.`']MD?F;-.V./'Y'>.?T5:_SJT]RN+?M.^\]=>2GOQP`_MLC\S9IVQQX
M_([QS^BK7^=6GN5Q;]IWWGKKR4]^.`']MD?F;-.V./'Y'>.?T5:_SJT]RN+?
MM.^\]=>2GOQP`_MLC\S9IVQQX_([QS^BK7^=6GN5Q;]IWWGKKR4]^.`']MD?
MF;-.V./'Y'>.?T5:_P`ZM/<KBW[3OO/77DI[\<`/[;(_,V:=L<>/R.\<_HJU
M_G5I[E<6_:=]YZZ\E/?C@!_;9'YFS3MCCQ^1WCG]%6O\ZM/<KBW[3OO/77DI
M[\<`/[;(_,V:=L<>/R.\<_HJU_G5I[E<6_:=]YZZ\E/?C@!_;9'YFS3MCCQ^
M1WCG]%6O\ZM/<KBW[3OO/77DI[\<`/[;(_,V:=L<>/R.\<_HJU_G5I[E<6_:
M=]YZZ\E/?C@!_;9'YFS7JI]7\%Q4/1,W-[T9N]9H[I!@L91]X0BW]QW9AO#.
M,RT6Z7)EF5^O9Y>[A]U]HE:5=&.C*E/X]?X69+Q$RN:\&I<S+LG^RR4ODE+R
M!M8Y^%T;!V0ZH<:X6`DO7S?QYS[A#FT>7MT7E4?O#LQS6PCBMVQ@GO9&1@LE
MD/V2W"Y@ICD(`C7I+KVM?,Z:(FB)HB:(FB)HB:(FB)HB:(FB)HBFV+_-A_Y!
MK_IIU"Y%&?8S^-F?[9E?Z\5J3RCZ59W@]P*3^H55_]7[8^(;\F3?Z.O]ZK3[
M7\;E9G@K>M3_`"6K7^7X;_#AM%4\JT=OA:*W47WYZSL1[41#UGM.3EY`J1'9
M`CQBI)Q]U[`9#:>A80A2\YYN5=W/^[77O+RVR^TN+Z]F$=I$PN>X\C6@5)/:
M`7:L,OO<VO[3+,NMG37\[PR-C?">]QHUHY-I/(H_9WXV7QT_++U#&!JK$79Y
M7;<OS45:P.B,P4QS^N\U;$P](,(&2G.77UOMI0G.5IQG$'56G!CKG,'>VS+@
M]]__`$R%HC?]#RYH8.5Q<T`&H6>&A=8'HZ:=N>_O)+4=Z=MQ"'&6+EV&(,>7
MD]ZT,<7$!IITYW_V3P]7V,S-0PJTC"F0+G;,SU4\<Z4>@Q%X,ZYU093\TPL/
M"'EMKZTG+7)TGX.J^]NFL=BS]Z@K<M#HSBV.#GF-O?4PBL@+*.(.,8?"V*XT
M#K(QYE(--W-+-[FS##WS"R,2N&&N)U(B)26@CHSCKAVJZO[S;0"IL"B)NA-8
MJA3`5DY]O<PJ$,))ZB.)(I[9YPQ3Y^,CH;5CGJ)2IK&.D3E..P_4>01B^+\Z
MM1ZLX-E_%9^&XG"&NV["7=Z!REP+?"!"ZD>C]5S'+!%IN]<;QA=!2&3\5K6X
MW.9WO?-#._)&P,(>>](*KXW=+;&8F&*]$'4J4G"H@>?&B8ZUO&GDPA;3!`LL
M.,-,.N/QY`Q+3J'4XRA33J%XSS5)SGGM\ZR>ZNF6-KFMO)>.B$@8V1CG&-P!
M#P`22T@@@C800>0A=:ZTWJ&QL9,SO<BNX<O9.872/BD8QLK26NC+G``/:YKF
MEIVAS7-.T$"^$V>IQJLM&1U?`5T)QF6R9HX575P6VRY,O*'9-O/0AM$)=?<_
MX6TN84O.,*QG.36$[B[Q[#72V!"A8B&)&/PE0)`\M)/,&I6TM]*A'FY)39&%
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M#"]I/-/!-:V[+NZB,5JZ,R![P6L+`Y["\.-&E@<Q[2ZM`YC@35IIZ`U^XU*U
M0,):*[&P\Q7[)$1L]!2P4E,.ARD-,!LR$9(B.=?QT@QH1"'6U<G=0K&=<RXN
MXK;'UG;6)LLS<XK:RD1EPL333%@M<?&J"LLZPP@5IAF9G1G&Y23:9:!92A+[
MJ\)2RC&.XA/(2JRGM.*^#@/GTQ[?T4=Q5';PO5NI]C,]4YW/ZKVK.]6Y_+SN
M?T':71<[E[O+R<O+HIJJ?M.*^#@/GTQ[?T4=Q.TXKX.`^?3'M_1.XM#UOBBV
M:M>\UHV&AX]#NX-/C>TIH%QR60,RA.65/,)=[54[EY@<L=U6<MX;QA]"<JPY
MRHQMEYHO/K#3-CJRY@:,GN),+'5VGEH:4Y"0X#;7O2:4H5KEKJO)[S/[S3<$
MI.9P,Q.%-@WBM>4`@G93:!R[%IASB"X6F-Y+M0H[8P63/LL29!;C[F5K;N9/
MKLZ\PN7&F:K9K#'C8,M@T?EIU@I3&9!ADIQ8[O,6AWF[.W2FN7Z;RO-ILZ++
M>"1LEM;R76&1@.$LEBC<^D1=L<W%T;BT![:@MKK[M1Z19GN89='E0?-*PLGG
M9;U8\C$'1R/#:R`;0ZF,!Q+30@TVS5]BN%7HV)RJ</VUHB5&LFM$@P9L<ZB2
MCN4=@UP=3HSS,D-A&<)=6C#W(K.>7.%<N==O]8ZX#WVV8:CO7.#2TATSG#"[
M:16I&$[@:<RSEGIG218RXLLBM`VH((B#=K=@-*`XAO.WG65";*</0(S`H?#_
M`+5#-"KAW!5-5QE)`JJ_FN*AL"EXSUL9N/74(M:$(6E'/!95G&5(QG71?K#5
M<CGN?J2])=CK^-)0])TF.HQ4.+I9*[.1[AR%=MFF-.,#6LR*T`;AI^$RHP8,
M-#2HP]&RG;:#V%LZ,]6X:-CX>)J$3'Q<2")&QL>(5+,B@QX+#8H88S*#\(:'
M&':2A"<=Q*4XQC6!GFFN9IKFXD+YY'%SG$U+G.-22>R2223O69BBB@BB@AC#
M86-#6@;``!0`#L`#8%'3=7B<A=J-P`JO+[;C%5U^M1LV]8QYJ7R3B4-7>#LU
ML.*R3C!<H16=OY0\;E>0AQ(3J591R)RKB7)W%B-FXTZO!R9@XNQUJ+BH'-N9
MM$F1,PHCXTI1FZ$198"#CDWDC,Q(1HUYY5$.O"1SJPU8%(*;=;=R16V;XAME
MJ7NAN%63.'^(),HF*^!%S=8`BE2TT)![>+W,M1(SLU+UP5$/MK$5&(94@<P@
MA!F!&FV,*91S"*B!XA.'C(DI,5WAO+C)G;MAD$)3U1B*^F,='I6Y&YC@$9*C
MVID4R(@%T24;+Q'O$,8DG4*'P^ESI\$6?TG=G8/<ZTPU78V+BQ3):IIW6BI.
M=C*B=$X1'2\!!!=.7`V^Q/Q-S0U8(TAD8EI@MH0EOERAU*FD$5E8XD=E:)<Y
MNKU_9H%?:5CHM9@K#MKZOJA;:NU5R%EZFR;(XMD$@53K\W()$=(_^WK'#?6T
M1E>'FFRCN*]U_C)VLLDM&1(.VMO9S)MPIC<@:J,8C!X6?N,'08^>?)1?W5+C
M\6J?;$(;90Z:(ZR^EYAM3*TX)W%*;M.*^#@/GTQ[?T3N*U0MPIUD`Q*UT6MS
M\6HN3CTR4+/F2H"CX63+A9@+!@,J^/DN)F(]\0EOG<]@EAQI>$K0I."GN*H3
M9*TL0@],7"*!$4<@HQ,Q(Y$&7%OOBR:"",2>6651Q(KK;^%9QEEQM25\F4YQ
M@H[BM-?W#V\MF'%59ZG65+($+*NYK]J=F<-1=ECTRU=DG,QTR3A`$_%+P2$]
MGD;*'SAQK*D9Y=%/<5Q5:ZFE,BI0-?2F'*:!EU*G#\)BS7Q03F`Y'.93D!*>
M"DQGD-N\U:FB&EXQS7$YR4=Q<?6ZH=;ZAU.N]>[4[#ZEV\;UOMKL7UD['ZMV
MKTW:GJ[_`-_U?DZ7J7\/S>B_"T3N*J,L-=CVD$'Q$."PX4""V\9+28S2S9,T
M>-C0T./22$**D)$MH=AO&>>Z^ZA",94K&,D[BJNTXKX.`^?3'M_1.XJ<:=@3
M&U/!PL24T@@H5;HTI*/MI*!*>!.&4MJ14E)`9H[C+J,YYS;J%(5C"DYQ@G<5
M1VG%?!P'SZ8]OZ)W%8'YJ$9>=:==B1W$+4E;#DIA#C*L9[K:T.%X<2I'W.17
M=_VZZSKRT8XM==1APY07"H_FNXRPOI&M?'8S.814$,<01O!HNKMZ!\KA?2S?
MMS4>O67]Y%XS?K5OVW,?9T_B/^I.WH'RN%]+-^W-/7K+^\B\9OUI^VYC[.G\
M1_U)V]`^5POI9OVYIZ]9?WD7C-^M/VW,?9T_B/\`J3MZ!\KA?2S?MS3UZR_O
M(O&;]:?MN8^SI_$?]2YHL%?2KE41"+QR*QS<RZ,8Y<ISC&>5)N,\J<YY?]_)
MW>YIZ]9?WD7C-^M/VW,?9T_B/^I<.WH'RN%]+-^W-/7K+^\B\9OUI^VYC[.G
M\1_U)V]`^5POI9OVYIZ]9?WD7C-^M/VW,?9T_B/^I.WH'RN%]+-^W-/7K+^\
MB\9OUI^VYC[.G\1_U)V]`^5POI9OVYIZ]9?WD7C-^M/VW,?9T_B/^I=K,O#D
MNI9'=BR'E\N$,L26'G5YQC*LX0VV4I:LX3C.>YC[F-69=VLC@R.YC<\]@.!/
M_55DL;V)CI);*5L8Y26N`'TDBB[296*CVL+/;`$0^\P*P\6:Z,G)3[J4,L-*
M<);0X^0K\!".[E6<]S'+KL+J;-R[6RA76T.M##N-.(2XVXV^^MMQM>,*0M"T
MO92M"TYY<9QW,XT39N7+IF/(VO"D>-T2HW+BDH5>7$H&'6II>&W4I??5EMS+
M:'<(<QA[.4+RTXE7)GDSS58S]S.-$V;D<*%:;6ZZ,.VTVA3CCCC[Z&VVT8RI
M:UK4]A*$(3CESG/<QC1-FY<4&!N*>0VP,XL=S#+Z$$/+4PZIII_#3R4OYRVY
MEA]"\)5R9YBTY^YG&B;-R['#`VF5+=$&:2UTCKI#A!*$H:2C&5=)E3^&T-MX
M3E65=S[O=SR:)LW)TS'D;7A2/&Z)4;EUK,#;4RAQ@9M9#F66$+(>0I]U+3K^
M6F4J?QEQS##"UY2GESS$*S]S&=$V;EV=,QY&UX4CQNB5&Y.F8\C:\*1XW1*C
M<G3,>1M>%(\;HE1N7)1`V<(Y`&4\U/(K.'BL\]7.5GGYYSV<8SR9QCDQR8[F
MB5&Y<>F8\C:\*1XW1*C<G3,>1M>%(\;HE1N3IF/(VO"D>-T2HW)TS'D;7A2/
M&Z)4;DZ9CR-KPI'C=$J-RFD-_-A_V/X!KN?_`"TZA749]C/XV9_MF5_KQ6I/
M*/I5G>#W`I/ZA57_UOMCXAOR9-_HZ_WJM/M?QN5F>"MZU/\`):M?Y?AO\.&T
M53RJ(7&35)>\TF\TZ`0PY-6;;.3A8M!3Z1AUG'YF!QTO$*PI++>7%XY59QGD
MQK7]69;=9QIC/LJL@TW=Q:R1LJ:#$YI`J>P*]E;7H/.;+3VM=+9YF3G"PM+V
M*60M&)V!CP74'9-!L"\X8SA=W*@;!-3XJ8&3R#,P1M:"<E%"-'UG;G=+;B;I
M-3*6MDC`62Z51EJ4M27&FCB.:K/-SSD^56_#O/[*^N[V,0R%DL;HFE^$.BM;
MNUDMX3L.&L%N:G:!(ZAV;1[G=\7M*9CEEAELQN81)!*V=XCQ%D][E]]%=7#:
M%N/#=78``(<Z)E1MV&[9V0WM-;E8N3CX$M-LKY55+G'9^)&S6HYS>6;O3$@\
MQ"UR+;G95FO'HSEUD,51,CG+CG,YRE8[1TAJZ5MS;7$$+A<P&%TAD8.B:;Z2
MX#B&1,$CQ&X;6L9CEJYU*DKI#B!H"!]G>6ES<L=97+;AL0AD=T[QED5H6`RS
MR&&,S,(#72R"."C6XJ`&YC[#;I1U@JT^T'`FXVPF3BHH3%G>8=W!$D]QK+<7
M'GU.PN6H,L*.FF>1)"GL*.2ZG"L-X0^OL,T9J."]RZ];%"_]NE<6-Z4@W+7W
M4LY)K'2-S6R-V.Q5D#A7#1YZDG$;2%UEN<9:Z>XC_=X&-D=T`(LG1V,%L`*2
MUE:]\3JE@;2(L-,1=&WOV.X=-QML+A7CI*6'=BPY0NQSI`EMF38DQF5VOB:<
MY41*D2`,!@Z#LT4T0Q,Y2TZ[&,H8Y$<Y36+Z/T+GVGLTL9KBY:;=LAED+9I'
M,<'VC(#"V$M#<4<K`YL^QQB:&4%2T<?$'BAI;5N1YG;VEDYMV^%L$+76T39&
MF._DN1<NN6O<_!+!(YC[:KFMG<Z2KJ!YCM?>%W=2]TOB-AW]M*M=+/N?3=XZ
MS4+;;7@80ZG3^+KQ4/AYBT%+;E!XZ]A;KQ3T.\.4^!@:1/;/P.T,TT;[)7DV
MKYY6TSN&JT/"L6E.U->DFG+5Q2656RQEGBX2/34MV-N+3`0^W1DE#]:K(!FX
M-F+P=-/B8)8C3)HKF$%H9R0_%>VI7;M7PX6>L;D[*6P?;8>KOUZS7F];GVZ0
M*H<0].&W:&W_`,R58AJ339&WOTV%JU[W59)JL8'8I2)=A9>6>FU.SPH)I0GE
M4+(1-G-\3=M[[$WQ1M_*=XC*)NM5*A9[I'V=HS9NKW.CV</:CK<R(/%#6.M`
M0!66U&+='E)=MA9,IAM]P@545[B+34!PH7:/O%PFB=A*`)`YNSM\#AH>S5P2
M.F*S(;,\--*"VH@,GQ\ZZZBK7+:PV;4+,#!5TL^`BAL8ZD<\[&J[.5%)C@QV
MQO&T]+N-4N8:8](=CJ04(QT*<*+"@=G=LJRY*J,8PQ'&/NYA4B&9!8'C>U`2
MUAHP*XSC`FJ*8VJHFB+Y`N+0+=>ZWEB.<X6=^R('>3<^5N&Y-6'VHW/$EAIV
M[IF!X8.M/S-=(`<=VLS;SL5\@0H4$^_NV23;Z2(D0EJUW0UJ^VXA:ASJ]RSU
M%P@Z:*Y[P![F5A(8YAQ^NO;;6[VN=L$`M8L0P/:,SJ&5LNE\KL8+[U@=)T;X
MN^.$'\3O@[O?5PZ60%HV](9GT[YI/U`<+4M.S/#QM"19:9([?S0-+C*Z9592
M$G:R2%BJ=)5Q3F:W:`HZSUZ-GPX=N0#!DF&9`0,IIHE&'D+QK99&M9(]C'AS
M`2`0"`0#L-#M%>7;MWK"@DAKG-HXBI'+3M5&S9VEOW5%*:(FB)HBZ2&UO,NM
M-D/"+<0I*"1TL*>85G')AQI)3!(^5I^[CGMK3_MQG5V.#'M<Z,.:#R&M#VCA
M(/,055[2YKFAY:3V12H^BH(YP5%ZU\-S+\I<;=4K*5$7"X0<K&2TR%6:-$V0
MQ1P+H>>AN$'!0,_'./-KSA)`Y`Y;#CCCC;^%N*7K?LLUDT0Y;EV9V^++;>5K
MF,+YI(FX78ML,DDC'"O*US7,<``6D`!:;?Z7?TM]?9?-2^GC<USPV)DAJ*;)
M&,8YII]IKFN!)(<"25Y<A\/C;%]M%(KMPR`WM_%E6+<E$]:MYGCZS6HE)B3Y
MAMY,P17WGF\B.8$"6:PV?AI2DDH1E2V_>YM6L_9['-+N`RNNY!';!D%D&RRO
MIA9MCQ@;1C?@)945830'QN+3;QF=YE]O+T;;9ADG+YKHF.-M:NV/P$[#A9B`
M?0]\!4C;])X\.'@,055`VNXBYI<D;"UA8L?<IIV7-E"!CB@6GJ^K<A:!T\Q"
MN1_F-#H<+3A*L-+4O&M9GPKUK-)(S-]09+&&-?)5T,>`-!`-'^K`G_\`7:XA
MA)!<`%GLOXAZ4B8QV69+FKW.+64$KRXN()%6=.:?3L%7<M"2MZ1GUC6V#M;3
M*QFUN]DF.OL@>&98BX.1-DG9EBI*AF2,2-M3.MDSSUS!1'(4P^1()>0XTA27
M6<N:G/P5S\W;HYL]RMCZOQG$]K6X#+C\&+HZ,Z)^,@AK""'$%KJ;'%Q6R7U<
M/BRC,'-HW#WK7.=B$>'PI,=7=(W!4$O!!%016>5'M0MZI=0NX`1T:#<:O`6H
M..E$C)DP!;#$B2XX4BD(DP-)PK)F$/8:>=:PXG/-6I/(K/D>:6$F59GF.5RR
ML?+;3R1%S:X7&-Y87-J`<)(J*@&G*`=B]+R^\9F-A8YA'&YD<\+)`UU,30]H
M<`ZA(J`:&A(KR$J[EQ$4>O+AT9'FN9PTG+A80Q"\I808VQC*GFUJSAE$@0E'
MXN'W,8_XU<O07<5O34JJAL9I-9KR6@PUQPC286-PV+'N#1H3@`R,#<U@-P.&
M#:4TG&$9:$93G'-:1A)%!VC;P[M'U6J+N>Q+<MN#*-PO;T6[72HH.M$[A6!4
M/.*`.577`I"'9K*`9*6>ZQAX@V>:8>0*V.4V&19_M5NX1<K/`Q-KV)7MT)=*
M5*6*0DY.`-1AJU!6DFBP]7EWB:X`,\?8:F^^2-E3BT]40\TA;K6>=DBU^K<>
M\B/OQ6-A88,D*PUR*A+B-5I1*ECL2`%R?=<BHZHKZBL><G7%!X2^H+K(Y1!#
M[#CF$Y(MG;.E1V\L0=&[C;)1]>=@V:K86G9BM9"3)RLQ,S$S*9YA,%#9R=ZR
M0&9`]*$(:*[13AQI;*\/%$4D"*94"\2F"*O7G<S8ZA9=>8>/P[)CJ6V[EHYY
M(^'248=90O'/5GD6A*L<F4XS@BOIB"G!"FP"&1#G!GT!E$C*-'&*4TI(Y#X:
M"0UELLO9PI36'FLN)QE.%IY>=@BA51N$"8V]'&"B-V\S0\.YM\[62[70Q"IJ
M#]29>-LTB"D^KV2H!$P]XM#19LLS@1ITI;HZG'G'A>G>(KKMSPE?%\^`XW?^
MO,!4JSU5;`E8(A<'2%JF+M-2EA/ZO:R6#2)`NZ<IK+S3F#5Q4<XI:714+T1:
MYSP02L>B.C(?<P\<:3*'B;+/18+M;DH;;RIA79S;FIUL4>4DTN^K1J:,*A67
M!U*'J3CZG.>:IC!2LY@^$(R$,26WN;EW"IU<XXUBJ&IP#E5837515=<?NI3D
M)"G9REXP;.2&W41T4RUT"(_'3E"S2N\/D_5:]`Q,-N!%#R41N`U<R)CU(-QD
MT7XF7MGS!VQ6KRT\+9SVW>UW999#[:CU+Y0\I7^"1:T<X,)4F"`K3^\TJ%%L
MPE;C32(&NGQ\W@^O[@RUV5,0$C)76<&@7CV)9;&49&*Z,M/6\*SRY8T15K7!
MFT4W)+L5XBIDJ2)F"\--T-P6#C79V[4ZU'-0T"=<I@:,&1!5PFN-8;7AS%?)
M'#<6ZR'A#Q%LW:_8*2V[OYEW,O;=F29!6^'<#=JZHZ4=<M-SC[<R^;8,V.1=
MD!(3JCS(X[HZN8LM]UM;72N-K(I)Z(OGVW^X3N-2Z[X;MVNI[!5R4JT]N);I
M&M2K^]M'C7I:`?FS,PTL]&ELI+C'92.PV^H9WE<'RYT:LYRG.<_+>I^#.H,Z
MU%G>;0SM;#<7,DC11AV.<2.64'D[07WAH;_D)H/3NC=+Y%>3R&[M+&&)]&2T
MQM8`X;(G`T=45!(-*A:B^A-QZ?JZ5?Y^=O\`Q>L'\!=2_P!TSF9Z9;5\SW#O
M^K+XDWH4^A-QZ?JZ5?Y^=O\`Q>GP%U+_`'3.9GID^9[AW_5E\2;T*?0FX]/U
M=*O\_.W_`(O3X"ZE_NF<S/3)\SW#O^K+XDWH4^A-QZ?JZ5?Y^=O_`!>GP%U+
M_=,YF>F3YGN'?]67Q)O0I]";CT_5TJ_S\[?^+T^`NI?[IG,STR?,]P[_`*LO
MB3>A3Z$W'I^KI5_GYV_\7I\!=2_W3.9GID^9[AW_`%9?$F]"GT)N/3]72K_/
MSM_XO3X"ZE_NF<S/3)\SW#O^K+XDWH4^A-QZ?JZ5?Y^=O_%Z?`74O]TSF9Z9
M/F>X=_U9?$F]"GT)N/3]72K_`#\[?^+T^`NI?[IG,STR?,]P[_JR^)-Z%9=0
MN![C=+N=:8GMJ*YMU$*EA%'WD?>:K31%68:7TN9D:*@4)F#BA%(QEML=2',K
MY.12>ZK'-;\"-4,GA?'F+(GAX(?L&"AKB!9*75'**"M:<G*.GF'_`"<X=.L;
MMAMI;H&-PZ'`^DE13`>DB#*.Y'8C2E=AY#[F2^S:[+2]OZ9;KS8;8FI%22[)
M89-D4:?NX$Q0;K0I..(,C5"+AL$@W-?(6C+\@EIGDZ?)*\%H^I\GL;G+<LL[
M&[S*6[N(V`.ED#0]YWG"!W*U=3PG.=5Q^"]09I:9QG.8YG89-!E]I-(7-MX2
MXQQ@]AN(D]LT#65)P,8VC1H`7A)W5BQZ]'0'%9N#`0];KD17P8R.CYU8[>8G
M,;E!S0YNX9<?_"(#=92.\.^,T*]AI*/X-*LY.G;6'Q#;L6YI79VS+@&G8^\.
MF7^'V@WAVY@[6?B6"D52VY4A5)>)FUV)4M.V"(9KIU0'3R-K+>5C*74*0IE*
M%E`/-5:FL7"EN7+.6AR$XG+Y456BXKMI"X(:SC$HPN,CHIJ(?/'W(%D#!(T.
M&$8$<4ZE[`C70D*)QS%-J=M2'#9WJK)WA:W$G8FPPA/$G>GXRPTB(J+\?),6
M.2!22/6X:$L,T^VO<%DHO-I/"*.('R\G"%%88PM3&"$%J)4;EL%>Q%C;W=F]
MR([=VU1=?L%JKUJDMO@LS+4243!UVMU]\0DINU-C/BS#=;96_C(6,<Q#;&,=
M#UA!)1792BUS<^$NR66)W'C(3>>2HS6X\YF5E0ZM`3D;7\B/A7&)E`#:X#N$
M$#(/V"&F(8>1*QEAXQ4'AU?\(4M3:BG%R;%F5NV(OMKW2-N:-WYZ&K0]SVBN
M]:KHIEJ6U%YI,'>*]>:BW'`VJ%B@H>^"SX;Q!;6%./9Z=E\=:4LN9("`.17R
M:V0GIR_V>[R&XC\H%+P943`4>=AI.5IE:>D*,1499?8R+<$Q)1<T8[@TP3&!
ME/<W+>'DKST^"BO)L6*0W"P/#2)TD/?#V"'YRL3X!`%?CV2HB2@J^[#&2("9
M$N7B69(DTLLT+"0T@1JY$QE`C@[_`$2"$U6]MKJ&QMC0*S019,B8%K`+D<+(
M%LH8)>%ZV20,AYM#CN,K'8>2USLJ4I?,YRL\[.=%!V[5GVB)HB:(FB)HB:(F
MB*;8O\V'_D&O^FG4+D49]C/XV9_MF5_KQ6I/*/I5G>#W`I/ZA57_U_MCXAOR
M9-_HZ_WJM/M?QN5F>"MZU/\`):M?Y?AO\.&T53RJ/G$5N6WM9&3=Q/8R3"U>
MFD6.2'%A8*4E'AP'9-XAL'MA#;:GEM,<B&U/M-\[]G'+G.L=G&:6^295F&;W
M;'NMK:)TC@P`N+6BI#02T$[JN`[:R^G\DN]2Y[E.G["2-EY>3LA8Z0D,#GG"
M"XM:]P;4[2&N.X%1'&XVJB88J.#B)\D_-.HUM$#;I-'P_($;AR5<B*W30T.%
M-_\`_8KD;6$V0P[EL4;#F5K(PA.58U"/B3D,LI@BMKMTWJMO,UH8RKC<OB9%
M`VL@_'Q31AS31C*U,E`2M_EX-ZI@@%U/>V#+;UZ[MG.,DE&-LHYY)[IU(3_Z
MP9;RECVXI'X0&Q%Q`5T.XNPHQZ-;D:5<@&'X46?L)9M%H`B:/&DW$VBJ?M`1
M,DU+K;&G@%]([&#23'5,I)0M;&>DUV)M>9?;OMVSY3?L88A)*YS(V^KM,[K>
MLS3*'T$C34Q-E;@I("6'$NI;\+<VNX[IUKGV522-N'0PM;),XW;VVS+NENYM
MN8P70O&%L[X'=)6)S6R#"JU7%O6<ED@#BR1L@N0[-K00U%K73WHA%A,JI+E1
MR^PPR4*%.Q[[3SQ2PVT(;Z;ERRI#BN8ZZR7I)(&1W#YR_!$T,VW!Z5T)Z&K@
M"&R-<UQ>6``8JX"UQZXX7ZDZ&*YEFM([818YWND-+0&%MPT7-&$M<^%['-;&
M)"2[!3I`YHJ*UQ4`6RSU*MQ5<LG17B+/F:Y8RJ#4QZZ9'1<4Q)R9+C^<JDQ&
MXYXID%_+HB<-2#R&%<F5ISF^7ZTR[,LPRRPMK"\PWD;GQ2F,")S6,#WDG'C`
M:2V-U6"DK@P[2%QYKPXS?)LISK-;S-,NQY?,R*>!LKC.U\DACC:!T?1N+PUT
MK<,AQ0M=(-@(6T!=V0#6G'F)ZK9:;E)>%RX[$5D9"Y2`D2XB:#843&-8)=BY
M0!\=[H^<E#S#B,YYR%8QN"\]JL&M7%%M]2ITZKV.XU\.R`5:KW-<$-31Y>6-
MKMUNB-NJD7"@0U9D";`78KRZU%"!@))->-(9;2UG+[//FA45732>*O;7<:17
M%TN]U:<)361[BR\U501(R0K+\-4K"]+1$U(5P2'FF(J&OT&_(I$??<BTS`>#
M$L*)92M0A359#=]_J[MW#,3UIFHYF/*E'H43$+16[;(ER@L/*6(T,2%J-8G)
MDER/K\&8>3EL=21@A77W<H:;4K`"J56JV^.O8QZ.E99C<>%(`B9&2C%/#[:R
MCZI=Z%DKM$S1=289HZR+O"PI>VT_DV0AD'@"#Q!+[SR&&E.:82BWU7=SVK;$
MLSM:E:]-1#Y,D&S(`05=>&67#R9D-*C87B*QR/1\K'OCNISW4.M*3GNXU"BJ
MO?K7,?\`E7^G:][UZ)5/6N8_\J_T[7O>O1*KQ+XD_KG-P-B[CN5'PO#A&VZD
M;;7,_;^0M)]BIT&2[:`C+7'@AD18M5FB`5V`VA2[^&\H<5%U[J4R7GHSF0\X
MW),TML_U-<:3LVR,S>.X;%^*UT<;L45M+TK97#`80+J.-TE0!*V6/:Z-R[V8
M6,N6Y1#G5PYCK)\1?WA#WBCY68"P=\)#T+G!E*EA8[D<%[$T/=DO<"C4R^1H
M28R.NU4KMN`C9JJUH29CPK)$!S(H,L(T"0T+)B,&I;?;2XM*'4JQA2L8Y<Y)
M=([-BROUKF/_`"K_`$[7O>O1156&S;J"4N$-LEMG:K6X&.PQUR7F8NK1X#"R
MB&@Q&5$$QS:%$FFD-L,-)Y7'WW$-H2I:DISQ3SP6L,MQ<S,CMV-)<YQ#6M`Y
M2YQ(``[))H%RPPS7,L<%O$Z2=Y`:UH+G.)Y```22>P`HZ1G&_`35@B18B!*.
MI<UN*UM/'[@IBMM&07[RX\X!D7U1(-:W`:A69Y&(QPQV+;RDU7.Z+J6,F:\]
MM^+&B+O73>'=KFO2:E='C#6BK'#H/6.]>#WPZ'OND:#%BK%TG2M<P;:_0FHX
M]-W.J9;0-RV&A>#4/:TS-@!<"W""97!HC+A+A(DZ/HB'F5/K7,?^5?Z=KWO7
MKT=:;5/6N8_\J_T[7O>O1*J*E7XRY.P\0VX.Q)>WI,"%M_#8EB]QI&*K>*X7
M_P!HT<IE2\UMJ,%1@;IE84F0>=ST*^5I/1$]7WV^T,ZST=D^JX\WAEDNY2P6
M[0>D&VE>7$=M!X`&T4<<3,6G6>KVW6I\STX_+)(V6T>(SN(P'96G)0;*_:)V
M&H&%V'4@'UA,_/;OE0-3I$?9]HQV&A&;2%`U>.LDB=C/*5801;&J#"75$Y7S
M&N5OI'4H2\EW/3MM)V:3A0^UT['>7^9"#4#CB,3JNC:WL1N,;7N$O9.V@)+2
MWO2XX%G$=MQGC[6RL#-DS13I&T#W'LO:'N8.C[`V5-,5>^`$VZGNPBU1PQ$2
MN&'6H?+G9#L/25R03#+F1E].)%M2#3+;+J.9RI7E')E.<9RA;:E>7YEE=YET
MTC+D8@#X8#L))V["YK2:C;M%>7L@T]`L<QM;Z)CH#A)'@G#44V<C21L[1W=@
MA97ZUS'_`)5_IVO>]>L8N_5/6N8_\J_T[7O>O1*J*V\&\W$-4-PP\T>J^M='
M]6(C#\?%[<PLB\];2<[B3*\NRC-><ZM#KBZ:P`6I+N7!C92.QA&.LY7HI6`6
M3B)XKT'K.@:$!F)C1+EU2(QLC*9*MSE7"VPDXB=(D'Q27ZT#>FK-*,@PRQL2
M8;@KB'7WWQ"F6B+(K/Q`<3,)N+N$##;:9FZ6VZK.WAQ.VD:]'&AT7;J:L=V;
M=(A!'9T>4N-YR'"0SI[#`[^.5\)DY*58=(J9KB.XEY..N0Y&T(\'(P.<"1)X
MVWA!)$JMK;'<>R%R\(,=5B(S.9*S5:,!!3AV0P([-(&*;>(0ALDBR[;WB4W7
MG;7!1ETV_<K%=EJ*U,%S9&TDY#LQ=WD;E$5V*ICQ4Q7>@61AN6=9=4M#25]0
MZ^A?5#$('(L*LW%9O5`V@[`>WIZJ/,7.HUZ"FK#LG,,.P(=C%K\&?(%L1\`.
M3(MP=Q"D6$!*0E^8=D1%`E*8Z#!)%50_%/O^[*9]8]G?5V!CA(><L9I.V4JO
MLV-,NM>I\W#!2#$`0%,R==BC3;&HP9#C9$:/AKJK7,67DBF9ZUS'_E7^G:][
MUZ**K3L7Q1TH\1HD^PPM8<)`8F8\&TURMPYTM`R+*"X"=AFG(]UN7C;,"YT@
M'5ENO/.-OC*;08&8,.4KMA.*7;>PC,%Q>X-'='+DBHL)QV,K0R3B!I^=K27@
M5/Q;:3`#92LGX%);RI@ED1UYM:FD+7@FU4@7%AMJ>J&:'OE-4_-B+,'8;BJN
M4H5*&G%88D70HXH4,D@AEP8=.7,];+:6RQEQQ.4Z)5<#.+3;`4U0*-P:0>XT
M"5*%$1L=5#(T*+!L59JQLB9+-@8BV!!YFUC,\[+W*ZM#Z&L..#NH217P;B1I
M,A)1T/#W.FSLI)G-QXX$+&U22)0^HWLTCK#0X"E,XCCE-M%XS^&*M]G#J4]*
MWSB*@3Q/4]AY]J=G8:I-<MB>B#K77JO#1MGB:E@K-CGZV>\$H:1AX?(3F2%Y
M4VZRWEIU;:6217'R*Z(XCZ`MUEA.X^VV2",MH8&SZEI)<=6K"7&,#J#P]UD+
M&<**:RGI`V\X6_AM&<*T455UK6^5;N1;H%5MU,GS60!I1P6+CJL4]B.+:%?'
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MWN'^86GQCX;]8O\`'NO0I\O'&/JA_EV/ZE<V^/KA;;5ST;N`<O(I/X6W&X*\
M<BTJ0K\%=!4GEYJL\F>3EQGNX[NGQCX;]8O\>Z]"GR\<8^J'^78_J5P^GMPL
M_*V%\W>X?YA:?&/AOUB_Q[KT*?+QQCZH?Y=C^I3Z>W"S\K87S=[A_F%I\8^&
M_6+_`![KT*?+QQCZH?Y=C^I3Z>W"S\K87S=[A_F%I\8^&_6+_'NO0I\O'&/J
MA_EV/ZE9]MWQ4;'[KSOJQ0=R(2;L"F5/L1!$!-5XPY#>%+=3&(M%=A4RC[3:
M,K6T-EUU+:<KRG"<9SC,Y'Q#T9J2\_;\GSQDEZ14,<R2(NIRX>E8S$1RD-J0
M-M*+7=3\).(VCLN.;:ATS+#EH=0R-DAF:VO(7]!))@!-`'/PM)(`-31;UZ\1
M_P"!YH)XC6ZKS>I6)W'<ZO;=Q;<I;I1B(C#G31DE=@O26,*BH&9ML@XYB-BC
MWPA@8"M&EO/KPVTAH=6%+Y<X2HE2598?>W;2?CX.3B]PZ.^+9`8Z0A$O2L$$
M8<-+.-LQ_-C3LC2+)!!+F&>A<:0\DCE:4C#F,IPV*>^5ZSN55,$QXWK/7E*E
M*W/W$`AM<:['D5>K%0@=@G<2C;:HUN-BR;$&EQQ;J<?PW+CEPE>4E%2K+G>W
M;1&9;!&X='!1"2;4/(OR4K!1@K<@_&P\LTR.9(9&%/0H*?$_A!UNM8==Z+*L
M.H6A+8I[Y=DIO/MS#0LM83[]3$Q$'$%3TF4+(PDBIB)#0.IXM`L=UHPK&<F,
MH;0RVXXZZ^TVA*EN(2IL45*K!=UZ49.35:9MU:3/UZ;%KDM$$NQH1[$T;&UZ
M5$!8',:87(+?$M<?A*Q^E;Z<E+'.Z=*VTMB5*L9O$%MA&QEK-D[W6HP6C.2*
M[,U)#,1TG'Y`BVY<AQN,,`8F909Z+YKPRA6GVBTYY1\N9SG38I[Y5,QO?MQ7
ML73$W=ZU&.[>D#B6\0O`K4A%%FUD>X`"HCLC=?DR)*NDI(%0(V0HG*7&FL+=
M:<;0V)WVQ<T;U;?.1<1,(M\$H*>DXR(AL8&;Z[)&3%T$V\C<B1?4NU'0B;B>
MR%@K#/54J<PXIS#/*YIL3OE:WN(/;`?$QDJX1XF*^QUB8ZY!GB9!:7"/V47I
M<$PS65.2==%>."0GG+.$9<='PXAM:DMB=\L]@[K$V1R=:@I,"3769XJL3N!Q
M&,XCI\(0$TR,=6L5"%D##R+.5\S*DI4OFYSSDJ3@HJ5?>O$?^!YH)XC1*E<U
MR12\(PKJW(VCHT\T$%'X.%*5^%E(Z<K5RJSW5<N>3N<O)C&B5*X=>(_\#S03
MQ&B5*=>(_P#`\T$\1HE2G7B/_`\T$\1HE2G7B/\`P/-!/$:)4IUXC_P/-!/$
M:)4J:`W=&'S_`.`U_P!-.H5U&?8S^-F?[9E?Z\5J3RCZ59W@]P*3^H55_]#[
M8^(;\F3?Z.O]ZK3[7\;E9G@K>M3_`"6K7^7X;_#AM%4\JC#Q3;?&;GU^S48<
M@F-1;:$97<S#,8[*ICE23DJ/DG(:"`\%*8P[A71],USOQL<O+K$:@RG]]R/-
M<F]8Z+UJ!\>/#BPXQ3%AJW%3=B%=X6?TIGWNOJ?(=1^J=/ZE=1S='BP8^C<'
M8<>%^&M*5PNIN*@^-P8$1DI/S4-:9$*3D+`Y:(1XFG/&LPDN#N)4+S5&R&,3
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M:C8@\M>VYQ/<[:&86MV#MGL`5MU-"2W:$I.)B=N*]MY!COP3H:XYD*6E9^TR
MJB$E$I>>MLR:.ZII#;*1FPFV^<[C"<HS>G])1Y%=Q7/KQF$5A%;1@MPX0U[Y
M)GUQ&IF>YI(`:&B-K:NV$:SJS7LVJ+":R_;!;F;-)KV5P>7!Y?''#;QTP-H+
M:)CVAQ<XO,KG49M#O.'>7@`WTN-O@RJW&UN2%B=QU7A^=ND2J>(?BFK[Q+R0
ML*F6<L$=,D#G1&_(1TM#+C61)$\`U[$FTXIAHC<PX+S[:I!T[@)OU`G&K=5]
MZI%%F2S,5]04OM.Q)41C;FRP=":L6W<5`,6N.MD3`D6FALE@H;L*FHJ/?4(*
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MN3]SCO-"/%ZA10[D[+D_<X[S0CQ>B4.Y?-!Q`?5[?6.;D[AU&:!VSVQE&S;-
M.3^XC[EUC"J9/';GBA`;K&33TI7(&[,`V1ELF")'#CSG1J`!`!C+?D125(Q&
ME;2]RK56?YQG4T<V77%K2(1@B42-=.UD,F,X!:]$Z(O+29#*Z=P`!81D<XGM
MKS)LML;!CX[N*:KRZF#`1&3(W#WQFQA]*T8&",$FCE[]\/E+W;J>S&WM7W;0
MW)7ZN028.8/BW#)5HH.*+*"KCQTJ[$P^).>56&`^TR&Q1V'Y+IUM-I:4C&LU
M(8S)(8@1%B-`=I`KLKVZ<JQK0["W'X=!6G)7LT[55N3LN3]SCO-"/%ZHIH=R
MP'<':1.Y0$(#(2%QJ9E;L(]JK]EJ\?'ERL-.B1DK$L%(CK``=#2+*P9DAI;;
MS?.1TF'6'&26V7F]9UCI+)]=:;S'2V>B;]KNNC+NBD?#('12LGC<R1A#FELD
M;';-AIA<"TD'*Y)G%[D&9V^:V&#UJ(.`Q-#VD/8Z-[7-<""',<YI![!WJ)D)
MP"R,!N3'W]JQU6<)B-W,[L.;L6"@N+XH+8IQ3X^:1,VR-C`(6%K*(4KL9Y(9
M*@RH%CH<@MOO*=;\YTKP>N-'ZNM,WRC7.8#2%M!@BRMP#H@XP=$]TD[GF20/
ME,EV\%H)N7EY<0`U;GF_$`9YD=]89CIZU?G,^$&Z%6EC62L>WHXF@,:]L<;+
M9KZG#;@Q@;:J>/9<G[G'>:$>+U[8O-Z'<NMV'D7FW&EQ\EA+B%(5EIDUAS&%
M8Y,Y;>8PV\TOD^XI*L*Q^QG5FN+7!PI4;P".8U![JAS<0+36AW5'\QM6JIWA
M_JUC%(&E`MS%I):+9)ZKN?NT#@Y@]ME@L.02Q:\-E@D,C-)6TI.4J2TC&<<F
M,<FQV.J<QLI&/9':=Z00?5+5Q:6DD%M8MC@2:$$4J2L%=Z>LKJ-[7/N34$$>
MLW`!!H"'4DV@@#80>0*!BN#NP&W:QB+I5X@*;4(UZ9<+;M6XDK(71U//=%@*
MST9)0N$R0[3V$O)=(,`<0STPKRGNAQZZ>(-C%E-G*R\AFS2Y>&!I@@8V'L&2
M78#WA(-"&MD&+"]H;B7F@T5>R9C<QOM98LO@87DB69SI>6C(]M.^H=M2YFS$
MQQ.%4=(W;XF,J%BQ.!4ZF2H8[8L621MI:78K#[@$@E@DFR/)BWA(X@YP-HIY
M?2',#NDOJ8>=;ZLMF.F=&4DFEXJ.N(7$EP$[`Z@<VH$8Q`N`QEH%(W$,:'M!
MQBUCGVJZQQ1\.VP2``-)B?05!H2_O32N$..UX!<XM)&$[,A-^N,4P6$43P:V
M2&:DY"&%D>@066;7PYA=*PF0[$.=KHTL2VS:WGB!U2`#`"@"&2"TJ'*<8P=Q
MHOAXUUR6\1HY',:\BH`#RSI=F(![F@]&`TACR_&US&$.8'96'56MW"`'0SV-
M<6UI4EN+H]M"6-)[\DC&T-PN:YU6N+9QT?-PG:53YNTU<RO6:8JU?E;%`-BR
M*D0<[(1(A<O#HR:*,9E$9(/.,XRZVV[R(_"2E7+C'E&:06EKF>8VMA<]-8QS
MR-CDV=_&UY#'["1WS0';"1MV$A>CY?+<W%A8W%Y!T5V^%CGLV]X]S07-V@'O
M7$C:`=FT+*>RY/W..\T(\7KH+MT.Y.RY/W..\T(\7HE#N4$J!0^-*N5*K5N6
M.DI"SCMU)-MM\H5#SD+*X(L.2+8:"/-OSMDC)6,JKD9'L"M\\!>`Y@C*R#GP
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M`!#J:DY1Q<HB)&OEPZVF:TIM@IEP=;$RIAMR60>XGG9*=JR@/A7I0,4Q",@7
M%<</U5E#1)Y9;KD:WG<%,E$%%DANF&AV`?=2?9-<><66IN0ST3S2FF%-$H=R
MM:N#[;CL.,KR(.RXCX@`&/";*PQ+-]#%V2SW&*48%-Q$G%2/9]JM+IN&R!W6
M'E#LLOMNC=,R\2AW+I7P;[:*"F8MN%M8T7-Q[D05'!D*%%;BER]5GD"-]!&H
M>=>9E:<&O!CZWI!3"$BK?6(R*P.2AW++`^&NIA7AJ_M1UJ7-L'SLF.V^0^^$
M.;9+4W<9=3&'0E&M!/S3"%MAX?ZB/GI7&F4/DENODH=RM-BX5:?:5(Q,M7H@
M4=RS8CHW$D^F+B`[7ES,C'14?F/4*&RQUPQ(S^$Y-89.>8P_U?HFFB4.Y<Y/
MA5HTP6^_(Q%F+#(OLIN<Y"E909#8N\\B1"GY]`AL62MLZ4@9%4<A>%\^.&3T
MD?D0MQ\ETE#N684O8R"H<VN>@(R>;,54Z[34H(2I;6(>LQL;$Q_3K:!8,D2<
M!0XR4Y+=(;%4EU0J!U%FY))0[EM'LN3]SCO-"/%Z**'<O'/=OZK?=/<[=+<3
M<1CBR16Q;O=;+:`JXKAVC)A5>`FI<L\""7+KW2C5RRX<-]`V2E#L*(RWTF6T
M95E./%<XX*9/G.:YCFUQF#A-<S/D(P.V%[B:;)@-E:5H*[E]1::_Y-9CIK3V
M2:?@TP'Q65K'"'>L`8NC8&EU#;.IB()IB=2M*FE5KW['[=?]<QK_`-,L7^E_
M6-^`61>TG>([TRS?S:YOU4;^9;^D3['[=?\`7,:_],L7^E_3X!9%[2=XCO3)
M\VN;]5&_F6_I$^Q^W7_7,:_],L7^E_3X!9%[2=XCO3)\VN;]5&_F6_I$^Q^W
M7_7,:_\`3+%_I?T^`61>TG>([TR?-KF_51OYEOZ1?N/J?-V59Y$\9;:L\F<\
MF.&2+SGDQC.<YY,;O_<QC'+G_=I\`LB]I.\1WID^;7-^JC?S+?TB_/L?MU_U
MS&O_`$RQ?Z7]/@%D7M)WB.],GS:YOU4;^9;^D3['[=?]<QK_`-,L7^E_3X!9
M%[2=XCO3)\VN;]5&_F6_I$^Q^W7_`%S&O_3+%_I?T^`61>TG>([TR?-KF_51
MOYEOZ12-X:?JUV=F;JNZ;J;K9WW?C<QY5/AW-L!=O(F`F0WW7US$DR);[6JR
M.IST61V7>@89<;RM:7<Y3A&:T_P6TSDN9V^9SN=<R0D.8UP(8'@U#G`O?BPT
MJT;!7:0[934M:?\`)75>J,DN,DRZR&7Q3@MED;())'1D4+&.$471AP)#G"KB
M-C2W;7TY4T0K.5*:=RI6<YSG+:^7.<]W.?N:]B7S>L=GJ9$6ER">G8?$HFL3
M*K!&,DL+>$9DUPLS7<$$#*2I@E*(ZP$)0EU*DI=4E>,86A&<$4>"^"O8<]P9
M9M1F"D"0X\".R[8['A+,6RT`.X.RZ@Y!;'6A(QEM64.)RWG"W&>C?===6HIQ
M%;0D]DZK(5<JL-"R(#1%%W"H+4@*O."AHO<]Z/-MI;8^6NS<GFRD6P2C/08:
M96G*&T(:5E&B56O)_@]V6L[DL[-UJ;-<GK`1;)A2K!.-]=LIC3C<A,H2T4A$
M<1)K?6X2V)@<<A>4<]M6&!L,J*<1"J3.$798[KZGJG(8>DJY`U0HIN6EDFYA
M*U7(^HQ`S!F7U%!K9K8&1%K96A;J"'5KSEQ25H448BLS*V$V],W#?W2?@35W
M(F3AYAX_K\EAA<E7XEB#ABL`]-U5M8,4TME.$)2E>'W,KPK*L9P2II18U:N%
MG;"[!SH]KB9^838YD2:/+=E31#,G1KES>CL(,CD!O.XC?C`DDLY>RZZVRXRU
MA?1##(:40.(7.]\+FT^X\G9Y>U5Z6,,N,E5Y6Q=!-S0;!Y=.BGX>OK2.P2AD
M/(0C^?PV,-N+SRX4K*''4.*('$461*V$V]7)0TLJ!-R;`M0#4<O)\EE+7JO<
MW+[`NK3E[//=C[&2^O&?_?9(<:7SD9QA)*JG<X?J"5B8[3C)66=GHR6B9,H\
MU_)1(LN)<(]UU9`K8KBI,<#<*<8;-5E1BFI-U+CKF$,="2I6=52@0-)]8<5J
M+)`19Y]5FEFE$R!C3DNN&AH%;PR#7R,`L*CH$;'0L\QG"TJ7A.%+5G)16JRW
MH'_87?!K_:T1?N1R,<G*P]CG8YR>5I>.=CESCEQRI[N.7&=$7YT#_L+O@U_M
M:(G0/^PN^#7^UHB=`_["[X-?[6B)T#_L+O@U_M:(G0/^PN^#7^UHBFL+_-A_
MY!K_`*:=0N11GV,_C9G^V97^O%:D\H^E6=X/<"D_J%5?_]'[8^(;\F3?Z.O]
MZK3[7\;E9G@K>M3_`"6K7^7X;_#AM%4\JB[Q5[@2&V5;M-X!:=.54Z`;8416
M#WX]D]V.<EB,,./LH>RSTW183E>$+SC'[&=8;46:NR+(<WSED`D=:V[Y`TF@
M=@!-*T-*[Z%;#I'(FZGU3D&G7W)A9>W4<)>!B+`]P;B#:BM*\E17>H4TGC'=
MLES$K4S$24($]7=O<$2(\P;)/B[A7F3I<0[3G!<##)2/"GWD-#I65XSS<\[+
M:<=S&CY3Q+AO\UCR^[RXPPF"VJX.+B+FX?`PP$81LC=<,#GU[9:%Z9G_``9N
M<KR*;-K#.!<7#;J]PL+0P.LK2.ZD%R'8G=]*RTD+8Z4KL#BJXWC`Y)Z/"A(*
MQ3D%,KVX;CIAJ0-&?91>U;F-ODR$?U8E3:8I>WO*EM*^<^A]Q7.1T6,.<TO$
MBW]=ABM,LDFLY3:AKP2"/6/6P2YN$TP>K;!7O@YQJ,-'<$'!V[.77,]_G<5O
MF,`OB^(@.!-IZ@0UC\;:](+W:XBC"QHH['5M7(\8,`#2RYM#L\18&=N&;F*-
MT,\Q53YHW:@W=J*K35G?$2D<B4K\:0MK#K*'L(95SF\+YJ%<L_$C*H<IENQ$
M]U\+`3@8'B%TCK-UXR(2ENPOC:XBK0ZC35H-`>"VX.9[<9]#8&>-N6.S0VKG
M8XS<,B9F+<NDG,`?M$<SV!V%Q;5PHXMJX;.H_$!5[]99.FPEADW+)#!FE'B*
M4<@9>88\2&L*`"UJ2DK$#-FMB$9SA'\*O',YR>56-@R?5V39UF%QE5G.3?Q,
M<7-H0.\<UDN%W9Z.1P8[DVG94;5J6H=`ZCTWE5IGF86P&53R-:QV(%PZ5CI8
M2]H\'IHF.D9M/>@XJ'8M#QW%Y>%TE,Y)5`;%EL%-VXN.W\%$W24-'L2=R+1F
MI`0<B05!@D14K%R">F>RV@IE8RLJ2K&6UXUIL'$:_=E`O+C)(OW">UM9[:-D
MSG"7UJ;H6QN)B:6/8[OG4#P6FH/>E>BW7!_*FY^<OM=2S_M-M?7MM>320-:Z
M'U&W]9?*QK9GB2.1G>M#C&X/%".^:KJ[Q;S!-THU=@08V2C[M#;12X.";A*"
M6(IC=9R>0LJ(C&(4X,T.ECPO6I++I#"L,*SA&.?R)SV'<1'29MD]C964$D%W
M%9/;65S92+PR;6,$;FN;`&8Y:N:</)MV+J,X1,BR'4.:9CF=U%<V$^91OPP-
M=`TY>(2&R2&9CFNNC+T<&%CQC`Q=[M5]A>)^4C4R/QFL=CDYO=BH->`HYEMN
M9TM(4YYYNS2#HN("-=9!'0L=;"&\/$OX<5C#7*GDSW;377JXG]X+5D4GKDMM
M$VWZ6=SW0$B5Q'1-(:.]+0,3W5/>U"QM_P`,/6C:^Z=])/%^W07DS[OH+5D;
M+D`P,#NG>"]U'AY=AC80*OH:B4?:DG[HG>=D>,UZ(O(:G>G:DG[HG>=D>,T2
MIWIVI)^Z)WG9'C-$J=Z=J2?NB=YV1XS1*G>G:DG[HG>=D>,T2IWKYU^+CZS#
MC:VGW!W<QM\]2!JO2+]=Z'!524`D'[&:S08Z=L4[906"Q'W;?'4VEQ419K2^
M(<*VB)MP48(R.>._(ZQ6G\QFSG5U]IB\L76EM#*T^LES9(_5G10/-PYC2'MI
M(^XB$5"YPM))00UP`R.9VD5AD=KF\%R)II&'\*A8[I@^1HB#C5IJQL3\>P`S
M-802#7WVVZNMIM^WU$MD^*;6IVT4VL6*:KB94DU,!+34(#)24+@S.&,EXBC"
M5L=+E".DZ/G<W'+R:RJQY/;69=J2?NB=YV1XS114[U@&XN["-MX>/D9#UEG9
M"<FQ*W6JS7R@>W++/%BG2.(V,<GYJ!@1EC0\48:^\:<(,P((ZXMW'-QC.OZI
MU1D>C,AO]2ZCO6V^3VV#'(02`9)&11MV=E\LC&`FC07`N+6U(RF3Y1?Y]F5M
ME66QX[R7%05IL:TO<=_>L:YU`"XTHT.<0#">$XVMQIS=F.K+8?9T.7ODC9HN
ME'4RT&2,2W@%Y]V<D>(BO[@S6QOK%D3HY1JNC,%%O"YR$E_)V<)3YAIKC`_5
MNMK')<ER)DFD[F$OCO3<P!SP(7/+Q;&03X1*Q\`#8G-<&^L-EZ(@'>\TX?,R
M73>89CF682,SN`,<8>BEP''+&UK,?1X`3%*V<O?(PL/_`*[HNE-1Z+]J2?NB
M=YV1XS7MZ\PJ=Z=J2?NB=YV1XS1*G>G:DG[HG>=D>,T2IWIVI)^Z)WG9'C-$
MJ=Z=J2?NB=YV1XS1*G>G:DG[HG>=D>,T2IWIVI)^Z)WG9'C-$J=Z=J2?NB=Y
MV1XS1*G>G:DG[HG>=D>,T2IWJ)D5Q@=I;AW*@9JUK2_3)-^)(.9F4Y7*G)OD
MAM\('$B2+<4PX6;+F5U2>E):'PW8$JP]E`KR\E-3O77+<:]1`:*D01[?,5]B
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M)B-A)BKMX=;<=L4=+6BD;?/K99).`>!=BMQ;JB+?4\E(O(.X[A_E0\TR4[5<
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M:#VE]#Z>_P"-.NM2Y%E.H+'-LI99WD#)F-DEN`\->`X!P;:N:'4.T!SAN)6(
M_:=[!_!O>GT!2_TB:QOS!:.]F9GYN#]2LQ\IO$7VUDOGKK]&GVG>P?P;WI]`
M4O\`2)I\P6CO9F9^;@_4I\IO$7VUDOGKK]&GVG>P?P;WI]`4O](FGS!:.]F9
MGYN#]2GRF\1?;62^>NOT:?:=[!_!O>GT!2_TB:?,%H[V9F?FX/U*?*;Q%]M9
M+YZZ_1K]Q]9[L(G/*FN;U)SR9QRX@:9C/)G&<9QRXW%^YG&>3/\`NT^8+1WL
MS,_-P?J4^4WB+[:R7SUU^C7Y]IWL'\&]Z?0%+_2)I\P6CO9F9^;@_4I\IO$7
MVUDOGKK]&GVG>P?P;WI]`4O](FGS!:.]F9GYN#]2GRF\1?;62^>NOT:E%LGQ
M$[=<0$*;+[?RTFDF)<PW-5J?:9CK-#)=<6@0DP$0^1$>`.PWSFB!B'V>7\!:
MDNI4C'HND-<Y!K6UEN,GF>)HS1\4@#965Y"6AS@6N[#FN<.P2'`@>1<0.&.J
MN&U]!::AMXW6\PK%/"7/@DH!B:USFL<'-K1S7L:[[0!:0XZ/D^,W-+EY]N_T
M6R#UL:WWFK5N;K;@)9,RY4;;:JTCEB)F7B"EY,Q4"N8MCI.G)YK+*%<J5+W"
MJ\_P[BME[;<4M+W9L153IH-I[:8B)&40N>:`C8=:@"%"=55(@RLP^O+K^,*R
MX..2AME:'%=QUG#A000L2M'&/7ZA"T*1E:[8DDW*CT?<"2%`.BS`X>#M]4O]
MN4(@I^0C#2S(X7;8]OK#X8D<IY8R%D-.$(1A53A5FB>/7:Z813WAJSNJV/=Z
M5:+Y$/O0];ST,)5%VU@]N2&'N1!P9Y!=)/9;;Z)26U-X40MAO.7,*IA.U7<3
MB_B90!-@BZS8'*UBW-5PAYXN'[:&%8V_OMXDI)V/;F\Q;;2':-D5M;A[;6&"
MDFJ5U=.,N%%.57>4XJX_&W]>W&KE9D9*,L(>X<@+7YZ>"K=P?!VV+=&G9`"&
M':GQ'P&D!$*6L@L13;F11^8HHUAC*JG#MI55\)Q($R4O"1\C5V8@:9.J(392
M[<HDQ?K<Q"C!DQD0N!$+F1,STRA#;C&<H5%Y1(.Y80I;+1118-GC@I\<;*QU
M@J5X&+%:%E(AN(7`R3TW`F4N#OKC[,>=/0TLS,5V"G4]L!X'=P"MI6>E6C/+
MA53A*K-QN+.4J[$4]4*:=<';50ML[13ZUDTH2RDRV[+]U#KJIF/CV)A8-?CC
MJL&'(/L-DK;+E6$(YV>;AQ5`WMJQP/&0N1G)L@V(YU(B*C>]P!C87&3[%.U*
MN[L/;6UXR)!=G!Q'$3BVE'X6M227%-.BMA\_#3KJJ85*_;^\)OU6$LXB"!1R
MI"PQ[:%/+6EWU?L<M75FL+SA&5"2*XK)#.>3NLNI[N?NY*I%%FG3O^S.^$7^
MWHB=._[,[X1?[>B)T[_LSOA%_MZ(OW)!&>3E?>SS<<U/*ZO/-QRYSR8Y5=S'
M+G.B+\Z=_P!F=\(O]O1$Z=_V9WPB_P!O1$Z=_P!F=\(O]O1$Z=_V9WPB_P!O
M1$Z=_P!F=\(O]O1%-87^;#_R#7_33J%R*,^QG\;,_P!LRO\`7BM2>4?2K.\'
MN!2?U"JO_]+[8^(;\F3?Z.O]ZK3[7\;E9G@K>M3_`"6K7^7X;_#AM%4\JCYQ
M$;>B;EA2]0EGV&86S4YZOR>43T+#R.!#WI-DA0G:A*5(7T3WX+G1+1SN7'=S
MC.,8_-LLMLZRR_RF\+A:W$3HWX31V%PH:$@@'=L*RN19U>:<SO*\^R\,-]9S
MLECQBK<3#48@""14;0"/I44E<']"0=)28)3T5(24^7:>MQU[J33@4^5?H?<=
M,D"AYY]E#@=@@AD,H<2ZTD5'1Y0K/(K&K'AYI\37%Q"9XYY)W38FO`+9#<LN
ML3:M([V2-H:""`P82#RK=QQ;U8ZWM+2X%K-;16S;?"]A(?"VSEL<#R'@T=#,
M\N+2UQD.($#8N0?")38\0$4.6/85')I21"\7VG++;]1"+H]$Y4MU2VG<EHOL
M@T5SD9Z1M:.;T:T<_,Q</\C@BACBFN08_5\+L;<0]7,Y9RLH<0N)0^HV@BF$
MBJB?BQJ:YFN)I[>R<)?6L3>C<&GUL6HDV"0$839PNCH1A<'5Q-=18L+P60+C
M\]'S-@R94GJU`U:MPC%XK#2P!(G:(G9]<Q)J43E@RQ-5Z3,P,\E*64*(RM32
ME(;YF.CX:Y8Y][!=74S\L-O'#%&'4PAED;+&_O:.E$3WX7`!H+JEI(;3+S<9
MLZ;'EUS8V-M'G3;N:XGE+*XW29DW,A%'W]6P&:.+&TDN(9A#P'.Q;=I/#[!4
M&P3-B@#4X(F<RBE@&7JMOQ(+L[)LS4Z0"$B09Y")B79P0ZMY3RD+RI+71MJR
MC.SY1I?+,EO;J^LG38Y<?>N?5C3(\22%K:#:]XQ$N+J&H;A::+2L_P!;YUJ3
M+;'+,R9;]'!T='M921XAC,4(>XD][%&<#0T-!%"_$X!RUS&\%NWH@L`#*'FV
ML*M9K@\6)9[[33A$0U3#GAH"N.B"Y!&<A`2+&07E&$8>>*PTMUU>&D)Q@K?A
MKIV**RAN'W-S%;]$&-E>UPZ.%L@CB(#&CHVF5SZ4Q.?A+G$-`&T77&75\TV9
M7%G'9V<]WTYD=!&YCC+<.A=-.'.D>X2O;`R.M2QL>-K&-+W$WR"X3J971&`H
MXUWH!"]N2P</WFH.9!QM9<IZ[5$4;.'480(,?8GQG49PK+@*4-XRE6,K5W+/
M0>1V,;(H'3X&NM7-JX'#ZG/)<0M'>^"'2N81MK&`VH()./S'BEJ;-)I)[IEK
MTCV7K7T8X8_W"UAM;ESN_/?.9`R1I%*2ESJ$$-%59.%FIVN*,A):1*S%25RL
M-VDP!MP:V,-(R5G(03*"%,(-Z)0:7$8ZLXG"30\YRI@AM><JS>_T/DV96TMI
M<R7'JTEU+</:)*!SI35[7"E,-?`(I(SE8]I)*X<JXF:CR>\@S"SBM/7(K&&U
MC>Z+$YC(&EL;FDNKBH?Q`28I=@DC<T`+>GJ\?Y1!_P"IZU[[:W%>>43U>/\`
M*(/_`%/6O?;1*)ZO'^40?^IZU[[:)1/5X_RB#_U/6O?;1*)ZO'^40?\`J>M>
M^VB47@?NO]35Q'[@72CV0/BWVZ8>JLX%,%6!5:1'2,D^1(+G;'(R-6=W7LD!
M.3TU<S92Q2!+Y#2)>2GBQG&QXYD49&,TWES]/:BSG/3>/N8KN"@AD#0(YPZ7
M#<![0'.P1OCA;"?P\$+2:N<\N[^:W;,SRJQRWU9L3X9:F1I-7Q496(M)H*O:
MYY>.^K(:4`;3V4V'V4LNSVT5&VQF;K!W<REQ3D*S84R$%`CN13)YCD%$1\09
M<[0<#$UF$='C`TDR1Y610VU/$.NY6M66D>'R/>U@:"XF@K05/(*U-!R"I6/:
MTAK07$D`;32I[9[96W/5X_RB#_U/6O?;5%-%8;'ME!W2-5"7.$J-HA5O-DJC
M9*T0C:6RF,*ZN:&:!/!R49(BY7G+)`SS3[6<_@JQRYY>G?Y?89K9SY?FEC#<
MV$HH^*5C9(W@$&CF/!:X5`-"#M`*Y[>XN+2:.XM9WQW##5KFN+7`[P001W"M
M,QW!IM3#248;#&3\;7("Y)W!K.T0^XE'^*F`NV)ARP*M##3B%WV3/587W9/#
M)TV2&V>[ST,I;0VTC1[+A1P]RW6/O]8:;CAU3T;8Q*R29K&M;;MM6AEL)/58
MR+=C80YD+78!2NTUV276VJ)\CN-.39JY^4RGOVN;&7O_`!NGHZ8L,Q:9OQ2T
MR82^CB*@*0GJ\?Y1!_ZGK7OMKT1:I1/5X_RB#_U/6O?;1*)ZO'^40?\`J>M>
M^VB43U>/\H@_]3UKWVT2B>KQ_E$'_J>M>^VB43U>/\H@_P#4]:]]M$HGJ\?Y
M1!_ZGK7OMHE$]7C_`"B#_P!3UKWVT2B>KQ_E$'_J>M>^VB46%%;*TDTN8D#*
M3M<6?84$(GS2D[?/ESB"\PF2D3!+I"WI-!.:U&])AY2\+[/&Y>7H&N:4KID=
MC*%+\F9:A;42F4X=2G,BQMT;S4OR,A,/XQUEYWDP]+RQ12_QB277<_AN+5DH
MHN6=CZ*H=L55$VJR*U(,R[0V6MN\CMRH\E-3(\FVSE_HT2#$Q9)$M#V,=(DD
M\EW"L+?=4HI620E`"K,6)!UN.IM?A0,.I!AX26IT3%AI??=*>2)'@2`X@^'B
M7UN*PA&.<M:E9[N<YT2BNOJ\?Y1!_P"IZU[[:**)ZO'^40?^IZU[[:)1:YC^
M'_;R),%D(NC;;1QP33+`90)=+%>%8'LB+@TRPMF01EII-I9;D.;CDQDMIMS/
M*IM&4E*H'N&O:L@5`+^W.UCP;:Q5-BNNTAQA"0E-.##I:6?E"0VBF$D=!R=#
MDOE(RG+^<N9)1;!A:&Q78P2%@AZS%Q8*%I%"#L58:9;RZZX0^YG&);G.$%$O
M+=><7E3CSJU+6I2U*SDHHKIZO'^40?\`J>M>^VB43U>/\H@_]3UKWVT2B>KQ
M_E$'_J>M>^VB43U>/\H@_P#4]:]]M$HGJ\?Y1!_ZGK7OMHE$]7C_`"B#_P!3
MUKWVT2B\N-R/JI-H]R]P;QN'-[X<2T=+WFVV&V2,;`;G;;#P$878)4J4>C((
M<O;62*&A(Y970B-N$D+;'0A*G%YQSL^:YAPITEFE_>9C=PR.N9Y7/<?P_"<2
M3RQ$TV[*DFG97NN2_P#(77F0Y1EF26$-B+*T@CA95L]<,;0T%V&X:,1`JXAH
M!))`'(L*^QMV.^7SBL^=3:_]$^NG\&M%?VTG^UZ)9/YF^(_]*P\6X_4I]C;L
M=\OG%9\ZFU_Z)]/@UHK^VD_VO1)\S?$?^E8>+<?J4^QMV.^7SBL^=3:_]$^G
MP:T5_;2?[7HD^9OB/_2L/%N/U*?8V['?+YQ6?.IM?^B?3X-:*_MI/]KT2?,W
MQ'_I6'BW'ZE<T?4U;(+5S4[^\56,\BL_A[K[6-IY$IRK/X3FU*4\N<8[F.7E
MSGN8Y<YQC3X-:*_MI/\`:]$GS-\1_P"E8>+<?J5P^QMV.^7SBL^=3:_]$^GP
M:T5_;2?[7HD^9OB/_2L/%N/U*?8V['?+YQ6?.IM?^B?3X-:*_MI/]KT2?,WQ
M'_I6'BW'ZE3^V"X>:5PY;?A[?45Z2DAVWWBY:TVV9AI6YVDUQ]]UDNR3``D0
M*8L%A_JXS;0S#++*<82CGJ<6O=M.Z7R72MI)9Y-:"-CW8GNV8GGL%Q`'(-@`
M``VT%22?*-::ZU'K[-&9IJ*\QR,9@C8VHCB;V0QKG.(Q':YQ<YSC2IH&@;KZ
MH[^.-YZ'X_6P+3J)U1W\<;ST/Q^B45,U!#I,+EFAHEN1(#!!-D,$13<@6!'D
M'/1P3Q/3)*+%`)EB7&6N5265$NJ3C'/7G)2JGJCOXXWGH?C]%%$ZH[^.-YZ'
MX_1*)U1W\<;ST/Q^B43JCOXXWGH?C]$HJ<6)9";4R&Q'",K(++6T*_',-K+D
M"WCSRE(:=0E1!IQ+CSR\XYSCKBEJSE2LYR4T55U%[F8<YX?-RK*.3M`#G\J<
M)5G.6^L])A/(KN*SCFYSRXQGEQG111<>J._CC>>A^/T2BZ!HML-E(XC4>*.C
M+BD,#$1[#*5.N*==4EIIU*$Y<=6I2LXQW59SG/=SHI7?U1W\<;ST/Q^BBB=4
M=_'&\]#\?HE$ZH[^.-YZ'X_1*+DH%Y.$9RL///3S\<V0`7G&.52>1>$$JRVK
ME3_PJY%<G)GDY,XT2BX]4=_'&\]#\?HE$ZH[^.-YZ'X_1*)U1W\<;ST/Q^B4
M3JCOXXWGH?C]$HG5'?QQO/0_'Z)132&_FP_\@U_TTZA<BC/L9_&S/]LRO]>*
MU)Y1]*L[P>X%)_4*J__3^V/B&_)DW^CK_>JT^U_&Y69X*WK4_P`EJU_E^&_P
MX;15/*H=\:=EFZ;0+_:ZV;V=/U[:Z6EH<_JPAG4Y`+MAX8CJI[!01'1.IQGF
M.MK0K[F<9QK7-89A=Y5I74&96$O1WL%I(]CJ-=A<UI(-'`M-#V""-X6W\/LJ
ML,]UUI/)LU@Z7+;F_ACE9B<W$QSP'#$PM<*CLM<".P5YR[?\26Y[FX;$992D
M3<*,WM]ME(1;D=$0^'-PW+WMQM_?[DR4#&Y.RVS-6PQ+87/0+A8N4H2G&4KU
MY9DFO=0NSQEOF$@FM&BVM',+6,K<^L6MM<S@M9BV23/`CJ&580`!0KW#4O"O
M2+=,27>50FWOW&\OV2!\DM+(6E]>6=J6ODP5,5O$3+0R4D!<2:M5T^D7NA8)
MV$D(#LB.@9Q>S:GX,E8KN8]FU*WQ3/ICY/U?*))<DFJ.&O"WN5+"QTX;3A+K
MV<]GW[U%>WEI/9=%'9S&QK&:'")OW#I,+^C))<+=AJ[8TM`:*.=7J?"_2.6Y
M=?VV9=/+F-N,SI*T.&,V_P"T]#CCZ9K6AANY!1NUX>2XDL91+<55R'VX+(#A
MF&CG-J8HL"WO3,<?9Q;I8>'">WFC)DRM-5&.K)P(15>>:)6A`XZG%)4@1+7.
M:PN>(^:LR&5\5J!,<M8YLYD:Z43RY7)?,>Z(0MB<UIB<'D!K22"(@VK4L^#N
M12ZIABGOG&W&<R-?;")[('6L.=PY9)$V<W+YV/>V9KHP2]X:"'3%]'G>^TF^
M<EN)<INI&5AN-"B1K.D&=5*Y69)E4FR`5*;<*AW8L!#3$A(F=..X(Z4RVTGF
M/9;<6A*MRTSK"XSS-;O+)<N$<4;9<,F/OGFWE;#(2PL:`'.=B:6.>T#8XM<0
M#YUK3A[::8R*PSJ#-S+/,^#'#T?>QMNH'W,0;*)'DEC&X'MD;&YSCB8'-#B(
MM,;_`.Z<1M]"M&[CNRMIW(V\V8GX:PR5<I^"*19KY:I2/L#;<?`UH*-.ATU:
M%+.$9,"))2L1S^$=3G^#\Z9K74=MDEHV7/C)F-_8V,D<KHH*V\MQ,]L@#8XF
MM<SH8WR,:^-[JL/?.![WU^7AMI"]U+?O@TL(<HRO,\TAEA9/<X;J"SMXWPDO
MFG>]DOK$L<4CHI6,(D;WK".^R0#?O<>VVS;N1AK#.1M5G(CAPS.,CPU#?JL=
M)[FSUP@+<#8W3XLF]-S,E(0C84,J-SD$8]K/7>C:6GG]^'6>?9GF>1SVE]-'
METT65](`RW,+7W<D\<[92YAN!(YT8C@,7X;)`>FPM(KBKGASI;)<FU-:W^66
M\N<6\V=]$72W@N'QV$-M-;/@#)&VAB8R4RW(G`EDA</5\3VFF3(WNO.V,589
M.P2\GN>PC=&^5#!-J(JU:%JU9V_*6WVIE&WNVK4D21+-FMX-,)'5&A="EUQ8
M;659<[XU=G&GK:^N+VYDS%@S&Y@K,88A#%;&F/\`]:U#R7APZ1[FF*/"'.,3
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ME&FI6W13`@L;9Y63K$87)3X(@#3`0@LL<ZX^AEI"&VDKYB4IQCDQFEC#RE;1
MT4)HB:(FB)HB\R=X.(C="N;["55F[,U';_MBDUZ`B6(VM25GW8O-NW:E**[5
M:\I^')D8FO52OQI!LR\GE-;6PQA#[*3F,YU>\S*[COVQ";!;8FM`HTND>Z0L
MPMV5`:`2[L\FT8@OKS0O"S1V:\.9\Y?D#K[5'J]U/-(7SQV^6V=KEK+P7,])
M6LDFNIGLAM6FD)#I"8Y'6\M-LS'%G+QEYW!J*:?!**IUD!@PZZY/3?KR1%N[
MD[.4)=RG(?%71%P];FAMTW)"'6R87@T8#EYZ5]::"VE?(BMA7&6^J+9GH.J0
M-FC5[!U/<E`<%;@)*9DMT[D58H6(V?AXT7+DH=)M6>(&!*>9$>6$LU*B6V,<
MW"X[-%?HS@+]M*T_Z?\`6OU5[%7M3Q?G[G;A4>F,4D6-=L6&(VX5TPZ:'W`V
MWFV=K3+W.R$Y`KK[@+]-@[9&KJCT@Z2#C,V0PTWAQ65(S*HIRZA0FB)HB:(H
M];E[\#;>W4*C+B.N24\'2FH`E9"6@\3-ZLU@J$9F7SR],-#!SH(""'FD.<QL
MQ6<YP[@=DDBW369T>T5NOV81D@86Q0<3.C#E(RV4P/+@#R#+)+>>3*"&FR,)
M7C]A6,XT17S1$T14IS)!`1@XABX\M\4AD4]#+)*P2'6EH8,0.2E8[ZQG%87A
M#F,H5E/(K&<9SHB@KMKOUO\`31\;'6O;HJ/(L<17I#"CJA8QQ*?(.;ET7:N8
MCCC6T1K4EUP)Z<LS#.<(4@4;ER3T'*V,1<P>)3>(6LCE';2RQ4HY5XA\?!M;
MNR7$V\JW05<]69Y5?JYJU&%U+)=K<)#CV4,@E,L($5D=3I)%+?;2S2MQHU>L
MDW%$0TI*"O.%`$@.Q;N,L&DB-%]G.G2O4FI)@=)+;:##F4-O)PT44WS2'"+.
MM$31$T1-$31$T1>(.^'UG-QVWWBW.V^B++LBB.I-YLM5&:E76G)1C$%*DQK@
MTDI-M&Y)`5X93;Z<MMJ0ZE2<I3G&<8^8=3<4^(.6:ASK+LNRJ)]C!<R,8XV\
MKB6M<0"7!X!.SE`7W#HG@!PRSW2&FLZS;,KQF97=E%+(T7$3`'/8'&C71$@;
M=@).SLK5GVMVX?PGV"^^W^>FL'\8N)WL:'\M-Y:VGY:N$/M>]_-0^B3[6[</
MX3[!??;_`#TT^,7$[V-#^6F\M/EJX0^U[W\U#Z)/M;MP_A/L%]]O\]-/C%Q.
M]C0_EIO+3Y:N$/M>]_-0^B3[6[</X3[!??;_`#TT^,7$[V-#^6F\M/EJX0^U
M[W\U#Z)3NX&>-&T\3]BO%=F@JC-#5B'CYA=HH#K.8R"=,*=$%A[&TJ:E,X)G
M\-/.`Y;5AQ74W^5"D)6XUZ?PPU[JO5&87]AJ')3'&R(/;*R-T;6FM,#@]QJ7
M5JW":C"ZH(VCPSCCPDT7H'*<HS73&?.=-+.8W02R-E>\8<721F-C:".E'XA3
MOV4<'4:[TCU[6OFA-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$4VQ?YL/\`R#7_`$TZA<BC/L9_&S/]LRO]>*U)Y1]*L[P>X%)_4*J_
M_]3[8^(;\F3?Z.O]ZK3[7\;E9G@K>M3_`"6K7^7X;_#AM%4\JTKO-!5RPR&8
MJR*!*CI&O(!/AI.'Q,1TB`\7(I>9-%>2X(2,^E:D+:<0I*L8[N,XSKBN+>WN
MX);6[@9+;2-+7,>T.:YIY0YI!!![((H5S6MW=6%U;WMC=207L3@YDD;G,>QP
M-0YKVD.:X':""".PM)&;5[22*#VY"$IIR)3)69-!E#CR42.3I9F?.R>EX1>"
M\F3H[9KO2<[I"T)>5RN8PK'0ER+))Q,V?)K5XDKCQ11G%B>)'8JM[[%(!(:U
MJ\!Q[X564@U/J2U-NZVU'?1NAP]&6SRMP8(S"S!1XPX87&)M*88R6"C20NKX
MI=GLBH!S7Z3D)O$/AL/U`C>JHQ7B#RX#"!^I]$G$&7*%.A\F/^V<)=4WS<N+
MSFO[!D71B']DM.B&"C>ACI^$7.CV8:?AE[RS_L+G%M"XUM[UZHZ9UQ[S9ATY
MZ6KO6)L1Z9K&S5..OXK8XVR[?Q&L8'5#6TL(&PFRL?-3TXF+KI1$]$@5Y8IU
M-CB8Z*K@-:'J6:W!B*`QB,KQT",@<D).<CO-XYF4\S\'73ATEIZ"[O;P93`Y
M\T38J.CC+61-B$/11C#WD3HP&N8.]<-A%-BR5SKW5MS89=EYSZZ9%;3/F#F2
MRM?).^=UST\KL?XDS)G%[)3W[7;0<6U9I&4/;J$DY&:AF*_$3$PEE$O+1E18
M`DY1`Z4H'3(GBLM%')80C&$8=6K"<8QC')R:RMOEF76EQ/=VN7P174M,;V,:
MU[Z<F)P`+J=BI-%@;O.<WO[2UL+[-[F:Q@),<<DKWQQEVUV!CG%K*DDG"!7L
MJS0>T.S59Z#U;K=&KW59)$R-V'M[%Q/5Y=L(N-;E6.H!#]#)(CCWQ\/IY'<,
M/.(PKFK5C/5L]/9!E^#U#([.##)C'1PQLH\-<P/&%HH\-<YN(;<+G"M"0N]F
M&K=59MTG[KJC,+G'$8G=+<328HR]LAC.-YJPO8QY8>]QM:ZE6@BM&VRVJ#2X
M@.*J0B'28LQU`U'"82X7"3)MBA2G$M#)PLF(L$D0<*O/*H<Q]QYO*7%J5GEC
MR7)X@X193;-!<QQI$P5=&]TL9-&\K)'.D8>5KW.>*.)*X)=1ZAG+73Y_>O<&
M2-!=-*:-EB;#*T5=L;)"QD4@Y'Q,;&ZK&@#]-VTVLDD-MR,75#VV9MZS,H-I
M`12&K(0YTQ%@;2^,XE$V^]CGK+QR/J5W<KSG4RY-E$X:V?*;9[1,91BB8:2D
MU,HJW_["=I?X1/940:BU!:N<ZUSZ\C<ZW$!+9I6DP-%!":.%8@-@C\`#8`LK
MZA"^[_\`=1??ZR2PU!O3J$+[O_W47W^B4&].H0ON_P#W47W^B4&].H0ON_\`
MW47W^B4&].H0ON__`'47W^B4&]>+F\'U:/U:DG;Z[$[D\3%II\G1W:N>!09?
M?2!B#`8UD6'J]9`PJULF7Z%B3:[!QL.(L*0#>4@1#[#J9)\HPCHY/EUCD&;9
MCGF4VS8<TN[9UO*\5=CB=)+*1A<2UK^DFD<)6@2#%0/PAH';OKRZS*QM<NO9
M3)90S"5C:4H\-8P&HH2W#&P8"2S97#4DGU@VHV@V\V:H,#MO3)V237J]VHX,
MY,-R4M*%FSLU(V*:D#SR%X4\5)3<N20O"$MLMY=YC3;;24(3D9)'RO?)(:O<
M22=Y)J3SKIM:UK6M;L:``/H'(MA]0A?=_P#NHOO]44T&].H0ON__`'47W^B4
M&].H0ON__=1??Z)0;TZA"^[_`/=1??Z)0;TZA"^[_P#=1??Z)0;UKN0V6V<E
MKQ$[D24;#'7:#4^]$3I,(<ZZ`:2$-&/2[`BG^SL3RHH)D3$AEG)R1&4,8=PT
MA*,=9UG;/G9=.@:9V\AW&E*TY*T`%:5ILK1;3:ZVU79:=O=)VF?3QZ>N*"2%
MI`#V->Z01EU,?0](]TO0XNB,KG2%A>XN.53DK0JP*DVRWZ%KP:U<Q!<YS(D5
M2^Y^`E\\H=I2OPL=S&>7NZS.793FN;RFWRG++BZG`J6PQOD<!OHP.-%H&;Y]
MD6GX&W6?9W:65LXT#[B6.%I.X.D<T$[>2JPR"W;V%L\FQ"5[?';^9FRL\T:&
MCYJ,)ER%=)EKFL1C<CDYY7/QR<B6\Y_"3G[BD\N7S'16L,HMWW>::6S""T;R
MR/@E:P;*[7EN$=T[]Q6%R?B!H34%PRTR366675V[DCBN8GO.VFQ@?B/<'9&\
M+9O4(7W?_NHOO]:PMPH-Z=0A?=_^ZB^_T2@WIU"%]W_[J+[_`$2@WIU"%]W_
M`.ZB^_T2@WIU"%]W_P"ZB^_T2@WJPR-(H<L\>1)/@&OR<:/$'OOP9*WB8X3M
M7(@KCG/POFB9G#>BSC.%-=:=YN<<]7*2@WJ^(C(%I"&FIQ#;;:$H;;1$%(0A
M",82A"$)5A*4)3CDQC'<QC1*#>N74(7W?_NHOO\`1*#>G4(7W?\`[J+[_1*#
M>G4(7W?_`+J+[_1*#>G4(7W?_NHOO]$H-Z=0A?=_^ZB^_P!$H-Z=0A?=_P#N
MHOO]$H-Z=0A?=_\`NHOO]$H-Z=0A?=_^ZB^_T2@WIU"%]W_[J+[_`$2@WIU"
M%]W_`.ZB^_T2@WIU"%]W_P"ZB^_T2@WIU"%]W_[J+[_1*#>HZS?"CPJV*9E[
M!8.'G8&P3T[)GS,W/36R6WLG,3<O)E.FR4O+21]<?.D)*2,?6\^^\M;KKJU*
M6K*LYSK&29+DTKWRRY3;.E<223$PDD[222VI).TD\JV*#6&K;6&&VMM4YC';
M1M#6-;<S-:UK11K6M#P&M```````H%;/H<<'WZL7#=\PFV7YKZK^PY'[&M/,
MQ^2N7WWUIUOS3\U/Z1/H<<'WZL7#=\PFV7YKZ?L.1^QK3S,?DI[[ZTZWYI^:
MG](GT..#[]6+AN^83;+\U]/V'(_8UIYF/R4]]]:=;\T_-3^D3Z''!]^K%PW?
M,)ME^:^G[#D?L:T\S'Y*>^^M.M^:?FI_2+9&WNS.S.U.99.UVW.V^V")_`2I
M[.WNWM<IF)M40D_,3B8368R,[3S'YDB,#Y?Y_0=9=YG)SU\O;M;"QLL?J5E%
M#BI7`QK*TK2N$"M*FE>2I6+S+/,ZSGH?WC-[J[Z.N#II9)<.*F+#C<[#BPMK
M2E:"O(%L/HAO*_\`D.?MZ[2Q:=$-Y7_R'/V]$3HAO*_^0Y^WHB=$-Y7_`,AS
M]O1$Z(;RO_D.?MZ(N26!,I7G)O-SC&,H3U9W//SE6,9QRXSR)Y$YSGN_[-$7
M'HAO*_\`D.?MZ(G1#>5_\AS]O1$Z(;RO_D.?MZ(G1#>5_P#(<_;T1.B&\K_Y
M#G[>B+ET`G,PKKOX>59QE'5G>XG&$YPKG<O)GG9SG')^QR:(N/1#>5_\AS]O
M1$Z(;RO_`)#G[>B)T0WE?_(<_;T1.B&\K_Y#G[>B)T0WE?\`R'/V]$7)3`F,
M(YIO.SE/*K'5G<<Q7.5CF]W/X7X.,9Y?]^B+CT0WE?\`R'/V]$3HAO*_^0Y^
MWHB=$-Y7_P`AS]O1$Z(;RO\`Y#G[>B)T0WE?_(<_;T131&_FP_\`(-?]-.H7
M(HS[&?QLS_;,K_7BM2>4?2K.\'N!2?U"JO_5^V/B&_)DW^CK_>JT^U_&Y69X
M*WK4_P`EJU_E^&_PX;15/*H6\<W:?Q8;F=C=>[6^*:;[.[,ZQVCUSFS/0=2Z
MI_W/6>?R<SF?A<OW-:MKCUCW.U-ZIC]9]2EPX*XL6$TPTVUW4VK>.&7JGQ$T
M7Z_T?J7[C!CZ3#@PXQ7%B[W#3EKLIRKS!O4M=^=+Q6TD+N+,4JM;@V3=^F)"
M(D0NCB-OMO:(PX'T]RD8P\RE2&Y4_).-ABY*>(<$=ZL,\E/-UX]G%SF];JVT
MS:7TN4V][+>P82YM&6UM;C#6=S'.@==22D,9C<XL=T<;P*+Z$T]9:?I97FM+
M_*X,^N\M@RVZQM8^LEY>W9#J6S)&-NF6,,`,L@C:QLC.EE8359E4828L>Y-@
MF9@*;73[P=Q`-@X:,M8A9Z0CJK-5@>R!O&-Q0T6,*EUR+R(A+_3I4GG9;Y^,
MY3++.[O\^OKJZAF.5WC\R#:.F:7870R1"5I<&!@%3#@`=B!%<-5@\[S"QRO2
MN66-C/;C/,OCR8OJVW<UF)EQ%<&!P:9'2.=A%QTA+,!!H'4*EUP^Q.(C9+:M
MMT<P>1.V_ITM.8D'373W9^2K<65,D'9D''24&/'K6IU"N3FKSG')C[FO3M$6
MWJND=.-<QS9WV4#Y,1<7&1\3#(78B3B+JU'8/8"\3XEWOKNOM8.9(QUK'F5S
M'%@#0P0LGD;$&8`&EH8`&D5J*;2MQ:VE:.FB)HB:(FB)HB:(FB)HB^,7C6F-
MLK+N%:WF+:1%HWWW3O\`:ZS?E.GQT77:E<XR>E*2%;&0SCXPX#=B'W!BY2TE
M%MLF(VH]514\Q39P6-9X>R17O$O49M;^2ZCMBV[=:S'I81@C9;ODZ)PHVQ8^
MQ>Q[`:.G=>R.Y65SFIFR0:2RGIK5L+I`8!-&,$AJYTH;C!J;DMN6EKCR1B!@
MY"OK#X8+#"V;AYV;D($V7/""V_KM9)=L27D6-B<I@+=0L\98\/ND+S8H>R09
M8A^<.O)46PYE+CB<X6K:9(WQ2/BD;21I((W$&A'<*P0<U[6O::M<*CZ#M"WO
MJBE-$31$T1-$6%;D6"3J>W]VM$,#B2EJ]59Z:C@,MO.X*,C8PDL=K+(Z%OO8
MRXUCE0C'.7_PXSCEY<9W2^76>;ZDR'*LPN.BL;F\BCD?4#"Q[VM<:G8-AY3L
M'+0THM8UKFV89#I#4^=Y3:B;,[2PGFB802'21QN<T$-[YPJ!5HVNY`16H\0[
M=O55KP)+6ZVR*S9%EN'@1[C(,O)61-)JKDV4/'QJ(N6%3&.6:M9'=RL%S+8,
M[AI3;;+:4+^]LKTU?Z=-IDF36[8K(F64VS"*"/I^B:7R8V.,@@G#Q245EM,8
M>][RX?E[FN>V.L9+W4NH[F2YS4""!MY*UQ+I1;=,]L<6"1@B-U;%CB83A@ON
MCZ-D4;6NC4]MK4MVKIFJ;'R]FOMNYL.7&B1P\_&J>E,6)B+DI%^;51P8^H50
M.-)1*J..2PL/*%!H4^XEIY_+9IJS,L@RMV8ZLMK:SRVKVN+C&^C#$7L:&"=S
MIIB\&'HV5$FR6C&ES&9W26@LISC-([#25U<WN8$,<W"U[*R"4,>XO-NUL$(9
M2?&^AC-8:O(;(_Z8Z?&2T)4JM#3TIF;G(BN0D9-36>?RR\L!&"BR,IGI?X7E
M/,:6[^%^%^'W>[K\Y,TN+:[S+,;JSM^AM)9Y'L9_V,<\EK-FSO6D#9N7Z?99
M;W-IEN7VMY<=+=Q01L>__O>UH#G[=O?.!.W>LCUT5WDT1-$31%%7=VU[HQ6Y
M`<=5"B@Z<Q7ZB_:#D0;\F/$1,],7H&VV%LEE3"0I*NP,.R<.Z[UIE#X[;2QU
M=93A9%(RJES,A6*X?8@41=@-@8<N=C$9RI$=,DQX[TF"A6<YRI`AJUMXS^SA
M.B*_:(FB*E."&D@C(XUKI@SQ2`BV>>XWTHQ32V'VND:6VZWTC3F<<Y*DJQR\
MN,XSHB@KMKMAQ25D^-'L5S*)#D(BO(N10LU`G#%S<5N718Q<I$*,B6)2,=)V
M.J)@IC>&W$.&'H=96E]2L"$V+F#4>,&,K(\6/86NT,5>(KN'1CJ:EJ+LC5N@
MI%RT1:"HA0_JX!MC&]C*8=:6^Y/+(=P(L9W!ZB*6^V@MN"HU>%O93IEJ9%>3
M*$$9!R2O&325`8+3&NE!,F-QJF4O--E2&&G4J1DT[*<F/D6=:(FB)HB:(FB)
MHB^>GB#XC.*R(WTW>AZ@#Q:IK$/N-;X>#]6J!N617%1T5.&QX[D`3'QRP2X5
MU(W.%>95EIUC*5HSE.<:^4]4P\5GZCSQV4YC?MRSUJ3H@U\@:&8CAP@"E*<E
M-E%]]Z$M>!HT7I;]^R[)'YR;"$S&06Y>9#&TNQESJXZGOJ[:UKM6G_I.<9_D
M7&A\W>ZWO7K`^K<9_:F9><E^I;9ZM_QW]E9!XMMY2?2<XS_(N-#YN]UO>O3U
M;C/[4S+SDOU)ZM_QW]E9!XMMY2?2<XS_`"+C0^;O=;WKT]6XS^U,R\Y+]2>K
M?\=_960>+;>4GTG.,_R+C0^;O=;WKT]6XS^U,R\Y+]2>K?\`'?V5D'BVWE+T
MA^KJW1XC=R+'N6C=1G=-BG0D+`K;^.2L6N`FG+'*&2&(S%/>L@PJBP$`1IG:
MB6^>EI61.7"5.)RKU?A2SB)'F.9C5-U+)E?1"G3%SGB2O>]&7`4:6XL?**X.
M1?/W'^'A)'E&1.T3:6L>>&=]?5.C$9A#1CZ8,)[[$8^B.PTZ3E`V>JNO<U\L
MIHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBFV+_`#8?
M^0:_Z:=0N11GV,_C9G^V97^O%:D\H^E6=X/<"D_J%5?_UOMCXAOR9-_HZ_WJ
MM/M?QN5F>"MZU/\`):M?Y?AO\.&T53RJU62B1%H.://)DF7F1$!I2&\*VUEI
MMY]Y*E)>#(7ES*R%<N>=C')C'<_VE!%5C_Q05KRZ<\Y`][-351A"?%!6O+IS
MSD#WLTJF$)\4%:\NG/.0/>S2J80GQ05KRZ<\Y`][-*IA"?%!6O+ISSD#WLTJ
MF$)\4%:\NG/.0/>S2J80GQ05KRZ<\Y`][-*IA"?%!6O+ISSD#WLTJF$)\4%:
M\NG/.0/>S2J80GQ05KRZ<\Y`][-*IA"?%!6O+ISSD#WLTJF$)\4%:\NG/.0/
M>S2J80HV2WU;'!-.2P4[+<.VTYTM'',R@1KVVNWG2,20Y;IS9Z4IJB6U&9+?
M4XMQ2<K<5G\/*N3')5C6QRON(VAL[F8"X;'%E2<)(VEM23A.RI.S:KESG1MB
M<\F,.Q`$[`[DJ!R`[!MY=BWW7^'_`&ZJ<+'5RJ@.5FO1`^!(F!KXL'#0L6(E
M2EI%CHN.A1@0ATJ7G.$--I3C.<]S4JM%>/B@K7ETYYR![V:FJC"$^*"M>73G
MG('O9I5,(3XH*UY=.><@>]FE4PA/B@K7ETYYR![V:53"$^*"M>73GG('O9I5
M,(3XH*UY=.><@>]FE4PA:;L/`UPSVMS+MAVTK\FM1YLHYTT+7FT/2<CV;B0D
M2&F(9IL@XU,0.EUY>%..(;YJLY2I6,[?8\0-;Y:S!9:JOHV]&UG_`-KS1C,>
M%@))(:WI'EK10`FH%0*:5?<-=`9G)TM]I#+WOZ1TA_!8*R/P8WN#0`Y[A&P.
M<X$D-H30FN=5+AGVEH,=V11Z^/3XO.4J6!68VO08KJT85A+KS,;!C(?>_"SR
MK7A2\YSG.<\N<ZP.9YSF^=7'K6<9G<75S_W2R/D<.T"\D@=H;%L>5Y)D^1VX
MM,FRNWM+7_LAC9&WZ2&``GMG:LJ^*"M>73GG('O9K'562PA/B@K7ETYYR![V
M:53"$^*"M>73GG('O9I5,(3XH*UY=.><@>]FE4PA/B@K7ETYYR![V:53"$^*
M"M>73GG('O9I5,(3XH*UY=.><@>]FE4PA/B@K7ETYYR![V:53"$^*"M>73GG
M('O9I5,(3XH*UY=.><@>]FE4PA/B@K7ETYYR![V:53"$^*"M>73GG('O9I5,
M(3XH*UY=.><@>]FE4PA/B@K7ETYYR![V:53"$^*"M>73GG('O9I5,(3XH*UY
M=.><@>]FE4PA/B@K7ETYYR![V:53"$^*"M>73GG('O9I5,(3XH*UY=.><@>]
MFE4PA:F)K@+)#[272\I:>=;3E2V<JRE"U)QG.<,8QR\F/]FE4PA=/8`?LI/[
MMKQ.E4PA.P`_92?W;7B=*IA"=@!^RD_NVO$Z53"$[`#]E)_=M>)TJF$*L`K`
M!1.&7'C,)RR4YRH<9PKE9%>?1CE4.K')E;>.7N?<TJF$*C[`#]E)_=M>)TJF
M$)V`'[*3^[:\3I5,(3L`/V4G]VUXG2J80G8`?LI/[MKQ.E4PA.P`_92?W;7B
M=*IA"K!ZP`Z,>\IXS"A667&\)<9PG.7"F6%87C(^<YQA#F>3DSCNZ53"%1]@
M!^RD_NVO$Z53"$[`#]E)_=M>)TJF$)V`'[*3^[:\3I5,(3L`/V4G]VUXG2J8
M0G8`?LI/[MKQ.E4PA5BJP!B/;*Z8SI%F/CY3TC/,YC;([B<XQU?G<[*G<\O=
MY.3D[FE4PA4?8`?LI/[MKQ.E4PA.P`_92?W;7B=*IA"=@!^RD_NVO$Z53"$[
M`#]E)_=M>)TJF$)V`'[*3^[:\3I5,(5876`&$!*0\9G)(:2%\YQG.,+R^0UG
M".0?'(GFM8^[RYY>7NZ53"%1]@!^RD_NVO$Z53"$[`#]E)_=M>)TJF$)V`'[
M*3^[:\3I5,(3L`/V4G]VUXG2J80G8`?LI/[MKQ.E4PA2N'QR#L8_V,M8^\A.
MH5E&;8S^-F?[9E?Z\5J3RCZ59W@]P*3^H55__]?[8^(;\F3?Z.O]ZK3[7\;E
M9G@K>M3_`"6K7^7X;_#AM%4\JR#1$T1-$31$T1-$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$4<3OYZ9_2B/^JO1%2Z(FB)HB:(KG$?SY/]&/_P`/*T16S1$T1-$31$T1
M7,/^8R_]&%_Q`71%;-$31$T1-$31%<U?_AF/[3+_`*J'HBMFB)HB:(FB)HBN
M<C_%17]F(_KANB*V:(FB)HB:(FB*2;'\0S_)-_O,:(HR[&?QLS_;,K_7BM2>
M4?2K.\'N!2?U"JO_T/MCXAOR9-_HZ_WJM/M?QN5F>"MZU/\`):M?Y?AO\.&T
M53RJ(?%Y;=UH24VO:VOKVY<TQ49$S>&[JV]4D9DNO4*8K`SM3L?33$-FQQ-J
MBIZ22N&$Q('E*&2ZT&O+.'6N6,-.+$1N7#*7`MP@[-IIVE:*HO<Z:X@Y>I3)
M6Z:*FQ<=])664LN^0]8]0;13-K@MNLP]I&<"ALY1*N2BHUF/,ZY&E(*<;2PZ
MAU6!PAE12M!S]E!B+Z&M*G?R;*+3<F%NQ7MBMOE8DN(9\F2(XBI":*CK)O7:
M[YG<2/:G(G8@(P@>2FK8)5WW8EC#0#F40!A66EEM.9*<R];O2]W)V-W=5"'!
MC=KNSOK7L?QR*\[RN<1ID+ND+`2NY49:\W_AQ3!NUHNR#1XSZMN0"[D-#XBU
MX$35"K8A29=L;.!7<J7AW.%9Y=&X-FP4H?\`JC^DHZA-:C_HM3M63B<$ID;>
M%.[YE2;/%;9-X#ZJZ]<%'/;8-\.D+O'\4BX_#N6,4W%BR17QXY..H(D^5AI/
M6,<FK496FSP:=VM*JM9,(=WU<5>Y2M/_`(58_GB:KFS4)#FSV^LS<%P/&9MR
MB;$>W!DIJ2W"*W`J,?LO('$Q>"2X]+L9$R:X64?Z($$93G1/M-NXY\=X7'8*
M;#]:G\0,`)=6CAV>6NS_`/"V7$R/$*)Q0V`$TO=$O:Z;W`WK,@U.$69<!"MU
MW:G`P<8KG+R&U7).3E8XF$:Y,#8DABUL<KV5<D'!@')6@4C'TIJ3AJ?^BD)P
M3OSQ.R,$];I"W2-R=$K[EJ<NDKO+*334XNHU]<HT=G>,HD@20Q*Y(R2S!\R"
M2[G/5TXSS]4EIB-.3N?_``N2&N`5K7N__/\`_"EWKC7*FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(HXG?STS^E$?]5>B*ET1-$31$T17.(_GR?Z,?_AY6B*V:(FB)HB:(FB*YA_S
M&7_HPO\`B`NB*V:(FB)HB:(FB*YJ_P#PS']IE_U4/1%;-$31$T1-$31%<Y'^
M*BO[,1_7#=$5LT1-$31$T1-$4DV/XAG^2;_>8T11EV,_C9G^V97^O%:D\H^E
M6=X/<"D_J%5?_]'[8^(;\F3?Z.O]ZK3[7\;E9G@K>M3_`"6K7^7X;_#AM%4\
MJH+#>*_5R,#S#[S"NIX.4M+.5,MC<]]O+CCN5)0C"<CJSGE[F,8Y=0XAK2YQ
M`:!4D\@"EK7/<UC&DO)H`!4DGD`'9)5GQNI4<XQG#YN<9QC.,X"7G&<9[N,X
MSA7=QG4\NT<BJ30T/*J%S>?;]DGJ3LOT1G/%;ZHXEM!/2'8)R$CH%/8=YYF`
MGNBQR<KG1+YO+S5<G"ZXMVR=$Z=@EJ!0N%:NKAV5KWV%U-]#3D*[#;6Z?%T[
M+:0P4<<0:XMHS#C-:4HW$W%_VXFUI4*N^-2I>S'>9+[[7,NO4)\:E2]F.\R7
MWVB5"Z'-WJ2R\..Z>^T07EU(C#C&$/%*9;R\\D=I3F%O9::3E2L)QGFIQRY[
MFJ.DC:]D;G@/=6@)%305-!V:#::<@7(V.1\<LK(W&)E,1`)#:F@Q'D%3L%>4
M[%W_`!J5+V8[S)??:NN.H3XU*E[,=YDOOM$J$^-2I>S'>9+[[1*A/C4J7LQW
MF2^^T2H3XU*E[,=YDOOM$J$^-2I>S'>9+[[1*A/C4J7LQWF2^^T2H3XU*E[,
M=YDOOM$J%12>\U!A8V0F9F6[)B(D$N3E9630V!&QD:`PX4=(2!Q3S0H0(0K2
MG'77%);;;3E2LXQC.=$J%8B>(_9L*!@K29>((2L6A^O#5FQDRD6Q`V(FW.BL
M50>"EW3DQ\N_9WS641Z!W'%&J>1AG"\K3RQ44#JC"?\`YY.=3MJ10U"RKXU*
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M*,S'-#<][I4&OOYQT2N;T;C`S:>[R_=YS6>YI1,05%VV!^,YX-6E$Q!.VP/Q
MG/!JTHF()VV!^,YX-6E$Q!.VP/QG/!JTHF()VV!^,YX-6E$Q!5IEBC'D`I0M
M[E'"2PYRM*QR.8()<SR=WNXYKN.[I1,05%VV!^,YX-6E$Q!.VP/QG/!JTHF(
M)VV!^,YX-6E$Q!.VP/QG/!JTHF()VV!^,YX-6E$Q!2I'SRL,9Q]S++>?OH3J
M%91FV,_C9G^V97^O%:D\H^E6=X/<"D_J%5?_TOMCXAOR9-_HZ_WJM/M?QN5F
M>"MZU/\`):M?Y?AO\.&T53RJ('&=7)&W4#<:LP[!A4Q-[162/B`P"E!$GRSX
M5@Q&QZ7\/,)Z*0.Z-EU"UX:=:6I#GX"E8UKVKK"?,]*ZCR^U8]UU-93-8UIP
MESS&[`VM1L<ZC2":$$AVPE;9H'-+7)-=:/S:^DC98V^96SY'/;B:R,2MZ1]*
M':QE7-(!<UP#F]\`O,N95O[5HNP2<C+[F1%<:)V\AHT/*F6B.QY;=#9B&JP,
M5-%W)]U%O>K!<J)(8Q'BI6^Z1@\AY2F%8\ANCK7+K:^N)[K,(K$.MF-;L!P/
MN[%D+62.G)$QB,S)?PV`N+^F>\EA7T!8CAOG%YEMI:V64SYH67LKW;2WI8[#
M-);A\D3;4`VPG;;R0_C2$,;&;>)@$@-_KU4WH%F$V2?@;P<IZ1VQ62]TXSMJ
M-IM=E^)%\./-,:,1E=DC:O8(!HI:GL/8-(3E;F7.>K7=L<MU9'="_O;*\>3)
M:5-09G01/S0M:YP=_P#:V&2V#SBQ=(X5=6I6-S/.=!S6)RK+<QR^,-BOPT4<
M+=EU/'D8<]K2TT@?<0WCHP&X>B8<+0W"%35H3B($CH5W+&\3A-@-B")@.7E3
M"V:@8O>+;B8D(=@F7F'90J!C-L&3`%%YZ51CW7,XQAMQ6$TL(M<QP6CL&:F2
M=["]KWN<(7>O6KW,!>\O,;+0/C+^^QNZ79A<:<N:S\,9KJ_9TF1B*VCD;$Z.
M-K3<M_;+Z)DI;'$(VS27YBF$?>B)O0;2YHK>H>#XC`)J%DU&[EG)3(U"1.C#
M9YM<:^LC<O=6-L8#C9_61!P44!N$7S%)4RUTC;_-R[CE3V[6SUW#=VEP9LP>
M.D@<YCI!A-;N\;*TAU6AOJWJYH1A%6OH7;1T+[,.%UQ87]H(,IC)BN6,D;"0
M\4L,O?`\%F%SGF\-T*@ASJ/CJ&&AUZ]6^(B08CY&5BMX"S8ARP2E;(2?'^M,
M-.6#9M^/0C,JY*,,KCD;A82V\EI(@F>564!CAKRUC"/R_7,[()[FVS1TT1D?
M$<3>FCDDL2WP\8&'UF@=3`SE(B9$<*V6/->&-M)<VUG>9(RWG$,<[<#_`%>6
M*',P\GHQ&3C-E5S2XR2#8'3R3M#UL[>%O<J4W7V[B;.S:Y';>,K%`FKU7*"=
M96).V`DB[P1>Z+@L54"HV6L`E0W*^*PLA@1;S^(HHQKH'12"F7?H"TZ?U2V]
M;IZWT;<=.3'08J=JM:+Y1OO53>WGJ`/J/2OZ.O+@Q'!6NVN&E:]E1XHFWV[`
MK<BS9J]Q*1\:/#;C"WUJ4LE^O<@_+'[K;(G;$ESCL=>JL=O+%4ZIQ-D=M*:F
M9D^6AU%`Y6MTUH1WL[%U%,C@T<W+QM.]';G+L#\M"2E>B!R;78UV^R+E&-K-
MN"-TPIJTJ3AJ=.KV_1-MB\OLY4+A(.$,<C*&TI@TKL12TU5$T1-$31$T1:AW
M[V7J/$1L_?=E[RA_-9OL+V6:Z-GD("*%,%EH:49;5G#)+D3-QXQ6&7<*8?RS
MT;J5MJ6G-7L$C',)(!'*-A';!WJS'%CFO`!(W\B^;;;#@UWCWIWKC/J]]V]_
M2+)L=PH'O[E'1PX)C"YR%EIYH1$-&J)6027*,,G-)$)D77,1CIARV4N"/.1Q
M'GN63RW6H\PTW(ZEAEKL3*;"<45O(!R[&Q].^.-HV-939C8Q[=MO&1P91:YP
MQO\`[5X*.KR#"^5I^DNZ)KGGE<ZOV7.:?J;CH\.)CP8N/9P,!&AC1X(Z5+6D
M<,-A`XS*5NJ6XO#3+:4XRI659Y.[G.=>B+4%6:(FB)HB:(FB)HB:(FB)HB:(
MH+B5KBGC=SMRI1XVSR-)5('.45@"Q5%U&8U=]$D4KBXFQV!T7M7U%W"F11FI
M-E@+!E7!PM+3*&.M$5+9Q>,UYLDZ/$<S,$Q4.<B/KLS1F*V)9:WO%83A85MN
M<E@I'%1G-L.K]?>PKM$QQ8[+JT)P^TP1=K:.-&0@)1Z<B(^/LA[U6`$9J\]6
MT"C(@I2ZQYYSW7YM`H<%9D`QTN<L1/;#`DJT"WUE8CF&"*4NT;VXA&WM>>W8
M&9#O[F)3,^*.U$LML\DU)8BD<R#E9J*RYB%P-SU,DK2M?*K*6\YRV@BV1HBZ
MGV&"F'AB66B!B&G&"!WVT.L/L.HRVZR\TYA3;K3K:LI4E6,X5C/)G1%H/;+:
MR0HDI3'A168B,`I-]A;'$Q4F2S!.S4E<JQ,U>08KC#K<'VFF+:DFWSVQT%+;
MRTRZXMMME+9%':H;4\1E1@*JW4VO4YL22I*Y"NMS=6,6-'05-@(VXB$CK3)1
M/4[E<X0R1RS'GLJ6Y)I-?7TZC!%D5SBMMN*I`&WT(?<BV:E`,[4NR\0,9`8M
M;[=)E8(N^1I=O%+!00]9CXQ+L2A+#K9$3AT<TD%:UL&$5SA*/Q9'!6*/O5S:
MF69O9.XU_#(C-;KT<UN3(-&BB20ZHTJ4EANL'/\`2"92ZEAN.RVM60WD+CU$
M622NUV_$`36H+;W<!F-J(Q<$F7:CH2$`$$&EK9N;/VX:MPT@82Y78*'"F(,&
M/:P3(."@`M-,MN92_P!,184/2^-EV+.:D]QXQJ3(K<PZ,J$#K0S(=@+E>NP3
M")"39DLK<BV&GAB&\@8&4&\.K!#S^'>A(KCG;SB<BS[8W6K2:&#)E;PO0)I\
MQ7)(P=^9F+T;2"Y=R3CY,DIH8:4C<133><-QV6\)*:<91T&"*7-'$L0%4A0;
M8:J2L`8JAI"0<6,X\;EA]YL8HAP-@49PI\-+:G5(;0G+F59Y,:(LKT1?/)Q!
M_6;;A;?[Z;OT.!WQC8B)I6X]PJ8D2K;VH'*B\5V<-B'HY1AU%,+*4"0&MK+B
MWG5+RGEYZN7ES\IZIUIQ4M-1YY:Y3F#AED=U(V(=%:FC&N(`J^,N-*<KB3O*
M^^]"<(^#>9Z+TMF.>9`'YO<6$,DKO6+UN)[XVN)PQSA@K6M&@`=@!:?^UDW9
M_6"C/FSHWZ/-8'W\XR^TG>9L_1+;/@KP&ZN-_,YA^H3[63=G]8*,^;.C?H\T
M]_.,OM)WF;/T2?!7@-U<;^9S#]0GVLF[/ZP49\V=&_1YI[^<9?:3O,V?HD^"
MO`;JXW\SF'ZA/M9-V?U@HSYLZ-^CS3W\XR^TG>9L_1)\%>`W5QOYG,/U"?:R
M;L_K!1GS9T;]'FGOYQE]I.\S9^B3X*\!NKC?S.8?J$^UDW9_6"C/FSHWZ/-/
M?SC+[2=YFS]$GP5X#=7&_F<P_4)]K)NS^L%&?-G1OT>:>_G&7VD[S-GZ)/@K
MP&ZN-_,YA^H3[63=G]8*,^;.C?H\T]_.,OM)WF;/T2?!7@-U<;^9S#]0GVLF
M[/ZP49\V=&_1YI[^<9?:3O,V?HD^"O`;JXW\SF'ZA/M9-V?U@HSYLZ-^CS3W
M\XR^TG>9L_1)\%>`W5QOYG,/U"?:R;L_K!1GS9T;]'FGOYQE]I.\S9^B3X*\
M!NKC?S.8?J$^UDW9_6"C/FSHWZ/-/?SC+[2=YFS]$GP5X#=7&_F<P_4)]K)N
MS^L%&?-G1OT>:>_G&7VD[S-GZ)/@KP&ZN-_,YA^H3[63=G]8*,^;.C?H\T]_
M.,OM)WF;/T2?!7@-U<;^9S#]0GVLF[/ZP49\V=&_1YI[^<9?:3O,V?HD^"O`
M;JXW\SF'ZA/M9-V?U@HSYLZ-^CS3W\XR^TG>9L_1)\%>`W5QOYG,/U"?:R;L
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M<SI5?6N2SYI=9587&=6;+?-'Q@R1L=C:UW9`/_45=A/>XG4Q'\^=26N266>Y
MI:Z<S&2[R..9PAFD9@<]@Y"6U[@=1N(`.+&5P#*=9181-$31$T1-$31$T1-$
M4VQ?YL/_`"#7_33J%R*,^QG\;,_VS*_UXK4GE'TJSO![@4G]0JK_T_MCXAOR
M9-_HZ_WJM/M?QN5F>"MZU/\`):M?Y?AO\.&T53RK0V_%DJM1<*LMM64'#P56
MS*2DFV9AD<*-$)DW2'G!VXB2)=Z%*%*SS.7.<<F,)Y<=WJWU]:Y;9W.87TPC
MLX6%[W$$AK6BI-`"=@W`E=S+<LOLYS&RRG++<RYC<2-CC8"`7/<:-:"X@"IW
MD!1N<WUV%>P\T[8</)8J==OSC:Y!;J<UFR%QS-7E&DYJBL$/RY\B*@0=OG%N
M//-I0USE)QG!NU?IA^-KLUB(;;17)%''\*4M$+QWNTO<Y@8T5>7.:`VI"V9G
M#_6T?1O9D4[2Z]FLP0Y@_'@:\W$9[[O1&QDAD>:1M:UY+Z`K]SO]L3AV`:S8
MB.2RBBFQ)'6S,@9',FWZR.J1D<5'J$&M5B%<!R@YT9:"T9:5C"^YI[Y:9Q63
M?W9G_L-#F'"_#1TAB&)V'#'^*#'20M(>,)`.Q/AUK,LS)_[#)_ZCW-D;CBQX
MFQ"=V!F/'*.A<V6L37@QD/!+=JNK^\VR0K5H>(MD:PU3,/9LRW;?%(3%=7>)
M%>P[E4)CIU-&AO#9PUTF<%-+8_C4J1CLOU1IV-N8ODSJW:VTKTM7@8*$@UWT
M<US=E>_!9X0(73CT1JZ5^41Q:<O'/OZ=`!&X])4-<*;-E6.:^KJ?AN;)X!#E
M?$[@;9+M;E&3)I5;VAL%.5[%EC^TDM9&0;S<L=A_SG`+J2,L\O38'5AWF]'G
M"M=P9QE9S)V3B_B_=`VIBQ#'2F+DWX2'8?"PG%3#M6..GL[;DS=0G*I_V0OP
MB;"<%<1;R_\`;C!9B\'&"RN(47Y);A;50Q)`4Q8XF*,$B)"?+$DKW7`218&)
M+<`E9LA@J-:=9B(PYI;)!*L899=3E"U85C.-9+:L/W$:W"VJ?:%?9L<2\R;7
M";@&\U>ZXXT74@NBZY:17$1N4/UP3IT=*<C.1F^>GG+QRXTVIW$`W"VJE94&
M"B['$R4W*0K-DC88"]UPR5D:Z1CE'G@8\>-<++A7\?\``4VA3"OV%9TVIW%>
MIB?IE>C#9J?=7!PT<SDB0EIBSQ49&`#ISA*GS3S89@45G"E8QE2UI3RY^[HF
MQ8P1NKLP(J:25<ZV,JM@1LK8DD;C51E4!%S+8CL/)36'`4YB@)5J084,\_T;
M;Z7V\HRK"T\LT*=Q<'-V=E&HQZ:=NU8:AAHJ-G2)9S<BIHC&(.9DG(>(F7CU
M!8%:BI67:6*,0I>&7R4Y:0I2\93I0IW%F`$O4Y41D^+03)`D(2X.:!8XTP1]
MM:<+0XR0/"N,NH6A6,XRG.<9QGEU";%6=-!^YTKZ9#]X=%&Q>?NZOUH7`_LS
M?K)MS?+I8@9ZIOD!S+H+#\F`B1CG5M3<<"H.O.'2K\$MA]DAP9AT9<@(3&L.
MO2@[P2..VFBO;F2SLY&S7;)1&YC"'/;(YK'MC+6U<'EDD;@TC$6O8X"CFD\L
ML,D$++B=A9`YA>'.[UI8"YI<":`M#FN:36@+7#E!4[H.PTRS0L/9*_DF9@+!
M%Q\W"2\=8`"H^5B)41D^-D@26H-39`9P1"'6G$YRE:%8SCN9UR+C[BPR#VFV
M1K5^L^ZE?VOB8?<BZ"-`6R\@8AA[1806,AY9"E9ENN8-+$;5'L*PVI>484TG
M/)RXY=<38(6R/F;$T3.Y7`"IV`;3RG8`-O8`W*YED<QL;GN,;>05V#EY!V.4
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M2VR,*,TI:UJSC"4ISG/<T4[%:4W?;A0<&>F3:R'91(^0KS^+7$\R;`ECH.,C
MC8O'8W..$+D;-',(<;PI&73F$\O*ZC"B;%5E6BC!2;<*6Z\/+O"L',QCMBCT
M'OA$R8T*T8P)F#Z=X7$L:P.MQ*<H;=?;2O*<N(Y2C8KSTT'[G2OID/WAT38G
M30?N=*^F0_>'1-BP&0W/VQBCBXV2W`IL8>$^X,7'2-_K`AP3[2LI<&+%()9?
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MC">I\N%8SR\N>7N_[/\`:38N/3,_BE>=I]K:)L3IF?Q2O.T^UM%.Q<.<+["_
MYRW[5T4;$YPOL+_G+?M71-B<X7V%_P`Y;]JZ)L7+*@_P>:P3C.$_A<I32N57
M+GNIQ@-/-3R<G<[O=_9_8P38N/.%]A?\Y;]JZ)L3G"^PO^<M^U=$V)SA?87_
M`#EOVKHFQ.<+["_YRW[5T38G.%]A?\Y;]JZ)L4U!OYL/_(-?]-.H7(HS[&?Q
MLS_;,K_7BM2>4?2K.\'N!2?U"JO_U/MCXAOR9-_HZ_WJM/M?QN5F>"MZU/\`
M):M?Y?AO\.&T53RJ(W&)4I6^TVZTN#4(B8M&VLE"1JCWECA)-D%3`[&2GVVG
MW&F,.+QSE80K.,?L9U@-599<YUIK/,ILRT75Q;21LQ&C<3FD"I`-!OV%;3H;
M.K/3FL],9]F`>;&SO8I9,`!=A8\$X02`30;`2/I7G3&\*FX,#/S=@CS:Q(/C
M3L3+5@0R2/$8(AZ'N?MY8:/5CW6XLQ0##E,HG1..(0\EDY_[BT<Y>O+X.&^=
MV5[=WT$MN][9F/B:YSF@LM[NVEMX7'`["#!;X20'!LCN0BI7MUUQBTSF.6V&
M67,%W'&^WDCG<UC'%LMW87L-W<,!D;C(NKO$UI+2Z)G*TT:KJK83>HQN3C)5
MZJG,6NOD525F2[2<076H=>[TS>F7A$-5(1=GD!JZ<AA#CB0,O&_PKO-QE6NP
M=%ZLE%Q;W+K9[+F`PO>9G%T3/77W`+:0MZ5PB<&@D1XI.^=3:NF.(^@H'6EW
M9LO(Y+*Y;<1Q-MV!L\HRV*T(<3<N$#'3,+RT&;#%WC*FBN,CPWWF3JNX=<-]
M4R5.;;[@46C%.RAI>98VXWR6NP,_-CDP#*:\3%-E#C_P+IJ^GZ9:5<S",KYY
M]!9Q<9;GEC-ZLXFPN;>W)>YV-T]P^X;)(#&.B+`6M[TR'%B(-*5ZMKQ3T]:9
MQIG-+?UQ@&:V=W=M$;6]&RUM([5T,3FS'IFR%KW]\V(8,#2,6(#:8FTUM8WC
MS:7'H9=/:W*F=U&#<2AN9]P^7V8CMI/5AV%S$=2P(*L9P[!>#O\`@Z-OHN7G
M*QL<6FLS9JG]Q<^(Y6,P?>!V-W2%S[%MET1CP8<((,F/I.3"W#6I6GSZSR63
M0W[.V.<9V<JBR\LZ-O0AD6:/S'IQ+TF+$X.;$8^BY<3\=*`PV%X6]Z3MHK74
M#*KMW9[79$Q-A)O=TDCH^T`7^M[#M;(VUBLA(KY6(IJZ7N+D["++*.(&(BKA
M*XR,T^ZEQ_T"HJO*U<9WA8WC45'ST1MGL>?(-7_=_=LN$GI]1L)(R=^5Q#KI
MU1L835`CS95Z@3.[HDNVIF58BS7Y>S-.H2_F,D'50H5]VRX3]R:CO]MW?DY:
M#HE>D6;I9`YRQU^0D)"Z2%)XE(*W33,=7Z<*IFS3EOWR0<.T(>%70HEXT=L)
M+K0.$*[".RBSR!V/WTCZW++L\UF_R@/$Q`[UU.L6K<NP3L<SMK'(!3"[7=L3
M\-*]4E]MWD9D`GE,NM2LR`,2\8PX\LD94=C<BP"N\->_54L=ZL-0@=H*)-A1
MUPL>V)M6E#L5N/MUBX2]@MDH.@!0I=8P=&;90NXNUY$H6ZXO"W!8F)4@!UQQ
M;82H18UNEP1[B8NC$IL[).0-2K<UM%88(#US@7ILTBC7O@L=D!Q/6+:^21&.
MLTCA=>?2Q(GR\>5-8&*=0M9CJ8R<6_\`CE129X.-H[ILQ19ZG7'`#;@#VV<0
M(B+20]&GDT_83:2CST['R1@D69(!ES=:>#2O((#3JH]1#([#9"66X)JBE]JJ
M+X[^+R3M%TO.8M6P.]J8'>;=>2M5]KB=L]PXVS1<Q>%65-,B*Y%6.GCG/E;7
M'WF3+B<"/-!RVYY%D7A+H60U)UO05L;;B/J+.I\L.7SMA%Q%<G"UKW,;ZN7-
MD:277[V6EN6`C9;LM68AWX6;U'+TVE,KL67HN8S(8G0[26M)Z4!S2`!;!T\N
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M6QP<X[`.'%1N%)';'+5@Q!%D^Y?"O![E3UPG#[.</ZXLS3)L:4&1,Q8F9.K;
M;5H1X*+.F<1(I,>O;S!2W61FGBW"6TNKS@5G.B+%I?@WC9',\AB[D#C6>2W5
M-G4G1,Q/$R*-S40/.=<=F+F4,Q+1ST"W@AYEAH4YG.$X%'6G+JB+/1>'`&*J
MFYE'KUD9K-:W3D)HB<8@ZM'!EQT?/3RGCHZ%Y2W(=G.*62]"-N/@D80V@5S"
M.B&ZLZ1:^;X*JLJ-?C9.Q!S_`$K.83M.<I$&7,.TV/D]EB*Q5SBV2!1S&82(
MV6%#6OH4,$Y->=2PSG',415)'!I7")=$TY96EG+B"H@XQRJA+D2$G[S9W@D)
M!F1Q)H(&E#7F!HMQY72\\-CE5C.<H2V12+VFV_:VMV_K]#8,$.8@,2:67P(M
MR&!0S(S,C+-"!Q[\E-&-#`(/PPA9)IA;R6\.$/O/K<<41;%T1>!&_/!IQH7K
M>S=BX57;C;,JKV/<*VRM:,.W2;`.-KY4V8N%.-`5`.*`,-C>B==8RI70K7E'
M.5S>7/S'J7@MG6=:@SG-H[MC8[BYDD`V;`YQ([.Y?<NB?^16B]-Z0TSD-S'<
M.N;2QAB>1&ZF-C`'4W@.J`>R-JU-]`GCN^3':GYW6OS=UA/@%GO]\S_Q\I;/
M\TNA?Z-QYMR?0)X[ODQVI^=UK\W=/@%GO]\S_P`?*3YI="_T;CS;D^@3QW?)
MCM3\[K7YNZ?`+/?[YG_CY2?-+H7^C<>;<GT">.[Y,=J?G=:_-W3X!9[_`'S/
M_'RD^:70O]&X\VY/H$\=WR8[4_.ZU^;NGP"SW^^9_P"/E)\TNA?Z-QYMR?0)
MX[ODQVI^=UK\W=/@%GO]\S_Q\I/FET+_`$;CS;D^@3QW?)CM3\[K7YNZ?`+/
M?[YG_CY2?-+H7^C<>;<GT">.[Y,=J?G=:_-W3X!9[_?,_P#'RD^:70O]&X\V
MY2CX2."#B0K&Z@=OWA?C=JX>L--2485ME>T3L_8Y#!"$KKY3N8L0>,A"1^7K
MBG$$X(9Y6,-XZ3+B-ETEP4S7)\]L\TN<\D@BA.+\$@/>:CO,52`QWVZ@AS>]
MIMJ-%XC?\C]+Y]I:_P`DRO3[+VXN1@(N6'HHP0?Q<.PND::='A<TM=1^+O<+
MO:Y2N<I2N:E/+G.>:G'(G'+^QC'=Y,:^DE\6K\T1-$31$T1-$31$T1-$31$T
M1-$31$T1-$31$T1-$31%-L7^;#_R#7_33J%R*,^QG\;,_P!LRO\`7BM2>4?2
MK.\'N!2?U"JO_]7[8^(;\F3?Z.O]ZK3[7\;E9G@K>M3_`"6K7^7X;_#AM%4\
MJCQQ&[A@[8QLU<Y:.1(1%6IC]AD61XF,DI5T6/>DWGV0,23@S*G5-L_@(6\T
MWSL]U6.7.=8[.,TM\DRK,,WNV/=;6T3I'!@!<6M%2&@EH)W5<!VUE]/Y)=ZE
MSW*=/V$D;+R\G9"QTA(8'/.$%Q:U[@VIVD-<=P*B_5.+3;^VV<.K#`HB##JA
M3;:R=/UNM1\9A=Z(@Q(*JK>0:01BWJ+L0;3HF&LH2X]A*759SC&=;RW7^0YG
MF$671F6*5]K!,'2!K6?^P8VQPUQD]/BE8"RE`7`!Q*W#.>%.JLERF?.)1!-!
M'?75L60E[Y/_`%&RNFN`#&UOJV&"1S9,52UI)8`#3LE>+/;2(GAX%UV))4>Y
M36XN5"AJR["2B[PNY-1743EEM94V*]2"FREK0VAI;S&$Y7SE]':YU]IRVO66
M3K@N+S`&/;@,;_6.G#,+L8V`V[P\D``N90FIPTL^%6L+W+I<Q99M8(Q=&2-P
MD$L?JGJQDQL$9VN%U&8P"2X-DJ&T;BNAG$[MR#62Y]^2J2Y`*@/[C/4P1%)/
MN#D&/3U7E;`80,F3%R)RZ^G+K:AS'0W4XRM#ZF<=+KL2ZUT]#E\MZ^^89V61
MNC`V2)TYC$'K%&M;(6.=T>T%KRP\H>6]\NI#PWU;<9M!EL>62"VDS(60NG13
MLMA*;GU0%SGQ-D8P3=ZX/B;(T]ZZ,/[Q9W`;MU6SR!L-!RM)D9R+&'*EH(4>
MO$R\2V0EO*<2((^'7AEMK=2ASE[B',\W.<9SC69LLYRK,)YK6SOXI+R-H+XP
M]I>P&GA-!)%*T.X[#M6NYEIW/<HMH+[,,JGBR^9[FQRNC<V.0MKX#W-`<"`2
M-XVC8M(@\9%/*ILI=#*/8H88*LU*X1<+)5.CN3EJKUXFO5VMG5MN)L<I%$.&
M3><#+')+%)8<4GI&TX6C*M1AXCY/)E5QFTN77L4;+>&=D;VQ&2:*XDZ*)T09
M,]A+I.]+7O8]I(Q-`()W^XX/:AASVSR&#-\MGEDN[FVDE8^<16\UI%TT[)S)
M;QR`-B[\/9')&X`X7$M(%^-XJ*T+882#&ITI*BS@FVA35DC:Y1UP0:MW294*
MAC&)+GPYU;LL7#/(6L8$@<;'-6\XAO//QW)=<Y9'?6EG'8W4L<S;4B5@BZ-O
MKI>VW#L4S9*O+'`EL;FLV%[@-JQT'#'.ILLO\PES.QAEMWWS3`\SB9W[:V-U
MVYN&W="!&V5I`?*Q\FUK&N<*&MKO$Y5I,>5+M4(%M6-&6@JF-/;D8VMC&YBS
M1KQ+$S%PZH&VV/!#D*XPGIW'.B94EY"F5NIPYE'-8ZTRJX9<RYC$_+8X[@P`
MW4ELP/E82)&,Z.XEJ8R!B)PM(<"TN&*G!F?#?/+26SAR>:+.)9;1MT18Q7DA
MB@D#3%))TUK!02@G`UN)P+7![6'"';Q[?(]SX/T'&>UM;>O/:IV^1[GP?H.,
M]K:)5.WR/<^#]!QGM;1*IV^1[GP?H.,]K:)5.WR/<^#]!QGM;1*KQ9XB_KEY
M382][BP;/"T/;:5M];'*,5<"KC7JP0_8FY*Y0H;;D.S1K.@9%BE]O9SJ3*R$
MD,Q@+,D7A@0YO+./R/,[/4&I)])Y?(1G,=TV`MD!C87.BMIL8D<`PQ!EW"'2
M8L(>71UQ,<!W<PL9\LRF'.KD#U%\)E!:0]V$/ECPEH[X/+H7D,I4MPNY'`KU
M]H^Y@M_I5/O<-$!BP]UJU?ML4-+5J+"E1XVR1(DR"Q)AI;?2)(,BFI2\UA:\
M-N8RGG9Y.76073.S8LI[?(]SX/T'&>UM%%4[?(]SX/T'&>UM$JG;Y'N?!^@X
MSVMHE4[?(]SX/T'&>UM$JG;Y'N?!^@XSVMHE5!.R<<]J%W%H=/IVQ5>LT%N4
M99!Z58)FW5RGS-I$JS[@I$Q7JH13Y?$A$60L=U$*\L]C#S:4ER'9D>\P8[MD
M.FH765W<W.9X)8`W&UL9>UI?MHY^(4+01C&$T\%F-X+1B7YH\30QQ6N)CR<)
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M'L;M^R@C?K;N&::<>1"1UGE^IPID[(J#V_JR<QH4=$VR:D$&,ES@I*21`*@\
MK*$(7S\OM8;ROF$]7N_0.>Q`&7H6U<&BKCM)+&BE&G82\<QKRMK#=0V#ZX,9
MH*G8-E`2>SVOXVT]'FK$0XTVYF,AFLN-H7EIV"B\.MY6G"LMN82PM.'$<O)G
MDSG'+^SK2B*$BJS=5V=OD>Y\'Z#C/:VH2J=OD>Y\'Z#C/:VB53M\CW/@_0<9
M[6T2JQ.>W9J]6S(8L4E4(;,7&-2YN#XN,8RV`^Q.E,.-84+RE//#5B0<0RUS
MWE-ANJPC.$9SHE5EG;Y'N?!^@XSVMHE4[?(]SX/T'&>UM$JG;Y'N?!^@XSVM
MHE52G6@D((PQ,-&FJ$%()2$#`1+II>6&ENX%#:=;9;<*(RCF-I4M"<KSC&<X
MQW=$JM*5?BOVJM^'U1$I#*2AF&*#4NHMN(F19U^IQH+T(L*/,3).8L-T`BW6
M&\]9;/<PC+?1K:<<*=JN`G%!M01#+G2+/2XL%B"'LAJY*+B64!0SYT3#KD5F
M,L$1AD>'/S#<:\6*^0&B2:(&Z7+HQ"6B56T86\"V&,$F(D>%(`-0M32W:V,$
M0VMEUP<D4P`X`8^//"*96R0,0TT^.\VIMQ"5I4G!1573M\CW/@_0<9[6T2J=
MOD>Y\'Z#C/:VB53M\CW/@_0<9[6T2J=OD>Y\'Z#C/:VB53M\CW/@_0<9[6T2
MJ=OD>Y\'Z#C/:VB546;7QF\.%,LLY5+-N1'1=AKTF7$S,<FB7LO`4B&\IDH;
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MKJ.KN&>N="VUI>:JR!UK:SO+&/$D,K2X"N$F&20-)%2`["7`.PUPFFX.M+]B
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M]B%\V8[S1*]I.M+]B%\V8[S1*]I32&[HP_\`(-?]-.H5U&?8S^-F?[9E?Z\5
MJ3RCZ59W@]P*3^H55__6^V/B&_)DW^CK_>JT^U_&Y69X*WK4_P`EJU_E^&_P
MX;15/*HN<5-%>W*@+-1&S7(K%NH)E>S+HCU2>([,D[+#=:ZDDD+!>6,.<[H^
MF:YWW.=C[NL1J#*?W[(\UR;UCHO6H'QX\.+#C%,6&K<5-V(5WA9_2F?>Z^I\
MAU'ZIT_J5U'-T>+!CP.#L./"_#6E*X74W%0;&X.EQ4U*3\'<G1)`JV-6Z-1(
M5!Z1#!+C=R:=>J]'&-,62-(D(F'BJ4+$=&VZ*M;.,.I6US<-9T*/A@RVN[B]
ML\YPSNN1.W%#B:US;J"XB:X"5A<QC(&0T#F$M[X%M,*]2EXV27EA:9;F&G2^
MV99&V>67&!SVOL;FTF>TF"0,DEDNI+G$6R`.[PM?7&JN*X3)2($BD#7KI#HI
M.VN&R2*2^H9[-`(W.44IP-JU,N)[<%W+<0C&'L=3<$2O/3I7EM/);<.);6*V
M$>>-,T?JNTP;#ZL;NM6B8'\071`[[O"P'OP<(X;SC%#>S7CI=,N%O-Z]5K;D
M8AZX+##1QMR/PG6+2:M_$;(6CHRT..&-<(%JDV)VH2MF;!J0%2JE<@95JKX)
MDIV8B.'N5V5]8G6T61*XF-CU6`HI<:XEQ9+B&L(*;1A:G,4WAG?7#+S*[G,V
MLRQEM#%&\1`OD>S+'V'2D=+WC&]*]YB-2XAH$C0"79U_&C++23+L[L\E?)G4
ME[<3S1F<MCABESF/-.@!,%)'O$,<8G!`8TO)A<X@-WAMAP^N[;76?MB)UR88
ME$6G$?'KKKHIL>NYV0&U3O6)A^7D^LL=J!8P.R*.`TEG.,/8(<0AW&WZ>T:W
M(,VO<R%^)62";"WHZ.;T\K9I*O,CZC&WO6L;&`WPP]P#AY]J[B*[560Y=DSL
MJ,$D)M\;Q+B:_P!5@?;PX8Q%'A/1O.-TCYG%U>C,;'.8=817![,X!I4?9-R2
MSV*0'0X(!5:I;M7>(K&WRY^3B@W72[195)FR[-*C'/G?A-)2`AIH9O*U.ZUZ
MVX93]#E,%_J(O9:-MXV]%#T),5MTCV-),TOXCI7LD=)R4C#6QMJ7+;KSC5;&
MXSZYRK2`CDS!]Y,_I[GU@-GO!#'(X!MO!^$V".2)L6QQ,SGOE>&ABN=:X0FZ
M^36I-VS]J3U,1M/'U2POTU+<U"U_;*VV>7+@QI#$VZ2V-<:G8&H4WHUM-Y0)
MAY;;N%)8:[&7\-(K*2PN'9H)+VT%FV&4P@21QVDTKS&'=(32>&0024(%&!Y:
MZH8WJ9KQGN,SBS6T9DCH<NOCF+[B$7),4LU_;01ME<SH0TNMKB%UU%B#G5D,
M;7,H9'WJV<,)UECR`QKB3#D$[BWB\]J#U@A4D$+>"&7BXF-+&L(#S)(;;.$=
M(^HB.-QGFEQ[[>,-X[>9:!=?POB9G'1/=?W%QC$1Q-%P07,81*T@M`I5Q=%)
MR2P/;1JZ&3<5695<QSRZ>Z>)N5VEIT;IA@>ZT:0V1[70/!:XFM&!D\7+!<QN
MJY2FZJ3Y._X)SO=>BKR!.JD^3O\`@G.]T1.JD^3O^"<[W1$ZJ3Y._P""<[W1
M$ZJ3Y._X)SO=$7S$\0G`O]8QN/N#5IH'9.F3S$Q:YFQ;IH]>]OF*-:9#<L,2
M%W/.GG#CH2WLQLA&"Y@&V1HR1(&HT7!J:4].8D$(Q&E;6^RW5F?9MG;HWY;-
M:4A,=3+TC73-9;/:X81;&,QO>]IZ3IGRT;A#",CG$UI=9)EUEE^-MY'/WX=3
M!@(C)E:0:F4/#VM:1AP-94U+J_0?P\5[=&O[*;=5_=L5A-^@*^W!3"@'FI#I
MA(<HF-KI,D:".-&D6(NLC!NRJ@VT!=IK?ZLG#'1XUFI.CZ1_1`]%B.&O+2NR
MM-E:<M.RL:W%A;C(QT%:<E>S3M5Y%N?JI/D[_@G.]U12G52?)W_!.=[HB=5)
M\G?\$YWNB)U4GR=_P3G>Z(G52?)W_!.=[HB\2=UOJ^N-61WIJ5MVNWYJH%0V
MPB)FK[%%S,0\#-[/523B*M#!1:HQFN3`5I)@Q:WRX?>=5U]U]6<H#3R(QZCE
M^KM-,RRXM[_)Y#<SN:Z<--6S/!>XFN(%@<7<@'>@?:Y5JMQD^9NNHY+>\:(X
MP1'4;6`@`"E#6E.[7L*6U\V,XMZ/!`/<..X-?3*0U$,7,Q5E0^+%7K<F3LUS
MO%NE0ZG(P4_6Z^NV3]ESEA_!XS[.<MM$$J'8Y7=>M,ST_=2O&=6,G1NF&$MV
MF.(-8Q@+PYKG8&MVC"0=I#<1V9&:US&)@-C.W$&;0>1SB7.)H00*D[QN)H%K
MZ,V9^LKF`*U:YK>6B5^_@DUP@B,[3DB*DN*8@K;'SD1.TV"VW'JQD@879AB'
M'$.FJP;%MN,F)8Z!@?MR9CHJ-\]O%E<S[0AU#A&.N)A:6O=)C``:0-C>]<06
MUJ7<+;;/'!DC[I@F%-E=E*$$%H;3LU[.T;#2@&U=J]CN*ZI[OU^\VF[;<G56
M4!D?C<CH^)9/M]QEGQK%B'(:MY6V,1-Y!@'BXII@-HJ.CFV(W.&!!VWNKM]"
M_P`SR&XRZ:UM[2<7#2.A))#&"K:]X)2VKJ/))#G5=M<2*GLV]KF$=RR62:,Q
MD''0=\X[:;<(-!LV5`V;`.13LZJ3Y._X)SO=:FLLG52?)W_!.=[HB=5)\G?\
M$YWNB)U4GR=_P3G>Z(M%7[8MVZVN6N+,Y+PDL30@Z4!@0$`H3#0DK/3CB946
M7C95DD$R6.`?RH3`1[*H["4$]&^ZC1%NL&)5'!!QXHI21@11PQTK2^ZM+`S2
M&&L+=<PIQQ>&T8Y5*SG.<]W/=T15752?)W_!.=[HB=5)\G?\$YWNB)U4GR=_
MP3G>Z(M`5[A9VFJLA#24%5I4$BOQX\3#I[;L#XX,:/N(#NI@-H8DUUG#+EVB
MQ2E8SC/*D=+>.1O+B5D5&CA-VD:"$`'@+,&P"(!&"9!MMO!(8AH^?8M[$,V4
M'*LD)CU7)C$NK'.Z3)RLYPO#?(W@BW+3J/&4.LQ-1K4:2'"0@ZQP!E].]EM#
MK[Q3W(I>.:VA9#ZU);;PAEE.<(:0AM*$)(LFZJ3Y._X)SO=$3JI/D[_@G.]T
M1.JD^3O^"<[W1$ZJ3Y._X)SO=$3JI/D[_@G.]T1.JD^3O^"<[W1%X^;M?5:[
MJ[G[H[B;BC\6*:X)>+I9;2#7<\.D;,*K\?-RY<A'P2IA6Z4:N75#A/MCY*4.
MPHG+?29;1E64X\5SC@ID^<YMF.;7&8.$US,^0C`[87N)ILF`V5I6@KN7U%IK
M_DUF.FM/9)I^#3`?%96L<(=ZP!BZ-@:74-LZF(@FF)U*TJ:56O?L>]VOURD?
M^F.,_2]K&_`+(O:3O$=Z99OYM<WZJ-_,M_2)]CWNU^N4C_TQQGZ7M/@%D7M)
MWB.],GS:YOU4;^9;^D3['O=K]<I'_ICC/TO:?`+(O:3O$=Z9/FUS?JHW\RW]
M(GV/>[7ZY2/_`$QQGZ7M/@%D7M)WB.],GS:YOU4;^9;^D4O>#_@-G.&.W6:Y
MV[=K&\DO*0K$+6W,;5L[>YJC3K[SDX0VH6Y6I$H],L889Y5(9RPVVO"<JPZK
M&-NT;PNR71V92YK;RF6[,98TD.&`$]]2LCQ4@`5V$"H[)7FW$WCIG7$?)K7(
MWY?ZG8-FZ20"1LG2EH[P&D,1`:232I!-#2K0O0CJI/D[_@G.]UZ<O"TZJ3Y.
M_P""<[W1$ZJ3Y._X)SO=$3JI/D[_`()SO=$3JI/D[_@G.]T1.JD^3O\`@G.]
MT1.JD^3O^"<[W1$ZJ3Y._P""<[W1$ZJ3Y._X)SO=$3JI/D[_`()SO=$3JI/D
M[_@G.]T1.JD^3O\`@G.]T1.JD^3O^"<[W1$ZJ3Y._P""<[W1$ZJ3Y._X)SO=
M$3JI/D[_`()SO=$3JI/D[_@G.]T1.JD^3O\`@G.]T1.JD^3O^"<[W1$ZJ3Y.
M_P""<[W1$ZJ3Y._X)SO=$3JI/D[_`()SO=$3JI/D[_@G.]T134&_FP_\@U_T
MTZA<BC/L9_&S/]LRO]>*U)Y1]*L[P>X%)_4*J__7^V/B&_)DW^CK_>JT^U_&
MY69X*WK4_P`EJU_E^&_PX;15/*OTZU5R,3*+D)J.#;@UQC4R\02VVQ%.3+K3
M4:W(OJSAD-9.7VU8PXI.4MN(6KD0M*LD7&U6RLT>#+LMOG8RN0(3L>,1*2Q;
M08N#)>2$AH:/:6ZK&29.:FI`<((5K"R##"&F&4+=<0A1%CU*W9VRW',D`*!?
M*M<BHN`IMK.16ID*80U6-Q(\V5HEB0^"Z\P1!VZ.C2'H\IM2V"D,.9;5GF*Y
M%$5=<-QJ'M^PZ3=[=`54=BN6NWO/3DD-'-MU>BQ[$K<I]:B%HPF*K,:2V^:]
M_P``[2\*5G&,Z(LTT1-$5EC['`RTK/P<;+@'3%6)`#LD:*2V\9"%2D:/,1P\
MDPA65B.FQ1;1#:5XQE;3B58[F=$54#*Q\FN0;`+:*7%2#D5(I:SG.1)!E@<E
MT1WEQCD=0P6VK/)RXY%XT17#1%992QP,(=6XR7EP(V0N$T_7*L&82VP18)X6
MNS]N(B(II:L*-/9K%6DCU-(Y58%"><Y.:VK."*WQMWJ,Q5:Y>8FQ14G3[>+5
M3JO9`"D%Q$\#>'HP>HF19@_2-%BV%V:$P*XG.4.8?1G&>3/+HBN$)8X&RM2+
MT!+@3#41-2U<DW(\ELE`$]!%K`F8@I32E89/C#6E-/-9Y%-K3G&<<NB*]:(F
MB+J??9%8>)(<2TP.TX^\ZK_A;9:1EQQQ7)RYYJ$)SG.B*P,7&K$RE>@V)Z,<
MF;76Y:XUN*ZTVF0FJM`D5@.;GH\164OD1D45=(ELAW">:TN182KDRXGE(NG-
MWJ*55A"[%%-+NL_(U6I-O%(9<L5CB(BRV"3A8AMWF+-D0H.FRI;C2,94D>/?
M<_X6U9T176"G82T0D/9JS,15BKEBBH^=K]@@I`27A)V$EQ&9"*F(>5CWB`).
M*DP"&WQR&'%LO,K2M"LISC.2*ZZ(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBC!L9_&S/]LRO]>*U)Y1]*L[P>X%)
M_4*J_]#[8^(;\F3?Z.O]ZK3[7\;E9G@K>M3_`"6K7^7X;_#AM%4\J\EN)S@U
MJ^\&]F[DJ7Q`4VFV2P!REMCXHX1]ZV4N+W#V,I/"U9GV98.7B2(""8CPQ9'*
M'%&#FG20Z5-1W,R8;<&@&Q%Z"<3T/4Y3:Q)5OOH>V0=>W`VHL<-<I%F0,CPK
M?&[E59-/B"XZ)F:]*R:;?8R!H9L<0X0Y;T@CJCS16&7$U"+R:J7U8^SN\V[.
MYF[]<XQ2=W9^8J^ST-)R$0,988N$E:55:D)4[TW+PFYW8EXGI'-#;SS9G$W$
MN1QLG'EB%=:4XU;$:4HH6WJ_]631MK(*\5*6WP@01M[HSBEVSK+KFW:X^9@9
M#BM@%,>HE(DYG<F=,70MO8RO/'P];4I:W#W9$M9>,DJ2VQ5["E4=H^I\J,];
M;%9`-TH:($E)S?R5A(5.T`BPZV)O=N1%;B1L-D.,OL)7[)&[2F@O]@,R<<2,
ML@US!S)<:EN*2Q(MJ;J_5D5C<_<JZ;E9W7L-;F;AN!%;@$2(`$[(6%;L0R>@
M&M2I<I?"*H56XA4BMN-2!!Q9H8;:&5$O9Z1QR`Z@HBT6']5#0]P(^T3-:WPI
M;U.W#8'K]CA*)LZ-7J,^/0WZ#7TQ5=#JNYT83"=+-;5NHL"L%/DFD&E88=!<
M2A29Q=I%U57ZG3;&0CR+$UO43:82Z1$/-L035((KNV\P<^Q7D`6(RO4R^5>=
M,:13(MJ+"RW+#'I#;%P265T+J26,[E"E1NGP"L;VD[>RMYW*.BY.F4Z/H<DW
M7(^2D&IZ#@YZQUV+D<RMHL4E,,VJ1X<=T]Q*+)GOK*43B_&R"4H6,P.N,5*J
M5$8OZKO8VBW`&:LG$-7A[32[1PH;E"AV>APJAQX392K;F;&5Z*GQ'K@U)'5O
MB%G+TRY=>:4,BS3K)^>1KM+"`YQ$]A%UF_4Z;6PFW-2VMEN)&W5T6NU>D-Q<
MM7Z\%6908+8^0JELAI:))S/R&(5JF66W;KRT=A*U=G$;JOYRI_$2QUEC[2A;
MOVU^K3H++^Z6X<3NP.4WO]MQNU#1,SMC7)RCP5.@=^(>4:RUME`B[F3])&V_
MC@YY,J%'%QI[ZYI*#L')3A(Z1<>2BE8[>_JBZ;N#.'34KN/`PS)PV_*TURI;
M-0L%5(Z2WRV!5L8TB)@LVTT<"M;4/"#6&J`8RI^.ER99U9;SLGTXK&BK)?ZH
MG;*3)OQ8NX"ZZ7<;]NA=(25K>WM?BI_;P;</=:O[IQ4+2YAN26[$>H!\`EF*
M?90VEEU>"$,MJ1A&8Q=I%;1_JHMJJ3)1UO=OM<&,:J55VI"18-MC;E`07:UU
MW-<7+4,:_P"XMPG*?=)^?W;$R"0B1("!E6'RNJNX.RT-.*J*Q;9_5H;9[>";
MW)>XA(B<BXW9S<+8O<L,#;H")'K!MW>V:W=EK-<8T>YRD8NT?%Y4H#)3+8@7
M:09C1K_/><4IT75IL1:7GOJJ*,3NG9X:\[Q;,U?;W;J)W[L-541"QYVX\8CC
M:V])V/V^+M0LWBNURGU?;"Z5J7Q0112SEN&`Y:8>&6YEL><6SD_@*%Z#\(/`
M:'P@S^9"HW:KR,.9MYM_MY/1H.URZY)V`?;JGQ-1A+`9->OTVR#-.,P`KKS8
M08T>\MPM;@RR2$%,5+JJ5Z$ZJB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*,&QG\;,_VS*_UXK4GE'TJSO![@4G]0
MJK__T?MDXAOR9-_H[G[Q6GVE9G@K>E3_`"6K7^7X;_#AM%4\J\M^)W@&!WNO
M._5C-WGK-+^-'U;BPC'VE8NM$D;G#[!T`"/K%@S+A+IJ[)*[&AC9:::)5;`K
M%(0V$`K<2<Y<.I38BGCQ&T*G[G;=`TF[7=-`AR=SMF+>W--S[]8D##]HMVJ9
MO0/7XF;"G*Y*QLA/M[=+&ZR$6V6&RXX2WA66>;FH-$7ES&_5<\.5JF;I>MH-
MX=HQ-I9FFS441"4VAUJ8!I;EOA-Q+G2[7`;D5+<6'+AW8[:/B';4U@CIF)6'
M<BY/\%;4:2/;$>R-J+=5>^K,V=.V7NM&AK?`3-;WAW/$WJ78`:OBU0Y$43L$
MSM)6JM"F6FZW*7FJ#7E%OS==25,'(C62DBCJRVG#ZF(U18=0?JZMNN&3<>)W
M_NW$368,:NRMML$M89NK16WJD=?VMG*Y/2,?8IK<0^G5"9D(8+$S/R@T0DDA
M,4K(ZHX59J7F*HI1%W5OZI2IU,F!,B=S(\IJ"&H[3E5M&WLQ==O;&92K)7K*
MF8M58M^Z<U(R<G+E5$1*\,R0H@?:]C6&P.N>>R.Q]I%K0SZIW;O;]NH/V[B6
MKD5#0%TW*L=.>MVWT'"J8MVXVVVSM<GB`NL;BQM2E9&LT_ATQ*1(;\43'"OJ
M*),"-$&P.EB)["+--K_JE:YL'$;?S=1W?[<N&Q\40YMK,WZ&M,36ZYV*FGW"
MN1Q`=#W.J?1U(7=."G9*28+5(-D0-MDHI*6DI:*PQUV41;6W#^KBHN[^ZKN^
M(6[)S<?*6V'W$K=3"A`9S;B4CA7A;?&5FTA,SPS-^V]LM\M5WEY<=+HBI@*\
MEA)?9:;2Z[`=04HBT0)]2EMDQD!!^YK5E#?H4GMQ<(ZS[81DB%9H&8WCK.[3
M\HRV+:XY<3;X$6L8K,#(+46F&K<E(B-,K25C+4XSN4465M_5&0F)X"X2&^\Y
M:+0WTYTXW<J()/4NV6"=&-D;O)V"GHMD?UD&U;BV:<M.04&(8%F"@W$Y7U#&
M2&+L44K+:7]6IM]LKM!*5PW=:.,BH>?`W!L]CW1KTA9:#.A5.K[MQC\QNQ3+
MEN4=4)$J'#W4)D42(2X(40NNP9+K#O9>.E8B3R(L1&^IZVYRY*N36Y*;$LVK
MUFI".3&VD$8^@:L[4V?:DBU2[I,X1B9W'W`$L*):VS.$C9GI@?+RF&$*0TRQ
MHK?+?5([3BL5*-.W9C0)J1N,:8K)U/:A7=V)>,*NU]G*I9LUN^U.V6H&S`,L
M&RH8DHR40/5AR%N<P3&66,[D5#(?5-;5/[=;@T"O;UUP%YN8A";G?)W;:J7W
M<"M2U6WGN'$C"Q%EM%HM)IRXIVL[J",RH<WDDB5'&`D77DCNNBD,7:173;OZ
MN?93<SAQO.WM/X@:3NI1=P.(G?C?B-M='@(.WTRKS&[W#'=^'>&J=8;5N#=$
M+'VH"O8DW$DO2KQN'(X9K.6\JP2EB-:T1:$H7U2E7)CMQ[EN]O!L8S88G<GA
M\D)14)6X[<.KUIWAMX=)K:)N+W6LEG-HATY;=R)6["6>V*<%ALF%!BN8;0LA
M#H[%N"A>MG"CPV*X6Z1*;<QEIB9^H/28DO`1X%.)K94$6F+%A)-),H7;K2?8
MFI<*&!*6X:M9B)-9SB7^I/@Q\94FNU2MW7O<W;?:V.CIC<[<&D;<Q,Q*Y@HF
M4O=L@:A'2DVF(EK!F'CC;`?'C&RN(&`/-R.TI3W5`GWN;T;+BDQ2O(BQ><XA
M-@JQ(R,/9-\-H*]+Q$[ZK2T7.;ETN)D8NSYKE=N/JY(@GS0Y(4[ZHV^)E>IN
MI21V;*"$\SH265KFAW(K[4MV]J;_`%Z9MM$W-V]NM4KI4N#8+-4KI6['7H(Z
MOJ?1/!S,U#R1D;&%0BQG,%MONH6-EM6',)YN>10[D5XLEZI--@%6NWW&JU6K
M(%(.79;)88F#@$`B11DZ48J8DRQ8Y(HT)'$&..9<YB!6''<YPVA2L0BNLW.P
ME9B3IZR3$57X.+8R5)S4W("143'#)RE*B#I$]X<,1A*E8QE;BTIQG..[HBL$
MEN1MW#5Z;MLQ?:7$U2LRI$%9+-)6F#!KU?FQ)5J"*AYN:*.:C8F5&FWT!N#O
MN-O(+6EG*<.9PG2B*_RT["0+83LY,14,U)RL=!1SDM("1S<A-S!*`HB'"68\
MRDJ5E#'$M##MY4\^ZK"4)4K.,:(L6JVZ^UMYD"(FD[DT&XR@O:76HVK7&NV&
M0&[%S")F.L!Q,B60SV3FRQV"><G'09D!N?S>G:YTT.Y%ET9+1<V&B1AI*/EX
M]UTIAL^,,'/#<?!+?`-904(XZPMT,X9QEU.%<K;K:D*Y%)SC$(KAHB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*,&QG\;,_P!LRO\`7BM2>4?2
MK.\'N!2?U"JO_]+[?-\HIZ1KIB&D95E0[F,8QC_^E6-3V59G9"VK2C!#ZA6B
M0GVR!U0<8VEQM6%8PXP&TP^RO&,YYCS#S:D.(S^$A:<ISC&<9U"JO/?>;@:M
M^YNY&^UR"W!C``MW$MBPR92`)EYW;9%BVKVTVBL-BVLG!;!`*H=NC!MO>U2G
MW1YAF;0L8/"`^@<=>L';`BE?Q0[$-<2FREJV?5:RZ,_83JE(AV\",3+'P9-5
MN$#:N<('F0B5K[5'AG`'LH)95U8MS'+G&<I5`-#5%#_;/ZM@;;:_A7AC>F6E
MV8^%N-;!@'ZH4$''P!</N]M[MI&`.BW?F=6HNREZK-9/;)9*'G%4*).2U'NH
M;;'DNJ*(M$R/U/T[AX#%3XH4T4.!CZX!5/5C9?,7,55N/KBXBT,0\U&;LQRV
MHBZ3#KLH0`IK(C!I13R$**+)*=G'O"+8^Y7U54-N#M-NSM4O=>-P+N/?YBY1
M1]IVN7<`*LQ)PN]M;&Z6M.[B0\3*W2&K^]*PQYX7LMW(\'&LN#K8&::;C%R(
MLTH_U<3E)EN(\\7?2<<$WSBM]8&KQ8-5*AA=I*SN_:Z]8(&DP8X=X5'2U$VU
MCJPR!'Q^!@7$(/DLAOQ[1RAVF+DV(HN3?U.]LO%HM\Q8-^:Y6D![Y;D[D;>R
M$#M.1)&,0&ZO#]MUMH[&ACE[DB*I8NR=AC9AC;8)I^0Q5XY+:E/&*)=0W.+M
M(I$;<_5D(IEV3<IO>9BTMYCJC"9KB=L\QL(%`U_A\XB=B;)#0C,AN#8W8T'<
MX_>X"WV-M:B&I.SPA!+B,]HL]F075["*MVJ^K>D=L=L3MN\[SP=B;?8VB:PT
M9M`Z/2[`C:_=R?W37'[CTA6YYN+G`$`S3-9B@V)"*S$5N,"#><D$,\BF+;6B
M+JS]7S=*QM??JO7]Z#+;/6HF@M#1<W&RT'1)IBO[MSE\GK#NI#DVRV2&X]RE
M(*U.1A!F2X[!L9!Q0:D-X84\IBVA%KH;ZI)0Z[<1](5U1UWD&BI8_&UN4%0\
M6)7MQ(4:ETYW&Y&5PE"*^,/JYT61D]LB%@X@%I0Z@LE.SCY-B*U;E?4]AWVM
M;AU&/WY&K%=W`H4Q2TQ#&T#9L=4RS+GFS@6>K1S&Y,5'!2SU=CXNH2V5LN*D
MJ:"J,:6$AQIP<'=I%OFN_5Z'5VBNU%.\,?,$/[N.;HFN3>V\F35)U6=N+_0!
M1['3!-T06BK1'&7AB<'FP3(YQJ7K\0]@?G!-YU&+;R(H_(^IZ4PV@S._\-8[
M,%,;5RT3/[B[&MW]L1[;_:[??:VRFDPTMNHR`[,[F#;QBS,LX-U,%^?@L&$!
ME9+6AF<7:1;#V9^J[D=J]PCMP)7B#=N9KJ=N`8P5_;0J-<A:_0N%3>7AF,KH
M,B;N;8241EI(W,B[$2VG"&L$5H<=3;JEM%B075%*(L0$^J3F1XH`'/%%.)*;
MF=GIB2-;HMBD5/L[04QFEO5:-)MV\MKGQJ1O+%!"!7N,/D)1,O!1X44`N)$!
M"2/./M(NXKZHD%QVL.A[Z)"5"R9<Q,YSM@0<]9CQ]F2=JJ6](&F[FO2#RMN9
M`UZ6A%EO'/@\_J[+C:^<4IC[2+6>?JD-S8F[[?PE>WNKWQ5UY.P$Q(RS],+"
MF(D_93AONVR5UK->J+-H+CL5OB.N,Z'8KH-DQM,V*^6.^^V8$P;*,7:VHI9U
MOZOF5HVSVW.W5*W>KPUKH>[%\W++OEIVGE+4W90KOLAO1LDQ5#X;XVH>>6-4
MXG>!3L:05.&]"/&MB9:RAS+C<8MI-$6HP?JDV8PZ8+8XE+H>U-[-[K[=%"3%
M3:9;3;KW,6^1JUQ-=I]NII-UJM3C+?F*DJQ:UV(>RQ$7'`$EL@!H%S.+M(MW
MO\`AOK?/6J/WA;C56"#XG(4U+-"-?D^AXA]SN)/<L%@>0)W$<CXR.H\AQ"IP
M0@`$(NPDP`CQ9*&VPQ@(Q=I%IFS?5/B6+8BV;+.[RPKKEHEP['FQS6S;4V(#
M:TUG>NG2=SQ75;D!9)N1=>W=':'D^O-DC+@!,KR^US669Q;:T19Q!?5H,0)N
M_#[&])C@.[H>_@E5BT4=T,':T+>*_@WJMU",##O3,;-;8[;O13.&(3(P;CYK
MQA(I<:DGJ[<8N38BTUOY]3^7OU7=X!)3B)CZ_:]Z;*[8+/80-EG3(P80V\SU
MXE:G'P1&[;<DNH2AQL<IT(B4?2LN+02O*U9:0/(?2FQ%M/;SZLDFB;A5^^/[
MX#67,/N!2[R_%2FUY/0MDTJW-6KM"JYSN:_'TZ\W5G"8RR38X;N)>,`C&<B-
M=0QEZ,2+"]Q_JHYN^S<?)"[_`-7@XR'VQMVTT)7BMBI&V1U=K%JF=O)A1%45
M8][2WJ68"JA(8&CX;,?5XAI;*H.(AGF7G2YQ=I%BD)]3J;"0+T6/Q'`]H,E6
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M>3A6%)SCNXQG[N.3_P#7ETY?I2I!J%H`O:ZQ1!)#U4L$U`H)<4Z\Q&'/LB/.
MJ3S.E=#PO(KCN$]S"E(RK'<[NI^D*U6E6W-.W<_8W"LV/_G-Y_\`HZ5[2FC4
M]3=W/E"LWAF_%:5[2B@3U-W<^4*S>&;\5I7M)0+]Q3MW.7N[@V;./Y=O'_T<
MZ5[24&]<O4[=KY0+-YPCQ&E?NI0;PGJ=NU\H%F\X1XC2OW4H-X3U.W:^4"S>
M<(\1I7[J4&\)ZG;M?*!9O.$>(TK]U*#>$]3MVOE`LWG"/$:5^ZE!O">IV[7R
M@6;SA'B-*_=2@WA/4[=KY0+-YPCQ&E?NI0;PGJ=NU\H%F\X1XC2OW4H-X3U.
MW:^4"S><(\1I7[J4&\)ZG;M?*!9O.$>(TK]U*#>$]3MVOE`LWG"/$:5^ZE!O
M">IV[7R@6;SA'B-*_=2@WA/4[=KY0+-YPCQ&E?NI0;PGJ=NU\H%F\X1XC2OW
M4H-X3U.W:^4"S><(\1I7[J4&\)ZG;M?*!9O.$>(TK]U*#>$]3MVOE`LWG"/$
M:5^ZE!O">IV[7R@6;SA'B-*_=2@WA/4[=KY0+-YPCQ&E?NI0;PGJ=NU\H%F\
MX1XC2OW4H-X3U.W:^4"S><(\1I7[J4&\)ZG;M?*!9O.$>(TK]U*#>$]3MVOE
M`LWG"/$:5^ZE!O">IV[7R@6;SA'B-*_=2@WA/4[=KY0+-YPCQ&E?NI0;PGJ=
MNU\H%F\X1XC2OW4H-X3U.W:^4"S><(\1I7[J4&\)ZG;M?*!9O.$>(TK]U*#>
M$]3MVOE`LWG"/$:5^ZE!O">IV[7R@6;SA'B-*_=2@WA/4[=KY0+-YPCQ&E?N
MI0;PGJ=NU\H%F\X1XC2OW4H-X3U.W:^4"S><(\1I7[J4&\)ZG;M?*!9O.$>(
MTK]U*#>$]3MVOE`LWG"/$:5^ZE!O">IV[7R@6;SA'B-*_=2@WA/4[=KY0+-Y
MPCQ&E?NI0;PGJ=NU\H%F\X1XC2OW4H-X3U.W:^4"S><(\1I7[J4&\)ZG;M?*
M!9O.$>(TK]U*#>$]3MVOE`LWG"/$:5^ZE!O">IV[7R@6;SA'B-*_=2@WA/4[
M=KY0+-YPCQ&E?NI0;PGJ=NU\H%F\X1XC2OW4H-X3U.W:^4"S><(\1I7[J4&\
M)ZG;M?*!9O.$>(TK]U*#>$]3MVOE`LWG"/$:5^ZE!O">IV[7R@6;SA'B-*_=
M2@WA/4[=KY0+-YPCQ&E?NI0;PGJ=NU\H%F\X1XC2OW4H-X3U.W:^4"S><(\1
MI7[J4&\)ZG;M?*!9O.$>(TK]U*#>$]3MVOE`LWG"/$:5^ZE!O">IV[7R@6;S
MA'B-*_=2@WA/4[=KY0+-YPCQ&E?NI0;PGJ=NU\H%F\X1XC2OW4H-X3U.W:^4
M"S><(\1I7[J4&\)ZG;M?*!9O.$>(TK]U*#>$]3MVOE`LWG"/$:5^ZE!O">IV
M[7R@6;SA'B-*_=2@WA/4[=KY0+-YPCQ&E?NI0;PGJ=NU\H%F\X1XC2OW4H-X
M3U.W:^4"S><(\1I7[J4&\+CFG;M_L;@V;'_SV\__`$<:5[24&]?GJ;NY\H5F
M\,WXK2O:2@3U-W<^4*S>&;\5I7M)0)ZF[N?*%9O#-^)TKVDHU5;>V=OF\M,V
MBTS\R&A;:\A&GO=16MM>5H6Z&VIL9YQ&<\N%+3G./V,Z5W!*M"WU78`>"#;'
M90E/,3A/<QC&.Y_LQJ.3Z54G$>TLCT1?_]3[^-$7%7['_#_\7_\`+4CNJ#W%
MP\%JW.HYD\%ISIS)X+3G3F3P6G.G,G@M.=.9/!:<Z<R>"TYTYD\%ISIS)X+3
MG3F3P6G.G,G@M.=.9/!:<Z<R>"TYTYD\%ISIS)X+3G3F3P6G.G,G@M.=.9/!
M:<Z<R>"TYTYD\%ISIS)X+3G3F3P6G.G,G@M.=.9/!:<Z<R>"TYTYD\%ISIS)
MX+3G3F3P6G.G,G@M.=.9/!:<Z<R>"TYTYD\%ISIS)X+3G3F3P6G.G,G@M.=.
M9/!:<Z<R>"TYTYD\%ISIS)X+3G3F3P6G.G,G@M.=.9/!:<Z<R>"TYTYD\%IS
MIS)X+3G3F3P6G.G,G@M.=.9/!:<Z<R>"TYTYD\%ISIS)X+3G3F3P6G.G,G@M
M.=.9/!:<Z<R>"TYTYD\%ISIS)X+3G3F3P6G.G,G@M.=.9/!:<Z<R>"TYTYD\
M%ISIS)X+3G3F3P6G.G,G@M.=.9/!:<Z<R>"TYTYD\%ISIS)X+3G3F3P6G.G,
;G@M.=.9<D_=_]S_X?NZ@]U2.XN>JJ4T1?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETUBK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="1">24 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>May 16, 2006</div>
        </th>
        <th class="th">
          <div>Oct. 12, 2004</div>
        </th>
        <th class="th">
          <div>Oct. 16, 2013

</div>
          <div>IPO [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 11, 2011

</div>
          <div>Series D-2 Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2003

</div>
          <div>Series A Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 12, 2004

</div>
          <div>Series B Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Series B Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>May 16, 2006

</div>
          <div>Series C Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Series C Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Series D Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 16, 2008

</div>
          <div>Series D Preferred Stock [Member]

</div>
          <div>Raven Biotechnologies Inc [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011

</div>
          <div>Series D Preferred Stock [Member]

</div>
          <div>Raven Biotechnologies Inc [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Series A- One Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Series A- Two Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>May 16, 2010

</div>
          <div>Series D Two Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 19, 2008

</div>
          <div>Series D Two Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Series D Two Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Undesignated Preferred Stock [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">18,427,388<span></span></td>
        <td class="nump">34,239,374<span></span></td>
        <td class="nump">71,401,237<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">110,952,217<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,916,110<span></span></td>
        <td class="nump">38,337,678<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 12,014,816<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 34,000,000<span></span></td>
        <td class="nump">$ 30,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 44,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 24,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 16.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuanceCosts', window );">Related offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">238,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">101,246<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">156,788<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares of common stock allocated</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,003,300<span></span></td>
        <td class="nump">13,604,016<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued to acquire entity</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,466,039<span></span></td>
        <td class="nump">14,446,227<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchased shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">518,708<span></span></td>
        <td class="nump">2,875,327<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.65<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Accrued noncumulative dividends on preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.0341<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.0324<span></span></td>
        <td class="nump">$ 0.0522<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.08<span></span></td>
        <td class="nump">$ 0.08<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.0522<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock series</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.14<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.00<span></span></td>
        <td class="nump">1.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.506<span></span></td>
        <td class="nump">1.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ConvertiblePreferredStockConversionPrice', window );">Conversion price of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.95<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 7.70<span></span></td>
        <td class="nump">$ 12.20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 12.39<span></span></td>
        <td class="nump">$ 18.77<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 12.20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption', window );">Additional shares sold under over-allotments Option to underwriter</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering net of expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 83,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
        <td class="text">1-for-18.7739<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">125,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">425,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Undesignated preferred stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Undesignated preferred stock, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Undesignated preferred stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ConvertiblePreferredStockConversionPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Convertible preferred stock conversion price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ConvertiblePreferredStockConversionPrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockholdersEquityLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_StockholdersEquityLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Costs related to the issuance or offering of stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_StockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period, shares to underwriters for exercise of over allotment option.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of equity interests issued or issuable to acquire entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued for each share of convertible preferred stock that is converted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePerDollarAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount per share used to calculated dividend payments on preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockDividendRatePerDollarAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceInitialPublicOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityReverseStockSplit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Product Milestone Payments and Royalty Agreements - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">36 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2005</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2005

</div>
          <div>Minimum [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2005

</div>
          <div>Maximum [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RoyaltyAgreementLineItems', window );"><strong>Royalty Agreement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPaymentUponAchievementOfMilestone', window );">Additional consideration of asset purchase agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10,950,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement', window );">Common stock shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">36,135<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement', window );">Maximum royalty payments percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.75%<span></span></td>
        <td class="nump">4.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement', window );">Payments related to the additional considerations</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPaymentUponAchievementOfMilestone">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional payment upon achievement of milestone.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AdditionalPaymentUponAchievementOfMilestone</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of additional consideration paid under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of potential shares to be issued as additional consideration under asset purchase agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RoyaltyAgreementLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_RoyaltyAgreementLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty payment as percentage of net sales under licensing agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUAAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Lease Exit Liability - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 16, 2008</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LeaseExpirationYear', window );">Operating Lease</a></td>
        <td class="text">2018<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement', window );">Onetime purchase payment under purchase agreement</a></td>
        <td class="nump">$ 5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense', window );">Additional amounts recorded</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts', window );">Onetime payment paid under license of product</a></td>
        <td class="nump">8,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts', window );">Onetime payment paid under license of product</a></td>
        <td class="nump">$ 12,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Convertible Preferred Stock Series D [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued in connection with acquisition</a></td>
        <td class="nump">12,466,039<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contingent consideration recorded as incremental in process research and development expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LeaseExpirationYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Lease expiration year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_LeaseExpirationYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>One-time milestone payment to be paid under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>One-time milestone payment to be paid under agreement upon specified level of sales of products.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringCostAndReserveLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>32
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0"0-LX-*`(``(`B```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,VEUKVS`4!N#[P?Z#T>V(
M%7VX:TN<7NSC<BNL^P&:?1*;V)*1U"[Y]Y.=MI22I80%]M[$Q);.>6/(<Z.S
MN-GV7?9`/K3.EDSD<Y:1K5S=VG7)?MY]G5VR+$1C:],Y2R7;46`WR_?O%G>[
M@4*6=MM0LB;&X9KS4#74FY"[@6QZLG*^-S%]]6L^F&ICUL3E?'[!*V<CV3B+
M8PVV7'RFE;GO8O9EFV[ODWCJ`LL^[1>.O4IFAJ%K*Q-34OY@ZU==9H\=\K1S
M6A.:=@@?4@S&#W88G_R]P>.^[^G5^+:F[-;X^,WT*0;?=ORW\YM?SFWRXT4.
MI'2K55M1[:K[/KV!/`R>3!T:HMAW^73->]/:I]Q'^D^+`Y\NXLQ!QM\W%3XQ
MAP3)H4!R:)`<!4B."Y`<'T%R7(+DN`+)(>8H05!$%2BD"A13!0JJ`D55@<*J
M0'%5H,`J4&25*+)*%%DEBJP215:)(JM$D56BR"I19)4HLDH4616*K`I%5H4B
MJT*15:'(JE!D52BR*A19%8JL"D56C2*K1I%5H\BJ4635*+)J%%DUBJP:15:-
M(JM&D;5`D;5`D;5`D;5`D;5`D;5`D;5`D;7X7[+&=+Y/?/K\]S_N5.:-`^80
M=QV%,Q\*[8N^U;DQGNH?T:=)B+,'>%G[6(XT)W#KW1#2Q(2GT]_"TTC$N'LV
MI$+D8TO/0Q&'A@N>.Z9IB],;OIINH'&>HZ;Z0&\^S8\L_P```/__`P!02P,$
M%``&``@````A`+55,"/U````3`(```L`"`)?<F5L<R\N<F5L<R"B!`(HH``"
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````",DL].PS`,QN](O$/D^^IN2`BAI;M,2+LA5![`
M).X?M8VC)$#W]H0#@DICV]'VY\\_6][NYFE4'QQB+T[#NBA!L3-B>]=J>*V?
M5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L<J61
M,%'*86C1DQFH9=R4Y3V&OQY0+3S5P6H(!WL'JC[Z//FRMS1-;W@OYGUBETZ,
M0)X3.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1R?LB8P.>)MI<3_3_MCAQ(DN)T$C@
M\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````__\#`%!+`P04``8`
M"````"$`.F@U2&D"``#U(0``&@`(`7AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS(*($`2B@``$`````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````O)K-
M;MLP$(3O!?H.`N^UO+NDDQ21<PD*Y-JF#R#8]`]B2X;(M/7;EW`3Q0':Z<68
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M`EM.0'+8:P67BMW'L(V%362!1%8VD1426=A$%DAD91-9(9&-W<D&6]G8N]S@
M-O=L(GM(9,\FLH=$#NR<'&!.#A?-R;D\3\1B@"^1_719GS[A]F:O$%P@89-8
M((G9Y(/@8Y<&5D;8I1%8&V6;@D)34+8I*#0%8YN"05,P-G(,,L>S3<%#4_`7
M-87QX.;-&,:AE[,<#P]/`CNJ!QC5V<7!M6$']0"=G-W'L(V%362!1!8VD042
M6=D(5(A`H[<.[!UC[W*#V]RS$>@A`L-%@V#*QUWYNV)\;/ASC8ZUE)TF%*8)
MSX:PAQ`.[&`<8#!F%P?6AKV/X#82-H(%(EC9"%:(8&4C6"&"C=TZ!GO'7Q3!
M8R!_H_`X])K1X<-X8(>;`,.-L`U"H$$8FX$&(>C9!N&A001V3@\PI\\NVCMI
MTPYQ^2T/Y4V-\XQS/OP:=>IW+VO,?P,``/__`P!02P,$%``&``@````A`#7X
MH7.V!```A!$```\```!X;"]W;W)K8F]O:RYX;6R4F%]SVC@4Q=]W9K\#X_<M
M^!\AF9!.DI+9S*0MNZ3MHT>Q!=;$EEQ9;L)^^KTVP1PCQU.>B#`Z'-W[NU<W
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M$M&2@8H/*DVLWS6R,N2G3G<9J77TM>"@$H!*,.BEJ[(R&!2*>QN4\`256X9Q
MF8)*PP2>Z*O>,"G^:T!MDO2%F4IS^T0A%5QKYNS8S*K*<Z:W];:5V$A!U<"D
MB:[C6%720&#"<Y"9'<LL-=6G)D8:7'Y6HJCC"]NG!&OKXOQX.T4O?DY5EE"5
M10O:3DJ?.'D1'8T.:Q-+)&6:)S>L)-:6;-LD&!T@9JZ%ZCTUJ9Q'C^R5&M(!
M[REBY5IT/G#ZNFCQ*DST(-B3R,@Y[D:<W!XJLXP]*7U(X@,U(TF*UQN-5$X1
M*+>'RSP79D=TG0`J.T/]EOJNZ!X&B7(M,"F)216;Z#/UN])0=V[#6*<5CW4&
MR70M-!=YD:DMY]$-EY1$$RVI\'$[$NE:2/Y3,6VXSK;1G9#4,03+^EO/%)%T
M+297U5/)?U;$8;3X55<[6#A#'%V;Q\&J(`R;2JS;WQDR21WYJ`$.EQ<1>1!"
M/#T+S_X"(UR?*%<H@[QZ%J^KGAKI$4%L/0M;+)6>S<BJ9[':5S$](DBJ9Y%Z
MJP:`CS`<2.KN8L4F.HQ:)\_(K&<Q.]R-.T((K=<#[5`_IN2VP,P08>]$A"G!
MK9"/0K0X"6%*]D$(:\&W$!ZN!4KX00AKP;<A'JQ.ROA!"*O!MT`>=E0/JOLI
MQ\>*H,5),:*,'X2P.FAF.Q+ZE\>*AF>ZP5;U5R,X/I8$+8YVOM,@5G'*DXIF
MU8,#+`G?(OD=G>N$YMS.X.=C1=#BR,_`E1Y=XV4RZU!C<]S7L=[<2`;GFB$T
M@8UQG\Y;=#BVC`#]T.+X7(,ZF+"@8\BF>%"(]K89"Y!B6APYZK3C-C+[.Q-U
M$.+`@KBC0QVVH`G@;48V*4<=9#BP&.[HU$#3%9Z)W8RCUJB#1`<6T<,ZG4@C
MTH&%=.^5TP8*#2'2@85TK\YMRFC2*B.!.MCC`POI7IV[JAG?EQIT0NS,M#A*
M_*T:&A\Q0#,D*+28'KY.42A$IFEA.1JZEY'IL./(8GIX%$5',X0ZM*#NG46I
M`37=#(?2&4(=6E`/3PJ=DR'5H46U-96V9NHQ%Y./4(<-U..F)=!_ZC'+8OH)
MH7ZIA]"&C/'^!Y2K_P$``/__`P!02P,$%``&``@````A`)D!4S6C!```*A``
M`!@```!X;"]W;W)K<VAE971S+W-H965T-"YX;6R4E]MNJS@4AN]'FG=`W#=@
M#K:)DFP54&>V-%L:C6;VOJ;$25`!1T";]NUGF44`.STD-VT"'S__.M@K7GU[
MK4KK131M(>NU31:N;8DZE]NBWJ_M__Y]N..VU799O<U*68NU_29:^]OF]]]6
M)]D\M0<A.@L4ZG9M'[KNN'2<-C^(*FL7\BAJN+.3395U\+79.^VQ$=FV?Z@J
M'<]UJ5-E16VCPK*Y1D/N=D4N4ID_5Z+N4*019=:!__90'-NS6I5?(U=ES=/S
M\2Z7U1$D'HNRZ-YZ4=NJ\N7W?2V;[+&$N%])D.5G[?[+A7Q5Y(ULY:Y;@)R#
M1B]CCIS(`:7-:EM`!"KM5B-V:_N>+%/";&>SZA/TLQ"G=O;9:@_R]$=3;/\J
M:@'9ACJI"CQ*^:30[UMU"1YV+IY^Z"OP=V-MQ2Y[+KM_Y.E/4>P/'90[A(A4
M8,OM6RK:'#(*,@LO5$JY+,$`_+6J0K4&9"1[[?^?BFUW6-L^783,]0G@UJ-H
MNX="2=I6_MQVLOJ%$!FD4,0;1`)P/]SW%AX/24B_5G'041]@FG799M7(DP5=
M`^]LCYGJ0;($9169#_E!'V.L'X4*,2J1>Z6RMJ'=X?$6ZO.R86SEO$!*\P&)
M+Q&B$\F94/E3JNGL@@-V1\^0B;GG]ZMPMJ9@9>VL&N,%T!Z]>H:12\(WO*:7
M"..CBF;6O\6L@J$`,V\L&F7[I,2(0*E&^Z%.)%\2Z6>$9AY><WVF%;RV(3.C
M,^[JUF)$6-\A(64A+`!?1Q(-B6@0<F*D()TC`7/#P(^F;M/\P^JZWK^"#?]&
MV6-$:.^?>)R$@9G\.1$0[GIF`=,Y05P2>A&=`M3<TUO<*]AP;_1UC`BZ#[GK
M!Y1.3=MW5S)'J,\]ZD8&DLZ1D'DN\RD=:ZCY9[?X5[#>^MQHC1@1J/[88&;V
MOR32SPC-O)K=LXWQ\TU&P4;R@S$GN&X1P>0'5'6U;ZR.1$.@JST>&2JIAA"7
M<QY]T#S1+?X5;/@W4ALC,K0^O!E6[_1F;!X-<0EGE_YUA%/.HFF-:?DG,(6N
M+T!/&Q%,78D5&)BA_QDT/^5F"#H#D]5EW%P`.D.BD-%H*J4>A!IA5W<1P8&G
M[:#3QC8$@0P&X=,P,O>79%!!@GLN;+*3NUXDU9#0"R+*IF3I`:A!=WT`.!:U
M`(SLQ009M'='/<J)T>2)AL#/F\#<95.=""@+@DE$#T#-NNL#P,FH!6"T2$R0
MP2%V!SLD]XVUDF@(]REAH8&D&D(98<2;JJ1'H,;=+(+S3[3/=R2"0W(>R:Q)
MAUY")NK'V9V[<*<<]D`RB&"HD[VAB?!I\Z;N70V[V[WCB-2\3[O$X!V93[PC
M8-H;O+]_4_>N!MWMWG$\:M[-.4SF(Y3R`/8/8YDG&@*[K>_-5N@0PUR%N%Y(
MW>E%>B1JZ-T>"8Y*+1)S(L.A2PT.7,P?1#)'/HA$1]Z+!(]F>'*I1+,7B2C+
MULKELSIV>=#!X]7Q2'COJ1_]QO58'175=6>\`2>U8[87/[)F7]2M58H=2+H+
M!CW2X%D/OW3RV)^7'F4'9[3^XP'.Y`*.*NX"X)V4W?F+>L%XRM_\#P``__\#
M`%!+`P04``8`"````"$`6>%*;FX%```8&0``&0```'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6R<F=ENJT@0AN]'FG=`W,?0[+9L'QV6S!SIC#0:S7)-<-M&
M,<8"LKW]5%-MQUTX34@NXH6/'_Y:FDIG^>VU.AC/O&G+^K@RV<PV#7XLZDUY
MW*W,?_Z^OXM,H^WRXR8_U$>^,M]X:WY;__K+\J5N'ML]YYT!"L=V9>Z[[K2P
MK+;8\RIO9_6)'^'(MFZJO(./S<YJ3PW/-_U)U<%R;#NPJKP\FJBP:#ZC46^W
M9<'3NGBJ^+%#D88?\@[NO]V7I_:L5A6?D:ORYO'I=%?4U0DD'LI#V;WUHJ91
M%8L?NV/=Y`\'\/W*O+PX:_<?!O)5631U6V^[&<A9>*-#SW-K;H'2>KDIP8$(
MN]'P[<K\SA:9XYK6>MD'Z-^2O[17[XUV7[_\UI2;G^610[0A3R(##W7]*-`?
M&_$5G&P-SK[O,_!G8VSX-G\Z='_5+[_S<K?O(-T^.!+&%INWE+<%1!1D9HXO
ME(KZ`#<`OXVJ%*4!$<E?^]>7<M/M5Z8;S/S0=AG@Q@-ON_M22)I&\=1V=?4?
M0DQ*H8@C1>!5BCC>S'/\,)JBXDH5>#VKN--5/*D"KU*%.3,G\ID?3'`$WONP
MP.N[RB?#8F&(^XRE>9>OETW]8D`;0!#;4RZ:BBU`^)PJ#.PE>1_E#I(F1+X+
ME5X+TM)"P3VO0^8OK6<HDD(R,3+0XQ>&J41R)D1%"-F4?I&=KR.J#PQ<7$"2
MJ0L7RO9VP9UO6IQ$;SI0;RD>,HY*)$/");[2(1)&JDHV1(+P74;Q"J4XW:LX
M"=KH*OBN0YS$R$"-7A)$4IB,$NDHD>D(Q2?<R'2?XJ25"=&\>`A9J,8Z1B;H
MR]1UO+GOO4>ZK[L$"?A]42&12$>)3$<H/J'KKGWJ:U;`U!^II1@9],=<.V0V
M]8>$SM\HD>D(Q5\PQ9^`J;\YR1\RZ.^..4%D>P1)%"0*7!:2QDX5PIM'D:M>
M)4/@=HP4?^$4?P(F_AQ;O7*,C/07A8%+BB]!X/:MX<(Y2F0Z0K$GAK*K!X2^
M/`5,[9'BBY$YMY]MSWU2P(E*W&C0%`E-!#(=H?B;3_$G8.J/+J/(R/8+HLCQ
M2002)#1WGXX2F8Y0_#%X#GX^@3U-'9+6B"4D4V@[SMRC*92(SN,XDFD1U:68
M#*[*5,PQXQ,`PWE">5PX'FE'"<W[YX4]FY/CB3RNM8K7T2#9QU=1?8I!8;I/
M'"]4GV15B1E"Z)/9,_+83.1QC8ET',FTB&I53`K3K>)\H5HEBW_,$#JG-"*A
M2.1QK57='-,OPIE61;4*5_J"57$6[562M9@A)+,Z8\R^_J$KDZ2UQE%0@V1:
M%=6XF"*FYQAG#S7'9`6*Q1^<$!TT[LWFU[9M>]#$U_2PR5.IIG7]H81J60P6
MTRWC.*):)E-/S!`ZE_5PI=+--/(OKE$DDU>Y'0K5JA@RIEO%T42QZM(9B2%T
MSF[@SJ]_2!,DDKY]R]*X;B"2_:Q#5.-B^IAN'&<6U3CIT)@-!YO0)2-(<A,B
M3_'T!D36P4R+J([%/#+=,4XQJF/2FC$;CCKA8"2^`1$SZ3B2:1'%KT.F*C%O
M>+``Z,?C_BRR8KOTX22AZV(-75K1-R#J=QS)M(CJ]TOSE7-COG+I0BVAL)^O
M@M`?5+,$K@,R\#H^8&E55*]0C]>U/))30=.<TI7900@G9L]Q&6GK1`):CZBA
M03*MBNKQ2\,5;!H/O'IT:9:0S*?GAZ2A$PEHC*3CB-C`%O=R6P6]X@8U;G=6
MO-GQA!\.K5'43V+SF4'!7;[%C?&8+6#/46PN7@[`OO0IW_$_\F97'EOCP+=P
M*@S'T.L-[FSCAZX^]7N)#W4'.]+]VSW\!X+#-J8]`WA;U]WY@[C`Y7\:Z_\!
M``#__P,`4$L#!!0`!@`(````(0`D9&:'?P4``%D:```9````>&PO=V]R:W-H
M965T<R]S:&5E=#0T+GAM;)Q978^J2!!]WV3_`^']BJ""8]2;`3*[-]F;;#;[
M\<Q@JV2$-L!\W'^_U52+5,$T>N=A9H33Q3E=U77:9OWU(S]9;Z*L,EEL;'<R
MM2U1I'*7%8>-_<_?3U^6ME752;%+3K(0&_N'J.ROVU]_6;_+\J4Z"E%;$*&H
M-O:QKL\KQZG2H\B3:B+/HH`[>UGF20T?RX-3G4N1[)I!^<GQIE/?R9.LL#'"
MJKPEAMSOLU3$,GW-15%CD%*<DAKX5\?L7%VBY>DMX?*D?'D]?TEE?H80S]DI
MJW\T06TK3U??#H4LD^<3Z/YPYTEZB=U\Z(7/L[24E=S7$PCG(-&^Y@?GP8%(
MV_4N`P5JVJU2[#?VH[N*9U/;V:Z;"?HW$^]5YW^K.LKWW\IL]T=6")AMR)/*
MP+.4+PKZ;:<NP6"G-_JIR<"?I;43^^3U5/\EWW\7V>%80[H7H$@)6^U^Q*)*
M848AS,1;J$BI/`$!^&WEF2H-F)'DH_G[GNWJX\:>^9-%,)VY`+>>154_92JD
M;:6O52WS_Q#DZE`8Q--!YL!>W_<FWG+A+OSQ*`XR:@3&29ULUZ5\MZ!JX)G5
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M,93_`^/?QW#^)@3AKVR<]<CQ-:`&,1T+5N<A8J@.GH<^ANLP(8B.!ZK#G`<%
MYOQ9$PP1XS=K>+F8JA^6!41T%7+V)@1A[T+;N3\-S2BN@W=4#>K2#!:L844#
M(*[%"*%BE+7=75,N&B)IK`O>I#2(BF%,HP$0@\1&"!6CS/!^,6BA5`SO5"Z"
ML,0>_-E0C6E,5W!/"X89AE`MRAF9ECET;/-B<=%/J1:VDD,-0BWN<E"*R9?U
MGL@$H5)`;E?*B`2%Y@N%-UX70?-!U]8WM3YW0%_<CK\ZZ#55E+QRR4X>1LBC
MI]+Y9XX0JAT[*/R$O.%F_,E(2EC988?P;3LE%TV4$/=9$PTUJ%N]@<]Z<30`
MNDZM+IV;'=M5WGB_&'14*J;7:_NV&_B]7ML']<28(#0SRB`[8D9*">V4B'![
M/=;DN;@'=T<AL1%")2B7O%T">BHTBLX^M9<'D_%J":.0V#5!B`3OI^R[&<6Z
MDL^SH4'8>.!H!'[8-D0CNBN(UY,10I4P[S;7D]?W;'_)DZ%!!G[1."0V0J@$
M*._;Z\E3Z+%OI1IDE(!Q#)#8&(5*4#[861*W]5L/W9.L[GX](4@;V7RPH!!B
ME&*"4"D0IBMEI*`4FB\)5LVAAR`#OV@<$ALA5,)==JW.J\8+ZN+(UR[&5$8Z
MCD%E;(10"<S`1[(P9-Q\]^HA2!?2=#ZXY],@HXB;C=M3KMA9%2,BT$/I:N#;
MUB;DQM;==18,+@>3&>/F0X<9EDD3<9=?>P-^[?-]JP8-/QS-;AP2&R%4@K+%
MV].`)@K]PN#7GLEIM8112&R,0B2H$X[;)31HWI3X<M`@///SIX-?YC3&D"EU
MTH_[^.MT71L#:L"3?#SHSD5Y$)$XG2HKE:_JE-Z#KR_MU?8-PJ.GCHC9]1#>
M+#3'\$Y[`P[VS\E!?$_*0U94UDGL(>1T$D"[*O'5`'ZHY;DY7G^6-1SI-_\>
MX16.@(/MZ03`>RGKRP=XL-.^%-K^#P``__\#`%!+`P04``8`"````"$`N?I[
MO/@#``#+#0``&0```'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6R4EUMOHS@4
M@-]'VO^`>&_`&#".DHR&5-T=:48:C79GG@EQ$E3`$:9-^^_WF$,#=BZ3O+2E
M^3C^SO'Q);//;U7IO(I&%;*>NV3BNXZH<[DNZNW<_>_?IX?$=52;U>NLE+68
MN^]"N9\7?WV:'63SK'9"M`Y$J-7<W;7M?NIY*M^)*E,3N1<U?+*1396U\-AL
M/;5O1+;N7JI*+_#]V*NRHG8QPK2Y)8;<;(I</,K\I1)UBT$:468M^*M=L5<?
MT:K\EG!5UCR_[!]R6>TAQ*HHB_:]"^HZ53[]NJUEDZU*R/N-A%G^$;M[.`E?
M%7DCE=RT$PCGH>AISMSC'D1:S-8%9*#+[C1B,W>_D.F2,-=;S+H"_2K$08W^
M=M1.'OYNBO6WHA90;9@G/0,K*9\U^G6M_P4O>R=O/W4S\*-QUF*3O93M3WGX
M1Q3;70O3'4%&.K'I^OU1J!PJ"F$F0:0CY;($`?CI5(5N#:A(]M;]/A3K=C=W
M:3R)F$\)X,Y*J/:IT"%=)W]1K:Q^(T3Z4!@DZ(-0L.\_#R9!$I$H_G,4#XVZ
M!!^S-EO,&GEPH&M@3+7/=`^2*436F847,X.4]#M?]$O=JT`KF([7!8OYS'N%
M$N8]DYXR@4DL3PE*CH@'?D=)2'TL>;[L'W(:A@*[SE&.)OXQ;I=`BDPX8B*3
M6%XC##<8:.RF"TBAP:X[ZI?F+HPQ<AQR1T=D6%=>&D<Q(=R6-)"(4I_$[)B'
M80FICBVOVVG8MK,F+T4F1CM*HHB$QY$[_Z5!1`%AP1##<(-VN]U-P[8;-4=.
MD>G=6`*E&T9&MS$1,,82/K2OX1;?XZ9AV\VJ2HH,NA&>)-1GL:F_-!&?\I@,
M&1IV[!X[#9MV)+#MD$&[B-`@C!)+SB`"DOC^4%O#39]]HXWE>L=IV'8;<L;U
M@`RZ)0&)XY/E,"8X9=R/A_P,-WZ/FX9--YI8"S%%II_5D"8A&]8A=IQ!!/`Y
MNU`W`IO'[87K:-O.:JBTAP:]A%D;XM)$(A:QY)*?=6)<GUB"F[RYTUFU27L(
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MD;+]>-#7_>/7L,7_````__\#`%!+`P04``8`"````"$`,\`KZRT$``#N#0``
M&0```'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6R45\&.HS@0O8^T_X"X)V`#
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M\B0SL./\14*_[.4M6.S<K7[N,O!/8^W9(;N4[3=^_8L5QU,+Z0[`D32VVK^G
M3.004:!9XD`RY;P$`?!I584L#8A(]M9]7XM]>]K8'ED&U/40P*T=$^US(2EM
M*[^(EE?_*A#JJ10)[DE\4-\_QTL<!B@@OV=QE*+.8)JUV7;=\*L%50/O%.=,
MUB!:`;-TYD%\E([!Z_]9!8^2Y$FR;&PH=U@N(#^O6TK=M?,*,<U[3'R/03HB
MN2%D`"5M.KGA@-Y!-(1B*OK7:;AIDV"I[<8:JQO`/8C%AI![A&=H3>\A-!Q8
M-+'>1\1*,&1@HLVC9.#MHA(K#"1KT!_HB.2WB'0.H:F'UTQ#?:N/^9#+11L;
M0C0H]%VS'!2&=L6RB!"./,/$%(`C3`@R;*8:P@O<*!H3J9F`338U,2]>@DWQ
M(Z]*@<*03CQQ(]_,43(%()^X.(QT>ZF."%T4CO8T\>0CXB78%&\$-E88)7X1
M!@'RC-PD&B)`V*.C-K4S%0(2,&1X1&CJJ:[^L?J1BTP7YBY0F-Z%Y_MHLO\Z
MC8E"_%JC<C&'T%S(1CXY)><+2()-]>/9H`I(87KU&`?$'>.GU"O$G/HYA*8^
M^HAZ"=;5>Z&OUVZL,+<*\CV?&#66:`@_C`)"S1-4@U`W(,2EPWLT_0@:TN/A
M[]"Z`Q\9^N(>I"S`V6.(2[3GE.!1F:H<[;E/HK$Z=>6R@SU<.$CUN^FY2<VP
MQ3VH5^[#X6)H2W0$C1`Q:BO5$!0'(1K]Z_IEFYOH?VS[(M4<ISY\\_".>U#O
M`X4A-0[91$,L`DQ](XNICO`C@MUQH^E&9,.;&)G?P4BU1]W`R*RV<`]2!A`.
M280-?8D&H2%US2:7:@@<10A-2E%W(+O=XPXDVMP$1@N*8626H.D9@SS#9O((
M2`[?<TS*B!JOU?19L>;($E:6PLKY18[.&)KI<'<8ZY^PG-N,^[$<]^5]9W@`
MT_8Y.[*_L^98U,(JV0$HW26%+MNH>5U=M/S<S;P[WL*<W?T\P?\J!M.FNP3P
M@?/V=B%?,/Q3V_X'``#__P,`4$L#!!0`!@`(````(0"9@B5W+`,``'$)```9
M````>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;)Q66V^;,!A]G[3_@/Q>S"5<
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M08L$W;F+-$9XM>SR^<WH00ZN+5GRPR?!\J^LH1`V;)/>@"WG#QKZ)==3L!B?
MK;[O-N"[L'):D'VE?O##9\IVI8+=#L"0]K7(GU,J,P@4:&POT$P9KT``_%HU
MTY4!@9"G[O_`<E4FR`_M(')\%^#6EDIUSS0ELK*]5+S^8T#ND<J0>$>2&:@_
MWO=L+P[<('R;!1M%G<&4*+):"GZPH&C@F;(EN@3=!3!K9S/09'3T7O]E%3QJ
MDCO-DB"H=E@N87L>5U'D+?$C9)H=,>MSC#M&;$X(':"F30<3&/3VHB&*H>C7
MM^&D38.UMA/KVDP`=R]V(G5SCO`G6M-S2!3W=D9B_?\1J\%0'0-M?A3VO%TJ
M:X.!S>KU!V/$YDU$>@DQ4@^/N3YJ#4X01-,KFWF3X-8&$W5%X@9SSP^BB?HQ
MPO?G\22!=(3P9J'CO20P4@^5/%2OJ]N'TW^Y8/2BJ8M)A:P-)C0NW"!P)H#-
M$!#$?C2)(1W>]^)H'KX`1@["]SC0BZ8._''*:X.!)/N]<OV7"NXJ;7,%)KV,
M&7F)WN-%+YIZF4V\&,QE+U=@TLN8D1?=V0?OS<L5I<%3#R\5:TZUP1S/1>1$
M<3`?N]R,$*^='&B!^CFGLS4^.4:]:7&F`]14[.B&5I6T,K[7[<N#>NYG^\YZ
MY^EWYV1^#1VWZT^XOP$=KR4[^HV('6ND5=$"*!T[@E(7IF>:@>)MUW>V7$&O
MZRY+^+2A\,9W;``7G*O3`!Z,^X^EU5\```#__P,`4$L#!!0`!@`(````(0`P
M@(AJ7@0``.<1```9````>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;)1878^J
M2!!]WV3_`^%]@$81->K-*#N[-]E--IO]>$9LE0S0AL9QYM]O%05<NG%:9AX<
M@=.'<ZJZNKI=?7O/,^N-ES(5Q=IFCF=;O$C$(2U.:_N?OU^>YK8EJ[@XQ)DH
M^-K^X-+^MOGYI]5-E*_RS'EE`4,AU_:YJBY+UY7)F>>Q=,2%%_#D*,H\KN"R
M/+GR4O+X4`_*,]?WO)F;QVEA$\.R',,ACL<TX9%(KCDO*B(I>197H%^>TXML
MV?)D#%T>EZ_7RU,B\@M0[-,LK3YJ4MO*D^7W4R'*>)^![W<VC9.6N[X8T.=I
M4@HICI4#="X)'7I>N`L7F#:K0PH.,.Q6R8]K^YDM([:PW<VJ#M"_*;_)WG=+
MGL7MUS(]_)X6'*(-><(,[(5X1>CW`]Z"P>Y@]$N=@3]+Z\"/\36K_A*WWWAZ
M.E>0[@`<H;'EX2/B,H&(`HWC!\B4B`P$P*>5IS@U("+Q>_W_EAZJ\]J>S)P@
M]"8,X-:>R^HE14K;2JZR$OE_!&(-%9'X#<D4U#?/?<>?!RR8/69Q25%M,(JK
M>+,JQ<V"60/OE)<8YR!;`C,ZFX(FTM%Y_<PJ>$229V19VS#=8;B$_+QM0F^Q
M<M\@IDF#V0XQ3$7L6@0&$&FCW@T7]':B(11]T??3T&I#,&IK6;=T`[@[L;XF
M9(B8:%JC(22<=RR*V(DJMHVP630.@EG2TQ@RK^.OH[,E#"2M\Q&HB-U#1&1"
M*"[@->-#CN"U#2'JE(5,"^"6,";UA)AY]7S2S$>?/%0TPSP>KQG!JN;))%3C
MN26,23,A6LU.H+F.M.>S'S-/43[[BG($Z\KUXB.,23DA&N7,8?-?GGZ(HW+4
M().@#U'TAU_1CV!5?\BT5V\)T]<_6^BS?00F,F,4#]B\>RNCN5X1K'N8:+.'
M,'T/N@-"-#D(H$/T`TPYT"%SK__G]P<H;A9?<8-@W<U4<T,8DYN'B,B$4-0S
M:-G]9(Q;1.M1CU;1!F0R\A@2&2&J%6QJH^<5HQ9H7DH;4+OJJ(G:-4\-!B,C
M1%6/?6^\>NJ2??7#1941J%7O!%K=[!J`T0!QW(>H!K#CC3=`_5$UH*^MC$#=
MTNE/^U58E^VNP=P72)5MA*@>@.8+'A"M5[,6XRTC4+?T>,%"^;OCB$;`9]?D
MM>4L:DCO0U1'V!?'9X6Z:#\KL[G>,7!_#K;OO[Q)RD-(9&11+6!W[%D8N411
M3X49U$5QN-%C!#):>0B)C"RJ%>R2/2OFUL>HI_:S<:?("=05^4S;6NT:%H/'
MR`A1#6"7'&^`>JIJ8%#D2N/U87^DU,?B3H'0"*,C$T1UA*URO"-JK'U'(1N4
M/(&ZDK^SV]C!H?I!$>&Y^W,(>:!S-1T[<UZ>^(YGF;02<<4SLP_[^^YN=YY_
M]O'`IMW?XCD?[[O=`SAF7^(3_R,N3VDAK8P?@=)S0BCMD@[J=%&)2WW8W8L*
M#MCUUS/\H,+AF.DY`#X*4;47^();^Q/-YG\```#__P,`4$L#!!0`!@`(````
M(0"7:5Z66P,``.4*```9````>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;)26
M6V^;,!B&[R?M/R#NR_F01"%5$]1MTB9-TP[7#IA@%3"RG:;]]_N,$XK)"ME-
M$LSCU^]WB.WU_4M=&<^8<4*;Q'0MQS1PD]&<-(?$_/7S\6YA&ER@)D<5;7!B
MOF)NWF\^?EB?*'OB)<;"`(6&)V8I1+NR;9Z5N$;<HBUNX$U!68T$/+*#S5N&
M4=Y-JBO;<YS(KA%I3*6P8K=HT*(@&4YI=JQQ(Y0(PQ42X)^7I.47M3J[1:Y&
M[.G8WF6T;D%B3RHB7CM1TZBSU9=#0QG:5Q#WBQN@[*+=/5S)UR1CE--"6"!G
M*Z/7,2_MI0U*FW5.(`*9=H/A(C$?W%7J.J:]67<)^DWPB0]^&[RDIT^,Y%])
M@R';4"=9@3VE3Q+]DLLAF&Q?S7[L*O"=&3DNT+$2/^CI,R:'4D"Y0XA(!K;*
M7U/,,\@HR%A>*)4R6H$!^#1J(EL#,H)>NN\3R469F'YDA;'CNX`;>\S%(Y&2
MII$=N:#U'P6Y9RDEXIU%`G!_?N]9WB)TPVA>Q5:.N@!3)-!FS>C)@*Z!-7F+
M9`^Z*U"6D?F0'^6CC_6]4"%&*?(@51(3VAVF<ZC/\R9V@K7]##G-SLSVFG%U
M8G<A9`*E;#H8L,%O;QI2,33][S)<O$E8>KNH;M4`:/=FO9&1:\(?>4VOD7C1
MJVAF?=VLS'#P;N]<3,M)4(F!Q]@)>_TN.UO%0-'Z.$;$;I9(IP@M"ECF]I1+
M.#$A1;VSV(E&[A43=\VRB#PW&A=!`_R%OQQ%EPX!SP_BP%_V:VC>(=NW>Y?P
MV'O<ZZK,*P;6[^,;>=O-$ND4H;F/=/>W]8^<--<_BIF*8I9(IP@MBEB/8OHO
M*^%Q#<;]HYBHZY_0B=U@W#]#((C=A?/6'6IW&0*NXRZ6_EL5->_R&!_LD=/>
M)3SV_K8SJ/Y1S%3F9XETBM#<+W7WM_6/G#37/XJ9BF*62*<(+0HXWO^C"!T]
MKL*X@\Z0VH+\,'0\1_^?[W0BBL+%2$/>.F2BE(;KPW$\./=4`.I6H0[=&K,#
MWN&JXD9&C_+&X$$#]Z/];>;!D\?5:'PK;SERW.Y?P"6C10?\#;$#:;A1X0(D
M'2N&S86I:XIZ$+3MCOH]%7"]Z'Z6<)W$<,@Z%L`%I>+R(!?H+ZB;OP```/__
M`P!02P,$%``&``@````A`!]GGN?5"```/#8``!D```!X;"]W;W)K<VAE971S
M+W-H965T-#`N>&ULG)M;<^(Z%H7?IVK^`\7[`=M@&U-)3C7X?IV:.F?FF1`G
MH1IP"DBG^]\?R;*)M4UK0?*0A.W/2[*TK,O&OOOSYVX[^%$>CIMJ?S_41]IP
M4.[7U=-F_W(__/LO_X_9<'`\K?9/JVVU+^^'O\KC\,^'?__K[J,Z?#^^EN5I
MP!3VQ_OAZ^GT-A^/C^O7<K<ZCJJW<L^./%>'W>K$/AY>QL>W0[EZJD_:;<>&
MIEGCW6JS'PJ%^>$:C>KY>;,NW6K]OBOW)R%R*+>K$ZO_\77S=FS5=NMKY':K
MP_?WMS_6U>Z-23QNMIO3KUIT.-BMY]'+OCJL'K?LNG_JT]6ZU:X_].1WF_6A
M.E;/IQ&3&XN*]J_9&3MCIO1P][1A5\";?7`HG^^'W_1Y81C#\<-=W4#_VY0?
MQ\[_@^-K]1$<-D_I9E^RUF;]Q'O@L:J^<S1ZXB%V\KAWME_WP'\.@Z?R>?6^
M/?VW^@C+S<OKB76WR:Z(7]C\Z9=;'M>L19G,R#"YTKK:L@JPWX/=AEN#M<CJ
M9_WW8_-T>KT?3JR1:6L3G>&#Q_)X\C=<<CA8OQ]/U>[_`M(;*2%B-"+L;R.B
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M4E)PB2%N"@7#&JSC!%*=Z`HF[C.D-@DD4DAD?<*:$=_F?8;4I%`1DE_8<"3Y
MA=_Y$S;6J7W#SY)\0P-+&G!IP*,!GP8"&@A%0.[)J>R:Z!)CR4Q\B;%E)KG$
M$(>FEQ@RWF57,/D%9D8<6EQB/GM=ZE,V24A]JNY+3DM]20-+&G!IP*,!GP8"
M&@A%0.Y+4^Z#Z`HF;IEV"$MH(*6!C`9R&BC:0&?(Z'2(U-ALMI0:F]]`4Q94
M-SH_B]UHW3%I1L:MA6!85<[C%FF?)21<2'B0\"$10"*$1`2)&!())%)(9)#(
M(5&H",D\;)TLF4=M&D[?#]G0?C:$-2/#WT(P*M-`PH6$!PD?$H$@K'J9:&BF
M;DW)M810(X)$W"U%GVBV0>ZA!$JDD,BD0AQ+TRTR4^10HU`1DF?8KN@&SW":
M>H8TP4(P*L]`PA6$Z,WI9&+9$[)H\:"&W]68V(YF6T0C@!HA)")(Q-UZZ*9F
M.'1M`"522&20R"%1J`C),SSAU-W?J<<93E//D"740C`JSPA".&+"$E..26X*
M5R:FCCDEBQX/EN)#(H!$"(D($K$@FM%L8IG4,M)QTW0TG5QKVB4L?68XQ/P9
MK$0.B4)%2(YA69,;',-IZAC2`@O!./5XKXT<,M@ONX>G(T>3?@CL=N&^EB<.
M*\SI0R*`1-BMA#Z:$7='W</3D25?$;F@N`MK([H43+J']9'YN>ZODQ^I=-@9
M::;3_9$7U9F`%8V30Z)0$9*->/[L!A_5.#42:=A%`RFN8(D1MT'$'6M.38=F
MASPLXDLBNCUQ=)T,E`%6"3$2823&2(*1%",91G*,%$I$]A#/=75GK^MR%#SE
MVAN4R.Y\T4!*+PD=!>)B%0\C/D8"C(08B3`28R3!2-H@EM8,^AH9]C*LD6.D
M4"*RE7A>C%H)[]9UD4Z3=EYT>EXT4-<GED,F^>4%B*S&78QX&/$Q$F`DQ$B$
MD1@C"492C&08R3%2*!'93CPI1^V$LZ>ZR.7)=B)S^J*!NG8B3EDVB)C"=,?0
M9W15Y6(5#R,^1@*,A!B),!)C),%(BI$,(SE&"B4BFXEUM60F]29-YSA9*CDT
MA=A`2A,)'07B8A4/(SY&`HR$&(DP$F,DP4B*D0PC.4:*"XBE?8X&LHUX\K$[
M)@$;B5RE/!:1:7K!OQ)F7E-X9'D!L9S/*M;[%/<:R+L&\B]`I+``(R%&(HS$
M&$DPDF(DPTA^`>EU0W$!^FP\V4P\*WF#F4024S83V1`M=%6FL_;)LD&:B<U@
M7X!.R<+=E9"9-=%M4HXG$5-G1C?5/JY(@)$0(Q%&8HPD&$DQDF$DQTBA1&0'
M\1QEUT%7;MY$:E-V$LTHZ:K\9^,D@=CU!D37ZZ22G`]Q&Q6!3*V9T3-25\.<
M&/0K!!_7(\!(B)$((S%&$HRD&,DPDF.D4"*RD7CJ\@M&$AE/V4B]C)(J+=H8
M22`B?6F-Z,;.U;O'+Z0DP7&_.:Z88@.,A!B),!)C),%(BI$,(SE&"B4B>XCG
M+;_@(9'NE#U$)J2%KLJ)-AX22)MRO#@8=1'#9ILZ4H[7E-/,C9HQU8F;?5R3
M`",A1B*,Q!A),))B),-(CI%"B4A6,FY+;->XO%NS-?(%SZ*!%&/`LD%$[T]G
M[!M2LN5S)6+&OD4UR&K>DP@V)\YTC<RL/JY)@)$0(Q%&8HPD&$DQDF$DQTBA
M1&0+7<IKXV2DT<]KVQK),RX:2&DEH2/6/<Q(_(<LC;"*AQ$?(P%&0HQ$&(DQ
MDF`DQ4B&D1PCA1*1S<1FIR],;>SM")I%LC6:BFP@I9F$3A=AKS%0._6ASWUG
M/45ZN"@?(P%&0HQ$&(DQDF`DQ4B&D1PC_%V8W^=QA)W$NR[BY8!=>7@IE^5V
M>QRLJW?^'@O[TN[A[AP^OV3S;<J?("?QI3YG3^7WXZ$^9X_5]^,Y>UGG4GQA
MS!<7]8TY>S*UK^,:<_:`:C_N&7/VG&H_[AMS]KAJ/QX8<_;4*HN/SQ?&WMUY
M6[V4V>KPLMD?!]ORF;6)-K)9>NP@WOX1'T[56_U.Q6-U8F_MU/^^LK>T2O:B
M@C9B\'-5G=H/O(#S>U\/_P```/__`P!02P,$%``&``@````A``RASF8B!@``
M.B```!D```!X;"]W;W)K<VAE971S+W-H965T,S4N>&ULG)G;CJ,X$(;O5]IW
M0-QWP)"0@SH]FC3AE*RT6NWAFB8D01-"!/3T]-MO&1."C<>5S%P,'?MS8=?O
M,F7[^<N/_*1]3\LJ*\Y+G8Q,74O/2;'+SH>E_L_?WM-,UZHZ/N_B4W%.E_IG
M6NE?7G[_[?FC*+]5QS2M-;!PKI;ZL:XO"\.HDF.:Q]6HN*1GJ-D791[7\+,\
M&-6E3.-=TR@_&99I.D8>9V>=65B4]]@H]OLL2=TB><_3<\V,E.DIKJ'_U3&[
M5%=K>7*/N3PNO[U?GI(BOX")M^R4U9^-45W+DT5X.!=E_':"<?\@XSBYVFY^
M#,SG65(65;&O1V#.8!T=CGENS`VP]/*\RV`$U.U:F>Z7^E>RV)*);KP\-P[Z
M-TL_JM[?6G4L/OPRVVVS<PK>!IVH`F]%\8VBX8X606-CT-IK%/BSU';I/GX_
MU7\5'T&:'8XUR#V!$=&!+7:?;EHEX%$P,[*:;B3%"3H`_VMY1J<&>"3^T3P_
MLEU]7.JV,YI,39L`KKVE5>UEU*2N)>]57>3_,8C03G5&K-:(#;UOZZV1-9N0
MB?.`E7%K!9Z=E;N[`)UMQ@'/KO'#XW!:(].^D8?'`:'5=`6>75?N'L>\;0S/
MKO'#XR`PC9BJH,S-S+TC,=@<:::<&]?QRW-9?&@0QS`+JDM,5P6R(&":3K8Q
M>)Q-C6[Z_6SVP8RA5KY2,TL=W`/-*PB9[R\.,9^-[S#-DY99R1C",Z]7ADY%
M:M@5"]9B@2<6^&)!(!:$8D%T+;AU7^C8YDI<.[;M%1C@R\ZAX$/.H?*HO?J-
MTM1O5[,K5@#&.T=:@HN&A$,$QI4Q-F]G+6/&/.,-&5MPC#]$'#+AS00RQN&9
M4,9,>28:,L+`-T-"[/!VB$QGW7LX*6'M>T!*2L-2VU..C,408`RLAIVZ@JM>
M4<)%B35*>"CAHT2`$B%*1"BQ08FMBN#D!+<_(">EESI,EDXJ8@KS<<68:;/>
M/=F6.3%-0?'7/N(XYGA`N'WBR9H/B35'V#:8$5_C<8A%)#WQ^XCEF&1@).@3
M]F0\?$W8)\8PX(&-J$\\P6MFMC##-WUB9CMD.A&(;9]PIF1*K)M7.47A.\4I
M2C]>-GPHU6LN;<4K:TV%A6_%&.A(I[[0R5>4<%%BC1(>2O@H$:!$B!(12FP8
MX;!8D.O*(4IA(6O[!6%I*U%8,609HQ(6)5R46*.$AQ(^2@0H$:)$Q(A6-FF\
MHC:V*H*+5TC"?T%6VDJ4]?;%;M+$%6-4LJ*$BQ)KE/!0PD>)`"5"E(@8P61U
M9N.I,Q<"8=,G""S3UE3(R+8\84T<\Y9M<;+2@X?^'D*]_%):E'/>)6!,3L;,
MV6)BCB"1XOX).>AK'T=IMT\_P1Y:6/O77+TUF@N)L\?5D]'\YI6F\SZK9UG!
M[</5U`6*NE!1%W'O-$>FT.>-HNU67L<I"%O3!Q2D-*_@,#5B3+NNR%.C/B)/
MC?J$/#7B"'EJQ"&6-#7J(_+4J$_(4Z,^(4^-^H0\->H3\D]HGU!^0>EY`2?I
M=6.O#LZF&:^M-1/";=5"JM461UP<6>.(AR,^C@0X$N)(A".;%E&F23RC5IF>
M0O27WOLR8,(.+_J;&VLJ?"!6+:14F=E1("YN98TC'H[X.!+@2(@C48NTNSYI
MRH1;V2H1;FVFIW*_HC$[Y^`U%M.FQC8<^"GV.3CBXL@:1SP<\7$DP)$01Z(6
M4>5/'")/H`1$D4$1>HC1CV-DE69G'IRV,R$-634V$6U59R=-PN+B5M8XXN&(
MCR,!CH0X$DD08@N!L;D'VB(0'\408YS"=Z[4M)GX/182TA5AD#**4<3%K:QQ
MQ,,1'T<"'`EQ)&H1910SOS#D)U',(ZHHI@<<_2B^4V-V+L)'LY#@K^@%($R$
MN[=$'`\;!B&'<[EZV2Z(!R3;(!Z0[(-:0+X14E6&JLJ(?Z]D+Z1J32]NJ1_%
M3K%895>R['XL3\M#^IJ>3I66%._TNM6&[6A7VET%?[7HY8U0OB(+N&0:ED?T
MZIB6&UT#N+F]Q(?TC[@\9.=*.Z5[>)4YFD(_2W;WRW[4Q:6YK7LK:KBS;?X\
MPAU]"I=DY@C@?5'4UQ_T!=VM_\O_````__\#`%!+`P04``8`"````"$`N$V&
M\54%``#4&0``&0```'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6R4F5]OXC@4
MQ=]7VN\0Y7T(3B`0!(P:K.Z.M"NM5OOG.0T&HI(8)6GI?/N]-S=0VV'MS$M;
MPL^7>^P3G^"NOWZ49^]=U$TAJXW/)E/?$U4N]T5UW/A___7\9>E[39M5^^PL
M*['QOXO&_[K]^:?U5=:OS4F(UH,*5;/Q3VU[605!DY]$F343>1$5O'.0=9FU
M\+(^!LVE%MF^&U2>@W`ZC8,R*RJ?*JSJ,37DX5#D@LO\K1152T5J<<Y:Z+\Y
M%9?F5JW,QY0KL_KU[?(EE^4%2KP4YZ+]WA7UO3)??3M6LLY>SJ#[@\VR_%:[
M>S$H7Q9Y+1MY:"=0+J!&AYJ3(`F@TG:]+T`!3KM7B\/&?V(K'B9^L%UW$_1/
M(:Z-\K?7G.3UE[K8_U94`F8;U@E7X$7*5T2_[?$2#`X&HY^[%?BC]O;BD+V=
MVS_E]5=1'$\M+/<<%*&PU?X[%TT.,PIE)N$<*^7R#`W`3Z\LT!HP(]E']_M:
M[-O3QH_BR7PQC1C@WHMHVN<"2_I>_M:TLOR7(-:7HB)A7V0&W??OAY-P.6?S
MV%TEH(XZ@3QKL^VZEE</7`.?V5PR]"!;0654-H.>J(^[UO^3"AJQR!-6V?A@
M=QC>P/J\;V.V7`?O,*=YSZ1#ANG$[D;@!&)9KEP(H-][TS`5:M./E^'6&\+8
MVZUJ2A>@]KW9T&AD2$1&KWR(+#X%:\U&>K,XPQ$XT-XT#MKX\"'W'N.IWF1*
M"*S9'9GKQ,Y)<!NAB8"/46?\9A.["!P$8I4.8Y;H/:;$V%0X"6XC-!5@;%6%
MO7N$C24(S34@1NV>19\VZ$R\(R;N[HH0;E;&9OH<<!NA]1_K_8^S$@XR=>@-
MI(2H,DPK.0EN(S01BZ$(W''LBX&#7%8BQJ;"27`;H:G`:%?V37OW")M+8%J)
M&+7[H96((2M%21@N3"=9`*W[1.]^G)%PD*$B,HQ$B"K"-)*3X#9"$\%@%U77
M8-RFU(UR6:F';$+<"+<BNA1,NM%V8I2+6CH,MJ8>4B4,#=5#Y*A9%,73:*$O
M*;<BN@C,1$7$.%<Q2E)-C&'KM&=4+::OW`BW(KH2S$5#B7N/8I2F]KSK(:L4
MJF-!N+6*+@7*J%+L&Q5#VKC'A\XB2.WO@;,((F?-DVF23&/3639$%X$)::R'
M^QD*G]`'8HSGN+2'5#$#:U$="\*M570IF).&E!'6HG1U6,L6P?0LPIP(MR*Z
M%`Q+18K#6A2MVGT^M-8P?Q]8BR"RUB).9K'QR,69A=`E8&`J$D9N612SFA3#
MW"DCQF*:G1OA5D17@K%I*!GA*PI;AZ]LB=S[RHEP9D,T*:&1ZW9?=;1KR^HA
M=36&ONJA_O$J2EB2&+L%MR*Z""/1QSDK?)3LQK?3M(=4,>:6Y4:X%=&E8$+_
ML+5"'.5ZSNHAJQ2J8T&XM8HN!:-5D>*P%@6Q=I\/MJR0('(-B]@R24QFUS.J
MAH']N`/2=4"I']"!M'Z+S)>&9=*0(+5'`]FY$6Y%=`D/,MV]8>%)E]M5SL#>
M]74L:KD5T:48F>YP%66PPU7#H!XX9A<2U%MO.5TLC0=G;B-T"9B8XV\,RE==
M@OE=,"3(,L4[-\*MB"[A09:/,!3EM#T!0W>8NQ%N170IF)7C5X.255\-\W@!
MCL?QQB&OA!&+DH6![#0D"F=`&-&#A^Q*E>5R/F.?WQ=)`AVBTQES*>JCV(GS
MN?%R^88'Y"$<@]VOW@_OGT(\G36NIW"HWYV`!_<WX$S]DAW%[UE]+*K&.XL#
ME)Q.%G"_UW0J3R]:>>E.ME]D"Z?IW9\G^.^)@#/EZ03@@Y3M[05\<'#_?\SV
M/P```/__`P!02P,$%``&``@````A`%2=O<='!```IA$``!D```!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&ULE)A1;^(X$,??3[KO$.6]Q(Z)0Q"P6JAZM]*M
M=#K=[3ZGP4!4$J,D+>VWOW'&A=C)FO`"!'Z>_#U_>R9F\>6].'IOHJIS62Y]
M.B&^)\I,;O-RO_3_^_?I8>9[=9.6V_0H2['T/T3M?UG]_MOB+*N7^B!$XT&$
MLE[ZAZ8YS8.@S@ZB2.N)/(D2?MG)JD@;N*SV07VJ1+IM!Q7'("2$!T6:ESY&
MF%=C8LC=+L_$H\Q>"U$V&*02Q[0!_?4A/]6?T8IL3+@BK5Y>3P^9+$X0XCD_
MYLU'&]3WBFS^;5_**GT^PKS?Z33-/F.W%[WP19Y5LI:[9@+A`A3:GW,2)`%$
M6BVV.<Q`I=VKQ&[I?Z7S3<C\8+5H$_0C%^>Z\]FK#_+\1Y5O_\I+`=D&GY0#
MSU*^*/3;5GT%@X/>Z*?6@;\K;RMVZ>NQ^4>>_Q3Y_M"`W1',2$ULOOUX%'4&
M&84PDS!2D3)Y!`'PZA6Y6AJ0D?2]?3_GV^:P]!F?1#%A%'#O6=3-4ZY"^E[V
M6C>R^(D0U:$P2*B#,%"O?P\GX2RB$;\=)4!%[00?TR9=+2IY]F#5P#WK4ZK6
M()U#9#6SZ2]G!E-28[ZJ0>U0H&NPXVW%P^DB>(,49II9]YG0)#9]@M$+$H"^
MBTB8NBV2@8G#Z?\4J09!HGWO*I)<X[<362,S[3#114%+;%R$H1%NU-7HUJ;@
MI0^Q+]H88>:=U\C$;7I#$O$9X8F);+H(C3F)P^0:Q5`'4QRO3L&V.MM>9'BK
M[H%&$0MG++;DF<R4L62:7!E#'RRY\?H4;.F;F;=>(X+R(L*BD-FKKTNPD,=Q
MPB\Q#&G\'FD*-J5Q0BYQ<=$A`\FYF&\O.A=A:(M-;6KWWMX8:M"MC8&,2Z.+
M,#2J)MBI,.Z-H6`S?_V-@0QZ&[(X"2-K<6X,@A`6DU]XF]RC3<&F-M[;M,BX
M\N8BC+Q1J'#=Q(TSMQUURUT-N60Z$5.GU4+<!E.L^N[2IR&TF$[C>$JO!F)=
M-A$6,C*[%G=3GRKAHQ<@Q8+?U<>)M;[6&G+F#^,,(Z8^JW.,]!EK/[Q>J@CO
MM3>*T+`(G4<78NJ$,'?D4='F;NGO9(J0+M-)PB.K5FY<A*GNK@ZB'MXL=?`0
M9=5I#3FSAW&&$5.?U49&NHR=X(;+KG:A778AIDZKI=S8S=@%NKMEP&6$]&ZF
ME'-.[2<9VF5F,6SYY+H43(%W]1/:;R@\M&K)6D/#+NH$8IQAQ-1G]9211F-;
MN&&TJW=HG2[$T!E:[<5M=$O?VLX:TMN9,GZU$-4Y`%/;72TE[+<43NP'0@T-
M&ZC589QAQ-2GBGNGI8SS.,26X/980\,BM,[1K07.Q(;.&QXK^J;'".&Q9#I+
M6!SW7#:1&>T_?N%)&P^BIW0OOJ?5/B]K[RAVT,[()(:Z6N$Y&R\:>6H/G,^R
M@?-Q^_$`_X<(.(V2"<`[*9O/"W62O_S#LOH?``#__P,`4$L#!!0`!@`(````
M(0`0"#*WF0(``&4&```9````>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;(Q5
M76_:,!1]G[3_8/F]<1(*%$2H2J-NE59IFO;Q;!PGL1K'D6U*^^]W;9.4P-:6
M!XCC<X_/N1]F=?TL&_3$M1&JS7`2Q1CQEJE"M%6&?_V\N[C"R%C:%K11+<_P
M"S?X>OWYTVJO]*.I.;<(&%J3X=K:;DF(8367U$2JXRWLE$I+:F&I*V(ZS6GA
M@V1#TCB>$4E%BP/#4G^$0Y6E8#Q7;"=Y:P.)Y@VUH-_4HC,]FV0?H9-4/^ZZ
M"Z9D!Q1;T0C[XDDQDFQY7[5*TVT#OI^32\IZ;K\XHY>":654:2.@(T'HN><%
M61!@6J\*`0Y<VI'F989ODF5^B<EZY?/S6_"].7I&IE;[+UH4WT3+(=E0)E>`
MK5*/#GI?N%<03,ZB[WP!OFM4\)+N&OM#[;]R4=46JCT%0\[7LGC)N6&04*")
MTJEC8JH!`?"-I'"=`0FAS_YW+PI;9W@RBZ;S>)(`'&VYL7?"46+$=L8J^2>`
MD@-5($D/))>@_K"?1NG5-)G.WF<A09$WF%-+URNM]@B:!LXT'74MF"R!N7<6
M=`Q>_V<5/#J2&\?BN<"%@?(\K6?I?$6>(*?L@-D$#$S$@$G&B-L>X1+H:/.C
M%P3T#J(A%<>B_UV&7IL#GVJ[&I^\.<>D8\3M.6)R(C\_A\Q?SQGIGXSUNZ1/
MH"G?]N&"`'>4OW3QRN\3M@D8J..0X^F)CW<1^5N(D0LXYK@*'W/A@C(,J1H4
MSM+%6.,F8!:^CY+HM!)A=QYVQY%P!SCV/C*)1Y_7>@4;8=S#-$BN*W[+F\8@
MIG9NE!,X8'@;;ID-W#)^)LFP`5/>T8H_4%V)UJ"&EQ`:1W,8:QWNB;"PJO,]
MN%46YML_UG"=<^CR.`)PJ93M%^XF&OX@UG\!``#__P,`4$L#!!0`!@`(````
M(0`<@@K>H`L``"-5```9````>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;)S<
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M]GYBAWO(]BC?L<G+OWIVW+`:96%Z?#,V^P^V`>S?SFZ;-PU6(^M_BL^?VY?3
M^U-7T7K#T4"1&.]\RXXG<YN'['8VWX^G_>Y_'$GY1IV#R&40]ED&D92>I`ZT
M.V(H90SU$D/NR>.A-+PG"MOF8G?89[4E;,?OC:*54=AG%87MVHV5,2H79I_5
MPDIO/!RJVGAT>Y6R_"QVA'V647[CN#R40=AG%42^^^!*K$WR)L(.T26,*@]'
MXWL:B<2.+(]S.<3*;VQ.=8BER]%1U/OWJCI,\J71WE[#?9Y%15+JZ]/Z^?&P
M_]EA9SJ6)\>O=7[>E"9YY"H=>?*<$_17^<ER*H_R5Q[FJ<N./4N](SNI_'C6
ME,%C_P<[$6Q*,ZT;212S2N2IFH?5>0'/W;S`H`4F+;"J&)<M&6J*N!Z[,M5Z
MG"K*92%-(1LWKYM:X$7=D"AN7=2B>-Q<5R:)LJQ$M0.K&\+Z=:,ILE@S017X
M4A%DU6$EJE5'5<%ED=H>Q96I%DIX`?OWW%[(>M)*L$7ZK*V>&RQKHT*#;;YN
M5.TRUWF[K%8\K0HN*R95,*N+T5BL);U.:&LQ.-'D(A>4\7A(VJ!9CZ$IQ%C<
M7-?24%/%;;'K1E.(<9K,4(PS;S)D>Q9U0RK/Y4*3?K7;'@RQA&)5%YI*3C9^
MDR$;&]0-$2$4$1?E#JNL%T+J/JZ'T%1-K/ND;LB&I&U"2`]VR1/2(S^?*^R"
MV)XF^5)"FM""&2W0:8'!"UB+KW+-I,3B!6)[)NW0KAN-5)?30!1BYDUF)%;[
MX@;C-AER.O!N,,LF\R!NS^H&X]]@@@:CDE0.FPQINE&3(8<KOL$D-YBTR5R.
ME]#$66],:.+M33O70M.F!3-:H-,"@Q=<-VU*+%YPZ:G8M,"A!7-:L*`%+BWP
M:,&2%JRJ@LOU35/)I=6_P025J9(YI`41+8AI04(+TJL"X8BR'O(=1S37[*1V
MU7?05)*24V[8^L[]"])P9U#H4!A0F%!84-A0.%#,H5A`X4+A0;&$8@6%#T4`
M10A%!$4,10)%VB:$%&'WCG>D2*Z?NJS3<&[^FDJN-E-NVE($"AT*`PH3"HL+
MK>A3#@?%CWCEM*^%-%;E$>MQB\2Y)HHJ*P_*B%SOYM=DQ)X&2;)RN005-Z0+
M3EHJS;T.(DF#AZ$L2R2*!Z,LH5A!X4,10!%"$7'!#X[V(&ELG\6:CZ^%,E:4
MD49OJ!*XFK1-"(G"'I,(B7);!SA?BB3,D.S'E)N68S_C8E0T5$D>2.I8(OU2
M'08QH#"AL*"PH7"XX#NCJ$UI-Q?(0&G(S`5<CWL=1%4?&H)X,,@2BA44/A0!
M%"$4$10Q%[SB977<4"$)#)*V"2%?V&,F(5_:>].YIGE"NI=3;MKR!`H="@,*
M$PJ+BS)?2:;:<'%'6%P\Z<WAT@LH7"@\*)90K*#PH0B@"*&(H(BA2*!(VX20
M%VP(XHZ\R#7-"_(,9\I-6UY`H4-A0&%"84%A0^%`,>>"]QQD)3_/B3FT@"'<
MZQ`2ZZ_1)VL>#+&$8@6%#T4`10A%!$7,!:]1-@PYHIW@!(9(VX20'_DHVQT)
M4G":(>2AU+1$;2F"B8Z)49*RIEC+4UCG16Q]IF@4;<!N",@UPL*KLC%Q,)EC
MLL#$Q<3#9(G)"A,?DP"3$),(DQB3!).TE8BYDP]N78^ZMG>Z)#X6)MS.#\G-
MZ[1$K;G#X[00'4<Q,#$QL3"Q,7$PF6.RP,3%Q,-DB<FJ).69B5W0M(%"GMSX
MHE%559-E\H@AP*L*,8DPB3%),$E;B9@[^5#8';G#1\[$W"'/@J<21RV),<-$
MQ\3`Q,3$PL3&Q,%DCLD"$Q<3#Y,E)BM,?$P"3$),HI+P/!Y*X]&`/)",!2&S
M5ZT4FL0)7D_:2L3$R8?8[D@</B(G)@[I_TPECEH3!Q(=1S$P,3&Q,+$Q<3"9
M8[+`Q,7$PV2)R0H3'Y,`DQ"3"),8D^1,\E?1!CV-G/'3\_>7$9(+$=.&->Y[
MTB;G]#Z'7)RG^9N%#+6F#20ZCF)@8F)B86*7I.JV%,\LR0V5@\/,,5E@XF+B
M8;+$9(6)CTF`28A)A$F,28))VDK$U,E'-Z^O.+>-Q>1O@]=2B%P]IR5J3:&V
MP=7R_5)(#+PB$Q,+$QL3!Y,Y)HN2//!W]'KJX.'Z9VS\01Y<NCBF1V*RX=7K
MGWK,I;#`L">SO\*X^E%J&['"&^%C$@BK'?1HIRP$WT=X%3$FB;"6&W8^;8TI
MYEP^4'J=<^#1`A]7%7MYY'YSFK^XCBY7D.@XBH&)B8F%B8V)@\D<D\69Y/T0
MJ2>)>4$JVCWKIEY)<<;RSJ0(*#ZR7+9]N3I_^<O@/B;!F?`=&@[(+4$H`G$#
MH_.7O]R&&)/D3!KJ(#U_V;0*,57R,=([4H4/J0JIHI$^SE1J&W<MCN`,$QT3
M`Q,3$PL3&Q,'DSDFBY+PRY+6>[CTQXMZ<W$(3P@QZI%N]U+X6F)_K"6VSA5>
M@X])0-="']^%(ACW1F0[([R2&)-$7$UM;]/6$&*BY(.FUXER8S^.C[6*"4-?
M%I#:!F3+A(%$QU$,3$Q,K)+P^YQ1\3*:V(AL',3!9([)`A,7$P^3)28K3'Q,
M`DQ"3"),8DP23-)6(B90/JKZ&PG$!V/%!"(GK:G4-F);)A`D.HYB8&)B8I6$
MOW,S+D;]Z<BKC<,XF,PQ66#B8N)ALL1DA8F/28!)B$F$28Q)@DG:2H04DN][
MW:#@Y#$<_3/0:8FNGR%H]._K9@V(]$QT3`Q,3$PL3&Q,'$SFF"PP<3'Q,%EB
MLL+$QR3`),0DPB3&),$D;25B[MSWNH'<\+H!N5.=EJ9ZWMOX5OZL1-?Y54L=
MOBX>A_V%?M.#8P/',3&Q,+$Q<3"98[+`Q,7$PV2)R0H3'Y,`DQ"3"),8DP23
MM)6(R<.Z7[_1=\OG4J`/L>DHU+1$+0DRPT3'Q,#$Q,3"Q,;$P62.R0(3%Q,/
MDR4F*TQ\3`),0DPB3&),$DS2DO`S-SUOBQE$7SRX[?&!W/`"`OU3\&F)6C,(
MOX"`HQB8F)A8F-B8.)C,,5E@XF+B8;+$9(6)CTF`28A)A$F,28))6A+^P).-
M15T>C8GIPQKW[UR`\L7H'1!YTCB5.6I-'TAT',7`Q,3$PL3&Q,%DCLD"$Q<3
M#Y,E)BM,?$P"3$),(DQB3!),TC/)1X$NXS!B[OS>&PCY+'"UW*%O()2H-7?@
MZP4ZCF)@8F)B86)CXF`RQV2!B8N)A\D2DQ4F/B8!)B$F$28Q)@DF^02/?$2_
M*7?XU(U\EKA==GC+9MG'Q[&SV7_/IV5D;VH_/YZ+^9R1ICPQU7S>'U+.YI+\
MJZE\*DW87&]U;TD3-C=;O=R3)FS*LWIY($W"IO)(FK`IQ^I^*D^F3=LSDR=L
M%IBZU^4)FPRF7F[($S8G#"OOGW>835'YM7[+O/7A;?MY['QDKZRN!KU\`L4#
MG^22_W+:?Q63[GW;G]CDE,5_W]EDI!F;W&[08_AUOS]5O^0K.$]O^OQ_````
M__\#`%!+`P04``8`"````"$`YH=I,14$```J$0``&0```'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6R<F-N.HS@0AN]7VG=`W`^G!$A'24;-H6=&FI%&JSU<
M$W`2U(`1)IWNM]\J'%CL]-J=R442R,=/_54V=F7S^;6NC!?2L9(V6].U'-,@
M34Z+LCENS;_^?/JT,@W69TV15;0A6_.-,//S[O??-A?:/;,3(;T!"@W;FJ>^
M;]>VS?(3J3-FT98T\,N!=G76PV%WM%G;D:P8+JHKVW.<P*ZSLC&YPKK[B`8]
M',J<)#0_UZ3IN4A'JJR'^-FI;-FH5N<?D:NS[OG<?LIIW8+$OJS*_FT0-8TZ
M7W\[-K3+]A7X?G6763YJ#P<W\G69=Y310V^!G,T#O?7\8#_8H+3;%"4XP+0;
M'3ELS4=WG;J^:>\V0X+^+LF%S;X;[$0O7[JR^%XV!+(-=<(*["E]1O1;@:?@
M8OOFZJ>A`C\[HR"'[%SU?]#+5U(>3SV4VP=':&Q=O"6$Y9!1D+&\(8R<5A``
MO!MUB4,#,I*]#I^7LNA/6W,16'[H+%S`C3UA_5.)DJ:1GUE/ZW\XY&)0DXAW
M%8'/JXCK6TO/#U?WJ"RN*G#?4<6SO)7O^H$^%IO[&M*49'VVVW3T8L#8@\A9
MF^%(=M>@/.:'NYDR]G\)`Y,H\H@J6Q,F#>2"095?=F&XV-@O4)G\RD2<@?>)
M"1:>R,2W.JY()".!^<5;I[,3-GB:C$&RY\;>+_@8/\(8_Z@:\1-"L$M'#"6^
M920[R2VQD/RDMTBXFNXC&(+ZSPUAI18P']3&\"+@9DD/P^6D/V0PXLQRQO@B
M$6N)1$ND*D+P"8',?:K](;PU(8G3H`I#*?J(,W-_81A(#F\92271$JF*$!S"
M/)L[_%@E\2+9:2BZB#@3#A/0=X:72,2<F.="]JDE4A4A^`Q$G^I*(BS[^V\F
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M1[#+(4558CV2Z)%4B8AN<1MQ?VWYYD.LK;2GCK#!@Y3P)['K+8/`64C#/;XR
MBHPD>@1;5[S3^RK<+F]-><]5D^Y(8E)5S,CI&=M.#U:+Z>S4$C]ZV(E(YV-L
ME8=F=_H!.M4V.Y(?67<L&V94Y`"2CA5"5!WO=?E!3]NAT]O3'GK4X>L)_I,@
MT#\Y%L`'2OOQ`&YL3_]R[/X%``#__P,`4$L#!!0`!@`(````(0#U5[.=X`(`
M`,`'```9````>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;)2576^;,!2&[R?M
M/R#?EV]P$H54)56W2ILT3?NX=L"`5<#(=IKVW^\8)R1.MJR]23"\?OV<#P[+
MVY>N=9ZID(SW&0I<'SFT+WC)^CI#/W\\W,R0(Q7I2]+RGF;HE4ITN_KX8;GC
MXDDVE"H'''J9H4:I8>%YLFAH1Z3+!]K#DXJ+CBA8BMJ3@Z"D'#=UK1?Z?NIU
MA/7(."S$6SQX5;&"WO-BV]%>&1-!6Z*`7S9LD`>WKGB+74?$TW:X*7@W@,6&
MM4R]CJ;(Z8K%8]US038MQ/T2Q*0X>(^+"_N.%8)+7BD7[#P#>AGSW)M[X+1:
ME@PBT&EW!*TR=!<LUAAYJ^68GU^,[N3)M2,;OOLD6/F%]122#672!=AP_J2E
MCZ6^!9N]B]T/8P&^":>D%=FVZCO??::L;A14.X&`=%R+\O6>R@(2"C9NF&BG
M@K<``+].QW1G0$+(R_B_8Z5J,A2E;H+]*`"YLZ%2/3!MB9QB*Q7O?AM1L+<R
M)N'>)`+Z_?/0#6=)D*3_=_$,T1C@/5%DM11\YT#3P)ER(+H%@P4XZ\@BR(_A
MF&+]5Z@0HS:YTRX9@FZ'[1+*\[S"LW#I/4-.B[TFO]0$MF)]4.A2`-[$")&?
M,OX]ZP<4+=8HN@J:+3<WP'MB.R-;7RJB(YI%`AEZ.XD69PC,IX/Q++)#SHTF
M/M$DMF)]36&Q@<DIVZ&2U[.E-T'%3\['.+8)<J.YQGA-83%"MY\R7F?3XO/\
MG;,9#1Y;+O!]',VCN8V_MB6IC^/Y46+1I>^ATV*;+HZP?71N-.E(=Y.&,YP>
M3QZ;<VTIDBA*4G_RL-CP>]BTV&;#L[.^RHW&9&X>QTF`CR<;ME/%16X-G)F8
M9J!T5-1T3=M6.@7?ZFD80N#3W6E0WX7ZW3R[G\,`'\>=-SV``3J0FGXEHF:]
M=%I:@:7O8JBG,"/8+!0?QC&VX0I&YWC9P)>2PKOONR"N.%>'A9XLT[=W]0<`
M`/__`P!02P,$%``&``@````A`.'O*"=V`P``P0L``!D```!X;"]W;W)K<VAE
M971S+W-H965T-3`N>&ULE%9;;YLP&'V?M/^`>&_`W!.%5*VJ;I,V:9IV>7;`
M)%8!(^PT[;_?9YN`(:5-7I(0'Y_SW7SP^O:E*JUGTG+*ZM1&"]>V2)VQG-:[
MU/[S^_$FL2TN<)WCDM4DM5\)MV\WGS^MCZQ]XGM"A`4,-4_MO1#-RG%XMB<5
MY@O6D!I6"M966,!CNW-XTQ*<JTU5Z7BN&SD5IK6M&5;M)1RL*&A&'EAVJ$@M
M-$E+2BP@?KZG#3^Q5=DE=!5NGP[-3<:J!BBVM*3B59':5I6MONUJUN)M"7F_
MH`!G)V[U<$9?T:QEG!5B`72.#O0\YZ6S=(!IL\XI9"#+;K6D2.T[M+I'B>UL
MUJI`?RDY<N.WQ??L^*6E^7=:$Z@V]$EV8,O8DX1^R^5?L-DYV_VH.O"SM7)2
MX$,I?K'C5T)W>P'M#B$CF=@J?WT@/(.*`LW""R53QDH(`#ZMBLK1@(K@%_5]
MI+G8I[8?+<+8]1'`K2WAXI%*2MO*#ERPZI\&H8Y*DW@="7QW),A;>$F(PNAC
M%D='I!)\P`)OUBT[6C`UH,D;+&<0K8!99A;,9@8IR3UW<I/:"F@.[7C>Q$FT
M=IZAA%F'N3_'>#W"`?$^`E"=1N!#A]ZN[2D"N0FJ:%M&!''/KZ*\UYC`P(0]
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M4W3YF@[F(>0C-'.VT%46IM!&O@-IIVN:F.<GH1_/V#6ZRL44>GRRSAVE`YE#
M/6LI<*6ZILWGAG9F*HHQM?7K<1D$8-]34]&7,'U':?"._,#MCM;<*DD![WIW
M$4/76GT%TP^"->HNLF4"KD[JYQZNR@0N*NX"P`5CXO0@+WG]Y7OS'P``__\#
M`%!+`P04``8`"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE
M,2YX;6SL64]OVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-))
M?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\
M_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ(
M[]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!
MW8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6
M-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!<QM6)M85W?_-)U
MZ8+Q=,WP%,$H9UKKUUM7=G+Z!L#4,J[7ZW5[M9R>`6#?!TVM+$6:]?Y&K9/1
M+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P
M]<YVM]MT\`9D\<TE?/]*JUEW\084,AI/E]#:H?U^2CV'3#C;+85O`'RCFL(7
M*(B&/+HTBPF/U:I8B_!]+OH`T$"&%8V1FB=D@GV(XBZ.1H)BS0!O$ER8L4.^
M7!K2O)#T!4U4V_LPP9`1"WJOGG__ZOE3].KYD^.'SXX?_G3\Z-'QPQ\M+6?A
M+HZ#XL*7WW[VY]<?HS^>?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)
MBZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>
M"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8
M>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20
M$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3
M>H<<NDA(",Q*A!\2YICQ.IXI')61'.*(%0U^$ZNP3,C!7/A%7$\J\'1`&$>]
M,9&R;,UM`?H6G'X#0[TJ=?L>FT<N4B@Z+:-Y$W->1.[P:3?$45*&'=`X+&(_
MD%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?
MP9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW
M"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8T
MO;>$#6C<AT&]SAPZ27X02T)XU)D,#!Q<(+!9@P17'U$5#D*<0-]>\S210*:D
M`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-
MX*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY
M"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:<E,7*DB):#QL,^NQX
MBM4*W%J:[!MP.XN3BNSJ*]AEWGL3+V41O/`24#N9CBPN)B>+T5';:S76&A[R
M<=+V)G!4AL<H`:]+W4QB%L!]DZ^$#?M3D]ED^<*;K4PQ-PEJ</MA[;ZDL%,'
M$B'5#I:A#0TSE88`BS4G*_]:`\QZ40J45*.S2;&^`<'PKTD!=G1=2R83XJNB
MLPLCVG;V-2VE?*:(&(3C(S1B,W&`P?TZ5$&?,95PXV$J@GZ!ZSEM;3/E%N<T
MZ8J78@9GQS%+0IR66YVB629;N"E(N0SFK2`>Z%8JNU'N_*J8E+\@58IA_#]3
M1>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_
M((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/9<E$WRG$:NG>94FRE)")J(*X,K%B
MC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL
M,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;
MK:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#
M47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,
M9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TP
MP:<J@:&''I@\@.2W',W2K;\```#__P,`4$L#!!0`!@`(````(0`BOLZIVPL`
M`"%J```-````>&PO<W1Y;&5S+GAM;.1=>V_CQA'_OT"_`\%KBP:H+8FB+,FQ
M')QDLSW@X@0Y!RG0%`4E439C/E2*NK-3]+MW9OF:E41R*2VU`1HA9XG2SOSF
MN;NSR^7--Z^^IWUVHHT;!A.]=]G5-2=8A$LW>)KH/SY:%R-=V\1VL+2],'`F
M^INST;^Y_?WO;C;QF^=\>G:<6`,2P6:B/\?Q^KK3V2R>'=_>7(9K)X!O5F'D
MVS%\C)XZFW7DV,L--O*]CM'M7G5\VPWTA,*UOQ`AXMO1RW9]L0C]M1V[<]=S
MXS=&2]?\Q?6'IR",[+D'4%][IKW(:+,/>^1]=Q&%FW`57P*Y3KA:N0MG'^6X
M,^X`I=N;8.M;?KS1%N$VB">ZD5_2DF\^+"?ZE:XE(L_")8#XT[^W8?SU'Y(_
M[_[R[EWW7U]]_8\?G.4_?_[S_G<_?Z5W,C:$)MB@FN9EMY(L?)U0[J02W-ZL
MPH`(,@8UH;:N7X+P2V#A=^`,(![^[/9F\ZOVV?;@2@_A+4(OC+08K`SRL2N!
M[3O)+V:VY\XC%W^VLGW7>TLN&WB!.4;Z.]\%,^'%3L+AO'SFB":3:80P.)GZ
M>(7*Y(-(-EZLELG^Y8!,'*]!/:]3],?Q8E)4RR6-U[Y?[.GP%%ZYK0B?Z&D^
MT2T+<DBOVT6U4H.UQ&P\ZP*_LS&[&IQ-LK[5MX92)>-\<=]NR+!OR51E#4/K
M_?#N;.J4SZQ,NC0-GRL",.#D:M&%T*V([Z&%KW/XR9D[M'8LQJAR29^%7I$;
M'UW?V6@/SA?MA]"W`U0L[=38K[D^F7.\=LAS+B"?1>Y=^SW]CG).&[V<20R6
MI:M,?)H4N;;8F*U]/K5&.<ECY5//]8.A4Z6>DW"/+_O[8\4=;VW`@$7T!D+=
M];Q\^M(W<8`/5VYO8"85.U%@P0<M??_XMH;A?0"3/A2TD_RNYM=/D?W6,QAP
ML0:;T'.7B.)IQB85Z:!N=G5OS>X97X),%$4)4<N:#5L@>C\=S^0CG8W'LHD:
M%KPD$WT_P)=DHA;\-Y.FT[1;-V6!S.EIL8M%@.[E<#P>CWI7H]%H;/9[ILF4
M/$\]V@V6SJN#=0%I:MI',``$X_YH?&4`D*XY8JS.BJ`/`(:#P6C0&QLF_,]2
M5?L(9.MTH*NV*D&@R*H$@2*KLA%.1T+F3R,%2G**8Y4@4&15@D"158>2,_!0
MN54)`D56)0@4694-L"7&*I2Z%<<J0:#(J@2!(JM*&WRF&1C6%Q1;E2!09%6"
MX-Q6S:95L_M[B]72]D=FY>-C-I.#N>,\C):P3I@M?O5P]IA<N[WQG%4,L\3(
M?7K&OW&XAG_G81S#JMKMS=*UG\+`]N!M)VN1_:UH">N.L,0XT>-G=_$"S+C)
M=H(W8=$6A]QG31SAFT.S.S0'QE4RB9+$VG>6[M;?ER[G?=!70(VHVWK!B0Z#
MG$GJ#D5IM8-62,TGV(*9FEE:L`'X1.82@BUDR%@L,XC*2%J(R4@:",I(6HC*
M"*%S*+@R32[#+2QY[QK8LD;=;E+1%>5339``/^`QAT&0-OOZK&UR0*.U;9K*
M"OEE+S:F!K[8B/6`I#4M]N6L:7!`RIH6HC+R?I-9ER.>EQ,P/1]`LJ-O[N?'
MP0!&2<,,STX23/,3KC0E:TW"Z>ZPN+7DB=1`H5EWE<FPHZ9]&60P:2))!JRV
M3941T_X:NO^%XWF?L$/^^RH?`T"IZ_;F=45VJL#V(=S*@1MA\"W4D].W27^?
M?``=ES4R2AMI]GKMO3UL_;D366Q/$6/!KF+=NO@T90.5XO-[SWT*?(<5Z_2$
MS/=1&#N+F.UY8@M.97CZ)7AZ*2$1/*?P-TOX@YZ$]7$*?R@&'30BZ$4I?W`N
M8?XR_0%W=Z5.#2:@3EV%1R8"F/)G",`(*A#@;K14!^">*A#`5"I#``Y:(``X
M%5YQ2AST2#8#'RA8`O^V6$*.R:3D6+8H95GZ!?X54EI<^CU)S23?@J,7:H8/
M%0!.8EF68E6E&&)VB+1"!?"A0@46]+IRNKQ>6<Y7IA"2=`%#H1%(`U4:D>>5
M).<"SP)`M4:F$L<AQ"DP%:F&`'"40""&Z"GJ?WL4@Z(>F'J#HBZ80N#ZX#/&
M!+4$UT,JP@!XE$1%,4[H<3W&&=5`(*C*D,0;#%4IDF)0E2,+4QBJ4B2!H"I#
M4DNH2I$4@ZH<24RA*D42"*`1)1F26D)5BJ085.7(PA1]52F20%"5(8DE^BVG
MR`XMFR9%5%(_O>H?53_57E>UA=1>V:0)[)XU3V9/R<P1;,'F4F0JC??_V5GM
M5'L.(_=7F&3B?8`+**8ZD8[WC<;N@E[Y$MGK1^<5IJ+)NM/KJKS6"TBR^L:N
M,_((2S$5_*&XKFM-F$O7SPE83E=$K>1L4E];F-_Q#+ZX7>LAM2"PN*,:`X:%
M:@QH[Q2#=#>4%*;02680A;U3MKM0-4&'*98K+%`L)I^:;%;KJY0Y*B,M>,-E
M;@##)ZH6F`MKOXTDB?,H99(;8$1ES'$BW8QYQ:)F<V(UWDN#'+<GT)ZX>4_8
M6-0:="?TA$9%,;[U4(,;EQK:O$8139*,439>PW)OE>C3M,I<F_*HTV0#N"8(
MJ1?W=Z?U50@M5HAOA*_6J36\KR;)]!!XG:IA9MNXC]6AE*Z$&E5<:>QPAGVE
MD?$955HUT,.]OF!/2.&S75,-!_&R4]<^'M7>11&U9>"::!:Q\!$Q?J*]:T#S
M#IC!$^RDCZ)=TQE00R:BU[F60>H4U3'("ULZ$FR2J4J9PQE`<OJC1FA(U]R&
M<1IA*3,+KDA6]8/"/743-.*)6M!)J)^*)YSZ:@\%VH8)*>XC4LMO?_RE=GA*
M`I#+16K20=E@&:!516!I9J3.<\S8N-Q[9&7+]A#"J*]*9\)9ZU2$-$%P+G:L
M47\S:?2(=-0C!:^VLZ74+$]P2S$B]2J90`&<6'VG-&<T<B_9:FG"_/^WBF?@
MC%95Y59M+0O&HN>5'#T\6]0@T_*:Y-72W/*8/EQZ_T-3ES"@$C56YU(1+9;F
ML:-@8OIL;FU^"I)-RAM,G(75R/;K-P<HHL@V89/52>J.:H+HF&&+>.0?Y0M-
MEQ:H&PCW^(>=H#1^:KMBNO8NOMY[&`6OM5),AV*ZT)UX%.&L+XLBX3F7(N1L
MJPULKB&W*O(W*N9;<30\#A..[^[^4;O0WB]0'?DT#0?>\ZWKP7$5N,<&MTDM
MMANXUWZ:7$PWME31RLM`./R@M&!QJRFM?'*&]3A*"P*M*2U@GTST^B`MH05W
M<3:F!8Z1TH)WE!9X25-<T"2EQ>M^(*A[\Y`=V19@8D<06007I578$31'9(23
M&1O3*NP(AJ.T0.2FN`H[`D)"RP0F36D5=@0K4%K@;DUIY78TP7"$UD!0]U<'
M[<C[*N[7$\%%:15VY'VU+^BKE%9A1]Y74>2FN`H[`E6B+Q.^:$JKL".?)TS!
M/$%E+.S(ZWX@J/O=C,I[O"'H\0F5PG;PCN@(1T0B.DJH%%;CO;POZ.4)E<)>
MO'^;@OZ=4"DL!?2(1"9\(2Y1;J,^KUU34+M3>YEE7=YAL)\1@0&'#"^V'CR`
M(\3'=[#]J%@*)@+AW0="E)Z=Q8LV@^,%<D)\/&`W*D+H_G7MV8$=A]&;AGM0
M<W*\T0>"Y/X:AKF.>`I8[14!]#=XV`D\1T4#O20:XGT8QX)-R.2QP*L';TAK
M0@9:)VAX_\/Y1A,RT#HAPR=5'#^)D/D0K+>YA?A<BEVW"(F/;O#B+'G/X36,
M)1@12@_.-H[LW/_XD#($%?.`AU+D-/@4D1QJGIV@D8X_'^`,BDR).$<@L8/S
M%A'@WVUCHD9L18C@!CH1(H]N#&<'94',D4!80B1"V!>>D]C)*((T?K*C`*.%
M"]T='RV1J-AE#Z/_Y6MQ0`G3>XR/`V)'E^3S`5#4TEG96R]^S+^<Z,7[;]FI
M7.!,Z:^^=S^',2,QT8OW'_&X,XAB6,B'=/-Q`T=HP5]M&[D3_3_WT^'X[MXR
M+D;=Z>C"[#N#B_%@>G<Q,&?3NSMKW#6ZL_^"RO#92=?P\)T3GDW$GJ$$^^Q[
MYO7&@R<81:FP*?A/Q;6)3CXD\-D91P`;=E%E0G0V^;.=;O\'``#__P,`4$L#
M!!0`!@`(````(0!\Q7,H`)4``#,'`@`4````>&PO<VAA<F5D4W1R:6YG<RYX
M;6SLG=N.&U>6IN\'F'<(".ZQ!&2F,E.6#U6V&FD=W.JV)8TR58U"8RZ89&1F
ME$D&BT%*SKKR.\S<##`#"/,H>A0_R7S_6GOOV!%!4BE5V3V'0KELB8S8AW7\
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M_*`X_M*^_*S_95K/R>;U_-O)>;-:CL:K_])_\]/^!VFHL^M%V?_RTZ/#_7_I
M?W@")29&C2?3T67_VT\O1M-F,%":Y46YK&K1<%(\&JVV/_>D:L:C:?''<K0L
MGD#]9C#/)J*E:<+K8;;-`SSY8W_,P-F7Y64E\L'O9Z/98(V?_G#R\.7S[QX_
M>_KPM'CZ[.&641XB+TNV\!36_U3\2WG=?^[3P\/#HZ/C^_<^N]__ZN%ZN92X
MY5381K)/]_>/CO?O'?7'")OYUW(ZW?]Q7K^9%Z?EJ$&')L73IEF7R_X+GSZK
M^Q^%,>)R7I:+>KE",XO3U6BU@2=_+`=\"D/\H9ZNYZO1\IH]3='V+3/9E\5#
M)..R7@XI]JR>[X_&XY(1>&3B8VT9ZF$]FZ&:IZMZ_.-><7HU6I9-\7R],F/"
M'K:\]F)]/JW&Q9-I/5KU'WE8SYMZ6DUL[F]'T]%\7#(R1J799@)R'3\>C!?8
M/&H:AOC=X.M1<V469ZP_E']>5Z]'TW*^&A#O9&QFK"F6Y;CDH?/I0&A?+,O%
MJ)H4Y4\8QV;(IK-ZA:R..POJK^=EB5948Q%>*^I__6*)X5UB&64DM=J%C,1>
M,2\'A'R^NBJ7A6^[/XRO9/-W41"GU>B\FE:KJAQ2+1%C,;K>1`F^7Z[9PC9*
M?(^6E'Q;K8HXS?5^($Q_K8_*BQ)-G4#XU^5\76Y[SO<;AV/5VQ[LLB%[H3_S
MIE4:J8OZ(K'1M+6>]]_-5HV-B9,,M`V1";MKI$/%F]'2;.+6%[)QC1HW78]O
M.@X+=?H+-AV^JJ<3#,>G)EI(V>U)>5&-J]6=H=ZXYMNJ]XI/#@\.CXH%?@3M
M@458W#TLK_Y?-&X51NO55;VL_@(C);L\</3%%WOWO_HB/E"W9J,8K0J4NIR=
M(\'1>?^^^.R]HQ[M'7[UY=Y71Y_=<-"!M3@#PC1K+&C8&`L9U\WJ]\719WOW
MOCR*PVY:GVVKO^K!!">3"2I5SS$$LA7[U1P]7U08ACY#T*'U;#TU.QC8T'_$
MF6I+W<JYS>]D@F#K_K`Q3@$8&/J3_:,"<PVP7%68PZ(5YE,3YG_[P3@XP$?Y
M.XNN`O17FV8Z_JB9PNO?_C4O/_QK7G[TD20*"W^T_W'[WNE$7^"E`<SEJ@+]
MW=GF5(-K#WJ05+O/H.YC`UV_T>.9YO>?[^NC3]!_:H=`[;56Z8/>NL%.6L'O
M"?%>-!.5,.`@)-FYVC#O#I*<7%XNRTO,`EX%``!04G3D2R"J&Z"2CBP(4Y:"
M#(U\V'.PA+W>F!&`EPQS!7:I7I=@ZG$]*XO;W]=-LU5*<N@U0,<OW6$/X4/X
MHKA8UC/LZW0Z.J^U$&8%0!*.C`?`YSMSBP$"]#GI=C!\.?!L#S'@OL$(1P;>
M#-1ELQH9)BQ[6ANPZD_T73F'8E-[;#2957.+8;3P_I,!9`RF[C\7J3PU*AM!
MA/"<*_V''>)4@3%A-W?Z3STKY;1R5L8W;)+^X]^.&K`X`++H/%:P"@TC?&]"
MV7_O435="Z9^^)L^XYNRNKS2`",<R.BR+.9K\_?"5MFT`W;&>3_V_1WZ8&XK
M>=+':)<PT.:\@S&X3Y.'63Q4;'-_R:;M]I(94G@AI/!T3LQF2&'KR#ED`"@*
MN6U]]EL"\/E<<68,LAS4I&S)87]S@S=2Q/>^-T\%`??/P?Q$-4@F%L8$O#^#
M8F:+]S(9$)*X.\Y01N8:@W.2!/)&?0&4UH:$V`9B\[<<.VZ\OWYG:+TPBUS^
M5"['U88P</-3V\:4-G<4LS\I.8L=7!P8Y>[C<=:`N!/SW_-:__$!S+W9+(/7
MW#4J32F&]MQJL:J399!4]`GQ02_'C?<'Z2Z\O\][NQ^/@[[WM1TVZ*'R$&1&
MWFQ-=P2OC:"3?*Q>6X3>7]?)Y$_K9N6.'K*1LZCG8Y)"N;7F<VF.)3X6R_IU
M-4$]SS%X:^EI-;]3!$_4F6G@.Q^5\&E<F4+'@+^_G">C*H2&Q2BM3"Q^;[S[
M\&HTOR36($[*5F.Y'//"62`S6-FF^+V_LGX\O>/[^2#%(MTT\K4DRPF9+7@K
MHXS=%\9N<_X5J+*Q]-]VYKY8`Y`PIH;AF'!#1JB_C;32P%OH^?YY^FN[J.98
M9QF;'6M;UN.RG#2.[02`HT'O:7-_A62VMKP8T8!T/J4[=AO[M-V<'3=9OKUH
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M&H(2_("UZS$E.(LPR*G4D^N`FI3+'2UL`E2K7A;:VHIDE=EXD7\L/2/?R^"D
MVNIJ-EO/2\VK5&O3W<:EA3$KF54BHT6U*-F2,1%]F:S'LFJ@"N7@HR+K.2P-
M>1\K,#1`8WMA7OZTV@_CR6U3T+%U%ZMR?#6OI_7E=;$@B:4Z7E.\N:K&5TR*
M3DPKPBP60)P"86P_")"5^Y3Q9T=#:DAP;(-ADGV2E=!MPJ/3<KR>AGV26A[N
M8R],+L)%=F)$"[P>HUU4C+*Z6M;K2ZVOH4RI1*AJHN(1JPF4%+MM4UJ'$WE_
M5DYP?UH&>T8]FAD2.!N1I)],B&>;^.Y^L\!1`LL+'IM299!C<Y)(^N8U=/?B
MP/0:"FGB&1X&ETRFW)V"RP%TZ#)T+$E@L/-Z=<5L`L+:E2\JTH;]88TTTZ3"
M8VO!@@!0GZ*$2P^\O:1*LD?9H'A#44O_18'8\_YYN5I!$90H6_)DN;YD>V53
M7:KFQ7"1G^L%PC`;+7\LG3`3U'[.L@<&95X\'Z]J$KWHW.=>IMTS:8A,&J.]
M4QME-$=9@#NHQ\(K2,D+W&:53U\\-Q6'6>(@[UGLZF[#R0PWUE,M"*V7(#34
M>L3<^WM?W,^SU7NR$=.U\1Y.B9$Q:]N$=/;K447:@M?9M*EV(?W>Y^G:<1=$
MA-I(8N7B_,G1YP>DPQ%RCZ>['/2J$BN;PW&DUWWA>8E"J%#B!25WJEHX>]6Z
M/_GR_L'GQ:R:3DWW+N`0W)`&2WA,AM\L63E_,0NT5N)'DBOBX)QY"[U6S0HA
MRS1CP*;3]0QF7FO.4W@M(5;I=H-E[S/X^*#X^)>5*3"4\T)Y(6J;%EEI`R\P
MI>,*P;"O6SS-COHK.(->P-^VJAA\)6*$@L=TF#/<#=$HUOK8[M"MF.9#QS=D
M"E!4JKZPK5F?-Q5F8'F]E[]2_"MH+KBC$P2IFL,B2;3\0YI&(ZH6W@A7B257
MY$2P`.6\P$Z29C)%%B!)V^"QK@"UEL-A)X3A!4K1&6YNRDN%!#A8]]6(1?@(
MJ9!=(&>@S:#U6B,OAT0AFL<?RR7"C'$E6[=>!2O04/*4(S7Y6J*FS&I&W#@E
M?YD4A8]-QL9754FTGI8PP2A:R#<;_5@N]PH>RS^2\%YBF!=22OO&U/*J?B/5
MD[Z--3\"4H.+V;:HJ=(FXLVKF5/I$NQU51)CR5*$I8CP>G<VFN/7_:OS-8/(
MA`=:!G)%9\+^,D\^=%A;W;?;6TQ$ZZI-K.87&.:J7B>?,;28K^``<OD8AT#K
MS;"0)W$':QM;D!(]*\W>(O0FA,N)@?0W%=[#?;D$&_$L%S*604Z-FJW:R>1^
M=W+RPFSN4N`8%N1&1.P12PL%-+94(^^?UA.30J,ID&4UDF!72ZI=\K?BH#LJ
MO!A(1&MG-_1$:"4S]0V9RGOQ>B^55O&)>SQH15'G8[2:4!FN+@%Y&D)VD#QH
M`*THE*PCPFTB$ZQC%E0>`"4#.;5_5@/Y6S5DP$V$E?N7$$G;4.:&OT[0#(8_
MAQA;"0*K(D'B3H-92AYK\VR7I`%8W63M:P/3>`;968#BXC/)9:+X0FA8A<M:
MSY.1JZ":2/PPV*12!5R)E:TV<2YWB-1QH4&D)TP.5.>_XQK?(,W?*RY2R-]A
M%Z3#37J]<-&M_1F;Y)@0VI#9ZS\Q2!?8NE2F6(U^D@#PPG[$YPRRGGBG1/J(
MW@K,/@*]7--"93,"F2S3'01!T<D!)CRQ3VG+'C4@8'$%(J.>K08J"1K`V&#K
M4M^]'M&`M6;?-C22NIY93C!(=HY_(=^YB*FN(8,3YK2-)1V=.,#7KE@SCPK"
MR$"OIY)F8;V$"^!+8MG`AR/($<>(4)7,<9TS_Y>?_WMCR`*%#*#,VN:Z$D*0
M,[4R?IK)R)CODO<GN(*E"B2N-)DXR"#U\5G7,E^JUH-FF1!@G=TG@J9B2E6K
MEYT08@8!&%D=T+52MVD:.;:X,,8/F.?;>K2T"/N1P>)ZB1R9*:SF"_R<I65:
M=>[(AH5WLB$EWI)5E^*Z:Y#Y<0@1J/0A=#B/"W*<SH+R54M;(^FQ/DG-HJ'/
M-4@:SD81R5%67JG/_R0O`\20802YQ+]>@#]L^RWZ);PKEPI('<N;Z4OF!04R
M(QTW1YR0A7W5?+*FF<DU4*N.*A/9!T<=ENO+:("`::S)07:0E)X5&`AVRI[8
M'U2VV=+#=9;-(QNNC;`'PV5*AWF^%*9=49K"`WJ!-;/PU9P-69<J\$_>4L9T
M65%),0J1"E'%R#SNLK1X7HVI*)I)*?O53A56ZYE%2.-)"[$!EL;)<DP'E'NV
M]*8Y%W`DC"*'87!<-IN_3_"5#1;&X41G5QC6\CHR\@)#$S8AB0&5RC*>C^8_
MNEEL'8TV7:U0>R@6%I4MTX"CX6C<,]/.U+VH+A]58;`S4S3"["T?&?J%SA$^
MC19$.C\%;-!*\H#!)Q&/O]S:>Y<>\4#*(S/%NZWFFB,6`[0,.7SA1&MQ(_91
M$$=(#N`0$$Z``UG0&Q*6U)1X'IH2K=.9S<&&O'7)(0K`1(8)^1!"?6/X2@!X
M4J_/5Q=K\T&&9;JF3]&:\?&"Z"VLR'IKVFTI\"`PT+*FU8_$!U<US;Z2!-^`
M,!^X=%G.4,8!*<]X+:I:Z^M]C[;_2!$&A&T.M]K)W930?T!CTM+Q@V\@[1*/
MS)MSPB`6X>;'<@'1)P8;`Q-B@*W)6VF#U!YK&W_H+W0,9=[65(N<V@J/+RLM
M[0--2('!(.#Y+AF:CF?F668B0Q9W)?ZK+E+/R,C$9<$B84@<K+QZ3)*XF2LN
MUI;L;`F=SW!0//-PQ)FM1"-TJY<3!)\_0\]'H:7MW=O8TR;30(_U,5OI0F=A
MQE$PF+[KP%S<J:PY.^X(7=C3@-TOT;;03BIKLBDTCM)@,F,HWA(Y:MUW:+[%
MP!A(;\JEW(C@"%T<N`ILB,0\<KN-\J:6AS2FINQK0=X*9F/Z<,"1+R"=@/+'
M4T"%I^:8`>`3MV*F$C*XV.Y0353YD\\./]O[\OZA]'0#`R0$XL"`<D_D6/^@
M;D:Q[HF7/MC=T]8%=*FYY!"##DO\KEF0"O[FUH(%BSJW'IQ)P#5<\*$""&ZL
MNZ*?>Y>;X?Z03S55&GH0(W;'Z$<:(V^MZ14961Q,6%[+DX?E[:;7G@4;CA]Y
MN:&W<[4OR,<FS0T.<I1Q;I,/-(-,IV83`^:TG+>?M(Z`]*>Z,4/#$K988^3!
MJNC7LN;$M4"CGMIIEB4>SM&=@M4G)Z??6K"Z\;F''(=15DMNKM#C)Z</[>DO
MCP_W"F<U+-8_+_A7=9<#*'\1K3A0<WB+OZ$!"#XKFL'\(WVR?`(R]$?.JAD<
M?X:%>EGCD?3MQ8B\W74801_<M8%7#S+)^R'?ORCU*$6OH<$A6]*OLYS-(ATI
M5$`=40FE/7VHOX`_L.7LM>7BGN`J#KG"8<JJM=]@X+`8%#-5*XF]ZB81600>
MA0`+`1A/<%?67U%]R#M@K?D[IK:-[YG+$E7M.W$HPWGNM^*RVY4`XX%`DJP_
M$V\%/$>T&]KAS1I;9(`#\D7'Z&ZOL'@@8(88:+A$84.R=726[IF,P;:ECZI*
M='8=L6)F&:%"V+,A+-R#62QMX`*C7+]Q="X\JD099SY0S5`:1'JRHU2__/R_
MNB9M]>![]<(51[_\_-^>),K+L<?-,251E))D2C=[;9_/_KP&>TPBSD]UAS87
M:+KL-2^K$7A1RVLQ"JDWTV1@I'UYQS=:GO,L@`"6-"_"YK:MUJ,O97B7H)7V
M;^<RZP*8R@T1(>+\&"P8[-Y@$NN&#*[0TN8]\2)FK4,*WND24*.\CS8:!R?5
M&>F@>!FR7F'S6BAY#\HTP65X+B>*K2Q_$%?R&$C0TE@HYL[J23E%XILU!3R\
M<83RA9*_PKF3XKHJ"=VPZZKK&<\UG2*;>KFLK</3Q:5.%(P>D9!HM(6Y]][#
MW+"S)&/K>3:\EC576:VW@N"(;=KBE2=4V2Y_",/1'E%/M0]5MF*U0Z-ET7*;
MR/0`SG)\:,,(J[0(9[A`DEB0=V]_^?F_%N7!Y0%N,TN,B!ORPZ0S%!-FK3&,
M.#*U%@#'<B@N-QNI4@\F#]3$1$U3J_$&JGHP6I`')#1HY%QY8$#1,VQ"A'LM
M^&^Q]Q8)#7N6[<EL6,<W"Y.R[>C4+;&HY^-N0UTEV^S4+`O&+:0`",#<J%DA
M:E:4(P2M):0R;/5$-CNS/BZKR0?(Y,7M,;?EGC?R"_GE>SW>LG=L5C.P/RI$
M7+XT(-NZ!($@#'1IZA!>HJ)M?`CV?^!9!NQHD<O'$_Z-5L%^W-1'N]X>C]W4
MQ&&F_`\&;;L`8Q-"[GN$_VRF_=W;%Y:">_>VFO>?.'$;](,;]OZWV++^1T^M
M!"^S?V*-7?WOLXKCN[?/8=M@A.?)HO3??6H6NO]I-F+_JU>9_>A_%QS&YH\'
MS8S^]*!ET/<XZ,WYI#\J=F\3\WX8)''Z+WKK^692?@CKAQO:<2+P]OWCO:\^
M^Z*_ECO#%J*3S;$P,7!'?X%A#:EM'?Q3MK@3QGCNRA*S3N1CZ7/@#AYG/$*!
M;;B@FLKI<#PWST>,HH\-OL!2R@,5/6M-BF7'XQS!Q(*DY"$90E#>4HJ>E>L%
MJWM`!')YG;09-F2X*0>ET8A%\V/^=$O6U[`!!-JP,H=E`4K<;N'9'?/J#+H1
M5^!H(M;5]@;P9!>-6GOO"!K@;]F]3IZZN^+CZ*XTF:]8<M!"5UI@KNI)\[O(
M+V.4K[V+K.[N7+8J10;6'-<8`.RBK`0A,@"AM6HY9J#3!/3(NC/OHJ"]+@0"
M0>"@_`2M_/[%B,*-XR5"HM7XX([!IK"L-#LY:>MI8I_J<"#50W2D@S(LI8]C
M?"_9>G-@T]=%R7)+5D5DUB>EOE^%94N"!;9+B<VRB=IUD$.3_$6O6+>A%.>>
M7(DOO5S/M?"4-VF3&S$*ZX<V&S&$2T3KIE>$&=E^`_%NN_3?@Z**312!6L4T
M^."!L>T>>;!3BBDI-S![;D_7<XIT7OBZ)#5&=[9.TY0<C<I3-9PB4LEK</K@
M]N?'G^_=^^RK/D].Z:J:>IF8"'$+C0>C[5K^P-\\58D"H9*)C/IH#,H`#7.+
M9?WY4X4B,!O\K\=24P3H-O:$6-+(NBO;8)_8L"T_*485F(4Q9@O5\^Q117$;
M"JJ&:U@8V$<VX:R5OB(5'('+X6R%;(!%)68;M#.?7ZL+M2,7'+HUVPH_`+.B
M"9'2[O3:"M\NL$P+=),*$-CI#U`#,$*&-50>:?1I(P/4P,H$FFKS`3R/AIB7
MU+3UM9R7]/.HW!K(G!KT'/+ZC/(-JM"?6!.71O=/PL["JYM(+X5+GF+B+%K9
M50.=$<#-;,J:92S!JREBFC8\V.HH@4\(]'HR002HAKI$&T'AWB-M82N*S8&N
MY@"/IYIZE$-E=3&2^&J'XW@+I-"@OC[*Z:N)MM"4)KL112<:0(FR+8H0I6V=
MX3"7"]0FXKG<!!6&0EFM/NMP($:SMEB34%Y1?X=:&UDK_7JAU\)7J+.&+#VT
M!06ULK=IA,N"25I`K?_3=XY\Y5._L>(^($(>PP)[=7AB;>[2&>5_BB0;:G%>
M&$@<Z!N>,[CO0K+=L(4,>Y^]<<R-AD_)H600$4PI8.@D$U/<805]OQTZ=&1"
MC5`"4*G,9C5%*_[H/83"HKVH7,/CC61C*&-:)RZ.!PLAUWW#_@9IN_1AZU8M
MS(KM!SBN)(RR9Z"`.IH=UGKJ5N31_G%_O%CWM-&(3!OT#AOJT!%KH<$8"HJ!
M#%V`!VCK(0W_O!-DCND>>@WE9=4,3D2=,@6)<'7,,H>9-#?TN6,W:VP;&D!4
M4',L`[$RRS',1G^"KEVW'HO#D8VOZ`'B>7+PI(8.J+I819JN1N6';!0O,ZM%
MNOQ)G:Y&?&]YDI1@A];@?T)R%,_/)8D>LDBAO,VPW_E9W"F51EB'`L6O6+/:
MIS$MDQ+7.BFL_CCAVBJXQO_M><PXG;5[/(?-4)_*C/"3[L8?!P1OH_3</!I<
M6Y#EC-1-21+$*)#7>9FQRUV+\TMSR:#AB-3PBTH$K,?^M[+$D]ZIDD+")5Q%
MXP;.'>S2K*$<&OR+%A[D2$[*58CFK`XL2_P3@2Y549V;WM'`QJK</:DC(I;K
M)%/JP1R22BK'_J\A*J51R\</:V[6Y'UL.D3EC:NYM@BFM0'!16OI,VB1660H
MAPZ,,;9:M$IMJB/0*(JX6^$5PL!Z`\ZO#DX/-NV+9@95+?WL.9QPV?R>#7_O
M'];6TH@^4ULF?\M$3T,O!,)&;G5,*H+_-U)Y>^2VRJ#>6R.YI(H4OE&-9(]:
M5'FEHA>#/>7?4^INL^*[V?D_63FE_=:?_H[S>B/4"!8@0V"OIW:H16V7]HT_
M]>*";@NZ9M.7_H&^M!4_GE;%]V0-24+^I]%L\7OVS,D8!DE?^*->.[.0T/@!
M'Y>1^*"27L&YE3P7,W4>&JW%_HYU2116&Y-(N)4;FUQ4/UXA(2A>B\>:":\@
M8XB@RFQHW7FD$$5'H!Q9"$[&X86\%&<2E#P=1`>Z$.W=V\<2WW=O._+;7Z(2
M-/J?[DF+?][QS/$-GCG:]DR0I/[P_S#,L+2"U'_8!:?_J4M,_]/O6D-P$@Q!
M_Y$D0OTOSN#-7\6Z#29NP*:=G/$]#2S4B_RTY&,@]T*6KK_\SE/"QO:4V5-#
M)1:YJK_IH'BUP#/1]XZE<*Q"O8=#)8["]8@)II]7)03"$R*)DE4T01(<31H;
MSF[[0<CCB5H9<?7R)&NFMQ)Y-(R.$CA45$BDX%2I`D6G`F/>8J%)P<:TU5WR
M1S!&"ZA4).((2-!.\_>ESGFJ;F,79["``-28R]"=#BF1B\>QM^O45""]M3Q_
MF\:A96.D:Q[V[8"9IW*L9\<VWXI(#`CT;JGVJ"GF>YC-EF5A!GIT(E/ZK+OG
MSJ?_\6E]L0*W#J[I>+(F7E=33_^%H\/-`T7/$-H:.8"DXSU;EW-_RR@"\XI-
MXGDIR<X@S#]54P6;15RL>X8S=?17P,=$HXO!NI]RM*1:NBA>%-_3Z;W_O7G"
M3?E@RK\[6E8BBE'N2_\$>;7#3EF7F+*SG%F\A,6243W-)PBAA+3?K&%XSH\=
ML2O2,Z1=/O^-^RNB=N\5+[A=<.5>LBM/OWI7Q0-OF&#OJ"YSH[^0EVK8D)*&
M9-7<!G&5CN2$7>2P&@&!1ZEES57<PDKHW^D?3^[.IY$120T_+?`FPV+\,P@]
MIW!JDP>.J^`-YK&.N]`V"0\U4G_1LCNA/&C]`1X$DB1O,);AG0VSFV63^,A`
MA5X[NE3;Q)'.QJ7D4;=#CX7BI!0D0B:*L.U8$,7W9(>(B!*%K_-6IQ"#N'S3
MJJ\5=J9MIW2S'A6#.=I&]Z`?PW"<H<KEU#JK.NLXP6QGO&3+@=@4G-4_VZ.A
M;<@:X[2]4#3=S,5V[[;ESOY:0SM<:7=YKL>^K([G6F;]L4BL9B.7YW9*?TG4
MC7)%O)B:1T)?K+L6!F\X98HN;*X)W3/=]`9)C1P)WV:[DC2S*(NJYW8$E>E:
M4R0?>060YBO;H0>B^^C2OEQUP`C=5AC0M#*29SI5TG<-C^*5C9PYB2-JCKS\
M(*^=K3+E06/J#SP/NU=O=,1/.VL#LK;D;1"!*;R8CE"&U0_F$@9@OJ1QK?O%
MD7L+*\-(-1R!<]H]6!N]EO>YGJL!HBC]Y%5J,\X7W7]#&'O98!G.V$5X$24G
M!^^UNQTTTHX$2;!7FE5/^AJ1?'"%CA+9;9$&.<0-/<0L,3\H<VDY@?AF&,PC
MDK!U7UC6JV#@:\/ZI&\(S7I<DB"@A7E.;-TT=I[3>CJ4*/1^`\*,T-#-8W2O
M2E%U2M>ZL65YL**RG6;/&RV<R-O:"F6*%$BYU1S2B`"4KY/=]7+#0=;A:.C3
MG'L@D`\K0HH(EF=1_^**8W>&`GO,]<^AHS\/;@7_:`.;9'5DV\*MTV1^O:]M
M[?NV<%:&76P?,"%-ZV?6FS7+5`7&;*TXUEG;S*[R7:F/@P/W/I3;U7,,^`4$
MW6D*0:`:DE0O9S1QWFX2C=:1$<:!^X?_D#@2SUAY^<;20216K3*)`8H5&!>5
M8&.\YD4R<HR59DJ_0X?26"KY20U)_XX8"+V*.)X':=PGE2<8GN\;J>0?P\AV
MKE920-)'XJ''`L(>!"PO/?TQ,$+A\T(..9RYZ]JIFV$[8*>.P%@&4[F+E`PQ
MR\ON=9%Q,>+&00MOTH&1^*2">H$2L22[-T^;(X5YD\LL()C=8X';$-UL7L\2
M0YO%E&N]<3Z6^W;^"`.;MV#*[M*4$A+5N31UI9/A+$B0=*E"IPY-Z.H)I0:A
M.D?[N=FPHCLA;)'L"KN(!1_65)_;6.W76B>;S,5C10+(KKBP4X#IEHNL20X@
M_&3,:6MD+;\TY1&-I?LGA`[$'M>P</_,[EU0^*;,S*.3EV>6E&DG4/KG=J4%
M<]KH2MF/A)#:A]1!$^Y?L'C"7K%WH)2EQR2S.9OP#N$"J:!TV%;8J:0I5D1U
MJZGN5;.=M^(A2@E46=EE^#4&R/.4MZO7+%A4(_6Z5A,;@9:>7^2G-!DJ'<_4
M*6&=T&R%*I_UH'CAQT%L^QDW!-<0G8%$Y-RFQYR<+P]:W3M*]D4IRH:JHO\E
M9OD+_VLX@>(KPER]CY`<>8J+C(KQP;O7J6;7O#P<C^-F,SBN,(,F<E`[U:TJ
M,?J+9HCV4TPE5L?=_[*^#D8+'A.0665+2(BD^G.&X5R/&^(!F5T2NEH7M4GS
MFVQ*DH3JXM"RC:IC2;I3BK!E*QHJW("'C%KMU3P6BRZG&U,NRYK<[@(E5A1,
M=Z.U,7=,=L@XL6J6T@TT]8G:_ZU+_:Q>,,KGA_?WN4_Z-^WLWV"TK37TW=L?
M@LW:?QRZ`4YT#[@?(`^V_U>/23=W^KLJJY$BHQL_F>'>)EO4KW@B8@/=:*C]
M(8IU\8.U`0Q6].L<B'B@3J*8@3.AQH(A8!VU`/H(?YE5(NS(DNO])[LAY0SL
M%*\D\B"VX\2"LGD5C55(KI-S-M<9VWJ#O^N\G9+GZ"<U(FPMAE/I&_0Z+%'[
M2<&*C;[9I(QU3A%++5K$<WS$"[P1L8"Y7OP(OR-A]D@GVJQPQ!4Y.J(0&C;<
MJ[;FH%ZZ3EME#/(YY`;M>CT'*";X;7E[83^6JU7NVH\+L.U%C1YCL_]+AU68
MI@2?R)3ZGBR8\J:0B8R9=2(')]B=:&/H^,3%(80IZ@]$--3WTN6T(E(MJLV!
MKMY`#'X@QOG1@UQZ%)X9UO2C`!<Z''+.3<5O?E<<W5&0SU%;6=..@\?A@Z/"
M\=Z(02*JT>[6R*T&WPAL*!K/)W?EH0.BC?7[%0:>.I<N),#2@AK`,0P6NQX$
MW6CVF<`M:Y8B4/.KKUARN&.JN)T:RG@1N>&^*V&*=A]QE7=^;Y)]?,>`5#V_
MVWKAEDB,83V9ZCO+SALQG?"BVN_2I<XVVFZBJ&8^P*-0*=[!%GV;0&N\)XT5
MY&(L'QC.C_JE6G$)XIJK=B`Y)^G"2;@(1$*$NX5"YF7W5S6WG]F>6@O0W!G$
M#V>BK$DTZ8^`[@2TU9'*?W1HT_":R$11.(:I#I5R+RKND+$*>D`"+;DGQ(<@
M,*'O`.&RE(9TF22G53$E)9FX#=;[.(GQ]PZ!!I$/.X*4&;)W\$?0/1"=EC+9
MM38Y8!F^T5V>18&"XXA1NL[..AB001T/UG;H&TO"+<$A#QF$W$V/4&CGT$UG
M]5G@^$'0OE4"Q:$YH.Z(^D<"?/-?C8)3DI]8I(QE%D/9!560/"!GJ&#&23T,
M>)7@F<9)1",BC6@S5QL)#YL!`#D\],:SI-D#"?G.TKP4M&FB3<(2;$7+<%6C
M/!SL`G\S!Q:R1C@M<R#[0"QO%TLI?8*(^8-1W.-RP-[>D>)"GY/%<C<64[(A
M?9%;`Q,D9?H!XNT8-^-AH^8")0P9=\[Y/=IYE.2F9T0?AAY&E-SSW^KT,>?9
MV"4')JQO1&,WW>1=2&)$3^)]9EX6C`&FJN4\8.?NZ<A6?5.[>6]LD:)-&\"#
M#/JPPD!Y1(AX9*+E;1XY)=\G5QT!W^C@8%L0-8GN>P2,([D*B"BB0E==U:1#
MN4M,G2HK6E?<BT1B*"C!BAN'E1P:.L:@UPJ^<XP4S7\,.!6=B7?1KIO2Z"4^
M&@]\N`_:#8"T]"2?,EB6F"!M3(^1570U6J.[56RJS*;E:0-O@_$K>O(\3W!3
MHHA1(NA&*^;*/"8T.KRX[(P7XYXG-916-C$=JY2ZTH(N"KFG:<<%?YAR!1'4
M?8<QGN6K<R`<=DK9=W(^BKDCOZ+L#4S(T[9L(\"K'6T`PIU+O"*NEL*U,'=H
M@#;#W!3WRE?UD#$2.@3!71!N^CR)8#C0'<?!HL+I0,D.@M*Y14VD,.R:.6N2
MR:1AE+6+8V))S%R#K&,2V%%`[B<[ABI7/WZ[*/U*6,0&,BY4XFQ%(FTX]:N3
M$(X?6E<:<V;V;-!8.0-/LB@G"N(%H`:'$BP<*JKF6UX>ZPRNIZ>B9+$O2^\%
MQ=<"HG/8S!L1CJ>\(=`%[5SF+G:KBXR6NNU@_V[,U(7VC-8*&'*N-2"PX22,
M<B.2NF"_`S?C&K4:JQ%H29NDLI6,T(+,AOW"%%!N.A"3PS/+\1J;$32#GID+
M<+O,(S"GO9\VWH82F\"U@XY##-3V+#G!E%UWUFILUQ+H7CZU:;'E['8V$]AP
ME3*#0Q^(XD`@9H)VPFV9]?<$+U&\H(QVT%VTGR!8J(G0O2N4%T^TC'1#5G@S
MNVC'W$FRG&9@>\:3U!<"I-/`/NT'O&Q'B,W6,0*;ZX<*1N^6S+&E3IL#NX?L
MJOZ6="B!!_'>:F?(\R"_.S3VXDX0,'>+4H,H7G'0GF'=7G)XM<`"2@`BK%"0
MU@=OV+"EH'VH'%)<DQANLFPT[JFW&*8B`]INU)[D5@R?#M(-))#SMO#1),!7
M=/#$]5W,/U5[*Z>@&IJ[."%.H8"<_,GI*TO)/ZL/U.YW^-7^T;U_GR18GAET
M5QV3AS1DM6'1;Y<-@Y?_3'X?R,05SM;<R[\S?4M^!7$VCEG'4(CN"HSXCWPQ
MX)7\NAWCI"!(B&U@P;A*._!$I7N/N<:MKG)QDS(C8RLQ=*RL<?`/I\\?BX5N
M\:Q9`.!P;D?%#"4[0`[YJFB"D,D4Z9J7$D;SHB.2V3N`GXNB39"$V<QZNAK-
MD"6UP)!4\7`_'@[(*6<I$@,(>*#L"[>[).#\YB\=)0A]_KC*U[JY0.#1@CA.
MP4NH]7+7OT?'PS7D7&07_A8R#[;`T&.BK`XJB4GQ1FP9`GQ.Z+[N.!?,)U\&
M.-/1KM-7W(Z5:T[>IQLO4C#Z!D<I#P(DV6`#[2D"2+\DF?^JB89(G!>TR=AT
M<I$6'')\UE,#M`R7)/A.#XI_2O=XAI,$'3>14=-US>G8YI*@FXJZ+4X.+K%W
MC;[=/6<7.N<;#]8+M$/0!@=UZS`#9@#+A16X2PI1\J9^`W`2X2B?Q+IM<J)6
M.J.;QAKOX'IO1UF$&.&(I`HR1[9S:FJS*(FI]CL6"D)%`]`AEP.+2T%R6AIT
MG+]S*V"R^#(:'%_+??*6N=4JUQ4?F,P0KA$I:VL.*EQ[C,";QGFJ6/(?X6[$
MMG`MU8ECBCI7=7`25YY4%]:WI0VW+4P(EG7L2<5B6=!5(TB:D47S8XX]J184
M4'`ED`L&5A.E3ST/[IVQ'LUU3%<0B-:NAUHG<I\O5Y$?[IT8P9HP8P<00&]?
M<)QS-M$VRIF=O0B64-"6]Z@Y1('0^CH+,-OY[>-3N^?9.F-D2*6;"M_2C3Z^
M](2;-(Q>"KT3T?+(9:LVA_&7++1=;$$,"D](8%OL+G06I[JDVG'T7N23K'6(
M"*+C3V&GG1-IU%F+:/*Z^7(K.%@;U8'NS290Y"XJ284O,=[UTAY0-"7NF*4H
M/^0'8GM!`,EY"60`R8/X8Z'F0WB=O^D7\43<+?O*E;(D9PVWI[1/M.1IN^!3
MC$+\J0;K3:$C!6L2;`BO^\T]$!""QY@.QQ4OK4*:?1HT/"R_7JAA21$Q.;:L
M_3+O@XSRTNTGL+8^RV^=9QW"1!%DJAS(B8]VRG/.L2\!`C_NYM>/TN\%SV(<
MF)*$.E"JWQ'"\GBD'+AN_@W]L=_`#"HFCG8"]Y9Q,7#WEC,K+__(L=2<%N9N
MF*0KKR8EALH][=DY9-+VO&EKH3B5V<5<2^-:W`CE_7])J/+<L#KL!XIOL^28
M!,S<B4S-8F3E/)3'LI)ZL4T^4.J:F5/JUN'6]`E0+-JL/";,WH42-#+?7)`M
MV!S]3&$Y*IF"T&AFHJ825>!C=SE*PMIV[<8M7)(B%4M;!9N9)T]L_1BA2%)$
M";E!ZC`7,KV9+T$;,HN1.QRI&3DGMUWY7N*HSBA7'4Q]]1/38#.C>/AL6QQB
M/AX+;<N68?,[F9;78+E>,1&N8YJ;L/`%.\>F*E2)("WW1&8`9(C[-<UH3T6O
M^*(>:^$#'^=]F)9-BF_Q9.)?YU+L-I^98YUD3;'<D7XR9U$KN>ZJ%79;;5>L
M)4:M5(?(DX@SN[_N:7=D"?PN(G>#E)C@Z^9H!T&J=1)G7J6K/AD.;/,T76$*
MLOP;9>\PL%`A90/$Z0Q=4MP9IN]:("=TP`MF<5[;S]VD'%Y:?AIZD*QS9Q*3
M=#CC\!LZ7;)'XJ!841*85M`B&:W.@LC*X=L%I+2LZ/Z%_115R@'JV)X\AHY:
MF>+KQTJ<"C01+`@4'$UPJ(IN08E@)GCX4S=P>L%Y&QZ/4_EM"RH6*:,5@HZ^
M94*)(!PCJ?M.0W7VP&(]UO105D9,FT*+!=)LK8,!>ZF6U8,S1HVH23<"$`Y8
M1``5',V;'\C,8!X9>FUC"+\(GDBX_D61!>.L0]8F;ET-<;8QW:S&G](O.?)G
M_FG-D#EF;5LA(R"QNWT,B-(Z<K,ZVD'J<<[IT5PLI>JQJ#H67:Q%K<4#HHZ0
MJZZ=Q-Y[1T$4!LYTPW`\#MSU?;@;8KXH-KD/2*F\3@.#X#4_%,7-]W8SXW`)
MT8@3B<3YI2[QST9WG:L..<#(J5!P4S^K(E41VWV,MDQFH15*0;`,1D1>P`,B
M`*X5DIC@^K'".8\7G0RK%W]QI^P&E5)&>;@32:JXG4W]OL2">@<4;B00V&.X
M.<PM[/%C&I"/]Y525M-!OS<F7G\1?(^D*_HG$6D':6QF/^RA0-D3TP``"[WE
MS.)UW&$\%Q;I=/>RZ92X2<^%N-<2@C#+#QYTFR;B[\=)\EMJYNS)TPDA@N%Z
M5FPR/R(5[5+"]@.5OV$6-<2"F>NV(FX+KMS^1:W^F#SKYDK*SBI73&^U5>H8
MC(3R*"(1SGPEE1QDUU5)",6AF(,V@R2*[^JRE8P/FXP'!#[KV-0@?:WL&0K#
MN;#2M`R-C)RU/SJ3V[&T1A/+&[;?(8MLA[@$[0X@6/K!QSIFI__RM6L^7Q,7
M6=-7BN_-D.2Y`?>WLAO8BHT0UI-,<E$8YLSFQ/TB2>&:"0V!!3&8[>`S&K8D
M;1O))?Y\`)O;TGNR,)V2LP%9;^0+4KR3E33529(P`X&>6F-LY'8;:?<_W825
M><SNHFQU*XD!B522R=A.N#0PLP`+K'#;49_EP'&E66G=DX$!C5HJK;^L6"O+
M$H;\#&/'@;J#U!P#`!N"AIQO*G7$E+;S&B$7I$I4:OOR?6-\S]=)O).8YI;:
MK$&+>Q3VQ?%V<<M2+]$V)5L8?A(O5?[;2I*#&%^M.091W]$?NT)/1I=D2R]#
M)L7<=N\J;$>:N=ZF:1(<]%^\H'!.6C!U'[C>!)1G#?39EPK>VS1Q^Y*M*9/(
MT;5%D8!?Y:L&<@-JXP>U6#UP#GPQH>)/+D5`5_!)/_XDA)5LF_^^U0+[K&[^
ME_8[';U5;UF`^0A\5?A92.._0WC)LX$[\'";!+=K/)[HIT<D^X\D@2<37:2C
M(_]F191I?/+HQ,IFK-WQAU75=<L:?$8>]#LBMCY^"(_3[FS5-XJNF"0Z7">]
MKU3I<#F>?I5U&8>.4U%)PA"C#5X+%WV@2Y#D5.<<,C9MH8:S8TY5BRM%[!4P
M-N>'8LF&U@NNPQ[(\8E'&IWDN+=@Q`8RC'>;A\L6D@2Z&Q[%J+1M.['ADCAU
M\!\:)EXPOETNA(38[\$N0MMPB%4L#QK!AL-O#!FM99T"<II!9AZKGQFD-M&#
MQ%K<89U*.)X8P=T>I;#'?V3)!8)A8!,/ZW8GDA56=2M)YH)+;Q^%5U@*>4>O
MHF0I(#83VW_$[K0\.[=U^SB]S"G%<3H`HR<[05Q*6(!XR]EM+F_$G>KB:FL_
ME.MLPP["1E9K1JM_>N6#UWC[?"-!W,&"X/F)7KP3>UR,R,4'<YHZMFZ/-[X-
M.17XA=^-L[%";@U?%QF<Q[8F':$$']HYLL18EJ_JNO96!F-Z.F\+:70]T4I7
MI`N<17VFO3AUK-FTKOV22^$71-1..A`#J-1H=.YQ&)ZHP58[RI@MCIKN:7]^
M;,B&!U@#%4P.0W7&8%HN,IL&M'>CU';DBO7W1'<'K=]#Y(#T,P)CD[!FH3`+
M'ULU&I@4?N"=WT9)!]=R-R5E;TG>DBE06,ZO=_XWT`,;T15[;?TA%I3HRC0O
M'LC*<`E"N;O:;)8T4@V`D.*>:)983D*)MH(8TVWK,>TP1`B8HH4Y(XDW7[8U
MZ3"NN9U4$-3^J:N1FTP>VT5/7RC#M&6QY]G]T8$H!&AXC?`./I8,`[2U4VLQ
MEQU(&TVAJ4@27$<B;>C3\B'=]GD#^LJV[R9B;Q$#`H;0P0E@E41+N,.MD-65
M28EI,8D7AP:@DC(TAFHS@UQ31`-5R:M^/&N^OKMZD&=P7]I=01QM"-BI.(E^
M<^,Q@%QD+;S8?"I"J,HR:RT:5>>4N1\2&2U$;KO9>\=_+5GE<,Y,!@8K':DA
MKDKG%"'DYH.*0V"G[+GA0]ZQIKRD@;'"JZV3ZEP8%HKA"CQ9;`LW(WCDOS15
MSP+2CY^F])E%/[E+,T@17C()D__PQEP6(+O<>L60:Z,.@7%NEYY3EDNQ+#^'
M]"G+E3C(M8-*(,92-3D_AI:(1B7+F^<[$$H/Y=:S<S`&4P;0#/DQP*;/`@2,
MS69T_+0Y75]X"')3NLX0HW@DNJ5&]F278D5#3@>!:<5D-+9.``C4M\NYA#CZ
MB3%-?_%I<*-.MFZ:=W5OW1W'L^WJ>,1/5C=V/L-ZF'P*+2^Y?FBO$0<.Y4S$
M;+O=+'**:A=VD3%-`-//1@@C!@C9A8I.CL;O7G2!$<.Z(O$\W*4LT[/%[E87
M&)(-`!I\MG5]7;0L3QK`K](D=0*D_?6@^]!IS"\G0B6>2SS0@W$_?!Z.E-V8
MN:C<$X(561<#.;W=8B@BCB:FBK@CSJ>'<Z<9\V.V)E"2L3;]5BN\UA>96C@M
MTB4:/18`#[@X(-YKD%)U23W-'*I4$F@A>Y]1PP>W"^VVT2M'H'HS7"\<B@B1
MZ2:I'CG;^D-5B#BKO0-'RE/%7V/E)&'X#5L]GTM5'\5L7OE``9Z@0-LERB(M
M.)'M71+RP9*@E]IX/K>ND1*H2L;NKB3G>,-^IM;6<W,YU.SG2`>ZFSH(-BJ7
M\2"::*07VG@KRBX*80K(.^C@`-,L;MKT)X'_6Q"VIU1;::@D=<KC:Y^QAA(=
M@^"H'RMV))T2OM83%]%I.@84$%K`Q&WQK".27LHS[R@>),,2E5SF]N9LM$`,
M$^53.XI,C:\:'L"7J82E"UMF/E4\VUF=>S]A_^#'M9R!E$H[Z4>,G8#@=U^]
M_(G[`]).=L&6!2"I0R!1:EI=I$8W?W4O]H00YAX=ZVX8?AB9;`QSV,E0S+YC
M@=U=H^)B0`L>IRBZ3[XO&M16=?OI$1R$:5]V-DYH:M>D=(CR0P79Q+#/ZU9@
M&7W<:<F(87<@&//98O13&#%;-^8'%,+-7\QM<!(+MR)C%5["LO<;'FE<?]\C
M;C\ZB_EK>@=I$;2$H[7(D?2^*/Y/:OO;;IS^WO_W_T'_WW;V_[TE4/T6F)5=
MC4_2YM1=TTV)_KTE\.\M@0KT'!!Y5[NBJO][6@+;GSX<PI^(QMA0BN*UTQ#&
M"Q?=&)MMQ/==$#]:A52AHX`XN\&H`'=N/%TW)?\!$"2D'?AM8B62XAJTT&6]
MYC<=>DWOYZ314U]/WM9I>"O.FR!7!V\0#X2CMY;]C-4"8+B5JH6-LOVVOZ$3
M?T7#I"XUF<?&=9JV:)!96UE=8"I>@2"P:RD\?9BC7)'*]_8(?#\[+[G,_YX?
M3+NW1T;3?Q^Y7NL84SRWH\$6?FY9I6;RH3^I)5U3)U$Q)$C.CA];>/\8.K(V
MC`+26,H9/BG/ESHUI]^?_PPL#+A^!BF*HWO#"B8XG1H\JQQ$LZ]RMOXM$E1=
M&?96++N^)(DS),D[U5*,U48)ZI)()=@([6/<Z\*38B^%(&)AS(]UY+2+IUF:
M1PF9&+G09/E8'SZ,UE4;IF%9X>>^-&=LN]\/Z6\BPN%)GE10^-#);6E>J,C"
M<-+E^%](:+N)&N4)AZR'<N-2VF-"&.74U]T/:;2S/$K*LGT+O]%4-!]$PV8>
MXB52@7[\S)V:-->4>=&$<R(\?ISMJ9^T$ZGP%#MR*?^/]OIUA,KLXG9`&AI7
MK/\P\=J2ZG#-KA@=QMG#G.T3^+5KCK]19@4!C]6"D+#")0(FMQ?+NL8B:KC[
MNQLK*8]_3+;*U.NOTN;$$#-`[U&^#M?;@N"'7&`2G8KUV[JU]`Z6FY-J8/]?
MIDXV@,PC+RE9$?*A?KUC4&#+G\YGM?N'N4=B39G<>&X?F-:KVT@_[*T+G3NS
MY>_[A>[D`FG2Z?T6K@ZRU==XM]A/&(:6(4R7!])DPXN:FVW$^T=UPQ.=]M;7
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ME@U$G3M2[G8QUW*LO"K5]H/)=-QA*M29S&>$+F;"B1`5?$6P+YN<?@:TK0H2
M1-*TIQ?TPWW;)[`D/U];](;::4'ZY9CA,MSZ9N>!M2W=9"I'(.!CK2$Z3V;U
MTL$@N]?!8+K)?/"617=:U`?]3&(K#]F)Q]/,E(LDT93?U)3F[Z>JF#8>0@;M
M'->C8,XR0-:2F()N?,SKJOMC3E\<_<970^>[MKNTN;Y'OT^<?SY0VU_'Q/*;
M3F=P-;LH`N'+G6VB,!*:#C8HF6`B&D\6V7V(I&O^-WMGLES7<>;Y5\$"CH8B
M`!@7]V)J=RB")$@7JR210=*NJ.CHQ<5`$C8((#"(9JWZ(7K3.V[K-5AOTD_2
MO_\W9.89+@9)5+DJM+`,WG-.#E]^\Y0J;K,'C]4B9^TUV0J6NGR.+>DS07B9
MQE/NUU'$*[+AU/"$/%O2R]M>AD)QJ3]XB*VM9,06LSR'SVN:FI#4U"964O/3
M]*LKKZ,X*5M%J0JJ\E_+K^=<OD:5@>U-U2RA:FBU67.HJL[<<O?:N'0\R$F3
M%K#-XH.FVF;6%,',)DE-RAPYY>=G=\X(?N,#4%HR=F[X[=KY7C6-HGO'>M@0
M7KNQMH:[FX9L=0ILIC=0`,GV`V!TMM(6.3Z!RR_RX:9S>>@:?Y@?S,`N$"J*
M".2KB1O4W2P;02<C\L!('4$7A<6L#8U+9DP<(]<%>`N8&H7U9A.M8B]L&9E2
MR<)5AIR<<:V?P*%K9MDO-O%?(OG7LCX]>2@44[LQ2$:)44?S7/6=U'GA9$LE
MFZ'F?IF1EF'+7C,ZZ^Z0+PSV1E:$V]LQW41Q]XS2E]?>JGS$\M=9KW7<`'*.
M7W9$1^C$U`8?+7TZX;[CY@%]F5`%K0NB9*!65,ZUC9C[4KHL_/K;'Y!@'75Y
MZ24)L*_5S+/_ZF-*P@Y[X@XLD<2U>Z6M`2@(5LQ?RT"T=>OT>W(RB,&J5#`R
M<A!QV;A=/?,7/QXKQ>CX:&VN;"5N=3J[D?=5YYI?:6K"TC?75D*OV0:8#">B
M)$"92-(#`"6P%B4VHQB'%_J`>*X/[)^<DI*KC!1F*JJ&-NWM3MDM#_QV2K(M
MRU[M$$BS8R6XNG1G)@K*+[YCNQ\RUMK9O(2KEA`T;/)#M^%0(*&&4!)DSO#$
M*`V[.8%R;/;ID78N8XAT9$A&8-*(3YSTS3O5$F_<D$R/EN)U?YKV^6N;\.4-
M=QJK/ODEMR,Z7;@5";>E+P_,(+'WY"U]:4F\MWO+?X%UHDE&8HFM>,#27K:9
M1NT&O4;JE+HODI(/`0'#<*(X^P=J7T4)*_J=GQZJ`@G,\9(Y@8X^_-BX\("$
MO3\*4PG)IKQ,1QA\HQ'B06I`T[Q9?P&3I$D5VYZC\WP=&[N/SOI<2C`-*"]`
M>"C#4LZ\(JH5)=8.I-1&F%?0'&CA4'?<AO^@)7<<M296M+_'Y\ABX<D^M^0=
M6K+BT3$;MHR>\KD\#$;S\%F+R8"JKB^C]@%%]7)U#LR89VLM21O)6?()-&<<
M1XCE'I-D&8&FKSFHXZLOGQ^M$:!YM(8%_WAUZ<GJTK[S^OVU37$!H=B).KOT
M,"3:11V`_*H:.N48`7("0GOULD9M-MFRM4<(KL#/_1$-2A[T8-B$0>P4&-FE
M8Y6O?912YJ,--BSAH!146=AV\,Z*1B;UI#'!44E[A:9,''E?6@>>0PLX]8!E
MN"=8">$6(1%MU,#=@/OX<?W,TR@+URFT1^^Q1YT'KU#$X:&L7$M+R<]?OAB0
MO8LST8?QNE$NG[.E:./?SNPQ+?V&C>%EPKKF>^FIM0OI!`K[XG1EDQMJ=Z=;
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MUA4P$3>_XW-7U]P$&PGT$`BXQOYY3M4<+/-1K?AX7?H;/U+*Z?%1_UA0&_[Q
MAD]QFD]=\#S3W6DG,5)MQCF9KDT018N<R#LSW6[]#FU#ZLQ%ST^(<GG#E7PE
M>UBW8&;Q`O%,5$\CWKBHG@'L1GMY97]X\9T5E=M%PZC0<@.@+Y3VU!I)+^-:
M47:S_GF(<D/KU/8+C"]T-;0D$=?0U1GM:FV+[,)M5=9LFH;7ZOJ&X#R+-X+X
M47FQ(DI!?4HQ"BU7"T/-A(&S"0W#QCI+M`UDT^W<E3:U8$L8U7,(7C8%H]G<
M>2FQKHP&IJ7,>OR2TE"H;,%N\FI)3!B>4A#V4P!<@L]FXCW!>_XQY;F%9+T[
MQU](V[E2MVYM7A*\J=1&8=-=G&K899P:\\8-FG'PF&(6C1W\S.20+G42>4)G
MQQ^!M\*5PCGE+H`)"FKJ&XRH<M"RJ)ROR7A"ITV5&L37<;SET_EI^&@/CFGM
M8;W"YE:P6?6%"3$ET8DOZ4DX7,JR#BB_(";+QCISM\TDTU?1]#&6QV74[]VG
M5*%NSJERARS5QAI!UP-`<OEX+I0$@;D^](?4L*&'G5BJ"C2"SG5<L7R-$I59
M;98Z(W%FMI<SRFFC.>;(?C1E+-,,TO'I,7B+@[^_T9=I<\@HO5YZQ-J>0I(7
M%NG^GX]H?ZWH[__J?\:QE"^UG_)-_\7.6R)V'UD+%9-(U"XR>"#TOIL?F)5O
MW_5'?\%5KX<8*3EN__GX[/VWI"3)#W]#UI*9K-3E@>HT!X&Z^B^O@)A;TTWT
MUIWAH]GJ=+JW.ML;/-IO1BRN3%&#3O!!X0K+PU^>K%/K0:D="UQ=XE\;^2]C
M!OPPR1^LLU,4_)]^&M@`)NO"=OQO=HPPCY5]KHL^/+GN18ZOO]4Q\WPQ7BC=
M3MI3C`A2WCGF/JP,CD+K?\PL4(D_0C@F`2;=H'9>PSFPM*:SU4T`/=V9-29B
M47HF-D[YY^V6KN1>OMHW6DT8ZI0$X0TYD\*^A>U%@``C7NK>Q>7Y(47%AL\6
MH_];>IB7I[-Z.@/POSA;>G%X?6ZIE!.,=#8_<\T@-X]8A'?(`8<R@R@VN][(
M)GHY@P)$)N;$'H#B\G1C?5J/7DL#7)D?DOX;V%307F^MF]/=U8T-(M2EC%$]
M6C3$SF1UMC$!ZCL-Q,5.`W:/Q?H6NA,:(#\>`[)Y5!B`N^%-HI5(6!D=@@SA
M?F7:>6YEE:S.U6V`MC'9;E9VV/A'G/EV[,;&6>(SF*.DOS(3]!*O12E'V,:-
M]V,G^?W\$Q<U;-LI\M^&.=OY<(C+L]GZW@..9WDBF,\8;'`@D\G&ZM[6YNKF
M9,&)/+GOB3SI[UMH?]>)##X"23@@<)`3V0")IJM32&;<8W6?$UD:(,I#CT.J
M=CD/HJ?M>01+@>1FV]NK&].]9J4-5N_?$X9?/N^/`1&BA=EC?G#AL*NBXXXB
MNL6>B+,Y:HL)ML1TAD-9<7SW&D*+K_`GG"T]/N'WO"==Z4?/SP[7K:F\/?=#
MK'6`NK*`Y7QOUY4K:\>8R36^/1/U<MI:)R:PM%`?K$\]JWT^6UP2SH%.6@Q'
M0'6V'*0Z`$2J/4P^1N$^N.5Y$3V5.@N?F\Q69V#]YF;B]ABYO>:>A,A"G^P9
MT?4.64Q11+<Y6]]]$-%MX13:9;`!T<$>I].=U>V=W07XLG9O8;//JSVFYD?V
MINIT*)M79)^Y>=A[&3T@H@:I1A1+%Q1!/]G96IT6^(F%YP$-)W8=>^$$IKQ&
MBJ5YKI7$0?33VLV3#H*`Y,R:XP"]@)ZZQ1*'PQ<>S3;F9TNX(=T!K5(`I)D4
MTUH3`$"DSK'6Y8WU[2T3N+%-0J)"WD+0\)@.06<&J$95R!.BT5"LZ^GIR=)W
MJ$JRB4:S+1;#I3H/2C6_J5-5]@O]=3Z6O\&ZMU?W$`#PY@8_;AE?I#[/D]1B
MRQEN`<&=C=V2ZR_N$#&^VT\2,-7L/2_.X+\M[PNR>(=E!EMI%)?ER69558;(
MSXIFFSNKT]W=+Y_K6EIN.899SQ,ZXWF/6ICI&(9DG%H),0](?O_&SO,P+_>I
M23(<K,9I`-WRSP5X77MQ&'AD<"5%V5K"\+7(AX('"B[1C0MT[=K_;2U/VG4*
M0H==U[TZT`<5X[30#RZ*9,`@C_9@,6J7CS0,@L,[;39;6[2=QB%AO#Q;\N($
MJ4DL0CC9LY8V[WVFV1"(U[YS;2O!?2!*M``+'5;5-9EEHP.K6U7-*'$WV1HA
MQ$,]_]YNC/=0,WU`)/DLHT"9#-ZF*AL%HW>_8,=*@D);([0<J2O?P`9%J@8-
MG&N6:6$0:VWK:M)JD>'+DB;LTG-A$EOOIK+0LLUXAC=IWM#'S?D`KT)B:R4+
MH!Z6?<-]@)H*#S!)W4UHN!3H"*A-C:_4T]%3F7Q,0HZ%;O8C%R+F)WLXK%?Y
M7(RK'!Y>RCTI>5I)PP)<@4L6%(R_B0W&7T_*7_LVCO^,?C.D;;6]P`<'!P^.
MO0'3AW%O3&=P'/MC<V:#Z.^M3>0=ISVG]R.=@+"@BE'J$L$`E5J.^RG%'95-
M$3'4Z.8T#+/2$K3`PZY_MZJ'\ATRM)!C;CZW^>5SL_=FQTM#/2862/T9!Z6[
M!]?H,\<*^5^-0P%RCAZL,4^F=_P(TAX'9>!KB>:N4ZO6Q%2UG:AQ"2@4@:MS
M=<12JJ#.8`Q1H>V?BF1OF*`ED(2=HJ3E;XS6^+L!9/EMOP/2$1PRH$::`3!K
M^;:1RF1]:P/S1_:W_HMB6/[&O!#PS#1WBNJC%2#I[#U8,K[Y!F"NTCJ;;<!I
MR3$"ZF'(FZMB>0]Y`7E<GE@E5NI<+UF8%W-%;Q&P(Z,[2WD7D]GOYWB?5`B2
M/G]XXNG-$:_K2-LS$#.08QUWHH&./G)=^Q2!CEF@#7H%C`:HAS7@8X*@QBA7
M#F@'G6\F@V\:*+G")N.!SY"2=L^FJO"Z@"\JDMXTMN$?5H\*S55@).%@U_R#
M23I4M#2P/VF.1M:S/KLK#C[.Y,<#]_VCIIONN8+L>+`KMNJ8:&14U#,MOSVS
M,1QL?/G-3@WIY!3&OH/)N!M]@)H5Z-+8\(/AG]I=W]GA_[?7]_";+^^L[T`N
M>KKI1!)_RE3H9DP4U("F'R(1EB00?.6C&21=4ASH<FBIU>]E'I.,B`7@A#\7
MIS2$@=OB93*[`8AX1&S+G%0XJNX+=",5'/-PZVL9",7,F&QW''ND<I2V67G'
MGX5C/M)!F9[PR63;TY7:4.6_SO[M#4I#39#A)T*]ZN&S)B>4-U,-'M1Q).K;
M]+=A*S6=EG>VY%*Y]W;OVN2;BJ`(XFC5U'=C+N].J]E<K0$[B?`K%M!(/5-(
MZ/PFT]B$\U"]L2'Q&(]SI8\H7>!7MU"M323UZV=3IM8":PCOBFNW#Z&_OI__
M^5!/@T^@`P@,(K'`V"&CT0FWN#-494RD=5PMYJ+]$3J8+TW6&'W-:!V/E4JJ
M+S%;?%]7%R3`CN%GNWMG)6,?'I"7@!)>`W<`K+7H@T8]U\E8G:VT,O#L<P^1
M:I?BP\-`F!O\7OGBDD>N+=[G5IESCW.9LL,_+\^M"DY)VL5.$6R%$6Z$R'@E
M3H9_W/CONR97TV08@<&1G;8IU."^6W5V&:5([H,PV#6X%(06LS6%@:UQR#7C
MO(6LWFX(]F)^<K3&^^'9,V]J/C8_7(%MV!D_#S.T<NPU\^2%G&S13"J,&DF'
MJBZ#BUN<3-AP6N?HW]`'EW/K(#@-T!AW8J@Q6AB!=5/1P`E&5Z!=%Y"9ZZ:7
M&2HPR&ZUR"Q6$^,YLCC+#9M:ZW14M&4+MV$1'*:[@VY=KKG$?&VN'46#>Q5E
MU/1!F]38=>>0S*$WVZSR@^5.ZC_=$&D&K"_6`<7TZO9[80ESG2)@6C21]8,2
ME:#HJV_W'%DJ%%N$`EI^B#K%B>P/VG$,!.YK:2=':R2F,<C+N"V\S]CV2U1_
MZ85756;=T]*KN,SRB46.;#3/G<VQ;@D*;A$4O,_TKRVRXPX%2Y+NK^]-CWT2
M+=N(LJ3X2GB$'QS\$C>P1&O%GNQ%_4LN5K&0\X^`0>Q$Z&WE"X;92G@Q=T68
MI_8CQ)4W7>C?D^G&ZL[F5J@>J;!+L86NE&+.R$(K1/;F7OJO23@9IH]W4#/X
M)FOZH'<9*S;A[-WU!<A2A<(R,-T5U7OH_Y3$R/#UDN<QFSI&1K454L1;07*=
M'W4WJ?M0G!F`M5J1=\PWZ"`!%N`<I54E<Z4`W'QK::S$)@2>XN@4UVW!NTDX
M;RO!)DATH-3!?:ER@X3!5,4:)6]C?7?:HS\%6C<</RR]P]W43O^80V]O+HT7
M1N%0=%8.$JR[O`"C@(=Z.A;EO[/<QBJ,H>K'=07FG'!/.>#*J[M`&:0=H+.3
M^$@H`R,3&U$PEJ%(.8XJJ_B+$WK+;0_.'5!$(N/-`SE`3()5JHF)5BFGJGN*
M+CPV2T<+E6>_LXF#8WWLFY=C#P&,MB"77;FDV+6>]/2V>Z3GSFLCZU&JY&FA
MRIL+X47IB,UN^NQ\P-0\-5"4GBU_OGP&K%-#NE2TE/[C02X1)N2N-S(K8715
M/,Y5.4:@6)GA*AG+(&(R12L+I]03]U/6LI",E$'73`@+%/.RJ34V9WM"_`Q.
MA'KSL]C1YNK&UF1U>]9F0FB7[8+:XUQ?>AQ-,EG,MNV%<,V&0>;#G+2%FP\#
MP`_(L!&1G!EV?Y!&%QA=?N!`-4!61LD'I&5CPDYJ^)X1IZL[>W#9[0T\>S>F
M5FM+RI,A35!',)!XN*'TRG_(#K9F6ZM[.\4Z8_W*`R*&2#)&8']ROBCP&X5,
M<)FXMV6!`'"'*.H80`AH/U>&"*B$C/8>2T^H9+5`\/-73R3PC,9OD1L#NKHG
MA_<3?3B'7]W:VB-?8]*&D5H4[6HX]^7R>`K=PVR\.`Q+X01#RY/0N/S,M-2C
M2H_FPDK6"T]UZ^37$@1!&__%!8$8G]KE/9C//R_>(DZL[R@:LO>0*LERXY\H
M!'99176+%KVOHT79T;OV8[]'0Q>7WR"&0BZ(0/Y?(;QX.J8GO0'!JFK3%V8#
MGEJ=X`O$*G*]7-8^HDWD-C%[)ZM[5-9,MDN@UD%QYQ)D3E_*U2#-6"P]VA)H
MNQW'9S)PA9=JM%E;,N^B,6JSM>I#R^:=P:0]:U;TQ2@XN:5<=%]#!4S>1F$^
M2]+`=O55V5C1ONT"*#+L?J=W1-*>C'+G5EM%DDVT\B1'DA)-<CO+P]N+V$'X
M:&/&3<O-47=.5(I*"[\>.GW<JQ(;"%5R`1+T="O3):0DD@[]SBKY.D?7HHR`
MDVJ?MKA`P."JP,1'0?$@B:NE:/R82LD>G8*D)\K<`7I95WRKGNF]^1I-6?9^
MQ_C0/HHN:V".;PS;F_FM]IN\$EL6^.YA]*KOHE&9\MR_T':!EGXHWVR5ISY;
M5^NUOIMY,BRS>SH";6$FZ>9!(#N5-NTM!;,8Q7B]=BS@O:>@?6D%&)>FP=^8
MD32GND"/\5P+#ZD'\#VC8A`I-7PO1UJ<VO7P-+Q2*AZVVOM)_V`W#Y;^VZ21
M;.X590E$_`5$_]XZJFSUL/3]!FZ!O'",?AH)>?V77D1R7*8,DB$GUT&^OK2/
MO\NU*1WW$]?WU2O2+7$YK>8H^QW&8C,B,#C#2GMV4&9#DU:\2XH/K'!YMKZ]
M9_.]",,@6D!PG:.2,=]814#_F8<`TQ"T@3#_Z&H",MN<J78&88(90W3!/;4W
M\[Q!_]:\B`XLFUV^@[=V@ZU0D+U;J!(WJ>6,^-V1U2G:`"=*$AKG.[Q"SSLP
M);.KMV4%4[FF1`:MN%G)H+0H3MD@8\V1/\?F$U??6/Q1\`+;]ZOA3N"Q@]#.
MR&OLU=N=P$+$\#*A)-J=V+%I"X,ULTKR$6W!>EZ]QM"J?N@!'O4!-R(=4`_8
MI?7_'&CA;RS;7=IK\<*1@M3I&J>!QS8A[SOE%0P=0L6XTUB'CM&]".H>:?.M
MD/4_TMD&#8%=U?XI!]JU>R>,E\FQ,C]%1!R5:\+]*1ZXZR$>T#GA],:"`>Y(
M$QK"0Y4VAK(UW+=3'C[M5.QU6J[HF'I2OF_@%RE&9H1&(C?0]TEU@%?E?)M\
MJ`#A&)PE.&PGP]<'",)U&.V4,6J/%!Z%_L)3=)W-R>HNM#D8R@@AR<*)9&1U
M0X0"6TJAC8>-QKH59B0GR*W4$0HKA`_P65+`Y.ZD`$U!@$'-CF-NJSUWL#A.
MH<^`>^TR@@/UWWJC3=2$-@!E*J=SNDB?$V)>>8\?*,!YSE$$/UQ.U_RU;@L=
M'V9-+%H"USL!UY?!PYL/P=2+PU;N&Y?.E(8/8/$T*23[)'C[FO7!Z907?RSM
M;/I[WYK^[LOGM2^?MW=^UW_TJG30(6T&;0:B4696_S7JAF8^QN;Z9&\P2EF#
M6-]@A3M?/ENI4G_0\E4H;S>H'9I\N,<MY+1/O[6^U=^$&E-^6\;*C*ZE?U&W
M'Y_RJ_?L^_;__>__(P1+Z2X6=J8P*\PZTJ\@`@7WFA0MR6][$:4,"Q=N0@(7
M^2#J&^K,X5R&U;&E3K^]N08\`5KV4WK.=7?_YQX._"H[KY.*M<^SU"5E2`1'
M\3I%77)32ODCP6_;7]Y@BQ]7+O'PP@L\;T^IU>5.(832"D6;M$=1%LU2Q?9O
MI+/W9$KYR--#+7S1?A%-CHBX&5.RX(1X5!Y@J1?]1"64U5%>W:AF4%?KTA-+
MJZ#="L8048_SCV?-:MR?F.-H`VH^I3`J&[@23K#XB'[J=[]@F[YT)]3E82I>
MG?SK,4YZ\SW]345S0A,"G%2",%_;X5</@(3WRZ&M]1ALFH3;NOTX&`(#FH:F
MO.52P@%B&7MX=DF#+?,6BCV\*NSA5T$N*Q+F='4Z=L7Y&QF/:L<D5E'TIH_'
MQW_5OEJF[BP[CEK?NQF>2JWI:8R+4O%!RH(*DY4V(*+[`$M.\1Z:2ML1S-G]
MG=3X!F[XJW(@X!2@<KRVDZ;MG^]2(/"5E\9_%B@Z3E$#`_+;9O$SI]Y)C^D7
M(;D,GF"QT0-D'EY_\7R;B.0SX_.N3"4)I$2]$YQQ'A87$*&,CG:CWM,P"7GO
MG*:BSQ5K+\1@R)+-4^KNJFP:X'D1'\\\)B91]*LC>O%BI"#,PTP0DC!,^$WZ
MK7.#_F$:+O<X(=IUB%=I]9<`R<-_TF^PZY16#4-R&^C@F%=U&QI\09J)Q_S4
MWU"MQM\T_#%7Y(?:D]\:39,AQ6XNSTS718LBYBIS-D.D9FH<92\Y)>'PNIL\
MEEP33&HIFY4SDWHWG7^PP\V=FZX9>+F`',<;+4=%\LD9OJ0;J?RB',N48!K%
M/.J\$D?JMGIC&4/LM8G"F&^XVW%U:V-KC1C^TH#POV)OXMC-XTZ6A@#V`SM)
M_3A:DGQ]KHTT!5S69"23(1-?,#HZ.KA8$GGOWGDBCT)HCP^5$0*+]-+\DL8-
MYM'5-]`!!^'Y!2!K7$[J_10X(+UBBKO^D&^:FBZ-R4QRV.E$)?HL3W0$;:Z_
M?<-W;[F,IM'0\2[0)^L2\=SMO@END#2B'0@U%&<8Z/*O+<K?5W__.;LS]A\\
MDI+P;J"#/XW8^Y?/+U&!!H_+<`L^?Y7WB/>G>Q*M^N$#7SY7D57O;5KY%Z#?
M;P=__>VC3+_H#XBJ0.R5EI?]!W]6,4__QY63LR^?U5_R"H5F.,N+VIJ2+G3]
MA*7-_FA_5$?$80>=A-V@M<X*==+;%*_/]OHC/6NS(Q`BPIS^.RN[%'4.&Y'=
MON9I?Y3!KH88%.N7JMS_^L_&GDU-K*+.N]+V7]WWF+C'POAO-D[`92E"28D=
MC+!`9G5I=WNZ.MGQJ/]L;W67O)AP1Z-RB?[@]6:V=].W+6,11O\7FMN8N\4D
M@+U8XP2>4!(>F%R"0BB(!"FX5^\5@?,N":6P-K63D!(EFS7E`LNR3(O:3J'3
MVF*9(N'=3=_/\M:4@N&M['LZ`ISNIH)?5/(0K\ATHM)IU632F.,L5YC*5*BG
M(].:MTF9^5X5A4-'&K^[7>%_?@*]M9F0]E`6]KQ38?6QYMP)/:S1Q1AAF2L7
M@+["<&M]5NNAES?I[;"WN>>KFFQ0$J_J7;3G4J#E.H,OI\OW6QS`]VHM&5W/
MN&M)RS/1G')UEG=W2`?(4K')ZH0ZLLD&U0S=)3PRW]R0QMQ0\\5U^EY),A3/
MJ4B*^TX8\]1,T-`.8JV=;7AW4S`OWT4>*+]*VES*ORL2H3`)*;38KI"L+M-$
M?R=D4WDD"-]Q;PJJN_P)-7.MH%I5];LH_U8WJKE"WF<$S[UT\@U]HIK<S<7M
M6;:5B`Q<CI?XY'C0VPQ6:0S$)EN4:<.)#5@.D!$XR)S+V$!1J$R:OCV6AFA!
M.<OQE8=7J_"`UI$7]HIU\8.Y$=1E#/GL$`4/J+B6#H'*QAER-*=T/SO\-.CK
M-;P6142M;%UL##1FC$.0(BY'8)B&6UJP8MA!3,V+\6RHNS3F]3<><6&KKE0,
M>U_2.>?8KG"N.Y3W^OAZ^.JS`(I9PU91`09XAUIM'Y99FX+U#_[UM8SF!W[T
M"H/8VC^(_[0>"&_B9GC?G^C%Y85:GAU=WA`&1W*>7(^^UO8W&@P!E"_[/_[1
MJL\+O`?0ZK\OE<-=_98N)^.G_\H*;&2Z0P7^;&OX"-6`C+*-S4G_T0\XANZ_
MC+'C;?!CH#&N3/=F:M/2GW7Q]IO1^A_=NM3?%SS]-&C;)")(EE3XT)7)DQY,
M@U715L^R_AV5(<K`X;3LPA68=NH'69NJB,7KPF^T1"+H#(<]$+\E59G<?*^`
M$%&7NPCL@Y/WYY23&[/5B[8<76!YAN)L@<BT+R'$DV^^?';_*</"1*]T"PB?
M6K_!B(\;]Z`MR`7E#?B6ZMW@5W]@@&:$Y#2!>413B#XIE=36HM%MQ)&13%"V
MQ.E#:^S>H/A_B23`M>QMM4YU/JY["NM/6$D0?@0\/;\#`4"_;=^+]P#\@\VZ
M<O*CSV*>9NN;IP9MUW31\T9\Y9R-G8D_+,1M66<ZIUL.+ZXWD'JAQ!ICE[HS
M0S!J_*A7""C99?P:Q].#@WDXO;N:('QP?OY7ZR-9.+QYHBJ;EX`4:VZ\4-H*
M1R6?(=FF[E=73X$>_NJ15#!MKEFT;DQMF7U<Q2&9PJSC3%&+IDRFQ_T\'MSO
M)YF2*E=X9)-UP%^(R)6I?#/WXKQUX>C'$!C%<VIIB?]=L"$@48!1SEAD<<99
M:>T%G(#$.WZF;!98*S#C7$>`.:HA)Q^11_S2VD(`Q/9$3;=G>T3#%9G-A*^!
MXD9NK/C2$)2@45<!H@M6T\''%`K)3)A!2%!MM_<)J<.E#YI]X7J'9:^[$2C(
M*VR!P1I469M1&A9M3LOB-S>FTUX-E\Z@A85)\5R0#CM/E.TL;T[7=U)/#*7F
M02M1>K;GS=E*^H)!<`S%J%F6L8#.L@1KP:HNKZ-DX#H[2PIV%5`.%O`HT[2"
MH@YK6X_^=,10X)SO3R[*/'GI`[0>MT&71+@$GR%H5BU8"`>8#?#%+(7UK0)&
MWNG/SOZ8Q601[!2\E"?'`-/A*.(0,[_3:'.#%DG,GQ$MO`[NDO4XEI4#ZH:+
M&_*SD&:%(8XX777.&[4MH_@E^3W,$WT:'=W=+R_1LKRWW:`H7]OJ@RF?$D72
M!G1:Z*V:.\A__HXL(Z(<HYRVG^32(PK2C5KPV811S\$QET`_E#UGQC.J_L0U
M(V&S9,^L17'C6K8MLV8=5=`_\^*955C4%7W-%+1P,K?-F`[91;MNJ$UI\!&9
MJ'M$NW`E')'NL@B@S#$*2'RW4B_\W%:Z(-3FT)W:]8^FY-#PVT]:K+G;`!G\
M/)+'6#VKB,"-\C[!Z.P06\"E3F!@X8)I'%IF:Y@W%8XN/EO-R=M^.Y\66Y?4
MMTI4`:Q#N-H.";@H-+8EZ?[!MD,N:C90YQ;#Y$]4=H%09CA@O@3GU'#$S>KX
M4B;Z[&4%S\7FWL#=94-I08!NQ0"*_(]Q`WL&FNB8_EQ[3PP,TI7=K:U5"NX&
M*]JB<]]T9Z#GE^&U(10-I>VR:6VJ:7$QG&8ZF^$7V^U/\RIU`^?EHY;/"CXG
M_!B#I:SLSJ8T%QQ`;65&3@]?[`PLD94=2GFV&6O0/?8%"$':`4KB7/?Z$:T^
M_C#8A,<.1A)Z^KMZ5CWW%?12WB[ZQ:S>#ZO27G^D%?I/[LQ&MKA'[[Z-`3B?
MF-QPN3O0W/IC/R\>`DLRPW?S^Y5%6/7(N->0,JM`%^L!%\1W@P+9KW=`Z_B,
M1`\QBP))MQ'4X]*Z^H`K=D?L479@&MK5[U=26<.!()'44<0TY<6Y]SX<'.KB
M,=RP,%7NUA&0H[X*[44MT^5+T6F;%E08F7,`]ZU(]MB#P7*>.@@7;/C1`@^=
M23'YC,CI=J'MWKH[X+_:U^F:IL<V9-OF.!JLOYW_B.&GB_D(+/>4?M.':H,#
M5-3DT>(/`W?CJ6(9[]XCQJKQ$QI+^(J0/H@=!Z&9PN+;11=OQC<'4*SP;)')
MA8A/&<K.QXSS>BN/!)&B:B8YH5KL[]6E?SV^C&LY?.L=\2*//7J.5MAN8B$X
M7%MI7ZV-[9N=)>)6'H'LCO9RN4B)JA&H(#5X$%J-UB4T+MIB1T,(FAUZ]YY!
M3/K4M55G]F.*8\=AV54WM%R=2:O_D*5?LNB8`<\QJ@86-B^=@BHHT"[,;P7)
MT``UG;)`#.[2#K=P\VE;FDZDE2J5R4IY4QOMG%7MW._.9TMMZO"XL>-C0XV7
M%/))CF7!_D`<<DG0!ZE^PH8G4G3]?G@@;WKX95K,L\9,<\'<+(%\:Y(+T$@N
M20F@'H\0UKD[F".%I:FA/O[;O!!<F,&&-#>0*@UZ1GT@/F2QGC;V`EEB=)1`
M;!X.N1F;\A++8C#Z-_P:YXZ&ZFY,0HD-FQC5+JOVZZY=Y9$QL8KJBYT"H'&<
M9^#%5SK01+\S'\A3DLKH:QI:<5]ZHKF0#T&^G17//D+ZO0K4?>11;F'SXCC!
MSOK2W;.0@'`]GI3QPN\YR4H*]05L&$^U`^_=R%@,$8'WH_2XUU18O%]ZC?[_
M#&OM4%V'&J5'%39OSP\Q^O#>.+]K/=W('S#WG!0Q%<RJ<]K!.>GIK.YR?G$,
M01W*M0]3@15?2UO`^**R8SUZ("O(D0Y))E`GE!^/3\_M;H(UD`3;$?WL^)*U
MXJ;B9?B>E>IRL(]>/_GR>4_76OAA-?D;7S&C9+\N4+H_"WP:R8J#57RURWN?
M#_LE"1V:GL]=_,BX]<]JS@W$,T/>3M1JPES[:$MTTH;U"*#1:-/''G8+G613
M2I#',#8HLDT^\TR3$)>>5W0M+R?J5D.'D6$R(DD:6$A'\FFBZF?A&'!1;Q*(
M30VM6Z\MM@T>DN(*[I[J[%'ZY/$!WA)I9@YAX)H&>"I&`O.9RZ1U[OF(LA=/
M;@7MUU(^`0!/K;(TK</,N)$FKX%-"1T7OAM[`_8UC@V0RZ)]0OPZ@_8:<_P?
M0*D!6A>!`#HZX,G5>Z/1[KC5D5!T#9/G\),21V@\`P*1RU=I>Z;@:LN]-_A4
ML`4:Z:6C25>?)[OY8TX(#6'0UYS7C?(DYQ6[711=)!_KTM/\S.*0Z3Y0=P9V
MY4MD@.Z^)%UY0=^?E:WI='5K>V!FWV>Z06AK97N3UM7;@SR<^PPV,"6?6;J\
M>']O"](2T)BMW^2-RHH,$QVFI5FWLW)@;9K+6\4>PJ_I)`&3MUN'@#CH-(#D
MU'R)MQS'&\2&#]$_:YXT+6YH;NG!+(N*XQ9SCK14NX*Z0<0BLHP0*2/Y(VL?
M_R$(3=`:A5E)SL*1FIG)1//#][H+R<)ES1!,)K9@+04EB9"?HG;I6<*_XHUU
M*7R==PE\PHE(VWF)7.;T'N^.-P+2,B4<Q:6)<@B_R&,(I=B',WZ:/5!N"+G;
MG%[CGA5;%XA8;?`(ZQ=V%=SD[<DEY/T2O9S^#"1S\XWJ!/!!\U]6(`F?6QML
MRB>G;/.)R6U$WO&'I2>JUW]Y>4ZJSH=UZBG583=(0<DWS1:(RPDT.;G/"3.!
M]QQ)]TAC(=NU2L5`6XA\V[AP`@F/O;%+OC5C8>RK%H^%NIT8/%NF./Z<)@<X
M0S>TP<ZJ^.Z74DM@98N#59Y_^0TO1<Y5J,@IE30`445+@Q$<?P84!42)E2&*
MR(&NPS0T6]YMD07\L`[S%7VX9TEB`Q0P#&E[_YCLTG$3Y`7Q^2/.?`23[W7H
M8Q3:$%D7UHG7\TZZ,)R@*>[.@(68TR'D!#B*Q<N;'#0F!GL#:T_.J"@C]8VD
MCH4G*&M-"4KF3$<F8!X>B6N0*WYY?N"AX-)3/ID#=2R8AT&$R#-"`PJU@]_-
M0MWA16$)F?1N.)9U1MJ8</Y!)O10MI%C2Q5K(+E@\5U@VJ-D?@-GTAN9DX]/
M=1?W8DL$,GKR$\9&R?B!/"N[)1UB)/-.>TQ*X%1@W'+3@Y/XQ'2[^MKU^5IH
M\Y!L9S>Y`T]\?ZTT9.C:S`0&;4P`0P+4(RY-X?:P3&<0\G[_QT>DV8G%B=U8
M#KKN9RXM%]$^M,".DY[[FDF#.)JOTE3_;R>'<.1_G%_,S^BM;1;0/^'TF=N,
MS_'*S0='8NV0R1`\Q*H1FW+65F2CM>BVC9@,)4)\SJ61;Y&EAFO)'_EL>9,&
MAB5N%%P^0-EU/8"SI0\%[P4CBHXONIJJ#@,DDA=9!B61`]UALSS;Z;Y4^'^1
M@LFZ]?9DUAOS\OC=#2X:14J&'QBPV`U<J6R'=3B'&7D=:9"'G9F6$L'2_@12
MO)D'HC@1=9G5(F[$TEW"0P<X?43X7H+1X@:G[UC1A2&,*+3ZXE(<`LIT`(P3
MD.\4J2Z/)\.A&VAU<)Z(O>>9ZZ(83Z?ISB5QUO0GL0FM\.H"NP?]0]MP!2R/
M04&]8O$:/)N]5Q"""+AM$)P,\B/Z\Z-PIO9AS9I19K21Y+]09?.ED2V!,5ZZ
MNA:;$^>R+,J\4J:K^FC[=14K5JXK:22B\Y8^*69C(",-JO#A!R?SAD-2C/0-
MO/)PKN@QH[(`7ZG9=@9S5DK[/;>+#'+N;[U@9%EE+-5S,=J9[(3T'VJY+)]`
M"]9[UR.89C6)D42A)OY2"'%%MP=0.$M#S3=H3U`O?&V`-S3%"E69`QKA!+X#
M]+ESK*=WZ>G48%IG<D\3[514H+?=@'?D6+U#7D'O'^AY>WV,/^WR_%,X3&$\
M(;?CZ*$W[0MX`W2<=J5DL9N'G7,)0^O=FUI%$:#W8M*21&-8[@)6X9!(F*DD
MXER>JR"O3R@LZ5`8%&]A.%B_EZP$G&1Y=REKA(J=:4BN-PAN)#0@=/'"D"^\
M7C\4H<CG5&C^/B0O>](QF+&2S(S'%_<U-2]E#3%;087D?"A[P%(GT*@6+#0,
M,:N)-BTN/TB)$P,2)=?168$6"(!%8S<D0NYHYZ)15Z-63M:A#!*)"Y!@0ME:
MW)*,K<3,6Z(D2EH\IGR`EH-J/79&I>`+2"S`H]#/V:S<1Y82J)(@2MF,$U#3
M;=@;]ZYQIYK93;)05I>NK*Q8F<8&*_E;3M4W118[5,"B&.GJYN*"NW0$M@XZ
MJW0<'[+Y:_7`S2!SK20;+WJ(3N("HX0Z9ME0DNZJ`&3%)NT!@`2-.JBX7FIA
MOW'#H;S8Q=^^5&!%,,)%8"UG"W;*E(-LU$A6&!`:-#\"'TDFVW5RIE*>;;JI
MY,41/?+5S$7I:(9;*8$5P$+OL<^#.]BQ%_BS>T'8'*_`IVRL"REDD0CPD+B>
MH!Q-UU!1X&IPX51[Y.@M,2N!&XSQCE#!SM5N&FT7.J)^/+.+<K3-G36+CPA@
MM,K('L$%3*Y%>'R&<?PM0:OE[4EN[68'A]Y!(7W1CE!`T#W;IG*SU32^AN#O
M&UW[%;\?9&^TIP[E%AT@V3>@6]Z<K$^+:8ENN%?OP#5RI,U1\QCR+^4MM7$Q
MIUS$(C[_K@37D2.^!'(C2YFN(YU(IU+`W"\[1T-M%=26154U)7&.?7FME+'1
M<(IH-F<%Z2UA"?/P4$SD.D&!^-L%;2?$!@[/"81!(^DK"06S?PR/1MR&4T`&
MB(IB#$@3NAXJ8Z^%(K`2S./6P@N'D;2LMYG?"`450+#FS'E(_ZLD_]+80L@2
MZ$*M64F'+,<7T3GWAZS&D*0/`L\6T[3M7N!0[]!T*)=O=].'\O/F!@6+:-YJ
MA%XIMPR>\I-L45%^%J*)[YK6")<AOFXF"DBKW@]7NJ1"?JP4;<K:-X>0O1N\
MPP`AWI%6[/'2_J-7;R+(]N$<D7:#N:'F%M9E2L(;0,.>P46<FWDU0,_]!`R_
M_^-^]ARV/ZGQXM=LISEGB!."H9J,*)U/8Z6'_]5L9C`CE:@N3J0KYQ8K>AL'
M;"%2Z"I%:<>*WNN9N&F^-<91<!V.T3%;IRCG;AG;N-#S'_8EPK$GY4\UG=0[
M<\BEH</$.:'_WS&D67""6/XM%V31HT9CKL@)<;OO+GB8F1Z\2.PSJ4%$TK'&
M`]\!P1V&/&C*MQV20%`4R\89D<$E3J.3*QZJ'L11>#Y3:F4AVFWTJN?`1?%*
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M]FKWC<6PN+>)F3??R,*<U3!`>F$A87E;:W5S"2@LMO9<LS=/65LP(`S/8;OZ
M:_%<R.'1VA#)5RQDD&J0`J=:5#(?K-2[UH*-,@@;T,EB@175+N?.U9B9HZWU
MLFBXP3933PH=8K><9E1$GYAUY*7:I@QJ9PX\/L;?*IM*[TTWZ""CAH3$6S^F
MNR_,XV?[CP8$R,[B1@2=*J2G0=)8Z`:O@4%Q"YL4^R/90MP9K:7HJW1S#P-W
MK3D33N2W$:JUCB-C-K\S:,\),M>FS>-3F@:3^"'$EALWG/\6QO'62^;T0;8J
M%+"Z%*OUIMNRJ1JDT/?BDFF_R6/^414#MC%B1W:!$BNX(2CCV3U80S&BS^@.
M?)(JSB]/CSZ2A>/^%0^NN,YGHV%FN9-+)U;&ZDN%-\TI5!S33;W8`BAV=(/9
M*@PR-U+L\G(D[LX;`:^;F8C<,?,_'0;,,QC:\F,ZLZ-,-=MK-B<(CDR-?\L`
M$;%6`IO6:A4<=7AV)3-+3.$\MM2XX:62IV##1<0<X#(-FB"G4YE.T#1X4'6L
M0F;@P:&U!VFWX!ZL>DKF)<JC,CR):2_XL;8ZVISEO-6S@;+10"3&T'(:&"?Q
M2RS7X#[8V'-#&.`"YQ+Y"140;&ZF2`P6-@>;88_N+74BS0[K#0P:KT)0D3Z/
ML^^>QYC5KW$]Y!V?,",^!3D9S7+E3)I`XE7&*/1.,58().72/<*M.+B,F_0U
MWM>Z&8W!?@U%[C>_Q*A?(A#4[DX%WW^$$XJ$O9HO144(&./C5O[D)1*D.9#<
M;!>,I3`!B_`\E6@J;#IE$-R]U(FK9V1,7*+)MWH^Y/'(^&%)*N@G&G`U$%%`
M_,\*HA'SO"/A8"!;6R9N0D*11A?JC;ADA[>D@"4XH<<QTOO*R05?PU60?$4\
MNAOA-M9:#EXLJ+7;KJ(G9Y<?]2PVL:*6UQ"U,BY2@[XPPQKTU1Q\DF6-K;F-
MSG)@]30+H\RZ,-#BQIJT]*I18+F=(E$^):FFO'./KH:5)0PCW$LKFK0?2H[M
M0$71@'KA1)?')Q\.N.3+DXJ^N=OXMAQB`LS2B38G49.7G+S`K1=M;H\OS.[;
M%!TM/_#=SLMXB-$[IW2N/`YBX)1:H+O]Y1RV4>$H!=-S$'@OBDP4?!*0WBEF
M?F8Q!4V@?Q$W>D_HRK4["W0?<_W,_T5@6EM694NFP=LP'#2^[X?-HHA5DD<K
M).I&_Y4GH>E]I76!<?5B+[>&A?7S("!M^4@D`SLO<\<32O=(VRI6,AJT[Z^`
M03L#$I9A*G,8:S(#_7NF4+MNN+'4S:APCBW51(NB:%KY?N3]W7;$C4LA0KZF
M4/::A[3V<AY$&_\MT]X:'+?DY$;+L8U9-6LH1B3VC3C1!VQ\D8]B6GTLPJ4,
M87<<6V,3_(3H=1^D6&TO#J_/#T`ZK#:U[%EDM/6E"XA6.%%*4D]#>WQ^_%YF
M)&-"1)8'!:D48\Z8L]"XAFI="R9]<US-=]_)U062LZ2XB4ZB^E$ZXAR:^E.<
M`=3:ECT5.=\U25,=;%;+^,7I`$=*^PMUVG(#/ZT=N'V\6G;NIR+A,YXXQ?Z3
M<Y;]N\445U#)(J`A/GUK%..N>-1P"\[$"K0RD<C6-<"M/UW(?+HE<[H]V=80
M[+-^$+#C#^E*2:G9U&Q@!Y-#5(9Q.R?:N7\@O9BC-#Y9PJ,U7BN9B=FBY<@*
MQN;@9O!+3LP$`IX#FU"!Q[%QI.H/<II*+E--T!M-3^IN15J05E'SAB4:YI<@
M618O96K5&&N939JX<^-CN6C-0\F)M,I:'03'Y"[WOQ6SLOF^,=W*.N"S#+2\
M.QW_9&#>255H[="NW3G&2O)(:'F,_:2>>%AZE4@S!JU'A01S5!5L07YO&M8Q
MIF'^9CHIS?A72=)N>1IE<?(._4+FD_`0`5JZV4,RT'A';"C:VPD!+\ZLMI2#
MMN9ENKK4K/U,-T$86Z2UU\E:5!X>0@S#$G@5O1^=6,%;Y:;=;!ZS00QI:]V@
M*0`=DFU43>&TW$;*G%:)L1Q,EKBJ0K3FO69NLMC>(?C@Y+B56S]NH>7D*9*-
M#4]>IS-`%#D:V9&YDK61>JMKVH5$&*G^[,HXD6%ATC2O;D(28TR@3:L)L2!A
M99=TM-Q82##8#SRJID6ET$M[O9-;TCGCK$B#O772#F$T#73LZ/#%2Z'>7]ND
M,#);%K^^5BT6`J5Q/D_BX#C7M]X-UBH[30O&S$,9B7XH@C1BTY\6I_H3:L4I
MV+0YN75;@S<ZTG0@>EO&U]>]M8>.&9EP/VX1O:@HS&5IF+;W4*_\2`M$!?P6
M]]*:%3X=E'1G$+"+_*YU."JIL._#N5#Y]VC_-VHTZCFN.5:7F8]8QK2O*&-`
M&HVY8[D$[H#3`Q9KOZ`W_`7JT2+3"WMV_(XUN!??8(\61V4,SNQ&!&9ID@5V
M:@IT;_Z0]M"J[(XVZU$;+D9LK7S(>(;8EZ?=0]Y^4\>MQSL""AUHK[;&E?@%
M5:\Y#^:1VAB<7'K:^)T@3V6[FW[N*>?@,.D:U6'@-^JL'*^_6^>>3D4M#*%,
M#%C.;5#7G4CUC9T@0'3'!DX0"%`P+H:Z)LX,S:%WX=9='=12I>C575BX&)>F
M*6V#`N.C>U31OSEQMD+E14F];\2''+VI-%.F>N.HM>!8&A2N5R?VA$5Z*9@5
M4%+[P;6KEPB_'B/_CJ;2'TGI[_`Y;\>I/:EVI*5O?3_G01K^GY96VI4'-W)W
MI;8@G'5Y;J,L/,-F1^DZ:B;Y9@S/TWTEJDF[(/%.93,BYX7S%<0V@K=F-!*#
M\A'`9]T%UL.0&+"DQE=%/OU.0Y*E/FYPG>S=:TJ)^9JLT%)A2]&[FY8%F\/M
M5.I\QLV(__'[ZV_K)8C=-BH"48.#O[F?S"<4Y-SQ%C57C(L5_OWZH:(8+64&
M#*?K'3-K%IX@;<)]A[B[#M7'170TQ."DQCNQ=IQ$W:]F[B<87_&LM5<+@\;B
M2:RI:A:UD&E^%+$Y=O+H]9]P_&SLK=%^'"D22A1-L*P?Q&1L!26HCV:9=:VW
MN.`FLYHZ@MD[F31=I44L]%NH!1Q-+=GMB4"]^SSZB4BO;JV"(5B-T!XM@]&*
M+#6J*!$CBBYPZ^CVMHV%:5&KQ<G8R]8HCH$R!59T-X7*6&EQ,H;;Y#9?):KO
M(B_C9+-1_]G"`]R,A.FKKX)/QY.91JIEC,$#JZ^0"C7K+NDANVGMLH?OIO7;
M+/SZWJE0C67!O7UB&"GPNSDS/%(UC)U])6J+9;]\RV45#_6U+DBIZ"ILZ2.-
M&:S?PEIQD=[B(2T*FDBC6*#X5U.KR"0K`#@@I8[56F@C[69X&F-^E3CP;7(=
M7CJ6-C*R/+;4BT),6O)I7'T7]W$5.@E-]EJD;<:0T$E'NMM2`L]BCV`Z[3C:
M#^-1BY_HR*LUK5I`:Z%6&`'$)D\#5O5;BX61@HR@-H"%AH!;_^I$'0ND-2C]
MYGY(X\D.J6E@+^B\>UZ8=IZXG%*VQ5WN/-XAO^&NI@DU',,^.MXK*I<(`73P
M4*_<<`.5117<O8]?R&Y$%3*U7!%\I\.!_#>*NA05JFI9->+*J+'QGG]H=JM:
M(_;S4]HW))-DP1JB[PGZ3YA@T83#"D/G]+NY%J9Z$3:AB*5/^,4BU(.?Z&D:
M_\R=2E_=S;1@<@6A9,D7'3$4LU_0T32"/5U_D?P>9J:/NY_TJ!#'HG-I++`N
MB64M^*#VJ/A_S*[]NW<^/<,'(I.>@C?3I''?65L[<8^Z1WEH:W^@@&L-)W#2
MYG;1*%_%916,HW7Z_,>XJV(AO[FJ:$B';@3'EB[G[?2$`J*CQNC]^MZJ)J9!
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MYZD[+8<!VE&/F(%(JP=R.UP5-7&8T9"G9.7`_9,GW2,73\::$@10)4@BCTJ)
M>WO*!MCP1]P]9TM/5%/2]TL\A_O<G!U_^:R4O5N=1AW#JP&>^8V:&8J+<D03
M"KJR<+@R+];^X>DK]7>('(R_GG%_GESD].WYATU=EW.)KG_YCBLR5-%R(':O
M@VN:U9E;Z6JIG1^*KGZE##EA:Z"Q>3]H0$N3,N3R2XRKXR4_+?^[WW#9/42M
M8T3)9'5%L@:;=J0#R-^92M<N_,Y&I*2)E19.@U#AF\;?!Y#&/$S%2]P>C1AA
MW>`8R8&[GE6Y/*MLH2MZQZS47I+6PR9G!QWW3F]WEH6-C7]R?<HY<KBA:BQU
M$H34%L+=5VSAMF/K^*D$D/983-+B_E`OXDSROJ+LPLH;!;F2Y'UXSJU$EF9D
M#,"RNA7JK!G<Q$6<C*57\.W%_$QY*)6VU#G..523MCE`JQ8:0Q]#'<TZ=+R#
M^BW_9T"IVNG8R:7<3([5$IP-4O+V.ODH4&MD0%C"9A6KQ"*:%1OU-X>[Z*,"
MB0ZO#F,+`(]3><>C(-AJDXT"P`E`LXO/L;-4\8RV1YQ.+3G*_>U7K8`O?W+>
M0TT":-'R`:;5*/YP>U@-Q/P,S1UV79)I'J2W-_I^\>4G<#-#H'MPG)U.P&L'
M1DCP_MD":8)]C-[AC8Y43#%E?J=".-05)#4)[]$;NB]2&U076[I/7-,UF7&$
M#VVKS<&M\9O%X<?;PW_)9#JDU>AU]YJAO_%1W0B5:'O+%#4WX]PNNX<.1`Y?
M^>S>JH]1^_)6G7#\R_&0VFBXTW2Z.EZRQ*^[@09B#]E`_T!0[B(F*/UN@W9S
M(I\GGI/H-S4ATTBQ5];0"#L5XUHD3%:NS]'+X&H^Z*.4,ESQ:"+BZ>D)/?!/
M2>UG=*-8_@R]PTZIZAR$'"FSN*!?_`U*'OKNTGO^..-G!*ZTQ"?[*-+#:ZLL
MD4\<(JFT+F)UJ<Y?+OK0YJMF:&9@9#>@U$6_O0$UCVMPXS/=J<`IT7^Q!L=Q
M?3__9$?%C6%U`]9;N#TYBJ#Z904"`191.[Q.#U$70TJ[9\@OG_U0;$P.O2GY
MKF/:6,U0`Z"\:!&+M;KQX".?X>,T[;I=,2-*,!^A>5O2(#@A]NJZDEZL#-:O
MI('.U"N"[Q3AL5`U?U<=DM:S]2J7EY?GU__^;^_^_=^B\R>[?O/I_S-WIKMQ
MW5@>?Y6+(`W)@$K1XB6>[@X@6W+&`R]J24Y_:,R'LE2V"RY+@DIEQX-YF#Q+
MGFQ^_\/E\I*7MZH4=S"?XJ@NR4/R\.S+M21[&@-03PPIP%</Y;X)#97+QY"T
MQ;KMYI2BN.IRPKQC3M>DREBL&`B)T4.$_-K0,I)RQ^?\0X*%I?RQGO8POUU<
MT#V&:TR+DF2]%Q29&CQDC&E?@;-+%`CI=AF10?F=)GAJP:'H#>A6<MUS_+ES
MNQ5=0RN9P:!F=ARZ$`.'ZND<-*_-RI.C9\>3"SR#PGSQO(5C1S02A?%;T=4>
M2:]=3'(NSYDB[I*'7*>H3A`=,#MR%X/H[$LY+&?*@T8+\5%T\D9.+F_X,U]$
M"+V@%2B<"9IT`B-XF`DI#"NNS^:T48/6/D#7IM:Y`SS*+\FSB#CGJLIZ8?YK
M9-9TE(NDKB4+TF(1H]WQVJ5*2(J'])]77S#%0#O]6"IL^Z.Q;V,FK,$:"+8V
MW7<QH)\>2>OV-!C]'HNWF^%/+D'H+>\7(5$ZL@!&*=,8\4F*%,'S]XMFM=2S
MC,%9W1BK6OWAH?BE@(S?5(!AARASKJ6!<.FIW0DY(.HSDS/7]..#_./FD+Z,
MLZOY`HRJ-W=YK.8N:RSY&NSG(8/%+]27K0#I++DE:P4F0Q_4RD7;^@8UZ@U"
M_B-_!&].R'CX#)<FP/@EQ&VF7;NCI12-U@`!\55A`9_R3D`S?7;^(1K(H/T:
MXA=3<FZ:`^"3GM5-MEUIR?R%#>Y^5R.3O@K?\F&'#E:3C3VX2:<((6UK2?/[
MT2-*.J$%/()ZC^DA+Z;4I6%8W\AZ0EU=[4"=,>@4"&-WSG4W3,N?@[8VBE]6
MY($D1O9#`/YD?D[+;0OW<(7Y`?F9[4NIDLJ-;ND=P0^TW%6Y8C?4MUGBW9Q3
M9/6]XW.^G1\N35VQXO]OQK*2CR@!9<W6^+Q7+S+H3`Z#KA97MV_(X0RC*061
M,5U41"V<62V6U38(0TEIZLHCTNRU1,,FXP\Q`+!+152O7&?C-ZA[UIKBD3F-
MB^B;$SI+ZV&)1\%N"R5+_B]`4*%C!:GUW?L0<Z:?%A3+M@<5+=D.]7"$X1\^
MAPTK,B?KJPBJ]Y4JQP+*DU8VF=CB_#]RT@1_-DOGRR@E'H<.EGJM)RX%N6FY
M53X!Z5-B\G]LDN=EVU.>Q<%\CE7N>`$5$7F),#B![`PQ7%UM)S(8A:1L<!=7
MP7:S25^[^`$MV.YU51BOOGK%?(>(_!3G?(F#--O02I0V<<94%N:Y)4WKDJ-N
M-J?W?O\-W73KL5<**1QU3A:8'F>4H+DW;HC\S#0-3M"X4EDA\\_9G/>]5&#8
M]8Y6I$Y*^4S]M*N%7)FQ_M*UOY)@)2$VD'\:(9C_%<@$VO[#K=W]!ZZ"LLB_
M29@\:DM,^ZNMP8?ZTF>B(S[Y[J:A\BYAU0_^8E\2&/L7S=$QI'HHV&,09*V\
M'>\-08PGR)O&W]L>*S_X9!$/OE6=57:T^S*Y)2@)W0U3X:MS#^GEO44B'T\#
MM](<`Y@%.>7[EN0DT5YZ$*DY/-`/UX?NTH0JUU(NGE,F,U?!-<-Q;)6XKG4E
MJR04<"PJ2MJ#*1(=-$>.!\XFFL&1,$(T7/<]0-'1U((JX-A`9R2<79^PBC/9
MV"4'#'16=>9P$7:U--F"(AX1<7?U%9OX$\H4O$-`/D;DR*F/!$VB5AR#.Q#!
MH@VG:R:XFEQ%8D"STDKHL5$!0>^&9&`F00M)4+*M\*(S`LU>JCC;SQ.Z<LZ;
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MP.>7("`I/>QDS<]7?&1[V\V2=9O-Q>5X0;V]R<6]+@ST#K_]R7=J3AK!O_WA
MI[^%-NR/M_<??,?_8X!THMRGR=^_V]5?;IZ!%$K3_/MW9S22FS>OL!2=7*%[
MZ-=W8]CP5_>S??[#S;$M-[]U,%36^_&;+O;[;_YLXIH_A`YO!HQO&UV!Y9OO
M_?(BPJ$E=2!OD[/^<_>^/PC+-]_[S?^GO=__<_=^^V%PO3_MWF]_VC22CD"+
MP`6EQ0Y/^JS,>;[9ARRO&9&X_>G$R1YN#^'],-?^UO[#A\5?]Q[[T^U\N;?S
M(/_R%1H(?N0K%/Y-C#2X+"(<E%<<SZ?G^8A-]%"/MLGD.]M[Y8H[V[O%'P<7
MO)C.X*L7Y9);NR7HF[O;CXN6\P>NKH:D],JV]'?UY()E(6I@PH;CF7;@OR?$
MZ`I%(HB!07B0*D)C)BS.="HO^?=IK.#4'"$DWA8&J>*#`6.8JC45W^>'@DZ9
MVM:_<<'O4]_:V+S"[Z71M>ZB5$>0S@#V^&2I8+CG<T5JX9>7R")KV>)62J1D
M#)WZF^W3[35[&J/W,E1]I>*L7>'4($5<$:QU"*?_XV1IY_(R<\V_H;!YEA*D
M+0\4")<=SXJ$>[%Z28UPMNW*X0@E,2,D2I="D%NGFM?2@@`H78("+-)(_>T6
M4BAGG.&40`\#N>=KER2$8\CL+2.T:==KGINE*`P02<U/`GO"V/G5[*+9W?ZQ
MA<X:&[F'Q_MC;J1MIYK+TJ.62K+6@C#?[S_<?K#3TB4NK5-85B":`>F+->^U
M*?6W`!&8JU2^N3]=J\'E&J%[=$1JET6/=I.S*S-Y!Y.J\X?HF-F3II2NIT'=
M4[_OS1_MCI)3\_+X&KL[2XX<<=PU`A1!0^,\GTPN;(/?/WK8FN:"^T^FR7@-
M&@&H\62T#:L:R)M$R_#O%L./J1/Z?V>::*N]A;F"(;&/ZGTR1R#KG-+K3?U.
M\5(W!VUP__$59AE1@,WPKX*SG2Y6G^1,IL'YT!3/5/OE%VL9^A+]$*^#*5ZM
M,N!L(]KO"SRBV)A$SW/BFL!T3'".*W=T:D61_FDA8+=Q]-=\[%&L<_%F3EC_
MC"]1Y?*O3BCO@L)I%Y%6@7(IAJ;$.O,M9F'500S6ET,US\6P;88S+ER/4CRS
M:>NK=$W6F-X^J"XL&&XX[%ZNL*&]:1K:"E`5W"E-J'K"BUNW(!?]1$*!@7WH
MN#64&2"0'UZ8_'#,.@S1:SY5[[)\XZ>JX4#70"&GS<"B$*3`61L.[4+$_NEX
M1G/!N&Q8[`AC&<#/&ZW3OT`_/GD!JOG72PML_N\"KG884],*\5;6!(!\NL!@
M"(.3#TQ_EM^I5"03C.EY"G,,-WK)0M\:`,>A+[!P\PA[UK5A[F8-YY-S[!]:
M[%#7<3'B`CGAXV#J7&5^PWP_4.@035)'#D>+E1+8D@?YVG4<.?@B<T/[3,`4
M$<Q#A"Z=]\]8O6]!`Z&H_OYD-C[_.`)M,(C/&S?'Z!CNH`]>7A%W.;2\>[1A
M91=^6CQ9C\%GXU]%J2H'KHWC7!;U!,J$Q&]0/2W0"*9PUE?F2>A+0;%`![`)
MZA,1'(*`7YZ;:0^F!2L8"?.=EM/8B4WHAZ%78L_TR-5V/_@D:<P=,`^5NJ[0
MD1"1)["]';*@5"_,5W/T*R;*L".**=4.B4+L[SE$&&;?N!Q^[Q;B-CF,Z_&L
M1<LW%OOKYHB>D7RXZ$S52UV%,:5`+[U#R@/BUHMO@W\8P\G776KLJ9T.*(0(
M!L)`2Q")K++B16([.G$1&+HE[^'FNWSUUS?O%1+F,$?$XM7X5M[USJ!FE(A)
MT--H`6LV#R4DS^XUFV].#YOO"]2$]N(M4U^.5CDU0FLA08I0L)+[)BVH(!<N
M=)]%D`.ZP_/$@CHG+N:BU.J(Q]MN=FD;JC"+?*@J!-8(96?_!^W^7[]KGH@+
MJB'`OU[(7?N<JE3S@M*G9FOP[@JOL"L3C.)=L*OGOJ/+-6YO^%Z4B2X72H_1
MF9O8UTC`+391&>M$VZAHY\.@YD[.,S^#\Y-1H2`#X.V$*]6E.[D["FGY;,.,
M240B2&9W1YG3R7OQJGSI5_&,6F?NW'W:@]2^B0]V6BG99H57Q)(SX4XOD6H6
M6J08N6$1D:!9OOR!7,+F016EDX>]^,)HHK0OLA==J!["%F(_&I9UO:%PKS<;
MM;:.KG2`M1]ZA\+BR.N,*G687'$+O)67;4PDIV0S&$=#:!5A<_`XO+[D:O0=
MV%IWE7R<\-@UA-ZEE.`?BRLQ)/%:1](/Q#_E][GY.($-RJWS_(([0>R?!;;W
M`D/5C'C#VNM-I:/7<*N;YC6U%&],-().(6K.81V:8V^E.=Y<7E7&[]?'M[)>
M"DZ?WC+"$A/UDZ6ZP-(C;6]J*W)3J4?^VI#3B0^2,&R1C9*U(<+E%O5-*C\,
MD;N@L-0NY`D>*X49O(U2`T1-+IG\M80/)Y#<RB?)6:UWL!V).QT:Q/:6:YVB
MA$/@O1A?L*]@N0H?Y+OH2/'-R73^<9!9=%^[K%KS1-,-'F%."Q=^OE12L;`&
MC>^G4?O99SC7?OY96MVEJ0D'/C8O'DP.3!N:69OMKI>77I=_0JF^D[R)OE\#
M-.5%)N?<,S#?WUK0MS)VJJ-'2/.Y)?JC9-\D:ED`._\TJ&);Y@J'+W24N:%W
M"A\S1V@^X^G5NULT)J(G*YKK,\H!3$T"K'VQ00^*WKE?C-]*]E$@I`!][4(D
M6^6S.N&#RGS2%5#4T.`_75-.U;A<^UCSK6V<?I#.8V+4S-0,11TJUS5:)-X5
M$ME:%^UN+BI9ZQHO(D;4A.7]01&7B(IM6C[VB[A$9]5_A,7RHT^]SH\MG;;P
M@*33%C^FTQ8_KG6PJ1+U3<PX\:CSW1X@7US(U)09BH[4R12ASED_LXLNS43#
M5+YKY,M!@*>(21]*;8/BDJ.-_2H7!FIOY<A<3.*8=QF=VB_J#RE0G8S<(+PD
MEIC*1RUG[=<'H1$KT+V524<%BF^CKJZNFW;LJ*)]"/!<K->J?>A;@0>R`(N\
MT:-JPPX%/87SP^X]O;UW=_UI[_X@&=D=_-7IT81J$;!U/X>8>BHHV;[N;/XC
M4<J!R.P4&KC'^8.5\=P/>++N@*?K#CA<><!_+6;!Q+#S8[[[DS&.VN;)%!WG
M_,,EH37O]<:QN549;4H]?<1.JQ:&\QHUK[$\K$H<VE%GU`Y=<]1AL]X@F-'N
M8\.3XC!D;I-@:X[OE<%(GD-X#4,23FL/,)L)5L*Y52.$W_>93Z`4J1V$;TU/
M@9"B^T0R?!U)-V;Z\X_Y+9ORVCH/\Y]/?-)7-*.8_R7_RLQ?9O8][_@I0ZA`
MY7N_/8P!/CY84=J8-O+/0P@X%49EHB\,&4?>@>E\HL7HSC$%%V7_3,C1-\HY
M4ZC]@M(%"$;H\Q=3];$A&$7:YY+S3'E8]BF&#;')'#XWPG(=G>&+"\Q&YD-:
M!V^(WC;_\<)LPEU?;?`(R.1BOSLO<#YCADL5PYSWF7KJ7^Q$NNB-#)[F")P3
M<5Z8O#9V1UA%1KL_;C]ZM/\XAZ+SRK(S(&34+K\9+W#8W<ANM-YPTG]=PX;U
MAOE5':[>::B".]0E`UMB/OZTU^5T9U[_<-BB;/396Y0+^IPPN]V='$ZB'K:;
M/4O?[>&$=MW>A23B7I/T7A.783F6[MNZN)8*=4;#:S-V/E0$KYC\3A4`L8,S
MNG,HLLQ$P3,K;UW.4ENO9X(I"AI\TLT!=Q0)@V88,+5I3"2I:2_2+A&;LJG8
MUWYU7R]=V'3U]^A^DQ80G9,'27$DRW%^#HY"Z1;CV99S'8_>=GVA0\SKX#UY
M_>^]C[*?NK(E3+X0"+Q?X^6?`VP;\V(S6IQ4Y2E]F2@-#=J-V'(CUW0(:^GG
M"GYRN[8<V[LVK?7`."3C[F;J'+D0<J+"S./7F%=<2@ZDRSV"*_N([E4TC&G(
MPL.-ZV(Q_`\Y5!LX5XUX\E\+/2SH[YGBRML%PBL+,*`)(DFD*_DO\I7"0*N8
MI>8W/BS?<A[SC^7B-E_`;/K.?&P._-YO-Q[UFT72(XYTOI_B/L7CP(VFDD^\
M:$YW;K3(@5"<SS\]BHP"BM@&1W)K)3V1[)+\W?@3R/?<XCH5,;!$*^+CL\74
MZ(+]V`!6P:;,QAT_=T^E<=D,^4(=)_1Y^G@EAW&72"B@/+Q=53)]1H2=@7^Z
MG3%)<:;B;.HK>6[/8N8.M\`:?',T4\ZAW;C??[VG%2Z7*M_V$`="**+YHV9I
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ML:KZ;0?"(Q>MLP0\O[Z"4VH[^`6OM*0%)$'6=RP,.BH:F@^)?*,Y\+)%V!\6
M"4C-NH>X?+[*\2X?&``K#G/YT%6N9/DL:US6\LD&KG'YX#]TP2<3!9TJ^@/U
M',I+KTJH\1E$HW/9.:9L/'0<D*1'U5]1;`^V2W(F"WX;1*$F1&<TNS_V?EAN
M=`BV@1,+W+FA)H$#[9NLN,8QQ]-9!D$K7SV/\M4ODJ\ZAT])G$%B,##+P#$-
MC%ICJZ@ZBOEU$9-WUN<[LZ1U8@:BM[#D?':5LR3MOYM@BP=S94(D1EFJEP%V
MJU#.''M?*20>T0XY`\17NA,]AF]NOC*10E+)3Q:A=H*390<;LN>S;%#J<#__
MXSI33]RM]H58,/=^,?<SOT<%::)@DD2Z.J`]E@YW8/V3#8!6[G#Y&6!/GTV)
MT(0/Z;*T8RI#6`F0?#`[[T\6ZUY8[XS..M`SX]ZC_(\M;;F6N\=)R&;VZ^#%
M*KCC"LE$V9K`,?II^US^4-.KS<T9J43#:'HY.A]?3U%C<\!^5DEJ+)A>"Y&T
M#@Z'"0M4[J@S*&F45%6Y,I6=I<A77TJ#?VN:=/(KB<&8^K5]NY,D63WY;:LY
M43"O'M9-(3-P7SN%C>WN:T#I\A,11A0^ZA(+,XP@<*#!5>SB[MB?4G5<3B#:
MS+0\1S+1R'ER;R()IZF)ON7Z71*2;^+-:9R]?7&>[.A-B.[D8TZ-D$EP>X$:
M-Z,J^<UT?D%`HNZK!EB'E([@ZG\@6'T%,;U#_;-@--,Y];S`X3;0I@4P1)HO
M7<99"D<R!C$52T8=-S^R=G+0860J;S>Z_H^'Q2^%MB_>_>XN831J`EY#"W%I
M[";*2]&^P?PZI"KZR'%8G(&4GY7>5>'_PZQ-="J%9$(UHI`\N#"?2_QSK+F2
MSYJX;/"D+Y0E(5+6%W4;UW(I*&GQFE#.!Q3"!J:B2_DZJ?_I.+K^G+;IG:F'
MU4?BM+/@=L1*>WYU>8EJI(=E9DKST\U)"2L3?"K7^W0XX2'!FB!HFY0=R&]X
MS@1Y]@;C#P[*S\:\>Q",I5IN^!"J*TFHHFQ6=ES/V7"XXH;%G(WD!/JWZ.<+
M1@<;3GI7R$]Z8PCH_TI.30CK+^(%GY*2ZL+9=)U&/M%=+^$'$1;1A@11U\F*
MR/.QZSBFR%P*]5AK%11N;PV#(J?@A7O/K_"E+[Z;_QW3C4P(T:`2:@Q7P7B1
M[]W0KNZ2<C;Q]JBJ$R-_8S4N;$OAOG+`+0#%NX(*>2'U$Q62:EKAO79<-H'S
MVY5.O7@$7$?W]!.$&"*DW4&1],D459A=-EXIVE$I(9#78J,;A.RU'=(+J68C
M:7M4B/\;;/+*3UP<TH:O\5;N/AFV4XC!KSH]IV+->4_T\SM,GDP@T.8X0/LJ
M!>6G5&VS?(!8`DYEN'HS-T[:>F[+/W9AW\N_XZ4X8Y>SX<L"GI0#R+>VL4>!
M0[,6E+\$+;[\9;<R)C&UA\AP1Q,C[N1SD6D%HY?'JW+VT;49)IR&-@QB7ZZ@
M&4I6-9-Y<'QO\?<<Q($+=1$7;<7J?"@!$RI=[6XB_W%C?Z?7((3HFO7>Y0I#
M4?)"@$]P,Y0G5H6H6"A0?$`Q,13ORH^ZF*N-3_(J0YJ8'9!88HWEY.?[X?)=
MKKZ[(3%6WTM"E6$O95]+YQ-@!4CYG+F$$^2P0F>(#IBVQK0)S-1K$#?LI5@0
MJ@>CG2)(Q33Q4:G<'3OG$9=1Q>:T_6R^E3.+[':)L]4)6'MO9[13%+3QB,3:
MX9*UI7&^QH:K!9?_61A53Q.]LTB0R=GPUE8Z*9(.7Y"52+&_&?$!PHS454ES
MI];XH/B!N56HG7P!8U#L"U:;%G?-M^J$K\`NF_\-(?TF#K7!_J?7JGH</NN?
M)#&&]:%/L=++3L'C9V-E-\L045T&D4K'T<)Q1W"776_JA@U29G^^KWO"\JHL
ME5H1@]:K"7MWT7/_X6#\;Q+P7Q9)*@K<#B)I2DQ)_R4HT%M#]>BM6FT@0'4:
MH-N`XL#4SC]6XAE#.$]1=I5GX`LOY"AY'-2!)"1`.OTXEH*1+M="7-#VZ#Y/
MRVW>_4XL!2-4R<R!)1<K_Y-BQ%7DU?0Y58\453Y&.]%_#V`%+A7R&#U?)1=]
MU1(%69%VL$H!==*[*'FI)^?J5X;JHD0%DIY);KVM2!!.40(1NNX/7;)2J+"I
MXR3TPT.*'@,3I0QDOJ_*8'D9S633SI&/!$^N72Y\OI*`).2CQTBZ+._>V;W6
MS[!?^MIS[6\E13(?%`EA3=DO!PPPE,X[R[+1Z4/5DXZ>CMAR46/UP.B$%,Q=
M7*JF]`)?'H(;0J(Z(;@#2_PPG]_^]'\"````__\#`%!+`P04``8`"````"$`
MHW:X?XL%``!$'0``&````'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)Q976_B
M.!1]7VG_0Y3W(;$3$D#`:*#J[D@[TFJU._.<A@!128R2M+3_?J]]7<!VZGST
M@9;F^.;XWGONR<?RZUMQ<EZSJLY9N7+)Q'>=K$S9+B\/*_>_?Q^_S%RG;I)R
MEYQ8F:W<]ZQVOZY__VUY8=5S?<RRQH$(9;URCTUS7GA>G1ZS(JDG[)R5<&3/
MJB)IX&MU\.ISE24[L:@X>=3W(Z](\M+%"(NJ3PRVW^=I]L#2ER(K&PQ29:>D
M`?[U,3_7']&*M$^X(JF>7\Y?4E:<(<13?LJ;=Q'4=8IT\?U0LBIY.L&^WTB8
MI!^QQ1<C?)&G%:O9OIE`.`^)FGN>>W,/(JV7NQQVP-/N5-E^Y7XCBVU(7&^]
M%`GZF6>7^NYOISZRRQ]5OOLK+S/(-M2)5^")L6<._;[C_X+%GK'Z453@[\K9
M9?ODY=3\PRY_9OGAV$"YI[`COK'%[OTAJU/(*(29T"F/E+(3$(!/I\AY:T!&
MDC?Q^Y+OFN/*#:+)-/8#`G#G*:N;QYR'=)WTI6Y8\0M!8D?7(%0&"8"]/$XG
M=#8ETZ@[BH>,Q`8?DB99+RMV<:!KX)SU.>$]2!80F>\L@/RT[PRVQ-=\XXO$
M4D#74([7=10OO5?(8"HA&Q-"5<361`3D"O&`WI4C[/R>HYT;!Z]<^+QQFUW#
M"OH;A,P%<7_BW\XJ#F\_/:R0@F3U)\7!&JFY1@HAD2`%;>&+'Q6SO<>$!D:A
M%PZAQ\$JO=A73[U!"-*C4Q+'T[E6\NT]A/CSV9R$UR`*-^CY_JGC8(V;5K`-
M0F3JPF"F'=]^?ERA%:FT^DF!+U+I17KJ$`+9N7;D])H7[#@;0J$8JQ3M2N!@
ME5JL:7"#$!LU1+1H1>'%C6[P%.&+-'Z!FI@-0FS\$"'[,IK%83R_;5+A.!_#
MD2_2.-Z:&J<)0FP<$=&'(X'1.SR18I7&4FNQC<38:$I(+YZ:;=@;D>"HOY_)
M<:156F*L_#!,+$8DC;4)J=2:\!D^N"'%*C6/T:V9L-H28^6)!M(.46D.,A%B
MNH@A:(EI/S<.&PGIDC2!&"-2R%>I*8QU48O(*]?*$<-@*\9!%$YGMT*H*=3,
MI-_4YA=O.DU=UQ)CI7GO+'::H\R%F.X2&\*VF8>L.$+Z9'.0P9`6AS%TW6TQ
M,HRD9Y7U*)\AIM%$1D]V.XT,T]X/:D]J5M,Q'5L\YM;L<NITFPQ!2)>LZ2B'
M$:LZ9"TQ[?G!1I0066D2^H0&MZM()8=4<YA^NA:K-)ZZKB7&RA.=IA?/44Y#
MT2+@\WI-:`A;8JP\,4POGH.LAK98C:YLB;'RPS#(+R`V:5.(,]QNQ"JUWI%1
M;Q[9;C<R3/M6U+;4[,8N;7Y?KMN,+FV):3^WE`V&Z93V*(^A+1ZC3T>)L7*\
M]Q@"MW]32LEGVM9<IJ>V6]S&J'6WVU"$8$]V$1WE-]3T&U/<W7XCP_0C.LAQ
M:(OC&.KN=AP9!@F&^A,+13;\D=)P=8M5FKKURQ^)L;6F%:+2U$S'KNX`74(9
MXKJZ)<9*#\-TJ3O@LW[P+8U8I:;0N!Z7&"O'>Z,)<([?'G.H.=2,II^X@Q;#
MT<4M,5:>]X9#PC",*/UD"`409T0^^2HMGT9+(L;*$R%2VW:>@QPG:'$<7=H2
M8^6'89#?/!0%O]ZPJ^4>93J!:3J101,Q5IHVB$I3LYP.9;=8C:'L;JL)$-*I
M[%$N$[2XC.[;$F--(8;!2L?V(:Z93$]EMYB-H>QNLPD0@CRC()H1<O<,2:EU
M.,ILQ*H.94N,+9\2THOG(+>!]UO&Y-$E(S%6?A@&'Z*%!`NN21O?@^%KHG-R
MR'XDU2$O:^>4[>%VQ9_$,!TJ?`N&7QIV%J^#GE@#;Z_$GT=X6YG!NR)_`N`]
M8\W'%_Z>[?K^<_T_````__\#`%!+`P04``8`"````"$`\#D-MOL&``#>(```
M&````'AL+W=O<FMS:&5E=',O<VAE970R+GAM;)R:VV[;1A"&[POT'03=V^*>
MN*1A.P@9I`W0`D71PS4M4181211()D[>OK.<C;@[E%9D;V++^3C\=V9G_J7I
MQW??#OO%U[)IJ_KXM&3WT7)1'M?UICJ^/BW__NOC7;)<M%UQW!3[^E@^+;^7
M[?+=\\\_/;[5S>=V5Y;=`B(<VZ?EKNM.#ZM5N]Z5AZ*]KT_E$?YG6S>'HH./
MS>NJ/35EL>DO.NQ7/(KBU:&HCDN,\-!,B5%OM]6Z_%"OOQS*8X=!FG)?=*"_
MW56G]D>TPWI*N$/1?/YRNEO7AQ.$>*GV5?>]#[I<'-8/GUZ/=5.\[&'=WY@L
MUC]B]Q]&X0_5NJG;>MO=0[@5"AVO.5VE*XCT_+BI8`4F[8NFW#XMW[.'7.KE
MZOFQ3]`_5?G6.M\OVEW]]DM3;7ZKCB5D&^ID*O!2UY\-^FEC?@07KT97?^PK
M\$>SV)3;XLN^^[-^^[6L7G<=E%O!BLS"'C;?/Y3M&C(*8>ZY,I'6]1X$P+^+
M0V6V!F2D^-9_?:LVW>YI*>)[I2/!`%^\E&WWL3(AEXOUE[:K#_\BQ&PH#,)M
M$/AJ@S`^.XBP0>#K$(0GBJGXMI05+JO/TH>B*YX?F_IM`5L/A+>GPFQD]@"1
M+Z<%\F'8]P;N+X$5MU#+K\\B>EQ]A?2O+9*-$>X3^9@0[(RL0-99&Z1KNC8#
M0W&6BT$;N7.&B'00=;YQO\`\1'C2X#[3I1GX:0FQ!VG"OW&&B.YSRE@L$R:C
MU&=REY%:2\'4H-]3!TN<KL[`1)WT[YPA$O?J8'[)B%%M/B%C[A">-&B:Z=(,
M3*0-*^XKEB&"TE+-=$2`W`68T+$8%N<)B^<(,S`1%I.<(8+"&$NETDR0JN<N
M(].4ZRA*SF$\=7J..@,3=?H<%M.&"*J3D4P4Z>,\`'C"C$].GA\&)L*&]:(P
M1%"8BH3B@G1Q[A*"QUJG0^H]:>D<:08FTL@>SQ!!:0G,W7BX+TX/%V!2<SD`
MGC`&+C8]:3WM2Y.D6IEE[&[C2B=<),-417D>I(26<1H-@7R%\VP!1SK,I_.`
MD^3F&4,&YL29H9T:1'QY9DY/WG4,I[H[?R795)EE,(&"06:<.6'3AV$LHD4*
M)X!S5_GRS*2>+@_GNB>/#(J,(6/OK1*A%%E![B&,"QU=E6>&]71Y.-H]><,(
MQ:9E[OAG4B2:)CCWD)@G.AXZWT_>+(<P1SG2MW*HBE7G6@"/8&0(3A*<VSB8
M8"XA?TQ?Z]Y93L'&5N&,!2O0]0$1\Y0/;6GW'A*7N\=/WRRG8&.KD-0J+&-3
MDR2<@96=-[[5Y]H%3S5/HG38)+Y`XACF0"Y@(-XX>8ZM0PX;R*;1=88$'K,D
M)TC.7"254C%G*;[,6>[!QO8AJ7U8QN8QC23G)-6YCR01B]6P43UY?):%]+1O
M(=3P,\M<WF)898O@"A1/G:WBBR/N,:W$'!W"'32*[+/,,J@`#E0J3F@./82E
MJ8(3W[4DFHD^>1!R0Y,DDB&<60;UR3B)=<J&F]LL8AQD8I8FDE\[]?%91M+3
M_B.0LWVP1RP3K#)ZS67$KS,P;OY,G=.;K<S-522/PZRP,I'!'''H4DV&>FZC
M(,&B-!G:S==([,1HE/"S\+@Q#]14(U&06085W"EX(".[(0\1OLA9EL+'EJ(&
MK[()="V%*YAT`FR/3&T;R.8PED+(V#$G7^(L7^%C7U&D43/+V/PQK;0`7Z83
M>T29<W4TK,072;SE1I''GJ+([3/N&H9.4B:AJVD:7>8.3MY:7&UHXBH3)^/8
M7=2PW6W!D;&UO/($P%TH_`1@+)GV]FV;[J_R>SLF9YG,,I?G2[^8/(AX%1?$
M:L(5[^D;$](R07FA9QE?WBR'$6.'B:D#6B8HSS48#@[IG)1\=<1>INU&@?X`
M-SD_R<5D\F66":J<;#,"PKA;\4:-#7VKQL@$Y840/XO$86[(&SO+N,;(!.4A
M@NVNQ=6Q+8BS3"SQV&'B8>3BP.DC@Y<ZVX`X9!Y$_!S.<A>![@(;Z+P#1P<=
MRP3E89C+B"]OEJ^(L:^,2XS,Y7O;(>C:BH;?![.ARWQU_\M4Q-A48GH,LTQ0
M)8:YC'@R)7&4<)_T](TVMLSE>V,2@X@O;Y:3R/'#RJC&E@G*PS#6M>$8J_B5
M(DOB)-,:N;^*^#'ITLPR09GH*)<1/XO$4FX4&3T@V,@2F<OWMD4.(;X\"#/=
M2J2A2?:H'ULF*`_#V")+.$%>JS%QDHDUON`H]''`//'`2H(J0XB?1.(I-VJ,
M7A*N,3)!>2'$ES?+2^#=\^T:AXS";D%$\`5>+.)D-*SQ#36^>ST5K^7O1?-:
M'=O%OMR"BT7W&O+?X/MI_-#5I_Y=ZTO=P7OE_ML=_!U!"2]BHWN`MW7=_?A@
MWH"?_S+A^3\```#__P,`4$L#!!0`!@`(````(0#^Q(_1.@,``.0*```9````
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;)16VVZC,!!]7VG_`?F]@)-`2!12
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MZ&?3@9_"26E&=H7ZQ?=?*=OF"MH=@"-M;)F^/U&90$6!QIT$FBGA!20`GT[)
M]-*`BI`W\[UGJ<IC-`W=8.Y/,<"=#97JF6E*Y"0[J7CYSX)P0V5))@T)?#<D
M.'!GDV`>7<'BV8R,P2>BR'HE^-Z!50.:LB9Z#>(E,&MGLY/.P)*.>=!!)A30
M$MKQNH["8.6]0@F3!O,XQH3328OQ0+[-`72'.4RA1Q]7]Y"##NKG$(1'?I/G
MXQ@S_3B#:3^#\\H:#!U$3L=]V/):98N9=3#'^O2\`Z3K_;RR!L<(7!V5,1XH
M6\S<=.6$)O3W>DT-'FKZ`TV+F1E-?$(TO$54@P>BDV/K;(DMIEOB:#)K$^L5
M>7Z+M@8/M,-YRVNU+2:TAB-?_[6(GK(^`3K;ZWQ[-7BH'+6\5MEB%D99#Y'V
M=4]VT9?5N_KRCM)!??DP'*XNB['&9\%IWQCV;]?XE7-%1_53B,)%:]%6P%#'
MZ%()\&"RG2^]0?>5PV#8]09DU_D\=(_O>\7'@WEV0=D.J>ZF#J*19POJ+O83
MG<<WC3*#OC3+&M`UXGKX7+W<L4;W:QZ-QED#LC4_Y?FF@:8/[I'L<?LVB\R"
M[!@]-=+@RG&+W6N&FJ&$([@[XD=3S=Y3[#%>DRW]0<265=(I:`8;W7?GD+RP
MMQ3[H'AMCLH-5W"[,#]SN$U2.,M]%\`9Y^KPH.]![?UT_1\``/__`P!02P,$
M%``&``@````A`-<_H,63!```.!$``!D```!X;"]W;W)K<VAE971S+W-H965T
M-38N>&ULE)C;DJHX%(;OIVK>@>)>2$!.EKJK/9^F:FK7GIEKQ*A4`[&`;KO?
M?J\0Q20P'OJBT>3+GY7UKP"Q_^,K3;1/DA<QS08Z-I"ND2RBNS@[#/1_?LTZ
MOJX599CMPH1F9*!_DT+_,?SSC_Z9YN_%D9!2`X6L&.C'LCSU3+.(CB0-"X.>
M2`8]>YJG80E?\X-9G'(2[JI!:6):"+EF&L:9SA5Z^3,:=+^/(S*AT4=*LI*+
MY"0)2XB_.,:GXJJ61L_(I6'^_G'J1#0]@<0V3N+RNQ+5M33J+0\9S<-M`NO^
MPMTPNFI77QKR:1SEM*#[T@`YDP?:7'-@!B8H#?N[&%;`TJ[E9#_0WW!OX^GF
ML%_EY]^8G`OALU8<Z7F>Q[M-G!%(-MC$#-A2^L[0Y8XUP6"S,7I6&?!WKNW(
M/OQ(RI_TO"#QX5B"VPXLB*VKM_N>D"*"A(*,83E,*:()!`#_M31FE0$)";^J
MZSG>E<>!;KN&XR$;`ZYM25'.8B:I:]%'4=+T/P[ABQ07L2XB-D1_Z;<,RW>P
MX[Z@TKVHP+56>3H$"+9:!USKP2^OP[V(>*+(R^N`G56%`M<ZE*?7$5P&P[4>
M_/(Z,)01=Q6<N<D\NQ*3UTA5<I.P#(?]G)XUV,90!<4I9#<%W,,@S8K-AKEX
M:=3E]W_5!V7'5-Z8S$"'],#P`G;,Y]!WNWWS$\H\NC"C)N-B+#/C*\.JF@E/
MU(:IVC!3&^9JPT)M6*H-JVO#+7PEL/65N`:V$1I,R&6=4,BAE-#V77O-&Z-9
MWJZR(]X`XG4B+25%3<+%"C-I8VQ99]K&*);-FHRM)&;>1%SLR%,MVAA79I9M
MC"<SJR:C+'S=)-2`-TW$\^MY)"OAWB=9>=T;]RUEHV`/"0XZ**@GJ*IZQ!FX
M*]8N*RD;/R0F#XGI0V+VD)@_)!8/B>5#8O606#\D-O<(R59(NV3K?3L9/="A
M:&Y68:5V1YSQJOL>[@;(10C)CH]%Q$*6#:]4"C(1$6Q90=!`IA*"G,!O(#,1
M";P6D;E(8!?YS5`6$N)U;:<QSU)$+.1@()0%K43$\9'===W;3JLVPEI$7-NW
M7!0HR$9$',]"GNW>\B\9"R\*+QC+:-E8C)0;SH@SW-@.>-;,PUA$7!=U&VF8
MB$3'"IK$5")L6%]#9"8A%FZ)9"XBD$CFB%R$"Y&PG6YSFJ5(=*LB5316(M&!
M:7Q;N76M1<*W7>PY"K$1"=?#'K9NLTB.PMO;"XXR6G;4$83YG9<S0;55.\C`
MS`WA3WFZC47\(3T1:1"WE,?I5.JWC$!Y),^D?FP$RM-MSOMY.=XR5BUL<:=O
M>:=O)<V)#*3$O+XS=M/>)SD([]TO.,AHU4$EH!%GGG90Q&%YBL$3L;O-,JF_
MQ3*IO\4RWM]NV9V^Y9V^E31GBV5WQL*YE658C8=;QD^D_'B0DOQ`QB1)"BVB
M'^RT:<.>J5OK@_";Q=Y=E?81[L$[=K-]!0?GJMVL!\#!]10>R%]A?HBS0DO(
M'J9"A@>WB)P???F7DIZJP\J6EG!DK3X>X1<*`F<$9`"\I[2\?H&)S?HWC^%O
M````__\#`%!+`P04``8`"````"$`Q5)K9F0#``"]"@``&0```'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6R<5MMNHS`0?5]I_P'Q7JXA(2A)U0#=K;0KK59[
M>7;`)%8!(]MIVK_?,0XD)BWI]H6$X<SQG)FQ/8O;YZHTGC#CA-9+T[4<T\!U
M1G-2;Y?F[U_W-Z%I<('J')6TQDOS!7/S=O7YT^)`V2/?82P,8*CYTMP)T42V
MS;,=KA"W:(-K^%)05B$!KVQK\X9AE+=.56E[CC.U*T1J4S%$[#T<M"A(AA.:
M[2M<"T7"<(D$Q,]WI.$=6Y6]AZY"[''?W&2T:H!B0THB7EI2TZBRZ&%;4X8V
M)>A^=B<HZ[C;EPOZBF2,<EH("^AL%>BEYKD]MX%IM<@)*)!I-Q@NEN:=&Z6A
M::\6;7[^$'S@9_\-OJ.'+XSDWTB-(=E0)EF`#:6/$OJ02Q,XVQ?>]VT!?C`C
MQP7:E^(G/7S%9+L34.T`!$E=4?Z28)Y!0H'&\@+)E-$2`H"G41'9&9`0]-S^
M'D@N=DO3GUK!S/%=@!L;S,4]D92FD>VYH-5?!7*/5(K$.Y+`[Y'$#:R)%\S"
M_V'QCRRP;L?B65X8N,'T>BRVTM6F*4$"K1:,'@QH/8B<-T@VLAL!<Y<?I:;/
MV%L)@TQ)DCO)LC1AST`N.!3Y:14&TX7]!)7)CIBUPL"SQP137\?$ESRNCD@Z
MA"R57#H],]B@J1<&R3X7]GK!N_@E6,;?L:Z5X3S8,)CIH<2=TTF0IR.22X0_
MT)->0F9ASZ()@OJ_7Y`$:X*401=T6JA-93QT2H:&],R@Q3;18Y-=-'ESEW5)
METZPG\X:(@SFO?8VI+7"P//4-#HBOHI(KB+2,82F$S2=UT#J].%,&F\NZ;0T
MH="]AG#JZ"K6"C-IMXXWZ)&X^W@B"'3WY"HB'4-H$J<?D2B=AA('*M8*,W5:
MC8./L?HX4N?D*B(=0V@29Q^1*)V&$@?[?:TP(RIBA7@]"<E5]W0,H4F4X\O9
ML3[>H!(\E#8XF=<*,R9-(6:JA0-O[@]Z/-$`7N#.!UT,<X",X\C@SISYZ<15
MXM0UK^ZO"K,MCG%9<B.C>WF%![!T;^VGBSM?GNH#>PQ31WM'#^U>!*?@)3[Q
M(C@,+^VI%\&9"':[)X+IH4%;_!VQ+:FY4>("0G.L&6Q`IN8/]2)HT]Z^&RI@
M;FC_[F!,Q'"G.1:`"TI%]R(7Z`?/U3\```#__P,`4$L#!!0`!@`(````(0#%
M*GNJNQ(``"Z6```9````>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;)S=6W/:
MRM*`X?NOZOL/+M_O&(&QP15GESB?S^<[XI#$M6R3`K*RUK_?+33"3&NB5V1=
M[.T,CWM&TG3KP(`__O>?UY>KOS>[_?/V[?':^Y"YOMJ\/6V_/+]]>[R>3FK_
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M%QF`_._5ZW,P-V27K/\Y_O^OYR^'[X_7N;L/^?M,SA-^]7FS/]2>@Y#75T\_
M]X?MZSQ$QRTZ!<F:(+<R>O-Z]D.VD/?R=Q=$D?Z.0Y'_-U&R]Q^\V\PE,>Y,
M#)G?T4CN4V]&,=H7P5'XXYWAG7:I_!`-XO)]ZD4[-?@A"E.\^-!XN6BCY(?W
M,(5\_O:N<)_^$'MR;,.)\GZ0<_E+#T\P,\,H[P<Y=WOY5/&BXQS\8+9*)LN]
MERGF+MDHF1OA<.301V$R%X?)RGPYA@E^,&'^)(NBB9-]W\5>_L/%ARI(N7`X
MLGG15GF7;Y7DT#%,[FSFW*4>SDU8:(YUJ[(^K#]]W&U_7<G90+9R_V,=G%N\
MAR!T5+'"^G*J8;\K85*[@BA^$.;Q6L8HU6DOA??O3_>%PL>;OZ56/AE3BAO/
M%N5(!(4Q"%L)&\+R%C14HX;W?NYR63M*+8KR;E0_]4A$_31T0U,WM'1#6S=T
M=$-7-_2BAM\.K!^):&`#W3#4#2/=,-8-DZCAO=O8/IM&)NIX%C6\_Y+:B?-(
M1+^RT`U+W;#2#?YIWD1!?,<LB8W6CTT4W\R4PO&<>IR19JJ<3TFU!?YIIIQZ
M/Y\9-Y(AIS21JF^EB?N$'F5#H(-LB.*6HH;WO:DF;3DN[E7^5.(DI[:H&A+9
MS:<TS*GDB`LUDGI<Z&X:<:('VXP3U4\K+G0_[3A103HHNBAZ*/HH!BB&*$9Q
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M@L>Z81(UO._E.Q5D&B?W1;4#9RZ3M]-I'IEH,`O=L-0-*]W@^[&64JS%S,_W
MV>>;"7K6$INA?FR*^N=SU,HK>9Q@Y55R/@7:RB?=4-8-%=U0#1O>QU_3#77=
MT-`-3=W0T@UMW=#1#5W=T(L:WJ=/;&[T4YB!RZCY,W09-0]'D8GFV%@W3'3#
M5#?,=,-<-RQTPU(WK'2#[\=:2K$6,Q'>#[-O9L)92VPJ^+&YX)]/!FOBRK-!
M:^*F.R$$OR4GCK,[VD)&[?=2:"053W>]ZNB545105%'44-11-%`T4;10M%%T
M4'11]%#T40Q0#%&,4(Q13%!,4<Q0S%$L4"Q1K%#X/A/..I_3SN>\\SGQ?,X\
M/S'UK#HEC^FM.I5\@@WTX[7<SI]J3R&C+KI*H4FJ3R@J**HH:G%1R*B+OWK<
MJ%K:0-&,BT)&74"VXD;UTXZ+0D:93MPHT4710]%',4`QC(M"1EWKCN)&;<T8
MQ03%-"YB(YG%C1K)',4"Q3(N"AGUJ'(5-VHDOL^$,]`O<Q3.0=^1A(6,>K+J
M._)0;U-B&EK52M[?N*!:!5I7*_78KA2:I&J%HH*BBJ(6BOOC@UA9QW+\S[ZI
MJV.0!HHF=]/"(.WS(/=YQU`[&*.+HH>BCV*`8AB*<+][X;:H)Q\C##)&,4$Q
M/1^(<QPS%'/L98%B>=Z+YYJ'*XSA^TPX\?PR1^'4\TWNA4?XUKE%OLF^A"K@
M)V:?5:-D.<<%-2K0JD9Y:@*60I,PNC**"HIJ*.Z.%<B=";5SD@OGAAIK'?MI
MH&B>=W/GS(46!FF?!W$7*8S11=%#T4<Q0#%$,4(Q1C%!,44Q0S%'L4"Q1+%"
MX?M,./%\SCR?4\\WN9>0X;[)O222F'M6B?+DG8D+:M21ZR*E'TL9E##`,I,*
MDZHA8:%R5H>:16[O76>Q.O?48-*T>BK*.^S!?_9U6XO#M)ETF'29])CTF0R8
M#`T)CY+[M#OB,&,F$R93)C-#S.G/.67F'&;!9&GU=!M.8'O&K#B*K"4+<OCQ
M.B'?9'49FQ1)*<O-.$Z4EDGCB?(RR23GI5W%Y(W@2ZI8P'45TP^O@@74R7NU
MS*3"I,JD9HB9DK=A;5'%I<YQ&DR:5E?1E9WJJL5QVDPZ3+I,>DSZ3`9,AH:$
M!Z%0#`^"G:XC#C-F,F$R93)C,F>R8+)DLF(B90P33LH8FQ19*66,XZ3(2UE(
MRW&2\](N8\'JN/-%Z<F/X(./9,3*F'JN73(HH="6F5285)G4#`DS*)MQ7B/5
M.4Z#2=/JZBZJ8W:VMCA.FTF'29=)CTF?R8#)T!!3QLR>L7?,B,.,F4R83)G,
M##'GOJ+S,G_.<19,EDQ63*20A7F9D')2R-BDR$LI9!PG169*(>,XR9EI%[)@
MH=\%A2Q<%RA#>'\S4:\$*P4?(:/K,205CE)E4G.0@J?>RZ@[D"(-)DT'*7CJ
M#;26`ZFNV@Y2\-2;3AT'4G&Z3'I,^DP&3(9,1DS&3"9,IDQF3.9,%DR63%9,
MI(YA.DD=8U-.85+DI9\B,:6.\7B2$].N8U+#+ZEC`=?WE>I=T%+P$5:J8T@J
M'*7*I&:(N2#SPHL!^UJ@;IEB^*Z)31HV.=X8V:)IB<*=@[0L8M[WM*.T+>*\
M>NP8(COP="J)53#<NSV.TF<R8#(TQ%S<W(9W]O96CVSCA0^D;#.VC+DWM<F$
M1S-E,K,ZRKD>6<TMDG>1A4W"@VT/=VD1UZQ;H9`*%AYJLWL=LTX*&,X&^=0E
MFQ0)*07L?#CA_+6W6NK7.9%O/W"-V4[)7"9\%'&*9%>P8+WK!5=BX?)8^TI,
M+Y0(/CY/%0Q)A:-4F=0,.3_"^JE[G<,TF#29M)BTF728=)GTF/29#)@,#0F/
M@//N;&019VD?<T<3)E,F,R9S0\ZWZ)1<QX_G+SC(DLF*B50P3"0I86S*QIQO
MDWJH*_>281S+:)0B)Z6(\8"2D](N8<&:W`M*6+B$][R$>=G84S%<YUL.OM,C
MN<I5F%29U`P)=[NJY<?I5K>$6;>B#DR#.VI:88JN:XV613SG)5:;>^HPZ3+I
M,>DS&3`9&A(>`2_K.C./;&/>@K'+PIB[FC"9,IDQF3-9,%D:$NZ9<`&.O<TK
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M<!5PQ9`PBE<LYN]RM^K:K\IA:DSJ5D^NJ[8&!VE:05R7'2U+.*_9VMQ/ATF7
M28])G\F`R="0\"CF7?ME9!'G6HPQ=S1A,F4R8S)GLF"R-,3LEV/EME-D90G7
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MK'IOL)3%A;=E)A4F528U)G4F#29-)BTF;28=0TPM<W\`M&LC4\Q4Q>MQ9WTF
M`R9#)B,F8R83)E,F,R9S)@LF2R8K)E+-,-^DFK%)D91R9<9Q4J2EW#ARG.3$
MM*N97!3]234+?DU?F:FW&DO!WSY*7OQ59E)A4F528U)GTF#29-)BTF;28=)E
MTF/29S)@,CR1X(Y.O9L\.KWX?G)43R/&3"9,IDQF3.9,%DR63%9,I(9AEDD-
M8Y,B%:6&<9P4R2@UC.,DIZ-=PX*5LG]P118NL+6OR/0'C8(_P$8U#$F%HU29
MU)C4F328-)FTF+29=)ATF?28])D,F`P-"2\@;PO.-14<9LQDPF3*9,9DSF3!
M9,EDQ41*&6:2E#(VY10F14K*S27WE2(IY>8R*8Y=RH(5L^>E#)[CAPML[1*F
M/VF4#5'XC8V%W%TVF\NK,E>VC'Q@RKN-?12[8HR4[M,=K#I)5YG4F-29-)@T
MF;28M)ETF'29])CTF0R8#)F,F(R93`PQWP4;+FA1-])3#C-C,F>R8+)DLF(B
M18P7O9=2F"@E$])-KL>XKQ0Y*==C'"<Y*^TB%JR7O:"(A<MKK2*64Q.EE,4U
MN&4F%295)C4F=28-)DTF+29M)ATF728])GTF`R9#!RGHOX`X<B!UNAHSF3"9
M,IDY2$'_Y>&Y`ZD!+Y@LF:R82!7#?)-+,38IDE*J&,=)D992Q3A.<F+:52Q8
M+GM!%0M7U]I53#WG*&5Q"6Z9285)E4F-29U)@TF328M)FTF'29=)CTF?R8#)
MD,F(R9C)A,G40>[T7Z*9.9`J4',F"R9+)BLF4L,PVZ2&L4F1DE+#.$Z*I)0:
MQG&2T]*N8<%"V0MJ6+BNUJYA:OE2*8N+;\M,*DRJ3&I,ZDP:3)I,6DS:3#I,
MNDQZ3/I,!DR&3$9,QDPF3*9,9B?B6#0W/[WXV^<;"R9+)BLF4KLPRZ1VL4F1
MBE*[.$Z*9)3:Q7&2T]&J7<&?^[V@=AVY>D<RITY/)8,2[JG+3"I,JDQJ3.I,
M&DR:3%I,VDPZ3+I,>DSZ3`9,ADQ&3,9,)DRF3&9,YDP63)8.(D^-U6<D'4@E
MF_PU<U[BGB(CY6^9<YP4.>FG2$H_15;ZR6EIU[!@I6WZZZ]<N##7OO[2JRH,
M2JQAN,"WPE&J3&I,ZDP:3)I,6DS:3#I,NDQZ3/I,!DR&3$9,QDPF3*9,9DSF
M3!9,EDQ63*2"82+Y)8<IY-3[:U+#.%**G)0:QG%29*74L*0X80V[V7_?;`Z5
M]6']Z>/K9O=M4]Z\O.ROGK8_W^0-0/FNZ[/FJ]WFZ^/US'N0#Y1>RU\P/_GP
M!?D(Z8-\_-/U2E5>J;M>*64?2GG';Y2S#_+7QN-]5+(/\C?'X^V^=.!JER&5
M7?W6O(>VJ[WC/71=[3WO8>QJGW@/TV/[S6EG[#]]_+'^MNFN=]^>W_97+YNO
MLB,S'^[E[>'=\[=@'7'XC\/VA^S@ZZO/V\-A^WK\\?MF_66S"X#@K]OM(?J'
M;/#-K^WNK^/!^O0_`0```/__`P!02P,$%``&``@````A`-B:^NG(`P``I`X`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-3(N>&ULE)==;YLP%(;O)^T_(.[+
M1T(^E:0JH&Z5-FF:]G'M@)-8!8QLIVG__8XQ(=CI3'J3-O'#R_L>'VR\NG\M
M"^<%,TYHM79#+W`=7&4T)]5^[?[^]7@W=QTN4)6C@E9X[;YA[MYO/G]:G2A[
MY@>,A0,*%5^[!R'JI>_S[(!+Q#U:XPI&=I252,!7MO=YS3#*FXO*PA\%P=0O
M$:E<I;!DMVC0W8YD.*79L<254"(,%TB`?WX@-3^KE=DM<B5BS\?Z+J-E#1);
M4A#QUHBZ3IDMG_8596A;0.[7,$+96;OY<B5?DHQ13G?"`SE?&;W.O/`7/BAM
M5CF!!++L#L.[M?L0+M-PXOJ;55.@/P2?>.]_AQ_HZ0LC^3=28:@VS).<@2VE
MSQ)]RN5/<+%_=?5C,P,_F)/C'3H6XB<]?<5D?Q`PW1-()(,M\[<4\PPJ"C+>
MJ+&1T0(,P*=3$MD:4!'TVOP]D5P<UNYXZDUFP3@$W-EB+AZ)E'2=[,@%+?\J
M*)2F.I%1*Q*!^W9\Y(WFDW`R'5;QE:,F8(H$VJP8/3G0-7!/7B/9@^$2E,_)
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M:P"E\3ZB!Y#[7"_`C>VD=D<]R-1X*$+;%MJL\\DPDEH1/0K$[4>Q+TJAI(=6
MI19ZOXYM!*5C05*KBAY!;GR]V1B(H+9)?1:,;HGEBSGD/*]-T=1XZI,6L`88
MWH_584&]2Y>8[7&"BX([&3W*@T`(*V/WJSJDQ/*0TAPSN@$X(]1HC[\CMB<5
M=PJ\@TL#;P9W9^J4H;X(6C=OL%LJX'30_'N`TR"&=^3``WA'J3A_D>>8[GRY
M^0<``/__`P!02P,$%``&``@````A`#.2&=^_`@``:P<``!D```!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&ULE%5=;YLP%'V?M/]@^;V`^0J)0JI65;=*FU1-
M^WAVP`2K@)'M-.V_W[6=$$C6+GT).#X^YYY[KR_+ZY>V0<],*BZZ'!,OP(AU
MA2AYM\GQKY_W5QE&2M.NI(WH6(Y?F<+7J\^?ECLAGU3-F$;`T*D<UUKW"]]7
M1<U:JCS1LPYV*B%;JF$I-[[J):.E/=0V?A@$J=]2WF''L)"7<(BJX@6[$\6V
M99UV))(U5$/\JN:].K"UQ25T+95/V_ZJ$&T/%&O></UJ23%JB\7#IA.2KAOP
M_4)B6ARX[>*,ON6%%$I4V@,ZWP5Z[GGNSWU@6BU+#@Y,VI%D58YOR.)VCOW5
MTN;G-V<[-7I'JA:[+Y*7WWC'(-E0)E.`M1!/!OI0FK_@L']V^MX6X%&BDE5T
MV^@?8O>5\4VMH=H)&#*^%N7K'5,%)!1HO#`Q3(5H(`#X12TWG0$)H2_VN>.E
MKG,<I5XR"R("<+1F2M]S0XE1L55:M'\<B.RI'$FX)X'GGH2$7I@E)$G_S^*[
MB*S!.ZKI:BG%#D'3@*;JJ6E!L@!FXRQ^TQE8,F=NS"%[%-`*JO&\RN+9TG^&
M%!9[S.TY)AP0/H@/$8#J:0015.C?N3U$8`Y!%C$:(HCGR<!OH[QUF'B$.2(F
M$0#-.(+WE0TXQZ%U'08D/A%UVS.[':4)B4,R(":B$-?EH@8\$CWZ<$[==NI$
M(Q)DV3&LB2A4]G)1`QZ)IH,/)^JV]Z(Q"4(2#(B):/H140,>B9YVE=O>BR9P
M?<@1,1&=?434@$>BV>##.77;3C2<94$T/R(FHF;<CR[3^XUDP$9TU,)Q=*+L
M,.,6)M$;VO./:!OP5/OL]CB(:V22IFD21Z?U=?/2C9.>;MAW*C>\4ZAA%5S+
MP)M!BT@W+=U"B]Z.C;70,.7L:PT?-08S)?``7`FA#PLSCX?/Y.HO````__\#
M`%!+`P04``8`"````"$`(4D4+W4#``!."P``&0```'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6R45MN.FS`0?:_4?T"\+]=`"$JR6@+;KM1*5=7+LP-.8BU@
M9#N;W;_O&(<D)EO(YH&+<^8P9\X89G[_6I7&"V:<T'IANI9C&KC.:4'J[<+\
M_>OQ+C(-+E!=H)+6>&&^86[>+S]_FA\H>^8[C(4!##5?F#LAFMBV>;[#%>(6
M;7`-_VPHJY"`6[:U><,P*MJ@JK0]QPGM"I':5`PQNX6#;C8DQRG-]Q6NA2)A
MN$0"\N<[TO".K<IOH:L0>]XW=SFM&J!8DY*(MY;4-*H\?MK6E*%U";I?W0G*
M.^[VYHJ^(CFCG&Z$!72V2O1:\\R>V<"TG!<$%,BR&PQO%N:#&V>1:2_G;7W^
M$'S@%]<&W]'#%T:*;Z3&4&RP21JPIO190I\*N03!]E7T8VO`#V84>(/VI?A)
M#U\QV>X$N!V`(*DK+MY2S',H*-!87B"9<EI"`G`T*B([`PJ"7MOS@11BMS#]
MT`JFCN\"W%AC+AZ)I#2-?,\%K?XJD'ND4B3>D03.1Q(WM"9>,(T^PN(?6>#<
ML0#AC2E,CL%P[H)G']8!BMMBP/E,$@7!)(RFH]6P565;HU(DT'+.Z,&`YH?:
M\0;)K>3&P-(YI.IY\NQ_EH%7DN1!LBQ,V+7@!H<V>UE&DVANOT!OY$=,HC!P
MO,#,=,RJP\A6D,3I-7'H>WI0UF%D)X*JDS3PYU+:^TW7*9!@J:![<M(MG-/M
M/7=UC8@"1\\M51A-=!^3#6,T2=!]MTN28$U2?V'57TC5PF6Z4W>B2\JN,6%T
M+HV6+O3[[>E*,&SPR_X(7/W9B<+`\=1#@8Y8C2+2440VA-#TP8:YU"<WCP\O
MR>%.DT$+$TP_:8B"<_W:MD\49DBG0DS;O>8ZL\"!GUZ*=)0D&T)H0D-=Z+!`
M">X+]/7<$H49$J@082O0#UV_9W0ZRI`-(31U4UW=;3;*H+[*WE9)%&9(Y2@B
M58C044Y;T]9IZ7;[\[*[7N]D6H!C.>>D--%RQ.J]^,=[5P;U1?>,211&=6:O
M)5?JOX&"I*,(F%=D#N]S*(5J'E&?N0JS+5[ALN1&3O=RUIA`)4^KIS'HP9>O
M_MYZ"N-1.TSTUA,O3M[#K[P8WJGR.W0*@'&F05O\';$MJ;E1X@VDX("-IL'4
M0*1N!&W:C_&:"AADVLL=S*T8/H*.!>`-I:*[D0\X3<++?P```/__`P!02P,$
M%``&``@````A`',B,*?D`P``50X``!@```!X;"]W;W)K<VAE971S+W-H965T
M,2YX;6R4E]N.FS`0AN\K]1T0]PV8G*,DU<)JVTJM5/5X[8"3H`5,;6>S^_8=
M8P*V"1&Y24+X^>?SV&,/ZX^O>>:\$,936FQ<-/)=AQ0Q3=+BL'%__WKZL'`=
M+G"1X(P69..^$>Y^W+Y_MSY3]LR/A`@''`J^<8]"E"O/X_&1Y)B/:$D*N+.G
M+,<"+MG!XR4C.*D>RC,O\/V9E^.T<)7#B@WQH/M]&I-'&I]R4@AEPDB&!?#S
M8UKRBUL>#['+,7L^E1]BFI=@L4NS5+Q5IJZ3QZLOAX(RO,M@W*]H@N.+=W71
ML<_3F%%.]V($=IX"[8YYZ2T]<-JNDQ1&(-/N,++?N`]H%:&YZVW758+^I.3,
MM=\./]+S)Y8F7]."0+9AG@3>_209B05)8.9<1\[(CM)G^>@7^,N'(+P2R"#\
MWR7,0R"C>$T8_?<EY%,U;=^9DY`]/F7B!SU_)NGA*"#2%-(@L[%*WAX)CV$:
M(-8HF$K7F&9@`9].GLKU!&G$KXHN3<1QXXYGH^G<'R.0.SO"Q5,J+5TG/G%!
M\[]*A&HK91+4)O!]5O<#?[283B>SQ7RXR[AV@>_:!05#43PUK"ICCUC@[9K1
MLP/K%<!YB>7J1RLPOJ1'#:9)6%^^(%'2Y$&Z;%PH-$@%ATE[V?IK[P6F):X5
MH5+`9Z-`IB*Z*.3,`EQ#"$G3":]/W`5$BB6(G$A)%JH_]+B!%;>K&#<*`P32
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M6R[\($"+=A`*4#7MJ@7-"3N0B&09=V)ZDDTX@F>;?YNWBKK=;VY`?U[B`_F&
MV2$MN).1/3SJCV0KS52'KRX$+:L&=T<%=.;5SR.\OA'H"_T1B/>4BLN%[#J;
M%\+M?P```/__`P!02P,$%``&``@````A`!:Y]^!/`P``U0L``!D```!X;"]W
M;W)K<VAE971S+W-H965T,S0N>&ULE%;O;YLP$/T^:?\#\O<&0QJR1"%3NZI;
MI4V:IOWX[(`)5@$CVVG:_WYG+J$FE)1\20)Y?N_NW7'<ZO-S67A/7&DAJY@$
M$TH\7B4R%=4V)G]^WU]](IXVK$I9(2L>DQ>NR>?UQP^KO52/.N?<>,!0Z9CD
MQM1+W]=)SDNF)[+F%?R3254R`Y=JZ^M:<98VA\K"#RF-_)*)BB##4HWAD%DF
M$GXGDUW)*X,DBA?,0/PZ%[4^LI7)&+J2J<==?97(L@:*C2B$>6E(B5<FRX=M
M)17;%)#W<W#-DB-W<]&C+T6BI):9F0"=CX'V<U[X"Q^8UJM40`;6=D_Q+"8W
MP?(VF!-_O6H,^BOX7CN_/9W+_5<ETN^BXN`VU,E68"/EHX4^I/86'/9[I^^;
M"OQ47LHSMBO,+[G_QL4V-U#N&61D$UNF+W=<)^`HT$S"F65*9`$!P*=7"ML:
MX`A[;K[W(C5Y3*;19#:GTP#@WH9K<R\L)?&2G3:R_(>@X$"%).&!!+Z/).%8
M$A\#:O*[8X:M5TKN/6@:D-0ULRT8+('XF!B&T:8ZE"FD:$EN+$M,H-LA"0WE
M>5K/%HN5_P26)@?,+6+@L\4$+<*':-J0(`PWI+<]/BI;L%6VGMM0;O&&*Q.^
M+3.]1,:"8P+<;?`1I2TO*B/FVL',6D0G08"X"5K/I]"2YQ.UAP#GL$?TU4",
M`#$C(H"F<R,XKVS!W=QGTWF;&2HCQE6.Z(#OT27:%MS5CNCT1!LQKO:`[_.N
M\CC?[:'W?$?,B`CL^\!YVL[[;L'=W/N^(\95'O1]<8FV!7>U(WI]XCMB7.T!
MWP-H;C?M<<8WI]YS_@`:$X2=/Z.]#W!:N0]\W_P#R!6/Z)`'=BXY\B,]P&GF
MAA'1Z*0.`8+<,(:".)EY(X/`P79^]`0(&A,$8%PGSC\$@45W._&-0B#(%8_H
MZXCJ#%_[VKY`OC_\(OKIM`#]Z3=4@)/A-[(`..'>*<#H,0B+TB4.X'!S6S`,
M>P[T)V!$7Q<`+`!N5[A]E%QM^1=>%-I+Y,YN3@&L#>W==JN["9N]K/T#EJJ:
M;?D/IK:BTE[!,SA*)W.H@,*U#"^,K)O=9B,-K%/-SQS69PX;`IT`.)/2'"_L
MXM<NY.O_````__\#`%!+`P04``8`"````"$`RQ:,^GT$```'$P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970S,BYX;6R46%UOJS@4?%]I_P/BO8!)2$B4Y*K$
MV]TKW956J_UX)L1)4`%'F#3MO]]C3`C'=.VT#VT@XV'&9_"IO?KV7A;.&ZM%
MSJNU2[S`=5B5\7U>'=?NWW^]/,6N(YJTVJ<%K]C:_6#"_;;Y^:?5E=>OXL18
MXP!#)=;NJ6G.2]\7V8F5J?#XF57PS8'79=K`97WTQ;EFZ;X=5!9^&`0SOTSS
MRE4,R_H1#GXXY!FC/+N4K&H42<V*M`']XI2?Q8VMS!ZA*]/Z]7)^RGAY!HI=
M7N3-1TOJ.F6V_'ZL>)WN"O#]3J9I=N-N+T;T99[57/!#XP&=KX2./2_\A0],
MF]4^!P=RVIV:'=;N,UG2,'#]S:J=H']R=A6#SXXX\>NO=;[_D5<,9AOJ)"NP
MX_Q50K_OY2T8[(]&O[05^*-V]NR07HKF3W[]C>7'4P/ECL"1-+;<?U`F,IA1
MH/'"2#)EO``!\-LI<QD-F)'TO?U[S??-:>U.9EXT#R8$X,Z.B>8EEY2NDUU$
MP\M_%8AT5(HD[$BFH+[[/O3"."+1S,[B*T6M09HVZ695\ZL#J8%GBG,J,TB6
MP"R=34&3TM%[_3^KX%&2/$N6M0MQA^$"ZO.VB>)XY;_!G&8=)AEC"$9L;P@Y
M@9*6#F[XH+<7#5,Q%/UY&6[:)%AJN[$FZ@9P]V)#3<@8,=&TTC%D?C>,Q$Z^
M(E:"URZ0]]JB>('5)0H#Q;IC,&)K15`3`JF'QSP^U1(,V1XJ6P186Z(P)O56
M!#4AD'I(\E"]3/<$WGYS8.0@K08+K?R)PLR"-NN!%Y%9,/S1X%L-3N;A`OW@
M.:(*_OD<(7\S[,_L2X)U7UKR$X7Y_,GM.[FU(J@)@=3/OZ)>@FW94AB3>BN"
MFA!(O6SNVLIISY8<I-=`"TNB,'VVPNE]85$ET``DGFKYT0'1K`<@"PMLP1P?
M"=:E3WK>5EFB,*8"6!'4A$#J";S)PPJ8Y;=H6X`ZD,F`'4*-$&Q!=K@OAXBH
MOHBZQ&B%ZD!]C,@D'JY0@9:Z;8<W6*=&"/8EV^/`EZ4TJIEB/UJF$Z)`!GU;
M.X0:(=B";)&/6U`-U=SZB`(9+5@AU,B"+<"3AA8>:W]$CM)?="TM20?JTQ7<
M5QBU1F%`[,U0OUM,?WG26@_%(P*/!/=U#]N2[?'QRJAFBL,5:>N6_&<>/!LK
M8X50(PNV('ODXQ941[6$R]1VNYI8(928(-B";)0#"P^&2[577(U1N!2H"U?H
M$9R=Q2@[6X)&P-X*+75!.!I!\0A(VUQ+:)\0[%JVUH%KR\*F&C%VJ[TI"5$@
M8_:L$&IDP19D@WW<@FK'ENR9>G:7/2N$$A,$68"]/K+P6/;:4;:%K0-UV2/>
M>*':8DC@3>,8![2/3FM=GDS(Q:5?*Z-[:U.NU+F#VI:7K#ZR+2L*X63\(L\4
M0MAC]'?[\X[G4&YHM?L)G(.TAP9^_P4<0YS3(_L]K8]Y)9R"'8`R\.:PFM7J
M($-=-/S<'@;L>`,'$.W'$QPX,=B&P_;&=0Z<-[<+>+`O#U#:TX3-?P```/__
M`P!02P,$%``&``@````A`(<`);^8%```W&T``!D```!X;"]W;W)K<VAE971S
M+W-H965T,3(N>&ULK)U;<]NXDL??MVJ_@\OO)Q9%75U)3L42[Y?:VCI[SK/C
M*(EK;"ME>R8SWWX;!)I`]Y^DK)EY&4]^^G>CV6B``*C+^W_^_OAP\=OA^>7^
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MNGM)5V0N[/K+'_O#RQUEE-R\FR^-I[OC`P5`_[UXO#>E01FY_;W[^_/^R^OW
M#Y?Q[-UBOEQO(M)??#Z\O*;WQN?EQ=VO+Z_'Q_]85>1\62]SYX7^LI?5N^5Z
M%I_C)'9.%KV3:/8N6LQ6)I")QNG5[A+H[T#C$X8K9TA_G6$T?9EK9T"#APW>
M%.'6V='?\R*,J!YL]YC"<)F?CM%<@C7QG?&V/$;<`>9_SHR3^LPV&G3>8)Q7
MMOZZ<M[?OMY^?/]\_'E!<P2I7W[<FADGNH[("Q>R[;^^M,<JFTK:>/EDW'RX
MI`ZBFGVAX?C;QWD\?W_U&PVA.Z>Y04TD%3M6F/%BW.XU2#1(-<@TR#4H-"@U
MJ#2H-6@T:`-P1:GM\TO5\'?DU[@Q^>7,W#`($JZ2R0HVV6N0:)!JD&F0:U!H
M4&I0:5!KT&C0!D`DDP;(WY%,XX8FW*!8X_5*9N_&:A8T1_45O92272_I,PPD
M`9("R8#D0`H@)9`*2`VD`=*&1"2;)H._(]G&#4TNU*5](G%JL*+);/>2/MM`
M$B`ID`Q(#J0`4@*I@-1`&B!M2$2VZ2XJLCV\D.#IUJB[I'(R;BQ9T*VR3W.\
M7JN*[45LM@>2`$F!9$!R(`60$D@%I`;2`&E#(G)(@_6,'!JUS*$EB[!4X_5&
MY;`7]3D$D@!)@61`<B`%D!)(!:0&T@!I0R)R2`5T1@Z-6N;0$I7#K<IA+^IS
M""0!D@+)@.1`"B`ED`I(#:0!TH9$Y-!L\G!-]6Y-A3L]K(VA3*<E2[OL-TNB
M'9`]D`1("B0#D@,I@)1`*B`UD`9(&Q*1.UJKB]Q-)\RH9<(<"1(&9`\D`9("
MR8#D0`H@94C$A9H]AKA2N_+NJN3U^_W=+S='FLEI63F0@9A6V&[=;;S(#'2.
M"6W[Q>+.(W]WB%9JR;-WJICFAOX>,H_4/23Q*AZ\*:(,48ZH0%0Z9*.7"3-+
M[)%A=4;"[$*=UB,<_HW9NID<A@GKD4_%0,*L:A'9#<\LBN4\ESC/).#&4FPL
M0Y1[PVXK-8O47JKP`O9<"C<R<V8]'69NH*1HL]_7E%U^BQ19-*<+[DLCWLSD
MY>[,(H\2.:<_O6H@:[V*0T^\(:,4488H1U0@*@62F3&KWS`S9A#.E^].SM1F
MKZ['G45S^M-??;R!+:XS##,YD*,AE?:5N"#FBZ[^XM5R%45;M4M).5*ZI#XL
M:#!CE:_4W*/`4,=0J!B6<3R+5FK.*-G56`RR3\P:.>R3$]5JE]34QUP[-^8<
MP]1A.)'%&S6$=JPZ4:W.EW>?L.':ICV.ELMH(8="RAJZSTUE'9SG;.C;*QBY
M]I8T)\_5Q92L&6M/9ICZX9P,&[FZQUBD:EU-?SMS(&H,3]1ZK^(.3)PA%_9Z
M0Y6MKCAEYV0]E6%PGK.A+_5"MC=?K]>;K5JSEFPVUI[,L%E?GU'#=CDN:M@B
M5<.JS':14YVHX5[E,^R0K:EHN]G$,WT&DK+WL:+JEB`9JWS%YH@*1MS@+-ZN
M]/VR9-%8@S+'9OU]1H[M<EWDV")1Q=$<<NP,3U1QK_(Y=N[M]+R,XOEBJ7:3
M:>3,QJK*I1B<YVP85K%L;QYM9C,U:DHV&VM/9ICZX9P,&[F:)RP251S-89YP
MJA-5W*M\AAVR1;69TWT-[W].0W^FY@EPGD>`"D:VO6V\WLY6JEQ*UHRU)S-L
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MR+E*ZV/@,L[9T#=8J`8WLRW=IM0VJ62[L09EJ9G=4CB+_JFC%)-@G7J+U!A7
M]_"=,XSIZJ=2[WSY89BP87B1\48M/%.GFHM1MU%!9.S+N\_9T*."5:+%K9I7
M2C8<:U$FW^QAPN1/;]>HSB#+%HEQWJ/)E#J5+Z[$N8\]2AF%X[QW[PL5?!5L
MZ'V5C`;&.:7TG#08N1KG%L442%]&\58-C)UY4\8;QKE3^=`39TA78(Z4XNUB
MNU3S>\J^R;B/`(\*6.6/RW)&]ITNYIBZX.:$+[RCN#B%*CB8E)5F]BQG5)K=
MXH0+?C.0*7EFMNXO,-ZJ-.R<ZM1X=K[\Z$K8O4<IHLR[]\4'O@HT+`62F3$K
M_S`S?VX"=+L,'_[-W&TI:.[R"<-%CC,\<>]QJK`F+5H(]UNU/4A=$&8#W@<1
MX038!^'3ZE!8EA:9Z@Q\J0HH!UL<+4N:)D7R3TR`1JY&OD5B`NQ1$&<007?#
MW9M[`OD*9KL$4<HHG`![]SY9X*M@0]]C):.!"="LRL,:/)$&MX@/B\TB4^9]
MW]`\)4_6=G.K.C4ZG2_O/F'#L.MC+#9G2-GH@Q@HMCX(G[_>D%'A6C1_`E]0
M;+UAH`JZ6HQTJA&9Y3\UTCLOL@8=4G<?O8]D0W%%0:RV+%D59CK2)\>)4TT/
MQ730EVXQ8U5P3V(T&43QIB#*05]!$+*+],9'=]&_CC\H]X,/]B@9_!2&!K6>
M)QRB:+C$=AX-%X_K$.LKCGO#A`T]2AEY]QFBG)$W+!"5C'">,`-7S!,F/?2`
MV[W5],WO..S\J!JV^P_YYH.MWI([0U)Q%O>($D0IH@Q1CJA`5"*J$-6(&D2M
M0+(4S9XCG)--KNWCK3/?WTFE`]5HD<JVVCGNG*'(=F_('9"@*D64(<H1%8A*
M1!6B&E&#J!5(9MML(72VXXUY`_C9Q6UW(^':U<S,=*]7Z5;;P)U7<6[WB!)$
M*:(,48ZH0%0BJA#5B!I$K4`RW916D>[I!4=LY&J^L$BE5.V_=\Y05'!OR%E.
M4)4BRA#EB`I$):(*48VH0=0*)%-J]B&Z@J/E&]ZY9-XTHK-K4?C>):<*T!Y1
M@BA%E"'*$16(2D05HAI1@Z@52*;2;#3"5)ZH3K=5\3>EF]@AO_K>(=HC2A"E
MB#)$.:("48FH0E0C:A"U`LG\F>U(F#^]BGK3VZ-BNZD1\ZA#?JFX8]6)5:TU
M-%W>K^;G^N%$XGR1BJ>&%%&&*$=4("H158AJ1`VBUB$Z,J909?+-EN2O)]]N
M;$3R'0J3WR.?5CATVL=6-?Y6*R_P>>\],\J<REYRMS;.O>'(6ZV\@-V4Z*9"
M5'M#YUF=Y35>P)Y;X4;TR4+O_*8GE$XN;W<.B=.OQ4P=_NY8-7V:/:B"+9Y3
MF1M./V06,Y6&E'W1^.I5N.5FE9\A<X]"0^6^8)5]LC7?SE>K2.UK2]:($((-
M7E<J%:M\"+5'$R$TK'(AQ,O95I\ZMJP9"T$6@]G0A0/T1#'@7I)&DKEAF^55
MG_2%?KO`SJE./#?V*J[CQ"%WVKR:;1?P[A*V"HL#!G[&*G\7S!$5LKEHL9K-
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M6(VH860;6ZST@7S+@K'&9$>>=ZYB/A"K!ZA%8H`N]!OX=VQX8H#"&4WB#-W*
M=TZ>]<<A4O8M*E</_HQ5?JSDB`K5W'H;K6")Y(*<;*Y"WS6B1C:WGB\WD2K4
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MM8SP.;EY)/[7AT[G167:.-8'!9':&>R<H7FV/#Z5[9W*O"O(J^`8D%4T%`*5
M6L^EK!*^8/+T<?%@S0<-=1`%JR:#*%DU&42%0=2#ACJ(AE630;2L&@M"#CWJ
MH<DZ>=O;39;&C2H4B\20[%'0D[J/]LX7/2GG/DH0I8S\,,H0Y8R\KP)1R<C[
MJA#5C+RO!E'+:&!(FM.&\&XVO419NL,)?]>]<<@<(?4C83%7N[>=5W'^]H@2
M1"FB#%&.J$!4(JH0U8@:1*U`LGK-1C],:;!`.)%=>T00'H$N+:+APWG;(=HC
M2A"EB#)$.:("48FH0E0C:A"U`LE4TIU:I/)$_HQ<#7B'POP!VB\!)8A21!FB
M'%&!J$14(:H1-8A:@63^S`Y\I!3?_OT22[N/%V7I4/#0DU7B/H#SJ#4\\<39
M^0J?."/*$.6("D0EH@I1C:A!U#HT\,1Y:?:H?SWY;J<;SK@.A<GOD9^$X<'3
MOHN(WF\U^N4>7L"S3>I0\'@Y\VBBL=S[&GD([07<6.D],ZH\FFBL]KY&GDM[
M`7MNO6="<MC0*D7TW(EIQ\C5M&.1W+?K3X3MEDX5WCH'>FU(I9=A"?NR6_EH
M29N[I=KGIJPAA_VM&MK+6#4953ZHTE$5K.*HXGBK/VI1LF8RJHI5DU'5@RH=
M5<,J%]7</%M5)TPM:\:BD@5#DYXHF+<>^2R-H2H=B\P'UOI.6N@OQ]BQX?0Q
M@%=QU2<.\3$`?=&'?D*>LA7=%/L(!LK$A3X90<Z^_/VWD!$L-_%:';>5;#09
M0,6JR0!JK^(4-#*`^69-7]L@GV6T;#46@>C]E3XI>&OO=X:R]QT2'QA9Z'.:
M':LF!\.>5?YQ<,*(^LYWK7X<G+)JK/;M,1"K)H/(6>6#*!A-!E&R:C*(BE63
M0=2L\D$TC":#:%DU%H2L`W,*H6_X\U7W9NFWK[96QHLJ"HO4E*"?O['AY'C8
ML\I_@"QQ:/KI=>H-@]+1Z[N,59-!Y*SR011O"J+TAA-!5*R:#*)FE0^B>5,0
MK3<<#D(6!56F*(KIM<3*R%7O6Q2>63@5H>$(N@&Z9Y6?>Q-$*2-_SI!Y-.$^
M9Y5W7R`J&7GWE4<3[FM6>?<-HI81GFRL],E&L`T_8S3B@4?G6!\VZO7#SJE.
M'#:R+S%]Z?5*PBJW7EG/Z-NCU.%FRIJQF<K-V?9RIJ/*V==D5`6K>&TWL.(L
M63,95>54TU'5[&LRJH95'-7`BK-ES5A4<@!/'.=T=?2VP\@5GNTX)`:V59T:
MV$[E#_T2]N51RLB/O,RCB9&7L\K[*A"5C+S[RJ,)]S6KO/L&4<MH8&";PQJX
MS79?<'CF)\!6QI.:;"U2IYGJ$>7.&9**%Y5[1`FB%%&&*$=4("H158AJ1`VB
M5B!9_D-'2'_J\W8K/$9R2&5;;5MW7N6S;7T%'9"@*D64(<H1%8A*1!6B&E&#
MJ!5(9GOBS.C$P@'/B586A6?'B/:($D0IH@Q1CJA`5"*J$-6(&D2M0#*5-+O_
M3=.$\:2F"8M4X>IG]?1K/<8PJ-(]H@11BBA#E",J$)6(*D0UH@:1^?DA?T$V
MV_;GA.SOKSP>GK\==H>'AY>+N^.OYJ>"Z);^\7V/[>\8T1.C:_/XA`8SO+*@
M5Q9#KZR6].-'W4I=VZQ6]$KWT21X94VOK`>];?BGE+0--3/<"AD,>:(F!EN@
M!KK-IO8?SZ_-AYL'KCVFK-C'B\IFOUQ=FY-GM*$#W>N$CC'Q%3I]O2X&7Z&C
M4O(V9$._+_5I,#+ZW:EN$:[BNJ%+&=2;"QF(Z=/B^A,5$`9[0[T^U.GT[=W7
MYONTT6(?1=?FFZCQ%?J::;(9>F4?;Z[-1\;0ACZ)=9W0IY3P%?HDU74Q^`I]
M$HJ\#=G<Q'0Y]"8>]'834W71FY^&7J$BMD\[KOHLTV]K_;C]=FANG[_=/[U<
M/!R^TH":=1]<?;:_SF7_\>J^>^'S\95^5(OF*?K%(_H5M0-]9=',?.OSU^/Q
ME?]!35_UO\OV\?\%````__\#`%!+`P04``8`"````"$`B*VQ?,H'```1(@``
M&0```'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6RL6MMNXT8,?2_0?S#TOK%U
M\15V%K&M:1?8`D6Q;9\568Z%V)8A*9O=OR\ISHR&,XJM!'U9K8\X%`_)(2E-
MEI]_G(Z#[UE9Y<5YY?EW(V^0G=-BEY^?5M[?W\2GF3>HZN2\2X[%.5MY/[/*
M^WS_ZR_+UZ)\K@Y95@]`P[E:>8>ZOBR&PRH]9*>DNBLNV1GN[(ORE-3PLWP:
M5I<R2W;-HM-Q&(Q&D^$IR<\>:5B4?704^WV>9MLB?3EEYYJ4E-DQJ<'^ZI!?
M*J7ME/91=TK*YY?+I[0X74#%8W[,ZY^-4F]P2A=?GLY%F3P>@?<//TI2I;OY
MX:@_Y6E95,6^O@-U0S+4Y3P?SH>@Z7ZYRX$!NGU09ON5]^`O1!AYP_MEXZ!_
M\NRU,OX_J`[%ZV]EOON:GS/P-L0)(_!8%,\H^F6'$"P>.JM%$X$_R\$NVR<O
MQ_JOXO7W+'\ZU!#N,3!"8HO=SVU6I>!14',7C%%36AS!`/AW<,HQ-<`CR8_F
M^IKOZL/*"R=WX^DH]$%\\)A5M<A1I3=(7ZJZ./U+0KY414H"J02N'4JN+`SE
MPD@O-!Y^91V8UE@-5_7`<6OUE843N1"N<N&TB]F0O-0X?9O4R?VR+%X'D,G@
MA^J2X+[P%Z!#>9N>J/W_EOO![ZCD`;6L/-B"X-D*<N;[?13,E\/O$.=4RJQ=
M&9]+;)0$!A75;FT@M@%A`$-@I&E!X/X'6J@%:2F#U@IH>086!R6AEFQM(+8!
M80",`^22S2&$[=2]$50D<!&DO!F)<,1M7)-,!.'6X1ISD8T6T3P<)'8082*,
M"FP'FPKNZ7=F&6J!/`5_:;O=-".AJ^2TB";G(+&#"!-AY("(2>YZ?%"XX:">
MO28D@FW;L@KMK:&%U+*M@\0.(DR$F0RA-TW&73\)[Z8@_\Z0H").AY"(!2FT
M=XD6TG0<)'8082*,#OC.IA/.L#V\EPXJXG0(L>B$UF[10IJ.@\0.(DR$T<%1
MQJK)`72#=[-!/9P-(1:;R&*CA30;!XD=1)@(8S/G;*YO#Q3F)A-BF6R7*RVD
M37:0V$&$B3"3?2BS=@3\<;,_KIO?+.3V2VA,`P:VM8T+;5TH=B'!(&XQ-D(C
M9VZ826T3*JGRU]J7D&FF`VU=J=B%!(.XF=CK^IM)G9&925``IAG5<F)E,+8(
M2*,0+EK*GUA26RD5M%Z()32>-3.,/YJ,IM'<&F2$6@<9WZF=,\:>:#"F`:M)
MI?J0I\_K`G0`FXZ`A6"$'*^HL<*#VW@1!)-X:T043FU'R(60Z9VFRC%+2K6Q
MCWV"(KCHA5$XX^J%E,)6KJ7\62O%/8$-U/!$!V.HV)HRM5M&F2"8@907-KZ&
M#`/<0$LIDY\#B587J.>6`[]W6([25@T@R,I:*Z\VZ,8>62MUM;D0RX7!5&;M
M:!K.0TN[4$+]LA9;K1&KCV4M]6L60H)N9:U<>"-KI90958)XUD;6^"M\N1`<
MV2-KL4L;GKB1M=33&66"6-9JR##`S5HI9?)S(.%K74[68D<V+/]8#*FM,T($
M\62.[('5)ZE;)5CJ,I.9(%F"YU$T]J=.!.4RN+01-!S(=R^V^2M^^%9<WJK`
M9CVB88$Y@B`660UU&R;KK90*=2&+?0<2"J+/)>SEMF,\^="`&*`B7JHDQ.>M
MR)[?6RE5BK<N%+N08!`+$^;3&V&ZON>:A18)FES,F4M*&=#6A6(7$@SB%N.4
M8236#3-I)C$3"":/QOWM#M^XT-:%8A<2#.)F8BOO;Z:<!=H=N0X("B9->PE&
MOOW"(`5N['6EA@UE,ZMNQ$I*]C*8.:9V]@DETVO[!]CI^].GN8!%B2!X*'[7
M`OKVRT?S!$A`V,*=U8@VO9)J@QU+""ZHV9]$_GQD*1=J&6M6;Y4Z?.-]!U>:
M)!A7@MI06S/SIGG"S<E:2D%.JO(0*TC&=3:9P!=9:YQ4,OWBBEV\?UQESV\M
M6@-)W'UM7.WA60K<BJO4;,95:J:X!KX?^GX[%#?I()3R?G'%)M^?*XT$+*X$
MM7&US-G`[-AC]I12+*Y2,\4U"&?C<&K5!Z&6]8LK2)E</S2V!*C$Z@D$\=$S
MLK_DJ(4W]K)43^</^$X?RX68PFT1F%E]4RCU3.K-W8PS0?^HTP3!HDZ0.:`$
M&C+,-`R0M4I*F3GM0*+598^>\$1F^8=BV"CA,930>*[KRD9"-WJ/E,(F:43'
MJC^QDJ)<[AX]E0QD0*O)<"!KO>';,TWS\M]O]&RT6(Z@`0>,405V(Z70OD[#
M*+)*RA@]74@HR!T]T<]F3C:1'0'XSN_&C1Z+$ZI>>=;D:=62C5P(4HKYUH5B
M%Q(,XE&R!B0C6Z^/=*$[*TG(&#,W+K1UH=B%!(.XQ=9,@Q9_[(,WED.K4$K(
MBH,UEVQ:J38.I,L(3>Q*X=FQ#+.N&G063,>2IZQ\RC;9\5@-TN(%SWGA#?=^
MJ6$ZA%Z'D3J%MN_,%_!=%U3;N#]:X/?3CCL!W('WDJX[<-8-\W_'G3"`YS<Y
M:#\G#.%.L[VL.W!P_M"Y`A[2^0QX1*<\/J##IH=H\0#.[3`6?-6)CQ=P0M0A
M/UG`44L'/EW`F44'/EO`UW_`AYHQ',A?DJ?LCZ1\RL_5X)CM(9"CYJMG24?Z
M]*.6[]Z/10U'\1!K.(&&/[W(H*..\,!C7Q2U^H$/T'_,<?\?````__\#`%!+
M`P04``8`"````"$`=&*Y8U<&``#Q'P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970Q-"YX;6R<F5MOJS@0Q]]7VN^`>#\A!CLD49*C=JON'FE76JWV\DR)DZ"&
M$`&]G&^_X\%0?`ON>6F;J6?^S-CSLXDW7]_+<_#*ZZ:H+MN0S.9AP"]YM2\N
MQVWXS]^/7Y9AT+3999^=JPO?AM]Y$W[=_?S3YJVJGYL3YVT`$2[--CRU[74=
M14U^XF76S*HKO\!_#E5=9BU\K(]1<ZUYMD>G\AS%\_DB*K/B$G81UK5/C.IP
M*'+^4.4O);^T79":G[,6GK\Y%=>FCU;F/N'*K'Y^N7[)J_(*(9Z*<]%^QZ!A
M4.;K;\=+56=/9\C[G=`L[V/C!R-\6>1UU52'=@;AHNY!S9Q7T2J"2+O-OH`,
M1-F#FA^VX1U9WR_B,-IML$#_%ORM&?T=-*?J[=>ZV/]>7#A4&^9)S,!353V+
MH=_VP@3.D>']B#/P9QWL^2%[.;=_56^_\>)X:F&Z&60D$EOOOS_P)H>*0IA9
MS$2DO#K#`\#/H"S$TH"*9._X^ZW8MZ=MF+#9DC&Z6*80YHDW[6,A8H9!_M*T
M5?E?-XK(6%V46$:!WWV4Q8RE\X2`Z$20J'LB3/`A:[/=IJ[>`E@U(-E<,[$&
MR1H"VS."5,38.S%X&\*JAF=M8!I>=Y0N-M$KE"Z78^Z[,?!S&$.&$1&(#LJ@
MYJ\L!@ME45OQ*/>=82P3VV62S\B(P3`YHX>G-!WB=LK=&#H:PX812H(PQ#]!
M,1CF`-(:ZF;6MAOD(0WKP5]:#$;IH;C2`GTR>IBE/<O%9Z3$8%5*6L8EC^<K
MNU2J2HDN3%/1<1/+5OBIJM(R7CZ4.E0%Q$<=(E23=#Z;5!5^JJJT**IL;L]U
M9:K2^6H&Y;K=HL)/59465=71DP2F7$^6Q$N/&J.G*MR;5&5'FQ(892C/XYG@
MX^V,T5-3%L'`I"HG]DJ+GC.4F8^P9!!N/!T;,!8((Z@4&!"!#6T9$0H/.)%<
M1QN(.S0G1C*2HX[D-`CAZETF/A,Z$.E#69K4LCKH)_9'/>%D-;E^T4V;31')
M2/ACWU'K+("BU=D+$D22:%QI:5+S_=@/5&$+G3Q;Q^03L0&*.0@,J\U(V6=I
MF8#"2$:E'5PD%D3%SI65,#@OR%.$R2B,!<)4+'.EK+%&I-OM@J/5U=.;E!V&
M."@4PU3KJX<0-@U[=-2$12R]F`L'[F,+A+QXCXZ:L.22LFP7#N+'%B[%%(P3
MA3:YA)&,?%V%MG")L,2#NK')I=ZD)NS`O3@NZ%.\H!XS+"DTX@.&,C)VD#BV
M@"F!3IBHLTDE#&2H.B@<:U2:4#-)A`%`36T?UV+Z,1+%)HEZDSJE#N;'%A)!
MTTX?'=`1DAO/J823N8,G&HG$5NK5HNBHJO0F-3W'SI+`*'W%^O4*>FK*(AB8
M5&7'SI)8J.0!!W339*U,<NPLB85)Q.LLB)Z:LB25DG#JP'!BP](*GOUVWZ";
M)FL[*Z6.OH'-T9CA:3:@EZ9J.RJE#@8G%B+%S*=OT%-3MIV54@>#DT]1"4=K
M:A)4*I5<:C8J>;W4)":8>I.ZG!S,%W.H=VXR7WB0"3VUG"695&4']ZD%5F1Z
M(:.;*MN;5%D'B<4+C9ZPWY)"3TU9!`.3JNR`)+6@RH\9Z*DIVVB5.B`I#DMZ
MSEYG1G34A*VP<F"2VF#ET[[HJ`E+7)G;'K6PB:0KCS=(]-1D;'Q:.F!,+7R:
MIB)Z::I6-CFH2#4VB6W>;SK-PQ/&$N[C+]*6CDV`6C#%B`<KT%'+6()+%79E
MK%'J]EY')89&9Z;>-*8Q73IHS&QD\GG%0D<US=ZDINF`,8-11I]Z+63TU)1%
M,&-F'3!F-C;Y*4L0C8J-P0QE!X^9C4U>)RGTU'*VP6GIX#&SP&FZ>=%+4[4>
MI!Q+F5E@Y?7M#SIJPE96.38!9F&5URL(.FK"$E<FB]F/L@D=-16)*[5W'%L-
MT]AT&Q$X6E.30!HC(B:N?M&`A`CV6[4FG)@T*7FN'%O.P@*G%=ANYXM>:KZ]
M255UD'\A8*)]9QDOB<<6BYZ:L@@&)E79T2]P:6HH>^1K4@D#&:KZ%M!=L';W
MCR6OC_P7?CXW05Z]B,O3&+XA'*S#Q>X=LD^WT_5==^$;#?^!"]=K=N1_9/6Q
MN#3!F1\@YASWS[J[LNT^M-45'A0N3*L6;EKQSQ-<K7.X5<1;G4-5M?T'\6WD
M<%F_^Q\``/__`P!02P,$%``&``@````A`'&)5X./!0``C14``!D```!X;"]W
M;W)K<VAE971S+W-H965T,34N>&ULK%C;CJ-&$'V/E']`O*^A`=^0[=78AF2E
MC11%F^29P6T;C7%;P%SV[U-%7]P7UN-9Y659GZDJZM0INKI[\?FM/GDOM&DK
M=E[Z9!3Z'CV7;%>=#TO_[V_YIYGOM5UQWA4G=J9+_SMM_<^K7W]9O++FJ3U2
MVGD0X=PN_6/77=(@:,LCK8MVQ"[T#'_9LZ8N.OC9'(+VTM!BUSO5IR`*PTE0
M%]79YQ'2YIX8;+^O2KIEY7--SQT/TM!3T4'^[;&ZM#):7=X3KBZ:I^?+IY+5
M%PCQ6)VJ[GL?U/?J,OUR.+.F>#P![S>2%*6,W?]PPM=5V;"6[;L1A`MXHB[G
M>3`/(-)JL:N``9;=:^A^Z3^0-(]"/U@M^@+]4]'75ON_UQ[9ZV]-M?M:G2E4
M&W1"!1X9>T+3+SN$P#EPO/->@3\;;T?WQ?.I^XN]_DZKP[$#N<?`"(FEN^];
MVI9040@SBL88J60G2`#^]>H*6P,J4KSUS]=JUQV7?CP9C:=A3,#<>Z1MEU<8
MTO?*Y[9C];_<B(A0/$@D@L!S(,@-QU@X)LJ1D%$2C:>S_O4W/"&Y/F]X?NR5
M$^$(3^'XSBL#7K%>@&W1%:M%PUX]Z&JH27LI\!LA*423E>=)*RU^)`5H@$$>
M,,K2A\\1JMQ"_[RLDGFR"%Y`\U+8K%T;8EILI`4*C&&W-I#90*X!`3!2M$#$
M_X$61D%:,J&U!*X\(XN#M)`N6QO(;"#7`(,#])7-(89/:_BCD$J@$[2_H<38
MS''-;1*06\EEF6R4B>+A()F#Y#IB4(%/PZ:"W_<'NPRC0)]"O53>;IMQHYOD
ME(DBYR"9@^0Z8I`#(CJYV_J@<<]!OGO-D61JL)J8DFV4D73;.DCF(+F.&"F#
M]/>GC,9FRAQ)S.]]:J6LC%3*#I(Y2*XC1LI0'SUE7*AF<QP''^TB#&32X4AB
M]M7,HJ.,%!T'R1PDUQ&##FY=G'5W-`4ZM_L'_<SL.3+FPPR7S8V#;!TD<Y!<
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M@&?"$3<W*CR964>-7(8WK+25TOR:<;QKE1A@#*]3E-':ZG`.P0E$RK4A"M+2
MU!(0:Y6PN@ZF3#I>H5Q"_*)`/\H1G/):YC^G(=\J&!IR:#S7"'$H?J=QN94Y
MH=S9(ZQX+\,$FXR3V%FDA!&4Z"JT5D%#0KB!N5F(;^SRHV;6I.VCF-(*2)?V
M"@TGQJ655K$J8>9">'.$S<3#<T;\)HA?1-2T.=`-/9U:KV3/>,L#*JT6"N97
M4.MY"ML]:#T;)V&*VRKW+W!I]=!/7L<#'`;LUQ%<<@WA<0H'VX'X"<0?>O$Z
M2>&PZ#JLQRF<R`;P20K'G@%\FL+Y80"?I;!9!SQ0S.`R[%(<Z!]%<ZC.K7>B
M>RACV*]S#;].XS\ZT2*/K(-KL+Y;CG#M26'1"4>PCNP9Z^0/?(&Z2%W]!P``
M__\#`%!+`P04``8`"````"$`\8``47P"```0!@``&0```'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6R45%UOFS`4?9^T_V#YO1C(1U<44J6KLE5:I6G:Q[-C
M+F`58V0[2?OO=XT31)M&RUX0OAR?<^X7B]MGU9`=&"MUF],DBBF!5NA"ME5.
M?_U<7WVBQ#K>%KS1+>3T!2R]77[\L-AK\V1K`$>0H;4YK9WK,L:LJ$%Q&^D.
M6OQ2:J.XPZ.IF.T,\**_I!J6QO&<*2Y;&A@R<PF'+DLIX%Z+K8+6!1(##7?H
MW]:RLT<V)2ZA4]P\;;LKH56'%!O92/?2DU*B1/90M=KP38-Y/R=3+H[<_>&$
M7DEAM-6EBY".!:.G.=^P&X9,RT4A,0-?=F*@S.DJR>[FE"T7?7U^2]C;T3NQ
MM=Y_,;+X)EO`8F.;?`,V6C]YZ$/A0WB9G=Q>]PWX;D@!)=\V[H?>?P59U0Z[
M/<.$?%Y9\7(/5F!!D29*9YY)Z`8-X),HZ2<#"\*?<YJBL"Q<G=/)/)I=QY,$
MX60#UJVEIZ1$;*W3ZD\`);VIP-5;N^>.+Q=&[PFV&]&VXWYXD@R)CYX"P^#R
MG$ETYTE6GB6G.*>H;[&PN^4LCA=LA]40!\Q=P.!SP"0#@J&;P1+:&%MZOSQ'
M90_VRKY<WLI="(QETO=E)O\CX\%8[Y'YZ?1ZX`W*`3,=868#XE6""+D\00_&
MYF!:0]U.:QM`%TCCH(RE?;O3N1^W,U-X++._U[L8ZGR(X!:,?)WIZ/Q4=9+<
M1/]4]?=>JQXBX_;.XK<-#AL8QER!J>`S-(TE0F_]=J4XGT-T6/Q5ZD?H;7R:
MK?H?`AL^X$)VO()';BK96M)`B91Q=(VYF+#2X>!TA\YQ+;7#5>Q?:_SS`HYH
M[!,OM7;'`PJSX5^^_`L``/__`P!02P,$%``&``@````A`(A3&/HW%```&G$`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3$N>&ULK)W;<ALYDH;O-V+?0:'[
MED@625$,VQ,MLL[GBMG=:[5,VXJ61(>D;G>__20(9`'(OU0BO3T7H_:''PD4
M$J=$@>2'?_WU^'#VY^[YY7[_]/%\>C$Y/]L]W>T_WS]]_7C^/_^.?EF=G[V\
MWCY]OGW8/^T^GO^]>SG_UZ?__J\//_;/O[]\V^U>S\C"T\O'\V^OK]_7EY<O
M=]]VC[<O%_OONR=*^;)_?KQ]I7\^?[U\^?Z\N_U\R/3X<#F;3):7C[?W3^?:
MPOKY&!O[+U_N[W;;_=T?C[NG5VWD>?=P^TKU?_EV__V%K3W>'6/N\?;Y]S^^
M_W*W?_Q.)GZ[?[A__?M@]/SL\6Z=?GW:/]_^]D#/_==T?GO'M@__`/./]W?/
M^Y?]E]<+,G>I*XK/?'UY?4F6/GWX?$]/H)K]['GWY>/YK]-UMYR<7W[Z<&B@
M_[W?_7AQ_OOLY=O^1_Q\_[FX?]I1:Y.?E`=^V^]_5]+TLT*4^1)R1P</-,]G
MGW=?;O]X>.WV/Y+=_==OK^3N!3V1>K#UY[^WNY<[:E$R<S%;*$MW^P>J`/W_
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MD02Q!(D$J029!+D$A02E!)4$M02-!*T$G0,\A]`<`0X):.H97GAXC*A<M,1X
M8T0T^(W6S&DFZ0?20OBDE_1.`1("B8#$0!(@*9`,2`ZD`%("J8#40!H@+9#.
M)9Z/:%8&'ZG-P8D3FS)#<R/UA-XA.+-IT:C7>DGO-2`AD`A(#"0!D@+)@.1`
M"B`ED`I(#:0!T@+I7.)YC1SD>6U\1"GUP3G<J#>:S&E!==P5B!'4BSC;%D@(
M)`(2`TF`I$`R(#F0`D@)I`)2`VF`M$`ZEWB^H$GH!%\HM>\+3>;^IF`N?-&+
M>E\`"8%$0&(@"9`42`8D!U(`*8%40&H@#9`62.<2SQ?4H3U?J&U:0'M%<MZ)
M$YJRY/M)D[D_Q<E5IQ?U?@(2`HF`Q$`2("F0#$@.I`!2`JF`U$`:("V0SB6>
MGZBS@Y]FBXO3W:0,^6[21+AI*893+^K=!"0$$@&)@21`4B`9D!Q(`:0$4@&I
M@31`6B"=2SPW46#YS[A)&?+=I(EPTY5P4R_JW00D!!(!B8$D0%(@&9`<2`&D
M!%(!J8$T0%H@G4L\-ZEP'ORTH##IQ#GO8,=WDT'"3ROA)ZOJ'84H1!0ABA$E
MB%)$&:(<48&H1%0AJA$UB%I$G8=\OZE(UCU5&-_&377@2YML;N4;@\3FX5JZ
M1V<D%6?<VHR,0D01HAA1@BA%E"'*$16(2D05HAI1@ZA%U'G(=X^*:UWWJ-W$
M3ZU2*BX2\Y]!_L`*)M)S.B.IV$U;FY%1B"A"%"-*$*6(,D0YH@)1B:A"5"-J
M$+6(.@_YGE/A[C_C.1TX4U'<VC?JZ).<*3P'9W2]BC-N;49&(:((48PH090B
MRA#EB`I$):(*48VH0=0BZCSD>TZ%O*[GWID2=83LN<<$S=X^/1`'2)MIKV)?
M;!&%B")$,:($48HH0Y0C*A"5B"I$-:(&48NH\Y#O'A4%N^[1Y^`7ZLW(.YY2
M.<7>0B/:J+`/-NKDB50.VB(*$46(8D0)HA11ABA'5"`J$56(:D0-HA91YR'?
M+2H@=MWRCB]T_.R-&H-<7P#:JE<WRHE6%2**$,6($D0IH@Q1CJA`5"*J/.2W
MGPI4W?9SNO7KM_N[WV_VM/33+FJ@70-ZC6->[NAPUVM6@ZZ=+MXC>_8V78H`
M=:O>=5%+!]3@_0G=[$K,8J%5\0B*$,6($D0IH@Q1CJA`5"*J#)H>6L)O?!5^
M_O\;7P>Q7N,;Y#9^CVRS#C2^5LVGAS=TL\E4G(R&Z@T@>8<$MMU[RXQBHZ)'
M'BDLL;;4ZT`J3#@YM0*VG%G+C'*+1@HKK"U3F-BVE%;`EBMKF9#O.161NIX;
M&!YT]-:/#QW`>B[2:$9#J^_F*WGVJ1J06GOFKN@#3AM2K<3SA6SKZN#:Q>1J
M.A?M';&$'-K7"8J+635:J610)2N5LDI7:GXU74U$")>Q9+12.:M&*U4,JF2E
M2E;I2DTGT]5U($X[*]:\52NOM\R&3BFFB\/>X?A)]F#%WT<8%-"6KG?82E1U
MP_G<G@9>W5H5=__0H-G\T&."Q6(R$U%:Q+EH\])7`&S'K!JM06)57(-4U&"Y
M7*S$<I%QKM$:Y*P:K4%A55R#TJ_!-*"[%Q,Q2BO.]E85_+Y`53AAYE#S@]IW
M.%&80?0ZF6NYL6C$#5M6V;D[1!0QLN9CBT;,)ZRRYE-$&2-K/K=HQ'S!*FN^
M1%0QTO?"O#L2-#5X#?]3.QTU%4M_:*1*[L=`$(B%<V,R!J,3U-:H_`E?3E`A
MJ_0$M5K.IDLYE;/DK?GIL&^+C6J\4@G;\JHN*Y6RRE0J6`778B;*6#):J?RH
M2A5L:[12):MTI6;!_&H>B`6F8LU;M?*'[]#YBCN5_WO__:W]LK,AF.'ABD'>
ML-8J=7&D[UDPNVXY8]#/!R&BB)$==[%%(^835EGS*:*,D36?6S1BOF"5-5\B
MJA@-#&MUG''\3HP6,QB_&BW<GA0$8I+?F(RDXEEWBRA$%"&*$26(4D09HAQ1
M@:A$5"&J$36(6D2=A_SQHHXU3G"/DHOE3B-QZ"BFEHUZSTT9W>-B1"&B"%&,
M*$&4(LH0Y8@*1"6B"E&-J$'4(NH\Y+M''6NX[G$6Q?&09F8.1.QXN#'(.<+:
M(-HB"A%%B&)$":(4488H1U0@*A%5B&I$#:(64><AWRWJ#,1URSN^,`<KKB\,
MLKNES0S0%E&(*$(4(TH\Y#\-K:S>TSB=[(3P1UD14X-!SC''K$<CB\[6J-XY
M8[(JGO(C1#&BQ$-^4ZA0W77LSS6%#OB]H,`@MREZ--H46D4QC#D7$1O7<':,
MF<BHK!FQ(8V/,I.`&7N*X;6CVA)Y[3@^0`YRO^\8)';M(KK<L,K=&^`.S*@6
MZD#TST\B1@Z/LA&-VHB/LI&\9<-ONM,"T``#4(.\4X<@D#=8.*,;%@TTG3:_
M<$\P@D#<L@B/LA49U4*=NY$;+A:V\^APYR@SB33CQ%9^0U*G.*4/*KGH@QJ)
M/BCBDXV*SBBC"E-&H@"C6KC'YL$<^N(QMB*V90[`+J:K\!<YGH^J52(M!0O7
MDM^<,K)Z9TAC!!68<,GK2W/1"39&I2X_C#6GMN7W2WE@&AYE*S*J<5OQ4;:2
M]VSY3:HB&W>U>:=)=2#D+BMJC*N^YS96,!=+Q(95[_10;4OT4!%GA4?9BHQJ
MH7LH79^\<ON5&>VF[J.U2L#2:N+^;^;:]1OWM,@FP,C&(/\N^EQ&-E;%NY`M
MHA!1A"A&E"!*$66(<D0%HA)1A:A&U"!J$74>\MWSTY&-VA7*B5HC-[(Q*@=M
M$86((D0QH@11BBA#E",J$)6(*D0UH@91BZCSD.^6TR*;`",;@\2H@8V;SD@J
M.VH`A=86JR)$,:($48HH0Y0C*A"5B"I$-:(&48NH\Y#O'AFJO;-B8$P6:"3<
M`YO#7L4-O[49&86((D0QH@11BBA#E",J$)6(*D0UH@91BZCSD.\>%8N=L*";
MT,TY%P@T$NX1^^V-5;$OMHA"1!&B&%&"*$64(<H1%8A*1!6B&E&#J$74><AS
MS_RTJ/0@]R,"@X1[9$1@5;U[$(6((D0QH@11BBA#E",J$)6(*D0UH@91BZCS
MD.\>%6L>/WKHCHO<!QCDGT4O1)"UL2KK'FW+.9X.414ABA$EB%)$&:(<48&H
M1%0AJA$UB%I$G8=\]ZC8]`3WZ%#6C5:47VCG)MPC`T"KLN[I,S(*414ABA$E
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MZQ"`MJRR;W]"1!$CVS(QHH21UPP+<4R76A4W0\;(FL\1%8Q\\R(^+*V*S5>,
MK/D:4</(,[\46X#6JMA\QVC`B:<=6:B]NS@^,LASHE8Y:,LJUXE&95'$*ML,
M,:*$D=<,"W&TF%H5-T/&R)K/$16,?/,BBBRMBLU7C*SY&E'#R#/OO(8YG.^V
M5L7F.T8#3I0'&\[NY?AWT.K3IM*W&CF.W!B5@[:,EOV\'B**&-G6B1$EC*RM
M%%'&R-K*$16,:$IQE@T1;Y96Q2U=,;+F:T0-(\_\4BP;K56Q^8[1@".I4YRR
MWU%R$6-KY+_36(H);C,W*HH,^I:!56IK55SUD)%^-1',YM<+^0XJ8@WUG;>-
MQZRRQS>)14Y&N(II5'0XKE^$7HN'R]C,:/DYJT:;H+`J;H+2+__J0CB\XBRC
MQ=>L&BV^L2HNOD74><A;HA>GG=D<Y'Y_,DA=4>R=&2S%7+OAC.Z;-.Q/5L5/
M$[)Y?0M_&M`'-R9B/8LX&VTH^RJ`\9A5=J.?($H-HHA#=9[IY$*LS1GG&2TL
M9]7H\Q96Q<];(JH0U1:-/'%C56R^1=1YR.\<ZMCF^."*PEDYV1BDKGKUG@GD
M9]XVK!KMZENKXJ<)#5*OP1SSPF,19_3&VTHLUS&KG.D&46I+U'.+_+A)QGF\
MPN03YZP:?>+"JOB)2T05HMHBVRXP(!JK8O,MHLY#?O>@VGO=XZ<V%>KBL5BB
M#!)3BG#8AC..#K&M5?%#A@:I0P6GUXA5/^*,;M^:8J\QM7<G%4"I+?$PJ5Q,
MI^Y+=CF?98-%8Q_JR[&/`4XNV):M8(FH0E1;-&*^L2INWA91YR&_#\ECM?$0
MD>Z806?1B"Y_<0TV1J7N@_4.AI;9LLJV3(@H8F3-QX@21"FB#%%NT4A5"ZOB
M9RP158AJBT;,-U;%YEM$G8=\)\I#N)^;"/!L3MT9HKG!WZM>B3.)C5&IRU9C
M[C:V[/P>LGG>JTXFUPLQRT2L&9W/8UL%;L&$,]KR4E;IC>G\XMJ;!>0'ZS*V
M,%ITSD9'G[Y@6[8V)6?4M5E>B`FPXBRCQ==L9;3XAFUY*KEQ;UFE_;&\6LAO
M[^A8\5:=_&Y)4_?H^G3<AY7H0B7,.1IY<TZ/1CNA4=F/^X3&/-ULXZX3,7+G
MG-X\JQ)4I8@R1+E%(U4MK(I++!%5B&J+1LPW5L7F6T2=AWSGJF/`$_:F2BX"
M%XW4#;A^V@BN1&RQ4??U5$:*AWO5P%IB5.Y:`BAB6U85,[)'7`DCJTH198AR
M1J-5+5AES9>(*D0UHU'S#:NL^191YR'?KZ<=-](52/"K1G[,(;]!8V,ROK=H
M&%MVV@Q-1OJ\QV$OMURM9O*F=<2:MZ8I?4/35H&'0,(9;7DIJ]X\S>`\HX7E
M;,:;@>6>LF!;MOR2,_*B)1;(BK.,%E^SE='B&[9EBV\9Z>:>SX*I&*$=*]ZJ
M@-^]2'7*M*'D8MK0R`].KL09SV9A,HX.EBVK[&`)#:*/%*KN%4QFL^NY:/*(
ML]&:\/:<%+/*G5I,K6QYJ5&9\X[YQ3*X=O\G8NF,C8X6G;-J].D+5MG:E'YM
MEA?BR2O.,EI\S:K1XAM6V>);@TSC+^>+*W%TV'&FMRK@=S:JP"F=3<E%9]-(
M74OH/1W(2FT6O8HGDBVB$%&$*$:4($H198AR1`6B$E&%J$;4(&H1=1[RW$,_
MO>.[1X4M/_4UCP=+ON<,$IZ3QZ)6U7L.48@H0A0C2A"EB#)$.:("48FH0E0C
M:A"UB-1/(ZGQ0$U(C:,]IW_J2/]`R^/N^>MNLWMX>#F[V_^A?L:(!N>G#SW6
MO[%TL[A>JSY`)F3*<L(_OR13@M5:74,=R!.0-;H!.9`R)VMT^6XHA7[FB>Y]
M#:7,*.7P>+(&\X!2#B&!3)G-U^H#YP/69@M*.?R.$^194LKAA9E,"2@/'9\.
M6`LH#UUD'TJYHI3#JREI;4IM0-]Z.Y!G2FV@OST.\E`;Z/LXD$)M0%\8.62-
MVH"^JW`HA9Z'OBYO((6R#.:@#(-Z>OS!IZ>''WQVZC*#/88ZS%!_H?L6:W6;
M`FM*+_$I9:AL>C-,*4.ETZM&2ADJGZYGT(,/I="OC_TZV/>4JP;J=4..&M23
MFX:\].M\_2L-87Q`NMRR5E=7AE*6E#+TZ/3.G5*&'IU>XE+*T`/279BU>E.+
MY="5F+5Z88LI=-5GK2[R#*4L*66H;G3=@%*&ZD8OJREEJ!RZ&;16+ZFQ'+H@
MM%;OJC&%OAMPK;YA;RAEM5;?38<I]"US:_5%<IA"7PE'UH92Z//A:_4A;LQS
M0W6[&:P;W=-:JS?_F&=+*>IM/Z;0Y:NU>NF/*70':ZW>_5/*93\KT"_3?;_]
MNBMOG[_>/[V</>R^T)1/[^=H*_:L?]M._^/5?`7-;_M7^DTZ6I7I1[OH-PAW
M]'M9]*'8\[,O^_TK_T,5\(-_U?#3?P0```#__P,`4$L#!!0`!@`(````(0`S
M21P75@,``-`*```9````>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;)2676_:
M,!2&[R?M/T2Y+XD3((`(5;NJVZ1-FJ9]7)O$`:M)'-FFM/]^Y]@AQ0%*=@/D
M</P^/A\^\?+VI2J]9R85%W7JDU'H>ZS.1,[K3>K__O5X,_,]I6F=TU+4+/5?
MF?)O5Q\_+/="/JDM8]H#A5JE_E;K9A$$*MNRBJJ1:%@-_Q1"5E3#H]P$JI&,
MYF915091&$Z#BO+:MPH+.41#%`7/V(/(=A6KM161K*0:]J^VO%$'M2H;(E=1
M^;1K;C)1-2"QYB77KT;4]ZIL\753"TG7)<3]0L8T.VB;AQ/YBF=2*%'H$<@%
M=J.G,<^#>0!*JV7.(0),NR=9D?IW9'%/IGZP6IH$_>%LKXY^>VHK]I\ES[_Q
MFD&VH4Y8@;403^CZ-4<3+`Y.5C^:"OR07LX*NBOU3['_POAFJZ'<$X@(`UOD
MKP],99!1D!E%$U3*1`D;@$^OXM@:D!'Z8K[W/-?;U(^2432;D,D4_+TU4_J1
MHZ;O93NE1?77>I%6RZI$K0I\MRKQ=#1)PIA<%PGLCDR`#U33U5**O0==`TC5
M4.Q!L@#A\Q%!*.A[A\ZI#UT->U50AN=5',Z6P3.D+FM][JT/?'8^I/,(`-J1
M@3:<C,Y(QMSB5NZMX1@3G<?$_X-!Y]2'SV[S<3CO="W9^HR/?":=AQ,@N`P/
M$)VA!A#6$;J?6^LT``U--1R-S@;=);>UP#EYVPP)ST<Y=5%X-!)H;I!XOY=P
MG4MM+<<UC<F%YDE.J22:#<#B0A?;6ESLA6;"@7YT6LP<()/1U6!QG4MM+2XU
M/I_B^1GJ&%:^GV!<Y3);B\L<GV<2*'X_U&@.K?<^U"QSJ0>3B[UP9@AXG6#'
M<.2N8'%9#]N:7.ST0K2]860*F\P']!.>V#ZY-;GDY`(9QTFOI>(X&D*V@P@V
MT)U;TII<\ML4<<83P6G2(T<DN=[,9F$OV78R8?6.)L;;Y'3!.%YZ8#A$R=53
MA*_<?JY;DWDSN)0S@RF>)$,PIZ,)+A>&[,07]2>BO3_8UVO%Y(9]8F6IO$SL
M\&X0P0NSLW;WECM3OKY]O+BS]YF@^P?N$PW=L.]4;GBMO)(5H!F:<*2]D=@'
M+1JH#5PJA(:+A/FYA9LC@Y=FB+4MA-"'!VB<H+N+KOX!``#__P,`4$L#!!0`
M!@`(````(0`6))YA[P<``-HA```8````>&PO=V]R:W-H965T<R]S:&5E=#DN
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MB(#+/BBSW>/PF:UBVQF.GQX:@?[)L_>J\_]!M2_>@S+?_IZ?,E`;UHFOP$M1
M?.'4:,LA,!X3:[]9@3_+P3;;)6^'^J_B/<SRUWT-RSV%B'A@J^UW-ZM24!3<
MC.PI]Y06!Y@`_#LXYCPU0)'D6_/YGF_K_>/0F8VF<\MA0!^\9%7MY]SE<)"^
M575Q_%>0F'0EG-C2"7Q><'+%T)&&$V5X=2"84C-;^)0#L>F(3:P9G^R5<6;2
M#CYQ@B-[,6736X9S:0B?[8!71X*Z:F8(GSC25?Y2\N&S'>`C$3'(%+%P/&7D
MREV-:2Q6ODDD-ZF3IX>R>!]`=<+:5N>$USI;<;>80D+/-JGZ<@J2B7MYYFX>
MAQ`WI$L%A?#UR6;+A_%72-Y4<M:4PW3&!AD\4[E;UP0\$_!-(#"!T`0B$X@[
MP!AD:;6!C/X_M.%NN#88U1J!CEB&$,A`$]<$/!/P32`P@=`$(A.(.X`F!%0J
M$<*!9+F\SV!.<"O84;HYL5SH@:X%9P*EV2;.5*=L6DHK!D$\@O@$"0@2$B0B
M2-Q%-$U@UR*:\+WWSL+A;J#V0/E6`%HY@G15I9;2JD00CR`^00*"A`2)"!)W
M$4TE$$13Z7K&<'8C!@:Q%L@$=F`ES]+86#8M"<U<@G@$\0D2$"0D2$20N(MH
ML4-2WQ$[9^NQ"V3230W'LHSJ:$EM[`3Q".(3)"!(2)"(('$7T6*'!=-B%\?*
M:`YB74\!;JC+()"I:#KXJ;`AB$L0CR`^00*"A`2)"!)W$2UFWE5WC]+K@7*V
M'JA$.H$2Q"6(1Q"?(`%!0H)$!(F[B!8HM"M:H)W%K?=Y^F5=0+'"H7I!``=Z
M`]$Q<"=Z_!)9M@?EID54];/93*\`5Y`<2$6U1;"Y3O):$I:)3Y"`("%!(H+$
M`F'-K#65>#?U\S(U7G2=$.H(I2`E`E5*LB9,-&@6<PR5%*&527E&**!0J`R;
MUL]BMNXY4@1T$VMN=.5X0_;Q2F*B?X,S%'VO)63#+RHI;-)N"D.[N\->4.T2
M:V'X\G#$N=#6F2_MZ407P4<.%%8[*S)>@"P53JB@CJ$YA0A9<@J6Y<PMHUAB
MY/1-05\'W@_>L0Z<;J2J@!SH#]J(;=M(NPWO?KAA=[6(+JYBX3)[$K(GC>AL
M,I]/F!&QCV9P\K13(,X#9*G--Z109(SGV(YEKD*,9GWCZ0KS]O(.A44W"D.@
M!&LF("/3C<S;(`N$[A?!52QT[R$D<FJZ7,ZF1@?B(Z4OI9KM/D"6FGI(H0BA
M_N%BI/0-I^O+&],[]!5]K*:O@+0,=BRC^C=,&M[(X):E]!409C"#S)R9#\X^
M>N]+*:DP\1ZBH<KJ2$)RP,4<:F9IK&B,9GWCZ1(#ZQZ).=W8)`2DI;!C&2?(
MAC];@>&MS;IE*8DE)'.*.3,C7A]=]Z64U)>X#M%0)76$4.]H,3+Z1M/5Y1UV
M-X%_J-=BHD_7\EI`6E[;MO%XOD'#&WDMW:LT\Z2A3+/)8NG,YT1V:0:Z]F]*
M@9H"KFA(H<@<;\$NG'TWQM.%YVU^5_@+S2S<.V(WR\13@::P@.">!">^D2Q^
M==(?L8NLKIS2EX)\9"GW`85"A)1A1*$8(7';W+T"8Y"E]\C`Z49U"\@&\=N8
M'8NT`(+EW#B@I"]5;UXS0=@61+W9UG2VL&;&!8&/)#!OYW"A!VCG@`L6HJ$:
M,$)(#,CF,VMN+XUP8B3U#:BG&G^$Z*;:C]6X?!!14UW#0PE?#:W&'8OT!NT3
MS!5Q7.D+>C04QY/0!#J05E7',J[O?#34JGQA;#0!LM0S38B0&C&Z/*+1\<5H
MV#>B)KYM/J5=K_.&KB>XA+IUKB"E#,DW%UDJ0(]"/D*=.J=0B)#R%5$H1HC6
M.3]\?SX'&R^&.MPQU*=6_L;J;Z3=C>J7++T#,/MO#UGR`+:<J>T8O82/G+[R
M%`>^FA6F?(B&VC9E3B%"EIB"8\^@QS*3%#E]4]"3E#\@7=LA/A=GD/WBC4OG
MD.+*&;NSA+3D%:P;AQ0:-F\W&[T\"OD(=9.W=:]4E9#R%:&A@F*$+B2O^13%
M-U![.H(-X,[;>'A92Q02D'$-:]PO;:0AL#`JET(>A7P*!10**111B+]JYK,7
MDQ`))%X=BS=^QZQ\S3;9X5`-TN*-OQ:&9ZFGAQ86[ZS7LQ5<ZT(4)CY?P=7G
M!=QV\"6W8>$N5W!?1BU<9JT\N/VAO\`]THI?%=%?X$WZ<Z.M,<8:WK`W>YZ)
MVS"I"W[6,-DFIPS^\P3\7_IA/5G!VPTZH?5T!3?_@(];3_!F_9R\9G\DY6M^
MJ@:';`<26\V==RG>S8LOM2S6EZ*&=^I-W>[A;R@RN-JV>,[NBJ+&+WR`]J\R
MGOX#``#__P,`4$L#!!0`!@`(````(0"'%'V:50D``'@V```8````>&PO=V]R
M:W-H965T<R]S:&5E=#4N>&ULG)M;;^,Z#L??%]CO$.2]C>6[B[8'QX[O7F"Q
MV,MS)G7;8)JX2#+3F6^_DJFV)J.(S<$`:3+^F1'YEV22CF__^+5]F?WL]X?-
ML+N;BVMG/NMWZ^%ALWNZF__GW\55/)\=CJO=P^IEV/5W\]_]8?['_=__=OLV
M[+\?GOO^.),6=H>[^?/Q^'JS6!S6S_UV=;@>7ON=//(X[+>KH_RX?UH<7O?]
MZF$\:?NR<!TG7&Q7F]T<+-SLOV)C>'S<K/OEL/ZQ[7=',++O7U9'.?[#\^;U
M\&YMN_Z*N>UJ__W'Z]5ZV+Y*$]\V+YOC[]'H?+9=W]1/NV&_^O8B_?XE_-7Z
MW?;XX<3\=K/>#X?A\7@MS2U@H*<^)XMD(2W=WSYLI`<J[+-]_W@W_U/<=&XT
M7]S?C@'Z[Z9_.TS>SP[/PUNYWSQTFUTOHRUU4@I\&X;O"JT?U'_)DQ<G9Q>C
M`O_<SQ[ZQ]6/E^._AK>JWSP]'Z7<@?1(.7;S\'O9']8RHM+,M1LH2^OA10Y`
MOLZV&S4U9$16O\:_;YN'X_/=W`NO@\CQA,1GW_K#L=@HD_/9^L?A.&S_!Y#0
MIL"(JXW(O]J(<"\VXFDC<F;^]9$DVHC\JXVX_K7PG?`";X04`6*BU`!_7>\Z
M$D[B15\/BO@(K7SS[I'_Y9B*]Z"J-^^CD&[9)5F`O.-L6:Z.J_O;_?`VDTM0
MCN'PNE(+6MPHBVJ>>-(_\SR1$T2=]*<Z:SQ7T@<YN7_>)_[MXJ><CVN-I`8D
MP$AVBH0.1I8&Q,5(;D`\C!0&A`RW-"!DN)4!"?$7U:=(0I#&@$382FM`8HQT
M!B3Y0!92VP^!I:9(8+NPBKZ;R]</885#-$F!B4;9K[PX]'PG(./+IHP;QI%/
M@.44B+S0)V'*T7&Y4`61O9@"0B[!P"5$B0C?]T,"5%/`#]S`(X.LIX",@T.$
M:J;'KX(H\LDWM%-`^(GKR'_$2#=EKD3B!(%PH\^1(#'E7HC$_-IJ56=14<7'
M;!E7=`J,W(8^A"?3/P,B'&4?)8T2XNYRBBA1@Y@0.2)&63T2CV**:&$%84K$
MC-+2L%939!0WBC^#.OI<3Q$E;QB3J#2(\#UZO(7CEJAU-@))*XT@:>WK5-%4
M4A+K%!@MF.='OO>Y18P!R("0K^=$7[)$SA(%2Y0L4;%$S1(-2[1`6"+6V6P@
M.64^@.3\VDI59U%9R<4L!08&*5Q'^+&@2Q40.=:SNK)$SA(%2Y0L40&AG8E]
M-R+7Y9HUT;!$B[Y$Q)X3^&2A=S8C2-?0H*LOS[8O5W46U95XF@)C$2UCB25+
MY"Q1L$3)$A40$UF]D\V7-=*P1,L2G8U`ND9$5[N>BJ9ZDD68`@,QB!R?IE$9
M'+?HO62)G"4*EBA9HF*)^IU0E8`?DQVK>3]Z=CMJ@8!8A4E"K_>=S0*24;4O
MIN6,749%4QE)(IH"`T/SDY@ZE\%QFXPLD;-$P1(E2U0L40.A?8T]G^0+#6NA
M98G.1B`I94U[@92*IE*2K#$%1L^R2$3RZHFSX`P(FY@LD;-$P1(E2U0L4;-$
MPQ(M2W1`F&.*Y%3=DPOT''$J*$G@4PW!MU\)667Z;DRNJQF"C+4H(DS%*`9,
MU2@BS.4H1DSU*")"3Y8C)*6O$2$</R$3N$&`L21%A)#%NY\D+HE9AZ`KF3+)
MS4!,BGRLK&I&?'W35?VODZ5*=II40Y:5F&D$Q#]3D"+&7)%BQ%R2(N9<38HA
M<U&*F%%A$9$+3HV846/O1&4((;@N#'6IMF$)7V=%L+ZJ0W&!OM#0D*\?U8=P
MR$1.5:M13@+P0$VOA*1/F28L+BQY).>1@D=*'JEXI.:1AD=:C9R/7&<U@I55
MW8D+E(5F!E:6Z)8*@&!\?AB[9'YG&K`*:^N:C*V+G+=2\$C)(Q6/U!_(F/XF
M9"]K/@Y_+@@2M%8C[T'S:#>KL]K`FLK`7J*IPNEUEDB6"H#TG`N]DTTKTX15
M5#!B07+>2L$C)8]4/%)K1$LB$W]RC6QX&RV/=%8$"ZMZ%!<L5FAIX,5*,V)U
M1W"R#8<B"LC4S#1BD6W)(SF/%#Q2\DC%(S6/-#S2\DBG$;UL/!Q=K*WJ4UR@
M+;0UD+:")`FI``B^_2IVO<AS2`*=(<:<&T^M&'-C!!ASXREQ)C=&B#$WGA+F
MW'A*R!M"\<D^/`7,N?&4$*'O>?[)G:D.Q4P6'8$?N;[SV?/`PJK.Q07"0J,#
M"TMZE:FP=4.@L:\1T/Y<;@QF@#F3&R/D3&X\9<[FQ@@ZDQM/F7.Y\909-18G
MVS)"3+DQ`)8-K;-&&.NKVAD7Z`O=#Z3O:6X,D-XV0E?0&Y>9L#51QAFPY)&<
M1PH>*7FDXI&:1QH>:35R/G*=U0A65G4VILI^[0Z.@(8(5OAS<QC%236DQ^F%
MKNM-BFN]A-G>RU*;L<SDG$<*'BEYI.*16B/@=1`%M"/>\#9:9"/V@M"/:>0Z
MJQFDL4M[4DIC_F[.>!K-F<D^E&K((D[&(TL>R7FDX)&21RH>J34RD?A$9-Y*
MRR.=%<$:T^[4U]:Q:^A2T79<JB%P5\2A$R3D8ITAY,J88F'$E&,1PI1D8<2<
M91'&E&9AQ)AG(41$3NB0<K'1A&7JM\B('WJ1B$EMTEFM8(GE;OL7MFI7G4:6
ML:!;M88LOF0:@5D`$I_^-`9#YG2+,.9\"T/G$BY"F3,N#)U)N1`$<GMDKVLT
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M?2Q$N('O!UX8D<RF0Y#J8T6>YTY^`HWU54V3"_2%'@O6E_B1RL=?U`*W")/Q
MR))'<AXI>*3DD8I':HW`D@)Y$[*I-8@QW=[EOT<]6W0^N"`M/#L$3X.\KI[Z
M?ZSV3YO=8?;2/\HRV+E6S[3LX<DA^'`<7L>'/KX-1_G$S_CV63[AU<LG0IQK
M"3\.P_']@WHVZ>.9L?O_`P``__\#`%!+`P04``8`"````"$`]8_A59T&```A
M&P``&````'AL+W=O<FMS:&5E=',O<VAE970V+GAM;)R9;X^;.!#&WY]TWR'B
M?0)C`X;59JL"ZEVEJW0ZW9_7+"$):@@1L-WVV]\8$_"8A"15I>TF^\MDGIFQ
M'P//'[Z7A\6WO&Z*ZKBV8.58B_R859OBN%M;__S]:1E8BZ9-CYOT4!WSM?4C
M;ZP/+[_^\OQ>U5^;?9ZW"XQP;-;6OFU/3[;=9/N\3)M5=<J/^)=M59=IBR_K
MG=V<ZCS==!\J#S9S'-\NT^)HJ0A/]3TQJNVVR/*DRM[*_-BJ('5^2%O,O]D7
MI^8<K<SN"5>F]=>WTS*KRA.&>"T.1?NC"VHMRNSI\^Y8U>GK`75_!S?-SK&[
M%Y/P99'555-MVQ6&LU6B4\VA'=H8Z>5Y4Z`"6?9%G6_7UD=X2CA8]LMS5Z!_
MB_R]T7Y?-/OJ_;>ZV/Q1''.L-O9)=N"UJKY*]/-&OH4?MB>?_M1UX,]ZL<FW
MZ=NA_:MZ_STO=OL6V^VA(BGL:?,CR9L,*XIA5LR3D;+J@`G@ST59R-'`BJ3?
MN__?BTV[7UO<7WG"X8#XXC5OVD^%#&DMLK>FK<K_%-0I&H*P/HB+V?=_9RL6
M>.#YMZ/8*J-.8)*VZ<MS7;TO<&KP.YM3*F<0GC#R69G*8]!Z32IJE$$^RBAK
M"\<=5338GV\O`/ZS_0UKFO5,=(&A1'PF9`%EV$1[P\9\AZ2Q%'K2E]MPSDW"
M,K=SU$B]@;&'9)F1R)3@0)%DBHA@0$BR_)%D)8S3H>4&((:X754BQ6"SAOP]
M2L0WB62.(-GCU]Q?:@FO+2S-D!DX9O:*$=V0+)GO!-S,7B<"[H/P#"+1"5^`
M`.8,%2#9X^K2LY?3[5Y=M^>!D1\R>S#V5O5`,9C'H-3(,;Y))',$4>%3%?/C
M+F&C!Q`.U5'9*\;O%VK(N3O6KR-BG0B],.0&D.@`@"NX,Q(D>?%(\A(VDG>,
MQ1DI1B4?^`Q\`X@)P`,>&JU)=(!Q5[A\+!#)7?JWL3ER-(_Y!L@/&1JT\50-
M4(S2X#.?NV,"JOXZL`3/\2<B*.%ZH:LM)*(B_!D5\D/&(F#&'A@I9FX1W"22
M.8*H`"R\WHSY)G0T[0)WC570,ZH++L,S%05B`@#WP/<,)*$(\SQP_-'XJ`#I
M9MHTW1"@O$_?2[7^JBD"Q2@!RP!7L3!:%%,D1%>>*-"#"#\0U]*7CG=_^LH?
M2?JF$X!BYN:G1Y1"$(*;,Y@,0>2A8^D!'WI(BR\-[_[LE3V2[(T5&H%B^N)S
MX3G3^3F[K,Q-!)/*DPC`N0C&K8QF+PWO_NPE36??'0/WHZ.8/GL\BCKA9'0(
M(O"LRB>G("`,.$R`XXY>245(O[M?A')'O07NV-M>A&*4"-S(?8\9,Q;+4SK6
MHA^@P)LL\H003+`PN):_M+S[\U<&J></;-(%W467/L/%9XQ9#`3Q./>F*Y@@
MKBL<S?!I"Z3SW2]!^225,.F!;J9+\'V!F^1$!(6<`!PG,*`$".0RX857]R)I
M?O?K4%9)=4S,0/=3'&1/&$0,.N&Z*,(\5Q""<?PWQJ!]D*ZGY2_/I;</%J"\
MDNHP<HAZJ%_8X()@N'"'35&=+BCD>P&$TW:H;U.!?.$)_9!(U+"'G+FCS9/%
MZ#EJ9?<0[BY7S]>WD606H1(>\F8V]68P=YZHA_I&L-!WA#;.J@^4"5W',?>X
MA")H,NR:Q3$<#'VHYL\7'4U-`MBX\_5MD"'/N^?RB@;"7-9`D%D-TA*UA7%#
M@S)0_#E,"3!C6XF8@F9'Z2:2S$:AHR0M49-PW]IFRDBQ4*,4\YHKZJ%9*2K.
M#)+T47I+9`ZX@7:OAFHQ+/M.+5/K!O/D$,E;5L-H!5X@`#QSFR*,ZP?,V"82
M`@@'U\^PT5$=TB$?[XGR5=H3T\*9;K[7=.C,11TZ@#<S\)QRM272)1^7HKR5
M2C'*'3'=@/%"@`?,&PVLW[%T9BE<@2>J25=T!O"R!(]FXW?1QAA&?N>`73#T
MR=4=(W8M\"(?S/M(,6$\++J\W32,4*<X(0R7UT<.C/LD5?-3MLXNV/KD4J^'
M^D4+/JY9=W+,(I![47)"F(ED(D>>2/11F]^,.]KP=6Z,1M1#,]M3?!M)9A$J
MX2%?QT<(YH43<..*(NHA=0.3A:Y@YAVJN$=TE<#'F5%S=0-2,M03"77#OLSK
M71[GAT.SR*HW^;2!X0V\X=WA2<A')F]U&^]'^(2D>YQ@#W_`!Q2G=)=_2>M=
M<6P6AWR+(9V5P(VY5H\XU(NV.G6/"5ZK%A]-=+_N\5%4CC?HG17"VZIJSR_P
MB^WAX=;+_P```/__`P!02P,$%``&``@````A`/D;G_6.`@``G@8``!@```!X
M;"]W;W)K<VAE971S+W-H965T-RYX;6R455UOFS`4?9^T_V#YO1A(TC0HI$I7
M=:NT2M.TCV?'7,`*QLAVFO;?[QJG-&FR-7L!;)][SOTT\^LGU9!',%;J-J=)
M%%,"K="%;*N<_OQQ=W%%B76\+7BC6\CI,UAZO?CX8;[59FUK`$>0H;4YK9WK
M,L:LJ$%Q&^D.6CPIM5'<X=)4S'8&>-$;J8:E<7S)%)<M#0R9.8=#EZ44<*O%
M1D'K`HF!ACOTW]:RLR]L2IQ#I[A9;[H+H56'%"O92/?<DU*B1'9?M=KP58-Q
M/R5C+EZX^\41O9+":*M+%R$="XX>QSQC,X9,BWDA,0*?=F*@S.DRR6ZFE"WF
M?7Y^2=C:O6]B:[W];&3Q5;:`R<8R^0*LM%Y[Z'WAM]"8'5G?]07X9D@!)=\T
M[KO>?@%9U0ZK/<&`?%Q9\7P+5F!"D29*)YY)Z`8=P"=1TG<&)H0_]>^M+%R=
MT]$E)2NP[DYZ*DK$QCJM?H?#9$<1C-.=,;X'XV@RC4<):KU#PH(C?5RWW/'%
MW.@MP5Y!2=MQWWE)AL2G`\$(/';IP3G%7D9?+2;_<9&,9G/VB!D3.\Q-P.#S
M%3,@&(H.RJAVOK('>V6?4N_*3=C8ETE/RXS^1\:#L2;[SH_C@3<H!\QX#S,9
M$`<!(N3\`#T8:X!AO>;M*+<!=(8T]L/YTA[<2P_)W>W@>+PZ,TY.1XG]NR_E
M)R*=H8O_[B1O=:BYV]FO:#+^2TVGQYI)>N5'[AU9;W@HN]LYE!V]"37<!V%N
M%)@*/D'36"+TQL]ZBI,P[`[7T#+US?IV?YPM^^N)#0=X/72\@@=N*ME:TD")
ME'$TQ5A,N&#"PND./<<YUPXOB/ZSQO\`X##$$8)+K=W+`H79\&=9_`$``/__
M`P!02P,$%``&``@````A`(..5*3C.@``ZF$!`!@```!X;"]W;W)K<VAE971S
M+W-H965T."YX;6RLG5N3&S>V9M\G8OZ#0^]'*K(NK'+8/M$J,LGDG8PS,\]J
M6=U6M&4Y)/7MW\\'`CL![)65+);[/!QUK][8">8"D,#FI7[X[W]]^O6[?WSX
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MMT0%!7_^_/EO(;3].2`U?H/6S4G!_LMW/W_XR[N___KM^/F?BP\?__K+-_F^
MU4L*K^S[G_\]_?#UO6ZITKP>WX9,[S__J@[H_W_WZ6,8&[HE[_[UXZNQ+OSQ
MYV^__/CJ^N[U[>3J>J3P[_[\X>NWYF-(^>J[]W__^NWSI_\7@T8I54QRG9+H
MWY1$XVL@_B;%Z]^>BPXT5)=.O=6_/0V?V=N[E$3_IB2C\>O[V]N;N_N)$@]<
M?I):ZM4]ZW4^I'C]V]/=@0N--`Y.+S3\APL[.3*EH^QT6,?(_(7_<&%'3>4H
MNWSNW0S#-+[(;.),1TW`2/\A=70\>3V^OQW=WH7Q.G1+E3I>K;"71SI;OHDS
MY33QIN^^O?OIAR^?__F=EC/=WZ^_OPN+X^C[D9+9E(LINDGXU!S4Y`M9_A32
M_/A*[36]OFKE^,=/HYN;'][\0Y/]?8IYVQ-31SQ:1)C9(>W4@YD'C0=S#Q8>
MM!XL/5AYL/9@X\'6@YT'>P\.'AP+\$9Z.D<:^O\)1R%-<&1W]ZV!+&WLA%B$
M-9EZ,/.@\6#NP<*#UH.E!RL/UAYL/-AZL/-@[\'!@V,!*B%:6?X30D(:/:*J
M27-5&W@;8VZTJ'0SZ[8.>>Q".DL@,Y`&9`ZR`&E!EB`KD#7(!F0+L@/9@QQ`
MCB6II&E-_T]("VFT6&IH=$*XU,6@06M=2&<-9`;2@,Q!%B`MR!)D!;(&V8!L
M078@>Y`#R+$DE34]!RMK_5M!>PR%Z),<NZEO([G1([;0Y6=0%V3-IB`SD`9D
M#K(`:4&6("N0-<@&9`NR`]F#'$".):E<:!&ZP$6(KEU$<E/O$N[<:M8%=2Y`
M9B`-R!QD`=*"+$%6(&N0#<@69`>R!SF`'$M2N="`KER$?=OX]K7<7;AS"XEJ
M39'<U"O<Q&GJ@CI-(#.0!F0.L@!I098@*Y`UR`9D"[(#V8,<0(XEJ31IK%>:
MAI>O$%V[B,1-F7OGH@OJ7(#,0!J0.<@"I`59@JQ`UB`;D"W(#F0/<@`YEJ1R
MH8-KY2),F>O[4$FX=,Z$3+6G2-R<>7">NJ#.$\@,I`&9@RQ`6I`ER`ID#;(!
MV8+L0/8@!Y!C22I/H4P`42]:VTZ9:E$)U:9NW:[[,4=UJHAF1`W1G&A!U!(M
MB59$:Z(-T99H1[0G.A`=*U2;"R=87TT87Y^F6,_*=WVK2D&J'\2SK[;5=L/?
MAM*/9MG-0X<>B:9$,Z*&:$ZT(&J)ED0KHC71AFA+M"/:$QV(CA6JM81S;*FE
MQX56P<Y%//96+B*JGT.W([>^A4-1,)9+#%.B&5%#-"=:$+5$2Z(5T9IH0[0E
MVA'MB0Y$QPK5>L*1M=3SXKU<*'FZ!U-";KWS=9X<9=-O2C0C:HCF1`NBEFA)
MM"):$VV(MD0[HCW1@>A8H=I<.+:6YLY,K'C*U4BPN_PV5)KCE"G.I[?7?F)U
M4=9PFAL:FA$U1'.B!5%+M"1:$:V)-D1;HAW1GNA`=*Q0K2><9"_0$P^^E9Z(
MW.QQA>W'4/L/$K/7*=&,J"&:$RV(6J(ET8IH3;0AVA+MB/9$!Z)CA6H]X7!;
MZGGYNA>/R96Y='+6(RD7?FY]X6?41=DLFA+-B!JB.=&"J"5:$JV(UD0;HBW1
MCFA/="`Z5J@V%\Z[I;DSZUX\'E=ZTHE9A[5"CZ\%A7?&_(8":,:HAFA.M"!J
MB99$*Z(UT89H2[0CVA,=B(X5JO6$(_`%>N*)N=*3#M'U[/$UH/!^H5_W@&:,
M:HCF1`NBEFA)M"):$VV(MD0[HCW1@>A8H5I/./E>H"<>E"L]Z>RLFUW,'E\6
M&G51>7$#FC&J(9H3+8A:HB71BFA-M"':$NV(]D0'(GV.I5A:*CWCOO+#R^I$
MIU1U_2$AMZ/PE:(<U:DCFA$U1'.B!5%+M"1:$:V)-D1;HAW1GNA`=*Q0K<[7
M'X:?2V,6'1*Z/7U.Z52:>"2:$LV(&J(YT8*H)5H2K8C61!NB+=&.:$]T(#I6
MJ'81B@'E*A=V=[>ZXV><Q!I"N=J-$XH?TPJ?"WDTI.U;7@#O7!5O:E&3[KPU
M,U0WS(6,^B7X@_F9KO/T/8ZH&DY`4T;-B!JB.=&"J"5:$JV(UD0;HBW1CFA/
M="`Z5JAVX8_:83B-;DX?!#PWI'CL'B=4#JF$ZI&!(96BRB'5VS!76.J7<=F1
M-+PWH1U6-1LBJH84T#0U+*)F1`W1G&A!U!(MB59$:Z(-T99H1[0G.A`=*U2[
M"(<_OT*-KK3:G)GGH9V3DE`YGA+2/T-+5(HJQU-OPUP2JE]#.`[A-=R^#I_]
M//,JXD&J&EH1:9&V7<?C&&A*-"-JB.9$"Z*6:$FT(EH3;8BV1#NB/=&!Z%BA
M6DLX!I5:SKB(IZ;*17>0*H>/KSR-NR@S-B6:$35$<Z(%44NT)%H1K8DV1%NB
M'=&>Z$!TK%"M)VS^+]`3SPJ5GG1\T&)1S&Y?7AIW45D/T(Q1#=&<:$'4$BV)
M5D1KH@W1EFA'M"<Z$!TK5.FY[CN!C9ZSJ)U:UDMS0N6B1C0EFA$U1'.B!5%+
MM"1:$:V)-D1;HAW1GNA`=*Q0K>6RT]4U3U>&B@<,T91H1M00S8D61"W1DFA%
MM";:$&V)=D1[H@/1L4*UBW`F*E>PTW8X3I%OOWQ\_[>WG\/^N'<3<-V]TWN=
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MZ9WJ0XZRWA\-]4@,Q^\+),;3>KF;U`>APHFRT/-(-"6:$35$<Z*%H?HVN&I'
MFZ/L-BP-Y;N\(EH;JM.[T\LF1UGZK:&<?D>T-S28_I"C+/W14(_$<.HN);[L
M@9K.[N4$C:AR"S0-C\UZ!,R(&J(YT<*04N8).LDUSM,,:G.4W9VEH7SS5T1K
M0Z?O`:?9F'J?T=:B<JX=T=Y0;G@@.AKJL390_KA@&\12B'2=:CQY?7G,J+BM
M_B$Q35&AR]W-?W#/B%D.LGO?Y.R&YD2+A&ZTL>NRCR9ND]7F*,NU9*Y51D4N
M_WK6.5<1-7$/]DV.LBMN<WI#NXR*7/Z*^YRKB)JXY\LA1UGZ8TXO5#]F+RO'
M:$?D"WP)A;<[\HV_=^OEHT7550'W<)GF*.OZC*@AFA,MB%JB)=$JH^(%>1?K
M'&5=W1!MB789#:3?YRA+?R`Z5JCVJ@=`M6B?V3Z%<%<=B"B\[]!YO7:;C<?K
MU*Z2[^_5M#?JWBV[LQ2E-R#"EZ0?KFZN;VZNW?K06"IM"[I>C?P%YQ:53].+
MC(J&O@_M<_JPM%2#?5A9U."M65M4E<MW:V/=JJ/<CG[;F\O?FYU%#?9K;U'U
M%9VRP[/Z=>S-5?2K&KCAG'3!P#V%UP,WH7'YG!G=^Y%K4<,+4HZR:3@S-#D-
MT_'=U<W=P\3MWQH+TG(Y,$PM*N^)%D2MH:$++BUH\((KBQI\T6N+RD?=C2%-
M]_QZ[OT`M*C!3NPL:K`3>XO*G3@8&NS$T:*>ZD0]VC0+JM'VHKUMV'2XU3.A
M>O5TNY%':S<X%:<Y*H_!>,&T5-Y<W=S[[^DTUJJ:P,6D.VU/YQ95+)1$;4(#
MEUM:J\'+K2QJ\`6O+2K^CDWX5,/&>E"EY_A+'JHH_YIWEGZP$WN+RITX/*L3
MQ]RPF"I%)^KQITE0C;_AQW3X;)0?:!&I-FVCXS%%A7)UGJQ%#T[JIQ:5U<^(
M&D,Y_9QH82CG:HF6AG*N548#75U;5$Z_(=H:RNEW&0VDWUM43G\@.AHZI:\E
M^D+ERQ81UB]O(G);:_>L>4Q1H9`ZI#OEJJ+\1F-F5XS/FM'H[OY>/[CC3AB-
M13VUQ*:U)5Y1_;*1N;"&@YUH+6JP$TN+&NS$*D4-WYQU;RY_<S86-?C\V5K4
M8+]VS^K7OC>7[]?!H@;[=;2HI_I5#^E01!RJ^?S/Y]^?>A-%'RNQ[\O=Q%ID
M6=!+J%JO4L7RS'J5HJZ[X32S7!DUAO(B,"=:&,H-6Z*EH9QKE='`7%M;5$Z_
M(=H:RNEW&0VDWUM43G\@.AKJ6:_T?*SDGGGHA'"WQ4XHKYB/-Q%IE;39/B6:
M$35$<Z(%44NT)%H1K8DV1%NB'=&>Z$!TK%`]T4)]<&BB/>O=RO!S.EY10D69
MSJ*J=8+[@MBP*M.-[MTY?)9R*<IT-T1SH@512[0D6A&MB39$6Z(=T9[H0'1,
MJ.?=RO`[.I7(,Y.*A=53AOJMCHP&UH.I1>6CTHRH(9H3+1(*AZAB,^&*FFV.
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M;7.4W9VEH7SS5T1K0_D1OB':&LJY=D1[0SG7@>AHJ,=:J-S\X6U0^`Z-FY&&
MBFU01L5M]0^):8JJMD%XMS('V;UO<G9#<Z)%0J%65*AU]<$V1UFN)7.M,BIR
M^=>SSKF**+Q;F:/LBMN<WM`NHR*7O^(^YRJB\&YECK+TQYQ>J-HMWX9B5SE,
MAC=9IW`WBT,&_1Y<=>/Q;F5J&+X2E?7X%SC-4=;U&5%#-"=:$+5$2Z)51@-=
M7><HZ^J&:$NTRV@@_3Y'6?H#T;%"M==0*KK`:ZPLE66%VU3>TC^=,;Q;F8+"
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M%A6?-3?WHYO[JRM7J6XLZ*D5-CW<8N?+-RNMX6`?6HL:ZL/2@@;[L$I1P[=F
MW9O+WYJ-10T^?;86-=BOW;/ZM>_-Y?MUL*C!?ATMZJE^U0-:4=6JY`?T\]ZK
MO`UIW&,QHO*]RA1UYK,5%I7?H9L1-8;R$C`G6AC*N5JBI:&<:Y71P'*RMJB<
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M+8A:HB71BFA-M"':$NV(]D0'HF.%ZKEW6?WXCO7CA,*'///S_\&]C_J8HZP`
M,26:$35$<Z(%44NT)%H1K8DV1%NB'=&>Z$!TK%"M)]0EGU\WN(MES+*\GY#3
MXYZ"CSDJZXFYB@DU8U1#-"=:$+5$2Z(5T9IH0[0EVA'MB0Y$QPK5>D(AJM13
M/+G.K'.AI5OG(M)[>.;@\0YH2C0C:HCF1`NBEFA)M"):$VV(MD0[HCW1@>A8
MH5K+9=6V.U;;$G*SQKT1\YBCS-B4:$;4$,V)%D0MT9)H1;0FVA!MB79$>Z(#
MT;%"M9Z!.MJ96</:V5U$U:P!FC)J1M00S8D61"W1DFA%M";:$&V)=D1[H@/1
ML4*U%FW6J\7LC(L0[E:PA,H5#&AZ!S0C:BI4]U-'HDOZ&<)=/R.JZZT/_GN.
M=S'JW%$WY:JV/_XT-[-<6L_S)HE'W91+-ZB(RD?=ZC9,^NH`\2]:#8L[-:QO
M2$)UI>?!%Z"MH7J9N^</P5.+RH-@EE#X'D5NZ#\2U%C#^AX]]>K/G1F?]>GO
M"8^,";FQX8M>*>K,V+!<N2@Q,Q2+WG>3A_&#R]U82#4*BMM<CX++CE>3>)8J
M-X@)E6?DC`I?10_B&TL658J.Z?438_9`;"R*)\.)/WH4FZ?G_\[&*8L;S?&0
MXD:SJRL]6L,SHSD=>.I!Z;;/LY0K_"QL'N"^B-38%:NHXK;68OW.W]^=Y]7F
M)SP1)%0)CU%GBB+6,)<"9D2-H1[A>N'5PAU>TLM^!#_\%*U;U!-R6[:\?)P&
M[6..LA$Z)9H1-41SH@512[0D6A&MB39$6Z(=T9[H0'2L4#T:_8XZJ'O1GT^<
M<+.=D#/G"SPY*IN+N<HC*J,:HCG1@J@E6A*MB-9$&Z(MT8YH3W0@.E:H-N<W
MVV<V!]QA3R(*G_[O%K?QE2_PY*BLIVMH:,:HAFA.M"!JB99$*Z(UT89H2[0C
MVA,=B(X5JO6$S7!903BC)X2[IUU$U>P97[DGU..DBS(74Z(944,T)UH0M41+
MHA71FFA#M"7:$>V)#D3'"M5ZPH[\`CUQ`U]MKR)R>GPE8=)%93U`,T8U1'.B
M!5%+M"1:$:V)-D1;HAW1GNA`=*Q0I>?^Z3/0A7^Q_)2IGE@).7/^E)BC.G-$
M,Z*&:$ZT(&J)ED0KHC71AFA+M"/:$QV(CA6JS0V<WX:7P'N>V1(J:T!$4Z(9
M44,T)UH0M41+HA71FFA#M"7:$>V)#D3'"M5:+CM.WO,XF9";-;Z4D*/RK(FY
MU-#0C%$-T9QH0=02+8E61&NB#=&6:$>T)SH0'2M4ZQDX,I^9->D<F^_NV_N(
MJED#-&74C*@AFA,MB%JB)=&*:$VT(=H2[8CV1`>B8X5J+?ZL?L8%S^3W">7"
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MW<DDHJK`/1[Y([\U+*=1V:E8Q<]1V69,K[=K@LWQS6LW>!MKHP5WR&;J>)Z@
M"VN849M0NMCH_O7U0_5_]5^M7UJ&P4NO+"I?9TVT<9>^]:-V:VV>NEBM-9S7
M+]`:C_=EJ>`^HGJ2CGRIP*+.3-*4*X_N66J8)NGHFEI3&WD;THK,"^M2GC>M
M(05WN49^WBPMJKPBANC*HO)K61O*5]P8&KSBUJ*>NF*E],&7%X;W=:?P>J8F
MY&:J6[`>K>'P3,U1W4Q-*$T>O^A:@Z>&;_S^CD7EN;(@:NLKW;^^JR:I?^]\
M:1D&+[VRJ'SI-=&FOO3HRH_;K;5YZF*UTU`^>/XT?0CASFE$;IKZ$VYJ>.:'
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MED0KHC71AFA+M"/:$QV(CA6JM6AN7;+VA7#W1$LHS_3'!Z`IT8RH(9H3+8A:
MHF6%ZM<<3OKE>E\,Q>=7C!Y2O2`_J=X:*HH6&15;V>)C._$<E:+JBM'(/=1F
M.<I6GH9H3K0@:HF6"?54>1Y\">%E-XR5A5-B#:?RAJ6H:B?.&Q:CJA_R8I4G
MI2^K/+SBG&B1&V9KXROGH\U1YF-9Y:H'G;8BU:`[L^B%<#?1(G);1[>E>WQ(
M47K8Y[,3[U\795V?I896AKGF+B.UT3]=YC'*,/GZEGEA*)^W6D.599SP+*J\
M8GG"JV^P<EUR@T.XN\$1N5V<JU\\/J2&VFEWMZ'L5)K1793=AEEJ:+NXL2\]
M-999JV>7N><&(_/"&N8EN*TO=G/K;2ZMS5,7J^[MZ.JRPVR,K^^N,3=^?>&I
M"QL>P$58=X.-69%"QY^Z`-181/A#W`.WN`O+:_NBA[7&[()NJ"SM?W_R<NXF
MA\-;^5P:7B)&5_&P5QY$C+DQ[$\B%G;F*%*$%3<Y7C4-8[<FZ@ZG3CTUKN)9
MI`O+0U9W.#7-3'>XNMKXWBO5/3YS07>/PR'HDGN<#DUY)+P=7456#V34P[NP
M<P,Y9<M7F%G3[BSM#D:ZRZG1N7&,W+K+75-SJKN<F):6;EJPX-:%E5<MESYW
MJR\[D(VN>"(SYH:SNQV/%G9V.*<KY`&F6YT.?;%>??/ZMJY-N=.?[GS*<6Y\
MXU*Z\V"Z\]7E[[%,6\#HJ>NY>^Y/6>>6$)ZM1E>1U1_9'+DR@.YY%V;C:-K#
M=(,1IYL(-N]ANF.(TQT#TQH`MNIAZQZVZ6';'K;K8?L>=NAAQYHY8Q)[T8(4
MXOV3-;*Z<#%V;Y#)6!=6&`.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P
M&0.3,3`9*YDS-G!\/#?=>&8<7456UC)ZF.86XF0*3*;`9`I,IL!D"DRFP&0*
M3*;`9`I,IL!D"DRFP&0*3*9*YDSY<^LY/3RACJX2R\\,320PZ2F9ZX:>EQ=-
M\1#OIWAD]8-PS,US:JH]47Z0X_0WNNH)&X_S;MGU/YPX+MDSI1-*WM&\'5U%
MYOKOW\NRL+,/\G2%\F4^W?_1A8>74[R[_XFY_F,C8DW+CI4[I'@X'/6%C<=Y
MEU[?_W`W+KG_IWC?_Y!#7YC2@[(;&..QV]T\CJSIN?[';)6F\3B?!5S_P^[R
M@O&C`PW&?V*N_^[`I?ZGIN?ZWQ,V'N<MCNM_V*-=TO^TSRO'_RCM\S3Q\OV_
MQB,ZA^5'--EL1-;TL'D/6_2PMH<M>]BJAZU[V*:';7O8KH?M>]BAAQUKYHR%
M_6!I+!0L7_9EP=$H[BVK4W9B]8;K&JMQ#BMLIJUJ'ARR"2:;8+())IM@L@DF
MFV"R"2:;8+())IM@L@DFFV"R"2:;)7,VPU[,VQQ?OP[?F.UYHI].S:>%]D^C
M<&SRC]+$]+=,S(K6C;3=RVS:PV0*<3(%)E-@,@4F4V`R!2938#(%)E-@,@4F
M4V`R!2938#)5,F<J[,5*4SUZBK]3J#]TV:,GLOKX>9WW)B>S,M:%F449`Y,Q
M,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!DKF3,6MJVEL3^R4J8M
M<%[:WHY&D;F5$ON^'%;8[)H:DTTPV02333#9!)--,-D$DTTPV02333#9!)--
M,-D$DTTPV2R9LQGV]:7-<_,OG0,J8Y&Y^<>=;A=F=C3_P&0,3,;`9`Q,QL!D
M#$S&P&0,3,;`9`Q,QL!D#$S&P&0,3,9*YHQ=>+;26Z5\H$46_LY+L;?,IPE;
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M@<D8F(R!R1B8C(')&)B,@<D8F(R5S!F[L+02_E0.C$7F'G^YF&-SK`LS.S(&
M)F-@,@8F8V`R!B9C8#(&)F-@,@8F8V`R!B9C8#(&)F-@,E8R9RR<T\LY]@<6
MS'CDKRHK^FM%07`]_6Y0)\MAA<RNJ3')!)-,,,D$DTPPR0233##)!)-,,,D$
MDTPPR0233##)!)/,DCF9X2CO9;ZP3A:J,9B:J52@!2#O3&]0)TM-Z\6T:UK8
M!)--,-D$DTTPV02333#9!)--,-D$DTTPV02333#9!)/-DCF;X9A?VCSW^(ME
M@7K^I5)!;0S5E_!W'N(T-3M:3,$T_\!D#$S&P&0,3,;`9`Q,QL!D#$S&P&0,
M3,;`9`Q,QL!DK&3.6#C*E\;"8JIW@B\_2,2:0*VRJQ.4DP^EEW$75J@$DTHP
MJ0232C"I!)-*,*D$DTHPJ0232C"I!)-*,*D$DTHPJ2R94QG.^%ZEJMHO.Q?&
M@D&M,Q41ZIF)NDSXK"%F)IAT@DDGF'2"22>8=()))YAT@DDGF'2"22>8=())
M)YAT@DEGR9S.4`#P.E]X+HRUA%IF9&Z;@Y+-N`LKYB:89()))IAD@DDFF&2"
M22:89()))IAD@DDFF&2"22:89())9LEJF>&G22'SA=N<4RY7LDG,V43))H=E
MFV2S$5G3P^8];-'#VAZV[&&K'K;N89L>MNUANQZV[V&''G:LF;,9"@#EU#RS
MS=$/"F-CFI@SAKI,#BN,E?6'T]E2QL!D#$S&P&0,3,;`9`Q,QL!D#$S&P&0,
M3,;`9`Q,QL!DK&3.6"@`E,9>?F8,/YKM3QF).9DHV>2P0F9,IZ;&)!-,,L$D
M$TPRP2033#+!)!-,,L$D$TPRP2033#+!)!-,,DOF9(;:P'](9BPS5$_&Z\B<
M3%1S<IB)FX[()+-+9W&2"2:98)())IE@D@DFF6"2"2:98)())IE@D@DFF6"2
M63(G,]0&O,ST^TWGEM585JCE159]EC5\9$LSMF`R!2938#(%)E-@,@4F4V`R
M!2938#(%)E-@,@4F4V`R!2938#)5,F<JG/N]J9=M2/4!&:ZA75FA."SB#SB.
M4M-BO93,KJE-,<D$DTPPR0233##)!)-,,,D$DTPPR0233##)!)-,,,D$D\R2
M.9FA).!EOG1#&LL+]3SL2@ZE3=3=PO>-_5F13#81)YM@L@DFFV"R"2:;8+()
M)IM@L@DFFV"R"2:;8+())ILE<S9#5<#;?.'4C`6&6F97="AEHB1WW879--34
M!)-,,,D$DTPPR0233##)!)-,,,D$DTPPR0233##)!)-,,,DLF9,9:@*ES'./
MP5A#J(U%5K\C=8O*VW475A@#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y,Q
M,!D#DS$P&2N9,Q8._J6Q/W"ZB#6$6F975RBG'^INUUU8(1-,,L$D$TPRP203
M3#+!)!-,,L$D$TPRP2033#+!)!-,,L$DLV2US)N^4LW+UM)3*E>I2:P^7=RB
M[I;#LDRRV8BLZ6'S'K;H86T/6_:P50];][!-#]OVL%T/V_>P0P\[ULS)#"4!
M/S-/WR*^](-2X8<^_+$_,><25;<<5K@L:Q6IAL,XN42<7(+))9A<@LDEF%R"
MR2687(+))9A<@LDEF%R"R67)G,M0$?`N7S@Q8W&A6F6#Q;@5+5=9%.1R6"&S
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MF$R!R1283(')5,F<J5`1*$W]:W3S[OWW/_][^N'K^P^_::Y<A:^H_?3#:8/Q
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ML&/-G+%PN"^GWSECL1A0S;'PV50<T^]0/\MAA;&NJ3$9`Y,Q,!D#DS$P&0.3
M,3`9`Y,Q,!D#DS$P&0.3,3`9`Y.QDCECX01_B;%XXJ^-=56`<HZA2A;>JXAB
MS<YT1"9CB),Q,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y.QDCECX91>
M&GOY(^XV'OAKF5T1H)2)*EEJ6NTPR22S2V?2)1-,,L$D$TPRP2033#+!)!-,
M,L$D$TPRP2033#+!)+-D3F8XI9<RSRV8\51?&TLG_?H1ATK8;1=F)C3]P&0,
M3,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QL!D#$S&P&0,3,9*YHR%TWII[`],OWCP
MKV6F8H#F?[%?027LM@LK9()))IAD@DDFF&2"22:89()))IAD@DDFF&2"22:8
M9()))IADELS)#`=Y+_.%1>K;6!2H;:9"065S@MI+:EHOIEU3,RR;8+())IM@
ML@DFFV"R"2:;8+())IM@L@DFFV"R"2:;8+)9,F<SG.1+F^<6TWCRKXUUU8!B
M_DU08+GMPLR.%E,P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3
ML9(Y8^$D7QH+B^GS/AMZ&XL`M;S(M-TU*X^C%%<PF4*<3(')%)A,@<D4F$R!
MR1283(')%)A,@<D4F$R!R1283(')5,F<J7!,+TV=FUOQ6%_K2:S2`R8]8-(#
M)CU@T@,F/6#2`R8]8-(#)CU@T@,F/26K;^>=+VT4`__Y?Q]F=$KC*A[&RK=C
M,LNK6L]OAJ:P\#G$O/F8N%KES*ZJ,)MF30^;][!%#VM[V+*'K7K8NH=M>MC6
MF'YT1WUV+L+IN!O:VOF]T$4\9%<C_BZQRD7'\DWN<Q'#]'&)TQ\YO1JY*J,T
M=!&%ABZY,6D`DX:N;<KN)$M*%V&9)`69)`5,4KJV*;M[?DI1%V'9I:C,Y!2%
MXW"IZ,SJ<Q>/S[6+R,)ONW2#6S^I7/_YCL=1:AI^4"2'\>>->\/NW>N4HWC1
M\#GM+MMXXE1J]J2^:?WMPD;W[@@GDRDL?YA!)CM6-G4=D<X4-CD-I_OKN]'$
M?R9-?ONZX5^[E'>7-'E2WK&!;LA[U8V[R6BB7TZJ%6@@G.F&&QOA=%V.C=.!
M[.[TTYV7+*7QD%X/F<C"5R8Z+>,)BL=WJ6DULOQMFXXL[+9;-C4^8M/PBPO=
M%?!7,30^TA6J,'\%C8^N(R9&XP-,@R&R\'F/[JKCB2NQ:CBDIM55_:C4<,`5
M-!S`Y#XR=U57)I3],U=U]L-)O;1_;F6()_M:<V3Z3JS=-BT#'<NWJ&^53F%Y
M2R.G8!+8I;-+R!:8;*&M;(%)#=K*`Y@\H*T\@.FFEVW='9;^Z@Z_<'Z%-'ZK
M$EFU)(\G7))C6/C"8#=<^URD;%58SY*<LNF?+EO?DIRRG5N24[9J2>YMRB4Y
MA6F7V'4$<U^J^[+YN2_[Z(CL]S7U=T0#XCD=T1CIRU9TQ`V;<$XO)Z;?5?W/
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MU[>^?7'*5BW"J>G@TT`#(34-'Z+[QT^N`QH"*8O^R1WPPTY#(&7)'=`02$T'
M.Z!1D9KV=D#C(671/[T=<.,A5!PN&0^I0I'[_79T%UDUX?O.2:FI_NGMF*VW
M*:S:&_>,AQCF]H8\)Z5LY;#I&P\I+!^[M0H\IR,:#S$L+49/G9/ZNM$S*M`-
MC8KG=$.CHNK&4^>D,]VHQ\:D*CEIMH<'<OB:U`6'I%,.MXE+K-[$><./HQ1V
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M@(AAPQW1&.G+5G3$#9M0ZRB?UR\\)$U2S22O)&]'B=43-L:=G;`IK#PD6;K,
M-&&[=#:Q-6'!-&&13Q,63!;15LK`I`QMY0=,,LJV[LZ'@H>_\\\Z)$UBJ:3:
M0R=6/P,G>3D^/7KT#(Q-SSX#8UCQ7-"$3"S6;Y\X)%E0]50H!I\]`;MNF#8I
MPC6EJ+KF$X<D"QJ\IC3BFM*(:TJCNV;O(<F"GKJF4ZU%`:K3F\R7['U"&K\V
M1U:OS7YG(N^IZ;FU.865!>+4='C9T4SLFA;+>H_YKB.%^:ZI,9F/;/BJFJ]=
MTX&KRCVN*O==4[NJW#_GJIK57=/^JSK[H5!23O0S1^1)+*S4T[LLMMA<[EA_
M+TYAVONDL+Q7T5P&D\`NG=T/+:5@FJ=H*UM@4H.V\@`F#V@K#V"ZZ65;=X=#
MR:*[PYJ3+]S[I,I']0Q+)9-RMS*^=\="S:\8=G9=3=GR%>0BL>%U-04]M=[8
MNMIUPQS*%ZXI7]4UGUI7GW--.<4UY137E%-WS?YU]<PUG7?=#G@OU]5G5G@G
M(8]?6".K-R\=&YYQ*2QO5&093#.N2V>V-./`9!!M91!,,PYM90=,=M!6=L`T
MX\JV[L[K05+=^7-K6HCW=SBR\.73[B`POL=[FY/45/]T82H^UV_9:IE+8>5$
M'?E-M#RDBVI?UF7K*?M9MK)O?<>*KF]F4+:>TQ$)[#K26_:S+%4'_*N67G1`
M>I_3`1D?ZH#DIRQ/=:`>#_=5:4?CYLQX.,6[\9!8_17\>_>>\.,HA]D]G_:P
M60]K>MB\ARUZ6-O#ECUL]?]9.]?EMI$C"K^**P^P)@!2(E@;5TFB)%(B)<IO
MH$UH9RO>*"4KE=?/UYP+@>DC@$KM+Y=/=\\TYIP9S@V0P#8"VPKL06"/`ML)
M[$E@7_M8P9AM)92_F:==?)Q;:$E>P#J7'&'*83#E,)AR&$PY#*8<!E,.@RF'
MP93#8,IA,.4PF'(83#D,IAP&4PZ#*8?!5!<KF+(%?9>IL;X5-P".DXQ+#G4#
M9<=)(/0X#'H<!CT.@QZ'08_#H,=AT.,PZ'$8]#@,>AP&/0Z#GBY6-*<MR;O-
M6>YX7+[PRP`=HID;SF@.4ZV+:AY6]KU9>L*.FSNT<O1C.,T_..+G*[J-77P\
MNJ7!#RY"#9W+D'#A,+AP&%PX#"X<!A<.@PN'P87#X")@ZN+CW-;:?P(78<G>
MYR)B/2XR-LQ%<!NX^'C(FW?EC]T)&G+AB1IHR-A`A3!35E@<RL)3]DB%PU,N
M/&'PE+&!"J$N%_?>]<BC1RH<(G/A8$6G8IK0(U)T'M;RQ]YC_N5/2,#Z6UCS
M8J)'AXIN]/#!#A7=NL<X*;37%\O-$IC,H0,U0.XIB4!N=DLM"9T1"VN^FE=*
MJJJ8^,+O*6E`>2Y_(%LHSVXI#7KK>!JP/I)&(01;I7=[])@0PJJ^WW7C2A^Y
M98;K>7$A`R'$4(;J[*9&UNC6W=.*H<.[2P@AAP[4@!!.200A9+?$`$((6#SL
M;=K:7>Y$!Z=D@0YR\0/)HH/LEK)`!Z-9((.1+`H9V#K^(S((Z_Z^#.)>0)??
MNCS71`;1;6P\B&Z]\2!B8^-!#AUH661P2B+((+LE`I!!Q,)X,&V:LTE3Z!T=
MG)(&.LCE#V2+#K);2@,=C*>!$$;2*(1@>P@?$4+8<^@+(>Y#],<#=S]H'D.[
M>E'C073KC0<!&QT/<NA`TR*$4Q)!"-DM,8`08B+A)MJLG;3MI/@%1`BGI($0
M<OD#V2*$[);20`CC:2"$D30*(=A^PD>$8/[E#"%@_1E"6UR98D2(;F,C0G3K
MC0@1XY_C;XJ8(>30CENY.X,0HMM@(@@ANR4&$$+$PHC`?<3I67&8APY.R0(=
MY.('DD4'V2UE@0Y&LT`&(UGT9=!^<*/HX%_((&+],Z^V.+B_JE+HR'B0W+KC
M0<3&QH-CZ$#+WIZ6R*KCE@A8)RS-#YJV:LL'O4M.%1.UHVA+-=YGM\'VV'3<
M4AK;A`VE\9"<WDVC$`)I?&0\:,V_%$+`BO&@6#PAA.@VV`V7';?TX-<9"]V0
M/_\T;]OR=:&;[,6`^#X!Z."4/-!!=#N.2^@@8O2U8PWEN(02<FC'32CAE$10
M0BXM-0A*."41M)!#=2*%%F"FIX7#^=WL%P0]LGQH+;)41<"*X<$=V:50,CTV
M:=E6J"+6T!L>`C8Z/.30@1J0170;3`199+?$!K*(B83I`MN]Y^7Y"9HX)0M&
MAUS\0+)H(KNE+-#$:!8(8B2+0A"V9?2!R4(;MYBZ6YX1*P:'8I7-X!!"^]?%
MA0RR6WIN!H>(Q55\PR?_RR]K,#9$I[&Q(9<_T/R((+NE-!!!+XVFGI)%,0:B
M@E/20`6Y_($T4$%V2VF@@EX:+-1FTZI8PR"#D30*&=B&TT=D$#>H>C((6/_S
M>ZT[56JS6WHBNK[#X-QA4.PP.K7#(,]AD.<PN'(8Q#@,%AP&"PZCT1WV*+"=
MP)X$]K6/%8S99E&7,1O)_\_/V;1AXZFW%(Q8_XRP+59(=.H0VON<C<=@T_G!
MIL-@TV&PZ3#8=!AL.@PV'0:;#H--A\&FPV#38;#I,-AT&&QVL8)-V_/ILCGV
M:QSWB'K]+V`%8\7``&/9K=/_'`9C#H,QA\&8PV#,83#F,!AS&(PY#,8<!F,.
M@S&'P9C#8,QA,.8P&.MB@;'//_^QW[\MG]^>O_SZQ_[U^_YJ_^/'ST]_>_F/
M?:+;+NMW\$^O^V]__<LE'UM9'+ZX0HOGF&2;3[!QU"YME=D.9Q\NKIUB8\!1
M<>W,;(>)E(\[,]OA>Q[.-JNQ\3U"5>:L,=OAIHV/LUSXD)J,LUSX+I>T62Y\
MY4G:SLUV+FU3B^/+W"IN:G%\Z%G:C`=^H*2M-=OA$,L_GW'$]V!5W,PX"J?Q
M+FYJ<?Q5'Q4WM;APKN7CC(<PIGJ;\<!E?5FF\<#;?=)F/'`%2-D:BV,:+VT6
MQSLJTF8\A.-0EV=C//"7T62<\<#?X)(VXX%WE92MMCA>A)$VB^.](65KC(=P
MP<SG:3R$]U6\S7@(;P]YF_'`WT)5]=46%^YTN[C:XNIWXHP'UOZR3..!A9"T
M&0^U[@^U\5!K'BJ+JW1<97'5.W'&0Z5YJ(R'<`3MG]UXJ'5_J(T'UA#J^2;6
M+A/=+A-KEXENEXD]W^2=YS,>*LU#9?55NK[*ZF/K1>1Y3K-PE4]9:!3N>0F+
M#?]Z])_3('KLGR,O[EVHTG@H;@$(BW4!W0/.*(W/L(B8,TKC$QW*0@/Q'0EE
MH7GX>H"R0`:OL@N+4:^9M\ZB^TI-/;HWF."UWFWXT*-'#3_OC!U&MWR>0^>1
MSW/H.KKG6,>1"CET&ZF0&N9TGR%I&5%9-].]S#J9[F.'(4NQ4UE'D2HX=!.E
M@HMJ<2$59=6K.JA<^E.UJOEBNKAX9PZ#,%5&E]`H6311JHP0D600`A5_?&UB
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M&GWY'P```/__`P!02P,$%``&``@````A`"OZ\3P#!```,1```!D```!X;"]W
M;W)K<VAE971S+W-H965T,S,N>&ULE%==;YLP%'V?M/^`>"]@$O*E)%.3KMND
M39JF?3P3<!*K@)'M-.V_WS4F!)O6@3RT?!P?']]CW\M=?GK),^<9,TYHL7*1
M%[@.+A*:DN*P<O_\?KR;N0X7<9'&&2WPRGW%W/VT_OAA>:;LB1\Q%@XP%'SE
M'H4H%[[/DR/.8^[1$A?P9D]9'@NX90>?EPS':34HS_PP""9^'I/"50P+UH>#
M[O<DP0\T.>6X$(J$X2P6H)\?2<DO;'G2ARZ/V=.IO$MH7@+%CF1$O%:DKI,G
MBV^'@K)XE\&Z7]`X3B[<U4V'/B<)HYSNA0=TOA+:7?/<G_O`M%ZF!%8@P^XP
MO%^Y]VBQ#0/77R^K`/TE^,Q;UPX_TO,71M+OI,`0;?!).K"C]$E"OZ7R$0SV
M.Z,?*P=^,B?%^_B4B5_T_!63PU&`W1&L2"YLD;X^8)Y`1('&"R/)E-`,!,!?
M)R=R:T!$XI?J_YFDXKAR1Q,OF@8C!'!GA[EX))+2=9(3%S3_IT"HIE(D84TR
M`O7U^]`+9Q&*)K=9?*6H6N!#+.+UDM&S`[L&YN1E+/<@6@"S7-D8-"D=S5K?
M6RJL49+<2Y:5"]L=AG/PYWD=S:=+_QEBFM2831>#=,3V@I!6@+Q&(ZR\K?'M
MJ%^D2+"4(EV0VC;J`7`WVD)CWBYB=)6F*8$(]5<BP2L7R)N)H_E(GWJC,.,V
M1D=L;0A-&Y#TUR;!L`O;\\X#?>:-PMBTV1":-MA1_;5)L!FWF:%-829!M=<"
M+QJ-@_;/"/-6P=M+0:,KI29U,D2J!)M2QX94A6G/'>F(K0VA:9L.T2;!MRQ6
M&)LV&T+3)FM=*Y'8#ZD$FW&[^J'.K<(T%J/0--4`C"-]#[QSA.=#=$JPJ=/(
M'AN%L<70AM!BB*`R]0]BA;[E<`VRR;-"='TR0_<V&:E\KB=`T^4:U++9B.^V
M@[A2Z.)D&N\O3B5]7=Q$/Y@;I$#6X-D@NCZ9R?OK4WG?GJ&1`EGUV2"Z/J`9
MH$^BS:-Q=48=8:1`M;E3KYVBX7KZ^:YCMC8"/J=F:-[^73\J=.V#"HS\=#.U
MS^:F]]V:8>;MF@<D7RM\PZ+K&U15D"H(-[RW58TJ_-N:IX^^094%J:*@GYV.
M]PI4>S_Q].0<H#>\[]::=ZLT&E1N*K2Y60TW-S7H[6C5`54EYVV(;OB@,H-4
MA;AAN*V,U/IL$$T?=$L##GN%-N-G&EZ#:L/'7M0^MW#=-5P?,3.W2-0>H=2K
M#DTU,#EF![S%6<:=A)YD]Q7"UV#SM.D,[T/9"QC/-]`Q5NV5W[R`AJV,#_A'
MS`ZDX$Z&]T`9>%/(`TRU?.I&T+)JFW940*M671ZA-<?0:\"'J.OL*167&]G)
MG"_-_OH_````__\#`%!+`P04``8`"````"$`SI*6AH0"``!K!@``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q-RYX;6R,55UOFS`4?9^T_V#YO1A(2%844J6K
MLE7:I&G:Q[-C+F`58V0[2?OO=XU3E#11EQ>$+\?GW'NNKUG</:N6[,!8J;N"
M)E%,"71"E[*K"_K[U_KF$R76\:[DK>Z@H"]@Z=WRXX?%7ILGVP`X@@R=+6CC
M7)\S9D4#BMM(]]#AETH;Q1TN3<UL;X"7PR;5LC2.9TQQV='`D)MK.'1520$/
M6FP5="Z0&&BYP_QM(WO[RJ;$-72*FZ=M?R.TZI%B(UOI7@922I3('^M.&[YI
ML>[G9,K%*_>P.*-74AAM=>4BI&,AT?.:;]DM0Z;EHI18@;>=&*@*NDKR^SEE
MR\7@SQ\)>WOT3FRC]U^,++_)#M!L;)-OP$;K)P]]+'T(-[.SW>NA`3\,*:'B
MV];]U/NO(.O&8;<S+,C7E9<O#V`%&HHT49IY)J%;3`"?1$E_,M`0_ES0%(5E
MZ9J"3F91-H\G"<+)!JQ;2T])B=A:I]7?`$J&I`+7D-H#=WRY,'I/L-V(MCWW
MAR?)D?AR+IB$QZX\N*!X'%'&HG^[919/%FR'18L#YCY@\#EBDA'!4'141K7K
ME3W8*WM7?"KW(7`LDUZ6F9S*>-,GV+KW"_6;$'=41!9/1_Z00<!,CS$CXJ10
MA%Q?J`=C+["\T;]SCP/H"FD\%]=+>_`@/9I\B*!=1\EDEZN<G4H-ASO)(J1X
MWVJ_[U3U$#GN;1;/+JO.+ZC&:33_KZS?>"I[B)S*SM_(AN$.$Z3`U/`9VM82
MH;=^<%.<B3$ZWBFKU!_;M_%IOAKN&C9^P%GO>0W?N:EE9TD+%5+&0RTFW!9A
MX72/F>/$:X=3/KPV>*D#CD7L_:ZT=J\+%&;C;V+Y#P``__\#`%!+`P04``8`
M"````"$`$TAG*(X"``"H!@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6R45=]OFS`0?I^T_\'R>V,@3=*@D"I=U:W2*DW3?CP[Y@"K&"/;:=K_?F=,
M6-)F*GLQ^/C\?7?GNV-U_:QJ\@3&2MUD-)Y$E$`C="Z;,J,_?]Q=7%%B'6]R
M7NL&,OH"EEZO/WY8[;5YM!6`(\C0V(Q6SK4I8U94H+B=Z!8:_%)HH[C#K2F9
M;0WPO#ND:I9$T9PI+AL:&%(SAD,7A11PJ\5.0>,"B8&:._3?5K*U!S8EQM`I
M;AYW[870JD6*K:RE>^E(*5$BO2\;;?BVQKB?XTLN#MS=Y@V]DL)HJPLW03H6
M''T;\Y(M&3*M5[G$"'S:B8$BHYLXO5E0MEYU^?DE86^/WHFM]/ZSD?E7V0`F
M&Z_)7\!6ZT</O<^]"0^S-Z?ON@OX9D@.!=_5[KO>?P%95@YO>X8!^;C2_.46
MK,"$(LTDF7DFH6MT`%>BI*\,3`A_[IY[F;LJH\EB,EM$TQCA9`O6W4E/28G8
M6:?5[P"*>ZI`DO0D^.Q)IO.Q)"PXU,5WRQU?KXS>$ZP9E+0M]Q48ITA\/B",
MQ&,W'IQ1K&GTU>(E/*UGR=6*/6'F1(^Y"1A<!TP\(!B*#LJH-E[9@[VR3ZUW
MY288CF62\S+3_Y'QX(SB.C@_2Y8#;U`.F,MCS(`X"1`AXP/T8+P##.M(^G5N
M`VB$-!;5>&D/[J2'Y/86;)._SDRC\U'.3Z6ZSE@L?1N\4TS^X*EL;SF^U-GT
M']6S.",[QW9X3]6?.U7M+:>JKXLI3(;0.0I,"9^@KBT1>N>[/L%>&*S#0-HD
MOEQ?VR_333>HV/`!!T7+2WC@II2-)3442!E-%AB+":,F;)QNT7,<%]KAB.A>
M*_PC`+9#Y`,OM':'#0JSX1^S_@,``/__`P!02P,$%``&``@````A`'OFXH$D
M"0``NBH``!D```!X;"]W;W)K<VAE971S+W-H965T,C<N>&ULK)I=<ZI($X#O
MMVK_@^7]*J!H8B79BI^@J&"][^ZUQY#$.BHI(2?G_/OM8:89IIL0W=IS<=`G
M/=T]_3$S('=__CP>&C_B<[I/3O=-NV4U&_%IESSM3R_WS?__;_K'3;.19MO3
MT_:0G.+[YJ\X;?[Y\/MO=Q_)^7OZ&L=9`S2<TOOF:Y:]#=KM=/<:'[=I*WF+
M3_"7Y^1\W&;P]?S23M_.\?8I'W0\M!W+ZK6/V_VI*34,SI?H2)Z?][MXG.S>
MC_$IDTK.\6&;@?_IZ_XM16W'W27JCMOS]_>W/W;)\0U4?-L?]MFO7&FS<=P-
M_)=3<MY^.\"\?]K=[0YUYU^8^N-^=T[2Y#EK@;JV=)3/^;9]VP9-#W=/>YB!
M"'OC'#_?-Q_MP<;N-]L/=WF`_MK''VGI<R-]33YFY_U3L#_%$&W(D\C`MR3Y
M+D3])X%@<)N-GN89",^-I_AY^W[(-LF'%^]?7C-(MPLS$A,;//T:Q^D.(@IJ
M6HXK-.V2`S@`_S>.>U$:$)'MS_SZL7_*7N^;G5[+[5L=&\0;W^(TF^Z%RF9C
M]YYFR?%O*60K55*)HY3`%94XK:[C]F^NT=)16N"JM-BM&]?M]F[ZE[O254K@
MJI0X+>?&M=V>F$_-'."O>2#@J@;V6W;7^FI83PV#*]J[.&S0@[E)N.+84M1J
M?+U5`^%:^%KDK&:<#>4ELRWJ3&82<G9AEFU,L_B`HR\+KHVY%1\*EW6%U/F,
M&155K8;^B[JP,5'BPY7.]S%J\.%*YS'%=BG'7P6\+5LT[_CQ-ML^W)V3CP8L
MH]"$Z=M6+,KV0"C$7I?1*[K_L^:'KA=:'H6:^R:,A[Y.8<7Z\>"ZMW?M'[#*
M[)3,D,O8IL0()<22(M2.*9A0,*5@1H%'@4_!G((%!0$%2PI6%*PI""F(*-B4
M0!O24^0(6N._R)%0(W*$T1TBT$ES2$)0`H>,*9A0,*5@1H%'@4_!G((%!0$%
M2PI6%*PI""F(*-B4@)$06'!80CJP_%5OD-@C8A1LA>4>L6B/2)DNK">ZD4A.
M"I$B*8Q,&)DR,F/$8\1G9,[(@I&`D24C*T;6C(2,1(QLRL3($2SQ+$=BN;]R
M81-J8&V$2M`)Z5EF2H92J#9KA4B1-48FC$P9F3'B,>(S,F=DP4C`R)*1%2-K
M1D)&(D8V96)D#1)D9*V^HX1TGAP,ZE`1>9046\B(D3$C$T:FC,P8\1CQ&9DS
MLF`D8&3)R(J1-2,A(Q$CFS(Q`@\KCA%X>0YHB5-R]KK??1\F\L1>D9`.[/?R
M%""4F/E0Y+;8=$8%T0UE]WIF0XVE4`<NNNML<EJ8%$*8_6FA&\F,$:\8559-
M]CV_$$)%<Z9HP4A0C"JK[IA36Q9"J'K%%*T+HA6Q&(6%(BWDVEW36E0(H;5-
MH1N(40%P$#4JH"+3<+N#J1;29JH5*:6Z(-I#-HVQ%.K`;4<IU:XYC4DAA-.8
M,C)CQ&/$9V3.R(*1@)$E(RM&UHR$C$2,;"2Q\R@:Z8&S]17I$=)F>B3I=O/#
MN6/9I"Y'\N].>:/CR2J$,`\31J:,S!CQ&/$9F3.R8"1@9,G(BI%U073)L:F&
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M$F/28QL<:#A1BK%95^)!1?FA4?U1P9;/->`>"IT:*F0N<`ZYK1KAP/H5KE**
M-M9$276-)=4A"^$4=94+TBZ%(3_FSE!*WV5X&I5KE*CWJYT@2\X<==4ZL4`I
M[42@48T32^V$>$QGB0?2QC_B]`JU&N[P^E1)KLU5B+H,*9JK2'NHY^$ZY,"R
M05V&7Z5<F24+?7--R0IQLA1*9"R%KD.:>20>%,#`+XY1E5(T#!,E978N+UEE
M\;/.525;^(4]Z%WDA%_M!"O92YQ8:(OH1*"13K5-(['43LB2M5B-5MGG-5H$
MH62,2H47N11IE[2NBAJM\NO3&A7/LJY85N6C+W`$HSD4OX1`]77%;=J/!SCD
MDSR-E(!H';V5T@B,M11JGG`TY6C&D<>1S]&<HP5'`4=+CE8<K36JF7:HI7#:
M$4<;`YEKC'BJ=47^Y$,P(W\2F6N,38Z`(UM)06W5);%*BG;6!'7)TXECN3;9
MA*<H8:POM&1F**6+T=.HY"9UP$<IZ8#=[W;(O?\<)6H=6*"4=B#0J,:!)4HI
M!WK6#6F:%4K4.K!&J=JLA)52-"@12DF?;OOTEFB#`I^Y9-8E[)#7U*40)WN?
M1,9QS>:W`6K@%XM+(85=-A&/Y<6F*>\_NQUZ$)PJ`7'YO.)G**5/1!Y'OD+*
M6`=>!3#O9N8XIM;8`J6TL8"CI6G,Z?&-2T6CUMA::ZZ9?ZBE,+*10N342SIL
M@P,-)S[=I<0#Q"M6.?6\4??E4/Q:+M)=OJET:<Y'*%7;3^-**=I/$R4%)ZG\
M_&`F?(HZ/FLF=8)27NN)>#C0<)$:]VN-SU%'K?$%2FGC@4:EFJ#&E[7&5ZBC
MUO@:I8QITAT@K)2B_D3:'^VUZY`6W*`NPZ]/"U(\,KVB(-435AW*(;Q+E1>D
M>6_(CO9JX!?+6Y44#<-$682^K"Q(I</H1QKPF=(!9SEL=T\C'5UVFO9KC<]1
M1ZWQ!4IIXX%&-<:7M<97J*/6^!JE:C,15DK13$3:'^UU14%69805I'RA3KY>
M<XS/+_$H/AS2QBYY%R_+0:(>[@HLW^0;=@?P6RCDC_!Q;P`_;W'N]0;PVQ3G
M06\`/RQQ'O8&414?]P=1_@(AL0MO%C[FC4'X4+QQ6*%_Z`S@)0EN=]@9P"_S
MG#]V!X\0<?A#N[``;PZ^;5_BY?;\LC^EC4/\#,&R\E\>S_+=0_DE2]X@B/"B
M4Y+!.X/YQU=X1S2&'WFM%A3,<Y)D^$48*-XZ??@'``#__P,`4$L#!!0`!@`(
M````(0"-$G6H\0(``(D(```9````>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM
M;)1676^;,!1]G[3_8/%>/I(`"0JIFE3=)FW2-.WCV3$&K&*,;*=I__VN[804
M$D5I'@##N<?GGGMM9WG_RAOT0J5BHLV]R`\]1%LB"M96N??G]]/=W$-*X[;`
MC6AI[KU1Y=VO/G]:[H5\5C6E&@%#JW*OUKK+@D"1FG*L?-'1%KZ40G*L82BK
M0'62XL(&\2:8A&$2<,Q:SS%D\A8.49:,T$=!=IRVVI%(VF`-^E7-.G5DX^06
M.H[E\ZZ[(X)W0+%E#=-OEM1#G&3?JE9(O&T@[]=HALF1VP[.Z#DC4BA1:A_H
M`B?T/.=%L`B`:;4L&&1@;$>2EKGW$&6;N1>LEM:?OXSNU;MGI&JQ_R)9\9VU
M%,R&,ID";(5X-M!OA7D%P<%9]),MP$^)"EKB7:-_B?U7RJI:0[5C2,CDE15O
MCU01,!1H_$ELF(AH0`!<$6>F,\`0_&KO>U;H.O>FB1^GX30".-I2I9^8H?00
MV2DM^#\'B@Y4CF1R(('[@21*_-DD3N<?89D>6.!^9(EO9@E<7M:F1ZSQ:BG%
M'D'K@7+58=/(40;,QI\IN'S9'S#&Q#R8(!L*:`4U?5G%2;0,7J`0Y(!9GV-&
MB,TY(DZF/4L``GN5X-S'59J@L<I)SV\S63L,+/8^DQ%B<XEEUK,,5()_[U5>
M]]"`C3K3<\;4M7MAUX)]L3DB3MKB)+X\\VPX\VU5-$%0[7>YQTG2\SM1#@/7
MWI^3`J?R&F+@#JR7V]TQX-P#[T_S)NE(F\/$MO^F21J/*^>^7]8^4)8,E=WF
MG@D:*YR/%#K,907./8=(W!I*XQ!^/<=`8SK4>+VW#'BL;='SNLHZS#5M#I%:
M;=&I,0:RS#'YX>W#!(WDI:>TG3R'N2;/(196WCSVQP+=D>#V.DYE13>T:10B
M8F>V^PC"^K?N)%I/,EB#YC#I/\!)T.&*_L"R8JU"#2TA-/13Z"SISA(WT**S
M&\U6:#@#[&,-1SZ%91WZ`"Z%T,>!F:#_$['Z#P``__\#`%!+`P04``8`"```
M`"$`+L.T:@@#``#@"```&0```'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6R4
MEEMOVC`8AN\G[3]$OF\.A!"("!6DZE9IDZ9IAVN3.,1J$D>V*>V_W^>8!&PZ
MQFZ`V*]?/]\A-LO[UZ9V7@@7E+4I"EP?.:3-64';78I^_GB\FR-'2-P6N&8M
M2=$;$>A^]?'#\L#XLZ@(D0XXM")%E91=XGDBKTB#A<LZTL),R7B#)3SRG2<Z
M3G#1+VIJ;^+[,Z_!M$7:(>&W>+"RI#EY8/F^(:W4)IS46`*_J&@G!K<FO\6N
MP?QYW]WEK.G`8DMK*M]Z4^0T>?*T:QG'VQKB?@VF.!^\^X<+^X;FG`E62A?L
M/`UZ&?/"6WC@M%H6%")0:7<X*5.T#I)L@;S5LL_/+TH.XNRW(RIV^,1I\86V
M!)(-95(%V#+VK*1/A1J"Q=[%ZL>^`-^X4Y`2[VOYG1T^$[JK)%0[@H!47$GQ
M]D!$#@D%&W<2*:><U0``GTY#56=`0O!K_WV@A:Q2%,[<*/;#`.3.E@CY2)4E
M<O*]D*SYK47!T4J;3(XF(=`?YR?N9!X%T>S?+IXFZ@-\P!*OEIP='&@:V%-T
M6+5@D(#S$)GF&&/]6Z@0HS)9*Y<40;=#%`+*\[**XF#IO4!.\Z-F<ZFQ%-F@
M4*4`O)$1(C]G?#_K`XH2*Q15!<6VT0/@/;)-3+)L6')2A"<T@P0R=#N)$ALD
M>N"<)(IMEK-%QL[3_]E9B:''SD(.IKX9]$9KX'-,2V0JLFL*@PUZ^/:L*'&*
M(.6G?>/0W'FC-=.^D4Z5Z,N9#7-GZ\?5!M7,I%*='<*;?[U[U"*;;CKZZX;2
M&B-SL9V[ZQJ#,S8YK_,IL<TWL_BT)NZS9U4]>W_.X%%WUMF)<)U'B6V>V.+1
M&LTS]:?SR(:Z(C#(%B;9;155BVS"N46H-3-?I\RUBZFGC8*/!AI0WQSZ8&T(
MWY&,U+5P<K97MT((ON/H>&&M0W5&6>,;N,CZ8]\:SR9)UNN]<0(NF`[OR%?,
M=[053DU*V,IW8WA!N+ZB](-D77_,;YF$JZ7_6<$_"0)GH^^"N&1,#@_JY!W_
MFZS^````__\#`%!+`P04``8`"````"$`1T%MY=L$``!&%P``&0```'AL+W=O
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M\0KL&'OEZ(\]_Q<,]HS1+Z("?U;.GA[2MW/S%[O^3O/CJ8%RQ[`BOK#%_O.9
MUAED%,),@IA'RM@9!,!/I\CYUH",I!_B]S7?-Z>5&TXG\<P/">#.CM;-2\Y#
MND[V5C>L^`\A(D-AD$`&"4&]_#Z8!$E,XNGC*!XJ$@M\3IMTO:S8U8%=`W/6
MEY3O0;*`R'QE4\A/_\I@27S,=SY(#`6ZAG*\K^/9?.F]0PHSR6Q,)E")K4F$
MI$4\T->*A*5W1=K%<1@2[#JM.)+X;5RQ@`TR48>)56)K(Q1M,-%P;1Q>N1"[
MU1:&ZL0;1&8BJW,_"J,HU+5U$9),YS&9S]HHBCA8X7!Q'%;%D417A\Q4J`NF
M?C2=SZ)V:I';K8+`"F;S.&D111WL_>'J.*RJ"V^+QJHB@N(B/TIBK>Q;"Z`(
MFXX1QF%5&$FTG&R0066$3),$CJQV8+9=)DI(E/C^K?"*O-D8>1S6C\.TK0<F
M#ADH7+LM;S-C46V$HHVWO(Z?V(\JA]74Z27;(&*3A@3F]BD.YM%M6RC*YJHR
M[G3A0Z?C@S2%AID@8Y-H(Q2-!`0-3Y^@]=IJ>WXC(9L\*Z+JT]J%O;P$'=YJ
M=Y+!\MWQ.X6Q&Q[AOCUX_PE:+:]I>1)"A7<\3V6LID=&-0Q!JPH-VY,,"NSU
M/1NAUA>VR8CT<5H59UH?00C5W?,^!;*;'W_N&B$1+1]RWEH;;"#-_D3(E6L]
M(ABG'U%3.*IY$+-[&!8HF?ZYT9Y[$!+>Z;I$:Q_#C%",4FL=)[?'->PC$K(J
M'=Q)R*A6(NB'7OBXF\@X_4M0"ZTUE`=>:'82X]&/F'VB6T59:CND2`Q&M1-!
MJR4VW5!"W?R8&A]`JL91+27H:2FW?H^[4#(/)&*@>Y`J<513"3BMIU%_()30
MO>FQU`\@5>.HMA+@*X3=%B74U:@_%EH151^$&6[;`:?5'!JV*!FK/`S31;J;
M516H]95AMLC?O'6AB?:BNY%05X:1R,'])1C57P3]R!8E9-6'?:H?4?.HM1>[
M+0;8#JR/B)+ISMVMHCPK9E_I0JK$49TEP*;1E=ACBV9GZ4XO-=HA5>.H[A+T
M=!?#%NV-0TJT0XI$_O8T_$@+6CW2YL.BA.RE?@"I&D=UEQ";@MT6)=35J)]F
M*Z+J&]5:X([3<!O]?4\R5GD8!N^8>E^9\284+PHOZ9'^3*MC7M;.F1[@.=J?
MS,"N*KP'Q0\-NX@+P1UKX/Y2_'F"^VH*MX7^!.`#8\W7!W[3VMZ`K_\'``#_
M_P,`4$L#!!0`!@`(````(0!??13Z[`(``$D(```9````>&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;(Q676^;,!1]G[3_8/F]?$,@"JG:5=TJK=(T[>/9`0-6
M`2/;:=I_OVN<4*!IQDO"Q_&YYYQ[8V=S_=+4Z)D*R7B;8M=R,*)MQG/6EBG^
M_>O^*L9(*M+FI.8M3?$KE?AZ^_G3YL#%DZPH50@86IGB2JEN;=LRJVA#I,4[
MVL*;@HN&*+@5I2T[04G>+VIJVW.<R&X(:[%A6(LE'+PH6$;O>+9O:*L,B:`U
M4:!?5JR3)[8F6T+7$/&T[ZXRWG1`L6,U4Z\]*49-MGXH6R[(K@;?+VY`LA-W
M?_..OF&9X)(7R@(ZVPA][SFQ$QN8MIN<@0,=.Q*T2/&-N[YU'6QO-WU`?Q@]
MR-$UDA4_?!4L_\Y:"FE#GW0'=IP_:>A#KA_!8OO=ZON^`S\$RFE!]K7ZR0_?
M*"LK!>T.P9$VMLY?[ZC,(%&@L;Q0,V6\!@'PB1JF1P,2(2_]]X'EJDJQ'UGA
MRO%=@*,=E>J>:4J,LKU4O/EK0.Z1RI!X1Q+X/I*XD15XX2I>P&(;1;W!.Z+(
M=B/X`<'40$W9$3V#[AJ8M3,?\C$Z!J\?606/FN1&LZ08QAV62^C/\S:,_8W]
M#)EF1\RMP<#G@'$'A`UJ!DD@8RSI?,BGRAJL*^O0M91;\V!<QCM?QI^6T<Z#
M#WMZ*J<704(C$V$<#/Q&@<$$8\R`F!@%R'*C&IQB</<67Q(-O*:RP:SZ!KAQ
MY(3)!Q&#S^65-7A:.8S#666#6>`YFE9>EKI>]+_4#6:!@M54P>7QTN"Y]WGJ
M!A/UJ5^%7A*LAG`F[=:GP9F?VF4!>M%4@)O,!\Y@C@(B+_*#Y+R"9*K@<F4-
MGE>>6S<84SE:)=YH(B?687.>>+]<N4=/2X?Q6ZAFUH^@<<-=/Y[Y-CNZV?`:
M*DKZA=:U1!G?Z]W:A98-3X>3Y,;KSX+A!6SD'2GI(Q$E:R6J:0%+'6L%(R_,
M46!N%._Z[73'%6SA_64%1S:%3<FQ`%QPKDXW^K`9_@1L_P$``/__`P!02P,$
M%``&``@````A`)(F[]4N"@``BC$``!D```!X;"]W;W)K<VAE971S+W-H965T
M,3@N>&ULK)M=<^(Z$H;OMVK_`\7]`6P^0J@DIX8/8X,--K6[YYHA3D)-P"E@
M)C/__K1LMV7UZWC"UIF+,7G2:K6Z6VU)*'=__CR\-G[$I_,^.=XWK5:GV8B/
MN^1Q?WR^;_[W/\X?PV;C?-D>'[>OR3&^;_Z*S\T_'_[]K[OWY/3M_!+'EP9I
M.)[OFR^7R]NHW3[O7N+#]MQ*WN(C_>8I.1VV%_KQ]-P^OYWB[6/:Z/#:MCN=
M0?NPW1^;F8;1Z3,ZDJ>G_2Z>)KOOA_AXR92<XM?MA>P_O^S?SJSML/N,NL/V
M].W[VQ^[Y/!&*K[N7_>77ZG29N.P&WG/Q^2T_?I*X_YI];8[UIW^`.H/^]TI
M.2=/EQ:I:V>&XIAOV[=MTO1P][BG$2BW-T[QTWWSBS7:V%:S_7"7.NA_^_C]
M7/K<.+\D[_/3_M'?'V/R-L5)1>!KDGQ3HMZC0M2X#:V=-`+AJ?$8/VV_OUXV
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M,)/`D6`N@2N!)\%"@J4$O@2!!"L)UA*$$D02;$J@3>$I8D13XY^(D5*C8L3>
M'3/00;-%0%B"FTPEF$G@2#"7P)7`DV`AP5("7X)`@I4$:PE""2()-B5@!(0*
M#@2D2^6O^@7)<T2UHE>A,4=N38>/,YD>U1,]D4R122%2!`7(#(@#9`[$!>(!
M60!9`O&!!$!60-9`0B`1D$V9&#&B$@\Q4N7^RL*FU%!MI$S0`8'*E@G51JT0
M*:(&9`;$`3('X@+Q@"R`+('X0`(@*R!K("&0",BF3(RH48",J-7/*"6=!H>=
M.LY(CUZJ.EQ61\R@0HB;38',@#A`YD!<(!Z0!9`E$!](`&0%9`TD!!(!V92)
M$0LJ0D8LLJ5!2RV<Z\.B&IIAR4@_6^&K-_L$R!3(#(@#9`[$!>(!60!9`O&!
M!$!60-9`0B`1D$V9&#&@1#9B4.]X)6TZ/B<EQP.9`ID!<8#,@;A`/"`+($L@
M/I``R`K(&D@()`*R*1/#\;24-1Q?2O[+RW[W;9Q0@:$%6T5`NK3^S5;%2HD9
MCYS<%HNP24%TQ;(&`[-B33.A+J5)J:R)U?.L$.*RYA2ZF<R!N$6KLFJQ#O0*
M(5:T`$5+('[1JJRZ:PXM*(18]0H4K0NB%8&/PD*1%NI;/;.WJ!#BWC:%;B)&
M!M!&V,B`BDC3]I]#K:3-4.>D%.J":`MA&--,J$N/4JC[YC!FA1`/PP$R!^("
M\8`L@"R!^$`"("L@:R`AD`C()B-6ZD4C/.K<X8KXI.)F@'+4ZZ7[5;MCB=2<
MY`)V>?&'`=-2'(P9(@?1')&+R$.T0+1$Y",*$*T0K372*0C##K44#SM"M#&0
M&3^UVRV?/-3/+RO;'--"G+L;Y\BF+4!IJHC2.>&&U+Z0@M%,*Z6&LL)RCUG&
M6)W^K3CC<%@/K9$^[FW.4OJU[&I4:B@-\(0!MGTK-I`+UE-KP)*EM`&^1C4&
M!*8!=L?NBE?%BO74&K!FJ=JHA)52TBF1:9/5N^V('-BPGH]L,A-3[?JO2,SL
MD,!(S`S9Y=>UU;DQ:_A$[2GIE?&[ZE)(<=[/\H;=\FCZEE#OL'IZO^E,'(I\
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M`S+44YNY'P^T#Q!QFJAC8]6F=I9.M13':8;(031'Y"+R$"T0+1'YB`)$*T1K
MC72P8.4<:BD>=H1H8R`S?NKLZXH:DQV5&34F0V:-L<0:<**^H_W$<JM*2LZL
M&>O*5B=VIR^/F!V6J)U:<Y;2[WA7HY+3I0$>2V4&6#>]KC@A6+!$K0%+EM(&
M^!K5&!"P5&[`H#,4DV;%$K4&K%G**!M87#X3E8AU93;=WLB]T88%/C+)S$MU
M-'A%7N8GB=J38RM#QG*M8AM0'$&6_"T],,UU40GB639C]=EFM->5"T&'VU#U
M^G@A.&<IK=E%Y)F==>D"C;F;67";VLZ6+*4[\Q$%9F?V`%]<N<]J.UMKS37C
M#[44>S;*D5CUBAFVX8:&$1^NI"CGKLDF)2[>4ADRJYR,^41=X?A$E:N2DD5F
MENNBE52Z?C`#[G!/I*HNNXJ>V+LN-S2FO.S<J^U\P3IJ.U^RE)Z3OD8EJV7G
M06WG*]91V_F:I8QARGD=5DI)>R)MC[:Z;XLIN&%=AET?)J0Z6+VBO.7GL-J5
M8SJ335/-W!O"TCYO^)NU4Y64=,,L[Y'F965"YCJ,^2@=/L]UE`JIJY'V+JRF
MO=K.%ZRCMO,E2Y7+WV=&'M1VOF*UM9VO6:HV$F&EE(Q$I.W1+JM(R*J(?)20
MMCS/+WWC5G\TG+8TBV6.RE\X(YHBFB%R$,T1N8@\1`M$2T0^H@#1"M$:48@H
M0K0QD+$,LBE=KJ@3J;B(A=)PW^R5"V'?%L>5D[PA2?&+8HIHALA!-$?D(O(0
M+1`M$?F(`D0K1&M$(:((D;KLG;N0G).%)[N\G5WE/,2GYW@2O[Z>&[ODN[J8
M3=NMA[L"9[?&Q[T1W;LA!9+W1W0'I((/1IM!%;<[=/T\O4$N-=G%Q73QF^EP
M1%]/8Q_N<$3?+2/WAR/Z8AAY.!Q%57QZ.XK2KPA%OW13_DN:48*/R="T"$MN
MT]`J^AUW1W33#.WYTB/]J:)VH8ENPK]MG^-@>WK>'\^-U_B)`M))K\V<LKOT
MV0^7Y(T"11=WDPO=@4\_OM#?/,1T.Z;3HE+^E"07_H%Z;A=_1?'P-P```/__
M`P!02P,$%``&``@````A`'HD#\X'!0``'!(``!D```!X;"]W;W)K<VAE971S
M+W-H965T,C8N>&ULK%C?CZ,V$'ZOU/\!\7[A-TE0DM.&0'O25:JJ:_O,$B=!
M"S@"=K/WWW<&VV";',U6?;E<OGPSGF]F;(]W\_F]*HTWTK0%K;>FL[!-@]0Y
M/1;U>6O^^2W]M#*-MLOJ8U;2FFS-[Z0U/^]^_FESH\U+>R&D,\!#W6[-2]==
M(\MJ\PNILG9!KZ2&7TZTJ;(.OC9GJ[TV)#OV1E5IN;8=6E56U";S$#6/^*"G
M4Y&3`\U?*U)WS$E#RJR#^-M+<6V%MRI_Q%V5-2^OUT\YK:[@XKDHB^Y[[]0T
MJCSZ<JYIDSV7H/O=\;-<^.Z_3-Q71=[0EIZZ!;BS6*!3S6MK;8&GW>98@`),
MN]&0T]9\<J+4"4UKM^D3]%=!;JWT?Z.]T-LO37'\6M0$L@UUP@H\4_J"U"]'
MA,#8FEBG?05^;XPC.66O9?<'O?U*BO.E@W('H`B%1<?O!]+FD%%PLW`#])33
M$@*`?XVJP-:`C&3O_>>M.':7K>F%BV!I>P[0C6?2=FF!+DTC?VT[6OW-2`YW
MQ9RXW`E\"B=@/&/@<0-_,`@7[BIP@A!7G3&$7_MPX5.L!"F;,0BY`7QR@_F5
M+):?/MV'K,MVFX;>#.AAR$![S7!'.!$X$WEF2P^9_U'B(>/HY`F];$W8?)#3
M%KKE;1<$RXWU!A7..6<_Y3@J(Q8,+">Z/>A`H@.I!%B@:)`%)?L?9*$7E"4"
MV@M@U.EJ&@1#F!QT(-&!5`(4#=!-N@8/NN+^%A"50"-H=JD2_CI08]PSC@_E
M'LNE4N*!,NB8(,D$265$D0(;0I>"N_F#789>H$\A7V/<P4J-?,](L^(&RB!N
M@B03))4111P(D<7-UP?)O0:Q]IXAOJS*7Z]55?%`$F:'"9),D%1&E)"A]'+(
M;-<OEL"?CQ[MU.@9$K"#$S=M/$$.$R29(*F,**$NU5#GXT.R&A]'I/@FR&&"
M)!,DE1$E/IPXI`-T/CXDJ_$QQ`W[0].U'5\K//]=[@XG#%72X1YII9VN"2<M
M^Y6\,'!\5Z.DG`(?PP:3%U-TKS^B&\FJ;H:XGM"MG5$QMX#S_6XH['X82&)7
M)-RMST1ZCKU::1E-N1'T^EW/BD@'SMO'J]NS59D<&NNKE2X6A/D"CZQ!J8!X
M/7W'=AU;[8M4<!XJJ(-WZ<.=W+,UK>PR'FNJ30"QL)DOZL@:M7+/O*P!#'&.
MYCP59H_5%=+]`:W(UK0R:*RK=@W%>$N!C0L?=]N,#S@#:]3*(597=[FRO;7F
M/!7.'ZLKWLI27:7#OKL4^<N>0H"0X#LG%^Y./N"QJQT6%H'N'09Y<"\."GW?
M4ULPYBRLSL"2SQ2>!^Z>C?)XC23<$`?GT7"EC5NI<*^PI/-1W<UXA4N9N*,8
MEALDLPM?D<P@F,)$%F)G@*0PI0"X/LX:KZ%$&(Y0*B#V-)+'61R6Y,C_6PW1
MB=;&#`K6DB`&>?_2N(REMO?DRNG#ADW`>AG*'@:^-SFDN*O'FAGG!*F$>B*^
MT>N/FEDN+9LVE-(R2"GM`,V6EK.\(84)/(PQT=X(X5NYAZ32LK<O>XQ5I#F3
MF)1E:^3T%=^U*^C#`1W>W$_]_M/P/;[%<74==R-X6]S!O0@F]2G^Y$=/[$VO
M._(CF'ZG!OL@@A'S#AY&,,\!;@V.X&U^S<[DMZPY%W5KE.0$&NU^XFS8ZYY]
MZ7C]GFD'K_*^E!?X*PR!$\%>0*.<*.W$%UQ@^+O.[A\```#__P,`4$L#!!0`
M!@`(````(0`VU:&>%Q,``*-C```9````>&PO=V]R:W-H965T<R]S:&5E=#(T
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M:!`8WRGKN!F!?[S=/.Z^;7\^G?YY^)7N]M]_G&"X0[@B<V&KQS\WN^,#1!3<
M?/!#X^GA\`0=@/_>/.]-:D!$MG]\NO6AX?WCZ<>GVV#V(9Q/`@_D-U]WQU.\
M-RYO;QY^'D^'YW];47-%K9/`.9F2DU$]>&X:A9^N42^D1D<:FCE#^(F]_>`O
M0B^<F=Z.&,Z=(:0]&H[JETX//Z_KH0<CV%R;^1]LZK(^>C@67F<P1GOI8>#-
M_V`_81!&`N'!Q[9_G<$:[=^=S9@F`3?;T_;SQ[?#KQNH:NCN\75KY@AO9=QB
MZMG6VV0<RD5(0N/EBW'SZ18&!M+L"`7T^^<PG'R\^QV2_L%I[K7&XXHU*DR&
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M)#G]V#_\=G^P*^6>``2PL+'+'>.$7[\CR_8.O6X)37S>3-QF-E84P+"TLZ/O
MS7G91JT(RS96)%$D5213)+?$:WK-H@1+YO\^2L8)CY(CG2BUA`*@HV1%4Z]9
M6/H3+Q`!:C]O`]2Z19(HDK969KD*7L4"*FL_1Q]YUP<+E]DGL'CU9`]L;C!]
M&CF/C$,^K"/;3`@68@F]1E5WFM?A(A7V/-(HUBC1*-4HTRAGB$?&+(QEO?FP
M43PW)YN-E,@>AWQ8LG1B)-82:S3L1K(G1LX]4RV$KPA;G#:9%\S"F><M0YY]
M,38(E]1V2S68H(IFR)10QU#V(1-]"(-@XLW$%)&CJZ$^\#$QZ^ONF)S)5B,7
MV6J1WYVW@H4HH+59](&A#S^&`[,A%66K,YS;L`=>&'I3&76G@2ELV'FBG:<:
M98A<>R%,P;ZXF!PU0^WQ")M5]141MHMP:`)#<&\.`TSL>*Z+B6_M5&;TAX.P
M(16ZC]"]2^SY`C);7'&,9D,YU=P*$U1U\]I=#J&,M^?/Y_/%4JQ.<_0TU!Z/
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MT+W-*6\:+*9S<7>/T?E03KD(*^<I&E):9Z(]'UJ;JQQVGH;:XQ&&<6`1[FR[
M+]]1><:+F#PL8JD=+,0.:NT,SRTRG"\:UP@-W7P)@5_,Q7H[1@U8CTT>RGF*
MAM1>ALBU%\[#N5PQY:@9:H\'WFQ'KDAMMWNA+MW#QL\$/6B>3C5)M"8T<L4;
M5%%>11K%B,A]HE&*B'QE&N6([(,T=L)^W=[+-W*>:`Z)"A=%N$9#B-EP+FQ0
M15<3H7M;X?/E?.XMEL)[C'9#)6=+'%6T@4X148.9:'`Q6<)M2FQM<K0;:I"E
MFMF6LE1[5XTW7D3HC6-8YL*=H`TJ%"*_AZ^=83!^^W(JF`G:VQ<:=B\R6(B%
M9XR&K.ID)Q+T1>Y3-"24H8JUN!3S2HZ&0RWRX)N=SN5U;F9"F>`6=>O<J0!1
MX-6F=8,J2JY(HQA1I\XU2A&1KTRC'%%/G9M=Q15A<)L0&IM[4^!FNH/E-"7;
M4A3&VJG,A-.J>B*C]CB1,W2KPV`Y78;BQAJC[VYV*-\)JKI5[IJS3__-@72&
MS3%?ZHZ"OIBJ<PS),\UL-*X(L=V7=)>C</%-/7>7\L%2A&'M5.?JV?FB$8S0
M/:%8HX3<XT20:E6F4<X0CPS$CT7F?1.@\2(F0(O,,+79IA<YYL4(8W@F)YV*
M*BQRAE/F?BFV!S&Z!_NV$YZ>`-M.4%@=ZJ:E1<9EQY?(@+RWQ<&T-/N$*]+2
M;BM86EK$)L`6=?K9Z4%SP]V8&Y.9,KHA52A&57<";-U3L)1AAH;D/D?4,P&:
M5?D587"+>*J5>]\BTT0[-C!/R;NM59VK3N>+W$?.?=`=^D`GFS,<NO>YE4[;
M"8I?:X@HPPMB=:'GP-:0+KL[Z_)*AWZQ*+^OTHT74>D6B;N/W$?ZSI!=D4Y+
MI^I&VI,GQY'S-5Z*,;;(?,D6$U1U[TF7="*[J!,YNA_J!!\B",[H$/WK\`JQ
M/_>$P3=NQ!A9Q.:)%O4GCYLGG"KHK#T5BEV+'?>)1BDB\I5IE"/2\X19T_6$
M!]\HN_B=KL9/$Q^Z\E`N:>Z=:O3=#=)@Y6XTBC2*-4HT2C7*-,HU*C0J-:HT
MJAEBN0EW"AU\^[SKRE?J&D\\/1WB;WG(<_0UJ2C:=IL%AH@BK8HU2C1*-<HT
MRC4J-"HUJC2J&>+1EENCSF0]_E#+W-U$\3O4?>E#HXU&D4:Q1HE&J4:91KE&
MA4:E1I5&-4,\E&:'<?GJ(G`;$LJH>T2TF%EKM-$HTBC6*-$HU2C3*->HT*C4
MJ-*H9HC'3^Z=.JEX^3&H61W(M'2([KQK5,$=IEW'=1<T]I[D5/SE$GG6&Y$*
MIX98HT2C5*-,HURC0J-2HTJCVB'8!4%7>?!AW<"2]WW!-U[$C.M0-_@M&@V^
M50V_LV)6R=`8""CNK6=$B5/92VZ&-27#@?=62(!N<NVFT*@D0^=9'(U4)$#/
M-7/#Q\1L=ZZ84.SNJ+MK,YD+(3*'96V:3R?B+&V-*IC06U5/,3A?3*56S,Z7
MN:C6UW0BPA!CB[#^;55ZNXPJFB%30EU#X3Y#E7U0X"_]V<P3VX0<-:P+<M%>
MH(JZ4!(:Z4*%*M>%()PLY2%.C9JA+O!D,%NP*Y+![MA8,EADYH`VZ%/Y]'4=
M.,-NRO0D0ZO"/(Z<(9P`F=R?3993];`>?7>30_E.4$5UG6J4\>:\Z6SBRV/I
M',U&VRM01>V5&E6RO<7$DX\P:S0;:H\/J-G\73&@1BZF5HM$=8NCJ77@5*QN
M9:)O2$4#:@U%*8NSCA@-0=QF54\IMYU`]RD:4FEE#HD65>4Z7Z,M%MI]B8A^
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M6*"*6BPUJOI;%)E4H^%0BWQ<H8"N&5<C%_5J$:]7^4+@VIPEF34V_*`BD.F]
M(16-JS/$56H@`ARCS5`:-Q-B@BHJG%2C#)%M;#[SQ7R?HV"TL0)5U%BI487(
M-C:=+<6]JT;!4&-\(*\[5S%9*P?2(E:@4_D^]!H-SQ2H<T_Y'#E#M_+UP;-\
MNSQ&WRQS99(DJ"+?J4:9:&Z^]&9RB816H\T5J*+F2HTJWMS<#Q>>2-0:K8::
MX\/9=\QSR>\S3/7)CD.B0D4TUJ@Z4Z'6/=0Q5:A#KD)A62L/?V+T/93)KD:5
M[Q0-J;G,(7X#]T3MY&C(6I0W\`)5Y+[4J.IO44P--1H.M<B'%Y*`3;OO.DB:
M&B]B-K9(%+%:/3G#,T7<JFBL+7)%[/F+V5*^!!QCKT`Z/-4GJ**R2C7*''+M
MS>'-2?F<-T>KT>8*5%%SI485;\Y?+CU/WF]J-!MJCX_S=8=3YNF6'%"+X$D0
M#L+:J<S#H>$`;U!%5QQI%",B]XE&*2+RE6F4(R)?A48E(O)5:50CTH\=I^90
MI;L2?5_IN*,9JOS[QK$\!O3$SF#M5.8!QUCPK7OSN)E4ZA@06QQ=I\>H8K[T
M7=&V"/W"/$E[#64G,E2-=B)'U6@G"J?J=*+L-92=J%`UVHD:54.=X*4'JM$\
MN>SI_=2X$7.L1:PD6]09;SE&&^<+'N[@&$4:Q8BHC!*-4D3D*],H1T2^"HU*
M1.2KTJA&U%.2,&P]H;[Z38"I\=/$FJ(8AN*H[MZIS`S1UI9:S%A/H,%(;\@,
M4:11K%&B4:I1IE&N4:%1J5&E4<T0R_/PNA.71L[SV2&SW6@#.O7%UGE-*HS?
M1J-(HUBC1*-4HTRC7*-"HU*C2J.:(1Y2<Y8P<(L9/\^"A_IRMG"H^[A?HXU&
MD4:Q1HE&J4:91KE&A4:E1I5&-4,\E&;[W@WEF?@9N<A.AVB]L`X5VF@4:11K
ME&B4:I1IE&M4:%1J5&E4,\3C)[?U[UKMA'JWCZCSQ)D0S0/JP=/&J<QCN7:V
M\.6.+R(5SA:Q1HE&J4:91KE&A4:E1I5&M4,]C_M#LR'M)N_[@F^WM=UG%XUC
M2/-N\)V*K8#4"L(9PA&?>W0N;HX1"2CNK6=$";5/8ZA&.B5?`V\`D``]Y^09
M44%HI+&2?`V\%$`"]%R39T"\;,P^M3MR9Z8=(Q?3CD7\T$3^=M,Z="J8D-IB
M4('<]*KD&CA"E3U'\4+868?BD"%&#2PWA]M+4#7:J[17)7N5H0I[%01+^;N1
M.6I&>U6@:K179:]*]JI"E>N5;QYLBS5@C9JA7O&$,=OL;L*84K_DO"VT^W-6
MW1:QW[68RB]Z6*/A^!D,J3#K(X?P#`:^M$*^GA"C%63G6)JXKH_V($5?=/_-
M>`_"13`79YTY&HUVH$#5:`=*4F$(*MX!?S&'KR#@#Y)JM!KJ`1_]OC.%BT9?
M'R.$;NL/P6UC/Y6'9&M4C1;#!E7T;"]"Q.X3\EE\C*JAW+<'KJ@:[42**NI$
MAFBT$SFJ1CM1H&JT$R6JJ!,5HM%.U*@:Z@3/`U#I66!FO@WWYO*7*T/C1=Q-
M+!)3@GSXB8:C];!!%3W(CQP:?W4@)D/*3'6S2E`UVHD45=2)[*).Y&0XTHD"
M5:.=*%%%G:@NZD1-AOV=X$D!"<:2XLQ:PLC%Z%O4/3`*6]3?@Z9`-ZBBN3?2
M*$9$ASP)H1'W*:K(?:91CHC<%X1&W)>H(O>51C4B?:PTDR<;[UI^-U[X>#@D
MUG9B_;!VJC,GO>B+35]RO1*ARJU7YA/X)B1QLARC9FBFLG/V1;U*T==HKS)4
MX=JN9\69HV:T5\5%O2K1UVBO*E1AKWI6G#5JAGK%"AB^4IT7L,RCRTZ"&S<B
MD8QG_L463G7FX0RJZ,0UTBA&1)67$!JIO!15Y#[3*$=$[@M"(^Y+5)'[2B/S
M3?84'#L@]IOI[1>#/^_>ON_6NZ>GX\W#X:?YUGGX+<O/'UOLOA)_NEQ]`4^P
M]!.?P#GPRAR+]GP23E;F=*_O$_B&?3BLZOL$/NCC,_A*_A[^)9BLOL")>(\G
M^,3\XE;?)]`Z_))1WR<^?-(\NA%7"<<M*W-HH6TVX71EMOOZ$]BXK[+>3V"7
M#=[Z;.!/#WSI:_\>NMS;8^APKSZ`"^GITY<I^.\=K"F,8H_!9K&"+Q+5%[=9
MKJ(^/^ER!=^DV:,/X)+A<7C?)^$J@M<(]"?PNP^KK/<3^-T%\-;8W+4C!7\B
MX77[?5=MW[[O7XXW3[MOD,R3YJM>W^P?6;#_.+E?%_UZ.,$?1X"9!+X&'_X8
MQ@Z^96%BOJCRV^%PPG]`I^[:/Z_Q^3\"````__\#`%!+`P04``8`"````"$`
MX8[PCYD^``#&>0$`&0```'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6RLG5V3
M&[>UKN]/U?D/*MUO:<CY=MG>M46RR>8W63GG7"NR$JMB62Y)<9)_?UX06`U@
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MK\:W(=.[3[^H`_J_+SY^"&-#M^3MOW]X.=:%/_ST]><?7E[?O;J]O[H>*?S%
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M#PX>'`OP6GHZ1QKZ?X:CD"8XLKO[QD"6-G9"+,*:3#V8>=!X,/=@X4'KP=*#
ME0=K#S8>;#W8>;#WX.#!L0"5$*TL?X:0D$:/J&+2C&ZN:@-O8LR-%I4\L^J0
M21?260*9@30@<Y`%2`NR!%F!K$$V(%N0'<@>Y`!R+$DE36OZGR$MI-%BJ:'1
M"1G=W-5*WL2@06M=2&<-9`;2@,Q!%B`MR!)D!;(&V8!L078@>Y`#R+$DE34]
M!RMK_5M!>PR%Z),<NZEO(KDIGTS0->F"K-D49`;2@,Q!%B`MR!)D!;(&V8!L
M078@>Y`#R+$DE0LM0I6+L%<8W[Y2_(6[A9"HUA3)33VK[NM9->F".DT@,Y`&
M9`ZR`&E!EB`KD#7(!F0+L@/9@QQ`CB6I-&D["4UA>WJAI)`&"]U#K>1-#!I<
MZ+J0SAK(#*0!F8,L0%J0)<@*9`VR`=F"[$#V(`>08TDJ:UJA*FO#"UV(KF=0
M)&ZA<[HF75#G`F0&TH#,018@+<@29`6R!MF`;$%V('N0`\BQ))4+'7$K%V&A
MNWX(-8=+)U'(5'N*Q*UTC_6TFG1!G2>0&4@#,@=9@+0@2Y`5R!ID`[(%V8'L
M00X@QY)4GD)!`:*>]40Z9:I%)52;NG7[\TF.ZE01S8@:HCG1@J@E6A*MB-9$
M&Z(MT8YH3W0@.E:H-A?.NG]&W2&>F>OM^*VK*[P)521-P\''5([)(KMFAF:,
M:HCF1`NBEFA)M"):$VV(MD0[HCW1@>A8H5ID.".7(H>?6T&46Q`3JI]<7N$D
M1YF+*=&,J"&:$RV(6J(ET8IH3;0AVA+MB/9$!Z)CA6H]X3A<ZGGVGCV44[VY
M=-:N=NVWOH:4&FH=S>:ZAH9FC&J(YD0+HI9H2;0B6A-MB+9$.Z(]T8'H6*':
M7#@2>W//V,:'6G;T5A0L;E&;[0[@.>K6;4I2)JVB9FU*-"-JB.9$"Z*6:$FT
M(EH3;8BV1#NB/=&!Z%BA6F0X3Y<BSZR0(=SM1")R*Z13.`EC0PT5E?4`S1C5
M$,V)%D0MT9)H1;0FVA!MB79$>Z(#T;%"M9YPCKY`3SQV:\6UN_QFU)W$\]P9
MW=[XV=-%6<-I;FAH1M00S8D61"W1DFA%M";:$&V)=D1[H@/1L4*UGG!@+O4\
M_P$6C]Z5N70:KQ]@6/>Z*-,T#:_LPES+HV!&U!#-B19$+=&2:$6T)MH0;8EV
M1'NB`]&Q0K6Y<+SVYL(\O+`.%=Y*\@'F*^XI:GB+GP[\Y0,,:)8SF>Z&:$ZT
M(&J)ED0KHC71AFA+M"/:$QV(CA6J18;S=RGRS`,L'M>K>99.\+K9^:7)K5,X
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M1'NB`]&Q0K4Z7^HX\P3K*AIVE]^,([H]?;WT]-6Q"=&4:$;4$,V)%D0MT9)H
M1;0FVA!MB79$>Z(#T;%"M8M0,B@W>^&\=:O'PQDGL=)0;OK"V[*P;X_?K@U?
MYYL8TE$X[P/OW"N5J46=OFA\DCDS5#?,9?[Z(X23=OD1SG0]'LRKKD=4#2>@
MZ1AH1M00S8D61"W1DFA%M";:$&V)=D1[H@/1L4*UBW!0+EV$X:1ON9W>I9[Q
M$L_8E9>$RB&5D%P,#:D450ZIWH:Y>%U_C'!,+#_&F:['4V75]8BJ(04T'0/-
MB!JB.=&"J"5:$JV(UD0;HBW1CFA/="`Z5JAVX8^CIR%UI2W2&2D\EXX3*L=3
M0F?&4XHJQU-OPURDK3[#M3^SG3[#[:OPE?WA3W%J61_?$M(B;<_#"=&4:$;4
M$,V)%D0MT9)H1;0FVA!MB79$>Z(#T;%"M19_5COCHCN2V8U_<YT.4AJ-Q7+D
M:\$YRAI.B69$#=&<:$'4$BV)5D1KH@W1EFA'M"<Z$!TK5.L)QZ"GK\+7\=14
MKL()U=OX.U_PS5%93\Q5%GP9U1#-B19$+=&2:$6T)MH0;8EV1'NB`]&Q0K6>
MOA/8Z$F+&@]<UQ%5BQK0E%$SHH9H3K0@:HF61"NB-=&&:$NT(]H3'8B.%:JU
M7':ZNN;IRE#Y@$E1&4T9-2-JB.9$"Z*6:$FT(EH3;8BV1#NB/=&!Z%BAVD7?
MZ2I-D:\_?WCWCS>?POZX=Q-PK1^KBC]L=<W#EJ''8@^0HK0O*1Y%KN@^30VO
MZ_V.J_W.<I2MB`W1G&A!U!(MB59$:Z(-T99H1[0G.A`=$U+M71^[%AG.?A<\
MBD*XV[5%=)VWD),@05%"@\925'[//[.&&35$<Z)%0C?:CA9CQ%4DVQQE]I?,
MM<JHS.7&VSKG*J+N\['K-,(W.<JNN,WI#>TR*G+=N2ON<ZXBZMX]\P\YRM(?
M+?W)4&T_G!TOL)^.FOEM\9O@.*JVRTV(ID0SHH9H3K0P5"\'KH+9YBCKU])0
M'J@KHK6A*OU]/OXDK^ECYV5J:PUS^AW1WE"=WJD^Y"CK_=%0C\1PUKY`8CR:
M5[O)B'0)N]SD&FA*-"-JB.9$"T/U;7`%M#9'6;^6AG)75T1K0W5Z=WK9Y"A+
MOS64T^^(]H8&TQ]RE*4_&NJ1J%R5Q.(@?<$#-61QRW-$E5N@Z370C*@AFA,M
M#&EYSVOQ?:YQGF90FZ/L[BP-Y9N_(EH;RE]^V!!M#>5<.Z*]H9SK0'0T1&OA
M>?/'K9VRU-8,Y?5EDE%Q6_U#8IJBPI+?W?Q']XR8Y2"[]TW.;FA.M$CH1AN[
M+OOHWFVRVAQEN9;,M<JHR.4_SSKG*J+NW8-]DZ/LBMN<WM`NHR*7O^(^YRJB
M[MWSY9"C+/TQIQ>J'K/A?E7#9+@<<PIWXR&68\)+W7SC']QZ.4D-P[O%'.4_
MX#1'6==G1`W1G&A!U!(MB589#71UG:.LJQNB+=$NHX'T^QQEZ0]$QPK57B^K
MXX1JC5N=$PJO%#MC_O=-3*Q=)9]:4_8JZL$MNS.[X,WI=UL\7MU<W]Q<N_6A
ML0OJX-7U:N0O.+>H?'1>9%0T]'UHG]*'I:4:[,/*HJH/[7NZMJ@JE^_6QKI5
M1[D=_;8WE[_BSJ(&^[6WJ/J*3MGA2?TZ]N8J^E4/W%"!>OJ6\286K,HM8T+A
MA5D>(@]NFSRQJ#,+4DRO9<NFX<P:WI^&Z?CNZN;N\=[MWQH+TE8U]Z'XR*>-
MQMRB<O8%46MHZ()+"QJ\X,JB!C_TVJ+R47=C2'NQ_'D>,`#3W1KLQ,YR#79B
M;U&Y$P=#@YTX6M2W.E&/-E^X>];>]H;UO(3JU=/M1B;6;G`J3G-4'H/Q@OJ*
M0?@U0#=7-P_^AR8;:U5-8(Y`U!@7UC"OG6U"`Y=;6JO!RZTL:O`#KRTJ_OJQ
M\*V&C?6@2L_QESY-%>4_\\[2#W9B;U&Y$X<G=>*8&Q93I>A$/?[4U4M6NQ#N
MME\1Z86;C8[)38?Z>W!:?*86E3W/B!I#.?V<:&$HYVJ)EH9RKE5&`UU=6U1.
MOR':&LKI=QD-I-];5$Y_(#H:.J6O)89J8?G(>MXB$K(XMQ&YK;5[UDS"%U'5
M,+PTRFMS,>"2[I2KBO(;C5G*-8[/FM'H[N%!OR?-G3`:B_K6$IN>;EV_;&0N
MK.%@)UJ+&NS$TJ(&.[%*4<,W9]V;R]^<C44-/G^V%C78K]V3^K7OS>7[=;"H
MP7X=+>I;_:J'M*^^^B']ET^_::SVOD31%\GL+<H-J[()5>M5JEC6%7)7>)Q:
MP^MNH9L1-8;R(C`G6AC*N5JBI:&<:Y71P%Q;6U1.OR':&LKI=QD-I-];5$Y_
M(#H:ZEFO-`2J]>K,F3^$NX4IH;QB3L(WKA6EO;[-]BG1C*@AFA,MB%JB)=&*
M:$VT(=H2[8CV1`>B8X7JB:9)6[GP$^U);RMO0A:G**&R3->A@=$U3;FJ,MWH
MP9W#9SG*=#=$<Z(%44NT)%H1K8DV1%NB'=&>Z$!T3*CG;:6^=5B+')Y4I_#:
M6$)E.3RC(6,6E8]*,Z*&:$ZT2"@4#(O-A"MJMCG*["^9:Y51F<NMZ^N<JXC"
MV\H<95?<YO2&=AD5N?Q6:)]S%5%X6YFC+/W1TK/:'KZ]74WC,_9#N+,?464?
M:'JZSNGUM75J1M00S8D6AK0J%*K=7J_-47;%I:'\`F-%M#94I<?;RAQEZ;>&
M<OH=T=Y0G=X-KD..LO1'0ST2M2V]1&((=Q(CJB0"36^!9D0-T9QH8:B^#:[Z
MWN8HNPU+0_DNKXC6ANKT[@2RR5&6?FLHI]\1[0T-IC_D*$M_--0CT=</G_5`
MO659,:'*;8PJT)11,Z*&:$ZT,*1S5)Z@>%N9H^SN+`WEF[\B6AO*;Q@W1%M#
M.=>.:&\HYSH0'0WU6`N5FS]\A+Y-]9^\!WUCJ-@&953<5O^0F*:H:AN$MY4Y
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M%O7F\C)V%C78K[U%U5?T;RN?U*]C;ZZB7_7`]76R,P.7];#;B,Z\K;0H[1R_
M/9"F.<JFX<Q0>GFHM^KWC[?N.-=8D$HXW\X^MZC\=%T0M8:&+KBTH,$+KBQJ
M\$.O+2J??C>&JFTEWA99U&`G=A8UV(F]1>5.'`P-=N)H4=_J1#W:%%4MD\_;
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MPAH.]J&UJ*$^+"UHL`^KW(>!GJY[<_E;L[$H3:[\J;$$6=1@OW9/ZM>^-Y?O
MU\&B!OMUM*AO]:M:E>ZT-%:KDA_03WM7>4KC1G3(K&IKGJ.3%"54W%>_:$\M
M*K^AFQ$UAG+Z.='"4,[5$BT-Y5RKC`:ZNK:HG'Y#M#64T^\R&DB_MZB<_D!T
M-'1*7\O5[*OD#C]R[D*XDQA1^('!8B:X0O'$&E;CDEY3^KSVSJQA1@W1W%`N
M0RT,Y88MT9)H96BPJVN+RNDW1%NBG:'!]'N+RND/1,<*U5[_E#+M'<NT"57G
M*?_EN$D*.O<0BMGK*I!?T6:6J]K&/;C-<V/=JE:T!W<0FUNNXHC5W]`=;5N+
MJJ3YY7YI454G_"!?Y4X4$\9'K7MS^9NSL:C!?FTM:K!?NR?U:V^Y-%.+Z>[N
MU\%R#4H[6JZJ7X6T>D2?*V$_\3'$&O9=1-5CJ$/%I_2.IM8P+[XSHL907MOG
M1`M#.5=+M#24<ZTR&NCJVJ)R^@W1UE!.O\MH(/W>HG+Z`]'14,]C2`/EDL=0
M"'>/H8C"=^&+<>G>MD[NNBC;ADZ)9D0-T9QH0=02+8E61&NB#=&6:$>T)SH0
M'2M4S[W+ZL=WK!\G5.MY].\%<E36$W,5WWN:,:HAFA,MB%JB)=&*:$VT(=H2
M[8CV1`>B8X5J/9=52>]8)4W(Z7&K^B1'93TQ5Z4'J&'#.=&"J"5:$JV(UD0;
MHBW1CFA/="`Z5JC6H^=;M;@5!Z@SV^W0TJUS$>E;%N9@<@<T)9H1-41SH@51
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M+*'P\X6YH?]*4&,-ZWOTK4]_[LSXI&]_W_/(F)`;&[[HE:+.C8V8OOP96$L?
MB]YW]X_C1Y>[L9!J%!2WN1X%X=ASP62(IZ1JTD94GI'#+_K4`_%,J=:B2M&I
M84:-1?%D>.^/'L7FZ>F_'>64Q3T2XL'"C68WV2;6\,QH3@<>?;`\='VQ9I9R
MA5\$742Y[4)C5ZRBOBG6[_S]W7E:4>2>)X*$*N$QZISP%)5+`3/+E5%CJ$=X
MV,V68S5\I.?]$OS[N#&NQG%$;LN6EX_3V]!):EB<:J9$,Z*&:$ZT(&J)ED0K
MHC71AFA+M"/:$QV(CA6JEYFPT_7JGO6W;._CGKDR%Y$SYPL\J6%EKFMH^^\9
MHQJB.=&"J"5:$JV(UD0;HBW1CFA/="`Z5J@R]]"_V;[X#UV=\IS6V;S$C:]<
MF>=-B@H_,=DMA.ZU\B3'F+4IT8RH(9H3+8A:HB71BFA-M"':$NV(]D0'HF.%
M:I&7;<\?N#U/*/Q(72<'"B<Y*NN)N=30T(Q1#=&<:$'4$BV)5D1KH@W1EFA'
MM"<Z$!TK5.NY[%3RP%-)0M4R.+YR)XE)CC(74Z(944,T)UH0M41+HA71FFA#
MM"7:$>V)#D3'"M5Z_&EI^(STP#-20DZ/V^--<E36$W,5#ZX9HQJB.=&"J"5:
M$JV(UD0;HBW1CFA/="`Z5JC6TW><>];^XH%'NH2<.7_<SU'97,Q5F0-JV'!.
MM"!JB99$*Z(UT89H2[0CVA,=B(X5JLV%(Y_?&3[I]ZH_A);UR2VALIA'-"6:
M$35$<Z(%44NT)%H1K8DV1%NB'=&>Z$!TK%"MQ1^NSZQWZ9A;%,D>(G*SQM>$
M<E2>-5U#0S-&-41SH@512[0D6A&MB39$6Z(=T9[H0'2L4*UGX'1_QA0/]`\1
M5;,&:,JH&5%#-"=:$+5$2Z(5T9IH0[0EVA'MB0Y$QPK56GR%XHP+5B$>$LH5
ML`G1E&A&U!#-B19$+=&2:$6T)MH0;2M4W[^^,L'%?T'@@24"0_E;@).,\FD&
MO\]RFJ*J'T8=^V\ZSW*4+5D-T9QH0=02+8E61&NB#=$VH9[?H_'8?](__=FF
MI]=33UGJI[*AXN9G-'3S4U3UL[KC*U?OGN6H[N;G](;F1(O<,'=B?.7JO&V.
MLEQ+YEH1K7/#,KTK*&YRE*7?5KFJ^?%XV1G^%.Y<Q*-X]7IB?.5K9:EA_?W+
MHM(<?S(D1UG79PGI3TN$7X]X.WKE9#76IJHAC%P9:&Y1>3NQ(&KKBXWN7[DM
M^=+:#%YL95'Y8FM#N6"Q,:2UI2M^C/SW/+<655ZQ7%1JFY<=^1]YY$^H>E,Q
M'ODCOS64^MQUVDSI\Y-GEAKJO5NP.;YYY09O8YG+-Q)CVD3FA37,%VOKBXT>
M7ET_5O_Y_O7O^IGT=^D7G"TMP^"E5Q:5K[,FVKA+W_I1N[4VW[I8K?6R4L$C
M2P4)U9-TY$L%%J6[.Z0UIB_?(::&:9*.KJDUM2E'<8]69%Y8E_*\:0T-SINE
M1957+.?-:<%9650Y4[NNVAJTL:C!*VXMZEM7K)7Z\L+PONZ1-82$W$QU"];$
M&IZ9J2E]'M2SU##-5"RZJ<&WAN_I[L[SQ>U6+HC:^DH/K^ZJ2>J_!+&T#(.7
M7EE4_D1KHDU]Z=&5'[=;:_.MB]5.%545'LXX#>'N61J1FZ;^A/N8HLY,TR[*
M;OXL-4S3=/Q*I?;R/VXY:.PZY8#NF;2XSL(:YEG5UI>^>^5>P2RMR>"U5A:5
M$Z^)-O6U]!1W&["MM?G6Q6JKE]4M'EFW2,C-5'<')M;PS$Q-Z?.XGJ6&:::.
M7KGATEAB>>I6]1Z-2+RPAOE:;7VMFX=7;I^WM#:#%UM95,Z\)MK4%[MUGVMK
M+;YUJ=JB+V^<F9NL:3Q&5%>?1FYAG.0HFW53HAE10S0G6A"U1$NB%=&::$.T
M)=H1[8D.1,<*U7HT%:NEL_ANR1E3H:5;12,JJT^/0%.B&5%#-"=:$+5$2Z(5
MT9IH0[0EVA'MB0Y$QPK56D+=HRREGW$1PIV+A/),GSP"38EF1`W1G&A!U!(M
M*U1]YM'5GU*UB&GJF]&QHFY1L+P\8Z,ZM;"Z;#1R3[99$6;K3]/#YCULT</:
M'K8TUE/P&5V%8D`Y8(IY_/2*3TSC[UU(+5;=NXX-W[L8=J;J8U=56''ONBL8
MT[T#T[WKO833H]O9A5DZW<XRG1N*X9Q;WL[A^3<*?]7=34!C;D_I]GJ3+FQX
M4UF$V0?0F(M7M1+--78@%A'^2/W`%J0+R]L[W=B87$WM@KJ+B6DAZ=*A<J(;
MVS4MPHHJA;O7X=QWR;V.Y\3R:V.CJ\C<3L_5.'2O4U.)S_TO.A:+8468?73=
MZ]C4-GMC7Z'2;$_)O[4MBD>S+BP/=MWKKE]V0=WKZH(WMUZN;O.9"[K;?-G!
M=W3%DZ\Q-Z1]D:H+TS`8O,WQ"F4]PYI:04-'I;I8I-N<6IT;TDBNVPRFVQR9
M7=`-&=WD,Y=S-UGR+QK+(=ZOMY&YL>Q/+:.KU/3<6.[";&AI+$>6QK);*W6'
M4Q/]T^D;HQ38A54#&5?3':ZN-G[P2G6/SUS0W>/+SH6C*QX,C=4#&;7S+NS<
M0(Y7J`=R9&E<W?G9J[N<&IT;Q\BM<=PU-:>ZRXF=6YJ[IMEMN>EQM_JRP]OH
MBJ<W8VXXNS.EEN;4]-QP[L+LHVLX1Y:&\\VKV[J.Y4Z*NO,IQ[GQC4OISH/I
MSE>7?_"F-;S/7,_=\W!B*A^'<2=W\;=T1U<AT6EMR:K'(U<W>&-A@]_3+8+L
MMFMC'/.KH3&I`-/M!M-.#DSW%DSW%DRW$VS5P]8];-/#MCULU\/V/>S0PXXU
M<V[#":QT>VY;F4YL>5\F7Y'57]WU6C6?NC"S(V-@,@8F8V`R!B9C8#(&)F-@
M,@8F8V`R!B9C8#(&)F-@,@8F8R6KC8W\F?2,L5.\>Z`G5A>PQNY%Z624P[(Q
MLEE/7-/#YCULT</:'K;L8:L>MNYAFQZV[6&['K;O88<>=JR9,Q9.=>4<*T["
MY^2%IEY>9&5-:Q1^]['B"C;M83*%.)D"DRDPF0*3*3"9`I,I,)D"DRDPF0*3
M*3"9`COT,)DJXYRI<$PL39W3$X^5U<%/_^.D+&]"-9'`I*=DKAOA&'5)-]*Q
MJUR41Y'5FYPQ#D8I+-R3;F==[K[2^;,O;#S.)R'7_W!"N:3_\413W\9T"M(_
M7<?&8_].<S1*3<_UOR=LH/]A]W])_]-IH;K_D;G[CTWF*#4]U_^>L/$XG\#<
M_0];ZDOZ'[?@]?V/S/7?[5PULE/3<_WO"1N/\SG/]3]L3R_I?]K.5O<_,M=_
M=YA6_U/3<_WO"1N/\\[5]3_L!\O^/W?#/(H;R[!4Y$EP[9[3;T8I;'C#G(.*
MASDVKGI$@.D1`:9'!)@>$6!Z1(#I$0&F1P28'A%@>D2`Z1$!ID<$F!X18'I$
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MAYD=&8OIRI\D[F$RAC@9`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3L9(Y
M8_ZD\D?6UIY33/C3%3+LUE:<`G)88;-K:DSS#TPVP6033#;!9!-,-L%D$TPV
MP6033#;!9!-,-L%D$TPV2^9LAE-2.?^>O;:FXY8&3K%O=8<?K:TQ[,S:V@69
M1\U4,+D%DULPN0636S"Y!9-;,+D%DULPN0636S"Y!9-;,+D%D]N2.;?A!%FZ
M/;-O#;\N"&MK9&YM=5JUMG9AA3$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y,Q
M,!D#DS$P&0.3L9(Y8^',?(FQ=,;.&T?-L,C"W]4L)F*N&YPV.3+6A17&P&0,
M3,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QL!D#$S&P&0,3,9*YHR%*D%I+*R?=]>G
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M&)B,@<D8F(R!R1B8C)7,&0M'^=)86$SU_8X7EQXDPAM03+Y4)]"`R<?"&Y35
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M33#9!)--,-D$D\V2.9NA`%#:/+?-B06#VEA71"B-H2YSW845QL!D#$S&P&0,
M3,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QL!D#$S&2N:,A0)`:>P/G!EC+:&6V=47
M2IDHV5QW885,,,D$DTPPR0233##)!)-,,,D$DTPPR0233##)!)-,,,D$D\R2
MU3)O?,GF^3)/J5PU)S'W9$0U)X=EF62S$5G3P^8];-'#VAZV[&&K'K;N89L>
MMNUANQZV[V&''G:LF9,9:@-^9C[I=^>.PD]7^R-'8L4WU"<65[!I#Y.IF*^(
MDRDPF0*3*3"9`I,I,)D"DRDPF0*3*3"9`I,I,)D"DZF2.5/AW.]-/6]#&N86
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M6&3U&ZE;5-Y24X69'1GKFAJ3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P
M&0.3,3`9*YDS%@[^I;$_L"&--81:9E=7**<?ZF[A^VV^5$,FF8B33##)!)-,
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M+)4P\J]6U&P$DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!D#D[&2.6.A
M4%`:>_[9\C;6'&J971VBE(DZ76I:+*/3$9ED=NE,NF2"22:89()))IAD@DDF
MF&2"22:89()))IAD@DDFF&26S,D,-00O\UE+:RQ&2&6IS57DM+3&L#-+:Q=D
MSN063&[!Y!9,;L'D%DQNP>063&[!Y!9,;L'D%DQNP>063&[!Y+9DSFTH*91N
MSRVML011S\94EJB75J=52VL75A@#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9
M`Y,Q,!D#DS$P&2N9,Q;J!J6Q/["TQA)$+;,K2Y1S%#78VRZLD`DFF6"2"2:9
M8)())IE@D@DFF6"2"2:98)())IE@D@DFF6"263(G,Q0.O,QG+:VQ`N&65E=M
MU=(:P\XLK5U0X19,;L'D%DQNP>063&[!Y!9,;L'D%DQNP>063&[!Y!9,;L'D
MMF3.;:@CE&[/+:VQ[E#/QE2+T%6*7:O3JJ6U"RN,@<D8F(R!R1B8C(')&)B,
M@<D8F(R!R1B8C(')&)B,@<D8F(R5K#9VY\L[9XR=XET))['ZU'^'DV$.R\;(
M9B.RIH?->]BBA[4];-G#5CULW<,V/6S;PW8];-_##CWL6#-G+!0$+IAC=[&`
M4,VQQ)PQU,-S6&&LK$><?EY.QL!D#$S&P&0,3,;`9`Q,QL!D#$S&P&0,3,;`
M9`Q,QL!DK&3.6#CFE\:>OWVYBQ6#6F:J(M1'#-3#4]/J9$@FF5TZDRZ98)()
M)IE@D@DFF6"2"2:98)())IE@D@DFF6"2"2:9)7,R0P7`RWS.]N4NEA+<]L45
MOM^,4MCP]B4'F;-IT="8W*;R12[$R2V8W(+)+9C<@LDMF-R"R2V8W(+)+9C<
M@LDMF-R"R6W)G-M0$"C=GGL8Q@)"/1M34:'>OCBMD]%=%V9V9`Q,QL!D#$S&
MP&0,3,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QL!DK&3.6#CFE\;^P-(:*P:US%1%
MT')0[$7Q/N.N"RMD@DDFF&2"22:89()))IAD@DDFF&2"22:89()))IAD@DDF
MF&26S,D,%0`O\YFO&N]B-:&VF2H,E<U[]YI#4[,+*VR"R2:8;(+))IAL@LDF
MF&R"R2:8;(+))IAL@LDFF&R"R2:8;);,V0PE@-+FN<4TE@QJ8UT9H9A_]RAZ
MWW5AA3$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3L9(Y8^%@
M7QH+B^G3ON%_%VL"M;S(]`+3K&AN@>FQ!R938#(%)E-@,@4F4V`R!2938#(%
M)E-@,@4F4V`R!2938#)5,F<J'.A+4^?F5BP`U'H2J_2`20^8](!)#YCT@$D/
MF/2`20^8](!)#YCT@$E/R>K;>>^+(,7`O^!/$Y[2N-J(L?)/$V:65S6MI/6?
M$9N.4ECX8=6\^;AW[QAF19A-LZ:'S7O8HH>U/6S9PU8];-W#-CUL:TR_I%E]
M=B[".;H<VL]T$8_CU8B_3ZQRT;%\D_M<Q##]T,V/W__^X_AJY-X.2$,746CH
MDAN3!C!IZ-JF[$ZRI'01EDE2D$E2P"2E:YNRN^>G%'41EEV*RDQ.43@=EXK.
MK#[W\31=NX@L_/+?;G#KSU#5<V`R2DW#;YS-83U3)66KPA[<YY2C&!9^EK_+
M-KYW*C5[4C:MOUW8Z,$=X62RNZC=-9GL6-G4=40Z4]C]:3@]7-^-[F]=O51^
M^[KA/[N4=Y>T;DAYQP:Z(>]5-^[N)=W_T1\-A#/=<&,CG*[+L7$ZD-V%GX-X
M<<E2&@_I]9")+/QBC4[+^!XO!NY3TVID^=NFU36%W7:[$XV/R$Y]_>'EEY,<
M_/%0C8^N:>X(U@R-CZXC)D;C`TR#(;+P4T/%Y^)P2$W+P8M1J>&`*V@X@,E]
M9.ZJ[B$D^V>NZNR'DWII_]S*$$_VM>;(]/O6[+9I&>A8OD6XXW*:PO*61D[!
M)+!+9Y>0+3#90EO9`M-,15MY`),'M)4',-WTLJV[P^'X7-[A9\ZOD,9O52*K
MEN3Q/9?D&!9^N50W7/M<I&Q56,^2G++IGRY;WY*<LIU;DE.V_&-2DMC;E$MR
M"M,NL>L(YKY4]V7SJXOLHR.RW]?4WQ$-B*=T1&.D+UO1$3=LPCG=#YMTM#LM
MRW_Y])N&P]G?0GL?S_OUA(VLGK`=*^YFT;O3BR--V!1VW<UU35@P3=@N73%A
MP>0:;35AP601;:4,3,K05G[`)*-LZ^Y\.&_[.Q]_&.+<XAA/ZO6]CLP]`]W6
M1.ME:EH-YI[;G\*J]3(R_>;PL%N\>[BYOWMT:X!\I(8:@WFR^/Q:4[MNF#8I
MPC6EJ+JF_CSE]?C>/8GD["G7E$9<4QIQ36ETUQS?WEVY;;>\GKFF4QT.[*7J
M<X+C`;\6'%GXJ=/NSH[O47&^CV%G%^$85F^?_9*C*9>RE3K'#ZXP*NLIF_[I
M^H8=B*RG;-4BG)H./@TT$%+3\$.SO__H.J`AD++HG]P!/^PT!%*6W`$-@=1T
ML`,:%:EI;P<T'E(6_=/;`3<>0L7ADO&0*A2YWV]&]Y%5$[[OG)2:ZI_>CMEZ
MF\*JO7'/>(AA;F_(<U+*5@Z;OO&0PO*Q6ZO`4SJB\1##TF+TK7/2_V?M7)<;
M.6XH_"I;?H"8,Z16I,IQE2A*(B52*^D--HF\=L6.4KN;RNOG`_LRW8VC&<J5
M/]K:`Z"!Z0-@IGLN5&&(K'!AD!6GA$%65&&\M4Z:"*/.C:7:<K)/Z;QCD70<
MH[F(BUA]$=<R?-5%M:G^D48K7P-(F,4ZLDA*:F^5RC$C;XM`AE-$,AWJ8)?U
MRESKS]TB*9E67MNE^WT>;?"P3QB],D5R2%BS8="<FAZ2FGUNO)B2X:S<4$_U
MO:<M+$V_I3E@U357U+,/50]1M'6PZ9):>=+WV$W6&]9AL.7<;C,VC`=;46_`
M[C(VC`</;CQX<+;PX#`FO;1M9I@N7\WPGULD+6V8=N(#5O5CL4A*IE61""ZB
M!PYEH*RMUFN6(<=`IOIQ<EK6B.C'2:WLQPFK3=TB*:J-;Y!`=3RL:K3VZ&$_
MJ@V!P+XR;6>$A`AJXX&0(VJT(I`F;6ROHSQ?MUO/)RZ2EG'/9.@DZRYB=<$&
MO<F"C6KE(BD--V`4;!XN-3`*UF$4K!N/@G48+#I;*',8E#E;^'$89)2VS<S;
MAD<[\R<MDI9AJZ2ZAHY8?0X\']KQ\=3#.3#NLI`C0_$5R1&OF=)H`YL49##E
MQT)&%DE)J3HKM.-#40XCT09%<?S!)Q15/M]8)"6E49_0Z'Q"H_,)C8U/N4A*
M2F_Y;*BF*3BJRYV(]2MLT!#%XFG.=!]9N>R6-DS;FP-6]^9ELZB#]V@ZU9NC
M6KE!'$W'VPZ5F$U',@OF<R`%\]DT83`?L'&OU&LV'?$*]\XKW&?3Y!7N3_%*
M56=3[;5AWS9*RD(7+'.<`\UA8Z4N[W*S)=5RQG04J9:CVG!=0BT[#`+S<&D^
M8,MAU*FSA2V'08VSA0>'P8.SA0>',>FE;3/#MF51SO"?O/:).Q]#!^(<%K=,
MRJN5?MDL"ZFOH#:YMHBC#1[@(F+C?34JO=5OCES#5PXC<0A?SB=\53[?ZJNG
M^(13YQ-.G4\X;7SJOCKAL^&=Z7"\EWWUU(L7&Z=MK`&K+UXR-EYQ46VX4(%E
MAU%Q>;C$%@PZ#`:=+0PZC(ISMK#C,-AQMK#C,"JNM&UFGA-)-?-3/<WTVQD.
MF'VZ+%^+]$MW;W,93?DGJXE[+TFM+%362_7-=7B(3KDNRZ.);;\T6AD;\U&/
M!ELYML0@;$5L-!`(S('(;;\T2A5`>R$%O2X`Z#TE`!@?"P#RXRAO!5#GPZK=
MVIG(AZ-^DP\1JU_063;;'5?=H);F?".P:X'=".Q68%N![01V)[![@>T%=A#8
M@\`^">Q18$\">ZZQAC'RLZK@8N$W19Z9MN0%K'KP<>4PF'(83#D,IAP&4PZ#
M*8?!E,-@RF$PY3"8<AA,.0RF'`93#H,IA\&4PV"JQ!JF;$%?7MU,T1,W`(:+
MC'6WBMAP$4@A.0QZ'`8]#H,>AT&/PZ#'8=#C,.AQ&/0X#'H<!CT.@YX2:Z;3
MEN3E=!:)_XZ-Z%58V5=7Z0D;-G>8Y:A'.\TG'''ZBFI3#SX.:JGYP47P@&G"
MX,)A<.$PN'`87#@,+AP&%PZ#"X?!1<#4@X\K6VO_'[@(2_::BXA57&1LG(N@
M-O+@XS%N?GAF*"=HR(,7-&1LQ"',M`Z;]3L\98TT.#SEP1,&3QD;<0AU>3B[
M^.#1SN8Z"2*S1AH<(O/@8$U1<9E0$3G5HTR_/84$K-["6C8W'BBHJ$:%CQ94
M5"MOXR33JA;;S1*8S*8C'JBQ4P*!W*R69A(Z(Q;6?#W?`>FZYL(7?D\)`\KS
M^"/10GE62V%`\G08L#X11I,(MDHO*WHJ$<*JOB[=N-(GW3+#_;)Y((-$B*:<
M.;.:ZJQ1K=S3BJ;CNTLD0C8=\4`BG!((B9#5$@,D0L#BS=[YJG</=Y('IT1!
M'N3A1X(E#[):BH(\F(R"-)B(HDD#6\>_)PW"NK].@[@74/+;MVLPTB"J3?6#
MJ%;U@XA-]8-L.C*SI,$I@9`&62T10!I$+/2#Q7S^<39O\IT\."4,\B"//Q(M
M>9#54ACDP708),)$&$TBV![">Q(A[#G4B1#W(>I^X)X/6D73,E]4/XAJ53\(
MV&0_R*8C4TLBG!((B9#5$@,D0@PD/(EVMIJM5K/F#$@BG!(&B9#''XF61,AJ
M*0P283H,$F$BC"81;#_A/8E@^NT50L#J*X15\\@4'2&J376$J%9UA(CQSW!.
M$5<(V;10:W=G2(2H-AH(B9#5$@,D0L1"1^!YQ,7'9O>)/#@E"O(@#S\2+'F0
MU5(4Y,%D%*3!1!15&O2S]VT4!?TZ#1)6W_-:-9>P5TFM&^\'6:WH!PF;Z`=)
MS;Z$,62+2X.L-AK(ME!+!.P2EJX/YBNFNSG0NZ0T'L9]5AL-8U^HI3`."1L+
MXR$IO1E&DPB$\8Y^P!K%]8.$-?V@63R1",&T?B*TI6E3J*4#O\Y8*$-^*WRY
M6K6O"]UD+1KB:!Z<$@=Y$-6&OD0>1(Q:&SRT?8E,R*:%6GND9,(I@9`)>;0T
M(63"*8&0"]E4!]+D`@VRRH7C_;NSOU!7X\N'?F:6;7L(6-,>VEMVV91(AREM
MYXJLB!ZJ]A"PR?:034<\W&8/HX&0%G&T8<^!M(B!A,L%GLD[;^^?D!.G1$%.
MY.%'@B4GLEJ1$Y-1D!`3430)85M&IU\L]+.XQ51L>2:L:0[-*IOF$$PGFT-6
M2\=-<XA87,7/^5G(]LL:](:H--4;\O@CTT\29+44!DE0A3'O%T31]$"RX)0P
MR((\_D@89$%62V'0&:HP6*B=+;IF#4,:3(31I(%M.)5I$+9JW_VQ]WX6=ZY(
MPESK_:JYM;1.:J/?G2J4TK'3),+X&":,['`8R>`PRM]AT.PP:'88K#H,"AT&
M7PZ#+X=!C\,^">Q18$\">ZZQAEO;5BJYG>KT81NJ7!CVLX#5'WMO::7$LUIB
M!\8<!F,.@S&'P9C#8,QA,.8P&',8C#D,QAP&8PZ#,8?!F,-@S&$PYC`8*[&&
M,=L!*AFS:OQSGRKJ9W$WJ6K8`:OO_ZZ:U2]L9K6"38?!IL-@TV&PZ3#8=!AL
M.@PV'0:;#H--A\&FPV#38;#I,-AT&&PZ##9+K&'3MG%*-J?J+VS[U/47L(:Q
MING#6%8K&',8C#D,QAP&8PZ#,8?!F,-@S&$PYC`8<QB,.0S&'`9C#H,QA\&8
MPV"LQ`)C/W[[]>7E^^;S]\\___3'R]<O+U<OO__^[</?7_]C/[=H&[,%_N'K
MRR]__>&2SGO!GW,['V6;(%N;#$<++3LSV?%BU]M]--GQ'.=EYR93_B[Y^J#%
M<GP:JK4S&5_]>4-&G/8A/'$,?%+-9#).]OQ,)N/D4U`F4W&N^?B0R8[++A?G
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M.(V'N<[=N?'`X[S*W]QXF&L>YL8#6P_>[K+K._*LUW;(.`8=2V^QA'?TW#'T
M%HL<$U><`W3.KTV&G8H3F?'.YH8_!F3&>Z_[4F^\\WZ(M#/>>5G0RRYY_)@X
M.VV'[!D%8;?N9L;[3//>&>^=SI?.YIIM815+9['T;]A9+)V.I;-8PB,NGB.+
M18YYN9SA3IXVUXB>>;73![E>$C]O`BH)F<+[7TI"GO`RDI*0";S.HB3D`:\Z
M*`E9P//X2D(.\*2WD*R0<.]02*R>=#G965Z?Y.T<KT_Q=H;7)W@[O^O3^T?8
MXUMY/K9+JUE>A?:2M56L+EBK5UVN5JVR6-=6C[H<K>)TP?4<CRRIM74]W?3F
M1*U;GG4\V?`N.^LCDCDD=&4U.YWU$)D[G740F3N=]0_EAU>?[`I2^K&:U"5I
M%:F98W;D:)?G5HW*#9&IP-9XE\[Q+5T?VY+R0`/$MRS0T*Y45-WQQ"`E=EI0
MHUWB1C8(ZXEJ),MEA5O-"OR27)'DDBDR4<@3F296WV)\OI\SN^#K!&H.D747
M?-E#'0>?7^@N^+B"DO%-A,[&5#(>B9TCXQE&WP*0+?#'8W%>QEW=!?ZDC'NM
M"QM3V6U8:%S+=<86R4Y*]D@.4K+I9ACQ1T2(S&:+.S4J>F38*=EZ1=)S[]];
M/=L%N+P>WIPQ4?)J>(MD)R5[)`<I>43R)"6;Y>KBP)L+/K8U:?,LLV9]SO'P
MD1-E0QG+YO_`D3[((_V$Y).4/")YDJN3Q[,.B9KK1Y8?3W+U\<CBXTGZN<//
MG93<([F7DCV2@XQM3VP'&=N>V`XRMCVQ':2?S6)U\:17;T2PEC972*ZD9(/D
M6DIND-Q(R2V26RG9(MG).=@R!SLY!UOF8"?G8,L<[*2?9ULZR57.AD7.M5SC
M;)'LI&2/Y"`ECTB>I.3*%MAR??U`;`\RMD](/DG)(Y(GN1)\G)\C4>?-1Y:!
M3W(5^,@B\$GZN<//G93<([F7DCV2@XQM3VP'&=N>V`XRMCVQ':2?#4OE)[U2
M)H*UM+E"<B4E&R374G*#Y$9*;I'<2LD6R4[.P98YV,DYV#('.SD'6^9@%_S\
MF!<ZWW[^Z=^?O[P</G_]\MN_OGWX_>47-B9G?['/]7W][8O=)@C_^1X_N/>W
MU^_?7_]@[_*'#[^^?/['RU=30/F7U]?OZ3^TXQ__^_KUG\?-SY__!P``__\#
M`%!+`P04``8`"````"$`A&;(ZH`F``"RV@``&0```'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6RLG=ER&TFRIN_';-Y!IOM#,;&#5JIC(I#[@L7.S%RS)%9)
M5I(H(UE=W6\_'LCP]`C_`Y&`K/JBJ?KR#P_/\%@]$\`O__WO;U_?_.OQ^>7+
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M`_3_;[Y],7V#FN3AW^_?3JCB+Y]>/[]_.UW<S)>WTX3D;WY[?'G-OAB3;]]\
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M`]Y1>(88T0CX)V)DS)@8<>O>,Y"@351`6,%%MAJD&F0:Y!H4&I0:5!K4&C0:
MM!IT&NPTV&MPT.#H`"\@-*_\$P$Q9FC<42W.J)G[(;CO13.:5$3D2S:#9`@3
MD!1(!B0'4@`I@51`:B`-D!9(!V0'9`_D`.3H$B]J-*-[40MO,'A&,^I3<+A1
M[WLR<\.5+%2X-H.(BVV!I$`R(#F0`D@)I`)2`VF`M$`Z(#L@>R`'($>7>+&@
MQ=*+1;_LW)@=3#PLIJ`?EI[,^_V<634V0+9`4B`9D!Q(`:0$4@&I@31`6B`=
MD!V0/9`#D*-+O!C0E.+%(-[P1NTWO"5.PP/9`DF!9$!R(`60$D@%I`;2`&F!
M=$!V0/9`#D".+O$:GG9Y7L,[G?_U\Y>/?]X_]>>50$"FM+?J=US&B!\/2];#
M`K\9B*P=R6+AKQ[;7C0E;X<%)EDL?5$ZB'A:RX#D0`H@)9`*2`VD`=("Z8#L
M@.R!'(`<>Y*<6M&+&FUNO:@%HD,'-PZ/4?OAZ<ET*>$9B-OR.CQ6)-NV%$@&
M)`=2]&1&QPHGS"L_S.4@XC!78*@>B&M(>=T,AAS14NTNVT'$M76#;2:[@3B&
M=!?>#X8<T5*MS(=!Q+:/UO8I(EZHZ:![1:B-V@]U3]Q0`]D"28%D0'(@A27T
MQXGK6L5U$/&]5V"H!M(,I1S3RZEONAU$;+H#0SL@^Z&4:UIUHL,@8M-'UY`7
M,9-?N")D)[D?,XO<H"':(DH198AR1`4CNBD)W?+6;]]25-P*%2.92FI$#2/?
MO#J4MZ)B\QTC,;]#M&<4-7\0%9L_,L)A9W(^7A!_:F$\65&Q[4_67FP!;6U!
M1Y4BRA#EB`I&WJJZ5/F.4E3<.A4C:?P:4<-H,2PF+:*.D=C:(=HS$EL'1$=&
M@:B94S*FD$Y[^<NW,^84K&911LZ&1I`S9/1RL+4J;TNS5LM!*B)N^TRL,\H1
M%1;-J`,YPU9MF$I1L:T*;=6"'%OZ?AJQY:B6:NUN1<4U=F*>T4Z08TO7N!=;
MCFJI5I6#J-@\/2GHPXC;)Y.,];I)?/]TDJM1W)_L)U[#K]1\N;$%)_XQ72TM
M6U&QZRFB#%&.J$!4(JH0U8*<5M:Q:$3%KK:(.D0[01'S>U&Q^0.BHX?\E=><
M\=WA/Q+7/B5`_82KNS>I=AKZ$PKO,*"F:INQL2(S#0TB/,L$52LU[:9<X>R4
MJ%[?SJ:SV53-#QF;HN/S^0IS5LDAN!#D%-0^E)?X4+&IJ`\UJZ)-T[#*LZ7=
M:MDM7Z4V[EW0ENZX.U9%_=JSRJ]1A>QPD5_'H"W'+[_C4HW7=%PC5Q-2CR;>
M(K^"GFM5(Q/2H.)QD9J'H&9<+$_==+*XG2W62[5_RUA$9YE8-P7K!1>4@5@R
MBE58L2A:8<VJZ$TWK)+#;<O(VU:NH`/:^XDZL6-;42?VK!(G#HRB3AQ9=<X)
MO[>9;)`[3?[<WM9849VP1_[LJ78C&_-,TI2+#L6MJ*0/6NO]5#F[G:WF:L'-
MN!2%)-8#!P_8=L$%9>XL+9J<KZ[B4M'J:E9%;[AA5?]:@<D=M^R!9Q[[G[T;
M3^5,-*<4W8[-1YW8LTJ<.%SDQ%$*AAO>[W\FK^7VOY%EVJ;!9':X-P^GJ0]-
M3V]SG&YP(RCL@7V(:PM*G%,N*"AC).9S1`4C*5@BJAB)K5I0Q-6&56*^1=0Q
M$O,[01'S>U:)^0.B(Z.3>3^(--5X0?RY2<1849-(C]366JTU&_-^@.D!T?ET
M:U7^!EQO-%)6]6M-DBQ6*WIU09TP,E91Q;&Y9?!+YA9[0YZKVHF2S4>=J%@5
M=:*VJGCC-$%;VJ^65='UIV-5U*_=17[M@[:T7P=61?TZLNJ<7WZ7)EO1+OT_
M3S^HKXX]%J1\/?3I'GGSU8`BW6EK;4VGPQ$E190QDDD@1U0P$ELEHHJ1V*H%
M15QM6"7F6T0=(S&_$Q0QOV>5F#\@.C+"^8I>&_2#&U]T3G)_8F(D,^;&(GH.
MSZ-]BRA%E"'*$16(2D05HAI1@ZA%U"':(=HC.B`Z>L@;:&9NCPZTBYXZGJRH
M$!G#A)PT':MHN)V?MK=6Y:7IDI4ZAZ>BXG!GB')$!:(2486H1M0@:A%UB':(
M]H@.B(X6]:WJ!Y+6-"^0(X/*R%7$>N0DNC=FM39+.VW58A&S*CDJI5Q04(8H
M1U18-/)`4E0<_0IMU8(BWC=BRU'!0TE1<8V=F&>T$^38T@>`O=AR5/!@4E1L
M_LCF,=MNSGG71+_/F;KIMI.%4ZBYN@VB+:(4488H1U0P\J<#M=<K1<5^58SD
M`4:-J&'DF8?GE*)B\QTC,;]#M&?DFU<)Y8.HV/R142"(U^5,Z3@,0[A'WA`&
MM+4%'56**$.4(RH8^<V@D@&EJ+@9*D;2RC6BAI%O7IU`6E&Q^8Z1F-\AVC.*
MFC^(BLT?&06"2(=_;R3^U&',O.NOI^<>.5';6)6#MHA21!FB'%'!B+(:,OO#
MTTI1<>M4C*3Q:T0-(WG"V"+J&(FM':(]([%U0'1D%(B:R=RX>9"?BYK-_\@>
M]-YD@?4V:$!.L^I%8FL+>ML@>%HI(F[[#"O,$146C3RM%!6;K]!6+2AR/XW8
M<E3PM%)47&,GYAGM!#FV=`ONQ9:C@J>5HF+S1S%/R-]DF9R5VTU&-EE]BLM;
M9GMD]G$RIN!I)27W3:\QZ[VH]`UN1<6NIX@R1#FB`E&)J$)4"XJXVHB*76T1
M=8AV@B+F]Z)B\P=$1P_Y<35YH2OB:N1J\]PCL[@/$8.GE1-;S@L^AC6DTDF7
MU-JBA<A\K"99+=;S9*T2_!E7&$U(YZR2TW0A2&XGT3Z4E_A0L:FH#S6KHDW3
ML,JSI=UJV2U?I1\6!6WI8.Q8%?5KSRJ_1OVT\B*_CD%;CE]^QZ6=RS4=U\A5
MQ^V1F?.&CIO`T\J)58U,2(.*AV'*!>W#0WJJOES/U3LJ&8NHXXL/SBV?'ACD
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MW"1BK*C8]DAMK56N8&.>Q%'!^`.YK57Y&W"]T4A9U:\ULU4R6]W>JDQUQJ)S
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M&(FM$E'%2&S5@B*N-JP2\RVBCI&8WPF*F-^S2LP?$!T9G<S[P=6)YSZX_&5`
M%W\A#STJLA.6>#N?JL7HWJKBWR[26R(-3Q5;*<8H190ARA$5B$I$%:(:48.H
M1=0AVB':(SH@.GK(#R2-91BED_D-3017?K?2U%A2:T^/_.\B6:O$Y\86=-^4
M0I0BRA#EB`I$):(*48VH0=0BZA#M$.T1'1`=/>1'CM80B!Q].=OXEY-,34D5
MJ1ZY7T]B50[:(DH198AR1`6B$E&%J$;4(&H1=8AVB/:(#HB.'O+"8MX4\L(2
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M2&IMF;=B')7:+F1<HZ=RFM4/[#]S"#$[3]T\>`BQJI',/:MDZYTBRA@%`OX/
M;;UGP:VWBN^]51EWAIBH*6<C&NZO6T0IH@Q1CJA`5"*J$-6(&D0MH@[1#M$>
MT0'1T4-^WS2[8W?R'5EP^LVT^_+.K$=FRI?@3&6N/\TP&U%)>(:"C%)498AR
M1`6B$E&%J$;4(&H1=8AVB/:(#HB.'O+#\]/[ZQGNKRUR-M,;1%M$*:(,48ZH
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MJ$'4(NH0[1#M$1T0'3WD!U)O>$=&_K"OY5:^G_?(VR=-]`<'-J+B@EM$*:(,
M48ZH0%0BJA#5B!I$+:(.T0[1'M$!T=%#?GCT-M9YSC,2*=S1SGM$BQK'8(-H
MBRA%E"'*$16(2D05HAI1@ZA%U"':(=HC.B`Z>L@/B]Z^CL0"]ZQSB]Q8`-JB
M*D64(<H1%8A*1!6B&E&#J$74><AKOX7>9SK=^O+O"SQ9\1=$1O+JPT:0+#&X
M^EF5>2@W[`<G^H.AJ:AX!&6(<D0%HA)1A:A&U"!J$746!3X\O*`5WMMV_%SC
M&RNJ\2UR&W]`TJR!QN]5E%LV&<?);:*VO.G)Y?=O22#M/EAFE%N5\RGT0@I:
MR[)W/VTM2A&PF0K-U(@:*6@MJQ-&*P*VW'EF_`%QW=EA@6<'B_RD\*WL//MT
M!:NH_-#-`_'HS8^\BV)MF?<6!EL3_9G;C&NDM6=0)<YK#2>_<E9)&KH0Y!94
MK5RRJD]6KZ:+9#F7D\+)>,4:SP4GJ7E2U:P2%QI!$1=:5G&^/%G2;V7YW^#;
ML>:<"WYGT*>QTV.3A?GIJS=7S(YX2%N$#FGZZ^0V5C5R2&.5O`2>6C228I:"
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M@@MZ&VT]N9=<T/QFS+]^59O&BFUXE>L^5K,-=SZ]I`5:+ABLO!NKW.\`)G5Q
M>29[8>2J`_3(&]()'E]L0?HCX=`MLF7S=$(4E6[[U*K4WE&=/#.VY7:30`<8
M_)(.8%'4B=*:MU/-F>.+M>2YH&^Z9D?=H7^)"ZWOPF(9/+Z,N.!UAF4HN6/>
MZ;O\['(RX7<0B_R=EP[JQJI&9@BV)1^@3AD9-_GG2V&'D[$J.B)S<6+H#5Q0
M!FG)*C>L>';A@EZ->F-7LRTQWW!!02VK_!K52M-QP7,U^K$V69C+!_[2)FW$
MJ7N+W(V2("<6NL-O624+6XHH8R2;FQQ1P4ALE8@J1F*K1M0P$ELMHHX1;I26
M)OGB-NE/G?Y/5M0(ZK,ZWA2+9Q<NZ`T$;/S>EI\CT*,QM;9&IEBNT>V6.,6R
M2N:W@I%?4!T;2JN*9R6JH"U]VS6KQ(F&4=2)]B(GNJ`MQPE_Z(6R1/85]=-,
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MLC%($66,9$;+$16,Q%:)J&(DMFI$#2.QU2+J&`5FQV!FY]IDZQ+3/!;Y4R5\
M6Y55C4V5O7EOJK0H.E5:S;FIY+3NY>("#Y:"?9>IJV3$4U<HS<.::'TUUM=P
M0:FO9<3U!:?*D?OSQPYY%9TJ+]QQ&#-J:]HC;TP-*#RJ[8[#JF1E3Y>`,D8R
M#G)$!2.Q52*J&(FM&E'#2&RUB#I&@3%%ZX'7U"/3E)&K)NV1^4#'L&.;K/0+
MF4M;D/X,*GQ,Q*IH+B.U*G^W#QDUMN7Z%=CM#W[)B+(HZD0I3H0R:L'*]7)8
ML\I=G"ZIO(U6WK%9[\Z=RKVQM@HE4<RO35WYP>&3G5//D`#/9RK3>&]5T1<L
M1<,AV2)*$66(<D0%HA)1A:A&U"!J$76(=HCVB`Z(CA[R`WE=AF2%&1*+_!<L
M]6\D;$0EX>EM44%&*:HR1#FB`E&)J$)4(VH0M8@Z1#M$>T0'1$</^>$)95LN
M^J#WRJ9`I'7O+7)?L$2T190BRA#EB`I$):(*48VH0=0BZA#M$.T1'1`=/>2'
M12<WXNO?"I,8C&17NT&T190BRA#EB`I$):(*48VH0=0BZCSDMU\H8W'UJ7:%
MZ0M&LC9N!,D2@WL(JQIYP5)4/&5EB')$!:(2486H1M0@:A%U%@5>L%S1,NUM
MWDRZZ/K&-U;\/=W),"&W\:TJOH&S!<^_8"D":??!,J-<ZH]$NA!;9]ZY%`%;
MKL0RHUI0I+)&;)UY#5,$;+D3RX3\87-==F"%V0&+U)E5/6/9L(J6D,BVFU7.
M8RI&7KAU4BEC%9V$SIO/615UHA`5MU_)J#]83I+Y(DG4P:)B3=2%FE51%QI1
ML0LMHX@+'6O.N>!'WAR$W:<N(PM.?VYV/R^\ZI'*]ZGW1C96Y3\X<0X!_;&6
M59(+2RT:R?=)P6CDK??>44H[4;`M64%+=J+_<N7IFC[:!H&WMFGV.-_W:K$=
M436BDL#WYNT#\Y`''9<ZYX$?=Y,MN"+N1JXFY1ZI$:\_@[>RJFA/W[+*'?&V
MX,B(MRKZ<[[5<S8?=:(0%;=ZR:@?;K/I='$[53V[8DW4A9I541<:4;$++:.(
M"QUKSKG@1]X<Z:^(O)&KR/=(C7CUX<7-RA:,#K8MJ]P1WQ<<&_'6_+G>WF<H
MV7S4B4)4W.RE17:\S=>WZ_6M6LTJ+A9UH695U(5&5.Q">X$+'1<[YX(7^;7.
MK<3G^I/<C[Q%_IA?JZS*AE71OKYEE3/F&5%H933#*L^J<[V]CSRKHDX4HN)F
M+QGU`XY>@9PMU*16L23J0<VJJ`>-J-B#EM%Y#SJ6G//`CSMUO2M&_-K(5=Q[
MY(_XM7KC8,,%HSU]RRIGQ%LT,N*EH-,[].J=LRKJ1"$J;O62G;!K_'2=K/4=
M5ESLW'`[=;V:55$7&E&Q"^T%+G1<[)P+?N2I[UT3>2-7D>^1&O'JK=G-VJKH
MCPQ<'9JMJ/B.4T9]5T^FR6J]UA\BREATKK/;`7^)#X788A]*1M%9IV)5U(F:
M5=&&:%@E4U_+*.I$QZIS3OC!U[FD2]_>6&-6R2(U`:B71C=<,-KQMZQR)X"^
MQK$)P/IUKNO;?F!542<*=L+9Y%MDE_QD=;O4CXTJ+A7UH&95U(-&5-P3VW$/
M.BYUS@._!^ALV,B"CVFO=8_4\%=GGPVKHKU^*RJ^X911/_PGTV2Z7JK=1,::
M<WW>1MTZ&G6A8%N2NRX9]2Y,)S/R0$UO%6NB+M2LBKK0B(I;H65D6V&UFL\2
M=<KH6'/.!3_NU#N\:=^,?'K(_&8D_J88?3#+F<3)$_\#(/?K7A1]9"8:OL<M
MHA11ABA'5"`J$56(:D0-HA91AVB':(_H@.CH(3]L.@O7YT^O?O:Y'M)SLAK/
M9ZI3WUM5/)"])=)((`&E8HE5&:(<48&H1%0AJA$UB%I$':(=HCVB`Z*CA_Q`
MFF3-Y4?LM4T=R:QT;Y'_[/,6YMV^H/.@<RL%.18IH@Q1CJA`5"*J$-6(&D0M
MH@[1#M$>T0'1T4-^>&@2]<+C/*<8F2%-2;5![I'[[',-:(LH190ARA$5B$I$
M%:(:48.H1=0AVB':(SH@.GK(#XO)Z%PQ:HQ<Q<(BV=1MUH"VB%)$&:(<48&H
M1%0AJA$UB%I$G8>\]DMN=7['Z=>7?P:I-^,W[,"<)W`.DV4&GW^RS'\`JG]`
M+'5D/'%E`98'6!%@98!5`58'6!-@;8!US`*/0I-;VOQ[G?DG8V',Z%A8YL5B
M8/%8]#+S9>;#.7VB\YH4BT'FQ&*H@1G%`AC%8BCK5J&VLQ2>0<;F*#Q@CL(#
MC,(SE'6K4$DZBM@@XRHH8JXY-7IHW^M%++X4)+=&KT/3,_^X=*LSXUS4_Z0N
MI$L<&=\`A::O@;X6P3SWG2<W*BE-@\;Z0(N0Q#A1IRJ*G97)IH-B!XP"Y568
M+&_4H9_"=DF%%$DP3I$<BO(=4M@LHXE[\!\^D4B1'(HZ,J<-57!-4N#RM26Y
MM4D$:9U[9GX.)%'GHPW+1IYT.C*^=0IN7RN]27IZJ#^[47V:@FO]<H__DT!P
MK4P60@HN,`JN5V&RNIFNO?_Y9S\*]2754ZBA*@HU,`JU7_U<=V:*\DB%*LK7
MY3N26TQX,/.'<*(.3Q3E2_(-6T?F1+DO:H=P,@U$V1H?&\*##VR<HCP49491
MMBPZHBBX0]'PB.J3VX-,A@8%=RC*M5)P+ZF5(CP4#=>J(JPS&V.3=)^M<-]7
M2&Y[IL:QFM8HPK8HK1@R#SD3S*DY*,*#C&^=QG'/[#C&&=H6H3^#Y=`@!LL4
M7F`4WI[9VE8W"V\(Z]].H3A;&_3G?/4TB*$JBC,PBG//;/7)K>[.%&);BOX$
M*U0AUEF0L1`/V0X.`$W5/5.#6!^?!QDM)8-CH1VLM28]GD+<,SN()S>36^]_
M:KZ@B=O:&!O24!7%'!C%W*M^<:._^HT%WA=X0!^C((-M"C(P"K)7'^T"U(:.
M@FQ+G;M!%>3K,B3TC1B!S5;/U#A6+4'CV!8=&\>#C+L1!;EGW+5O5`>BJ-I"
MYWIVGYL>9-YR#/515+WZ9JL;M7.DL7M)A116,$YA!49A]2J<J_NCH(Y4IX)*
ML?<V6>;,,YYVI@_/GH+KCL+Y3,W'-*9[531?Z8@XBC1##P69462!43"!T2X9
M&(U'8!0Y8!0K8!088!088!088!0,8+L`VP?8(<"./E.1-%D3=[O<GUZOSD0G
MMS;]XL=6S8X4VUXV$MM!Q'&DV`*CV`*CV`*CV`*CV`*CV`*CV`*CV`*CV`*C
MV`*CV`*CV`*CV`*CV`*CV+K,CVVBLT0CZ^M)K\ZYEOGIZ41M=#:)R"1BR-*`
M+@NP/,"*`"L#K`JP.L":`&L#K`NP78#M`^P08$>?J8B9I`6.Q@M^E#$QIU"=
MI+#,S5BSSF';`*-(]?8<'44*&$4*&$4*&$4*&$4*&$4*&$4*&$4*&$4*&$4*
M&$4*V"'`*%*N3D7*)"7<2(V-+:/78\LRV2S00`)&X0%&X0%&X0%&X0%&X0%&
MX0%&X7&9NGUS6A]NG^:9GTMZ)O;0+_OM^X29F_04%MV^6YF?@-8/V*GM^EI)
MQI,5M1TP:CM@U';`J.V`4=OU+)0P3LPY^!]HN_XX34'BNZ"VL\QKNX'%VZZ7
MC26,;0WN]Y0':J6V&VIE[ZCM@E6H\P4UYR#CHM2<KCG5%<V9TVW.L9%HSZA>
MN_5,G2+5YH4&IY71N(B=(D7&-T!]KB_*V=PIGC"X%.W]!N,33/BQ3-RGAK5^
MR5MFU(J6T?9@,`?)56K8H:@C<W(?JJW-T>^:MNZ/BGX?M0=,BNC@V"11^4]J
M:UN4IN!!%CBQB\QIZ[XH'^8F.I%-H]T:IYL?C(?:>O"!C5-;`Z.V]BJ<S75P
MJ9E'*E3-;`YCUS2S/;Q)GZ"IH&>J2T,.FV5C7=I:DQJH2_>,LYN4&?&3R-3,
MMM18EP;CU,S`J)G]"E67H48>J4XULCED7=/(_:',[\L]&TM,)+;H6%\>9-S=
MJ)%[9ONRFBNIA6V1L8X,EJF%@5$+>[5-5CJDU,8C%:HV-H>3:]JX/\SX;=PS
MOR/CDS9::<T&:^Q)F\B<-NZ+VHZ\T*.76MG:IGN/3A>#"VR;6GDHRHQ:V3+Z
M,Y@+3<U#44=V=FJ>>(<]^H^19?"D5QM2RU1W5KFB#?WVPZFIS>Y8_'<<L_ER
MD?&MIUS4=N?9S=S/8*MS9<9ZLTH-504F:JRJ&(K*[KID9JM?Z4A7+#A;7]^]
MW[U\?GQ\W3Z\/OSZR[?'YS\>-X]?O[Z\^?CTUW?RTCS*<OB;Y\??W[_]0`?U
MNP_&/C7&4*:_=F^N'<U)/G0MN:5K=)8.7DO,M=,=:IOK^9UY`1%+?5@OR!'*
M]^$E>E.0"IVVQ6!N25?"959TY;3ST&4H[V1N*W3MPYR<H*^+"?A`5\RON86N
MD`_T0V*A*U01_9857OFPNKW[0&_4XA7Z1I@[\Z4FH2O4JO1]&J$K$[IR6@/5
MO7Z8+N\^]"]/JBOW=.4X#7H]):^G(:_OI]0?Z/N$T8,/,ZJ'?NT0K]!/+=^9
M7PL.7:%ZZ(=J0U>H'OJM5+SR(;G[$+K/>]/A`OI[:IB0_L/T[D-_SH)FH3L,
M&9J11R%.W3ETVY08O+VC3%LHD'0MN:,L8<AA2@`F=Y3Q"UVC9%YB;(:NT6E\
M2N7H>(>-1M=F5!^=5?`:K00S4RYT;;L@-^F7DP*EZ(KY`2>\0K_.=&=^@`FO
M;%>S._-M#J$K\[N4OAH`K]`W&MR5P2OT]0-D+53F.#$Q#UW93A9WZ20TA`NZ
M4@:O-'2E#5[9TY5#\,IV0:&G7P'#^^G(MR[HVXZN[()7]G3E0-L'M+:?3.E*
M*.+[R8RNA-IZ/YG3E5#K5%1/%;Q2TY4Z>*6A*VW0MX9\:X.^->1;&_2M(=_:
M8#W;24)>AWK5/7EP'RRSH2N;X)4M74F#5S*ZD@6OY'0E#UXIZ$H9;(."VJ`,
MMD%!;5`&VZ"@-BB#]1S-HA5J@FU"M]-O3=5D1IL-&MNAKM/0E39X94]7#L$K
MFPFM3,&-0K>ZHR1GH(?N5G>4Z0Q<V*_N#J&9?[^^.X3F?7KN0%Z%AA1E3>E*
MJ(YJ=4?G@D#E]>J.\KF!"\V*YI007]^U(:]H0C;S<:@$>46YX,"5[?+N$%P-
M5W=T.`X4V*SN*.L0N+!=F4D]<"%;W='9('`A7]U1!BQPH5C1-!OBZ[LR=..T
M2IE%*E2";IR6$W/EW=`;7W[]Y<?#'X_MP_,?7[Z_O/GZ^#MM1V]/3P^>O_QA
M4K3]?[P^_:!MZMLWOSV]OCY]._WS\^/#I\=G(Z"M]N]/3Z_\'Z:"OY^>_SQM
M>7_]_P(```#__P,`4$L#!!0`!@`(````(0!`BA_*^08``.P<```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;*Q9VXZC1A!]CY1_0+RO<7,QMF5[-<9T
MLE(B1=$F>68PMM$88P$SL_OWJ:*[H2\$,ZN\+#N'4\=57=75!6P^?RNNUEM6
MU7EYV]ID-K>M[):6Q_QVWMI_?:6?EK95-\GMF%S+6[:UOV>U_7GW\T^;][)Z
MJ2]9UEB@<*NW]J5I[FO'J=-+5B3UK+QG-[AS*JLB:>#/ZNS4]RI+CJU1<77<
M^7SA%$E^LYG"NIJB49Y.>9H=RO2UR&X-$ZFR:]*`__4EO]="K4BGR!5)]?)Z
M_Y26Q1TDGO-KWGQO16VK2-=?SK>R2IZO$/<WXB>IT&[_,.2+/*W*NCPU,Y!S
MF*-FS"MGY8#2;G/,(0)<=JO*3EO[B:RIN[2=W:9=H+_S[+V6_F_5E_+]ERH_
M_I;?,EAMR!-FX+DL7Y#ZY8@0&#N&-6TS\$=E';-3\GIM_BS??\WR\Z6!=`<0
M$0:V/GX_9'4**PHR,S=`I;2\@@/PKU7D6!JP(LFW]OJ>'YO+UO86LR"<>P3H
MUG-6-S1'2=M*7^NF+/YA),*EF(C+1>`Z(#)BZ'%#OS/T9^XR(,$"?WW$$.ZV
M;L.5_Z+KS7PW")>MWR.6"VX)5V[I]_&:=@Y;KW;Y#TF3[#95^6Y!3<.*U/<$
M=PA9@Y98=Z;09>*_$@$90)$G5-G:L!EAC6NHGK==$/@;YPTRGG+.WN00E1$)
M!J8790\Z$.L`E0`'(NK"@A3^#V&A"H8E'-H+H(_3U6(0#&%RT(%8!Z@$*#%`
M5>DQ>+"QAK>$R`0:0?%+F?"]N>KCGG%\2'>?+I42=90N#@.)#83*B!(*;`P]
M%-S='ZPR5($ZA?7J_0X"U?,](XT&UU&ZX`PD-A`J(TIP$(@<W'A^D-S&('Y[
MSQ!?CLKWM*BBCB3,#@82&PB5$<5E2+WL,MOULQ#XX]ZCG>H]0P+62''31@9R
M,)#80*B,**Z&JJOC_B%9]8\CDG\&<C"0V$"HC"C^X00B-=!Q_Y"L^L<0%_I8
M5].^MU!K.F(D3RX1LM!(!Z[D=MTJ9DBP;!LRF2_FH;]:J=*46\&E^WU96@EU
MI88J54USR=.7?0D2$,C`$GC@`CLI4$-=`89XL+TZ#WPO5-V,N!E<.I+L)CLN
M.*G/=<P0'_I29^9[2U6;<C,H_HY$ECU)60("#7AZNENV&BV'H)&+G1SUD.2`
MD5[!DJ(S(2H@-FW))R+!HW)RH;9LS7-VUFJEJM53Q`T?U"IGN5*Q"BCDU3H/
MO96GJ5-!FE2N>%#($?]0O;8BVD*@+IRQXQ4K#,=+5K#DK#)YM6A][0RGPG!:
MU>+!/#WW[!B'7Q`ENB<,4JJV@T:KEK/D^`R(*O+J?L-35_+\QW+(CFXE(`:I
MQ>P;`REC/2IFKM6O5TP8Q%OORO<#$AH9Y&;3:AF/\I%U^%K>H4@'>R\\@HCF
MBS.7UGTYI&26L7#6[!NBV8\XR^NJ)!9:/40%--"/\,0W(OKP3$C8X(#;H7,V
M"+2S<<]9HU-ASQ%E?S"AV(2H`JG5BU.#%J,;S&#E/CCY$CY^]"6VYY`Z-_KZ
MXTC/ZH-B6F`HH-AD4052@\*100N*!!.&1X*&6BMED#P^<I8$'4PH-B&J0*K'
M>,)+'@\,*/(FX?-`OSY[PJ&^BT4F=#"AV(2H`BENNA^:+5JVNIH<<A?M$>K.
MB?8('G'"@WXF9.0M199:;XP%BY_7,%:%>O51P9G4XK`73\]2R];"YP,*#IMO
M.PA??X@2-N-'LF#UR8XYY/IL-EGX9#77Q*DP@\W=-2)Y1%53C6?\Y(J$,4G?
M.!SJ4ZUUO(@3'J6:*<MSF%#F>5TN%O`239N8!6=:7O&\GQXKFP[DL]IE$%QX
M7O6'`T[`G36X].SI0+#DO')EEE>7$(^0?O!OS:@PFY97/-.GQ\HF`"56/A1T
M6UAS)X(:;(=/97,:AS-G*7GERBROKK<,O%#K#U283<LK#@!2K#\TFN'[4>U,
MX)`Z7ON>6H*1,'R0<R[/7AGCZXF8&^*E+Y:E=FY2(:^PI&56=[,VRHR?+[!G
MC9`9)`]AG/5@"!,LN::Y5@]1P3*','=@0.%G^?1'^E9$:\5LQ@A6W8P1<=:C
MAL0,L<%(V='Z3\RUX((=87B\%IQIM0RLL5J>-E[#!Q(CLPQ2,MM!4HA2:?%N
MQ5G]+!US>:^'\)-,VPVDS+)/+.P=?Y%5YRS*KM?:2LM7_'P"O6:WZ6#Q;6>Q
M?@(E&`>U.S`WKW&\';H3PIUP\,X2[@RIP3>DIW:H,GX%#(:47/CF-(1[:WC3
M;/KTY*^?X'G#O+'WU_#V=@`/UO"*=`"'J-N@G<Y3^-9T3\[9[TEUSF^U=<U.
ML)CS=NBMV-<J]D?#G\.>RP:^,L%ZPR<5^*J80>>9X]Q_*LM&_`$_['3?*7?_
M`@``__\#`%!+`P04``8`"````"$``&^_]8,'``"8'P``&0```'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6RL6=N.VS80?2_0?S#\'EM7W[#>(+9U10L41=H^
M:VUY+<2V#$F;3?Z^0Y%#BAS+N][V)8K/GAER#@^ID?3P^<?I./B>5W51GI=#
M>V0-!_EY6^Z*\_-R^-?7\--L.*B;[+S+CN4Y7PY_YO7P\^.OOSR\EM6W^I#G
MS0`RG.OE\-`TE\5X7&\/^2FK1^4E/\-?]F5URAKX63V/ZTN59[LVZ'0<.Y8U
M&9^RXCSD&1;5>W*4^WVQS3?E]N64GQN>I,J/60/SKP_%I<9LI^U[TIVRZMO+
MY=.V/%T@Q5-Q+)J?;=+AX+1=),_GLLJ>CE#W#]O+MIB[_4'2GXIM5=;EOAE!
MNC&?**UY/IZ/(=/CPZZ`"ICL@RK?+X=?[$7JV,/QXT,KT-]%_EIW_C^H#^5K
M5!6[WXIS#FK#.K$5>"K+;XR:[!@$P6,2';8K\$<UV.7[[.78_%F^QGGQ?&A@
MN7VHB!6VV/W<Y/46%(4T(\=GF;;E$28`_PY.!;,&*)+]:*^OQ:XY+(?N9.1/
M+=<&^N`IKYNP8"F'@^U+W92G?SBIK4@F<402N(HDSO3=P:X(]F2P/9KYOC>9
M3=\_`V"V9<!5S&`^<F:^[4_N*&,BDL`5RWAW%;"?V@G`5<1^H(JY2`+7CU=A
M@X?XDC(S\>6"A;F]E&-NB]9EFZS)'A^J\G4`6Q<6OKYD[""P%RPS^HN[03JN
MSW#@-);E"TNS'((XX*4:=LGW1]_S'L;?P=E;P5E1CJTSULA@-F9I-R80F$!H
M`I$)Q":0F$#:`<8@B]0&5/T_M&%IF#98U0H!)99C"($,#-F80&`"H0E$)A";
M0&(":0?0A(`M3(1PP2S7#R'T!(N"XZ;C"6<^TPM=<8X'.U(91Z>L)46*09"`
M("%!(H+$!$D(DG8131,XSH@F[&"^<^.P-+#W0'DE@.?K$JPXZ:9*DB)5(DA`
MD)`@$4%B@B0$2;N(IA((HJETVS&,W8J!1:PXXG7E<2U+EV<M21BV(4A`D)`@
M$4%B@B0$2;N(5CN86JN='ZTC=M>[+0,+U&7@B,_ORNQD7!-D0Y"`("%!(H+$
M!$D(DG81K69H"[2:;Q?*V'JA`ND42I`-00*"A`2)"!(3)"%(VD6T0EE_3>^;
M[>(VAV+[;57RKNJ*`"[<'_E=DR71ZQ?(7-XLUA)1!X0]F>@[8,-)+BR+/$4<
M>ZJ3`DG";1(2)")(3)"$("E'[';6FDK0Z/QWE5@2726!=%22B!*`JL1)GMWV
M)XYENX9`\N]2()D6D8@@L8QB70]D->[EB?P[YDB[.32Y6`.FZ77%/=#OHGU:
MNJZ,@!QH:903'-)GL7&60Z=[K%*Y,)?&FAFY`F1-N:KN=.[X1N<7(@=\(F=%
MQHN0Y4CSQPKJ!)I32)`EIF!9[M0R=DB*G+XIZ.O`.L+N[GYC'7@#"3=Q7.*5
MS2$7;HRR8L<Q#+<6+':1+*++1K$P?2`@QVM%M[WIU+.-BD,,@]M-?_((6>K$
MC2F4&..YCFN9JY!B6-]XNL)@JGL49G3#Z1PRG&XX;\T:JW<X7;*4P@+BGO+G
M\XEOM!TAYNZS5'O&1\A2YH@IE"#4/UR*E+[A='U9WWJ'@WF;"T.@`"N;0YJ#
M7<O8_6O!8FO?;[*-8F'Z0$#H8!ML/['G^H$<8ER?I83"8O)="Q,HT0><36'/
MS(T53=\:3Y>8-;UW2,Q[9$UB#FD6=BWC_K&V!0L,>4MBR5(2"TAXRG8G1KTA
MINZSE-"7I(XQ4/DE0:AWM!09?:/IZL*::^IVNN?W-UCL@<P\-SBD^=IQC.?2
M-0:^X6N17CDO$('"U]YL[DZG1'81!I?^%8W4%'!%8PHEYG@S^\J][XWQ=.%9
M;W^'K?FC@&9K#L$+`ISXVI;0C8HWR.K**0(5%")+I8\H%".D`A,*I0CQ=[#=
M=S\VZ_SOD$$\**@-L6HS0),%%<A5=BW2`O!`]XW=S5G0L*&D`:;G^\VQ_,G,
MFI`#5,3U;3FQP>4<,'N,V=6`"4)\0'LZL:;.W"@G15+?@+K5@*5I_+$]SK(8
MO0&'M#WN6J0W$('0CLL%NM)]"98R4F!SR(.;C`QT+>.E32A8;(-*ECTS#IH(
M6>I9)D9(C9A<']'H^%(,[!M1%Y\]A=QA</'0H@RQ@N<])KRVSR74J9D\K6*@
M*C"@4(A0=Y_+],JH`E*Y$@Q44(H0W>>.^<CU(0^V670/"DC?_L;JKP7IC=V/
MJ;0SPNR_`V2)&[#E^HYK]!(A<L#`RI/F^D1J5E)F#+PYA019?`JN,X$>RS0I
M<OJFH)F4M4::2<W5^5I>0/:W7JBU:8SE89EU\PH6>['=+\X&6:XZBBD4(M0Q
M+X5BA%2NA$+L\Z*:*I>'?R[D'W).>?6<K_/CL1YLRQ?V*1"Z\<<'"?/OE*O)
M`M[:P7H:^&:V@!<Z5_#Y(FC/)(,?SQ?P1H/RX3OHE_9L,/@K^#[:;D03=^"[
MZ94\*W<![]ROY/<@_]5$W@)>/].`E;^`5[.`C^7(\%WTDCWGOV?5<W&N!\=\
M#V)9[3N[BG]9Y3\:8:JGLH$OHJV_#O`%/(?WKM8(#M=]63;X@PT@OZD__@L`
M`/__`P!02P,$%``&``@````A`-'#-6U\$```3E0``!D```!X;"]W;W)K<VAE
M971S+W-H965T,C,N>&ULK)S;<MLX$H;OMVK?P>7[D451YTHR%8E'D=2I9G>O
M%5M)5&-;+DN9S+S]-D@T0?1/P?+LSL7(^=#X`:)Q:D#BAU__?'J\^6/_>CH<
MGS_>>IWN[<W^^?[X<'C^]O'V7[]%OXQO;T[GW?/#[O'XO/]X^]?^=/OKIW_^
MX\//X^OOI^_[_?F&%)Y/'V^_G\\OT[N[T_WW_=/NU#F^[)\IY>OQ]6EWIG^^
M?KL[O;SN=P]EIJ?'NUZW.[Q[VAV>;RN%Z>LU&L>O7P_W^^!X_^-I_WRN1%[W
MC[LSU?_T_?!R8K6G^VODGG:OO_]X^>7^^/1"$E\.CX?S7Z7H[<W3_33]]GQ\
MW7UYI.?^T^OO[EF[_`?(/QWN7X^GX]=SA^3NJHKB,T_N)G>D].G#PX&>0#7[
MS>O^Z\?;S]YTV_=O[SY]*!OHWX?]SU/C[YO3]^//^/7PD!^>]]3:Y"?E@2_'
MX^_*-'U0B#+?0>ZH],#Z]>9A_W7WX_&\/?Y,]H=OW\_D[@$]D7JPZ<-?P?YT
M3RU*,IW>0"G='Q^I`O3_FZ>#ZAK4(KL_R\^?AX?S]X^W_K`S&'5]C\QOONQ/
MY^B@)&]O[G^<SL>G_U1&GI:J1'I:A#Y;1!P9?9V1/G7&7L?K=X>J;$>VOLY&
MGSJ;YW?&@T%_.!ZY<U)J^;CTR3F[UY0XU/GH4^<;=49>=^*_4=Y(YZ//]SP@
MC<ZRFO3YKN(F.A]]UOFN:A>/.E[5#\C3[ZFIQ[Y7?]09KVD:CYVO_M`YE8C#
M[QX[7O7PNK`K.HS'_E-_U!FOJB5[T#,N'%_E>H^=J/ZHR[Q<V;MJ9)8#/=B=
M=Y\^O!Y_WM#L21XYO>S47.Q-E18/\:JAZD%_:<S38%<JGY7,QUO*3\/Y1!/5
M'Y]HO'RX^X,FEWMM,T,;S[:8LX6:291L($$H021!+$$B02K!0H),@ER"0H*E
M!"L)UA)L)-@VP!VYI_81]=O_AX^4C/(1M^Z,@7%:3SB$+3A+($$H021!+$$B
M02K!0H),@ER"0H*E!"L)UA)L)-@V@.40FE/`(3Y-<NWK(H\1E8M6P,88\7NB
MP6>539\F$C.0A$]JD]HI0$(@$9`82`(D!;(`D@')@11`ED!60-9`-D"V36+Y
MB&9S\)&:V=\YL2D9FANI)QB']$>V2V:5D=-KM4GM-2`AD`A(#"0!D@)9`,F`
MY$`*($L@*R!K(!L@VR:QO$8.LKSF'E'*NG0.-^JL(OVFNWQ?#+)Y;<39`B`A
MD`A(#"0!D@)9`,F`Y$`*($L@*R!K(!L@VR:Q?$&3D.6+:FO049M2MUM41MLM
M%1E4&WNULL^!!$!"(!&0&$@")`6R`)(!R8$40)9`5D#60#9`MDUB^8#VA98/
MW`VOK.V&UZ31\$`"("&0"$@,)`&2`ED`R8#D0`H@RR:Q&HRVH%:#-3KM^?OA
M_O?9L0HX6QK2IWUKM9M5(G8[:C*I-T_SFIB%P1N*+6]0&?GDWGKUZ(W$=!36
M1CP=14!B(`F0%,@"2`8D!U(`65;$*Y_>:FT*!?_WUE8B=FMKTFCMFIB&Q-:N
MC/I>&7_TNIYO+]-AG5XW="W+)*Z)HZ"D%E*!#A4D/)K6Z2R[J&699#5Q%)37
M0KH@$3`5=3K++FM9(I:K5!!N^:IE!-#)"`^!TMSVBD8]"E/JWCSNVVT\9Z/F
M"HR>:K4:BZ<+V6I4!93=D=<7+1VQ"?70NDY07,Q6SDHEK5:R4BE;597JC[QQ
M=V*WP8)-G)7*V,I9J;S52E:J8*NJ4E[7&T_\@5VK)=M<JI7=6U0LBN<"Y>)_
M_3SJ51$M[9ZY?\XT\FD'6#ML+*HZYWS-G@9>#8P5JX<:]?IEC_$'@VZO:S=#
MQ+EH%U-7`+1CMG+6(#%67(-4U&`X'(S%HK#@7,X:9&SEK$%NK+@&A5T#S^^-
M!UTQ2I><[5(5[+Y`/=3J"V_,',I<S!P5HA"9:SE7$159J:CYLAL"MC+[EQ!1
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MZXV%L8KR:;[G5IZI&R-RH3BO$I/0W%AQQ@!1B"A"%"-*$*6(%H@R1#FB`M$2
MT0K1&M$&T=9"MGO4(4'3/8WE\PU/Z>.%IJ<JU#S"4I=VY+P&"A"%B")$,:($
M48IH@2A#E",J$"T1K1"M$6T0;2UDNX56+<LM;_A"F8OMBT9F7S575Y?*RJ``
M48@H0A0C2BQD/XT*N"]TLG<$2CIL;W:X9B1?KI%S.H`I'Y(^7!NRRNJ-0R>M
M158\IT2(8D2)A:RFZ,D3AL9XN[XI2A7;WXP:YT$&N9I"6]&'/C\16]SP*ID(
M9,36-;Y*)@$9<]YAMR/MQ:PNY1X@:A<O!HA&8G\OXM`Y6UG[43C"U%8#=3KZ
MQR<138=7:41.C?@JC>22AMUT]"SO:3IE+OI:A:SS"=\7%W[SGL[H#,X#;36@
MW6X]7GU?;-#"J[0BUE(G=.2&SL!TGBHPNDHFD3*-*,QN2!EZOM$'J]BMN;7I
MZ7"NV42^C&3F;$7M63<1G,8$VFK0/$?W^]`7=8E.K8BU]%%9QQN'O\!XOD8I
MD4K^H*ED-Z<*>)JKQ!O-6<5'5G/JD,GJ2WW1">9T\*6706=S5E9VOY1'J^%5
M6I&V<FO%5VDE;VG932JCJ#>:M`Z6>+V;J>\!TNA7$TO=]_R^6"+F;.7L58&V
M$CU4'+N%5VE%K%7UT`%]8;+9K_1HUW5WUBH!I7&W^5^OJ6LWKHQLJJ7\W2%J
MKPYY3!,/^N(X8Z:MG"&JL6'_!8A"1!&B&%&"*$6T0)0ARA$5B):(5HC6B#:(
MMA:R'2ECH#=&"08^=&2G1HD=HLK59VZLC'OJC(Q"M(H0Q8@21"FB!:(,48ZH
M0+1$M$*T1K1!M+60[1X9"S6VS&]X"L.B7H4:\>@<48`H1!0ABA$EB%)$"T09
MHAQ1@6B):(5HC6B#:&LAVRTJA'K'<JWCLD;TUM/(Q*-S1`&B$%&$*$:4($H1
M+1!EB')$!:(EHA6B-:(-HJV%+%^H&Z)W^*(TM[?T&OFC.M2=&V36)=QVLA7Y
MTFP0!F*S&!HKGN<B1J;$&%'"R)87^X_46+'\@I&1SPPR584'RMG*+E'$A86Q
MXA*7C$R)*X,<):[9RBIQ*';N&V/%)6X9E27:'4+%N]</3E^9BPY1(:M#``IT
M1M^<.H2((D:F96)$"2.K&09B>Y@:*VZ&!2,CGR'*&=GR(F@MC!7++QD9^16B
M-2-+?BABCXVQ8ODMHQ8GTL;U/4Y4YL*)%;*<""A0EY>4T7(BH(BM3#/$B!)&
M5C,,Q&%]:JRX&1:,C'R&*&=DRXO3@L)8L?R2D9%?(5HSLN0;X7\95VR,%<MO
M&;4X487)S9'8V+U<?^!'5W[@VPI9O@44Z(R-(\P04<3(M$Z,*&%DCD-31`M&
M1BM#E#.R3BL&(N@IC!6W])*1D5\A6C.RY(=BV=@8*Y;?,FIQI#H0:#K2O?=4
MAV-R-%;(CJ6'8H*;ZXSJ$*I>4&&5"HP55SUD5(7$?J\_&<BSCXAM:!=\63QF
M*[-72PQJ9)3?8$BUE<\'<!/Q<`N6<9:?L96S"7)CQ4U0V.6/.L+A2\[B+'[%
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M3BJ`4E-B.:ET/*]YN"OGLT5KT=B'ZG+,8\#SYZQE*E@@6B):&>207QLK;MX-
MHJV%[#Y$X^0]^QEE+J*+"E$4RC68^S5R5#U@*],R(:*(D9&/$26(4D0+1)E!
MCJKFQHJ?L4"T1+0RR"&_-E8LOT&TM9#M1(I4+"?^O8E`J0C?5LC>JX[$F<2<
M0D:5444_KHE`:YG)/-09Z=!7#4N?7EDR&8A9)F(;ZE*7Q6-3!6[!A#.:\E*V
MJC:F_<[$F@7D5[\7K.`L.F-1Y]/GK&5J4W#&JC;#CI@`EYS%6?R*59S%KUG+
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M98M+%;"[ESJ<?,>TH<Q%]ZJ0^DI1W9#^2)SQS%5PH3(Z!TO`5F:PA!KI\PZ_
MV^M-Y`\%(LYFA28R/HC9JCFUZ%J9\E)M11]J#]3O#/U)\S\12R]8U%ETQE;.
MI\_9RM2FT(@^5&V&'>AL^@&<Q:]8V%G\FJU,\1N-=.,/^X.1.#I4[W`K_7JI
M`E5GJU[35KV]Z6G_^FT_WS\^GF[NCS_4*]A(X].'&NOWP_6&T\^40#.!2*'O
MW$S5UT;:4D:44IX10YXQI93O#Y(I?7H/79O68+HMWPLG[:GPMK(_>X/I9_K2
M4DNM*$7]$J,MA<3H1P!M*?0D]#UT3*%KR:FZ=&Q+\2BE=)ZH,UV@4$HYAT"*
M3REMK4RWF%-U[([ET)O[/K=IS>B-?FVESWK4]"TZ,Y\*:.&?^]//]`LD+)CN
M@*?JAK<MQ:.4ML+I:HI2VHJGNPY*::L`71E/U84&ED,WQU-UKX$I=",^5??=
M;2D>I;35C6[E**6M;G2G0REMY=`%^E3=Y6`Y=(\^55<ZF!*,I_1BA!8^F=)[
M!9`GDRF]!@!Y/IG2K_:1!]YDJKY;CRDSJM.LM4[T-8;IO#4EH!1U&89J]-V$
MJ;H3PQ3ZBL)478U1REW=P^EMCB^[;_MB]_KM\'RZ>=Q_I:F&CJ]IIGJMW@=9
M_>.L?T/XY7BF]SC2$D5ODJ/W=N[I52_T7>7;FZ_'XYG_H0KXR6\"_?1?`0``
M`/__`P!02P,$%``&``@````A`%D\:&2D`P``Z`T``!``"`%D;V-0<F]P<R]A
M<'`N>&UL(*($`2B@``$`````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
MG%=;;],P%'Y'XC]4>6?IQL9E2H.ZKA-(@Q52X-%RG=/6FF,'VZE:?CTG29LE
M["R;^I;8YSOWFZ-/VTP--F"=-'H4G)X,@P%H85*I5Z/@Y_SFS8=@X#S7*5=&
MPRC8@0L^Q:]?13-K<K!>@AL@"^U&P=K[_#(,G5A#QMT)7FN\61J;<8^_=A6:
MY5(*N#:BR$#[\&PX?!?"UH-.(7V3-PR#FN/EQA_+-#6BU,_]FN]R5#B.QGFN
MI.`>K8R_2F&-,TL_F&X%J"AL7T:H70*BL-+OXF$4MG^C1'`%$V0<+[ER$(4/
M!]%GX*739EQ:%T<;?[D!X8T=./D7W786#!;<0:G.*-AP*[GVJ%9)5O]4WRIW
MWL:_C;UW:P#OHA`)ZL/JLTW;_I;G\<7[B@*_NI0EAUH3O.CJ.)=>@;M;SKCU
MA,H7[]LZ5UK4&M<*':+(,#?85'OT%_NBZVA+T]:\L6%BM#-*IMQ#RJZXXEH`
M2QY9^A)Z-N//BT@\2BHSS3&S9'<Y!JSA7;J^-J2C51>2^!<8TH5,>"=JC90[
MN^):_JTRL'+9-^X+"WV*)466<;LK21*YTA)K![.&C84PA?:D+?NBW-5!^5/(
MO#2?)$7;Q/W:J!1KGTV1%.-W#2A#/D&_YA;2*TSB%)V_J]Q*,OZ"[2,#-N=;
MH%UQ"\B$3;?2LUO)%U*A:)+3Q"C%%\8^..T6VX=&\'AEGPIFEDE?Q[Q,3`RN
MQZK$EH:-BA2"+DL+X=E7B<7@L<<UUI5.)"'3+%=F!\"N0*/'/)MA*I.4WPNL
M+;!JQVZDQG277#U7)$FQ</"GP+"QZ:;,79)Q?VZ<'H$Y(S%T0F%P%^@M$I$0
M>=)'WTZ7/CHJ:_KH)Z8G$QBI>G^T:*?VUS6-Z0_>6U*W?LSY$9B+(S#OCL#4
M@VD_Q9I^V&_/AR/D?"0Q/T`87&^P:56#A@[($UF>X":3%K@@-%H_3(TG(.,T
ME;ADD)">CLO&=*<ABVDO0W-:"E5_>TN`SGM22@.A7=:/H9M)I]0;*PX=D;2F
M`\&2SK%![^>Y7],CH`,IPX]M5\EZAICE\U(>06@'D/VH,8H40T(F:X[SR3'Y
M<LA-4:T.,TM"^J<F;4Q_LSP&0V=`_["EY9#3%@NF*K1CQBZMVJ.YVX@H9W;;
MTYV5^K\E^E;J>_<SGYMK7#T/KX3N8527#N[/A_N'@^@S/A"L*IG4>9$>:!Y?
ME&^:7_7#+3X]/QF^'>)SI746A?L>A9M/_`\``/__`P!02P,$%``&``@````A
M`'F!XTDU`0``0`(``!$`"`%D;V-0<F]P<R]C;W)E+GAM;""B!`$HH``!````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````)2174_#(!2&[TW\#PWW+;3S
M8R$M2]3LRB4FSFB\0SA;B8420+O]>UG7UAF]\9*\+P_/.92+G6Z23W!>M:9"
M>490`D:T4IEMA9[6RW2.$A^XD;QI#51H#QXMV/E9*2P5K8,'UUIP08%/(LEX
M*FR%ZA`LQ=B+&C3W66R8&&Y:IWF(1[?%EHMWO@5<$'*%-00N>>#X`$SM1$0#
M4HH):3]<TP.DP-"`!A,\SK,<?W<#..W_O-`G)TVMPM[&F0;=4[84QW!J[[R:
MBEW79=VLUXC^.7Y9W3_VHZ;*''8E`+'#?AKNPRJN<J-`WNS9[LTUB?=UB7]G
MI12]'14.>`"9Q/?HT6Y,GF>W=^LE8@7)+U(R2PNR+@@EES2_?BWQV!KNLPFH
M!X%_$><GQ!'`>N^??\Z^````__\#`%!+`0(M`!0`!@`(````(0"0-LX-*`(`
M`(`B```3``````````````````````!;0V]N=&5N=%]4>7!E<UTN>&UL4$L!
M`BT`%``&``@````A`+55,"/U````3`(```L`````````````````800``%]R
M96QS+RYR96QS4$L!`BT`%``&``@````A`#IH-4AI`@``]2$``!H`````````
M````````AP<``'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!`BT`%``&
M``@````A`#7XH7.V!```A!$```\`````````````````,`L``'AL+W=O<FMB
M;V]K+GAM;%!+`0(M`!0`!@`(````(0"9`5,UHP0``"H0```8````````````
M`````!,0``!X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"+0`4``8`"```
M`"$`6>%*;FX%```8&0``&0````````````````#L%```>&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+`0(M`!0`!@`(````(0`D9&:'?P4``%D:```9````
M`````````````)$:``!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L!`BT`
M%``&``@````A`+GZ>[SX`P``RPT``!D`````````````````1R```'AL+W=O
M<FMS:&5E=',O<VAE970T-2YX;6Q02P$"+0`4``8`"````"$`,\`KZRT$``#N
M#0``&0````````````````!V)```>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM
M;%!+`0(M`!0`!@`(````(0"9@B5W+`,``'$)```9`````````````````-HH
M``!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L!`BT`%``&``@````A`#"`
MB&I>!```YQ$``!D`````````````````/2P``'AL+W=O<FMS:&5E=',O<VAE
M970T,BYX;6Q02P$"+0`4``8`"````"$`EVE>EEL#``#E"@``&0``````````
M``````#2,```>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+`0(M`!0`!@`(
M````(0`?9Y[GU0@``#PV```9`````````````````&0T``!X;"]W;W)K<VAE
M971S+W-H965T-#`N>&UL4$L!`BT`%``&``@````A``RASF8B!@``.B```!D`
M````````````````<#T``'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M+0`4``8`"````"$`N$V&\54%``#4&0``&0````````````````#)0P``>&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+`0(M`!0`!@`(````(0!4G;W'1P0`
M`*81```9`````````````````%5)``!X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L!`BT`%``&``@````A`!`(,K>9`@``908``!D`````````````````
MTTT``'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"+0`4``8`"````"$`
M'((*WJ`+```C50``&0````````````````"C4```>&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+`0(M`!0`!@`(````(0#FAVDQ%00``"H1```9````````
M`````````'I<``!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L!`BT`%``&
M``@````A`/57LYW@`@``P`<``!D`````````````````QF```'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"+0`4``8`"````"$`X>\H)W8#``#!"P``
M&0````````````````#=8P``>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M`0(M`!0`!@`(````(0#[8J5ME`8``*<;```3`````````````````(IG``!X
M;"]T:&5M92]T:&5M93$N>&UL4$L!`BT`%``&``@````A`"*^SJG;"P``(6H`
M``T`````````````````3VX``'AL+W-T>6QE<RYX;6Q02P$"+0`4``8`"```
M`"$`?,5S*`"5```S!P(`%`````````````````!5>@``>&PO<VAA<F5D4W1R
M:6YG<RYX;6Q02P$"+0`4``8`"````"$`HW:X?XL%``!$'0``&```````````
M``````"'#P$`>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!`BT`%``&``@`
M```A`/`Y#;;[!@``WB```!@`````````````````2!4!`'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+`0(M`!0`!@`(````(0#^Q(_1.@,``.0*```9````
M`````````````'D<`0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L!`BT`
M%``&``@````A`-<_H,63!```.!$``!D`````````````````ZA\!`'AL+W=O
M<FMS:&5E=',O<VAE970U-BYX;6Q02P$"+0`4``8`"````"$`Q5)K9F0#``"]
M"@``&0````````````````"T)`$`>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM
M;%!+`0(M`!0`!@`(````(0#%*GNJNQ(``"Z6```9`````````````````$\H
M`0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L!`BT`%``&``@````A`-B:
M^NG(`P``I`X``!D`````````````````03L!`'AL+W=O<FMS:&5E=',O<VAE
M970U,BYX;6Q02P$"+0`4``8`"````"$`,Y(9W[\"``!K!P``&0``````````
M``````!`/P$`>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+`0(M`!0`!@`(
M````(0`A210O=0,``$X+```9`````````````````#9"`0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L!`BT`%``&``@````A`',B,*?D`P``50X``!@`
M````````````````XD4!`'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+`0(M
M`!0`!@`(````(0`6N??@3P,``-4+```9`````````````````/Q)`0!X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L!`BT`%``&``@````A`,L6C/I]!```
M!Q,``!D`````````````````@DT!`'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"+0`4``8`"````"$`AP`EOY@4``#<;0``&0`````````````````V
M4@$`>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+`0(M`!0`!@`(````(0"(
MK;%\R@<``!$B```9``````````````````5G`0!X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L!`BT`%``&``@````A`'1BN6-7!@``\1\``!D`````````
M````````!F\!`'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"+0`4``8`
M"````"$`<8E7@X\%``"-%0``&0````````````````"4=0$`>&PO=V]R:W-H
M965T<R]S:&5E=#$U+GAM;%!+`0(M`!0`!@`(````(0#Q@`!1?`(``!`&```9
M`````````````````%I[`0!X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!
M`BT`%``&``@````A`(A3&/HW%```&G$``!D`````````````````#7X!`'AL
M+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"+0`4``8`"````"$`,TD<%U8#
M``#0"@``&0````````````````![D@$`>&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+`0(M`!0`!@`(````(0`6))YA[P<``-HA```8````````````````
M``B6`0!X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"+0`4``8`"````"$`
MAQ1]FE4)``!X-@``&``````````````````MG@$`>&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L!`BT`%``&``@````A`/6/X56=!@``(1L``!@`````````
M````````N*<!`'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+`0(M`!0`!@`(
M````(0#Y&Y_UC@(``)X&```8`````````````````(NN`0!X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"+0`4``8`"````"$`@XY4I.,Z``#J80$`&```
M``````````````!/L0$`>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!`BT`
M%``&``@````A`"OZ\3P#!```,1```!D`````````````````:.P!`'AL+W=O
M<FMS:&5E=',O<VAE970S,RYX;6Q02P$"+0`4``8`"````"$`SI*6AH0"``!K
M!@``&0````````````````"B\`$`>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM
M;%!+`0(M`!0`!@`(````(0`32&<HC@(``*@&```9`````````````````%WS
M`0!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!`BT`%``&``@````A`'OF
MXH$D"0``NBH``!D`````````````````(O8!`'AL+W=O<FMS:&5E=',O<VAE
M970R-RYX;6Q02P$"+0`4``8`"````"$`C1)UJ/$"``")"```&0``````````
M``````!]_P$`>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+`0(M`!0`!@`(
M````(0`NP[1J"`,``.`(```9`````````````````*4"`@!X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L!`BT`%``&``@````A`$=!;>7;!```1A<``!D`
M````````````````Y`4"`'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M+0`4``8`"````"$`7WT4^NP"``!)"```&0````````````````#V"@(`>&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+`0(M`!0`!@`(````(0"2)N_5+@H`
M`(HQ```9`````````````````!D.`@!X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L!`BT`%``&``@````A`'HD#\X'!0``'!(``!D`````````````````
M?A@"`'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"+0`4``8`"````"$`
M-M6AGA<3``"C8P``&0````````````````"\'0(`>&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+`0(M`!0`!@`(````(0#ACO"/F3X``,9Y`0`9````````
M``````````HQ`@!X;"]W;W)K<VAE971S+W-H965T,C`N>&UL4$L!`BT`%``&
M``@````A`(1FR.J`)@``LMH``!D`````````````````VF\"`'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"+0`4``8`"````"$`0(H?ROD&``#L'```
M&0````````````````"1E@(`>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M`0(M`!0`!@`(````(0``;[_U@P<``)@?```9`````````````````,&=`@!X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L!`BT`%``&``@````A`-'#-6U\
M$```3E0``!D`````````````````>Z4"`'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"+0`4``8`"````"$`63QH9*0#``#H#0``$```````````````
M```NM@(`9&]C4')O<',O87!P+GAM;%!+`0(M`!0`!@`(````(0!Y@>-)-0$`
M`$`"```1``````````````````B[`@!D;V-0<F]P<R]C;W)E+GAM;%!+!08`
1````0@!"```2``!TO0(`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EFOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 25, 2002

</div>
          <div>Age</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract', window );"><strong>Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan', window );">Eligibility of employee participation plan</a></td>
        <td class="nump">21<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of employee contribution to salary</a></td>
        <td class="nump">100.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage', window );">Percentage of employee vested contribution</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Company's contribution to plan total</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 252,930<span></span></td>
        <td class="nump">$ 225,195<span></span></td>
        <td class="nump">$ 217,097<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Defined contribution plan, employees contribution, annual vesting percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Employee eligible age to participate in benefit plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECLAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">United States federal tax at statutory rate</a></td>
        <td class="num">$ (91,293)<span></span></td>
        <td class="nump">$ 2,926,615<span></span></td>
        <td class="nump">$ 2,350,992<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes (net of federal benefit)</a></td>
        <td class="nump">609,476<span></span></td>
        <td class="nump">1,460,289<span></span></td>
        <td class="nump">1,480,185<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxReconciliationDeferredTaxAdjustments', window );">Deferred income tax adjustments</a></td>
        <td class="num">(855,130)<span></span></td>
        <td class="num">(512,375)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments', window );">Deferred state blended rate adjustments</a></td>
        <td class="num">(344,178)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research credit, net</a></td>
        <td class="num">(225,605)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther', window );">Orphan drug credit, net</a></td>
        <td class="num">(843,463)<span></span></td>
        <td class="num">(4,895,671)<span></span></td>
        <td class="num">(7,056,607)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other permanent items</a></td>
        <td class="nump">2,931<span></span></td>
        <td class="nump">7,627<span></span></td>
        <td class="nump">4,696<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Equity- based compensation</a></td>
        <td class="nump">241,467<span></span></td>
        <td class="nump">279,165<span></span></td>
        <td class="nump">725,811<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability', window );">Fair value adjustment of preferred stock warrant liability</a></td>
        <td class="nump">218,872<span></span></td>
        <td class="num">(52,743)<span></span></td>
        <td class="num">(496,208)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
        <td class="nump">1,286,923<span></span></td>
        <td class="nump">787,093<span></span></td>
        <td class="nump">2,991,131<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense/(benefit)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncomeTaxReconciliationDeferredTaxAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income tax reconciliation deferred tax adjustments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_IncomeTaxReconciliationDeferredTaxAdjustments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income tax reconciliation fair value adjustment of preferred stock warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income tax reconciliation state deferred taxes adjustments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_IncomeTaxReconciliationStateDeferredTaxesAdjustments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32123-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationOtherReconcilingItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationTaxCreditsOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EMCAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Significant Accounts Receivable (Detail) (Accounts Receivable [Member])<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Gilead [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant Accounts Receivable</a></td>
        <td class="nump">53.40%<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Pfizer [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant Accounts Receivable</a></td>
        <td class="nump">12.30%<span></span></td>
        <td class="nump">45.40%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Boehringer [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant Accounts Receivable</a></td>
        <td class="nump">12.20%<span></span></td>
        <td class="nump">18.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Eli Lilly [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant Accounts Receivable</a></td>
        <td class="nump">7.00%<span></span></td>
        <td class="nump">28.20%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Servier [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant Accounts Receivable</a></td>
        <td class="nump">6.40%<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Government Agencies [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant Accounts Receivable</a></td>
        <td class="nump">4.60%<span></span></td>
        <td class="nump">8.40%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskPercentage1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJEAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) (Subsequent Event [Member], USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 28, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement', window );">Clinical milestone payments</a></td>
        <td class="nump">$ 5.0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalLicenseGrantFeesUnderAgreement', window );">Additional license grant fees</a></td>
        <td class="nump">15.0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ReviewPeriodByRegulatoryAuthority', window );">Review period</a></td>
        <td class="text">30 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock number of shares sold</a></td>
        <td class="nump">1,800,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock, price per share</a></td>
        <td class="nump">$ 36.50<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption', window );">Additional shares sold under over-allotments Option to underwriter</a></td>
        <td class="nump">450,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Additional shares sold under over-allotments option to underwriter, price per share</a></td>
        <td class="nump">$ 36.50<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of shares</a></td>
        <td class="nump">76.7<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Servier [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement', window );">Clinical milestone payments</a></td>
        <td class="nump">5.0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalLicenseGrantFeesUnderAgreement', window );">Additional license grant fees</a></td>
        <td class="nump">$ 15.0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ReviewPeriodByRegulatoryAuthority', window );">Review period</a></td>
        <td class="text">30 days<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential clinical milestone payments available to be earned under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalLicenseGrantFeesUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional license grant fees under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AdditionalLicenseGrantFeesUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ReviewPeriodByRegulatoryAuthority">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Review period by regulatory authority.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ReviewPeriodByRegulatoryAuthority</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period, shares to underwriters for exercise of over allotment option.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit of equity securities issued by non-development stage entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesIssuedPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Lease Exit Liability (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring And Related Activities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Changes in Lease Exit Liability</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Changes in the lease exit liability are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrual balance at December&#xA0;31, 2011</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">$10,607,499</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Principal payments</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(533,560</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrual balance at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,073,939</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Principal payments</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(628,769</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrual balance at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">$9,445,170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future Principal Payments Under Lease Agreement</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Future principal payments to be made under the lease agreement for
 the next five years and thereafter as of December&#xA0;31, 2013 are
 as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2014</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,438,742</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2015</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,641,905</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,866,031</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,113,118</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,385,374</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,445,170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringAndRelatedActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6FAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Lease Exit Liability - Future Principal Payments under Lease Agreement (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems', window );"><strong>Future Minimum Leases Payments Under Leases (Line Items)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2014</a></td>
        <td class="nump">$ 3,651,421<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2015</a></td>
        <td class="nump">3,310,884<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2016</a></td>
        <td class="nump">3,410,210<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2017</a></td>
        <td class="nump">3,512,517<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2018</a></td>
        <td class="nump">2,780,398<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump">16,665,430<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Contract Termination [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems', window );"><strong>Future Minimum Leases Payments Under Leases (Line Items)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2014</a></td>
        <td class="nump">1,438,742<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2015</a></td>
        <td class="nump">1,641,905<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2016</a></td>
        <td class="nump">1,866,031<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2017</a></td>
        <td class="nump">2,113,118<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2018</a></td>
        <td class="nump">2,385,374<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump">$ 9,445,170<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_FutureMinimumLeasesPaymentsUnderLeasesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the forth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the third fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the second fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing after the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EA5AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shared-Based Payments - Schedule of Fair Value Option Award Estimated on the Date of Grant Using the Black-Scholes Option-Pricing Model (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">51.00%<span></span></td>
        <td class="nump">62.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.18%<span></span></td>
        <td class="nump">1.35%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">7 years<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">7 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Expected forfeiture rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.57%<span></span></td>
        <td class="nump">5.58%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">53.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">1.24%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Expected forfeiture rate</a></td>
        <td class="nump">5.06%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">67.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">2.19%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Expected forfeiture rate</a></td>
        <td class="nump">5.57%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(v)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUHAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump">$ 20,568,069<span></span></td>
        <td class="nump">$ 17,607,293<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
        <td class="num">(15,532,837)<span></span></td>
        <td class="num">(14,339,497)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">5,035,232<span></span></td>
        <td class="nump">3,267,796<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Computer Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump">2,379,254<span></span></td>
        <td class="nump">2,003,706<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Software [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump">1,477,416<span></span></td>
        <td class="nump">1,323,081<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Furniture [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump">599,650<span></span></td>
        <td class="nump">599,650<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Lab Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump">11,166,619<span></span></td>
        <td class="nump">8,747,790<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Office Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump">51,360<span></span></td>
        <td class="nump">51,360<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Leasehold Improvements [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump">$ 4,893,770<span></span></td>
        <td class="nump">$ 4,881,706<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZVAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent liability</a></td>
        <td class="nump">$ 2.9<span></span></td>
        <td class="nump">$ 2.8<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Lessee leasing arrangements, operating leases, renewal term</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
        <td class="nump">$ 2.7<span></span></td>
        <td class="nump">$ 2.7<span></span></td>
        <td class="nump">$ 2.9<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Lease [Member] | Office and Laboratory Space [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
        <td class="text">Mar. 31,
				 2018<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Lease [Member] | Manufacturing Facilities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
        <td class="text">Dec. 31,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Sublease [Member] | Office and Laboratory Space [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
        <td class="text">Dec. 31,
				 2018<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLeasesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_OperatingLeasesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39896-112707<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseExpirationDate1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Term of the lessee's leasing arrangement renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesRentExpenseNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2LAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
        <td class="nump">$ 1,592,357<span></span></td>
        <td class="nump">$ 1,533,986<span></span></td>
        <td class="nump">$ 1,246,025<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases/(decreases) for current year tax positions</a></td>
        <td class="nump">115,502<span></span></td>
        <td class="nump">58,371<span></span></td>
        <td class="nump">287,961<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases/(decreases) for prior year tax positions</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Decreases as a result of expiration of statute of limitations</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
        <td class="nump">$ 1,707,859<span></span></td>
        <td class="nump">$ 1,592,357<span></span></td>
        <td class="nump">$ 1,533,986<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Unrecognized Tax Benefit<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>3. Property and Equipment</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Property and equipment consists of the following:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Computer equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,379,254</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,003,706</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,477,416</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,323,081</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Furniture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">599,650</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">599,650</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Lab equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,166,619</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,747,790</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51,360</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51,360</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,893,770</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,881,706</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Property and equipment</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,568,069</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,607,293</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Less accumulated depreciation</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(15,532,837</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14,339,497</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Property and equipment, net</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,035,232</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,267,796</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Depreciation expense for the years ended December&#xA0;31, 2013,
 2012 and 2011 was $1.2 million, $1.0 million and $1.1 million,
 respectively.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>45
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\V,CEC-&)C85]C9&$W7S1D865?830T-5\Q,C0U
M864R-#AC.30B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?4W1O/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N='-?;V9?0V%S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N7V%N9%].871U<F5?;V9?3W!E
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R
M>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4')O<&5R='E?86YD7T5Q=6EP;65N=#PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R
M<U]%<75I='E?1&5F:6-I=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-H87)E9$)A<V5D7U!A>6UE;G1S/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$Q
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YC;VUE7U1A>&5S/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#$R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3&5A<V5?17AI=%],:6%B
M:6QI='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#
M;VQL86)O<F%T:6]N7V%N9%],:6-E;G-E7T%G<F4\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,30N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN
M9V5N8VEE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E!R;V1U8W1?36EL97-T;VYE7U!A>6UE;G1S7V%N9#PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q
M-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D5M<&QO>65E7T)E;F5F:71?4&QA
M;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E%U87)T
M97)L>5]&:6YA;F-I86Q?26YF;W)M871I;SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q."YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-U8G-E<75E;G1?179E;G1S/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#$Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N
M:69I8V%N=%]!8V-O=6YT,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,"YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#(\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,C$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0<F]P97)T>5]A
M;F1?17%U:7!M96YT7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,BYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/E-H87)E9$)A<V5D7U!A>6UE;G1S7U1A8FQE<SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970R,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]487AE
M<U]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,C0N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y,96%S95]%>&ET7TQI86)I;&ET>5]486)L97,\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C4N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN
M9V5N8VEE<U\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,C8N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y1=6%R=&5R;'E?1FEN86YC:6%L7TEN9F]R;6%T:6\Q/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N7V%N9%].
M871U<F5?;V9?3W!E,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R."YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#,\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,CDN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I
M9VYI9FEC86YT7T%C8V]U;G0T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,P+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT-3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970S,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?
M;V9?4VEG;FEF:6-A;G1?06-C;W5N=#8\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S(N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U
M;G0W/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#,S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5M
M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT.#PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-"YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?
M06-C;W5N=#D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,S4N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0Q,#PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R;W!E<G1Y7V%N9%]%<75I
M<&UE;G1?4V-H961U;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-RYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E!R;W!E<G1Y7V%N9%]%<75I<&UE;G1?061D:71I;SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970S."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%
M<75I='E?1&5F:6-I=%]!9#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S.2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-H87)E9$)A<V5D7U!A>6UE;G1S7T%D9&ET:6]N83PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970T,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-H87)E9$)A<V5D
M7U!A>6UE;G1S7U-C:&5D=6QE7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/E-H87)E9$)A<V5D7U!A>6UE;G1S7U-C:&5D=6QE7S$\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T-#(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3:&%R961"
M87-E9%]087EM96YT<U]38VAE9'5L95\R/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0S+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^26YC;VUE7U1A>&5S7T%D9&ET:6]N86Q?26YF
M;W)M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#0T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YC
M;VUE7U1A>&5S7T-O;7!O;F5N='-?;V9?=&AE/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0U+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^26YC;VUE7U1A>&5S7U)E8V]N8VEL:6%T
M:6]N7V]F/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#0V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M26YC;VUE7U1A>&5S7U)E8V]N8VEL:6%T:6]N7V]F,3PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T
M-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DQE87-E7T5X:71?3&EA8FEL:71Y
M7T%D9&ET:6]N83PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970T."YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/DQE87-E7T5X:71?3&EA8FEL:71Y7T-H86YG97-?:3PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970T.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DQE87-E7T5X:71?3&EA8FEL
M:71Y7T9U='5R95]0<CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U,"YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/D-O;&QA8F]R871I;VY?86YD7TQI8V5N<V5?06=R93$\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T-3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A
M;F1?0V]N=&EN9V5N8VEE<U\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#4R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E;F-I97-?,CPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970U,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R;V1U8W1?
M36EL97-T;VYE7U!A>6UE;G1S7V%N9#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-30N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y%;7!L;WEE95]"96YE9FET7U!L86Y?061D:71I
M;VX\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T-34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y1=6%R
M=&5R;'E?1FEN86YC:6%L7TEN9F]R;6%T:6\R/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#4V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4W5B<V5Q=65N=%]%=F5N='-?061D:71I
M;VYA;%])/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#4W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S
M:&5E="!(4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!
M8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R
M=6-T=7)E/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E
M8W17:6YD;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E
M;%=O<FMB;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB
M;V1Y/@T*("`@/'`^5&AI<R!P86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-
M:6-R;W-O9G0@17AC96P@6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(Y8S1B8V%?8V1A-U\T9&%E
M7V$T-#5?,3(T-6%E,C0X8SDT#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S8R.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-"]7;W)K
M<VAE971S+U-H965T,#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5%2D%%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N
M(#(X+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D1O8W5M96YT($%N9"!%;G1I='D@26YF;W)M871I;VX@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<Q,"U+/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B=F86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@
M1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^1&5C(#,Q+`T*
M"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<R,#$S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L
M(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)T99/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^16YT:71Y(%)E9VES=')A;G0@3F%M93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)TU!0U)/1T5.24-3($E.0SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT
M<F%L($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)S`P,#$Q,C4S-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I<V-A;"!996%R($5N9"!$871E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG+2TQ,BTS,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET
M>2!796QL+6MN;W=N(%-E87-O;F5D($ES<W5E<CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-U<G)E;G0@4F5P;W)T:6YG
M(%-T871U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)UEE<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5N=&ET>2!6;VQU;G1A<GD@1FEL97)S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG3F\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=.;VXM86-C96QE<F%T960@1FEL
M97(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;G1I='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-RPT-S$L,S(Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;G1I='D@4'5B;&EC($9L;V%T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`V.3@L,#(R+#$X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-C(Y8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E
M,C0X8SDT#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A
M7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-"]7;W)K<VAE971S+U-H965T
M,#(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$516$)'/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG
M/D-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#=7)R96YT(&%S<V5T<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q-BPT.#$L-#`Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`T-RPW-#,L,34U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P-"PP,3D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`T-BPR,3D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A
M:60@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDW
M,2PW,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,S<L-C,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q.2PT-3<L,3,S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#DL.3(W+#`P.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S=')I8W1E9"!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,#0L.#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#`T+#@U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N="P@;F5T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`S-2PR,S(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(V
M-RPW.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#@U+#$V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$T-RPR-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-2PW.#(L,S@Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3,L-S0V+#DP,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY#=7)R96YT(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,38Y+#`S-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-S,Y
M+#$R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPU.#,L-34R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PR,S<L,#(U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,96%S92!E>&ET(&QI86)I
M;&ET>2UC=7)R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#0S."PW-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV,C@L-S8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E+6-U<G)E;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#(V-RPS,C,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-"PQ,C,L
M,3<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/=&AE<B!L:6%B:6QI=&EE<RUC=7)R96YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS-C(L.3(P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@;&EA
M8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X+#@R
M,2PU-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR.2PW,C@L,#DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,96%S92!E>&ET(&QI86)I;&ET>2P@;F5T(&]F
M(&-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^."PP,#8L-#(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.2PT-#4L,3<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R96YT(&QI86)I;&ET
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY,#0L,C(W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX
M,#$L-C4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F5F97)R960@<W1O8VL@=V%R<F%N="!L:6%B:6QI='D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,BPY-#<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D
M(')E=F5N=64L(&YE="!O9B!C=7)R96YT('!O<G1I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<L,3,U+#8X-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y+#DU-BPS-#,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#8L.#8W+#DQ,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8Q+#DX-"PR,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!E
M<75I='D@*&1E9FEC:70I.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@)#`N,#$@<&%R('9A;'5E
M+3$R-2PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D(&%N9"`R-2PQ-S<L-3DW
M('-H87)E<R!O=71S=&%N9&EN9R!A="!$96-E;6)E<B`S,2P@,C`Q,SL@-#(U
M+#`P,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960@86YD(#$L,#DX+#DQ-"!S:&%R
M97,@;W5T<W1A;F1I;F<@870@1&5C96UB97(@,S$L(#(P,3(\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(U,2PW-S4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PY.#D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R96%S=7)Y
M('-T;V-K+"!A="!C;W-T.R`Q-"PS.#$@<VAA<F5S(&%T($1E8V5M8F5R(#,Q
M+"`R,#$S(&%N9"!$96-E;6)E<B`S,2P@,C`Q,CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-3<L-S0R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#4W+#<T,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I
M9"UI;B!C87!I=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-30L-#4S+#8W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$V-"PS,S0L-C0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D969I8VET/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-S4L-S,S+#(S."D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-S4L
M-#<R+#0P,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L('-T;V-K:&]L9&5R<R<@97%U:71Y("AD969I8VET
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S@L.3$T+#0V.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L
M,C,W+#,P."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<R!A;F0@<W1O8VMH;VQD97)S
M)R!E<75I='D@*&1E9FEC:70I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,C4L-S@R+#,X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4S+#<T-BPY,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!!+3$@0V]N=F5R
M=&EB;&4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G(&5Q
M=6ET>2`H9&5F:6-I="DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8X+#<T.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S
M($$M,B!#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K
M:&]L9&5R<R<@97%U:71Y("AD969I8VET*3H\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R
M960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,RPV
M-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-E<FEE<R!"($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4W1O8VMH;VQD97)S)R!E<75I='D@*&1E9FEC:70I.CPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE
M('!R969E<G)E9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<Q-"PP,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-E<FEE<R!#($-O;G9E<G1I8FQE(%!R969E<G)E9"!3
M=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!E<75I='D@*&1E9FEC:70I.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,3`Y+#4R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S($0M,2!#;VYV97)T:6)L
M92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@97%U:71Y
M("AD969I8VET*3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#0L-#8R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@1"TR
M($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD
M97)S)R!E<75I='D@*&1E9FEC:70I.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S
M=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C,V+#@Q
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(Y
M8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X8SDT#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R
M-#5A93(T.&,Y-"]7;W)K<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M,D)'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!"86QA
M;F-E(%-H965T<R`H4&%R96YT:&5T:6-A;"D@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO
M;B!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&%U=&AO
M<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-2PP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#(U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&]U='-T86YD
M:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PQ-S<L-3DW
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PP.3@L.3$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4<F5A<W5R>2!S=&]C:RP@<VAA<F5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PS.#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PS.#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!!+3$@
M0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R
M<F5D('-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@
M<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-BPX-S0L-SDR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL
M('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-BPX-S0L-SDR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL('-H
M87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(V+#@W-"PW.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!L:7%U:61A=&EO;B!P<F5F97)E
M;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-RPP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y397)I97,@02TR($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P
M<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-RPS-C0L-3@R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P
M<F5F97)R960@<W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW+#,V-"PU.#(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E
M<G)E9"!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-RPS-C0L-3@R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@;&EQ=6ED
M871I;VX@<')E9F5R96YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4V5R:65S($(@0V]N=F5R=&EB;&4@4')E9F5R<F5D
M(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!P87(@=F%L=64\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E
M<G1I8FQE('!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,2PT,#$L,C,W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV
M97)T:6)L92!P<F5F97)R960@<W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,2PT,#$L,C,W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T
M:6)L92!P<F5F97)R960@<W1O8VLL('-H87)E<R!O=71S=&%N9&EN9SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<Q+#0P,2PR,S<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E
M9V%T92!L:7%U:61A=&EO;B!P<F5F97)E;F-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S$L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S($,@0V]N=F5R=&EB
M;&4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K
M+"!P87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&%U
M=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3`L
M.34R+#(Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!S:&%R97,@
M:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$P+#DU
M,BPR,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&]U
M='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$P
M+#DU,BPR,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%G9W)E9V%T92!L:7%U:61A=&EO;B!P<F5F97)E;F-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R
M:65S($0M,2!#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L
M92!P<F5F97)R960@<W1O8VLL('!A<B!V86QU93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D
M('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E
M9"!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$T+#0T-BPR,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S
M=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,30L-#0V+#(R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E(&QI<75I9&%T:6]N
M('!R969E<F5N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-E<FEE<R!$+3(@0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T
M;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!P87(@=F%L=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I
M8FQE('!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-2PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T
M:6)L92!P<F5F97)R960@<W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,RPV.#$L,3<V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L
M92!P<F5F97)R960@<W1O8VLL('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8S+#8X,2PQ-S8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T
M92!L:7%U:61A=&EO;B!P<F5F97)E;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T,2PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P15(R044^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@3W!E<F%T:6]N<R!A
M;F0@0V]M<')E:&5N<VEV92!);F-O;64@*$QO<W,I("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E)E=F5N=65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y2979E;G5E(&9R;VT@8V]L;&%B;W)A=&EV92!R97-E87)C
M:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U-BPW-3,L,3(S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`U.2PV-#4L.#$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T-RPP-30L,SDW/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N="!R979E;G5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(X,2PU-#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#$X,"PR-SD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,"PQ-3(L.38Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P@<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4X+#`S-"PV-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,RPX,C8L,#DX/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3<L,C`W+#,V-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY#;W-T<R!A;F0@97AP96YS97,Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E
M;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8L-3@Q
M+#DS,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0U+#0S,BPX.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT,2PP.#@L.#DY/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES
M=')A=&EV93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L,#@V
M+#<U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P+#$X-RPX.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,"PX-C@L-SDQ/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V]S=',@86YD(&5X
M<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-RPV-C@L
M-C@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-34L-C(P+#<X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4Q+#DU-RPV.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@*&QO<W,I(&9R;VT@
M;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8U
M+#DW.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@L,C`U+#,Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L,C0Y+#8W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@:6YC;VUE("AE>'!E;G-E
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C(V+#@Q-"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-38L
M-#0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PT-C<L-#0T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&-O;7!R96AE;G-I=F4@:6YC;VUE("AL;W-S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R-C`L.#,U*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M."PS-C$L-S4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`V+#<Q-RPQ,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VEC(&YE="!I;F-O;64@*&QO<W,I
M('!E<B!C;VUM;VX@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,"XP-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1I;'5T960@;F5T(&EN8V]M92`H;&]S<RD@
M<&5R(&-O;6UO;B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@P+C`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0F%S:6,@=V5I9VAT960@879E<F%G92!N=6UB
M97(@;V8@8V]M;6]N('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-BPX-#<L-CDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PP.#,L,C<V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,C4L-C`R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:6QU=&5D('=E
M:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.#0W+#8Y-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#@S+#(W-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,#(U+#8P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?-C(Y8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X8SDT#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A7V-D83=?-&1A95]A
M-#0U7S$R-#5A93(T.&,Y-"]7;W)K<VAE971S+U-H965T,#4N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$531$%+/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E
M9"!3=&%T96UE;G1S(&]F(%-T;V-K:&]L9&5R<R<@17%U:71Y("A54T0@)"D\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^5&]T
M86P\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5R:65S($$M
M,2!#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5R:65S($$M,B!#;VYV97)T
M:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5R:65S($(@0V]N=F5R=&EB;&4@4')E9F5R
M<F5D(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<FEE<R!#($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397)I
M97,@1"TQ($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397)I97,@1"TR($-O
M;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y#;VUM;VX@4W1O8VL@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^5')E87-U<GD@4W1O
M8VL@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M061D:71I;VYA;"!086ED+4EN($-A<&ET86P@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^06-C=6UU;&%T960@1&5F:6-I="!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F5G:6YN:6YG($)A;&%N8V4@870@1&5C+B`S,2P@,C`Q,#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@S."PV,S0L,#4X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C8X+#<T.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-S,L-C0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`W,30L,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+#$P.2PU,C(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$T-"PT-C(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0U,BPU,S@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$P+#`P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H-3<L-S0R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,30Y+#(P,BPP,C<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$Y,"PU-3$L,C<X*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F5G:6YN:6YG($)A;&%N8V4L(%-H87)E<R!A="!$96,N(#,Q+"`R,#$P/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L.#<T+#<Y,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,S8T
M+#4X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<Q+#0P,2PR,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,3`L.34R+#(Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#0T-BPR,C<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-2PR-3,L-S@X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PP,#`L-C@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,30L,S@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPS-#<L-#,Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#,T-RPT,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VLO8V]N=F5R
M=&EB;&4@4V5R:65S($0M,B!S=&]C:RP@;F5T(&]F(&]F9F5R:6YG(&-O<W1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPP,30L.#$U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ.#0L,C<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,2PX,S`L-30Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T
M;V-K+V-O;G9E<G1I8FQE(%-E<FEE<R!$+3(@<W1O8VLL(&YE="!O9B!O9F9E
M<FEN9R!C;W-T<RP@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ."PT,C<L,S@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@;W!T:6]N(&5X97)C
M:7-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`L-#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8Y+#DQ-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO;B!E>&5R8VES97,L(%-H87)E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#DL.#@S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#@L,S0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@:6YC;VUE("AL;W-S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-BPW,3<L,3(P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPW,3<L,3(P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;F1I;F<@0F%L86YC92!A="!$96,N(#,Q+"`R,#$Q/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q-RPT.#0L,C@T*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V."PW-#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,RPV-#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,30L
M,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PQ,#DL-3(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,30T+#0V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8S-BPX,3(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PT.3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U-RPW-#(I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38S+#0T
M.2PY,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q.#,L.#,T+#$U."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E+"!3:&%R97,@870@
M1&5C+B`S,2P@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(V+#@W-"PW.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW+#,V-"PU.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW,2PT,#$L,C,W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$P+#DU,BPR,3<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PT
M-#8L,C(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C,L-C@Q+#$W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,#0Y+#`S,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#,X,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E
M9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@S."PS.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C@S."PS.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!O<'1I;VX@97AE<F-I
M<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-BPX,C8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#8L,S(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1O8VL@;W!T:6]N(&5X97)C:7-E<RP@4VAA<F5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-C,L,3<V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#DL.#@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@:6YC;VUE("AL;W-S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^."PS-C$L-S4U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PS-C$L-S4U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;F1I;F<@0F%L86YC92!A="!$96,N(#,Q+"`R,#$R/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@X+#(S-RPS,#@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8X+#<T.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<S+#8T-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<Q-"PP
M,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#$P.2PU,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-#0L-#8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C,V+#@Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#DX.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4W+#<T,BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C0L,S,T
M+#8T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$W-2PT-S(L-#`S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4L(%-H87)E<R!A="!$
M96,N(#,Q+"`R,#$R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C8L.#<T+#<Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<L,S8T+#4X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<Q+#0P,2PR,S<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3`L.34R+#(Q-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#0T
M-BPR,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV,RPV.#$L,3<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PP.3@L.3$T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30L,S@Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D
M(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#8R+#$V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#8R+#$V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:R]C;VYV97)T:6)L92!397)I97,@1"TR('-T;V-K+"!N970@;V8@;V9F
M97)I;F<@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@S
M+#8R,BPS-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU-RPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#,L-38T+#@U.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F
M(&-O;6UO;B!S=&]C:R]C;VYV97)T:6)L92!397)I97,@1"TR('-T;V-K+"!N
M970@;V8@;V9F97)I;F<@8V]S=',L(%-H87)E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-S4P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO
M;B!O9B!P<F5F97)R960@<W1O8VL@=&\@8V]M;6]N('-T;V-K/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@V,"PU.3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-C@L-S0X*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<S+#8T
M-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@W,30L,#$R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$L,3`Y+#4R,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q-#0L-#8R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8S-BPX,3(I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<P+#8P-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M+#8S-RPQ.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VYV97)S:6]N(&]F('!R969E<G)E9"!S=&]C:R!T;R!C
M;VUM;VX@<W1O8VLL(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(V+#@W-"PW.3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-RPS-C0L-3@R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<Q+#0P,2PR,S<I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$P+#DU
M,BPR,3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,30L-#0V+#(R-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@V,RPV.#$L,3<V*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#`V,"PV,S0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T
M;V-K(&]P=&EO;B!E>&5R8VES97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,#8W+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#8X,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`U-"PX,C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C
M:R!O<'1I;VX@97AE<F-I<V5S+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,C8X+#`T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C8X+#`T.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M(&EN8V]M92`H;&]S<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(V,"PX,S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,C8P+#@S-2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E(&%T
M($1E8RX@,S$L(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-S@L.3$T+#0V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,C4Q+#<W-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-3<L-S0R*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C4T+#0U
M,RPV-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#$W-2PW,S,L,C,X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4L(%-H87)E<R!A
M="!$96,N(#,Q+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C4L,3<W+#4Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$T+#,X,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)604<^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@0V%S:"!&;&]W
M<R`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY/<&5R871I;F<@86-T:79I=&EE<SPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@:6YC
M;VUE("AL;W-S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R
M-C`L.#,U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@."PS-C$L-S4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`V+#<Q-RPQ,C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T
M;65N=',@=&\@<F5C;VYC:6QE(&YE="!I;F-O;64@=&\@;F5T(&-A<V@@<')O
M=FED960@8GD@*'5S960@:6XI(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R
M96-I871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PQ.3,L,S0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.34Y+#DS,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,30W+#,P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M
M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-C(L
M,38R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#,X+#,Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L,S0W+#0S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!A9&IU<W1M96YT(&]F
M('=A<G)A;G0@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV,C8L,S0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,34P+#8Y-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q+#0U.2PT,S4I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG
M97,@:6X@;W!E<F%T:6YG(&%S<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U
M;G1S(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0R+#(P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,S4Q+#8U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$R+#4U,2PP-C8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@S-"PP-S$I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.3$L,38P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<V+#@W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5S=')I8W1E9"!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3<W+#,R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#4Q,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S<U+#`P,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW.#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,S,L-S@R*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C;W5N=',@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-3<P+#`Y,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@W+#,Q,BPS,S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3`L,C<Q+#`T."D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@97AP
M96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S0V+#4R
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$X-2PR,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-S(L.3@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,96%S92!E>&ET(&QI86)I;&ET>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C(X+#<V.2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,S,L-38P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0T-RPP
M,3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q-BPV-S8L-3`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$P+#@Q,"PP.#DI/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PR-S4L.3<V*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F
M97)R960@<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`R
M+#4W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0T,"PX,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,S(L,S(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@*'5S960@:6XI('!R;W9I
M9&5D(&)Y(&]P97)A=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q-"PQ-S(L,3(S*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L-3@Q+#DX.2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#<U-RPS-#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0V%S:"!F;&]W<R!F<F]M(&EN=F5S=&EN9R!A8W1I=FET:65S
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!U<F-H87-E<R!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#DV,"PW-S8I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.30P+#`T,RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,#`L
M,C$S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!C87-H('5S960@:6X@:6YV97-T:6YG(&%C=&EV:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L.38P+#<W-BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y-#`L
M,#0S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#4P,"PR,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO=W,@9G)O;2!F:6YA;F-I
M;F<@86-T:79I=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F('!R969E
M<G)E9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,BPP,30L.#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:RP@;F5T(&]F(&]F9F5R:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX-2PX-S$L,34S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8L.#(V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`L-#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A
M<V@@<')O=FED960@8GD@9FEN86YC:6YG(&%C=&EV:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@U+#@W,2PQ-3,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-BPX,C8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPP.#4L
M,C$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&-H86YG92!I;B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV."PW,S@L,C4T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RPT
M-S4L,C`V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$X+#,T,BPS-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@
M870@8F5G:6YN:6YG(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#<L-S0S+#$U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4U+#(Q."PS-C$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-BPX-S8L,#$X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H
M(&%N9"!C87-H(&5Q=6EV86QE;G1S(&%T(&5N9"!O9B!P97)I;V0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q-BPT.#$L-#`Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<L-S0S+#$U
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4U+#(Q."PS-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]N8V%S:"!F:6YA;F-I;F<@86-T:79I
M=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]N=F5R<VEO;B!O9B!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPY-#<L,C`R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S8R.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y
M-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,CEC-&)C85]C9&$W
M7S1D865?830T-5\Q,C0U864R-#AC.30O5V]R:W-H965T<R]3:&5E=#`W+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3W)G86YI
M>F%T:6]N(&%N9"!.871U<F4@;V8@3W!E<F%T:6]N<SQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG
M(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]R9V%N:7IA=&EO;B!A;F0@3F%T=7)E(&]F
M($]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O
M='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86XG/@T*(#QB/C$N($]R9V%N:7IA=&EO;B!A;F0@3F%T=7)E(&]F
M($]P97)A=&EO;G,\+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M-G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M
M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*($UA
M8W)O1V5N:6-S+"!);F,N("AT:&4@)B-X,C`Q0SM#;VUP86YY)B-X,C`Q1#LI
M('=A<R!I;F-O<G!O<F%T960@:6X-"B!$96QA=V%R92!O;B!!=6=U<W0F(WA!
M,#LQ-"P@,C`P,"X@5&AE($-O;7!A;GD@:7,@82!C;&EN:6-A;"US=&%G90T*
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M#0H@=&\@;F]V96P@8V%N8V5R('1A<F=E=',L(&%S('=E;&P@87,@)B-X,C`Q
M0SMB:6\M8F5T=&5R<R8C>#(P,40[('=H:6-H#0H@87)E(&1R=6=S(&1E<VEG
M;F5D('1O(&EM<')O=F4@=7!O;B!M87)K971E9"!M961I8VEN97,N/"]P/@T*
M(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP
M<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!/;B!/8W1O8F5R)B-X03`[,38L(#(P
M,3,L('1H92!#;VUP86YY(&-O;7!L971E9"!A;B!I;FET:6%L('!U8FQI8PT*
M(&]F9F5R:6YG("@F(W@R,#%#.TE03R8C>#(P,40[*2!O9B!I=',@8V]M;6]N
M('-T;V-K+"!W:&EC:"!R97-U;'1E9"!I;@T*('1H92!S86QE(&]F(#4L-S4P
M+#`P,"!S:&%R97,L(&EN8VQU9&EN9R!A;&P@861D:71I;VYA;"!S:&%R97,-
M"B!A=F%I;&%B;&4@=&\@8V]V97(@;W9E<BUA;&QO=&UE;G1S+"!A="!A('!R
M:6-E(&]F("0Q-BXP,"!P97(@<VAA<F4N#0H@5&AE($-O;7!A;GD@<F5C96EV
M960@;F5T('!R;V-E961S(&)E9F]R92!E>'!E;G-E<R!F<F]M('1H92!)4$\@
M;V8-"B`D.#4N-B!M:6QL:6]N(&%F=&5R(&1E9'5C=&EN9R!U;F1E<G=R:71I
M;F<@9&ES8V]U;G1S(&%N9`T*(&-O;6UI<W-I;VYS('!A:60@8GD@=&AE($-O
M;7!A;GDN/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-C(Y8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E
M,C0X8SDT#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A
M7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-"]7;W)K<VAE971S+U-H965T
M,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(%-I9VYI
M9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CXR+B!3=6UM87)Y
M(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\+V(^/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`V<'0G/@T*(#QB/CQI/D)A<VES(&]F(%!R97-E;G1A=&EO;B!A;F0@4')I
M;F-I<&QE<R!O9@T*($-O;G-O;&ED871I;VX\+VD^/"]B/CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
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M92!A;F0@:6YF96-T:6]U<PT*(&1I<V5A<V5S+CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@
M/&(^/&D^57-E(&]F($5S=&EM871E<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%
M6%0M24Y$14Y4.B`T)2<^#0H@5&AE('!R97!A<F%T:6]N(&]F('1H92!F:6YA
M;F-I86P@<W1A=&5M96YT<R!I;B!A8V-O<F1A;F-E('=I=&@-"B!G96YE<F%L
M;'D@86-C97!T960@86-C;W5N=&EN9R!P<FEN8VEP;&5S("@F(W@R,#%#.T=!
M05`F(W@R,#%$.RD-"B!R97%U:7)E<R!T:&4@0V]M<&%N>2!T;R!M86ME(&5S
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M:71S(&)E<W0@97-T:6UA=&5S(&%N9`T*(&IU9&=M96YT<R!O9B!C97)T86EN
M(&%M;W5N=',@:6YC;'5D960@:6X@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S
M+`T*(&=I=FEN9R!D=64@8V]N<VED97)A=&EO;B!T;R!M871E<FEA;&ET>2X@
M3VX@86X@;VYG;VEN9R!B87-I<RP@=&AE#0H@0V]M<&%N>2!E=F%L=6%T97,@
M:71S(&5S=&EM871E<RP@:6YC;'5D:6YG('1H;W-E(')E;&%T960@=&\@<F5V
M96YU90T*(')E8V]G;FET:6]N+"!F86ER('9A;'5E<R!O9B!A<W-E=',L(&-O
M;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:R!A;F0-"B!C;VUM;VX@<W1O8VLL
M('!R969E<G)E9"!S=&]C:R!W87)R86YT(&QI86)I;&ET>2P@:6YC;VUE('1A
M>&5S+`T*('!R92UC;&EN:6-A;"!S='5D>2!A;F0@8VQI;FEC86P@=')I86P@
M86-C<G5A;',@86YD(&]T:&5R#0H@8V]N=&EN9V5N8VEE<RX@36%N86=E;65N
M="!B87-E<R!I=',@97-T:6UA=&5S(&]N(&AI<W1O<FEC86P-"B!E>'!E<FEE
M;F-E(&]R(&]N('9A<FEO=7,@;W1H97(@87-S=6UP=&EO;G,@=&AA="!I="!B
M96QI979E<R!T;R!B90T*(')E87-O;F%B;&4@=6YD97(@=&AE(&-I<F-U;7-T
M86YC97,N($%C='5A;"!R97-U;'1S(&-O=6QD(&1I9F9E<@T*(&9R;VT@=&AE
M<V4@97-T:6UA=&5S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-
M"B!);B!A9&1I=&EO;BP@<')I;W(@=&\@=&AE($-O;7!A;GDF(W@R,#$Y.W,@
M25!/(&EN($]C=&]B97(@,C`Q,RP@=&AE#0H@0V]M<&%N>2!U=&EL:7IE9"!E
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M:71S('!R969E<G)E9`T*('-T;V-K+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3AP=#L@34%21TE.+51/4#H@
M,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#!P="<^#0H@/&(^/&D^0V%S:"!A;F0@
M0V%S:"!%<75I=F%L96YT<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@8V]N<VED97)S(&%L;"!I;G9E<W1M
M96YT<R!I;B!H:6=H;'D@;&EQ=6ED(&9I;F%N8VEA;`T*(&EN<W1R=6UE;G1S
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M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+51/4#H@,3AP="<^#0H@/&(^/&D^06-C;W5N=',@4F5C96EV86)L93PO:3X\
M+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@06-C;W5N=',@
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M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H
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M,2P@,C`Q,R!O<B`R,#$R+"!A<R!T:&4@0V]M<&%N>2!H87,@82!H:7-T;W)Y
M(&]F#0H@8V]L;&5C=&EN9R!O;B!A;&P@;W5T<W1A;F1I;F<@86-C;W5N=',N
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y297-T<FEC=&5D($-A<V@\+VD^/"]B
M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
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M-"PX-3`@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,PT*(&%N9"`R,#$R+CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+51/4#H@,3AP="<^#0H@/&(^/&D^1F%I<B!686QU92!O9B!&:6YA;F-I86P@
M26YS=')U;65N=',\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
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M<G)Y:6YG('9A;'5E<R!A=`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,3,@86YD
M(#(P,3(L(&1U92!T;R!T:&5I<B!S:&]R="UT97)M#0H@;6%T=7)I=&EE<RX@
M5&AE($-O;7!A;GD@86-C;W5N=',@9F]R(')E8W5R<FEN9R!A;F0@;F]N+7)E
M8W5R<FEN9PT*(&9A:7(@=F%L=64@;65A<W5R96UE;G1S(&EN(&%C8V]R9&%N
M8V4@=VET:"!T:&4@1FEN86YC:6%L($%C8V]U;G1I;F<-"B!3=&%N9&%R9',@
M0F]A<F0@*"8C>#(P,4,[1D%30B8C>#(P,40[*2!!8V-O=6YT:6YG(%-T86YD
M87)D<PT*($-O9&EF:6-A=&EO;B`H)B-X,C`Q0SM!4T,F(W@R,#%$.RD@.#(P
M+"`\:3Y&86ER(%9A;'5E($UE87-U<F5M96YT<PT*(&%N9"!$:7-C;&]S=7)E
M<SPO:3X@*"8C>#(P,4,[05-#(#@R,"8C>#(P,40[*2X@05-#(#@R,"!D969I
M;F5S(&9A:7(-"B!V86QU92P@97-T86)L:7-H97,@82!F86ER('9A;'5E(&AI
M97)A<F-H>2!F;W(@87-S971S(&%N9`T*(&QI86)I;&ET:65S(&UE87-U<F5D
M(&%T(&9A:7(@=F%L=64L(&%N9"!R97%U:7)E<R!E>'!A;F1E9`T*(&1I<V-L
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M(&9O;&QO=VEN9R!T:')E92!C871E9V]R:65S.CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@-G!T.R!-05)'24XM
M5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P/@T*(#QT<CX-
M"B`\=&0@=VED=&@],T0U)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0R)2!A;&EG;CTS1&QE9G0^)B-X,C`R,CL\+W1D/@T*(#QT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1T;W`@86QI9VX],T1L969T/DQE=F5L(#$F(W@R,#$T.T9A:7(@
M=F%L=64@:7,-"B!D971E<FUI;F5D(&)Y('5S:6YG('5N861J=7-T960@<75O
M=&5D('!R:6-E<R!T:&%T(&%R92!A=F%I;&%B;&4@:6X-"B!A8W1I=F4@;6%R
M:V5T<R!F;W(@:61E;G1I8V%L(&%S<V5T<R!A;F0@;&EA8FEL:71I97,N/"]T
M9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#9P=#L@34%21TE.+51/4#H@,'!T)SX-
M"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!
M4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H
M/3-$-24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,B4@86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P
M(&%L:6=N/3-$;&5F=#Y,979E;"`R)B-X,C`Q-#M&86ER('9A;'5E(&ES#0H@
M9&5T97)M:6YE9"!B>2!U<VEN9R!I;G!U=',@;W1H97(@=&AA;B!,979E;"`Q
M('%U;W1E9"!P<FEC97,@=&AA=`T*(&%R92!D:7)E8W1L>2!O<B!I;F1I<F5C
M=&QY(&]B<V5R=F%B;&4N($EN<'5T<R!C86X@:6YC;'5D92!Q=6]T960-"B!P
M<FEC97,@9F]R('-I;6EL87(@87-S971S(&%N9"!L:6%B:6QI=&EE<R!I;B!A
M8W1I=F4@;6%R:V5T<R!O<@T*('%U;W1E9"!P<FEC97,@9F]R(&ED96YT:6-A
M;"!A<W-E=',@86YD(&QI86)I;&ET:65S(&EN(&EN86-T:79E#0H@;6%R:V5T
M<RX@4F5L871E9"!I;G!U=',@8V%N(&%L<V\@:6YC;'5D92!T:&]S92!U<V5D
M(&EN('9A;'5A=&EO;B!O<@T*(&]T:&5R('!R:6-I;F<@;6]D96QS+"!S=6-H
M(&%S(&EN=&5R97-T(')A=&5S(&%N9"!Y:65L9"!C=7)V97,@=&AA=`T*(&-A
M;B!B92!C;W)R;V)O<F%T960@8GD@;V)S97)V86)L92!M87)K970@9&%T82X\
M+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@-G!T.R!-05)'24XM5$]0.B`P<'0G
M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED
M=&@],T0U)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0R)2!A;&EG;CTS1&QE9G0^)B-X,C`R,CL\+W1D/@T*(#QT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T
M;W`@86QI9VX],T1L969T/DQE=F5L(#,F(W@R,#$T.T9A:7(@=F%L=64@:7,-
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M>2X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@
M,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E)SX-
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M<R!L:64@=VET:&EN('1H92!!4T,@.#(P(&AI97)A<F-H>2X\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R
M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@1FEN86YC:6%L(&%S<V5T<R!A;F0@
M;&EA8FEL:71I97,@<W5B:F5C="!T;R!F86ER('9A;'5E(&UE87-U<F5M96YT
M<PT*('=E<F4@87,@9F]L;&]W<SH\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P
M="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#
M3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-
M"B`\='(^#0H@/'1D('=I9'1H/3-$,S@E/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#@E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#@E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#$T(&%L:6=N/3-$8V5N=&5R/CQB/D9A:7(@5F%L=64@365A
M<W5R96UE;G1S(&%T#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,SPO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY1=6]T960F(WA!,#M0<FEC
M97,F(WA!,#MI;CQB<B`O/@T*($%C=&EV92!-87)K971S/&)R("\^#0H@9F]R
M/&)R("\^#0H@261E;G1I8V%L($%S<V5T<SPO8CX\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@86QI9VX],T1C96YT97(^/&(^4VEG;FEF:6-A;G0F(WA!,#M/=&AE
M<CQB<B`O/@T*($]B<V5R=F%B;&4\8G(@+SX-"B!);G!U=',\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E-I9VYI9FEC86YT
M/&)R("\^#0H@56YO8G-E<G9A8FQE/&)R("\^#0H@26YP=71S/"]B/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M/CQB/E1O=&%L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M8CY,979E;"`Q/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CY,979E;"`R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CY,979E;"`S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!!<W-E=',Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#87-H(&%N9"!C87-H
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M(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($UO;F5Y(&UA
M<FME="!F=6YD<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(V
M+#`T-BPY-S0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C8L,#0V
M+#DW-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)E<W1R:6-T
M960@8V%S:#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0P-"PX
M-3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#`T+#@U,#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M(%1O=&%L($%S<V5T<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q-BPX.#8L,C4Y
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$Q-BPX.#8L,C4Y/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R/@T*(#QT9#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$,38^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,30@86QI9VX]
M,T1C96YT97(^/&(^1F%I<B!686QU92!-96%S=7)E;65N=',@870-"B!$96-E
M;6)E<B8C>$$P.S,Q+"`R,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R/CQB/E%U;W1E9"8C>$$P.U!R:6-E<R8C>$$P.VEN/&)R("\^#0H@
M06-T:79E($UA<FME=',\8G(@+SX-"B!F;W(\8G(@+SX-"B!)9&5N=&EC86P@
M07-S971S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<CX\8CY3:6=N:69I8V%N="8C>$$P.T]T:&5R/&)R("\^#0H@3V)S97)V86)L
M93QB<B`O/@T*($EN<'5T<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&(^4VEG;FEF:6-A;G0\8G(@+SX-"B!5;F]B<V5R=F%B
M;&4\8G(@+SX-"B!);G!U=',\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^5&]T86P\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#$\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#(\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L
M(#,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%S<V5T<SH\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/@T*($-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3@L-CDU+#$Y-SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,3@L-CDU+#$Y-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F
M(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R
M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@36]N97D@;6%R:V5T(&9U;F1S/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,CDL,#0W+#DU.#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XR.2PP-#<L.34X/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@4F5S=')I8W1E9"!C87-H/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#`T+#@U,#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XT,#0L.#4P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^
M#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H
M=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5&]T86P@07-S971S/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-#@L,30X+#`P-3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT
M."PQ-#@L,#`U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!,:6%B:6QI=&EE<SH\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@4')E9F5R<F5D('-T;V-K('=A<G)A;G0@;&EA8FEL:71Y/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#4R+#DT-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/B@U,BPY-#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($%S
M(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,3(L('1H92!#;VUP86YY('1R86YS
M9F5R<F5D(&ET<R!M;VYE>0T*(&UA<FME="!F=6YD<R!F<F]M($QE=F5L(#(@
M=&\@3&5V96P@,2!B96-A=7-E('1H92!I;G!U=',@87)E(&YO=PT*(&)A<V5D
M('5P;VX@82!Q=6]T960@;6%R:V5T('!R:6-E+CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$58
M5"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M<&%N>28C>#(P,3D[<R!,979E;"`Q
M('-E8W5R:71I97,@<')I;6%R:6QY(&-O;G-I<W0@;V8-"B!R97-T<FEC=&5D
M(&-A<V@L(&-A<V@@97%U:79A;&5N=',@86YD(&UO;F5Y(&UA<FME="!F=6YD
M<RX@5&AE#0H@0V]M<&%N>2!D971E<FUI;F5S('1H92!E<W1I;6%T960@9F%I
M<B!V86QU92!F;W(@:71S($QE=F5L(#$-"B!S96-U<FET:65S('5S:6YG('%U
M;W1E9"`H=6YA9&IU<W1E9"D@<')I8V5S(&9O<B!I9&5N=&EC86P@87-S971S
M(&]R#0H@;&EA8FEL:71I97,@:6X@86-T:79E(&UA<FME=',N/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q
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M;&ET>2`H92YG+BP@:6YT97)E<W0-"B!R871E<RP@>6EE;&0@8W5R=F5S('9O
M;&%T:6QI=&EE<RP@9&5F875L="!R871E<RP@971C+BD@86YD(&EN<'5T<PT*
M('1H870@87)E(&1E<FEV960@<')I;F-I<&%L;'D@9G)O;2!O<B!C;W)R;V)O
M<F%T960@8GD@;W1H97(-"B!O8G-E<G9A8FQE(&UA<FME="!D871A+CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#!P=#L@
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M8V%N="!U;F]B<V5R=F%B;&4@:6YP=71S("A,979E;"`S*2!A<R!D969I;F5D
M(&EN($%30PT*(#@R,#H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@
M)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!3
M13H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0V."4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^
M#0H@/'1D('=I9'1H/3-$.#(E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$P)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!"86QA
M;F-E(&%T($1E8V5M8F5R)B-X03`[,S$L(#(P,3(\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XH-3(L.30W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5&]T86P@=6YR
M96%L:7IE9"!G86EN<R`H;&]S<V5S*2!I;F-L=61E9"!I;B!E87)N:6YG<SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#8R-BPS-#D\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!3971T;&5M96YT(&]F('!R
M969E<G)E9"!S=&]C:R!W87)R86YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-C<Y+#(Y-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0F%L86YC92!A="!$96-E;6)E<B8C
M>$$P.S,Q+"`R,#$S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
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M('1O(&QI<75I9&%T:6]N(&%N9`T*(&-O;G9E<G-I;VX@8F5H879I;W(@;V8@
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M92!O9B!T:&4@;W5T<W1A;F1I;F<-"B!W87)R86YT<RX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE('1O=&%L('5N<F5A;&EZ960@9V%I
M;G,@*&QO<W-E<RD@;VX@=&AE('!R969E<G)E9"!S=&]C:R!W87)R86YT<PT*
M(&EN8VQU9&5D(&EN(&5A<FYI;F=S(&ES(&EN8VQU9&5D(&%S(&$@8V]M<&]N
M96YT(&]F(&]T:&5R(&EN8V]M90T*("AE>'!E;G-E*2!I;B!T:&4@8V]N<V]L
M:61A=&5D('-T871E;65N="!O9B!O<&5R871I;VYS(&%N9`T*(&-O;7!R96AE
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M8V]M;6]N('-T;V-K+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^/&D^0V]N8V5N=')A
M=&EO;B!O9B!#<F5D:70@4FES:SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@4W5B<W1A;G1I86QL>2!A;&P@;V8@=&AE($-O;7!A
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M<F4L(&)E87(@;6EN:6UA;"!R:7-K+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
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M9V5N8VEE<R!O9B!H:6=H(&-R961I="!S=&%N9&EN9RX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@1F]R('1H92!Y96%R<R!E;F1E9"!$96-E
M;6)E<B8C>$$P.S,Q+"`R,#$S+"`R,#$R(&%N9"`R,#$Q+"!A;&P@;V8-"B!T
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M;6)(("@F(W@R,#%#.T)O96AR:6YG97(F(W@R,#%$.RDL($=I;&5A9`T*(%-C
M:65N8V5S+"!);F,N("@F(W@R,#%#.T=I;&5A9"8C>#(P,40[*2P@4&9I>F5R
M+"!);F,N#0H@*"8C>#(P,4,[4&9I>F5R)B-X,C`Q1#LI(&%N9"!%;&D@3&EL
M;'DF(WA!,#LF86UP.R!#;RX@*"8C>#(P,4,[16QI#0H@3&EL;'DF(W@R,#%$
M.RD@86-C;W5N="!F;W(@86QL(&]T:&5R(')E=F5N=64N($%L;"!O=71S=&%N
M9&EN9PT*(')E8V5I=F%B;&5S(&%R92!D=64@9G)O;2!T:&4@0V]M<&%N>28C
M>#(P,3D[<R!C;VQL86)O<F%T;W)S(&%N9"!5+E,N#0H@9V]V97)N;65N="!A
M9V5N8VEE<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE(&9O;&QO=VEN
M9R!T86)L92!R97!R97-E;G1S('1H92!P97)C96YT86=E(&]F(&%L;"!S:6=N
M:69I8V%N=`T*(')E=F5N=64@96%R;F5D(&EN('1H92!P97)I;V1S(&EN9&EC
M871E9#H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P
M/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X
M-"4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I
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M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX-"B`\8CY996%R)B-X03`[
M16YD960F(WA!,#M$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX-"B`\8CXF
M(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LR,#$S)B-X03`[)B-X03`[)B-X03`[
M)B-X03`[/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX-"B`\
M8CXF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LR,#$R)B-X03`[)B-X03`[)B-X
M03`[)B-X03`[/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX-
M"B`\8CXF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LR,#$Q)B-X03`[)B-X03`[
M)B-X03`[)B-X03`[/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!397)V
M:65R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3$N-CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3<N,SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R
M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M0F]E:')I;F=E<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(T
M+C@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X+C0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
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M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!':6QE860\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XQ,RXX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%!F:7IE<CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N,#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^."XW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,"XX/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1V]V97)N;65N
M="!!9V5N8VEE<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(N
M,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BXU/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ-RXW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@16QI($QI
M;&QY/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2XT/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XT."XY/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XU-"XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R
M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE(&9O;&QO=VEN9R!T86)L92!R
M97!R97-E;G1S('1H92!P97)C96YT86=E(&]F(&%L;"!S:6=N:69I8V%N=`T*
M(&%C8V]U;G1S(')E8V5I=F%B;&4Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P
M<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M
M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$-S8E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^
M#0H@/'1R/@T*(#QT9"!W:61T:#TS1#<U)3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3`E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@
M86QI9VX],T1C96YT97(^/&(^1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M#0H@/&(^)B-X03`[)B-X03`[)B-X03`[)B-X03`[,C`Q,R8C>$$P.R8C>$$P
M.R8C>$$P.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^#0H@/&(^)B-X03`[)B-X03`[)B-X03`[)B-X03`[,C`Q,B8C>$$P.R8C
M>$$P.R8C>$$P.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M1VEL96%D/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3,N-#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@4&9I>F5R+CPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C$R+C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0U
M+C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B4F(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!"
M;V5H<FEN9V5R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3(N
M,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3@N,#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($5L:2!,:6QL>3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C<N,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C@N,CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-E<G9I97(\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+C0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG
M:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($=O=F5R;FUE;G0@06=E;F-I97,\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XT+C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C@N-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-
M"B`\8CX\:3Y0<F]P97)T>2!A;F0@17%U:7!M96YT/"]I/CPO8CX\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z
M(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!0<F]P97)T>2!A;F0@97%U:7!M
M96YT(&%R92!S=&%T960@870@8V]S="X@57!O;B!R971I<F5M96YT(&]R('-A
M;&4L#0H@=&AE(&-O<W0@;V8@87-S971S(&1I<W!O<V5D(&]F(&%N9"!T:&4@
M<F5L871E9"!A8V-U;75L871E9`T*(&1E<')E8VEA=&EO;B!A<F4@<F5M;W9E
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M#0H@97-T:6UA=&5D('5S969U;"!L:79E<SH\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU4
M3U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/
M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N=&5R(&)O<F1E
M<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4Q)3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X\+W1D/@T*(#QT9"!W:61T:#TS
M1#0W)3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#;VUP=71E<B!E<75I<&UE;G0\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XS('EE87)S/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@4V]F='=A<F4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XS
M('EE87)S/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1G5R;FET=7)E/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^,3`@>65A<G,\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!,
M86)O<F%T;W)Y(&%N9"!O9F9I8V4@97%U:7!M96YT/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^-2!Y96%R<SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($QE87-E
M:&]L9"!I;7!R;W9E;65N=',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3Y3:&]R=&5R(&]F(&QE87-E('1E<FT@;W(@=7-E9G5L(&QI9F4\+W1D/@T*
M(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^/&D^26UP86ER;65N
M="!O9B!,;VYG+4QI=F5D($%S<V5T<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%
M6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@87-S97-S97,@=&AE(')E
M8V]V97)A8FEL:71Y(&]F(&ET<R!L;VYG+6QI=F5D(&%S<V5T<R!I;@T*(&%C
M8V]R9&%N8V4@=VET:"!T:&4@<')O=FES:6]N<R!O9B!!4T,F(WA!,#LS-C`L
M(#QI/E!R;W!E<G1Y+"!0;&%N=`T*(&%N9"!%<75I<&UE;G0\+VD^+B!!4T,@
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M965D<R!T:&4@<W5M(&]F('5N9&ES8V]U;G1E9`T*(&-A<V@@9FQO=W,L('1H
M92!#;VUP86YY('1H96X@9&5T97)M:6YE<R!T:&4@9F%I<B!V86QU92!O9B!T
M:&4-"B!U;F1E<FQY:6YG(&%S<V5T(&=R;W5P+B!!;GD@:6UP86ER;65N="!T
M;R!B92!R96-O9VYI>F5D(&ES(&UE87-U<F5D#0H@8GD@=&AE(&%M;W5N="!B
M>2!W:&EC:"!T:&4@8V%R<GEI;F<@86UO=6YT(&]F('1H92!A<W-E="!G<F]U
M<`T*(&5X8V5E9',@=&AE(&5S=&EM871E9"!F86ER('9A;'5E(&]F('1H92!A
M<W-E="!G<F]U<"X@07-S971S('1O(&)E#0H@9&ES<&]S960@;V8@87)E(')E
M<&]R=&5D(&%T('1H92!L;W=E<B!O9B!T:&4@8V%R<GEI;F<@86UO=6YT(&]R
M#0H@9F%I<B!V86QU92P@;&5S<R!C;W-T<R!T;R!S96QL+B!!<R!O9B!$96-E
M;6)E<B8C>$$P.S,Q+"`R,#$S(&%N9`T*(#(P,3(L('1H92!#;VUP86YY(&1E
M=&5R;6EN960@=&AA="!T:&5R92!W97)E(&YO(&EM<&%I<F5D(&%S<V5T<R!A
M;F0-"B!H860@;F\@87-S971S(&AE;&0M9F]R+7-A;&4N/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q.'!T.R!-
M05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T)SX-"B`\8CX\
M:3Y);F-O;64@5&%X97,\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
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M9"!B87-E9"!O;B!A(&UO<F4M;&EK96QY+71H86XM;F]T('1H<F5S:&]L9`T*
M(&]F('1H870@<&]S:71I;VX@8F5I;F<@<W5S=&%I;F5D+B!)9B!T:&4@=&%X
M('!O<VET:6]N(&UE971S('1H:7,-"B!T:')E<VAO;&0L('1H92!B96YE9FET
M('1O(&)E(')E8V]G;FEZ960@:7,@;65A<W5R960@87,@=&AE(&QA<F=E<W0-
M"B!A;6]U;G0@=&AA="!I<R!M;W)E('1H86X@-3`E(&QI:V5L>2!T;R!B92!R
M96%L:7IE9"!U<&]N('5L=&EM871E#0H@<V5T=&QE;65N="X@5&AE($-O;7!A
M;GDF(W@R,#$Y.W,@<&]L:6-Y(&ES('1O(')E8V]R9"!I;G1E<F5S="!A;F0-
M"B!P96YA;'1I97,@<F5L871E9"!T;R!U;F-E<G1A:6X@=&%X('!O<VET:6]N
M<R!A<R!A(&-O;7!O;F5N="!O9@T*(&EN8V]M92!T87@@97AP96YS92X\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$X<'0G/@T*(#QB/CQI/E)E=F5N=65S/"]I/CPO8CX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`R
M)3L@34%21TE.+51/4#H@-G!T)SX-"B`\:3Y2979E;G5E(%)E8V]G;FET:6]N
M/"]I/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP
M86YY(&5N=&5R<R!I;G1O(&-O;&QA8F]R871I;VX@86YD(&QI8V5N<V4@86=R
M965M96YT<R!W:71H#0H@8V]L;&%B;W)A=&]R<R!F;W(@=&AE(&1E=F5L;W!M
M96YT(&]F(&UO;F]C;&]N86P@86YT:6)O9'DM8F%S960-"B!T:&5R87!E=71I
M8W,@=&\@=')E870@8V%N8V5R(&%N9"!O=&AE<B!C;VUP;&5X(&1I<V5A<V5S
M+B!4:&4@=&5R;7,-"B!O9B!T:&5S92!A9W)E96UE;G1S(&-O;G1A:6X@;75L
M=&EP;&4@9&5L:79E<F%B;&5S('=H:6-H(&UA>2!I;F-L=61E#0H@*&DI)B-X
M03`[;&EC96YS97,L(&]R(&]P=&EO;G,@=&\@;V)T86EN(&QI8V5N<V5S+"!T
M;R!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS('1E8VAN;VQO9VEC86P@<&QA=&9O
M<FUS+"!S=6-H(&%S(&ET<R!&8PT*($]P=&EM:7IA=&EO;B!A;F0@1'5A;"U!
M9F9I;FET>2!292U487)G971I;F<@*"8C>#(P,4,[1$%25"8C>#(P,40[*0T*
M('1E8VAN;VQO9VEE<RP@*&EI*28C>$$P.W)I9VAT<R!T;R!F=71U<F4@=&5C
M:&YO;&]G:6-A;`T*(&EM<')O=F5M96YT<RP@*&EI:2DF(WA!,#MR97-E87)C
M:"!A;F0@9&5V96QO<&UE;G0@86-T:79I=&EE<R!T;R!B90T*('!E<F9O<FUE
M9"!O;B!B96AA;&8@;V8@=&AE(&-O;&QA8F]R871O<B!O<B!A<R!P87)T(&]F
M('1H90T*(&-O;&QA8F]R871I;VXL(&%N9"`H:78I)B-X03`[=&AE(&UA;G5F
M86-T=7)E(&]F('!R92UC;&EN:6-A;"!O<@T*(&-L:6YI8V%L(&UA=&5R:6%L
M<R!F;W(@=&AE(&-O;&QA8F]R871O<BX@4&%Y;65N=',@=&\@=&AE($-O;7!A
M;GD-"B!U;F1E<B!T:&5S92!A9W)E96UE;G1S(&UA>2!I;F-L=61E(&YO;G)E
M9G5N9&%B;&4@;&EC96YS92!F965S+`T*(&]P=&EO;B!F965S+"!E>&5R8VES
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M;WEA;'1I97,@;VX@<')O9'5C=`T*('-A;&5S+B!/=&AE<B!B96YE9FET<R!T
M;R!T:&4@0V]M<&%N>2!O9B!T:&5S92!A9W)E96UE;G1S(&EN8VQU9&4-"B!T
M:&4@<FEG:'0@=&\@<V5L;"!P<F]D=6-T<R!R97-U;'1I;F<@9G)O;2!T:&4@
M8V]L;&%B;W)A=&EV92!E9F9O<G1S#0H@;V8@=&AE('!A<G1I97,@:6X@<W!E
M8VEF:6,@9V5O9W)A<&AI8R!T97)R:71O<FEE<RX@5&AE($-O;7!A;GD-"B!F
M;VQL;W=S('1H92!P<F]V:7-I;VYS(&]F('1H92!&05-"($%30R!4;W!I8R`V
M,#4M,C4L(#QI/E)E=F5N=64-"B!296-O9VYI=&EO;B8C>$$P.R8C>#(P,3,[
M)B-X03`[375L=&EP;&4M16QE;65N="!!<G)A;F=E;65N=',\+VD^+`T*(&%N
M9"!!4T,@5&]P:6,@-C`U+3(X+"`\:3Y2979E;G5E(%)E8V]G;FET:6]N)B-X
M,C`Q,SM-:6QE<W1O;F4-"B!-971H;V0\+VD^+"!I;B!A8V-O=6YT:6YG(&9O
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M:"!O9B!T:&4-"B!S97!A<F%T92!U;FET<RX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@1F]R('1H92!P97)I;V1S('!R97-E;G1E9"P@=&AE
M($-O;7!A;GD@:&%D('1H92!F;VQL;W=I;F<@='=O('1Y<&5S#0H@;V8@86=R
M965M96YT<R!W:71H('1H92!P87)T:65S(&ED96YT:69I960@8F5L;W<Z(#$I
M(&5X8VQU<VEV90T*(&1E=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO
M;B!L:6-E;G-E<R!T;R!U<V4@=&AE#0H@0V]M<&%N>28C>#(P,3D[<R!T96-H
M;F]L;V=Y(&%N9"]O<B!C97)T86EN(&]T:&5R(&EN=&5L;&5C='5A;`T*('!R
M;W!E<G1Y('1O(&1E=F5L;W`@8V]M<&]U;F1S(&%G86EN<W0@<W!E8VEF:65D
M('1A<F=E=',@*')E9F5R<F5D#0H@=&\@:&5R96EN(&%S(&5X8VQU<VEV92!L
M:6-E;G-E<RD[(&%N9"`R*2!/<'1I;VXO<F5S96%R8V@@86=R965M96YT<PT*
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M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H97)E(&%R
M92!N;R!P97)F;W)M86YC92P@8V%N8V5L;&%T:6]N+"!T97)M:6YA=&EO;B!O
M<B!R969U;F0-"B!P<F]V:7-I;VYS(&EN(&%N>2!O9B!T:&4@87)R86YG96UE
M;G1S('1H870@8V]N=&%I;B!M871E<FEA;`T*(&9I;F%N8VEA;"!C;VYS97%U
M96YC97,@=&\@=&AE($-O;7!A;GDN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z
M(#$X<'0G/@T*(#QI/D5X8VQU<VEV92!,:6-E;G-E<SPO:3X\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P
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M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
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M=&%I;B!M:6QE<W1O;F5S+"`H:6EI*28C>$$P.V5A<FX@<F]Y86QT>0T*('!A
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M;B!R:6=H=',N(%1H92!#;VUP86YY(&UA>2!P<F]V:61E('1E8VAN:6-A;`T*
M(&%S<VES=&%N8V4@86YD('-H87)E(&%N>2!T96-H;F]L;V=Y(&EM<')O=F5M
M96YT<R!W:71H(&ET<PT*(&-O;&QA8F]R871O<G,@9'5R:6YG('1H92!T97)M
M(&]F('1H92!C;VQL86)O<F%T:6]N(&%G<F5E;65N=',N/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T
M.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY(&1O97,@;F]T(&1I
M<F5C=&QY(&-O;G1R;VP@=VAE;B!A;GD@8V]L;&%B;W)A=&]R('=I;&P-"B!A
M8VAI979E(&UI;&5S=&]N97,@;W(@8F5C;VUE(&QI86)L92!F;W(@<F]Y86QT
M>2!P87EM96YT<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
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M<V5A<F-H(&%N9`T*(&1E=F5L;W!M96YT(&-A<&%B:6QI=&EE<R!O9B!T:&4@
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M:&4-"B!#;VUP86YY)B-X,C`Q.3MS('!R979I;W5S(&-O;&QA8F]R871I;VX@
M86=R965M96YT<RP@<F5C96YT#0H@<')E+6-L:6YI8V%L(&%N9"!C;&EN:6-A
M;"!T97-T:6YG(')E<W5L=',@;V8@=&AE<F%P975T:6,@<')O9'5C=`T*(&-A
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M;W(@<VEM:6QA<B!S97)V:6-E<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@57!F<F]N="!P87EM96YT<R!O;B!E>&-L=7-I=F4@;&EC96YS
M97,@87)E(&1E9F5R<F5D(&EF(&9A8W1S(&%N9`T*(&-I<F-U;7-T86YC97,@
M9&EC=&%T92!T:&%T('1H92!L:6-E;G-E(&1O97,@;F]T(&AA=F4@<W1A;F0M
M86QO;F4-"B!V86QU92X@4')I;W(@=&\@=&AE(&%D;W!T:6]N(&]F($%C8V]U
M;G1I;F<@4W1A;F1A<F1S(%5P9&%T90T*("@F(W@R,#%#.T%3528C>#(P,40[
M*2!.;RXF(WA!,#LR,#`Y+3$S+"`\:3Y2979E;G5E($%R<F%N9V5M96YT<R!W
M:71H#0H@375L=&EP;&4@1&5L:79E<F%B;&5S/"]I/BP@;VX@2F%N=6%R>28C
M>$$P.S$L(#(P,3$L('1H92!#;VUP86YY#0H@9&5T97)M:6YE9"!T:&%T(&ET
M<R!L:6-E;G-E<R!L86-K960@<W1A;F0M86QO;F4@=F%L=64@8F5C875S92!I
M=`T*(&1I9"!N;W0@:&%V92!V96YD;W(M<W!E8VEF:6,@;V)J96-T:79E(&5V
M:61E;F-E(&]F('-E;&QI;F<@<')I8V4-"B`H)B-X,C`Q0SM64T]%)B-X,C`Q
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M:6YT;R!P<FEO<B!T;R!T:&4@861O<'1I;VX-"B!O9B!!4U4@3F\N)B-X03`[
M,C`P.2TQ,RP@<VEG;FEF:6-A;G0@:G5D9VUE;G0@86YD(&5S=&EM871I;VX@
M:7,-"B!U<V5D(&)Y('1H92!#;VUP86YY(&%N9"!C86X@:&%V92!A;B!I;7!A
M8W0@;VX@=&AE(&%M;W5N="!O9B!R979E;G5E#0H@<F5C;V=N:7IE9"!I;B!A
M(&=I=F5N('!E<FEO9"X@2&ES=&]R:6-A;&QY+"!T:&4@0V]M<&%N>28C>#(P
M,3D[<PT*(&EN=F]L=F5M96YT('=I=&@@=&AE(&1E=F5L;W!M96YT(&]F(&$@
M8V]L;&%B;W)A=&]R)B-X,C`Q.3MS('!R;V1U8W0-"B!C86YD:61A=&4@:&%S
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M;G9O;'9E;65N="X-"B!!4U4@3F\N)B-X03`[,C`P.2TQ,R!A;65N9',@=&AE
M(&-R:71E<FEA(&9O<B!S97!A<F%T:6YG(&%N9`T*(&%L;&]C871I;F<@8V]N
M<VED97)A=&EO;B!I;B!A(&UU;'1I<&QE(&5L96UE;G0@87)R86YG96UE;G0@
M8GD-"B!M;V1I9GEI;F<@=&AE(&9A:7(@=F%L=64@<F5Q=6ER96UE;G1S(&9O
M<B!R979E;G5E(')E8V]G;FET:6]N(&%N9`T*(&5L:6UI;F%T:6YG('1H92!U
M<V4@;V8@=&AE(')E<VED=6%L('9A;'5E(&UE=&AO9"X@5&AE('-E;&QI;F<-
M"B!P<FEC97,@;V8@9&5L:79E<F%B;&5S('5N9&5R(&%N(&%R<F%N9V5M96YT
M(&UA>2!B92!D97)I=F5D('5S:6YG#0H@=&AI<F0M<&%R='D@979I9&5N8V4@
M*"8C>#(P,4,[5%!%)B-X,C`Q1#LI+"!O<B!A(&)E<W0@97-T:6UA=&4@;V8-
M"B!S96QL:6YG('!R:6-E("@F(W@R,#%#.T)%4U`F(W@R,#%$.RDL(&EF(%93
M3T4@:7,@;F]T(&%V86EL86)L92X@5&AE#0H@;V)J96-T:79E(&]F($)%4U`@
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M:7!L92!F86-T;W)S+`T*(&EN8VQU9&EN9R!M87)K970@8V]N9&ET:6]N<R!A
M;F0@8V]M<&%N>2US<&5C:69I8R!F86-T;W)S+"!I;F-L=61I;F<-"B!T:&]S
M92!F86-T;W)S(&-O;G1E;7!L871E9"!I;B!N96=O=&EA=&EN9R!T:&4@86=R
M965M96YT<RP@87,@=V5L;`T*(&%S(&EN=&5R;F%L;'D@9&5V96QO<&5D(&UO
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M;B!V86QI9&%T:6YG('1H90T*($)%4U`L(&UA;F%G96UE;G0@8V]N<VED97)S
M('=H971H97(@8VAA;F=E<R!I;B!K97D@87-S=6UP=&EO;G,@=7-E9`T*('1O
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M;VX@82!S=&%N9&%L;VYE(&)A<VES(&%N9"`H:6DI)B-X03`[:68@=&AE(&%R
M<F%N9V5M96YT#0H@:6YC;'5D97,@82!G96YE<F%L(')I9VAT(&]F(')E='5R
M;B!R96QA=&EV92!T;R!T:&4@9&5L:79E<F5D(&ET96TL#0H@9&5L:79E<GD@
M;W(@<&5R9F]R;6%N8V4@;V8@=&AE('5N9&5L:79E<F5D(&ET96T@:7,@8V]N
M<VED97)E9`T*('!R;V)A8FQE(&%N9"!S=6)S=&%N=&EA;&QY('=I=&AI;B!T
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M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4
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M:`T*(&5X<&5R=&ES92!I;B!T:&4@;6%R:V5T<&QA8V4N($EN(&%D9&ET:6]N
M+"!T:&4@0V]M<&%N>2!C;VYS:61E<F5D#0H@=VAE=&AE<B!O<B!N;W0@*&DI
M)B-X03`[=&AE(&-O;&QA8F]R871O<B!C;W5L9"!U<V4@=&AE(&QI8V5N<V4@
M9F]R#0H@:71S(&EN=&5N9&5D('!U<G!O<V4@=VET:&]U="!T:&4@<F5C96EP
M="!O9B!T:&4@<F5M86EN:6YG#0H@9&5L:79E<F%B;&5S+"`H:6DI)B-X03`[
M=&AE('9A;'5E(&]F('1H92!L:6-E;G-E('=A<R!D97!E;F1E;G0@;VX-"B!T
M:&4@=6YD96QI=F5R960@:71E;7,@86YD("AI:6DI)B-X03`[=&AE(&-O;&QA
M8F]R871O<B!O<B!O=&AE<@T*('9E;F1O<G,@8V]U;&0@<')O=FED92!T:&4@
M=6YD96QI=F5R960@:71E;7,N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@
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M('1O(&1E=F5L;W`@86X@86QT97)N871I=F4@<')O9'5C=`T*(&-A;F1I9&%T
M92!T;R!T:&4@<V%M92!T87)G970@;W(@82!T87)G970@<W5B<W1I='5T92P@
M=&AE($-O;7!A;GD-"B!W;W5L9"!C96%S92!A;6]R=&EZ871I;VX@;V8@86YY
M(')E;6%I;FEN9R!P;W)T:6]N(&]F('1H92!U<&9R;VYT#0H@9F5E('5N=&EL
M('1H97)E(&ES('-U8G-T86YT:6%L('!R92UC;&EN:6-A;"!A8W1I=FET>2!O
M;B!A;F]T:&5R#0H@<')O9'5C="!C86YD:61A=&4@86YD(&ET<R!R96UA:6YI
M;F<@<&5R:6]D(&]F('-U8G-T86YT:6%L#0H@:6YV;VQV96UE;G0@8V%N(&)E
M(&5S=&EM871E9"X@26X@=&AE(&5V96YT('1H870@82!S:6YG;&4@=&%R9V5T
M#0H@;&EC96YS92!W97)E('1O(&)E('1E<FUI;F%T960L('1H92!#;VUP86YY
M('=O=6QD(')E8V]G;FEZ92!A<PT*(')E=F5N=64@86YY('!O<G1I;VX@;V8@
M=&AE('5P9G)O;G0@9F5E('1H870@:&%D(&YO="!P<F5V:6]U<VQY(&)E96X-
M"B!R96-O<F1E9"!A<R!R979E;G5E+"!B=70@=V%S(&-L87-S:69I960@87,@
M9&5F97)R960@<F5V96YU92P@870@=&AE#0H@9&%T92!O9B!S=6-H('1E<FUI
M;F%T:6]N(&]R('1H<F]U9V@@=&AE(')E;6%I;FEN9R!S=6)S=&%N=&EA;`T*
M(&EN=F]L=F5M96YT(&EN('1H92!W:6YD(&1O=VX@;V8@=&AE(&%G<F5E;65N
M="X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@57!F<F]N="!P
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M=7)E('1E8VAN;VQO9VEC86P@:6UP<F]V96UE;G1S+`T*(')E<V5A<F-H('-E
M<G9I8V5S(&%N9"!T:&4@;6%N=69A8W1U<F4@;V8@<')E+6-L:6YI8V%L(&%N
M9"!C;&EN:6-A;`T*(&UA=&5R:6%L<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@<F5C;V=N:7IE<R!R979E;G5E(')E
M;&%T960@=&\@<F5S96%R8V@@86YD('!R92UC;&EN:6-A;`T*(&1E=F5L;W!M
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M<&QI8V%B;&4@;&EC96YS92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@5&AE($-O;7!A;GD@='EP:6-A;&QY('!E<F9O<FUS(')E<V5A<F-H
M(&%C=&EV:71I97,@86YD('!R92UC;&EN:6-A;`T*(&1E=F5L;W!M96YT('-E
M<G9I8V5S+"!I;F-L=61I;F<@9V5N97)A=&EN9R!A;F0@96YG:6YE97)I;F<@
M<')O9'5C=`T*(&-A;F1I9&%T97,L(&]N(&)E:&%L9B!O9B!I=',@;&EC96YS
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M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM
M5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@
M-"4G/@T*(%1H92!#;VUP86YY)B-X,C`Q.3MS(&QI8V5N<V4@86=R965M96YT
M<R!H879E(&UI;&5S=&]N92!P87EM96YT<PT*('=H:6-H(&9O<B!R97!O<G1I
M;F<@<'5R<&]S97,@87)E(&%G9W)E9V%T960@:6YT;R!T:')E92!C871E9V]R
M:65S.@T*("AI*28C>$$P.V1E=F5L;W!M96YT(&UI;&5S=&]N97,L("AI:2DF
M(WA!,#MR96=U;&%T;W)Y(&UI;&5S=&]N97,L#0H@86YD("AI:6DI)B-X03`[
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M:6YI<W1R871I;VX@*"8C>#(P,4,[1D1!)B-X,C`Q1#LI(&]R(&]T:&5R#0H@
M8V]U;G1R:65S)B-X,C`Q.3L@<F5G=6QA=&]R>2!A=71H;W)I=&EE<R!O<B!O
M;B!R96-E:7!T(&]F(&%C='5A;`T*(&UA<FME=&EN9R!A<'!R;W9A;',@9F]R
M('1H92!C;VUP;W5N9"!O<B!F;W(@861D:71I;VYA;"!I;F1I8V%T:6]N<RX-
M"B!386QE<R!M:6QE<W1O;F5S(&%R92!T>7!I8V%L;'D@<&%Y86)L92!W:&5N
M(&%N;G5A;"!S86QE<R!R96%C:`T*(&-E<G1A:6X@;&5V96QS+CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
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M86X-"B!A<W-E<W-M96YT(&]F('=H971H97(@*&$I)B-X03`[=&AE(&-O;G-I
M9&5R871I;VX@:7,@8V]M;65N<W5R871E#0H@=VET:"!E:71H97(@*#$I)B-X
M03`[=&AE(&5N=&ET>28C>#(P,3D[<R!P97)F;W)M86YC92!T;R!A8VAI979E
M('1H90T*(&UI;&5S=&]N92P@;W(@*#(I)B-X03`[=&AE(&5N:&%N8V5M96YT
M(&]F('1H92!V86QU92!O9B!T:&4-"B!D96QI=F5R960@:71E;2AS*2!A<R!A
M(')E<W5L="!O9B!A('-P96-I9FEC(&]U=&-O;64@<F5S=6QT:6YG(&9R;VT-
M"B!T:&4@96YT:71Y)B-X,C`Q.3MS('!E<F9O<FUA;F-E('1O(&%C:&EE=F4@
M=&AE(&UI;&5S=&]N92P-"B`H8BDF(WA!,#MT:&4@8V]N<VED97)A=&EO;B!R
M96QA=&5S('-O;&5L>2!T;R!P87-T('!E<F9O<FUA;F-E(&%N9`T*("AC*28C
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M87-S97-S;65N="X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
M3F]N+7)E9G5N9&%B;&4@9&5V96QO<&UE;G0@86YD(')E9W5L871O<GD@;6EL
M97-T;VYE<R!T:&%T(&%R90T*(&5X<&5C=&5D('1O(&)E(&%C:&EE=F5D(&%S
M(&$@<F5S=6QT(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&5F9F]R=',-"B!D
M=7)I;F<@=&AE('!E<FEO9"!O9B!S=6)S=&%N=&EA;"!I;G9O;'9E;65N="!A
M<F4@8V]N<VED97)E9`T*('-U8G-T86YT:79E(&%N9"!A<F4@<F5C;V=N:7IE
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M;G0@;V8@<W5C:`T*(&UI;&5S=&]N97,@87)E(&=E;F5R86QL>2!A8VAI979E
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M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#(E.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\:3Y2:6=H="UT;RU$979E
M;&]P($%G<F5E;65N=',\+VD^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T
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M)B-X03`[870@=&AE#0H@:6YC97!T:6]N(&]F('1H92!A<G)A;F=E;65N="`H
M<F5F97)R960@=&\@87,@)B-X,C`Q0SMU<&9R;VYT)B-X,C`Q1#L-"B!F965S
M(&]R('!A>6UE;G1S*2P@*&EI*28C>$$P.W1H92!S96QE8W1I;VX@;V8@82!T
M87)G970@9F]R(&$-"B!P<F]G<F%M+"`H:6EI*28C>$$P.W5P;VX@=&AE(&5X
M97)C:7-E(&]F(&%N(&]P=&EO;B!T;R!A8W%U:7)E(&$-"B!D979E;&]P;65N
M="!A;F0@8V]M;65R8VEA;&EZ871I;VX@;&EC96YS92`H<F5F97)R960@=&\@
M87,@97AE<F-I<V4-"B!F965S(&]R('!A>6UE;G1S(&5A<FYE9"D@9F]R(&$@
M<')O9W)A;2P@;W(@*&EV*28C>$$P.W-O;64-"B!C;VUB:6YA=&EO;B!O9B!A
M;&P@;V8@=&AE<V4@9F5E<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@5&AE(&%C8V]U;G1I;F<@9F]R(')I9VAT+71O+61E=F5L;W`@86=R
M965M96YT<R!I<R!D97!E;F1E;G0@;VX@=&AE#0H@;F%T=7)E(&]F('1H92!O
M<'1I;VYS(&=R86YT960@=&\@=&AE(&-O;&QA8F]R871O<BX@3W!T:6]N<R!A
M<F4-"B!C;VYS:61E<F5D('-U8G-T86YT:79E(&EF+"!A="!T:&4@:6YC97!T
M:6]N(&]F(&$@<FEG:'0M=&\M9&5V96QO<`T*(&%G<F5E;65N="P@=&AE($-O
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M=&AE(&)E;F5F:70@=&AE(&-O;&QA8F]R871O<B!M:6=H=`T*(&]B=&%I;B!F
M<F]M('1H92!A9W)E96UE;G0@=VET:&]U="!E>&5R8VES:6YG('1H92!O<'1I
M;VYS+"!T:&4@8V]S=`T*('1O(&5X97)C:7-E('1H92!O<'1I;VYS(')E;&%T
M:79E('1O('1H92!T;W1A;"!U<&9R;VYT#0H@8V]N<VED97)A=&EO;BP@86YD
M('1H92!A9&1I=&EO;F%L(&9I;F%N8VEA;"!C;VUM:71M96YT<R!I;7!O<V5D
M(&]N#0H@=&AE(&-O;&QA8F]R871O<B!A<R!A(')E<W5L="!O9B!E>&5R8VES
M:6YG('1H92!O<'1I;VYS+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
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M871I;VX@;&EC96YS97,@=&\@8F4@82!D96QI=F5R86)L92!A=`T*('1H92!I
M;F-E<'1I;VX@;V8@=&AE(&%G<F5E;65N="X@1F]R('1H;W-E(')I9VAT+71O
M+61E=F5L;W`-"B!A9W)E96UE;G1S(&5N=&5R960@:6YT;R!P<FEO<B!T;R!T
M:&4@861O<'1I;VX@;V8@05-5#0H@3F\N)B-X03`[,C`P.2TQ,R!W:&5R92!T
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M<B!C;W5L9"!E;&5C=`T*('1O(&5X97)C:7-E(&]P=&EO;G,@9F]R(&1E=F5L
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M,#`Y+3$S+"!T:&4@0V]M<&%N>28C>#(P,3D[<R!E=F%L=6%T:6]N(&]F('=H
M971H97(@=&AE#0H@;W!T:6]N(&ES('-U8G-T86YT:79E(&ES(&-O;G-I<W1E
M;G0@=VET:"!P<F4M861O<'1I;VX@;V8@05-5#0H@3F\N)B-X03`[,C`P.2TQ
M,RX@2&]W('1H92!#;VUP86YY(&1E=&5R;6EN97,@=&AE('-E;&QI;F<@<')I
M8V4@;V8-"B!T:&4@;W!T:6]N(&ES('1H92!O;FQY(&1I9F9E<F5N8V4@8F5T
M=V5E;B!P<F4@86YD('!O<W0@861O<'1I;VX@;V8-"B!!4U4@3F\N)B-X03`[
M,C`P.2TQ,RX@4&]S="!A9&]P=&EO;B!O9B!!4U4@3F\N)B-X03`[,C`P.2TQ
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M;W5N=&5D(&-A<V@@9FQO=W,L(&5S=&EM871E9"!D979E;&]P;65N=`T*(&-O
M<W1S+"!P<F]B86)I;&ET>2!O9B!S=6-C97-S(&%N9"!T:&4@=&EM92!N965D
M960@=&\@8V]M;65R8VEA;&EZ90T*(&$@<')O9'5C="!C86YD:61A=&4@<'5R
M<W5A;G0@=&\@=&AE(')I9VAT+71O+61E=F5L;W`@86=R965M96YT+B!);@T*
M('9A;&ED871I;F<@=&AE($)%4U`L(&UA;F%G96UE;G0@8V]N<VED97)S('=H
M971H97(@8VAA;F=E<R!I;B!K97D-"B!A<W-U;7!T:6]N<R!U<V5D('1O(&1E
M=&5R;6EN92!T:&4@0D534"!W:6QL(&AA=F4@82!S:6=N:69I8V%N=`T*(&5F
M9F5C="!O;B!T:&4@86QL;V-A=&EO;B!O9B!T:&4@87)R86YG96UE;G0@8V]N
M<VED97)A=&EO;B!B971W965N#0H@=&AE(&UU;'1I<&QE(&1E;&EV97)A8FQE
M<RX@1&5L:79E<F%B;&5S('5N9&5R('1H92!A<G)A;F=E;65N="!A<F4-"B!S
M97!A<F%T92!U;FET<R!O9B!A8V-O=6YT:6YG(&EF("AI*28C>$$P.W1H92!D
M96QI=F5R960@:71E;2!H87,-"B!V86QU92!T;R!T:&4@8W5S=&]M97(@;VX@
M82!S=&%N9&%L;VYE(&)A<VES(&%N9"`H:6DI)B-X03`[:68@=&AE#0H@87)R
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M>2!R96-O9VYI>F5D(&%S(&5A8V@@96QE;65N=`T*(&ES(&1E;&EV97)E9"X@
M36%N86=E;65N="!E>&5R8VES97,@<VEG;FEF:6-A;G0@:G5D9VUE;G0@:6X-
M"B!D971E<FUI;FEN9R!W:&5T:&5R(&$@9&5L:79E<F%B;&4@:7,@82!S97!A
M<F%T92!U;FET(&]F#0H@86-C;W5N=&EN9RX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@268@82!C;VQL86)O<F%T;W(@97AE<F-I<V5S(&%N
M(&]P=&EO;B!A;F0@86-Q=6ER97,@82!D979E;&]P;65N=`T*(&%N9"!C;VUM
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M:"!M86YA9V5M96YT)B-X,C`Q.3MS#0H@8F5S="!E<W1I;6%T92X@36%N86=E
M;65N="8C>#(P,3D[<R!D971E<FUI;F%T:6]N(&]F('-E;&QI;F<@<')I8V4-
M"B!I;F-L=61E<R!S=6-H(&9A8W1O<G,@87,@<W1A9V4@;V8@9&5V96QO<&UE
M;G0L(&UA<FME="!P;W1E;G1I86P@86YD#0H@8V%S:"!F;&]W(&UO9&5L<R!U
M<V5D(&1U<FEN9R!T:&4@;F5G;W1I871I;VX@=VET:"!T:&4@8V]L;&%B;W)A
M=&]R+@T*(%1H<F]U9V@@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RP@;F]N92!O
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M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*
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M8VEA;&EZ871I;VX@;&EC96YS92!A;F0@;W1H97(@9&5L:79E<F%B;&5S+`T*
M(&EF(&%N>2P@=&\@9&5T97)M:6YE('1H92!A<'!R;W!R:6%T92!R979E;G5E
M(')E8V]G;FET:6]N(&UE=&AO9"X-"B!4:&ES(&UO9&5L(&ES(&-O;G-I<W1E
M;G0@=VET:"!T:&4@0V]M<&%N>28C>#(P,3D[<R!A8V-O=6YT:6YG('!O;&EC
M>0T*(&9O<B!U<&9R;VYT('!A>6UE;G1S(&]N(&5X8VQU<VEV92!L:6-E;G-E
M<R`H9&ES8W5S<V5D(&%B;W9E*2X@26X-"B!T:&4@979E;G0@82!R:6=H="UT
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M=6-H('1E<FUI;F%T:6]N+@T*(%1H92!#;VUP86YY)B-X,C`Q.3MS(')I9VAT
M+71O+61E=F5L;W`@86=R965M96YT<R!H879E(&)E96X-"B!D971E<FUI;F5D
M('1O(&-O;G1A:6X@<W5B<W1A;G1I=F4@;W!T:6]N<RX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@1F]R(')I9VAT+71O+61E=F5L;W`@86=R
M965M96YT<R!W:&5R92!T:&4@;W!T:6]N<R!T;R!S96-U<F4-"B!D979E;&]P
M;65N="!A;F0@8V]M;65R8VEA;&EZ871I;VX@;&EC96YS97,@=&\@<')O9'5C
M="!P<F]G<F%M<R!A<F4-"B!N;W0@8V]N<VED97)E9"!S=6)S=&%N=&EV92P@
M=&AE($-O;7!A;GD@8V]N<VED97)S('1H92!D979E;&]P;65N=`T*(&%N9"!C
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M:6%L:7IA=&EO;B!L:6-E;G-E<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$X<'0[($U!4D=)3BU43U`Z(#!P
M="<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*(#QB/CQI/E)E<V5A<F-H(&%N
M9"!$979E;&]P;65N="!#;W-T<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N
M9&ET=7)E<R!A<F4@97AP96YS960@87,@:6YC=7)R960N#0H@4F5S96%R8V@@
M86YD(&1E=F5L;W!M96YT(&-O<W1S('!R:6UA<FEL>2!C;VYS:7-T(&]F(&5M
M<&QO>65E#0H@<F5L871E9"!E>'!E;G-E<RP@:6YC;'5D:6YG('-A;&%R:65S
M(&%N9"!B96YE9FET<RP@97AP96YS97,-"B!I;F-U<G)E9"!U;F1E<B!A9W)E
M96UE;G1S('=I=&@@8V]N=')A8W0@<F5S96%R8V@@;W)G86YI>F%T:6]N<RP-
M"B!I;G9E<W1I9V%T:79E('-I=&5S(&%N9"!C;VYS=6QT86YT<R!T:&%T(&-O
M;F1U8W0@=&AE#0H@0V]M<&%N>28C>#(P,3D[<R!C;&EN:6-A;"!T<FEA;',L
M('1H92!C;W-T(&]F(&%C<75I<FEN9R!A;F0-"B!M86YU9F%C='5R:6YG(&-L
M:6YI8V%L('1R:6%L(&UA=&5R:6%L<R!A;F0@;W1H97(@86QL;V-A=&5D#0H@
M97AP96YS97,L(&QI8V5N<V4@9F5E<R!F;W(@86YD(&UI;&5S=&]N92!P87EM
M96YT<R!R96QA=&5D('1O#0H@:6XM;&EC96YS960@<')O9'5C=',@86YD('1E
M8VAN;VQO9VEE<RP@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N#0H@97AP96YS
M92P@86YD(&-O<W1S(&%S<V]C:6%T960@=VET:"!N;VXM8VQI;FEC86P@86-T
M:79I=&EE<R!A;F0-"B!R96=U;&%T;W)Y(&%P<')O=F%L<RX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X
M<'0G/@T*(#QB/CQI/D-O;7!R96AE;G-I=F4@26YC;VUE("A,;W-S*3PO:3X\
M+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@169F96-T:79E
M($IA;G5A<GDF(WA!,#LQ+"`R,#$R+"!T:&4@0V]M<&%N>2!A9&]P=&5D($%3
M52`R,#$Q+3`U+`T*(#QI/E!R97-E;G1A=&EO;B!O9B!#;VUP<F5H96YS:79E
M($EN8V]M92P\+VD^('=H:6-H(&%M96YD960@05-##0H@5&]P:6,@,C(P+"`\
M:3Y#;VUP<F5H96YS:79E($EN8V]M93PO:3X@*"8C>#(P,4,[05-5#0H@,C`Q
M,2TP-28C>#(P,40[*3QI/BX\+VD^(%1H92!A;65N9&UE;G1S(&EN($%352`R
M,#$Q+3`U(')E<75I<F4@=&AE#0H@<')E<V5N=&%T:6]N(&]F('1H92!C;VUP
M<F5H96YS:79E(&EN8V]M92`H;&]S<RD@86YD(&ET<R!C;VUP;VYE;G1S#0H@
M87,@<&%R="!O9B!T:&4@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE
M;G1S+B!#;VUP<F5H96YS:79E#0H@:6YC;VUE("AL;W-S*2!I<R!C;VUP<FES
M960@;V8@=&AE(&YE="!I;F-O;64@*&QO<W,I(&%N9"!O=&AE<@T*(&-H86YG
M97,@:6X@97%U:71Y('1H870@87)E(&5X8VQU9&5D(&9R;VT@;F5T(&EN8V]M
M92`H;&]S<RDN#0H@0V]M<')E:&5N<VEV92!I;F-O;64@*&QO<W,I(&5Q=6%L
M<R!N970@:6YC;VUE("AL;W-S*2!F;W(@=&AE('EE87)S#0H@96YD960@1&5C
M96UB97(F(WA!,#LS,2P@,C`Q,RP@,C`Q,B!A;F0@,C`Q,2X\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X
M<'0G/@T*(#QB/CQI/E-T;V-K+6)A<V5D($-O;7!E;G-A=&EO;CPO:3X\+V(^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@4W1O8VLM8F%S960@
M<&%Y;65N=',@87)E(&%C8V]U;G1E9"!F;W(@:6X@86-C;W)D86YC92!W:71H
M('1H90T*('!R;W9I<VEO;G,@;V8@05-#)B-X03`[-S$X+"`\:3Y#;VUP96YS
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M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.
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M;'D@97AP96-T960@=&\@=F5S="!D=7)I;F<@=&AE('!E<FEO9"X\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z
M(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@=71I;&EZ
M97,@=&AE($)L86-K+5-C:&]L97,@;6]D96P@9F]R(&5S=&EM871I;F<@9F%I
M<@T*('9A;'5E(&]F(&ET<R!S=&]C:R!O<'1I;VYS(&=R86YT960N($]P=&EO
M;B!V86QU871I;VX@;6]D96QS+`T*(&EN8VQU9&EN9R!T:&4@0FQA8VLM4V-H
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M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q.'!T)SX-"B`\8CX\:3Y.970@26YC;VUE("A,;W-S*2!097(@4VAA<F4\
M+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($)A<VEC
M(&EN8V]M92`H;&]S<RD@<&5R(&-O;6UO;B!S:&%R92!I<R!D971E<FUI;F5D
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M;F4@=&AE(&1I;'5T:79E(&5F9F5C="!O9@T*('1H92!#;VUP86YY)B-X,C`Q
M.3MS('-T;V-K(&]P=&EO;B!G<F%N=',L('!O=&5N=&EA;"!%;7!L;WEE92!3
M=&]C:PT*(%!U<F-H87-E(%!L86X@87=A<F1S(&%N9"!W87)R86YT<R!A;F0@
M=&AE(&EF+6-O;G9E<G1E9"!M971H;V0@:7,-"B!U<V5D('1O(&1E=&5R;6EN
M92!T:&4@9&EL=71I=F4@969F96-T(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS
M#0H@<')E9F5R<F5D('-T;V-K+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z
M(#0E)SX-"B!0<FEO<B!T;R!T:&4@0V]M<&%N>28C>#(P,3D[<R!I;FET:6%L
M('!U8FQI8R!O9F9E<FEN9RP@;F5T(&EN8V]M90T*("AL;W-S*2!P97(@<VAA
M<F4@=V%S(&-A;&-U;&%T960@=6YD97(@=&AE(#QF;VYT('-T>6QE/3-$)U=(
M251%+5-004-%.B!N;W=R87`G/G1W;RUC;&%S<SPO9F]N=#X@;65T:&]D('5N
M9&5R('=H:6-H(&%L;`T*(&5A<FYI;F=S("AD:7-T<FEB=71E9"!A;F0@=6YD
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M:65S)B-X03`[02TQ+"!!+3(L($(L($,L($0L(&%N9"!$+3(@8V]N=F5R=&EB
M;&4@<')E9F5R<F5D('-T;V-K#0H@=V]U;&0@8F4@96YT:71L960@=&\@<F5C
M96EV92!T:&4@86UO=6YT(&]F(&1I=FED96YD<R!P97(@<VAA<F4@;V8-"B!P
M<F5F97)R960@<W1O8VL@=&AA="!W;W5L9"!B92!P87EA8FQE(&]N('1H92!L
M87)G97-T(&YU;6)E<B!O9@T*('=H;VQE('-H87)E<R!O9B!C;VUM;VX@<W1O
M8VL@:6YT;R!W:&EC:"!E86-H('-H87)E(&]F('!R969E<G)E9`T*('-T;V-K
M(&-O=6QD('1H96X@8F4@8V]N=F5R=&5D+B!4:&5R969O<F4L('1H92!397)I
M97,@02TQ+"!!+3(L($(L#0H@0RP@1"!A;F0@1"TR(&%R92!P87)T:6-I<&%T
M:6YG('-E8W5R:71I97,N($%L;"!O9B!T:&4@;W5T<W1A;F1I;F<-"B!S:&%R
M97,@;V8@4V5R:65S)B-X03`[02TQ+"!!+3(L($(L($,L($0L(&%N9"!$+3(@
M8V]N=F5R=&EB;&4-"B!P<F5F97)R960@<W1O8VL@8V]N=F5R=&5D('1O(&-O
M;6UO;B!S=&]C:R!U<&]N('1H92!C;VYS=6UM871I;VX@;V8-"B!T:&4@0V]M
M<&%N>28C>#(P,3D[<R!)4$\N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@
M-"4G/@T*($)A<VEC(&%N9"!D:6QU=&5D(&EN8V]M92`H;&]S<RD@<&5R(&-O
M;6UO;B!S:&%R92!I<R!C;VUP=71E9"!A<PT*(&9O;&QO=W,Z/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T
M.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N
M=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4X)3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0U)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0U)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A
M;&EG;CTS1&-E;G1E<CX\8CY996%R($5N9&5D#0H@1&5C96UB97(F(WA!,#LS
M,2P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&(^,C`Q,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T
M(&EN8V]M92`H;&]S<RD\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(V
M,"PX,S4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
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M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@3&5S<SH@=6YD:7-T<FEB=71E9"!E87)N:6YG<R!A;&QO8V%T
M960@=&\@<&%R=&EC:7!A=&EN9PT*('-E8W5R:71I97,\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B@X+#,V,2PW-34\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/B@V+#<Q-RPQ,C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M($YE="!I;F-O;64@*&QO<W,I(&%L;&]C86)L92!T;R!C;VUM;VX@<VAA<F5S
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(V,"PX,S4\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!"87-I8R!W96EG:'1E9"!A=F5R86=E(&-O;6UO;B!S
M:&%R97,@;W5T<W1A;F1I;F<\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L
M.#0W+#8Y-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,#@S+#(W-CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$L,#(U+#8P,CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@/&(^0F%S:6,@:6YC;VUE
M("AL;W-S*2!P97(@8V]M;6]N('-H87)E/"]B/CPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/B@P+C`T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C`P/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C`N,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($YE="!I;F-O;64@
M*&QO<W,I/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(V,"PX,S4\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C@L,S8Q+#<U-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#<Q-RPQ,C`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($QE
M<W,Z('5N9&ES=')I8G5T960@96%R;FEN9W,@86QL;V-A=&5D('1O('!A<G1I
M8VEP871I;F<@<V5C=7)I=&EE<PT*(&%N9"!O=&AE<B!A9&0M8F%C:W,@=&\@
M;F5T(&EN8V]M92`H;&]S<RD\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH."PS-C$L-S4U/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B@V+#<Q-RPQ,C`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($YE="!I;F-O
M;64@*&QO<W,I(&%L;&]C86)L92!T;R!C;VUM;VX@<VAA<F5S/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#(V,"PX,S4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!"87-I8R!W96EG:'1E9"!A=F5R86=E
M(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C8L.#0W+#8Y-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,#@S
M+#(W-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,#(U+#8P,CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^#0H@169F96-T(&]F(&1I;'5T:79E('-E8W5R
M:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F
M(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!$:6QU=&5D('=E:6=H=&5D(&%V97)A9V4@8V]M;6]N('-H87)E
M<R!O=71S=&%N9&EN9SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPX-#<L
M-CDW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PP.#,L,C<V/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,2PP,C4L-C`R/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M(#QB/D1I;'5T960@:6YC;VUE("AL;W-S*2!P97(@8V]M;6]N('-H87)E/"]B
M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C`T/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C`P
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C`N,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H
M92!F;VQL;W=I;F<@8V]M;6]N('-T;V-K(&5Q=6EV86QE;G1S('=E<F4@97AC
M;'5D960@9G)O;2!T:&4-"B!C86QC=6QA=&EO;B!O9B!D:6QU=&5D(&YE="!I
M;F-O;64@*&QO<W,I('!E<B!S:&%R92!B96-A=7-E('1H96ER#0H@969F96-T
M('=O=6QD(&)E(&%N=&DM9&EL=71I=F4Z/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0
M.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$
M15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS
M1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#8S)3X\+W1D/@T*(#QT9"!V86QI
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M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E
M<CX\8CY996%R($5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&(^,C`Q,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4V5R
M:65S($$M,2!0<F5F97)R960@4W1O8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*
M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C(L,34V+#$Q-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XR+#$U-BPQ,30\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*(%-E<FEE<R!!+3(@4')E9F5R<F5D(%-T;V-K/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XS.3(L,C<T/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C,Y,BPR-S0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-E<FEE<R!"(%!R969E
M<G)E9"!3=&]C:SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-"PS,S8L,#,W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C0L,S,V+#`S-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4V5R:65S
M($,@4')E9F5R<F5D(%-T;V-K/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R
M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
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M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-2PY,#DL.3`V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!397)I97,@1"!0<F5F97)R960@4W1O8VL\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<V.2PT-C@\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S8Y+#0V.#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4V5R:65S($0M,B!0<F5F97)R960@
M4W1O8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L,SDQ
M+#DY,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#,Y
M,2PY.3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($5F9F5C="!O9B!#;VYV97)T960@4')E9F5R<F5D(%-T;V-K/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3,L,3@Y+#DR,#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
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M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XQ.#`L-S@T/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$X,"PW.#0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-T;V-K($]P=&EO;G,\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#,Q,RPY-S`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPR-#DL-S`R/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.#@U+#0Q-SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB
M/CQI/E)E8V5N=&QY($ES<W5E9"!!8V-O=6YT:6YG(%-T86YD87)D<R!!9&]P
M=&5D/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!)
M;B!*=6QY(#(P,3,L('1H92!&05-"(&ES<W5E9"!!4U4@3F\N)B-X03`[,C`Q
M,RTQ,2P@=VAI8V@@86UE;F1E9`T*($%30R!4;W!I8R`W-#`@<F5G87)D:6YG
M('!R97-E;G1A=&EO;B!O9B!A;B!U;G)E8V]G;FEZ960@=&%X(&)E;F5F:70-
M"B!W:&5N(&$@;F5T(&]P97)A=&EN9R!L;W-S("@F(W@R,#%#.TY/3"8C>#(P
M,40[*2!C87)R>69O<G=A<F0L(&$-"B!S:6UI;&%R('1A>"!L;W-S+"!O<B!A
M('1A>"!C<F5D:70@8V%R<GEF;W)W87)D(&5X:7-T<RX@5&AE#0H@86UE;F1M
M96YT<R!I;B!!4U4@3F\N)B-X03`[,C`Q,RTQ,2!R97%U:7)E(&%N(&5N=&ET
M>2!T;R!P<F5S96YT(&%N#0H@=6YR96-O9VYI>F5D('1A>"!B96YE9FET(&%S
M(&$@<F5D=6-T:6]N(&]F(&$@9&5F97)R960@=&%X(&%S<V5T(&9O<@T*(&%N
M($Y/3"!C87)R>69O<G=A<F0L(&]R('-I;6EL87(@=&%X(&QO<W,@;W(@=&%X
M(&-R961I=`T*(&-A<G)Y9F]R=V%R9"P@<F%T:&5R('1H86X@87,@82!L:6%B
M:6QI='D@=VAE;B`H,2DF(WA!,#MT:&4-"B!U;F-E<G1A:6X@=&%X('!O<VET
M:6]N('=O=6QD(')E9'5C92!T:&4@3D],(&]R(&]T:&5R(&-A<G)Y9F]R=V%R
M9`T*('5N9&5R('1H92!T87@@;&%W(&]F('1H92!A<'!L:6-A8FQE(&IU<FES
M9&EC=&EO;B!A;F0@*#(I)B-X03`[=&AE#0H@96YT:71Y(&EN=&5N9',@=&\@
M=7-E('1H92!D969E<G)E9"!T87@@87-S970@9F]R('1H870@<'5R<&]S92X@
M5&AE#0H@05-5(&1O97,@;F]T(')E<75I<F4@;F5W(')E8W5R<FEN9R!D:7-C
M;&]S=7)E<RX@5&AI<R!A;65N9&UE;G0@:7,-"B!E9F9E8W1I=F4@<')O<W!E
M8W1I=F5L>2!F;W(@9FES8V%L('EE87)S(&)E9VEN;FEN9R!A9G1E<@T*($1E
M8V5M8F5R)B-X03`[,34L(#(P,3,N(%1H92!#;VUP86YY(&1O97,@;F]T(&)E
M;&EE=F4@=&AI<R!A;65N9&UE;G0-"B!W:6QL(&AA=F4@82!M871E<FEA;"!I
M;7!A8W0@;VX@:71S(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
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M871E9"!F:6YA;F-I86P@<W1A=&5M96YT<RX\+W`^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4')O<&5R='D@4&QA;G0@06YD($5Q=6EP;65N="!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T
M>2!A;F0@17%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=CX-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'0[(&UA<F=I
M;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N)SX-"B`\8CXS+B!0<F]P97)T>2!A;F0@17%U:7!M96YT
M/"]B/CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P=#L@;6%R9VEN
M+6)O='1O;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!0<F]P97)T>2!A;F0@
M97%U:7!M96YT(&-O;G-I<W1S(&]F('1H92!F;VQL;W=I;F<Z/"]P/@T*(#QP
M('-T>6QE/3-$9F]N="US:7IE.C$R<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6)O='1O;3HP<'0^#0H@)B-X03`[/"]P/@T*(#QT86)L92!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-S8E(&)O<F1E<CTS1#`@
M<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.D-/3$Q!4%-%.R!F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)R!A;&EG;CTS1&-E
M;G1E<CX-"B`\='(^#0H@/'1D('=I9'1H/3-$-C$E/CPO=&0^#0H@/'1D('9A
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M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0V(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,2XP
M,'!T('-O;&ED(",P,#`P,#`G/CQB/D1E8V5M8F5R)B-X03`[,S$L/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@
M9F]N="US:7IE.CAP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,2XP,'!T('-O;&ED(",P,#`P
M,#`G/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L:60@(S`P,#`P
M,"<^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1B!S='EL
M93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ
M,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I
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M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPP,#,L-S`V/"]T9#X-
M"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T
M97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!3;V9T=V%R93PO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$L-#<W+#0Q-CPO=&0^#0H@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ+#,R,RPP.#$\+W1D/@T*(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[
M('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*($9U<FYI='5R93PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C4Y.2PV-3`\+W1D/@T*(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-3DY+#8U,#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E
M;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;B<^#0H@3&%B(&5Q=6EP;65N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C$Q+#$V-BPV,3D\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^."PW-#<L-SDP/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G
M8V]L;W(],T0C0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N
M=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N)SX-"B!/9F9I8V4@97%U:7!M96YT/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-3$L,S8P/"]T9#X-"B`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C4Q+#,V,#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M
M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N
M="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@
M3&5A<V5H;VQD(&EM<')O=F5M96YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C0L.#DS+#<W,#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XT+#@X,2PW,#8\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(]
M,T0C0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,RXP,&5M.R!T97AT+6EN9&5N=#HM,2XP
M,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N)SX-"B!0<F]P97)T>2!A;F0@97%U:7!M96YT/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ93HX
M<'0^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XR,"PU-C@L,#8Y/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3<L-C`W
M+#(Y,SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=F
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T
M.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[
M(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@3&5S<R!A8V-U;75L
M871E9"!D97!R96-I871I;VX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q-2PU
M,S(L.#,W/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q-"PS,SDL-#DW/"]T9#X-"B`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XI)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@[/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HS+C`P96T[('1E
M>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86XG/@T*(%!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L
M(&YE=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L,#,U+#(S,CPO=&0^#0H@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N="US
M:7IE.CAP=#XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XS+#(V-RPW.38\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T1F;VYT+7-I>F4Z,7!X.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS+C`P<'@@9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS+C`P<'@@9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!T.R!M87)G:6XM8F]T=&]M.C!P
M=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86XG/@T*($1E<')E8VEA=&EO;B!E>'!E;G-E(&9O
M<B!T:&4@>65A<G,@96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RP-"B`R
M,#$R(&%N9"`R,#$Q('=A<R`D,2XR(&UI;&QI;VXL("0Q+C`@;6EL;&EO;B!A
M;F0@)#$N,2!M:6QL:6]N+`T*(')E<W!E8W1I=F5L>2X\+W`^#0H@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y
M("A$969I8VET*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY%<75I='D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VMH;VQD97)S)R!%
M<75I='D@*$1E9FEC:70I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=CX-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'0[(&UA<F=I
M;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N)SX-"B`\8CXT+B!3=&]C:VAO;&1E<G,F(W@R,#$Y.R!%
M<75I='D@*$1E9FEC:70I/"]B/CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM
M=&]P.C9P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F
M;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-
M"B!$=7)I;F<@,C`P,B!A;F0@,C`P,RP@=&AE($-O;7!A;GD@:7-S=65D(&$@
M=&]T86P@;V8@,S0L,C,Y+#,W-`T*('-H87)E<R!O9B!397)I97,@02TQ(&%N
M9"!397)I97,@02TR(&-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:PT*("@F
M(W@R,#%#.U-E<FEE<R!!('!R969E<G)E9"!S=&]C:R8C>#(P,40[*2!F;W(@
M)#$N,#`@<&5R('-H87)E#0H@<F5S=6QT:6YG(&EN(&YE="!P<F]C965D<R!O
M9B!A<'!R;WAI;6%T96QY("0S-"XP(&UI;&QI;VXN/"]P/@T*(#QP('-T>6QE
M/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M
M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N)SX-"B!/;B!/8W1O8F5R)B-X03`[,3(L(#(P,#0L('1H92!#
M;VUP86YY(&5N=&5R960@:6YT;R!A('-E<FEE<R!O9@T*('1R86YS86-T:6]N
M<R!R86ES:6YG("0S,"XS(&UI;&QI;VXL(&YE="!O9B!R96QA=&5D(&]F9F5R
M:6YG(&-O<W1S#0H@;V8@87!P<F]X:6UA=&5L>2`D,C,X+#`P,"P@9G)O;2!T
M:&4@<V%L92!O9B`W,2PT,#$L,C,W('-H87)E<R!O9@T*(&ET<R!397)I97,@
M0B!C;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL@*"8C>#(P,4,[4V5R:65S
M($(@<')E9F5R<F5D#0H@<W1O8VLF(W@R,#%$.RDN($EN(&-O;FYE8W1I;VX@
M=VET:"!T:&4@4V5R:65S($(@<')E9F5R<F5D('-T;V-K#0H@;V9F97)I;F<L
M(#$S+#8P-"PP,38@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!W97)E(&%L;&]C
M871E9"!T;PT*(&AO;&1E<G,@;V8@4V5R:65S)B-X03`[02TQ('!R969E<G)E
M9"!S=&]C:R!A<R!A;B!A;G1I+61I;'5T:6]N#0H@;65A<W5R92X\+W`^#0H@
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!T.R!M87)G:6XM8F]T=&]M.C!P
M=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86XG/@T*($]N($UA>28C>$$P.S$V+"`R,#`V+"!T
M:&4@0V]M<&%N>2!R86ES960@)#0T+CD@;6EL;&EO;BP@;F5T(&]F#0H@<F5L
M871E9"!O9F9E<FEN9R!C;W-T<R!O9B`D,3`Q+#(T-BP@9G)O;2!T:&4@<V%L
M92!O9B`Q,3`L.34R+#(Q-PT*('-H87)E<R!O9B!I=',@4V5R:65S($,@8V]N
M=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K("@F(W@R,#%#.U-E<FEE<R!##0H@
M<')E9F5R<F5D('-T;V-K)B-X,C`Q1#LI+B!);B!C;VYN96-T:6]N('=I=&@@
M=&AE(%-E<FEE<R!#('!R969E<G)E9`T*('-T;V-K(&]F9F5R:6YG+"`Q,"PP
M,#,L,S`P('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=V5R92!A;&QO8V%T960@
M=&\-"B!H;VQD97)S(&]F(%-E<FEE<R!"('!R969E<G)E9"!S=&]C:R!A<R!A
M;B!A;G1I+61I;'5T:6]N#0H@;65A<W5R92X\+W`^#0H@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HQ,G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E
M;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86XG/@T*($]N($IU;'DF(WA!,#LQ-BP@,C`P."P@=&AE($-O;7!A;GD@
M:7-S=65D(#$R+#0V-BPP,SD@<VAA<F5S(&]F(&ET<PT*(%-E<FEE<R!$(&-O
M;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:R`H)B-X,C`Q0SM397)I97,F(WA!
M,#M$#0H@<')E9F5R<F5D('-T;V-K)B-X,C`Q1#LI(&EN(&5X8VAA;F=E(&9O
M<B!A;&P@;V8@=&AE(&]U='-T86YD:6YG#0H@8V%P:71A;"!S=&]C:R!A;F0@
M8V]N=F5R=&EB;&4@;F]T97,@<&%Y86)L92!O9B!2879E;@T*($)I;W1E8VAN
M;VQO9VEE<RP@26YC+B`H)B-X,C`Q0SM2879E;B8C>#(P,40[*2X@4W5B<V5Q
M=65N=&QY+"!I;B!-87)C:`T*(#(P,3$@82!S971T;&5M96YT('=A<R!R96%C
M:&5D('=I=&@@=&AE(&9O<FUE<B!2879E;B!S=&]C:VAO;&1E<G,-"B!B<FEN
M9VEN9R!T:&4@=&]T86P@4V5R:65S($0@<')E9F5R<F5D('-T;V-K(&ES<W5E
M9"!I;B!C;VYN96-T:6]N#0H@=VET:"!T:&4@4F%V96X@86-Q=6ES:71I;VX@
M=&\@,30L-#0V+#(R-R!S:&%R97,N/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I
M;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT.C0E
M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M)SX-"B!/;B!397!T96UB97(F(WA!,#LQ.2P@,C`P."P@=&AE($-O;7!A;GD@
M<F%I<V5D("0R-"XX(&UI;&QI;VXL(&YE=`T*(&]F(')E;&%T960@;V9F97)I
M;F<@8V]S=',@;V8@)#$U-BPW.#@L(&9R;VT@=&AE('-A;&4@;V8@,S@L,S,W
M+#8W.`T*('-H87)E<R!O9B!I=',@4V5R:65S($0M,B!C;VYV97)T:6)L92!P
M<F5F97)R960@<W1O8VL@*"8C>#(P,4,[4V5R:65S#0H@1"TR('!R969E<G)E
M9"!S=&]C:R8C>#(P,40[*2X@5&AE($-O;7!A;GD@86QS;R!I<W-U960@<')E
M9F5R<F5D#0H@<W1O8VL@=V%R<F%N=',@9F]R('1H92!P=7)C:&%S92!O9B`R
M+#@W-2PS,C<@<VAA<F5S(&]F(%-E<FEE<R!$+3(-"B!P<F5F97)R960@<W1O
M8VLN(%1H92!P<F5F97)R960@<W1O8VL@=V%R<F%N=',@=V5R92!E>&5R8VES
M86)L92!A=`T*(&%N>2!T:6UE('!R:6]R('1O(%-E<'1E;6)E<B8C>$$P.S(P
M,3@L(&)U="!E>'!I<F5D('5P;VX@86X@25!/+"!A;F0-"B!H860@82!S=&%T
M960@97AE<F-I<V4@<')I8V4@;V8@)#`N-C4@<&5R('=A<G)A;G0N($]N($UA
M>28C>$$P.S$V+`T*(#(P,3`L('1H92!#;VUP86YY(&5X97)C:7-E9"!A('!U
M="!N;W1I8V4@=&\@16QI($QI;&QY(&EN(&%C8V]R9&%N8V4-"B!W:71H('1H
M92!397)I97,@1"TR('!R969E<G)E9"!S=&]C:R!P=7)C:&%S92!A9W)E96UE
M;G0L(')E<W5L=&EN9PT*(&EN('1H92!I<W-U86YC92!O9B`V+#DQ-BPQ,3`@
M<VAA<F5S(&]F(%-E<FEE<R!$+3(@<')E9F5R<F5D('-T;V-K#0H@86YD(&$@
M=V%R<F%N="!T;R!P=7)C:&%S92`U,3@L-S`X(&%D9&ET:6]N86P@<VAA<F5S
M(&]F(%-E<FEE<R!$+3(-"B!P<F5F97)R960@<W1O8VLN($]N($IA;G5A<GDF
M(WA!,#LQ,2P@,C`Q,2P@=&AE($-O;7!A;GD@<F%I<V5D(&=R;W-S#0H@<')O
M8V5E9',@;V8@)#$R+C`@;6EL;&EO;B!F<F]M('1H92!S86QE(&]F(#$X+#0R
M-RPS.#@F(WA!,#MS:&%R97,-"B!O9B!I=',@4V5R:65S($0M,B!P<F5F97)R
M960@<W1O8VLN($ES<W5A;F-E(&-O<W1S(&%S<V]C:6%T960@=VET:`T*('1H
M92!S86QE('=E<F4@;F]T(&UA=&5R:6%L+CPO<#X-"B`\<"!S='EL93TS1"=M
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M<W1E9"!T;R!F86ER('9A;'5E(&%T('1H92!E;F0@;V8@96%C:`T*(')E<&]R
M=&EN9R!P97)I;V0@=7-I;F<@=&AE($]P=&EO;BU0<FEC:6YG($UE=&AO9"P@
M=VET:"!C:&%N9V5S(&EN#0H@=F%L=64@<F5C;W)D960@87,@)B-X,C`Q0SM/
M=&AE<B!I;F-O;64@*&5X<&5N<V4I)B-X,C`Q1#L@:6X@=&AE#0H@86-C;VUP
M86YY:6YG(&-O;G-O;&ED871E9"!S=&%T96UE;G1S(&]F(&]P97)A=&EO;G,@
M86YD#0H@8V]M<')E:&5N<VEV92!I;F-O;64@*&QO<W,I+B!0<FEO<B!T;R!T
M:&4@0V]M<&%N>28C>#(P,3D[<R!)4$\@:6X-"B!/8W1O8F5R(#(P,3,L(&%L
M;"!T:&4@<')E9F5R<F5D('-T;V-K('=A<G)A;G1S('=E<F4@97AE<F-I<V5D
M(&%N9`T*('-U8G-E<75E;G1L>2!W97)E(&-O;G9E<G1E9"!I;G1O('-H87)E
M<R!O9B!C;VUM;VX@<W1O8VL@:6X-"B!C;VYN96-T:6]N('=I=&@@=&AE($E0
M3RX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!T.R!M87)G:6XM
M8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*($1I=FED96YD<R!W97)E
M(&YO;F-U;75L871I=F4@86YD(&%C8W)U960@;VX@=&AE(%-E<FEE<R!!+3$L
M(%-E<FEE<PT*($$M,BP@4V5R:65S($(L(%-E<FEE<R!#+"!397)I97,@1"!A
M;F0@4V5R:65S)B-X03`[1"TR('!R969E<G)E9`T*('-T;V-K(&%T(&$@<F%T
M92!O9B`D,"XP."P@)#`N,#,T,2P@)#`N,#,R-"!A;F0@)#`N,#4R,B!P97(@
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M;B!C;VYN96-T:6]N#0H@=VET:"!T:&4@25!/+CPO<#X-"B`\<"!S='EL93TS
M1"=M87)G:6XM=&]P.C$R<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN
M9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;B<^#0H@5&AE($-O;7!A;GDF(W@R,#$Y.W,@4V5R:65S($$M,2P@
M4V5R:65S($$M,BP@4V5R:65S($(L(%-E<FEE<R!#+`T*(%-E<FEE<R!$(&%N
M9"!397)I97,@1"TR('!R969E<G)E9"!S=&]C:R!W97)E(&EN:71I86QL>2!C
M;VYV97)T:6)L90T*(&EN=&\@,2XU,#8L(#$N,#`L(#$N,30L(#$N,#`L(#$N
M,#`@86YD(#$N,#`@<VAA<F5S+"!R97-P96-T:79E;'DL#0H@;V8@8V]M;6]N
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M>#(P,3D[<R!)4$\@:6X@3V-T;V)E<B`R,#$S+"!A;&P@;W5T<W1A;F1I;F<@
M<VAA<F5S(&]F#0H@<')E9F5R<F5D('-T;V-K(&%U=&]M871I8V%L;'D@8V]N
M=F5R=&5D('1O('-H87)E<R!O9B!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS(&-O
M;6UO;B!S=&]C:R!A="!T:&4@87!P;&EC86)L92!C;VYV97)S:6]N(')A=&EO
M<PT*('1H96X@:6X@969F96-T+B!4:&4@8V]N=F5R<VEO;B!P<FEC92!W87,@
M)#$R+C,Y+"`D,3@N-S<L("0V+CDU+`T*("0W+C<P+"`D,3(N,C`@86YD("0Q
M,BXR,"!F;W(@96%C:"!S:&%R92!O9B!397)I97,@02TQ+"!!+3(L(%-E<FEE
M<PT*($(L(%-E<FEE<R!#+"!397)I97,@1"!A;F0@4V5R:65S($0M,B!C;VYV
M97)T:6)L92!P<F5F97)R960@<W1O8VLL#0H@<F5S<&5C=&EV96QY+CPO<#X-
M"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'0[(&UA<F=I;BUB;W1T;VTZ
M,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@3VX@3V-T;V)E<B8C>$$P.S$V+"`R
M,#$S+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@:71S($E03RP@:6X@=VAI8V@-
M"B`U+#`P,"PP,#`@<VAA<F5S(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O
M;6UO;B!S=&]C:R!W97)E('-O;&0@870@80T*('!R:6-E(&]F("0Q-BXP,"!P
M97(@<VAA<F4N($%D9&ET:6]N86QL>2P@=&AE('5N9&5R=W)I=&5R<R!O9B!T
M:&4-"B!#;VUP86YY)B-X,C`Q.3MS($E03R!E>&5R8VES960@=&AE(&9U;&P@
M86UO=6YT(&]F('1H96ER#0H@;W9E<BUA;&QO=&UE;G0@;W!T:6]N(')E<W5L
M=&EN9R!I;B!T:&4@<V%L92!O9B!A;B!A9&1I=&EO;F%L#0H@-S4P+#`P,"!S
M:&%R97,@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@8V]M;6]N('-T;V-K(&%T
M(&$@<')I8V4@;V8-"B`D,38N,#`@<&5R('-H87)E+B!4:&4@0V]M<&%N>2!R
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M;3HP<'0^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M,'!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M
M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*($EN
M(&-O;FYE8W1I;VX@=VET:"!P<F5P87)I;F<@9F]R(&ET<R!)4$\@:6X@3V-T
M;V)E<B`R,#$S+"!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS($)O87)D(&]F($1I
M<F5C=&]R<R!A;F0@<W1O8VMH;VQD97)S(&%P<')O=F5D(&$-"B`Q+69O<BTQ
M."XW-S,Y(')E=F5R<V4@<W1O8VL@<W!L:70@;V8@=&AE($-O;7!A;GDF(W@R
M,#$Y.W,@8V]M;6]N#0H@<W1O8VLN(%1H92!R979E<G-E('-T;V-K('-P;&ET
M(&)E8V%M92!E9F9E8W1I=F4@;VX-"B!397!T96UB97(F(WA!,#LR-BP@,C`Q
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M8V%P:71A;"X@26X@861D:71I;VXL(&EN(%-E<'1E;6)E<B`R,#$S+"!T:&4@
M0V]M<&%N>28C>#(P,3D[<R!";V%R9`T*(&]F($1I<F5C=&]R<R!A;F0@<W1O
M8VMH;VQD97)S(&%P<')O=F5D(&%N(&%M96YD;65N="!O9B!T:&4-"B!#;VUP
M86YY)B-X,C`Q.3MS(&-E<G1I9FEC871E(&]F(&EN8V]R<&]R871I;VX@=&\L
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M;V8@8V]M;6]N('-T;V-K(&9R;VT@-#(U+#`P,"PP,#`@=&\@,3(U+#`P,"PP
M,#`L(&%N9`T*(&%U=&AO<FEZ960@-2PP,#`L,#`P('-H87)E<R!O9B!U;F1E
M<VEG;F%T960@<')E9F5R<F5D('-T;V-K('=I=&@@80T*('!A<B!V86QU92!O
M9B`D,"XP,2!P97(@<VAA<F4N(%1H97)E('=E<F4@;F\@<VAA<F5S(&]F('5N
M9&5S:6=N871E9`T*('!R969E<G)E9"!S=&]C:R!I<W-U960@;W(@;W5T<W1A
M;F1I;F<@87,@;V8@1&5C96UB97(F(WA!,#LS,2P-"B`R,#$S+CPO<#X-"B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S8R.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-`T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,CEC-&)C85]C9&$W7S1D865?830T
M-5\Q,C0U864R-#AC.30O5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4VAA<F5D+4)A<V5D(%!A
M>6UE;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D1I<V-L;W-U<F4@3V8@0V]M<&5N<V%T:6]N(%)E;&%T960@
M0V]S=',@4VAA<F5B87-E9"!087EM96YT<R!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R960M0F%S
M960@4&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`Q.'!T)SX-"B`\8CXU+B!3:&%R960M0F%S960@4&%Y;65N=',\
M+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`V<'0G/@T*(#QB/CQI/E-T;V-K($]P=&EO;B!0;&%N/"]I
M/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M
M<&%N>28C>#(P,3D[<R`R,#`P(%-T;V-K($]P=&EO;B!A;F0@26YC96YT:79E
M(%!L86X-"B`H)B-X,C`Q0SLR,#`P(%!L86XF(W@R,#%$.RD@86QL;W=E9"!F
M;W(@=&AE(&=R86YT(&]F(&%W87)D<R!I;@T*(')E<W!E8W0@;V8@86X@86=G
M<F5G871E(&]F(#$S,"PW,C4@<VAA<F5S+"!W:&EC:"!W87,@:6YC<F5A<V5D
M('1O#0H@,34P+#(Y-R!S:&%R97,L(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS
M(&-O;6UO;B!S=&]C:R!I;B!T:&4@9F]R;2!O9@T*(&EN8V5N=&EV92!S=&]C
M:R!O<'1I;VYS+"!N;VXM<75A;&EF:65D('-T;V-K(&]P=&EO;G,L('-T;V-K
M#0H@87!P<F5C:6%T:6]N(')I9VAT<RP@<F5S=')I8W1E9"!S=&]C:R!A;F0@
M<F5S=')I8W1E9"!S=&]C:R!U;FET<PT*(&%N9"!O=&AE<B!P97)F;W)M86YC
M92!A=V%R9',N($%S(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,3,L('5N9&5R
M#0H@=&AE(#(P,#`@4&QA;BP@=&AE<F4@=V5R92!O<'1I;VYS('1O('!U<F-H
M87-E(&%N(&%G9W)E9V%T92!O9@T*(#(S+#8U-R!S:&%R97,@;V8@8V]M;6]N
M('-T;V-K(&]U='-T86YD:6YG(&%T(&$@=V5I9VAT960@879E<F%G90T*(&5X
M97)C:7-E('!R:6-E(&]F("0P+C@S('!E<B!S:&%R92X@5&AE(#(P,#`@4&QA
M;B!H87,@97AP:7)E9"P@86YD#0H@;F\@9G5R=&AE<B!A=V%R9',@;6%Y(&)E
M(&ES<W5E9"!U;F1E<B!T:&4@<&QA;BX@06YY('-H87)E<R!O9@T*(&-O;6UO
M;B!S=&]C:R!S=6)J96-T('1O(&%W87)D<R!U;F1E<B!T:&4@,C`P,"!0;&%N
M('1H870@97AP:7)E+`T*('1E<FUI;F%T92P@;W(@87)E(&]T:&5R=VES92!S
M=7)R96YD97)E9"P@8V%N8V5L960L(&9O<F9E:71E9"!O<@T*(')E<'5R8VAA
M<V5D('=I=&AO=70@:&%V:6YG(&)E96X@9G5L;'D@97AE<F-I<V5D+"!O<B!R
M97-U;'1I;F<@:6X-"B!A;GD@8V]M;6]N('-T;V-K(&)E:6YG(&ES<W5E9"P@
M=VEL;"!B96-O;64@879A:6QA8FQE(&9O<B!I<W-U86YC90T*('5N9&5R('1H
M92`R,#$S(%-T;V-K($EN8V5N=&EV92!0;&%N("@F(W@R,#%#.S(P,3,@4&QA
M;B8C>#(P,40[*2!U<"!T;PT*(&$@<W!E8VEF:65D(&YU;6)E<B!O9B!S:&%R
M97,N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($5F9F5C=&EV
M92!&96)R=6%R>28C>$$P.S(P,#,L('1H92!#;VUP86YY(&EM<&QE;65N=&5D
M('1H92`R,#`S#0H@17%U:71Y($EN8V5N=&EV92!0;&%N("@F(W@R,#%#.S(P
M,#,@4&QA;B8C>#(P,40[*2P@86YD(&ET('=A<R!A;65N9&5D#0H@86YD(&%P
M<')O=F5D(&)Y('1H92!#;VUP86YY)B-X,C`Q.3MS('-T;V-K:&]L9&5R<R!I
M;B`R,#`U+B!4:&4@,C`P,PT*(%!L86X@;W)I9VEN86QL>2!A;&QO=V5D(&9O
M<B!T:&4@9W)A;G0@;V8@87=A<F1S(&EN(')E<W!E8W0@;V8@86X-"B!A9V=R
M96=A=&4@;V8@,BPP-3$L-C0T('-H87)E<R!O9B!T:&4@0V]M<&%N>28C>#(P
M,3D[<R!C;VUM;VX@<W1O8VLN#0H@0F5T=V5E;B`R,#`V(&%N9"`R,#$P('1H
M92!M87AI;75M(&YU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N('-T;V-K#0H@
M875T:&]R:7IE9"!T;R!B92!I<W-U960@8GD@=&AE($-O;7!A;GD@=6YD97(@
M=&AE(#(P,#,@4&QA;B!W87,-"B!I;F-R96%S960@8GD@,2PW,SDL,3$V('-H
M87)E<R!T;R`S+#<Y,"PW-C`N($1U<FEN9R!T:&4@>65A<B!E;F1E9`T*($1E
M8V5M8F5R)B-X03`[,S$L(#(P,3(L('1H92!M87AI;75M(&YU;6)E<B!O9B!S
M:&%R97,@;V8@8V]M;6]N#0H@<W1O8VL@875T:&]R:7IE9"!T;R!B92!I<W-U
M960@8GD@=&AE($-O;7!A;GD@=6YD97(@=&AE(#(P,#,@4&QA;@T*('=A<R!I
M;F-R96%S960@8GD@-30U+#DW,"!S:&%R97,@=&\@-"PS,S8L-S,P+B!3=&]C
M:R!O<'1I;VYS(&=R86YT960-"B!U;F1E<B!T:&4@,C`P,R!0;&%N(&UA>2!B
M92!E:71H97(@:6YC96YT:79E('-T;V-K(&]P=&EO;G,@87,-"B!D969I;F5D
M(&)Y('1H92!);G1E<FYA;"!2979E;G5E($-O9&4@*"8C>#(P,4,[25)#)B-X
M,C`Q1#LI+"!O<@T*(&YO;BUQ=6%L:69I960@<W1O8VL@;W!T:6]N<RX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@07,@;V8@1&5C96UB97(F
M(WA!,#LS,2P@,C`Q,RP@=6YD97(@=&AE(#(P,#,@4&QA;BP@=&AE<F4@=V5R
M90T*(&]P=&EO;G,@=&\@<'5R8VAA<V4@86X@86=G<F5G871E(&]F(#(L-34Y
M+#`Q,28C>$$P.W-H87)E<R!O9B!C;VUM;VX-"B!S=&]C:R!O=71S=&%N9&EN
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M;F1E<B!T:&4@,C`P,R!0;&%N('1H870-"B!E>'!I<F4L('1E<FUI;F%T92P@
M;W(@87)E(&]T:&5R=VES92!S=7)R96YD97)E9"P@8V%N8V5L960L#0H@9F]R
M9F5I=&5D(&]R(')E<'5R8VAA<V5D('=I=&AO=70@:&%V:6YG(&)E96X@9G5L
M;'D@97AE<F-I<V5D+"!O<@T*(')E<W5L=&EN9R!I;B!A;GD@8V]M;6]N('-T
M;V-K(&)E:6YG(&ES<W5E9"P@=VEL;"!B96-O;64@879A:6QA8FQE#0H@9F]R
M(&ES<W5A;F-E('5N9&5R('1H92`R,#$S(%!L86XL('5P('1O(&$@<W!E8VEF
M:65D(&YU;6)E<B!O9@T*('-H87)E<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@26X@3V-T;V)E<B`R,#$S+"!T:&4@0V]M<&%N>2!I;7!L
M96UE;G1E9"!T:&4@,C`Q,R!0;&%N+B!4:&4@,C`Q,PT*(%!L86X@<')O=FED
M97,@9F]R('1H92!G<F%N="!O9B!S=&]C:R!O<'1I;VYS(&%N9"!O=&AE<B!S
M=&]C:RUB87-E9`T*(&%W87)D<RP@87,@=V5L;"!A<R!C87-H+6)A<V5D('!E
M<F9O<FUA;F-E(&%W87)D<RX@5&AE(&%G9W)E9V%T90T*(&YU;6)E<B!O9B!S
M:&%R97,@;V8@8V]M;6]N('-T;V-K(&EN:71I86QL>2!A=F%I;&%B;&4@9F]R
M(&ES<W5A;F-E#0H@<'5R<W5A;G0@=&\@87=A<F1S('5N9&5R('1H92`R,#$S
M(%!L86X@:7,@,2PY-C`L,38X)B-X03`[<VAA<F5S+@T*(%1H92!N=6UB97(@
M;V8@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!R97-E<G9E9"!F;W(@:7-S=6%N
M8V4@=VEL;`T*(&%U=&]M871I8V%L;'D@:6YC<F5A<V4@;VX@2F%N=6%R>28C
M>$$P.S$@;V8@96%C:"!Y96%R(&9R;VT-"B!*86YU87)Y)B-X03`[,2P@,C`Q
M-"!T:')O=6=H(&%N9"!I;F-L=61I;F<@2F%N=6%R>28C>$$P.S$L(#(P,C,L
M(&)Y#0H@=&AE(&QE<W-E<B!O9B`H82DF(WA!,#LQ+#DV,"PQ-C@@<VAA<F5S
M+"`H8BDF(WA!,#LT+C`E(&]F('1H92!T;W1A;`T*(&YU;6)E<B!O9B!S:&%R
M97,@;V8@8V]M;6]N('-T;V-K(&]U='-T86YD:6YG(&]N($1E8V5M8F5R)B-X
M03`[,S$@;V8-"B!T:&4@<')E8V5D:6YG(&-A;&5N9&%R('EE87(L(&]R("AC
M*28C>$$P.W1H92!N=6UB97(@;V8@<VAA<F5S(&]F#0H@8V]M;6]N('-T;V-K
M(&1E=&5R;6EN960@8GD@=&AE($)O87)D(&]F($1I<F5C=&]R<RX@06QL(&]F
M('1H90T*('-H87)E<R!A=F%I;&%B;&4@9F]R(&ES<W5A;F-E('5N9&5R('1H
M92`R,#$S(%!L86X@87)E(&5L:6=I8FQE(&9O<@T*(&ES<W5A;F-E('!U<G-U
M86YT('1O('1H92!E>&5R8VES92!O9B!I;F-E;G1I=F4@<W1O8VL@;W!T:6]N
M<RX@268@86X-"B!O<'1I;VX@97AP:7)E<R!O<B!T97)M:6YA=&5S(&9O<B!A
M;GD@<F5A<V]N('=I=&AO=70@:&%V:6YG(&)E96X-"B!F=6QL>2!E>&5R8VES
M960L(&EF(&%N>2!S:&%R97,@;V8@<F5S=')I8W1E9"!S=&]C:R!A<F4@9F]R
M9F5I=&5D+`T*(&]R(&EF(&%N>2!A=V%R9"!T97)M:6YA=&5S+"!E>'!I<F5S
M(&]R(&ES('-E='1L960@=VET:&]U="!A;&P@;W(@80T*('!O<G1I;VX@;V8@
M=&AE('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@8V]V97)E9"!B>2!T:&4@87=A
M<F0@8F5I;F<-"B!I<W-U960L('-U8V@@<VAA<F5S(&%R92!A=F%I;&%B;&4@
M9F]R('1H92!G<F%N="!O9B!A9&1I=&EO;F%L#0H@87=A<F1S+B!(;W=E=F5R
M+"!A;GD@<VAA<F5S('1H870@87)E('=I=&AH96QD("AO<B!D96QI=F5R960I
M('1O('!A>0T*('=I=&AH;VQD:6YG('1A>&5S(&]R('1O('!A>2!T:&4@97AE
M<F-I<V4@<')I8V4@;V8@86X@;W!T:6]N(&%R92!N;W0-"B!A=F%I;&%B;&4@
M9F]R('1H92!G<F%N="!O9B!A9&1I=&EO;F%L(&%W87)D<RX@07,@;V8-"B!$
M96-E;6)E<B8C>$$P.S,Q+"`R,#$S+"!U;F1E<B!T:&4@,C`Q,R!0;&%N+"!T
M:&5R92!W97)E(&]P=&EO;G,@=&\-"B!P=7)C:&%S92!A;B!A9V=R96=A=&4@
M;V8@-C$X+#(Y,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&]U='-T86YD:6YG
M#0H@870@82!W96EG:'1E9"!A=F5R86=E(&5X97)C:7-E('!R:6-E(&]F("0Q
M.2XP-B!P97(@<VAA<F4N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y3=&]C:R!/
M<'1I;VX@17AC:&%N9V4\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.
M5#H@-"4G/@T*($]N($UA<F-H)B-X03`[,38L(#(P,3$@*"8C>#(P,4,[17AC
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M97AE<F-I<V4@<')I8V4@;V8-"B`D,"XY-"`H)B-X,C`Q0SM297!L86-E;65N
M="!/<'1I;VYS)B-X,C`Q1#LI+"!R969L96-T:6YG('1H92!C=7)R96YT#0H@
M9F%I<B!M87)K970@=F%L=64@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@8V]M
M;6]N('-T;V-K(&]N('1H90T*($5X8VAA;F=E($1A=&4N($]R:6=I;F%L($]P
M=&EO;G,@<W5B;6ET=&5D(&9O<B!E>&-H86YG92!W97)E#0H@<F5P;&%C960@
M;VX@82!O;F4M9F]R+6]N92!B87-I<R!W:71H(%)E<&QA8V5M96YT($]P=&EO
M;G,N#0H@061D:71I;VYA;&QY+"!T:&4@4F5P;&%C96UE;G0@3W!T:6]N<R!R
M971A:6X@86QL('1E<FUS(&%N9`T*(&-O;F1I=&EO;G,@;V8@=&AE($]R:6=I
M;F%L($]P=&EO;G,@97AC97!T(&9O<B!T:&4@<F5D=6-T:6]N('1O('1H90T*
M(&5X97)C:7-E('!R:6-E(&%S(&1E<V-R:6)E9"!A8F]V92X\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R
M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&]T86P@8V]M<&5N<V%T:6]N(&%S
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M=&]T86P@;V8-"B`Q+#DR,2PX.30@3W)I9VEN86P@3W!T:6]N<R!W97)E(&5X
M8VAA;F=E9"!F;W(@4F5P;&%C96UE;G0-"B!/<'1I;VYS+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP
M="<^#0H@5&AE(&9O;&QO=VEN9R!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@
M86UO=6YT<R!W97)E(')E8V]G;FEZ960@9F]R#0H@=&AE('!E<FEO9',@:6YD
M:6-A=&5D.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\
M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#@T)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@
M=VED=&@],T0U.24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^/&(^665A<B!%;F1E9`T*
M($1E8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3$\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)E<V5A<F-H(&%N9"!D979E;&]P
M;65N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU,#<L,30R/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT-S$L.#`Y/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XQ+#`Q."PY,S4\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/@T*($=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,S4U+#`R,#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS-C8L-3@V/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,S(X+#4P-#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A;"!S=&]C
M:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C@V,BPQ-C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.#,X+#,Y-3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#,T-RPT,SD\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QI/D5M
M<&QO>65E(%-T;V-K($]P=&EO;G,\+VD^/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.
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M.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B
M;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#0E(&%L:6=N
M/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4Y
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M;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0U(&%L:6=N/3-$8V5N=&5R/CQB/EEE87(@
M16YD960@1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&(^,C`Q,3PO
M8CX\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!%>'!E8W1E
M9"!D:79I9&5N9"!Y:65L9"XN/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1C96YT97(^,"4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$8V5N=&5R/C`E/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1&-E;G1E<CXP)3PO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X<&5C=&5D('9O;&%T:6QI
M='D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E
M<CX\9F]N="!S='EL93TS1"=72$E412U34$%#13H@;F]W<F%P)SXU,R4F(WA!
M,#LM)B-X03`[-C<E/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1C96YT97(^-3$E/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1&-E;G1E<CXV,B4\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!2:7-K+69R964@:6YT97)E<W0@<F%T93PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/C$N,C0E)B-X03`[+28C>$$P.S(N
M,3DE/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
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M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!%>'!E8W1E9"!T97)M+CPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/C<F(WA!,#MY96%R<SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^-R8C>$$P.WEE
M87)S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CXW)B-X
M03`[>65A<G,\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!%
M>'!E8W1E9"!F;W)F96ET=7)E(')A=&4N+CPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)U=(251%
M+5-004-%.B!N;W=R87`G/C4N,#8E)B-X03`[+28C>$$P.S4N-3<E/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^-2XU-R4\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/C4N-3@E/"]T
M9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@/&(^17AP96-T960@1&EV:61E;F0@66EE;&0\+V(^)B-X,C`Q-#M4
M:&4@0V]M<&%N>2!H87,@;F5V97(@9&5C;&%R960-"B!O<B!P86ED(&1I=FED
M96YD<R!A;F0@:&%S(&YO('!L86YS('1O(&1O('-O(&EN('1H92!F;W)E<V5E
M86)L90T*(&9U='5R92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@
M)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&(^17AP
M96-T960@5F]L871I;&ET>3PO8CXF(W@R,#$T.U9O;&%T:6QI='D@:7,@82!M
M96%S=7)E(&]F('1H90T*(&%M;W5N="!B>2!W:&EC:"!A(&9I;F%N8VEA;"!V
M87)I86)L92!S=6-H(&%S(&$@<VAA<F4@<')I8V4@:&%S#0H@9FQU8W1U871E
M9"`H:&ES=&]R:6-A;"!V;VQA=&EL:71Y*2!O<B!I<R!E>'!E8W1E9"!T;R!F
M;'5C='5A=&4-"B`H97AP96-T960@=F]L871I;&ET>2D@9'5R:6YG(&$@<&5R
M:6]D+B!!<R!T:&4@0V]M<&%N>2!D;V5S(&YO="!Y970-"B!H879E('-U9F9I
M8VEE;G0@:&ES=&]R>2!O9B!I=',@;W=N('9O;&%T:6QI='DL('1H92!#;VUP
M86YY(&AA<PT*(&ED96YT:69I960@<V5V97)A;"!P=6)L:6,@96YT:71I97,@
M;V8@<VEM:6QA<B!S:7IE+"!C;VUP;&5X:71Y(&%N9`T*('-T86=E(&]F(&1E
M=F5L;W!M96YT(&%N9"!C86QC=6QA=&5S(&AI<W1O<FEC86P@=F]L871I;&ET
M>2!U<VEN9R!T:&4-"B!V;VQA=&EL:71Y(&]F('1H97-E(&-O;7!A;FEE<RX\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&(^4FES:RU&<F5E
M($EN=&5R97-T(%)A=&4\+V(^)B-X,C`Q-#M4:&ES(&ES('1H92!5+E,N(%1R
M96%S=7)Y(')A=&4-"B!F;W(@=&AE('=E96L@;V8@96%C:"!O<'1I;VX@9W)A
M;G0@9'5R:6YG('1H92!Y96%R+"!H879I;F<@82!T97)M#0H@=&AA="!M;W-T
M(&-L;W-E;'D@<F5S96UB;&5S('1H92!E>'!E8W1E9"!L:69E(&]F('1H92!O
M<'1I;VXN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(#QB/D5X
M<&5C=&5D(%1E<FT\+V(^)B-X,C`Q-#M4:&ES(&ES('1H92!P97)I;V0@;V8@
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M960-"B!T97)M+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\
M8CY%>'!E8W1E9"!&;W)F96ET=7)E(%)A=&4\+V(^)B-X,C`Q-#M4:&4@9F]R
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M92!G<F%N=&5D+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!%
M<75I='D@:6YS=')U;65N=',@:7-S=65D('1O(&YO;BUE;7!L;WEE97,@87)E
M(&%C8V]U;G1E9"!F;W(@=6YD97(-"B!T:&4@<')O=FES:6]N<R!O9B!!4T,F
M(WA!,#LU,#4M-3`L(#QI/D5Q=6ET>2!"87-E9"!087EM96YT<R!T;PT*($YO
M;BU%;7!L;WEE97,\+VD^+B!!8V-O<F1I;F=L>2P@=&AE(&5S=&EM871E9"!F
M86ER('9A;'5E(&]F('1H90T*(&5Q=6ET>2!I;G-T<G5M96YT(&ES(')E8V]R
M9&5D(&]N('1H92!E87)L:65R(&]F('1H92!P97)F;W)M86YC90T*(&-O;6UI
M=&UE;G0@9&%T92!O<B!T:&4@9&%T92!T:&4@<V5R=FEC97,@<F5Q=6ER960@
M87)E#0H@8V]M<&QE=&5D+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E
M)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE('-U;6UA<FEZ97,@<W1O8VL@;W!T
M:6]N(&%C=&EV:71Y(&9O<B`R,#$S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@
M,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52
M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P
M/@T*(#QT<CX-"B`\=&0@=VED=&@],T0T,B4^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$."4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY3:&%R97,\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E=E:6=H=&5D+3QB<B`O
M/@T*($%V97)A9V4\8G(@+SX-"B!%>&5R8VES928C>$$P.U!R:6-E/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S
M='EL93TS1"=72$E412U34$%#13H@;F]W<F%P)SY796EG:'1E9"U!=F5R86=E
M/"]F;VYT/CQB<B`O/@T*(%)E;6%I;FEN9SQB<B`O/@T*($-O;G1R86-T=6%L
M)B-X03`[5&5R;3QB<B`O/@T*("A996%R<RD\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D%G9W)E9V%T93QB<B`O/@T*($EN
M=')I;G-I8SQB<B`O/@T*(%9A;'5E/&)R("\^#0H@*&EN)B-X03`[=&AO=7-A
M;F1S*3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3W5T<W1A;F1I;F<L
M($1E8V5M8F5R)B-X03`[,S$L(#(P,3(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
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M/C`N.30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-RXS
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@1W)A;G1E9#PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C$L,S`W+#$P,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XQ,"XW,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!%>&5R8VES
M960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,2PR-C@L,#0Y
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C@U/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($9O<F9E:71E
M9"!O<B!E>'!I<F5D/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M*#@W+#8S-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2XQ,3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!/=71S=&%N9&EN9RP@1&5C96UB97(F(WA!,#LS,2P@,C`Q,SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPR,#`L.34X/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^-"XY,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C8N.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV-RPU,S(\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,SH\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M17AE<F-I<V%B;&4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-C@X+#(U
M,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N.30\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XT+C@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XT,BPS,3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%9E<W1E9"!A
M;F0@97AP96-T960@=&\@=F5S=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,RPP,C(L.30X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"XV-#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N.#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C8T+#4W-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO
M=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@1'5R:6YG(#(P
M,3,L(#(P,3(@86YD(#(P,3$@=&AE($-O;7!A;GD@:7-S=65D(#$L,C8X+#`T
M.2P@.#8S+#$W-@T*(&%N9"`T.2PX.#,@<VAA<F5S(&]F(&-O;6UO;B!S=&]C
M:RP@<F5S<&5C=&EV96QY+"!I;B!C;VYJ=6YC=&EO;@T*('=I=&@@<W1O8VL@
M;W!T:6]N(&5X97)C:7-E<RX@5&AE($-O;7!A;GD@<F5C96EV960@8V%S:"!P
M<F]C965D<PT*(&9R;VT@=&AE(&5X97)C:7-E(&]F('1H97-E('-T;V-K(&]P
M=&EO;G,@;V8@87!P<F]X:6UA=&5L>2`D,2XQ#0H@;6EL;&EO;BP@)#0V+#@R
M-B!A;F0@)#4S+#(R-2!D=7)I;F<@,C`Q,RP@,C`Q,B!A;F0@,C`Q,2P-"B!R
M97-P96-T:79E;'DN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*
M(%1H92!W96EG:'1E9"UA=F5R86=E(&=R86YT+61A=&4@9F%I<B!V86QU92!O
M9B!O<'1I;VYS(&=R86YT960-"B!D=7)I;F<@,C`Q,RP@,C`Q,B!A;F0@,C`Q
M,2!W87,@)#8N.3$L("0P+CDT(&%N9"`D,"XY-"!P97(@<VAA<F4L#0H@<F5S
M<&5C=&EV96QY+B!4:&4@=&]T86P@:6YT<FEN<VEC('9A;'5E(&]F(&]P=&EO
M;G,@97AE<F-I<V5D(&1U<FEN9PT*(#(P,3,L(#(P,3(@86YD(#(P,3$@=V%S
M(&%P<')O>&EM871E;'D@)#4N-"!M:6QL:6]N+"`D,C<Q+#DR.2!A;F0-"B`D
M,3`R+#0Q."P@<F5S<&5C=&EV96QY+B!4:&4@=&]T86P@9F%I<B!V86QU92!O
M9B!S=&]C:R!O<'1I;VYS('=H:6-H#0H@=F5S=&5D(&1U<FEN9R`R,#$S+"`R
M,#$R(&%N9"`R,#$Q('=A<R`D-#@W+#8P,RP@)#@W.2PP,C0@86YD#0H@)#$L
M,3`X+#$P-RP@<F5S<&5C=&EV96QY+B!!<R!O9B!$96-E;6)E<B8C>$$P.S,Q
M+"`R,#$S+"!T:&4@=&]T86P-"B!U;G)E8V]G;FEZ960@8V]M<&5N<V%T:6]N
M(&5X<&5N<V4@<F5L871E9"!T;R!N;VXM=F5S=&5D('-T;V-K#0H@;W!T:6]N
M<RP@;F5T(&]F(')E;&%T960@9F]R9F5I='5R92!E<W1I;6%T97,L('=A<R`D
M-RXV(&UI;&QI;VXL#0H@=VAI8V@@=&AE($-O;7!A;GD@97AP96-T<R!T;R!R
M96-O9VYI>F4@;W9E<B!A('=E:6=H=&5D+6%V97)A9V4-"B!P97)I;V0@;V8@
M87!P<F]X:6UA=&5L>2!F;W5R('EE87)S+CPO<#X-"B`\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R.6,T8F-A7V-D
M83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\V,CEC-&)C85]C9&$W7S1D865?830T-5\Q,C0U864R-#AC
M.30O5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^26YC;VUE(%1A>&5S/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487@@
M1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*(#QB/C8N($EN
M8V]M92!487AE<SPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-
M"B!&;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,3,L
M(#(P,3(@86YD(#(P,3$@=&AE<F4@=V%S#0H@;F\@8W5R<F5N="!P<F]V:7-I
M;VX@9F]R(&9E9&5R86P@;W(@<W1A=&4@:6YC;VUE('1A>&5S(&1U92!T;R!T
M:&4-"B!T87AA8FQE(&QO<W-E<R!W:&EC:"!R97-U;'1E9"!O<B!U<V4@;V8@
M;&5G86-Y($Y/3`T*(&-A<G)Y9F]R=V%R9',N/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4
M+4E.1$5.5#H@-"4G/@T*(%1H92!S:6=N:69I8V%N="!C;VUP;VYE;G1S(&]F
M('1H92!#;VUP86YY)B-X,C`Q.3MS(&1E9F5R<F5D('1A>`T*(&%S<V5T<R`H
M;&EA8FEL:71I97,I('=E<F4@87,@9F]L;&]W<SH\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)
M3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@86QI9VX],T1C96YT97(@8F]R
M9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-C$E/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#8@86QI9VX],T1C96YT97(^/&(^1&5C96UB97(F(WA!,#LS,2P\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C
M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1&5F97)R
M960@:6YC;VUE('1A>"!A<W-E=',Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@1F5D97)A;"!5+E,N(&YE="!O<&5R871I;F<@
M;&]S<R!C87)R>69O<G=A<F0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,S8L-38Q+#$Y-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,S4L,S,P+#$V
M-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@4W1A=&4@;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9#PO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L,S$U+#4Q-#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#4R,2PW,C(\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*(%)E<V5A<F-H(&%N9"!D979E;&]P;65N="!C<F5D
M:70L(&YE=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L-S@U
M+#8Q,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#<W-RPX.3D\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M($]R<&AA;B!D<G5G(&-R961I="P@;F5T/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,3DL.#@S+#`W-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XQ.2PP,SDL-C$S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!$969E<G)E9"!R96YT/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-2PQ,S(L-#4X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L
M,C$X+#`P,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@1&5F97)R960@<F5V96YU93PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C@L,C$V+#8Y-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XY+#,W.2PP-C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M($1E<')E8VEA=&EO;CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C$L-#,X+#0W-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#(T
M-RPW-S(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($]T:&5R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,2PT,S@L.#<P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-3<U
M+#<X,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*($=R;W-S(&1E9F5R<F5D(&EN8V]M92!T87@@
M87-S971S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW.2PW-S$L.#DW/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S@L,#DP+#`R,3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5F%L=6%T:6]N(&%L
M;&]W86YC93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#<Y+#,W-BPY-#4\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^*#<X+#`Y,"PP,C$\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T(&1E
M9F5R<F5D(&EN8V]M92!T87@@87-S971S/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XS.30L.34R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@1&5F97)R960@:6YC;VUE('1A>"!L:6%B:6QI=&EE<SH\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@3W1H97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/B@S.30L.34R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!'<F]S<R!D969E<G)E9"!I
M;F-O;64@=&%X(&QI86)I;&ET:65S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XH,SDT+#DU,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!.970@9&5F97)R960@:6YC;VUE('1A
M>"!A<W-E="\H;&EA8FEL:71Y*3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
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M;6%N86=E;65N="!C;VYS:61E<G,-"B`H:2DF(WA!,#MF=71U<F4@<F5V97)S
M86QS(&]F(&5X:7-T:6YG('1A>&%B;&4@=&5M<&]R87)Y#0H@9&EF9F5R96YC
M97,[("AI:2DF(WA!,#MF=71U<F4@=&%X86)L92!I;F-O;64@97AC;'5S:79E
M(&]F(')E=F5R<VEN9PT*('1E;7!O<F%R>2!D:69F97)E;F-E(&%N9"!C87)R
M>69O<G=A<F1S.R`H:6EI*28C>$$P.W1A>&%B;&4@:6YC;VUE#0H@:6X@<')I
M;W(@8V%R<GEB86-K('EE87)S(&EF(&-A<G)Y8F%C:R!I<R!P97)M:71T960@
M=6YD97(@87!P;&EC86)L90T*('1A>"!L87<[(&%N9"`H:78I)B-X03`[=&%X
M('!L86YN:6YG('-T<F%T96=I97,N(%1H92!#;VUP86YY)B-X,C`Q.3MS#0H@
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M=&AE('9A;'5A=&EO;B!A;&QO=V%N8V4@:6X@,C`Q,R!I<R!D=64-"B!T;R!T
M:&4@9F%C="!T:&4@0V]M<&%N>2!G96YE<F%T960@<F5S96%R8V@@86YD(&1E
M=F5L;W!M96YT(&%N9`T*(&]R<&AA;B!D<G5G(&-R961I=',@86YD($Y/3"!C
M87)R>69O<G=A<F1S('=H:6-H(&EN8W)E87-E9"!T:&4@;F5T#0H@9&5F97)R
M960@=&%X(&%S<V5T+B!4:&4@:6YC<F5A<V4@:6X@=&AE(&-R961I=',@86YD
M($Y/3`T*(&-A<G)Y9F]R=V%R9',@=V5R92!O9F9S970@8GD@=&AE(&1E8W)E
M87-E(&EN(&1E9F5R<F5D(')E=F5N=64@86YD#0H@<F5S=6QT960@:6X@82!N
M970@8W5R<F5N="!Y96%R(&EN8W)E87-E('1O('1H92!V86QU871I;VX-"B!A
M;&QO=V%N8V4N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H
M92!#;VUP86YY(&AA<R!R97!O<G1E9"!B;V]K(&QO<W-E<R!F<F]M(&EN8V5P
M=&EO;B!T:')O=6=H#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,"X@5&AE($Y/
M3"!C87)R>69O<G=A<F1S(&]F(&%P<')O>&EM871E;'D-"B`D,3`T+C@@;6EL
M;&EO;B!F;W(@52Y3+B8C>$$P.V9E9&5R86P@86YD(&%P<')O>&EM871E;'D@
M)#8P+C,-"B!M:6QL:6]N(&9O<B!S=&%T92!W:6QL(&5X<&ER92!I;B!V87)I
M;W5S('EE87)S(&)E9VEN;FEN9R!I;B`R,#(S#0H@=&AR;W5G:"`R,#,S+B!)
M;B!A9&1I=&EO;BP@=&AE($-O;7!A;GD@:&%S(%4N4RX@9F5D97)A;"!T87@@
M8W)E9&ET<PT*(&]F("0R,RXW(&UI;&QI;VX@=VAI8V@@=VEL;"!E>'!I<F4@
M:6X@=F%R:6]U<R!Y96%R<R!B96=I;FYI;F<@:6X-"B`R,#(P('1H<F]U9V@@
M,C`S,RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE('5S
M92!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!5+E,N(&9E9&5R86P@3D],(&%N
M9"!T87@@8W)E9&ET#0H@8V%R<GEF;W)W87)D<R!I;B!F=71U<F4@>65A<G,@
M87)E(')E<W1R:6-T960@9'5E('1O(&-H86YG97,@:6X@=&AE#0H@0V]M<&%N
M>28C>#(P,3D[<R!O=VYE<G-H:7`@86YD('1A>"!A='1R:6)U=&5S(&%C<75I
M<F5D(&)Y('1H90T*($-O;7!A;GD@:6X@82!P=7)C:&%S92X@07,@;V8@1&5C
M96UB97(F(WA!,#LS,2P@,C`Q,RP@)#@N-2!M:6QL:6]N#0H@;V8@=&AE($-O
M;7!A;GDF(W@R,#$Y.W,@3D],<R!A<F4@;&EM:71E9"!F;W(@=7-E(&]V97(@
M=&AE('EE87)S#0H@,C`Q-"8C>$$P.R8C>#(P,3,[(#(P,C<@:6X@=VAI8V@@
M82!R86YG92!O9B!S=6-H(&%M;W5N=',@8V]U;&0@8F4-"B!U=&EL:7IE9"!O
M;B!A;B!A;FYU86P@8F%S:7,@;V8@)#`N,B!M:6QL:6]N('1O("0Q+C0F(WA!
M,#MM:6QL:6]N+@T*(%1H92!R96UA:6YI;F<@)#DV+C,@;6EL;&EO;B!O9B!.
M3TQS(&ES(&YO="!L:6UI=&5D(&%N9"!C86X@8F4-"B!O9F9S970@86=A:6YS
M="!F=71U<F4@=&%X86)L92!I;F-O;64N($%D9&ET:6]N86QL>2P@87!P<F]X
M:6UA=&5L>0T*("0Q+C@@;6EL;&EO;B!O9B!.3TQS('=I;&P@8F4@<F5C;V=N
M:7IE9"!A<R!A(&)E;F5F:70@=&AR;W5G:`T*(&%D9&ET:6]N86PM<&%I9"UI
M;BUC87!I=&%L('=H96X@<F5A;&EZ960N($9U<G1H97(L(&1E<W!I=&4@=&AE
M($Y/3`T*(&%N9"!C<F5D:70@8V%R<GEF;W)W87)D<RP@=&AE($-O;7!A;GD@
M;6%Y(&AA=F4@82!F=71U<F4@=&%X#0H@;&EA8FEL:71Y(&1U92!T;R!A;B!A
M;'1E<FYA=&EV92!M:6YI;75M('1A>"!O<B!S=&%T92!T87@-"B!R97%U:7)E
M;65N=',@:6X@=VAI8V@@;F5T(&]P97)A=&EN9R!L;W-S97,@9&\@;F]T(&5X
M:7-T+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
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M(')A=&4@=&\@=&AE(&YE="!I;F-O;64@:7,@87,@9F]L;&]W<SH\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R
M<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@86QI9VX],T1C
M96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-3,E/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P
M(&%L:6=N/3-$8V5N=&5R/CQB/EEE87(@16YD960-"B!$96-E;6)E<B8C>$$P
M.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\8CXR,#$Q/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!5
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M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
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M,S4P+#DY,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4W1A=&4@=&%X
M97,@*&YE="!O9B!F961E<F%L(&)E;F5F:70I/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-C`Y+#0W-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
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M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,2PT.#`L,3@U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!$969E<G)E9"!I;F-O;64@=&%X(&%D:G5S=&UE;G1S
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#@U-2PQ,S`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U,3(L,S<U/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*
M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!$969E<G)E9"!S=&%T92!B;&5N9&5D(')A=&4@861J=7-T;65N=',\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S0T+#$W.#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I
M9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!297-E87)C:"!C<F5D:70L
M(&YE=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R,C4L-C`U
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*($]R<&AA;B!D<G5G(&-R961I="P@;F5T/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#@T,RPT-C,\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B@T+#@Y-2PV-S$\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/B@W+#`U-BPV,#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!/=&AE<B!P97)M86YE;G0@:71E;7,\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#DS,3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XW+#8R-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XT+#8Y-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@17%U:71Y
M+6)A<V5D(&-O;7!E;G-A=&EO;CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C(T,2PT-C<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,C<Y+#$V-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW,C4L.#$Q
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!&86ER('9A;'5E(&%D:G5S=&UE;G0@;V8@<')E9F5R<F5D('-T;V-K('=A
M<G)A;G0@;&EA8FEL:71Y/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,C$X+#@W,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-3(L
M-S0S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-#DV+#(P.#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*($-H86YG92!I;B!V86QU871I;VX@86QL;W=A;F-E
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PR.#8L.3(S/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<X-RPP.3,\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPY.3$L,3,Q/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*($EN8V]M92!T87@@97AP96YS92\H8F5N969I
M="D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)
M3D1%3E0Z(#0E)SX-"B!!(')E8V]N8VEL:6%T:6]N(&]F('1H92!B96=I;FYI
M;F<@86YD(&5N9&EN9R!A;6]U;G0@;V8@9W)O<W,-"B!U;G)E8V]G;FEZ960@
M=&%X(&)E;F5F:71S(&ES(&%S(&9O;&QO=W,Z/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM
M5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$.#0E(&%L:6=N/3-$8V5N=&5R(&)O<F1E
M<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4U)3X\+W1D/@T*(#QT9"!V
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M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E
M;G1E<CX\8CY996%R($5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&(^,C`Q,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M0F5G:6YN:6YG(&)A;&%N8V4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,2PU.3(L,S4W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#4S
M,RPY.#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,C0V+#`R
M-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@26YC<F5A<V5S+RAD96-R
M96%S97,I(&9O<B!C=7)R96YT('EE87(@=&%X('!O<VET:6]N<SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q-2PU,#(\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3@L,S<Q/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(X-RPY-C$\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
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M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*($1E8W)E87-E<R!A<R!A(')E<W5L="!O
M9B!E>'!I<F%T:6]N(&]F('-T871U=&4@;V8@;&EM:71A=&EO;G,\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!%;F1I
M;F<@8F%L86YC93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-S`W+#@U.3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XQ+#4Y,BPS-3<\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,2PU,S,L.3@V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($%S
M(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,3,@86YD(#(P,3(L(&]F('1H92!T
M;W1A;"!G<F]S<PT*('5N<F5C;V=N:7IE9"!T87@@8F5N969I=',L(&%P<')O
M>&EM871E;'D@)#$N,B!M:6QL:6]N(&%N9"`D,2XQ#0H@;6EL;&EO;B!W;W5L
M9"!F879O<F%B;'D@:6UP86-T('1H92!#;VUP86YY)B-X,C`Q.3MS(&5F9F5C
M=&EV92!I;F-O;64-"B!T87@@<F%T92P@<F5S<&5C=&EV96QY+B!!;'1H;W5G
M:"P@9'5E('1O('1H92!#;VUP86YY)B-X,C`Q.3MS#0H@9&5T97)M:6YA=&EO
M;B!T:&%T('1H92!D969E<G)E9"!I;F-O;64@=&%X(&%S<V5T('=O=6QD(&YO
M="!M;W)E#0H@;&EK96QY('1H86X@;F]T(&)E(')E86QI>F5D+"!A('9A;'5A
M=&EO;B!A;&QO=V%N8V4@=V]U;&0@8F4-"B!R96-O<F1E9"P@=&AE<F5F;W)E
M+"!Z97)O(&YE="!I;7!A8W0@=V]U;&0@<F5S=6QT('=I=&AI;B!T:&4-"B!#
M;VUP86YY)B-X,C`Q.3MS(&5F9F5C=&EV92!I;F-O;64@=&%X(')A=&4N(%1H
M92!#;VUP86YY)B-X,C`Q.3MS#0H@=6YC97)T86EN(&EN8V]M92!T87@@<&]S
M:71I;VX@;&EA8FEL:71Y(&AA<R!B965N(')E8V]R9&5D('1O#0H@9&5F97)R
M960@:6YC;VUE('1A>&5S('1O(&]F9G-E="!T:&4@=&%X(&%T=')I8G5T92!C
M87)R>69O<G=A<F0-"B!A;6]U;G1S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B!&;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B-X03`[
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M;6]N=&AS+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M<&%N>28C
M>#(P,3D[<R!5+E,N($9E9&5R86P@86YD('-T871E(&EN8V]M92!T87@@<F5T
M=7)N<R!F<F]M#0H@,C`P,2!T;R`R,#$R(')E;6%I;B!S=6)J96-T('1O(&5X
M86UI;F%T:6]N(&)Y('1H92!T87@@875T:&]R:71I97,N#0H@5&AE($-O;7!A
M;GDF(W@R,#$Y.W,@,C`P,2!T:')O=6=H(#(P,#D@>65A<G,@<F5M86EN(&]P
M96X@9F]R#0H@97AA;6EN871I;VXL(&5V96X@=&AO=6=H('1H92!S=&%T=71E
M(&]F(&QI;6ET871I;VYS(&AA<R!E>'!I<F5D+`T*(&1U92!T;R!T:&4@;F5T
M(&]P97)A=&EN9R!L;W-S97,@86YD(&-R961I=',@8V%R<FEE9"!F;W)W87)D
M(&9O<B!U<V4-"B!I;B!P<F]S<&5C=&EV92!Y96%R<RX\+W`^#0H@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQE87-E($5X:70@3&EA8FEL:71Y
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E)E<W1R=6-T=7)I;F<@06YD(%)E;&%T960@06-T:79I=&EE<R!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,96%S92!%>&ET($QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/C<N($QE87-E($5X
M:70@3&EA8FEL:71Y/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G
M/@T*($]N($IU;'DF(WA!,#LQ-BP@,C`P."P@=&AE($-O;7!A;GD@86-Q=6ER
M960@4F%V96X@0FEO=&5C:&YO;&]G:65S+`T*($EN8RX@*"8C>#(P,4,[4F%V
M96XF(W@R,#%$.RDL(&$@<')I=F%T92!3;W5T:"!386X@1G)A;F-I<V-O+6)A
M<V5D#0H@8V]M<&%N>2!F;V-U<V5D(&]N('1H92!D979E;&]P;65N="!O9B!M
M;VYO8VQO;F%L(&%N=&EB;V1Y#0H@=&AE<F%P975T:6-S(&9O<B!T<F5A=&EN
M9R!C86YC97(N(%)A=F5N('=A<R!C;VYS:61E<F5D(&$-"B!D979E;&]P;65N
M="US=&%G92!E;G1E<G!R:7-E(&%S(&1E9FEN960@:6X@05-#)B-X03`[.3$U
M+`T*(#QI/D1E=F5L;W!M96YT(%-T86=E($5N=&ET:65S/"]I/BX@26X@8V]N
M;F5C=&EO;B!W:71H('1H90T*(&%C<75I<VET:6]N+"!T:&4@0V]M<&%N>2!I
M<W-U960@,3(L-#8V+#`S.2!S:&%R97,@;V8@:71S(%-E<FEE<R!$#0H@8V]N
M=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K(&EN(&5X8VAA;F=E(&9O<B!A;&P@
M;V8@=&AE(&]U='-T86YD:6YG#0H@8V%P:71A;"!S=&]C:R!A;F0@8V]N=F5R
M=&EB;&4@;F]T97,@<&%Y86)L92!O9B!2879E;BX\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%
M6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@=6YD97)T;V]K(')E<W1R
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M('1H90T*('EE87(@96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`P.2X\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@26X@8V]N;F5C=&EO;B!W
M:71H('1H97-E(')E<W1R=6-T=7)I;F<@86-T:79I=&EE<RP@87,@<&%R="!O
M9B!T:&4-"B!C;W-T(&]F(&%C<75I<VET:6]N+"!T:&4@0V]M<&%N>2!E<W1A
M8FQI<VAE9"!A(')E<W1R=6-T=7)I;F<-"B!L:6%B:6QI='D@871T<FEB=71E
M9"!T;R!A;B!E>&ES=&EN9R!O<&5R871I;F<@;&5A<V4N(%1H92!T97)M<R!O
M9@T*('1H92!O<&5R871I;F<@;&5A<V4@97AT96YD('1H<F]U9V@@,C`Q."X\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@0VAA;F=E<R!I;B!T
M:&4@;&5A<V4@97AI="!L:6%B:6QI='D@87)E(&%S(&9O;&QO=W,Z/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-C@E(&%L:6=N/3-$
M8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#<Y)3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!!8V-R=6%L(&)A;&%N8V4@870@1&5C96UB
M97(F(WA!,#LS,2P@,C`Q,3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)#$P
M+#8P-RPT.3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%!R:6YC:7!A
M;"!P87EM96YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#4S,RPU-C`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!!8V-R=6%L(&)A;&%N8V4@870@
M1&5C96UB97(F(WA!,#LS,2P@,C`Q,CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,3`L,#<S+#DS.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4')I
M;F-I<&%L('!A>6UE;G1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-C(X
M+#<V.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%C8W)U86P@8F%L86YC
M92!A="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XD.2PT-#4L,3<P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q
M,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($9U='5R92!P<FEN8VEP86P@<&%Y
M;65N=',@=&\@8F4@;6%D92!U;F1E<B!T:&4@;&5A<V4@86=R965M96YT(&9O
M<@T*('1H92!N97AT(&9I=F4@>65A<G,@86YD('1H97)E869T97(@87,@;V8@
M1&5C96UB97(F(WA!,#LS,2P@,C`Q,R!A<F4-"B!A<R!F;VQL;W=S.CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#8X)2!A;&EG;CTS
M1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0X,"4^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^#0H@,C`Q-#PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C$L-#,X+#<T,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@,C`Q-3PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PV-#$L.3`U/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`R,#$V/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XQ+#@V-BPP,S$\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/@T*(#(P,3<\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L
M,3$S+#$Q.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@,C`Q.#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPS.#4L
M,S<T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4:&5R96%F=&5R/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG
M;CTS1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CDL-#0U+#$W,#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
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M('1H92!F:7)S=`T*(%!H87-E(#(@8VQI;FEC86P@=')I86P@;V8@86YY('!R
M;V1U8W0@9&5R:79E9"!F<F]M('1H92!2879E;@T*("8C>#(P,4,[0V%N8V5R
M(%-T96T@0V5L;"!0<F]G<F%M+B8C>#(P,40[($YO('!A>6UE;G0@<VAA;&P@
M8F4@;6%D92!I9@T*('1H92!0:&%S92`R('1R:6%L('-T87)T(&1A=&4@:&%S
M(&YO="!O8V-U<G)E9"!O;B!O<B!B969O<F4-"B!*=6QY)B-X03`[,34L(#(P
M,3@N($]T:&5R(&-O;G-I9&5R871I;VX@:6YC;'5D97,@82!P97)C96YT86=E
M(&]F#0H@<F5V96YU92`H97AC;'5D:6YG(&-O;G-I9&5R871I;VX@9F]R(')E
M<V5A<F-H(&%N9"!D979E;&]P;65N="!A;F0-"B!E<75I='DI(')E8V5I=F5D
M(&)Y('1H92!#;VUP86YY(&9O<B!L:6-E;G-E(&]F(&$@<')O9'5C="!D97)I
M=F5D#0H@9G)O;2!T:&4@4F%V96X@)B-X,C`Q0SM#86YC97(@4W1E;2!#96QL
M(%!R;V=R86TF(W@R,#%$.R!A;F0@82!O;F5T:6UE#0H@<&%Y;65N="!R86YG
M:6YG(&9R;VT@)#@N,"8C>$$P.VUI;&QI;VX@=&\@)#$R+C`F(WA!,#MM:6QL
M:6]N#0H@9&5P96YD96YT('5P;VX@82!S<&5C:69I960@;&5V96P@;V8@<V%L
M97,@;V8@<')O9'5C=',@9&5R:79E9"!F<F]M#0H@=&AE(%)A=F5N("8C>#(P
M,4,[0V%N8V5R(%-T96T@0V5L;"!0<F]G<F%M+B8C>#(P,40[/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T
M.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
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M<B8C>$$P.S,Q+"`R,#$S+"`R,#$R(&%N9`T*(#(P,3$N/"]P/@T*(#PO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(Y
M8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X8SDT#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R
M-#5A93(T.&,Y-"]7;W)K<VAE971S+U-H965T,30N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VQL86)O<F%T:6]N(&%N9"!,
M:6-E;G-E($%G<F5E;65N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^5&5X="!";&]C:R!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VQL
M86)O<F%T:6]N(&%N9"!,:6-E;G-E($%G<F5E;65N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)VUA<F=I
M;BUT;W`Z,3AP=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T
M.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(#QB/C@N($-O;&QA
M8F]R871I;VX@86YD($QI8V5N<V4@06=R965M96YT<SPO8CX\+W`^#0H@/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!F
M;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-
M"B`\8CX\:3Y397)V:65R/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R
M9VEN+71O<#HV<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT
M)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;B<^#0H@26X@3F]V96UB97(@,C`Q,2P@=&AE($-O;7!A;GD@96YT97)E9"!I
M;G1O(&$@<FEG:'0M=&\M9&5V96QO<`T*(&-O;&QA8F]R871I;VX@86=R965M
M96YT('=I=&@@4V5R=FEE<B!F;W(@=&AE(&1E=F5L;W!M96YT(&%N9`T*(&-O
M;6UE<F-I86QI>F%T:6]N(&]F($U'03(W,2!I;B!A;&P@8V]U;G1R:65S(&]T
M:&5R('1H86X@=&AE(%5N:71E9`T*(%-T871E<RP@0V%N861A+"!-97AI8V\L
M($IA<&%N+"!3;W5T:"!+;W)E82!A;F0@26YD:6$N/"]P/@T*(#QP('-T>6QE
M/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M
M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N)SX-"B!5<&]N(&5X96-U=&EO;B!O9B!T:&4@86=R965M96YT
M+"!397)V:65R(&UA9&4@82!N;VYR969U;F1A8FQE#0H@<&%Y;65N="!O9B`D
M,C`N,"!M:6QL:6]N('1O('1H92!#;VUP86YY+B!4:&4@0V]M<&%N>2!I<R!E
M;&EG:6)L92!T;PT*(')E8V5I=F4@=7`@=&\@)#,P+C`@;6EL;&EO;B!I;B!L
M:6-E;G-E(&=R86YT(&9E97,L("0T-RXP(&UI;&QI;VX@:6X-"B!C;&EN:6-A
M;"!M:6QE<W1O;F4@<&%Y;65N=',L("0Q-#`N,"!M:6QL:6]N(&EN(')E9W5L
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M9VYI>F5D('5P;VX@86-H:65V96UE;G0@;V8@=&AE(&UI;&5S=&]N92`H87-S
M=6UI;F<@86QL#0H@;W1H97(@<F5V96YU92!R96-O9VYI=&EO;B!C<FET97)I
M82!H879E(&)E96X@;65T*2!B96-A=7-E('1H97)E(&%R90T*(&YO('5N9&5L
M:79E<F5D(&5L96UE;G1S('1H870@=V]U;&0@<')E8VQU9&4@<F5V96YU92!R
M96-O9VYI=&EO;B!A=`T*('1H870@=&EM92X@26X@=&AE(&5V96YT(%-E<G9I
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M('-A;&5S(&EN(&ET<PT*('1E<G)I=&]R:65S+CPO<#X-"B`\<"!S='EL93TS
M1"=M87)G:6XM=&]P.C$R<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN
M9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;B<^#0H@5&AE($-O;7!A;GD@:&%S(&5V86QU871E9"!T:&4@<F5S
M96%R8V@@8V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@=VET:`T*(%-E<G9I97(@
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M>2P@=&5C:&YI8V%L+"!S8VEE;G1I9FEC(&%N9`T*(&EN=&5L;&5C='5A;"!P
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M96-H;FEC86P@97AP97)T:7-E(&%N9`T*(&-O;6UI='1E92!P87)T:6-I<&%T
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M<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT
M.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N)SX-"B!$=7)I;F<@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B-X03`[
M,S$L(#(P,3,L(#(P,3(@86YD(#(P,3$@=&AE#0H@0V]M<&%N>2!R96-O9VYI
M>F5D(')E=F5N=64@;V8@)#(Q+C,F(WA!,#MM:6QL:6]N+"`D.2XQ(&UI;&QI
M;VX@86YD#0H@,"XY)B-X03`[;6EL;&EO;BP@<F5S<&5C=&EV96QY+"!U;F1E
M<B!T:&ES(&%G<F5E;65N="X@4F5V96YU90T*(')E8V]G;FEZ960@:6X@=&AE
M('EE87(@96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q,R!I;F-L=61E9"!A
M#0H@)#$P+C`@;6EL;&EO;B!S=6)S=&%N=&EV92!M:6QE<W1O;F4@<&%Y;65N
M="!R96-E:79E9"!U<&]N(&1O<VEN9PT*('1H92!F:7)S="!P871I96YT(&EN
M(&$@4&AA<V4@,2!D;W-E(&5X<&%N<VEO;B!C;VAO<G0@=')I86P@;V8-"B!-
M1T$R-S$N/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R
M9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P
M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!!="!$96-E;6)E
M<B8C>$$P.S,Q+"`R,#$S+"`D,"XY(&UI;&QI;VX@;V8@<F5V96YU92!R96UA
M:6YE9`T*(&1E9F5R<F5D('5N9&5R('1H:7,@86=R965M96YT+"!A;&P@;V8@
M=VAI8V@@=V%S(&EN8VQU9&5D(&EN(&-U<G)E;G0-"B!L:6%B:6QI=&EE<RX@
M070@1&5C96UB97(F(WA!,#LS,2P@,C`Q,BP@)#$P+C`@;6EL;&EO;B!O9B!R
M979E;G5E#0H@=V%S(&1E9F5R<F5D('5N9&5R('1H:7,@86=R965M96YT+"`D
M.2XQ(&UI;&QI;VX@;V8@=VAI8V@@=V%S#0H@:6YC;'5D960@:6X@8W5R<F5N
M="!L:6%B:6QI=&EE<R!A;F0@)#`N.2!M:6QL:6]N(&]F('=H:6-H('=A<PT*
M(&EN8VQU9&5D(&EN(&QO;F<M=&5R;2!L:6%B:6QI=&EE<RX\+W`^#0H@/'`@
M<W1Y;&4],T1F;VYT+7-I>F4Z,3)P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M8F]T=&]M.C!P=#X-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HP<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@
M9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^
M#0H@26X@4V5P=&5M8F5R(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960@:6YT
M;R!A('-E8V]N9`T*(')I9VAT+71O+61E=F5L;W`@8V]L;&%B;W)A=&EO;B!A
M9W)E96UE;G0@=VET:"!397)V:65R(&%N9"!G<F%N=&5D#0H@:70@;W!T:6]N
M<R!T;R!O8G1A:6X@=&AR964@<V5P87)A=&4@97AC;'5S:79E(&QI8V5N<V5S
M('1O(&1E=F5L;W`-"B!A;F0@8V]M;65R8VEA;&EZ92`\9F]N="!S='EL93TS
M1'=H:71E+7-P86-E.FYO=W)A<#Y$05)4+6)A<V5D/"]F;VYT/B!M;VQE8W5L
M97,L(&-O;G-I<W1I;F<@;V8-"B!T:&]S92!D97-I9VYA=&5D(&)Y('1H92!#
M;VUP86YY(&%S($U'1#`P-B!A;F0@34=$,#`W+"!A<R!W96QL(&%S(&$-"B!T
M:&ER9"!$05)4(&UO;&5C=6QE+"!I;B!A;&P@8V]U;G1R:65S(&]T:&5R('1H
M86X@=&AE(%5N:71E9"!3=&%T97,L#0H@0V%N861A+"!-97AI8V\L($IA<&%N
M+"!3;W5T:"!+;W)E82!A;F0@26YD:6$N/"]P/@T*(#QP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT
M.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N)SX-"B!5<&]N(&5X96-U=&EO;B!O9B!T:&4@86=R965M96YT+"!397)V
M:65R(&UA9&4@82!N;VYR969U;F1A8FQE#0H@<&%Y;65N="!O9B`D,C`N,"!M
M:6QL:6]N('1O('1H92!#;VUP86YY+B!);B!A9&1I=&EO;BP@=&AE($-O;7!A
M;GD-"B!W:6QL(&)E(&5L:6=I8FQE('1O(')E8V5I=F4@=7`@=&\@)#8U+C`@
M;6EL;&EO;B!I;B!L:6-E;G-E(&=R86YT#0H@9F5E<RP@)#DX+C`@;6EL;&EO
M;B!I;B!C;&EN:6-A;"!M:6QE<W1O;F4@<&%Y;65N=',L(&EN8VQU9&EN9R`D
M-2XP#0H@;6EL;&EO;B!U<&]N($E.1"!A8V-E<'1A;F-E(&9O<B!E86-H(&]F
M($U'1#`P-BP@34=$,#`W(&%N9"!A('1H:7)D#0H@1$%25"!M;VQE8W5L92P@
M)#,P,"XP(&UI;&QI;VX@:6X@<F5G=6QA=&]R>2!M:6QE<W1O;F4@<&%Y;65N
M=',@86YD#0H@)#8S,"XP(&UI;&QI;VX@:6X@<V%L97,@;6EL97-T;VYE('!A
M>6UE;G1S(&EF(%-E<G9I97(@97AE<F-I<V5S(&%L;`T*(&]F('1H92!O<'1I
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M=6-T('-A;&5S(&EN(&ET<PT*('1E<G)I=&]R:65S+CPO<#X-"B`\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C$R<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT
M+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;B<^#0H@5&AE($-O;7!A;GD@:&%S(&5V86QU871E9"!T:&4@
M<F5S96%R8V@@8V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@=VET:`T*(%-E<G9I
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M(&%N9"!A(')E<V5A<F-H(&%N9`T*(&1E=F5L;W!M96YT(&-O;6UI='1E92X@
M5&AE($-O;7!A;GD@9&5T97)M:6YE9"!T:&%T('1H92!P97)F;W)M86YC90T*
M(&]B;&EG871I;VYS('=I=&@@<F5S<&5C="!T;R!T:&4@<')E+6-L:6YI8V%L
M(&1E=F5L;W!M96YT(')E<')E<V5N=`T*(&$@<VEN9VQE('5N:70@;V8@86-C
M;W5N=&EN9RP@<VEN8V4@=&AE(&QI8V5N<V4@9&]E<R!N;W0@:&%V90T*('-T
M86YD+6%L;VYE('9A;'5E('1O(%-E<G9I97(@=VET:&]U="!T:&4@0V]M<&%N
M>28C>#(P,3D[<R!T96-H;FEC86P-"B!E>'!E<G1I<V4@86YD(&-O;6UI='1E
M92!P87)T:6-I<&%T:6]N+B!!<R!S=6-H+"!T:&4@:6YI=&EA;"!U<`T*(&9R
M;VYT(&QI8V5N<V4@<&%Y;65N="!W87,@9&5F97)R960@86YD(&ES(&)E:6YG
M(')E8V]G;FEZ960@<F%T86)L>0T*(&]V97(@=&AE(&EN:71I86P@,CDM;6]N
M=&@@<&5R:6]D+"!W:&EC:"!R97!R97-E;G1S('1H92!E>'!E8W1E9`T*(&1E
M=F5L;W!M96YT('!E<FEO9"X@5&AE($-O;7!A;GD@9G5R=&AE<B!C;VYC;'5D
M960@=&AA="!E86-H#0H@<&]T96YT:6%L(&9U='5R92!C;&EN:6-A;"P@9&5V
M96QO<&UE;G0@86YD(')E9W5L871O<GD@;6EL97-T;VYE(&ES#0H@<W5B<W1A
M;G1I=F4N/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R
M9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P
M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!$=7)I;F<@=&AE
M('EE87)S(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,3,@86YD(#(P,3(@
M=&AE($-O;7!A;GD-"B!R96-O9VYI>F5D(')E=F5N=64@;V8@)#@N-B!M:6QL
M:6]N+"!A;F0@)#(N,"!M:6QL:6]N+"!R97-P96-T:79E;'DN#0H@3F\@;6EL
M97-T;VYE<R!H879E(&)E96X@<F5C;V=N:7IE9"!U;F1E<B!T:&ES(&%G<F5E
M;65N="!D=7)I;F<@=&AE#0H@>65A<G,@96YD960@1&5C96UB97(F(WA!,#LS
M,2P@,C`Q,R!A;F0@,C`Q,BX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#HQ,G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z-"4[(&9O
M;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*
M($%T($1E8V5M8F5R)B-X03`[,S$L(#(P,3,L("0Y+C0@;6EL;&EO;B!O9B!R
M979E;G5E('=A<R!D969E<G)E9`T*('5N9&5R('1H:7,@86=R965M96YT+"`D
M."XV(&UI;&QI;VX@;V8@=VAI8V@@=V%S(&EN8VQU9&5D(&EN(&-U<G)E;G0-
M"B!L:6%B:6QI=&EE<R!A;F0@)#`N."!M:6QL:6]N(&]F('=H:6-H('=A<R!I
M;F-L=61E9"!I;B!L;VYG+71E<FT-"B!L:6%B:6QI=&EE<RX@070@1&5C96UB
M97(F(WA!,#LS,2P@,C`Q,BP@)#$X+C`@;6EL;&EO;B!O9B!R979E;G5E#0H@
M=V%S(&1E9F5R<F5D('5N9&5R('1H:7,@86=R965M96YT+"`D."XV(&UI;&QI
M;VX@;V8@=VAI8V@@=V%S#0H@:6YC;'5D960@:6X@8W5R<F5N="!L:6%B:6QI
M=&EE<R!A;F0@)#DN-"!M:6QL:6]N(&]F('=H:6-H('=A<PT*(&EN8VQU9&5D
M(&EN(&QO;F<M=&5R;2!L:6%B:6QI=&EE<RX\+W`^#0H@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HQ,G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E
M;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86XG/@T*($EN($9E8G)U87)Y(#(P,30L(%-E<G9I97(@97AE<F-I<V5D
M(&ET<R!E>&-L=7-I=F4@;W!T:6]N('1O(&1E=F5L;W`-"B!A;F0@8V]M;65R
M8VEA;&EZ92!-1T0P,#8N($%S(&$@<F5S=6QT(&]F('1H92!E>&5R8VES92P@
M=&AE($-O;7!A;GD-"B!R96-E:79E9"!A("0Q-2XP(&UI;&QI;VX@<&%Y;65N
M="!F<F]M(%-E<G9I97(@9F]R(&ET<R!L:6-E;G-E('1O#0H@9&5V96QO<"!A
M;F0@8V]M;65R8VEA;&EZ92!-1T0P,#8@:6X@:71S('1E<G)I=&]R:65S+B!)
M;B!A9&1I=&EO;BP-"B!T:&4@0V]M<&%N>2!R96-E:79E9"!A("0U+C`@;6EL
M;&EO;B!P87EM96YT(&9R;VT@4V5R=FEE<B!U<&]N('1H90T*(&%C:&EE=F5M
M96YT(&]F(&$@8VQI;FEC86P@;6EL97-T;VYE(')E;&%T960@=&\@=&AE($E.
M1"!A<'!L:6-A=&EO;@T*(&9O<B!-1T0P,#8@8VQE87)I;F<@=&AE(#QF;VYT
M('-T>6QE/3-$=VAI=&4M<W!A8V4Z;F]W<F%P/C,P+61A>3PO9F]N=#X@<F5V
M:65W('!E<FEO9"!B>2!T:&4@1D1!+CPO<#X-"B`\<"!S='EL93TS1&9O;G0M
M<VEZ93HQ.'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T/@T*
M("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#L@;6%R
M9VEN+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86XG/@T*(#QB/CQI/D=I;&5A9#PO:3X\+V(^/"]P/@T*
M(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P
M=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86XG/@T*($EN($IA;G5A<GD@,C`Q,RP@=&AE($-O
M;7!A;GD@96YT97)E9"!I;G1O(&%N(&%G<F5E;65N="!W:71H($=I;&5A9`T*
M(&9O<B!T:&4@<F5S96%R8V@L(&1E=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L
M:7IA=&EO;B!O9B!U<"!T;R!F;W5R#0H@1$%25"UB87-E9"!M;VQE8W5L97,N
M(%1H92!T:6UE('!E<FEO9"!F;W(@1VEL96%D)B-X,C`Q.3MS(&5X97)C:7-E
M#0H@;V8@;VYE(&]P=&EO;B!H87,@97AP:7)E9"X@070@<')E<V5N="P@1VEL
M96%D(')E=&%I;G,@82!L:6-E;G-E('1O#0H@;VYE(&%N9"!O<'1I;VYS('1O
M('1W;R!O9B!T:&4@;W)I9VEN86P@9F]U<B!P<F]G<F%M<RX@1VEL96%D(&AA
M<PT*(&5X8VQU<VEV92!W;W)L9'=I9&4@<FEG:'1S(&9O<B!E86-H(&]F('1H
M97-E(')E;6%I;FEN9PT*('!R;V=R86US+CPO<#X-"B`\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C$R<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N
M=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;B<^#0H@5&AE($-O;7!A;GD@<F5C96EV960@86X@:6YI=&EA;"`D-RXU
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M871E;'D@)#(T,"!T;R`D,C4P#0H@;6EL;&EO;B!P97(@<F5M86EN:6YG('!R
M;V=R86T@:6X@861D:71I;VYA;"!C;&EN:6-A;"P@<F5G=6QA=&]R>0T*(&%N
M9"!S86QE<R!M:6QE<W1O;F5S(&EF($=I;&5A9"!E>&5R8VES97,@8F]T:"!R
M96UA:6YI;F<@;W!T:6]N<R!A;F0-"B!A8VAI979E<R!A;&P@;V8@=&AE(')E
M<75I<VET92!M:6QE<W1O;F5S('5N9&5R(&5A8V@@;W!T:6]N(&%N9`T*(&QI
M8V5N<V4N(%1H92!#;VUP86YY(&AA<R!D971E<FUI;F5D('1H870@=&AE(&]T
M:&5R(&QI8V5N<V5S(&%R90T*(&-O;F1I=&EO;F%L(&1E;&EV97)A8FQE<RP@
M=VAI8V@@87)E('-U8G-T86YT:79E(&]P=&EO;G,@=&AA="!W97)E#0H@;F]T
M(&=R86YT960@=VET:"!A('-U8G-T86YT:6%L(&1I<V-O=6YT+B!4:&4@0V]M
M<&%N>2!H87,@9&5T97)M:6YE9`T*('1H870@96%C:"!P;W1E;G1I86P@9G5T
M=7)E(&-L:6YI8V%L+"!D979E;&]P;65N="!A;F0@<F5G=6QA=&]R>0T*(&UI
M;&5S=&]N92!I<R!S=6)S=&%N=&EV92X@06QT:&]U9V@@<V%L97,@;6EL97-T
M;VYE<R!A<F4@;F]T#0H@8V]N<VED97)E9"!S=6)S=&%N=&EV92P@=&AE>2!A
M<F4@<W1I;&P@<F5C;V=N:7IE9"!U<&]N(&%C:&EE=F5M96YT#0H@;V8@=&AE
M(&UI;&5S=&]N92`H87-S=6UI;F<@86QL(&]T:&5R(')E=F5N=64@<F5C;V=N
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M;B!T965N(')O>6%L=&EE<R!O;B!P<F]D=6-T('-A;&5S+CPO<#X-"B`\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C$R<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T
M97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;B<^#0H@5&AE($-O;7!A;GD@:&%S(&5V86QU871E9"!T
M:&4@<F5S96%R8V@@8V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@=VET:`T*($=I
M;&5A9"!A;F0@:&%S(&1E=&5R;6EN960@=&AA="!I="!I<R!A(')E=F5N=64@
M87)R86YG96UE;G0@=VET:`T*(&UU;'1I<&QE(&1E;&EV97)A8FQE<RP@;W(@
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M>'!E8W1E9`T*(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!R96EM8G5R<V5M
M96YT<RD@:7,@8F5I;F<@<F5C;V=N:7IE9`T*(')A=&%B;'D@;W9E<B!A('!E
M<FEO9"!O9B`R,2!M;VYT:',L('=H:6-H(')E<')E<V5N=',@=&AE(&5X<&5C
M=&5D#0H@9&5V96QO<&UE;G0@<&5R:6]D+CPO<#X-"B`\<"!S='EL93TS1"=M
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M9@T*('1H92!P87)T:65S)B-X,C`Q.3L@86-T:79I=&EE<R!U;F1E<B!T:&4@
M86=R965M96YT<RX@36%N86=E;65N=`T*(&-O;G-I9&5R960@=VAE=&AE<B!P
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M/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O
M='1O;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!4:&4@0V]M<&%N>2!R96-O
M9VYI>F5D(')E=F5N=65S(&]F(&%P<')O>&EM871E;'D@)#@N,"!M:6QL:6]N
M('5N9&5R#0H@=&AI<R!A9W)E96UE;G0@9F]R('1H92!Y96%R(&5N9&5D($1E
M8V5M8F5R)B-X03`[,S$L(#(P,3,N($YO#0H@;6EL97-T;VYE<R!H879E(&)E
M96X@86-H:65V960@=6YD97(@=&AI<R!A9W)E96UE;G0N/"]P/@T*(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E
M>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N)SX-"B!!="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S+"`D
M,RXV(&UI;&QI;VX@;V8@<F5V96YU92!W87,@9&5F97)R960-"B!U;F1E<B!T
M:&ES(&%G<F5E;65N="P@86QL(&]F('=H:6-H('=A<R!I;F-L=61E9"!I;B!C
M=7)R96YT#0H@;&EA8FEL:71I97,N/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I
M;BUT;W`Z,3AP=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T
M.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(#QB/CQI/D)O96AR
M:6YG97(\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P
M=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I
M>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!);B!/
M8W1O8F5R(#(P,3`@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@8V]L;&%B
M;W)A=&EO;B!A;F0-"B!L:6-E;G-E(&%G<F5E;65N="!W:71H($)O96AR:6YG
M97(@=&\@9&ES8V]V97(L(&1E=F5L;W`@86YD#0H@8V]M;65R8VEA;&EZ92!U
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M<F5S96%R8V@L(&1E=F5L;W`L(&%N9`T*(&UA<FME="!$05)4<R!G96YE<F%T
M960@=6YD97(@=&AE(&%G<F5E;65N="!T:')O=6=H;W5T('1H90T*('=O<FQD
M+CPO<#X-"B`\<"!S='EL93TS1&9O;G0M<VEZ93HQ,G!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUB;W1T;VTZ,'!T/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C!P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M
M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N)SX-"B!5<&]N(&5X96-U=&EO;B!O9B!T:&4@86=R965M96YT
M+"!T:&4@0V]M<&%N>2!R96-E:79E9"!A;B!U<&9R;VYT#0H@<&%Y;65N="!O
M9B`D,34N,"!M:6QL:6]N+B!4:&4@0V]M<&%N>2!S=6)S97%U96YT;'D@<F5C
M96EV960@=&AR964-"B!A;FYU86P@;6%I;G1E;F%N8V4@<&%Y;65N=',@:6YC
M;'5D:6YG(&]N92!I;B!T:&4@9F]U<G1H('%U87)T97(@;V8-"B`R,#$S+B!4
M:&5S92!M86EN=&5N86YC92!P87EM96YT<R!A<F4@8F5I;F<@<F5C;V=N:7IE
M9"!O=F5R('1H90T*(&5S=&EM871E9"!P97)I;V0@;V8@9&5V96QO<&UE;G0N
M(%1H92!#;VUP86YY(&AA<R!T:&4@<&]T96YT:6%L('1O#0H@96%R;B!M:6QE
M<W1O;F4@<&%Y;65N=',@;V8@87!P<F]X:6UA=&5L>2`D-#$N,"!M:6QL:6]N
M(')E;&%T960@=&\-"B!P<F4M8VQI;FEC86P@86YD(&-L:6YI8V%L(&1E=F5L
M;W!M96YT+"`D.#DN,"!M:6QL:6]N(')E;&%T960@=&\-"B!R96=U;&%T;W)Y
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M;V8@=&AE(&UI;&5S=&]N92`H87-S=6UI;F<@86QL(&]T:&5R(')E=F5N=64-
M"B!R96-O9VYI=&EO;B!C<FET97)I82!H879E(&)E96X@;65T*2!B96-A=7-E
M('1H97)E(&%R92!N;PT*('5N9&5L:79E<F5D(&5L96UE;G1S('1H870@=V]U
M;&0@<')E8VQU9&4@<F5V96YU92!R96-O9VYI=&EO;B!A=`T*('1H870@=&EM
M92X@0F]E:')I;F=E<B!A;'-O('!R;W9I9&5S(&9U;F1I;F<@9F]R('1H92!#
M;VUP86YY)B-X,C`Q.3MS#0H@:6YT97)N86P@86YD(&5X=&5R;F%L(')E<V5A
M<F-H(&-O<W1S(&%N9"!I<R!R97%U:7)E9"!T;R!P87D@=&AE#0H@0V]M<&%N
M>2!M:60M<VEN9VQE(&1I9VET(')O>6%L=&EE<R!O;B!P<F]D=6-T('-A;&5S
M+B!);B!.;W9E;6)E<@T*(#(P,3,L($)O96AR:6YG97(@;F]M:6YA=&5D(&$@
M8FDM<W!E8VEF:6,@86YT:6)O9'D@=&AE<F%P975T:6,-"B!C86YD:61A=&4@
M9V5N97)A=&5D(&)Y('1H92!#;VUP86YY)B-X,C`Q.3MS($1!4E0@=&5C:&YO
M;&]G>2!F;W(-"B!P<F4M8VQI;FEC86P@9&5V96QO<&UE;G0N(%1H:7,@9F]R
M;6%L('-E;&5C=&EO;B!O9B!A(&1E=F5L;W!M96YT#0H@8V%N9&ED871E('1R
M:6=G97)E9"!A("0U+C`@;6EL;&EO;B!M:6QE<W1O;F4@<&%Y;65N="!T;R!T
M:&4-"B!#;VUP86YY+B!&<F]M('1H92!C;VUM96YC96UE;G0@;V8@=&AE(&-O
M;&QA8F]R871I;VX@=&AR;W5G:`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,3,L
M('1H92!#;VUP86YY(&AA<R!R96-E:79E9"`D-#@N."!M:6QL:6]N#0H@=6YD
M97(@=&AI<R!A9W)E96UE;G0L(&EN8VQU9&EN9R!U<&9R;VYT+"!A;FYU86P@
M;6%I;G1E;F%N8V4@86YD#0H@;6EL97-T;VYE('!A>6UE;G1S(&%S('=E;&P@
M87,@<F5S96%R8V@@9G5N9&EN9RX@26X@861D:71I;VXL#0H@0F]E:')I;F=E
M<B!P=7)C:&%S960@)#$P+C`@;6EL;&EO;B!O9B!T:&4@0V]M<&%N>28C>#(P
M,3D[<R!397)I97,-"B!$+3(@4')E9F5R<F5D(%-T;V-K(&EN($IA;G5A<GD@
M,C`Q,2X@5&AI<R!P<F5F97)R960@<W1O8VL@=V%S#0H@8V]N=F5R=&5D('1O
M(&-O;6UO;B!S=&]C:R!U<&]N('1H92!#;VUP86YY)B-X,C`Q.3MS($E03R!I
M;B!/8W1O8F5R#0H@,C`Q,RX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O
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M('!E<FEO9"!T;R!P97)F;W)M('-E<G9I8V5S+CPO<#X-"B`\<"!S='EL93TS
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M;GDN($QI:V5W:7-E+`T*($)O96AR:6YG97(@8V]U;&0@;F]T('-E;&P@=&AE
M(&QI8V5N<V4@=&\@86YO=&AE<B!P87)T>2`H=VET:&]U="!T:&4-"B!#;VUP
M86YY(&%G<F5E:6YG('1O('!R;W9I9&4@=&AE(')E<V5A<F-H(&%N9"!D979E
M;&]P;65N="!A8W1I=FET:65S#0H@9F]R('1H92!O=&AE<B!P87)T>2DN/"]P
M/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O
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M9"!O9B!D979E;&]P;65N="X\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O
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M;&EV97)A8FQE+B!(;W=E=F5R+`T*(&AA9"!M86YA9V5M96YT(&-O;G-I9&5R
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M=&AE(')E<V5A<F-H(&%N9`T*(&1E=F5L;W!M96YT('-E<G9I8V5S+CPO<#X-
M"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'0[(&UA<F=I;BUB;W1T;VTZ
M,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@5&AE<F4@:&%V92!B965N(&YO(&UA
M=&5R:6%L(&UO9&EF:6-A=&EO;G,@=&\@=&AI<R!A9W)E96UE;G0@<VEN8V4-
M"B!T:&4@861O<'1I;VX@;V8@05-5(#(P,#DM,3,@;VX@2F%N=6%R>28C>$$P
M.S$L(#(P,3$N/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@
M;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z
M,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!4:&4@0V]M
M<&%N>2!R96-O9VYI>F5D(')E=F5N=65S(&]F(&%P<')O>&EM871E;'D@)#$T
M+C0@;6EL;&EO;BP-"B`D,3$N-R!M:6QL:6]N(&%N9"`D."XY(&UI;&QI;VX@
M9'5R:6YG('1H92!Y96%R<R!E;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L(#(P
M,3,L(#(P,3(@86YD(#(P,3$L(')E<W!E8W1I=F5L>2X@4F5V96YU90T*(')E
M8V]G;FEZ960@:6X@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L
M(#(P,3,@86YD(#(P,3(-"B!I;F-L=61E9"!M:6QE<W1O;F4@<&%Y;65N=',@
M;V8@)#4N,"!M:6QL:6]N(&%N9"`D,BXP(&UI;&QI;VXL#0H@<F5S<&5C=&EV
M96QY+"!F;W(@=&AE(&%C:&EE=F5M96YT(&]F(&-L:6YI8V%L(&UI;&5S=&]N
M97,N($YO#0H@;6EL97-T;VYE<R!W97)E(&%C:&EE=F5D(&EN('1H92!Y96%R
M(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,3$N#0H@070@1&5C96UB97(F
M(WA!,#LS,2P@,C`Q,RP@)#$R+C@@;6EL;&EO;B!O9B!R979E;G5E('=A<R!D
M969E<G)E9`T*('5N9&5R('1H:7,@86=R965M96YT+"`D-RXP(&UI;&QI;VX@
M;V8@=VAI8V@@=V%S(&EN8VQU9&5D(&EN(&-U<G)E;G0-"B!L:6%B:6QI=&EE
M<R!A;F0@)#4N."!M:6QL:6]N(&]F('=H:6-H('=A<R!I;F-L=61E9"!I;B!L
M;VYG+71E<FT-"B!L:6%B:6QI=&EE<RX@070@1&5C96UB97(F(WA!,#LS,2P@
M,C`Q,BP@)#$T+C`@;6EL;&EO;B!O9B!R979E;G5E#0H@=V%S(&1E9F5R<F5D
M('5N9&5R('1H:7,@86=R965M96YT+"`D-2XP(&UI;&QI;VX@;V8@=VAI8V@@
M=V%S#0H@:6YC;'5D960@:6X@8W5R<F5N="!L:6%B:6QI=&EE<R!A;F0@)#DN
M,"!M:6QL:6]N(&]F('=H:6-H('=A<PT*(&EN8VQU9&5D(&EN(&QO;F<M=&5R
M;2!L:6%B:6QI=&EE<RX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ
M.'!T.R!M87)G:6XM8F]T=&]M.C!P=#L@9F]N="US:7IE.C$P<'0[(&9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@/&(^/&D^4&9I>F5R/"]I/CPO
M8CX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA<F=I;BUB
M;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@26X@3V-T;V)E<B`R,#$P
M+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!T:')E92!Y96%R(&%G<F5E
M;65N=`T*('=I=&@@4&9I>F5R('1O(&1I<V-O=F5R+"!D979E;&]P(&%N9"!C
M;VUM97)C:6%L:7IE('5P('1O('1W;PT*($1!4E0M8F%S960@;6]L96-U;&5S
M+B!4:&4@0V]M<&%N>2!G<F%N=&5D(%!F:7IE<B!A(&YO;BUE>&-L=7-I=F4-
M"B!W;W)L9'=I9&4L(')O>6%L='DM8F5A<FEN9R!L:6-E;G-E(&%N9"!R96-E
M:79E9"!A;B!U<&9R;VYT('!A>6UE;G0-"B!O9B`D-2XP(&UI;&QI;VX@86YD
M(&AA<R!R96-E:79E9"!M:6QE<W1O;F4@<&%Y;65N=',@86YD(&9U;F1I;F<@
M9F]R#0H@=&AE($-O;7!A;GDF(W@R,#$Y.W,@:6YT97)N86P@86YD(&5X=&5R
M;F%L(')E<V5A<F-H(&-O<W1S('5N9&5R('1H90T*(&%G<F5E;65N="X\+W`^
M#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!T.R!M87)G:6XM8F]T=&]M
M.C!P=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(%1H92!#;VUP86YY(&ES(&5L:6=I
M8FQE('1O(')E8V5I=F4@;6EL97-T;VYE('!A>6UE;G1S(&]F#0H@87!P<F]X
M:6UA=&5L>2`D,3<N,"!M:6QL:6]N(')E;&%T960@=&\@<')E+6-L:6YI8V%L
M(&%N9"!C;&EN:6-A;`T*(&1E=F5L;W!M96YT(&%N9"`D,3DU+C`@;6EL;&EO
M;B!R96QA=&5D('1O(&-O;6UE<F-I86QI>F%T:6]N(&%N9`T*('-A;&5S(&UI
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M:`T*(&]B;&EG871I;VYS('5N9&5R('1H:7,@<')O9W)A;2!I;B!*86YU87)Y
M(#(P,30N/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R
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M<FT@<V5R=FEC97,N/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P
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M<F]V:7-I;VX@;V8@=&AE(')E<V5A<F-H(&%N9`T*(&1E=F5L;W!M96YT('-E
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M='DI+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'0[(&UA<F=I
M;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[
M(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@5&AE<F5F;W)E+"!T
M:&4@=7!F<F]N="!L:6-E;G-E(&9E92!A;F0@<F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT#0H@<V5R=FEC97,@=V5R92!T<F5A=&5D(&%S(&$@8V]M8FEN960@
M=6YI="!O9B!A8V-O=6YT:6YG(&%N9`T*(')E8V]G;FEZ960@;W9E<B!T:&4@
M97AP96-T960@;V)L:6=A=&EO;B!P97)I;V0@87-S;V-I871E9"!W:71H('1H
M90T*(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!S97)V:6-E<R!T:')O=6=H
M($IA;G5A<GD@,C`Q-"P@=VAI8V@-"B!R97!R97-E;G1S('1H92!E<W1I;6%T
M960@<&5R:6]D(&]F(&1E=F5L;W!M96YT+CPO<#X-"B`\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C$R<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N
M=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;B<^#0H@5&AE("0U+C`@;6EL;&EO;B!U<&9R;VYT('!A>6UE;G0@<F5C
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M<&UE;G0@<V5R=FEC97,L('=H:6-H#0H@96YD960@:6X@2F%N=6%R>2`R,#$T
M+CPO<#X-"B`\<"!S='EL93TS1&9O;G0M<VEZ93HQ,G!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUB;W1T;VTZ,'!T/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL
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M+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!T.R!M87)G:6XM8F]T
M=&]M.C!P=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(%1H97)E(&AA=F4@8F5E;B!N
M;R!M871E<FEA;"!M;V1I9FEC871I;VYS('1O('1H:7,@86=R965M96YT('-I
M;F-E#0H@=&AE(&%D;W!T:6]N(&]F($%352`R,#`Y+3$S(&]N($IA;G5A<GDF
M(WA!,#LQ+"`R,#$Q+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R
M<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US
M:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@5&AE
M($-O;7!A;GD@<F5C;V=N:7IE9"!R979E;G5E<R!O9B!A<'!R;WAI;6%T96QY
M("0S+C4@;6EL;&EO;BP@)#4N-0T*(&UI;&QI;VX@86YD("0U+C(@;6EL;&EO
M;B!D=7)I;F<@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L#0H@
M,C`Q,RP@,C`Q,B!A;F0@,C`Q,2P@<F5S<&5C=&EV96QY+B!);F-L=61E9"!I
M;B!T:&4@,C`Q,B!R979E;G5E<PT*(&%R92!M:6QE<W1O;F4@<&%Y;65N=',@
M=&]T86QI;F<@)#4P,"PP,#`N($YO(&%D9&ET:6]N86P@;6EL97-T;VYE<PT*
M(&AA=F4@8F5E;B!A8VAI979E9"!U;F1E<B!T:&ES(&%G<F5E;65N="!T:')O
M=6=H($1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q,RX\+W`^#0H@/'`@<W1Y;&4]
M,T0G;6%R9VEN+71O<#HQ,G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI
M;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86XG/@T*($%T($1E8V5M8F5R)B-X03`[,S$L(#(P,3,@86YD(#(P
M,3(L("0W+#(Y,2!A;F0@)#$N,R!M:6QL:6]N(&]F#0H@<F5V96YU92!W87,@
M9&5F97)R960@=6YD97(@=&AI<R!A9W)E96UE;G0L(')E<W!E8W1I=F5L>2P@
M86QL(&]F#0H@=VAI8V@@=V%S(&EN8VQU9&5D(&EN(&-U<G)E;G0@;&EA8FEL
M:71I97,N/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3AP=#L@;6%R
M9VEN+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86XG/@T*(#QB/CQI/D=R965N($-R;W-S/"]I/CPO8CX\
M+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA<F=I;BUB;W1T
M;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@26X@2G5N928C>$$P.S(P,3`L
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M;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT.C0E
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M8V]M;65R8VEA;"!M:6QE<W1O;F4-"B!P87EM96YT<R!O9B!U<"!T;R`D-"XU
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M=&4@=6YD97(@=&AE#0H@86=R965M96YT+CPO<#X-"B`\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C$R<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N
M=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;B<^#0H@5&AE($-O;7!A;GD@:&%S(&5V86QU871E9"!T:&4@8V]L;&%B
M;W)A=&EO;B!A9W)E96UE;G0@=VET:"!'<F5E;@T*($-R;W-S(&%N9"!H87,@
M9&5T97)M:6YE9"!T:&%T(&ET(&ES(&$@<F5V96YU92!A<G)A;F=E;65N="!W
M:71H#0H@;75L=&EP;&4@9&5L:79E<F%B;&5S(&]R('!E<F9O<FUA;F-E(&]B
M;&EG871I;VYS+B!4:&4-"B!#;VUP86YY)B-X,C`Q.3MS('-U8G-T86YT:79E
M('!E<F9O<FUA;F-E(&]B;&EG871I;VYS('5N9&5R('1H:7,-"B!A9W)E96UE
M;G0@:6YC;'5D92!A;B!E>&-L=7-I=F4@;&EC96YS92!T;R!I=',@=&5C:&YO
M;&]G:65S(&%N9`T*('!A<G1I8VEP871I;VX@:6X@82!J;VEN="!S=&5E<FEN
M9R!C;VUM:71T964N(%1H92!#;VUP86YY(&-O;F-L=61E9`T*('1H870@=&AE
M(&QI8V5N<V4@9&]E<R!N;W0@:&%V92!V86QU92!O;B!A('-T86YD86QO;F4@
M8F%S:7,@86YD#0H@=&AE<F5F;W)E(&1O97,@;F]T(')E<')E<V5N="!A('-E
M<&%R871E('5N:70@;V8@86-C;W5N=&EN9RX-"B!,:6ME=VES92P@1W)E96X@
M0W)O<W,@8V]U;&0@;F]T('-E;&P@=&AE(&QI8V5N<V4@=&\@86YO=&AE<@T*
M('!A<G1Y+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'0[(&UA
M<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P
M<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@5&AE("0Q+C`@
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M92!R96-O9VYI>F5D(&]V97(@=&AE('1E<FT@;V8@=&AE(&%G<F5E;65N=`T*
M('1H<F]U9V@@2G5N92`R,#(P+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM
M=&]P.C$R<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@
M9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^
M#0H@5&AE<F4@:&%V92!B965N(&YO(&UA=&5R:6%L(&UO9&EF:6-A=&EO;G,@
M=&\@=&AI<R!A9W)E96UE;G0@<VEN8V4-"B!T:&4@861O<'1I;VX@;V8@05-5
M(#(P,#DM,3,@;VX@2F%N=6%R>28C>$$P.S$L(#(P,3$N/"]P/@T*(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E
M>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N)SX-"B!4:&4@0V]M<&%N>2!R96-O9VYI>F5D(')E=F5N
M=65S(&]F(&%P<')O>&EM871E;'D@)#$P,"PP,#`@=6YD97(-"B!T:&ES(&%G
M<F5E;65N="!D=7)I;F<@96%C:"!O9B!T:&4@=&AR964@>65A<G,@96YD960-
M"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S+B!.;R!M:6QE<W1O;F5S('=E<F4@
M86-H:65V960@=6YD97(@=&AI<PT*(&%G<F5E;65N="!D=7)I;F<@=&AE('1H
M<F5E('EE87)S(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,3,N/"]P/@T*
M(#QP('-T>6QE/3-$9F]N="US:7IE.C$R<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6)O='1O;3HP<'0^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z,'!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z
M-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86XG/@T*($%T($1E8V5M8F5R)B-X03`[,S$L(#(P,3,L("0V-3`L,#`P(&]F
M(')E=F5N=64@=V%S(&1E9F5R<F5D('5N9&5R#0H@=&AI<R!A9W)E96UE;G0L
M("0Q,#`L,#`P(&]F('=H:6-H('=A<R!I;F-L=61E9"!I;B!C=7)R96YT#0H@
M;&EA8FEL:71I97,@86YD("0U-3`L,#`P(&]F('=H:6-H('=A<R!I;F-L=61E
M9"!I;B!L;VYG+71E<FT-"B!L:6%B:6QI=&EE<RX@070@1&5C96UB97(F(WA!
M,#LS,2P@,C`Q,BP@)#<U,"PP,#`@;V8@<F5V96YU92!W87,-"B!D969E<G)E
M9"!U;F1E<B!T:&ES(&%G<F5E;65N="P@)#$P,"PP,#`@;V8@=VAI8V@@=V%S
M(&EN8VQU9&5D(&EN#0H@8W5R<F5N="!L:6%B:6QI=&EE<R!A;F0@)#8U,"PP
M,#`@;V8@=VAI8V@@=V%S(&EN8VQU9&5D(&EN(&QO;F<M=&5R;0T*(&QI86)I
M;&ET:65S+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'0[(&UA
M<F=I;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N)SX-"B`\8CX\:3Y%;&D@3&EL;'D\+VD^/"]B/CPO
M<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P=#L@;6%R9VEN+6)O='1O
M;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!);B!/8W1O8F5R)B-X03`[,C`P
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M8VQU<VEV92!R:6=H=',@=&\@=&AE(&UO;&5C=6QE+CPO<#X-"B`\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C$R<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT
M+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;B<^#0H@57!O;B!E>&5C=71I;VX@;V8@=&AE($%G<F5E;65N
M=',L($5L:2!,:6QL>2!M861E(&$@;F]N<F5F=6YD86)L90T*('!A>6UE;G0@
M;V8@)#0Q+C`F(WA!,#MM:6QL:6]N('1O('1H92!#;VUP86YY+B!);B!-87DF
M(WA!,#LR,#`X+"!%;&D-"B!,:6QL>2!P86ED('1H92!#;VUP86YY(&$@;6EL
M97-T;VYE('!A>6UE;G0@;V8@)#4P+C`F(WA!,#MM:6QL:6]N#0H@86YD(&EN
M($UA>28C>$$P.S(P,3`L($5L:28C>$$P.TQI;&QY('!A:60@86X@861D:71I
M;VYA;"!M:6QE<W1O;F4-"B!O9B`D-2XP)B-X03`[;6EL;&EO;BX\+W`^#0H@
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!T.R!M87)G:6XM8F]T=&]M.C!P
M=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86XG/@T*($]N($]C=&]B97(F(WA!,#LR."P@,C`Q
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M('1H92!S='5D>2X@26X@1F5B<G5A<GD@,C`Q,2P@=&AE#0H@0V]M<&%N>2!R
M96%C<75I<F5D('1H92!C;VUM97)C:6%L(')I9VAT<R!T;R!T:&4@;6]L96-U
M;&4@9G)O;2!%;&D-"B!,:6QL>2X@1'5R:6YG('1H92!Y96%R(&5N9&5D($1E
M8V5M8F5R)B-X03`[,S$L(#(P,3(L($5L:28C>$$P.TQI;&QY#0H@<V%T:7-F
M:65D(&ET<R!O8FQI9V%T:6]N(')E;&%T960@=&\@=&AE(&-O<W0@;V8@;6]N
M:71O<FEN9R!P871I96YT<PT*('5N9&5R('1H92!0<F]T)B-X13D[9R8C>$4Y
M.R!A;F0@16YC;W)E('1R:6%L<RX@5&AE($-O;7!A;GDF(W@R,#$Y.W,-"B!O
M8FQI9V%T:6]N<R!C;VYT:6YU960@=&AR;W5G:"!397!T96UB97(@,C`Q,BP@
M=VAI8V@@<F5P<F5S96YT960@=&AE#0H@9F]L;&]W('5P('!E<FEO9"!F;W(@
M96YR;VQL960@<&%T:65N=',@86YD('1H92!#;VUP86YY)B-X,C`Q.3MS#0H@
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M/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O
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M('EE87)S(&5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RX\+W`^#0H@
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;6UI=&UE;G1S(&%N
M9"!#;VYT:6YG96YC:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#;VYT:6YG96YC
M:65S($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@86YD($-O;G1I
M;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`Q.'!T)SX-"B`\8CXY+B!#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N
M8VEE<SPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU43U`Z(#9P="<^#0H@/&(^/&D^3W!E<F%T:6YG($QE87-E
M<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE
M($-O;7!A;GD@;&5A<V5S(&]F9FEC92!A;F0@;&%B;W)A=&]R>2!S<&%C92!I
M;B!2;V-K=FEL;&4L#0H@36%R>6QA;F0@=6YD97(@82!L96%S92!T:&%T(&5X
M<&ER97,@;VX@36%R8V@F(WA!,#LS,2P@,C`Q."P@86YD#0H@;&5A<V5S(&$@
M;6%N=69A8W1U<FEN9R!F86-I;&ET>2!I;B!2;V-K=FEL;&4@=6YD97(@82!L
M96%S92!T:&%T#0H@97AP:7)E<R!O;B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T
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M(&]N#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q."X@06QL(&]F('1H92!L96%S
M97,@8V]N=&%I;B!R96YT(&5S8V%L871I;VX-"B!C;&%U<V5S+B!&;W(@9FEN
M86YC:6%L(')E<&]R=&EN9R!P=7)P;W-E<RP@<F5N="!E>'!E;G-E(&ES(&-H
M87)G960-"B!T;R!O<&5R871I;VYS(&]N(&$@<W1R86EG:'0M;&EN92!B87-I
M<R!O=F5R('1H92!T97)M(&]F('1H92!L96%S92X-"B!!<R!O9B!$96-E;6)E
M<B8C>$$P.S,Q+"`R,#$S(&%N9"`R,#$R+"!T:&4@0V]M<&%N>2!H860@<F5C
M;W)D960@80T*(&1E9F5R<F5D(')E;G0@;&EA8FEL:71Y(&]F("0R+CD@;6EL
M;&EO;B!A;F0@)#(N."!M:6QL:6]N+`T*(')E<W!E8W1I=F5L>2X@4F5N="!E
M>'!E;G-E(&9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(F(WA!,#LS,2P-
M"B`R,#$S+"`R,#$R(&%N9"`R,#$Q('=A<R`D,BXW(&UI;&QI;VXL("0R+C<@
M;6EL;&EO;B!A;F0@)#(N.0T*(&UI;&QI;VXL(')E<W!E8W1I=F5L>2X\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@1G5T=7)E(&UI;FEM=6T@;&5A<V4@<&%Y
M;65N=',@=6YD97(@;F]N8V%N8V5L86)L92!O<&5R871I;F<@;&5A<V5S#0H@
M870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,R!A<F4@87,@9F]L;&]W<SH\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L
M92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0V."4@86QI9VX]
M,T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-SDE
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*(#(P,30\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,RPV-3$L-#(Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B`R,#$U/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPS,3`L
M.#@T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B`R,#$V/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPT
M,3`L,C$P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`R,#$W/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPU,3(L-3$W/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`R,#$X/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPW.#`L,SDX/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4:&5R96%F=&5R/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XQ-BPV-C4L-#,P/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-C(Y8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X
M8SDT#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A7V-D
M83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-"]7;W)K<VAE971S+U-H965T,38N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0<F]D
M=6-T($UI;&5S=&]N92!087EM96YT<R!A;F0@4F]Y86QT>2!!9W)E96UE;G1S
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E1E>'0@0FQO8VL@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O9'5C="!-:6QE<W1O;F4@4&%Y
M;65N=',@86YD(%)O>6%L='D@06=R965M96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#HQ.'!T.R!M87)G:6XM8F]T=&]M.C!P=#L@9F]N="US:7IE.C$P<'0[(&9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@/&(^,3`N(%!R;V1U8W0@
M36EL97-T;VYE(%!A>6UE;G1S(&%N9"!2;WEA;'1Y($%G<F5E;65N=',\+V(^
M/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T
M=&]M.C!P=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*($EN(&-O;FYE8W1I;VX@=VET
M:"!A;B!!<W-E="!0=7)C:&%S92!!9W)E96UE;G0@=VET:"!4;VQE<F%N8V4-
M"B!4:&5R87!E=71I8W,L($EN8RX@*"8C>#(P,4,[5&]L97)A;F-E)B-X,C`Q
M1#LI(&5N=&5R960@:6YT;R!D=7)I;F<-"B!*=6YE(#(P,#4L('1H92!#;VUP
M86YY(&UA>2!B92!R97%U:7)E9"!T;R!I<W-U92!4;VQE<F%N8V4-"B!A9&1I
M=&EO;F%L(&-O;G-I9&5R871I;VX@87,@9F]L;&]W<SH@*&DI)B-X03`[)#$P
M+#DU,"PP,#`@:68-"B!C97)T86EN(&UI;&5S=&]N97,@87)E(&UE="P@:6YC
M;'5D:6YG('1H92!I;FET:6%T:6]N(&]F(%!H87-E(#,-"B!T<FEA;',@86YD
M(&9I;&EN9R!O9B!V87)I;W5S(')E9W5L871O<GD@<')O9'5C="!L:6-E;G-E
M#0H@87!P;&EC871I;VYS.R`H:6DI)B-X03`[,S8L,3,U('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL[(&%N9`T*("AI:6DI)B-X03`[<F]Y86QT>2!P87EM96YT
M<R!B971W965N(#$N-S4E(&%N9"`T+C`E(&]F(&YE="!S86QE<R!O9@T*('!R
M;V1U8W1S(&%C<75I<F5D(&9R;VT@;W(@<&%T96YT960@8GD@5&]L97)A;F-E
M(&]R(&]T:&5R('!R;V1U8W0-"B!F965S(&5A<FYE9"!B>2!T:&4@0V]M<&%N
M>2X@06YY(&%D9&ET:6]N86P@8V]N<VED97)A=&EO;B!R97%U:7)E9`T*('1O
M(&)E('!A:60@=6YD97(@=&AE($%S<V5T(%!U<F-H87-E($%G<F5E;65N="!W
M:6QL(&)E(')E8V]R9&5D(&%S#0H@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT
M(&5X<&5N<V4@=VAE;B!I;F-U<G)E9"X@3F\@<&%Y;65N=',@<F5L871E9`T*
M('1O('1H92!A9&1I=&EO;F%L(&-O;G-I9&5R871I;VX@:&%V92!O8V-U<G)E
M9"!D=7)I;F<@=&AE('1H<F5E#0H@>65A<G,@96YD960@1&5C96UB97(F(WA!
M,#LS,2P@,C`Q,RX@061D:71I;VYA;&QY+"!C97)T86EN#0H@86=R965M96YT
M<R!R97%U:7)E('1H92!#;VUP86YY('1O('!A>2!R;WEA;'1I97,N($-U<G)E
M;G1L>2P@=&AE#0H@0V]M<&%N>2!I<R!N;W0@;V)L:6=A=&5D('1O('!A>2!R
M;WEA;'1I97,L(&%S(&YO(')E=F5N=64@9G)O;0T*('!R;V1U8W0@<V%L97,@
M:7,@8F5I;F<@9V5N97)A=&5D(&)Y('1H92!#;VUP86YY+CPO<#X-"B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R
M.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\V,CEC-&)C85]C9&$W7S1D865?830T-5\Q
M,C0U864R-#AC.30O5V]R:W-H965T<R]3:&5E=#$W+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^16UP;&]Y964@0F5N969I="!0
M;&%N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-O;7!E;G-A=&EO;B!!;F0@4F5T:7)E;65N="!$:7-C;&]S=7)E
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5M<&QO>65E($)E;F5F:70@4&QA;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HQ.'!T.R!M87)G:6XM8F]T=&]M.C!P=#L@9F]N="US:7IE.C$P<'0[
M(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@/&(^,3$N($5M<&QO
M>65E($)E;F5F:70@4&QA;CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HV<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@
M9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^
M#0H@3VX@4V5P=&5M8F5R)B-X03`[,C4L(#(P,#(L('1H92!#;VUP86YY(&5S
M=&%B;&ES:&5D('1H92!-86-R;T=E;FEC<PT*(#0P,2AK*2!0;&%N("AT:&4@
M)B-X,C`Q0SM0;&%N)B-X,C`Q1#LI(&9O<B!I=',@96UP;&]Y965S('5N9&5R
M#0H@4V5C=&EO;B8C>$$P.S0P,2AK*2!O9B!T:&4@25)#+B!5;F1E<B!T:&ES
M(%!L86XL(&%L;"!E;7!L;WEE97,@870-"B!L96%S="`R,2!Y96%R<R!O9B!A
M9V4@87)E(&5L:6=I8FQE('1O('!A<G1I8VEP871E(&EN('1H92!0;&%N+`T*
M('-T87)T:6YG(&]N('1H92!F:7)S="!D87D@;V8@96%C:"!M;VYT:"X@16UP
M;&]Y965S(&UA>2!C;VYT<FEB=71E#0H@=7`@=&\@,3`P)2!O9B!T:&5I<B!S
M86QA<GDL('-U8FIE8W0@=&\@9V]V97)N;65N="!M87AI;75M<RX\+W`^#0H@
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!T.R!M87)G:6XM8F]T=&]M.C!P
M=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86XG/@T*($5M<&QO>65E<R!A<F4@,3`P)2!V97-T
M960@:6X@=&AE:7(@8V]N=')I8G5T:6]N<R!T;R!T:&4@4&QA;BX@5&AE#0H@
M0V]M<&%N>28C>#(P,3D[<R!C;VYT<FEB=71I;VX@=&\@=&AE(%!L86XL(&%S
M(&1E=&5R;6EN960@8GD@=&AE#0H@0F]A<F0@;V8@1&ER96-T;W)S+"!I<R!D
M:7-C<F5T:6]N87)Y+B!4:&4@0V]M<&%N>28C>#(P,3D[<PT*(&-O;G1R:6)U
M=&EO;G,@=&\@=&AE(%!L86X@=&]T86QE9"`D,C4R+#DS,"P@)#(R-2PQ.34@
M86YD("0R,3<L,#DW#0H@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B8C
M>$$P.S,Q+"`R,#$S+"`R,#$R(&%N9"`R,#$Q+`T*(')E<W!E8W1I=F5L>2X\
M+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E%U87)T97)L
M>2!&:6YA;F-I86P@26YF;W)M871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^475A<G1E<FQY($9I;F%N8VEA
M;"!);F9O<FUA=&EO;B!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E%U87)T97)L>2!&
M:6YA;F-I86P@26YF;W)M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CXQ,BX@475A<G1E<FQY($9I
M;F%N8VEA;"!);F9O<FUA=&EO;B`H=6YA=61I=&5D*3PO8CX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[
M($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT
M97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-30E/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M,3QS=7`@<W1Y;&4],T0G1D].5"U325I%.B`X-24[(%9%4E1)0T%,+4%,24=.
M.B!T;W`G/G-T/"]S=7`^)B-X03`[475A<G1E<CPO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#(@86QI9VX],T1C96YT97(^/&(^,CQS=7`@<W1Y;&4],T0G1D].5"U325I%
M.B`X-24[(%9%4E1)0T%,+4%,24=..B!T;W`G/FYD/"]S=7`^)B-X03`[475A
M<G1E<CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,SQS
M=7`@<W1Y;&4],T0G1D].5"U325I%.B`X-24[(%9%4E1)0T%,+4%,24=..B!T
M;W`G/G)D/"]S=7`^)B-X03`[475A<G1E<CPO8CX\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@86QI9VX],T1C96YT97(^/&(^-#QS=7`@<W1Y;&4],T0G1D].5"U3
M25I%.B`X-24[(%9%4E1)0T%,+4%,24=..B!T;W`G/G1H/"]S=7`^)B-X03`[
M475A<G1E<CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0Q-"!A;&EG;CTS1&-E;G1E<CX\8CXH:6X@=&AO=7-A;F1S+`T*(&5X8V5P
M="!P97(@<VAA<F4@9&%T82D\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M(#QB/C(P,3,\+V(^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!2979E;G5E/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$P+#4Y.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,3(L,CDY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
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M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T(&EN8V]M
M92`H;&]S<RD\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,RPS
M-C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R.30\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C8L-C`T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/B@S+#(P-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($YE="!I
M;F-O;64@*&QO<W,I('!E<B!S:&%R92P@8F%S:6,\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#(N.3,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XR-#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C`N,30\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/B@P+C$T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@3F5T(&EN8V]M92`H;&]S<RD@<&5R('-H87)E+"!D:6QU
M=&5D/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R+CDS/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#`N,C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C`Q/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XQ-#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/@T*(#QB/C(P,3(\+V(^/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!2979E;G5E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C(P+#4Q,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3<L-#,U/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XQ-BPP.#(\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CDL-SDY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!.970@:6YC;VUE("AL;W-S*3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C0L,S(P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L
M-30V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L-C`Q/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R+#$P-3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($YE="!I;F-O;64@
M*&QO<W,I('!E<B!S:&%R92P@8F%S:6,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,"XP,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XP,#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XP,#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#$N.3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!.970@
M:6YC;VUE("AL;W-S*2!P97(@<VAA<F4L(&1I;'5T960\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,"XP,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,"XP,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XP,#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$N.3(\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!!;FYU86P@;F5T(&EN
M8V]M92`H;&]S<RD@<&5R('-H87)E(&EN8VQU9&5S('1H92!E9F9E8W1S(&]F
M(&EN8V]M90T*(&%L;&]C871E9"!T;R!P87)T:6-I<&%T:6YG('-E8W5R:71I
M97,N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-C(Y8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X
M8SDT#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A7V-D
M83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-"]7;W)K<VAE971S+U-H965T,3DN
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6)S
M97%U96YT($5V96YT<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT<R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=6)S97%U96YT($5V96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/C$S+B!3=6)S97%U96YT($5V96YT
M<SPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!);B!&96)R
M=6%R>2`R,#$T+"!397)V:65R(&5X97)C:7-E9"!I=',@97AC;'5S:79E(&]P
M=&EO;B!T;R!D979E;&]P#0H@86YD(&-O;6UE<F-I86QI>F4@34=$,#`V+B!3
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M92!#;VUP86YY(')E8V5I=F5D(&$@)#$U+C`@;6EL;&EO;@T*('!A>6UE;G0@
M9G)O;2!397)V:65R+B!);B!A9&1I=&EO;BP@=&AE($E.1"!A<'!L:6-A=&EO
M;B!F;W(@34=$,#`V#0H@:&%S(&-L96%R960@=&AE(#,P+61A>2!R979I97<@
M<&5R:6]D(&)Y('1H92!&1$$L('1R:6=G97)I;F<@86X-"B!A9&1I=&EO;F%L
M("0U+C`F(WA!,#MM:6QL:6]N('!A>6UE;G0@=&\@=&AE($-O;7!A;GD@8GD@
M4V5R=FEE<BX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@26X@
M1F5B<G5A<GD@,C`Q-"P@=&AE($-O;7!A;GD@8V]M<&QE=&5D(&$@9F]L;&]W
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M;F%L#0H@-#4P+#`P,"!S:&%R97,@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@
M8V]M;6]N('-T;V-K(&%T(&$@<')I8V4@;V8-"B`D,S8N-3`@<&5R('-H87)E
M+B!4:&4@0V]M<&%N>2!R96-E:79E9"!N970@<')O8V5E9',@;V8@)#<V+C<-
M"B!M:6QL:6]N(&9R;VT@=&AI<R!O9F9E<FEN9RP@;F5T(&]F('5N9&5R=W)I
M=&EN9R!D:7-C;W5N=',@86YD#0H@8V]M;6ES<VEO;G,@86YD(&]T:&5R(&5S
M=&EM871E9"!O9F9E<FEN9R!E>'!E;G-E<RX\+W`^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15!#044^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!
M8V-O=6YT:6YG(%!O;&EC:65S("A0;VQI8VEE<RD\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N=&EN9R!0
M;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y"87-I<R!O9B!0<F5S96YT871I;VX@86YD(%!R
M:6YC:7!L97,@;V8@0V]N<V]L:61A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV
M<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CX\:3Y"87-I<R!O9B!0<F5S
M96YT871I;VX@86YD(%!R:6YC:7!L97,@;V8-"B!#;VYS;VQI9&%T:6]N/"]I
M/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!T.R!M87)G
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M;VYA;`T*(&%N=&EB;V1Y+6)A<V5D('1H97)A<&5U=&EC<R!F;W(@8V%N8V5R
M+"!A=71O:6UM=6YE(&%N9"!I;F9E8W1I;W5S#0H@9&ES96%S97,N/"]P/@T*
M(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^57-E(&]F($5S=&EM871E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/CQI/E5S92!O9B!%
M<W1I;6%T97,\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G
M/@T*(%1H92!P<F5P87)A=&EO;B!O9B!T:&4@9FEN86YC:6%L('-T871E;65N
M=',@:6X@86-C;W)D86YC92!W:71H#0H@9V5N97)A;&QY(&%C8V5P=&5D(&%C
M8V]U;G1I;F<@<')I;F-I<&QE<R`H)B-X,C`Q0SM'04%0)B-X,C`Q1#LI#0H@
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M26X@<')E<&%R:6YG('1H97-E(&-O;G-O;&ED871E9`T*(&9I;F%N8VEA;"!S
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M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@26X@861D:71I;VXL
M('!R:6]R('1O('1H92!#;VUP86YY)B-X,C`Q.3MS($E03R!I;B!/8W1O8F5R
M(#(P,3,L('1H90T*($-O;7!A;GD@=71I;&EZ960@97-T:6UA=&5S(&%N9"!A
M<W-U;7!T:6]N<R!I;B!D971E<FUI;FEN9R!T:&4@9F%I<@T*('9A;'5E(&]F
M(&ET<R!C;VUM;VX@<W1O8VLN(%1H92!#;VUP86YY(&=R86YT960@<W1O8VL@
M;W!T:6]N<R!A=`T*(&5X97)C:7-E('!R:6-E<R!N;W0@;&5S<R!T:&%N('1H
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M<FME=`T*(&-O;G-I9&5R871I;VYS(&%F9F5C=&EN9R!T:&4@8FEO=&5C:&YO
M;&]G>2!I;F1U<W1R>2!A;F0@=&AE#0H@:&ES=&]R:6,@<')I8V5S(&%T('=H
M:6-H('1H92!#;VUP86YY('-O;&0@<VAA<F5S(&]F(&ET<R!P<F5F97)R960-
M"B!S=&]C:RX\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!#87-H($5Q=6EV86QE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@
M,'!T)SX-"B`\8CX\:3Y#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S/"]I/CPO
M8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M<&%N
M>2!C;VYS:61E<G,@86QL(&EN=F5S=&UE;G1S(&EN(&AI9VAL>2!L:7%U:60@
M9FEN86YC:6%L#0H@:6YS=')U;65N=',@=VET:"!A;B!O<FEG:6YA;"!M871U
M<FET>2!O9B!T:')E92!M;VYT:',@;W(@;&5S<R!A=`T*('1H92!D871E(&]F
M('!U<F-H87-E('1O(&)E(&-A<V@@97%U:79A;&5N=',N($-A<V@@86YD(&-A
M<V@-"B!E<75I=F%L96YT<R!C;VYS:7-T(&]F(&-E<G1I9FEC871E<R!O9B!D
M97!O<VET(&%N9"!I;G9E<W1M96YT<R!I;@T*(&UO;F5Y(&UA<FME="!F=6YD
M<R!W:71H(&-O;6UE<F-I86P@8F%N:W,@86YD(&9I;F%N8VEA;`T*(&EN<W1I
M='5T:6]N<RX@0V%S:"!E<75I=F%L96YT<R!A<F4@<W1A=&5D(&%T(&%M;W)T
M:7IE9"!C;W-T+"!P;'5S#0H@86-C<G5E9"!I;G1E<F5S="P@=VAI8V@@87!P
M<F]X:6UA=&5S(&9A:7(@=F%L=64N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@
M4F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD
M:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#$X<'0G/@T*(#QB/CQI/D%C8V]U;G1S(%)E8V5I=F%B;&4\+VD^
M/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($%C8V]U;G1S
M(')E8V5I=F%B;&4@=&AA="!M86YA9V5M96YT(&AA<R!T:&4@:6YT96YT(&%N
M9"!A8FEL:71Y('1O#0H@8V]L;&5C="!A<F4@<F5P;W)T960@:6X@=&AE(&-O
M;G-O;&ED871E9"!B86QA;F-E('-H965T<R!A=`T*(&]U='-T86YD:6YG(&%M
M;W5N=',L(&QE<W,@86X@86QL;W=A;F-E(&9O<B!D;W5B=&9U;"!A8V-O=6YT
M<RX@5&AE#0H@0V]M<&%N>2!W<FET97,@;V9F('5N8V]L;&5C=&EB;&4@<F5C
M96EV86)L97,@=VAE;B!T:&4@;&EK96QI:&]O9"!O9@T*(&-O;&QE8W1I;VX@
M:7,@<F5M;W1E+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
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M86QL;W=A;F-E('=A<R!R96-O<F1E9"!A<R!O9@T*($1E8V5M8F5R)B-X03`[
M,S$L(#(P,3,@;W(@,C`Q,BP@87,@=&AE($-O;7!A;GD@:&%S(&$@:&ES=&]R
M>2!O9@T*(&-O;&QE8W1I;F<@;VX@86QL(&]U='-T86YD:6YG(&%C8V]U;G1S
M+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@0V%S:#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/CQI/E)E
M<W1R:6-T960@0V%S:#PO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@5&AE($-O;7!A;GD@:7,@<F5Q=6ER960@=&\@;6%I;G1A:6X@
M8V5R=&EF:6-A=&5S(&]F(&1E<&]S:70@=&AA=`T*('-E<G9E(&%S(&-O;&QA
M=&5R86P@9F]R('9A<FEO=7,@;W!E<F%T:6YG(&QE87-E<R!A;F0@8V]R<&]R
M871E#0H@8W)E9&ET(&-A<F0@86-C;W5N=',N($%M;W5N=',@8VQA<W-I9FEE
M9"!A<R!R97-T<FEC=&5D(&-A<V@@;VX@=&AE#0H@8V]N<V]L:61A=&5D(&)A
M;&%N8V4@<VAE971S(&%R92`D-#`T+#@U,"!A="!$96-E;6)E<B8C>$$P.S,Q
M+"`R,#$S#0H@86YD(#(P,3(N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!O
M9B!&:6YA;F-I86P@26YS=')U;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y&86ER(%9A;'5E
M(&]F($9I;F%N8VEA;"!);G-T<G5M96YT<SPO:3X\+V(^/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T
M.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!F86ER(&UA<FME="!V86QU97,@
M;V8@=&AE(&9I;F%N8VEA;"!I;G-T<G5M96YT<R!I;F-L=61E9"!I;B!T:&4-
M"B!F:6YA;F-I86P@<W1A=&5M96YT<RP@=VAI8V@@:6YC;'5D92!C87-H(&5Q
M=6EV86QE;G1S(&%N9"!M;VYE>0T*(&UA<FME="!A8V-O=6YT<RP@87!P<F]X
M:6UA=&4@=&AE:7(@8V%R<GEI;F<@=F%L=65S(&%T#0H@1&5C96UB97(F(WA!
M,#LS,2P@,C`Q,R!A;F0@,C`Q,BP@9'5E('1O('1H96ER('-H;W)T+71E<FT-
M"B!M871U<FET:65S+B!4:&4@0V]M<&%N>2!A8V-O=6YT<R!F;W(@<F5C=7)R
M:6YG(&%N9"!N;VXM<F5C=7)R:6YG#0H@9F%I<B!V86QU92!M96%S=7)E;65N
M=',@:6X@86-C;W)D86YC92!W:71H('1H92!&:6YA;F-I86P@06-C;W5N=&EN
M9PT*(%-T86YD87)D<R!";V%R9"`H)B-X,C`Q0SM&05-")B-X,C`Q1#LI($%C
M8V]U;G1I;F<@4W1A;F1A<F1S#0H@0V]D:69I8V%T:6]N("@F(W@R,#%#.T%3
M0R8C>#(P,40[*2`X,C`L(#QI/D9A:7(@5F%L=64@365A<W5R96UE;G1S#0H@
M86YD($1I<V-L;W-U<F5S/"]I/B`H)B-X,C`Q0SM!4T,@.#(P)B-X,C`Q1#LI
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M.B`V<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L
M92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&)O<F1E
M<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4E/B8C>$$P.SPO=&0^#0H@
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M:6%B:6QI=&EE<RX\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@-G!T.R!-05)'
M24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P/@T*(#QT
M<CX-"B`\=&0@=VED=&@],T0U)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0R)2!A;&EG;CTS1&QE9G0^)B-X,C`R,CL\+W1D/@T*
M(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/DQE=F5L(#(F(W@R,#$T.T9A
M:7(@=F%L=64@:7,-"B!D971E<FUI;F5D(&)Y('5S:6YG(&EN<'5T<R!O=&AE
M<B!T:&%N($QE=F5L(#$@<75O=&5D('!R:6-E<R!T:&%T#0H@87)E(&1I<F5C
M=&QY(&]R(&EN9&ER96-T;'D@;V)S97)V86)L92X@26YP=71S(&-A;B!I;F-L
M=61E('%U;W1E9`T*('!R:6-E<R!F;W(@<VEM:6QA<B!A<W-E=',@86YD(&QI
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M(&UA<FME="!D871A+CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`V<'0[($U!
M4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&)O<F1E<CTS1#`^#0H@
M/'1R/@T*(#QT9"!W:61T:#TS1#4E/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#(E(&%L:6=N/3-$;&5F=#XF(W@R,#(R.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^3&5V96P@,R8C>#(P,30[
M1F%I<B!V86QU92!I<PT*(&1E=&5R;6EN960@8GD@:6YP=71S('1H870@87)E
M('5N;V)S97)V86)L92!A;F0@;F]T(&-O<G)O8F]R871E9"!B>0T*(&UA<FME
M="!D871A+B!5<V4@;V8@=&AE<V4@:6YP=71S(&EN=F]L=F5S('-I9VYI9FEC
M86YT(&%N9`T*('-U8FIE8W1I=F4@:G5D9VUE;G1S('1O(&)E(&UA9&4@8GD@
M82!R97!O<G1I;F<@96YT:71Y)B-X03`[)B-X,C`Q,SL-"B!E+F<N+"!D971E
M<FUI;FEN9R!A;B!A<'!R;W!R:6%T92!A9&IU<W1M96YT('1O(&$@9&ES8V]U
M;G0@9F%C=&]R#0H@9F]R(&EL;&EQ=6ED:71Y(&%S<V]C:6%T960@=VET:"!A
M(&=I=F5N('-E8W5R:71Y+CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T
M.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
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M97)E('-U8V@@:6YP=71S(&QI92!W:71H:6X@=&AE($%30R`X,C`@:&EE<F%R
M8VAY+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!&:6YA;F-I
M86P@87-S971S(&%N9"!L:6%B:6QI=&EE<R!S=6)J96-T('1O(&9A:7(@=F%L
M=64@;65A<W5R96UE;G1S#0H@=V5R92!A<R!F;VQL;W=S.CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@
M34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E
M<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0S."4^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M."4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,30@86QI9VX],T1C96YT97(^/&(^
M1F%I<B!686QU92!-96%S=7)E;65N=',@870-"B!$96-E;6)E<B8C>$$P.S,Q
M+"`R,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#(^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E%U
M;W1E9"8C>$$P.U!R:6-E<R8C>$$P.VEN/&)R("\^#0H@06-T:79E($UA<FME
M=',\8G(@+SX-"B!F;W(\8G(@+SX-"B!)9&5N=&EC86P@07-S971S/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY3:6=N:69I
M8V%N="8C>$$P.T]T:&5R/&)R("\^#0H@3V)S97)V86)L93QB<B`O/@T*($EN
M<'5T<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M/&(^4VEG;FEF:6-A;G0\8G(@+SX-"B!5;F]B<V5R=F%B;&4\8G(@+SX-"B!)
M;G!U=',\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(^/&(^5&]T86P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#(\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#,\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*($%S<V5T<SH\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M($-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^.3`L-#,T+#0S-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M.3`L-#,T+#0S-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@36]N97D@;6%R:V5T(&9U;F1S/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,C8L,#0V+#DW-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XR-BPP-#8L.3<T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-
M"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@4F5S=')I8W1E9"!C87-H/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-#`T+#@U,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XT,#0L.#4P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@5&]T86P@07-S971S/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,3$V+#@X-BPR-3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$V+#@X-BPR-3D\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT
M/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D/CPO=&0^#0H@/'1D(&-O;'-P86X]
M,T0Q-CX\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0Q-"!A;&EG;CTS1&-E;G1E<CX\8CY&86ER(%9A;'5E($UE87-U<F5M
M96YT<R!A=`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,3(\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@86QI9VX],T1C96YT97(^/&(^475O=&5D)B-X03`[4')I8V5S)B-X
M03`[:6X\8G(@+SX-"B!!8W1I=F4@36%R:V5T<SQB<B`O/@T*(&9O<CQB<B`O
M/@T*($ED96YT:6-A;"!!<W-E=',\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/E-I9VYI9FEC86YT)B-X03`[3W1H97(\8G(@
M+SX-"B!/8G-E<G9A8FQE/&)R("\^#0H@26YP=71S/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY3:6=N:69I8V%N=#QB<B`O
M/@T*(%5N;V)S97)V86)L93QB<B`O/@T*($EN<'5T<SPO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY4
M;W1A;#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3&5V
M96P@,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M/&(^3&5V96P@,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&(^3&5V96P@,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M07-S971S.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0V%S:"!A;F0@8V%S:"!E<75I
M=F%L96YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ."PV.34L,3DW
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ."PV.34L,3DW/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!-;VYE>2!M87)K970@
M9G5N9',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR.2PP-#<L
M.34X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Y+#`T-RPY-3@\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!297-T<FEC=&5D(&-A
M<V@\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,#0L.#4P/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0P-"PX-3`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A
M;"!!<W-E=',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT."PQ-#@L,#`U/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C0X+#$T."PP,#4\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($QI86)I
M;&ET:65S.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!0<F5F97)R960@<W1O8VL@=V%R<F%N="!L:6%B
M:6QI='D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-3(L.30W/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#4R+#DT-SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@07,@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q,BP@=&AE
M($-O;7!A;GD@=')A;G-F97)R960@:71S(&UO;F5Y#0H@;6%R:V5T(&9U;F1S
M(&9R;VT@3&5V96P@,B!T;R!,979E;"`Q(&)E8V%U<V4@=&AE(&EN<'5T<R!A
M<F4@;F]W#0H@8F%S960@=7!O;B!A('%U;W1E9"!M87)K970@<')I8V4N/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY)B-X
M,C`Q.3MS($QE=F5L(#$@<V5C=7)I=&EE<R!P<FEM87)I;'D@8V]N<VES="!O
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M:V5T<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O
M;7!A;GD@9&5T97)M:6YE<R!T:&4@97-T:6UA=&5D(&9A:7(@=F%L=64@9F]R
M(&ET<R!,979E;"`R#0H@<V5C=7)I=&EE<R!U<VEN9R!T:&4@9F]L;&]W:6YG
M(&UE=&AO9',Z('%U;W1E9"!P<FEC97,@9F]R('-I;6EL87(-"B!A<W-E=',O
M;&EA8FEL:71I97,@:6X@86-T:79E(&UA<FME=',L(&EN<'5T<R!O=&AE<B!T
M:&%N('%U;W1E9`T*('!R:6-E<R!T:&%T(&%R92!O8G-E<G9A8FQE(&9O<B!T
M:&4@87-S970O;&EA8FEL:71Y("AE+F<N+"!I;G1E<F5S=`T*(')A=&5S+"!Y
M:65L9"!C=7)V97,@=F]L871I;&ET:65S+"!D969A=6QT(')A=&5S+"!E=&,N
M*2!A;F0@:6YP=71S#0H@=&AA="!A<F4@9&5R:79E9"!P<FEN8VEP86QL>2!F
M<F]M(&]R(&-O<G)O8F]R871E9"!B>2!O=&AE<@T*(&]B<V5R=F%B;&4@;6%R
M:V5T(&1A=&$N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P
M.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!F;VQL;W=I
M;F<@=&%B;&4@<')O=FED97,@82!R;VQL9F]R=V%R9"!O9B!T:&4@0V]M<&%N
M>28C>#(P,3D[<PT*('!R969E<G)E9"!S=&]C:R!W87)R86YT(&QI86)I;&ET
M>2P@=VAI8V@@=V%S('1H92!O;FQY(&9I;F%N8VEA;`T*(&EN<W1R=6UE;G0@
M;65A<W5R960@870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!B87-I<R!U
M<VEN9PT*('-I9VYI9FEC86YT('5N;V)S97)V86)L92!I;G!U=',@*$QE=F5L
M(#,I(&%S(&1E9FEN960@:6X@05-##0H@.#(P.CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.
M+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#8X)2!A;&EG;CTS1&-E;G1E<B!B;W)D
M97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0X,B4^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($)A;&%N8V4@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,CPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B@U,BPY-#<\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!4;W1A;"!U;G)E86QI>F5D(&=A:6YS("AL;W-S97,I(&EN8VQU9&5D
M(&EN(&5A<FYI;F=S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-C(V+#,T
M.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-E
M='1L96UE;G0@;V8@<')E9F5R<F5D('-T;V-K('=A<G)A;G1S/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XV-SDL,CDV/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!"86QA;F-E
M(&%T($1E8V5M8F5R)B-X03`[,S$L(#(P,3,\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!4
M15A4+4E.1$5.5#H@-"4G/@T*($EN(&]R9&5R('1O(&5S=&EM871E('1H92!F
M86ER('9A;'5E(&]F('1H92!P<F5F97)R960@<W1O8VL@<'5R8VAA<V4-"B!W
M87)R86YT<RP@=&AE(&)U<VEN97-S(&5N=&5R<')I<V4@=F%L=64@=V%S(&5S
M=&%B;&ES:&5D(&)A<V5D(&]N(&$-"B!D:7-C;W5N=&5D(&-A<V@@9FQO=R!M
M;V1E;"`H:6YC;VUE(&%P<')O86-H*2X@5&AE($-O;7!A;GD@=71I;&EZ960-
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M=6ET>2!I;G-T<G5M96YT<R!S=6-H(&%S('!R969E<G)E9`T*('-T;V-K+"!S
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M(&%S<W5M<'1I;VYS(')E;&%T960@=&\@<')O9'5C=`T*(&%P<')O=F%L+"!M
M87)K970@<&5N971R871I;VX@86YD(&-O<W1S('1O(&1E=F5L;W`@=&AE('!R
M;V1U8W0N#0H@4VEG;FEF:6-A;G0@8VAA;F=E<R!T;R!T:&5S92!A<W-U;7!T
M:6]N<R!W;W5L9"!R97-U;'0@:6X-"B!I;F-R96%S97,O9&5C<F5A<V5S('1O
M('1H92!F86ER('9A;'5E(&]F('1H92!O=71S=&%N9&EN9PT*('=A<G)A;G1S
M+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@=&]T86P@
M=6YR96%L:7IE9"!G86EN<R`H;&]S<V5S*2!O;B!T:&4@<')E9F5R<F5D('-T
M;V-K('=A<G)A;G1S#0H@:6YC;'5D960@:6X@96%R;FEN9W,@:7,@:6YC;'5D
M960@87,@82!C;VUP;VYE;G0@;V8@;W1H97(@:6YC;VUE#0H@*&5X<&5N<V4I
M(&EN('1H92!C;VYS;VQI9&%T960@<W1A=&5M96YT(&]F(&]P97)A=&EO;G,@
M86YD#0H@8V]M<')E:&5N<VEV92!I;F-O;64N($EM;65D:6%T96QY('!R:6]R
M('1O('1H92!#;VUP86YY)B-X,C`Q.3MS($E03PT*(&EN($]C=&]B97(@,C`Q
M,RP@86QL('1H92!P<F5F97)R960@<W1O8VL@=V%R<F%N=',@=V5R92!E>&5R
M8VES960-"B!A;F0@8V]N=F5R=&5D(&EN=&\@<VAA<F5S(&]F(%-E<FEE<R!$
M+3(@<')E9F5R<F5D('-T;V-K+"!W:&EC:"!W97)E#0H@<W5B<V5Q=65N=&QY
M(&-O;G9E<G1E9"!T;R!C;VUM;VX@<W1O8VLN/"]P/@T*(#PO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N
M8V5N=')A=&EO;B!O9B!#<F5D:70@4FES:SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/CQI/D-O;F-E;G1R
M871I;VX@;V8@0W)E9&ET(%)I<VL\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4
M+4E.1$5.5#H@-"4G/@T*(%-U8G-T86YT:6%L;'D@86QL(&]F('1H92!#;VUP
M86YY)B-X,C`Q.3MS(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',-"B!A<F4@
M;6%I;G1A:6YE9"!W:71H(&UA:F]R(&9I;F%N8VEA;"!I;G-T:71U=&EO;G,@
M:6X@=&AE(%5N:71E9`T*(%-T871E<RX@1&5P;W-I=',@:&5L9"!W:71H(&)A
M;FMS(&UA>2!E>&-E960@=&AE(&%M;W5N="!O9B!I;G-U<F%N8V4-"B!P<F]V
M:61E9"!O;B!S=6-H(&1E<&]S:71S+B!'96YE<F%L;'DL('1H97-E(&1E<&]S
M:71S(&UA>2!B90T*(')E9&5E;65D('5P;VX@9&5M86YD(&%N9"P@=&AE<F5F
M;W)E+"!B96%R(&UI;FEM86P@<FES:RX\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@1FEN86YC:6%L(&EN<W1R=6UE;G1S('1H870@<&]T96YT
M:6%L;'D@<W5B:F5C="!T:&4@0V]M<&%N>2!T;PT*(&-O;F-E;G1R871I;VYS
M(&]F(&-R961I="!R:7-K(&-O;G-I<W0@<')I;F-I<&%L;'D@;V8@8V%S:"!A
M;F0@8V%S:`T*(&5Q=6EV86QE;G1S+"!A;F0@86-C;W5N=',@<F5C96EV86)L
M92X@5&AE(&-O=6YT97)P87)T:65S(&%R90T*('9A<FEO=7,@8V]R<&]R871I
M;VYS+"!F:6YA;F-I86P@:6YS=&ET=71I;VYS(&%N9"!G;W9E<FYM96YT#0H@
M86=E;F-I97,@;V8@:&EG:"!C<F5D:70@<W1A;F1I;F<N/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T
M.R!415A4+4E.1$5.5#H@-"4G/@T*($9O<B!T:&4@>65A<G,@96YD960@1&5C
M96UB97(F(WA!,#LS,2P@,C`Q,RP@,C`Q,B!A;F0@,C`Q,2P@86QL(&]F#0H@
M=&AE($-O;7!A;GDF(W@R,#$Y.W,@9W)A;G0@<F5V96YU92!W87,@<F5L871E
M9"!T;R!C;VYT<F%C=',@86YD#0H@<F5S96%R8V@@9W)A;G1S(')E8V5I=F5D
M(&9R;VT@52Y3+B!G;W9E<FYM96YT(&%G96YC:65S+@T*($-O;&QA8F]R871I
M;VYS('=I=&@@3&5S($QA8F]R871O:7)E<R!397)V:65R(&%N9"!);G-T:71U
M="!D90T*(%)E8VAE<F-H97,@4V5R=FEE<B`H8V]L;&5C=&EV96QY+"`F(W@R
M,#%#.U-E<G9I97(F(W@R,#%$.RDL#0H@0F]E:')I;F=E<B!);F=E;&AE:6T@
M1VUB2"`H)B-X,C`Q0SM";V5H<FEN9V5R)B-X,C`Q1#LI+"!':6QE860-"B!3
M8VEE;F-E<RP@26YC+B`H)B-X,C`Q0SM':6QE860F(W@R,#%$.RDL(%!F:7IE
M<BP@26YC+@T*("@F(W@R,#%#.U!F:7IE<B8C>#(P,40[*2!A;F0@16QI($QI
M;&QY)B-X03`[)F%M<#L@0V\N("@F(W@R,#%#.T5L:0T*($QI;&QY)B-X,C`Q
M1#LI(&%C8V]U;G0@9F]R(&%L;"!O=&AE<B!R979E;G5E+B!!;&P@;W5T<W1A
M;F1I;F<-"B!R96-E:79A8FQE<R!A<F4@9'5E(&9R;VT@=&AE($-O;7!A;GDF
M(W@R,#$Y.W,@8V]L;&%B;W)A=&]R<R!A;F0@52Y3+@T*(&=O=F5R;FUE;G0@
M86=E;F-I97,N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P
M.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
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M1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO
M<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA
M<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M.#0E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W
M:61T:#TS1#8V)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^#0H@/&(^665A<B8C>$$P
M.T5N9&5D)B-X03`[1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^#0H@/&(^
M)B-X03`[)B-X03`[)B-X03`[)B-X03`[,C`Q,R8C>$$P.R8C>$$P.R8C>$$P
M.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^#0H@
M/&(^)B-X03`[)B-X03`[)B-X03`[)B-X03`[,C`Q,B8C>$$P.R8C>$$P.R8C
M>$$P.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M#0H@/&(^)B-X03`[)B-X03`[)B-X03`[)B-X03`[,C`Q,28C>$$P.R8C>$$P
M.R8C>$$P.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4V5R
M=FEE<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4Q+C8\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$W+C,\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M($)O96AR:6YG97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR
M-"XX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ."XT/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ-2XV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@1VEL96%D/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,3,N.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!09FEZ97(\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+C`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C@N-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3`N.#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($=O=F5R;FUE
M;G0@06=E;F-I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR
M+C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N-3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,3<N-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5L:2!,
M:6QL>3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N-#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#@N.3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-30N,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q
M,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!F;VQL;W=I;F<@=&%B;&4@
M<F5P<F5S96YT<R!T:&4@<&5R8V5N=&%G92!O9B!A;&P@<VEG;FEF:6-A;G0-
M"B!A8V-O=6YT<R!R96-E:79A8FQE.CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@
M,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52
M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#<V)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P
M/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W-24^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3$E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$P)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V
M(&%L:6=N/3-$8V5N=&5R/CQB/D1E8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M/@T*(#QB/B8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.S(P,3,F(WA!,#LF(WA!
M,#LF(WA!,#LF(WA!,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/@T*(#QB/B8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.S(P,3(F(WA!,#LF
M(WA!,#LF(WA!,#LF(WA!,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M($=I;&5A9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4S+C0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*(%!F:7IE<BX\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ,BXS/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT
M-2XT/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M0F]E:')I;F=E<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R
M+C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X+C`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!%;&D@3&EL;'D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XW+C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(X+C(\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!397)V:65R
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BXT/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I
M9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!';W9E<FYM96YT($%G96YC:65S/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-"XV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XX+C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B4F(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y0<F]P97)T>2!A
M;F0@17%U:7!M96YT/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z
M(#0E)SX-"B!0<F]P97)T>2!A;F0@97%U:7!M96YT(&%R92!S=&%T960@870@
M8V]S="X@57!O;B!R971I<F5M96YT(&]R('-A;&4L#0H@=&AE(&-O<W0@;V8@
M87-S971S(&1I<W!O<V5D(&]F(&%N9"!T:&4@<F5L871E9"!A8V-U;75L871E
M9`T*(&1E<')E8VEA=&EO;B!A<F4@<F5M;W9E9"!F<F]M('1H92!A8V-O=6YT
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M;"!L:79E<SH\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[
M/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0Q,#`E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT
M9"!W:61T:#TS1#4Q)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X\+W1D/@T*(#QT9"!W:61T:#TS1#0W)3X\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!#;VUP=71E<B!E<75I<&UE;G0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XS('EE87)S/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4V]F='=A<F4\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XS('EE87)S/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@1G5R;FET=7)E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M,3`@>65A<G,\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!,86)O<F%T;W)Y(&%N9"!O9F9I
M8V4@97%U:7!M96YT/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^-2!Y
M96%R<SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*($QE87-E:&]L9"!I;7!R;W9E;65N=',\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3Y3:&]R=&5R(&]F(&QE87-E
M('1E<FT@;W(@=7-E9G5L(&QI9F4\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-
M"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DEM<&%I<FUE;G0@;V8@3&]N9RU,:79E9"!!<W-E=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-
M"B`\8CX\:3Y);7!A:7)M96YT(&]F($QO;F<M3&EV960@07-S971S/"]I/CPO
M8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M<&%N
M>2!A<W-E<W-E<R!T:&4@<F5C;W9E<F%B:6QI='D@;V8@:71S(&QO;F<M;&EV
M960@87-S971S(&EN#0H@86-C;W)D86YC92!W:71H('1H92!P<F]V:7-I;VYS
M(&]F($%30R8C>$$P.S,V,"P@/&D^4')O<&5R='DL(%!L86YT#0H@86YD($5Q
M=6EP;65N=#PO:3XN($%30R`S-C`@<F5Q=6ER97,@=&AA="!L;VYG+6QI=F5D
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M9V5N97)A=&5D(&)Y('1H92!A<W-E=`T*(&]R(&%S<V5T(&=R;W5P+B!)9B!C
M87)R>6EN9R!V86QU92!E>&-E961S('1H92!S=6T@;V8@=6YD:7-C;W5N=&5D
M#0H@8V%S:"!F;&]W<RP@=&AE($-O;7!A;GD@=&AE;B!D971E<FUI;F5S('1H
M92!F86ER('9A;'5E(&]F('1H90T*('5N9&5R;'EI;F<@87-S970@9W)O=7`N
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M('-E;&PN($%S(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,3,@86YD#0H@,C`Q
M,BP@=&AE($-O;7!A;GD@9&5T97)M:6YE9"!T:&%T('1H97)E('=E<F4@;F\@
M:6UP86ER960@87-S971S(&%N9`T*(&AA9"!N;R!A<W-E=',@:&5L9"UF;W(M
M<V%L92X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*(#QB/CQI/DEN
M8V]M92!487AE<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@1&5F97)R960@=&%X(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@87)E
M(&1E=&5R;6EN960@8F%S960@;VX-"B!D:69F97)E;F-E<R!B971W965N('1H
M92!F:6YA;F-I86P@<F5P;W)T:6YG(&%N9"!T87@@8F%S:7,@;V8@87-S971S
M#0H@86YD(&QI86)I;&ET:65S(&%N9"!A<F4@;65A<W5R960@=7-I;F<@=&AE
M(&5N86-T960@=&%X(')A=&5S(&%N9`T*(&QA=W,@=&AA="!A<F4@97AP96-T
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M8F4@<F5C;V=N:7IE9"!I<R!M96%S=7)E9"!A<R!T:&4@;&%R9V5S=`T*(&%M
M;W5N="!T:&%T(&ES(&UO<F4@=&AA;B`U,"4@;&EK96QY('1O(&)E(')E86QI
M>F5D('5P;VX@=6QT:6UA=&4-"B!S971T;&5M96YT+B!4:&4@0V]M<&%N>28C
M>#(P,3D[<R!P;VQI8WD@:7,@=&\@<F5C;W)D(&EN=&5R97-T(&%N9`T*('!E
M;F%L=&EE<R!R96QA=&5D('1O('5N8V5R=&%I;B!T87@@<&]S:71I;VYS(&%S
M(&$@8V]M<&]N96YT(&]F#0H@:6YC;VUE('1A>"!E>'!E;G-E+CPO<#X-"B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3AP="<^#0H@/&(^/&D^4F5V96YU97,\+VD^/"]B/CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`V<'0G/@T*(#QI/E)E=F5N=64@4F5C
M;V=N:71I;VX\+VD^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
M5&AE($-O;7!A;GD@96YT97)S(&EN=&\@8V]L;&%B;W)A=&EO;B!A;F0@;&EC
M96YS92!A9W)E96UE;G1S('=I=&@-"B!C;VQL86)O<F%T;W)S(&9O<B!T:&4@
M9&5V96QO<&UE;G0@;V8@;6]N;V-L;VYA;"!A;G1I8F]D>2UB87-E9`T*('1H
M97)A<&5U=&EC<R!T;R!T<F5A="!C86YC97(@86YD(&]T:&5R(&-O;7!L97@@
M9&ES96%S97,N(%1H92!T97)M<PT*(&]F('1H97-E(&%G<F5E;65N=',@8V]N
M=&%I;B!M=6QT:7!L92!D96QI=F5R86)L97,@=VAI8V@@;6%Y(&EN8VQU9&4-
M"B`H:2DF(WA!,#ML:6-E;G-E<RP@;W(@;W!T:6]N<R!T;R!O8G1A:6X@;&EC
M96YS97,L('1O('1H90T*($-O;7!A;GDF(W@R,#$Y.W,@=&5C:&YO;&]G:6-A
M;"!P;&%T9F]R;7,L('-U8V@@87,@:71S($9C#0H@3W!T:6UI>F%T:6]N(&%N
M9"!$=6%L+4%F9FEN:71Y(%)E+51A<F=E=&EN9R`H)B-X,C`Q0SM$05)4)B-X
M,C`Q1#LI#0H@=&5C:&YO;&]G:65S+"`H:6DI)B-X03`[<FEG:'1S('1O(&9U
M='5R92!T96-H;F]L;V=I8V%L#0H@:6UP<F]V96UE;G1S+"`H:6EI*28C>$$P
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M(%1O<&EC(#8P-2TR-2P@/&D^4F5V96YU90T*(%)E8V]G;FET:6]N)B-X03`[
M)B-X,C`Q,SLF(WA!,#M-=6QT:7!L92U%;&5M96YT($%R<F%N9V5M96YT<SPO
M:3XL#0H@86YD($%30R!4;W!I8R`V,#4M,C@L(#QI/E)E=F5N=64@4F5C;V=N
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M<VED97)A=&EO;B!R96-E:79E9`T*(&ES(&%L;&]C871E9"!A;6]N9R!T:&4@
M<V5P87)A=&4@=6YI=',@;V8@86-C;W5N=&EN9RP@86YD('1H90T*(&%P<&QI
M8V%B;&4@<F5V96YU92!R96-O9VYI=&EO;B!C<FET97)I82!A<F4@87!P;&EE
M9"!T;R!E86-H(&]F('1H90T*('-E<&%R871E('5N:71S+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
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M86QI>F%T:6]N(&QI8V5N<V5S('1O('5S92!T:&4-"B!#;VUP86YY)B-X,C`Q
M.3MS('1E8VAN;VQO9WD@86YD+V]R(&-E<G1A:6X@;W1H97(@:6YT96QL96-T
M=6%L#0H@<')O<&5R='D@=&\@9&5V96QO<"!C;VUP;W5N9',@86=A:6YS="!S
M<&5C:69I960@=&%R9V5T<R`H<F5F97)R960-"B!T;R!H97)E:6X@87,@97AC
M;'5S:79E(&QI8V5N<V5S*3L@86YD(#(I($]P=&EO;B]R97-E87)C:"!A9W)E
M96UE;G1S#0H@=&\@<V5C=7)E(&]N(&5S=&%B;&ES:&5D('1E<FUS+"!D979E
M;&]P;65N="!A;F0@8V]M;65R8VEA;&EZ871I;VX-"B!L:6-E;G-E<R!T;R!A
M;G1I8V%N8V5R(&%N9"!O=&AE<B!T:&5R87!E=71I8R!P<F]D=6-T(&-A;F1I
M9&%T97,@=&\-"B!C;VQL86)O<F%T;W(@<V5L96-T960@=&%R9V5T<R!D979E
M;&]P960@8GD@=&AE($-O;7!A;GD@9'5R:6YG(&%N#0H@;W!T:6]N('!E<FEO
M9"`H<F5F97)R960@=&\@:&5R96EN(&%S(')I9VAT+71O+61E=F5L;W`-"B!A
M9W)E96UE;G1S*2X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
M5&AE<F4@87)E(&YO('!E<F9O<FUA;F-E+"!C86YC96QL871I;VXL('1E<FUI
M;F%T:6]N(&]R(')E9G5N9`T*('!R;W9I<VEO;G,@:6X@86YY(&]F('1H92!A
M<G)A;F=E;65N=',@=&AA="!C;VYT86EN(&UA=&5R:6%L#0H@9FEN86YC:6%L
M(&-O;G-E<75E;F-E<R!T;R!T:&4@0V]M<&%N>2X\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`R)3L@34%2
M1TE.+51/4#H@,3AP="<^#0H@/&D^17AC;'5S:79E($QI8V5N<V5S/"]I/CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!D96QI=F5R86)L
M97,@=6YD97(@86X@97AC;'5S:79E(&QI8V5N<V4@86=R965M96YT(&=E;F5R
M86QL>0T*(&EN8VQU9&4@=&AE(&5X8VQU<VEV92!L:6-E;G-E('1O('1H92!#
M;VUP86YY)B-X,C`Q.3MS($1!4E0-"B!T96-H;F]L;V=Y('=I=&@@<F5S<&5C
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M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($=E;F5R
M86QL>2P@97AC;'5S:79E(&QI8V5N<V4@86=R965M96YT<R!C;VYT86EN(&YO
M;G)E9G5N9&%B;&4@=&5R;7,-"B!F;W(@<&%Y;65N=',@86YD+"!D97!E;F1I
M;F<@;VX@=&AE('1E<FUS(&]F('1H92!A9W)E96UE;G0L('!R;W9I9&4-"B!T
M:&%T('1H92!#;VUP86YY('=I;&P@*&DI)B-X03`[870@=&AE(&-O;&QA8F]R
M871O<B8C>#(P,3D[<R!R97%U97-T+`T*('!R;W9I9&4@<F5S96%R8V@@86YD
M('!R92UC;&EN:6-A;"!D979E;&]P;65N="!S97)V:6-E<R!A=`T*(&YE9V]T
M:6%T960@<')I8V5S('=H:6-H(&%R92!G96YE<F%L;'D@8V]N<VES=&5N="!W
M:71H('=H870@;W1H97(-"B!T:&ER9"!P87)T:65S('=O=6QD(&-H87)G92P@
M*&EI*28C>$$P.V5A<FX@<&%Y;65N=',@=7!O;B!T:&4-"B!A8VAI979E;65N
M="!O9B!C97)T86EN(&UI;&5S=&]N97,L("AI:6DI)B-X03`[96%R;B!R;WEA
M;'1Y#0H@<&%Y;65N=',L(&%N9"`H:78I)B-X03`[:6X@<V]M92!C87-E<R!G
M<F%N="!T:&4@0V]M<&%N>2!A;B!O<'1I;VX-"B!T;R!P87)T:6-I<&%T92!I
M;B!T:&4@9&5V96QO<&UE;G0@86YD(&-O;6UE<F-I86QI>F%T:6]N(&]F('!R
M;V1U8W1S#0H@=&AA="!R97-U;'0@9G)O;2!S=6-H(&%G<F5E;65N=',N(%)O
M>6%L='D@<F%T97,@;6%Y('9A<GD@;W9E<B!T:&4-"B!R;WEA;'1Y('1E<FT@
M9&5P96YD:6YG(&]N('1H92!#;VUP86YY)B-X,C`Q.3MS(&EN=&5L;&5C='5A
M;"!P<F]P97)T>0T*(')I9VAT<R!A;F0@=VAE=&AE<B!T:&4@0V]M<&%N>2!E
M>&5R8VES97,@86YY(&-O+61E=F5L;W!M96YT(&%N9`T*(&-O+6-O;6UE<F-I
M86QI>F%T:6]N(')I9VAT<RX@5&AE($-O;7!A;GD@;6%Y('!R;W9I9&4@=&5C
M:&YI8V%L#0H@87-S:7-T86YC92!A;F0@<VAA<F4@86YY('1E8VAN;VQO9WD@
M:6UP<F]V96UE;G1S('=I=&@@:71S#0H@8V]L;&%B;W)A=&]R<R!D=7)I;F<@
M=&AE('1E<FT@;V8@=&AE(&-O;&QA8F]R871I;VX@86=R965M96YT<RX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@9&]E
M<R!N;W0@9&ER96-T;'D@8V]N=')O;"!W:&5N(&%N>2!C;VQL86)O<F%T;W(@
M=VEL;`T*(&%C:&EE=F4@;6EL97-T;VYE<R!O<B!B96-O;64@;&EA8FQE(&9O
M<B!R;WEA;'1Y('!A>6UE;G1S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
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M=7)E(&]F('1H92!R97-E87)C:`T*('-E<G9I8V5S('1O(&)E('!E<F9O<FUE
M9"!O;B!B96AA;&8@;V8@:71S(&-O;&QA8F]R871O<G,@86YD(&UA<FME=`T*
M(')A=&5S(&9O<B!S:6UI;&%R('-E<G9I8V5S+CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
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M)B-X,C`Q1#LI($YO+B8C>$$P.S(P,#DM,3,L(#QI/E)E=F5N=64@07)R86YG
M96UE;G1S('=I=&@-"B!-=6QT:7!L92!$96QI=F5R86)L97,\+VD^+"!O;B!*
M86YU87)Y)B-X03`[,2P@,C`Q,2P@=&AE($-O;7!A;GD-"B!D971E<FUI;F5D
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M;VUP86YY#0H@<F5F97)S('1O(&%S('1H92!#;VUP86YY)B-X,C`Q.3MS('!E
M<FEO9"!O9B!S=6)S=&%N=&EA;"!I;G9O;'9E;65N="X-"B!);B!M86MI;F<@
M=&AE(&1E=&5R;6EN871I;VX@;V8@=&AE(&QE;F=T:"!O9B!T:&4@<&5R:6]D
M(&]V97(@=VAI8V@-"B!T;R!D969E<B!R979E;G5E(&9O<B!C;VYT<F%C=',@
M96YT97)E9"!I;G1O('!R:6]R('1O('1H92!A9&]P=&EO;@T*(&]F($%352!.
M;RXF(WA!,#LR,#`Y+3$S+"!S:6=N:69I8V%N="!J=61G;65N="!A;F0@97-T
M:6UA=&EO;B!I<PT*('5S960@8GD@=&AE($-O;7!A;GD@86YD(&-A;B!H879E
M(&%N(&EM<&%C="!O;B!T:&4@86UO=6YT(&]F(')E=F5N=64-"B!R96-O9VYI
M>F5D(&EN(&$@9VEV96X@<&5R:6]D+B!(:7-T;W)I8V%L;'DL('1H92!#;VUP
M86YY)B-X,C`Q.3MS#0H@:6YV;VQV96UE;G0@=VET:"!T:&4@9&5V96QO<&UE
M;G0@;V8@82!C;VQL86)O<F%T;W(F(W@R,#$Y.W,@<')O9'5C=`T*(&-A;F1I
M9&%T92!H87,@8F5E;B!S:6=N:69I8V%N="!A="!T:&4@96%R;'D@<W1A9V5S
M(&]F(&1E=F5L;W!M96YT+`T*(&%N9"!L97-S96YS(&%S(&ET('!R;V=R97-S
M97,@:6YT;R!C;&EN:6-A;"!T<FEA;',N($%C8V]R9&EN9VQY+"!T:&4-"B!#
M;VUP86YY(&=E;F5R86QL>2!E<W1I;6%T97,@=&AI<R!P97)I;V0@;V8@<W5B
M<W1A;G1I86P@:6YV;VQV96UE;G0-"B!T;R!B96=I;B!A="!T:&4@:6YC97!T
M:6]N(&]F('1H92!C;VQL86)O<F%T:6]N(&%G<F5E;65N="!A;F0-"B!C;VYC
M;'5D92!A="!T:&4@96YD(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS('-U8G-T
M86YT:6%L(&EN=F]L=F5M96YT+@T*($%352!.;RXF(WA!,#LR,#`Y+3$S(&%M
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M=FED96YC92`H)B-X,C`Q0SM44$4F(W@R,#%$.RDL(&]R(&$@8F5S="!E<W1I
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M=W,L(&5S=&EM871E9"!D979E;&]P;65N=`T*(&-O<W1S+"!P<F]B86)I;&ET
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M)B-X03`[=&AE(&1E;&EV97)E9"!I=&5M(&AA<R!V86QU92!T;R!T:&4-"B!C
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M=VET:&EN('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O;G1R;VPN(%1H90T*(&%R
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M;&EV97)E9"X@36%N86=E;65N=`T*(&5X97)C:7-E<R!S:6=N:69I8V%N="!J
M=61G;65N="!I;B!D971E<FUI;FEN9R!W:&5T:&5R(&$@9&5L:79E<F%B;&4-
M"B!I<R!A('-E<&%R871E('5N:70@;V8@86-C;W5N=&EN9RX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R
M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@26X@9&5T97)M:6YI;F<@=&AE('-E
M<&%R871E('5N:71S(&]F(&%C8V]U;G1I;F<L('1H92!#;VUP86YY#0H@979A
M;'5A=&5D('=H971H97(@=&AE(&5X8VQU<VEV92!L:6-E;G-E(&AA9"!S=&%N
M9&%L;VYE('9A;'5E('1O('1H90T*(&-O;&QA8F]R871O<B!B87-E9"!O;B!C
M;VYS:61E<F%T:6]N(&]F('1H92!R96QE=F%N="!F86-T<R!A;F0-"B!C:7)C
M=6US=&%N8V5S(&9O<B!E86-H(&%R<F%N9V5M96YT+B!&86-T;W)S(&-O;G-I
M9&5R960@:6X@=&AI<PT*(&1E=&5R;6EN871I;VX@:6YC;'5D960@=&AE(')E
M<V5A<F-H(&%N9"!D979E;&]P;65N="!C87!A8FEL:71I97,@;V8-"B!T:&4@
M8V]L;&%B;W)A=&]R(&%N9"!T:&4@879A:6QA8FEL:71Y(&]F(')E;&5V86YT
M(')E<V5A<F-H#0H@97AP97)T:7-E(&EN('1H92!M87)K971P;&%C92X@26X@
M861D:71I;VXL('1H92!#;VUP86YY(&-O;G-I9&5R960-"B!W:&5T:&5R(&]R
M(&YO="`H:2DF(WA!,#MT:&4@8V]L;&%B;W)A=&]R(&-O=6QD('5S92!T:&4@
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M:61E('1H92!U;F1E;&EV97)E9"!I=&5M<RX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@<F5A<W-E<W-E<R!I=',@<&5R
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M;G,@:71S(')I9VAT('1O('5S92!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS('1E
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M86=R965M96YT+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
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M<F5D(&5L96UE;G1S+"!W:&EC:`T*(&=E;F5R86QL>2!I;F-L=61E(')I9VAT
M<R!T;R!F=71U<F4@=&5C:&YO;&]G:6-A;"!I;7!R;W9E;65N=',L#0H@<F5S
M96%R8V@@<V5R=FEC97,@86YD('1H92!M86YU9F%C='5R92!O9B!P<F4M8VQI
M;FEC86P@86YD(&-L:6YI8V%L#0H@;6%T97)I86QS+CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
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M9B!T:&4@87!P;&EC86)L92!L:6-E;G-E+CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
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M96YU92!F<F]M#0H@8V]L;&%B;W)A=&EV92!R97-E87)C:"X\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[
M($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GDF(W@R,#$Y.W,@;&EC96YS92!A
M9W)E96UE;G1S(&AA=F4@;6EL97-T;VYE('!A>6UE;G1S#0H@=VAI8V@@9F]R
M(')E<&]R=&EN9R!P=7)P;W-E<R!A<F4@86=G<F5G871E9"!I;G1O('1H<F5E
M(&-A=&5G;W)I97,Z#0H@*&DI)B-X03`[9&5V96QO<&UE;G0@;6EL97-T;VYE
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M1')U9R!!9&UI;FES=')A=&EO;B`H)B-X,C`Q0SM&1$$F(W@R,#%$.RD@;W(@
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M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($%T('1H92!I;F-E
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M;F-L=61E<R!A;@T*(&%S<V5S<VUE;G0@;V8@=VAE=&AE<B`H82DF(WA!,#MT
M:&4@8V]N<VED97)A=&EO;B!I<R!C;VUM96YS=7)A=&4-"B!W:71H(&5I=&AE
M<B`H,2DF(WA!,#MT:&4@96YT:71Y)B-X,C`Q.3MS('!E<F9O<FUA;F-E('1O
M(&%C:&EE=F4@=&AE#0H@;6EL97-T;VYE+"!O<B`H,BDF(WA!,#MT:&4@96YH
M86YC96UE;G0@;V8@=&AE('9A;'5E(&]F('1H90T*(&1E;&EV97)E9"!I=&5M
M*',I(&%S(&$@<F5S=6QT(&]F(&$@<W!E8VEF:6,@;W5T8V]M92!R97-U;'1I
M;F<@9G)O;0T*('1H92!E;G1I='DF(W@R,#$Y.W,@<&5R9F]R;6%N8V4@=&\@
M86-H:65V92!T:&4@;6EL97-T;VYE+`T*("AB*28C>$$P.W1H92!C;VYS:61E
M<F%T:6]N(')E;&%T97,@<V]L96QY('1O('!A<W0@<&5R9F]R;6%N8V4@86YD
M#0H@*&,I)B-X03`[=&AE(&-O;G-I9&5R871I;VX@:7,@<F5A<V]N86)L92!R
M96QA=&EV92!T;R!A;&P@;V8@=&AE#0H@9&5L:79E<F%B;&5S(&%N9"!P87EM
M96YT('1E<FUS('=I=&AI;B!T:&4@87)R86YG96UE;G0N(%1H92!#;VUP86YY
M#0H@979A;'5A=&5S(&9A8W1O<G,@<W5C:"!A<R!T:&4@<V-I96YT:69I8RP@
M<F5G=6QA=&]R>2P@8V]M;65R8VEA;`T*(&%N9"!O=&AE<B!R:7-K<R!T:&%T
M(&UU<W0@8F4@;W9E<F-O;64@=&\@86-H:65V92!T:&4@<F5S<&5C=&EV90T*
M(&UI;&5S=&]N92P@=&AE(&QE=F5L(&]F(&5F9F]R="!A;F0@:6YV97-T;65N
M="!R97%U:7)E9"!T;R!A8VAI979E#0H@=&AE(')E<W!E8W1I=F4@;6EL97-T
M;VYE(&%N9"!W:&5T:&5R('1H92!M:6QE<W1O;F4@8V]N<VED97)A=&EO;B!I
M<PT*(')E87-O;F%B;&4@<F5L871I=F4@=&\@86QL(&1E;&EV97)A8FQE<R!A
M;F0@<&%Y;65N="!T97)M<R!I;B!T:&4-"B!A<G)A;F=E;65N="!I;B!M86MI
M;F<@=&AI<R!A<W-E<W-M96YT+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
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M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QI/E)I9VAT
M+71O+41E=F5L;W`@06=R965M96YT<SPO:3X\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)
M3D1%3E0Z(#0E)SX-"B!4:&4@0V]M<&%N>28C>#(P,3D[<R!R:6=H="UT;RUD
M979E;&]P(&%G<F5E;65N=',@<')O=FED90T*(&-O;&QA8F]R871O<G,@=VET
M:"!A;B!E>&-L=7-I=F4@;W!T:6]N('1O(&]B=&%I;B!L:6-E;G-E<R!T;PT*
M(&1E=F5L;W`@86YD(&-O;6UE<F-I86QI>F4@:6X@<W!E8VEF:65D(&=E;V=R
M87!H:6,@=&5R<FET;W)I97,-"B!P<F]D=6-T(&-A;F1I9&%T97,@9&5V96QO
M<&5D(&)Y('1H92!#;VUP86YY('5N9&5R(&%G<F5E9"!U<&]N#0H@<F5S96%R
M8V@@86YD('!R92UC;&EN:6-A;"!D979E;&]P;65N="!P<F]D=6-T('!R;V=R
M86US+B!4:&4@<')O9'5C=`T*(&-A;F1I9&%T97,@<F5S=6QT:6YG(&9R;VT@
M96%C:"!P<F]G<F%M(&%R92!A;&P@9&ER96-T960@=&\@80T*('-P96-I9FEC
M('1A<F=E="!S96QE8W1E9"!B>2!T:&4@8V]L;&%B;W)A=&]R+B!5;F1E<B!T
M:&5S90T*(&%G<F5E;65N=',L(&9E97,@;6%Y(&)E(&1U92!T;R!T:&4@0V]M
M<&%N>2`H:2DF(WA!,#MA="!T:&4-"B!I;F-E<'1I;VX@;V8@=&AE(&%R<F%N
M9V5M96YT("AR969E<G)E9"!T;R!A<R`F(W@R,#%#.W5P9G)O;G0F(W@R,#%$
M.PT*(&9E97,@;W(@<&%Y;65N=',I+"`H:6DI)B-X03`[=&AE('-E;&5C=&EO
M;B!O9B!A('1A<F=E="!F;W(@80T*('!R;V=R86TL("AI:6DI)B-X03`[=7!O
M;B!T:&4@97AE<F-I<V4@;V8@86X@;W!T:6]N('1O(&%C<75I<F4@80T*(&1E
M=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!L:6-E;G-E("AR969E
M<G)E9"!T;R!A<R!E>&5R8VES90T*(&9E97,@;W(@<&%Y;65N=',@96%R;F5D
M*2!F;W(@82!P<F]G<F%M+"!O<B`H:78I)B-X03`[<V]M90T*(&-O;6)I;F%T
M:6]N(&]F(&%L;"!O9B!T:&5S92!F965S+CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
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M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.
M1$5.5#H@-"4G/@T*($9O<B!R:6=H="UT;RUD979E;&]P(&%G<F5E;65N=',@
M=VAE<F4@=&AE(&]P=&EO;G,@=&\@<V5C=7)E#0H@9&5V96QO<&UE;G0@86YD
M(&-O;6UE<F-I86QI>F%T:6]N(&QI8V5N<V5S('1O(&$@<')O9'5C="!P<F]G
M<F%M(&%R90T*(&-O;G-I9&5R960@<W5B<W1A;G1I=F4L('1H92!#;VUP86YY
M(&1O97,@;F]T(&-O;G-I9&5R('1H90T*(&1E=F5L;W!M96YT(&%N9"!C;VUM
M97)C:6%L:7IA=&EO;B!L:6-E;G-E<R!T;R!B92!A(&1E;&EV97)A8FQE(&%T
M#0H@=&AE(&EN8V5P=&EO;B!O9B!T:&4@86=R965M96YT+B!&;W(@=&AO<V4@
M<FEG:'0M=&\M9&5V96QO<`T*(&%G<F5E;65N=',@96YT97)E9"!I;G1O('!R
M:6]R('1O('1H92!A9&]P=&EO;B!O9B!!4U4-"B!.;RXF(WA!,#LR,#`Y+3$S
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M;W9E<B!T:&4@;&EF92!O9@T*('1H92!O<'1I;VXL(&=E;F5R86QL>2`Q,B!M
M;VYT:',N(%-U8G-E<75E;G0@=&\@=&AE(&%D;W!T:6]N(&]F($%350T*($YO
M+B8C>$$P.S(P,#DM,3,L('1H92!#;VUP86YY)B-X,C`Q.3MS(&5V86QU871I
M;VX@;V8@=VAE=&AE<B!T:&4-"B!O<'1I;VX@:7,@<W5B<W1A;G1I=F4@:7,@
M8V]N<VES=&5N="!W:71H('!R92UA9&]P=&EO;B!O9B!!4U4-"B!.;RXF(WA!
M,#LR,#`Y+3$S+B!(;W<@=&AE($-O;7!A;GD@9&5T97)M:6YE<R!T:&4@<V5L
M;&EN9R!P<FEC92!O9@T*('1H92!O<'1I;VX@:7,@=&AE(&]N;'D@9&EF9F5R
M96YC92!B971W965N('!R92!A;F0@<&]S="!A9&]P=&EO;B!O9@T*($%352!.
M;RXF(WA!,#LR,#`Y+3$S+B!0;W-T(&%D;W!T:6]N(&]F($%352!.;RXF(WA!
M,#LR,#`Y+3$S+"!T:&4-"B!S96QL:6YG('!R:6-E<R!O9B!D96QI=F5R86)L
M97,@=6YD97(@86X@87)R86YG96UE;G0@;6%Y(&)E(&1E<FEV960-"B!U<VEN
M9R!44$4@;W(@82!"15-0+"!I9B!64T]%(&ES(&YO="!A=F%I;&%B;&4N(%1H
M92!O8FIE8W1I=F4@;V8-"B!"15-0(&ES('1O(&1E=&5R;6EN92!T:&4@<')I
M8V4@870@=VAI8V@@=&AE($-O;7!A;GD@=V]U;&0@=')A;G-A8W0-"B!A('-A
M;&4@:68@=&AE(&5L96UE;G0@=VET:&EN('1H92!R:6=H="UT;RUD979E;&]P
M(&%G<F5E;65N="!W87,-"B!S;VQD(&]N(&$@<W1A;F1A;&]N92!B87-I<RX@
M17-T86)L:7-H:6YG($)%4U`@:6YV;VQV97,-"B!M86YA9V5M96YT)B-X,C`Q
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M03`[=&AE(&1E;&EV97)E9"!I=&5M(&AA<PT*('9A;'5E('1O('1H92!C=7-T
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M:&EN('1H92!#;VUP86YY)B-X,C`Q.3MS#0H@8V]N=')O;"X@5&AE(&%R<F%N
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M<R!A('-E<&%R871E('5N:70@;V8-"B!A8V-O=6YT:6YG+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
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M+B!-86YA9V5M96YT)B-X,C`Q.3MS(&1E=&5R;6EN871I;VX@;V8@<V5L;&EN
M9R!P<FEC90T*(&EN8VQU9&5S('-U8V@@9F%C=&]R<R!A<R!S=&%G92!O9B!D
M979E;&]P;65N="P@;6%R:V5T('!O=&5N=&EA;"!A;F0-"B!C87-H(&9L;W<@
M;6]D96QS('5S960@9'5R:6YG('1H92!N96=O=&EA=&EO;B!W:71H('1H92!C
M;VQL86)O<F%T;W(N#0H@5&AR;W5G:"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S
M+"!N;VYE(&]F(&]U<B!C;VQL86)O<F%T:6]N('!A<G1N97)S#0H@:&%D(&5X
M97)C:7-E9"!A;B!O<'1I;VXN($AO=V5V97(L(&]N92!O9B!O=7(@8V]L;&%B
M;W)A=&EO;B!P87)T;F5R<PT*(&1I9"!E;&5C="!T;R!E>&5R8VES92!A;B!O
M<'1I;VX@:6X@1F5B<G5A<GD@,C`Q-"X@4V5E($YO=&4@,3,@9F]R#0H@861D
M:71I;VYA;"!I;F9O<FUA=&EO;BX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4
M.B`T)2<^#0H@57!O;B!E>&5R8VES92!O9B!A;B!O<'1I;VX@=&\@86-Q=6ER
M92!A(&1E=F5L;W!M96YT(&%N9`T*(&-O;6UE<F-I86QI>F%T:6]N(&QI8V5N
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M8V]N<VES=&5N="!W:71H('1H92!#;VUP86YY)B-X,C`Q.3MS(&%C8V]U;G1I
M;F<@<&]L:6-Y#0H@9F]R('5P9G)O;G0@<&%Y;65N=',@;VX@97AC;'5S:79E
M(&QI8V5N<V5S("AD:7-C=7-S960@86)O=F4I+B!);@T*('1H92!E=F5N="!A
M(')I9VAT+71O+61E=F5L;W`@86=R965M96YT('=E<F4@=&\@8F4@=&5R;6EN
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M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
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M;&P@97AE<F-I<V4@:71S(&]P=&EO;G,@9F]R(&1E=F5L;W!M96YT(&%N9`T*
M(&-O;6UE<F-I86QI>F%T:6]N(&QI8V5N<V5S+CPO<#X-"B`\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E
M<V5A<F-H(&%N9"!$979E;&]P;65N="!#;W-T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#!P="<^#0H@/&(^/&D^4F5S96%R
M8V@@86YD($1E=F5L;W!M96YT($-O<W1S/"]I/CPO8CX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@
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M;VYS+`T*(&EN=F5S=&EG871I=F4@<VET97,@86YD(&-O;G-U;'1A;G1S('1H
M870@8V]N9'5C="!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS(&-L:6YI8V%L('1R
M:6%L<RP@=&AE(&-O<W0@;V8@86-Q=6ER:6YG(&%N9`T*(&UA;G5F86-T=7)I
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M;"!A8W1I=FET:65S(&%N9`T*(')E9W5L871O<GD@87!P<F]V86QS+CPO<#X-
M"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;7!R96AE;G-I=F4@26YC;VUE("A,;W-S*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB
M/CQI/D-O;7!R96AE;G-I=F4@26YC;VUE("A,;W-S*3PO:3X\+V(^/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@169F96-T:79E($IA;G5A<GDF
M(WA!,#LQ+"`R,#$R+"!T:&4@0V]M<&%N>2!A9&]P=&5D($%352`R,#$Q+3`U
M+`T*(#QI/E!R97-E;G1A=&EO;B!O9B!#;VUP<F5H96YS:79E($EN8V]M92P\
M+VD^('=H:6-H(&%M96YD960@05-##0H@5&]P:6,@,C(P+"`\:3Y#;VUP<F5H
M96YS:79E($EN8V]M93PO:3X@*"8C>#(P,4,[05-5#0H@,C`Q,2TP-28C>#(P
M,40[*3QI/BX\+VD^(%1H92!A;65N9&UE;G1S(&EN($%352`R,#$Q+3`U(')E
M<75I<F4@=&AE#0H@<')E<V5N=&%T:6]N(&]F('1H92!C;VUP<F5H96YS:79E
M(&EN8V]M92`H;&]S<RD@86YD(&ET<R!C;VUP;VYE;G1S#0H@87,@<&%R="!O
M9B!T:&4@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+B!#;VUP
M<F5H96YS:79E#0H@:6YC;VUE("AL;W-S*2!I<R!C;VUP<FES960@;V8@=&AE
M(&YE="!I;F-O;64@*&QO<W,I(&%N9"!O=&AE<@T*(&-H86YG97,@:6X@97%U
M:71Y('1H870@87)E(&5X8VQU9&5D(&9R;VT@;F5T(&EN8V]M92`H;&]S<RDN
M#0H@0V]M<')E:&5N<VEV92!I;F-O;64@*&QO<W,I(&5Q=6%L<R!N970@:6YC
M;VUE("AL;W-S*2!F;W(@=&AE('EE87)S#0H@96YD960@1&5C96UB97(F(WA!
M,#LS,2P@,C`Q,RP@,C`Q,B!A;F0@,C`Q,2X\+W`^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C
M:RUB87-E9"!#;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y3=&]C:RUB87-E9"!#
M;VUP96YS871I;VX\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@
M-"4G/@T*(%-T;V-K+6)A<V5D('!A>6UE;G1S(&%R92!A8V-O=6YT960@9F]R
M(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4-"B!P<F]V:7-I;VYS(&]F($%30R8C
M>$$P.S<Q."P@/&D^0V]M<&5N<V%T:6]N)B-X03`[)B-X,C`Q,SL@4W1O8VL-
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M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
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M871E9`T*(&%T=')I8G5T:6]N(&UE=&AO9"X@4F5C;V=N:71I;VX@;V8@<W1O
M8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4-"B!I<R!B87-E9"!O;B!T
M:&4@=F%L=64@;V8@=&AE('!O<G1I;VX@;V8@<W1O8VLM8F%S960@87=A<F1S
M('1H870@:7,-"B!U;'1I;6%T96QY(&5X<&5C=&5D('1O('9E<W0@9'5R:6YG
M('1H92!P97)I;V0N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*
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M('1H90T*(&%W87)D+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!);F-O;64@*$QO<W,I
M(%!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD
M:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#$X<'0G/@T*(#QB/CQI/DYE="!);F-O;64@*$QO<W,I(%!E<B!3
M:&%R93PO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
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M;6UO;B!S=&]C:R!E<75I=F%L96YT<RX@1&EL=71E9`T*(&EN8V]M92`H;&]S
M<RD@<&5R('-H87)E(&ES(&-O;7!U=&5D(&)Y(&1I=FED:6YG('1H92!E87)N
M:6YG<R`H;&]S<RD-"B!A='1R:6)U=&%B;&4@=&\@8V]M;6]N('-T;V-K:&]L
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M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.
M1$5.5#H@-"4G/@T*(%!R:6]R('1O('1H92!#;VUP86YY)B-X,C`Q.3MS(&EN
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M92!#;VUP86YY)B-X,C`Q.3MS($E03RX\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@0F%S:6,@86YD(&1I;'5T960@:6YC;VUE("AL;W-S*2!P
M97(@8V]M;6]N('-H87)E(&ES(&-O;7!U=&5D(&%S#0H@9F]L;&]W<SH\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L
M92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX]
M,T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-3@E
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#$P(&%L:6=N/3-$8V5N=&5R/CQB/EEE87(@16YD960-"B!$96-E;6)E<B8C
M>$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CXR,#$Q/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!.970@:6YC;VUE("AL;W-S*3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XH,C8P+#@S-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L,S8Q+#<U-3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPW,3<L,3(P/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!,97-S.B!U;F1I<W1R:6)U=&5D(&5A<FYI;F=S(&%L
M;&]C871E9"!T;R!P87)T:6-I<&%T:6YG#0H@<V5C=7)I=&EE<SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#@L,S8Q+#<U-3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#8L-S$W+#$R,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@3F5T(&EN8V]M92`H;&]S<RD@86QL;V-A8FQE('1O(&-O;6UO;B!S
M:&%R97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,C8P+#@S-3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*($)A<VEC('=E:6=H=&5D(&%V97)A9V4@8V]M
M;6]N('-H87)E<R!O=71S=&%N9&EN9SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-BPX-#<L-CDW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PP.#,L,C<V
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PP,C4L-C`R/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`\8CY"87-I8R!I
M;F-O;64@*&QO<W,I('!E<B!C;VUM;VX@<VAA<F4\+V(^/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^*#`N,#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N,#`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,"XP,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T(&EN
M8V]M92`H;&]S<RD\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,C8P+#@S-3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^."PS-C$L-S4U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L-S$W+#$R
M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@3&5S<SH@=6YD:7-T<FEB=71E9"!E87)N:6YG<R!A;&QO8V%T960@=&\@
M<&%R=&EC:7!A=&EN9R!S96-U<FET:65S#0H@86YD(&]T:&5R(&%D9"UB86-K
M<R!T;R!N970@:6YC;VUE("AL;W-S*3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@X+#,V,2PW
M-34\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#8L-S$W+#$R,#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T
M(&EN8V]M92`H;&]S<RD@86QL;V-A8FQE('1O(&-O;6UO;B!S:&%R97,\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XH,C8P+#@S-3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)A<VEC('=E:6=H=&5D(&%V
M97)A9V4@8V]M;6]N('-H87)E<R!O=71S=&%N9&EN9SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^-BPX-#<L-CDW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,2PP.#,L,C<V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PP,C4L-C`R/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!%9F9E8W0@;V8@9&EL=71I=F4@
M<V5C=7)I=&EE<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT
M/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/@T*($1I;'5T960@=V5I9VAT960@879E<F%G92!C;VUM;VX@
M<VAA<F5S(&]U='-T86YD:6YG/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV
M+#@T-RPV.3<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#`X,RPR-S8\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XQ+#`R-2PV,#(\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@/&(^1&EL=71E9"!I;F-O;64@*&QO<W,I('!E<B!C;VUM;VX@<VAA
M<F4\+V(^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,#0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C`N,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XP,#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^
M#0H@5&AE(&9O;&QO=VEN9R!C;VUM;VX@<W1O8VL@97%U:79A;&5N=',@=V5R
M92!E>&-L=61E9"!F<F]M('1H90T*(&-A;&-U;&%T:6]N(&]F(&1I;'5T960@
M;F5T(&EN8V]M92`H;&]S<RD@<&5R('-H87)E(&)E8V%U<V4@=&AE:7(-"B!E
M9F9E8W0@=V]U;&0@8F4@86YT:2UD:6QU=&EV93H\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)
M3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(@8F]R
M9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-C,E/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$
M8V5N=&5R/CQB/EEE87(@16YD960-"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CXR,#$Q/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!397)I97,@02TQ(%!R969E<G)E9"!3=&]C:SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG
M:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,BPQ-38L,3$T/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C(L,34V+#$Q-#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@4V5R:65S($$M,B!0<F5F97)R960@4W1O8VL\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,Y,BPR-S0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,SDR+#(W-#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4V5R:65S($(@
M4')E9F5R<F5D(%-T;V-K/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
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M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-"PS,S8L,#,W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!3
M97)I97,@0R!0<F5F97)R960@4W1O8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*
M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C4L.3`Y+#DP-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XU+#DP.2PY,#8\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-E<FEE<R!$(%!R969E<G)E9"!3
M=&]C:SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S8Y+#0V
M.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW-CDL-#8X
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!397)I97,@1"TR(%!R969E
M<G)E9"!3=&]C:SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,RPS.3$L.3DQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C,L,SDQ+#DY,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@169F96-T(&]F($-O;G9E<G1E9"!0<F5F97)R960@4W1O
M8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,RPQ.#DL.3(P
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5V%R<F%N=',@=&\@
M<'5R8VAA<V4@4V5R:65S($0M,B!0<F5F97)R960@4W1O8VL\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X,"PW.#0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3@P+#<X-#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4W1O8VL@3W!T:6]N
M<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,S$S+#DW,#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#(T.2PW,#(\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPX.#4L-#$W
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E8V5N=&QY($ES<W5E9"!!8V-O=6YT:6YG(%-T86YD87)D<R!!9&]P=&5D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP
M="<^#0H@/&(^/&D^4F5C96YT;'D@27-S=65D($%C8V]U;G1I;F<@4W1A;F1A
M<F1S($%D;W!T960\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@
M-"4G/@T*($EN($IU;'D@,C`Q,RP@=&AE($9!4T(@:7-S=65D($%352!.;RXF
M(WA!,#LR,#$S+3$Q+"!W:&EC:"!A;65N9&5D#0H@05-#(%1O<&EC(#<T,"!R
M96=A<F1I;F<@<')E<V5N=&%T:6]N(&]F(&%N('5N<F5C;V=N:7IE9"!T87@@
M8F5N969I=`T*('=H96X@82!N970@;W!E<F%T:6YG(&QO<W,@*"8C>#(P,4,[
M3D],)B-X,C`Q1#LI(&-A<G)Y9F]R=V%R9"P@80T*('-I;6EL87(@=&%X(&QO
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M;&4@:G5R:7-D:6-T:6]N(&%N9"`H,BDF(WA!,#MT:&4-"B!E;G1I='D@:6YT
M96YD<R!T;R!U<V4@=&AE(&1E9F5R<F5D('1A>"!A<W-E="!F;W(@=&AA="!P
M=7)P;W-E+B!4:&4-"B!!4U4@9&]E<R!N;W0@<F5Q=6ER92!N97<@<F5C=7)R
M:6YG(&1I<V-L;W-U<F5S+B!4:&ES(&%M96YD;65N="!I<PT*(&5F9F5C=&EV
M92!P<F]S<&5C=&EV96QY(&9O<B!F:7-C86P@>65A<G,@8F5G:6YN:6YG(&%F
M=&5R#0H@1&5C96UB97(F(WA!,#LQ-2P@,C`Q,RX@5&AE($-O;7!A;GD@9&]E
M<R!N;W0@8F5L:65V92!T:&ES(&%M96YD;65N=`T*('=I;&P@:&%V92!A(&UA
M=&5R:6%L(&EM<&%C="!O;B!I=',@9FEN86YC:6%L('-T871E;65N=',N/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY(&AA
M<R!E=F%L=6%T960@86QL($%357,@=&AR;W5G:"!T:&4@9&%T92!T:&4-"B!C
M;VYS;VQI9&%T960@9FEN86YC:6%L<R!W97)E(&ES<W5E9"!A;F0@8F5L:65V
M97,@=&AA="!T:&4@861O<'1I;VX-"B!O9B!T:&5S92!W:6QL(&YO="!H879E
M(&$@;6%T97)I86P@:6UP86-T(&]N('1H92!#;VUP86YY)B-X,C`Q.3MS#0H@
M8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO<#X-"B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R
M.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\V,CEC-&)C85]C9&$W7S1D865?830T-5\Q
M,C0U864R-#AC.30O5V]R:W-H965T<R]3:&5E=#(Q+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M6$I!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI
M9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*%1A8FQE<RD\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@1F%I
M<B!686QU92!-96%S=7)E;65N="!&:6YA;F-I86P@07-S970@86YD($QI86)I
M;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/
M4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!&:6YA;F-I86P@87-S971S
M(&%N9"!L:6%B:6QI=&EE<R!S=6)J96-T('1O(&9A:7(@=F%L=64@;65A<W5R
M96UE;G1S#0H@=V5R92!A<R!F;VQL;W=S.CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/
M4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]2
M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(]
M,T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0S."4^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,30@86QI9VX],T1C96YT97(^/&(^1F%I<B!686QU
M92!-96%S=7)E;65N=',@870-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E%U;W1E9"8C>$$P
M.U!R:6-E<R8C>$$P.VEN/&)R("\^#0H@06-T:79E($UA<FME=',\8G(@+SX-
M"B!F;W(\8G(@+SX-"B!)9&5N=&EC86P@07-S971S/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY3:6=N:69I8V%N="8C>$$P
M.T]T:&5R/&)R("\^#0H@3V)S97)V86)L93QB<B`O/@T*($EN<'5T<SPO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^4VEG;FEF
M:6-A;G0\8G(@+SX-"B!5;F]B<V5R=F%B;&4\8G(@+SX-"B!);G!U=',\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&(^5&]T86P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/CQB/DQE=F5L(#$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R/CQB/DQE=F5L(#(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#,\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($%S<V5T<SH\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-A<V@@86YD
M(&-A<V@@97%U:79A;&5N=',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M.3`L-#,T+#0S-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.3`L-#,T+#0S
M-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@36]N
M97D@;6%R:V5T(&9U;F1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,C8L,#0V+#DW-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR
M-BPP-#8L.3<T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4F5S
M=')I8W1E9"!C87-H/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-#`T+#@U,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,#0L.#4P
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@5&]T86P@07-S971S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$V+#@X
M-BPR-3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$V+#@X-BPR-3D\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H
M=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P
M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(^#0H@/'1D/CPO=&0^#0H@/'1D(&-O;'-P86X],T0Q-CX\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q-"!A
M;&EG;CTS1&-E;G1E<CX\8CY&86ER(%9A;'5E($UE87-U<F5M96YT<R!A=`T*
M($1E8V5M8F5R)B-X03`[,S$L(#(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&(^475O=&5D)B-X03`[4')I8V5S)B-X03`[:6X\8G(@
M+SX-"B!!8W1I=F4@36%R:V5T<SQB<B`O/@T*(&9O<CQB<B`O/@T*($ED96YT
M:6-A;"!!<W-E=',\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R/CQB/E-I9VYI9FEC86YT)B-X03`[3W1H97(\8G(@+SX-"B!/8G-E
M<G9A8FQE/&)R("\^#0H@26YP=71S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\8CY3:6=N:69I8V%N=#QB<B`O/@T*(%5N;V)S
M97)V86)L93QB<B`O/@T*($EN<'5T<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY4;W1A;#PO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3&5V96P@,3PO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3&5V96P@
M,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M3&5V96P@,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@07-S971S.CPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ."PV.34L,3DW/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ."PV.34L,3DW/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT
M/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*
M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!-;VYE>2!M87)K970@9G5N9',\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR.2PP-#<L.34X/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Y+#`T-RPY-3@\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!297-T<FEC=&5D(&-A<V@\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,#0L.#4P/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C0P-"PX-3`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A;"!!<W-E=',\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XT."PQ-#@L,#`U/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C0X+#$T."PP,#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($QI86)I;&ET:65S.CPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!0<F5F97)R960@<W1O8VL@=V%R<F%N="!L:6%B:6QI='D\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XH-3(L.30W/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^*#4R+#DT-SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(%!R969E
M<G)E9"!3=&]C:R!787)R86YT($QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E
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M;&4@:6YP=71S("A,979E;"`S*2!A<R!D969I;F5D(&EN($%30PT*(#@R,#H\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT
M86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0V."4@86QI
M9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$
M.#(E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X\
M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!"86QA;F-E(&%T($1E8V5M8F5R
M)B-X03`[,S$L(#(P,3(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-3(L.30W/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^#0H@5&]T86P@=6YR96%L:7IE9"!G86EN<R`H
M;&]S<V5S*2!I;F-L=61E9"!I;B!E87)N:6YG<SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^*#8R-BPS-#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!3971T;&5M96YT(&]F('!R969E<G)E9"!S=&]C:R!W
M87)R86YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-C<Y+#(Y-CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@0F%L86YC92!A="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T
M86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5S=&EM871E9"!5<V5F=6P@3&EV97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M
M24Y$14Y4.B`T)2<^#0H@4F5P86ER<R!A;F0@;6%I;G1E;F%N8V4@8V]S=',@
M87)E(&5X<&5N<V5D(&%S(&EN8W5R<F5D+@T*($1E<')E8VEA=&EO;B!I<R!C
M;VUP=71E9"!U<VEN9R!T:&4@<W1R86EG:'0M;&EN92!M971H;V0@;W9E<B!T
M:&4-"B!F;VQL;W=I;F<@97-T:6UA=&5D('5S969U;"!L:79E<SH\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R
M<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$
M8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4Q)3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X\+W1D/@T*
M(#QT9"!W:61T:#TS1#0W)3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#;VUP=71E<B!E
M<75I<&UE;G0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XS('EE87)S
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@4V]F='=A<F4\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XS('EE87)S/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1G5R;FET=7)E
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^,3`@>65A<G,\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!,86)O<F%T;W)Y(&%N9"!O9F9I8V4@97%U:7!M96YT/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^-2!Y96%R<SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($QE87-E:&]L9"!I;7!R;W9E;65N=',\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3Y3:&]R=&5R(&]F(&QE87-E('1E<FT@;W(@=7-E9G5L
M(&QI9F4\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!U
M=&%T:6]N(&]F($)A<VEC(&%N9"!$:6QU=&5D($EN8V]M92`H3&]S<RD@4&5R
M($-O;6UO;B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@0F%S:6,@86YD
M(&1I;'5T960@:6YC;VUE("AL;W-S*2!P97(@8V]M;6]N('-H87)E(&ES(&-O
M;7!U=&5D(&%S#0H@9F]L;&]W<SH\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P
M="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#
M3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-
M"B`\='(^#0H@/'1D('=I9'1H/3-$-3@E/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R/CQB
M/EEE87(@16YD960-"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR
M,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R
M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$Q/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!.970@:6YC;VUE("AL;W-S*3PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,C8P+#@S-3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C@L,S8Q+#<U-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-BPW,3<L,3(P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!,97-S.B!U
M;F1I<W1R:6)U=&5D(&5A<FYI;F=S(&%L;&]C871E9"!T;R!P87)T:6-I<&%T
M:6YG#0H@<V5C=7)I=&EE<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M*#@L,S8Q+#<U-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#8L-S$W+#$R
M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T(&EN8V]M92`H;&]S
M<RD@86QL;V-A8FQE('1O(&-O;6UO;B!S:&%R97,\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XH,C8P+#@S-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*
M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)A
M<VEC('=E:6=H=&5D(&%V97)A9V4@8V]M;6]N('-H87)E<R!O=71S=&%N9&EN
M9SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPX-#<L-CDW/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,2PP.#,L,C<V/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,2PP,C4L-C`R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B`\8CY"87-I8R!I;F-O;64@*&QO<W,I('!E<B!C;VUM
M;VX@<VAA<F4\+V(^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,#0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C`N,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XP,#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@3F5T(&EN8V]M92`H;&]S<RD\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XH,C8P+#@S-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^."PS-C$L-S4U/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C8L-S$W+#$R,#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3&5S<SH@=6YD:7-T<FEB=71E
M9"!E87)N:6YG<R!A;&QO8V%T960@=&\@<&%R=&EC:7!A=&EN9R!S96-U<FET
M:65S#0H@86YD(&]T:&5R(&%D9"UB86-K<R!T;R!N970@:6YC;VUE("AL;W-S
M*3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B@X+#,V,2PW-34\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M*#8L-S$W+#$R,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T(&EN8V]M92`H;&]S<RD@86QL;V-A
M8FQE('1O(&-O;6UO;B!S:&%R97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,C8P
M+#@S-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($)A<VEC('=E:6=H=&5D(&%V97)A9V4@8V]M;6]N('-H87)E<R!O
M=71S=&%N9&EN9SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPX-#<L-CDW
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PP.#,L,C<V/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,2PP,C4L-C`R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!%9F9E8W0@;V8@9&EL=71I=F4@<V5C=7)I=&EE<SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H
M=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1I;'5T960@
M=V5I9VAT960@879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#@T-RPV.3<\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ+#`X,RPR-S8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M+#`R-2PV,#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@/&(^1&EL=71E9"!I;F-O
M;64@*&QO<W,I('!E<B!C;VUM;VX@<VAA<F4\+V(^/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^*#`N,#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N,#`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,"XP,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y38VAE9'5L92!O9B!$:6QU=&EV92!396-U<FET:65S(%5S960@
M26X@0V%L8W5L871I;VX@;V8@1&EL=71E9"!%87)N:6YG<R!097(@4VAA<F4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T
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M5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-
M"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E
M(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T
M:#TS1#8S)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX\8CY996%R($5N9&5D#0H@1&5C
M96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,CPO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,3PO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^#0H@4V5R:65S($$M,2!0<F5F97)R960@4W1O
M8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,34V+#$Q
M-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#$U-BPQ
M,30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
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M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XS.3(L,C<T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C,Y,BPR-S0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*(%-E<FEE<R!"(%!R969E<G)E9"!3=&]C:SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PS,S8L,#,W/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L,S,V+#`S-SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@4V5R:65S($,@4')E9F5R<F5D(%-T;V-K/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#DP.2PY,#8\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2PY,#DL.3`V/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!3
M97)I97,@1"!0<F5F97)R960@4W1O8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*
M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C<V.2PT-C@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^-S8Y+#0V.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@4V5R:65S($0M,B!0<F5F97)R960@4W1O8VL\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I
M9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C,L,SDQ+#DY,3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XS+#,Y,2PY.3$\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5F9F5C="!O9B!#;VYV
M97)T960@4')E9F5R<F5D(%-T;V-K/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,3,L,3@Y+#DR,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*
M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^
M#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
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M;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M.#`L-S@T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X
M,"PW.#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*(%-T;V-K($]P=&EO;G,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XR+#,Q,RPY-S`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,RPR-#DL-S`R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C(L.#@U+#0Q-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(%-I9VYI9FEC86YT(%)E
M=F5N=64@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-U;6UA<GD@;V8@4&5R8V5N=&%G92!O9B!#=7-T;VUE<B!#;VYC96YT
M<F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/
M4#H@,'!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!F;VQL;W=I;F<@=&%B
M;&4@<F5P<F5S96YT<R!T:&4@<&5R8V5N=&%G92!O9B!A;&P@<VEG;FEF:6-A
M;G0-"B!R979E;G5E(&5A<FYE9"!I;B!T:&4@<&5R:6]D<R!I;F1I8V%T960Z
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\
M=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#0E(&%L
M:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS
M1#8V)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,3`@86QI9VX],T1C96YT97(^#0H@/&(^665A<B8C>$$P.T5N9&5D
M)B-X03`[1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^#0H@/&(^)B-X03`[
M)B-X03`[)B-X03`[)B-X03`[,C`Q,R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P
M.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^#0H@/&(^)B-X
M03`[)B-X03`[)B-X03`[)B-X03`[,C`Q,B8C>$$P.R8C>$$P.R8C>$$P.R8C
M>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^#0H@/&(^
M)B-X03`[)B-X03`[)B-X03`[)B-X03`[,C`Q,28C>$$P.R8C>$$P.R8C>$$P
M.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4V5R=FEE<CPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4Q+C8\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$W+C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)O96AR
M:6YG97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-"XX/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ."XT/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XQ-2XV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@1VEL96%D/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,3,N.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!09FEZ97(\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XV+C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C@N-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3`N.#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($=O=F5R;FUE;G0@06=E
M;F-I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+C(\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N-3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,3<N-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5L:2!,:6QL>3PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N-#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-#@N.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-30N,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT<R!296-E:79A8FQE6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA
M<GD@;V8@4&5R8V5N=&%G92!O9B!#=7-T;VUE<B!#;VYC96YT<F%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE(')E<')E
M<V5N=',@=&AE('!E<F-E;G1A9V4@;V8@86QL('-I9VYI9FEC86YT#0H@86-C
M;W5N=',@<F5C96EV86)L93H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^
M#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,
M05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0W-B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\
M='(^#0H@/'1D('=I9'1H/3-$-S4E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$Q)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG
M;CTS1&-E;G1E<CX\8CY$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX-"B`\
M8CXF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LR,#$S)B-X03`[)B-X03`[)B-X
M03`[)B-X03`[/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX-
M"B`\8CXF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LR,#$R)B-X03`[)B-X03`[
M)B-X03`[)B-X03`[/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!':6QE
M860\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU,RXT/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!09FEZ97(N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,3(N,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#4N-#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)O96AR
M:6YG97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,BXR/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ."XP/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@16QI($QI;&QY/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-RXP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR."XR/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4V5R=FEE<CPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N-#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-
M"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@1V]V97)N;65N="!!9V5N8VEE<SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C0N-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^."XT
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@*%1A
M8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4')O<&5R='D@4&QA;G0@06YD($5Q=6EP;65N="!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y38VAE9'5L92!O9B!0<F]P97)T>2!A;F0@17%U:7!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C9P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT
M.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N)SX-"B!0<F]P97)T>2!A;F0@97%U:7!M96YT(&-O;G-I<W1S(&]F('1H
M92!F;VQL;W=I;F<Z/"]P/@T*(#QP('-T>6QE/3-$9F]N="US:7IE.C$R<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0^#0H@)B-X03`[/"]P
M/@T*(#QT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$-S8E(&)O<F1E<CTS1#`@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%
M.D-/3$Q!4%-%.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M
M<VEZ93HQ,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`\='(^#0H@/'1D('=I9'1H
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M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ,2XP,'!T('-O;&ED(",P,#`P,#`G/CQB/D1E
M8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.CAP="<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ,2XP,'!T('-O;&ED(",P,#`P,#`G/CQB/C(P,3,\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3HQ+C`P<'0@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B
M9V-O;&]R/3-$(T-#145&1B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E
M;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;B<^#0H@0V]M<'5T97(@97%U:7!M96YT/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C(L,S<Y+#(U-#PO=&0^#0H@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,BPP,#,L-S`V/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US
M:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT
M+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!3
M;V9T=V%R93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-#<W
M+#0Q-CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#,R,RPP.#$\
M+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%
M1D8@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT
M+7-I>F4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O
M;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*
M($9U<FYI='5R93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4Y
M.2PV-3`\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3DY+#8U,#PO
M=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=F;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E
M;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@3&%B(&5Q=6EP;65N=#PO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q+#$V-BPV,3D\+W1D/@T*
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^."PW-#<L-SDP/"]T9#X-"B`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P
M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!/9F9I8V4@97%U
M:7!M96YT/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3$L,S8P
M/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4Q+#,V,#PO=&0^#0H@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=F;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;B<^#0H@3&5A<V5H;VQD(&EM<')O=F5M96YT<SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L.#DS+#<W,#PO=&0^
M#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#@X,2PW,#8\+W1D/@T*(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P
M,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C
M,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P
M,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,RXP
M,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!0<F]P97)T>2!A;F0@97%U
M:7!M96YT/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,"PU-C@L,#8Y/"]T9#X-
M"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T1F;VYT+7-I>F4Z.'!T/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,3<L-C`W+#(Y,SPO=&0^#0H@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N
M,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;B<^#0H@3&5S<R!A8V-U;75L871E9"!D97!R96-I871I;VX\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N
M="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B@Q-2PU,S(L.#,W/"]T9#X-"B`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XI)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE.CAP=#XF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q
M-"PS,SDL-#DW/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1&9O
M;G0M<VEZ93HQ<'@[/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P
M>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X
M('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ
M+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I
M>F4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M
M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M
M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(%!R
M;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L
M,#,U+#(S,CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#(V-RPW.38\+W1D/@T*(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P,#`P,#`G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P,#`P,#`G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C
M,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C
M,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,CEC-&)C85]C9&$W7S1D865?830T
M-5\Q,C0U864R-#AC.30-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M-C(Y8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X8SDT+U=O<FMS:&5E
M=',O4VAE970R,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14M(/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-H87)E9"U"87-E9"!087EM96YT<R`H5&%B;&5S*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$:7-C
M;&]S=7)E($]F($-O;7!E;G-A=&EO;B!296QA=&5D($-O<W1S(%-H87)E8F%S
M960@4&%Y;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@4W1O8VLM0F%S960@
M0V]M<&5N<V%T:6]N($5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B!4:&4@9F]L;&]W:6YG('-T;V-K
M+6)A<V5D(&-O;7!E;G-A=&EO;B!A;6]U;G1S('=E<F4@<F5C;V=N:7IE9"!F
M;W(-"B!T:&4@<&5R:6]D<R!I;F1I8V%T960Z/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM
M5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$.#0E(&%L:6=N/3-$8V5N=&5R(&)O<F1E
M<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4Y)3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0U)3X\+W1D/@T*(#QT9#X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0U)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)3X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E
M;G1E<CX\8CY996%R($5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&(^,C`Q,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C4P-RPQ-#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C0W,2PX,#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,#$X
M+#DS-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1V5N97)A;"!A;F0@
M861M:6YI<W1R871I=F4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XS-34L,#(P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C,V-BPU.#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,2PS,C@L-3`T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*(%1O=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E
M;G-E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.#8R+#$V,CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XX,S@L,SDU/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L
M,S0W+#0S.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L
M93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($9A:7(@5F%L=64@3W!T:6]N($%W
M87)D($5S=&EM871E9"!O;B!T:&4@1&%T92!O9B!'<F%N="!5<VEN9R!T:&4@
M0FQA8VLM4V-H;VQE<R!/<'1I;VXM4')I8VEN9R!-;V1E;#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@5&AE(&9A:7(@=F%L=64@;V8@96%C:"!O<'1I;VX@87=A
M<F0@:7,@97-T:6UA=&5D(&]N('1H92!D871E(&]F#0H@9W)A;G0@=7-I;F<@
M=&AE($)L86-K+5-C:&]L97,@;W!T:6]N+7!R:6-I;F<@;6]D96P@=7-I;F<@
M=&AE#0H@87-S=6UP=&EO;G,@:6X@=&AE(&9O;&QO=VEN9R!T86)L93H\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L
M92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@86QI9VX]
M,T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-3DE
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#4@86QI9VX],T1C96YT97(^/&(^665A<B!%
M;F1E9"!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&(^,C`Q,CPO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CX\8CXR,#$Q/"]B
M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X<&5C=&5D
M(&1I=FED96YD('EI96QD+BX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1&-E;G1E<CXP)3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1C96YT97(^,"4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M8V5N=&5R/C`E/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@17AP96-T960@=F]L871I;&ET
M>3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)U=(251%+5-004-%.B!N;W=R87`G/C4S)28C>$$P
M.RTF(WA!,#LV-R4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1&-E;G1E<CXU,24\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M8V5N=&5R/C8R)3PO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M(%)I<VLM9G)E92!I;G1E<F5S="!R871E/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1C96YT97(^,2XR-"4F(WA!,#LM)B-X03`[,BXQ
M.24\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/C$N,3@E
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CXQ+C,U)3PO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
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M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CXW)B-X03`[>65A
M<G,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/C<F(WA!
M,#MY96%R<SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X
M<&5C=&5D(&9O<F9E:71U<F4@<F%T92XN/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G5TA)5$4M
M4U!!0T4Z(&YO=W)A<"<^-2XP-B4F(WA!,#LM)B-X03`[-2XU-R4\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CXU+C4W)3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^-2XU."4\+W1D
M/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(%-T
M;V-K($]P=&EO;B!!8W1I=FET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE
M(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S('-T;V-K(&]P=&EO;B!A8W1I
M=FET>2!F;W(@,C`Q,SH\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@
M)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!3
M13H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^
M#0H@/'1D('=I9'1H/3-$-#(E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#DE/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#DE/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@86QI9VX],T1C96YT97(^/&(^4VAA<F5S/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY796EG:'1E9"T\8G(@+SX-"B!!=F5R
M86=E/&)R("\^#0H@17AE<F-I<V4F(WA!,#M0<FEC93PO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G
M5TA)5$4M4U!!0T4Z(&YO=W)A<"<^5V5I9VAT960M079E<F%G93PO9F]N=#X\
M8G(@+SX-"B!296UA:6YI;F<\8G(@+SX-"B!#;VYT<F%C='5A;"8C>$$P.U1E
M<FT\8G(@+SX-"B`H665A<G,I/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX\8CY!9V=R96=A=&4\8G(@+SX-"B!);G1R:6YS:6,\
M8G(@+SX-"B!686QU93QB<B`O/@T*("AI;B8C>$$P.W1H;W5S86YD<RD\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]U='-T86YD:6YG+"!$96-E;6)E
M<B8C>$$P.S,Q+"`R,#$R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,RPR-#DL-30Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+CDT/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<N,SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($=R86YT960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
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M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,3`N-S`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@17AE<F-I<V5D/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$L,C8X+#`T.3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,"XX-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!&;W)F96ET960@;W(@97AP
M:7)E9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@X-RPV,S4\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N,3$\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M3W5T<W1A;F1I;F<L($1E8V5M8F5R)B-X03`[,S$L(#(P,3,\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C,L,C`P+#DU.#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C0N.3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+CD\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^-C<L-3,R/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*($1E8V5M8F5R)B-X03`[,S$L(#(P,3,Z/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X97)C:7-A
M8FQE/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#8X."PR-3$\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XP+CDT/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-"XX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#(L,S$Q
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!697-T960@86YD(&5X<&5C
M=&5D('1O('9E<W0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L,#(R+#DT
M.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0N-C0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XV+C@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XV-"PU-S0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*
M(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?-C(Y8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X8SDT#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A7V-D83=?-&1A95]A
M-#0U7S$R-#5A93(T.&,Y-"]7;W)K<VAE971S+U-H965T,C0N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5+2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O;64@5&%X97,@
M*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^26YC;VUE(%1A>"!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;7!O;F5N=',@;V8@=&AE($-O;7!A;GDG<R!$969E<G)E9"!487@@07-S971S
M("A,:6%B:6QI=&EE<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!S:6=N
M:69I8V%N="!C;VUP;VYE;G1S(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&1E
M9F5R<F5D('1A>`T*(&%S<V5T<R`H;&EA8FEL:71I97,I('=E<F4@87,@9F]L
M;&]W<SH\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P
M/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W
M-B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I
M9'1H/3-$-C$E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#@E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^/&(^
M1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,SPO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@1&5F97)R960@:6YC;VUE('1A>"!A<W-E=',Z/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1F5D97)A
M;"!5+E,N(&YE="!O<&5R871I;F<@;&]S<R!C87)R>69O<G=A<F0\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,S8L-38Q+#$Y-3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,S4L,S,P+#$V-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4W1A=&4@;F5T(&]P97)A=&EN9R!L
M;W-S(&-A<G)Y9F]R=V%R9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C,L,S$U+#4Q-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS
M+#4R,2PW,C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)E<V5A<F-H
M(&%N9"!D979E;&]P;65N="!C<F5D:70L(&YE=#PO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C,L-S@U+#8Q,CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XR+#<W-RPX.3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*($]R<&AA;B!D<G5G(&-R961I="P@;F5T
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3DL.#@S+#`W-CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ.2PP,SDL-C$S/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!$969E<G)E9"!R96YT/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2PQ,S(L-#4X/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C4L,C$X+#`P,CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1&5F97)R960@<F5V96YU
M93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L,C$V+#8Y-3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY+#,W.2PP-C0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*($1E<')E8VEA=&EO;CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-#,X+#0W-SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ+#(T-RPW-S(\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]T:&5R/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PT,S@L.#<P/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$L-3<U+#<X,CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($=R;W-S
M(&1E9F5R<F5D(&EN8V]M92!T87@@87-S971S/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XW.2PW-S$L.#DW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S@L
M,#DP+#`R,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@5F%L=6%T:6]N(&%L;&]W86YC93PO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^*#<Y+#,W-BPY-#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#<X+#`Y
M,"PP,C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@3F5T(&1E9F5R<F5D(&EN8V]M92!T87@@87-S971S
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS.30L.34R/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-
M"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1&5F97)R960@:6YC;VUE('1A>"!L
M:6%B:6QI=&EE<SH\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3W1H97(\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@S.30L.34R/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!'<F]S<R!D969E<G)E9"!I;F-O;64@=&%X(&QI86)I;&ET:65S/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,SDT+#DU,CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P
M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!.
M970@9&5F97)R960@:6YC;VUE('1A>"!A<W-E="\H;&EA8FEL:71Y*3PO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG
M:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E8V]N8VEL:6%T:6]N(&]F(%)E<&]R=&5D($5S=&EM871E9"!);F-O;64@
M5&%X($)E;F5F:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!R96-O;F-I
M;&EA=&EO;B!O9B!T:&4@<F5P;W)T960@97-T:6UA=&5D(&EN8V]M92!T87@@
M8F5N969I="!T;PT*('1H92!A;6]U;G0@=&AA="!W;W5L9"!R97-U;'0@8GD@
M87!P;'EI;F<@=&AE(%4N4RX@9F5D97)A;"!S=&%T=71O<GD-"B!T87@@<F%T
M92!T;R!T:&4@;F5T(&EN8V]M92!I<R!A<R!F;VQL;W=S.CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@
M34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E
M<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U,R4^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI
M9VX],T1C96YT97(^/&(^665A<B!%;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L
M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/CQB/C(P,3$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%5N:71E
M9"!3=&%T97,@9F5D97)A;"!T87@@870@<W1A='5T;W)Y(')A=&4\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#DQ+#(Y,SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C(L.3(V+#8Q-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPS-3`L
M.3DR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!3=&%T92!T87AE<R`H
M;F5T(&]F(&9E9&5R86P@8F5N969I="D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XV,#DL-#<V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$L-#8P+#(X.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M+#0X,"PQ.#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($1E9F5R<F5D(&EN8V]M92!T87@@861J=7-T;65N=',\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH.#4U+#$S,#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^*#4Q,BPS-S4\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M($1E9F5R<F5D('-T871E(&)L96YD960@<F%T92!A9&IU<W1M96YT<SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@S-#0L,3<X/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I
M9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^
M#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)E<V5A<F-H(&-R961I="P@;F5T
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(R-2PV,#4\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@3W)P:&%N(&1R=6<@8W)E9&ET+"!N970\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XH.#0S+#0V,SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#0L.#DU+#8W,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^*#<L,#4V+#8P-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($]T:&5R('!E<FUA;F5N="!I=&5M<SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C(L.3,Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C<L-C(W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C0L-CDV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!%<75I='DM8F%S
M960@8V]M<&5N<V%T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,C0Q+#0V-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-SDL
M,38U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<R-2PX,3$\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($9A
M:7(@=F%L=64@861J=7-T;65N="!O9B!P<F5F97)R960@<W1O8VL@=V%R<F%N
M="!L:6%B:6QI='D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR
M,3@L.#<R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U,BPW-#,\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@T.38L,C`X/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@0VAA;F=E(&EN('9A;'5A=&EO;B!A;&QO=V%N8V4\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#(X-BPY,C,\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S@W+#`Y,SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XR+#DY,2PQ,S$\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@26YC;VUE('1A>"!E>'!E;G-E+RAB96YE9FET*3PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;VYC:6QI
M871I;VX@;V8@=&AE($)E9VEN;FEN9R!A;F0@16YD:6YG($%M;W5N="!O9B!'
M<F]S<R!5;G)E8V]G;FEZ960@5&%X($)E;F5F:71S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z
M(#0E)SX-"B!!(')E8V]N8VEL:6%T:6]N(&]F('1H92!B96=I;FYI;F<@86YD
M(&5N9&EN9R!A;6]U;G0@;V8@9W)O<W,-"B!U;G)E8V]G;FEZ960@=&%X(&)E
M;F5F:71S(&ES(&%S(&9O;&QO=W,Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P
M<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M
M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$.#0E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^
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M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX\
M8CY996%R($5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^,C`Q,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C
M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0F5G:6YN
M:6YG(&)A;&%N8V4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PU.3(L
M,S4W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#4S,RPY.#8\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,C0V+#`R-3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@26YC<F5A<V5S+RAD96-R96%S97,I
M(&9O<B!C=7)R96YT('EE87(@=&%X('!O<VET:6]N<SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$Q-2PU,#(\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-3@L,S<Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C(X-RPY-C$\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
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M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*($1E8W)E87-E<R!A<R!A(')E<W5L="!O9B!E>'!I
M<F%T:6]N(&]F('-T871U=&4@;V8@;&EM:71A=&EO;G,\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!%;F1I;F<@8F%L
M86YC93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-S`W+#@U.3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ+#4Y,BPS-3<\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,2PU,S,L.3@V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-C(Y8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X
M8SDT#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A7V-D
M83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-"]7;W)K<VAE971S+U-H965T,C4N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4R1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY,96%S
M92!%>&ET($QI86)I;&ET>2`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-T<G5C='5R:6YG($%N
M9"!296QA=&5D($%C=&EV:71I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E<R!I;B!,96%S
M92!%>&ET($QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@0VAA;F=E
M<R!I;B!T:&4@;&5A<V4@97AI="!L:6%B:6QI='D@87)E(&%S(&9O;&QO=W,Z
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\
M=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-C@E(&%L
M:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS
M1#<Y)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\
M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!!8V-R=6%L(&)A;&%N8V4@870@
M1&5C96UB97(F(WA!,#LS,2P@,C`Q,3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^)#$P+#8P-RPT.3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%!R
M:6YC:7!A;"!P87EM96YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#4S
M,RPU-C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!!8V-R=6%L(&)A;&%N
M8V4@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,CPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,3`L,#<S+#DS.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@4')I;F-I<&%L('!A>6UE;G1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XH-C(X+#<V.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%C8W)U86P@
M8F%L86YC92!A="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XD.2PT-#4L,3<P/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE
M/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1G5T=7)E(%!R:6YC:7!A;"!087EM96YT<R!5;F1E<B!,
M96%S92!!9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($9U='5R92!P
M<FEN8VEP86P@<&%Y;65N=',@=&\@8F4@;6%D92!U;F1E<B!T:&4@;&5A<V4@
M86=R965M96YT(&9O<@T*('1H92!N97AT(&9I=F4@>65A<G,@86YD('1H97)E
M869T97(@87,@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q,R!A<F4-"B!A<R!F
M;VQL;W=S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\
M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#8X)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@
M=VED=&@],T0X,"4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$."4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@,C`Q-#PO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C$L-#,X+#<T,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@,C`Q-3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PV-#$L.3`U
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B`R,#$V/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#@V-BPP,S$\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#(P,3<\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C(L,3$S+#$Q.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^#0H@,C`Q.#PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,BPS.#4L,S<T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4
M:&5R96%F=&5R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDL-#0U+#$W,#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R.6,T8F-A7V-D83=?-&1A95]A
M-#0U7S$R-#5A93(T.&,Y-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\V,CEC-&)C85]C9&$W7S1D865?830T-5\Q,C0U864R-#AC.30O5V]R:W-H
M965T<R]3:&5E=#(V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@*%1A8FQE
M<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V]M;6ET;65N=',@06YD($-O;G1I;F=E;F-I97,@1&ES8VQO<W5R
M92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!-:6YI;75M($9U='5R92!,96%S92!0
M87EM96YT<R!087EA8FQE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!&=71U<F4@
M;6EN:6UU;2!L96%S92!P87EM96YT<R!U;F1E<B!N;VYC86YC96QA8FQE(&]P
M97)A=&EN9R!L96%S97,-"B!A="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S(&%R
M92!A<R!F;VQL;W=S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F
M(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%
M.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#8X)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-
M"B`\=&0@=VED=&@],T0W.24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C
M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@,C`Q-#PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#8U,2PT,C$\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*(#(P,34\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XS+#,Q,"PX.#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*(#(P,38\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XS+#0Q,"PR,3`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*(#(P,3<\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS
M+#4Q,BPU,3<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*(#(P,3@\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XR+#<X,"PS.3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1H97)E
M869T97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$V+#8V-2PT
M,S`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E%U87)T97)L>2!&:6YA;F-I86P@26YF;W)M871I;VX@
M*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^475A<G1E<FQY($9I;F%N8VEA;"!);F9O<FUA=&EO;B!$
M:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!A;GDG<R!#;VYS;VQI9&%T960@475A
M<G1E<FQY(%)E<W5L=',@;V8@3W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]2
M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(]
M,T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U-"4^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXQ/'-U<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#@U)3L@5D525$E#04PM04Q)1TXZ('1O<"<^<W0\
M+W-U<#XF(WA!,#M1=6%R=&5R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\8CXR/'-U<"!S='EL93TS1"=&3TY4+5-)6D4Z(#@U)3L@5D52
M5$E#04PM04Q)1TXZ('1O<"<^;F0\+W-U<#XF(WA!,#M1=6%R=&5R/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXS/'-U<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#@U)3L@5D525$E#04PM04Q)1TXZ('1O<"<^<F0\+W-U
M<#XF(WA!,#M1=6%R=&5R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CXT/'-U<"!S='EL93TS1"=&3TY4+5-)6D4Z(#@U)3L@
M5D525$E#04PM04Q)1TXZ('1O<"<^=&@\+W-U<#XF(WA!,#M1=6%R=&5R/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$T(&%L:6=N
M/3-$8V5N=&5R/CQB/BAI;B!T:&]U<V%N9',L#0H@97AC97!T('!E<B!S:&%R
M92!D871A*3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@/&(^,C`Q,SPO
M8CX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*(%)E=F5N=64\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,3`L-3DX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
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M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,30L.3`V/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!.970@:6YC;VUE("AL;W-S*3PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@S+#,V-CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^*#(Y-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-BPV,#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M*#,L,C`U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T(&EN8V]M92`H;&]S
M<RD@<&5R('-H87)E+"!B87-I8SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XH,BXY,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C(T/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,"XQ-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M*#`N,30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!.970@:6YC;VUE("AL;W-S*2!P97(@<VAA<F4L(&1I;'5T960\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(N.3,\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XH,"XR-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N,#$\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B@P+C$T/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@/&(^,C`Q,CPO8CX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M(%)E=F5N=64\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C`L-3$P/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-RPT,S4\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C$V+#`X,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^.2PW.3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($YE="!I;F-O
M;64@*&QO<W,I/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PS
M,C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPU-#8\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPV,#$\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(L,3`U/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3F5T(&EN8V]M92`H;&]S<RD@<&5R
M('-H87)E+"!B87-I8SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C`P
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C`P/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XP+C`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XH,2XY,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($YE="!I;F-O;64@*&QO
M<W,I('!E<B!S:&%R92P@9&EL=71E9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XP+C`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C`P/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XP+C`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XH,2XY,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE
M/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?-C(Y8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X8SDT#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A7V-D83=?-&1A
M95]A-#0U7S$R-#5A93(T.&,Y-"]7;W)K<VAE971S+U-H965T,C@N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5*1T%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D]R9V%N:7IA
M=&EO;B!A;F0@3F%T=7)E(&]F($]P97)A=&EO;G,@+2!!9&1I=&EO;F%L($EN
M9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^26X@36EL;&EO;G,L(&5X
M8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T
M+B`Q-BP@,C`Q,SQB<CY)4$\@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N($%N9"!.
M871U<F4@3V8@0G5S:6YE<W,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%C<F]'96YI8W,@:6YC
M;W)P;W)A=&5D(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/D%U9R`Q-"P-"@D),C`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN:71I86P@<'5B;&EC(&]F9F5R:6YG(&YU
M;6)E<B!O9B!S:&%R92!S;VQD/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2PW-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);FET:6%L('!U8FQI8R!O9F9E<FEN9R!P<FEC
M92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]C965D<R!F<F]M(&EN:71I86P@<'5B;&EC(&]F9F5R:6YG(&)E
M9F]R92!O9F9E<FEN9R!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@.#4N-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-C(Y8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X
M8SDT#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A7V-D
M83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-"]7;W)K<VAE971S+U-H965T,CDN
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4V2$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U
M;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`M($%D
M9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY3
M96=M96YT/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R
M(&]F(&]P97)A=&EN9R!S96=M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D]R:6=I;F%L(&UA='5R:71Y(&]F(&9I;F%N8VEA;"!I
M;G-T<G5M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S,@
M;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)S,@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;&QO=V%N8V4@<F5C;W)D960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO=6YT<R!C;&%S<VEF
M:65D(&%S(')E<W1R:6-T960@8V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`T,#0L.#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`T,#0L.#4P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(&QA
M<F=E<W0@86UO=6YT(&QI:V5L>2!T;R!B92!R96%L:7IE9"!U<&]N('5L=&EM
M871E('-E='1L96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S8R.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,CEC-&)C85]C9&$W7S1D865?
M830T-5\Q,C0U864R-#AC.30O5V]R:W-H965T<R]3:&5E=#,P+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%,U)!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY3=6UM87)Y(&]F
M(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@+2!3=6UM87)Y(&]F
M($9A:7(@5F%L=64@365A<W5R96UE;G0@1FEN86YC:6%L($%S<V5T(&%N9"!,
M:6%B:6QI=&EE<R`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!<W-E
M=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Y,"PT,S0L-#,U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q."PV.34L,3DW/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-;VYE
M>2!M87)K970@9G5N9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(V+#`T-BPY-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR.2PP-#<L.34X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(&-A<V@\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P-"PX-3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#0L.#4P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,38L
M.#@V+#(U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0X+#$T."PP,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EA8FEL:71I97,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R
M<F5D('-T;V-K('=A<G)A;G0@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-3(L.30W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^475O=&5D(%!R:6-E<R!I;B!!8W1I
M=F4@36%R:V5T<R!F;W(@261E;G1I8V%L($%S<V5T<R!,979E;"`Q(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY!<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.3`L-#,T+#0S-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#8Y-2PQ.3<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUO
M;F5Y(&UA<FME="!F=6YD<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C8L,#0V+#DW-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(Y+#`T-RPY-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@8V%S:#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`T+#@U,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P-"PX-3`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!!<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q
M-BPX.#8L,C4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#@L,30X+#`P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6%B:6QI=&EE<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F
M97)R960@<W1O8VL@=V%R<F%N="!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:6=N:69I8V%N="!/
M=&AE<B!/8G-E<G9A8FQE($EN<'5T<R!,979E;"`R(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!<W-E=',Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUO;F5Y
M(&UA<FME="!F=6YD<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@8V%S:#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!!<W-E=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/DQI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:R!W87)R86YT(&QI86)I
M;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-I9VYI9FEC86YT(%5N;V)S97)V86)L92!);G!U=',@3&5V96P@
M,R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^07-S971S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y-;VYE>2!M87)K970@9G5N9',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M97-T<FEC=&5D(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@07-S971S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY,:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O
M8VL@=V%R<F%N="!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#4R+#DT-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S8R.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R-#5A93(T
M.&,Y-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,CEC-&)C85]C
M9&$W7S1D865?830T-5\Q,C0U864R-#AC.30O5V]R:W-H965T<R]3:&5E=#,Q
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%,DE!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@+2!3
M=6UM87)Y(&]F(%!R969E<G)E9"!3=&]C:R!787)R86YT($QI86)I;&ET>2`H
M1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($QI86)I;&ET:65S($UE
M87-U<F5D(&]N(%)E8W5R<FEN9R!"87-I<RP@56YO8G-E<G9A8FQE($EN<'5T
M(%)E8V]N8VEL:6%T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5T=&QE;65N="!O9B!P<F5F
M97)R960@<W1O8VL@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2PX-C`L-3DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L
M($QI86)I;&ET:65S($UE87-U<F5D(&]N(%)E8W5R<FEN9R!"87-I<RP@56YO
M8G-E<G9A8FQE($EN<'5T(%)E8V]N8VEL:6%T:6]N(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L
M86YC92!B96=I;FYI;F<@;V8@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-3(L.30W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@=6YR96%L:7IE9"!G86EN<R`H;&]S
M<V5S*2!I;F-L=61E9"!I;B!E87)N:6YG<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-C(V+#,T.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E='1L96UE;G0@;V8@<')E9F5R<F5D
M('-T;V-K('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV-SDL,CDV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"86QA;F-E(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P149/04<^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG
M(%!O;&EC:65S("T@4W5M;6%R>2!O9B!097)C96YT86=E(&]F(%-I9VYI9FEC
M86YT(%)E=F5N=64@*$1E=&%I;"D@*%-A;&5S(%M-96UB97)=*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<G9I97(@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY#;VYC96YT<F%T:6]N(%)I<VL@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E
M;G1A9V4@;V8@86QL('-I9VYI9FEC86YT(')E=F5N=64@96%R;F5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,2XV,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RXS,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y";V5H
M<FEN9V5R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0V]N8V5N=')A=&EO;B!2:7-K(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y097)C96YT86=E(&]F(&%L;"!S:6=N:69I8V%N="!R979E;G5E(&5A<FYE
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0N.#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@N-#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,34N-C`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y':6QE860@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYC96YT<F%T:6]N(%)I<VL@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@86QL('-I9VYI9FEC86YT(')E=F5N
M=64@96%R;F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RXX
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4&9I>F5R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]N8V5N=')A=&EO;B!2:7-K(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y097)C96YT86=E(&]F(&%L;"!S:6=N:69I8V%N="!R979E;G5E
M(&5A<FYE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BXP,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M+C<P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P+C@P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1V]V97)N;65N="!!9V5N8VEE<R!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;F-E
M;G1R871I;VX@4FES:R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!A;&P@
M<VEG;FEF:6-A;G0@<F5V96YU92!E87)N960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(N,C`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-BXU,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RXW,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5L:2!,:6QL>2!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-O;F-E;G1R871I;VX@4FES:R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G
M92!O9B!A;&P@<VEG;FEF:6-A;G0@<F5V96YU92!E87)N960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$N-#`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#@N.3`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,CEC-&)C85]C
M9&$W7S1D865?830T-5\Q,C0U864R-#AC.30-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO-C(Y8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X
M8SDT+U=O<FMS:&5E=',O4VAE970S,RYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U#04<^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!
M8V-O=6YT:6YG(%!O;&EC:65S("T@4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!
M8V-O=6YT<R!296-E:79A8FQE("A$971A:6PI("A!8V-O=6YT<R!296-E:79A
M8FQE(%M-96UB97)=*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y':6QE860@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;F-E;G1R871I;VX@4FES:R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:6=N:69I8V%N="!!8V-O=6YT<R!296-E:79A8FQE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,RXT,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y09FEZ97(@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-O;F-E;G1R871I;VX@4FES:R!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3:6=N:69I8V%N="!!8V-O=6YT<R!296-E:79A8FQE/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BXS,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-2XT,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)O96AR:6YG
M97(@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-O;F-E;G1R871I;VX@4FES:R!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:6=N
M:69I8V%N="!!8V-O=6YT<R!296-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,BXR,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ."XP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5L:2!,:6QL>2!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0V]N8V5N=')A=&EO;B!2:7-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-I9VYI9FEC86YT($%C
M8V]U;G1S(%)E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C@N,C`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y397)V:65R(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYC96YT<F%T:6]N
M(%)I<VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VEG;FEF:6-A;G0@06-C;W5N=',@4F5C96EV
M86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BXT,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y';W9E<FYM96YT($%G96YC:65S(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYC96YT
M<F%T:6]N(%)I<VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VEG;FEF:6-A;G0@06-C;W5N=',@
M4F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"XV
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX+C0P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?-C(Y8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X8SDT#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A7V-D83=?-&1A95]A
M-#0U7S$R-#5A93(T.&,Y-"]7;W)K<VAE971S+U-H965T,S0N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$561T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@
M4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`M($5S=&EM871E9"!5
M<V5F=6P@3&EV97,@*$1E=&%I;"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;7!U=&5R($5Q=6EP;65N="!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P
M97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S=&EM871E
M9"!5<V5F=6P@3&EV97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<S('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3;V9T=V%R92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD
M($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S=&EM871E9"!5<V5F=6P@3&EV97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<S('EE87)S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&=7)N
M:71U<F4@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%<W1I;6%T960@57-E9G5L($QI=F5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQA8F]R871O<GD@86YD($]F
M9FEC92!%<75I<&UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I
M<&UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%<W1I;6%T960@57-E9G5L($QI=F5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R<SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V5H;VQD
M($EM<')O=F5M96YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP
M;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DQE87-E:&]L9"!I;7!R;W9E;65N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=3:&]R=&5R(&]F(&QE87-E('1E
M<FT@;W(@=7-E9G5L(&QI9F4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S8R.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R-#5A93(T
M.&,Y-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,CEC-&)C85]C
M9&$W7S1D865?830T-5\Q,C0U864R-#AC.30O5V]R:W-H965T<R]3:&5E=#,U
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%,5="1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@+2!#
M;VUP=71A=&EO;B!O9B!"87-I8R!A;F0@1&EL=71E9"!);F-O;64@*$QO<W,I
M(%!E<B!#;VUM;VX@4VAA<F4@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$.#XS
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S
M,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N=&EN9R!0;VQI8VEE<R!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&EN8V]M92`H;&]S<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,RPR,#4L,#`P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BPV,#0L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@R.30L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,RPS-C8L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,BPQ,#4L,#`P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPV,#$L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`S+#4T-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#0L,S(P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C8P+#@S-2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L,S8Q+#<U-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-BPW,3<L,3(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,97-S.B!U;F1I<W1R:6)U=&5D(&5A<FYI;F=S(&%L;&]C
M871E9"!T;R!P87)T:6-I<&%T:6YG('-E8W5R:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L,S8Q+#<U-2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#<Q-RPQ
M,C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&EN8V]M92`H;&]S<RD@86QL;V-A8FQE('1O(&-O;6UO;B!S
M:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,C8P+#@S-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0F%S:6,@=V5I9VAT960@879E<F%G92!C;VUM;VX@<VAA
M<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8L.#0W+#8Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,#@S+#(W-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#(U+#8P,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@
M:6YC;VUE("AL;W-S*2!P97(@8V]M;6]N('-H87)E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#`N,30I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C$T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C(T*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,BXY,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#$N.3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@P+C`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&EN8V]M92`H;&]S
M<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L,C`U+#`P,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M+#8P-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R.30L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#,L,S8V+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#$P-2PP,#`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPV,#$L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPU-#8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-"PS,C`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,C8P+#@S-2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#,V,2PW-34\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#<Q-RPQ,C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DQE<W,Z('5N9&ES=')I8G5T960@96%R;FEN9W,@86QL;V-A=&5D('1O('!A
M<G1I8VEP871I;F<@<V5C=7)I=&EE<R!A;F0@;W1H97(@861D+6)A8VMS('1O
M(&YE="!I;F-O;64@*&QO<W,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@X+#,V,2PW-34I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPW,3<L,3(P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-O
M;64@*&QO<W,I(&%L;&]C86)L92!T;R!C;VUM;VX@<VAA<F5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C8P+#@S-2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F%S:6,@=V5I9VAT960@879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD
M:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L
M.#0W+#8Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,#@S+#(W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,#(U+#8P,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^169F96-T(&]F(&1I;'5T:79E
M('-E8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&EL=71E9"!W96EG:'1E9"!A=F5R86=E(&-O;6UO;B!S:&%R97,@;W5T
M<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-BPX-#<L-CDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PP.#,L,C<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,C4L-C`R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:6QU=&5D(&EN8V]M
M92`H;&]S<RD@<&5R(&-O;6UO;B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@P+C$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XR-"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(N.3,I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q+CDR
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,"XP-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S8R.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R
M-#5A93(T.&,Y-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,CEC
M-&)C85]C9&$W7S1D865?830T-5\Q,C0U864R-#AC.30O5V]R:W-H965T<R]3
M:&5E=#,V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%04M"1SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I
M97,@+2!38VAE9'5L92!O9B!$:6QU=&EV92!396-U<FET:65S(%5S960@26X@
M0V%L8W5L871I;VX@;V8@1&EL=71E9"!%87)N:6YG<R!097(@4VAA<F4@*$1E
M=&%I;"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y397)I97,@02TQ($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D%N=&ED:6QU=&EV92!396-U<FET:65S($5X8VQU9&5D(&9R;VT@
M0V]M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R(%-H87)E(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F5F97)R960@4W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#$U-BPQ,30\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$U-BPQ,30\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!!
M+3(@0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT:61I
M;'5T:79E(%-E8W5R:71I97,@17AC;'5D960@9G)O;2!#;VUP=71A=&EO;B!O
M9B!%87)N:6YG<R!097(@4VAA<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!3
M=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,Y,BPR-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS.3(L,C<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@0B!#;VYV97)T:6)L92!0<F5F
M97)R960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%
M>&-L=61E9"!F<F]M($-O;7!U=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R
M92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')E9F5R<F5D(%-T;V-K/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PS,S8L,#,W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PS,S8L
M,#,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y397)I97,@0R!#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O
M;7!U=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')E9F5R<F5D(%-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2PY,#DL.3`V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PY,#DL.3`V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@1"!#
M;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!;G1I9&EL=71I
M=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O;7!U=&%T:6]N(&]F($5A
M<FYI;F=S(%!E<B!3:&%R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D(%-T;V-K
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S8Y+#0V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<V.2PT-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!$+3(@0V]N=F5R=&EB;&4@4')E9F5R
M<F5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^06YT:61I;'5T:79E(%-E8W5R:71I97,@17AC
M;'5D960@9G)O;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG<R!097(@4VAA<F4@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R969E<G)E9"!3=&]C:SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,SDQ+#DY,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,SDQ+#DY
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^169F96-T(&]F($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D%N=&ED:6QU=&EV92!396-U<FET:65S($5X8VQU9&5D(&9R;VT@0V]M
M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R(%-H87)E(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F5F97)R960@4W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$S+#$X.2PY,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N
M="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D%N=&ED:6QU=&EV92!396-U<FET:65S($5X8VQU9&5D(&9R
M;VT@0V]M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R(%-H87)E(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F5F97)R960@4W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ.#`L-S@T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@P+#<X-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@3W!T
M:6]N<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D%N=&ED:6QU=&EV92!396-U<FET:65S($5X8VQU9&5D
M(&9R;VT@0V]M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R(%-H87)E(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F5F97)R960@4W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L,S$S+#DW,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L,C0Y+#<P,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.#@U+#0Q-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(Y8S1B8V%?8V1A
M-U\T9&%E7V$T-#5?,3(T-6%E,C0X8SDT#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S8R.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y
M-"]7;W)K<VAE971S+U-H965T,S<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$552$%'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,3X\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@+2!3
M8VAE9'5L92!O9B!0<F]P97)T>2!A;F0@17%U:7!M96YT("A$971A:6PI("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M
M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C`L-38X+#`V.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3<L-C`W
M+#(Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3&5S<R!A8V-U;75L871E9"!D97!R96-I871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$U+#4S,BPX,S<I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,30L,S,Y+#0Y-RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4L,#,U+#(S,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C8W+#<Y-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<'5T97(@
M17%U:7!M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N
M="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,W.2PR-30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P,RPW,#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-O
M9G1W87)E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0W-RPT,38\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,R,RPP.#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U<FYI
M='5R92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3DY+#8U,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Y.2PV-3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQA8B!%<75I<&UE
M;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$Q+#$V-BPV,3D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#<T-RPW.3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]F9FEC92!%
M<75I<&UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q+#,V,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q+#,V,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V5H;VQD
M($EM<')O=F5M96YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I
M<&UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#@Y,RPW-S`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0L.#@Q
M+#<P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M-C(Y8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X8SDT#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A7V-D83=?-&1A95]A-#0U
M7S$R-#5A93(T.&,Y-"]7;W)K<VAE971S+U-H965T,S@N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$580D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%
M<75I<&UE;G0@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A5
M4T0@)"D\8G(^26X@36EL;&EO;G,L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E!R;W!E<G1Y(%!L86YT($%N9"!%<75I<&UE;G0@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;B!E>'!E;G-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XQ/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15150DL^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D@*$1E
M9FEC:70I("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,C0@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXP($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87D@,38L(#(P,#8\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`Q,BP@,C`P-#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#$V+"`R,#$S/&)R/DE0
M3R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M86XN(#$Q+"`R,#$Q/&)R/E-E<FEE<R!$+3(@0V]N=F5R=&EB;&4@4')E9F5R
M<F5D(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,#,\8G(^4V5R:65S($$@4')E9F5R<F5D(%-T
M;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D]C="X@,3(L(#(P,#0\8G(^4V5R:65S($(@4')E9F5R<F5D(%-T;V-K(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^4V5R:65S($(@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA>2`Q-BP@,C`P
M-CQB<CY397)I97,@0R!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY3
M97)I97,@0R!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY397)I97,@
M1"!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5L+B`Q-BP@,C`P.#QB<CY397)I97,@1"!0<F5F
M97)R960@4W1O8VL@6TUE;6)E<ET\8G(^4F%V96X@0FEO=&5C:&YO;&]G:65S
M($EN8R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$Q/&)R/E-E<FEE<R!$(%!R969E<G)E9"!3=&]C:R!;
M365M8F5R73QB<CY2879E;B!":6]T96-H;F]L;V=I97,@26YC(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^4V5R:65S($$M($]N92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,SQB<CY397)I97,@02T@5'=O(%!R969E<G)E9"!3=&]C:R!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87D@,38L(#(P,3`\
M8G(^4V5R:65S($0@5'=O(%!R969E<G)E9"!3=&]C:R!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#$Y+"`R,#`X/&)R
M/E-E<FEE<R!$(%1W;R!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY3
M97)I97,@1"!4=V\@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^56YD
M97-I9VYA=&5D(%!R969E<G)E9"!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E
M<G,@17%U:71Y(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB
M97(@;V8@<VAA<F5S(&ES<W5E9"!O<B!S;VQD/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#0R-RPS.#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"PR,SDL
M,S<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S$L-#`Q+#(S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,3`L.34R+#(Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.3$V+#$Q,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X+#,S
M-RPV-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VYV97)T:6)L
M92!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$R+#`Q-"PX,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S0L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S`L,S`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0T+#DP,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-"PX,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R:6-E('!E
M<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;&%T960@;V9F97)I;F<@8V]S=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,X+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,#$L,C0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$U-BPW.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&]F(&-O;6UO;B!S
M=&]C:R!A;&QO8V%T960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P+#`P,RPS,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,RPV,#0L,#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA
M<F5S(&ES<W5E9"!T;R!A8W%U:7)E(&5N=&ET>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#0V-BPP,SD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PT-#8L
M,C(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0=7)C:&%S960@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q."PW,#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@W-2PS
M,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AE<F-I<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C8U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O
M;2!S86QE(&]F('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3(L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&YO
M;F-U;75L871I=F4@9&EV:61E;F1S(&]N('!R969E<G)E9"!S=&]C:SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`S-#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C`S,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N,#4R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#4R,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:R!S97)I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N-3`V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;G9E<G-I;VX@<')I8V4@;V8@<')E9F5R<F5D('-T;V-K/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8N.34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W
M+C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$R+C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,3(N,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$X+C<W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R+C(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L
M('-H87)E<R!S;VQD('5N9&5R(&]V97(M86QL;W1M96YT<R!/<'1I;VX@=&\@
M=6YD97)W<FET97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!I;FET
M:6%L('!U8FQI8R!O9F9E<FEN9R!N970@;V8@97AP96YS97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X,RPX,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y2979E<G-E('-T;V-K('-P;&ET/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG,2UF;W(M,3@N-S<S.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,C4L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YD97-I9VYA=&5D('!R969E<G)E
M9"!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5
M;F1E<VEG;F%T960@<')E9F5R<F5D('-T;V-K+"!P87(@=F%L=64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y5;F1E<VEG;F%T960@<')E9F5R<F5D('-T;V-K+"!S:&%R97,@
M:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E5N9&5S:6=N871E9"!P<F5F97)R960@<W1O8VLL
M('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15DS0DD^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4VAA<F5D+4)A<V5D(%!A>6UE;G1S("T@061D:71I;VYA;"!)
M;F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^-C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,38L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#(X+"`R,#`S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,38L(#(P,3$\
M8G(^4W1O8VL@3W!T:6]N($]N92!;365M8F5R73QB<CY/<FEG:6YA;"!/<'1I
M;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,38L(#(P,3$\8G(^4W1O8VL@3W!T:6]N(%1W;R!;365M8F5R73QB
M<CY/<FEG:6YA;"!/<'1I;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^4W1O8VL@3W!T:6]N
M(%!L86X@,C`P,"!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/E1W;R!4:&]U<V%N9"!A;F0@5&AR
M964@4W1O8VL@3W!T:6]N(%!L86X@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY4=V\@5&AO=7-A
M;F0@86YD(%1H:7)T965N(%-T;V-K($EN8V5N=&EV92!0;&%N(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,S$L(#(P
M,3,\8G(^5'=O(%1H;W5S86YD(&%N9"!4:&ER=&5E;B!3=&]C:R!);F-E;G1I
M=F4@4&QA;B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/D5Q=6ET>2!);F-E;G1I=F4@4&QA;B`R
M,#`S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^36%X:6UU;2!;365M8F5R73QB<CY%<75I='D@
M26YC96YT:79E(%!L86X@,C`P,R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$969E<G)E9"!#;VUP96YS
M871I;VX@07)R86YG96UE;G0@=VET:"!);F1I=FED=6%L+"!3:&%R92UB87-E
M9"!087EM96YT<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@
M;V8@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L,#4Q+#8T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3,P+#<R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY-C`L,38X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E87-E(&EN
M(&%G9W)E9V%T92!O9B!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-"PS,S8L-S,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L-SDP+#<V,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,"PR.3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N('-T;V-K('-H87)E(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,RPR,#`L.34X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR-#DL-30Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPV
M-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#4U.2PP,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV,3@L,CDP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#YW96EG:'1E9"!A=F5R86=E(&5X97)C
M:7-E('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0N.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,"XY-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2XX.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"XV.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XX,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XU,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3DN
M,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!3=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU-#4L.3<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-S,Y+#$Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G
M92!O9B!#;VUM;VX@<W1O8VL@<VAA<F4@;W5T<W1A;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5S
M8W)I<'1I;VX@;V8@97AC:&%N9V4@<F%T:6\@;V8@;W)I9VEN86P@;W!T:6]N
M<R!W:71H(')E<&QA8V5M96YT(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B=O;F4M9F]R+6]N92!B87-I<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&]R:6=I;F%L($]P=&EO;G,@97AC:&%N9V5D(&9O<B!R97!L86-E
M;65N="!/<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PY,C$L.#DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS(&=R86YT960L(&UA>&EM
M=6T@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<Q,"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17AP96-T960@;&EF92!O9B!O<'1I;VX@=&5R
M;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<W('EE87)S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S<@
M>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG-R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S<@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL
M('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#(V."PP-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX-C,L,3<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#DL.#@S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!P<F]C
M965D<R!F<F]M(&5X97)C:7-E(&]F('-T;V-K(&]P=&EO;G,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,3`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#8L.#(V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U
M,RPR,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"UA=F5R86=E(&=R86YT+61A=&4@
M9F%I<B!V86QU92!O9B!O<'1I;VYS(&=R86YT960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#8N.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.30\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!9V=R96=A=&4@:6YT<FEN<VEC('9A;'5E(&]F(&]P=&EO;G,@97AE<F-I
M<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PT,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C<Q+#DR.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P,BPT,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F('-H87)E
M<R!V97-T960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.#<L
M-C`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#<Y+#`R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,3`X+#$P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N<F5C;V=N:7IE9"!C
M;VUP96YS871I;VX@8V]S="!R96QA=&5D('1O(&YO;BUV97-T960@<W1O8VLM
M8F%S960@8V]M<&5N<V%T:6]N(&%R<F%N9V5M96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-RPV,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5
M;G)E8V]G;FEZ960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@<F5C;V=N:71I;VX@
M<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S0@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S8R.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y
M-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,CEC-&)C85]C9&$W
M7S1D865?830T-5\Q,C0U864R-#AC.30O5V]R:W-H965T<R]3:&5E=#0Q+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%2TE!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3:&%R
M960M0F%S960@4&%Y;65N=',@+2!38VAE9'5L92!O9B!3=&]C:RU"87-E9"!#
M;VUP96YS871I;VX@17AP96YS92`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%
M;7!L;WEE92!397)V:6-E(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@06QL
M;V-A=&EO;B!O9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T<R!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#8R+#$V,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#,X+#,Y-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPS
M-#<L-#,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y297-E87)C:"!A;F0@1&5V96QO<&UE;G0@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%;7!L
M;WEE92!397)V:6-E(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@06QL;V-A
M=&EO;B!O9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T<R!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4P-RPQ-#(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-S$L.#`Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,3@L.3,U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'
M96YE<F%L(&%N9"!!9&UI;FES=')A=&EV92!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5M<&QO>65E(%-E
M<G9I8V4@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!!;&QO8V%T:6]N(&]F
M(%)E8V]G;FEZ960@4&5R:6]D($-O<W1S(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB
M87-E9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`S-34L,#(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S-C8L-3@V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#,R."PU,#0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R.6,T8F-A
M7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\V,CEC-&)C85]C9&$W7S1D865?830T-5\Q,C0U864R
M-#AC.30O5V]R:W-H965T<R]3:&5E=#0R+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%035!13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3:&%R960M0F%S960@4&%Y;65N=',@
M+2!38VAE9'5L92!O9B!&86ER(%9A;'5E($]P=&EO;B!!=V%R9"!%<W1I;6%T
M960@;VX@=&AE($1A=&4@;V8@1W)A;G0@57-I;F<@=&AE($)L86-K+5-C:&]L
M97,@3W!T:6]N+5!R:6-I;F<@36]D96P@*$1E=&%I;"D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E
M+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E
M9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!D:79I9&5N
M9"!Y:65L9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X<&5C=&5D('9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV,BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VLM9G)E92!I;G1E<F5S
M="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XQ."4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+C,U)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AP96-T960@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)S<@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG-R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<W('EE87)S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!F;W)F
M96ET=7)E(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M+C4W)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4N-3@E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y-:6YI;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N
M<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A
M<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&1I=FED96YD('EI96QD/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!V
M;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,RXP
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4FES:RUF<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$N,C0E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&9O<F9E:71U<F4@
M<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2XP-B4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M36%X:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A
M;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV-RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4FES:RUF<F5E(&EN=&5R97-T(')A=&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(N,3DE/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C
M=&5D(&9O<F9E:71U<F4@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2XU-R4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?-C(Y8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X8SDT
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A7V-D83=?
M-&1A95]A-#0U7S$R-#5A93(T.&,Y-"]7;W)K<VAE971S+U-H965T-#,N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$4R4$%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-H87)E
M9"U"87-E9"!087EM96YT<R`M(%-C:&5D=6QE(&]F(%-T;V-K($]P=&EO;B!!
M8W1I=FET>2`H1&5T86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC
M97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,38L(#(P,3$\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1&ES8VQO<W5R92!/9B!#;VUP96YS871I;VX@4F5L871E9"!#;W-T<R!3:&%R
M96)A<V5D(%!A>6UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<RP@3W5T<W1A;F1I
M;F<L($)E9VEN;FEN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#(T.2PU-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<RP@1W)A;G1E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS,#<L,3`Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,L
M($5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PR
M-C@L,#0Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#@V,RPQ-S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-#DL.#@S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<RP@1F]R9F5I=&5D(&]R
M(&5X<&ER960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@W+#8S
M-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-H87)E<RP@3W5T<W1A;F1I;F<L($5N9&EN9R!"86QA;F-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(P,"PY-3@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(T.2PU
M-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4VAA<F5S+"!%>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PV.#@L,C4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,L(%9E<W1E9"!A;F0@
M97AP96-T960@=&\@=F5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,RPP,C(L.30X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"T@079E<F%G92!%>&5R8VES92!0
M<FEC92P@3W5T<W1A;F1I;F<L($)E9VEN;FEN9R!"86QA;F-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XY-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT
M960M($%V97)A9V4@17AE<F-I<V4@4')I8V4L($=R86YT960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`N-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960M($%V
M97)A9V4@17AE<F-I<V4@4')I8V4L($5X97)C:7-E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"T@079E<F%G
M92!%>&5R8VES92!0<FEC92P@1F]R9F5I=&5D(&]R(&5X<&ER960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XQ,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960M
M($%V97)A9V4@17AE<F-I<V4@4')I8V4L($]U='-T86YD:6YG+"!%;F1I;F<@
M0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+CD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#`N.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`P+CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y796EG:'1E9"T@079E<F%G92!%>&5R8VES92!0<FEC
M92P@17AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,"XY-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V5I9VAT960M($%V97)A9V4@17AE<F-I<V4@4')I8V4L
M(%9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`T+C8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"T@079E<F%G92!2
M96UA:6YI;F<@0V]N=')A8W1U86P@5&5R;2P@3W5T<W1A;F1I;F<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<V('EE87)S(#$P(&UO;G1H<R`R
M-"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)S<@>65A<G,@,R!M;VYT:',@,3@@9&%Y<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"T@
M079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@5&5R;2P@17AE<F-I<V%B
M;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<T('EE87)S(#D@
M;6]N=&AS(#$X(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D+2!!=F5R86=E(%)E;6%I;FEN
M9R!#;VYT<F%C='5A;"!497)M+"!697-T960@86YD(&5X<&5C=&5D('1O('9E
M<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<V('EE87)S(#D@
M;6]N=&AS(#$X(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64L
M($]U='-T86YD:6YG+"!%;F1I;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`V-RPU,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS
M:6,@5F%L=64L($5X97)C:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT,BPS,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64L
M(%9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`V-"PU-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R.6,T8F-A7V-D83=?-&1A95]A-#0U
M7S$R-#5A93(T.&,Y-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V
M,CEC-&)C85]C9&$W7S1D865?830T-5\Q,C0U864R-#AC.30O5V]R:W-H965T
M<R]3:&5E=#0T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%-C9!1SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY);F-O;64@5&%X97,@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N
M("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487AE<R!$:7-C;&]S
M=7)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]V:7-I;VX@9F]R(&9E9&5R86P@;W(@<W1A
M=&4@:6YC;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYE="!O<&5R871I;F<@;&]S<R!C87)R>69O<G=A<F1S
M(&5X<&ER871I;VX@<W1A<G0@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)S(P,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R
M=V%R9',@97AP:7)A=&EO;B!E;F1I;F<@>65A<CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)S(P,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F5D97)A;"!487@@8W)E9&ET(&5X
M<&ER871I;VX@<W1A<G0@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)S(P,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1F5D97)A;"!487@@8W)E9&ET(&5X<&ER871I;VX@
M96YD:6YG('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<R
M,#,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!O<&5R871I;F<@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^."PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!O<&5R871I;F<@;&]S<V5S
M(&QI;6ET960@9F]R('EE87(@;6EN:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S(P,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S97,@;&EM
M:71E9"!F;W(@>65A<B!M87AI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG,C`R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y296UA:6YI;F<@<&]R=&EO;B!O9B!N970@;W!E
M<F%T:6YG(&QO<W-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.38L,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@;W!E<F%T:6YG(&QO<W-E<RP@<F5C;V=N:7IE
M9"!A<R!A(&)E;F5F:70@=&AR;W5G:"!A9&1I=&EO;F%L+7!A:60M:6XM8V%P
M:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D=R;W-S('5N<F5C;V=N:7IE9"!T87@@8F5N969I=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ
M960@:6YT97)E<W0@;W(@<&5N86QT:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEN8V]M92!T87@@97AA;6EN871I;VX@>65A<B!S
M=6)J96-T('1O(&5X86UI;F%T:6]N+"!286YG92!S=&%R=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S(P,#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE('1A>"!E>&%M
M:6YA=&EO;B!Y96%R('-U8FIE8W0@=&\@97AA;6EN871I;VXL(%)A;F=E($5N
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S(P,3(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EN
M:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/DEN8V]M92!487AE<R!$:7-C;&]S=7)E(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@;W!E<F%T:6YG(&QO<W-E<R!L:6UI=&5D(&9O<B!U<V4@=71I
M;&EZ960@;VX@86X@86YN=6%L(&)A<VES/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O;64@
M5&%X97,@1&ES8VQO<W5R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L
M;W-S97,@;&EM:71E9"!F;W(@=7-E('5T:6QI>F5D(&]N(&%N(&%N;G5A;"!B
M87-I<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E4N4RX@1F5D97)A;"!';W9E<FYM96YT(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A
M>&5S($1I<V-L;W-U<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!O<&5R871I;F<@;&]S
M<R!C87)R>69O<G=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,#0L.#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y54R!&961E<F%L(%1A>"!C<F5D:71S(&-A<G)Y
M(&9O<G=A<F0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#<P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W1A=&4@86YD($QO8V%L($IU<FES9&EC=&EO;B!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DEN8V]M92!487AE<R!$:7-C;&]S=7)E(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;W!E
M<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`V,"PS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R.6,T8F-A7V-D83=?-&1A95]A-#0U
M7S$R-#5A93(T.&,Y-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V
M,CEC-&)C85]C9&$W7S1D865?830T-5\Q,C0U864R-#AC.30O5V]R:W-H965T
M<R]3:&5E=#0U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%-DM!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^
M/'-T<F]N9SY);F-O;64@5&%X97,@+2!#;VUP;VYE;G1S(&]F('1H92!#;VUP
M86YY)W,@1&5F97)R960@5&%X($%S<V5T<R`H3&EA8FEL:71I97,I("A$971A
M:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E9F5R<F5D(&EN8V]M92!T87@@
M87-S971S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9E9&5R86P@52Y3+B!N970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF
M;W)W87)D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,V+#4V
M,2PQ.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#,U+#,S,"PQ-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T871E(&YE="!O<&5R871I;F<@;&]S<R!C
M87)R>69O<G=A<F0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M,S$U+#4Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L-3(Q+#<R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&-R
M961I="P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#<X
M-2PV,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#<W-RPX.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]R<&AA;B!D<G5G(&-R961I="P@;F5T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PX.#,L,#<V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL,#,Y+#8Q
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&5F97)R960@<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-2PQ,S(L-#4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PR,3@L,#`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#(Q-BPV.34\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#,W.2PP-C0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1E<')E8VEA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PT,S@L-#<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PR-#<L-S<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PT,S@L.#<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU-S4L-S@R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)O<W,@9&5F97)R
M960@:6YC;VUE('1A>"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<Y+#<W,2PX.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW."PP.3`L,#(Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y686QU871I;VX@86QL;W=A
M;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W.2PS-S8L.30U
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#<X+#`Y,"PP,C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&1E9F5R<F5D(&EN8V]M92!T87@@87-S971S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.30L.34R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY$969E<G)E9"!I;F-O;64@=&%X(&QI86)I;&ET:65S.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S.30L.34R*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S
M<R!D969E<G)E9"!I;F-O;64@=&%X(&QI86)I;&ET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S.30L.34R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@9&5F97)R960@
M:6YC;VUE('1A>"!A<W-E="\H;&EA8FEL:71Y*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R.6,T8F-A
M7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\V,CEC-&)C85]C9&$W7S1D865?830T-5\Q,C0U864R
M-#AC.30O5V]R:W-H965T<R]3:&5E=#0V+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%0TQ!13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O;64@5&%X97,@+2!296-O;F-I
M;&EA=&EO;B!O9B!297!O<G1E9"!%<W1I;6%T960@26YC;VUE(%1A>"!"96YE
M9FET("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487@@1&ES8VQO
M<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E5N:71E9"!3=&%T97,@9F5D97)A;"!T87@@870@
M<W1A='5T;W)Y(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H.3$L,CDS*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,BPY,C8L-C$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#,U,"PY.3(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T871E('1A>&5S
M("AN970@;V8@9F5D97)A;"!B96YE9FET*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C`Y+#0W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L-#8P+#(X.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#@P+#$X-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R
M960@:6YC;VUE('1A>"!A9&IU<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH.#4U+#$S,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@U,3(L,S<U*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D('-T871E
M(&)L96YD960@<F%T92!A9&IU<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,S0T+#$W."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@8W)E9&ET+"!N970\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(R-2PV,#4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]R
M<&AA;B!D<G5G(&-R961I="P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@X-#,L-#8S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#0L.#DU+#8W,2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#`U-BPV,#<I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!P
M97)M86YE;G0@:71E;7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L.3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-RPV,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT+#8Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17%U:71Y+2!B87-E9"!C;VUP96YS871I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T,2PT-C<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-SDL,38U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S(U+#@Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1F%I<B!V86QU92!A9&IU<W1M96YT(&]F('!R969E<G)E9"!S
M=&]C:R!W87)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C$X+#@W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#4R+#<T,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@T.38L,C`X*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN('9A
M;'5A=&EO;B!A;&QO=V%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,C@V+#DR,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<X-RPP.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#DY,2PQ,S$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@=&%X(&5X
M<&5N<V4O*&)E;F5F:70I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R.6,T8F-A
M7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\V,CEC-&)C85]C9&$W7S1D865?830T-5\Q,C0U864R
M-#AC.30O5V]R:W-H965T<R]3:&5E=#0W+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,DQ!0SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O;64@5&%X97,@+2!296-O;F-I
M;&EA=&EO;B!O9B!T:&4@0F5G:6YN:6YG(&%N9"!%;F1I;F<@06UO=6YT(&]F
M($=R;W-S(%5N<F5C;V=N:7IE9"!487@@0F5N969I=',@*$1E=&%I;"D@*%53
M1"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^26YC;VUE(%1A>"!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F5G:6YN:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,2PU.3(L,S4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+#4S,RPY.#8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,C0V+#`R-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC<F5A
M<V5S+RAD96-R96%S97,I(&9O<B!C=7)R96YT('EE87(@=&%X('!O<VET:6]N
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$U+#4P,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X+#,W
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(X-RPY-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DEN8W)E87-E<R\H9&5C<F5A<V5S*2!F;W(@<')I;W(@>65A
M<B!T87@@<&]S:71I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M8W)E87-E<R!A<R!A(')E<W5L="!O9B!E>'!I<F%T:6]N(&]F('-T871U=&4@
M;V8@;&EM:71A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD
M:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,2PW,#<L.#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q+#4Y,BPS-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-3,S+#DX-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(Y8S1B8V%?8V1A-U\T9&%E
M7V$T-#5?,3(T-6%E,C0X8SDT#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S8R.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-"]7;W)K
M<VAE971S+U-H965T-#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5504%'/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/DQE87-E($5X:70@3&EA8FEL:71Y("T@061D:71I;VYA
M;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,38L(#(P,#@\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4F5S=')U8W1U<FEN9R!#;W-T(&%N9"!297-E<G9E(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W!E<F%T:6YG($QE87-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG,C`Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3VYE=&EM92!P=7)C:&%S92!P87EM96YT('5N
M9&5R('!U<F-H87-E(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@86UO=6YT<R!R
M96-O<F1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY297-T<G5C='5R:6YG($-O<W0@86YD(%)E<V5R
M=F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/;F5T:6UE('!A>6UE;G0@<&%I9"!U;F1E<B!L
M:6-E;G-E(&]F('!R;V1U8W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^36%X:6UU;2!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-T<G5C='5R
M:6YG($-O<W0@86YD(%)E<V5R=F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/;F5T:6UE('!A
M>6UE;G0@<&%I9"!U;F1E<B!L:6-E;G-E(&]F('!R;V1U8W0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R
M=&EB;&4@4')E9F5R<F5D(%-T;V-K(%-E<FEE<R!$(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E<W1R
M=6-T=7)I;F<@0V]S="!A;F0@4F5S97)V92!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E
M<R!I<W-U960@:6X@8V]N;F5C=&EO;B!W:71H(&%C<75I<VET:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPT-C8L,#,Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,CEC-&)C85]C
M9&$W7S1D865?830T-5\Q,C0U864R-#AC.30-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO-C(Y8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X
M8SDT+U=O<FMS:&5E=',O4VAE970T.2YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14E*04,^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^3&5A<V4@17AI="!,:6%B:6QI='D@+2!#
M:&%N9V5S(&EN($QE87-E($5X:70@3&EA8FEL:71Y("A$971A:6PI("A#;VYT
M<F%C="!497)M:6YA=&EO;B!;365M8F5R72P@55-$("0I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G1R86-T(%1E<FUI
M;F%T:6]N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY297-T<G5C='5R:6YG($-O<W0@86YD(%)E<V5R=F4@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-C<G5A;"!"96=I;FYI;F<@0F%L86YC93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,"PP-S,L.3,Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,"PV,#<L
M-#DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<FEN8VEP86P@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#8R."PW-CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-3,S+#4V,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U86P@16YD:6YG($)A
M;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.2PT-#4L
M,3<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q,"PP-S,L.3,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P139&044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^3&5A
M<V4@17AI="!,:6%B:6QI='D@+2!&=71U<F4@4')I;F-I<&%L(%!A>6UE;G1S
M('5N9&5R($QE87-E($%G<F5E;65N="`H1&5T86EL*2`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^1G5T=7)E($UI;FEM=6T@3&5A<V5S(%!A>6UE;G1S(%5N9&5R($QE
M87-E<R`H3&EN92!)=&5M<RD\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/C(P,30\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,RPV-3$L-#(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#XR,#$U/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#,Q,"PX.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,38\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L-#$P+#(Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPU,3(L-3$W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$X/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#<X,"PS.3@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1H97)E869T97(\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPV-C4L-#,P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYT<F%C="!497)M:6YA=&EO;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&=71U<F4@36EN:6UU;2!,96%S
M97,@4&%Y;65N=',@56YD97(@3&5A<V5S("A,:6YE($ET96US*3PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,S@L-S0R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$U/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8T,2PY,#4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,38\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.#8V+#`S,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q
M-SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ,3,L,3$X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR
M,#$X/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,X-2PS-S0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1H97)E869T97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#DL-#0U+#$W,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-C(Y8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X
M8SDT#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A7V-D
M83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-"]7;W)K<VAE971S+U-H965T-3$N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5/-4%-/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O
M;&QA8F]R871I;VX@86YD($QI8V5N<V4@06=R965M96YT<R`M($%D9&ET:6]N
M86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0V/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0V/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#8^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#,^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1F5B+B`R."P@,C`Q-#QB<CY3=6)S97%U96YT($5V96YT
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^4V5R=FEE<B!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/E-E<G9I97(@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,3QB<CY397)V:65R(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^4V5R=FEE<B!;
M365M8F5R73QB<CY396-O;F0@4FEG:'0@=&\@1&5V96QO<"!#;VQL86)O<F%T
M:6]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3(\8G(^4V5R=FEE<B!;365M8F5R73QB<CY396-O;F0@
M4FEG:'0@=&\@1&5V96QO<"!#;VQL86)O<F%T:6]N(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^
M1VEL96%D(%M-96UB97)=/&)R/DUO;&5C=6QE/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^1VEL96%D(%M-96UB
M97)=/&)R/DUI;FEM=6T@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY':6QE860@6TUE;6)E<ET\
M8G(^36%X:6UU;2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/D=I;&5A9"!;365M8F5R73QB<CY%
M>'!I<F5D($]P=&EO;B!!9W)E96UE;G0@6TUE;6)E<ET\8G(^36]L96-U;&4\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,SQB<CY':6QE860@6TUE;6)E<ET\8G(^3&EC96YS92!!9W)E96UE;G0@5&5R
M;7,@6TUE;6)E<ET\8G(^36]L96-U;&4\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY':6QE860@6TUE;6)E<ET\
M8G(^3W!T:6]N($%G<F5E;65N="!;365M8F5R73QB<CY0<F]G<F%M/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^
M0F]E:')I;F=E<B!;365M8F5R73QB<CY087EM96YT<SQB<CY-;VQE8W5L93QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/D)O96AR:6YG97(@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CY";V5H<FEN9V5R(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,S$L
M(#(P,3$\8G(^0F]E:')I;F=E<B!;365M8F5R73QB<CY397)I97,@1"TR($-O
M;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#,Q+"`R,#$P/&)R/E!F:7IE
M<B!;365M8F5R73QB<CY-;VQE8W5L93QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/E!F:7IE<B!;365M8F5R73QB
M<CY0<F]G<F%M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^4&9I>F5R(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^4&9I>F5R(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^1W)E96X@0W)O<W,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY'<F5E;B!#
M<F]S<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$Q/&)R/D=R965N($-R;W-S(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,C@L(#(P,3`\8G(^
M16QI($QI;&QY(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA>2`S,2P@,C`Q,#QB<CY%;&D@3&EL;'D@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%Y(#,Q+"`R,#`X/&)R
M/D5L:2!,:6QL>2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/D5L:2!,:6QL>2!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/D5L:2!,:6QL>2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/D5L:2!,:6QL>2!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY,:6-E;G-E($%N9"!#;VQL86)O<F%T:6]N($%G<F5E;65N=',@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A
M=&EO;B!A9W)E96UE;G0@9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B=.;W9E;6)E<B`R,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG4V5P=&5M8F5R(#(P,3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)TIA
M;G5A<GD@,C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)T]C=&]B97(@,C`Q,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=/8W1O8F5R(#(P,3`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG2G5N92`R,#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG3V-T;V)E<B`R,#`W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BUR969U;F1A
M8FQE('5P9G)O;G0@<&%Y;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,C`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,"PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RPU,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2PP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`T,2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@
M;&EC96YS92!G<F%N="!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C4L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#4P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;&EN:6-A;"!M:6QE<W1O
M;F4@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0W+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDX+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5G=6QA
M=&]R>2!M:6QE<W1O;F4@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`P+#`P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#DL,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A;&5S(&UI;&5S=&]N92!P
M87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P
M."PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV,S`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,RPP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y
M-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('!E<FEO9"!O9B!D979E
M;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<R
M-R!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<R.2!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S(Q(&UO;G1H<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E8V]G;FEZ960@<F5V96YU92!U;F1E<B!A9W)E96UE;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PS,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.2PQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C@L-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,30L-#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$Q+#<P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#DP,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-3`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L
M-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS,2PR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S`L.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EL97-T;VYE('!A>6UE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.2PT,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3@L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#@P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E
M(&EN8VQU9&5D(&EN(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(P+#(V-RPS,C,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0L,3(S+#$W-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PQ
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@L-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C@L-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-C`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-RPR.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$969E<G)E9"!R979E;G5E(&EN8VQU9&5D(&EN(&QO;F<M=&5R
M;2!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-RPQ,S4L-C@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$Y+#DU-BPS-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDP,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL-#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L.#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDL,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-3`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0VQI;FEC86P@;6EL97-T;VYE('!A>6UE;G1S('5N9&5R(&%G
M<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V:65W('!E
M<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S,P(&1A
M>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM97)C:6%L:7IA
M=&EO;B!O9B!M;VQE8W5L97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VQI;FEC
M86P@;6EL97-T;VYE('!A>6UE;G1S('5N9&5R(&%G<F5E;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#`P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@8VQI
M;FEC86PL(')E9W5L871O<GD@86YD('-A;&5S(&UI;&5S=&]N92!P87EM96YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T
M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C4P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M
M8F5R(&]F(&%N;G5A;"!M86EN=&5N86YC92!P87EM96YT<R!R96-E:79E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V5I=F5D(&EN8VQU9&EN9R!U<&9R;VYT
M+"!A;FYU86P@;6%I;G1E;F%N8V4@86YD(&UI;&5S=&]N92!P87EM96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M."PX,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D(%-T;V-K('!U
M<F-H87-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X,RPV
M,C(L,S4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q,BPP,30L.#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&]B;&EG871I;VX@8V]M<&QE=&EO
M;B!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG,C`Q-2TP.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG,C`Q-"TP,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)I
M;V0@;V8@86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S,@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1!
M4E0@<')O9W)A;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1E<FT@;V8@=&AE(&%G
M<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG,C`R,"TP-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979I97<@;V8@
M8VQI;FEC86P@9&%T83PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,2!Y96%R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R.6,T8F-A7V-D
M83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\V,CEC-&)C85]C9&$W7S1D865?830T-5\Q,C0U864R-#AC
M.30O5V]R:W-H965T<R]3:&5E=#4R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%6E9!13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N
M8VEE<R`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D
M*3QB<CY);B!-:6QL:6]N<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^3W!E<F%T:6YG($QE87-E<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5N
M="!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,BXY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`R+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,97-S964@;&5A<VEN9R!A<G)A;F=E;65N=',L(&]P97)A
M=&EN9R!L96%S97,L(')E;F5W86P@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5N="!E>'!E;G-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXW/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+CD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE87-E
M(%M-96UB97)=('P@3V9F:6-E(&%N9"!,86)O<F%T;W)Y(%-P86-E(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^3W!E<F%T:6YG($QE87-E<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V4@97AP:7)A
M=&EO;B!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y-87(@
M,S$L#0H)"3(P,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&5A<V4@6TUE;6)E<ET@?"!-86YU9F%C='5R:6YG
M($9A8VEL:71I97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY/<&5R871I;F<@3&5A<V5S(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,96%S92!E>'!I<F%T:6]N(&1A=&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/D1E8R`S,2P-"@D),C`Q-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)L96%S92!;365M
M8F5R72!\($]F9FEC92!A;F0@3&%B;W)A=&]R>2!3<&%C92!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P
M97)A=&EN9R!,96%S97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE87-E(&5X<&ER871I;VX@
M9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^1&5C(#,Q+`T*
M"0DR,#$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S8R.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,CEC-&)C85]C9&$W7S1D865?
M830T-5\Q,C0U864R-#AC.30O5V]R:W-H965T<R]3:&5E=#4S+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%3D9!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VUM:71M96YT
M<R!A;F0@0V]N=&EN9V5N8VEE<R`M(%-C:&5D=6QE(&]F($UI;FEM=6T@1G5T
M=7)E($QE87-E(%!A>6UE;G1S(%)E8V5I=F%B;&4@*$1E=&%I;"D@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#;VYT:6YG96YC:65S($1I
M<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^,C`Q-#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`S+#8U,2PT,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,34\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L,S$P+#@X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPT,3`L,C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$W/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#4Q,BPU,3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3@\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L-S@P+#,Y.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&AE<F5A9G1E<CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$V+#8V-2PT
M,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R
M.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y-`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\V,CEC-&)C85]C9&$W7S1D865?830T-5\Q
M,C0U864R-#AC.30O5V]R:W-H965T<R]3:&5E=#4T+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M5T]!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0<F]D=6-T($UI;&5S=&]N
M92!087EM96YT<R!A;F0@4F]Y86QT>2!!9W)E96UE;G1S("T@061D:71I;VYA
M;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,V($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`P-3QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#`U
M/&)R/DUI;FEM=6T@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2G5N+B`S,"P@,C`P-3QB<CY-87AI;75M(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)O
M>6%L='D@06=R965M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!C;VYS
M:61E<F%T:6]N(&]F(&%S<V5T('!U<F-H87-E(&%G<F5E;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L.34P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@<W1O8VL@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S8L,3,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DUA>&EM=6T@<F]Y86QT>2!P87EM96YT<R!P97)C96YT
M86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N-S4E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"XP
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!A>6UE;G1S(')E;&%T960@=&\@=&AE(&%D9&ET:6]N86P@8V]N<VED
M97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(Y
M8S1B8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X8SDT#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R
M-#5A93(T.&,Y-"]7;W)K<VAE971S+U-H965T-34N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5&
M3T%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D5M<&QO>65E($)E;F5F:70@
M4&QA;B`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#(U+"`R,#`R/&)R/D%G93QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$969I;F5D($-O;G1R:6)U
M=&EO;B!096YS:6]N($%N9"!/=&AE<B!0;W-T<F5T:7)E;65N="!0;&%N<R!$
M:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5L:6=I8FEL:71Y(&]F(&5M<&QO>65E
M('!A<G1I8VEP871I;VX@<&QA;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@96UP;&]Y964@8V]N=')I8G5T
M:6]N('1O('-A;&%R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!E;7!L;WEE92!V97-T960@8V]N
M=')I8G5T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUP86YY)W,@8V]N=')I8G5T:6]N('1O('!L86X@=&]T86P\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(U,BPY,S`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(R
M-2PQ.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(Q-RPP.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S8R.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R-#5A93(T.&,Y
M-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,CEC-&)C85]C9&$W
M7S1D865?830T-5\Q,C0U864R-#AC.30O5V]R:W-H965T<R]3:&5E=#4V+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%5#9!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY1=6%R
M=&5R;'D@1FEN86YC:6%L($EN9F]R;6%T:6]N("T@0V]M<&%N>2=S($-O;G-O
M;&ED871E9"!1=6%R=&5R;'D@4F5S=6QT<R!O9B!/<&5R871I;VYS("A$971A
M:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#@^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E%U87)T97)L>2!&:6YA;F-I86P@26YF;W)M871I;VX@1&ES8VQO<W5R92!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q-"PY,#8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,"PR,S(L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,BPR.3DL
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q,"PU.3@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Y+#<Y.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$V+#`X,BPP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$W+#0S
M-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(P+#4Q,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#4X+#`S-"PV-C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8S+#@R-BPP.3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4W
M+#(P-RPS-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!I;F-O;64@*&QO<W,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#,L,C`U+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L-C`T+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,CDT+#`P
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#,L,S8V+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#(L,3`U+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L-C`Q+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPU-#8L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`T+#,R,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#(V,"PX,S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X+#,V,2PW-34\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L-S$W+#$R
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&EN8V]M92`H;&]S<RD@<&5R('-H87)E+"!B87-I8SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C$T*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XQ-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XR-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#(N.3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@Q+CDR*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XP-"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-O
M;64@*&QO<W,I('!E<B!S:&%R92P@9&EL=71E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@P+C$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XR-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(N.3,I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q
M+CDR*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H,"XP-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S8R.6,T8F-A7V-D83=?-&1A95]A-#0U
M7S$R-#5A93(T.&,Y-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V
M,CEC-&)C85]C9&$W7S1D865?830T-5\Q,C0U864R-#AC.30O5V]R:W-H965T
M<R]3:&5E=#4W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%2D5!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY3=6)S97%U96YT($5V96YT<R`M($%D9&ET:6]N86P@26YF;W)M
M871I;VX@*$1E=&%I;"D@*%-U8G-E<75E;G0@179E;G0@6TUE;6)E<ETL(%53
M1"`D*3QB<CY);B!-:6QL:6]N<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S
M<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1F5B+B`R."P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0VQI;FEC86P@;6EL97-T;VYE('!A>6UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@;&EC96YS92!G<F%N
M="!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V
M:65W('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S,P
M(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:R!N=6UB97(@;V8@<VAA<F5S('-O;&0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-T;V-K+"!P<FEC92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,S8N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!S:&%R97,@<V]L9"!U;F1E
M<B!O=F5R+6%L;&]T;65N=',@3W!T:6]N('1O('5N9&5R=W)I=&5R/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-3`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L
M('-H87)E<R!S;VQD('5N9&5R(&]V97(M86QL;W1M96YT<R!O<'1I;VX@=&\@
M=6YD97)W<FET97(L('!R:6-E('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`S-BXU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('-A;&4@;V8@
M<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-BXW/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M97)V:65R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-U8G-E<75E;G0@179E;G0@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;&EN
M:6-A;"!M:6QE<W1O;F4@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@;&EC96YS92!G<F%N="!F965S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979I97<@<&5R
M:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,S`@9&%Y<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C(Y8S1B
M8V%?8V1A-U\T9&%E7V$T-#5?,3(T-6%E,C0X8SDT#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S8R.6,T8F-A7V-D83=?-&1A95]A-#0U7S$R-#5A
M93(T.&,Y-"]7;W)K<VAE971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS
M.F\],T0B=7)N.G-C:&5M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E
M(CX-"B`\;SI-86EN1FEL92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#`S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,3$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-BYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C`N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Q+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970R,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,C,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(T+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R."YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,CDN:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#,P+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970S,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S(N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,S+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970S-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,S4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,V
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,S@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#,Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T
M,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#$N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0R+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970T,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M-#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0U+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970T-BYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T-#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#0X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T.2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3`N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#4Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970U,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3,N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4T+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970U-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T-38N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4W+FAT;6PB
M+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%\V,CEC-&)C85]C9&$W7S1D
8865?830T-5\Q,C0U864R-#AC.30M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2PAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shared-Based Payments - Schedule of Stock Option Activity (Detail) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Mar. 16, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Beginning Balance</a></td>
        <td class="nump">3,249,541<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
        <td class="nump">1,307,101<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised</a></td>
        <td class="num">(1,268,049)<span></span></td>
        <td class="num">(863,176)<span></span></td>
        <td class="num">(49,883)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited or expired</a></td>
        <td class="num">(87,635)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Ending Balance</a></td>
        <td class="nump">3,200,958<span></span></td>
        <td class="nump">3,249,541<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable</a></td>
        <td class="nump">1,688,251<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, Vested and expected to vest</a></td>
        <td class="nump">3,022,948<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Beginning Balance</a></td>
        <td class="nump">$ 0.94<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.94<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Granted</a></td>
        <td class="nump">$ 10.70<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercised</a></td>
        <td class="nump">$ 0.85<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Forfeited or expired</a></td>
        <td class="nump">$ 1.11<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Ending Balance</a></td>
        <td class="nump">$ 4.90<span></span></td>
        <td class="nump">$ 0.94<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.94<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercisable</a></td>
        <td class="nump">$ 0.94<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Vested and expected to vest</a></td>
        <td class="nump">$ 4.64<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding</a></td>
        <td class="text">6 years 10 months 24 days<span></span></td>
        <td class="text">7 years 3 months 18 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Exercisable</a></td>
        <td class="text">4 years 9 months 18 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested and expected to vest</a></td>
        <td class="text">6 years 9 months 18 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Ending Balance</a></td>
        <td class="nump">$ 67,532<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
        <td class="nump">42,311<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
        <td class="nump">$ 64,574<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6HAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Segment</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum', window );">Original maturity of financial instruments</a></td>
        <td class="text">3 months<span></span></td>
        <td class="text">3 months<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairedFinancingReceivableRelatedAllowance', window );">Allowance recorded</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Amounts classified as restricted cash</a></td>
        <td class="nump">$ 404,850<span></span></td>
        <td class="nump">$ 404,850<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority', window );">Percentage of largest amount likely to be realized upon ultimate settlement</a></td>
        <td class="nump">50.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Liquid investment maturity period to be classified as cash equivalent maximum.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage likely of largest amount of tax benefit being realized upon ultimate settlement with taxing authority.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedFinancingReceivableRelatedAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of allowance for credit losses related to recorded investment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28368275&amp;loc=d3e5212-111524<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairedFinancingReceivableRelatedAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NumberOfOperatingSegments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Nature of Operations - Additional Information (Detail) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Oct. 16, 2013

</div>
          <div>IPO [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OrganizationAndNatureOfBusinessLineItems', window );"><strong>Organization And Nature Of Business [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">MacroGenics incorporated date</a></td>
        <td class="text">Aug. 14,
				 2000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment', window );">Initial public offering number of share sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,750,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalCommonStockIssuePricePerShare', window );">Initial public offering price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 16.00<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses', window );">Proceeds from initial public offering before offering expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 85.6<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when an entity was incorporated</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityIncorporationDateOfIncorporation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalCommonStockIssuePricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional common stock issue price per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AdditionalCommonStockIssuePricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OrganizationAndNatureOfBusinessLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_OrganizationAndNatureOfBusinessLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance initial public offering before offering expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares new issues including underwriters over allotment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ET6AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Quarterly Financial Information - Company's Consolidated Quarterly Results of Operations (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="8">3 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
        <td class="nump">$ 14,906,000<span></span></td>
        <td class="nump">$ 20,232,000<span></span></td>
        <td class="nump">$ 12,299,000<span></span></td>
        <td class="nump">$ 10,598,000<span></span></td>
        <td class="nump">$ 9,799,000<span></span></td>
        <td class="nump">$ 16,082,000<span></span></td>
        <td class="nump">$ 17,435,000<span></span></td>
        <td class="nump">$ 20,510,000<span></span></td>
        <td class="nump">$ 58,034,668<span></span></td>
        <td class="nump">$ 63,826,098<span></span></td>
        <td class="nump">$ 57,207,366<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="num">$ (3,205,000)<span></span></td>
        <td class="nump">$ 6,604,000<span></span></td>
        <td class="num">$ (294,000)<span></span></td>
        <td class="num">$ (3,366,000)<span></span></td>
        <td class="num">$ (2,105,000)<span></span></td>
        <td class="nump">$ 2,601,000<span></span></td>
        <td class="nump">$ 3,546,000<span></span></td>
        <td class="nump">$ 4,320,000<span></span></td>
        <td class="num">$ (260,835)<span></span></td>
        <td class="nump">$ 8,361,755<span></span></td>
        <td class="nump">$ 6,717,120<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic</a></td>
        <td class="num">$ (0.14)<span></span></td>
        <td class="nump">$ 0.14<span></span></td>
        <td class="num">$ (0.24)<span></span></td>
        <td class="num">$ (2.93)<span></span></td>
        <td class="num">$ (1.92)<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="num">$ (0.04)<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted</a></td>
        <td class="num">$ (0.14)<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="num">$ (0.24)<span></span></td>
        <td class="num">$ (2.93)<span></span></td>
        <td class="num">$ (1.92)<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="num">$ (0.04)<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.23)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E66AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Provision for federal or state income taxes</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart', window );">Net operating loss carryforwards expiration start year</a></td>
        <td class="text">2023<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd', window );">Net operating loss carryforwards expiration ending year</a></td>
        <td class="text">2033<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TaxCreditCarryforwardExpirationYearRangeStart', window );">Federal Tax credit expiration start year</a></td>
        <td class="text">2020<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TaxCreditCarryforwardExpirationYearRangeEnd', window );">Federal Tax credit expiration ending year</a></td>
        <td class="text">2033<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount', window );">Net operating loss</a></td>
        <td class="nump">8,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart', window );">Net operating losses limited for year minimum</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd', window );">Net operating losses limited for year maximum</a></td>
        <td class="text">2027<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation', window );">Remaining portion of net operating losses</a></td>
        <td class="nump">96,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward', window );">Net operating losses, recognized as a benefit through additional-paid-in-capital</a></td>
        <td class="nump">1,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Gross unrecognized tax benefits</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized interest or penalties</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart', window );">Income tax examination year subject to examination, Range start</a></td>
        <td class="text">2001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd', window );">Income tax examination year subject to examination, Range End</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Net operating losses limited for use utilized on an annual basis</a></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Net operating losses limited for use utilized on an annual basis</a></td>
        <td class="nump">1,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">U.S. Federal Government [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
        <td class="nump">104,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">US Federal Tax credits carry forward</a></td>
        <td class="nump">23,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">State and Local Jurisdiction [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
        <td class="nump">$ 60,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net operating loss carry forward expiration ending year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net operating loss carry forward expiration start year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncomeTaxesDisclosureLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_IncomeTaxesDisclosureLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income tax examination year under examination range end.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_IncomeTaxExaminationYearUnderExaminationRangeEnd</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income tax examination year under examination range start.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_IncomeTaxExaminationYearUnderExaminationRangeStart</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating loss carryforwards annual limitation amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_OperatingLossCarryforwardsAnnualLimitationAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating loss carryforwards limitations on use amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating loss carryforwards limitations on use year end.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_OperatingLossCarryforwardsLimitationsOnUseYearEnd</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating loss carryforwards limitations on use year start.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_OperatingLossCarryforwardsLimitationsOnUseYearStart</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating loss carryforwards not subject to limitation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_OperatingLossCarryforwardsNotSubjectToLimitation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TaxCreditCarryforwardExpirationYearRangeEnd">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tax credit carryforward expiration year range end.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_TaxCreditCarryforwardExpirationYearRangeEnd</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TaxCreditCarryforwardExpirationYearRangeStart">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tax credit carryforward expiration year range start.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_TaxCreditCarryforwardExpirationYearRangeStart</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CurrentIncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Carryforwards<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TaxCreditCarryforwardAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of an unrecognized tax benefit that is directly related to a position taken in a tax year that results in a net operating loss carryforward. This amount is presented as a reduction of the related deferred tax asset in the balance sheet if that deferred tax asset is not used. This amount is presented separately from the deferred tax asset for a net operating loss carryforward if this unrelated tax benefit is associated with a different tax position.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Unrecognized Tax Benefit<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e31996-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 17<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28638-109314<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e31986-109318<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28619-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3RAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 90,434,435<span></span></td>
        <td class="nump">$ 18,695,197<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
        <td class="nump">26,046,974<span></span></td>
        <td class="nump">29,047,958<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RestrictedCashFairValueDisclosure', window );">Restricted cash</a></td>
        <td class="nump">404,850<span></span></td>
        <td class="nump">404,850<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
        <td class="nump">116,886,259<span></span></td>
        <td class="nump">48,148,005<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Preferred stock warrant liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(52,947)<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Quoted Prices in Active Markets for Identical Assets Level 1 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
        <td class="nump">90,434,435<span></span></td>
        <td class="nump">18,695,197<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
        <td class="nump">26,046,974<span></span></td>
        <td class="nump">29,047,958<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RestrictedCashFairValueDisclosure', window );">Restricted cash</a></td>
        <td class="nump">404,850<span></span></td>
        <td class="nump">404,850<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
        <td class="nump">116,886,259<span></span></td>
        <td class="nump">48,148,005<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Preferred stock warrant liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Significant Other Observable Inputs Level 2 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RestrictedCashFairValueDisclosure', window );">Restricted cash</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Preferred stock warrant liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Significant Unobservable Inputs Level 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RestrictedCashFairValueDisclosure', window );">Restricted cash</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Preferred stock warrant liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (52,947)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_MoneyMarketFundsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Money market funds fair value disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_MoneyMarketFundsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RestrictedCashFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Restricted cash fair value disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_RestrictedCashFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesFairValueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of warrants not settleable in cash classified as equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2IAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Preferred Stock Warrant Liability (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Settlement of preferred stock warrants</a></td>
        <td class="nump">$ 1,860,591<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance beginning of year</a></td>
        <td class="num">(52,947)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Total unrealized gains (losses) included in earnings</a></td>
        <td class="num">(626,349)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Settlement of preferred stock warrants</a></td>
        <td class="nump">679,296<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance end of year</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of unrealized (holding) gain (loss) which is included in the statement of income (or changes in net assets) related to those liabilities still held at the reporting date for which fair value is measured on a recurring basis using significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gross value of stock issued during the period upon the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>2. Summary of Significant Accounting Policies</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Basis of Presentation and Principles of
 Consolidation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The consolidated financial statements include the accounts of
 MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics
 West, Inc. All intercompany accounts and transactions have been
 eliminated in consolidation. The Company currently operates in one
 operating segment. Operating segments are defined as components of
 an enterprise about which separate discrete information is
 available for the chief operating decision maker, or decision
 making group, in deciding how to allocate resources and assessing
 performance. The Company views its operations and manages its
 business in one segment, which is developing monoclonal
 antibody-based therapeutics for cancer, autoimmune and infectious
 diseases.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Use of Estimates</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The preparation of the financial statements in accordance with
 generally accepted accounting principles (&#x201C;GAAP&#x201D;)
 requires the Company to make estimates and judgments in certain
 circumstances that affect the reported amounts of assets,
 liabilities, revenues and expenses, and related disclosure of
 contingent assets and liabilities. In preparing these consolidated
 financial statements, management has made its best estimates and
 judgments of certain amounts included in the financial statements,
 giving due consideration to materiality. On an ongoing basis, the
 Company evaluates its estimates, including those related to revenue
 recognition, fair values of assets, convertible preferred stock and
 common stock, preferred stock warrant liability, income taxes,
 pre-clinical study and clinical trial accruals and other
 contingencies. Management bases its estimates on historical
 experience or on various other assumptions that it believes to be
 reasonable under the circumstances. Actual results could differ
 from these estimates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In addition, prior to the Company&#x2019;s IPO in October 2013, the
 Company utilized estimates and assumptions in determining the fair
 value of its common stock. The Company granted stock options at
 exercise prices not less than the fair value of its common stock as
 determined by the Board of Directors, with input from management.
 Management used contemporaneous valuations in estimating the fair
 value of its common stock. The board of directors determined the
 estimated fair value of the common stock based on a number of
 objective and subjective factors, including external market
 considerations affecting the biotechnology industry and the
 historic prices at which the Company sold shares of its preferred
 stock.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Cash and Cash Equivalents</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company considers all investments in highly liquid financial
 instruments with an original maturity of three months or less at
 the date of purchase to be cash equivalents. Cash and cash
 equivalents consist of certificates of deposit and investments in
 money market funds with commercial banks and financial
 institutions. Cash equivalents are stated at amortized cost, plus
 accrued interest, which approximates fair value.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Accounts Receivable</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Accounts receivable that management has the intent and ability to
 collect are reported in the consolidated balance sheets at
 outstanding amounts, less an allowance for doubtful accounts. The
 Company writes off uncollectible receivables when the likelihood of
 collection is remote.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company evaluates the collectability of accounts receivable on
 a regular basis. The allowance, if any, is based upon various
 factors including the financial condition and payment history of
 customers, an overall review of collections experience on other
 accounts and economic factors or events expected to affect future
 collections experience. No allowance was recorded as of
 December&#xA0;31, 2013 or 2012, as the Company has a history of
 collecting on all outstanding accounts.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Restricted Cash</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company is required to maintain certificates of deposit that
 serve as collateral for various operating leases and corporate
 credit card accounts. Amounts classified as restricted cash on the
 consolidated balance sheets are $404,850 at December&#xA0;31, 2013
 and 2012.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Fair Value of Financial Instruments</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The fair market values of the financial instruments included in the
 financial statements, which include cash equivalents and money
 market accounts, approximate their carrying values at
 December&#xA0;31, 2013 and 2012, due to their short-term
 maturities. The Company accounts for recurring and non-recurring
 fair value measurements in accordance with the Financial Accounting
 Standards Board (&#x201C;FASB&#x201D;) Accounting Standards
 Codification (&#x201C;ASC&#x201D;) 820, <i>Fair Value Measurements
 and Disclosures</i> (&#x201C;ASC 820&#x201D;). ASC 820 defines fair
 value, establishes a fair value hierarchy for assets and
 liabilities measured at fair value, and requires expanded
 disclosures about fair value measurements. The ASC 820 hierarchy
 ranks the quality of reliability of inputs, or assumptions, used in
 the determination of fair value and requires assets and liabilities
 carried at fair value to be classified and disclosed in one of the
 following three categories:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 1&#x2014;Fair value is
 determined by using unadjusted quoted prices that are available in
 active markets for identical assets and liabilities.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 2&#x2014;Fair value is
 determined by using inputs other than Level 1 quoted prices that
 are directly or indirectly observable. Inputs can include quoted
 prices for similar assets and liabilities in active markets or
 quoted prices for identical assets and liabilities in inactive
 markets. Related inputs can also include those used in valuation or
 other pricing models, such as interest rates and yield curves that
 can be corroborated by observable market data.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 3&#x2014;Fair value is
 determined by inputs that are unobservable and not corroborated by
 market data. Use of these inputs involves significant and
 subjective judgments to be made by a reporting entity&#xA0;&#x2013;
 e.g., determining an appropriate adjustment to a discount factor
 for illiquidity associated with a given security.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The Company evaluates financial assets and liabilities subject to
 fair value measurements on a recurring basis to determine the
 appropriate level at which to classify them each reporting period.
 This determination requires the Company to make subjective
 judgments as to the significance of inputs used in determining fair
 value and where such inputs lie within the ASC 820 hierarchy.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Financial assets and liabilities subject to fair value measurements
 were as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="38%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 December&#xA0;31, 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;Prices&#xA0;in<br />
 Active Markets<br />
 for<br />
 Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;Other<br />
 Observable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br />
 Unobservable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">90,434,435</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">90,434,435</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,046,974</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,046,974</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total Assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">116,886,259</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">116,886,259</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 December&#xA0;31, 2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;Prices&#xA0;in<br />
 Active Markets<br />
 for<br />
 Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;Other<br />
 Observable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br />
 Unobservable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,695,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,695,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29,047,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29,047,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total Assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,148,005</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,148,005</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Preferred stock warrant liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of December&#xA0;31, 2012, the Company transferred its money
 market funds from Level 2 to Level 1 because the inputs are now
 based upon a quoted market price.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company&#x2019;s Level 1 securities primarily consist of
 restricted cash, cash equivalents and money market funds. The
 Company determines the estimated fair value for its Level 1
 securities using quoted (unadjusted) prices for identical assets or
 liabilities in active markets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company determines the estimated fair value for its Level 2
 securities using the following methods: quoted prices for similar
 assets/liabilities in active markets, inputs other than quoted
 prices that are observable for the asset/liability (e.g., interest
 rates, yield curves volatilities, default rates, etc.) and inputs
 that are derived principally from or corroborated by other
 observable market data.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table provides a rollforward of the Company&#x2019;s
 preferred stock warrant liability, which was the only financial
 instrument measured at fair value on a recurring basis using
 significant unobservable inputs (Level 3) as defined in ASC
 820:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="82%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Balance at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total unrealized gains (losses) included in earnings</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(626,349</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Settlement of preferred stock warrants</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">679,296</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Balance at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In order to estimate the fair value of the preferred stock purchase
 warrants, the business enterprise value was established based on a
 discounted cash flow model (income approach). The Company utilized
 an option pricing method to value the shares using a contingent
 claims analysis, which applies a series of call options whose
 inputs reflect the liquidation preferences and conversion behavior
 of the different classes of equity. After the equity value of the
 business enterprise was determined, the total equity value is
 allocated to the various equity instruments such as preferred
 stock, stock options and preferred stock purchase warrants. Key
 management estimates relate to the time period to liquidation and
 conversion behavior of a particular class of stockholders. The
 business enterprise value includes assumptions related to product
 approval, market penetration and costs to develop the product.
 Significant changes to these assumptions would result in
 increases/decreases to the fair value of the outstanding
 warrants.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The total unrealized gains (losses) on the preferred stock warrants
 included in earnings is included as a component of other income
 (expense) in the consolidated statement of operations and
 comprehensive income. Immediately prior to the Company&#x2019;s IPO
 in October 2013, all the preferred stock warrants were exercised
 and converted into shares of Series D-2 preferred stock, which were
 subsequently converted to common stock.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Concentration of Credit Risk</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Substantially all of the Company&#x2019;s cash and cash equivalents
 are maintained with major financial institutions in the United
 States. Deposits held with banks may exceed the amount of insurance
 provided on such deposits. Generally, these deposits may be
 redeemed upon demand and, therefore, bear minimal risk.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Financial instruments that potentially subject the Company to
 concentrations of credit risk consist principally of cash and cash
 equivalents, and accounts receivable. The counterparties are
 various corporations, financial institutions and government
 agencies of high credit standing.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For the years ended December&#xA0;31, 2013, 2012 and 2011, all of
 the Company&#x2019;s grant revenue was related to contracts and
 research grants received from U.S. government agencies.
 Collaborations with Les Laboratoires Servier and Institut de
 Recherches Servier (collectively, &#x201C;Servier&#x201D;),
 Boehringer Ingelheim GmbH (&#x201C;Boehringer&#x201D;), Gilead
 Sciences, Inc. (&#x201C;Gilead&#x201D;), Pfizer, Inc.
 (&#x201C;Pfizer&#x201D;) and Eli Lilly&#xA0;&amp; Co. (&#x201C;Eli
 Lilly&#x201D;) account for all other revenue. All outstanding
 receivables are due from the Company&#x2019;s collaborators and U.S.
 government agencies.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table represents the percentage of all significant
 revenue earned in the periods indicated:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">
 <b>Year&#xA0;Ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2013&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2012&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2011&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Servier</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Pfizer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Government Agencies</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.5</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Eli Lilly</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">48.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following table represents the percentage of all significant
 accounts receivable:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2013&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2012&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">53.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Pfizer.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">45.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Eli Lilly</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Servier</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Government Agencies</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Property and Equipment</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Property and equipment are stated at cost. Upon retirement or sale,
 the cost of assets disposed of and the related accumulated
 depreciation are removed from the accounts and any resulting gain
 or loss is credited or charged to operations. Repairs and
 maintenance costs are expensed as incurred. Depreciation is
 computed using the straight-line method over the following
 estimated useful lives:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="51%"></td>
 <td valign="bottom" width="2%"></td>
 <td width="47%"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Computer equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Furniture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">10 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Laboratory and office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">5 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">Shorter of lease term or useful life</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Impairment of Long-Lived Assets</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company assesses the recoverability of its long-lived assets in
 accordance with the provisions of ASC&#xA0;360, <i>Property, Plant
 and Equipment</i>. ASC 360 requires that long-lived assets be
 reviewed for impairment whenever events or changes in circumstances
 indicate that the carrying amount of an asset may not be
 recoverable. Recoverability of the long-lived asset is measured by
 a comparison of the carrying amount of the asset to future
 undiscounted net cash flows expected to be generated by the asset
 or asset group. If carrying value exceeds the sum of undiscounted
 cash flows, the Company then determines the fair value of the
 underlying asset group. Any impairment to be recognized is measured
 by the amount by which the carrying amount of the asset group
 exceeds the estimated fair value of the asset group. Assets to be
 disposed of are reported at the lower of the carrying amount or
 fair value, less costs to sell. As of December&#xA0;31, 2013 and
 2012, the Company determined that there were no impaired assets and
 had no assets held-for-sale.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Income Taxes</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Deferred tax assets and liabilities are determined based on
 differences between the financial reporting and tax basis of assets
 and liabilities and are measured using the enacted tax rates and
 laws that are expected to be in effect when the differences are
 expected to reverse. The effect on deferred tax assets and
 liabilities of a change in tax rates is recognized as income in the
 period that such tax rate changes are enacted. The measurement of a
 deferred tax asset is reduced, if necessary, by a valuation
 allowance if it is more likely than not that some portion or all of
 the deferred tax asset will not be realized. Financial statement
 recognition of a tax position taken or expected to be taken in a
 tax return is determined based on a more-likely-than-not threshold
 of that position being sustained. If the tax position meets this
 threshold, the benefit to be recognized is measured as the largest
 amount that is more than 50% likely to be realized upon ultimate
 settlement. The Company&#x2019;s policy is to record interest and
 penalties related to uncertain tax positions as a component of
 income tax expense.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Revenues</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 6pt">
 <i>Revenue Recognition</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company enters into collaboration and license agreements with
 collaborators for the development of monoclonal antibody-based
 therapeutics to treat cancer and other complex diseases. The terms
 of these agreements contain multiple deliverables which may include
 (i)&#xA0;licenses, or options to obtain licenses, to the
 Company&#x2019;s technological platforms, such as its Fc
 Optimization and Dual-Affinity Re-Targeting (&#x201C;DART&#x201D;)
 technologies, (ii)&#xA0;rights to future technological
 improvements, (iii)&#xA0;research and development activities to be
 performed on behalf of the collaborator or as part of the
 collaboration, and (iv)&#xA0;the manufacture of pre-clinical or
 clinical materials for the collaborator. Payments to the Company
 under these agreements may include nonrefundable license fees,
 option fees, exercise fees, payments for research and development
 activities, payments for the manufacture of pre-clinical or
 clinical materials, license maintenance payments, payments based
 upon the achievement of certain milestones and royalties on product
 sales. Other benefits to the Company of these agreements include
 the right to sell products resulting from the collaborative efforts
 of the parties in specific geographic territories. The Company
 follows the provisions of the FASB ASC Topic 605-25, <i>Revenue
 Recognition&#xA0;&#x2013;&#xA0;Multiple-Element Arrangements</i>,
 and ASC Topic 605-28, <i>Revenue Recognition&#x2013;Milestone
 Method</i>, in accounting for these agreements. In order to account
 for these agreements, the Company must identify the deliverables
 included within the agreement and evaluate which deliverables
 represent separate units of accounting based on the achievement of
 certain criteria, including whether the delivered element has
 stand-alone value to the collaborator. The consideration received
 is allocated among the separate units of accounting, and the
 applicable revenue recognition criteria are applied to each of the
 separate units.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For the periods presented, the Company had the following two types
 of agreements with the parties identified below: 1) exclusive
 development and commercialization licenses to use the
 Company&#x2019;s technology and/or certain other intellectual
 property to develop compounds against specified targets (referred
 to herein as exclusive licenses); and 2) Option/research agreements
 to secure on established terms, development and commercialization
 licenses to anticancer and other therapeutic product candidates to
 collaborator selected targets developed by the Company during an
 option period (referred to herein as right-to-develop
 agreements).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 There are no performance, cancellation, termination or refund
 provisions in any of the arrangements that contain material
 financial consequences to the Company.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt">
 <i>Exclusive Licenses</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The deliverables under an exclusive license agreement generally
 include the exclusive license to the Company&#x2019;s DART
 technology with respect to a specified antigen target, and may also
 include deliverables related to rights to future technological
 improvements, research and pre-clinical development activities to
 be performed on behalf of the collaborator. In some cases the
 Company may have an option to participate in the co-development of
 product candidates that result from such agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Generally, exclusive license agreements contain nonrefundable terms
 for payments and, depending on the terms of the agreement, provide
 that the Company will (i)&#xA0;at the collaborator&#x2019;s request,
 provide research and pre-clinical development services at
 negotiated prices which are generally consistent with what other
 third parties would charge, (ii)&#xA0;earn payments upon the
 achievement of certain milestones, (iii)&#xA0;earn royalty
 payments, and (iv)&#xA0;in some cases grant the Company an option
 to participate in the development and commercialization of products
 that result from such agreements. Royalty rates may vary over the
 royalty term depending on the Company&#x2019;s intellectual property
 rights and whether the Company exercises any co-development and
 co-commercialization rights. The Company may provide technical
 assistance and share any technology improvements with its
 collaborators during the term of the collaboration agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company does not directly control when any collaborator will
 achieve milestones or become liable for royalty payments.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In determining the units of accounting, management evaluates
 whether the exclusive license has stand-alone value from the
 undelivered elements to the collaborator based on the consideration
 of the relevant facts and circumstances for each arrangement.
 Factors considered in this determination include the research and
 development capabilities of the partner and the availability of
 technology platform and product research expertise in the general
 marketplace. If the Company concludes that the license has
 stand-alone value and therefore will be accounted for as a separate
 unit of accounting, the Company then determines the estimated
 selling prices of the license and all other units of accounting
 based on market conditions, similar arrangements entered into by
 third parties, and entity-specific factors such as the terms of the
 Company&#x2019;s previous collaboration agreements, recent
 pre-clinical and clinical testing results of therapeutic product
 candidates that use the Company&#x2019;s technology platforms, the
 Company&#x2019;s pricing practices and pricing objectives, the
 likelihood that technological improvements will be made, the
 likelihood that technological improvements made will be used by the
 Company&#x2019;s collaborators and the nature of the research
 services to be performed on behalf of its collaborators and market
 rates for similar services.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Upfront payments on exclusive licenses are deferred if facts and
 circumstances dictate that the license does not have stand-alone
 value. Prior to the adoption of Accounting Standards Update
 (&#x201C;ASU&#x201D;) No.&#xA0;2009-13, <i>Revenue Arrangements with
 Multiple Deliverables</i>, on January&#xA0;1, 2011, the Company
 determined that its licenses lacked stand-alone value because it
 did not have vendor-specific objective evidence of selling price
 (&#x201C;VSOE&#x201D;), and were combined with other elements of the
 arrangement and any amounts associated with the license were
 deferred and amortized over a certain period, which the Company
 refers to as the Company&#x2019;s period of substantial involvement.
 In making the determination of the length of the period over which
 to defer revenue for contracts entered into prior to the adoption
 of ASU No.&#xA0;2009-13, significant judgment and estimation is
 used by the Company and can have an impact on the amount of revenue
 recognized in a given period. Historically, the Company&#x2019;s
 involvement with the development of a collaborator&#x2019;s product
 candidate has been significant at the early stages of development,
 and lessens as it progresses into clinical trials. Accordingly, the
 Company generally estimates this period of substantial involvement
 to begin at the inception of the collaboration agreement and
 conclude at the end of the Company&#x2019;s substantial involvement.
 ASU No.&#xA0;2009-13 amends the criteria for separating and
 allocating consideration in a multiple element arrangement by
 modifying the fair value requirements for revenue recognition and
 eliminating the use of the residual value method. The selling
 prices of deliverables under an arrangement may be derived using
 third-party evidence (&#x201C;TPE&#x201D;), or a best estimate of
 selling price (&#x201C;BESP&#x201D;), if VSOE is not available. The
 objective of BESP is to determine the price at which the Company
 would transact a sale if the element within the license agreement
 was sold on a standalone basis. Establishing BESP involves
 management&#x2019;s judgment and considers multiple factors,
 including market conditions and company-specific factors, including
 those factors contemplated in negotiating the agreements, as well
 as internally developed models that include assumptions related to
 market opportunity, discounted cash flows, estimated development
 costs, probability of success and the time needed to commercialize
 a product candidate pursuant to the license. In validating the
 BESP, management considers whether changes in key assumptions used
 to determine the BESP will have a significant effect on the
 allocation of the arrangement consideration between the multiple
 deliverables. Deliverables under the arrangement are separate units
 of accounting if (i)&#xA0;the delivered item has value to the
 customer on a standalone basis and (ii)&#xA0;if the arrangement
 includes a general right of return relative to the delivered item,
 delivery or performance of the undelivered item is considered
 probable and substantially within the Company&#x2019;s control. The
 arrangement consideration that is fixed or determinable at the
 inception of the arrangement is allocated to the separate units of
 accounting based on their relative selling prices. The appropriate
 revenue recognition model is applied to each element and revenue is
 accordingly recognized as each element is delivered. Management
 exercises significant judgment in determining whether a deliverable
 is a separate unit of accounting.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In determining the separate units of accounting, the Company
 evaluated whether the exclusive license had standalone value to the
 collaborator based on consideration of the relevant facts and
 circumstances for each arrangement. Factors considered in this
 determination included the research and development capabilities of
 the collaborator and the availability of relevant research
 expertise in the marketplace. In addition, the Company considered
 whether or not (i)&#xA0;the collaborator could use the license for
 its intended purpose without the receipt of the remaining
 deliverables, (ii)&#xA0;the value of the license was dependent on
 the undelivered items and (iii)&#xA0;the collaborator or other
 vendors could provide the undelivered items.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company reassesses its periods of substantial involvement over
 which the Company amortizes its upfront license fees and makes
 adjustments as appropriate. In the event a collaborator elects to
 discontinue development of a specific product candidate under a
 single target license, but retains its right to use the
 Company&#x2019;s technology to develop an alternative product
 candidate to the same target or a target substitute, the Company
 would cease amortization of any remaining portion of the upfront
 fee until there is substantial pre-clinical activity on another
 product candidate and its remaining period of substantial
 involvement can be estimated. In the event that a single target
 license were to be terminated, the Company would recognize as
 revenue any portion of the upfront fee that had not previously been
 recorded as revenue, but was classified as deferred revenue, at the
 date of such termination or through the remaining substantial
 involvement in the wind down of the agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Upfront payments on exclusive licenses may be recognized upon
 delivery of the license if facts and circumstances dictate that the
 license has stand-alone value from the undelivered elements, which
 generally include rights to future technological improvements,
 research services and the manufacture of pre-clinical and clinical
 materials.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company recognizes revenue related to research and pre-clinical
 development services that represent separate units of accounting as
 they are performed, as long as there is persuasive evidence of an
 arrangement, the fee is fixed or determinable, and collection of
 the related receivable is probable. The Company recognizes revenue
 related to the rights to future technological improvements over the
 estimated term of the applicable license.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company typically performs research activities and pre-clinical
 development services, including generating and engineering product
 candidates, on behalf of its licensees during the early evaluation
 and pre-clinical testing stages of drug development under its
 exclusive licenses. The Company records amounts received for
 research materials produced or services performed as revenue from
 collaborative research.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The Company&#x2019;s license agreements have milestone payments
 which for reporting purposes are aggregated into three categories:
 (i)&#xA0;development milestones, (ii)&#xA0;regulatory milestones,
 and (iii)&#xA0;sales milestones. Development milestones are
 typically payable when a product candidate initiates or advances
 into different clinical trial phases. Regulatory milestones are
 typically payable upon submission for marketing approval with the
 U.S. Food and Drug Administration (&#x201C;FDA&#x201D;) or other
 countries&#x2019; regulatory authorities or on receipt of actual
 marketing approvals for the compound or for additional indications.
 Sales milestones are typically payable when annual sales reach
 certain levels.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 At the inception of each agreement that includes milestone
 payments, the Company evaluates whether each milestone is
 substantive and at risk to both parties on the basis of the
 contingent nature of the milestone. This evaluation includes an
 assessment of whether (a)&#xA0;the consideration is commensurate
 with either (1)&#xA0;the entity&#x2019;s performance to achieve the
 milestone, or (2)&#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&#x2019;s performance to achieve the milestone,
 (b)&#xA0;the consideration relates solely to past performance and
 (c)&#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. The Company
 evaluates factors such as the scientific, regulatory, commercial
 and other risks that must be overcome to achieve the respective
 milestone, the level of effort and investment required to achieve
 the respective milestone and whether the milestone consideration is
 reasonable relative to all deliverables and payment terms in the
 arrangement in making this assessment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Non-refundable development and regulatory milestones that are
 expected to be achieved as a result of the Company&#x2019;s efforts
 during the period of substantial involvement are considered
 substantive and are recognized as revenue upon the achievement of
 the milestone, assuming all other revenue recognition criteria are
 met. Milestones that are not considered substantive because the
 Company does not contribute effort to the achievement of such
 milestones are generally achieved after the period of substantial
 involvement and are recognized as revenue upon achievement of the
 milestone, as there are no undelivered elements remaining and no
 continuing performance obligations, assuming all other revenue
 recognition criteria are met.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt">
 <i>Right-to-Develop Agreements</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company&#x2019;s right-to-develop agreements provide
 collaborators with an exclusive option to obtain licenses to
 develop and commercialize in specified geographic territories
 product candidates developed by the Company under agreed upon
 research and pre-clinical development product programs. The product
 candidates resulting from each program are all directed to a
 specific target selected by the collaborator. Under these
 agreements, fees may be due to the Company (i)&#xA0;at the
 inception of the arrangement (referred to as &#x201C;upfront&#x201D;
 fees or payments), (ii)&#xA0;the selection of a target for a
 program, (iii)&#xA0;upon the exercise of an option to acquire a
 development and commercialization license (referred to as exercise
 fees or payments earned) for a program, or (iv)&#xA0;some
 combination of all of these fees.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The accounting for right-to-develop agreements is dependent on the
 nature of the options granted to the collaborator. Options are
 considered substantive if, at the inception of a right-to-develop
 agreement, the Company is at risk as to whether the collaborator
 will choose to exercise the options to secure development and
 commercialization licenses. Factors that are considered in
 evaluating whether options are substantive include the overall
 objective of the arrangement, the benefit the collaborator might
 obtain from the agreement without exercising the options, the cost
 to exercise the options relative to the total upfront
 consideration, and the additional financial commitments imposed on
 the collaborator as a result of exercising the options.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to a product program are
 considered substantive, the Company does not consider the
 development and commercialization licenses to be a deliverable at
 the inception of the agreement. For those right-to-develop
 agreements entered into prior to the adoption of ASU
 No.&#xA0;2009-13 where the options to secure development and
 commercialization licenses are considered substantive, the Company
 has deferred the upfront payments received and recognizes this
 revenue over the period during which the collaborator could elect
 to exercise options for development and commercialization licenses.
 These periods are specific to each collaboration agreement. If a
 collaborator selects a target for a product program, any
 substantive option fee is deferred and recognized over the life of
 the option, generally 12 months. Subsequent to the adoption of ASU
 No.&#xA0;2009-13, the Company&#x2019;s evaluation of whether the
 option is substantive is consistent with pre-adoption of ASU
 No.&#xA0;2009-13. How the Company determines the selling price of
 the option is the only difference between pre and post adoption of
 ASU No.&#xA0;2009-13. Post adoption of ASU No.&#xA0;2009-13, the
 selling prices of deliverables under an arrangement may be derived
 using TPE or a BESP, if VSOE is not available. The objective of
 BESP is to determine the price at which the Company would transact
 a sale if the element within the right-to-develop agreement was
 sold on a standalone basis. Establishing BESP involves
 management&#x2019;s judgment and considers multiple factors,
 including market conditions and company-specific factors, including
 those factors contemplated in negotiating the agreements, as well
 as internally developed models that include assumptions related to
 market opportunity, discounted cash flows, estimated development
 costs, probability of success and the time needed to commercialize
 a product candidate pursuant to the right-to-develop agreement. In
 validating the BESP, management considers whether changes in key
 assumptions used to determine the BESP will have a significant
 effect on the allocation of the arrangement consideration between
 the multiple deliverables. Deliverables under the arrangement are
 separate units of accounting if (i)&#xA0;the delivered item has
 value to the customer on a standalone basis and (ii)&#xA0;if the
 arrangement includes a general right of return relative to the
 delivered item, delivery or performance of the undelivered item is
 considered probable and substantially within the Company&#x2019;s
 control. The arrangement consideration that is fixed or
 determinable at the inception of the arrangement is allocated to
 the separate units of accounting based on their relative selling
 prices. The appropriate revenue recognition model is applied to
 each element and revenue is accordingly recognized as each element
 is delivered. Management exercises significant judgment in
 determining whether a deliverable is a separate unit of
 accounting.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 If a collaborator exercises an option and acquires a development
 and commercialization license to a product program, the Company
 attributes the exercise fee to the development and
 commercialization license. The Company determines the selling price
 of the option license, upon exercise, through management&#x2019;s
 best estimate. Management&#x2019;s determination of selling price
 includes such factors as stage of development, market potential and
 cash flow models used during the negotiation with the collaborator.
 Through December&#xA0;31, 2013, none of our collaboration partners
 had exercised an option. However, one of our collaboration partners
 did elect to exercise an option in February 2014. See Note 13 for
 additional information.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Upon exercise of an option to acquire a development and
 commercialization license, the Company would also attribute any
 remaining deferred option fee, in addition to the consideration
 received for the license upon exercise of the option, to the
 development and commercialization license. The Company then applies
 the multiple-element revenue recognition criteria to the
 development and commercialization license and other deliverables,
 if any, to determine the appropriate revenue recognition method.
 This model is consistent with the Company&#x2019;s accounting policy
 for upfront payments on exclusive licenses (discussed above). In
 the event a right-to-develop agreement were to be terminated, the
 Company would recognize as revenue any portion of the upfront fee
 that had not previously been recorded as revenue, but was
 classified as deferred revenue, at the date of such termination.
 The Company&#x2019;s right-to-develop agreements have been
 determined to contain substantive options.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to product programs are
 not considered substantive, the Company considers the development
 and commercialization licenses to be a deliverable at the inception
 of the agreement and applies the multiple-element revenue
 recognition criteria to determine the appropriate revenue
 recognition. The Company does not directly control when any
 collaborator will exercise its options for development and
 commercialization licenses.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Research and Development Costs</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Research and development expenditures are expensed as incurred.
 Research and development costs primarily consist of employee
 related expenses, including salaries and benefits, expenses
 incurred under agreements with contract research organizations,
 investigative sites and consultants that conduct the
 Company&#x2019;s clinical trials, the cost of acquiring and
 manufacturing clinical trial materials and other allocated
 expenses, license fees for and milestone payments related to
 in-licensed products and technologies, stock-based compensation
 expense, and costs associated with non-clinical activities and
 regulatory approvals.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Comprehensive Income (Loss)</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Effective January&#xA0;1, 2012, the Company adopted ASU 2011-05,
 <i>Presentation of Comprehensive Income,</i> which amended ASC
 Topic 220, <i>Comprehensive Income</i> (&#x201C;ASU
 2011-05&#x201D;)<i>.</i> The amendments in ASU 2011-05 require the
 presentation of the comprehensive income (loss) and its components
 as part of the consolidated financial statements. Comprehensive
 income (loss) is comprised of the net income (loss) and other
 changes in equity that are excluded from net income (loss).
 Comprehensive income (loss) equals net income (loss) for the years
 ended December&#xA0;31, 2013, 2012 and 2011.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Stock-based Compensation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Stock-based payments are accounted for in accordance with the
 provisions of ASC&#xA0;718, <i>Compensation&#xA0;&#x2013; Stock
 Compensation</i>. The fair value of stock-based payments is
 estimated, on the date of grant, using the Black-Scholes model. The
 resulting fair value is recognized ratably over the requisite
 service period, which is generally the vesting period of the
 option.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For all time-vesting awards granted, expense is amortized using the
 straight-line attribution method. For awards that contain a
 performance condition, expense is amortized using the accelerated
 attribution method. Recognition of stock-based compensation expense
 is based on the value of the portion of stock-based awards that is
 ultimately expected to vest during the period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company utilizes the Black-Scholes model for estimating fair
 value of its stock options granted. Option valuation models,
 including the Black-Scholes model, require the input of highly
 subjective assumptions, and changes in the assumptions used can
 materially affect the grant-date fair value of an award. These
 assumptions include the risk-free rate of interest, expected
 dividend yield, expected volatility and the expected life of the
 award.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Net Income (Loss) Per Share</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Basic income (loss) per common share is determined by dividing
 income (loss) attributable to common stockholders by the
 weighted-average number of common shares outstanding during the
 period, without consideration of common stock equivalents. Diluted
 income (loss) per share is computed by dividing the earnings (loss)
 attributable to common stockholders by the weighted-average number
 of common share equivalents outstanding for the period. The
 treasury stock method is used to determine the dilutive effect of
 the Company&#x2019;s stock option grants, potential Employee Stock
 Purchase Plan awards and warrants and the if-converted method is
 used to determine the dilutive effect of the Company&#x2019;s
 preferred stock.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Prior to the Company&#x2019;s initial public offering, net income
 (loss) per share was calculated under the <font style="WHITE-SPACE: nowrap">two-class</font> method under which all
 earnings (distributed and undistributed) are allocated to each
 class of common stock and participating securities based on their
 respective rights to receive dividends. In the event that the Board
 of Directors declared a dividend payable in cash or other property
 on the then-outstanding shares of common stock, the holders of the
 Series&#xA0;A-1, A-2, B, C, D, and D-2 convertible preferred stock
 would be entitled to receive the amount of dividends per share of
 preferred stock that would be payable on the largest number of
 whole shares of common stock into which each share of preferred
 stock could then be converted. Therefore, the Series A-1, A-2, B,
 C, D and D-2 are participating securities. All of the outstanding
 shares of Series&#xA0;A-1, A-2, B, C, D, and D-2 convertible
 preferred stock converted to common stock upon the consummation of
 the Company&#x2019;s IPO.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Basic and diluted income (loss) per common share is computed as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(260,835</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,361,755</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,717,120</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: undistributed earnings allocated to participating
 securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,361,755</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,717,120</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(260,835</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,025,602</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>Basic income (loss) per common share</b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.04</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(260,835</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,361,755</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,717,120</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,361,755</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,717,120</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(260,835</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,025,602</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Effect of dilutive securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Diluted weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,025,602</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>Diluted income (loss) per common share</b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.04</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following common stock equivalents were excluded from the
 calculation of diluted net income (loss) per share because their
 effect would be anti-dilutive:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series A-1 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series A-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series B Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series C Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series D Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Effect of Converted Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,189,920</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Warrants to purchase Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Stock Options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,313,970</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,249,702</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,885,417</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Recently Issued Accounting Standards Adopted</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In July 2013, the FASB issued ASU No.&#xA0;2013-11, which amended
 ASC Topic 740 regarding presentation of an unrecognized tax benefit
 when a net operating loss (&#x201C;NOL&#x201D;) carryforward, a
 similar tax loss, or a tax credit carryforward exists. The
 amendments in ASU No.&#xA0;2013-11 require an entity to present an
 unrecognized tax benefit as a reduction of a deferred tax asset for
 an NOL carryforward, or similar tax loss or tax credit
 carryforward, rather than as a liability when (1)&#xA0;the
 uncertain tax position would reduce the NOL or other carryforward
 under the tax law of the applicable jurisdiction and (2)&#xA0;the
 entity intends to use the deferred tax asset for that purpose. The
 ASU does not require new recurring disclosures. This amendment is
 effective prospectively for fiscal years beginning after
 December&#xA0;15, 2013. The Company does not believe this amendment
 will have a material impact on its financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company has evaluated all ASUs through the date the
 consolidated financials were issued and believes that the adoption
 of these will not have a material impact on the Company&#x2019;s
 consolidated financial statements.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EFOAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Percentage of Significant Revenue (Detail) (Sales [Member])<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Servier [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump">51.60%<span></span></td>
        <td class="nump">17.30%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Boehringer [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump">24.80%<span></span></td>
        <td class="nump">18.40%<span></span></td>
        <td class="nump">15.60%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Gilead [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump">13.80%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Pfizer [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump">6.00%<span></span></td>
        <td class="nump">8.70%<span></span></td>
        <td class="nump">10.80%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Government Agencies [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump">2.20%<span></span></td>
        <td class="nump">6.50%<span></span></td>
        <td class="nump">17.70%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Eli Lilly [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump">1.40%<span></span></td>
        <td class="nump">48.90%<span></span></td>
        <td class="nump">54.00%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskPercentage1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EY3BI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shared-Based Payments - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1">60 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 16, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2003</div>
        </th>
        <th class="th">
          <div>Mar. 16, 2011

</div>
          <div>Stock Option One [Member]

</div>
          <div>Original Options [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 16, 2011

</div>
          <div>Stock Option Two [Member]

</div>
          <div>Original Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Stock Option Plan 2000 [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Two Thousand and Three Stock Option Plan [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Two Thousand and Thirteen Stock Incentive Plan [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2013

</div>
          <div>Two Thousand and Thirteen Stock Incentive Plan [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Equity Incentive Plan 2003 [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Maximum [Member]

</div>
          <div>Equity Incentive Plan 2003 [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate of shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,051,644<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">130,725<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,960,168<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease', window );">Increase in aggregate of shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,336,730<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,790,760<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,297<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Common stock share outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,200,958<span></span></td>
        <td class="nump">3,249,541<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">23,657<span></span></td>
        <td class="nump">2,559,011<span></span></td>
        <td class="nump">618,290<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">weighted average exercise price</a></td>
        <td class="nump">$ 0.94<span></span></td>
        <td class="nump">$ 4.90<span></span></td>
        <td class="nump">$ 0.94<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.88<span></span></td>
        <td class="nump">$ 4.69<span></span></td>
        <td class="nump">$ 0.83<span></span></td>
        <td class="nump">$ 1.52<span></span></td>
        <td class="nump">$ 19.06<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Common Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">545,970<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,739,116<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Percentage of Common stock share outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockOptionExchangeRatioDescription', window );">Description of exchange ratio of original options with replacement options</a></td>
        <td class="text">one-for-one basis<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged', window );">Total original Options exchanged for replacement Options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,921,894<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, maximum term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,268,049<span></span></td>
        <td class="nump">863,176<span></span></td>
        <td class="nump">49,883<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,100,000<span></span></td>
        <td class="nump">$ 46,826<span></span></td>
        <td class="nump">$ 53,225<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.91<span></span></td>
        <td class="nump">$ 0.94<span></span></td>
        <td class="nump">$ 0.94<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,400,000<span></span></td>
        <td class="nump">271,929<span></span></td>
        <td class="nump">102,418<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">487,603<span></span></td>
        <td class="nump">879,024<span></span></td>
        <td class="nump">1,108,107<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 7,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award equity instrument number of shares exchanged.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award number of shares authorized after increase.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sharebased compensation arrangement by sharebased payment award option exercised intrinsic value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockOptionExchangeRatioDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock option exchange ratio description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_StockOptionExchangeRatioDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Minimum Future Lease Payments Receivable (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2014</a></td>
        <td class="nump">$ 3,651,421<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2015</a></td>
        <td class="nump">3,310,884<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2016</a></td>
        <td class="nump">3,410,210<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2017</a></td>
        <td class="nump">3,512,517<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2018</a></td>
        <td class="nump">2,780,398<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump">$ 16,665,430<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the forth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the third fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the second fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing after the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQXBG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 116,481,409<span></span></td>
        <td class="nump">$ 47,743,155<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
        <td class="nump">2,004,019<span></span></td>
        <td class="nump">2,046,219<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">971,705<span></span></td>
        <td class="nump">137,634<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">119,457,133<span></span></td>
        <td class="nump">49,927,008<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
        <td class="nump">404,850<span></span></td>
        <td class="nump">404,850<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">5,035,232<span></span></td>
        <td class="nump">3,267,796<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">885,166<span></span></td>
        <td class="nump">147,246<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">125,782,381<span></span></td>
        <td class="nump">53,746,900<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">3,169,034<span></span></td>
        <td class="nump">3,739,125<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump">3,583,552<span></span></td>
        <td class="nump">1,237,025<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Lease exit liability-current</a></td>
        <td class="nump">1,438,742<span></span></td>
        <td class="nump">628,768<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue-current</a></td>
        <td class="nump">20,267,323<span></span></td>
        <td class="nump">24,123,176<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities-current</a></td>
        <td class="nump">362,920<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">28,821,571<span></span></td>
        <td class="nump">29,728,094<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveNoncurrent', window );">Lease exit liability, net of current portion</a></td>
        <td class="nump">8,006,428<span></span></td>
        <td class="nump">9,445,171<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent liability</a></td>
        <td class="nump">2,904,227<span></span></td>
        <td class="nump">2,801,653<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Preferred stock warrant liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">52,947<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
        <td class="nump">7,135,687<span></span></td>
        <td class="nump">19,956,343<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">46,867,913<span></span></td>
        <td class="nump">61,984,208<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value-125,000,000 shares authorized and 25,177,597 shares outstanding at December 31, 2013; 425,000,000 shares authorized and 1,098,914 shares outstanding at December 31, 2012</a></td>
        <td class="nump">251,775<span></span></td>
        <td class="nump">10,989<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 14,381 shares at December 31, 2013 and December 31, 2012</a></td>
        <td class="num">(57,742)<span></span></td>
        <td class="num">(57,742)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">254,453,673<span></span></td>
        <td class="nump">164,334,646<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(175,733,238)<span></span></td>
        <td class="num">(175,472,403)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
        <td class="nump">78,914,468<span></span></td>
        <td class="num">(8,237,308)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
        <td class="nump">125,782,381<span></span></td>
        <td class="nump">53,746,900<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A-1 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">268,748<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A-2 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">73,646<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series B Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">714,012<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series C Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,109,522<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series D-1 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">144,462<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series D-2 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 636,812<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386993&amp;loc=d3e5879-108316<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Subsection 4<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringReserveCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Paragraph Question 4<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringReserveNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph i<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6KAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal U.S. net operating loss carryforward</a></td>
        <td class="nump">$ 36,561,195<span></span></td>
        <td class="nump">$ 35,330,167<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforward</a></td>
        <td class="nump">3,315,514<span></span></td>
        <td class="nump">3,521,722<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit, net</a></td>
        <td class="nump">3,785,612<span></span></td>
        <td class="nump">2,777,899<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Orphan drug credit, net</a></td>
        <td class="nump">19,883,076<span></span></td>
        <td class="nump">19,039,613<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
        <td class="nump">5,132,458<span></span></td>
        <td class="nump">5,218,002<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
        <td class="nump">8,216,695<span></span></td>
        <td class="nump">9,379,064<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation</a></td>
        <td class="nump">1,438,477<span></span></td>
        <td class="nump">1,247,772<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
        <td class="nump">1,438,870<span></span></td>
        <td class="nump">1,575,782<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred income tax assets</a></td>
        <td class="nump">79,771,897<span></span></td>
        <td class="nump">78,090,021<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
        <td class="num">(79,376,945)<span></span></td>
        <td class="num">(78,090,021)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
        <td class="nump">394,952<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
        <td class="num">(394,952)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred income tax liabilities</a></td>
        <td class="num">(394,952)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset/(liability)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComponentsOfDeferredTaxAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Liability<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510232<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph b(2)<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredIncomeTaxLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsDeferredIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsLiabilitiesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to other deductible tax credit carryforwards not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsValuationAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxLiabilitiesOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2VAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="num">$ (260,835)<span></span></td>
        <td class="nump">$ 8,361,755<span></span></td>
        <td class="nump">$ 6,717,120<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by (used in) operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump">1,193,340<span></span></td>
        <td class="nump">959,930<span></span></td>
        <td class="nump">1,147,300<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
        <td class="nump">862,162<span></span></td>
        <td class="nump">838,395<span></span></td>
        <td class="nump">2,347,439<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrant liability</a></td>
        <td class="nump">626,349<span></span></td>
        <td class="num">(150,695)<span></span></td>
        <td class="num">(1,459,435)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="nump">42,200<span></span></td>
        <td class="nump">1,351,650<span></span></td>
        <td class="nump">12,551,066<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
        <td class="num">(834,071)<span></span></td>
        <td class="num">(91,160)<span></span></td>
        <td class="nump">76,876<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities', window );">Restricted cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">177,321<span></span></td>
        <td class="num">(513)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
        <td class="num">(375,000)<span></span></td>
        <td class="nump">780<span></span></td>
        <td class="num">(133,782)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="num">(570,091)<span></span></td>
        <td class="num">(7,312,331)<span></span></td>
        <td class="num">(10,271,048)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
        <td class="nump">2,346,527<span></span></td>
        <td class="nump">185,200<span></span></td>
        <td class="nump">272,988<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestructuringReserve', window );">Lease exit liability</a></td>
        <td class="num">(628,769)<span></span></td>
        <td class="num">(533,560)<span></span></td>
        <td class="num">(447,019)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="num">(16,676,509)<span></span></td>
        <td class="num">(10,810,089)<span></span></td>
        <td class="num">(4,275,976)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
        <td class="nump">102,574<span></span></td>
        <td class="nump">440,815<span></span></td>
        <td class="nump">232,324<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
        <td class="num">(14,172,123)<span></span></td>
        <td class="num">(6,581,989)<span></span></td>
        <td class="nump">6,757,340<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num">(2,960,776)<span></span></td>
        <td class="num">(940,043)<span></span></td>
        <td class="num">(500,213)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(2,960,776)<span></span></td>
        <td class="num">(940,043)<span></span></td>
        <td class="num">(500,213)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,014,816<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
        <td class="nump">85,871,153<span></span></td>
        <td class="nump">46,826<span></span></td>
        <td class="nump">70,400<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">85,871,153<span></span></td>
        <td class="nump">46,826<span></span></td>
        <td class="nump">12,085,216<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
        <td class="nump">68,738,254<span></span></td>
        <td class="num">(7,475,206)<span></span></td>
        <td class="nump">18,342,343<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump">47,743,155<span></span></td>
        <td class="nump">55,218,361<span></span></td>
        <td class="nump">36,876,018<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">116,481,409<span></span></td>
        <td class="nump">47,743,155<span></span></td>
        <td class="nump">55,218,361<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred stock</a></td>
        <td class="nump">$ 2,947,202<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInDeferredRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase decrease in deferred rent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_IncreaseDecreaseInDeferredRent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConversionOfStockAmountConverted1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAdjustmentOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as operating activities. This may include cash restricted for regulatory purposes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestructuringReserve">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to the exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestructuringReserve</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoncashInvestingAndFinancingItemsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1WBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Common Share (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="8">3 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="num">$ (3,205,000)<span></span></td>
        <td class="nump">$ 6,604,000<span></span></td>
        <td class="num">$ (294,000)<span></span></td>
        <td class="num">$ (3,366,000)<span></span></td>
        <td class="num">$ (2,105,000)<span></span></td>
        <td class="nump">$ 2,601,000<span></span></td>
        <td class="nump">$ 3,546,000<span></span></td>
        <td class="nump">$ 4,320,000<span></span></td>
        <td class="num">$ (260,835)<span></span></td>
        <td class="nump">$ 8,361,755<span></span></td>
        <td class="nump">$ 6,717,120<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities', window );">Less: undistributed earnings allocated to participating securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(8,361,755)<span></span></td>
        <td class="num">(6,717,120)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) allocable to common shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(260,835)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,847,697<span></span></td>
        <td class="nump">1,083,276<span></span></td>
        <td class="nump">1,025,602<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic income (loss) per common share</a></td>
        <td class="num">$ (0.14)<span></span></td>
        <td class="nump">$ 0.14<span></span></td>
        <td class="num">$ (0.24)<span></span></td>
        <td class="num">$ (2.93)<span></span></td>
        <td class="num">$ (1.92)<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="num">$ (0.04)<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="num">(3,205,000)<span></span></td>
        <td class="nump">6,604,000<span></span></td>
        <td class="num">(294,000)<span></span></td>
        <td class="num">(3,366,000)<span></span></td>
        <td class="num">(2,105,000)<span></span></td>
        <td class="nump">2,601,000<span></span></td>
        <td class="nump">3,546,000<span></span></td>
        <td class="nump">4,320,000<span></span></td>
        <td class="num">(260,835)<span></span></td>
        <td class="nump">8,361,755<span></span></td>
        <td class="nump">6,717,120<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings', window );">Less: undistributed earnings allocated to participating securities and other add-backs to net income (loss)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(8,361,755)<span></span></td>
        <td class="num">(6,717,120)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) allocable to common shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (260,835)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,847,697<span></span></td>
        <td class="nump">1,083,276<span></span></td>
        <td class="nump">1,025,602<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,847,697<span></span></td>
        <td class="nump">1,083,276<span></span></td>
        <td class="nump">1,025,602<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted income (loss) per common share</a></td>
        <td class="num">$ (0.14)<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="num">$ (0.24)<span></span></td>
        <td class="num">$ (2.93)<span></span></td>
        <td class="num">$ (1.92)<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="num">$ (0.04)<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.23)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate of earnings distributed and earnings allocated to participating securities under the two-class method to the extent that participating securities may share in earnings as if all of the earnings for the period had been distributed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Earnings allocated (not distributed) to participating securities under the two-class method to the extent that participating securities may share in earnings as if all of the earnings for the period had been distributed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
        <td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Property and equipment consists of the following:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Computer equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,379,254</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,003,706</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,477,416</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,323,081</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Furniture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">599,650</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">599,650</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Lab equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,166,619</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,747,790</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51,360</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51,360</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,893,770</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,881,706</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Property and equipment</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,568,069</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,607,293</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Less accumulated depreciation</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(15,532,837</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14,339,497</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Property and equipment, net</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,035,232</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,267,796</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAKBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Dilutive Securities Used In Calculation of Diluted Earnings Per Share (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A-1 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2,156,114<span></span></td>
        <td class="nump">2,156,114<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A-2 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">392,274<span></span></td>
        <td class="nump">392,274<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series B Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">4,336,037<span></span></td>
        <td class="nump">4,336,037<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series C Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">5,909,906<span></span></td>
        <td class="nump">5,909,906<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series D Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">769,468<span></span></td>
        <td class="nump">769,468<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series D-2 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">3,391,991<span></span></td>
        <td class="nump">3,391,991<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Effect of Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="nump">13,189,920<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">180,784<span></span></td>
        <td class="nump">180,784<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="nump">2,313,970<span></span></td>
        <td class="nump">3,249,702<span></span></td>
        <td class="nump">2,885,417<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Company's Deferred Tax Assets (Liabilities)</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The significant components of the Company&#x2019;s deferred tax
 assets (liabilities) were as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred income tax assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Federal U.S. net operating loss carryforward</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">36,561,195</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">35,330,167</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 State net operating loss carryforward</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,315,514</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,521,722</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Research and development credit, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,785,612</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,777,899</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Orphan drug credit, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,883,076</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,039,613</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Deferred rent</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,132,458</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,218,002</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,216,695</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,379,064</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,438,477</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,247,772</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,438,870</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,575,782</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Gross deferred income tax assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">79,771,897</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">78,090,021</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(79,376,945</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(78,090,021</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net deferred income tax assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">394,952</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred income tax liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(394,952</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Gross deferred income tax liabilities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(394,952</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net deferred income tax asset/(liability)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Reported Estimated Income Tax Benefit</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The reconciliation of the reported estimated income tax benefit to
 the amount that would result by applying the U.S. federal statutory
 tax rate to the net income is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="53%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 United States federal tax at statutory rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(91,293</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,926,615</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,350,992</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 State taxes (net of federal benefit)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">609,476</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,460,289</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,480,185</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred income tax adjustments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(855,130</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(512,375</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred state blended rate adjustments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(344,178</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research credit, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(225,605</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Orphan drug credit, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(843,463</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,895,671</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7,056,607</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other permanent items</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,931</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,627</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,696</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Equity-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">241,467</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">279,165</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">725,811</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Fair value adjustment of preferred stock warrant liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">218,872</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(52,743</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(496,208</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Change in valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,286,923</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">787,093</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,991,131</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Income tax expense/(benefit)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 A reconciliation of the beginning and ending amount of gross
 unrecognized tax benefits is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Beginning balance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,592,357</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,533,986</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,246,025</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Increases/(decreases) for current year tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">115,502</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">58,371</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">287,961</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Increases/(decreases) for prior year tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Decreases as a result of expiration of statute of limitations</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Ending balance</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,707,859</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,592,357</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,533,986</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the change in unrecognized tax benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 217<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32707879&amp;loc=d3e36027-109320<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Nature of Operations</a></td>
        <td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>1. Organization and Nature of Operations</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 MacroGenics, Inc. (the &#x201C;Company&#x201D;) was incorporated in
 Delaware on August&#xA0;14, 2000. The Company is a clinical-stage
 biopharmaceutical company focused on discovering and developing
 innovative monoclonal antibody-based therapeutics for the treatment
 of cancer and autoimmune diseases. The Company generates its
 pipeline of product candidates from its proprietary suite of
 next-generation antibody technology platforms which it believes
 improve the performance of monoclonal antibodies and
 antibody-derived molecules. These product candidates, which the
 Company has identified through its understanding of disease biology
 and immune-mediated mechanisms, may address disease-specific
 challenges which are not currently being met by existing therapies.
 The Company creates both differentiated molecules that are directed
 to novel cancer targets, as well as &#x201C;bio-betters&#x201D; which
 are drugs designed to improve upon marketed medicines.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 On October&#xA0;16, 2013, the Company completed an initial public
 offering (&#x201C;IPO&#x201D;) of its common stock, which resulted in
 the sale of 5,750,000 shares, including all additional shares
 available to cover over-allotments, at a price of $16.00 per share.
 The Company received net proceeds before expenses from the IPO of
 $85.6 million after deducting underwriting discounts and
 commissions paid by the Company.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28200181&amp;loc=SL6228881-111685<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668296&amp;loc=d3e288-107754<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EM2BG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">125,000,000<span></span></td>
        <td class="nump">425,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">25,177,597<span></span></td>
        <td class="nump">1,098,914<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockNumberOfSharesHeld', window );">Treasury stock, shares</a></td>
        <td class="nump">14,381<span></span></td>
        <td class="nump">14,381<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A-1 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">26,874,792<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">26,874,792<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">26,874,792<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Aggregate liquidation preference</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 27,000,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A-2 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,364,582<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,364,582<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,364,582<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Aggregate liquidation preference</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,000,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series B Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">71,401,237<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">71,401,237<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">71,401,237<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Aggregate liquidation preference</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,000,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series C Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">110,952,217<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">110,952,217<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">110,952,217<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Aggregate liquidation preference</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">45,000,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series D-1 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,446,227<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,446,227<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Aggregate liquidation preference</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,400,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series D-2 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">63,681,176<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">63,681,176<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Aggregate liquidation preference</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 41,500,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockLiquidationPreferenceValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockNumberOfSharesHeld">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares held for each class of treasury stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockNumberOfSharesHeld</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>11. Employee Benefit Plan</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 On September&#xA0;25, 2002, the Company established the MacroGenics
 401(k) Plan (the &#x201C;Plan&#x201D;) for its employees under
 Section&#xA0;401(k) of the IRC. Under this Plan, all employees at
 least 21 years of age are eligible to participate in the Plan,
 starting on the first day of each month. Employees may contribute
 up to 100% of their salary, subject to government maximums.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Employees are 100% vested in their contributions to the Plan. The
 Company&#x2019;s contribution to the Plan, as determined by the
 Board of Directors, is discretionary. The Company&#x2019;s
 contributions to the Plan totaled $252,930, $225,195 and $217,097
 for the years ended December&#xA0;31, 2013, 2012 and 2011,
 respectively.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationAndRetirementDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for pension and other postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EEJAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">MACROGENICS INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001125345<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Non-accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">27,471,329<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 698,022,185<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Quarterly Financial Information<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>12. Quarterly Financial Information (unaudited)</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="54%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>1<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">st</sup>&#xA0;Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">nd</sup>&#xA0;Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>3<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">rd</sup>&#xA0;Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>4<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">th</sup>&#xA0;Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(in thousands,
 except per share data)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>2013</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,598</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,299</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">20,232</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,366</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(294</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,604</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,205</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss) per share, basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.93</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.24</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.14</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss) per share, diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.93</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.24</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.01</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>2012</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">20,510</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,435</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16,082</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,799</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,320</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,546</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,601</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,105</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss) per share, basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(1.92</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss) per share, diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(1.92</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Annual net income (loss) per share includes the effects of income
 allocated to participating securities.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25249566&amp;loc=d3e1280-108306<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section G<br><br> -Subsection 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-K (SK)<br><br> -Number 229<br><br> -Section 302<br><br> -Paragraph a<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>70
<FILENAME>0001193125-14-108048-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-14-108048-xbrl.zip
M4$L#!!0````(`&R`=$0"E(B80H`!`(V2#P`1`!P`;6=N>"TR,#$S,3(S,2YX
M;6Q55`D``XQ)*U.,22M3=7@+``$$)0X```0Y`0``[%U;;^-8<GX/D/^@^"%(
M@!S[W"_&="](BMPTTC-MN'MV!GD1U!)M$RM3#BEUV_OK4X>Z6!=*I&B2HH/L
M8-'=(BF>KZI.W4Y5Z9>_/#].>C_")(VF\8<+<HDO>F$\FHZC^/[#Q3Q%PW04
M11>]=#:,Q\/)-`X_7+R$Z<5?/O[S/_WR+PCU;F][_6D<AY-)^-+[<Q1.PF0X
M"WN?8OO$*(2+H_EC&,_^H_=]F(;CWC3N_>G>?N[12]+K/<QF3]=75S]__KQ,
MDO'J:RY'T\>K'D*K5_QML;KK7D]>4ECAQJ7;Z3P>7_?$QD=>$@YG<'MO#.NX
M[E%,.,(,$?V-R&MJKH7X[\V[IT\O273_,.O]V^C?X68L$#S!>K>7MY<;P/ZU
M]W4:IW#WX],P?NDYDTGOUCZ5]F[#-$Q^A./+Y9<^?T\F/:!IG'ZXV(!G/[Z<
M)O=7\`IV%2VI<[&X\]I>G1RY?Q+%?[?D6]]O/]BZ_R?+[B;&F*OLZNK6*)UR
M2M2QQ2SN6']W&N5],]Q*KO[\]?/7T4/X.$2["$!2[H?#I_63=\/T>_;<\L*5
MI2K"!#&R>F0<OKXH6U$:CB[OIS^NX$+.[8_W\?/6PAZ'HV1Z'\;1*,TDQCY"
MZ.L#\.;9RU.8YJXINY+S%KN0\6Q[74OXXFIQ<>O6*/=6N;@U6MV:SIZ2?*SV
MBET&V5[&".1ZEKSD/[.\F+/ZT3Q)8/<>>FYYU3Y(MQ\,GT</^0_9*SEOBN(?
M83K+?V1Q+>>A>/Z8+X?C67)E.7(%=X1)-%H_`!NP^)EIC':>F\^2@P)OKN#J
M!6S57B_;K)/K-!/IV_"NE^V<:_NM'R[2Z/%I8N4[^VR8@+!-PG)[-'OB(0GO
M/EQ8J44KR;Q\3L<5MG!Y[7"U@+7<<]=?'X9)Z%JU:Q57&*>98G229!C?AU8I
MNR^OM]P,7^Q'SL]A,OYM_O@]3+[<95=39SY[F";1/T![CZ;Q+'R>W5IHX70R
MN/&),M1PA``A1O^%,5:#K]_Z`SRP2\.4Z@%8E'D<+9Y)LR^\Z(W#4?0XG,#>
M_/1;<-&+QA\NHO&`,T,5)P/'T\+O*XT(=33B7I\A%U,/U'A?<N)H3H49$/CB
MCQ0+(CG_Y:HQR#D433^EZ?QD8DB[U`K$()+TW;[VD!O(/@+X$AF'"22);YS`
MPZ;O]>WWDP&[^$C@G8QAO$.0Y8JWL7B389I^N?MC:(DS^Y)D!FU-AA"T132+
MPM0;@@4<NR_+^]+EC>EI\&%A&?R!8=1H_$R(%-CPDZF!<<`%E@:1OH\1%SI`
M1K@!XE)2SGTJI.:9Z`WDQ4=!M,+ZE19O1-RIS64_8B0C*-;8/,._A"#F9()Z
MOM!8VVW&)0$R`D$UTRX(FBL"[+I.WV,#8L4+MALQ$A.I&]]NX`%<^_$LFKW<
MS+]/HE$PF0YG)]*'[RF?I:,S^/UK?Y,J>%_(I"+25RXB1$O$%6PY38D+>ASH
MHXSC@O`.Z,!<?)0@RY02+7ZYREWS+AR@TN,T_CJ;COZ^0/YE/LM<:W"WWXRO
MY`XJ!TZ#<E5<$=BNF]B.`5B`M1;OVAF/(RL)PXD'UBD:#2>_1A-P"B!^6$I!
M^GL\#A/G/@DS.:D&?F`H,8(_$V"!`LZ"<A&8/QM&A%'%G$=B7]OZ7#!L#))&
M>(ACHI#Q?84"'^N^8HSWN5YH6]@.`F?_^^6J&N9<>GV.1K"-PK]:S1.$X;LG
M$P&M<8A.Q[$>MKPWX.J%-V&2?5:5),4T&#R%R:#<IM*.1[##%7)]PQ`W"B-7
MVDWE^%1IK9BOU9H>3%Z*`Q9Z"UD.`;+K[PPQRT><03F'RGBS\`NN`S<`:==<
M@@_B@6^F/2R0'U#XG!NJX:85L]^/CFB1+KA.I5#%_?CR9&_<-%Y_A-;'"\?.
MCS`9WH?^<YB,HK32AK..F3SD>1S88G2?FD8QJGP78=#:B#,!09"Q<;O/6.`Y
M/@93O7#,Z,5'?&GJ"().(\L[X@580(.9!B]9&TV9=9H-4<]&:?BX#4:MU`&_
ME.;_&57,**/@3]D^G]A*/5WJ.L*<*GS:T8?+K_O]"5XX>HC"']D+O]RM#<>)
M>0B(GAFN%A>YGA\$PC'(<!MR`]F081QB11GXK@*-'OCTE8+8B%P%7PAH@PRK
M,/%F.H-[HN%DX2Q]F[KAPF%RT@V3"I2.QO;\`?ZY,!MI&LYNYLGH`1A3T4#F
M$*R<AU2>6IE/2)A8DJH1T!M$_1*'L^@QW/4\[/??#*/Q6[P)K+$Z;/L*_`>7
M<NU[#")3SS@0F1*.'"8,LLDS*5TB*'$&.8'727BJTL&*Z]<G6/Y=%(X_@]!.
MOMQ]'<*3P*=D.IZ/3LV(K4@%&D]R!CJ.,O#%&B3<TE4@M#KQ2A"AN_1EU(@#
M-J0.^JXLO&Z!O#6DHSG!A%;0:E1BUS!ED]"NCW@`?W.PT8@YO,^TX8ZB&^EH
M)C''1'8N'6U3IL2TEX[.J$&U$N"!-)F/KN)YP4?+S#Q1V.HAR?7;\P.R+ZE2
MGH,T\X`R#D2$QC<!TO`^R5P.;IVP.HEF&2)YN7=F<20_\)J#S`3I+>F@9L!K
MJAWL^`'J&VOP30"NIA\XB#*W[RN/>(%'=\&?`K(>SN/L4/)U$X"S#5[QF\$K
M[3K@MON(.-K8<P0)3._WD:<DZ0<@%@&5BSUAK=%1QJ\^_SU.PM'T/K8G!-^&
MSVX8AW?1Z4=0"[A5/-_``"1%E#T@`6D&V47:GDCZ5$KEB;[1&VEA0KG$5+S"
M.K#\'2Y:5C],)V`04O]_YM'LI3UXS)&"^@Z`@N@8E#HUR"'80RR`6`R$UC6!
M#_(*&I-FW@-(+6):,H[%9I2TAV!'PP_3!R<>VS_LY1]@V4";.3,/]-H+A$9_
M&T[FI^[?-X`6OF%]!_O(#_H6-.XC5W*%3.!Y`7?[3!&VE%-A'72M)":;IXEE
MX-1EKU=`P9M1PE![W$>,$B<;K)*<AC>3S(VQ6]1&<A1(6L:*UR7%AW'6+=06
M*ED*]1)J>9&ND:%6:Y#F&"H&>LE/<%_MN\_#SCV4M;-3#,R2FPN@YV$F^'_Z
M=.>Z+$8RX$MF4E!+'!9V'F;NHJR=F:"EE\S,@)Y@;.IE)B>R,6:R@5SM3"8A
MA#@;+[=!ULY+-E"KC0DXY5E8F1V`ZZ982<B`K#8F%U0PM9=$;H>9>S!K]P0!
MZ6IG9DC/LS.II7%S:M8,%LDRZP1QSB6EYS&:>S!KWYN`E*U\H`SI.=AI*.>F
M,6X2,2!ZS4VFR3E8N0>Q]HT)*%?^#Q)*\5,X63M8PTB)C&MUL!!SKUQW!+"%
M(%2=11,9AB5GC8DN&Y"5CV#QRC,)[R[(VOD).%<^@L6ISBB[C`K=I#M$LNJH
ME<HU%,-_)^"M)R-&&LZ(95Y?5NS#F-&R[8S8&^"5XB)[S8@9JX$@0.%4\_-F
MQ-X`NE1&+..IS8@)`6XFD^1-&;';,)TE\]%LGL#U92]=-<#VG,\08JV.$=5V
MKB_@/3)`JN^YB/<#AK2F&K$^E8QRF]/&BZ`TTT\2*VXVBGGRH-1F;TB+Z3^V
M3O\1W';ZKQ!GW3MXG?XS[:;_=H$VF?YCJ_2?Y6>KZ;]"E+6S<YG^,ZVF__9@
M-IC^8ZOTGV5FJ^F_0I2U,W.9_C.MIO]R8#:6_F.K]%^V,UM,_Q6"K)V7R_2?
M:3/]MXNRR?0?6Z?_+"\E@R"-J%*5+[4SL^'T'WM-_YDETO.HV2;3?VR=_LN<
MH#;3?X4P:]^;J_2?:37]1]I+_[%U^F_!S;;2?T40:]^8J_2?.4/Z;P]LH^D_
M]IK^RX)OS33CY)1ZE!I%M\'T'UNG_S+1Q2!`K%1_?^W\;#;]QU[3?V:)\XRR
MVVSZC[VF_RQ6R4`M@&XX(7%47Q\YW<L7E1->X(^D3$KD!'T?<5\[2)-`(*-=
MPOR`8T$!XT!F4RF,-F0#7G$7>;>;E?9I5J4AR?/[@4L#@SP7!X@[+D=&NB`T
MU'7[VA4@@>XZW_1_J\-O4>3<DJ3ZGB\DQPPI.]V"NSY'MC\9!=AQ*5A+[<C^
MFLZ,<B/XKG=0)^IMHGY+PF$Z3UZRS;`]%>,_P\FI=JGIS2SVG*>"]1>HK<K3
M3YH&:BLXZ+K-J,3Z#P*]&29?DJ^S(6RQ+/]=L5"]BLIY"P$RE8-)+O9#D(I3
M^UXV@NS4%O6CV(^;XY)P"8=`EFJU.=OFR/JW@3JC40+>U^=H^#V:+#HVN@K3
M&F,*P>1F=?K!Y>^AG#_.)Y;I_?`I@<5DBA#^/@DSC1B/G<=I,HO^D7U^DTQ!
M*&<O-Y,AZ,-X;+V8IPKC"=Y`%(<HX?0=4/G$EZ#WM49`#A<QZ7#7(YH:UTZZ
M49E.8X8;M4646M#NT'"C"38:?XJ]X5,T&TXZ)R=26J\4B,*W,G4'EK\G)W8^
M80JF</A]TMT=#QJ>*6;(SE;(6?LVOGYX%\+']M@ZZ[1-K0I<^`23R?1G-O2T
M-;#,\912E$%X83S$^T(CA[,`]:GG<NII[-!@V6AD$\P:@[M#-Y1Z"3#;Z-^#
MDH,-38VB`';#8RY2;_445+P!7=F""KHHJ#"4B0U]U4Y!10N:1U]\1!`G*X9/
MR.2L.B-!\RY:(^L,A^N&2&T#.[Q_@WO'UK^-]-/CTS""#1M$,6S.S#$9A=$/
MJZUNP\Q<G4$+.4)[`07=XV/&$1?29C\D1E0$V.>>SZ4*!IG<;OC2)R#9]2MG
MPR@.Q_XPB>&Q=,M4WT6CJ'LJ2:JL/$AP12$.W70QBZ#DVY[;\$<8S[MK6R%,
MI-R^9O,`+'_QAP#&,P_^C&:_3>-15V':<VF-B10L#^4^@H,Q8I4ZKQ:D%B]3
M=[E!8$XQUX:-!4WV'JP-<%`PQ:79C/*+8!2'N5T66C"PAG-!%#D>ZAX2VPWJ
M=`X<!:=>$O"4Z*;WL+'B(FW3%**<H2(J@(!3^`K"4;"7W*$.@O\+Y&#B>@[3
MOO:\@5C,C=A)0^VO.]\=^FTZ^QK.9I/0&E4;KJ4/`=C<;.?VHW0TF:;S>A-1
M!=&*VW>49!Z"`!RBE2!@R!!N$)'@SW+/8$<MN_YL=';`1RH'ZJC=[/#VI+:T
MU!:P,IYK5';67RJ&^?8PG/TQG4_&UN4:S?R[NW`TBWZ$<,NM_:V.]F2>4X,]
MXE'D*$)!YI6+C.$$.;[?#SR7<>XL'<5%328N#'`*L.VD)K(0MZM>$SA-]A10
MX4W=M;7D;31?9@_+85]IAP5:V^P:N+T;CF#NPK>QW20A1`=C_]D>N'36S^5V
MPA$HM(TT0^[""Q)(7YZR\6WQ_>=IFF:U\G?3Q)X@I5F.'7R0S]-1FUG"\EDE
MFT03\)V;1=-5\150Z:\)/-U%&IA2B;5L^3F>8S2"8"^_<:)S\BY!0V&N-T<Y
M%V$HT^_R3GP2>TZ@I1%D\YR@-*(\2]0Y!N>&0XNUYJW_G3#.IKZY)AS<:+$+
MJY!33;1HM>!&`F*E."-"%,GJT?:L/36V$4O]%M9LD9_3Z#J.)A\N(!8-WW+4
M(?9^"6EUL/.:8X35=]6ML"$?YI(2LW\RE0>@@&4=.(DMSSN5C4^S-Q^QI25/
M6P_>UK(K4?(<VIZY*HD5-6S3GSR&H8#S\)?59TN'=)G;L7FM[-@?5KR93.BB
M1-A.4VI+MX])Q,E(BRFW2*QLN:OV.X?)Z*&+9+)*`V[5FQVI)\(JH,GJ@T_Q
M:/K8R3-NV$&&*5"R_`@-MF%4#LWZ\'`ZBT9=I(,M8Q2,82)5I;!LA:W2)LFB
M^RY2Q4;K!C,C24YFK0RH(EGI*G";@A%**'TT2-]'N%7:V4T_5P)3=]I<]E==
MTBNHW9^M`9^R!<E2*2-+N`0`8&->\G9D_DY"-?.:82@'8@/PK],X?/EUF/P]
MG`7S>/Q>HE/[0WL&<V5LZU)9(+4/T:"M#M%@KS]7JIAA;0W1>`79_!`-\3I$
M0[8]1*,09[W=3&(]1,,6?K0Y1&,7:)-#-,1ZB(9L>8A&(<K:V;D8HF&YV>(0
MC3V8#0[1$.LA&K+E(1J%*&MGYF*(1E:3U=X0C1R8C0W1$.LA&K+=(1J%(&OG
MY6*(1K8Q6QNBL8NRR2$:XG6(AFQYB$8AS+J9N1JB8;G9XA"-/9P-#M$0KT,T
M9,M#-`IAUKXWET,T,A^HO2$:.SB;'*(A7H=HR#:':!1!K'UC+H=H6$ZV/D1C
M#VRC0S3$>HA&!C:G1+T(\#HX_35+NV0=T7]$LX??X^EW&[TMJO2>YMG1U30>
M19-%)YW]YSRQ49X[3*/UN>++&_),&S23A%>A&6%<@]ZG"&,W^P7C/M*N-(@:
M#QLIA60^67>*[]0G-D*(QM1$@P-+Q.O`$IDS^Z%%1='LP!*Q'EB2J?SM0OG6
M]42S`TO$>F!)AG6_-;0([TX%:V6P&N[)?#.M[>^6,4S%XI_*5/MI1^P)ARF.
M..:`OL\$<C2'O6^%1RKA:NZ]=MVM?]OQ`*SFNG7."MW^JJ4\CKR@FZ>6LNNS
MTH#:MHGC-#A4S-I&.;[]W6QE,-@^`9%AQ0J;DCGKK'EZM\*FX=*^<OCJR,C3
M!@K]WB49*I7--7GTU";X3AY$M4F`&HZE6M9[6I!F]1X[K]YK`9_:+YQL3'^U
MP2Z\QM.27FH!E-G&U(:R:0&5WI.\=K6'T>P@QCH4*J^[I;$UO7.,,O5PG[>I
M=]J`T[K>:0-4^WJG#53[>J>)JG&+24L!F!@QM+$:\E69HR!,XA(%8SDUY`VC
M9[12W4*Y"OIEM3C7FBA<IF"N=?Q:X^:XSY9EX+:809E.\M\05BDO7PH_7Z:J
M"*,,;QY-=0:_G8?37`>)6&8I81^P;LH_HY16"EM+X9?+-)TP1HK*XK],Z=4Y
M6GL`P(W&E>L-2]4*+W1_?JEA`:IB$KQU3&^+%."E*7!H=N_VO?6.[SU,B`:G
M^2X(PW8'^I;#62P<;SN/;$TP1&G!R#N;W+[O38?4)22@AMZ!!6B:4X^;`^48
MUL\1Z,OQ<LJMO1#&H_#=$$#9WR??/;4K"[!-VU"Q=+E<'TE&BMS?_NN.:6B<
M`$R7)<!9+<.QZN[:Y[QG=%&=M@S-RX4I*Q?M&(;JY?TG8);[I?U=L0MMX.>V
M19:\"[M0K0NB%"FRC`'5>1T0';(+C1,@MP6D>W;A2*-(W79A01?1;;O0N%RH
MLG+1DEVHW"ET`F:^WR74&;O0!GX[TEF]$[M0I:&J%"FR3"KC.<U4G3(+#>.G
M)?&?VRH<;#FKVRHLR++WPU!=LPH-BP4K*1:M&86*+8<G0,9[[88=L@G-P[?=
MEN_!)%1LS"Q%B>QP2>B\GLSNV(3F"6##YH)T8@>,PK'6U;J-PH(NW0X5FI<+
M579CM&,5JO<NGX"9[[<M=\4LM(+?EH@3\1[L0K4.[U*DR`[=!<UK[NZ076B<
M`.`A,=Q]NW"D![YNNY#1A9MNVX7&Y8*4W1@MV87*0Q!.X+G>GW_0&;O0`G[!
M<CH%JYF%FIIFEVV26&*.2Y3?Y;1).CX#A(Y"+O<XXD8%R.$:HS[W74Q87QIB
M7KMD^1F[9-O$:F<`%$!MIRVV3="V#[8`]*$^V+K%F0M<R<=3_2!0AG'$?!(@
MK@U&1@F)9%]1A^#`#8A<3'G`JW#OO++</%"2S6+LD"0W#]G^5-QQWI:4XWJX
M3(A0NL2PBIS-RQ0A#A4!,M+Y7_:NK;=Q8TG_E<5Y[T'?+R\!NLGFG@&2\2!G
MLD&>#(U,.SJ0):\DSV3VUV\5=:,D2B(ID9:#\Q#$8UD2OZ^KJZNJZT()#ELE
M7@E/8I(&&XWT(C,;C<7$Y>M\(=0+ZO6YC5PSP";3"'K*IYHXKP7A-+H0F(;7
M09B+4^C`'.]_YW8/%!;4W=+&[1[QYOQIO&U+LTLO];#%06/@:Z:KWFMLYJ^8
M,6JG`\&)YZ_H$Q0&\_P!WH/3$)83W;'8\*GH2Q1^;/_D\^`'_LICG_.[EZ(C
M4?PKGPU'\V+*R.OSU\9=S=O2$Y.HM*2"&&U!>0>0`VM$)!GU@<.J6Z_39>]@
MS'/7U@))>XV%KHGZNJ265NOW'(=\YP_^6SX;/.6K+\X_ST:-IW8?4GW>I^<'
MQ"<QS0+/'$D"!>)]D'"6!$XD#R&U02FKPY)XK*_Z4"XNZHF6SM;B1@5<8>-W
M2HON"YVAOBZI_Y//<?$FQ006+';],L5?_3WD'O/(/^C]-F9OQE;?*W>CNP3'
M(U`.#W#%75*7C!.S,I9_</>X/*;_F8^;!BJ[MB_40?O.,\_?F7WQCE6"QMBV
MNZ)*J$G+&:NV]:U)UT*'ET3\(&!VXOF/`KW2]4@;@;F$@(/,J1J0S@_Z:.>J
MGL1^C>JK>R:72F:G?>X)``<#&V>O^4-IW.3-XA0X;<L*I4HXCS[^W@COS0@N
MT+[Y/'L%8O)?1I/1\^OS2D',T]?\X^3+]^D?^6#6M`#[`O34&B6U3$G@$M"[
MF!(?(B.)SF*J&#?:TTWL4,!W6UM2A8V!'9VM5:*PS8"M"QBH.V!K)0)..E4]
M8&L?PH&DOSZ_CG'GI_G+#!ZH.#;@YW%>G!^3!_\\G2U&_[>Z,+K.-,\+B*G7
MBZ1HHZB4X+9<5G4MM-7RLISIMTOY30J,/"XP51CV).;A883D#,:?!Z,'[!?U
M,EHTG@_?O6;46%BCI%1"FU)'\2./WTHSWJ(^+&)36BLI:&.%6#VU&/X`C<*;
M/0$Y%M-I1X7<V>@5S][R^,NFK[.;/?^*\Y]AO+;%^;=!=F:X)!J%2W=B/)Y^
M'TRNZQU=3:_AA:D31CNI*H_"8V!VT;\'JP^+PZSE3)F207\E>^\+&`GYX'%Q
M;6OG=-.T^A)_.%_]MPD<Y=.G";IML,PAG^2/HT6/VS5S7E###)':4C!,C"*6
M\H1$KK5)5.JLM,N'1[?$4&-5J5O_D<>_<LO^'DY<;'&`XQ:`A?J]^>LKJ]&W
M_&;5,%8N&DN%LVW4\!K9+C,?GU\&(]!<V6@"6JIP68?YJ!CE\6M>&+%OH(Z]
MLDG&00E'.'")5!I'-VA*N,IHE$G$!(#E'7C)_FB`9#_DL!B,)OE#',PF\+;Y
MC@'_.!J.;D\W:[,<96.$X,*6@P_GH'20$]##4823_2@'&YM7#+:NEP4P62R'
M7K=.!.@!IEMV)-])I3V%X&CXL$TF:0]22]>7_I4!PHKTT)*U`:[Q>SB>7!$"
M-I;OW#V<PW$^!GK+8@M'LJ542VY/AT&/">Z;A#)J@N/@^8&IH8UCHG(]VX8[
M_YSEMVMIH+LK&>6LN7]?AG9.%W<%O2+WRF32&14-@2571'KN"?RGB*<L)%[8
M:)/D7J*GRX\G7ZV?>V_-,>+Y'APZ#:NJN>/E1:U^]FY2Z7K8K0R;/@FE;>4)
M>C)Y[HB'].7/P>+WZ>OX`>W+X2(^/N;#!=C2\">_@EW5HPA+D,R$)9QXPSB(
ML`G$.<F(CS'-DB"D](=6<3M4K91:[W)?7Y]A\9I6##ZVL3ZKW!%'6(5S[G6,
M'_EQ\BE?;+]@.I\G@]GLQ^-TAI?A/<J,MR$$E6I"HS%`D=7$)BJ0E"FI4J!)
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MJ!1@U<(W<`W?F2B=;.YA-=@H<L=(>S.*ZF@7ORB.'/B0VPQ)%MWC-<X`I>Z<
M7MG#<N;$+#G58"3W><O9X#+[\)ISG=2PO3R!I[]5$U`4HV`D967%<@+`F26[
M@<2S^FMGEKFGTIRR>QHFEVW>=W6)O5+R!3N9A;AY]@X'_G2?5(@I951I2[4K
M>S;U)_P<,`(_K'^W<HU6`7F\C"CR>.&)RU'.6UQ[50Q]X[)<+G8YTO/,+2.^
M.XX3?N9@-OSS%FG"5"UCE6:GMLAI6!46V-?SYL77\R4?N^8#NTD3"Z][X'O8
MH8G5"0=GY&\W8_86Y0VTE>5,:W<J&VX71F>%KN_`@H<#3!N%=:_=%!B?LM#C
M\\MX^B//_P4*<33,J[_UTW3R;>D0%#KARW0Q&)=?3Z;SQ:?IXH\<.%J'AGN,
M9P<)YV(6!/$:/$XX#"@)UC#B%#BD,05)]&J3+&7T7CR[,P9:QQA3V`_SQ6AX
MBUN;%9<FFK&3>_L\ME9G[,U6PF!RI;-6T'(?U":@SLG*K0*W2X?#FHJK\=VG
M/U$W?)M1`(T3A<U.&=_A4]=T*GIUG6KB,]C&32@N>`V/8N,_=3+8NY>0H]R&
MRNN!Z'3J=R^0,12BJ=3.R!7H&D!*L(^K<3CK_O7Z]=_Y</%E^O/H>;0H3L&;
MO,,&']'I=?>O5K!J,>(G$_`CMV_RSQAQ:L?(O>-@+IIB;KKLD)_UOF"R'CW5
M&$OT;&O<DO%H,AH.QFG^+1]/"QWRRV@,6PX$<)U(\=OD(9_YIUF>MX^G[5)5
M[@FI71WF]&%#+I,ZM!D)3YPC,O@`=B78[4F6,I-2'D+&MMMK4]A_,?Z3-/Z:
M/V'&]G3V`U-%!_!!?SLVU9;-XW0VYN'M]J[@X']TMW?%6@+?_]8MF.I-V,0J
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M9,8=\8PF1&146"Y"<%F\-Y2I^R*O'V=`[W5$/#Z7Y5J5ED<A-HA/UT:)=5LX
MT9GLA7+/E5M>'ZP3K(8[V!ZLO>=L#;:B"OP<X$TD\)<BQEU8X+^/%G_^-IE^
M15-C>4_]\EHD44TGP]%XV<(*_PE;`?9+&,Q'FPRW'Q<$]4N<:79TL,?I<Y,)
M:3D#PB@-E,C$IL0&[0AW"75:*RTBPSF7>*+LGYM7W,6"@E/6V2X6]TRO=O%A
MW_0>-_(^RJO+-@`U*]G>KQ7O?2,+KFP[Z[\F6'-?A":68`_:B)W#>]G,BBU8
M"W^S'&Q@KS+G(-!$>3#;B*02T*="$6\E;$V4'FU4L')[*!\,DNI^B,4M(&?_
M^,GNIR?T.=;B%CC@1=^`4Q3L5ZCMQ9NV<::NXFS7)D='&;,L6**%]\`0%P0'
M4Q$9I5(Z".IXV-S5K.<M'@;::@,_&:[\^Y&&54+V3'"R#6.[,<SWSY/"P;;'
MA.LDV$IZ/D\7\-*H@MMM%OYO+]/)I_Q[.GM]\B\O8UB)XFYB.,Q?%NV[2[TI
MBZ(T':\#1BJI_GDTQ+3F_YX-)HLL_QN((EL/*:M@\3387JL;@2-G'`5'!=RM
M=C9AS5P.WD&MX[NDH57A8)=)2WV"O\D4ICX)N""AJ7^58!5K6:M7DP\!2N&@
M5*^SK=T#G.T51D\[M@=,<A=3']NP!U3B0/!ZVU?.BH[AR3[W51]P^MY7?6#J
M?U_U@>IP7W51J(J8K%9%FI_CW96MKD(6B@E-VY6M=HQ><-49^K5/+:T3QMPD
M?O#KNEO]=8(B8S@6@K6L6^Z6`,=$C<'Q+0F0ZQPO:>`]^@;Q"V9T=U7K:A7,
MYP(>2<E;Q,\Y;^6QU,*O5\%'Y9Q6+??_34_?O7>"6NK^8E0HQ8[$A!I,(,RB
MB"8`G1('86>*!`G$2FLR395E+,IMWJ3[0'4GQ;+O;AKO\56H=]E<GW?8RQIE
MNYLJY7<W?'I+O#3LF,M56_S3C*HLQ>GODL-:`/%@(T8P&6661!>-C=YOQ?]#
MN=O)?Z2_:A'J27]]VHL^]<I1=L79ZW\+\6?4,G7$CJPM_EIZL!.!>$>M(C)&
M20+X6R21-B9&)_`WVPIT^L&*_XC_Z46H)_[U:2\,.:WV$XQN4/AWQSA?.A?X
M4H;!N[?<@()AWF(M/9J*F1%$N)A(EN@D&K/T%3$955##U14H/L;!L73>_7*Q
MUEQQS2UF=FK3KO9-RS10E@K"I/)$9BD*9%3$)T(QFRB7*;7-W:5R/U?D.*2]
M!@15O1@NJ_OK$7N1!6_VH)^`U->R:\N/AL@NA[ZY&J:BY:I_GJU2B4J#MTMJ
MJ#U\9REH"*'`8&ZL(8R6@NJ@2<8D>)06>]?+E&';>N%=(I(8W&;9=_S(DV#.
M([^":NP)."LE5=1#=`K]=>>H'V>AW5CU^JSP_<'J]6">%XS+4I_[$@IQ=C=4
M)3\GV,EIMAA]'>?'WX)9.,L_G+=N:[$E0BOJ9&,B/`.=&)TF06/*I+*".*53
MPJD60081G;>;#A?L0WEKM,"X1])X,)_?/?X^0$MC<3?[%<WB'6MX\^)\]>H%
M9T<U2_N[9_5]YVBC-).*:D=8&BG2E@%M`21):RYEY$I;N<FFH!]T.9NF!>HW
M%RXKF6GN]M82KHU5^D&5@VV72U?O+'%F#6MNN]=B26QB,M?=@GV3A+<AQG3#
MD5PWFGGO'`D*4+KA2*WOR]X]1]R8CHZ[]94*^U`>;W(Q1U>JF=FVW)"TQK5B
M5>>7*"15WH#)DT@BG<F(!Q>7I#*">R12[9C;>K_\3*%$EU4R?6+%^6W[UO^;
ME,7T"1HO#F^\$.9R.AQX^MJY0!S''KG2),1%GQ!M70B11Y,E=F/L6_<>"U_Z
M)`G[5+/W4NG2)S%@>EC1OK*E:Q5:KT/3(0$V*!9BFA)O,6HFC24AM0[XR(+7
M-@3X@OO5H,,&^K.7ZI++T=?J3[4Y0-3EU237-A/`3[5MLD],FF7&"4E$9!@B
M<90XHS31J>&>T0QP:P3.BQM[]?8V0O=`T?^Z*0NA>\AH()Q>VS/V05\'7STJ
M*C9X(F(2$Z^)\/!M<+(%8K&AO@'%CJK?)%QL-K@\LL$;G7N=[@/&E+'MVB08
MQCQ7&7':4R(U6HU*>!*3--AHI!>9V;@%!OSX5GJ^'WFHRT*5\>Q32;U1A(*>
M)_`F3H))-%C0*F/><6O2L/6.S)'S_E8-H5Z(*5+GCE56MK>$+H1^04TIMY%K
M!GM!IA&SUS"3QVM!.(U@!#(-K\,?%3TEZCC+;^1"74"`]90;ABVN0!,LF\6Z
MQ`8B36I39TRP8MM)CQWMTOD>?*A>6$(?ZKVICEZ(P9P#>JR/0O/V`)UZ%;T0
MPK;-.%JY%<NW%/D9=X\E(9M.YJ.'(I]A.OD\&#VT9891IR\<-1"2F&7*@T<I
M\0I-B`QG&`$9.HO!,$6S"(;H*B^A'9XK)WV51+)UC@.SO"".'A!7,Y2=6!53
M<,89]Y;()!4$//&$4)%JR;R57+G[I<]BA&/L&HGLY_&7A.[J:64>FZ1^G`QQ
M/DH#8Z`GHG$DNG'4Z+60=HN_HO_8\@HB+3KW?LYGH^G#\A,^Y=^+EQI<GG.\
MEM54@1MXZ;44TRP-J4U(R'0*_I5'VTDHHEET/DNH2Y-TVTP4U(GBH#7V6I&=
MA790SS/,\X=Y-IL^X^O8T^3N\>@-SI5YJ7\,U.<&3$OL8[F?G-0(9GEOKDG%
MM^!8L6O+1FWE7Y^"(OK"N-3K_76`H?L]`0^R@[MMVDVM_!&V[%;PDW9`$J/M
MML26JF5"=/QK^"<JH%]1&Z7Y?#@;O32;JE/PP*A`'@Z`*6<$-S$0"M81G.4*
ME*4#3Y%&.-83'ZGS83D^&2PX\CB=$?C_?WW%II[E93W]K+OK'%[G([`&YW[X
MOZ^C>7$N+5L6?@1`0,AB=3=[-RN$!<<R[RC8IGEHA?Q;:I9RP*TR>FD+<GEA
MED,JHF`*R`,I`%E0:!_">4(2E5$:9,IC4KZ8E=AXN53Q>ATB#EQP^$PXP7"Z
MX]?7PKH:#R:_#/["3L7+>1_E%^<@BNM9A_#CL)$M63#+J>-JYYA^>9WEYZAS
M65#:&$<RX<%#EU80F["4"):D/$NMB"&[K\B@N0*^TCY;OQ+'HR?4O_XI_S+]
M/`!E/!R]%%/L0SZ!;US@=US,"WSZE6C!L@NVVG^-,/1@A4A4^A<G?G!-@Q,&
M#Y<0B<S@)T^=)4!+*JR3WO"M%6*81&/QIHV0<[0T"&[5I@:O^`ZRXM_0"&G)
MP>&I59\"5DP&V#KC;V&$8*40<_T9(<6>$%8`06:_U_=-[8FSO-3?%/6Y0=UY
M4"#TAINB+0F'NZ(^!WBLPCEC[5N:YO"KE6G.#,7I<EK:YC:83C5HD<03*Q(`
M[<'\<M%EQ,+G8XX@&';;TK"#<I%K[8F/\-"CP?CSZ]?Q:'CW"*+2J'"H%A\-
MZJ9J<X()5*+.9J@$6+4-JHC\,BVB>]]G([!KY]ETMDZ?OWN\@PWFQ^/I`J,I
M=VT\F[[%B*_31O;WSN7(Z_*Y$<R/D^'X%<NZRM^R\\%O0J;EUE,?,Y(Z#`N[
M#)S*F'G"<?*Z25B2)7R[)^NSV0!WB<K:XAQR\&_S];_B7Q@#O+I6:W#G4)M%
M[(ZNUKE<U\#<@_8'FMBJH;"@:E6,81N+6E2IT2YA<-RAPV0YYOVE*9%&XDR?
MU$JY+55G5G(C;!<VT0SONNX>F\Z2J$=%?9FI3P>:`'S_.#P/;:=AX+=1_GU)
M6/A1&N2X#(`WH@&GO8(3Q[DM>&!.R14/!@TC127VI5+.',8CHU2".D>T4PD!
M/]"`XHZ&9)':U`@A4[G-@_TL:+KIDGOFZ3O>`[N(=R&>V`.5=Y,)HUX:T`Y.
M8/8X)4&S0+B/'$P\(Z(UI2W0D074>@?4(J+)36U=-B0<Y'J_7+[1#G@;HZ>E
MY%0>U+7)XNM<NDZMGNY4RDD=HJ3-0@9*PTI=C(5*B$VH(C'C\'L)>EFR"W3(
M\F^G/P;CQ8_UO>%\%8P</`$IG_)%D2I1L+9,$@!&6USN"\Q[H.`#P@_'Y\77
MB<_6NN/?%%Q_H'+3?;P]SMM@:W]"]]786H\=P>I\G%5U1;J*H81@O(V6^10X
MH[$I#:L+DD/'R`I7Y-=2A9DO7GL2!(4-@A.OP-P5.M!51)JR=3RAXGD:'*>E
M^Y`&)^H.C$TTA3(03=U8,0J7AI!D&>$<;W:,Q83K)"6*4\43!4:%.G6S4QM>
M:0TW`\8'BT%9L8#ZW"SYEWSV/)H,FAT8!3%(Q$H3;I*A0#`/LZLY^!$QM23U
MF&FNP;#R&0/@&083$X$QVPWPS^R/U8(W?/@2[$_3"4!XG3S@_18F134`QE;`
MKI4QR_#*TWE#E`(S4G*OB5?6D^@BCGE+J4GB?<4PEP,,Y66=CL>#KU/<"-_R
M#1=+=HH(XV(V&#916B=!MP/$\%3;+&6M!ZY&.)WXR<,JRVWSUO\G[^F?&S66
M_%>H?7FII$HX#,/'S.[E50%".5]V[2VOD[O<+UM8X#4O"'0@>]?WUU_W#"!`
M2$*R).M>*A^V)1BZF_Z>GFY?[&:&P!H[%`$=`TW@V.OI(L.V:KCV*K[;P&^R
M;;D3^R%+HNEC@CZ/&XVCIRC)YE&(+>^SV0R=GB`1I4"HV%M/.CR?5Z!L+?`9
M1BVP5'K%WR]&=I#V%_UH]HBE)'T(YEZZW1W8(4X4:AYU?=/75,(-+"CSP00:
M$&Q2KIG$L_ADXCKUZ1NB=8/J0=B^;HE$14%:S7@Z?8V$K'PT#,/2=?NX-1)E
M;3].K/V2BB7K&N4/$7CN8?N"G:I$!27!"S&[E<?"V.YCD\9C@_K@=8TYGO)Q
M=6`^G;MHD'W&+'O"#'UY]&N%^7;']<2TP@JM4].*-FAU.%+M73]:3Z5P@%EG
ML@WF35S\.0$+5+'YS6[6TS*%0*]4T':#&6-57HD!8N]:JN_B\6F(CE2(C+#[
MGN,PQ@R?3(S/9A7'T$.TI1R*?YO<?I"GH$R+JH'9.$X>%SNQWSHB[=.I=F*9
MGLZHJSICG:L&(P1^T[@*VL^V'-VV'=_Y3#\32;<&UZU!HXUKIP-MI>+*:U_0
ML7`M#59Q7@T-A^*,+7Y`M"VMT9UZ1XR.*&FXYX%3;W[/$E@&AY0?2=9ZNGL/
MDS71V]@Z1&OOX?@/X+]U[\H)__E8[+CYN)4/M\QU9]0G%K6!D)ZG&@3\"]?T
M?%4#IN/C,9O8)G(B7YFCTY4^G%8_/7,50K:I$(%$C\3<;>>8NUTX!@-ZLC^Q
M]A,&"+X_VG]T9.$HF!U1Y^#X*3P1-<GRCUFQ>`(#!R^PFL"U8W1X=%LO6B)J
MILF.I(&V4^.P7=;%^;OB,I5Q6$>WB2\QV*\A?25UX!I,LR8N51UK0K&:"W0:
M>,8J-W'_'UN<."`-F-30+KAQ@%>S'W5.8)G'\5,<1FEX;G99ZRKBHV/?)O95
MM,!1?1_S#*\(W>??8-G+M&Y[[8#P/$$@LU,N90`+;_8*39_3L:/YJC\9ZT`R
M;8S-^VR53SQO8KAC:A.*9LQZ\P_+-FUJ-`@X'*-!_O&*:W(H\WY([Y@.]X[[
M\=EA9Z5Q5J>H]F0/$3$-;.*LF<Z$V9I*-8<B9V@JTS1#Y=C+AGB>R;V)U&@&
M9ZU9'COCU*;);VE>Q^RWP;?R/$11'<TLP-0\)LA?N.O_$9;.Y0/@6C!(.V]$
M#1*AS0[MA#M4LS$]:X'>-XAM`JET3_5UR[(]<\R9P3[W3?HM<Q0GE?B!G([;
M)K:NV=2R5I(NQ0M>6-F]YOBO;",-AKTP/([`;&XU>O$<!M<#N?NE'/T.OA<J
MWG(3K[).+W#V]^@R,,S_$;,D-4:T[@R:(Z#?&9BQ>(CRJRS-*NL$KRR;164-
MY1D*(,<$NV4;1L-;W(S$\&V;8UF6X=VP',O4?0?$CC-T.X`0#M$\E4XTRG3J
MNGSB?S8TPC_KHNS1PO:QQM!]F@%&1A(.9!+SP^DT3F+!=?7\E4*0^I0DT2W?
M9R[U55?7P8UU*55=SV"JKDT8<SS/(29Z8B92PK2LI@0-0V:%`$)CC2/Y$_PV
MO&CIO(EAV>?HBHH92]1F>HL``Y#IM;VHIV40=88Z0.Q0$E/G%E\QPDO`UTP&
MDESQ?J<1JR?#C(%[H1O<LAO>10_DVWCV8Q[-@SA\!2T^D%L!3]6V6!/-;5AL
MP]F9BOP+N!K3*'["3=0SQ-L&O(ENFD2S-J*^BLQ*U'S6?(S:R`)/DNCMP'@=
M"R_3[<5MMFST@SV5+E,OF,>+LNO/BD-T$\D]]>A3E#_%TTC:N\;^YQ'27X<U
MXA1/]QJVT:R].S8]M@E3E;>$M8/B89+E_S_R,>`<FH1N$JPAB!VWSN?D_&6(
M0S($9-5\43U/U1$0&!+K6/)H[;3O,^0,PD2QA-[DCN$(M0E1%=>E82ECQ<Z]
M0D^GB$7/1Q/N:CC&:Q%HX[E,Z-;::#DEZ@S?L8G&U3"YT2SHV(C$H.!'^,SU
M1^"&+:+92=$?&`)!,&A8W-H:__3BTYVL4RP*%("=CX^>C+%M5/7<M*WFS/8N
MW&VL?HE2T/4)?.^$LSB-P1*(^N#S3798&.@P\).;?:^WH#%H>V42IP&\_C,W
MYSH5IHN9>K.1Y'"4!HFW)[I]7:95TV2X0,;%J#5DSBU)LJ]XANX,A1X\'IUS
M`H_?*O<[(-HW9PMG2UW?"[]!=D(M&XM$X<$SJINW%88R#UO95UAU!_=N]GTZ
MQP7<-]7`FO;-P?+&X1?]>[IGB*W1$POU`]]A45`(6,(//]!I>PH2=.RD3]NE
MU1FBK:./SJ@!N#?\TUV0&J3JKK(4%.;C5#0#*LU%/W71D)ZAMK-Q!H0)UG*K
MLML-U75#Q,N]JW11K@"FYWA4Z:D%MR<&M_'((K4L((NC.RK\9ZJ.1ES/H<QG
MGB<=7[W;IG4C$H/:+98]^7*L;,HCD8#(GYL7[3I3_@!L8E+#(\16+8^`.-F:
MI3H^P_,_$T)=CXTU5FU0$EMKACPOPW%`[A$L5?@^#NZP^/0\O2DLV]9MG3=;
MAPQ!99!J$<.X\>!9-@V2^IK3TF&@$A%'=)A&F+E5BZS#:F@N^F/P?*:):"S`
M50G.`]",;?S01&589[W9#&FW4R^]T]E:?673="L:@T2@_KC4LV41A+.81#@C
M($%F>L3."LO[#U,+>&@!P6/PU-0XU[<*R'XX#PI1+].RAO:L0U0"`9C:32P.
MQZB[]UI$03Y%IZ\\F#I;FNTS3$^88B@G8XRW]F$W(+%>?;QZ[<7`PC[0FR8%
M\>G7'H/J^$),V:!_$875J0>,O*<!%NTWNA[#%Y^BZ6-^<MX?>!*%].SQ[8E=
MUR&=YP">T##P>Q*5I]K!&8.[__?(P6M?MV+'981Q$Y;60!D8!/QP2L:J9_L>
M8;;N.[8C%2=9G=6X'9=!NW$0RXB-&I2O_.DL?0J*J0KPR@G?N@77P:83S<L"
MP37&Y;28$]NDW%9=CHUC(.92<2RABCVE+.HZNLG]\OQ"(V[?"'YW4ZU7'L9+
M(0)>Z16J,U0(5H]"V!_!]3KA#'E?5'`:-ETG^IURATHA]J<D7J-NQ^`3C>N:
MZD!\"!:?C55LLZ@:8ZKY8].@FNG+RJO56H5!R`RMC98B\S%*@P3Y!)BC.CW]
M"E0AA&G4MBW5MFP3_2!/9;YKJIJG<XU;8\<3^8:V^+\`MT%$NI%Y+3Q?WJRJ
M?A_,L3>=,Y\G\11#->E[PT?OXUF\V+E?R^D.`-"51/W1.K:?+LHD==6%M3W0
MW-BA?24$.ZXYW/Q*A^98M/J=BN8[F_8KSK->!'.J%/XQRO9!FS'H3J#;OVZ_
MCAHN,0F9%O'TY`5L`P\MB-%8NE'WRSL.XFTFZLM!]%9XM`6IK/>HDIH[=.`\
M6=(%*V(-;ND:6S+<@;!MM3E+T5Y$8O=V.;L2'Y&'V/1*L#DNBOE.H:Z*XFS2
M$HSI8'T]KNH$.[U.P$EQ''.B:IH^H;X'7&LYM3D^$KZG=.0^`]H:,;]QW614
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MX(O(L]V._YRNWT--"JI9!CV:=&!K$*2#_>8?!J/&T*[:`[:/3G9^>2VE#LXT
M0"R[/,UL#.B8,?0L\RM0"OQTZYB4LC_+:3>8:.=\P,#RH;0ZU_-WIR?MZY_&
M.XDA/!U!T0X2G`EED!=90@<B^1"[-<9/T7(?R?^&0]2B4/05`<(_RD3W]7VW
MG^#+BA7KL58:)=PV][`;3'>);H`_"0&G87%?Y;Y-5->G&DY&XY;CR"@+&\QP
MC7.M$6<=!/5SI"8.G2!'HJ9>MD@V*+6TYECE?UUJ6I;.=N]H-8B:M,R(Z,2T
M(!#Z:U#3('L,71E"3:/,I\`]K0#A7Y:8>P>C`XA9!>24<L*;!^7^5:G)=0-L
M[W&(:2$Q&3;X8F"P_P):$RZUR.YCS`<1TT9BVF)>H<W^`F(.3B7MG:ZQ>4]Y
M$"T9TM):J10X#[RY3;3=IXH,PIN7:6?;XH;%CLI#95N`EW8S.,2T&MWR;(M-
M7-6;<!R"X3BJ.]&I:INN9^J<<=<JAV"`3\*Z9Y\ZB!P;2\/4]LHHCC7B>YQS
ME;MC@IN_FLJ);@'.C%-O8GN,-,;^OB:.+QA'IML.(3Z6#DZ`OPW3]56F48[=
MGS3#8/[8<_WZ39KZ:V+Y@J$M-N?C\9CK(+NX<^#HMNH`"ZMC,G&ML3Z&X-BM
ML:3:JS(L3D2R^5YHFHZK&V-@5D_TE-9UHC+=IRJ#L-\P7&;HWG*BX"`DPRA^
MZX,J6^#D4='*(%U<!;/=L:1K.O)KEDTLWW950IBE&K9C`<@X'58SL*^"XQ*X
M7TR/^^!X-]>_^%>7WB?E\LK[MY_6P=:%O*SWO8GF6-*=?A&%=[MG:%Z(`7C`
M?T1%$^I^N);0.[,H#3&K-4F"W<>MK`-WS*GEFMY8=:F%)S,M"U2W8ZL>0,\<
M^->9V)+@]\!FD02X!4J7OI,XB7(O6$1?LGSWTIT7DA7<MZLL58/I-$JP>B0*
M%0%/D]`M`)?0C[/IH\`I+J9!@O-#)_#)X1AC(*6IF&I*)<!K8%H%^O9Y?C@A
M'`BI,'/JKVU($9!5\&2^T$]WG<AX$#AU25&5Z"KVW5@+5Y>1<?LKGY?C!/&"
MZ_O61P?#P_0,T]<F!JIH#^?5,?`L;*:.=>X8U*0>,=QJWJVFJ1I3,:4S'-`5
M#2AVOI/+-(R^_1J=7$9Q'A48'8+'P\V6!FS#U07[/Z,D^37-OJ:?HJ#(TB@4
M>>?=V]N^$'P#54P3[#5P+<$O-?M2B`\M"`,AQP,_32E8!]<ZG5C-UWT%K0A$
MG_S1IQ,;,'7YY?<L@:`IR*7"/[F%M[I\TH&G<V`&L$FRXC&71YD;6U()6C'1
M*FMED$=Q"_BXR3XU]>N0\\:3B>-S/%=)01=1@Z@.U0@H'=?U"?,L77>D+OH^
M6;P+XZ?OORS>`2;XUUPI%L])]/.;#\[-+Y=7JGM]>WO]X:VBS1?OE,GUU:WZ
MZ?*__;<*67XP<3Y<OO_CK7(;SZ)"N8J^*C?9+$C?*>42M]<?X7HV7[QI/.<.
M?S<O%$&/4!4442J2X`4_B2O$;_,3P&?U@(>_Q/B+//(@]W,5;&(AP(IK`$\.
MZCOEUO^O6_7R:NQ?W;Y5C+]7L-\^1`JR7I`^?Q_,YN_^]@WXA+\K%+0Z2@N/
M(`V52U%!%3]%`BNX_X?E7=X[<8]`M_YP_.Y')<">5?"V[K-<6<#SOJ"7KF3W
M2H"EY842XT)Y5.`<&O$Q/.O+ESSZ@NH2_B94&]FZJ<B4S4CY^A!/'Y2O`=XI
M*_U#99'!&L341CJWZPOAWL4Z_*:B=0!0'#&,4W$A`#B#FV"EN,937I#)K?F1
MDH*C^3^/01+?Q_#4SI?B3[@[F#<.PN4X8@6^S.NVIN5M2,^5#S'B*W`)^#(3
MC=SG48YPB>9FDF`7BE,@;N-H&N'`EA(Q1WM'R0A'3M,1K!-&.:R#:-6O981_
MYI'R%?]70@V44^:/^?0!VRYU*`_WZW1DF15%\:$MNF6-69#!0@E@93E01@GD
M1!E8(2K+&90Y("K>YW?:!:.(EUSV0C!A#:0"D,!-\QC$?(1T@#723+E_S`4Y
M2IZ9!<_*7:3$<@"QP%;@.H<5@#[I\Q)DN+\%=/%X]T_D-$"\7&QY^Q**Q0,@
M),$8(1W+H?(1<!4`@?1#<+XB8H4PJ6$D`)[BBTKP-WAK]U&,Q,ARP>`5F4/E
M:[QX`-H!JD](NKLH2@'!)'FNJ16*Y^35Z3$I(\#$;53N(O&=(`+(19PD\!'6
M;P']@S@1C4U0ZN+R(!.LT<25T%+"VV+=%6JX;%6H'^=2Y@(%Y5:*0RKF!^$K
MEL2_.)F*(_H&'>??WT=3@=TDNLL?P1@O)0:WH$=-+:'$LWDBCAN@5I$L07$1
M,0UZ"Z6T'DH)'E;BA5!8`0;145@*..J)[`F><_>\7E&)-_V0)2&Z,Z"HX"EF
M+3((F0`D`S4#_(DLM%W=MI4M`M-4M_I(,\G(,HR&U`]2HQ>PDALMOB(W`VR6
MP!$G+XO;9\&W>/8X6V&2KE)!<!Y!/'(QY!F$="GF;3*UQ592'HDLU7=I%^`6
M,K(I'Q%B50^$->G(YF!4+.U"D<4M8IEG<(>5Z@6MU:[Z:"`^L$BIZ??&!Y9H
MVSFXQ33,$;>U!C;&B%(+L`1L/C4MDGSU`IL^6I4Z%'04*M8U)D\1!`UE;ZX*
M8G$F%KA-J1*>7A9&;6&XO/$Z8B"TX`;[>2;:8J!M;=.R:5EAC0&V%<3,-/D(
M0N+E(]8RT%8[VV=ER86IHY7%5:2=_6V>24<'EB_;7%3"??GQ>M0K2K7AD\9X
M'U-<`;#J/VPQQ71IBH4C(8SQ'J88;FX:XWU,L?10:V.\ERF68-3&N&N*)1\)
MN]IO56LZGHFD7*;*]721(7!2,#:;T1+%RG:1VG;-91.F8M5B=311[1.+SU51
MRHGF0K`.L&<!<@%TAY_3H'B0W_?ZSPA!+8RHE;;8)'CC\2*6UG6=8P4LA;^O
M8^82>[@##!*WM!&Q6%?R+\J`;"LXN6S)$K;Y"9E.6D]XD8MX*N"M3(<"-_]'
MD+:]'X(K1P%$4\+TW>?9#!98O4QH/@,PR;/'+P_2H4EQ&QMYOO]R"!S`6I01
M2!(5A43HA^#'YH4E(>J([8>[QM?&A?;W2C\MLD60#'E3354)'_;I<2E*0D5!
MF!;)2?;8N34$&B`AA&+Y8=H`9='_5KJA11A)Y;2TE&X&G"`,"N@N$)8<HS?@
M48G64C/VLU4O!Z'&BQ)P]\JKT=^IKF\R(=Y5FP5XWAH#?Z%<EEZ@_*#4LP72
MH%:U4C91KG.1[^Q3FZC>NHHSOA<W+=_5:A2<1TOEC)H:T9=W"2EJP#!J@@9R
M5$2+1=)0X0'2%:!$8<3MM*5U6\,K4W"^\^6[DL\3BKRD*:)0/()X5&\I[T96
M;0>[KCNOM=*%\N_@C,-C1DU"B.`2%T/0'Z(D5'Z`M4)XJP*@'X7C$*#TB`O`
M^1<NJNC6B0\5W[9?<&WW,1@H$S;P@#1#TSD(YG9V89,'W/&!R*H/U/"`I&KL
M]X$LPD8ZUP;(,B(QV/'A%Q!\+/,+I[.6?3G+_J2@_VTJ>KV?;6+P.E4^X`G[
MAK:VQ,LG;3^_0D3!382.Q]_P!V#%619*AV8:Y8L`?*B6JB[Y!?F]\TZ+TIME
MK`R;OS,N+-Z&XKH,?TOR%BU`A+V'U;H7H7@AKU9^8IF1`[]U6FJ5&JQ2S07I
M*K_!*M_A9/0V0#=R&3%JIP\FS`?>)YB6*&//J=R7024:Q#DXU?F?T4)Y$B=S
M!N<QI7N/V8KF6[E8P1P=[UF\6)0>1%1=788O-0U0B<#_(A6N4N&G`BY57+ZD
M'@S1?UF>O4F>)0?T7`A/$!R`&AOU>U'F^:99&I8S=4N<5R`'6*/YHM9C>=5I
MJ;1XJPE'\`;!MYSF\1V^X3M0^6?B/M^B2R-"L;K;?U`4&>:-*_9;0SY)*7@3
M(IZY7RIT-43%*ABHQ3DK5)1N@TRD2S*6AZ"40IZ"0O499R&:V:@<$%_F+JKX
M"DT6K('9VB`!KR!\EL%3]?V/J+!Q[18OCB`L?"S*-Q4O.WL`0L6B%W^I-J9!
M;<^17X1(KZS0H&14-K'`[,D,7)9'A#@H2IN)+426+M@JO?I8%GT%N4O0O1RU
M99?`>:0V'UNNVQ%+1[JU4HF`,ZR3$0-%LK*8T%*5D$J1;4"(CS]Y!J5AZ6[%
MS@DF'5&7-4*S#F^+<M82F677M)(5A3<N6`ZS76$L.GB\W1\?(7A-B+6&::Y-
MVLKZ"^$DE<_8D3[N]<W8OU&]Z_?OG8^?X*8I$`4[OKT!BY<DQ3S`T3>BRA3_
MGJ/G5?[]-0X7#S^_8:`<0)CB+^G/;]!7C_(WRAUVP<GQJB:8>?./L+K?Y%*Y
M"+068?N:IW+ANVP!\6']3'/]+8?Z_*_XZ)_:KRCOX2FVC:7>;$1%/+?-R5N0
M[]RQ^=X2WI*I*SG[FR@8U10")KC(DCA\LT)AX'I@=?@`&\RUF;DBE?!RL?9$
M\3<EVSL>\6[8_1][;]K<-I+D#[]WA+X#PH\G0HX`V+B/[IV.X#GKW>ZV_[9[
M-N:5`R)!"=,4P,4A6_OIG\RL`E``#TF42((4(N:P)*!0E969E9F5^<MN1U9W
M1-^Z(>C(O2S)V[]@_;4M6#NX4#U\=,(A=PTKB.&4^_^&P_%X,MD@9UF\%/^R
MW/&@YF;!;^,)V.-:<-NPT!7X5?&9`F>.7,-9A32W8CB\*!^L>??=HTXW_B.E
MG-!KENK(FJD_ZN4H_I[XR[^_9?__[!D?8;6F`P:TZKV2U6JRJKFR9UC[7>_+
MB'A;!)IWYF3I%[7>G`<7Z:>]L;K_AF7)JJZ>&K<_>]FV+5NN_=J6K<F&[LJ6
M:AY?VI<_'F$''X"D3:W![29R]RNCZ0<WFM9LPE.E?:\?W+-MV=&OH]^SZ'?N
MICX+QV\,7_*`\FY6`OQE'D?9^I##=C[$]YZB4'<T)EU;ES7[.([""5#'<&7#
MV[.A?;+4T67#=&33V+/C=6ZFB0&:>A;G5XO@4&?#[E]LY^':4;"CX";]\!-=
MY:V;U9Z3?BB9AS>M#FH5=*Q,L4KV.7X&PLIM-N6"%NECE`Z'"0!I%M[2I3Q/
M'Y^5Y6$LC2Q/BRR6P<('\^G+]"9>8-X.#:1@'@8^<!O/@D7U,+SNIVE^RR^Y
MRQJ\XB:9-K"[`M[_%;#Y],O0-@[57?"]M1YYX_KT^];72]Q]WI@>9<K/N_,\
MRI2WWEJ>>V!B7.3?S4(LDXEFTGT8+&:]U6RO?5J4:W9(_=MK_NAYW8N53'87
M+_R,>M(=F[WP03'R\3__^>'K6/GRJ3^$Y0O1`\OX6_4MI?JG[;!=>VH4Y`67
M8&G'X%9;WQN[ME=+8C\G99Z`RQ7RAKT20L$=FXFUGFZN9T^]IWG'X`ZMI[G'
M^:YAO1XUBEGJ1S^@G6H$+&M,NRFLG\*YZ\:2*WFA98X9^%B!<'0.??09WU/M
M]6K4ZEDM..?+21S\N^MT^;$BH=MBC:4[5S+CJ'!G_H7NC.#A,:I@Q?DO`CP9
M51I%6$J+`,@+1(&[H&KAI1]6OA%#":!'8T*@(!".60Q^IX#R%:1!4"`RY"@.
MSZB<V3',N*]-4)^T!_^L6_LK]*_^CH%@ORBEJ@J?6%4/5E"S8C)?FH>1'TU#
M?P'\FX0LF(HEU%@GQ@IR>6'>#>&+S!?Y-,LINGQY$Z99G"!P@>"&O.?5WF(9
M6OD2#'`9K+HN[Z490_7Q>5$1%36+\!2S.$`6R:3[``NH;GPLB\_G\W`:8M$7
MF\D]E<UGJ11_CX31ZT`7;!G(?!D'M4$>A24L\ZM%.)7P]XC[3\`!X6T(G`O_
M_W^!S%%8?B!Q6?ECBJU(\3DATYCX&2@RS1=4A[^61K6@NO!KMDTI`WSQH[`U
MT"$E)Y+9/D&S_4-AMG\NS/8UV@#X(&0;^6?O2T_ZFA`_WM-I=O&FK`K]'@1_
M-:\SV%7%K([V))>5O62Q7;QAI?FW6(R(T)S!XI[`-FZO%D%1/,BY;1'.RWI!
M]HFVT;:4\J^PM(<IRBL^<4GP;48(QE$-."F&0"&(8Q+<8C5O'I7(#[VR=K&"
MH"(9\TO<+*0WJ^>,:"LX+$LA5L6E4U$KNH7N;"A6G8K"MVX\&"%/`U)!B$S#
M)/4VR&YB6D$I8`P(HL068-^\>+/!GF_)_DXJLVZ;\`1-^X_O/%*WO.);ECV1
MD<C-G2>F6*D)OFC@*Y4%]80:"O^)<E!7K';\*L#SEV$CH>`19`AJK0"KF;?P
MP,KD69(6;G^>1%B="Z/,_,QGI<,%2!452L\"CMY]'2)[<'`4,"+*,F`IX#>V
MA'D5PVD6WPHLQLM6.1E:P@@<DC",TBPA=.2T`.&"!2#06KDF!EPRG>)9S0N(
M18!0`F!*B[+[_I>A8%ZKEF*ILG"SS3Y:Q]]E,!\(PE]<?`MWW7#VPI<3O.DL
M(`$J=EM73!TTUX4<AQ7#R:RZ@P8)7X0,CH<KKP+EZ8*!\H34#93?52?5O37A
MP;`B]Y35O2=,I;'W$!>M-3O\=?5"'*R4VUL?P033&HX/;&\&-C#0#7<7;Z9>
MV]6YIS_OZMS4GWYUON6V_:5^O^G3[O$^?<15[_W3K_>B^Y%%I*P-NF!C/'T!
M+_/&OA?Z/QQJ2J'?)-)/_/-]9ATV?EMT[:XF_0F]W`/3Z;@4>VPTKZ2L0,I:
M^$Z@ZV?R+4#5-WX_C+%O"$8!%M6J"T='>.X2LU[2]Z]J'_H%QEJ#%N!B@_>;
MAM/&[_^)]E>3;F%4K0+Q]5(_FKTT'<\]\/ZQ0CB3MP!*KQA2;2]&-&3=]&3+
MU![U^OZJ,!_YQHYU#8CJ=N0%'GQGG9YQ<DO>^W.G=D=M;"^!9T&,DU,ZFFP@
MFH5Z(DKGV<M5>\[I%?<?Z[E6S_GTS9SM&J7P?4Y/IUQJLFZ[LFKN7+OX_A1T
MB=ISCU.\VFJQ/,4YGY<I,A%OC7C/K]/3(:XCV[NC,)V$`M%ZVK'-KA8*XRG.
M^=RJZ,\'8.7%9+WC^S.9\^G[#2\1'C5VLP@6A\-->8%PJJK*GN4>Y8A]$J&.
M01ZSYQTG$')"+&3WC@-[>D`2[1C%MQW9,O8,;'5N1M4YP<)T9E4WY]..H6PW
MHC;;3:L)@&U3Z<=\;L\VSTFLK%OC\==X^D[>HRZ'J`:Q]?KHV5?4MNO*NG6<
M6.G^E=JSKZ&.E%!S0BQD]DX@"G!D$NFRL>_KB%.S$;?KX']2<165DHJ56UAS
M=?8ZV9!579<]\P3$ZCCZQNYT\H/!M1-@GB.3R)0MYZ"]2=H!:S%B]>2L*3KF
M<I.2I3;9(D@`K\LLLXUDR;4-67/L"];2&G[CNL:&/NC8*SI%K1W>!5A!&498
MU?KO/*+&QQ>L27R]&+`HQ&X452?!-(!!$%`@O<&RSVD0S`B%(>'EKF7SY!(Z
M0!R7IN8OX<4?5+^YN,?&W!H,<!LN%O"`++TS;=G5;=:HVS)D7;>*HOLU1)(O
MWM06UZ*ZRZ+3O%)4@V_LL!ROE+IO7C`U)'YG]SQ-YFW#B5#TK[)C_0I5:$*L
M5W!8U'"L?K^LON??AU$VS:"QAU;/%'90=[`7L<=!*=YIJBZ;FBMOG%*=&G5^
M(520BZ*\^T'"F)A+H\+?WKF.!P>W64Y"UE07_NLTI]$GGMP<!&,%QS11&">/
MA,[#:QM&)\'"SZH2:CYO6M1%B80@2U&0X7>+IX7:]+)H769+<GIV2=L+L>=V
M6>5.%EG*@!3XY%BW:7^%"6&`"J:AOHGS.$\X\,&J33<+[_#'__@I3Y5KWU_^
M/`I3Q+>`"7^<#P4Z?&8+&L9IEE*E'Q5Z%W7>7X,?V6`!I/@5!I;^HQ@,1*S/
MBLMA<S\E<03_9+VITT_Q(IS>L_\MWT;UE<$/GX/YW]\&\>+;I['F`,>9BJ(9
MFJK\MZJJSK<O7T??#-OZAKNHZ8;V37TKA;._OPUGWTS#TQU3^V9K@Y':'UA*
MWQ[IBCD8CQ1O,AHJ@_%X8IF&[CF6^@U?_!6IP(FP;\72P(._*HYA*H;_'&#!
M%FS7!W8B5'23ON!5N)_,4JD_`S[CF7`57'PYT$'TH[U%/7Z(I/_*80V5?$WZ
M7P;%(=?_\J?T1]RK1!$?4T#7%Q!!MP'O^MO_,I2^QDO098ZI2EBR1B@!<##!
MP1-E9<MW/ZH+;N;_D*Z"*)B'&4E4$(&HD$0N">@!A@#>3J5+/@>8P/"7/S[^
M5OTX^N4]G(%)<@^"BS#WLN3#2`4\#XZ/`\B8ENC3C],DF(59[1T0W!"DI&A%
M3\OB*`S11B(4B`.X)D(&ND>YYPN&7S9UE+!4AJ`$\\BG)6&D63`/DH0_Z*<I
M$($U5(?Q8<6-1<;)RAH)&Z%<(+Q8?P/(>4-][Q''`[^_"/TK!BY$=+_4A/Q%
M!M^`LI]D"`B#XR[C-*3I?H_SQ8Q-GX$PX/3@XS&#Z1"^2F/,`H;90//TOQ<X
M#Z#S0)40SL"_X2Q)9R$C!AXCE_K*7#B)$1(4L<&`U'G*OKZ><`S@9)DG,.V@
MV%G<RQ(OJMB_",0&]BE/Z$";E>J4^`&QL@IV`+'`B<SG[,Q"JZLZO^B;<W@9
MCE'2W;#9UV$4$231/".$CM6S3;/8V58W[LHI7@6+,+C#98KS(#MQL:A@>&!T
M1.D*X>UIAK`:B'15H7>E('],A[?(*!.QX`(T.>CT]6%9L$D($Y/$^?5-#>P#
M61J.;,S88T=UL4*.Z<*U%C(0)UQ:8A])_HR=^'CT%P8Q41'IO)F2PO%>Z1SO
MEW3C7+92>_7T?NJ!VSBN<V2GC_./A;;\$EPSQ;7SN9Q'(7N+#_46,?K`,EFD
M?W_[X8_)RL%M]O6Q-U*'BCX:&HJI3^`('TY,9:R[MJ-KAC<V1^S@UH15;YIW
M?7G#$OPE[4<SK!.'1P,@<Y!65L_+VR*CP=BQ!ZZF:$-CH)@C5U5<51LHX/%Y
MGMGW8!RM%;:(UY,$$A'CUXAT'&-CL\E4;K?T6P#&:+.+3GO,(E%!+6BJH#3F
M"'6(-%[X5S&L`U$%$<P&<:KA`]._[D"=D,?WNY_<+_!)=OCY;`RFBUAM1(JZ
MY7?L1[[BYX![QCPE_F%42U$^1X`$.J#@7QS&4?CJFB]=O!&_M=&M,GLKZA@,
M!!Y\**"E"'V/#QV3G(51SD[?RH?C#[!S\"[@IZ"(3I7ZB$87)+>-8`8HEUA*
M,65H,ZG1J"N(_27.LQOI"\QSDJ#63:?Q=E)O2ZYPP?.$8X!;)7P*N$2T>Q(\
M]@,\U'U^>$P7?D[1F`FML]#Z2;",$V)M;G*D,G^9>Z-P@$_!"[MF&'1Q8>!2
M)`:-7FQ>C1ZBL@BC@".LD>M(IE.!L%?,L(?&S`/^<N&0ZTV4RUD%P86V<FD_
MT7PKJQ`&?Z?WO,+E9>$-O>>*/G#=@_\L+KA`<&1L$&QN5K,EN`&?<\1P1O53
M,1M/C%B]4/SIA'!@)X1Y*V'W<T1B9,R_++#<F$Q$<<1@_,C6%APK8G5T,+*M
M7(0N3LK!R]+7!D5FN\^#(G-VZ.+EM``9ZZ035?!8V^TV]!EW/#LF-1NR;6FR
MJ7>WX$_;8.O@&_S\ZVOP0F37/>C=VED*MWV">V_"WNO:GJM?SD[*G1/<:0LL
M;HO/O.4[W6HI=T]N[W79<579\/:<8W)J4KZ]ZN'K39`$%"$_Z'X_0/X=1ECE
MA\JQ(=SV/4WU%56SG0]$P''T]Z/W<='Z8E#-EFW;DDVC!2;5*8G0.16$/I!&
MN'K;]K0+I?IEU&?L1Y('G]F-/D9N]Y4+8]J.UN][0\5P=$TQ7=M0^KKG*HYN
MZ]:H[[B>-6S%_1/^@^?"$&V.=J'#[`S];UOOHL292L(V-B;=IKLG"CAB%@K=
MNBSX;4@1_@;NHTB[?YT$[,J8\D?QDJ)\-D[2,A(O]J**Y])M',7`\I&_@-&R
M\"J>W2O4B87=UH":#/(LG%*N108F6L:ZP23T;9[KP?I>8=($!9-Y+B'>\%P(
M]^S"!(N+E=M\D87P+DQJ$6)&'+5E8FE%MSY>;DT7^8RZ@H5"+@A?,LOG*3(3
M\3;EBD:M_LP:PUR\67MY#S.<WD1P<%Y3]ZWEPL^PY0B\5O0WPP2*R11>Q^9'
MM^'_540?Y?Y"Z<_G881W))\#Y2M>ZE!`O9:D-.I__EK+4D*JEI_%*5Z&XLKH
M9*.UL#YV]3G"R^$M-G=A9*27:V\#F?$VD:98ZSG&>HE@U[*BP0]OL,(:L%P%
M-_YB7MPMB7Q#&5.IM/23K&KH4F-"F>7JA'?U9!WAOI+22)=)H$P70"^D-64T
ME3\5"1<5CXHSZ(E=:<0[K`LAK:C.7@+KX+U'$LSA0;I`*(1E'@#M+XK\3_9C
ME2O-?BPO4'!6FTB+%R<E<1OO[$@%N9PE(N5G`5XN5M<YPC<*,<V7/$7%G]Y@
MODLAVD7:UFT(4I7%4<"2`Y+XWE^P#G819B]A_AF,DOH+%-V/)-(\1:U)\K7"
M7`DIW00C!^-K:;!8%,-C8YX491UOKHO4=(&+[@),J(J3K%(8Q'(X25@`WN>%
M\W`J70?Q-6@DT`^H7I(0.^<%*XW!^"75FE9(96ICE:EHJY:B6_+*V7#QIG8Z
M-.TQ/+@%J^1WKLB4\8*1OY\D/A@51*'J:$&6PRUH?-Y=_?R:C],G?R_V$D;Z
MG=J=":,CK?PJ`97S8&VW>ICL23=7N$?\X8LW:Y^MWQC?YFE6M$6\YR=)I;11
M-3$^F-'QPWMSEH.Q6C6>X<4U?./])"C2)M,`-A^?PS0D5J-0K:IJ$[;"\2A.
MG.>GP!PH3C*?%K[Y_2;@R8_EW&&D@.\8Z_M(^%6*#P=BP%/@B^9B-97TE7XC
M=B(K2C&0$"EFL,53ELL&!^PU;U*U>55,B?(6G%5*9,*9(:F8H5P9NY+%9UEV
M.^N-6*CH^L=:DO$WX4J1I;RG19IL,%O-3<CJG;*^PR;<+P.N'AJF3EU=5(T[
MKT!)?X<IO0?-#CR0PO9<O%GMQ0G>`.I]<&OX`5_8#T)ZZ8,F!+7\_`E[Y7$&
M9*81ZN_%(J"V)GCH)GCQSG*$^3S(>@(NP$ZWUS[V2"O4'>6RHE612I<)S\ZX
MH*P1C)6%E+];+JR<]/M?6/+$>]ZQ\:?JY"JIQD9),=LU0$D"C0+L%J8WO-$Y
M2/Z#5((Q1#JA[;AB&`KV8W$2H/4XHVQ)WF2N9FS`F<&+6?G"^31P,^_K_5YY
M/]BH.L1Y(45)JSJEZ%Q2LECA0Z*@E01YWQ(!H2@H"39V.ZY:X,F\!>."6URX
M26'$\^G1.$$#A_%7<=KAJLL#&X:LCB.6%E6:X-SLP#.@S&-"U1;\;PX^<=`T
M`0Y"J?6>7-/[9/T+2PGXC;-C"SVYFGO#<]2B5>$5CLMK,,`2G[72+$Q95L_7
M?*>^/77UA.Z'Z''<,WW),Z1(;@5M@S)\C>TT2?C8D82F-";F"=.H+48HKWJB
M[U*SJ&MV\4;/!<:X"A[KN9"ED\:W`19'EFUG2VO&O^?YWF6:(]9MX"$R#9?4
M2S7B0RIUCYF)V8HN0YEB1BZS<)D/6=E=[5`P_RC82M[&?96#7O>>"I=^3EW:
M[\M\8SPNE@'A?A:&&3U::I]B8)EI*.XL\)S\8DLH#[_FY_,'Q%VM\S<6;\#A
M)1>J;Q8\DJW*AJ&4(1L%UW$6LG:Y"?V:5S9AB]B"8LS>2S-\G:3H.RZ`#CI:
M39C,2B.$U<:P3,^FBP^SBX3D/.Z[D1_Y@/>VXN_34,R=0SU1N8BK'GE8DP76
M.ULD?BD&S#98(P@/VTWDWS)_K]C?;1(!S$LSI^Z_S&F_\[%'.\]W19>`/T&9
MKRL\ME;EB197:6_A4$P[X<Q%/Z`JVN0%UG1J-H2>96+#+U?7S(:M)S+C2@IV
M)!W(]9^?(O^0-X_3H-)@^IR@GT4=R=@LS-*56)[0]5Q,"FX$!]NF?-86-\U"
M<&XR)EY9$B]X^1]M@F`9HG*H9$0,:<0):SX=4-+R@J4<%XQ3B$1+*``GTBQ@
MQENQ?VN=01C59]9:Z3,C$XB,NZJ^,6E_U7TMPBT\6M;P>M-U[FW=Q:ZYN55X
M!@Y^F!I,$*-;3*ZF83+-;QF'LP@8^:2"[8D)ZQ-X'GFX&!>^1!HF3$O:,/X5
MS1Y1JS=\N*F_9+GJ89"*L:.(NR)T`-WYX:+*:*^;1$7@EY\8[&@O/XB)[*`+
MTU(/\@,!QKCUD[^"#%Z?!F!LS&OZ!%9'LQ=JSX1]6AMHX)--6$-U.@VOFEV^
MJ62S\.UI2\.LR3SB-#(4IH*LO.]ZV:R;P@2+!:O0I6.O*"XH#(*(U>(Q;VX-
MIZ)!5O`*HP8N?!;RHOJB-K7F?=!M!FTZAJ+OFV<G.[Q8G:=2!O[FG&F*R'S3
MQ-CDGX,!<!?&>;I1-<H4N*$06,U8('XN?LB09$`E=IH5WVRZMJBE&P9A49SZ
M4.Q`N'O8NIAPRC8+K>(I#^<6OXVO_LVJ'LI!%N%?(.\W<3SC3%B[[VB<-(S;
M;OU9L,/K^%HY1IZ6[OJFE=1/LT)*0>YYF%P4>>)2;JW1Y<4F!R#,U@W,V!(-
M`-J6N5`R70S;DL/ASR7H:E!HI6T8KW$14S)*RV*=<%[I7^2_F@;&6FI6--O0
M0.7A2QZ0H(E@"-)%/>E3$L9)<3@45;-(Y;4`!W\N9TP?U2Z_^E_^K%?H-PKH
M54_!@I^5T+<8.R_N,HL`NS02O$\Q]`VS^R\_RL&`%.JJ909*T[@U*O4A9VQD
MG)*\H,W_(H"0IGH&(P-KOB0JJ@<IKP@(LY[%2:6L2DF$PQO#D5.&HR*JVB:I
M_OGEX[A&*Z8&J:`9;)LKFBR9@TP7E\=WJ?X$'<OT-AKUM[A5*1J>\93Y-V6\
MM.`%_,2%4/Y%[]YB%1O"%7#8DL(782$V>17TA,+W<[REQIA"NEGI56@G:7Z%
M1,ZHTCJZBQ=WI8GP`4^3OPH+J6X5E/5OT75V4Y[W?%2<;8%00R%6F%(91$?1
MG_(NTXUC:+F.VYFMLP;X@?-M&EY'N-]H!/T[GUU7UQSL@"4;!H]Z02$*_A:"
M-D5E#*)>:\XVC@'2%+=1`H@$QO:D:V"P8D=ZTG^"9Q$GJ)G1M]]2KRZ0NF*&
M1DZ`O\7E7G/8D>5Y%<!L1))PG0,Z'(Q[V.EK9E\(GRINPT"24^!%=N..'X#3
M.4V#(N.A/(7I=K1'&HAP1?A*A:A.Y:R7J#W,LGR0[1C#$%A#,7.P/X.ER',;
M;(C2/>3V:K'P:%:\N%82MO#_)IYCX`],NLIK(#K1F$7((N(X&7[_A+^H7U,1
MZY1I%\7=EZ@\R"2[C6?A_+Z00`$0BL-EB!?CJU=4;`Z@J)G4%IY.*I[MX0P=
M=#;H+5UD,B>:JTFRQPJ;='WX5)PTNMQ7R,<)P:'!D4E#D&6IH&5Y7^GBFN+]
M^JFI=PDBY@KXI^0AYC'4]'=]D,'XRZ?&*'`PHT['NT`\)[@#LB@Q2*HS`M:'
M[^.3I++XV<1OKZD$.ENK<%F0"=19E*+J\.D&'S],W+>H1)P[+BMA/AP#?<9X
M,2NJC_%`IS./2H][TKBX&<*5LVDR5DW)_RF\U#IGUY1AP7YIQ77<F)?+F#(.
MON(^%$$F7.V*(R!<Z](VQVDY+$O`NUVRN#3&,'ETK^!#T?CW$32$1198Z"B)
M2'U4]TX@"<&"F_.%1PKG:7[+TXZJ`'CI$4KQ$LO`T5\"#850,MR#(Y2^.>8F
MR)47UL@FF2)2%\5)KX02;/![0!8J4QG>1<B:8,9"[V)<BHR!U1`U5J2G.87]
M8I$=*$R..9VSDD(P`&YU+0Q1;6,1A)C>H/311=-?P7V-)GE:W%36V9D82`2M
M$<\+AJ@C5>%0KL(J_2L*?%VK7079=SQ_*..&LQD9-97>Z-4L1P&0J&8X)<UK
M>G[A7!F](%^U&'4]F0!T\BT=AV+N`.YJ#L<S;-%Z.>/Q6G'8<&7)U0T,Q@#X
M2<?3;<A0`.<I8NR(:H7O<GUJ<D64>U1TPA5C060Q2$2K"<50#0NT7U&<C6*8
MU2&VN!>5S0:WCT)\)<+6QOUDTH;H13]8+]'2!J0/9YRJ*R>T.&(M"X-38R4%
M@T**:U-+PJ2B93U*PLXI`NN#7S"_9]TI2)J#IM%(TBA/74S&XB^2H>A7EHUH
M[N$]O_@>1<KX'O6DWTLAQ3.W#&.OM4[#>ORQ$&5?E!2>P%*G55T(6N(PKXFF
M;L^QJ9^?%=[40W'5F2BQ3<E>&SBML_/&D.F*R[XV:+HE9"IXL[6@Z6PE:KHM
M9GKQ9C4&O"%T6BU"B,^LQ$CKD5%0>3-VJ->#DS6U4NQ!G)#!M*)C:Y.;DNE3
M1-?*I$Y*J`RSE./#X74>@V$AS13G&:?*-`B76;4KF&;)#`GQP&C>V^&S)2AJ
MS8/V4WXW1>Y3Q*G95*2EEM^ZL@)`#R,Q%%9(^6++"Z5U0[=$(,4+GB1`$#[F
MQF5IF?*UV0,C[_UB':!J$8Y@(^4\3":F\O)(WU\,R&3V;SAM^>5T*BIJXD42
M\CO2OW724^X13S,@HXWC&ZTXQZ4QNFID<><$W054XP'/I2@F*TM7.4H.!E/8
M:LITV<<GF@FY8^@%+<AH+:`(5WSSXN0CT"4V&0Z"2?^FS0BS/`N:ZI'?81.6
M#-\!`<#SOI(;B3"/*C7'-PCS!`*D2!8NV+T&GBOBYM<#[BS1XYXLI*B0@54*
MXTX3X:K/K_/M&Y$.#+5<"5<?#4X@>\.O[]G%FUJ,C,>>"UW;S%DLT#`+O%\_
M%:P"?&`]D8A$]'4\95#Q%3<6BWL*J?#`#X-I2HL1&1^AXIDN\%:9I>^D(H@3
M?ZZTE6;,D64W*(W\,1%FL:+K9FIR+?\]Q&,E_EZ97X5GU1)]],B(.@\>"!87
M9F743.6ZQA>C[@_$W`4NVGX_N_9V5BZCF55DJW!"MZ=;U9.MB(NX+5"EOO`3
M?EN)@G@-1OXMKU%HR0;7#QR^?:E@C5?):9O2@AJWR=55$TM?>51*NL_R7=`+
M3H3K*0HO+&)ZH-*`\&?PP]/F]0!EL@I6'U,OJ!XV^4$RCY!0M@M3+=ST*-;-
M<M+)9PK3TG%;:2'0(!LQRT)TFY[`:F+V3A7B$)-4A/3V(@31/F;*[I<LEE[L
M9BIP4)62^$AF$HL0F"`7H5HIB*[#*`@2YEZNWB/+JW><G&I!+0V(A=FY2\,N
M+U82X(IK;"$8G^37M1DS^X7%/58UY2KGX.5?<<M4-J-@=GA)KZJ\BRV0<7(I
M:-5M;G6^D5:L.5<XC6+$UP'J)Y"Z;@JN2=>D<%J9$U6>=Z4US0+U36Q*5D%R
M?8U`[5EQ%0:V0(!I@EEP3<55/U\TBB]%=FGD)M9*$:_S!4-'%1[B7-EP@JCR
M3'@,0W7KOH'S10U7R:9_3WJ$(\:O&HM8GAG2+1#:O+,[.J/)F$$C.IR#M436
M8>V*25K>L"K6S^O6L'$2E,D)-M-MF*944PB?9'XPR3IZ(2"=Y9T;FB>]+P@@
M&K-+UQ'*8G^&P0Q$`26-7KMEF(SZ]>MTP5>DHPBW2V052=@$/P<'..$./X4A
M!3?8+^I35N<KUF2R.A5\G5*1N$]/7AR8/0S&%*^OOC3VD_ALTZY%$=X#,19(
M,/1Q415Q+9`-VF)K]-?<"K)037D1*%X2"`2X$%-S1:>AS.TKHQ\T8"7(%.`I
M[?`[GI$%=DF8_D4.">Q_F73,[XXY:&Q5J\OA#;)&?DWY%0YP7YT=0IR9SA'R
MXPOWMYCII;\2QJC=,Z;L4B)*<YZJ1HP?A.SE1I<!GN^UDBI0!J>I5O&&H^#C
M:.7LZ<*NV2D`QKOQ.8)ZL5XQ=E/9]CR"<IF^+]HQ4,)RW<^/\XP23.M%K-S8
M>MK4A8FC8KW:2D1FAM$-'?86H+SL-*N-SH*(E].'-@/#,7'$BPJK*P*_Q#QN
M1+^8]<"XEF?:B66=8G12.*B$J&JZ-F<OG8:L/&\J"]I)%BZP^!'!TER0S[DI
M3N6G5ZR1#FU&@ZX5ZF^=.UBR".@1DE<J,F8QA`A;`='R^)WV3!BR-*1+6.M*
M*)LIY-5?FE0G*V@CW1\@=UA>A(F7&D)F3)@*HMD2)?E''"E"P4BS9F"M5<"C
M+W2LBMTLK\KRWEE3-C?>,%55Y()M_&#R!QU0M6CTBLY-:O$!P5+=4'S/&4A@
M1+H@I:.US*A]J+P7.3D`"?M]E584*Q+N`\0)%YEJM7!BE?1'MW#A59X51?=E
MXE.]``7E5I2EM%$/4VT.PK9MIG0C>/0(<C8FLJ+Q2W>:5TJN36RO`EGXQ2@N
MS\*<!PVKF\^K17CM\YSES=MT\6;C1M$VM:PP\G-1\,J-::E?^@LMK)!<*\W-
MFEW1Y:D*R>HYOV1FU(HKJ_*^!CX,#_67L?1Z35,@($\`7ZV'GE@7HMY2M<RO
M!W`599#Q<05KQ5<H.\XO6B>LS3QO0&V02<E?8QX?GCU4=<.//-1WA:E37`L4
MA=A\`?7"RC\KV)6+-[5\&KJ,*9*Q*O"$8OUKJOL>NL:OE7.#X(L>$0^BBUX1
MNW4@'Z>PN=^ON\EC"RS;;O%EDU_#]A3)M5)P5RI[L:UFK8+4G_)V8!=/0!I8
M660Q_)K58*0G"F;OV5RKF:(57*OXPW(_D@[,'JYN;DJ#CU^=M<1PH)2*.G3)
M-ND/ZU>NG)'J#DZCC>=Z((^/_"%VVFXX4,.YO#8IU-^**E#W]=!:XXZ;3Z%4
MT804YW3!^WI-;^*8E7>7S":NJ@)P6%>IN`G2HLHE*`V)6E)!9<"+^2%Q1:0Z
M780*+;3+?<JDJZ4V-L29T:1H@+=R^WV+Y*0A2%&7=R.5BUU<Y'.:%"9>V<>3
M#9GR?-ZUE&NF2+&FI]6M9<V*+X%9Q'B'")10-5X*;S&J-JLR`.KY%'4+=OW\
M6R*,DP>D[SL97VNY\2EJCQ4+-(^VK:)8ERG1I*6'2T?V*3-`/T-TQEA-^(JP
MUR\X.98-2NA69)%'U!GP*@/RGM;D?&\A]I-$ORGLFZ@*@]R(5\GB;75Y")6Q
M?N;5E5=(/">IL.;+UD7<,>!.697BL2:KAP[FAO@6*Y_3%=AC-[?'SI6T`APB
M!5::.CP=;T-:/Y5T^A=K$6K2ALG0Y&'4&O<--[*"FF.GEU!O([A")<46X3RH
M_$CVLBQX7YJ.T(W9#:CT+_`50FO)GL9:F^M$Q&"@$/-CTL6'%I,Y[H(R350`
M2$!C]G$SZ4G_&7^OBW:]9K6>?-\@"Z7.XT\19F[SJ/XT*+."EPESXD$]9R)I
M+C976O2D3XV'MQ0"91QQJUE*^]2RA8LWK'!!^OIIS))T6!KVUEJ"VG%[\6:7
M6H)&)0'JKX=J"3:?#IB5@M3HB@HN7F%1P6:^P(RKBS>-2H.GUQFP^XA:I<'3
MZ@PNWM0K#7:I,RB">^O0:Q];9W#1Q.C;J<[@XDT#I7"W.H.5*/-3ZPQ6+E3D
M'>H,ZE;?[G4&/-)75!H\H<[@XHVTIM+@274&G#<>#6&YIL[@HJA]6ZDT>&R=
MP<6;;94&CZPSN'BSL=+@X3H#@9(;*PW6UQE<O&EAI4&S)K:&%U28(1399O&?
ME%9:0PG>&@!:YP@UK7(_XV'[M!Z"HA32HMKGT?Y`H]?X%G/KXDT]HE(E,U,X
MK)@'3I>ED6XXPB_>U,LJ18:JG_4K%=_-^90*BNX6BS.:Y5=>!\TRX^($7<9H
MFX8LK9%BIOSD+,YC.DV$BZ/RD,=V]T6M="U^1!X&6_7FYIDRPJC1K.(\:;@;
M'*DF):]K5A)S5K$5V<:PF@13P1X>!9$)R$>I.5`5DX+>G`17"0(E\,:_7X!_
M_@#22.!LLM2M6FH'*6Z:2#MD\4^1Z3;'7Y\B"^M2N:D;<2ER4H%Q4-PIE?Y;
MY=8Q^&5.NBK:6$=/$I/DN)_'-$#>7);H]@F'[".=W[IX9Y1J0\=#VC!>E.*,
MV'H9^?0)"+?XM:H:E%XJ()!7[;8'3SI6)TY"!V='>?`U'<^-;JUP!B^I;<<%
M`S-<B6^L3Q2_1+,[3TD\K\!3?\^-6E+'O*1DFV>TL8Q`N*9=+21X9!G!!8?<
MVU!(L+6,X.+-(PL)-I81]':]QR,+G5<ZB,`L<8E!N1I$>8UQTN8%(/<A-J<!
MK*^U2YMVPD.FR:80:=TPKFR$.N([USE;-<ZF>_7'J(?ZN[TG0@PV@WOD,I8Z
MF.SVS8''[?<LJUV-5MH0/=A*J-YY:.PG>/*DGX+D"R)'CL)%3O[_KOV&T-ZF
MM\(T-G7-^?;GE]$W\-2^$3!E^A86/`5#;9'^_:V^TIUH8EM#W34&2G^D>XKI
M:AK\2_448VPX=E]WG/ZX_TW[INEO?U74GFI6R]ZPCOIB_R=`L0IF?62XZ^"/
M'"VKCW/^++V7?LPS<G`YR,DSB;"ZZ-663(]=M/GV5]LU'=MSJF4_<45U<GR9
MW@2S?!%\G-.#`_0?D<V!UXCOOF3`+OPJL\\+Z;ZBH+Y\6RJG[]J:86O*P+1<
MQ1P,^\I`[QN*XZJZIQF>.]"=@[>E>NAF6>@DP/K(Y[?@$]"-18JD*SVXH@@1
MY1V)\-H:W7OZ\QK=F_K3&]U[^VYTO_G3[O$^?<15[_W3C^B6Z.[8F7;G/KV-
M-[:_6^]C6(AXU0XTX^U`5R@,`@=2%M&)61>C@E+4#8^I^T9WO!=O3?R(-_:]
MT.+44^@WB?1344S!3L'&;\?<]*HF_0D#/@>FTW$IAO\0FZ[^SW]^^#I6OGSJ
M#T%JA+ZE)64%4M:ZK@IT_5R$+1J_'W(TQ-Q?5*O^"A9WX[G+?P5^DKY_5?O0
M+^KB&K3X@,G3X$M-&[__)U[#-.D61N(%#CCC8-R]-!U/OP?\]L[@@E$L;PZR
MZJL.5\O;Q!NR;GJR96J/>GWGSL4O)9@[-FA6>YYYY`4>?&>=GG%R2][[<R^C
MI@ZGE(RM2ND?+*?XY)2.)ANJ(VOJB2B=9R]7[3E[[@Q_BK)XBG,^?3-GNT8I
M?)_3TRF7FJS;KJR:WJZ2]OX4=(G:<ZU.E9S#G,_+%)G$R3P(,X:J$_Q88B7[
MZ>D0UY%M8V?Y.@D%HO6T8YM=+13&4YSS8Q3(\L<C(M@'H$93$?&`&=U(5=&R
M'SQ:MH;/GZI&]OK!0TANQ_?G-.?3]QM>(CQJ[&81+.IW$?7[N^V;+UY%'"B<
MJJJR9[E'.6*?1*ACD,?L><<)A)P0"]F]G3W84R'1CE%\VY$M0]\O<<[-J#+`
MQIG%^=4B.)15M?L7.[.JF_-YQU"V&U&;[:;5!,"VJ?1C/K=GF^<D5M:M\?AK
M/'TG[U&70Y@:W'Y]].PK:MMU9=TZ3JQT_TKMV==01TJH.2$6,GLG$`4X,HET
MV=CW=<2IV8C;=?`_@S3C>$TB2C&B2)^]3C9D5==ESSP!L3J.OK$[G?Q@<.T$
MF.?()#)ER]DS(]5U\D]4;2;^8J5*]?FEA_521GPW"6[@]?`N^!`AE#\K>VT4
MO[Y8P>)X9$PLQQXKAJ>ZBNG8`\7MNT-EH+F.:0\MNV\<OF"Q`=A]5;`9@7+7
M2"0Q&DF7O\4I+QVHD+O+]XZ.X3TF3"V<[W_Y$8*+5$S($_3K]>B$K`<G**+J
MP5\U1;5D/GU:WB?6=ZU$@%E'$[FB!@>U\V]9V]?^ER$,]C5>AE-)UU59VDI;
M89A:PQV&5\AG5_UA],O[<KB>\"YA->$$.!QL)"ZN:#+!T1Z6C>5EO,%.-;60
M;_L"M[WL>DE->"+>V\E/"?BE>C^B.W4"HJH@:E/L1TA3ZM6I>/&F\1'6LV69
M$/X,'S0*LC53*=L.5=ALN+SLOH(5)O@,W`L"\5T9!O$BAEL6#,-A\Z'5SQ>X
M*?=8D@2#L`W?!KZ#S$>SQJUX3&'^8U74(TK6-Y5W]\L>M2]8NOXC#7^.P@48
MQTD>K.A!S37&FFTXRG@P'"JF9JO*P!J.@3=MU1N-W(EC8?&Z]U;ZJ:&Q_?2F
M'\WP_\:PR7`4(3-]!KLW"=$*7O]W1JL7T^+FR',-QP*U/5+'BJF/1XIGPS"N
MXWBV,78&ZE!OEQ:O""0A:5JKN47(#&H45#7#P:I!@F#!AEP$\I85R*;+.`U9
MPZN+-]3+CY!JJ-X\(\!`E-,[/T$$&BE>%BT/%]A.N$#A3)8Q[PTUA0^&B"N9
MS`J,'M!6?=Y8L`Y-DU1T)0"O$OV]IO^N_`6A#:8W09`QX-]WIFK*KJ4B>,EF
M?7'QIM`5^J-TQ3.$HX'Q@(;43;Q`D)8Q*5,$"$G2@/[P9;D(GZ$K&M(T&*OF
ML#\Q%*L_T<$F&EE*W^I;BCEQG;YJC_K&2&/2I"FPD8KF]AS'\`2K\.')-E:W
MUGCL5SB*Z>"^>N83PV'J?P>&X+8E3W/-8?L_1)\(S[FA<8L,>JH9/A(LRG`\
MF@STB:<,!^I$,?L#$]34`$BL#P8C=V!9KCWX9JDJ*#2@;4_3!)(>F$+U_?F4
MH)!F]Y]`;#)@6-Q4@KIY>8/<<,>6,W(TQ1VA06YKNN(.M8%BPRLCPX4SRIL\
MJ,IO_>0ZC)0L7OY,RHW_S/RCGTD]XF25D%I$_&S^[1<)W3DE#?\O^)FI3_IY
M[M^&B_N?-P2="JJPJ$]!D@)OK.BR5\&+;($+$;Z.R"#"_-7JQVKZY;FR^1*?
M(84\$MC#L?\F(GDTT@A*Q)#B'UNITR3ENCKJ,NA7]V/Y;&SMZ3`AFOH*$3,>
MN0L-0V0/&>]/"VV4-?;V"IH,7QACQ8+AM9ZJ%A7[13I+27$RE=8>V`U+ZIDA
MFG/=@Q6<@UWWH,PC?3&2OT@<;2\+U??,6RM7S4_D-DW=R&Z;KD;X&;,(YAG1
M`&\[Q#-2*7ZYPT&))DN.70#+0W+5=MYSSM..J8VZ;#B>K%OKXZZ-..N+YVD=
M;I6J:LB.:N]WE<]4H2UCZB_Q/`/[>L>4BR-6TVFRZ3BRJ>UYMX^D[]<LU]`-
M67777V?OC[G/3(=/\B0B]_'D^-WR/-FVUM<WG!VW'V2QYZ7(?_.OCFB8/%N]
M:;)FV[*MK:]..3L&=V7'=&1G0[U2I\X?R?0?YW.,@YXNWUMPKMNO1:D?8*UG
MIM/Q)@EO(+#O:A+?"9W-3XG)3=GUP#';@%)U=GP.RW6U(_NAC,^6/WYY1+CN
M`!S4%!H>K,*;`8I4_5@7J7K98L(7_N0A6.MU4JYM-HOQPDI]_7W;;DI]44_\
M7`W4MR;O4U=E"P'4[.,8^$\AU#'(HSFRK3JR[JU'5>WLHPWV44K]KO+;?,$[
MPBZ38,JZV9V[1%UJ%@(6R*[A[,HSNT"*M5V2+C53-@Q/-KW]D*4SN]IL/'1F
M5V=V/<7LDC'[NNTGQ8[WH9:L&I:L;\"T.76+:T>B&+)N8^"U<\X?HW@,IG@8
MX,Z!E-V+?+,%Y\39TN[)Y74/Y]UN[P(Y\--PVO(>D-J#/2!I%9M:'O:C+)QA
M'4UX%WS!YJEA%@;IF-<739+XEF4?D6?S<=X<^^43F%U'<ZV!-U`FJC-2S,G$
M4SQ;'2N>-79&AJ=9MN.VN`4B=BV-(][X,*B*$EA_XGK=%J^L\!=3]")YL=J,
M=QY=+<X"SI&(<Z2K8.KG*96[A5@I%E!](.]NC.UD85.58E>[+HM/Z[)H&T]/
MG][RRDO]_C5^NFMU^%93MS92P]YQTABK-"\V`*W1O*YV-.FZ'7E$(G1M0XZ0
MQGWT!;]P.G?[%ZP=7*A:#K"V'0#R2Y!@F_J^HDF?DF`>)%@!2[6,.[DAN[J<
M#^!Z[##"JI=?&4;`)N:^IKH_X=G'!9P,-KNL::^N4^&!%GYJ0&"/U!5ZIRM>
MGZXP/%W6]XW2]$J7_4JLC$&G-UZ?WL";=UM6-R0D=`MOA^YHF:88=IKB]6D*
M2_94#_Z[_AJV6W@[-$7KK8Q1ISM>G^YP;$\V[>,@[9[[LL_2PAAU48S7J"<,
MV?`TV?-.KR'Q:2S\W&T,!O?,@)FCNR#!=)!CJI&78`W-D#47[$_].(TR.P7:
MD:QU&J@M^N9_?,1!S5)$)5[FR?3&3X/.A#E9"7P1=>VJLN.^NHN8@RS[W,T7
M4A(2QTT^.4,%6W<9LK<!,^*,>=^0==.3'77/G:C;MW!==EU+-K6#WJ$\J3G0
M2R7I/Q*5?!2FTT6<YOM([S>&KNX.^[;2UP<&8K@;V&5"5RQM:(TT:V@.!P\W
M#!+PO35W`T#Y#I5Z^(TK$H5>O6IO7`-+H$=6]%H'GBZ(30>>7KSS4K_?].T.
M//UIVK\#3V_1'G3@Z1UX>@>>OL43Z<#3._RA#CS]>#S]_.5VX.D=>'H'GMXI
M\@X\_0P8O`-/[\#32=%UX.F=3N_`T\^*SSOP])5WFT)S_EB4+\6,KX]R;;-9
M.O#TEU"*'7CZ=O^G`T_OP-.?QC(=>/H&LG3@Z:_7>.C,KL[LZL#3._#T;;FI
M'7CZHQ7/V0*`'^"<.%O:/9!^O#:W5M]?_NI(L/FEX,<RB%+,5DTH:_4^\)-4
M"A#6=CVHK80)7S(,@_E0=#8@*J?TW4^E=UI/E^#+"QA8QI_4XB=Z#GZAE7^&
M`9(@70933*Q>W/=6B?QX2/DU2=,-S'5,Q;[RTV"&*4FP7EI['TNOKBE$/+BO
M'OGDW^.O^M_]9,8K*3[F69K!$L+H^G\"U(S!K'\7)/YU\#FX]4/,^!X"W1-_
MFN7^XFN0W.HOEK6M.ZKA64--L4:NH9BF:RO]H=97!D/5UCQ7G=CV\)O^37O[
MZR?[7YKZNVZ.A#SVPR]\$]K]),<L@M_AG=O\]C-\QU_P#Z:3./D(.PMSBZXI
M@I]^11%Y^0SXX7BD]]UA7QF-!SIFP*M*WQJZBCX8#H>Z;MB.:;0*X)X135HF
M830-E_Y"6G*28;W@50`*8A9(.0@K$]X%$D_RKY.`-A>%&@;!OT1`/FD.HL8%
M'.41?I\$_AP3]'S*6M\L[Q+P"(P$C[&L]O2U(=O;[O.0[=TM>>J;\LO=%F"\
MM[P:SMA:#8<EI2_BJM0AUEOAJVBR:6!.Q)Y+QDZMVOI!AK!:SQ#/3WRT34WV
M5.L4.*/5RL-^!;SBVHAA>1*H,2WB#.?L.4.7-<2-T4X">ZS56L1]!;QBN)9L
MG`:*]N$X8SM4P]?2^VHU?[P*$)C'<-;R1SN#S]RW)4^ZZK3#[[[V$3U]T0\^
MQ$['.1_:)H3/\!,]V30M6=LWILJY29!17@H<2H1V_^+39.A)Z"?/"-JNB<`/
M'@Y$#S8$HO]!*&D?HD]!$L:S%^@+N]H']L,?DY6`\7@XMFQ3-13'=B>*.1B;
MBNL88V6B]@>ZIZINWQY]LU15^Z:__54S5$=3M4;T_<46_4)7&A,_3/[I+_*@
MGZ;Y+?O0^`=>Q`0S#.!K+Q9M'VFFYKH#6QD/QI9B6JJM>+K=5\Q)O^^ZKCG6
M)N8WXYOQ]M=/SK]>X,[BP975*2@^'F1I/YK]%OI7X8(`?GX'C@;.GWV,/B/H
M3P),#@_\$4=)\2.V]MW7/<78Z`_ZKCU4[(&-2#U]2_',T4@Q==4=.0/;L<96
MN^XIPLB/IJ&_D'PB)MTO+"IR2FE^]6\$5LUB:0YT1R69!](MHS+I$QB%^O2^
MWCN&YW;/-;9<&!SMCF'SIYWC??J(JV[#I<ZYMXG5S*U=1%'Q2Z3YI=\%!23Y
MV<6&1K[2RX/<G/PV;:2^_OPOO\P;^^Y&^__R&"R+:A*?DG`:I-7/(6747R72
M3WQ>?4IVD7[WD[\"5I4H_'$>)XW??,`DGW`*ARJS4%Z6`8\NI=N)^P7^$LYA
M]>`EES/YB"D+#2I]O$J#Y(Y\F@;YHF7^BHE6)\:?47Q(.IV\=MOW3GV-P94^
M,&\>8YV_!7?!0GKAIMTMWUNVYM?5F9VM^?`V4LLO![=?`;%C?=7-W7<`]&C/
MG>),NSF_R'.G=GF[_5I_Z*<W%..:XC^P.`KF<A2HD5VOA539-$SX[YZSQ%Y*
M$9SZ,I]]D?TX`K3_JKVC5)<:Q3[S>QP%]UCB]%>02?,\FIT>3I-NRZIIR]Z^
M,Y\.Y`R>SGI?4@3/0UMT)#O[?,+MZO1SD&9)B'?=9)2>G"XU55-V-R#8GITB
M;<=B.Y70D:S+_#O;W-F74G8=U3JNZ^AWWAGO+VFG/E#W@C>?8D9#6RM?\(^[
M%F=KMNRZMJQ;Z\$[]VVO/(E"'5T.43-U+E')CK*=(?VX$_*<2F@.:4J_*KIU
M%.PH>-#RMV;MQ`W!FOW]K69O5I[",T*2^:87NMS'_23@[[OYZJEMTY9,O4,=
M9WMGI"X!_VC$[1+PGTFT19>`W^*=ZA+PSW=ONP3\PVF1DXY%=PGX)S#3;LXO
M\MQY93N=?`*^YLJV9\G:AJ9+K<MX.O5E/CN(?R[7#!VE7O)"IMW6S_DGX'NR
M:CJR9^T9IK8M>:.M6>]+BN!Y:(N.9%T"?I>`?RJ*M!V+[51"1[(N;^AL4WD/
MF37TBJC6T:^C7Y>`WR7@;S/O7%F#_ZK[;H+U$@3JR-(EB7>4/3IES\V,/J<4
MWD,:TJ^*;AT%.PH>./V^[4'>[<:ST")DQ[2A`QK/QWQNO_;O::RL6^/QUWCZ
MWOSV6Z=/23`/DB3`#%-L0?3=QT9)6=E\Y[[U6FI'7_;2TF7/W#FMZ'W;W/IS
M]JTZK_4\*=M2\>U<^?:Z`YTKWSFB'05/DX)/;B3[\BTV&TU0RT:UE'R53[,<
MWX,?@N0N&-Q_O5_"WX9QFKU\CT[;="W-4U6E/U(GBCFT=,6=:!-E,IZX$]MS
MK;%FM*I'Y_`&&ZBF4AA)V4T@+;!GKQ3\"`5?0?)?=0-.VWU>`T['>WH#3KL%
M_2!;[@`_4,,WG2:YOY"N_(4?38%]L\T0$EKKG>'GYC6^TU395AW9]/:,L'9>
M8=U/<&Q,PR6PT9*W-S][3KFT#$.V[)U38%^5!]9E-YWC<:"?O9##::`ZANP9
MW6G0G09;3P-;=V7'WIE-NM.@.PU._#0PSE[(WWFR:5JRYNRY[NG<Y/U5Q_!V
MB+'5@W3_+_>3+$@6]Y,P`B$,_<6':!XGMWX6QM'+Q^4F(VTR&>N:XIJ#B6*Z
M8U,93(:.,AC;CJ6/AI8V<0X>EW.%Z->"(S9I>D\J:2.5Q)$$ZDB7>>3GLS`+
M9N]I=ZY*L7@]43E/?UY4SC);&)7;_&GK57ZZ#6'0UPV(2+'1-%]GE+G6WWZ1
M_CG^_/7#L/^;TO_MPS_^^%DJC+F4D"Y_@C?KR^&JK:&V]G(7?&3*Z3M2+IJ]
M=LH9.U(N:17ECDM#<T<:9C<'I.'):]^-F_,`U/DEW;;&>>I'LU2&\8(?TP#V
M?!D`#6[PNG7F9W[3N-L_M4_:JZ\T;^&UK[>+]^T['NVY;J;[G&D+YWQJ\?6'
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M4U`KY8G[KG3;5P&@N@67JQ]%6*(<;59F^/M%/H/A$;@KF,^#:99*\9P_#V/X
MBT4\];'U9!9+2S_)0L0OR,+H6DH138T`UWJKNG"EVO-QQ9J;4-C&?A+!-]-/
M0?(%)XX`;M-^-!LQ75R'<GNQBD_5&SM#S;44IV^IBFFIFN+9_8FBFYKK&9KI
M]?MVJY#8B"S4O9X?4FLV'GZ^C:-B_U/\>4F/^BF,\$H!VIY="NIVI:`M^?3)
M5P0]OZY+4[>6#OTK\!-I',V"&7QT+6H%S>OJL5O[$#VZ'7FHSG.UVN@84;X#
M++-Y,7ZFR]0.+D`MCP9N3YTX_JW&SHE;MBJ[N]](MCG%R94-6Y,=Z[RO6VW9
MT1Q9V_>5U*F%QQ[H516DZ<]2'LW"-$O"*_(>`NZA;?$8X<W*9SRHB+^*=NUM
MN0N\?+;F.(GZF<MGJXX.VG!=(.#H'SP$.W54ZZCV&*J].LN?FP\8"P3S08Q5
MMA\J]X2<B"=1Y:FTZ-JB=?1\2<?HE,R<<T)T/>21W=&MH]MY!4G87>SW`'4M
MWJ[>!8E_'=1-&BG.LS3S([R.;+UY\UR'V99=TY%M;^?6G.T]H5^"/)JLNH:L
M.\?)&#\%\NB6;*M[+HTY=X<+/T/W4DP];4\/(8)4MUAM5DZ[%S?O#H+3.L?K
M&80X6H[AZR7(>9D[+W2'>P(JX]S"-<^@Q7'OB-M*E9.Z4VZOJ;+C+;-PQPR#
M8"YLG-V`8>//9LJ5/_TKQ3=6<J);K:U>\_5UZQV3XUQWMY\LW?7XZ[RR["YZ
M.ZJ=UO5X6PR>[C+\#+VK<[Z\[>C978:_ELO)[E*WH]OI78:W-[K378]WU^-/
M(4]W/7X^U^-MT4%C`KQ`O`N"2PCO@F<7*!U(X701X0.Z%QUA.\*^3@?N?"*%
M77RUH]II1:7;Z[IQT*W.>>N<M\YY.S/G[92LDW,*]W5ATHYNIQ=>;HM%@I^Y
MPG^/'@5[202X*E59FPV3KJZA[6G\'4&VJI85I.55:.`=87X;6,$9_.HF7LR"
M)!W_;QYF]W_$63`*TRGH@#S9`SJP:UNZI;M#19\,5,4<PKN>98Z4D>H,^\.^
M;4WL\8/HP+=^<AU&"JC,GS4"P>2_8+OP,ZE)Y`PE#?\O^%FK?I[[M^'B_N<M
M&ID4G-F31,I4X3'O%XF12;H<!?-P&F;OMZC%=?.U-TP7B:N$T2R(LI_-O^TT
M_5&>8":WKJHZ97##/PR9,*J'\>W2C^ZE,$US]#RE+,[\!8;P#5/6#4\V'!,&
M*%S0N?0E2$+X5U_1:*3R1QWY`/S6+,3TJF42S(,D"1`=$J@%(UQ6I!K^4KS5
M?*YZ9O3+>UA8(KW30+XJ@&T8".:1+R@Q/8PH[WR9Q-,@F-'L_"7\]".\];-@
M<2^],\R>*@%A%F$<K8)JKV4:?7^[\#&2/DZSN`8.J^DR[H99WPU"P:1C-XMA
M3U)&KG@.@V2)'Z7^%%&^4RGQPQ0I\<Y0>T:Q4)FH`L1(@@5E],=SH#$^-HW3
M#)/X5PFE&ZX,<BI+\R2^I:FD/FPC/.AHLJEJP`I.Q00P1)BEQ=X/MNW\VGT?
M5$\A;ZWL?$_Z$.&@44#KE+Z'V0U-:O7]DK^*1<J29H#K9\JJ9@ML6Y@K-*?O
M0-Q:Q0.\SP6Z8O%JCY#7F\OR4V!_^$\6*NRN*XY@D-O`1]W8"E;[W;\7V,PF
M-K/K;(;L`RMZ9YH]K\D])&GK^`<I]$Y#EC#M-?RB::KL6;JL:TY-;P@,,WPR
MPPQAJ&VJXB&&&:XRG,@PJHSZT`!%\QR&667+$^"2_\H7JVSBKCT;0%69MBVK
MAE??5AB($V#TU(VMOCQZ8(=1V0<_IC=^=!W0P0"[@=_'>0J!41AEZB]#/,+X
M#L`9)4XJ`B,FE9;^/64!PP"?_;L`-V40PE^F-U&\B*]A9C)PU+17GS,]VN"[
M+_E5&OQO#INPN)=QDK_[R?0&QD/48E+=6;8(;N'OTG?@AB3PT3BK&!1;-L#A
M1D.S*7.^@B&ND#U1[O!!=BZ7A&X2E^]1*(H!#%%^AWW`GX*)DH8D(W"R:*9L
M@A#K>J';6\&27X)EUH!0U[QU?%FH+]WLN37UQ8ZX;>K+LF7'==>H+S@'#<.1
M;<?=I+U&VTV==6R.%AB\M5V#?156YB_2N-C25<WUW4_`"(`9H1S@Y)<Y\)R?
MT@)TV74LV="=59L-YK`J9>S#S464GR#-%_P(DFF8DLCX2%V<8P8;".^%.(=X
MW:;!PH#"5WD&[R]#'#M?QJ@-I0^?/LHHF:A%?30Z07RI&I%]AX:=TFK>J3W;
M(O./SZBW[FACXJ8V;"@^&(Z_A$F`Y..@,-?Q(I1^`W:Y1W'QI],XF?G1-!#%
M1=CK)FE*8OO724"2+5<V*5I&$8V`NX>CXBILV8-9PLFX=D_6&#.HM?QBR521
M67S4`IHZJHO5ER3&J.@>N<^H[?TH]Q.1>)I,FFJM8%TG<9K22)6!_4[3*Y-Z
MS>GORJ;NR(;K5M]@\V,RV9"CE3E^**C&9-5/TW@:$F_@UJ#Y6WR,&!/V5$(3
M-@G]Q?%UURAG=26@&7S@`B#;'2A;M-,Y3SRD09H2+K(8O`_;7Y?+!$X>$BSX
MZA7R[W0!%`OG(76?`0Y:A/Y5N`"GM`<R$_G7[""Z"A9A<(>OW?@9#HQOALDT
MO\5C=!JD?&#2F7YZ(QYB_,CU82*S8A*W<'+V8(ROVP6G6%0Y*7XBHOSAA%&Q
MS/TPP<@)4!)E`%@>9HL'U^S?><JKD\5G,M9H"8N2YQ*>K62V+N.$'$30&V$,
M:B<M#M&/2Y09Y1.H%_S5[T%V$\]D)O;,ML"]@C'8\-7<4DG4ZA^I`+J(B8)V
M"Z(T>"_J<[[C*,K3*9,J=@)%=$-.'$U*#XE*@A7#9'WFU3'-B*\EP0T,C7ET
MM0!L3_I4Z%U!;,581(HZEBV%NYPHYN#SH]F4/5;AX\II+JE@Y;`G./\6/NH&
MNYDFL,XNA]FU0%[#NQ#>GZ6%,HE`!'(P&I#@I(*GTP2/X+@FON`.RE)YL/<5
M72X=@/)?0[DRU:HPB6#NBO)1BCVPLP_*-RN./C1X\/\,4^/_T$T:#O]MZ3H=
MC'X4Y;<R"XPLD<YW`9JB^!@MJ[!UO]^@'$7$S+,`-`5N_M4]K6P0HSB3TS<"
MA0(<DZ0]@3YX2I..J=Y,XU)]E(212U>@6JE`$S%@M&K!\LF&,\8UB_"O0/DK
MC(@%!40"-!/^-_?Q]";VCYG94TVC1N3:.<A\@8H]>](?L32K+9*43;G&PKKA
MYP[C>=3HQ1>;:Q"J"CG_;S#'6\'_7S?ICE5&W\CFHO,G;N\Z_1]0@SPP6VCW
MA!.0K";T1WH6AB@PY(?_"^Y)^6_PS7%X^@=3-G*=X9E]4:,^Y\Z8E'ZQ9<R]
M8E:OL*&D>_D8_/PNHVYKE&6**O'?F.R,6\Z\TE+EP]F*%Q4P-W84E\G0M=A=
M/)WF."8</S?A]*9H'3CC@VQ2ZC3SI+1_ZL$%M#FR@'\`O`/.N$*0=B5"`43%
M4>A\I1.>'RH5#ZS:DB+AF*F.%&$*XM:?`2GFH,C$O<`=+DP[?)8T'7NU:IX(
MQ@[:<JA7HJ;`T;-L?];'=0J1_A-]##QG\UO6"Y&_LH6DN'.KIZ005:A%/E<H
MF(-,PI>F(E<S2Z4Z%;=,8!W+^LOE(F2%RDT>3=F>1A00H7S[%5ZNM@2M=0-\
MYW>:VW,<^'^[YUDH*N^<GJ/*]'>=21;_)[J4:$?Q+:D%_&51"V#(Y('C[B%7
MN7EH'5\CKHW04TQ,:]R7H'6V",C^R5+FT,*&D"3#.!8%T]5:0'&CI;8::00;
M<48B0NQ6N,*:7;L*Z4G]T@?$`Q_'SV'UR?<DS'A@\@&^K\P\"D7EP/7^;9R7
M9GZ("B2&[5,P]LG4`]>FM5L8T0/$>&<Y+WC=L78CA*`A2.Q6ER\&3,!F"4)T
M:9H70N]<HX>AG!6/E;:,7Y249,/US,)TBC1(2WL!-!<JU`L1_:@,*G'K/]VL
M>7BX8X'46*M4GJ!2F%_P)'U1:`L\F)B^V"QF@LB@E`E2IU8_5C+7*!)8ET>S
M3H+5_0GPFFL`("Y8CTAPU&U<6E=5_A91*:SCRC8F1A"CM>P^#1D09593X%,*
MZ5S#`][$#0GXCJ6P4]DCQ*!P"AB?KQOC*ICZMT67830OZ*5U@3BNP4!C+'BX
MB!G5Y<G+I#ZM3)B:HSHO.@R++BLS'#+6ZC@)X+2[\6$.:$"36L^2V.=ZO?+>
MB\`]<\Q3W)L4[SKIM+S&-;#5%#9WF*Y;N<QM)=S3).`Q#_*O4?DP!48^`H[!
MK!F0K9SQ!`9F_")^T+08\;:U"JRA,Z(P%Y;=*=`U4_$`*?R2VJM'Q!H>8O;+
MH[@(%P)>B1!SV6@_X.DZ#Z?<;<1`0;*,62P!%B0C18`TI+884:-K,)ZYT8H3
MG@5S,LN9QO+AYS2\CFCKE_D5*)9*V]&^8,3GCKU:L1!3U3PBA=-FC$NKX+X7
M;#;%>9&@VR9-T6\V/W8R@3Z\B1-0!,!R.5&;CH0-00=2\:9>G<'H650_%I%G
M8=!UQS6>"149F@X`*A8ZG4560J]<:YQ0@J6^?NPU%B4/_(.LB,>%3Z^N;2_+
MXM_&8]J&/SJMIY$-Q+.'@AGR(!QXM%-]C!FQH&(ZN*^>^>3?X^_Z&"1D(;?T
M'Q1=^A!](LG_'U[IT&>%#F-NAWPB'MHYGR@')J:WPC0V=<WY]N>7T3?8CF^,
M\F_1L0]O@;NHXV@C^V@X'DT&^L13A@-UHIC]@:EX]D!73'TP&+D#RW+MP3=+
M5;5O^MM?-17,9X&HAZ-.?5LF?IC\$]GO-QY3!:O[=W:[//L8?<;:6Q1;3/M*
M_XSB*W!I[]!*^!`M<R`54'H*;]5;QK]8/I=A>H;5-PUEX!B.`C^,E,'$&BFJ
M.QEY^LC63=TX=+=W=4NS]Z]T'8OMVDG3^<QCB3$\A+'T!/X$Y]=W;@MLTO1K
MY'DE\%VX_.0U8X0B@D.R/&4I&I)F24[*GR<+D#\@1+Y13>+AQS98NL(=9H%N
M5(R@6TB[PONYL.TP+NQ[*EW^!H?J0C+>LU@@?)E='?>_8**%JZNOK5V][3ZO
M7;VK/[U=O::VH'/[2=?-#?P%!91`,M8>BU+9(/L<,](M7?;,G>OCG@T&>CK%
M#%\I<R:/D@"F@.;>M0_ZE5VE!>G[*O"*$36>,-UZKGENB=RE#5XAG-`MYI_V
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M//6C68IWHL&/:0![7MU1S_S,;U;E[Y_:)QWJJC1OX?X^`^?EF?@?1WFNF^D^
M9]K".9]:6,O8*K^?,1D]#PXNKSO>:FFJ;'GNH]Y]:8"A@RU1EW5OYWN7DUBB
MKLJZL6?PQ?:PK"E[:@LN0=IM96S74B_4[/I@LK'F/M60#7MG+M@%(>[P2]2]
M@T+@'7R!-N(&G9K6>@'&U=7]M`<\+TMJM9MDZ5C*E'\W/14CZU+O>4:K)7EW
ME$Z]W2IJ9Y!)[>04T^Y[N/M:SSPKZ1D*:L80/SL5U:FH?:DH5>M45"M4U.$4
MTN-CQRP:T,6.NYEVL>/3-3%.+)JLJ[*E'0>N_F#11T<VC9W=]]-8HBVK[FN)
M)GNRL^_+@5,S,LX]=&S*AGXB2NJY2S5DRSQ.S[*#+U67[=-SB)Y_12!KK0XF
MM]>T.I_P\M%:!'4+/)\%'BR6H_6\G6W+LXKEO)[@<@O8NUO@J2_PW!34D_K*
M/:&J[HDX4L\!2J(_COPL*`L,CX0E-3!=U9X,#*5O3PS%M%Q5&;B.IGB6,1B-
M1[IF]RU6`&CW/.T).%(O2YWZUGP.$'-HFE&KN'XT^\S:I_01Q(]*-/?9^V\T
M<#W+&R$XU&BHF/K84#Q5U157M[6)-M3TH6D=&BM*<P7DH@6_RG!ZTF\!-N(8
M_P@SJ2A@O2>!67^[L:_IV5N@K![9V(G:`2%P!>L.U&R!=/'F44V09`;4>H=8
M?E_B/+N1OOB1-$E0,:336+E";KU@#0WPJ_-XFJ<5JOX,L:CB98&F<1M',;`9
MXB\BM/55/+N_(,1CT&E!GH53WO8&L:)9@XIHBGC>;`F(J(78E>&,^N<A1)\P
MOI)F(`BLNQ[,&'NX-/&O*I)Y&B$EXQ:&2-:1,,\O-,X8YH>"05M.SVSJ0W;Q
M1FR]]*3N6B66,E%P<]NAO?;'V@(9^])"IS^`T%:0C3![LSC^BV`E2\4E^:6^
M*AM`,0S0^AY42\-1TV#S*`4\T,6;"D64D%*!IO,Y/KQ`SF!HGM3Y!]B+,"^#
M'PSI=1%P"9C[4U[NSJ%8$=L4^5<IIKID2CTMFFR4(-,%,.M]X"<2&WX33(7J
MM62[ULO"%EK+*(_8ZJ&"/,4^0(1*NDE\$%/T:A&F-]3HJ3;RQ1NAUXR?94EX
ME7-^\%%:PI0T".^\0AL)&\5P2T%#W!8=-ZF'0.T9>!GW&/Z4Q/GU#6*#N"TA
M^K!L8T,3+Z8;BGUW"/(WY6"':0?V]S20`\=K(<C!Z8='M^>2]+$5#YQ:5X^`
MZ=%V"T0L3@=YZYVFRK;JR&9W5_@4)OH$IP(V$5J4Y^S9<\JE91BR9>\<+7EV
MB/.44)DZ;+9S/`[:#P'[7"''!M:.(7M&=QITI\'6T\#67=FQCX?ZVIT&W6EP
MW-.@W1B>+^(<>+)I6K+F[/F*[-SD_15A<AXE,C7)LYPU"FH<NV+G2`KK"I&K
ML@.VT,XR"G[`C]@M"J.A9>`U"?PYMH_<TBB'%`"&OS`8W`7`=@R`N5LZ5VP*
M@+E=`.QY"3@(O-SZHVO7#'_9-,`N-?><Y']J[LN##&&UGB&>[=G*MJG)WNXY
MQ8?DC%8K#_L5\(I+%^A[SKH_.RWBG#UGZ+*F&?#?/0/+O0(MXKX"7C%<2S:<
M/>.MG)H6>:#%5NE]M9H_'MBN'4;H6J5T8=B6AV';)H3/\!.[P&87V&QA8!/S
M!9=Y,KVI!RS+WL&4CBNERV`:SD/*/\3\6VQ;'B29SQK,@P"%T34U_`T709K%
M48"]@?V,DO4HA;I(F/:G-V%P5[8?K`:!#V)^JI3Z,((T"Y(06\E3.W3V7BW;
MNTSUOL=DU!0;Q<,8\-T,"%'$9JFMN=53JRV!Z2U8.N=B449M688M&Q@&J?6T
MSY=\WM1CWB^2;Y?P+_S`+,:FQ46ZXCQ,T@Q&^$2TU*7I`MZ:`K6R)&0TPYS/
M8J$K2RPF(":L#RE!7/J2!;?2,(!)?TKBZ\2_[8E)[-(?<;GD],87EA86*:#%
ME-A,T@S35&>8\PZ_Q[1I*9YBXRJV3[#C5P'L.P::&YGXELS21:6/&+,NL]49
M87BR,?:;7@8)!F<QT9S24!.&O2)=!C_P&<I]K[V+;)8$:>`#)U),7,RL9SWO
M`^KX_AX;1P=$N:O[6C(M#K$(X;,IY7[[34K#$'5:/XK2-4+CQ/R"S9!I.=6Q
MQ@771.._<]>Q''#9.TU?\Y<+S/)?8E8T-KQ>4F_L2MPH/1N7P^2".G;2JNHR
MPK?Y\<NJ,="*8MOW%<*Q.J0+FJK.?H5"\*?3.(\PSYKT'K#R;$9YV]39O-23
M2^QF3]P`S(B7#S-\%O@_(<T&(A9&"FS4-$C3&EM?U$HZI.#'DMCU^PUL6YA)
M(>XJ##'#7;ZB>Q92HT4Z.9_]%%/[RREGJ$&#60_50#5=R;_%E:0@X7>@@P-2
M+>5L9RQ['7F&74-MS\K7#):,Q)>`::JK&>.K-7>[5&75Z[J`6T&59/>?%GZ4
MP0ACT`%$ND]@XT[O7[Z62^WKFCU2^XJE.P/%'.F>XCFNK>C]H6>8GMLWQVXK
M:KGP'U2V4Y"(V+&D#VU(6!IRY2M'K^ZJ33<HIDN&`AQ+*'E^1H43/>E/5(8)
MZ-J$VPL):4&9*[NRNB)-`U2'8;J,R=*8E]4L164*B'5^F]._F;H%0>"G.7X8
MQH\;UL:4"0\I?#A;0(;S!9507#-S!<^:&(0;)!:$'H0./PP'XHV?7+,J#5YU
M`6JF)WT.EG[(+GOAW5N?JFPHVP,7D=(DN"XH-`F=QCV02&&N87K!*M&H$B1/
M"Q$&*?/1SU#`X("3/\AN8IC-';^+9A?%K*0$!#*\]=G;P3Q?P(%Y%[RZ.V1-
M59_9*E)[^B6RON45_HCI;'KFO")N0\;"227_NT7>GN%Z&NS<.W=*?XGGV7?0
M+AU]]T/?29Z`8Y@?@<":^CHH_)L/BMG/XH19#/%\CJ;W\12']4K(C@EL&`61
MPEN,!07/R#%_!K6_W,2(U5$6(E-I*QI:I?DR#YX<9UMU5![K9M2=DZ&?WL##
M^'_X`DP?:;0OS\3V'-7J&ZYB&)JCF&/;4_I]PU,L;=)W5,?J#_L;&W/OT=_>
M[)@@74AFZ1\"A5KKFX@E^D5\("4P@C`",SEC"9]A)-V`M;VX!^Z#18';4.#(
MP!!AA"XO+X/'HG$?XVGA=8@N.5C>X`J#[T,5XDD0(&!$=I.2-X&A`C_CO@W%
MYC#84T0<6);I%"D95)3L2261\4\\2,;_R):0EG'6$#2GG[$@$KA`<1I29*VQ
M-O1/XBBXA\DF?P69-,^C&5\*>!ZW08(+E:[\Z"_F'347#Z<A=WJ&C<DV?#S_
M%D0[_+]@1CZ0+"T7.;HW/J;#$V@`B'J`?_A^$V+P9`EJZ`<Y+ZDT!V\*U44>
M/"8,\2@YK8OV;[`;08!*$",7%89-^K&HI2<%F7X.HN"[O_B*6NFE!-V9F)YC
MC1W%L&U+,?MZ7X'_6DI?U09#4`!C=S@$03??_OK)^E>URAVFW(`W*A&2_HPP
M4'0=X>Y\]7\,X(UYF*6?P<^:Q`EB]M1ADEYLZ<9`&]IC3U=&MCH&'>>.%1>)
M,+%=VYE,K/'0-@\>?=EV>]*GD%J$R!CEY0#*[U4`$A\10`2&.0B^A$?D\)'K
M)$Z1V7.!T%+F_X#W&*DQKO!Z<[Q=\YGNN?5T]WS+*R_U^]?XZ9-OZ/W\MNR:
MNK7S][\0%&<<,9">M0'XAI7TS#RR;D<0]&[+AJQI%O[BJ7MM6W"SP\W9+U@[
MN%"U/'MV>SA@4-HSO$SUX)&`G:MS+$^7#<MYU.NGC[@*ZS4,V7./W:C@<.O5
M35M6]9.HL3F<-&_/A?^`B0KH"_YT.0OX/]]3Q@-=.X*/0DA]Z)!0F`#]^8,+
M_+,K:C1+MM23:[WSW&5;KFPXKZYWA^XZLF>?1/%4>TMD-JN%91+"_QY9*;R*
M`HB.9!W)VE%F<SKFS*A05I2PR7.U,,P:_%B&21F7Q:N'G%VK+,+;,/,[%=;)
M8T>R$R79N=4YG4^E8$>_CG['I-_INVG;8[%C=IO\K$#LHO7ELIKLJ([L6GM&
MA3UA^APSL'T2]#E$(/S<S)!S*K?N*-A1\-@4?$:?PJ=FX=6S^?X(,DQX_,3J
M^&>#^S_38/8A*I,!JR+,E^TS*#877$WPL\:>,>JK8V4\&>F*.5%'RL`V'<6;
M#(<3<S`R',WXIGW3[+>_*IJI.3I\JJ+-X]?TQ,:-Z0.]"<<_,.\U#3:U)RS^
M_HGJ@H_3MW$X'DT&^L13A@-UHIC]@:EX]@"(K`\&(W=@6:X]^&:IJO;->/NK
MVG.M)[1N?%'Z-/8FOTJ#_\UAP/$=?NGEDTJMP5B#1QV@A*HJYM"QE?Z@;RBC
MH3;0/$]U^\:P%26]FM&3*G)(C!ZD):H\E6.GR'^(I$EPE>1^<D^HKC*V^+L+
ML9:/[_&,&O\1SD.*,,<QL0@FL//*=QB%->XKLLE!P4F__V.DJG:O'(VJV['6
M5AA)J)Q?&4,BRX^2\S%?G\IWJ?4@]@\$95$DYO[9^]*3I:$?^3,?"XE_#WZ$
MTUB6_LM?^I',6T#^=YP$/GW@`_A:/C5&S&[B-*C&E7E-?E$N0/--`BS%;T)7
MU%;*HM%LLCVIGQ)N216QQBD6A*RWBBM1+WSIG6;U5*F"CRA0**A\F1.0YER@
M`;"18#,QBWZ!50`%Y`8C.XR!."#31>`C!`@^;*C*S,>OPF#?$<X#A+H`W)B,
M^C(BB5Q?!ZP''DY"0!Y8C[E2S)+#K13K@C&+*1^,P1]J_-?@\*Q6%E)T-?1Y
M=K8":V/0)/!R/)\3361D1%:X(+Z=8D&5UG-7J5-KFWE!5=ZW^&O6YS)C74JG
MQ,;O#+MGJ54+<V"CDO:+^X(Q"8O\>Q)F6,)2]-+DLQ-DE0K$\\5"2$Z'7X6(
M5HX%Y`H,&6>L^I[)<54)SU%OL"2?U=S7P3),2Y71MJI6)E"BBAU[OZ1;%@OC
MK"[WZSJQB`("+9H&P8P^]LZQ>PZ\7A"8U_:'J;!'^`X\6I(*5S7#MJ]%[3_?
MB#!-J6\F%2`2\$U51R_0E.KWT\=4I&P\].IGXQAX+;X/`A*0:;#^F/XCIOH=
M.&OQ0$Z_(CZ3^/=AG&9_Q-F_`CA)"W.2'=)@1?)?X7/:BQVXC^P@;;W]]9,I
M%+`<=K5U2C?LE3]R3,+^.*<YI!^K%K0PGW#Z`@;>JD&W2L:);0UUUQ@H?40A
M,5U-@W^IGF*,#<?NZX[3'_?15@9SSG9-Q_:<BI9/6D^=%!\B8/D`'(Y]MLS6
M)T/#=$9]96C`RZ;IC!7/';B*JWJ3L3G2^YIY<)ML73&CC><HTD,"@@1M,\8F
M<;(3A`\!^+"N$]AT&D:*XC+UCY#?TL)`F`>(D;0@[!4LW4-H$B1'AN209GE0
M-2B&7U'5$.*B(#X1G7[LN&#@*#D#YEH$U_[T7OKCXV^H7OTDN9\S=W:-ZCP:
M)%X:@J+`@DF"BKI=QA&5,&X[Q69%3VL@!!I$#);FLNA<&V(R%75&?KV%78[]
MO,(N>P?<E;TW[]C\Z8UP+EUU%7_W^94>]M9*CZZ>JA75-H>NISK2,E^XBNK<
M+[)'Q8%9V13\U%P]%_>>@'ZLYUHXT_/*#IUP"Q8C?\SC+ZX+&(*?:($>G.UV
MO-PV;-FR-5GS]ESV]%(\N^LR+=DP5%FS]YSD</J*=KL(?"'/K6V\_]R:'T,V
ML,1+VW.SDP.9)X]8KJ5KLJ-W?>:>P/F?-T&*,]!6"@&?(.,[KB7;VK%K&P^T
M7%UV'$=VO9/H#]_>0^!CLKSQ(VF6Y-<GS?V:)[NN(:O.L4O<#[=>U?!`W(U3
MX/^V<'OI6R;'``E][IY;LF;HLFGMN>=?6UC<DG7-E=5]%^N?NX87>)ZZK9P<
MV[O`![9LGXI7^]SE>K+A@'*WNVZ-3V+RJB'"R3$XZQ5N.L=&(SK8<G73`>N]
MT^O/L]SQIOY$>=W==[_#]O"ZY5C@F+>`UT^IWNA\RDY?BA%?%]7.RSCY!^(Z
M5XE`*_>:NRGQQ>DT(`=[UG$TV?5.H"SU*/0!-]=3957OH,J>)6C_]!<Y[]^&
MB70G40C_7-ZY=-!AM&7/W-D_?G^.,G7Y?*':2I?.Y&JK\="97*_!Y-J>1/9'
MD+UF@\OP3-FSCG,3O->3H0,Q.PDS[>D9GD(]Q(YIGH<4SR,^MV>K:^_/G=HY
ML[<@[`D=)Y?//$]:YV!TQTCGH70>RHE1[?3-HEW#Q()QU)TUW5ESHF=-FZRZ
M9T0/?BIKM^_?MUH:U^WFXTINVL]O;1'D<Z'GN=F*YP06>4AK\9SH]@#(YM%`
M1`20*@9%E"+MFA>7*4*HP/F33X,-&"(<,HU#=&4W?H;]H6_C)`"#\:]@@;!L
M?@0Z(>-]XI/`1U2]6>^"\,QPF!3;@M,P]$IX$\<(7L4?]1E,'"S19XB/K'G\
M+$@0'>8R%&RM>9[E24`YQDGJ+U+6:"5,J:JPP(#)@MMEG/@)8J+-0H3("G"E
MO\!0:\8JWN('L(`=..??@;%AI')484R&L">BR-!'Q*_4A[_`/O6\HQ6]=^5/
M_^(0.N%<^!60>!DDMV&&\#6$$5;`Y\%@%V^8O>Y__X5F<!G>U;\H+1<^ZYB9
M9HF?!==@TM>@RZICP/N%('BVF2(X&=S>S7L.(^192+LNP/+`!&$EV/PFG\_#
M:8@[F\9Y,F6(;'7Z$V7HNT33_#9?`%_`-ES%\5]U6)\;_RX0L'U@BS@($-&1
MK1,7%/*68@58W!KVQS\A1`0N$2:.A&53G_O3K(:>=QU$6+U*">X;ROH89EN\
M4NK$L-O^^/A;G57X:HI9,C@\F#=RK2");`_8JIHK:HQ_\:;Y!43\B>=SW$2.
MGU@T5Y,(*[*>L\]74)(6\2R)DK7.C.4D.*E*LJ+.*`C;(C2E8@<193()0(9Q
M:2)7$3H?K"K@8*$W29Q?WUQL:(B-_**R[5C=4H0B7"Z3^`<!]"U0`[W35+/G
M5E"`(/F(!B#H(8X1@)M8>UEZ9ZL]X^)-[5T&A$6(G]1ABC;RS@>-DJ=<D5R5
M_7*)NW4<@B\*?C2,-?"<(HT(JZ"8%#(@YS+D[;GT3C=Z3CDCQL*/G@T,`?-1
MZ[-I#Z=PC+"-(%LURN#FXY95%%H1/Z`%5W*,%#X=7:"2PVE6:<KI#2(=IURF
M+]ZL_W;\'?1/>A,NRX_Z&0QTE6?8>FSZOWF(@LR$O!J#B?`2="[L;$"8K[#`
M;3!M[]R>)<"[;B,'4("MB3J:P=?G!<X:5\ELV;3IFKEBB^/W?D%^<"J\4E\B
MV&=V:.#/MPP.<QKGBUGCH$$]CO^)<MB-*S\-&?2FVM-+]@3JOM-ZPJ?Y'WI\
MPY/@U@^)-]]Y=L\HWX-Q:''\X"O6QT[[B,V#JU4?<8+33%IK333145=U@Z`9
MBH^2-)$=56!(LM9R5PR#7=!/%>2ILO3#F1)&RM1?AAG0X_M-$%66F#3)$[Q"
MDD'EI_!`0+O#3@Q:%/%OG7OKBN'6OV?GKB^L%-XN@Q0%-^.6P.&11.STO@7R
MWN:WQ+"E]F*O)@$Q+4%\5QRP"A2!4'\Q[0-9>BW2%[A#T1267[;YR^BW_(RI
M<%H%BZK<Q9BT<MVP_DYLSA&909;1Y+LO3.>:]F']!&.R<7'8A.@:%S9$\<4P
M?<6`?Z[Y/,`_R^@`_UKRZ0[G[JVF;D6`^Q>:YF-$8=UDN-*\KE[JDJ7;D0YY
MD"_SA9$'V[I,[>`"U/)[YNVW6W]&9#,3_%=:\R?]K#)?R'#9*>K[G-C^CI!P
MEYXFZ][.4"B[W!D?:FFZ[.FV;&LG@GZP\RH-2Y4]KP5ULJ=S3?VE\-E@A$O>
MM:(09^[-['A#?3"66>4$6_5D\]6@.,FFK<JZ>YQVIL=8KJO*FKMG77;N!_A:
MA.39O_.46O+LF")V1)&_="V$MMH9$N(@Q_>S%VEI<,@Y!RW2?,GDD1U&.-$\
ME],Q`$I%P**W5PO6[(5"CB>M$`S3E#5G9YR[3E;:8C6\"D*=N[U1PB6?,D#L
MI:Y;LJUVYV^G4TZ!4.=EJ)P+RO2E:QK@LK<[T/CL19JRZX&N=/8#G-*:93JR
M:MEP).P,2O5L?)A3-@JH\IE287UL@BB%67![>IZ&+GO&GD&WVL+OCFSKKP1A
MUI1M;\\1Y/,ZG\?4J5RYHFSGJ=`X^?0$VL28^BOA<]WQ9,T^D9O!9^LO\-]<
MK4-(?):@3_PPH;H`,4"(]X;+I(HE8DOO[WZ28)?C,HWT]#2!ACC3KZ0;TJ6E
MRXYY[GZ)9\NZNI^H\'F=YT.J7&`E'R\$B7I$2=9DW;5E3]]SJZ.V\+GC@F>Z
M>S+3:2T6'#!/D[5].V'G5M]^/J@^+\6('=4ZJCU$@W.W[C]4^4#!#_3A@Y\N
MGY<(N.B@:O9TTCZ)LAT].WIVIM'C3H]S@K`YY#'?T:VC6QLAD_H;JKDK^`HL
ME`^B&?V3U6S#(]>(I@FOYY%0KB_4>:=="?:S2K"MIY=@;WGEI7[_&C_=%?QV
M)=BMVY'6E6`??<&'+L8^^H*[LNPG!6\&I3USY2^.<D^S8^VN)EL>UN\>.^GB
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M8W>8![/6Y&8G*DWHJH.#PB^TBZHS%6M<,O?OX@3H<B^%M\M&`[7*Q\360<%\
M'DRI04S9%Z_H8B)CV&?)_KJX[TG]17:#_6YDL;/<AC9VLR##IGF1SQMY^1GO
M>;:ILQV;=]'<[N+-2GL[H9\AT`2Y<J6%W/>J-Q%2,YGAHPA;$LQA3%GZOR")
M64\61I1:DY?O87:SO?%3DU0EH;8V],MA9DGFP]#"6T6T7^C:@PV_K@+J%<2F
MSAK3K*$8:Q7)NQX1*XD]J&J]@V``WKBI)<UZ)K'0CTIB\)7;FF"AR!2RH\F-
MEEI(,F0-L3\3==H"W@O2#-L<+8/(7V`?=7AH01V`&-\^M#&IR./4@I"Z8)7[
M%J;$9-60&[>@UBL19WN/+0!AHR^J#EHU!@*M&:2\RQ)*GX2YJS7]4,T7QBBG
M!+-(05&'\W#J1QF(3ME@L&)MX/X?P#/?@\4=DN`6[,:;Y[#&CJFP^V(]]7$-
M".MB3=V<)D+K/P:N*LIXD.5)Q-H37F`/-55#:A-OLL9EP!U7_\:]@E\'/_Q2
M\?%6C\0=.6C/)$1>[&V;#AN];,NG>EQ6^(=BX&B\/X0AA`_)$O:-E)A^ID^N
MC\R3R+#^@#,9M4M>ZU6UTNZK:DF6$E.'K+<<\G718^Z"-U*-BZ."-_]</>9G
MX1W^^!\_Y:ER[?O+GUGYVE?_QRA,I_#%/`F^`G\.%O'TKU_A+>D_BB<+1,I^
M-!M5?3['K.;M4[P(I_?8JC:#MS\'\[^_#>+%MT]CS?%TSU04S=!4Y;_!*'&^
M??DZ^F;8UC?4+IIN:-_4MU(X^_O;</;--#S=,;5OH[ZC]CU34U1[XBKFV!HH
M@[':5_I>W[0\H^\Y7O\;OO@KKHHO:O^,+1I>98Y=B/_X++9!%<@#_)5R,."P
M](>J]+Q#"*2]12`_;^K>2J6,P'+`#JRK(:]MI.Y[():83T,]C3>.,,6%XPW[
MK9^$BWO6Q3AE]U>WRT5\'P2"^N;#@ZD%@R]RB@2E_@)>Y1)0V6+%H\3T;")%
M3^#K).`=]%#=$C<F>&Z436KCY-J/>(_E5*81[K`QW37KSP=:O!`X^#M8)#Z.
M1983_&*6,R-NDVTR7801Z/V%!$>0O^`M`Y$,U`B5FE+RR@E4^WZ4XYF6T^_J
MKTIH9](8-)>84-_0Q)HBK4CK%-0"J<-_2?,`V\J`-L`7P`Z%1<51("W]>T:/
MZIBD12O\O1DJ#5P7^U(63&^B>!%CAV29@=*LP:>J)B!S6N%.@PD93T/Z"!$_
MBB.E7):/6HGT;ME5]QI;&F//&[*MP91\E+IZA!*J:ZV/A3K]C:Y2/\Y_"T"K
M!FNTW8LI+T<U5,\<>?\_>]?ZV[B-[;\O,/^#4&R!*2#[6O)+[F`O8#M)[P#M
M3C#3;K&?%K1$VVQDT16E9+)__3WGD)(HCYTF3IQ8B3]L-R-+?!R>Q^\\2+:&
MW8M!JS><3EJCR?0,I'7<[WL7HW._UWL!Y;4;#^HK+(O+*6/"*R7G:-&"U0P1
MW\>T@<:R4415A+C9G9X7M/]V]_T,@L?M^QF.'K[OYQ@N(3SR=,3=U1=T2^]>
M28CGKQ;NNH.^Y_;\1A0*'M$"]Y]]@1];$-IUP12Y0=!KPDH?M7`/&KCV/5A[
MW]O[SIXW*N7#!JXT7ES4]PZ<!'T#4AXT;NU]=QATW.YH[R,77Z>4WUT[\BLF
M&-@<D/6SKO>I(K&!I0"GBK#'Z>][KV-\_,4T`W<PZ+N]_:]!?)LB](8J&;X-
M0=X_HEB/1$Z8$O#V.`PQ&0S?ZW"E_N_31R&GDW&O/YET6^?G@W&K-[RX:(W.
MNMW617?J^6<]?SB]N/C+*.2*I0N1M$#T?Z0T@OFW7KP?2;>@J+:4^"__T:O^
M/6<K$=_^>`=<J*=/B#88)K_$4'V2F:J")(('(@G%.N;X,T7>$]*EU4T)]\ZK
M6)/1<<0MLT'2MT02P1A^['V_U^Q^I:A_,4I,UHF$P1Q8K+.:.JRJTQR<<@1,
MLX29X2\L3.5//!&A<G'O8IOH@-F_FZ6,XUM'WB1X9'P^4R(2++UU[4^@@=^Y
MRLR7XSC6J?C0Y+7+KBC<G[)$86A>9R6O>9$3YYBN3&CP(K$F`R_6T^1F7S4.
MBJ2"X\0<F6".I`H2*[[`2;>=3YN/=&XIXD`BG5K"<<J$E\1@B4,!TW4J%!!J
M)O/,Y/(57S.Z=#,"P4LY98OG,EVQJC:`73.A`]9S4_(0+@6?6R.+>"@4OK]B
M5SQUL5JA>$0YFBM\:9'*?(V)*?J-4E-+>8,YVR(G@PDFF:>A21YA-8U2\!ZT
M`5W1J)*P7J+B7`M^HVA9S7!P$2A[PQ*VX/03?#_+H2%HS="U()QKJ`!28Y)N
M.*R53"0HH83%1+I,S&14W#""222VYGD&3*+WQ..88,XLSZ18K7)HG!@MH0H;
MF5,)$5`=E=Q]4C/WTV]UG?AE">M/XYM:":8Q7H.P($&9W%:O7.J4Q!@SWY_6
M1+#SK\#:0N$:_\[1K/-H?`WS7/#/E*J'44Q-$C!G\:\\77E/IF#]8:<[ZD^]
M5O\LZ+9ZO6#0&D^]<6LR[0R\4="Y&`RF__'_XW_WOY>]?X]^\8*SBE8O,.^G
M)?R_0,=`GTET3O4Q//I5XJ-/>08ZC@KYCW4]NK`>@Z=>CZ<C1WV9+F$H.)`D
MHJN_+J7*0-6)5(_)I,0/F<L$XOGC<1"TNI/^M-4;GW5;D\ZTWQJ?^1>=<3`\
MFWC^0U"$%QP`1GA>VSDW-06.H8IS&;/D@:A@%\1Y`E#P*7&^\'6VD1_U^Y@?
M[?BN7<;I`..`8`NUU%I[P[KW.M[[JQ]H>LY[_+F*#DP_T*3+?Y]]T,<<H)$I
M:BY,0A<:^D)J/JE&8UHVM;$?/T_;SF^4_,V68&:P:1<MGM44RZ`=3`%GCN^9
M&BFL=5AP73,"4%^@^053"<8:+(]8Z[(NZH%:A`9@NBE98ZF?ST4*#4;LEFI%
M&%@YJI&KUEC!(NE:(UWK!VWD:^S$ZW2^-^,7J:X?`71DU84M)(A?0O4I*_85
MT]UW5=X]$V"LIH5$HSE<DSXQA(*IE',EE&"JQ9!^A"G>[2I(L;ZR/W(1:175
MP="-KI"#5B82B\JPB!I43)C)%.MQ5(&PH!6@YYV%MCO'J4NMH:^_^WV\_Z_C
MPE_`_MZHKRNH?0\OX!A"&_-'E:>^^UN]8OH>P&5?);MA4;%:YJ-2.8_.J*CG
MDJ="1F0V%/U8M]U45+.GDLX3H;]2U/IW!$Q7+%;_^.[C/R^V%*3TQQ?!L-/J
M=L9@&2\ZG5;0Z?1:H]&P/_"FT_YH:EQ!SQ\$G=[(,HP/GE6=*F#>L.)!X]O/
M0EU-J9(1_WHZ3W?0[9S[XW[KXFP"GNYX=-Z:G(&UFEQXTXG?/Y]T@^"YZVV\
MX*YJP1I54-XT51PDR\-\VF>L%?P"#B<6Q($C"_X>&@)C*;;K'J9T32#]P?_,
MQ37(?T(^#:HYA#]8^%V4BZW8'R#WE:LL$I6)S"@28S!^`[:G^K<OZ$>K-J@%
MJKP&YY7'IIT92ZZT?>!?0VXL:'5",32;I^CXH&N6RFN!VD4FNK(\,LVU';"V
M6(H<WY)E5KS\B5HVNQLB+#:,P/1(]`Q7Y/DE]=T.,SQ:B`JK8$K@PEX=RQ:`
M&IW37/OB5.BXEADO%KFTG!8ZH0K"T&9@LOFZ0IGF6)9ZKG7LAIK"5VR6P"A#
MQ12ZD+`,3H#QX?`30(>V":?D%`1`G*#-)'Q^S5+T4N''="W-2-Q='(3-5\8?
M>7#!X36**CE+@.;%!`J\?BP+];B]&EI*H9V=<KJ@&P=3+%W/N7/#:ILTB@+:
MJFK3U-'25\4Z88@KE2M=Q&\AK(+$;<(G<<QFQ3)I4?T9:/*S?B@%UAE_X>FU
MX+J&]:-9/9"L=UAE'()0P?^JE]YC&5YAYMT:"C:OU("P2_"&+]&&P=<?X;\Q
M0*N5\]-J]G_.>_OSZK5Z"\Y/`K`NZ1^8%@A`$9^K?:U?VOCR<@Z(,-6OP_>U
M#_1O==2.%#B/A?.S`-G9B.;C_X">&]W"V]"P_7[1E!8J71R,[$#5Q&;!=810
M5FXJ+7(A?"8Z!WQ!Z[M;UY>+"XB1QHZL`$UM8X;]Y:IA&UUTL2OZ-;KZ-.5K
M'=Q61,DU\#-&NA>T/P17QMHY1,N@11($+BE=`?P*X!=:Q$A0-?A;JZ5][!GZ
M@\'#:VF]SLN=9']'Z6_CNSX=V;[C$'W;:<!S]*MAT('ZU3]/Y^H_QR)M/76]
MYMAM&\N6O^@(_GN^^[2KN-<7QT4Y_T2Y/2GGO0SEFE]>>G?18>%F[%/S\I(5
MIGVOO??I0=\?>KA/,4%OV-[[)N>#3_!4,]JXZF(K(-`T6?=[[;T+R9LAZT%[
M[[U0S9A@_T#:^K6;9Q.(:YK$>MTCEM@W8;Q.A'J35M[$X9NF+P;MO3<O-,+^
M!>V]=T$V8GY>YT#Z_M7;]RJY-#;)I<8)K]_>^R*O1C#WH+WW!7:-F)\W/)!V
M>EVFM4IE-TU`O5?N7?:"]MXGT3=B@OW>@?#1,9Z`_`1E!UMJL-Y:B<%P\,CC
MNNZX?7YGB8'W<GG^PY<WG'+(WPWNO+G[E,<_Y?'?2C;ZA?+XK]X=;F:XN]\]
M8H1]BN(VSM744=PMV[Z.7`X\_XAK%I[$T^P?2-!?NV)O</6!]]KCFU[P+-&%
MIBOEYL;_AJ\\N^8'!Y+0UZZ5FUK\.3C![1/</B5A:\CTE9=#'ZI"\L$G)]YQ
M&,3&61KADD=YS#_-SXO[_LI[JCZSC'_FN`%=Q():^A4[?OJCCP:]?G<Z'?5;
MW7[@M7J3[K`5##K=UG3@=X9G_FARYC_[-2Y_F?U):Y0I3FA(^5JF=,V2RN@2
MR]KEC^9J);VSWSHN@8X#J-W/.*/;>N);RB[A@0RXXWMNKFW3MYW)]/9==7VE
M?;&9Z5&H-WP3S&-WK_:[#T\M!2^763KX)30OV/4IG[)C\RHV3U%[W+GJT(95
MZ/24X7JQ#%>Y()2V>E*2'U,ZRIZF_S:FZ3V[`#7:9]?G1YG3HTK<HJ\-KN`+
M`9=G=V+V/,'^_<AS_='>F8,?GL-_V7-JOCOR!^[`V[N"]/E\RD?-LMOON*/1
MWE&XMQAU(`DVU["_ITN3YZ4X&V_FA\:%(0:=D=L;[AV*>%YN?W3BQ.T-.JX?
M[%U\VKCI!AW7"PZLRUZ[`3_C<T[W/5O1"Q;]D:N,#C!LG,B_#_I]U]O_]IEG
M,=^/GB3>9=<=[LWZ!Y_D*>W0.`!0*@*Z4<69Q?ID3`HY-EHA='L]UQONO2'P
M)"O'@AK>!*%>.][X7)QWJP\'=C&/T3R=@N?L#SHG^WO2*4T@U.L"*I_2]9(E
M3I3FBV8KD:#7!9?]N`.-CYYDSPU&H"N'WNN>YM#M]`=@$O;>NG[G-%\[**!+
M8G`?+7R(=4\BXZOF>1IX"<_>;-ZLX-O0'?A[LWJSIMIS!Z,#1Y!?EWT^_S,7
M67%%9FC=_=<\@>YA3/V-\+D_'+G>H"&9P4?K+_#?`N_`ROJU6^T+)E+L/K<#
MA)@W7*=5+!'+1V]82E?BQ(+-1`S*H7F:P`O<8'C@A/*Q",?[ON\.>Z_=+QD-
M7+]SF*CPZ[+GTR7>V(NWY:"LFVODL=08[WQKG"1[KA\,W)&_-WLW2Y:'`=X!
M^D8F"P[8R'.]0SMA]Q'O]=<=\FM/]QG$95--F-))JNZOZB:_FKK)+8OP4-D^
M:(?/P58GJIVH=A^JO79T_[&J!^)?T8?G__/^<86`\`M>W;U]#\'=F@Z_NZ_*
MW*;8[U=)>OR9G*>@[(F>)WJ>H-']K$<7K$<D\UG,G\M>[=_C,9GY$]U.='OP
M7O;';%&O;W:?6EF'S_KN[:E4F;H$(!C>/OV^]K->,/6\_K@U&DS/6CUOTFF-
MNY-AZVP\]<;3'OPT&C_[OO;`VKP=%V=*PA\"__B"@5F3HYENYFA$J8++CY[E
M^N?!'3OQ[0&OV2W5HM)=VN9T9;PQ7:88I<(':83!*7TG>K;$Z\[7J;P6BFY*
MEW-G_&5:L>[0"URGI$R-&IOF!7G@@QX+1L:V$JZMSXRN@N/0G]HV>J&@C?+X
M`->1^C[J""MNX1NZ$-YU<E4<#3")&30"4B+Q'O&5C'A,?;W[FSE,`%^T^A5T
MXK1<).*_NI`7).;6P=-%S`D&?^9`D0R_5WCT3EC<A>TZ-TL1+K&!!2#^E,7P
M'7YRC:.%3O1KYB@$^%RND02/N(?\*<]LN#"WL@-=>:L8,;MA::0T39'6QJ6A
MHQ-6,LV(1"6ID2)9RA!7M6*1`)-E62IF.<4^5SQ;RJBM^]'-TK$.J$P8\A]R
M&T^!&U?$A/`\$OCE7_6*G,MCCA77N+U[6Y^?]7H6!U'8;&5G6HN.H!7H2O]N
MN*MD23JY',?P;5/VK(A)D;>028$-L.40I2V3Q`Y.E*?%^#5;'`D;H!"B@++D
MU@$BQD!KM4N,2'4822R$")HH:25`6G4J2W-ZR4AMYQ,]L$+CU*!RD?1)&.?1
M'=+K:AD$)88OB&2=4_IL"7P7XY$?*I_]H>V@PY3*5[IOUV$)+#=%Y55QB;WU
M.S`4L@-+H`5<M%20_#*RJ?0R#;Y%>J:NIEBBUY[4"K&/W:Z>CQYL*M15:YYR
MKC<(((UP.S70T"U9!#X'4R<B#L.]%3R.JI^<:PE6F7*!-!MLLOPM%G->Z18]
MH&_1R):C<.YE]#>.Q1'E2?UC;4A@O>@+P=73`X7QN#?I3X)N:^B=]UN]WM1O
M3<Z&XU:OWQM/NY.Q-^F='P50\-O.EWRU8NDMKH1%):<BDU/0Z66@PFYP,V%*
MD)F_U-<TF)P5\-DEZ*I0K%$"Y9PL>$+!P9?'/G^IR\)RJ`AU1`*V19@C@KC!
M$Y9\EG=.T#1_86$J?^*)"$%[`*9N$S%0J]V`.D)0<)-@MCZ?*1$)6'37_@0:
M^)T$F[X<@VDE60^-<BV[(D$&U:)8J!7&DH'FFG&.FHC'8@6#UN<D69-!W%#3
MU6&>IC`='-2:;"'I.)EHG(%/D/447^"D4?]N/-*H,.)`(C1EB@RC3'A)#%!R
M=/3#&G08$&HF0>MJO*/XFI$ZBX0*4YZA3B8S3OQ#EI!=,Q'3>4=H,I#2X5+P
MN36RB(>$,T'W7O$44%U:/B*%?(4O+5*9KUV<&/Y&-F(I;]"F8F8UQ#$`Z\H\
M#;FF*^AAKA`HU,%%G737@M\H6E8S'%P$_!K>960L,IS##!$'M&;H6A#.0GT1
MO^:Q7..P5C*182P3%A/I,C&345'<A56;;,W!NH:*Z!'BF&#.+,^D6*UR1$[(
M:`FY<S)79!(4AZ_5,\*$.SVAWQ09FW.#P]71>D"XTNM4LZAU$-D.5;#I!D$#
M%99'H+E&4625,E]7JO%]Y>U,/_PT'E]6_S[[\`.Y&P1;-)XJN`^8%UF^]&@T
MZ_V11XMR3,`<")&AA5"D8;Z"$2<A-TC3`BCEX6KZV#32Y2@!&>&JHHP(+`\B
MJ&N>Y*8S`WL-1$HU""!ICJ7*4ZX5`!IS//P9C)ENE-ZV6FV#IC.D-NA-U?4O
M-+*-[*X1-*J#6H+J63%0QRB/,T3*-<)`$Q5I8'J&-.6,C3*/"H"WM3]<5$!8
MJ'5R/4(1&<'7RZ'1'Z`L4)1H`4'>%Q+?GZ&)=`W$*E:0:Q2K%44U7+>&9*7B
M)66A#T-_8HK2-W$M7&DO'@X1W$]0(C'_IDI,$P6T-:@<_<C]ZTHRU]JWSHD@
M\$DK!*<-T`K2*H\TPBP?94@19/PT9[%>>HF*S&:,D)C@EVHQ4=]M4`4=JJ6`
M8:78+%JXK^C_<!0X4(7D$Z2H\W3S-22M/2MH%JPBT$\A(6>:ADR!KD7RY$ED
M'/6:K(`!#C,8N7'YT;SA:8*1`.G!.<Q3N3(<6P[U2#PR$"H\OD\S"*@;-*#2
M5B&5FAE]4,['RT_(_)_"3,Z`$HBJ-QG6^'71ALZI.RU@S4`,`'P4GM@V[\YF
MN[I1-9[>AO_',EIQ0$$((F`RJ,82"9R)AC7##4K9-U&@S8Y@H&@0S?"@CYD.
MLTPDN#SXP1DH69A^"I)#H2SM(M(25YJF30"O9%7M_:&_`K`'QLZ1!4OWE`AB
M>;KWI\>L&%14#,H>N5Z7ZBS,^L2)B^V)ER$)YB0YGF&G-;.L_-TDLMW?.3-D
MJ#01N&,\!5@"E$BO>*;%M])_RMB38I(S(3,>+A,9R\4M-!/E*DM+YQ.^+F2Y
M6$Q6H$+;QH$%@'$M6:K5&E*J5%$4-$)R[2]MP7X'<!Y*FCMWX:8I4TLB'_V!
M1?^PW.4)`<<*H$HOP_"*HE"A2#"45<(4'8`!(P.3LGPM"ND`U^3Z19)(-*FI
M6`C-B%F>8D2#.!YC(\#PV5*A.2"U0$K##O&N`>`#3N!:_P-\!DKRBI)MIR0R
M_H0"5OVHIZ"R`CR0?YYIOHP`/RFP+QI\VW-#%P0P_ZV1&F<.9L9,!044]1D>
M^,22*ZU*-R<O,@I(%D.SQX-N%V&3"&6GBF^&$GW'=4SHG^PNH9HB6J2%C*W7
MJ?QJ='BE/([%21@7/N[G\@K'HV7S\;?736K`L0%.=<PQ(QB,1E,#*GUD,9["
MBV`<U[0$XP:)U@(1,Q:3BZ&6G(`T<C@XU`A62$L;..L:`;`JA\EAQ,QC-L_C
M,HA0)#0*.;T!@2*>G@,@,J,2^@[.8G(8Q.!Z:+&X`D2UE)2;J*:AO7?X9`4V
MX$C`D*V,*MRMZ4N#+M8#T?.6%:5H`H,GBSQFJ<;SVE"7%`9KB2%=Q,A%$B!?
M5[@4P:(VJQN1ZLK5*%,7Q"$F<64LY:TA,=A1P-\I^5R47$*%"EZ!`**@:BJ7
M0-40<E*B[EK\"%.\<@56N!@:!N:O2;_8F0?C*\YST+B\MM!V+VWGG])BN!NF
M$V)II`-#-/ZMA^@2V,2N\=Q3UV%U1Q>%AVU0P?0/%-35\74A*)C[2+399U"\
M`'*0EJC%CU:3V3)"\DM1ATB[MD)GVW:9/M1X)K')=10P1I\5CS-$Q5/Z9F7<
M+J:HE#:V,D7H3)E1?<(`V-\TLI34V'CI80R^!G2O&2JMZ$JF7*?<##+=J3)!
MQ?Z]U^FY0;^#AG,W0U(`+B*>/!9.HBU@_RI@_D6I.#Y6..FXH^H$-0P6JL(5
M=2UH@[Z-L,S.0)`)I9J(_":PTT%9Q&$4$J;>"^9R;2R$?0B,JZ8IW1!@ADBL
M?8?F*MC$I;B0=K*A&;4$0]Y"GTVG!A&M4J3#%K12':.8@+K,4PJ"89.)3%KE
M$S(?I9.W`ND!5;PK^D@4K=BCRB%190>T30EG[??6HH\7XR^36O31SC^57Q)@
MB+0:0&M5:Z*J]3`M!'['JO>P6/@7:Q)&V,[*V*'%R-^TCTW6^F@[YJE)1*B:
MD^VBHPQ67(`*0%-BT7$I0!^!4W!+Y*_"D_6P9T%N0MK5UT78TP1GP1`R<U1\
M%0)5)N.Q8^TT+Q2#+T>#H2GR"7`=_\Q9@4Q27D;B=`YXG2,'R[2>L*:8!#D?
MY/V8L$$9QK;&4IO`]N@LZE.0![$Y^\*)LE1R4@9_M<1BMJ-,+%NWNI.SAB9D
M`<X<?\05&H,FWJ#A=3K?/_#.C.\?4@.)>Q>*+_WJLHZ8SVNUU'[']^_?D/?P
M(6SV^S-FN1S/KIB^L*NGOHG-Z4J=/-&[G>'9G[G$_S,1(YW%P)*T,DE(/,]T
M#$OK>:U7L2@BHW#TC@S$@\LI3QSZ:CG4?RB':C5L\@X4BS:LOH5AD3\Q7TY!
M74RZ8PUE]:\9`FA<>\R)4:LA-%?@&MT<)5VH061M)58"/=+MC*VQ04T>)-K%
M^L#N(R+8$M@0:JM$40I+Y&)395`.E\5*6M41F,$R%LFJVZ)A:)+A*'3NFTJY
M')5CA$J502LG+5,-5->$-0O7%3VQ2S1$,DWEC/P(6IN*E@7D`W^`G23]).FE
MI'?O+^F&O4N;DR<6?VFPGFVR8.5L$.<YIO1!9PM-@R*YEC$RL[)JOC0`M?(Q
M5>I:@RY*=.-59B9:2`D:$-_L=GL)-8:RVXNV6\O-H:2BZP/B5S]TF"(^A.3H
M$C4=&B($!VHBUF%ZJB142H:")JN#\Y@=YXFCT&?!)/C!9&W?J],.F+EY8.2Q
M<F-WJ%NS^CH^O,OSHXQ>Y3125!)7K^3=HJC36N>86+]*M\D"PE,R=.5P!D\K
MMC)%QC01H3:<B3L+4RK^?6<77S!5I*$KE@]YY<Z4ML+FU5K.%$EU`X:#:TMA
M/HN%]GU-V/P;G^I(`M$7]U_X7<L.K=S@[-_N)80C_W&7$';ON%'P_]G[U^:V
MD211`/WN"/T'AL],A!U!J/%^]$QW!)^SWG6W=2WW[-W[Q0&1D(1ID.``H&3-
MK[^9655``00?HD@*I'CBS+8E`87*K*Q\/Q:J,]_T$,)7A'KOGSY/VWNOF2L'
MM"UQUJUSB%8\SR\L[SSZ8UJ*??WE7][-&_L>]/?_(7.SV,05V9W%SR$5`]PD
MK9_XOCI,[_V-69F5/X(>6OG-I]QX[9!0W2T!OOHM78U<J5JDV`FU^*U@Z4MN
ML5311QK4FT5:&1E_2);=`?!T]-QMWR?U+<[\Z,"T^1IP"O?X6[J%PN'Z]F`^
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M`"7`+^\U>SGSE)Z1DLR7O7#.?=Q/`OZ.$^J._IA69.H=2ISMG9#."?BOAMQS
M`OX+D1:=$_`;?%+G!/S3/=MS`O[AN,A1^Z+/"?A'L-/SGG?RW&EE.QU]`K[F
MMFW/:FN>L]'[KY[Q=.Q@OMB)?RIAAC.F=AF0:;;V<_H)^%Y;-9VV9[G'P45/
M!MY=7L'3X!9GE)T3\,\)^,?"2)L![)DEG%%VSALZV53>0V8-O2&LG?%WQM\Y
M`?^<@+]*O7/;&OQ/55^G[\>S$'1&RSE)_(S95\?LJ:G1IY3">TA%^DWA[8S!
M,P8/G'[?="?O:N7Y<S'38LNTH0,JSZ_YW'[UW^.`[`SCZ\-X_-;\ZJC351+<
M!@E.<4VS>/1GZ]%/$IRVE8]4;3R7VM*6_6#I;<_<.JWH8]/,^E.VK<Y6ZVEB
MMJ'7]VS*-]<<.)OR9T/TC,'CQ."NYISN<O)D)\4AF\N+QMOE*9Z@&Z=<7PZS
MM#7!%-B+=Z4DV-9M$D_XL&L=!U:*N=<WP<B?IS1]5(SGQ*&Y()5@A1L?!WS.
M9S2\E`^BYJO2/.J&#.J4YK86BHOWMS0'DH^YQ9F=L&^`((R>6J-XFH9I!IB&
M)9)RGEM[H02#ZC(F"\G%E_AQ>%^<13[.E0U:A57A<[BJ-""4AO-F^>[@;6E_
M;$XYQ_6'^93-^@W&'U=.`*>AORN'B3?OJ+;`E5Z'*WR7#5>ER>1!=A^/TY]K
MYJ;S^>NP!L/:3RL1UJX9%E^=ZI[/F)8F3..7<$OTC?P33ZT/;*RSF)2.-(?C
MA=OE0>D/<>1G?$\X`_K6GT>9>#+(1I<?B1#9UF"-?`?C(('-$[S343CS(Z!P
MNO.PG85YZP@1O+QJ[OHA)]2^UJSG@FK8C-Q9$C_`U4IQ4C/\"4[RT4_&?!!X
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MW:7[=2I]FK;(?$._IO`B,;>09$(S([XJOF?S9'3OI^C"$Y*<.5=OT+P.TK1%
M!N(L"=.`KX1V/'P%``_3>W2HD),437189!RFHW@^%7[$UFT4/[8F\1@,\`^@
M>L83X#FS61+[H_N/ER5OV!S=/O\A[Y(/\,RR$)9$/U/AU4+XV!YPA^F]G^1.
M,!_=F1G\"[8+*XPB/YR@S]*/GM(P%2X(^'04DG\C#1+\!V!EY$<1_UP*C\6$
M"^XZ`&1%P2BCST7AO^?AV.?;0BP&4_2!4;^:>/H0)"G^Z2:X]Q]"\D=RE(_#
M6WHXPUVA$HY_0,]J]G39ZMQF`?.7L=^43@L]T#7'\$A^#.X['+/CRDCM+ZT1
MHG<&@(M'Y/<"W.&##WX2QO-4/%KX7M)6.D<4I06-H',%J:3-B45@"4%>1D@Y
M&5VV_H=[X:?^'5,?!6TB8B.B4;8G^"U0)IP(.V(9T_`I/,Y%_"**_-;,3[)P
M-(_\A"$7?TO[N8\CN!"Y>WHY-7-[*$5_Y7S"`63;H\T`K8[G(Z0IHEMXJ9V'
M`()ID"7Y/F&7*6`1WAFCPRF>\0M'[U^B(BTYJ@!70*LIQT`:E#[_&,^C,;KD
MT?<93HD>1V#0`>W\-`[XOP3R%N]X#*2;P8:8>RP_C^8XP+,U-BK@LXY7"4@8
M/A:L6"#XXO=^2BQA,HNGW'!A;FS&@V"%#\$/.+\T0(N8OH;A$%0<Z>`!?UEN
M\L1`FGY.^42.$]C;/;R._G*VY&7KTV02C$-X+WI"OA4GXH1J0S.?KKX0'*TO
MHRP&]8LTKC;>UY6PMQZ!E;2"'T$R`AIFS%+PGXSP`1_EG!&V?LW87%_1JROF
M7EE8#^_Y_"8%E@`0L\@07PX6`^`F<"#TT@%IR)4<J1%OAXC_"/$?O7B*CDM^
M]P#.'L`59JVO8?HG;3',U9_\Q8-LVUY!^=>`8KB664BQ"9(ZRQWK3'K6]4+#
M(T\P8`%'[9,O^S',[N'G?P'%Y6YU8NQA-F=DRTG\CVG(PC?72-[`'/O!+$XQ
MO'2/(1A:Y\:?_IG":D]`9*,`20!C.1.4Z;A?6':>H.E`GG\*%Y#L)]DQYLM=
MMOX!K#%!.-N<O8D_T<HW`44<QP%<,1Y>'0<3!!;^1V\`K<9)T(8G@;.#F`.Q
M$;6`:Q^2`E=QL6$)ST*`4C!J%F>!.&2X5?\2^D,>K8Z90"L(F*DAC((1QCPR
M*\>R2%.12`(6D8BB3;_W1Z1[H?P:!2$%09B.Q52RA*1E0`%N>%UH`J,XF<5\
M)^UE%(3+W\7`%:83IF&!3(?'&)>Y!]-)`"`D3U,.BD<CGX"04/HCN2ZW>)D3
MG8"%?VAM?DLISKCDGMY1L"L!B3_ENK&D/*!.FOBC3`@.X,JP#[@I=XR9LW/"
MB"]&*O^XO+Z4D)RC&'6''@9Y;L0QL:OZ&7#RF?TR#I'A`[=_"$&4X/X_\=.#
MFW6!;6Q&<*G@?\5#'S!N%%#(%Z]I`57O;_R1XE?]OWULH]<@#NXQ``=O?X+_
M&]T'X:3UC\G-?[4^R*\7CY57:/TCC`*?^`^`A<IS&]8979;?9@]5WKRZ!3TA
M88^C\)9?8'\KO4`8&$1AZW,(=Z=BWN+_`)^5S\+3%^]*SXNEV*6BN#:1`^D1
M_,!!@<=?E12NXO*Q5)(QAO'Q?)?S^OQPXX1=-20%6*J.&`X>K&Q*=#H)9GA_
M&*,E>P%9*."%3`$X!BD03,?`KB2JATQ1Y&^!E8$2<1R27?36@K^N^;+@KVTW
M,?B[_-O>"7_Z/`\`2*NN@;IL-/P?,(!B&P/4`(H?:U6!BMWPPMC2^9#JF]R7
M#+NZO=3\BZ(2&SZ[VU/<ZHUF84X_8VY+S&FO@[G33RQ@9L968<:7%%*],!/`
MTBZW3@/XZR'*:%X*H.9<&HT%\-S^\?BR#0J'P+'===V\W+HK]W'<=??2/&T`
MK3UQZU,7S]P1=VPW5C,:?&/?A/`Z(^I-2GGNAS\V?F%?;MTP_BCDGWNY==G$
M4<"GJ7OB]R<OWXO@4H<'EX[N\NJ7^DD3MWVY=5/?HX!/<_;$G4Y+M!:A[&.[
MH-J)6Y>F>[EU5=E1`&B9>]*/FIA(OX.T@YH<K+>68N#8+TLQ<*PM4@RTUXOS
M-Z*V_=1CR/;*0>GG./XYCO]6HM&O%,<_>7/X.-W=EM%@#?OLQ3TZ4Y-Y<1>S
MC)M^#S2]P3D+.[$TK3U=]%-G[$><?:"=NG]3<P_B73AVIGR\_C_GQ*-KNKNG
M&WKJ7/E8DS_ML[I]5K?/0=B29GKBZ=#[RI!\K0C(RM8*5PFVN\B>6`GMO^?A
M#(F3-MC$I@JE[09BNU1W2ST\J),P-F:Y;/V!?0:2(`L3WMD#6(<?!5C8S/I_
M4"]TT5%\'*:SF!H;W=+:^(BH[/9'H_ED3O^&E\<8(!J%O`],@H]-XKRHF]HG
MB)@0:W'PQ%N[8(P).Y_`&K`7;'Z"+4Q8'3U^.,$N,<D=*R4OFI!<MKX&,S],
M1%$Y=8((IM3/C;6@\:E%"+4WH4XHX10[)P=C:OA0[)4:!&$ODSE^KF@FGF:)
MC\2O1.$T$*V7D$^56XW#RT7+\GD:W,ZC5A0^U,W0.^UXEZ:J+PMX62N"5\N"
M3JMZ,/-'3&?9,Z<E0WN,A)/B_A]<A!JLP<2I8_HZOLT>@;N<\;L?_`[GR33,
MYJ^`8$U]&Q@6_5(2IC'$M[?A*'A%QF&]$;1CRSKLR=<*)]@VBC2PPULZU_=Q
M@H("=+H(=]3")HJH:.7JRVUP)'KZIPGJ@*)%W>=X>J=\IE9"'=)?&ZNPRRT_
MJ1MFRL??@%Z*.J88%X.]QD"5C1"PB`#CBCGIRZA1)V-2>:D5$N^T^!"FHI]6
MY[HG)8/8:KNU8.*T6U<13]JJMW4N<946O`R;@[\F8N+-XJ9X1[.','A$Q1^'
M]A3G\W@?3`-4G[$C#0TKRML_AM/6*$S`FL#^0:.`M39DG6G8I\@R\9/DB9J<
MYFW8_"G[,K53F\:9V`!'(?;]^KJ`3^IB6MDZ6ASYT)4;[-?)VB;Z29BRUGI+
M=I"/^$'CY':.0@M>GD^E!K!3^&/>!#8EBV3$&V/=!*T[:A'')_+DJS%;B"U\
ME\3SV67KTVWQ_0?J<\DZTS&R2><3W([\8;1J\L]61H7!453G+BTTT&1P!$G$
M0);WTH$UI)-ED"#:[Z;4R%+")JPB`&-(@Y]8R\6U&*6/H7DEP5D['6KQK4M^
M_]G6+MZ5[5@R3F=QPNUB1A"/C"'6[@K;V!;?:P/73-.BSVD*]M#ENF%M!C=3
M%^>V%3UL<UJ'#5*#RVG,T5Q<,;;*O3_&/_+?8=M"!6Z;@H;\"SICN8WKC+6"
M\;,NRM_\'T%SN7Q?]!K-_!_2`99&M+&I73D)B#;21+.W>7OEFR![#`+6O*OH
M3<BHF"AURC["9D+E_AO.U$O?0^<+=LX4[*[P>`13GW$F6(AFC7%JB_Q':<A9
MA8%AZUG8YX@Q^%*KYU'>9%%^!SN2)2EOR<A?I=:7M;BZ*`^THW;'3&Q0+[-\
MIV$J,R#F[4$"80W/8!716!G!H#:=XMU<"A%P#`5L<QQ%0KN@QMX+NV1?'L]'
MV(,ZO`5V#V"G?@)R%5B=3RR#'$T7K`WU(XGK$.4Z\<DXP:;:?V*[7!HNAV*,
M;1*W3^>+$B@I-V&LV<=C"`\P(=@2+84OI1:=>3-?+B(!5:)OK$_+4&M2_$WF
M_QG0)RM'S7X?LA;GA+X`!!YZT.HH&%9%X!0&G(+`*0PXT"!0";[@O<&I6RC_
M]$V`Q)C.4];4E<0>]<:6]S<)B+7?AVST'5^.-VP'>7H;KI9)+3Z"+4*W(LW@
MXXR>]B(.A4[#4O^:GTXL8Y;U:T7W)8JC"QQ(*.;#7"Z?1#F+HW#TA)^@BX#:
M6SX*D%/[#$@P(EJ7.FC.@6821$D)$>EB?V?2G(CP\4'N_6Q*O^*OK!?AJ_%K
M9J+I?UU@X/*6Y9V2]LCO2673KRU:9`."?*TI:WH]DCND<N8_0B)H^7=)P`Q.
M,A;(Z2TWW!03*WG;=L'U)O$T'H&^C%-&IUEX$X^?%+KBC!,E_BR89^&(-6*'
MVX'*+E(K<RQ0EU`DT"CX@4H8]6QG%P091BIX0%#>(':,16J?X`6#=V%3J*TG
MK)THTQ]1Y^>-SF&5#Z$TG8J##%HO=LCG[>0Q>G!#JQ9_9JW)+][5W]8L&-U/
MXRB^HQFK,[B-@*,)O"9&!*!I-AS!ZU_@&Y/P/P72^W,_4CJW(*K1ZO@:*-^0
MUY"H+O5;[7>^?BM^[O_M(V(U_RQN\4,H0T;AN+0P-LI[Q-LO.1;HY=+;HO$N
M;E$^9YIYRB2LT)A!7B*TC)7CN('H-M>/);IA=@I-("CLAA(1LJ;,'\(':2.X
M"I#[_!8^C%"PB5K**`)\(:Y)X\Y_0@Z;@`@K:%3>P67KRG_BG:=+G>:%`;-(
M7A+I@,2<)@$.\:7@B;@LMP'@'HF3#>"@'_-^\_S'F?@L[FH9:LE*%\BMO+,E
M%MKY+N68EUA9^H:XIB2J6`3N/@P><H5&R)1)"+<JBZ=<.TSB)RZ!:,:'&/R`
MQ@5<W2]TI;F8K:*\]C(7EY0<'$C!PFP2RZ=2+#"/%TI4]$":(NA"!<-HB3;>
M`$`*:@K6GH$U'=\!1P+^@.PE"8$\0L%O"JI@L;NTQEV"OQEVKKOD\?@6SV`=
M6[44W6HOR(:+=R7I4'7'H<DGN>9^XXQ,&?`9<AT<9'`G.0!I[397V"N?=Q<_
M7_-Q^N1OXBQAI=\H9BFMSL8;DW^`,!TOWHW+TA@=_C#A;/'9LAT[`:6-CZ2^
M?>*2I&#:%]*T"A0_O!%QOAB+7#-E.>`<OO)^7H((I`.'C\_-ITB#J,$64.7Z
MYR+%XW7B-#\"XL#KU.;;PC?!@.%#GO.]PTH!/[%['S=!':X5'P2B&)W";T"9
M)7WCHS0`'UP4BR;GB(A4&D@#JJ<(.*^`JBVB[Q?OV/B>$:_*9,0@Z_,",K)G
MV*@?TB$#P$7!HLL?:UB;>M&>FI^WF.XC*`V]'^5QW]DC',+3+.#LH:+JE-D%
MHU!$R@TPZ4?8TD=T,45S'&-")IXD%VFJR&2"?!_U?G:40G\@S3P--E(A*-#R
M$_H\.0&*02Q90/WGYR2]9R*/0QJ?0^H]#ID'L'!`3";8'5E_J%6DK0_2K")X
M%3U(>-73`K!\TQ__QAK[?R2E)9[^5$BN'&ML%1JQ3E.GY3E7I+:UUV.)#/<"
M3SY-JJ\HAI+^*"0!:H]C&C^3BAD1DK(!,H,;I!QPOHW"?9I[U>8)\XL40IQ[
M`')<E3%%<DG)8H4OB1<M1\C'AER0;^0;])EKD&MHB-0V4[JCB&M<S!CWA>N`
M*3@7[V1IAU#G`KOE2^*(F<&Y"L[5#I0!N2\!61O-R1D%517@()BJM^2JUB<)
MO4%^`SYS<FR@)5<R;YC2ZD\7+Z\D+N_$:)E"L#(?WL([J\8OH?DA6QQ/C%\"
M2YC1P)889\3EW`;O\!WZ^.CR,9&$JC3HI+&TC1(PDA/CF;9+2:,NZ<5++1<,
M-@2;6BZDZ9"3;>3SZ%O!Q0FN>Q_06$SAPS%H-&@MG*'@S`=F*66+F5VS!5Z&
M=XK/,B,-E]F0A=[5#`8C32Q:07V%@5ZVGH1)C\IB;H70,*-Q,`MH,HA0S.C1
MG/N(A=MBFA(9"WYY9!`Y.$MVOH@,2J=:IF\,6(+P:E_D8YHV)*L4\_+)?XW*
M[S2XB[.0Z!A',>8N"&3$^444\XHHUHFWZ!$!($%'T(3).%="V&@[EM=8-?%Q
M4D>!/6&[D1VYQGI;L/=I*6;.(9\H3,1%BSPLW04VSD=&?GX-F&Y0<Q'6ZTUD
MWS)[3YSOJAL!Q$L[YQY^O)$/?O*4YV"B2<"?H`2&!1JK97FRQI7K6[@4XTZX
M<]D.R'ULW/9/26I6+KV8AZ<LPLR6+<_X1$@$.1(/Y/S/3Y%^V$1BV`;-KZ//
M2?Q9YI&,S,(L7?#E<>U'7+1%]D=^JJ8Q'QE'XQ@6P7#!.`3CAH_CRY(X8F$F
M=@B29HC,H;@CLDLC1F\%N<0QD!0%S%W#"4=<B89@X%,1EA?G5VL,RM-$N<V,
M1"`3[B+[!@.VQGP5[A;N+:M8O6F=>5LVL4MF;N&>`<$/6\.)46+R5SG'@XZ!
M;%))]\1I3T-X'FE8K"NF%DE1)IZX+:D],E>OV'`C?U:*'PIC<,I-$1)`#WX8
M%3DB995(.'ZYQ&"B/?\@QEB`%Z8Y'^0"X>(='Y`*KX^"/)`EZ!M'W[&)J[F<
MD\ZIUM'`-\N&`C)I>)-GU?-\&Y]-]66V/1UIF%6)9UTF2)YC06Z"*$)*Y&)/
MI,\(A0!CR?DPL!I*185,T`H?%PN`CT,^92\-X9[Z2=GZH&B&F.%)N3@EV<F$
M%]KPV9.2._YN.=$(SWQ5Q5AFG\\P6XF-_ZMGC6URW)`+K*0L$#V+'S)$&6")
M23/QS:IIBURZHA!R[\%:WX$4>U@)#!L3/<-A>Z&8RBQ^&],01JQ,$(M08#.\
MCT58O!SOJ$@:1FT3?QQL\3J^EJ\Q3W-S?1DDBZ/@$$MP[[F;7+[R1*5<6V,Q
MVB4&0)C5+<S($A4`.A:\1((LQ;(-$0Y_S(!7`T/+=<.XQD04"27<Q1'>%OP7
MZ:_$@<?A*"NEV(E[G0M?LH`D3G3QCO&BR]:5/-K7'W,3"3,."T_L-;[H)^,4
MMCYF_*@4_.I<_U&*?;5^CR_E'C^JI^`PR@77M^P[%[%,X6!O]27K4W9]P^[^
MVY_.08$L/L%2L[022R3I4<[(H@Q,@5[@YG^RT<@5]@Q*AH_W.41B@EM>(!!V
M/<;L+,&L\IL(PAO=D2.BZ1*KK:+JG]=?!B5<,39(66*@V]P4$W`9+\[%=\[^
M)!Z;%V"QM`<:^AV/F'V3^TL%+?#)R#E%T;L33$O!+`C2Q?W<%F$NMK:4X5=@
ME=QNS!>8+F=ZW$F'^"@&!8,L>(BCAUQ%^(32Y$^A(96U`B&B@NE==I_+>[XJ
M[I;VQJP8`BIWHN/5+T:5EL30K([:F:X#1+R$;J6.B*U_S<=W19B#"=B\^$QB
MB)*]A0-NI[D/`O,`6:)45II$G.31*#G7!9-O[H#`Q(E<MOX++(LX0<[,IQ'7
MHI^\.#FJ"V*HY`3X*TSN&F%'FN<-IJ_)*.$\!W@XC@C&5I)$K=*G1#0,TRT#
MENT2XCC@&*0S)4RSC(=<"E-T])(X4()V((=4\NH4QKI0<E@>T7JR8P1S$]PA
M;MG.0?\,9C+-+=$A<O.0ZZL"<"J\6'X35M#_,IH#N@BF/%,V#P.11&,:(<\4
MO'@GXD_XBW*8BD@G3[L0L2^9>9!*-HG'X>V3N(%2+BY/$9<#XXLA*K8'8-3L
MU@I+)Y5E>SA&`YTMRHHOF1'-V23I8T(GK7>?RIMF\[;AP822OBGG46B6"FJ6
M3P4O+C'>;U=5OHM:-JR59CD-,8NAQ+\KHX`'UU>554`P(T_'6"#*"6Z`\$G5
MR%ER&0'PX?L\:2R733QZC=_RLUJ&RYQ,P,ZF*;(.GR+X^&&BOJBXXMQP67#S
MX1IH,V+!"N7SD=!C,H\232];`Q$90LC9-AFIIF3_""NU3-DE9BC(+RVHCBOS
M[=RGC(LOF`_"R830+A@"4EB7CCE.\V6)QP>3&?-+HP^3>_<$'<K*/X#_&##/
M`G,=)5-B'T7<"6Y"$'%U7EBD($_G$YYV5#C`<XNP%<\PKQ/M)>!04JF`G*]?
M9+J7LTDH[9S\I#=240/8/9AVFJO*\"[HRT$P%A.X"[\4*0.++NK6;)ZD<Y^E
M\TOD0&YR+"(:YQB"!?"H2VZ(XAB%$T(J[O@S>"KA9)Z*2&69G(F`R$Q@8J\D
M+XI48:[0<!96\%_YPI>YFIP^+<B,E)J";UR6-,<B<ZBL."75,#T/.!=*+]RO
MDH^ZG$P`/'E"XE#.'<!3G8-XGF`)0MT]X_Y:>=EP`>0B`H,^`"[I>+H-*0J4
MJTODB&R%GW)Y:^T"*4_(Z*00HT"R["0B:$+95<,<[3?D9R,?9B'$HB>9V2PQ
M^\C%)WC@\O,4B;JWX0_6(B#7`>G#&<?J@H265RQE87!L+*1@7+Q;EEH2)@4N
MRUX2)J?\&3J7DY#9/752D#@';:.2I)%+74S&XB^2HN@7FDTEV[WT'GG*^!E=
MMG[++RG*W-R-7:N=AF7_H[C*OGQ3>`)+&5?E2]`0@[G&F[HZQZ8L/X5G=;S6
MKSJ6;VSU9M<Z3LODO-1ENF"RUSI-5[A,)6NVY#05G3R6Y(-6?*87HC>(!,H2
MUVD!A.2?6?"1ECVCP/+&3*B7G9,EMB+.`#Z-"M,"CRUM;D2JC_"NY4F=E%`9
M9DR2XPAL%'I8%T:<*9YG'"NC()QEQ:E@FB53)&2!48W;X;.E>K3<@O93'ILB
M\VG*L5EEI#F77PD9_G\>4F1NA90#FP>4ZI9NR(64`SQ)D->]XHF(E*_E%AA9
M[T0(%54W=T>PE>;<32:G\G)/WY^DEOKC?X&TY<'I5&;41(MTR1^(_Y913[E'
M/,V`E#;D&O,:XSA71A>5+&Z<H+F`;#S@N11BL^W6S1QO#CI3&#1YNNSFB692
M[AA:01$IK22GZFQS(?G\2;X9LG#XO^DPPFR>!57VR&/85$#.3R#G9NR`^;TI
MBIBX!L$."/,$`L1(%D8LKH%R13[\LL.=)7H\D88T%7=@$<-XTH2XXO-UMGW%
MTX&NEALI]%&A!%;\5CZSBW<E'YFHD>*\MIJSR+"5"^V6GTI:`3Y0CR1"$7V=
ME7QF><0B>B*7"G?\)&.F!_`5&1TAXQE%&%5FZ3MIX<7+G\MUI3$S9'EM7#E_
M++M/XOG=?9D=KL`FY_*/(8J5^+%0OX1EU1!^M*%'G3L/)(T+LS)*JG*9X\M>
M]S4^=XF*5L=G:Z.S[=R;67BVA!&Z.MVJG&Q%5,1U@2+UA4OX524*<AB,[%M>
MH]"0`RX+''Y\J:2-%\EIR]*"*M'D(M3$TE<V2DGW6;X+6L&)%)XB]P*V(N`>
M<<8!X<]@AZ?5\`!ELDI:'V,OR!Z6V4%M[B&A;!?&6KCJ(>`NAO/0A[GA=KD&
M;40LD6PV/8/4Y.R=PL4A)ZE(Z>W"!=$\8LJ>9LR7+DXSE2BH2$G<D)CD(@3>
M$$(4=0?3NW`:!`DS+Q?CR.W%&"?'6E!*`V)N]J!4C5Q-@!-A;,D9G\SO2CMF
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M*8FCEZ(,PWZG'$Z7;$4217A<,JFTI$/PYV``)]S@)S>D9`;[HCYE<;]R32:K
M4\'7*16)V_1DQ5$S'VK;":M<5\Z3Z&S9J4VG&`=B))"@Z^.B*.**D`R:HFMT
M:J*"S%63!P+E((&$@`LY-5<V&O+<OMS[00L6%YD</+D>_L`SLD`O"=,_R2"!
M\\^3CGGL.&\1(OQ3I*/@]LKY-?E7D*O#&X7LD/S,)$?(CA?FK]CI!W_!C5&*
M,Z8L*#%-YSQ5C0@_"-G+6N5EEN^UD"J0.Z>I5I&E?C*P\MU3P.Z#OK#>/;XG
M-EWUW12Z/?>@?$@_LMPZGK!<MO/C>48)IN4B5JYL/6_KTL:1L=ZL1")3PRA"
MQSM4S/PT*ZW.G(@?1NL.`]TQ\907%18A`M9TI(P2%B`A[8%1+<^TD\LZ9>^D
M)*@DKVI:F[.7CD)6GC=J2]RI+06PN(A@:2Y(YUP5I_)3L-)0OV0-,,IXY34M
MK,9/H@Z6+`)\A.XK%1DS'\+T(6!>(A'3'DM+YHJT6%2ZE-44\N(O5:R3%K04
M[VO0G7>V*04UI,R8,)6N9D.8Y._Q5)$*1JHU`[5:04NT'KIX5^U(PT]C7+V;
M2R-,116YI!NO3?X@`57R1B_PW*3D'Y`TU27%]YR`)$*D`"F)UCRC=EUY+U)R
M`#?LMT5<D:](B@?(&Q:9:B5W8I'T1U&X\&:>B:+[//&I7(""]U:^2VFE'J8X
MG-LL2)9CNN(\V@"=E8TL</S<G.:5DK6)[84C"[\XC7-9..=.PR+R>1.%=S[/
M65Y^3!?OEAX4'5/#"B._BH)7KDRW.KF]T,`*R=K;7*W9E4V>HI"LG/-+:D:I
MN+(H[ZOTA^&N_MR77JYI"J3.$T!7]:TGZES4*ZJ6>7@`H<B=C)L5K(FO4':<
M/^&F>&WF>:75!JF4_#5F\:'LH:H;+O*0WPE51X0%1"$V!Z!<6/E'T7;EXETI
MGX:",2(9JVB>(."OJ>Y;%\8OE7/#Q9<M(NY$EZTB%G4@&T?HW!_K(GD,0*D_
M&H%-=@T[4T370L%=SNSS5C&L2VE!8OZ(=`G>3&[#3@,+0(KE:Z!!3\\T&']D
M>RUVBEIPJ>(/R_WH=F#V<!&YR14^'CIKB.)`*17EUB6K;G]8#KER0BH;.*(Q
M%!4[%L[,,BE_X0\Q:;M$H(:W[=JD4']E5X&RK8?:&C?<?'*ERBJDO"<RE>"4
M1O=QS,J[<V*3H2H:.-15*BYK:5'D$N2*1"FIH%#@Y?R0N$!2&2]2A19UX:5,
MNE)J8^4Z5YKX5:/?$T0G+4&,NA@MDIO8(I#/<2)4/+[#-E\RY?F\M9BKIDAE
M<0;,MHA:EK3XO#&+[.^0&R5,)B&/-8<3WH)69`"4\RG*&FS]_AMR&8=K;M\C
M*5^UU/@<ML>*!:JB;>55K+36E51:>C@W9)^S`[0S9&.,U80O7/9R@)/WLL$;
MNK*SR`9U!KS*@*RGFISO%<A^UM6O7O9E6+UX1Y'*H@.I%*W.A5#NZV=671Y"
MXCE)0IO/Q^EPPX`;95*#Z,6L'A+,E>LK(+^E$-BFAWO)Y$I:-!PB!I:K.CP=
M;TE:/Y5T^A>U'6K2BLI0I6'D&D\5,[)H-<>DEU1O(YE".<:P27]A1[*7VY+U
MI>G8NC&[!Y9^#5^A;BW9\TAK>9V([`R4?'[L=O&EY62.AR!/$Y4:)*`RN]E.
M+EO_%3^6KW:Y9K6<?%]!"Z7.XT]3S-S.FQ/G6<&SA!GQ,YQ])6WH8GFEQ67K
MJO+PBD*@C'?<JI;2/K=LX>(=;];\[6K`DG18&O;*6H*2N+UXMTTM0:62`/G7
MNEJ"Y=(!LU(0&^>B@HLW6%2PG"XPX^KB7:72X/EU!BP>4:HT>%Z=`6JX<J7!
M-G4&PKE7U[UVTSJ#BVJ/OJWJ#"[>5;H4;E=GL.!E?FZ=P4)`I;U%G4%9Z]N^
MSH![^D2EP3/J#"[>M6HJ#9Y59\!I8^,6EC5U!A>B]FVATF#3.@,D\N65!AO6
M&5R\6UIIL+[.0,+DTDJ#^CJ#BW<-K#2HUL26^@4)-80\VR,^0L>O=@E>Z0"J
M,X2J6KF?<;=]6G9!40JIJ/;9V!XHY_*L4K<NWI4]*D4R,[G#Q#YPNRR-=(D(
MOWA7+JN4":HLZQ<JOJO[R1D4Q1:%C&;YE7=!M<Q82-!9C+IIR-(:+Z3Q.4(>
MDS21`D>YD(==Y+72)?\161@,ZN6C8=K81HUV%<^3BKG!.]6D%VSHBT#FN"`K
MTHUQI@:F@JU?!3L3D(U2,J`*(@6^.0QN$FR4@)LSP7P`^OD=4-,"8Y.E;I52
M.XAQTT::<1?_D(ENN?_U.7>A+I4;FQX65ZXE>AR(F%)NOQ5F'6N_S%%7>!O+
MW9/D)#ENYS$.,*^")9M]DI#=T/@M7^^,4FU(/*05Y441,F)E,/+Y&Y"B^*6J
M&KR]5$#07M3;UDHZ5B=.EX[&>'#!5S4\EYJUD@QFHSHN6#/#!?]&?:+X!U2[
MYRE=SQNPU#]RI9;8,2\I6649+2TCD,*TBX4$&Y817/"6>TL*"5:6$>#EV*B0
M8&D9P>6V<3S2T'FE@]R8)<Y[4"XZ4=ZBG[0:`.0VQ/(T@/I:N[2J)ZQ339:Y
M2,N*<:$CE#N^<YZSDN,LBZMOPA[*[UX^L\5@U;E')F/.@TEO7^YX7!UG>1M3
MVK[*L6LY:;>'#H?&SFW[NJPNE@8JC6DV\8KY\JM68%,#@4A!YPR+IK$4\IG,
MHO@ID.LK^/*E`H'4C_Q$%!>(.1SM_%&F_=)&Y'0"SG!0^HD>1T5F09S<^5-.
MHMQ#ALEOE/2"9F?(9\'1;N&6^G*7<.(ZV8I>;N7^/$4(CAF]J(X5?6F*6B-J
M35/.NRX*!0K=(3>M+]Y)V"K5?M[R:N7%_/>R'RV<*OR]O,TC]WV5!O+`$J,_
MV0@D\A3""T)YXQL0A3=I36LMT/07:AKY8=*Y%PG9(L&Z*=.[\'"3`#@CZ3Q\
M_N*'SW&:?FSL11Z0)P_WNZ3W6V46)_GS@S'Y\K$SG*):[0LI9^J*57OE=F<=
M3MH%-D2;Z`DK-N]<]U`+HKDNNB[/XJU;1UJFVC7OXIW872GA/U_N4GJ7/$2X
M`1Z$GLK`B=16?G]G%?`RGM9?;(T/E_L0X;'GM;;Y!+J4^;2E:5#$,F+RZ:)1
MLSB-,+TL8_'B7>4C+%,<."8?W\H,[ZQF*WFQ0^$11O"RIR*9@91V/`M*'5A8
MYI(SL64`PW+(?A8_+ZPU&F..G(`.?)7)C\1'N\:C:,H=OY9X6T_B;8V]X/*&
MBX[S2;4M+I][5)F5?5$:B!%7IF4[FENYH3DV:H<]L;UP`EI$'-,]RU.+T[K=
MDY\[#]2T11A"&%:4K=26IK9VL2.E<CVZCZFJ!FU>T4!'RO0KOEN>E`J*+2CL
M15-UQA%0XE_D?54K;1UA@2+,C*\\\+K!(KM7#@0WR!;#Y#8,8BEBQ_XCM2?E
M&6"Y$D6.Y[S'98YJQ`AH3F3016AT"/>/Y'M@WV'+EN:H4-J@%.;(8X[KOHJ4
M"Q91PI6<NF]*L\"J9"5K*.)#S'%?:N)=:EPB^1#DI62H6-]*/OT4"TNEO'Q$
M[F)Z?4/(0#8``8D1STJIO4:LVPYOULDO41Y0X\6VA*!J*J%(&RR&_W(/<CGZ
MO.2S;5DJP^.S.0G3>Z"[B">-B(B^%.KD2F<A^HATJJ'0$55L"44:D_19K!,?
MILTKQ&?*;`J3$O#L+UFV3"7$6FK#'J9_*K=8()IP=B6FV[9S$B$?-!6VCUM/
M81"-BS^U'F*,=%'\602=\[_QA!<1CJ0--41L_@[Z0$DA;ET!-[W&^0V-E9Q=
M/P4UM*S%S-BPU@D6JM+PB<IDYR=V<BP$6=&_.%MB<V#B?!F\'CB=&3U+><_O
MQP!Y:#!6?/07W8$^-T<U"4]7_GR*A744HR:/>LY1+MX5$HFG>R[TTY*_3UH@
M4#/3-OMA-&=DN`A\#C6RS7E6AIF1HY^@?S_E;TD,>3WDR^!FSK$2XJ4=EY`@
M]$S1UI?)>9R[F\Z3)PXN$PL(1GWZPQ@QP&=J4J*#2)>J[T,K<3C&(S!3)`^5
M#;C7(E=_KN;)"`ND6U>18!Q\K`I%Q;,BGR2\5>#<`!6(Z'S3%^\VWO:J"/\L
M3YDG`!HB?DIMTY?,IPE9\Z/Y382EI9BM1LWI"J,#UEF@6>KUXT>C.7-H%&DE
M".HMA@`XM/_[7Y^^#93KJTX/8)O&CXD_H\UEC[%"/GY"%+Y!YB,_%K8>-V<I
M=:FX"&.L1Z<H&,M6A&>+WWP4)25%HT51Q(T?6[BJK,Y1#!<B?Q?ZPYF3I)P7
MP11<47]9]"#A(;1<RJ1US9Q(]L9`F^SR]<D%3*-S`M@8)5X68DI4I./<4(P)
MB\)Z>7X05Z0PDJ;(-U9PLC*<S.T@V$,NU:X#J48?[(N.`O9B1]';K6Z[U6NW
M^DS*]Q6]Q6].B/NJT/J%:,YUPZN/(]'CAB&&-(.\@WB.)HF:^!2STJH,;_G"
M`B<<[@BS74'ORSDY;@*5FB4(8/G.C*`HJ41\N/@LJ=OX*,O[I1CE3=#*6<8E
M&X>(TU`8.AGV6C+2T!P#M.58H_X[2\CKLM7)BU]DIHO[R&'8[H1JL%EPOHK,
M*"I&R=LZF0B9MHI)?[KZTA`.Q_0*<GLS0;N!CI%+6Y]-CZ/QS#\?O(L+$^'\
M&\_$3_?+U_[@J]+[\OESY^H:7J+`T2P-WK=P+F<Z\W$(RR_O5?;S#/,`^,^/
MX3B[_^6]I__U/3#*\&[ZR_L1506\;]W0)&9\2MYF(O\P%N];+CL#`BL;EY]Y
MX`O?Q%D63_)OVLM?V=7OEWW:.N%/_U0^HJ2&IMQU)/5^)2CTW3(EKP&^\L;J
M=_E^.5&+>_;_5/I_+6V6M<BG^WX!PT#U0.KP"TVM$K-`%9E`_P?J0VN`3E+X
M:*V;M&(N/0^Z\XDLGHB^\D#0A;E;E&_UQ@'`U-\&F-K!+]!Z,0D"[0X@B$&B
M_;]>;S`8#I?<J2R>R7^9;2F42TT1M&!245H4^%7>F*0:TEG0#G9ZG6O>_<M&
M(HS_2-8.O?9!M]6V:U@;O<WLO5_>2W;?QYT3]^Y@<]N&K;4=:VO@7G(>!X/2
M;CN:T]9T=;]0[N8&-^6^?@[2].>RJZ%P293<#25SCX):PN`[Z!5?<W!;K+!(
M285Y@YG;^]KJ`6[2,_>[R!1?S#D.PA9?#.:+6<=*,#?A&+,?&ZC%!Y">5<[#
M52NR_@N]Z@?7JVJ0_UP^L-</'H*<SE@[8VT3K+TYS9^K#Y5P'GF`M],8HG($
MINQS6,WY1!SF!(V(9V'EN;BHV^1FN#E:)>N,SST:1L>DYA@@"<;Q'/C7H63/
M]E]LDL@^X^V,M]-RDK!8K,@Z:HFLHZ4Y5HU7;UYJ,-MMUW3:MN><GH3>!7JT
MMNH:;=VQS^A9@A[=:MNJ_OKZR#$;7/@9BDMMDH)*""FB6$UF3MO:7NJE:IZ,
MX?4"1``>]AP".2/DI-6='<5PCX!EG)J[Y@6X>-T8<5.Q<E0QY>:J*EM&F:48
M\X4\KL@?CY4;?_0GI:DO%!$WFEN]Y?!UXPV3UPEW-Q\MY_#XVPQ9G@.]9ZP=
M5WB\*0K/.1A^@M;5*0=OS_@\!\/?2G#R'-0]X^WX@N'-]>Z<P^/G\/AST',.
MCY].>+PI/&B0][+)V]N\M$#I0`SG[!$^H'EQ1NP9L6_3@#L=3^'9OWK&VG%Y
MI9MKNO$FCF?C[6R\G8VW$S/>CDD[.25WW]E->L;;\;F7FZ*1X&=N\-_]C=I>
M$@)N<E;69,7D7-?0]#3^,T)6LI:?J+%K'3LX].0)UMJ61ILMZ4_/AH"6QQ2Q
MWM"BNS=O<"^ZZR[.(BK:.-\$(W^>!GF[;-XX/>_AC(,@%>%W/O?;?5Z_7=MX
M?K_=%:_LZO=O\=/G[J[G?KN-.Y'&]=M]=8`/W7GWU0$^]^!]E@E5S&]H7>73
M$FBLS'8VTGYB;UNLT,`PX>[=92_U0.IMS;+;FK:US7@&_`VY6W)>H9]YQ=OC
M%8:GMW7GS7&*@X#]1K2,[IEOO#V^8;8-PVZKQNO$R$\?\)/4,7IG3O'V.(75
M]E0/_O<ZZ2*G#_@;T3+Z9][Q]GB'8WMMTW;/8#>6;S2-2YR]&&^13QAMP]/:
MGJ>=`6\PKVBNCE'4#O;R8=*OR49V01J:T=9<T#_WW;GPS$#/*-L_RDY+6_E?
M/TE\S%'#?I?S9'3OI\%9A3G:&[@3=NVJ;<=]<X&8@X!]ZNH+,8G6EQEFM!YV
M%NLN2$!O&Z"K>,Y1Z2F[4=YUTVL[^ZX4:Q[@>MMUK;:I'32&<KC<=5?*V8YX
M#AO^(\1_?`TPQ2UZ:GU*TSD(^,YH%,^GU.OZ&@ML_62<MCKC>`8V"&T[%*\O
M*7+9%QCVB@S\3]/6?\\!!LR];&-2?&O8N>ZV0@[2]1^MW^/+XFCP,473VJW'
M^W!TW_(G`<^?[5SW6M_B63AJ.:;:2H([@!XQ,4N"%+"4I^C[T]9\F@2C^&X:
M_@?;A/L_6C?!-+@-,UCE\3Z8MGS*WX]G0<(:AV,&?^M#H67T_O;[E\_%C_V_
M?6R-0`M[NHV31_AJN^7#2FDX"2,_H?5Q@78K3F!E_'$$VEB8E=YI!3_"-$LO
ML2`!7B:P)E1Z$$Z7(@&@_/<\3+!DH`7/AMD3*8$,8/@E++0,U):?PF9@'_-1
MCIC66&B*^*"?IH`$V!YN9]H"B"M``CA5&/%W!8`7[RIO`#JQX7IV#^O1]Z/0
MOPDCW#?A_8,F51BQ^HKY=`0FM`](P'5G<1K2=EFQ!&V?"BEH>_!QUM%=_BJM
M,::O!FR?_B-"BS_ZLUD4LC:J_YHG83H.&3*P-_P'?6$O',7A-(/#(7V;EW$L
M01P"FJ%.#ML.Q,GB68YCN"K3.,O/;PK7)L$&0PF2VSA,1X#-.9PCOA6F!3G`
MM;@0%2/8E6B6Q.F,_1NN$'[S%E[VH]93X"<I'/9=.,6^^"W_-@OP)!>SS#6K
M37>/-MCJQ9.9/WTJMG@31&'P@&#*^\";$D91Z]Z'/_FMB0^KA_#9$-Y&Y\>T
M%0+IWH93?SK"WZ=P_P*BY\N#,9VU=3\"5K"86@%(BCF-#?`!+#@D.-_[))[?
MW;,#AC^)BA_0BS`%F1[.(>0E0IQK(0%QQ*6,"HC<D!,#?<$BC`"!>@B+B.?E
MF,R*K18\Q_M;NG0O*[']TSA\P!___M,\5>Y\?_;S-4C(\!;NP30K!,@5+#L"
M$_);\"/K1J`2_@KOM_XNWOF6^..@,QU_P?O&WTI1'(4/>)WH[2?<7@;O?PUN
M?WD?Q-'WJX'F>+IG*HIF:*KR/ZJJ.M^OO_6_&[;U'6E0TPWMN_J^%8Y_>1^.
MOYN&ISNF]MT9JF['TKK*P.K8BMD?JHK7UVREJ[D=>*O;,57K.[[X*T+(`7Q5
MR2Q0TBIPTE@!G.\UR??*:!96\>^(CNB*(!T2[\N(O@7GSF(BQ"A"KR?6MR7!
M+$Y8K2V]4R+2&S\"(@U:Z7T0P"=]Y"12/Q#@,+27=BL*0)R@G,#:/'H%N1O6
M/&>W\ZCE\TT+MBKN\F,29MABY/8610?;58@0%<"E3-C@UJ+P3[BE]W$\AC<*
M,%`&A(B/29P%#618@EFE'+^T:7$>*,EK3I38#DK\NSE*[!L_#1GR"@RW6R&J
M1T]M!!X>@..:SP`5#WX2QG/D-[?`DN($=1*LA,3SP@T4C`>.>ASF(G3F/S'B
M`<TF3IXXBN?PPR1(X(CA=&-L$`,<,`D>PH#D<G$$P)1_S-"/A8>/*@KR&@1"
M0(??`.5F&D]`Z1-;`R(!KHM_QK='?!",SYSRM_,,I&KIH.6O7(*6)1'<HT\8
MQ.K#,>HKM/_:,BT2H/AIK*=IM_AED>6+7\$"_SY@,"8:+U\"0=P;<.^-.'&9
M>5^/[D%QBH(OMWVNMWSS?W10:TEAH<]<)T/FCROD$F!G[+QO=)SAL&LJ0\?0
M%5,'QMXQ=$L9NHX-RW7[=D<_.#M?=_?20DIBF3#<"R(RKDG6R>>25HAT2QAN
M?8@*!']D6@/0!ZM!3M]:N:]CO[#<5WM^N:_[>C6WSKGF=LV[+Z__LU?6_YVK
M;`]Q!HVKLGTE,'=<6WOJL0>ACHC6&;DWI48N[MTO_5K/-7"GQQ8P-U92V3`8
MH]'1^N/R^K+.T2M[#P].=ELV[S'LMF5K;<U[G8&K!P/3:AN&VM;LHZB8>4U&
MN_H*7*.#L'&TOX,$1LUJ6Z]>JWXP<"U=:SMZ`YJ#'@_S_QJD@9]@X'`Z!@/]
M(8CB&3FI6,BJC9?B"`G?<:VVK;UV\/]`X.IMQW':KN<=`^$W5PA\2688B!TG
M\[NCIG[-:[NNT59?J8GT:\"K&AY<=^,8Z+\IU)[;E@EP^Z.C<:NM&7K;M%Z[
M?.U@X.J:VU:;T/?\F#F\1/,/P70>'!W9NT`'=ML^%JOVI>!Z;<,!YFX?10IS
M<XA\E@2CD/+[CH[`M;9IN&W3>>W6)P<#5S<=T-[/?/UEFCO&^H^4UMU7S\T_
M&+B68X%AW@!:/Z;9+:<S[6M7A/BVL'9:RLD_$O2JCY?&-;=CXM'QS#\#?=9Q
MM+9['H"V!#]@YGIJ6]7/71=>=-'^21FQ82PE#)_\W?K@H,%HMSUS:_NXD1-]
M7HZ7%U^JE7@YJUQ-51[.*M=;4+E6)Y']'F1O6>$R/+/M6:\3"=ZK9'@3O42.
M7TU[?H:G5`^Q99KG(:_G*SZW9ZUK[\\=FYS9FQ/VB,3)AQ?*D\89&&<Q<K90
MSA;*D6'M^-6B;=W$DG)TEC5G67.DLJ9)6MT+O`<_Y;7;3Q\;?1OK3G.SDIOF
MTUM3+O*IX//4=$4#E!!L$Q,%AU)[MO]BD[3%4\+;FFZ--3VPMFN)4NFK<N\G
M01?[YF`[D&":4D"R@^V961NE[E/QR!5KCM/!2CO>;748)[=!B!UJTD_3JR`)
MX_'V/5?FTY"]E>(GT_<@U4;AQ(_27]Y_^GVXT)-ET!M8MJD:BF.[0\7L#DS%
M=8R!,E0[7=U35;=C][];JJI]-]__ZCJV84G(VSW<9<1^FLS\,,'7OB3],)W%
MJ1]]N?T<3^\^AP_!F)T3ZW2S^VXUFNUU.T;?5C37Z2NFJ]J*JWM]Q;(&CCXT
M35OO><UJ/E:@"]O3()H4PE.K4X1`FMB(3&YQA?H6_G_JKH--F+!15-'A"KL+
M1@A81(#QUCHA];@:8<<FUL`IS%C[OED2/X0I=7N"ESO7O8)Y&+;:;N6HNTJP
M(#9[:K>N(I_:'&*=X.#?\Y"J!`O475*_47A9]'#D??X6-W6#_:98?RMLTA<G
MU-J/GP]V(@L`--&S"OXZNL=K0WT_1V$RFD^P+=0HP/9;X70<CE@G0MY2D.IU
MB[YIO+\IZT`Y\9]X!T?:`$=A%%QB4[H*/JD96F7KV`5L$OC8AW+<NGE"7%#G
M(S\)4]8Q=,D.J-<AK9#%1<NM^13[6N(SL!R6'H_\]+YUBUV/2JVZ;H+6'2`E
M8>WBGHK58`WLH$H+WR7Q?';9^G1;?!^$T#R`E49!,&9DD\XGN!WYPQ?OI,^V
M2UVZ,FP*-PZR()F$4TYXMW!.?&$&UP7O)AHQD.6]=&`-Z609)%+S50F;L(H`
MC"'MYHFWLUV+4?H8O"_#&:19.&$M(*O[K6R1421M#=88$RL-QD0U<N,^3ER`
M(Z#,9>>,K=B*[_&&?:,X91](@RC"#^+K*UJFP>V"95C7-/DP\G,8Y[0.&Z1F
M6=.8H[FX8FR5>W^,?^2_NP^BL0*W30%94=/#;U$%V$;(+.NK-IC,HO@I"*Z#
MY"$<!4L$9`1+T+^^W'[-Z83)OQ[B<?>RS/.&FM:UNXIE]TS%'`P'2L?J]Y6.
MW=55^/\=S>N_IBQ#"<`ZH2&EI=B*7F&-"$<2XD232$8/TA5CS8J)X1,6TYQC
MCM]:8S77?%EC-<M[?F,UZ_4:JYWRI\_]Q-YKZLI.6_\7^$EKP/O`GSN\'>)$
M&M?A[=4!WG&OM^8#K!W\4C4\QK<ZLK"L\\Q6[K67.%&W[+UEJ4Y;,U^[Q<RA
MH#6Q:$7=<X>9QD"KM57-;7O&GNOL3RM4^`_R4D2L&?X8C-4PS;"7VL/Q]5DP
M+*NM'M=PSYV`;=MMRWWMMD$'!UMK&[K;MM0&M)DXIL#BZ:13G?%WQM]KXN_4
M5?UO<493F):X+S':,4V;7Y^ZI3+IVGI;LX^@`NEUL&.X;>.5&EHU'SMZVS"=
MMFDTH+7G,:DFIY2[<\;@&8.OC<$7Y(_M./1;CC#_D>(7>+@_W5E8V+;-3M=P
M+<7L=U7%=%Q5\2S-5;J.J>H=U=`UMV'S%0$1F%F0HX).I:DY3;,DF/E)/H"X
M/#*OF-6)&3^5Y"58@.7"1-$3_BV847I&,>9YEH2PS`R'&I;F$_^CT[DJ?N[_
M[>/%.SE12<IZB5L3_\\BAX1-U?O7?'R7[XD/X(452OE(+#&##]9C65HB?82'
MYS&MA+(FVO"N5,C2%OU(^0@_I@[30$!L51I1*DLQ!%=,S".(:?IDGO4AKWJ)
MDZ09JOE@PK0\>Q(6J4-[NSKG<N*/`THPNP&DE!$#2Q2HP6&%?#:Q@)C-12Q&
M7]9^#P\U?*!!OW.VPW`<</*@XV`38,/LZ;+U94I3$J=W,3Y/0QO;/`]I<1@D
M[CG?;KLTI#%.@QRS\`V._XMW(GL"/]Z6TGGDP\,M/@"@-$83$,R+(\B\X4@!
M\V8"NZ=?M1>>>?0Q%30KICVWI<J*@!`"KRBC*)R&(\+5?/Q$QYO_*J.9N$#X
MR1QG[>+?Q#C(G#!&1`2_%8>)IE<%*SAMD0UBQ&4OWI5&3":M8M@EGR0-*)A/
M6)8JH_<PDP;[QB*WSD_C*:5[%*.F2W?ELM499;!S>#2=1QER;IQ?/0[A]E`>
M51)/.,7F6VW(W%&X5)A=P@@$V`V.M8Z7SSS\=/4%B?_+*(MO@J08ZBX1[#P#
M(L!TG3+/D5$=%IEX^9!1H$U8)$]N"PF+!=F5QU??(<'E!!CS96G:;/`C2$9A
MBJ0<COB0:\I=H['DBUE_U0_!1F$5*4&-I_)U8QSCCNENP&1I%FF;):"&T]D\
M8T=<<)I+6$,BU3ES$L">)\!$_6F`)/@@>EH10CBVGH>/&[&IL=A4.;6.QIJO
M2!\L`<Y<&9A_U9K.,<6"<>;XYE]\&CD>8SK/?^0C665.!-I*D$SA(DS\Y$]*
MZ2SQOY3+$P'D31AGP>A^&D?Q'0Y>'\_3+&&L@>U=W&5QF'XF)5(*8@`)`/NB
M-'B!J9Q%P1H,78LZXX*25]:^RIK9E^3.!R6.H.CE0@=5O>GX"CX,A\SUO:&0
M"=>Y2.CGLF[W*7^NT;,[FF4KFN>XBJGV7<6UO:YB6)8V[*JVXVC&6MT.3NLN
MG"I9//N9,0O^"Z:P_TS\!CT$2@H7^V>M^/G6GX31T\\K0GBDJFD@Z20$T@'_
M[F=,^+>^S`1Y;*+<27NUEVP5$:L`-0'N?S;_NM76?_-'2?R/`*03T/>GZ>BR
M]0%)3M;!%O@CJ&$T4QB%7X+7G`W)OL"<I<A_Q!1<@+TSOP,J+ZP3S<1<654M
M,[@01PH+\:B`F+G#ZP#W909T/O%'`7#9$4UD9L_?QJ,YO[V4#0T"G9)YBUP$
M^/$"4\RG\0,%,5MP\6,@RRF%.$'ZQ^,G[LU$T>C/Z!,I9;0CZ!F(P0S)^8+&
MVX]0\"6,L\^S.)Q,YM,`OQV@5*YP:Y[O3<(:M8%P!C)V2H<_2^+Q?(39XM,Q
MZ7$I8Z7L%L=P[X/,!YZ0SL.,JXI3/%Z^)J,FMON6Q$MFH`O!SB<IYQ>27$<L
M3+!B(!"II/@@Z>2PGT6LA+ENF*,)^!GET4_B*!B!6<C@)9E3A:9=,"Q)1J(>
M&B)]AK<A(3R)YW?W!#2I&/FH:&+MA%,\?`3M@M4L,(0KDV`<$IU-`BPL"-,)
M*;Q/*-03E'K\;26=!2.<;XPL^1[LC8"*$-C>?$J[AEW/$YR>`;;(38`?GP24
MNA[\`"[,63;0!:IA%^5JCA'2!BP'E_">:ST(&]N8P!$W*)*`"RMBSJ!K`$$&
MD:`G..L[4DI]3/^-(ORO?.D`"<I-D(&42>6+QP!!U.#RR?P.Y2".=&;ZL#AO
M&G?.1!.A;!R.L!9@A2JV"6?<`;OYDJM4$F.PVX5^5:`:_AO1]D&;"5&S!TJ=
MS6\B.MH848]'5;(606DK<ZD:?4+0*=-@!>.B,@L_HIMAM1U+;:-CALE:6>[C
MA'.A1J*&3P_@<3SX842:,YP"<24:":]@$\^,FV=(%$R^XU?^HMF7\`FXE6R5
M*JFQD?>\Q`1.E95)W`1PAX/<U,P5;M)7B6G\Q;4N[1:<040LXQ8H"$@$+RON
MGR[=8Q+2#Z*<))6LGS!EY44S/\PU0KZE352+7:L/9>5DX">H1Z=704+^J'V5
MRAF.9VJVYRFV-<3R@FY?\4#C4`;]?J?G69T^+-0L/Q*6^W]BMNB'SW&:?FP!
MCEJ$I,:ZE+I^"@HOMZ`_1+1KO`[BMN+F43\HFRB`[7`L9+S\JI^!<7TSSXI;
M6%SZ>]"<@9-R@H97'P,,U01CQ<?ZL;N@,`1*GP<]>Y[E,FH\%QX9E.WDY&2F
M$3Q4\7](ZY#)@2XK,$B0RB_!L(KF3"HL`I]#C?QOGI5A9E52_!+PMY#Y;`SY
M,KBYJB,C7MIQ"0E"36+PDSZ`_#.ADK`G#BX(U/N82L5(68,]Y8=(+X\1`ZB;
M!<SM1IQKJ2TN&[_,(@9N.@.+:DI"07BJ6]?X'"QT-4]`](,F@;6/+51(Q\PT
MYPZ<5!A>K?!6X4XA$I-\T[#$IMM>NFGF"Y+=1PWQ@URM=7V4A6TN:FFH'J=8
M6&>!9M$B`$T=5"!2APH/4C5<^[__]>G;0+F^ZO0`-BGDF3W&RBCRT[04J!7'
MPM;C>EQ$+J_\(HPQ8Q%O`&D+8U8I*7[SD70EGT4JV*D&/NE0]+&%JXH+S/P$
M;()PQMP4*>AU"?EF"]<!`$9^"^`1,^XFH.AORMR2)+O9O0VF8^;3I<O[0#65
MHNR5?"WL\O4EQP9LC*H"\P5@0T]TN]&-C76?Z.,CQ]Z,%_KB(NP36/^IR#>V
M\!B4]2!\6+"'O"KT&KV(::&<=12MW>HH>KO5;;=Z[5:?>;?[BK[*G8H<ECR#
M-P`RW-(L$OY:AABI9)04?XXFB9J((U0=L(2W?&&!$PYWA!IUFI5<.H\`7[`$
M`8!+V!$C*"2(_,.+3A7NYJ3*VIN@E;,,XGX)J60,G0Q[+1EI:`P!VG*LX3>6
MD==EJP/Z)><JTA'B/G(8MCNA&FP6G*\B,YCYP-QFTW0^F0B9MHI)@P+:$`['
M]`KR"#!!NX&.D4M;<HJRTLV:+JZG76OIZ2^LM72?7VMIGW#!X[G6\EQK>3Z1
M!M=:OA*8AZZP?"4PSW65S^[86%)4MLHW>X6BNP^ZK;;=[6ONMFEW>BC8W+9A
M:VW'.I+!O5M":;<=S6EK^RZ<.ZVRR<]!FOY<=C44+HF2NZ%D[J$MEQM\![WB
M;Z*+[X'$YWJF^&+.<1"V^&(P7\PZSA/*CK+T[9`=7<]8>]M8>W.:/U<?*N$\
M\@!OIS%$C2^8>PTCXEE8>2XN3KG5^AF?YS+.MU)"=TB1?<;;&6^GY21AL5B1
M==0264=+<ZP:K]Z\U&"VVZ[IM&W/.3T)O0OT:&W5-=JZ\SJ]K(X!/;K5MM4]
M-R4Y=8,+/T-QJ4U24`DA112KR<QI6]M+O=R^AUKC#*\7(`+P\#J]`]\N0DY+
MW=E1#/<(6,:IN6M>@(O7C1$W%2M'%5-NKJJR9919BC%?O"O:3&#MFG+CC_ZD
M-/7I47&KMQR^;KQA\CKA[N:CY1P>?YLARW.@]XRUXPJ/-T7A.0?#3]"Z.N7@
M[1F?YV#X6PE.GH.Z9[P=7S"\N=Z=<WC\'!Y_#GK.X?'3"8\WA0<-\EXV>7N;
MEQ8H'8CAG#W"!S0OSH@](_9M&G"GXRD\^U?/6#LNKW1S33?>Q/%LO)V-M[/Q
M=F+&VS%I)Z?D[CN[2<]X.S[W<E,T$OS,#?Z[OU';2T+`3<[*FJR8G.L:FI[&
M?T;(2M:R,'GS51KCXG@)UMH6,X27]:<'BX8F3/`)@&+"!+PONGOS!O>BN^Y"
M&K'4QODF&/GS-,C;9?/&Z7D/9YPTHPB_\[G?[O/Z[=K&\_OMKGAE5[]_BY\^
M=W<]]]MMW(DTKM_NJP-\Z,Z[KP[PN0?OLTRH8GY#ZRJ?ED!C9;:SD?83>]MB
MA0:&"7?O+GNI!U)O:Y;=UK2M;<8SX&_(W9+S"OW,*]X>KS`\O:T[;XY3'`3L
M-Z)E=,]\X^WQ#;-M&'9;-5XG1G[Z@)^DCM$[<XJWQRFLMJ=Z\+_721<Y?<#?
MB);1/_..M\<['-MKF[9[!KNQ?*-I7.+LQ7B+?,)H&Y[6]CSM#'B#>45S=8RB
M=K"7#Y-^33:R"]+0C+;F@OZY[\Z%9P9Z1MG^479:VLK_^DGB8XX:]KN<)Z-[
M/PW.*LS1WL"=L&M7;3ONFPO$'`3L4U=?B$FTOLPPH_6PLUAW00)ZVP!=Q7..
M2D_9C?*NFU[;V7>E6/,`U]NN:[5-[:`QE(7<]9_&X0/^^/>?YJERY_NSGP>\
M(?55D%QCVO=5'(6CIV_!CZP;P0W[%5YL_5T\?#VZ#\;S*/AR2\]V082/K_RG
M23#-.H]^,J9+R>_D/_UH3OGFG32=3]COON%V\K5;HWB:P0]?@]M?W@=Q]/UJ
MH#F>[IF*HAF:JOR/JJK.]^MO_>^&;7W'G$=--[3OZOM6./[E?3C^;AJ>[IC:
M=],S[4[7'"JVV]<4TW9ZBN?T#&6HZCW=Z@ZU?D?]CB_^BCC@**BRJH-G\_MA
M@N<^#]`&"_S1?2LF++5\1&4K3%M!FH43ZA$.O\W@G3'\`$_#"G>H2[7F*58#
MX%^ZD3_Z4X'SB2.L7*:%E%D28AY[:Q*/@ZAX&%[WBS-IA6SMHKJ`B.:M)?2[
MYLL2^BWO^0G]YO-3VYNXU#E=^[VU8?[\\[/GWRYR5R#TQ?GOK[+EEV6PO\J6
M5^:@G[J),?@Q"T8H?4%C",?!=-QZ"H-H?'EY6-_$X@FI?WW+'STMMUA.9`\Q
MEF=&8?;TVN2%#\JEO__[7Y^^#93KJTX/P)<L$LOX:_$MI?BG[;!3>T$7DI>"
M8&FO0:VVOC=R;2Z7_!JF?RJW21"`(0&(`)NEE8"9\MI$K%WJ9CUYZI>:]QK4
MH5UJ[NM\U[#>#AL%J">O+J"=8H4GT/W3\Q;JMW#JO#&GRMLXN0W";)X$Q!Q?
M7X7<6,9?JG8]&[4NK0;(^7P3!_]N'2]_MO=UMP[5LK-VZ(<)O@.+#\.I/QV%
M?O1IFF;)')=/F:-W9SY8NV,;/=/K*KKJZ8KI=@=*M^_U%,OI]SMF1^_!H@?W
MP;J2XU%8M?B/$/^!^&G]4SA@<Q2U)!S1H84Y;1=V\%9^T;UXD"=^\F>0,4=R
MBH"0+S<')BR`P48OK"\,\_C"*L5S:09LB1YKMQ[OP]&]>+HU\M/[4H\9G$@Y
MB:?!$RS`O^Z/1O&<WO5GLR3^05YKUC@&WD^2)W0K\RWZV<62)A(M)"]:'ITE
M[=9X3F.CV#+I?9QD"DIW^FS&FYQ?$B9Z\63F3Y_R?2"_;278"3W!+^.2TWBJ
MY+]!T`OW^R3P4^#,`DFT2C(&Q`2MQS"[)XP6Y-%AWV"K7&-_4+BG::L;H]/^
M0Q'B[_UMV+GN%C_W__91>K=X$U;IQ>/P-ARQ[CRE)3K7O?(*KJZV6W4D_)L$
MQ`4;&]H/TU$4XV\E0EY8'Y<L?>.RQ7_;&@=`('!DB"M8D[#5QJ@$<)TPO<?#
ME/%X'P:)GXSNGPC]?IH&C%K@U2CT;]"VQ60/CNXQ4(+T=INVG""A8>_5X`<<
M*&LX,B[`:/DW\3Q;=G:,%L3F\]W`$HD_Q;&I\-=_SWTTL?&B)('8%?T83F=S
MI&"V=<%@VZUY2C<&5J$(3(`D",0@.BE)>RD!4(`O`W_QCNY#6(4>Z?P&[EH$
MKP$IX)^G8P$YN[%PX_CU1NHM@C7W:'KA)-F[&'-IMH_;V,<8MM%4]:_/#-3\
M]3D>;]09Q9M2RZ<HN"WU0--57=]\(>WY6ZA^]W/P$$0M3<XH&A;4%"*A"5(%
M\KEYXM&_^=0?_VN>HDKZ[WF,_\$888!W`^@1NW[Y#WX8T9$2S?LCFBK!^#SC
MJ^@*S8!;14MH_/+9>M&90D^60O7G4BACPWSD-5#EM,5)O89@D3Z!9,?`<$=9
M](2L.YP6/]VD0?*`9W\).AVM.H+EA%[#EH,E^()(VFDX`>)/EA`VTPU*]R%&
MN5C>V"97!%<"&4)KY5H4R*^O0>2S[I_Y=OTHC?,]9_<@#81$(DQR.83;8"@K
MQ?Q!?*5ST.7\M.R<8QNB:$8+5**'`I_X211$<9+$0+.TFQL9ET+E&_N9?[[I
MYYN>WW1C\YO.R3N7.?.I1%],6<^J)%@8&T1YK3]2H0ZE@5@PG#[$$1)S"ALD
MC7J:<04TG=_\*V!W]U_S\1W3]9G2-?'A9L&N?%#>9F!DX.W!ZYL]+3@,T$!!
MK`27=Y?M'"AF8C#3!ZX?FCY,RN)7\",^:7*H^8/*-\KHMA*;B*(0U,4Q:J#`
M*.)12,"2T>&W[F"S4S'/Z6E_=VW;?)U]V;WJ&K-7&'L!XW_(<G/C;`F[Y:</
M9['"\L/,*\EHO/'3D$@DIUV1.R6=<T2D#V3,;&8<<LQ4^"=\>,+2N@JRF@5)
M&(\O"1!8O&Q,Y*9#)@$)*T[\/P.)?N'E@H+]E%O($LF/@L*<R66%3*NR.4>H
M>KS'MK$D*?AK4<AL7YX;MF!3+?HO7\4+,MS\X)<=.ZQ"37/]E!M5+["@CC/S
M[:6M;`WW^9EO*U[9U>^7?=IYO4^_(M1[__3;S5,KNNB:*].IECCKUCE$*Y[G
M%Z:J'_TQ+<6^_O(O[^:-?;>&_?^0N5ELXHKLSN+G<$J/)JV?^+XZ3._]C5F9
ME3^"'EKYS:?<>.V04-TM`;[Z+5V-W.O"<BAV\@4MZPJ6ON062Q5]I$&]6:25
MD?&'9-D=`$]'S]WV?5+?XLR/#DR;KP&G<(^_I5LH'*YO#^;#ZTA'G97$Q/JB
MF;OW$LK7>NX8=WK>\TZ>.[8L5V/ES>UA+@[ZN*I).0>_RUL.[_+4MFF8\#]K
MH_?W5__]1L!\GBU=LX_-$/#6FI^<,J:.7_M9S4-_P]1%$4N\G4_'1]@]Q&ZK
MIMWV7GV&P5N#=Y=7\#2XQ1EE)]_6;34[_1JD61)2D0LJI4?'2TW5;+O6:_=A
M>E/`GEG"&64'X:*S'QLX\P_`HZK<F+M#*4.D\(7^X+[0FN-Z+D/=ZP</P;K.
M6#M3W1E_A\3?\9O]JX,>%/F4,QJ>K:1&Y8KI<DQY-;4]MT)Z2[>CIMEMU[7;
MNN6]BK[R+`R=\;)KRCEEK^09LV=%>C,):8"$',?SFR@XE$S>_HM-4J7?%-[.
M&#QC<,\8K/+5\G;O`Y0`O[S7[.7,4WI&2C)?]L(Y]W$_"?@[3J@[^F-:D:EW
M*'&V=T(Z)^"_&G+/"?@O1%IT3L!O\$F=$_!/]VS/"?B'XR)'[8L^)^`?P4[/
M>][)<Z>5[73T"?B:V[8]JZUY>YY#MBM&<.Q@OMB)?RIAAC.F=AF0:;;V<_H)
M^%Y;-9VV9[G'P45/!MY=7L'3X!9GE)T3\,\)^,?"2)L![)DEG%%VSALZV53>
M0V8-O2&LG?%WQM\Y`?^<@+]*O7/;&OQ/55^G[\>S$'1&RSE)_(S95\?LJ:G1
MIY3">TA%^DWA[8S!,P8/G'[?="?O:N7Y<S'38LNTH0,JSZ_YW'[UW^.`[`SC
MZ\-X_-;\ZJC351+<!@E.<4UQ1'7KT4\2G+:5CU1M/)?:TI;]8.EMS]PZK>AC
MT\SZ4[:MSE;K:6*VH=?W;,HWUQPXF_)G0_2,P>/$X*[FG.YR\F0GQ2&;RXO&
MV^4IGJ`;IUQ?#K.T-<$4V(MWI238UFT23_BP:QT'5HJYUS?!R)^G-'U4C.?$
MH;D@E6"%&Q\'?,YG-+R4#Z+FJ](\ZH8,ZI3FMA:*B_>W-`>2C[G%F9VP;X`@
MC)Y:HWB:AFD&F(8EDG*>6WNA!(/J,B8+R<67^'%X7YQ%/LZ5#5J%5>%SN*HT
M()2&\V;Y[N!M:7]L3CG']8?YE,WZ#<8?5TX`IZ&_*X>)-^^HML"57H<K?)<-
M5Z7)Y$%V'X_3GVOFIO/YZ[`&P]I/*Q'6KAD67YWJGL^8EB9,XY=P2_2-_!-/
MK0]LK+.8E(XTA^.%V^5!Z0]QY&=\3S@#^M:?1YEX,LA&EQ^)$-G68(U\!^,@
M@<T3O--1./,CH'"Z\["=A7GK"!&\O&KN^B$GU+[6K.>":MB,W%D2/\#52G%2
M,_P)3O+13\9\$'@MAR%26..K://QS8\^H_-XBD<C9@O#"N$4>,^<QGGSV<%C
M'/HLW8+:X=%$_7@APF(<>6G6.:??#[R*]B-.(0:*HCGI0.Z=ZQZ\[>KJ6QM)
M;+LO&TGLZL\?2:RI#1B1VW"?X.H@1=>/:/HXW(PUW73.?L&=.Q:.)Y;%$L'F
MTR2`+?P'.-V=#_RU]2&*01ZG'X'QC:+YF''`P$]P9'WS$\:>Z7A;)!];M]N&
MN75_T@/03W,9SW6091$U\T)-8(FX/WT:LAVOK7OVMB3T-O.5S@G$S902FR@3
M1J.O]"G'?TZ-"YS=I?MU*GV:MLA\0[^F\"(QMY!D0C,COBJ^9_-D=.^GZ,(3
MDIPY5V_0O`[2M$4&XBP)TX"OA'8\?`4`#]-[=*B0DQ1-=%AD'*:C>#X5?L36
M;10_MB;Q&`SP#Z!ZQA/@.;-9$ONC^X^7)6_8'-T^_R'OD@_PS+(0ED0_4^'5
M0OC8'G"'Z;V?Y$XP']V9&?P+M@LKC"(_G*#/TH^>TC`5+@CX=!22?R,-$OP'
M8&7D1Q'_7`J/Q80+[CH`9$7!**//1>&_Y^'8Y]M"+`93](%1OYIX^A`D*?[I
M)KCW'T+R1W*4C\-;>CC#7:$2CG]`SVKV=-GJW&8!\Y>QWY1."SW0-<?P2'X,
M[CL<L^/*2.TOK1&B=P:`BT?D]P+<X8,/?A+&\U0\6OA>TE8Z1Q2E!8V@<P6I
MI,V)16`)05Y&2#D97;;^AWOAI_X=4Q\%;2)B(Z)1MB?X+5`FG`@[8AG3\"D\
MSD7\(HK\ULQ/LG`TC_R$(1=_2_NYCR.X$+E[>CDU<WLH17_E?,(!9-NCS0"M
MCN<CI"FB6WBIG8<`@FF0)?D^89<I8!'>&:/#*9[Q"T?O7Z(B+3FJ`%=`JRG'
M0!J4/O\8SZ,QNN31]QE.B1Y'8-`![?PT#OB_!/(6[W@,I)O!AIA[+#^/YCC`
MLS4V*N"SCE<)2!@^%JQ8(/CB]WY*+&$RBZ?<<&%N;,:#8(4/P0\XOS1`BYB^
MAN$05!SIX`%_66[RQ$":?D[Y1(X3V-L]O([^<K;D9>O39!*,0W@O>D*^%2?B
MA&I#,Y^NOA`<K2^C+`;UBS2N-M[7E;"W'H&5M((?03("&F;,4O"?C/`!'^6<
M$;9^S=A<7]&K*^9>65@/[_G\)@66`!"SR!!?#A8#X"9P(/32(@W]-`X?\,>_
M_S1/E3O?G_V,?:#_B>3XY78HG+R?"BYS!3@>/?T*K[?^+E[Y1!C\YO]@?_P6
M_,BZ$4*-/!U^^!K<_O(^B*/O5P/-\73/5!3-T%3E?T#4.]^OO_6_&[;U'1&H
MZ8;V77W?"L>_O`_'WTW#TQU3^]X;]+1NU]456^L/%5-53<4=F#W%T/6!UE5-
M^,_P.[[X*\+$0=J_<UY69VZ$PA;B/QA&6H"2@%G68:[/Y0\>Y"[;*ZYR7Q!4
MYO\0@3BD1CFLQ$(S0E;EN@)I"K>Y#+T)LL<@8/<PCPP``YS%24;2?<H^PAS_
MR/GI:YSZ2]^#G_&;>2"AB)$%4Y_BF[@0!93X;8[\1RF2A6QAQ$G_)B#^`OL$
M'>#QGF]0WKA/ET=^)PE04@5,M^&OPO49U^.J$K4DF<9$`[&E?*<ARJ11#/+C
M/XRY<5V*\2Z,PG#IB6"0'!?OYI*&@&,H8)N;%%W:Z<-X)@N[9%\&"8:*1GC;
MFH*UF*9^\M3&0)I/@H=X(]<U'LFLA`=#>G42)Z@Y_8D\D2*(TSCCF\3MT_G&
MJ+T2XZ-(-*%X<1^/(3R`;\.A"+EQV<HY3,&Q,;#(4,661I3B,K,X9;_)_#\#
M^F3EJ-GO0Z;'$OJ";)Y,$8P:"H95$3B%`:<@<`H##E@O:A]"`018\T_?!$B,
MZ1PVBXN!S&`2N[2_28#$D=V'++[)E^-:.:@<MX!:MF.))!#7>>R,Q=E`*;IC
M@59_@BHYVXLX%#H-2_UK?CJQC%F6\P#J!^EK*!]R)^#E\G2#&;%O_`1=A!$8
M)7F\EU,[R%P_(EJ7=*PYT$R"*"DA(ET4XDSR(^7@@UR";R*4EDF8LASZ8UI@
M%)[M,F2GGX3R]94T,CC"81)/KE#$7]&UHW7%IK>667.@6'HK3&-3UYSO?USW
MW[=^I.'/TS#ZY3T(T&!!L`V]CJ$ZFJ.8MJLJIN98BJOJ/66@V[;3L_J>:[H@
MV/3WK9_*H'X%-C6=!SO?+JBG0#)12O'&ZF9MJZ>[1E?I]'5/,5U-@W^IGF(,
M#,?NZ([3&71@L\;[7RU7-4S;=HL#%/M]P8'UY@E:8?L_LI4XV.S`M/>_:IIE
MJ7J!@=W`6L;?-2J*Q-'P/L-E(E;>0563F6S=I^*1*_\)?]7!G(`OS%+Y9X"I
M.9^F[#NYYJ<=$J-=TU7M8==0.O;04$P@':7K.IKB64:W/^CKFMVQ&%69KF.K
M1H'1?4%?QO'O0<:XSV>P;CH/?ABAR^A;W".]^EHR5KN@W8P.B3K--0::;3C*
MH-OK`3':@#JK-U!4RU:]?M\=.E:'N,>OBFZKKF$5N'LF5&64T,")W^,I-ZRF
M=VRI`>/G#61)'F#`UFU7,PL,K`:B<L\0'Y_`P@_&_3FFL#"2(7*AOW&*&@B[
M[I`X,#JVI0\ZP(@\L)#,(2"BHZE@'`U5P]6-;M<;#KY[(.&_ZSI\5@=RT%3;
ML515NDK/!7")`?@56!SH<Z`3X^/PBQXH-,#E"-F'1(IN#P9NUQ@H75VW%+-K
M&$JW9[J*K@Y=M]/K=33+`,*PWO_JFB"JC!I58R4L"_`3$^]SY\ZG*3WT19`6
MZ^MR2/BM@6?T.^I`&0S[2!1J7^G:IJ-XPUYO:';[AJ,A_!J8S`:2@EI"P`;`
M;,LD^V$TSPY[039DD\Z+V"2'JU9+0XG^#^;^:1YO1':@NYIE6@O:6K'O"O\O
MLTS$30,!<X&T;<MS/(GG+VY\W46^2H*9'XY?0;9M>(4!3-<P02===8/+4*R#
MN3.B&!"HI*,@9+F8S8,;KZN)$FT5W(N0K.!;#:1AY,^KF=+FBDHO#\)\N67_
MSD)`R'61C]Y@I07PH+FV:GG:9DK+6F#+>.M0E0(YN+_%G?&8C"T_NH([\VG:
M\V=AYD?UYL97#,2!<09+)P_A*&![^%IXL&@[#4:M!A?)M<',DFS5?:-C<Z+]
M/7BDOS29.#5BP;:N&Y:[&77F4)41P6U4Q/D(T)@$5PE:)]G3501"N#,=#^"W
M,W+X-H\?(Q9TSU8=QRZ0L#E$94Q\!M(!004/<#I*N4K21![]_E<+S"G\4`'X
M4@#*<.9.A^+&?;G]7Q$K;-XA@[T$=K1A>C7QPCH0-C(3R;S(?P7*619,#@K\
MAL:BC01N:&M-Q5IXRICH8:H!DC]3R)JH>H!8L!S;=FU7.NSJOLM0_2.8@GX=
MP=\[XTDX#5/*KGAHL&/(1C^MZL+UE8!<`\:"!HECKZY8Z=6X^_1'BCY%'M@"
M:QF+\@ZN7FUXG74#))?E.AH0>$F_W!"DC:YWCP*8GZ8BW`P/,!?"/T7LL9,'
M'IMWZ3TRCVU/7^\B>@:@56Y0**ND-G0HX-<3:1Q[],=_^GVX-?&0P#<=78YR
MK`5E(Y+Y/9Z.,6A-.CN_=E^#-/"3T3U<RS[+SSJT(K0AQ9AHLND6&"MK*69S
M.->9[(+F7D%-VE0_1+QHMNW8ENJMLMDKH-1$O+I5JZ.!X)J+5E7]WBNL`!@O
MG#S^9U`4[S/3H8JJ!D*M`]BVZX"59$FAEN<`M35_J,<N*BP-Y!&@7.FF9MK.
M5BQB.:A+_+2?>81YFO$50,3O#RN*M8`69VAZCC5P%,.V`2T=O:/`_RREHVK=
M7L=P!VZOQ\P+W:$*@!J?;1T097C[K#@<A$V6A#=S1`K:F8/)+(J?@J0?ID!C
MY,I(GN2'F(PZ*)E8AMG3-$>Q>QI<)T>UE<[`=113'VI&M^?V59>G$>@6V!P2
M.EX&XP:>WV0>C*6&J@UD,IH.:#%,V]*=-;[?"BP;\99K3$0#;O4Y'F'B*W_F
ML(C8D(L`>=@J:&#V6BZR#*A-(P%7_E-#PP`:($&Q@&EX*P,@%4`J?K<D'@7!
M.,5X%_KE4$-'MW$>XVL@W!C&7S3=UD*RT17(?\T9+<]5ZF3#8(R6,5+3/(N3
MI^)]RE1MW`7!Z(FG`0-=>T&V`WDC5\`G,'W2K.FN``US9!;\MYN#5`U\UQDQ
MS?4#@>(!\L352J)V)1#+.<B!$X+JM"W5Z@Q=1U4,M6/@D:N*BS43'NA@MM;K
M65YOR"/_6D7;6@M(5>.:);`3ND+P[X@T#W2<33`S_#][-LYJ0-<[75=S/0N6
M5H':30T434/K*SUGT--<1Q]TG`YC#)I>`7T36-;)2QHW"LHZ!7R0?I*'1@I-
M@Q+B7,=>:8G705,Q5UF>ZA+N>5C(-<<R/$?I>F!FF&!4*%T7#0Y0JVVCV]$M
M;\`.7CKRU=M?3NH-/%(#+[-G&.82BJ[$NT59:;TI^1K9+J8W5#U=53J>ZP*C
M=ON*:YI#Q>P;ZJ!OF89J#1C/6@A6;P3+IHGGO,Q`E#G`_?_$*R!>`2F:YJH&
M"&3%L1T+I5=/<0==2U%[NJ=Z=K_3(S.Q3-0O@&TC)'UE[@@0"J64]<_8P^S+
M;0=+M$>H8S.5"7[U.9R$F=_<Z@ICH;KB0/QL]>XW-0+5?/N3N^F/E0[59B8.
M6)B0K%N.^?>?-H!``K7^PB\6`'2K!0`#*IXOJEI_GV,'E2^W]#3H.JSF;A=*
M&ROE71=QL9V!876UKM(U^UW%[`P'2J?GZ*"P>0.[X^JN[9A<:_%T4&\$IO:-
M@#)9U=E-<JRK2!IJH"F(11"N96FHX#\?(`D12S-8!J+_*]A(M_/H<W@+JV.V
M\,[+H;OFH&,86`YM]#7%=(:VXG4-5=&'IM<9FKK5[=N'+H=>56C\%9-/$]Z"
MV,>*PBF/]J:\73,O!12EL:B6C2^I1%E2NL*4B@DI?;PH"\;H/+;^4:)P&HA&
M(_$#Z\H!2Q1-4HL&O7,ZH584/M1-C#KM[J%@\;VL?:BE/;]]Z*J.H_P1TUGV
MS&FU[NHQ$DZH@PLQCNWZ=+V@YY/1>@K\)#UU3%_'MQD(N^",W_W@=SA/0%K/
M7P'!FOHV,/S9IZ[G<?)$LC.^O0U'P2LR#NN-H!VM#JSK:H43[!E%JO26'5)?
M@.WK^SA!01'?MB+*]\`F%MCX(E=?;H-G-[@K>BN\4)N55.*\-K+G)\D3;SL/
MIG/(VB[]']#,5[0G!M,7F%15DPDL)57K&XIF6ATP+OLF^OLLL)L,2W-[EC>T
M+)ZSJQH&A_89&ZTS?08__$DXS1_]8PHZD_0[>O4Z\Y,76-D5*/NZ,;"&8-)T
MP&A63!?L:*_?,12U8V@N^L?<`8]SZ:JJ52V;C?<K`?N9FK>Q``_2P6\^NG^!
M0%@K@K@;]+!16W@;!N-.6D[I^<W_$4[FDYU!/]1UW?1<2[%<#Z!WP*KK=FP'
M_L]`'5@F&,T>A_[*^(T#OX/]2]@HDD_B-)6))I6<6E^F<$?VG4-2$^OHN-UN
MU^K;BCIP'`4092M`^%VEC\6<_>$`/:<,/:[%8QU;`;7M5=CE==_P(F#"C*KI
MVUR$\IW?E%/L]KIOR-0P34K5U6<RM>I-AQN!YI]_%WRF%D)?;C^SCD/LU+_<
M%C[?;D`!(-9;Z(]9//V#=Q8J>HO_;YC=PPL8$YZ#"8Y7;@>780;:I7P+]`64
MN4/;L;O&4!G:^D`Q3;VO>$:OJW0'/?B3:W8U7>4N\DM+H&SOH*]WG%%&CN1L
M"M)F^\^,][\:IJDY[FKWV4JP)*SPM`JLC\(W?@^R1:XTY%RI3,NO<N-TNG%"
MC7CAYB4T?(V?_"A[ZMPE`9$2IN]%,;8!V[W7L.]9W7[/5!7'L(>*J5N:`G\8
M`A_MN<!*3:/KK6^B.(%[$DX5T,E_UEQ4NODOF-KZ,^GAV`9<2>&^_*P5/]\"
MMXV>?EZA\M\PR^ZR=<5:KK9^"R.XDO$T:(DR0K*".,Y:.=+23?HJ2ANWE^P;
ML:R$4YQ-]K/YUZW@^$2AX6E`\;'6(S`&;(9,52"M*]%A-]\X>^!;'`'Q3$?H
MK/QV#_^<!?,L'*5M6&UTV?I0]&CK_2U_MOAE_V\?65=<T3UT3.%Z6.R_YX`Z
MT`NM\KB]B?_$6L51028U<`NQ&+6T$3\O^F5SYL:!:)2;<H]J^G/K0R@-UOB+
MIK8]2VUC^^X0.[V)GG`3<8PI[^R8M7F?5^'"#;$TV!?M_JX(20:LD"4A,"TZ
M]%NJI,,_BP;(27`WCYAMS'OT@D%$19<7[UBCZ!'39/X&^Y0W:MAMS;"D)JMR
MA]2_\3YW\(K\3L)I;B8(472\U"X=ZZ^T0_-2_2NN-H6C3D&=3%F_.[XW@&+$
M\2VFFLV`=4SY1+,<]?@'UNFV:%Q\&\!BV"67/2N=Y66K`P>Z]*S$$2,JJ3T@
M]H``$3'F+:M7T&44B0:%"6O'>T$S!BD?BL`=2S4XW'O/6FSF[OO6[W&!+]XM
MD.V$QLLMV_2]_P!8&+%%.#&S)HOWL#U8@%P00/*XK^7##P`U^1>BI[:@1J2-
MG&\(!)6G4=*N6^S$PR"];/$L$5PE*PU+#%/J:!G?@.F>]YN6WVWC=9FRIJ)8
ME8-'7]`$)Y,PY7TE[ZCN,%L\Y14-$C>5(M6HZ?9MT_),L$^87`XG-]ISAX,:
MRV?#GG$@M2U3MGSV`_IZ9:^V1OI*-'2F/#M>,?TYG[?8/!40Z_W`V'(6S*L7
M`RMAL)>/`>C);.$KYT0=UC`1%\5$=DI73-/&I)NZKC[H6CU/T34/,R_=OM+I
M6$-%5?6A`1:):MN=/&%G3_"6D!E%S(7,4AE%5X*<`^Y3W[1T,--[Z)YP!IIB
M]H8=Q;4`*[V>95FZU[<LU7UU?=,%]BXCB60;1]/N-<R7[#3O+4X-)4#D/:NM
M^,'4W]_17<[[X6MEQ;.DI?HM&M@#.U*X*H$J8_DHRGHRASL?4"MK('E?_PER
M:#36<W7RMW]T=$>COM`1ZAISY-U!:2PNKO8'W'723\BD`\G=\Z?^V&^W?@M^
MA*.XW?IO'X!HMZYCL/%;_Q,G@4^T\FDZ#E>-G)4)6-\?YM$S@6,%1G,!-RE9
M`H/M''L3?PR_!Z5D"AP95$'TZ:-*PH0=OO@77;U446N/J-MV7%8XY9$OH+D$
MH/I@92(\1QHBMMD*6O,9OO<70UX(#H#KYZT[&C"+:FV[]1?3*3V$QPBJ/@V'
MSBV'7(^$YS6SLJID".0O%!`Q\P%@<LMO,=UK\0O8^YSCZN)=/JB!3[XE+:`-
M"E]&`R^D+XOA(D2=C!K3^0AY]>T\HI$,!6G":HPHR]A$&<J&7U"C;Z9J+J*,
MCS?/@/XQ?R7!`TQ;[`54OH.91`&H[A;:3?E[]Z4Q-.RC@0_J_2Q&PP2;LM_.
M,;PK'4F[>NMJL8^$@0,I,M@S;!$3>3I1=A_/[^ZK>"_`$58`#K@HWB4.\L3[
M]*<9VB52UW0VV7UT'P8/>1]\1$.QDP\TEX5F$$0XJYC=>J&/RXWF1PDP`#`X
MF0%R@\8=F*H?Y0'SL%.VD6E,5A3A'[811-R>(!RRZ2^8MX2G6?LM'\TZ=LHA
MC1YA/`B?S/*;6M`>#A#G`Y5HH`=J#'/<AWP8.:N3[CJH7V20^(MT=-DB+SCM
M`XZKAE,P.&Z"1?M&9NK<I,$Q46Q@5VL,'($ZW$_"L9(A'G-[J$6SETK&SQ2A
MPUV`=A@"&:'%]>K<M'I-`C8F@6Y)4-C!J\052A*.2+PF=9>-C5CP<PJ1;JI8
M8H+YU3-$JG39V^0]"!)@-1/F,V`'A,Z.TA4GD5AE*H*2RG>4C>@0CPAJ07Y#
M*70)HY+B5;RQOKRKS3@0GVV0!"R9CRN\^'H^0R![JFX5ELAI,9^<PS=<<B3`
M=DN.#BX3Z86+?)X7!R+!U,*4L?PLE9(#TR`B7Q/.+@,&$E["79G&%^\*=,&G
MQ)PT&N9U!TB8?EPQ6$%"],6[94>7.V9H9$<MB?'Q2!<T8BWX`3^D6'[WA,.S
MB$?%!$L6C.ZG<13?H<<"_\U8=SH*D:_?AB,NH3`3,\(!:7.`:,8S`6"S,YSK
M(21_OI59!!^5_#&W84+3*=`?LZ!PL!EC--TKG'%=;,IV33H*E45-)F&6!0R<
M,5V$)0ZF_-&R!"LN5,Y.:1;7,@3G1XX#Y``,(KN0#Z;P684P_+J-?QP%I9LP
MC@-&]"0=:#R7XD<H8?A`NUBZ\'AY04U</CPJ/Q1RG0&2TD!280G2,O(N6QTV
MWZTM.4PCH'!@O],LU]X>R4^73U]!-.;>)4EL`C7!G7O*LV3S]71'F<!Z]Q=B
M((V8,B5=%A)48O(*'UL#IU_5"TJ>LLJ8D2I9E,BL<O8R3LJG?SM/1%=QF<7M
M1X5Y=9'4+R[>9@Y0-E">`$13K.*ZE*F!BQ]2_;5+HUB*J\N@='N76JX\,T)5
M+[V:!^$4D3(`8^@ME1A:SA@N6[ROS\4[>1-\B!OQDG6025/B8)&_:+(]((NT
M!>5>V"=<-(SCE`5*<FZ&/GGDD60M\D"$AL\1R?O3E-7^W1-[Q.`$8QU<FW]U
M&NFLF@8,IPAGEB,*3KO03"<^9Z(YZZ@[NC8?\B0FS_G2O#Y`V(BYR2]*([$N
M5VY*;U>.K]@5"GW2F59NJ$28\LXNWM7M;6'46!4ER]X'3G^G4/J=#-OR`Y<.
M#\];.G^U^+$X_0V*!NIH2=VK)^<:]+C<E:.O=.6DZ`!&^JGZ=#;SZ.!)D&%"
M-(@"F0_2A,69K<V"/_`=D!W8:D+H/KF`EN=V7HBABI+)33B4YUK#26>!@O42
MP<_2@.=^Y^LWA=S_=`)BHG5K$H.>-"?EF]16ZGX@!IXA?Q@':7@WK8G>H,K[
MVS_ZJFK3KNB?#@6&'D'YHAE9S`A+@.?!U_-/M3?T60F/%7+WL\^JSF<%Q"RL
MA!(9(X_AD4[)CU7U8MG6"B\6#\\B)ZHXF%9ZL8KX]U]@=33T^(LDF#[]WD=U
M%.X?J;!H?I%60R8^4E*;DQ'7FXEX4$<HD\]?#'4#5UG)48;RU*ZZ[39PE4G.
M"NYGD6TMQFM+_C!^5=,Z9]K%NY([K;UXF]%J%GX$)A@(/_QD\,"E%(9B1F_A
M=2IS,UR_T-V!("@W`)9@&@!3HGA:0L4N2;-TE5=-V"6U2NE&*BFCC7JE=+U7
MC7D`5OK5UGO5BN-<XE?;P*L&:ZSSJVW@5:/8^4J_FNQ5^Z-.99#-M(T<7"+3
MXQY$F\*L1E24R,E%!8VU7B[,`CE[NE[1T\48YE:N+OG5[9WM]!F:]HSO4X;5
MF&>$U7J2Q*CS=0ZD#=Q'<JY.K0-II?N(2'0#!])J]U&1Z;/:@;3<?402?B,'
M4HW[J.(<7^M`*@A"0B\R/@G!='C<PA7``3M2<DDO?S'WF"!55+Q-S_$U4=AC
MT=NTA:_IXEW9V_1L7Q->#W(WB8U*;J>-G4Z(TP6WD\?<3ILYG2I'R][9V#6$
M5+6-'"Y)8=D9?)3.(>$6TBOJ\!*WD'MIMW(?#XNG%BIBV>N#P;[?8UD5*>2^
MK&/4R&:)-UQLFN:7`_+ZA[#.^^)=FG7>%_GRP"I+_!S2"3S3`R/\'.[Z]W,O
MQ[-]..Y+?#C+8-O4AU-![*Y\.`<B&S!.A\%-,O>!QP`ZS?:"335F`:K<Y5&$
M@E<Y/)BE2,R<1"/H5T+,BH6KQG#N'O7A2&6K5S!Z2EV6\W!P8T(:4`A$^'V6
M[8>KP24EN&2?<W>LY*?.M[1V1V2X<$6LG!3@UYGCT@1S_"19W47>.%<&^;9'
M$;`CP6,W]"49JC+VG\I^)+@9(5``CYMP3]&PW]G,E^@>WI>XDY2U?P#._7%#
M,];^VY^*RV>L\G(NN"\95'E\O-!T%_6(VLPTYE^ZC><)]]TPQV/A:V1*#1JS
M@F#P2QR9)26O'.5&XN9,@FPZ+$'"A/P.VJ2D4;7Y*K!EYGWQR]<85Z".`X4C
M-GN,<Z].`M8O!=QA[ZCYWR7^!';+U[PGUEOPJ\<XB<:/(=KLZ!Y.2PXMYIEA
M(0@6C<G7>W76_*V6$4USO?4OSJ65<Z2%#!L$LQ1<JCGBME"7:_R/%Z4JG)I$
M,-3,Y!V@-[7`*O%SCE4ZO#H*0Q=>X0@*(A;5!;;$CO*R@@38J%"MESM,_:F\
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M;+=NYF`G!&G*"`R4PM5IB,T2-=O[8<61'MH->S"WI:2E5#+=.&M<FD*6\C&<
M&^1<EWR]X[B2]M62'7$\TRD)`+2@77'Z@=)W0\A?ZOV[;/69-X_<?_[H3_PS
M?84^`JNPSXB[**!G/'`-I*):,=_&XO=;'W#5:A:9R*R4'&Y+/Y8$X>1FGJ2,
M%WVL\_SAZW+"F2]EC>E:BSQ_Z58^OT;=6L1,K@!CE`'Y*MU0LC!!,``*PA3%
MY+_BD$A$HG;AB46#P,=2.HSI$PKN$&FL7R9IY#1>#]1HD7S`O;=!*E\]..-\
MUD0-$X9;\)L_]>^$_)*$X.-]0-*J-DF/-B[MEI>2^^5+PXED@?<\^C5YPY>M
M_R(;:I+O1][-1KO@*132HFWZ'(F4_/+>(V-LH6I(B5LAG!JP?\EAD%\*<=OD
MRHE&D=JBEY:,@8KV*_ODYK6Y_CFD&Z7=84&WK&[)GEVN#M6[^%X?>>M<LT;9
M`_DLU^P6.7&;X6,?Y8ZY1Z8;!_?HSVIL'>&741;SW#-U5>K9J%J]6=A'57]-
M`3/Y3M$^`7[1EGV6%^\J7DMF5X)A4F\^LU-/86.YYL28LNCB@9J[GQ:Y"*R)
M7UJ3[%1VQ0K#2MJS%+,%!I<[5=I<KWU2;IB+LBUA@)$L:DKUP5HRWBM.JS9'
M!!SMGP'S6J12;X(:<8(6.MI9/`Z);G_<W2GG1Z[-7:MW8D^%LG513E^3O>UE
M#155Z.#?\P#[3Q0+"9>(/YWB><I-M8OLK#S'C&QC)CO18P=7X=]SG[>6A$48
M<__&4J3J5D+K<R&>*[78+FIG:NL!%CT`I+7DYCYY'+&_25V.V:)<,S5)L!4^
M?&;\%CXE<KO61.8QX.0M6Z$NWLNC3*Y1^]*";Z&41,+(HNRNJ@U]\N,988X9
M'0JFR4F\2&3/X9*YC2;6I08S"U@FE6B#\L[E?I8E"'F>GX5[BK;SLRQ&<C;V
MLQ31[.>5=[):KYV6=\I,7/:V;.1KN7BWQMLBVN@S1[+<UHD[3PKKG)+52MZ3
M%3X1N9J?<XFV#,HTIOZ)%)N["15,`>"I05EX$X^?9#&(<A4V&([1JEG6YZ;L
M.R#BENQ[YDU?EF^#U!]29&&"EX4\V9PQ^]5RHGPC61+>W=$15Z*+BY4CS$8O
M,'G9PIDW[,[B)05^*5-H62OAXA&C/"NTT*S")'-F_Q?3+:+W2_70@MUS$=.N
MDPY<M-<D_Q;YZ#EA<?)<"-!*1##CS:/&BX4<2T_V.L"P+V)#T5MY8Y@6F[09
ME@)R&C_76?X4=>GBT?V1F"K/RJ*++EYY)+A^`Y^NON!WN(HI)."K6RGK,M-*
M?JE"#2M.X^)=2:(P!B7YC=IE9^)BI9UP'8DJ6N:R6[BH;:G";Q0KP#8F,=+&
M3P#,_-;G`^.>XW*35T$^5W@O*(.2A1\X`Z3?@`SY%T_#XQ$IE#/!72P:R1$%
M)"CPF-ZRT*FAG.:VN`>NRO!:9]FHDQU3DBOS0A1-$NMEJ"MPT"CJJJD*KQ%X
MS!1>FE.9$PMZ5F[],&'.RF<TM2@7U3)7)XI/R07:`HL+CN!#<`ELR+])F;41
ML##Q0YA*O&:M0_1CV5V+X(@-E"J#19%1G;]V9<ZQI$NTQLG\3A(U]]SW]11D
MI'P4N`S&[9)O-R0=;QH7J9X2NY6R/5%GGJ9S1MU+()>]@/G`'!2L%^4<7V;&
M$I^-9\"<,V2_U2H:;)7[B%E#90DPRMUL6#A?`H6"P7'N3GQJ?2CO/W>=(M.B
M[>6ZT>H3+>"2LB^D#WULQ'4340'9QRZEFZ_TXLO,F!A>!KPL8P.2_*4N?;ZD
MY'G/<VUK&)9@5Z!#QSAC2<1Q9=3SH'?MO>=J3;E0T%KTY',W]3HKL0E'5O+F
M2T1^]N@_RZ,?/P;H6:.H]KCAKOV6\$?D1%G>&;6D(F5;QE(VNN>QV<7[5$T'
M6R$[&T'T22`9Q2!X<D1.XC%:='Z1`U9V6E#I`B=9?QSGM3"=ZS^P[["G:`:>
M`M?G"YN'F3P-*)A_?E!%,XMD8Z3OOP`8CMP:`>,N14GYN#8Q?XTA6.K;4,FN
M7]L]X1DI\Q=2?G2]YZUD%"_D_3-^)_5[R&]7V653D^:U&$LB(9>'D9[1#D*[
MW"#`H^GE_/?G)=\[9</VV<GWUGZ3[\V7)-];2V"[V#CY?J/W7Y)\O]=`V-4M
M+'`,0;"5#1A8>P2Z+OGA(@&@.L<@7!KRJ@]X/>+U7)Z3++8APE3\&U2CK^11
M*A$(J@U359)9%B(D@A%=O*OE1"4/67TQN^Q>O2B5%3PGF:V:RB8[69HEP>K3
MB.M9^\6[!<GFU,<WE@95*BH-<0/-L^I764R`YTTRJQ&#/'8B!TV6=!(J99YM
MWL]2:K^UJ)F=HQS;1CDX#V#=ZV:(""1$ZH<:11N3$;MM0I/@YU]IX2%_29YP
M4$T678AVL%S1Q7+]BW?5V(?4.Z#DRV]3,+5$FY2X.!(S`GB@=#9/J.!;Y-(5
M_K#)+`HR7M,E6=E+&@%*Z>F26]QL%N/9/F%5R(V335B=+K8JJB^S7^N]9,TF
M9`>[Y"-:YW1MU7OF44!OZE]?[ETOAXGK_>M+-B`EXF_@83\:_WH-'9>=Y(+'
M2PP8_;E120!LD,LL/"T5AVH-`:SSN5^\6^]U7^US7^+BJ'C=5_O<228M>MV'
M_BB3BD]D,1L6D-9T1&8Y%<()#U]EUOA*7SUYK<K>^LU]]8RA<=5;]&78RD_/
M]>^7^>DY?SW[Z)OCHR<UCN?6+"13/=--?[%!P4/NII?U!TY*]'XYX?X8G/0E
M8[!:O9`;A94V?"2NT3PM>LC]K6!+;:X:AVQ>$W?'8WGL/)D*\KU84GJ7'V1:
M:"H+AU7S?=B[LDARXKS6AIE7Q6U65(6(DV=^M<T5RZ//V:S&=SAS/,=V-H_M
MY&(S))6-^O`5GT811\#BDO3N5.9CY9P@=-OFZLLV8:*+=Y5`T59A(C2]IMQK
MW?@*D'.D9O-(C5%4QI.;V[IX5PYE6)?ZFCA-O=_]XMTF<9I/%7.&'A;;18=/
M4NN9R^+,CUA?4)5F:=(81:DRO91HO&$!3BY25L'S^F>\,HB31ZTP'M/6/8T[
M'"\-*?Q`7'HQLK,D]E$.7K$Z'M3<5X5WFA:^^$>"I]_#G@D-C6'@%-KB.-=&
M,DI^%-G7SGNN%/#6#@++>U_4NG?0LZ/\U^"K7B0I_SF-'Z>L1W/GOW0=/4<7
M5/MR!ZH?<I,;GH(J^YXH[)&6-B-[>@H]D<_K89Y%EB`=C//&\D5;6;T(DK*A
MMQ=U+9WD72%-2GV=7__VKJV(D;&U04=G[5)=&#"P9AH9N5`6`R"U_1G+V*V?
M');WZ/F+60B3M5TW<!?EL,.S-K#87K`:Y"%=%9?.(J:M"D`K+FUY$O%*VEFL
M8TY8BB([+)(R/!&8J\-`6T%`(K.D#(_B.!E340`W<4G_1?6L4'#A%!F'S5CN
M/'P4?UW<^^`88FV++N^5G>[+"-VUN_M@WN[%[/(5#N["<\63!2ZJ#5UIRL8R
M>EKBTKXH)OULD4?,=K&A,[+.%0EOY_ZU$D?;R,7&,5`ST?E5W"C:KMPHON3I
M?Z8391,'7-4&Y(;,4DZTWAEW\:[BCBN-/*\ZY2AOI2K0:!/<LP8J#NBFNMJ(
M<ST;B<](YV-&UK+^"-PL7&A&MG$RWV6E%VXYRVT);ZW.O-]TXOT)N^[6Y??9
M%CO'):E]2\ZW71#`5FE]UIIWMT[I<VK!N5@[GVDM.$6FPB(X]K;@-,`,'D0A
MR.4H>FJH$<P3^60[&(<`+;>#:]2JW"2LUS,_9/$=.8/9LL7L\H],!044D?*"
MTU?@"R0\BT$L-=9F%LS@OW.P%]H@0>_A'Z*HA,SH7M_`WDWQ*.*9`\R@IK`_
M"FS!,(N-M%OY,9'\%87*]_(\)]XBE!MZ(NWP]65+O7E;"]PFUJVYD7D+E/.;
M_U2B&K==.DD:="J3D5]3O$SYDVK-!SE)A0N?02<-?*;XE?2U<G]/V7#F>9H+
MGWG]T_M2=P7=-D^L9<!A=@"Y9V1T`D@L5V<<C%CF`[6#25CI>UDC;/FW&<O,
MPQ;/O`\O'V]Q(8TU'_N9SQI7X^M729SQ30V\O]T5_^03!N%POCW-:`XA\%RP
M&%,B)9I3F.9:+@L`YC?VLG4-^CC_DA]R/T$^V9474((:E`#CN46E<(0<"%1M
MTJFYSSK-YF-&A7*'<JV:;8)Y0-)=EIP:]9>9P2Y1\65U@,$Z74>OHT[TF@!:
M4CI#&IE=A)XJK;XQR9"<(O&4FI!CPA['Z,4[*02W_&SPV@RFHY@,#738+9_^
M>U%.[A/CN\>MVOHY?:%^+L]MN07.'S^B2THJ-`JF"?R:`F6<)"HIA]6]W(8L
MNQDI@<VP8YHF0E%V#["F\2DWTYA5=_&NKDTN)U7NY7F2,%@PQ8)5XAHX=)F?
M2LI($SU"')-Y6)"__90C+15M6GC7P=)=1734G"A2,][$/$63A`\Y/>B#K\^=
MUHSOJ`\W29!?+!W<(8U]P#9GFA3R(IW/4"^](BZVV?S618OFXMV:^-,JBV:U
M_;1P-C^-PP?\\>\_3>ZF/W[NR=I09SK^S'2E@MCZ80H:2CI/@F]P4-TH'OWY
M*RS5^CN]W@]NT2W0BW'`X@V)]JO(GPXFLRA^"H)4_D.'NFG\,Z#1CU?`X6!Y
M_XZ2T9`&O@:WO[P/XNC[U4!S/-TS%;"7-57Y']"IG>_7W_K?#=OZCD!INJ%]
M5]^3+X+>FL'NWI.$F0#]__+^T^_#]ZUP_,O[</S=-#S=,;7ONF68/4US%+NG
MZ8KIJ+;2&;B.8NI#S>CVW+[JNM]QV5]!LU`Y=G8`GH2L88##VB/`,DV<_#W(
MOLRPD0L\_SE.TYZ?)$_#.'GTDW$ZP)[S="C_!T<](.5R2S15$&&;_:ZJ]0U%
M,ZV.8@[[IM)U!Y;2Z1F6YO8L;VA9@`CC_:^Z:A@<$2_:NH2"Q;=N^5N?PPEF
M@2"+_S+](PWP7?A6DNT,\([;[7:MOJVH`P?.W7-M!<#M*GW-,JW^<-`WU`$`
MKB'@FLD!WV+#6X.[RU/>$%@=@=6=K8#-3W:>*G>^/_OY<^"G07'Z?2`4;5N`
MOGMP81WWAZ8ZEJ%;WSU#AY=^P!\=T]`6P'6&IN=8`T<Q;-M2S([>4>!_0-2J
MUNUU#'?@]GK?P;BG"PY?<1754`SM[S^MVOO!H?,L4S/M[8#3$3A.NPIPN-<'
MSG,]RW%V<G(&`J?SD]L8.*+IW^<H&;_<_B8*\+[%W:`OTI&!H?5DHWW<28%U
MEX1B^@(\V+IA_-`T2[4M%Q!AJ+H%9VZKMB>+KRM6H[).@MF#@>9U.D-EV.OT
M%-,<J$JG.W05#ZA(,[V!Y@YL1N,F8(I?Z9>#WRQ<ZJ;F:BMP*;:V$V3JG.RT
MTT2FI[NV8QP(EW2%C=WC4K"!:QPYW,5:6U3J08=E&FT1`>X^%8]<,<=.!V7;
MT`^3?V+(LX-%@FQ.Q]<P_7,(&O`G\BFFV5?T5;P`VZ;A`+8-S5REM9H+B.UK
M0.UNUU8&75#03&`C"BR&2ENGX[JN.="&YG<=*52]5'7-*YCBWK&Q1^0/>,[V
M/V.P;M%'_G00].O;HE]#]-O.GI!?CXT]HK_/Y\Z`.G\5I]D#,VB^PG^2</1B
MOK/?FV#23;"L?1W&>MS4',S-^H_?5#]>Z#-7S%6U$Y0#JU==U0,I"LBL430'
MFMJS=5BNUP=4FXZN*UW/Z"M6UQD.W(ZA#09NKD5?:>K_5="\"TB/C:L;NF<9
MNZ=EC7-U4'C.7/T%Z-^2JVN,JUO&F:N__DW@7%VUF\35=TT)_1!+0J?C9M\*
ME8Y"W?.MD'%11CU?(86CHO.9BX+X%V#,TS20CYYGV1+&PC0V=<WY_L=U7T;<
MHJ/-&%CP)7NH./U>5S'[0T-Q7=U5C+YN&[IIJ-Y`_>YPJ]S67<>6U/1EX)2!
M[D11/,+P6SVR$6N8[;<]"AQ5LP`%EFOHVZ#`,KVAZNE@]7FNJYBNVU=<TQP"
M,@QUT+<`!]:`J0W`5`W+4G6)@#8#[G40XGJVL3>$Z%R/LM!(UE^&D%X\Q7`#
MTZ-0L!?QAY>X\1S-8WX!4S5!=X0C1$W2MO15O,585"N=GF'WM;[2-?&*]'JV
MTNT,-*6G]>&_@)W!L,_H@W0>39>PL0JR5\6!YSP+!ZIC6%K'TQ75&``A.'U#
M\3J:IQA=`^A!TTRWH^5W1+W43;>).+`]==]T(*X%*E_F$>!@'W2@%W?!:"`=
M.*:J>?NF`_(76J1NF/81X&`?=&!PM0&]>\WCB9IF.:ZQ;SHP<YX(GS\"'.R#
M#DSN.P<ZL-7&X4#77$>S]DT'5H$#YQAPL`\ZL`J>J#5/-A(.G'W3@5WP1/L8
M<+`/.K`+'4G;2C;2J*!/*7989+ESS/=*%@<F-5'7E7CZY9;].\.*X.M@!(]F
MK-9T:RQ9G@[2T]`\QY+PDM*'U\49C0Z0U*!C*:[GZHHYU#VEHZD]Q1BJAJL;
MW:XW''SW\-N`?57506HHFJ9ZE@Y6F^2R>!'P&R&2'!NO@,?-O1:;HQ)QJ:L%
M*M<B<C/@&T60FF[:VOX(TOKN"GH$6U_%5)A3),<%+.Z<'"W\/XP:&2)/DAAM
M6W?5O1$CJ9.,&'7;=4S8VTD28Q6+.R=&TL<8,1(BW1,E1E.S]T:,!NHRG#,:
MMFFYITJ+923NG!8-##%PQ@AXM$^1%$FW=O=%BIKV7<L9HVW8KJ8YZ]%XA,2X
M@,9=$R-B,N>,A,F3%-,Z9CGO3TQ[WS4]-V),T[1U_225Q@4T[IPW`B:-W(8A
M3.Z%''\/LD_343P)/K-V-B]""SQJ:%O%'C>]I.YWG2P[D]07U36L`BLE4,I0
MYF'[ST4#@]\"'^O#QE^F7Q$WB,8N=@OJW6,2P*?I'],D8%F\__##Z8[08VOF
M-NC1#-,%#J@KJMI5%;.'H=FN[2FZUU,]V[9L8\#];#IR+]TV3"E>OQOH&W3]
M#H%(X_VO-N[I%)42SU!MT]B;3F)\UX1^K#D8>Y1#H@>0`6PM^N,7D:*#.?DX
MT>HX,(<5!V"=J?(M?CZPST#6[\$C_>E(2$OSWO]J.:BNJ1LB*`=P<S9V&`+:
MN8@$%)%5I7,:VHQ_;4]`!V+Y!\.;*KC6(1D_+;6_2[@O9(%%QN[A9KAJSB74
M+7>?G@U82E?%)50MT#E.YAH>"G-P#4W;`)M_O?VXS3WLC/\U3S-*8_T6=_+>
M)E=^./XT[?FS,/.C^NJ0KSA\+@TS6)IF:[`]?"U&Y-%VC@;1FO/^5]?6-=F^
MW#=R7H4E'@J?P!+!++5-U]K0M;Z$*_*>)BD?_?P"!+BLDEUS75?-ZV;Q1\=;
MCQ#%6L"(V[/L/MA.BJNYMF*ZJJ%XUG"H=*R!WC'[EJYY=EYPY:*^)@N("EQR
M;3'2C^B<-@Q>=.B[AMD>F(/AL.LJMM'I*":HZ$IG8)B*.3`MR^X:JJ=WI58-
M*@>Z'BX)YC]8\UN>4B]=E!=7T*W$0+7OAJH[C@-'"'J#JYB6#F?K]3N*IO7M
M3M>VG<[0*$KH=.\W#MF:W4MPKNO8,V!]$/LOJR-Y#LR&WK<\;]!5NHZ)O48\
M3>D8EJI8'=M6G4&OWU$'.<SE9ET;=B&28*H(GVD6CL-HCAV7"@$U^,&:;@Z3
M>((\=<Y:EWRY'?C)%%@&UI(3U^U,L.[G)6@R5&M%/LN/-/QY&D:_O,^2>5##
M#UV]J^FFXG7<OF+:WD#Q!HZF=`>&VO?,KF=W.@QOH('^U$3`E^9-[`!PG@3=
M4,"7Q>AW`+C!;DIC`:^/!^\`<)[JVTS`ET8?=P`XS^ML).">;H*ZMH4;:@.X
M*8\1M#SXH.')6;T[@;R1R*RXVW=(1%1CZ#24B`S=<)S]$)&+<-OO?X5ONIZG
MOP4J\AQ-K</F#JB()8@M4-%5$L^")'O"[H<9*&@#,$YI#,\?*>CCT>?P]B7*
MIN?:R&%50[47[06G8S@`,%@)EH<EE)J+W84&2K?O##N]7M<P+4=H2;]>65)/
MB@TVO2&4`S'55;SY\"*3BN#U=`,LZ>W`U7D2_/5]G&#+Y/BV%6$;-#YI(VG-
M:9^M"$#<`!]UX!W\_#T#=(N:YG>;X,/@14)7QEZ.?Z=`.O:B9V0C($UA-38?
M2%W7MSQ)$7HO=Y=Y-I37H_M@C%W%R(595$5\N<6ZB.X3-3_Q1UF<Y%UMMX<:
M>+)N8[&':KN+C14\KVLY1D^Q]:$&QK'F*9U>WU!4U>P/AK;C>OJ`-5;`[KR\
M.6^UC_)OG:__^/2[TOWR[=N7WWYN45_DX9??ORG7G_Y_@Y];6O&+8>>W3Y__
M[^=6I5/RWUI\B6]?KOC[WP;_WV_*I]_[@]^__=PR_RK/@&&-LJGC,`VMK<RX
MGA6]>W$B3!2UTO!N2J-Q^*!?YF<+0/H5`SQ9SVWL)CT.J;[]Y^5]H]?!2[VD
M*Q!M,'2%0<._\4S\=;]\[0^^*KTOGS]WKJ[A)9HC,4M!SHZ"*$IG_@@01FY/
M_'F&7;[YSX_A.+O_Y;T+2`9L`:I^>3^B:17O6S=Q,@X2?$K>9B+_,!;OVS8[
M)`(K&Y>?>>`+L\[:^3<U=?D[N_K]LF][)_SIG\IGE-00E;N.IMZO!(6^6R;E
M-<!7WEC]+M\OIVIQT?X?\[:VM%G62N,H'+]?P#"0/=#Z%$FK2LW5Z3+8)+C8
MQ@";E1<_UO8LK\R<>1[`YT-:/"1]W1G5[J7F7RCO-GUVMZ>XU1O-PIQ^QMR6
MF-->!W,;<([U.@-(]SM`2@SB_?_U>H/!<+B$F63Q3/[+;$L-A>M#GP=#4.BT
M8%)1\13XE?@,Q92!]RX,A]@E]WHQM0HRHBDX]+ZE7=H;O3F-'Q-_]LM[]E]Z
M]Z_[WNXN`-2<2Z.Q`-9]]&4K+"*@4."QD?W6Q+9FJWN_^DVYZ-TXN,<DB2.\
MZ[IYZ3;V*NSDKKN7YFD#:.V)6Y^Z>/Y'&`7^^.ANK&8T^,:^">%U1M2;E/)7
MM^%_CE#"VY=J8]G%+N!S+YV3AD]3]\3O3UZ^QP]!,J7)CIV[8#H*@_3H+J]^
MJ9\T<=N7UDG#ISE[XDZG)5KS^;M'=T&U$[<N3??2.VD`+7-/^E'YAOY$47'Y
M%_F$X!=D4[Q^.H:A6\9B?TVKIUN]@6DHGJMZF`1G*=Y0M11+=;RNU3.,?G=X
MZ'0,ELZPOWP,?T3C37`@^2@('W")MY9[X=@OR[UPK"UR+[372X#8?]['.;C^
MWJX+=.+J%(<\)SB<$QS>2IC^E1(<3MY/<)QQ`,MHL.EQ=F\?G0W.W-N71W</
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M2W]VZY">I[JZT[<5K>/V%+/ONHH[=`S%\`8]4^O9O8'CY/.6-4O5/8<?P'[Q
M48F+UK9^7/S63?5;>2/Z#ASO1'0YG06C+!A_"Y+)"R89<KQCKS=SL8A_H*D]
M6X<%>OVNK9B.KBM=S^@K5M<9#MR.H0T&+FM/@>T8'*F&?W^P5AL<!+=!D@1C
M(O9^^!".@^GXJY]A"\T^!@Z3E[9A,73/5;$7EJ5Z2YKG?Y\%R??-2+7;-=W>
MT#:4H0<$:NI67^G:EJMH@SZ0Y="U!YTA(U4V^K,T@V]C:$L=!/.FKN77B\ZO
M5TDX>LG=W2F"[*ZJN6K74GI=`^>"FEVEHPUZRM#H=_O.0'4Z;H$@]$^H>5O!
MS0!]-0)R3<W1#D-`Q5QUU3T6\MD->C8B'X$>]-EZ1T(^U))./PSYB`X[1T0^
M.T+/1N0CT*.YEXYS'.0#CVJEGFQ[I!ZS&-I\--)K1_C9B'P$?HY(>(&>"+L^
M#/E(L]\-W3P2\MD-?C8B'X$?Y](Y&NK1'>=`JK/-6XHA]9C:L5#/3O"S$?4(
M_-B7GO4BZME9GWW>;ERUX0IM,)RLILF\;O<<VQUVE=[04Q6SV^DHW:%N*([5
M[5F`8:]KZWE+<LTT-^FL+_[(?RGU:/\MC((TBZ?!;P$8_>/R`_]YR925EV-"
M[1G=@350%<W#AO2]`6#"M'J*X:F6UK.]X;#;80G/EEK!PO,!W<\(@I<CP3.'
M?=OSNHJG#RS%-)V>X@TZ/<4&0N@.]($S[+D,"5J.A;4#!P[2B+\">Y7_V4/#
ML>$T/=<Q@?_U^XH[T!W%<7NNWC%<PS`=!M>741;SIOOJMDWWF7\RGU`0A`\X
M];"\C'CY"$@>U'73=>73WA`VF<JYS^^W.`I&Z`;_%G>#/ER+*)X%8T`JNFQQ
M^)!/$R`[V`FXM.@>KH78RUKAN1GQH%637X<7@UN#N\YT.O>CW_P0\#!%5W7E
M&':/(?Z!M>)S0[8!&#(J"%H'DX0&]-7[R>C^RTT4WA&2T#\:!?BO??(.VQUT
M!VK'P(F=/<745$MQ71"6GM7U=%L?=$R<5,*&L&B6H@JOR+K][ETGL+T-Q@77
M#9ZQ/+7;U3U%[8!&9/95$V#%=MBJ:9NN9UJ:K3*`W:HD/,BDG9=#J#M]KZ]K
MMJ+W/`^U'E#W;+,/2E!?<T`C[G:'&H.037Q\U;$Z%7"KXV7UCNT,0*FWAWW@
MX4[/5+JN;BF:#NJL9QK:T.I]YT-TM(8.T5D-H3T8:%ZG,U2&/6`II@GRJM,=
MNHJGJ8YF>@/-'=@,PO_V@9DD3RB[C1?)[F9(JS)U;RJM-D07"O4="ZO]L3+3
M4MWU%WV1=/HJ&'$>7'&OV\>>TC9P;4VWX9Z[GM$;.CU7HX"(01KMJ_*RS4"L
MX64]8]`;]#JV8G3@>R">NHJ+<PL<$+HHEIV>SL63UE"-G8%>`<NT>R!WN[IB
M.%W@:_V^I7@=/,E>U^M8IF,.K'YNF/[W?!J\7&/G7!%P`:]<^6#6C\(9GS&8
M<\A]PNP-[+ZN@C&N>GU',0=>#P?<F<I`[[LJR-I!Q\TU#5U5<%[L\S:^WWNJ
M:9;C;C`#ME8@=S1M8#C*8.@-%-/J#A17-3S%P8G4ICOH][K%9#3#>L6;^@(@
M!Y:G62XP(D/U@*3=CJJXO6Y7L53=[)N.:@";SH'<W+P6[/LJB>\2?[('$/G*
MZR1/I],WU8X#*C`H4V`G:;K2=7JVTC&MH=;Q=-?I=[^3!TVK2!ZQ]4-J^P+*
M[8`P2-LW%55KA+9/(3QK*ZIT/*_?[WL`YF`P5,P.&+8=N^<H?6W8!7;4-X9J
M,6;2?<6;]P(8M7[?-`9V1^E['?1RZAT%[!NX>4-GX+JV,W1-/4]R,ILI)P7X
M6X-6<FZISDLG2NZ!A+>=E&IUNL!!@;&"E`"#5=<UQ=4'AN(:W:YI=@$#/2]7
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M`6U#V^KI((243E_WP/31-/B7ZBD&V'PVJ)Q.9]#Y#GH*PYM$GDO`*,/ZOP'6
M>P3CSD.0^'>!H$S^+"\.*.H`]G(K%YU/F\*,Z4RJ:^B.78#]3(CV>--$`OD_
MXPB6B<+L:4]W;9%H-KQKE&QI:7NZ:?7P;T!_R\ZJ,_[7/,V>&_I=0X>K!YIJ
MKC'0;/2N="F"9:M*U^H-%-6R53#^W*%C(25Z"]-,J[</,!:.&LY"M'4LA(#8
M47G)%T8DTO%6:.%K,/%#_'POQHJO43;W(ZS%T+?'XH+K3#4\JZ<I5M\U%-,$
M3;?3T\`*[*FVYKGJT+9[WT65B?&;YO9W4&JR/=Q-K.M9B=\-N9#Q2E4\.V5V
M_3"E#HC#.+F*T^P!-`LXPJ_PGR0</3NNM6\EB^=)6\Z>6/]Z;.SH*/AM^@<\
MF*6?N'E6N5#T1S1>\IV^$A_NFJYJ#[N&TK&'P&\L%X2)ZVB*9QG=_@"CZAVP
M^U@%C6?NX&BVP\X!5"(Y$[9)"I%:E8![A[Z,[-^#K.>G]U=)C$^,NT]_P+*?
MIE^`PGR\01VX/`\T#WZW)+Q:';<&GM'OJ`-E,.SK@#(54Z!-1_&&O=[0[/8-
M1S-0?[#?_ZK8E@NBTRLPN#E(&UDF"TKAKA2K7=HEQN9V23T\E2N(:=%89`VD
M,\>>3NPBLU=9J;8@,,PU2`_H/7%4JS-T'54Q,,T+2$-57!6SGCS'LK5>S_)Z
M0\;27!OGDDLWZ]E`E9'RQS3)7:G?_!_=8!K<ALCE6!$TUJ?/(R2P81)/KF#I
MA'T`G@61%.Y*))<NT6I;8NAU#-71'"S55\&6<"S`E=Y3!KIM.SVK[[FF"[C2
M%VP)[CH^Z)W?D-2!TFW#U<$8<A=\X>D+#JPW3Q)@I?L_LI4XV.S`P#ZP7."!
M!0)V`^IN#:U_@O*%C)=])Q=/+]#VGX_0#14@("K7\52]J@+M`?HRCK]D]T'R
M>SR-A7""$XLG`<KMZ?/Z3!SH^GE836";IE5@:C4,&PD60LV^Y,K&*#`ZMJ4/
M.G#G/!>U#L!#1U-[BC%4@>,8W:XW''RW5<W[KF,@"AV@<$_U]2)F.7AE[##$
MP8W$^,]T%$8A$1W\HI<$8[C/A.I#HD2W!P.W:PR4KJZ#%MLU#*7;,UU%5X>N
MV^GU.IJ%BIB%50>>9<LL:3-@%A!`_*H?B-8O]%"ANJ5ID#52$P5]0W%<M03^
M!J#4BEWDT<R":B`#0*+70"@YWH+X+?9=87)EQO`Y3IL(F`LR0%<M0Y,.L6;G
MZPCV*@EF?CA^!0Z^(:D"G)ZFV2M)M0S$.I`[?!3'UWP21P/!=N"":H:%W5M6
M0;X(RX*]W&@J1D;D&C9HCE;)(EY&P$6$(_T6%^'A*SC]3].>/PLS'BM>4(6^
M!O^>AZ`X!M1A<A0P42=E+NS!\;5;^:TAJES#DS"U;W2LNTK"80EK^^G],$Z.
MPQ'CX>5R'$/75MVM38"KE.[SFC8XBQ&@-PFN$M0RLR=L]Y9UIN,!_':VH_C<
MSG4"Y+2FJIJ&5)Z_,4"U"7SP`">O;5+Y#L6"P#KU;!/=<@MY>XL`E.$LG)CY
M1?QR^[]^<G!M:,,SMI#P+=66><A*&#92^$E3S'\%VD<6/"]5_$!JO_W^5\?6
MG;4Z?RT\94STXC1+D?Z9RM%$T0H:A&79NNJXDN>INN\R5/\(IL#A(OA[9SP)
MIV%*C40?&FS?V^A(UES'E<-!:\#8**(P#+%DN.F"3#<6;/K-X=GH;O?NT8'T
M:=KG'4C@`68*(LM@/B:<BX?EU0V\\2#H'==1/6/MG7\&G%5.(+JQ?+DEGPGK
M5\.[MP3CG?L/5_O0-R4<=\&)OJ@`"5R\@NS>5&<Q4:"IKJ:J<DAM+2B;1'`;
M"*ZY:`'4[[U"HL`/L-06_H/ZVH,?H4['-/XJJAH(M8Z'[)B.I:L2GWL.4!MQ
MNM_C*?#+^8@Z+G%148]=%*(-9'8@\'7'TVQK+;-['JA+O&.?>:1FFO$50/+L
M#RMUU65#TW.L@:/`6A96EW44^)^E=%2MV^L8[L#M]9C.JSN58I250)3A!<X1
M3A$I4S`&;^94XP#&SV`RB^(G3,5,@<;([$Z>Y(>>WZ/MQ61B&69/TQS%[FEP
MG1S55CH#UU%,?:@9W9[;5UT>C0,RTF0F\C(8-_"W@:0:?P[]&TQR;:8FA=$1
MS046L\[=5@%E(]9RG?D9VI*?XY$?Y<\<%@\;,A&LW3)M5:^(T^=`M:G_]<I_
M:JCS%5UMBH/51<9*#U$%DFH?QW@4!.,4PPQB``"-$1#C`QH(N+X8(UP+QD8W
M(/\U9[,\XM_)AL$8;36DI7D6)T_%^[O)?-OU_<"J/D^W;6V]E-T.YHVLTT]3
MGC'::.M40S]KU:6X.4358",K@@>&P_O'3`JIW4#/!,:8+=/02YZ)E4`L9Q^O
MGFJP81:;MI)[;)2S-D9O#:H7P5@45Z#A/?(Q13V6&I!,[ZZ#T3PY..UO6/"B
MU<2UMH2NJH_.$M@><1CX-^L"@:ZN20QO_V?/IFM=?Y5.U]5<SX*E56`&I@9J
MN*'UE9XSZ&FNHP\Z3H<QSKSYP7-@V2@$!:8,Y:_PF3M-Y(4&\$++,*S5D>PZ
M:"K&/,N&6R)<#@LYD+?A.4K7PSIX,+F4+E;$&V!TV$:WHUO>@&?K2V;[RNU7
MPVFU]Z%?7"*@E=I+U4"&8-<PA.T!7,X3&DC[0/J>Y7G&DIM?B?`+?OC_;^]:
MF]O&D>U?V9KO3/`@02*5G2H]K%G?ZXQ3B>=^33$2;'-7%CVDY-C[ZR\`4A(E
MRQ(D"U131-74Q+8HDNAS&F@T^K'9(7&*0!6?#Q`GR.OP2-56BOI>Y/L#S^]3
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MV1"+W>FE\G5/\F18>W"@82:(<N:'6+Y#5?&./O#="K<QB&BU;4D94C3WG;\`
MU,9(::/\`MVNC`<,=K5]C3),A(X1R).1R!;E5+.1(K>>YM1-E5==.U#R'(SW
M*XJ(-/-ZW".8*T^0-(8[G6#@(40&]*(G2<LZ"[O/TG@W!UT.TFQE]WRH5'YP
MPCC&JO<8#]A!@;T7@7P2&WAAO]>5VP2IP%)LD4?[A%$B]PO\`A7MQN3TO^X3
M>&LX=>Z2I`A"A`,I@B"B;W3O.\*>:=YZ69W?1NQ]VZ:Z!!)Q9E"A]]!-I!*(
M5!T_E+LK_CZ!]*J=P%5-KV53ZX-#DI08,%^TL_C!Y<4HE%)A`:E*97=K[HNP
M1UD?2[/;5RK2ZS%E'6"OA_OR7RD=:9@7_-!ENW`U56G;R$XJ`Q[N)0,4TD"5
M_976M*J.&TKCFG<P]VB72CY@[$<=7&E/CB,?H@P81SMXL'TO:<2$4C'6-\-V
MQQ;Z*O?",L>I&EG14QHBOJ]D8(/C6@9%Q9UJ\!(0&13%O&WSP%_HN1_`X\%K
M&=C@@99!T6(T"L')H"B2;9L'P4(&)"(-D($-'@2+.=&OAB%!DD%H?\UCQ:Q8
MZYKW>FPV\&6EF2MMFI`>@N]1LEK5H`-.U#Z/XH-L>M,$SN@'44??V-\OU[6^
MJD8+45#$?+JWE]A4#O0'9DH.*FE%[H*JU4O>6>NHMCH=;TKJZ*21P@KG53LX
MWRDJTYH=)Y`4D9M[FY(*?^@Z^T5]$UK-[WNGK*`FF]<OVI.GGK^C(\B:Y")Y
M5=$I(#I.-XA>P/I^+_(B'#'/CY!<\8+!0'77(AV_'Q#,6;&+7S:$,.P/TIE,
MDY$J]9P\B65TR,7S<#P;B9$NC27%.BL.L*]OUXL1OR\#08F*(K4'I)B'P0&+
M0D2Z6+7V5!WC?,8O/'X18J][05&?^UW..IU"+JIS`$>J[42%7<<8.D1I2HDP
M;$F:I/27J;-81,,V2),Q$NU_K&TD33K761PP:;BV0YH^9G:D.?=OR._(+[5`
MF'HK%=D1YGR#3"G'G./SER8GOK14[`A3[T8C*4SB\Q"1-@B3,^S;$6:HA!FJ
M5#H41BU0<VF"TS#<(,OM#B`C649*ENR5`PC&N'F(T:9Q'X%#O#P."!GW6625
M0T?;5BP[:_O(/V@?05@O9-&@Z_4&7#5;['2\[H!0+PRZO8#PB'<96>PC,%[/
M:#YAH\'320)OV%$=VF?0'B5L=QBOY-88\N'88ZRA.[,>9&#4G?F$K#<5Q*96
M.Z9RP/,&SG`Y7T/+8,T'BLDI:5]#,U4]3+Z7<F_UI?\I?NF/]C@U"2E2GH5E
MKTTY!2/E`/?I_GZ,,.IV5/R;ASL1]WS<95Z$^RI9D.'^H,_(@+!E,W:?4$Y#
MTW."Q=C,\O!U?295`&4U<O/H@MF#^\;"41MI?WWEVW.@1^[IR)'NR(KH,?JQ
M=0>47G3Z<KV33Y(6@%P#$0\]A/VPQU`X&"CM4(Y#CWRH%O<R:NGXSLYS)Q@H
MV3G0#4U1]F^*83"R%0:_/OXU'(^V5P(>;5K$\J,<]=8V%%4IA,KU864H6PYU
MWZ]G6"]%1Z$?[?&^WQWT/7SA2TN[%\G%MH>8UR51I$Q-?M&EA9X=T#GUO6I6
M_SAW=H@]CI;M'M@.:AH.1Y\W!7BCJ7@D+:MK**JP!"6H=B5C<HFOA7SDM$I6
MXSCK5;(M`SL&,XNM=R@-/OM*9GTHRJ@,_+I7,GH4\AFMUEK)//2AVC>I/BVK
M=:!DYT"/J&9;1W8,,ZM0,T(XMZUF-0Q%68Q$5<6J2\U(,7_PNN9X>J*UK/YQ
MUK26[1[8,18`JI6,H8A85+*ZAJ).!AC"-2L9/0KYC.:1N9+A4RA9K>,L$@"M
MKV2[!W:,Z9\6NS)"K2M9#4.12L;4,5_-*]E16HT;S2.^-ACQ!TY.LI35.5"R
M<Z#'7,N,RPT>N`#H1N4\M&HOUC42;2]B%-2]EAV%?48SB5_NR[9-\A87LSH'
M2G8.])BKV3O(:3@>93+Z'#'KJYG]H6A//MFM9^6;ZZ?L\>;ZR_+K8C*=UX/1
MOR<C]9?;1&3_R(?WXD'\\[?[Z?3QT\>/OW[]^I"+X8>[].EC[_)_I1FD,C%4
ME?_@\\?EU^8W_KARY\^/^F1T^9Q\&F?3OBHPK5[*DV^J;,?E7Q<7BLFH<AGQ
M5`GT^=_FCZK<_//'4B`'28=`E`XQDPZQ+IVY#0=*.M1#H1%W5$UL9),[$*5#
MS*1#;$IGQ9,%2CJ2%+X9=YA=Z1"(TB%FTB$U2(="G)41-I,.M38KKT05@)(.
M-9,.M2B=K?%0MH6EY"'N="?:S\\_L_$H^22>5;W?9/I%J)JB_Q@E\E/5I^^?
MORW#R:0(U'=T;<EY_[[G)/_M]\4E4BXB[ZR&3A5W_/QQXX-^EQB4;[(_CLB,
MY<BF9;8]VA$DD#T5VB^R1RFRES_C!U%@6!06%?E5_#/-XFF:J&("*N=89/80
M-)^G3H&@"LMM&H(7X^0J&8]?6HE9&5'>-,R^WB;_U06;6PE:F?/1--#^R(28
M]+(TSWMI]I@6A7A:"J#.7FH:@-U4W*NH>*5Y=V)\+Y*'=L&WDIP($KUW)C%V
M7S;?H$*"PF+MOQGWWTI&%&FZ[6-$I;::8\-:`GQ[V5!6IV\G]KJ21'NQ+YLZ
M5^N?M9$'\_HL[2-"U4@@;EW84`"IU9SH.$YL*C'6;DY@QXD-1?Q:S8FNH\2&
M*IFMID3/46)WC5F0##GV^9GQ@V]>'E5GUF5_NA52201&WY*[^^E-6G8!ZZ7C
M<?$V[=NW5&L^@V31XCA=M6:<OJA))9W(7]=VH&\4BVXGFKJ,?)/1E']_2"=M
MG.6KW2.:C.`W,8V3R;*W?-M@?+OS"4A47[5)Z;YTQ61X_Q!GZ[%+\5CL0M/X
ML5_B?Z=9;Y9/TP>1K=E^[8NHV=8+J.&LZ0R'RAK,OXFA2)YB:<L["MFFT'I+
MK893J)Z)IYUQ8=NZT36<-B>8>5K-H8U='1O.H7JFGI:&-V[KB-IPWIQ@[FDW
MB3:V%FXXB>J9?/[Z_D?Z)+*)=I?>R3=)=CZT+11R\Y#CTSOXM*F;O>/3OGSZ
M(QF+>/1=TDB^9-[:]4VG$+CU;7_^N"R&MQCDIB-'IT/HA+`*?(XX`\J?HL3.
MXKCJ*AUJ)JT?4^4BSH;W'2FQ(AA`'VT]J[["NUATIH@&$24-1O0/,1%9/):`
M=D8/R23)]0SR)-J)*>,8J^-D'@`-[Y`*.,UFPZENO--+\ZD$3BEE]B1>)1M)
M)(?3&Y%)6%L7J@.K,`@(\0252FBM#(A[#\&-2[N<`D%74*)AF+F"$@T$S164
M:#R`RK78/`!K=.6!!L]5`VDB?&4!.A*&0-$S+D#7K2V?!C".JM5`PW'L.1SE
MI1AJ+19C'/L.QV+W!]3_N`7(:E[SS:_4`8EQY.,0-QK(ZTE]&:>`@60!XLTS
M=:H52=JND2A"O'"-^D"/`;Z.X\FZ0TWGEUWJ0^#D2:@K)(XW]^DLCR>CF_M,
MV#S,@0LC1A$.@*Z0&V"LE(12GZH69:V$#=$@P$`/)C;`5E&UCM*V))L*463D
MKJADV[`,"-/I\A2LM_M5U(PJA[!VEBK7P63ZZM)68DD88F"=X"98EM%)+4=3
MVJI,EV0E!*J)DZ5RW-,7-6NJ*`=EW^AHHTVH#F;9))G.,B$O'"3/ZB>;X=.`
M`<4A`^J?VPO0HAB2R!87M11-QLY!/>=H?D]OI[_B3%Q.IO'D3I6HZN2Y:">V
MA$JSZ`RPO1)Q+N[3\>CRX3%+G[1[H95SK^K8A5B3(2U"J\JXJNQ%7G9]>YL,
M15LG8=?(X)2-#.`RPC4R<&QPC0SJ:V0`&'O7R*#&1@9@>>`:&9RLD0%<3KA&
M!J=J9`":$ZZ1P4D:&0#FA&MD<)I&!G`IX1H9G*B1`4A*N$8&#6]D`)%5KI'!
M&:+I&ADT'$'`OD1#!-OI#71M*,X'1DRDY$.@F_0=.%;=<6Z;O8HJ8!?M'J@Z
MA]H*JI"=K.:H.C?I*U3!NDGW0-7-P*NH`G9TFJ/J7)4KH$)V59J#ZIR-KA%;
M0[IH-8DUKE:RH]#^%'*-V`Y@33OK*;I&;(Y#1^*0:\1V*&U:6A;4-6)S)#H6
MB5PCMD-Y4W/CK"91R,U#CD_OX-.K1FQN2H+7>ZU)_''SD2/3X61RC?P.XD_K
M"Y"[1GZ.3D>EDVOD=YZ(ND9^9X2I:^1W1ECZ-%2I*CP`.N-^4_E&JZA]D1KX
M,&O;VE@@)7_S6UQ&^UVTB9_;31N8/'%(S9$BE"KCEX6T;6W5]EG9-YC6E:S4
MQ8J>?A79;9H]#-+L>GHO-UH;ZRLF0V6_=>[DS*.^K>R`MGFD->TP\7&$(\<[
MN[PK5L'GQR03HZ*BTX)ZK60=#A`+'.OJ8%V[Z1;0,'KF$0]"%4-+BJH/-/0I
MT*Y0\Y*RWV<__RT4OM=9YRE.QLH/J3"6'\K=ZN1.%PBNHJQKRDJ^+"O-?G^,
MAT<SJY5?73_S9SS\SXWD82[9)Z_HBWR8)8]+STD1;3N3KQNWSC^BR891&%`2
MS-G&`Q^#W:D=2+8O\61V&Y=NED$\3,:ZVLQIN';EB.:F-4<U*U2S3J:&B@>O
M]=%N4^&H]Q`<FR&(3X)@"#6-=@N"-207P,6L"!)O'&9U!&7#!0TQ/T!`*X9L
MV^K+[?.DEZ5YWDNS1_O5[2`#J&)^&@=@O3$V`.%SC5=.VG@%+B-<XQ7'!M=X
MI;Y2BX"Q=XU7:FR\`I8'H*OZG7?C%;B<@%P3\+P;KX#F!-B*@N?=>`4P)P#7
M(SSKQBMP*0&YFN%9-UZ!2`G7(N,,T70M,AJ.H&NR<`XP@MZX0R_'#Q)55[\3
M>NU%N+1QM1<AE\V#RQM7-J\A9<X`4\A5%FI$*1B0#'*E8,X345<*YEPPA946
M`$$\6$D'H<#%E!M!ACP4&$"F+[,)&8H<9&:0H<@(LN(RJUJ&$9V?+@4A*W)O
MB+(U"8^0\F1BJ-&,W5F>3$2>=X9_SY(\64LN^Q8_B4DW2:=B>#])Q^E=<M24
M\L7JUAO'>7Y]J]UI:Q9NX7VKT^-&C29N>9EE2N%R%M`<*MVH[8MX/P:9FN/'
ME9?9-0?4P;=+5S*S!]1:;V`/R/]L889*S$CD[`$S$XY[A!M!1B)[D$D3+L2L
M,GG+9_H(>FS!&_/FF_-E.:':M>^8AT,#^R[T,+./)Z@])ASI!(C)'UP!S[>`
M"A10N[<I^C**:@3*%6($!Q319IJ/2+GDDP#Y4J,PV,.*[[.?N?A[IAS)<J\X
M?5W6<.T"B\N_[R'BH6C7\J\OL[3\K\%',`_\2K]<L&B.1/+I2MS%XPO]-GLW
MJ75T.8PNY4X?NTPG,-MTC(RVZ=C.EH\4E8Y0N7W`87%6[4?`)HRJNDI`X^Q%
MG45O=.%=?KVVB!E5FSD<&!1@0K:L8%)L$3CFE2T?9@'B0!UTAJZRFU]I7:JG
M=BG<P[LFX_(R;@]&7ZH>6<(H_PG#YJ&XZCWOUH:BK[5LIP%=7$;LH4@0)P&T
M_3K1WBE_EW"*RP*;,U7IG'*'5<T^K"I=.[O6/JL>H-*"I>#<8\41W6[#H+C,
MHG`0"E9\P<XPV#\L8S>,Q646[3NV"B.GR$=`?6?&,U6OMIF*&:%87F8'11P1
M5ARGP8L7TVY'L\-&:_%B&'$&MLRNX0&ZS3*[:*7<M2NRNPN_9"*QDE=789G_
MS38L+JP!"A*NM"I,5%K1VZ99B+0CGJ\1F#C?'WQPW/X++CB`?8@PW'@G!*<X
M7P::]6;F@.I8=D"=$AT<^3@$VC')$)WKB=4C^Y.BXYRWD-&A`4-`(^-WH?/7
M9"3RY&XBKQJ=(3Z,1"J.)2)`I[8BW?HF?N[,IO=IMHB!6X%/]7Q+A_'X?V99
MDH^2X;DX!4IT?!8"]9GM0J<O/\VGR5#O5+,CIYB<!A,54"1G-!3A`*BM]G4<
M3];<`94B]>I3(A]Z/E@@/\0!T.EK`Q9RG;^Y3V=Y/!G)>>OF/EOI(:"^<$;0
MT"#`0(]A#*!)LJD01:7/2UWZ)WD29P*0-,R8[N=#"-#\MWD;6"7PJ81#E8+4
MA7&J7<OG%P]FV229SC)E"@R29_73D:MIG10E'#*@/K6]4"IBT$6VN.A\("(<
M4Z#[S[T@^I[>3G_%6H_F/U9J4O72?'I&>D6B"$$UXO8![1SUB5("U&.P%S2Z
M#?A].AY=/CQFZ9/V-)R3!E',ST&#BM[QYZ5'(=<G/A$%NC<:Q$GV?_%X)KHO
MBQ__)>^I2B&^7*E%9\W&FU]T.9%61*ZOH&>$5!!!W<4>`RER3DB%%.BFZ1A(
MX7-`*I+7%&&@43NC0HT?K!;#Z]N.ZF1ZI\V3E:,I*?_1M^3N?GJ3EON`7CH>
M%V]S'EYVUV6H,1"YUD$080'<!=H0%BM]G$\+B6O1!!8;WX<:XFV(S4TFXGR6
MO9S-/,8XQDII>`#4`O@F\FDV&TYG*J9;.6$[TBH3N30$7WG857^*X?1&9`_)
MY&Q,M$K]NK;E2H`KH7=R!L"$O`WBUW4)G0+NP0`;I1%/S@"8D)^Q^$^>\UWG
MF(E+Y3Z`BJ1N6%PJ-Q0D7"HW3%1<XC`<3,H,.RG%$*CY8I@EA&NJOWI2F``7
MVC6$J:XRN:>$"3/F8Z`.,\.,R);`1*)&3WJ=-DQZF/@,:O<@,YBZ+4`)4<S#
M1J/4.V>47%9+DU!R62W0(7)9+4T$S66U@(7&9;4T`R:7U0(5()?5TBRD7%9+
M8Y!R62W0D7)9+<W.:JF1*BZKI2D0N:P6B+"XK!:`D+BL%K#8N*P6D,`T(^9E
M,S*MB7N90]6$N)?=4)UU4$4)52-B7W9"==[Q+TNHX,>_[(:J#1-@(V)@=D)U
MUG$P)5*-B(/9B=1YQ\*XK&;(`$'*Z;(^9NS<DN^D):X=(N>6A`B+\X$!QL;Y
MP$`"XWQ@#8+*^<":`I7S@34)*N<#:PA4S@?6$*2<#PP^4LX'!AD@2#XPZV-&
MS@?V3EJBVB%R/C"(L#@?&&!LG`\,)##.!]8@J)P/K"E0.1]8DZ!R/K"&0.5\
M8`U!ROG`@",%R<5B>\QHV7Y>5^N2^W>?0B?GZV)=BTN*";\>0J(::IDCS#0X
M.$2JE#SSHQ`H.+.?>3)*8KD)C,=B(SB77Z^MS0T2"JDJS)Z>1(ACOE(B,D`<
M>K+C]H*K-[_2FA0E\A#W,+>'CJ_F;E`S-_(U(XE-1H;%Y.`:O6RF7&AY0E@5
MOVOS<0KQ0])XZV,.$*,(UI@##S&/(HO'GM)"+=2,(QH]\U#^R^0J+)=CJ71A
M)/\*4^DZO^)LU)<+<67AO<Z2NV02CZ\?U1G@KB.,_1ZU+&56K/%J02^><ST1
M%H^]E15LC_/K^&,4\8A01X!]""`-O<83`-"D9W_,/B(D*C8;`?)5V=^``][W
MB;]GRF7T)/^WH8[LZ@76B.A[B'@DJ@$4@GG@ET=.(62,1B+Y="7NXO&%?IO5
M'>`Q*X>UC@209B/K8Z9J"M:SD?*"*`=V$&"@Q?-4C=>UHGER];NY3V=Y/!EU
M)J.;^R2;"E'$]UQ.ANJA3T)]S:YORJK?&@6EF]#YIO9&!WER$V-SU\8*=`!-
M&7++9GG,%-PT*2VVO:?)V20I!IS?QYG(%Z-YT-%.XO?BSY\_SG\O;J&^M?;]
M)$]](FV%O[[W7]VD_.R3_&R_._V0+_YC[<U&R9.4T7+\ZGM_SAZ$JABZ5%N3
MIQ>RV?Q]?=N^F*0ZJGKSC3?)9GG/UU_^_+'R[D9#+VOU`1R[GLC*USNF!![E
M;5[Q1_W1@#B=N]=?U>\I/S#X^I=T+(:S\1OWF']J<*/OQ3R]^3[EAP:W^9JE
M=UG\L/DVY8<FMXE?U`-?JW9QG_+3-VY4+$;RA_\'4$L#!!0````(`&R`=$2K
MG_RT,A,``(0.`0`5`!P`;6=N>"TR,#$S,3(S,5]C86PN>&UL550)``.,22M3
MC$DK4W5X"P`!!"4.```$.0$``.U=6V_CNK5^+]#_X),"Q3E`G4PRG=U.L*>%
M<]L(D(OK)#W[]*50)-IA1R:]22F)]Z\_B]3=%B7*DBPR[<M,;/.ROL5%<EW(
MQ1__^K[T1Z^(<4S)MX/CPT\'(T1<ZF&R^';P]#">/)Q?7Q_\]2^__<V/_S4>
MCV:ST04E!/D^6H]^=I&/F!.@T:/S3@E=KD?GCN^&OA-`:Z,;3+X_.QS]823^
M]4;PU<]GLYO1R>'Q:/02!*O3HZ.WM[=#QKRDR4.7+H]&XW'2W=\CPDY'/QR>
M`&VY7V8T)-[IZ$ONJW.&HHX](.ET=/+I^(_C3Y_'QW]^//[A].3KZ9<O_\B7
MIJLUPXN78/3?[O]`X4]?QE#C\VAV.#O,8?S]Z($2#J67*X>L1Q/?'\U$+3Z:
M(8[8*_(.XT;]&.X(.$KXMX,<PO=GYA]2MCB";CX?)04/?ON;453X])WC0H6W
MSTGQXZ.?;V\>W!>T=,:8\,`A;J&B:*RLZO'7KU^/Y*]1:8Y/N6SEAKJ22QH$
MCI0EQ*=Q4FPLOAH?GXP_'Q^^<^_@+Z+#'QGUT0S-1Y*&TV"]0M\..%ZN?'00
M?_?"T/S;P7)!WB7GCT^B^K^[H&ZX1`2@>I<DP,'ZFLPI6TJJ#T:BW:?9=8'\
MI>,RND`$NUQ*4!"+XY$H?%39WE%;:F=0\Y\/`8B<Z.-^?H4)C!%V_"GE6'1Q
M[CN<XSE&WB[$:[:\3QA3AZ&=!J)!\\$+"K#K^-T#NX;5;8DF?H`8`1%X12V1
M;+?7.<D/+\"2%^I[L!I>_A*"!$^(=P\L8F)9@I\0X=!Q1$E+.,WZZASJN<-?
MKGSZQJ^)AQER@Y9PMMMK3?(%YJY/><C0/5LX!/\J%Q+@TIT3B"_G]RNQ*<)W
M?.)Y4K@=O^T2UK;/#E$_A,NEP]8@*GA!8,:Z#@DFK@O[<0!*PY3ZV,6H#^AM
M.MX[_K34E8/9WQT_1+?($=6%7*:KWX1S%,`PWF#G&?M`-^+[X-'NQ`W'QRDT
MB!A#WD-`W>__ZS`&Y1/2UGOE6@TI`_((,5<H.@M4J#%#KXB$.^T,?9$R'(^V
M2_$9<A%^=9[]_;*HFI*]<^B2!QA62^0]<30/_1O8Y?>R&)7VNW?T0KL)`[E9
MW,_/'(Y=6/DNL!\"89&R<T,YGTHU:$F)5)/VP9V=Z-K_[`+3T@M]F.N2-!C"
M!^2&3.X9,*Q`:<XQ$!="WJ7#"#0BJ-\;/SNBM$,.3QD%Y4WJV4+A7HD].*.R
M[-=V?-JAOY[1]J`KZG?3Y5P1ZD#!=KI`((>X#X`-^^H2I9@`WIEPZ4V=M6!L
M+\J^;B_](LLFAF2X_$TLR6`%R^XOW\6?;5>NW?O=%_K44+A?2<OSS6%>NG'?
MD\<7=`%_W<]_$JKP$X>U$KXZ\QWW.[0!Q/&HWI2!B)+%+?60WR//^J!VKW(6
MT^W"_M3>N&G:6X=((PWET7GOQ2%0VWH_2,0\I$3P\7X.<A.'!OA%;!1"&6DY
M\\Z,^I9]]\,%,%4H<:&/6%.:H15E0E5*YEE:]@P1V)I::BVM>MX/!\0:@A:8
M"$U1Z!U$!-$F2Z&`BJ4&U/0GPJ`.:*>_RJ&*R>M..KJCJ$..W2!8>B[?<>8A
MZ6$IT.VD5USG+PY9('Y-MG_J&EU55[UBO`H#J5YCD+.5XR<[RA,!1526GBP8
M0NVME%8]=\B!<^K[SC-EB</]!KM"\4K[ZF-?V['/3E$OESB(^B*@>$H3&I&>
M'/N->]L/TDQ+NL4$+\-E)(%2UA+IZ\IUV!T9W=KJ7N@&MQ@TX@"TCM00(]Z,
MKAT?%MD^IT'[[CODQ244IVN$XAURZCND!\C:O72([&^A`]H3\]=IX"?74:)@
M@D1RZF-QLL9+*\P0#WVAB6;1QW;PNR6E4R_H,T>_A"!IEZ]].3RTNN@FX'Y'
M`\0?:<KE-&#.\^'EC-'1-C1EB(N03J1;EE3.P#RB]^#,!]-R%Y[LD;J^V5GI
MBNZ)29I]F@$]^6((%J1]F\&*1[%]#\*(N.>^V9#XY,6N%N0=\[VO&XUZ-HD-
M?<C$#OWW/D&V@AFB;.]BH=]MWPS(G>^:Y]W\,^0+->><<J!6^'$+;MR>V-*6
M&,.9U<><ZH:DOAF7>@I[GUF5/0T)LX_!U^BO;\A@_@0,;.6019[>6.[BD`[L
M];V/^$X4F,B6/B2D!1U]LZC6U]B[Y.Q$0?]L4?KC]L"01GV;Q8H^IL].%/2^
MMFRX(/M?834Z[-UV$;<_Y"R55T*FH-<P%.#HX'@2/.S?G-N5BK[94^F_[(D9
MFGV:`;V/U:%1S[U;LAM>W+XL5V4W,4`W.\0JKN$6@$)91#QQ'3'Z5O35U77*
MJ/>CC>Y[ITGSEJ2D`R@!3A5Z]\6=6,J*8Q]W+B^^SAW^+&^_AGR\<)S5D9")
M(^0'//E&2LGXTW%\"?9W\=?_3$[V@\TG)/`\9$S&QJ.>0/%!_K>#FL)'`]*=
M11;O4*!'?6F5@3"P$.7O+]4"4)0?A'IYD$M%:O3C<'35<+)09@@JQ<5/H2S"
M?\*U]^KX4GT,SAW&UJ`^RN.A"NKUZ@Z!*CGG-P."SN%_'-Q1XE8.166583'(
MJV#5@J0H;`#=#1B_67X(Z@N'44OIW3XR.AB%,/FV??/U9)=7&QA+M7P;LM=(
M.RI:M&OENKSL8%1KLUI5>@C*IPRM'.S%MSBJZ2XO.PS5BL@AZ'E*XBNJ#(%!
MNF*Q*X(RI;N\`D=MM<&P)&[E.!U1M2Q5U3`%0>T"5%-I"!S:NY4A^U.<LT`>
MI939K.[#0.26$O<#%)175DDQY&S\"2O"<9B;-`U_;AGXQ013<8DC+B[UBM;&
M&`S\I/Z<T>66+91T1E5FR(@R8+M,<O;'3Y\.1F](X)"?X=.*8<I@/+X=G!R,
M0@[$T55T_LY4=/5+60;XRT<`7+W_9&!_^`A@%2I9AO)/MJ'<V)KR8#6M]0S\
M\0<"7^UJRS"??"#,"@4X`_O9'K`EIG4>:IF!DN(\_C@XZW2Y#+-%NV\-YFI_
M7(;8HNVW!G&UYI@AMF@/UA[C+;]?!M>BS5C7SZ98P_*H__RQ49>52L&?V+ER
M:^@AFZ'*;%.V<[RK(:LBA!GJKQ\-=:7?*)O=GSX:;E7D*8-LD5FA!UGI(L\P
M[V)6F'K"HY@[>GA2MY-##Q$*%[</A+LD,K94+NZM8D,X)G]"!#''!S(FWA(3
M#`N5Y%N:9ZN4]+I:PX0`HV/,H&S`^@H?>)J&51$)5)4?@OH[%&39)144%\L,
M$@",+GN312VM924'"UF""4&+]%2+=TVE@0(W"'8KX;2[`#'UJ?3#5L.HKC,,
M"CG#KF!CE:G@U-&_S7(#4EM#)!]6+5%M-AOZ9Y7P6!FFT<%=N[E9&:\IW2H*
M.FC9*FUE'*,>:LWR;J4I7;'+%F=ULCQ9Z<771+D]SQ5QQ['9<#<WDZ*W3ZFZ
M6AF!J\):H@*TB[@-:F\V>[UG>'JWG^<QYJCX%,%(BU2B3"1:NT#1_RK;N4D3
MPQQ>AM%W<9RGJA1#H<@0-*99FR?>OT(>1!*2Q)L41%?7&0+%YG!?DPV_N@))
M?3VST.0S'S8$M)6MT`!,&V&`)I@VJS;#M'W%4'Q3TE,^UKQ!GDX-,SB]X8+7
M9O-F/3/0R)TU51PK+VQI5C8#5_%TCC:BC6IF8"F>DKRB.9:GZ3>T$6HU9A#N
MC2!?,YR;E0?R0PM.3QE]Q:!QGJVC-WKB$)#&&#9HP"!\U^051J`%OK(&#,*G
M/P<;-/"?.(GRXDZ2<(Q.7#!/LN>1MDY2*R`T:&"@BTDN0AX75OPUYZ%X)%LF
M8A,OH@4R^T(YK-IZ)J&!*<T"#%IS\?W)AMA4K0QR;29-B9=/FJ<`I"@\K-=_
M!]=!WOO49'FT\OQL3PPJW1^M/'S:$X-*%:2,018=:6NN`6Y<&6JVEEIYI+<?
M'N5V3RN/_#;7K0M<::`S*0[Z&QX":JZ;;RP\Y?%<BP)#[3A0]*E;>4^K'0-4
MZIN5\=]VK*B)75AYI*4=1_0B!XH3+Q]ZY:SWM]IYI*!KKNAY;A4'B?[->%4>
MB5`<-_HWX\U6_-7*JST]<&4KYFGEW9]>EIVMP(F5=X2Z9LU6]+;=+2*KN*(5
ME6]WKW__1[%R[Y;DGE8#X_;.">1C)MES>N7OT0U.]X,8<+:^GU<^=64U\6FI
MU,BX!=D+HW3GZ64XN>?+YQ.R!7VP[+`II1E6A5=?7=Z<K+'Z:/3K=W)(Z)82
MM+YUV'<47(7$TR!4NUHG]&UH\'K4U5<R(+5-!9;ZO$:EE:UTH&DQ0U]4K?2A
MZ?-`8SJT<YU9M)<5XRZQIRQ[P]XZ.(BYXDV$!2K42!1EV^!LE\I[[2Q!<\D#
MO!3O;(%^/P_]&_R:J$3FTRX<ZF'RF/&9P[$K+DMB/PR$J9*$7:;R7H<(TPE/
M_!#JGAWGGPH43%X=[`LY?J2Y&&=\:4:R6@>'1BMF(XV%J376I)UASK6Q`*;+
M2IKM#\@-6?*:'NRSSX(LF#5/Q,L^7SJ,0%F5J+9H<`C\I91,?-DC\AZI`HX"
M_*ZM#9+`6"I&,!ROB,&F>Q<NGQ&+15$NAOF\=%E,3H%\U]:,07X_5U';!'%%
M*P8AW2*N:LUNUL;0;LE=-JD/>":C+1MV7A85]J?Y\;+=]GPMT;'K"$=[1K31
M*13'/`R7GQUWE$)6V&9+M95Y3OIBDX[6TBZWO?GF[H/[@KS01S$[P5+/9EX4
MG3O/B$UYGDP\,(-S!O"0:),SHOGCH1FVLE\'>I,R7(;R"?+\&4;XVT=Q_&^R
MI+`,1N'`II>%.FO>J#>.?F)J#T=-):-PM'VK:8BE5P>,UD,A\2!:&6=HRH3N
M9KE"&=15:TQ;D$T]#+"5;?P"P7Z)C:57;+F>//Z=W)6PA])L4Y9LWSK$GAS%
M-9OV-(1X+V?<Y,UA7AKUN">/+^@"_KJ?R\Q63QQT)?CJS'?<[]`&],.C>E.&
MQ2VA6^JAP9(F-QFM&&UT3,N`6&%D=#XZ[\8>-,I1**2<$L'5^SE(@_CHD#5/
MSK%!F2B@/?`YHH2>E/+ZY#R5589\,3CE:9'"&ABJ6D8@J=*&%86-H#LG$FI%
MN*Z6$4@:D&\,S>D16^&@DV^[P1HI-BU^`9(-&Y?*C;]+2X8CEED0Q7E-*IXJ
M:`V[V)P9V,6=%&UDLK`1=#?U=S1HP`A\\$?T5EE!@!J-5E43!F-,$H^W@YFV
M8@K2Y+O8:(GOK(@LQ?*2C^/SXBT%;?`-&S:"'\(>BAPSOD_?1"X#7<`E-0=&
ME-,[-*?G5HU!758Z2GS9`TVET*V\:U2M."NPZRM+5D;X>^')ACIEI8>W!6/J
M]CLKX_F=\V-S);$I&T,[9C15$:R,T+=@T:9GQLK'Y%O@UXK^6)01J\T>L[E(
M6)3R2M/?58E?EK/RNGL+].4:JN(ZM^'GN:I<A94COQ4=MR@]QLZ@R^Q%11X,
M&P+>N4C/#+F4N"#,\:FI&5I1)HY-)1'"M.P9(FB.!SF+E-(0:R8)*>66KJKT
M0"G7(UJ*?#Y_<<@BEQBBN6.B@X:[>H*BC(Y\_^D1Q<U8T`X-]$ES:7JVFBNH
M^H!V:=T@B55,JDEPA3SQ7J$PK4,@:9W5A]6CF?#NV(=!7+JC8GT.79DU-F=&
M.5L/63;C3(-V#>=&>3I(\6!>>XY4M&T05Z3ID'Y%%M>@KE0\+J+?A$$8"XZV
MG+;1#*:RE3YW`=EI;O<1QW5VV<"JVS%HK%(O6&7X0+/RH.I]C9JXD;:LRUW.
M2A=[>W:II[F5KG4-ANRB\UKI5F_)BYI5U,X[<.TG3!/]T$KO>GL6;6U'=N8Y
M;L\(A9YHI:>]GYE394M8Z9EON>CNY,"PTI';7IX:>>#:I3PVU-,K;GF@!2;B
M=JP(YD7WB9?BTJVX#$(Y?R(,ZBP(_E7R)V:R`>FQ;D1:W<MWG,FQH5<JM@F-
MY(Y?D^V?3"3W*@SD!3E,1+8#/[EK\P3=,5EZLF`(97>4AZ3^G/I@M-(H%;%,
M<NN*M2&ET-1[-R+S!(XT8Y$&E,I+[X@8G)*X@N+L%M8M)G@9+B,)DK*22,]F
MEL#]ND&RXV&")A[1%Q.;4'BA?'5:M_80#AY-VLY#V/"4'NB&C1B,4[QM]HK^
M#XPKE=]QAX;,QDM#U@W>M"&C\3Y"K]T,<*XELQ&_T6[P)NT8C!845(:<>:#T
M23=O9U"CI>'&DS=BFJ[L5OJC^^=/?OY8Z:'>"XMRBZJ5KNM],"FWTUIY4'PO
M/,JT+RM]V?WS*+_#V9N];<JH<,S>8A_Q@)+4S`/3<$;7CA^LC3?!+Y<KGZY1
MXD<4!]P-I?1OH<-`7OQU^J9/CKPD3P=8Y)SZV!/G-],*,\1#7R3TR)YK&A[.
M0_C,T2\AB,;EJW'R<4<#Q!]IRFD9U)1BG'\(*V-VY'::,L3%*P^1E[6D<H;^
M$0@\\\7CV<8AK,S$:#W=R1>VTO\HG&<&4J^\(62%S#>AWM01V$X0)\I:P?[<
M.X/S?$!WAF1^0A'7Y5G(-]$R/BX@4T4LC2E:(555U)K*X<+KLD*-C@0F>W/4
M"L[O@L+4$:F-+5HQ(A5QNP](OZFRM&D46\'Z*8A[)/KR7-H4]BZ&`AR]+YN<
M#+$"2:4%;3W=I@K]IJ&OP>@?CP0)SZ`;P8?_!U!+`P04````"`!L@'1$@=_4
M9Z@T``!>B0,`%0`<`&UG;G@M,C`Q,S$R,S%?9&5F+GAM;%54"0`#C$DK4XQ)
M*U-U>`L``00E#@``!#D!``#M?5MSXSB6YOM$S'_P>B(V9B,V+W9V]4Y5=,V$
M?*OQAM/RR'95S[Y4T"0DH9,B50!I6_7K]P"D1%(D0(`"!5"IETQ9PN5\![>#
M<\/?_N-]$9Z\(D)Q'/U\>O;Q\^D)BOPXP-'LY]/GQP^CQ\O;V]/_^/=__J>_
M_8\/'TXFDY.K.(I0&*+5R=]]%"+B)>CDR7N/HWBQ.KE"4QSA!!H[N</1MQ>/
MHO]]POX-3N"KOU],[D[./YZ=G,R39/G3IT]O;V\?"0G6+7[TX\6GDP\?UKW]
MFM'UT\E?/YX#::5?)G$:!3^=_%#ZZI(@CW<<`$4_G9Q_/OO+A\]?/IS]V]/9
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MZ>P\J_\O5[&?+E`$C`FNHP0GJ]MH&I,%I_KTA+7[/+FMD+_P?!+/4(1]RN=;
MDL_=3ZSP)VE[GW:E=@(U?W],8(*R/L;3&QS!B&(O?(@I7S67H4<IGF(4="%>
ML>5]PGCP".HT$!K-)W.48-\+S0.[A:UP@49A@D@$4^`5[8BDWIYQDA_GP))Y
M'`:P=U[_D<(,'D7!&%A$V"8&/Z&(0L<9)3O"T>O+.-1+C\YOPOB-WD8!)LA/
M=H13;V]GDJ\P]<.8I@2-R<R+\)]\(P$NW7L)^W(Z7K(3%+ZCHR#@D]L+=]W"
M=NW3(.K'=+'PR`JF"IY%L&)]+TI&O@^G=P(2QD,<8A^C/J#OTO'>\6]*W7B8
M_.J%*?J*/%:=S<O-[C>B%"4PC'?8>\$AT(WH/GC4G3A[?'R`!A$A*'A,8O_;
M;QXA4'Y-VFJO7&LAQ2*/$/&9H#-#E1H3](JBM-/)T!<I]GA4+T4GR$?XU7L)
M]\LB.25[Y]`U33#LEBAXIFB:AG=PRN]E,VKL=^_HF723)ORP&$\O/(I]V/FN
M<)@"89FP<Q=3^L#%H$4<<3%I']SI1-?^5Q=<+8,TA+7.28,A?$1^2OB9`<,*
ME%YZH9^&.8Z<_FN/1-`(HWYO_#1$J4$./Y`8A#<N9S.!>\G.X(+*IE]WXU.'
M_GI&VX.LJ-Z-R;7"Q('*W8GISGS<!T#-ODRB9`L@N&`*P`=OQ1C;B["OVDN_
MR(J%P1G.?V-;,MR">??7[^SCKCM7]W[WA7YS41@O^<WSS2/!YN`>1T]S=`6?
MQM-?F"C\3&&OA*\N0L__!FT`<32K]T!@BD:SKW&`PAYYU@>U>YUG.=T^G$^[
M7VYT>S.(-)-0GKSW7A0"K:WW@X2MPSAB?!Q/8=[DA@1ZE5\*H0R_.5-CE_H=
M^^Z'"W!5B2,?^L@EI0E:QH2)2NMUMBE[@2(XFG:46G;J>3\<8'L(FN&(28I,
M[HB8Q6VT8`(HVVI`3'^."-0!Z?1//E0Y>>9FASF*#'+L#L'6<_V."PU)#UN!
M:B>]XKJ<>]$,T=NH_I-I=+*N>L5XDR9<O,8PSY9>N#Y1GB,01'GIT8P@M/LM
M9:>>#7+@,@Y#[R4F:X7['?:9X+7IJX]SK6.?1E$O%CC)^HI`\.17:!3UI-C7
M[FT_2`LIZ2N.\")=9#.0S[7U[#.E.C1'AMF[>I#ZR5<,$G$"4L?F(A8%DWCE
MA;#)]KD,=N_>("^NH7B\0B@_(1]"+^H!LG(O!I']5^J!]$3"U<;P4^IH+6#"
MC*1QB)D?3K"I,$$T#9DD6E@?=X-OEA2C6M`7BOY(8:9=O_:E\%#JPHS!_3Y.
M$'V*-US>&,QIV;Q<,#H[AAX(HLRDD\F6#94+,$_H/;D(X6K9A2=[I*YO=DI5
MT3TQ2;%/-Z"OO[#!@DW?;K#BB1W?5AB1]]PW&]8Z>7:J)67%?._[AE;/+K&A
MCSG1H?_>%TC-F,'*]CXMU+OMFP$E_ZYI6<T_02$3<RYC"M0R/6Y%C=L36W8E
MQG%F];&FS)#4-^,VFL+>5Y:T)YLP^QA\A?[ZA@S7GX3`73DEF:8WGW>Y20?.
M^MY'O!,%+K*ECQFR`QU]LZA5U]C[S.E$0?]L$>KC]L`0K;[=8D4?RZ<3!;WO
M+5LJR/YW6(4.>[^[L.@/ODIY2,@#R#4$)3AS'%\;#_N_SG6EHF_V2/67/3%#
ML4\WH/>Q.VCUW/M-=DN+V]?-5=A-#M`COBI&09#G.GR417?^P*%[87AZDC=<
M!K*IA:/D4X`7G_(RGUB%'NF!KK*-X$.`IEX:)GK4U:OOA]9XX>&H,ZE9[3XI
MY3U\6*#%"R*:9%:J]DCC')H@?OJ"/FPXHT=I4P,YO<$FW/T.**O0#(L,10&+
MX\V^94V9BD/..O]4[;UOBA2#BSD90`AL,)7>0Q9*'I/&0>2LGWKTA?,_I1]F
MGK?\Q+;23RA,Z/H;OKE^^'R6QX[_2_[U[^N`F`=OQ3;NRY00[E*2]03W!13^
M?-I2^)-%N@N#_#U*U*AOK&()`TE1.>RO%8"@O!7J-W;3!P_S<(XE3KQ01+N@
MM!7*N>>FB-#L1WMTC5Y`RO9\X22H%K)'9\M<K92Q3J424[?+VJ":Q=&SNS?\
MQRPEKU[(;^/)I4?("F[CW-M>@$*MKA54[(S+G>"O<KFL&4*]H!5ZLQ@_1H64
MX=O%;-"Z=DF?P&!?PO\XN8\C7[HXI57L8N!1R_*M15#8`;HU&+]=W@;UE;B)
M1GKKT0W6*(2-K6Y&;B>[N9J+6%J.*.7JEK')UZXCLFN=#'7NNR`E<'5L)K2T
M[CG-9:U1K3Q51*5M4%Y-1"(3"9I*6J)X"1>M/'Q5SNGFLG:H%KA,P4U=2+RD
MB@T,W`:-?>:-TBB/"W"T5K.&96U/S[,VRN>2K(8K"%JWS)9*=G`D<!DJ$F2,
M?#]=I-R[(<]'(,326E$/3]U4P[[Y_1$1)IJ<7<;1*ZQ'_!*BZE[X-5=T5ZC4
MJFJ2SO/N=+96-4CG16<R6VL:I/*R,Y6M-0U2>=5];K97-4EG][G97M7&WK6Q
M?I2U.Z-W+#H*Q>6M4G\'V^@M?&PENRAHE=ZG+%I23NM3*99QWW0JWN8=N;]K
MW]@=NZ,_$9YZ<M5ZA6DH:(/>/-TCCT+E:</':<*2>+/4"@+*I54V&`HS[XA4
MT7C$7[><&[!U;?%Y[2F)%T*3S;K+N,W^<!(3F#LLL_R7+Y\_GYXL"8X)3*.?
M3\]/3U(*Q,7+S*;F-+CV"U&!\R\#QBF_O!88?Q@P1H'BJ0#WUP&#6]N%"S3_
MQW$T`N5E&92B07&#^<SUZ:F`6>X<4D!U?;(J0!7H^0J,!S"%M_P-"FS_YBPV
ML<&;`=-3F&SPGKL[ENIXVR^W!=X#&-]V!4X!]\?APVW7!!6'Z^?APU50*15X
MSPX`K\;J_7+N+%Y=4WSY,)*9CHN3R=VEO`OV-F-*L96YN[9WP2]WM2K0N[O2
M=T$O5\@4Z`]SW4M<O0KH[JII#&UY9;#NZFIV`2LK76!W]Y)L:*`%[G8%!]R]
M.[<[=S7I"K8#8#9(/P]B-U=#*@HW*<`.8O-6`"OU7"G@#F+#5H`K<J`ND`YB
MMU9`*G0B+*`.8G-6@"I':6L#K@78-@%M-?E75-0-U\\"IZ6K!`_"ED*[V_8'
MJ(H152O\&L_GSSFB+-3V)Y8Z`04_G\)FA8HOXRA![\EUR%OX^92B69;HV\E)
MK<:0;?-+,<#N:C75D*E+7`5F2YK-QGAN*?**$TGC!*^O<.MK5VEH=03C1O_O
M`J:[VAX]F/6PMT*C=2A#V>0&4Z!T5];70RD,SBZ@NBOIZRHEVSVC"]3N"OR[
MJBG**-6$?3>S8%2?I3\&*_=)[^_GML.K8;3'A$^,@&_&Q1.ES1`4:EI&Q(F@
MHS29P^K[LU@L8B2U&DX@:'>WE%:Q'Z9WAV%?S)XMR'Y`D8_48_<DU>UCTUPV
MBI7MXU)</"V57,%Q2VFJA2&OX`K][5M`6ZUC:-DQM&PG*H^A9<?0,FE0SC&T
M[!A:)@UUND_9[(2AYH?3?Z)0=""WU1J`?YZ.-['#&KU>O(D=UNWUX4WLL'ZO
M#V]BAQ5[O7@3*ZKXW,:KLWIM&?7KN:^E]K+!VKOW8M?__=P!I$?+OEG[MZIF
M:@@>=5T0UW560W"GZXYTK=4:@A===Y3-SNT.N]%U@2I3D0_!GTX-LY*YR;YC
M70]P95O3T-VNY`8KZZY6QG"V*C.L^R&YZ55FT;LA>ZAR%":(1+"YOB+KKX[P
M^5)U+LD?]6*OJ,)/;-A>44:XE7=(FAV6&K72:G7LO(GQCY1F#^@]Q0+R^%"\
ML.=IJP_8PJA0G""X&K]BGQU,.`XFR(]GV>20&:Y[[]:R0X)T%M3+V:`V6U2,
MM7$$XR#UPVDN.TBJ+3D0W:,DVZKN8BJRF53+N)"S53J-!86/!O2C`7TG*H\&
M]*,!76;2;7=4LNZ:M)%CMXX@JF+H;ZQS-/8?CK%_D'EDL]5TQ:.3,YD[6V79
M%L%NT.-I:;MX1#X4E3S4LV.CSO'A'KWQGSKA+2H[AXO_..:*"GK]CHB/J7C?
MU6_((;S\XFAX.BNVZ1H7.D[FK;JNH3(PE27M6'<;DU[6FDK:TR-+;_&[>(BY
M:]?3@JSC9N*N?4\'LHZ?F+O6/1W$.JYB[AKX=!!K>8NY:^S3@JRSDMVU^[5"
MEJC`AY!B4AE?XX$[A"22R@A;S%I#2!FIC%6D[K:?&5+3AU.F9BH#%G#&NH.C
MIBOG3G"/'IT'Z-$I32XQ>.]-D1?CT'TU^W<^.!R/3T5US>'X?:IJ6P_'ZW-'
MO>3A^(/N:G`X')?1#NK,P_$C[6*7L.Y::@S]EL>0]2C8/GQFFP7Y`?G-LD?*
M;L+XC=Y&`2;(3^SXS5YARD3]E*`QF7D1_I,+2:,HN/<2]N5T#&/'OZ.%F'4;
M36.RX-_J^<\*_$V*EDM:(+Y\'T@FHC4E_-&JVMW&0I'_<1:_PKC@S+P"'[:M
M*O#5[]=1`E.-+3RRC#.67<%H9Q[2FZ^V,&A4M&$ENGT82VU#Q>]&_(X$4_`B
MI;#=45K;],H30;GN/BAM<B-1KV>$P@<2^P@%]`9V6+8>O,A'MVP/@5M2^A)B
M?SR=(G8T7B!8S&C]5_ZX7B.+=VW2BE77"U$>6G'O+>#C$_'@)NCS529S`5:H
M>&!XM/V;1=Z#2M<OV-S"E,4O/</I1=[@F`;1?`PR^2@,XR13*]6GH+&VK8Q=
M^D)Q@#VR*@V&S*]/6'Y?NL5.N_+&D*6V21Z@!K(SVW3D")>5E+O-&W,;B,L*
MS]UXI"PRNZS'W(T%.TLXUC6>K1=C;5FS<E<6'S?6K5@JN@YE2:<,NG1CL:_>
M5;3%MHD%E4%5X(K]T54SRIK%W<4Z:T_;\I@N%H`<(.%9A*?8]Z(D?YZ-'7@Q
M;%_,G4^L<G&=]$VI&P\3KG7^RAU@N."V28G/7\J!3:W\[**-6&;^8,^&T@*K
M0#(7E[<2B2VB9OM1!544FWI68J$].H<9P?YC2MY76/B1SMBHU[>!;D-'_D94
M9>KG*R081Q-FDV+2"COPXXBL_[SP*!;JP?KI8ZA<DH5RF6O?*G<N5IN/_XD1
M@>-WOKI#KRB4*!44*UO%=1LMTX1R8LZD^F=9#5<0G&LC.'<,P1=M!%]<0%"2
M-VA]JDN5I7IM?!<H+66_*.W+^@*.8F4C6N^O<8167SWR#24W:10H""S*U8S0
MQQ\)QGZ"N&2D2%U[)1MSXC>/P.4OH?=Q\HB2)$3L)&9N?RJX.C9B3P^B+-U7
MHBG4A6CK6C#3/%!?CO8U1'U`5UCI0W#XZS3O)1=YZZY]0L_]7NZ$9:X8O$X=
MH+5N;\.@,*.'X(+9.Y]493[K'IO*CHW&]1F-J[M%'>"264!F#]%3;S1R0NU2
MY!)#)':2/?'#B>@VG>U'Y^;;R)4F-9/+7A6]<N"\S@'W?"9ZY<"7.@?<<YGH
MIA<I0]>]/>N&#PS&,%E-JI"S9<W7E0TSY#`3ZVYFC5RFX4+,Y=R+9C#;GD&X
M\4*6IO\7(%N2V=90XZ[SY3F*7R@BK]E:A"V)!:1&/M3R\C6C9O$SV=7`>:9D
M_S/5C2LF@-]P,J\13*L4T\G652S?\619U_OIZYA@]9B(T(`A0&J>K)890&J9
M+5#6+R3M:LL>SK=&6=W8F?`]*#'W-2AF#Y]!73X=FO<RN7H(U]E]\=18H@Q7
M(P;Z%J1[#,8?=&ZPP_,]+_0D,.,`IS=#E1H3](JB5/,!+8%SRD6,YFPZ(G(+
M_X1SA!?B)R;$A>T\W10Q[F11>1-,OUV@R)\#Y[Y)U3>MU0X(BR77L3I9JPUA
MDLM>:S4GL+1IA"05G*"_V%3.5!&4JSB!0:9A$A0VXLIW'>(['(8K\1:Y5<)(
MK[_@$'G!(QP-@(Q%WXJ[%Q6U,6I?O7_$Y#*E2;P`X4ZR[AL*6GGNC4>W58B1
M;K[B\H.FWE0RBH<I7(:(=+9N%[&5UD/^9EZYA*E'OEXQ(M*GO$H%C/3Y_/A+
M#/>JB(G;(Y!4?2Q`W5;:WDU554;:#EZMIXBVYN*EYH:C*CY5D[BW,6<@E\(^
MP#OA8"/4YK9+F%*LAZ]9W9%!%8'7NB^RLAY)+O3*I__VDK$^^7M`W21>YCC/
M7=CC9#N\6#2N9!,5BW36!U1M,]\1IQ/[ML(&U2I[EU^8*8M^UDV,1L%)=(E#
ML"ZI`Q5>R(=@\%&'6;O!63?"&(4GNQ(-(3Y-'>FVVDHW"&TP!I-Z*6;U1I@;
MV*RDMZE1(54U"(L;T0$<;3V.VGJ.UI&C=>1H'3E:1X[6$7>L"T?=O6W=O5AV
M<DF1OV=5M@,*D:,B^ZC(WKM*]Z!4U\H*>R<4V?WI=QT8W7WK!0]!SRO1"QZ"
M=E=)C7T(^EVQ6O`0U+M"4\LA:'35=->'H=V]I@E>>`D*GBF:IN$=?K63JIS%
M':0)(BP*8<D8+U7EBDK;T1!EM#S&T^3-(^@6A,AHQD)L>%8D)1SRNE:BL%,"
M$Y3EW(B"&_S./LD=^205C-S3[[P7]D903%;0P7@*\QG)YXIJ+2OI7Y%'$7N=
M_7:Q)+#7\$0O4O;*:MA`\$!BD-R3U4/(MI4HV'#U8O4$?4M4;BHUG4+4N$5J
M8FMLPRF4;;8%A8I.X6%S2:I#5:GI%*+UU)F*S`\J-:UX@?MS%*3LH1LQSR56
M%>7J5F_K&AMB^?JN-'^M7^2%6DGU[:3B.*X\(0Y87]F-=4J[PQ#R(!N&WWQ(
M6]?C[L*(^@E657,*+DQ#4(?MB+GEJC4$C5E'#LBN94/0GVG"5K[Y#4&[UG'(
MI7=%ZXHW90..KA"HM.N79:M#2U21;7;<BC6>LH0F/B"_PB%L@`%[,WF!6!Z<
M!T3REW+YN[B#0%9,!0X'CNHB&0T<WP'+VAKZ:9ACSS%?>[#U13.Z>0/8AL<I
MX`AJ-%^_LR>;4<!>[*V,VC;)HP7CA,@]U4C;5AYJW(WRBU5S`Q(=4I\]#I"#
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M#>?QU'YT4`;%0ODE:3CFMK7UL&PXK%LCR[]:2F:2+IC-"P57:$F0G[U2`)]#
MQ.=F%("<#IO:G_Q[H4E4I`XWU;Q-%_OA!0>H4>P"I?8<_H\N]1D]*D$-\K).
MN2L?7B#`+T3\H&=+):=PM)F+A^;J?X]$IYZTBE,8#B]<P00B2T^L[#U@89_8
M<M]9H&;]\8H]$QYSNBYCVG)JJM>WFP7XH.,Q;(>D.)$[^!B48EX;8S@J(Y>8
MAJ!NZX;<W*U]"+HZP[.#RVW6%7;'$!V3F#7$BR&8'(]A.CJPOZ>PG-9`)'<-
MBOT&(EDR)1X#D<Q81D9!@#/R;J-I3!9<;K$>5\0,?6SJ(4*S=XJOH%<?RZAU
M(4KA&`/S?<9Y](3%DCKL(J4@WU,Z\F'IT6S'9A\)DL-IKW=0:!P:'?&N(2KM
M".79YGX;P:T)P57AEM(4!6/"_F=G\GW*I(WQE.]@^:_J0+LT;L7<'7J4`AWL
MT)._P%$O:)'>W/EH3"9X-D^NWT$<PQ1D#!"3-S_2_%?A"Q9=FG(&\V8&;?;N
M2R\,47"QV@6^1JN6G#-8^#F;@]G*&:7)'"3>/X5+4U;#2(2.T/\O^X%R31S,
MI2WZ].HZ%3]:WK.>EW%4$"L<`_V6;""^?1A+S5'%[W:,GV767>%7',"%9^(E
MZ(%EEPU#CTAC_M7KVT?WX)$Q>4R8JOM7+TS1)@^#"C1A9?NX%#>MEDJNX)#*
M1)(*KM`_3A.:>%$`5U4-$.5:EIP@?(0"RF[=7)R,?'3+E")>^)"^A-@?3X%F
M&2;5^JZ@&T^%)X@&1EDKSB`E[)W[\32[/>B`JU8T(ME,O%<47>`X0?X\BL-X
MAEM>Y9)7L.*`PIG"QSA+R?X$,BSU?&XWE=UV%"J:S#TPCG13#HAJ6.%R1I)&
MEA%9#9-\?7J+-?DJJF&/KQ?:?&VN80_!I3:"YAJ'F?G!)*>OM#G=7,,DI[77
MH+"&%;XRF:_I`M]0P!I]<DG<NNS-[V+<):.D0Y3HC<7ES<S+FH'O3N"DWEK<
M#C>WZ9D@IC7)#)>/RQ"+-``J-7OB<),+L[2H.3K6(C+W!Q*24"UE;5RS57J5
MLOO7`^R&<9"MWGOTQG\2+QFERF:YVM374_P<P5B^$9S`B-[$9*U0'T_',-=&
M81@G;&EGD;32X3#0O)5Q3%\H#K!'5J5+A&RW$Y8W,EJ,7Q3/(J8.4SV'6^O8
M=;<_)F0ZB$163CCVNY$3X]Q=]TQE%X8-_!:]40':EBNNVB[3XNM0GND*/+(_
MT96V").@A[*^Q2X0%6=SF9*KF-/N.MGKP!3HG`J8[CH<Z\`4**8*F.ZF*M*!
M*=`*%3#=C922PU12H1<PW0UV4H<IU*85,-V-;5*&*58:;F!^&>J!HG@K*X"Z
M>Z2HF]?*FU+)S::8M+9B=I2DHE8%9B42KV'TK8M!M?AE54UHL3!%.KT#C%#6
M88ZN^L[E>,PNN+4=-EP.Q>PT\"4+D<OQEMU6_);VW.4@R\Z#MS&?N1Q0V06=
MJ:`'ZP&7AOFRLT.]RTDFC#&D-:K"Y302QHZR+8\\EU-(=,.L[%7N<LK^3I.^
M2X!#P81ABV^:L2L%[&$+;>8-V`5GABWR=7`O+Z`?B#"HXEE3@#X,&5$:4E>`
M/0S!KRT:I\![&'*=:E15@?M0)#EQM%*!]1`EN(;(ID+):DEN:TV7H^(T6-VH
MA?I8ZYI6XV"%)OD<ZOGA0-W'(Q)?#H==$D_#'.Q?''<W:?65K,!5L#8-)Q\6
MG['!A4=1\."M>'XS=Q),O7DDN((]5I82JE+&2N*C-07R/$=;I09#J:44/YR*
M[93-391NRMB@\BJ7>=AY`/N,EVU;L!_,N%SP&T[FMR#^O.(@]<+L<"BOM)I`
MM0706/-6WH%9OUB%R"OV44%>&<T]T_!0N`GPL:1/<>*%Y=^9O><^3OX;)1/D
MQ[-(DJV@O_X.BGN9DNDF)OE7K-S9OEG:3(210(.U9<F'%0#B%TM;^?06/\WC
ME,)-Y`GJ(G'$@7IE&W/BJ_>.%^E"&DY9+6.$HV."9QBD@4S5V/Q4@J2@$1I@
MPK`Q\69H;11DQOW%THM6M*0Z*ETX87+!.!*6P/4VRJI,$(6)C-B\6ZL4N9(U
MTTK`6#>!VE//5E(_0,=,A)4]6%0N8I-&^;,JU4(#H=.29%76K)=>DZ1K`X,X
MDTY;/1MH)DP8DDS@XG=KU$GWZW()N^_^-)_N)7&37JQJ,F8F@BL]#+1K^V:"
M1MN($-&PE@QH0E+^D$/%0^7ZW9^S%K;7SG[ZM!;P_](.ZJ4&ZGV)2?8R"!<"
M1?/&6/N#XLZ-APDWBHQ`3%BL-]@E\D&^?D)D(9+4>^S0&O^Z+)GU$BET6(JY
M[OKL<9`<W!??^DF':IRLT31!&['>Z"ZOUJ,YKG39)3)1;R/IW48)P1'%/M\Y
MA-PPW].@5E(N'__"W15O\^/H-\2\%F%T7Q&!.R7_D2E;-_NPZ776D8HA<KIT
M!\\654^\K/<S<&YM38>*QVW_/)3V/BCI+<?V*U>'KM?:9DT9E]W:NG-R5@IO
M>84U)PJ4M"F]='7DF797MEXLEKG/ZBBV.C1D+H'56M[)[O(3-AQ7B/H$RQ-3
MM50S3=\XDAA-&LN9IH!-.>8XID3&5F'3M#R]Q4ID%.6,4%"R1(V8,0J3!*',
M^E"Q6(EITVRA%ZH)0ELCI4ZOL*[E1&!-?BH5A[)MQPOK[H&*F;HT@0TEU8[`
M$683F2&P>%KW8-69C]N^,[5P4^,"A_V15Y_4^^:.$RM#^'J\:3>FYC?F=S8P
M'6"*A[V,@'E5L,O9(_IDZ5YTRRYGIG!ZOHK5@"XGQ!@82^6Z0I<3<SC-:!7#
MI<MY07K?=??E`>ARDI'^CS85E93+64?</?R5'8A<3F>RMRW4C&>1RUE2G&:E
M@AN2RVE8]L+;#N8'E[.V[(-G"J['+F=X<5J`[.IMXG+BF/V<YCTX1+F<DL;I
M@Z?5@\+EO#?[X&R/494N9]D9-&L%(9?VL_RHF9.:PL0JI_HP[4!ZL)PPX"@L
MD&8OH*8+_K9'A<O)EQ31J?L:V'_]QSC8-G<0^TGN=X:L$=MM_XT8I4VH%KY8
MWH$JT8-#V'P:PAW+>+;BUZV_5M2:":FW(,G:*`\E:]A>.%(]F=W/+[87IFRY
MK;B?1FQ_7"D\U.SG&U-XK:9';^\F.:_DN^MRSDE;["DY\^J^@^E4UK;2,F/@
M:AQDZON((BMYW$+>.`J:QW9-6=[S=I(OM<K.YFC*Z6<+<;JM$N"OF=1T$EV2
M,&GT8H-3OZ`($2^$A3D*%K`Z:,(,=:\H'SUIA@RUNC90P44D7J!-%MB[?`0D
MV4AD-1Q"(`TADM<Y"!26(IJ8=PJ<E'.8ZE?H%87QDI&FLD94:MK-+F-F%U/+
M-&.RKWV[8O=TIC1[9!L=E`/VSM[#H*C*2/8]K]6,!@IG8^4Q3OD6;ETQHJ;-
M,PEZ*`8'I<.WHN]2.>6&X`.OC5Q1"K;NK-Y!M=/#\:ZP4KII31V]MF^\'#*]
M1.;22!.\8*?".'J:(Z;G&D^Y$\\SQ=$,OKH(/?\;M`']T-S*1;`/OWV-`Q3:
MN.SWG:36$)4PUJU45LH<DUL>DUNZDMS2<@*A)N]@MLFQ]QEO8O(`6SGSD8%=
M",[Z!/8C7D+$PSU3,7A.K_VPRX]D[H.WC?T.*CW3,;EF?[/BUSB$9D+V6.&>
MY^-6SX/GZ`33;S<$H?7CV/OB9V._@^)FFR7%0,-'9Z&].0M5)73[>J_>W)]L
MJ3C<\.!PR?U)J)4WMR4=4Z,8=PCIQOO^17+K>KS#8NZVA#F$5!,#8&^SN#F$
M5!,],K?OF&F'<TL,8,JJZ)ITDU0X:A0H.2J.`-HK0#BU3&]FBWGRWI$[+\5>
MIH0`XS:DY1:U"Q0!0S86ZJWK8$LE*^^)`B4PF?U+-KW)2JI<;RYK)&?K#0IR
M0R4WN=VC9`Q7!8^MLKN8TDN/D!4L/AX!663=^&_DD>NH\0FDW1JTC`G*D^TY
M9*1)>[YR,-OSQ%+)JM5=L5;8#;H5W/L:B@^8=FVO1,%**&W@Q:XNTIVIU.B/
MJB;C6UMIL]1<OWL+'&T6+L\65OJ.:R\$FYYV&_NG7+BU=6CE$%_$_9Z<#>IG
MUS0_NP0D2RJ8>7=8V/XHBE(OO,,+G&3WB`63@9KFL78;/5->]$?'T3-%72@7
MM+%GRB72GGXC%F@7;GU=FNF9_OLX>4Q?_H'\Y"DNB-`C7M#&T:UI@&Y-[+8!
MMP[F!AG^WY1@&F1Z#RG5;;5L(`$!XY*@`"?EJ=JX)ZK4,/->25,'U=N;3.C3
MJ;Y7>H7[G5X#-F;)<T0VWL)`;:Z@H1L9]0%%7IA@!&=ZL%9CRX-*=VG1(0Y,
M$$U#MMO?1HW*AWPP]9B@VJA#?'B:>\EO<1H&MXNEYR?7TREBRE(VDA+OF8Z-
MN1!7(]+?U'WFF[0.UNWL.M$TNT`=5@R-6$%4QBI0$0\A>Y<.S%89Q_IC3#5G
M$0WEVB81A4SK=8`^'9HL4C7ON.P<UA&R3!MCW7/,'%PSIAF7/6WVRQ!^*W'9
M,Z;C<I!>%%UV5NDR_)I7.I>]2OJ$OS77W7N,I`MX?=6QR^^%],N!QA/`O<QF
M_3.ANA(<?)##+`M$YA^7G]<PRP&10<#EUS,ZGOR[JKY<?M_"+$M:M6`NOTIA
MEA5JJF&7WY+829F@X?KA\J,/O?-@Z]RT)$&VQF$I^D?)-:*.A%CU`;8>0F8O
M6?0QDK.&1Q3)Z7`2XGX3V3OAN\_B,.*(11N,IT]S=)D_I;I^8(=M'90BEK7.
M>V%15W"&.A1YP-)'13[0M4DGM8Q)@HJ$29NR:R6QN[2S-$YHAJ,(Y%<04Z[Y
MX[79G89E>P*)5B#EV,9TQY[6O7['R7J.K-P)"`D]2O/P&:FS=4-!(VX9EW'$
M[B.PON`3Q0'*E%=L[&&W"$:4/TW,3#2,5_QA1$JEJ?&:?#=ZZ,44^E=$$@P'
M]@/)=Q3.XD=$8".Y:G14TJEIA,I\_I85BTTD-14[.CO;<G86.4]&"'9^]!6'
M<,.#<RT/I7N*+^`C#KCX/YH1A#*K:'V4]1K8/\W/<%H_+I&/IQ@%=VS=PJ[E
ML;1_4UC70>HGC:$;QOLX.HP.SV&4A\;"Z/%WBEFF3=CZV2E`7H5Q/UI5[>;V
MJY#(R0N9!*B1,+R]!6MNOFQ9EF44R2H0E[=#O>1][)'_1XHISF.U!6A4Z]N[
M)HJES(T^2E42LF_$/2HN5!47#IJ:=U1<V#(="Q,NZ9Q8S2F5%$Z%`W2PVYE_
MZKNVRTYW7=D@OA:Z['.W$UK-BY/+KG;[XX/29<QE-[R=6-6';LNZ#U^';(C*
M%X^:8WNS5&]=9-H7#X9GL&N]BU7<U1NN!<-YI**NU;^<L_&"55W_R8IN'[8?
MXOD)2ZJ66_.EVA=Q>1OWXG6.KYN85-:.@'AA<<?T2#+M7$LMQY`,5B-6(2RG
M2`7#NNA1B]<'PB?H8(LVJ4%27'[0U)>35UD)G%7<NRI!)V+PUD4U176=0=!.
M!-,>%4:.7`3EA\XAZH;:!3CK.J*]W=_:MA7K^X3"^+<>;94KG?C.H:OF<>EF
M=Y,"</0`V'V\],+UU.;*+EZZT/Q]1Q<]4099SJS<*,2Y0^L,J[_R6\D8J]G$
M'ND6IMK4J6XW;R$GI$+NFM"K5'1]4*WM,+(\.\)N`->-.(SS-KK!KSS>L3TC
MI7)#;N.-4V(&[Z8AI_$^0:]F!KC4DMN(WV(S>-?M.(SV:8X(\J:)\/S6;\>Z
MFFW02M`>5%/[2+'440XKLJOHR$,'>.7?E8E=Q1/KUV-W>%+>^%WVJ-@_6TH2
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M:AK4;>6[06KJ4<&+&,V9M(+(+?P3SA%N3@'04M@&W^WG"EE+"U[B3=`K1F]9
MU-5-7*R]DHS7Q%'=)@QE^9"+;M<\X5YP57^"0[NZ:7I?BVXR1HVG:VFZA519
M32NSE^4)0F3ID61U[RUD-HC&HC9H7B>9@IF*(J%I?KN4`Y3*3>V"P@[0#:>`
MKT-ZJ;R1E7<=XCL<ALT/6C>5,-,KB^%$0?Y\^GK52FB0E3="T2\@67G!HX\1
MB*TL3$Y,C*BH&3H`6W3)4HM=QF29;\$26B3%#65BHG?9_AK#"-!'1.`((V*"
MI.5MK+?MLXN=M7(Y35;##$_S#J*@>M!N%"LUC6J%P^JU]T.MT#]-L:;%64'E
MY]QVJ6-N,<=RB]VSV.9I&@5L(C&E2],TK!<RTW?*<(RG6<[[KW#G2%#$E!ZY
M*B'3DJ#&MRB5ZQJE]&L<(C\-$66A\[D"%`5\>2X6B/C8"UD>RQ$%\;FR8IO9
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MJ5;UF#56G_K&_(._>F&*[M$;_T4S8^Q672NHTA>*_DB93>M5=(63EW6`ZA:I
M1E3:$<JEIZRX_*"IMR0[9SZ,)1E%,FN:RQK9WY^74Q)S)RD0GA[@5H%9C/LZ
M46%^7(O$%O7*)FDM="7K+K(M3$*AL(H]']:.?BR;^"QE`:)X=\D]S_9VYY(2
M7D5!9(/WBZVL*FJIEF0N"54W=64E@GW?;26'=>/(W4RZU-&^6&185C3V'6KP
MY0ZLT_*Y<CD-TZZ,:##*.1]@N@-<=>]QY^-)C7!!.;[!^2A2(^S0<%EW/GS4
M"$-:?."=CQ7=@0FMEPGG(T*[@1=ZW5@/^NP7;Q=M=L$2]Q[A-<"2FH-Q\>BP
M>[&?YO'64VZ<'90`J.#E7"`_9%G03'Q>P:O#DQ@5+&4%_,.3$$TXY17\.62!
ML4L(>,&9PY,BC81C%PPZ*$E3TS.WX,)!R9]ZGJ$%$PY2XE0T7!<FBX.20Q7=
M@PKT!R6.:@67%CPX/,&T[B1?H#T\T5+#P%RPX?!$3.WH]8(9KC[UUR$BK9J7
MJ<D*:-V,US=L@=^']1?^^L8M])/*D7\Y7.2M;UG^Y6"Q&XH0R/GTP^'RJ?;6
MYU]=<.*0/A4VH$?NU?(H*@)RPMO$P"OWU3#APFUJN(BJX=D%(O?$R<X18J7W
MUV7)(`KIT3V=V^[8A0E"BB%W[R*U.VQ)]K`"^"&.=RU@N8#KGL;4P/26Y9TI
MH+NG)MT=^G8*I`*M+7VH\KNIYB)A#0G0Y9`(^_**:BIKA]DX&,'/9*AML32E
M><(*@<,]PT5O?%'*:U5L8>ZILON=,6U3Y8LM2[G27M0:(EI19C8$L-C?*M3.
MKI8(QA8EGHMH9:-J`.Q0SH'6$$D)VOJ^;DO<5)O$TG#*,D[MN#O[(ZTTL?MB
M0)?);O.=C,4")VML[-1B]^7(Q\C$"QFFL\["V0+_X_9TLYN"5O(S9@]B@_3G
MK6VU9P**&XL:RGT*+<M2G18_V^$1I8@_'<X>B"^ML*TWEV`HT9L7,@%1R$+]
MEHQP^*L7I5,O?T[GQO/9T^>P;,0\EU<PD]5O.@71F@7PY:I.LGI<>KYD(K34
M,)1KL#(2=[(,L<*R-F9I?0HEL%C9U>4>*;Z,O56G#WX*<]@VEK/!QP<2`RG)
M"F2F?R!V*1J3T:N'0QYD"1>C"IV2O`[Z[3B/5IJ#HTM+WQUB2_E(F*LRI^+%
M\[^5Q,`K1'V"LYN\)*^-8FV7D+6F7U2H>&!X3.7`@^D>R@6VK1)[S<G0=GZ7
M%%A-!].AYEM088O\3N!\)@4=B$W7-.=S)^B-88<[B_-Y$W0XT"(/6T^*H.9U
M)A.?*QH^U1/>NL;++.X.TKIU;UQ%K6?GBTAG_@Q,W6^+04,Q$>QPTRFDI!8E
MC<M91$SRH46!9C^?B*(Y4.\BJ'+"##!'7:]<&,KNH'[3++FEEJY]+B=1V@'C
M]NU6-W..D^:Q1W^.@C1$XVGN&'Z3PDZ6L::>+N/4,A#8KX/4K^<>`%23>.6%
MR:H(NC!@^!.H.4HI1K+^61:1D3_'Z)5WS7B9$]BD`]&I;D0M,UHP+\SQM)2U
M((:M,$#9+?[!PX'",]C:C1R?:G/MJ;9U!/(Z,<[CW"-9UI,L.']$!:.;C2RE
M*'G8]O!MFBO]='1\C&J?CU&)'M?8VF:E5E!QX5YH$5H0FPN:I"'?R7F*(!\^
M>#,X4>]1PC/!\$F=.8LRE9MLY>S2W""BZ(8A`7>,H7-8WNT80V?K[MYLP6G=
M?(IT*\U;PZ':<-09HR6[.F_84<?=D^SCO&5(>\ET.\F<MP]IK!#]V])`+$92
M>4F>EF``/L#7BV48KQ"Z0!'TECR$7B11`=BC\[]2CR2(A*L;S#+BX0IQ+"F8
M%ZTHFW)QB`,O0<&FP@31%&X%XVFNEV8)*"V#V0H?V(O213F[O4SUHMJ(&06,
M\OL$,I);ZG:_@%+D?YS%KS")<';WA`_;5T[XZO=K.#B35:.O4>UGIZC9R;=.
ME9X[-//"K-<&A4%3"4L^CCY"`;V!8X$)/BPGYYBPPWT\O?XCK;^.J5'Q.WB]
MLY)MHTY'M8`5+T$FUCX0[&\K0AH*6*./9B(WIP(&C7\G([>QO$,O<&9$=GR"
M<[NRF9DJZ^LIYD?'&RP,1.A-3*[?699K"BMY_`I'2AC&W%B4!?(VSG.#S3OP
MBJ1(B=E:W`':!_I>:H.J5EK4!9I7W_,;KWN[KHMDN_*3D(TYKZR]UB)WL)'(
MA@Q2':Y]!;E4XZ^)QPFGEYHZ6?4@D"4&.%B5L@YS=G]YSCW5\@[XU=\?=$]?
MK`U;Y_D8!_7"G?8`Q0N`=8VP:=SB:]L0K)_*4]KHO<FZ%;6/29#K%NR[-9O%
MIJ(7L_Y48JN91^6VM1;2:C*<=2G-&+S6"YQ+@3X]9ZUR8%SWG;-*\1G+?5O-
M[N.$G2$;L]\FTQP=DYD7X3]S"^#:\L>X'\%IBR@SP[,_Q].&RH4Q[@D(O`CA
M`+-C%13C>\2S"$_A7A`E(]]GYG5VL@)*YH$^<*K77PR3>KYU4AOIL&">,_>2
MS(X]P?1;/9/KEI)*5L.&DJU&3ZN:359C\`@L)3#)8O1K=$G5XO(Z5E"D-(D7
M['E1+1PMM6P@N?$PX0_[<9<Y%IESA[V735"DQPZJ8,Q>`4L)NV!EN0C)^L\+
MC^(LIKLX%YK!]]"157[)J>?D/D<Q2#Z$AV+=1LN4OU\?L8A3/O+*'#/9E1%S
MY3H.ESEM)3!0[,;%<Q%?TP0OF!/4,T73-+S#4R2='+NV9L58LPG!&\$A'>`P
M9:\D/K+AX$-T_>Z'*8@([&K*_,/2M3!X[9$(QHNN=3%MX]]#1W;YM4T7F[D^
M2V;-H*%`:1OIVII-Y)2_F5EL^>-I)@ZQ?V\\'WI71:W3DAV'BUR>K2EO:LX5
MM8)6Z94:N*N%[,;]*\CAU><;)2*C?4V#DEK%'&0GC)L*ZA4%0;^"N$T:'8+V
M5Q>S_!YA7?<K-F$+M\C&URB_`[.U$D/ZN*<,PJBMQQVCMY)!6+_5EE,726P0
MQG`I_)TO:X.PBVO-`.U;R"#LY9HL,'=QM6XS5S="-HKZ4L&QX6UC9P/KQ)8%
MX?H?@"5*A_:R;<0=!-Q#91Z','MHYIC`R@Z`]06)[,Q<L'RKV<)`(3LS+F,*
MX/+]$P5KO\%#A>/FY+J-H#0<VN\#F$\R6MWD[@11N%;EF2)9RK)LJHQ\.#;Y
M@3D`KG?!X.9H7,9AF&4NS1PMME]S',)H2!+['1SU;LZB[9P*`V#[0R;5`LOY
M4YX/<%(1E&#"?\VS)PQA^D@3*0R<:C<G^W:VAW8F_^T3H^`%1"#XX_\#4$L#
M!!0````(`&R`=$2R5?UJ)HH``$ZT!P`5`!P`;6=N>"TR,#$S,3(S,5]L86(N
M>&UL550)``.,22M3C$DK4W5X"P`!!"4.```$.0$``.6]Z7+D2)(F^']$YAUL
M<U:FLT0B,AWP._L889`1V=QA!MDDHZI[4U9*0,"<1"4<\`+@C&`]_=J!^U3`
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MWRZ]2(4UO6ILM]N?V5_YTY'[2\2DW`0V\Q)`0=3Z!/W7^_2Q]_17[PWS_=SX
MZ5OD_/!OM,%_"0,/W^,=8CK\$K\=\+_^$+G[@X=_2'[W$N)=LQ9>&/Y,W__9
MQ\_D6SJTA2UMP5C1%OY'\FL69S\@^N27^^M6@[8E6?REGZ4I>8=#-W`^^N.T
MK;PM6^V'V`KC$Q0OO"]/]<<@MKQ12A?>3-3UZ#\HD944QM]B[#O8256F,CKP
MQ)I@4&1"J=C`+@GT*"B#L-$%3-;.BIZ8P&/T_MFR#C]3KOH9>W&4_H:QU_N9
MD:#P?R2__NN%;1.JC`F5WP6>:[LXNGB*XM"RX[0U9N.__@!XX>=,?_I*R8(0
M1\$QM/$@E_!O-%"+OWI/]*6]1UZA_1/VWW]Y^`&YSK_^X#I_7<RWYGIA_'5K
M;K;KS5^-OQH__%LN"Z7"T.^IN/_O7[@>8DV+2<>%;Z:WSQQGWT58CC\KM%,]
MR8\]!B9/_&P'I"\ZQ.]+GW$7!GM0+*7M!V"?_*P./=&=]68]>?CR&(;8[T%.
M]6'YJ*EH`(RH^7R]7I80$Z%$$$HD*<7**5:9):L.7)`&R&@)K`94-%FO$A'W
MV,;N*]7H-[Q_PF'/MZL]K@`551V@3+M:FO,*+G)1Z'<N3&T_<IIMYAC;9".E
M+>":L-+H#3W0\AG'L%ZD\16EJ,GU@'+O9CV;M2.'R-.C8SG9Q#*`PDR<7KBI
MAUXW=BK.4(2?\$@F[:[UY'IN3(:$O>!I>5XN<IJ5``]9#"/O<*@H5)"E'#("
M;#.+MN%O!^Q'.%(,ENXXJR"EPP>*8'+<'SVZAG&%#X1_7+;&1W[V,/WAPG<N
M]D$8N_]@O[\+@P,.X[<[\JEB\K>/?S^ZAWTGJL2(EPM"(3J#XWJQWF:835M&
MQ:91UC8B#:!BZRAM'K'VV=\S#<0"O6DU5"</+J@+;W`4(:O@1Z>@@&*>$`JT
M"JV(\_<P%MH_^]\8MQAFPBST-W^]<!R7-F5YE^1AU[:\*_R*O8`U\YOKX2@.
M?$PFIO3?T1??P>'%<XAQ`Y6<+D\P=S@!\3:1RWPI6EE8R!O&>KE8+O\ZIR%_
M%\3D1=?RT#Z5':'C@7##]><KB@42F73SYZ=)^OTF)I7L!<Z=67,H;0\5&D19
MBRAM$K$V4=:HW&&19!^Q<5/FF"Q0Z((6=\:1.</J<L;45"F,.2@WBO'O1&0H
MA`'UISTQ$6PNC-5LS;GNXIF\3,<?Z)"QGMT1U=:KY7ILR2`.T!-&V`I],BC@
MP6X''OE;$/*!5!;ZRGE2J-M:R?%,"%&H,_I84"/6.YWJ%/+;/7ZFP]$@?"/#
MRP>+Z"&$\8:+5<^!@W6&1_3&2$:`!7BG9/@.A5G#R"*3PH@V#>CXE;/?Q`YK
MY<.\73:)9BV?"TE.[#/SU"#3B%='4U,'TXYSOVCN#?;[P'^(`_N/ZR@ZXKO0
MM?$=#A]>K!#WA%'GJPHYM$LO8`C/MJOU=EOG228:150V<JEP=*#2T8&`.Z+R
MU1&A.*MK9,>M9K(1$XZ8=$3$(R9?+9V)LYQ1UK7OLAG"X?CDN38*=CL<TERG
MRI?6@9T@X&UBH%Z/"6:9&R+?C_"OH>7'GS`>-(SK>5<=SW0K-F"*L:P3C<=E
MHV<J'.TPUF?$)=+L*M,DLA$3CJATK09.(DVOCH[J7UP#@H'AMH%A`)Y2LF^9
M*7AGN<ZU?VD=W-AJW9!J>5KFKF*S"O!<Q"R3+(\T*@E=^RB1I6A?7X!A50@=
MB*3WKH_L=L.D[=MU!UII&Z[#$QIAI#OKLO,=]7@9E*,X-Y>;51]J5*=A"K.S
M"B(J[SW03L5HZLC+['6/X`%N,F'_<@C\"_O%Q:^LG[O=93/Z[H%%_^OJAKF]
MN@'#;;DUUIO:0#=9Z^$[SU8NGTR[\A4A96-=L;;7*87;3L6C@GQTN\N7$)4.
M>,7:7UL0#/S(=7"RDT8^N!5%.";S[M!^H<=!==I6!@.\83`,\Z)H1DIW.FN+
MBGG"+=7H,_YZ%1Z?+PX',@-A7^(BR_WH"0X1+2CD-0'J#YCRF0W<5T_!R3=8
M\J1NSHT^_HH<H@>R<D5T2-.1[\8:C69N;-AW*:3_,YHE:B"J!RHH@G)-U+*M
M=%>>87Z/2%YKXFI1WT`PG>>;12?MB</%J"-FL([07+;E<KZ=M6<"A7AO$03X
MS\5]R:%9058U+R@,B4YJ5VHG<F25?PM;X)IO?$_D$,:B]UVQHP%O#B:0!G(<
MYC_!#%C>(1_$>MVOJF.Z3KT&].0&B-U:<WG.*MU1H,^J1%9)WM&+NP3:S?CJ
M0=^D&Q#2&^BIWT5JUM/_=HQBYMO'H&5ADFV\LZIEM/`7]B.&MGO\]Z,;N3%^
MP.$KWZ%W`X>,0X-GGTGYL^4=JY-T:<U*7=6?UA;H@OERNUBDK)%IA!X#U+%/
MD.N%BHJA3#.4J(:X;JB@'&+:J=IAT,CGG+%H:^^Y*^U">VIW)N2`N[RY(>'+
M*&=*JI5ONZPJP+5/OC>^"2+R^TLK>KD+@U?7P<Z'MR_$PFO_]L`6D?WG"SMV
M7]D)Z;ZB8U,TI8H1!>D/+>&R-1>;1A;,]&"5-K@FB*I"_TB50:DVZ,,;HOI0
MHLPT0KE*ZLNEJ?:O6?4O&9J'F7]]XE^7^Y?\GO[+INX]I.Y]>D,_'JE_7?]/
M*,@<;&4Z_:(-:0K&>2M1BOR(2LC18\*QPZC]0Y7:/_*B%FWA#'M9)H&!-`)"
M9C$S-^ET+I7+!U[H0WWDE<A61"SB[>:#(YK,VS`X2JN=*,7[H-`M(1CNK?&8
MC+#]TW/P^K.#70Y'\D,5A>17?[T@3.)0-OGD6<^5SUO_NP0LU1J%]C#&=I$>
M\4Q?1_1]N9`X37T3IO[4,=X:&#2,FRT4LRZZI\6S;G?%I/Y"-@6=#`!62`<+
MD;Y6.E1#Z$J8L=FL5\FJ*6N#Y9^TY:;0S%+5"?C3>L(H>.)V5US0*#7#ES<T
M6!>=UAN,7.[R5`Q>%(@,M>,7W!HE"I=.QY)!OH@ZRI]*QL%^[#JN=R0#<_R`
M[6/(AN<?O]G>D8S@/Q&GT!'"D5/*[>ZC%=+-CR@]W<0-;1N<"9$M<Q0M0F'H
M2IRQ6J7S_D*S*&\7I0TCVC(J-$TI)6T\/S6(>/N*!N+27<=)A4`!AR&=G]`1
MN])AN4@DE4;MPEQ[A@3SX:U9P,4W-YHF%#M;/!\RZC(#?$?!?+842U$?:%V'
M9E&_4\U4K4]JXFNSR]?M#CH3BH-@62#Q]7Z5,Z3#&]?'US'>3\1]N?CS(;I,
M9RC2YHN-*9;5?J<Z(*;$>1+8.!]VLE7FPUW5A\$H'YX)Q]4`*I#0RE])'_;Z
M;.WQ54#SX@9%9^$UY6R3ZP)%P'JQ672S")6)?N=2M:*%D<9VP?U=O[5J`5R/
MT7Y@5ORD!'!YWGMTX3N?`[^0"?](?HKH)G3@1]WGR0=*D0G'8:I!5PAFJW6Z
M@UEH@-64*S>!BFVH/H4^H2_,FB\L[HOW[<[0`<SCXK^$[1%>50)U>EJW=5S/
M_R@3F*Q%\#4Z1E;C@;TW#8`*-X.*TGE%=687A_+CTFJO,2F%0"F(<\O4Q69?
M$F#Y(>FQ.O@&SL5R5HQ9]5ERX\TPNZ$G-X`[D\CJ-JH+Z)[+J$K/2`_G@1<S
MK8U*-$]ZSQ2,B<>84"!DF[^N#3%WW2E5LU=Y5(/8NOJLJB@?2GHK8[%LBG9-
M./P4JW@1@5+HJTTO[@JJ5@QHPO"?+#=DIS"NW,CV@NA8J\+<_[QT3#0H`1_3
M;A<E7%!9_-P3RJ6I[!-.-:[0/^@RWND(LCH^VNS7"B.@OJ/K/1TP,YA]S>S:
MS@[L:-+#B+*W,''0H)<!A"((4>I[GZ]6Z%Q9,>[*4RD](Q,QQ8;!JXA;(TUR
MIZ\C^K[:G(W15IA@*Z1%?U.XE"*]9JS2J.[>[:L\I2*R!VYOS1;;>FRKW;D[
MP9):?.NPD-\<.HTQKGK/C>KQ2%KIX^[L&=D1GC8,/@([FV^*\4W?5\_=HZPP
MP59(C>QJN-3BNF2LBJC^8$5N=+N[L&V:#NSZSW>!Y]IO_'\?\;?X`VG\CY;O
M!7Q9(@Y@&H&'!;-5LGC*Y+(C.YEDQ(6F__F=2D=,O"+T3&"[F=L>[-`=43L]
M1L;VB>]"U[?=`RUQ1/Y,S[*0MASEY4*&Q701DP-<*.1\X8<`O]!;CW!X3?['
M>\'NOC%CH^=AV><%6S6!W@.UFBUF"WXN,)>%,F'D)Q+MOI6<__IU__3ODL\!
M"K+0:+5034J)2-O,BFTJKS"`@2D[A]?M`27=\#%R?1Q%%S:O'<0JW9(?0]P]
MJ>I_3V;GVZ<,>`EJODXF7JE(5)")4J&*YV)BS37;S'T'LU=:YPJ-U%*_"G*5
M+L!KG]^U/:T89$/.$RW38^B-T%(Y^Q-A62N*-)@1]H1:'UZ4SA+K^GPD/\5O
M;*"&HSAB-UPZMR']+RUR^_E(^]/;'3NAD/P5_MW'"%>+P1$:PS.Y9IL.R/*6
M4=8TOSO60;<A2EM'O'DZ?^4*),]H@_.IO9=7MHSXA<*LS(3%NR!$:SC';YI1
MPPGXZF&2L<Y603RT;MR%[]#_4+5?+8_E:\>75AB^D1%\5VU>V+L2:0.D$#CK
MP=PDV]*LYB,]PL!^*$A&%S%*94]8Y/;`ZIM^])TNT(NW?9'93I>B6&5&7+#=
MB@FN';HNQ?6;T/2'V`ICN<8O>XU_PL^NSRK23^N"7KH7;[S9:;Q*'A]$5T6:
MACM)'Q:&)]'!WU?.QB?EH:6'R]H966+>W3A<GFK_N6$3F*0WS%GZ8)37'K_V
M[1!;$;["_+^#(J)%A'*D-NL%#M;5K!>LR54!:1,H;4--GNQD7F"IL[26N/U"
MSS\B=K?WV0"X.\+[,=SA0(U@#-J.A[VK'KBC-J3-S2K=%.A`K"Y[\>(M+W>L
M5<LUQ&7_;CO<2?H@\1Y'<>C:,7:ZM!\4%4"1RG$+TQ,:U$MCV;M^D;>(^C"O
M$\PG<%1R^6')'?IA?A@X^JE@@".5,(1G1='MCI48[=RE;WA0)IIKK4.'A^8R
M+6;$9+#]`RI%\<;[B0:9N4$!Q"!IF&H-IQ)2FHU7&/]_8853XMOPWGU^B3]^
MPZ'M1OB.`!=G?XR2O[9MK(\2)1]#@_0#!^5V6459(HKNX3%9*&T*L;8*CT39
M,Q,55P&"<3K/,+AF]A^H1`U0.BKH&W`\W&_:(#W;*,PJHUU:GD?O=SH%]`.D
MJL8_7%7P6&^V6?=106$O/R\JR!NF=92UYH6)/,9KOA,37MC-3!';N=:.)(;C
MI9<O!OI32,[Z)7G$M2WORHJM>_SJXJ]\">U3D-];\8C#O>NWYH\/%2$[OWV@
M?O!;3[;K-<]Z3UM`#FD"A:R-9)<6[8+"_3<HSMN1G`,_J1>,DA=H$XBWD:ZZ
MDU;RNV]0H1T%&?.3>B*9VC/;R7S$+D:&LESZD2#/,NS'>$P,.P4>L2G@%^I<
M^,X-&4CY$<X:_<C2GMAYTL8O/>!UZ:P$UPUZDF.[-!?).9R2=+;&[''Y!2["
MO`4:FE@V&4UEO%$WGBXS)O(+%)2TP,Y.J^"@J1Q@-GS]S&BGQ5@Y)#0<RSD!
M#727%/*)\CR!MKV\\7)THZ,F)8?<#[<$\U*$G*PIS6CI="=`^2DJ%2-2M@$J
MR2M-I-7H%6W)JXL+P"S6ZDC1=/::M\D'<K>[R\!O*@8VY$V%E-6A%K3[7"ZV
MJVV-I%Z+`Z9D1D>']8EP=?PDS.(J([T61TG)[.V6E0-@PM7RCS"K^1I3]CVS
M;ZP#P0#0V40I?;Y1LM(<[/=NG%;EI^K0<]J^[>((7(=PF`R9J\A#%(,7ZJ!1
MRC&9B>>I$L4&=*I5.)T?S*H?K/%^D+98/";D2TO#@]VI+;)[4QR'"=$-VX-3
M_^;;[6PHN-4G/T[GBGY\:X_D[I3(X:Y3A>7`9SDHG3=,U9^3C,A2X_";D1;S
M''1D:IGD""F]!>HT:\Q!ULC$2V,852%1-UQQU-]9X6WX0&::V&$'@-*[&/L_
M7NN;:I#1I@[XSO5U<?2911<12Q,0N.#DP%MVJ:=R``DQN@BIB$I]AP[$ZM>V
M<]8*0-47I2TPZW2/8N#QJ@07Q_@E"-U_M-84Z7I##="J:@RXIF_5`+"DF$4N
M3SFH3C*P`4P\BP=9G18J`%5;!+:`J=$M6H#H]AA',1D_DQ$F].L67U$)HX(>
MX.G#<K-IQU%!H"9`&FMB.Y*";AN50:DA#CNQ5/6,8C!UEJ"I/J8&-(-*;"Q7
MFV4#4*:K'S,$&\,M:<##_SW[:6;D@[7WAKE\-YO-Z/_7>QVVPD`>,-;K=\OM
MN@%,M-K*%;;9W`3-C7>(QLP_HT6O5./=;+MYMS460*&F)K!MKV+2]*$4P?.`
M_2C=-KW'L1NR?8XA>PA@"7)!#54+7#]_9>1+C)EPML:8B]=L]V`2'Y@U'U@C
M?2`1DT/#O`+708Y4C>1[[-$YZ640@2LB`-]6A.`.E<"SI\UBVX#>1#)BHC4J
MBS"!\;RV(^USWC^QXQ_%1G1!)R!TVY#9YR=5J`Q\NDMQN[O".QR&V'FTOH'N
M`X>]*QF1O0K!=ZEFA=Z4BZ79,*E@1"0C32X6%V\XPV)FJNO;P1ZCF%BLP86U
M@V*V"D:8FS2"XHUK/;D>.Q(V#H]-`M2#LD$K\&%BPS1ZD5F0KRL\3W5!*T:]
M7+".0.V(:`!:V[RF"K(A?B$=O/N*K]D'&'+K%OAUR7"%Z`0_UCM?Y&#-)",N
M6KNKMR8QWVPU_\>;((K^I!JC0T*XBE"PLU3A\TB^.:TT=*#SX;X<E\:G):.O
M007X=O:J,&:E@E`F27W6R\F6F2,LDXFCCE"KPJ;-%2I1\A#LXJ]62)`<DV_A
M/GF8C8Q!F.E^5P&".A4"1]UJM:K@*96+<L%\%J@)OL39S9=C4G-UPA@H4)L0
MU^\<-?@CEM/3&FR1R(W^^(!]^V5OA3VUZ/I>DXJZ;EW@9=V,;!&T(!%1D2B3
MJ;IJG4ACS9.,E8<\6(B600=PDQYX>\M4Z[@RKO<UI7@KZP(F^MELW8ZWMV(4
M*KQ/3JBU`,`IOV`.&J'=<&MPDB9P>WPKWZ;>_[VS-]2"+%4#O*^U-%==^*+R
M=(/6*!O;4-5CH$)`56.P!TLEKV@!H\L0.VY,?X)^V\(;*F&4JP$.L?6\?5C(
MQ;&?-<'02`,;,!3L^LQ3AJ!Z^'4BJ.(3+1!TX_KX.L9[<#^4OZ`2/YD6X(G&
M(C][6H//[U0<8O)TZ8/&&=C6!?49J`Q!M?#K!%#9*5K@YPZ']!?6,S:@G[;X
MBDH,%?0`SQ[FB_:Y4BX/&9J@:*R):7V4U!Y:(\7S4.0^^^[.M6D)XQ"_8O^(
M$;9"?Z(#2Z\X?`HD66SPI<Z"@1>V'1SYQ24V=E_I;;I:44<#\CK)H^H9+>CC
MD;H5^FWYPRHI@VD`SD.>+3?M72X3I4MO.]RNUIZVW2YE2"D%62=&<C_H@0[2
MXK#U_\(;2G&2J0$-JO76,%K!PE<0]%KP'VEB]R*)CLO\]2#LAE#9+X)J%R:E
M4V+R4^0Z.&D.VT'H8.<B8C<^LFJ!WK5_%P8VCNA]4V1L8M.;IJ[(6,4+V#[[
MQV\T%[NE7+3P5N371!1MPH!*GJNLR&NJ!"V4F&M!AHQ<#61%-%4Q583>47K@
MJI!'N"[LM(Z3:X,P5T=ZQ46U_C0J_BQI@5(UT$6$"HJ0GU&B"DIU82?`"MJ@
M1!TE]1S5^I0Q\(7CN+15XBUKSX?Y:70JK`$Y%<L5ZD5.XGM%@R66^%NX>*`G
M2ZGM>;D#I68EP&/O[3+?3&*BBK=I*,\_$F&=.<HZB<.C[K"K#(XZ'*((-:_D
M,Q)%DEL'+QC[\5_'V.E8Q.MY3RZ*NI6!KORL-]F5F)G(_%Y,+A5E8A6NZ@DT
MUZR8&^S(X"L]0,)J*BB&%RP^*S`#.$C43(3*I&F#=ZG76).Y#NRZOY:!#^Q=
M!;,&D&+0&ML+=C/K/`\T)KH:9G1RD`8ANPA2_MA^`JN-JM69[(15"M"[:[O^
M<OH1^`265XF%?5--Z&44=HNC9KB_U/7J#0KVC8@[WY+>H[>J`MX#GJ_7_0A4
M/D@69BJ_37>WPV2@'.S06*/E=NZ]85KOVKN]-6W'_H!#6J^Y$4E#WM2F4R^I
M!:5X0O*S57^7'C'9Z$J7KOP$6WMIY"&Q51&?3&:X*<1PM3UZ(VC[^_.ZU[3J
MS7G%Q.LH.F+GRR'P\^''T+ZF0Y(.O7Z[>N"<#G.Y!$"85^KC#2':4F%XKMGP
M0)!/:NANIG`MAPG]\0\:.O1X4@WD(W9'1+*HWIZ,6GE,*EC+;8,7G8Q-EK<=
M)=>=I#*F@5@06UXWQ$ZP9$4M>:1-()O90S<J<8<]\E#3'$)E2#18KD.\]U8U
M:GE<8?P/+:FU-O+2[U4<:%"=2(!Q9FY<$12*RP]U!UH7.C0H+72D%QL?K#!^
M^VSMNX_+-3PJ%1WU]J&\.I^9V5@MEX*H&,7GXDZTR1QJDSQ4M`=6&1$M'E""
M!G9ZJ)9OUKW$V?F.3'QT*0(O%C!/K[+B!\*:\F_5+FX*,Y.GXQ_W>RM\HVN;
M/9GY6BQO0@*T!*]>;XW'683MGYZ#UY\=['*(D1^JR"*_^NOED<R+_/B3&]F6
M]U_8"C_ZSI455S<P.Q^5@*.N]J&#%-)"NC_')2$N"E%9Z"--D"/2Y`)'F%WF
M&+NF1@8DP"@@>KV@I+_A"O&:=H_6MV18^`'[>.>VSE2Z7Y+9XW1J`HRM!7&-
M6<9,4K60UE=-1*)$IJ(N1YR=_-1;&+RZ;`-[%X1HAVF.I(?(CQ&]0ZU08E7Q
M=!\4G:7>IM]1:F`6Q42A<.#`KN<MJ4#K5`7*XJO9*CTME@C4<'@GT-2N`=Y]
M<K94BU$=+#[+2.MWDPJHI1642U>%A"'Y5BSE^R]N_'+M.^ZKZQPMCZV2?Z!W
M,-Q9;^P.XYN>4@G"Q$L$KRB=X85RTAL%LJ+=Y8MZ\K81;1SEK?/=*L3:1ZD"
M&I1N4.)"$^;"KV47ON,^3*X6`?M0%M6(QF>1DX1^)97DE8U?"D7@>R*S\14%
M)-.D!WA!<34W*L11&(D7!(HE@2VWSL?/]-J:Q[ZM-7&6;JFIOX9!%"&G^WH#
M'1#;%91-*&SUCTIDW=-C86Q)JN?K%AY4@**\=6A$K<SYLH*=>W::DDE1VVN.
MM*;<_[&)>0J)-QT`48^E)AA4C-<C^#\3*_E4&?SI"J\H!42N!_Q6U=6Z'1HH
M%Z@+2D::>#YXJ8=?-W(J#E&+(39M[_V6_"DE2&%-@R/'7%4G:XD$U6@8;D85
M`*UFR(_\4M`T!WMNKP;Q?0GL'4H/JXOVRX%TN6@+>G2I1U<PVJI&#-!9A7=T
MV/0")4S:-[TXV5I`93L17['1X/<=/;HB\%]".KR:&S2@@@%CQ>KSZ@AA^!!J
M1>*IA1/T&2&>8EL_,WB!__R>:+/7D!O&?M!&J]\A'[/3A"D7'H)0]>7+O:CK
M8`R-QL?9/;/E9:">C]SVE@(":5$%&G5;TYA7:*1P@7)E75,MG8BP5-LA=T\<
M-H&IRQ]:0(HM%4,_*G]8)8"8!N"#)]OT"KHFW#!1:D[2"#!KU;W.SZ\:UPHT
MI4CKQ$KN#2T@4MAK^(S[!JQM;ZD$35D5:)AM%NE]<DWH*=X13H1J@J,3+&6`
M(B^UP^GG'[.E3Z77#@,#M!-B#8[2`FL#`*8:54,";+.L;D(7H*0/?(::U(\9
MO;H@*#JT@L3M@54;]9_I?>>75AB^[8+PJQ4ZT15Q=12[-O3S`B2I!%2_>N"L
MY+E977<IX"UK!]&&4*DEE#:ER31*L$_8U.I3DIO]Y:>'G_BB1>80CSK$+C2C
M%7SA2.A$-]"GFH/_@:;57_C.#=%&0#B5Q>E)`R4=X<4[NX:QG5S`VF,'SEF+
MVE/">/_PI')F[O=!"(WH&,D*=;?J00WQ2^LQCY:'E<*::@#NK%:US+,B:*DH
M7=`XV"R&M583U&&I&$[=2,E,U@('=R&EJ_CMCO@^IF4H_GYT6:5]Z"=L%Z`2
M+ZU:P6=H\VJ*6@%#J7C$Y/.J*FD+FD!+C`>2W81#B&W7TF5##AZ\G4CL]I`6
MZ"0_),?UBUWJH+ZK2X1*A';H!>X0%H;9CE'Z8UJQHC0PU:D#%.4%WBV&AQ?+
M1TYX?$8VD\JVU;6"+""B.T';YS"-89O>:'-:;&12]`-OJAIXOWK6M3/?BM^T
M&:TA/,H7#,7W;9>1G1>DJ]$^`M4E'^H"[/1W22$#JF/XBFD%MPO;#H^6ER4K
MW`\810\7K!C^P[0=@(*>'CW[?5H&)&V9#<+3MO/'[O49D4_KM?I9$]U(8AQR
M^GACA$NUH)(_6]Z1GX?VO."KY==N[QGRIDHRJ*L#C=O%;-O1_V=R429XRE/&
M@Z!\JLT+:G1NH-5EH#+(MD=H)R9;?*,8=(64#>#TN?:&&I!5U0`?:%\T[N(6
M,X\FF`B/PM1I)BYT6Q%N"[46U#1:KP@MKD]K=?AQZ#X=*83O2)=*D>P[3+6[
M((I#'+O\LE:Z;A9=N9'M!=$QQ#W5M$5)EXM"$2J#RUF;A;U6VC`JMHR2IMDX
MES6.RJVSM6@R\LW:5U[?6X7_S%[_68+\)Y%91,*RPD+"/I"0^[":%")M?MP?
MO.`-XZCXAPO?)Z/[/].4$__Y#H>TZ)GUW'@'I@BQLF_2$J#S@!O*UQM^S5:*
M'+N(G`-Y_1W":<NE/[XC>**-HU?>.CIDS4N^CDNZPSJHFKR.LH;+?^--HZ1M
ME#>NX"(OZ2[CM4ZSE^F!OS2L6`!5(D_9%5\">2B[_TN4LW49&N:ZA[1+H+U$
MX%OA6\D.=B7R@.'!`*&*!X)P3<$;[EO#`))*B$IM5AB&M:K/D&\B3R7W7.P/
MEO_V3^5."<4!Z[002^+7;?`V'#A]8[:!'M:(07ZSOKG[XY[S7?&/$6&]E!H3
M`AP6<H,DJ^>2(>J"*QX;ZW4?H23MIL.24LMT<)(-8]*1BE:\,IG7N@8J5::)
M+(]@34.6&0,N`-4,=KH:OLESUEICJO"(5`;(VP4G^9BK;*ND.QE/!A9'ZE]+
M)DQO:U.+G7J@E$%0L59U-).?/<PG"0[IU,/8_0<TREM?513];?J`-[[76Z..
M"I2)Y3D!!<'J`2/$Y#J0Z**F51"G&[+Z@K8-<9WN4H+$;/7S=E>L:GZ//;KC
MQ6YS9(7,GXJ%S/OV1DX3*A.])VD*+K9/QF`)KO/5^-M=N>)^TB3B=W_FC18J
M[*O>_Y#G++/BK*#+66T7$NBQW2$$8"4^.?TS:,TTI2L3'O&W^`/1ZH]38[)%
MJHY<TZPJ=+XW-[(Z1X/(IG8G"FT9L:9UYQL!#N-G7JDPYWW9$6=!'MV8&<4>
M'4X5LS>:[!C2DTI^[,9OU_XN"/<\U:IY?`%_3_KN)D`I8#PN#7.V3G8O$ZG\
M0!Z3BPJ"IQX0M&]-BK;6T,#:GJU%T2:;IYLL9^MP`$SSO4&HMZ:_FC=5A5^)
M>H=#-W`^D=]5RQQV/ROI<MY6!>"WV&8Y5VEH)=?8<F&(29-_.Z\8P\PQADV-
M$E"0I??S=OM!-AKH!<$P+.1/*D%"UCPT7(SM>M&,`W:=LQ8H&&=4(P:ZC9*/
M@%I@-<=_V0/RHI_CKOV.]N;G)$=^J7%XB&RJ_)_PH[J;V4\WR!QJD,R(;PRF
M:KS7;9<7[8]$;,=G87^6'-NTS0$14*5R^KJZ.!ZLO`E27F;,%D.B&JJ9>4H6
M"9.:>Y<TN2=\Z[R]O/E9F0MZ30I`(V.Q6J<[X(D8E,A1?#WYZ5:Q>&?U)-/B
MDK\&KSCT6?CK<!MY9Y25%LM:?:$"'!^MT'?]9YJ6DJ[0M99[;7Y6(C@:%8"&
MT7)E)AOAJ1B6NY6M4T]4D?401&[LOG;"XW2[YF9:*#FIC_PCK:OX)WK2`$54
MY#OT-)F)O?`_W3YF'GNMP4#R[WW@<SM57?PC(#0+-OJ-'[+/3EE4U\D91:IK
M=XH.5'?E>L<8.\`/FCZMD.X2%<#]YGR[;B6\1)8VE#?&-@#I.1.:.9CVQMB8
M)"VP%\^$^D:%:<G.\Z*_"H]T$6#1-3I0X%W@N?9;7SY$WUL**;&B"C0?R-AT
M4".7J4&N@DAC,ZJ\3G!UPW"56:T3H%JBL@M83:X1DE'PT7-O7,]K7C5H>D)V
MED"Y>?A1T[6QY`D!1`!B$M#_M/:'?T:7@>1#R:=88)0M4+/*<;(5)MP**?OS
MS4&?[<0WF"H&:\FY&"+_V7WR\,4S?@SNK#!V;?=@Q?C:_X!]O'-9C87&;S!(
M@'2D#M$.&$"SY7*]38&<'K["20.(GLJBQSSS-NB%N4^\%7;Z4S;4IW.!47)!
MV@`B+:#'`!7:(#T@2EIAQ_M4<,5T;DBIA,AE]\B53N7E@9"6K%!',6.PGC/0
M8`<J&6TG6C[@\-6U<9X!6<R1I!7@;/;3[>X>V\&S[_X#.WQOCR5.WK@^OH[Q
MONT.5=&MR!S-BU4=.B`VM^M5A2\2#4I9RZ7DYEP+FO><ZY'N'/.DY]^I+H@I
MHVK.H-"E9KM+DW,4127>%7T:C/>IM%G*-&@NS6HF^'C:$M_GP.?E;"Y8(>M'
M6H:B^'=JR^<@_B\<YU:>$O2CVM.-#,<8`3Y_;*QF0VDQTP=QA1#3J/P,U8D\
M&".B50'E&O/CY%[FN]E^F%.>7?2833T6)L=IR`#>#_SWB9NC.+#_2-BT](X5
MAJ1=K/QXR>38'TR8H[_F=T6=:5YPF/R*/F?(!DFS$M\#R39:!MT"V2Y7:XG,
MFZ>WAZB@+C*^,TH^_9OT\'120`"%!2<>6*/?)0-W4H@46F[_HDJYFO;)MP>J
M3&=R8?OS*ABPJ@1XOW:SW53)BLI"7)CB3$,QYB6WU>9615KD&/8&7",(&STQ
M?:HX/Z1W2<:CH>5=^P[^]K_Q6^6KM3\G*7F\L7%X(G:VB\R/629R$!.$B"3Y
M">6G&V0.-4A&DGEG,*79YNVV2XMVEJ+"$,<ZO>CV&$>QY3NN_]S^L;I>DHN#
M#DW@ARH79AD4/&V'LRD7BPIRE4%$E*UFBZWO@,9*A`\@.BM8ZG.2-&`=0WI=
MUST^T/I6_C.],;WQB&GGXW+!U*@#G(JK,.+B4"8/<8'*\'.Z>>9(\R0BIC/L
M*EAI=X@LE%P%>\NMYA[4_BP5!;S-`:>19Z6H_YV_+WDR<9+Z)E!]>5%<#HMR
MU!8,E!6EGUP/AY=6C)^#L'U"4'Y*:LR6FH9_^^6R%+I,"DK%J`K@\;:8@VR1
M%\V-X5,.ZKK1LF*;9M>&I`/@A3F)!K>[TJ]:OU/OBU(1T*?-@`GEJ@2*DA1V
MU)ZF4Y1^JPHI0FUFX/G-(F']*_9=.V+'&;@H["!'88F!87%:QA7(1;*@=G=\
M\ES[DQ=8U9)NS<](!5"AX0%Q,R]AA<M`3(@J4(RUPQQ@A[RH;PB9<H!7S945
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MSZTGE8<D1WG>,O@<R#S+9&3O*[]?Y`0S3+`9,J.['C+5X*Z8JRZV:38?Z5#\
MN'%?JOM9Z9%>40!*ANNYN2P%?"9'T=Z5.*O,P5;)Q4%+>-7AT.0$,0?6F?AK
MG][BZ+YB>MCT\6OP^!(<(\MW'LF[N*-N!/AEZ0?5H9H-N-A\L4H.J?-X<E/A
MR1W$7P,4)_+)#Z0!V0?3IS&Y2`R9<'ZI+!&/4OF(-:"T>L4T]IOM]E/--*AT
M,13!^1'T01X30S??#FZ('9[+>_%,6FB=)O4_+YU4.I2!!M7"V!B;A$>XN#3I
M/!,X+8C:^4.8=88ZZWHH0IB)YF@3Y7`"`&8Y#?1Y1<7P^Y/EAG^VO".^</YV
MC&*JT>WN+^R$:-Q61J+['8G#\4Y%H!.X]2Q-S:?B$).'<H$TZ2`5J69X+LY*
M,[/RE5EIY58&._25BT2>:_&","K'[:"X+([?^[VD%EY1A./HPG=N$N^Z./H-
M6_0B/.?6O\?V,0Q=_YD\\#F@APCY/VD5W-ZJ+F+;4`)?`8J#ER2-E5&'.U.`
M78-64`&E.J!;>F5ETBQ[JJ@'JPBN0T$7=?XTR_Y\ESK4:G-H4'2H-<ZA\JE(
M((:;J4O4=SM7JGNTGKQJ3HMX^6=&<4QI\'*T,9]/0V],C3-FMN%NK+!:ZB]6
M-^5=%W]U^.J<2*N$1M&$E7^.LR:KOH+8$S1TCO0U^%;LU2J]05$PCS%U-*C8
MK=BUO&S!<;^GB5ID\M=,<^B3ZUN^[5H>]WUU0/==,%QG]?")/I-2SOOPEOWX
M[RX.B<]?WF[P*_ETW]S>26;WRRJXJ5,C<`V?]796XYL/;T5<9,(1DXY^I_)5
MLX<XXVMSN-S>=DNE@QT4NXT`[O>44E!>^X=C'#&%C,YTMJXW5,"OK@;X+JOU
M?%7#'!>70,Q0G/8FRDB&K?\X!O1$UUWHVIB>\D(7-MOC_,T*_Z##FET0HFN'
M[A'::7\+\X-T$+;':B/R6IRG"]S,P7`S]8";.3`2-\OZRF<);J:&<!MC)!_<
MNL^^NR-8HGLX\0L.T>U3A,-7-OX?8+9*=)G#T&5JB*[Y8'3-]4#7?%C@;3?S
M'G1UY["H0=<8(VOH^N('+<A2F[8S("S[D#77!5G=LT\VW;Q\H=6=KWU:C-3R
M:"W,7RW7IY=X]07&:<)5X/4DC:&+P8O-LKZFWK\`Q=>;>//T)IE<`40U0%0%
MQ4P@SWV,-'C=X6/NAV<B*N(7-^+H3S35TSLZ[/9*A)-KV[0@#B&H:^28T[^`
M[G14[!T8H]*"O+Y-WF()@.#L!I%-:4I54/W!@V$CO>UJ!''5>W545D>GC`=5
MSJTMFO5G.S!EW@EPKXXL.!3L8SEQT,<\<X8$)46(:N8\F7'(WKZY)O.8*5E1
MBT0)%3Z=E`PU2JD0#.F).%"3!`L!AD!3+$0V=:8\.#078+W=FI-RH39I%JJ<
M6TVTN",@PR'U*"]SGJ2H9T[7(^M^`M1.17/ZY%44\P/K>\V=)]N'R5!!3A#%
MH"M"LWEZ+TQ+=F5SVH7:4_+3>:*:9PJS6#HG#`GO1K"#':<+BO_BQB\U^HG*
M_!.5V2JC<29K0"B=WI9B5CC9`/!Z\K+A!$\Q:9%JTK@I55&F-J#)].%"Q?+,
MEKO5Q\^TL"^_GNRC[PRE',EN7E$_?[#(HS9&V'?H$.8-6X+KLC7YYB&VPEAS
M[ZR+WGG"SZY/]RRZ?*22M87161^[B_D*2GN!VUV6^GSM1W'(*A9$=X'GVM6+
M"(:]JX*ENQ2"!KRQG=?';+>[0H9X033BLA4/U(2971V@!2UF:P%X2.0V`KC7
M74(JDWS"#AGP>1<^)?@8?\;Q[0'3FO#^,]W2O"33X;=/0<@N^F05$QA;_!>A
M4])95KZX`(&R:YN<I"VT=L;<V&QGO/@):0`%:0N(;K0CF[9!LTUI(_1BVJ01
MVKW3AVC7);FFDD2O<`KC[;$S0JQ%1/V4M<E2,Q!K%:7-HKQ=1!M&I&4%I54D
M>LKLBI]=ZI;F^%%6D44(O60E6T[WMF+.9(-HL7'$19X/;S)]@9%O;(W-W!S.
MG!%MX[R(<X1;A%$G:_NLR'.$MP;39QY$9\B>):(1P)^YPY5,`X^A[\9D-DLT
M_^1^HS]%W7GL[2_(G/"U:@&N>V":Z9&L5!9#>BI-=0J[&`/-LH%:Y*CW1EQI
MSM;M!S&#CB,5^YOKN_OC_@9;$8[NK#<V)_SB$UCS7]4RNDI\.U"$]$'%,/V`
M_#];+Q:+-1]$T'>12U]&QP@[*`Z0XT8VZ0@PXJVCI'G$&T.I`HAID/[VQYLL
M%_!/DD<84_HH81JX']2EG$[O#'.H,_J"0LZ081Q-Y$.$$2Z5R&]-R9>#7]>3
MUP8D^)$0W2[7R<0H"=%]$J(>#\9#&J)'%J+\M[)G0U/9/9RG5"2!3NN#P?2D
M,&5S+,`'LI+:%,M?L9],KBX<"D9ZD0<M*$`F4MB/VG(/^MZ2.%WI405<VG8Q
M2W:F$H%LQE(6B1*9:J8M(@TUBX;2<DQ62:3*.0PP((L3&8AG-,16YUH`[%U]
M<#:TP$*Z$MB/-L6K!>+MKH&O8K<.*PF#0G<`%D6O+_SJDC&B\V"[F)@47?MV
M^^T4;8_*'E>WZ`$=1ZUFJW1;EDM"J:AW],H3R8-E(<88#<906U3>/B'$,+-@
MF/)K)GJ@DHU:NRP7@]D08_\RI$OW07@(^')]!VX['I>.W79=P)&Q6,Z2.V68
M-,3$H8(\V1`699/189-2*(LRT*P:J![3_5#*<=WC!A4CY.O]P:+7V20Y8_[S
M/;:QR](][[%'TW@O/"_X2C-C6X9G0R1('"T/4`LZ<5LNTOM\4^$HDXYR\2B1
MC[(&U(R;I_(``V'V*@JQ'80.;LRBDC58'A'%Q2'S4$^I`RJ[#R>\<J-#$%G>
M[>XF\)]OR.#>X74F>99GWTG;4:*D0W>8?N!$X/6RA&%^-U2(TG9H+C1M";&F
MTO*=O#$-SL%.[AJSXIJ`N^-]T1WJD3X.!G7(CW"D$NS[=K#'+/>&:MQS@WC;
MTS(1W*P"^,3U9IG,2;D@E$E2?KNX",O,$99)PU=WJ)4@U.$*#5!R0UNB5S2V
M5\/O>D,=6HIJ@.-J9BQ;$).*4UKH7I2)S=`!F*@(/TU!V(&AFE\TPE%GX8/N
M=]1C:=AQ?F,[,WK1I+2*@3@S^Q"E0>D"4$`"4*6X-`'7ZM'Z=G&,7X+0C=]Z
MNZ;:P]*15-4`G*"[,C<E"!%!*).D05]TDF'F",/DHJ4MS.HP:72$'O@`=#D-
MCRO%R"`&-K>S])K'YF#2H(\YT;@.I&C3L[2'7#=:=.E/KG@J.CU'`%D9:'Y#
M!6KJ:H!9>&Z:->#DXC19)CC=Q"I\P"9*1U![$#:"J,4OFN"H=P6]ZQ6U2!I<
MWG"[7B\[H:1^T5N4E14TJ;WX$A)V/=`Y966Z)34D:P5'>3LW7:?#>MZ0G2#2
MK0XP7+8;@TR-Y]5P*<'B9N(C3*WI(@(M-)1:V)TT(M#,&NZ'F"DEC00&NRR3
M!.";Z=B@]2Q5Q]-:L,"0TS(&F;XLUR4*B%GD.)DXR5EBHDSJQKRR`T^BS.O&
MNN*S3/UXZH;XV)-*??#^^,W:NWY6M8&=C2K\[I[>7-12MVNP#&54`%00FI&X
M76Y,LTH0".<"60V0Y!QE\=<ANTD,^XXJ`IG$$=491$$@KQ;##Q46?\T:4E2`
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M[F3++R1/&^;Y%?S`2M:V\D-H<IW&0)^XQO71:^8&J\L-TEG@9"`U\L5I+A8[
M!2_K4M3!^=LQBED)IL[)"TB`LHDW1#OHK&JV,>;UA<2P#'<G!3G]FY4WHFJR
M+=X!/7Q79KF\$943;/%.8/R5F>KFX6!U6RQW[CP$W/5I,]AK4S)2=EU*WNCM
M+KO4D]WIF5SIF5UI-"`4QDC7A,M&J`Z]C\+8;);S/J+;T?MY7MG]/'G,TV.H
MA^S&U8C=N/HUN7'52]70@PHG]U\/3Q;N-\HUH*>:1]U8JX9))_=A?A/4J$C3
MC8%/(+,^>A[[*32:I[8L-UW$R;4&])S0D:CTEK]OQ0.GK"/;4#][':<X=$ZV
MG?4/[-I7:M%%C-)[2C(]BL]35;2:UDKP)J.N+[X;X^3BE@CM$A^Q<6),-U@2
M5X4M_E$\WST-D("I[PF?02/>^ASX#G:.=NP^>6GUQGL<87K-\H7O7.%7[`4'
MRLC#@G2`7/7\!%<6O$ZTW?8NKI5:S6@I;9>52BVTK!4%3>0P1CN9`VS2][OQ
M.^1C)3NYPH$#X)2!?M6<1QY>K!!_L"+L7`9[^AN^9!A$`KBD0[:>?-*N,!0B
MF]6ZEE@+XQ36-F*-HV+KB#:O/;$(\APCEX]_/Y+)PWOTQ'QA%^2="<7T8VHD
MS?1X62.JN8U?<)C]RG]N.C0T2H1ZXFC4"]R%&NO:89LJ/[`&4*$%?B9%*PXX
MW0D,ZMS4`P[WED_77-PV0Q6CO#.<`6!N=Y=&F&632#*"H552O,*I@V&1T2I%
M/7+;5`-W4=M-[R(&OT*5S@M8*X5%BN:\$V4(%N(,!F)N<LR.V/SH8[9RFJY$
M:)60-BS<`;#N].&4FU:LX<*&&8[&[:9WR]%D(ZI32>B9L-5JM9CU;3E%+)*+
M.^PDI+7;8Q?H#Q"9%3?<B3\FVW+?<G?X^)D66AZZ5232*XO2YCN/"C(*IP-R
MMI2J\R8\B!KZ-GOZG:G1N(7\XI(M0T5LF#6L&ZR^K'Z44M$(VA\O%@T5I"IX
MIK]*9/-9AFP`3VDZ`^UM>'BQ?.2$QV?-UR9;HA8PZFCRDB(XAO3:Q"O,_WOM
M7]AV<"0,<6>]-90&@+\G%X3=R@P8#^<K?TP42F72W-Q4*DK$*IL+"+26W_^0
M&G9H-TPBU&`164$9P"=Z`2R_EF+PARZ\J@7,<GW@=X\L%Q"DY9(5=G."K5Z4
M(!=V6J@>=?4PA0&OXAUML!<>R?=.LIO<KH6Q_E=58Z^B#YSWC54W]JA@5)"L
M44=WBLUI7\?,2\Y;JEZI!@=H+^J:/"-J_:K26CJKO*^GJT#>4+`FU:$.]-3N
MVECGQ10X6IP4-F[A3$=(9,I?9!)E8#LO9&LI]]*S9$0;63Z8$;;8(VL%"`"N
MXEI/GQ/TZ&ESM5ZQ?X0/<:OO*>UC*\J`.QO#Z)I&%H#$Q.K2NYYB;151K8:I
MZUI;(K*[7VWRB1X`NSU@>N>H_WQI'=S8\OJKA4,%*(5<FU;0TL!DAC7OP%XF
M'B7R=2@N/H4+"F>G(SH\"3+#+7ZHW/*=[`P,&2[^HA=8^Z*[&[6='M0$OG39
M-].3G^6&1TC3RVIAVZ`1>.E_.5MV09;E%^7`;;^V4LURT.FF+_(T*DO]G9R#
M0K4'AVVNT0.#=R$^6*Z3)&:"/WCE-:6X*^L"#KOMIJN33(2F:<WZ0.T4:QG(
M4LOT7/QICL=NB#6X1`]PW6/2Y[HV^<:75O3R*2CP@!V[K\,67T'"E`(1HB$T
M8%?FMJM#S)M"M"U$&BMVCUES^N!6O',6R0FFU!$VD:L7F(?$?S?$P=[3"/A'
M.SZ&1$-ZJ"I\A?>MC2^K!W9%(_`9WXTYZP-R*AHELG69A9YL-YN!WC!;\3=7
M<<&%<>$*P&63AY3@\.[V-[Q_:D^=R_XN$TUIH]"EB]4B2\!!=^@6_<Y?5[4T
M,TI]7JKRKEMY:?%>#8M22)?L$[)72-P9A/3IMPO?N=WM7!O3HX#L*&UC?$+?
MDKUGV*\2M$C-;#Y;+?G&82Z4+;\%3"S"J5S)NX:B330J)M(#-%PLRN0J0O0D
M]IH-GW20O5(V&.&(S#89@8Y2T<VQ\029[+HAKS='YB)&"WLW/BJQ\VMJ'W[!
M888G-H#*Q2`J!QEJ.L2332J-"3.3',65;;J"JMA?MIHOINLL2Z>7$#2R6,-C
MTCO'N@[0RIB;C6DD-['5XH#>-R&[#SS5DF:04CDJ>KA3K>$'NK.U)"9/7<_5
M#HB\JVJQ6%G?]!)XSO7^$`:OF!VTZIR4=;TANZ=J5@/*[O.Y6>RPJ#!4E*9X
M)B?*0G.DA5)[LNX0K'5H'6X1UZ]US/T*?U;2CPT:^L_62QH'>?^EHK\:HW&A
MGU(Y!1NKO@E37UZ_U#9UJA@XOA^*L/W3<_#ZLX-=W@61'ZH]#_D5:?'9\C[Z
ML1N_77QSJUMJ34](Z%D:FH7RK+%-3P8Q`8A+0+]3&9)#]E0KS`%63!VY':%"
M@[?-5$$]0)0N*;CD`SW@\-7%85>7T/&\_#ZB79D!=:K3LP-$'"K*0XE`Z?V(
M**N,+JO4]C6B3.05<@`62>I^^M%4Z(]ZG*!FHA1%&-.NDNYAA^RV43;TS&:>
MK!N-[K&/OUK>(P[WK>/ZX9*D3JP&JP?M8#:K33:HHXV@I!54;`95IO+T/"UK
M"=&F5$W%IO6)6?")E_C$*C3SKI`*[;&6WM$30,PK<8M7Y$W?1@.C/*T;YV(E
M7-![%%?1B=L1ATQ71GIAZ>1G9_MN*!VK/;N5])%*+QX.4(J)[J.PIYUX%1[#
M%SZ_1H,NJA`FY&5P^[]1\VMJHKU1%W"%@_5Z4X,`VPDNRD1<J')HG&YJ,U[8
M5G!4D/Q/;).?3`!_=/#.M1474X3&:PO.VKVF(_AZSL6!7]<(C(,/A,TW<%`J
M/Q`WB?5FU?KS1FC7<;A!_E.,V,MC&+9?>=+PH!H4)JV##YP0P^MX2X0H[_3&
M&%/HYFS^NH;#PTHPM6"B:+X>T0_OH:HO*$7#4![>KM/<W@94Z-3KG&(?/W9=
MAXC2X]7](=>-%9UZC.P*PRLWLKT@.H88CI^NE]5@J4,C<-S-TM-B15P5;@[-
M1>N$,E&65T=VNB`-$*@MJ.OSC!H$VO1\Z<5SB-E2(ETS[,EMZGA#*M9:U8`O
M*Z_G*<"8,)1)8^OHRI.;!)EHCC51'KIZ@[`,J6Z_B-G;3AKQG<O`\_A6FQOX
M6:/1C>OCIIN3AKXM?=\;K!HTDV>VGB]6R2YX&F4^O2BM(#Z/.Q)RM`5^;](T
MR&K?'9_(=D,?VWOVSB=R@"G,`7*VV@>#.]]X'^9!.5STV%!M>LB;VG'0([SZ
MLC%;&C/RWQ+_T%5`NQ2"5B9;=D;.!+8.X!LF74NJ&6'W`)IIMUL/AGFL5MX>
MZC25LP7?80E'-DTUZ"H#VOZ\@IE"30GP!OK::.CB4V%JJWV*,2ZY-YJ]B&@4
M%\GS%:,PN4)9ATE":^PU31&:W:(0.C#`*(3)T/A9S"O]D1Z`&&5&`@,[>/;=
M?^3E;M'1=V@)OY2$-4`!(/9/B/C68>C?CZYS[;]B?MG8;Q8MD1*_W>'0#9S'
MX`.^]*PH<G<N=BXB6M.(;DR^6AY[]IN[/U;3/86)E3^`/5EG\#D98[TUT]$M
M;16Y6;-HG[1+K^DE#:,X0$\8V5G;R(I8"2VV"<Z;)^^P]J4/@R5[S"AX+&\6
MI>TBWC!Z#-`'C/*VT47$JZ_ES:.D?26#:,E>XP>%0_?9]2TO#R]Z:RSYC6^[
MY+>N3^LCJ;U@42`7%0;?8IRM8GCQF_6W(+P\1G&P)P'5<&"LXT&)@XQZZ]"5
M[+61[H8Q&2@3HN0$F2![DEUE_KK"0V3]450<8+08+62,\9OE'W=64GOMDV4G
M6V?M9\JZ7Y`]+NC4!A@:RX61+J>7Q*%=)D]RWRW.*J-N52Y/Y:$R<2::HTV4
MTG&"`)9UB?UN4=/9L<ZV<YNZ_(S4+J[0,+@(A9%>^)V\KGCK>;P1)M0(>7U:
M0["4N[.JK4IBVO7[8[KTC,R8+C8,75(QM\LDO2)Y775,CS;"A!HA+::;@J44
MTS5;Q8S.`A^__6:%?^#XT]%WFC*:&CM7P&O21VK].@%GSL9\L]@D50"85#)M
MIF+1CLHEHS8W1*\L8<_)1,L>P(DVULB-Y6(1D]N<G:AB."?:8+/YZZH;QL&1
MF`_F@$Y1T?U]MO;X=E>:65X%>\NM8K?_>8G=8JL2T!'3<K%.4N>I*'2[0^7%
M#?0[EZ>HQQ1C7V61H\,B6=UG;[`5N])N)RC!"H[IXN-=&+RZ#G8^O'V)L'/M
M?^(+M(![6`8(D(DFL%;0P=MZD8Y`B6R^JI]*1Q_>$)5/KVO(6ICLCA7H::Z)
M7+!*7<"V@@ZI"Y[>TD5]6DJCTW1IR!P<VB6H#G.?WMCM.?TR0I"66!Y\ZG<U
MFXW$M/)3,A-[A7>TU",[+_@:\42>\T5XUZF:D9[4"/%\F_&$WKI)@'J$-V@%
MOES(3'?M.Y&=M:!K;WVJ"\J]]9&:[?I)TH?V..X(:P!^VURG-V[']=1=@K3$
M\>`^:9&6)QZ,9UU[:E%>:>RISQ?A(WKJ/D]JA'CX_:8#!*A'^/BK.LW-9@[I
MJ:>_N_3$GOI4%Y1[ZA^3KOI/I1EV7I12:U0#+S$=Z$B]43RNW^X2I"6J!_90
M\]EVMAV);EW[;5%>J5RC<VZ('M%/]WE.$<*O?3O8XYL@ZNB*"\_(Q67>,+CD
MY&J^RB''WT=4@#(4C;3!3&UPN0T_>D1"8\4]*9W^2"OR?CW8'T+\@OV(GH*;
MWJ97'#X%4WT;`_YQ)%)7'<D55JI8JYQP+EXMUZ.G<!^#RV"_#_QB)<8/5N3:
MD"\'D***M/I5@X;=?&VN&VD-96W0\S>\E7+-4M:.!KPAV!FK1@@BRZ/12]T1
M!Y1TJ#NB%RM4/K`8$_:M^`7Z4F^$7[G>,<;.R;&3RM$2Y8ERX,.SZ_5V),Z3
MEG1'^AB'?*=8KP!@'-J+_E2#]Z\7MAT<?3JU(7,>G_QH\PH;=X'GVF_\?Q_Q
MM_@#4>./U@`:*$8JVH?I!L[R7YK9XM]7E#>!RFT@+C[]S^^T'<0:4K8T,*$_
MTLH!1)KWAJZCZ$A/$N>^>8@MW[%"AS"B$QQ:"$\>UL<%?QGJ([RI!.G$'U;T
MDN\W^$Z6)<#*=/6M`H+?EXEMJ%+@8P[S50IJ+KJX+><[A70:)E[].M\D#C"+
M#FA*G%%:@W9P))?P.LAA0@Z+D";O,<V2IX.`3[BV:];RD.R#(#4-@"&SF<V,
M&3_U<>V3Z+`\M,.T5)*-W5?"_M4R2F28%X3(2PO4I<5D))\$.<W:E"%0+@-1
M(0I.>)QF2(KT]V%NR/%`/ID?HX/UIJK*3S=NLH,<S;:+`>V1GAB[W5WX_M'R
M?K-</\:4)O`=]\I]$MZ-GP3ZKG2(`Q4;<'MH>N"+BZ;U42PF'.USZ6DD99P@
M&^N3F&T4S+[=(2X<%:2C1#Q*Y:M@ATE,-Z%?/,H^N3H6&0CDG%R&N$XHY_Q&
M[+*/'HYHJ9TK_(J]X(`=5@MSO\<AK3U$R[)=1'<X+)7';!Y9G"Y5%4^-5WE(
M/!M5!MNGS29EQ)RTY:2<;K%M6ECL0%XK#7!DUR61[:\*]67-)D7$LI:3TK0E
M?UU$M.)8N6"MDG&39)_Q5,>"S&0H7`@WY1QY.O'4V/-$]RI9*4E4SU(^'O`S
MZ\S:YN"MS\M<"6E3`KQ\MUK7QC1YAD\J3=$JAQ#C*J.6/"$QZC!.VJ)&7]"5
M%C$Z_2%T+'(7D%$/G=0_L*T9BF*^JGL173B.2Y%J>9<$KJZ#.7"_T"*Q%U&$
MXSL2""]6X8*2+AX6VY"J$8M0*Z`=S&*S7-2F88=4DV13+1G+N'Q)GHQ:K$P?
M,G@I*)16^:4JH4.BD[IU&O6.K9!BI@GBJB2#GG2O@^YL9(XM*8281HBIA%*=
M\EK]"L=`"IV;#8OH[B_=&%6X!SP]\=6&1^(]+Y;]P^`YM)JO=JH]HXQS$P6`
M@X'M8F;.:VR9R%#%;F-,J/)2(D,ECXPQ@S'`U<7]8_H1U$._$O5UU!;M%`*X
MV]W.M>DU#3=\`A2$;P\'R\;M]5Y[WI`-QFYUH'W"?+V8)\LQ7"!;<?$RD2BB
M,B6#5*1I1L$TNCB2BT1,ILK2KR+M-"N?<)"=4L`.0UP&?8!S5*Q5<+5H^?4#
MJ]3>536S^5F):Q2-"L"+JJ95$9*PRN0H+J=YNE7F8*MDK4ITAE=Q1:+="6*Z
M1Q_'[A[_YGJ83!+\=`N&#I?O+-?A8^*N589A`J1WGD.T@]YCL=DL-DGY="+_
M/6T`[=,6LBU9OBIP(*U4;_>1W<M.YP,C\0%S0=9`MCW+Y^^TD72&KG!*/J$;
MS*(;LH6=-!#XUZ^O]ZCKH,=@/N^O!_M1/E%].03^PP';["*5&[HW<KM[L,B;
M;(;A'.W:EL,T;6A-=P`#!FS$K>8G,"(Z'N@J5:H,\J@V=/4@HOHDRPA,(YVY
M4[A#1],KHJJ@3!?$E*%+&4R=9$V#*:0[$0OW:9FK$T\68C)-G\QC[CQX>@#E
MC:-RZ)=0,EE+M^MZ3^TW/2ESHE9O'GSB:[-,!US9_NKDY_C[SK>=:L^*)S<7
M3Z^QK.9D"[DE@47:)*T]K$I3M!8G*$7"#2:#S>C3,3Z&.+FK(8%W=-5Z.2ST
M;16(Z58)?D8Z+2R5HXA+1EPT2F_A2(6C*U47S4YA.NO^'BFL%1.&0)M6G39)
M)PL8\AH)!.`4C4GE\AB&]56BD4+THYA$,_"UYZLTE7T(TZ"D%:T99XPG&/&0
M^%J<`48K@3P"JD4/:8Q86L_Z%?\7ML+>\3)<D'[(+6@'KF<T6QDCT,OJPK]B
MQ-K2&L-C?9+B>',&.&X([Q%8KGI*;SR3@!*#YTR0EGA.M0//-F?I/4B#\4R:
M.@\\C_))BN?U>>"Y&M[C\%SRE-9X?B2MBNF@"Y)T1'2N'GA8:8SMHEE;9X'I
MD5Y)0;TZ"U#78WP4JBN^TAO67P,QH$[E:`GI1#GP8HZYG(T$]-?@/.`\QB,I
MF)?G`>9*9(^#<M%/&@/Y\06'V-K%[9F!@^7H!^1<.?#`TIPO1P`Y;TAK&(_T
M!U]Y[S11,S#7HWL$F"O>$I,+5&[ZQO4QJS#5F&W0]JSTW)P61:"W1!NSY6*=
MY-A44?4[E<8+ITV3J]N>("/$JF:NF-RJGCP5(::9HTR3DU_2`Z,\3Z3+$QIT
MS[>[&QQ%N'#+>%]9U0$"U'7('5J![Q0A_FM!U^T.<?$HEZ]!$=6)?,!@^&"_
M8.?HL>2N=`22#$A8:_EPA/Q`*Y_ID7T"#O*.[KG/CQJ@^)YX_N.W`\V^^XR!
MN\B5=]1AM:P(-#0WZV7;'C$5B!*)B(C4`HTG6)G4+R9&82Y`(V@U1UX'FAK\
M,,7`]I%R$&!HPI]3/*!E2D#'1DMSO36K@UF/R9&=X7VR%2V#5R9)@W'K"(M:
MQJSM%JD8KI;`T394S8U7V\$%471IA>';+@B_TB+MO71;>T%)UU;5`GS+M+'9
MU'!!;^LH25/=I9UD77;555[MBN8O([O/0OE]7%OP-7=PC5X1W+M5V^"50&_<
MO<N[FXL]K?O?36Y`&>IZ19B"4&8VU\;6J/68M8A+2\9Z63/(8NTHZU:G<$,O
MM:1%@_-F$&]':7\\A2M:>(CTURP$:)GX($1',HDXQBXO%$ICPD\#Y<F*7'4U
MH<920D-_/\"Y$[-9WF9TZW^)\!@V:Y&A#YLU*P@^-SU;+V8`-LMI+*)A2\-8
M,SH3X8=^.BNT@FY]>D.RCGPFPA<M?*8A0W7#',!0'>Z2S%!TL_VCWWCEPG`A
M^G)4HN&`@DNSU3B2>B,M(>S+OH]A8E>,XBG:$B)-:<U4H]P!&WJQ4-A;W^AN
MPQFP6(4*1M!8T9<*>.PAML(3!UNY&+VYC.DX)&:7)[!91!O3FL]&N&,\H['&
MM.>T$2X9PFI\#_5,6*U$#"-Y+??GQ,SV.8@?CD]_PW;\&.2*#`N(%AGZ<%JS
M@M#UC^UF84*&9WX0HX@W0TL0Y?RF#9F)\$,_DY%64-(,+1V4-Z05BXGP1;+7
M3*_-HKXX!&%Z(XS?P&L:TE<W^@'<U>%%0<3%EM32VD`=Q90;'Y1/00U:@/=$
M9ZOE)N49OI2<U=F:M$!J!Y.<;(XAWYP^1CC9)G.P39)@WH&5`I;;[!<#V/#9
M\I.KL2Y\Y[-%L]YN=Q^.D>OCJ">%&OJN=%@#%0-N[*Y)_Y$.*`J263EQ+ILF
M3:;2529=3V&WH8W=/40QA?&F*./E,,I`,.<D,\1W,GBG/<,-\IYF?#,@TVJ[
M6:W,30/7T)+^/@\[,EQ]2B3+GJF(MA/.+>JRYD3;#*<4U7EU`R`*91+%>7<%
MY>@53X'G.JFF=R1T4HS?[CZY].)A>DL4^0T;>$473U$<6G9K`KH0V3*S^40H
M#+UU8;TQEPUH+[7+<%!LF:(A:QOEC:/?T^95G461[KH::;RK^,ZJ^BX8Y3MI
M28@BD5C*5Q3V:<Z.H`:<<A/=S+G0U@FGQ8S-LFF\,I+!]#I:I]*E]>&0E0^'
M@NQ&9-45GR<"IC#J$G-^KW6RYCZ3)CV^%A5UK.HV/BA_.M:@!73:O]G.TALK
M$C$HD:-J4?=D:PSYUO3-J4XUR1QLDJ0I4P=0"G.D-O.5C#GBE^1ZV^@S,:^[
M5G/CLS)[_R8%H/W->KE=)&"@8OB]T'3_,Q6DJ/L]V28SMXE=(JZVJ^R*IU)_
MUVJW,AC<N-:3Z[FQBZ.>HN4M3\N&0ET%<#U`<[LI@J$@27&M<0%V%0#AY9+>
M=\!<*CK:PZR&CQ9'*$,(06J6)\&O-4G.NW=]S?:79..E51-X;=S-N@B;HL#T
MVIV/[84,),%'C)D%%+G)53Q)C88_*8=0;QS6D-3M$Q6`NK/"V+7=`U/I`1-V
M8C@G4[DX=)^.,7;(S.^+[^3__FB%-'.I[9CX"0(E`G&\EL#H7<R,](J-4ELH
M;PP56F.K-J7V4-J@6`AON6]\_$QF[4X7B&6Y:$%]1`L`_4)ON2LX`"?BD.4Q
M`)!?Q0$ZE+P9Y=ZD2S8!'W\ZSOLGR_XCHL_3K#JW>(F72MHX'6U%2CGQ"PE9
MEDFJ4MUC&[NOV+GU+P//XY>E%U.&FF;@T%=E+]T`]8(>'=PNMYMD-YW=`X5(
M\T>/R'K-[GB,4)@T1B/6(:&>7/AH%UM6=DGS)`Y)J)'?<9F*IJ<82L*5WLH\
MB=U)_F]B+V$F[^A0)CL>"%7X\;OT[#M-$(XQ76/%C-IJ5]8J6V`:"/ELR6F(
M.]4,A3@8/P7A/7%U>+1CPJC^<VO_V/*XU&%,LP[@B>K"6)60&"$B"I5DJ1M_
MB+"-C2[NR'NTG_0RPE4[".B.LW(7W^$$E2!Y#"[LOQ_=$-^%=$83O]V1KQ&3
M\<9'\MM#0Y<_0H`"(/5K!0Z_I;&H0.LQ0(ETE(I'3#X;_6<MJ`:<:!]P"!*%
M7UBI-GYY-;>>=FRXRV[9F(2'=1-*@9Y3@EOL1WP;ERU$W`6$3'!,5*5:?<`^
MWKE#LC=&BY.)Z9$Z@FOWKM)#NDE+#,9\K:K<&$I;TROG0HJ#V'CWX_[@!6\8
MIXY@M*<4[R?"H83^4]PH9A*.26B0&>TSOG'_P-[;[>[&"I_)>(%7;;G=/5K?
M$D4^8#)ZN,<6J[;UY1#X7[S8W9.NX0''L<=4_HL;OY`7R',7Q_@E"-WXK7%V
M-'FCTB?^4UL$/3(V7QE&4H$VUPEY3"G:?WI<K:3<%/U-;'U#3PFVGJAN*$R4
M(Q-+6BDA40]%F7[H*U&0ODB?ME(592\MZ.5RH^)RKA0K1Y^XG.M%?T,:RNB,
MZ892Y1#5#J7JH5P_1!5$7$.4J:AB94,OMYL5M]=#/(G]."#1W1_:ZI9&9!%Q
MOJ@BY4L*[J5N=P\O5D@+_U\&^X/EOT7DO_O`?XA)MWA[C*.83`R($F36>^W;
M(:V6?.WS5\@L&(>OV*%_BJ(C71[[0I=*V:MT5-$=[I.VK*Z_FM(L<'F#^6R[
MJ'5:!,H1:X?^9'/E_BFB/Q'U4$0;04&N(*O?XB8JDA_2E\-$2_[W1,]DD9P+
M.1#ME'5>^OB_VH.1CHJW0W]*E4-<.\3:0`7]V.I?JB&]O#!Y-U62_SUU/],S
M$=(VH)?6D>GS"1IZL\MBN+.0+@:]!MV5#$9NZ+,F_VAB.JX=Z3&I`NU)Y]5'
MI'<%Y?;!UX`MUYLDTYQ+H."7S:*GJ&Z455>94'Z2'6;!#N49Y"WQGN.WP5(E
M:YK$LY^M/;[XYK9F(Q4?D;GV6&@7O%RVF:490^1!1%]'OU,!JI8'Q]I@0FV0
MMMK7$"BE%;RJI2JC^2J@6_\]WR1Y2$%$\Y;!Q^OFFU4MIKD(Q5$]PHYJ7'?8
M(3NRRT'3%-L%>Y5$-Y&%PQ`[;'QVY;ZZ#O:=>RO&9#1X11-!PL:K"(:_+Q,3
M4*6@Y^P7B_1RZDQT,K]*A2,J'1'QB,M74FI_6OL9S"YL.SP2ZWUZ*B?+EW.2
M)ECUWT/F(C:O4@K#H=%=0N@@+ZH'[XW[]V-R*IC_`1/__-GRCFWG+\"O*X-N
MNT[@PPH;<]Z,W()LE`M'3+H.L!5D.T?M\W/($DV05[#ZD(G5!Z/]0=P.T1Z/
MJ4?HG17>ANQ<OL/4(CS"%DU`\=#ZLC)TMFD$C4]SF980K&*32$:W(2^*X7!(
MLKZ5B=<!G$),9]"\#/Q7',;NDX>K/><[>J@"O4Y&2*3=IT"ZU08SFZX)1NZS
MSS[P,+O5$%,?=MMIJ=-KZDF)+]LF^XK_P-4+?8`O*2.AJB;0(>UVF5ZB526?
M9&\E%ZD#X9QD9C_1)-MYUK0V#R:<TSXN@&A`=JLAG#9<MA--H[=T(1BZ&32(
M7)(7%!,+UP+<P9%!=R>I<''Z$,H(\\!DXDYGZT@B&?,QX232;J]*`BGCKH\\
M"A[2A3@*V\T#/G7Q+<444E`%VG^MC(79R2.WW5D*:LADK*%@1NG)S5!%*Z,_
M,)Q;%&>E#,1G'\M4'::>:N#+I(I71`<M`,YGRY9M"VU6.8?;T\<6^N`#N&RI
M?(7R8+E.4N^FN[)9\[-RL5!7`%P.;SU;9VB@8M)B3&IKFIUNDUFT*:G"I/8D
M=5=,58#08KL:*`0VQD[TB1B3YBY>^V[L6M[=\<ES[=L=@6W7.!3ZOE3(`)6"
MAAP)NFSAC(M&5':>?IQ(1UP\2N6K0M<4YILE\VGP(S>Q^L"M#A*Q_/;`G2:P
M'!C?9:@.<:28_%YHDQ_P+J`WB?!_)6S2>"W9J2*EYP^?IB\PJ%?&9IZF&Y>#
M.L5T6W0_L6;S?Z=A+CM76:*;1E`?XLWF__[8P0;3<:)T5PV@R;9`4I=L+89\
M\N1L`7[795#$CH6DQT$&=+SE]Q0/@DK*0'O_S38[R]7,`+>[TB$N?08]X\UM
M0G%J+C\\F)VA>I<.=S(<VT&DN*H3-'[[!CMU!^H$QVPYI+RV,#!`VJ1H`-46
MU<`U35=SLQ^X^:)29<%,+QR+\$4OJ@<ML,E9>I\P,GK<H=4:XR@&@-!;ER>U
M(;OPP?*(MK1T5ZT`SH`755-:21OP<I]AK+M9+$14+F4S+EDCXAIO<0,X(VIE
M5L1`.SPV!FDO!.L>4HTZ?N";WT7T\1L.;3?J2.+I>T\1YAJ5`:_WK=*[4,J0
M2VHT)+=+96+5X^UT:_D.FQ6]T(*0!<SA1!K#':\0<E!^^QXX6MO0U^XO1>!K
MKE#9<\5P_WMRP=>M##1-8K-9Y=/MUL*LRN_\%6NO6;3W76*P-<!@B="#Q6H%
M>@!?:06]#V^/I.VN:@:`-W6`7ZX..)%ZLUH"`/CA#5'):LLB"+:Z'X;O^HQ6
M#L1ZY(*@6/&85F`<4`MYB`@=X#F^I*^Y7)L0G.I5YG@J/Y206X:LEBB%UC,>
MZB]1F_#-K7Z,>)5*YTN$=T?OQMWA1^O):X7EJ=(4;+V/5!5Z\<Q\O=[FV^X\
M6@]9-Y/5WT<X;1`=68O((TW*WV&7XHU^#LL:1+Q%1)M$K$V%I";52;QV>]T/
MKVKWRT_DB>)6^2ENU&JX4E/YM9:8-$Z&#@.6)L6@/?5ZO9F-0WM+E"L<L)SL
M!Y/?M6A%^"7P'.3N#V'PBM7?B#0FJD%#EE:/:07>7\,@&HQ6_I(.\&2:@%,]
M-DO(#(+)U`Q^P^VLSQ#TN.T(%(@@@.4^T0I1-ZZ/KV.\'XRJ_$4=D)5I`YZ7
MSM=;R$(V%8R89-TFY>-,AJQE]]BL''RUF`4!L.POK4#X&0_>1:*OZ``\H@<X
MKV>S,@"0(Q(U0]I0&SLZ,Y:/.8UY],ID*>:M1IBGG#,*$`.Q1>H4K7CB+O!<
M^VWT,GOU=1WXHZ(3>%]V96P`7,*EZ[RT?HK]Y[:LWA*^(#PV^4DK;(Y&I5YX
M'+[!LUBM(0-I?2$XSF0&O@?[!3M'GOAX1D`<!T&=P4=:[KX.`/"F%O#+U`%?
M)+%80):)>&*$V@L%!!L-SP?1X?X!>.C"P%CVF59HS#>#AD9"X4T=T)BK`QZ7
M+4#YD86-4LVP.-)DS39`1X0H"'45[TR;SY$W1G[+:A)%+3G'X^5HD\/1H21T
M*WY-9T65[(VF]<UBE@*%)6]MZISEX8D<PEPRB(\DNF1D[H8POYC3A(K:[`X`
M:_3G=?2Y6.5PX^'X]#=LQX_!;7CQ:KD>S3?Y%(2WY(^$=OQGMFL/R`V'RU$P
M%`$K!ZZ=:VZK`Y.D#?08T%.*63/LZMJL(<1:TB*/?!J?F(T^B0,4%'VR&^03
MV<.;P9!H&NP,<Z_V#`!:#A@B25<6&#1S-I=DP'X*#VBQ@C"57T[@`HV6&$;`
M8S0?*%Z"^(^C%9*H\=X^N;[EVZ[E7?OD\^S9_"//PN\YJCE4BD0F&*@:>,Z^
M34^190V@K`54:*)T0$7QH<XI?6$*]84LQ(\,_R+:QSA5.Z3W[;T!7]8%UX,W
MI%:;#1#.ZK?A)K`<`EYM8=JY%S?`62I`>4^^3==4._^[1&AEC8)C:#%/=K#9
MJTKGNN.4-R'*RXKV6E`4`[ILG[*8_0WOGW#8]0V2)V3'+6\6O`VZ2;.@DH_/
M7U<9NR,,*$:O!M.HA@"I17#!2B%[0/?6*_8_N$&,[1<_\()G%T?7OMT8IH`7
M9._J=&H#7),WC<W&7/#M&R8/502^(]VY+?F0K4##C%;#J%V*H"O:2'.\D5)V
M34`XR[9'^AVCI`/#!_+]7^AB['.(V9G$2WKI/0X/9+#X]MG:=Z]]PM^7V?E!
ME8*.BQ:S17*^)Q>-,MFH*!Q1Z8I7-J>Q/[F9:8BITGK9H5%<ZH,'>4L-2"-,
MO/%RX3M7^!5[`:^H%89T],#U]=F"RF-PAT,ZI:-+J_$+B9/>XE9B9$L%MP"%
MP1,B,[T2(FV6[=P7&D:%EE':--W]2!KG&Q^L>2WJ:,EWGUERG]7NOG>Y_^+<
M?[O,?]H4Y!**QS(5B?HX9T93O2G78F2?!TT-SF`V%^9J*XZF-,CNEN\]X2RE
MQ;!(("`%\90&J>;-VB=7\0P*R/0=Y;R2*`*N`[U([\ILY8M$HD[P'V-D'=9.
M+E`_;%:"L!]S19]HAZ7NA7'`F[K@:M`Z-,T!Z)LTI%?3*EYC%VQS=Q^J<KUN
M1+B"L:=\!:]#-W[0><SG3][4!8%<'7B%Y_4*B$`N6$/\C;"X&W^7JN]J&Q"I
M8/`5O"1F[RQI[/;)<Y_9%M5EL#]XF"4P67%U>`A[1_H.6H]"X&V8+:VF-B]%
M59#)I%<#)D*10Z3*WDT3:F29+'*9*!>*J%05.VI"#36!7U/=KAH0@?G&&L0_
MBGKF.'3M&#OTMAU"7_0_]%34J^41^':LR'>_)K=/[M0%7)9Q5NB0$XF(W4%$
M^V7V0T&JLMY8G*T,9A=[NH\4(=NSHLC=N<1F*T)A[@&;M*#JOD6QG]:L?-LV
MRR2.-4#8JPPT^CTB:I11:.F3Y8;L6&2>(=W2#_2\I&"<T:T1]`3M9KN=K[*!
M1C&&T(Y(1:]4+'(RN?*'&B+M;.1!*I6?""Z<#%`SVA!IJRZ\,`QVQ;$%P!O*
M!A='.S[2>[@)5]UCCQ;+N+!C]]6-W=;J#L/?ESW<@"@%/I2[F6T*>$M%LU%'
M(ASETI4?2IK&?K-NOS7&?JE]]Y#0KG7B8!=JB5SX'5BC1.F$YQ/N@MHL-ML!
MT-;J;JS)_9+?.($^?G-C=.-:3Z[7<F&T-K@&WI0UVGO*T4Z78)G"$0Y?>[+R
M.M]2A>&Z*N!4L*UA-,&52DPPRV2J3HX39FM#KZM/^AHD)%LAU^(8S=!UTW,7
M!>A5/7!V,_1RAI4Q6\#`=J/Z1@KA9C?@CIEM#3!;`R36PA<(QQOE%U.4E$NT
M@GS\]%%5F$O:ATZM%K-U8X>6B)D$30<<NH'ST7?`B!ICU(*M7=MV>+0\1!JC
M5GVPR(OVE%8]Q%883VK7LFC7!_SL^GZ/:4IXH`*95MP77:`+SB^/88A]T)I3
MY0W%J$_4@,83/6O<`7Z4B-.@2SW!OL(D$M-)I)=.(M_;[>:IA$PE^OJ04_2)
M+@#Z3"P?C*'"2XIAE&L"C;3EIK,;1;E$?<`TTLI6/+&+CNBM#XE4=`A"U65F
M8,'9![&*I]2@++;(F-CY:(6TNX_(`."X/[(5HRN\<VVW'6F]+TI%6Y\VX%A<
M+#/$<9DH%8H*4E$B5A7LA)IK)D._S#BGW3AY"(,&9AEE(,?H@+2>]/_&AQ4B
M:EC"^W9NS-M0I#JK_V2[:G!)0DN3'/ZN,.O"BO),_5?L'_$G8LVOH=65`%A]
M3BHJ*HV#I]B;>;;5SD0@*@-Q(:J0<(HM#`3L/11R06JCOB5XR@'?9+#"6+_'
M=O#LNW0P^YOKD0%BX./?</P2..4'_H&=[F\X1)!\M`S0#AR"R_6Z#*="(RAK
M!?%F4.4ATI!2R$WE$(;)W/B#]:;^'.?80&\`[E"WZ8%LV$6R_>\IQ>W(JU,7
MYG+;#E-M;HP5:Z]9L%?QB3)@+'9C39?K8%.7=G]$%<-!\,AI;AAE/*@=^@W3
MNQC7:JY5'Z4VNT+]D8I.!ZHZ@+)K@*I\7-J?'5UY3`'DAEX]0,AY7H:>!OG,
M)YA2ZF5^T2&BN_..&TP5=%CHU<5?[]@F^8>W>_Q,UV2"\.WB2`:&H1M7C_<#
M7Y)_6*A'(^@YUL76G,W3PT)4)N()!.CIC?!?*A99J5SIAX6$VFD4[.1":1G!
M7"S*Y"HY+"345K/V314>%0*"KG!4".(+,8P0O%E>_):5*^T_,`!^33HK].L$
MC:'9?&5N$U[@4I&5E>A5=W90M(%&T<"\!K$6YQNFL3B]2,TYVG%AY>N.+_Y$
M/+.SZA`E0^"AZ,S)`^BS2>CCIB53NN=AU51Q,RP]V)AM5LOMLDP0.7XFSX0&
M,\1(NUIX05V&MTCCS''&*<%[#4ZM*+\Y(5<;B.U'>M$BY,/P!U5CFFD!#@W#
M-%<M';[B7GZ$'6WX9:)T@.X(F]I@VVZ3$L260-**UMQ^D4A-1C$7$9DYV!0J
MS_AV]QG'#Q89YWSQ'1S>N.3W$3WJF&K2\;5&B5.$^C&Z`N//6"W66[/,#<EF
M(2W!<\@:I%F7-/DRHFVB(VT4>6FKJNED>@>52"=I#EU$*&\0W>X0:1*Q-A%K
M%&6MYIA6QT_3.XEO.EO?W/UQC\)R-!5C236?G4(E5=8;[545B_I4*997_639
M?SR&EA]9-JO^AB,[=`_TQXZSUM"W)6X!`%4"7T<^7R>I650PRB2C@FA4D*WT
M#/84MIO=MK\#&B]KOV%@/!>W(89X3R>H]EXT!GA1`X".N%IK;BQZL:G!G6*"
M+>Y%I#9WB\$C%H)##6X3HZK=[A[BP/Z#:G.[*])$'P1[7I0,P6YMH$D4QG([
M*T"0#'B95!Z"Y%]%)*H'H4";<Q`&B<T)[@*XT3)A"(O:*@P!#E,%P^XC,L4G
M)`-KX*&1U7*[SA&D^@#,6`-,F`$R([[C<$O52B4Q;+]@YT@A=N''KN-ZQ]A]
MQ0_8/H:L$-?';[9W=+!##R30HMQ'OB9TNTM/Y)#9Y<.+%>*F9>J)&I&))*&:
M@PO`F6;:G27MTTZLJ`'*54"I#ORT3D$+^E)VHHTH@I@F:M:C-7"H67)H`'#H
MKNK08*A#I3'-)#`ND97X#W?>?-=S6&*"ALZ2]X8>3UBN9\:4W*?Z'(=BS]9(
M\*K!JU\BXM%K'UU:GDUSX!+J8X\63TEG?OT^J*_KR,E$GTTM!5[A'0Y#[#Q:
MWRZB",?1A>^D=6:)38RIX3PW3)H2,AND(G@BODA+-189*VT*D;80;XS5;2PT
MAUA[6G'2=`YBQ$.1$?ALTXWP2?R"&65;_ML_18T.^['0]I_T()E1F&EFDN'.
M5DL752K[8$6N3>]TX_W"0+H8)DT)70Q2$=H-KPVS@2X:QBJL-7[K8=+QZL<7
MTWDHXXO"W(M[Q"IXY-JW@STF/!%$T9^8[\@K>_*T1L.24;!I9HSA[E;,&+L=
MIC7=,?].A.CNK9B=V_5MPG+LPPZEC>$BU7#'8#VAW>ELO=HV$$C:7HH)VHW2
M)E&Y31U)9%I7)6>22DX@9'*/:8T^.IV)8G=O%=B$>NX#]O%.;74Q$3!JH9%Q
M#E?,)?N#%[QA,N<*7UT;I_R''=I)8#]B6E]X3!<V\\HK;?`C7>SV7-@RM<BV
MU+"/.`/`RPNKF=E`2XDB*-$D']O0:],*RJ!<&_I>KD]Z9I)II,OBM2K_UI9O
MFOW[_JGFWW=%!P>C'*R`^,1COH41!7_/[X(JX6,RP>V=,V4.7AS9&"L9M*G1
M<$^AHVO\R1)+WC?X-;F=_KOB0>#H<(+OHY8//QWC8XA_<WV:_W]/<^&]].CQ
MIR"\/>"06.(_LVR_H:O>I\A6PG,G*#S@%I^&H2!O&"4M(]YT?@:<-(ZRUGE.
MJ8XKY++<QY@J<=E=Z)*)V:'HK>08#RM%WWF$1SY9"4!;,S&=ZGJU)'07!D3#
M^.V.?'QZVQ.]EOS0=L!W\.M*J*1;)W#';"P:LIU2V8@)9\O@F7A=9H$"[4\K
M9#!Y[Q*C+:C1\D$.B^9F'`/<IA:J_W&T0A(&WMLGU[<(\UK>M;\+POV8]>HA
MLI2`>(""X'2[F='0_V<-H:PE5&A*P[Y^*M=D>UM\Y_LR\*/`<QVV!IU[Z1Y'
M1X_OE"=]&WE.#_2/`$@S%0SUL%I>*-V/DU];/&!AN5^"$@[H50M\,FR[;.C+
MR_="%:_WUFI15ZP7:DL-92]80[P@'^'@4&_&-<R5&J$YN>WJP]LC4>!V1Q6%
M]_%P2>K1W:4>>(*Z7C:L63;?_O;AC5^:31Y@E_CJU+]/XQC>N[^0!W&$7#^9
MI'^D]\6EV5V-E3X5@QR"``#8>]VH%O0MJYEA2#\76TKX\)8_D];0^&J%#JR#
M/U6^$H(X46EP-L8R*V)1H(WVG8U"^Y1&B@]FA6ZH$KJ,'V2ZL;Z1T;+O6W;C
MTUOI0;`;Y7.3(*`V,Y:(+Z4CC['=K%M6(R2ZH!D^I*L9N%XQ6K!&S-6O+7@D
MOTDK\H,HBU<=2%I&:=,:KFQ(\5OS9FOBGLP[.M,-'$]#>`;H9ET(IDA_1=7_
M;'E'SIM1=-SSWXTFFQ,:44P\XS6'9RYL>\9-Y7Z\S$*9'JB@B-:4),FC-7KZ
M9+DA<Q?..(KY,T\0)K^BAY:N:%HU>8%?+?F%U5&DO__@6?8?[XG(@%:@X#+>
MWX6N31_X+7"PIQO9G8[M/N([\6.J)<$O?ICEMCQ:WY*D\.@^\+Q/09B-!^&$
M-UB@$G(;JB5X\V.];M@7*K96S+V/$&T0)2UJR%B3NJGEU`*C&?SL^GZZB/S1
M=]BJ^CXX$C)BK!1$4;M7]:"@L<AJIIM17T(EM41T9<RG95G#-(G.C?[X\$;_
M]Y-ED]:AG#)$D@(R&:`>>&ZQV%;./T5\=;G0#%N/)DVPFY;H?WE;&M''5([A
MHYKC?F^%;Y0-[DJ%LB^/41SLV3')0MLZ4,((1#1QP5"W"BD$_T!IVKEWGU_B
MQ^`*OV(O.%P2[K&>`JY%8Y&X0:_*+O`.U`MZ#9"QV6QFO)@[EXQ"*AK%`7*X
M<&07I4NNUCZ)M4;!6B8:/08H$8Y*TA55VYO.=+-F>CS&="FEUP>"-RNS/L1Q
M@E@F='%T81!^>\5A[)(!S5V8E)!@,ZLNEH&]*I]E0'J!B_VOS)QEJ&1T81!>
MR62C0RH<152Z=):9P%JC:"TR4$$XRJ0G2T)*:68"V\VB[>_'VRZ)9P;!M\`S
M<,^)Y!ES/,_TOJJ(9_KT@D??PEB5><;4CV?$6EOF&5-SGA%K>YEGQMLNDV>@
M\*WR#,AS(GGFUA]*+VUO*&*5%G6@(;99&&NC3";O23^N!84(,:W,'+>^CGPA
MQ-`R30RV5"8[]("N2@I=[E&RC,K5`O`&Y`V9RZ+M:H#3OQ;S9053>N!)M(WF
M:!NEK5WVAV%IC;+',2)[U<>OP<!>M>T-1;UJBSKP=:BU859[U?AKH$>_*L2X
M,@<0D9KP@'!#*_WJ4$ME]JL]L*OVJUWN$<@&'T9/Y7O?5,,.?6I!QVWF8F4L
M2RSQ0;MYO%A;C9*M6D_BQ1IN"C%<(I=`05OA%)#7U(W9/PP>LS>_(7W,WJ@&
M=#QKKM>+"O3T@)MH&\W1-LH=LW>&87W,WNX8@;WTY>A>NO=--;UTGUI``I_-
MC>VZW$M?:M=+B[75*-FJ=2\MUG!3B.$2>VDH:"N]-,AKZGKIR\&]=/,;TGOI
M1C7@JTZS605Z>L!-M(WF:!OE]M*=85COI=L=(["7OAJ??]/_JII^NE<OZ'*-
MN9ROR_DW5_KEWPBVML@75[KGWPBVO<@C5^>1?P.&;Z7#AGE.),^,S[_I?U41
MSPC*RF#+PILRS^B7?R/8VC+/:)Y_(]CV,L^<1?X-&+Y5GI&=?W,UGF8T91DA
MH;?=KHW9NLPQ^E&,2%/+!*,WO8BTVQ1BMTQJ&<DL>B\Y7`U><FA^0_J20Z,:
MT"-[6V-=19X>:!-MHSG:1KE+#IUA6%]R:'>,R"YZ<#)/ZQN*NN33TD",U7*V
M793[8C(*U*('%F)9F0"TS.018ZAYDJ$R^]AAB3R=WA'%!*\N#CN!7WA``<[S
MUH=,[O(A-GU?/H;':FT4M%:,SK$FF%`39.&N'N!%F%7,5#)2;2SGUC9R:GY8
MYOBT40/H3M%FD9W=:"EWJ&A$>KI59F954@?5[K%*VABT,\!*P\]V+XCI;_HJ
MI+852*67N<1OUSXM"4U_^?E((9M4!(L^?K-986RGD<NF;E-ZKSBQ0=!UCOG2
M2(?/#,KUH$=6KA0M$AP5GCLDQ04M5H8+,]60F^F&?*8<K2[#WHH03O63W9WK
MY.Y.YBP69>XN;<U50[ENB"N758",4*:?BN&'3BYGM/X8T%L%@]!]=GWR0UH%
M,XM)M`M"%.*#9]G<_<D3Z@8^DI@V'TO)^&;*AF=/_88]U0S[=G!YS19^@6G7
MR$.(?-F#0!%*@^_`6&97`&5R^\FOJ1Y]KD%RF;'"`:=T#S(R2]GKF1::Q<X[
MM+>^L<M3B=)[Y0-5D5"KC6V%.5R?B2*`8FD)8E:!N%`5]\J-;%K;\U,0W@51
M_(JCF-^S$H>NS9X8-%.:3@OE4]O)3(,B=[U>S$2-_`K5J(N%NU-EV7W)!751
M45^=9N9Z?!1&I_1.=SOF8\`==MG=RH0OU%[RKH8J^M<2IOUN9\_*:2Q=N:^N
M@WWGGL21#%PTMGNNS-MD#+A*]FJQF9AK,[Y(]4/W+6QQ9N1ZLM_+=.JD[GES
ML=<X2C]+-NV"^&3\V?IISFI&W679(YF[&*+G6OT-GL.<N]<*\!1ROMZ(F83W
M42-5"QEG-C,7Z^<R&7KNCI5:#_@5,FTS]9.]\XK#I^`L_&.4'72V:Q=@4A.R
MF`'[!M_-./K/@4?$T+MQ98^D*RV?^UBZ;`X4J,O9JF>W7]QH.M?P>QM/G^#[
M,D>^9H*4,Z4<H$\^GF[X-&?/G>Q2DQ#C:Y^$.XYB6<S9V.ZY\F:3,>`;=_+T
M_:E8D]]>1/1#J8+?"VF>['A^11J1\GY'_>.F_OFNEG2[,#X9:;9^FK.BS!O7
MQ]<QW@O?'\L%GP/I9=J")VV+K;"5U=]IZX@UK^H$DUR_U7)+6_WVE/CM?=.R
M2Y_?M.>R&OB$D%7YFYP5&Z794A>.X])7+(_G35T<XY<@I#=7B@Y@0(OGP%_]
M9D`!.I\OA6W/YVF8N5YI1F:NV9E1GF!7,RXD*NR)8]FIJ+-D,CAPA5`<\!N<
M)??)8KRSYKFQD-O.YQ.PV_=":2=YE1'9Q?-SB)_)3"@_ZG#6?":%Q01PE^@3
M2FVJ7>Q(%%[[=HC)&T(/.\!:/)O322!SP"<W5L9,U-FDVDDD*],-650YY";:
MG<O))/&NGKZ#0$PYE&IW3J>2Q+N;]1SIFR3\D*5'+R*10D\_>`3_+.)ZEC%;
M]ORXQL=O.+1=\J=K/PY=/W)MMKS:&JCB6U+2DP@W`UK-8#9?;8O'6X$]2%,'
MDN3LX%0ANJ?`-4*O5"45W89BOPI)(N/ZH$PAE&G$=[Q4]1&*?5N95E2"+4\B
MB_*(5-M73$:*Y3YBFL]R5@FTMVGV`K/'>O)PV2+A";3]#9Y#`FVO%=`Z(=O9
M<BZ2^R)4T*E*?V>7/RO6S14:K#CG7=%SRA=<)L6RD+Q1V+<YJ^7CNDE\1B!Z
MK;"UG7-8/FY3'IQ2,Y\+RV5JXCRNS9FM'@MQ:IX2$.E%9E-@4<CJ<:?;SYRZ
M_H+=YY<8.Q>O.+2><3IBO0M=6WCRYL#6SY/FNDP"7XMD+I=3DE^J(TJ4S*;"
MB*EY]JPH[!LPKDREO6]QU_?(HA!:F(A;>S_>F<^<*_;=X[WE^J[_?!F0@;%E
MQT?+F^1,Z@F:G.=<&VH>F!$,4]`I5A`G9_JB@L+G><!5TK=I8>MV1^K%W&KH
M9:)9_J`/?(YCZ$]9T9[H&E"H3W!+9S0V;E`?BFIC20]KBQT'%]1!U].4\MMR
MI_IL`=&9<LQ[LF\7Q<6`1!IQ71`B3*O7J=GAD0!1D6/7MH]PCJSV*RWM.#6A
M51HY(RXK:PX^B6.LA%5@3FF,:S(5@\F:LY_@S](RYJ^\(NDYDU4S\D3R5(.S
MSY^B*N-,]L<KTNUFYTBE1&Z_%F=+<KVF@2NUS9?"=W2J+%B?1;,G$%6X<*3]
M>R!+L=^E/'6V$N>Q0L_O'>J\'75>+1'H^7OC73"=3$?,L`][CLQ]>XRCV/(=
MUW_N3$:=OKTS8N-6(\!)+>N9<-XM**4V>5(O+_>E#A5:>8<^<O=]L(C@YCVW
M<Z'07ER+),ON+W7FM#AI(E&]G?.DP6$Y+QO#G)3^)DPD.K#Q`.$)2<PWPK&E
M]<.!]";(/P^Q%<;Z>FC9ZJ$/^-GU_:F=)+/K'.&>8E$&=G%R<J`RR*5^)UWC
M=(EIS5_@S+M"!8EIT-;/L]L4D!1EKM?B[A)LZDQ5)*;)[F6%?8<%+#GM^^^5
MA7ET.<*CWU\O+LR=K&__FD(Z751,#P^B0QNDS[!SEYTO.>1SG6.^9+M];9E$
MYD1):V,T.:-\R1'F@0N);^8KL?F2G4.%CGQ)\SSS):?^-B/R)6\UFI:IH1>1
M^9)C/_`Y3NW^C"-JGN]DMX8$]%<%%V0+YU(VA\;K<T;3O]%&0K<]-N9:V$4=
M*<MSI1'1NG"O4\!^7>H!6C=:SG,$+N=;]6U1)<XG#=(,T.2*I`#1BS.5$[Y*
M]A$Y>#_M2W^?Y#_ISA>X^>^*VH>MQF\W&V%E]H<R^3D?QI_D.Y226_^/I>3I
M=DP&?;3ODW`5[*^<J-1W1<XB%EDWIOC=&"AE?Y<E!"1^-F!E@?]CN5_V@KJ`
M3W^.Z^R#S99=KD"@@F>T*B_.:O`!^OG2%+M8/[HG^?X*'RCZG"/6]W7N;[3X
M`%-L`P@.C_/MA](C,-E1EVE[E8;FSJZ/J-L`I8CY8CT-X^>G\0J7R)XU<Y_H
M9,;#GTH'Z%B2:\1X58/C<Q,"5SQ/MGP,+5=IHK99!_N?1Z(?8?T[$D*?K3V^
M"BBKCYW:CFE*IQ65$?J#)]S+S8!RBE'W0@G_7ZH/&]I2C1!5"?W.E=+U7MFI
M_<M([N/?CV[\EEX:V^$0;18J3D#HH.6'L>X_+UHKUP'#;6>:A2PVBU7B+*AP
MC&7@?:?%<B6,)"L%#G%GB8:S6#E6]TV&U:#58#0IG3G$$/'H#WF6%-U0M$P%
M20]5XYQH>J!MX-3=^6+`O8E`HFZLBOB=4O64WP5(UF=7:7$B.A'*W&.^ZUER
M=V>]("FT/4"#<V)LN%G@<W#F9BZ<K/NKGGT7/#W1UP!2]#F4E!1/%$()>>`'
M5,;%O52IALF&)14M%Z7T7=7`'ZX\/YG@."Z-'<M+MTBBP'/0T7?H3>HD<MY;
MGA?$G"QY%4*Z/\W^_C4D(ZKP'3]7C`[D!29B$B<039Z"2=Q@,#_<]=L@E86Z
M24(##$?7473$G16KTT=DXSAI%YZZ42IZ3_IY]KKBVA=CC&`%*LH5)][QX4WC
M)?."K(%5GAAC#RL/4:OW,*E),+(=8TSAB`'=D+:+)9@HQ]J6#J.?"JQKS%.T
M7#7W,!8D8QWV.\#G*C^OB)5*2L`SF$NSFI2B^*"#3DHX)-0C8KQUM;IDH'&%
M"FPTAET;4.H.48(:]]EW=ZY-I@<7MAT<_9CPZ5W@N;:+HT?\+?Y`&O^C[?O"
M7I:))Y!&X(M99IMM`JY<+LH%HU0R^IW*1DRXJJP#\9;S?NFXWUOA&^V8>IR@
M%(6#PK@$2;C?E.`SV,5D'D]3$M(?K_`K]H(#G7A=!E$<_8:[SNN"WY>)4JA2
MX-U98YX>OTKDL8R@[!\%Z8B)1[_S!E2!=1('F"4'=%DH#99#H[>$S$%.4@+.
MF(S,B7HWI`GO_SF&;N2X-ET(Z89DSULR@=BM"O@6H(V9EAZA`AGVF$A4E*D:
M<P)M-7-;K>&V2D,?+#Q+F`,X21G2&.P]*XIN=P]T'G#QS8VZ/G;C\[+1U:0$
M=!1F;C>S`JYX]T5EH5LR&F/K`[]3>2H1=;)]?'K'K`KZK9**G:Z`JZ&FU1%*
M\<+3@.FN4>#3E7H(9AK?48&;)D7`&XS+K5G%3I(3G0O4`SXGFUE,^`89)QU%
M76'8B*16GRA%TXWKXVOR8R^$\@=5X"9K'3RH6:YK'<WO5`IB8E0#9)P]YC![
MI&.B%DR-0"C;KC3Z;W>75O3RR0N^1A=/$3OMVO?EFEY1@8@&/<"#E'66C9_%
M$AE^47F("20\FXA4C9-3K:P@)AA@I73T=`1C(X[:?*,849]<W_)MU_+N@HBE
M6\"1U?ZJ&H2UZ@-E[<5J.V]`6B87I8)U0IP8J^O(&VRU`@3V!F\+$KM]IAB1
M;/+V$G@."0(^"H5#LN-=-9AL5P@\E#*S/;`B*(N"TWF51J@49'<=ED7!_P0S
M7`$P^V.X!9D]?E,*S4?KR6M-YB@_I`)LK&5P=*W71FW"Q22HQLYP,ZKSK'8S
MI".A%#*-(9^;JR:VJW!K_3RU!Z7&>+5UZ+1BL=IDJW"U#D-A'N5I!C5D4RK-
MHCS-FN9<2E4T=)(IC(H>@YCFK)<Z:LP[ZA\=O'-M-_Z36G9J`WV9H1H]H0=+
M]8Z(]1@&GSH&7!J;52M[:3#<%6*?6;6OCI9?]()+]UA6X`!V_^Q_8Z`PS`02
M]#<-;;3M"_0^+A@.3F`?Z:B&'0\;J`LL:(S99K59FW^=MZ)BZFV#)LB+M:T=
M\<JV1,0:6(,\U,"I,0^%%T4\R"5Z=)>?@QA?N9'M!=$QQ+U9U>#WE7:F+4J!
M-Z[IE>.M2*/"42Y=A_SJ21S0T/DF'OCQ2LNA:D\H=W?%71[3`ZGW^)4&`OO#
MP\%SX2/<^IM*T5E3!UX[Q5RTXS(1FZ1I,<&ZP/$TBQD04^OXT;NHS3IUZ&L-
MSV[<-;MFHK%PTS)MYZ/JQ\!#UCS7J^U\VS#\Y7.FGU0/>8>;TC[:5;$>+<RL
M]C&NNO5I"&(ZAK9CUZJ[H$O/(M+E/G:<HO5;E)]2`MB2"M#ISFJYFFTX6/FQ
MGQ![5G*10OR"D9L(I;6_@MT.AW0!E-8$IRVJP/()5N8X1JD4?M9)%8!/L"7I
MC?FWRCZ,W6:-/-PVPJ4,V;K9RH:V_*#QU9%ZCU?^X0>0+VS")SSSHCV3%?J^
M[&$N1"GPL;FY.:\"AT0<%YZ6]$H.UA?E*QSS"C>_6'W"Y?:[/L&:[V-^E.FK
M&[\@*Q>O?$@\)*QK`V.P_[1#[67@TV$\4?!VQW^.73(@>,`V>31V\2@H]PO5
M!=^]FL(S>^:UWK(-]'FC+.<W;Q;E[6I(!F)]E13@R#Q!!D@'$O0X#(G;^%R9
MC*?L4H6.]D(\6E`%&$M@_H"Y7#M2^8R_LC^-(H_\95U((M,(G/>^68-'`$0X
M__M$-;-8,NSK>-2/,W[.X,TO62[<AY0,!<C$B);]TY#CQEE;*R:$_*KED]D+
MJ50X07`SD[,I8:7`&&720I\6TF(V5^_-E,9]S+)>RU,P[=F]1FI@%B^[6.PR
M2V=[U[[M'6E"V9>\?F9T2[[,15IDLW.>?:IL94LZ)RH.1,)R/E\7%VU3=G,X
MS?,\NQ3_/J%Y]G="@JD"Q;*F$:M^BK+JIZK6B62Z;G`/B3(%4%$#1%5`F0XJ
MEZ9DNH]3L$^Z=\M#A^.3Y]HYIU8ZH-;^1^XJER"VJJ^-B?"[=L-H]L?*M36M
M%7"'"])E>-VH';C6Z6H%GG?S)ZIW5^DX##W=)0WU+4MC<"W'H@(B(=^A2\N'
MX_3"IVD*^6ZYZ3Y^IOL**DU?Y&NNNEP7-IK=P&/K=K]-/\Y^#(H=RJ<@3!6X
MW95Z%Z[>X''#0/%:C;:'Z0X=]ICSQ;)OP)WQ7/G:@`CMV%5,R24@=/I9&F\G
M;*'3L'M"'P([S,>@/,XF.N3WJ-SN*N/NI&?5;?@]H1N'7VEQVW2EA9[C\G'L
M!AN:C_@F&HW.V:WD@C?.@#+5C]EABD)'+LO-?-W+1JS)\]LUF\!3PS?--!OG
M3Q$]?,B/X]C+"BI4G?+5"ME=51H.AH>1"6!</,#%NG'JR'W#RKN:<.3@C975
MTC"!7#CQIN%)C#?.;N'[23H2W\B02&X,2RF-1\>!Z/YBZ3G!;P8SE+M.V2Z;
MGJ,$+,IVR-&$NTY:C5K,E_TS3,YCY[`B*\@A'0N3NB+XU!6Z'L^)6Z#CXC]^
M(X3H/^-[NF1UA2,[=+L7WGI>4[*@UJT3,.'=H%FX\^)*619R7"X*J6#DY))5
M+'R)M+7`-\D:2RH7,<&H(%G5"I5(>QF=%-ZF`Z#*UZ5#HM!]=NG*5)!0+$N[
M#O'!LVQ<6/94?``"AM_RTA+`F:()YM;'C7>PM#^GD$(R):`'W,SM;%6DC`1&
M1,ZT=ZQ`.&*<,75.F-P8,`N,L\@<;)%L$-<PTH3:LO&B87I''$G4GX&P6GE8
M(6#+FD![@]G&6)H-/3UA>!]1<>HZ]E,,JD/W+C5($P"?8ET=QC#K9(.Y&4E-
MB&[PAFA8/WX-0(C.GU,(YDP)<`VE[<:<-W2_1)#Z[G>D-7403VX-&+XC3:HC
MM\\DV9BMP:0)KF7KQ2#U^.1A*^H:(9>?D([.4O/`8==FNURO$U@F[\ON4,>K
M;1355HJ[\3:88!OD`*TQRG.(U0U5LGY]?(KPWX_TQJM7R`53;8_+7(UNT0%\
MX<5LO<D"/I&$F"@=[IP289PYRCAIZ\@](5=:+NYRAP9XZ;YHM_%9=4@9Q*ES
M8[E=M\%$[46Z)UO5@@\=KLSM"J\.8.C5B_1>S];VN#IL#+VPS"0CCEDS/#2X
MD$V$;8T@T>8:MIZ`ZX"*!M>O513J+<C;^KQ"O`RN-[M=&MM6P*@OKRO$O&;,
MZ`24[HJYG4[0`"J=5S`U/:H.($,J1LYG:V/>-M92>BO3J3:UC+0TN**I([`Z
M(*'XNJ:*,J2]KOO46YY6B(E$!7#]D.5LT0(+*DKM[>D"3&M&1X]IJA!2";8N
MD!1]H0E.KH*]Y587>_N?5XL5K@1X!)*7DFH.*2Y.'[R,,*\+,1WF*<1,.?!Z
M4%/PB"K<N(YKA6\/EH>3VSA[>ICFYR7CIE$)\)+0>E98Z.*B$)65W3.KO*,Y
MW3ZS;-\[;F#0;Z!,Z'3&7A4Z[3Y1`9U'Z]MEB!TWOK3"\&T7A%^MT+G8!\=:
MX2S(&Q+ATZ$&,,`6L\TBZ7B(,,2EH:(XQ.6IP8\H`QF"OCR@3]C!H>4A:JO-
M!$?(IJ)1(ELEB@!A6,11GV^$;/<W-O+QV\%EN<?^?V$KO*>)N1_]ZN&8P:_+
M3A08H!NX`/ULL4G2"/((XP&6H@EG#:`WT@(*628W]AW)^0:36=_))7D#B+:`
M6!.(M*$@6V$R#S"RJ3--\=-C?O\OC0!E.0XCH)TE0`SUG50N8G<>G_+%N0!=
M^8AI!TY$71K&=@PC1;0533EIA`=&L!)K16->&N$%`#.Q[WX>Q%3"^6!JRMVG
M9,J1[L[T[+;7GY,YO:@V#IZUFK,DMS_?&U2^L7Z:->8@:Z1-&=K"J#11:#1<
M2=2'EH,O?.<V?L'AA6W3N4ITCVWLOM*]F;O`<^VWML\'>E<F.B`*P6-LDR*&
MBD5$+F*"42H9Y:(1EZT(1L+-YN75ZF8J!=:02"V!#>P>-0#$5G0,W]B:6V?^
M8].34L%5:QZ<1;O8SE(H<2'I.JG2S,=3+3('6B0/*:TA5<9%L_G*4<`O+[G=
M\8J%_XZ]MBHO?6^I0D==%7"6QVS9C)3D0A>ZA<)+75*I&L#F1%/+$"J5R]8&
M0>WAV(JF%J\H1Q:K"P/YK/Q!5?AAK8-W$]:S92-DF!15)<=/M6?1!`PK9A76
M_AD9BW?SC9%6O26_OB+#&480<^,=HI&`+#)<K?[6U`93I4!LA5'N-S&KE5^#
MQY?@&!'7D.'@XXL;QAC[O(024=^GMW71X]3M!RD'2I"^7CE(/>@2^GRYS!8L
MO]*+EGD++,+BI(VDVJ>;ML*J(,A>JYS0>B.U/FV!30?3-A+"R5KA1044'ON<
MTA5FS1762:Z0LX`Y"OKY"N9P?T["6"$N5G4;QE6M[ZIFJ3;%H&&Y6!M+HY6?
MB/2$G`KU610SDQB+VSB)6EPO<:(1&XDQOXV'AINOA('ZH-S*/9W>4S+#(`W<
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MMP_8QSLW;B>$YJ>E`KY1!?#%&(O5.@5T+H@EH*:B)NEQ^4VA'_T>O)YN&X/C
M1Y[3_V1Y]&ZC"0UBF:M3F[2D)GW`SZ[O]U@ECS`Z45,FA'8':`3X:]\.]IC\
MX@[[ED<IZ<)WKGTR4"3SGX_?#MB/VO;/3Y&HGC@@:H)WL.=IYF0KN2#>'OM=
MUB);OT[;1$FC:I8!9'G)K'G)3>T/0G1(6]$0Y$.0`B`"L&?U(@N:K8"C>QP=
M/3J2^40\=WDDLR`_YA<Q48."B-U2/'`P,52X%A0R1&-HWS>?S[8`-N%-HZQM
M1!M'2>OIW6>,;E(%=&.6R9S';WA,&_CY1P<G/_Z)7<UN)SYB1\UBXJ%#EX?4
MT\X8S,$8:/`7T)Z,[HC:X314U"9:5R)JT1>,),.`#&J::8BU?:XD),)Q/11T
M8/XY8P+JP=EH^NGRO4;D<X^=(]\-+FE_8QTBNM]Z.'BN3<_:D'ER?(S)KV[<
MO<NW4@9RT4DMJ:>F4]0'3RR6FU4?4^5Z5*F*J<)2&S)E4*(-_6U!'W7+N8I=
MN^`W0*9<;Y'_0R%KD]\%F9W<)O^*$M>1'[UNURGF-1$0!M#<R5])*]9+++CV
M/^/X]H!#MIQ]$T11\:3[T#"&"=6!RT":@F]<WVP6_;25<M6UCTBC*&L5T69+
M-22T&EE-X2LVIJ)."#(G>$0>CMZA@O\8.SUQ-6@Z;'!\?D&6X["!A.6]/UBN
M\][UW]O6@>#,TY*9!L$,1$+PKZ$1WSR^6/%?@J/G7.\/EAU_W.VP33//R2/W
MI-,<%I%]PM3S2X^&8*PLE[V\0IM"K"W$&T-9:^Q!VIY6?"+2-XQ'?@TI?QZ+
M'J(SL:>.S4#%M`!$`X`.(,X4D^=V();Y\2=,RQ$4ML`#_Y[K17^\JD-YX,O2
M,]^@F@$SIDQCLUTG5W(FLM$.8Y:)?"B*3_LY]K-#&I!\KF,BPXVBX40XVQ<K
MB4<%^>A*.CE-:7Q2U2?<TRE3_$*^^G.(6:ZVNKRXH;#-$^0&^4@DQ]Q9;]1G
MA6;X*E+'EVQ]11&?M.D#/29$7#.?E5GDP$66>(-G<*AA#C$FEO@B$5EB""Y4
M'4>(,9,Q`]T*MFD.'?]LE"0<_(J]X*`#1?2AKDH,G8Y1,O.@JS`?H]C=$U)J
M79HM/R1SIE!J&5S2:K-,4\WYTF8F0=&8?KP59FI%T&.%M,%Y8\"4!MUU:\5T
M=`^_!J\X]-DQKF?LVRZ..HZ+M#\MO7MK507*A^O%+*W(\`4]H.=,'!DL<7FR
MNS-!)AFI2;DXE,I3>A1$D'U\JCW0-CD=6"^:\KZKVQDJNJV_L,.IW=<'EY^1
MV&F5&@9?S[,RDE6KY'7%M?+&&V%"C9#5934&2[''JMNJ,*9I'N2]^_P21[?'
M.(HMEM+>_9&:7Y$?\8UZ0(<[2S-="4FEL640+@\5!"K%P^DF,GCD1P%YJ9*O
M"5P\UWIR/3=N+"PK&2^=@=@`GW;7J$33YR!^P''L8;K)?.U?6M'+)\L-6:6Q
M*S>RO2`ZAFU;*0.%*$`<3#/P]L!\850P2!I`>0MT&Y:V@6@CO.`>RIM1E2`R
MI3,69P/789'>!.`!_E,":4S9!3L79#!*YCV\YN:5Z]$CA[SP9H%X+IR_':.8
M#EG;@F:D-)D@'Z<B^)IZPTPR7-.&4-)26GTV:2LM05MH#>7-*>J/)?B&+T"R
MW4&V[DBETQUB/4[OG@B'$@&<X$QMF.!VUZ;QD!#JD*(:^>VJ@:N8;](:'&V(
MO]UU@%XCI`OR!4-X:O#7U"=6XA.?^X1`WP[V>WHS3VNAZM/=$,26I\H-JTXW
ME(Q'07<\*&6_?@KH9;T>CVK$=C4%/UB1:P^+GA89ZIFN63'P.M1ZM>GEN89!
M#6MDFK(!["3'ZQBB$^"*.>,Y]MZ)\%9&]P*\H(\32*-/@2HW&%U^&-#E*6;Z
M;OH#\'R'*SG_)4;?$'GDW^1?Y(<G*\+D'_\_4$L#!!0````(`&R`=$18.B/S
M44D``$&>!0`5`!P`;6=N>"TR,#$S,3(S,5]P<F4N>&UL550)``.,22M3C$DK
M4W5X"P`!!"4.```$.0$``.U]:W/CMIKF]ZF:_^#MJ=K:K=I.I]US9B>ID]F2
M;QGON"V-;"=S]DN*)B$9)Q2I@*3<RJ]?`"3%BP@0`$&"@O@E<=L`^+X/;N\=
M?_T_WS;^Q0Z@"(;!3Q\^?_?]APL0N*$'@_5/'UZ>/LZ>KN_O/_R??_O'?_CK
M?_OX\6*YO+@)@P#X/MA?_)<+?("<&%P\.]_"(-SL+Q8(1""(G1@/=_$`@]]?
MG0C\KPOR7^\"_^J_KI8/%Y???;ZX>(OC[8^?/KV_OW^'D)>/^9T;;CY=?/R8
M?^^7E+(?+_[ENTM,7.DORS`)O!\O_E+ZU34"Z8<]3-./%Y???_[GC]]_^?CY
M7Y\__\N/ES_\^)>__+]RZW"[1W#]%E_\#_=_XL;?_^4C[O'E8OG=\KL2D__]
MXBD,(MQZLW6"_<7,]R^6I%=TL<2LHAWPOLL&]3-V+S"D0?33AQ*'WUZ1_UV(
MUI_P9[Y\RAM^^,=_N$@;__@M@I4.[U_RYI\__=?7AR?W#6R<CS"(8B=P*QW)
M8$U=/__PPP^?Z%_3UA'\,:*C/(0N14F`P`MF"_*OCWFSC^17'S]??OSR^;MO
MD??AW\@'_XI"'RS!ZH+2\&.\WX*?/D1PL_7!A^QW;PBL?OJP60??*/*?+]/^
M_W03NLF&K*+`NPUB&._O@U6(-I3J#Q=DW)?E?87\C>.B<`T"Z$9T!<79>OQ$
M&G_BCO>I*[5+W/.W)[SD`?G&?'4'`SQ'T/$7803))ZY])XK@"@)/A7C!D8=D
M8^$@H#01$L/';R"&KN/K9^P>'V\;,/-C@`*\!':@(R?'XVDG^>D-0_(6^AX^
M#6__2/`*G@7>'$.$R+&$_P2""'\XI:0C.W+?TL[JM1.]W?GA>W0?>!`!-^[(
MSO%XG4F^@9'KAU&"P!RMG0#^20\2C-*C$Y-?KN9;<BOBWT4SSZ.+V_&['F%=
MOZF1ZZ=DLW'0'B\5N`[PCG6=()ZY+KZ/8RPU+$(?NA#TP7J7#P_._Z'5G0/1
M+XZ?@*_`(=W)NCR<?K,H`C&>Q@?HO$(?TPVB(3!2)\X<CEBT7`&$@/<4A^[O
MOSH(X?8Y:?M!46LAQ2!&`+E$T%F#2H\EV($@4;H9^B+%'$;'K:(E<`'<.:_^
ML!#Q*1D<H=LHAOBT!-Y+!%:)_X!O^4$.H\;O#LX]D6Z25'&=KZZ<"+KXY+N!
M?H()2X6=AS"*%E0,VH0!%9.&0$>)KN%W%U8MO<3'>YV2AJ?P";@)HG<&GE9,
MZ;7CNXF?\9'1?^N@``]"J!\,3TV4:D1X@4(LO%$YFPC<6W('%U0V_;4;3@K?
MZYG;'F1%\<_HW"M$'*CH3C<`KT/8!X.2W]+))=D`WA4QZ2V</0&V%V%?]"O]
M<E9L#`HX_1LYDK$63#]_^XW\V/7D4O_N4-P?%(7YEFJ>[P[R#A?W/'A^`S?X
MI_GJ9R(*OT3XK,2_NO(=]W<\!B8N2OLM$%ZBP?IKZ`&_1\SZH';0=9;1[>+[
MJ;MR(_LUC9RF$LJS\ZT7@T#KZ/UP0O9A&!`<YRN\;C+70'23*86X#=6<(VU*
M?<=O]X,"5E7"P,7?R"2E)=B&B(A*^3X[M+T"`;Z:.DHMG;X\#`+D#`%K&!!)
MD<@=`?&BS39$`"5'#1;37P*$^V#I]$\Z51EY^E:'/HHT(O8`\-%S^PT6%I(>
MC@+1C_3*U_6;$ZQ!=!\<_TDW=[Q/]<KC71)3\1KB=;9U_/Q&>0FP($I;S]8(
M@.Y:2J<O:T3@.O1]YS5$N<']`;I$\#I\JX][3?&;6KG>;&"<?BO`@B=5H4'0
MDV%?^FO#<%I(25]A`#?))EV!=*WEJT^7Z5`?&7IU=2]QXZ\02\0QECH.BEC@
M+<.]X^-#ML]MT/WS&K&XQ<W#/0#9#;GPG:`'EH6_HI&S_TP<+#TA?W]P_)0^
ME`N8>$5&H0])9(UWZ+`$4>(32;3P/G9C7R\I6JV@KQ'X(\$K[7;7E\%#Z!-Z
M'.Z/80RBY_"`\L%A'I7=RP70Z354#NXJ17`4G0MFGL&W^,K'JJ4*)@-2US><
M7%-T3R`)?G,<K.>_,`'!X=OC@.*97-]&@,B^W#<,N4V>W&IQV3#?^[DA]>4Q
MP=#'FE#X?N\;Y,B90=KVOBS$/]LW`*7XKE79S+\$/A%SKL,(4TOLN!4S;D^P
M="5FY&#UL:?TD-0W<`=+8>\[B_LEDVSV,?D"W^N;9:S^Q`CKR@E*+;W9NLM<
M.OBN[WW&E2@8(RQ]K)`.=/0-4:NML?>5HT1!_[`P[7$#`"+U[7%!T<?V4:*@
M][.E9H+L_X05^&#ON@O)_J"[E*:$++!<@T`,T\#QW'G8OSJG2D7?\'#MESV!
M(?C-<;#>Q^D@]>7>-=F:%;<OS97YF8S!;<D:2O)P*YSBQB#P2#YB^EOR,5WY
ME/3SF`!,3.6;/DD[#5$5WNR3-+<T`NYWZW#WR0/P$T&<_$"A__C]YRRS])_P
MKWZ;X4][-$_%=];Y<%B``/Y/'X[__JEW>JX3A&C63.0Z_M^`@VX#CT27-9#&
M;"I'Y?&B)+_Y+9^66<.TS%[Q$>F0;+H*4>+]^L<Q)R-%9P$0#+T[_+NH`4AV
MVZ'I)+,H1F71<C@:4V38"[*YW7#T/>-A.631/_=/3;KJK_$'$;D[//#M/\"^
M@:SF=H/1E^9W$),EM21%\R0FY0!(2!>;6%ZGP2A/C[TT3`]_F%QCC1N&VWPH
M:N^@#]`UW@?K$+%70;754+0MDE<?NG=^Z-1/\N8V0]&U!&M(+HH@?G0V33NZ
ML=E0U/T2^@F65E`Z:>R%5V\W%'V_`M__CR!\#YZ`$X4!\.ZC*`&(22>K_8'>
MLO`W0U7:'>3F`^,?CR2_:IF/K,6G+2W)\-%]@_Y!:%RA<",C0>14A`UG_$6(
M/(!H_9G/WW__X6*;)]@^I+PS":348>$_`K0EZ0E#A"GXZ</EAXLDPLR%VS2*
MXK3@J4FY!3Z7$SX<":?`Z<N$$U=:+9#ZYPFI%OVCP.HO$U;L6[^`Z5\FF#B*
M18'3_YYPXIM0"JC^=8)*0&(L\/IAPJM=`SW`A:7."2ZVPE3@-(GG3"-`":5)
M2!>U095`FR1VAA6GA%'?LOI?/]4=1_V[DP0K7"H;8U9.]$HQ2:*/:\?9IA89
MX,=1_INZ:2;[]6]Y5::%LR?>P^P6J=EE6AJK&Y&ZTUUDA3V"6(SZQBZ&>$`)
M*->>:V6`T=X(]8?DG84#:4VA+8SQ+F/0SFAMA'):/H!%:/I'<W0Q_)B,1N;H
M;%FKE3;&J10"M=[6!-6DF"L)`,/_(^'Z.\<GL0^S^-I!:(^E"5KRA<&%6%\C
M7)$[+JO$<A-N'!BP6#AN:(3>0I[C`EYO9H+6O"[*$D_V-?X_C!_#P.5N3FX7
MLSS0TIG\HX71>`1T2P!?;V^"^DKQGD9ZCTOL&*,0'VS'N4SM9#=W&R,O+5>4
M<'?#O/'W[DADUV,RQ-$?@Y1`8X)3H:7US&EN:XQJX:7":FV"\FHU;)Y(T-32
M$,5;K&AE-13Y2#>W-4,U(V\7:^I,XCE=3/!`$Z&@2U(B&^5Q!A^MW8SQDB=U
M98\!\=<2K\=8.&@],ELZF>$CQLI04:5YYKK))J$I=EE17"8OK1VUA&8_`41$
MD\_78;##^Q&^^J!Z%GX%F]>CB"^IKCKIO%2GL[6K1CJOE,EL[:F1RFME*EM[
M:J3R1GUMMG?52:?ZVFSO:N+L.G@_RM:=V3?(N@K9[8U2_X"/T7O\8RO914.C
M]#;XFEJT'*&N1GEZ3LL0\JE_+A4)')I.00O%2&P2TE:(D=D=GA%]TVG?JI8U
M-#1!;_:.$BWO2%_89">X"'4QX?7G>ZN(B[_%`W-P]7^Q*QQ"')AV%;'`2"$<
M`@L`K^'IH\0W!A0(V16P+(X/PPA8`&-7B++LN5-&0B4(.8P=_Q208!BPRX`(
M.I6+&"R;MY0`7OS@H@(FFS>8`$P,&W.!CUVQ__++J!HG4^"B$N@__N.('>1!
M0)$S$AZPNK1S#8ECU6X,*K"R*X%$&JMV8VD!E5VY(])0M5ML"^')KKP1::@$
MS,8%5G;ECLAC)7%:?;$K@T0US*<L,/#"4@KIP<ZCJPMN;4[>XMBW\RSK@AT_
M?+1`SLZ3K0MR?&-N@=QTSK'7W%'8;`&;@G'X)`R?FBZ(,E0J*7/CUR>[`,5K
M7>!FIYE+TP)C!%P7Z*E8OTYJU4E8"NOID[86>U)&B97H:&O5)S6@N/&6MA9^
M4H.*E3+4J>C3J0D0`C@Q@^YMK?BD!A,?(3NONM:XO(H/L<$&5`!DIU[-#OT[
M=O,TR)>6U;Z20T5<"K6U`)9*0&95AZD&/9[-;JL$>38B<GQ@Y>!\/Z%3WI<'
M6"S&14:_;4SDL[6BG!I$Q[4/;"TAIX9/4\RQ6O&X'U*$`K`FV5@V8<2L#61K
M_3@UF$22^FPM'J>&&-<B><:EXQ84YS<00Q=3.U7XD:GP@[&;(PJS1X_S!4"T
MB".+`8&>ACE*:U#.DO@-K^<_BZ7'YN2HQR@X:,^.Z>GQ%UV5(AX@/J,\>BZD
M?P"!"\3+1W"ZF^=-<ML(=C;/E^#F:>DT%CYHU6P9'K(.8Z&__0AHZS55-YBJ
M&W2B<JIN,%4WX.903]4-INH&YU#=H&+Y>DS(CL/+EUZX_PY\EI#1UNLD`MME
M4I8LM9+VDK)DV6,;?:8L66HQ[2-ER5)3:2\I2[T;3<>.E<QI96>DU!0'I"7B
M1=0\9GMLL`I:QT8WVP.#U5'*37JVQP.K(]2<B&79*[!=8.+Y)6R/"Q;#2\@_
M:.MKL,I0\8[Q<PZ&%7P?T/8`6"Y&K=8E^\/TICCAP>*$)W!,A0D;#J*Z#_"?
MP<S'-`?X6SM@)%HJC&C=@*QT&LOG<M3,3%1.E8@6+PNSN0G:\\#*7&2[<B+H
M,@AO;CL&JF^@G\3,(`Y6:Q.4_PP"@!P?3__,V\``DJDG>RQ;#`P.VGJ9X"0]
M)@[G1LNB9[4V\[:52U`C25<`[?`_HBQ%ED$[N[T)ZA]!G(+Y$$:L8[':QLA+
M5EM`EFBP;J6UJ:6QM[<>\958I8>_,5LZ&7K/!V!IB)2SO<'+U`]I16@^&_P^
M9KB@.^P.BVX_TQI"3,KK[0Q2VT*D6=I:#NBC9D:J_P-2)@IXLQW>3FN0Z[C9
MA2T:[R@[RH@X/2*.)X_)C6'4U]@B(=<J?/#.+]N-U3)0M0J3MENJ9<`ZUBAM
MKU[1(J%7-UW]DK#=+"T!#GN5V6Z7E@"I4>#O9I"V:H>UJ1>V!T=*0%73<+N%
M0EJUB!C6NDX1D"=1T:L#1@?;8*?@1]M0DM0_.@5#G@EV;"W5]O!(EHFA6NV*
M:72U/=Q/!)X&>Y?M\7T2L$1=8_EDI`##[E=Z?E3+?00>E1ZOPPVFX0UO(ZSC
MI^>5"=<LHW1-8VZB6!\3!KB9]_<DB@GDT7/(((].Q:L3`8]`CW&G<[\$>%8B
M&(/L(,."!@R])7##=4!'X94OZ/VSALM2<%?!<3LCSF.ZJ0BT88#G@5N+I;GM
MY/9C.QNJ]9JXRX'1>"I',)4CZ$3E5(Y@*D?`.:,$RKX8+_0B2>-OEV;3\FO7
M9"12W*&QSU3@0:K`0WMI0':%!T[?J<0#C\[C^HH,6H\:GAB]QDX53$AZKMW0
M9SY232<][](+)<+JSGQ5NER>@(N;IJ\^L;E3'W1T.#R"=_HG)7Z+SJ/CB_YQ
M3@TRT>TW@%P8L6]`^8%&Q"]5US4O9\$QQX:"XF*N]1T;5QJ6,F<<X^6-N*I]
M4TN3MF:NS:=+)2,[$\NEX)(I#V)GS)X,7#+UC.ST%LJ@)5/2R,X,<QFTI*H:
MV1G6)P67S,EE9X!?*UP<%X_M[ZT+8],H%MG^HKHP.BWN8MO?3Q?&B>4ZL_V9
M="$C<B7`KQG1LZE;<&2F%G[^126^:IO:5&('Q5;@PR@0IK"W+$.F_X"8J1R;
MA"',]CRW3F`=V<`[);J=1'QR]\4E8&N>RK7I<$#9GCK7?2DR3..VI]-I6'ZM
MR"GHXA:=?\S4L4DGJ'GVNZ75I;+O;3#Z-UEE=8(J,LI:P>D@(Q)$--52K,<E
M-2+2;,"8WET_]X**UT[T=N>'[]%]X$$$\+XRG>]"=//`A3ZHW)?/(:%T@<(=
MQ'Q?[5^P:'$?'!+[9VX,=U3$;0DR[.531O):,(VSP"/_(WM[Y_AT6\?7#D)[
M3"8OT4>LKY5<&8H;;*8M%9[QRB-.&G`#TO]+L<<8PDRF5:%]IC5[-V$2Q)DB
M"KS/+,9:^YG@Y@;@$]B%]/QE$%YI8H+&.P<BNJJ+4VV^^A4O=TY1.GX?0\4Z
M*XOW/IBY+ED!T<+9<P*NV_N-BQM\VP"\;548*G4=#4\(:R0/T'F%/B\85*BK
MEHR@XR_=9$+;$J_Q&GDB/<:!=$$2KPQL>[]Q<'.0HC*G37ME7M$!1L(?R84O
M1,4H`LR#6+#S./A:(+!UH,>OU-K:;1R\+`%>,M#%D@55?D+4(-H+<R@TV(CX
M3MR8VFU))4NT$Y_)QLZ&<LV;U+/LS0V!.9088-S\M9R="@.-B-][+/Q'0GM2
M8H!Q\Z<VG[R!1L2O^!DK,<"X^5.;S['9F4ZCML=C&+@8S&(S!-[AH*-&W;;)
M$.YO@CNLS^:Q3^X?"40`+QJ\3.+]PL=:.ZG^BG]+2U$SV),8P`A_*'0!\")2
M88RXNC#N@$0P',*Z66RU]AL3-XQP?DG>6*,8JP1Q50^Y8S#$:&RX2L'!_R%>
MG."XBTD/5Y^^D[*?K&H/M3T"<"A463O(]N+X0^';8B&W/:90W@!7!D_,E*T6
MWO5#BF$`UN1EWO-"L6Y,4XL$.V<$Q4QX:E%DYXQKL_E:+>;LG'$\<F#:7I2A
M!P"/_(NV5VKHY9`\LO?;7L%!-XI'_E?;BSJH`2CD@K>]P(.Z[Z:\!J7M1YT*
M09Q$@D6_P);,C+;7C=`#I(P/MENMB?&_D*3NWZLL30D+OUH*WRF)XWHPE?$L
M=\ON.]E5*FE-8V6P6?HVCA[0^C%UVOX`CQ[L9619VRM`2+O(JR6V6F/[;2^6
M).(T%+A^Q':U[?64M&-8QJ[O1[A.&CNN$%5@:*>)31.&7'6IP-!.`YLLAG*I
M;P5Z=KY[K@>]HX3(`C8%R]KI%0O3"5ZEJL*E@OIW>E45Q,X^<7FQ@*]OJYF)
M;/D;&+E^&"4(S-':">"?Z:P%WJ,3DU^N,G$D#**B--U]L`K1)HWFT9'=5HQ<
MLE?2LB`+E):UHZ%$36ENHEW5(_$BX'ZW#G>?/`#3(#S\0SWV#O_JM]L@QI-+
M]%ZT#5/(;O"BG*\JOZKQ(-'12)[-8LY];:#XNY8L1\82O$HB&(`H>F`\$R77
M=PA*FYY2$N]G8J;+A&'%-PI]Z.54+DKGSWR5G9..?SASV\)+]8RM9=Z:O"3W
MI%:FXR^25Q^Z\Q4^W<GSZP`?<2#_5Q;-U+CPN@YI)$88"PN9K>/1V>`?GY$3
M1!AE<O;PGF45Z*CG!42A\I/X@/03\M+["[X!T3N^7/%U.]\!-//],&Y(&=`[
MMI&92UXCZ$$'[4M3P7OUC]G>A+BF=,H3N4WF@K75<J\,GN8=9:MUOAN^PC*L
MK:;X;O!UOIAM3=J0%C<K&1CLV\+:ZGA*@$DNWB%KZ)DQJ&C5!T01/I?*EL+2
M=\7=6^CBMB=0M0JYE3-.`,WA5I19&]Y3LME@U#`<<!W`%71)?%4:KD\D/KR)
M7>+.Z6[(TU0:\YBTE@*7[`Y&S&.;K0/Q,CJ8CHO4L27P22@:$9O?B2S#,J!)
MC*!%L7Z`?R3D71%B]R9G]5=R!.,%G6H#S^$5N/:=*,)K!W\ZJCH7OCK?X";9
M-.G4.H8U4EHA(2?JP<H=K)_`FEYAC/EBM]=CG@+():?$&CS`WX&/-_*#@]88
MTS0B!9]MSK<K$(`5C*\`72V.#_\$WLLV#%[\&.*M#)Y`'/OT'OX5QF^X`W%O
M)/$;/;<:#5B]?]3$S%:SZ(X=98P);NUF-+&X];RL^+C8:]M6$XD<4/H.1%M-
M(FH+3^I:M-4<H@9=^ZEEJYU#]MPN+$?]WYG#Z5NGH#X<6AWJ3WRES[!2_`[6
M`)I?C:>OG.4ZJ1CR]-,T]0/2Q5RQR&>V'Q7U;9/0VF\\=>[%YT:\O]EZZQ3\
MZM;-=K@W#Y;DO364ADP]A@'*_WGE1)`9H='/-TX5I:;H$/WC&T7G:G_X\=\A
M5C^0^[9_`#O@<US5@IV-\G4?;),XHL1\YD9&\7J,A8-+:0XN1\;!%VD.OHR!
M@Y*\%!TO=6X`CMP8)K@LG5?R%[]@9RW&MJ]A`/9?'?0[B.^2P!.XR(6[::&O
M5@=*C+KV3B;61%Z4[C&,4U6+W%#D<6L1OA0'.1VE7Z-,8;OK5%BA:,^4:%QX
MMEM7I/`3/R5M=TC+PR9P>-M>GU-IKW+L'=U>]QY_]EPO"K@0MDUU`NQ\"+QW
MC$6EWT[OAI\)T,RP1E$S@[4QCL.BK&>OV!\S*6?]:H1:S#)@NY2O9"AIQ+/)
M7F=[\$,OZ%T>HV=GJ$,OZ'TY1L_.:`<YXU\9-ED3T9!UY4_**U\MH)K!FL_+
M?O+!R]-/C$;QGKQA$@9XNKGV^>:V1KT-?*F-BFG7;TZPQKOM!8MO:73,SYAL
MSJ-HF@8?.RXO0?A*2HNG9Q$^SO,2AS#?\V+N;IV?.G',A)S?NCXS%B\?B2H[
M(CBJ4APM:YI3=F)G19"$O8'=OS6AIO"MWR[-OO96NW@B7DT`;A\S7#0FIU-@
MR]4Y2W7BG\A<\)Y:[3:F02\I-Z:AVN8$?9S:;A#;C2!<J;-!<SH[\T8/\EN;
M34[#C:1F/ZGJK8M3J6DX^%QUU'5L-\\,-1\=[_-.41@G\>;+21]BE:*B4A$?
M3<?8Z&N+]J7\5C<,5XP_'T=FCQCWL^?L=VL*J9AEH!F2ZU2$H]E>?\A?K/3(
MG^0[*WL](Q+Z*@1O9&L"=(__X[\!N&E4DEL:&\D9PZ<&GMVT-N$21K]?@<!]
MPS/_.]>-T-IM'+SL#V1QS$VMW4;!2YLMG]-A%/07Q\AG40[*74;!`\\WP&BL
MY7RY]>$#]/T]^U"IM=#RU9^A#QSO"1^7F#-2>9/]>593$[/VU?E[B*Z3*`XW
M^$[F[/N&AD9*_-"B8!5BN$<ON[V>$C\K^">YFCBS76]BJD)TQ+5$EUOHJ?F,
MY6T($!N7:@,MWWQY^CG<`100\7:&93L7,KAN:WTZEGC6J6N[/5U4$JO7%HR.
M#>MVQL:+BG?<Q70$ZMDM*ZX]CB^V=<MP.4&LF+::]K5HO4E,'*PFB2R'YWSV
MG?A:.BOK'5M<K]0*9`O)MA_@K?I!\81"54"UW=$N#@S'/F=[NH`X2$QUWW:G
MLSA$1[JQ[>GXXM#P%%7;L^_%4:H;\H9+L3\IE]-QJZ@HT7I>'B>M])=0Y)K.
MF,TG;]GD+9N\99.W;/*63=ZRR5LVA+=L\D5-OJ@1&"\%?%%L&7-R3$V.J1$[
MIDXB(%^/M\5:+T(?GKOSV7F3:VIR31EW+IR[DXKC7#AWUY20_^[<G5-LW\*Y
M^Z:8?O%S=T>).>TFUQ2(;J/T(3;O)0*KQ'^`N^FY,#4C\6:;X-5!4O"V]#E+
MGA^*U=HDY4_A*G['>_`>K\Q@33+#:?E9(3[X?8V4-4I0`,DC][/`NX/?R$_\
MJ'I.!SWO/SNO(2*M]_@#\Q7>CX"_5D1[&7EJ!C@1>`M][WZS1?BDI;4ZN?#R
M>IC@8('"+4#Q?N&38S'P#JA>[9_QMSG^`I&>H^*H\8B7Y*UQC%%QV>88%>@X
M*G[(6N(Z@$1ZCHJC?.FL6+Y3D9Y&4K+<-^`E/B`E7EF8<US"PMU/QWTDCHCM
MEB*)>Z0,H-"V/UOLN`X3H?/%]B=^-$/7+"+8GA4E<?=6?0<,5<]VDV]'O%H4
M3-NMPHKH\119VVW$DI`)Z]FV6Y`5EQI7J[?=N"PKY`O=JV4AT/I0A5X0-.27
M/P73?7JO4E+F*U(\S\7`W4`?W[7>?8#'!Z2VZ@(@W'`3!D]O>`8GT[["*R0.
MOH&#-4&28DBA9I#>W'8,5&<+0Y#NO+612&@0%\N7%?U<:7,25!IZIZ!"PVSG
M0)^<P<]A=BB0>L'DRL>'(V]=RXXR;D[Y>T%^'"-F5@?%^&S<.N2<+&HXXTLD
M1O"5D(5O@Y?`*_Z=[W&6]55]0!/\-U(R\^D7@?<<,MAA,*\ZFI'7*@!<OY'I
MV`'DK,%C0@3T;"G2PSN:)W&$=6R/O`WJ_3V)8B)),3A7'6TTG,]7+&IE..:,
M,B).CXCCG=ER8YP%E^4[>/1.EIJ$8;MU40X<Y>-?QS,@-@$I+1]V,SJ&L>/;
M!)_D$6:[Y5$./(9F;;NIL<,&K;X`HN#;/(F<,#F`NFA":B[.Z38HZ=#=DF#/
M^CZH[N8?Y.';AA%>ZSNKMK.R>JOV,+FMUX:TKES`IZ)?V+:/F>;S`J:^PQ1.
MP0=5^/PH0/@H*B[@EXCXH:X=WTW\S$N5H5@'=_)**="/2?&.,+_]YOH)GOX[
MO/0K_L$ZY+,-88;%JI:Q3Q"5JWWS`)QT@#Z_>(((/K2$X6L;?CS8D+1$;J1^
M:S=#5<WR%T`7^1U&Y?N6A"]^+R.>[LW6#_<`4#KF]`[E\L!N;S:YH./6$$M!
MT/(1796^R#GW66XA2G752>>E.IVM7372>:5,9FM/C51>*U/9VE,CE3?J<][>
M52>=ZF2.\3S_U4'(:4F@KK8Y';52]VEO>XK0`/)\I=1?JX`W`2XG_K>C*ZVR
M6F_G$]0RRF5@Q"0IZT,(%)%KO^=M3TY21*Y=VK0]14D1N'8!V/I(`37@VF5=
MZZ,'%(&3.>3L3)J604[83&9[DK0*:#4-SO8RV2H0<8R6G2("3@"N?BR>&A4-
MOM9X1GF<(YV?AW/,"<TS9,O)L<<9M^6_&O*J)QOB[@?>#<#`N)#"@G_V`5W"
M@8?5>'R?_DE_STS[9?O@]0P_E8B4\K`)43P&2LV5?9P**Z;TB)2VY+<=5=$Z
M^\I!_HS8"<LMG4;%1UNDR:D5?'P$K%N/VV54/!@H6LEZOZR]2AS^[2^.GS`#
M_]3'.8LBE4/REE4.P]3D/]Z`'?!#2M=U&+7<D>+]1UFU:2HE.70]Q.R.M-VV
MIX::/AU/S3!X2ME7FM<EE1&ZV0?'GZ@QE>4<!"^)2]5V[_=4FG,HR*92G&(X
MM18NM=.WW6_A4KN\VIW5W*F@/]_[-=6!'1&"D\\O`V+F>3`E\3Y8A6A#23#A
MZA/1_1CV&*&NHS)LMN0&M_<;Y:W*NQ'$IG<XW<IP-GRI\@F!+][?`"RAP?%L
MQRGS><KN+7BY2B)\84;1S,6+-:(KE/Z(`)^9]GYCX8:]+EFM1T)Y>GS<!_CT
M`U$<W4=1`KPY(O\G4E&U8E#Z5W%&508W$@OC.U&$Z2#'*G=!-C0T2&\6V#I'
M2U)<Y_8;0"Z,L)B&=?7#'Z/LKZSEJ334:'@^K*##27?M^#[PKO9=V)<8U5#D
M5E[]+-TYLR1^P^+*G\RMR>NAQ;_-C$M/_Q!1QPM>2TT^;>&^HZI+43ZS7K9A
M4!#+G`/YD4Q%UV$=CZ]AU!J9H/-^,>=ZV8N_FU'=RE-\`W?0PZ+_THG!@CP3
M[_L.XM8\$N]OGKN%@^;H*2;N3VK:.]31$F&-V=D\7X*':TNGL?#!E=TX'<9"
M?WLE_;9>ADPX+@!>1/1/*O8&+K@/L$SA^(ODU8?N?(5IYO$DVG\LW,U7S)M.
M@D?>**/A%#TYQ*Z<7H8RS%4[:I'`ELX.!%<PC('[%H1^N,92ZWW@LDNN\#L8
MB:NCH-`Y)O:*^>H9R]H1EB^(S8^GE0ETU%E[:1[(EEQB]3""<DJ21)4U7@^=
MN#Z_AY*XLGJ8P_5*&M?F'N8XN);FH+F'G96O=")](XUT<P^=2$OO068/([@2
MF:_)T-#0P!A]?$G<N.Q-=3$:<U>R=7+LV^SV>M;ED:OK@9%IT]K<#)IU>I:`
M6'=2%][3UH<L"X!(SYX0;LK,X#;51T<N(M.`3R8)U5;&YC7=I3<)T;\6^#0,
MLT+VC^"=_HF]980ZZT6UZ5O/X4N`Y_(=0>+\O@M1;OB?K^9XK9$'K.AK!FE%
M".YT:!C>R#PFKQ'TH(/V)26"=]HQVVN9+8)7!-<!,8>)WL.M?<97C&2JF#B*
MZB^*]9@N[8PA%PY2.$#78G,I`+,S3Z$E#J*\+P6PM7UCLF,,*I'//.M,L:#L
M3!V2@8AA:"D@LC,E008BAB6G@,BN#`05B!@FF`(B.S-M^1`)V;H+B.RLHB<.
M$=-D5D!D9^4\88C85L4#1%_.\=(75/D*D.R\]ILCCHHUQ+)/V2XQBOM#RQ=;
M*2ZJ.(#LS&9M-557$O(;MJ*M*TC4<EX1B`0MFIUR;,;]0JP*;-(A,+96+U!:
M<R5_7:<2!:-^1UP&&:8GQ-;*!,K+YN!&M;4*@0HRNA)\K*Y2((EIY\036^MV
M:0.S-7/)UI+]V@2.6B2JK37[U?`2SL2P]2DOI8VJDOA4`&B7I4):@A//ARL@
M.U]U0'^@2H&J7;YJ71<&(P6E@&U2,H0B]PK`)MV#FY9<`#4I%&U9A@56"OJ"
M-980V5S3`C4%'<%RU!C*_6<%[>`LD*KDFA9>%`6MX!3A8I;#X_A;K"TC*(L1
M,R@N1^A<G$UFG\.[/'>4.8'M.49?SA6C]FMBR**>AGSG;8D/E<4D$(DPG"_=
M<.U%<@AY5TX$O(6SI[6=QU-U\=U!W@V^I'EU$BMMC%0VS"G@%S*LM3)&:<N+
M:]4V)JB\R78:N38!WI;I*8)WZ)H*:[_"^.T>R[([Z"6.G]ZAY=5[)!W7&-0V
MO!%L#ON6!&44#"P!?3&&.M<IS:^5#<VO?M5Q4"-5O?('G@':01<4TU2F_Y$8
MIR/,`5W3T3-YG*7\=\+88QC_#<1+X(;K@%,4J;_O685>:N.^"U'V*]+N\]"0
M-A.A)9\Q#SYP\0;`TCHI^?S\'CZ_A4F$U>MGW!>P$QO%.YM8$U^=;W"3;+A5
M&ZIMM"`Z1W`-L:21>CJ:'YKC--3SFB%`9$Z<-<CC1M)ST`GV4<D*7+*BX,6%
MYQ&1AS'N@[3+$@MK:`?(NLN]$M3'DYKY\%PW,370EXU4F,(?)L(U[W'7<A.3
M-/(?U:PV,EVM*UT0Z2;(O8;L,GAM_4QPLR2B%F=9%'\W1AWW%"RW,/L6:?.=
M61)FHZO]D02;"OA"CY5V'5]/Q8<V(E@TY/<M%E,3^KQ?)33P]IO[1D:H[YUA
MOFFL6L]K.U.O1TQ]VT*4OC9)12O6NM$V_DFA<^=`1'UW,WSY;O(#=@M<++4^
M`[1AR;\]?M`8?BI;)M\BA=5)L%!MGU\\202'PJV?FNO:R9JM8G`0EK6>\F)?
MU(>*RBF1BGH'2>\^B!$,(NC2DX.)AOXOG=1.RN3CGVF\]GUV'?T*2-@VGMT=
M0%A3HW\DAMS#.:Q[GRE2<8I(ES3;=%/UA.7Q=TX<K=IRJ*0<](\A]^LG);UE
MO/U"C8SY7COL*>VR6]OG1KDJF5I>X2L*/"%;2B^?&EV]1!D3C<)`^NHHYC=W
MJI4NR63<@,A%D%\?L:6;;OKF`<>HWMA.-P5DP9%H.2$R:HUUT_+\'@J14;33
M0D')4S$CS@J(8@!2ZW3%H\&F37*$7JA&`-1F2IQ>9E^CY1&;(B0JT6GUX`1;
M:T2T1&,<XJ08#J=.4;&G`DL]].,H"5V[%&#[:M,=JR(U(_+VH.$>%+9G.@8Q
M3ME:1674^X1M@^A4O&6:CF&,'+:6D!GU)(EX:VRM8-/[+3-4()*MY7#Z%P-$
MK":VUL<9KY`E'.EA:^&=P:X,/>$CMM;S&?4T",2IV%HP:)!Y4?`(V%I?:`B\
M!6)B;:U%-&H%036$PM821\-(33U$"-E:/&G4EW1K.(*M%9J&F)4>DP9MK0=U
MTM/"R$;L5(_J%.9*2XYPY3C3EW%BNT.P*>VM(K:>F8.T.2RLR:!6#[+I5`#M
M])$1#UVQ_5U&2:#:(I-L?T6F!2Z)%';;'Q\\2D0M']25/%#;3^F&I-<R%K7:
M`+:_VZD]P?9H75E>9'`0(*N2EK7E"`?!LA8=:&W5P>'`+&)RK2U/.`B8^@P/
M9U`#L<=$GB:-K928T:D&\P0M)WNC)&WU[1@972'*TLE"H#G"G[BO@P@8*4WI
MT\&!U[PR<LJR+]=K+(IUG@H,CKS`8#:/Y"A<U<W.E*DCN[=*#3R)KYA`ZF<0
M`.3X^'B;>1L80#)IQ+*0K6)N*26QOB:XN@_P604.%>(?LAG@E*WB]1@1!]S\
M7'X?(^6X\-6#K^DWO$1NP`[XX980)K*V1'J:+=^E9_>+E?+2^2U;G5M:Y\-V
MDV%/%V1%D1:4L6S/:A.XB\JPM1S\MB],H7NO8I$5N6)L3]"31DU0[+,]DZ[7
MVUQ@5Y^=)Z%GF+5?:T.:'4=LP#G$,*;VK30Q)(KAAMSO\^#Y#1"+^7Q%0X-?
M(ABL\:^N?,?]'8^!OQ-E<0\(NOAO7T,/`S*91XR91_JN%J^)2GPOM5)9:3/5
MPY[J88^E'K;AFH--^6+DI")OR]^%:(%/)1*1BT]C+$#'^%RF+5@8#DS%R2.=
M9^;=$-<FOI^7^"88`MO&[YY41<>I'G=_J^*7$$LDT">/AP^\'FM?/GE$ES#Z
M_0X!<!]@"1^?7$/AV?C=DT*SS:>F86!;#=Q3]L84$:PI(KBJ6=EN@5>,C[;4
M5CS%1Y\"D#HNV"EF4EP,T8*]N"IHO6/E=":FKA797ICP!*:F6;VRO3!ACQ/3
M=\4IE4J$.X!>PS.>DR&MNL,5-1RQ$[,4H#_#P.PP&Y,3TIP3LFN5G:ST$1&@
MJ\6/^GKVA_/!DS+!';/3Z^-=Q]\Y<;0,/-XE^O43W\<UWI:`A*_AR^PZ#.@Y
ME3A^+SZ@#I2<XEK&DL(*P!A?%H<2?SVMVZ8OG2)BU7J(/8%5^\@IXE2J;<Y]
MLK3_[YTX>M-SFN-%Z[?+4\=K>G[T_)`UN6H[R&1L[E@RV65/TJ$*):>XFM/J
MM;/`.QC[0O*K$ONS]1J!M1.#0>YX=7KL1+_7RT[X\W9B:^#X[DC4*9[ITBP/
M;0C02.`H]PDS'*'V"@/K!0`M^T(O$2>)<X-YQ`32LF2<)-;<)RT&@5F"`B,(
M*SR!TPR4_$"6A>SJMVQT"M'<IOC'#HK'[6T?WU34#;^V!X?V,`-=7M:2BH[[
M(44YH*J@=W8X]^$44HN%FR9"M[VY6^Q;>O[?!M-4=`^1L/[QW=%-@KA%S/JG
M>T<W-PJOO2L\!S/)K\.HO=8_[#N^Z9&TM%G_Q._X9DC:1F?]L\"G>@M5Y&B5
M1X4G.;KOX%GKGQ$>W=1T]8E:_\YP/S,V=$2,]0\/CVZ:E,+:K7^(>'33I#,6
M87J:V*#D5X]%L_T!VO%M)5Y"GNTO3(UO:W0(XRS>K+*[Y'%:E/O9^0:BF>?!
ME++[8!6B#?VRB>S@ZP21M78@+2O(?@4"L(*L[-^63D9>HL*41#%TKTEJ.MIS
M2]`VMY6CFCS!1FGY?)E10A]ENP->5N>>UEY_!/$<:_$.R9!_"*/HVD%H?Q<B
MLF](<0.(Z,3_#3@(J_DU<C4,:)@G:D+7RU4ZI+D7DO!JGR7Q&SUF6I]W.FH\
M#KH%'G5J:&Z4]N(0;2E,P.NA93>4#O'B$P^,*I,B/?JCJJE,=5MKO=3<?G,V
M,#ALWA=\C:+2[VCU-L;!)SW&\)0SCS>%4::R_*==EO_X_EIE]Q>#9$X'+2N9
M/?XL"!+'?X`;F*DL&R('-:UCZ3%ZIKSX7C0/7B*@0CECC($IYTA\\H,8H)UY
M]*D,TS/]CV'\E+S^'2NESV%!A!SQC#&F!T!.\`$0HG%@S8.\B>7_WP3!R$OK
MEG&I;NME@A,L8%PCX,&XO%0;ST21'EIV8>,'JAH<3^B3Z3XHO<SS3FX`$ZOD
M)4"'1\<PM9F1)CK(J`L0.'X,`;[3O;P`)O]!\BXCC@B!)8@2/Z:F_$8#1#:9
M<B"(#CHB')[?G/C7,/&]^\T6J\FWJQ4@Y0K)3'+>F5`<S/RKE2P+SO'SB4TV
M$]LK^;=9B\HH,6RNMGO"9"!J%3:&\WT8!HMMP2-XM1JQ;-UW$C;%\KIJ<]O8
M^L2&(EP\ZXRM*9:24.EQ]=CZSL"P8%+MR-9W`12W,%?9M;54O\JRDU1I;4TP
M[!.ZVOZT*_I.!3AYDWVG!+VS1:_QIK4KPJU_`*N[U[+,-KWPL5R%MN:<Z46/
MY7CJE!1F#WJZS+.V)G'IA;/5RFMK9I5>&,7<)K:F/ZF<CRHA5;;F)?6.7TVV
M.1?-A/FL*<OE8^UCL0H8-;RA>T9F]B-8A/:H_4_=3H^;<T*:1!XWMS3S3/%Q
M\\N^%<71I':1]+DP(.EV\]7S&R#_=()]=)-Q3NZB*`)Q]`"=5_(,,!8AC21^
ME<@\HJTER4*LKXD0%P9E):S56&L:P$B:6T;28;V55U$S1]PN)GDXK)@JA2UL
ML'J-@I.?41BUS4.M\2CH+BV)1\!\\[6EUR@XD2!_-#2S+8AYA)4H2P(CC9SC
M2L!4=[:KPXV#]_B-G9G<W'@4="]0B&&.]PO?"6*2Y_]'`K>D"H`H+^P!1L%?
MH_-7;K9X0XR8QR66D+$"\-:-S<,H8^$T_UUFE27TH1VUU\Y<%R6.?Q`AEA*K
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M6;?'(&N"`Z&RS6.JUWR@I;I2KM](>-E]H.Z_T#"PWDJB53K*W_?^GD0Q+<Q>
MXT5A@#YIOG,@HJ7:BP_.5XO\%*-O*O_JD$+Q<7[\[2484AE]1"N6L:EF<9;^
M3RSO"29I7_1G%U72^XT1H?08DALF<6/XZH.2W9(8T6>!=P-VP`]YT03=QQTY
M&LWO+Y"''+HCPAE[1*A0%?'PJV#=5%!;:8@1\5CQPY7D)3DVF:/T>0O0CY9N
M'_*(A<H%QA]G1'-U<%AQHPP$.Y^0:J/YHK.U%)5>=-D'@ZWUJ23Q4Q&J;:U&
MI1&ZEE-=S>IS2O9:/=M71KZUM5B57D2/;E^U,+#S6XH,,=KVD*_^]C%/,[,]
M_$O##:-D/;(]'DS/:I6REMH>!:8**;-TKE+,EXQ[<+3>FN<W#,<:!N3981++
ME3[?26M_S5<TYH91'6?RXJAPP`*SF7I6ZY.E_+?+,=&.%P<"^+(OZH_=X6,F
MJ[>]`'A/D]:+,*+OMTJR*COXZ'%9D#.N'U180X\(DV4J*F*J*I0_.-L(S%>S
M[=:'+BDODYK&\*]*Y2CE(.KTI1.ZE9D'2B<KXI:N(EI;S"H91M<1-ID8U6%E
MGH"3\5&LRF>7(W0R3XJAC$6L;F;']`3%BL!IZ#8/9)_>?H.%26'F>3`E\#Y8
MA6B3EN(U4:'(=Z)HOJ)V#^Y#W`T-M;AWK\.`[#(\"?BG"'H@+6Y/=$"\0KQ9
M>LX1,PW!:H%"%T11LRV[^9FXOKZBB_L=0-2\5[5!/>$5#J*;QD<@97IJH3);
MO^6'!YI(:FHV/21MZB%IUL.T`8CA!GR%/HCB,``+9T]6]7-XA7^$'BWC.ELC
M`!JBGQ0&&)[FEVT8/&V!"U<0WR9DW^)3R\$]B9DW)-=[8WB(]F],C_&>WF.\
M^,2/$9Z]!*6FQB7PB4PV(Z7)1<KUB?<WSAUQ&%$*:;;V0[W>,X\Q5E<CSR>[
M;UAD]P&)Z6_$GA`;5:KJUEB3&<'8`]'DT"E+8)P]SFYOAGK\]?LH2H!W0W%-
M=5/JQ(QF[A\)Y-OHQ/L;31%C2M$'=Z2HI&=[>9FID#/G.A0IY&QIP(1B(6=+
M`QVD!9'**[\R=Z+UNTQ"Z*D^E2Q\<=D>4BP+(=MF8+ME7PDI28W<=D-^_Q@*
M60AL3S!7@KD/8ZWM\<<*&FKU'F*J?]:^&J0)NG-X24@75$*G@?W/#+4:6RI%
M-QJT_N'$Z;&Y--/H7WP#'/_)S(,R`560G@'*GZ3CFI[9[4V8S3+Y);H+465K
M,HAG-C=N9CXG(SK/\=+2:V2<G*P[H$)81I$(#WG3$Z394+RR_8Z79_R!&FW<
M"!EV^]'H>9,EL1^-F24A<I;0&:/%M;LVGX;G$6^MBAE;6M11HM-.S!A7:3?S
MJG1<JFW&@LDP-5E;Q&%LE;"J)4Z9"OUPMOJQ&5WN$@P;6&#D7+AU_/PBH/X.
MVKIP')V1#8811IJ"E<554'2B8\`BENZK-,2`=#>I6M+=3>A9Q3-1E)`*N3FA
M-PE+BQ3M/6+.LE2X;@SF@XR8S_O@#NX`B01@V944!AHWOV&"]/![&&C4_#[C
MK^J9X-)(X^;X/=3#;S[.B+E]?@,(.*N8>7_+CV/<WCKY)T;KGSAM^VL7B;.L
M]LC*$+:&V`V,9_EDMS7B;GA(2^*!K?%U@X-:DC%M#:4;'M-"3[$U'V=@3,NR
MHZVI+`-#:F\6C*K5:W)2=$5/;0G;[ZE0BJ*0GX@S#@J80B@&<(_UG9]FUCUV
M'?J^\QJF.2GD\0KHDA23@PLLTE!UB>&B*4:^QHVAZ_BE5)=Z5E+47F2ETWA:
MG$['%&AAPQ#M2[!.?-)_C]<%S?72PHW\L)KYRY;XSZ1>^1T`4DRT]-5,Z2+$
MNSR&#2M@"5P`=^0")(EYC^#]!B7KK-0>W<FN"[9QPQN+?7Q!,]?%`NFTWL2'
MT4Q_=4U+T<SO:L*@/"-E_=?951!XCYC*XC?/^*?(26L_<H,49$?1,B-7(7@C
M]S]`]_@__AN`S87#6AJ;0-U\A<'\!G5B9PEV$+RGJ?QW8;$>2U)3$Z*R0VBJ
M#<@79VX#+)L![^;X_4[I[KKIW16?28&:KW+YM(547D\CJY>\,@`0%M;C_:.S
MX?G0&IN:H#E_?P.O5!`P`V?JK49`*3\0AM%X!'3C.\"5(;W47LO.N_7A`_3]
M/?M*J+70\U52W`-X<ZH"'G8MAP9>>RT4_8RE#<=[<B'`HARI1<`FAM54#QV8
MM^":/$QR':)M=@1S:.$TUU2_-7I(S]<0ST#T!!"^PA";(&Y[$_NM?G>1NY8O
MI?%ZZ,$T^T#@52_:@['AR,1?05B\]S#4,J-'!7L:7!41_YZKMYHJ$H^L(O$C
M*2"S2@*/+"1BB&A:AL>-]'P[(7S,5[,@2!S_*]8Y8A`00T"F7J>6@\(V62%)
MM*]62K^&/G`3K%63VD:941!X='MN-@"YT/%)M?U9A,7GRHYMAK7[J%JY6Z!P
MC9SF,_.HC9[:TJ+BBPZY15.X)EH[`?PS>_<QB$(?>KF6MRA9VN>K.T@6)$Q?
MP\Y,%OS@1CUC:YF9VC::!\T74--<B7;50^<*;PW$E3;K3:;:X*=8&WR;(/>M
MG%-5U_BYYBWQ_H;"AAN*M)5LG0?_8HBO`.(\NPL1?=LWNMH31R4_N%C#V">&
M"J&[93WH&%O+"9:3,G_UX3H[^C=;'Y"?6.;%UCYFYHO*^,OTT2&J1N<.B*\@
M?@N]:H,_CP2[#@-IFHG"N'RU+[D7$_Q11-\B;IJ*MDY::'LBS[)Z2[A^PTLR
M6[*5>Y5]_XEVU40G+:A^R:RXSJ-3K.OT#H`\]8WEE.E+W(_@G?Y%\@V`6E\C
M7"6O$?@C(=Z4'4MYX+<=`=4MMS>K]4@HY]ZQ[/;F$II*-SP']>:V6L['E^T*
MA33D@^AT6/:$I'9`7L<WN^Y8U[YX9YVT%OI<_HGT".!0R.QB,J)/,0+A$$PJ
M?`4?0OXN[0JQ;P\J*&$E*`8<L/IB9_E^G@N[&C$OK.#:&GFKZ-DIU4>7"-FP
M]=F(KB`V^`.L3FKM`)5X(*C5.:Q:$!0.<[8Z<U4+E!)1KU:GK&H!LR4$U^K\
MU`X`MFH.5F>AJ@''#*RP.M&T&U8J)N<"SA\F.*MP'L6N'K#Z/*D:?*R.2\!\
MGA0+/F3EP-T"M4G':)9$]*1P%3A/FD@99P'77P'=I'E4+`8:8N,*;"=%A*\@
MRV0V%ZA.V@D?584,Y0+<28-I.@[:@WH+!">]IHR@<.AE`>"DR=1$3<&(A\)3
MIZ#?[`!Z#2W$4#`JK<!N4G08;BAN)FZ!WZ3R-%T@139"@=2DM#18645B20H(
M)^6ELEE]R?($!9#GJ*DP"_XUASG87>5/'2U&+)JU[V1WA(L9,ID#=CD!)OML
M_9<)LGK%4ATI.#F\_SS!6X6WR'_+(?K+!%$AA\B(,/87?-6:8RN.\;G4@:WG
MHAYMU./:I18C<1SMS2C)4(0JGR<:U3(:!1IV:93*&<?%.<,M^%,HD'8Y9;KC
MQBP@52PUN^P_W2'C5*8L0)O66<V_4B\944!EERM/PY;DU5(K8+/+?]<=MGI)
MP`(INQQUO=2OT*25E]-3K9=C=5;**%8QM\1D(<=,:UH(4Z%RBL5)89=3L-^5
MVK9$O]CEJQ$N2E'QT#0D[=I^+K;46FCQ,9PQ2NS3BU%TH[@-[)0%N=4CROA(
M%QD8;G69?A]HLX%QC@LYYHG>&KCD^:[N+P/IJC?/I+%@I*6&H]P89NNGXYL#
M_Q^V%TX_-#12:9@\TD:%42</:/G,H+BQJ:8JWGAD7M'NXL]F,(HB``@5Y(F\
MTAE4>\X23R5X=WPB<S(AE!])"\)?G2!9.=E3:W>."WWZMA\;<WX'/?5I5RLL
MK9-:$IE!%^V?MH[+60@M/315S:W,Q`.OUCFSK9':N4=+*,:;E6A#CX!9$Y?;
MIP\\F=78&]N9P'&!0DQ*O,?"V-\!T97F:+9SH$]K=F!]J4(GI\Z5_#BCYY9;
MD4QE)".5UAR?GL#@U7%_+PF--R!R$4R574[-.,'>8^*LM8"O0$<]]2L3O!:X
M5WVMA=GB4@KR:LEJTG3LV:KM"MV<%3M=H]AI==TH&7B:M`BK*T7)K1T%<=SJ
M*E$RZ+6(B5:7@.+)HA4[G*B(8'<,OBA<"A*SW='X;<"U;%K[8U"5=2SE97<N
M_H8.^ERQ,EL,,[869M.)88O!S=82;8I*MLCE>PY5>N4U^5)@;$FQMK7V9`=\
MZK:'X0K_C=8U^.2^`2_QP7R5!>/?)?B\2H$]KG\U^0P'LMRGLY!-23X/-\Q7
M0$5[CY@S_NO8DH.,F,_[X`[NP-^`@UCF986!QLUOF"`]_!X&&C6_S_BK>B:X
M--*X.7X/]?";CS-B;I_?``+.*F:^A"0_SDEZ.%2/=UOM^T,#6MYUMKH%#&!:
M.KMM=1<,CVI)`K#5MV``U$*,M%W5'PK4\MUNNX%S*$R[VCG#V/%/P\JR0*&7
MN,=5@S&\RW#O^/&^J(2A(2*;$5]3*FB>?I_4+)_AA0!V]-/$T),1V!1\(]-=
M2SS0;$-2/N>K4LW@,(B@!]*HD(4#O7IEX`:JI0<QH6'4"CPT:@_5-D:HK!;E
M:*:RTD;+.CA4I<S+\#^]X3.,UCI/R\S.(L;LIC,;12!>U-.)F]9*/Q\RHK'J
MK.)3UV*UC&WDE?1Z]9T:9\7?C5''W5OE%GI>7:]=/D>A0>7=P6[<"RW,4/#F
MACIIR.XW^ER"2Y;S&LQ7CR"FU>GI5D\3B4F`&>\\Z3*<?37`&!-LN[-V*OG%
M.>!$2GY9JKDJEORR3.<4NX::WF1J5V%LM2=+8M:3^&RK95D2W4XB@ZUV9-E=
M+:_HVVHL;A>%6TK[6A<4+(9(VXH;,FC:K*WQ=K/UPST`5R``*Q@O?"<839&'
M&TQ1`*A)&<'7A&YN<BA2S8*6&EJ$6'L`,43IRRV8>/%0+EVC:U$EFXC!W\MG
M)RK_(7VOZQ<LMZ2O)6472)-*J6-80X4O.'0C,@N(/G#DH'V%!WHU2$RXQ*`C
MPB&3]M,9*_^1R!/YY&93*`>&U,A:5GX^Z*T/UQ`?T[,U>`Z+)W+`?5`ZFIK6
MN-P`)G4XS>=94?Y/#D);%9T>8=:Z'VU5A?I>YEKN2%MU*'.+7_A2'DX),RM2
M_V>"CUZ`_/W!W%V2H\G;C$ZPCPI#.?`.'98@2K!4,%]E(1'DQ64#4L>M@P*\
M;<CA18T_5TX$788<T=S6A*Q4I^0&^DE<3&<+W7EK$Y0_@O@^P"L*/(01R]E8
M;6."2NZR%M:Z9$<QXEH%.Q#05V>;_:KYGTV>\XJS42W9G;-INT2H`:S:'K5=
MAM.`&.,6Z22`;<,(DL=ZSPZ\PV7628B2A<^L'%4K8#Q(J&/^RNQ1[*5`Z*#T
M('K"'@^?S<K5_XP<^M*P%,DM?=5OX0BXWZW#W2</P/0"QC_4[UW\J]]N@QBO
MQ,;"<D=_[I^:![!V_/2;#0%@32T,E5MT`?"B.WSZ$-\L/FO`'!$?XGQU^T>"
M26-(,`(=]01(E=YIOL+:S3KQ:0&061*_T9.G,0RJM9.>\H'5Q[Z.Z:@V,%*"
MD9S\"X2W)F,>2PV,T1>E40&4BORVXI';V-X(]>1]A928&UI8)5UR*9&/X)W^
MB5FY4ZRSGI7*^]9S2(_J=[PQL%1Y%Z+;;P"Y,,([>;[#1[COAS0W(WUXHW&=
M:QS>R#Q6Q82CN('ZS+&:CX!V;CAO<]L14-T6`<YL/@+:F\*&N4W'0'/M<906
MLO/6(Z&<7SN8V=Z$/L>22XLR0(P'0[^WZZ$MCD1,H#B&R?;0Y+8KIR$`55BQ
MM-T6IX!=FV)KNS%.&#(!?<MV_Z<(5K(:@*W1HTJ8L74^VU,PA+>A5H7-UE0.
MY<67&42L+WHJ@8N((7"X$I6CP*LQL9"O!)Z9U'H4%-\HYEN;*""*2JL2;FWU
M^8X(/9A)IQ@'1OOI_5HQE-3?K_UL8V+.8Q@3$;$A4;Y3EGWA5'_&!%[Y6#XU
M$5@X<UT2"DHD8DP^?5"6;SKF=#BY.BE-<]#,M?;/F-SS[7->J06F'>'A[&GC
M.B^>X#J`*^@Z07P\!=,IT,6I(88LP\,AUOET=JPH&M,^Y.&3_V+:C_+TD\#2
M:+ZJ4;5/_]NV'P4[F^#KVHG>2$5-_#]BQ-DY/EE/8FR)]1T/5TN`%Q!T8^#Q
M*)=B5G!((QB$&_)((CV)EL`G.4#7820\MX*]37&&P!O).-N!-&!>9C<*=S?#
M6T#2"-/$K"6,?D\?4R4_,=EA]QA#BI38I+3U,L')G0/1+XZ?@)(B<!_@#9]L
M6H\+L;XFN+K?;#%MU/M#TBFW8>3X\]5#&*P?\'[P:&TEP4-":2@C/--=_NQ\
M$^2+U=Q,XMY[27!`6!Y,\(8OK2(QGJ2',11L3M\Q)"F_,;Y-R4VZI1G$0CP*
M=S>3\!<!K!\1(>$&[(`?4LJREXRY9XE(3X,IC$O@AEC]H*G:0M/4WL\$-\_(
M\4">OYYME=)C<MP9$NMK@JL7XO._C6*XP2(<*YJSUNAT[`*B6IGM\6YRJ-77
MA.VA;7+H"&K$ML>XR8$F>'C:'N2F8Z6)6BELCX23PU)05[,]T$UR`?*,#;;'
MOLE!):Z9V!X#)X>;FK7!UB0710R9UHOAXE1.`2<!?;0`;%($!$T2!623=B#C
M>RAPFQ0$"6]4`=ND(@@X4PJX)BU`Q59>X->W0G"*$2,T#'N*%]'AQ[W:MZ34
M\WJ,@H/6Q'I>#R,<4&WVB"IN`0Q^'R-<)%&,I0PDR4=++Z/^]%3KPU+G`W1>
MH8]%=1!]!0X)JO7F6#QP$T0R&G&#QS!`^3^IL9^>2&T.IAX^9!0O/O64W)<@
M?(T`HM;6^V";Q$0+PF>^#^G,"R.F\U-:"A,Q#2^Y`\-[B<`J\1_@"G`71]?1
MC$0!NV_`2TB&Y0Q?;1ZISXC5CB<R'72*;K^Y?H+%`Y*3223L)`]<K\N-K1'#
M^C]D%J_&PJ!$STUK7`H=(ZJCF>0\FJ\J1_Y\E8H2Y+]W6!@*D2C7,B.9*:V6
MR;(/;<6XCAL:I9=;#JK:Z'0TKSIWMF<9"LCW7$_+.65D"F@2%:S:!%[;/5.R
M>/'5'-O]4>Q[H-$_K%'WL#VJ2!)9K5J*[3%)8M@J276V1R;QH>NL--H>HR2W
M\J0U*=O#DF3ATZ>XVQZ[U*P@<:7HLM!MNQ3=#D_3TK3]D6&VAXMY!XRD3@F3
MOA9'5WN_467NB%<DD1K"Y$X4GCFA`,*IH(CBIC7GG#Z3K:N\86W<IM/FC&C)
MV;?0Q]Q':<5/TG8DUVE*4,L&K#4R]B*,$(@L#X%H?Y-[KWDVCNIBB^%PKONM
M`(.8?YKC)W.5''AYK7^CNU"8Y-<RR2V[MN.@)G9YUZGK"`1C5*-OAFM9&96G
MPKMB/)TK2L"9D[NGT^7(.+O9^N$>`/I(D`N*62MS0LK]N[G?($V.^1-S0M\+
MH.Q)!,)H_IY9])K)IY))^C)"-'-CN,,[6S)>2'G@L>"1+?/9NX.\,MG$T9?.
M<10EF_1WRMAT^(A=-UF/^]EV'W6?DZ%G.]CNR1YF!F0/Z.&<X..2[0ZYPB,Q
MRS30TR*/\7H8K1TG;J/A=C&Y5P5FHS'Q?#++"&XQ<[K1Z6^TXMB_R582IJTI
M7$]2X)0;S;`^MUH!<J.!P^0L\;*K1<E)YB[(#VD6@Q<2=ID)M9C:*Q"`%8RC
M9>C[=R$B(I@D`M(#GM`1K;QI;%<,E'%4V8*VR_C*8,KOY7,5W&G9M\2-DRSZ
M/%.?,OT&;^"1"/2M=+9('>+]#17IE9\%14;'IAQ(SVRME)`"<.>J0JB@94ZU
ML'O+%Y?578))!%]A`#?)9DE6A9^;J_!E-=\"$G@<K!^`$TDK(5W&-HM*9?9(
MQ3"T`VG<-;'W1:U18BHCG>PQJ`2;[:*X)D0[;<_A)/1QW3376-)V7L,T98)J
MA"XI[C=;(Z#IU4Y&W0ZE#U=/$/5QC+P?D'^]Y38\;F=R;S*I/N32J4WDN4IV
MU^%F`^/4Q15XUR$MH``"=SP*G!"%+6M8;@Q#;X3)S$,'-L<AM2C-:JU`IQ1@
MTP87P<F<TG8>V[PF]<U7#R"*@$0XO<0`)[V]98`ZUZV]#/>.'^\/DDU?HK'(
M=QHD89%ND^"K3_`5FJ9SW2L+4@&=Z@/TR9]%B$$$,43TK[F;9SP2;Q$[2<P/
M.9TR%Z'P"$92.%5GHYE=Y>$,7Y&RLUQ)_%2&\%R/@/],'(3)]_>E!Y=6(=K4
M2CD9V`Y<RH0WO>PH)C:^X!PH,#B.3:TXD^6-+0K1M(UY^)A39,]G,Q>N#OZ<
MR'D>9<8Z\:VN"."Y[ORGY#4"?R3XQ]N=\<SQ.C$M^YG9W,C&90(I1OPX-F#;
M#%1V&IMCP[OIKY\(L237"/_C_P-02P,$%`````@`;(!T1&$Q61FR%@``>?0`
M`!$`'`!M9VYX+3(P,3,Q,C,Q+GAS9%54"0`#C$DK4XQ)*U-U>`L``00E#@``
M!#D!``#M75MSX[BQ?D]5_@./'TYFJR)K[-G99%PSF_)URU6VY2-Y-IN\;,$D
M)"%+@5H`M*W]]>D&;^!%$$G)'NH47V9D$MWH1G\$&HT&\/D?+PO?>:)"LH!_
M.3@Z?'_@4.X&'N.S+P=?)X/3R?GU]<$_?OSSGS[_SV#@C,?.1<`Y]7VZ<GYQ
MJ4\%4=1Y("\!#Q8K9^+.Z8+\U7DDDGI.P)U?SL8WSO'AD>/,E5J>#(?/S\^'
M0G@)DT,W6`R=P2"IX.=(E!/GA\-CD,9X,PY"[ITX'XU'YX(2!:4=#X0X<8[?
M'WT_>/]A</3WAZ,?3HX_G7S\^&^S=+!<"3:;*^>=^QT4?O]Q`!0?G/'A^-#0
MZG^=2<`EE%XL"5\YI[[OC)%*.F,JJ7BBWF',5&IE'6A!+K\<&/H]?S@,Q&P(
M51P-?[F]B1KEX,]_<J*R)R^/PF<Y"GR2T'P8,BX5X2XU2'S&?[-0X&ML<[.2
M$DDLUM&G3Y^&^JU1.I2#&2'+M/R4R$==.GXQQ*8:O#\:?#C*4ZG5DLI*,OVF
MFFXQXR\YT1;$%<&,<N9*C0BD.CK.T7"P4+BH;@-/B2%6-X1"`RA%!7--TLUT
M)1HLXZF4S&SNC\/HI5':!7`JL<H7E]0]G`5/P_AE=5.XH1#PQ:TCC=\B[7&)
MUJ.LF@Q>5-=&7]QY-0F^J:9A_(E*54T5O:NFDVHIJJGP#=(<&32*B!E5=V1!
MY9*XM#XZH`]:4*ZN`K&XH%,2^B#J[R'QV911[\`A2@GV&"J:*Q#RK,B/R.4S
MX3Q0NC?1?^.3Y9+Q:1#_"0_PDSD1@4\?`#(._O@ZOK8*JN)^<8B%AQ>!&Z*H
MA'N77#&UN@;V8J$K/7"8]^7`6B(5)!'%HU/&F1;YZ/V1,W`2<O,GL'(B7H[!
M[/.PR*'(/(0.?,1_U+]=XKNAKPEOX.^8."YA(UP*Z#*Y:D&92;:>+GZ:6&1W
MAIJ`Q!I4H^D5X]`3,^+?!U*+<^X3*6-LH<G&0/!K30*[!3^`V5)&#HY77`8^
MP['-<\Z(CR.",YE3JF1OONW-=T^@9U5SJABT3V-;:NH-!OV^OD&==SEQONL-
M7-/`U^"L+NBIKZC@H,83K;9DN9C==!]MIDM?2">8.J,E^L`,?4;L:]%O%'1.
MN81:G*A>Y]U-(&5OU+I&G<SA8Y@'O@>3@<O?0QB[3KDW@H]#Y%HW:MQJ@S=C
M80?##_7!,%&!^UM<[5^<J.+>[#7-?D[D_,H/GN4U]YB@KJHV;;F8W7Q_JV\^
M9.UHWKW1;$:["Q25#T$Z/F:M.!(SPMD?6J&LH>$/^/SN#66-P34COF#2]0,9
M"OI`7]29#]^2`8$WK-0.J+^C?YU2P1]F_7H0N",*W^1&AQY1[1`U83,.+I=+
MN#IU]52:\=D]F-AE0-$()S59V:W_J6C]2;A8$+'2W7]6@9/5X"15]!!H!X%[
M$<!GI%;W/EH.YL8PKB[Q3=L.HQ%#*QR.WA?AD/".9MX)X][T+;]^PZ&*W"DL
MV];N];G9C7Y4Z@,J_#[GW070N$SUCG]+XV=-#%X?N.W@LVOEQM1'Y^T\D&!2
M=/3/<+GAGJPT53-(;%N''2C'):`@*V^@F3D)MQX?[?`1S=X>R$O;_L#*P&[9
M#T7+QE-]8-8/]&T-.J92B=`%YQG<)AB7XX_PU%7L":2EK6<(K1C;`?!]$0`W
M%#YJY_*%*>>&D4?F]W/_UD`X#WR?/`8BF<7=,!<Z9GHZ$W2[J6(KQG8@?"P"
M(5>'=@/C6IRLFAX8;8&Q6#"E?X+U8+*/$RS*W2WZAH8L[6#XH0R&E'L<'S;X
M]RAH.4X$*^*K5?HYM1X6:O"QV_MO%=,_#P8:YY;Y,.8$G*9>GC9_7&/?$VP?
M%,`(ON[#=5C_'AQU0143^NT9Y2!U^V&B-7,[6DJ1P\O%T@]6E#HQ3P<C$CTB
MVB'B_T(B%!7^*GUG9#PTLW]-5G9KER*%*5<G9=LG9>P@1A0^2OI["#\OGYH'
M`-936ZU[7`K\98R<B%-OS]>,^"</=ACY3UG:+5^._M5>`7#>);_ZH."KHN.!
M//H[Q4;,T(Z,<KBO`3*B&GI<O,$B40-TM&!KQT@I<%B]8-3CX=LN'C2`R&YJ
MLJ.F%&VL7$CH0?.**PH-$%&#C=W<I9BBN;K06_D;+#,TL/X6[.VH*`47JY8<
M>G2\:8BY`2Y:,;8CHA1^M(:;>VB\282I`20:,;1#H11;W!!MZL%0;]-6YMP9
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M\[8CK!SS;8FPBL)XFDTB1H^O5\'7I51L@8&_KY).0_^&/;7USRHYV;%3"B`W
MPDY:H1/5Z.@J>YR\"DYPR2A,-JB>$<E<<+(OF!]"^T=A?SP]X%[O7%\$7"_\
MM,-1JYKL."N%I!OAS!`(";1(VHN/A<J?GX`CI1.)%BU_]8!\G8'1G5,O],$I
MTF:`3W]"W5#H.17T!P"5\ZP%XT+4NR2"`Q.$SQ80W5'==M"6HN;-!M981"R=
M".ED4F*7B<!U#$'3HO`FD56CN8=Q&Q@G&1-F.D8&G*JW13"VX&"'5"GZOB:K
M(P^?=:D?/1ZVQD.M8&M]0KOU2_'WM=;OPZB[&<A*&[GCO=;U8NS-J*VV_[X<
M5K?N!>\QL#,,Z`RH7$Y5/>O7I;/;O1S<KLS(ZLW]>N;.1FS]S>EW9@+>Y0O^
M+'NB[3G9(5%OMW_!!]`5QD7,*IVXSAXHNP1*NL(U6NH5^&<BO#3:,>(/<WH!
MOT;3GS#,_U6"HPZ/SGSB_@8\H!X9T=T+Z,SY[#;PJ-\(7J]1OQV4Y3AU#5`:
M"VY1A8Z6U`@,P2,UIPY*BP1:7D<+K)]KD0>QS#&/02RUH\7N<;WS#C#&5)1G
M6%Z`:TIOQU7-C.2*SBZ%5%Q1CX2&2$C3BVOFE&PL;[>T/1FY=W!V;U7T`P*.
MW\]H"OU_?!>!O(@7HZ&,3GB0ELR/+;G9$5&*^A80D=6('SV.!W&E?Y%.4BT6
MCO(VI//.J/J['CCM@3.F;L!=:,DX/CJFRT!@@#09M].R\89S"VR:\[*#IA1U
M+8`F7Q\")ZG1<#LRFG3+?`^7G<$%?4TZ8YQ'&Q<N.=X#<[K`(#BZI(&47[D`
MFAEG?^B.(SD*H0&,VM=AAU<I`KL17MI/342)+TI`89Q(FLBM!7D<4R`3>OV*
M:%/LZ0TKN%\E3:"JY<#4);,CI!2EK=P^T_LSKV;K\SGA,RJO>?G59HO;B*UV
M_UB*T*ZQ>UR#P_B:C54]`+8$P%6H]*H+@XYX2?QDDOB5>U3HTNFQ2)OQT("7
M'1ZE0.X:>$05.FF-V1PWQ#ICLK36'BX-X;+Q:+Y:0T5++G:(E`*[=8[XZT>2
MW2%C[<;)FIAH2&]'0RFB:M]TV</@]6&0!3)O0=)%N(@Z:]TE)]WT^IS>W3&V
M`Z<4,MT$'#-T&M>?#$/1:),.07TV[S;9(WAB8WI@8[HHS+WB^9#UNIOM&=IA
M5(K'-CYSLN^3=@6>Y`#'."*`IP35PDAM.CL42H'8R@,E>W/ORMS6_?I)8-V\
M8"HE&%,9^AB!S_9?%S&Q6^9VX)2"L9M."Q@8(?S<#5H982Q%89-Y#[&F.=KY
M\RAK[AJO0V2'1"F`6CK0LN]'X#'^@U=MC^G4T;=HG^`-TE\.)(.N%US+Z!D1
M+M+;[]\>+J,T47#VA@G;A$&).G_AMP9-H?UBJ1(.<T&G7P[PJNU!<F'RKT!Q
M^++PDR***:S%S%1'1O*O#O']@V%W-<^;L8;B0%"A^$7*9D_T]LDC]6NJ#&4K
M5+Y!#GNB;?$SKZ$TD%0H;5X"6*7[YZ%YV3?\E;\,_#.H'@CE\,K;R?.",RX5
M7NQ[X$B8O"W(3>!J1A82_&N0T`WPT>#H>/#AZ/!%>K&(323(6KJ9!`E=4PE,
M5A_U7YZJ77="@)5^K%7=E,A'31W*`2)3FK?/KZM65VE2S@A9:L(A!9<EY37(
M>#5O?4^)(7(9\G!!!7/K-4*1"EOB$S;_T0_;B!#P04LQ`G[73I+*]MW>,/BD
MJ5TT6TG=PUGP--2;N,2JMCA5=,D?VPD2"D&YJSD>-Y+$)$S_&F1LFLOB4=:X
M01(:_+%50]`7=]ZX]I1(_]JJ?L:?J%2-)3#(XM];22'54B"SHR8RI$3ZUR`C
M-^NG?K0$A0)\.<A\]G/HX_%^^0OZ1/U`[TDJ1:GT`EIA'0['V%^W8Q,Y$:@*
M.UE`.47$ZEK1!7K8!PYYE$H05WTYF!)?.PFZ(#@/+/`>-&DT0*KDU2/Q<;C\
M<N#11TQCX@Q79'"P5P(/!I$P>8'1/T2)?Q)!N$PJ9U!IW7;:IG'^?[;(F,YP
MIA`(W#,W(:#B-FW4@MM^M5JTCQZ3GJ^E#'&UVJ7Y#=+%EK%31-K#P(XJZ6?M
M=-^IEO'2I]X"<$5I'0!L(MDK*\=0_;K$W/DY@TX1_\05HQC+E4U0@^K56L$5
MU-M],P0*'K.*GB];G$)M[^CSA0AGI\NESZ*1[M1UZ3*>-56UU$X8[Q6DLHZQ
M3??:@'JO6B4_0M1IB0T4^Z!]G!EK#A%<,B^.K]\3YJUOA^:T6[>(%XHX0OUJ
M37(6T#D>K4[%-?SCSRE;W-+%(Q6&ZI8R\1@:<!Q&O6!!&*_2,!+/IN`.5$D]
M::+(F#XQ^GROJ[H*,J,\4+%@W`C[:P4;4YJ6371H:=E=*+XA3>N2*PJ#%&XO
M-)5N0A4IG$1V3G"U:J(0$]W5>OU]A;74KR;/X5TESSO1"$^9[!%Z\0(5KJ6I
M5MM*T#6$Q[D\*M?IXC8$X5'O%"\)B<ZQQ46Z>Q&X5.+5$90(=X[G<F63Z]P^
M]KA)=L]\'[I^T/8)%Q2`2_Z`V.@%WMFI9TSYIJI)LN7D:M?HJ99Z`C52>5$:
M\.H2=&GTT\MO5"?<"?:H*3%=)<EAD>:+4Q"8^#^#(X>GA:5'IAHML!-N.0S@
MTV\'@8O`#?6!1+A)"FA7QH+[:2R+J7ZMXN9'+M>.AF]B_4N?W0"750G*Q1==
M@FR")I!QAM_:Z8P^!/<$/CS<$Z#H-3<RNDR=FM&99F+@U*`?^\V`&!UA!",*
MSL*?*$KX\!P\S(-0$NX]S&%`+MNP/DVGS/NR9-!QQ@<A)*Y&63MKL2XI=$71
M-_`QO(J7SMQ1%:=F\1F>J7E.A%C!E`$/]Y!:*UWUO\!/N.2>H?&6?$P\S_#I
MMT-S>TV@O%`[:9.84Y=:16>5QSGF.K=<EG=4R1L88%%&:;9"4\H.#4'U9'_(
M]@PTT#BF>F-M/74R7Z'K$C[J]J[6^R?F4^)-7$:A@\:Y0JF'6UNB2YW;3]#Q
M\G/<HGT>B&4\+RZK8BO5)76,3?/&QL>*3VY3P0Y]896B%C\H6Z%.?C^IP)<O
M)(FP8?^M/W_CV1@W%.<'TN:D'1HE&@E?'"[;$'=1]_Q!$N8I.MY_0AGMYJI2
MNQ[=/D1AUJB4GFV7*53ODB!;.[5BNL>-J%U)`QRX1;4!K#:0OU[#['!)6<<N
MP86ZH-'_U^G',LZO;VTJN`\PN(DBVU$*S&@Z92Y-SXLNN3)U"G?)HXE/;3"G
M/J8V56\[U.-K^<HV,)]VJ[%E@@\FJ)Q0\<2HJ)#?5JQ3"L7+6[@EVUSX2I>[
MJGSC)D0=\I,WBEWTF>L2=-)_OF'0:WG7.H56]UUX.RV,W-&:WD-P1L]](B6;
M,ES+.B=RCMW<$_%UV1><=^>:8@?<NK5X>$MX."7Q%?)7Q(W/1BQ]S!O*=>EK
MOH4!>'5+Q&]4787<DZECETWY3,7JE-Z#])T[7)2=@@;(!S,=#1TKWNV%?W87
M(KI&TV@1[9;@`@5N&4Z2S**L/&K.>NN3=&KE(Q'[-O"I&_IXB?L9C=?.H2_!
MOG>Q@,Z.$1_/!CR-[LXRNF-9T0;;,.MDZZ3YF7K-7*NE<Y=!A3699U'6&9[]
M>A\*=UX^^"O78#OFGQL1-<=OED.=:BB"F2"+*K1DKSIE^VCR@3E(Z91D@CM=
M2B/4IH)=&J)&T.&R!2TFS2+@K'F6#>E>;=C:81_?2"5,OIXLJ:L]K!OLT493
MG7FKX8M'T\BVK56+]5XT:+HTN'8E;7V1#DU4"D(6IR75KSLY"2DOUD[CQ=K(
M2[EA"Q9M`H_RJ"NUK$NZ!Z[J>J4R=>2(?X7!M'Y[K"/=A]!<?:W*^1(M:#L4
M^6HF?7&AIQ7U7FA_%ZA)^/@?ZL)HE>E22_5UI'O1,=BSH?8@#6HD9H2S/Y+$
M^3N,$-'1]"R4,,C*ZM&X-DF71F>[T*71NE;Q;H[>@LT8S/LB\)4C8VO>=PF4
MA=C'B%='<@VE:E/L11PIR[N^8;]1?S6:WA`Q@TE!LF\MN_SAC`+JQC2*C."<
MX*L?W0@RH4I%3/_)U!P(\#*)4,T#D5]=?H.Z8FAU(74\TQ9F2SK$@?MDD@,$
MTQWFHU#AV(%W7EP%(EE-O8XN?M?;102@#%])&:+Y]=Q,DQ;2F]^JPBZU\13P
M(:IRYTIO.M7IX%X@ZLDK$2R25K[&,]"(?Q\^^LP=3:<4^_@S"JX+3?Z*=PF9
M`^36G/9A#I!<Y(SP4^8UT>F51.#&3D.8\4VCC+6J?7O;,,EAIP.[]];JDJD`
M3_52C:S8I=*.O$,>UI@\47[&`D7=.0_\8,:J$V@WE.M2EY#L"QS!1SO3;+'K
M]JE.4\MOP-U<M#2/NPVXFG\[O(+$`!@7OC%<^+4O.M8HNP?3-7,W^-G*.&*G
MPBVJ4;9;"^/%`]3M&Z9KE>Y:#UL4NFIR:BG3I;ZR(&5Q^KGF?2?GF[&L\0Q,
M+\ZF'N\=57I-(MK]H1-S<&I0,8';BDN'G-\))IUZ8S:;JX<@7L/.S45+XV%M
MBBZ-C-'>Z=.CM9NK*]2L2=%!-8\;J[F9HH-JCGA-[=86[*!2#\]!/:76%NR>
M4F=-\;B9H'M*GC=5<C-!]Y2\:-R#UJ#HH)J->]`:%!U4L[&6^ZADW1YU?<&.
M*56Y&Z##Z?\Z*'Q&)![ILL"88;3(@7N]9KK<V2HKDGC4N-::G#T!TNH349)4
MNBC*?/GBZGM>S=7ZUZ\J-Z=IGG38C8;-:Q?'"#!5=:IH&LW?1;/6K*ASC?JX
M6=?'HJ[1`N7E"V;^PJMK/*0(9GZN#CT5&_,5*MB'*+SN5N>!#Q-C&7UR54$1
M:ZD.A47*<A8#(VM+=#(TDIY6C68_#Z0J&:7P<F\@%Z697^C=-5&0-.J1[NBS
M?H41?3_$Y4P=M'D6P$_($?@ZI[X?J$+P9W<L.]7QV;1Z"$PMK@*1=$.C:4ZE
MJ(^JVU9-N7:NN9(N.7(/QLC]@DI7L,IFV%2Z7J?PYNJ->'DW0/7K3GF=F82X
M1GG\_OU[FQ;%,AU5!>8H-BV,UYU2(`3ZJCW8Q1==$OJ!O)SK'"DS_3._R[WB
M6)A&5*4UUF_WO=>5NY@CW)"N2QIGQQB>XDF&3"A*XQL[S.,.2Z!M2M@I4!=D
M%Y06.L&-ZJXGZ9*BZ%A(-N.8E+,A_+.Y:*<46TY%H"];`6MD!X^RZ-#H670+
M9B';HP%-U](^8M&SA-E$W,B/+"NYOF2W$B"^3GX*P,?E>GH_H]RM.A;`5N@;
M@O+S,+KA#'[^%U!+`0(>`Q0````(`&R`=$0"E(B80H`!`(V2#P`1`!@`````
M``$```"D@0````!M9VYX+3(P,3,Q,C,Q+GAM;%54!0`#C$DK4W5X"P`!!"4.
M```$.0$``%!+`0(>`Q0````(`&R`=$2KG_RT,A,``(0.`0`5`!@```````$`
M``"D@8V``0!M9VYX+3(P,3,Q,C,Q7V-A;"YX;6Q55`4``XQ)*U-U>`L``00E
M#@``!#D!``!02P$"'@,4````"`!L@'1$@=_49Z@T``!>B0,`%0`8```````!
M````I($.E`$`;6=N>"TR,#$S,3(S,5]D968N>&UL550%``.,22M3=7@+``$$
M)0X```0Y`0``4$L!`AX#%`````@`;(!T1+)5_6HFB@``3K0'`!4`&```````
M`0```*2!!<D!`&UG;G@M,C`Q,S$R,S%?;&%B+GAM;%54!0`#C$DK4W5X"P`!
M!"4.```$.0$``%!+`0(>`Q0````(`&R`=$18.B/S44D``$&>!0`5`!@`````
M``$```"D@7I3`@!M9VYX+3(P,3,Q,C,Q7W!R92YX;6Q55`4``XQ)*U-U>`L`
M`00E#@``!#D!``!02P$"'@,4````"`!L@'1$83%9&;(6``!Y]```$0`8````
M```!````I($:G0(`;6=N>"TR,#$S,3(S,2YX<V155`4``XQ)*U-U>`L``00E
>#@``!#D!``!02P4&``````8`!@`:`@``%[0"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ER2AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Revenue from collaborative research</a></td>
        <td class="nump">$ 56,753,123<span></span></td>
        <td class="nump">$ 59,645,819<span></span></td>
        <td class="nump">$ 47,054,397<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant revenue</a></td>
        <td class="nump">1,281,545<span></span></td>
        <td class="nump">4,180,279<span></span></td>
        <td class="nump">10,152,969<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="nump">58,034,668<span></span></td>
        <td class="nump">63,826,098<span></span></td>
        <td class="nump">57,207,366<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">46,581,930<span></span></td>
        <td class="nump">45,432,894<span></span></td>
        <td class="nump">41,088,899<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">11,086,759<span></span></td>
        <td class="nump">10,187,894<span></span></td>
        <td class="nump">10,868,791<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
        <td class="nump">57,668,689<span></span></td>
        <td class="nump">55,620,788<span></span></td>
        <td class="nump">51,957,690<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
        <td class="nump">365,979<span></span></td>
        <td class="nump">8,205,310<span></span></td>
        <td class="nump">5,249,676<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
        <td class="num">(626,814)<span></span></td>
        <td class="nump">156,445<span></span></td>
        <td class="nump">1,467,444<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net comprehensive income (loss)</a></td>
        <td class="num">$ (260,835)<span></span></td>
        <td class="nump">$ 8,361,755<span></span></td>
        <td class="nump">$ 6,717,120<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per common share</a></td>
        <td class="num">$ (0.04)<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per common share</a></td>
        <td class="num">$ (0.04)<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average number of common shares</a></td>
        <td class="nump">6,847,697<span></span></td>
        <td class="nump">1,083,276<span></span></td>
        <td class="nump">1,025,602<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average number of common shares</a></td>
        <td class="nump">6,847,697<span></span></td>
        <td class="nump">1,083,276<span></span></td>
        <td class="nump">1,025,602<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs of sales and operating expenses for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 52<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.23)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(d),(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicenseAndServicesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br><br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueFromGrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>6. Income Taxes</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 For the years ended December&#xA0;31, 2013, 2012 and 2011 there was
 no current provision for federal or state income taxes due to the
 taxable losses which resulted or use of legacy NOL
 carryforwards.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The significant components of the Company&#x2019;s deferred tax
 assets (liabilities) were as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred income tax assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Federal U.S. net operating loss carryforward</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">36,561,195</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">35,330,167</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 State net operating loss carryforward</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,315,514</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,521,722</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Research and development credit, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,785,612</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,777,899</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Orphan drug credit, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,883,076</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,039,613</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Deferred rent</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,132,458</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,218,002</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,216,695</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,379,064</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,438,477</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,247,772</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,438,870</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,575,782</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Gross deferred income tax assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">79,771,897</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">78,090,021</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(79,376,945</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(78,090,021</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net deferred income tax assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">394,952</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred income tax liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(394,952</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Gross deferred income tax liabilities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(394,952</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net deferred income tax asset/(liability)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company recognizes valuation allowances to reduce deferred tax
 assets to the amount that is more likely than not to be realized.
 In assessing the likelihood of realization, management considers
 (i)&#xA0;future reversals of existing taxable temporary
 differences; (ii)&#xA0;future taxable income exclusive of reversing
 temporary difference and carryforwards; (iii)&#xA0;taxable income
 in prior carryback years if carryback is permitted under applicable
 tax law; and (iv)&#xA0;tax planning strategies. The Company&#x2019;s
 net deferred income tax asset is not more likely than not to be
 utilized due to the lack of sufficient sources of future taxable
 income and cumulative book losses which have resulted over the
 years. The net increase in the valuation allowance in 2013 is due
 to the fact the Company generated research and development and
 orphan drug credits and NOL carryforwards which increased the net
 deferred tax asset. The increase in the credits and NOL
 carryforwards were offset by the decrease in deferred revenue and
 resulted in a net current year increase to the valuation
 allowance.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company has reported book losses from inception through
 December&#xA0;31, 2010. The NOL carryforwards of approximately
 $104.8 million for U.S.&#xA0;federal and approximately $60.3
 million for state will expire in various years beginning in 2023
 through 2033. In addition, the Company has U.S. federal tax credits
 of $23.7 million which will expire in various years beginning in
 2020 through 2033.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The use of the Company&#x2019;s U.S. federal NOL and tax credit
 carryforwards in future years are restricted due to changes in the
 Company&#x2019;s ownership and tax attributes acquired by the
 Company in a purchase. As of December&#xA0;31, 2013, $8.5 million
 of the Company&#x2019;s NOLs are limited for use over the years
 2014&#xA0;&#x2013; 2027 in which a range of such amounts could be
 utilized on an annual basis of $0.2 million to $1.4&#xA0;million.
 The remaining $96.3 million of NOLs is not limited and can be
 offset against future taxable income. Additionally, approximately
 $1.8 million of NOLs will be recognized as a benefit through
 additional-paid-in-capital when realized. Further, despite the NOL
 and credit carryforwards, the Company may have a future tax
 liability due to an alternative minimum tax or state tax
 requirements in which net operating losses do not exist.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The reconciliation of the reported estimated income tax benefit to
 the amount that would result by applying the U.S. federal statutory
 tax rate to the net income is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="53%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 United States federal tax at statutory rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(91,293</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,926,615</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,350,992</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 State taxes (net of federal benefit)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">609,476</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,460,289</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,480,185</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred income tax adjustments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(855,130</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(512,375</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred state blended rate adjustments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(344,178</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research credit, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(225,605</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Orphan drug credit, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(843,463</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,895,671</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7,056,607</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other permanent items</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,931</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,627</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,696</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Equity-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">241,467</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">279,165</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">725,811</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Fair value adjustment of preferred stock warrant liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">218,872</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(52,743</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(496,208</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Change in valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,286,923</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">787,093</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,991,131</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Income tax expense/(benefit)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 A reconciliation of the beginning and ending amount of gross
 unrecognized tax benefits is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Beginning balance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,592,357</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,533,986</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,246,025</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Increases/(decreases) for current year tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">115,502</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">58,371</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">287,961</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Increases/(decreases) for prior year tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Decreases as a result of expiration of statute of limitations</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Ending balance</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,707,859</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,592,357</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,533,986</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of December&#xA0;31, 2013 and 2012, of the total gross
 unrecognized tax benefits, approximately $1.2 million and $1.1
 million would favorably impact the Company&#x2019;s effective income
 tax rate, respectively. Although, due to the Company&#x2019;s
 determination that the deferred income tax asset would not more
 likely than not be realized, a valuation allowance would be
 recorded, therefore, zero net impact would result within the
 Company&#x2019;s effective income tax rate. The Company&#x2019;s
 uncertain income tax position liability has been recorded to
 deferred income taxes to offset the tax attribute carryforward
 amounts.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For the years ended December&#xA0;31, 2013, 2012 and 2011, the
 Company has not recognized any interest or penalties related to the
 uncertain income tax positions due to the fact such position is
 related to tax attribute carryforwards which have not yet been
 utilized. The Company does not expect its unrecognized income tax
 position to significantly decrease within the next twelve
 months.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The Company&#x2019;s U.S. Federal and state income tax returns from
 2001 to 2012 remain subject to examination by the tax authorities.
 The Company&#x2019;s 2001 through 2009 years remain open for
 examination, even though the statute of limitations has expired,
 due to the net operating losses and credits carried forward for use
 in prospective years.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shared-Based Payments<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Shared-Based Payments</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>5. Shared-Based Payments</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Stock Option Plan</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company&#x2019;s 2000 Stock Option and Incentive Plan
 (&#x201C;2000 Plan&#x201D;) allowed for the grant of awards in
 respect of an aggregate of 130,725 shares, which was increased to
 150,297 shares, of the Company&#x2019;s common stock in the form of
 incentive stock options, non-qualified stock options, stock
 appreciation rights, restricted stock and restricted stock units
 and other performance awards. As of December&#xA0;31, 2013, under
 the 2000 Plan, there were options to purchase an aggregate of
 23,657 shares of common stock outstanding at a weighted average
 exercise price of $0.83 per share. The 2000 Plan has expired, and
 no further awards may be issued under the plan. Any shares of
 common stock subject to awards under the 2000 Plan that expire,
 terminate, or are otherwise surrendered, canceled, forfeited or
 repurchased without having been fully exercised, or resulting in
 any common stock being issued, will become available for issuance
 under the 2013 Stock Incentive Plan (&#x201C;2013 Plan&#x201D;) up to
 a specified number of shares.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Effective February&#xA0;2003, the Company implemented the 2003
 Equity Incentive Plan (&#x201C;2003 Plan&#x201D;), and it was amended
 and approved by the Company&#x2019;s stockholders in 2005. The 2003
 Plan originally allowed for the grant of awards in respect of an
 aggregate of 2,051,644 shares of the Company&#x2019;s common stock.
 Between 2006 and 2010 the maximum number of shares of common stock
 authorized to be issued by the Company under the 2003 Plan was
 increased by 1,739,116 shares to 3,790,760. During the year ended
 December&#xA0;31, 2012, the maximum number of shares of common
 stock authorized to be issued by the Company under the 2003 Plan
 was increased by 545,970 shares to 4,336,730. Stock options granted
 under the 2003 Plan may be either incentive stock options as
 defined by the Internal Revenue Code (&#x201C;IRC&#x201D;), or
 non-qualified stock options.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of December&#xA0;31, 2013, under the 2003 Plan, there were
 options to purchase an aggregate of 2,559,011&#xA0;shares of common
 stock outstanding at a weighted average exercise price of $1.52 per
 share. Upon the completion of the IPO, the 2003 Plan was
 terminated, and no further awards may be issued under the plan. Any
 shares of common stock subject to awards under the 2003 Plan that
 expire, terminate, or are otherwise surrendered, canceled,
 forfeited or repurchased without having been fully exercised, or
 resulting in any common stock being issued, will become available
 for issuance under the 2013 Plan, up to a specified number of
 shares.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In October 2013, the Company implemented the 2013 Plan. The 2013
 Plan provides for the grant of stock options and other stock-based
 awards, as well as cash-based performance awards. The aggregate
 number of shares of common stock initially available for issuance
 pursuant to awards under the 2013 Plan is 1,960,168&#xA0;shares.
 The number of shares of common stock reserved for issuance will
 automatically increase on January&#xA0;1 of each year from
 January&#xA0;1, 2014 through and including January&#xA0;1, 2023, by
 the lesser of (a)&#xA0;1,960,168 shares, (b)&#xA0;4.0% of the total
 number of shares of common stock outstanding on December&#xA0;31 of
 the preceding calendar year, or (c)&#xA0;the number of shares of
 common stock determined by the Board of Directors. All of the
 shares available for issuance under the 2013 Plan are eligible for
 issuance pursuant to the exercise of incentive stock options. If an
 option expires or terminates for any reason without having been
 fully exercised, if any shares of restricted stock are forfeited,
 or if any award terminates, expires or is settled without all or a
 portion of the shares of common stock covered by the award being
 issued, such shares are available for the grant of additional
 awards. However, any shares that are withheld (or delivered) to pay
 withholding taxes or to pay the exercise price of an option are not
 available for the grant of additional awards. As of
 December&#xA0;31, 2013, under the 2013 Plan, there were options to
 purchase an aggregate of 618,290 shares of common stock outstanding
 at a weighted average exercise price of $19.06 per share.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Stock Option Exchange</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On March&#xA0;16, 2011 (&#x201C;Exchange Date&#x201D;), the Company
 modified certain outstanding options with exercise prices of $1.88
 and $4.69 (&#x201C;Original Options&#x201D;). These Original Options
 were canceled and replaced with options having an exercise price of
 $0.94 (&#x201C;Replacement Options&#x201D;), reflecting the current
 fair market value of the Company&#x2019;s common stock on the
 Exchange Date. Original Options submitted for exchange were
 replaced on a one-for-one basis with Replacement Options.
 Additionally, the Replacement Options retain all terms and
 conditions of the Original Options except for the reduction to the
 exercise price as described above.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Total compensation associated with the Replacement Options
 consisted of the grant-date fair value of the Original Options for
 which the requisite service period is expected to be rendered (or
 has already been rendered) at the Exchange Date, plus the
 incremental cost associated with the modification of terms. The
 incremental compensation expense was measured as the excess of the
 fair value of the Replacement Options over the fair value of the
 Original Options re-measured as of the Exchange Date. A total of
 1,921,894 Original Options were exchanged for Replacement
 Options.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 The following stock-based compensation amounts were recognized for
 the periods indicated:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">507,142</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">471,809</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,018,935</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">355,020</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">366,586</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,328,504</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total stock-based compensation expense</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">862,162</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">838,395</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,347,439</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Employee Stock Options</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The fair value of each option award is estimated on the date of
 grant using the Black-Scholes option-pricing model using the
 assumptions in the following table:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="5" align="center"><b>Year Ended December&#xA0;31,</b></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2011</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected dividend yield..</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">53%&#xA0;-&#xA0;67%</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">51%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">62%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">1.24%&#xA0;-&#xA0;2.19%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">1.18%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">1.35%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected term.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">7&#xA0;years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">7&#xA0;years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">7&#xA0;years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected forfeiture rate..</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">5.06%&#xA0;-&#xA0;5.57%</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5.57%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5.58%</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <b>Expected Dividend Yield</b>&#x2014;The Company has never declared
 or paid dividends and has no plans to do so in the foreseeable
 future.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 <b>Expected Volatility</b>&#x2014;Volatility is a measure of the
 amount by which a financial variable such as a share price has
 fluctuated (historical volatility) or is expected to fluctuate
 (expected volatility) during a period. As the Company does not yet
 have sufficient history of its own volatility, the Company has
 identified several public entities of similar size, complexity and
 stage of development and calculates historical volatility using the
 volatility of these companies.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <b>Risk-Free Interest Rate</b>&#x2014;This is the U.S. Treasury rate
 for the week of each option grant during the year, having a term
 that most closely resembles the expected life of the option.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <b>Expected Term</b>&#x2014;This is the period of time that the
 options granted are expected to remain unexercised. Options granted
 have a maximum term of ten years. The Company estimates the
 expected life of the option term to be seven years. The Company
 uses a simplified method to calculate the average expected
 term.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <b>Expected Forfeiture Rate</b>&#x2014;The forfeiture rate is the
 estimated percentage of options granted that is expected to be
 forfeited or canceled on an annual basis before becoming fully
 vested. The Company estimates the forfeiture rate based on turnover
 data with further consideration given to the class of the employees
 to whom the options were granted.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Equity instruments issued to non-employees are accounted for under
 the provisions of ASC&#xA0;505-50, <i>Equity Based Payments to
 Non-Employees</i>. Accordingly, the estimated fair value of the
 equity instrument is recorded on the earlier of the performance
 commitment date or the date the services required are
 completed.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following table summarizes stock option activity for 2013:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="42%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-<br />
 Average<br />
 Exercise&#xA0;Price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Weighted-Average</font><br />
 Remaining<br />
 Contractual&#xA0;Term<br />
 (Years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate<br />
 Intrinsic<br />
 Value<br />
 (in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding, December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,249,541</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,307,101</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10.70</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,268,049</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.85</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Forfeited or expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(87,635</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.11</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding, December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,200,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.90</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">67,532</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 December&#xA0;31, 2013:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercisable</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,688,251</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.8</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42,311</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Vested and expected to vest</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,022,948</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.64</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.8</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">64,574</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 During 2013, 2012 and 2011 the Company issued 1,268,049, 863,176
 and 49,883 shares of common stock, respectively, in conjunction
 with stock option exercises. The Company received cash proceeds
 from the exercise of these stock options of approximately $1.1
 million, $46,826 and $53,225 during 2013, 2012 and 2011,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The weighted-average grant-date fair value of options granted
 during 2013, 2012 and 2011 was $6.91, $0.94 and $0.94 per share,
 respectively. The total intrinsic value of options exercised during
 2013, 2012 and 2011 was approximately $5.4 million, $271,929 and
 $102,418, respectively. The total fair value of stock options which
 vested during 2013, 2012 and 2011 was $487,603, $879,024 and
 $1,108,107, respectively. As of December&#xA0;31, 2013, the total
 unrecognized compensation expense related to non-vested stock
 options, net of related forfeiture estimates, was $7.6 million,
 which the Company expects to recognize over a weighted-average
 period of approximately four years.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shared-Based Payments (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 The following stock-based compensation amounts were recognized for
 the periods indicated:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">507,142</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">471,809</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,018,935</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">355,020</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">366,586</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,328,504</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total stock-based compensation expense</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">862,162</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">838,395</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,347,439</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Option Award Estimated on the Date of Grant Using the Black-Scholes Option-Pricing Model</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The fair value of each option award is estimated on the date of
 grant using the Black-Scholes option-pricing model using the
 assumptions in the following table:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="5" align="center"><b>Year Ended December&#xA0;31,</b></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2011</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected dividend yield..</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">53%&#xA0;-&#xA0;67%</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">51%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">62%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">1.24%&#xA0;-&#xA0;2.19%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">1.18%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">1.35%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected term.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">7&#xA0;years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">7&#xA0;years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">7&#xA0;years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected forfeiture rate..</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">5.06%&#xA0;-&#xA0;5.57%</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5.57%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5.58%</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following table summarizes stock option activity for 2013:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="42%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-<br />
 Average<br />
 Exercise&#xA0;Price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Weighted-Average</font><br />
 Remaining<br />
 Contractual&#xA0;Term<br />
 (Years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate<br />
 Intrinsic<br />
 Value<br />
 (in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding, December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,249,541</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,307,101</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10.70</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,268,049</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.85</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Forfeited or expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(87,635</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.11</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding, December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,200,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.90</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">67,532</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 December&#xA0;31, 2013:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercisable</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,688,251</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.8</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42,311</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Vested and expected to vest</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,022,948</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.64</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.8</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">64,574</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>13. Subsequent Events</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In February 2014, Servier exercised its exclusive option to develop
 and commercialize MGD006. Servier will gain exclusive development
 and commercial rights in all countries outside of the U.S., Canada,
 Mexico, Japan, South Korea and India. In those countries, the
 Company will retain development and commercialization rights. As a
 result of the exercise, the Company received a $15.0 million
 payment from Servier. In addition, the IND application for MGD006
 has cleared the 30-day review period by the FDA, triggering an
 additional $5.0&#xA0;million payment to the Company by Servier.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In February 2014, the Company completed a follow-on equity
 offering, in which the Company sold 1.8&#xA0;million shares of its
 common stock at a price of $36.50 per share. Additionally, the
 underwriters of the offering exercised the full amount of their
 over-allotment option resulting in the sale of an additional
 450,000 shares of the Company&#x2019;s common stock at a price of
 $36.50 per share. The Company received net proceeds of $76.7
 million from this offering, net of underwriting discounts and
 commissions and other estimated offering expenses.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>9. Commitments and Contingencies</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Operating Leases</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company leases office and laboratory space in Rockville,
 Maryland under a lease that expires on March&#xA0;31, 2018, and
 leases a manufacturing facility in Rockville under a lease that
 expires on December&#xA0;31, 2014. The Company has an option under
 each lease to continue the respective lease for five years under
 the same terms. The Company also subleases office and laboratory
 space in South San Francisco under a lease that expires on
 December&#xA0;31, 2018. All of the leases contain rent escalation
 clauses. For financial reporting purposes, rent expense is charged
 to operations on a straight-line basis over the term of the lease.
 As of December&#xA0;31, 2013 and 2012, the Company had recorded a
 deferred rent liability of $2.9 million and $2.8 million,
 respectively. Rent expense for the years ended December&#xA0;31,
 2013, 2012 and 2011 was $2.7 million, $2.7 million and $2.9
 million, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Future minimum lease payments under noncancelable operating leases
 at December&#xA0;31, 2013 are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,651,421</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,310,884</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,410,210</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,512,517</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,780,398</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16,665,430</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Lease Exit Liability<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring And Related Activities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Lease Exit Liability</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>7. Lease Exit Liability</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On July&#xA0;16, 2008, the Company acquired Raven Biotechnologies,
 Inc. (&#x201C;Raven&#x201D;), a private South San Francisco-based
 company focused on the development of monoclonal antibody
 therapeutics for treating cancer. Raven was considered a
 development-stage enterprise as defined in ASC&#xA0;915,
 <i>Development Stage Entities</i>. In connection with the
 acquisition, the Company issued 12,466,039 shares of its Series D
 convertible preferred stock in exchange for all of the outstanding
 capital stock and convertible notes payable of Raven.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company undertook restructuring activities related to the
 acquisition of Raven. These restructuring activities included
 reductions in staffing levels and the intended exit of leased
 facilities. All severance-related payments were completed in the
 year ended December&#xA0;31, 2009.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In connection with these restructuring activities, as part of the
 cost of acquisition, the Company established a restructuring
 liability attributed to an existing operating lease. The terms of
 the operating lease extend through 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Changes in the lease exit liability are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrual balance at December&#xA0;31, 2011</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">$10,607,499</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Principal payments</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(533,560</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrual balance at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,073,939</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Principal payments</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(628,769</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrual balance at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">$9,445,170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Future principal payments to be made under the lease agreement for
 the next five years and thereafter as of December&#xA0;31, 2013 are
 as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2014</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,438,742</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2015</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,641,905</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,866,031</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,113,118</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,385,374</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,445,170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The purchase agreement provides for a specified total of certain
 contingent milestones that are based on the achievement of certain
 product sales derived from the acquired Raven technology. Also, a
 onetime payment of $5.0&#xA0;million will be made to the Raven
 stockholders upon the initiation of patient dosing in the first
 Phase 2 clinical trial of any product derived from the Raven
 &#x201C;Cancer Stem Cell Program.&#x201D; No payment shall be made if
 the Phase 2 trial start date has not occurred on or before
 July&#xA0;15, 2018. Other consideration includes a percentage of
 revenue (excluding consideration for research and development and
 equity) received by the Company for license of a product derived
 from the Raven &#x201C;Cancer Stem Cell Program&#x201D; and a onetime
 payment ranging from $8.0&#xA0;million to $12.0&#xA0;million
 dependent upon a specified level of sales of products derived from
 the Raven &#x201C;Cancer Stem Cell Program.&#x201D;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The contingent consideration will be accounted for as additional
 purchase price and recorded as incremental in-process research and
 development expense when it is deemed probable that the
 contingencies will be attained. No additional amounts have been
 recorded during the years ended December&#xA0;31, 2013, 2012 and
 2011.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringAndRelatedActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>8. Collaboration and License Agreements</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Servier</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In November 2011, the Company entered into a right-to-develop
 collaboration agreement with Servier for the development and
 commercialization of MGA271 in all countries other than the United
 States, Canada, Mexico, Japan, South Korea and India.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Upon execution of the agreement, Servier made a nonrefundable
 payment of $20.0 million to the Company. The Company is eligible to
 receive up to $30.0 million in license grant fees, $47.0 million in
 clinical milestone payments, $140.0 million in regulatory milestone
 payments and $208.0 million in sales milestone payments if Servier
 exercises the option, obtains regulatory approval for and
 successfully commercializes MGA271. The Company concluded that the
 license grant fees are not deliverables at the inception of the
 arrangement. The Company has determined that each potential future
 clinical, development and regulatory milestone is substantive.
 Although sales milestones are not considered substantive, they are
 still recognized upon achievement of the milestone (assuming all
 other revenue recognition criteria have been met) because there are
 no undelivered elements that would preclude revenue recognition at
 that time. In the event Servier exercises its option to continue
 development of MGA271, Servier must pay a license grant fee. Under
 this agreement, Servier would be obligated to pay the Company from
 low double digit to mid-teen royalties on product sales in its
 territories.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company has evaluated the research collaboration agreement with
 Servier and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The Company
 concluded that the option is substantive and that the license fees
 for this option is not a deliverable at the inception of the
 arrangement as there is considerable uncertainty that the option
 would be exercised and the additional fee to be paid upon exercise
 of the option represents its estimated selling price (i.e. no
 substantial discount was given). The Company&#x2019;s substantive
 performance obligations under this research collaboration include
 an exclusivity clause to its technology, technical, scientific and
 intellectual property support to the research plan during the first
 year of the agreement and participation on an executive committee
 and a research and development committee. The Company determined
 that these performance obligations represent a single unit of
 accounting, since the license does not have stand-alone value to
 Servier without the Company&#x2019;s technical expertise and
 committee participation. As such, the initial upfront payment was
 deferred and is being recognized ratably over the initial 27-month
 period, which represents the expected period of development and the
 Company&#x2019;s participation on the research and development
 committee. The Company further concluded that each potential future
 clinical, development and regulatory milestone is substantive.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 During the years ended December&#xA0;31, 2013, 2012 and 2011 the
 Company recognized revenue of $21.3&#xA0;million, $9.1 million and
 0.9&#xA0;million, respectively, under this agreement. Revenue
 recognized in the year ended December&#xA0;31, 2013 included a
 $10.0 million substantive milestone payment received upon dosing
 the first patient in a Phase 1 dose expansion cohort trial of
 MGA271.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 At December&#xA0;31, 2013, $0.9 million of revenue remained
 deferred under this agreement, all of which was included in current
 liabilities. At December&#xA0;31, 2012, $10.0 million of revenue
 was deferred under this agreement, $9.1 million of which was
 included in current liabilities and $0.9 million of which was
 included in long-term liabilities.</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In September 2012, the Company entered into a second
 right-to-develop collaboration agreement with Servier and granted
 it options to obtain three separate exclusive licenses to develop
 and commercialize <font style="white-space:nowrap">DART-based</font> molecules, consisting of
 those designated by the Company as MGD006 and MGD007, as well as a
 third DART molecule, in all countries other than the United States,
 Canada, Mexico, Japan, South Korea and India.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Upon execution of the agreement, Servier made a nonrefundable
 payment of $20.0 million to the Company. In addition, the Company
 will be eligible to receive up to $65.0 million in license grant
 fees, $98.0 million in clinical milestone payments, including $5.0
 million upon IND acceptance for each of MGD006, MGD007 and a third
 DART molecule, $300.0 million in regulatory milestone payments and
 $630.0 million in sales milestone payments if Servier exercises all
 of the options and successfully develops, obtains regulatory
 approval for, and commercializes a product under each license. In
 addition to these milestones, the Company and Servier will share
 Phase 2 and Phase 3 development costs. The Company has determined
 that each potential future clinical, development and regulatory
 milestone is substantive. Although sales milestones are not
 considered substantive, they are still recognized upon achievement
 of the milestone (assuming all other revenue recognition criteria
 have been met) because there are no undelivered elements that would
 preclude revenue recognition at that time. Under this agreement,
 Servier would be obligated to pay the Company between high-single
 digit and mid-teen royalties on net product sales in its
 territories.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company has evaluated the research collaboration agreement with
 Servier and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The Company
 concluded that each option is substantive and that the license fees
 for each option are not deliverables at the inception of the
 arrangement and were not issued with a substantial discount. The
 Company&#x2019;s substantive performance obligations under this
 research collaboration include an exclusivity clause to its
 technology, technical, scientific and intellectual property support
 to the research plan during the first year of the agreement and
 participation on an executive committee and a research and
 development committee. The Company determined that the performance
 obligations with respect to the pre-clinical development represent
 a single unit of accounting, since the license does not have
 stand-alone value to Servier without the Company&#x2019;s technical
 expertise and committee participation. As such, the initial up
 front license payment was deferred and is being recognized ratably
 over the initial 29-month period, which represents the expected
 development period. The Company further concluded that each
 potential future clinical, development and regulatory milestone is
 substantive.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 During the years ended December&#xA0;31, 2013 and 2012 the Company
 recognized revenue of $8.6 million, and $2.0 million, respectively.
 No milestones have been recognized under this agreement during the
 years ended December&#xA0;31, 2013 and 2012.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 At December&#xA0;31, 2013, $9.4 million of revenue was deferred
 under this agreement, $8.6 million of which was included in current
 liabilities and $0.8 million of which was included in long-term
 liabilities. At December&#xA0;31, 2012, $18.0 million of revenue
 was deferred under this agreement, $8.6 million of which was
 included in current liabilities and $9.4 million of which was
 included in long-term liabilities.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In February 2014, Servier exercised its exclusive option to develop
 and commercialize MGD006. As a result of the exercise, the Company
 received a $15.0 million payment from Servier for its license to
 develop and commercialize MGD006 in its territories. In addition,
 the Company received a $5.0 million payment from Servier upon the
 achievement of a clinical milestone related to the IND application
 for MGD006 clearing the <font style="white-space:nowrap">30-day</font> review period by the FDA.</p>
 <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Gilead</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In January 2013, the Company entered into an agreement with Gilead
 for the research, development and commercialization of up to four
 DART-based molecules. The time period for Gilead&#x2019;s exercise
 of one option has expired. At present, Gilead retains a license to
 one and options to two of the original four programs. Gilead has
 exclusive worldwide rights for each of these remaining
 programs.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company received an initial $7.5 million license grant fee for
 the first DART-based molecule, and is eligible to receive
 additional license grant fees of $7.5 million on each of the
 remaining two DART-based molecules if they are selected by Gilead.
 The Company is further eligible to receive up to an additional $20
 to $25 million in pre-clinical milestones across each of the three
 remaining DART programs and up to approximately $240 to $250
 million per remaining program in additional clinical, regulatory
 and sales milestones if Gilead exercises both remaining options and
 achieves all of the requisite milestones under each option and
 license. The Company has determined that the other licenses are
 conditional deliverables, which are substantive options that were
 not granted with a substantial discount. The Company has determined
 that each potential future clinical, development and regulatory
 milestone is substantive. Although sales milestones are not
 considered substantive, they are still recognized upon achievement
 of the milestone (assuming all other revenue recognition criteria
 have been met) because there are no undelivered elements that would
 preclude revenue recognition at that time. Gilead also provides
 funding for the Company&#x2019;s internal and external research
 costs under the agreement. Additionally, Gilead would be obligated
 to pay the Company high single digit to low double digit, but less
 than teen royalties on product sales.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company has evaluated the research collaboration agreement with
 Gilead and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The
 Company&#x2019;s substantive performance obligations under this
 research collaboration include a license to its technology and
 research and development services. The Company concluded that the
 deliverables do not have stand alone value and therefore, represent
 a combined single unit of accounting. Due to the lack of standalone
 value for the license and research and development services, the
 combined unit of accounting (the upfront payment and the expected
 research and development reimbursements) is being recognized
 ratably over a period of 21 months, which represents the expected
 development period.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company and Gilead have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable. Had
 management considered participation on the joint committee as a
 deliverable, it would not have had a material impact on the
 accounting for the arrangement.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company recognized revenues of approximately $8.0 million under
 this agreement for the year ended December&#xA0;31, 2013. No
 milestones have been achieved under this agreement.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 At December&#xA0;31, 2013, $3.6 million of revenue was deferred
 under this agreement, all of which was included in current
 liabilities.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Boehringer</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In October 2010 the Company entered into a collaboration and
 license agreement with Boehringer to discover, develop and
 commercialize up to ten DART-based molecules which span multiple
 therapeutic areas. Under the terms of the agreement, the Company
 granted Boehringer an exclusive, worldwide, royalty-bearing,
 license under its intellectual property to research, develop, and
 market DARTs generated under the agreement throughout the
 world.</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Upon execution of the agreement, the Company received an upfront
 payment of $15.0 million. The Company subsequently received three
 annual maintenance payments including one in the fourth quarter of
 2013. These maintenance payments are being recognized over the
 estimated period of development. The Company has the potential to
 earn milestone payments of approximately $41.0 million related to
 pre-clinical and clinical development, $89.0 million related to
 regulatory milestones and $83.0 million related to sales milestones
 for each of the DART programs under this agreement in the case of
 full commercial success of multiple DART products. The Company has
 determined that each potential future clinical, development and
 regulatory milestone is substantive. Although sales milestones are
 not considered substantive, they are still recognized upon
 achievement of the milestone (assuming all other revenue
 recognition criteria have been met) because there are no
 undelivered elements that would preclude revenue recognition at
 that time. Boehringer also provides funding for the Company&#x2019;s
 internal and external research costs and is required to pay the
 Company mid-single digit royalties on product sales. In November
 2013, Boehringer nominated a bi-specific antibody therapeutic
 candidate generated by the Company&#x2019;s DART technology for
 pre-clinical development. This formal selection of a development
 candidate triggered a $5.0 million milestone payment to the
 Company. From the commencement of the collaboration through
 December&#xA0;31, 2013, the Company has received $48.8 million
 under this agreement, including upfront, annual maintenance and
 milestone payments as well as research funding. In addition,
 Boehringer purchased $10.0 million of the Company&#x2019;s Series
 D-2 Preferred Stock in January 2011. This preferred stock was
 converted to common stock upon the Company&#x2019;s IPO in October
 2013.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company determined that the deliverables under the Boehringer
 agreement include the license, the research and development
 services to be performed by the Company, and the
 co-promotion/manufacturing services. The Company concluded that the
 co-promotional activities were optional and were subject to further
 negotiation upon reaching regulatory approval. As such, the
 co-promotional period is not included in the expected obligation
 period to perform services.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company concluded that the undelivered element of research and
 development services had fair value. The Company concluded that the
 license does not have value on a standalone basis (e.g. absent the
 provision of the research and development services) and therefore
 does not represent a separate unit of accounting. The Company
 concluded that because the drug candidate has not yet been
 developed, the license is of no value to Boehringer without the
 ensuing research and development activities using the DART
 technology, which is proprietary to the Company. Likewise,
 Boehringer could not sell the license to another party (without the
 Company agreeing to provide the research and development activities
 for the other party).</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Therefore, the upfront license fee and research and development
 services were treated as a combined unit of account and recognized
 over the expected obligation period associated with the research
 and development services through September 2015, which represents
 the estimated period of development.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company and Boehringer have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable. However,
 had management considered participation on the joint committee as a
 deliverable, it would not have had a material impact on the
 accounting for the arrangement as the period of participation in
 this committee matched the obligation period for the research and
 development services.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 There have been no material modifications to this agreement since
 the adoption of ASU 2009-13 on January&#xA0;1, 2011.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company recognized revenues of approximately $14.4 million,
 $11.7 million and $8.9 million during the years ended
 December&#xA0;31, 2013, 2012 and 2011, respectively. Revenue
 recognized in the years ended December&#xA0;31, 2013 and 2012
 included milestone payments of $5.0 million and $2.0 million,
 respectively, for the achievement of clinical milestones. No
 milestones were achieved in the year ended December&#xA0;31, 2011.
 At December&#xA0;31, 2013, $12.8 million of revenue was deferred
 under this agreement, $7.0 million of which was included in current
 liabilities and $5.8 million of which was included in long-term
 liabilities. At December&#xA0;31, 2012, $14.0 million of revenue
 was deferred under this agreement, $5.0 million of which was
 included in current liabilities and $9.0 million of which was
 included in long-term liabilities.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Pfizer</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In October 2010, the Company entered into a three year agreement
 with Pfizer to discover, develop and commercialize up to two
 DART-based molecules. The Company granted Pfizer a non-exclusive
 worldwide, royalty-bearing license and received an upfront payment
 of $5.0 million and has received milestone payments and funding for
 the Company&#x2019;s internal and external research costs under the
 agreement.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company is eligible to receive milestone payments of
 approximately $17.0 million related to pre-clinical and clinical
 development and $195.0 million related to commercialization and
 sales milestones for each DART program under this agreement. The
 Company has determined that each potential future technical and
 development milestone is substantive. Although sales milestones are
 not considered substantive, they are still recognized upon
 achievement of the milestone (assuming all other revenue
 recognition criteria have been met) because there are no
 undelivered elements that would preclude revenue recognition at
 that time. Pfizer is responsible for all pre-clinical and clinical
 development costs for the program. In addition, Pfizer is required
 to pay the Company mid-single digit to low-teen royalties on
 product sales. Under this collaboration, one DART program is
 currently being pursued and the Company completed its research
 obligations under this program in January 2014.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company has evaluated the research collaboration agreement with
 Pfizer and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The
 Company&#x2019;s substantive performance obligations under this
 research collaboration include an exclusive license to its
 technology, research and development services and manufacturing
 services. The Company concluded that the manufacturing services
 were optional and were subject to further negotiation upon reaching
 regulatory approval. As such, the manufacturing services are not
 included in the expected obligation period to perform services.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company determined that it had fair value of the undelivered
 element of the research and development services. However, the
 Company concluded that the license does not have value on a
 standalone basis (e.g. absent the provision of the research and
 development services) and therefore does not represent a separate
 unit of accounting. Facts that were considered included the
 development of the candidate noting that because the drug candidate
 has not yet been developed, the license is of no value to Pfizer
 without the ensuing research and development activities using the
 DART technology, which is proprietary to the Company. Likewise,
 Pfizer could not sell the license to another party (without the
 Company agreeing to provide the research and development activities
 for the other party).</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Therefore, the upfront license fee and research and development
 services were treated as a combined unit of accounting and
 recognized over the expected obligation period associated with the
 research and development services through January 2014, which
 represents the estimated period of development.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The $5.0 million upfront payment received by the Company is
 non-refundable; therefore, there is no right of return for the
 license. The Company recognizes revenue associated with this
 non-refundable up-front license fee through the expected obligation
 period associated with the research and development services, which
 ended in January 2014.</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company and Pfizer have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable because it
 is a participating right and not an obligation of the Company.
 However, had management considered participation on the joint
 committee as a deliverable, it would not have had a material impact
 on the accounting for the arrangement.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 There have been no material modifications to this agreement since
 the adoption of ASU 2009-13 on January&#xA0;1, 2011.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company recognized revenues of approximately $3.5 million, $5.5
 million and $5.2 million during the years ended December&#xA0;31,
 2013, 2012 and 2011, respectively. Included in the 2012 revenues
 are milestone payments totaling $500,000. No additional milestones
 have been achieved under this agreement through December&#xA0;31,
 2013.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 At December&#xA0;31, 2013 and 2012, $7,291 and $1.3 million of
 revenue was deferred under this agreement, respectively, all of
 which was included in current liabilities.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Green Cross</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In June&#xA0;2010, the Company entered into a collaboration
 agreement with Green Cross for the development of the
 Company&#x2019;s anti-HER2 antibody known as MGAH22, or
 margetuximab. This arrangement grants Green Cross an exclusive
 license to conduct specified Phase 1 and Phase 2 clinical trials
 and commercialize margetuximab in South Korea.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Upon execution of the agreement, Green Cross made a nonrefundable
 payment of $1.0&#xA0;million to the Company. The Company is
 eligible to receive clinical development and commercial milestone
 payments of up to $4.5 million. The Company has determined that
 each potential clinical development and commercial milestone is
 substantive. The Company is also entitled to receive royalties on
 net sales of margetuximab in South Korea. The Company and Green
 Cross have formed a joint steering committee to coordinate and
 oversee activities on which the companies collaborate under the
 agreement.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company has evaluated the collaboration agreement with Green
 Cross and has determined that it is a revenue arrangement with
 multiple deliverables or performance obligations. The
 Company&#x2019;s substantive performance obligations under this
 agreement include an exclusive license to its technologies and
 participation in a joint steering committee. The Company concluded
 that the license does not have value on a standalone basis and
 therefore does not represent a separate unit of accounting.
 Likewise, Green Cross could not sell the license to another
 party.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The $1.0 million upfront payment received by the Company is
 non-refundable; as such, there is no right of return for the
 license. Therefore, the upfront license fee and participation on
 the joint steering committee were treated as a combined unit of
 accounting and will be recognized over the term of the agreement
 through June 2020.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 There have been no material modifications to this agreement since
 the adoption of ASU 2009-13 on January&#xA0;1, 2011.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company recognized revenues of approximately $100,000 under
 this agreement during each of the three years ended
 December&#xA0;31, 2013. No milestones were achieved under this
 agreement during the three years ended December&#xA0;31, 2013.</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 At December&#xA0;31, 2013, $650,000 of revenue was deferred under
 this agreement, $100,000 of which was included in current
 liabilities and $550,000 of which was included in long-term
 liabilities. At December&#xA0;31, 2012, $750,000 of revenue was
 deferred under this agreement, $100,000 of which was included in
 current liabilities and $650,000 of which was included in long-term
 liabilities.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Eli Lilly</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In October&#xA0;2007, the Company entered into an exclusive license
 and collaboration agreement (together, the Agreements) with Eli
 Lilly to jointly develop and commercialize teplizumab, a humanized
 anti-CD3 monoclonal antibody. As part of the Agreements, Eli Lilly
 acquired the exclusive rights to the molecule.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Upon execution of the Agreements, Eli Lilly made a nonrefundable
 payment of $41.0&#xA0;million to the Company. In May&#xA0;2008, Eli
 Lilly paid the Company a milestone payment of $50.0&#xA0;million
 and in May&#xA0;2010, Eli&#xA0;Lilly paid an additional milestone
 of $5.0&#xA0;million.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 On October&#xA0;28, 2010, Lilly notified the Company of its
 decision to terminate the agreement after review of one year of
 clinical data from the Prot&#xE9;g&#xE9; trial in Type 1 diabetes
 patients treated with teplizumab. Such data failed to support the
 primary efficacy end point in the study. In February 2011, the
 Company reacquired the commercial rights to the molecule from Eli
 Lilly. During the year ended December&#xA0;31, 2012, Eli&#xA0;Lilly
 satisfied its obligation related to the cost of monitoring patients
 under the Prot&#xE9;g&#xE9; and Encore trials. The Company&#x2019;s
 obligations continued through September 2012, which represented the
 follow up period for enrolled patients and the Company&#x2019;s
 final reporting of the trial&#x2019;s results. There is no
 additional clinical trial activity under the Eli Lilly Agreements
 as it relates to such trials. However, Eli Lily continues to
 reimburse the Company for monitoring patients in one currently
 active trial.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 During the years ended December 2013, 2012 and 2011, the Company
 recognized revenue of $0.8 million, $31.2 million and $30.9
 million, respectively, under this agreement. No milestones were
 achieved under this agreement during the three years ended
 December&#xA0;31, 2013.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration and license agreements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TextBlockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Product Milestone Payments and Royalty Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RoyaltyAgreementDisclosureTextBlock', window );">Product Milestone Payments and Royalty Agreements</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>10. Product Milestone Payments and Royalty Agreements</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In connection with an Asset Purchase Agreement with Tolerance
 Therapeutics, Inc. (&#x201C;Tolerance&#x201D;) entered into during
 June 2005, the Company may be required to issue Tolerance
 additional consideration as follows: (i)&#xA0;$10,950,000 if
 certain milestones are met, including the initiation of Phase 3
 trials and filing of various regulatory product license
 applications; (ii)&#xA0;36,135 shares of common stock; and
 (iii)&#xA0;royalty payments between 1.75% and 4.0% of net sales of
 products acquired from or patented by Tolerance or other product
 fees earned by the Company. Any additional consideration required
 to be paid under the Asset Purchase Agreement will be recorded as
 research and development expense when incurred. No payments related
 to the additional consideration have occurred during the three
 years ended December&#xA0;31, 2013. Additionally, certain
 agreements require the Company to pay royalties. Currently, the
 Company is not obligated to pay royalties, as no revenue from
 product sales is being generated by the Company.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RoyaltyAgreementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty agreement disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_RoyaltyAgreementDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TextBlockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Computer Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Software [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Furniture [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
        <td class="text">10 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Laboratory and Office Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Leasehold Improvements [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Leasehold improvements</a></td>
        <td class="text">Shorter of lease term or useful life<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EO5AM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="6">12 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="6">12 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="6">12 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2014

</div>
          <div>Subsequent Event [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Servier [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Servier [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Servier [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Servier [Member]

</div>
          <div>Second Right to Develop Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Servier [Member]

</div>
          <div>Second Right to Develop Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Gilead [Member]

</div>
          <div>Molecule</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Gilead [Member]

</div>
          <div>Minimum [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Gilead [Member]

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Gilead [Member]

</div>
          <div>Expired Option Agreement [Member]

</div>
          <div>Molecule</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Gilead [Member]

</div>
          <div>License Agreement Terms [Member]

</div>
          <div>Molecule</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Gilead [Member]

</div>
          <div>Option Agreement [Member]

</div>
          <div>Program</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Boehringer [Member]

</div>
          <div>Payments

</div>
          <div>Molecule</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Boehringer [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Boehringer [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2011

</div>
          <div>Boehringer [Member]

</div>
          <div>Series D-2 Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2010

</div>
          <div>Pfizer [Member]

</div>
          <div>Molecule</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Pfizer [Member]

</div>
          <div>Program</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Pfizer [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Pfizer [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Green Cross [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Green Cross [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Green Cross [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 28, 2010

</div>
          <div>Eli Lilly [Member]</div>
        </th>
        <th class="th">
          <div>May 31, 2010

</div>
          <div>Eli Lilly [Member]</div>
        </th>
        <th class="th">
          <div>May 31, 2008

</div>
          <div>Eli Lilly [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Eli Lilly [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Eli Lilly [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Eli Lilly [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementEnteredDate', window );">Collaboration agreement date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">November 2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">September 2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">January 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">October 2010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">October 2010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">June 2010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">October 2007<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableFees', window );">Non-refundable upfront payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 20,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 20,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 7,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 15,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,000,000<span></span></td>
        <td class="nump">$ 5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 41,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalLicenseGrantFeesUnderAgreement', window );">Additional license grant fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,000,000<span></span></td>
        <td class="nump">30,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">65,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement', window );">Clinical milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">47,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">98,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">41,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement', window );">Regulatory milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">140,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">300,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">89,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalSalesMilestonesUnderAgreement', window );">Sales milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">208,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">630,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">83,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">195,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Expected period of development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">27 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">29 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">21 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">21,300,000<span></span></td>
        <td class="nump">9,100,000<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="nump">8,600,000<span></span></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="nump">8,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,400,000<span></span></td>
        <td class="nump">11,700,000<span></span></td>
        <td class="nump">8,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,500,000<span></span></td>
        <td class="nump">5,500,000<span></span></td>
        <td class="nump">5,200,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">800,000<span></span></td>
        <td class="nump">31,200,000<span></span></td>
        <td class="nump">30,900,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">50,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,400,000<span></span></td>
        <td class="nump">18,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,800,000<span></span></td>
        <td class="nump">14,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">650,000<span></span></td>
        <td class="nump">750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
        <td class="nump">20,267,323<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">24,123,176<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,600,000<span></span></td>
        <td class="nump">8,600,000<span></span></td>
        <td class="nump">3,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,000,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,291<span></span></td>
        <td class="nump">1,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue included in long-term liabilities</a></td>
        <td class="nump">7,135,687<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19,956,343<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">800,000<span></span></td>
        <td class="nump">9,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,800,000<span></span></td>
        <td class="nump">9,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">550,000<span></span></td>
        <td class="nump">650,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance', window );">Clinical milestone payments under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ReviewPeriodByRegulatoryAuthority', window );">Review period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">30 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations', window );">Commercialization of molecules</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="nump">10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement', window );">Clinical milestone payments under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20,000,000<span></span></td>
        <td class="nump">25,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement', window );">Additional clinical, regulatory and sales milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">240,000,000<span></span></td>
        <td class="nump">250,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfAnnualMaintenancePaymentReceived', window );">Number of annual maintenance payments received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PaymentReceivedOnCollaborationAgreement', window );">Received including upfront, annual maintenance and milestone payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">48,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Preferred Stock purchased</a></td>
        <td class="nump">$ 83,622,358<span></span></td>
        <td class="nump">$ 12,014,815<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ResearchObligationCompletionDate', window );">Research obligation completion date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2015-09<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2014-01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementPeriodOfContract', window );">Period of agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPrograms', window );">DART program</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontFeeAndParticipationRecognitionDate', window );">Term of the agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2020-06<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ClinicalDataReviewPeriodForAgreementTermination', window );">Review of clinical data</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Potential milestones upon IND acceptance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential clinical milestone payments available to be earned under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional clinical, regulatory and sales milestone payments under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalLicenseGrantFeesUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional license grant fees under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AdditionalLicenseGrantFeesUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional potential milestone payments receivable upon new drug application acceptance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential remaining regulatory milestone payments available to be earned under a collaboration arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalSalesMilestonesUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential remaining sales milestone payments available to be earned under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AdditionalSalesMilestonesUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ClinicalDataReviewPeriodForAgreementTermination">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Clinical data review period for agreement termination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ClinicalDataReviewPeriodForAgreementTermination</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementEnteredDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration and license agreement entered date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_CollaborationAndLicenseAgreementEnteredDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:dateStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementPeriodOfContract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative agreement period of contract.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_CollaborativeAgreementPeriodOfContract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LicenseAndCollaborationAgreementsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_LicenseAndCollaborationAgreementsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Initial fee received from collaboration or license agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_NonRefundableFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfAnnualMaintenancePaymentReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of annual maintenance payment received.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_NumberOfAnnualMaintenancePaymentReceived</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of molecules to be developed and commercialized as per collaborations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPrograms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of programs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_NumberOfPrograms</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PaymentReceivedOnCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total cumulative payments received to date under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_PaymentReceivedOnCollaborationAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ResearchObligationCompletionDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research obligation completion date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ResearchObligationCompletionDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearMonthItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ReviewPeriodByRegulatoryAuthority">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Review period by regulatory authority.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ReviewPeriodByRegulatoryAuthority</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontFeeAndParticipationRecognitionDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Upfront fee and participation recognition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_UpfrontFeeAndParticipationRecognitionDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearMonthItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPaymentRecognitionPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Upfront payment recognition period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_UpfrontPaymentRecognitionPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicensesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurement Financial Asset and Liabilities</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Financial assets and liabilities subject to fair value measurements
 were as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="38%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 December&#xA0;31, 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;Prices&#xA0;in<br />
 Active Markets<br />
 for<br />
 Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;Other<br />
 Observable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br />
 Unobservable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">90,434,435</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">90,434,435</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,046,974</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,046,974</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total Assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">116,886,259</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">116,886,259</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 December&#xA0;31, 2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;Prices&#xA0;in<br />
 Active Markets<br />
 for<br />
 Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;Other<br />
 Observable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br />
 Unobservable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,695,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,695,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29,047,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29,047,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total Assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,148,005</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,148,005</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Preferred stock warrant liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Preferred Stock Warrant Liability</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table provides a rollforward of the Company&#x2019;s
 preferred stock warrant liability, which was the only financial
 instrument measured at fair value on a recurring basis using
 significant unobservable inputs (Level 3) as defined in ASC
 820:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="82%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Balance at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total unrealized gains (losses) included in earnings</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(626,349</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Settlement of preferred stock warrants</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">679,296</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Balance at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Estimated Useful Lives</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Repairs and maintenance costs are expensed as incurred.
 Depreciation is computed using the straight-line method over the
 following estimated useful lives:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="51%"></td>
 <td valign="bottom" width="2%"></td>
 <td width="47%"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Computer equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Furniture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">10 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Laboratory and office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">5 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">Shorter of lease term or useful life</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Income (Loss) Per Common Share</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Basic and diluted income (loss) per common share is computed as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(260,835</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,361,755</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,717,120</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: undistributed earnings allocated to participating
 securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,361,755</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,717,120</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(260,835</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,025,602</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>Basic income (loss) per common share</b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.04</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(260,835</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,361,755</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,717,120</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,361,755</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,717,120</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(260,835</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,025,602</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Effect of dilutive securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Diluted weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,025,602</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>Diluted income (loss) per common share</b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.04</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Dilutive Securities Used In Calculation of Diluted Earnings Per Share</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following common stock equivalents were excluded from the
 calculation of diluted net income (loss) per share because their
 effect would be anti-dilutive:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series A-1 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series A-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series B Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series C Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series D Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Effect of Converted Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,189,920</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Warrants to purchase Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Stock Options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,313,970</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,249,702</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,885,417</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Summary of Significant Revenue [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Percentage of Customer Concentration</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table represents the percentage of all significant
 revenue earned in the periods indicated:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">
 <b>Year&#xA0;Ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2013&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2012&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2011&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Servier</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Pfizer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Government Agencies</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.5</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Eli Lilly</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">48.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Summary of Significant Accounts Receivable[Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Percentage of Customer Concentration</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following table represents the percentage of all significant
 accounts receivable:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2013&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2012&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">53.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Pfizer.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">45.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Eli Lilly</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Servier</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Government Agencies</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Property plant and equipment estimated useful life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a,b,bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=SL7498348-110258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19279-110258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6327-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6442-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of Minimum Future Lease Payments Payables</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Future minimum lease payments under noncancelable operating leases
 at December&#xA0;31, 2013 are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,651,421</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,310,884</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,410,210</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,512,517</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,780,398</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16,665,430</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.  Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6851643&amp;loc=d3e12069-110248<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6452660&amp;loc=d3e36991-112694<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 1,3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EIJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Lease Exit Liability - Changes in Lease Exit Liability (Detail) (Contract Termination [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Contract Termination [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrual Beginning Balance</a></td>
        <td class="nump">$ 10,073,939<span></span></td>
        <td class="nump">$ 10,607,499<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Principal payments</a></td>
        <td class="num">(628,769)<span></span></td>
        <td class="num">(533,560)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrual Ending Balance</a></td>
        <td class="nump">$ 9,445,170<span></span></td>
        <td class="nump">$ 10,073,939<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForRestructuring</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringCostAndReserveLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringReserve</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shared-Based Payments - Schedule of Stock-Based Compensation Expense (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump">$ 862,162<span></span></td>
        <td class="nump">$ 838,395<span></span></td>
        <td class="nump">$ 2,347,439<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and Development [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump">507,142<span></span></td>
        <td class="nump">471,809<span></span></td>
        <td class="nump">1,018,935<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and Administrative [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump">$ 355,020<span></span></td>
        <td class="nump">$ 366,586<span></span></td>
        <td class="nump">$ 1,328,504<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESDAK">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Series A-1 Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Series A-2 Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Series B Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Series C Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Series D-1 Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Series D-2 Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Treasury Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional Paid-In Capital [Member]</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit [Member]</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2010</a></td>
        <td class="num">$ (38,634,058)<span></span></td>
        <td class="nump">$ 268,748<span></span></td>
        <td class="nump">$ 73,646<span></span></td>
        <td class="nump">$ 714,012<span></span></td>
        <td class="nump">$ 1,109,522<span></span></td>
        <td class="nump">$ 144,462<span></span></td>
        <td class="nump">$ 452,538<span></span></td>
        <td class="nump">$ 10,007<span></span></td>
        <td class="num">$ (57,742)<span></span></td>
        <td class="nump">$ 149,202,027<span></span></td>
        <td class="num">$ (190,551,278)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning Balance, Shares at Dec. 31, 2010</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">26,874,792<span></span></td>
        <td class="nump">7,364,582<span></span></td>
        <td class="nump">71,401,237<span></span></td>
        <td class="nump">110,952,217<span></span></td>
        <td class="nump">14,446,227<span></span></td>
        <td class="nump">45,253,788<span></span></td>
        <td class="nump">1,000,681<span></span></td>
        <td class="nump">14,381<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">2,347,439<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,347,439<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock/convertible Series D-2 stock, net of offering costs</a></td>
        <td class="nump">12,014,815<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">184,274<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11,830,541<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock/convertible Series D-2 stock, net of offering costs, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,427,388<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
        <td class="nump">70,400<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">483<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">69,917<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises, Shares</a></td>
        <td class="nump">49,883<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">48,349<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="nump">6,717,120<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,717,120<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2011</a></td>
        <td class="num">(17,484,284)<span></span></td>
        <td class="nump">268,748<span></span></td>
        <td class="nump">73,646<span></span></td>
        <td class="nump">714,012<span></span></td>
        <td class="nump">1,109,522<span></span></td>
        <td class="nump">144,462<span></span></td>
        <td class="nump">636,812<span></span></td>
        <td class="nump">10,490<span></span></td>
        <td class="num">(57,742)<span></span></td>
        <td class="nump">163,449,924<span></span></td>
        <td class="num">(183,834,158)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, Shares at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">26,874,792<span></span></td>
        <td class="nump">7,364,582<span></span></td>
        <td class="nump">71,401,237<span></span></td>
        <td class="nump">110,952,217<span></span></td>
        <td class="nump">14,446,227<span></span></td>
        <td class="nump">63,681,176<span></span></td>
        <td class="nump">1,049,030<span></span></td>
        <td class="nump">14,381<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">838,395<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">838,395<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
        <td class="nump">46,826<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">499<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">46,327<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises, Shares</a></td>
        <td class="nump">863,176<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">49,884<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="nump">8,361,755<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,361,755<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2012</a></td>
        <td class="num">(8,237,308)<span></span></td>
        <td class="nump">268,748<span></span></td>
        <td class="nump">73,646<span></span></td>
        <td class="nump">714,012<span></span></td>
        <td class="nump">1,109,522<span></span></td>
        <td class="nump">144,462<span></span></td>
        <td class="nump">636,812<span></span></td>
        <td class="nump">10,989<span></span></td>
        <td class="num">(57,742)<span></span></td>
        <td class="nump">164,334,646<span></span></td>
        <td class="num">(175,472,403)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, Shares at Dec. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">26,874,792<span></span></td>
        <td class="nump">7,364,582<span></span></td>
        <td class="nump">71,401,237<span></span></td>
        <td class="nump">110,952,217<span></span></td>
        <td class="nump">14,446,227<span></span></td>
        <td class="nump">63,681,176<span></span></td>
        <td class="nump">1,098,914<span></span></td>
        <td class="nump">14,381<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">862,162<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">862,162<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock/convertible Series D-2 stock, net of offering costs</a></td>
        <td class="nump">83,622,358<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">57,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">83,564,858<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock/convertible Series D-2 stock, net of offering costs, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
        <td class="nump">1,860,591<span></span></td>
        <td class="num">(268,748)<span></span></td>
        <td class="num">(73,646)<span></span></td>
        <td class="num">(714,012)<span></span></td>
        <td class="num">(1,109,522)<span></span></td>
        <td class="num">(144,462)<span></span></td>
        <td class="num">(636,812)<span></span></td>
        <td class="nump">170,606<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,637,187<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(26,874,792)<span></span></td>
        <td class="num">(7,364,582)<span></span></td>
        <td class="num">(71,401,237)<span></span></td>
        <td class="num">(110,952,217)<span></span></td>
        <td class="num">(14,446,227)<span></span></td>
        <td class="num">(63,681,176)<span></span></td>
        <td class="nump">17,060,634<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
        <td class="nump">1,067,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,680<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,054,820<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises, Shares</a></td>
        <td class="nump">1,268,049<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,268,049<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="num">(260,835)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(260,835)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2013</a></td>
        <td class="nump">$ 78,914,468<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 251,775<span></span></td>
        <td class="num">$ (57,742)<span></span></td>
        <td class="nump">$ 254,453,673<span></span></td>
        <td class="num">$ (175,733,238)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, Shares at Dec. 31, 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,177,597<span></span></td>
        <td class="nump">14,381<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-30)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gross value of stock issued during the period upon the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Deficit)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit)</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>4. Stockholders&#x2019; Equity (Deficit)</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 During 2002 and 2003, the Company issued a total of 34,239,374
 shares of Series A-1 and Series A-2 convertible preferred stock
 (&#x201C;Series A preferred stock&#x201D;) for $1.00 per share
 resulting in net proceeds of approximately $34.0 million.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 On October&#xA0;12, 2004, the Company entered into a series of
 transactions raising $30.3 million, net of related offering costs
 of approximately $238,000, from the sale of 71,401,237 shares of
 its Series B convertible preferred stock (&#x201C;Series B preferred
 stock&#x201D;). In connection with the Series B preferred stock
 offering, 13,604,016 shares of common stock were allocated to
 holders of Series&#xA0;A-1 preferred stock as an anti-dilution
 measure.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 On May&#xA0;16, 2006, the Company raised $44.9 million, net of
 related offering costs of $101,246, from the sale of 110,952,217
 shares of its Series C convertible preferred stock (&#x201C;Series C
 preferred stock&#x201D;). In connection with the Series C preferred
 stock offering, 10,003,300 shares of common stock were allocated to
 holders of Series B preferred stock as an anti-dilution
 measure.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 On July&#xA0;16, 2008, the Company issued 12,466,039 shares of its
 Series D convertible preferred stock (&#x201C;Series&#xA0;D
 preferred stock&#x201D;) in exchange for all of the outstanding
 capital stock and convertible notes payable of Raven
 Biotechnologies, Inc. (&#x201C;Raven&#x201D;). Subsequently, in March
 2011 a settlement was reached with the former Raven stockholders
 bringing the total Series D preferred stock issued in connection
 with the Raven acquisition to 14,446,227 shares.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 On September&#xA0;19, 2008, the Company raised $24.8 million, net
 of related offering costs of $156,788, from the sale of 38,337,678
 shares of its Series D-2 convertible preferred stock (&#x201C;Series
 D-2 preferred stock&#x201D;). The Company also issued preferred
 stock warrants for the purchase of 2,875,327 shares of Series D-2
 preferred stock. The preferred stock warrants were exercisable at
 any time prior to September&#xA0;2018, but expired upon an IPO, and
 had a stated exercise price of $0.65 per warrant. On May&#xA0;16,
 2010, the Company exercised a put notice to Eli Lilly in accordance
 with the Series D-2 preferred stock purchase agreement, resulting
 in the issuance of 6,916,110 shares of Series D-2 preferred stock
 and a warrant to purchase 518,708 additional shares of Series D-2
 preferred stock. On January&#xA0;11, 2011, the Company raised gross
 proceeds of $12.0 million from the sale of 18,427,388&#xA0;shares
 of its Series D-2 preferred stock. Issuance costs associated with
 the sale were not material.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Due to certain provisions in the Series D-2 convertible preferred
 stock warrant agreement, these warrants were required to be
 classified as a liability. Management believed that the
 circumstances requiring cash settlement of the award were remote.
 The Series D-2 preferred stock warrant liability was recorded at
 fair value and has been adjusted to fair value at the end of each
 reporting period using the Option-Pricing Method, with changes in
 value recorded as &#x201C;Other income (expense)&#x201D; in the
 accompanying consolidated statements of operations and
 comprehensive income (loss). Prior to the Company&#x2019;s IPO in
 October 2013, all the preferred stock warrants were exercised and
 subsequently were converted into shares of common stock in
 connection with the IPO.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Dividends were noncumulative and accrued on the Series A-1, Series
 A-2, Series B, Series C, Series D and Series&#xA0;D-2 preferred
 stock at a rate of $0.08, $0.0341, $0.0324 and $0.0522 per annum,
 respectively, and were payable when and as declared by the Board of
 Directors. Dividends had to be declared so that the Series A,
 Series&#xA0;B, Series C and Series D preferred stock were paid in
 like-kind and participated equally to those of the Series&#xA0;D-2
 preferred and common stock. No dividends had been declared prior to
 the conversion of the preferred stock to common stock in connection
 with the IPO.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company&#x2019;s Series A-1, Series A-2, Series B, Series C,
 Series D and Series D-2 preferred stock were initially convertible
 into 1.506, 1.00, 1.14, 1.00, 1.00 and 1.00 shares, respectively,
 of common stock at the option of the holder. The conversion ratio
 of certain series of preferred stock was subject to change in the
 event specified dilutive transactions occurred, which included the
 Company&#x2019;s IPO. There were no anti-dilution protections for
 the Series A-2 preferred stock and no adjustment to the Series A-1
 preferred stock conversion price was to be made if a common stock
 issuance was at a price per share greater than the conversion price
 of the Series C preferred stock. Upon consummation of the
 Company&#x2019;s IPO in October 2013, all outstanding shares of
 preferred stock automatically converted to shares of the
 Company&#x2019;s common stock at the applicable conversion ratios
 then in effect. The conversion price was $12.39, $18.77, $6.95,
 $7.70, $12.20 and $12.20 for each share of Series A-1, A-2, Series
 B, Series C, Series D and Series D-2 convertible preferred stock,
 respectively.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 On October&#xA0;16, 2013, the Company completed its IPO, in which
 5,000,000 shares of the Company&#x2019;s common stock were sold at a
 price of $16.00 per share. Additionally, the underwriters of the
 Company&#x2019;s IPO exercised the full amount of their
 over-allotment option resulting in the sale of an additional
 750,000 shares of the Company&#x2019;s common stock at a price of
 $16.00 per share. The Company received net proceeds of $83.8
 million from the IPO, net of underwriting discounts and commissions
 and other offering expenses. Upon consummation of the IPO, all
 outstanding shares of preferred stock automatically converted to
 common stock at the applicable conversion ratios then in
 effect.</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In connection with preparing for its IPO in October 2013, the
 Company&#x2019;s Board of Directors and stockholders approved a
 1-for-18.7739 reverse stock split of the Company&#x2019;s common
 stock. The reverse stock split became effective on
 September&#xA0;26, 2013. All share and per share amounts in the
 consolidated financial statements and notes thereto have been
 retroactively adjusted for all periods presented to give effect to
 this reverse stock split, including reclassifying an amount equal
 to the reduction in par value of common stock to additional paid-in
 capital. In addition, in September 2013, the Company&#x2019;s Board
 of Directors and stockholders approved an amendment of the
 Company&#x2019;s certificate of incorporation to, among other
 things, change the definition of a designated public offering to
 remove the per share price requirement. The amended and restated
 certificate of incorporation also changed the authorized number of
 shares of common stock from 425,000,000 to 125,000,000, and
 authorized 5,000,000 shares of undesignated preferred stock with a
 par value of $0.01 per share. There were no shares of undesignated
 preferred stock issued or outstanding as of December&#xA0;31,
 2013.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Quarterly Financial Information (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Company's Consolidated Quarterly Results of Operations</a></td>
        <td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="54%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>1<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">st</sup>&#xA0;Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">nd</sup>&#xA0;Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>3<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">rd</sup>&#xA0;Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>4<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">th</sup>&#xA0;Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(in thousands,
 except per share data)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>2013</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,598</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,299</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">20,232</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,366</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(294</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,604</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,205</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss) per share, basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.93</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.24</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.14</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss) per share, diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.93</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.24</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.01</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>2012</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">20,510</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,435</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16,082</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,799</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,320</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,546</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,601</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,105</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss) per share, basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(1.92</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net income (loss) per share, diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(1.92</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25249566&amp;loc=d3e1280-108306<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>269</ContextCount>
  <ElementCount>306</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>88</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock</Role>
      <ShortName>Property and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Stockholders' Equity (Deficit)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Shared-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Shared-Based Payments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Lease Exit Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock</Role>
      <ShortName>Lease Exit Liability</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Product Milestone Payments and Royalty Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock</Role>
      <ShortName>Product Milestone Payments and Royalty Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock</Role>
      <ShortName>Employee Benefit Plan</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Quarterly Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock</Role>
      <ShortName>Quarterly Financial Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Shared-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Shared-Based Payments (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Lease Exit Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables</Role>
      <ShortName>Lease Exit Liability (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Quarterly Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables</Role>
      <ShortName>Quarterly Financial Information (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Organization and Nature of Operations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation</Role>
      <ShortName>Organization and Nature of Operations - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Summary of Significant Accounting Policies - Summary of Preferred Stock Warrant Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Preferred Stock Warrant Liability (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Summary of Significant Accounting Policies - Summary of Percentage of Significant Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Percentage of Significant Revenue (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Summary of Significant Accounting Policies - Summary of Significant Accounts Receivable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Significant Accounts Receivable (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Common Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShare</Role>
      <ShortName>Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Common Share (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities Used In Calculation of Diluted Earnings Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesUsedInCalculationOfDilutedEarningsPerShare</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Dilutive Securities Used In Calculation of Diluted Earnings Per Share (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>139 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformation</Role>
      <ShortName>Stockholders' Equity (Deficit) - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>141 - Disclosure - Shared-Based Payments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsAdditionalInformation</Role>
      <ShortName>Shared-Based Payments - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>142 - Disclosure - Shared-Based Payments - Schedule of Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense</Role>
      <ShortName>Shared-Based Payments - Schedule of Stock-Based Compensation Expense (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>143 - Disclosure - Shared-Based Payments - Schedule of Fair Value Option Award Estimated on the Date of Grant Using the Black-Scholes Option-Pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel</Role>
      <ShortName>Shared-Based Payments - Schedule of Fair Value Option Award Estimated on the Date of Grant Using the Black-Scholes Option-Pricing Model (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>144 - Disclosure - Shared-Based Payments - Schedule of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity</Role>
      <ShortName>Shared-Based Payments - Schedule of Stock Option Activity (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>145 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>146 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfTheCompanysDeferredTaxAssetsLiabilities</Role>
      <ShortName>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>147 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefit</Role>
      <ShortName>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>148 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTheBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefits</Role>
      <ShortName>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>149 - Disclosure - Lease Exit Liability - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation</Role>
      <ShortName>Lease Exit Liability - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>150 - Disclosure - Lease Exit Liability - Changes in Lease Exit Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability</Role>
      <ShortName>Lease Exit Liability - Changes in Lease Exit Liability (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>151 - Disclosure - Lease Exit Liability - Future Principal Payments under Lease Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement</Role>
      <ShortName>Lease Exit Liability - Future Principal Payments under Lease Agreement (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>152 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>153 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>154 - Disclosure - Commitments and Contingencies - Schedule of Minimum Future Lease Payments Receivable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable</Role>
      <ShortName>Commitments and Contingencies - Schedule of Minimum Future Lease Payments Receivable (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>155 - Disclosure - Product Milestone Payments and Royalty Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation</Role>
      <ShortName>Product Milestone Payments and Royalty Agreements - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>156 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>157 - Disclosure - Quarterly Financial Information - Company's Consolidated Quarterly Results of Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureQuarterlyFinancialInformationCompanysConsolidatedQuarterlyResultsOfOperations</Role>
      <ShortName>Quarterly Financial Information - Company's Consolidated Quarterly Results of Operations (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>158 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_DeferredRevenue had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_DeferredRevenueCurrent had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_DeferredRevenueNoncurrent had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_LicensesRevenue had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_StockIssuedDuringPeriodValueNewIssues had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">'Monetary' elements on report '149 - Disclosure - Lease Exit Liability - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '152 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 103 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 107 - Statement - Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>mgnx-20131231.xml</File>
    <File>mgnx-20131231.xsd</File>
    <File>mgnx-20131231_cal.xml</File>
    <File>mgnx-20131231_def.xml</File>
    <File>mgnx-20131231_lab.xml</File>
    <File>mgnx-20131231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
        <td class="nump">$ 1.2<span></span></td>
        <td class="nump">$ 1.0<span></span></td>
        <td class="nump">$ 1.1<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
        <td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Basis of Presentation and Principles of
 Consolidation</i></b></p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The consolidated financial statements include the accounts of
 MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics
 West, Inc. All intercompany accounts and transactions have been
 eliminated in consolidation. The Company currently operates in one
 operating segment. Operating segments are defined as components of
 an enterprise about which separate discrete information is
 available for the chief operating decision maker, or decision
 making group, in deciding how to allocate resources and assessing
 performance. The Company views its operations and manages its
 business in one segment, which is developing monoclonal
 antibody-based therapeutics for cancer, autoimmune and infectious
 diseases.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Use of Estimates</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The preparation of the financial statements in accordance with
 generally accepted accounting principles (&#x201C;GAAP&#x201D;)
 requires the Company to make estimates and judgments in certain
 circumstances that affect the reported amounts of assets,
 liabilities, revenues and expenses, and related disclosure of
 contingent assets and liabilities. In preparing these consolidated
 financial statements, management has made its best estimates and
 judgments of certain amounts included in the financial statements,
 giving due consideration to materiality. On an ongoing basis, the
 Company evaluates its estimates, including those related to revenue
 recognition, fair values of assets, convertible preferred stock and
 common stock, preferred stock warrant liability, income taxes,
 pre-clinical study and clinical trial accruals and other
 contingencies. Management bases its estimates on historical
 experience or on various other assumptions that it believes to be
 reasonable under the circumstances. Actual results could differ
 from these estimates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In addition, prior to the Company&#x2019;s IPO in October 2013, the
 Company utilized estimates and assumptions in determining the fair
 value of its common stock. The Company granted stock options at
 exercise prices not less than the fair value of its common stock as
 determined by the Board of Directors, with input from management.
 Management used contemporaneous valuations in estimating the fair
 value of its common stock. The board of directors determined the
 estimated fair value of the common stock based on a number of
 objective and subjective factors, including external market
 considerations affecting the biotechnology industry and the
 historic prices at which the Company sold shares of its preferred
 stock.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Cash and Cash Equivalents</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company considers all investments in highly liquid financial
 instruments with an original maturity of three months or less at
 the date of purchase to be cash equivalents. Cash and cash
 equivalents consist of certificates of deposit and investments in
 money market funds with commercial banks and financial
 institutions. Cash equivalents are stated at amortized cost, plus
 accrued interest, which approximates fair value.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Accounts Receivable</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Accounts receivable that management has the intent and ability to
 collect are reported in the consolidated balance sheets at
 outstanding amounts, less an allowance for doubtful accounts. The
 Company writes off uncollectible receivables when the likelihood of
 collection is remote.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company evaluates the collectability of accounts receivable on
 a regular basis. The allowance, if any, is based upon various
 factors including the financial condition and payment history of
 customers, an overall review of collections experience on other
 accounts and economic factors or events expected to affect future
 collections experience. No allowance was recorded as of
 December&#xA0;31, 2013 or 2012, as the Company has a history of
 collecting on all outstanding accounts.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Restricted Cash</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company is required to maintain certificates of deposit that
 serve as collateral for various operating leases and corporate
 credit card accounts. Amounts classified as restricted cash on the
 consolidated balance sheets are $404,850 at December&#xA0;31, 2013
 and 2012.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Fair Value of Financial Instruments</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The fair market values of the financial instruments included in the
 financial statements, which include cash equivalents and money
 market accounts, approximate their carrying values at
 December&#xA0;31, 2013 and 2012, due to their short-term
 maturities. The Company accounts for recurring and non-recurring
 fair value measurements in accordance with the Financial Accounting
 Standards Board (&#x201C;FASB&#x201D;) Accounting Standards
 Codification (&#x201C;ASC&#x201D;) 820, <i>Fair Value Measurements
 and Disclosures</i> (&#x201C;ASC 820&#x201D;). ASC 820 defines fair
 value, establishes a fair value hierarchy for assets and
 liabilities measured at fair value, and requires expanded
 disclosures about fair value measurements. The ASC 820 hierarchy
 ranks the quality of reliability of inputs, or assumptions, used in
 the determination of fair value and requires assets and liabilities
 carried at fair value to be classified and disclosed in one of the
 following three categories:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 1&#x2014;Fair value is
 determined by using unadjusted quoted prices that are available in
 active markets for identical assets and liabilities.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 2&#x2014;Fair value is
 determined by using inputs other than Level 1 quoted prices that
 are directly or indirectly observable. Inputs can include quoted
 prices for similar assets and liabilities in active markets or
 quoted prices for identical assets and liabilities in inactive
 markets. Related inputs can also include those used in valuation or
 other pricing models, such as interest rates and yield curves that
 can be corroborated by observable market data.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 3&#x2014;Fair value is
 determined by inputs that are unobservable and not corroborated by
 market data. Use of these inputs involves significant and
 subjective judgments to be made by a reporting entity&#xA0;&#x2013;
 e.g., determining an appropriate adjustment to a discount factor
 for illiquidity associated with a given security.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The Company evaluates financial assets and liabilities subject to
 fair value measurements on a recurring basis to determine the
 appropriate level at which to classify them each reporting period.
 This determination requires the Company to make subjective
 judgments as to the significance of inputs used in determining fair
 value and where such inputs lie within the ASC 820 hierarchy.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Financial assets and liabilities subject to fair value measurements
 were as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="38%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 December&#xA0;31, 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;Prices&#xA0;in<br />
 Active Markets<br />
 for<br />
 Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;Other<br />
 Observable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br />
 Unobservable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">90,434,435</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">90,434,435</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,046,974</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,046,974</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total Assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">116,886,259</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">116,886,259</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 December&#xA0;31, 2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;Prices&#xA0;in<br />
 Active Markets<br />
 for<br />
 Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;Other<br />
 Observable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br />
 Unobservable<br />
 Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,695,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,695,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29,047,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29,047,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total Assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,148,005</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,148,005</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Preferred stock warrant liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of December&#xA0;31, 2012, the Company transferred its money
 market funds from Level 2 to Level 1 because the inputs are now
 based upon a quoted market price.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company&#x2019;s Level 1 securities primarily consist of
 restricted cash, cash equivalents and money market funds. The
 Company determines the estimated fair value for its Level 1
 securities using quoted (unadjusted) prices for identical assets or
 liabilities in active markets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company determines the estimated fair value for its Level 2
 securities using the following methods: quoted prices for similar
 assets/liabilities in active markets, inputs other than quoted
 prices that are observable for the asset/liability (e.g., interest
 rates, yield curves volatilities, default rates, etc.) and inputs
 that are derived principally from or corroborated by other
 observable market data.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table provides a rollforward of the Company&#x2019;s
 preferred stock warrant liability, which was the only financial
 instrument measured at fair value on a recurring basis using
 significant unobservable inputs (Level 3) as defined in ASC
 820:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="82%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Balance at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total unrealized gains (losses) included in earnings</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(626,349</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Settlement of preferred stock warrants</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">679,296</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Balance at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In order to estimate the fair value of the preferred stock purchase
 warrants, the business enterprise value was established based on a
 discounted cash flow model (income approach). The Company utilized
 an option pricing method to value the shares using a contingent
 claims analysis, which applies a series of call options whose
 inputs reflect the liquidation preferences and conversion behavior
 of the different classes of equity. After the equity value of the
 business enterprise was determined, the total equity value is
 allocated to the various equity instruments such as preferred
 stock, stock options and preferred stock purchase warrants. Key
 management estimates relate to the time period to liquidation and
 conversion behavior of a particular class of stockholders. The
 business enterprise value includes assumptions related to product
 approval, market penetration and costs to develop the product.
 Significant changes to these assumptions would result in
 increases/decreases to the fair value of the outstanding
 warrants.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The total unrealized gains (losses) on the preferred stock warrants
 included in earnings is included as a component of other income
 (expense) in the consolidated statement of operations and
 comprehensive income. Immediately prior to the Company&#x2019;s IPO
 in October 2013, all the preferred stock warrants were exercised
 and converted into shares of Series D-2 preferred stock, which were
 subsequently converted to common stock.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Concentration of Credit Risk</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Substantially all of the Company&#x2019;s cash and cash equivalents
 are maintained with major financial institutions in the United
 States. Deposits held with banks may exceed the amount of insurance
 provided on such deposits. Generally, these deposits may be
 redeemed upon demand and, therefore, bear minimal risk.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Financial instruments that potentially subject the Company to
 concentrations of credit risk consist principally of cash and cash
 equivalents, and accounts receivable. The counterparties are
 various corporations, financial institutions and government
 agencies of high credit standing.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For the years ended December&#xA0;31, 2013, 2012 and 2011, all of
 the Company&#x2019;s grant revenue was related to contracts and
 research grants received from U.S. government agencies.
 Collaborations with Les Laboratoires Servier and Institut de
 Recherches Servier (collectively, &#x201C;Servier&#x201D;),
 Boehringer Ingelheim GmbH (&#x201C;Boehringer&#x201D;), Gilead
 Sciences, Inc. (&#x201C;Gilead&#x201D;), Pfizer, Inc.
 (&#x201C;Pfizer&#x201D;) and Eli Lilly&#xA0;&amp; Co. (&#x201C;Eli
 Lilly&#x201D;) account for all other revenue. All outstanding
 receivables are due from the Company&#x2019;s collaborators and U.S.
 government agencies.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table represents the percentage of all significant
 revenue earned in the periods indicated:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">
 <b>Year&#xA0;Ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2013&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2012&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2011&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Servier</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Pfizer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Government Agencies</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.5</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Eli Lilly</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">48.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following table represents the percentage of all significant
 accounts receivable:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2013&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2012&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">53.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Pfizer.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">45.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Eli Lilly</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Servier</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Government Agencies</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Property and Equipment</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Property and equipment are stated at cost. Upon retirement or sale,
 the cost of assets disposed of and the related accumulated
 depreciation are removed from the accounts and any resulting gain
 or loss is credited or charged to operations. Repairs and
 maintenance costs are expensed as incurred. Depreciation is
 computed using the straight-line method over the following
 estimated useful lives:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="51%"></td>
 <td valign="bottom" width="2%"></td>
 <td width="47%"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Computer equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Furniture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">10 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Laboratory and office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">5 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">Shorter of lease term or useful life</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Impairment of Long-Lived Assets</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company assesses the recoverability of its long-lived assets in
 accordance with the provisions of ASC&#xA0;360, <i>Property, Plant
 and Equipment</i>. ASC 360 requires that long-lived assets be
 reviewed for impairment whenever events or changes in circumstances
 indicate that the carrying amount of an asset may not be
 recoverable. Recoverability of the long-lived asset is measured by
 a comparison of the carrying amount of the asset to future
 undiscounted net cash flows expected to be generated by the asset
 or asset group. If carrying value exceeds the sum of undiscounted
 cash flows, the Company then determines the fair value of the
 underlying asset group. Any impairment to be recognized is measured
 by the amount by which the carrying amount of the asset group
 exceeds the estimated fair value of the asset group. Assets to be
 disposed of are reported at the lower of the carrying amount or
 fair value, less costs to sell. As of December&#xA0;31, 2013 and
 2012, the Company determined that there were no impaired assets and
 had no assets held-for-sale.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Income Taxes</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Deferred tax assets and liabilities are determined based on
 differences between the financial reporting and tax basis of assets
 and liabilities and are measured using the enacted tax rates and
 laws that are expected to be in effect when the differences are
 expected to reverse. The effect on deferred tax assets and
 liabilities of a change in tax rates is recognized as income in the
 period that such tax rate changes are enacted. The measurement of a
 deferred tax asset is reduced, if necessary, by a valuation
 allowance if it is more likely than not that some portion or all of
 the deferred tax asset will not be realized. Financial statement
 recognition of a tax position taken or expected to be taken in a
 tax return is determined based on a more-likely-than-not threshold
 of that position being sustained. If the tax position meets this
 threshold, the benefit to be recognized is measured as the largest
 amount that is more than 50% likely to be realized upon ultimate
 settlement. The Company&#x2019;s policy is to record interest and
 penalties related to uncertain tax positions as a component of
 income tax expense.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenues</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Revenues</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 6pt">
 <i>Revenue Recognition</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company enters into collaboration and license agreements with
 collaborators for the development of monoclonal antibody-based
 therapeutics to treat cancer and other complex diseases. The terms
 of these agreements contain multiple deliverables which may include
 (i)&#xA0;licenses, or options to obtain licenses, to the
 Company&#x2019;s technological platforms, such as its Fc
 Optimization and Dual-Affinity Re-Targeting (&#x201C;DART&#x201D;)
 technologies, (ii)&#xA0;rights to future technological
 improvements, (iii)&#xA0;research and development activities to be
 performed on behalf of the collaborator or as part of the
 collaboration, and (iv)&#xA0;the manufacture of pre-clinical or
 clinical materials for the collaborator. Payments to the Company
 under these agreements may include nonrefundable license fees,
 option fees, exercise fees, payments for research and development
 activities, payments for the manufacture of pre-clinical or
 clinical materials, license maintenance payments, payments based
 upon the achievement of certain milestones and royalties on product
 sales. Other benefits to the Company of these agreements include
 the right to sell products resulting from the collaborative efforts
 of the parties in specific geographic territories. The Company
 follows the provisions of the FASB ASC Topic 605-25, <i>Revenue
 Recognition&#xA0;&#x2013;&#xA0;Multiple-Element Arrangements</i>,
 and ASC Topic 605-28, <i>Revenue Recognition&#x2013;Milestone
 Method</i>, in accounting for these agreements. In order to account
 for these agreements, the Company must identify the deliverables
 included within the agreement and evaluate which deliverables
 represent separate units of accounting based on the achievement of
 certain criteria, including whether the delivered element has
 stand-alone value to the collaborator. The consideration received
 is allocated among the separate units of accounting, and the
 applicable revenue recognition criteria are applied to each of the
 separate units.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For the periods presented, the Company had the following two types
 of agreements with the parties identified below: 1) exclusive
 development and commercialization licenses to use the
 Company&#x2019;s technology and/or certain other intellectual
 property to develop compounds against specified targets (referred
 to herein as exclusive licenses); and 2) Option/research agreements
 to secure on established terms, development and commercialization
 licenses to anticancer and other therapeutic product candidates to
 collaborator selected targets developed by the Company during an
 option period (referred to herein as right-to-develop
 agreements).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 There are no performance, cancellation, termination or refund
 provisions in any of the arrangements that contain material
 financial consequences to the Company.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt">
 <i>Exclusive Licenses</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The deliverables under an exclusive license agreement generally
 include the exclusive license to the Company&#x2019;s DART
 technology with respect to a specified antigen target, and may also
 include deliverables related to rights to future technological
 improvements, research and pre-clinical development activities to
 be performed on behalf of the collaborator. In some cases the
 Company may have an option to participate in the co-development of
 product candidates that result from such agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Generally, exclusive license agreements contain nonrefundable terms
 for payments and, depending on the terms of the agreement, provide
 that the Company will (i)&#xA0;at the collaborator&#x2019;s request,
 provide research and pre-clinical development services at
 negotiated prices which are generally consistent with what other
 third parties would charge, (ii)&#xA0;earn payments upon the
 achievement of certain milestones, (iii)&#xA0;earn royalty
 payments, and (iv)&#xA0;in some cases grant the Company an option
 to participate in the development and commercialization of products
 that result from such agreements. Royalty rates may vary over the
 royalty term depending on the Company&#x2019;s intellectual property
 rights and whether the Company exercises any co-development and
 co-commercialization rights. The Company may provide technical
 assistance and share any technology improvements with its
 collaborators during the term of the collaboration agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company does not directly control when any collaborator will
 achieve milestones or become liable for royalty payments.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In determining the units of accounting, management evaluates
 whether the exclusive license has stand-alone value from the
 undelivered elements to the collaborator based on the consideration
 of the relevant facts and circumstances for each arrangement.
 Factors considered in this determination include the research and
 development capabilities of the partner and the availability of
 technology platform and product research expertise in the general
 marketplace. If the Company concludes that the license has
 stand-alone value and therefore will be accounted for as a separate
 unit of accounting, the Company then determines the estimated
 selling prices of the license and all other units of accounting
 based on market conditions, similar arrangements entered into by
 third parties, and entity-specific factors such as the terms of the
 Company&#x2019;s previous collaboration agreements, recent
 pre-clinical and clinical testing results of therapeutic product
 candidates that use the Company&#x2019;s technology platforms, the
 Company&#x2019;s pricing practices and pricing objectives, the
 likelihood that technological improvements will be made, the
 likelihood that technological improvements made will be used by the
 Company&#x2019;s collaborators and the nature of the research
 services to be performed on behalf of its collaborators and market
 rates for similar services.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Upfront payments on exclusive licenses are deferred if facts and
 circumstances dictate that the license does not have stand-alone
 value. Prior to the adoption of Accounting Standards Update
 (&#x201C;ASU&#x201D;) No.&#xA0;2009-13, <i>Revenue Arrangements with
 Multiple Deliverables</i>, on January&#xA0;1, 2011, the Company
 determined that its licenses lacked stand-alone value because it
 did not have vendor-specific objective evidence of selling price
 (&#x201C;VSOE&#x201D;), and were combined with other elements of the
 arrangement and any amounts associated with the license were
 deferred and amortized over a certain period, which the Company
 refers to as the Company&#x2019;s period of substantial involvement.
 In making the determination of the length of the period over which
 to defer revenue for contracts entered into prior to the adoption
 of ASU No.&#xA0;2009-13, significant judgment and estimation is
 used by the Company and can have an impact on the amount of revenue
 recognized in a given period. Historically, the Company&#x2019;s
 involvement with the development of a collaborator&#x2019;s product
 candidate has been significant at the early stages of development,
 and lessens as it progresses into clinical trials. Accordingly, the
 Company generally estimates this period of substantial involvement
 to begin at the inception of the collaboration agreement and
 conclude at the end of the Company&#x2019;s substantial involvement.
 ASU No.&#xA0;2009-13 amends the criteria for separating and
 allocating consideration in a multiple element arrangement by
 modifying the fair value requirements for revenue recognition and
 eliminating the use of the residual value method. The selling
 prices of deliverables under an arrangement may be derived using
 third-party evidence (&#x201C;TPE&#x201D;), or a best estimate of
 selling price (&#x201C;BESP&#x201D;), if VSOE is not available. The
 objective of BESP is to determine the price at which the Company
 would transact a sale if the element within the license agreement
 was sold on a standalone basis. Establishing BESP involves
 management&#x2019;s judgment and considers multiple factors,
 including market conditions and company-specific factors, including
 those factors contemplated in negotiating the agreements, as well
 as internally developed models that include assumptions related to
 market opportunity, discounted cash flows, estimated development
 costs, probability of success and the time needed to commercialize
 a product candidate pursuant to the license. In validating the
 BESP, management considers whether changes in key assumptions used
 to determine the BESP will have a significant effect on the
 allocation of the arrangement consideration between the multiple
 deliverables. Deliverables under the arrangement are separate units
 of accounting if (i)&#xA0;the delivered item has value to the
 customer on a standalone basis and (ii)&#xA0;if the arrangement
 includes a general right of return relative to the delivered item,
 delivery or performance of the undelivered item is considered
 probable and substantially within the Company&#x2019;s control. The
 arrangement consideration that is fixed or determinable at the
 inception of the arrangement is allocated to the separate units of
 accounting based on their relative selling prices. The appropriate
 revenue recognition model is applied to each element and revenue is
 accordingly recognized as each element is delivered. Management
 exercises significant judgment in determining whether a deliverable
 is a separate unit of accounting.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In determining the separate units of accounting, the Company
 evaluated whether the exclusive license had standalone value to the
 collaborator based on consideration of the relevant facts and
 circumstances for each arrangement. Factors considered in this
 determination included the research and development capabilities of
 the collaborator and the availability of relevant research
 expertise in the marketplace. In addition, the Company considered
 whether or not (i)&#xA0;the collaborator could use the license for
 its intended purpose without the receipt of the remaining
 deliverables, (ii)&#xA0;the value of the license was dependent on
 the undelivered items and (iii)&#xA0;the collaborator or other
 vendors could provide the undelivered items.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company reassesses its periods of substantial involvement over
 which the Company amortizes its upfront license fees and makes
 adjustments as appropriate. In the event a collaborator elects to
 discontinue development of a specific product candidate under a
 single target license, but retains its right to use the
 Company&#x2019;s technology to develop an alternative product
 candidate to the same target or a target substitute, the Company
 would cease amortization of any remaining portion of the upfront
 fee until there is substantial pre-clinical activity on another
 product candidate and its remaining period of substantial
 involvement can be estimated. In the event that a single target
 license were to be terminated, the Company would recognize as
 revenue any portion of the upfront fee that had not previously been
 recorded as revenue, but was classified as deferred revenue, at the
 date of such termination or through the remaining substantial
 involvement in the wind down of the agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Upfront payments on exclusive licenses may be recognized upon
 delivery of the license if facts and circumstances dictate that the
 license has stand-alone value from the undelivered elements, which
 generally include rights to future technological improvements,
 research services and the manufacture of pre-clinical and clinical
 materials.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company recognizes revenue related to research and pre-clinical
 development services that represent separate units of accounting as
 they are performed, as long as there is persuasive evidence of an
 arrangement, the fee is fixed or determinable, and collection of
 the related receivable is probable. The Company recognizes revenue
 related to the rights to future technological improvements over the
 estimated term of the applicable license.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company typically performs research activities and pre-clinical
 development services, including generating and engineering product
 candidates, on behalf of its licensees during the early evaluation
 and pre-clinical testing stages of drug development under its
 exclusive licenses. The Company records amounts received for
 research materials produced or services performed as revenue from
 collaborative research.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The Company&#x2019;s license agreements have milestone payments
 which for reporting purposes are aggregated into three categories:
 (i)&#xA0;development milestones, (ii)&#xA0;regulatory milestones,
 and (iii)&#xA0;sales milestones. Development milestones are
 typically payable when a product candidate initiates or advances
 into different clinical trial phases. Regulatory milestones are
 typically payable upon submission for marketing approval with the
 U.S. Food and Drug Administration (&#x201C;FDA&#x201D;) or other
 countries&#x2019; regulatory authorities or on receipt of actual
 marketing approvals for the compound or for additional indications.
 Sales milestones are typically payable when annual sales reach
 certain levels.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 At the inception of each agreement that includes milestone
 payments, the Company evaluates whether each milestone is
 substantive and at risk to both parties on the basis of the
 contingent nature of the milestone. This evaluation includes an
 assessment of whether (a)&#xA0;the consideration is commensurate
 with either (1)&#xA0;the entity&#x2019;s performance to achieve the
 milestone, or (2)&#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&#x2019;s performance to achieve the milestone,
 (b)&#xA0;the consideration relates solely to past performance and
 (c)&#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. The Company
 evaluates factors such as the scientific, regulatory, commercial
 and other risks that must be overcome to achieve the respective
 milestone, the level of effort and investment required to achieve
 the respective milestone and whether the milestone consideration is
 reasonable relative to all deliverables and payment terms in the
 arrangement in making this assessment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Non-refundable development and regulatory milestones that are
 expected to be achieved as a result of the Company&#x2019;s efforts
 during the period of substantial involvement are considered
 substantive and are recognized as revenue upon the achievement of
 the milestone, assuming all other revenue recognition criteria are
 met. Milestones that are not considered substantive because the
 Company does not contribute effort to the achievement of such
 milestones are generally achieved after the period of substantial
 involvement and are recognized as revenue upon achievement of the
 milestone, as there are no undelivered elements remaining and no
 continuing performance obligations, assuming all other revenue
 recognition criteria are met.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt">
 <i>Right-to-Develop Agreements</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company&#x2019;s right-to-develop agreements provide
 collaborators with an exclusive option to obtain licenses to
 develop and commercialize in specified geographic territories
 product candidates developed by the Company under agreed upon
 research and pre-clinical development product programs. The product
 candidates resulting from each program are all directed to a
 specific target selected by the collaborator. Under these
 agreements, fees may be due to the Company (i)&#xA0;at the
 inception of the arrangement (referred to as &#x201C;upfront&#x201D;
 fees or payments), (ii)&#xA0;the selection of a target for a
 program, (iii)&#xA0;upon the exercise of an option to acquire a
 development and commercialization license (referred to as exercise
 fees or payments earned) for a program, or (iv)&#xA0;some
 combination of all of these fees.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The accounting for right-to-develop agreements is dependent on the
 nature of the options granted to the collaborator. Options are
 considered substantive if, at the inception of a right-to-develop
 agreement, the Company is at risk as to whether the collaborator
 will choose to exercise the options to secure development and
 commercialization licenses. Factors that are considered in
 evaluating whether options are substantive include the overall
 objective of the arrangement, the benefit the collaborator might
 obtain from the agreement without exercising the options, the cost
 to exercise the options relative to the total upfront
 consideration, and the additional financial commitments imposed on
 the collaborator as a result of exercising the options.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to a product program are
 considered substantive, the Company does not consider the
 development and commercialization licenses to be a deliverable at
 the inception of the agreement. For those right-to-develop
 agreements entered into prior to the adoption of ASU
 No.&#xA0;2009-13 where the options to secure development and
 commercialization licenses are considered substantive, the Company
 has deferred the upfront payments received and recognizes this
 revenue over the period during which the collaborator could elect
 to exercise options for development and commercialization licenses.
 These periods are specific to each collaboration agreement. If a
 collaborator selects a target for a product program, any
 substantive option fee is deferred and recognized over the life of
 the option, generally 12 months. Subsequent to the adoption of ASU
 No.&#xA0;2009-13, the Company&#x2019;s evaluation of whether the
 option is substantive is consistent with pre-adoption of ASU
 No.&#xA0;2009-13. How the Company determines the selling price of
 the option is the only difference between pre and post adoption of
 ASU No.&#xA0;2009-13. Post adoption of ASU No.&#xA0;2009-13, the
 selling prices of deliverables under an arrangement may be derived
 using TPE or a BESP, if VSOE is not available. The objective of
 BESP is to determine the price at which the Company would transact
 a sale if the element within the right-to-develop agreement was
 sold on a standalone basis. Establishing BESP involves
 management&#x2019;s judgment and considers multiple factors,
 including market conditions and company-specific factors, including
 those factors contemplated in negotiating the agreements, as well
 as internally developed models that include assumptions related to
 market opportunity, discounted cash flows, estimated development
 costs, probability of success and the time needed to commercialize
 a product candidate pursuant to the right-to-develop agreement. In
 validating the BESP, management considers whether changes in key
 assumptions used to determine the BESP will have a significant
 effect on the allocation of the arrangement consideration between
 the multiple deliverables. Deliverables under the arrangement are
 separate units of accounting if (i)&#xA0;the delivered item has
 value to the customer on a standalone basis and (ii)&#xA0;if the
 arrangement includes a general right of return relative to the
 delivered item, delivery or performance of the undelivered item is
 considered probable and substantially within the Company&#x2019;s
 control. The arrangement consideration that is fixed or
 determinable at the inception of the arrangement is allocated to
 the separate units of accounting based on their relative selling
 prices. The appropriate revenue recognition model is applied to
 each element and revenue is accordingly recognized as each element
 is delivered. Management exercises significant judgment in
 determining whether a deliverable is a separate unit of
 accounting.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 If a collaborator exercises an option and acquires a development
 and commercialization license to a product program, the Company
 attributes the exercise fee to the development and
 commercialization license. The Company determines the selling price
 of the option license, upon exercise, through management&#x2019;s
 best estimate. Management&#x2019;s determination of selling price
 includes such factors as stage of development, market potential and
 cash flow models used during the negotiation with the collaborator.
 Through December&#xA0;31, 2013, none of our collaboration partners
 had exercised an option. However, one of our collaboration partners
 did elect to exercise an option in February 2014. See Note 13 for
 additional information.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Upon exercise of an option to acquire a development and
 commercialization license, the Company would also attribute any
 remaining deferred option fee, in addition to the consideration
 received for the license upon exercise of the option, to the
 development and commercialization license. The Company then applies
 the multiple-element revenue recognition criteria to the
 development and commercialization license and other deliverables,
 if any, to determine the appropriate revenue recognition method.
 This model is consistent with the Company&#x2019;s accounting policy
 for upfront payments on exclusive licenses (discussed above). In
 the event a right-to-develop agreement were to be terminated, the
 Company would recognize as revenue any portion of the upfront fee
 that had not previously been recorded as revenue, but was
 classified as deferred revenue, at the date of such termination.
 The Company&#x2019;s right-to-develop agreements have been
 determined to contain substantive options.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to product programs are
 not considered substantive, the Company considers the development
 and commercialization licenses to be a deliverable at the inception
 of the agreement and applies the multiple-element revenue
 recognition criteria to determine the appropriate revenue
 recognition. The Company does not directly control when any
 collaborator will exercise its options for development and
 commercialization licenses.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Research and Development Costs</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Research and development expenditures are expensed as incurred.
 Research and development costs primarily consist of employee
 related expenses, including salaries and benefits, expenses
 incurred under agreements with contract research organizations,
 investigative sites and consultants that conduct the
 Company&#x2019;s clinical trials, the cost of acquiring and
 manufacturing clinical trial materials and other allocated
 expenses, license fees for and milestone payments related to
 in-licensed products and technologies, stock-based compensation
 expense, and costs associated with non-clinical activities and
 regulatory approvals.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Comprehensive Income (Loss)</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Effective January&#xA0;1, 2012, the Company adopted ASU 2011-05,
 <i>Presentation of Comprehensive Income,</i> which amended ASC
 Topic 220, <i>Comprehensive Income</i> (&#x201C;ASU
 2011-05&#x201D;)<i>.</i> The amendments in ASU 2011-05 require the
 presentation of the comprehensive income (loss) and its components
 as part of the consolidated financial statements. Comprehensive
 income (loss) is comprised of the net income (loss) and other
 changes in equity that are excluded from net income (loss).
 Comprehensive income (loss) equals net income (loss) for the years
 ended December&#xA0;31, 2013, 2012 and 2011.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Stock-based Compensation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Stock-based payments are accounted for in accordance with the
 provisions of ASC&#xA0;718, <i>Compensation&#xA0;&#x2013; Stock
 Compensation</i>. The fair value of stock-based payments is
 estimated, on the date of grant, using the Black-Scholes model. The
 resulting fair value is recognized ratably over the requisite
 service period, which is generally the vesting period of the
 option.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For all time-vesting awards granted, expense is amortized using the
 straight-line attribution method. For awards that contain a
 performance condition, expense is amortized using the accelerated
 attribution method. Recognition of stock-based compensation expense
 is based on the value of the portion of stock-based awards that is
 ultimately expected to vest during the period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company utilizes the Black-Scholes model for estimating fair
 value of its stock options granted. Option valuation models,
 including the Black-Scholes model, require the input of highly
 subjective assumptions, and changes in the assumptions used can
 materially affect the grant-date fair value of an award. These
 assumptions include the risk-free rate of interest, expected
 dividend yield, expected volatility and the expected life of the
 award.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Net Income (Loss) Per Share</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Basic income (loss) per common share is determined by dividing
 income (loss) attributable to common stockholders by the
 weighted-average number of common shares outstanding during the
 period, without consideration of common stock equivalents. Diluted
 income (loss) per share is computed by dividing the earnings (loss)
 attributable to common stockholders by the weighted-average number
 of common share equivalents outstanding for the period. The
 treasury stock method is used to determine the dilutive effect of
 the Company&#x2019;s stock option grants, potential Employee Stock
 Purchase Plan awards and warrants and the if-converted method is
 used to determine the dilutive effect of the Company&#x2019;s
 preferred stock.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Prior to the Company&#x2019;s initial public offering, net income
 (loss) per share was calculated under the <font style="WHITE-SPACE: nowrap">two-class</font> method under which all
 earnings (distributed and undistributed) are allocated to each
 class of common stock and participating securities based on their
 respective rights to receive dividends. In the event that the Board
 of Directors declared a dividend payable in cash or other property
 on the then-outstanding shares of common stock, the holders of the
 Series&#xA0;A-1, A-2, B, C, D, and D-2 convertible preferred stock
 would be entitled to receive the amount of dividends per share of
 preferred stock that would be payable on the largest number of
 whole shares of common stock into which each share of preferred
 stock could then be converted. Therefore, the Series A-1, A-2, B,
 C, D and D-2 are participating securities. All of the outstanding
 shares of Series&#xA0;A-1, A-2, B, C, D, and D-2 convertible
 preferred stock converted to common stock upon the consummation of
 the Company&#x2019;s IPO.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Basic and diluted income (loss) per common share is computed as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(260,835</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,361,755</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,717,120</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: undistributed earnings allocated to participating
 securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,361,755</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,717,120</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(260,835</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,025,602</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>Basic income (loss) per common share</b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.04</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(260,835</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,361,755</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,717,120</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,361,755</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,717,120</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(260,835</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,025,602</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Effect of dilutive securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Diluted weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,847,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,083,276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,025,602</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>Diluted income (loss) per common share</b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.04</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following common stock equivalents were excluded from the
 calculation of diluted net income (loss) per share because their
 effect would be anti-dilutive:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series A-1 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series A-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series B Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series C Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series D Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Effect of Converted Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,189,920</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Warrants to purchase Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Stock Options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,313,970</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,249,702</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,885,417</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards Adopted</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Recently Issued Accounting Standards Adopted</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In July 2013, the FASB issued ASU No.&#xA0;2013-11, which amended
 ASC Topic 740 regarding presentation of an unrecognized tax benefit
 when a net operating loss (&#x201C;NOL&#x201D;) carryforward, a
 similar tax loss, or a tax credit carryforward exists. The
 amendments in ASU No.&#xA0;2013-11 require an entity to present an
 unrecognized tax benefit as a reduction of a deferred tax asset for
 an NOL carryforward, or similar tax loss or tax credit
 carryforward, rather than as a liability when (1)&#xA0;the
 uncertain tax position would reduce the NOL or other carryforward
 under the tax law of the applicable jurisdiction and (2)&#xA0;the
 entity intends to use the deferred tax asset for that purpose. The
 ASU does not require new recurring disclosures. This amendment is
 effective prospectively for fiscal years beginning after
 December&#xA0;15, 2013. The Company does not believe this amendment
 will have a material impact on its financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company has evaluated all ASUs through the date the
 consolidated financials were issued and believes that the adoption
 of these will not have a material impact on the Company&#x2019;s
 consolidated financial statements.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Subparagraph a<br><br> -Article 9<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationRelatedCostsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskCreditRisk</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144681<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144749<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32247-109318<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3, 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28368275&amp;loc=d3e5093-111524<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28368275&amp;loc=d3e5212-111524<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TradeAndOtherAccountsReceivablePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
